RIN 0938-AU84, 48780-49499 [2022-16472]
Download as PDF
48780
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
42 CFR Parts 412, 413, 482, 485, and
495
[CMS–1771–F]
RIN 0938–AU84
Medicare Program; Hospital Inpatient
Prospective Payment Systems for
Acute Care Hospitals and the LongTerm Care Hospital Prospective
Payment System and Policy Changes
and Fiscal Year 2023 Rates; Quality
Programs and Medicare Promoting
Interoperability Program Requirements
for Eligible Hospitals and Critical
Access Hospitals; Costs Incurred for
Qualified and Non-Qualified Deferred
Compensation Plans; and Changes to
Hospital and Critical Access Hospital
Conditions of Participation
Centers for Medicare &
Medicaid Services (CMS), Department
of Health and Human Services (HHS).
ACTION: Final rule.
AGENCY:
This final rule will: revise the
Medicare hospital inpatient prospective
payment systems (IPPS) for operating
and capital-related costs of acute care
hospitals; make changes relating to
Medicare graduate medical education
(GME) for teaching hospitals; update the
payment policies and the annual
payment rates for the Medicare
prospective payment system (PPS) for
inpatient hospital services provided by
long-term care hospitals (LTCHs). In
addition it will establish new
requirements and revise existing
requirements for eligible hospitals and
critical access hospitals (CAHs)
participating in the Medicare Promoting
Interoperability Program; and update
policies for the Hospital Readmissions
Reduction Program, Hospital Inpatient
Quality Reporting (IQR) Program,
Hospital VBP Program, HospitalAcquired Condition (HAC) Reduction
Program, PPS-Exempt Cancer Hospital
Reporting (PCHQR) Program, and the
Long-Term Care Hospital Quality
Reporting Program (LTCH QRP). It will
also revise the hospital and critical
access hospital (CAH) conditions of
participation (CoPs) for infection
prevention and control and antibiotic
stewardship programs; and codify and
clarify policies related to the costs
incurred for qualified and non-qualified
deferred compensation plans. Lastly,
this final rule will provide updates on
the Rural Community Hospital
khammond on DSKJM1Z7X2PROD with RULES2
SUMMARY:
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Demonstration Program and the Frontier
Community Health Integration Project.
DATES: This final rule is effective
October 1, 2022.
FOR FURTHER INFORMATION CONTACT:
Donald Thompson, and Michele
Hudson, (410) 786–4487 or DAC@
cms.hhs.gov, Operating Prospective
Payment, MS–DRG Relative Weights,
Wage Index, Hospital Geographic
Reclassifications, Graduate Medical
Education, Capital Prospective Payment,
Excluded Hospitals, Medicare
Disproportionate Share Hospital (DSH)
Payment Adjustment, Sole Community
Hospitals (SCHs), Medicare-Dependent
Small Rural Hospital (MDH) Program,
Low-Volume Hospital Payment
Adjustment, and Critical Access
Hospital (CAH) Issues.
Emily Lipkin, and Jim Mildenberger,
DAC@cms.hhs.gov, Long-Term Care
Hospital Prospective Payment System
and MS–LTC–DRG Relative Weights
Issues.
Adina Hersko, Adina.Hersko@
cms.hhs.gov, New Technology Add-On
Payments and New COVID–19
Treatments Add-on Payments Issues.
Mady Hue, marilu.hue@cms.hhs.gov,
and Andrea Hazeley, andrea.hazeley@
cms.hhs.gov, MS–DRG Classifications
Issues.
Siddhartha Mazumdar,
siddhartha.mazumdar @cms.hhs,gov,
Rural Community Hospital
Demonstration Program Issues.
Jeris Smith, jeris.smith@cms.hhs.gov,
Frontier Community Health Integration
Project Demonstration Issues.
Sophia Chan, sophia.chan@
cms.hhs.gov, Hospital Readmissions
Reduction Program—Administration
Issues.
Tyson Nakashima, Tyson.
Nakashima@cms.hhs.gov, Hospital
Readmissions Reduction Program—
Measures Issues.
Jennifer Tate, jennifer.tate@
cms.hhs.gov, Hospital-Acquired
Condition Reduction Program—
Administration Issues
Yuling Li, yuling.li@cms.hhs.gov,
Hospital-Acquired Condition Reduction
Program—Measures Issues.
Julia Venanzi, julia.venanzi@
cms.hhs.gov, Hospital Inpatient Quality
Reporting Program and Hospital ValueBased Purchasing Program—
Administration Issues
Melissa Hager, melissa.hager@
cms.hhs.gov and Ngozi Uzokwe,
ngozi.uzokwe@cms.hhs.gov—Hospital
Inpatient Quality Reporting Program
and Hospital Value-Based Purchasing
Program—Measures Issues Except
Hospital Consumer Assessment of
Healthcare Providers and Systems
Issues.
PO 00000
Frm 00002
Fmt 4701
Sfmt 4700
Elizabeth Goldstein, elizabeth.
goldstein@cms.hhs.gov, Hospital
Inpatient Quality Reporting and
Hospital Value-Based Purchasing—
Hospital Consumer Assessment of
Healthcare Providers and Systems
Measures Issues.
Ora Dawedeit, ora.dawedeit@
cms.hhs.gov, PPS-Exempt Cancer
Hospital Quality Reporting—
Administration Issues.
Leah Domino, leah.domino@
cms.hhs.gov, PPS-Exempt Cancer
Hospital Quality Reporting ProgramMeasure Issues
Ariel Cress, ariel.cress@cms.hhs.gov,
Long-Term Care Hospital Quality
Reporting Program—Data Reporting
Issues.
Elizabeth Holland, elizabeth.holland@
cms.hhs.gov, Medicare Promoting
Interoperability Program.
Dawn Linn, dawn.linn@cms.hhs.gov,
Lela Strong, lela.strong@cms.hhs.gov,
and Alpha Wilson, alpha.wilson@
cms.hhs.gov, Conditions of Participation
(CoP) Requirements for Hospitals and
Critical Access Hospitals (CAHs) to
Continue Reporting Data for COVID–19
and Influenza After the PHE ends as
Determined by the Secretary.
SUPPLEMENTARY INFORMATION:
Tables Available Through the internet
on the CMS website
The IPPS tables for this fiscal year
(FY) 2023 final rule are available
through the internet on the CMS website
at https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/. Click on
the link on the left side of the screen
titled ‘‘FY 2023 IPPS Final rule Home
Page’’ or ‘‘Acute Inpatient—Files for
Download.’’ The LTCH PPS tables for
this FY 2023 final rule are available
through the internet on the CMS website
at https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
LongTermCareHospitalPPS/
under the list item for Regulation
Number CMS–1771–F. For further
details on the contents of the tables
referenced in this final rule, we refer
readers to section VI. of the Addendum
to this FY 2023 IPPS/LTCH PPS final
rule.
Readers who experience any problems
accessing any of the tables that are
posted on the CMS websites, as
previously identified, should contact
Michael Treitel, DAC@cms.hhs.gov.
Table of Contents
I. Executive Summary and Background
A. Executive Summary
B. Background Summary
C. Summary of Provisions of Recent
Legislation Implemented in This Final
Rule
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
D. Issuance of Proposed Rulemaking
E. Advancing Health Information Exchange
F. Use of FY 2021 Data and Methodology
Modifications for the FY 2023 IPPS and
LTCH PPS Ratesetting
II. Changes to Medicare Severity DiagnosisRelated Group (MS–DRG) Classifications
and Relative Weights
A. Background
B. Adoption of the MS–DRGs and MS–DRG
Reclassifications
C. FY 2023 MS–DRG Documentation and
Coding Adjustment
D. Changes to Specific MS–DRG
Classifications
E. Recalibration of the FY 2023 MS–DRG
Relative Weights
F. Add-On Payments for New Services and
Technologies for FY 2023
III. Changes to the Hospital Wage Index for
Acute Care Hospitals
A. Background
B. Worksheet S–3 Wage Data for the FY
2022 Wage Index
C. Verification of Worksheet S–3 Wage
Data
D. Method for Computing the FY 2022
Unadjusted Wage Index
E. Occupational Mix Adjustment to the FY
2023 Wage Index
F. Analysis and Implementation of the
Occupational Mix Adjustment and the
FY 2023 Occupational Mix Adjusted
Wage Index
G. Application of the Rural Floor,
Application of the State Frontier Floor,
and Continuation of the Low Wage Index
Hospital Policy, and Budget Neutrality
Adjustment
H. FY 2023 Wage Index Tables
I. Revisions to the Wage Index Based on
Hospital Redesignations and
Reclassifications
J. Out-Migration Adjustment Based on
Commuting Patterns of Hospital
Employees
K. Reclassification From Urban to Rural
Under Section 1886(d)(8)(E) of the Act
Implemented at 42 CFR 412.103
L. Process for Requests for Wage Index
Data Corrections
M. Labor-Related Share for the FY 2023
Wage Index
IV. Payment Adjustment for Medicare
Disproportionate Share Hospitals (DSHs)
for FY 2023 (§ 412.106)
A. General Discussion
B. Eligibility for Empirically Justified
Medicare DSH Payments and
Uncompensated Care Payments
C. Empirically Justified Medicare DSH
Payments
D. Uncompensated Care Payments
E. Supplemental Payment for Indian
Health Service and Tribal Hospitals and
Puerto Rico Hospitals for FY 2023 and
Subsequent Fiscal Years
F. Counting Days Associated With Section
1115 Demonstrations in the Medicaid
Fraction
V. Other Decisions and Changes to the IPPS
for Operating Costs
A. Changes in the Inpatient Hospital
Updates for FY 2022 (§ 412.64(d))
B. Rural Referral Centers (RRCs)—Annual
Updates to Case-Mix Index (CMI) and
Discharge Criteria (§ 412.96)
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
C. Payment Adjustment for Low-Volume
Hospitals (§ 412.101)
D. Changes in the Medicare-Dependent,
Small Rural Hospital (MDH) Program
(§ 412.108)
E. Indirect Medical Education (IME)
Payment Adjustment Factor (§ 412.105)
F. Payment for Indirect and Direct
Graduate Medical Education Costs
(§§ 412.105 and 413.75 Through 413.83)
G. Payment Adjustment for Certain Clinical
Trial and Expanded Access Use
Immunotherapy Cases (§§ 412.85 and
412.312)
H. Hospital Readmissions Reduction
Program: Updates and Changes
(§§ 412.150 Through 412.154)
I. Hospital Value-Based Purchasing (VBP)
Program: Policy Changes
J. Hospital-Acquired Conditions (HAC)
Reduction Program: Updates and
Changes (§ 412.170)
K. Rural Community Hospital
Demonstration Program
VI. Changes to the IPPS for Capital-Related
Costs
A. Overview
B. Additional Provisions
C. Annual Update for FY 2023
VII. Changes for Hospitals Excluded From the
IPPS
A. Rate-of-Increase in Payments to
Excluded Hospitals for FY 2023
B. Critical Access Hospitals (CAHs)
VIII. Changes to the Long-Term Care Hospital
Prospective Payment System (LTCH PPS)
for FY 2023
A. Background of the LTCH PPS
B. Medicare Severity Long-Term Care
Diagnosis-Related Group (MS–LTC–
DRG) Classifications and Relative
Weights for FY 2023
C. Changes to the LTCH PPS Payment
Rates and Other Changes to the LTCH
PPS for FY 2023
IX. Quality Data Reporting Requirements for
Specific Providers and Suppliers
A. Assessment of the Impact of Climate
Change and Health Equity
B. Overarching Principles for Measuring
Healthcare Quality Disparities Across
CMS Quality Programs—Request for
Information
C. Continuing To Advance to Digital
Quality Measurement and the Use of Fast
Healthcare Interoperability Resources
(FHIR) in Hospital Quality Programs—
Request for Information
D. Advancing the Trusted Exchange
Framework and Common Agreement—
Request for Information
E. Hospital Inpatient Quality Reporting
(IQR) Program
F. PPS-Exempt Cancer Hospital Quality
Reporting (PCHQR) Program
G. Long-Term Care Hospital Quality
Reporting Program (LTCH QRP)
H. Changes to the Medicare Promoting
Interoperability Program
X. Changes for Hospitals and Other Providers
and Suppliers
A. Codification of the Costs Incurred for
Qualified and Non-Qualified Deferred
Compensation Plans
B. Condition of Participation (CoP)
Requirements for Hospitals and CAHs To
PO 00000
Frm 00003
Fmt 4701
Sfmt 4700
48781
Continue Reporting Data for COVID–19
and Influenza After the PHE Ends as
Determined by the Secretary
C. Request for Public Comments on IPPS
Payment Adjustment for N95 Respirators
That Are Wholly Domestically Made
XI. MedPAC Recommendations
XII. Other Required Information
A. Publicly Available Files
B. Collection of Information Requirements
I. Executive Summary and Background
A. Executive Summary
1. Purpose and Legal Authority
This FY 2023 IPPS/LTCH PPS final
rule makes payment and policy changes
under the Medicare inpatient
prospective payment systems (IPPS) for
operating and capital-related costs of
acute care hospitals as well as for
certain hospitals and hospital units
excluded from the IPPS. In addition, it
makes payment and policy changes for
inpatient hospital services provided by
long-term care hospitals (LTCHs) under
the long-term care hospital prospective
payment system (LTCH PPS). This final
rule also makes policy changes to
programs associated with Medicare IPPS
hospitals, IPPS-excluded hospitals, and
LTCHs. In this FY 2023 final rule, we
are implementing a permanent policy to
cap wage index decreases as well as
continuing policies to address wage
index disparities impacting low wage
index hospitals. We also are making
changes relating to Medicare graduate
medical education (GME) for teaching
hospitals and new technology add-on
payments.
We are establishing new requirements
and revising existing requirements for
eligible hospitals and CAHs
participating in the Medicare Promoting
Interoperability Program.
This final rule also acknowledges
feedback we received on requests for
information on health impacts due to
climate change, on overarching
principles in measuring healthcare
quality disparities in hospital quality
programs and value-based purchasing
programs, the LTCH QRP, and on
advancing the Trusted Exchange
Framework and Common Agreement
(TEFCA). We thank commenters for
their feedback.
Additionally, due to the impact of the
COVID–19 PHE on measure data used in
the Hospital VBP Program and HAC
Reduction Program, we are finalizing
our proposals to suppress several
measures in both of those programs for
purposes of FY 2023 scoring and
payment adjustments. For transparency,
we will continue to publicly report
measure information for all measures,
including suppressed measures. In
addition to these measure suppressions
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48782
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
for the Hospital VBP Program, we are
finalizing our proposal to implement a
special scoring methodology for FY
2023 that results in each hospital
receiving a value-based incentive
payment amount that matches their 2
percent reduction to the base operating
MS–DRG payment amount. Similarly,
we are finalizing our proposal to
suppress all six measures in the HAC
Reduction Program for the FY 2023
program year. We are not finalizing our
proposal to not calculate measure
results or scores for the CMS PSI 90
measure. Although we will not calculate
or report the CMS PSI 90 measure
results for use in the HAC Reduction
Program scoring calculations for the
program year, we will still calculate and
report CMS PSI 90 that is displayed on
the main pages of the Care Compare tool
hosted by HHS after confidentially
reporting these results to hospitals via
hospital-specific reports and a 30-day
preview period. Additionally, we will
continue to calculate and report
measure results for the NHSN CDC HAI
measures. For the FY 2023 program
year, hospitals participating in the HAC
Reduction Program will not be given a
Total HAC score, nor will hospitals
receive a payment penalty. We are also
providing estimated and newly
established performance standards for
the Hospital VBP Program. For the
Hospital Readmissions Reduction
Program, we are resuming the use of the
one measure (which was previously
suppressed for the FY 2023 applicable
period) for the FY 2024 applicable
period, and incorporating measure
updates to the six condition/procedure
measures addressed by the Hospital
Readmission Reduction Program to
account for patient history of COVID–
19.
Under various statutory authorities,
we either discuss continued program
implementation or make changes to the
Medicare IPPS, the LTCH PPS, other
related payment methodologies and
programs for FY 2023 and subsequent
fiscal years, and other policies and
provisions included in this rule. These
statutory authorities include, but are not
limited to, the following:
• Section 1886(d) of the Social
Security Act (the Act), which sets forth
a system of payment for the operating
costs of acute care hospital inpatient
stays under Medicare Part A (Hospital
Insurance) based on prospectively set
rates. Section 1886(g) of the Act requires
that, instead of paying for capital-related
costs of inpatient hospital services on a
reasonable cost basis, the Secretary use
a prospective payment system (PPS).
• Section 1886(d)(1)(B) of the Act,
which specifies that certain hospitals
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
and hospital units are excluded from the
IPPS. These hospitals and units are:
rehabilitation hospitals and units;
LTCHs; psychiatric hospitals and units;
children’s hospitals; cancer hospitals;
extended neoplastic disease care
hospitals, and hospitals located outside
the 50 States, the District of Columbia,
and Puerto Rico (that is, hospitals
located in the U.S. Virgin Islands,
Guam, the Northern Mariana Islands,
and American Samoa). Religious
nonmedical health care institutions
(RNHCIs) are also excluded from the
IPPS.
• Sections 123(a) and (c) of the BBRA
(Public Law (Pub. L.) 106–113) and
section 307(b)(1) of the BIPA (Pub. L.
106–554) (as codified under section
1886(m)(1) of the Act), which provide
for the development and
implementation of a prospective
payment system for payment for
inpatient hospital services of LTCHs
described in section 1886(d)(1)(B)(iv) of
the Act.
• Sections 1814(l), 1820, and 1834(g)
of the Act, which specify that payments
are made to critical access hospitals
(CAHs) (that is, rural hospitals or
facilities that meet certain statutory
requirements) for inpatient and
outpatient services and that these
payments are generally based on 101
percent of reasonable cost.
• Section 1886(a)(4) of the Act, which
specifies that costs of approved
educational activities are excluded from
the operating costs of inpatient hospital
services. Hospitals with approved
graduate medical education (GME)
programs are paid for the direct costs of
GME in accordance with section 1886(h)
of the Act.
• Section 1886(b)(3)(B)(viii) of the
Act, which requires the Secretary to
reduce the applicable percentage
increase that would otherwise apply to
the standardized amount applicable to a
subsection (d) hospital for discharges
occurring in a fiscal year if the hospital
does not submit data on measures in a
form and manner, and at a time,
specified by the Secretary.
• Section 1866(k) of the Act, which
provides for the establishment of a
quality reporting program for hospitals
described in section 1886(d)(1)(B)(v) of
the Act, referred to as ‘‘PPS-exempt
cancer hospitals.’’
• Section 1886(o) of the Act, which
requires the Secretary to establish a
Hospital Value-Based Purchasing (VBP)
Program, under which value-based
incentive payments are made in a fiscal
year to hospitals meeting performance
standards established for a performance
period for such fiscal year.
PO 00000
Frm 00004
Fmt 4701
Sfmt 4700
• Section 1886(p) of the Act, which
establishes a Hospital-Acquired
Condition (HAC) Reduction Program,
under which payments to applicable
hospitals are adjusted to provide an
incentive to reduce hospital-acquired
conditions.
• Section 1886(q) of the Act, as
amended by section 15002 of the 21st
Century Cures Act, which establishes
the Hospital Readmissions Reduction
Program. Under the program, payments
for discharges from an applicable
hospital as defined under section
1886(d) of the Act will be reduced to
account for certain excess readmissions.
Section 15002 of the 21st Century Cures
Act directs the Secretary to compare
hospitals with respect to the number of
their Medicare-Medicaid dual-eligible
beneficiaries (dual-eligibles) in
determining the extent of excess
readmissions.
• Section 1886(r) of the Act, as added
by section 3133 of the Affordable Care
Act, which provides for a reduction to
disproportionate share hospital (DSH)
payments under section 1886(d)(5)(F) of
the Act and for a new uncompensated
care payment to eligible hospitals.
Specifically, section 1886(r) of the Act
requires that, for fiscal year 2014 and
each subsequent fiscal year, subsection
(d) hospitals that would otherwise
receive a DSH payment made under
section 1886(d)(5)(F) of the Act will
receive two separate payments: (1) 25
percent of the amount they previously
would have received under section
1886(d)(5)(F) of the Act for DSH (‘‘the
empirically justified amount’’), and (2)
an additional payment for the DSH
hospital’s proportion of uncompensated
care, determined as the product of three
factors. These three factors are: (1) 75
percent of the payments that would
otherwise be made under section
1886(d)(5)(F) of the Act; (2) 1 minus the
percent change in the percent of
individuals who are uninsured; and (3)
a hospital’s uncompensated care
amount relative to the uncompensated
care amount of all DSH hospitals
expressed as a percentage.
• Section 1886(m)(5) of the Act,
which requires the Secretary to reduce
by two percentage points the annual
update to the standard Federal rate for
discharges for a long-term care hospital
(LTCH) during the rate year for LTCHs
that do not submit data in the form,
manner, and at a time, specified by the
Secretary.
• Section 1886(m)(6) of the Act, as
added by section 1206(a)(1) of the
Pathway for Sustainable Growth Rate
(SGR) Reform Act of 2013 (Pub. L. 113–
67) and amended by section 51005(a) of
the Bipartisan Budget Act of 2018 (Pub.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
L. 115–123), which provided for the
establishment of site neutral payment
rate criteria under the LTCH PPS, with
implementation beginning in FY 2016.
Section 51005(b) of the Bipartisan
Budget Act of 2018 amended section
1886(m)(6)(B) by adding new clause (iv),
which specifies that the IPPS
comparable amount defined in clause
(ii)(I) shall be reduced by 4.6 percent for
FYs 2018 through 2026.
• Section 1899B of the Act, as added
by section 2(a) of the Improving
Medicare Post-Acute Care
Transformation Act of 2014 (IMPACT
Act) (Pub. L. 113–185), which provides
for the establishment of standardized
data reporting for certain post-acute care
providers, including LTCHs.
• Section 1861(e) of the Act provides
the specific statutory authority for the
hospital CoPs; section 1820(e) of the Act
provides similar authority for CAHs.
The hospital provision at section
1861(e)(9) of the Act authorizes the
Secretary to issue regulations the
Secretary deems necessary to protect the
health and safety of patients receiving
services in those facilities; the CAH
provision at section 1820(e)(3) of the
Act authorizes the Secretary to issue
such other criteria as the Secretary may
require.
khammond on DSKJM1Z7X2PROD with RULES2
2. Summary of the Major Provisions
The following is a summary of the
major provisions in this final rule. In
general, these major provisions are
being finalized as part of the annual
update to the payment policies and
payment rates, consistent with the
applicable statutory provisions. A
general summary of the changes in this
final rule is presented in section I.D. of
the preamble of this final rule.
a. MS–DRG Documentation and Coding
Adjustment
Section 631 of the American Taxpayer
Relief Act of 2012 (ATRA, Pub. L. 112–
240) amended section 7(b)(1)(B) of Pub.
L. 110–90 to require the Secretary to
make a recoupment adjustment to the
standardized amount of Medicare
payments to acute care hospitals to
account for changes in MS–DRG
documentation and coding that do not
reflect real changes in case-mix, totaling
$11 billion over a 4-year period of FYs
2014, 2015, 2016, and 2017. The FY
2014 through FY 2017 adjustments
represented the amount of the increase
in aggregate payments as a result of not
completing the prospective adjustment
authorized under section 7(b)(1)(A) of
Public Law 110–90 until FY 2013. Prior
to the ATRA, this amount could not
have been recovered under Public Law
110–90. Section 414 of the Medicare
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Access and CHIP Reauthorization Act of
2015 (MACRA) (Pub. L. 114–10)
replaced the single positive adjustment
we intended to make in FY 2018 with
a 0.5 percent positive adjustment to the
standardized amount of Medicare
payments to acute care hospitals for FYs
2018 through 2023. (The FY 2018
adjustment was subsequently adjusted
to 0.4588 percent by section 15005 of
the 21st Century Cures Act.) Therefore,
for FY 2023, we are making an
adjustment of + 0.5 percent to the
standardized amount.
b. Use of FY 2021 Data and
Methodology Modifications for the FY
2023 IPPS and LTCH PPS Ratesetting
For the IPPS and LTCH PPS
ratesetting, our longstanding goal is
always to use the best available data
overall. In section I.F. of the preamble
of this final rule, we discuss our return
to our historical practice of using the
most recent data available for purposes
of FY 2023 ratesetting, including the FY
2021 MedPAR claims and FY 2020 cost
report data, with certain modifications
to our usual ratesetting methodologies
to account for the anticipated decline in
COVID–19 hospitalizations of Medicare
beneficiaries at IPPS hospitals and
LTCHs as compared to FY 2021. As
discussed in greater detail in section I.F.
of the preamble of this final rule, we
believe that it is reasonable to assume
that some Medicare beneficiaries will
continue to be hospitalized with
COVID–19 at IPPS hospitals and LTCHs
in FY 2023. Given this expectation, we
believe it is appropriate to use FY 2021
data, as the most recent available data
during the period of the COVID–19 PHE,
for purposes of the FY 2023 IPPS and
LTCH PPS ratesetting. However, as also
discussed in greater detail in section I.F.
of the preamble of this final rule, we
believe it is reasonable to assume based
on the information available at this time
that there will be fewer COVID–19
hospitalizations in FY 2023 than in FY
2021. Therefore, we are finalizing our
proposal to use the FY 2021 data for
purposes of the FY 2023 IPPS and LTCH
PPS ratesetting but with modifications
to our usual ratesetting methodologies
to account for the anticipated decline in
COVID–19 hospitalizations of Medicare
beneficiaries at IPPS hospitals and
LTCHs as compared to FY 2021.
c. Continuation of the Low Wage Index
Hospital Policy
To help mitigate wage index
disparities between high wage and low
wage hospitals, in the FY 2020 IPPS/
LTCH PPS rule (84 FR 42326 through
42332), we adopted a policy to increase
the wage index values for certain
PO 00000
Frm 00005
Fmt 4701
Sfmt 4700
48783
hospitals with low wage index values
(the low wage index hospital policy).
This policy was adopted in a budget
neutral manner through an adjustment
applied to the standardized amounts for
all hospitals. We also indicated our
intention that this policy would be
effective for at least 4 years, beginning
in FY 2020, in order to allow employee
compensation increases implemented
by these hospitals sufficient time to be
reflected in the wage index calculation.
We are finalizing our proposals for the
low wage index hospital policy to
continue for FY 2023, and to apply this
policy in a budget neutral manner by
applying an adjustment to the
standardized amounts.
d. Permanent Cap on Wage Index
Decreases
Consistent with section 1886(d)(3)(E)
of the Act, we adjust the IPPS
standardized amounts for area
differences in hospital wage levels by a
factor (established by the Secretary)
reflecting the relative hospital wage
level in the geographic area of the
hospital compared to the national
average hospital wage level and update
the wage index annually based on a
survey of wages and wage-related costs
of short-term, acute care hospitals. As
described in section III.N. of the
preamble of this final rule, we have
further considered the comments we
received during the FY 2022 rulemaking
recommending a permanent 5-percent
cap policy to prevent large year-to-year
variations in wage index values as a
means to reduce overall volatility for
hospitals. Under the authority at
sections 1886(d)(3)(E) and
1886(d)(5)(I)(i) of the Act, for FY 2023
and subsequent years, we proposed to
apply a 5-percent cap on any decrease
to a hospital’s wage index from its wage
index in the prior FY, regardless of the
circumstances causing the decline. That
is, we proposed that a hospital’s wage
index for FY 2023 would not be less
than 95 percent of its final wage index
for FY 2022, and that for subsequent
years, a hospital’s wage index would not
be less than 95 percent of its final wage
index for the prior FY. We also
proposed to apply the proposed wage
index cap policy in a budget neutral
manner through a national adjustment
to the standardized amount under our
authority in sections 1886(d)(3)(E) and
1886(d)(5)(I)(i) of the Act. After
consideration of the public comments
received, we are finalizing these
proposals without modification.
e. Application of the Rural Floor
As discussed in section III.G.1. of the
preamble of this final rule, based on the
E:\FR\FM\10AUR2.SGM
10AUR2
48784
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
district court’s decision in Citrus HMA,
LLC, d/b/a Seven Rivers Regional
Medical Center v. Becerra, No. 1:20–cv–
00707 (D.D.C.) (hereafter referred to as
Citrus) and the comments we received,
we are not finalizing our rural floor
wage index policy as proposed, which
would have excluded § 412.103
hospitals from the calculation of the
rural floor and from the calculation of
‘‘the wage index for rural areas in the
State in which the county is located’’ as
referred to in section 1886(d)(8)(C)(iii)
of the Act. Rather, we are finalizing a
policy that calculates the rural floor as
it was calculated before FY 2020. For FY
2023 and subsequent years, we are
finalizing a policy to include the wage
data of hospitals that have reclassified
from urban to rural under section
1886(d)(8)(E) of the Act (as
implemented in the regulations at
§ 412.103) and have no additional form
of reclassification (MGCRB or Lugar) in
the calculation of the rural floor, and to
include the wage data of such hospitals
in the calculation of ‘‘the wage index for
rural areas in the State in which the
county is located’’ as referred to in
section 1886(d)(8)(C)(iii) of the Act.
f. DSH Payment Adjustment and
Additional Payment for Uncompensated
Care
Under section 1886(r) of the Act,
which was added by section 3133 of the
Affordable Care Act, starting in FY
2014, Medicare disproportionate share
hospitals (DSHs) receive 25 percent of
the amount they previously would have
received under the statutory formula for
Medicare DSH payments in section
1886(d)(5)(F) of the Act. The remaining
amount, equal to 75 percent of the
amount that otherwise would have been
paid as Medicare DSH payments, is paid
as additional payments after the amount
is reduced for changes in the percentage
of individuals that are uninsured. Each
Medicare DSH will receive an
additional payment based on its share of
the total amount of uncompensated care
for all Medicare DSHs for a given time
period.
In this final rule, we are updating our
estimates of the three factors used to
determine uncompensated care
payments for FY 2023. We are also
continuing to use uninsured estimates
produced by CMS’ Office of the Actuary
(OACT) as part of the development of
the National Health Expenditure
Accounts (NHEA) in conjunction with
more recently available data in the
calculation of Factor 2. For FY 2023, we
are using the 2 most recent years of
audited data on uncompensated care
costs from Worksheet S–10 of the FY
2018 cost reports and the FY 2019 cost
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
reports to calculate Factor 3 in the
uncompensated care payment
methodology for all eligible hospitals. In
addition, for FY 2024 and subsequent
fiscal years, we are using a 3-year
average of the data on uncompensated
care costs from Worksheet S–10 for the
3 most recent fiscal years for which
audited data are available. Beginning in
FY 2023, we are discontinuing the use
of low-income insured days as a proxy
for uncompensated care to determine
Factor 3 for Indian Health Service (IHS)
and Tribal hospitals and hospitals
located in Puerto Rico. In addition, we
are implementing certain
methodological changes for calculating
Factor 3 for FY 2023 and subsequent
fiscal years.
We recognize that discontinuing the
use of the low-income insured days
proxy to calculate uncompensated care
payments for Indian Health Service
(IHS) and Tribal hospitals and hospitals
located in Puerto Rico could result in a
significant financial disruption for these
hospitals. Accordingly, we are using our
exceptions and adjustments authority
under section 1886(d)(5)(I) of the Act to
establish a new supplemental payment
for IHS and Tribal hospitals and
hospitals located in Puerto Rico,
beginning in FY 2023.
As noted in section IV.F. of this final
rule, we are not moving forward with
the proposed revisions to the
regulations relating to the treatment of
section 1115 demonstration days for
purposes of the DSH adjustment in this
final rule. We expect to revisit the issue
of section 1115 demonstration days in
future rulemaking, and we encourage
interested parties to review any future
proposal on this issue and to submit
their comments at that time.
g. Changes to GME Payments Based on
Milton S. Hershey Medical Center, et al.
v. Becerra Litigation
On May 17, 2021, the U.S. District
Court for the District of Columbia ruled
against CMS’s method of calculating
direct GME payments to teaching
hospitals when those hospitals’
weighted full-time equivalent (FTE)
counts exceed their direct GME FTE
cap. In Milton S. Hershey Medical
Center, et al. v. Becerra, the court
ordered CMS to recalculate
reimbursement owed, holding that
CMS’s regulation impermissibly
modified the statutory weighting factors.
The plaintiffs in these consolidated
cases alleged that as far back as 2005,
the proportional reduction that CMS
applied to the weighted FTE count
when the weighted FTE count exceeded
the FTE cap conflicted with the
Medicare statute, and it was an arbitrary
PO 00000
Frm 00006
Fmt 4701
Sfmt 4700
and capricious exercise of agency
discretion under the Administrative
Procedure Act. The court held that the
proportional reduction methodology
impermissibly modified the weighting
factors statutorily assigned to residents
and fellows. The court granted the
motion for summary judgment to
plaintiffs’ motions, denied defendant’s,
and remanded to the Agency so that it
could recalculate plaintiffs’
reimbursement payments consistent
with the court’s opinion.
After reviewing the statutory language
regarding the direct GME FTE cap and
the court’s opinion, we have decided
implement a modified policy to be
applied prospectively for all teaching
hospitals, as well as retroactively to the
providers and cost years in Hershey and
certain other providers as described in
greater detail in section V.F.2. of the
preamble of this final rule. The
modified policy will address situations
for applying the FTE cap when a
hospital’s weighted FTE count is greater
than its FTE cap, but would not reduce
the weighting factor of residents that are
beyond their initial residency period to
an amount less than 0.5. Specifically,
effective for cost reporting periods
beginning on or after October 1, 2001,
we are specifying that if the hospital’s
unweighted number of FTE residents
exceeds the FTE cap, and the number of
weighted FTE residents also exceeds
that FTE cap, the respective primary
care and obstetrics and gynecology
weighted FTE counts and other
weighted FTE counts are adjusted to
make the total weighted FTE count
equal the FTE cap. If the number of
weighted FTE residents does not exceed
that FTE cap, then the allowable
weighted FTE count for direct GME
payment is the actual weighted FTE
count.
h. Reduction of Hospital Payments for
Excess Readmissions
We are making changes to policies for
the Hospital Readmissions Reduction
Program, which was established under
section 1886(q) of the Act, as amended
by section 15002 of the 21st Century
Cures Act. The Hospital Readmissions
Reduction Program requires a reduction
to a hospital’s base operating MS–DRG
payment to account for excess
readmissions of selected applicable
conditions. For FY 2023, the reduction
is based on a hospital’s risk-adjusted
readmission rate during a multi-year
period for acute myocardial infarction
(AMI), heart failure (HF), chronic
obstructive pulmonary disease (COPD),
elective primary total hip arthroplasty/
total knee arthroplasty (THA/TKA), and
coronary artery bypass graft (CABG)
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
surgery.1 In this FY 2023 IPPS/LTCH
PPS final rule, we are discussing the
following policies: (1) resuming use of
the Hospital 30-Day, All-Cause, RiskStandardized Readmission Rate (RSRR)
following Pneumonia Hospitalization
measure (NQF #0506) for the FY 2024
program year; (2) modification of the
Hospital 30-Day, All-Cause, RiskStandardized Readmission Rate (RSRR)
following Pneumonia Hospitalization
measure (NQF #0506) to exclude
patients with COVID–19 diagnosis
present on admission from the measure
numerator (outcome) and denominator
(cohort),2 beginning with the Hospital
Specific Reports (HSRs) for the FY 2023
program year; and (3) modification of all
six condition/procedure specific
measures to include a covariate
adjustment for patient history of
COVID–19 within 12 months prior to
the index admission beginning with the
FY 2023 program year. In the FY 2023
IPPS/LTCH PPS proposed rule we also
sought comment on updating the
Hospital Readmissions Reduction
Program to incorporate provider
performance for socially at-risk
populations.
khammond on DSKJM1Z7X2PROD with RULES2
i. Hospital Value-Based Purchasing
(VBP) Program
Section 1886(o) of the Act requires the
Secretary to establish a Hospital VBP
Program under which value-based
incentive payments are made in a fiscal
year to hospitals based on their
performance on measures established
for a performance period for such fiscal
year. In this final rule, we are finalizing
our proposals to: (1) suppress the
Hospital Consumer Assessment of
Healthcare Providers and Systems
(HCAHPS) and five Hospital-Acquired
Infection (HAI) measures for the FY
2023 program year; and (2) update the
baseline periods for certain measures for
the FY 2025 program year. We are also
finalizing our proposal to revise the
scoring and payment methodology for
the FY 2023 program year such that
hospitals will not receive Total
Performance Scores (TPSs).
Additionally, we are finalizing our
proposal to award each hospital a
payment incentive multiplier that
results in a value-based incentive
payment that is equal to the amount
1 We note that in the FY 2023 IPPS/LTCH PPS
proposed rule we described the policy for FY 2017
and subsequent years, without reference to
flexibility due to the COVID–19 PHE. We have
updated this information to describe the policy for
FY 2023.
2 We note that in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28113) we inadvertently
omitted reference to removing COVID–19 diagnosed
patients from the numerator. We have corrected this
omission here.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
withheld for the fiscal year (2 percent).
We note that we are also announcing
technical updates to the measures in the
Clinical Outcomes Domain.
j. Hospital-Acquired Condition (HAC)
Reduction Program
In this FY 2023 IPPS/LTCH PPS final
rule we are finalizing several changes to
the HAC Reduction Program, which was
established under section 1886(p) of the
Act, to provide an incentive to hospitals
to reduce the incidence of hospitalacquired conditions. We refer readers to
the FY 2022 IPPS/LTCH PPS final rule
for further details on our measure
suppression policy (86 FR 45301
through 45304). In this FY 2023 IPPS/
LTCH PPS final rule, we are not
finalizing our proposal to not calculate
or report measure results for the CMS
PSI 90 measure for the FY 2023 HAC
Reduction Program. Although we will
not calculate or report CMS PSI 90
measure results for use in the HAC
Reduction Program scoring calculations
for the program year, we will still
calculate and report CMS PSI 90 that is
displayed on the main pages of the
Compare tool hosted by HHS after
confidentially reporting these results to
hospitals via CMS PSI 90 specific HSRs
and a 30-day preview period. We will
continue to calculate and report
measure results for the NHSN CDC HAI
measures.
In this FY 2023 IPPS/LTCH PPS final
rule, we are finalizing our proposals to:
(1) suppress the CMS PSI 90 measure
and the five CDC NHSN HAI measures
from the calculation of measure scores
and the Total HAC Score, thereby not
penalizing any hospital under the HAC
Reduction Program FY 2023 program
year; (2) suppress CY 2021 CDC NHSN
HAI measures data from the FY 2024
HAC Reduction Program Year; (3)
update the measure specification to the
minimum volume threshold for the
CMS PSI 90 measure beginning with the
FY 2023 program year; (4) update the
measure specifications to risk-adjust for
COVID–19 diagnosis in the CMS PSI 90
measure beginning with the FY 2024
HAC Reduction Program Year; and (5)
update the NHSN CDC HAI data
submission requirements for newly
opened hospitals beginning in the FY
2024 HAC Reduction Program.
In this FY 2023 IPPS/LTCH PPS final
rule, we acknowledge feedback we
received on Requests for Information
from stakeholders on two topics: (1) the
potential adoption of two digital
National Healthcare Safety Network
(NHSN) measures: the NHSN
Healthcare-associated Clostridioides
difficile Infection Outcome measure and
NHSN Hospital-Onset Bacteremia &
PO 00000
Frm 00007
Fmt 4701
Sfmt 4700
48785
Fungemia Outcome measure; and (2) on
overarching principles for measuring
healthcare quality disparities across
CMS Quality Programs. In the FY 2023
IPPS/LTCH PPS proposed rule and this
final rule, we also clarified the removal
of the no mapped location policy
beginning with the FY 2023 program
year.
k. Hospital Inpatient Quality Reporting
(IQR) Program
Under section 1886(b)(3)(B)(viii) of
the Act, subsection (d) hospitals are
required to report data on measures
selected by the Secretary for a fiscal year
in order to receive the full annual
percentage increase.
In this FY 2023 IPPS/LTCH PPS final
rule, we are finalizing several changes to
the Hospital IQR Program. We are
adopting 10 new measures: (1) Hospital
Commitment to Health Equity beginning
with the CY 2023 reporting period/FY
2025 payment determination; (2)
Screening for Social Drivers of Health
beginning with voluntary reporting for
the CY 2023 reporting period and
mandatory reporting beginning with the
CY 2024 reporting period/FY 2026
payment determination; (3) Screen
Positive Rate for Social Drivers of
Health beginning with voluntary
reporting for the CY 2023 reporting
period and mandatory reporting
beginning with the CY 2024 reporting
period/FY 2026 payment determination;
(4) Cesarean Birth electronic clinical
quality measure (eCQM) with inclusion
in the eCQM measure set beginning
with the CY 2023 reporting period/FY
2025 payment determination, and
mandatory reporting beginning with the
CY 2024 reporting period/FY 2026
payment determination; (5) Severe
Obstetric Complications eCQM with
inclusion in the eCQM measure set
beginning with the CY 2023 reporting
period/FY 2025 payment determination,
and mandatory reporting beginning with
the CY 2024 reporting period/FY 2026
payment determination; (6) HospitalHarm—Opioid-Related Adverse Events
eCQM (NQF #3501e) inclusion in the
eCQM measure set beginning with the
CY 2024 reporting period/FY 2026
payment determination; (7) Global
Malnutrition Composite Score eCQM
(NQF #3592e) inclusion in the eCQM
measure set beginning with the CY 2024
reporting period/FY 2026 payment
determination; (8) Hospital-Level, Risk
Standardized Patient-Reported
Outcomes Performance Measure
Following Elective Primary Total Hip
Arthroplasty (THA) and/or Total Knee
Arthroplasty (TKA) (NQF #3559)
beginning with two voluntary periods,
followed by mandatory reporting for the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48786
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
reporting period which runs from July 1,
2025 through June 30, 2026, impacting
the FY 2028 payment determination; (9)
Medicare Spending Per Beneficiary
(MSPB) Hospital measure (NQF #2158)
beginning with the FY 2024 payment
determination; and (10) Hospital-Level
Risk-Standardized Complication Rate
(RSCR) Following Elective Primary
THA/TKA (NQF #1550) beginning with
the FY 2024 payment determination. We
are refining two current measures
beginning with the FY 2024 payment
determination: (1) Hospital-Level,
Risk-Standardized Payment Associated
with an Episode-of-Care for Primary
Elective THA/TKA measure; and (2)
Excess Days in Acute Care (EDAC) After
Hospitalization for Acute Myocardial
Infarction (AMI) measure (NQF #2881).
In this FY 2023 IPPS/LTCH PPS final
rule, we acknowledge feedback we
received on the potential future
development and inclusion of two
National Healthcare Safety Network
(NHSN) measures: (1) HealthcareAssociated Clostridioides difficile
Infection Outcome; and (2) HospitalOnset Bacteremia & Fungemia Outcome.
We thank commenters for their
feedback.
We are finalizing changes to current
policies related to eCQMs and hybrid
measures: (1) Modification of the eCQM
reporting and submission requirements
to increase the number of eCQMs to be
reported beginning with the CY 2024
reporting period/FY 2026 payment
determination; (2) removal of the zero
denominator declarations and case
threshold exemption policies for hybrid
measures beginning with the FY 2026
payment determination; (3) adoption of
data submission and reporting
requirements for patient-reported
outcome-based performance measures
(PRO–PMs) beginning with the FY 2026
payment determination; and (4)
modification of the eCQM validation
policy to increase the requirement from
75 percent to 100 percent of requested
medical records, beginning with the FY
2025 payment determination.
With respect to public reporting, we
are establishing a hospital designation
related to maternity care to be publiclyreported on a public-facing website
beginning in Fall 2023. In the FY 2023
IPPS/PPS LTCH PPS proposed rule, we
sought comments on other potential
associated activities regarding this
designation (87 FR 28549 through
28550). Additionally, we sought
comments on ongoing ways we can
advance digital quality measurement
and use of Fast Healthcare
Interoperability Resources (FHIR) (87 FR
28486 through 28489). We thank
commenters for their feedback.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
l. PPS-Exempt Cancer Hospital Quality
Reporting Program
Section 1866(k)(1) of the Act requires,
for purposes of FY 2014 and each
subsequent fiscal year, that a hospital
described in section 1886(d)(1)(B)(v) of
the Act (a PPS-exempt cancer hospital,
or a PCH) submit data in accordance
with section 1866(k)(2) of the Act with
respect to such fiscal year. There is no
financial impact to PCH Medicare
payment if a PCH does not participate.
In this FY 2023 IPPS/LTCH PPS final
rule, we are finalizing our proposal to
adopt a patient safety exception into the
measure removal policy. We are also
finalizing our proposal to begin public
display of the 30-Day Unplanned
Readmissions for Cancer Patients
measure (NQF #3188) (PCH–36). We are
finalizing with modification our
proposal to begin public display of the
Proportion of Patients Who Died from
Cancer Receiving Chemotherapy in the
Last 14 Days of Life measure (NQF
#0210) (PCH–32), the Proportion of
Patients Who Died from Cancer Not
Admitted to Hospice measure (NQF
#0215) (PCH–34), the Proportion of
Patients Who Died from Cancer
Admitted to the ICU in the Last 30 Days
of Life measure (NQF #0213) (PCH–33),
and the Proportion of Patients Who Died
from Cancer Admitted to Hospice for
Less Than Three Days measure (NQF
#0216) (PCH–35). In addition, along
with the Hospital IQR and HAC
Reduction Programs, we respond to
comments received on our request for
comment on the potential adoption of
two digital National Healthcare Safety
Network (NHSN) measures: the NHSN
Healthcare-associated Clostridioides
difficile Infection Outcome measure and
NHSN Hospital-Onset Bacteremia and
Fungemia Outcome measure.
m. Medicare Promoting Interoperability
Program
For CY 2023, we are finalizing several
proposed changes to the Medicare
Promoting Interoperability Program.
Specifically, we are: (1) requiring the
Electronic Prescribing Objective’s Query
of Prescription Drug Monitoring
Program (PDMP) measure while
maintaining the associated points at 10
points beginning with the EHR reporting
period in CY 2023; (2) expanding the
Query of PDMP measure to not only
include Schedule II opioids but also
Schedule III and IV drugs beginning
with the CY 2023 EHR reporting period
and are adding exclusions; (3) adding a
new Health Information Exchange (HIE)
Objective option, the Enabling Exchange
under the Trusted Exchange Framework
and Common Agreement (TEFCA)
PO 00000
Frm 00008
Fmt 4701
Sfmt 4700
measure (requiring a yes/no response),
as an optional alternative to fulfill the
objective, beginning with the CY 2023
EHR reporting period; (4) modifying the
Public Health and Clinical Data
Exchange Objective by adding an
Antibiotic Use and Antibiotic
Resistance (AUR) measure in addition to
the current four required measures
(Syndromic Surveillance Reporting,
Immunization Registry Reporting,
Electronic Case Reporting, and
Electronic Reportable Laboratory Result
Reporting) beginning with the CY 2024
EHR reporting period; (5) consolidating
the current options from three to two
levels of active engagement for the
Public Health and Clinical Data
Exchange Objective, requiring the
reporting of the active engagement
option selected for the measures under
the objective beginning with the CY
2023 EHR reporting period, and
modifying the amount of time spent at
the option 1 level of active engagement
(pre-production and validation) to one
EHR reporting period beginning with
the CY 2024 EHR reporting period; (6)
modifying the scoring methodology for
the Medicare Promoting Interoperability
Program beginning in CY 2023; (7)
instituting public reporting of certain
Medicare Promoting Interoperability
Program data beginning with the CY
2023 EHR reporting period; (8)
removing regulation text for the
objectives and measures in the Medicare
Promoting Interoperability Program
from paragraph (e) under 42 CFR 495.24
and adding new paragraph (f) beginning
in CY 2023; and (9) adopting two new
eCQMs in the Medicare Promoting
Interoperability Program’s eCQM
measure set beginning with the CY 2023
reporting period, two new eCQMs in the
Medicare Promoting Interoperability
Program’s eCQM measure set beginning
with the CY 2024 reporting period, and
modifying the eCQM data reporting and
submission requirements to increase the
number of eCQMs required to be
reported and the total number of eCQMs
to be reported beginning with the CY
2024 reporting period, which is in
alignment with the eCQM updates
finalized for the Hospital IQR Program.
n. Condition of Participation (CoP)
Requirements for Hospitals and CAHs to
Continue Reporting Data for COVID–19
and Influenza After the PHE ends as
Determined by the Secretary
In this final rule, we are revising the
hospital and CAH infection prevention
and control CoP requirements to
continue COVID–19-related reporting
requirements commencing either upon
the conclusion of the current COVID–19
PHE declaration or the effective date of
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
this proposed rule, whichever is later,
and lasting until April 30, 2024 (unless
the Secretary determines an earlier end
date). We have withdrawn our proposal
to establish additional data reporting
requirements to address future PHEs
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
related to epidemics and infectious
diseases.
3. Summary of Costs and Benefits
benefits associated with the major
provisions described in section I.A.3. of
the preamble of this final rule.
The following table provides a
summary of the costs, savings, and
PO 00000
Frm 00009
Fmt 4701
Sfmt 4700
48787
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48788
VerDate Sep<11>2014
Jkt 256001
PO 00000
Medicare DSH Payment Adjustment and
Additional Payment for Uncompensated Care
and Supplemental Payment
Frm 00010
Beginning in FY 2023, we are discontinuing the use of low-income insured days as a proxy for uncompensated
care to determine Factor 3 for Indian Health Service (IHS) and Tribal hospitals and hospitals located in Puerto
Rico. In addition, we are implementing certain methodological changes for calculating Factor 3 for FY 2023 and
subsequent fiscal years. We project that the amount available to distribute as payments for uncompensated care
for FY 2023 will decrease by approximately $318 million, as compared to our estimate of the uncompensated
care payments that will be distributed in FY 2022. The uncompensated care payments have redistributive effects,
based on a hospital's uncompensated care amount relative to the uncompensated care amount for all hospitals that
are projected to be eligible to receive Medicare DSH payments, and the calculated payment amount is not directly
tied to a hospital's number of discharges.
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.000
Description of Costs, Transfers, Savings, and Benefits
Section 414 of the MACRA replaced the single positive adjustment we intended to make in FY 2018 once the
recoupment required by section 631 of the ATRA was complete with a 0.5 percentage point positive adjustment
to the standardized amount of Medicare payments to acute care hospitals for FYs 2018 through 2023. (The FY
2018 adjustment was subsequently adjusted to 0.4588 percentage point by section 15005 of the 21 st Century
Cures Act.) For FY 2023, we are making an adjustment of +0.5 percentage point to the standardized amount
consistent with the MACRA.
For FY 2023, we are updating our estimates of the three factors used to determine uncompensated care payments.
We are continuing to use uninsured estimates produced by OACT as part of the development of the NHEA in
conjunction with more recently available data in the calculation of Factor 2. For FY 2023, we are using the 2
most recent years of audited data on uncompensated care costs from Worksheet S-10 of the FY 2018 cost reports
and the FY 2019 cost reports to calculate Factor 3 in the uncompensated care payment methodology for all
eligible hospitals. In addition, for FY 2024 and subsequent fiscal years, we will calculate Factor 3 for all eligible
hospitals using a 3-year average of the data on uncompensated care costs from Worksheet S-10 for the three most
recent fiscal years for which audited data are available.
Application of the Rural Floor
Because we recognize that discontinuing the use of the low-income insured days proxy to calculate
uncompensated care payments for IHS and Tribal hospitals and hospitals located in Puerto Rico could result in a
significant financial disruption for these hospitals, we are using our exceptions and adjustments authority under
section 1886(d)(5)(T) of the Act to establish a new supplemental payment for THS and Tribal hospitals and
hospitals located in Puerto Rico, beginning in FY 2023. This provision is not budget neutral and we estimate the
impact of the new payment will increase Medicare spending for FY 2023 by approximately $96 million.
Based on the district court's decision in Citrus HMA, LLC, d/b/a Seven Rivers Regional Medical Center v.
Becerra, and the comments we received, as discussed in section 111.G .1. of the preamble of this final rule, we are
not finalizing our rural floor wage index policy as proposed, which would have excluded § 412.103 hospitals
from the calculation of the rural floor and from the calculation of"the wage index for rural areas in the State in
which the county is located" as referred to in section 1886(d)(8)(C)(iii) of the Act. Rather, we are finalizing a
policy that calculates the rural floor as it was calculated before FY 2020. For FY 2023 and subsequent years, we
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
Provision Descri_I!_tion
Adjustment for MS-DRG Documentation and
Coding Changes
khammond on DSKJM1Z7X2PROD with RULES2
VerDate Sep<11>2014
Provision Description
Jkt 256001
PO 00000
Frm 00011
Update to the TPPS Payment Rates and Other
Payment Policies
Fmt 4701
Sfmt 4725
Update to the L TCH PPS Payment Rates and
Other Payment Policies
E:\FR\FM\10AUR2.SGM
Changes to the Hospital Readmissions Reduction
Program
10AUR2
Value-Based Incentive Payments under the
Hospital VBP Program
Changes to the HAC Reduction Program
48789
ER10AU22.001
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
Changes to GME Payments Based on Milton S.
Hershey Medical Center, et al. v. Becerra
Litigation
Description of Costs, Transfers, Savin2s, and Benefits
are finalizing a policy to include the wage data of hospitals that have reclassified from urban to rural under
section 1886(d)(8)(E) of the Act (as implemented in the regulations at§ 412.103) and have no additional form of
reclassification (MGCRB or Lugar) in the calculation of the rural floor, and to include the wage data of such
hospitals in the calculation of "the wage index for rural areas in the State in which the county is located" as
referred to in section 1886(d)(8)(C)(iii) of the Act. The law requires that a national budget neutrality adjustment
be applied in implementing the rural floor.
After reviewing the statutory language regarding the direct GME FTE cap and the court's opinion in Milton S.
Hershey Medical Center, et al. v. Becerra, we are implementing a modified policy to be applied retroactively for
all teaching hospitals, Specifically, effective for cost reporting periods beginning on or after October 1, 2001, we
are specifying that if the hospital's unweighted number of FTE residents exceeds the FTE cap, and the number of
weighted FTE residents also exceeds that FTE cap, the respective primary care and obstetrics and gynecology
weighted FTE counts and other weighted FTE counts are adjusted to make the total weighted FTE count equal the
FTE cap. If the number of weighted FTE residents does not exceed that FTE cap, then the allowable weighted
FTE count for direct GME payment is the actual weighted FTE count. We estimate the impact of this change for
FY 2023 to be approximately $170 million.
As discussed in Appendix A of this final rule, acute care hospitals are estimated to experience an increase of
approximately $1.4 billion in FY 2023, primarily driven by: (1) a combined $2.4 billion increase in FY 2023
operating payments, including supplemental payments for eligible IRS/Tribal hospitals and Puerto Rico hospitals,
as well as changes in uncompensated care payments, and (2) a combined decrease of$ 1.0 billion resulting from
estimated changes in new technology add-on payments (including the expiration of payments for technologies
that were provided a one-year extension in FY 2022), the change to the GME weighting methodology, the
expiration of the temporary changes to the low-volume hospital payment adjustment, and capital payment, as
modeled for this final rule.
As discussed in Appendix A of this final rule, based on the best available data for the 339 LTCHs in our database,
we estimate that the changes to the payment rates and factors that we present in the preamble of and Addendum to
this final rule, which reflect the update to the L TCH PPS standard Federal payment rate for FY 2023, will result
in an estimated increase in payments in FY 2023 of approximately $71 million.
For the FY 2023 program year, MS-DRG reductions in payments are based on a hospital's risk-adjusted
readmission rate during a multi-year period for acute myocardial infarction (AMT), heart failure (HF), chronic
obstructive pulmonary disease (COPD), elective primary total hip arthroplasty/total knee arthroplasty
(THA/TKA), and coronary artery bypass graft (CABG) surgery. Overall, in this rule, we estimate that 2,273
hospitals will have their base operating MS-DRG payments reduced by their determined estimated FY 2023
hospital-specific readmission adjustment. As a result, we estimate that the Hospital Readmissions Reduction
Program would save approximately $320 million in FY 2023.
We estimate that there would be no net financial impact to the Hospital VBP Program for the FY 2023 program
year in the aggregate because, by law, the amount available for value-based incentive payments under the
program in a given year must be equal to the total amount of base operating MS-DRG payment amount
reductions for that year, as estimated by the Secretary. We are finalizing our proposals which will result in
hospitals not receiving a Total Performance Score (TPS) for FY 2023. The estimated amount of base operating
MS-DRG payment amount reductions for the FY 2023 program year and, therefore, the estimated amount
available for value-based incentive payments for FY 2023 discharges is annroximatelv $1.8 billion.
For the FY 2023 program year, we are fmalizing our proposal to suppress all six measures in the HAC Reduction
Program. We are not finalizing our proposal to not calculate or report CMS PSI 90 measure results for the FY
2023 HAC Reduction Program. Although we will not use the calculated scores for the CMS PSI 90 measure
khammond on DSKJM1Z7X2PROD with RULES2
48790
VerDate Sep<11>2014
Jkt 256001
PO 00000
Frm 00012
Changes to the Hospital IQR Program
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.002
Changes to the Medicare Promoting
Interoperability Program
Condition of Participation (CoP) Requirements for
Hospitals and CAHs to Continue Reporting Data
for COVID-19 and Influenza After the PHE ends
as Determined by the Secretary
Description of Costs, Transfers, Savin2s, and Benefits
results to implement the HAC Reduction Program for the program year we will still calculate and report CMS PSI
90 that is displayed on the main pages of the Care Compare tool hosted by HHS after confidentially reporting
these results to hospitals via CMS PSI 90 specific HSRs and a 30-day preview period for the NHSN CDC HAI
measures. Accordingly, for the FY 2023 HAC Reduction Program, no hospital would receive a payment
reduction. As a result, for the FY 2023 program year, we anticipate reductions to the Medicare trust fund that is
otherwise estimated at approximately $350 million.
Across 3,150 IPPS hospitals, we estimate that our finalized changes for the Hospital IQR Program in this final
rule would result in a total information collection burden increase of 746,300 hours associated with our finalized
policies, and updated burden estimates and a total cost increase of approximately $23,437,906 across a 4-year
period from the CY 2023 reporting period/FY 2025 payment determination through the CY 2026 reporting
period/FY 2028 payment determination.
Across 4,500 eligible hospitals and CAHs, we estimate that our finalized changes for the Medicare Promoting
Interoperability Program in this final rule would result in a total information collection burden increase of 5,513
hours associated with our finalized policies, and updated burden estimates and a total cost increase of
approximately $233,730 across a 2-year period from the CY 2023 EHR reporting period through the CY 2024
EHR reporting period.
As detailed in section XII.B.10. of the preamble of this final rule (Collection of Information requirements), we
estimate that our changes to the CoPs, which would require hospitals and CAHs to comply with continued
COVID-19-related reporting provisions, will result in an estimated burden increase of 483,600 hours based on
weekly reporting (52 weeks per year) of the required information by approximately 6,200 hospitals and CAHs
and at an average response time of 1.5 hours for a registered nurse with an average hourly salary of $79. This
would result in an estimated total of $38,204,400 for weekly reporting (or annroximately $6, 162 per facility).
1For the purpose of modeling the estimated FY 2023 payment adjustment factors that account for the suppression of the pneumonia readmission measure for this final rule, we used
the data from the FY 2022 Hospital Readmissions Reduction Program for the five non-suppressed measures (that is, AMI, HF, COPD, THAffKA, and CABG).
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
Provision Description
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
B. Background Summary
1. Acute Care Hospital Inpatient
Prospective Payment System (IPPS)
Section 1886(d) of the Act sets forth
a system of payment for the operating
costs of acute care hospital inpatient
stays under Medicare Part A (Hospital
Insurance) based on prospectively set
rates. Section 1886(g) of the Act requires
the Secretary to use a prospective
payment system (PPS) to pay for the
capital-related costs of inpatient
hospital services for these ‘‘subsection
(d) hospitals.’’ Under these PPSs,
Medicare payment for hospital inpatient
operating and capital-related costs is
made at predetermined, specific rates
for each hospital discharge. Discharges
are classified according to a list of
diagnosis-related groups (DRGs).
The base payment rate is comprised of
a standardized amount that is divided
into a labor-related share and a
nonlabor-related share. The laborrelated share is adjusted by the wage
index applicable to the area where the
hospital is located. If the hospital is
located in Alaska or Hawaii, the
nonlabor-related share is adjusted by a
cost-of-living adjustment factor. This
base payment rate is multiplied by the
DRG relative weight.
If the hospital treats a high percentage
of certain low-income patients, it
receives a percentage add-on payment
applied to the DRG-adjusted base
payment rate. This add-on payment,
known as the disproportionate share
hospital (DSH) adjustment, provides for
a percentage increase in Medicare
payments to hospitals that qualify under
either of two statutory formulas
designed to identify hospitals that serve
a disproportionate share of low-income
patients. For qualifying hospitals, the
amount of this adjustment varies based
on the outcome of the statutory
calculations. The Affordable Care Act
revised the Medicare DSH payment
methodology and provides for a new
additional Medicare payment beginning
on October 1, 2013, that considers the
amount of uncompensated care
furnished by the hospital relative to all
other qualifying hospitals.
If the hospital is training residents in
an approved residency program(s), it
receives a percentage add-on payment
for each case paid under the IPPS,
known as the indirect medical
education (IME) adjustment. This
percentage varies, depending on the
ratio of residents to beds.
Additional payments may be made for
cases that involve new technologies or
medical services that have been
approved for special add-on payments.
In general, to qualify, a new technology
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
or medical service must demonstrate
that it is a substantial clinical
improvement over technologies or
services otherwise available, and that,
absent an add-on payment, it would be
inadequately paid under the regular
DRG payment. In addition, certain
transformative new devices and certain
antimicrobial products may qualify
under an alternative inpatient new
technology add-on payment pathway by
demonstrating that, absent an add-on
payment, they would be inadequately
paid under the regular DRG payment.
The costs incurred by the hospital for
a case are evaluated to determine
whether the hospital is eligible for an
additional payment as an outlier case.
This additional payment is designed to
protect the hospital from large financial
losses due to unusually expensive cases.
Any eligible outlier payment is added to
the DRG-adjusted base payment rate,
plus any DSH, IME, and new technology
or medical service add-on adjustments
and, beginning in FY 2023 for IHS and
Tribal hospitals and hospitals located in
Puerto Rico, the new supplemental
payment.
Although payments to most hospitals
under the IPPS are made on the basis of
the standardized amounts, some
categories of hospitals are paid in whole
or in part based on their hospitalspecific rate, which is determined from
their costs in a base year. For example,
sole community hospitals (SCHs)
receive the higher of a hospital-specific
rate based on their costs in a base year
(the highest of FY 1982, FY 1987, FY
1996, or FY 2006) or the IPPS Federal
rate based on the standardized amount.
SCHs are the sole source of care in their
areas. Specifically, section
1886(d)(5)(D)(iii) of the Act defines an
SCH as a hospital that is located more
than 35 road miles from another
hospital or that, by reason of factors
such as an isolated location, weather
conditions, travel conditions, or absence
of other like hospitals (as determined by
the Secretary), is the sole source of
hospital inpatient services reasonably
available to Medicare beneficiaries. In
addition, certain rural hospitals
previously designated by the Secretary
as essential access community hospitals
are considered SCHs.
Under current law, the Medicaredependent, small rural hospital (MDH)
program is effective through FY 2022.
For discharges occurring on or after
October 1, 2007, but before October 1,
2022, an MDH receives the higher of the
Federal rate or the Federal rate plus 75
percent of the amount by which the
Federal rate is exceeded by the highest
of its FY 1982, FY 1987, or FY 2002
hospital-specific rate. MDHs are a major
PO 00000
Frm 00013
Fmt 4701
Sfmt 4700
48791
source of care for Medicare beneficiaries
in their areas. Section 1886(d)(5)(G)(iv)
of the Act defines an MDH as a hospital
that is located in a rural area (or, as
amended by the Bipartisan Budget Act
of 2018, a hospital located in a State
with no rural area that meets certain
statutory criteria), has not more than
100 beds, is not an SCH, and has a high
percentage of Medicare discharges (not
less than 60 percent of its inpatient days
or discharges in its cost reporting year
beginning in FY 1987 or in two of its
three most recently settled Medicare
cost reporting years). As section 50205
of the Bipartisan Budget Act extended
the MDH program through FY 2022
only, for FY 2023, beginning on October
1, 2022, the MDH program will no
longer be in effect absent a change in
law. Because the MDH program is not
authorized by statute beyond September
30, 2022, beginning October 1, 2022, all
hospitals that previously qualified for
MDH status under section 1886(d)(5)(G)
of the Act will no longer have MDH
status and will be paid based on the
IPPS Federal rate.
Section 1886(g) of the Act requires the
Secretary to pay for the capital-related
costs of inpatient hospital services in
accordance with a prospective payment
system established by the Secretary. The
basic methodology for determining
capital prospective payments is set forth
in our regulations at 42 CFR 412.308
and 412.312. Under the capital IPPS,
payments are adjusted by the same DRG
for the case as they are under the
operating IPPS. Capital IPPS payments
are also adjusted for IME and DSH,
similar to the adjustments made under
the operating IPPS. In addition,
hospitals may receive outlier payments
for those cases that have unusually high
costs.
The existing regulations governing
payments to hospitals under the IPPS
are located in 42 CFR part 412, subparts
A through M.
2. Hospitals and Hospital Units
Excluded From the IPPS
Under section 1886(d)(1)(B) of the
Act, as amended, certain hospitals and
hospital units are excluded from the
IPPS. These hospitals and units are:
Inpatient rehabilitation facility (IRF)
hospitals and units; long-term care
hospitals (LTCHs); psychiatric hospitals
and units; children’s hospitals; cancer
hospitals; extended neoplastic disease
care hospitals, and hospitals located
outside the 50 States, the District of
Columbia, and Puerto Rico (that is,
hospitals located in the U.S. Virgin
Islands, Guam, the Northern Mariana
Islands, and American Samoa).
Religious nonmedical health care
E:\FR\FM\10AUR2.SGM
10AUR2
48792
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
institutions (RNHCIs) are also excluded
from the IPPS. Various sections of the
Balanced Budget Act of 1997 (BBA)
(Pub. L. 105–33), the Medicare,
Medicaid and SCHIP [State Children’s
Health Insurance Program] Balanced
Budget Refinement Act of 1999 (BBRA,
Pub. L. 106–113), and the Medicare,
Medicaid, and SCHIP Benefits
Improvement and Protection Act of
2000 (BIPA, Pub. L. 106–554) provide
for the implementation of PPSs for IRF
hospitals and units, LTCHs, and
psychiatric hospitals and units (referred
to as inpatient psychiatric facilities
(IPFs)). (We note that the annual
updates to the LTCH PPS are included
along with the IPPS annual update in
this document. Updates to the IRF PPS
and IPF PPS are issued as separate
documents.) Children’s hospitals,
cancer hospitals, hospitals located
outside the 50 States, the District of
Columbia, and Puerto Rico (that is,
hospitals located in the U.S. Virgin
Islands, Guam, the Northern Mariana
Islands, and American Samoa), and
RNHCIs continue to be paid solely
under a reasonable cost-based system,
subject to a rate-of-increase ceiling on
inpatient operating costs. Similarly,
extended neoplastic disease care
hospitals are paid on a reasonable cost
basis, subject to a rate-of-increase
ceiling on inpatient operating costs.
The existing regulations governing
payments to excluded hospitals and
hospital units are located in 42 CFR
parts 412 and 413.
3. Long-Term Care Hospital Prospective
Payment System (LTCH PPS)
The Medicare prospective payment
system (PPS) for LTCHs applies to
hospitals described in section
1886(d)(1)(B)(iv) of the Act, effective for
cost reporting periods beginning on or
after October 1, 2002. The LTCH PPS
was established under the authority of
sections 123 of the BBRA and section
307(b) of the BIPA (as codified under
section 1886(m)(1) of the Act). Section
1206(a) of the Pathway for SGR Reform
Act of 2013 (Pub. L. 113–67) established
the site neutral payment rate under the
LTCH PPS, which made the LTCH PPS
a dual rate payment system beginning in
FY 2016. Under this statute, effective for
LTCH’s cost reporting periods beginning
in FY 2016 cost reporting period, LTCHs
are generally paid for discharges at the
site neutral payment rate unless the
discharge meets the patient criteria for
payment at the LTCH PPS standard
Federal payment rate. The existing
regulations governing payment under
the LTCH PPS are located in 42 CFR
part 412, subpart O. Beginning October
1, 2009, we issue the annual updates to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the LTCH PPS in the same documents
that update the IPPS.
4. Critical Access Hospitals (CAHs)
Under sections 1814(l), 1820, and
1834(g) of the Act, payments made to
critical access hospitals (CAHs) (that is,
rural hospitals or facilities that meet
certain statutory requirements) for
inpatient and outpatient services are
generally based on 101 percent of
reasonable cost. Reasonable cost is
determined under the provisions of
section 1861(v) of the Act and existing
regulations under 42 CFR part 413.
5. Payments for Graduate Medical
Education (GME)
Under section 1886(a)(4) of the Act,
costs of approved educational activities
are excluded from the operating costs of
inpatient hospital services. Hospitals
with approved graduate medical
education (GME) programs are paid for
the direct costs of GME in accordance
with section 1886(h) of the Act. The
amount of payment for direct GME costs
for a cost reporting period is based on
the hospital’s number of residents in
that period and the hospital’s costs per
resident in a base year. The existing
regulations governing payments to the
various types of hospitals are located in
42 CFR part 413.
C. Summary of Provisions of Recent
Legislation Implemented in This Final
Rule
1. The Medicare Access and CHIP
Reauthorization Act of 2015 (Pub. L.
114–10)
Section 414 of the Medicare Access
and CHIP Reauthorization Act of 2015
(MACRA, Pub. L. 114–10) specifies a 0.5
percent positive adjustment to the
standardized amount of Medicare
payments to acute care hospitals for FYs
2018 through 2023. These adjustments
follow the recoupment adjustment to
the standardized amounts under section
1886(d) of the Act based upon the
Secretary’s estimates for discharges
occurring from FYs 2014 through 2017
to fully offset $11 billion, in accordance
with section 631 of the ATRA. The FY
2018 adjustment was subsequently
adjusted to 0.4588 percent by section
15005 of the 21st Century Cures Act.
D. Issuance of Proposed Rulemaking
In the FY 2023 IPPS/LTCH PPS
proposed rule appearing in the May 10,
2022 Federal Register (87 FR 28108), we
set forth proposed payment and policy
changes to the Medicare IPPS for FY
2023 operating costs and capital-related
costs of acute care hospitals and certain
hospitals and hospital units that are
excluded from IPPS. In addition, we set
PO 00000
Frm 00014
Fmt 4701
Sfmt 4700
forth proposed changes to the payment
rates, factors, and other payment and
policy-related changes to programs
associated with payment rate policies
under the LTCH PPS for FY 2023.
The following is a general summary of
the changes that we proposed to make.
1. Proposed Changes to MS–DRG
Classifications and Recalibrations of
Relative Weights
In section II. of the preamble of the
proposed rule, we include the
following:
• Proposed changes to MS–DRG
classifications based on our yearly
review for FY 2023.
• Proposed adjustment to the
standardized amounts under section
1886(d) of the Act for FY 2023 in
accordance with the amendments made
to section 7(b)(1)(B) of Public Law 110–
90 by section 414 of the MACRA.
• Proposed recalibration of the MS–
DRG relative weights, including a
proposed 10-percent cap on decreases in
an MS–DRG relative weight from one
fiscal year to the next.
• A discussion of the proposed FY
2023 status of new technologies
approved for add-on payments for FY
2022, a presentation of our evaluation
and analysis of the FY 2023 applicants
for add-on payments for high-cost new
medical services and technologies
(including public input, as directed by
Pub. L. 108–173, obtained in a town hall
meeting) for applications not submitted
under an alternative pathway, and a
discussion of the proposed status of FY
2023 new technology applicants under
the alternative pathways for certain
medical devices and certain
antimicrobial products.
• A proposal to use National Drug
Codes (NDCs) to identify cases
involving use of therapeutic agents
approved for new technology add-on
payments.
• A proposal to publicly post online
future applications for new technology
add-on payments. Specifically,
beginning with the FY 2024 application
cycle, we proposed to post online the
completed application forms and certain
related materials and updated
application information submitted
subsequent to the initial application
submission for new technology add-on
payments, with the exception of certain
cost and volume information and
certain additional materials (as
discussed more fully in section II.F.9. of
the proposed rule), no later than the
issuance of the proposed rule.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
2. Proposed Changes to the Hospital
Wage Index for Acute Care Hospitals
In section III. of the preamble of the
proposed rule, we proposed to make
revisions to the wage index for acute
care hospitals and the annual update of
the wage data. Specific issues addressed
include, but were not limited to, the
following:
• The proposed FY 2023 wage index
update using wage data from cost
reporting periods beginning in FY 2019.
• Calculation, analysis, and
implementation of the proposed
occupational mix adjustment to the
wage index for acute care hospitals for
FY 2023 based on the 2019
Occupational Mix Survey.
• Proposed application of the rural,
imputed and frontier State floors, and
continuation of the low wage index
hospital policy.
• Proposed revisions to the wage
index for acute care hospitals, based on
hospital redesignations and
reclassifications under sections
1886(d)(8)(B), (d)(8)(E), and (d)(10) of
the Act.
• Proposed adjustment to the wage
index for acute care hospitals for FY
2023 based on commuting patterns of
hospital employees who reside in a
county and work in a different area with
a higher wage index.
• Proposed permanent cap on annual
wage index decreases.
• Proposed labor-related share for the
proposed FY 2023 wage index.
khammond on DSKJM1Z7X2PROD with RULES2
3. Other Decisions and Proposed
Changes to the IPPS for Operating Costs
In section V. of the preamble of the
proposed rule, we discuss proposed
changes or clarifications of a number of
the provisions of the regulations in 42
CFR parts 412 and 413, including the
following:
• Proposed inpatient hospital update
for FY 2023.
• Proposed updated national and
regional case-mix values and discharges
for purposes of determining RRC status.
• Proposed payment adjustment for
low-volume hospitals for FY 2023 and
subsequent years.
• The statutorily required IME
adjustment factor for FY 2023.
• Proposed changes to the
methodologies for determining
Medicare DSH payments and the
additional payments for uncompensated
care.
• Proposed new supplemental
payment for IHS/Tribal and Puerto Rico
hospitals.
• Proposed revisions to the
regulations regarding the counting of
days associated with section 1115
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
demonstrations in the Medicaid
fraction.
• Discussion of statutory expiration of
the MDH program at the end of FY 2022.
• Proposed requirements for payment
adjustments under the Hospital
Readmissions Reduction Program for FY
2023.
• The provision of estimated and
newly established performance
standards for the calculation of valuebased incentive payments, as well as a
proposal to suppress multiple measures
and provide net-neutral payment
adjustments under the Hospital ValueBased Purchasing Program.
• Proposed requirements for payment
adjustments to hospitals under the HAC
Reduction Program for FY 2023.
• Discussion of and proposed changes
relating to the implementation of the
Rural Community Hospital
Demonstration Program in FY 2023.
• Proposed GME payment change in
response to Milton S. Hershey Medical
Center et al v. Becerra litigation.
• Proposed nursing and allied health
education program Medicare Advantage
(MA) add-on rates and direct GME MA
percent reductions for CYs 2020 and
2021.
• Proposal to allow Medicare GME
affiliation agreements within certain
rural track full-time equivalent
limitations.
• Proposed payment adjustment for
certain clinical trial and expanded
access use immunotherapy cases.
4. Proposed FY 2023 Policy Governing
the IPPS for Capital-Related Costs
In section VI. of the preamble to the
proposed rule, we discussed the
proposed payment policy requirements
for capital-related costs and capital
payments to hospitals for FY 2023.
5. Proposed Changes to the Payment
Rates for Certain Excluded Hospitals:
Rate-of-Increase Percentages
In section VII. of the preamble of the
proposed rule, we discussed the
following:
• Proposed changes to payments to
certain excluded hospitals for FY 2023.
• Proposed continued
implementation of the Frontier
Community Health Integration Project
(FCHIP) Demonstration.
6. Proposed Changes to the LTCH PPS
In section VIII. of the preamble of the
proposed rule, we set forth proposed
changes to the LTCH PPS Federal
payment rates, factors, and other
payment rate policies under the LTCH
PPS for FY 2023.
PO 00000
Frm 00015
Fmt 4701
Sfmt 4700
48793
7. Proposed Changes Relating to Quality
Data Reporting for Specific Providers
and Suppliers
In section IX. of the preamble of the
proposed rule, we addressed the
following:
• Proposed requirements for the
Hospital Inpatient Quality Reporting
(IQR) Program.
• Proposed changes to the
requirements for the quality reporting
program for PPS-exempt cancer
hospitals (PCHQR Program).
• For the Long Term Care Hospital
Quality Reporting Program (LTCH QRP),
we requested information on CMS’
overarching principles for measuring
healthcare disparities across CMS
Quality Programs, including the LTCH
QRP. We also requested information on
the potential adoption of one future
National Healthcare Safety Network
(NHSN) digital quality measure (dQM)
for the LTCH QRP, as well as quality
measure concepts under consideration
for future years.
• Proposed changes to requirements
pertaining to eligible hospitals and
CAHs participating in the Medicare
Promoting Interoperability Program.
8. Other Proposals and Comment
Solicitations Included in the Proposed
Rule
Section X. of the preamble to the
proposed rule includes the following:
• Proposed codification of policies
related to the costs incurred for
qualified and non-qualified deferred
compensation plans.
• Proposed changes pertaining to the
CoPs at 42 CFR part 482 for hospitals,
and at 42 CFR part 485, subpart F, for
CAHs.
• Solicitation of comments on the
appropriateness of payment adjustments
that would account for the additional
resource costs for hospitals for the
procurement of wholly domestically
made NIOSH-approved surgical N95
respirators.
9. Other Provisions of the Proposed Rule
Section XI. of the preamble to the
proposed rule includes our discussion
of the MedPAC Recommendations.
Section XII. of the preamble to the
proposed rule included the following:
• A descriptive listing of the public
use files associated with the proposed
rule.
• The collection of information
requirements for entities based on our
proposals.
• Information regarding our responses
to public comments.
E:\FR\FM\10AUR2.SGM
10AUR2
48794
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
10. Determining Prospective Payment
Operating and Capital Rates and Rate-ofIncrease Limits for Acute Care Hospitals
In sections II. and III. of the
Addendum to the proposed rule, we set
forth proposed changes to the amounts
and factors for determining the
proposed FY 2023 prospective payment
rates for operating costs and capitalrelated costs for acute care hospitals. We
proposed to establish the threshold
amounts for outlier cases. In addition, in
section IV. of the Addendum to the
proposed rule, we addressed the
proposed update factors for determining
the rate-of-increase limits for cost
reporting periods beginning in FY 2023
for certain hospitals excluded from the
IPPS.
11. Determining Prospective Payment
Rates for LTCHs
In section V. of the Addendum to the
proposed rule, we set forth proposed
changes to the amounts and factors for
determining the proposed FY 2023
LTCH PPS standard Federal payment
rate and other factors used to determine
LTCH PPS payments under both the
LTCH PPS standard Federal payment
rate and the site neutral payment rate in
FY 2023. We are proposed to establish
the adjustments for the wage index,
labor-related share, the cost-of-living
adjustment, and high-cost outliers,
including the applicable fixed-loss
amounts and the LTCH cost-to-charge
ratios (CCRs) for both payment rates.
12. Impact Analysis
In Appendix A of the proposed rule,
we set forth an analysis of the impact
the proposed changes would have on
affected acute care hospitals, CAHs,
LTCHs and other entities.
khammond on DSKJM1Z7X2PROD with RULES2
13. Recommendation of Update Factors
for Operating Cost Rates of Payment for
Hospital Inpatient Services
In Appendix B of the proposed rule,
as required by sections 1886(e)(4) and
(e)(5) of the Act, we provided our
recommendations of the appropriate
percentage changes for FY 2023 for the
following:
• A single average standardized
amount for all areas for hospital
inpatient services paid under the IPPS
for operating costs of acute care
hospitals (and hospital-specific rates
applicable to SCHs and MDHs).
• Target rate-of-increase limits to the
allowable operating costs of hospital
inpatient services furnished by certain
hospitals excluded from the IPPS.
• The LTCH PPS standard Federal
payment rate and the site neutral
payment rate for hospital inpatient
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
services provided for LTCH PPS
discharges.
14. Discussion of Medicare Payment
Advisory Commission
Recommendations
Under section 1805(b) of the Act,
MedPAC is required to submit a report
to Congress, no later than March 15 of
each year, in which MedPAC reviews
and makes recommendations on
Medicare payment policies. MedPAC’s
March 2022 recommendations
concerning hospital inpatient payment
policies address the update factor for
hospital inpatient operating costs and
capital-related costs for hospitals under
the IPPS. We addressed these
recommendations in Appendix B of the
proposed rule. For further information
relating specifically to the MedPAC
March 2022 report or to obtain a copy
of the report, contact MedPAC at (202)
220–3700 or visit MedPAC’s website at
https://www.medpac.gov.
E. Advancing Health Information
Exchange
The Department of Health and Human
Services (HHS) has a number of
initiatives designed to encourage and
support the adoption of interoperable
health information technology and to
promote nationwide health information
exchange to improve health care and
patient access to their digital health
information.
To further interoperability in postacute care settings, CMS and the Office
of the National Coordinator for Health
Information Technology (ONC)
participate in the Post-Acute Care
Interoperability Workgroup (PACIO) to
facilitate collaboration with industry
stakeholders to develop Health Level
Seven International® (HL7) Fast
Healthcare Interoperability Resources®
(FHIR) standards. These standards could
support the exchange and reuse of
patient assessment data derived from
the post-acute care (PAC) setting
assessment tools, such as Minimum
Data Set (MDS), Inpatient Rehabilitation
Facility-Patient Assessment Instrument
(IRF–PAI), Long Term Care Hospital
(LTCH) Continuity Assessment Record
and Evaluation (CARE) Data Set (LCDS),
Outcome and Assessment Information
Set (OASIS), and other sources.3 4 The
PACIO Project has focused on HL7 FHIR
implementation guides for functional
status, cognitive status and new use
cases on advance directives, reassessment timepoints, and Speech,
3 HL7 FHIR Release 4. Available at: https://
www.hl7.org/fhir/.
4 HL7 FHIR. PACIO Functional Status
Implementation Guide. Available at: https://
paciowg.github.io/functional-status-ig/.
PO 00000
Frm 00016
Fmt 4701
Sfmt 4700
Language, Swallowing Cognitive
communications and Hearing
(SPLASCH).5 We encourage PAC
provider and health information
technology (IT) vendor participation as
the efforts advance. The CMS Data
Element Library (DEL) continues to be
updated and serves as a resource for
PAC assessment data elements and their
associated mappings to health IT
standards, such as Logical Observation
Identifiers Names and Codes (LOINC)
and Systematized Nomenclature of
Medicine Clinical Terms (SNOMED).6
The DEL furthers CMS’ goal of data
standardization and interoperability.
Standards in the DEL can be referenced
on the CMS website (https://
del.cms.gov/DELWeb/pubHome) and in
the ONC Interoperability Standards
Advisory (ISA). The 2022 ISA is
available at https://www.healthit.gov/
isa/sites/isa/files/inline-files/2022-ISAReference-Edition.pdf.
The 21st Century Cures Act (Cures
Act) (Pub. L. 114–255, enacted
December 13, 2016) required HHS and
ONC to take steps further
interoperability for providers in settings
across the care continuum.7
Specifically, section 4003(b) of the
Cures Act required ONC to take steps to
advance interoperability through the
development of a a Trusted Exchange
Framework and Common Agreement
aimed at establishing full network-tonetwork exchange of health information
nationally. On January 18, 2022, ONC
announced a significant milestone by
releasing the Trusted Exchange
Framework 8 and Common Agreement
Version 1.9 The Trusted Exchange
Framework is a set of non-binding
principles for health information
exchange, and the Common Agreement
is a contract that advances those
principles. The Common Agreement
and the incorporated by reference
Qualified Health Information Network
Technical Framework Version 1
establish the technical infrastructure
5 PACIO Project. Available at: https://
pacioproject.org/about/.
6 CMS Data Element Library Fact Sheet. Available
at: https://www.cms.gov/newsroom/fact-sheets/cmsdata-element-library-fact-sheet.
7 Public Law 114–255, sections 4001 through
4008. Available at: https://www.govinfo.gov/
content/pkg/PLAW-114publ255/html/PLAW114publ255.htm.
8 The Trusted Exchange Framework (TEF):
Principles for Trusted Exchange (Jan. 2022).
Available at: https://www.healthit.gov/sites/default/
files/page/2022-01/Trusted_Exchange_Framework_
0122.pdf.
9 Common Agreement for Nationwide Health
Information Interoperability Version 1 (Jan. 2022).
Available at: https://www.healthit.gov/sites/default/
files/page/2022-01/Common_Agreement_for_
Nationwide_Health_Information_Interoperability_
Version_1.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
F. Use of FY 2021 Data and
Methodology Modifications for the FY
2023 IPPS and LTCH PPS Ratesetting
We primarily use two data sources in
the IPPS and LTCH PPS ratesetting:
claims data and cost report data. The
claims data source is the MedPAR file,
which includes fully coded diagnostic
and procedure data for all Medicare
inpatient hospital bills for discharges in
a fiscal year. The cost report data source
is the Medicare hospital cost report data
files from the most recent quarterly
Healthcare Cost Report Information
System (HCRIS) release. Our goal is
always to use the best available data
overall for ratesetting. Ordinarily, the
best available MedPAR data is the most
recent MedPAR file that contains claims
from discharges for the fiscal year that
is 2 years prior to the fiscal year that is
the subject of the rulemaking.
Ordinarily, the best available cost report
data is based on the cost reports
beginning 3 fiscal years prior to the
fiscal year that is the subject of the
rulemaking. However, in the FY 2022
IPPS/LTCH PPS final rule (86 FR 44789
through 44793), as discussed in more
detail below, we finalized our proposal
to use FY 2019 data for the FY 2022
ratesetting for circumstances where the
FY 2020 data (the most recently
available data at the time of rulemaking)
was significantly impacted by the
COVID–19 PHE.
As we discussed in the FY 2022 IPPS/
LTCH PPS final rule, the FY 2020
MedPAR claims file and the FY 2019
HCRIS dataset both contained data that
was significantly impacted by the
COVID–19 PHE, primarily in that the
utilization of services at IPPS hospitals
and LTCHs was generally markedly
different for certain types of services in
FY 2020 than would have been expected
in the absence of the PHE. However, the
most recent vaccination and
hospitalization data from the CDC at the
time of development of that rule
supported our belief at the time that the
risk of COVID–19 in FY 2022 would be
significantly lower than the risk of
COVID–19 in FY 2020 and there would
be fewer COVID–19 hospitalizations for
Medicare beneficiaries in FY 2022 than
there were in FY 2020. Therefore, we
finalized our proposal to use FY 2019
data for the FY 2022 ratesetting for
circumstances where the FY 2020 data
was significantly impacted by the
COVID–19 PHE, based on the belief that
FY 2019 data from before the COVID–
19 PHE would be a better overall
approximation of the FY 2022 inpatient
experience at both IPPS hospitals and
LTCHs. For example, we used the FY
2019 MedPAR claims data for purposes
where we ordinarily would have used
the FY 2020 MedPAR claims data. We
also used cost report data from the FY
2018 HCRIS file for purposes where we
ordinarily would have used the FY 2019
HCRIS file (since the FY 2019 cost
report data from HCRIS contained many
cost reports ending in FY 2020 based on
each hospital’s cost reporting period).
Similar to our analysis of the FY 2020
MedPAR claims file and the FY 2019
HCRIS dataset for the FY 2022 IPPS/
LTCH PPS rulemaking, in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28123 through 28125) we discussed that
the FY 2021 MedPAR claims file and
the FY 2020 HCRIS dataset also both
contain data that was significantly
impacted by the virus that causes
COVID–19, primarily in that the
utilization of services at IPPS hospitals
and LTCHs was again generally
markedly different for certain types of
services in FY 2021 than would have
been expected in the absence of the
virus that causes COVID–19.
Specifically, the share of admissions at
IPPS hospitals and LTCHs for MS–DRGs
and MS–LTC–DRGs associated with the
treatment of COVID–19 continued to
remain significantly higher than levels
prior to the COVID–19 PHE. For
example, in FY 2019, the share of IPPS
cases and LTCH PPS standard Federal
payment rate cases grouped to MS–DRG
and MS–LTC–DRG 177 (Respiratory
infections and inflammations with
MCC) was approximately 1 percent and
2 percent, respectively. In comparison,
in FY 2021, the share of IPPS cases and
LTCH PPS standard Federal payment
rate cases grouped to MS–DRG 177 was
approximately 6 percent and 8 percent,
respectively.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28123 through
28124), we reviewed the most recent
data from the CDC on new inpatient
hospital admissions of patients with
confirmed COVID–19. We presented
this CDC graph which illustrates new
inpatient hospital admissions of
patients with confirmed COVID–19 from
August 1, 2020 through February 15,
2022 (https://www.cdc.gov/coronavirus/
2019-ncov/covid-data/covidview/
02182022/images/hospitalizations_
02182022.jpg?_=35767, accessed
February 22, 2022).
10 The Common Agreement defines Individual
Access Services (IAS) as ‘‘with respect to the
Exchange Purposes definition, the services
provided utilizing the Connectivity Services, to the
extent consistent with Applicable Law, to an
Individual with whom the QHIN, Participant, or
Subparticipant has a Direct Relationship to satisfy
that Individual’s ability to access, inspect, or obtain
a copy of that Individual’s Required Information
that is then maintained by or for any QHIN,
Participant, or Subparticipant.’’ The Common
Agreement defines ‘‘IAS Provider’’ as: ‘‘Each QHIN,
Participant, and Subparticipant that offers
Individual Access Services.’’ See Common
Agreement for Nationwide Health Information
Interoperability Version 1, at 7 (Jan. 2022), https://
www.healthit.gov/sites/default/files/page/2022-01/
Common_Agreement_for_Nationwide_Health_
Information_Interoperability_Version_1.pdf.
model and governing approach for
different health information networks
and their users to securely share clinical
information with each other, all under
commonly agreed to terms. The
technical and policy architecture of how
exchange occurs under the Common
Agreement follows a network-ofnetworks structure, which allows for
connections at different levels and is
inclusive of many different types of
entities at those different levels, such as
health information networks, healthcare
practices, hospitals, public health
agencies, and Individual Access
Services (IAS) Providers.10 For more
information, we refer readers to https://
www.healthit.gov/topic/interoperability/
trusted-exchange-framework-andcommon-agreement.
We invite providers to learn more
about these important developments
and how they are likely to affect LTCHs.
Comment: A commenter expressed
support for efforts across HHS to
advance health information technology
exchange and encouraged use of a
standard set of data by providers and
health IT vendors, including efforts
through the PACIO project. The
commenter also noted a recent National
Academies report describing technology
barriers for PAC settings due to not
being eligible for previous incentives to
purchase technology certified under the
ONC Health IT Certification Program.
The commenter supported
recommendations in the report for HHS
to pursue financial incentives for postacute care settings to adopt certified
health information technology in order
to enable health information exchange.
Response: We will take this comment
into consideration as we coordinate
with Federal partners, including ONC,
on interoperability initiatives, and to
inform future rulemaking.
khammond on DSKJM1Z7X2PROD with RULES2
48795
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00017
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
48796
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
en
,;t
0
-
~· 20,(lOO
-0
QI
E
2014
00:20 Aug 10, 2022
Jkt 256001
Apr2021
Jan2021
Jul2021
in hospitalizations (see https://
www.cdc.gov/coronavirus/2019-ncov/
variants/about-variants.html, accessed
February 25, 2022).
Given the effects of the virus that
causes COVID–19 in the Medicare FY
2020 data, the Medicare FY 2021 data,
and the CDC hospitalization data,
coupled with the expectation for future
variants, in the proposed rule we stated
our belief that it is reasonable to assume
that some Medicare beneficiaries will
continue to be hospitalized with
COVID–19 at IPPS hospitals and LTCHs
in FY 2023. Accordingly, we stated that
we believe it would be appropriate to
use FY 2021 data, specifically the FY
2021 MedPAR claims file and the FY
2020 HCRIS dataset (which contains
data from many cost reports ending in
FY 2021 based on each hospital’s cost
reporting period) as the most recent
available data during the period of the
COVID–19 PHE, for purposes of the FY
2023 IPPS and LTCH PPS ratesetting.
However, we also stated our belief that
it would be reasonable to assume based
on the information available at the time
that there will be fewer COVID–19
hospitalizations in FY 2023 than in FY
2021 given the more recent trends in the
CDC hospitalization data since the
Omicron variant peak in January, 2022.
Accordingly, because we anticipated
Medicare inpatient hospitalizations for
COVID–19 would continue in FY 2023
but at a lower level, we proposed to use
FY 2021 data for purposes of the FY
2023 IPPS and LTCH PPS ratesetting but
with modifications to our usual
ratesetting methodologies to account for
the anticipated decline in COVID–19
hospitalizations of Medicare
beneficiaries at IPPS hospitals and
LTCHs as compared to FY 2021.
First, we proposed to modify the
calculation of the FY 2023 MS–DRG and
MS–LTC–DRG relative weights. We
PO 00000
Frm 00018
Fmt 4701
Sfmt 4700
Oct202l
Jan2022
observed that COVID–19 cases were
impacting the relative weights as
calculated using the FY 2021 MedPAR
data for a few COVID–19-related MS–
DRGs and MS–LTC–DRGs. As an
example, for MS–DRG and MS–LTC–
DRG 870 (Septicemia or Severe Sepsis
with MV >96 hours), the MS–DRG and
MS–LTC–DRG relative weights
calculated using the FY 2021 MedPAR
data are approximately 9 and 3 percent
higher, respectively, compared to their
relative weights if calculated excluding
COVID–19 cases. Because this MS–DRG
contains a mix of COVID–19 cases and
non-COVID–19 cases with different
average costs, the relative weight for this
MS–DRG is dependent on that mix of
cases. As stated in the proposed rule, we
believed it is reasonable to assume that
there would be fewer COVID–19
hospitalizations among Medicare
beneficiaries in FY 2023 than there were
in FY 2021; however, we also stated that
it is not possible to know precisely how
COVID–19 hospitalizations in FY 2023
will compare to FY 2021. We stated our
belief that averaging the relative weights
as calculated with and without the
COVID–19 cases reflected in the FY
2021 MedPAR data would reflect a
reasonable estimation of the case mix
for FY 2023 based on the information
available at the time, and more
accurately estimate the relative resource
use for the cases treated in FY 2023.
Therefore, we proposed to calculate the
relative weights for FY 2023 by first
calculating two sets of weights, one
including and one excluding COVID–19
claims, and then averaging the two sets
of relative weights to determine the
proposed FY 2023 relative weight
values. We believed this proposed
modification to our relative weight
setting methodology would
appropriately reduce, but not remove
entirely, the effect of COVID–19 cases
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.003
khammond on DSKJM1Z7X2PROD with RULES2
Oct2020
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
on the relative weight calculations,
consistent with our expectation that
Medicare inpatient hospitalizations for
COVID–19 will continue in FY 2023 at
a lower level as compared to FY 2021,
and provide a more accurate estimate of
relative resource use for FY 2023 than
if we were to calculate the proposed
relative weights using all applicable
cases in the FY 2021 data.
We also proposed to modify our
methodologies for determining the FY
2023 outlier fixed-loss amount for IPPS
cases and LTCH PPS standard Federal
payment rate cases. The methodologies
for determining both of these outlier
fixed-loss amounts include calculating
and applying a charge inflation factor to
increase charges from the claim year to
the rulemaking year, as well as
calculating and applying cost-to-charge
ratio (CCR) adjustment factors to adjust
CCRs used to make payments in the
current year to the rulemaking year. The
charge inflation factors calculated using
the 2 most recently available years of
MedPAR claims data (FY 2020 and FY
2021) that would ordinarily be used for
the FY 2023 proposed rule to inflate the
charges on the FY 2021 MedPAR claims
were abnormally high as compared to
recent historical levels prior to the PHE
(for example, for the IPPS,
approximately 10 percent based on the
FY 2020 and FY 2021 MedPAR claims
data as compared to approximately 6
percent based on the FY 2018 and FY
2019 MedPAR claims data).
Furthermore, the IPPS operating and
capital CCR adjustment factors
calculated based on the percentage
changes in the CCRs from the December
2020 update of the Provider Specific
File (PSF) to the December 2021 update
of the PSF that would ordinarily be used
for the FY 2023 proposed rule to adjust
the CCRs from the December 2021
update of the PSF were also abnormally
high as compared to recent historical
levels prior to the PHE (for example, for
the IPPS operating CCR adjustment
factor, a factor of approximately 1.03
based on the December 2020 and
December 2021 updates to the PSF as
compared to a factor of approximately
0.97 based on the March 2019 and
March 2020 updates to the PSF). In the
proposed rule, we stated our belief that
these abnormally high charge inflation
and CCR adjustment factors as
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
compared to historical levels were
partially due to the high number of
COVID–19 cases with higher charges
that were treated in IPPS hospitals and
LTCHs in FY 2021. We also stated our
belief that there will be fewer COVID–
19 cases in FY 2023 than in FY 2021
and that therefore, we do not believe it
is reasonable to assume charges and
CCRs will continue to increase at these
abnormally high rates. Consequently,
when determining the FY 2023 outlier
fixed-loss amounts for IPPS cases and
LTCH PPS standard Federal payment
rate cases, we proposed to inflate the
charges on the FY 2021 MedPAR claims
using charge inflation factors computed
by comparing the average covered
charge per case in the March 2019
MedPAR file of FY 2018 to the average
covered charge per case in the March
2020 MedPAR file of FY 2019, which is
the last 1-year period prior to the
COVID–19 PHE. We also proposed to
adjust the CCRs from the December
2021 update of the PSF by comparing
the percentage change in the national
average case-weighted CCR from the
March 2019 update of the PSF to the
national average case-weighted CCR
from the March 2020 update of the PSF,
which is the last 1-year period prior to
the COVID–19 PHE. We stated our belief
that using the charge inflation factors
and CCR adjustment factors derived
from data prior to the COVID–19 PHE
would provide a more reasonable
approximation of the increase in costs
that will occur from FY 2021 to FY 2023
because we do not believe the charge
inflation that has occurred during the
PHE will continue as the number of
higher cost COVID–19 cases declines.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28740 through
28741) we also requested comments on,
as an alternative to our proposed
approach, the use of the FY 2021 data
for purposes of FY 2023 ratesetting
without these proposed modifications to
our usual methodologies for the
calculation of the FY 2023 MS–DRG and
MS–LTC–DRG relative weights or the
usual methodologies used to determine
the FY 2023 outlier fixed-loss amount
for IPPS cases and LTCH PPS standard
Federal payment rate cases. We noted
that the FY 2023 outlier fixed-loss
amount would be significantly higher
under this alternative approach. In order
PO 00000
Frm 00019
Fmt 4701
Sfmt 4700
48797
to illustrate the effect of our proposed
modifications on the relative weights
and fixed loss amount, we made
available supplemental information,
including the relative weights and fixedloss amount calculated without the
proposed modifications to our usual
methodologies.
The comments we received on our
proposal to use FY 2021 data for
purposes of the FY 2023 IPPS and LTCH
PPS ratesetting were focused on the
specific use of FY 2021 data when
determining the FY 2023 relative
weights or outlier fixed-loss amounts.
Therefore, we refer the reader to section
II.E. of the preamble of this final rule for
our summary and response to comments
received on our proposed use of FY
2021 data and our proposed
modifications to our usual methodology
when determining the FY 2023 IPPS
MS–DRG relative weights. We refer the
reader to section VIII.B. of the preamble
of this final rule for our summary and
response to comments received on our
proposed use of FY 2021 data and our
proposed modifications to our usual
methodology when determining the FY
2023 LTCH PPS MS–LTC–DRG relative
weights. We refer the reader to section
II.A.4. of the addendum to this final rule
for our summary and response to
comments received on our proposed use
of FY 2021 data and our proposed
modifications to our usual methodology
when determining the FY 2023 outlier
fixed-loss amounts for IPPS cases. We
refer the reader to section V.D.3. of the
Addendum to this final rule for our
summary and response to comments
received on our proposed use of FY
2021 data and our proposed
modifications to our usual methodology
when determining the FY 2023 outlier
fixed-loss amounts for LTCH PPS
standard Federal payment rate cases.
Since the publication of the proposed
rule, we have continued to monitor
hospitalization data reported by the
CDC. This CDC graph illustrates new
inpatient hospital admissions of
patients with confirmed COVID–19 from
August 1, 2020 through July 6, 2022
(https://www.cdc.gov/coronavirus/2019ncov/covid-data/covidview/07082022/
images/Hospitalizations.png?_=90548,
accessed July 08, 2022).
E:\FR\FM\10AUR2.SGM
10AUR2
48798
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
m
6
25K
25.000
~
20K
£
j
15,000
ll
C
i
.6
0
10,000
1i
E
~
SK
5,000
j
0
Ocl:2020
Jan2021
Apr2021
Juf 2021
Ocl:2021
Jan2022
Apr2022
The graph shows that new COVID–19
hospital admissions reached a low point
in early April 2022, however have
steadily increased since.
After reviewing the latest CDC
hospitalization data, coupled with the
expectation for future variants,12 we
continue to believe that it is reasonable
to assume that some Medicare
beneficiaries will continue to be
hospitalized with COVID–19 at IPPS
hospitals and LTCHs in FY 2023. We
also continue to believe that it would be
reasonable to assume based on the
information available at this time that
there will be fewer COVID–19
hospitalizations in FY 2023 than in FY
2021 given that the current levels of
hospitalizations are much lower than
the Omicron variant peak in January
2022.
Therefore, after considering the
comments received and based on our
evaluation of the information available
at this time, we are finalizing our
proposal to use FY 2021 data for
purposes of the FY 2023 IPPS and LTCH
PPS ratesetting. (That is, the FY 2021
MedPAR claims file and the FY 2020
HCRIS dataset (which contains data
from many cost reports ending in FY
2021 based on each hospital’s cost
reporting period).) We are also
finalizing, as proposed, modifications to
our usual methodology for determining
the FY 2023 IPPS MS–DRG relative
weights and FY 2023 LTCH PPS MS–
LTC–DRG relative weights. Specifically,
for FY 2023, we calculated the relative
weights by first calculating two sets of
weights, one including and one
excluding COVID–19 claims, and then
averaging the two sets of relative
weights to determine the final relative
weight values. The finalization of our
12 https://www.cdc.gov/coronavirus/2019-ncov/
variants/about-variants.html.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
proposal to use FY 2021 data and to
modify our methodology for
determining the FY 2023 IPPS MS–DRG
relative weights is discussed in greater
detail in section II.E. of the preamble of
this final rule. The finalization of our
proposal to use FY 2021 data and to
modify our methodology for
determining the FY 2023 LTCH PPS
MS–LTC–DRG relative weights is
discussed in greater detail in section
VIII.B. of the preamble of this final rule.
As discussed in section II.A.4. and
section V.D.3. of the addendum to this
final rule, we received many comments
supportive of our proposed
modifications to our usual
methodologies for determining the FY
2023 IPPS and LTCH PPS outlier fixedloss amounts. As discussed in these
sections, after considering comments
received, we are finalizing our proposal
to inflate the charges on the FY 2021
MedPAR claims using charge inflation
factors computed by comparing the
average covered charge per case in the
March 2019 MedPAR file of FY 2018 to
the average covered charge per case in
the March 2020 MedPAR file of FY
2019, which is the last 1-year period
prior to the COVID–19 PHE. We are also
finalizing our proposal to adjust the
CCRs from the March 2021 update of the
PSF by comparing the percentage
change in the national average caseweighted CCR from the March 2019
update of the PSF to the national
average case-weighted CCR from the
March 2020 update of the PSF, which is
the last 1-year period prior to the
COVID–19 PHE.
We also received many comments that
suggested other modifications CMS
should make to our usual methodologies
for determining the FY 2023 IPPS and
LTCH PPS outlier fixed-loss amounts.
As also discussed in section II.A.4. and
section V.D.3. of the addendum to this
PO 00000
Frm 00020
Fmt 4701
Sfmt 4700
final rule, after consideration of the
comments received, we are modifying
our proposed methodologies for
establishing the FY 2023 IPPS and
LTCH PPS outlier fixed-loss amounts by
calculating the FY 2023 IPPS and LTCH
PPS outlier fixed-loss amounts as
averages of the fixed-loss amounts as
calculated including and excluding
COVID–19 claims. We believe this
adjustment to our proposed
methodology will better reflect a
reasonable estimation of the case mix
for FY 2023 based on the information
available at this time and is also
consistent with the approach we are
finalizing for determining the FY 2023
IPPS MS–DRG and LTCH PPS MS–LTC–
DRG relative weights.
In addition, as discussed in section
II.A.4. of the Addendum to this final
rule, after consideration of comments
received, we are also further modifying
our proposed methodology for
establishing the FY 2023 IPPS outlier
fixed-loss amount by including the
increases in payments for COVID–19
cases provided by the CARES Act in the
calculation of the outlier fixed-loss
amount.
II. Changes to Medicare Severity
Diagnosis–Related Group (MS–DRG)
Classifications and Relative Weights
A. Background
Section 1886(d) of the Act specifies
that the Secretary shall establish a
classification system (referred to as
diagnosis-related groups (DRGs)) for
inpatient discharges and adjust
payments under the IPPS based on
appropriate weighting factors assigned
to each DRG. Therefore, under the IPPS,
Medicare pays for inpatient hospital
services on a rate per discharge basis
that varies according to the DRG to
which a beneficiary’s stay is assigned.
The formula used to calculate payment
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.004
khammond on DSKJM1Z7X2PROD with RULES2
• Daily Admissions of Patients with Confirmed COVID-l9 - - 7-0ay Moving Average
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
for a specific case multiplies an
individual hospital’s payment rate per
case by the weight of the DRG to which
the case is assigned. Each DRG weight
represents the average resources
required to care for cases in that
particular DRG, relative to the average
resources used to treat cases in all
DRGs.
Section 1886(d)(4)(C) of the Act
requires that the Secretary adjust the
DRG classifications and relative weights
at least annually to account for changes
in resource consumption. These
adjustments are made to reflect changes
in treatment patterns, technology, and
any other factors that may change the
relative use of hospital resources.
khammond on DSKJM1Z7X2PROD with RULES2
B. Adoption of the MS–DRGs and MS–
DRG Reclassifications
For information on the adoption of
the MS–DRGs in FY 2008, we refer
readers to the FY 2008 IPPS final rule
with comment period (72 FR 47140
through 47189).
For general information about the
MS–DRG system, including yearly
reviews and changes to the MS–DRGs,
we refer readers to the previous
discussions in the FY 2010 IPPS/RY
2010 LTCH PPS final rule (74 FR 43764
through 43766) and the FYs 2011
through 2022 IPPS/LTCH PPS final
rules (75 FR 50053 through 50055; 76
FR 51485 through 51487; 77 FR 53273;
78 FR 50512; 79 FR 49871; 80 FR 49342;
81 FR 56787 through 56872; 82 FR
38010 through 38085, 83 FR 41158
through 41258, 84 FR 42058 through
42165, 85 FR 58445 through 58596, 86
FR 44795 through 44961, respectively).
C. FY 2023 MS–DRG Documentation
and Coding Adjustment
1. Background on the Prospective
MS–DRG Documentation and Coding
Adjustments for FY 2008 and FY 2009
Authorized by Pub. L. 110–90 and the
Recoupment or Repayment Adjustment
Authorized by Section 631 of the
American Taxpayer Relief Act of 2012
(ATRA).
In the FY 2008 IPPS final rule with
comment period (72 FR 47140 through
47189), we adopted the MS–DRG
patient classification system for the
IPPS, effective October 1, 2007, to better
recognize severity of illness in Medicare
payment rates for acute care hospitals.
The adoption of the MS–DRG system
resulted in the expansion of the number
of DRGs from 538 in FY 2007 to 745 in
FY 2008. By increasing the number of
MS–DRGs and more fully taking into
account patient severity of illness in
Medicare payment rates for acute care
hospitals, MS–DRGs encourage
hospitals to improve their
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
documentation and coding of patient
diagnoses.
In the FY 2008 IPPS final rule with
comment period (72 FR 47175 through
47186), we indicated that the adoption
of the MS–DRGs had the potential to
lead to increases in aggregate payments
without a corresponding increase in
actual patient severity of illness due to
the incentives for additional
documentation and coding. In that final
rule with comment period, we exercised
our authority under section
1886(d)(3)(A)(vi) of the Act, which
authorizes us to maintain budget
neutrality by adjusting the national
standardized amount, to eliminate the
estimated effect of changes in coding or
classification that do not reflect real
changes in case-mix. Our actuaries
estimated that maintaining budget
neutrality required an adjustment of
¥4.8 percentage points to the national
standardized amount. We provided for
phasing in this ¥4.8 percentage point
adjustment over 3 years. Specifically,
we established prospective
documentation and coding adjustments
of ¥1.2 percentage points for FY 2008,
¥1.8 percentage points for FY 2009,
and ¥1.8 percentage points for FY
2010.
On September 29, 2007, Congress
enacted the TMA [Transitional Medical
Assistance], Abstinence Education, and
QI [Qualifying Individuals] Programs
Extension Act of 2007 (Pub. L. 110–90).
Section 7(a) of Public Law 110–90
reduced the documentation and coding
adjustment made as a result of the MS–
DRG system that we adopted in the FY
2008 IPPS final rule with comment
period to ¥0.6 percentage point for FY
2008 and ¥0.9 percentage point for FY
2009.
As discussed in prior year
rulemakings, and most recently in the
FY 2017 IPPS/LTCH PPS final rule (81
FR 56780 through 56782), we
implemented a series of adjustments
required under sections 7(b)(1)(A) and
7(b)(1)(B) of Public Law 110–90, based
on a retrospective review of FY 2008
and FY 2009 claims data. We completed
these adjustments in FY 2013 but
indicated in the FY 2013 IPPS/LTCH
PPS final rule (77 FR 53274 through
53275) that delaying full
implementation of the adjustment
required under section 7(b)(1)(A) of
Public Law 110–90 until FY 2013
resulted in payments in FY 2010
through FY 2012 being overstated, and
that these overpayments could not be
recovered under Public Law 110–90.
In addition, as discussed in prior
rulemakings and most recently in the
FY 2018 IPPS/LTCH PPS final rule (82
FR 38008 through 38009), section 631 of
PO 00000
Frm 00021
Fmt 4701
Sfmt 4700
48799
the American Taxpayer Relief Act of
2012 (ATRA) amended section
7(b)(1)(B) of Public Law 110–90 to
require the Secretary to make a
recoupment adjustment or adjustments
totaling $11 billion by FY 2017. This
adjustment represented the amount of
the increase in aggregate payments as a
result of not completing the prospective
adjustment authorized under section
7(b)(1)(A) of Public Law 110–90 until
FY 2013.
2. Adjustments Made for FYs 2018,
2019, 2020, 2021, and 2022 as Required
Under Section 414 of Public Law 114–
10 (MACRA) and Section 15005 of
Public Law 114–255
As stated in the FY 2017 IPPS/LTCH
PPS final rule (81 FR 56785), once the
recoupment required under section 631
of the ATRA was complete, we had
anticipated making a single positive
adjustment in FY 2018 to offset the
reductions required to recoup the $11
billion under section 631 of the ATRA.
However, section 414 of the MACRA
(which was enacted on April 16, 2015)
replaced the single positive adjustment
we intended to make in FY 2018 with
a 0.5 percentage point positive
adjustment for each of FYs 2018 through
2023. In the FY 2017 rulemaking, we
indicated that we would address the
adjustments for FY 2018 and later fiscal
years in future rulemaking. Section
15005 of the 21st Century Cures Act
(Pub. L. 114–255), which was enacted
on December 13, 2016, amended section
7(b)(1)(B) of the TMA, as amended by
section 631 of the ATRA and section
414 of the MACRA, to reduce the
adjustment for FY 2018 from a 0.5
percentage point positive adjustment to
a 0.4588 percentage point positive
adjustment. As we discussed in the FY
2018 rulemaking, we believe the
directive under section 15005 of Public
Law 114–255 is clear. Therefore, in the
FY 2018 IPPS/LTCH PPS final rule (82
FR 38009) for FY 2018, we implemented
the required +0.4588 percentage point
adjustment to the standardized amount.
In the FY 2019 IPPS/LTCH PPS final
rule (83 FR 41157), the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42057), the
FY 2021 IPPS/LTCH PPS final rule (85
FR 58444 and 58445), and the FY 2022
IPPS/LTCH PPS final rule (86 FR 44794
and 44795), consistent with the
requirements of section 414 of the
MACRA, we implemented 0.5
percentage point positive adjustments to
the standardized amount for FY 2019,
FY 2020, FY 2021, and FY 2022,
respectively. We indicated the FY 2018,
FY 2019, FY 2020, FY 2021, and FY
2022 adjustments were permanent
adjustments to payment rates. We also
E:\FR\FM\10AUR2.SGM
10AUR2
48800
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
stated that we plan to propose a future
adjustment required under section 414
of the MACRA for FY 2023 in future
rulemaking.
3. Adjustment for FY 2023
Consistent with the requirements of
section 414 of the MACRA, we proposed
to implement a 0.5 percentage point
positive adjustment to the standardized
amount for FY 2023. We stated that this
would constitute a permanent
adjustment to payment rates. We also
stated that this proposed 0.5 percentage
point positive adjustment is the final
adjustment prescribed by section 414 of
the MACRA. Along with the 0.4588
percentage point positive adjustment for
FY 2018, and the 0.5 percentage point
positive adjustments for FY 2019, FY
2020, FY 2021, and FY 2022, this final
adjustment will result in combined
positive adjustment of 2.9588
percentage points (or the sum of the
adjustments for FYs 2018 through 2023)
to the standardized amount.
We received no public comments on
the proposed adjustment for FY 2023
and are finalizing our proposal to
implement a 0.5 percentage point
positive adjustment to the standardized
amount for FY 2023. As indicated, this
finalized 0.5 percentage point positive
adjustment for FY 2023 is the final
adjustment prescribed by section 414 of
the MACRA.
D. Changes to Specific MS–DRG
Classifications
1. Discussion of Changes to Coding
System and Basis for FY 2023 MS–DRG
Updates
khammond on DSKJM1Z7X2PROD with RULES2
a. Conversion of MS–DRGs to the
International Classification of Diseases,
10th Revision (ICD–10)
As of October 1, 2015, providers use
the International Classification of
Diseases, 10th Revision (ICD–10) coding
system to report diagnoses and
procedures for Medicare hospital
inpatient services under the MS–DRG
system instead of the ICD–9–CM coding
system, which was used through
September 30, 2015. The ICD–10 coding
system includes the International
Classification of Diseases, 10th
Revision, Clinical Modification (ICD–
10–CM) for diagnosis coding and the
International Classification of Diseases,
10th Revision, Procedure Coding
System (ICD–10–PCS) for inpatient
hospital procedure coding, as well as
the ICD–10–CM and ICD–10–PCS
Official Guidelines for Coding and
Reporting. For a detailed discussion of
the conversion of the MS–DRGs to ICD–
10, we refer readers to the FY 2017
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
IPPS/LTCH PPS final rule (81 FR 56787
through 56789).
b. Basis for FY 2023 MS–DRG Updates
Given the need for more time to
carefully evaluate requests and propose
updates, as discussed in the FY 2018
IPPS/LTCH PPS final rule (82 FR
38010), we changed the deadline to
request updates to the MS–DRGs to
November 1 of each year, which
provided an additional five weeks for
the data analysis and review process. In
the FY 2021 IPPS/LTCH PPS proposed
rule (85 FR 32472), we stated that with
the continued increase in the number
and complexity of the requested
changes to the MS–DRG classifications
since the adoption of ICD–10 MS–DRGs,
and to consider as many requests as
possible, more time is needed to
carefully evaluate the requested
changes, analyze claims data, and
consider any proposed updates. We
further stated we were changing the
deadline to request changes to the MS–
DRGs to October 20 of each year to
allow for additional time for the review
and consideration of any proposed
updates. However, in the FY 2021 IPPS/
LTCH PPS final rule (85 FR 58445), due
to the unique circumstances for the FY
2021 IPPS/LTCH PPS final rule for
which we waived the delayed effective
date, we maintained the deadline of
November 1, 2020 for FY 2022 MS–DRG
classification change requests. We also
noted that we expected to reconsider a
change in the deadline beginning with
comments and suggestions submitted
for FY 2023. In the FY 2022 IPPS/LTCH
PPS proposed rule, we stated that while
we continue to believe that a change in
the deadline from November 1 to
October 20 would provide hospitals
sufficient time to assess potential
impacts and inform future MS–DRG
recommendations, we were maintaining
the deadline of November 1 for FY 2023
MS–DRG classification change requests.
As discussed in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 44795), we
received public comments expressing
support for a future change to the
deadline for requesting updates to the
MS–DRG classifications from November
1 to October 20, and we noted in
response that we may consider any
changes to the deadline or frequency for
submissions of requests for MS–DRG
classification changes for future fiscal
years. Beginning with FY 2024 MS–DRG
classification change requests, we are
changing the deadline to request
changes to the MS–DRGs to October 20
of each year to allow for additional time
for the review and consideration of any
proposed updates. As previously
discussed, we continue to believe such
PO 00000
Frm 00022
Fmt 4701
Sfmt 4700
a change would allow hospitals
sufficient time to assess potential
impacts and inform future MS–DRG
recommendations, while also providing
CMS the additional time needed for
evaluation of the requested changes,
analysis of claims data, and
consideration of any proposed updates.
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule, we are also
changing the process for submitting
requested updates to the MS–DRG
classifications, beginning with the FY
2024 MS–DRG classification change
requests. CMS is in the process of
implementing a new electronic
application intake system, Medicare
Electronic Application Request
Information SystemTM (MEARISTM), for
users to submit new technology add-on
payment applications, requests for ICD–
10–PCS procedure codes, and other
requests. To simplify and streamline the
process for submission of standardized
applications and requests that inform
payment policy under the IPPS, we will
also be using this new system for
submission of MS–DRG classification
change requests. We believe that
submission of MS–DRG reclassification
requests through MEARISTM will not
only help CMS to track such requests,
but it will also create efficiencies for
requestors when compared to the
previous submission process.
Accordingly, beginning with the FY
2024 MS–DRG classification change
requests, CMS will only accept such
requests submitted via MEARIS,TM and
will no longer consider any such
requests that are sent via email. We note
that, beginning April 5, 2022,
MEARISTM became available for users
to begin gaining familiarity with this
new approach for submitting MS–DRG
classification change requests.
MEARIS,TM including the mechanism
for submitting MS–DRG classification
change requests, can be accessed at:
https://mearis.cms.gov. As stated in the
proposed rule, within MEARISTM we
have built in several resources to
support users, including a ‘‘Resources’’
section (available at https://
mearis.cms.gov/public/resources) and
technical support available under
‘‘Useful Links’’ at the bottom of the
MEARISTM site. Questions regarding the
MEARISTM system can be submitted to
CMS using the form available under
‘‘Contact’’ at: https://mearis.cms.gov/
public/resources?app=msdrg.
We also note that, as discussed in
section II.D.17. of the preamble of the
proposed rule and this final rule,
effective January 5, 2022, MEARISTM
was made available for users to begin
gaining familiarity with a new approach
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
and process to submit ICD–10–PCS
procedure code requests.
As noted previously, interested
parties had to submit MS–DRG
classification change requests for FY
2023 by November 1, 2021. As we have
discussed in prior rulemaking, we may
not be able to fully consider all of the
requests that we receive for the
upcoming fiscal year. We have found
that, with the implementation of ICD–
10, some types of requested changes to
the MS–DRG classifications require
more extensive research to identify and
analyze all of the data that are relevant
to evaluating the potential change. We
note in the discussion that follows those
topics for which further research and
analysis are required, and which we
will continue to consider in connection
with future rulemaking. Interested
parties should submit any comments
and suggestions for FY 2024 by October
20, 2022 via the new electronic intake
system, Medicare Electronic
Application Request Information
SystemTM (MEARISTM) at: https://
mearis.cms.gov/public/home.
We provided a test version of the
ICD–10 MS–DRG GROUPER Software,
Version 40, in connection with the FY
2023 IPPS/LTCH PPS proposed rule so
that the public can better analyze and
understand the impact of the proposals
included in the proposed rule. We noted
that this test software reflected the
proposed GROUPER logic for FY 2023.
Therefore, it included the new diagnosis
and procedure codes that are effective
for FY 2023 as reflected in Table 6A.—
New Diagnosis Codes—FY 2023 and
Table 6B.—New Procedure Codes—FY
2023 that were associated with the
proposed rule and did not include the
diagnosis codes that are invalid
beginning in FY 2023 as reflected in
Table 6C.—Invalid Diagnosis Codes—
FY 2023 associated with the proposed
rule. We noted that at the time of the
development of the proposed rule there
were no procedure codes designated as
invalid for FY 2023, and therefore, there
was no Table 6D—Invalid Procedure
Codes—FY 2023 associated with the
proposed rule. Those tables were not
published in the Addendum to the
proposed rule, but are available via the
internet on the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatient
PPS/ as described in section
VI. of the Addendum to the proposed
rule. Because the diagnosis codes no
longer valid for FY 2023 are not
reflected in the test software, we made
available a supplemental file in Table
6P.1a that includes the mapped Version
40 FY 2023 ICD–10–CM codes and the
deleted Version 39.1 FY 2022 ICD–10–
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
CM codes that should be used for testing
purposes with users’ available claims
data. Therefore, users had access to the
test software allowing them to build
case examples that reflect the proposals
that were included in the proposed rule.
In addition, users were able to view the
draft version of the ICD–10 MS–DRG
Definitions Manual, Version 40.
The test version of the ICD–10 MS–
DRG GROUPER Software, Version 40,
the draft version of the ICD–10 MS–DRG
Definitions Manual, Version 40, and the
supplemental mapping files in Table
6P.1a of the FY 2022 and FY 2023 ICD–
10–CM diagnosis codes are available at
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/MS-DRGClassifications-and-Software.
Following are the changes that we
proposed to the MS–DRGs for FY 2023.
We invited public comments on each of
the MS–DRG classification proposed
changes, as well as our proposals to
maintain certain existing MS–DRG
classifications discussed in the
proposed rule. In some cases, we
proposed changes to the MS–DRG
classifications based on our analysis of
claims data and consultation with our
clinical advisors. In other cases, we
proposed to maintain the existing MS–
DRG classifications based on our
analysis of claims data and consultation
with our clinical advisors. As discussed
in section I.F of the preamble of the
proposed rule, we proposed to use the
FY 2021 MedPAR data for purposes of
this FY 2023 IPPS rulemaking, with
certain proposed modifications to the
relative weight and outlier
methodologies. For the FY 2023 IPPS/
LTCH PPS proposed rule, our MS–DRG
analysis was based on ICD–10 claims
data from the September 2021 update of
the FY 2021 MedPAR file, which
contains hospital bills received from
October 1, 2020 through September 30,
2021, for discharges occurring through
September 30, 2021. In our discussion
of the proposed MS–DRG
reclassification changes, we referred to
these claims data as the ‘‘September
2021 update of the FY 2021 MedPAR
file.’’
In this FY 2023 IPPS/LTCH PPS final
rule, we summarize the public
comments we received on our
proposals, present our responses, and
state our final policies. For this FY 2023
final rule, we generally did not perform
any further MS–DRG analysis of claims
data. Therefore, the MS–DRG analysis is
based on ICD–10 claims data from the
September 2021 update of the FY 2021
MedPAR file, as set forth in the
proposed rule, except as otherwise
noted.
PO 00000
Frm 00023
Fmt 4701
Sfmt 4700
48801
As explained in previous rulemaking
(76 FR 51487), in deciding whether to
propose to make further modifications
to the MS–DRGs for particular
circumstances brought to our attention,
we consider whether the resource
consumption and clinical characteristics
of the patients with a given set of
conditions are significantly different
than the remaining patients represented
in the MS–DRG. We evaluate patient
care costs using average costs and
lengths of stay and rely on the judgment
of our clinical advisors to determine
whether patients are clinically distinct
or similar to other patients represented
in the MS–DRG. In evaluating resource
costs, we consider both the absolute and
percentage differences in average costs
between the cases we select for review
and the remainder of cases in the MS–
DRG. We also consider variation in costs
within these groups; that is, whether
observed average differences are
consistent across patients or attributable
to cases that are extreme in terms of
costs or length of stay, or both. Further,
we consider the number of patients who
will have a given set of characteristics
and generally prefer not to create a new
MS–DRG unless it would include a
substantial number of cases.
In the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58448), we finalized our
proposal to expand our existing criteria
to create a new complication or
comorbidity (CC) or major complication
or comorbidity (MCC) subgroup within
a base MS–DRG. Specifically, we
finalized the expansion of the criteria to
include the NonCC subgroup for a threeway severity level split. We stated our
belief that applying these criteria to the
NonCC subgroup would better reflect
resource stratification as well as
promote stability in the relative weights
by avoiding low volume counts for the
NonCC level MS–DRGs. We noted that
in our analysis of MS–DRG
classification requests for FY 2021 that
were received by November 1, 2019, as
well as any additional analyses that
were conducted in connection with
those requests, we applied these criteria
to each of the MCC, CC, and NonCC
subgroups. We also noted that the
application of the NonCC subgroup
criteria going forward may result in
modifications to certain MS–DRGs that
are currently split into three severity
levels and result in MS–DRGs that are
split into two severity levels. We stated
that any proposed modifications to the
MS–DRGs would be addressed in future
rulemaking consistent with our annual
process and reflected in Table 5—
Proposed List of Medicare Severity
Diagnosis Related Groups (MS–DRGs),
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Relative Weighting Factors, and
Geometric and Arithmetic Mean Length
of Stay for the applicable fiscal year.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 44798), we finalized a delay
in applying this technical criterion to
existing MS–DRGs until FY 2023 or
future rulemaking, in light of the PHE.
Commenters recommended that a
complete analysis of the MS–DRG
Criteria Number
1. At least 500 cases in
the MCC/CC/NonCC
group
2. At least 5% of the
patients are in the
MCC/CC/NonCC group
3. There is at least a 20%
difference in average cost
between subgroups
4. There is at least a
$2,000 difference in
average cost between
subgroups
khammond on DSKJM1Z7X2PROD with RULES2
5. The R2 of the split
groups is greater than or
equal to 3
Three-Way Split
123
(MCC vs CC vs NonCC)
500+ cases for MCC group;
and
500+ cases for CC group;
and
500+ cases for NonCC
group
5%+ cases for MCC group;
and
5%+ cases for CC group;
and
5%+ cases for NonCC group
20%+ difference in average
cost between MCC group
and CC group; and 20%+
difference in average cost
between CC group and
NonCC group
$2,000+ difference in
average cost between MCC
group and CC group; and
$2,000+ difference in
average cost between CC
group and NonCC group
R2 > 3. 0 for the three way
split within the base MSDRG
In general, once the decision has been
made to propose to make further
modifications to the MS–DRGs as
described previously, such as creating a
new base MS–DRG, or in our evaluation
of a specific MS–DRG classification
request to split (or subdivide) an
existing base MS–DRG into severity
levels, all five criteria must be met for
the base MS–DRG to be split (or
subdivided) by a CC subgroup. We note
that in our analysis of requests to create
a new MS–DRG, we typically evaluate
the most recent year of MedPAR claims
data available. For example, in the FY
2023 IPPS/LTCH PPS proposed rule we
stated our MS–DRG analysis was based
on ICD–10 claims data from the
September 2021 update of the FY 2021
VerDate Sep<11>2014
00:20 Aug 10, 2022
changes to be proposed for future
rulemaking in connection with the
expanded three-way severity split
criteria be conducted and made
available to enable the public an
opportunity to review and consider the
redistribution of cases, the impact to the
relative weights, payment rates, and
hospital case mix to allow meaningful
comment prior to implementation.
Jkt 256001
Two-Way Split
1 23
MCC vs (CC+NonCC)
500+ cases for MCC group;
and
500+ cases for
(CC+NonCC) group
Two-Way Split
12 3
(MCC+CC) vs NonCC
500+ cases for (MCC+CC)
group; and
500+ cases for NonCC
group
5%+ cases for MCC group;
and
5%+ cases for (CC+NonCC)
group
5%+ cases for (MCC+CC)
group; and
5%+ cases for NonCC
group
20%+ difference in average
cost between MCC group
and (CC+NonCC) group
20%+ difference in average
cost between (MCC+ CC)
group and NonCC group
$2,000+ difference in
average cost between MCC
group and (CC+ NonCC)
group
$2,000+ difference in
average cost between
(MCC+ CC) group and
NonCC group
R2 > 3.0 for the two way
1_ 23 split within the base
MS-DRG
R2 > 3.0 for the two way
12_3 split within the base
MS-DRG
MedPAR file. However, in our
evaluation of requests to split an
existing base MS–DRG into severity
levels, as noted in prior rulemaking (80
FR 49368), we typically analyze the
most recent 2 years of data. This
analysis includes 2 years of MedPAR
claims data to compare the data results
from 1 year to the next to avoid making
determinations about whether
additional severity levels are warranted
based on an isolated year’s data
fluctuation and also, to validate that the
established severity levels within a base
MS–DRG are supported. The first step in
our process of evaluating if the creation
of a new CC subgroup within a base
MS–DRG is warranted is to determine if
all the criteria are satisfied for a three-
PO 00000
Frm 00024
Fmt 4701
In our analysis of the MS–DRG
classification requests for FY 2023 that
we received by November 1, 2021, as
well as any additional analyses that
were conducted in connection with
those requests, we applied these criteria
to each of the MCC, CC, and NonCC
subgroups, as described in the following
table.
Sfmt 4700
way split. If the criteria fail, the next
step is to determine if the criteria are
satisfied for a two-way split. If the
criteria for both of the two-way splits
fail, then a split (or CC subgroup) would
generally not be warranted for that base
MS–DRG. If the three-way split fails on
any one of the five criteria and all five
criteria for both two-way splits (1_23
and 12_3) are met, we would apply the
two-way split with the highest R2 value.
We note that if the request to split (or
subdivide) an existing base MS–DRG
into severity levels specifies the request
is for either one of the two-way splits
(1_23 or 12_3), in response to the
specific request, we will evaluate the
criteria for both of the two-way splits,
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.005
48802
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
however we do not also evaluate the
criteria for a three-way split.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we stated that using the
September 2021 update of the FY 2021
MedPAR file, we analyzed how
applying the NonCC subgroup criteria to
all MS–DRGs currently split into three
severity levels would affect the MS–
DRG structure beginning in FY 2023.
We noted that findings from our
analysis indicated that approximately
41 MS–DRGs would be subject to
change based on the three-way severity
level split criterion finalized in FY
2021. Specifically, we found that
applying the NonCC subgroup criteria to
all MS–DRGs currently split into three
severity levels would result in the
deletion of 123 MS–DRGs (41 MS–DRGs
× 3 severity levels = 123) and the
creation of 75 new MS–DRGs. We
further noted that these updates would
also involve a redistribution of cases,
which would impact the relative
weights, and, thus, the payment rates
proposed for particular types of cases.
We referred the reader to Table 6P.1b
associated with the proposed rule for
the list of the 123 MS–DRGs that would
be subject to deletion and the list of the
75 new MS–DRGs that would be
proposed for creation for FY 2023 under
this policy if the NonCC subgroup
criteria were applied.
We stated in the proposed rule that in
light of the ongoing public health
emergency (PHE), we continue to have
concerns about the impact of
implementing this volume of MS–DRG
changes at this time, and believe it may
be appropriate to continue to delay
application of the NonCC subgroup
criteria to existing MS–DRGs to
maintain more stability in the current
MS–DRG structure and until such time
additional analyses can be performed to
assess impacts, as discussed in response
to comments in the FY 2022 IPPS/LTCH
PPS final rule. Therefore, we proposed
to delay application of the NonCC
subgroup criteria to existing MS–DRGs
with a three-way severity level split for
FY 2023, and to instead maintain the
current structure of the 41 MS–DRGs
that currently have a three-way severity
level split (total of 123 MS–DRGs) that
would otherwise be subject to these
criteria. We stated that we intend to
address the application of the NonCC
subgroup criteria to existing MS–DRGs
with a three-way severity level split in
future rulemaking.
Comment: Commenters expressed
overwhelming support for our proposal
to delay application of the NonCC
subgroup criteria to existing MS–DRGs
with a three-way severity level split for
FY 2023 and to maintain the current
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
structure of the MS–DRGs. A few
commenters who agreed with the
proposal to delay the application of the
NonCC subgroup criteria also requested
that CMS provide interested parties
with an opportunity to review and
comment on impacts to the relative
weights before a proposal is finalized.
The commenters stated it would be
helpful if CMS made claims data
available, including volumes by MS–
DRG, that support the proposal to
reduce the 123 MS–DRGs.
Response: We thank the commenters
for their support. In response to the
commenters who requested the
opportunity to review and comment on
impacts to the relative weights before a
proposal is finalized, we intend to
provide a comprehensive analysis in
future rulemaking based on the
comments and feedback we have
received. We are providing the claims
data from the September 2021 update of
the FY 2021 MedPAR file that was
reviewed for FY 2023 in our analyses of
how applying the NonCC subgroup
criteria to all MS–DRGs currently split
into three severity levels would have
potentially affected the MS–DRG
structure beginning in FY 2023. We
refer the reader to Table 6P.1b
associated with this final rule and
available via the internet on the CMS
website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS.
Comment: A commenter who strongly
agreed with the proposal to delay the
application of the NonCC subgroup
criteria stated that in addition to
providing a detailed explanation and
impact files in the future, that CMS
should consider clarifying and
addressing the following issues: why the
list of MS–DRGs that were proposed to
be removed in FY 2022 is not the same
list of MS–DRGs proposed to be
removed for FY 2023, why the list of
MS–DRGs that were proposed to
become a single, base MS–DRG for FY
2022 now appear to meet the criteria for
a three-way severity level split for FY
2023, and why MS–DRGs proposed to
maintain a three-way severity level split
for FY 2022 now appear to meet the
criteria for a two-way or three-way
severity level split for FY 2023. This
commenter also stated that the MS–
DRGs displayed in Table 6P.1b
associated with the proposed rule
include a list of MS–DRGs that would
be subject to deletion and a list of MS–
DRGs that would be proposed for
creation with XXX for the numbers.
According to the commenter, many of
the listed MS–DRGs have the same
narrative description, however, it
appears they would obtain a new MS–
PO 00000
Frm 00025
Fmt 4701
Sfmt 4700
48803
DRG number. The commenter
questioned why MS–DRGs with the
same description would have new MS–
DRG numbers assigned. This commenter
also suggested that CMS consider
patient case-mix with regard to
volumes, and stated Medicare would
not have the volume for the obstetric
related MS–DRGs. The commenter
requested that CMS also examine the
impact of maternal health quality
initiatives and maternity hospital
designation in connection with the
solicitation for comments on low
volume MS–DRGs. Lastly, the
commenter recommended that CMS
utilize two years of good data to
examine the impact of the proposed
redistribution in future analyses and
determine if the proposed MS–DRG
changes and associated relative weights
appropriately reflect resource
consumption.
Response: We appreciate the
commenter’s feedback. We acknowledge
that the list of MS–DRGs identified as
potentially subject to removal for FY
2022 differs from the list of MS–DRGs
identified as potentially subject to
removal and provided for FY 2023 in
connection with the NonCC subgroup
criteria discussion. We also
acknowledge that the list of MS–DRGs
identified as potentially subject to
creation for FY 2022 differs from the list
of MS–DRGs identified as potentially
subject to removal and provided for FY
2023 in connection with the NonCC
subgroup criteria discussion. The lists
differ as a result of the claims data that
was analyzed for our MS–DRG analysis
and rulemaking each fiscal year. We
provided the results of both the FY 2019
and FY 2020 MedPAR claims data as
displayed in Table 6P.11 in association
with the FY 2022 IPPS/LTCH PPS final
rule (available via the internet on the
CMS website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS).
By comparison, for FY 2023,
consistent with our finalized policy to
use the FY 2021 MedPAR data for
purposes of this FY 2023 rulemaking,
we have provided the FY 2021 MedPAR
claims data for the listed MS–DRGs in
Table 6P.1b in association with this
final rule, as noted earlier in this
section. Because there is variation in the
claims data reported from year to year,
it is expected that there may be
fluctuations in the data that could affect
the list of MS–DRGs potentially subject
to change in connection with the
application of the NonCC subgroup
criteria for a particular fiscal year.
However, we believe that reliability and
stability of the data is an important
consideration with respect to the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48804
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
application of the NonCC subgroup
criteria and will give careful
consideration to the number of years of
data to analyze in connection with any
future proposed policy changes as well
as the impacts on relative weights, as we
continue to assess all the comments and
feedback we have received, particularly
in light of the ongoing public health
emergency. We also take this
opportunity to note that the listed MS–
DRGs as displayed in the tables (for both
FY 2022 and FY 2023) are for
illustrative purposes as the intent was to
show the MS–DRGs that would
potentially be subject to deletion and
the MS–DRGs that would potentially be
subject to creation if the NonCC
subgroup criteria were to be applied for
the applicable fiscal year. Because we
did not propose the application of these
criteria to existing MS–DRGs with a
three-way severity level split for either
FY 2022 or FY 2023, and we have not
yet completed the comprehensive
impact analysis of any such future
proposed changes, as previously
discussed, we are clarifying that both
the MS–DRG numbers and MS–DRG
titles that may eventually be subject to
change in connection with a future
proposal to apply the NonCC subgroup
criteria may, in the interim, be subject
to further modifications as a result of
our annual review of the MS–DRG
classifications. As such, any future
proposed MS–DRG changes will be
considered in connection with the
analysis that is performed for
application of the MCC, CC and NonCC
subgroup criteria to the MS–DRGs that
are in effect at that time.
In response to the commenter’s
question regarding why new MS–DRG
numbers would be considered, we note
that new MS–DRG numbers are
preferred because we anticipate that
individuals, payers, and organizations
conducting analysis would need to be
aware if proposed changes to base DRG
concepts are made to allow them time
to adjust their programs, analyses, or
queries that may have hard coded the
DRG numbers. Other agencies that
utilize MS–DRGs may perform minimal
updates to their relative weights, quality
risk adjustment or exclusion criteria and
only focus on new MS–DRGs, thereby
potentially creating additional
operational or system challenges if an
existing MS–DRG number were to be
reused. To minimize confusion for those
who rely on MS–DRG concepts year to
year, and avoid unintended
consequences from the reuse of an
existing DRG number for a different
concept, we believe it is appropriate to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
consider revisions to both the MS–DRG
number and corresponding description.
Comment: Other commenters
requested CMS consider continuing the
delay beyond the period of the public
health emergency (PHE). The
commenters indicated that hospital
claims and cost report data impacted by
the COVID–19 pandemic should not be
used as the basis of MS–DRG
consolidation since utilization may be
artificially low during the PHE.
Response: We thank the commenters
for their feedback. As stated earlier in
this section, we are giving careful
consideration to all the
recommendations and suggestions we
have received in connection with the
NonCC subgroup criteria discussion.
Comment: Another commenter
expressed concern with regard to how
the NonCC subgroup criteria are to be
applied. The commenter stated they
understood the policy to mean that the
NonCC subgroup criteria would only be
applied to new requests for MS–DRG
splits, not to existing MS–DRGs. The
commenter also stated they were
unclear when the proposal was finalized
since, according to the commenter, CMS
would have needed to specify the intent
to apply the NonCC subgroup criteria to
all existing MS–DRGs versus only for
the creation of new MS–DRGs.
Additionally, this commenter urged
CMS to conduct a full analysis that
demonstrates the explanatory power of
the proposed new MS–DRGs is an
improvement over the current MS–
DRGs, similar to the analysis that was
performed for the transition from CMS
DRGs to MS–DRGs in FY 2008. The
commenter indicated that a
comprehensive analysis is critical for
interested parties to provide meaningful
comments.
Response: In the FY 2022 IPPS/LTCH
PPS final rule (86 FR 44796), we
summarized the discussion pertaining
to the NonCC subgroup criteria policy
finalized for FY 2021. In that discussion
we noted that the application of the
NonCC subgroup criteria going forward
may result in modifications to certain
MS–DRGs that are currently split into
three severity levels and result in MS–
DRGs that are split into two severity
levels. We stated that any proposed
modifications to the MS–DRGs would
be addressed in future rulemaking
consistent with our annual process and
reflected in Table 5—Proposed List of
Medicare Severity Diagnosis Related
Groups (MS–DRGs), Relative Weighting
Factors, and Geometric and Arithmetic
Mean Length of Stay for the applicable
fiscal year. As discussed in the
proposed rule, we applied the nonCC
subgroup criteria to each of the MCC,
PO 00000
Frm 00026
Fmt 4701
Sfmt 4700
CC, and NonCC subgroups, in our
analysis of the MS–DRG classification
requests for FY 2023 that we received by
November 1, 2021, as well as any
additional analyses that were conducted
in connection with those requests. We
also note that new requests to subdivide
a MS–DRG frequently pertain to existing
MS–DRGs which differs from requests
to create a new base MS–DRG for which
the criteria to create subgroups is
subsequently applied. In response to the
commenter’s recommendation that CMS
conduct a full analysis similar to the
analysis that was performed for the
transition from CMS DRGs to MS–DRGs
in FY 2008, we appreciate the
commenter’s suggestion and will take it
under advisement.
Comment: Another commenter who
recognized differences between the list
of MS–DRGs shown for FY 2022 and FY
2023 requested additional transparency
for the data being presented for review
and for CMS to consider analyzing data
from other databases, such as Medicaid
or States, to supplement the MS–DRGs
known to have lower volumes among
the Medicare population (for example,
Obstetric MS–DRGs). This commenter
also expressed concern about the
potential impact to community
hospitals if proposed MS–DRG changes
in connection with the NonCC subgroup
criteria result in significant MS–DRG
redistribution.
Response: We thank the commenter
for their feedback. As discussed
previously, we intend to conduct a
comprehensive analysis of the
application of the NonCC subgroup
criteria that would be made publicly
available for review and comment in
connection with any proposed MS–DRG
changes for future rulemaking.
After consideration of the public
comments we received, we are
finalizing our proposal to delay the
application of the NonCC subgroup
criteria to existing MS–DRGs with a
three-way severity level split until FY
2024 or later, and are finalizing for FY
2023 to maintain the current structure of
the 41 MS–DRGs that currently have a
three-way severity level split.
We are making the FY 2023 ICD–10
MS–DRG GROUPER and Medicare Code
Editor (MCE) Software Version 40, the
ICD–10 MS–DRG Definitions Manual
files Version 40 and the Definitions of
Medicare Code Edits Manual Version 40
available to the public on our CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/MS-DRGClassifications-and-Software.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
2. Pre-MDC: MS–DRG 018 Chimeric
Antigen Receptor (CAR) T-cell and
Other Immunotherapies
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 44798 through 44806), we
finalized our proposal to assign
procedure codes describing CAR T-cell,
non-CAR T-cell, and other
immunotherapies to Pre-MDC MS–DRG
018 and to revise the title for Pre-MDC
MS–DRG 018 to ‘‘Chimeric Antigen
Receptor (CAR) T-cell and Other
Immunotherapies’’ to reflect this
assignment. In that discussion, we noted
that a few commenters recommended
we continue to work with interested
parties on ways to improve the
predictability and stability of hospital
payments for these complex, novel cell
therapies and that we should continue
to monitor and assess the
appropriateness of therapies assigned to
MS–DRG 018, if they continue to be
aligned on resource use, and whether
additional refinements or MS–DRGs
may be warranted in the future.
We also noted that the process of code
creation and proposed assignment to the
most appropriate MS–DRG exists
independently, regardless of whether
there is an associated application for a
new technology add-on payment for a
product or technology submitted for
consideration in a given fiscal year.
Specifically, requests for a new code(s)
or updates to existing codes are
addressed through the ICD–10
Coordination and Maintenance
Committee meetings, held annually in
the spring and fall, where code
proposals are presented and the public
is provided the opportunity to
comment. All codes finalized from the
fall meeting are subsequently proposed
for assignment under the ICD–10 MS–
DRGs through rulemaking. We refer the
reader to section II.D.17 of the preamble
of this final rule for additional
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
information regarding the ICD–10
Coordination and Maintenance
Committee meeting process.
As stated in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28130), there
were no requests or proposals for new
procedure codes to describe the
administration of a CAR T-cell or
another type of gene or cellular therapy
discussed at the September 14–15, 2021
ICD–10 Coordination and Maintenance
Committee meeting. For the March 8–9,
2022 ICD–10 Coordination and
Maintenance Committee meeting, there
were topics included on the agenda and
in the related meeting materials that
included proposals for new procedure
codes to describe the administration of
a CAR T-cell or another type of gene or
cellular therapy product. The agenda
and related meeting materials for these
specific topics are available via the
internet on the CMS website at: https://
www.cms.gov/Medicare/Coding/ICD10/
C-and-M-Meeting-Materials.
As stated in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 44805) and noted
previously, the process of code creation
and proposed assignment to the most
appropriate MS–DRG exists
independently, regardless of whether
there is an associated application for a
new technology add-on payment for a
product or technology submitted for
consideration in a given fiscal year. We
also clarified that the assignment of a
procedure code to a MS–DRG is not
dependent upon a product’s FDA
approval. Similarly, the creation of a
code to describe a technology that is
utilized in the performance of a
procedure or service does not require
FDA approval of the technology.
Because the diagnosis and procedure
code proposals that are presented at the
March meeting for an October 1
implementation (upcoming FY) are not
finalized in time to include in Table
PO 00000
Frm 00027
Fmt 4701
Sfmt 4700
48805
6A.—New Diagnosis Codes and Table
6B.—New Procedure Codes in
association with the proposed rule, as
noted in prior rulemaking, we use our
established process to examine the MS–
DRG assignment for the predecessor
codes to determine the most appropriate
MS–DRG assignment. Specifically, we
review the predecessor code and MS–
DRG assignment most closely associated
with the new procedure code, and in the
absence of claims data, we consider
other factors that may be relevant to the
MS–DRG assignment, including the
severity of illness, treatment difficulty,
complexity of service and the resources
utilized in the diagnosis or treatment of
the condition. We have noted in prior
rulemaking that this process does not
automatically result in the new
procedure code being assigned to the
same MS–DRG or to have the same
designation (O.R. versus Non-O.R.) as
the predecessor code.
As stated in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28130), in
response to commenters’
recommendation that we continue to
assess the appropriateness of the
therapies assigned to Pre-MDC MS–DRG
018, we provided the results of our data
analysis using the September 2021
update of the FY 2021 MedPAR file for
cases reporting the administration of a
CAR T-cell or other immunotherapy in
Pre-MDC MS–DRG 018 and the number
of cases reporting a secondary diagnosis
of Z00.6 (Encounter for examination for
normal comparison and control in
clinical research program). We noted
that if a procedure code that is assigned
to the logic for Pre-MDC MS–DRG 018
is not listed it is because there were no
cases found. We also noted there were
no cases reporting diagnosis code Z00.6
as a principal diagnosis. Our findings
are shown in the following table.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
MS-DRG
khammond on DSKJM1Z7X2PROD with RULES2
018
ICD-10-PCS Code
All cases
XW033C7 - Introduction of autologous
engineered chimeric antigen receptor t-cell
immunotherapy into peripheral vein,
percutaneous annroach, new technology group 7
XW033M7 - Introduction ofbrexucabtagene
autoleucel immunotherapy into peripheral vein,
percutaneous annroach, new technology group 7
XW033N7 - Introduction of lisocabtagene
maraleucel immunotherapy into peripheral vein,
percutaneous approach, new technology group 7
XW043C7 - Introduction of autologous
engineered chimeric antigen receptor t-cell
immunotherapy into central vein, percutaneous
approach, new technology group 7
XW043M7 - Introduction ofbrexucabtagene
autoleucel immunotherapy into central vein,
percutaneous annroach, new technology group 7
XW043N7 -Introduction oflisocabtagene
maraleucel immunotherapy into central vein,
percutaneous annroach, new technology group 7
The data show that there is a wide
range in the volume of cases (4 cases
versus 435 cases), average length of stay
(11.3 days versus 20.3 days), and
average costs ($157,950 versus
$310,561) reporting the administration
of CAR T-cell therapies in MS–DRG 018.
This is to be expected since these
therapies continue to evolve and the
ICD–10–PCS coding to identify and
describe these therapies also continues
to be refined through the ICD–10
Coordination and Maintenance
Committee meeting process. As
additional claims data becomes
available for these therapies, we will
continue to evaluate to determine if
further modifications to Pre-MDC MS–
DRG 018 are warranted.
We noted in the proposed rule that in
response to our statement in the FY
2022 IPPS/LTCH PPS final rule that we
plan to continue engaging with
interested parties on additional options
for consideration in this field of cellular
and gene therapies, we received
additional feedback and suggestions,
including recommendations for Town
Hall meetings/listening sessions to
discuss the interconnectedness of these
issues; exploration of what was
described as a different set and kind of
MS–DRGs that would reward providers
for controlling patient care costs,
without consideration of product costs
outside of their control; and evaluation
of the creation and assignment of
multiple MS–DRGs for cell and gene
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Number
of Cases
558
50
Average
Length of
Stay
16.5
13.2
Average
Costs
$194,717
$212,265
Secondary
Diagnosis
Z00.6
185
16
11
14.1
$157,950
4
4
11.3
$310,561
1
435
16.7
$186,038
152
43
20.3
$264,932
7
15
14.2
$182,700
5
therapy cases: one to cover patient care
costs, the other to cover product costs
across therapeutic product categories.
We stated we appreciated this
additional feedback and will continue to
consider these issues and suggestions in
connection with future rulemaking. We
also stated we intend to continue
engaging with interested parties by
sharing updates from our analysis of
claims data as we examine and explore
potential refinements for these therapies
under the IPPS.
Comment: Several commenters
expressed support and appreciation that
for FY 2023, CMS proposed to maintain
the current structure of Pre-MDC MS–
DRG 018 that includes ‘‘Other
Immunotherapies’’, and to maintain its
current methodology used to determine
the relative weight. Some commenters
acknowledged that it is difficult to
predict what the associated costs will be
in the future for CAR T-cell and other
immunotherapies that remain under
development. These commenters urged
CMS to consider factors such as new or
different side effects and how other
therapeutic agents that could be
administered simultaneously in
connection with these therapies may
potentially lead to toxicity, as continued
monitoring of resource utilization and
data analysis for Pre-MDC MS–DRG 018
occurs. Other commenters commended
CMS for its commitment to engage with
interested parties as the agency
continues to analyze claims data and
PO 00000
Frm 00028
Fmt 4701
Sfmt 4700
consider the feedback that has been
received to date for these therapies.
Response: We thank the commenters
for their support and appreciate the
additional feedback on other factors to
consider as we continue to monitor and
analyze the data for Pre-MDC MS–DRG
018. As noted in prior rulemaking, we
have received several suggestions,
recommendations, and options
pertaining to how CAR T-cell and other
immunotherapies may be classified
under the IPPS in the future. We intend
to further examine the feedback
received and maintain transparency in
our approach moving forward, with the
shared goal of enabling continued
access to these and other vital
treatments for Medicare beneficiaries.
Comment: Similar to the public
comments received in response to the
FY 2022 IPPS/LTCH PPS proposed rule,
for FY 2023, some commenters again
expressed concerns with the non-CAR
T-cell therapies and other
immunotherapies that may be assigned
to Pre-MDC MS–DRG 018 and stated
that these potential assignments could
lead to fluctuations in the relative
weight. A few commenters requested
that Pre-MDC MS–DRG 018 be limited
to CAR T-cell therapies. Other
commenters encouraged CMS to clarify
its methodology and criteria for
assigning new procedure codes to PreMDC MS–DRG 018. Some commenters
expressed continued concern with the
revision to the title for Pre-MDC MS–
DRG 018 that was finalized effective FY
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.006
48806
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
2022 to include ‘‘Other
Immunotherapies’’.
Response: In the FY 2022 IPPS/LTCH
PPS final rule (86 FR 44798 through
44806), we provided detailed
summaries and responses to these same
or similar concerns and comments. In
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28129 through 28131), we
provided an overview of the assignment
of new procedure codes to Pre-MDC
MS–DRG 018 and reiterated much of the
discussion from FY 2022 rulemaking.
As stated in prior rulemaking, the MS–
DRG system is a system of averages and
it is expected that within the diagnostic
related groups, some cases may
demonstrate higher than average costs,
while other cases may demonstrate
lower than average costs. We have not
made any changes to our established
processes or methodologies for MS–DRG
assignment of new procedure codes,
including with regard to case
assignment to Pre-MDC MS–DRG 018,
and we refer the reader to the detailed
discussion related to Pre-MDC MS–DRG
018 in the FY 2022 IPPS/LTCH PPS
final rule. We note that additional
claims data is needed to fully analyze
and consider all the recommendations
we have received, and to potentially
develop alternative proposals with
respect to payment for these therapies
under the IPPS. There is also
uncertainty with regard to the number
and types of therapies currently under
development or undergoing studies and
how soon they will be available. We
recognize the concerns that have been
expressed by commenters and we are
also continuing to assess the reliability
and stability of the data in light of the
ongoing public health emergency.
Comment: Many commenters
expressed appreciation to CMS for
providing transparency with the cases
reporting the administration of a CAR Tcell or other immunotherapy in the FY
2021 MedPAR claims data for Pre-MDC
MS–DRG 018. However, a commenter
indicated there was confusion about the
coded claims data as presented in the
proposed rule since the procedure codes
described as new technology group 7
became effective October 1, 2021 (FY
2022), which is one year later than the
FY 2021 data that was shown in the
table in the preamble of the proposed
rule. The commenter requested that
CMS provide clarification to help
eliminate any additional confusion for
readers and interested parties who also
analyze the data for these therapies.
Response: We thank the commenters
for their support. The FY 2021 MedPAR
claims data were regrouped using the
proposed FY 2023 MS–DRG
classifications, therefore, coded claims
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
data for the procedure codes describing
the administration of CAR T-cell and
other immunotherapy agents reported in
FY 2021 was mapped from the FY 2021
MedPAR coded claims data to the
procedure codes that are effective for FY
2023. Specifically, the codes that were
effective for FY 2021 and are no longer
valid were mapped to the new
procedure codes that are valid for FY
2023. We also note, as generally stated
in the preamble of the proposed rule
each year, the diagnosis and procedure
codes from the specified FY MedPAR
claims data are grouped through the
applicable version of the proposed FY
GROUPER. For example, as discussed in
section II.E.1. of the preamble of the
proposed rule (87 FR 28197), the
proposed FY 2023 relative weights are
based on the ICD–10–CM diagnosis
codes and ICD–10–PCS procedure codes
from the FY 2021 MedPAR claims data,
grouped through the ICD–10 version of
the proposed FY 2023 GROUPER
(Version 40).
Comment: A commenter suggested
that CMS consider establishing a
timeframe that would enable the public
to comment on procedure codes that
may be assigned to Pre-MDC MS–DRG
018 upon being approved and finalized
after the spring ICD–10 Coordination
and Maintenance Committee meeting.
The commenter stated that currently,
because procedure codes that are
discussed at the spring ICD–10
Coordination & Maintenance (C&M)
Committee meeting do not receive
proposed assignments and are not
published with the IPPS proposed rule
given the timing, there is no opportunity
for interested parties to provide
feedback to CMS about MS–DRG
assignments for new codes, including
assignment to MS–DRG–018. The
commenter acknowledged the C&M
meeting is not the appropriate forum for
the public to provide input on MS–DRG
assignment, however, because Pre-MDC
MS–DRG 018 currently has a limited
number of procedure codes assigned to
it, the commenter stated that interested
parties should have the opportunity to
review and comment on potential
assignment to Pre-MDC MS–DRG 018.
This commenter also maintained that it
has a unique relationship with the
therapies currently assigned to Pre-MDC
MS–DRG 018 as its membership is the
predominant specialty society
associated with these therapies and has
the experience and clinical
understanding related to resource
utilization associated with the
administration of these therapies.
Response: We appreciate the
commenter’s feedback. As discussed
elsewhere in this rule as well as in prior
PO 00000
Frm 00029
Fmt 4701
Sfmt 4700
48807
rulemaking, because the procedure code
proposals discussed at the Spring ICD–
10 Coordination and Maintenance
Committee meeting are not finalized in
time to include in Table 6B.—New
Procedure codes associated with the
proposed rule, CMS uses an established
process to determine the most
appropriate MS–DRG assignment for
these new procedure codes for the
upcoming fiscal year. While we
understand and acknowledge the
uniqueness of CAR T-cell, gene, and
cellular therapies, we believe it is
necessary to further examine how and
when we could alter our current
methodology and timelines to provide
the opportunity for interested parties to
submit comments and feedback in the
assignment of new procedure codes that
are finalized after the spring meeting.
We also note, as discussed in the
proposed rule (87 FR 28130), all codes
finalized from the fall meeting are
subsequently proposed for assignment
under the ICD–10 MS–DRGs through
rulemaking, therefore, interested parties
seeking the opportunity to more fully
comment on potential MS–DRG
assignment(s) have the opportunity to
submit requests for consideration of
proposed new procedure codes in
association with these therapies to be
discussed at the fall meeting versus the
spring meeting. Alternatively, interested
parties may use current coding
information as shown in the ICD–10
Coordination and Maintenance
Committee meeting materials to
consider the potential MS–DRG
assignments for any procedure codes
that may be finalized after the March
meeting and submit public comments
for consideration.
As noted in the proposed rule, for the
March 8–9, 2022 ICD–10 Coordination
and Maintenance Committee meeting
there were two topics included on the
agenda and in the related meeting
materials that included proposals for
new procedure codes to describe the
administration of a CAR T-cell or
another type of gene or cellular therapy
product. The two topics are
Administration of afamitresgene
autoleucel (afami-cel), a specific peptide
enhanced affinity receptor (SPEAR) Tcell therapy and Administration of
Tabelecleucel (tab-cel®), an allogeneic
Epstein-Barr virus (EBV)-specific T-cell
immunotherapy, both of which were
approved for new procedure codes
following the March meeting. We refer
the reader to the CMS website at https://
www.cms.gov/Medicare/Coding/ICD10/
C-and-M-Meeting-Materials for
additional detailed information
regarding these code requests.
E:\FR\FM\10AUR2.SGM
10AUR2
48808
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Because the diagnosis and procedure
code proposals that are presented at the
March ICD–10–CM Coordination and
Maintenance Committee meeting for an
October 1 implementation (upcoming
FY) are not finalized in time to include
in Table 6A.—New Diagnosis Codes and
Table 6B.—New Procedure Codes in
association with the proposed rule, as
we have noted in prior rulemaking, we
use our established process to examine
the MS–DRG assignment for the
predecessor codes to determine the most
appropriate MS–DRG assignment.
Specifically, we review the predecessor
code and MS–DRG assignment most
closely associated with the new
procedure code, and in the absence of
claims data, we consider other factors
that may be relevant to the MS–DRG
assignment, including the severity of
illness, treatment difficulty, complexity
of service and the resources utilized in
the diagnosis and/or treatment of the
condition. We have noted in prior
rulemaking that this process does not
automatically result in the new
procedure code being assigned to the
same MS–DRG or to have the same
designation (O.R. versus Non-O.R.) as
the predecessor code. As shown in
Table 6B.—New Procedure Codes
associated with this final rule and
available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS, new
procedure codes for these two therapies
have been finalized for assignment to
Pre-MDC MS–DRG 018 effective with
discharges on and after October 1, 2022
(FY 2023).
We appreciate the public comments
we received, and, as noted, will
continue to evaluate the
recommendations and options provided
by commenters related to these
therapies as well as to monitor the
available claims data.
khammond on DSKJM1Z7X2PROD with RULES2
3. MDC 01 (Diseases and Disorders of
the Nervous System)
a. Laser Interstitial Thermal Therapy
(LITT)
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 44812 through 44814), we
finalized the reassignment of 31 ICD–
10–PCS procedure codes describing
laser interstitial thermal therapy (LITT)
of various body parts to more clinically
appropriate MS–DRGs, as shown in
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Table 6P.2b associated with the FY 2022
IPPS/LTCH PPS final rule and available
via the internet on the CMS website at:
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS, including the
reassignment of procedure codes
D0Y0KZZ (Laser interstitial thermal
therapy of brain) and D0Y1KZZ (Laser
interstitial thermal therapy of brain
stem), which were reassigned from MS–
DRG 023 (Craniotomy with Major
Device Implant or Acute Complex CNS
Principal Diagnosis with MCC or
Chemotherapy Implant or Epilepsy with
Neurostimulator), MS–DRG 024
(Craniotomy with Major Device Implant
or Acute Complex CNS Principal
Diagnosis without MCC), and MS–DRGs
025, 026, and 027 (Craniotomy and
Endovascular Intracranial Procedures
with MCC, with CC, and without CC/
MCC, respectively) to MS–DRGs 040,
041, and 042 (Peripheral, Cranial Nerve
and Other Nervous System Procedures
with MCC, with CC and without CC/
MCC, respectively).
We also finalized the redesignation of
these two LITT procedures (codes
D0Y0KZZ and D0Y1KZZ) and the
reassignment from extensive O.R.
procedures in MS–DRGs 981, 982 and
983 (Extensive O.R. Procedure
Unrelated to Principal Diagnosis with
MCC, with CC, and without CC/MCC,
respectively) to non-extensive O.R.
procedures in MS–DRGs 987, 989, and
989 (Non-Extensive O.R. Procedure
Unrelated to Principal Diagnosis with
MCC, with CC, and without CC/MCC,
respectively) (86 FR 44889).
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28131),
for FY 2023, we received two requests
from the manufacturers of the LITT
technology (Medtronic and Monteris®
Medical) to reverse the MS–DRG
reassignment for the ICD–10 procedure
codes that identify LITT of the brain and
brain stem (codes D0Y0KZZ and
D0Y1KZZ) from the MS–DRGs for
peripheral, cranial nerve and other
nervous system procedures (MS–DRGs
040, 041, and 042) back to the MS–DRGs
for craniotomy and endovascular
procedures (MS–DRGs 023, 024, 025,
026, and 027). The first requestor
acknowledged that the technique
utilized in the performance of LITT
procedures for the brain and brain stem
are minimally invasive and do not
PO 00000
Frm 00030
Fmt 4701
Sfmt 4700
involve a craniotomy however, the
requestor also stated the procedures
assigned to MS–DRGs 025, 026, and 027
are not exclusive to craniotomies. The
requestor further stated that these LITT
procedures involve a twist drill or burr
hole and are similar to other noncraniotomy procedures in MS–DRGs
025, 026, and 027 including radioactive
elements and neurostimulator leads that
involve inserting these devices into the
brain.
In its review of the other procedures
assigned to MS–DRGs 040, 041, and
042, the requestor stated that there are
distinct clinical differences between the
invasiveness of LITT that involves
instrumentation being placed deeply
within the brain tissue and the noninvasiveness of stereotactic radiosurgery
that does not involve entering the brain
with instrumentation. The requestor
also indicated LITT utilizes a different
modality via direct thermal ablation
compared to stereotactic radiosurgery
that utilizes externally-generated
ionizing radiation.
The requestor performed its own data
analysis for LITT procedures of the
brain and brain stem using MedPAR
data from FY 2019 through FY 2022
impact files. According to the requestor,
its findings demonstrate that the costs of
the cases reporting LITT of the brain or
brain stem are better aligned with MS–
DRGs 025, 026, and 027 compared to
MS–DRGs 040, 041, and 042.
The second requestor similarly
discussed the steps and resources
involved in the performance of LITT
procedures for the brain and brain stem,
provided its detailed analysis on the
indications for LITT (brain tumors and
epileptic foci), compared LITT to other
procedures in MS–DRGs 025, 026, and
027 and stated that the majority of the
procedures currently assigned to MS–
DRGs 040, 041, 042 are not performed
for the treatment of brain cancer or
epilepsy. The requestor stated that the
LITT procedure is on the inpatient only
list and is only performed on Medicare
beneficiaries in the inpatient hospital
setting. The requestor provided the top
10 principal diagnoses associated with
LITT of brain cases it found based on its
analysis, and identified the diagnoses
for which there were less than 10 cases
with an asterisk, as reflected in the
following table.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
167.89
G40.919
G40.804
C71.3
khammond on DSKJM1Z7X2PROD with RULES2
The requestor asserted that the
statement in the FY 2022 IPPS/LTCH
PPS final rule that the technique to
perform the LITT procedure on brain
and brain stem structures is considered
minimally invasive and does not
involve a craniotomy, and that
therefore, continued assignment to the
craniotomy MS–DRGs is not clinically
appropriate, mischaracterizes both the
LITT procedures and universe of
services assigned to MS–DRGs 023
through 027. The requestor
acknowledged that the craniotomy
procedures listed in the logic for MS–
DRGs 023 through 027 include open
procedures but stated the logic also lists
less invasive procedures including
percutaneous and percutaneous
endoscopic procedures. The requestor
asserted that open procedures are a
minority of the ICD–10–PCS codes
assigned to these MS–DRGs.
In addition, the requestor stated that
LITT and craniotomy are in fact very
ICD-10CM Code
163.9
163.40
163.89
G45.9
163.412
El 1.610
163.411
163.512
C79.31
163.81
VerDate Sep<11>2014
clinically similar; in that both
procedures are intended to remove and
destroy the targeted tumor and lesion
with a different surgical tool used
(scalpel versus heated ablation probe).
According to the requestor, brain LITT
procedures involve insertion of laser
probes into the brain which requires
opening both the skull and dura, similar
to a craniotomy. The requestor also
stated that craniotomy and LITT share
several procedural characteristics and
provided the following list.
• Require an operating room;
• Performed under general
anesthesia;
• Require creation of burr holes and
invasive skull fixation;
• Require a sterile field, incision,
opening of the skull and dura;
• Cause tissue to be immediately
destroyed or excised;
• Carry a risk of immediate
intracranial bleeding;
• Require closure of the scalp wound;
Cerebral infarction, unspecified
Cerebral infarction due to embolism of unspecified cerebral artery
Other cerebral infarction
Transient cerebral ischemic attack, unspecified
Cerebral infarction due to embolism of left middle cerebral artery
Type 2 diabetes mellitus with diabetic neuropathic arthropathy
Cerebral infarction due to embolism of right middle cerebral artery
Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral
artery
Secondarv mali!!llant neoplasm of brain
Other cerebral infarction due to occlusion or stenosis of small artery
Jkt 256001
PO 00000
Frm 00031
Fmt 4701
Sfmt 4725
13
*
*
*
*
*
*
*
• Risk intracranial infection; and
• Require a hospital stay of one or
more nights.
In contrast, the requestor stated that
procedures assigned to MS–DRGs 040,
041, and 042 are primarily nerve
procedures or excision or detachment
procedures performed on parts of the
body other than the head, including the
upper and lower extremities. According
to the requestor, none of the procedures
in MS–DRGs 040, 041, and 042 require
drilling into the patient’s skull, a step
which is integral to LITT. The requestor
provided the following top 10 principal
diagnoses associated with cases it found
in MS–DRGs 040, 041, and 042 during
its analysis and stated that most of the
procedures assigned to MS–DRGs 040,
041, and 042 are not typically
performed in the treatment of brain
cancer or epilepsy.
Description
00:20 Aug 10, 2022
Cases
39
17
E:\FR\FM\10AUR2.SGM
10AUR2
Cases
1,928
610
489
456
378
371
341
335
326
271
ER10AU22.008
C71.9
C71.1
C71.2
G40.419
Description
Secondary malignant neoplasm of brain
Localization-related (focal) (partial) symptomatic epilepsy and epileptic
syndromes with complex partial seizures, intractable, without status
epilepticus
Malignant neoplasm of brain, unspecified
Malignant neoplasm of frontal lobe
Malignant neoplasm of temporal lobe
Other generalized epilepsy and epileptic syndromes, intractable, without
status epilepticus
Other cerebrovascular disease
Epilepsy, unspecified, intractable, without status epilepticus
Other epilepsy, intractable, without status epilepticus
Malignant neoplasm of parietal lobe
ER10AU22.007
ICD-10-CM
Code
C79.31
G40.219
48809
khammond on DSKJM1Z7X2PROD with RULES2
48810
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
However, the requestor stated an
exception is stereotactic radiosurgery
(SRS) procedures performed on the
brain and brain stem that are assigned
to MS–DRGs 040, 041, and 042 and are
used to treat brain cancer. According to
the requestor, craniotomy, LITT and
SRS are all image-guided procedures
used to treat a variety of brain disorders
including tumors and epilepsy,
although it stated that is where any
similarity between LITT and SRS ends
and where the procedural similarities
between craniotomy and LITT begin.
The requestor stated SRS is a noninvasive procedure that gradually
destroys or inactivates tissues in or
around the brain and is typically
performed on an outpatient basis while
inpatient SRS treatment is rare.
According to the requestor, SRS does
not require an operating room, is rarely
done under general anesthesia (children
and highly claustrophobic individuals
being an exception), and does not
require (but can use) rigid skull fixation.
In addition, the requestor stated that
because it is non-invasive, there is no
need for a sterile field, incision,
opening/closing of the skull, opening/
closing of the dura, suturing/stapling
the wound, and produces essentially no
risk of immediate intracranial bleeding
or delayed infection. According to the
requestor, LITT is much more invasive
than SRS using a head frame and
involves and requires the same surgical
skill and hospital resources as
craniotomies.
In the proposed rule we noted that
following the submission of the two FY
2023 MS–DRG classification change
requests for LITT, these same two
requestors (the manufacturers of the
LITT technology) submitted a joint code
proposal requesting an overall change to
how LITT is classified within the ICD–
10–PCS classification and for
consideration as an agenda topic to be
discussed at the March 8–9, 2022 ICD–
10 Coordination and Maintenance
Committee meeting. The proposal was
presented and discussed at the March
8–9, 2022 ICD–10 Coordination and
Maintenance Committee meeting. We
referred the reader to the CMS website
at: https://www.cms.gov/Medicare/
Coding/ICD10/C-and-M-MeetingMaterials for additional detailed
information regarding the request,
including a recording of the discussion
and the related meeting materials.
Public comments in response to the
code proposal were due by April 8,
2022.
Because the diagnosis and procedure
code proposals that are presented at the
March ICD–10–CM Coordination and
Maintenance Committee meeting for an
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
October 1 implementation (upcoming
FY) are not finalized in time to include
in Table 6A. —New Diagnosis Codes
and Table 6B.—New Procedure Codes in
association with the proposed rule, as
we have noted in prior rulemaking and
discuss further in this section, we use
our established process to examine the
MS–DRG assignment for the predecessor
codes to determine the most appropriate
MS–DRG assignment. Specifically, we
review the predecessor code and MS–
DRG assignment most closely associated
with the new procedure code, and in the
absence of claims data, we consider
other factors that may be relevant to the
MS–DRG assignment, including the
severity of illness, treatment difficulty,
complexity of service and the resources
utilized in the diagnosis and/or
treatment of the condition. We have
noted in prior rulemaking that this
process does not automatically result in
the new procedure code being assigned
to the same MS–DRG or to have the
same designation (O.R. versus Non-O.R.)
as the predecessor code. Under this
established process, the MS–DRG
assignment for the upcoming fiscal year
for any new diagnosis or procedure
codes finalized after the March meeting
would be reflected in Table 6A.—New
Diagnosis Codes and Table 6B.—New
Procedure Codes associated with the
final rule for that fiscal year. However,
as stated in the proposed rule, in light
of the unique circumstances relating to
these procedures, for which there was a
pending proposal to reclassify LITT
within ICD–10–PCS and for new
procedure codes discussed at the March
meeting, as well as an MS–DRG
reclassification request to reassign the
existing codes describing these
procedures, we addressed in this section
first, the code proposal discussed at the
March meeting and the possible MS–
DRG assignments for any new codes that
may be approved, and then secondly,
the requested reassignment of the
existing codes, in the event the new
codes are not approved.
To summarize, as discussed at the
March meeting, the code proposal was
to reclassify LITT procedures from the
Radiation Therapy section of ICD–10–
PCS (Section D) to the Medical and
Surgical section of ICD–10–PCS.
Specifically, the proposal was to
reclassify LITT procedures to the root
operation Destruction. In ICD–10–PCS,
the root operation Destruction is defined
as physical eradication of all or a
portion of a body part by the direct use
of energy, force, or a destructive agent.
According to the requestors, LITT is
misclassified to section D-Radiation
Therapy in ICD–10–PCS possibly
PO 00000
Frm 00032
Fmt 4701
Sfmt 4700
because of terminology that was used
for predicate devices, whose indications
included the phrase ‘‘interstitial
irradiation or thermal therapy’’ in
describing LITT’s method of action. The
requestors stated LITT is thermal
therapy, destroying soft tissue using
heat generated by a laser probe at the
target site and that the LITT procedure
does not use ionizing radiation, which
is what the term ‘‘radiation’’ commonly
refers to in the general medical sense.
The requestors also stated that by itself,
radiation is a broad term and provided
an example that the spectrum of
electromagnetic radiation technically
encompasses low energy non-ionizing
radio waves, microwaves, and infrared
to high energy ionizing X-rays and
gamma rays while ionizing radiation
creates ions in the cells it passes
through by removing electrons, a
process which kills or alters the cells
over time.
The requestors further stated that only
certain medical uses of radiation are
classified to section D-Radiation
Therapy. For instance, section DRadiation Therapy categorizes
treatments using ionizing radiation,
including beam radiation,
brachytherapy, and stereotactic
radiosurgery. All of these deliver
concentrated ionizing radiation to
eradicate abnormal cells, most
commonly neoplasms. Other treatments
classified to section D-Radiation
Therapy, such as hyperthermia, are used
as adjuncts to ionizing radiation. The
requestors asserted that while LITT
eradicates abnormal cells, it does so
with heat, not ionizing radiation and
rather than a radiation therapy
procedure, LITT is a surgical procedure.
According to the requestors, LITT
would be more appropriately classified
as an ablation procedure with the root
operation Destruction.
As stated in the proposed rule, the
original request for a new code(s) to
describe the LITT technology was
initially discussed at the September 24–
25, 2008 ICD–9–CM Coordination and
Maintenance Committee meeting. At
that time, the requestor sought an April
1, 2009 implementation date. Public
comments opposed an April 1, 2009
implementation date, therefore, effective
October 1, 2009 (FY 2010), ICD–9–CM
procedure codes were created to
identify procedures performed utilizing
the LITT technology. The following
table lists the ICD–9–CM procedure
codes describing LITT and their
respective MDC and MS–DRG
assignments under the ICD–9 based
MS–DRGs. We refer the reader to the
ICD–9 and ICD–10 MS–DRG Definitions
Manual Files V33 (available via the
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ICD-9-CM
Procedure
Code
17.61
17.62
17.63
khammond on DSKJM1Z7X2PROD with RULES2
17.69
Downloads section) for complete
documentation of the GROUPER logic
for ICD–9.
Description
Laser interstitial thermal therapy [LITT] of lesion or tissue of
brain under guidance
Laser interstitial thermal therapy [LITT] of lesion or tissue of
head or neck under guidance
Laser interstitial thermal therapy [LITT] of lesion or tissue of
liver under guidance
Laser interstitial thermal therapy [LITT] of lesion or tissue of
other and unspecified site under guidance
The requestors maintain that although
LITT was used to treat a variety of
anatomic sites when it was first
introduced, its current primary use is
intracranial, specifically to treat brain
tumors and epileptic foci. However, the
requestors stated it is also used to treat
radiation necrosis, an inflammatory
response from prior treatment with
ionizing radiation.
We noted in the proposed rule that
currently, in the U.S., there are only two
LITT systems in use, VisualaseTM MRIGuided Laser Ablation (Medtronic) and
the Neuroblate® System (Monteris®
Medical). The requestors also stated that
over the last six years, the Indications
for Use (IFU) for one of the two U.S.
approved LITT technologies
(Neuroblate®) has been updated to
reflect the system’s current use in the
brain and to align with the intended
neurosurgical patient population. The
requestor indicated applications in the
spine are also anticipated in the future
within the central nervous system.
As previously noted, the deadline for
receipt of public comments for the
proposed reclassification of LITT
procedures that was presented at the
March 8–9, 2022 ICD–10 Coordination
and Maintenance Committee meeting
along with the corresponding proposal
for new procedure codes was April 8,
2022, and the final code decisions on
these proposals were not yet available
for inclusion in Table 6B.—New
Procedure Codes associated with the FY
2023 IPPS/LTCH PPS proposed rule.
However, as discussed in prior
VerDate Sep<11>2014
AcuteInpatientPPS/Acute-InpatientFiles-for-Download-Items/FY2016-FinalRule-Correction-Notice-Files in the
00:20 Aug 10, 2022
Jkt 256001
rulemaking (86 FR 44805), codes that
are finalized after the March meeting are
reviewed and subject to our established
process of initially reviewing the
predecessor codes MS–DRG assignment
and designation, while considering
other relevant factors (for example,
severity of illness, treatment difficulty,
complexity of service and the resources
utilized in the diagnosis and/or
treatment of the condition) as
previously described. The codes that are
finalized after the March meeting are
specifically identified with a footnote in
Tables 6A.—New Diagnosis Codes and
Table 6B.—New Procedure Codes that
are made publicly available in
association with the final rule via the
internet on the CMS website at https://
www.cms.gov/medicare/medicare-feefor-service-payment/acuteinpatientpps.
The public may provide feedback on
these finalized assignments, which is
then taken into consideration for the
following fiscal year.
We stated in the proposed rule that
the MS–DRG assignment for any new
procedure codes describing LITT, if
finalized following the March meeting,
would be reflected in Table 6B.—New
Procedure Codes associated with the
final rule for FY 2023. However, in light
of the unique circumstances with
respect to these procedures, for which
there was both a proposal for
reclassifying LITT from the Radiation
Therapy section of the procedure code
classification to the Medical/Surgical
section with new ICD–10–PCS
procedure code(s) and a separate MS–
PO 00000
Frm 00033
Fmt 4701
Sfmt 4700
MDC
MDC0I
MS-DRG
023-027
MDC 10
MDC 17
MDC 17
MDC06
MDC07
MDC04
MDC09
MDC 12
MDC 17
MDC 17
625-627
820-822
826-828
356-358
405-407
163-165
584-585
715-718
820-822
826-828
DRG reclassification request on the
existing procedure codes, we provided
the opportunity for public comment on
possible MS–DRG assignments for the
requested new procedure codes
describing LITT that may apply based
on the application of our established
process and analysis, in the event the
new codes were finalized for FY 2023.
We also noted that while we discussed
the potential MS–DRG assignments for
new procedure codes describing LITT,
interested parties may use current
coding information to consider the
potential MS–DRG assignments for any
other procedure codes that may be
finalized after the March meeting and
submit public comments for
consideration. Specifically, in the ICD–
10 Coordination and Maintenance
Committee meeting materials (available
via the internet on the CMS website at:
https://www.cms.gov/Medicare/Coding/
ICD10/C-and-M-Meeting-Materials), for
each procedure code proposal we
provide the current coding that is
applicable within the classification and
that should be reported in the absence
of a more unique code, or until such
time a new code is created and becomes
effective. The procedure code(s) listed
in current coding are generally, but not
always, the same code(s) that are
considered as the predecessor code(s)
for purposes of MS–DRG assignment. As
previously noted, our process for
determining the MS–DRG assignment
for a new procedure code does not
automatically result in the new
procedure code being assigned to the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.009
internet on the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
48811
48812
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
same MS–DRG or having the same
designation (O.R. versus Non-O.R.) as
the predecessor code. However, this
current coding information can be used
in conjunction with the GROUPER
logic, as set forth in the ICD–10 MS–
DRG Definitions Manual and publicly
available via the internet on our CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/MS–DRGClassifications-and-Software to review
the MS–DRG assignment of the current
code(s) and examine the potential MS–
DRG assignment of the proposed
code(s), to assist in formulating any
public comments for submission to CMS
for consideration.
We noted in the proposed rule that,
unlike the typical code request for a
new or revised procedure code that
involves a new technology or a new
approach to performing an existing
procedure, the circumstances for this
particular request are distinct in that the
code request would reclassify LITT
within the ICD–10–PCS classification
from section D—Radiation Therapy to
the root operation Destruction in the
Medical and Surgical section of ICD–
10–PCS. Therefore, in light of the
unique considerations with respect to
the requested reclassification of the
LITT procedures in connection with the
pending code proposal, we stated we
Section
ody System
Operation
believe it was appropriate to utilize the
assignments and designations of the
procedure codes describing Destruction
of the respective anatomic body site as
predecessor codes rather than the
current codes describing LITT from the
Radiation Therapy section of ICD–10–
PCS in considering potential MS–DRG
assignment for the requested new LITT
procedure codes.
As previously discussed, under our
established process for determining the
MS–DRG assignment for newly
approved procedure codes, we examine
the MS–DRG assignment for the
predecessor codes to determine the most
appropriate MS–DRG assignment for the
new codes. Specifically, we review the
predecessor code and MS–DRG
assignment most closely associated with
the new procedure code, and in the
absence of claims data, we consider
other factors that may be relevant to the
MS–DRG assignment, including the
severity of illness, treatment difficulty,
complexity of service and the resources
utilized in the diagnosis and/or
treatment of the condition. As we have
noted in prior rulemaking, this process
does not automatically result in the new
procedure code being assigned to the
same MS–DRG or to have the same
designation (O.R. versus Non-O.R.) as
the predecessor code.
Applying this established review
process to the proposed codes for the
LITT procedures, we stated we believe
that, based on the predecessor codes,
and as previously noted, the potential
assignments and designations would
align with the assignments and
designations of the procedure codes
describing Destruction of the respective
anatomic body site. For example, as
discussed in the preamble of the
proposed rule and earlier in this section
of this final rule, the code request
involved reclassifying LITT procedures
from section D—Radiation Therapy to
the root operation Destruction in the
Medical and Surgical section of ICD–
10–PCS. The root operation Destruction
is appropriate to identify and report
procedures, such as ablation, that are
performed on various body parts. The
code request also involved creating
what is referred to as a qualifier value,
to uniquely describe LITT as the
modality. The qualifier value is the
seventh character or digit, in a valid
ICD–10–PCS procedure code.
We presented the following ICD–10–
PCS table in the proposed rule, which
illustrates an example of the proposed
procedure codes for LITT of the brain
and brain stem, and cervical, thoracic,
and lumbar spinal cord body parts,
including the qualifier value that was
presented and discussed at the March
8–9, 2022 ICD–10 Coordination and
Maintenance Committee meeting.
0 Medical and Surgical
0 Central Nervous System and Cranial Nerves
5 Destruction: Physical eradication of all or a portion of a body part by the
direct use of energy, force, or a destructive agent
Body Part
Approach
Device
Open
Percutaneous
Percutaneous Endoscopic
Cervical Spinal Cord
Thoracic Spinal Cord
Lumbar Spinal Cord
khammond on DSKJM1Z7X2PROD with RULES2
We noted in the proposed rule that
the code proposal presented only
provided the body part value 0 Brain,
for reporting any LITT procedures
performed on the brain, as well as, the
brain stem, consistent with the current
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
available body part option in Table 005,
Destruction of Central Nervous System
and Cranial Nerves, where the
predecessor code is located. We also
noted that the predecessor code(s) and
associated MS–DRG assignments for the
PO 00000
Frm 00034
Fmt 4701
Sfmt 4700
proposed new procedure code(s)
describing LITT of the brain and spinal
cord under MDC 01 are identified as
follows.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.010
0 Brain
Qualifier
DD 3 Laser
nterstitial Thermal
No Device
Therapy
No Qualifier
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ICD-10-PCS
Code
00503ZZ
00504ZZ
ooswozz
005W3ZZ
005W4ZZ
oosxozz
khammond on DSKJM1Z7X2PROD with RULES2
005X3ZZ
005X4ZZ
00SY0ZZ
005Y3ZZ
005Y4ZZ
MS-DRG
Destruction of brain,
Destruction of brain,
Destruction of brain,
Destruction of cervic
Destruction of cervica
Destruction of cervica
Destruction of thoraci
Destruction of thoraci
Destruction of thoraci
Destruction of lumba
Destruction of lumbar s
Destruction of lumbar s
As shown in the table, the procedure
codes describing destruction of brain
with an open, percutaneous or
percutaneous endoscopic approach are
assigned to MS–DRGs 023 through 027
(craniotomy and endovascular
procedures) and the procedure codes
describing destruction of cervical,
thoracic or lumbar spinal cord with an
open, percutaneous or percutaneous
endoscopic approach are assigned to
MS–DRG 028 (Spinal Procedures with
MCC), MS–DRG 029 (Spinal Procedures
with CC or Spinal Neurostimulators),
and MS–DRG 030 (Spinal Procedures
without CC/MCC).
We referred the reader to Table 6P.2a
associated with the proposed rule (and
available via the internet at: https://
www.cms.gov/medicare/medicare-feefor-service-payment/acuteinpatientpps)
to review the potential MDCs, MS–
DRGs, and O.R. versus Non-O.R.
designations identified based on this
analysis of the proposed new procedure
codes describing LITT as presented and
discussed at the meeting. We noted that
Table 6P.2a also includes the
predecessor codes that we utilized to
inform this analysis. We stated that if
finalized, the new procedure codes
would be included in the FY 2023 code
update files that are made available in
late May/early June via the internet on
the CMS website at: https://
www.cms.gov/medicare/coding/icd10.
Additionally, we noted that if finalized,
the new procedure codes describing
LITT would be displayed in Table 6B.—
New Procedure Codes, and the existing
codes describing LITT would be deleted
and reflected in Table 6D.—Invalid
Procedure Codes, in association with
the FY 2023 IPPS/LTCH PPS final rule.
We referred the reader to section II.D.14.
of the preamble of the proposed rule for
further information regarding the files.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
023-027
028-030
We note that the proposal to reclassify
LITT procedures of the brain, brain stem
and other anatomic sites in ICD–10–PCS
that was discussed at the March 8–9,
2022 ICD–10 Coordination and
Maintenance Committee meeting was
approved and new procedure codes
describing LITT of the brain and other
anatomic sites were finalized as
reflected in the FY 2023 ICD–10–PCS
Code Update files that were made
publicly available via the internet on the
CMS website at https://www.cms.gov/
Medicare/Coding/ICD10 on May 26,
2022. We also note that the new
procedure codes effective October 1,
2022 describing LITT of the brain and
other anatomic sites are displayed in
Table 6B.—New Procedure Codes, and
the existing codes describing LITT of
the brain, brain stem, and other
anatomic sites that are being deleted
effective October 1, 2022 are reflected in
Table 6D.—Invalid Procedure Codes, in
association with this FY 2023 IPPS/
LTCH PPS final rule and available via
the internet on the CMS website at
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS. Below we
summarize the public comments we
received and present our responses.
Comment: Commenters expressed
appreciation that the proposal to
reclassify LITT procedures in ICD–10–
PCS that was discussed at the March 8–
9, 2022 ICD–10 Coordination and
Maintenance Committee meeting was
approved and new procedure codes
have been finalized as reflected in the
FY 2023 ICD–10–PCS Code Update files
that were made publicly available via
the internet on the CMS website at
https://www.cms.gov/Medicare/Coding/
ICD10 on May 26, 2022. Commenters
also indicated it is appropriate to utilize
procedure codes with the root operation
Destruction as the predecessor codes for
PO 00000
Frm 00035
Fmt 4701
Sfmt 4700
MS–DRG assignment of the new LITT
procedure codes for all the anatomic
body sites. Several commenters
expressed support for the assignment of
cases reporting new procedure codes for
LITT of brain (includes brain stem) from
MS–DRGs 040, 041, and 042 to MS–
DRGs 025, 026 and 027 and urged CMS
to finalize this assignment. The
commenters commended CMS for
recognizing the unique clinical
circumstances related to LITT
procedures of the brain as being more
appropriately aligned with MS–DRGs
025, 026 and 027. A commenter
acknowledged that the new procedure
codes for LITT of brain had not yet been
finalized at the time of the development
of the proposed rule and therefore, were
not reflected in the V40 Test GROUPER
software, however, the commenter
encouraged CMS to ensure the final V40
GROUPER logic reflects the new
procedure codes for LITT of brain and
assignment to MS–DRGs 025, 026 and
027.
Response: We thank the commenters
for their support. In addition to the new
procedure codes describing LITT being
made publicly available in the FY 2023
ICD–10–PCS Code Update files via the
internet on the CMS website at https://
www.cms.gov/Medicare/Coding/ICD10,
we note that, as previously stated, the
new procedure codes are also reflected
in Table 6B.—New Procedure Codes, in
association with this final rule and
available via the internet on the CMS
website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS with their
finalized MS–DRG assignments. As
shown in the table, procedure codes
describing LITT of brain (root operation
Destruction), are assigned to MS–DRGs
025, 026 and 027 for FY 2023. This
assignment is also reflected in the final
V40 GROUPER logic. Existing procedure
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.011
oosoozz
48813
48814
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ICD-10-PCS
Code
All Cases
23
D0Y0KZZ
24
All other cases
All Cases
All Cases
25
Number of Cases
11,599
1
11,598
4,391
19,586
77
19,509
6,956
25
6,931
7,323
20
7,303
D0Y0KZZ
All other cases
All Cases
26
D0Y0KZZ
All other cases
All Cases
27
D0Y0KZZ
All other cases
MS-DRG
ICD-10-PCS
Code
All Cases
40
D0Y0KZZ
Number of Cases
3,547
14
3,533
4,958
16
1
4,942
1,667
24
1
1,642
All other cases
All Cases
41
D0Y0KZZ
D0YIKZZ
All other cases
All Cases
khammond on DSKJM1Z7X2PROD with RULES2
42
D0Y0KZZ
D0YIKZZ
All other cases
As shown, we found a total of 123
cases reporting LITT of the brain across
MS–DRGs 023, 025, 026, and 027. There
were no cases found in MS–DRG 024.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Average Length of
Stay
15
10.1
5.2
9
5.6
9
5.1
2.6
5.1
2.4
2.1
2.4
Average Costs
$45,134
$60,994
$45,133
$31,759
$35,956
$27,148
$35,991
$24,566
$24,741
$24,565
$20,498
$34,874
$20,459
Average Length of
Stay
9.9
8.1
9.9
5
3.4
1
5
2.9
1.7
2
2.9
Average Costs
$30,212
$40,458
$30,171
$19,090
$23,278
$10,222
$19,076
$15,451
$22,426
$32,668
$15,325
IO.I
The cases reporting LITT of the brain
grouped to these MS–DRGs because
another O.R. procedure that is assigned
to the respective MS–DRG was also
PO 00000
Frm 00036
Fmt 4701
Sfmt 4700
In the proposed rule we stated that we
examined claims data from the
September 2021 update of the FY 2021
MedPAR file for MS–DRGs 023, 024,
025, 026, and 027, in addition to MS–
DRGs 040, 041, and 042 for cases
reporting LITT of the brain (code
D0Y0KZZ) or brain stem (code
D0Y1KZZ). We noted that if a procedure
code is not listed it is because there
were no cases found reporting that
procedure code. Our findings are shown
in the following tables.
reported. We referred the reader to
Table 6P.2b in association with the
proposed rule for the list of the other
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.013
MS-DRG
identify LITT of the brain and brain
stem (codes D0Y0KZZ and D0Y1KZZ).
We stated in the proposed rule that in
the event there is not support for the
proposed reclassification of LITT
procedures and the corresponding new
procedure codes as presented at the
March 8–9, 2022 ICD–10 Coordination
and Maintenance Committee meeting,
we were also providing the results of
our analysis of these existing codes and
our proposed MS–DRG assignments for
FY 2023, if those existing codes are
retained.
ER10AU22.012
codes D0Y0KZZ (Laser interstitial
thermal therapy of brain) and D0Y1KZZ
(Laser interstitial thermal therapy of
brain stem) will be deleted effective
October 1, 2022, as reflected in Table
6D.—Invalid Procedure Codes, in
association with this final rule and
available via the internet on the CMS
website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS.
As discussed in the proposed rule and
previously discussed in this final rule,
we also received requests to reassign the
existing ICD–10 procedure codes that
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
O.R. procedures we identified that were
also reported with LITT of the brain.
For MS–DRGs 040, 041, and 042, we
found a total of 54 cases reporting LITT
of the brain and 2 cases reporting LITT
of the brain stem. While the average
costs of the cases reporting LITT of the
brain were higher compared to all the
cases in their respective MS–DRGs, the
average length of stay was shorter. For
example, the data demonstrates a
shorter average length of stay (8.1 days
versus 9.9 days) and higher average
costs ($40,458 versus $30,212) for the 14
cases reporting LITT of brain in MS–
DRG 040 compared to all the cases in
MS–DRG 040. There were no cases
found to report LITT of brain stem in
MS–DRG 040. For MS–DRG 041, we
found 16 cases reporting LITT of brain
with an average length of stay of 3.4
days and average costs of $23,278 and
1 case reporting LITT of brain stem with
an average length of stay of 1 day and
average costs of $10,222. The average
length of stay for all the cases in MS–
DRG 041 is 5 days with average costs of
$19,090. The data demonstrates a
shorter average length of stay (3.4 days
and 1 day, respectively, versus 5 days)
for the 16 cases reporting LITT of brain
and the 1 case reporting LITT of brain
stem. The data also demonstrates higher
average costs ($23,278 versus $19,090)
for the 16 cases reporting LITT of brain,
and lower average costs for the 1 case
reporting LITT of brain stem ($10,222
versus $19,090), as compared to the
average costs of all cases in MS–DRG
041. For MS–DRG 042, we found 24
cases reporting LITT of brain with an
average length of stay of 1.7 days and
average costs of $22,426 and 1 case
reporting LITT of brain stem with an
average length of stay of 2 days and
average costs of $32,668. The average
length of stay for all the cases in MS–
DRG 042 is 2.9 days with average costs
of $15,451. The data demonstrates a
shorter average length of stay (1.7 days
and 2 days, respectively, versus 2.9
days) for the 24 cases reporting LITT of
48815
brain and the 1 case reporting LITT of
brain stem. The data also demonstrate
higher average costs ($22,426 and
$32,668, respectively versus $15,451)
for the 24 cases reporting LITT of brain
and the 1 case reporting LITT of brain
stem, compared to all the cases in MS–
DRG 042.
We noted in the proposed rule that,
based on the findings from our analysis,
we considered whether other factors,
such as the reporting of secondary MCC
and CC diagnoses, may have contributed
to the higher average costs for these
cases. Specifically, we conducted
additional analyses of the claims data
from the September 2021 update of the
FY 2021 MedPAR file to determine what
secondary MCC diagnoses were also
reported for the 14 cases reporting LITT
of brain in MS–DRG 040 and what
secondary CC diagnoses were reported
for the 17 cases (16 for LITT of brain
and 1 for LITT of brain stem) in MS–
DRG 041. Our findings are shown in the
following tables.
ICD-10-CM
Code as
Secondary
Dia2nosis
D61.810
G93.5
G93.6
161.1
khammond on DSKJM1Z7X2PROD with RULES2
J69.0
J96.01
VerDate Sep<11>2014
Description
Antineoplastic chemotherapy induced pancytopenia
Compression of brain
Cerebral edema
Nontraumatic intracerebral hemorrhage in hemisphere,
cortical
Pneumonitis due to inhalation of food and vomit
Acute respiratory failure with hypoxia
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00037
Fmt 4701
Sfmt 4725
Frequency
of
Dia2nosis
1
6
1
Average
Length
of Stay
9
12.2
9.3
48
Average
Costs
$59,102
$56,313
$43,788
$80,745
2
3
28
17
$60,889
$41,486
11
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.014
Secondary MCC Dia2noses Reported with LITT of Brain in MS-DRG 040
48816
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
We noted that we did not find any
other O.R. procedures reported on the
claims in addition to the procedures for
LITT of brain or brain stem for MS–
DRGs 040, 041 and 042.
The data shows that at least one of the
listed secondary MCC diagnoses was
reported with each claim for LITT of
brain identified in MS–DRG 040 and the
average length of stay for these cases
ranged from 9 days to 48 days and the
average costs of these cases ranged from
$41,486 to $80,745. We note that this
data reflects the frequency with which
each of the listed diagnoses was
reported on a claim with LITT of brain.
Therefore, multiple MCCs from this list
of diagnoses may have been reported on
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
a single claim. In addition, while the
logic for case assignment to MS–DRG
040 requires at least one secondary MCC
diagnosis, we conducted additional
detailed analyses for MS–DRG 040, as
shown in Table 6P.2f, to determine
whether there were also secondary CC
diagnoses reported in conjunction with
one or more of the listed MCC diagnoses
that may be contributing to the higher
average costs for cases reporting LITT of
brain in MS–DRG 040 in comparison to
all the cases in MS–DRG 040. We found
that 6 of the 14 cases reporting at least
one or more secondary MCC diagnosis
also reported one or more secondary CC
diagnosis, which would appear to
support that the severity of illness for
PO 00000
Frm 00038
Fmt 4701
Sfmt 4700
these patients, as identified by the
secondary MCC and CC diagnoses, may
be more directly related to the higher
average costs for these patients than the
LITT procedure itself.
Similarly, the data for MS–DRG 041
show the frequency with which each of
the listed secondary CC diagnoses was
reported with LITT of brain or brain
stem. Results from the analysis for the
17 cases (16 for LITT of brain and 1 for
LITT of brain stem) show the average
length of stay for these cases ranged
from 1 day to 29 days and the average
costs ranged from $9,101 to $57,999.
These data analysis findings for MS–
DRG 041 also appear to support our
belief that the severity of illness for
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.015
khammond on DSKJM1Z7X2PROD with RULES2
Secondary CC Dia2noses Reported with LITT of Brain and Brain Stem in MS-DRG 041
ICD-10CM
Frequency Average
Code as
Secondary
of
Length Average
Description
of Stay
Dia2nosis
Dia2nosis
Costs
C34.91
Malignant neoplasm of unspecified part of right bronchus
1
1
$9,755
or lung
1
29
$22,347
C79.51
Secondary malignant neoplasm of bone
Other pancytopenia
D61.818
1
1
$29,883
Acute posthemorrhagic anemia
D62
1
2
$9,101
1
2
$17,940
E22.2
Syndrome of inappropriate secretion of antidiuretic
hormone
E44.0
Moderate protein-calorie malnutrition
1
1
$29,883
F33.0
Maior depressive disorder, recurrent, mild
1
8
$57,999
Major depressive disorder, recurrent, moderate
F33.1
1
1
$20,461
F84.0
Autistic disorder
1
1
$12,450
G40.89
Other seizures
1
1
$12,109
G40.919
Epilepsy, unspecified, intractable, without status
1
1
$34,287
epilepticus
Hemiplegia, unspecified affecting right dominant side
G81.91
1
2
$17,940
G81.94
Hemiplegia, unspecified affecting left nondominant side
1
8
$57,999
G96.01
Cranial cerebrospinal fluid leak, spontaneous
1
1
$25,514
H47.10
Unspecified papilledema
1
29
$22,347
Hypertensive emergency
1
1
$30,372
116.1
Other cardiomyopathies
142.8
1
1
$55,389
148.21
Permanent atrial fibrillation
1
1
$29,883
150.22
Chronic systolic (congestive) heart failure
1
1
$55,389
Chronic diastolic (congestive) heart failure
150.32
1
1
$29,883
169.354
Hemiplegia and hemiparesis following cerebral infarction
1
1
$12,109
affecting left non-dominant side
Urinary tract infection, site not specified
2
15.5
$16,866
N39.0
Q0l.9
Encephalocele, unspecified
1
2
$9,101
Q04.8
Other specified congenital malformations of brain
2
1
$13,925
Aphasia
R47.01
3
3.3
$28,841
Z68.42
Body mass index [BMl] 45.0-49.9, adult
1
1
$10,222
Z94.0
Kidney transplant status
1
1
$25,514
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
these patients, as identified by the listed
secondary CC diagnoses, may be more
directly related to the higher average
costs for these patients than the LITT
procedure itself.
As stated in the proposed rule and
previously in this final rule, we did not
find any other O.R. procedures reported
on the claims in addition to the
procedures for LITT of brain or brain
stem for MS–DRGs 040, 041 and 042.
Since the logic for case assignment to
MS–DRG 042 is not based on the
reporting requirement of any CC or MCC
diagnoses, we conducted a detailed
analysis of the claims data to determine
what other factors may be contributing
to the higher average costs and shorter
average length of stay for these cases in
comparison to all the cases in MS–DRG
042. We refer the reader to Table 6P.2g
associated with the proposed rule for
the findings from our analysis. As
shown in the data, the majority of the
cases (15 of 25) had a principal
diagnosis of epilepsy, 8 cases had a
principal diagnosis related to malignant
neoplasm of the brain or brain
structures, 1 case had a principal
diagnosis of hemangioma of intracranial
structures and 1 case had a principal
diagnosis of unspecified convulsions.
The data also demonstrate that 16 of the
25 cases reported in MS–DRG 042
include patients who were under the
age of 65, with ages ranging from 32
years old to 64 years old. We note that
patients diagnosed with epilepsy are
eligible for coverage since it is a
condition that qualifies under certain
criteria. It is not entirely clear if the age
of these patients had any impact on the
average length of stay since the average
length of stay of the 24 cases reporting
LITT of brain was 1.7 days and the 1
case reporting LITT of brain stem was 2
days.
As stated previously, the logic for case
assignment to MS–DRG 042 is not
dependent on the reporting of any CC or
MCC diagnoses, however, based on the
diagnoses reflected in the claims data
for MS–DRG 042, it is possible that
conditions such as obesity and chronic
conditions requiring the long-term use
of certain therapeutic agents may be
contributing factors to the consumption
of resources, separately from the LITT
procedure. We found 17 of the 25 cases
reporting LITT of brain or brain stem to
also report one or both of these
conditions.
We also reviewed the number of cases
of LITT of the brain or brain stem
procedures reported in the data since
the transition to ICD–10. Specifically,
we examined the claims data for cases
reporting LITT of brain or brain stem as
a standalone procedure or with another
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
procedure in the FY 2016 through FY
2021 MedPAR data files across all MS–
DRGs. The findings from our analysis
are shown in table 6P.2e associated with
the proposed rule.
The data demonstrates that since the
implementation of ICD–10, a shift in the
reporting of LITT of brain and brain
stem procedures has occurred. For
example, the FY 2016, FY 2017 and FY
2018 MedPAR data reflect that the
number of cases for which LITT of brain
or brain stem procedures were reported
as a standalone procedure is higher in
comparison to the number of cases
reported with another procedure.
Conversely, the FY 2019, FY 2020, and
FY 2021 MedPAR data reflect that the
number of cases for which LITT of brain
or brain stem procedures were reported
as a standalone procedure is lower in
comparison to the number of cases
reported with another procedure. The
data also reflect that the average length
of stay is shorter and the average costs
are lower for cases reporting LITT of
brain or brain stem as a standalone
procedure in comparison to the average
length of stay and average costs for cases
reported with another procedure across
the FY 2016 through FY 2021 MedPAR
data files. Lastly, the data demonstrate
that overall, the number of cases for
which LITT of brain or brain stem
procedures was performed had
remained fairly stable at over 100 cases
with increases in the FY 2017, FY 2020
and FY 2021 MedPAR data files of 156,
154 and 185 cases, respectively.
As discussed in the proposed rule, we
also analyzed claims data from the
September 2021 update of the FY 2021
MedPAR file for cases reporting LITT of
other anatomic sites across all MS–
DRGs. Although the requestors
indicated that LITT is primarily
performed on intracranial lesions, as
shown in Table 6P.2c associated with
the proposed rule, we identified a small
number of cases reporting LITT of the
lung, rectum, liver, breast, and prostate,
for a total of 29 cases where LITT was
performed on other body parts/anatomic
sites.
For example, we found a total of 5
cases reporting LITT of lung across 5
different MS–DRGs. Of these 5 cases, 2
cases had a longer average length of stay
and higher average costs in comparison
to all the cases in their respective MS–
DRG. Specifically, for MS–DRG 163
(Major Chest Procedures with MCC), we
found 1 case reporting LITT of lung
with an average length of stay of 17 days
and average costs of $41,467. The
average length of stay for all cases in
MS–DRG 163 is 10.7 days with average
costs of $38,367. The data demonstrates
a difference of 6.3 days (17¥10.7 = 6.3)
PO 00000
Frm 00039
Fmt 4701
Sfmt 4700
48817
for the average length of stay and a
difference of $3,100 in average costs
($41,467¥$38,367 = $3,100) for the 1
case reporting LITT of lung in MS–DRG
163 compared to all the cases in MS–
DRG 163. For MS–DRG 167 (Other
Respiratory System O.R. Procedures
with CC), we found 1 case reporting
LITT of lung with an average length of
stay of 7 days and average costs of
$22,975. The average length of stay for
all cases in MS–DRG 167 is 4.6 days
with average costs of $15,397. The data
demonstrates a difference of 2.4 days
(7¥4.6 = 2.4) for the average length of
stay and a difference of $7,578 in
average costs
($22,975¥$15,397 = $7,578) for the 1
case reporting LITT of lung in MS–DRG
167 compared to all the cases in MS–
DRG 167. The data for the remaining 3
cases reporting LITT of lung
demonstrated a shorter average length of
stay and lower average costs in
comparison to all the cases in their
respective MS–DRGs.
We found 1 case reporting LITT of
rectum in MS–DRG 357 (Other Digestive
System O.R. Procedures with CC) with
a shorter average length of stay (4 days
versus 5.6 days) and lower average costs
($3,069 versus $18,065) as compared to
all the cases in MS–DRG 357. We also
found 1 case reporting LITT of liver in
MS–DRG 405 (Pancreas Liver and Shunt
Procedures with MCC) with a longer
average length of stay (20 days versus
12.3 days) and higher average costs
($49,0695 versus $43,771) as compared
to all the cases in MS–DRG 405.We also
found 1 case reporting LITT of right
breast in MS–DRG 580 (Other Skin
Subcutaneous Tissue and Breast
Procedures with CC) with a longer
average length of stay (19 days versus
5.4 days) and higher average costs
($32,064 versus $13,767) as compared to
all the cases in MS–DRG 580.
Lastly, we found 21 cases reporting
LITT of prostate across 14 MS–DRGs. Of
those 21 cases, 6 cases had a longer
average length of stay or higher average
costs, or both, in comparison to the
average length of stay and average costs
of all the cases in their respective MS–
DRG. For example, in MS–DRG 650
(Kidney Transplant with Hemodialysis
with MCC) we found 1 case reporting
LITT of prostate with an average length
of stay of 36 days and average costs of
$67,238. The average length of stay for
all cases in MS–DRG 650 is 8.1 days
with average costs of $38,139. The data
demonstrates a difference of 27.9 days
(36¥8.1 = 27.9) for the average length of
stay and a difference of $29,099 in
average costs
($67,238¥$38,139 = $29,099) for the 1
case reporting LITT of prostate in MS–
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48818
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
DRG 650 compared to all the cases in
MS–DRG 650. We also found 1 case
reporting LITT of prostate in MS–DRG
659 (Kidney and Ureter Procedures for
Non-Neoplasm with MCC) with an
average length of stay of 26 days. The
average length of stay for all cases in
MS–DRG 659 is 7.8 days, demonstrating
a difference of 18.2 days
(26¥7.8 = 18.2). We found 1 case
reporting LITT of prostate in MS–DRG
712 (Testes Procedures without CC/
MCC) with average costs of $15,669. The
average costs for all cases in MS–DRG
712 is $10,482, demonstrating a
difference of $5,187
($15,669¥$10,482 = $5,187). We found
1 case reporting LITT of prostate in MS–
DRG 987 with an average length of stay
of 23 days and average costs of $35,465.
The average length of stay for all cases
in MS–DRG 987 is 10.9 days with
average costs of $26,657. The data
demonstrates a difference of 12.1 days
(23¥10.9 = 12.1) for the average length
of stay and a difference of $8,808 in
average costs
($35,465¥$26,657 = $8,808) for the 1
case reporting LITT of prostate in MS–
DRG 987 compared to all the cases in
MS–DRG 987. Lastly, we found 2 cases
reporting LITT of prostate in MS–DRG
988 (Non-Extensive O.R. Procedures
Unrelated to Principal Diagnosis with
CC) with average costs of $17,126. The
average costs for all cases in MS–DRG
988 is $13,670, demonstrating a
difference of $3,456
($17,126¥$13,670 = $3,456) for the 2
cases reporting LITT of prostate in MS–
DRG 988.
We refer the reader to Table 6P.2c
associated with the proposed rule for
the detailed findings from our analysis.
We note that if the procedure code
describing LITT of a specific anatomic
site is not listed it is because there were
no cases found.
We noted in the proposed rule that for
the 10 cases previously described, for
which LITT of a different anatomic site
from the brain or brain stem was
reported and had a longer average
length of stay or higher average costs, or
both, in comparison to the average
length of stay and average costs of all
the cases in their respective MS–DRG,
that with the exception of MS–DRG 712,
all the other MS–DRGs include a ‘‘with
MCC’’ or ‘‘with CC’’ designation, or
were reported in a surgical MS–DRG.
We stated we believe that these other
factors may have contributed to the
longer average length of stay and higher
average costs for these cases, therefore
we conducted additional analyses of the
claims data to determine what diagnoses
or procedures were also reported. We
refer the reader to Table 6P.2d
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
associated with the proposed rule for
the findings from our detailed analysis
of these 10 cases.
As shown in Table 6P.2d associated
with the proposed rule, the data
demonstrate that a number of MCC and/
or CC secondary diagnoses were
reported for each of the 10 cases and
that the surgical procedures that were
reported in addition to the LITT
procedure seem to have contributed to
the longer average length of stay and
higher average costs for those cases
when compared to the average length of
stay and average costs for all the cases
in their respective MS–DRG. For
example, in case number 1 there are 2
diagnoses that are designated as MCC
conditions and 5 diagnoses that that are
designated as CC conditions with
procedure codes describing a kidney
transplant, hemodialysis, and insertion
of a ureteral stent that were reported
along with LITT of prostate. For case
number 3 there are 4 diagnoses that are
designated as MCC conditions and 6
diagnoses that are designated as CC
conditions with procedure codes
describing bronchoscopic treatment of a
bronchial tumor with and without
stents, as well as the use of mechanical
ventilation. Overall, the data appear to
indicate that the performance of the
LITT procedure was not the underlying
reason for, or main driver of, the
increase in resource utilization for those
cases.
As noted in the proposed rule, the
requestors indicated that LITT is
primarily being performed on
intracranial lesions. However, as
previously summarized, we identified a
limited number of cases reporting LITT
procedures for other anatomic sites. We
stated in the proposed rule that we are
interested in comments regarding the
use of and experience with LITT for
these other anatomic sites.
As discussed in the proposed rule,
based on our analysis of the FY 2021
MedPAR claims data for cases reporting
LITT of brain or brain stem (codes
D0Y0KZZ and D0Y1KZZ) in MS–DRGs
040, 041, and 042, we agree with the
requestors that the average costs of these
cases are higher as compared to the
average costs of all cases assigned to
MS–DRGs 040, 041, and 042. For the
reasons summarized, in the proposed
rule we also stated we believe that other
factors, including the reporting of
secondary MCC and CC diagnoses, may
be contributing to the higher average
costs for these cases. As discussed in the
FY 2022 IPPS/LTCH PPS final rule (86
FR 44813), we examined procedure
codes D0Y0KZZ and D0Y1KZZ
describing LITT of brain and brain stem,
respectively, and stated that the
PO 00000
Frm 00040
Fmt 4701
Sfmt 4700
technique to perform the LITT
procedure on these structures is
considered minimally invasive and does
not involve a craniotomy, therefore,
continued assignment to the craniotomy
MS–DRGs is not clinically appropriate.
As noted in the proposed rule, our
clinical advisors continue to maintain
that LITT is a minimally invasive
procedure, requiring only a tiny incision
for purposes of a burr hole and that
patients are often only kept overnight
(as reflected in the detailed claims data).
However, we stated that we also
recognize that craniotomy and LITT
share common procedural
characteristics including use of an
operating room, carry risk of immediate
intracranial bleeding or infection, and
cause tissue to be immediately
destroyed or excised. We noted that
while the data do not demonstrate that
the LITT procedure is the underlying
reason for the higher average costs and
consumption of resources for the small
number of cases reporting LITT of brain
(54 cases) or brain stem (2 cases) that we
found in MS–DRGs 040, 041, and 042,
the data do demonstrate that the
patients receiving this treatment therapy
have brain tumors or epilepsy combined
with multiple comorbidities or chronic
conditions necessitating long-term use
of medications, or both, and we noted
the indications for LITT (brain tumors
and epileptic foci) are better aligned
with MS–DRGs 025, 026, and 027 as
compared to MS–DRGs 040, 041, and
042.
As discussed in the proposed rule, we
intend to more fully evaluate the logic
for the procedures specifically involving
a craniotomy, as well as the overall
structure of MS–DRGs 023 through 027,
and we believe that reassignment of
cases reporting LITT of brain or brain
stem to MS–DRGs 025, 026, and 027
would be an appropriate first step in
connection with these efforts. For
example, while we recognize the
distinctions between open craniotomy
procedures and minimally invasive
percutaneous intracranial procedures,
we also recognize that the current logic
for MS–DRGs 025 through 027 also
includes other endovascular intracranial
procedures performed using
percutaneous or percutaneous
endoscopic approaches, and we believe
that further review of the clinical
coherence of the procedures assigned to
these MS–DRGs may be warranted. Our
clinical advisors noted that while the
typical patient treated with LITT
usually has a single small scalp incision
through which a hole approximately the
diameter of a straw is drilled, with no
extensive surgical exposure, that LITT
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
can still be employed for another subset
of more complex patients, including
patients with primary brain
malignancies and those with larger
metastatic lesions or multiple lesions.
For this subset of more complex
patients, a longer post-operative stay
with direct medical supervision may be
necessary. As such, we stated in the
proposed rule that we believe
reassigning these procedures to MS–
DRGs 025 through 027 for FY 2023
would be appropriate as we consider
restructuring MS–DRGs 023 through
027, including how to better align the
clinical indications with the
performance of specific intracranial
procedures. Accordingly, for these
reasons, we stated in the proposed rule
that in the event there is not support for
the proposed reclassification of LITT
procedures and the corresponding new
procedure codes as presented at the
March 8–9, 2022 ICD–10 Coordination
and Maintenance Committee meeting,
we were proposing to reassign the
existing procedure codes describing
LITT of the brain or brain stem from
MS–DRGs 040, 041, and 042 to MS–
DRGs 025, 026, and 027 for FY 2023. We
also proposed to maintain the MS–DRG
assignments for the existing procedure
codes describing LITT of other anatomic
sites as finalized and displayed in Table
6P.2b in association with the FY 2022
IPPS/LTCH PPS final rule, for FY 2023.
Lastly, we noted in the proposed rule
that we did not receive any comments
or requests to reconsider those finalized
MS–DRG assignments for FY 2023.
As noted, we stated in the proposed
rule that we were proposing to reassign
the existing procedure codes describing
LITT of the brain or brain stem from
MS–DRGs 040, 041, and 042 to MS–
DRGs 025, 026, and 027 for FY 2023, in
the event there was not support for the
proposed reclassification of LITT
procedures and the corresponding new
procedure codes as presented at the
March 8–9, 2022 ICD–10 Coordination
and Maintenance Committee meeting.
As the proposed reclassification of the
LITT procedures and the corresponding
new procedure codes were approved
following the March meeting, and the
existing procedure codes D0Y0KZZ
(Laser interstitial thermal therapy of
brain) and D0Y1KZZ (Laser interstitial
thermal therapy of brain stem) will be
deleted effective October 1, 2022, we are
not finalizing the proposed
reassignment of these existing codes for
FY 2023. As previously noted, and as
reflected in Table 6B.—New Procedure
Codes associated with this final rule, the
new procedure codes describing LITT of
brain (root operation Destruction) are
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
assigned to MS–DRGs 025, 026 and 027
for FY 2023. We did not receive any
public comments on our proposal to
maintain the MS–DRG assignments for
the existing procedure codes describing
LITT of other anatomic sites as finalized
and displayed in Table 6P.2b in
association with the FY 2022 IPPS/
LTCH PPS final rule, for FY 2023. As
previously noted, the existing procedure
codes describing LITT of other anatomic
sites will also be deleted effective
October 1, 2023; therefore, we are not
finalizing the proposed reassignment of
these existing codes for FY 2023. The
MS–DRG assignments for the newly
approved procedure codes describing
LITT of other anatomic sites for FY 2023
are displayed in Table 6B in association
with this final rule.
As noted in the proposed rule, in
connection with our analysis of cases
reporting LITT procedures performed on
the brain or brain stem in MDC 01, we
have started to examine the logic for
case assignment to MS–DRGs 023
through 027 to determine where further
refinements could potentially be made
to better account for differences in the
technical complexity and resource
utilization among the procedures that
are currently assigned to those MS–
DRGs. Specifically, we are in the
process of evaluating procedures that
are performed using an open craniotomy
(where it is necessary to surgically
remove a portion of the skull) versus a
percutaneous burr hole (where a hole
approximately the size of a pencil is
drilled) to obtain access to the brain in
the performance of a procedure. We are
also reviewing the indications for these
procedures, for example, malignant
neoplasms versus epilepsy to consider if
there may be merit in considering
restructuring the current MS–DRGs to
better recognize the clinical distinctions
of these patient populations in the MS–
DRGs. We believe it is worthwhile to
also compare the claims data for
epilepsy patients who are treated with
a neurostimulator implant versus a LITT
procedure, as well as the claims data for
patients with a diagnosis of epilepsy or
malignant neoplasms who undergo a
LITT procedure. Our analysis also
includes reviewing the claims data with
regard to the cases that reflect a
procedure that is generally performed
with another O.R. procedure versus a
standalone procedure.
As we continue this analysis of the
claims data with respect to MS–DRGs
023 through 027, we stated that we are
also seeking public comments and
feedback on other factors that should be
considered in the potential restructuring
of these MS–DRGs.
PO 00000
Frm 00041
Fmt 4701
Sfmt 4700
48819
Comment: In response to CMS’s
request for public comment and
feedback on the potential restructuring
of the craniotomy MS–DRGs for future
consideration, some commenters
disagreed and stated that such a
restructuring is not necessary. These
commenters stated that should CMS
consider future modifications to the
logic for case assignment to MS–DRGs
023 through 027, the agency provide
adequate notice for interested parties to
assess the impact of any proposed
changes.
Another commenter expressed
appreciation that CMS indicated it is
continuing to analyze if additional
restructuring for MS–DRGs 023 through
027 may be warranted and agreed that
the logic for these MS–DRGs has
become more complex. The commenter
stated they will be performing analyses
and plan to submit their findings by the
October 20, 2022 deadline. Another
commenter urged CMS to also consider
the costs of procedures with respect to
whether a device is inserted or
implanted in combination with the
approach and clinical indications
because of the various diagnoses and
procedures that may group to MS–DRGs
023 through 027. This commenter
expressed support for further
collaboration to better align resources
and clinical characteristics among
within these MS–DRGs.
Another commenter who also
expressed appreciation that CMS has
signaled its intent on analyzing MS–
DRGs 023 through 027 recommended
that CMS also expand its analysis to
include MS–DRGs 020 through 022
(Intracranial Vascular Procedures with
Principal Diagnosis Hemorrhage with
MCC, with CC, and without CC/MCC,
respectively). According to the
commenter, the payment rates for a
subset of the procedures that group to
these MS–DRGs appear to no longer
adequately reflect the utilization of
resources. The commenter encouraged
CMS to analyze these MS–DRGs and
determine if additional modifications
may be warranted.
Response: We thank the commenters
for their feedback and will take these
recommendations into consideration as
we further examine the logic for case
assignment. We note that we would
address any proposed modifications to
the existing logic in future rulemaking.
As previously described in the
proposed rule and this final rule, we are
examining procedures by their approach
(open versus percutaneous), clinical
indications, and procedures that involve
the insertion or implantation of a
device. We recognize the logic for MS–
DRGs 023 through 027 has grown more
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
complex over the years and believe
there is opportunity for further
refinement. We refer the reader to the
ICD–10 MS–DRG Definitions Manual,
version 40, which is available via the
internet on the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS/MS-DRGClassifications-and-Software for
complete documentation of the
GROUPER logic for MS–DRGs 023
through 027. Feedback and other
suggestions may be submitted by
October 20, 2022 and directed to the
new electronic intake system, Medicare
Electronic Application Request
Information SystemTM (MEARISTM),
discussed in section II.D.1.b of the
preamble of this final rule at: https://
mearis.cms.gov/public/home.
b. Vagus Nerve Stimulation
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28141 through
28151), we discussed a request we
received to review the MS–DRG
assignment for cases that identify
patients who receive an implantable
vagus nerve stimulation system for heart
failure. The vagus nerve, also called the
X cranial nerve or the 10th cranial
nerve, is the longest and most complex
of the cranial nerves. There is one vagus
nerve on each side of the body that runs
from the brain through the face and
thorax to the abdomen. According to the
requestor, cranial nerve stimulation
(CNS), which includes vagus nerve
stimulation, is a well-established
therapy for various indications
including epilepsy, treatment resistant
depression (TRD) and obstructive sleep
apnea (OSA), and is now being
investigated and studied for use in
patients with heart failure.
khammond on DSKJM1Z7X2PROD with RULES2
ICD-10-PCS
Code
00HE0MZ
with
0JH60BZ
nerve and the insertion of a stimulator
generator are reported with a principal
diagnosis of heart failure, the cases
instead are assigned to surgical MS–
DRGs 252, 253 and 254 (Other Vascular
Procedures with MCC, with CC, without
MCC respectively) in MDC 05 (Diseases
and Disorders of the Circulatory
System).
The requestor stated that the
treatment of autonomic nervous system
dysfunction is the underlying
therapeutic objective of cranial nerve
stimulation for heart failure, and
therefore the diagnosis of heart failure is
more clinically coherent with other
diagnoses in MDC 01. As a result, the
requestor, who is developing the
VITARIA® System, an active
implantable neuromodulation system
that uses vagus nerve stimulation to
deliver autonomic regulation therapy
(ART) for an indicated use that includes
patients who have moderate to severe
heart failure, submitted a request to
reassign cases reporting a procedure
code describing the insertion of a
neurostimulator lead onto the vagus
nerve and a procedure code describing
the insertion of a stimulator generator
with a principal diagnosis code
describing heart failure, from MS–DRGs
252, 253 and 254 in MDC 05 to MS–
DRGs 040, 041 and 042 in MDC 01. This
requestor also submitted an application
for new technology add-on payment for
FY 2023. As discussed in section II.F.7.
of the preamble of this final rule, the
new technology add-on payment
application for the VITARIA® System
for FY 2023 was withdrawn prior to the
issuance of this final rule.
According to the requestor, the
following ICD–10–PCS procedure code
pair identifies the insertion of a vagus
nerve stimulation system for heart
failure:
Description
Insertion of neurostimulator lead into cranial nerve, open annroach
Insertion of single array stimulator generator into chest subcutaneous tissue and fascia, open annroach
We stated in the FY 2023 IPPS/LTCH
PPS proposed rule that the requestor
performed its own analysis of Medicare
claims from 2020 and stated that it
found that patients enrolled in their
pivotal clinical trials had an average
length of stay of 6.38 days. According to
the requestor this finding indicated a
resource coherence more similar to
cases assigned to MS–DRGs 040, 041
and 042, whose average lengths of stay
VerDate Sep<11>2014
According to the requestor, heart
failure, or the heart’s inability to pump
an adequate supply of blood and oxygen
to support the other organs of the body,
is an autonomic nervous system
dysfunction. The brain controls the
function of the heart through the
sympathetic branch and the
parasympathetic branches of the
autonomic nervous system. In heart
failure, there is an imbalance in the
autonomic nervous system. The vagus
nerve stimulation system for heart
failure is comprised of an implantable
pulse generator, an electrical lead, and
a programming computer system. The
pulse generator, which is usually
implanted just under the skin of the
pectoral region, sends the energy to the
vagus nerve through the lead. The lead
is a flexible insulated wire that is
guided under the skin from the chest up
to the neck and is implanted onto the
vagus nerve and transmits tiny electrical
impulses from the generator to the
nerve. These electrical impulses to the
vagus nerve are intended to activate the
parasympathetic branch of the
autonomic nervous system to restore
balance.
The requestor stated that cases
reporting a procedure code describing
the insertion of a neurostimulator lead
onto the vagus nerve and a procedure
code describing the insertion of a
stimulator generator with a principal
diagnosis code describing epilepsy, TRD
or OSA are assigned to surgical MS–
DRGs 040, 041 and 042 (Peripheral
Cranial Nerve and Other Nervous
System Procedures with MCC, with CC
or Peripheral Neurostimulator, and
without CC/MCC, respectively) in MDC
01 (Diseases and Disorders of the
Nervous System). However, when the
same codes describing the insertion of a
neurostimulator lead onto the vagus
00:20 Aug 10, 2022
Jkt 256001
ranges from 2 to 8 days, when compared
to the average lengths of stay of 1 to 3
days for cases assigned to MS–DRGs 252
and 253. The requestor stated their own
analysis of 2019 and 2020 Medicare
claims data also showed that fewer than
11 cases with procedure codes
describing the implantation of a vagus
nerve stimulation system map to MS–
DRGs 252, 253 and 254 annually but it
is expected that Medicare patients will
PO 00000
Frm 00042
Fmt 4701
Sfmt 4700
receive vagus nerve stimulation system
for heart failure on an inpatient basis.
Because of the shared clinical and
resource similarity of the procedure to
implant the VITARIA® system to other
CNS procedures, regardless of
indication, the requestor stated that CNS
procedures for the treatment of heart
failure should also be assigned to MS–
DRGs 040, 041 and 042. The requestor
also noted that the title of MS–DRGs
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.016
48820
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
252, 253 and 254 is ‘‘Other Vascular
Procedures with MCC, with CC, without
MCC respectively’’. Since no vascular
access is involved in the procedure to
implant vagus nerve stimulation
113.2
150.1
150.20
150.21
150.22
150.23
150.30
150.31
150.32
150.33
150.40
150.41
150.42
150.43
150.810
150.811
150.812
150.813
150.814
150.82
150.83
150.84
150.89
150.9
197.130
197.131
Description
Rheumatic heart failure
Hypertensive heart disease with heart failure
Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4
chronic kidney disease, or unspecified chronic kidney disease
Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic
kidney disease, or end stage renal disease
Left ventricular failure, unspecified
Unspecified systolic (congestive) heart failure
Acute systolic (congestive) heart failure
Chronic systolic (congestive) heart failure
Acute on chronic systolic (congestive) heart failure
Unspecified diastolic (congestive) heart failure
Acute diastolic (congestive) heart failure
Chronic diastolic (congestive) heart failure
Acute on chronic diastolic (congestive) heart failure
Unspecified combined systolic (congestive) and diastolic (congestive) heart failure
Acute combined systolic (congestive) and diastolic (congestive) heart failure
Chronic combined systolic (congestive) and diastolic (congestive) heart failure
Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure
Right heart failure, unspecified
Acute right heart failure
Chronic right heart failure
Acute on chronic right heart failure
Right heart failure due to left heart failure
Biventricular heart failure
High output heart failure
End stage heart failure
Other heart failure
Heart failure, unspecified
Postprocedural heart failure following cardiac surgery
Postprocedural heart failure following other surgery
khammond on DSKJM1Z7X2PROD with RULES2
The ICD–10–PCS codes that identify
the insertion of a neurostimulator lead
ICD-10-PCS
Code
00HE0MZ
00HE3MZ
00HE4MZ
VerDate Sep<11>2014
BILLING CODE 4120–01–P
onto the vagus nerve are listed in the
following table.
Description
Insertion of neurostimulator lead into cranial nerve, open approach
Insertion of neurostimulator lead into cranial nerve, percutaneous approach
Insertion of neurostimulator lead into cranial nerve, percutaneous endoscopic approach
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00043
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.018
113.0
describe heart failure are found in the
following table. These diagnosis codes
are all currently assigned to MDC 05.
ER10AU22.017
ICD-10-CM
Code
I09.81
111.0
systems, the requestor stated MS–DRGs
252, 253 and 254 were not appropriate
mappings for these procedures.
We stated in the proposed rule that
the ICD–10–CM diagnosis codes that
48821
48822
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
The ICD–10–PCS codes that identify
the insertion of a stimulator generator
are listed in the following table.
0JH60BZ
0JH60CZ
0JH60DZ
0JH60EZ
0JH60MZ
0JH63BZ
0JH63CZ
0JH63DZ
0JH63EZ
0JH63MZ
0JH70BZ
0JH70CZ
0JH70DZ
0JH70EZ
0JH70MZ
0JH73BZ
0JH73CZ
0JH73DZ
khammond on DSKJM1Z7X2PROD with RULES2
0JH73EZ
0JH73MZ
VerDate Sep<11>2014
Description
Insertion of single array stimulator generator into chest subcutaneous tissue and fascia,
open approach
Insertion of single array rechargeable stimulator generator into chest subcutaneous tissue
and fascia, open approach
Insertion of multiple array stimulator generator into chest subcutaneous tissue and fascia,
open approach
Insertion of multiple array rechargeable stimulator generator into chest subcutaneous
tissue and fascia, open approach
Insertion of stimulator generator into chest subcutaneous tissue and fascia, open approach
Insertion of single array stimulator generator into chest subcutaneous tissue and fascia,
percutaneous approach
Insertion of single array rechargeable stimulator generator into chest subcutaneous tissue
and fascia, percutaneous approach
Insertion of multiple array stimulator generator into chest subcutaneous tissue and fascia,
percutaneous approach
Insertion of multiple array rechargeable stimulator generator into chest subcutaneous
tissue and fascia, percutaneous approach
Insertion of stimulator generator into chest subcutaneous tissue and fascia, percutaneous
approach
Insertion of single array stimulator generator into back subcutaneous tissue and fascia,
open approach
Insertion of single array rechargeable stimulator generator into back subcutaneous tissue
and fascia, open approach
Insertion of multiple array stimulator generator into back subcutaneous tissue and fascia,
open approach
Insertion of multiple array rechargeable stimulator generator into back subcutaneous
tissue and fascia, open approach
Insertion of stimulator generator into back subcutaneous tissue and fascia, open approach
Insertion of single array stimulator generator into back subcutaneous tissue and fascia,
percutaneous approach
Insertion of single array rechargeable stimulator generator into back subcutaneous tissue
and fascia, percutaneous approach
Insertion of multiple array stimulator generator into back subcutaneous tissue and fascia,
percutaneous approach
Insertion of multiple array rechargeable stimulator generator into back subcutaneous
tissue and fascia, percutaneous approach
Insertion of stimulator generator into back subcutaneous tissue and fascia, percutaneous
approach
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00044
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.019
ICD-10-PCS
Code
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
0JH80BZ
0JH80CZ
0JH80DZ
0JH80EZ
0JH80MZ
0JH83BZ
0JH83CZ
0JH83DZ
0JH83EZ
0JH83MZ
0JH60BZ
0JH60CZ
0JH60DZ
0JH60EZ
0JH60MZ
0JH63BZ
0JH63CZ
0JH63DZ
0JH63EZ
0JH63MZ
khammond on DSKJM1Z7X2PROD with RULES2
0JH70BZ
0JH70CZ
VerDate Sep<11>2014
Description
Insertion of single array stimulator generator into abdomen subcutaneous tissue and
fascia, open approach
Insertion of single array rechargeable stimulator generator into abdomen subcutaneous
tissue and fascia, open approach
Insertion of multiple array stimulator generator into abdomen subcutaneous tissue and
fascia, open approach
Insertion of multiple array rechargeable stimulator generator into abdomen subcutaneous
tissue and fascia, open approach
Insertion of stimulator generator into abdomen subcutaneous tissue and fascia, open
approach
Insertion of single array stimulator generator into abdomen subcutaneous tissue and
fascia, percutaneous approach
Insertion of single array rechargeable stimulator generator into abdomen subcutaneous
tissue and fascia, percutaneous approach
Insertion of multiple array stimulator generator into abdomen subcutaneous tissue and
fascia, percutaneous approach
Insertion of multiple array rechargeable stimulator generator into abdomen subcutaneous
tissue and fascia, percutaneous approach
Insertion of stimulator generator into abdomen subcutaneous tissue and fascia,
percutaneous approach
Insertion of single array stimulator generator into chest subcutaneous tissue and fascia,
open approach
Insertion of single array rechargeable stimulator generator into chest subcutaneous tissue
and fascia, open approach
Insertion of multiple array stimulator generator into chest subcutaneous tissue and fascia,
open approach
Insertion of multiple array rechargeable stimulator generator into chest subcutaneous
tissue and fascia, open approach
Insertion of stimulator generator into chest subcutaneous tissue and fascia, open approach
Insertion of single array stimulator generator into chest subcutaneous tissue and fascia,
percutaneous approach
Insertion of single array rechargeable stimulator generator into chest subcutaneous tissue
and fascia, percutaneous approach
Insertion of multiple array stimulator generator into chest subcutaneous tissue and fascia,
percutaneous approach
Insertion of multiple array rechargeable stimulator generator into chest subcutaneous
tissue and fascia, percutaneous approach
Insertion of stimulator generator into chest subcutaneous tissue and fascia, percutaneous
approach
Insertion of single array stimulator generator into back subcutaneous tissue and fascia,
open approach
Insertion of single array rechargeable stimulator generator into back subcutaneous tissue
and fascia, open approach
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00045
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.020
ICD-10-PCS
Code
48823
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ICD-10-PCS
Code
0JH70DZ
0JH70EZ
0JH70MZ
0JH73BZ
0JH73CZ
0JH73DZ
0JH73EZ
0JH73MZ
0JH80BZ
0JH80CZ
0JH80DZ
0JH80EZ
0JH80MZ
0JH83BZ
0JH83CZ
0JH83DZ
0JH83EZ
0JH83MZ
Description
Insertion of multiple array stimulator generator into back subcutaneous tissue and fascia,
open approach
Insertion of multiple array rechargeable stimulator generator into back subcutaneous
tissue and fascia, open approach
Insertion of stimulator generator into back subcutaneous tissue and fascia, open approach
Insertion of single array stimulator generator into back subcutaneous tissue and fascia,
percutaneous approach
Insertion of single array rechargeable stimulator generator into back subcutaneous tissue
and fascia, percutaneous approach
Insertion of multiple array stimulator generator into back subcutaneous tissue and fascia,
percutaneous approach
Insertion of multiple array rechargeable stimulator generator into back subcutaneous
tissue and fascia, percutaneous approach
Insertion of stimulator generator into back subcutaneous tissue and fascia, percutaneous
approach
Insertion of single array stimulator generator into abdomen subcutaneous tissue and
fascia, open approach
Insertion of single array rechargeable stimulator generator into abdomen subcutaneous
tissue and fascia, open approach
Insertion of multiple array stimulator generator into abdomen subcutaneous tissue and
fascia, open approach
Insertion of multiple array rechargeable stimulator generator into abdomen subcutaneous
tissue and fascia, open approach
Insertion of stimulator generator into abdomen subcutaneous tissue and fascia, open
approach
Insertion of single array stimulator generator into abdomen subcutaneous tissue and
fascia, percutaneous approach
Insertion of single array rechargeable stimulator generator into abdomen subcutaneous
tissue and fascia, percutaneous approach
Insertion of multiple array stimulator generator into abdomen subcutaneous tissue and
fascia, percutaneous approach
Insertion of multiple array rechargeable stimulator generator into abdomen subcutaneous
tissue and fascia, percutaneous approach
Insertion of stimulator generator into abdomen subcutaneous tissue and fascia,
percutaneous approach
khammond on DSKJM1Z7X2PROD with RULES2
We stated our analysis of this
grouping issue confirmed that, when a
procedure code describing the insertion
of a neurostimulator lead onto the vagus
nerve and a procedure code describing
the insertion of a stimulator generator
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
are reported with a principal diagnosis
code describing heart failure, these
cases group to surgical MS–DRGs 252,
253 and 254 (Other Vascular Procedures
with MCC, with CC, without MCC
respectively).
PO 00000
Frm 00046
Fmt 4701
Sfmt 4700
We noted that cases involving the use
of a peripheral neurostimulator and a
diagnosis from MDC 01 are assigned to
MS–DRG 041 only. The GROUPER logic
for MS–DRGs 040, 041, and 042 is
reflected in the logic table:
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.021
48824
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
MCC
cc
Peripheral
Neurostimulator
Combinations
Yes
n/a
n/a
040 (Peripheral Cranial Nerve and Other Nervous System Procedures with MCC)
No
Yes
n/a
041 (Peripheral Cranial Nerve and Other Nervous System Procedures with CC or Peripheral Neurostimulator)
No
No
Yes
041 (Peripheral Cranial Nerve and Other Nervous System Procedures with CC or Peripheral Neurostimulator)
No
No
No
042 (Peripheral Cranial Nerve and Other Nervous System Procedures without CC/MCC)
MS-DRG
00:20 Aug 10, 2022
Jkt 256001
252, 253 and 254 to identify the subset
of cases within MS–DRGs 252, 253 and
254 reporting a procedure code
describing the insertion of a
neurostimulator lead onto the vagus
nerve and a procedure code describing
the insertion of a stimulator generator
with a secondary diagnosis of heart
failure and similarly found zero cases.
We indicated in the proposed rule
that the results of the claims analysis
demonstrated that there was not
sufficient claims data in the MedPAR
file on which to assess the resource use
of cases reporting a procedure code
describing the insertion of a
neurostimulator lead onto the vagus
nerve and a procedure code describing
the insertion of a stimulator generator
with a principal or secondary diagnosis
of heart failure as compared to other
cases assigned to MS–DRGs 252, 253,
and 254.
As discussed in the proposed rule, in
reviewing the requestor’s concerns
regarding clinical coherence, our
clinical advisors acknowledged that
heart failure is a complex syndrome
involving autonomic nervous system
dysfunction, however our clinical
advisors disagreed with assigning the
diagnosis codes describing heart failure
to MDC 01 (Diseases and Disorders of
the Nervous System). Our clinical
PO 00000
Frm 00047
Fmt 4701
Sfmt 4700
advisors noted the concept of clinical
coherence requires that the patient
characteristics included in the
definition of each MS–DRG relate to a
common organ system or etiology. As
the listed diagnosis codes describe heart
failure, we stated these diagnosis codes
are appropriately assigned to MDC 05
(Diseases and Disorders of the
Circulatory System). Our clinical
advisors also stated it would not be
appropriate to move these diagnoses
into MDC 01 because it could
inadvertently cause cases reporting
these same MDC 05 diagnoses with a
circulatory system procedure to be
assigned to an unrelated MS–DRG
because whenever there is a surgical
procedure reported on the claim that is
unrelated to the MDC to which the case
was assigned based on the principal
diagnosis, it results in a MS–DRG
assignment to a surgical class referred to
as ‘‘unrelated operating room
procedures’’.
To further examine the impact of
moving the diagnoses describing heart
failure into MDC 01, we stated we
analyzed claims data for cases reporting
a circulatory system O.R. procedure and
a principal diagnosis of heart failure.
Our findings are reflected in the
following table.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.022
khammond on DSKJM1Z7X2PROD with RULES2
We refer the reader to the ICD–10
MS–DRG Version 39.1 Definitions
Manual (which is available via the
internet on the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS/MS-DRGClassifications-and-Software) for
complete documentation of the
GROUPER logic for the listed MS–DRGs.
In the proposed rule, we stated that
we examined claims data from the
September 2021 update of the FY 2021
MedPAR file for MS–DRGs 252, 253 and
254 to identify the subset of cases
within MS–DRGs 252, 253 and 254
reporting a procedure code describing
the insertion of a neurostimulator lead
onto the vagus nerve and a procedure
code describing the insertion of a
stimulator generator with a principal
diagnosis of heart failure. We stated we
found zero cases in MS–DRGs 252, 253
and 254 reporting a procedure code
describing the insertion of a
neurostimulator lead onto the vagus
nerve and a procedure code describing
the insertion of a stimulator generator
with a principal diagnosis of heart
failure. In an attempt to further examine
this issue, we then examined claims
data from the September 2021 update of
the FY 2021 MedPAR file for MS–DRGs
VerDate Sep<11>2014
48825
48826
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
MS-DRG
215
216
217
218
219
220
222
223
224
226
227
228
229
231
233
234
235
236
239
khammond on DSKJM1Z7X2PROD with RULES2
240
242
243
244
VerDate Sep<11>2014
Description
Other Heart Assist System Implant
Cardiac Valve and Other Major Cardiothoracic Procedures
with Cardiac Catheterization with MCC
Cardiac Valve and Other Major Cardiothoracic Procedures
with Cardiac Catheterization with CC
Cardiac Valve and Other Major Cardiothoracic Procedures
with Cardiac Catheterization without CC/MCC
Cardiac Valve and Other Major Cardiothoracic Procedures
without Cardiac Catheterization with MCC
Cardiac Valve and Other Major Cardiothoracic Procedures
without Cardiac Catheterization with CC
Cardiac Defibrillator Implant with Cardiac Catheterization
with AMI HF or Shock with MCC
Cardiac Defibrillator Implant with Cardiac Catheterization
with AMI HF or Shock without MCC
Cardiac Defibrillator Implant with Cardiac Catheterization
without AMI HF or Shock with MCC
Cardiac Defibrillator Implant without Cardiac Catheterization
withMCC
Cardiac Defibrillator Implant without Cardiac Catheterization
withoutMCC
Other Cardiothoracic Procedures with MCC
Other Cardiothoracic Procedures without MCC
Coronarv Bypass with PTCA with MCC
Coronary Bypass with Cardiac Catheterization or Open
Ablation with MCC
Coronary Bypass with Cardiac Catheterization or Open
Ablation without MCC
Coronary Bypass without Cardiac Catheterization with MCC
Coronary Bypass without Cardiac Catheterization without
MCC
Amputation for Circulatory System Disorders Except Upper
Limb and Toe with MCC
Amputation for Circulatory System Disorders Except Upper
Limb and Toe with CC
Permanent Cardiac Pacemaker Implant with MCC
Permanent Cardiac Pacemaker Implant with CC
Permanent Cardiac Pacemaker Implant without CC/MCC
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00048
Fmt 4701
Sfmt 4725
Number
of Cases
375
Average
Length
ofStav
12.9
Average
Costs
$89,802
554
17.7
$90,282
9
9.2
$59,655
2
6
$36,309
147
16.8
$85,238
7
8.4
$62,843
923
11.6
$61,254
80
6.3
$40,806
1
6
$41,102
1,602
8.1
$51,116
219
345
9
13
3.5
11.4
5.6
17.2
$40,176
$43,864
$28,662
$91,948
482
17.3
$75,283
4
70
19.8
15
$77,000
$61,655
6
5
$41,809
196
17.6
$43,110
2
1,993
105
5
5
8.7
5.2
3.4
$10,803
$33,121
$23,927
$21,763
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.023
Cases Reporting Circulatory System O.R. Procedures with
a Principal Diagnosis of Heart Failure
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
48827
MS-DRG
245
246
247
248
249
250
251
252
253
254
255
256
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
khammond on DSKJM1Z7X2PROD with RULES2
274
VerDate Sep<11>2014
Description
AICD Generator Procedures
Percutaneous Cardiovascular Procedures with Drug-Eluting
Stent with MCC or 4+ Arteries or Stents
Percutaneous Cardiovascular Procedures with Drug-Eluting
Stent without MCC
Percutaneous Cardiovascular Procedures with Non-DrugEluting Stent with MCC or 4+ Arteries or Stents
Percutaneous Cardiovascular Procedures with Non-DrugEluting Stent without MCC
Percutaneous Cardiovascular Procedures without Coronary
Artery Stent with MCC
Percutaneous Cardiovascular Procedures without Coronary
Artery Stent without MCC
Other Vascular Procedures with MCC
Other Vascular Procedures with CC
Other Vascular Procedures without CC/MCC
Upper Limb and Toe Amputation for Circulatory System
Disorders with MCC
Upper Limb and Toe Amputation for Circulatory System
Disorders with CC
Cardiac Pacemaker Device Replacement with MCC
Cardiac Pacemaker Device Replacement without MCC
Cardiac Pacemaker Revision Except Device Replacement
withMCC
Cardiac Pacemaker Revision Except Device Replacement
with CC
Cardiac Pacemaker Revision Except Device Replacement
without CC/MCC
Vein Ligation and Stripping
Other Circulatory System O .R. Procedures
AICD Lead Procedures
Endovascular Cardiac Valve Replacement and Supplement
Procedures with MCC
Endovascular Cardiac Valve Replacement and Supplement
Procedures without MCC
Aortic and Heart Assist Procedures Except Pulsation Balloon
withMCC
Aortic and Heart Assist Procedures Except Pulsation Balloon
withoutMCC
Other Major Cardiovascular Procedures with MCC
Other Major Cardiovascular Procedures with CC
Other Major Cardiovascular Procedures without CC/MCC
Percutaneous and Other lntracardiac Procedures with MCC
Percutaneous and Other lntracardiac Procedures without
MCC
Total Cases
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00049
Fmt 4701
Sfmt 4725
Number
of Cases
196
Average
Length
of Stay
7.6
Average
Costs
$42,062
4,529
7.4
$27,962
174
4.7
$19,268
92
7.3
$26,922
7
5.1
$19,763
288
7
$25,284
8
1,603
29
2
3.4
10.4
4.6
1
$14,789
$32,014
$21,692
$10,169
105
10.7
$24,075
2
267
28
8
6.8
4.3
$14,155
$22,749
$21,145
279
8.4
$28,176
20
4.3
$17,726
3
9
2,422
83
2.7
35.7
10.7
10
$18,186
$50,529
$28,866
$38,286
666
13.9
$76,663
36
3.8
$44,643
46
16.7
$62,285
1
1,026
22
2
1,064
1
13.8
8.7
1.5
8.8
$14,357
$48,958
$26,730
$8,289
$33,132
41
20,199
6.2
9.9
$26,180
$40,428
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.024
Cases Reporting Circulatory System O.R. Procedures with
a Principal Diae:nosis of Heart Failure
48828
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
As shown in the table, if we were to
move diagnosis codes describing heart
failure to MDC 01, 20,199 cases would
be assigned to the surgical class referred
to as ‘‘unrelated operating room
procedures’’ as an unintended
consequence because the surgical
procedure reported on the claim would
be considered unrelated to the MDC to
which the case was assigned based on
the principal diagnosis.
In response to the requestor’s
concerns regarding the title of MS–DRGs
252, 253 and 254, we noted that, as
stated in the ICD–10 MS–DRG
Definitions Manual, ‘‘In each MDC there
is usually a medical and a surgical class
referred to as ‘‘other medical diseases’’
and ‘‘other surgical procedures,’’
respectively. The ‘‘other’’ medical and
surgical classes are not as precisely
defined from a clinical perspective. The
other classes would include diagnoses
or procedures which were infrequently
encountered or not well defined
clinically. For example, the ‘‘other’’
medical class for the Respiratory System
MDC would contain the diagnoses
‘‘other somatoform disorders’’ and
‘‘congenital malformation of the
respiratory system,’’ while the ‘‘other’’
surgical class for the female
reproductive MDC would contain the
surgical procedures ‘‘excision of liver’’
(liver biopsy in ICD–9–CM) and
‘‘inspection of peritoneal cavity’’
(exploratory laparotomy in ICD–9–CM).
The ‘‘other’’ surgical category contains
surgical procedures which, while
infrequent, could still reasonably be
expected to be performed for a patient
in the particular MDC. There are,
however, also patients who receive
surgical procedures which are
completely unrelated to the MDC to
which the patient was assigned. An
example of such a patient would be a
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
patient with a principal diagnosis of
pneumonia whose only surgical
procedure is a destruction of prostate
(transurethral prostatectomy in ICD–9–
CM). Such patients are assigned to a
surgical class referred to as ‘‘unrelated
operating room procedures.’’ ’’ We
further noted that MS–DRGs 252, 253,
and 254 (Other Vascular Procedures
with MCC, with CC, and without CC/
MCC, respectively) are examples of the
‘‘other’’ surgical class, therefore it is
expected that there will be procedures
not as precisely clinically aligned
within the definition (logic) of these
MS–DRGs.
We stated in the proposed rule that
considering that there was no data in
the FY 2021 MedPAR file to support a
reassignment of these cases based on
resource consumption, the analysis of
clinical coherence as discussed
previously, and the impact that moving
the diagnoses describing heart failure
into MDC 01 from MDC 05 would have
on heart failure cases, we did not
believe a reassignment of these cases
was appropriate at this time. We stated
we could continue to evaluate the
clinical coherence and resource
consumption costs that impact this
subset of cases and their current MS–
DRG assignment as data become
available for future rulemaking.
In summary for the reasons stated
previously, we did not propose to
reassign cases reporting a procedure
code describing the insertion of a
neurostimulator lead onto the vagus
nerve and a procedure code describing
the insertion of a stimulator generator
with a principal diagnosis of heart
failure from MS–DRGs 252, 253 and 254
to MS–DRGs 040, 041 and 042.
Comment: Commenters expressed
support for CMS’ decision to not
propose to reassign cases reporting a
procedure code describing the insertion
PO 00000
Frm 00050
Fmt 4701
Sfmt 4700
of a neurostimulator lead onto the vagus
nerve and a procedure code describing
the insertion of a stimulator generator
with a principal diagnosis of heart
failure from MS–DRGs 252, 253 and 254
to MS–DRGs 040, 041 and 042.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to maintain the
current assignment of cases reporting a
procedure code describing the insertion
of a neurostimulator lead onto the vagus
nerve and a procedure code describing
the insertion of a stimulator generator
with a principal diagnosis of heart
failure to MS–DRGs 252, 253 and 254,
without modification, for FY 2023.
We further stated in the proposed rule
that as we examined the GROUPER
logic that would determine an
assignment of a case to MS–DRGs 252,
253 and 254, we noted the logic for MS–
DRGs 252, 253 and 254 includes ICD–
10–PCS procedure codes that describe
the insertion of the stimulator generator.
We refer the reader to the ICD–10 MS–
DRG Version 39.1 Definitions Manual
(which is available via the internet on
the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS/MS-DRGClassifications-and-Software) for
complete documentation of the
GROUPER logic for the listed MS–DRGs.
We stated that during our review of the
stimulator generator insertion
procedures assigned to these MS–DRGs,
we identified the following 24
procedure codes that describe the
insertion of a stimulator generator,
differentiated by device type (for
example single array or multiple array),
that did not exist in the logic for MS–
DRGs 252, 253 and 254.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
0JH60BZ
0JH60CZ
0JH60DZ
0JH60EZ
0JH63BZ
0JH63CZ
0JH63DZ
0JH63EZ
0JH70BZ
0JH70CZ
0JH70DZ
0JH70EZ
0JH73BZ
0JH73CZ
0JH73DZ
0JH73EZ
0JH80BZ
0JH80CZ
0JH80DZ
0JH80EZ
0JH83BZ
0JH83CZ
0JH83DZ
khammond on DSKJM1Z7X2PROD with RULES2
0JH83EZ
Description
Insertion of single array stimulator generator into chest subcutaneous tissue and fascia, open aooroach
Insertion of single array rechargeable stimulator generator into chest subcutaneous tissue and fascia, open
annroach
Insertion of multiple array stimulator generator into chest subcutaneous tissue and fascia, open approach
Insertion of multiple array rechargeable stimulator generator into chest subcutaneous tissue and fascia,
open approach
Insertion of single array stimulator generator into chest subcutaneous tissue and fascia, percutaneous
approach
Insertion of single array rechargeable stimulator generator into chest subcutaneous tissue and fascia,
percutaneous approach
Insertion of multiple array stimulator generator into chest subcutaneous tissue and fascia, percutaneous
approach
Insertion of multiple array rechargeable stimulator generator into chest subcutaneous tissue and fascia,
percutaneous approach
Insertion of single array stimulator generator into back subcutaneous tissue and fascia, open aooroach
Insertion of single array rechargeable stimulator generator into back subcutaneous tissue and fascia,
open approach
Insertion of multiple array stimulator generator into back subcutaneous tissue and fascia, open approach
Insertion of multiple array rechargeable stimulator generator into back subcutaneous tissue and fascia,
open approach
Insertion of single array stimulator generator into back subcutaneous tissue and fascia, percutaneous
approach
Insertion of single array rechargeable stimulator generator into back subcutaneous tissue and fascia,
percutaneous approach
Insertion of multiple array stimulator generator into back subcutaneous tissue and fascia, percutaneous
annroach
Insertion of multiple array rechargeable stimulator generator into back subcutaneous tissue and fascia,
percutaneous approach
Insertion of single array stimulator generator into abdomen subcutaneous tissue and fascia, open
annroach
Insertion of single array rechargeable stimulator generator into abdomen subcutaneous tissue and fascia,
open approach
Insertion of multiple array stimulator generator into abdomen subcutaneous tissue and fascia, open
annroach
Insertion of multiple array rechargeable stimulator generator into abdomen subcutaneous tissue and
fascia, open aooroach
Insertion of single array stimulator generator into abdomen subcutaneous tissue and fascia,
percutaneous approach
Insertion of single array rechargeable stimulator generator into abdomen subcutaneous tissue and fascia,
percutaneous approach
Insertion of multiple array stimulator generator into abdomen subcutaneous tissue and fascia,
percutaneous approach
Insertion of multiple array rechargeable stimulator generator into abdomen subcutaneous tissue and
fascia, percutaneous aooroach
For clinical consistency with the
other procedure codes describing the
insertion of the stimulator generator
currently assigned to these MS–DRGs,
we proposed to add the 24 ICD–10–PCS
codes listed previously to MS–DRGs
252, 253 and 254, (Other Vascular
Procedures with MCC, with CC, and
without CC/MCC, respectively) in MDC
05 (Diseases and Disorders of the
Circulatory System) effective October 1,
2022 for FY 2023.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Comment: Commenters supported the
proposal to add the 24 ICD–10–PCS
codes to MS–DRGs 252, 253 and 254,
(Other Vascular Procedures with MCC,
with CC, and without CC/MCC,
respectively) in MDC 05 (Diseases and
Disorders of the Circulatory System).
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to add the 24
PO 00000
Frm 00051
Fmt 4701
Sfmt 4700
ICD–10–PCS codes listed previously to
MS–DRGs 252, 253 and 254, (Other
Vascular Procedures with MCC, with
CC, and without CC/MCC, respectively)
in MDC 05 (Diseases and Disorders of
the Circulatory System) without
modification, effective October 1, 2022
for FY 2023.
Also, in the proposed rule we stated
that as we examined the GROUPER
logic that would determine an
assignment of a case to MS–DRG 041,
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.025
ICD-10-PCS
Code
48829
48830
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
we noted that the logic for case
assignment to MS–DRG 041 as
displayed in the ICD–10 MS–DRG
Version 39.1 Definitions Manual,
available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/MS-DRGClassifications-and-Software.html
contains code combinations or
‘‘clusters’’ representing the insertion of
a neurostimulator lead and the insertion
of a stimulator generator that are
captured under a list referred to as
‘‘Peripheral Neurostimulators.’’ During
our review of the procedure code
clusters in this list, we noted that ICD–
10–PCS procedure code clusters
describing the insertion of a
neurostimulator lead and the insertion
of the stimulator generator differentiated
by device type (for example single array
or multiple array), approach and
anatomical site placement are captured.
However, procedure code clusters
describing the insertion of stimulator
generator, that is not differentiated by
device type, and a neurostimulator lead
were inadvertently excluded. We refer
the reader to Table 6P.3a associated
with the proposed rule (which is
available via the internet on the CMS
website at: https://www.cms.hhs.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/
index.html) for the list of the 108 ICD–
10–PCS code clusters that were
inadvertently excluded and do not exist
in the logic for MS–DRG 041.
For clinical consistency, our clinical
advisors supported the addition of the
108 procedure code clusters to the
GROUPER logic list referred to as
‘‘Peripheral Neurostimulators’’ for MS–
DRG 041 that describe the insertion of
stimulator generator, not differentiated
by device type, and a neurostimulator
lead. Therefore, we proposed to add the
108 ICD–10–PCS code clusters listed in
Table 6P.3a in association with the
proposed rule that describe the insertion
of a stimulator generator, that is not
differentiated by device type, and a
neurostimulator lead to MS–DRG 041,
effective October 1, 2022 for FY 2023.
Comment: Commenters expressed
support for CMS’ proposal to add the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
108 ICD–10–PCS code clusters listed in
Table 6P.3a in association with the
proposed rule that describe the insertion
of a stimulator generator, that is not
differentiated by device type, and a
neurostimulator lead to MS–DRG 041. A
commenter stated that this proposal will
clinically align these procedures with
other procedures in their respective
MS–DRGs.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to add the 108
procedure code clusters listed in Table
6P.3a in association with the proposed
rule that describe the insertion of
stimulator generator, not differentiated
by device type, and a neurostimulator
lead to the GROUPER logic list referred
to as ‘‘Peripheral Neurostimulators’’ for
MS–DRG 041 (Peripheral, Cranial Nerve
and Other Nervous System Procedures
with CC or Peripheral Neurostimulator)
without modification, effective October
1, 2022 for FY 2023.
4. MDC 02 (Diseases and Disorders of
the Eye): Retinal Artery Occlusion
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28151 through
28155), we discussed a request we
received to reassign cases reporting
diagnosis codes describing central
retinal artery occlusion, and the closely
allied condition branch retinal artery
occlusion, from MS–DRG 123
(Neurological Eye Disorders) in MDC 02
(Diseases and Disorders of the Eye) to
MS–DRGs 061, 062, and 063 (Ischemic
Stroke Precerebral Occlusion or
Transient Ischemia with Thrombolytic
Agent with MCC, with CC, and without
CC/MCC, respectively) in MDC 01
(Diseases and Disorders of the Nervous
System).
Retinal artery occlusion refers to
blockage of the retinal artery that carries
oxygen to the nerve cells in the retina
at the back of the eye, often by an
embolus or thrombus. A blockage in the
main artery in the retina is called
central retinal artery occlusion (CRAO).
A blockage in a smaller artery is called
branch retinal artery occlusion (BRAO).
According to the requestor, in the
PO 00000
Frm 00052
Fmt 4701
Sfmt 4700
current mapping to MS–DRG 123,
diagnoses of CRAO and BRAO are being
captured inappropriately as eye
disorders in MDC 02. Instead, the
requestor stated that CRAO and BRAO
are forms of acute ischemic stroke
which occur when a vessel supplying
blood to the brain is obstructed.
The requestor stated the retina is a
core component of the central nervous
system and there is growing recognition
that damage to it is a vascular
neurological problem and not an
ophthalmological one. Patients with
CRAO or BRAO are typically very sick,
have an underlying condition, and are at
imminent risk for further events
including heart attack or brain stroke. A
diagnosis of CRAO or BRAO requires an
urgent, structured and multidisciplinary
team-based examination to evaluate and
treat other diagnoses that may be
present such as high blood pressure,
dyslipidemia, diabetes mellitus, obesity,
obstructive sleep apnea and smoking to
ameliorate the risks of a subsequent,
potentially lethal, cardiovascular event.
The requestor further stated new
evidence outlines treatment of patients
with CRAO with acute stroke protocols,
specifically with intravenous
thrombolysis (IV tPA) or hyperbaric
oxygen therapy (HBOT), to improve
outcomes. According to the requestor,
BRAO is less commonly treated with IV
tPA than CRAO but also requires an
urgent and thorough diagnostic workup
as with any other form of stroke. The
requestor stated the current assignment
of these conditions to MS–DRG 123
does not properly recognize disease
complexity and allocation of resources
for care for these cases. The requestor
stated that patients with CRAO or BRAO
more closely resemble patients currently
mapped to MS–DRGs 061, 062, and 063
in terms of in resource intensity and
criticality and that in instances where
HBOT is the chosen treatment modality,
any revised MS–DRG mapping should
include the ICD–10–PCS codes for
HBOT.
As noted in the proposed rule, the
ICD–10–CM codes that describe CRAO
and BRAO are found in the following
table.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ICD-10-CM
Code
H34.10
H34.11
H34.12
H34.13
H34.231
H34.232
H34.233
H34.239
48831
Description
Central retinal artery occlusion, unspecified eye
Central retinal artery occlusion, right eye
Central retinal artery occlusion, left eye
Central retinal artery occlusion, bilateral
Retinal artery branch occlusion, right eye
Retinal artery branch occlusion, left eve
Retinal artery branch occlusion, bilateral
Retinal artery branch occlusion, unspecified eye
Thrombolytic therapy is identified
with the following ICD–10–PCS
procedure codes.
ICD-10-PCS
Code
3E03017
3E03317
3E04017
3E04317
3E05017
3E05317
3E06017
3E06317
Introduction of other thrombol
Introduction of other thrombol
Introduction of other thrombol
Introduction of other thrombol
Introduction of other thrombol
tic
tic
tic
tic
tic
into
into
into
into
into
The requestor identified three ICD–
10–PCS codes that they stated describe
HBOT.
administration of a thrombolytic agent
or a procedure code describing HBOT is
reported with principal diagnosis code
describing CRAO or BRAO, these cases
group to medical MS–DRG 123. We
began our analysis by examining claims
data from the September 2021 update of
the FY 2021 MedPAR file for MS–DRG
123 to (1) identify cases reporting a
principal diagnosis code describing
CRAO or BRAO without a procedure
code describing the administration of a
thrombolytic agent or a procedure code
describing HBOT; (2) identify cases
reporting diagnosis codes describing
CRAO or BRAO with a procedure code
describing HBOT; and (3) identify cases
reporting diagnosis codes describing
CRAO or BRAO with a procedure code
describing the administration of a
thrombolytic agent. Our findings are
shown in the following table:
ER10AU22.027
We stated in the proposed rule that
during our review of this issue, we
included the three procedure codes as
identified by the requestor as describing
HBOT, as well as the similar procedure
code 5A05221 (Extracorporeal
hyperbaric oxygenation, continuous)
that also describes HBOT, differing only
in duration.
We stated that our analysis of this
grouping issue confirmed that, when a
procedure code describing the
ER10AU22.028
Description
Extracorporeal hyperbaric oxygenation, intermittent
Decompression, circulatory, single
Decompression, circulatory, multiple
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00053
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.026
khammond on DSKJM1Z7X2PROD with RULES2
ICD-10-PCS
Code
5A05121
6A150ZZ
6A151ZZ
48832
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
MS-DRG
All cases
Cases reporting a principal diagnosis of CRAO
or BRAO without a procedure code describing
the administration of a thrombolytic agent or a
procedure code describing HBOT
Cases reporting a procedure code describing
HBOT with a principal diagnosis of CRAO or
BRAO
Cases reporting a procedure code describing the
administration of a thrombolytic agent with a
principal diagnosis of CRAO or BRAO
All other cases
123
As shown in the table, we identified
a total of 2,642 cases within MS–DRG
123 with an average length of stay of 2.5
days and average costs of $6,457. Of
these 2,642 cases, there are 774 cases
that reported a principal diagnosis code
describing CRAO or BRAO without a
procedure code describing the
administration of a thrombolytic agent
or a procedure code describing HBOT
with an average length of stay of 2.2
days and average costs of $5,482. There
are nine cases that reported a principal
diagnosis code describing CRAO or
BRAO with a procedure code describing
HBOT with an average length of stay of
2 days and average costs of $6,491.
There are 47 cases that reported a
principal diagnosis code describing
CRAO or BRAO with a procedure code
Number
of Cases
4,531
7,955
1,548
061
062
063
Average
Costs
$6,457
774
2.2
$5,482
9
2
$6,491
47
1,812
2.3
2.6
$14,335
$6,669
days) and the average costs ($6,491
compared to $6,457) are slightly higher
than the average length of stay and
average costs compared to all cases in
that MS–DRG. For the 47 cases in MS–
DRG 123 reporting a principal diagnosis
code describing CRAO or BRAO with a
procedure code describing the
administration of a thrombolytic agent,
the average length of stay is slightly
shorter (2.3 days compared to 2.5 days)
and the average costs are higher
($14,335 compared to $6,457) than the
average length of stay and average costs
compared to all cases in that MS–DRG.
We also examined claims data from
the September 2021 update of the FY
2021 MedPAR file for MS–DRGs 061,
062, and 063. Our findings are shown in
the following table.
Average
Length
of Stay
6.6
3.7
2.5
procedure code describing HBOT for the
presence or absence of a secondary
diagnosis designated as a complication
or comorbidity (CC) or a major
complication or comorbidity (MCC).
ER10AU22.030
principal diagnosis code describing
CRAO or BRAO with a procedure code
describing the administration of a
thrombolytic agent and the nine cases
reporting a principal diagnosis code
describing CRAO or BRAO with a
Average
Costs
$23,720
$15,733
$13,023
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00054
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.029
khammond on DSKJM1Z7X2PROD with RULES2
We stated in the proposed rule that
because MS–DRG 123 is a base DRG and
there is a three-way split within MS–
DRGs 061, 062, and 063, we also
analyzed the 47 cases reporting a
Average
Length
of Stay
2.5
describing the administration of a
thrombolytic agent with an average
length of stay of 2.3 days and average
costs of $14,335.
The data analysis shows that the 774
cases in MS–DRG 123 reporting a
principal diagnosis code describing
CRAO or BRAO without a procedure
code describing the administration of a
thrombolytic agent or a procedure code
describing HBOT have average costs
lower than the average costs in the FY
2021 MedPAR file for MS–DRG 123
($5,482 compared to $6,457), and the
average length of stay is shorter (2.2
days compared to 2.5 days). For the nine
cases in MS–DRG 123 reporting a
principal diagnosis code describing
CRAO or BRAO with a procedure code
describing HBOT, the average length of
stay is shorter (2 days compared to 2.5
MS-DRG
BILLING CODE 4120–01–C
Number
of Cases
2,642
khammond on DSKJM1Z7X2PROD with RULES2
123
MS-DRG
Cases reporting procedures describing the administration of a thrombolytic agent
with a principal dimmosis of CRAO or BRAO with MCC
Cases reporting a procedure code describing HBOT with a principal diagnosis of
CRAO or BRAO with MCC
Cases reporting procedures describing the administration of a thrombolytic agent
with a principal dia~osis of CRAO or BRAO with CC
Cases reporting a procedure code describing HBOT with a principal diagnosis of
CRAO or BRAO with CC
Cases reporting procedures describing the administration of a thrombolytic agent
with a orincipal diagnosis ofCRAO or BRAO without CC/MCC
Cases reporting a procedure code describing HBOT with a principal diagnosis of
CRAO or BRAO without CC/MCC
We stated that this data analysis
showed that the cases in MS–DRG 123
reporting a principal diagnosis code
describing CRAO or BRAO with a
procedure code describing the
administration of a thrombolytic agent
or with a procedure code describing
HBOT when distributed based on the
presence or absence of a secondary
diagnosis designated as a CC or an MCC
have average costs lower than the
average costs in the FY 2021 MedPAR
file for MS–DRGs 061, 062, and 063
respectively, and the average lengths of
stay are shorter. Accordingly, we stated
that we did not believe the data
adequately supported a potential
reassignment of these cases to MS–DRGs
061, 062, and 063 respectively.
Our clinical advisors reviewed this
issue and the related data analysis and
did not believe that the small subset of
patients with a diagnosis of CRAO or
BRAO receiving a thrombolytic agent or
hyperbaric oxygen therapy warranted a
separate MS–DRG or reassignment at
this time. We stated our clinical
advisors noted the average costs for
cases of patients with a diagnosis of
CRAO or BRAO receiving HBOT are
only slightly higher than the average
costs for all cases in MS–DRG 123
($6,491 compared to $6,457). The
average costs for cases of patients with
a diagnosis of CRAO or BRAO receiving
a thrombolytic agent are higher than the
average costs for all cases in MS–DRG
123 however when distributed based on
the presence or absence of a secondary
diagnosis designated as a complication
or comorbidity (CC) or a major
complication or comorbidity (MCC), we
stated that it was unclear to what degree
the higher average costs for these cases
are attributable to the severity of illness
of the patient and other circumstances
of the admission as opposed to the
administration of a thrombolytic agent,
as the claims data reflects a wide
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
variance with regard to average costs for
these cases.
Our clinical advisors further noted
that ischemia is defined as a condition
in which the blood vessels become
blocked, and blood flow is stopped or
reduced. The condition has many
potential causes, including a blockage
caused by a blood clot, or due to
buildup of deposits, such as cholesterol.
Ischemia can occur anywhere in the
body, and the different names for the
condition depend on the organ or body
part affected such as the brain (cerebral
ischemia), heart (ischemic heart disease,
myocardial ischemia, or cardiac
ischemia), and intestines (mesenteric
ischemia or bowel ischemia), legs
(critical limb ischemia—a form of
peripheral artery disease), and skin
(cutaneous ischemia), while they are
similar in that they all involve a blocked
blood vessel.
In ICD–10 the body or organ system
is the axis of the classification and
diagnosis codes describing ischemia
affecting other body parts are classified
by the body or organ system affected.
For example, codes describing
myocardial ischemia are assigned to
MDC 05 (Diseases and Disorders of the
Circulatory System) and codes
describing mesenteric ischemia are
assigned to MDC 06 (Diseases and
Disorders of the Digestive System). Our
clinical advisors disagreed with
assigning the diagnosis codes describing
CRAO and BRAO to MDC 01. Our
clinical advisors noted the concept of
clinical coherence generally requires
that the patient characteristics included
in the definition of each MS–DRG relate
to a common organ system or etiology
and that a specific medical specialty
should typically provide care to the
patients in the DRG. While closely
related, the eyes and the brain are
different organs. Our clinical advisors
stated that because the diagnosis codes
PO 00000
Frm 00055
Fmt 4701
Sfmt 4700
48833
Number
of Cases
Average
Length
of Stay
Average
Costs
9
3.2
$20,220
1
3
$10,768
19
2.3
$13,145
3
2
$6,107
19
1.8
$12,737
5
1.8
$5,867
used to report CRAO and BRAO
describe ischemia affecting the retina,
these diagnosis codes are appropriately
assigned to MDC 02 (Diseases and
Disorders of the Eye). The retina is a
collection of cells at the back of the eye
where the processing of visual
information begins. Due to the retina’s
vital role in vision, damage to it can
cause permanent blindness. The
presence of CRAO or BRAO requires
input from an ophthalmologist and
treatment for these diagnoses would be
expected to utilize different resources
than a diagnosis of cerebral ischemia
which may or may not involve visual
impairment. Other possible
interventions for CRAO or BRAO
include attempting to lower the
intraocular pressure with medication or
by using a small-gauge needle to remove
fluid to try to dislodge the embolus or
ocular massage to dislodge the clot,
which are not interventions generally
performed for a diagnosis of acute
ischemic stroke.
We stated in the FY 2023 IPPS/LTCH
PPS proposed rule that to explore other
mechanisms to address this request, we
also reviewed claims data to consider
the option of adding another severity
level to the current structure of MS–
DRG 123 (Neurological Eye Disorders)
and assigning the cases with a principal
diagnosis of CRAO or BRAO with a
procedure code describing the
administration of a thrombolytic agent
to the highest level. This option would
have involved modifying the current
base MS–DRG to a two-way severity
level split or to a three-way severity
level split of ‘‘with MCC or thrombolytic
agent, with CC, and without CC/MCC.’’
Therefore, it would have included
proposing new MS–DRGs if the data and
our clinical advisors supported creation
of new MS–DRGs. However, as
displayed in the data findings in the
table that follows, we found that the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.031
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
48834
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
FY
Data
2021
2020
2019
Number
of
Cases
2,642
2,664
3,100
Number
of
Cases
MCC
374
345
376
Number
of
Cases
cc
1,220
1,163
1,393
We stated that we applied the criteria
to create subgroups for the three-way
severity level split. We referred the
reader to section II.D.1.b. of the
preamble of the FY 2023 IPPS/LTCH
PPS proposed rule, for related
discussion regarding our finalization of
the expansion of the criteria to include
the NonCC subgroup and our proposal
to continue to delay application of the
NonCC subgroup criteria to existing
MS–DRGs with a three-way severity
level split to maintain more stability in
the current MS–DRG structure. We
found that the criterion that there be at
least 500 cases for each subgroup was
not met, as shown in the table based on
the data in the FY 2019, FY 2020, and
FY 2021 MedPAR files. Specifically, for
the ‘‘with MCC’’, ‘‘with CC’’, and
‘‘without CC/MCC’’ split, there were
only 376 cases in the ‘‘with MCC’’
subgroup based on the data in the FY
2019 MedPAR file, only 345 cases in the
‘‘with MCC’’ subgroup based on the data
in the FY 2020 MedPAR file and only
374 cases in the ‘‘with MCC’’ subgroup
based on the data in the FY 2021
MedPAR file.
We then applied the criteria to create
subgroups for the two-way severity level
splits. For the ‘‘with MCC’’ and
‘‘without MCC’’ (CC+NonCC) split, the
criterion that there be at least 500 cases
for each subgroup failed due to low
volume each year, specifically, for the
‘‘with MCC’’ subgroup as previously
described. For the ‘‘with CC/MCC’’ and
‘‘without CC/MCC’’ (NonCC) split, we
found that the criterion that there be at
least a $2,000 difference in average costs
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
However, as discussed in the FY 2022
IPPS/LTCH PPS proposed rule (86 FR
25092), our MS–DRG analysis last year
was based on ICD–10 claims data from
the March 2020 update of the FY 2019
MedPAR file, which contains hospital
claims received from October 1, 2018
through March 31, 2020, for discharges
occurring through September 30, 2019
and the ICD–10 claims data from the
September 2020 update of the FY 2020
MedPAR file, which contains hospital
claims received from October 1, 2019
through September 30, 2020, for
discharges occurring through September
30, 2020 given the potential impact of
Number
of
Cases
NonCC
1,048
1,156
1,331
Average
Costs
No Solit
$6,457
$5,943
$5,659
Average
Costs
MCC
$8,605
$7,710
$8,276
Average
Costs
cc
$6,738
$6,235
$5,743
between the ‘‘with CC/MCC’’ and
‘‘without CC/MCC’’ subgroups also
failed. In the FY 2019 MedPAR file, our
data analysis shows average costs in the
hypothetical ‘‘with CC/MCC’’ subgroup
of $6,282 and average costs in the
hypothetical ‘‘without CC/MCC’’
subgroup of $4,832, for a difference of
only $1,450 ($6,282 minus $4,832 =
$1,450). In the FY 2020 MedPAR file,
our data analysis shows average costs in
the hypothetical ‘‘with CC/MCC’’
subgroup of $6,573 and average costs in
the hypothetical ‘‘without CC/MCC’’
subgroup of $5,122, for a difference of
only $1,451 ($6,573 minus $5,122 =
$1,451). In the FY 2021 MedPAR file,
our data analysis shows average costs in
the hypothetical ‘‘with CC/MCC’’
subgroup of $7,176 and average costs in
the hypothetical ‘‘without CC/MCC’’
subgroup of $5,364, for a difference of
only $1,812 ($7,176 minus $5,364 =
$1,812). We stated that our data analysis
indicated that the current base MS–DRG
123 maintains the overall accuracy of
the IPPS, and that the claims data did
not support a three-way or a two-way
severity level split for MS–DRG 123.
Lastly, we stated we explored
reassigning cases with a principal
diagnosis of CRAO or BRAO that receive
the administration of a thrombolytic
agent to other MS–DRGs within MDC
02. However, our review did not
support reassignment of these cases to
any other medical MS–DRGs as these
cases would not be clinically coherent
with the cases assigned to those other
MS–DRGs.
PO 00000
Frm 00056
Fmt 4701
Sfmt 4700
the PHE for COVID–19. Therefore, for
the FY 2023 IPPS/LTCH PPS proposed
rule, we reviewed the claims data for
base MS–DRG 123 using the March 2020
update of the FY 2019 MedPAR file and
the September 2020 update of the FY
2020 MedPAR file, which were used in
our analysis of claims data for MS–DRG
reclassification requests for FY 2022.
We also reviewed the claims data for
base MS–DRG 123 using the September
2021 update of the FY 2021 MedPAR
file, which were used in our analysis of
claims data for MS–DRG reclassification
requests for FY 2023. Our findings are
shown in the table:
Average
Costs
NonCC
$5,364
$5,122
$4,832
Average
Costs
MCC/CC
Combo
$7,176
$6,573
$6,282
Average
Costs
CC/NonCC
Combo
$6,103
$5,681
$5,298
Therefore, based on the various data
analyses we performed to explore the
possible reassignment of cases with a
principal diagnosis of CRAO or BRAO
with a procedure code describing the
administration of a thrombolytic agent
or a procedure code describing
hyperbaric oxygen therapy, and the
clinical analysis as previously
discussed, for FY 2023 we did not
propose any MS–DRG changes for cases
with a principal diagnosis of CRAO or
BRAO with a procedure code describing
the administration of a thrombolytic
agent or a procedure code describing
hyperbaric oxygen therapy.
Comment: Some commenters
expressed support for CMS’ decision to
not propose any MS–DRG changes for
cases with a principal diagnosis of
CRAO or BRAO with a procedure code
describing the administration of a
thrombolytic agent or a procedure code
describing hyperbaric oxygen therapy.
Response: We appreciate the
commenters’ support.
Comment: Other commenters opposed
or expressed concerns with CMS’
decision to not propose any MS–DRG
changes for cases with a principal
diagnosis of CRAO or BRAO with a
procedure code describing the
administration of a thrombolytic agent
or a procedure code describing
hyperbaric oxygen therapy. These
commenters stated from a
pathophysiologic perspective, CRAO is
the same process as a stroke of the brain
and that the retina, although located
within the eye, is a core component of
the central nervous system and consists
of brain cells (neurons) that also extend
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.032
data did not support this option. We
applied the five criteria as described in
section II.D.1.b. of the preamble of the
proposed rule and this final rule to
determine if it would be appropriate to
subdivide cases currently assigned to
MS–DRG 123 into severity levels. This
analysis generally includes two years of
MedPAR claims data to compare the
data results from one year to the next to
avoid making determinations about
whether additional severity levels are
warranted based on an isolated year’s
data fluctuation and also, to validate
that the established severity levels
within a base MS–DRG are supported.
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
cerebral ischemia, which may or may
not involve visual impairment. Our
clinical advisors continue to believe
CRAO and BRAO are appropriately
classified with other eye conditions
currently assigned to MDC 02.
Therefore, after consideration of the
public comments we received, and for
the reasons discussed, we are finalizing
our proposal, without modification, to
maintain the current assignment of
cases with a principal diagnosis of
CRAO or BRAO with a procedure code
describing the administration of a
thrombolytic agent or a procedure code
describing hyperbaric oxygen therapy.
5. MDC 04 (Diseases and Disorders of
the Respiratory System): Acute
Respiratory Distress Syndrome (ARDS)
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28155 through
28156), we discussed a request we
received to reassign cases reporting
diagnosis code J80 (Acute respiratory
distress syndrome) as the principal
diagnosis from MS–DRG 204
(Respiratory Signs and Symptoms) to
MS–DRG 189 (Pulmonary Edema and
Respiratory Failure).
According to the requestor, when a
patient presents with the condition of
acute respiratory failure that progresses
to acute respiratory distress syndrome
(ARDS) during the hospital stay, official
coding guidance instructs to only report
the diagnosis code for ARDS (code J80).
The requestor stated that in the
American Hospital Association’s (AHA)
Coding Clinic for ICD–10–CM and ICD–
10–PCS, Fourth Quarter 2020
publication, for a patient who is
admitted in acute hypoxic respiratory
failure that progresses to ARDS, the
MS-DRG
khammond on DSKJM1Z7X2PROD with RULES2
204
All Cases
Cases with principal diagnosis code J80
(Acute respiratory distress syndrome)
All other cases
As shown in the table, the data
demonstrate a longer average length of
stay (7.6 days versus 2.8 days) and
higher average costs ($15,077 versus
$6,780) for the 96 cases reporting ARDS
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Number
of Cases
5,241
96
Average
Length
of Stay
2.8
7.6
Average
Costs
$6,780
$15,077
5,145
2.7
$6,625
(code J80) as a principal diagnosis when
compared to all 5,241 cases in MS–DRG
204.
We also examined claims data from
the September 2021 update of the FY
PO 00000
Frm 00057
Fmt 4701
Sfmt 4700
advice is to assign code J80, Acute
respiratory distress syndrome.
Additionally, in the ICD–10–CM
Tabular List of Diseases, per the
Excludes 1 note under category J96
(Respiratory failure, not elsewhere
classified) only code J80 should be
assigned when respiratory failure and
ARDS are both documented. The same
publication also maintained that ARDS
is a life-threatening form of respiratory
failure and is not an unrelated
condition. Therefore, when acute
respiratory failure is documented along
with ARDS, only one code is reported
to capture the highest level of severity.
The requestor also conveyed the
Fourth Quarter 2020 publication’s
reference to previously published
advice from the Fourth Quarter 2017
publication that stated, ‘‘Acute
respiratory distress syndrome (ARDS) is
a life-threatening condition. ARDS is a
rapidly progressive disorder that has
symptoms of dyspnea, tachypnea, and
hypoxemia. Fluid builds up in the
alveoli and lowers the amount of oxygen
that is circulated through the
bloodstream. Low levels of oxygen in
the blood threatens organ function.
ARDS is often associated with sepsis,
pneumonia, trauma and aspiration. The
majority of people who develop ARDS
are already in the hospital in critical
condition from some other health
complication. The focus of treatment is
getting oxygen to the organs.’’
We examined claims data from the
September 2021 update of the FY 2021
MedPAR file for all cases in MS–DRG
204 and the cases reporting ARDS (code
J80) as a principal diagnosis. Our
findings are shown in the following
table.
2021 MedPAR file for all cases in MS–
DRG 189. Our findings are shown in the
following table.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.033
through the entire course of the brain.
These commenters also stated that the
relationship of any particular tissue to
its organ is related to its structure and
function, and not its location. According
to the commenters, acute CRAO is a
medical emergency, equivalent to acute
cerebral ischemic stroke, that needs to
be treated in the same way with urgent
inpatient evaluation, cerebrovascular
and cardiac workup, and intervention.
The commenters urged CMS to assign
cases reporting diagnosis codes
describing central retinal artery
occlusion with a procedure code
describing the administration of a
thrombolytic agent or a procedure code
describing hyperbaric oxygen therapy to
MS–DRGs 061, 062, and 063 to ensure
appropriate payment for these cases.
Response: We thank the commenters
for their feedback. Our clinical advisors
reviewed the commenters’ concerns and
note that although commenters’ state the
relationship of any particular tissue to
its organ is related to its structure and
function, and not its location, in ICD–
10, however, the body or organ system
is the axis of the classification. By
design, the patient characteristics
included in the definition of each MS–
DRG relate to a common organ system
or etiology. Our clinical advisors agree
with commenters that the retina is
similar to the brain in terms of cellular
and functional elements, but they note
the retina is a part of the eye. Our
clinical advisors state that the presence
of CRAO or BRAO, which typically
presents sudden, painless monocular
loss of visual acuity and peripheral
vision, requires input from an
ophthalmologist which would not
always be expected in a diagnosis of
48835
48836
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
MS-DRG
Number of Cases
189
77,626
We stated in the proposed rule that
the data analysis supports that cases
reporting ARDS (code J80) are more
appropriately aligned with the average
length of stay and average costs of the
cases in MS–DRG 189 in comparison to
MS–DRG 204 when ARDS is reported as
a principal diagnosis. We also stated in
the proposed rule that we agree,
consistent with the coding clinic advice,
ARDS is a life-threatening form of
respiratory failure and the conventions
of the ICD–10–CM classification as
displayed in the Tabular List of Diseases
Excludes note, support the concept that
cases reporting ARDS as a principal
diagnosis are more clinically coherent
with the other conditions currently
assigned to MS–DRG 189.
For these reasons, we proposed to
reassign cases reporting ARDS (code
J80) as a principal diagnosis from MS–
DRG 204 to MS–DRG 189 effective FY
2023.
Comment: Commenters supported the
proposal to reassign cases reporting
diagnosis code J80 as a principal
diagnosis from MS–DRG 204 to MS–
DRG 189.
Response: We thank the commenters
for their support.
After consideration of the public
comments we received, we are
finalizing our proposal to reassign cases
reporting ARDS (code J80) as a principal
diagnosis from MS–DRG 204 to MS–
DRG 189 effective FY 2023.
6. MDC 05 (Diseases and Disorders of
the Circulatory System)
a. Percutaneous Transluminal Coronary
Angioplasty (PTCA) Logic
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28156 through
28157), we stated that we identified a
replication issue from the ICD–9 based
MS–DRGs to the ICD–10 based MS–
DRGs for procedure code 02UG3JE
(Supplement mitral valve created from
left atrioventricular valve with synthetic
substitute, percutaneous approach) that
was created effective October 1, 2016
(FY 2017), to identify and describe
further interventions that may occur for
a patient who had previously undergone
cardiac valve surgery to correct a
congenital anomaly, such as repair of a
complete common atrioventricular canal
defect.
As stated in the proposed rule, we
used our established process in the
assignment of new procedure code
02UG3JE to the most appropriate MS–
DRG(s) for FY 2017. Procedure code
02UG3JE was proposed for assignment
to the same MS–DRGs as its predecessor
$9,780
code. The predecessor code for
procedure code 02UG3JE as shown in
the 2017 ICD–10–PCS conversion table
(available via the internet on the CMS
web page at: https://www.cms.gov/
Medicare/Coding/ICD10/2017-ICD-10PCS-and-GEMs) is 02UG3JZ
(Supplement mitral valve with synthetic
substitute, percutaneous approach). The
ICD–9–CM comparable translation for
this code (02UG3JZ) is procedure code
35.97 (Percutaneous mitral valve repair
with implant), which identifies the use
of the MitraClip® technology that has
been discussed extensively in prior
rulemaking.
In the FY 2017 rulemaking, using our
established process, new procedure
code 02UG3JE was proposed and
finalized for assignment to the following
MS–DRGs for FY 2017, as also shown in
Table 6B.—New Procedure Codes in
association with the FY 2017 IPPS/
LTCH PPS proposed and final rules
(available via the internet on the CMS
web page at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/AcuteInpatient-Files-for-Download). We noted
that the listed MS–DRGs also reflect the
MS–DRGs that the predecessor code
(02UG3JZ) was assigned to at the time
of the proposed rule.
Description
Coronary Bypass with PTCA with MCC
Coronary Bypass with PTCA without MCC
Coronary Bypass with Cardiac Catheterization with MCC
Coronary Bypass with Cardiac Catheterization without MCC
Coronary Bypass without Cardiac Catheterization with MCC
Coronary Bypass without Cardiac Catheterization without MCC
Percutaneous Intracardiac Procedures with MCC
Percutaneous Intracardiac Procedures without MCC
Extensive O.R. Procedures Unrelated to Principal Diagnosis with MCC
Extensive O.R. Procedures Unrelated to Principal Diagnosis with CC
Extensive O.R. Procedures Unrelated to Principal Diagnosis without CC/MCC
However, as also discussed in the FY
2017 IPPS/LTCH PPS final rule (81 FR
56809 through 56813), in connection
with replication efforts between the
ICD–9 and ICD–10 based MS–DRGs and
the surgical hierarchy, the predecessor
procedure code (02UG3JZ) was
reassigned from MS–DRGs 273 and 274
VerDate Sep<11>2014
4.6
00:20 Aug 10, 2022
Jkt 256001
to MS–DRG 228 (Other Cardiothoracic
Procedures with MCC) and revised MS–
DRG 229 (Other Cardiothoracic
Procedures without MCC), and was
removed from the PTCA logic for MS–
DRGs 231 and 232. However, these
proposed and finalized MS–DRG
changes for procedure code 02UG3JZ
PO 00000
Frm 00058
Fmt 4701
Sfmt 4700
were not considered for purposes of the
MS–DRG assignments for new
procedure code 02UG3JE, which were
instead finalized as proposed based on
the existing MS–DRG assignments for
the predecessor code, and code
02UG3JE continued to remain on the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.035
khammond on DSKJM1Z7X2PROD with RULES2
231
232
233
234
235
236
273
274
981
982
983
Average
Costs
ER10AU22.034
MS-DRG
Average Length of
Stay
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
PTCA list in the GROUPER logic for
MS–DRGs 231 and 232.
As noted in the proposed rule, our
clinical advisors stated that procedure
code 02UG3JE does not describe a PTCA
procedure. As also noted in the
proposed rule, we analyzed claims data
from the September 2021 update of the
FY 2021 MedPAR file for cases in MS–
DRGs 231 and 232 to determine if there
were any cases reported with procedure
code 02UG3JE, and there were no such
cases found.
Accordingly, because the procedure
described by procedure code 02UG3JE is
not clinically consistent with a PTCA
procedure and it was initially assigned
to the list for PTCA procedures in the
GROUPER logic as a result of replication
in the transition from ICD–9 to ICD–10
based MS–DRGs, we proposed to
remove procedure code 02UG3JE from
the list for PTCA procedures in the
GROUPER logic for MS–DRGs 231 and
232 effective FY 2023. We also proposed
to maintain the MS–DRG assignment for
procedure code 02UG3JE in MS–DRGs
266 and 267 (Endovascular Cardiac
Valve Replacement and Supplement
Procedures with and without MCC,
respectively) for FY 2023.
Comment: Commenters agreed with
the proposal to remove procedure code
02UG3JE from the GROUPER logic for
MS–DRGs 231 and 232 and to maintain
the assignment in MS–DRGs 266 and
267.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to remove
procedure code 02UG3JE from the list
for PTCA procedures in MS–DRGs 231
and 232 and to maintain the assignment
for code 02UG3JE in MS–DRGs 266 and
267 in the GROUPER logic for FY 2023.
b. Neuromodulation Device Implant for
Heart Failure (BarostimTM Baroreflex
Activation Therapy)
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28157
through 28162), the BAROSTIM NEOTM
System is the first neuromodulation
device system designed to trigger the
body’s main cardiovascular reflex to
target symptoms of heart failure. The
system consists of an implantable pulse
generator (IPG) that is implanted
subcutaneously in the upper chest
below the clavicle, a stimulation lead
that is sutured to either the right or left
carotid sinus to activate the
baroreceptors in the wall of the carotid
artery and a wireless programmer
system that is used to non-invasively
program and adjust BAROSTIM NEOTM
therapy via telemetry. The BAROSTIM
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
NEOTM System is indicated for the
improvement of symptoms of heart
failure in a subset of patients with
symptomatic New York Heart
Association (NYHA) class II and III
heart failure with low cardiac ejection
fractions who do not benefit from
guideline directed pharmacologic
therapy or qualify for Cardiac
Resynchronization Therapy (CRT).
The BAROSTIM NEOTM System was
approved for new technology add-on
payments for FY 2021 (85 FR 58716
through 58717) and FY 2022 (86 FR
44974). We refer readers to section
II.F.5.a of the preamble of the proposed
rule and this final rule for a discussion
regarding the FY 2023 status of
technologies approved for FY 2022 new
technology add-on payments, including
the BAROSTIM NEOTM System.
For the FY 2023 IPPS/LTCH PPS
proposed rule, we received a request to
(1) reassign the ICD–10–PCS procedure
codes that describe the implantation of
the BAROSTIM NEOTM System from
MS–DRGs 252, 253 and 254 (Other
Vascular Procedures with MCC, with
CC, without MCC respectively) to MS–
DRGs 222, 223, 224, 225, 226, and 227
(Cardiac Defibrillator Implant with and
without Cardiac Catheterization with
and without AMI/HF/Shock with and
without MCC, respectively) and (2)
reassign the procedure code that
describes the placement of a
BAROSTIM NEOTM IPG alone from MS–
DRGs 252, 253 and 254 to MS–DRG 245
(AICD Generator Procedures).
We stated in the FY 2023 IPPS/LTCH
PPS proposed rule that the following
ICD–10–PCS procedure codes uniquely
identify the implantation of the
BAROSTIM NEOTM System: 0JH60MZ
(Insertion of stimulator generator into
chest subcutaneous tissue and fascia,
open approach) in combination with
03HK3MZ (Insertion of stimulator lead
into right internal carotid artery,
percutaneous approach) or 03HL3MZ
(Insertion of stimulator lead into left
internal carotid artery, percutaneous
approach). The requestor noted that
ICD–10–PCS codes 0JH60MZ,
03HK3MZ and 03HL3MZ are
individually assigned to MDC 05 in
MS–DRGs 252, 253, and 254 but not
mapped to the logic of these MS–DRGs
in a code combination or code cluster.
According to the requestor this means
that cases with a principal diagnosis
from MDC 05 with procedure codes
describing the implantation of a
BAROSTIM NEOTM system (0JH60MZ
with 03HL3MZ or 03HK3MZ); with
procedure codes describing placement
of the stimulator generator alone
(0JH60MZ); or with procedure codes
describing the placement of a carotid
PO 00000
Frm 00059
Fmt 4701
Sfmt 4700
48837
sinus lead only (03HL3MZ or
03HK3MZ) are all assigned to MS–DRGs
252, 253, and 254, despite the
significant differences in the clinical
coherence and resources required to
perform these distinct procedures.
The requestor stated that cases
reporting procedure codes describing
the implantation of a BAROSTIM
NEOTM system are more clinically
similar to, and have costs that are more
closely aligned to, cases within MS–
DRGs 222, 223, 224, 225, 226, and 227.
The requestor stated that according to
its own analysis, the population of
Medicare patients surgically treated
with procedures assigned to MS–DRGs
222, 223, 224, 225, 226, and 227 is
essentially identical to the population
treated with the BAROSTIM NEOTM
System. According to the requestor, this
congruent patient population accounts
for essentially all cases assigned to MS–
DRGs 222, 223, 224, 225, 226, and 227.
The requestor stated their analysis
demonstrated that over 80% of the cases
in MS–DRGs 222, 223, 224, 225, 226,
and 227 had a diagnosis of heart failure,
compared to only 30% of cases with a
diagnosis of heart failure assigned to
MS–DRGs 252, 253, and 254. The
requestor stated that the subset of
patients that have an indication for the
implantation of a BAROSTIM NEOTM
system also have indications for the
implantation of Implantable
Cardioverter Defibrillators (ICD),
Cardiac Resynchronization Therapy
Defibrillators (CRT–D) and/or Cardiac
Contractility Modulation (CCM) devices,
all of which also require the permanent
implantation of a programmable,
electrical pulse generator and at least
one electrical lead. The requestor
specifically highlighted that the
procedure code combinations describing
the implantation of a cardiac
contractility modulation (CCM) device
system, which consists of a
programmable implantable pulse
generator (IPG) and three leads, one of
which is implanted into the right atrium
and the other two leads which are
inserted into the right ventricle is
assigned to MS–DRGs 222, 223, 224,
225, 226, and 227, and the codes
describing the insertion of contractility
modulation device generator alone are
assigned to MS–DRG 245. The requestor
stated that the average resource
utilization required to implant the
BAROSTIM NEOTM System
demonstrates a significant disparity
compared to all procedures within MS–
DRGs 252, 253, and 254 and noted that
the cost of the BAROSTIM NEOTM
implantable device is $35,000, which is
in range with the cost of the other
E:\FR\FM\10AUR2.SGM
10AUR2
48838
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
cardiac implantable devices (for
example ICD, CRT–D, and CCM)
assigned to MS–DRGs 222, 223, 224,
225, 226, and 227.
The requestor stated that the majority
of the procedures assigned to MS–DRGs
252, 253, and 254 are primarily
designed to identify, diagnose, clear and
restructure veins and arteries, excluding
those that require implantable devices.
Furthermore, the requestor stated the
surgical procedures within MS–DRGs
252, 253, and 254 are not intended to
treat or improve the function of the
heart, nor treat the symptoms of heart
failure.
The requestor acknowledged that
there are very few cases within the
publicly available Medicare inpatient
claims data that potentially includes
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
procedure codes describing the
implantation of a BAROSTIM NEOTM
system. The requestors’ own analysis
revealed fewer than 11 cases with
procedure codes describing the
implantation of a BAROSTIM NEOTM
system in the combined FY 2019 and FY
2020 MedPAR data and noted that
during much of this time period, the
BAROSTIM NEOTM System was only
implanted as part of a controlled
clinical trial. The requestor stated that
this incomplete data should not be used
to determine initial MS–DRG
assignments, especially for new FDA
designated ‘breakthrough’ medical
technologies like the BAROSTIM
NEOTM system. Rather, the requestor
stated that CMS should use available
PO 00000
Frm 00060
Fmt 4701
Sfmt 4700
information and expert knowledge to
make initial MS–DRG assignments,
while waiting for a substantial number
of Medicare covered, post-approved
claims from a disperse set of hospitals
to reconsider MS–DRG assignments as
necessary. The requestor cautioned that
upon new technology add-on payments
expiration, and if the inadequate MS–
DRG assignment for these procedures
continues, inpatient admissions to
implant the BAROSTIM NEOTM system
will be paid less than outpatient
admissions to perform the same
procedures.
The ICD–10–CM diagnosis codes that
describe heart failure are found in the
following table. These diagnosis codes
are all currently assigned to MDC 05.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
113.0
113.2
150.1
150.20
150.21
150.22
150.23
150.30
150.31
150.32
150.33
150.40
150.41
150.42
150.43
150.810
150.811
150.812
150.813
150.814
150.82
150.83
150.84
150.89
150.9
197.130
197.131
Description
Rheumatic heart failure
Hypertensive heart disease with heart failure
Hypertensive heart and chronic kidney disease with heart failure and stage 1
through stage 4 chronic kidney disease, or unspecified chronic kidney disease
Hypertensive heart and chronic kidney disease with heart failure and with
stage 5 chronic kidney disease, or end stage renal disease
Left ventricular failure, unspecified
Unspecified systolic (congestive) heart failure
Acute systolic (congestive) heart failure
Chronic systolic (congestive) heart failure
Acute on chronic systolic (congestive) heart failure
Unspecified diastolic (congestive) heart failure
Acute diastolic (congestive) heart failure
Chronic diastolic (congestive) heart failure
Acute on chronic diastolic (congestive) heart failure
Unspecified combined systolic (congestive) and diastolic (congestive) heart
failure
Acute combined systolic (congestive) and diastolic (congestive) heart failure
Chronic combined systolic (congestive) and diastolic (congestive) heart
failure
Acute on chronic combined systolic (congestive) and diastolic (congestive)
heart failure
Right heart failure, unspecified
Acute right heart failure
Chronic right heart failure
Acute on chronic right heart failure
Right heart failure due to left heart failure
Biventricular heart failure
High output heart failure
End stage heart failure
Other heart failure
Heart failure, unspecified
Postprocedural heart failure following cardiac surgery
Postprocedural heart failure following other surgery
khammond on DSKJM1Z7X2PROD with RULES2
We stated in the proposed rule that
first, we examined claims data from the
September 2021 update of the FY 2021
MedPAR file for MS–DRGs 252, 253 and
254 to identify cases reporting a
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
diagnosis of heart failure and procedure
codes describing the implantation of the
BAROSTIM NEOTM system with or
without a procedure code describing the
performance of a cardiac catheterization
PO 00000
Frm 00061
Fmt 4701
Sfmt 4700
as MS–DRGs 222, 223, 224, 225, 226,
and 227 are defined by the performance
of cardiac catheterization. Our findings
are shown in the following table.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.036
ICD-10-CM
Code
109.81
111.0
48839
48840
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
As shown in the table, the data
analysis performed indicates that the
two cases in MS–DRG 252 reporting
procedure codes describing the
implantation of a BAROSTIM NEOTM
system have an average length of stay
that is shorter than the average length of
stay for all the cases in MS–DRG 252
(4.5 days versus 7.6 days) and higher
average costs when compared to all the
cases in MS–DRG 252 ($67,588 versus
$27,488). These two cases did not also
report a procedure code describing the
performance of a cardiac catherization.
The one case in MS–DRG 253 reporting
procedure codes describing the
implantation of a BAROSTIM NEOTM
system had a length of stay that is
shorter than the average length of stay
for all the cases in MS–DRG 253 (1 day
versus 5.2 days) and lower costs when
compared to all the cases in MS–DRG
253 ($19,237 versus $21,978). This case
did not also report a procedure code
describing the performance of a cardiac
catherization. We found zero cases in
MS–DRG 254 reporting procedure codes
0
2
18,373
4.5
5.2
$67,588
$21,978
1
$19,237
0
1
describing the implantation of a
BAROSTIM NEOTM system.
We stated that our clinical advisors
reviewed this data and noted that was
it is difficult to detect patterns of
complexity and resource intensity based
on the three cases that reported
procedure codes describing the
implantation of a BAROSTIM NEOTM
system. The claims data also reflect a
wide variance with regard to the length
of stay and average costs for the three
cases that did report the implantation of
a BAROSTIM NEOTM system. We stated
that the results of the claims analysis
demonstrated we did not have sufficient
claims data on which to base and
evaluate any proposed changes to the
current MS–DRG assignment. We also
stated that our clinical advisors also
expressed concern in equating the
implantation of a BAROSTIM NEOTM
system to the placement of ICD, CRT–
D, and CCM devices as these devices all
differ in terms of technical complexity
and anatomical placement of the
electrical lead(s). Our clinical advisors
noted there is no intravascular
component or vascular puncture
involved when implanting a
BAROSTIM NEOTM system. Our clinical
advisors also noted the placement of
ICD, CRT–D, and CCM devices generally
involve a lead being affixed to the
myocardium, being threaded through
the coronary sinus or crossing a heart
valve and are procedures that involve a
greater level of complexity than affixing
the stimulator lead to either the right or
left carotid sinus when implanting a
BAROSTIM NEOTM system.
Next, to evaluate the request to
reassign the procedure code that
describes the placement of a
BAROSTIM NEOTM IPG alone from MS–
DRGs 252, 253 and 254 to MS–DRG 245
(AICD Generator Procedures), we stated
in the proposed rule that we examined
claims data from the September 2021
update of the FY 2021 MedPAR file for
all cases in MS–DRGs 252, 253 and 254
and compared the results to cases with
a procedure code describing placement
of the stimulator generator alone. Our
findings are shown in the following
table.
MS-DRGs 252-254: Cases Reporting Procedures Describing Placement of a BAROSTIM NEO™
Stimulator Generator
Average
Number
Average
Length of
MS-DRG
ICD-10-PCS codes
of Cases
Costs
Stay
All cases
24,839
$27,488
7.6
252
Cases with procedure code 0JH60MZ alone
12
8.8
$56,622
All Cases
18,373
5.2
$21,978
253
Cases with procedure code0JH60MZ alone
4
2.5
$30,451
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00062
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.038
253
Average
Length Average
of Stay
Costs
7.6 $27,488
ER10AU22.037
252
MS-DRG
All cases
Cases with diagnosis of heart failure with
0lli60MZ and 03HL3MZ or 03HK3MZ
with cardiac catheterization
Cases with diagnosis of heart failure with
0lli60MZ and 03HL3MZ or 03HK3MZ
without cardiac catheterization
All cases
Cases with diagnosis of heart failure with
0lli60MZ and 03HL3MZ or 03HK3MZ
with cardiac catheterization
Cases with diagnosis of heart failure with
0lli60MZ and 03HL3MZ or 03HK3MZ
without cardiac catheterization
Number
of Cases
24,839
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
As shown in the table, the data
analysis performed indicates that the 12
cases in MS–DRG 252 reporting a
procedure code describing placement of
the stimulator generator alone have an
average length of stay that is longer than
the average length of stay for all the
cases in MS–DRG 252 (8.8 days versus
7.6 days) and higher average costs when
compared to all the cases in MS–DRG
252 ($56,622 versus $27,488). The four
cases in MS–DRG 253 reporting a
procedure code describing placement of
the stimulator generator alone have an
average length of stay that is shorter
than the average length of stay for all the
cases in MS–DRG 253 (2.5 days versus
5.2 days) and higher average costs when
compared to all the cases in MS–DRG
253 ($30,451 versus $21,978). We found
zero cases in MS–DRG 254 reporting a
procedure code describing placement of
the stimulator generator alone.
We stated that our clinical advisors
reviewed this data, and found, similar to
the analysis of the data from the three
cases that reported procedure codes
describing the implantation of a
BAROSTIM NEOTM system, that it was
difficult to detect patterns of complexity
and resource intensity based on the few
cases that reported procedure codes
describing placement of the stimulator
generator alone. The claims data
similarly reflects a wide variance with
regard to the length of stay and average
costs for these cases that did report the
placement of the stimulator generator
alone, indicating there may have been
other factors contributing to the higher
costs. When reviewing the consumption
of hospital resources for this small
subset of cases, the claims data also
suggest that the increased costs may be
attributable to the severity of illness of
the patient and other circumstances of
the admission as the patients tended to
have a major complication or co-morbid
(MCC) condition reported based on the
MS–DRG assigned.
We stated in the proposed rule that
we recognized the average costs of the
small numbers of cases reporting a
procedure code describing placement of
the stimulator generator alone are
greater when compared to the average
costs of all cases in their respective MS–
DRG. We noted that the MS–DRG
system is a system of averages and it is
expected that within the diagnostic
related groups, some cases may
demonstrate higher than average costs,
while other cases may demonstrate
lower than average costs. We further
noted that section 1886(d)(5)(A) of the
Act provides for Medicare payments to
Medicare-participating hospitals in
addition to the basic prospective
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
payments for cases incurring
extraordinarily high costs.
In response to the requestor’s
concerns regarding procedures currently
assigned to MS–DRGs 252, 253 and 254,
as discussed in section II.D.3.b. of the
preamble of the proposed rule and this
final rule, we note that MS–DRGs 252,
253, and 254 (Other Vascular
Procedures with MCC, with CC, and
without CC/MCC, respectively) are
examples of the ‘‘other’’ surgical class,
and therefore it is expected that there
will be procedures not as precisely
clinically aligned within the definition
(logic) of these MS–DRGs. In regard to
the concern about the implications for
reimbursement when these procedures
are performed in the outpatient setting
as opposed to the inpatient setting, we
noted that the goals of reviewing the
MS–DRG assignments of particular
procedures are to better clinically
represent the resources involved in
caring for these patients and to enhance
the overall accuracy of the system.
In the proposed rule, in response to
the requestor’s statement that CMS
should use available information and
expert knowledge to make initial MS–
DRG assignments, while waiting for a
substantial number of Medicare
covered, post-approved claims from a
disperse set of hospitals to reconsider
MS–DRG assignments as necessary, we
noted that we use our established
process for GROUPER assignments for
new diagnosis and procedure codes.
Specifically, consistent with our
established process for assigning new
diagnosis and procedure codes, we
stated that we review the predecessor
code and MS–DRG assignment most
closely associated with the new
diagnosis or procedure code, and in the
absence of claims data, we consider
other factors that may be relevant to the
MS–DRG assignment, including the
severity of illness, treatment difficulty,
complexity of service and the resources
utilized in the diagnosis or treatment of
the condition. We noted that this
process will not automatically result in
the new diagnosis or procedure code
being assigned to the same MS–DRG or
having the same designation as the
predecessor code. Members of the
public have the opportunity to provide
feedback on the assignment and
designation of the codes if they disagree.
We referred the reader to section II.D.17
of the proposed rule for a more detailed
discussion of this process. We noted
that when BAROSTIM NEOTM applied
for new technology add-on payment, it
was noted that the technology could be
uniquely identified using a combination
of existing ICD–10–PCS codes that were
already assigned to MS–DRGs, and this
PO 00000
Frm 00063
Fmt 4701
Sfmt 4700
48841
circumstance generally would not
provide a basis for MS–DRG
reassignment.
Lastly, as discussed in the proposed
rule, our clinical advisors expressed
concern regarding making proposed
MS–DRG changes based on a specific,
single technology (BAROSTIM NEOTM
system), identified by only one unique
procedure code combination versus
considering proposed changes based on
a group of related procedure codes that
can be reported to describe that same
type or class of technology, which is
more consistent with the intent of the
MS–DRGs.
We stated that we believed that as the
number of cases reporting procedure
codes describing the implantation of
neuromodulation devices for heart
failure increases, a better view of the
associated costs and lengths of stay on
average will be reflected in the data for
purposes of assessing any reassignment
of these cases. We indicated that our
clinical advisors stated that it would not
be appropriate to reassign cases for
patients from MS–DRGs 252, 253 and
254 to MS–DRGs 222, 223, 224, 225,
226, and 227 in the absence of
additional data to better determine the
resource utilization for this subset of
patients to help inform whether a
reassignment would be clinically
warranted. Therefore, for the reasons
stated previously, we proposed to
maintain the assignment of cases
reporting procedure codes that describe
the implantation of a neuromodulation
device in MS–DRGs 252, 253 and 254
for FY 2023. We also proposed to
maintain the assignment of cases
reporting a procedure code describing
placement of a stimulator generator
alone in MS–DRGs 252, 253 and 254 for
FY 2023.
Comment: Commenters expressed
support for CMS’ proposal to maintain
the assignment of cases reporting
procedure codes that describe the
implantation of a neuromodulation
device for heart failure in MS–DRGs
252, 253 and 254 and to maintain the
assignment of cases reporting a
procedure code describing placement of
a stimulator generator alone in MS–
DRGs 252, 253 and 254 for FY 2023.
Response: We appreciate the
commenters’ support.
Comment: A commenter opposed
CMS’ proposal. The commenter stated
that in their own analysis of the
MedPAR data, and from their real-world
experience, patients with an indication
for implantation of a neuromodulation
device were not always admitted with a
heart failure diagnosis. Many patients
presented with multiple comorbidities,
and various cardiovascular diagnosis
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
(for example, syncope, tachycardia,
atrial fibrillation etc.) which lead to
heart failure or are concomitant with
heart failure.
This commenter further stated that in
their review of the data that CMS
presented, the cost of cases with a
diagnosis of heart failure with
procedure codes describing the
implantation of a neuromodulation
device without cardiac catheterization
and the cost of cases with a procedure
code describing placement of the
stimulator generator alone are both more
than twice that of all cases in MS–DRG
252. The commenter stated even given
these disparities, they did not believe
that the full costs of the implantation of
a neuromodulation device system have
been appreciated in the MedPAR data
files. According to the commenter, the
manufacturer did not charge a cost for
the device during clinical trials for the
BAROSTIM NEOTM so such claims do
not reflect the full device cost. The
commenter also stated that the COVID–
19 pandemic has had a negative impact
on inpatient hospital uptake of this new
technology, which in turn has also
limited the data available to support an
accurate and appropriate MS–DRG
assignment. The commenter stated they
believe the fact that there are few cases
in the MedPAR data files to date is not
a reason to allow an overly mispriced
MS–DRG assignment. The commenter
stated that while BAROSTIM NEOTM
procedures are typically performed in
the outpatient setting, it is important to
preserve inpatient access for those
patients with comorbidities or other risk
factors that necessitate an inpatient
level of care. According to this
commenter, the current MS–DRG
assignments for procedure codes that
describe the implantation of a
neuromodulation device for heart
failure would result in a lower payment
than procedures performed in the
outpatient setting and could result in
barriers to treatment for patients who
are not suitable candidates for the
outpatient setting.
This commenter urged CMS to
reassign the ICD–10–PCS procedure
codes that describe the implantation of
a neuromodulation device for heart
failure from MS–DRGs 252, 253 and 254
ICD-10-CM
Code
197.130
197.131
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
to MS–DRGs 222, 223, 224, 225, 226 and
227 as requested. As alternatives, the
commenter recommended to CMS, to
instead, consider reassigning the ICD–
10–PCS procedure codes that describe
the implantation of the BAROSTIM
NEOTM System from MS–DRGs 252, 253
and 254 to MS–DRGs 270, 271 and 272
(Other Major Cardiovascular Procedures
with MCC, with CC, and without CC/
MCC, respectively) or even create a new
MS–DRG that appropriately describes
these procedures.
Response: We appreciate the
commenter’s feedback and concern.
With regard to the commenter’s concern
that patients with an indication for the
implantation of neuromodulation
devices are not always admitted with
heart failure diagnoses, we wish to
confirm that the examination of claims
data from the September 2021 update of
the FY 2021 MedPAR file for MS–DRGs
252, 253 and 254 to identify cases
reporting a diagnosis of heart failure and
procedure codes describing the
implantation of neuromodulation
devices for heart failure with or without
a procedure code describing the
performance of a cardiac
catheterization, as discussed in the
proposed rule, included cases reporting
a diagnosis of heart failure as either a
principal or secondary diagnosis.
Our clinical advisors reviewed
commenter’s concerns and continue to
note we do not have sufficient claims
data on which to base and evaluate any
proposed changes to the current MS–
DRG assignment, given the difficulties
of assessing patterns of complexity and
resource intensity based on the limited
number of cases identified. Our clinical
advisors also continue to express
concern in equating the implantation of
neuromodulation devices for heart
failure to the placement of ICD, CRT–D,
and CCM devices as these devices all
differ in terms of technical complexity
and anatomical placement of the
electrical lead(s), as discussed in the
proposed rule. In regard to the concern
about the implications for payment
when these procedures are performed in
the outpatient setting as opposed to the
inpatient setting, as noted in the
proposed rule, and in prior rulemaking,
the goals of reviewing the MS–DRG
assignments of particular procedures are
to better clinically represent the
resources involved in caring for these
patients and to enhance the overall
accuracy of the system.
With regard to the commenter’s
concern that there may have been other
contributing factors that limited the data
available to support an accurate and
appropriate MS–DRG assignment of
these cases, our clinical advisors believe
that as the number of cases reporting
procedure codes describing the
implantation of neuromodulation
devices for heart failure increases, the
associated resource utilization can be
better assessed for purposes of
evaluating any reassignment of these
cases. As additional claims data
becomes available, we will continue to
analyze the clinical nature of procedure
codes describing the implantation of
neuromodulation devices for heart
failure and their MS–DRG assignments,
including potential alternative MS–DRG
assignments, to further improve the
overall accuracy of the IPPS payments
in future rulemaking.
Therefore, after consideration of the
public comments we received, and for
the reasons stated earlier, we are
finalizing our proposal to maintain the
assignment of cases reporting procedure
codes that describe the implantation of
a neuromodulation device in MS–DRGs
252, 253 and 254, without modification,
for FY 2023. We are also finalizing our
proposal to maintain the assignment of
cases reporting a procedure code
describing placement of a stimulator
generator alone in MS–DRGs 252, 253
and 254, without modification, effective
October 1, 2022 for FY 2023.
In the proposed rule, we also noted
that during our review of this issue, as
we examined the GROUPER logic that
would determine an assignment of a
case to MS–DRGs 222, 223, 224, 225,
226, and 227, we found two diagnosis
codes describing heart failure that are
not currently in the listed principal
diagnoses in the GROUPER logic for
MS–DRGs 222 and 223 (Cardiac
Defibrillator Implant with Cardiac
Catheterization with AMI, HF or Shock
with and without MCC, respectively).
These diagnosis codes are listed in the
following table.
Post rocedural heart failure followin
PO 00000
Frm 00064
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.039
48842
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
We stated that as a result, when either
of these codes are coded as a principal
diagnosis, MS–DRGs 224 and 225
(Cardiac Defibrillator Implant with
Cardiac Catheterization without AMI,
HF, or Shock with and without MCC,
respectively) are instead assigned when
reported with a procedure code
combination describing the
implantation of a cardiac defibrillator
and a procedure describing the
performance of a cardiac catherization
procedure. We referred the reader to the
ICD–10 MS–DRG Definitions Manual
Version 39.1, which is available via the
internet on the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatient
PPS/MS-DRG-Classifications-andSoftware for complete documentation of
the GROUPER logic for MS–DRGs 222,
223, 224, and 225.
In the proposed rule, we stated that
our clinical advisors reviewed this issue
and believed that cases reporting
diagnosis code I97.130 or I97.131 as a
principal diagnosis are associated with
a severity of illness on par with cases
reporting a principal diagnosis of a type
of heart failure. We noted that in order
to code postprocedural heart failure in
ICD–10–CM, instructional notes at
category I50 direct to ‘‘code first heart
failure following surgery’’ (that is,
I97.130 and I97.131) with a second code
from subcategory of I50 listed after the
postprocedural heart failure code to
specify the type of heart failure. We
stated that our clinical advisors
recommended adding diagnosis codes
I97.130 and I97.131 to the logic list of
principal diagnoses that describe heart
failure for clinical consistency,
recognizing that coding guidelines
instruct to code I97.130 and I97.131
before the codes from subcategory of I50
that specify the type of heart failure, as
the codes from subcategory of I50 are
currently in the listed principal
diagnoses in the GROUPER logic for
MS–DRGs 222 and 223. Therefore, we
proposed to modify the GROUPER logic
to allow cases reporting diagnosis code
I97.130 or I97.131 as a principal
diagnosis to group to MS–DRGs 222 and
223 when reported with qualifying
procedures.
Comment: Commenters expressed
support for CMS’ proposal to modify the
GROUPER logic to allow cases reporting
diagnosis code I97.130 or I97.131 as a
principal diagnosis to group to MS–
DRGs 222 and 223 when reported with
qualifying procedures.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to modify the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
GROUPER logic to allow cases reporting
diagnosis code I97.130 or I97.131 as a
principal diagnosis to group to MS–
DRGs 222 and 223 when reported with
qualifying procedures, without
modification, effective October 1, 2022
for FY 2023.
c. Cardiac Mapping
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28162
through 28163), we identified a
replication issue from the ICD–9 based
MS–DRGs to the ICD–10 based MS–
DRGs for procedure code 02K80ZZ
(Map conduction mechanism, open
approach). Cardiac mapping describes
the creation of detailed maps to detect
how the electrical signals that control
the timing of the heart rhythm move
between each heartbeat to identify the
location of rhythm disorders. Cardiac
mapping is generally performed during
open-heart surgery or performed via
cardiac catherization.
In the FY 2016 IPPS/LTCH PPS final
rule (80 FR 49363 through 49369), we
discussed a request to remove the
cardiac ablation and other specified
cardiovascular procedures from the
following MS–DRGs, and to create new
MS–DRGs to classify these procedures:
• MS–DRG 246 (Percutaneous
Cardiovascular Procedure with DrugEluting Stent with MCC or 4+ Vessels/
Stents);
• MS–DRG 247 (Percutaneous
Cardiovascular Procedure with DrugEluting Stent without MCC);
• MS–DRG 248 (Percutaneous
Cardiovascular Procedure with NonDrug-Eluting Stent with MCC or 4+
Vessels/Stents);
• MS–DRG 249 (Percutaneous
Cardiovascular Procedure with NonDrug-Eluting Stent without MCC);
• MS–DRG 250 (Percutaneous
Cardiovascular Procedure without
Coronary Artery Stent with MCC); and
• MS–DRG 251 (Percutaneous
Cardiovascular Procedure without
Coronary Artery Stent without MCC).
The requestor recommended that
CMS assign the following ICD–9–CM
procedure codes that identify and
describe cardiac ablation procedures
and the other percutaneous intracardiac
procedures to the newly created MS–
DRGs:
• 35.52 (Repair of atrial septal defect
with prosthesis, closed technique);
• 35.96 (Percutaneous balloon
valvuloplasty);
• 35.97 (Percutaneous mitral valve
repair with implant);
• 37.26 (Catheter based invasive
electrophysiologic testing);
• 37.27 (Cardiac mapping);
PO 00000
Frm 00065
Fmt 4701
Sfmt 4700
48843
• 37.34 (Excision or destruction of
other lesion or tissue of heart,
endovascular approach);
• 37.36 (Excision, destruction, or
exclusion of left atrial appendage
(LAA)); and
• 37.90 (Insertion of left atrial
appendage device).
We stated we agreed that creating
these new MS–DRGs would better
reflect utilization of resources and
clinical cohesiveness for intracardiac
procedures in comparison to
intracoronary procedures. Therefore,
after consideration of the public
comments we received, we finalized our
proposal to create MS–DRGs 273
(Percutaneous Intracardiac Procedures
with MCC) and MS–DRG 274
(Percutaneous Intracardiac Procedures
without MCC) for the FY 2016 ICD–10
MS–DRGs Version 33 and finalized the
assignment of the procedures performed
within the heart chambers using
intracardiac techniques to the two new
MS–DRGs.
In the FY 2016 rulemaking, we stated
that the comparable ICD–10–PCS code
translations for ICD–9–CM procedure
code 37.27 (Cardiac mapping) were
ICD–10–PCS codes 02K83ZZ (Map
conduction mechanism, percutaneous
approach) and 02K84ZZ (Map
conduction mechanism, percutaneous
endoscopic approach). However, code
02K80ZZ (Map Conduction Mechanism,
Open Approach), which is also a
comparable ICD–10–PCS code
translation for ICD–9–CM procedure
code 37.27, was inadvertently excluded.
Consequently, procedure code 02K80ZZ
continued to remain in the GROUPER
logic for MS–DRGs 246, 247, 248, 249,
250 and 251.
In the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58477), we finalized a
revision to the titles for MS–DRGs 273
and 274 to ‘‘Percutaneous and Other
Intracardiac Procedures with and
without MCC, respectively’’ to better
reflect the procedures assigned to them.
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule, in the ICD–10
MS–DRGs Definitions Manual Version
39.1, procedure code 02K80ZZ is
currently recognized as a non-O.R.
procedure that affects the MS–DRG to
which it is assigned. We stated that our
clinical advisors reviewed this grouping
issue and stated that procedure code
02K80ZZ does not describe a
percutaneous cardiovascular procedure.
We stated that our clinical advisors
supported the reassignment of code
02K80ZZ for clinical coherence, noting
the procedure should be appropriately
grouped along with other procedure
codes that describe cardiac mapping
currently assigned to MS–DRGs 273 and
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48844
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
274. Accordingly, because the
procedure described by procedure code
02K80ZZ is not clinically consistent
with percutaneous cardiovascular
procedures and it was initially assigned
MS–DRGs 246, 247, 248, 249, 250 and
251 as a result of replication in the
transition from ICD–9 to ICD–10 based
MS–DRGs, we proposed the
reassignment of procedure code
02K80ZZ from MS–DRGs 246, 247, 248,
249, 250 and 251 to MS–DRGs 273 and
274 (Percutaneous and Other
Intracardiac Procedures with and
without MCC, respectively) in MDC 05
effective FY 2023.
As discussed in section II.D.1.b of the
preamble of the proposed rule, we noted
that we were providing a test version of
the ICD–10 MS–DRG GROUPER
Software, Version 40, so that the public
could better analyze and understand the
impact of the proposals included in the
proposed rule. We noted that at the time
of the development of the test software
this issue was unable to be addressed
and therefore, it did not reflect the
proposed reassignment of procedure
code 02K80ZZ from MS–DRGs 246, 247,
248, 249, 250 and 251 to MS–DRGs 273
and 274 (Percutaneous and Other
Intracardiac Procedures with and
without MCC, respectively) in MDC 05
for Version 40.
Comment: Commenters agreed with
our proposal to reassign procedure code
02K80ZZ from MS–DRGs 246, 247, 248,
249, 250 and 251 to MS–DRGs 273 and
274 (Percutaneous and Other
Intracardiac Procedures with and
without MCC, respectively). A few
commenters stated that they appreciate
CMS identifying a replication issue from
the ICD–9 based MS–DRGs to the ICD–
10 based MS–DRGs and supported the
reassignment of procedure code
02K80ZZ. A commenter agreed that
cardiac mapping is generally performed
during open-heart surgery or performed
via cardiac catheterization to create
detailed maps of electrical signals to
identify the location of rhythm
disorders.
Response: We thank the commenters
for their support.
Comment: Other commenters opposed
the proposal. Several commenters noted
that CMS stated that code 02K80ZZ
affects the MS–DRG to which it is
assigned, however, based on their
review of the MS–DRG logic, code
02K80ZZ is designated as a non-O.R
procedure and does not affect MS–DRG
assignment. Other commenters
expressed concern that data was not
analyzed to see if code 02K80ZZ had
been found in MS–DRGs 246, 247, 248,
249, 250 and 251. A commenter stated
that should it be determined that code
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
02K80ZZ had not been found in MS–
DRGs 246, 247, 248, 249, 250 and 251,
then they agreed with removal of code
02K80ZZ from these MS–DRGs and
reassignment to MS–DRGs 273–274.
However, should the analysis show
code 02K80ZZ assigned to MS–DRGs
246, 247, 248, 249, 250 and 251, this
commenter suggested CMS consider if
the assignment of code 02K80ZZ to
these MS–DRGs should be maintained,
and if not, what ramifications the
reassignment would have.
A few commenters recommended that
CMS consider assigning code 02K80ZZ
to MS–DRGs 228 and 229 (Other
Cardiothoracic Procedures with and
without MCC, respectively) instead.
Some commenters stated that they
believe that procedures to map
conduction mechanism share similar
clinical and resource consumption as
the surgical ablation procedures
performed via an open approach that are
currently assigned to MS–DRGs 228 and
229. These commenters further stated
that given that 02K80ZZ (Map
conduction mechanism, open approach)
does not describe a percutaneous
cardiovascular procedure, they did not
recommend the assignment of the code
to MS–DRGs 273 and 274. A commenter
stated that based on their own analysis,
02K80ZZ is more often assigned to MS–
DRGs 228 and 229 than to MS–DRGs
273 and 274, and furthermore, the ICD–
10–PCS codes included in MS–DRGs
273 and 274 are ablation procedures via
percutaneous approach. Another
commenter asserted that the procedures
in MS–DRGs 273 and 274 are all
percutaneous approach procedures.
Response: We thank the commenters
for their feedback.
We note that in the ICD–10 MS–DRGs
Definitions Manual Version 39.1,
procedure code 02K80ZZ is in fact
recognized as a non-O.R. procedure
affecting MS–DRGs 246, 247, 248, 249,
250 and 251, specifically. Under the
IPPS MS–DRGs, each ICD–10–PCS
procedure code has designations that
determine whether and in what way the
presence of that procedure on a claim
impacts the MS–DRG assignment. First,
each ICD–10–PCS procedure code is
either designated as an O.R. procedure
for purposes of MS–DRG assignment
(‘‘O.R. procedures’’) or is not designated
as an O.R. procedure for purposes of
MS–DRG assignment (‘‘non-O.R.
procedures’’). For each procedure that is
designated as a non-O.R. procedure, that
non-O.R. procedure is further classified
as either affecting the MS–DRG
assignment or not affecting the MS–DRG
assignment. We refer to these
designations that do affect MS–DRG
assignment as ‘‘non O.R. affecting the
PO 00000
Frm 00066
Fmt 4701
Sfmt 4700
MS–DRG’’ because these procedure
codes describe procedures that would
generally require a greater intensity of
resources for facilities to manage the
cases included in the definition (logic)
of these MS–DRGs. We refer readers to
the ICD–10 MS–DRG Version 39.1
Definitions Manual at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS/MS–DRGClassifications-and-Software.html for
detailed information regarding the
designation of procedures as O.R. or
non-O.R. (affecting the MS–DRG) in
Appendix E—Operating Room
Procedures and Procedure Code/MS–
DRG Index. Procedures designated as
‘‘non O.R. affecting the MS–DRG’’ are
listed in Appendix E with an asterisk.
In response to the comments
expressing concern that data was not
analyzed to determine if there were any
cases reported with procedure code
02K80ZZ in MS–DRGs 246, 247, 248,
249, 250 and 251, we refer the reader to
Table 6P.1e associated with this final
rule and available via the internet at
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS. This table displays
the findings from our analysis of the
claims data from the September 2021
update of the FY 2021 MedPAR file to
determine if there were any cases
reported with procedure code 02K80ZZ
assigned to MS–DRGs 246, 247, 248,
249, 250 and 251 and reflects that there
were no such cases found.
With regard to the commenters’
concerns that procedures to map
conduction mechanism share similar
clinical and resource consumption as
surgical ablation procedures performed
via an open approach, our clinical
advisors note that while cardiac
mapping can be used to identify and
localize areas responsible for rhythm
disturbances to serve as a target for
surgical ablation, each of these
procedures are defined by clinically
distinct definitions and objectives,
which is why there are separate and
unique ICD–10–PCS procedure codes
within the classification for reporting
purposes. Our clinical advisors note that
cardiac mapping describes the creation
of detailed maps, generally involving
the use of electrodes and a mapping
system (consisting of amplifiers and a
recording and analysis system), to detect
how the electrical signals that control
the timing of the heart rhythm move
between each heartbeat to identify the
location of rhythm disorders. Surgical
ablation, however, describes the burning
or freezing of tissue on the inside of the
heart to disrupt faulty electrical signals
causing the arrhythmia.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
We also note in response to the
comments received that percutaneous
ablation procedures are not the only
procedures assigned to MS–DRGs 273
and 274. Of note, left atrial appendage
closure (LAAC) procedures, with and
without an implant, are also assigned to
MS–DRGs 273 and 274. In response to
the commenters who did not agree with
the proposal to reassign procedure code
02K80ZZ from MS–DRGs 246, 247, 248,
249, 250 and 251 to MS–DRGs 273 and
274 based on the open approach of the
procedure, as noted in the proposed
rule, in the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58477), we finalized a
revision to the titles for MS–DRGs 273
and 274 to ‘‘Percutaneous and Other
Intracardiac Procedures with and
without MCC, respectively’’ to better
reflect the procedures assigned, as not
only percutaneous procedures are
assigned to these MS–DRGs. We refer
the reader to the ICD–10 MS–DRG
Definitions Manual, version 39.1, which
is available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/MS–DRGClassifications-and-Software for
complete documentation of the
GROUPER logic for MS–DRGs 273 and
274.
Our clinical advisors continue to note
that code 02K80ZZ (Map Conduction
Mechanism, Open Approach), which is
a comparable ICD–10–PCS code
translation for ICD–9–CM procedure
code 37.27 (Cardiac mapping), was
inadvertently excluded in FY 2016
rulemaking when we finalized our
proposal to create MS–DRGs 273 and
MS–DRG 274 to better reflect utilization
of resources and clinical cohesiveness
for intracardiac procedures in
comparison to intracoronary
procedures. Our clinical advisors
continue to support the reassignment of
code 02K80ZZ for clinical coherence,
noting the procedure should be
appropriately grouped along with other
procedure codes that describe cardiac
mapping that are currently assigned to
MS–DRGs 273 and 274.
Therefore, after consideration of the
public comments we received, and for
the reasons discussed, we are finalizing
our proposal to reassign procedure code
02K80ZZ from MS–DRGs 246, 247, 248,
249, 250 and 251 to MS–DRGs 273 and
274 (Percutaneous and Other
Intracardiac Procedures with and
without MCC, respectively) in MDC 05
for Version 40, without modification.
d. Surgical Ablation
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 44836 through 44848), we
discussed a two-part request we
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
received to review the MS–DRG
assignments for cases involving the
surgical ablation procedure for atrial
fibrillation. The first part of the request
was to create a new classification of
surgical ablation MS–DRGs to better
accommodate the costs of open
concomitant surgical ablations. The
requestor identified the following
potential procedure combinations that
would comprise an ‘‘open concomitant
surgical ablation’’ procedure.
• Open CABG + open surgical ablation
• Open MVR + open surgical ablation
• Open AVR + open surgical ablation
• Open MVR + open AVR + open
surgical ablation
• Open MVR + open CABG + open
surgical ablation
• Open MVR + open AVR + open CABG
+ open surgical ablation
• Open AVR + open CABG + open
surgical ablation
As discussed in the FY 2022 IPPS/
LTCH PPS final rule, we examined
claims data from the March 2020 update
of the FY 2019 MedPAR file and the
September 2020 update of the FY 2020
MedPAR file for cases reporting
procedure code combinations describing
open concomitant surgical ablations. We
refer the reader to Table 6P.1o
associated with the FY 2022 final rule
(which is available via the internet on
the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS) for data analysis
findings of cases reporting procedure
code combinations describing open
concomitant surgical ablations. We
stated our analysis showed while the
average lengths of stay and average costs
of cases reporting procedure code
combinations describing open
concomitant surgical ablations are
higher than all cases in their respective
MS–DRG, we found variation in the
volume, length of stay, and average
costs of the cases. We also stated
findings from our analysis indicated
that MS–DRGs 216, 217, and 218
(Cardiac Valve and Other Major
Cardiothoracic Procedures with Cardiac
Catheterization with MCC, with CC, and
without CC/MCC, respectively) as well
as approximately 31 other MS–DRGs
would be subject to change based on the
three-way severity level split criterion
finalized in FY 2021. We refer the
reader to section II.D.1.b. of the FY 2022
IPPS/LTCH PPS final rule (86 FR 44796
through 44798), for related discussion
regarding our finalization of the
proposal to delay application of the
NonCC subgroup criteria to existing
MS–DRGs with three-way severity level
split to maintain more stability in the
current MS–DRG structure.
PO 00000
Frm 00067
Fmt 4701
Sfmt 4700
48845
In the FY 2022 final rule, we finalized
our proposal to revise the surgical
hierarchy for the MS–DRGs in MDC 05
(Diseases and Disorders of the
Circulatory System) to sequence MS–
DRGs 231–236 (Coronary Bypass) above
MS–DRGs 228 and 229 (Other
Cardiothoracic Procedures with and
without MCC, respectively), effective
October 1, 2021. In addition, we also
finalized the assignment of cases with a
procedure code describing coronary
bypass and a procedure code describing
open ablation to MS–DRGs 233 and 234
and changed the titles of these MS–
DRGs to ‘‘Coronary Bypass with Cardiac
Catheterization or Open Ablation with
and without MCC, respectively’’ to
reflect this reassignment for FY 2022.
In response to this final policy, as
discussed in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28163), we
received a request to again review the
MS–DRG assignment of cases involving
open concomitant surgical ablation
procedures. The requestor stated they
continue to believe that the average
hospital costs for surgical ablation for
atrial fibrillation demonstrates a cost
disparity compared to all procedures
within their respective MS–DRGs. The
requestor suggested that when open
surgical ablation is performed with
MVR, or AVR or MVR/AVR + CABG
that these procedures are either (1)
assigned to a different family of MS–
DRGs or (2) assigned to MS–DRGs 216
and 217 (Cardiac Valve and Other Major
Cardiothoracic Procedures with Cardiac
Catheterization with MCC and with CC,
respectively) similar to what CMS did
with CABG and open ablation
procedures in the FY 2022 rulemaking
to better accommodate the added cost of
open concomitant surgical ablation.
In the proposed rule we stated the
change to the surgical hierarchy in MDC
05 and the assignment of cases with a
procedure code describing coronary
bypass and a procedure code describing
open ablation to MS–DRGs 233 and 234
is recent, only becoming effective
October 1, 2021. We stated that we
believed more time was needed before
considering to again review the MS–
DRG assignment of cases reporting
procedure code combinations describing
open concomitant surgical ablations as
the data from the September 2021
update of the FY 2021 MedPAR file
does not reflect our FY 2022
finalization. In addition, our clinical
advisors continued to state that in open
concomitant surgical ablation
procedures, the CABG, MVR, and AVR
components of the procedure are more
technically complex than the open
surgical ablation procedure. They also
stated that the finalized revision to the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48846
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
surgical hierarchy leads to a grouping
that is more coherent and better
accounts for the resources expended to
address the more complex procedures
from other cases redistributed during
the hierarchy change. As noted, we
stated that we believed that additional
time was needed to allow for further
analysis of the claims data to reflect our
FY 2022 finalization, and also to
determine to what extent the patient’s
co-morbid conditions are also
contributing to costs and to identify
other contributing factors that might
exist with respect to the increased
length of stay and costs of this subset of
cases in these MS–DRGs, as discussed
in the FY 2022 IPPS/LTCH PPS final
rule.
Comment: Commenters expressed
support of CMS’ decision to allow
additional time for the claims data to
reflect our FY 2022 finalization before
further analysis. Commenters stated that
the finalized changes to surgical
hierarchy for cardiac procedures were
positive and will improve patient
access. Other commenters stated that
the finalized changes to the MS–DRG
assignment of cases with a procedure
code describing coronary bypass and a
procedure code describing open
ablation were timely.
Response: We thank the commenters
for their support.
Comment: Some commenters opposed
CMS’ decision and suggested that
Medicare cover both aortic valve
replacement surgery and surgical
treatment for atrial fibrillation.
Response: We note that the
Definitions Manual display of the
GROUPER logic assignment for each
procedure code is not an indication of
whether or not a particular procedure is
covered for payment purposes. The MS–
DRG logic must specifically require a
condition to group based on whether it
is reported as a principal diagnosis or a
secondary diagnosis, and consider any
procedures that are reported, in addition
to consideration of the patient’s age, sex
and discharge status in order to affect
the MS–DRG assignment. In other
words, cases will group according to the
GROUPER logic, regardless of any
coding guidelines or coverage policies.
It is the Medicare Code Editor (MCE)
and other payer-specific edits that
identify inconsistencies in the coding
guidelines or coverage policies. These
data integrity edits address issues such
as data validity, coding rules, and
coverage policies. Since the inception of
the IPPS, the data editing function has
been a separate and independent step in
the process of determining a DRG
assignment. The separation of the MS–
DRG grouping and data editing
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
functions allows the MS–DRG
GROUPER to remain stable even though
coding rules and coverage policies may
change during the fiscal year.
Comment: Other commenters opposed
CMS’ decision and stated CMS needs to
finish the work that was started and
improve hospital payment for valvular
procedures with surgical ablation for
atrial fibrillation. These commenters
stated that the finalization of the
revision to the surgical hierarchy for the
MS–DRGs in MDC 05 and the
finalization of the assignment of cases
with a procedure code describing
coronary bypass and a procedure code
describing open ablation to MS–DRGs
233 and 234 in FY 2022 rulemaking
does not address the increased costs of
cases describing open concomitant
surgical ablation performed with open
valve procedures that are assigned to
MS–DRGs 216 through 221. A few
commenters asserted that hospitals are
forced to lose money on these lifesaving
treatments because CMS has not
addressed this underpayment. Other
commenters stated that CMS did not
provide transparent data analysis of
cases describing open surgical ablation
for atrial fibrillation performed during
open valve procedures so the provider
community could appropriately
evaluate.
Commenters stated that treating atrial
fibrillation during the same surgical
session as an open valve procedure
requires significant device costs,
additional operating room time, and
specialized staff. A commenter stated
that even if the surgical ablation
procedure is less technically complex
than CABG, MVR, and/or AVR,
hospitals still bear significant costs for
furnishing the ablation procedure when
the additional costs of the innovative
device technologies (such as
radiofrequency ablation clamps,
cryoablation probes, and left atrial
appendage management devices) that
are used during the procedure are
considered. Commenters expressed
concern that given the added costs of
performing as many as three procedures
at the same time, hospitals may more
likely schedule the patient for separate
procedures even though guidelines of
the Society for Thoracic Surgeons and
the Heart Rhythm Society recommend
performing surgical ablation for atrial
fibrillation at the time of open-heart
procedures when indicated. These
commenters further stated they believed
it did not seem financially prudent to
compel patients to undergo multiple
procedures, potentially costing more in
the long run, when their atrial
fibrillation could be treated during the
same open-heart operation. Many
PO 00000
Frm 00068
Fmt 4701
Sfmt 4700
commenters urged CMS to either (1)
assign the cases to a different family of
MS–DRGs or (2) assign these cases to
MS–DRGs 216 and 217 (Cardiac Valve
and Other Major Cardiothoracic
Procedures with Cardiac Catheterization
with MCC and with CC, respectively) as
originally requested.
Another commenter stated they
respected the position of CMS’ clinical
advisors given the complexity of the
involved procedures and noted that the
issue of multiple procedures or
interventions performed during a single
hospital stay is also a problem in other
areas of cardiology and warrants a
meaningful solution. This commenter
stated they believed that since
performing procedures concomitantly is
more efficient, more convenient,
provides a better prognosis for the
patient and could be more cost effective
than the procedures being performed in
different hospital stays, there should be
a mechanism for differentiated payment
when procedures are performed
concomitantly, when it is best for the
patient. This commenter recommended
that CMS create a supplemental
payment mechanism that could be
modeled based on the respective costs
of the individual procedures determined
by claims data and then adjusted for
efficiencies of a single operative session
to facilitate incremental payment when
two major procedures are performed
during the same hospital admission and
urged CMS to solicit further comment
on possible methodological solutions to
accommodate costs when two
procedures are performed
concomitantly.
Response: We appreciate the
commenters’ feedback.
We refer readers to Tables 6P.1c and
6P1.d associated with this final rule
(which are available via the internet on
the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS) for the data analysis
of cases reporting procedure code
combinations describing open
concomitant surgical ablations in the
September 2021 update of the FY 2021
MedPAR file. Table 6P.1c associated
with this final rule sets forth the list of
ICD–10–PCS procedure codes reflecting
mitral valve repair or replacement
(MVR), aortic valve repair or
replacement (AVR), and coronary artery
bypass grafting (CABG) procedures that
we examined in this analysis. Table
6P.1d associated with this final rule
shows the data analysis findings of
cases reporting procedure code
combinations describing open
concomitant surgical ablations assigned
to MS–DRGs 216, 217, 218, 219, 220 and
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
221 from the September 2021 update of
the FY 2021 MedPAR file.
As shown in Table 6P.1d associated
with this final rule, while the average
lengths of stay and average costs of
cases reporting procedure code
combinations describing open
concomitant surgical ablations are
higher than all cases in their respective
MS–DRG, we found there is variation in
the volume, length of stay, and average
costs of the cases. For MS–DRG 216, we
found 870 cases reporting procedure
code combinations describing open
concomitant surgical ablations with the
average length of stay ranging from 16.8
days to 20.5 days and average costs
ranging from $90,122 to $156,617 for
these cases. For MS–DRG 217, we found
168 cases reporting procedure code
combinations describing open
concomitant surgical ablations with the
average length of stay ranging from 7.5
days to 12 days and average costs
ranging from $48,644 to $74,594 for
these cases. For MS–DRG 218, we found
zero cases reporting procedure code
combinations describing open
concomitant surgical ablations. For MS–
DRG 219, we found 1,940 cases
reporting procedure code combinations
describing open concomitant surgical
ablations with the average length of stay
ranging from 11.2 days to 13.4 days and
average costs ranging from $70,816 to
$86,805 for these cases. For MS–DRG
220, we found 1,338 cases reporting
procedure code combinations describing
open concomitant surgical ablations
with the average length of stay ranging
from 7.1 days to 8.8 days and average
costs ranging from $49,326 to $65,611
for these cases. For MS–DRG 221, we
found 60 cases reporting procedure code
combinations describing open
concomitant surgical ablations with the
average length of stay ranging from 5.6
days to 6.3 days and average costs
ranging from $44,247 to $47,418 for
these cases.
As noted, and similar to our analysis
of the data for the FY 2022 IPPS/LTCH
PPS rulemaking, the data analysis
shows that while the average lengths of
stay and average costs of cases reporting
procedure code combinations describing
open concomitant surgical ablations are
higher than all cases in their respective
MS–DRG, there is variation in the
volume, length of stay, and average
costs of the cases. As we discuss later
in this section, the analysis also shows
that the cases reporting an open
concomitant surgical ablation code
combination are predominately found in
the higher (CC or MCC) severity level
MS–DRGs of their current base MS–DRG
assignment. Moreover, as also
previously noted, the data from the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
September 2021 update of the FY 2021
MedPAR file does not reflect our FY
2022 finalization. We continue to
believe that additional time is needed to
allow for further analysis of the claims
data to reflect our FY 2022 finalization,
and also to determine to what extent the
patient’s co-morbid conditions or other
factors may be contributing to the
increased length of stay and costs of this
subset of cases, as discussed previously.
In response to comments that urged
CMS to assign cases reporting procedure
code combinations describing open
concomitant surgical ablations currently
assigned to MS–DRGs 216, 217, 218,
219, 220 and 221 to MS–DRGs 216 and
217 only, MS–DRGs 216, 217 and 218
are defined by the performance of
cardiac catheterization. The
performance of a cardiac catherization
procedure could be also contributing to
the increased average costs of cases
reporting procedure code combinations
describing open concomitant surgical
ablations currently assigned to MS–
DRGs 216, 217 and 218. Our clinical
advisors have expressed concern about
the effect on clinical coherence of
assigning cases reporting procedure
code combinations describing open
concomitant surgical ablations that do
not also have a cardiac catherization
procedure reported to MS–DRGs that are
defined by the performance of that
procedure.
We also note, as discussed in Section
D.1.b of the proposed rule and this final
rule, using the September 2021 update
of the FY 2021 MedPAR file, we
analyzed how applying the NonCC
subgroup criteria to all MS–DRGs
currently split into three severity levels
would affect the MS–DRG structure
beginning in FY 2022. Similar to our
findings discussed in the FY 2022 IPPS/
LTCH final rule, findings from our
analysis using the September 2021
update of the FY 2021 MedPAR file
indicated that MS–DRGs 216, 217, 218
as well as approximately 40 other MS–
DRGs would be subject to change based
on the three-way severity level split
criterion finalized in FY 2021. While we
are finalizing the delay of the
application of the NonCC subgroup
criteria to existing MS–DRGs with a
three-way severity level split until FY
2024 or later, and to maintain the
current structure of the 41 MS–DRGs
that currently have a three-way severity
level split (total of 123 MS–DRGs) that
would otherwise be subject to these
criteria, we note that the total number
of cases in MS–DRG 218 is again below
500, and that we may consider
consolidating these MS–DRGs into two
severity levels based on the application
of the NonCC subgroup criteria in future
PO 00000
Frm 00069
Fmt 4701
Sfmt 4700
48847
rule-making. We refer the reader to
Table 6P.1b associated with the
proposed rule and this final rule (which
is available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS) for the list
of the 123 MS–DRGs that would be
subject to deletion and the list of the 75
new MS–DRGs that would have been
proposed for creation under this policy
if the NonCC subgroup criteria were
applied.
In response to comments that the
finalized revision to the surgical
hierarchy did not adequately address
the increased costs of cases associated
with open concomitant surgical ablation
and that urged CMS to create new MS–
DRGs for these open concomitant
procedures as originally requested, our
clinical advisors continue to believe
additional time is needed to review the
clinical nature of cases reporting an
open concomitant surgical ablation code
combination before exploring a proposal
to create new MS–DRGs for this subset
of cases currently assigned to MS–DRGs
216 through 221 given the complexity of
these code combinations and the
corresponding data. Our analysis using
the September 2021 update of the FY
2021 MedPAR file reflects that the cases
reporting an open concomitant surgical
ablation code combination are
predominately found in the higher (CC
or MCC) severity level MS–DRGs of
their current base MS–DRG assignment,
suggesting that the patient’s co-morbid
conditions may also be contributing to
higher costs of these cases. Secondly, for
the numerous procedure combinations
that would comprise an ‘‘open
concomitant surgical ablation’’
procedure, the increase in average costs
appears to directly correlate with the
number of procedures performed. For
example, cases that describe ‘‘Open
MVR + open surgical ablation’’
generally demonstrate costs that are
lower than cases that describe ‘‘Open
MVR + open AVR + open CABG + open
surgical ablation.’’ Therefore, our
clinical advisors continue to believe that
additional time is needed to allow for
further analysis of the claims data to
determine to what extent the patient’s
co-morbid conditions are also
contributing to higher costs and to
identify other contributing factors that
might exist with respect to the increased
length of stay and costs of these cases
in these MS–DRGs. Our clinical
advisors continue to believe that future
data findings may demonstrate
additional variance in resource
utilization for this patient population.
With respect to commenters’ concerns
regarding a mechanism for
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48848
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
differentiated payment when
procedures are performed
concomitantly, we agree that the
performance of concomitant procedures
is an area that warrants more analysis
across the MS–DRG classification, as the
performance of ‘‘concomitant
procedures’’ may affect the
consumption of resources in other
clinical scenarios as well, especially
when the use of devices is involved. As
discussed in prior rulemaking, the MS–
DRGs are a classification system
intended to group together diagnoses
and procedures with similar clinical
characteristics and utilization of
resources. It has been difficult to
identify other MS–DRGs that would be
more appropriate MS–DRG assignments
for these concomitant procedures based
on the variance in the clinical
characteristics and utilization of
resources for concomitant procedures,
which can depend on the number of
procedures being performed
concomitantly and the nature of these
procedures. We are interested in
receiving feedback on possible
mechanisms through which we can
address concomitant procedures. We are
also interested in receiving feedback on
how CMS can mitigate any unintended
negative payment impacts to providers
providing concomitant procedures.
Commenters can continue to submit
their recommendations via the new
electronic intake system, Medicare
Electronic Application Request
Information SystemTM (MEARISTM) at:
https://mearis.cms.gov/public/home.
We will consider these public
comments for possible proposals in
future rulemaking as part of our annual
review process.
Comment: Some commenters noted
that cases describing standalone hybrid
percutaneous endoscopic surgical
ablation are assigned MS–DRGs 228 and
229 (Other Cardiothoracic Procedures
with and without MCC, respectively)
and noted that payment for MS–DRGs
228 and 229 has been trending
downward over the last six years. These
commenters stated that the downward
payment trend for MS–DRGs 228 and
229 has resulted in hospitals being
undercompensated for the costs of
furnishing standalone hybrid
percutaneous endoscopic surgical
ablation procedures for atrial
fibrillation. Other commenters stated
that CMS did not provide transparency
to the details of its analysis to support
why standalone hybrid surgical ablation
procedures should not be moved from
MS–DRGs 228 and 229.
Some commenters stated that the
decline in payment for standalone
hybrid percutaneous endoscopic
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
surgical ablation procedures makes it
impossible for their facilities to
continue to provide these needed
procedures to patients suffering from
atrial fibrillation. A commenter stated
the proposed relative weight does not
accurately reflect the costs of these
device intensive procedures and that
there has been no transparency into the
cause for these significant declines.
Another commenter stated that their
facility has been especially impacted by
COVID–19 and stated that for CMS to
expect facilities to be able to continue
to provide patients with needed medical
services such as hybrid percutaneous
endoscopic surgical ablation at such a
steep decrease in payment is intolerable
for hospitals. Other commenters
asserted that hospitals will be forced to
postpone or ‘‘trim back’’ on providing
patients access to more complex,
resource intensive procedures such as
these, to better align their costs with
what they asserted were Medicare’s
inadequate payment levels. These
commenters proposed two possible
remedies to this underpayment, that
CMS either (1) use its statutory
authority to not reduce the relative
weight and payment for MS–DRGs 228
and 229, or (2) assign cases reporting
procedure codes describing standalone
percutaneous endoscopic surgical
ablation from MS–DRGs 228 and 229 to
the higher (MCC) severity level MS–
DRG of its current base MS–DRG
assignment, which is MS–DRG 228
(Other Cardiothoracic Procedures with
MCC), to prevent underpayment for
these procedures and avoid disruptions
in beneficiary access.
Response: We appreciate the
commenters’ feedback. We note that we
did not receive a specific request to
change the MS–DRG assignment for
standalone percutaneous endoscopic
surgical ablation procedures for
consideration for the FY 2023 IPPS/
LTCH PPS proposed rule. We note a
request to reassign cases describing
standalone percutaneous endoscopic
surgical ablation from MS–DRGs 228
and 229 (Other Cardiothoracic
Procedures with and without MCC,
respectively) to higher weighted MS–
DRGs 219 and 220 (Cardiac Valve and
Other Major Cardiothoracic Procedures
without Cardiac Catheterization with
MCC and with CC, respectively) was
discussed in the FY 2022 IPPS/LTCH
PPS proposed rule. In the FY 2022 IPPS/
LTCH final rule, in response to
comments received on the proposed
rule, we also discussed the assignment
of cases reporting procedure codes
describing standalone percutaneous
endoscopic surgical ablation from MS–
PO 00000
Frm 00070
Fmt 4701
Sfmt 4700
DRGs 228 and 229 to the higher (MCC)
severity level MS–DRG of its current
base MS–DRG assignment in the FY
2022 IPPS/LTCH PPS final rule. We
refer readers to the FY 2022 IPPS/LTCH
PPS final rule (86 FR 44844 through
44848) for a complete discussion.
In the request to again review the MS–
DRG assignment of surgical ablation
procedures in FY 2023 rulemaking,
however, the requestor stated in their
submission that while surgical ablation
represents losses across all procedure
types, they recommended focusing on
addressing open concomitant surgical
ablation in FY 2023 rulemaking and did
not request a change to the MS–DRG
assignment for standalone percutaneous
endoscopic surgical ablation. Therefore,
cases describing standalone
percutaneous endoscopic surgical
ablation were not considered in the FY
2023 IPPS/LTCH PPS proposed rule.
In response to the comment that
hospitals may postpone or ‘‘trim back’’
on providing patients access to these
procedures in order to better align their
costs with Medicare payment levels, as
we have stated in prior rulemaking, it is
not appropriate for facilities to deny
treatment to beneficiaries needing a
specific type of therapy or treatment
that potentially involves increased
costs.
We acknowledge the reduction in the
proposed FY 2023 relative weights for
MS–DRGs 228 and 229 (approximately
7% and 4%, respectively from the FY
2022 relative weight), however, we note
we did not propose a change to the
GROUPER logic of MS–DRGs 228 and
229 for FY 2023. However, there have
been previous changes to the structure
of MS–DRGs 228 and 229 over the past
six years. It is to be expected that when
MS–DRGs are restructured, such as
when procedure codes are reassigned or
the hierarchy within an MDC is revised,
resulting in a different case-mix within
the MS–DRGs, the relative weights of
the MS–DRGs will change as a result.
We believe the trending reduction in
relative weights for MS–DRGs 228 and
229 over time to be appropriately driven
by the underlying data in the six years
since CMS began using the ICD–10 data
in calculating the relative weights and is
reflective of the change in case-mix
within these MS–DRGs. Specifically, in
the FY 2017 IPPS/LTCH PPS final rule
(81 FR 56809 through 56813), we
finalized our proposal to collapse MS–
DRGs 228, 229, and 230 from three
severity levels to two severity levels by
deleting MS–DRG 230 and revised the
structure of MS- DRG 229. We also
finalized our proposal to reassign ICD–
9–CM procedure code 35.97 and the
cases reporting ICD–10–PCS procedure
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
code 02UG3JZ (Supplement mitral valve
with synthetic substitute, percutaneous
approach) from MS–DRGs 273 and 274
to MS–DRG 228 and revised the titles of
MS–DRG 228 and 229. In the FY 2020
IPPS/LTCH PPS final rule (84 FR 42080
through 56813) we finalized our
proposal to modify the structure of MS–
DRGs 266 and 267 by reassigning ICD–
10–PCS procedure code 02UG3JZ
describing a transcatheter mitral valve
repair with implant procedure from
MS–DRGs 228 and 229 to MS–DRGs 266
and 267 and revised the titles of MS–
DRGs 266 and 267. Finally, as discussed
in the FY 2022 IPPS/LTCH PPS final
rule, and earlier in this section, we
finalized a revision to the surgical
hierarchy for the MS–DRGs in MDC 05
to sequence MS–DRGs 231–236
(Coronary Bypass) above MS–DRGs 228
and 229 for FY 2022. Therefore, the data
appear to reflect that the difference in
the relative weights shown in Table 5–
List of Medicare Severity Diagnosis
Related Groups (MS–DRGs), Relative
Weighting Factors, and Geometric and
Arithmetic Mean Length of Stay
associated with final rule for the
applicable fiscal year can be attributed
to the fact that these previously
finalized policies resulted in a different
case-mix within the MS–DRGs, which is
then being reflected in the relative
weights. We refer the reader to section
II.E. of the preamble of this FY 2023
IPPS/LTCH PPS final rule for a
complete discussion of the relative
weight calculations for FY 2023,
including our finalized policies to use
50 percent of the relative weights
calculated using all cases in the FY 2021
MedPAR data and 50 percent of the
relative weights calculated without
COVID–19 cases in the FY 2021
MedPAR data to calculate the relative
weights for FY 2023, and to apply a
permanent 10-percent cap on the
reduction in a MS–DRG’s relative
weight in a given fiscal year, beginning
in FY 2023.
We appreciate the commenters’
support and feedback, and intend to
continue to consider these issues. For
the reasons summarized earlier, and
after consideration of the public
comments we received, we are not
making any MS–DRG changes for cases
involving the open concomitant surgical
ablation procedures or for cases
describing standalone percutaneous
endoscopic surgical ablation for FY
2023.
7. MDC 06 (Diseases and Disorders of
the Digestive System): Appendicitis
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28163 through
28165), we discussed a request we
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
received to reconsider the MS–DRG
assignment for diagnosis code K35.20
(Acute appendicitis with generalized
peritonitis, without abscess). According
to the requestor, when this code is
reported in combination with any one of
the corresponding procedure codes that
describe an appendectomy, the case is
grouping to MS–DRGs 341, 342, and 343
(Appendectomy without Complicated
Principal Diagnosis with MCC, with CC,
and without CC/MCC, respectively).
Alternatively, the requestor stated that
when diagnosis code K35.32 (Acute
appendicitis with perforation and
localized peritonitis, without abscess) is
reported in combination with any one of
the corresponding procedure codes that
describe an appendectomy, the case is
grouping to MS–DRGs 338, 339, and 340
(Appendectomy with Complicated
Principal Diagnosis with MCC, with CC,
and without CC/MCC, respectively).
The requestor asserted that the
difference in MS–DRG assignment
suggests that localized peritonitis is
more severe or requires an additional
level of care over and above that for
generalized peritonitis. The requestor
stated that clinically, both localized and
generalized peritonitis, when treated
with an appendectomy require the same
level of patient care, including extensive
intraoperative irrigation at the surgical
site, direct inspection or imaging of the
abdomen to look for possible abscess,
use of intravenous antibiotics, and
prolonged inpatient monitoring. The
requestor added that generalized
peritonitis can be thought of as a
progression of the localized peritonitis
condition and that patients progress
from localized to generalized peritonitis
and not vice versa.
In the proposed rule we noted that
this topic has been discussed previously
in our FY 2019 (83 FR 41230) and FY
2021 rulemakings (85 FR 32500 through
32503) and (85 FR 58484 through
58488). Effective FY 2019 (October 1,
2018) diagnosis code K35.2 (Acute
appendicitis with generalized
peritonitis) was expanded to K35.20
(Acute appendicitis with generalized
peritonitis, without abscess); and
K35.21 (Acute appendicitis with
generalized peritonitis, with abscess). In
addition, code K35.3 (Acute
appendicitis with localized peritonitis)
was expanded to K35.30 (Acute
appendicitis with localized peritonitis,
without perforation or gangrene);
K35.31 (Acute appendicitis with
localized peritonitis and gangrene,
without perforation); K35.32 (Acute
appendicitis with perforation and
localized peritonitis, without abscess);
and K35.33 (Acute appendicitis with
PO 00000
Frm 00071
Fmt 4701
Sfmt 4700
48849
perforation and localized peritonitis,
with abscess).
We finalized the severity level
designations for these new diagnosis
codes in the FY 2019 IPPS/LTCH PPS
final rule and stated our clinical
advisors believed that the new diagnosis
codes for acute appendicitis described
as ‘‘with abscess’’ or ‘‘with perforation’’
were clinically qualified for the MCC
severity level designation, while acute
appendicitis ‘‘without abscess’’ or
‘‘without perforation’’ were clinically
qualified for the CC severity level
designation because cases with abscess
or perforation would be expected to
require more clinical resources and time
to treat while those cases ‘‘without
abscess’’ or ‘‘without perforation’’ are
not as severe clinical conditions.
As discussed in our FY 2021
rulemaking, we received the request to
add K35.20 (Acute appendicitis with
generalized peritonitis, without abscess)
to the list of complicated principal
diagnoses so that all ruptured/
perforated appendicitis codes in MDC
06 group to MS–DRGs 338, 339, and 340
(Appendectomy with Complicated
Principal Diagnosis with MCC, with CC,
and without CC/MCC, respectively) as
K35.20 is the only ruptured appendicitis
code not included in the list of
complicated principal diagnosis codes.
At that time, we noted that the inclusion
term at subcategory K35.2 (Acute
appendicitis with generalized
peritonitis) is: ‘‘Appendicitis (acute)
with generalized (diffuse) peritonitis
following rupture or perforation of the
appendix’’. The requestor stated that
code K35.20 (Acute appendicitis with
generalized peritonitis, without abscess)
describes a generalized, more extensive
form of peritonitis than code K35.32
(Acute appendicitis with perforation
and localized peritonitis, without
abscess). We noted that our clinical
advisors agreed that the presence of an
abscess would clinically determine
whether a diagnosis of acute
appendicitis would be considered a
complicated principal diagnosis. As
diagnosis code K35.20 is described as
‘‘without’’ an abscess, our clinical
advisors recommended that K35.20 not
be added to the list of complicated
principal diagnoses for MS–DRGS 338,
339, and 340. We also proposed to
remove diagnosis code K35.32 (Acute
appendicitis with perforation and
localized peritonitis, without abscess)
from the complicated principal
diagnosis list.
In response to that proposal, some
commenters disagreed. A commenter
stated that when ruptured appendicitis
results in generalized peritonitis,
resources are greater because the
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
infection is not walled off, not localized,
and has spread to two or more
compartments within the abdominal
cavity. According to the commenter,
clinical literature supports the statement
that generalized peritonitis is a more
morbid (severe) presentation than just
perforation or localized abscess. After
consideration of the comments received
and for the reasons discussed in the FY
2021 final rule, we did not finalize our
proposals in that final rule. We
concurred that the expansion of
diagnosis codes K35.2 and K35.3 to
introduce additional clinical concepts
khammond on DSKJM1Z7X2PROD with RULES2
Proposed
ICD-10-CM
Code
K35.200
K35.201
K35.209
K35.210
K35.211
K35.219
Acute
Acute
Acute
Acute
Acute
Acute
a
a
a
a
a
a
endicitis with
endicitis with
endicitis with
endicitis with
endicitis with
endicitis with
We refer the reader to the CDC
website at: https://www.cdc.gov/nchs/
icd/icd10cm_maintenance.htm for
additional detailed information
regarding the proposal, including a
recording of the discussion and the
related meeting materials.
We noted in the proposed rule that
the deadline for submitting public
comments on the diagnosis code
proposals discussed at the March 8–9,
2022 ICD–10 Coordination and
Maintenance Committee meeting was
May 9, 2022 and according to the CDC/
NCHS staff, the diagnosis code
proposals are being considered for an
October 1, 2023 implementation (FY
2024). We stated that any future
proposed changes to the MS–DRGs for
Appendectomy would be dependent on
the diagnosis code revisions that are
finalized by the CDC/NCHS. Since it is
not clear what code changes may be
finalized, including whether public
comments expressed support for the
proposed changes or provided
alternative options for consideration, we
stated in the proposed rule that we
believe it is appropriate to delay any
possible MS–DRG modifications for
future rulemaking. Therefore, we did
not propose a change to the MS–DRG
assignment or the current structure for
MS–DRGs 338, 339, 340, 341, 342, and
343. Although we did not propose a
change to the MS–DRG assignments for
FY 2023, we made the findings from our
data analysis available for the listed
VerDate Sep<11>2014
00:20 Aug 10, 2022
effective October 1, 2018 significantly
changed the scope and complexity of
the diagnosis codes for this subset of
patients. We also stated NCHS’ staff
acknowledged the clinical concerns
based on the manner in which diagnosis
codes K35.2 and K35.3 were expanded
and confirmed that they would consider
further review of these newly expanded
codes with respect to the clinical
concepts.
We communicated with the CDC/
NCHS staff regarding this repeat request
submitted for FY 2023 consideration.
The CDC/NCHS staff included these
Jkt 256001
eneralized
eneralized
eneralized
eneralized
eneralized
eneralized
MS–DRGs and the associated diagnosis
codes to help inform future comments.
We referred the reader to Table 6P.4a
associated with the proposed rule
(which is available via the internet on
the CMS website at: https://
www.cms.gov/medicare/medicare-feefor-service-payment/acuteinpatientpps).
Comment: Commenters agreed with
our proposal to maintain the structure of
MS–DRGs 338, 339, 340, 341, 342, and
343 including the MS–DRG assignment
for diagnosis code K35.20 to MS–DRGs
341, 342, and 343. However, a
commenter opposed CMS’s proposal
and stated they agreed with the
requestor that all diagnosis codes
describing a ruptured or perforated
appendix should group to MS–DRGs
338, 339, and 340. The commenter
stated that the condition described by
code K35.20 can be associated with the
risk of postoperative abscess formation
and extended length of hospital stay,
thereby warranting classification as a
complicated diagnosis. This commenter
urged CMS to reassign code K35.20 from
MS–DRGs 341, 342, and 343 to MS–
DRGs 338, 339, and 340 for FY 2023.
Response: We thank the commenters
for their support and feedback. In
response to the commenter who urged
CMS to reassign diagnosis code K35.20
from MS–DRGs 341, 342, and 343 to
MS–DRGs 338, 339, and 340 for FY
2023, we note that the CDC/NCHS staff
are in the process of reviewing public
comments related to the proposed
revision to certain diagnosis codes
PO 00000
codes describing appendicitis on the
agenda and a proposal for further
revisions was presented for discussion
at the March 8–9, 2022 ICD–10
Coordination and Maintenance
Committee meeting. Specifically, the
CDC/NCHS staff proposed to expand
current diagnosis codes K35.20 and
K35.21, making them sub-subcategories
and creating new diagnosis codes to
identify and describe acute appendicitis
with generalized peritonitis, with
perforation and without perforation, and
unspecified as to perforation, as shown
in the following table.
Frm 00072
Fmt 4701
Sfmt 4700
describing acute appendicitis that was
presented at the March 8–9, 2022 ICD–
10 Coordination and Maintenance
Committee meeting, as discussed in the
proposed rule. Accordingly, we
continue to believe it is appropriate to
delay any potential MS–DRG
modifications as we do not yet know
what the finalized code updates,
including any corresponding changes to
the Index to Diseases and Injuries and
Tabular List of Diseases, might be. We
will continue to collaborate with the
CDC/NCHS regarding this issue.
After consideration of the public
comments we received, we are
maintaining the current structure of
MS–DRGs 338, 339, 340, 341, 342, and
343 and the MS–DRG assignment of
diagnosis code K35.20 for FY 2023.
8. MDC 07 (Diseases and Disorders of
the Hepatobiliary System and Pancreas):
Laparoscopic Cholecystectomy With
Common Bile Duct Exploration
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28165), we stated
that we received a request to review the
MS–DRG assignment when procedure
code 0FC94ZZ (Extirpation of matter
from common bile duct, percutaneous
endoscopic approach) that describes a
common bile duct exploration with
gallstone removal procedure using a
laparoscopic approach, is reported with
a laparoscopic cholecystectomy. The
procedure codes describing a
laparoscopic cholecystectomy are
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.040
48850
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Description
Destruction of gallbladder, percutaneous endoscopic approach
Destruction of gallbladder, via natural or artificial opening endoscopic
Excision of gallbladder, percutaneous endoscopic approach
Excision of gallbladder, via natural or artificial opening endoscopic
Resection of gallbladder, percutaneous endoscopic approach
According to the requestor, when a
laparoscopic cholecystectomy is
reported with any one of the listed
procedure codes with a common bile
duct exploration and gallstone removal
procedure that is performed
laparoscopically and reported with
procedure code 0FC94ZZ, the resulting
assignment is MS–DRGs 417, 418 and
419 (Laparoscopic Cholecystectomy
without C.D.E. with MCC, with CC, and
without CC/MCC, respectively). This
MS–DRG assignment does not recognize
that a common bile duct exploration
(C.D.E.) was performed. However, the
requestor stated that when procedure
code 0FC90ZZ (Extirpation of matter
from common bile duct, open approach)
that describes a common bile duct
exploration with gallstone removal
procedure using an open approach is
reported with any one of the listed
procedure codes describing a
laparoscopic cholecystectomy, the
MS-DRG
Number of Cases
116
152
76
10,448
17,336
9,479
411
412
413
417
418
419
referred the reader to the V39.1 ICD–10
MS–DRG Definitions Manual, which is
available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/MS-DRGClassifications-and-Software for
complete documentation of the
GROUPER logic for MS–DRGs 411, 412,
413, 417, 418 and 419.
As stated in the proposed rule, we
analyzed claims data from the
September 2021 update of the FY 2021
MedPAR file for all cases in MS–DRGs
411, 412, 413, 417, 418, and 419.
Because the logic for MS–DRGs 411,
412, and 413 includes cholecystectomy
procedures performed by either an open
or percutaneous endoscopic
(laparoscopic) approach, we also
analyzed the cases reported with each
approach separately. The findings from
our analysis are shown in the following
tables.
Average Length of
Stay
8.5
6.8
3.6
6.3
4.1
2.7
Average Costs
$29,332
$21,042
$12,427
$19,384
$13,627
$10,728
ER10AU22.042
Number of Cases Reporting Open Cholecystectomy in MS-DRGs 411-413
Average Length of
MS-DRG
Stay
Average Costs
Number of Cases
411
10.73
$36,135
56
412
82
7.61
$23,390
413
28
4.3
$12,969
Total
166
8.1
$25,932
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00073
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.041
khammond on DSKJM1Z7X2PROD with RULES2
resulting assignment is MS–DRGs 411,
412, and 413 (Cholecystectomy with
C.D.E. with MCC, with CC, and without
CC/MCC, respectively). The requestor
stated that this MS–DRG assignment
appropriately recognizes that a common
bile duct exploration was performed.
The requestor questioned why only the
common bile duct exploration with
gallstone removal procedure performed
using an open approach (code 0FC90ZZ)
grouped appropriately when reported
with the laparoscopic cholecystectomy.
We stated in the proposed rule that
we reviewed procedure code 0FC94ZZ
and found that it is currently designated
as a non-O.R. procedure, therefore, the
GROUPER logic does not recognize this
procedure for purposes of MS–DRG
assignment. We also noted that MS–
DRGs 411, 412, and 413 include
cholecystectomy procedures performed
by either an open or a percutaneous
endoscopic (laparoscopic) approach. We
ER10AU22.043
ICD-10-PCS
Code
0F544ZZ
0F548ZZ
0FB44ZZ
0FB48ZZ
0FT44ZZ
48851
48852
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Number of Cases Reporting Laparoscopic Cholecystectomy in MS-DRGs 411-413
Average Length of
Stay
Average Costs
MS-DRG
Number of Cases
411
$22,982
60
6.5
412
70
5.8
$18,293
413
48
3.1
$12,110
Total
178
5.3
$18,206
In MS–DRG 411, we found a total of
116 cases with an average length of stay
of 8.5 days and average costs of $29,332.
Of those 116 cases, there were 56 cases
reporting an open cholecystectomy,
with an average length of stay of 10.7
days and average costs of $36,135 and
60 cases reporting a laparoscopic
cholecystectomy, with an average length
of stay of 6.5 days and average costs of
$22,982. The data show that the cases
reporting an open cholecystectomy have
a longer average length of stay (10.7
days versus 6.5 days) and higher average
costs ($36,135 versus $22,982)
compared to the cases reporting a
laparoscopic cholecystectomy. The data
also show that the cases reporting an
open cholecystectomy have a longer
average length of stay (10.7 days versus
8.5 days) and higher average costs
($36,135 versus $29,332) compared to
all the cases in MS–DRG 411. Similar
findings are demonstrated for MS–DRGs
412 and 413, where the data show that
the cases reporting an open
cholecystectomy have a longer average
length of stay and higher average costs
compared to the cases reporting a
laparoscopic cholecystectomy, and also,
when compared to all the cases in their
respective MS–DRGs.
We then analyzed claims data from
the September 2021 update of the FY
2021 MedPAR file for cases reporting
procedure code 0FC94ZZ in MS–DRGs
417, 418, and 419 to assess how often
it was reported. The findings from our
analysis are shown in the following
table.
Number of Cases Reporting Procedure Code 0FC94ZZ in MS-DRGs 417-419
Average Length of
Stay
Average Costs
MS-DRG
Number of Cases
417
70
6.3
$17,685
418
4.4
$14,615
96
419
65
3.2
$13,914
Total
231
4.6
$15,348
Number of Cases Reporting Procedure Code 0FC94ZZ without another O.R. Procedure Across All MSDRGs
Average
Number Length Average
MS-DRG
of Cases of Stay
Costs
438 - Disorders of Pancreas Except Malignancy with MCC
2
14
$26,092
441 - Disorders of Liver Except Malignancy Cirrhosis or Alcoholic Hepatitis
1
16
$30,076
withMCC
444 - Disorders of the Biliary Tract with MCC
6
5.2
$10,237
445 - Disorders of the Biliary Tract with CC
11
4
$14,015
446 - Disorders of the Biliary Tract without CC/MCC
5
2.6
$15,036
871 - Septicemia or Severe Sepsis without MV >96 Hours with MCC
$22,737
6
8.8
872 - Septicemia or Severe Sepsis without MV >96 Hours without MCC
1
$5,322
3
$16,087
Total
32
5.9
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00074
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.046
MS–DRGs without another O.R.
procedure reported, to assess the
number of cases and in which MS–
DRGs procedure code 0FC94ZZ was
found. The findings from our analysis
are shown in the following table.
ER10AU22.045
412, and 413, we found a total of 178
cases with an average length of stay of
5.3 days and average costs of $18,206.
We also examined claims data from
the September 2021 update of the FY
2021 MedPAR file for cases reporting
procedure code 0FC94ZZ across all the
ER10AU22.044
khammond on DSKJM1Z7X2PROD with RULES2
We found a total of 231 cases across
MS–DRGs 417, 418, and 419 with an
average length of stay of 4.6 days and
average costs of $15,348 reporting
procedure code 0FC94ZZ. In our review
of the cases reporting a laparoscopic
cholecystectomy across MS–DRGs 411,
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
The data analysis shows procedure
code 0FC94ZZ was reported in a total of
32 cases across 7 MS–DRGs with an
average length of stay of 5.9 days and
average costs of $16,087. While
procedure code 0FC94ZZ is designated
as non-O.R., we also analyzed the
average length of stay and average costs
of the cases found within each of the 7
MS–DRGs reporting procedure code
0FC94ZZ against all the cases in their
respective MS–DRGs, to determine if
there was any indication that the
performance of the procedure described
by procedure code 0FC94ZZ may have
had any impact. For instance, as shown
in the table, for MS–DRG 438 we found
2 cases reporting procedure code
0FC94ZZ with an average length of stay
of 14 days and average costs of $26,092.
In the September 2021 update of the FY
2021 MedPAR file, the total number of
cases for MS–DRG 438 is 10,240 with an
average length of stay of 6.4 days and
average costs of $13,341. The 2 cases
reporting procedure code 0FC94ZZ have
approximately twice the average length
of stay (14 days versus 6.4 days) and
approximately twice the average costs
($26,092 versus $13,341) compared to
all the cases for MS–DRG 438. In the
absence of additional analysis, it is
unknown if these differences can be
attributed to other factors, such as the
MCCs that were reported in these cases.
Similar findings were found for MS–
DRGs 441, 445, 446, and 871. We noted
in the proposed rule that we will
consider if further detailed analysis may
be warranted for these cases.
As stated in the proposed rule, our
clinical advisors agreed that procedure
code 0FC94ZZ describes a common bile
duct exploration procedure with
removal of a gallstone and should be
added to the logic for case assignment
to MS–DRGs 411, 412, and 413 for
clinical coherence with the other
procedures that describe a common bile
duct exploration. Therefore, for FY
2023, we proposed to redesignate
procedure code 0FC94ZZ from a nonO.R. procedure to an O.R. procedure
and add it to the logic list for common
bile duct exploration (CDE) in MS–
DRGs 411, 412, and 413
(Cholecystectomy with C.D.E. with
MCC, with CC, and without CC/MCC,
respectively) in MDC 07 to
appropriately reflect when this
procedure is performed and improve the
clinical coherence of the patients
assigned to these MS–DRGs.
Comment: Commenters agreed with
our proposal to redesignate procedure
code 0FC94ZZ from a non-O.R.
procedure to an O.R. procedure and to
add it to the logic list for common bile
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
duct exploration (CDE) procedures in
MS–DRGs 411, 412, and 413.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to redesignate
procedure code 0FC94ZZ from a nonO.R. procedure to an O.R. procedure
and to add it to the logic list for
common bile duct exploration (CDE)
procedures in MS–DRGs 411, 412, and
413 for FY 2023.
In addition, we noted in the proposed
rule that MS–DRGs 414, 415, and 416
(Cholecystectomy Except by
Laparoscope without C.D.E. with MCC,
with CC and without CC/MCC,
respectively) also reflect
cholecystectomy procedures, however,
the logic is specifically defined for open
cholecystectomy procedures without a
common bile duct exploration
procedure performed. Since MS–DRGs
411, 412, and 413 reflect cases where an
open or laparoscopic cholecystectomy is
performed with a common bile duct
exploration procedure, MS–DRGs 414,
415, and 416 reflect cases where only an
open cholecystectomy is performed
without a common bile duct exploration
procedure, and MS–DRGs 417, 418, and
419 reflect cases where only a
laparoscopic cholecystectomy is
performed without a common bile duct
exploration procedure, we stated we
believe there may be an opportunity to
further refine these MS–DRGs once
additional analysis is performed for
consideration in future rulemaking. For
example, we indicated we could
consider proposing to restructure these
cholecystectomy MS–DRGs to reflect the
following two concepts, if supported by
the data, and relatedly, to determine if
severity levels are also supported
according to the existing criteria.
• Open Cholecystectomy with or
without C.D.E.; and
• Laparoscopic Cholecystectomy with
or without C.D.E.
Comment: Commenters agreed that
there may be an opportunity to further
refine the MS–DRGs for
cholecystectomy procedures and
encouraged CMS to conduct further
review and analysis of the procedure
codes describing cholecystectomy with
common bile duct exploration for
consideration in future rulemaking.
Response: We thank the commenters
for their support and continue to solicit
any additional feedback from the public
on this and any alternative
recommendations or options to further
refine these MS–DRGs for future
consideration. As discussed in section
II.D.1.b. of the preamble of the proposed
rule and this final rule, feedback and
PO 00000
Frm 00075
Fmt 4701
Sfmt 4700
48853
other suggestions should be directed to
the new electronic intake system,
Medicare Electronic Application
Request Information SystemTM
(MEARISTM) at: https://mearis.cms.gov/
public/home, with any comments and
suggestions for consideration for FY
2024 to be submitted by October 20,
2022.
9. MDC 10 (Diseases and Disorders of
the Endocrine System): Eladocagene
Exuparvovec Gene Therapy
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 44895), we finalized the
redesignation of code XW0Q316
(Introduction of eladocagene
exuparvovec into cranial cavity and
brain, percutaneous approach, new
technology group 6) from a Non-O.R.
procedure to an O.R. procedure,
assigned to MS–DRGs 628, 629, and 630
(Other Endocrine, Nutritional and
Metabolic O.R. Procedures with MCC,
with CC, and without CC/MCC,
respectively) in MDC 10 (Endocrine,
Nutritional and Metabolic Diseases and
Disorders) and to MS–DRGs 987, 988,
and 989 (Non-Extensive O.R. Procedure
Unrelated to Principal Diagnosis with
MCC, with CC and without MCC/CC,
respectively). In the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28167
through 28168) we discussed a request
we received to reconsider this
assignment for FY 2023. According to
the requestor, the clinical characteristics
and costs of cases assigned to MS–DRGs
628 through 630 are significantly
different from those associated with the
administration of eladocagene
exuparvovec. The requestor performed
its own analysis, using deep brain
stimulation for epilepsy and selective
dorsal rhizotomy for cerebral palsy as
proxies, and stated that based on its
findings for the initial cost analysis and
clinical comparison, that MS–DRG 23
(Craniotomy with Major Device Implant
or Acute Complex CNS Principal
Diagnosis with MCC or Chemotherapy
Implant or Epilepsy with
Neurostimulator), MS–DRG 24
(Craniotomy with Major Device Implant
or Acute Complex CNS Principal
Diagnosis without MCC) and MS–DRGs
25, 26, and 27 (Craniotomy and
Endovascular Intracranial Procedures
with MCC, with CC, and without CC/
MCC, respectively) may be more
appropriate. However, the requestor also
stated that while the clinical aspects of
eladocagene exuparvovec cases are
similar to those of MS–DRGs 23 through
27, the costs are much higher and
neither MS–DRGs 628, 629, 630 or MS–
DRGs 23 through 27 are appropriate.
Therefore, the requestor stated its belief
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48854
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
that assigning eladocagene exuparvovec
cases to new MS–DRGs is warranted.
Eladocagene exuparvovec is a gene
therapy for the treatment of patients
with aromatic L-amino acid
decarboxylase (AADC) deficiency, a rare
genetic and fatal condition identified
with ICD–10–CM diagnosis code E70.81.
Patients with AADC deficiency are
generally observed to have onset of
symptoms in the first year of life, most
notably hypotonia (muscle weakness),
followed by movement disorders,
developmental delay and autonomic
signs, such as hyperhidrosis (profuse
sweating unrelated to heat or exercise).
It is understood that the long-term
implications of this disease are severe,
resulting in severe deficits and
limitations in life expectancy. Because
the condition is primarily diagnosed in
the pediatric population, we would not
expect to find any meaningful volume of
cases in the MedPAR data.
As discussed in the proposed rule, we
analyzed claims data from the
September 2021 update of the FY 2021
MedPAR file for MS–DRGs 628, 629,
and 630 for cases reporting procedure
code XW0Q316 and did not find any
cases. We then extended our analysis to
all MS–DRGs and found 1 case reporting
the administration of this therapy in
MS–DRG 829 (Myeloproliferative
Disorders or Poorly Differentiated
Neoplasms with Other Procedures with
CC/MCC) with an average length of stay
of 2 days and average costs of $1,544.
As we have discussed elsewhere we
generally prefer not to create a new MS–
DRG unless it would include a
substantial number of cases. However,
as discussed in section II.D.19.b. of the
preamble of the proposed rule and this
final rule, we are seeking public
comment on possible mechanisms
through which we can address rare
diseases and conditions that are
represented by low volumes in our
claims data. We believe this topic,
relating to the administration of
treatment to address the rare genetic and
fatal condition of AADC deficiency, is
appropriately aligned with and should
be considered as part of that effort.
Therefore, we stated in the proposed
rule that we are maintaining the current
structure for MS–DRGs 628, 629, and
630 for FY 2023, but would continue to
consider this request in connection with
our evaluation of possible mechanisms
to address rare diseases and conditions
in the MS–DRG structure, as discussed
later in this rule.
Comment: Commenters agreed with
our decision to maintain the current
MS–DRG assignment for cases reporting
the administration of eladocagene
exuparvovec. Other commenters urged
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
CMS to consider appropriate MS–DRG
assignment and payment for gene
therapy intracerebral infusion therapies.
The commenters stated there is
anticipated rapid development and
potential for these therapies to help
patients. The commenters also
expressed appreciation for CMS’ request
for feedback on MS–DRG assignment for
rare diseases and stated that gene
therapy represents an area of significant
innovation in treating these conditions.
The commenters suggested that CMS
carefully consider the MS–DRG
assignment for procedures that involve
an intracerebral infusion of gene therapy
or stem cell products that are currently
under development for several
neurologic disorders including
Parkinson’s, which is very common, and
aromatic L-amino acid decarboxylase
deficiency, which is very rare. The
commenters stated that intracerebral
infusion therapies are unique
procedures requiring vastly different
hospital resources compared to more
traditional neurosurgical procedures.
According to the commenters,
appropriate MS–DRG assignment or
consideration for creating new MS–DRG
categories will be essential to assuring
access to these therapies.
Response: We appreciate the
commenters’ support and feedback.
Comment: A couple commenters
disagreed with CMS’s decision to
maintain the current MS–DRG
assignment for cases reporting the
administration of eladocagene
exuparvovec. The commenters
requested that CMS consider creating a
new MS–DRG for neurosurgical gene
therapy. A commenter indicated that
because eladocagene exuparvovec has
not yet been approved by the FDA they
are unable to appropriately identify
cases in the claims data. This
commenter stated that there are
currently approximately 68 gene
therapy trials for central nervous system
disorders, therefore, the decision to
create or not create a new MS–DRG may
have broader implications.
Response: We appreciate the
commenters’ feedback. As discussed in
the proposed rule, our analysis of claims
data, which identified only one case
reporting the administration of this
therapy, did not support a proposal to
create a new MS–DRG. The MS–DRGs
are a classification system intended to
group together those diagnoses and
procedures with similar clinical
characteristics and utilization of
resources. As discussed previously and
in prior rulemaking, we generally prefer
not to create a new MS–DRG unless it
would include a substantial number of
cases, as having large clinical cohesive
PO 00000
Frm 00076
Fmt 4701
Sfmt 4700
groups within an MS–DRG provides
greater stability for annual updates to
the relative payment weights. We
acknowledge the complexities related to
classifying cases that are represented by
low volumes in our claims data and
believe that further review of this issue
also aligns with our intent to consider
how rare diseases or conditions may be
classified under the IPPS.
After consideration of the public
comments we received, we are
maintaining the current MS–DRG
assignment for cases reporting the
administration of eladocagene
exuparvovec for FY 2023. We will
continue to explore appropriate
mechanisms to address therapies
indicated for rare diseases. We also refer
the reader to section II.D.19.a of the
preamble of this final rule for a
discussion of the feedback received in
response to the comment solicitation on
possible mechanisms to address rare
diseases and conditions in the MS–DRG
structure.
10. MDC 15 Newborns and Other
Neonates With Conditions Originating
in Perinatal Period: MS–DRG 795
Normal Newborn
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28168 through
28170), we discussed a request we
received to review the MS–DRG
assignment of newborn encounters with
diagnosis codes describing contact with
and (suspected) exposure to COVID–19
when the condition is ruled out after
clinical evaluation and negative
workup. The requestor expressed
concern that a newborn encounter
coded with a principal diagnosis code
from category Z38 (Liveborn infants
according to place of birth and type of
delivery), followed by codes Z05.1
(Observation and evaluation of newborn
for suspected infectious condition ruled
out) and Z20.822 (Contact with and
(suspected) exposure to COVID–19) is
assigned to MS–DRG 794 (Neonate with
Other Significant Problems). The
requestor stated that this assignment
appears to be in error and that the
assignment should instead be to MS–
DRG 795 (Normal Newborn).
In the proposed rule we stated that
our analysis of this grouping issue
confirmed that, when a principal
diagnosis code from category Z38
(Liveborn infants according to place of
birth and type of delivery), followed by
codes Z05.1 (Observation and
evaluation of newborn for suspected
infectious condition ruled out) and
Z20.822 (Contact with and (suspected)
exposure to COVID–19), the case is
assigned to MS–DRG 794.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
We stated that as we examined the
GROUPER logic that would determine
an assignment of cases to MS–DRG 795,
we noted the ‘‘only secondary
diagnosis’’ list under MS–DRG 795
includes the following five ICD–10–CM
Description
Contact with and (suspected) exposure to other intestinal infectious diseases
Contact with and ( suspected) exposure to pediculosis, acariasis and other infestations
Contact with and (suspected) exposure to anthrax
Contact with and (suspected) exposure to other bacterial communicable diseases
Contact with and ( suspected) exposure to other communicable diseases
As discussed in the proposed rule, in
reviewing the ICD–10–CM diagnosis
code classification and the GROUPER
inadvertently omitted from the ‘‘only
secondary diagnosis’’ list under MS–
DRG 795.
Description
Contact with and (suspected) exposure to intestinal infectious diseases due to Escherichia coli (E. coli)
Contact with and (suspected) exposure to tuberculosis
Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission
Contact with and ( suspected) exposure to rabies
Contact with and (suspected) exposure to rubella
Contact with and ( suspected) exposure to viral hepatitis
Contact with and (suspected) exposure to human immunodeficiency virus rHIVl
Contact with and (suspected) exposure to meningococcus
Contact with and (suspected) exposure to varicella
Contact with and ( suspected) exposure to Zika virus
Contact with and (suspected) exposure to COVID-19
Contact with and ( suspected) exposure to other viral communicable diseases
Contact with and (suspected) exposure to unspecified communicable disease
We reviewed section I.C.21.c.1 of the
2022 ICD–10–CM Official Guidelines for
Coding and Reporting which state
‘‘category Z20 indicates contact with,
and suspected exposure to,
communicable diseases. These codes are
for patients who are suspected to have
been exposed to a disease by close
personal contact with an infected
individual or are in an area where a
disease is epidemic . . . Contact/
exposure codes may be used as a firstlisted code to explain an encounter for
testing, or, more commonly, as a
secondary code to identify a potential
risk.’’ Per the Excludes1 note at category
Z20, when applicable, diagnoses of
current infectious or parasitic disease
are coded instead of codes from category
Z20.
We stated in the proposed rule that
our clinical advisors reviewed this issue
and agreed that patients exposed to
communicable diseases that are worked
up or treated prophylactically or both,
VerDate Sep<11>2014
logic list, we noted that the 13 ICD–10–
CM diagnosis codes, also from category
Z20, listed in the following table were
00:20 Aug 10, 2022
Jkt 256001
and for whom those conditions are later
determined after study to not be present,
are distinct from patients with
identified signs or symptoms of a
suspected problem or diagnosed with
having that communicable disease. Our
clinical advisors supported adding the
13 diagnosis codes listed previously to
the logic of MS–DRG 795 for clinical
consistency with the five other
diagnosis codes describing contact with,
and suspected exposure to,
communicable diseases currently
assigned to the ‘‘only secondary
diagnosis’’ list under MS–DRG 795.
After review of the coding guidelines
and conventions, and discussion with
our clinical advisors, we stated that we
agreed with the requestor that in these
circumstances, these encounters should
not map to MS–DRG 794 (Neonate with
Other Significant Problems) and should
instead be assigned to MS–DRG 795
(Normal Newborn). Therefore, we
proposed to add the 13 diagnosis codes
PO 00000
Frm 00077
Fmt 4701
Sfmt 4700
listed previously that describe contact
with and (suspected) exposure to
communicable diseases to the ‘‘only
secondary diagnosis’’ list under MS–
DRG 795 (Normal Newborn). Under this
proposal, cases with a principal
diagnosis described by an ICD–10–CM
code from category Z38 (Liveborn
infants according to place of birth and
type of delivery), following by codes
Z05.1 (Observation and evaluation of
newborn for suspected infectious
condition ruled out) and Z20.822
(Contact with and (suspected) exposure
to COVID–19) will be assigned to MS–
DRG 795.
Comment: Commenters expressed
support for CMS’ proposal to add the 13
diagnosis codes listed previously that
describe contact with and (suspected)
exposure to communicable diseases to
the ‘‘only secondary diagnosis’’ list
under MS–DRG 795 (Normal Newborn).
Response: We appreciate the
commenters’ support.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.048
khammond on DSKJM1Z7X2PROD with RULES2
ICD-10-CM
Code
Z20.01
Z20.l
Z20.2
Z20.3
Z20.4
Z20.5
Z20.6
Z20.811
Z20.820
Z20.821
Z20.822
Z20.828
Z20.9
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/MS-DRGClassifications-and-Software for
complete documentation of the
GROUPER logic for the MS–DRG 795.
ER10AU22.047
ICD-10-CM
Code
Z20.09
Z20.7
Z20.810
Z20.818
Z20.89
diagnosis codes from ICD–10–CM
category Z20. We refer the reader to the
ICD–10 MS–DRG Version 39.1
Definitions Manual (which is available
via the internet on the CMS website at:
https://www.cms.gov/Medicare/
48855
48856
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ICD-10-CM
Code
P07.00
P07.20
khammond on DSKJM1Z7X2PROD with RULES2
P07.26
Descri tion
Extremely low birth weight
newborn, uns ecified wei ht
Extreme immaturity of newborn,
uns ecified weeks of estation
Extreme immaturity of newborn,
estational a e 27 com leted weeks
We stated our clinical advisors
reviewed this grouping issue and noted
that while virtually every neonate under
1000 grams, which is the definition of
extremely low birth weight (ELBW), will
have a weight documented somewhere
in the medical record, in the rare
VerDate Sep<11>2014
‘‘only secondary diagnosis’’ list under
MS–DRG 795 are currently
inappropriately included and requested
that either the 13 codes for contact with
and (suspected) exposure remain
assigned to MS–DRG 794 and the five
codes currently in MS–DRG 795 be
reassigned to MS–DRG 794 or a new
MS–DRG be created that would include
newborns that fall into the ‘‘exposure
only’’ category, with a relative weight
that falls somewhere between the
relative weights of MS–DRG 794 and
795 to accurately capture resource
utilization.
Response: We thank the commenters
for their feedback. Our clinical advisors
reviewed the commenters’ concerns.
While our clinical advisors agree that
patients exposed to communicable
diseases can require workup or
prophylactic treatment, they continue to
state these patients are distinct from
patients with identified signs or
symptoms of a suspected problem or
diagnosed with having that
communicable disease. Our clinical
advisors noted that the subset of
newborns with a principal or secondary
diagnosis listed in the logic list for MS–
DRG 794 (Neonate with Other
Significant Problems) are clinically
distinct and often represent a more
severe set of patients. Accordingly, our
clinical advisors continue to believe that
the five other diagnosis codes describing
contact with, and suspected exposure
to, communicable diseases are
appropriately assigned to the ‘‘only
secondary diagnosis’’ list under MS–
DRG 795, and also continue to support
adding the 13 diagnosis codes listed
previously to the logic of MS–DRG 795
for clinical consistency. We appreciate
the commenters’ feedback suggesting
further review of the newborn MS–
00:20 Aug 10, 2022
Jkt 256001
MS-DRG
791 and 792 (Prematurity with and
without Ma· or Problems, res ectivel
795 ormal Newborn
791 and 792 (Prematurity with and
without Ma· or Problems, res ectivel
instance that it is not, if the diagnosis
documented by the provider is ‘‘ELBW’’
the neonate would be in a higher risk
category. Our clinical advisors also
noted that whereas weight is measured
with high precision, gestational age is
more complicated. With the exception
PO 00000
Frm 00078
Fmt 4701
Sfmt 4700
DRGs and agree that these groupings
warrant special consideration. As
discussed in prior rulemaking, we
generally do not adopt the same
approach to refine the maternity and
newborn MS–DRGs because of the
extremely low volume of Medicare
patients there are in these DRGs.
After consideration of the public
comments we received, and for the
reasons discussed, we are finalizing our
proposal to add the 13 diagnosis codes
listed previously that describe contact
with and (suspected) exposure to
communicable diseases to the ‘‘only
secondary diagnosis’’ list under MS–
DRG 795 (Normal Newborn), without
modification, for FY 2023.
In addition, as discussed in the
proposed rule, as we examined the
GROUPER logic that would determine
an assignment of cases to MS–DRGs in
MDC 15, we noted the logic for MS–
DRG 790 (Extreme Immaturity or
Respiratory Distress Syndrome Neonate)
includes ICD–10–CM diagnosis codes
that describe extremely low birth weight
newborn, extreme immaturity of
newborn and respiratory distress
syndrome of newborn. We referred the
reader to the ICD–10 MS–DRG Version
39.1 Definitions Manual (which is
available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/MS-DRGClassifications-and-Software) for
complete documentation of the
GROUPER logic for MS–DRG 790. We
stated that during our review of the
diagnosis codes assigned to these MS–
DRGs, we identified three diagnosis
codes that do not exist in the logic for
MS–DRG 790. The three diagnosis codes
and their current MS–DRG assignments
are listed in the following table.
of in vitro fertilization, gestational age is
an estimate. Our clinical advisors stated
similar to documentation of ‘‘ELBW’’, if
the diagnosis documented by the
provider is ‘‘extreme immaturity of
newborn’’ the neonate would be in a
higher risk category. These diagnoses
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.049
Comment: A few commenters
opposed CMS’s proposal and stated that
newborns exposed to communicable
diseases often require care and
treatment well above that of a normal
newborn in terms of requiring increased
evaluation, monitoring, testing, and
prophylactic treatment. Some
commenters stated that these newborns
are not ‘‘normal newborns’’ due to the
specific exposures they have had. These
commenters listed a number of
communicable diseases as examples and
indicated the specific interventions
such as evaluations, screenings,
assessments, extra monitoring,
laboratory studies, prophylactic
treatments and sometimes isolation that
can be required to prevent disease or
complications when contact or
(suspected) exposure occurs. Another
commenter noted that there is a
substantial difference in the FY 2023
proposed relative weights between MS–
DRG 795 and MSDRG 794 and stated
that ‘‘exposure only’’ cases fall in
between the two MS–DRGs in terms of
resource utilization. This commenter
stated that a review of the cases at their
facility shows that cases assigned to
MS–DRG 794 with only a diagnosis
code describing contact with and
(suspected) exposure to communicable
diseases driving the MS–DRG
assignment had longer lengths of stay
and higher charges than cases assigned
to MS–DRG 795, while having shorter
lengths of stay and lower charges than
other cases assigned to MS–DRG 794
with diagnoses describing conditions
other than contact with and (suspected)
exposure driving the MS–DRG
assignment. This commenter also stated
that they believed that the five ICD–10–
CM diagnosis codes from ICD–10–CM
category Z20 currently listed in the
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
11. Review of Procedure Codes in MS–
DRGs 981 Through 983 and 987
Through 989
We annually conduct a review of
procedures producing assignment to
MS–DRGs 981 through 983 (Extensive
O.R. Procedure Unrelated to Principal
Diagnosis with MCC, with CC, and
without CC/MCC, respectively) or MS–
DRGs 987 through 989 (Non-Extensive
O.R. Procedure Unrelated to Principal
Diagnosis with MCC, with CC, and
without CC/MCC, respectively) on the
basis of volume, by procedure, to see if
it would be appropriate to move cases
reporting these procedure codes out of
these MS–DRGs into one of the surgical
MS–DRGs for the MDC into which the
principal diagnosis falls. The data are
arrayed in two ways for comparison
ICD-10-PCS
Code
khammond on DSKJM1Z7X2PROD with RULES2
06L43DZ
06L83DZ
06V43DZ
06V83DZ
a. Embolization of Portal and Hepatic
Veins
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28170),
we received a request to reassign cases
with a principal diagnosis from MDC 07
(Diseases and Disorders of the
Hepatobiliary System and Pancreas)
when reported with procedures
involving the embolization of a hepatic
or portal vein from MS–DRGs 981, 982
and 983 (Extensive O.R. Procedures
Unrelated to Principal Diagnosis with
MCC, with CC, and without CC/MCC,
respectively) to MS–DRGs 423, 424, and
425 (Other Hepatobiliary or Pancreas
Procedures with MCC, with CC, and
without CC/MCC, respectively) in MDC
07.
We noted that in ICD–10–PCS, the
root operation selected to code
embolization procedures is dependent
on the objective of the procedure. If the
objective of an embolization procedure
is to completely close a vessel, the root
operation Occlusion is coded. ICD–10–
PCS procedure codes 06L43DZ
(Occlusion of hepatic vein with
intraluminal device, percutaneous
approach) or 06L83DZ (Occlusion of
portal vein with intraluminal device,
percutaneous approach) may be
reported to describe embolization
procedures to completely close off a
hepatic or portal vein with an
intraluminal device. If the objective of
an embolization procedure is to narrow
the lumen of a vessel, the root operation
Restriction is coded. ICD–10–PCS
procedure codes 06V43DZ (Restriction
of hepatic vein with intraluminal
device, percutaneous approach) or
06V83DZ (Restriction of portal vein
with intraluminal device, percutaneous
approach) may be reported to describe
embolization procedures to narrow or
partially occlude a hepatic or portal
vein with an intraluminal device.
These four ICD–10–PCS procedure
codes, as well as their MDC
assignments, are listed in the table:
Description
Occlusion of hepatic vein with intraluminal device, percutaneous approach
Occlusion of portal vein with intraluminal device, percutaneous approach
Restriction of hepatic vein with intraluminal device, percutaneous approach
Restriction of portal vein with intraluminal device, percutaneous approach
We stated in the proposed rule that
our analysis of this grouping issue
confirmed that when a procedure code
describing the percutaneous occlusion
or restriction of the hepatic or portal
vein with intraluminal device is
reported with a principal diagnosis from
MDC 07, these cases group to MS–DRGs
981, 982, and 983 (Extensive O.R.
VerDate Sep<11>2014
purposes. We look at a frequency count
of each major operative procedure code.
We also compare procedures across
MDCs by volume of procedure codes
within each MDC. We use this
information to determine which
procedure codes and diagnosis codes to
examine. We identify those procedures
occurring in conjunction with certain
principal diagnoses with sufficient
frequency to justify adding them to one
of the surgical MS–DRGs for the MDC in
which the diagnosis falls. We also
consider whether it would be more
appropriate to move the principal
diagnosis codes into the MDC to which
the procedure is currently assigned.
In addition to this internal review, we
also consider requests that we receive to
examine cases found to group to MS–
DRGs 981 through 983 or MS–DRGs 987
through 989 to determine if it would be
appropriate to add procedure codes to
one of the surgical MS–DRGs for the
MDC into which the principal diagnosis
falls or to move the principal diagnosis
to the surgical MS–DRGs to which the
procedure codes are assigned.
Based on the results of our review of
the claims data from the September
2021 update of the FY 2021 MedPAR
file, as well as our review of the requests
that we received to examine cases found
to group to MS–DRGs 981 through 983
or MS–DRGs 987 through 989, we
proposed to move the cases reporting
the procedures and/or principal
diagnosis codes described in this
section of this rule from MS–DRGs 981
through 983 or MS–DRGs 987 through
989 into one of the surgical MS–DRGs
for the MDC into which the principal
diagnosis or procedure is assigned.
00:20 Aug 10, 2022
Jkt 256001
Procedure Unrelated to Principal
Diagnosis with MCC, with CC, and
without CC/MCC, respectively).
Whenever there is a surgical procedure
reported on the claim that is unrelated
to the MDC to which the case was
assigned based on the principal
diagnosis, it results in an MS–DRG
assignment to a surgical class referred to
PO 00000
Frm 00079
Fmt 4701
Sfmt 4700
MDC
05,06,21,24
05,06,21,24
05,21,24
05,21,24
as ‘‘unrelated operating room
procedures’’.
As noted in the proposed rule, to
understand the resource use for the
subset of cases reporting procedure
codes 06L43DZ, 06L83DZ, 06V43DZ or
06V83DZ with a principal diagnosis
from MDC 07 that are currently
grouping to MS–DRGs 981, 982, and
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.050
describe conditions that require
advanced care and resources similar to
other conditions already assigned to the
logic of MS–DRG 790 even in cases
where the birth weight, or weeks of
gestation, are unspecified.
For clinical consistency, our clinical
advisors supported the addition of these
three diagnosis codes to the GROUPER
logic list for MS–DRG 790. Therefore,
we proposed to reassign ICD–10–CM
diagnosis codes P07.00, P07.20 and
P07.26 to MS–DRG 790, effective
October 1, 2022 for FY 2023.
Comment: Commenters expressed
support for CMS’ proposal to reassign
ICD–10–CM diagnosis codes P07.00,
P07.20 and P07.26 to MS–DRG 790.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to reassign ICD–
10–CM diagnosis codes P07.00, P07.20
and P07.26 to MS–DRG 790, without
modification, effective October 1, 2022
for FY 2023.
48857
48858
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
983, we examined claims data from the
September 2021 update of the FY 2021
MedPAR file for the average length of
stay and average costs for these cases.
Our findings are shown in the following
table:
MS-DRGs 981-983: Cases Reporting Procedure Describing Percutaneous Occlusion or Restriction
of Hepatic or Portal Vein with lntraluminal Device with Principal Dia~nosis from MDC 07
Average
Number of
Length of
Average
Stay
MS-DRG
Cases
Costs
12.1
22,967
!All cases
$35,790
Cases reporting 06L43DZ; 06L83DZ; 06V43DZ
981
or 06V83DZ with a principal diagnosis from
23
13.9
$45,634
MDC07
10,465
$19,803
IAll cases
5.9
Cases reporting 06L43DZ; 06L83DZ; 06V43DZ
982
or 06V83DZ with a principal diagnosis from
10
8.6
$16,772
MDC07
1,905
2.7
IAll cases
$13,877
Cases reporting 06L43DZ; 06L83DZ; 06V43DZ
983
or 06V83DZ with a principal diagnosis from
1
1
$15,140
MDC07
findings are shown in the following
table:
khammond on DSKJM1Z7X2PROD with RULES2
MS-DRG
423 -All cases
424 -All cases
425 -All cases
As noted in the proposed rule, while
the claims analysis based on the
September 2021 update of the FY 2021
MedPAR file identified only 34 cases for
which these procedures were reported
with a principal diagnosis from MDC 07
resulting in assignment to MS–DRGs
981 through 983, and the average length
of stay and average costs for these cases
vary in comparison to the average length
of stay and average costs of all cases in
MS–DRGs 423, 424, and 425, given the
clinical indications for hepatic or portal
vein embolization procedures, such as
to induce regrowth on one side of the
liver in advance of a planned hepatic
resection on the other side, we stated we
believed it was clinically appropriate to
add these procedure codes describing
the percutaneous occlusion or
restriction of the hepatic or portal vein
with intraluminal device to MS–DRGs
423, 424, and 425 in MDC 07. Our
clinical advisors stated that these
procedures are clearly related to the
principal diagnoses as they are
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Average
Length of
Stay
10.9
6
2.9
procedures performed for hepatobiliary
diagnoses, namely hepatocellular
carcinoma and liver metastases, so it is
clinically appropriate for the procedures
to group to the same MDC as the
principal diagnoses. Our clinical
advisors also stated the procedures
describing the percutaneous occlusion
or restriction of the hepatic or portal
vein with intraluminal device are
consistent with the existing procedure
codes included in the logic for case
assignment to MS–DRGs 423, 424, and
425.
Therefore, we proposed to add ICD–
10–PCS procedure codes 06L43DZ,
06L83DZ, 06V43DZ and 06V83DZ to
MDC 07 in MS–DRGs 423, 424 and 425.
Under this proposal, cases reporting
procedure codes 06L43DZ, 06L83DZ,
06V43DZ or 06V83DZ in conjunction
with a principal diagnosis code from
MDC 07 would group to MS–DRGs 423,
424 and 425.
Comment: Commenters expressed
support for CMS’ proposal to add ICD–
PO 00000
Frm 00080
Fmt 4701
Sfmt 4700
Average
Costs
$32,145
$19,514
$12,113
10–PCS procedure codes 06L43DZ,
06L83DZ, 06V43DZ and 06V83DZ to
MDC 07 in MS–DRGs 423, 424 and 425.
A commenter stated that this proposal is
in line with resources utilized in
performing the procedures and also
helps organizations better manage their
Program for Evaluating Payment
Patterns Electronic Report (PEPPER)
data related to DRG 981 and 982.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to add ICD–10–
PCS procedure codes 06L43DZ,
06L83DZ, 06V43DZ and 06V83DZ to
MDC 07 in MS–DRGs 423, 424 and 425,
without modification, effective October
1, 2022 for FY 2023.
b. Percutaneous Excision of Hip Muscle
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28171),
we received a request to examine cases
reporting a procedure describing
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.052
Number
of Cases
1,222
547
98
ER10AU22.051
We also examined the data for cases
in MS–DRGs 423, 424, and 425, and our
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
percutaneous biopsies of muscle. The
requestor stated that when procedures
describing the percutaneous excision of
the left hip muscle for diagnostic
purposes are reported with a principal
diagnosis from MDC 06 (Diseases and
Disorders of the Digestive System) such
as K68.12 (Psoas muscle abscess), the
cases are assigned to MS–DRGs 981,
982, and 983 (Extensive O.R. Procedure
Unrelated to Principal Diagnosis with
MCC, with CC, and without CC/MCC,
respectively). However, when
procedures describing the percutaneous
excision of the retroperitoneum for
diagnostic purposes are reported with
the same principal diagnosis of psoas
muscle abscess, the cases are assigned to
ICD-10-PCS
Code
0KBN3ZX
0KBN3ZZ
0KBP3ZX
0KBP3ZZ
percutaneous excision of the left hip
muscle for diagnostic purposes appear
to be related to a diagnosis of psoas
muscle abscess.
We stated in the proposed rule that in
order to analyze this request, we first
identified the similar ICD–10–PCS
procedure codes that also describe the
excision of hip muscle. We noted that
under the ICD–10–PCS procedure
classification, biopsy procedures are
identified by the 7th digit qualifier
value ‘‘diagnostic’’ in the code
description. The four ICD–10–PCS
procedure codes that describe the
excision of hip muscle, as well as their
MDC assignments, are listed in the
table:
Description
Excision of right hip muscle, percutaneous approach, diagnostic
Excision of right hip muscle, percutaneous approach
Excision of left hip muscle, percutaneous approach, diagnostic
Excision of left hip muscle, percutaneous approach
We stated in the proposed rule that
our analysis of this grouping issue
confirmed that when procedure codes
0KBN3ZX, 0KBN3ZZ, 0KBP3ZX or
0KBP3ZZ are reported with a principal
diagnosis from MDC 06, such as K68.12,
these cases group to MS–DRGs 981, 982,
and 983. As noted in the previous
discussion, whenever there is a surgical
procedure reported on the claim that is
unrelated to the MDC to which the case
was assigned based on the principal
diagnosis, it results in a MS–DRG
assignment to a surgical class referred to
as ‘‘unrelated operating room
procedures’’.
As noted in the proposed rule, we
examined the claims data from the
MDC
08
01;08;09;21;24
08
01;08;09;21;24
September 2021 update of the FY 2021
MedPAR file to identify cases reporting
procedure codes 0KBN3ZX, 0KBN3ZZ,
0KBP3ZX, or 0KBP3ZZ with a principal
diagnosis of K68.12 (Psoas muscle
abscess) that are currently grouping to
MS–DRGs 981, 982, and 983. Our
findings are shown in this table:
As shown, in our analyses of the
claims data for MS–DRGs 981 through
983, we found a total of seven cases
reporting procedures describing
excision of hip muscle with a principal
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
diagnosis of K68.12 in the September
2021 update of the FY 2021 MedPAR
file.
We stated in the proposed rule that to
further evaluate this issue, we examined
PO 00000
Frm 00081
Fmt 4701
Sfmt 4700
claims data from the September 2021
update of the FY 2021 MedPAR file for
cases reporting any one of the four
procedure codes (0KBN3ZX, 0KBN3ZZ,
0KBP3ZX, or 0KBP3ZZ) in MS–DRGs
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.054
MS-DRGs 981-983: Cases Reporting Procedures Describing Excision of Hip Muscle with a
Principal Dia~nosis of Psoas Muscle Abscess
Average
Number of Length of
Average
MS-DRG
Stay
Cases
Costs
12.1
$35,790
22,967
!All cases
981
Cases reporting excision of hip muscle with
principal diagnosis ofK68.12
2
$12,388
7.5
[All cases
10,465
$19,803
5.9
982
Cases reporting excision of hip muscle with
principal diagnosis ofK68.12
4
9.8
$13,810
[All cases
1,905
2.7
$13,877
983
Cases reporting excision of hip muscle with
tprincipal diagnosis ofK68.12
1
2
$7,781
ER10AU22.053
khammond on DSKJM1Z7X2PROD with RULES2
medical MS–DRGs 371, 372, and 373
(Major Gastrointestinal Disorders and
Peritoneal Infections with MCC, with
CC, and without CC/MCC, respectively).
The requestor stated the cases at their
facility with a principal diagnosis of
psoas muscle abscess when reported
with a procedure describing a biopsy of
the left muscle had an average length of
stay comparable to other cases assigned
to MS–DRGs 371, 372, and 373. The
requestor provided ICD–10–PCS
procedure code 0KBP3ZX (Excision of
left hip muscle, percutaneous approach,
diagnostic) in its request and
recommended that CMS evaluate the
assignment of procedure code 0KBP3ZX
because procedures describing the
48859
48860
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
981 through 983 with a principal
diagnosis from MDC 06. Our findings
are shown in the following table.
MS-DRGs 981-983: Cases Reporting Procedures Describing Excision of Hip Muscle with
Principal Dia2nosis from MDC 06
Average
Number of Length of
Average
MS-DRG
Stay
Cases
Costs
k-\..11 cases
22,967
12.1
$35,790
981
Cases reporting excision of hip muscle with
any principal diagnosis from MDC 06
5
9.6
$15,599
k\..11 cases
10,465
5.9
$19,803
982
Cases reporting excision of hip muscle with
any principal diagnosis from MDC 06
8
8.5
$12,346
[All cases
1,905
2.7
$13,877
983
Cases reporting excision of hip muscle with
any principal diagnosis from MDC 06
1
2
$7,781
Number
of Cases
11,415
15,680
3,090
khammond on DSKJM1Z7X2PROD with RULES2
MS-DRG
371 -All cases
372 - All cases
373 - All cases
As discussed in the proposed rule, we
reviewed these procedures and our
clinical advisors stated that procedures
that describe the percutaneous excision
of hip muscle are not surgical in nature
and would not be the main reason for
inpatient hospitalization or be
considered the principal driver of
resource expenditure. Our clinical
advisors stated although a correlation
cannot usually be made between
procedures performed in general
anatomic regions, such as the
retroperitoneum, and procedures
performed in specific body parts, such
as muscle, because procedures coded
with general anatomic region body parts
represent a broader range of procedures
that cannot be coded to a specific body
part, they agreed that in this instance
procedures that describe the
percutaneous excision of hip muscle
should have the same designation as the
ICD–10–PCS procedure codes that
describe the percutaneous excision of
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Average
Length of
Stay
6.9
4.6
3.3
the retroperitoneum that are currently
designated as non-O.R. procedures.
We stated that our clinical advisors
reviewed this analysis and believed
that, for clinical coherence and
consistency, it would be appropriate to
designate ICD–10–PCS codes 0KBN3ZX,
0KBN3ZZ, 0KBP3ZX, and 0KBP3ZZ as
non-O.R. procedures.
Therefore, we proposed to remove
codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX,
and 0KBP3ZZ from the FY 2023 ICD–10
MS–DRGs Version 40 Definitions
Manual in Appendix E—Operating
Room Procedures and Procedure Code/
MS–DRG Index as O.R. procedures.
Under this proposal, these procedures
would no longer impact MS–DRG
assignment. Cases reporting procedure
codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX,
and 0KBP3ZZ in conjunction with a
principal diagnosis code from MDC 06
would group to MS–DRGs 371, 372, and
373.
PO 00000
Frm 00082
Fmt 4701
Sfmt 4700
MS–DRGs 371, 372, and 373, and our
findings are shown in the following
table:
Average
Costs
$13,284
$8,072
$5,860
Comment: Some commenters
expressed support for CMS’ proposal to
remove codes 0KBN3ZX, 0KBN3ZZ,
0KBP3ZX, and 0KBP3ZZ from the FY
2023 ICD–10 MS–DRGs Version 40
Definitions Manual in Appendix E—
Operating Room Procedures and
Procedure Code/MS–DRG Index as O.R.
procedures.
Response: We appreciate the
commenters’ support.
Comment: A commenter opposed
CMS’ proposal to designate ICD–10–PCS
codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX,
and 0KBP3ZZ as non-O.R. procedures
and stated that they did not believe this
proposal was warranted based on the
work involved in performing the
procedures.
Response: We thank the commenter
for their feedback. Our clinical advisors
reviewed the commenter’s concerns and
continue to support a non-O.R.
designation for procedure codes
0KBN3ZX, 0KBN3ZZ, 0KBP3ZX, and
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.056
diagnosis from MDC 06 in the
September 2021 update of the FY 2021
MedPAR file.
We also stated in the proposed rule
that we examined the data for cases in
ER10AU22.055
As shown, in our analyses of the
claims data for MS–DRGs 981 through
983, we found a total of 14 cases
reporting procedures describing
excision of hip muscle with a principal
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
0KBP3ZZ that describe the
percutaneous excision of hip muscle.
Our clinical advisors continue to state
that procedure codes that describe the
percutaneous excision of hip muscle are
not surgical in nature and these
procedures should have the same
designation as the ICD–10–PCS
procedure codes that describe the
percutaneous excision of the
retroperitoneum that are currently
designated as non-O.R. procedures.
After consideration of the public
comments we received, for the reasons
stated, we are finalizing our proposal to
remove codes 0KBN3ZX, 0KBN3ZZ,
0KBP3ZX, and 0KBP3ZZ from the FY
2023 ICD–10 MS–DRGs Version 40
Definitions Manual in Appendix E—
Operating Room Procedures and
Procedure Code/MS–DRG Index as O.R.
procedures, without modification,
effective October 1, 2022 for FY 2023.
Under this final policy, these
procedures will no longer impact MS–
DRG assignment.
In addition, as discussed in the
proposed rule, we also conduct an
internal review and consider requests
that we receive to examine cases found
to group to MS–DRGs 981 through 983
or MS–DRGs 987 through 989 to
determine if it would be appropriate for
the cases to be reassigned from one of
the MS–DRG groups to the other. In the
proposed rule, we stated that based on
the results of our review of the claims
data from the September 2021 update of
the FY 2021 MedPAR file we did not
identify any cases for reassignment. We
also stated we did not receive any
requests suggesting reassignment.
Therefore, for FY 2023 we did not
propose to move any cases reporting
procedure codes from MS–DRGs 981
through 983 to MS–DRGs 987 through
989 or vice versa.
Comment: Commenters expressed
support for CMS’ decision to not
propose to move any cases reporting
procedure codes from MS–DRGs 981
through 983 to MS–DRGs 987 through
989 or vice versa.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing the structure of MS–DRGs 981
through 983 and MS–DRGs 987 through
989 for FY 2023 without modification.
12. Operating Room (O.R.) and Non-O.R.
Issues
a. Background
Under the IPPS MS–DRGs (and former
CMS MS–DRGs), we have a list of
procedure codes that are considered
operating room (O.R.) procedures.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Historically, we developed this list
using physician panels that classified
each procedure code based on the
procedure and its effect on consumption
of hospital resources. For example,
generally the presence of a surgical
procedure which required the use of the
operating room would be expected to
have a significant effect on the type of
hospital resources (for example,
operating room, recovery room, and
anesthesia) used by a patient, and
therefore, these patients were
considered surgical. Because the claims
data generally available do not precisely
indicate whether a patient was taken to
the operating room, surgical patients
were identified based on the procedures
that were performed. Generally, if the
procedure was not expected to require
the use of the operating room, the
patient would be considered medical
(non-O.R.).
Currently, each ICD–10–PCS
procedure code has designations that
determine whether and in what way the
presence of that procedure on a claim
impacts the MS–DRG assignment. First,
each ICD–10–PCS procedure code is
either designated as an O.R. procedure
for purposes of MS- DRG assignment
(‘‘O.R. procedures’’) or is not designated
as an O.R. procedure for purposes of
MS–DRG assignment (‘‘non-O.R.
procedures’’). Second, for each
procedure that is designated as an O.R.
procedure, that O.R. procedure is
further classified as either extensive or
non-extensive. Third, for each
procedure that is designated as a nonO.R. procedure, that non-O.R. procedure
is further classified as either affecting
the MS–DRG assignment or not affecting
the MS–DRG assignment. We refer to
these designations that do affect MS–
DRG assignment as ‘‘non O.R. affecting
the MS–DRG.’’ For new procedure codes
that have been finalized through the
ICD–10 Coordination and Maintenance
Committee meeting process and are
proposed to be classified as O.R.
procedures or non-O.R. procedures
affecting the MS–DRG, our clinical
advisors recommend the MS–DRG
assignment which is then made
available in association with the
proposed rule (Table 6B.—New
Procedure Codes) and subject to public
comment. These proposed assignments
are generally based on the assignment of
predecessor codes or the assignment of
similar codes. For example, we
generally examine the MS–DRG
assignment for similar procedures, such
as the other approaches for that
procedure, to determine the most
appropriate MS–DRG assignment for
procedures proposed to be newly
PO 00000
Frm 00083
Fmt 4701
Sfmt 4700
48861
designated as O.R. procedures. As
discussed in section II.D.14 of the
preamble of this final rule, we are
making Table 6B.—New Procedure
Codes—FY 2023 available on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/
index.html. We also refer readers to the
ICD–10 MS–DRG Version 39.1
Definitions Manual at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS/MS–DRGClassifications-and-Software.html for
detailed information regarding the
designation of procedures as O.R. or
non-O.R. (affecting the MS–DRG) in
Appendix E—Operating Room
Procedures and Procedure Code/MS–
DRG Index.
In the FY 2020 IPPS/LTCH PPS
proposed rule, we stated that, given the
long period of time that has elapsed
since the original O.R. (extensive and
non-extensive) and non-O.R.
designations were established, the
incremental changes that have occurred
to these O.R. and non-O.R. procedure
code lists, and changes in the way
inpatient care is delivered, we plan to
conduct a comprehensive, systematic
review of the ICD–10–PCS procedure
codes. This will be a multi year project
during which we will also review the
process for determining when a
procedure is considered an operating
room procedure. For example, we may
restructure the current O.R. and non
O.R.-designations for procedures by
leveraging the detail that is now
available in the ICD–10 claims data. We
refer readers to the discussion regarding
the designation of procedure codes in
the FY 2018 IPPS/LTCH PPS final rule
(82 FR 38066) where we stated that the
determination of when a procedure code
should be designated as an O.R.
procedure has become a much more
complex task. This is, in part, due to the
number of various approaches available
in the ICD–10–PCS classification, as
well as changes in medical practice.
While we have typically evaluated
procedures on the basis of whether or
not they would be performed in an
operating room, we believe that there
may be other factors to consider with
regard to resource utilization,
particularly with the implementation of
ICD–10.
We discussed in the FY 2020 IPPS/
LTCH PPS proposed rule that as a result
of this planned review and potential
restructuring, procedures that are
currently designated as O.R. procedures
may no longer warrant that designation,
and conversely, procedures that are
currently designated as non-O.R.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48862
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
procedures may warrant an O.R. type of
designation. We intend to consider the
resources used and how a procedure
should affect the MS–DRG assignment.
We may also consider the effect of
specific surgical approaches to evaluate
whether to subdivide specific MS DRGs
based on a specific surgical approach.
We plan to utilize our available
MedPAR claims data as a basis for this
review and the input of our clinical
advisors. As part of this comprehensive
review of the procedure codes, we also
intend to evaluate the MS–DRG
assignment of the procedures and the
current surgical hierarchy because both
of these factor into the process of
refining the ICD–10 MS–DRGs to better
recognize complexity of service and
resource utilization.
In the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58540 through 58541), we
provided a summary of the comments
we had received in response to our
request for feedback on what factors or
criteria to consider in determining
whether a procedure is designated as an
O.R. procedure in the ICD–10–PCS
classification system for future
consideration.
We stated in the proposed rule that in
consideration of the ongoing PHE, we
continue to believe it may be
appropriate to allow additional time for
the claims data to stabilize prior to
selecting the timeframe to analyze for
this review. Additional time is also
necessary as we continue to develop our
process and methodology. Therefore, we
stated that we will provide more detail
on this analysis and the methodology
for conducting this review in future
rulemaking.
Comment: Commenters supported
CMS’ plan to continue to conduct the
comprehensive, systematic review of the
ICD–10–PCS codes that includes a
process for determining when a
procedure is designated as O.R. or nonO.R. These commenters expressed
support of CMS’ decision to allow
additional time for the claims data to
stabilize prior to selecting the timeframe
to analyze for this review in
consideration of the ongoing PHE. A
commenter stated they appreciate that
CMS is taking the appropriate time
before deciding whether and how to
restructure the current O.R. and nonO.R. designations. Another commenter
acknowledged that O.R. and non-O.R.
designation determinations are a
substantial undertaking that may
significantly restructure many MS–
DRGs.
Response: We thank the commenters
for their support and appreciate their
acknowledgement of the magnitude of
this effort.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Comment: Other commenters stated
that designation of O.R. versus non-O.R.
may no longer be the most critical
differentiator between resourceintensive procedures for MS–DRG
purposes. These commenters noted that
medical practice is changing and
presently, there are increasingly
complex and resource-intensive
procedures performed by hospitals that
do not involve the use of an operating
room. A commenter stated that because
of technological advances, sophisticated
resource-intensive procedures are no
longer confined to the operating room
setting.
Other commenters highlighted stem
cell transplants (SCT), Chimeric Antigen
Receptor (CAR) T-cell therapy, and
other novel cell and gene therapies as
examples of therapeutic interventions
that have similar or greater resource
utilization and complexity than some
O.R. designated procedures, while not
being currently designated as O.R.
procedures themselves. Another
commenter noted that some procedures
performed in interventional radiology
suites and cardiac catheterization labs
can utilize more advanced equipment
and supplies than procedures performed
in a traditional operating room with
minimally installed equipment. As part
of the broader and continuing
conversation about future MS–DRG
assignments and designations for these
procedures and therapies, these
commenters encouraged CMS to
consider how other factors influence
resource utilization, and recommended
CMS consider questions such as
whether:
• certain types of interventions, such
as the administration of certain complex
drugs/biologics or therapies (for
example, radiation therapy), that
demonstrate higher costs and resource
utilization, warrant consideration of a
designation as an O.R. procedure or
another equivalent designation?
• certain types of procedures and
therapies make up a substantial
percentage of the costs within a
particular MS–DRG?
• there is an average amount of cost
within the relative weight of a MS–DRG
that represents significant resource
utilization and complexity?
• complex infusion-type
administration of novel and potentially
curative cell and gene therapies should
be considered for new category of MS–
DRGs, to be added to the current
categories of Pre-MDC MS–DRGs,
Surgical MS–DRGs and Medical MS–
DRGs?
Response: CMS appreciates the
commenters’ feedback and
recommendations as to factors to
PO 00000
Frm 00084
Fmt 4701
Sfmt 4700
consider in evaluating O.R.
designations. As stated previously, we
have typically evaluated procedures on
the basis of whether or not they would
be performed in an operating room. We
agree with commenters and believe that
there may be other factors to consider
with regard to resource utilization,
particularly with the implementation of
ICD–10. As discussed in the proposed
rule, we are exploring alternatives on
how we may restructure the current
O.R. and non-O.R. designations for
procedures by leveraging the detail that
is available in the ICD–10 claims data.
We continue to develop our process and
methodology, and will provide more
detail in future rulemaking.
Comment: Several commenters
suggested that CMS work closely with
physician specialty societies and
interested parties to identify the most
important drivers of complexity and
resource use in the hospital setting.
Other commenters suggested CMS
engage the broader community by
convening town halls or listening
sessions. A few commenters suggested
that CMS allow sufficient time for
provider review and stated that
thorough data analysis with provider
input is critical to allow for appropriate
insight in provider comments. A
commenter recommended that CMS be
transparent in its methodology, identify
criteria or metrics used to determine
what does and does not constitute
significant resource utilization and
complexity across MS–DRGs, and be
receptive to public opinion. Another
commenter stated that they look forward
to CMS providing more detail on this
analysis and expressed that they would
appreciate advanced notice for comment
in future rulemaking regarding the
proposed methodology for conducting
this review.
Response: CMS appreciates this
feedback. We note that CMS has already
convened an internal workgroup
comprised of clinicians, coding
specialists and other policy analysts,
and we look forward to further feedback
from the public. Recognizing sufficient
time is needed to provide feedback on
what factors or criteria to consider in
determining whether a procedure
should be designated as an O.R.
procedure in the ICD–10–PCS
classification system, we have provided
opportunity for the public to provide
feedback beginning with the FY 2018
final rule and we continue to solicit
input. We encourage the public to
submit comments on other factors to
consider in our refinement efforts to
recognize and differentiate consumption
of resources for the ICD–10 MS–DRGs
timely for consideration. We will also
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
explore additional means of eliciting
feedback, and will notify the public of
any such other opportunities for
communication and comment in the
future. Once we are in a position to
provide more detail on this analysis and
the methodology for conducting this
comprehensive review, we will do so in
future rulemaking.
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28174
through 28175), we received the
following requests regarding changing
the designation of specific ICD–10–PCS
procedure codes from non-O.R. to O.R.
procedures. In this section of this rule,
as we did in the proposed rule, we
summarize these requests and address
why we are not considering a change to
the designation of these codes at this
time and, further, respond to the public
comments we received regarding these
requests.
We received a request to change the
designation of all ICD–10–PCS
procedure codes that describe
diagnostic and therapeutic percutaneous
endoscopic procedures performed on
thoracic and abdominal organs, from
non-O.R. to O.R. According to the
requestor, thoracoscopic and
laparoscopic procedures are always
performed in the operating room under
general anesthesia. In the proposed rule,
we stated we believed additional time
was needed to fully examine the
numerous ICD–10–PCS codes in the
classification that describe diagnostic
and therapeutic percutaneous
endoscopic procedures performed on
thoracic and abdominal organs as there
are over 19,000 ICD–10–PCS codes in
the classification that describe
procedures performed using a
percutaneous endoscopic approach. As
we have signaled in prior rulemaking,
the designation of an O.R. procedure
encompasses more than the physical
location of the hospital in which the
procedure may be performed. We also
examine if, and in what way, the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
performance of the procedure affects the
resource expenditure in those
admissions in the inpatient setting, in
addition to examining other clinical
factors such as procedure complexity,
and need for anesthesia administration
as well as other types of sedation. We
stated we will continue to evaluate the
ICD–10–PCS procedure codes that
describe diagnostic and therapeutic
percutaneous endoscopic procedures
performed on thoracic and abdominal
organs as we conduct a comprehensive,
systematic review of the ICD–10–PCS
procedure codes.
Comment: A commenter stated that
they agreed with the request to change
the designation of all lCD–10–PCS
procedure codes that describe
diagnostic and therapeutic percutaneous
endoscopic procedures performed on
thoracic and abdominal organs from
non-O.R. to O.R. and stated that these
procedures would likely occur in an
operating room under general
anesthesia. Another commenter stated
that while they did not dispute that
there may be over 19,000 ICD–10–PCS
codes that describe procedures
performed using a percutaneous
endoscopic approach, they believed that
this list could be whittled down
substantially by considering only codes
describing procedures performed on
thoracic and abdominal organs. This
commenter stated that even with a
smaller list utilizing the criteria they
suggested, they could not think of a
thoracoscopic or laparoscopic procedure
that would not require general
anesthesia and be performed in an
operating room and urged CMS to
designate all ICD–10–PCS procedure
codes that describe diagnostic and
therapeutic percutaneous endoscopic
procedures performed on thoracic and
abdominal organs as operating room
procedures.
Response: We appreciate the
commenters’ feedback. We also
appreciate the commenter’s suggestion,
PO 00000
Frm 00085
Fmt 4701
Sfmt 4700
48863
however, as stated in the proposed rule,
and in prior rulemaking, we plan to
conduct a comprehensive, systematic
review of the ICD–10–PCS procedure
codes. Our clinical advisors
recommended that rather than
evaluating the procedure codes
describing diagnostic and therapeutic
percutaneous endoscopic procedures
performed on thoracic and abdominal
organs in isolation, analysis should be
performed for this subset of procedure
codes across the MS–DRGs, as part of
the comprehensive procedure code
review. As a component of our broader
comprehensive procedure code review,
we are also reviewing the process for
determining when a procedure is
considered an operating room
procedure. For example, we may
restructure the current O.R. and nonO.R. designations for procedures by
leveraging the detail that is available in
the ICD–10 claims data. Therefore, after
consideration of the public comments
we received, and for the reasons
discussed, we are not making changes in
this final rule to the designation of all
ICD–10–PCS procedure codes that
describe diagnostic and therapeutic
percutaneous endoscopic procedures
performed on thoracic and abdominal
organs, from non-O.R. to O.R. We will
provide more detail on the
comprehensive procedure code review
and the methodology for conducting
this review in future rulemaking.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 44892 through 44895) CMS
finalized the proposal to remove the 22
codes that describe the open drainage of
subcutaneous tissue and fascia listed in
the following table from the ICD–10
MS–DRGs Version 39.1 Definitions
Manual in Appendix E—Operating
Room Procedures and Procedure Code/
MS–DRG Index as O.R. procedures.
Under this finalization, these
procedures no longer impact MS–DRG
assignment.
E:\FR\FM\10AUR2.SGM
10AUR2
48864
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Descri tion
In the FY 2022 final rule we noted
that the designation of the 22 procedure
codes that describe the open drainage of
subcutaneous tissue and fascia as O.R.
procedures was a result of a replication
error in transitioning to ICD–10. This
replication error led to ICD–10–PCS
procedure codes that describe the open
drainage of subcutaneous tissue and
fascia being listed as comparable
translations for ICD–9–CM code 83.09
(Other incision of soft tissue), which
was designated as a non-extensive O.R.
procedure under the ICD–9–CM MS–
DRGs Version 32, as opposed to being
listed as comparable translations for
ICD–9–CM code 86.04 (Other incision
with drainage of skin and subcutaneous
tissue) which was designated as a nonO.R. procedure under the ICD–9–CM
MS–DRGs Version 32. We stated in the
FY 2022 final rule that designating the
22 procedure codes that describe the
open drainage of subcutaneous tissue
and fascia as non-O.R. procedures
would result in a more accurate
replication of the comparable
procedure, under the ICD–9–CM MS–
DRGs Version 32 which was 86.04, not
83.09 and is more aligned with current
shifts in treatment practices.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule, we received a
request to re-examine this change in
designation. According to the requestor,
open procedures for the drainage of
subcutaneous tissue and fascia are
indeed typically performed in the
operating room under general anesthesia
and involve making incisions through
the subcutaneous tissue into fascia for
therapeutic drainage, breaking up of
loculations, and irrigation. We stated
that while our clinical advisors did not
disagree with the requestor that these
procedures can involve making
incisions through the subcutaneous
tissue into fascia, they continued to
state procedures describing the open
drainage of subcutaneous tissue and
fascia can now be safely performed in
the outpatient setting and when
performed during a hospitalization, they
are typically performed in conjunction
with another O.R. procedure. For the
reasons discussed in the FY 2022 final
rule, our clinical advisors stated that the
non-O.R. designation of the 22
procedure codes that describe the open
drainage of subcutaneous tissue and
fascia as finalized in the FY 2022 final
rule better reflects the associated
PO 00000
Frm 00086
Fmt 4701
Sfmt 4700
technical complexity and hospital
resource use of these procedures.
Comment: Some commenters opposed
the non-O.R. designation of the 22
procedure codes that describe the open
drainage of subcutaneous tissue and
fascia as finalized in the FY 2022 final
rule and urged that these codes be
designated as O.R. procedures for FY
2023. These commenters stated that
procedure codes that describe the open
drainage of subcutaneous tissue and
fascia are indeed performed in the
operating room under general
anesthesia, are surgical in nature, and
an O.R. designation would more
accurately capture the utilization of
resources. A commenter stated that a
review of the cases at their facility
shows that approximately 80% of the
procedures describing open drainage of
subcutaneous tissue and fascia are
performed in an O.R. setting requiring
anesthesia, with a much lesser
percentage performed at the bedside.
Another commenter noted in the FY
2018 IPPS proposed rule, these same 22
ICD–10–PCS codes were identified and
a commenter opposed the proposal to
re-designate these codes at that time. In
response to the issues raised by this
commenter, CMS agreed in the FY 2018
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.057
khammond on DSKJM1Z7X2PROD with RULES2
ICD-10-PCS
Code
0J900ZZ
0J910ZZ
0J940ZZ
0J950ZZ
0J960ZZ
0J970ZZ
0J980ZZ
0J990ZZ
0J9B0ZZ
0J9C0ZZ
0J9D0ZZ
0J9F0ZZ
0J9G0ZZ
0J9H0ZZ
0J9J0ZZ
0J9K0ZZ
0J9L0ZZ
0J9M0ZZ
0J9N0ZZ
0J9P0ZZ
0J9Q0ZZ
0J9R0ZZ
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
IPPS final rule to maintain the
designation of the 22 procedure codes.
This commenter stated the rationale to
maintain these 22 codes as O.R.
procedures has not changed and that
there is no safe way to effectively drain
an infection involving the subfascial
plane without the resources of an
operating room.
Response: Our clinical advisors
reviewed the commenters’ concerns and
continue to state that treatment
practices have continued to shift since
FY 2018 rulemaking. As stated in the FY
2022 final rule in response to similar
comments, procedures describing the
open drainage of subcutaneous tissue
and fascia can now be safely performed
in the outpatient setting and when
performed during a hospitalization, it is
typically in conjunction with another
O.R. procedure. In cases where
procedures describing open drainage of
subcutaneous tissue and fascia are the
only procedures performed in an
admission, the admission is quite likely
due to need for IV antibiotics as
opposed to the need for operating room
resources in an inpatient setting.
We refer the reader to Table 6P.1f
associated with this final rule (which is
available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS) for the
data analysis of cases reporting the 22
procedure codes that describe the open
drainage of subcutaneous tissue and
fascia in the September 2021 update of
the FY 2021 MedPAR file. We note that
within each MDC, the MS–DRGs are
divided into medical and surgical
categories. In general, surgical MS–
DRGs are further defined based on the
precise surgical procedure performed
while the medical MS–DRGs are further
defined based on the precise principal
diagnosis for which a patient was
admitted to the hospital. In Table 6P.1f
associated with this final rule, column
B displays the category of each MS–DRG
in MS–DRG GROUPER Version 39.1.
The letter M is used to designate a
medical MS–DRG and the letter P is
used to designate a surgical MS–DRG.
As shown in the table, when the
procedure codes that describe the open
drainage of the subcutaneous tissue and
fascia are reported, approximately 70%
of the MS–DRGs assigned are classified
as surgical MS–DRGs which indicates at
least one procedure code designated as
an O.R. procedure was also reported in
these cases. We refer the reader to the
ICD–10 MS–DRG Version 39.1
Definitions Manual (which is available
via the internet on the CMS website at:
https://www.cms.gov/Medicare/
Medicare-Feefor-Service-Payment/Acute
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
InpatientPPS/MS-DRGClassificationsand-Software) for complete
documentation of the GROUPER logic
for the listed MS–DRGs.
Our clinical advisors continue to state
that procedure codes that describe the
open drainage of subcutaneous tissue
and fascia do not reflect the technical
complexity or resource intensity in
comparison to other procedures that are
designated as O.R. procedures. They
also continue to state that the non-O.R.
designation of the 22 procedure codes
that describe the open drainage of
subcutaneous tissue and fascia as
finalized in the FY 2022 final rule better
reflects the associated technical
complexity and hospital resource use of
these procedures.
Therefore, after consideration of the
public comments we received, and for
the reasons discussed, we are not
making changes in this final rule to the
designation of the 22 codes that describe
the open drainage of subcutaneous
tissue and fascia listed in the previous
table.
13. Changes to the MS–DRG Diagnosis
Codes for FY 2023
a. Background of the CC List and the CC
Exclusions List
Under the IPPS MS–DRG
classification system, we have
developed a standard list of diagnoses
that are considered CCs. Historically, we
developed this list using physician
panels that classified each diagnosis
code based on whether the diagnosis,
when present as a secondary condition,
would be considered a substantial
complication or comorbidity. A
substantial complication or comorbidity
was defined as a condition that, because
of its presence with a specific principal
diagnosis, would cause an increase in
the length-of-stay by at least 1 day in at
least 75 percent of the patients.
However, depending on the principal
diagnosis of the patient, some diagnoses
on the basic list of complications and
comorbidities may be excluded if they
are closely related to the principal
diagnosis. In FY 2008, we evaluated
each diagnosis code to determine its
impact on resource use and to
determine the most appropriate CC
subclassification (NonCC, CC, or MCC)
assignment. We refer readers to sections
II.D.2. and 3. of the preamble of the FY
2008 IPPS final rule with comment
period for a discussion of the refinement
of CCs in relation to the MS–DRGs we
adopted for FY 2008 (72 FR 47152
through 47171).
PO 00000
Frm 00087
Fmt 4701
Sfmt 4700
48865
b. Overview of Comprehensive CC/MCC
Analysis
In the FY 2008 IPPS/LTCH PPS final
rule (72 FR 47159), we described our
process for establishing three different
levels of CC severity into which we
would subdivide the diagnosis codes.
The categorization of diagnoses as a
MCC, a CC, or a NonCC was
accomplished using an iterative
approach in which each diagnosis was
evaluated to determine the extent to
which its presence as a secondary
diagnosis resulted in increased hospital
resource use. We refer readers to the FY
2008 IPPS/LTCH PPS final rule (72 FR
47159) for a complete discussion of our
approach. Since the comprehensive
analysis was completed for FY 2008, we
have evaluated diagnosis codes
individually when assigning severity
levels to new codes and when receiving
requests to change the severity level of
specific diagnosis codes.
We noted in the FY 2020 IPPS/LTCH
PPS proposed rule (84 FR 19235
through 19246) that with the transition
to ICD–10–CM and the significant
changes that have occurred to diagnosis
codes since the FY 2008 review, we
believed it was necessary to conduct a
comprehensive analysis once again.
Based on this analysis, we proposed
changes to the severity level
designations for 1,492 ICD–10–CM
diagnosis codes and invited public
comments on those proposals. As
summarized in the FY 2020 IPPS/LTCH
PPS final rule, many commenters
expressed concern with the proposed
severity level designation changes
overall and recommended that CMS
conduct further analysis prior to
finalizing any proposals. After careful
consideration of the public comments
we received, as discussed further in the
FY 2020 final rule, we generally did not
finalize our proposed changes to the
severity designations for the ICD–10–
CM diagnosis codes, other than the
changes to the severity level
designations for the diagnosis codes in
category Z16– (Resistance to
antimicrobial drugs) from a NonCC to a
CC. We stated that postponing adoption
of the proposed comprehensive changes
in the severity level designations would
allow further opportunity to provide
additional background to the public on
the methodology utilized and clinical
rationale applied across diagnostic
categories to assist the public in its
review. We refer readers to the FY 2020
IPPS/LTCH PPS final rule (84 FR 42150
through 42152) for a complete
discussion of our response to public
comments regarding the proposed
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48866
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
severity level designation changes for
FY 2020.
As discussed in the FY 2021 IPPS/
LTCH PPS proposed rule (85 FR 32550),
to provide the public with more
information on the CC/MCC
comprehensive analysis discussed in
the FY 2020 IPPS/LTCH PPS proposed
and final rules, CMS hosted a listening
session on October 8, 2019. The
listening session included a review of
this methodology utilized to
mathematically measure the impact on
resource use. We refer readers to https://
www.cms.gov/Outreach-and-Education/
Outreach/OpenDoorForums/
Downloads/10082019Listing
SessionTrasncriptandQandAsand
AudioFile.zip for the transcript and
audio file of the listening session. We
also refer readers to https://
www.cms.gov/Medicare/MedicareFeefor-Service-Payment/
AcuteInpatientPPS/MS-DRGClassifications-and-Software.html for
the supplementary file containing the
mathematical data generated using
claims from the FY 2018 MedPAR file
describing the impact on resource use of
specific ICD–10–CM diagnosis codes
when reported as a secondary diagnosis
that was made available for the listening
session.
In the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58550 through 58554), we
discussed our plan to continue a
comprehensive CC/MCC analysis, using
a combination of mathematical analysis
of claims data as discussed in the FY
2020 IPPS/LTCH PPS proposed rule (84
FR 19235) and the application of nine
guiding principles and plan to present
the findings and proposals in future
rulemaking. The nine guiding principles
are as follows:
• Represents end of life/near death or
has reached an advanced stage
associated with systemic physiologic
decompensation and debility.
• Denotes organ system instability or
failure.
• Involves a chronic illness with
susceptibility to exacerbations or abrupt
decline.
• Serves as a marker for advanced
disease states across multiple different
comorbid conditions.
• Reflects systemic impact.
• Post-operative/post-procedure
condition/complication impacting
recovery.
• Typically requires higher level of
care (that is, intensive monitoring,
greater number of caregivers, additional
testing, intensive care unit care,
extended length of stay).
• Impedes patient cooperation or
management of care or both.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
• Recent (last 10 years) change in best
practice, or in practice guidelines and
review of the extent to which these
changes have led to concomitant
changes in expected resource use.
We refer readers to the FY 2021 IPPS/
LTCH PPS final rule for a complete
discussion of our response to public
comments regarding the nine guiding
principles.
In the FY 2022 IPPS/LTCH PPS
proposed rule (86 FR 25175 through
25180), as another interval step in our
comprehensive review of the severity
designations of ICD–10–CM diagnosis
codes, we requested public comments
on a potential change to the severity
level designations for ‘‘unspecified’’
ICD–10–CM diagnosis codes that we
were considering adopting for FY 2022.
Specifically, we noted we were
considering changing the severity level
designation of ‘‘unspecified’’ diagnosis
codes to a NonCC where there are other
codes available in that code subcategory
that further specify the anatomic site. As
summarized in the FY 2022 IPPS/LTCH
PPS final rule, many commenters
expressed concern with the potential
severity level designation changes
overall and recommended that CMS
delay any possible change to the
designation of these codes to give
hospitals and their physicians time to
prepare. After careful consideration of
the public comments we received, we
maintained the severity level
designation of the ‘‘unspecified’’
diagnosis codes currently designated as
a CC or MCC where there are other
codes available in that code subcategory
that further specify the anatomic site for
FY 2022. We refer readers to the FY
2022 IPPS/LTCH PPS final rule (86 FR
44916 through 44926) for a complete
discussion of our response to public
comments regarding the potential
severity level designation changes.
Instead, for FY 2022, we finalized a new
Medicare Code Editor (MCE) code edit
for ‘‘unspecified’’ codes, effective with
discharges on and after April 1, 2022.
We stated we believe finalizing this new
edit would provide additional time for
providers to be educated while not
affecting the payment the provider is
eligible to receive. We refer the reader
to section II.D.14.e. of the FY 2022 IPPS/
LTCH PPS final rule (86 FR 44940
through 44943) for the complete
discussion.
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule, as this new
edit became effective beginning with
discharges on and after April 1, 2022,
we stated our clinical advisors believed
it was appropriate to not propose to
change the designation of any ICD–10–
CM diagnosis codes, including the
PO 00000
Frm 00088
Fmt 4701
Sfmt 4700
unspecified codes that are subject to the
‘‘Unspecified Code’’ edit, as we
continue our comprehensive CC/MCC
analysis to allow interested parties the
time needed to become acclimated to
the new edit.
Comment: Commenters stated that
they appreciate and agree with CMS’
decision not to propose any further
changes to the designation of any ICD–
10–CM diagnosis codes, including the
unspecified codes, at this time. These
commenters recommended that CMS
allow one to two full years of data
availability before proposing any
additional changes to the designation of
any ICD–10–CM diagnosis code, given
that the new MCE edit was recently
implemented on April 1, 2022 and
stated that having one to two full years
of data will afford more meaningful
analysis in future rulemaking
considerations as part of the
comprehensive CC/MCC analysis.
Response: We appreciate the
commenters’ support. With respect to
the commenters who suggested allowing
one to two full years of data availability
before proposing any additional
changes, we appreciate the feedback and
will take these suggestions under
consideration.
We continue to solicit feedback
regarding the guiding principles, as well
as other possible ways we can
incorporate meaningful indicators of
clinical severity. We have made
available on the CMS website updated
impact on resource use files so that the
public can review the mathematical data
for the impact on resource use generated
using claims from the FY 2019 MedPAR
file, the FY 2020 MedPAR file and the
FY 2021 MedPAR files. The link to
these files is posted on the CMS website
at https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/MS-DRGClassifications-and-Software. When
providing additional feedback or
comments, we encourage the public to
provide a detailed explanation of how
applying a suggested concept or
principle would ensure that the severity
designation appropriately reflects
resource use for any diagnosis code. We
also continue to be interested in
receiving feedback on how we might
otherwise foster the documentation and
reporting of the most specific diagnosis
codes supported by the available
medical record documentation and
clinical knowledge of the patient’s
health condition to more accurately
reflect each health care encounter and
improve the reliability and validity of
the coded data. Interested parties can
submit any comments and
recommendations for FY 2024 by
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
October 20, 2022 via the new electronic
intake system, Medicare Electronic
Application Request Information
SystemTM (MEARISTM) at: https://
mearis.cms.gov/public/home.
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28177),
for new diagnosis codes approved for
FY 2023, consistent with our annual
process for designating a severity level
(MCC, CC or NonCC) for new diagnosis
codes, we first review the predecessor
code designation, followed by review
and consideration of other factors that
may be relevant to the severity level
designation, including the severity of
illness, treatment difficulty, complexity
of service and the resources utilized in
the diagnosis or treatment of the
condition. We noted that this process
does not automatically result in the new
diagnosis code having the same
designation as the predecessor code. We
refer the reader to section II.D.14 of this
final rule for the discussion of the
proposed changes to the ICD–10–CM
and ICD–10–PCS coding systems for FY
2023.
c. Requested Changes to Severity Levels
In the FY 2023 IPPS/LTCH PPS
proposed rule, we noted that we
received several requests to change the
severity level designations of specific
ICD–10–CM diagnosis codes, including
a request to analyze a subset of the
social determinants of health (SDOH)
diagnosis codes. We stated our clinical
advisors believed it was appropriate to
consider these requests in connection
with our continued comprehensive CC/
MCC analysis in future rulemaking,
rather than proposing to change the
designation of individual ICD–10–CM
diagnosis codes at this time. However,
we refer the reader to section II.D.13.d
for further discussion related to the
diagnosis codes describing social
determinants of health. As discussed in
the proposed rule and noted earlier in
this section, we plan to continue a
comprehensive CC/MCC analysis, using
a combination of mathematical analysis
of claims data and the application of
nine guiding principles. We will
consider these individual requests
received for changes to severity level
designations as we continue our
comprehensive CC/MCC analysis and
will provide more detail in future
rulemaking.
d. Request for Information on Social
Determinants of Health Diagnosis Codes
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28177
through 28181), we solicited public
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
comments on how the reporting of
diagnosis codes in categories Z55–Z65
may improve our ability to recognize
severity of illness, complexity of
service, and/or utilization of resources
under the MS–DRGs as described
further in this section. Consistent with
the Administration’s goal of advancing
health equity for all, including members
of historically underserved and underresourced communities, as described in
the President’s January 20, 2021
Executive Order 13985 on ‘‘Advancing
Racial Equity and Support for
Underserved Communities Through the
Federal Government,’’ 13 we stated we
were also interested in receiving
feedback on how we might otherwise
foster the documentation and reporting
of the diagnosis codes describing social
and economic circumstances to more
accurately reflect each health care
encounter and improve the reliability
and validity of the coded data including
in support of efforts to advance health
equity.
Social determinants of health (SDOH)
are the conditions in the environments
where people are born, live, learn, work,
play, worship, and age that affect a wide
range of health, functioning, and
quality-of-life outcomes and risks.14
These circumstances or determinants
influence an individual’s health status
and can contribute to wide health
disparities and inequities. While SDOH
do not describe current illnesses or
injuries at the individual level, they are
widely recognized as important
potential predictors of risk for
developing medical conditions like
heart disease, diabetes, and obesity. In
ICD–10–CM, the Z codes found in
Chapter 21 represent reasons for
encounters, and are provided for
occasions when circumstances other
than a disease, injury or external cause
classifiable to categories A00–Y89 are
recorded as ‘diagnoses’ or ‘problems’.
The subset of Z codes that describe the
social determinants of health are found
in categories Z55–Z65 (Persons with
potential health hazards related to
socioeconomic and psychosocial
circumstances). These codes describe a
range of issues related—but not
limited—to education and literacy,
employment, housing, ability to obtain
adequate amounts of food or safe
drinking water, and occupational
exposure to toxic agents, dust, or
13 Available at: https://www.federalregister.gov/
documents/2021/01/25/2021-01753/advancingracial-equity-and-support-for-underservedcommunities-through-the-federal-government.
14 Available at: https://health.gov/healthypeople/
objectives-and-data/social-determinants-health.
PO 00000
Frm 00089
Fmt 4701
Sfmt 4700
48867
radiation. We noted that effective
October 1, 2021, the Centers for Disease
Control and Prevention (CDC) National
Center for Health Statistics (NCHS)
added 11 new diagnosis codes
describing SDOH to provide additional
information regarding determinants
such as housing, food insecurity, and
transportation. In addition, section
I.B.14 of the FY 2022 ICD–10–CM
Official Guidelines for Coding and
Reporting was updated to provide
clarification of the term ‘‘clinician’’ in
reporting codes related to social
determinants of health and clarified the
documentation that can be utilized to
assign SDOH codes when included in
the official medical record. In this
context, ‘‘clinicians’’ other than the
patient’s provider refer to ‘‘healthcare
professionals permitted, based on
regulatory or accreditation requirements
or internal hospital policies, to
document in a patient’s official medical
record.’’ 15
As stated in the proposed rule,
reporting SDOH Z codes in inpatient
claims data could enhance quality
improvement activities, track factors
that influence people’s health, and
provide further insight into existing
health inequities.16 17 18 More routine
collection of SDOH Z codes could also
likely improve coordination within
hospitals to utilize the data across their
clinical care and discharge planning
teams, including with post-acute
partners. CMS has heard from interested
parties about a number of reasons for
why there may be less routine
documentation and reporting of SDOH
in the inpatient setting. First, Z codes
are not required to be reported by
inpatient hospitals and generally do not
affect MS–DRG assignment. Rather,
these codes are currently reported
voluntarily by providers when and if
supported in the medical record
15 Available at: https://ftp.cdc.gov/pub/Health_
Statistics/NCHS/Publications/ICD10CM/2022/
10cmguidelines-FY2022-April%201%20
update%202-3-22.pdf.
16 Maksut JL, Hodge C, Van CD, Razmi, A, & Khau
MT. Utilization of Z Codes for Social Determinants
of Health among Medicare Fee-For-Service
Beneficiaries, 2019. Office of Minority Health
(OMH) Data Highlight No. 24. Centers for Medicare
& Medicaid Services (CMS), Baltimore, MD, 2021.
17 Truong HP, Luke AA, Hammond G, Wadhera
RK, Reidhead M, Joynt Maddox KE. Utilization of
Social Determinants of Health ICD–10 Z-Codes
Among Hospitalized Patients in the United States,
2016–2017. Med Care. 2020;58(12):1037–1043.
doi:10.1097/MLR.0000000000001418.
18 Wark K, Cheung K, Wolter E, Avey JP. Engaging
stakeholders in integrating social determinants of
health into electronic health records: A scoping
review. International Journal of Circumpolar
Health. 2021 Jan 1;80(1):1943983.
E:\FR\FM\10AUR2.SGM
10AUR2
48868
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
documentation. As such, consistent
protocols may not be in place for
documenting and reporting. Second,
many of the circumstances captured
through SDOH Z codes are dependent
on the willingness of patients to discuss
personal social, economic, or
environmental conditions. Providers
may or may not be able to reliably
document certain circumstances,19 as a
result, in the medical records. There are
also questions of how bias can play into
screening for SDOH and how systemic
bias within the health care system can
play a role in this process.20 CMS has
also heard of the significant pressures
on provider time, and whether
providers have access to comprehensive
care and coordination teams, including
social workers, who may be more
appropriately skilled to assess certain
SDOH.
Given that SDOH diagnosis codes
describe economic and environmental
circumstances faced by patients and
often correlate with substantial variance
in health outcomes,21 more widely
adopted consistent documentation and
reporting in the inpatient setting could
better identify non-medical factors
affecting health and track progress
toward addressing them. Doing so could
also aid in work toward formulating
more comprehensive and actionable
policies to address health equity and
promote the highest quality, best-value
care for all beneficiaries.
As we discuss more fully later in this
section of this final rule, as we did in
the proposed rule, we believe reporting
of SDOH Z codes may also better
determine the resource utilization for
treating patients experiencing these
circumstances to help inform whether a
change to the severity designation of
these codes would be clinically
warranted as we continue a
comprehensive CC/MCC analysis, using
a combination of mathematical analysis
of claims data as discussed in the FY
2020 IPPS/LTCH PPS proposed rule (84
FR 19235) and the application of nine
guiding principles.
There are 96 diagnosis codes that
describe the social determinants of
19 Garg A, Boynton-Jarrett R, Dworkin PH.
Avoiding the Unintended Consequences of
Screening for Social Determinants of Health. JAMA.
2016;316(8):813–814. doi:10.1001/jama.2016.9282.
20 Egede LE, Walker RJ, Williams JS. Intersection
of Structural Racism, Social Determinants of Health,
and Implicit Bias With Emergency Physician
Admission Tendencies. JAMA Netw Open.
2021;4(9):e2126375. doi:10.1001/jamanetworkopen.
2021.26375.
21 Commission on Social Determinants of Health.
Closing the gap in a generation: health equity
through action on the social determinants of health:
final report of the commission on social
determinants of health. World Health Organization,
2008.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
health found in categories Z55–Z65.
These 96 diagnosis codes for which we
solicited comments as described in the
proposed rule are shown in Table 6P.5a
associated with the proposed rule
(which is available via the internet on
the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatient
PPS). We note we also made available
the data describing the impact on
resource use when reported as a
secondary diagnosis for all 96 ICD–10–
CM Z codes that describe the social
determinants of health from categories
Z55–Z65. These data are consistent with
data historically used to mathematically
measure impact on resource use for
secondary diagnoses, and the data
which we plan to use in combination
with application of the nine guiding
principles as we continue the
comprehensive CC/MCC analysis.
In Table 6P.5a associated with the
proposed rule, column C displays the
FY 2021 severity level designation for
these diagnosis codes in MS–DRG
GROUPER Version 38.1. Column D
displays CMS’s current FY 2022 severity
level designation in MS–DRG GROUPER
Version 39.1. Columns E–N show data
on the impact on resource use generated
using discharge claims from the
September 2021 update of the FY 2021
MedPAR file and MS–DRG GROUPER
Version 39.1. For further information on
the data on the impact on resource use
as displayed in Columns E–N, we refer
readers to the FY 2008 IPPS/LTCH PPS
final rule (72 FR 47159) for a complete
discussion of the methodology utilized
to mathematically measure the impact
on resource use. Also, as discussed in
the FY 2021 IPPS/LTCH PPS proposed
rule (85 FR 32550), to provide the
public with more information on the
CC/MCC comprehensive analysis
discussed in the FY 2020 IPPS/LTCH
PPS proposed and final rules, CMS
hosted a listening session on October 8,
2019. The listening session included a
review of this methodology utilized to
mathematically measure the impact on
resource use. We refer readers to https://
www.cms.gov/Outreach-and-Education/
Outreach/OpenDoorForums/
Downloads/10082019ListingSession
TrasncriptandQandAsandAudioFile.zip
for the transcript and audio file of the
listening session. We also refer readers
to https://www.cms.gov/Medicare/
MedicareFee-for-Service-Payment/Acute
InpatientPPS/MS-DRG-Classificationsand-Software.html for the
supplementary file containing the data
describing the impact on resource use of
specific ICD–10–CM diagnosis codes
when reported as a secondary diagnosis
PO 00000
Frm 00090
Fmt 4701
Sfmt 4700
that was made available for the listening
session. We note that the supplementary
file that was made available for the
listening session contains the
mathematical data for the impact on
resource use generated using claims
from the FY 2018 MedPAR file. We have
also made available on the CMS website
updated impact on resource use files so
that the public can review the
mathematical data for the impact on
resource use generated using claims
from the FY 2019 MedPAR file, FY 2020
MedPAR file and the FY 2021 MedPAR
files.
In the FY 2008 IPPS/LTCH PPS final
rule (72 FR 47159), we described the
categorization of diagnoses as an MCC,
a CC, or a NonCC, accomplished using
an iterative approach in which each
diagnosis was evaluated to determine
the extent to which its presence as a
secondary diagnosis resulted in
increased hospital resource use. As
such, the designation of CC or MCC is
intended to account for the increased
resources required to address a
condition as a secondary diagnosis. In
Version 39.1, the 96 diagnosis codes
that describe the social determinants of
health from categories Z55–Z65 have a
severity designation of NonCC.
In the proposed rule, we noted that if
SDOH Z codes are not consistently
reported in inpatient claims data, our
methodology utilized to mathematically
measure the impact on resource use, as
described previously, may not
adequately reflect what additional
resources were expended by the
hospital to address these SDOH
circumstances in terms of requiring
clinical evaluation, extended length of
hospital stay, increased nursing care or
monitoring or both, and comprehensive
discharge planning. In the proposed
rule, we sought public comment on
whether CMS should consider requiring
more robust documentation and claims
data reporting to inform the impact on
resource use these determinants have on
caring for patients affected by these
circumstances in an inpatient setting
and inform our decision-making in a
future year in determining the most
appropriate CC subclass (NonCC, CC, or
MCC) assignment for each SDOH Z code
as a secondary diagnosis. We also
sought public comment on developing
protocols to standardize the screening
for SDOH for all patients, and then
consistently document and report such
codes and on whether such protocols
should vary based on certain factors,
such as hospital size and type. For
instance, we noted in the proposed rule
that we recognized that hospitals have
different mixes of patients and volume
of patients, and as such, may have
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
different staffing resources to devote to
proper documentation and coding of
SDOH. In particular, we stated we were
interested in hearing the perspectives of
different sized hospitals in both urban
and rural settings, and hospitals
disproportionately serving members of
historically underserved and underresourced communities in regard to
their experience with reporting of
SDOH. We also stated we were
additionally interested in learning how
reporting SDOH Z codes may be used to
inform community health need
assessment activities required by nonprofit hospitals.
In the proposed rule, we also
recognized that there is a potential for
different uses and complexity in
appropriately determining and reporting
the full range of Z codes. For instance,
certain code categories like Z62
(Problems related to upbringing) and
Z63 (Other problems related to principal
support group, including family
circumstances) may require specialized
clinical training to diagnose and
document, which may not be the
primary purpose of the inpatient
admission. Category Z57 describes
occupational exposure to risk factors,
which also may not be apparent in most
inpatient admissions and would rely
upon the patient providing this
information voluntarily. Category Z60
(Problems related to social environment)
also describes problems of adjustment to
life-cycle transitions, which also may or
may not be readily apparent or
discussed by the patient in relation to
the inpatient admission.
Thus, we sought comment on which
specific SDOH Z codes were most likely
to influence (that is, increase) hospital
resource utilization related to inpatient
care, including any supporting
information that correlates inpatient
hospital resource use to specific SDOH
Z codes. In the proposed rule, we stated
CMS believed a potential starting point
for discussion was consideration of the
SDOH Z diagnosis codes describing
homelessness. Homelessness can be
reasonably expected to have an impact
on hospital utilization.22 Healthcare
needs for patients experiencing
homelessness may be associated with
increased resource utilization compared
to other patients due to difficulty
finding discharge destinations to meet
the patient’s multifaceted needs which
can result in longer inpatient stays and
can have financial impacts for
22 Koh HK, O’Connell JJ. Improving Health Care
for Homeless People. JAMA. 2016;316(24):2586–
2587. doi:10.1001/jama.2016.18760.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
hospitals.23 Longer hospital stays for
these patients 24 can also be associated
with increased costs because patients
experiencing homelessness are less able
to access care at early stages of illness,
and also may be exposed to
communicable disease and harsh
climate conditions, resulting in more
severe and complex symptoms by the
time they are admitted to hospitals,
potentially leading to worse health
outcomes. We stated in the proposed
rule that patients experiencing
homelessness can also be
disproportionately affected by mental
health diagnoses and issues with
substance use disorders. In addition,
patients experiencing homelessness may
have limited or no access to prescription
medicines or over-the-counter
medicines, including adequate locations
to store medications away from the heat
or cold,25 and studies have shown
difficulties adhering to medication
regimens among persons experiencing
homeless.26 Patients experiencing
homelessness may also face challenges
in accessing transplants and clinicians
may defer care because of the uncertain
post-acute discharge.
To further examine the diagnosis
codes that describe SDOH, in the
proposed rule we reviewed the data on
the impact on resource use for diagnosis
code Z59.0 (Homelessness) when
reported as a secondary diagnosis to
facilitate discussion for the purposes of
the comment solicitation. We noted that
prior to FY 2022, homelessness was one
of the more frequently reported codes
that describe social determinants of
health. We also noted that effective FY
2022, the subcategory was expanded
and now includes codes Z59.00
(Homelessness, unspecified), Z59.01
23 Canham SL, Custodio K, Mauboules C, Good C,
Bosma H. Health and Psychosocial Needs of Older
Adults Who Are Experiencing Homelessness
Following Hospital Discharge. Gerontologist. 2020
May 15;60(4):715–724. doi: 10.1093/geront/gnz078.
PMID: 31228238. https://pubmed.ncbi.nlm.nih.gov/
31228238/.
24 Hwang SW, Weaver J, Aubry T. Hospital costs
and length of stay among homeless patients
admitted to medical, surgical, and psychiatric
services. Med Care. 2011;49:350–354. https://
journals.lww.com/lww-medicalcare/Fulltext/2019/
01000/Trends,_Causes,_and_Outcomes_of_
Hospitalizations.4.aspx.
25 Sun R (AHRQ), Karaca Z (AHRQ), Wong HS
(AHRQ). Characteristics of Homeless Individuals
Using Emergency Department Services in 2014.
HCUP Statistical Brief #229. October 2017. Agency
for Healthcare Research and Quality, Rockville, MD.
www.hcup-us.ahrq.gov/reports/statbriefs/sb229Homeless-ED-Visits-2014.pdf.
26 Coe, Antoinette B. Coe et al. ‘‘Medication
Adherence Challenges Among Patients
Experiencing Homelessness in a Behavioral Health
Clinic. https://journals.lww.com/lww-medicalcare/
Fulltext/2019/01000/Trends,_Causes,_and_
Outcomes_of_Hospitalizations.4.aspx.
PO 00000
Frm 00091
Fmt 4701
Sfmt 4700
48869
(Sheltered homelessness), and code
Z59.02 (Unsheltered homelessness).
In the FY 2020 IPPS/LTCH PPS
proposed rule (84 FR 19243 through
19244), as part of our proposal to change
the severity level designations for 1,492
ICD–10–CM diagnosis codes, we
proposed to change the severity level
designation of code Z59.0
(Homelessness) from NonCC to CC. We
stated that because the C1 value (C1 =
1.5964) in the table was generally close
to 2, the data suggested that when
reported as a secondary diagnosis, the
resources involved in caring for a
patient experiencing homelessness
supported increasing the severity level
from a NonCC to a CC. In the FY 2020
IPPS/LTCH PPS proposed rule, we also
stated our clinical advisors reviewed
these data and believed the resources
involved in caring for these patients are
more aligned with a CC. As noted in
section II.D.13.b of the proposed rule
and this final rule, many commenters
expressed concern with the proposed
severity level designation changes
overall and consequently we generally
did not finalize our proposed changes to
the severity designations for the 1,492
ICD–10–CM diagnosis codes, at that
time. However, the proposal to change
the severity designation of code Z59.0
specifically did receive mostly
supportive comments. We stated in the
proposed rule that many commenters
stated that a patient experiencing
homelessness requires significant
coordination of social services along
with their health care. Another
commenter also recommended that CMS
expand the change in designation to all
the codes in category Z59, not just code
Z59.0. Another commenter, while
indicating their support of the proposal,
noted that it is unclear that the status/
condition would result in increased
hospital resource use.
As discussed in the proposed rule,
our proposal in FY 2020 was based on
the data for the impact on resource use
generated using claims from the FY
2018 MedPAR file. The following table
reflects the impact on resource use data
generated using claims from the FY
2019 MedPAR file, FY 2020 MedPAR
file and the FY 2021 MedPAR file,
respectively, for the diagnosis code that
describes homelessness as a NonCC. We
noted there is currently no data for
codes Z59.01 (Sheltered homelessness)
and code Z59.02 (Unsheltered
homelessness) as these codes became
effective on October 1, 2021. Again, we
refer readers to the FY 2008 IPPS/LTCH
PPS final rule (72 FR 47159) for a
complete discussion of our historical
approach to mathematically evaluate the
extent to which the presence of an ICD–
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
10–CM code as a secondary diagnosis
resulted in increased hospital resource
khammond on DSKJM1Z7X2PROD with RULES2
FY
2019
2020
2021
ICD-10-CM
Code
Z59.0
Z59.0
Z59.00
Description
Homelessness
Homelessness
Homelessness, unspecified
As shown in the table, we examined
data for the diagnosis code(s) that
describe homelessness as a NonCC in
FY 2019 through FY 2021. When
examining diagnosis code Z59.0
(Homelessness), the value in column C1
is closer to 2.0 than to 1.0 in FY 2019
and FY 2020, though we noted that we
did not use FY 2020 data for rate setting
purposes in light of impacts related to
the PHE for COVID–19 as described in
the FY 2022 IPPS/LTCH PPS final rule
(86 FR 44778). The data suggests that
when homelessness is reported as a
secondary diagnosis, the resources
involved in caring for these patients are
more aligned with a CC than a NonCC
or an MCC, as explained in the FY 2008
IPPS/LTCH PPS final rule (72 FR
47159). However, in FY 2021, the C1
value is generally closer to 1, which
suggest the resources involved in caring
for patients experiencing homelessness
are more aligned with a NonCC severity
level than a CC or an MCC severity
level. We also noted fluctuations in the
C1 values year to year. We stated we
were uncertain if the data from FY 2021,
in particular, reflect fluctuations that
may be a result of the public health
emergency or even reduced
hospitalizations of certain conditions.
We also stated we were uncertain if
homelessness may be underreported
when there is not an available field on
the claim when other diagnoses are
reported instead. We sought public
comment on these possibilities,
particularly to inform our
understanding of the trend of the C1
value.
As we have stated in prior
rulemaking, these mathematical
constructs are used in conjunction with
the judgment of our clinical advisors to
classify each secondary diagnosis
reviewed. We presented these data to
highlight that the resources expended in
caring for patients reported to be
affected by a SDOH such as
homelessness during an inpatient
hospitalization may not be consistently
expressed in the inpatient claims data
and to demonstrate how reporting the
SDOH Z codes could more accurately
reflect the health care encounter and
VerDate Sep<11>2014
00:20 Aug 10, 2022
use, and the explanation of the columns
in the table.
Jkt 256001
Total
Count
43,405
44,609
37,919
Cntl
7,022
6,393
5,225
Cl
1.6723
1.8374
1.4299
improve the reliability and validity of
the coded data.
In summary, we stated we would
appreciate public comment on these
issues, including on the following
questions:
• How the reporting of certain Z
codes—and if so, which Z codes 27—
may improve our ability to recognize
severity of illness, complexity of
service, and utilization of resources
under the MS–DRGs?
• Whether CMS should require the
reporting of certain Z codes—and if so,
which ones—to be reported on hospital
inpatient claims to strengthen data
analysis?
• The additional provider burden and
potential benefits of documenting and
reporting of certain Z codes, including
potential benefits to beneficiaries.
• Whether codes in category Z59
(Homelessness) have been
underreported and if so, why? In
particular, we stated we were interested
in hearing the perspectives of large
urban hospitals, rural hospitals, and
other hospital types in regard to their
experience. We also sought comments
on how factors such as hospital size and
type might impact a hospital’s ability to
develop standardized consistent
protocols to better screen, document
and report homelessness.
As discussed in the proposed rule, we
stated that the comments we receive on
these issues may also be informative as
we evaluate whether to develop a
proposal in future rulemaking to change
the severity level designation of the
diagnosis codes describing
homelessness from NonCC to CC and
whether other SDOH, as described by Z
codes, are also appropriate candidates to
be proposed for designation as CCs.
We noted that examining the severity
level designation of diagnosis codes is
just one area to possibly support
documentation and reporting of SDOH
in the inpatient setting. We stated we
were also interested in ideas from the
public on how the MS–DRG
classification can be utilized in agency
wide efforts to advance health equity,
27 https://www.cms.gov/files/document/zcodesinfographic.pdf.
PO 00000
Frm 00092
Fmt 4701
Sfmt 4700
Cnt2
22,336
22,416
18,158
C2
2.2963
2.1964
2.0823
Cnt3
14,047
15,800
14,536
C3
3.1374
3.0879
3.0710
expand access, drive high-quality,
person-centered care, and promote
affordability and sustainability in the
Medicare program. Specifically, we
invited public comment on ways the
MS–DRG classification can be useful in
addressing the challenges of defining
and collecting accurate and
standardized self-identified
socioeconomic information for the
purposes of reporting, measure
stratification, and other data collection
efforts. We stated we were interested in
learning more about the potential
benefits and challenges associated with
the collection of SDOH data in the
inpatient setting. Feedback on the
limitations and barriers providers could
experience as they consider more robust
documentation and reporting would
also help inform our development of
appropriately tailored efforts that
address and mitigate barriers for all
hospital types across communities and
patient mixes. We stated we would take
commenters’ feedback into
consideration in future policy
development.
In this FY 2023 IPPS/LTCH PPS final
rule, we present a summation of the
comments we received in response to
our request for information on SDOH
diagnosis codes, including how the
reporting of SDOH diagnosis codes may
improve our ability to recognize severity
of illness, complexity of service, and/or
utilization of resources under the MS–
DRGs, as well as how we might
otherwise foster the documentation and
reporting of the diagnosis codes
describing social and economic
circumstances to more accurately reflect
each health care encounter and improve
the reliability and validity of the coded
data, including in support of efforts to
advance health equity. We thank
commenters for sharing their views and
their willingness to support CMS in
these efforts.
Comment: Many commenters
applauded CMS’ efforts to encourage
documentation and reporting of SDOH
diagnosis codes given the impact that
social risks can have on health
outcomes. These commenters stated that
it is critical that physicians, other health
care professionals, and facilities
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.058
48870
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
recognize the impact SDOH have on the
health of their patients. Commenters
stated that they agree that better
reporting of these SDOH Z codes
through inpatient claims could enhance
coordination within hospitals across
clinical care teams and discharge
planning, and with post-acute care
providers. A commenter stated that
SDOH data can be extremely valuable
and powerful tools to improve
healthcare, and stated that they were
confident that CMS’ encouragement of
the use of this data would lead to better
healthcare for our country.
Some commenters stated that while
the documentation and reporting of
SDOH diagnosis codes is important to
address healthcare inequities, the
collection of this data may place
significant burden on facilities and
providers and have tremendous
operational and technology impacts.
Commenters stated that hospitals have
demonstrated significant variability in
screening capabilities and referral
practices, and inpatient settings require
additional time to develop screening
protocols and ensure that screening
results are documented in a place where
they can be captured for claims. Other
commenters stated assigning codes for
SDOH can be a time-consuming and
labor-intensive process, as many
electronic health records (EHRs) do not
have easy pathways to add a Z code to
the problem or diagnosis list. Other
commenters stated that one of the major
challenges to providers is ensuring that
SDOH information documented in the
EHR and reported on the claim is
accurate as patients’ circumstances are
ever changing. A commenter stated that
it is not feasible for hospitals to screen
for every SDOH due to the time and
resources involved for both patients and
providers and suggested that rather than
require this process be repeated with
each encounter, CMS should permit
SDOH information to carry forward
across encounters until new
documentation supports removal or
revision to the initial SDOH diagnosis
codes to minimize the administrative
burden. Commenters also stated that the
challenge of increased documentation
reviews by coding staff would be further
exacerbated by staffing shortages within
the industry, as well as coding
productivity standards. A few
commenters stated for rural hospitals,
bandwidth is already low due to
workforce shortages and heavy
caseloads. These commenters stated that
adding any screening and
documentation processes for SDOH, on
top of existing workloads, may require
more than a physician or nurse and
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
instead may require engaging a staff
such as social workers or psychologists
who may not be standard members of
care teams at all rural hospitals.
Many commenters stated there was a
lack of standard, nationally accepted
definitions of the SDOH Z codes and
that there are potential gaps that may
come with the use of, and reporting
related to SDOH Z codes. Other
commenters stated that SDOH Z codes
are informative but some descriptions
lack specificity and may be too broad to
distinctly capture enough detail around
the type of care that the patient needs
relative to their diagnosis and their
SDOH challenges. Commenters also
identified the lack of national data and
exchange standards for capture of the
SDOH Z codes as an additional barrier.
Commenters stated that while fully
supporting efforts to improve and
increase the collection of SDOH data,
they believed that other options exist
that would make it feasible for hospitals
of all sizes and types to consistently
collect data in a standardized manner
without creating undue burden and
suggested that CMS consider developing
a broader strategy for collecting SDOH
data. A commenter specifically
suggested that CMS coordinate with
states, which are often requiring their
own assessments to identify social risk
and needs, to reduce burden. Another
commenter stated that they believed
that the creation of a new Hierarchical
Condition Category for SDOH Z codes
could help improve documentation
efforts since, according to this
commenter, organizations that treat
these high-risk patients are reimbursed
at higher rates than those patients who
are not grouped into these HCCs.
Commenters recommended that CMS
consider reimbursement incentives for
documenting and reporting of SDOH Z
codes to help health care providers
build and sustain systemic screening
and documentation, which will
ultimately lead to better health for
patients. Many commenters stated that
they agree that codes in category Z59
(Homelessness) have been
underreported and that increasing the
severity level of the codes that describe
homelessness from a NonCC to a CC
could prompt more rigorous
documentation and reporting.
Commenters stated that they believe
that homelessness involves a level of
care in line with diagnoses currently
designated as CCs. Some commenters
stated that patients experiencing
homelessness can often increase
inpatient costs by creating discharge
disposition challenges that lead to an
extended length of stay. A few
commenters noted that in their
PO 00000
Frm 00093
Fmt 4701
Sfmt 4700
48871
experience, extended lengths of stay
were particularly high for patients
experiencing homelessness who
underwent surgery. Another commenter
stated that based on their own analysis,
homelessness has an effect on resource
utilization on par with other diagnoses
currently designated as MCCs but stated
elevation to a CC is the most reasonable
first step to help drive the reporting of
these SDOH Z codes, and help drive
subsequent, meaningful evaluation of
outcomes.
Commenters encouraged CMS to
examine other SDOH Z codes that
describe circumstances such as food
insecurity, lack of adequate food and
drinking water, extreme poverty, lack of
transportation and unemployment, to
determine the hospital resource
utilization related to addressing these
factors and to analyze whether these
SDOH Z codes should be considered for
designation as CCs as well. Some
commenters also pointed to conditions
outside of the SDOH Z codes such as:
medical debt, malnutrition, elder abuse
and neglect, underdosing of medication,
personal history of falling and awaiting
organ transplant status as examples of
other areas where fostering better
documentation and reporting could
improve health outcomes.
Other commenters expressed concern
and stated that they believed that while
some SDOH diagnoses could have some
impact for MS–DRG assignment due to
additional efforts needed around
discharge planning, generally SDOH
diagnoses should have limited impact
on severity of illness. Rather, according
to these commenters, the impact is more
important for risk adjustment for
population-based initiatives, such as a
readmissions program. A commenter
stated that simply elevating SDOH Zcodes to CCs and marginally increasing
reimbursement will be inadequate to
meaningfully drive CMS’ stated equity
mission. Another commenter noted that
in some cases, patients experiencing
circumstances described by SDOH Z
codes may require social services
support to address a need postdischarge, but the complexity of the
inpatient clinical services is not
affected. A commenter, while
supportive of the consideration of the
change in designation, expressed
concern that increasing the severity
level of the codes that describe
homelessness from a NonCC to a CC
could potentially lead to fraudulent or
abusive coding practices in order to
raise the payment rate for an encounter.
Another commenter recommended that
safeguards be put in place to disallow
oversight agencies (such as Recovery
Audit Contractors (RAC) and third-party
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48872
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
payer validations) from challenging
MS–DRG assignment, and instead honor
the reporting of the code when
supported by documentation, especially
in instances where homelessness might
be the only complication or comorbidity
coded.
While commending CMS’ efforts,
many commenters cautioned that
mandating the reporting of SDOH Z
codes could necessitate making changes
to the institutional claim form.
Currently, only 25 diagnoses are
captured on the electronic claim form.
Commenters noted that documenting
and reporting the social and economic
circumstances patients may be
experiencing may require a substantial
number of SDOH Z codes, and stated
that this could lead to the crowding out
of other diagnosis codes that also need
to be captured on the claim form such
as codes for medical diagnoses,
comorbidities, Hierarchical Condition
Category (HCC) coding, Hospital
Acquired Conditions (HAC), and patient
safety indicators (PSI) due to limited
space.
Several commenters expressed
concern and stated that they did not
believe that CMS proposed a clear,
compelling, or significant benefit to
patients as a result of collecting this
data. These commenters cautioned
against requiring hospitals to implement
the collection of sensitive information
for the purposes of analysis, and
asserted that CMS will be placing
hospitals in the precarious position of
asking sensitive and intimate social
questions, while often not having
solutions to mitigate or eliminate these
risks, as they stated the documentation
of social risks does not in and of itself
improve health outcomes. A commenter
stated that studies have shown that
many providers are wary of screening
for social needs, if they believe they do
not also have the ability to make
referrals or to connect patients to
resources to address their needs. Other
commenters expressed concern and
stated it is counterproductive for
hospitals to collect SDOH data without
having resources and pathways in place
to offer help. A few commenters stated
that by requiring medical facilities to
report this data, CMS is diverting
resources and time from patient care
and stated that CMS should not be
pursing an initiative that is meant to
collect data on non-medical
information. A commenter stated that
although the collection of SDOH
information can occur during inpatient
visits, documentation and reporting of
this data may be actually best suited to
outpatient office visits, where providers
may have a greater opportunity to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
interact with their patients and the
ability to consider more proactive
approaches to help address their social
needs.
Many other commenters also
expressed concern and stated that while
SDOH information can be useful for
administrative use and payment
adjustment, information about an
individual’s social risk and needs has
been shown to be sensitive, and
individuals are often hesitant to disclose
this information for fear of bias, misuse,
or discrimination. Commenters stated
patients may not see the relevance of
providing information to their providers
related to SDOH that may not be
directly applicable to why they are
seeking care. These commenters stated
that there are significant concerns from
physicians, other providers, and
patients about ‘‘medicalizing’’ SDOH in
the electronic health record and stated
mechanisms must be established to
shield this sensitive information on
certain forms, charts, health records,
and discharge papers. Commenters
noted that when SDOH Z codes are
entered via an EHR or other form of
collection, those results show up on the
patient’s after-visit summary, which
may be concerning for patients.
Commenters also expressed concern
that SDOH Z codes may ‘‘follow’’ a
patient for too many years and cause
potential discrimination, bias, or other
misunderstandings in the future.
Commenters stated that hospitals must
be equipped with tools to communicate
the context of SDOH Z codes with
patients at the point of screening or selfreporting so that patients understand
the rationale for data collection and how
it can help address their needs. Several
commenters stated that CMS should
also put in place Conditions of
Participation requiring hospitals to train
their staff on how this information can
and cannot be used to prevent
information being used in
discriminatory pricing, care, or other
purposes.
Many commenters stated that the
most immediate and important action
CMS could take to increase the use of
SDOH Z codes is to finalize the
evidence-based ‘‘Screening for Social
Drivers of Health’’ and ‘‘Screen Positive
Rate for Social Drivers of Health’’
measures proposed to be adopted in the
Hospital Inpatient Quality Reporting
(IQR) Program. These commenters
stated that these measures create an
opportunity to collect inpatient SDOH
data at a scale that could significantly
improve MS–DRGs’ precision and
ability to recognize severity and
complexity of service and utilization of
resources. Many commenters stated that
PO 00000
Frm 00094
Fmt 4701
Sfmt 4700
absent these measures and associated
data, SDOH Z codes will continue to be
underreported and unreliable. We refer
the reader to section IX.E.5.b of the
preamble of the proposed rule and this
final rule for further discussion
regarding new measures for the Hospital
IQR Program measure set. These
commenters urged CMS to start with an
incremental approach in requiring the
reporting of SDOH Z codes and
suggested that reporting should be
optional or voluntary for at least two–
three years to allow providers and CMS
to gain experience in reporting and
collecting this data. If the reporting of
the SDOH Z codes becomes mandatory,
these commenters recommended that
the requirement start with the subset of
SDOH Z codes that directly align with
the social needs identified in the five
core domains of the proposed measures.
Response: We again thank
commenters for sharing their views and
their willingness to support CMS in
these efforts. We will take the
commenters’ feedback into
consideration in future policy
development.
e. Additions and Deletions to the
Diagnosis Code Severity Levels for FY
2023
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28181) we noted
the following tables identify the
proposed additions and deletions to the
diagnosis code MCC severity levels list
and the proposed additions and
deletions to the diagnosis code CC
severity levels list for FY 2023 and are
available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/
Table 6I.1—Proposed Additions to the
MCC List—FY 2023;
Table 6I.2—Proposed Deletions to the
MCC List—FY 2023;
Table 6J.1—Proposed Additions to the
CC List—FY 2023; and
Table 6J.2—Proposed Deletions to the
CC List—FY 2023.
Comment: Commenters agreed with
the proposed additions and deletions to
the MCC and CC lists as shown in tables
6I.1, 6I.2, 6J.1, and 6J.2 associated with
the proposed rule.
Response: We appreciate the
commenters’ support.
The following tables associated with
this final rule reflect the finalized
severity levels under Version 40 of the
ICD–10 MS–DRGs for FY 2023 and are
available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS; Table 6I.
—Complete MCC List—FY 2023; Table
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
6I.1—Additions to the MCC List—FY
2023; Table 6I.2—Deletions to the MCC
List—FY 2022; Table 6J.—Complete CC
List—FY 2023; Table 6J.1—Additions to
the CC List—FY 2023; and Table 6J.2—
Deletions to the CC List—FY 2023.
f. CC Exclusions List for FY 2023
In the September 1, 1987 final notice
(52 FR 33143) concerning changes to the
DRG classification system, we modified
the GROUPER logic so that certain
diagnoses included on the standard list
of CCs would not be considered valid
CCs in combination with a particular
principal diagnosis. We created the CC
Exclusions List for the following
reasons: (1) to preclude coding of CCs
for closely related conditions; (2) to
preclude duplicative or inconsistent
coding from being treated as CCs; and
(3) to ensure that cases are appropriately
classified between the complicated and
uncomplicated DRGs in a pair.
In the May 19, 1987 proposed notice
(52 FR 18877) and the September 1,
1987 final notice (52 FR 33154), we
explained that the excluded secondary
diagnoses were established using the
following five principles:
• Chronic and acute manifestations of
the same condition should not be
considered CCs for one another.
• Specific and nonspecific (that is,
not otherwise specified (NOS))
diagnosis codes for the same condition
should not be considered CCs for one
another.
• Codes for the same condition that
cannot coexist, such as partial/total,
unilateral/bilateral, obstructed/
unobstructed, and benign/malignant,
should not be considered CCs for one
another.
• Codes for the same condition in
anatomically proximal sites should not
be considered CCs for one another.
• Closely related conditions should
not be considered CCs for one another.
The creation of the CC Exclusions List
was a major project involving hundreds
of codes. We have continued to review
the remaining CCs to identify additional
exclusions and to remove diagnoses
from the master list that have been
shown not to meet the definition of a
CC. We refer readers to the FY 2014
IPPS/LTCH PPS final rule (78 FR 50541
through 50544) for detailed information
regarding revisions that were made to
the CC and CC Exclusion Lists under the
ICD–9–CM MS–DRGs.
The ICD–10 MS–DRGs Version 39.1
CC Exclusion List is included as
Appendix C in the ICD–10 MS–DRG
Definitions Manual, which is available
via the internet on the CMS website at:
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
AcuteInpatientPPS/, and
includes two lists identified as Part 1
and Part 2. Part 1 is the list of all
diagnosis codes that are defined as a CC
or MCC when reported as a secondary
diagnosis. For all diagnosis codes on the
list, a link is provided to a collection of
diagnosis codes which, when reported
as the principal diagnosis, would cause
the CC or MCC diagnosis to be
considered as a NonCC. Part 2 is the list
of diagnosis codes designated as a MCC
only for patients discharged alive;
otherwise, they are assigned as a
NonCC.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we proposed additional
changes to the ICD–10 MS–DRGs
Version 40 CC Exclusion List based on
the diagnosis and procedure code
updates as discussed in section II.D.14.
of the proposed rule and set forth in
Tables 6G.1, 6G.2, 6H.1, and 6H.2
associated with the proposed rule and
available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS.
As discussed in section II.D.14 of the
preamble of this final rule, we are
finalizing, without modification, the
proposed assignments and designations
for the diagnosis codes after
consideration of the public comments
received. Therefore, the finalized CC
Exclusions List as displayed in Tables
6G.1, 6G.2, 6H.1, 6H.2, and 6K,
associated with this final rule reflect the
severity levels under V40 of the ICD–10
MS–DRGs. We have developed Table
6G.1.—Secondary Diagnosis Order
Additions to the CC Exclusions List—
FY 2023; Table 6G.2.—Principal
Diagnosis Order Additions to the CC
Exclusions List—FY 2023; Table 6H.1.—
Secondary Diagnosis Order Deletions to
the CC Exclusions List—FY 2023; and
Table 6H.2.—Principal Diagnosis Order
Deletions to the CC Exclusions List—FY
2023; and Table 6K. Complete List of CC
Exclusions—FY 2023.
For Table 6G.1, each secondary
diagnosis code finalized for addition to
the CC Exclusion List is shown with an
asterisk and the principal diagnoses
finalized to exclude the secondary
diagnosis code are provided in the
indented column immediately following
it. For Table 6G.2, each of the principal
diagnosis codes for which there is a CC
exclusion is shown with an asterisk and
the conditions finalized for addition to
the CC Exclusion List that will not
count as a CC are provided in an
indented column immediately following
the affected principal diagnosis. For
Table 6H.1, each secondary diagnosis
code finalized for deletion from the CC
Exclusion List is shown with an asterisk
PO 00000
Frm 00095
Fmt 4701
Sfmt 4700
48873
followed by the principal diagnosis
codes that currently exclude it. For
Table 6H.2, each of the principal
diagnosis codes is shown with an
asterisk and the finalized deletions to
the CC Exclusions List are provided in
an indented column immediately
following the affected principal
diagnosis. Tables 6G.1, 6G.2, 6H.1, and
6H.2 associated with this final rule are
available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/
index.html.
The ICD–10 MS–DRGs Version 40 CC
Exclusion List is included as Appendix
C of the Definitions Manual (available in
two formats; text and HTML). The
manuals are available via the internet on
the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS/MS-DRGClassifications-and-Software and each
format includes two lists identified as
Part 1 and Part 2. Part 1 is the list of all
diagnosis codes that are defined as a CC
or MCC when reported as a secondary
diagnosis. For all diagnosis codes on the
list, a link (HTML version) is provided
to a collection of diagnosis codes which,
when used as the principal diagnosis,
would cause the CC or MCC diagnosis
to be considered as a NonCC. Part 2 is
the list of diagnosis codes designated as
a MCC only for patients discharged
alive; otherwise, they are assigned as a
NonCC.
14. Changes to the ICD–10–CM and
ICD–10–PCS Coding Systems
To identify new, revised and deleted
diagnosis and procedure codes, for FY
2023, we have developed Table 6A.—
New Diagnosis Codes, Table 6B.—New
Procedure Codes, Table 6C.—Invalid
Diagnosis Codes, Table 6D.—Invalid
Procedure Codes, and Table 6E.—
Revised Diagnosis Code Titles for this
final rule.
These tables are not published in the
Addendum to the proposed rule or final
rule, but are available via the internet on
the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS/ as
described in section VI. of the
Addendum to this final rule. As
discussed in section II.D.17. of the
preamble of the proposed rule and this
final rule, the code titles are adopted as
part of the ICD–10 Coordination and
Maintenance Committee meeting
process. Therefore, although we publish
the code titles in the IPPS proposed and
final rules, they are not subject to
comment in the proposed or final rules.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48874
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
We are finalizing the MDC and MS–
DRG assignments for the new diagnosis
codes and procedure codes as set forth
in Table 6A.—New Diagnosis Codes and
Table 6B.—New Procedure Codes. In
addition, the finalized severity level
designations for the new diagnosis
codes are set forth in Table 6A. and the
finalized O.R. status for the new
procedure codes are set forth in Table
6B. Consistent with our established
process, we examined the MS–DRG
assignment and the attributes (severity
level and O.R. status) of the predecessor
diagnosis or procedure code, as
applicable, to inform our finalized
assignments and designations.
Specifically, we review the
predecessor code and MS–DRG
assignment most closely associated with
the new diagnosis or procedure code,
and in the absence of claims data, we
consider other factors that may be
relevant to the MS–DRG assignment,
including the severity of illness,
treatment difficulty, complexity of
service and the resources utilized in the
diagnosis or treatment of the condition.
We note that this process does not
automatically result in the new
diagnosis or procedure code being
proposed for assignment to the same
MS–DRG or to have the same
designation as the predecessor code.
We are making available on the CMS
website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/
the following tables associated with this
final rule:
• Table 6A.—New Diagnosis Codes—FY
2023
• Table 6B.—New Procedure Codes—
FY 2023
• Table 6C.—Invalid Diagnosis Codes—
FY 2023
• Table 6D.—Invalid Procedure Codes—
FY 2023
• Table 6E.—Revised Diagnosis Code
Titles—FY 2023
• Table 6G.1.—Secondary Diagnosis
Order Additions to the CC Exclusions
List—FY 2023
• Table 6G.2.—Principal Diagnosis
Order Additions to the CC Exclusions
List—FY 2023
• Table 6H.1.—Secondary Diagnosis
Order Deletions to the CC Exclusions
List—FY 2023
• Table 6H.2.—Principal Diagnosis
Order Deletions to the CC Exclusions
List—FY 2023
• Table 6I.—Complete MCC List—FY
2023
• Table 6I.1.—Additions to the MCC
List—FY 2023
• Table 6I.2.—Deletions to the MCC
List—FY 2023
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
• Table 6J.—Complete CC List—FY
2023
• Table 6J.1.—Additions to the CC
List—FY 2023
• Table 6J.2.—Deletions to the CC List—
FY 2023
• Table 6K.—Complete List of CC
Exclusions—FY 2023.
15. Changes to the Medicare Code Editor
(MCE)
The Medicare Code Editor (MCE) is a
software program that detects and
reports errors in the coding of Medicare
claims data. Patient diagnoses,
procedure(s), and demographic
information are entered into the
Medicare claims processing systems and
are subjected to a series of automated
screens. The MCE screens are designed
to identify cases that require further
review before classification into an MS–
DRG.
As discussed in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 44936), we
made available the FY 2022 ICD–10
MCE Version 39 manual file. The
manual contains the definitions of the
Medicare code edits, including a
description of each coding edit with the
corresponding diagnosis and procedure
code edit lists. The link to this MCE
manual file, along with the link to the
mainframe and computer software for
the MCE Version 39 (and ICD–10 MS–
DRGs) are posted on the CMS website
at: https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/MS-DRGClassifications-and-Software.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we discussed the
proposals we were making based on our
internal review and analysis. We noted
that we did not receive any specific
MCE requests by the November 1, 2021
deadline. In this FY 2023 IPPS/LTCH
PPS final rule, we present a summation
of the comments we received in
response to the MCE proposals
presented based on internal review and
analyses in the proposed rule, our
responses to those comments, and our
finalized policies.
In addition, as a result of new and
modified code updates approved after
the annual spring ICD–10 Coordination
and Maintenance Committee meeting,
we routinely make changes to the MCE.
In the past, in both the IPPS proposed
and final rules, we have only provided
the list of changes to the MCE that were
brought to our attention after the prior
year’s final rule. We historically have
not listed the changes we have made to
the MCE as a result of the new and
modified codes approved after the
annual spring ICD–10 Coordination and
Maintenance Committee meeting. These
PO 00000
Frm 00096
Fmt 4701
Sfmt 4700
changes are approved too late in the
rulemaking schedule for inclusion in
the proposed rule. Furthermore,
although our MCE policies have been
described in our proposed and final
rules, we have not provided the detail
of each new or modified diagnosis and
procedure code edit in the final rule.
However, we make available the
finalized Definitions of Medicare Code
Edits (MCE) file. Therefore, we are
making available the FY 2023 ICD–10
MCE Version 40 Manual file, along with
the link to the mainframe and computer
software for the MCE Version 40 (and
ICD–10 MS–DRGs), on the CMS website
at: https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/MS-DRGClassifications-and-Software.
a. External Causes of Morbidity Codes as
Principal Diagnosis
In the MCE, the external cause codes
(V, W, X, or Y codes) describe the
circumstance causing an injury, not the
nature of the injury, and therefore
should not be used as a principal
diagnosis.
As discussed in section II.D.14. of the
preamble of the proposed rule and this
final rule, Table 6C.—Invalid Diagnosis
Codes, lists the diagnosis codes that are
no longer effective as of October 1, 2022.
Included in this table are codes
currently subject to the External causes
of morbidity codes as principal
diagnosis edit. We proposed to delete
the ICD–10–CM diagnosis codes shown
in Table 6P.6a associated with the
proposed rule and available via the
internet on the CMS website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatientPPS
that are currently subject to the External
causes of morbidity codes as principal
diagnosis edit since they will no longer
be valid for reporting purposes.
Comment: Commenters agreed with
CMS’s proposal to remove the diagnosis
codes listed in Table 6P.6a from the
External Causes of Morbidity edit code
list since they are no longer valid.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to delete the
diagnosis codes listed in Table 6P.6a
associated with the proposed rule from
the External Causes of Morbidity edit
code list under the ICD–10 MCE Version
40, effective October 1, 2022.
b. Age Conflict Edit
In the MCE, the Age conflict edit
exists to detect inconsistencies between
a patient’s age and any diagnosis on the
patient’s record; for example, a 5-year-
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
old patient with benign prostatic
hypertrophy or a 78-year-old patient
coded with a delivery. In these cases,
the diagnosis is clinically and virtually
impossible for a patient of the stated
age. Therefore, either the diagnosis or
the age is presumed to be incorrect.
Currently, in the MCE, the following
four age diagnosis categories appear
under the Age conflict edit and are
listed in the manual and written in the
software program:
• Perinatal/Newborn—Age 0 years
only; a subset of diagnoses which will
only occur during the perinatal or
newborn period of age 0 (for example,
tetanus neonatorum, health examination
for newborn under 8 days old).
• Pediatric—Age is 0–17 years
inclusive (for example, Reye’s
syndrome, routine child health exam).
• Maternity—Age range is 9–64 years
inclusive (for example, diabetes in
pregnancy, antepartum pulmonary
complication).
khammond on DSKJM1Z7X2PROD with RULES2
Under the ICD–10 MCE, the Maternity
diagnoses category for the Age conflict
edit considers the age range of 9 to 64
years inclusive. For that reason, the
diagnosis codes on this Age conflict edit
list would be expected to apply to
conditions or disorders specific to that
age group only.
As discussed in section II.D.14. of the
preamble of the proposed rule and this
final rule, Table 6A.—New Diagnosis
Codes, lists the diagnosis codes that
have been approved to date which will
be effective with discharges on and after
October 1, 2022. We proposed to add
new ICD–10–CM diagnosis codes to the
edit code list for the Maternity
diagnoses category as shown in Table
6P.6b associated with the proposed rule
and available via the internet on the
Description
Maternal care for (suspected) central nervous system malformation in fetus, not annlicable or unspecified
Maternal care for ( suspected) central nervous system malformation in fetus, fetus 1
Maternal care for ( suspected) central nervous system malformation in fetus, fetus 2
Maternal care for ( suspected) central nervous system malformation in fetus, fetus 3
Maternal care for ( suspected) central nervous system malformation in fetus, fetus 4
Maternal care for ( suspected) central nervous system malformation in fetus, fetus 5
Maternal care for ( suspected) central nervous system malformation in fetus, other fetus
Maternal care for (suspected) chromosomal abnormality in fetus, not applicable or unspecified
Maternal care for (suspected) chromosomal abnormality in fetus, fetus 1
Maternal care for (suspected) chromosomal abnormality in fetus, fetus 2
Maternal care for (suspected) chromosomal abnormality in fetus, fetus 3
Maternal care for (suspected) chromosomal abnormality in fetus, fetus 4
Maternal care for (suspected) chromosomal abnormality in fetus, fetus 5
Maternal care for (suspected) chromosomal abnormality in fetus, other fetus
Comment: Commenters agreed with
CMS’s proposal to remove the diagnosis
codes listed in the previous table from
the Maternity diagnoses edit code list
since they are no longer valid.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to remove the
diagnosis codes listed in the previous
table from the Maternity diagnoses edit
VerDate Sep<11>2014
(1) Maternity Diagnoses
CMS website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS under the
Age conflict edit.
Comment: Commenters agreed with
CMS’s proposal to add the diagnosis
codes listed in Table 6P.6b to the
Maternity diagnoses edit code list.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to add the
diagnosis codes as shown in Table 6P.6b
associated with the proposed rule to the
Maternity diagnoses edit code list.
In addition, as discussed in section
II.D.14. of the preamble of the proposed
rule and this final rule, Table 6C.—
Invalid Diagnosis Codes, lists the
diagnosis codes that are no longer
effective as of October 1, 2022. We
proposed to delete the following
diagnosis codes from the Maternity
diagnoses edit code list.
00:20 Aug 10, 2022
Jkt 256001
code list under the ICD–10 MCE Version
40, effective October 1, 2022.
(2) Adult Diagnoses
Under the ICD–10 MCE, the Adult
diagnoses category for the Age conflict
edit considers the age range of 15 to 124
years inclusive. For that reason, the
diagnosis codes on this Age conflict edit
list would be expected to apply to
conditions or disorders specific to that
age group only.
PO 00000
Frm 00097
Fmt 4701
Sfmt 4700
As discussed in section II.D.14. of the
preamble of the proposed rule and this
final rule, Table 6A.—New Diagnosis
Codes, lists the diagnosis codes that
have been approved which will be
effective with discharges on and after
October 1, 2022. We proposed to add
the following new ICD–10–CM
diagnosis codes to the edit code list for
the Adult diagnoses category under the
Age conflict edit.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.059
ICD-10-CM
Code
O35.0XX0
O35.0XXl
O35.0XX:2
O35.0XX:3
O35.0XX:4
O35.0XX:5
O35.0XX:9
O35.lXX0
O35.lXXl
O35.lXX:2
O35.lXX:3
O35.lXX:4
O35.lXX:5
O35.lXX:9
• Adult—Age range is 15–124 years
inclusive (for example, senile delirium,
mature cataract).
48875
48876
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Descriotion
Vascular dementia, unsoecified severitv, with agitation
Vascular dementia, unspecified severity, with other behavioral disturbance
Vascular dementia, unspecified severity, with psychotic disturbance
Vascular dementia, unspecified severity, with mood disturbance
Vascular dementia, unspecified severitv, with anxietv
Vascular dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxietv
Vascular dementia, mild, with agitation
Vascular dementia, mild, with other behavioral disturbance
Vascular dementia, mild, with psychotic disturbance
Vascular dementia, mild, with mood disturbance
Vascular dementia, mild, with anxietv
Vascular dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
Vascular dementia, moderate, with agitation
Vascular dementia, moderate, with other behavioral disturbance
Vascular dementia, moderate, with psychotic disturbance
Vascular dementia, moderate, with mood disturbance
Vascular dementia, moderate, with anxietv
Vascular dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxietv
Vascular dementia, severe, with agitation
Vascular dementia, severe, with other behavioral disturbance
Vascular dementia, severe, with psvchotic disturbance
Vascular dementia, severe, with mood disturbance
Vascular dementia, severe, with anxiety
Unspecified dementia, unspecified severitv, with agitation
Unspecified dementia, unspecified severitv, with other behavioral disturbance
Unspecified dementia, unspecified severitv, with psychotic disturbance
Unspecified dementia, unspecified severitv, with mood disturbance
Unspecified dementia, unspecified severitv, with anxietv
Unsoecified dementia, mild, without behavioral disturbance, psvchotic disturbance, mood disturbance, and anxietv
Unspecified dementia, mild, with agitation
Unspecified dementia, mild, with other behavioral disturbance
Unspecified dementia, mild, with psychotic disturbance
Unspecified dementia, mild, with mood disturbance
Unspecified dementia, mild, with anxietv
Unspecified dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxietv
Unspecified dementia, moderate, with agitation
Unspecified dementia, moderate, with other behavioral disturbance
Unspecified dementia, moderate, with psychotic disturbance
Unsoecified dementia, moderate, with mood disturbance
Unspecified dementia, moderate, with anxietv
Unspecified dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
Unspecified dementia, severe, with agitation
Unspecified dementia, severe, with other behavioral disturbance
Unspecified dementia, severe, with psychotic disturbance
Unspecified dementia, severe, with mood disturbance
Unspecified dementia, severe, with anxietv
Atherosclerotic heart disease of native coronarv arterv with refractorv angina pectoris
Atherosclerosis of coronarv arterv bvoass graft( s), unsoecified, with refractorv angina pectoris
Atherosclerosis ofautologous vein coronarv arterv bvpass graft(s) with refractorv angina pectoris
Atherosclerosis of autologous arterv coronarv arterv bvpass graft( s) with refractorv angina pectoris
Atherosclerosis ofnonautologous biological coronarv artery bypass graft(s) with refractory angina pectoris
Atherosclerosis of native coronary artery of transplanted heart with refractory angina pectoris
Atherosclerosis of bypass graft of coronary artery of transplanted heart with refractory angina pectoris
Atherosclerosis of other coronarv arterv bypass graft( s) with refractorv angina pectoris
Comment: Commenters agreed with
CMS’s proposal to add the diagnosis
codes listed in the previous table to the
Adult diagnoses edit code list.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
finalizing our proposal to add the
diagnosis codes listed in the previous
table to the Adult diagnoses edit code
list under the ICD–10 MCE Version 40,
effective October 1, 2022.
In addition, as discussed in section
II.D.14. of the preamble of the proposed
PO 00000
Frm 00098
Fmt 4701
Sfmt 4700
rule and this final rule, Table 6C.—
Invalid Diagnosis Codes, lists the
diagnosis codes that are no longer
effective as of October 1, 2022. We
proposed to delete the following codes
from the Adult diagnoses edit code list.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.060
khammond on DSKJM1Z7X2PROD with RULES2
ICD-10-CM
Code
F0l.511
F0l.518
F0l.52
F0l.53
F0l.54
F0l.A0
F0l.All
F01.A18
F01.A2
F01.A3
F01.A4
F0l.B0
F0l.Bll
F01.B18
F01.B2
F01.B3
F01.B4
F0l.C0
F0l.Cll
F01.C18
F01.C2
F01.C3
F01.C4
F03.911
F03.918
F03.92
F03.93
F03.94
F03.A0
F03.All
F03.A18
F03.A2
F03.A3
F03.A4
F03.B0
F03.Bll
F03.B18
F03.B2
F03.B3
F03B4
F03.C0
F03.Cll
F03.C18
F03.C2
F03.C3
F03.C4
125.112
125.702
125.712
125.722
125.732
125.752
125.762
125.792
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Description
Vascular dementia with behavioral disturbance
Unspecified dementia with behavioral disturbance
Comment: Commenters agreed with
CMS’s proposal to remove the diagnosis
codes listed in the previous table from
the Adult diagnoses edit code list since
they are no longer valid.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to remove the
diagnosis codes listed in the previous
table from the Adult diagnoses edit code
list under the ICD–10 MCE Version 40,
effective October 1, 2022.
khammond on DSKJM1Z7X2PROD with RULES2
c. Sex Conflict Edit
In the MCE, the Sex conflict edit
detects inconsistencies between a
patient’s sex and any diagnosis or
procedure on the patient’s record; for
example, a male patient with cervical
cancer (diagnosis) or a female patient
with a prostatectomy (procedure). In
both instances, the indicated diagnosis
or the procedure conflicts with the
stated sex of the patient. Therefore, the
patient’s diagnosis, procedure, or sex is
presumed to be incorrect.
Comment: A commenter requested
clarification on how the sex conflict
edits consider patients who identify as
transgender.
Response: The sex conflict edit under
the MCE is consistent with 45 CFR
170.207(n) which states that birth sex
must be coded as Male, Female or
Unknown. Gender identity is a separate
data element under 45 CFR 170.207(o).
We note that any proposed changes to
account for gender identity on the CMS–
1450 form would need to be submitted
to the National Uniform Billing
Committee (NUBC) for consideration.
Comment: Another commenter
expressed concerns about the existing
ICD–10 codes and edits that appear to
be sex specific (that is, male only or
female only). According to the
commenter, reporting of these codes for
patients who identify as transgender
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
may result in treatment being delayed or
denied. The commenter acknowledged
the necessity in aligning a patient’s
historical health data with that of their
gender identity and personal anatomy,
however, according to the commenter,
removal of sex specific codes from the
MCE would be beneficial for nonbinary
people as well.
Another commenter stated that
transgender individuals may be
alienated and deterred from seeking
medical care in the future as a result of
inappropriate claims denial due to the
Sex conflict edit. The commenter stated
that obstetricians-gynecologists
specifically have conveyed the need to
document and report a patient’s gender
identity in combination with their sex to
provide quality, patient-centered care.
The commenter also stated they have
made recommendations to the Office of
the National Coordinator for Health
Information Technology (ONC) to
include the data element ‘‘gender’’ in its
minimum certification criteria for
electronic health records. The
commenter recommended that CMS
work with ONC to ensure that
automated claim editors, like the MCE,
do not require obstetrician-gynecologists
and other health care professionals to
misrepresent their patients’ genders to
provide the appropriate clinical care.
Lastly, the commenter encouraged CMS
to continue its efforts to reduce the
administrative burden by adapting the
MCE and other systems to fit the needs
of all physicians and their patients.
Response: We appreciate the
commenters’ feedback. We intend to
explore alternative options that may
help to address the challenges described
by the commenters with claims
processing for individuals who identify
as transgender or nonbinary.. We are
interested in feedback and comments on
other ways for which these issues could
be considered from a process, systems
and operational perspective. Comments
PO 00000
Frm 00099
Fmt 4701
Sfmt 4700
should be directed to the new electronic
intake system, Medicare Electronic
Application Request Information
SystemTM (MEARISTM), discussed in
section II.D.1.b of the preamble of the
proposed rule and this final rule at:
https://mearis.cms.gov/public/home by
October 20, 2022
(1) Diagnoses for Females Only Edit
As discussed in section II.D.14. of the
preamble of the proposed rule and this
final rule, Table 6A.—New Diagnosis
Codes, lists the new diagnosis codes
that have been approved to date which
will be effective with discharges on and
after October 1, 2022. We proposed to
add new ICD–10–CM diagnosis codes to
the edit code list for the Diagnoses for
females only category as shown in Table
6P.6c associated with the proposed rule
and available via the internet on the
CMS website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS under the
Sex conflict edit.
Comment: Commenters agreed with
CMS’s proposal to add the diagnosis
codes listed in Table 6P.6c to the
Diagnoses for females only edit code
list.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to add the
diagnosis codes as shown in Table 6P.6c
associated with the proposed rule to the
Diagnoses for females only edit code
list.
In addition, as discussed in section
II.D.14. of the preamble of the proposed
rule and this final rule, Table 6C.—
Invalid Diagnosis Codes, lists the
diagnosis codes that are no longer
effective as of October 1, 2022. We
proposed to delete the following codes
from the Diagnoses for females only edit
code list.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.061
ICD-10-CM Code
F0l.51
F03.91
48877
48878
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Descriotion
Candidiasis of vulva and vagina
Endometriosis of uterus
Endometriosis of ovarv
Endometriosis of fallopian tube
Endometriosis of pelvic peritoneum
Endometriosis of rectovaginal septum and vagina
Endometriosis of intestine
Maternal care for (suspected) central nervous system malformation in fetus, not applicable or unspecified
Maternal care for (suspected) central nervous system malformation in fetus, fetus 1
Maternal care for ( suspected) central nervous svstem malformation in fetus, fetus 2
Maternal care for (suspected) central nervous system malformation in fetus, fetus 3
Maternal care for ( suspected) central nervous system malformation in fetus, fetus 4
Maternal care for ( suspected) central nervous system malformation in fetus, fetus 5
Maternal care for (suspected) central nervous system malformation in fetus, other fetus
Maternal care for (suspected) chromosomal abnormality in fetus, not applicable or unspecified
Maternal care for ( suspected) chromosomal abnormality in fetus, fetus 1
Maternal care for (suspected) chromosomal abnormality in fetus, fetus 2
Maternal care for ( suspected) chromosomal abnormality in fetus, fetus 3
Maternal care for ( suspected) chromosomal abnormality in fetus, fetus 4
Maternal care for (suspected) chromosomal abnormality in fetus, fetus 5
Maternal care for (suspected) chromosomal abnormality in fetus, other fetus
ICD-10-PCS
Code
04LE0CV
04LE0DV
04LE0ZV
04LE3CV
04LE3DV
04LE3ZV
04LE4CV
04LE4DV
04LE4ZV
04LF0CW
04LF0DW
04LF0ZW
04LF3CW
04LF3DW
04LF3ZW
04LF4CW
04LF4DW
04LF4ZW
(2) Procedures for Males Only
As discussed in section II.D.14. of the
preamble of the proposed rule and this
final rule, Table 6B.—New Procedure
Codes, lists the new procedure codes
that have been approved to date which
will be effective with discharges on and
after October 1, 2022. Included in this
table are the following procedure codes
we proposed to add to the edit code list
for the Procedures for males only
category under the Sex conflict edit.
Occlusion ofri
Occlusion ofri
Occlusion ofri
Occlusion ofri
Occlusion ofri
Occlusion ofri
Occlusion ofri
Occlusion ofri
Occlusion ofri
Occlusion of left
Occlusion of left
Occlusion of left
Occlusion of left
Occlusion of left
Occlusion of left
Occlusion of left
Occlusion of left
Occlusion of left
Comment: Commenters agreed with
CMS’s proposal to add the diagnosis
codes listed in the previous table to the
Procedures for males only edit code list.
VerDate Sep<11>2014
finalizing our proposal to remove the
diagnosis codes listed in the previous
table from the Diagnoses for female only
edit code list under the ICD–10 MCE
Version 40, effective October 1, 2022.
00:20 Aug 10, 2022
Jkt 256001
roach
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
PO 00000
Frm 00100
Fmt 4701
Sfmt 4700
finalizing our proposal to add the
diagnosis codes listed in the previous
table to the Procedures for males only
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.063
khammond on DSKJM1Z7X2PROD with RULES2
Comment: Commenters agreed with
CMS’s proposal to remove the diagnosis
codes listed in the previous table from
the Diagnoses for females only edit code
list since they are no longer valid.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
ER10AU22.062
ICD-10-CM
Code
B37.3
N80.0
N80.l
N80.2
N80.3
N80.4
N80.5
035.0XX0
035.0XXl
035.0XX2
035.0XX3
035.0XX4
035.0XXS
035.0XX9
035.lXX0
035.lXXl
035.1XX2
035.1XX3
035.1XX4
035.1XX5
035.1XX9
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
edit code list under the ICD–10 MCE
Version 40, effective October 1, 2022.
disease, not the disease itself, and
therefore should not be used as a
principal diagnosis.
As discussed in section II.D.14. of the
preamble of the proposed rule and this
final rule, Table 6A.—New Diagnosis
Codes, lists the new diagnosis codes
that have been approved which will be
d. Manifestation Code as Principal
Diagnosis Edit
In the ICD–10–CM classification
system, manifestation codes describe
the manifestation of an underlying
F02.All
F02.Al8
F02.A2
F02.A3
F02.A4
F02.B0
F02.Bll
F02.Bl8
F02.B2
F02.B3
F02.B4
F02.C0
khammond on DSKJM1Z7X2PROD with RULES2
F02.Cll
F02.Cl8
F02.C2
F02.C3
F02.C4
131.31
Description
Dementia in other diseases classified elsewhere, unspecified severity, with agitation
Dementia in other diseases classified elsewhere, unspecified severity, with other behavioral disturbance
Dementia in other diseases classified elsewhere, unspecified severity, with psychotic disturbance
Dementia in other diseases classified elsewhere, unspecified severity, with mood disturbance
Dementia in other diseases classified elsewhere, unspecified severity, with anxiety
Dementia in other diseases classified elsewhere, mild, without behavioral disturbance, psychotic disturbance,
mood disturbance, and anxiety
Dementia in other diseases classified elsewhere, mild, with agitation
Dementia in other diseases classified elsewhere, mild, with other behavioral disturbance
Dementia in other diseases classified elsewhere, mild, with psychotic disturbance
Dementia in other diseases classified elsewhere, mild, with mood disturbance
Dementia in other diseases classified elsewhere, mild, with anxiety
Dementia in other diseases classified elsewhere, moderate, without behavioral disturbance, psychotic disturbance,
mood disturbance, and anxiety
Dementia in other diseases classified elsewhere, moderate, with agitation
Dementia in other diseases classified elsewhere, moderate, with other behavioral disturbance
Dementia in other diseases classified elsewhere, moderate, with psychotic disturbance
Dementia in other diseases classified elsewhere, moderate, with mood disturbance
Dementia in other diseases classified elsewhere, moderate, with anxiety
Dementia in other diseases classified elsewhere, severe, without behavioral disturbance, psychotic disturbance,
mood disturbance, and anxiety
Dementia in other diseases classified elsewhere, severe, with agitation
Dementia in other diseases classified elsewhere, severe, with other behavioral disturbance
Dementia in other diseases classified elsewhere, severe, with psychotic disturbance
Dementia in other diseases classified elsewhere, severe, with mood disturbance
Dementia in other diseases classified elsewhere, severe, with anxiety
Malignant pericardia! effusion in diseases classified elsewhere
Comment: Commenters agreed with
CMS’s proposal to add the diagnosis
codes listed in the previous table to the
Manifestation code as principal
diagnosis edit code list.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to add the
diagnosis codes listed in the previous
table to the Manifestation code as
principal diagnosis edit code list under
the ICD–10 MCE Version 40, effective
October 1, 2022.
In addition, as discussed in section
II.D.14. of the preamble of the proposed
rule and this final rule, Table 6C.—
Invalid Diagnosis Codes, lists the
diagnosis codes that are no longer
effective as of October 1, 2022. Included
in this table is ICD–10–CM diagnosis
code F02.81 (Dementia in other diseases
classified elsewhere with behavioral
disturbance), that is currently listed on
VerDate Sep<11>2014
effective with discharges on and after
October 1, 2022. Included in this table
are the following new ICD–10–CM
diagnosis codes that we proposed to add
to the edit code list for the
Manifestation code as principal
diagnosis edit, because the disease itself
would be required to be reported first.
00:20 Aug 10, 2022
Jkt 256001
the edit code list for the Manifestation
code as principal diagnosis edit. We
proposed to delete this code from the
Manifestation code as principal
diagnosis edit code list.
Comment: Commenters agreed with
CMS’s proposal to remove diagnosis
code F02.81 from the Manifestation
code as principal diagnosis edit code
list since it is no longer valid.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to remove
diagnosis code F02.81 from the
Manifestation code as principal
diagnosis edit code list under the ICD–
10 MCE Version 40, effective October 1,
2022.
e. Unacceptable Principal Diagnosis Edit
In the MCE, there are select codes that
describe a circumstance which
influences an individual’s health status
PO 00000
Frm 00101
Fmt 4701
Sfmt 4700
but does not actually describe a current
illness or injury. There also are codes
that are not specific manifestations but
may be due to an underlying cause.
These codes are considered
unacceptable as a principal diagnosis. In
limited situations, there are a few codes
on the MCE Unacceptable Principal
Diagnosis edit code list that are
considered ‘‘acceptable’’ when a
specified secondary diagnosis is also
coded and reported on the claim.
As discussed in section II.D.14. of the
preamble of the proposed rule and this
final rule, Table 6A.—New Diagnosis
Codes, lists the new diagnosis codes
that have been approved which will be
effective with discharges on and after
October 1, 2022. Additionally, as
discussed in section II.D.1.b of the
preamble of the proposed rule and this
final rule, we provided a test version of
the ICD–10 MS–DRG GROUPER
Software, Version 40, so that the public
could better analyze and understand the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.064
ICD-10-CM
Code
F02.81 l
F02.818
F02.82
F02.83
F02.84
F02.A0
48879
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
impact of the proposals included in the
proposed rule. We noted that at the time
of the development of the test software,
a subset of the listed codes (F01.511
ICD-10-CM
Code
F0I.511
F0I.518
F0l.52
F0I.53
F0I.54
F0I.A0
F0I.All
F01.A18
F01.A2
F01.A3
F01.A4
F0I.B0
F0I.Bl 1
F01.B18
F01.B2
F01.B3
F01.B4
F0I.C0
khammond on DSKJM1Z7X2PROD with RULES2
F0I.Cl 1
F01.C18
F01.C2
F01.C3
F01.C4
F06.70
F06.71
T43.655A
T43.655D
T43.655S
T43.656A
T43.656D
T43.656S
203.83
259.82
259.86
259.87
271.87
271.88
272.823
279.60
279.61
279.620
279.621
279.622
279623
279.624
VerDate Sep<11>2014
through F01.C4) that were proposed for
this edit were unable to be included and
therefore, the test software does not
reflect these codes. We proposed to add
the following new ICD–10–CM
diagnosis codes to the Unacceptable
Principal Diagnosis edit code list.
Description
Vascular dementia, unspecified severity, with agitation
Vascular dementia, unspecified severity, with other behavioral disturbance
Vascular dementia, unspecified severity, with psychotic disturbance
Vascular dementia, unspecified severity, with mood disturbance
Vascular dementia, unspecified severity, with anxiety
Vascular dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance,
and anxiety
Vascular dementia, mild, with agitation
Vascular dementia, mild, with other behavioral disturbance
Vascular dementia, mild, with psychotic disturbance
Vascular dementia, mild, with mood disturbance
Vascular dementia, mild, with anxiety
Vascular dementia, moderate, without behavioral disturbance, psychotic disturbance, mood
disturbance, and anxiety
Vascular dementia, moderate, with agitation
Vascular dementia, moderate, with other behavioral disturbance
Vascular dementia, moderate, with psychotic disturbance
Vascular dementia, moderate, with mood disturbance
Vascular dementia, moderate, with anxiety
Vascular dementia, severe, without behavioral disturbance, psychotic disturbance, mood
disturbance, and anxiety
Vascular dementia, severe, with agitation
Vascular dementia, severe, with other behavioral disturbance
Vascular dementia, severe, with psychotic disturbance
Vascular dementia, severe, with mood disturbance
Vascular dementia, severe, with anxiety
Mild neurocognitive disorder due to known physiological condition without behavioral disturbance
Mild neurocognitive disorder due to known physiological condition with behavioral disturbance
Adverse effect of methamphetamines, initial encounter
Adverse effect of methamphetamines, subsequent encounter
Adverse effect of methamphetamines, sequela
Underdosing of methamphetamines, initial encounter
Underdosing of methamphetamines, subsequent encounter
Underdosing of methamphetamines, sequela
Encounter for observation for suspected conditions related to home physiologic monitoring device
ruled out
Transportation insecurity
Financial insecurity
Material hardship
Encounter for pediatric-to-adult transition counseling
Encounter for counseling for socioeconomic factors
Risk of suffocation (smothering) under another while sleeping
Long term (current) use of unspecified immunomodulators and immunosunnressants
Long term (current) use ofimmunemodulator
Long term (current) use ofimmunosunnressive biologic
Long term (current) use of calcineurin inhibitor
Long term (current) use of Janus kinase inhibitor
Long term (current) use of mammalian target ofrapamycin (mTOR) inhibitor
Long term (current) use of inhibitors of nucleotide synthesis
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00102
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.065
48880
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Z91.110
Z91.118
Z91.119
Z91.190
Z91.198
Z91.199
Z91.A10
Z91.A18
Z91.A20
Z91.A28
Z91.A3
Z91.A4
Z91.A5
Z91.A9
Comment: Commenters agreed with
our proposal to add the diagnosis codes
listed in the previous table to the
Unacceptable Principal Diagnosis edit
code list.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
khammond on DSKJM1Z7X2PROD with RULES2
ICD-10-CM
Code
Z87.76
Z91.11
Z91.19
Invalid Diagnosis Codes, lists the
diagnosis codes that are no longer
effective as of October 1, 2022. We
proposed to delete the following codes
from the Unacceptable Principal
Diagnosis edit code list.
Description
Personal history of ( corrected) congenital malformations of inte!!lllilent, limbs and musculoskeletal system
Patient's noncompliance with dietary regimen
Patient's noncompliance with other medical treatment and regimen
Comment: Commenters agreed with
CMS’s proposal to remove diagnosis
codes Z87.76, Z91.11, and Z91.19 from
the Unacceptable principal diagnosis
VerDate Sep<11>2014
finalizing our proposal to add the
diagnosis codes listed in the previous
table to the Unacceptable Principal
Diagnosis edit code list under the ICD–
10 MCE Version 40, effective October 1,
2022.
In addition, as discussed in section
II.D.14. of the preamble of the proposed
rule and this final rule, Table 6C.—
00:20 Aug 10, 2022
Jkt 256001
edit code list since they are no longer
valid.
Response: We appreciate the
commenters’ support. After
consideration of the public comments
we received, we are finalizing our
PO 00000
Frm 00103
Fmt 4701
Sfmt 4700
proposal to remove the diagnosis codes
listed in the previous table from the
Unacceptable Principal Diagnosis edit
code list under the ICD–10 MCE Version
40, effective October 1, 2022.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.067
Z87.761
Z87.762
Z87.763
Z87.768
Description
Long term (current) use ofalkvlating agent
Long term ( current) use of antimetabolite agent
Long term ( current) use of antitumor antibiotic
Long term (current) use of mitotic inhibitor
Long term (current) use oftopoisomerase inhibitor
Long term (current) use ofmyelosunnressive agent
Long term ( current) use of other immunomodulators and immunosuppressants
Long-term (current) use ofiniectable non-insulin antidiabetic drugs
Personal histoiy of ( corrected) necrotizing enterocolitis of newborn
Personal history of other (corrected) conditions arising in the perinatal period
Personal histoiy of ( corrected) tracheoesophageal fistula or atresia
Personal history of ( corrected) persistent cloaca or cloacal malformations
Personal history of (corrected) congenital diaphragmatic hernia or other congenital diaphragm
malformations
Personal history of ( corrected) gastroschisis
Personal histoiy of ( corrected) prune belly malformation
Personal history of other ( corrected) congenital abdominal wall malformations
Personal history of other specified (corrected) congenital malformations of integument, limbs and
musculoskeletal system
Patient's noncompliance with dietary regimen due to financial hardship
Patient's noncompliance with dietaiy regimen for other reason
Patient's noncompliance with dietary regimen due to unspecified reason
Patient's noncompliance with other medical treatment and regimen due to financial hardship
Patient's noncompliance with other medical treatment and regimen for other reason
Patient's noncompliance with other medical treatment and regimen due to unspecified reason
Caregiver's noncompliance with patient's dietary regimen due to financial hardship
Caregiver's noncompliance with patient's dietary regimen for other reason
Caregiver's intentional underdosing of patient's medication regimen due to financial hardship
Caregiver' s intentional underdosing of medication regimen for other reason
Caregiver's unintentional underdosing of patient's medication regimen
Caregiver's other noncompliance with patient's medication regimen
Caregiver's noncompliance with patient's renal dialysis
Caregiver's noncompliance with patient's other medical treatment and regimen
ER10AU22.066
ICD-10-CM
Code
Z79.630
Z79.631
Z79.632
Z79.633
Z79.634
Z79.64
Z79.69
Z79.85
Z87.61
Z87.68
Z87.731
Z87.732
Z87.760
48881
48882
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
f. Unspecified Code
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 44940 through 44943), we
finalized the implementation of a new
Unspecified code edit, effective with
discharges on and after April 1, 2022.
Unspecified codes exist in the ICD–10–
CM classification for circumstances
when documentation in the medical
S06.36AA
Description
Contusion and laceration of cerebrum, unspecified, with loss of consciousness status
unknown, initial encounter
Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness status
unknown, initial encounter
khammond on DSKJM1Z7X2PROD with RULES2
Comment: Commenters agreed with
our proposal to add the diagnosis codes
listed in the previous table to the
Unspecified code edit code list.
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to add the
diagnosis codes listed in the previous
table to the Unspecified code edit code
list under the ICD–10 MCE Version 40,
effective October 1, 2022.
g. Future Enhancement
In the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38053 through 38054) we
noted the importance of ensuring
accuracy of the coded data from the
reporting, collection, processing,
coverage, payment and analysis aspects.
Subsequently, in the FY 2019 IPPS/
LTCH PPS proposed rule (83 FR 20235)
we stated that we engaged a contractor
to assist in the review of the limited
coverage and non-covered procedure
edits in the MCE that may also be
present in other claims processing
systems that are utilized by our MACs.
The MACs must adhere to criteria
specified within the National Coverage
Determinations (NCDs) and may
implement their own edits in addition
to what is already incorporated into the
MCE, resulting in duplicate edits. The
objective of this review is to identify
where duplicate edits may exist and to
determine what the impact might be if
these edits were to be removed from the
MCE.
We have also noted that the purpose
of the MCE is to ensure that errors and
inconsistencies in the coded data are
recognized during Medicare claims
processing. As we indicated in the FY
2019 IPPS/LTCH PPS final rule (83 FR
41228), we are considering whether the
inclusion of coverage edits in the MCE
VerDate Sep<11>2014
00:20 Aug 10, 2022
final rule, Table 6A.—New Diagnosis
Codes, lists the new diagnosis codes
that have been approved to date which
will be effective with discharges on and
after October 1, 2022. We proposed to
add the following new ICD–10–CM
diagnosis codes to the Unspecified code
edit code list.
Jkt 256001
necessarily aligns with that specific goal
because the focus of coverage edits is on
whether or not a particular service is
covered for payment purposes and not
whether it was coded correctly.
Comment: A few commenters
requested that CMS continue to include
the existing coverage edits in the MCE.
According to the commenters, the MACs
software and systems may not be
consistently updated and current,
therefore, coding edits may trigger
erroneously only to be dismissed on
appeal when it is discovered that the
code in question is covered under an
NCD. The commenters stated their belief
that the national MCE provides
important safeguards for claims
processing and coverage.
Response: We appreciate the
commenters’ feedback.
As we continue to evaluate the
purpose and function of the MCE with
respect to ICD–10, we encourage public
input for future discussion. As we have
discussed in prior rulemaking, we
recognize a need to further examine the
current list of edits and the definitions
of those edits.
We continue to encourage public
comments on whether there are
additional concerns with the current
edits, including specific edits or
language that should be removed or
revised, edits that should be combined,
or new edits that should be added to
assist in detecting errors or inaccuracies
in the coded data. Comments should be
directed to the new electronic intake
system, Medicare Electronic
Application Request Information
SystemTM (MEARISTM), discussed in
section II.D.1.b of the preamble of the
proposed rule and this final rule at:
https://mearis.cms.gov/public/home by
October 20, 2022.
PO 00000
Frm 00104
Fmt 4701
Sfmt 4700
16. Changes to Surgical Hierarchies
Some inpatient stays entail multiple
surgical procedures, each one of which,
occurring by itself, could result in
assignment of the case to a different
MS–DRG within the MDC to which the
principal diagnosis is assigned.
Therefore, it is necessary to have a
decision rule within the GROUPER by
which these cases are assigned to a
single MS–DRG. The surgical hierarchy,
an ordering of surgical classes from
most resource-intensive to least
resource-intensive, performs that
function. Application of this hierarchy
ensures that cases involving multiple
surgical procedures are assigned to the
MS–DRG associated with the most
resource-intensive surgical class.
A surgical class can be composed of
one or more MS–DRGs. For example, in
MDC 11, the surgical class ‘‘kidney
transplant’’ consists of a single MS–DRG
(MS–DRG 652) and the class ‘‘major
bladder procedures’’ consists of three
MS–DRGs (MS–DRGs 653, 654, and
655). Consequently, in many cases, the
surgical hierarchy has an impact on
more than one MS–DRG. The
methodology for determining the most
resource-intensive surgical class
involves weighting the average
resources for each MS–DRG by
frequency to determine the weighted
average resources for each surgical class.
For example, assume surgical class A
includes MS–DRGs 001 and 002 and
surgical class B includes MS–DRGs 003,
004, and 005. Assume also that the
average costs of MS–DRG 001 are higher
than that of MS–DRG 003, but the
average costs of MS–DRGs 004 and 005
are higher than the average costs of MS–
DRG 002. To determine whether
surgical class A should be higher or
lower than surgical class B in the
surgical hierarchy, we would weigh the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.068
ICD-10-CM
Code
S06.33AA
record does not provide the level of
detail needed to support reporting a
more specific code. However, in the
inpatient setting, there should generally
be very limited and rare circumstances
for which the laterality (right, left,
bilateral) of a condition is unable to be
documented and reported.
As discussed in section II.D.14. of the
preamble of the proposed rule and this
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
average costs of each MS–DRG in the
class by frequency (that is, by the
number of cases in the MS–DRG) to
determine average resource
consumption for the surgical class. The
surgical classes would then be ordered
from the class with the highest average
resource utilization to that with the
lowest, with the exception of ‘‘other
O.R. procedures’’ as discussed in this
final rule.
This methodology may occasionally
result in assignment of a case involving
multiple procedures to the lowerweighted MS–DRG (in the highest, most
resource-intensive surgical class) of the
available alternatives. However, given
that the logic underlying the surgical
hierarchy provides that the GROUPER
search for the procedure in the most
resource-intensive surgical class, in
cases involving multiple procedures,
this result is sometimes unavoidable.
We note that, notwithstanding the
foregoing discussion, there are a few
instances when a surgical class with a
lower average cost is ordered above a
surgical class with a higher average cost.
For example, the ‘‘other O.R.
procedures’’ surgical class is uniformly
ordered last in the surgical hierarchy of
each MDC in which it occurs, regardless
of the fact that the average costs for the
MS–DRG or MS–DRGs in that surgical
class may be higher than those for other
surgical classes in the MDC. The ‘‘other
O.R. procedures’’ class is a group of
procedures that are only infrequently
related to the diagnoses in the MDC, but
are still occasionally performed on
patients with cases assigned to the MDC
with these diagnoses. Therefore,
assignment to these surgical classes
should only occur if no other surgical
class more closely related to the
diagnoses in the MDC is appropriate.
A second example occurs when the
difference between the average costs for
two surgical classes is very small. We
have found that small differences
generally do not warrant reordering of
the hierarchy because, as a result of
reassigning cases on the basis of the
hierarchy change, the average costs are
likely to shift such that the higherordered surgical class has lower average
costs than the class ordered below it.
Based on the changes that we
proposed to make for FY 2023, as
discussed in section II.D. of the
preamble of the proposed rule and this
final rule, we are maintaining the
existing surgical hierarchy for FY 2023.
17. Maintenance of the ICD–10–CM and
ICD–10–PCS Coding Systems
In September 1985, the ICD–9–CM
Coordination and Maintenance
Committee was formed. This is a
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Federal interdepartmental committee,
co-chaired by the Centers for Disease
Control and Prevention’s (CDC) National
Center for Health Statistics (NCHS) and
CMS, charged with maintaining and
updating the ICD–9–CM system. The
final update to ICD–9–CM codes was
made on October 1, 2013. Thereafter,
the name of the Committee was changed
to the ICD–10 Coordination and
Maintenance Committee, effective with
the March 19–20, 2014 meeting. The
ICD–10 Coordination and Maintenance
Committee addresses updates to the
ICD–10–CM and ICD–10–PCS coding
systems. The Committee is jointly
responsible for approving coding
changes, and developing errata,
addenda, and other modifications to the
coding systems to reflect newly
developed procedures and technologies
and newly identified diseases. The
Committee is also responsible for
promoting the use of Federal and nonFederal educational programs and other
communication techniques with a view
toward standardizing coding
applications and upgrading the quality
of the classification system.
The official list of ICD–9–CM
diagnosis and procedure codes by fiscal
year can be found on the CMS website
at: https://cms.hhs.gov/Medicare/Coding/
ICD9ProviderDiagnosticCodes/
codes.html. The official list of ICD–10–
CM and ICD–10–PCS codes can be
found on the CMS website at: https://
www.cms.gov/Medicare/Coding/ICD10/
index.html.
The NCHS has lead responsibility for
the ICD–10–CM and ICD–9–CM
diagnosis codes included in the Tabular
List and Alphabetic Index for Diseases,
while CMS has lead responsibility for
the ICD–10–PCS and ICD–9–CM
procedure codes included in the
Tabular List and Alphabetic Index for
Procedures.
The ICD–10 Coordination and
Maintenance Committee holds its
meetings in the spring and fall to update
the codes and the applicable payment
and reporting systems by October 1 or
April 1 of each year. Items are placed on
the agenda for the Committee meeting if
the request is received at least 3 months
prior to the meeting. This requirement
allows time for staff to review and
research the coding issues and prepare
material for discussion at the meeting. It
also allows time for the topic to be
publicized in meeting announcements
in the Federal Register as well as on the
CMS website.
The Committee encourages
participation in the previously
mentioned process by health- related
organizations and other interested
parties. In this regard, the Committee
PO 00000
Frm 00105
Fmt 4701
Sfmt 4700
48883
holds public meetings for discussion of
educational issues and proposed coding
changes. These meetings provide an
opportunity for representatives of
recognized organizations in the coding
field, such as the American Health
Information Management Association
(AHIMA), the American Hospital
Association (AHA), and various
physician specialty groups, as well as
individual physicians, health
information management professionals,
and other members of the public, to
contribute ideas on coding matters.
After considering the opinions
expressed during the public meetings
and in writing, the Committee
formulates recommendations, which
then must be approved by the agencies.
A complete addendum describing
details of all diagnosis and procedure
coding changes, both tabular and index,
is published on the CMS and NCHS
websites in June of each year. Publishers
of coding books and software use this
information to modify their products
that are used by health care providers.
The Committee presented proposals
for coding changes for implementation
in FY 2023 at a public meeting held on
September 14–15, 2021 and finalized
the coding changes after consideration
of comments received at the meetings
and in writing by November 15, 2021.
The Committee held its 2022 meeting
on March 8–9, 2022. The deadline for
submitting comments on the procedure
code proposals that are being
considered for an October 1, 2022
implementation was April 8, 2022. The
deadline for submitting comments on
the diagnosis code proposals that are
being considered for an October 1, 2023
implementation was May 9, 2022. It was
announced at this meeting that any new
diagnosis and procedure codes for
which there was consensus of public
support and for which complete tabular
and indexing changes would be made
by June 2022 would be included in the
October 1, 2022 update to the ICD–10–
CM diagnosis and ICD–10–PCS
procedure code sets. It was also
announced at this meeting that we are
changing the process for submitting
requested updates to the ICD–10–PCS
classification, beginning with the
procedure code requests submitted for
consideration for the September 13–14,
2022 ICD–10 Coordination and
Maintenance Committee Meeting. As
stated in section II.D.1.b. of the
preamble of the proposed rule and this
final rule, CMS is in the process of
implementing a new electronic
application intake system, MEARISTM.
Effective January 5, 2022, MEARISTM
became available as an initial release for
users to begin gaining familiarity with a
E:\FR\FM\10AUR2.SGM
10AUR2
48884
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
new approach and process to submit
ICD–10–PCS procedure code requests.
Information on this new approach for
submitting an ICD–10–PCS code request
can be accessed at: https://
mearis.cms.gov. Effective March 1,
2022, the full release of MEARISTM
became active for ICD–10–PCS code
request submissions. ICD–10–PCS code
request submissions were due no later
than June 10, 2022 to be considered for
the September 13–14, 2022 ICD–10
Coordination and Maintenance
Committee Meeting. Moving forward,
CMS will only accept ICD–10–PCS code
requests submitted via MEARISTM.
Requests submitted through the
ICDProcedureCodeRequest mailbox will
no longer be considered. Within
MEARISTM, we have built in several
resources to support users, including a
‘‘Resources’’ section (available at
https://mearis.cms.gov/public/
resources) and technical support
available under ‘‘Useful Links’’ at the
bottom of the MEARISTM site. Questions
regarding MEARISTM can be submitted
to CMS using the form available under
‘‘Contact’’ at: https://mearis.cms.gov/
public/resources.
As discussed in earlier sections of the
preamble of this final rule, there are
new, revised, and deleted ICD–10–CM
diagnosis codes and ICD–10–PCS
procedure codes that are captured in
Table 6A.—New Diagnosis Codes, Table
6B.—New Procedure Codes, Table 6C.—
Invalid Diagnosis Codes, Table 6D.—
Invalid Procedure Codes, and Table
6E.—Revised Diagnosis Code Titles for
this final rule, which are available via
the internet on the CMS website at:
https://www.cms.gov/medicare/
medicare-fee-for-service-payment/
acuteinpatientpps. The code titles are
adopted as part of the ICD–10
Coordination and Maintenance
Committee process. Therefore, although
we make the code titles available
through tables in association with the
IPPS proposed and final rules, they are
not subject to comment in the proposed
or final rule. Because of the length of
these tables, they are not published in
the Addendum to the proposed or final
rule. Rather, they are available via the
internet as discussed in section VI. of
the Addendum to the proposed rule and
this final rule.
Recordings for the virtual meeting
discussions of the procedure codes at
the Committee’s September 14–15, 2021
meeting and the March 8–9, 2022
meeting can be obtained from the CMS
website at: https://www.cms.gov/
Medicare/Coding/ICD10/C-and-MMeeting-Materials. The materials for the
discussions relating to diagnosis codes
at the September 14–15, 2021 meeting
and March 8–9, 2022 meeting can be
found through the CDC website at:
https://www.cdc.gov/nchs/icd/icd10cm_
maintenance.html. These websites also
provide detailed information about the
Committee, including information on
requesting a new code, participating in
a Committee meeting, timeline
requirements and meeting dates.
We encourage commenters to submit
questions and comments on coding
issues involving diagnosis codes via
Email to: nchsicd10cm@cdc.gov.
Questions and comments concerning
the procedure codes should be
submitted via Email to:
ICDProcedureCodeRequest@
cms.hhs.gov.
We stated in the proposed rule that as
a result of the ongoing COVID–19 public
health emergency, the CDC
implemented three new diagnosis codes
describing immunization status related
to COVID–19 into the ICD–10–CM
effective with discharges on and after
April 1, 2022.
The diagnosis codes are as follows:
We refer the reader to the CDC web
page at https://www.cdc.gov/nchs/icd/
icd10cm.htm for additional details
regarding the implementation of these
new diagnosis codes.
As discussed in the proposed rule, we
provided the MS–DRG assignments for
the three diagnosis codes effective with
discharges on and after April 1, 2022,
consistent with our established process
for assigning new diagnosis codes.
Specifically, we review the predecessor
diagnosis code and MS–DRG
assignment most closely associated with
the new diagnosis code, and consider
other factors that may be relevant to the
MS–DRG assignment, including the
severity of illness, treatment difficulty,
and the resources utilized for the
specific condition/diagnosis. We note
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
that this process does not automatically
result in the new diagnosis code being
assigned to the same MS–DRG as the
predecessor code. The assignments for
the previously listed diagnosis codes are
reflected in Table 6A.—New Diagnosis
Codes associated with the proposed rule
and available via the internet on the
CMS website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS. As with
the other new diagnosis codes and MS–
DRG assignments included in Table 6A
in association with the proposed rule,
we solicited public comments on the
most appropriate MDC, MS–DRG, and
severity level assignments for these
codes for FY 2023, as well as any other
options for the GROUPER logic.
PO 00000
Frm 00106
Fmt 4701
Sfmt 4700
We did not receive any comments
opposing the MDC, MS–DRG, and
severity level assignments for the listed
codes and are therefore, finalizing the
assignments as reflected in Table 6A.—
New Diagnosis Codes in association
with this final rule.
In addition, we noted in the proposed
rule that CMS implemented nine new
procedure codes describing the
introduction or infusion of therapeutics,
including vaccines for COVID–
19prevention, into the ICD–10–PCS
effective with discharges on and after
April 1, 2022. The nine procedure codes
listed in this section of this rule are
designated as non-O.R. and do not affect
any MDC or MS–DRG assignment as
shown in the following table.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.069
khammond on DSKJM1Z7X2PROD with RULES2
ICD-10-CM Code
Description
Unvaccinated for COVID-19
~28.310
~28.311
Partially vaccinated for COVID-19
~28.39
Other under immunization status
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
The ICD–10 MS–DRG assignment for
cases reporting any one of the nine
procedure codes is dependent on the
reported principal diagnosis, any
secondary diagnoses defined as a CC or
MCC, procedures or services performed,
age, sex, and discharge status. The nine
procedure codes are reflected in Table
6B.—New Procedure Codes in
association with the proposed rule and
available via the internet on the CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS. As with
the other new procedure codes and MS–
DRG assignments included in Table 6B
in association with the proposed rule,
we solicited public comments on the
most appropriate MDC, MS–DRG, and
operating room status assignments for
these codes for FY 2023, as well as any
other options for the GROUPER logic.
We did not receive any comments
opposing the MDC, MS–DRG, and
operating room status assignments for
the listed codes and are therefore,
finalizing the assignments as reflected
in Table 6B.—New Procedure Codes in
association with this final rule.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
In the proposed rule we also noted
that Change Request (CR) 12578,
Transmittal 11174, titled ‘‘April 2022
Update to the Medicare Severity—
Diagnosis Related Group (MS–DRG)
Grouper and Medicare Code Editor
(MCE) Version 39.1 for the International
Classification of Diseases, Tenth
Revision (ICD–10) Diagnosis Codes for
2019 Novel Coronavirus (COVID–19)
Vaccination Status and ICD–10
Procedure Coding System (PCS) Codes
for Introduction or Infusion of
Therapeutics and Vaccines for COVID–
19 Treatment’’, was issued on January
14, 2022 (available via the internet on
the CMS website at: https://
www.cms.gov/Regulations-andGuidance/Guidance/Transmittals/
Transmittals/r11174cp) regarding the
release of an updated version of the
ICD–10 MS–DRG GROUPER and
Medicare Code Editor software, Version
39.1, effective with discharges on and
after April 1, 2022, reflecting the new
diagnosis and procedure codes. The
updated software, along with the
updated ICD–10 MS–DRG V39.1
Definitions Manual and the Definitions
of Medicare Code Edits V39.1 manual is
PO 00000
Frm 00107
Fmt 4701
Sfmt 4700
O.R. MDC MS-DRG
N
N
N
N
N
N
N
N
N
available at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/MS-DRGClassifications-and-Software.
In the September 7, 2001 final rule
implementing the IPPS new technology
add-on payments (66 FR 46906), we
indicated we would attempt to include
proposals for procedure codes that
would describe new technology
discussed and approved at the Spring
meeting as part of the code revisions
effective the following October.
Section 503(a) of Public Law 108–173
included a requirement for updating
diagnosis and procedure codes twice a
year instead of a single update on
October 1 of each year. This
requirement was included as part of the
amendments to the Act relating to
recognition of new technology under the
IPPS. Section 503(a) of Public Law 108–
173 amended section 1886(d)(5)(K) of
the Act by adding a clause (vii) which
states that the Secretary shall provide
for the addition of new diagnosis and
procedure codes on April 1 of each year,
but the addition of such codes shall not
require the Secretary to adjust the
payment (or diagnosis-related group
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.070
khammond on DSKJM1Z7X2PROD with RULES2
ICD-10-PCS
Description
Code
XW013V7
Introduction of COVID-19 vaccine dose 3 into
subcutaneous tissue, percutaneous approach, new
technology group 7
Introduction of COVID-19 vaccine booster into
XW013W7
subcutaneous tissue, percutaneous approach, new
technology group 7
Introduction of COVID-19 vaccine dose 3 into
XW023V7
muscle, percutaneous approach, new technology
group 7
XW023W7
Introduction of COVID-19 vaccine booster into
muscle, percutaneous approach, new technology
group 7
XW023X7
Introduction of tixagevimab and cilgavimab
monoclonal antibody into muscle, percutaneous
approach, new technolo!!v group 7
XW023Y7
Introduction of other new technology monoclonal
antibody into muscle, percutaneous approach, new
technology group 7
XW0DXR7
Introduction of fostamatinib into mouth and
pharvnx, external approach, new technolo!!Y group 7
XW0G7R7
Introduction of fostamatinib into upper GI, via
natural orartificial opening, new technolO!!Y group 7
XW0H7R7
Introduction of fostamatinib into lower GI, via
natural or artificial opening, new technolO!!Y group 7
48885
khammond on DSKJM1Z7X2PROD with RULES2
48886
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
classification) until the fiscal year that
begins after such date. This requirement
improves the recognition of new
technologies under the IPPS by
providing information on these new
technologies at an earlier date. Data will
be available 6 months earlier than
would be possible with updates
occurring only once a year on October
1.
In the FY 2005 IPPS final rule, we
implemented section 1886(d)(5)(K)(vii)
of the Act, as added by section 503(a)
of Public Law 108–173, by developing a
mechanism for approving, in time for
the April update, diagnosis and
procedure code revisions needed to
describe new technologies and medical
services for purposes of the new
technology add-on payment process. We
also established the following process
for making those determinations. Topics
considered during the Fall ICD–10
(previously ICD–9–CM) Coordination
and Maintenance Committee meeting
were considered for an April 1 update
if a strong and convincing case was
made by the requestor during the
Committee’s public meeting. The
request needed to identify the reason
why a new code was needed in April for
purposes of the new technology process.
Meeting participants and those
reviewing the Committee meeting
materials were provided the opportunity
to comment on the expedited request.
We refer the reader to the FY 2022 IPPS/
LTCH PPS final rule (86 FR 44950) for
further discussion of the
implementation of this prior April 1
update for purposes of the new
technology add-on payment process.
However, as discussed in the FY 2022
IPPS/LTCH PPS final rule (86 FR 44950
through 44956), we adopted an April 1
implementation date, in addition to the
annual October 1 update, beginning
with April 1, 2022. We noted that the
intent of this April 1 implementation
date is to allow flexibility in the ICD–
10 code update process. With this new
April 1 update, CMS now uses the same
process for consideration of all requests
for an April 1 implementation date,
including for purposes of the new
technology add-on payment process
(that is, the prior process for
consideration of an April 1
implementation date only if a strong
and convincing case was made by the
requestor during the meeting no longer
applies). We are continuing to use
several aspects of our existing
established process to implement new
codes through the April 1 code update,
which includes presenting proposals for
April 1 consideration at the September
ICD–10 Coordination and Maintenance
Committee meeting, requesting public
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
comments, reviewing the public
comments, finalizing codes, and
announcing the new codes with their
assignments consistent with the new
GROUPER release information. We note
that under our established process,
requestors indicate whether they are
submitting their code request for
consideration for an April 1
implementation date or an October 1
implementation date. The ICD–10
Coordination and Maintenance
Committee makes efforts to
accommodate the requested
implementation date for each request
submitted. However, the Committee
determines which requests are to be
presented for consideration for an April
1 implementation date or an October 1
implementation date. As discussed
earlier in this section of the preamble of
this final rule, there were code
proposals presented for an expedited
April 1, 2022 implementation at the
September 14–15, 2021 Committee
meetings that involved treatments
related to the COVID–19 PHE. One of
these code proposals was also in
connection with a request for a new
technology add-on payment application.
Following the receipt of public
comments, the code proposals were
approved and finalized, therefore, there
were new codes implemented April 1,
2022.
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule, consistent
with the process we outlined for the
April 1 implementation date, we
announced the new codes in November
2021 and provided the updated code
files and ICD–10–CM Official
Guidelines for Coding and Reporting in
December 2021. On January 24, 2022 the
Federal Register notice for the March 8–
9, 2022 ICD–10 Coordination and
Maintenance Committee Meeting was
published that includes the tentative
agenda and identifies which topics are
related to a new technology add-on
payment application. By February 1,
2022 we made available the updated
V39.1 ICD–10 MS–DRG Grouper
software and related materials via the
internet on CMS web page at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS/MS-DRGClassifications-and-Software.
Comment: A few commenters
expressed concerns with the meeting
process and timing for the
implementation of new ICD–10–CM
diagnosis codes by the CDC/NCHS. The
commenters urged CMS to work with
the CDC/NCHS on expediting the
finalization of proposed new diagnosis
codes in light of the option to
implement codes on April 1. Another
PO 00000
Frm 00108
Fmt 4701
Sfmt 4700
commenter expressed support for the
ability of an April implementation and
expedited diagnosis codes to improve
reporting and health equity. The
commenter requested that CMS consider
utilizing this April 1 pathway to
advance the Agency’s and the health
care system’s equity goals, specifically
for diagnosis codes that describe social
and economic circumstances to more
accurately reflect health care encounters
and episodes of care while also
contributing to reliability and validity of
coded claims data.
Response: We thank the commenters
for the feedback. As we have noted in
prior rulemaking (85 FR 58556) the
CDC/NCHS has lead responsibility for
the ICD–10–CM diagnosis classification
while CMS has lead responsibility for
the ICD–10–PCS procedure
classification. Each organization has
their own established process in
responding to requests for code updates,
including when specific topics may
appear on the agenda of an ICD–10
Coordination and Maintenance
Committee meeting and the fiscal year
in which code proposals are considered
for implementation.
ICD–9–CM addendum and code title
information is published on the CMS
website at: https://www.cms.gov/
Medicare/Coding/ICD9Provider
DiagnosticCodes/addendum. ICD–10–
CM and ICD–10–PCS addendum and
code title information is published on
the CMS website at: https://
www.cms.gov/medicare/coding/icd10.
CMS also sends electronic files
containing all ICD–10–CM and ICD–10–
PCS coding changes to its Medicare
contractors for use in updating their
systems and providing education to
providers. Information on ICD–10–CM
diagnosis codes, along with the Official
ICD–10–CM Coding Guidelines, can be
found on the CDC website at: https://
www.cdc.gov/nchs/icd/icd10cm.htm.
Additionally, information on new,
revised, and deleted ICD–10–CM
diagnosis and ICD–10–PCS procedure
codes is provided to the AHA for
publication in the Coding Clinic for
ICD–10. The AHA also distributes
coding update information to publishers
and software vendors.
In the proposed rule we noted that for
FY 2022, there are currently 72,750
diagnosis codes and 78,229 procedure
codes. We also noted that as displayed
in Table 6A.—New Diagnosis Codes and
in Table 6B.—New Procedure Codes
associated with the proposed rule (and
available via the internet on the CMS
website at https://www.cms.gov/
medicare/medicare-fee-for-servicepayment/acuteinpatientpps), there were
1,176 new diagnosis codes and 45 new
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
finalized at the time of the development
of the proposed rule results in a total of
331 (45 + 286 = 331) new procedure
codes for FY 2023.
We also note, as reflected in Table
6C.—Invalid Diagnosis Codes and in
Table 6D.—Invalid Procedure Codes,
there are a total of 287 diagnosis codes
and 64 procedure codes that will
become invalid effective October 1,
2022. Based on these code updates,
effective October 1, 2022, there are a
total of 73,639 ICD–10–CM diagnosis
codes and 78,496 ICD–10–PCS
procedure codes for FY 2023 as shown
in the following table.
FY 2022 ICD-10-CM
72,750 total codes
FY 2022 ICD-10-PCS
FY 2023 ICD-10-CM
1,176 additions
FY 2023 ICD-10-PCS
331 additions
FY 2023 ICD-10-CM
287 deletions
FY 2023 ICD-10-PCS
64 deletions
FY 2023 ICD-10-CM
73,639 total codes
As stated previously, the public is
provided the opportunity to comment
on any requests for new diagnosis or
procedure codes discussed at the ICD–
10 Coordination and Maintenance
Committee meeting. The code titles are
adopted as part of the ICD–10
Coordination and Maintenance
Committee process. Thus, although we
publish the code titles in the IPPS
proposed and final rules, they are not
subject to comment in the proposed or
final rules.
18. Replaced Devices Offered Without
Cost or With a Credit
a. Background
In the FY 2008 IPPS final rule with
comment period (72 FR 47246 through
khammond on DSKJM1Z7X2PROD with RULES2
Codes, there were procedure codes
discussed at the March 8–9, 2022 ICD–
10 Coordination and Maintenance
Committee meeting that were not
finalized in time to include in the
proposed rule and are identified with an
asterisk. We refer the reader to Table
6B.—New Procedure Codes associated
with this final rule and available via the
internet on the CMS website at: https://
www.cms.gov/medicare/medicare-feefor-service-payment/acuteinpatientpps
for the detailed list of these additional
286 new procedure codes. The addition
of these 286 new procedure codes to the
45 procedure codes that had been
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
FY 2023 ICD-10-PCS
47251), we discussed the topic of
Medicare payment for devices that are
replaced without cost or where credit
for a replaced device is furnished to the
hospital. We implemented a policy to
reduce a hospital’s IPPS payment for
certain MS–DRGs where the
implantation of a device that
subsequently failed or was recalled
determined the base MS–DRG
assignment. At that time, we specified
that we will reduce a hospital’s IPPS
payment for those MS–DRGs where the
hospital received a credit for a replaced
device equal to 50 percent or more of
the cost of the device.
In the FY 2012 IPPS/LTCH PPS final
rule (76 FR 51556 through 51557), we
clarified this policy to state that the
PO 00000
Frm 00109
Fmt 4701
Sfmt 4700
78,229 total codes
78,496 total codes
policy applies if the hospital received a
credit equal to 50 percent or more of the
cost of the replacement device and
issued instructions to hospitals
accordingly.
b. Changes for FY 2023
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule, for FY 2023
we proposed not to add any MS–DRGs
to the policy for replaced devices
offered without cost or with a credit. We
proposed to continue to include the
existing MS–DRGs currently subject to
the policy as displayed in the following
table.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.071
procedure codes that had been finalized
for FY 2023 at the time of the
development of the proposed rule. As
discussed in section II.D.14 of the
preamble of this final rule, we are
making available Table 6A.—New
Diagnosis Codes, Table 6B.—New
Procedure Codes, Table 6C.—Invalid
Diagnosis Codes, Table 6D.—Invalid
Procedure Codes and Table 6E.—
Revised Diagnosis Code Titles via the
internet on the CMS website at: https://
www.cms.gov/medicare/medicare-feefor-service-payment/acuteinpatientpps
in association with this final rule. As
shown in Table 6B.—New Procedure
48887
MS-DRG
01
001
002
023
01
01
01
01
01
01
01
03
03
03
05
05
05
05
05
05
05
05
05
05
05
05
05
05
05
024
025
026
027
040
041
042
140
141
142
215
216
217
218
219
220
221
222
223
224
225
226
227
242
243
MDC
MS-DRG
05
05
05
05
05
05
05
05
05
05
05
05
05
05
05
05
05
08
08
08
08
08
08
08
08
08
244
245
258
259
260
261
262
265
266
267
268
269
270
271
272
319
320
461
462
466
467
468
469
470
521
522
MS-DRG Title
Heart Transplant or Implant of Heart Assist Svstem with MCC
Heart Transplant or Implant of Heart Assist Svstem without MCC
Craniotomy with Major Device Implant or Acute Complex CNS Principal Diagnosis with MCC or Chemotherapy
Implant or Epilepsy with Neurostimulator
Craniotomv with Major Device Implant or Acute Complex CNS Principal Diagnosis without MCC
Craniotomv and Endovascular Intracranial Procedures with MCC
Craniotomv and Endovascular Intracranial Procedures with CC
Craniotomv and Endovascular Intracranial Procedures without CC/MCC
Peripheral, Cranial Nerve and Other Nervous Svstem Procedures with MCC
Perioheral, Cranial Nerve and Other Nervous Svstem Procedures with CC or Perioheral Neurostimulator
Peripheral, Cranial Nerve and Other Nervous System Procedures without CC/MCC
Major Head and Neck Procedures with MCC
Major Head and Neck Procedures with CC
Major Head and Neck Procedures without CC/MCC
Other Heart Assist Svstem Implant
Cardiac Valve and Other Major Cardiothoracic Procedure with Cardiac Catheterization with MCC
Cardiac Valve and Other Maior Cardiothoracic Procedure with Cardiac Catheterization with CC
Cardiac Valve and Other Maior Cardiothoracic Procedure with Cardiac Catheterization without CC/MCC
Cardiac Valve and Other Major Cardiothoracic Procedure without Cardiac Catheterization with MCC
Cardiac Valve and Other Major Cardiothoracic Procedure without Cardiac Catheterization with CC
Cardiac Valve and Other Major Cardiothoracic Procedure without Cardiac Catheterization without CC/MCC
Cardiac Defibrillator Implant with Cardiac Catheterization with AMI/Heart Failure/Shock with MCC
Cardiac Defibrillator Implant with Cardiac Catheterization with AMI/Heart Failure/Shock without MCC
Cardiac Defibrillator Implant with Cardiac Catheterization without AMI/Heart Failure/Shock with MCC
Cardiac Defibrillator Implant with Cardiac Catheterization without AMI/Heart Failure/Shock without MCC
Cardiac Defibrillator Implant without Cardiac Catheterization with MCC
Cardiac Defibrillator Implant without Cardiac Catheterization without MCC
Permanent Cardiac Pacemaker Imolant with MCC
Permanent Cardiac Pacemaker Implant with CC
MS-DRG Title
Permanent Cardiac Pacemaker Implant without CC/MCC
AICD Generator Procedures
Cardiac Pacemaker Device Replacement with MCC
Cardiac Pacemaker Device Replacement without MCC
Cardiac Pacemaker Revision Except Device Replacement with MCC
Cardiac Pacemaker Revision Except Device Replacement with CC
Cardiac Pacemaker Revision Except Device Replacement without CC/MCC
AICD Lead Procedures
Endovascular Cardiac Valve Replacement and Supplement Procedures with MCC
Endovascular Cardiac Valve Replacement and Supplement Procedures without MCC
Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC
Aortic and Heart Assist Procedures Except Pulsation Balloon without MCC
Other Major Cardiovascular Procedures with MCC
Other Major Cardiovascular Procedures with CC
Other Major Cardiovascular Procedures without CC/MCC
Other Endovascular Cardiac Valve Procedures with MCC
Other Endovascular Cardiac Valve Procedures without MCC
Bilateral or Multiole Maior Joint Procedures of Lower Extremitv with MCC
Bilateral or Multiple Major Joint Procedures of Lower Extremity without MCC
Revision of Hip or Knee Replacement with MCC
Revision of Hip or Knee Replacement with CC
Revision of Hip or Knee Replacement without CC/MCC
Major Hip and Knee Joint Replacement or Reattachment of Lower Extremity with MCC or Total Ankle Replacement
Major Hip and Knee Joint Replacement or Reattachment of Lower Extremitv without MCC
Hip Replacement with Principal Diagnosis of Hip Fracture with MCC
Hio Reolacement with Princioal Diagnosis ofHio Fracture without MCC
We did not receive any public
comments opposing our proposal to
continue to include the existing MS–
DRGs currently subject to the policy.
Therefore, we are finalizing the list of
MS–DRGs in the table included in the
proposed rule and in this final rule that
will be subject to the replaced devices
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
offered without cost or with a credit
policy effective October 1, 2022. The
final list of MS–DRGs subject to the
IPPS policy for replaced devices offered
without cost or with a credit will be
issued to providers in the form of a
Change Request (CR).
PO 00000
Frm 00110
Fmt 4701
Sfmt 4700
19. Other Policy Issues
a. Comment Solicitation on Possible
Mechanisms To Address Rare Diseases
and Conditions Represented by Low
Volumes Within the MS–DRG Structure
As discussed in section II.D.13.d of
the preamble of the proposed rule and
this final rule, we solicited public
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.073
khammond on DSKJM1Z7X2PROD with RULES2
MDC
Pre-MDC
Pre-MDC
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ER10AU22.072
48888
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
comments involving how the reporting
of certain diagnosis codes may improve
our ability to recognize severity of
illness, complexity of service, and
utilization of resources under the MS–
DRGs, as well as feedback on
mechanisms to improve the reliability
and validity of the coded data as part of
an ongoing effort across CMS to evaluate
and develop policies to reduce health
disparities. In concert with that effort, as
discussed in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28195
through 28197) we also solicited
comments to explore possible
mechanisms through which we could
address rare diseases and conditions
that are represented by low volumes in
our claims data.
We stated in the FY 2023 proposed
rule that one subset of our beneficiary
population for which we sought
comment on potential issues related to
patient access in the inpatient setting
were patients diagnosed with rare
diseases and conditions that are
represented by low volumes in our
claims data. We noted that the Orphan
Drug Act (ODA) added section
526(a)(2)(B) to the Federal Food, Drug,
and Cosmetic Act (21 U.S.C.
360bb(a)(2)(B)), defining a rare disease
or condition as ‘‘any disease or
condition which (A) affects less than
200,000 persons in the United States, or
(B) affects more than 200,000 in the
United States and for which there is no
reasonable expectation that the cost of
developing and making available in the
United States a drug for such disease or
condition will be recovered from sales
in the United States of such drug.’’ Most
rare diseases, however, affect far fewer
people. The Genetic and Rare Diseases
Information Center (GARD), which was
created in 2002 by the National
Institutes of Health (NIH) Office of Rare
Diseases Research, estimates that there
are as many as 7,000 distinct rare
diseases. Rare diseases, which can
include genetic diseases, autoimmune
conditions, some cancers, and
uncommon infections, are highly
diverse, may affect many organ systems
and have wide variations in the rates
and patterns of manifestations and
progression.
The ODA created a process for the
U.S. Food and Drug Administration
(FDA) to identify a drug as a drug
developed for the treatment of a rare
disease or condition called ‘‘orphandrug designation’’. The sponsor of a
drug that has orphan drug designation
may be eligible for certain financial
incentives, such as tax credits and
potentially seven years of market
exclusivity after approval, all of which
are intended to incentivize developing
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
drugs for small numbers of patients. We
stated that we heard from some
interested parties, however, that there
may be a number of barriers to providers
in treating these patients with these
orphan designated drugs in the
Medicare hospital inpatient setting.
According to these interested parties,
one significant barrier that continues to
present challenges to manufacturers is
accessing formulary coverage for
potentially high cost therapeutics for
rare diseases. These interested parties
stated that hospitals utilize formularies
for inpatient drugs as a costmanagement tool that strongly
incentivizes physicians to use onformulary drugs over off-formulary
drugs, whenever clinically appropriate
to do so. A drug formulary is defined as
a list of medications and continually
updated related information, that
represents the clinical judgment of
pharmacists, physicians, and other
experts in the diagnosis and treatment
of disease or promotion of health. It is
often described as a list of medications
routinely stocked by the health care
system. These interested parties stated
that although certain therapeutics can
be associated with better outcomes for
patients with rare diseases, the lack of
access to hospital formularies represents
a hurdle under the IPPS MS–DRGs.
According to these interested parties,
when Medicare reimbursement is
insufficient to cover the costs of certain
therapeutics that treat patients with rare
diseases, a disincentive can be created
in addressing these conditions.
For the purposes of the comment
solicitation in the proposed rule, we
described three selected requests we
had received relating to the MS–DRG
classification of rare diseases and
conditions that are represented by low
volumes in our claims data.
In the FY 2013 IPPS/LTCH PPS final
rule (77 FR 53311), the FY 2015 IPPS/
LTCH PPS final rule (79 FR 49901) and
the FY 2019 IPPS/LTCH PPS final rule
(83 FR 41200), we discussed requests
we received to revise the MS–DRG
classification for cases of patients
diagnosed with porphyria to recognize
the resource requirements in caring for
these patients, to ensure appropriate
payment for these cases, and to preserve
patient access to necessary treatments.
Porphyria is defined as a group of rare
disorders (‘‘porphyrias’’) that interfere
with the production of hemoglobin that
is needed for red blood cells. While
some of these disorders are genetic
(inborn) and others are acquired, they
all result in the abnormal accumulation
of hemoglobin building blocks, called
porphyrins, which can be deposited in
the tissues where they particularly
PO 00000
Frm 00111
Fmt 4701
Sfmt 4700
48889
interfere with the functioning of the
nervous system and the skin. Treatment
for patients suffering from disorders of
porphyrin metabolism consists of an
intravenous injection of Panhematin®
(hemin for injection).
In the FY 2019 proposed rule, we
stated our data analysis showed that
cases reporting diagnosis code E80.21
(Acute intermittent (hepatic) porphyria)
as the principal diagnosis in MS–DRG
642 (Inborn and Other Disorders of
Metabolism) had higher average costs
and longer average lengths of stay
compared to the average costs and
length of stay for all other cases in MS–
DRG 642. However, after considering
these findings in the context of the
current MS–DRG structure, we stated
that we were unable to identify an MS–
DRG that would more closely parallel
these cases with respect to average costs
and length of stay that would also be
clinically aligned. We further stated that
our clinical advisors believed that, in
the current MS–DRG structure, the
clinical characteristics of patients in
these cases are most closely aligned
with the clinical characteristics of
patients in all cases in MS–DRG 642.
Moreover, given the small number of
porphyria cases, we stated we did not
believe there was justification for
creating a new MS–DRG and did not
propose to revise the MS–DRG
classification for porphyria cases.
In response, some commenters
described significant difficulties
encountered by patients with acute
porphyria attacks in obtaining
Panhematin® when presenting to an
inpatient hospital, which they attributed
to the strong financial disincentives
faced by facilities to treat these cases on
an inpatient basis. The commenters
stated that, based on the lower than
expected average cost per case and
longer than expected length of stay for
acute porphyria attacks, it appeared that
facilities were frequently not providing
Panhematin® to patients in this
condition, and instead attempting to
provide symptom relief and transferring
patients to an outpatient setting to
receive the drug where they can be
adequately paid. The commenters stated
that this is in contrast to the standard of
care for acute porphyria attacks and
could result in devastating long-term
health consequences.
In the FY 2019 final rule (83 FR
41200), as we have stated in prior
rulemaking, we noted it is not
appropriate for facilities to deny
treatment to beneficiaries needing a
specific type of therapy or treatment
that involves increased costs. We further
noted the MS–DRG system is a system
of averages and it is expected that across
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48890
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
the diagnostic related groups that within
certain groups, some cases may
demonstrate higher than average costs,
while other cases may demonstrate
lower than average costs. While we
recognized the average costs of the small
number of porphyria cases were greater
than the average costs of the cases in
MS–DRG 642 overall, we also noted that
an averaged payment system depends
on aggregation of similar cases with a
range of costs, and that we seek to
identify sufficiently large sets of claims
data with a resource/cost similarity and
clinical similarity in developing
diagnostic-related groups rather than
smaller subsets of diagnoses. We further
stated that we were sensitive to the
commenters’ concerns about access to
treatment for beneficiaries who have
been diagnosed with this condition and
we would continue to explore
mechanisms through which to address
rare diseases and low volume DRGs.
Similarly, in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 44869), we
discussed a request we received to
review potential access issues in the
inpatient setting for the administration
of ANDEXXA®. ANDEXXA®
(coagulation factor Xa (recombinant),
inactivated-zhzo) is a recombinant
decoy protein that rapidly reverses the
anticoagulant effects of two direct oral
anticoagulants, apixaban and
rivaroxaban, when reversal of
anticoagulation is needed due to lifethreatening or uncontrolled bleeding in
indications such as intracranial
hemorrhages (ICHs) and gastrointestinal
bleeds (GIBs). We noted that while our
data findings demonstrated the average
costs for the cases reporting the
intravenous administration of
ANDEXXA® were higher when
compared to all cases in their respective
MS–DRG, these cases represented a very
small percentage of the total number of
cases reported in those MS–DRGs. We
stated we were unable to identify
another MS–DRG that would be a more
appropriate MS–DRG assignment for
these cases based on the indication for
this therapeutic drug. We also stated
that while we were sensitive to the
requestors’ concerns about continued
access to treatment for beneficiaries who
require the reversal of anticoagulation
due to life-threatening or uncontrolled
bleeding, we indicated additional time
was needed to explore options and other
mechanisms through which to address
low volume, high-cost drugs outside of
the MS–DRGs.
Lastly, in the proposed rule, we
discussed a request we received to
reconsider how cases reporting the
administration of Zulresso®
(brexanolone) are recognized for
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
payment under the ICD–10 MS–DRGs in
an effort to improve access to treatment
for maternal mental health. On March
19, 2019 Zulresso® (brexanolone)
became the first Food and Drug
Administration (FDA) approved drug,
specifically for postpartum depression
(PPD) in adults. According to the
requestor, PPD is one of the most
common complications during and after
pregnancy. The requestor stated PPD is
a serious but manageable disorder and
that with early treatment, the life of the
mother, baby, and the entire family
could be positively impacted. The
requestor indicated it shares CMS’s
goals of addressing disparities in access
to care, and urged CMS to take
additional steps to address inequities in
women’s health by permitting separate
payment for Zulresso® (brexanolone), in
addition to the MS–DRG payment.
As discussed in the proposed rule,
effective with discharges on and after
October 1, 2020, cases reporting the
administration of Zulresso® in the
inpatient setting are identified by ICD–
10–PCS procedure codes XW03306
(Introduction of brexanolone into
peripheral vein, percutaneous approach,
new technology group 6) or XW04306
(Introduction of brexanolone into
central vein, percutaneous approach,
new technology group 6). These
procedure codes are designated as nonO. R. procedures and do not affect the
MS–DRG assignment when reported on
an inpatient claim. We noted that an
application for new technology add-on
payment for Zulresso® (brexanolone)
was discussed in the FY 2021 IPPS/
LTCH PPS proposed rule (85 FR 32672
through 32676) and was not approved,
as discussed in the final rule (85 FR
58709 through 58715).
We stated we analyzed claims from
the September 2021 update of the FY
2021 MedPAR file for cases reporting
the administration of Zulresso®
(brexanolone). Our analysis of the
claims data identified only one case
reporting the administration of
Zulresso® (brexanolone) in MS–DRG
870 (Septicemia or Severe Sepsis with
MV >96 Hours) with an average length
of stay of 22 days and average costs of
$67,812. For all cases in MS–DRG 870,
the average costs are $55,459 and the
average length of stay is 15.9 days. We
stated that while the average length of
stay for the case reporting the
administration of Zulresso®
(brexanolone) was greater (22 days
versus 15.9 days) and the average costs
were higher ($67,812 versus $55,459),
than all cases in MS–DRG 870 it was
unclear if treatment with Zulresso®
(brexanolone) was the underlying
reason for these factors, given that the
PO 00000
Frm 00112
Fmt 4701
Sfmt 4700
MS–DRG assigned is for sepsis and it is
not uncommon for sepsis patients to
have multiple co-morbidities and
intensive treatment strategies to address
this severe, often life threatening
condition.
We stated we appreciated the
requestor’s interest in sharing CMS’s
goal of advancing women’s health,
however, we noted that the population
in which Zulresso® (brexanolone) is
indicated generally does not include our
inpatient Medicare population. As we
have stated in prior rulemaking, (83 FR
41210), we have not adopted the same
approach to refine the maternity and
newborn MS–DRGs because of the
extremely low volume of Medicare
patients there are in these MS–DRGs.
When there is not a high volume of
these cases (for example, maternity and
newborn) represented in the Medicare
data, we generally advise that other
payers should develop DRGs to address
the needs of their patients. We stated we
believed the same would apply with
respect to administration of Zulresso®
(brexanolone) for which, as noted, we
identified only one case in the FY 2021
MedPAR file.
As discussed in prior rulemaking, the
MS–DRGs are a classification system
intended to group together diagnoses
and procedures with similar clinical
characteristics and utilization of
resources. Rare diseases and conditions
that are represented by low volumes in
our claims data however, pose a unique
challenge to this methodology as these
conditions by definition affect small
subsets of the population. In the
proposed rule, we stated that it has been
difficult to identify other MS–DRGs that
would be more appropriate MS–DRG
assignments for these rare conditions
based on the wide variance in the
clinical characteristics and utilization of
resources for each condition, depending
on the diagnosis. Creating a new MS–
DRG for these conditions as a distinct
‘‘related’’ group is also challenging for
the same reasons.
As previously noted, we generally
seek to identify sufficiently large sets of
claims data with a resource/cost
similarity and clinical similarity in
developing diagnostic-related groups
rather than smaller subsets. In the
proposed rule, we stated that we have
been concerned that basing MS–DRG
reclassification decisions on small
numbers of cases could lead to
complexities in establishing the relative
payment weights for the MS–DRGs
because several expensive cases could
impact the overall relative payment
weight. Having larger clinical cohesive
groups within an MS–DRG provides
greater stability and thus predictability
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
for hospitals for annual updates to the
relative payment weights.
As also previously noted, the MS–
DRG system is a system of averages and
it is expected that within the diagnostic
related groups, some cases may
demonstrate higher than average costs,
while other cases may demonstrate
lower than average costs. However, as
noted, cases involving treatment of rare
diseases may involve more resource use
than other cases in their respective MS–
DRG. Section 1886(d)(5)(A) of the Act
provides for Medicare payments to
Medicare-participating hospitals in
addition to the basic prospective
payments for cases incurring
extraordinarily high costs, however we
solicited feedback on other mechanisms
we could explore through which we can
address concerns relating to payment for
patients with rare diseases and
conditions that are represented by low
volumes in our claims data. We stated
we were also interested in receiving
comments on other meaningful ways in
which we might potentially improve
access to treatment for postpartum
depression in certain populations,
including through activities pursuant to
Vice President Harris’s Call to Action to
Reduce Maternal Mortality and
Morbidity.28
To inform decision making, we stated
we were also looking for feedback on
how to mitigate any unintended
negative payment impacts to providers
serving patients with rare diseases or
conditions that are represented by low
volumes in our claims data. In
particular, we stated we were interested
in hearing the perspectives of large
urban hospitals, rural hospitals, and
other hospital types in regard to their
experience. We also sought comments
on how factors such as hospital size and
type might impact a hospital’s ability to
develop protocols to better address
these conditions. We stated we would
take commenters’ feedback into
consideration in future policy
development.
Comment: Many commenters stated
they appreciated CMS’ attention and the
acknowledgment of the challenging
nature of rare diseases as part of a
reporting and payment structure.
Commenters also expressed that they
fully support the Administration’s
initiatives that champion policies to
improve maternal health and equity,
especially as it relates to PPD. Most
commenters provided recommendations
28 Available at: https://www.whitehouse.gov/
briefing-room/statements-releases/2021/12/07/factsheet-vice-president-kamala-harris-announces-callto-action-to-reduce-maternal-mortality-andmorbidity/.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
and suggested CMS explore mechanisms
such as—
• Creating a ‘‘permanent’’ payment
methodology approach which combines
the MS–DRG ‘‘fixed price’’ with
continued partial payment for the actual
cost of treatment per stay;
• Creating new MS–DRGs for certain
low-volume therapies or for orphan
conditions with more flexible cost
outlier funding;
• Creating new MS–DRG categories to
ensure access to rapidly expanding
transformative therapies like cell and
gene therapies;
• Creating a new enhanced new
technology add-on payment-like
pathway that establishes separate
payment for low volume high-cost
drugs;
• Reimbursing hospitals for orphan
drugs based on the Average Sales Price
(ASP) as published in the HOPD
Addendum B file using the same
authority that the Agency relied on to
make the recent COVID–19 payment
adjustments;
• Carving-out ‘‘clinical trial’’
inpatient stays to ensure that the MS–
DRG payment rate is not adversely
impacted by facility-reported costs that
do not include acquisition costs;
• Exploring databases outside of the
MedPAR to obtain claims data for
inclusion analysis;
• Creating a rare disease diagnosis
code designation, similar to the
complication or comorbidity (CC) and
major complication or comorbidity
(MCC) severity designations;
• Establishing a central formulary to
provide high cost drugs for rare
conditions instead of utilizing
individual hospital pharmacy
formularies to ease burdens of carrying
high cost drugs on rural and smaller
hospitals, as drug transport can
potentially be cheaper then patient
transport;
• Waiving the 500 case threshold
when deciding whether an MS–DRG
change should be proposed.
Specifically, in discussing how cases
reporting the administration of
Zulresso® (brexanolone) are recognized
for payment, commenters stated that if
Medicare commits to creating MS–DRGs
around the Medicare population giving
birth, the impacts of this progress would
have far-reaching effects beyond
Medicare beneficiaries as it will serve as
the foundation for commercial and
Medicaid payments.
Response: We appreciate the input
provided by commenters in response to
this request for information and we
thank commenters for the
acknowledgment of the challenges rare
diseases or conditions that are
PO 00000
Frm 00113
Fmt 4701
Sfmt 4700
48891
represented by low volumes present as
part of a reporting and reimbursement
structure. We thank the commenters for
their support and consideration of these
issues. We will take the comments
received in response to the solicitation
into consideration as we continue to
explore mechanisms to address
concerns relating to payment for
patients with rare diseases and
conditions that are represented by low
volumes in our claims data.
20. Out of Scope Public Comments
Received
We received public comments on
MS–DRG related issues that were
outside the scope of the proposals
included in the FY 2023 IPPS/LTCH
PPS proposed rule. Because we consider
these public comments to be outside the
scope of the proposed rule, we are not
addressing them in this final rule. As
stated in section II.D.1.b. of the
preamble of this final rule, we
encourage individuals with comments
about MS–DRG classifications to submit
these comments no later than October
20, 2022 via the new electronic intake
system, Medicare Electronic
Application Request Information
SystemTM (MEARISTM) at: https://
mearis.cms.gov/public/home so that
they can be considered for possible
inclusion in the annual proposed rule.
We will consider these public
comments for possible proposals in
future rulemaking as part of our annual
review process.
II. Changes to Medicare Severity
Diagnosis-Related Group (MS–DRG)
Classifications and Relative Weights
E. Recalibration of the FY 2023 MS–
DRG Relative Weights
1. Data Sources for Developing the
Relative Weights
Consistent with our established
policy, in developing the MS–DRG
relative weights for FY 2023, we
proposed to use two data sources:
claims data and cost report data. The
claims data source is the MedPAR file,
which includes fully coded diagnostic
and procedure data for all Medicare
inpatient hospital bills. The FY 2021
MedPAR data used in this final rule
include discharges occurring on October
1, 2020, through September 30, 2021,
based on bills received by CMS through
March 31, 2022, from all hospitals
subject to the IPPS and short-term, acute
care hospitals in Maryland (which at
that time were under a waiver from the
IPPS).
The FY 2021 MedPAR file used in
calculating the relative weights includes
data for approximately 7,444,003
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48892
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Medicare discharges from IPPS
providers. Discharges for Medicare
beneficiaries enrolled in a Medicare
Advantage managed care plan are
excluded from this analysis. These
discharges are excluded when the
MedPAR ‘‘GHO Paid’’ indicator field on
the claim record is equal to ‘‘1’’ or when
the MedPAR DRG payment field, which
represents the total payment for the
claim, is equal to the MedPAR ‘‘Indirect
Medical Education (IME)’’ payment
field, indicating that the claim was an
‘‘IME only’’ claim submitted by a
teaching hospital on behalf of a
beneficiary enrolled in a Medicare
Advantage managed care plan. In
addition, the March 2022 update of the
FY 2021 MedPAR file complies with
version 5010 of the X12 HIPAA
Transaction and Code Set Standards,
and includes a variable called ‘‘claim
type.’’ Claim type ‘‘60’’ indicates that
the claim was an inpatient claim paid as
fee-for-service. Claim types ‘‘61,’’ ‘‘62,’’
‘‘63,’’ and ‘‘64’’ relate to encounter
claims, Medicare Advantage IME
claims, and HMO no-pay claims.
Therefore, the calculation of the relative
weights for FY 2023 also excludes
claims with claim type values not equal
to ‘‘60.’’ The data exclude CAHs,
including hospitals that subsequently
became CAHs after the period from
which the data were taken. We note that
the FY 2023 relative weights are based
on the ICD–10–CM diagnosis codes and
ICD–10–PCS procedure codes from the
FY 2021 MedPAR claims data, grouped
through the ICD–10 version of the FY
2023 GROUPER (Version 40).
The second data source used in the
cost-based relative weighting
methodology is the Medicare cost report
data files from the HCRIS. In general, we
use the HCRIS dataset that is 3 years
prior to the IPPS fiscal year.
Specifically, for this final rule, we used
the March 2022 update of the FY 2020
HCRIS for calculating the FY 2023 costbased relative weights. Consistent with
our historical practice, for this FY 2023
final rule, we are providing the version
of the HCRIS from which we calculated
these 19 CCRs on the CMS website at
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS. Click on the link on
the left side of the screen titled ‘‘FY
2023 IPPS Final Rule Home Page’’ or
‘‘Acute Inpatient Files for Download.’’
2. Methodology for Calculation of the
Relative Weights
a. General
We calculated the FY 2023 relative
weights based on 19 CCRs. The
methodology we proposed to use to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
calculate the FY 2023 MS–DRG costbased relative weights based on claims
data in the FY 2021 MedPAR file and
data from the FY 2020 Medicare cost
reports is as follows:
• To the extent possible, all the
claims were regrouped using the FY
2023 MS–DRG classifications discussed
in sections II.B. and II.D. of the
preamble of this final rule.
• The transplant cases that were used
to establish the relative weights for heart
and heart-lung, liver and/or intestinal,
and lung transplants (MS–DRGs 001,
002, 005, 006, and 007, respectively)
were limited to those Medicareapproved transplant centers that have
cases in the FY 2021 MedPAR file.
(Medicare coverage for heart, heart-lung,
liver and/or intestinal, and lung
transplants is limited to those facilities
that have received approval from CMS
as transplant centers.)
• Organ acquisition costs for kidney,
heart, heart-lung, liver, lung, pancreas,
and intestinal (or multivisceral organs)
transplants continue to be paid on a
reasonable cost basis.
Because these acquisition costs are
paid separately from the prospective
payment rate, it is necessary to subtract
the acquisition charges from the total
charges on each transplant bill that
showed acquisition charges before
computing the average cost for each
MS–DRG and before eliminating
statistical outliers.
Section 108 of the Further
Consolidated Appropriations Act, 2020
provides that, for cost reporting periods
beginning on or after October 1, 2020,
costs related to hematopoietic stem cell
acquisition for the purpose of an
allogeneic hematopoietic stem cell
transplant shall be paid on a reasonable
cost basis. We refer the reader to the FY
2021 IPPS/LTCH PPS final rule for
further discussion of the reasonable cost
basis payment for cost reporting periods
beginning on or after October 1, 2020
(85 FR 58835 through 58842). For FY
2022 and subsequent years, we subtract
the hematopoietic stem cell acquisition
charges from the total charges on each
transplant bill that showed
hematopoietic stem cell acquisition
charges before computing the average
cost for each MS–DRG and before
eliminating statistical outliers.
• Claims with total charges or total
lengths of stay less than or equal to zero
were deleted. Claims that had an
amount in the total charge field that
differed by more than $30.00 from the
sum of the routine day charges,
intensive care charges, pharmacy
charges, implantable devices charges,
supplies and equipment charges,
therapy services charges, operating
PO 00000
Frm 00114
Fmt 4701
Sfmt 4700
room charges, cardiology charges,
laboratory charges, radiology charges,
other service charges, labor and delivery
charges, inhalation therapy charges,
emergency room charges, blood and
blood products charges, anesthesia
charges, cardiac catheterization charges,
CT scan charges, and MRI charges were
also deleted.
• At least 93.0 percent of the
providers in the MedPAR file had
charges for 14 of the 19 cost centers. All
claims of providers that did not have
charges greater than zero for at least 14
of the 19 cost centers were deleted. In
other words, a provider must have no
more than five blank cost centers. If a
provider did not have charges greater
than zero in more than five cost centers,
the claims for the provider were deleted.
• Statistical outliers were eliminated
by removing all cases that were beyond
3.0 standard deviations from the
geometric mean of the log distribution
of both the total charges per case and
the total charges per day for each MS–
DRG.
• Effective October 1, 2008, because
hospital inpatient claims include a POA
indicator field for each diagnosis
present on the claim, only for purposes
of relative weight-setting, the POA
indicator field was reset to ‘‘Y’’ for
‘‘Yes’’ for all claims that otherwise have
an ‘‘N’’ (No) or a ‘‘U’’ (documentation
insufficient to determine if the
condition was present at the time of
inpatient admission) in the POA field.
Under current payment policy, the
presence of specific HAC codes, as
indicated by the POA field values, can
generate a lower payment for the claim.
Specifically, if the particular condition
is present on admission (that is, a ‘‘Y’’
indicator is associated with the
diagnosis on the claim), it is not a HAC,
and the hospital is paid for the higher
severity (and, therefore, the higher
weighted MS–DRG). If the particular
condition is not present on admission
(that is, an ‘‘N’’ indicator is associated
with the diagnosis on the claim) and
there are no other complicating
conditions, the DRG GROUPER assigns
the claim to a lower severity (and,
therefore, the lower weighted MS–DRG)
as a penalty for allowing a Medicare
inpatient to contract a HAC. While the
POA reporting meets policy goals of
encouraging quality care and generates
program savings, it presents an issue for
the relative weight-setting process.
Because cases identified as HACs are
likely to be more complex than similar
cases that are not identified as HACs,
the charges associated with HAC cases
are likely to be higher as well.
Therefore, if the higher charges of these
HAC claims are grouped into lower
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
severity MS–DRGs prior to the relative
weight-setting process, the relative
weights of these particular MS–DRGs
would become artificially inflated,
potentially skewing the relative weights.
In addition, we want to protect the
integrity of the budget neutrality process
by ensuring that, in estimating
payments, no increase to the
standardized amount occurs as a result
of lower overall payments in a previous
year that stem from using weights and
case-mix that are based on lower
severity MS–DRG assignments. If this
would occur, the anticipated cost
savings from the HAC policy would be
lost.
To avoid these problems, we reset the
POA indicator field to ‘‘Y’’ only for
relative weight-setting purposes for all
claims that otherwise have an ‘‘N’’ or a
‘‘U’’ in the POA field. This resetting
‘‘forced’’ the more costly HAC claims
into the higher severity MS–DRGs as
appropriate, and the relative weights
calculated for each MS–DRG more
closely reflect the true costs of those
cases.
In addition, in the FY 2013 IPPS/
LTCH PPS final rule, for FY 2013 and
subsequent fiscal years, we finalized a
policy to treat hospitals that participate
in the Bundled Payments for Care
Improvement (BPCI) initiative the same
as prior fiscal years for the IPPS
payment modeling and ratesetting
process without regard to hospitals’
participation within these bundled
payment models (77 FR 53341 through
53343). Specifically, because acute care
hospitals participating in the BPCI
Initiative still receive IPPS payments
under section 1886(d) of the Act, we
include all applicable data from these
subsection (d) hospitals in our IPPS
payment modeling and ratesetting
calculations as if the hospitals were not
participating in those models under the
BPCI initiative. We refer readers to the
FY 2013 IPPS/LTCH PPS final rule for
a complete discussion on our final
policy for the treatment of hospitals
participating in the BPCI initiative in
our ratesetting process. For additional
information on the BPCI initiative, we
refer readers to the CMS’ Center for
Medicare and Medicaid Innovation’s
website at https://innovation.cms.gov/
initiatives/Bundled-Payments/
index.html and to section IV.H.4. of the
preamble of the FY 2013 IPPS/LTCH
PPS final rule (77 FR 53341 through
53343).
The participation of hospitals in the
BPCI initiative concluded on September
30, 2018. The participation of hospitals
in the BPCI Advanced model started on
October 1, 2018. The BPCI Advanced
model, tested under the authority of
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
section 1115A of the Act, is comprised
of a single payment and risk track,
which bundles payments for multiple
services beneficiaries receive during a
Clinical Episode. Acute care hospitals
may participate in BPCI Advanced in
one of two capacities: as a model
Participant or as a downstream Episode
Initiator. Regardless of the capacity in
which they participate in the BPCI
Advanced model, participating acute
care hospitals will continue to receive
IPPS payments under section 1886(d) of
the Act. Acute care hospitals that are
Participants also assume financial and
quality performance accountability for
Clinical Episodes in the form of a
reconciliation payment. For additional
information on the BPCI Advanced
model, we refer readers to the BPCI
Advanced web page on the CMS Center
for Medicare and Medicaid Innovation’s
website at https://innovation.cms.gov/
initiatives/bpci-advanced/. Consistent
with our policy for FY 2022, and
consistent with how we have treated
hospitals that participated in the BPCI
Initiative, for FY 2023, we continue to
believe it is appropriate to include all
applicable data from the subsection (d)
hospitals participating in the BPCI
Advanced model in our IPPS payment
modeling and ratesetting calculations
because, as noted previously, these
hospitals are still receiving IPPS
payments under section 1886(d) of the
Act. Consistent with the FY 2022 IPPS/
LTCH PPS final rule, we also proposed
to include all applicable data from
subsection (d) hospitals participating in
the Comprehensive Care for Joint
Replacement (CJR) Model in our IPPS
payment modeling and ratesetting
calculations.
The charges for each of the 19 cost
groups for each claim were standardized
to remove the effects of differences in
area wage levels, IME and DSH
payments, and for hospitals located in
Alaska and Hawaii, the applicable costof-living adjustment. Because hospital
charges include charges for both
operating and capital costs, we
standardized total charges to remove the
effects of differences in geographic
adjustment factors, cost-of-living
adjustments, and DSH payments under
the capital IPPS as well. Charges were
then summed by MS–DRG for each of
the 19 cost groups so that each MS–DRG
had 19 standardized charge totals.
Statistical outliers were then removed.
These charges were then adjusted to
cost by applying the national average
CCRs developed from the FY 2020 cost
report data.
The 19 cost centers that we used in
the relative weight calculation are
shown in a supplemental data file, Cost
PO 00000
Frm 00115
Fmt 4701
Sfmt 4700
48893
Center HCRIS Lines Supplemental Data
File, posted via the internet on the CMS
website for this final rule and available
at https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS. The supplemental
data file shows the lines on the cost
report and the corresponding revenue
codes that we used to create the 19
national cost center CCRs. In the FY
2023 IPPS/LTCH PPS proposed rule, we
stated that if we receive comments
about the groupings in this
supplemental data file, we may consider
these comments as we finalize our
policy.
Comment: A commenter requested
that CMS create a dedicated cost center
line for cell and gene therapy product
cost information, which would enable
the agency to create a 20th cost center
that is separate from the drugs/
pharmacy cost center.
Response: We appreciate the
commenter’s request regarding the
creation of new cost centers for cell and
gene therapy product cost information
and may consider this request in
connection with future rulemaking.
After consideration of the comment
received, we are finalizing our proposal
to use the 19 national cost center CCRs
to calculate the relative weights for FY
2023.
Consistent with historical practice, we
account for rare situations of nonmonotonicity in a base MS–DRG and its
severity levels, where the mean cost in
the higher severity level is less than the
mean cost in the lower severity level, in
determining the relative weights for the
different severity levels. If there are
initially non-monotonic relative weights
in the same base DRG and its severity
levels, then we combine the cases that
group to the specific non-monotonic
MS–DRGs for purposes of relative
weight calculations. For example, if
there are two non-monotonic MS–DRGs,
combining the cases across those two
MS–DRGs results in the same relative
weight for both MS–DRGs. The relative
weight calculated using the combined
cases for those severity levels is
monotonic, effectively removing any
non-monotonicity with the base DRG
and its severity levels. For this FY 2023
final rule, this calculation was applied
to address non-monotonicity for cases
that grouped to MS–DRG 793 and MS–
DRG 794. In the supplemental file titled
AOR/BOR File, we include statistics for
the affected MS–DRGs both separately
and with cases combined.
We invited public comments on our
proposals related to recalibration of the
proposed FY 2023 relative weights and
the changes in the relative weights from
FY 2022.
E:\FR\FM\10AUR2.SGM
10AUR2
48894
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Comment: A commenter requested
that CMS study whether it might be
appropriate to define the labor portion
individually for each of the 19 cost
centers and only standardize that
portion, particularly if doing so
improves the explanatory power of all
MS–DRGs. This commenter requested
that CMS conduct this study in
collaboration with stakeholders and
release this analysis in future
rulemaking.
Response: We appreciate the
commenter’s request that CMS study the
appropriateness of defining the labor
portion individually for each of the 19
cost centers and standardizing only that
portion, and we may consider this
request in connection with future
rulemaking.
After consideration of the comment
received, we are finalizing our proposals
related to the recalibration of the FY
2023 relative weights. We summarize
and respond to comments relating to the
methodology for calculating the relative
weight for MS–DRG 018 in the next
section of this final rule.
b. Relative Weight Calculation for MS–
DRG 018
As discussed in the FY 2021 IPPS/
LTCH PPS final rule (85 FR 58599
through 58600), we created MS–DRG
018 for cases that include procedures
describing CAR T-cell therapies, which
were reported using ICD–10–PCS
procedure codes XW033C3 or
XW043C3. Effective for FY 2022, we
revised MS–DRG 018 to include cases
that report the procedure codes for CAR
T-cell and non-CAR T-cell therapies and
other immunotherapies (86 FR 44798
through 448106). We refer the reader to
section II.D.2. of this final rule for
discussion of the agenda items for the
March 8–9, 2022 ICD–10 Coordination
and Maintenance Committee meeting
relating to new procedure codes to
describe the administration of a CAR Tcell or another type of gene or cellular
therapy product, as well as our
established process for determining the
MS–DRG assignment for codes
approved at the March meeting.
For MS–DRG 018, we include a
modification to our existing relative
weight methodology to ensure that the
relative weight for MS–DRG 018
appropriately reflects the relative
resources required for providing CAR Tcell and non-CAR T-cell therapies and
other immunotherapies outside of a
clinical trial, while still accounting for
the clinical trial cases in the overall
average cost for all MS–DRGs. For cases
that group to MS–DRG 018, we do not
include claims determined to be clinical
trial claims that group to MS–DRG 018
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
when calculating the average cost for
MS–DRG 018 that is used to calculate
the relative weight for this MS–DRG,
with the additional refinements that: (a)
when the CAR T-cell, non-CAR T-cell or
other immunotherapy product is
purchased in the usual manner, but the
case involves a clinical trial of a
different product, we include the claim
when calculating the average cost for
MS–DRG 018 to the extent such claims
can be identified in the historical data;
and (b) when there is expanded access
use of the CAR T-cell, non-CAR T-cell
or other immunotherapy product, these
cases will not be included when
calculating the average cost for new MS
DRG 018 to the extent such claims can
be identified in the historical data (85
FR 58600). We also calculate an
adjustment to account for the CAR Tcell, non-CAR T-cell and other
immunotherapy cases determined to be
clinical trial cases, as described later in
this final rule and include revenue
center 891 in our calculation of
standardized drug charges for MS–DRG
018. We refer the reader to the FY 2021
IPPS/LTCH PPS final rule for further
discussion of our modifications to the
relative weight calculation for MS–DRG
018.
We proposed to continue to use the
same process to identify clinical trial
claims in the FY 2021 MedPAR for
purposes of calculating the FY 2023
relative weights. We continue to use the
proxy of standardized drug charges of
less than $373,000, which was the
average sales price of KYMRIAH and
YESCARTA, which are the two CAR Tcell biological products in the FY 2021
MedPAR data used for this final rule.
(As previously noted, effective
beginning FY 2022, we revised MS–DRG
018 to include cases that report the
procedure codes for CAR T-cell and
non-CAR T-cell therapies and other
immunotherapies (86 FR 44798 through
448106).) Using the same methodology
from the FY 2021 IPPS/LTCH PPS final
rule, we proposed to apply an
adjustment to account for the CAR T
cell therapy cases identified as clinical
trial cases in calculating the national
average standardized cost per case that
is used to calculate the relative weights
for all MS–DRGs:
• Calculate the average cost for cases
to be assigned to MS–DRG 018 that
contain ICD–10–CM diagnosis code
Z00.6 or contain standardized drug
charges of less than $373,000.
• Calculate the average cost for all
other cases to be assigned to MS–DRG
018.
• Calculate an adjustor by dividing
the average cost calculated in step 1 by
the average cost calculated in step 2.
PO 00000
Frm 00116
Fmt 4701
Sfmt 4700
• Apply the adjustor calculated in
step 3 to the cases identified in step 1
as clinical trial cases, then add this
adjusted case count to the non-clinical
trial case count prior to calculating the
average cost across all MS–DRGs.
Additionally, we are continuing our
finalized methodology for calculating
this payment adjustment, such that: (a)
when the CAR T-cell, non-CAR T-cell or
other immunotherapy product is
purchased in the usual manner, but the
case involves a clinical trial of a
different product, the claim will be
included when calculating the average
cost for cases not determined to be
clinical trial cases; and (b) when there
is expanded access use of
immunotherapy, these cases will be
included when calculating the average
cost for cases determined to be clinical
trial cases. However, we continue to
believe to the best of our knowledge
there are no claims in the historical data
(FY 2021 MedPAR) used in the
calculation of the adjustment for cases
involving a clinical trial of a different
product, and to the extent the historical
data contain claims for cases involving
expanded access use of immunotherapy
we believe those claims would have
drug charges less than $373,000.
Applying this previously finalized
methodology, based on the December
2021 update of the FY 2021 MedPAR
file used for the proposed rule, we
estimated that the average costs of cases
assigned to MS–DRG 018 that are
identified as clinical trial cases
($61,356) were 20 percent of the average
costs of the cases assigned to MS–DRG
018 that are identified as non-clinical
trial cases ($299,460). Accordingly, as
we did for FY 2022, we proposed to
adjust the transfer-adjusted case count
for MS–DRG 018 by applying the
proposed adjustor of 0.20 to the
applicable clinical trial and expanded
access use immunotherapy cases, and to
use this adjusted case count for MS–
DRG 018 in calculating the national
average cost per case, which is used in
the calculation of the relative weights.
Therefore, in calculating the national
average cost per case for purposes of the
proposed rule, each case identified as an
applicable clinical trial or expanded
access use immunotherapy case was
adjusted by 0.20. As we did for FY 2022,
we applied this same adjustor for the
applicable cases that group to MS–DRG
018 for purposes of budget neutrality
and outlier simulations. We also
proposed to update the value of the
adjustor based on more recent data for
the final rule.
Comment: Several commenters were
supportive of CMS’ continued use of
MS–DRG 018 as it is currently
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
structured, including the identification
and exclusion of CAR T-cell clinical
trial and expanded access use cases
assigned to MS–DRG 018. Commenters
stated that the stability of MS–DRG 018
will help ensure beneficiary access to
CAR T-cell therapy services. One
commenter stated that analysis of CAR
T-cell claims data from FY 2021 through
the first quarter of FY 2022 shows
significant improvement in patient
access to CAR T. Another commenter
requested that CMS reevaluate the
clinical trial threshold annually as
acquisition costs increase and
additional therapies are introduced to
MS–DRG 018.
Other commenters stated that they
were concerned with what they stated
were Medicare under-reimbursements
for CAR T-cell technology, especially
given the array of resources used to treat
patients undergoing these complex,
novel cell therapies and the adverse
impact inadequate reimbursement has
on beneficiary access. A commenter
stated that payment for MS–DRG 018 is
almost 30 percent below the cost of CAR
T-cell cases and does not cover the cost
of the therapy itself. A commenter
recommended that CMS cover the full
cost of the CAR T-cell therapy, while
another commenter requested that CMS
implement a policy solution that will
ensure providers recoup at least the
invoice cost of the CAR T-cell product.
The commenter referenced prior
comments about options for such policy
solutions. Some commenters stated that
the increase in the fixed-loss threshold
makes it even more difficult to obtain
adequate reimbursement. A commenter
requested that CMS closely monitor
reimbursement rates for CAR T-cell
therapies to ensure that hospital
facilities can continue to provide access
to these treatments.
Response: We appreciate the support
and feedback on our proposal to use the
same ratesetting methodology for MS–
DRG 018 in FY 2023 as we have in prior
years. With regard to the commenter
who requested that CMS reevaluate the
clinical trial threshold annually, we
note that we continue to monitor the
data and may engage further with the
public and consider this comment in
connection with future rulemaking.
With regard to the comments that the
MS–DRG relative weight for MS–DRG
018 is inadequate and does not result in
payment that fully covers the hospital
resource costs, we refer readers to the
FY 2022 IPPS/LTCH final rule (86 FR
44965) where we responded to similar
comments.
Comment: A commenter stated that
they understand that outliers are
removed in the development of MS–
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
DRGs so that they do not skew the
results. The commenter found that in
the calculation of the relative weights,
MS–DRG 018 has the highest percent of
cases removed as statistical outliers. The
commenter stated the removal of these
cases resulted in a lower standardized
cost per inpatient stay. Another
commenter requested that CMS monitor
the impact that the removal of these
statistical outliers has on MS–DRG 018
and other low volume services.
Response: We examined the cases
referenced by the commenter that were
removed as statistical outliers in the FY
2021 MedPAR claims data. We found
that these cases had very high charges
and very short lengths of stay, with
daily charges in excess of $1.2 million
relative to the average daily charge of
$114,000 for MS–DRG 018. As described
earlier in this section, our standard
method to identify and remove
statistical outliers excludes cases with
total charges and total daily charges that
are beyond 3 standard deviations from
the geometric mean of the log
distribution of both average total
charges and average total daily charges
of the respective MS–DRG. As described
in section III.B.4.b. of the preamble of
this final rule with respect to the MS–
LTC–DRGs, statistical outliers are
removed because we believe that they
may represent aberrations in the data
that distort the measure of average
resource use. For this reason, we believe
that the cases identified by the
commenters are appropriately excluded
as outliers, as their inclusion could
distort the measure of average resource
use for MS–DRG 018. We will continue
to monitor the removal of statistical
outliers in calculating the relative
weights for MS–DRG 018.
Comment: A commenter
recommended that CMS establish a
new, alternative payment model under
CMMI for gene and cell therapies,
outside of the constraints of the IPPS.
The commenter stated that this would
provide a clearer path to coverage and
payment policy that can improve
patient access. Another commenter
stated that some exceptions to the
standard IPPS process are and will
continue to be needed to allow hospitals
to make lifesaving therapies available at
launch to Medicare beneficiaries as soon
as possible.
Response: We believe that is
premature to make structural changes to
the IPPS at this time to pay for gene and
cell therapies. We may consider these
comments for future rulemaking as we
gain more experience in paying for these
therapies under the IPPS.
Comment: Some commenters
expressed concern that CMS mapped
PO 00000
Frm 00117
Fmt 4701
Sfmt 4700
48895
revenue codes 087X for cell and gene
therapy services furnished by hospital
staff to the drug cost group. One
commenter stated that the NUBC
definition states this revenue code series
is for ‘‘[c]harges for procedures
performed by staff for the acquisition
and infusion/injection of genetically
modified cells’’. The commenter stated
that there is no standard cost center to
report staff expense associated with the
087X series, but that it is inappropriate
to assign the revenue for cell collection
and processing services employed by
hospital nursing and laboratory staff to
the drug/pharmacy cost center. The
commenter stated that if CMS finalizes
this proposed mapping, it will be
inconsistent with the mapping of
revenues and expenses that hospitals
are required to adhere to in their cost
reports. A commenter suggested that
CMS should revise the mapping of the
087X revenue codes to more closely
reflect the departments where the staff
expenses are recorded on the cost
report. Commenters suggested that CMS
map revenue codes 0871 and 0874 to
the ‘‘other’’ cost center and 0872 and
0873 to the laboratory cost center. A
commenter requested that CMS allow
providers to bill for cell collection and
cell processing services on the day that
the services are rendered rather than
adding them to the inpatient claim. The
commenter stated that these are separate
from the manufacturing process and are
not included in the acquisition cost of
the product.
Response: We disagree with the
commenters that revenue center codes
087X are inappropriately mapped to the
drug cost center. Cell collection and
processing activities are part of the steps
required to manufacture the drug, and
thus assignment to the drug cost center
accurately allocates these costs. Given
this, we believe it is appropriate to
apply the drug CCR to these charges for
purposes of calculating the relative
weights. With respect to the commenter
who indicated that finalizing the
proposed assignment of the 087X codes
would be inconsistent with the mapping
of revenues and expenses hospitals are
required to adhere to in their cost
reports, it is unclear to us what
requirements are being referred to. With
respect to the commenter who requested
that CMS allow separate billing for the
cell collection and processing services,
as we discussed in the CY 2022 OPPS
final rule (86 FR 63550), CMS does not
believe that separate payment is
necessary for the various steps required
to collect and prepare the genetically
modified T-cells, and Medicare does not
generally pay separately for each step
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48896
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
used to manufacture a drug or biological
product.
Comment: A commenter requested
that CMS consider allowing hospitals to
use expanded access condition code 90
instead of the remarks field, which
would remove a layer of manual work
required by the MACs, which would
decrease the opportunity for errors.
Response: We agree with the
commenter that the availability of
condition code 90 obviates the need for
the use of the remarks field to identify
expanded access claims that group to
MS–DRG 018 for the purposes of
applying the clinical trial adjustment.
Effective October 1, 2022, providers
should submit condition code 90 to
identify expanded access claims that
group to MS–DRG 018, rather than the
remarks field. The MACs will no longer
flag cases as expanded access claims
based on information submitted in the
remarks field for claims submitted on or
after October 1, 2022.
Comment: A commenter requested
that CMS provide additional
clarification on the agency’s
methodology to develop the relative
weight for both MS–DRG 018 and its
overall ratesetting methodology. This
commenter requested that CMS describe
the order of operations, including stepby-step instructions of when to exclude
certain types of claims. This commenter
also requested that CMS clarify whether
the agency trims claims first, and then
sets aside clinical trial cases, or sets
aside clinical trial claims and claims
with less than $373,000 and then
performs trimming.
Response: In response to the
commenter’s specific question regarding
when CMS removes clinical trial cases
from MS–DRG 018, the trims to remove
clinical trial cases from MS–DRG 018
are done prior to the elimination of
statistical outliers. In response to the
commenter’s request that we clarify our
relative weight methodology more
generally, we note that in each year’s
IPPS/LTCH PPS proposed and final
rules, we include a section describing
the recalibration of the MS–DRG relative
weights and methodology for
calculating the relative weights. We
refer readers to sections II.E.1. and E.2.a.
of the preamble of this final rule, in
which we describe the trims we apply
to the MedPAR claims to exclude nonIPPS claims, and provide a detailed
description of the methodology we use
to calculate the relative weights. The
order that the trims are applied is
consistent with the narrative description
of our methodology. In addition, since
the creation of MS–DRG 018, we have
provided a description of the
calculation of the relative weight for
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
MS–DRG 018, including a step-by-step
calculation of the CAR T-cell clinical
trial adjustment factor, as set forth
earlier in this section.
We also note that some commenters
requested additional clarifications
regarding billing instructions for CAR Tcell therapies, such as appropriate CAR
T-cell billing and charges. We do not
believe changes to billing guidance are
needed at this time but will take these
comments into consideration when
developing policies and program
requirements for future years for CAR Tcell therapy policy.
After consideration of the public
comments we received, we are
finalizing our proposals regarding the
calculation of the relative weight for
MS–DRG 018. Applying this finalized
methodology, based on the March 2022
update of the FY 2021 MedPAR file
used for this final rule, we estimated
that the average costs of cases assigned
to MS–DRG 018 that are identified as
clinical trial cases ($61,540) were 21
percent of the average costs of the cases
assigned to MS–DRG 018 that are
identified as non-clinical trial cases
($293,546). Accordingly, as we did for
FY 2022, we are finalizing our proposal
to adjust the transfer-adjusted case
count for MS–DRG 018 by applying the
adjustor of 0.21 to the applicable
clinical trial and expanded access use
immunotherapy cases, and to use this
adjusted case count for MS–DRG 018 in
calculating the national average cost per
case, which is used in the calculation of
the relative weights. Therefore, in
calculating the national average cost per
case for purposes of this final rule, each
case identified as an applicable clinical
trial or expanded access use
immunotherapy case was adjusted by
0.21. As we did for FY 2022, we are
applying this same adjustor for the
applicable cases that group to MS DRG
018 for purposes of budget neutrality
and outlier simulations.
c. Averaging of Relative Weights for FY
2023
In section I.F. of the proposed rule
and this final rule, we discuss our
proposal to use the FY 2021 MedPAR
data for purposes of FY 2023 IPPS
ratesetting, with certain proposed
modifications to our usual
methodologies, including an averaging
approach for calculating the FY 2023
relative weights. As discussed in the
proposed rule, we observed that
COVID–19 cases were impacting the
relative weights as calculated using the
FY 2021 claims data for a few COVID–
19-related MS–DRGs. For example, for
MS–DRG 870 (Septicemia or Severe
Sepsis with MV >96 hours), the relative
PO 00000
Frm 00118
Fmt 4701
Sfmt 4700
weight calculated using the FY 2021
MedPAR data was approximately 9
percent higher than the relative weight
calculated excluding the COVID–19
cases in the FY 2021 data. As also
discussed in that section, we believe it
is reasonable to assume that there will
be fewer COVID–19 hospitalizations
among Medicare beneficiaries in FY
2023 than there were in FY 2021.
However, we cannot know the precise
number of COVID–19 hospitalizations
among Medicare beneficiaries in FY
2023. To account for the anticipated
decline in COVID–19 hospitalizations of
Medicare beneficiaries as compared to
FY 2021, we proposed to determine the
MS–DRG relative weights for FY 2023
by averaging the relative weights as
calculated with and without COVID–19
cases in the FY 2021 data, as described
in greater detail in this section. Given
the uncertainty in the number of
COVID–19 hospitalizations in FY 2023,
we proposed to use 50 percent of the
relative weights calculated using all
applicable cases in the FY 2021 claims
data and 50 percent of the relative
weights calculated without the COVID–
19 cases in the FY 2021 claims data. We
stated that we believe this proposed
approach would appropriately reduce,
but not remove entirely, the effect of
COVID–19 cases on the relative weight
calculations, consistent with our
expectation that Medicare inpatient
hospitalizations for COVID–19 will
continue in FY 2023 at a lower level as
compared to FY 2021. By averaging the
relative weights in this manner, we
stated that we believe the result would
reflect a reasonable estimation of the
case mix for FY 2023 based on the
information available at the time, as
discussed in section I.F. of the preamble
to the proposed rule and this final rule,
and more accurately estimate the
relative resource use for the cases
treated in FY 2023 than if we were to
calculate the proposed relative weights
based on 100 percent of the relative
weights as calculated for all applicable
cases in the FY 2021 data. For the
proposed rule, our proposed calculation
was as follows:
• Step 1: Calculate a set of relative
weights using all applicable cases in the
December 2021 update of the FY 2021
MedPAR data, using the methodology as
described earlier in this section, and
then applying a normalization
adjustment factor as described later in
this section.
• Step 2: Calculate a set of relative
weights using the December 2021
update of the FY 2021 MedPAR data
excluding cases with a principal or
secondary diagnosis of COVID–19 (ICD–
10–CM diagnosis code U07.1), and
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
otherwise using the methodology as
described earlier in this section, and
then applying a normalization
adjustment factor as described later in
this section.
• Step 3: Average the results of step
1 and step 2 to calculate a set of
averaged relative weights, geometric
mean length of stays, and arithmetic
mean length of stays.
• Step 4: Calculate the proposed FY
2023 relative weights by applying an
additional normalization factor to these
averaged relative weights. This
additional normalization factor is
necessary to ensure that the average case
weight as calculated in step 3 of this
proposed averaging methodology for
recalibration of the FY 2023 relative
weights is equal to the average case
weight before recalibration. We note
that this factor is very close to 1 and is
described later in this section.
We noted that in Step 5 of this
proposed calculation, we applied the
proposed 10 percent cap to the relative
weights for those MS–DRGs for which
the relative weight as calculated in Step
4 would otherwise have declined by
more than 10 percent from the FY 2022
relative weight, as discussed more fully
later in this section. We also noted that
we intended to update this calculation
for the final rule using the March 2022
update of the FY 2021 MedPAR file.
We set forth the proposed relative
weights, geometric mean length of stay,
and average length of stay as calculated
using this proposed methodology in
Table 5 associated with the proposed
rule, which is available on the CMS
website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS. We also
made available the relative weights,
geometric mean length of stay, and
average length of stay as calculated in
steps 1 and 2 of this proposed
methodology on our website at https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS.
Comment: Several commenters
supported our proposal to average the
relative weights calculated with and
without COVID–19 cases, stating that
this would more accurately account for
the anticipated change in case mix as
COVID–19 cases decline.
Another commenter supported an
alternative MS–DRG relative weight
methodology, but stated that the
proposed methodology does not do
enough to control for variability. This
commenter requested that CMS use FY
2019 claims or some other alternate
blend using the FY 2021 claims to
establish the FY 2023 relative weights.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Some commenters expressed concern
about policies that may limit the
reimbursement for COVID–19 cases. A
commenter suggested increasing the
relative weights for the MS–DRGs that
have documented COVID–19 cases, but
recommended that CMS consider a
process to differentiate patients who test
asymptomatically for COVID–19 from
those whose COVID–19 infection is
causing clinical symptoms to worsen.
The commenter stated that this
approach would better target the more
resource intensive beneficiaries without
artificially constraining reimbursement
for their care.
Response: We appreciate commenters’
support for and feedback on our
proposal. However, we disagree that we
should blend other data sources or take
additional steps to control for variability
in the FY 2023 relative weights. As we
stated in the FY 2023 IPPS/LTCH PPS
proposed rule, we cannot know the
precise number of COVID–19
hospitalizations among Medicare
beneficiaries as compared to FY 2021.
Our proposal to average the relative
weights is intended to reflect a
reasonable estimation of the case mix
for FY 2023 based on the information
available at this time, not to completely
remove all variability in the FY 2023
relative weights. Our proposed
methodology uses the FY 2021 MedPAR
claims file to determine the FY 2023
relative weights, as the most recent
available data during the period of the
COVID–19 PHE, with modifications to
account for the anticipated decline in
COVID–19 hospitalizations of Medicare
beneficiaries at IPPS hospitals as
compared to FY 2021. As discussed in
section I.F. of this final rule, after
reviewing the latest CDC hospitalization
data available at this time, we continue
to believe that it is reasonable to assume
that some Medicare beneficiaries will be
hospitalized with COVID–19 at IPPS
hospitals in FY 2023, but that there will
be fewer COVID 19 hospitalizations as
compared to FY 2021. With respect to
the commenters’ concerns about
policies that may limit reimbursement
for COVID–19 cases, we note that the
majority of cases that include a
diagnosis of COVID–19 (ICD–10–CM
diagnosis code U07.1) group to MS–
DRGs 177 and 871, and that the relative
weights calculated using the proposed
averaging methodology for FY 2023 are
higher than the FY 2022 relative weights
for these MS–DRGs. For MS–DRG 177,
the relative weight calculated using the
proposed averaging approach is also
higher than the relative weight
calculated using all applicable cases in
the FY 2021 MedPAR file. For MS–DRG
PO 00000
Frm 00119
Fmt 4701
Sfmt 4700
48897
871, while the relative weight calculated
using the proposed averaging approach
is lower than the relative weight
calculated using all applicable cases in
the FY 2021 MedPAR file, it is still an
increase as compared to the relative
weight for FY 2022. Moreover, as
previously discussed, we believe that
use of the proposed averaging
methodology would provide a more
accurate estimate of relative resource
use for FY 2023 than if we were to
calculate the proposed relative weights
using all applicable cases in the FY
2021 data, and is consistent with our
expectation, based on the information
available at this time, that Medicare
inpatient hospitalizations for COVID–19
will continue in FY 2023 at a lower
level as compared to FY 2021. With
regard to the suggestion about
differentiating between symptomatic
and asymptomatic COVID–19 cases, at
this time we do not believe it is
operationally feasible to make such a
distinction given that separate coding
does not exist to differentiate these
cases. We may consider this suggestion
in connection with future rulemaking.
After consideration of comments
received, we are finalizing our proposal
to determine the FY 2023 MS–DRG
relative weights by averaging the
relative weights as calculated with and
without COVID–19 cases in the FY 2021
data, as previously described. As
previously discussed, for this final rule,
we are using the March 2022 update of
the FY 2021 MedPAR file to determine
the final relative weights for FY 2023.
The relative weights, geometric mean
length of stay, and average length of stay
as calculated using this methodology are
set forth in Table 5 associated with this
final rule, which is available on the
CMS website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS. We are
also making available the relative
weights, geometric mean length of stay,
and average length of stay as calculated
in steps 1 and 2 of this methodology on
our website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS.
d. Cap for Relative Weight Reductions
In the FY 2018 IPPS/LTCH PPS final
rule, we summarized comments we had
received requesting a transition period
for substantial reductions in relative
weights in order to facilitate payment
stability. Specifically, some commenters
requested that CMS establish a cap on
the decline in a relative weight from FY
2017 to FY 2018, or a phase-in or multiyear transition period in cases of
substantial fluctuation of payment rates
(82 FR 38103).
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48898
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
After consideration of these
comments, and for the reasons
discussed in the FY 2018 final rule, we
adopted a temporary one-time measure
for FY 2018 for MS–DRGs where the
relative weight would have declined by
more than 20 percent from the FY 2017
relative weight, consistent with our
general authority to assign and update
appropriate weighting factors under
sections 1886(d)(4)(B) and (C) of the Act
(82 FR 38103). Specifically, for these
MS–DRGs, the relative weight for FY
2018 was set at 80 percent of the FY
2017 relative weight. In the FY 2019
IPPS/LTCH PPS final rule, in response
to similar comments, we adopted a
temporary one-time measure for FY
2019 for an MS–DRG where the FY 2018
relative weight declined by 20 percent
from the FY 2017 relative weight and
the FY 2019 relative weight would have
declined by 20 percent or more from the
FY 2018 relative weight (83 FR 41273).
Specifically, for an MS–DRG meeting
this criterion, we set the FY 2019
relative weight equal to the FY 2018
relative weight. In the FY 2020 IPPS/
LTCH PPS final rule, in response to
similar comments, we adopted a
temporary one-time measure for FY
2020 for an MS–DRG where the FY 2018
relative weight declined by 20 percent
from the FY 2017 relative weight and
the FY 2020 relative weight would have
declined by 20 percent or more from the
FY 2019 relative weight, which was
maintained at the FY 2018 relative
weight (84 FR 42167). Specifically, for
an MS–DRG meeting this criterion, we
set the FY 2020 relative weight equal to
the FY 2019 relative weight, which was
in turn set equal to the FY 2018 relative
weight.
In the FY 2021 IPPS/LTCH PPS
proposed rule, we noted the one-time
measure adopted for FY 2020 and
sought comment on whether we should
consider a similar policy for FY 2021, or
an alternative approach such as
averaging the FY 2020 relative weight
and the otherwise applicable FY 2021
relative weight for MS–DRG 215, which
was the only MS–DRG impacted by the
FY 2020 policy setting the FY 2020
relative weight equal to the FY 2019
relative weight. Commenters generally
supported either setting the FY 2021
weight for MS–DRG 215 equal to the FY
2020 relative weight or an averaging
approach. Some commenters requested
that CMS consider such an approach
when the relative weight for an MS–
DRG is drastically reduced in a given
year, particularly when it follows a
significant decline in prior years. After
consideration of comments received,
and for the reasons discussed in the FY
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
2021 final rule, we set the FY 2021
relative weight for MS–DRG 215 equal
to the average of the FY 2020 relative
weight and the otherwise applicable FY
2021 weight. With regard to the
concerns raised about other MS–DRGs
with significant reductions relative to
FY 2020, we noted that these other MS–
DRGs were low volume in our claims
data, and therefore typically experience
a greater degree of year-to-year
variation. We acknowledged the
longstanding concerns related to low
volume MS–DRGs and stated that we
would take into consideration the
unique issues relating to such MS–DRGs
and the stability of their weights for
future rulemaking.
As we stated in the FY 2023 IPPS/
LTCH PPS proposed rule, we have
continued to consider the comments we
received in response to prior rulemaking
recommending that CMS limit
significant declines in the relative
weights for the MS–DRGs more broadly,
including by establishing a cap on the
degree to which the relative weight for
an MS–DRG may decline from one fiscal
year to the next. For prior fiscal years,
as previously discussed, we have
adopted limited, temporary measures to
address potentially substantial declines
in the relative weights in certain outlier
circumstances to mitigate the impacts of
such declines. However, we have also
acknowledged commenters’ concerns
related to significant reductions in the
weights for other MS–DRGs, in
particular low volume MS–DRGs. For
these low volume MS–DRGs,
fluctuations in the volume or mix of
cases and/or the presence of a few high
cost or low cost cases can have a
disproportionate impact on the
calculated relative weight, thus
resulting in greater year-to-year
variation in the relative weights for
these MS–DRGs. This variation may
reduce the predictability and stability of
an individual hospital’s Medicare
payments from year-to-year. We also
recognize that significant declines in the
relative weights may occur for highervolume MS–DRGs, with such
fluctuations likewise affecting the
predictability and stability of hospital
payments.
In light of these concerns, we have
further considered requests made by
commenters that we address year-toyear fluctuations in relative weights,
particularly for low volume MS–DRGs,
and to mitigate the financial impacts of
significant fluctuations. In consideration
of the concerns that commenters have
raised about year-to-year fluctuations in
relative weights and the financial
impacts of significant fluctuations, we
stated in the proposed rule that we
PO 00000
Frm 00120
Fmt 4701
Sfmt 4700
believe it would be appropriate to limit
such fluctuations by applying a cap on
reductions in the relative weight for an
MS–DRG for a given fiscal year.
Therefore, consistent with our statutory
authority under section 1886(d)(4)(B)
and (C) of the Act to assign and update
appropriate weighting factors, we
proposed a permanent 10-percent cap
on the reduction in an MS–DRG’s
relative weight in a given fiscal year,
beginning in FY 2023. This proposal is
consistent with our general authority to
assign and update appropriate
weighting factors as part of our annual
reclassification of the MS–DRGs and
recalibration of the relative weights
under sections 1886(d)(4)(B) and (C)(i)
of the Act, as well as the requirements
of section 1886(d)(4)(C)(iii) of the Act,
which specifies that the annual DRG
reclassification and recalibration of the
relative weights be made in a manner
that ensures that aggregate payments to
hospitals are not affected. In addition,
we have authority to implement this
proposed cap and the associated budget
neutrality adjustment under our special
exceptions and adjustments authority at
section 1886(d)(5)(I)(i) of the Act, which
similarly gives the Secretary broad
authority to provide by regulation for
such other exceptions and adjustments
to the payment amounts under section
1886(d) of the Act as the Secretary
deems appropriate. As discussed, we
believe this cap on declines in the
relative weights would be appropriate in
order to promote predictability and
stability in hospital payments and to
mitigate the financial impacts of
significant fluctuations in the weights.
That is, by smoothing year-to-year
changes in the MS–DRG relative
weights, we stated that this proposal
would provide greater predictability to
hospitals, allowing time to adjust to
significant changes to relative weights.
Moreover, consistent with the budget
neutrality requirement for annual
updates to the relative weights,
including our implementation of similar
caps on significant declines in the
relative weight for prior fiscal years, we
believe that application of this proposed
10-percent cap on relative weight
reductions should not increase
estimated aggregate Medicare payments
beyond the payments that would be
made had we never applied this cap.
Accordingly, we proposed to apply a
budget neutrality adjustment to the
standardized amount for all hospitals to
ensure that application of the proposed
10-percent cap does not result in an
increase or decrease of estimated
aggregate payments. For a further
discussion of the budget neutrality
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
adjustment, we refer readers to the
Addendum of the proposed rule and
this final rule.
Under this proposal, in cases where
the relative weight for a MS–DRG would
decrease by more than 10 percent in a
given fiscal year, we proposed to limit
the reduction to 10 percent for that
fiscal year. For example, if the relative
weight for an MS–DRG in FY 2022 is
1.100 and the relative weight for FY
2023 would otherwise be 0.9350, which
would represent a decrease of 15
percent from FY 2022, the reduction
would be limited to 10 percent, such
that the proposed relative weight for FY
2023 for MS–DRG XYZ would be 0.9900
(that is, 0.90 × FY 2022 weight of 1.100).
The proposed relative weights for FY
2023 as set forth in Table 5 associated
with the proposed rule and available on
the CMS website at https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatientPPS
reflect the application of this proposed
cap.
As previously summarized, in the
past, we have adopted a temporary cap
of 20 percent on the decline in an MS–
DRG’s relative weight to address certain
outlier circumstances. However, as also
previously discussed, we recognize that
hospitals may benefit from the phase-in
of smaller declines in the relative
weight that may nonetheless contribute
to less stability and predictability in
hospital payment rates. Accordingly, for
purposes of this proposed permanent
cap, we considered that a higher cap,
such as the 20-percent cap that we have
applied previously (see, for example, 82
FR 38103), would limit declines in the
relative weights for fewer MS–DRGs (5
MS–DRGs in our analysis of the March
2022 update of the FY 2021 MedPAR
claims), while a lower cap, such as a 5percent cap, would limit declines in the
relative weights for more MS–DRGs (92
MS–DRGs in our analysis of the March
2022 update of the FY 2021 MedPAR
claims), but with a larger associated
budget neutrality adjustment to the
standardized amount. On balance, we
stated that we believe that a 10-percent
cap would mitigate financial impacts
resulting from significant fluctuations in
the relative weights, particularly for low
volume MS–DRGs, without the larger
budget neutrality adjustment associated
with a smaller cap. We noted that this
proposed policy would limit declines in
the relative weight for 27 MS–DRGs,
based on the FY 2021 claims data used
for the proposed rule; based on the
March 2022 update of the FY 2021
claims data used for this final rule, we
note that it would limit declines in the
relative weights for 31 MS–DRGs.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
We noted that this proposed 10percent cap on reductions to an MS–
DRG’s relative weight would apply only
to a given MS–DRG with its current
MS–DRG number. In cases where CMS
creates new MS–DRGs or modifies the
MS–DRGs as part of its annual
reclassifications resulting in
renumbering of one or more MS–DRGs,
we proposed that this limit on the
reduction in the relative weight would
not apply to any MS–DRGs affected by
the renumbering (that is, the proposed
10-percent cap would not apply to the
relative weight for any new or
renumbered MS–DRGs for the fiscal
year). We proposed to modify the
regulations at § 412.60(b) to reflect this
proposed permanent cap on relative
weight reductions. We sought comments
on our proposal to apply a 10-percent
cap on decreases in an MS–DRG relative
weight from one fiscal year to the next.
Comment: Many commenters
supported our proposal to cap yearly
reductions in an MS–DRG’s relative
weight to 10%. Commenters stated that
significant year-over-year reductions
can disrupt patient access to medically
necessary treatment, that large swings
are inconsistent with the principle of
payment stability, and that a permanent
10 percent cap would provide more
time for providers to adjust to
significant changes in relative weights.
A commenter stated that a cap on
relative weight decreases could
incentivize greater innovation, as
hospitals may avoid MS–DRGs with
significant declines, even if they offer
more innovative, cost-saving treatment
approaches. This commenter stated that
mitigating large year-to-year payment
changes would encourage providers to
use the most clinically appropriate care.
Commenters also stated that the cap is
particularly helpful for low volume
services, as they stated that shifts in
these MS–DRGs are not reflective of true
changes in the cost of care.
Some commenters requested that
CMS apply the cap in a non-budget
neutral manner. A commenter requested
that CMS monitor for any unintended
consequences of the cap, given that it is
budget neutral.
Many commenters requested that
CMS finalize a permanent lower cap,
with some commenters expressing
concern that with a 10% cap, there are
still sizable reductions for high-cost
MS–DRGs. Other commenters requested
that CMS finalize a one-year cap of 5%,
followed by a permanent cap of 10%.
Several commenters recommended a
permanent 5% cap, while others
requested CMS set the floor as low as
possible. Some commenters noted that a
broad range of MS–DRGs have weight
PO 00000
Frm 00121
Fmt 4701
Sfmt 4700
48899
fluctuations in FY 2023 due to unique
circumstances, such as the first use of
hospital data impacted by the COVID–
19 PHE for IPPS ratesetting. A
commenter stated that the 10% cap
benefits mostly medical MS–DRGs,
while many surgical MS–DRGs would
experience reductions greater than 5
percent but less than 10 percent. This
commenter stated that capping
reductions at 5% is consistent with the
rationale to blend hospital claims with
and without COVID–19, due to the
uncertainty around the degree to which
FY 2021 will reflect hospitals’ costs and
case mix in FY 2023. One commenter
noted that their analysis of the MS–DRG
relative weights showed that the average
yearly variation in relative weights was
5%, so a permanent 5% cap is more in
line with historical MS–DRG variation.
A commenter stated that there is
precedent of a 5% cap in other parts of
the IPPS, such as the wage index.
One commenter requested that if CMS
finalizes a 10% cap, that the agency
continue to monitor whether a 10% cap
is appropriate. A commenter requested
that CMS update this policy clearly and
transparently, and with additional
stakeholder input, on an annual basis to
maintain stability and predictability.
Some commenters acknowledged that
setting a lower threshold for the cap
would necessitate a larger budget
neutrality adjustment, but that the
redistributive impact would be minimal
overall. These commenters stated that
on balance it is still preferable to
smooth the impact of steep payment
declines for a larger number of services.
One commenter stated that it is
premature for CMS to adopt a
permanent cap, and recommended that
CMS implement the 10% cap for FY
2023 only without a budget neutrality
offset. This commenter stated that as
COVID–19 becomes more endemic in
the population, and less severe and
costly in hospitals, Medicare utilization
would be expected to return to its
former level of annual stability, negating
the need for a permanent cap on
reductions to relative weights.
A commenter requested that any caps
on the maximum annual change to the
MS–DRG relative weights should not
apply to just decreases but to increases
as well.
A commenter stated that any new
MS–DRG or modified version of an
existing MS–DRG would benefit from
the 10% cap in subsequent years
following its introduction or
modification. This commenter requested
that CMS apply the 10% cap to all MS–
DRGs once the MS–DRG has been
established and gone through at least
one year of the relative weight setting
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48900
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
process. This commenter also requested
that CMS consider how this type of
policy could support long term payment
stability for relative weights and
hospital payments.
One commenter suggested that similar
caps on payment reductions would be
beneficial under the OPPS and PFS for
revised or bundled coding updates.
Response: We appreciate commenters’
support for and feedback on our
proposal. However, we disagree with
the suggestion that the proposed cap be
applied in a non-budget neutral manner.
As we stated in the IPPS/LTCH PPS
proposed rule, our proposal is
consistent with the requirements of
section 1886(d)(4)(C)(iii) of the Act,
which specifies that the annual DRG
reclassification and recalibration of the
relative weights be made in a manner
that ensures that aggregate payments to
hospitals are not affected. Consistent
with this budget neutrality requirement
for annual updates to the relative
weights, we believe that application of
this proposed 10-percent cap on relative
weight reductions should not increase
estimated aggregate Medicare payments
beyond the payments that would be
made had we never applied this cap.
This is also consistent with our
implementation of similar caps on
significant declines in the relative
weight for prior fiscal years, as
previously summarized.
We appreciate commenters’ feedback
on the size of the cap on year-to-year
declines in an MS–DRG’s relative
weight, however we disagree that we
should finalize a lower cap, whether for
one year or on a permanent basis. As
discussed in the proposed rule, after
considering larger and smaller caps, we
determined that on balance, a 10percent cap would promote
predictability and mitigate financial
impacts resulting from significant
fluctuations in the relative weights,
particularly for low volume MS–DRGs,
without the larger budget neutrality
adjustment associated with a smaller
cap. With respect to commenters who
stated that we should finalize a five
percent cap because there were greater
fluctuations due to the first use of the
PHE data for ratesetting and that many
surgical MS–DRGs would experience
declines of between 5 and 10 percent,
we note that declines in relative weights
between 5 and 10 percent are not
uncommon. For example, we note that
prior to the PHE, and relative to the 25
medical MS–DRGs and 36 surgical MS–
DRGs for which the FY 2023 relative
weight is declining between 5 and 10
percent as compared to FY 2022 (based
on the March 2022 update of the FY
2021 claims data used for this final
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
rule), for the FY 2020 IPPS/LTCH PPS
final rule, 27 surgical MS–DRGs and 21
medical MS–DRGs declined between 5
and 10 percent, and for the FY 2019
IPPS/LTCH PPS final rule, 32 surgical
MS–DRGs and 25 medical MS–DRGs
declined between 5 and 10 percent.
Therefore, we do not believe that the
number of MS–DRGs for which the FY
2023 relative weight is declining
between 5 and 10 percent is unusual or
necessarily related to the first use of the
PHE data. We therefore continue to
believe that a 10-percent cap strikes the
appropriate balance between
considerations of promoting
predictability and mitigating financial
impacts resulting from significant
fluctuations in the relative weights,
without the larger budget neutrality
adjustment associated with a smaller
cap. We acknowledge commenters’
observation that most MS–DRGs
impacted by the cap for FY 2023 are
medical MS–DRGs; we note that the
particular MS–DRGs impacted in a
given year would be expected to
fluctuate based on changes in the
underlying data or as result of
reclassifications.
With respect to the commenters who
requested that CMS implement a 10percent cap for one year only or update
the policy on an annual basis, we
believe that in order to better promote
predictability and stability in hospital
payments, it is appropriate to finalize a
permanent 10-percent cap on year-toyear declines in the relative weight,
beginning with the FY 2023 relative
weights. We expect to continue to
monitor the effects of this cap, including
the number of MS–DRGs subject to the
cap for any given fiscal year, and to
present in the Addendum to the annual
proposed and final rules the budget
neutrality adjustment for reclassification
and recalibration of the MS–DRG
relative weights with application of this
cap. We also anticipate continuing to
make available on the CMS website a
supplemental file demonstrating the
application of the permanent 10 percent
cap for future years.
With regard to the comment
requesting that caps on maximum
changes to an MS–DRG’s relative weight
apply to increases as well, as discussed
in the IPPS/LTCH PPS proposed rule,
our goal in smoothing year-to-year
changes in the relative weights is to
mitigate financial impacts associated
with significant declines in an MS–
DRG’s relative weight and allow
hospitals more time to adjust to such
changes by phasing-in these declines. In
cases where the underlying data or MS–
DRG reclassifications result in an
increase to an MS–DRG’s relative
PO 00000
Frm 00122
Fmt 4701
Sfmt 4700
weight, we do not believe a such a
phase-in is appropriate.
With regard to new or modified MS–
DRGs, we are clarifying that after the
first fiscal year that these new or
modified MS–DRGs take effect, any
changes to the relative weights for those
MS–DRGs would also be subject to the
10-percent cap.
With regard to the commenter’s
suggestion about long-term payment
stability, we note that the goal of this
policy is to smooth year-to-year
changes.
With regard to similar caps on
payment under other payment systems,
we note that this comment is outside the
scope of the proposals included in the
FY 2023 IPPS/LTCH PPS proposed rule,
and we are therefore not addressing this
comment in this final rule. We may
consider this comment in connection
with future rulemaking.
After consideration of comments
received, we are finalizing the proposed
permanent 10-percent cap on the
reduction in an MS–DRG’s relative
weight in a given fiscal year and the
associated budget neutrality adjustment
to the standardized amount, as
previously described in this section,
beginning in FY 2023. We are also
finalizing our proposed modifications to
the regulations at § 412.60(b) to reflect
this permanent cap on relative weight
reductions. The final relative weights
for FY 2023 as set forth in Table 5
associated with this final rule and
available on the CMS website at https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatientPPS
reflect the application of this finalized
cap. For a further discussion of the
budget neutrality adjustment for FY
2023, we refer readers to the Addendum
of this final rule.
3. Development of National Average
CCRs
We developed the national average
CCRs as follows:
Using the FY 2020 cost report data,
we removed CAHs, Indian Health
Service hospitals, all-inclusive rate
hospitals, and cost reports that
represented time periods of less than 1
year (365 days). We included hospitals
located in Maryland because we include
their charges in our claims database.
Then we created CCRs for each provider
for each cost center (see the
supplemental data file for line items
used in the calculations) and removed
any CCRs that were greater than 10 or
less than 0.01. We normalized the
departmental CCRs by dividing the CCR
for each department by the total CCR for
the hospital for the purpose of trimming
the data. Then we took the logs of the
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
normalized cost center CCRs and
removed any cost center CCRs where
the log of the cost center CCR was
greater or less than the mean log plus/
minus 3 times the standard deviation for
the log of that cost center CCR. Once the
cost report data were trimmed, we
calculated a Medicare-specific CCR. The
Medicare-specific CCR was determined
by taking the Medicare charges for each
line item from Worksheet D–3 and
deriving the Medicare-specific costs by
applying the hospital-specific
departmental CCRs to the Medicarespecific charges for each line item from
Worksheet D–3. Once each hospital’s
Medicare-specific costs were
established, we summed the total
Medicare-specific costs and divided by
the sum of the total Medicare-specific
charges to produce national average,
charge-weighted CCRs.
After we multiplied the total charges
for each MS–DRG in each of the 19 cost
centers by the corresponding national
average CCR, we summed the 19 ‘‘costs’’
across each MS–DRG to produce a total
standardized cost for the MS–DRG. The
average standardized cost for each MS–
DRG was then computed as the total
standardized cost for the MS–DRG
divided by the transfer-adjusted case
count for the MS–DRG. The average cost
for each MS–DRG was then divided by
the national average standardized cost
per case to determine the proposed
relative weight.
As discussed earlier in this section,
we are finalizing our proposal to (a) use
50 percent of the relative weights
calculated using all cases in the FY 2021
MedPAR data and 50 percent of the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
relative weights calculated without
COVID–19 cases in the FY 2021
MedPAR data to calculate the relative
weights for FY 2023; and (b) apply a
permanent 10-percent cap on the
reduction in a MS–DRG’s relative
weight in a given fiscal year, beginning
in FY 2023.
In developing the relative weights
consistent with these finalized policies,
we first created a set of relative weights
using all applicable cases in the March
2022 update of the FY 2021 MedPAR
data, using the methodology as
described earlier in this section (Step 1).
These relative weights were then
normalized by an adjustment factor of
1.948410 so that the average case weight
after recalibration was equal to the
average case weight before recalibration.
The normalization adjustment is
intended to ensure that recalibration by
itself neither increases nor decreases
total payments under the IPPS, as
required by section 1886(d)(4)(C)(iii) of
the Act.
Next, we created a set of relative
weights using the March 2022 update of
the FY 2021 MedPAR data excluding
cases with a principal or secondary
diagnosis of COVID–19 (ICD–10–CM
diagnosis code U07.1), and otherwise
using the methodology as described
earlier in this section (Step 2). These
relative weights were then normalized
by an adjustment factor of 1.916445.
We then averaged the results of Step
1 and Step 2 (Step 3), and normalized
these relative weights by applying an
adjustment factor of 1.000212 (Step 4).
This normalization adjustment is
intended to ensure that this averaging
PO 00000
Frm 00123
Fmt 4701
Sfmt 4700
48901
methodology for recalibration of the FY
2023 relative weights neither increases
nor decreases total payments under the
IPPS, as required by section
1886(d)(4)(C)(iii) of the Act.
Finally, we applied the 10 percent cap
to the relative weights for those MS–
DRGs for which the relative weight as
calculated in Step 4 would otherwise
have declined by more than 10 percent
from the FY 2022 relative weight (Step
5). Specifically, for those MS–DRGs for
which the relative weight as calculated
in Step 4 declined by more than 10
percent from the FY 2022 relative
weight, we set the FY 2023 relative
weight equal to 90 percent of the FY
2022 relative weight. The relative
weights for FY 2023 as set forth in Table
5 associated with this final rule and
available on the CMS website at https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatientPPS
reflect the application of this cap. We
are also making available a
supplemental file setting forth the
relative weights as calculated with all
cases (Step 1), excluding cases with a
principal or secondary diagnosis of
COVID–19 (Step 2), following
application of the normalization factor
and prior to the application of this cap
(Step 4), and with the application of this
cap (Step 5) along with the other
supplemental files for this final rule, on
the CMS website at https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS.
The 19 national average CCRs for FY
2023 are as follows:
BILLING CODE 4120–01–P
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
CCR
Group
Routine Days
Intensive Days
Drugs
Supplies & Equipment
Implantable Devices
Inhalation Therapy
Therapy Services
Anesthesia
Labor & Delivery
Operating Room
Cardiology
Cardiac Catheterization
Laboratory
Radiology
MRis
CT Scans
Emergency Room
Blood and Blood Products
Other Services
khammond on DSKJM1Z7X2PROD with RULES2
Since FY 2009, the relative weights
have been based on 100 percent cost
weights based on our MS–DRG grouping
system.
When we recalibrated the DRG
weights for previous years, we set a
threshold of 10 cases as the minimum
number of cases required to compute a
reasonable weight. We are proposed to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
0.422
0.341
0.184
0.311
0.281
0.15
0.283
0.072
0.366
0.165
0.094
0.104
0.107
0.137
0.071
0.034
0.155
0.255
0.359
use that same case threshold in
recalibrating the proposed MS–DRG
relative weights for FY 2023. Using data
from the FY 2021 MedPAR file, there
were 7 MS–DRGs that contain fewer
than 10 cases. For FY 2023, because we
do not have sufficient MedPAR data to
set accurate and stable cost relative
PO 00000
Frm 00124
Fmt 4701
Sfmt 4700
weights for these low-volume MS–
DRGs, we proposed to compute relative
weights for the low-volume MS–DRGs
by adjusting their final FY 2022 relative
weights by the percentage change in the
average weight of the cases in other MS–
DRGs from FY 2022 to FY 2023. The
crosswalk table is as follows.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.074
48902
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
MS-DRG Title
Neonates, Died or Transferred to Another
Acute Care Facility
790
Extreme Immaturity or Respiratory Distress
Syndrome, Neonate
791
Prematurity with Major Problems
792
Prematurity without Major Problems
793
Full-Term Neonate with Major Problems
794
Neonate with Other Significant Problems
795
Normal Newborn
BILLING CODE 4120–01–C
We did not receive any public
comments on our proposals and we are
finalizing our proposals without
modification.
F. Add-On Payments for New Services
and Technologies for FY 2023
1. Background
khammond on DSKJM1Z7X2PROD with RULES2
Crosswalk to MS-DRG
789
Sections 1886(d)(5)(K) and (L) of the
Act establish a process of identifying
and ensuring adequate payment for new
medical services and technologies
(sometimes collectively referred to in
this section as ‘‘new technologies’’)
under the IPPS. Section
1886(d)(5)(K)(vi) of the Act specifies
that a medical service or technology will
be considered new if it meets criteria
established by the Secretary after notice
and opportunity for public comment.
Section 1886(d)(5)(K)(ii)(I) of the Act
specifies that a new medical service or
technology may be considered for new
technology add-on payment if, based on
the estimated costs incurred with
respect to discharges involving such
service or technology, the DRG
prospective payment rate otherwise
applicable to such discharges under this
subsection is inadequate. The
regulations at 42 CFR 412.87 implement
these provisions and § 412.87(b)
specifies three criteria for a new medical
service or technology to receive the
additional payment: (1) the medical
service or technology must be new; (2)
the medical service or technology must
be costly such that the DRG rate
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Final FY 2022 relative weight (adjusted by percent
change in average weight of the cases in other
MS-DRGs)
Final FY 2022 relative weight (adjusted by percent
change in average weight of the cases in other
MS-DRGs)
Final FY 2022 relative weight (adjusted by percent
change in average weight of the cases in other
MS-DRGs)
Final FY 2022 relative weight (adjusted by percent
change in average weight of the cases in other
MS-DRGs)
Final FY 2022 relative weight (adjusted by percent
change in average weight of the cases in other
MS-DRGs)
Final FY 2022 relative weight (adjusted by percent
change in average weight of the cases in other
MS-DRGs)
Final FY 2022 relative weight (adjusted by percent
change in average weight of the cases in other
MS-DRGs)
otherwise applicable to discharges
involving the medical service or
technology is determined to be
inadequate; and (3) the service or
technology must demonstrate a
substantial clinical improvement over
existing services or technologies. In
addition, certain transformative new
devices and antimicrobial products may
qualify under an alternative inpatient
new technology add-on payment
pathway, as set forth in the regulations
at § 412.87(c) and (d). We note that
section 1886(d)(5)(K)(i) of the Act
requires that the Secretary establish a
mechanism to recognize the costs of
new medical services and technologies
under the payment system established
under that subsection, which establishes
the system for paying for the operating
costs of inpatient hospital services. The
system of payment for capital costs is
established under section 1886(g) of the
Act. Therefore, as discussed in prior
rulemaking (72 FR 47307 through
47308), we do not include capital costs
in the add-on payments for a new
medical service or technology or make
new technology add-on payments under
the IPPS for capital-related costs.
In this rule, we highlight some of the
major statutory and regulatory
provisions relevant to the new
technology add-on payment criteria, as
well as other information. For further
discussion on the new technology addon payment criteria, we refer readers to
the FY 2012 IPPS/LTCH PPS final rule
(76 FR 51572 through 51574), the FY
PO 00000
Frm 00125
Fmt 4701
Sfmt 4700
2020 IPPS/LTCH PPS final rule (84 FR
42288 through 42300), and the FY 2021
IPPS/LTCH PPS final rule (85 FR 58736
through 58742).
a. New Technology Add-On Payment
Criteria
(1) Newness Criterion
Under the first criterion, as reflected
in § 412.87(b)(2), a specific medical
service or technology will no longer be
considered ‘‘new’’ for purposes of new
medical service or technology add-on
payments after CMS has recalibrated the
MS–DRGs, based on available data, to
reflect the cost of the technology. We
note that we do not consider a service
or technology to be new if it is
substantially similar to one or more
existing technologies. That is, even if a
medical product receives a new FDA
approval or clearance, it may not
necessarily be considered ‘‘new’’ for
purposes of new technology add-on
payments if it is ‘‘substantially similar’’
to another medical product that was
approved or cleared by FDA and has
been on the market for more than 2 to
3 years. In the FY 2010 IPPS/RY 2010
LTCH PPS final rule (74 FR 43813
through 43814), we established criteria
for evaluating whether a new
technology is substantially similar to an
existing technology, specifically
whether: (1) a product uses the same or
a similar mechanism of action to
achieve a therapeutic outcome; (2) a
product is assigned to the same or a
different MS–DRG; and (3) the new use
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.075
Low-Volume
MS-DRG
48903
48904
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
of the technology involves the treatment
of the same or similar type of disease
and the same or similar patient
population. If a technology meets all
three of these criteria, it would be
considered substantially similar to an
existing technology and would not be
considered ‘‘new’’ for purposes of new
technology add-on payments. For a
detailed discussion of the criteria for
substantial similarity, we refer readers
to the FY 2006 IPPS final rule (70 FR
47351 through 47352) and the FY 2010
IPPS/LTCH PPS final rule (74 FR 43813
through 43814).
(2) Cost Criterion
Under the second criterion,
§ 412.87(b)(3) further provides that, to
be eligible for the add-on payment for
new medical services or technologies,
the MS–DRG prospective payment rate
otherwise applicable to discharges
involving the new medical service or
technology must be assessed for
adequacy. Under the cost criterion,
consistent with the formula specified in
section 1886(d)(5)(K)(ii)(I) of the Act, to
assess the adequacy of payment for a
new technology paid under the
applicable MS–DRG prospective
payment rate, we evaluate whether the
charges of the cases involving a new
medical service or technology will
exceed a threshold amount that is the
lesser of 75% of the standardized
amount (increased to reflect the
difference between cost and charges) or
75% of one standard deviation beyond
the geometric mean standardized charge
for all cases in the MS–DRG to which
the new medical service or technology
is assigned (or the case-weighted
average of all relevant MS–DRGs if the
new medical service or technology
occurs in many different MS–DRGs).
The MS–DRG threshold amounts
generally used in evaluating new
technology add-on payment
applications for FY 2023 are presented
in a data file that is available, along with
the other data files associated with the
FY 2022 IPPS/LTCH PPS final rule and
correction notice, on the CMS website at
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/index.
We note that, under the policy
finalized in the FY 2021 IPPS/LTCH
PPS final rule (85 FR 58603 through
58605), beginning with FY 2022, we use
the proposed threshold values
associated with the proposed rule for
that fiscal year to evaluate the cost
criterion for all applications for new
technology add-on payments and
previously approved technologies that
may continue to receive new technology
add-on payments, if those technologies
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
would be assigned to a proposed new
MS–DRG for that same fiscal year.
As finalized in the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41275),
beginning with FY 2020, we include the
thresholds applicable to the next fiscal
year (previously included in Table 10 of
the annual IPPS/LTCH PPS proposed
and final rules) in the data files
associated with the prior fiscal year.
Accordingly, the proposed thresholds
for applications for new technology addon payments for FY 2024 were
presented in a data file that is available
on the CMS website, along with the
other data files associated with the FY
2023 final rule, by clicking on the FY
2023 IPPS final rule home page at
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/index.
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule, in the FY
2022 IPPS/LTCH PPS final rule, we
finalized our proposal to use the FY
2019 MedPAR claims data where we
ordinarily would have used the FY 2020
MedPAR claims data for purposes of FY
2022 ratesetting. Consistent with that
final policy, we finalized our proposal
to use the FY 2019 claims data to set the
thresholds for applications for new
technology add-on payments for FY
2023. We note that, for the reasons
discussed in section I.F. of the preamble
of the proposed rule and this final rule,
we proposed to use the FY 2021
MedPAR claims data for FY 2023
ratesetting, with certain proposed
modifications to our relative weight
setting and outlier methodologies.
Consistent with this proposal, for the FY
2024 proposed threshold values, we
proposed to use the FY 2021 claims data
to set the proposed thresholds for
applications for new technology add-on
payments for FY 2024. In addition, as
discussed in section III.E.1.c. of the
proposed rule and this final rule, we
proposed to use an averaging approach
for calculating the FY 2023 relative
weights, to account for the anticipated
decline in COVID–19 hospitalizations of
Medicare beneficiaries as compared to
FY 2021. Specifically, we proposed to
average the relative weights as
calculated with and without COVID–19
cases in the FY 2021 data to determine
the MS–DRG relative weights for FY
2023. Certain steps of calculating the
thresholds for applications for new
technology add-on payments use the
same charge data that is used to
calculate the MS–DRG weights. As a
result, different average charges per
MS–DRG are calculated using the charge
data for the relative weights as
calculated with and without COVID–19
cases. Therefore, for purposes of
PO 00000
Frm 00126
Fmt 4701
Sfmt 4700
calculating the FY 2024 thresholds, we
also proposed to average the data in the
steps of the calculation that use charge
data from the calculation of the MS–
DRG weights. In addition, as discussed
in section I.O. of the appendix of the FY
2023 IPPS/LTCH proposed rule (87 FR
28740 through 28741), we also
considered, as an alternative to our
proposal, calculating the FY 2023 MS–
DRG relative weights without the
proposed averaging approach to account
for COVID–19 cases. In connection with
this alternative approach, we made
available the threshold values as
calculated without this averaged data on
the ‘‘FY 2023 Final Rule Homepage’’ at
https://www.cms.gov/medicare/
medicare-fee-for-service-payment/
acuteinpatientpps, as well as other
supplemental files as discussed further
in section I.O. of Appendix A of this
final rule.
As discussed in section I.F. of the
preamble of this final rule, we are
finalizing our proposal to use the FY
2021 MedPAR claims data for FY 2023
ratesetting. Also, as discussed in section
II.E of this final rule we are finalizing
our proposal to average the relative
weights as calculated with and without
COVID–19 cases in the FY 2021 data to
determine the MS–DRG relative weights
for FY 2023. We did not receive any
public comments on our proposal to
average the data in the steps of the
calculation of the FY 2024 thresholds
that use charge data from the calculation
of the MS–DRG weights, as discussed in
the proposed rule. Accordingly, in this
final rule, we are finalizing to use FY
2021 claims data to set the thresholds
for applications for new technology addon payments for FY 2024, and we are
also finalizing to average the data in the
steps of the calculation of the FY 2024
thresholds that use charge data from the
calculation of the MS–DRG weights, as
described previously. The finalized
thresholds for applications for new
technology add-on payments for FY
2024 are presented in a data file that is
available on the CMS website, along
with the other data files associated with
this FY 2023 final rule, by clicking on
the FY 2023 IPPS Final Rule Home Page
at: https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/index.
In the September 7, 2001, final rule
that established the new technology
add-on payment regulations (66 FR
46917), we discussed that applicants
should submit a significant sample of
data to demonstrate that the medical
service or technology meets the highcost threshold. Specifically, applicants
should submit a sample of sufficient
size to enable us to undertake an initial
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
validation and analysis of the data. We
also discussed in the September 7, 2001,
final rule (66 FR 46917) the issue of
whether the Health Insurance
Portability and Accountability Act
(HIPAA) Privacy Rule at 45 CFR parts
160 and 164 applies to claims
information that providers submit with
applications for new medical service or
technology add-on payments. We refer
readers to the FY 2012 IPPS/LTCH PPS
final rule (76 FR 51573) for further
information on this issue.
(3) Substantial Clinical Improvement
Criterion
Under the third criterion at
§ 412.87(b)(1), a medical service or
technology must represent an advance
that substantially improves, relative to
technologies previously available, the
diagnosis or treatment of Medicare
beneficiaries. In the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42288
through 42292), we prospectively
codified in our regulations at § 412.87(b)
the following aspects of how we
evaluate substantial clinical
improvement for purposes of new
technology add-on payments under the
IPPS:
• The totality of the circumstances is
considered when making a
determination that a new medical
service or technology represents an
advance that substantially improves,
relative to services or technologies
previously available, the diagnosis or
treatment of Medicare beneficiaries.
• A determination that a new medical
service or technology represents an
advance that substantially improves,
relative to services or technologies
previously available, the diagnosis or
treatment of Medicare beneficiaries
means—
++ The new medical service or
technology offers a treatment option for
a patient population unresponsive to, or
ineligible for, currently available
treatments;
++ The new medical service or
technology offers the ability to diagnose
a medical condition in a patient
population where that medical
condition is currently undetectable, or
offers the ability to diagnose a medical
condition earlier in a patient population
than allowed by currently available
methods, and there must also be
evidence that use of the new medical
service or technology to make a
diagnosis affects the management of the
patient;
++ The use of the new medical
service or technology significantly
improves clinical outcomes relative to
services or technologies previously
available as demonstrated by one or
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
more of the following: a reduction in at
least one clinically significant adverse
event, including a reduction in
mortality or a clinically significant
complication; a decreased rate of at least
one subsequent diagnostic or
therapeutic intervention; a decreased
number of future hospitalizations or
physician visits; a more rapid beneficial
resolution of the disease process
treatment including, but not limited to,
a reduced length of stay or recovery
time; an improvement in one or more
activities of daily living; an improved
quality of life; or, a demonstrated greater
medication adherence or compliance; or
++ The totality of the circumstances
otherwise demonstrates that the new
medical service or technology
substantially improves, relative to
technologies previously available, the
diagnosis or treatment of Medicare
beneficiaries.
• Evidence from the following
published or unpublished information
sources from within the United States or
elsewhere may be sufficient to establish
that a new medical service or
technology represents an advance that
substantially improves, relative to
services or technologies previously
available, the diagnosis or treatment of
Medicare beneficiaries: clinical trials,
peer reviewed journal articles; study
results; meta-analyses; consensus
statements; white papers; patient
surveys; case studies; reports;
systematic literature reviews; letters
from major healthcare associations;
editorials and letters to the editor; and
public comments. Other appropriate
information sources may be considered.
• The medical condition diagnosed or
treated by the new medical service or
technology may have a low prevalence
among Medicare beneficiaries.
• The new medical service or
technology may represent an advance
that substantially improves, relative to
services or technologies previously
available, the diagnosis or treatment of
a subpopulation of patients with the
medical condition diagnosed or treated
by the new medical service or
technology.
We refer the reader to the FY 2020
IPPS/LTCH PPS final rule for additional
discussion of the evaluation of
substantial clinical improvement for
purposes of new technology add-on
payments under the IPPS.
We note, consistent with the
discussion in the FY 2003 IPPS final
rule (67 FR 50015), that while FDA has
regulatory responsibility for decisions
related to marketing authorization (for
example, approval, clearance, etc.), we
do not rely upon FDA criteria in our
evaluation of substantial clinical
PO 00000
Frm 00127
Fmt 4701
Sfmt 4700
48905
improvement for purposes of
determining what drugs, devices, or
technologies qualify for new technology
add-on payments under Medicare. This
criterion does not depend on the
standard of safety and effectiveness on
which FDA relies but on a
demonstration of substantial clinical
improvement in the Medicare
population.
b. Alternative Inpatient New
Technology Add-On Payment Pathway
Beginning with applications for FY
2021 new technology add-on payments,
under the regulations at § 412.87(c), a
medical device that is part of FDA’s
Breakthrough Devices Program may
qualify for the new technology add-on
payment under an alternative pathway.
Additionally, under the regulations at
§ 412.87(d) for certain antimicrobial
products, beginning with FY 2021, a
drug that is designated by FDA as a
Qualified Infectious Disease Product
(QIDP), and, beginning with FY 2022, a
drug that is approved by FDA under the
Limited Population Pathway for
Antibacterial and Antifungal Drugs
(LPAD), may also qualify for the new
technology add-on payment under an
alternative pathway. We refer the reader
to the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42292 through 42297) and
the FY 2021 IPPS/LTCH PPS final rule
(85 FR 58737 through 58739) for further
discussion on this policy. We note that
a technology is not required to have the
specified FDA designation at the time
the new technology add-on payment
application is submitted. CMS reviews
the application based on the
information provided by the applicant
only under the alternative pathway
specified by the applicant at the time of
new technology add-on payment
application submission. However, to
receive approval for the new technology
add-on payment under that alternative
pathway, the technology must have the
applicable FDA designation and meet
all other requirements in the regulations
in § 412.87(c) and (d), as applicable.
(1) Alternative Pathway for Certain
Transformative New Devices
For applications received for new
technology add-on payments for FY
2021 and subsequent fiscal years, if a
medical device is part of FDA’s
Breakthrough Devices Program and
received FDA marketing authorization,
it will be considered not substantially
similar to an existing technology for
purposes of the new technology add-on
payment under the IPPS, and will not
need to meet the requirement under
§ 412.87(b)(1) that it represent an
advance that substantially improves,
E:\FR\FM\10AUR2.SGM
10AUR2
48906
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
relative to technologies previously
available, the diagnosis or treatment of
Medicare beneficiaries. Under this
alternative pathway, a medical device
that has received FDA marketing
authorization (that is, has been
approved or cleared by, or had a De
Novo classification request granted by,
FDA) and that is part of FDA’s
Breakthrough Devices Program will
need to meet the requirements of
§ 412.87(c). We note that in the FY 2021
IPPS/LTCH PPS final rule (85 FR 58734
through 58736), we clarified our policy
that a new medical device under this
alternative pathway must receive
marketing authorization for the
indication covered by the Breakthrough
Devices Program designation. We refer
the reader to the FY 2021 IPPS/LTCH
PPS final rule (85 FR 58734 through
58736) for further discussion regarding
this clarification.
(2) Alternative Pathway for Certain
Antimicrobial Products
For applications received for new
technology add-on payments for certain
antimicrobial products, beginning with
FY 2021, if a technology is designated
by FDA as a QIDP and received FDA
marketing authorization, and, beginning
with FY 2022, if a drug is approved
under FDA’s LPAD pathway and used
for the indication approved under the
LPAD pathway, it will be considered
not substantially similar to an existing
technology for purposes of new
technology add-on payments and will
not need to meet the requirement that it
represent an advance that substantially
improves, relative to technologies
previously available, the diagnosis or
treatment of Medicare beneficiaries.
Under this alternative pathway for
QIDPs and LPADs, a medical product
that has received FDA marketing
authorization and is designated by FDA
as a QIDP or approved under the LPAD
pathway will need to meet the
requirements of § 412.87(d).
We refer the reader to the FY 2020
IPPS/LTCH PPS final rule (84 FR 42292
through 42297) and FY 2021 IPPS/LTCH
PPS final rule (85 FR 58737 through
58739) for further discussion on this
policy. We note, in the FY 2021 IPPS/
LTCH PPS final rule (85 FR 58737
through 58739), we clarified that a new
medical product seeking approval for
the new technology add-on payment
under the alternative pathway for QIDPs
must receive marketing authorization
for the indication covered by the QIDP
designation. We also finalized our
policy to expand our alternative new
technology add-on payment pathway for
certain antimicrobial products to
include products approved under the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
LPAD pathway and used for the
indication approved under the LPAD
pathway.
c. Additional Payment for New Medical
Service or Technology
The new medical service or
technology add-on payment policy
under the IPPS provides additional
payments for cases with relatively high
costs involving eligible new medical
services or technologies, while
preserving some of the incentives
inherent under an average-based
prospective payment system. The
payment mechanism is based on the
cost to hospitals for the new medical
service or technology. As noted
previously, we do not include capital
costs in the add-on payments for a new
medical service or technology or make
new technology add-on payments under
the IPPS for capital-related costs (72 FR
47307 through 47308).
For discharges occurring before
October 1, 2019, under § 412.88, if the
costs of the discharge (determined by
applying operating cost-to-charge ratios
(CCRs) as described in § 412.84(h))
exceed the full DRG payment (including
payments for IME and DSH, but
excluding outlier payments), CMS made
an add-on payment equal to the lesser
of: (1) 50% of the costs of the new
medical service or technology; or (2)
50% of the amount by which the costs
of the case exceed the standard DRG
payment.
Beginning with discharges on or after
October 1, 2019, for the reasons
discussed in the FY 2020 IPPS/LTCH
PPS final rule (84 FR 42297 through
42300), we finalized an increase in the
new technology add-on payment
percentage, as reflected at
§ 412.88(a)(2)(ii). Specifically, for a new
technology other than a medical product
designated by FDA as a QIDP, beginning
with discharges on or after October 1,
2019, if the costs of a discharge
involving a new technology (determined
by applying CCRs as described in
§ 412.84(h)) exceed the full DRG
payment (including payments for IME
and DSH, but excluding outlier
payments), Medicare will make an addon payment equal to the lesser of: (1)
65% of the costs of the new medical
service or technology; or (2) 65% of the
amount by which the costs of the case
exceed the standard DRG payment. For
a new technology that is a medical
product designated by FDA as a QIDP,
beginning with discharges on or after
October 1, 2019, if the costs of a
discharge involving a new technology
(determined by applying CCRs as
described in § 412.84(h)) exceed the full
DRG payment (including payments for
PO 00000
Frm 00128
Fmt 4701
Sfmt 4700
IME and DSH, but excluding outlier
payments), Medicare will make an addon payment equal to the lesser of: (1)
75% of the costs of the new medical
service or technology; or (2) 75% of the
amount by which the costs of the case
exceed the standard DRG payment. For
a new technology that is a medical
product approved under FDA’s LPAD
pathway, beginning with discharges on
or after October 1, 2020, if the costs of
a discharge involving a new technology
(determined by applying CCRs as
described in § 412.84(h)) exceed the full
DRG payment (including payments for
IME and DSH, but excluding outlier
payments), Medicare will make an addon payment equal to the lesser of: (1)
75% of the costs of the new medical
service or technology; or (2) 75% of the
amount by which the costs of the case
exceed the standard DRG payment. As
set forth in § 412.88(b)(2), unless the
discharge qualifies for an outlier
payment, the additional Medicare
payment will be limited to the full MS–
DRG payment plus 65% (or 75% for
certain antimicrobial products (QIDPs
and LPADs)) of the estimated costs of
the new technology or medical service.
We refer the reader to the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42297
through 42300) for further discussion on
the increase in the new technology addon payment beginning with discharges
on or after October 1, 2019.
Section 503(d)(2) of Public Law 108–
173 provides that there shall be no
reduction or adjustment in aggregate
payments under the IPPS due to add-on
payments for new medical services and
technologies. Therefore, in accordance
with section 503(d)(2) of Public Law
108–173, add-on payments for new
medical services or technologies for FY
2005 and subsequent years have not
been subjected to budget neutrality.
d. Evaluation of Eligibility Criteria for
New Medical Service or Technology
Applications
In the FY 2009 IPPS final rule (73 FR
48561 through 48563), we modified our
regulation at § 412.87 to codify our
longstanding practice of how CMS
evaluates the eligibility criteria for new
medical service or technology add-on
payment applications. That is, we first
determine whether a medical service or
technology meets the newness criterion,
and only if so, do we then make a
determination as to whether the
technology meets the cost threshold and
represents a substantial clinical
improvement over existing medical
services or technologies. We specified
that all applicants for new technology
add-on payments must have FDA
approval or clearance by July 1 of the
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
year prior to the beginning of the fiscal
year for which the application is being
considered. In the FY 2021 IPPS/LTCH
PPS final rule, to more precisely
describe the various types of FDA
approvals, clearances and classifications
that we consider under our new
technology add-on payment policy, we
finalized a technical clarification to the
regulation to indicate that new
technologies must receive FDA
marketing authorization (such as premarket approval (PMA); 510(k)
clearance; the granting of a De Novo
classification request, or approval of a
New Drug Application (NDA)) by July 1
of the year prior to the beginning of the
fiscal year for which the application is
being considered. Consistent with our
longstanding policy, we consider FDA
marketing authorization as representing
that a product has received FDA
approval or clearance when considering
eligibility for the new technology addon payment under § 412.87(e)(2) (85 FR
58742).
Additionally, in the FY 2021 IPPS/
LTCH PPS final rule (85 FR 58739
through 58742), we finalized our
proposal to provide conditional
approval for new technology add-on
payment for a technology for which an
application is submitted under the
alternative pathway for certain
antimicrobial products at § 412.87(d)
that does not receive FDA marketing
authorization by the July 1 deadline
specified in § 412.87(e)(2), provided that
the technology otherwise meets the
applicable add-on payment criteria.
Under this policy, cases involving
eligible antimicrobial products would
begin receiving the new technology addon payment sooner, effective for
discharges the quarter after the date of
FDA marketing authorization provided
that the technology receives FDA
marketing authorization by July 1 of the
particular fiscal year for which the
applicant applied for new technology
add-on payments.
e. New Technology Liaisons
Many interested parties (including
device/biologic/drug developers or
manufacturers, industry consultants,
others) engage CMS for coverage,
coding, and payment questions or
concerns. In order to streamline
engagement by centralizing the different
innovation pathways within CMS
including new technology add-on
payments, CMS has established a team
of new technology liaisons that can
serve as an initial resource for interested
parties. This team is available to assist
with all of the following:
• Help to point interested parties to
or provide information and resources
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
where possible regarding process,
requirements, and timelines.
• Coordinate and facilitate
opportunities for interested parties to
engage with various CMS components.
• Serve as a primary point of contact
for interested parties and provide
updates on developments where
possible or appropriate.
We received many questions from
interested parties with respect to
pursuing new technology add-on
payments who may not be entirely
familiar with working with CMS. While
we encourage interested parties to first
review our resources available at
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/newtech, we know
that there may be additional questions
about the application process. Interested
parties with further questions about
Medicare’s coverage, coding, and
payment processes, and about how they
can navigate these processes, whether
for new technology add-on payments or
otherwise, can contact the new
technology liaison team at
MedicareInnovation@cms.hhs.gov.
f. Application Information for New
Medical Services or Technologies
Applicants for add-on payments for
new medical services or technologies for
FY 2024 must submit a formal request,
including a full description of the
clinical applications of the medical
service or technology and the results of
any clinical evaluations demonstrating
that the new medical service or
technology represents a substantial
clinical improvement (unless the
application is under one of the
alternative pathways as previously
described), along with a significant
sample of data to demonstrate that the
medical service or technology meets the
high-cost threshold. CMS will review
the application based on the
information provided by the applicant
under the pathway specified by the
applicant at the time of application
submission. Complete application
information, along with final deadlines
for submitting a full application, will be
posted as it becomes available on the
CMS website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/
newtech.html. To allow interested
parties to identify the new medical
services or technologies under review
before the publication of the final rule
for FY 2024, the CMS website also will
post the tracking forms completed by
each applicant. We note that the burden
associated with this information
collection requirement is the time and
effort required to collect and submit the
PO 00000
Frm 00129
Fmt 4701
Sfmt 4700
48907
data in the formal request for add-on
payments for new medical services and
technologies to CMS. The
aforementioned burden is subject to the
Paper Reduction Act (PRA) and
approved under OMB control number
0938–1347, and has an expiration date
of 11/30/2023.
As discussed previously, in the FY
2020 IPPS/LTCH PPS final rule, we
adopted an alternative inpatient new
technology add-on payment pathway for
certain transformative new devices and
for Qualified Infectious Disease
Products, as set forth in the regulations
at § 412.87(c) and (d). The change in
burden associated with these changes to
the new technology add-on payment
application process were discussed in a
revision of the information collection
requirement (ICR) request currently
approved under OMB control number
0938–1347, with an expiration date of
November 30, 2023. In accordance with
the implementing regulations of the
PRA, we detailed the revisions of the
ICR and published the required 60-day
notice on August 15, 2019 (84 FR
41723), and 30-day notice on December
17, 2019 (84 FR 68936), to solicit public
comments.
2. Public Input Before Publication of a
Notice of Proposed Rulemaking on AddOn Payments
Section 1886(d)(5)(K)(viii) of the Act,
as amended by section 503(b)(2) of
Public Law 108–173, provides for a
mechanism for public input before
publication of a notice of proposed
rulemaking regarding whether a medical
service or technology represents a
substantial clinical improvement. The
process for evaluating new medical
service and technology applications
requires the Secretary to do all of the
following:
• Provide, before publication of a
proposed rule, for public input
regarding whether a new service or
technology represents an advance in
medical technology that substantially
improves the diagnosis or treatment of
Medicare beneficiaries.
• Make public and periodically
update a list of the services and
technologies for which applications for
add-on payments are pending.
• Accept comments,
recommendations, and data from the
public regarding whether a service or
technology represents a substantial
clinical improvement.
• Provide, before publication of a
proposed rule, for a meeting at which
organizations representing hospitals,
physicians, manufacturers, and any
other interested party may present
comments, recommendations, and data
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48908
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
regarding whether a new medical
service or technology represents a
substantial clinical improvement to the
clinical staff of CMS.
In order to provide an opportunity for
public input regarding add-on payments
for new medical services and
technologies for FY 2023 prior to
publication of the FY 2023 IPPS/LTCH
PPS proposed rule, we published a
notice in the Federal Register on
September 24, 2021 (86 FR 53056), and
held a virtual town hall meeting on
December 14, 2021. In the
announcement notice for the meeting,
we stated that the opinions and
presentations provided during the
meeting would assist us in our
evaluations of applications by allowing
public discussion of the substantial
clinical improvement criterion for the
FY 2023 new medical service and
technology add-on payment
applications before the publication of
the FY 2023 IPPS/LTCH IPPS proposed
rule.
Approximately 378 individuals
registered to attend the virtual town hall
meeting. We posted the recordings of
the virtual town hall on the CMS web
page at https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/newtech.
We considered each applicant’s
presentation made at the town hall
meeting, as well as written comments
received by the December 27, 2021,
deadline, in our evaluation of the new
technology add-on payment
applications for FY 2023 in the
development of the FY 2023 IPPS/LTCH
PPS proposed rule. In response to the
published notice and the December 14,
2021, New Technology Town Hall
meeting, we received written comments
regarding the applications for FY 2023
new technology add on payments. As
explained earlier and in the Federal
Register notice announcing the New
Technology Town Hall meeting (86 FR
53056 through 53059), the purpose of
the meeting was specifically to discuss
the substantial clinical improvement
criterion with regard to pending new
technology add-on payment
applications for FY 2023. Therefore, we
did not summarize the written
comments in the proposed rule that are
unrelated to the substantial clinical
improvement criterion. In section II.F.6.
of the preamble of the proposed rule, we
summarized comments regarding
individual applications, or, if
applicable, indicated that there were no
comments received in response to the
New Technology Town Hall meeting
notice or New Technology Town Hall
meeting, at the end of each discussion
of the individual applications.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
3. ICD–10–PCS Section ‘‘X’’ Codes for
Certain New Medical Services and
Technologies
As discussed in the FY 2016 IPPS/
LTCH PPS final rule (80 FR 49434), the
ICD–10–PCS includes a new section
containing the new Section ‘‘X’’ codes,
which began being used with discharges
occurring on or after October 1, 2015.
Decisions regarding changes to ICD–10–
PCS Section ‘‘X’’ codes will be handled
in the same manner as the decisions for
all of the other ICD–10–PCS code
changes. That is, proposals to create,
delete, or revise Section ‘‘X’’ codes
under the ICD–10–PCS structure will be
referred to the ICD–10 Coordination and
Maintenance Committee. In addition,
several of the new medical services and
technologies that have been, or may be,
approved for new technology add-on
payments may now, and in the future,
be assigned a Section ‘‘X’’ code within
the structure of the ICD–10–PCS. We
posted ICD–10–PCS Guidelines on the
CMS website at https://www.cms.gov/
medicare/icd-10/2021-icd-10-pcs,
including guidelines for ICD–10–PCS
Section ‘‘X’’ codes. We encourage
providers to view the material provided
on ICD–10–PCS Section ‘‘X’’ codes.
As discussed in more detail in section
II.F.8. of the preamble of this final rule,
in the FY 2023 IPPS/LTCH PPS
proposed rule, we proposed to use
NDCs instead of ICD–10–PCS Section
‘‘X’’ codes to identify cases involving
the use of therapeutic agents approved
for new technology add-on payments
beginning with a transitional period in
FY 2023. We refer the reader to section
II.F.8. of the preamble of this final rule
for a full discussion of this proposal and
the comments received.
4. New COVID–19 Treatments Add-On
Payment (NCTAP)
In response to the COVID–19 public
health emergency (PHE), we established
the New COVID–19 Treatments Add-on
Payment (NCTAP) under the IPPS for
COVID–19 cases that meet certain
criteria (85 FR 71157 through 71158).
We believe that as drugs and biological
products become available and are
authorized for emergency use or
approved by FDA for the treatment of
COVID–19 in the inpatient setting, it is
appropriate to increase the current IPPS
payment amounts to mitigate any
potential financial disincentives for
hospitals to provide new COVID–19
treatments during the PHE. Therefore,
effective for discharges occurring on or
after November 2, 2020 and until the
end of the PHE for COVID–19, we
established the NCTAP to pay hospitals
the lesser of (1) 65% of the operating
PO 00000
Frm 00130
Fmt 4701
Sfmt 4700
outlier threshold for the claim or (2)
65% of the amount by which the costs
of the case exceed the standard DRG
payment, including the adjustment to
the relative weight under section 3710
of the Coronavirus Aid, Relief, and
Economic Security (CARES) Act, for
certain cases that include the use of a
drug or biological product currently
authorized for emergency use or
approved for treating COVID–19.
In the FY 2022 IPPS/LTCH PPS final
rule, we finalized a change to our policy
to extend NCTAP through the end of the
FY in which the PHE ends for all
eligible products in order to continue to
mitigate potential financial
disincentives for hospitals to provide
these new treatments, and to minimize
any potential payment disruption
immediately following the end of the
PHE. We also finalized that, for a drug
or biological product eligible for NCTAP
that is also approved for new technology
add-on payments, we will reduce the
NCTAP for an eligible case by the
amount of any new technology add-on
payments so that we do not create a
financial disincentive between
technologies eligible for both the new
technology add-on payment and NCTAP
compared to technologies eligible for
NCTAP only (85 FR 45162).
Further information about NCTAP,
including updates and a list of currently
eligible drugs and biologicals, is
available on the CMS website at https://
www.cms.gov/medicare/covid-19/newcovid-19-treatments-add-paymentnctap.
5. FY 2023 Status of Technologies
Receiving New Technology Add-On
Payments for FY 2022
In this section of the final rule, we
discuss the proposed FY 2023 status of
37 technologies approved for FY 2022
new technology add-on payments,
including 2 technologies approved for 2
separate add-on payments for different
indications (RECARBRIOTM and
FETROJA®), and our finalized policies,
as set forth in the tables that follow. In
general, we extend new technology addon payments for an additional year only
if the 3-year anniversary date of the
product’s entry onto the U.S. market
occurs in the latter half of the upcoming
fiscal year. We note that, as discussed
later in this section, we provided a 1year extension of new technology addon payments for FY 2022 for 13
technologies for which the new
technology add-on payment would
otherwise have been discontinued
beginning in FY 2022 using our
authority under section 1886(d)(5)(I) of
the Act.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Additionally, we note that we
conditionally approved CONTEPO for
FY 2022 new technology add-on
payments under the alternative pathway
for certain antimicrobial products (86
FR 45155), subject to the technology
receiving FDA marketing authorization
by July 1, 2022. In the FY 2023 IPPS
LTCH/PPS proposed rule, we stated that
if CONTEPO receives FDA marketing
authorization prior to July 1, 2022, we
were proposing to continue making new
technology add-on payments for
CONTEPO for FY 2023. We stated that
if CONTEPO does not receive FDA
marketing authorization by July 1, 2022,
then it would not be eligible for new
technology add-on payments for FY
2022, and therefore would not be
eligible for the continuation of new
technology add-on payments for FY
2023. Because CONTEPO did not
receive FDA approval by July 1, 2022,
no new technology add-on payments
will be made for cases involving the use
of CONTEPO for FY 2022, and
CONTEPO is therefore not eligible for
the continuation of new technology addon payments for FY 2023.
a. FY 2023 Status of Technologies
Approved for FY 2022 New Technology
Add-On Payments
As noted previously, we used our
authority under section 1886(d)(5)(I) of
the Act to allow a 1-year extension of
new technology add-on payments for FY
2022 for 13 technologies for which the
add-on payments would otherwise be
discontinued beginning in FY 2022
because the technologies would no
longer be considered ‘‘new’’ for FY
2022. In this section, we discuss the
proposed FY 2023 status for the
remaining 24 technologies approved for
FY 2022 new technology add-on
payments and our finalized policies.
Specifically, in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28210–
28212), we presented our proposals to
continue the new technology add-on
payment for FY 2023 for those
technologies that were approved for the
new technology add-on payment for FY
2022 and which would still be
considered ‘‘new’’ for purposes of new
technology add-on payments for FY
2023. We also presented our proposals
to discontinue new technology add-on
payment for FY 2023 for those
technologies that were approved for the
new technology add-on payment for FY
2022 and which would no longer be
considered ‘‘new’’ for purposes of new
technology add-on payments for FY
2023.
Our policy is that a medical service or
technology may continue to be
considered ‘‘new’’ for purposes of new
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
technology add-on payments within 2 or
3 years after the point at which data
begin to become available reflecting the
inpatient hospital code assigned to the
new service or technology. Our practice
has been to begin and end new
technology add-on payments on the
basis of a fiscal year, and we have
generally followed a guideline that uses
a 6-month window before and after the
start of the fiscal year to determine
whether to extend the new technology
add-on payment for an additional fiscal
year. In general, we extend new
technology add-on payments for an
additional year only if the 3-year
anniversary date of the product’s entry
onto the U.S. market occurs in the latter
half of the fiscal year (70 FR 47362).
In the proposed rule, we provided a
table listing the technologies for which
we proposed to continue making new
technology add-on payments for FY
2023 because they would still be
considered ‘‘new’’ for purposes of new
technology add-on payments (87 FR
28213 through 28214). This table also
presented the newness start date, new
technology add-on payment start date,
3-year anniversary date of the product’s
entry onto the U.S. market, relevant
final rule citations from prior fiscal
years, proposed maximum add-on
payment amount, and coding
assignments for each technology. We
referred readers to the final rules cited
in the table for a complete discussion of
the new technology add-on payment
application, coding and payment
amount for each of these technologies,
including the applicable indications and
discussion of the newness start date.
We invited public comments on our
proposals to continue new technology
add-on payments for FY 2023 for the
technologies listed in the table in the
proposed rule.
Comment: Commenters
overwhelmingly supported our
proposed continuation of new
technology add-on payments for FY
2023 for those technologies that were
approved for the new technology add-on
payment for FY 2022 and which would
still be considered ‘‘new’’ for purposes
of new technology add-on payments for
FY 2023.
Response: We appreciate the
commenters’ support.
In the proposed rule, we noted, as
discussed in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45104 through
45107), on May 1, 2020, VEKLURY®
(remdesivir) received an Emergency Use
Authorization (EUA) from FDA for the
treatment of suspected or laboratory
confirmed COVID–19 in adults and
children hospitalized with severe
disease. The applicant asserted that
PO 00000
Frm 00131
Fmt 4701
Sfmt 4700
48909
between July 1, 2020 and September 30,
2020, it entered into an agreement with
the U.S. Government to allocate and
distribute commercially-available
VEKLURY® across the country. The
applicant stated that under this
agreement, the first sale of VEKLURY®
was completed on July 10, 2020. The
applicant stated that they transitioned to
a more traditional, unallocated model of
distribution as of October 1, 2020. In the
FY 2022 IPPS/LTCH PPS final rule (86
FR 45107), we determined that
VEKLURY® meets the newness criterion
with an indication for use in adults and
pediatric patients (12 years of age and
older and weighing at least 40 kg) for
the treatment of COVID–19 requiring
hospitalization. We stated that
consistent with our longstanding policy,
we considered the newness period for
VEKLURY® to begin on October 22,
2020, when the NDA for VEKLURY®
was approved by FDA for adults and
pediatric patients (12 years of age and
older and weighing at least 40 kg) for
the treatment of COVID–19 requiring
hospitalization. We also discussed
comments solicited regarding the
newness period for products available
through an EUA for COVID–19 in
section II.F.7. of the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45159
through 45160), including comments we
received regarding the potential
variability in cost estimates for
technologies available under an EUA
due to government price subsidies or
variable treatment practices in the
context of the global pandemic and
comments suggesting that CMS monitor
pricing changes for products available
under an EUA once a product receives
full marketing authorization, instead of
basing the newness period on data that
may have become available under an
EUA, and indicated that we would
consider these comments for future
rulemaking.
We stated in the proposed rule (87 FR
28212) that after further review of the
information provided by the applicant,
we believed that additional information
related to VEKLURY®’s commercial
availability is relevant to assessing the
start of the newness period for
VEKLURY®. We noted that the
applicant stated that once VEKLURY®
was issued an EUA, from May through
June 2020, the entire existing supply of
VEKLURY® was donated worldwide
and distributed to hospitals free of
charge.29 The applicant further stated
that the commercial list price of the
technology was announced when it
entered into the agreement with the U.S.
29 https://stories.gilead.com/articles/an-updateon-covid-19-from-our-chairman-and-ceo.
E:\FR\FM\10AUR2.SGM
10AUR2
48910
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Government previously described, in
anticipation of the post-donation phase.
Under this agreement, the U.S.
Government allocated VEKLURY® to
each hospital, and the hospitals would
then choose to purchase quantities of
VEKLURY® directly from the
applicant’s subsidiary who was the sole
distributor.30 31
We stated in the proposed rule that
we continue to believe this issue is
complex, particularly as it relates to
VEKLURY® as a technology that has
been available under both an EUA and
an NDA. As discussed in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45159
through 45160), while an EUA is not
marketing authorization within the
meaning of § 412.87(e)(2) for purposes
of eligibility for new technology add-on
payments, data reflecting the costs of
products that have received an EUA
could become available as soon as the
date of the EUA issuance and prior to
receiving FDA approval or clearance. In
the case of VEKLURY®, we stated that
we believe that there may be unique
considerations in determining the start
of the newness period in light of the
donation period, during which the
technology was distributed at no cost.
Accordingly, while we noted that we
continue to believe that data reflecting
the costs of a product that has received
an EUA could become available as soon
as the date of EUA issuance for that
product, we believed that with respect
to VEKLURY®, such data may not have
become available until after the end of
the donation period, when the
technology became commercially
available, on July 1, 2020. For these
reasons, after further consideration, we
stated that we believe the newness
period for VEKLURY® may more
appropriately begin on July 1, 2020, the
date on which the technology became
available for sale under the allocation
agreement. We noted that VEKLURY®
would still be considered new for FY
2023 regardless of whether the newness
period began on May 1 (the date of the
EUA), July 1 (the date the donation
phase ended), October 22 (the date of
the NDA), or some other date in
between, as in all cases the three-year
anniversary date would occur after
April 1, 2023, and therefore the product
30 Remdesivir for the Commercial Marketplace.
https://www.phe.gov/emergency/events/COVID19/
investigation-MCM/Pages/factsheet.aspx.
31 Department of Health and Human Services,
Office of the Assistant Secretary for Preparedness
and Response (ASPR). ASPR’s Portfolio of COVID–
19 Medical Countermeasures Made Available as a
Licensed Product. https://www.phe.gov/emergency/
events/COVID19/investigation-MCM/Pages/
Veklury.aspx.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
would remain eligible for FY 2023 new
technology add-on payments.
Therefore, we proposed to continue
new technology add-on payments for
VEKLURY® for FY 2023. We invited
public comments on this proposal,
including the newness start date for
VEKLURY®. As discussed, while we
continue to believe that data reflecting
the costs of a product that has received
an EUA could become available as soon
as the date of EUA issuance for that
product, we also recognize that there
may be unique considerations in
determining the start of the newness
period for a product available under an
EUA. We are continuing to consider the
comments as discussed in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45159)
regarding the newness period for
products available through an EUA for
COVID–19, and we welcomed
additional comments in the proposed
rule.
Comment: The applicant submitted a
comment with respect to the start of the
newness period for VEKLURY®. The
applicant noted that there is no material
impact on eligibility for new technology
add-on payments for VEKLURY®,
regardless of whether CMS uses July 1
2020, the date VEKLURY® became
available for sale under the allocation
agreement, or October 22, 2020, the date
of FDA approval as the start of the
newness period for VEKLURY®. The
applicant maintained that using either
date and applying CMS’ standard
methodology of calculating the period of
eligibility for new technology add-on
payments would result in VEKLURY®
staying within its newness period
through FY 2023 (October 1, 2022–
September 30, 2023), and that
VEKLURY® would not be eligible for
new technology add-on payments in FY
2024 in either circumstance.
The applicant stated that the primary
effect of CMS’ revisiting of the
VEKLURY® newness determination
would be to set a precedent that would
affect the future eligibility for new
technology add-on payments of other
EUA products. To this point, the
applicant referred to the FY 2022 IPPS
final rule where CMS originally
finalized the newness date for
VEKLURY® and stated that products
that do not have FDA approval or
clearance, including products available
in the U.S. under an EUA, are not
eligible for new technology add-on
payments (86 FR 45106–07). The
applicant also pointed to 42 CFR
412.87(b) which outlines additional
eligibility criteria for substantial clinical
improvement, cost, and newness that
must all be met in order for a product
to be eligible for new technology add-on
PO 00000
Frm 00132
Fmt 4701
Sfmt 4700
payments. The applicant stated it is
reasonable to assume these
requirements should not be in conflict
with respect to how they are evaluated
and implemented, including with
respect to the timelines applied to the
determination of eligibility for new
technology add-on payments.
Furthermore, the applicant stated that
CMS confirmed that using the date of
FDA approval as the beginning of the
newness period for VEKLURY® was
consistent with its longstanding policy,
with the commenter referencing CMS’s
statement that generally, its policy is ‘‘to
begin the newness period on the date of
FDA approval or clearance or, if later,
the date of availability of the product on
the U.S. market, when [data] reflecting
the costs of the technology begin to
become available for the recalibration of
the MS–DRGs’’ (86 FR 45159) (emphasis
added). The applicant asserted that
using a date prior to FDA approval as
the beginning of the newness period
would therefore serve as a departure
from how CMS has traditionally
determined newness for the purposes of
new technology add-on payments, as
there is no precedent to use a date
earlier than FDA approval as the date of
market availability.
The applicant stated that
VEKLURY®’s distribution and
commercialization framework over the
course of the COVID–19 pandemic,
through which VEKLURY® was
available through emergency and
compassionate use programs, donations,
and a post-donation model in
collaboration with the federal
government, were all implemented prior
to VEKLURY® receiving FDA approval
and does not in any way resemble the
current distribution and reimbursement
paradigm. The applicant further stated
that its experience during the EUA
period does not reflect the type of
distribution and reimbursement
environment that would support a
newness period that begins prior to the
FDA approval date for VEKLURY®. The
applicant stated that the data collected
on utilization and resource use during
the EUA period likely would not be
representative of utilization or resource
use following FDA approval, given that
the EUA period occurred within the
context of a global pandemic and a time
of extreme uncertainty for the health
care system. The applicant pointed to
CMS’s use of FY 2019 data for FY 2022
ratesetting for circumstances where the
FY 2020 data was significantly impacted
by the COVID–19 PHE, and reasoned
that VEKLURY®’s utilization would be
similarly impacted by the PHE as its
EUA period occurred almost entirely in
FY 2020.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
The applicant urged that CMS
continue to determine the start of the
newness period for VEKLURY® and
other products originally available in
the U.S. under an EUA using what it
stated was the same policy CMS has
applied for all other products approved
for new technology add-on payment,
which is to use the date of FDA
approval or, if later, the date of market
availability in the U.S. For VEKLURY®,
the applicant stated that this date is
October 22, 2020, the date of FDA
approval. The applicant stated that
maintaining this policy aligns to
existing precedent, simplifies the
newness determination process, and
applies a consistent policy across
products.
Response: We thank the applicant for
its input. As discussed in the FY 2018
IPPS final rule (82 FR 38115), the period
of newness does not necessarily start
with the approval date for the medical
service or technology and instead begins
with availability of the product on the
U.S. market, which is when data
become available. We have consistently
applied this standard and believe that it
is consistent with the purpose of new
technology add-on payments. Therefore,
while generally our policy is to begin
the newness period on the date of FDA
approval or clearance, we may also
consider a documented delay in the
technology’s market availability in our
determination of newness (77 FR 53348
and 70 FR 47341). Accordingly, we
agree that in general, we have begun the
newness period on the date of FDA
approval or clearance or, if later, the
date of availability of the product onto
the US market, based on such a
documented delay, as that is when data
reflecting the costs of the technology
begin to become available. However, as
we discussed in the FY 2022 final rule,
for a product with an EUA, the data
reflecting the costs of that product could
become available as soon as the date of
EUA issuance, and prior to FDA
approval or clearance. Therefore, while
a product approved under an EUA and
for which there is data reflecting the
costs of the technology prior to FDA
approval may be factually distinct from
a product for which there is a
documented delay in marketing
availability following FDA approval, we
disagree that beginning the newness
period on the date of EUA issuance and
prior to FDA approval would be
inconsistent with our longstanding
policy of beginning the newness period
with the availability of the product on
the U.S. market. With regard to the
additional criteria for eligibility for the
new technology add-on payment, we
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
refer readers to the FY 2022 final rule
for our discussion of the eligibility of a
product available only through an EUA
for the new technology add-on payment
under section 412.87(e)(2) (86 FR 45048
through 45049), as well as the comment
solicitation on the new technology addon payment newness period for
products available through an EUA (86
FR 45159 through 45160). With respect
to the applicant’s comment that
VEKLURY®’s utilization may have been
impacted by the COVID–19 PHE during
the EUA period, we note that the EUA
for VEKLURY® was directly related to
COVID–19.
We agree with the applicant that
regardless of whether VEKLURY’s®
newness period begins on July 1, 2020,
the date VEKLURY® became available
for sale under the allocation agreement,
or October 22, 2020, the date of FDA
approval, the application of CMS’
standard methodology for determining
the period of eligibility for new
technology add-on payments results in
VEKLURY® remaining within its
newness period through FY 2023
(October 1, 2022–September 30, 2023),
and that VEKLURY® would not be
eligible for new technology add-on
payments in FY 2024 in either
circumstance. Accordingly, we are
finalizing our proposal to continue new
technology add-on payments for
VEKLURY® for FY 2023, as reflected in
Table II.F.-01 of this final rule. As stated
previously, we also recognize that there
may be unique considerations
associated with determining the start of
the newness period for a product
available under an EUA prior to
receiving FDA approval, including as
discussed in the applicant’s comments.
Accordingly, we will continue to
consider the comments received
regarding the newness period for
products available through an EUA for
COVID–19 for future rulemaking.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we noted that we also
proposed to continue new technology
add-on payments for Caption Guidance
for FY 2023, a technology sold on a
subscription basis. We stated we
continued to welcome comments from
the public as to the appropriate method
to determine a cost per case for
technologies sold on a subscription
basis, including comments on whether
the cost per case should be estimated
based on subscriber hospital data as
described previously, and if so, whether
the cost analysis should be updated
based on the most recent subscriber data
for each year for which the technology
may be eligible for the new technology
add-on payment.
PO 00000
Frm 00133
Fmt 4701
Sfmt 4700
48911
We did not receive any comments
regarding the appropriate method to
determine a cost per case for
technologies sold on a subscription
basis, and we will continue to consider
these issues.
Comment: The applicant for Abecma®
submitted a comment stating its strong
support for the continuation of new
technology add-on payments for
Abecma® for FY 2023. The applicant
stated that although Abecma® received
FDA approval on March 26, 2021, it did
not enter the U.S. market until May 10,
2021, when the date of first sale
occurred and the new technology was
first reflected in claims data. The
applicant stated that the newness period
for Abecma® should therefore begin on
May 10, 2021 as CMS’ policy is to begin
the newness period on the date of a
product’s entry onto the U.S. market.
The applicant further stated that
Abecma®’s new technology add-on
payment status should be extended
beyond FY 2023, as CMS policy is to
extend new technology add-on
payments for an additional year when
the 3-year anniversary of market entry
occurs in the latter half of the fiscal
year.
Response: We thank the applicant for
its comment. As stated previously,
while CMS may consider a documented
delay in the technology’s market
availability in our determination of
newness, our policy for determining
whether to extend new technology addon payments for an additional year
generally applies regardless of the
volume of claims for the technology
after the beginning of the newness
period (83 FR 41280). We do not
consider the date of first sale of a
product as an indicator of the entry of
a product onto the U.S. market. The
applicant states that the date of first sale
of Abecma® was May 10, 2021, but it is
unclear from the information provided
when the technology first became
available for sale and, absent additional
information from the applicant, we
cannot determine a newness date based
on a documented delay in the
technology’s availability on the U.S.
market.
We further note that, as discussed in
section II.F.6.a. of the preamble of this
final rule, because CARVYKTITM is
substantially similar to ABECMA®, we
are using a single cost for purposes of
determining the new technology add-on
payment amount for CARVYKTITM and
ABECMA® for FY 2023. As discussed in
section II.F.6.a., we determined a
weighted average of the cost of
CARVYKTITM and ABECMA® based
upon the projected numbers of cases
involving each technology to determine
E:\FR\FM\10AUR2.SGM
10AUR2
48912
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
the maximum new technology add-on
payment. To compute the weighted cost
average, we summed the total number of
projected cases for each of the
applicants, which equaled 420 cases
(241 plus 179). We then divided the
number of projected cases for each of
the applicants by the total number of
cases, which resulted in the following
case weighted percentages: 57% for
CARVYKTITM and 43% for ABECMA®.
We then multiplied the cost per case for
the manufacturer specific drug by the
case-weighted percentage (0.57 *
$465,000 = $265,050 for CARVYKTITM
and 0.43 * $419,500 = $180,385 for
ABECMA®). This resulted in a caseweighted average cost of $445,435 for
the technology.
Under § 412.88(a)(2), we limit new
technology add-on payments to the
lesser of 65% of the average cost of the
technology, or 65% of the costs in
excess of the MS–DRG payment for the
case. As a result, the maximum new
technology add-on payment for a case
involving the use of CARVYKTITM and
ABECMA® is $289,532.75 for FY 2023,
as is reflected in Table II.F.-01 of this
final rule.
Comment: Several commenters
requested that CMS update the
maximum new technology add-on
payment amount to reflect the current
Wholesale Acquisition Cost (WAC) per
vial of their respective technologies. The
applicant for ZepzelcaTM requested the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
maximum new technology add-on
payment amount for ZepzelcaTM be
updated from $8,622.90 to $9,145.50 to
reflect the updated WAC of $7,035 per
vial of ZepzelcaTM. The applicant for
CoselaTM requested the maximum new
technology add-on payment amount for
CoselaTM be updated to reflect the
updated WAC of $1,439 per vial of
CoselaTM.
Response: We appreciate the updated
cost information. ZepzelcaTM’s current
new technology add-on payment
amount is $8,622.90 for 2 single-dose
vials and reflects the WAC at the time
of ZepzelcaTM’s entry onto the U.S.
market (2 single-dose vials per dose ×
$6,633 per vial multiplied by 0.65). For
FY 2023, the maximum new technology
add-on payment amount using the
updated WAC is $9,145.50 (2 singledose vials per dose × $7,035 per vial
multiplied by 0.65), as reflected in Table
II.F.-01 in this final rule.
Similarly, CoselaTM’s current new
technology add-on payment amount is
$5,526.30 (3 doses of CoselaTM × 2
single-dose vials per dose × $1,417 per
vial multiplied by 0.65). For FY 2023,
the maximum new technology add-on
payment amount using the updated
WAC is $5,612.10 (3 doses of CoselaTM
× 2 single-dose vials × $1,439 per vial
multiplied by 0.65) as reflected in Table
II.F.-01 in this final rule.
After consideration of the public
comments we received, we are
finalizing our proposal to continue new
PO 00000
Frm 00134
Fmt 4701
Sfmt 4700
technology add-on payments for FY
2023 for the technologies that were
approved for new technology add-on
payment for FY 2022 and would still be
considered ‘‘new’’ for purposes of new
technology add-on payments for FY
2023, as listed in the proposed rule and
in the following Table II.F.-01 in this
section of this final rule.
We note that Table II.F.-01 below is
the same as Table II.F.-02 that was
presented in the proposed rule, but
Table II.F.-01 in this final rule includes
the updated cost information for
ZepzelcaTM, CoselaTM, and Abecma®, as
discussed previously. Table II.F.-01 also
includes updated cost information for
aScope Duodeno® to reflect the cost of
the technology alone, rather than a caseweighted average with EXALT Model
DTM, as discussed later in this section.
The following table also presents the
newness start date, new technology addon payment start date, 3-year
anniversary date of the product’s entry
onto the U.S. market, relevant final rule
citations from prior fiscal years,
maximum add-on payment amount, and
coding assignments. We refer readers to
the final rules cited in the following
table for a complete discussion of the
new technology add-on payment
application, coding and payment
amount for these technologies,
including the applicable indications and
discussion of the newness start date.
BILLING CODE 4120–01–P
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
VerDate Sep<11>2014
3-year
Anniversary Date
Technology
Jkt 256001
1
Rybrevant'M
FDA/Newness
NTAP Start
of Entry onto US
Start Date
Date
Market
05/21/2021
Maximum NTAP
Amount for FY
Previous Final Rule Citations
10/1/2021
5/21/2024
86 FR 44988 through 44996
2023
Coding Used to Identify
Cases Eligible for NTAP
$6,405.89
XW033B7 or XW043B7
PO 00000
2
Cosela'M
02/12/2021
10/1/2021
2/12/2024
86 FR 45008 through 45017
$5,612.10
XW03377 or XW04377
3
ABECMA"
03/26/2021
10/1/2021
3/26/2024
86 FR 45028 through 45035
$289,532.75
XW033K7 or XW043K7
4
StrataGraft®
06/15/2021
10/1/2021
6/15/2024
86 FR 45079 through 45090
$44,200.00
5
TECARTUS®
07/24/2020
10/1/2021
7/4/2023
86 FR 45090 through 45104
$259,350.00
6
7
VEKLURY®
07/1/2020*
10/1/2021
7/1/2023*
86 FR 45104 through 45116
$2,028.00
XW033E5 or XW043E5
XW03387 or XW04387
Frm 00135
8
Zepzelca'M
06/15/2020
10/1/2021
6/15/2023
86 FR 45116 through 45126
$9,145.50
aprevo® lntervertebral Body
Fusion Device
12/03/2020
{ALIF and LLIF}
10/1/2021
12/03/2023 {ALIF
and LLIF}
6/30/2024 {TLIF}
86 FR 45127 through 45133
$40,950.00
Fmt 4701
6/30/2021
{TLIF}
86 FR 67875
XHRPXF7
XW033M7 or XW043M7
XRGA0R7 or
XRGA3R7 or
XRGA4R7 or
XRGB0R7 or XRGB3R7 or
XRGB4R7 or
XRGCOR7 or
XRGC3R7 or
Sfmt 4725
XRGC4R7 or
XRGD0R7 or
XRGD3R7 or
E:\FR\FM\10AUR2.SGM
XRGD4R7
9
aScope® Duodena
07/17/2020
10/1/2021
7/17/2023
86 FR 45133 through 45135
$1,296.75
XFJB8A7 or XFJD8A7
10
Caption Guidance'M
09/15/2020
10/1/2021
9/15/2023
86 FR 45135 through 45138
$1,868.10
X2JAX47
11
Harmonyrn Transcatheter
03/26/2021
10/1/2021
3/26/2024
86 FR 45146 through 45149
$26,975.00
12
Pulmonary Valve (TPV} System
Intercept® {PRCFC}
05/05/2021
10/1/2021
5/05/2024
86 FR 45149 through 45150
$2,535.00
86 FR 67875
02RH38M
30233D1 or 30243Dl in
combination with one of the
10AUR2
following D62, D65, D68.2,
D68.4 or D68.9
13
14
ShockWave C2 lntravascular
Lithotripsy {IVL} System
Fetroja®
{HABP/VABP}
02/12/2021
10/1/2021
2/12/2024
86 FR 45151 through 45153
$3,666.00
02F03ZZ or 02F13ZZ or
09/25/2020
10/1/2021
9/25/2023
86 FR 45156 through 45157
$8,579.84
XW033A6 or XW043A6 in
02F23ZZ or 02F33ZZ
86 FR 67876
combination with ICD-10-CM
code Y95 and one of the
following: J14, J15.0, J15.l,
J15.5, J15.6, J15.8, OR
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
TABLE II.F.-01: CONTINUATION OF TECHNOLOGIES APPROVED FOR FY 2022 NEW TECHNOLOGY ADD-ON
PAYMENTS STILL CONSIDERED NEW FOR FY 2023 BECAUSE 3-YEAR ANNIVERSARY DATE WILL OCCUR ON
OR AFTER APRIL 1, 2023
XW033A6 or XW043A6 in
ER10AU22.076
48913
combination with J95.851
khammond on DSKJM1Z7X2PROD with RULES2
48914
Jkt 256001
PO 00000
Frm 00136
B96.1, B96.20, B96.21,
B96.22, B96.23, B96.29,
B96.3, B96.5, or B96.89
15
Recarbrio'M (HABP/VABP}
06/04/2020
10/1/2021
6/04/2023
Fmt 4701
$9,576.51
XW033U5 or XW043U5 in
combination with ICD-10-CM
code Y95 and one of the
following: Jl4, J15.0, J15.l,
J15.5, J15.6, J15.8, OR
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.077
86 FR 45157 through 45158
86 FR 58023 through 58024
86 FR 67876
XW033U5 or XW043U5 in
combination with J95.851
and one of the following:
B96.1, B96.20, B96.21,
B96.22, B96.23, B96.29,
B96.3, B96.5, or B96.89
*See the previous discussion regarding the start of the newness period for VEKLURY®.
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
BILLING CODE 4120–01–C
VerDate Sep<11>2014
and one of the following:
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
In the proposed rule, we provided a
table listing the technologies for which
we proposed to discontinue making new
technology add-on payments for FY
2023 because they are no longer ‘‘new’’
for purposes of new technology add-on
payments (87 FR 28211). This table also
presented the newness start date, new
technology add-on payment start date,
the 3-year anniversary date of the
product’s entry onto the U.S. market,
relevant final rule citations from prior
fiscal years, and coding assignments for
each technology. We referred readers to
the final rules cited in the table for a
complete discussion of the new
technology add-on payment application,
coding and payment amount for these
technologies, including the applicable
indications and discussion of the
newness start date.
We invited public comments on our
proposals to discontinue new
technology add-on payments for FY
2023 for the technologies listed in the
table in the proposed rule.
Comment: A commenter supported
our proposal to discontinue new
technology add-on payments for
AZEDRA®, which will no longer be
considered new as its 3-year anniversary
date of entry onto the U.S. market will
occur prior to FY 2023.
Response: We appreciate the
commenter’s support and are finalizing
our proposal to discontinue new
technology add-on payments for
AZEDRA® for FY 2023.
Comment: Many commenters stated
their opposition to discontinuing new
technology add-on payments for
technologies whose 3-year anniversary
of entry onto the U.S. market will occur
prior to FY 2023 or in the first half of
FY 2023. These commenters encouraged
CMS to use its legal authority under
section 1886(d)(5)(I) of the Act to extend
new technology add-on payments
through FY 2023 due to a historic
decline in utilization during the
COVID–19 pandemic.
Response: We thank the commenters
for their input. Consistent with the
statute and our implementing
regulations, a technology is no longer
considered as ‘‘new’’ once it is more
than 2 to 3 years old, irrespective of
how frequently the medical service or
technology has been used in the
Medicare population (70 FR 47349). As
such, once a technology has been
available on the U.S. market for more
than 2 to 3 years, we consider the costs
to be included in the MS–DRG relative
weights regardless of whether the
technology’s use in the Medicare
population has been frequent or
infrequent. Therefore, we do not believe
that case volume is a relevant
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
consideration for making the
determination as to whether a product
is ‘‘new,’’ and we are not extending new
technology add-on payments for
technologies whose 3-year anniversary
of entry onto the U.S. market will occur
prior to FY 2023 or in the first half of
FY 2023. We refer readers to the FY
2022 IPPS/LTCH PPS final rule (86 FR
44975 through 44979) and section
II.F.5.b of this FY 2023 final rule for
discussion of our policy to allow for a
1-year extension of new technology addon payments for FY 2022 because of the
unique circumstances associated with
ratesetting for FY 2022, for which CMS
used FY 2019 data instead of FY 2020
data to develop the FY 2022 relative
weights.
Comment: Several commenters
disagreed with CMS’s proposal to
discontinue new technology add-on
payments for EXALT Model DTM SingleUse Duodenoscope while continuing
payments for aScope® Duodeno through
FY 2023 based on the different FDA
clearance dates for the two technologies.
These commenters recommended that
CMS create a single newness date and
extend new technology add-on
payments for both products through the
end of FY 2023. The commenters noted
that there is no mechanism for hospitals
to distinguish between the two devices
when reporting claims to CMS, as the
duodenoscopes share one add-on
payment amount and are identified
using the same ICD–10–PCS codes.
Another commenter, the applicant for
EXALT Model DTM, stated that creating
a single newness date and
discontinuation date for a combined
new technology add-on payment is
consistent with prior CMS decisionmaking regarding substantially similar
technologies such as IMFINZI® and
TECENTRIQ® from the FY 2021 IPPS
final rule, and the LUTONIX® and
IN.PACTTM AdmiralTM drug-coated
balloons in the FY 2016 IPPS final rule.
The commenter noted that, in these
instances, CMS finalized the proposal to
discontinue the new technology add-on
payment for both technologies on the
same date and calculated a caseweighted average cost resulting in the
same maximum add-on payment for
both technologies. The commenter
further noted that CMS determined the
drug-coated balloons were identifiable
using the same ICD–10–PCS procedure
codes, and that IMFINZI® and
TECENTRIQ® received a one-year
extension through FY 2022 based on
CMS’ decision to use FY 2019 data
(instead of FY 2020 data) for the FY
2022 IPPS rate setting. The commenter
requested that CMS discontinue the new
technology add-on payments for both
PO 00000
Frm 00137
Fmt 4701
Sfmt 4700
48915
EXALT Model DTM and aScopeTM
Duodeno at the same time, preferably at
the end of FY 2023. As an alternative,
the applicant recommended that CMS
recalculate the maximum payment
amount from the current case-weighted
average of $1,715 per case to reflect 65%
of the cost of aScopeTM Duodeno only.
Response: We thank the commenters
for their input. As stated previously, a
technology is no longer considered
‘‘new’’ once it is more than 2 to 3 years
old, irrespective of how frequently the
medical service or technology has been
used in the Medicare population (70 FR
47349). As such, once a technology has
been available on the U.S. market for
more than 2 to 3 years, we consider the
costs to be included in the MS–DRG
relative weights regardless of whether
the technology’s use in the Medicare
population has been frequent or
infrequent. Additionally, we note that
under § 412.87(c), applications received
for new technology add-on payments for
FY 2021 and subsequent fiscal years for
medical devices that are part of FDA’s
Breakthrough Devices Program and
received FDA marketing authorization
will be considered not substantially
similar to an existing technology for
purposes of the new technology add-on
payment under the IPPS. Because
EXALT Model DTM and aScopeTM
Duodeno both applied under the
alternative pathway for transformative
new technologies, the applicant’s
comparison to IMFINZI® and
TECENTRIQ® from the FY 2021 IPPS
final rule (85 FR 58672 through 58684),
and the LUTONIX® and IN.PACTTM
AdmiralTM drug-coated balloons in the
FY 2016 IPPS final rule (80 FR 49461
through 49470), where the technologies
were determined to be substantially
similar and therefore had the same
newness period, is not relevant. Thus,
we are finalizing our proposal to
discontinue new technology add-on
payment for EXALTTM Model DTM for
FY 2023.
We agree with the applicant’s
alternative recommendation that the
maximum new technology add-on
payment amount should reflect the cost
of aScopeTM Duodeno only. Based on
information provided in its application
for FY 2022 new technology add-on
payment, the cost of the aScopeTM
Duodeno is $1,995. Under
§ 412.88(a)(2), we limit new technology
add-on payments to the lesser of 65% of
the average cost of the technology, or
65% of the costs in excess of the MS–
DRG payment for the case. As a result,
we are finalizing that the maximum new
technology add-on payment for a case
involving the use of the aScopeTM
Duodeno would be $1,296.75 for FY
E:\FR\FM\10AUR2.SGM
10AUR2
48916
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
2022 (that is, 65% of the average cost of
the technology). Cases involving the use
of aScopeTM Duodeno will continue to
be identified by the following ICD–10–
PCS procedure codes: XFJB8A7
(Inspection of hepatobiliary duct using
single-use duodenoscope, new
technology group 7) or XFJD8A7
(Inspection of pancreatic duct using
single-use duodenoscope, new
technology group).
After consideration of the public
comments we received, we are
finalizing our proposal to discontinue
new technology add-on payments for
the technologies as listed in the
proposed rule and in the following
Table II.F.-02 of this final rule for FY
2023 because they are no longer ‘‘new’’
for purposes of new technology add-on
payments. This table also presents the
newness start date, new technology addon payment start date, the 3-year
anniversary date of the product’s entry
onto the U.S. market, and relevant final
rule citations from prior fiscal years. We
also refer readers to the final rules cited
in the following table for a complete
discussion of the new technology addon payment application, coding and
payment amount for these technologies,
including the applicable indications and
discussion of the newness start date.
BILLING CODE 4120–01–P
TABLE II.F.-02: DISCONTINUATION OF TECHNOLOGIES APPROVED FOR FY 2022
NEW TECHNOLOGY ADD-ON PAYMENTS NO LONGER CONSIDERED NEW FOR FY 2023
BECAUSE 3-YEAR ANNIVERSARY DATE WILL OCCUR PRIOR TO APRIL 1, 2023
FDA/Newn
ess Start
Date
Technology
NTAP
Start Date
3-year
Anniversary
Date of Entry
onto US
Market
1
Ba/versa™
04/12/2019
10/19/201
9
4/12/2022
2
Jakafi®
05/24/2019
10/1/2019
5/24/2022
BAROST/M NEO™
08/16/2019
10/1/2020
08/16/2022
3
System
4
Optimizer® System
10/23/2019
10/1/2020
10/23/2022
5
RECARBR/0™
07/16/2019
10/1/2020
1/6/2023
(cUTI/ c/AI)
commercial
ly available
in US
6
So/iris®
1/6/20
06/27/2019
10/1/2020
6/27/2022
7
XENLETA'M
08/19/2019
10/1/2020
9/10/2022
commercial
ly available
in US
8
ZERBAXA®
9/10/19
06/03/2019
10/1/2020
6/03/2022
9
Azedra®
05/21/2019
10/1/2019
5/21/2022
10
EXALT™ Model D
11
Fetroja® (Cefiderocol)
12/13/2019
11/19/2019
10/1/2021
10/1/2020
12/13/2022
2/24/2023
Commercial
ly available
in US
Citations
42242
85
86
85
86
FR
FR
FR
FR
58684 through
44973 through
58729 through
44973 through
58689
44975
58732
44975
85
86
84
85
86
86
85
86
86
FR
FR
FR
FR
FR
FR
FR
FR
FR
58732 through
44973 through
42194 through
58615
44973 through
45138 through
58721 through
44973 through
67876
58733
44975
42201
44974
42273
58618
44974
58717
44974
67876
58721
44974
58729
44974
67876
44975
45140
58723
44974
2/24/2020
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00138
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.078
khammond on DSKJM1Z7X2PROD with RULES2
(cUTI)
Previous Final Rule
84 FR 42237 through
85 FR 58616
86 FR 44972 through
84 FR 42265 through
85 FR 58617 through
86 FR 44973 through
85 FR 58716 through
86 FR 44973 through
86 FR 67874 through
85 FR 58720 through
86 FR 44973 through
85 FR 58727 through
86 FR 44973 through
86 FR 67874 through
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
BILLING CODE 4120–01–C
b. Status of Technologies Provided a
One-Year Extension of New Technology
Add-On Payments in FY 2022
As stated in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 44789), our goal
is always to use the best available data
overall for ratesetting. The best available
MedPAR data will typically be the most
recent MedPAR file that contains claims
from discharges for the fiscal year that
is 2 years prior to the fiscal year that is
the subject of the rulemaking.
In the FY 2022 IPPS/LTCH PPS final
rule, for the reasons discussed, we
finalized that we would use FY 2019
MedPAR data instead of FY 2020
MedPAR data to develop the FY 2022
MS–DRG relative weights (86 FR 44789
through 44793). Because we finalized
that we would use FY 2019 MedPAR
data instead of FY 2020 MedPAR data
for the development of the FY 2022 MS–
DRG relative weights, we stated that the
costs for a new technology for which the
3-year anniversary date of the product’s
entry onto the U.S. market occurs prior
to the latter half of FY 2022 may not be
fully reflected in the MedPAR data used
to recalibrate the MS–DRG relative
weights for FY 2022. Therefore, in light
of this final policy, we finalized our
proposal to use our authority under
section 1886(d)(5)(I) of the Act to allow
for a 1-year extension of new technology
add-on payments for FY 2022 for 13
technologies (as listed in the proposed
rule and in Table II.F.-03 of this final
rule) for which the new technology addon payment would have otherwise been
discontinued beginning with FY 2022.
We refer the reader to the FY 2022 IPPS/
LTCH PPS final rule (86 FR 44975
through 44979) for a complete
discussion regarding this 1-year
extension for FY 2022.
For FY 2023 ratesetting, as discussed
in section I.F. of this final rule, we
believe the best available data is the FY
2021 MedPAR file. As discussed in
section I.F. of this final rule, for FY
2023, we are finalizing our proposal to
use the FY 2021 MedPAR (the best
available data at the time of this final
rule) for FY 2023 ratesetting, including
for purposes of developing the FY 2023
relative weights. We refer the reader to
section I.F. of this final rule for a
complete discussion regarding our final
policy to use the FY 2021 MedPAR for
the FY 2023 ratesetting and
recalibration of the FY 2023 MS–DRG
relative weights.
As noted previously, our policy is that
a medical service or technology may
continue to be considered ‘‘new’’ for
purposes of new technology add-on
payments within 2 or 3 years after the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
point at which data begin to become
available reflecting the inpatient
hospital code assigned to the new
service or technology. For FY 2023,
because we proposed to use FY 2021
MedPAR data to recalibrate the FY 2023
MS–DRG relative weights, we stated in
the proposed rule that we believe the
costs of the 13 technologies as listed in
the proposed rule (87 FR 28216 through
28217) and in Table II.F.-03 of this final
rule, for which the 3-year anniversary
date of the product’s entry onto the U.S.
market occurs prior to FY 2023 (and
therefore are no longer ‘‘new’’), may
now be fully reflected in the MedPAR
data used to recalibrate the MS–DRG
relative weights for FY 2023. As a result,
we proposed to discontinue new
technology add-on payments for these
13 technologies in FY 2023. We also
refer readers to the final rules cited in
Table II.F.-03 for a complete discussion
of the new technology add-on payment
application, coding and payment
amount for these technologies,
including the applicable indications and
discussion of the newness start date.
We invited public comments on our
proposals to discontinue new
technology add-on payments for FY
2023 for these 13 technologies listed in
the proposed rule and Table II.F.–03.
Comment: Many commenters,
including several applicants for
technologies currently receiving new
technology add-on payments, stated
their opposition to discontinuing new
technology add-on payments for
technologies that received a one-year
extension in FY 2022. These
commenters stated that the FY 2021
MedPAR claims data are distorted due
to effects of the COVID–19 pandemic
and should not be used to recalibrate
the MS–DRG relative weights. The
commenters encouraged CMS to use its
legal authority under section
1886(d)(5)(I) of the Act to extend new
technology add-on payments through
FY 2023.
Another commenter stated that while
it is accurate that the costs of the
technologies are reflected in the FY
2021 MedPAR data used for ratesetting
purposes, the existence of such claims
data does not mean that the costs of the
technology are truly captured, nor does
it mean that the pandemic has not
impacted adoption of the new
technologies and services. This
commenter referenced several studies to
demonstrate the impact of the PHE on
hospitals, including critical staff
shortages and financial instability due
to lower revenues and inflation. The
commenter also provided an analysis of
FY 2021 claims data that found that the
average standardized costs when
PO 00000
Frm 00139
Fmt 4701
Sfmt 4700
48917
accounting for cases using its
technology or comparable technology
reported under the same ICD–10–PCS
codes increased by less than 0.5%
compared to average standardized costs
that do not account for cases reported
under these codes.
Response: We thank the commenters
for their input. Consistent with the
statute and our implementing
regulations, a technology is no longer
considered as ‘‘new’’ once it is more
than 2 to 3 years old, irrespective of
how frequently the medical service or
technology has been used in the
Medicare population (70 FR 47349). As
such, once a technology has been
available on the U.S. market for more
than 2 to 3 years, we consider the costs
to be included in the MS–DRG relative
weights regardless of whether the
technology’s use in the Medicare
population has been frequent or
infrequent. Therefore, we do not believe
that case volume is a relevant
consideration for making the
determination as to whether a product
is ‘‘new’’. Additionally, as previously
discussed, in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 44975 through
44979), we finalized a 1-year extension
of new technology add-on payments for
FY 2022 in light of the unique
circumstances associated with
ratesetting for FY 2022, for which CMS
finalized the use of the FY 2019
MedPAR data instead of the FY 2020
MedPAR data to develop the FY 2022
relative weights. For FY 2023, because
we are finalizing the use of the FY 2021
MedPAR data for FY 2023 ratesetting,
including for purposes of developing
the FY 2023 relative weights, we believe
the costs of these technologies are now
reflected in the MedPAR data used to
recalibrate the MS–DRG relative weights
for FY 2023. Therefore, we are not
extending new technology add-on
payments for technologies that received
a one-year extension in FY 2022. We
refer readers to sections section I.F. and
II.E. of this final rule for discussion of
CMS’s finalized policy to use the FY
2021 MedPAR claims data to recalibrate
the FY 2023 MS–DRG relative weights,
including the finalized modifications to
the relative weight setting methodology
to account for the anticipated decline in
COVID–19 hospitalizations of Medicare
beneficiaries at IPPS hospitals as
compared to FY 2021.
After consideration of the public
comments we received, we are
finalizing our proposal to discontinue
new technology add-on payments for
the technologies as listed in the
proposed rule and in the following
Table II.F.-03 of this final rule for FY
2023. This table also presents the
E:\FR\FM\10AUR2.SGM
10AUR2
48918
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
newness start date, new technology addon payment start date, the 3-year
anniversary date of the product’s entry
onto the U.S. market, and relevant final
rule citations from prior fiscal years. We
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
also refer readers to the final rules cited
in the following table for a complete
discussion of the new technology addon payment application, coding and
payment amount for these technologies,
PO 00000
Frm 00140
Fmt 4701
Sfmt 4700
including the applicable indications and
discussion of the newness start date.
BILLING CODE 4120–01–P
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
48919
TABLE II.F.-03: DISCONTINUATION OF TECHNOLOGIES WHICH RECEIVED A
ONE YEAR EXTENSION FOR NEW TECHNOLOGY ADD-ON PAYMENT IN FY 2022
BECAUSE 3-YEAR ANNIVERSARY DATE OCCURRED BEFORE THE SECOND
HALF OF FY 2022
khammond on DSKJM1Z7X2PROD with RULES2
Technology
NTAP Start Date
3-year Anniversary
Date of Entry onto
US Market
Previous Final Rule Citations
84 FR 42201 through 42208
85 FR 58615
86 FR 44975 through 44979
84 FR 42231 through 42237
85 FR 58615 through 58616
86 FR 44975 through 44979
83 FR 41355 through 41362
84 FR 42193 through 42194
85 FR 58614 through 58615
86 FR 44975 through 44979
84 FR 42247 through 42256
85 FR 58616 through 58617
86 FR 44975 through 44979
83 FR 41326 through 41334
84 FR 42190 through 42191
85 FR 58613
86 FR 44975 through 44979
84 FR 42278 through 42288
85 FR 58618
86 FR 44975 through 44979
85 FR 58625 through 58636
86 FR 44975 through 44979
1
Cablivi®
02/06/2019
10/01/2019
02/06/2022
2
Elzonris™
12/21/2018
10/01/2019
12/21/2021
3
AndexXa™
05/03/2018
10/01/2018
05/03/2021
4
Spravato®
3/5/2019
10/01/2019
3/5/2022
5
Zemdri®
6/25/2018
10/01/2018
6/25/2021
6
T2 Bacteria®
Panel
05/24/2018
10/01/2019
05/24/2021
7
ContaCT
10/01/2020
10/01/2021
8
Eluvia™ DrugEluting Vascular
Stent System
10/01/2020
10/04/2021
85 FR 58645 through 58658
86 FR 44975 through 44979
9
Hemospray®
10/01/2020
07/01/2021
85 FR 58665 through 58672
86 FR 44975 through 44979
10
IMF/NZ!®/
TECENTRIQ®
02/13/2018
(commercially
available
10/01/2018)
09/18/2018
commercially
available in US
10/04/2018
05/07/2018
(commercially
available
07/01/2018)
IMF/NZ/®:
03/27/2020;
TECENTRIQ®:
03/18/2019
Newness date is
3/18/2019 for
both
10/01/2020
03/18/2022
85 FR 58672 through 58684
86 FR 44975 through 44979
11
NUZYRA®
10/01/2020
2/01/2022
85 FR 58725 through 58727
86 FR 44975 through 44979
12
Spinelack®
System
10/01/2020
10/11/2021
85 FR 58689 through 58701
86 FR 44975 through 44979
13
Xospata®
10/02/2018
(commercially
available
02/01/2019)
08/30/2018
(commercially
available
10/11/2018}
11/28/2018
10/01/2019
11/28/2021
84 FR 42256 through 42260
85 FR 58617
86 FR 44975 through 44979
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00141
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.079
FDA/Newness
Start Date
48920
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
BILLING CODE 4120–01–C
khammond on DSKJM1Z7X2PROD with RULES2
6. FY 2023 Applications for New
Technology Add-On Payments
(Traditional Pathway)
We received 18 applications for new
technology add-on payments for FY
2023 under the traditional new
technology add-on payment pathway. In
accordance with the regulations under
§ 412.87(e), applicants for new
technology add-on payments must have
received FDA approval or clearance by
July 1 of the year prior to the beginning
of the fiscal year for which the
application is being considered. Five
applicants withdrew their applications
prior to the issuance of the proposed
rule. Subsequently, seven applicants
withdrew their respective applications
for lifileucel, narsoplimab, TERLIVAZ
(terlipressin), teclistamab,
mosunetuzumab, XENOVIEW, and
treosulfan prior to the issuance of this
FY 2023 IPPS/LTCH PPS final rule. In
addition, in accordance with
§ 412.87(c), applicants for new
technology add-on payments must have
FDA approval or clearance by July 1 of
each year prior to the beginning of the
fiscal year for which the application is
being considered. One applicant,
Boehringer Ingelheim Pharmaceuticals,
Inc., for spesolimab, did not receive
FDA approval for its technology by July
1, 2022. Therefore, spesolimab is not
eligible for consideration for new
technology add-on payments for FY
2023. Consistent with our standard
approach, we are not including in this
final rule the description and discussion
of applications that were withdrawn or
that are ineligible for consideration for
FY 2023 due to not meeting the July 1
deadline, described previously, which
were included in the FY 2023 IPPS/
LTCH PPS proposed rule. We are also
not summarizing nor responding to
public comments received regarding
these withdrawn or ineligible
applications in this final rule. A
discussion of the five remaining
applications is presented below.
a. CARVYKTITM (Ciltacabtagene
Autoleucel)
Janssen Biotech, Inc., submitted an
application for new technology add-on
payments for CARVYKTITM
(ciltacabtagene autoleucel) for FY 2023.
CARVYKTITM is an autologous
chimeric-antigen receptor (CAR) T-cell
therapy directed against B cell
maturation antigen (BCMA) for the
treatment of patients with multiple
myeloma. We note that Janssen Biotech,
Inc. previously submitted an application
for new technology add-on payments for
CARVYKTITM for FY 2022 under the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
name ciltacabtagene autoleucel, as
summarized in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 25233 through
25239), but withdrew that application
prior to the issuance of the FY 2022
IPPS/LTCH PPS final rule (86 FR
44979).
The applicant stated that
ciltacabtagene autoleucel refers to both
JNJ–4528, an investigational BCMAdirected CAR T-cell therapy for
previously treated patients with
multiple myeloma, and LCAR–B38M,
the investigational product
(ciltacabtagene autoleucel) being
studied in China. Both JNJ–4528 and
LCAR–B38M are representative of the
same CAR T-cell therapy, ciltacabtagene
autoleucel.
Multiple myeloma is an incurable
blood cancer that affects a type of white
blood cell called plasma cells.32 Plasma
cells, found in bone marrow, make the
antibodies that help the body attack and
kill various pathogens. According to the
applicant, when damaged, malignant
plasma cells rapidly spread and replace
the normal cells in the bone marrow.33
The applicant asserted the median age
of onset is 69 years old and only 3% of
patients are less than 45 at the age of
diagnosis; it was estimated that in 2021
nearly 35,000 people would be
diagnosed and more than 12,000 will
die from multiple myeloma in the US.34
According to the applicant, multiple
myeloma is associated with substantial
morbidity and mortality35 and median 5
year survival is 56%.36
According to the applicant,
introduction of new treatment options
in the last 2 decades has extended the
median survival of multiple myeloma
patients. The applicant asserted that the
introduction of proteasome inhibitors
(PI) (for example, bortezomib,
32 Ho, M., Chen, T., Liu, J. et al. Targeting histone
deacetylase 3 (HDAC3) in the bone marrow
microenvironment inhibits multiple myeloma
proliferation by modulating exosomes and IL–6
trans-signaling. Leukemia 34, 196–209 (2020).
https://doi.org/10.1038/s41375-019-0493-x.
33 Utley A, Lipchick B, Lee KP, Nikiforov MA.
Targeting Multiple Myeloma through the Biology of
Long-Lived Plasma Cells. Cancers (Basel). 2020 Jul
30;12(8):2117.
34 Surveillance, Epidemiology, and End Results
(SEER) Program. SEER database 2020; https://
seer.cancer.gov/statfacts/html/mulmy.html.
35 Cowan AJ, Allen C, Barac A, Basaleem H,
Bensenor I, Curado MP, Foreman K, Gupta R,
Harvey J, Hosgood HD, Jakovljevic M, Khader Y,
Linn S, Lad D, Mantovani L, Nong VM, Mokdad A,
Naghavi M, Postma M, Roshandel G, Shackelford K,
Sisay M, Nguyen CT, Tran TT, Xuan BT, Ukwaja
KN, Vollset SE, Weiderpass E, Libby EN,
Fitzmaurice C. Global Burden of Multiple Myeloma:
A Systematic Analysis for the Global Burden of
Disease Study 2016. JAMA Oncol. 2018 Sep
1;4(9):1221–1227.
36 SEER database 2020; https://seer.cancer.gov/
statfacts/html/mulmy.html.
PO 00000
Frm 00142
Fmt 4701
Sfmt 4700
carfilzomib, and ixazomib), histone
deacetylase inhibitors (for example,
panobinostat, vorinostat),
immunomodulatory agents (IMiD) (for
example, thalidomide, lenalidomide,
and pomalidomide), monoclonal
antibodies (daratumumab and
elotuzumab), and stem cell
transplantation, have allowed numerous
therapeutic options for patients with
multiple myeloma (Rajkumar 2020).
According to the applicant, the National
Comprehensive Cancer Network (NCCN)
recommended treatment regimen for
first-line therapy of multiple myeloma is
bortezomib (a PI), lenalidomide (an
IMiD) and dexamethasone.37 According
to the applicant, the strategy of triplet
therapies for patients with newly
diagnosed multiple myeloma, followed
by high-dose chemotherapy and
autologous stem-cell transplantation for
eligible patients, and subsequently
consolidation and maintenance therapy,
is the current treatment roadmap for
patients.38 However, despite these
treatments, according to the applicant,
most patients will relapse after first-line
treatment and require further
treatment39 with only 50% survival of
relapsed patients after 5 years.40 41 The
applicant stated that as multiple
myeloma progresses, each subsequent
line of treatment is associated with
shorter progression free survival (PFS)
and decreased rate, depth, and
durability of response and worsening of
quality of life.42 In addition, cumulative
and long-term toxicities are often
associated with long-term therapy
(Ludwig, 2018). Thus, according to the
applicant, there remains an ongoing
need for additional therapeutic
approaches when the disease is resistant
to available therapy.
The applicant asserted that relapsed
and refractory (r/r) multiple myeloma
(RRMM) constitutes a specific unmet
medical need. According to the
applicant, patients with r/r disease are
defined as those who, having achieved
37 National Comprehensive Cancer Network
(NCCN) NCCN clinical practice guidelines in
oncology. Multiple Myeloma. Version 2. 2021—
September 9, 2020.
38 Branagan A, Lei M, Lou U, Raje N. Current
Treatment Strategies for Multiple Myeloma. JCO
Oncol Pract. 2020 Jan;16(1):5–14.
39 Sonneveld P, Broij lA. Treatment of relapsed
and refractory multiple myeloma. Haematologica.
2016;101(4):396–406.
40 SEER database 2020; https://seer.cancer.gov/
statfacts/html/mulmy.html.
41 Global Cancer Observatory. GLOBOCAN
database 2018; https://gco.iarc.fr/today/data/
factsheets/populations/900-world-fact-sheets.pdf.
42 Yong K, Delforge M, Driessen C, Fink L, Flinois
A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos
MV, Raab MS, Schoen P, Cavo M. Multiple
myeloma: patient outcomes in real-world practice.
Br J Haematol. 2016 Oct;175(2):252–264.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
a minor response or better, relapse and
then progress while on therapy, or
experience progression within 60 days
of their last therapy.43 44 The applicant
stated the introduction of a new class of
agents, CD38-targeting monoclonal
antibodies (CD38 MoAbs),
daratumumab and isatuximab, have
improved options in r/r patients.45 The
applicant asserted that given these
advances, guideline recommendations
following first-line therapy are varied,
with treatment options including
combinations of novel agents with
existing standard of care regimens, and
include triplet and quadruplet regimens,
creating a complex treatment
landscape.46 According to the applicant,
while triplet regimens should be used as
the standard therapy for patients with
multiple myeloma, elderly or frail
patients may be treated with double
regimens.47 The applicant further stated
that for patients with RRMM who have
received at least three prior lines of
therapy, including a PI, an IMiD and an
anti-CD38, there does not exist a
standard or consensus for treatment at
this time, and often, supportive care/
palliative care is the only option.48
According to the applicant, multiple
myeloma remains incurable and most
patients eventually relapse, even with
the advent of new treatments.49 The
applicant further stated that novel,
innovative therapies are needed to
improve long-term survival and
outcomes. The applicant asserted that
CAR T-cell-based therapies offer
potential advantages over current
therapeutic strategies. According to the
applicant, while other therapies require
long-term repetitive administration
generally until progression of disease,
CAR T-cell therapy is a single infusion
treatment due to live T-cell expansion
in the patient and long-term disease
response. The applicant asserted that
43 Castelli R, Orofino N, Losurdo A, Gualtierotti
R, Cugno M. Choosing treatment options for
patients with relapsed/refractory multiple
myeloma. Expert Rev Anticancer Ther. 2014
Feb;14(2):199–215.
44 Nooka AK, Kastritis E, Dimopoulos MA, Lonial
S. Treatment options for relapsed and refractory
multiple myeloma. Blood. 2015 May
14;125(20):3085–99.
45 Van de Donk NWCJ, Richardson PG, Malavasi
F. CD38 antibodies in multiple myeloma: back to
the future. Blood. 2018 Jan 4;131(1):13–29.
46 National Comprehensive Cancer Network
(NCCN) NCCN clinical practice guidelines in
oncology. Multiple Myeloma. Version 2. 2021—
September 9, 2020.
47 Ibid.
48 Maples KT, Joseph NS, Harvey RD. Current
developments in the combination therapy of
relapsed/refractory multiple myeloma. Expert Rev
Anticancer Ther. 2020 Sep 24.
49 Rajkumar SV, Kumar S. Multiple myeloma
current treatment algorithms. Blood Cancer J. 2020
Sep 28;10(9):94.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
CARVYKTITM is an autologous CAR Tcell therapy directed against B cell
maturation antigen (BCMA) for the
treatment of patients with multiple
myeloma. The applicant stated that
BCMA, a protein that is highly
expressed on myeloma cells50 and is a
member of the tumor necrosis factor
(TNF) receptor family, plays a central
role in regulating B-cell maturation and
differentiation into plasma cells.51 52
The applicant stated BCMA is
selectively expressed on a subset of B
cells (plasma cell neoplasms including
myeloma cells) and is more stably
expressed specifically on the B cell
lineage, compared with key plasma cell
marker CD138, which is also expressed
on normal fibroblasts and epithelial
cells.53 54 55 According to the applicant,
these expression characteristics make
BCMA an ideal therapeutic target for the
treatment of multiple myeloma.56 57
CARVYKTITM, according to the
applicant, is a unique, structurally
differentiated BCMA-targeting chimeric
antigen receptor with two distinct
BCMA-binding domains that can
identify and eliminate myeloma cells.
The applicant asserted that CAR Tcell technology is a form of
immunotherapy and is a ‘‘living drug’’
that utilizes specially altered T cells,
part of the immune system, to fight
cancer. According to the applicant, a
sample of the patient’s T cells are
collected from the blood, then modified
in a laboratory setting to express a
CAR.58 The applicant stated chimeric
antigen receptors are specifically
designed receptor proteins that are
made up of three distinct features: (1) a
target recognition domain (typically
50 Cho SF, Anderson KC, Tai YT. Targeting B Cell
Maturation Antigen (BCMA) in Multiple Myeloma:
Potential Uses of BCMA-Based Immunotherapy.
Front Immunol. 2018 Aug 10;9:1821.
51 Cho SF, Anderson KC, Tai YT. Targeting B Cell
Maturation Antigen (BCMA) in Multiple Myeloma:
Potential Uses of BCMA-Based Immunotherapy.
Front Immunol. 2018 Aug 10;9:1821.
52 Tai YT, Anderson KC. Targeting B-cell
maturation antigen in multiple myeloma.
Immunotherapy. 2015;7(11):1187–99.
53 Cho SF, Anderson KC, Tai YT. Targeting B Cell
Maturation Antigen (BCMA) in Multiple Myeloma:
Potential Uses of BCMA-Based Immunotherapy.
Front Immunol. 2018 Aug 10;9:1821.
54 Tai YT, Anderson KC. Targeting B-cell
maturation antigen in multiple myeloma.
Immunotherapy. 2015;7(11):1187–99.
55 Palaiologou M, Delladetsima I, Tiniakos D.
CD138 (syndecan-1) expression in health and
disease. Histol Histopathol. 2014 Feb;29(2):177–89.
56 Ibid.
57 Frigyesi I, Adolfsson J, Ali M, Christophersen
MK, Johnsson E, Turesson I, Gullberg U, Hansson
M, Nilsson B. Robust isolation of malignant plasma
cells in multiple myeloma. Blood. 2014 Feb
27;123(9):1336–40.
58 June CH, Sadelain M. Chimeric Antigen
Receptor Therapy. N Engl J Med. 2018 Jul
5;379(1):64–73.
PO 00000
Frm 00143
Fmt 4701
Sfmt 4700
48921
derived from a single domain of an
antibody) that sits on the cell’s exterior;
(2) a co-stimulatory domain on the cell’s
interior that boosts activation, enhances
survival and expansion of the modified
cells; and (3) an interior stimulatory
domain that supports activation and
target killing.59 According to the
applicant, the binding domain
expressed on the surface of T cells gives
them the new ability to target a specific
protein. The applicant stated, when the
target is recognized, the intracellular
portions of the receptor send signals
within the T cells to destroy the target
cells. The applicant asserted these
engineered CAR T-cells are reinfused
back into the same patient, which
enables these specialized T cells to latch
onto the target antigen and abolish the
tumor cells.
According to the applicant,
CARVYKTITM is a CAR T-cell
immunotherapy designed to recognize
myeloma cells and target their
destruction. According to the applicant,
CARVYKTITM’s CAR T-cell technology
consists of harvesting the patient’s own
T cells, programming them to express a
chimeric antigen receptor that identifies
BCMA, a protein highly expressed on
the surface of malignant multiple
myeloma B-lineage cells, and reinfusing
these modified cells back into the
patient where they bind to and
eliminate myeloma tumor cells. The
applicant asserted that, unlike the
chimeric antigen receptor design of
currently approved CAR T-cell
immunotherapies, which are composed
of a single-domain antibody (sdAbs),
CARVYKTITM is composed of two
antibody binding domains that allow for
high recognition of human BCMA
(CD269) and elimination of BCMA
expressing myeloma cells. According to
the applicant, the two distinct BCMAbinding domains confer avidity and
distinguish CARVYKTITM from other
BCMA-targeting products. The applicant
stated the BCMA binding domains are
linked to the receptor’s interior
costimulatory (4–1BB) and signaling
(CD3z) domains through a
transmembrane linker (CD8a). The
applicant asserted these intracellular
domains are critical components for T
cell growth and anti-tumor activity 60 in
the body once CAR T-cells are bound to
a BCMA target on multiple myeloma
cells.
59 Sadelain M. Chimeric antigen receptors:
driving immunology towards synthetic biology.
Curr Opin Immunol. 2016 Aug;41:68–76.
60 Maher J, Brentjens RJ, Gunset G, Rivie
` re I,
Sadelain M. Human T-lymphocyte cytotoxicity and
proliferation directed by a single chimeric TCRzeta/
CD28 receptor.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48922
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
With respect to the newness criterion,
according to the applicant,
CARVYKTITM was granted
Breakthrough Therapy designation in
December 2019 for the treatment of
adult patients with relapsed or
refractory multiple myeloma, who
previously received a proteasome
inhibitor, an immunomodulatory agent,
and an anti-CD38 antibody. Per the
applicant, FDA approved the Biologics
License Application (BLA) for
CARVYKTITM on February 28, 2022 for
the treatment of adult patients with
relapsed or refractory multiple myeloma
after four or more prior lines of therapy,
including a proteasome inhibitor, an
immunomodulatory agent, and an antiCD38 monoclonal antibody. The
applicant stated that procedures
involving the administration of
CARVYKTITM can be uniquely
identified using the following ICD–10–
PCS procedure codes: XW033A7
(Introduction of ciltacabtagene
autoleucel into peripheral vein,
percutaneous approach, new technology
group 7) or XW043A7 (Introduction of
ciltacabtagene autoleucel into central
vein, percutaneous approach, new
technology group 7). The applicant also
noted that they will submit a request for
a Healthcare Common Procedure Coding
System (HCPCS) code specific to the
administration of CARVYKTITM once
the product is eligible for such a code.
As previously stated, if a technology
meets all three of the substantial
similarity criteria as previously
described, it would be considered
substantially similar to an existing
technology and therefore would not be
considered ‘‘new’’ for purposes of new
technology add-on payments.
With respect to whether a product
uses the same or a similar mechanism
of action when compared to an existing
technology to achieve a therapeutic
outcome, the applicant asserted that
CARVYKTITM has a unique mechanism
of action because it has two distinct
binding domains that confer avidity to
the BCMA antigen, a 4–1BB
costimulatory domain and a CD3z
signaling domain, whereas other CAR Tcell products have only one target
binding domain. The applicant asserted
that ABECMA® also targets BCMA, but
does so by binding to a single BCMA
domain. In addition to detail provided
in the applicant’s FY 2022 application
(as discussed in 86 FR 25235 through
25236), the applicant asserted that
CARVYKTITM differs significantly from
ABECMA® and other BCMA-targeting
agents, including Blenrep, because it
targets BCMA with two distinct binding
domains. According to the applicant,
the distinct BCMA-binding moieties
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
confer avidity and distinguish
CARVYKTITM from other BCMA CAR Tcell constructs providing a novel
mechanism of action.61 The applicant
added, the 4–1BB and CD3z domains on
the CAR optimize T cell activation and
proliferation.62 According to the
applicant, non-clinical pharmacology
and toxicology have been used to
characterize the biological activity and
mechanism of action of CARVYKTITM
and confirm the on-target specificity to
BCMA through (1) in vitro binding
characterization; (2) in vitro co-culture
assays to assess CAR T-cell cytotoxicity
and cytokine release; (3) in vivo efficacy
studies in mice with human CAR Tcells; and (4) an in vivo safety study.
According to the applicant, because
CARVYKTITM has a novel mechanism of
action with two distinct BCMA-binding
domains that confer binding avidity and
unprecedented clinical activity
compared with other novel antimyeloma treatments in comparable
study populations, it is unlike any
existing technology utilized to treat
relapsed/refractory multiple myeloma.
With regard to whether a product is
assigned to the same DRG when
compared to an existing technology, the
applicant asserted that because CMS has
suggested that all inpatient
hospitalizations involving a CAR T-cell
treatment will be assigned to DRG 018
(Chimeric Antigen Receptor (CAR) TCell and Other Immunotherapies),
CARVYKTITM is expected to be assigned
to the same DRG as other multiple
myeloma cases treated with a CAR Tcell therapy. We note that the DRG
assignment was finalized to Pre-MDC
MS–DRG 018, effective October 1, 2022
and is reflected in the V39.1 ICD–10
MS–DRG Grouper effective April 1,
2022 (86 FR 58021).63
With regard to whether the new use
of the technology involves the treatment
of the same or similar type of disease
and the same or similar patient
population when compared to an
existing technology, the applicant
asserted in its application that
61 Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF,
Xu J, Zhuang Y, Zhang W, Weng XQ, Wu J, Wang
Y, Wang J, Yan H, Xu WB, Jiang H, Du J, Ding XY,
Li B, Li JM, Fu WJ, Zhu J, Zhu L, Chen Z, Fan XF,
Hou J, Li JY, Mi JQ, Chen SJ. Exploratory trial of
a biepitopic CAR T-targeting B cell maturation
antigen in relapsed/refractory multiple myeloma.
Proc Natl Acad Sci U S A. 2019 May
7;116(19):9543–9551.
62 Weinkove R, George P, Dasyam N, McLellan
AD. Selecting costimulatory domains for chimeric
antigen receptors: functional and clinical
considerations. Clin Transl Immunology. 2019 May
11;8(5):e1049.
63 CMS Manual System, Pub. 100–04 Medicare
Claims Processing, Transmittal 11255. February 4,
2022; https://www.cms.gov/files/document/
r11255cp.pdf.
PO 00000
Frm 00144
Fmt 4701
Sfmt 4700
CARVYKTITM is indicated for a broader
population than other available
therapies, specifically multiple
myeloma patients having received three
prior therapies. The applicant asserted
in its application that Blenrep and
ABECMA® are indicated only for those
with at least 4 prior therapies whereas
CARVYKTITM had a proposed
indication for the treatment of patients
with 3 or more prior therapies.
According to the applicant,
CARVYKTITM could potentially be used
in a broader multiple myeloma
population, that includes patients after
3 prior therapies as opposed to 4 for
Blenrep and ABECMA®.
According to the applicant, in the
registrational trial CARTITUDE 1, 17%
(a total of 17 patients) of patients had
only three prior lines of therapy; results
were presented at the American Society
of Hematology (ASH) 2021 meeting on
fourth line patients. The applicant
stated that among those with three prior
lines of therapy, the response rate was
100%, the median duration of response
(DoR) was 21.8 months, minimal
residual disease (MRD) negativity was
found in 80%, the 18-month progression
free survival (PFS) was 75.6%, and the
18-month overall survival (OS) was 88.2
months. According to the applicant,
because the sample size was small (17),
median endpoints may not be as
rigorous as in the larger population.
According to the applicant, the
distinction between three and four
previous lines of therapy is important.
The applicant asserted with each
subsequent therapy patients generally
become frailer and their prognosis
worsens. The applicant stated that
studies comparing fourth line to fifth
line are not as common as trials
studying earlier lines, but in a realworld study by Yong et al. the percent
of myeloma patients who were able to
move from third line therapy to fourth
line was 15% of all diagnosed myeloma
patients, and only 1% of patients moved
to a fifth line.64 The applicant added
that in the same study of those patients
in first line therapy, approximately 90%
of patients were able to discontinue
treatment due to remission and/or
planned end of treatment while only
13% of those in fifth line ended
treatment due to stable disease/
remission.
The applicant asserted that for these
reasons, CARVYKTITM does not meet
the third criterion and is therefore a new
technology with regards to the
64 Yong et al. 2016. Multiple Myeloma: Patient
outcomes in real-world practice. British Journal of
Haematology, 175; 252–264. doi: 10.1111/
bjh.14213.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
population having been studied and
being targeted for use.
In summary, the applicant asserted
that CARVYKTITM meets the newness
criterion because it is not substantially
similar to other available therapies due
to its unique mechanism of action, with
two distinct binding domains that
confer avidity to the BCMA antigen, and
because it treats a different patient
population, RRMM patients who
received three prior therapies.
In the FY 2023 IPPS/LTCH PPS
proposed rule, as stated in the FY 2022
proposed rule (86 FR 25236), we noted
that CARVYKTITM may have a similar
mechanism of action to that of
ABECMA®. We also noted that
ABECMA® received approval for new
technology add-on payments for FY
2022 for the treatment of adult patients
with RRMM after four or more prior
lines of therapy, including an
immunomodulatory agent, a proteasome
inhibitor, and an anti-CD38 monoclonal
antibody (86 FR 45028 through 45035).
We stated that although the number of
BCMA binding domains of
CARVYKTITM and ABECMA® differ, it
appeared that the mechanism of action
for both therapies is the binding to
BCMA by a CAR construct, which
results in T-cell activation and killing of
malignant myeloma cells. We noted that
the applicant asserted that
CARVYKTITM’s mechanism of action is
unique due to its dual binding domain
which affects the therapy’s clinical
activity, as compared to existing
technologies with a single binding
domain. However, we were unclear as to
how the additional BCMA binding
domain represents a change in the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
mechanism of action of this therapy, or
if it may instead relate to an assessment
of whether the technology meets the
substantial clinical improvement
criterion. Because of the potential
similarity with the BCMA antigen and
other actions, we stated our belief that
the mechanism of action for
CARVYKTITM may be the same or
similar to that of ABECMA®.
We also noted that the applicant
stated that CARVYKTITM may serve a
new patient population if approved as a
fourth line treatment, as existing
treatments are approved for fifth line
treatment. However, because
CARVYKTITM’s recent approval stated
that it is indicated for fifth line
treatment, we questioned whether
CARVYKTITM treats a new patient
population.65
Accordingly, as it appeared that
CARVYKTITM and ABECMA® are
purposed to achieve the same
therapeutic outcome using the same or
similar mechanism of action, are
assigned to the same MS–DRG, and treat
the same or similar patient population
and disease, we stated our belief that
these technologies may be substantially
similar to each other. We noted that if
this technology is substantially similar
to ABECMA®, we believe the newness
period for this technology would begin
on March 26, 2021, the date ABECMA®
received FDA approval. We expressed
our interest in information on how these
two technologies may differ from each
other with respect to the substantial
similarity criteria and newness
criterion. We invited public comment
65 https://www.fda.gov/media/156572/download.
PO 00000
Frm 00145
Fmt 4701
Sfmt 4700
48923
on whether CARVYKTITM meets the
newness criterion, including whether
CARVYKTITM is substantially similar to
ABECMA® for purposes of new
technology add-on payments.
Comment: Several commenters voiced
their support for CARVYKTITM in their
general comments supporting all CAR
T-cell therapies. The commenters
encouraged CMS to consider approving
the new technology add-on payment for
new CAR T-cell therapies, including
CARVYKTI, as they stated this
encourages hospitals to adopt
breakthrough technologies by helping
them recover some of the increased
costs associated with offering innovative
treatments to patients.
Response: We thank the commenters
for their support.
Comment: The applicant submitted a
comment in response to concerns raised
by CMS in the proposed rule, reiterating
that CARVYKTITM meets the newness
criterion and is not substantially similar
to ABECMA® and other multiple
myeloma treatments. The applicant
stated that, while both CARVYKTITM
and ABECMA® are CAR T-cell therapies
directed against BCMA for the treatment
of patients with multiple myeloma,
there are mechanistic differences that
contribute to a different CAR T-cell
dose, pharmacokinetic/
pharmacodynamic profile, and a
different time frame for the
development of cytokine release
syndrome (CRS) as compared to
ABECMA®’s single binding domain.
The applicant presented the following
table outlining the key scientific
differences between CARVYKTITM and
ABECMA®.
E:\FR\FM\10AUR2.SGM
10AUR2
48924
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Key Scientific Differences Between CARVYKTJTM and ABECMA®
ABECMA®
[BCMA Binding Domain
Double
Single
[Dosage
0.75 x 106 CAR-positive
viable T cells
300 to 400
Expansion ofT cell
populations
CD8 central memory cells
CD4 cells
Onset ofCRS
Day7
Day 1
[L-6
Peaks at day 10
Peaks at day 5
Peak IL-6, CRS grade 3
~ 1000 pg/ml.
> 10,000 pg/nl
Other cytokines
Return to baseline levels in 2
to 3 months
Return to baseline levels
in 1 month
In terms of differences in dosage, the
applicant stated the clinical target dose
of CARVYKTITM is 0.75 ×106 CARpositive viable T-cells/kg whereas
ABECMA® is 300–400 × 106 cells/kg. In
terms of differences in expansion of Tcell populations, the applicant stated
that CARVYKTITM has preferential
expansion of CD8 T-cells as opposed to
CD4 T-cells for ABECMA®. In terms of
the differences in pharmacokinetic and
pharmacodynamic properties, the
applicant stated that the median time to
reach maximum expansion for
CARVYKTITM was approximately 13
days after infusion, whereas for
ABECMA® it was much sooner.
According to the applicant, because of
this longer lag time for maximal
expansion, the highest peak IL–6 levels
is around 10 days for CARVYKTITM as
opposed to 5 days with ABECMA®,
which resulted in differences in the side
effect profile, as the median time to
onset of CRS is 7 days for CARVYKTITM
as opposed to 1 day for ABECMA®. The
applicant stated that patients with CRS
of Grade 3 severity had IL–6 peak levels
of ∼1,000 pg/ml with CARVYKTITM as
opposed to over 10,000 pg/ml with
ABECMA®. The applicant also stated
that the return to baseline levels of IL–
6 occurred in 2–3 months for patients
treated with CARVYKTITM as opposed
to 1 month with ABECMA®. Lastly, the
applicant stated that another important
distinction between CARVYKTITM and
ABECMA® was that CARVYKTITM is
derived from llama antibodies directed
against BCMA whereas ABECMA® is
derived from mouse antibodies. We note
that the applicant agreed with our
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
assessment that CARVYKTITM does not
treat a new population.
Another commenter requested that
CARVYKTITM be considered for a
separate new technology add-on
payment and should not be combined
with other new technologies as the
commenter considers the newness, cost,
and substantial clinical improvement
requirements met for CARVYKTITM. Per
the commenter, this would ensure the
maximum impact for each product for
CAR T-cell therapy, which the
commenter stated is significantly
underpaid.
Response: We appreciate the
information submitted by commenters
regarding the newness criterion for
CARVYKTITM. However, we disagree
that CARVYKTITM has a unique
mechanism of action. While the
applicant highlighted differences
between CARVYKTITM and ABECMA®,
such as number of domains, dosage,
time to CRS onset, pharmacokinetic/
pharmacodynamic profile, side effects,
source of antibodies, and CD4/CD8
ratios, we do not believe these
meaningfully differentiate the
mechanism of action of CARVYKTITM
from other BCMA-directed CAR T-cell
therapies such as ABECMA®, as they are
both considered genetically modified
autologous T-cell immunotherapies that
bind to BCMA-expressing cancer cells.
While CARVYKTITM has two BCMA
binding domains as opposed to one
binding domain for ABECMA®, the
resulting mechanism of action produces
the same therapeutic outcome of CAR
expressing CD4 and CD8 T-cells
directed against BCMA for the treatment
PO 00000
Frm 00146
Fmt 4701
Sfmt 4700
X
106
of multiple myeloma. We also disagree
with applicant’s assertion that
CARVYKTITM’s preferential expansion
of CD8 T-cells leads to a different
mechanism of action, as both
CARVYKTITM and ABECMA® produce a
combination of CD4 and CD8 T-cells.
While the ratio of these T-cells may
vary, it does not substantiate a
difference in mechanism of action
which, as noted previously, is the
targeting of and binding to the BCMAexpressing cancer cells. Lastly, we
disagree that a difference in dosage and
production represents a different
mechanism of action. We refer the
reader to the FY 2022 IPPS/LTCH PPS
final rule (86 FR 44996 through 45000)
for a further discussion of this issue,
where we determined that BREYANZI®
had a similar mechanism of action to
KYMRIAH® and YESCARTA®.
After consideration of the comments
received, and for the reasons discussed,
we believe that CARVYKTITM and
ABECMA® use the same or a similar
mechanism of action to achieve a
therapeutic outcome, as both products
are BCMA-targeting CAR T-cell
immunotherapies that result in similar
T-cell activation and killing of
malignant myeloma cells. Furthermore,
as discussed previously, CARVYKTITM
maps to the same MS–DRG and treats
the same patient population (those with
multiple myeloma after 4 or more prior
lines of therapy) as ABECMA® and
other CAR T-cell therapies.
Accordingly, because CARVYKTITM
meets all three of the substantial
similarity criteria, we believe that it is
substantially similar to ABECMA®. In
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.080
khammond on DSKJM1Z7X2PROD with RULES2
CARVYKTI™
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
accordance with our policy, because
these technologies are substantially
similar to each other, we use the earliest
market availability date submitted as the
beginning of the newness period for
both technologies. Therefore, we
consider the beginning of the newness
period for CARVYKTI® to be March 26,
2021, which is the date that ABECMA®
received FDA marketing authorization.
Consistent with our policy statements
in the past regarding substantial
similarity, we will not be making a
determination on cost and substantial
clinical improvement for CARVYKTITM.
Specifically, we have noted that
approval of new technology add-on
payments would extend to all
technologies that are substantially
similar, and if substantially similar
technologies are submitted for review in
different (and subsequent) years, we
evaluate and make a determination on
the first application and apply that same
determination to the second application
(85 FR 58679). Since ABECMA® was
approved for new technology add-on
payments for FY 2022 and is still within
its newness period for FY 2023, and we
have determined that CARVYKTITM is
substantially similar to ABECMA®, we
apply that same approval for new
technology add-on payments to
CARVYKTITM. We note that we received
public comments with regard to the cost
and substantial clinical improvement
criteria for this technology, but because
the determination made in the FY 2022
IPPS/LTCH PPS final rule for
ABECMA® is applied to CARVYKTITM
due to their substantial similarity, we
are not summarizing comments received
or making a determination on those
criteria in this final rule.
Cases involving the use of
CARVYKTITM that are eligible for new
technology add-on payments will be
identified by procedure codes
XW033A7 (Introduction of
ciltacabtagene autoleucel into
peripheral vein, percutaneous approach,
new technology group 7) or XW043A7
(Introduction of ciltacabtagene
autoleucel into central vein,
percutaneous approach, new technology
group 7). In its application, the
applicant estimated that the cost of
CARVYKTITM is $465,000.00 per
patient. Because CARVYKTITM is
substantially similar to ABECMA®, we
believe using a single cost for purposes
of determining the new technology addon payment amount is appropriate for
CARVYKTITM and ABECMA® even
though each applicant has its own set of
codes. We also believe using a single
cost provides predictability regarding
the add-on payment when using
CARVYKTITM and ABECMA® for the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
treatment of patients with RRMM. As
such, we believe that the use of a
weighted average of the cost of
CARVYKTITM and ABECMA® based
upon the projected numbers of cases
involving each technology to determine
the maximum new technology add-on
payment would be most appropriate. To
compute the weighted cost average, we
summed the total number of projected
cases for each of the applicants, which
equaled 420 cases (241 plus 179). We
then divided the number of projected
cases for each of the applicants by the
total number of cases, which resulted in
the following case weighted
percentages: 57% for CARVYKTITM and
43% for ABECMA®. We then multiplied
the cost per case for the manufacturer
specific drug by the case-weighted
percentage (0.57 * $465,000 = $265,050
for CARVYKTITM and 0.43 * $419,500 =
$180,385 for ABECMA®). This resulted
in a case-weighted average cost of
$445,435 for the technology.
Under § 412.88(a)(2), we limit new
technology add-on payments to the
lesser of 65% of the average cost of the
technology, or 65% of the costs in
excess of the MS–DRG payment for the
case. As a result, the maximum new
technology add-on payment for a case
involving the use of CARVYKTITM or
ABECMA® is $289,532.75 for FY 2023.
b. DARZALEX FASPRO® (daratumumab
and hyaluronidase-fihj)
Janssen Biotech, Inc., submitted an
application for new technology add-on
payments for DARZALEX FASPRO® for
FY 2023. DARZALEX FASPRO® is a
combination of daratumumab (a
monoclonal CD38-directed cytolytic
antibody), and hyaluronidase (an
endoglycosidase) indicated for the
treatment of light chain (AL)
amyloidosis in combination with
bortezomib, cyclophosphamide and
dexamethasone (CyBorD) in newly
diagnosed patients and is administered
through a subcutaneous injection.
According to the applicant, AL
amyloidosis is a life-threatening blood
disorder caused by increased
production of misfolded
immunoglobulin light chains by an
abnormal proliferation of malignant
CD38+ plasma cells. Per the applicant,
these deficient immunoglobulin light
chains aggregate into highly ordered
amyloid fibrils that deposit in tissues,
eventually resulting in progressive
organ dysfunction and damage due to
the toxic effect of the misfolded proteins
(proteotoxicity) and the distortion of the
normal tissue architecture by the
PO 00000
Frm 00147
Fmt 4701
Sfmt 4700
48925
amyloid deposits.66 The applicant
stated that the most frequently affected
organs are the heart, kidney, liver,
spleen, gastrointestinal tract and
nervous system. Per the applicant,
patients often have a poor prognosis,
and as many as 30% of patients with AL
amyloidosis die within the first year
after diagnosis. The applicant stated that
approximately 4,500 people in the US
develop AL amyloidosis each year.67
The applicant stated that while there
were no FDA approved therapies prior
to daratumumab, a number of therapies
were used clinically to treat AL
amyloidosis including combination
therapies like cyclophosphamidebortezomib-dexamethasone (CyBorD),
bortezomib-lenalidomidedexamethasone (VRd), bortezomibmelphalan-dexamethasone (VMd),
melphalan-dexamethasone (Md), and
bortezomib-dexamethasone (Vd). The
applicant further noted that none of
these combination regimens are
approved for use by FDA in this specific
indication.
According to the applicant,
DARZALEX FASPRO® is the first and
only FDA-approved treatment for
patients with AL amyloidosis and is
also approved for multiple indications
for treatment of patients with multiple
myeloma. The applicant stated that the
indication for the technology for which
it is submitting a new technology addon payment application is for the
treatment of adult patients with AL
amyloidosis in combination with
bortezomib, cyclophosphamide and
dexamethasone in newly diagnosed
patients. The applicant noted that
DARZALEX FASPRO® is not indicated
nor recommended to be used in patients
with AL amyloidosis who have NYHA
Class IIIB or Class IV cardiac disease or
Mayo Stage IIIB, except in the context
of controlled clinical trials.
According to the applicant,
DARZALEX FASPRO® is the
subcutaneous formulation of
daratumumab, which is a human IgGkappa monoclonal antibody that targets
CD38, an enzymatic protein that is
uniformly expressed on human plasma
cells. Per the applicant, in DARZALEX
FASPRO®, daratumumab is coformulated with recombinant human
hyaluronidase (rHuP20), which
critically allows daratumumab to be
administered in a volume of 15 mL by
a 3–5 minute injection under the skin,
compared to the 500–1000 mL volume
66 Merlini et al. Systemic immunoglobin light
chain amyloidosis. Nat Rev Dis Primers. 2018; 4:38–
19.
67 Amyloidosis Foundation. AL amyloidosis facts.
https://www.amyloidosis.org/facts/al/. Accessed
September 2021.
E:\FR\FM\10AUR2.SGM
10AUR2
48926
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
and 3–7 hour administration time
required for IV daratumumab. The
applicant further noted that given the
cardiac and renal dysfunction which
afflicts many AL amyloidosis patients
and makes them poor candidates for
large volume IV administration, rHuP20
is a critical component of DARZALEX
FASPRO®. Per the applicant,
daratumamab binds to the CD38 protein
on the surface of the malignant plasma
cells which are responsible for abnormal
amyloid protein production in AL
amyloidosis, directly killing the
malignant CD38+ plasma cells and/or
directing the immune system to destroy
them. The immunomodulatory response
consists of CD8+ clonal expansion,
CD38 enzymatic inhibition, complement
activation and cell recruitment to enable
antibody dependent cellular
phagocytosis (ADPC) and antibody
dependent cellular cytotoxicity (ADCC).
Per the applicant, the mechanism of
actions of daratumumab in AL
amyloidosis are the same as the
mechanisms of action of daratumumab
in multiple myeloma, since both disease
entities are disorders of malignant
CD38+ plasma cells.68 69 70
The applicant stated that without
hyaluronidase, it is not possible to inject
more than 2–3 mL of drug directly into
the subcutaneous tissue under the skin.
Per the applicant rHuPH20 naturally
mimics natural hyaluronidase and
increases the permeability of
subcutaneous tissue by degrading
hyaluronan. By co-formulating
daratumumab with rHuPH20, it
becomes possible for 15 mL containing
1,800 mg of daratumamab to be
administered subcutaneously in
approximately 3 to 5 minutes. The
applicant stated that the ability to
administer daratumumab
subcutaneously reduces the reaction
rate to daratumumab, may improve
convenience and patient satisfaction,
and greatly reduces the volume of
administration, which is critical in light
of the cardiac dysfunction and kidney
dysfunction which afflict many patients
with AL amyloidosis.
With respect to the newness criterion,
the applicant stated that DARZALEX
68 de Weers et al. Daratumumab, a Novel
Therapeutic Human CD38 Monoclonal Antibody,
Induces Killing of Multiple Myeloma and Other
Hematogical Tumors. J Immunol 2011;186:1840–
1848).
69 Overdijk et al. Antibody-mediated phagocytosis
contributes to the anti-tumor activity of the
therapeutic antibody daratumumab in lymphoma
and multiple myeloma. MAbs.2015;7:311–321).
70 Krejcik J, Casneuf T, Nijhof IS, et al.
Daratumumab depletes CD38+ immune regulatory
cells, promotes T-cell expansion, and skews T-cell
repertoire in multiple myeloma. Blood 2016; 128:
384–94.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
FASPRO® was granted accelerated
approval from FDA on January 15, 2021,
indicated for the treatment of adult
patients with light chain (AL)
amyloidosis in combination with
bortezomib, cyclophosphamide and
dexamethasone in newly diagnosed
patients. Per the applicant, DARZALEX
FASPRO® is not indicated and
recommended for the treatment of
patients with AL amyloidosis who have
NYHA Class IIIB or Class IV cardiac
disease or Mayo Stage IIIB outside of
controlled clinical trials.71 The
applicant also stated that DARZALEX
FASPRO® received FDA approval on
September 26, 2019, for the treatment of
adult patients with multiple myeloma as
part of a combination therapy in newly
diagnosed patients eligible for
autologous stem cell transplant, and on
May 1, 2020, for the treatment of
patients with multiple myeloma. As
stated previously, the indication for
which the applicant submitted an
application for new technology add-on
payments is for the treatment of adult
patients with AL amyloidosis in
combination with bortezomib,
cyclophosphamide and dexamethasone
in newly diagnosed patients. The
applicant stated that DARZALEX
FASPRO® for newly diagnosed AL
amyloidosis was commercially available
immediately following the accelerated
approval granted by FDA. The
recommended dosage for DARZALEX
FASPRO® for newly diagnosed AL
amyloidosis is 1,800 mg of
daratumumab and 30,000 units of
hyaluronidase administered
subcutaneously over approximately 3 to
5 minutes in combination with
bortezomib, cyclophosphamide and
dexamethasone. According to the
applicant, patients receiving
DARZALEX FASPRO® for this
indication receive a weekly dose for the
first 8 weeks (week 1 to week 8), one
dose every 2 weeks from week 9 to week
24, followed by one dose monthly from
week 25 onward until disease
progression for a maximum of 2 years.
The applicant submitted a request for
a unique ICD–10–PCS code to identify
procedures involving the administration
of DARZALEX FASPRO®, and was
granted approval to identify DARZALEX
FASPRO® administration with ICD–10–
PCS code XW01318 (Introduction of
daratumumab and hyaluronidase-fihj
into subcutaneous tissue, percutaneous
approach, new technology group 8),
effective October 1, 2022. We note that
71 According to the applicant, continued approval
for this indication may be contingent upon
verification and description of clinical benefit in
confirmatory trials.
PO 00000
Frm 00148
Fmt 4701
Sfmt 4700
DARZALEX FASPRO® is also approved
for multiple indications for the
treatment of patients with multiple
myeloma, and this PCS code would not
uniquely identify use of the technology
for the indication for which the
applicant has applied for a new
technology add-on payment. The
applicant stated that E85.81 (Light chain
(AL) amyloidosis) may be used to
currently identify the indication for
DARZALEX FASPRO® under the ICD–
10–CM coding system. Therefore, the
administration of DARZALEX
FASPRO® for the AL amyloidosis
indication could be uniquely identified
with XW01318, in combination with
E85.81.
As previously discussed, if a
technology meets all three of the
substantial similarity criteria under the
newness criterion, it would be
considered substantially similar to an
existing technology and would not be
considered ‘‘new’’ for the purposes of
new technology add-on payments.
With respect to the first criterion,
whether a technology uses the same or
similar mechanism of action to achieve
a therapeutic outcome, the applicant
stated that it does not use the same or
similar mechanism of action as existing
technologies. The applicant stated that
DARZALEX FASPRO® was the first
drug approved by FDA for treatment of
AL amyloidosis and its mechanism of
action is different from that of any other
drug previously used to treat AL
amyloidosis. According to the applicant,
the other therapies currently used to
treat amyloidosis off-label (for example,
bortezomib, cyclophosphamide,
melphalan, lenlidomide) all have
different mechanisms of action; none of
them are monoclonal antibodies that
specifically bind to CD38 on malignant
plasma cells. The applicant stated that
bortezomib induces cell death of the
malignant plasma cell by inhibition of
the 26S proteasome which plays a key
role in cell survival by regulating
protein breakdown in a controlled
fashion. The applicant further stated
that when bortezomib inhibits
proteasome function, the normal
balance within a cell is disrupted,
resulting in a buildup of cell cycle and
regulatory proteins which eventually
leads to cell death.72 73 Per the
applicant, lenalidomide is an
immunomodulator which modulates the
E3 ubiquitin ligase complex.
Modulation of this E3 ubiquitin ligase
72 Adams et al. Proteasome Inhibitors: A Novel
Class of Potent and Effective Antitumor Agents.
Cancer Res 1999;55; 2615–2622.
73 Adams et al. The proteasome: a suitable
antineoplastic target. Nat Rev Cancer 2004; 4:349–
360.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
complex by lenalidomide eventually
leads to enhanced function of specific
immune cells and induction of cell
death and the exact mechanism of
action of lenalidomide is still not fully
understood.74 75 The applicant stated
that both melphalan and
cyclophosphamide are alkylating
chemotherapy drugs that add an alkyl
group to the guanine base of the DNA
molecule, preventing the strands of the
double helix from linking, which causes
breakage of the DNA strands, affecting
the ability of the cancer cell to multiply.
Per the applicant, like bortezomib and
lenalidomide, melphalan and
cyclophosphamide are not approved by
FDA for the use in patients with AL
amyloidosis. The applicant also noted
that while the National Comprehensive
Cancer Network® (NCCN®) Guidelines
for Systemic Light Chain Amyloidosis
state that both IV and SQ daratumumab
can be used to treat previously treated
amyloidosis,76 IV daratumumab is not
approved by FDA for the treatment of
patients with amyloidosis (newly
diagnosed and previously treated). The
applicant also stated that DARZALEX
FASPRO® is the more appropriate
option in the AL amyloidosis patient
population due to the fact that
subcutaneous dosing has a negligible
volume administration (15 ml for SC vs
up to 1,000 ml for IV), which is
particularly important in patients with
AL amyloidosis who often have
compromised cardiac and renal function
due to the amyloid deposition in cardiac
and kidney tissue.
With respect to the second criterion,
whether a product is assigned to the
same or a different MS–DRG, the
applicant stated that this product is not
expected to change the DRG assignment
of a case when used for the treatment of
AL amyloidosis.
With respect to the third criterion,
whether the new use of technology
involves the treatment of the same or
similar type of disease and the same or
similar patient population when
compared to an existing technology, the
applicant stated that DARZALEX
FASPRO® does not meet this criterion
because it was the first approved drug
to treat patients with AL amyloidosis.
The applicant also stated that the
NCCN® Guidelines for Systemic Light
Chain Amyloidosis reflect the limited
treatment options for this specific
disease. The applicant further stated
that DARZALEX FASPRO® in
combination with CyBorD is the only
treatment with a Category 1
recommendation 77 in the NCCN®
Guidelines for patients with newly
diagnosed AL amyloidosis.78
In summary, the applicant believes
that DARZALEX FASPRO® is not
substantially similar to other currently
available therapies and/or technologies
because it has a unique mechanism of
action and because it is the first FDA
approved treatment for AL amyloidosis.
We invited public comments on
whether DARZALEX FASPRO® is
substantially similar to existing
technologies and whether DARZALEX
FASPRO® meets the newness criterion.
Comment: The applicant submitted a
comment reiterating its belief that
DARZALEX FASPRO® meets the
newness criterion because it was the
first drug approved by FDA for patients
with newly diagnosed light chain
74 Kastritis et al. Primary treatment of light chain
amyloidosis with Bortezomib, lenalidomide and
dexamethasone. Blood Adv 2019;3:3002–3009.
75 Revlimid Prescribing Info.
76 NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®): Systemic Light Chain
amyloidosis (Version 1.2022). National
Comprehensive Cancer Network. www.nccn.org.
Published August 29 June 2021. Accessed July 21,
2021.
77 Per the NCCN®, a Category 1 recommendation
is ‘‘Based upon high-level evidence, there is
uniform NCCN® consensus that the intervention is
appropriate.’’
78 NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®): Systemic Light Chain
amyloidosis (Version 1.2022). National
Comprehensive Cancer Network. www.nccn.org.
Published August 29 June 2021. Accessed July 21,
2021.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00149
Fmt 4701
Sfmt 4700
48927
amyloidosis and that the mechanism of
action is different from that of any other
drug previously used to treat AL
amyloidosis in that it is a monoclonal
antibody that specifically binds to CD38
on malignant cancer cells. The applicant
stated that because of this unique
mechanism of action, DARZALEX
FASPRO® for AL is not substantially
similar to current treatments for AL and
therefore meets the newness criterion.
Response: We thank the applicant for
its comment. Based on our review of
comments received and information
submitted by the applicant as part of its
FY 2023 new technology add-on
payment application for DARZALEX
FASPRO®, we agree with the applicant
that DARZALEX FASPRO® has a unique
mechanism of action as the first FDA
approved treatment for AL amyloidosis.
Therefore, we believe that DARZALEX
FASPRO® is not substantially similar to
existing treatment options and meets the
newness criterion. We consider the
beginning of the newness period to
commence when DARZALEX FASPRO®
was approved by FDA for the treatment
of adult patients with light chain (AL)
amyloidosis in combination with
bortezomib, cyclophosphamide and
dexamethasone in newly diagnosed
patients, on January 15, 2021.
With respect to the cost criterion, the
applicant presented the following
analysis to demonstrate that
DARZALEX FASPRO® meets the cost
criterion. To identify cases representing
patients who may be eligible for
treatment with DARZALEX FASPRO®,
the applicant searched the FY 2019
MedPAR database released with the FY
2022 IPPS final rule and stated that it
used fee-for-service IPPS discharges,
plus Maryland hospital discharges. The
applicant searched for claims reporting
ICD–10–CM diagnosis code E85.81
(Light chain amyloidosis) in
conjunction with at least one of the
following additional ICD–10–CM
diagnosis codes:
BILLING CODE 4120–01–P
E:\FR\FM\10AUR2.SGM
10AUR2
48928
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
D63.1
E85.4
G62.9
Ill.0
Il2.0
Il2.9
I13.0
113.2
Anemia in chronic kidne disease
Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end
sta e renal disease
Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney
disease, or uns ecified chronic kidne disease
Hypertensive heart and chronic kidney disease with heart failure and stage 1 through
sta e 4 chronic kidne disease, or uns ecified chronic kidne disease
Hypertensive heart and chronic kidney disease with heart failure and with stage 5
chronic kidne disease, or end sta e renal disease
143
148.0
150.32
150.33
195.1
195.9
N17.9
Nl8.3
N18.4
Nl8.6
Z99.2
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
course of treatment, so it is unlikely a
patient would receive DARZALEX
FASPRO® during an inpatient stay
lasting longer than 7 days. The
applicant indicated that based on the
advice of clinical experts, it also
PO 00000
Frm 00150
Fmt 4701
Sfmt 4700
excluded cases mapped to the following
MS–DRGs, as DARZALEX FASPRO®
would not be an appropriate treatment
for patients receiving treatment for such
conditions:
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.081
khammond on DSKJM1Z7X2PROD with RULES2
The applicant excluded cases with a
length of stay greater than 7 days from
the analysis. According to the applicant,
administration of DARZALEX
FASPRO® would likely be delayed if a
patient becomes seriously ill during the
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
016
024
khammond on DSKJM1Z7X2PROD with RULES2
026
064
065
070
094
098
152
153
163
164
175
176
177
178
180
189
193
194
207
208
266
267
270
271
280
281
283
296
330
VerDate Sep<11>2014
ECMO or Tracheostomy with MV >96 Hours or Principal Diagnosis except Face, Mouth
and Neck with Ma· or O.R. Procedures
Autolo ous Bone Marrow Trans lant with CC/MCC
Craniotomy with Major Device Implant or Acute Complex CNS Principal Diagnosis
withoutMCC
Craniotom and Endovascular Intracranial Procedures with CC
Intracranial Hemorrha e or Cerebral Infarction with MCC
Intracranial Hemorrha e or Cerebral Infarction with CC OR TPA in 24 Hours
Nons ecific Cerebrovascular Disorders with MCC
Bacterial and Tuberculous Infections of Nervous S stem with MCC
Non-Bacterial Infection of Nervous S stem exce t Viral Menin itis with CC
Otitis Media and URI with MCC
Otitis Media and URI without MCC
Ma· or Chest Procedures with MCC
Ma"or Chest Procedures with CC
Embolism with MCC or Acute Cor Pulmonale
Embolism without MCC
Infections and Inflammations with MCC
Infections and Inflammations with CC
ort >96 Hours
Endovascular Cardiac Valve Re lacement and Su lement Procedures without MCC
Other Ma· or Cardiovascular Procedures with MCC
Other Ma· or Cardiovascular Procedures with CC
Acute M ocardial Infarction, Dischar ed Alive with MCC
Ma· or Small and Lar e Bowel Procedures with CC
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00151
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.082
003
48929
48930
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
469
470
481
483
521
535
536
602
603
652
666
742
813
820
823
824
834
835
khammond on DSKJM1Z7X2PROD with RULES2
837
840
841
853
854
856
864
867
868
870
871
872
918
919
920
981
982
Major Gastrointestinal Disorders and Peritoneal Infections with MCC
Maior Gastrointestinal Disorders and Peritoneal Infections with CC
Gastrointestinal Hemorrhage with MCC
Gastrointestinal Hemorrhage with CC
Inflammatory Bowel Disease with CC
Gastrointestinal Obstruction with MCC
Gastrointestinal Obstruction with CC
Laparoscopic Cholecystectomy without C.D.E. with MCC
Laparoscopic Cholecystectomy without C.D.E. with CC
Malignancy ofHepatobiliary System or Pancreas with CC
Combined Anterior and Posterior Spinal Fusion with CC
Major Hip and Knee Joint Replacement or Reattachment of Lower Extremity with MCC
or Total Ankle Replacement
Major Hip and Knee Joint Replacement or Reattachment of Lower Extremity without
MCC
Hip Femur Procedures except Major Joint with CC
Major Joint or Limb Reattachment Procedures of Upper Extremities
Hip Replacement with Principal Diagnosis of Hip Fracture with MCC
Fractures of Hip and Pelvis with MCC
Fractures of Hip and Pelvis without MCC
Cellulitis with MCC
Cellulitis without MCC
Kidney Transplant
Prostatectomy with CC
Uterine and Adnexa Procedures for Non-Malignancy with CC/MCC
Coagulation Disorders
Lymphoma and Leukemia with Major O.R. Procedures with MCC
Lymphoma and Non-Acute Leukemia with Other Procedures with MCC
Lymphoma and Non-Acute Leukemia with Other Procedures with CC
Acute Leukemia without Major O.R. Procedures with MCC
Acute Leukemia without Mai or O.R. Procedures with CC
Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose
Chemotherapy Agent with MCC
Lymphoma and Non-Acute Leukemia with MCC
Lymphoma and Non-Acute Leukemia with CC
Infectious and Parasitic Diseases with O.R. Procedures with MCC
Infectious and Parasitic Diseases with O.R. Procedures with CC
Postoperative or Post-Traumatic Infections with O.R. Procedures with MCC
Fever and Inflammatory Conditions
Other Infectious and Parasitic Diseases Diagnoses with MCC
Other Infectious and Parasitic Diseases Diagnoses with CC
Septicemia or Severe Sepsis with MV >96 HOURS
Septicemia or Severe Sepsis without MV >96 Hours with MCC
Septicemia or Severe Sepsis without MV >96 Hours without MCC
Poisoning and Toxic Effects of Drugs without MCC
Complications of Treatment with MCC
Complications of Treatment with CC
Extensive O.R. Procedures Unrelated to Principal Diagnosis with MCC
Extensive O.R. Procedures Unrelated to Principal Diagnosis with CC
After applying the case selection and
exclusion criteria, the applicant’s search
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
resulted in the identification of 114 MS–
DRGs using the FY 2019 MedPAR file
PO 00000
Frm 00152
Fmt 4701
Sfmt 4700
dataset. The applicant imputed a case
count of 11 for 104 MS–DRGs with
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.083
371
372
377
378
386
388
389
417
418
436
454
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
291
545
683
546
292
312
286
640
682
308
391
314
674
641
190
313
392
393
699
309
689
698
811
274
304
660
673
808
khammond on DSKJM1Z7X2PROD with RULES2
847
948
187
242
264
287
522
690
812
988
071
186
226
227
243
246
VerDate Sep<11>2014
of 1,494 cases mapping to the 114 MS–
DRGs.
Heart Failure and Shock with MCC
Connective Tissue Disorders with MCC
Renal Failure with CC
Connective Tissue Disorders with CC
Heart Failure and Shock with CC
Syncope and Collapse
Circulatory Disorders except AMI, with Cardiac Catheterization with MCC
Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes with MCC
Renal Failure with MCC
Cardiac Arrhvthmia and Conduction Disorders with MCC
Esophagitis, Gastroenteritis and Miscellaneous Digestive Disorders with MCC
Other Circulatory System Diagnoses with MCC
Other Kidney and Urinary Tract Procedures with CC
Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes without MCC
Chronic Obstructive Puhnonary Disease with MCC
Chest Pain
Esophagitis, Gastroenteritis and Miscellaneous Digestive Disorders without MCC
Other Digestive System Diagnoses with MCC
Other Kidney and Urinary Tract Diaimoses with CC
Cardiac Arrhythmia and Conduction Disorders with CC
Kidney and Urinarv Tract Infections with MCC
Other Kidney and Urinary Tract Diagnoses with MCC
Red Blood Cell Disorders with MCC
Percutaneous and Other lntracardiac Procedures without MCC
Hypertension with MCC
Kidney and Ureter Procedures for Non-Neoplasm with CC
Other Kidney and Urinary Tract Procedures with MCC
Major Hematological and Immunological Diagnoses except Sickle Cell Crisis and
Coagulation Disorders with MCC
Chemotherapy without Acute Leukemia as Secondary Diagnosis with CC
Signs and Symptoms without MCC
Pleural Effusion with CC
Permanent Cardiac Pacemaker Implant with MCC
Other Circulatory System O.R. Procedures
Circulatory Disorders except AMI, with Cardiac Catheterization without MCC
Hip Replacement with Principal Diagnosis of Hip Fracture without MCC
Kidney and Urinary Tract Infections without MCC
Red Blood Cell Disorders without MCC
Non-Extensive O.R. Procedures Unrelated to Principal Diagnosis with CC
Nonspecific Cerebrovascular Disorders with CC
Pleural Effusion with MCC
Cardiac Defibrillator Implant without Cardiac Catheterization with MCC
Cardiac Defibrillator Implant without Cardiac Catheterization without MCC
Permanent Cardiac Pacemaker Implant with CC
Percutaneous Cardiovascular Procedures with Drug-Eluting Stent with MCC or 4+ Arteries
or Stents
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00153
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
7.23%
4.22%
2.14%
2.01%
1.81%
1.47%
1.27%
1.20%
1.14%
0.94%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
ER10AU22.084
fewer than 11 cases, resulting in a total
48931
300
394
432
441
477
542
552
596
809
947
052
057
074
091
124
149
155
157
166
191
196
205
206
225
247
250
252
253
260
299
303
305
311
315
326
350
368
433
445
464
khammond on DSKJM1Z7X2PROD with RULES2
478
480
500
513
515
516
518
537
543
547
551
553
554
555
VerDate Sep<11>2014
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Peripheral Vascular Disorders with CC
Other Digestive System Diagnoses with CC
Cirrhosis and Alcoholic Hepatitis with MCC
Disorders of the Liver except Malignancy Cirrhosis or Alcoholic Hepatitis with MCC
Biopsies ofMusculoskeletal System and Connective Tissue with MCC
Pathological Fractures and Musculoskeletal and Connective Tissue Maliimancy with MCC
Medical Back Problems without MCC
Major Skin Disorders without MCC
Major Hematological and Immunological Diagnoses except Sickle Cell Crisis and
Coagulation Disorders with CC
Sie:ns and Symptoms with MCC
Spinal Disorders and Injuries with CC/MCC
Degenerative Nervous System Disorders without MCC
Cranial and Peripheral Nerve Disorders without MCC
Other Disorders ofNervous System with MCC
Other Disorders of the Eye with MCC
Dysequilibrium
Other Ear, Nose, Mouth and Throat Diagnoses with CC
Dental and Oral Diseases with MCC
Other Respiratory System O.R. Procedures with MCC
Chronic Obstructive Puhnonarv Disease with CC
Interstitial Lung Disease with MCC
Other Respiratorv Svstem Diae:noses with MCC
Other Respiratory System Dim.moses without MCC
Cardiac Defibrillator Implant with Cardiac Catheterization without AMI, HF or Shock
withoutMCC
Percutaneous Cardiovascular Procedures with Drug-Eluting Stent without MCC
Percutaneous Cardiovascular Procedures without Coronarv Arterv Stent with MCC
Other Vascular Procedures with MCC
Other Vascular Procedures with CC
Cardiac Pacemaker Revision except Device Replacement with MCC
Peripheral Vascular Disorders with MCC
Atherosclerosis without MCC
Hypertension without MCC
Angina Pectoris
Other Circulatory System Diagnoses with CC
Stomach, Esophageal and Duodenal Procedures with MCC
Inguinal and Femoral Hernia Procedures with MCC
Major Esophageal Disorders with MCC
Cirrhosis and Alcoholic Hepatitis with CC
Disorders of the Biliarv Tract with CC
Wound Debridement and Skin Graft except Hand or Musculoskeletal and Connective Tissue
Disorders with CC
Biopsies ofMusculoskeletal System and Connective Tissue with CC
Hip and Femur Procedures except Major Joint with MCC
Soft Tissue Procedures with MCC
Hand or Wrist Procedures, except Major Thumb or Joint Procedures with CC/MCC
Other Musculoskeletal System and Connective Tissue O.R. Procedures with MCC
Other Musculoskeletal System and Connective Tissue O.R. Procedures with CC
Back and Next Procedures except Spinal Fusion with MCC or Disc Device Or
N eurostimulator
Sprains, Strains, and Dislocations of Hip, Pelvis and Thie:h with CC/MCC
Pathological Fractures and Musculoskeletal and Connective Tissue Maliimancy with CC
Connective Tissue Disorders without CC/MCC
Medical Back Problems with MCC
Bone Diseases and Arthropathies with MCC
Bone Diseases and Arthropathies without MCC
Sie:ns and Symptoms ofMusculoskeletal System and Connective Tissue with MCC
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00154
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
ER10AU22.085
48932
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Aftercare, Musculoskeletal System and Connective Tissue with MCC
Trauma to the Skin, Subcutaneous Tissue and Breast with MCC
Diabetes with CC
Endocrine Disorders with MCC
Endocrine Disorders with CC
Urinary Stones without MCC
Kidney and Urinary Tract Signs and Symptoms without MCC
Chemotherapy without Acute Leukemia as Secondary Diagnosis with MCC
Viral Illness without MCC
0 .R. Procedures with Principal Diagnosis of Mental Illness
Acute Adjustment Reaction and Psychosocial Dysfunction
Organic Disturbances and Intellectual Disability
Other O.R. Procedures for Injuries with MCC
Other O.R. Procedures for Injuries with CC
Aftercare with CC/MCC
Non-Extensive O.R. Procedures Unrelated to Principal Dimmosis with MCC
khammond on DSKJM1Z7X2PROD with RULES2
BILLING CODE 4120–01–C
The applicant determined an average
unstandardized case weighted charge
per case of $47,599.
The applicant did not remove charges
for related or prior technologies
because, per the applicant, DARZALEX
FASPRO® would not replace other
therapies a patient may receive during
an inpatient stay. Next, the applicant
standardized the charges using the FY
2022 IPPS/LTCH PPS final rule impact
file and applied a 4-year inflation factor
of 1.281834 or 28.1834% based on the
inflation factor used in the FY 2022
IPPS/LTCH PPS final rule to update the
outlier threshold (86 FR 45542). The
applicant then added charges for the
new technology by multiplying the per
treatment cost of DARZALEX FASPRO®
by the inverse of the national average
drug CCR of 0.187 from the FY 2022
IPPS/LTCH PPS final rule (86 FR
44966).
The applicant calculated a final
inflated average case-weighted
standardized charge per case of $92,916,
which exceeded the average caseweighted threshold amount of $61,426.
Because the final inflated average caseweighted standardized charge per case
exceeded the average case-weighted
threshold amount, the applicant
maintained that DARZALEX FASPRO®
meets the cost criterion.
We invited public comment on
whether DARZALEX FASPRO® meets
the cost criterion.
Comment: The applicant submitted a
comment reiterating its belief that
because the final inflated average caseweighted standardized charge per case
exceeded the average case-weighted
threshold amount, DARZALEX
FASPRO® meets the cost criterion.
Response: We thank the commenter
for its comment. We agree the final
inflated average case-weighted
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
standardized charge per case exceeded
the average case-weighted threshold
amount. Therefore, DARZALEX
FASPRO® meets the cost criterion.
With regard to the substantial clinical
improvement criterion, the applicant
asserted that DARZALEX FASPRO®
represents a substantial clinical
improvement over existing technologies
because it offers a treatment option for
a patient population unresponsive to, or
ineligible for, currently available
treatments. The applicant also asserted
that DARZALEX FASPRO®
demonstrates significant improvement
in a number of clinical outcomes
including hematologic complete
response (hemCR), prolonged survival
free from major organ deterioration,
increased cardiac and renal response
rates, with a demonstrated safety and
tolerability profile and no negative
impact to health-related quality of life
based on patient-reported outcomes.
With regard to the claim that
DARZALEX FASPRO® offers a
treatment option for a patient
population unresponsive to, or
ineligible for, currently available
treatments, the applicant stated that the
initial standard of therapy (CyBorD) is
considered inadequate, as most patients
do not respond adequately to the
CyBorD regimen alone. Furthermore,
according to the applicant, the
ANDROMEDA data shows that >80% of
patients do not achieve a hemCR, >75%
of patients with cardiac disease do not
have an organ response, and >75% of
patients with renal disease do not have
an organ response when treated with the
initial standard of therapy CyBorD. Per
the applicant, there is a high unmet
need to improve treatment for AL
amyloidosis patients. The applicant
stated that rapid and deep response like
hemCR are critical and are strongly
PO 00000
Frm 00155
Fmt 4701
Sfmt 4700
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
0.74%
associated with organ response and
improved survival in AL amyloidosis.79
Per the applicant, adding DARZALEX
FASPRO® to CyBorD increases the
hemCR rate by three-fold and doubles
the cardiac and renal response rates,
thereby addressing this high unmet
medical need.
With regard to the claim that the use
of DARZALEX FASPRO® significantly
improves clinical outcomes for a patient
population as compared to currently
available treatments, as stated
previously, the applicant asserted that
DARZALEX FASPRO® represents a
substantial clinical improvement over
existing technologies because it: (1)
demonstrates a consistent safety profile;
(2) significantly improves hematologic
complete response (hemCR rates); (3)
maintains the increased hemCR rates for
pre-specified subgroups; (4) shortens the
time to hemCR; (5) improves very good
partial response (VGPR) or better rates;
(6) substantially improves cardiac
response at 6 and at 12 months; (7)
improves renal response at 6 and at 12
months; (8) improves major-organ
deterioration or progression-free
survival (MOD–PFS); (9) improves
Global Health status and fatigue as of
cycle 6 of treatment, and maintains
health-related quality of life (HRQoL);
and (10) provides important advantages
for the population with AL.
In support of these claims, the
applicant submitted the ANDROMEDA
phase 3 trial as well as presentations
related to these trials. The applicant
stated that data in the ANDROMEDA
study demonstrated that DARZALEX
FASPRO® led to significantly better
outcomes both at the time of the
79 Comenzo RL, Reece D, Palladini G, et al.
Consensus guidelines for the conduct and reporting
of clinical trials in systemic light chain
amyloidosis. Leukemia. 2012;26: 2317–2325.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.086
559
604
638
643
644
694
696
846
866
876
880
884
907
908
949
987
48933
48934
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
primary analysis 80 as well as at the time
of updated analyses which were
presented at the 2021 ASCO annual
meeting and 2021 EHA annual
meeting.81
ANDROMEDA was a randomized,
open-label, phase 3 study of 388
patients with newly diagnosed AL
amyloidosis randomized 1:1 to receive 6
cycles of CyBorD, either alone (control
group, n=193) or in combination with
daratumumab SC (that is, DARZALEX
FASPRO®), followed by DARZALEX
FASPRO® monotherapy every 4 weeks
for up to 24 additional cycles
(daratumumab group, n=195). The study
enrolled patients between May 3, 2018
and August 15, 2019. Median age was
64 (range 34–87). The study reported a
median 11.4 month follow-up for the
published trial, and 20.3 months for the
follow-up data. The primary endpoint
was hemCR, defined as having negative
serum and urine immunofixation and a
free light chain ratio (FLCr) within the
reference range or abnormal free lightchain ratio if the uninvolved free light
chain (uFLC) is higher than the involved
free light chain (iFLC). According to the
applicant, this definition of hemCR is in
line with a recent clarification of the
Internal Society of Amyloidosis
guidelines.82 Secondary endpoints were
survival free from major organ
deterioration or hematologic progression
(composite end point that included endstage cardiac or renal failure,
hematologic progression), or death,
organ response, overall survival,
hematologic complete response at 6
months, VGPR or better, time to and
duration of hematologic complete
response, time to next treatment, and
reduction in fatigue. The applicant
noted that the safety population in the
ANDROMEDA study consisted of 193
patients in the daratumumab arm and
188 patients in the control arm.
The applicant also cited an oral
presentation, presented at the American
Society of Clinical Oncology (ASCO)
2021 and European Hematology
Association (EHA) 2021 annual
80 Kastritis et al. Daratumumab-Based Treatment
for Immunoglobulin Light-Chain Amyloidosis. New
England Journal of Medicine (NEJM). 2021; 385:46–
58.
81 Kastritis E, et al., Subcutaneous Daratumumab
+ Cyclophosphamide, Bortezomib, and
Dexamethasone (CyBorD) in Patients with Newly
Diagnosed Light Chain (AL) Amyloidosis: Updated
Results from the Phase 3 ANDROMEDA Study, Oral
presentation at: American Society for Oncology
(ASCO) Annual Virtual Meeting; June 4–8, 2021 &
Oral presentation at: European Hematology
Association (EHA) Annual Virtual Meeting; June 9–
17, 2021.
82 Palladini et al. Daratumumab plus CyBord for
patients with newly diagnosed AL amyloidosis:
safety run-in results of ANDROMEDA.
Blood.2020;136:71–80.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
meetings, with updated data from the
ANDROMEDA study after 20.3 months
of follow-up, which described sustained
primary outcome of higher rates of
hemCR across subgroups as well as
improved secondary endpoints of
cardiac and renal response rate at 12
months. In the intent to treat
population, there were 11 deaths in the
CyBorD group compared to 7 deaths in
the control group.83
In support of its assertion that
DARZALEX FASPRO® demonstrates a
consistent safety profile, the applicant
cited Kastritis et al., discussed
previously, stating that the safety
profiles of daratumumab and
bortezomib, cyclophosphamide, and
dexamethasone in the ANDROMEDA
trial were consistent with their known
profiles and the underlying disease from
previous trials.84 To support its
assertion that DARZALEX FASPRO®
significantly improves hemCR rate, the
applicant stated that the trial results
showed that patients treated with
DARZALEX FASPRO® demonstrated a
statistically significant increase in
hemCR compared to control (53.3%
versus 18.1%; relative risk ratio, 2.9;
95% CI, 2.1 to 4.1; odds ratio, 5.1; 95%
CI, 3.2 to 8.2; p <0.001 for both
comparisons) at the 11.4 month median
follow-up. To support its assertion that
DARZALEX FASPRO® results in a
shorter time to hemCR, the applicant
noted that in the trial, median time to
hemCR was 60 days in the
daratumumab group and 85 days in the
control group. In support of its assertion
that the increased hemCR rate was
maintained for pre-specified subgroups,
the applicant also stated that hemCR
remained consistent in most
prespecified subgroups (for example,
sex, age, weight, race, cardiac stage, etc.)
receiving daratumumab.85 The
applicant also cited results from the oral
presentation, discussed previously,
stating that after a median follow up of
20.3 months, the percentage of patients
who achieved hemCR increased to 59%
in the daratumumab group vs 19% in
the control group (odds ratio: 5.9; 95%
CI, 3.7 to 9.4; P <0.001), and that this
83 Kastritis E, et al., Subcutaneous Daratumumab
+ Cyclophosphamide, Bortezomib, and
Dexamethasone (CyBorD) in Patients with Newly
Diagnosed Light Chain (AL) Amyloidosis: Updated
Results from the Phase 3 ANDROMEDA Study, Oral
presentation at: American Society for Oncology
(ASCO) Annual Virtual Meeting; June 4–8, 2021 &
Oral presentation at: European Hematology
Association (EHA) Annual Virtual Meeting; June 9–
17, 2021.
84 Kastritis E, et al., Daratumumab-Based
Treatment for Immunoglobulin Light-Chain
Amyloidosis, N Eng J Med. 2021; 385:46–58.
85 Kastritis E, et al., Daratumumab-Based
Treatment for Immunoglobulin Light-Chain
Amyloidosis, N Eng J Med. 2021; 385:46–58.
PO 00000
Frm 00156
Fmt 4701
Sfmt 4700
advantage was seen consistently across
all prespecified subgroups.86 The
applicant stated that rapid and deep
hematologic responses are critical and
are strongly associated with organ
response and improved survival in AL
amyloidosis.87
In support of its assertion that
DARZALEX FASPRO® improved VGPR
or better rates, the applicant also stated
that the trial demonstrated that the
secondary endpoint of VGPR or better
was 78.5% in the daratumumab group
and 49.2% in the control group (relative
risk ratio, 1.6; 95% CI, 1.4 to 1.9; odds
ratio, 3.8; 95% CI, 2.4 to 5.9).88 Per the
applicant, the substantial improvements
in hematologic response rates and other
endpoints like cardiac and renal
response and MOD–PFS indicate the
clinical meaningfulness of these efficacy
results.
In support of its assertion that
DARZALEX FASPRO® substantially
improves cardiac response at 6 and at 12
months, according to the applicant, of
the subgroup that was evaluated for
cardiac response (118 in the
daratumumab group and 117 in the
control group), 41.5% in the
daratumumab group and 22.2% in the
control group (odds ratio, 2.44; 95% CI:
1.35 to 4.42) demonstrated a cardiac
response at 6 months.89 The applicant
noted that at a median follow up of 20.3
months, cardiac response rates were
higher with in the daratumumab group
compared to CyBorD alone at 6 months
(42% versus 22%, odds ratio 2.4, 95%
CI 1.4 to 4.4; P = .0029) and at 12
months (57% versus 28%, odds ratio 3.5
95% CI 2.0 to 6.2; P <0.0001).90 In
addition, in support of its assertion that
86 Kastritis E, et al., Subcutaneous Daratumumab
+ Cyclophosphamide, Bortezomib, and
Dexamethasone (CyBorD) in Patients with Newly
Diagnosed Light Chain (AL) Amyloidosis: Updated
Results from the Phase 3 ANDROMEDA Study, Oral
presentation at: American Society for Oncology
(ASCO) Annual Virtual Meeting; June 4–8, 2021 &
Oral presentation at: European Hematology
Association (EHA) Annual Virtual Meeting; June 9–
17, 2021.
87 Comenzo RL, Reece D, Palladini G, et al.
Consensus guidelines for the conduct and reporting
of clinical trials in systemic light chain
amyloidosis. Leukemia. 2012;26: 2317–2325.
88 Kastritis et al., Daratumumab for
immunoglobulin light-chain amyloidosis. N Eng J
Med 2021; 385:48–58.
89 Kastritis E, et al., Daratumumab-Based
Treatment for Immunoglobulin Light-Chain
Amyloidosis, N Eng J Med. 2021; 385:46–58.
90 Kastritis E, et al., Subcutaneous Daratumumab
+ Cyclophosphamide, Bortezomib, and
Dexamethasone (CyBorD) in Patients with Newly
Diagnosed Light Chain (AL) Amyloidosis: Updated
Results from the Phase 3 ANDROMEDA Study, Oral
presentation at: American Society for Oncology
(ASCO) Annual Virtual Meeting; June 4–8, 2021 &
Oral presentation at: European Hematology
Association (EHA) Annual Virtual Meeting; June 9–
17, 2021.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
DARZALEX FASPRO® improves renal
response at 6 and at 12 months, the
applicant noted that in the subgroup
evaluated for renal response (117 in the
daratumumab group and 113 in the
control group), 53.0% of patients in the
daratumumab group and 23.9% in the
control group (odds ratio, 3.34; 95% CI:
1.88 to 5.94) demonstrated a renal
response at 6 months.91 The applicant
noted that at a median follow up of 20.3
months, renal response rates were
higher with in the daratumumab group
compared to CyBorD alone at 6 months
(54% vs 27%; odds ratio 3.3 95% CI 1.9
to 5.9; P <0.0001) and at 12 months
(57% vs 27%; odds ratio 4.1 95% CI 2.3
to 7.3; P <0.0001).92 The applicant noted
that the percentages of patients who had
a cardiac or renal response were
substantially higher in the
daratumumab group than in the control
group, which it stated was an important
finding given that organ responses are
also a predictor of improved survival.
In support of its assertion that
DARZALEX FASPRO® improves MOD–
PFS, the applicant noted significant
findings of secondary endpoint survival
free from major organ deterioration or
hematologic progression in the
daratumumab group compared to
control (hazard ratio for major organ
deterioration, hematologic progression,
or death, 0.58; 95% CI, 0.36 to 0.93; P
= 0.02).93
With regard to the claim that
DARZALEX FASPRO® improves Global
Health status (GHS) and fatigue as of
cycle 6 of treatment, as well as
maintains HRQoL, the applicant cited a
poster presentation of a subgroup
analysis on patient reported outcomes
(PRO) for patients participating in the
ANDROMEDA study.94 The applicant
noted that the patients were provided
with PRO questionnaires and assessed
on day 1 of cycles ¥1–6 as well as every
8 weeks thereafter in the daratumumab
91 Kastritis E, et al., Daratumumab-Based
Treatment for Immunoglobulin Light-Chain
Amyloidosis, N Eng J Med. 2021; 385:46–58.
92 Kastritis E, et al., Subcutaneous Daratumumab
+ Cyclophosphamide, Bortezomib, and
Dexamethasone (CyBorD) in Patients with Newly
Diagnosed Light Chain (AL) Amyloidosis: Updated
Results from the Phase 3 ANDROMEDA Study, Oral
presentation at: American Society for Oncology
(ASCO) Annual Virtual Meeting; June 4–8, 2021 &
Oral presentation at: European Hematology
Association (EHA) Annual Virtual Meeting; June 9–
17, 2021.
93 Kastritis et al. Daratumumab-Based Treatment
for Immunoglobulin Light-Chain Amyloidosis.
NEJM. 2021;385:46–58.
94 Sanchorawala et al., Health-Related Quality of
Life in Patients with AL Amyloidosis Treated with
Daratumumab, Bortezomib, Cyclophosphamide,
and Dexamethasone: Results from the Phase 3
ANDROMEDA Study, Poster presentation at:
American Society of Hematology (ASH) Annual
Virtual Meeting; December 5–8, 2020.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
group. The applicant stated that of the
388 patients randomized in the study,
compliance rates for all PRO
questionnaires were >90% at baseline
and >83% through Cycle 6. The
questionnaires included the European
Organization for Research and
Treatment of Cancer Quality of Life
Questionnaire Core 30-item (EORTC
QLQ–C30), the EuroQol 5-dimensional
descriptive system (EQ–5D–5L), and
Short Form-36 (SF–36). Secondary
endpoints centered around
improvements in EORTC QLQ–C30
global health status (GHS), fatigue scale
scores, and SF–36 mental component
summary (MCS) score. Exploratory
outcomes included physical function
assessment, symptom improvement,
functional improvement, and health
utility as measured by the SF–36,
EORTC QLQC30 with supplemental
symptom items, and the EQ–5D–5L.
The applicant stated that the results
from this presentation show that
following Cycle 6, improvements in
GHS and fatigue were reported in
patients in the treatment group, and that
these findings further support the value
of daratumumab SQ plus CyBorD (DaraCyBorD) in patients with AL
amyloidosis. The applicant also stated
that patients with AL amyloidosis
treated with Dara-CyBorD experienced
clinical improvements without any
decrement in HRQoL over 6 cycles. The
applicant noted that the findings
demonstrated that the median time to
improvement was shorter in the
treatment group than in the control
group for EORTC QLQ–C30 GHS
(CyBorD: 16.79 months, 95% CI:11.79 to
NE, Dara-CyBorD: 7.82 months, 95% CI:
3.94 to 17.58, HR 1.53; 95% CI: 1.10 to
2.13), fatigue scales (CyBorD: NE, 95%
CI:8.44 to NE, Dara-CyBorD: 9.30
months, 95% CI: 5.55 to 13.01, HR 1.39;
95% CI: 1.00 to 1.93) and EQ–5D–5L
visual analog scale (CyBorD: NE, 95%
CI:16.79 to NE, Dara-CyBorD: 10.05
months, 95% CI: 8.41 to NE, HR 1.21;
95% CI: 0.86 to 1.71). The applicant also
noted that the findings demonstrated
that median time to worsening was
longer in the treatment group than in
the control group for EORTC QLQ–C30
GHS (CyBorD: 2.89 months, 95% CI:2.23
to 3.78, Dara-CyBorD: 4.70 months, 95%
CI: 2.83 to 7.36, HR 0.87; 95% CI: 0.66
to 1.13) and fatigue scales (CyBorD: 3.75
months, 95% CI: 2.86 to 4.76 DaraCyBorD: 8.84 months, 95% CI: 3.75 to
NE, HR 0.78; 95% CI: 0.58 to 1.04) and
EQ–5D–5L visual analog scale (CyBorD:
3.38 months, 95% CI:2.79 to 4.67, Dara-
PO 00000
Frm 00157
Fmt 4701
Sfmt 4700
48935
CyBorD: 4.14 months, 95% CI: 2.86 to
7.66, HR 0.89; 95% CI: 0.67 to 1.19).95
Finally, the applicant stated that
DARZALEX FASPRO® provides
important advantages to the population
with AL amyloidosis because the
subcutaneous administration allows for
a negligible volume of administration
and a reduced rate of systemic
administration-related reactions.96
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28234 through
28235), after review of the information
provided by the applicant, we stated we
had the following concerns regarding
whether DARZALEX FASPRO® meets
the substantial clinical improvement
criterion. First, with respect to the
ANDROMEDA trial, we noted that the
study’s open label and unblinded design
adds a potential risk of bias which may
affect the treatment effect reported by
the applicant. Additionally, we noted
that the ANDROMEDA trial used
stratified randomization which resulted
in potentially substantive differences
between the treatment and control
group at baseline; for example, the
control group was slightly older, with
more males, and more people at higher
cardiac stage (based on N-terminal proB-type natriuretic peptide and highsensitivity cardiac troponin T). The
groups also differed by Eastern
Cooperative Oncology Group (ECOG)
performance-status scores and
uninvolved free light chain (dFLC)
levels, and renal function. Additionally,
compared to control, the daratumumab
group appeared to have higher rates of
peripheral sensory neuropathy, upper
respiratory infection, and neutropenia
in the longer term data.97 We questioned
whether these differences noted at
baseline are in fact significant and
would have the potential to impact the
treatment effect seen in this study. In
terms of study outcomes, the
ANDROMEDA study relied on
hematologic and organ-based laboratorybased outcomes, but we questioned
95 Sanchorawala et al., Health-Related Quality of
Life in Patients with AL Amyloidosis Treated with
Daratumumab, Bortezomib, Cyclophosphamide,
and Dexamethasone: Results from the Phase 3
ANDROMEDA Study, Poster presentation at:
American Society of Hematology (ASH) Annual
Virtual Meeting; December 5–8, 2020.
96 Kastritis et al. Daratumumab-Based Treatment
for Immunoglobulin Light-Chain Amyloidosis.
NEJM. 2021;385:46–58.
97 Kastritis E, et al., Subcutaneous Daratumumab
+ Cyclophosphamide, Bortezomib, and
Dexamethasone (CyBorD) in Patients with Newly
Diagnosed Light Chain (AL) Amyloidosis: Updated
Results from the Phase 3 ANDROMEDA Study, Oral
presentation at: American Society for Oncology
(ASCO) Annual Virtual Meeting; June 4–8, 2021 &
Oral presentation at: European Hematology
Association (EHA) Annual Virtual Meeting; June 9–
17, 2021.
E:\FR\FM\10AUR2.SGM
10AUR2
48936
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
whether a primary endpoint of overall
survival would have provided stronger
evidence.
Second, we had concerns about the
generalizability of the ANDROMEDA
population and subgroups. As clarified
by the applicant during the New
Technology Town Hall meeting, all
subjects in the ANDROMEDA trial
received DARZALEX FASPRO® in the
outpatient setting. As such, we
questioned whether the outcomes for
this outpatient population are
generalizable to patients who are
sufficiently ill to require hospitalization.
In regard to subpopulations, we noted
that the prespecified groups and the
studies of cardiac stage and Asian
cohorts exhibit the same potential
limitations of the main trial with small
sample size, open-label, and limited
follow-up. We noted that small sample
size resulted in wider confidence
intervals in some subgroups, which may
limit the generalizability of the
treatment results. For example, in the
ANDROMEDA prespecified groups, the
subgroups ‘other’ race, cardiac stage I at
baseline, and renal stage III had wider
confidence intervals than other
subgroups. Finally, while the applicant
provided a phase 2 poster presentation
in support of DARZALEX FASPRO® we
questioned the extent to which these
results are generalizable to the
indication for which the applicant has
applied for the new technology add-on
payment (that is, the treatment of adult
patients with light chain (AL)
amyloidosis in combination with
bortezomib, cyclophosphamide and
dexamethasone in newly diagnosed
patients) given that the indication
within this source (that is monotherapy
in patients with Stage 3B AL
amyloidosis), does not match.98
We noted that the applicant provided
the outcomes of secondary endpoints
which appear to be exploratory or novel
for some of the data presented in posters
in support of its claims, such as the
quality of life assessments 99 and
hematologic response as measured by
involved and uninvolved free light
98 Kastritis E, et al., Subcutaneous Daratumumab
+ Cyclophosphamide, Bortezomib, and
Dexamethasone (CyBorD) in Patients with Newly
Diagnosed Light Chain (AL) Amyloidosis: Updated
Results from the Phase 3 ANDROMEDA Study, Oral
presentation at: American Society for Oncology
(ASCO) Annual Virtual Meeting; June 4–8, 2021 &
Oral presentation at: European Hematology
Association (EHA) Annual Virtual Meeting; June 9–
17, 2021.
99 Sanchorawala et al., Health-Related Quality of
Life in Patients with AL Amyloidosis Treated with
Daratumumab, Bortezomib, Cyclophosphamide,
and Dexamethasone: Results from the Phase 3
ANDROMEDA Study, Poster presentation at:
American Society of Hematology (ASH) Annual
Virtual Meeting; December 5–8, 2020.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
chain,100 and we noted that some of the
endpoints are still being studied and
validated. Specifically, we questioned
whether these surrogate endpoints may
be used to appropriately evaluate the
measure for which they are intended to
assess. We requested further
information on whether these secondary
endpoints have been appropriately
validated in relevant clinical settings.
We invited public comments on
whether DARZALEX FASPRO® meets
the substantial clinical improvement
criterion.
Comment: The applicant submitted a
comment in response to CMS’ concerns
pertaining to substantial clinical
improvement. With respect to our
concern that the open label and
unblinded study design of the
ANDROMEDA trial may result in a
biased treatment effect, the applicant
stated that clinical trials designed to
evaluate treatment effects in patients
with AL amyloidosis need to account
for the heterogeneity of the disease, the
number of affected organs, including the
heart, kidney, and liver, and the severity
of organ involvement. Per the applicant,
in addition to randomization by chance
to the experimental Dara-CyBorD arm or
the control CyBorD arm, subjects in the
ANDROMEDA trial were randomized by
cardiac stage, by whether transplant was
typically offered, and by renal function.
The applicant stated that efficacy data
were adjudicated by an independent
review committee whose members were
unaware of the trial-group assignments.
The applicant stated that patients in the
control arm were marginally older and
that there were slightly more males than
females but that these small differences
are not expected to cause a major
difference in outcomes. The applicant
also stated that the slight increase in
males in this study is similar to an
analysis of U.S. commercial and
Medicare Supplemental claims data that
found the prevalence of AL amyloidosis
is higher in males (approximately 55%
male).101
The applicant stated that the
percentage of subjects in cardiac stage
IIIA was similar in the two treatment
100 Comenzo et al., Reduction in Absolute
Involved Free Light Chain and Difference Between
Involved and Uninvolved Free Light Chain is
Associated with Prolonged Major Organ
Deterioration Progression Free survival in Patient
with Newly Diagnosed AL Amyloidosis Receiving
Bortezomib, Cyclophosphamide and
Dexamethasone with or without Daratumumab:
Results from ANDROMEDA, Oral presentation at:
American Society of Hematology (ASH) Annual
Virtual Meeting; December 5–8, 2020.
101 Quock et al. Epidemiology of AL amyloidosis:
a real-world study using US claims data. Blood Adv
2018: 2: 1046–1053.
PO 00000
Frm 00158
Fmt 4701
Sfmt 4700
arms.102 Per the applicant, neither the
slightly higher percentage of subjects
with cardiac stage IIIB (3.1% vs. 1.0%)
in the CyBorD arm nor the observed
small differences in the ECOG status
and renal status between the two arms
are expected to have a major difference
on the final outcomes.
With regard to the concern regarding
higher peripheral sensory neuropathy,
upper respiratory infection, and
neutropenia in longer term data for the
daratumumab group compared to the
control group, the applicant stated that
the relative incidence of infections like
pneumonia as well as peripheral
sensory neuropathy and neutropenia
should be interpreted in the context of
longer treatment exposure for patients
receiving Dara-CyBorD vs. CyBorD. The
applicant stated that when adjusted for
exposure to trial treatment, the
incidence of overall and grade 3 or 4
adverse events was lower in the
daratumumab group than in the control
group.103
With regard to the concern regarding
hematologic and organ-based laboratorybased outcomes instead of overall
survival, the applicant stated that
primary treatment is targeted toward
suppression of amyloid light chain
synthesis in order to improve organ
function. The applicant stated that
treatment efficacy is typically
determined by hematologic response
and that the current staging systems for
AL amyloidosis are based on circulating
markers of cardiac, renal, and B cell
clonal disease and are used for clinical
trial design and to determine patient
management. The applicant stated that
because clinical presentation and longterm outcomes depend on adequate
organ function, complete response (CR)
does not completely describe the
clinical efficacy of treatment in patients
with AL amyloidosis. The applicant
stated that organ response rates can be
used but there are limitations with only
using these biomarkers to monitor organ
response. The applicant stated that, in
consultation with and with the approval
of the FDA, major organ deterioration–
progression free survival (MOD–PFS)
and major organ deterioration–event
free survival (MOD–EFS) were chosen
as secondary endpoints and were
calculated as a composite endpoint of
clinically observable endpoints. The
applicant stated that several clinical
studies have demonstrated that
hematologic and organ responses were
102 Kastritis
103 Kastritis
E:\FR\FM\10AUR2.SGM
et al., NEJM, 2021.
et al., NEJM, 2021.
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
very strong predictors of overall
survival.104 105 106
With regard to the concern for
generalizability of the study population
in an outpatient setting, the applicant
stated that many factors contribute to
whether a patient is treated as an
outpatient or as an inpatient. Per the
applicant, patients with similar clinical
status might be treated in the inpatient
setting because of the availability of
health care personnel, insurance status,
and available outpatient resources for
patient follow-up. The applicant stated
that the ANDROMEDA study was
performed in an outpatient setting but
there were patients with cardiac organ
involvement that might have been
hospitalized for treatment of cardiac
disease and may have also be receiving
treatment for AL amyloidosis, either as
initiation of treatment or a part of a
subsequent treatment cycle. The
applicant stated that although the
number of inpatient hospitalized
individuals receiving a treatment cycle
with Dara-CyBorD is expected to be low,
it is important to ensure health care
equity and access to the only FDA
approved drug for treatment of newly
diagnosed AL amyloidosis, regardless of
treatment setting.
With regard to the small sample size
and large confidence intervals in
subgroup studies, the applicant stated
that the variability in subgroup sizes
could lead to wide confidence intervals,
especially in the smaller subgroup sizes.
The applicant also stated that there is
strong numerical trend for improved
outcomes with similar odds ratios in the
Dara-CyborD arm across all subgroups.
With regard to the concern that the
poster presentation did not match the
indication for which the applicant has
applied for the new technology add-on
payment, the applicant stated that the
use of daratumumab monotherapy in
cardiac stage IIIB is still under
investigation and although related data
might be included in supporting
documents, this information should be
considered investigational. The
applicant stated that its request for the
new technology add-on payment is
limited to the FDA approved indication:
treatment of adult patients with newly
diagnosed AL amyloidosis with NYHA
or Mayo cardiac stage IIIA or less in
combination with CyBorD.
With regard to our inquiry about the
use of exploratory secondary endpoints
in relevant clinical settings, the
applicant stated that information about
104 Palladini G et al. Management of AL
amyloidosis in 2020. Blood 2020; 136:2620–2627.
105 Palladini et al., J Clin Oncology 2012.
106 Comenzo et al. Leukemia 2012.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
patient reported outcomes assessing the
impact of treatment on quality of life
provides early positive findings
associated with the addition of
DARZALEX FASPRO® to the CyBorD
treatment combination but agreed that
the information is preliminary and
additional patient reported outcomes
need to be obtained for AL amyloidosis
patients at the time of diagnosis, during
follow-up, and as the disease progresses.
The applicant stated that the
exploratory endpoints of iFLC ≤20mg/L
and dFLC ≤10 mg/L also confirm the
consistency of improved results of
adding daratumumab to CyBorD.
Finally, the applicant stated that besides
the exploratory endpoints, the
ANDROMEDA trial used the established
primary endpoint of hematologic CR
and the secondary endpoint of organ
response which are defined in the
International Society of Amyloidosis
(ISA) guidelines and have been shown
to be very good predictors for overall
survival.
We also received an additional
comment stating that DARZALEX
FASPRO® improves progression free
survival and organ survival across
staging and that its combination with
CyBorD has become standard of care
and frontline treatment for patients with
AL amyloidosis. The commenter further
stated that rapidly achieving
normalization of circulating
immunogloblin free light chain is
critical to offer the best chances of organ
response and survival as time is of the
essence in this disease, and organ
response cannot occur in the absence of
a hematologic remission. The
commenter stated that adequate
reimbursement will allow healthcare
providers to adequately serve this
critically ill patient population in both
inpatient and outpatient settings, and
will prevent having to withhold or delay
the best possible regimen in the face of
a requirement for an inpatient stay.
Response: We thank the commenters
for their comments regarding the
substantial clinical improvement
criterion. Based on the additional
information received, we agree that
DARZALEX FASPRO® represents a
substantial clinical improvement over
existing technologies for the treatment
of AL amyloidosis patients because it
demonstrates improved clinical
outcomes as compared to the standard
of care CyBorD, including a higher rate
of hemCR and longer major MOD–PFS.
After consideration of the public
comments we received and the
information included in the applicant’s
new technology add-on payment
application, we have determined that
DARZALEX FASPRO® meets the
PO 00000
Frm 00159
Fmt 4701
Sfmt 4700
48937
criteria for approval for new technology
add-on payment. Therefore, we are
approving new technology add-on
payments for this technology for FY
2023. Cases involving the use of
DARZALEX FASPRO® that are eligible
for new technology add-on payments
will be identified by ICD–10–PCS code
XW01318 (Introduction of
daratumumab and hyaluronidase-fihj
into subcutaneous tissue, percutaneous
approach, new technology group 8) in
combination with ICD–10–CM code
E85.81 (Light chain (AL) amyloidosis).
In its application, the applicant
estimated that the cost of DARZALEX
FASPRO® is $7,937.55 per patient.
Under § 412.88(a)(2), we limit new
technology add-on payments to the
lesser of 65% of the average cost of the
technology, or 65% of the costs in
excess of the MS–DRG payment for the
case. As a result, the maximum new
technology add-on payment for a case
involving the use of DARZALEX
FASPRO® is $5,159.41 for FY 2023.
c. Hemolung Respiratory Assist System
(Hemolung RAS)
ALung Technologies, Inc. submitted
an application for new technology addon payments for the Hemolung
Respiratory Assist System (Hemolung
RAS) for FY 2023. The applicant stated
that the Hemolung RAS is the first and
only FDA authorized technology for the
treatment of acute, hypercapnic
respiratory failure using an
extracorporeal circuit to remove CO2
directly from the blood. Per the
applicant, patients experiencing acute,
hypercapnic respiratory failure are
unable to remove excess CO2 waste
molecules from their blood via their
lungs, resulting in accumulation of CO2
in their blood (hypercapnia), acid/base
derangement (respiratory acidosis), and
life-threatening clinical sequelae.107 The
applicant stated that the Hemolung RAS
does not treat a specific disease but
removes CO2 directly from the blood to
treat a variety of underlying respiratory
disease states, including, but not limited
to, cystic fibrosis (CF), chronic
obstructive pulmonary disease (COPD),
and asthma, where CO2 retention
(hypercapnia) is the primary cause of
continued clinical deterioration.
Per the applicant, the Hemolung RAS
provides low-flow, veno-venous
extracorporeal carbon dioxide removal
(ECCO2R) using a 15.5 French dual
lumen catheter inserted percutaneously
in the femoral or jugular vein, providing
107 Nin, N. et al. Severe hypercapnia and outcome
of mechanically ventilated patients with moderate
or severe acute respiratory distress syndrome.
Intensive Care Med 43, 200–208 (2017).
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48938
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
partial ventilatory lung support
independent of the lungs as an
alternative or supplement to invasive
mechanical ventilation. The applicant
stated that the Hemolung RAS removes
up to 50% of basal metabolic carbon
dioxide (CO2) production at circuit
blood flows of 350–550 mL/min.
According to the applicant, the
Hemolung RAS is not intended to
provide therapeutic levels of
oxygenation. The applicant stated that
during the Hemolung RAS therapy,
blood passing through the circuit is
oxygenated; however, at low
extracorporeal blood flows, the limited
oxygen-carrying capacity of blood
precludes meaningful oxygenation of
mixed venous blood. The applicant
explained that extracorporeal therapy
with the Hemolung RAS requires
continuous systemic anticoagulation
with unfractionated heparin or a
standard of care alternative to prevent
clotting of blood in the circuit.
With respect to the newness criterion,
the applicant stated that the Hemolung
RAS received Breakthrough Device
Designation from FDA in 2015 specific
to COPD patients experiencing acute,
refractory, hypercapnic respiratory
failure. The applicant stated it is not
applying under the Breakthrough Device
Alternative Pathway in the current
application for new technology add-on
payments, as the Breakthrough Device
indication is different from its FDA De
Novo indication. The applicant
explained that the Hemolung RAS was
classified as a Class III device and
received a Breakthrough Device
designation for COPD only. According
to the applicant, on April 22, 2020, the
Hemolung RAS received an Emergency
Use Authorization (EUA) to treat lung
failure due to COVID–19 when used as
an adjunct to noninvasive or invasive
mechanical ventilation in reducing
hypercapnia and hypercapnic acidosis
due to COVID–19 and/or maintaining
normalized levels of partial pressure of
carbon dioxide (PCO2) and pH in
patients suffering from acute, reversible
respiratory failure due to COVID–19 for
whom ventilation of CO2 cannot be
adequately, safely, or tolerably
achieved. The applicant further
explained Hemolung RAS was later
classified as a Class II device under the
De Novo pathway. The applicant
indicated its De Novo classification
request (DEN210006) was granted on
November 13, 2021, for the indication of
respiratory support providing
extracorporeal carbon dioxide (CO2)
removal from the patient’s blood for up
to five days in adults with acute,
reversible respiratory failure for whom
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
ventilation of CO2 cannot be adequately
or safely achieved using other available
treatment options and continued
clinical deterioration is expected.
According to the applicant, the De Novo
classified Hemolung RAS became
available on the market on November
15, 2021, the first business day
following the FDA authorization. The
applicant indicated that it is seeking
new technology add-on payments for FY
2023 for the FDA De Novo indication for
the treatment of hypercapnic respiratory
failure due to all causes in adults, which
would include the EUA indication for
the use of the Hemolung RAS in
patients with respiratory failure caused
by COVID–19. The applicant stated that
the following ICD–10–PCS code may be
used to uniquely describe procedures
involving the use of the Hemolung RAS:
5A0920Z (Assistance with respiratory
filtration, continuous, ECCO2R).
As previously discussed, if a
technology meets all three of the
substantial similarity criteria under the
newness criterion, it would be
considered substantially similar to an
existing technology and would not be
considered ‘‘new’’ for the purposes of
new technology add-on payments.
According to the applicant, patients
experiencing acute, hypercapnic
respiratory failure are treated
pharmacologically and with noninvasive ventilatory support as a first
line treatment. The applicant stated that
if these treatments are insufficient to
support the failing lungs, escalation of
ventilatory support via intubation and
invasive mechanical ventilation (IMV)
are the only available treatment options.
According to the applicant, patients
who are intubated and invasively
mechanically ventilated are at
significant risk for increased morbidity
and mortality. The applicant stated that
no additional treatments are available if
IMV is insufficient to correct refractory
hypercapnia and respiratory acidosis,
which ultimately lead to
cardiopulmonary collapse and death.
Furthermore, the applicant stated that
no treatment options are available for
patients who have a Do Not Intubate
(DNI) order.
With respect to the first criterion,
whether a product uses the same or
similar mechanism of action to achieve
a therapeutic outcome, the applicant
stated that the Hemolung RAS has a
different mechanism of action compared
to existing technologies. According to
the applicant, IMV, the only existing
technology used to treat acute,
refractory, hypercapnic respiratory
failure, utilizes positive airway pressure
to deliver oxygen and remove CO2 from
the lungs, whereas the Hemolung RAS
PO 00000
Frm 00160
Fmt 4701
Sfmt 4700
removes CO2 directly from the blood,
independent of the lungs and allowing
the lungs to rest and recover. Thus, the
applicant asserted that the Hemolung
RAS uses a different mechanism of
action when compared to the existing
therapeutic option (that is, IMV). The
applicant also stated that extracorporeal
membrane oxygenation (ECMO) is a
rescue therapy for patients experiencing
refractory hypoxemic respiratory failure,
where insufficient oxygenation is the
source of the respiratory failure.
However, the applicant stated that
ECMO is not suitable, nor FDAapproved, as a treatment for acute,
hypercapnic respiratory failure.
Therefore, the applicant asserted that
ECMO and the Hemolung RAS are
fundamentally different technologies
used to treat different patient
populations.
With respect to the second criterion,
whether a product is assigned to the
same or a different MS–DRG when
compared to an existing technology, the
applicant stated that the Hemolung RAS
is assigned to the same MS–DRGs when
compared to an existing technology. Per
the applicant, the Hemolung RAS is an
escalation therapy to be used when
current therapies are unable to support
a patient’s failing lungs and continued
clinical deterioration is expected. The
applicant noted that MS–DRGs 207 and
208 (Respiratory System Diagnosis with
Ventilator Support >96 Hours and
Respiratory System Diagnosis with
Ventilator Support ≤96 Hours,
respectively) relate to the treatment of
respiratory failure using mechanical
ventilation, so the Hemolung RAS may
be assigned to the same MS–DRGs if
mechanical ventilation is unable to
safely or adequately remove CO2 from
the blood.
With respect to the third criterion,
whether the new use of technology
involves the treatment of the same or
similar type of disease and the same or
similar patient population when
compared to an existing technology, the
applicant stated that the Hemolung RAS
and IMV are both used to treat patients
experiencing acute, refractory,
hypercapnic respiratory failure due to
numerous disease etiologies and
pathophysiologies. However, the
applicant noted that the Hemolung RAS
is indicated for use as an escalation
therapy when IMV is unable to safely or
adequately remove CO2 from the blood
and continued clinical deterioration is
expected.
In summary, the applicant maintained
that the Hemolung RAS is not
substantially similar to currently
available therapies and/or technologies
because it uses a new mechanism of
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
action and therefore the technology
meets the ‘‘newness’’ criterion.
We stated in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28236
through 28237) that, as noted
previously, the applicant received an
FDA De Novo classification for the
device on November 13, 2021 (with the
product becoming commercially
available on November 15, 2021), for the
FDA De Novo indication that is the
subject of this application, for the
treatment of hypercapnic respiratory
failure due to all causes in adults. This
De Novo indication would include use
of the product for the indication for
which the applicant initially received
an EUA from FDA, for the use of the
Hemolung RAS in patients with
respiratory failure caused by COVID–19.
In the FY 2005 IPPS/LTCH PPS final
rule, we stated that the intent of section
1886(d)(5)(K) of the Act and regulations
under § 412.87(b)(2) is to pay for new
medical services and technologies for
the first 2 to 3 years that a product
comes on the market, during the period
when the costs of the new technology
are not yet fully reflected in the MS–
DRG weights (69 FR 49002). While our
policy is, generally, to begin the
newness period on the date of FDA
approval or clearance or, if later, the
date of availability of the product on the
U.S. market as discussed in prior
rulemaking (77 FR 53348), we have
noted that data reflecting the costs of
products that have received an EUA
could become available as soon as the
date of the EUA issuance and prior to
receiving FDA approval or clearance (86
FR 45159). We refer readers to section
II.F.7. of the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45159 through 45160),
for discussion of our solicitation of
comments regarding the newness period
for products available through an EUA
for COVID–19. As discussed in section
II.F.4. of the preamble of this final rule,
we are continuing to consider the
comments we received regarding the
newness period for products available
through an EUA for COVID–19 as
discussed in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45159), and we
welcomed additional comments in the
proposed rule.
Therefore, we stated that because data
reflecting the costs of the Hemolung
RAS used for the indication of COVID–
19 could be available beginning with the
EUA on April 22, 2020, we questioned
whether the newness period for the use
of the Hemolung RAS for patients with
COVID–19 should begin with the date of
EUA issuance, April 22, 2020, while the
newness period for the use of Hemolung
RAS for patients with other causes of
hypercapnic respiratory failure
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
unrelated to COVID–19 should begin on
the date of commercial availability of
the De Novo classified device,
November 15, 2021. As discussed in the
FY 2022 IPPS/LTCH PPS final rule (86
FR 45159 through 45160), under the
current regulations at 42 CFR
412.87(e)(2) and consistent with our
longstanding policy of not considering
eligibility for new technology add-on
payments prior to a product receiving
FDA approval or clearance, a product
available only through an EUA would
not be eligible for new technology addon payments. Therefore, cases involving
pediatric patients, or cases involving the
use of the Hemolung RAS for greater
than 5 days, would not be eligible for
new technology add-on payment if the
Hemolung RAS is approved for new
technology add-on payment for the
patient population indicated in its FDA
De Novo marketing authorization.
We invited public comments on
whether the newness period for the
Hemolung RAS when used for patients
with COVID–19 should begin on April
22, 2020 (the date of its EUA), when the
product became available on the market
for this indication. We also invited
public comments on whether the
Hemolung RAS is substantially similar
to existing technologies and whether the
Hemolung RAS meets the newness
criterion.
Comment: The applicant submitted a
public comment regarding the newness
date for the Hemolung RAS. The
applicant stated that the newness period
for COVID–19 Hemolung RAS cases
should begin on November 15, 2021 (the
date of commercial availability of the De
Novo classified device), instead of April
22, 2020 (the date of the Hemolung RAS
EUA). The applicant indicated that it
provided the Hemolung RAS to
hospitals free or at cost to swiftly
respond to the global pandemic, and
that it did not profit from EUA
therapies. The applicant stated that
additionally, during the EUA period,
hospitals were not seeking payment for
Hemolung RAS therapy. The applicant
stated that, therefore, cost data collected
during the EUA period and prior to FDA
clearance do not accurately reflect the
added cost of Hemolung RAS therapy.
Response: We thank the applicant for
its comment. We note that, as discussed
in previous rulemaking, the intent of
section 1886(d)(5)(K) of the Act and
regulations under § 412.87(b)(2) is to
pay for new medical services and
technologies for the first 2 to 3 years
that a product comes on the market,
during the period when the costs of the
new technology are not yet fully
reflected in the DRG weights. While the
commenter stated that it provided the
PO 00000
Frm 00161
Fmt 4701
Sfmt 4700
48939
Hemolung RAS to hospitals free or at
cost, and that hospitals were not seeking
payment for the Hemolung RAS therapy
during the EUA period, additional
information regarding whether hospitals
charged for use of the Hemolung RAS
therapy between the date of its EUA and
the date of commercial availability of
the De Novo classified device, and how
it impacts whether use of the technology
may be reflected in the data, would be
helpful in determining that data
reflecting the cost of the product did not
become available until the date of
commercial availability of the De Novo
classified device. However, we note that
regardless of whether we consider the
beginning of the newness period to
commence for the use of the Hemolung
RAS for patients with COVID–19 on
April 22, 2020 (the date of its EUA) or
November 15, 2021 (the date of
commercial availability of the De Novo
classified device), in both cases, the
three-year anniversary date would occur
after April 1, 2023, and, therefore, the
technology would be considered new
for this indication for FY 2023. As we
discuss elsewhere in this rule, we also
recognize that there may be unique
considerations associated with
determining the start of the newness
period for a product available under an
EUA prior to receiving FDA approval,
and will continue to consider the
comments received regarding the
newness period for products available
through an EUA for COVID–19 for
future rulemaking. We consider the
beginning of the newness period to
commence for the use of the Hemolung
RAS for patients with other causes of
hypercapnic respiratory failure
unrelated to COVID–19 on the date of
commercial availability of the De Novo
classified device, November 15, 2021.
Accordingly, we consider the Hemolung
RAS to be new for FY 2023 for use in
patients with both COVID–19 and
hypercapnic respiratory failure
unrelated to COVID–19, and therefore
the product meets the newness criterion
for all patient populations indicated in
its FDA De Novo marketing
authorization.
Based on the information provided in
the application for new technology addon payments, and after consideration of
the public comments we received, we
believe the Hemolung RAS is not
substantially similar to existing
treatment options and meets the
newness criterion.
With respect to the cost criterion, the
applicant presented the following
analysis. The applicant searched the FY
2019 MedPAR Limited Data Set (LDS)
for cases that received ventilator
support to identify patients who may
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48940
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
have been eligible for the Hemolung
RAS. The applicant reviewed multiple
ICD–10–CM and ICD–10–PCS codes
related to respiratory failure and
hypercapnic disease and determined
that two ICD–10–PCS codes were most
applicable: 5A1955Z (Respiratory
ventilation, greater than 96 consecutive
hours) and 5A1945Z (Respiratory
ventilation, 24–96 consecutive hours).
We noted that, in the applicant’s
analysis, it listed ICD–10–PCS code
5A1955Z as 5A1935Z (Respiratory
ventilation, greater than 96 consecutive
hours), but we believed the applicant
intended to reference the correct ICD–
10–PCS code 5A1955Z (Respiratory
ventilation, greater than 96 consecutive
hours) to correctly map to MS–DRG 207
(Respiratory System Diagnosis with
Ventilator Support >96 Hours).
The applicant identified 68,317 cases
mapping to MS–DRGs 207 (Respiratory
System Diagnosis with Ventilator
Support >96 Hours) and 208
(Respiratory System Diagnosis with
Ventilator Support <= 96 Hours). MS–
DRG 207 contained 24.6% of the cases
and MS–DRG 208 contained the
remaining 75.4% of cases.
Next, the applicant removed 100% of
the inhalation charges and charges
associated with a 1-day length of stay
(LOS) in the ICU. The applicant
explained that it removed the 1 day of
routine care plus ICU day charges based
on an assumed LOS reduction
associated with the use of the Hemolung
RAS from relevant cases (as compared
to cases without the Hemolung RAS) to
estimate the potential decrease in costs
as a result of the use of the Hemolung
RAS.108 The applicant then
standardized the charges and applied a
4-year inflation factor of 1.281834 or
28.1834%, based on the inflation factor
used in the FY 2022 IPPS/LTCH PPS
final rule and correction notice to
calculate outlier threshold charges (86
FR 45542). The applicant then added
charges for the new technology, which
it calculated by dividing the cost of the
Hemolung RAS by the national average
CCR for inhalation therapy, which is
0.147 (86 FR 44966).
The applicant calculated a final
inflated average case-weighted
standardized charge per case of
$178,436, which exceeded the average
case-weighted threshold amount of
$102,867. Because the final inflated
average case-weighted standardized
charge per case exceeded the average
case-weighted threshold amount, the
108 Tiruvoipati, et al., ‘‘Effects of Hypercapnia and
Hypercapnic Acidosis on Hospital Mortality in
Mechanically Ventilated Patients:’’ Crit Care Med.
Vol 456(7). e649–e656
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
applicant maintained that the Hemolung
RAS meets the cost criterion.
After review of the cost analysis
provided by the applicant, we
questioned whether the analysis should
have included patients who would also
require a tracheostomy, which could
result in cases mapping to the Pre-Major
Diagnostic Category (Pre-MDC) MS–
DRGs 003 or 004 if used with
mechanical ventilation, and whether the
inclusion of those additional MS–DRGs
would impact the cost analysis. We
sought comments on whether the
Hemolung RAS meets the cost criterion.
Comment: The applicant submitted a
public comment and updated cost
criterion analysis, which included a
subset of cases in MS–DRG 003 and
MS–DRG 004 in response to our
concerns. The applicant stated that
cases mapping to these MS–DRGs
included non-extracorporeal membrane
oxygenation (ECMO) cases with a
tracheostomy, receiving mechanical
ventilation, and with a primary
diagnosis code for hypercapnia or
chronic obstructive pulmonary disease
(COPD). The applicant followed the
same methodology as its original
analysis and stated that even when
including the subset of cases in MS–
DRGs 003 and 004, the case-weighted
standardized charges exceed the
threshold amount, and the Hemolung
RAS meets the cost criterion.
Response: We appreciate the
applicant providing an updated cost
criterion analysis that includes a subset
of patients who would also require a
tracheostomy, which resulted in cases
mapping to the Pre-Major Diagnostic
Category (Pre-MDC) MS–DRGs 003 or
004 if used with mechanical ventilation.
Based on the information provided by
the applicant, because the final inflated
average case-weighted standardized
charge per case exceeded the caseweighted threshold amount in all
scenarios presented by the applicant, we
agree with the applicant that the
Hemolung RAS meets the cost criterion.
With regard to the substantial clinical
improvement criterion, the applicant
asserted that the Hemolung RAS offers
a treatment option for patients
unresponsive to non-invasive
mechanical ventilation (NIV), patients
unresponsive to invasive mechanical
ventilation (IMV), and patients
ineligible for currently available
treatments (that is, failure of NIV with
DNI order). Further, the applicant
asserted that the Hemolung RAS
significantly improves clinical outcomes
relative to available services or
technologies.
With regard to the claim that the
Hemolung RAS offers a treatment option
PO 00000
Frm 00162
Fmt 4701
Sfmt 4700
for patients unresponsive to NIV, the
applicant noted that while acute
respiratory failure can often be treated
with NIV, which does not require
intubation and is typically safe and well
tolerated, 12–50% of patients are
unresponsive to NIV as a result of
several factors, including elevated
respiratory rates, uncorrected
respiratory acidosis, and reduced level
of consciousness.109 110 111 Further, the
applicant stated that if a patient fails
NIV, the only currently indicated
treatment is escalation to IMV; however,
per the applicant, intubation and IMV
following NIV failure is associated with
a 200% increase in mortality compared
to patients successfully treated with
NIV; 27% vs 9% mortality rate,
respectively.112
The applicant asserted that the
Hemolung RAS can be an effective tool
for patients unresponsive to NIV by
rapidly correcting respiratory acidosis
(pH and arterial partial pressure of
carbon dioxide (PaCO2)), thereby
reducing respiratory drive and
improving NIV efficacy. In support of
this claim, the applicant submitted a
consensus paper by Combes et al.113 In
this consensus paper, 14 clinical experts
in critical care and respiratory support
using ECCO2R convened to determine
how ECCO2R therapy is applied,
identify how patients are selected, and
discuss how treatment decisions are
made. Per the applicant, the results of
the paper showed that there were two
groups of patients where ECCO2R
therapy was indicated—patients with
acute respiratory distress syndrome
(ARDS) or patients with COPD. The
treatment goal for ECCO2R therapy in
patients with ARDS is to provide ultraprotective lung ventilation via managing
CO2 levels. The criteria for initiating
ECCO2R therapy in patients with ARDS
and on NIV is when there was no
decrease in PaCO2 and no decrease in
respiratory rate. In patients with acute
109 Conti, V. et al. Predictors of outcome for
patients with severe respiratory failure requiring
noninvasive mechanical ventilation. Eur Rev Med
Pharmacol Sci 19, 3855–3860 (2015).
110 Bott, J. et al. Randomised controlled trial of
nasal ventilation in acute ventilatory failure due to
chronic obstructive airways disease. Lancet 341,
1555–1557 (1993).
111 Phua, J., Kong, K., Lee, K.H., Shen, L. & Lim,
T.K. Noninvasive ventilation in hypercapnic acute
respiratory failure due to chronic obstructive
pulmonary disease vs. other conditions:
effectiveness and predictors of failure. Intensive
Care Med 31, 533–539 (2005).
112 Chandra, D. et al. Outcomes of noninvasive
ventilation for acute exacerbations of chronic
obstructive pulmonary disease in the United States,
1998–2008. Am. J. Respir. Crit. Care Med. 185, 152–
159 (2012).
113 Combes, A. et al. ECCO R therapy in the ICU:
2
consensus of a European round table meeting.
Critical Care 24, (2020).
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
COPD exacerbation, treatment targets
were patient comfort, pH between 7.30–
7.35, respiratory rate less than 20–25
breaths per minute, decrease of PaCO2
by 10–20%, weaning from NIV, decrease
in bicarbonate levels (HCO3 ), and
maintaining hemodynamic stability.
The clinical experts came to the
consensus that ECCO2R therapy may be
an effective support treatment for adults
with ARDS or COPD exacerbation, but
noted the need for further evidence from
randomized clinical trials and/or high
quality prospective studies to better
guide decision-making.
The applicant also submitted three
peer-reviewed publications in support
of this claim. First the applicant cited
Bonin et al.,114 a case study of a 50-yearold male awaiting a bilateral lung
transplant, admitted for COPD
exacerbation caused by infection. The
patient was initially treated with
antibiotics and continuous NIV, which
he tolerated for three days. After three
days, the patient decompensated due to
a spontaneous pneumothorax. The lung
was emergently reinflated, but the
patient’s respiratory status continued to
decline with a PaCO2 between 72–85
mmHg, pH of less than 7.3, and a
respiratory rate of 30–40. The patient
showed signs of exhaustion but did not
qualify for intubation due to the recent
pneumothorax. The patient consented to
the Hemolung RAS therapy and within
the first hour of treatment, the patient’s
respiratory rate improved to around 10
breaths/minute. However, the patient
was no longer able to tolerate the NIV
minimum set breathing rate, so the
minimum set breathing rate was turned
off. The PaCO2 decreased to 55–60
mmHg for the duration of therapy (6
days). The patient was able to be
successfully weaned from continuous
NIV. The patient was also able to take
oral nutrition and participate in
interventions against pressure sores.
After day 6, the patient was able to
wean from the Hemolung RAS support
and continue with intermittent NIV
support.
Second, the applicant cited a multinational pilot study done by Burki et
al.115 in India and Germany. There were
20 COPD patients with hypercapnic
respiratory failure treated with ECCO2R
therapy and placed into 1 of 3 groups.
114 Bonin, F., Sommerwerck, U., Lund, L. &
Teschler, H. Avoidance of intubation during acute
exacerbation of chronic obstructive pulmonary
disease for a lung transplant candidate using
extracorporeal carbon dioxide removal with the
Hemolung. The Journal of Thoracic and
Cardiovascular Surgery 145, e43–e44 (2013).
115 Burki, N. et al. A novel extracorporeal CO
2
removal system: Results of a pilot study of
hypercapnic respiratory failure in patients with
COPD. Chest 143, 678–686 (2013).
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Group 1 had seven patients on NIV with
a high likelihood of requiring IMV;
Group 2 had two patients who could not
be weaned from NIV; and Group 3 had
11 patients on IMV who failed weaning
attempts. The authors found that the
device was well-tolerated with
complications and rates similar to those
seen with central venous
catheterization. The patients in Group 1
successfully avoided IMV as a result of
ECCO2R therapy, although three
patients died within 30 days of ECCO2R
therapy due to underlying disease
states. The patients in Group 2 were
successfully weaned from continuous
NIV after receiving ECCO2R therapy and
were alive 30 days after ECCO2R
therapy, but remained on intermittent
non-invasive, positive-pressure
ventilation (NIPPV) support. Of the
patients in Group 3, nine of the 11
patients had been on IMV for greater
than 15 days prior to ECCO2R therapy.
In Group 3, three patients were weaned
from IMV, three patients had decreased
IMV support, one patient expired from
retroperitoneal bleed following
catheterization, and one patient
remained on the same level of
ventilatory support despite receiving
ECCO2R therapy. The authors
concluded that the single catheter, lowflow ECCO2R system, provided
clinically useful levels of CO2 removal
in patients with COPD and could be a
potentially valuable addition to the
treatment of hypercapnic respiratory
failure.
Third, the applicant cited a case series
by Tiruvoipati et al. (2016),116 which
retrospectively reviewed 15 patients
among three Australian ICUs treated
with the Hemolung RAS who had severe
hypercapnic respiratory failure due to
COPD, ARDS, asthma, or bronchiolitis
obliterans syndrome (BOS), to show that
ECCO2R was safe and effective in the
removal of CO2. For five patients (four
with COPD and one with BOS), the
indication for the Hemolung RAS was to
avoid intubation, whereas for the other
10 patients (five with acute lung injury/
ARDS, three with asthma, and two with
COPD), the indication was to institute
lung-protective ventilation. The median
age of the patients was 61.5 years; 12
patients were men, the median Acute
Physiology and Chronic Health
Evaluation III (APACHE III) score was
85, and the median duration of ECCO2R
was 5 days. The primary outcome
measures of the study were clearance of
CO2 and change in pH with the use of
116 Tiruvoipati, R. et al. Early experience of a new
extracorporeal carbon dioxide removal device for
acute hypercapnic respiratory failure. Crit Care
Resusc 18, 261–269 (2016).
PO 00000
Frm 00163
Fmt 4701
Sfmt 4700
48941
ECCO2R. Secondary outcome measures
included complications associated with
Hemolung RAS use, survival to weaning
from the Hemolung RAS, and survival
to ICU and hospital discharge. There
was no specified protocol for managing
mechanical ventilation across the three
centers; however, all centers used lowpressure ventilation for ARDS. For
asthma, the mechanical ventilation was
characterized by low tidal volume, low
respiratory rate, and short inspiratory
time associated with prolonged
expiratory time to avoid dynamic
hyperinflation. Four of the five patients
treated for this indication, as well as all
10 patients who were treated to institute
lung-protective ventilation, avoided
intubation; successful lung-protective
ventilation was achieved by a reduction
in peak inspiratory pressure, tidal
volume, and minute ventilation. The
clearance of CO2 and return of PaCO2 to
near-normal levels was achieved within
6 hours, and there was significant
reduction in minute ventilation and
peak airway pressures. Complications
reported during the study included
hemorrhage, thrombocytopenia, and
compartment syndrome, none of which
required cessation of the Hemolung RAS
therapy. Overall, 93.3% of the patients
survived to discontinuation of ECCO2R,
73.3% of patients survived to ICU
discharge, and 66.66% of patients
survived to hospital discharge. In
conclusion, the study authors stated that
the Hemolung RAS appears to be safe
and effective for managing hypercapnic
respiratory failure of various etiologies,
but noted that more research is needed
to clarify which patients may benefit
most from this therapy.
In addition to the previous peerreviewed studies, the applicant also
cited the Hemolung RAS Registry
Program Analysis in support of its
claim.117 Per the applicant, the
voluntary Hemolung RAS Registry
Program collected data from commercial
use of the Hemolung RAS outside of the
US as well as US EUA therapies. 176
patients from the Hemolung RAS
Registry were analyzed to evaluate the
benefits and safety of the Hemolung
RAS therapy. The applicant stated that
the Hemolung RAS Registry Program
Analysis demonstrated that 86% (19/22)
of patients failing NIV avoided
117 Alung, Inc., HL–CA–1600, Hemolung RAS
Registry. A Retrospective Registry Involving
Voluntary Reporting of De-identified, Standard of
Care Data Following the Commercial Use of the
Hemolung Respiratory Assist System (RAS).
ClinicalTrials.gov. Retrieved December 21, 2021,
from Hemolung RAS Registry Program—Full Text
View—ClinicalTrials.gov.
E:\FR\FM\10AUR2.SGM
10AUR2
48942
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
intubation due to the Hemolung RAS
therapy.
With respect to the applicant’s
assertion that the Hemolung RAS offers
a treatment option for patients
unresponsive to IMV and are retaining
CO2, the applicant stated that the
Hemolung RAS de-couples CO2 removal
from the mechanical ventilator thereby
allowing correction of hypercapnia and
hypercapnic acidosis without a
dangerous escalation of ventilator
settings. The applicant provided 10
publications that document the use of
the Hemolung RAS in patients
unresponsive to IMV to significantly
reduce ventilator settings to lung safe
levels or to significantly correct and
control hypercapnic acidosis, including
Tiruvoipati et al. (2016) 118 and Combes
et al.,119 discussed previously.
In the first case study, a 44-year-old
male with acute asthma exacerbation
went into respiratory arrest and was
intubated in the emergency department
(ED).120 The patient was found to have
a left tension pneumothorax, which was
decompressed, and then developed a
second tension pneumothorax on the
right side, which was also
decompressed. The patient was
transferred to the ICU for further
management. The patient continued to
deteriorate over the subsequent 48 hours
due to subcutaneous emphysema and
ongoing air leaks, and after 72 hours had
uncontrollable hypercapnia (PaCO2 73,
pH 7.22) despite optimal medical
management with corticosteroids,
nebulized and intravenous
bronchodilators, magnesium, ketamine,
and muscle relaxants. ECCO2R was
indicated for hypercapnia and to
facilitate de-escalation of IMV. After
initiating ECCO2R, it was possible to
decrease the support on the IMV while
maintaining satisfactory gas exchange
and allowing the withdrawal of muscle
relaxants. Within 1 hour of initiation of
ECCO2R, the pH improved from 7.22 to
7.28, and the PaCO2 went from 68.1 to
60.6. The patient remained on ECCO2R
for a total of 7 days mainly due to
ongoing air leaks from three chest drains
and a bleeding complication that was
managed with transfusion. After
discontinuing ECCO2R therapy, the
patient received a tracheostomy to assist
in weaning from IMV. The patient was
118 Tiruvoipati, R. et al. Early experience of a new
extracorporeal carbon dioxide removal device for
acute hypercapnic respiratory failure. Crit Care
Resusc 18, 261–269 (2016).
119 Combes, A. et al. ECCO R therapy in the ICU:
2
consensus of a European round table meeting.
Critical Care 24, (2020).
120 Tiruvoipati R., et al. Low-flow veno-venous
extracorporeal carbon dioxide removal in the
management of severe status asthmatics: a case
report. Clin Respir J. 2014;10(5):653–656.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
successfully weaned from IMV after 23
days in the ICU and was ultimately
discharged home. The authors discussed
that while this patient could have been
treated with ECMO, the use of ECMO is
limited to specialized centers and
requires a multidisciplinary approach
for a successful outcome.
In the second case study, the
Hemolung RAS system was used to treat
hypercapnia in a 58-year-old male
patient with an out-of-hospital cardiac
arrest where mechanical ventilation
failed to achieve normocapnia.121 The
patient was intubated in the ED and
treated with nebulized bronchodilators,
corticosteroids, and therapeutic
hypothermia. Initially, the PaCO2 was
82 mmHg (baseline 50 mmHg) with a
pH of 7.20, but as the next few hours
progressed, the patient became more
difficult to ventilate and the PaCO2
increased to 94 mmHg. ECCO2R therapy
was indicated to prevent lung injury
and secondary brain injury. After
initiating the Hemolung RAS, the
minute ventilation and the respiratory
rate could be decreased and the team
was able to optimize the inspiratory and
expiratory time ration to minimize the
risk of barotrauma. The patient was on
the Hemolung RAS therapy for 3 days
and was able to de-escalate the
ventilator settings, but still required
mechanical ventilation. After cessation
of the Hemolung RAS therapy, the
patient started to show signs of
significant hypoxic brain injury. Despite
maximal medical treatment, the
neurological prognosis was considered
to be very poor, and all life-sustaining
therapies were withdrawn. The authors
stated that ECCO2R therapy is safe to
use in a metropolitan hospital where the
staff have a limited period of education,
and that the extracorporeal therapy was
delivered without complications. The
authors also stated that ECMO is not an
option in every health care center since
it requires a specialized team including
cardiac surgeons and perfusionists and
is costly. The authors stated that
ECCO2R is less invasive and able to
provide partial respiratory support.
Thus, the authors concluded that
ECCO2R may have a role in patients
with severe respiratory failure when
IMV alone is inadequate and in centers
that are not capable of initiating ECMO
in the management of severe
hypercapnic respiratory failure.
Next, the applicant cited a United
Kingdom case study about a 48-year-old
male presenting to the ED with 7 days
of cough, fever, and shortness of
breath.122 He tested positive for COVID–
19 via respiratory viral swab and had a
chest x-ray demonstrating bilateral
infiltrates. He initially required
supplemental oxygen via facemask and
oral doxycycline to treat possible
bacterial co-infection. He continued to
deteriorate, was trialed on NIV and
failed, and was then transitioned to IMV
on day four of the hospitalization and
transferred to the ICU for further
management. The patient continued to
deteriorate and within a week and was
found to be in ARDS due to COVID–19
pneumonitis. The patient was treated
with several strategies for lung
recruitment, and was referred to ECMO
but was declined on the basis of futility.
The treatment team believed that
continuing to treat the patient with high
airway pressure was contributing to the
progression of the ARDS, so the
Hemolung RAS was initiated as a rescue
therapy. After initiation, the PaCO2 and
pH improved, which allowed the
treatment team to reduce the tidal
volume and respiratory rate. The patient
spent 6 days on the Hemolung RAS
without bleeding events or vasopressors
and could continue to receive prone
position ventilation without
complication. The patient was
successfully weaned from the Hemolung
RAS and then completed a slow
respiratory wean followed by a
percutaneous tracheostomy. The patient
was ultimately discharged from the ICU
to home with mobility and cognition
intact. The authors concluded that
ECCO2R can be used as a rescue therapy
for patients with hypercapnic
respiratory failure resulting from ARDS
in COVID–19 pneumonitis and to
facilitate lung protective ventilation in
patients on IMV. According to the
authors, refractory hypercapnia is an
acceptable indication for ECMO in
ARDS and that ECCO2R can be
considered as rescue therapy if ECMO is
deemed inappropriate or cannot be
delivered due to resource constraints.
Per the authors, potential advantages of
using ECCO2R over ECMO include lack
of requirement for transfer to an ECMO
center, smaller catheter size, and lower
blood flow rate which may reduce the
likelihood of complications.
The applicant also cited a case study
of an 18-year-old male with solitary
mediastinal metastasis and ARDS, in
which the Hemolung RAS was used to
facilitate de-escalation of mechanical
121 Tiruvoipati R., et al. Management of severe
hypercapnia post cardiac arrest with extracorporeal
carbon dioxide removal. Anaesth Intensive Care.
2014;42(2):248–252.
122 Tully R.P., et al. The successful use of
extracorporeal carbon dioxide removal as a rescue
therapy in a patient with severe COVID–19
pneumonitis. Anaesthesia Reports 2020; 8:113–115.
PO 00000
Frm 00164
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
ventilation.123 Post-treatment with
chemotherapy, a residual mediastinal
mass was found with extension to the
left lung hilum. The patient underwent
lung resection and was extubated
postoperatively without issue. The
patient became febrile and developed a
progressively extensive right lung
infiltrate. On postoperative day five, the
patient developed severe hypercapnia,
hypoxemia, and hypotension,
necessitating re-intubation and invasive
mechanical ventilation. The Hemolung
RAS was initiated to provide ECCO2R.
Arterial PCO2 decreased from 73 to 53
mmHg within 4 hours (with a
concomitant pH increase from 7.28 to
7.44), permitting tidal volume reduction
to 3.5 mL/kg, and plateau airway
pressure to 25 cm H2O, with
simultaneous hemodynamic
improvement. ECCO2R was titrated to
maintain an arterial PCO2 between 45
and 50 mmHg, and the patient was
weaned and decannulated after 71 hours
of support. The patient was removed
from mechanical ventilation within 24
hours and then transferred to an
intermediate care unit. No ECCO2Rrelated complications were observed.
The authors stated the Hemolung RAS
has a conceptual advantage over ECMO
as the Hemolung RAS uses one small
dual-lumen venous catheter, without
additional arterial access and its
attendant risks. The authors concluded
that in appropriately selected patients, a
minimally invasive ECCO2R approach
may be useful.
Next, the applicant cited a case study
by Saavedra-Romero et al.,124 which
describes the use of ECCO2R
immediately administered with lungprotective mechanical ventilation on a
patient with COVID–19 ARDS in her
mid-60s. The authors stated that, upon
arrival to the ICU, on inpatient day 5,
the patient’s oxygen saturation by pulse
oximeter (SpO2) was 77%, blood
pressure (BP) 90/40 on norepinephrine
at 10 mcg/min, and the patient’s initial
arterial blood gas (ABG) results were pH
= 7.14, PaCO2 = 90 mmHg, PaO2 = 52
mmHg, and HCO3 = 30 mEq/L. The
patient had significant whole-body
subcutaneous crepitus, and the chest xray (CXR) showed an inflated right lung,
subcutaneous emphysema, and an
appropriately positioned endotracheal
123 Akkanti B., et al. Low-flow extracorporeal
carbon dioxide removal using the Hemolung
Respiratory Dialysis System® to facilitate lungprotective mechanical ventilation in acute
respiratory distress syndrome. J Extra Corpor
Technol. 2017;49(2):112–114.
124 Saavedra-Romero R., et al. Treatment of Severe
Hypercapnic Respiratory Failure Caused by SARS–
CoV–2 Lung Injury with ECCO2R Using the
Hemolung Respiratory Assist System. Case Reports
in Critical Care 2021; 1–5.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
tube (ETT). The patient became
increasingly tachycardic and tachypneic
due to further worsening of hypercapnia
and respiratory acidosis. ECCO2R was
initiated using the Hemolung RAS and
was administered for 17 days without
complications. Ventilator settings were
maintained at PEEP of 14, rate of 26,
and minute ventilation at 7.8 liters
during the first 24 hours. Respiratory
rate and tidal volumes were
subsequently titrated downward,
maintaining adequate oxygen levels and
permissive hypercapnia. The patient’s
chest tubes were removed 4 days after
the Hemolung RAS decannulation, and
the patient was weaned from
mechanical ventilation 28 days from
ICU admission, and discharged 47 days
after admission. The authors stated that
this case report highlights the use of
ECCO2R to facilitate effective treatment
of a patient with severe hypercapnic
respiratory failure secondary to COVID–
19 ARDS and multiple risk factors for
death. The authors stated that treatment
with ECCO2R allowed a lung-protective
ventilator management strategy with
ultralow tidal volumes, minimizing the
risk of ventilator-induced lung injury,
attenuating severe hypercapnia and
acidosis, and limiting the expansion of
an existing pneumothorax. The authors
concluded that ECCO2R facilitates early
lung-protective ventilation and control
of refractory hypercapnia and can be
safely utilized to increase the likelihood
of survival among patients with severe
COVID–19 ARDS.
Finally, the applicant cited a case
study by Bermudez et al.,125 in which a
33-year-old male with cystic fibrosis
(CF), post double lung transplantation
who developed severe hypercarbic
respiratory failure due to adenovirus
pneumonia requiring hospitalization,
tracheostomy, and prolonged IMV for
greater than 30 days. The patient was
transferred to a tertiary care center and
was treated with the Hemolung RAS
because of persistent hypoxemia and
hypercarbia. The patient was not a
candidate for ECMO because of frail
clinical condition, volume overload,
and need for a redo lung
transplantation. After 4 days of the
Hemolung RAS support, the patient was
weaned from vasopressors, and after 9
days, the patient was accepted as a
candidate for redo lung transplantation
because of considerable clinical
improvement.
Lastly, the applicant provided a
retrospective, multicenter study of 31
125 Bermudez, et al. ‘‘Prolonged Use of the
Hemolung Respiratory Assist System as a Bridge to
Redo Lung Transplantation’’ Annals of Thorac Surg.
2015 Vol 100 (6). P. 2330–2333.
PO 00000
Frm 00165
Fmt 4701
Sfmt 4700
48943
patients placed on the Hemolung RAS at
8 sites across the U.S.126 The cohort was
comprised of patients with COVID–19
who were mechanically ventilated with
severe hypercapnia and respiratory
acidosis and treated with low-flow
extracorporeal CO2 removal treated
between March 4 and September 30,
2020. Two patients underwent
cannulation but were never started on
therapy due to a vascular access failure
in one patient and immediate circuit
clotting in the other. For the 29 patients
who received the Hemolung RAS
treatment, analysis of covariance
revealed a significant improvement
trend in both pH and PaCO2 (p <
0.0001). Comparison of time intervals
yielded a statistically significant
improvement in pH (7.24 ± 0.12 to 7.35
± 0.07; p < 0.0001) and decrease in PCO2
(79 ± 23 to 58 ± 14; p < 0.0001) from
baseline to 24 hours after start of
therapy. There were numerical, but not
significant, decreases from baseline to
24 hours in respiratory rate (26.6 ± 5.4
to 23.4 ± 4.9), tidal volume (407 ± 100
to 386 ± 75 mL), and minute ventilation
(10.2 ± 3.2 to 8.7 ± 2.2 L/min). The
authors indicated that this is the first
reported use of ECCO2R in the U.S. for
this patient population. The authors
reported that limitations of the study are
its small size and single-cohort
retrospective nature. The applicant
stated that the study results
demonstrated the efficacy of ECCO2R
using the Hemolung RAS to improve
respiratory acidosis in patients with
severe hypercapnic respiratory failure
due to COVID–19.
In addition to the case reports and
retrospective study, the applicant also
cited to the Hemolung RAS Registry
Program Analysis, discussed previously,
in support of its claim.127 The applicant
stated that the Hemolung RAS Registry
Program Analysis demonstrated
clinically and statistically significant
correction of pH and PaCO2 within the
first day of the Hemolung RAS therapy
(p<0.05).128 Additionally, the applicant
noted that the statistical analysis
showed this correction in pH and PaCO2
126 Akkanti B., et al. Physiologic Improvement in
Respiratory Acidosis Using Extracorporeal CO2
Removal With Hemolung Respiratory Assist System
in the Management of Severe Respiratory Failure
From Coronavirus Disease 2019. Critical Care
Explorations. 2021;3:e0372.
127 Alung, Inc., HL–CA–1600, Hemolung RAS
Registry. A Retrospective Registry Involving
Voluntary Reporting of De-identified, Standard of
Care Data Following the Commercial Use of the
Hemolung Respiratory Assist System (RAS).
ClinicalTrials.gov. Retrieved December 21, 2021,
from Hemolung RAS Registry Program—Full Text
View—ClinicalTrials.gov.
128 Ibid. ClinicalTrials.gov. Retrieved December
21, 2021, from Hemolung RAS Registry Program—
Full Text View—ClinicalTrials.gov.
E:\FR\FM\10AUR2.SGM
10AUR2
48944
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
was independent of the patient’s
primary diagnosis.
With respect to the applicant’s
assertion that the Hemolung RAS offers
a treatment option for patients ineligible
for currently available treatments (for
example, patients with a DNI order), the
applicant reiterated that intubation with
IMV is the only currently available
treatment option for patients failing
NIV; however, the applicant indicated
that these patients have no other
therapeutic options if they were to fail
NIV because of their preference to not
be intubated. According to the
applicant, the CO2 removal by the
Hemolung RAS would rapidly correct
the pH and PaCO2 which would reduce
the respiratory drive and improve NIV
efficacy and prevent continued clinical
deterioration.129 130
The applicant submitted three peerreviewed case reports that have
documented the use of the Hemolung
RAS in patients failing NIV with a DNI
order. In the first case study done in
Germany,131 a 72-year-old female with a
past medical history of severe COPD
(GOLD 4, nocturnal home ventilation
therapy) with a DNI order presented to
an ED in a hypercapnic coma. The
patient had a Glasgow Coma Score of 3,
pH of 6.97, and PaCO2 greater than 150
mmHg. The patient was
hemodynamically stable on NIV with a
respiratory rate of 28, oxygen saturation
of 88% on supplemental oxygen with an
inspired fraction (FiO2) of 30%. After 30
minutes of NIV treatment, the patient’s
PaCO2 improved, but the patient was
nearly unconscious and was transferred
to the ICU. Because of the high
predictive mortality for patients with
severe COPD who fail NIV and require
intubation and invasive mechanical
ventilation, combined with the patient’s
DNI order, the Hemolung RAS was
initiated to supplement treatment.
Within the first hour of treatment with
both NIV and Hemolung RAS, the
PaCO2 levels continued to decrease from
109 mmHg to 89 mmHg and the
patient’s level of consciousness
improved after about 25 minutes.
Ultimately, the patient was able to start
oral nutrition, communicate, and start
mobilizing early because of her
129 Burki, N. et al. A novel extracorporeal CO
2
removal system: Results of a pilot study of
hypercapnic respiratory failure in patients with
COPD. Chest 143, 678–686 (2013).
130 Tiruvoipati, R. et al. Early experience of a new
extracorporeal carbon dioxide removal device for
acute hypercapnic respiratory failure. Crit Care
Resusc 18, 261–269 (2016).
131 Engel, M., Albrecht, H. & Volz, S. Use of
Extracorporeal CO2 Removal to Avoid Invasive
Mechanical Ventilation in Hypercapnic Coma and
Failure of Noninvasive Ventilation. J Pulm Respir
Med 6, 1–3 (2016).
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
improved mental state within four hours
of starting the Hemolung RAS and was
discharged to rehabilitation.
The second case study by Mani et al.
described two patients with severe
COPD admitted to the ICU with an acute
COPD exacerbation requiring NIV, but
failed NIV treatments.132 A 69-year-old
female in India was admitted with acute
COPD exacerbation, waning
consciousness and a pH of 7.20 and
PaCO2 of 101 mmHg. After starting NIV
for 2 hours, the PaCO2 had risen to 105
mmHg and pH had dropped to 7.193.
After 1 hour of the Hemolung RAS
treatment and NIV, the PaCO2 declined
to 93 mmHg with a pH 7.25. After 6
hours of treatment with the Hemolung
RAS and NIV, the patient was awake
with a PaCO2 of 68 mmHg and a pH of
7.35. Ultimately, she was discharged to
home on home oxygen and nocturnal
NIV. There was also a report of a 78year-old male with COPD and other
comorbidities who had a DNI order in
Germany. He was admitted with an
acute COPD exacerbation and treated
with NIV after his initial arterial blood
gas (ABG) showed PaCO2 92 mmHg and
pH of 7.24. After treatment with both
the Hemolung RAS and NIV for 1 hour,
the patient’s PaCO2 dropped to 68
mmHg and pH 7.33. Ultimately, the
patient was discharged to home on
nocturnal NIV. Both patients were both
diagnosed with thrombocytopenia as a
known complication of extracorporeal
therapy, but neither required
transfusion.
The applicant submitted a third case
study in which Cole et al. describe a 62year-old female with past medical
history of COPD (GOLD class 3) and 2
recent hospitalizations for COPD
exacerbations in the past 60 days.133
The patient had hypercapnic respiratory
failure for which she did not want to be
intubated, so she was started on NIV.
She initially improved, but by day four
of NIV treatment, she deteriorated, as
evidenced by tachypnea and fatigue due
to increased work of breathing. She was
started on the Hemolung RAS and
within two hours therapy with the
Hemolung RAS alone (patient requested
to stop NIV with the initiation of the
Hemolung RAS), the patient’s
respiratory rate improved. Within 6
hours, the patient was able to converse
and fully engage with her treatment.
132 Mani, R.K., Schmidt, W., Lund, L.W. & Herth,
F.J.F. Respiratory dialysis for avoidance of
intubation in acute exacerbation of COPD. ASAIO
J 59, 675–678 (2013).
133 Cole, S. et al. Extracorporeal carbon dioxide
removal as an alternative to endotracheal intubation
for noninvasive ventilation failure in acute
exacerbation of COPD. J Int Care Soc 15, 344–346
(2014).
PO 00000
Frm 00166
Fmt 4701
Sfmt 4700
Ultimately the patient was discharged to
home at her baseline activity level and
did not require home oxygen therapy,
and was not readmitted to hospital
within 30 days of discharge.
Furthermore, the applicant claimed
that the Hemolung RAS significantly
improves clinical outcomes relative to
services or technologies previously
available by mitigating the harmful
clinical sequelae from hypercapnic
acidosis and facilitates de-escalation of
high pressure and high volume
ventilatory support or prevent
intubation, both of which are known
predictors for poor clinical outcomes.
Thus, per the applicant, the correction
of hypercapnia and hypercapnic
acidosis (that is, pH and PaCO2) are
appropriate surrogate markers for
improved clinical outcomes in critically
ill, mechanically ventilated patients. Per
the applicant, the use of correction of
hypercapnia and hypercapnic acidosis
as surrogate markers for improved
clinical outcomes was accepted by FDA
as evidence of the clinical benefit of the
Hemolung RAS as part of FDA’s
clearance of its De Novo request.
The applicant asserted that the pH
and PaCO2 correction due to the
Hemolung RAS therapy provide the
following six improved outcomes: (1)
reduced mortality in intubated and IMV
patients; (2) reduced length of stay in
IMV patients; (3) de-escalation of
mechanical ventilation settings
(decreased rate of subsequent diagnostic
or therapeutic interventions); (4)
avoidance of intubation following NIV
failure; (5) reduced mortality in NIV
patients; and (6) improvement in
activities of daily living/quality of life.
In support of its assertion that the
Hemolung RAS reduces mortality in
intubated and IMV patients, the
applicant cited two background
studies.134 135 In the study by Nin et al.,
the authors completed a secondary
analysis of 3 prospective, noninterventional cohort studies in 1,899
patients with ARDS among 40 ICUs. The
goal of the study was to determine the
relationship between severe
hypercapnia (PaO2 ≥50 mmHg) in the
first 48 hours following onset of ARDS
and mortality. The applicant stated that
the study results demonstrate that
severe hypercapnia in IMV patients was
independently associated with
increased risk of ICU mortality (odds
134 Nin, et al., ‘‘Severe hypercapnia and outcome
of mechanically ventilated patients with moderate
or severe acute respiratory distress syndrome’’
Intensive Care Med. 2017. p. 200—208.
135 Tiruvoipati, et al., ‘‘Effects of Hypercapnia and
Hypercapnic Acidosis on Hospital Mortality in
Mechanically Ventilated Patients’’ Crit Care Med.
2017. Vol 456(7). e649–e656.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ratio: 1.93, 95% CI: 1.32–2.81,
p = 0.001). The second study by
Tiruvoipati et al. (2017), was a
multicenter, binational, retrospective
study that included 252,812 patients of
3 cohorts: normocapnia and normal pH
(n = 110,104), compensated hypercapnia
(n = 20,463), and hypercapnic acidosis
(n = 122,245), that aimed to determine
the relationship between these states
and Acute Physiology and Chronic
Health Evaluation (APACHE) III score
and mortality. The study found that
those with compensated hypercapnia
and hypercapnic acidosis had higher
APACHE III scores (49.2 vs. 53.2 vs.
68.6, p<0.01); mortality was highest in
the hypercapnic acidosis patients (OR:
1.18, 95% CI: 1.1–1.25) and lowest in
the normocapnia and normal pH,
p < 0.001. The applicant stated that the
adjusted odds ratio for hospital
mortality remained significantly higher
in compensated hypercapnia and
hypercapnic acidosis when compared
with patients with normocapnia and
normal pH irrespective of their P/F
ratios.
In support of the applicant’s second
assertion that use of the Hemolung RAS
contributes to reduced LOS in IMV
patients, the applicant cited Tiruvoipati
et al. (2017), previously discussed.136
The median hospital LOS was 10.5 days
in the normocapnia and normal pH
group, 12 days in the compensated
hypercapnia group and 11 days in the
hypercapnic acidosis group (p<0.001).
The median ICU LOS was 1.9 days vs
2.2 days vs. 2.9 days in the
normocapnia/normal pH group vs.
compensated hypercapnia group vs. the
hypercapnic acidosis group,
respectively (p<0.001). The authors
noted that that there was increased
mortality in patients with hypercapnic
acidosis and compensated hypercapnia
with unclear cause.
In support of the applicant’s assertion
that use of the Hemolung RAS results in
de-escalation of mechanical ventilation
settings and decreased rate of
subsequent diagnostic or therapeutic
interventions, the applicant cited the
Tully et al. case report,137 discussed
previously, in which intubated patients
had a 20% decrease in peak airways
pressure and 30% decrease in driving
pressure during the Hemolung RAS
therapy. The applicant also cited the
Tiruvoipati et al. (2016) study,
discussed previously, in which 10
patients showed a 19% decrease in peak
136 Ibid.
137 Tully R.P., et al. The successful use of
extracorporeal carbon dioxide removal as a rescue
therapy in a patient with severe COVID–19
pneumonitis. Anaesthesia Reports 2020; 8:113–115.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
respiratory pressure and a 26% decrease
in minute ventilation within 1 day of
the Hemolung RAS therapy.138 The
applicant also cited the Hemolung RAS
Registry Program Analysis,139 which
demonstrated statistically significant
correction of pH and PaCO2 within the
first day of the Hemolung RAS therapy
(p<0.05).
In support of its assertion that use of
the Hemolung RAS contributes to
avoidance of intubation following NIV
failure, the applicant noted that
respiratory acidosis is the primary
determinant of NIV failure citing risk
charts using a background study from
Confalonieri et al.,140 in which data
from 1,033 patients admitted to
experienced hospital units was used to
predict the likelihood of failure of
noninvasive positive pressure
ventilation (NPPV). The prediction
charts were calculated using the
APACHE II, GCS, pH, and respiratory
rate data of 1,033 patients admitted with
acute respiratory failure due to
exacerbation of COPD treated with NIV.
The applicant stated that the study
results show that pH <7.25 (acidosis)
after 2 hours of NIV is the primary
determinant of NIV failure [odds ratio:
21.02; 95% CI: 10.07–43.87], and that
additionally, a pH between 7.25 and
7.29 (acidosis) after 2 hours of NIV is
also significant predictor of NIV failure
[odds ratio:2.92; 95% CI: 1.62–5.28].
The applicant stated that accuracy and
generalizability of the model’s ability to
predict NIV failure was validated on an
independent group of 145 COPD
patients treated with NIV.
In a prospective, single-arm feasibility
study, Burki et al., previously discussed,
stated that 100% (7/7) patients failing
NIV and treated with the Hemolung
RAS therapy avoided intubation and
100% (2/2) patients failing NIV with a
DNI and treated with the Hemolung
RAS therapy were successfully weaned
from NIV.141 The applicant cited a
retrospective review by Tiruvoipati et
138 Tiruvoipati,
R., et al. Effects of Hypercapnia
and Hypercapnic Acidosis on Hospital Mortality in
Mechanically Ventilated Patients*: Critical Care
Medicine. 2017;45(7):e649–e656.
139 Alung, Inc., HL–CA–1600, Hemolung RAS
Registry. A Retrospective Registry Involving
Voluntary Reporting of De-identified, Standard of
Care Data Following the Commercial Use of the
Hemolung Respiratory Assist System (RAS).
ClinicalTrials.gov. Retrieved December 21, 2021,
from Hemolung RAS Registry Program—Full Text
View—ClinicalTrials.gov.
140 Confalonieri M., et al. A chart of failure risk
for noninvasive ventilation in patients with COPD
exacerbation. European Respiratory Journal.
2005;25(2):348–355.
141 Burki N., et al. A novel extracorporeal CO
2
removal system: Results of a pilot study of
hypercapnic respiratory failure in patients with
COPD. Chest. 2013;143(3):678–686.
PO 00000
Frm 00167
Fmt 4701
Sfmt 4700
48945
al. (2016), also previously discussed, in
which 80% (4/5) of patients failing NIV
and treated with Hemolung RAS
therapy avoided intubation.142
Furthermore, the applicant cited an
unpublished study of the Hemolung
RAS Registry Program Analysis,143 in
which 86% of patients (19 of the 22
patients in the analysis) who failed NIV
and were treated with the Hemolung
RAS therapy avoided intubation.
In support of the assertion that the
Hemolung RAS reduced mortality in
NIV patients, the applicant submitted
two retrospective studies as background
studies, in addition to two case studies
that utilized the technology. The first
background study 144 was a
retrospective analysis of data from the
Healthcare Cost and Utilization Project’s
Nationwide Inpatient Sample between
1998 and 2008 to assess the pattern and
NIPPV use for acute exacerbations of
COPD. The patient cohort was defined
as people greater than 35-years-old
admitted with a primary diagnosis of
COPD or a primary diagnosis of
respiratory failure with a secondary
diagnosis of COPD. The study
demonstrated a decline over time in
overall in-hospital mortality for those
patients treated with NIPPV without a
subsequent need for IMV. Mortality was
high and increased over time in patients
who transitioned from NIPPV to IMV
(27%) compared to those patients who
did not transition (9%). Charges for
hospitalization increased from 1998 to
2008, especially for patients who
transitioned from NIPPV to IMV. LOS
decreased in all patients except those
who transitioned from NIPPV to IMV.
The authors noted a few limitations that
would have allowed for a more detailed
examination of predictors of NIPPV
failure and death, including the lack of
information on the severity of the
exacerbation, response to NIPPV
treatment, end-of-life decision-making,
142 Tiruvoipati R., et al. Early experience of a new
extracorporeal carbon dioxide removal device for
acute hypercapnic respiratory failure. Crit Care
Resusc. 2016;18(4):261–269.
143 The applicant cited an unpublished study
using data collected from physicians as part of the
Hemolung Registry Program. We believe
information regarding the Hemolung Registry
Program is available here: Alung, Inc., HL–CA–
1600, Hemolung RAS Registry. A Retrospective
Registry Involving Voluntary Reporting of Deidentified, Standard of Care Data Following the
Commercial Use of the Hemolung Respiratory
Assist System (RAS). ClinicalTrials.gov. Retrieved
December 21, 2021, from Hemolung RAS Registry
Program—Full Text View—ClinicalTrials.gov.
144 Chandra, et al, ‘‘Outcomes of noninvasive
ventilation for acute exacerbations of chronic
obstructive pulmonary disease in the United States,
1998–2008’’ Am J. Respir Crit Care Med. 2012. Vol
185 (2). p. 152–159
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48946
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
or location of the patient in the hospital
(ICU vs. medical ward vs. ED, etc.).
The applicant also cited a
retrospective study by Sprooten et al.145
as background, that looked at patients
admitted to the Respicare Unit located
in Maastricht University Medical Center
(MUMC) in the Netherlands between
2009 and 2011 who met the criteria of
admitted for exacerbation of COPD
requiring NIV therapy and a definitive
COPD diagnosis. In-hospital mortality
was 14% with a median LOS of 16.5
days. Overall, this single-center study
showed that patients who are admitted
to the hospital for a first hospitalization
requiring NIV for acute respiratory due
to COPD exacerbation have a high shortand long-term mortality rate. According
to the article, older age, NIV use greater
than eight days and lack of successful
NIV response were independent
prognostic factors to two-year mortality
rather than response of levels of PaCO2
or pH.
The applicant also cited two case
studies where the Hemolung RAS was
used to successfully treat patients in
hypercapnic respiratory failure caused
by COPD. The applicant stated that in
these case reports, the Hemolung RAS
therapy prevented imminent death in
COPD patients with a DNI order who
were failing NIV. In a case study by
Engel et al., previously described,146 a
72-year-old female with hypercapnic
coma due to COPD exacerbation was
administered the Hemolung RAS; after 4
hours, PaCO2, pH, and clinical
parameters improved, and the patient
was weaned off therapy after 7 days.
In a second study by Mani et al.,
previously described,147 the Hemolung
RAS was used to treat two patients. The
first patient, a 69-year-old female with
COPD, was placed on the Hemolung
RAS after failing NIV treatment. After 66
hours of treatment, the patient was
weaned off the Hemolung RAS, and was
discharged home 4 days later. The
second patient, a 78-year-old male with
COPD, was placed on the Hemolung
RAS after failing NIV treatment. After 48
hours of treatment, the patient was
weaned off the Hemolung RAS, and was
discharged home 10 days later.
In support of the assertion that the
Hemolung RAS improves activities of
daily living/quality of life, the applicant
submitted one randomized controlled
trial (RCT) abstract and three case
studies. In the RCT abstract by Barrett
at al.,148 18 patients (median age: 67.5
years) with acute hypercapnic
respiratory failure due to exacerbations
of COPD were randomized to receive
NIV alone or ECCO2R and NIV. The
applicant stated that the study included
patients who were at high risk of failing
NIV (pH<7.30 after ≥1 hour of NIV). The
applicant stated that the control arm
continued to be treated with NIV only
(n=9) and the test arm was treated with
ECCO2R (n=9). The primary endpoint
was the time to cessation of NIV.
Secondary outcomes included device
tolerance and complications, changes in
arterial blood gases (ABGs) and hospital
survival. The time to NIV
discontinuation was shorter in the
ECCO2R arm (7 hours) vs in the NIV
alone arm (24.5 hours), p = 0.004. The
study claimed that dyspnea rapidly
improved with ECCO2R, but that ICU
and hospital LOS were longer with the
ECCO2R group and there was no
difference in mortality or functional
outcomes at follow-up. The authors
concluded that ECCO2R can be an
alternative to NIV for patients who are
at risk of failing or cannot tolerate NIV,
or for patients in whom a more rapid
correction of hypercapnia is desirable.
The applicant referred to three case
studies using the Hemolung RAS to treat
hypercapnic respiratory failure, to
demonstrate improvement in activities
of daily living/quality of life. In the case
study by Engel et al., previously
described,149 the applicant stated that
early mobilization, communication, and
nutrition were facilitated with
Hemolung therapy. In the Bermudez et
al. case study, previously discussed,150
the Hemolung RAS was successfully
used to bridge a patient with COPD to
a lung transplantation. The applicant
stated that considerable clinical
improvement attributed to Hemolung
therapy permitted the patient to be
145 Sprooten, et al. ‘‘Predictors for long-term
mortality in COPD patients requiring non-invasive
positive pressure ventilation for the treatment of
acute respiratory failure’’ Clinical Resp J. 2020. Vol
14 (12). p. 1144–1152
146 Engel, et al. ‘‘Use of Extracorporeal CO
2
Removal to Avoid Invasive Mechanical Ventilation
in Hypercapnic Coma and Failure of Noninvasive
Ventilation’’ J. Pulm & Resp Med. 2016 Vol 6 (3)
p.1–3.
147 Mani, R.K., Schmidt, W., Lund, L.W. & Herth,
F.J.F. Respiratory dialysis for avoidance of
intubation in acute exacerbation of COPD. ASAIO
J. 59, 675–678 (2013).
148 Barrett, N., et al. A randomized controlled trial
of Non-Invasive Ventilation compared with ECCO2R
for Acute Hypercapnic Exacerbations of COPD.
ASAIO J. 2021; 67 (Supp 3) Presented at the 32nd
Annual ELSO Conference.
149 Engel, et al. ‘‘Use of Extracorporeal CO
2
Removal to Avoid Invasive Mechanical Ventilation
in Hypercapnic Coma and Failure of Noninvasive
Ventilation’’ J. Pulm & Resp Med. 2016 Vol 6 (3)
p.1–3.
150 Bermudez, et al. ‘‘Prolonged Use of the
Hemolung Respiratory Assist System as a Bridge to
Redo Lung Transplantation’’ Annals of Thorac Surg.
2015 Vol 100 (6). p. 2330–2333.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00168
Fmt 4701
Sfmt 4700
awake and mobilized to sit on the edge
of the bed. In the Bonin et al. case study,
previously discussed,151 the applicant
stated that drinking and recovery from
pressure sores were possible by day
three of the Hemolung RAS.
After review of the information
provided by the applicant, we stated
that we had the following concerns
regarding whether the Hemolung RAS
meets the substantial clinical
improvement criterion. We noted that
the evidence provided for several of the
claims of substantial clinical
improvement include small, nonrandomized studies without the use of
comparators or controls, including case
studies, which may affect the ability to
draw meaningful conclusions about
treatment outcomes from the results of
the studies. We stated that the benefits
of avoiding intubation or de-escalating
IMV settings are described in case
studies, but the absence of comparative
data may make it more difficult to
determine whether there are clinically
meaningful changes in these outcomes.
We also noted that in the one abstract
of an RCT using the Hemolung RAS,152
although the time to NIV
discontinuation was shorter in the
ECCO2R arm than in the NIV alone arm,
the ICU and hospital length of stay were
longer with the ECCO2R group and there
were no differences in mortality or
functional outcomes at follow-up.
Additionally, while the applicant stated
that the Hemolung RAS results in
improved clinical outcomes, such as
reducing mortality in NIV patients
compared to continuing the patient’s
previous treatment, given that many of
the case studies provided as evidence to
support improved clinical outcomes
included only one or two patients, it
was not clear whether or not the results
of these studies are generalizable to the
Medicare population. We also noted
that several of the case studies, for
example, Bonin et al., Mani et al., Tully
et al., etc., mentioned by the applicant
included patients and cases from
outside the U.S., and we questioned if
there may be differences in treatment
guidelines between these countries that
may have affected clinical outcomes.
Lastly, we noted that for several of the
claims of substantial clinical
improvement, the applicant provided
151 Bonin, et al. ‘‘Avoidance of intubation during
acute exacerbation of chronic obstructive
pulmonary disease for a lung transplant candidate
using extracorporeal carbon dioxide removal with
the Hemolung’’. J. Thorac Cardiovac Surg. 2013. Vol
145 (5). e43–e44.
152 Barrett, N., et al. A randomized controlled trial
of Non-Invasive Ventilation compared with ECCO2R
for Acute Hypercapnic Exacerbations of COPD.
ASAIO J. 2021; 67 (Supp 3) Presented at the 32nd
Annual ELSO Conference.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
evidence from background studies that
did not utilize the Hemolung RAS to
support the use of the technology to
improve clinical outcomes. For
example, in support of its assertion that
the Hemolung RAS reduces mortality in
NIPPV patients, the study cited by the
applicant only addressed NIPPV as a
treatment option to treat exacerbations
in patients with COPD, but did not
directly address the use of the
Hemolung RAS as an intervention.
We invited public comments on
whether the Hemolung RAS meets the
substantial clinical improvement
criterion.
Comment: The applicant submitted
comments in response to CMS’ concerns
in the FY2023 IPPS/LTCH PPS
proposed rule (87 FR 28243) regarding
whether the Hemolung RAS meets the
substantial clinical improvement
criterion. In response to our concerns as
to whether the results of non-controlled
data may affect the ability to draw
meaningful conclusions regarding
treatment outcomes and the use of
background studies to support claims of
substantial clinical improvement, the
applicant stated that it acknowledges
randomized controlled trial (RCT) data
is the gold standard and the limitations
of non-controlled data, but that large
RCTs investigating medical devices in
the critical care setting present unique
enrollment challenges. The applicant
stated that it is currently conducting the
VENT–AVOID RCT in the US (‘‘the
Trial’’—NCT03255057) investigating the
use of the Hemolung RAS in COPD
patients, which has faced slow
enrollment since it began in 2018, with
the COVID–19 pandemic further
slowing enrollment. The applicant
explained that one reason for the slow
enrollment is the highly specific
inclusion and exclusion criteria
required by RCTs, which is typical of
COPD trials. The applicant cited a study
that evaluated the number of patients
who would meet the inclusion criteria
commonly used in COPD clinical trials,
where the results demonstrated only
17% of the COPD population would
meet the inclusion criteria.153
The applicant stated that it believes a
substantial amount of real-world
evidence supports the technology’s use,
and as such, the background studies
(with a combined >200,000
mechanically ventilated patients) are
included to provide evidence
demonstrating the life-threatening
153 Herland
K, Akselsen JP, Skj2014
00:20 Aug 10, 2022
Jkt 256001
clinical sequelae that result from
hypercapnia and respiratory acidosis in
critically ill patients, including
increased risk of ICU and hospital
mortality, and longer ICU and hospital
lengths of stay.154 155 The applicant
stated that it believes the Hemolung
evidence submitted to demonstrate
substantial clinical improvement
reflects the real-world use and the true
impact the Hemolung RAS will have on
the Medicare population, and that it is
clear that providing clinicians with a
tool to effectively correct pH and PaCO2
independently of the lungs will have a
significant positive impact on the
outcomes of acute respiratory failure
patients.
In response to our concerns as to
whether the results of the Hemolung
RAS case studies that included only one
or two patients were generalizable to the
Medicare population, the applicant
stated that the epidemiology of acute
respiratory distress and need for
mechanical ventilation in older adults is
well established. The applicant noted
that there is a natural physiologic
decline in lung function with age,
which makes safely and adequately
ventilating older patients, especially
those with respiratory disease,
challenging. The applicant noted that at
generally accepted lung protective
ventilation settings, older patients are
more susceptible to an accumulation
CO2 due to poor baseline lung function.
The applicant also stated that use of the
Hemolung RAS in COPD patients is
highly generalizable to the Medicare
population given that the prevalence of
COPD increases with age, and that in
COPD patients failing non-invasive
ventilation (NIV), avoiding intubation
has a substantial mortality benefit (9%
vs 27%).156
In response to our concern as to
whether the potential differences in
treatment guidelines between countries
of case studies may have affected
clinical outcomes, the applicant
referenced the consensus guideline in
the US and Europe that generally the
154 Nin N., Muriel A., Pen
˜ uelas O., et al. Severe
hypercapnia and outcome of mechanically
ventilated patients with moderate or severe acute
respiratory distress syndrome. Intensive Care Med.
2017;43(2):200–208. doi:10.1007/s00134–016–
4611–1.
155 Tiruvoipati R., Pilcher D., Buscher H., Botha
J., Bailey M. Effects of Hypercapnia and
Hypercapnic Acidosis on Hospital Mortality in
Mechanically Ventilated Patients*: Critical Care
Medicine. 2017;45(7):e649–e656. doi:10.1097/
CCM.0000000000002332.
156 Chandra D., Stamm J.A., Taylor B., et al.
Outcomes of noninvasive ventilation for acute
exacerbations of chronic obstructive pulmonary
disease in the United States, 1998–2008. Am J.
Respir Crit Care Med. 2012;185(2):152–159.
doi:10.1164/rccm.201106–1094OC.
PO 00000
Frm 00169
Fmt 4701
Sfmt 4700
48947
goal when ventilating patients is to
utilize low volumes and pressures,
which can result in CO2 accumulation
in the blood. The applicant explained
that as CO2 accumulation is a basic
physiologic response to these ventilator
settings, patient location does not affect
clinical improvements resulting from
the Hemolung RAS therapy.
In response to our concern that the
ICU and hospital stays were longer with
the ECCO2R group and there were no
differences in mortality or functional
outcomes at follow-up, the applicant
submitted a recently published RCT 157
with additional data and analysis of its
study results on LOS. The applicant
cited that the ICU and hospital LOS
were both 4–5 days longer with ECCO2R
than with NIV, which was due to a
longer ICU LOS. The applicant noted
that time from ICU discharge to home
discharge was equal in both groups. The
applicant noted that with NIV, nurse-led
weaning occurred 24/7, based around
arterial blood gases, respiratory rate and
patient preference, and that patients
were discharged to the ward during the
daytime if they had been off NIV
overnight. In addition, the applicant
stated that patients who consistently
declined NIV were discharged to a ward
bed regardless of pH and this will have
contributed to the lower ICU length of
stay in the NIV arm. The applicant
noted that the protocol for patients
receiving ECCO2R did not allow
weaning overnight, and there was a
median of eight hours from cessation of
ECCO2R to decannulation and unit
protocols required a further overnight
stay for observation.
The applicant also explained that the
study results showed that time to NIV
cessation was significantly shorter in
the ECCO2R arm than in the NIV arm (7
hrs. vs 24:30 hrs., p = 0.004). The
applicant noted that at one-hour postrandomization the pH was significantly
higher in the ECCO2R arm (p<0.001),
and at 4 hours post randomization the
PaCO2 was significantly lower (p<0.001)
in the ECCO2R arm, compared to the
NIV only arm. The applicant stated that
ECCO2R also resulted in a significant
and rapid reduction in subjective
discomfort and dyspnea measured using
a visual analogue scale (VAS), where a
higher score indicates higher subjective
discomfort and dyspnea.
Several other commenters also
indicated their support for the
157 Barrett N.A., Hart N., Daly K.J.R., et al. A
randomised controlled trial of non-invasive
ventilation compared with extracorporeal carbon
dioxide removal for acute hypercapnic
exacerbations of chronic obstructive pulmonary
disease. Ann Intensive Care. 2022;12(1):36.
doi:10.1186/s13613–022–01006–8.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48948
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Hemolung RAS. A commenter stated
that the Hemolung RAS was used in
their center and proved to be reliable
(removing approximately 80 ccs of CO2/
min) and was well-accepted by staff.
The commenter noted that the staff
considered it easy to use compared to
ECMO, and were generally able to
manage it while also managing other
ECMO patients. The commenter stated
that the Hemolung RAS will occupy an
important niche in treating patients
with acute hypercapnic respiratory
failure, avoiding intubation up front in
some patients as well as facilitating
weaning off the ventilator in other cases
where intubation was necessary
initially.
A group of commenters submitted a
comment stating that their experience
with the Hemolung RAS underscored
the importance of this technology in the
Medicare population requiring inpatient
management of hypercapnic respiratory
failure. The commenters stated that IMV
not only does not address the
underlying clinical condition leading to
hypercapnia, but it also compounds it
by elevating pressures applied to the
lung in an attempt to increase tidal
ventilation, which contributes to
morbidity and mortality, and that prior
to the introduction of the Hemolung, it
was the only option available. The
commenters stated that they considered
the Hemolung RAS a new technology
that allows the patient on IMV to be
managed with lower pressures instead
of higher, earlier removal from
mechanical ventilation, or even avoid
mechanical ventilation, which the
commenter noted is particularly
important for patients with a do not
intubate order for whom there are no
other treatment alternatives. The
commenters considered the Hemolung
RAS as representing a significant
clinical improvement for patients with
hypercapnic respiratory failure in the
inpatient setting, particularly for
Medicare patients due to their age and
risk of complications of the current
standard of care.
Response: We thank the applicant and
other commenters for their comments.
Based on the additional information
received, we agree with the applicant
that the Hemolung RAS represents a
substantial clinical improvement over
existing technologies because the
technology offers a treatment option for
hypercapnic respiratory failure due to
all causes in adults while avoiding
intubation or facilitating extubation. We
also agree with the applicant that the
Hemolung RAS fills an unmet need for
patients ineligible for currently
available treatments, such as
mechanical ventilation (for example, in
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
patients with a DNI order). The
Hemolung RAS provides extracorporeal
CO2 removal from the patient’s blood for
up to 5 days in adults with acute,
reversible respiratory failure for whom
ventilation of CO2 cannot be adequately
or safely achieved using other available
treatment options and continued
clinical deterioration is expected. For
this reason, we agree that the Hemolung
RAS offers a valuable treatment option
for patients at risk for complications
from, unresponsive to, and/or ineligible
for, mechanical ventilation.
After consideration of the public
comments we received, we have
determined that the Hemolung RAS
meets the criteria for approval for new
technology add-on payments. Therefore,
we are approving new technology addon payments for use of the Hemolung
RAS for the indications approved under
its FDA De Novo marketing
authorization for FY 2023. As discussed
in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28236) consistent
with our longstanding policy of not
considering eligibility for new
technology add-on payments prior to a
product receiving FDA approval or
clearance, a product available only
through an EUA would not be eligible
for new technology add-on payments.
Therefore, cases involving pediatric
patients, or cases involving the use of
the Hemolung RAS for greater than 5
days, would not be eligible for new
technology add-on payments, as they do
not fall under the patient population
indicated in its FDA De Novo marketing
authorization. Cases involving the use of
the Hemolung RAS that are eligible for
new technology add-on payments will
be identified by ICD–10–PCS procedure
code 5A0920Z (Assistance with
respiratory filtration, continuous).
In its application, the applicant
estimated that the cost of Hemolung
RAS is $10,000, which includes the
$7,500 cost of the cartridge and the
$2,500 cost of the catheter. Under
§ 412.88(a)(2), we limit new technology
add-on payments to the lesser of 65% of
the average cost of the technology, or
65% of the costs in excess of the MS–
DRG payment for the case. As a result,
the maximum new technology add-on
payment for a case involving the use of
Hemolung RAS is $6,500 for FY 2023.
d. LIVTENCITYTM (Maribavir)
Takeda Pharmaceuticals U.S.A., Inc.
submitted an application for new
technology add-on payments for
LIVTENCITYTM (maribavir) for FY 2023.
LIVTENCITYTM is a cytomegalovirus
(CMV) pUL97 kinase inhibitor indicated
for the treatment of adults and
pediatrics (12 years of age and older and
PO 00000
Frm 00170
Fmt 4701
Sfmt 4700
weighing at least 35 kg) with posttransplant CMV infection/disease that is
refractory to treatment (with or without
genotypic resistance) to ganciclovir,
valganciclovir, cidofovir, or foscarnet.
According to the applicant,
LIVTENCITYTM is the only antiviral
therapy indicated to treat posttransplant patients with CMV in solid
organ transplant (SOT) and
hematopoietic stem cell transplant
(HCT). Per the applicant,
LIVTENCITYTM provides multi-targeted
anti-CMV activity by inhibiting protein
kinase UL97 and its natural substrates,
which subsequently inhibits CMV DNA
replication, encapsidation, and nuclear
egress of viral capsids.
The applicant stated that CMV is one
of the most common viral infections
experienced by transplant recipients,
with an estimated incidence rate
between 16%–56% in SOT recipients
and 30%–70% in HCT recipients.158
CMV is a beta herpesvirus that
commonly infects humans; serologic
evidence of prior infection can be found
in 40%–100% of various
populations.159 CMV typically resides
latent and asymptomatic in the body but
may reactivate during periods of
immunosuppression. The applicant
estimated that there are approximately
200,000 adult transplants per year
globally and an estimated 1,435 cases of
CMV post-transplant in the Medicare
population per year. The applicant
stated that in transplant patients,
reactivation of CMV can potentially lead
to serious consequences including loss
of the transplanted organ and, in
extreme cases, death.
Per the applicant, there are four FDAapproved therapies for the treatment
and/or prevention (that is, prophylaxis)
of CMV disease: valganciclovir,
ganciclovir, foscarnet, and cidofovir.
The applicant stated that ganciclovir
and valganciclovir are approved for
prevention of CMV disease in transplant
recipients and for treatment of CMV
retinitis in immunocompromised hosts,
including those with Acquired Immune
Deficiency Syndrome (AIDS); and
foscarnet and cidofovir are approved for
treatment of CMV retinitis in AIDS
patients. Per the applicant, none of
these four therapies are FDA-approved
for the treatment of resistant or
158 Azevedo L, Pierrotti L, Abdala E, et al.
Cytomegalovirus infection in transplant recipients.
Clinics.2015;70(7):515–523. doi:10.6061/clinics/
2015(07)09; World Health Organization (WHO).
International Report on Organ Donation and
Transplantation Activities—Executive Summary
2018.
159 Krech U. Complement-fixing antibodies
against cytomegalovirus in different parts of the
world. Bull WHO. 1973(49):103–106.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
refractory CMV infection and disease.
The applicant provided a table that
included the therapy, transplant type,
mechanism of action, approved
48949
indications that were CMV-related, and
the formulation(s).
BILLING CODE 4120–01–P
Therapies Indicated in Post-transplant Patients with CMV Infection/Disease
Therapy
Valganciclovir
Ganciclovir 161
Foscarnet 162
Cidofovir163
160
Approved
Indications
(CMVrelated)
HCT/SOT
HCT/SOT
HCT/SOT
HCT/SOT
Inhibition of
viral DNA
polymerase
(pUL54) activity
(inhibits DNA
replication)
Treatment of
CMV retinitis in
patients with
AIDS (adults)
Inhibition of
viral DNA
polymerase
(pUL54) activity
(inhibits DNA
replication)
Treatment of
CMV retinitis in
1mmunocompro
mised adult
patients,
including
patients with
AIDS
Inhibition of
viral DNA
polymerase
(pUL54) activity
(inhibits DNA
replication)
Treatment of
CMV retinitis in
patients with
AIDS
Inhibition of
viral DNA
polymerase
(pUL54) activity
(inhibits DNA
replication)
Treatment of
CMV retinitis in
patients with
AIDS
Prevention of
CMV disease in
kidney, heart,
and kidneypancreas posttransplant
patients at high
risk (adults)
Formulation
Prevention of
CMV disease in
kidney and heart
transplant
patients at high
risk (oediatric)
Oral
khammond on DSKJM1Z7X2PROD with RULES2
BILLING CODE 4120–01–C
With respect to the newness criterion,
the applicant stated that LIVTENCITYTM
was granted Breakthrough Therapy,
Priority Review, and Orphan Drug
designations from FDA, and
subsequently received FDA approval for
its New Drug Application on November
23, 2021. LIVTENCITYTM is indicated
for the treatment of adults and pediatric
patients (12 years of age or older and
weighing at least 35 kg) with posttransplant CMV infection/disease that is
refractory to treatment (with or without
genotypic resistance) with ganciclovir,
valganciclovir, cidofovir, or foscarnet.
Per the applicant, LIVTENCITYTM
VerDate Sep<11>2014
00:20 Aug 10, 2022
Prevention of
CMV disease in
adult transplant
recipients at risk
for CMV disease
Jkt 256001
Intravenous
Combination
treatment with
ganciclovir for
patients who
have relapsed
after
monotherapy
with either drug
Intravenous
became commercially available on
December 2, 2021. The applicant did
not explain the reason for the delay
between market authorization and
commercial availability. The
recommended dosing is 400 mg (two
200 mg tablets) orally twice daily with
or without food. The applicant stated
that if LIVTENCITYTM is coadministered with carbamazepine, then
the dosage is increased to 800 mg twice
daily; if co-administered with phenytoin
or phenobarbital, the dosage is
increased to 1,200 mg twice daily.
160 VALCTE® (valganciclovir) United States
Prescibing Information (2018).
PO 00000
Frm 00171
Fmt 4701
Sfmt 4700
Intravenous
According to the applicant, ICD–10–
PCS code 3E0DX29 (Introduction of
other anti-infective into mouth and
pharynx, external approach) may be
used to identify administration of
LIVTENCITYTM but does not uniquely
identify it. The following ICD–10–PCS
procedure codes were created to
uniquely describe the use of
LIVTENCITYTM, effective October 1,
2022: XW0DX38 (Introduction of
161 CYTOVENE–IV® (ganciclovir) United States
Prescibing Information (2018).
162 FOSCAVIR® (foscarnet) United States
Prescibing Information (2017).
163 VISTIDE® (cidofovir) United States Prescibing
Information (2010).
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.087
Transplant
Type
Mechanism of
Action
48950
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
maribavir anti-infective into mouth and
pharynx, external approach, new
technology group 8), XW0G738
(Introduction of maribavir anti-infective
into upper gi, via natural or artificial
opening, new technology group 8), and
XW0H738 (Introduction of maribavir
anti-infective into lower gi, via natural
or artificial opening, new technology
group 8).
As previously discussed, if a
technology meets all three of the
substantial similarity criteria under the
newness criterion, it would be
considered substantially similar to an
existing technology and would not be
considered ‘‘new’’ for the purposes of
new technology add-on payments.
With respect to the first criterion,
whether a technology uses the same or
similar mechanism of action to achieve
a therapeutic outcome, the applicant
stated that LIVTENCITYTM targets a
different gene locus (pUL97 vs. pUL54)
than the existing therapies to treat CMV
infection, including those resistant or
refractory to conventional therapy.
Specifically, LIVTENCITYTM inhibits
CMV DNA replication, encapsidation,
and nuclear egress of viral capsids
through inhibition of pUL97 and its
natural substrates. The applicant
provided the mechanisms of action for
the other existing anti-CMV drugs,
namely valganciclovir ganciclovir,
foscarnet, and cidofovir in the table
previously listed and concluded that
LIVTENCITYTM uses a different
mechanism of action compared to
existing anti-CMV drugs.
With respect to the second criterion,
whether a technology is assigned to the
same or a different MS–DRG when
compared to an existing technology, the
applicant stated that LIVTENCITYTM is
expected to be assigned to the same
MS–DRGs as therapies that are currently
used off-label for the treatment of CMV
infection or disease.
With respect to the third criterion,
whether the new use of technology
involves the treatment of the same or
similar type of disease and the same or
similar patient population when
compared to an existing technology, the
applicant noted that there are no other
existing therapies indicated to treat the
same or similar type of disease or
patient population as LIVTENCITYTM.
The applicant noted that currently
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
available therapies are used off-label to
treat patients with refractory or resistant
CMV infection or disease. Thus, the
applicant maintained that
LIVTENCITYTM is indicated to treat a
different patient population compared
to existing technologies.
In summary, the applicant asserted
that LIVTENCITYTM is not substantially
similar to other currently available
therapies because it uses a new
mechanism of action and is indicated to
treat a unique patient population and/or
disease and, therefore, the technology
meets the newness criterion. We invited
public comments on whether
LIVTENCITYTM is substantially similar
to existing technologies and whether
LIVTENCITYTM meets the newness
criterion. As noted in the proposed rule,
the applicant did not explain the reason
for the delay between market
authorization and commercial
availability, and we requested
additional information regarding this
point.
Comment: The applicant submitted
comments in response to CMS’ request
for additional information on the delay
between market authorization and
commercial availability of
LIVTENCITYTM. Per the applicant,
between FDA marketing authorization
on November 23, 2021 and commercial
availability on December 2, 2021, the
applicant applied final packaging and
labeling and worked to ship the product
to specialty pharmacies and distributors
as soon as finished goods were
available.
Response: We thank the applicant for
the additional information regarding the
delay between market authorization and
commercial availability. We agree with
the applicant that the beginning of the
newness period for LIVTENCITYTM is
December 2, 2021, the date the product
became commercially available.
Comment: A commenter agreed that
LIVTENCITYTM does not meet the first
and third substantial similarity criteria
as it stated that there are no other
antivirals with a similar mechanism of
action and LIVTENCITYTM offers a
novel treatment option for patients with
no other antivirals currently approved
for the treatment of post-transplant CMV
refractory to traditional treatments.
They agreed with the applicant that
LIVTENCITYTM is likely to share the
PO 00000
Frm 00172
Fmt 4701
Sfmt 4700
same MS–DRGs as off-label agents
currently used for CMV infection or
disease.
Response: We thank the commenter
for their input. We agree with the
commenter that LIVTENCITYTM has a
unique mechanism of action and offers
a novel treatment option for patients
with post-transplant CMV refractory to
traditional treatments.
Based on information submitted by
the applicant in its comment and as part
of its FY 2023 new technology add-on
payment application for
LIVTENCITYTM, as discussed in the
proposed rule (87 FR 28258 through
28259) and previously summarized, we
believe that LIVTENCITYTM has a
unique mechanism of action because it
inhibits pUL97, which is involved in
terminal DNA processing, including
DNA elongation, encapsidation, and
nuclear egress of viral capsids, whereas
existing therapies inhibit CMV DNA
polymerase (pUL54) or the CMV DNA
terminase complex (pUL51, pUL56, and
pUL89) that is required for viral DNA
processing and packaging. We also
believe that LIVTENCITYTM is indicated
to treat a unique patient population
and/or disease, as it is the only FDAapproved antiviral therapy indicated to
treat post-transplant patients with CMV
disease in solid organ transplant (SOT)
and hematopoietic stem cell transplant
(HCT). Therefore, LIVTENCITYTM is not
substantially similar to existing
treatment options and meets the
newness criterion. As stated previously,
we consider the beginning of the
newness period to commence on
December 2, 2021 based on information
provided by the applicant that the
product first became available for sale
on that date.
With respect to the cost criterion, the
applicant presented the following
analysis. To identify patients who may
be eligible to receive LIVTENCITYTM as
a treatment, the applicant searched the
2019 MedPAR dataset for cases with the
following ICD–10–CM codes for CMV
and post-transplant SOT and HCT
infection. The applicant included
inpatient discharges under Medicare
fee-for-service (FFS) and excluded
Medicare Advantage discharges.
BILLING CODE 4120–01–P
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ICD-10-CM Code
B25
B.25.0
B25.1
B25.2
B25.8
B25.9
B27.10
B27.11
B27.12
B27.19
T86.03
T86.822
T86.892
T86.93
T86.23
T86.812
T86.13
T86.43
T86.33
T86.852
T86.5
The applicant identified 1,435 claims
mapping to 108 MS–DRGs. For MS–
cases. The table lists the nine MS–DRGs
with the highest volume of cases.
Jkt 256001
on the inflation factor used in the FY
2022 IPPS/LTCH PPS final rule and
correction notice to update the outlier
threshold (86 FR 45542). The applicant
added charges for the new technology
by dividing the cost of LIVTENCITYTM
by the national average CCR for drugs
which is 0.187 (86 FR 44966). The
applicant estimated the costs of
LIVTENCITYTM based on 8-week dosing
regimens to complete the full treatment.
The applicant calculated a final
inflated average case-weighted
standardized charge per case of
$508,855 which exceeded the average
PO 00000
Frm 00173
Fmt 4701
Sfmt 4700
case-weighted threshold amount of
$76,739.
We invited public comments on
whether LIVTENCITYTM meets the cost
criterion.
We did not receive any comments on
whether LIVTENCITYTM meets the cost
criterion. Based on the information
submitted by the applicant as part of its
FY 2023 new technology add-on
payment application for
LIVTENCITYTM, as discussed in the
proposed rule (87 FR 28259 through
28260) and previously summarized, the
final inflated average case-weighted
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.089
khammond on DSKJM1Z7X2PROD with RULES2
The applicant did not remove charges
for a prior technology, as the applicant
claimed that any current treatment that
is used off-label to treat CMV patients
post-transplant SOT and HCT may not
be reflected in claims data. The
applicant further explained that in cases
where an off-label treatment is reflected
on the claim, LIVTENCITYTM might be
used as a second-line treatment rather
than to replace the off-label treatment.
The applicant then standardized the
charges and applied a 4-year inflation
factor of 1.281834 or 28.1834%, based
00:20 Aug 10, 2022
DRGs where the case volume was below
11, the applicant imputed a count of 11
Description
Other Kidney and Urinary Tract Diagnoses with CC
Other Kidney and Urinary Tract Diagnoses with MCC
Other Respiratory System Diagnoses with MCC
Complications of Treatment with MCC
Septicemia or Severe Sepsis without MV >96 Hours with MCC
Other Respiratory System Diagnoses without MCC
Complications of Treatment with CC
Other Respiratory System O.R. Procedures with MCC
Viral Illness with MCC
BILLING CODE 4120–01–C
VerDate Sep<11>2014
Description
Cytomegaloviral disease
Cytomegaloviral pneumonitis
Cvtomegaloviral hepatitis
Cytomegaloviral pancreatitis
Other cytomegaloviral diseases
Cytomegaloviral diseases, unspecified
Cytomegaloviral mononucleosis without complications
Cytomegaloviral mononucleosis with polyneuropathy
Cytomegaloviral mononucleosis with meningitis
Cytomegaloviral mononucleosis with other complication
Bone marrow transplant infection
Skin graft infection
Other transplanted tissue infection
Unspecified transplant organ and tissue infection
Heart transplant infection
Lung transplant infection
Kidney transplant infection
Liver transplant infection
Heart-lung transplant infection
Intestine transplant infection
Complications of stem cell transplant
ER10AU22.088
MS-DRG
699
698
205
919
871
206
920
166
865
48951
khammond on DSKJM1Z7X2PROD with RULES2
48952
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
standardized charge per case exceeds
the average case-weighted threshold
amount. Therefore, LIVTENCITYTM
meets the cost criterion.
With regard to the substantial clinical
improvement criterion, the applicant
asserted that LIVTENCITYTM represents
a new treatment option for a patient
population unresponsive to, or
ineligible for, currently available
treatments. To support this claim, the
applicant reiterated that there are no
existing therapies that are approved by
FDA to treat post-transplant patients
with refractory or resistant CMV
infection or disease. The applicant also
asserted that the use of LIVTENCITYTM
may significantly improve clinical
outcomes by improving efficacy and
reducing adverse effects compared to
available therapies.
To support the claim of improved
efficacy, the applicant cited results from
SOLSTICE, a phase III, open-label,
randomized controlled trial in which
352 transplant recipients [HCT (n=211)
and SOT (n=141)] with refractory 164 or
resistant 165 CMV were assigned 2:1 to
receive 400 mg of LIVTENCITYTM twice
daily (n=235) or investigator-assigned
therapy (IAT) with drug-specific dosing
(n=117) for 8 weeks, with 12 weeks of
follow-up.166 The choice of specific IAT
was at the investigators’ discretion and
included mono- or combination therapy
(≤2 drugs) with intravenous (IV)
ganciclovir, oral valganciclovir, IV
foscarnet or IV cidofovir, where
switching between ganciclovir and
valganciclovir was permitted. The
median (range) duration of exposure
was 57 (2–64) days in the
LIVTENCITYTM arm and 34 (4–64) days
with IAT. The primary endpoint was the
proportion of patients achieving CMV
clearance at 8 weeks, and the key
secondary endpoint was achievement of
CMV clearance 167 and symptom
control 168 at the end of week 8,
maintained through week 16. With
respect to the primary endpoint, the
applicant indicated that CMV clearance
at 8 weeks was achieved in 55.7%
(n=131/235) of the LIVTENCITYTM
group and 23.9% (n=28/117) of the IAT
group with an adjusted difference of
32.8%, where the results achieved
statistical significance [95% CI, 22.8–
42.7%, p<0.001]. With respect to the
secondary endpoint, the applicant
indicated that 18.7% (n=44/235) of the
LIVTENCITYTM-treated group and
10.3% (n=12/117) of IAT-treated group
maintained CMV viremia clearance and
symptom control through week 16
(p=0.013).169 The applicant stated that,
based on these results, LIVTENCITYTM
is superior to conventional antiviral
therapies in achieving and maintaining
CMV viremia clearance and symptom
control.
The applicant also claimed that the
efficacy of LIVTENCITYTM is consistent
across SOT types, as evidenced by an
unpublished subgroup analysis by
Avery et al.170 which evaluated 211
SOT patients from the SOLSTICE trial
for CMV clearance (LIVTENCITYTM vs.
conventional) by transplant type, with
the following results: heart: 42.9% (n=6/
14) vs. 11.1% (n=1/9) (adjusted
difference: 30.7% [95% CI, ¥1.72–
63.15%]); lung: 47.5% (n=19/40) vs.
13.6% (n=3/22), adjusted difference:
38.2% [95% CI, 16.89–59.53%]; kidney:
59.5% (n=44/74) vs. 34.4% (n=11/32);
adjusted difference: 26.7% [95% CI,
7.48–45.85%].
Finally, with regard to efficacy, the
applicant stated that LIVTENCITYTM is
active against refractory or resistant
CMV infections and tolerable across
doses. To support this claim, the
applicant pointed to a randomized,
dose-ranging, open-label, phase II study
by Papanicolaou et al.,171 in which HCT
and SOT recipients with refractory or
resistant CMV infections (n=120) were
randomized 1:1:1 to twice-daily
LIVTENCITYTM doses of 400 mg (n=40),
800 mg (n=40), or 1,200 mg (n=40) for
up to 24 weeks. The primary efficacy
endpoint was the proportion of patients
with confirmed undetectable plasma
CMV DNA within 6 weeks of treatment.
About two-thirds (n=80/120) of the
164 Failure to achieve >1 log
10 decrease in CMV
DNA after at least 14 days of anti-CMV treatment.
165 At least 1 genetic mutation associated with
resistance to ganciclovir/valganciclovir, foscarnet,
and/or cidofovir.
166 Avery RK, Alain S, Alexander B, et al.
Maribavir for refractory cytomegalovirus infections
with or without resistance post-transplant: results
from a phase 3 randomized clinical trial (accepted
manuscript). Clin Infect Dis. 2021; ciab988, https://
doi.org/10.1093/cid/ciab988.
167 Measured as CMV DNA level less than lower
limit of quantification.
168 Resolution or improvement in tissue-invasive
CMV disease or syndrome for participants
symptomatic at baseline or no new symptoms of
tissue-invasive CMV disease or syndrome for
participants asymptomatic at baseline.
169 Avery RK, Alain S, Alexander B, et al.
Maribavir for refractory cytomegalovirus infections
with or without resistance post-transplant: results
from a phase 3 randomized clinical trial (accepted
manuscript). Clin Infect Dis. 2021; ciab988, https://
doi.org/10.1093/cid/ciab988.
170 Avery RK, Blumberg EA, Florescu D, et al. A
randomized phase 3 open-label study of maribavir
vs. investigator-assigned therapy for refractory/
resistant cytomegalovirus infection in transplant
recipients: subgroup analyses of efficacy by organ.
in: The 2021 American Transplant Congress; 2021.
Abstract LB 9.
171 Papanicolaou GA, Silveira FP, Langston AA, et
al. MBV for r/r CMV infections in HCT or SOT
recipients: A randomized, dose-ranging, doubleblind, phase 2 study. Clin Infect Dis.
2019;68(8):1255–1264. doi:10.1093/cid/ciy706.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00174
Fmt 4701
Sfmt 4700
patients achieved undetectable plasma
CMV DNA within 6 weeks of treatment
among all doses [95% CI, 57–75%], and
70% of patients receiving 400 mg of
LIVTENCITYTM twice daily [95% CI,
53–83]; 62% of patients receiving 800
mg twice daily [95% CI, 46–77%], and
68% of patients receiving 1,200 mg
twice daily [95% CI, 51–81%] achieved
the primary endpoint. About a third of
patients experienced recurrent CMV
infection while on LIVTENCITYTM
(n=25) and 13 patients developed
mutations conferring LIVTENCITYTM
resistance.
To support the claim of decreased
adverse effects, the applicant cited the
results of two secondary endpoints from
the SOLSTICE trial. Per the applicant,
neutropenia and acute kidney injury are
known, common adverse effects
associated with valganciclovir/
ganciclovir and foscarnet, respectively.
The applicant noted that the rates of
treatment-related neutropenia and acute
kidney injury were both 1.7% (n=4/
234), separately, in the LIVTENCITYTM
treatment group. The applicant also
noted that the rate of neutropenia was
25% (n=14/56) in the valganciclovir/
ganciclovir group, and the rate of acute
kidney injury was 19.1% (n=9/47) in the
foscarnet group.172 The applicant
maintained that the rate of treatmentrelated neutropenia and acute kidney
injury was lower in the LIVTENCITYTM
group vs. conventional therapy group.
The applicant asserted that, based on
these results, LIVTENCITYTM has a
lower incidence of treatment-related
toxicities than existing therapies.
The applicant more specifically
claimed that transplant patients treated
with LIVTENCITYTM for CMV infection
experienced a lower incidence of
treatment-related neutropenia compared
with valganciclovir. To support this
claim, the applicant cited the primary
safety endpoint from Maertens et al.,173
a parallel-group, phase II study. In this
open-label, LIVTENCITYTM-blinded
trial, 120 HCT or SOT recipients with
CMV reactivation were randomly
assigned to receive LIVTENCITYTM at a
dose of 400 mg (n=40), 800 mg (n=40),
or 1,200 mg (n=40) twice daily or the
standard dose of valganciclovir for 12
weeks for preemptive treatment. The
primary efficacy endpoint was the
172 Avery R.K., Alain S., Alexander B., et al.
Maribavir for refractory cytomegalovirus infections
with or without resistance post-transplant: results
from a phase 3 randomized clinical trial (accepted
manuscript). Clin Infect Dis. 2021; ciab988, https://
doi.org/10.1093/cid/ciab988.
173 Maertens J., Cordonnier C., Jaksch P., et al.
Maribavir for preemptive treatment of
cytomegalovirus reactivation. N. Engl J. Med.
2019;381(12):1136–1147. doi:10.1056/
NEJMoa1714656.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
percentage of patients with a response
to treatment, defined as confirmed
undetectable CMV DNA in plasma,
within 3 weeks and 6 weeks after the
start of treatment. The primary safety
endpoint was the incidence of adverse
events that occurred or worsened during
treatment. Specifically, the applicant
cited the rate of treatment-emergent
neutropenia in this study which was
identified in 4% (n=5/118) of patients
administered LIVTENCITYTM versus
15% (n=6/39) of patients administered
valganciclovir through week 6. Similar
results were found through week 12: 5%
(n=6/118) vs. 18% (n=7/39). The
statistical significance of the difference
in treatment-emergent neutropenia
between the two groups was not
reported in the study.
Finally, the applicant stated that
LIVTENCITYTM had a lower incidence
of adverse events leading to
discontinuation. To support this
assertion, the applicant cited the rate of
treatment-emergent adverse effects
(TEAEs) leading to discontinuation from
SOLSTICE, which was lower in the
LIVTENCITYTM group (13.2% (n=31/
324)) vs. the conventional group (31.9%
(n=37/116)).174
In the proposed rule, we stated we
had the following concerns regarding
whether LIVTENCITYTM meets the
substantial clinical improvement
criterion. First, while the applicant
provided data to demonstrate that the
proportion of patients achieving CMV
clearance at 8 weeks was higher among
patients using LIVTENCITYTM, there
were similar rates of mortality and newonset CMV between the 2 treatment
groups in this trial: LIVTENCITYTM vs.
comparator: 11% (n=27/235) vs. 6%
(n=13/117) and 6% (n=14/235) vs. 6%
(n=7/113), respectively.175 We also
noted that it is unclear whether the
SOLSTICE study was sufficiently
powered to detect a difference in CMV
viremia clearance at week 16, one of the
study’s secondary endpoints.176 We
further noted that while the rate of
TEAEs leading to discontinuation was
lower in the LIVTENCITYTM group, the
rate of overall TEAEs and serious TEAEs
in the SOLSTICE trial was similar
between the two treatment groups
[LIVTENCITYTM vs. comparator: any
TEAE: 97.4% (n=229/234) vs. 91.4%
(n=106/116), serious TEAE: 38.5% vs.
174 Avery R.K., Alain S., Alexander B., et al.
Maribavir for refractory cytomegalovirus infections
with or without resistance post-transplant: results
from a phase 3 randomized clinical trial (accepted
manuscript). Clin Infect Dis. 2021; ciab988, https://
doi.org/10.1093/cid/ciab988.
175 Ibid.
176 Ibid.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
37.1%].177 Furthermore, we stated that
we would appreciate additional
information from the applicant
regarding safeguards taken to minimize
or prevent bias from the treating
physician in choosing the conventional
therapy for patients in the investigatorassigned therapy group of the phase III
trial.
We invited public comments on
whether LIVTENCITYTM meets the
substantial clinical improvement
criterion.
Comment: We received several
comments in support of approving new
technology add-on payments for
LIVTENCITYTM. The applicant
reiterated four reasons LIVTENCITYTM
meets the substantial clinical
improvement criterion, including: (1)
being a new treatment option for a
patient population unresponsive to, or
ineligible for, currently available
treatments; (2) more rapid resolution of
infection/disease; (3) reduction in at
least one clinically significant adverse
event, and (4) decreased number of
hospitalizations. The applicant also
submitted comments in response to
CMS’ concerns regarding the substantial
clinical improvement criterion.
With respect to the concern that there
were similar rates of mortality and newonset CMV between the two treatment
groups in the SOLSTICE study, the
applicant stated that the study was not
sufficiently powered nor was it long
enough in duration to detect a
difference in these two endpoints. With
respect to all-cause mortality, the
applicant stated that 8 weeks is often
the longest duration permissible due to
toxicities associated with the IAT
treatment group, and that the
underlying medical history of the
patients and the short study duration
contributed to the similar rate of
mortality. The applicant further
explained that all-cause mortality rates
were assessed based on the randomized
treatment group, regardless of
LIVTENCITYTM rescue treatment in the
IAT group. With respect to new-onset
CMV, the applicant stated that CMV
treatment, either via secondary
prophylaxis or treatment with
LIVTENCITYTM, was not allowed after 8
weeks which could explain the similar
rates between the two groups. They also
noted that a higher proportion of
LIVTENCITYTM patients with new onset
symptomatic CMV were primary
responders to LIVTENCITYTM treatment
versus the IAT patients. Furthermore,
the study participants had a history of
multiple past recurrences, increasing
the likelihood of CMV recurrence.
177 Ibid.
PO 00000
Frm 00175
Fmt 4701
Sfmt 4700
48953
Finally, the applicant emphasized that
clinically relevant recurrence is more
clinically meaningful than overall
recurrence.
Another commenter concurred with
the applicant, stating that the SOLSTICE
study design and imbalances in certain,
therapy-independent baseline
characteristics for the LIVTENCITYTM
group (for example, presence of CMV
disease) could make it difficult to
identify true differences in all-cause
mortality and new-onset CMV amongst
LIVTENCITYTM and comparators.
The applicant also responded to CMS’
concern that the SOLSTICE study was
not sufficiently powered to detect
difference in CMV viremia clearance at
week 16, one of the study’s secondary
endpoints. The applicant noted that the
study was powered to detect difference
in CMV viremia at week 8, which was
the primary endpoint of the study.
In response to CMS’ concern that
overall rate of TEAEs and serious TEAEs
in the SOLSTICE trial was similar
between the two treatment groups, the
applicant stated that the similar rate of
TEAEs was due to complexity of the
patient population. They noted that the
rate of TEAEs in the LIVTENCITYTM
group was driven by mild dysgeusia.
Similarly, a commenter stated that
while the rate of any TEAEs was similar
for LIVTENCITYTM versus IAT, patients
in the LIVTENCITYTM group primarily
experienced dysgeusia which did not
result in treatment discontinuation,
while patients in the IAT group
experienced cytopenias and renal
disorders that did lead to treatment
discontinuation. The applicant also
stated that the rate of TEAEs was not
adjusted for drug exposure; drug
exposure was longer in the
LIVTENCITYTM group versus the IAT
group due to toxicities in the IAT group.
Finally, they noted that TEAEs leading
to discontinuation was higher in the
IAT group versus the LIVTENCITYTM
group.
Another commenter stated, with
respect to the same concern, that while
the rates of any serious TEAEs were
similar between the groups, the rate of
treatment-related serious TEAEs was
lower in the LIVTENCITYTM group
versus IAT (5.1% vs. 14.7%,
respectively), with the benefit persisting
when taking into account
discontinuation rates. The commenter
cited this result in support of a finding
that LIVTENCITYTM is a unique oral
therapeutic option for CMV that does
not share the same problematic adverse
events of currently used off-label agents
which the commenter stated often lead
to treatment discontinuation and thus,
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48954
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
suboptimal treatment of CMV infection
and disease.
The applicant also responded to CMS’
request for additional information on
safeguards taken to minimize or prevent
bias from the treating physician in
choosing the conventional therapy for
patients in the IAT group of the
SOLSTICE study. The applicant noted
that SOLSTICE was designed as an
open-label study because the
investigators had to individualize the
selection of the effective comparator in
medically complex patients with
concomitant medications and adjust
dosing of the IAT agents based on renal
function. Thus, the applicant asserted
that an open-label design was a safe and
practical way to conduct the study. The
applicant also noted that the primary
endpoint of the study was assessed
based on an objective laboratory
endpoint at a fixed timepoint. They
stated that multiple sensitivity analyses
were conducted to address potential
bias due to different rates of early
treatment discontinuation and that the
primary endpoint was evaluated in
subgroups to establish treatment
consistency and study generalizability.
The results of these sensitivity analyses
of the primary efficacy endpoint were
consistent with the results of the
primary efficacy analysis and the benefit
of the technology was also consistent
across key subpopulations.
Response: We thank the commenters
for their input and appreciate the
clarifications in response to our
concerns regarding the similar rates of
mortality and new-onset CMV between
the two treatment groups, the
insufficient power to detect a difference
in CMV viremia clearance at week 16,
and the similar rates of overall TEAEs
and serious TEAEs in the SOLSTICE
study. Based on the additional
information received, we agree that
LIVTENCITYTM represents a substantial
clinical improvement over existing
technologies because it provides a new
treatment option for a patient
population unresponsive to, or
ineligible for, currently available
treatments, and significantly improves
the proportion of patients achieving
CMV viremia at 8 weeks and
maintaining CMV clearance and
symptom control at week 8 through
week 16, as well as reduces adverse
effects such as neutropenia and
nephrotoxicity compared to available
therapies.
After consideration of the public
comments we received, we have
determined that LIVTENCITYTM meets
the criteria for approval for new
technology add-on payment. Therefore,
we are approving new technology add-
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
on payments for LIVTENCITYTM for FY
2023. Cases involving the use of
LIVTENCITYTM that are eligible for new
technology add-on payments will be
identified by ICD–10–PCS procedure
codes XW0DX38 (Introduction of
maribavir anti-infective into mouth and
pharynx, external approach, new
technology group 8), XW0G738
(Introduction of maribavir anti-infective
into upper GI, via natural or artificial
opening, new technology group 8), or
XW0H738 (Introduction of maribavir
anti-infective into lower GI, via natural
or artificial opening, new technology
group 8).
In its application, the applicant
estimated that the cost of
LIVTENCITYTM is $50,000 for an 8week course of therapy. Under
§ 412.88(a)(2), we limit new technology
add-on payments to the lesser of 65% of
the average cost of the technology, or
65% of the costs in excess of the MS–
DRG payment for the case. As a result,
the maximum new technology add-on
payment for a case involving the use of
LIVTENCITYTM is $32,500 for FY 2023.
e. UPLIZNA® (Inebilizumab-Cdon)
HTI–DAC, the manufacturer under the
distributor Horizon Therapeutics USA,
Inc., submitted an application for new
technology add-on payment for
UPLIZNA® (inebilizumab-cdon) for FY
2023. Per the applicant, UPLIZNA® is
the first FDA-approved anti-cluster of
differentiation 19 (CD19) B-cell depleter
for the treatment of neuromyelitis optica
spectrum disorder (NMOSD) in adults
who are anti-aquaporin–4 (AQP4)
antibody positive, for which 80% of all
patients with NMOSD test positive.178
According to the applicant, the goal of
UPLIZNA® is to reduce the risk of
relapse and disability progression. The
applicant explained UPLIZNA® is a
CD19+ B cell-directed humanized
afucosylated immunoglobulin F1 (IgG1)
monoclonal antibody. The applicant
further explained that CD19 is a cell
surface antigen expressed on a broad
range of B lymphocytes. Per the
applicant, UPLIZNA® is a B-cell
depleter that binds specifically to CD19,
allowing it to target an extended range
of B-cells that play a role in NMOSD.
The applicant stated that following cell
surface binding to CD19+ B
lymphocytes, UPLIZNA® causes
antibody-dependent cellular cytolysis
(ADCC), resulting in significant and
robust B-cell depletion.
178 Wingerchuck, D. (2009, November 15).
Neuromyelitis optica: Effect of gender. Journal of
the Neurological Sciences. Retrieved October 6,
2021, from https://pubmed.ncbi.nlm.nih.gov/
19740485/.
PO 00000
Frm 00176
Fmt 4701
Sfmt 4700
NMOSD is a rare, severe autoimmune
disease of the central nervous system
that causes damage to the optic nerve,
spinal cord, and brain stem. NMOSD
affects approximately 10,000–15,000
people in the United States, and the
incidence rate may be up to 9 times
higher for women than for men, with
prevalence approximately 2- to 3-fold
higher among Black and Asian
populations.179 According to the
applicant, NMOSD is characterized by
unpredictable, recurrent attacks of
inflammation of the optic nerve (optic
neuritis) and/or of the spinal cord
(transverse myelitis), and may also
affect regions of the brain. The applicant
stated that attacks can be severe and
result in life-altering permanent
disability, such as blindness and
paralysis, and that recurring attacks can
have cumulative effects resulting in
significant morbidity. According to the
applicant, aquaporin-4 antibodies are
highly specific to NMOSD and AQP4 is
expressed on astrocytes throughout the
central nervous system. Per the
applicant, in NMOSD, AQP4 antibodies
bind to AQP4, resulting in astrocyte cell
death and inflammation. The applicant
stated that a sub-population of B-lineage
cells, CD19+ plasmablasts, produce
AQP4 antibodies and that certain CD19+
B-cells are increased in the blood of
AQP4-seropositive individuals with
NMOSD, with the highest levels
observed during an attack. According to
the applicant, by depleting a wide range
of B-cells that express CD19 (including
plasmablasts and some plasma cells),
UPLIZNA® reduces the risk of relapses
or attacks that may lead to permanent
disability in NMOSD patients.
With respect to the newness criterion,
the applicant stated that UPLIZNA® was
designated as a Breakthrough Therapy
and received Orphan Drug designation
on February 10, 2016 for the treatment
of NMOSD.180 Per the applicant,
UPLIZNA® received FDA approval on
June 11, 2020, for the treatment of
NMOSD in adult patients who are AQP4
antibody positive (BLA #761142). The
applicant stated that UPLIZNA® became
commercially available on July 9, 2020,
following FDA approval. According to
the applicant, UPLIZNA® is
administered as an intravenous
infusion, and titrated to completion,
over approximately 90 minutes under
the close supervision of an experienced
179 Flanagan, E.P. et al. (2016, April 4).
Epidemiology of aquaporin-4 autoimmunity and
Neuromyelitis Optica Spectrum. Wiley Online
Library. Retrieved October 6, 2021, from https://
onlinelibrary.wiley.com/doi/10.1002/ana.24617.
180 U.S. Food and Drug Administration website:
https://www.accessdata.fda.gov/scripts/opdlisting/
oopd/listResult.cfm.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
healthcare professional. The applicant
stated that the recommended initial
dose is a 300 mg intravenous infusion
followed 2 weeks later by a second 300
mg intravenous infusion. The applicant
also stated that subsequent doses,
starting 6 months from the first infusion,
consist of a single 300 mg intravenous
infusion every 6 months.
According to the applicant, the
following ICD–10–PCS procedure codes
may be used to identify administration
of UPLIZNA® in the inpatient setting,
though they are not specific to
UPLIZNA®: 3E033GC (Introduction of
other therapeutic substance into the
peripheral vein, percutaneous approach)
or 3E043GC (Introduction of other
therapeutic substance into central vein,
percutaneous approach). Effective
October 1, 2022, the following ICD–10–
PCS procedure codes were created to
uniquely describe the use of UPLIZNA®:
XW03398 (Introduction of
inebilizumab-cdon into peripheral vein,
percutaneous approach, new technology
group 8) and XW04398 (Introduction of
inebilizumab-cdon into central vein,
percutaneous approach, new technology
group 8).
As previously discussed, if a
technology meets all three of the
substantial similarity criteria under the
newness criterion, it would be
considered substantially similar to an
existing technology and would not be
considered ‘‘new’’ for the purposes of
new technology add-on payments.
According to the applicant, the only
approved treatments for NMOSD are
UPLIZNA®, Soliris® (eculizumab), and
ENSPRYNGTM (satralizumab). We note
that ENSPRYNGTM and Soliris®
previously submitted applications for
new technology add-on payments.
Please see discussion of ENSPRYNGTM
in the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45019 through 45028) and
Soliris® in the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58684 through 58689).
With respect to the first criterion,
whether a product uses the same or
similar mechanism of action to achieve
a therapeutic outcome, the applicant
stated that UPLIZNA® is the only
treatment for NMOSD that targets Bcells and causes B-cell depletion. The
applicant contrasted the mechanism of
action of UPLIZNA® with those of
Soliris® and ENSPRYNGTM. Per the
applicant, the mechanism of action of
Soliris® is the inhibition of aquaporin4-antibody induced terminal
complement C5b–9 deposition.181 The
181 U.S.
Food and Drug Administration. (2019,
June). Soliris Prescribing Information. Retrieved
October 6, 2021, from https://
www.accessdata.fda.gov/drugsatfda_docs/label/
2019/125166s431lbl.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
applicant explained that Soliris®
specifically binds to complement
protein C5, inhibiting its cleavage to C5a
and C5b and preventing the generation
of C5b–9. The applicant also stated that
ENSPRYNGTM is a recombinant
humanized anti-human interleukin–6
(IL–6) receptor monoclonal antibody.
Per the applicant, the mechanism of
action of ENSPRYNGTM involves the
inhibition of IL–6-mediated signaling
through binding to soluble and
membrane-bound IL–6 receptors.182
Thus, the applicant asserted that each of
the three FDA approved treatments for
NMOSD—UPLIZNA®, Soliris®, and
ENSPRYNGTM—bind to a different
molecular target and have different
mechanisms of action.
With respect to the second criterion,
whether a product is assigned to the
same or a different MS–DRG when
compared to an existing technology, the
applicant stated that cases representing
patients who may be eligible for
treatment with UPLIZNA® map to MS–
DRGs 058, 059, or 060 (Multiple
Sclerosis and Cerebellar Ataxia with
MCC, with CC, or without CC/MCC,
respectively), which are the same MS–
DRGs to which existing technologies
may also be assigned.
With respect to the third criterion,
whether the new use of technology
involves the treatment of the same or
similar type of disease and the same or
similar patient population when
compared to an existing technology, the
applicant asserted that, while
UPLIZNA® treats a patient population
with the same type of disease (NMOSD)
as Soliris® or ENSPRYNGTM, it offers a
treatment option for a subset of this
patient population, which differentiates
it from existing technologies. Per the
applicant, UPLIZNA® has not been
shown to carry an increased risk of
meningitis and may be used in patient
populations who are unvaccinated with
the meningococcal vaccine and/or are
not able to use prophylactic antibiotics.
The applicant noted that while patients
with NMOSD who are unvaccinated
with the meningococcal vaccine can
still receive other approved treatments
for NMOSD, such as Soliris® or
ENSPRYNGTM, they need to have a risk
reduction protocol instituted at the time
of treatment and, in some cases, may
require two weeks of prophylactic
antibacterial treatment first.183 184
182 Genentech. (2020, August). ENSPRYNG
Factsheet. Retrieved October 6, 2021, from https://
www.gene.com/download/pdf/genentech_
enspryng_factsheet.pdf.
183 Soliris® prescribing details: https://
solirispro.com/pdf/Soliris_USPI.pdf.
PO 00000
Frm 00177
Fmt 4701
Sfmt 4700
48955
In summary, the applicant maintained
that UPLIZNA® is not substantially
similar to other currently available
therapies and/or technologies because it
uses a new mechanism of action and
treats a different subset of the patient
population with NMOSD compared to
an existing technology.
In the proposed rule, we questioned
whether the subset of the patient
population with NMOSD—specifically,
patients who are unvaccinated with the
meningococcal vaccine—is considered a
new patient population since, as
previously discussed in the FY 2022
IPPS/LTCH PPS final rule (86 FR
45021), ENSPRYNGTM is also not
contraindicated in patients with
unresolved serious Neisseria
meningitidis infections, and therefore,
may be a treatment option for patients
with meningococcal disease as well as
UPLIZNA®. Furthermore, as we
previously stated in the FY 2022 IPPS/
LTCH PPS final rule, individuals that
are not vaccinated against Neisseria
meningitidis are not considered a
separate patient population because
eligibility can be easily attained via a
widely available vaccine (86 FR 45027).
Additionally, we questioned whether
the additional requirements for patients
taking Soliris®—namely participation in
a risk reduction protocol related to the
associated risk of meningococcal
infections, and prophylactic antibiotic
treatment that may result in a 2-week
delay for treatment—constitute a new
patient population for technologies
without those requirements.
We invited public comments on
whether UPLIZNA® is substantially
similar to existing technologies and
whether UPLIZNA® meets the newness
criterion.
Comment: The applicant submitted a
public comment regarding the newness
criterion. With respect to the first
criterion to determine newness, whether
a product uses the same or similar
mechanism of action, the applicant
reiterated its assertion that UPLIZNA®
has a novel mechanism of action which
satisfies the newness criterion. The
applicant stated that UPLIZNA® is the
first and only B-cell depleting
monotherapy approved for
neuromyelitis optica spectrum disorder
(NMOSD) in adult patients who are antiaquaporin–4 antibody positive. The
applicant explained that the mechanism
of action of UPLIZNA® involves binding
to CD19+ B-cells leading to antibodydependent, cell-mediated B-cell
depletion. As a result, the applicant
184 ENSPRYNGTM prescribing information:
https://www.gene.com/download/pdf/enspryng_
prescribing.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48956
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
stated UPLIZNA® reduces the damage
caused to the optic nerve, spinal cord,
and brain by NMOSD attacks, thus
reducing cumulative damage and rates
of disability.
With respect to the third criterion to
determine newness and our concern
that patients who are unvaccinated with
the meningococcal vaccine may not
represent a new patient population for
NMOSD, the applicant stated that in
small populations such as those with
rare diseases, special considerations
such as vaccination status, prior
therapies, drug interactions, or
contraindications are important as
certain nuances related to a particular
treatment within these small
populations can be uncovered, and
providers must often choose one
therapy over another due to specific
patient attributes and health histories.
Response: We appreciate the
applicant’s input and agree that
UPLIZNA® has a unique mechanism of
action when compared to existing
technologies for treating NMOSD, as
UPLIZNA® is the only CD19+ B-cell
depleting monotherapy approved for
NMOSD in adult patients who are antiaquaporin–4 antibody positive,
compared to Soliris® which specifically
binds to complement protein C5, and
ENSPRYNGTM which binds to soluble
and membrane-bound IL–6 receptors.
However, we continue to believe that
UPLIZNA® does not represent a
treatment option for a new patient
population. We stated in the FY 2022
IPPS/LTCH PPS final rule that
individuals who are not vaccinated
against Neisseria meningitidis are not
considered a separate patient
population because eligibility can easily
be attained via a widely available
vaccine (86 FR 45027). In addition,
ENSPRYNGTM, another approved
medication for the treatment of NMOSD,
is also not contraindicated in patients
with unresolved serious Neisseria
meningitidis infections and therefore,
may be a treatment option for patients
with meningococcal disease along with
UPLIZNA®.
Based on the comments received and
the information submitted as part of the
FY 2023 new technology add-on
payment application for UPLIZNA®, as
discussed in the proposed rule (87 FR
28303 through 28304) and in this final
rule, we believe that UPLIZNA® has a
unique mechanism of action and is not
substantially similar to existing
treatment options for NMOSD. While
the applicant stated that it became
commercially available on July 9, 2020,
we believe that the beginning of the
newness period for UPLIZNA® would
be June 11, 2020, which is the date that
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
UPLIZNA® received FDA marketing
authorization, as the applicant did not
provide documentation of a delay in
commercial availability.
With respect to the cost criterion, the
applicant presented the following
analysis. The applicant searched the FY
2019 Medicare Provider Analysis and
Review (MedPAR) Hospital Limited
Data Set (LDS) for cases with ICD–10–
CM diagnosis code G36.0 for
Neuromyelitis optica [Devic] (NMOSD)
coded in the first diagnosis position.
The applicant determined that cases
representing patients who may be
eligible for treatment with UPLIZNA®
would map to MS–DRGs 058, 059, or
060 (Multiple Sclerosis and Cerebellar
Ataxia with MCC, with CC, or without
CC/MCC, respectively).
The applicant determined a case
count of 257 after imputing a value of
11 for MS–DRGs with a case volume
under 11. The applicant then removed
100% of the drug charges to estimate the
potential decrease in costs due to the
use of UPLIZNA®. The applicant noted
that, although use of UPLIZNA® would
replace current drug charges for
therapies such as azathioprine,
methotrexate, and rituximab, it is not
possible to differentiate between drug
costs on MedPAR claims, and so it
removed all drug charges to be
conservative. The applicant then
standardized the charges and applied a
4-year inflation factor of 1.281834, or
28.1834%, based on the inflation factor
used to update the outlier threshold in
the FY 2022 IPPS/LTCH PPS final rule
(86 FR 45542). The applicant added
charges for the new technology by
dividing the estimated cost of
UPLIZNA® by the national average CCR
for drugs which is 0.187, from the FY
2022 IPPS/LTCH PPS final rule (86 FR
44966).
The applicant calculated a final
inflated average case-weighted
standardized charge per case of
$764,547, which exceeded the average
case-weighted threshold amount of
$48,165. Because the final inflated
average case-weighted standardized
charge per case exceeded the average
case-weighted threshold amount, the
applicant asserted that UPLIZNA®
meets the cost criterion.
We invited public comments on
whether UPLIZNA® meets the cost
criterion.
We did not receive any comments on
whether UPLIZNA® meets the cost
criterion. Based on the information
submitted by the applicant as part of its
FY 2023 new technology add-on
payment application for UPLIZNA®, as
discussed in the proposed rule (87 FR
28304) and previously summarized, the
PO 00000
Frm 00178
Fmt 4701
Sfmt 4700
final inflated average case-weighted
standardized charge per case exceeded
the average case-weighted threshold
amount. Therefore, UPLIZNA® meets
the cost criterion.
With regard to the substantial clinical
improvement criterion, the applicant
made two assertions. First, the applicant
asserted that UPLIZNA® offers a
treatment option for a patient
population that is ineligible for
currently available treatments.
Specifically, the applicant asserted that
UPLIZNA® is a new treatment option
for patients who carry an increased risk
of meningitis, patients following
treatments with more frequent and
burdensome dosing schedules, and
patient populations more likely to be
impacted by health disparities. Finally,
the applicant asserted that UPLIZNA®
significantly improves clinical outcomes
relative to currently available
technologies because it reduced the risk
of NMOSD attacks and disability
progression among patients with
NMOSD when compared to placebo in
the N–MOmentum trial, which the
applicant asserted is the largest NMOSD
study conducted.185
With respect to the applicant’s
assertion that UPLIZNA® is a
substantial clinical improvement over
existing technologies because it
represents a new treatment option for a
patient population ineligible for
currently available treatments, the
applicant stated that UPLIZNA® may be
used in patient populations who are
unvaccinated with the meningococcal
vaccine and/or are not able to use
prophylactic antibiotics because
UPLIZNA® has not been shown to carry
an increased risk of meningitis, as
compared with Soliris®.
To support this claim, the applicant
cited an article from the CDC explaining
that patients taking complement
inhibitors, such as Soliris®, are at an
increased risk for meningococcal
disease 186 and referenced the CDC’s
recommendation that patients receive
the meningococcal vaccination prior to
initiating treatment with a complement
inhibitor. The applicant also cited a
185 Marignier, R. et al., (2021, March 26).
Disability Outcomes in the N–MOmentum Trial of
Inebilizumab in Neuromyelitis Optica Spectrum
Disorder. Neurology® neuroimmunology &
neuroinflammation. Retrieved October 6, 2021,
from https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC8054974/.
186 Centers for Disease Control and Prevention.
(2019, May 31). Taking complement inhibitors
increases risk for meningococcal disease/CDC.
Centers for Disease Control and Prevention.
Retrieved October 1, 2021, from https://
www.cdc.gov/meningococcal/about/solirispatients.html.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
study by McNamara et al.187 that
identified 16 cases in the U.S. between
2008 and 2016 of patients who were
taking Soliris® who had meningococcal
disease despite having received at least
1 dose of meningococcal vaccine before
disease onset. Referring to the same
article by McNamara et al., the applicant
stated that some healthcare providers
recommend prophylactic antibiotics
even for vaccinated patients during
treatment with Soliris®, exposing them
to long-term antibiotic use, which
carries the risk of developing
antimicrobial resistance.
Furthermore, the applicant claimed
that UPLIZNA® represents a new
treatment option for patients following
treatments with more frequent and
burdensome dosing schedules than
UPLIZNA®. Per the applicant, the
dosing schedule for UPLIZNA® consists
of 2 initial doses delivered 2 weeks
apart, followed by 1 dose every 6
months after that.188 In comparison,
based on the FDA prescribing
information for Soliris®, the applicant
asserted that UPLIZNA®’s 6-month
dosing regimen is less frequent than that
of Soliris®, and, therefore, is less
burdensome to follow.189 The applicant
asserted the dosing schedule for
UPLIZNA® is more amenable to
NMOSD patients for whom more
frequent intravenous infusions may be
burdensome and stated that its
characteristics as a treatment regimen,
compared to SolirisTM, may help to
improve medication adherence and
decrease likelihood of relapse and
hospitalization relative to placebo. To
further demonstrate that UPLIZNA®
may help to improve long-term patient
adherence, compared to SolirisTM, the
applicant provided a review by Vlasnik
et al.190 noting that medication regimen
complexity is one factor that can
negatively affect adherence. The
187 McNamara, L. et al. (2017, July 7). High Risk
for Invasive Meningococcal Disease Among Patients
Receiving Eculizumab (Soliris) Despite Receipt of
Meningococcal Vaccine. Retrieved October 6, 2021,
from https://www.cdc.gov/mmwr/volumes/66/wr/
pdfs/mm6627e1.pdf.
188 U.S. Food and Drug Administration. (2007,
March). Highlights of prescribing information
administration. Retrieved October 6, 2021, from
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2007/125166lbl.pdf.
189 U.S. Food and Drug Administration. Alexion
briefing information for the November 18, 2014,
meeting of the Drug Safety and Risk Management
Advisory Committee. https://www.fda.gov/advisorycommittees/human-drug-advisory-committees/
drug-safety-and-risk-management-advisorycommittee.
190 Vlasnik, J. J., Aliotta, S. L., & DeLor, B. (2005,
April 7). Medication adherence: Factors influencing
compliance with prescribed medication plans. The
Case Manager. Retrieved October 6, 2021, from
https://www.sciencedirect.com/science/article/abs/
pii/S1061925905000263?via%3Dihub.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
applicant emphasized that, for NMOSD,
medication adherence to maintain
immune suppression is essential for
reducing the risk of attacks, which can
lead to hospitalization, vision loss and
paralysis. Finally, the applicant stated
that UPLIZNA® poses less of a barrier
for patient access, as it does not require
patients or providers to participate in
FDA’s Risk Evaluation and Mitigation
Strategy (REMS) program, or receive
additional counselling regarding the
program, as required by Soliris®.191
To support its claim that UPLIZNA®
is a new treatment option for
populations that are more likely to be
impacted by health disparities, the
applicant noted UPLIZNA®’s durable
efficacy and favorable safety profile
among African Americans with
NMOSD. To support this claim, the
applicant cited the safety results
published by Cree et al.192 from both a
randomized control period (RCP) and an
open label period (OLP) of the N–
MOmentum trial. The RCP phase of N–
Momentum was a multicenter, doubleblind, 2/3 study conducted at 99
outpatient specialty clinics or hospitals
in 25 countries that lasted up to 197
days. The primary endpoint was time to
onset of an NMOSD attack, as
determined by the investigator and
adjudication committee. Eligible
participants were randomized in a 3:1
ratio to receive either 300 mg
intravenous UPLIZNA® (n=174) or a
saline placebo (n=56) on days 1 and 15.
Participants continued through the RCP
for up to 28 weeks unless they had a
confirmed NMOSD attack, at which
point they could choose to continue in
the OLP phase of the trial. The OLP
included eligible adult participants
(n=230) who had had at least 1 NMOSD
attack in the year before screening or at
least 2 attacks requiring rescue therapy
in the 2 years before screening. During
the OLP, all patients received
UPLIZNA® for at least 2 years. As
recommended by an independent
committee, enrollment in the RCP phase
stopped prior to study completion due
to the early findings where 21 of 174
participants (12%) receiving UPLIZNA®
191 Alexion Pharmaceutical, Inc. (2020). Soliris
REMS. Retrieved October 6, 2021, from https://
solirisrems.com/.
192 Cree BAC, Bennett JL, Kim HJ, Weinshenker
BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul
F, Cutter GR, Marignier R, Green AJ, Aktas O,
Hartung HP, Lublin FD, Drappa J, Barron G, Madani
S, Ratchford JN, She D, Cimbora D, Katz E; N–
MOmentum study investigators. Inebilizumab for
the treatment of neuromyelitis optica spectrum
disorder (N–MOmentum): a double-blind,
randomised placebo-controlled phase 2/3 trial.
Lancet. 2019 Oct 12;394(10206):1352–1363. doi:
10.1016/S0140–6736(19)31817–3. Epub 2019 Sep 5.
PMID: 31495497.
PO 00000
Frm 00179
Fmt 4701
Sfmt 4700
48957
had an attack as compared with 22 of
the 56 placebo recipients (39%).
Marignier et al. (2021) assessed
treatment effects in N–MOmentum by
measuring score worsening of the
Expanded Disability Status Scale (EDSS)
and modified Rankin Scale (mRS)
scores.193 EDSS scores were measured at
baseline, then at RCP study weeks 12
and 28, and every 3 months during the
OLP, and within 5 days of a potential
attack. mRS scores were measured at
baseline, and at weeks 4, 8, 12, 16, 22,
and 28 of the RCP. The Marignier results
from the N–MOmentum study found the
annualized attack rate for African
Americans was lower at 0.06 compared
to an annualized attack rate of 0.09 in
the overall group exposed to
UPLIZNA®. The applicant stated that
among the 19 African American
participants who received UPLIZNA® or
placebo during the RCP and/or OLP of
the N–MOmentum trial, three had
attacks 18, 29, and 104 days after their
first UPLIZNA® dose. The summary of
baseline demographics and
characteristics of the intent-to-treat
population notes that there were 14
African American participants who
received UPLIZNA® and 5 who received
the placebo.194
With respect to its claim that
UPLIZNA® significantly improves
clinical outcomes relative to previously
available treatment options, the
applicant stated that patients taking
UPLIZNA® had a reduced risk of
NMOSD attacks and disability
progression when compared to placebo
in the N–MOmentum trial. The
applicant again referenced the results of
the N–MOmentum trial reported by Cree
et al., where 21 (12%) of the 174
participants receiving UPLIZNA® had
an attack by the time enrollment ended
versus 22 (39%) of the 56 participants
receiving placebo (hazard ratio (HR)
0·272 [95% CI 0·150–0·496]; p<0·0001).
The applicant also referred to the N–
MOmentum results from the OLP and
asserted that they show long-term
treatment with UPLIZNA® provided a
sustained reduction in NMOSD attack
risk, MRI lesions, and NMOSD-related
hospitalizations regardless of treatment
provided during the RCP. The applicant
193 Marignier R, Bennett JL, Kim HJ, Weinshenker
BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F,
Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin
FD, Williams IM, Drappa J, She D, Cimbora D, Rees
W, Smith M, Ratchford JN, Katz E, Cree BAC; N–
MOmentum Study Investigators. Disability
Outcomes in the N–MOmentum Trial of
Inebilizumab in Neuromyelitis Optica Spectrum
Disorder. Neurol Neuroimmunol Neuroinflamm.
2021 Mar 26;8(3):e978. doi: 10.1212/
NXI.0000000000000978. PMID: 33771837; PMCID:
PMC8054974.
194 Ibid.
E:\FR\FM\10AUR2.SGM
10AUR2
48958
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
referenced the disability data published
by Marignier et al.195 from the results of
the N–MOmentum trial on the use of
UPLIZNA® and asserted that they
showed favorable results among patients
with NMOSD when compared to
placebo. Specifically, Marignier et al.
assessed the treatment effects of
UPLIZNA® in comparison with placebo
by using a worsening score of the
Expanded Disability Status Scale (EDSS)
to measure confirmed disability
progression (CDP). The applicant
asserted that the results show
UPLIZNA® reduced the risk of 3-month
CDP compared with placebo (HR: 0.375;
95% CI: 0.148–0.952; p=0.0390). The
applicant also stated that UPLIZNA®
showed a significantly lower risk of
relapse among patients with NMOSD
when compared to placebo. The
applicant cited results from Pittock et
al.,196 a randomized, double-blind, timeto-event trial in which 143 adult
subjects were randomly assigned to
receive either UPLIZNA® or placebo
weekly and continued use of an
immunosuppressive therapy, as needed.
The primary endpoint was the first
adjudicated relapse, while secondary
endpoints included the adjudicated
annualized relapse rate. Pittock et al.
reported that adjudicated relapses
occurred in 3 of 96 patients (3%) in the
UPLIZNA® group and 20 of 47 (43%) in
the placebo group (hazard ratio 0.06;
95% confidence interval [CI], 0.02 to
0.20; P<0.001). The adjudicated
annualized relapse rate was 0.02 in the
eculizumab group and 0.35 in the
placebo group (rate ratio, 0.04; 95% CI,
0.01 to 0.15; P<0.001). Referring to the
results from the Pittock et al. study, the
applicant asserted that UPLIZNA®
showed a consistent effect in reducing
the risk of attack compared to placebo,
regardless of baseline disability status,
attack history, or disease duration.197
In the proposed rule, we stated we
had the following concerns regarding
whether UPLIZNA® meets the
195 Marignier R, Bennett JL, Kim HJ, Weinshenker
BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F,
Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin
FD, Williams IM, Drappa J, She D, Cimbora D, Rees
W, Smith M, Ratchford JN, Katz E, Cree BAC; N–
MOmentum Study Investigators. Disability
Outcomes in the N–MOmentum Trial of
Inebilizumab in Neuromyelitis Optica Spectrum
Disorder. Neurol Neuroimmunol Neuroinflamm.
2021 Mar 26;8(3): e978. doi: 10.1212/
NXI.0000000000000978. PMID: 33771837; PMCID:
PMC8054974.
196 Pittock SJ, Berthele A, Fujihara K, Kim HJ,
Levy M, Palace J, Nakashima I, Terzi M, Totolyan
N, Viswanathan S, Wang KC, Pace A, Fujita KP,
Armstrong R, Wingerchuk DM. Eculizumab in
Aquaporin–4-Positive Neuromyelitis Optica
Spectrum Disorder. N Engl J Med. 2019 Aug
15;381(7):614–625. doi: 10.1056/NEJMoa1900866.
Epub 2019 May 3. PMID: 31050279.
197 Ibid.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
substantial clinical improvement
criterion. First, we noted that while the
applicant provided data comparing
UPLIZNA® to placebo, we did not
receive any data to demonstrate
improved outcomes over existing FDA
approved treatments. We stated that
additional information comparing
outcomes such as relapse rate, risk of
relapse, and disability progression for
patients receiving UPLIZNA® versus
other currently available treatments
would help inform our assessment of
whether UPLIZNA® demonstrates a
substantial clinical improvement over
existing technologies. Second, while the
applicant asserted that UPLIZNA®
represents a new treatment option for
patients who are unvaccinated with the
meningococcal vaccine, similar to the
discussion in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45021) in response
to a similar assertion with respect to
ENSPRYNGTM, we noted that
ENSPRYNG® is also not contraindicated
in patients with unresolved serious
Neisseria meningitidis infection and
therefore may also be a treatment option
for patients with meningococcal disease.
We further noted that the use of
ENSPRYNGTM to treat patients with
NMOSD does not require a
meningococcal vaccination. We noted
that the applicant sought to support its
claim that UPLIZNA® represents a new
treatment option for patients who are
unvaccinated against Neisseria
meningitidis through the inference that
Soliris® has a high risk of causing
meningitis; however, as stated in the
proposed rule, we had concerns about
the applicant’s claim because Neisseria
meningitidis may easily be mitigated
through the use of a common vaccine or
antimicrobials. As discussed in the FY
2022 IPPS/LTCH PPS final rule in
response to similar claims with respect
to ENSPRYNG®, and as noted
previously, individuals that are not
vaccinated against Neisseria mengitidis
are not considered a separate patient
population because eligibility can be
easily attained via a widely available
vaccine and are also able to receive
treatment with UPLIZNA® which does
not require a vaccine (86 FR 45027).
With regard to the applicant’s claim
that UPLIZNA® is a new treatment
option for patients following treatments
with more frequent dosing schedules,
we stated in the proposed rule that we
are unsure whether these patients may
be considered as a separate patient
population ineligible for currently
available treatments. For example,
although the applicant compared the
UPLIZNA® dosing regimen against
Soliris®, it did not provide a similar
PO 00000
Frm 00180
Fmt 4701
Sfmt 4700
comparison against ENSPRYNGTM,
which—similar to UPLIZNA®—does not
require frequent intravenous infusions
or participation in the FDA REMS
program (see 86 FR 45020). Therefore,
we stated that it is unclear whether
UPLIZNA® provides a treatment option
for a separate patient population that is
ineligible for currently available
treatments, when there are other
available treatments, like
ENSPRYNGTM, without the limitations
that the applicant described with
respect to Soliris®. In addition, while
the applicant stated that UPLIZNA’s®
dosing regimen may help to improve
long-term patient medication adherence
and decrease the likelihood of relapse
and hospitalization, we questioned the
strength of the correlation between
UPLIZNA’s® dosing regimen and these
outcomes. We stated our interest in
additional information on the efficacy
results of UPLIZNA® among African
Americans with NMOSD, as cited by the
applicant, as we understand that
NMOSD disproportionately affects
African American and Asian
populations at rates approximately 2- to
3-fold higher than their Caucasian
counterparts.198 Specifically, we
questioned whether the retrospective
analysis of the results from the N–
MOmentum trial on the annualized
attack rate for African Americans (0.06
compared with 0.09 in the overall
group) is generalizable to larger
populations because the study included
low numbers of participants. Of the 20
African American participants
randomized in N-Momentum, 19 were
AQP4 antibody positive and 1 was
AQP4 antibody negative. As a result, of
the 19 participants, 14 received
UPLIZNA®, and only 5 received
placebo.199 200 We further noted that the
applicant did not provide comparative
data on the efficacy of UPLIZNA®,
198 Flanagan, E.P. et al. (2016, April 4).
Epidemiology of aquaporin-4 autoimmunity and
Neuromyelitis Optica Spectrum. Wiley Online
Library. Retrieved October 6, 2021, from https://
onlinelibrary.wiley.com/doi/10.1002/ana.24617.
199 Bernitsas, E., Cimbora, D., Dinh, Q., She, D.,
Katz, E. Safety and Efficacy of Inebilizumab in
African Americans with Neuromyelitis Optica
Spectrum Disorder. Poster presentation at the 15th
World Congress on Controversies in Neurology
(CONy Virtual). September 23–26, 2021.
200 Cree BAC, Bennett JL, Kim HJ, Weinshenker
BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul
F, Cutter GR, Marignier R, Green AJ, Aktas O,
Hartung HP, Lublin FD, Drappa J, Barron G, Madani
S, Ratchford JN, She D, Cimbora D, Katz E; N–
MOmentum study investigators. Inebilizumab for
the treatment of neuromyelitis optica spectrum
disorder (N–MOmentum): a double-blind,
randomised placebo-controlled phase 2/3 trial.
Lancet. 2019 Oct 12;394(10206):1352–1363. doi:
10.1016/S0140–6736(19)31817–3. Epub 2019 Sep 5.
PMID: 31495497.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Soliris®, and ENSPRYNGTM in these
populations.
We invited public comments on
whether UPLIZNA® meets the
substantial clinical improvement
criterion.
Comment: We received several
comments in support of new technology
add-on payments for UPLIZNA®,
including one from the applicant, in
response to CMS’ concerns in the
proposed rule. With respect to the
concern regarding the lack of data
comparing UPLIZNA® to existing FDAapproved treatments, the applicant
stated that conducting head-to-head
trials is often not possible when
studying rare diseases due to the small
patient populations and potential delays
if trials for the same indication are
running simultaneously. The applicant
noted that the timing and availability of
Soliris® and ENSPRYNGTM (approved
by FDA on June 27, 2019 and August 17,
2020, respectively) did not allow for
comparative trials, as there were no
approved medications for the treatment
of NMOSD for the entirety of the N–
MOmentum study. The applicant stated
that CMS has granted new technology
add-on payments in situations where
comparative head-to-head trials were
not available, referencing two
technologies without comparative
clinical data that were granted new
technology add-on payments in FY 2019
and FY 2022, as well as two additional
examples from FY 2022 that were both
FDA-approved based on the results of
single-arm clinical trials. We note that
the applicant did not identify the
specific technologies. The applicant
stated that, because these products were
granted new technology add-on
payments without direct comparative
data with their respective clinical
competitors, that substantial clinical
improvement can be ascertained
through product attributes and
randomized clinical trial outcomes in
the absence of direct, comparative headto-head trials.
With respect to the concern regarding
the lack of data demonstrating improved
outcomes over existing FDA approved
treatments, the applicant noted that N–
MOmentum is the largest-ever clinical
trial conducted in patients with
NMOSD, the results of which showed
that patients taking UPLIZNA®
experienced fewer relapses and fewer
hospitalizations than patients on
placebo. The applicant stated that
compared with placebo, patients treated
with UPLIZNA® had a reduced risk of
3-month EDSS-confirmed disability
progression (CDP). The applicant also
noted that although disability outcomes
data cannot be compared across
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
therapies, other therapies’ disability
data were studied using different
endpoints as secondary measures and/or
were not reported because of lack of
statistical significance. The applicant
referred to the PREVENT trial for
Soliris®, which studied EDSS and mRS
as secondary outcome measures up to
211 weeks and noted that there was no
significant difference in disability
progression between the Soliris® groups
and placebo. The applicant also referred
to the SakuraStar and SakuraSky trials
for ENSPRYNG and noted that no
significant effect on disability was
observed. In contrast, the applicant
stated that UPLIZNA® showed a
consistent effect in reducing the risk of
disability worsening compared to
placebo, regardless of baseline disability
status, attack history, or disease
duration. The applicant asserted that
despite head-to-head studies not being
possible at the time registrational trials
were conducted, the data and efficacy
and clinical efficiency attributes of
UPLIZNA® present an improvement for
patients over other therapies.
In response to CMS’ feedback
regarding the comparison of dosing and
long-term adherence to other available
treatments for NMOSD, the applicant
confirmed it had provided details of
dosing for Soliris® in its application and
included dosing details for
ENSPRYNGTM in its comments, noting
that ENSPRYNGTM requires more
frequent administration than
UPLIZNA®. The applicant referenced
long-term adherence data showing that
UPLIZNA® adherence was
approximately 85% after two years. The
applicant stated that the improved
medication adherence data from
analogue disease states suggest that
twice yearly dosing, as with UPLIZNA®,
is associated with improved adherence
over other regimens. The applicant also
stated that the data suggest that
adherence and persistence to therapy
may lead to improved clinical
outcomes.
In addition, the applicant
extrapolated results from a retrospective
claims analysis looking at the use of MS
disease-modifying therapies (DMTs) that
concluded that a twice-yearly dosing
schedule achieved superior adherence
and persistence at 12, 18, and 24
months versus other dosing regimens or
routes of administration. Other
commenters also mentioned the
convenient dosing schedule of
UPLIZNA®, which potentially
simplifies the lives of NMOSD patients
and thereby improves compliance,
which they noted is critical for the
prevention of disease relapse and for
ensuring good patient outcomes.
PO 00000
Frm 00181
Fmt 4701
Sfmt 4700
48959
The applicant noted that persistence
and adherence to a therapy such as
UPLIZNA® are important to achieving
positive clinical outcomes, and
reiterated that studies have shown that
relapses can lead to hospitalizations,
long-term disability, and permanent
harm to the patient. According to a
commenter, administration of
UPLIZNA® in the hospital setting,
immediately after diagnosis and acute
treatment of the relapse can be life
saving for the patient, as early treatment
leads to better outcomes and reduces
relapse rate and subsequent disability.
Commenters emphasized the potential
for permanent damage related to
relapses of NMOSD and therefore the
importance of timely treatment to
prevent relapse.
The applicant also responded to CMS’
question regarding the generalizability
of the retrospective analysis of the
efficacy results of UPLIZNA® among
Black/African American patients with
NMOSD, which the applicant provided
to support its claim that UPLIZNA® is
a new treatment option for populations
that are more likely to be impacted by
health disparities. NMOSD
disproportionately affects Black/African
American and Asian populations at
rates approximately 2-to 3-fold higher
than Caucasians. As noted in its
application, the applicant stated that the
annualized attack rates for Black/
African American participants observed
in the N–MOmentum study were
promising, despite the relatively low
number of participants in the study. The
applicant noted that the FDA Statistical
Review of UPLIZNA® confirmed that
the applicant could report subgroup
analyses based on sex, race, age, and
region and these data suggest that
UPLIZNA® is at least as effective in the
Black/African American subpopulation
as it is in the general patient population.
The applicant noted the difficulty of
enrolling large numbers of patients in
studies for rare conditions, and stated
that subgroup data provided can still
represent important considerations in
identifying a benefit in populations that
face disproportionately higher rates of
NMOSD. As is often the case with rare
diseases such as NMOSD, relatively
small numbers of participants result in
small subpopulations; however, the
applicant noted, interpreting results in
small subgroups must be done
cautiously.
Response: We thank the commenters
for their input. After further review, we
continue to have concerns as to whether
UPLIZNA® meets the substantial
clinical improvement criterion to be
approved for new technology add-on
payments. We agree with the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48960
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
commenters that timely treatment for
relapse prevention in NMOSD is
important. However, it is unclear
whether UPLIZNA® leads to improved
relapse prevention, or other improved
outcomes, as compared to other
available treatments for NMOSD. We
note that the applicant did not provide
data comparing outcomes such as time
to first relapse and number of relapses
with Soliris® or UPLIZNA®. We further
note that the applicant stated that, of the
available therapies, only UPLIZNA®
demonstrated a statistically significant
effect on disability progression
compared to placebo in its clinical trial.
However, as the applicant noted, there
were differences between the trials,
including size of the trials and disability
endpoints assessed. We believe this
makes it difficult to demonstrate
superior effect on disability progression,
especially without a comparison of
relapse rates, with which disability is
associated. We also note that time-tofirst-relapse is one endpoint that was
consistent across all three trials, and
that the results of a meta analysis
comparing published efficacy outcomes
for Soliris®, UPLIZNA®, and
ENSPRYNGTM showed that Soliris®
demonstrated greater efficacy in
prolonging time-to-relapse compared to
UPLIZNA® and ENSPRYNGTM.201
While we agree with the applicant that
substantial clinical improvement can be
determined without head-to-head trials,
we note that we evaluate every
application on its own data and merits
to determine whether it meets the new
technology add-on payment criterion for
substantial clinical improvement, and
we consider variations in the currently
available technologies that an applicant
technology is compared against for the
purposes of determining whether the
technology represents a substantial
clinical improvement over existing
technologies. We further note that it is
unclear which technologies the
applicant is referring to in stating that
CMS has previously approved new
technology add-on payments for
technologies without a demonstration of
comparative outcomes.
Furthermore, with regard to improved
adherence, while the applicant provided
information regarding UPLIZNA®
adherence, it did not compare these
values to adherence for other therapies
and therefore this information does not
support a finding of substantial clinical
improvement. Lastly, the retrospective
claims analysis the applicant provided
201 Wingerchuck, et al. Indirect comparison
analysis of FDA-approved treatment options for
adults with aquaporin–4 immunoglobulin Gpositive neuromyelitis optica spectrum disorder.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
to support a correlation between longterm medication adherence and
decreased relapse and hospitalization
assessed the adherence and persistence
of multiple sclerosis patients treated
with a drug that had the same dosing
regimen as UPLIZNA®—but not
NMOSD patients treated with
UPLIZNA®.
After review of the information
submitted by the applicant as part of its
FY 2023 new technology add-on
payment application for UPLIZNA® and
consideration of the comments received,
we are unable to determine that
UPLIZNA® meets the substantial
clinical improvement criterion for the
reasons discussed in the proposed rule
and in this final rule, and therefore we
are not approving new technology addon payments for UPLIZNA® for FY
2023.
7. FY 2023 Applications for New
Technology Add-On Payments
(Alternative Pathways)
As discussed previously, beginning
with applications for FY 2021, under
the regulations at § 412.87(c), a medical
device that is part of FDA’s
Breakthrough Devices Program and has
received marketing authorization for the
indication covered by the Breakthrough
Device designation may qualify for the
new technology add-on payment under
an alternative pathway. Additionally,
beginning with FY 2021, under the
regulations at § 412.87(d), a medical
product that is designated by FDA as a
QIDP and has received marketing
authorization for the indication covered
by the QIDP designation, and, beginning
with FY 2022, a medical product that is
a new medical product approved under
FDA’s LPAD and used for the indication
approved under the LPAD pathway,
may also qualify for the new technology
add-on payment under an alternative
pathway. Under an alternative pathway,
a technology will be considered not
substantially similar to an existing
technology for purposes of the new
technology add-on payment under the
IPPS and will not need to meet the
requirement that it represents an
advance that substantially improves,
relative to technologies previously
available, the diagnosis or treatment of
Medicare beneficiaries. These
technologies must still be within the 2–
3 year newness period to be considered
‘‘new,’’ and must also still meet the cost
criterion. We refer readers to section
II.H.8. of the preamble of the FY 2020
IPPS/LTCH PPS final rule (84 FR 42292
through 42297) and section II.F.6 of
preamble of the FY 2021 IPPS/LTCH
PPS final rule (85 FR 58715 through
58733) for further discussion of the
PO 00000
Frm 00182
Fmt 4701
Sfmt 4700
alternative new technology add-on
payment pathways for these
technologies.
We note, section 1886(d)(5)(K)(ii)(II)
of the Act provides for the collection of
data with respect to the costs of a new
medical service or technology described
in subclause (I) for a period of not less
than 2 years and not more than 3 years
beginning on the date on which an
inpatient hospital code is issued with
respect to the service or technology. Our
regulations in § 412.87(c)(2) for
breakthrough devices and § 412.87(d)(2)
for certain antimicrobial products state
that a medical device/product that
meets the condition in paragraph (c)(1)
or (d)(1) of § 412.87 will be considered
new for not less than 2 years and not
more than 3 years after the point at
which data begin to become available
reflecting the inpatient hospital code (as
defined in section 1886(d)(5)(K)(iii) of
the Act) assigned to the new technology
(depending on when a new code is
assigned and data on the new
technology become available for DRG
recalibration). After CMS has
recalibrated the DRGs, based on
available data, to reflect the costs of an
otherwise new medical technology, the
medical technology will no longer be
considered ‘‘new’’ under the criterion of
this section.
We received 19 applications for new
technology add-on payments for FY
2023 under the new technology add-on
payment alternative pathways. Six
applicants withdrew applications prior
to the issuance of the proposed rule.
Subsequently, five applicants withdrew
their respective applications for
LigaPASS 2.0 PJK Prevention System,
Magnus Neuromodulation System with
SAINT Technology, the Precision
TAVITM Coronary Module, the TOPSTM
System, and the VITARIA® System prior
to the issuance of this final rule. Two
applicants, Phagenesis Ltd. (the
applicant for Phagenyx® System) and
Neuro Event Labs, Inc. (the applicant for
the Nelli® Seizure Monitoring System),
did not meet the July 1 deadline for
FDA approval or clearance of the
technology and, therefore, the
technologies are not eligible for
consideration for new technology addon payments for FY 2023. A discussion
of the remaining 6 applications is
presented in this final rule, including 5
technologies that have received a
Breakthrough Device designation from
FDA and 1 that was designated as a
QIDP by FDA.
In accordance with the regulations
under § 412.87(e)(2), applicants for new
technology add-on payments, including
Breakthrough Devices, must have FDA
marketing authorization by July 1 of the
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
FY 2023 due to not meeting the July 1
deadline, described previously, which
were included in the FY 2023 IPPS/
LTCH PPS proposed rule. We are also
not summarizing nor responding to
public comments received regarding
these withdrawn or ineligible
applications in this final rule.
a. Alternative Pathway for Breakthrough
Devices
(1) CERAMENT® G
BONESUPPORT AB submitted an
application for new technology-add on
payments for CERAMENT® G for FY
2023. Per the applicant, CERAMENT® G
is an injectable bone-void filler made of
calcium sulfate, hydroxyapatite, and
gentamicin sulfate indicated for the
surgical treatment of osteomyelitis. Per
the applicant, this bone graft substitute
fills gaps resulting from debridement of
infected bone and prevents colonization
of sensitive bacteria, promoting bone
healing in two ways. The applicant
stated that the primary mode of action
is for CERAMENT® G to act as a
resorbable ceramic bone-void filler
intended to fill gaps and voids in the
skeleton system created when infected
bone is debrided. The applicant also
stated that the secondary mode of action
is to prevent the colonization of
gentamicin-sensitive microorganisms in
order to protect bone healing. Per the
applicant, CERAMENT® G may
eliminate the need to harvest autologous
bone, avoiding pain and infection at the
donor site. We note that
BONESUPPORT Inc. previously
submitted an application for new
technology add-on payments for
CERAMENT® G for FY 2022, as
summarized in the FY 2022 IPPS/LTCH
khammond on DSKJM1Z7X2PROD with RULES2
ICD-10-CM Code Range
M86.10 - M86.19
M86.20 - M86.29
M86.30 - M86.39
M86.40 - M86.49
M86.50 - M86.59
M86.60 - M86.69
M86.8X0 - M86.8X9
M86.9
With respect to the cost criterion, the
applicant identified candidate cases
using ICD–10–PCS procedure and ICD–
10–CM diagnosis codes, which are
detailed in the tables in this section.
With these codes identified, the
applicant then went through the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Description of Code Range
Other acute osteomyelitis
Subacute osteomyelitis
Chronic multifocal osteomyelitis
Chronic osteomyelitis with draining sinus
Other chronic hematogenous osteomyelitis
Other chronic osteomyelitis
Other osteomyelitis
Osteomyelitis, unspecified
Grouper logic in the MS–DRG v39.0
Definitions Manual and located where
cases with these codes would be
assigned in the MS–DRG system. This
process yielded 13 MS–DRGs which the
applicant used for their analysis. The
applicant also submitted an additional
PO 00000
PPS proposed rule (86 FR 25368
through 25373) but the technology did
not meet the deadline of July 1, 2021,
for FDA approval or clearance of the
technology and, therefore, was not
eligible for consideration for new
technology add-on payments for FY
2022 (86 FR 45126 through 45127).
According to the applicant,
CERAMENT® G is designated as a
Breakthrough Device for use as a bonevoid filler as an adjunct to systemic
antibiotic therapy and surgical
debridement as part of the surgical
treatment of osteomyelitis. The
technology received FDA De Novo
marketing authorization on May 17,
2022 with an indication for use as a
bone void filler in skeletally mature
patients as an adjunct to systemic
antibiotic therapy and surgical
debridement (standard treatment
approach to a bone infection) as part of
the surgical treatment of osteomyelitis
in defects in the extremities. The
applicant applied for and received a
unique ICD–10–PCS procedure code to
identify cases involving the
administration of CERAMENT® G in
2021. Effective October 1, 2021,
CERAMENT® G administration can be
identified by ICD–10–PCS procedure
code XW0V0P7 (Introduction of
antibiotic eluting bone void filler into
bones, open approach, new technology
group 7), which is unique to
CERAMENT® G administration. The
applicant stated that the following
existing ICD–10–CM codes for
osteomyelitis appropriately describe the
proposed indication for which the
device received Breakthrough Device
designation (‘‘Breakthrough Device
Indication’’):
Frm 00183
Fmt 4701
Sfmt 4700
subanalysis using only cases from the
applicant’s top three identified MS–
DRGs (464, 493, and 504), to
demonstrate that the technology meets
the cost criterion.
Under the first analysis, the applicant
searched claims in the FY 2019
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.090
year prior to the beginning of the fiscal
year for which the application is being
considered. Under the policy finalized
in the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58742), we revised the
regulations at § 412.87(e) by adding a
new paragraph (e)(3) which provides for
conditional approval for a technology
for which an application is submitted
under the alternative pathway for
certain antimicrobial products (QIDPs
and LPADs) at § 412.87(d) that does not
receive FDA marketing authorization by
the July 1 deadline specified in
§ 412.87(e)(2), provided that the
technology receives FDA marketing
authorization by July 1 of the particular
fiscal year for which the applicant
applied for new technology add-on
payments. We refer the reader to the FY
2021 IPPS/LTCH PPS final rule for a
complete discussion of this policy (85
FR 58737 through 58742).
As we did in the FY 2022 IPPS/LTCH
PPS proposed rule, for applications
under the alternative new technology
add-on payment pathway, in the FY
2023 IPPS/LTCH PPS proposed rule, we
proposed to approve or disapprove each
of these six applications for FY 2023
new technology add-on payments.
Therefore, in this section of the
preamble of this final rule, we provide
background information on each of the
remaining six alternative pathway
applications and our determinations as
to whether or not each technology is
eligible for new technology add-on
payments for FY 2023. Consistent with
our standard approach, we are not
including in this final rule the
description and discussion of
applications that were withdrawn or
that are ineligible for consideration for
48961
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
MedPAR final rule dataset within the 13
identified MS–DRGs that reported one
of the M86 ICD–10–CM diagnosis codes
listed previously in combination with
VerDate Sep<11>2014
the ICD–10–PCS procedure codes listed
in the following table, which identify
procedures that could involve the use of
CERAMENT® G as an adjunct to
systemic antibiotic therapy and surgical
debridement where there is a need for
supplemental bone void filler material.
BILLING CODE 4120–01–P
ICD-10-PCS Code
0PBK0ZZ
0PBL0ZZ
0PDK0ZZ
0PDL0ZZ
0PBC0ZZ
0PBD0ZZ
0PBF0ZZ
0PBG0ZZ
0PDF0ZZ
0PDG0ZZ
0PTC0ZZ
0PTD0ZZ
0PTF0ZZ
0PTG0ZZ
0PCC0ZZ
0PCF0ZZ
0PCG0ZZ
0PDC0ZZ
0PDD0ZZ
0PDF0ZZ
0PDG0ZZ
0QBG0ZZ
0QBH0ZZ
0QBJOZZ
0QBK0ZZ
0QCG0ZZ
0QCH0ZZ
0QCJOZZ
0QCK0ZZ
0QDG0ZZ
0QDH0ZZ
0QDJOZZ
0QDK0ZZ
OPCD0ZZ
0MR507Z
0MR50JZ
0MR50KZ
0P9H00Z
0P9J00Z
0P9K00Z
0P9L00Z
0PCH0ZZ
0PCJ0ZZ
Description
Excision of right ulna, open approach
Excision of left ulna, open approach
Extraction of right ulna, open approach
Extraction of left ulna, open approach
Excision of right humeral head, open approach
Excision of left humeral head, open approach
Excision of right humeral shaft, open approach
Excision of left humeral shaft, open approach
Extraction of right humeral shaft, open approach
Extraction of left humeral shaft, open approach
Resection of right humeral head, open approach
Resection of left humeral head, open approach
Resection of right humeral shaft, open approach
Extraction of left humeral shaft, open approach
Extirpation of matter from right humeral head, open approach
Extirpation of matter from right humeral shaft, open approach
Extirpation of matter from left humeral shaft, open approach
Extraction of right humeral head, open approach
Extraction of left humeral head, open approach
Extraction of right humeral shaft, open approach
Extraction of left humeral shaft, open approach
Excision of right tibia, open approach
Excision of left tibia, open approach
Excision of right fibula, open approach
Excision of left fibula, open approach
Extirpation of matter from right tibia, open approach
Extirpation of matter from left tibia, open approach
Extirpation of matter from right fibula, open approach
Extirpation of matter from left fibula, open approach
Extraction of right tibia, open approach
Extraction of left tibia, open approach
Extraction of right fibula, open approach
Extraction of left fibula, open approach
Extirpation of matter from left humeral head, open approach
Replace of r wrist bursa/lig with autol sub, open approach
Replace of r wrist bursa/lig with svnth sub, open approach
Replace of r wrist bursa/lig with nonautol sub, open approach
Drainage of right radius, open approach
Drainage of left radius, open approach
Drainage of right ulna, open approach
Drainage of left ulna, open approach
Extirpation of matter from right radius, open approach
Extirpation of matter from left radius, open approach
00:20 Aug 10, 2022
PO 00000
Jkt 256001
Frm 00184
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.091
48962
ICD-10-PCS Code
0PCK0ZZ
0PCL0ZZ
0PCMOZZ
0PCN0ZZ
0Q9200Z
0Q9300Z
0Q9400Z
0Q9500Z
0QC20ZZ
0QC30ZZ
0QC40ZZ
0QC50ZZ
0PC9C0ZZ
0P9D00Z
0P9F00Z
0P9G00Z
0Q9G00Z
0Q9H00Z
0Q9JO0Z
0Q9K00Z
0QCG0ZZ
0QCJ0ZZ
0S9F00Z
0S9G00Z
0P9700Z
0P9800Z
0P9C00Z
0P9D00Z
0P5H0ZZ
0P5JOZZ
0PBH0ZZ
0PBJOZZ
0Q9600Z
0Q9700Z
0Q9800Z
0Q9900Z
0Q9B00Z
0Q9C00Z
0Q9D00Z
0Q9F00Z
0QB80ZZ
0QB90ZZ
0QBB0ZZ
0QBC0ZZ
0QBG0ZZ
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
48963
Description
Extirpation of matter from right ulna, open approach
Extirpation of matter from left ulna, open approach
Extirpation of matter from right carpal, open approach
Extirpation of matter from left carpal, open approach
Drainage of right pelvic bone, open approach
Drainage of right pelvic bone with drain dev, perc approach
Drainage of r pelvic bone with drain dev, perc endo approach
Drainage of left acetabulum, open approach
Extirpation of matter from right pelvic bone, open approach
Extirpation of matter from left pelvic bone, open approach
Extirpation of matter from right acetabulum, open approach
Extirpation of matter from left acetabulum, open approach
Drainage of right humeral head, open approach
Drainage of left humeral head, open approach
Drainage of right humeral shaft, open approach
Drainage of left humeral shaft, open approach
Drainage of right tibia, open approach
Drainage of left tibia, open approach
Drainage of right fibula, open approach
Drainage of left fibula, open approach
Extirpation of matter from right tibia, open approach
Extirpation of matter from right fibula, open approach
Drainage of right ankle joint, open approach
Drainage of left ankle joint, open approach
Drainage of r glenoid cav with drain dev, open approach
Drainage of 1glenoid cav with drain dev, open approach
Drainage ofright humeral head with drain dev, open approach
Drainage of left humeral head with drain dev, open approach
Destruction of right radius, open approach
Destruction of left radius, open approach
Excision of right radius, open approach
Excision of left radius, open approach
Drainage of right upper femur, open approach
Drainage of left upper femur, open approach
Drainage of right femoral shaft, open approach
Drainage of left femoral shaft, open approach
Drainage of right lower femur, open approach
Drainage of left lower femur, open approach
Drainage of right patella, open approach
Drainage of left patella, open approach
Excision of right femoral shaft, open approach
Excision of left femoral shaft, open approach
Excision of right lower femur, open approach
Excision of left lower femur, open approach
Excision of right tibia, open approach
PO 00000
Frm 00185
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.092
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ICD-10-PCS Code
0QBH0ZZ
0QBJ0ZZ
0QBK0ZZ
0QB60ZZ
0QD80ZZ
0QD90ZZ
0QDBOZZ
0QDC0ZZ
0QDG0ZZ
0QDH0ZZ
0QDJ0ZZ
0QDK0ZZ
0Q560ZZ
0Q570ZZ
0QB60ZZ
0QB70ZZ
0QC70ZZ
0QD20ZZ
0QD30ZZ
0QD60ZZ
0QD70ZZ
0QC60ZZ
0QT60ZZ
0QT70ZZ
0QBM0ZZ
0QDL0ZZ
0QDM0ZZ
0Q9N00Z
0Q9P00Z
0QBP0ZZ
0QDN0ZZ
0QDP0ZZ
0P5K0ZZ
0P5L0ZZ
0PBK0ZZ
0PBL0ZZ
0PDK0ZZ
0PDL0ZZ
0PBH0ZZ
0PBJOZZ
0PDH0ZZ
0PDJ0ZZ
0PCH0ZZ
0PCJOZZ
0PCK0ZZ
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Description
Excision of left tibia, open approach
Excision of right fibula, open approach
Excision of left fibula, open approach
Excision of right upper femur, open approach
Extraction of right femoral shaft, open approach
Extraction of left femoral shaft, open approach
Extraction of right lower femur, open approach
Extraction of left lower femur, open approach
Extraction of right tibia, open approach
Extraction of left tibia, open approach
Extraction of right fibula, open approach
Extraction of left fibula, open approach
Destruction of right upper femur, open approach
Destruction of left upper femur, open aooroach
Excision of right upper femur, open approach
Excision of left upper femur, open approach
Extirpation of matter from left upper femur, open approach
Extraction of right pelvic bone, open approach
Extraction of left pelvic bone, open approach
Extraction of right upper femur, open approach
Extraction of left upper femur, open approach
Extirpation of matter from right upper femur, open approach
Resection of right upper femur, open approach
Resection of left upper femur, open approach
Excision of left tarsal, open approach
Extraction of right tarsal, open approach
Extraction of left tarsal, open approach
Drainage of right metatarsal, open approach
Drainage of left metatarsal, open approach
Excision of left metatarsal, open approach
Extraction of right metatarsal, open approach
Extraction of left metatarsal, open approach
Destruction of right ulna, open approach
Destruction of left ulna, open approach
Excision of right ulna, open approach
Excision of left ulna, open approach
Extraction of right ulna, open approach
Extraction of left ulna, open approach
Excision of right radius, open approach
Excision of left radius, open approach
Extraction of right radius, open approach
Extraction of left radius, open approach
Extirpation of matter from right radius, open approach
Extirpation of matter from left radius, open approach
Extirpation of matter from right ulna, open approach
PO 00000
Frm 00186
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.093
khammond on DSKJM1Z7X2PROD with RULES2
48964
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ICD-10-PCS Code
0PCL0ZZ
0PC90ZZ
0PCB0ZZ
0PD90ZZ
0PDB0ZZ
0PB90ZZ
0PBB0ZZ
0PC50ZZ
0PC60ZZ
0PD50ZZ
0PD60ZZ
0PB50ZZ
0PB60ZZ
0PB73ZZ
0PB74ZZ
0PB83ZZ
0PB84ZZ
0QBR0ZZ
48965
Desc
Excision of
Excision of
Excision of
Excision of
Excision of
Excision of
Excision of
0QDR0ZZ
The applicant identified 11,620 cases
across 13 MS–DRGs as identified in the
table that follows:
Description
Wound Debridement and Skin Graft Except Hand for Musculoskeletal System and Connective Tissue Disorders with MCC
Wound Debridement and Skin Graft Except Hand for Musculoskeletal System and Connective Tissue Disorders with CC
Lower Extremity and Humerus Procedures Except Hip, Foot and Femur with MCC
Lower Extremity and Humerus Procedures Except Hip, Foot and Femur with CC
Local Excision and Removal oflntemal Fixation Devices Except Hip and Femur with MCC
Local Excision and Removal oflntemal Fixation Devices Except Hip and Femur with CC
Local Excision and Removal Internal Fixation Devices of Hip and Femur with CC/MCC
Foot Procedures with MCC
Foot Procedures with CC
Shoulder, Elbow or Forearm Procedures, Except Mai or Joint Procedures with MCC
Shoulder, Elbow or Forearm Procedures, Exceot Mai or Joint Procedures with CC
Other Musculoskeletal Svstem and Connective Tissue O.R. Procedures with MCC
Other Musculoskeletal Svstem and Connective Tissue O.R. Procedures with CC
khammond on DSKJM1Z7X2PROD with RULES2
BILLING CODE 4120–01–C
The applicant noted that candidate
cases for CERAMENT® G with
osteomyelitis would qualify for the CC/
MCC MS–DRGs because osteomyelitis is
listed in the Grouper as a CC condition.
Therefore, the applicant concluded that
cases with osteomyelitis would not be
grouped in the uncomplicated MS–
DRGs (for example, 465, 494, etc.). The
applicant stated that because
osteomyelitis is never assigned to
uncomplicated surgical MS–DRGs, it
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
excluded uncomplicated MS–DRGs
from its analysis.
The applicant then removed charges
for the prior technology that may be
replaced by CERAMENT® G. The
applicant conducted a market analysis
that identified 3 types of prior
technology devices: Poly(methyl
methacrylate) (PMMA) manually mixed
with antibiotics, PMMA pre-loaded with
antibiotics, and calcium sulfate (CaS)
mixed with antibiotics. The applicant
researched the average sales price (ASP)
for major competitors for 5cc and 10cc
PO 00000
Frm 00187
Fmt 4701
Sfmt 4700
of each device type and calculated a
weighted average cost of $444 per 5cc
and $727 per 10cc.202 Then the
applicant converted costs to charges by
dividing costs by the Supplies &
202 The applicant’s analysis was informed by 2019
and 2020 data for Osteoset, Stimulan, and Calcigen
S (calcium sulfates mixed with antibiotics), Palacos,
Cobalt (PMMA manually mixed with antibiotics),
Cobalt G, Biomet Bone Cement R, and Refobacin
Bone Cement R (PMMA pre-loaded with antibiotics)
from three sources: an iData Market Research 2019
Sku Data Report, Global Data US Hospital Bone
Grafts and Substitutes Q3 2019 Report, and
feedback from sales representatives in the field.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.095
463
464
492
493
495
496
498
503
504
510
511
515
516
ER10AU22.094
MS-DRG
khammond on DSKJM1Z7X2PROD with RULES2
48966
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Equipment CCR of 0.297 (86 FR 44966).
Using this CCR, $444 per 5cc and $727
per 10cc yielded an estimated hospital
charge of prior technologies of $1,495
per 5cc and $2,449 per 10cc. The
applicant explained that the total
amount of antibiotics depends on the
amount of product required for different
sized bones. The applicant then
standardized the charges and applied a
4-year inflation factor of 1.281834 based
on the inflation factor used to update
the outlier threshold in the FY 2022
IPPS/LTCH PPS final rule (86 FR
45542).
The applicant added estimated
charges for the new technology by
dividing the estimated, expected
hospital list price for the device (based
on expected 5/10/15 cc costs for
CERAMENT® G, by MS–DRG), by the
aforementioned Supplies & Equipment
CCR of 0.297.
The applicant calculated a final
inflated case-weighted average
standardized charge per case of
$135,258 and an average case-weighted
threshold of $86,603. Because the final
inflated average case-weighted
standardized charge per case exceeded
the average case-weighted threshold
amount, the applicant asserted that the
technology meets the cost criterion.
The applicant also provided an
alternate cost analysis using the
applicant’s top three identified MS–
DRGs (464, 493, and 504), which
together constituted more than half of
the applicant’s identified cases. Using
the same methodology and data sources
noted previously, the applicant
calculated a final inflated case-weighted
average standardized charge per case of
$112,316 and an average case-weighted
threshold of $77,375. The applicant
maintained that CERAMENT® G meets
the cost criterion under this alternate
analysis.
We stated in the proposed rule that
we agree with the applicant that
CERAMENT® G meets the cost criterion
and therefore, subject to the technology
receiving FDA marketing authorization
for use as a bone-void filler as an
adjunct to systemic antibiotic therapy
and surgical debridement as part of the
surgical treatment of osteomyelitis by
July 1, 2022, we proposed to approve
CERAMENT® G for new technology
add-on payments for FY 2023.
Based on preliminary information
from the applicant at the time of the
proposed rule, the total cost of
CERAMENT® G for a typical patient was
determined to be $7,567 per procedure.
Per the applicant, the amount of
CERAMENT® G used per patient
depends on the complexity of the
patient’s injury, subsequent
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
comorbidities, as well as the location
and size of the bone void. The applicant
expects that an average patient will
require ∼10cc per procedure, based on
the case weighted volume of expected
utilization across the MS–DRGs. From
this weighted average, the applicant
derived the average, weighted cost of
$7,567 per patient. We noted that the
cost information for this technology may
be updated in the final rule based on
revised or additional information CMS
receives prior to the final rule. Under
§ 412.88(a)(2), we limit new technology
add-on payments to the lesser of 65% of
the average cost of the technology, or
65% of the costs in excess of the MS–
DRG payment for the case. As a result,
we proposed that the maximum new
technology add-on payment for a case
involving the use of the product
CERAMENT® G would be $4,918.55 for
FY 2022 (that is, 65% of the average cost
of the technology).
We invited public comments on
whether CERAMENT® G meets the cost
criterion and our proposal to approve
new technology add-on payments for
CERAMENT® G for FY 2023, subject to
CERAMENT® G receiving FDA
marketing authorization for use as a
bone-void filler as an adjunct to
systemic antibiotic therapy and surgical
debridement as part of the surgical
treatment of osteomyelitis by July 1,
2022.
Comment: We received a public
comment urging CMS to finalize its
proposals to approve new technology
add-on payments for multiple
technologies for FY 2023, including
CERAMENT G®, in order to foster
innovation and make life and abilitysaving devices more readily available to
patients.
Response: We appreciate the
comment.
Based on the information provided in
the application for new technology addon payments, we believe CERAMENT®
G meets the cost criterion. The
technology received FDA De Novo
marketing authorization on May 17,
2022 with an indication for use as a
bone void filler in skeletally mature
patients as an adjunct to systemic
antibiotic therapy and surgical
debridement (standard treatment
approach to a bone infection) as part of
the surgical treatment of osteomyelitis
in defects in the extremities, that is
covered by its Breakthrough Device
designation. Therefore, we are finalizing
our proposal to approve new technology
add-on payments for CERAMENT® G for
FY 2023. We consider the beginning of
the newness period to commence on
May 17, 2022, the date on which the
technology received its FDA De Novo
PO 00000
Frm 00188
Fmt 4701
Sfmt 4700
marketing authorization for the
indication covered by its Breakthrough
Device designation.
Based on the information available at
the time of this final rule, the cost per
case of CERAMENT® G is $7,567.00.
Under § 412.88(a)(2), we limit new
technology add-on payments to the
lesser of 65% of the average cost of the
technology, or 65% of the costs in
excess of the MS–DRG payment for the
case. As a result, we are finalizing that
the maximum new technology add-on
payment for a case involving the use of
CERAMENT® G is $4,918.55 for FY
2023 (that is, 65% of the average cost of
the technology). Cases involving the use
of CERAMENT® G that are eligible for
new technology add-on payments will
be identified by ICD–10–PCS procedure
code XW0V0P7 (Introduction of
antibiotic-eluting bone void filler into
bones, open approach, new technology
group 7).
(2) GORE® TAG® Thoracic Branch
Endoprosthesis (TBE Device)
W.L. Gore and Associates, Inc.,
submitted an application for new
technology add-on payments for the
GORE® TAG® Thoracic Branch
Endoprosthesis (TBE) device for FY
2023. According to the applicant, the
GORE® TAG® TBE device is a modular
device consisting of three components,
an Aortic Component, a Side Branch
Component, and an optional Aortic
Extender Component, each of which is
pre-mounted on a catheter delivery
system for treatment of thoracic aortic
aneurysms, traumatic aortic transection,
and aortic dissection.
According to the applicant, the
GORE® TAG® TBE device was granted
designation under the Expedited Access
Pathway (EAP) by FDA (and is therefore
considered part of the Breakthrough
Devices Program by FDA) on July 17,
2015, for endovascular repair of
descending thoracic aortic and aortic
arch for patients who have appropriate
anatomy. The applicant indicated that it
anticipated receiving premarket
approval of the GORE® TAG® TBE
device as a Class III device from FDA in
Spring 2022 with a proposed indication
for endovascular repair of lesions of the
descending thoracic aorta, while
maintaining flow into the left
subclavian artery, in patients who have
adequate iliac/femoral access, and
eligible proximal aorta, left subclavian,
or distal landing zones (isolated lesion
patients only). We noted in the
proposed rule that since the indication
for which the applicant anticipated
receiving premarket approval was
included within the scope of the EAP
designation, it appeared that the
E:\FR\FM\10AUR2.SGM
10AUR2
48967
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
proposed PMA indication was
appropriate for new technology add-on
payment under the alternative pathway
criteria. Subsequently, the applicant
received premarket approval on May 13,
2022 with an indication for
endovascular repair of lesions of the
descending thoracic aorta, while
maintaining flow into the left
subclavian artery, in patients who are at
high risk for debranching subclavian
procedures and who have appropriate
anatomy, which is within the scope of
the EAP designation.
The applicant noted that a
combination of two existing ICD–10–
PCS procedure codes can be used to
uniquely identify the GORE® TAG®
TBE: 02VW4EZ (Restriction of thoracic
aorta, descending with branched or
fenestrated intraluminal device, one or
two arteries, percutaneous endoscopic
approach), in combination with
02VX4EZ (Restriction of thoracic aorta,
ascending/arch with branched or
fenestrated intraluminal device, one or
two arteries, percutaneous endoscopic
approach). Per the applicant, the GORE®
TAG® TBE device is placed such that it
straddles two anatomic regions, the
descending thoracic aorta and thoracic
aortic arch, thereby necessitating the use
of both ICD–10–PCS procedure codes to
accurately describe the use of the
device.
With regard to the cost criterion, the
applicant searched the FY 2019
MedPAR dataset from the FY 2022 IPPS
proposed rule for cases reporting a
combination of a thoracic endovascular
repair (TEVAR) procedure and a bypass
procedure. The applicant listed the
following ICD–10–PCS codes for TEVAR
procedures and bypass procedures,
which the applicant used to identify
potential cases that may be eligible for
treatment with the GORE® TAG® TBE
device. Per the applicant, cases with at
least one ICD–10–PCS procedure code
from each category were included in the
analysis.
02VW3DZ
02VW4DZ
roach
03140JK
03140KK
03140ZK
03150Jl
03160JK
031J0JK
031J0N
03S40ZZ
The applicant identified 210 cases
mapping to five MS–DRGs. The
applicant then removed charges for the
technology being replaced. The
applicant stated that the use of TAG®
Conformable devices in cases that also
use the GORE® TAG® TBE device is
entirely dependent on the patient’s
anatomy. The applicant explained that
the average case utilizing the GORE®
TAG® TBE device uses 0.6 TAG®
Conformable devices, compared to an
average of 1.4 TAG® Conformable
devices per procedure for current
TEVAR cases, resulting in a difference
of 0.8 TAG® Conformable devices which
will no longer be used in cases utilizing
the GORE® TAG® TBE device.
Accordingly, 80% of all device implant
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
charges were removed from the claims
to be conservative, per the applicant.
The applicant then removed other
charges related to the prior technology.
According to the applicant, a research
study 203 that compared 24 patients
treated with TBE to 31 patients treated
with the traditional method at one
facility found that TBE device cases
have a 19% reduction in operating room
(OR) time compared to the OR time for
the combined procedures (TEVAR with
a bypass procedure), and a 48%
203 Shultze W, Baxter R, Gable C, et al.
Comparison Of Surgical Debranching Versus
Branched Endografts In Zone 2 TEVAR. Oral
presentation at the Society for Vascular Surgery
Meeting; March 2021, Miami FL. https://
symposium.scvs.org/abstracts/2021/M76.cgi.
PO 00000
Frm 00189
Fmt 4701
Sfmt 4700
41.0%
36.7%
11.9%
5.2%
5.2%
reduction in length of stay. Accordingly,
the applicant removed 19% of OR
charges (revenue code 0360), removed
48% of routine charges (revenue code
01XX) when a claim showed routine
charges, and removed 48% of intensive
care unit (ICU) charges if a claim
included no routine charges. The
applicant then standardized the charges
and applied a 4-year inflation factor of
1.2818 based on the inflation factor used
in the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45538), to update the
charges from FY 2019 to FY 2023. The
applicant then added charges for the
new technology by dividing the average
per patient cost of the GORE® TAG®
TBE device by the national CCR for
implantable devices (0.293) from the FY
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.097
Cardiac Valve and Other Maior Cardiothoracic Procedures without Cardiac Catheterization with CC
Cardiac Valve and Other Mai or Cardiothoracic Procedures without Cardiac Catheterization with MCC
Cardiac Valve and Other Maior Cardiothoracic Procedures without Cardiac Catheterization without CC/MCC
ECMO or Tracheostomv with MV >96 Hours or Principal Diagnosis Except Face, Mouth and Neck with Mai or O.R. Procedures
Cardiac Valve and Other Major Cardiothoracic Procedures with Cardiac Catheterization with MCC
ER10AU22.096
khammond on DSKJM1Z7X2PROD with RULES2
220
219
221
003
216
roach
khammond on DSKJM1Z7X2PROD with RULES2
48968
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
2022 IPPS/LTCH PPS final rule (86 FR
44966). The applicant calculated a final
inflated case-weighted average
standardized charge per case of
$400,515 and an average case-weighted
threshold of $217,182. Because the final
inflated average case-weighted
standardized charge per case exceeded
the average case-weighted threshold
amount, the applicant asserted that the
technology meets the cost criterion.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28324), we noted
that the charges removed for prior
technology are based on length of stay
in a small study conducted at a single
institution. Specifically, the study
involved 24 patients who received the
TBE device during elective procedures
and 31 who had the procedures with
bypass. Three of these procedures were
emergent and only 14 and 17,
respectively, were procedures in Zone 2
where the GORE® TAG® TBE would be
indicated. Given the small percentage of
procedures that directly relate to the
proposed GORE® TAG® TBE indication,
we questioned the extent to which these
results are generalizable to the cost
analysis performed above and the
greater Medicare population.
Additionally, the applicant did not
specify the revenue codes used to
identify and remove intensive care unit
charges. We noted the applicant listed
two ICD–10–PCS codes (03S43ZZ and
03SQ3ZZ) in their analysis which are
percutaneous procedures and
questioned whether the inclusion of
these codes was appropriate as the
devices currently used to repair the
aortic arch require the creation of a
bypass performed in an open surgery.
We also questioned whether the cases
that the applicant identified were
appropriately representative of cases
eligible for treatment with GORE®
TAG® TBE and requested additional
information to clarify this issue.
Subject to the applicant adequately
addressing these concerns, we stated in
the proposed rule that we agreed that
the technology meets the cost criterion
and therefore proposed to approve the
GORE® TAG® TBE device for new
technology add-on payments for FY
2023, subject to the technology
receiving FDA marketing authorization
for the proposed indication by July 1,
2022.
Based on preliminary information
from the applicant at the time of the
proposed rule, the per-patient
anticipated hospital cost of the GORE®
TAG® TBE device was $42,780. We
noted that the cost information for this
technology may be updated in the final
rule based on revised or additional
information CMS receives prior to the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
final rule. Under § 412.88(a)(2), we limit
new technology add-on payments to the
lesser of 65% of the average cost of the
technology, or 65% of the costs in
excess of the MS–DRG payment for the
case. In the proposed rule, we stated
that in the event we were to receive
supplemental information from the
applicant to adequately address our
concerns regarding the cost criterion,
and we were to approve new technology
add-on payments for the GORE® TAG®
TBE device in the final rule, the
maximum new technology add-on
payment for a case involving the use of
the GORE® TAG® TBE device would be
$27,807 for FY 2023 (that is, 65% of the
average cost of the technology).
We invited public comments on
whether the GORE® TAG® TBE device
meets the cost criterion and our
proposal to approve new technology
add-on payments for the GORE® TAG®
TBE device for FY 2023, subject to the
technology receiving FDA marketing
authorization for the proposed
indication that corresponds to the EAP
designation by July 1, 2022.
Comment: The applicant provided
comments and a revised cost analysis in
response to CMS’ concerns identified in
the proposed rule. With respect to the
concern that the charges removed for
prior technology were based on length
of stay in a small study conducted at a
single institution, the applicant stated
that the pivotal trial for the GORE®
TAG® TBE device was conducted at 40
U.S. sites and the separate outcome substudy was based at a site that had the
highest numbers of enrolled
participants. In addition, the applicant
stated that the length of stay and length
of time in the ICU was similar for all
sites in the clinical trial and therefore
the cost estimates from a single
institution are reflective of the cost of
care provided at other sites.
With respect to the concern about
results being generalizable to the greater
Medicare population, the applicant
stated that the median age of outcome
sub-study participants was 65 years, and
that half of all participants were of
Medicare-eligible age. The applicant
also noted that the outcome sub-study
population (24 GORE® TAG® TBE
patients and 31 SR–TEVAR patients)
represented more than a quarter of a
total of 202 GORE® TAG® TBE-eligible
cases in the FY 2019 Medicare claims.
Per the applicant, this sample of the 202
eligible cases in the FY 2019 Medicare
claims is large enough to appropriately
estimate the costs associated with the
GORE® TAG® TBE procedure and that,
based on the median age, the estimate
is generalizable to the Medicare
population.
PO 00000
Frm 00190
Fmt 4701
Sfmt 4700
With respect to the concern as to
whether the cases identified by the
applicant were appropriately
representative of cases eligible for
treatment with GORE® TAG® TBE, the
applicant stated that the GORE® TAG®
TBE device replaces two separate
operating room procedures: a left
subclavian artery (SA) bypass
procedure, usually an open surgery, and
a percutaneous thoracic endograft
implant procedure, commonly referred
to as SR–TEVAR, because it contains a
branched element that is inserted into
the left subclavian artery thereby
maintaining blood flow and eliminating
the need for a SA bypass procedure. The
applicant stated that the outcome substudy provides information on resource
use differences between patients
undergoing TBE procedures compared
to a combination of surgical
revascularization and thoracic endograft
implant. The applicant stated that
including cases that involved both
procedures (that is, the SA bypass
procedure and the TEVAR procedure) in
the cost criterion analysis and removing
100% of device charges as well as other
related service charges (19% of OR
charges and 48% of routine care
charges) better reflects the estimate of
the GORE® TAG® TBE standardized
charges. In the updated analysis, the
applicant removed 100% of all device
charges from the MedPAR cases
compared to removing 80%, which it
did in its original application.
The applicant further indicated that
while every patient presentation of
aortic disease is unique in length, type,
and severity of disease, all patients in
the outcome sub-study had serious
aortic disease that needed repair in the
left subclavian artery, even if cases were
characterized as an elective surgery for
purposes of the study reporting. The
applicant also stated that the ends of the
device must exceed the length of the
diseased aorta on both ends, the
proximal and distal locations of the
implanted device varied, depending on
the length of the aortic disease, and as
such, the devices can span several
zones. The applicant further noted that
all cases, emergent or elective, had
similar resource use.
With respect to the concern that the
revenue codes used to identify and
remove intensive care unit charges were
not specified, the applicant stated that
it used CMS revenue codes 020x and
021x to identify intensive care unit
charges in the rate-setting methodology.
We note that revenue code descriptions
for 021x and 021x are Intensive Care
Unit and Coronary Care Unit,
respectively.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
With respect to our inquiry about the
inclusion of two codes for percutaneous
procedures, the applicant explained that
it included the two percutaneous
approach codes in its original cost
analysis in order to pick up all bypass
surgery codes. The applicant then
explained that eliminating these two
codes from the inclusion criteria for the
revised analysis excluded only one case.
The applicant noted that removing the
one percutaneous SA bypass case
limited the revised cost criterion
analysis to only those cases where the
subclavian artery bypass surgery was
coded as an open approach.
The applicant reported that the
updated cost criterion analysis resulted
in a threshold amount of $217,080 and
a new standardized charge estimate of
$377,857. The applicant stated that the
new standardized charge estimate still
greatly exceeds the new technology addon payment threshold and the GORE®
TAG® TBE device meets the cost
criterion requirement.
The applicant also stated that upon
further consultation with clinical
experts, the better combination of ICD–
10–PCS codes to identify cases utilizing
the technology would be 02VW3DZ
(Restriction of thoracic aorta,
descending with intraluminal device,
percutaneous approach), in combination
with 02VX3EZ (restriction of thoracic
aorta, ascending/arch with branched or
fenestrated intraluminal device, one or
two arteries, percutaneous approach)
and requested that these codes be used
to identify the GORE® TAG® TBE for
purposes of new technology add-on
payment instead of the codes included
in the proposed rule.
Another commenter familiar with the
applicant’s cost study submitted a
public comment reiterating the
applicant’s statements regarding the
characteristics of the single institution
upon which the applicant’s cost
analysis was based, disease severity in
the patient population, the uniform
requirement of Zone 2 repair despite
variation of distal zones treated, and
generalizability of the study population
to the Medicare population. Based on
the results achieved for patients
receiving the TBE graft as compared to
the TEVAR and subclavian artery
bypass, this commenter recommended
that CMS approve the GORE® TAG®
TBE for new technology add on
payments.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Response: We thank the commenters
for their comments and appreciate the
additional clarification regarding the
cost criterion. Based on the information
provided in the application for new
technology add-on payments, and after
consideration of the public comments
we received, we believe the GORE®
TAG® Thoracic Branch Endoprosthesis
(TBE) meets the cost criterion. GORE®
TAG® TBE received marketing
authorization from FDA on May 13,
2022 for the indication covered by its
Breakthrough Device designation for
endovascular repair of lesions of the
descending thoracic aorta, while
maintaining flow into the left
subclavian artery, in patients who are at
high risk for debranching subclavian
procedures and who have appropriate
anatomy. Therefore, we are finalizing
our proposal to approve new technology
add-on payments for the GORE® TAG®
TBE for FY 2023 and we consider the
beginning of the newness period to
commence on May 13, 2022, which is
the date on which the technology
received FDA marketing authorization
for the indication covered by its
Breakthrough Device designation.
Based on the information at the time
of this final rule, the cost per case of the
GORE® TAG® TBE is $42,780. Under
§ 412.88(a)(2), we limit new technology
add-on payments to the lesser of 65% of
the average cost of the technology, or
65% of the costs in excess of the MS
DRG payment for the case. As a result,
we are finalizing that the maximum new
technology add-on payment for a case
involving the use of the GORE® TAG®
TBE is $27,807 for FY 2023 (that is, 65%
of the average cost of the technology).
Cases involving the use of GORE® TAG®
TBE that are eligible for new technology
add-on payments will be identified by
ICD–10–PCS codes: 02VW3DZ
(Restriction of thoracic aorta,
descending with intraluminal device,
percutaneous approach) in combination
with 02VX3EZ (Restriction of thoracic
aorta, ascending/arch with branched or
fenestrated intraluminal device, one or
two arteries, percutaneous approach).
(3) iFuse Bedrock Granite Implant
System
SI–BONE, Inc., submitted an
application for new technology add-on
payments for the iFuse Bedrock Granite
Implant System for FY 2023. According
to the applicant, the iFuse Bedrock
Granite Implant System is a sterile,
PO 00000
Frm 00191
Fmt 4701
Sfmt 4700
48969
single-use permanent implant intended
to provide sacropelvic fusion of the
sacroiliac joint and fixation to the pelvis
when used in conjunction with
commercially available pedicle screw
fixation systems as a foundational
element for segmental spinal fusion.
The applicant stated that the joint
fusion occurs as a result of the device’s
porous surface and interstices, and
fixation occurs through the device’s
helical threaded design and traditional
posterior fixation rod connection. Per
the applicant, the iFuse Bedrock Granite
Implant System can be placed into the
pelvis in two trajectories: sacroalar-iliac
(SAI) trajectory (that is, into the sacrum,
across the SI joint and into the ilium) or
directly into the ilium, and joint fusion
occurs only when the SAI trajectory is
used.
According to the applicant, the iFuse
Bedrock Granite Implant System
received FDA Breakthrough Device
designation on November 23, 2021 for
sacropelvic fixation and as an adjunct
for sacroiliac joint fusion (when used
with commercially available sacroiliac
joint fusion promoting devices) in
conjunction with commercially
available posterior pedicle screw
systems for the treatment of the acute
and chronic instabilities or deformities
of the thoracic, lumbar, and sacral
spine; degenerative disc disease (DDD)
as defined by back pain of discogenic
origin with degeneration of the disc
confirmed by patient history and
radiographic studies; severe
spondylolisthesis (Grades 3 and 4) of
the L5–S1 vertebra in skeletally mature
patients receiving fusions by autogenous
bone graft having implants attached to
the lumbar and sacral spine (L3 to
sacrum) with removal of the implants
after the attainment of a solid fusion;
spondylolisthesis; trauma (that is,
fracture or dislocation); spinal stenosis;
deformities or curvatures (that is,
scoliosis, kyphosis, and/or lordosis);
spinal tumor; pseudarthrosis; and/or
failed previous fusion. Subsequently,
the iFuse Bedrock Granite Implant
System received 510(k) clearance from
FDA on May 26, 2022 (K220195) for the
same indication.
The applicant stated that ICD–10–PCS
codes that may be utilized to describe
the placement of an internal fixation
device into the pelvic bone or
acetabulum, listed in the following
table, do not distinctly identify the
iFuse Bedrock Granite Implant System.
E:\FR\FM\10AUR2.SGM
10AUR2
48970
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
0SG734Z
0SG834Z
0SG804Z
0SG704Z
The applicant submitted a request to
the ICD–10 Coordination and
Maintenance Committee for approval of
XNH6058
XNH6358
XNH7058
XNH7358
XRGE058
XRGE358
XRGF058
XRGF358
the following procedure codes effective
October 1, 2022:
Insertion of internal fixation device with tulip connector into right pelvic bone, open
a roach, new technolo
rou 8
Insertion of internal fixation device with tulip connector into right pelvic bone,
ercutaneous a roach, new technolo
rou 8
Insertion of internal fixation device with tulip connector into left pelvic bone, open
a roach, new technolo
rou 8
Insertion of internal fixation device with tulip connector into left pelvic bone,
ercutaneous a roach, new technolo
rou 8
Fusion of right sacroiliac joint using internal fixation device with tulip connector,
o en a roach, new technolo
rou 8
Fusion of right sacroiliac joint using internal fixation device with tulip connector,
ercutaneous a roach, new technolo
rou 8
Fusion of left sacroiliac joint using internal fixation device with tulip connector,
o en a roach, new technolo
rou 8
Fusion of left sacroiliac joint using internal fixation device with tulip connector,
ercutaneous a roach, new technolo
rou 8
utilized, the applicant searched the FY
2019 MedPAR final rule file for claims
reporting a combination of at least one
of the ICD–10–PCS procedure codes for
the placement of an internal fixation
device into the pelvic bone or
acetabulum, noted previously, and at
least one of the following ICD–10–CM
diagnosis codes used to describe the
indication under the Breakthrough
Device designation.
BILLING CODE 4120–01–P
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00192
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.098
ER10AU22.099
With regard to the cost criterion, the
applicant conducted two analyses based
on 100% of identified claims and 78%
of identified claims. To identify
potential cases where the iFuse Bedrock
Granite Implant System could be
khammond on DSKJM1Z7X2PROD with RULES2
a unique code for FY 2023 and was
granted approval to identify the iFuse
Bedrock Granite Implant System using
M40.00
M40.04
M40.05
M40.10
M40.13
M40.14
M40.15
M40.204
M40.205
M40.209
M40.294
M40.295
M40.35
M40.36
M40.37
M40.40
M40.45
M40.46
M40.47
M40.55
M40.56
M40.57
M41.124
M41.125
M41.126
M41.127
M41.129
M41.20
M41.24
M41.25
M41.26
M41.27
M41.30
M41.34
M41.35
M41.40
M41.45
M41.46
M41.47
M41.50
M41.54
M41.55
M41.56
M41.57
M41.84
M41.85
M41.86
M41.87
M42.10
M42.14
VerDate Sep<11>2014
00:20 Aug 10, 2022
48971
Postural kyphosis, site unspecified
Postural kyphosis, thoracic region
Postural kyphosis, thoracolumbar region
Other secondarv kyphosis, site unspecified
Other secondarv kyphosis, cervicothoracic region
Other secondarv kyphosis, thoracic region
Other secondarv kyphosis, thoracolumbar region
Unspecified kyphosis, thoracic region
Unspecified kvohosis, thoracolumbar region
Unspecified kyphosis, site unspecified
Other kyphosis, thoracic region
Other kyphosis, thoracolumbar region
Flatback syndrome, thoracolumbar region
Flatback syndrome, lumbar region
Flatback syndrome, lumbosacral region
Postural lordosis, site unspecified
Postural lordosis, thoracolumbar region
Postural lordosis, lumbar region
Postural lordosis, lumbosacral region
Lordosis, unspecified, thoracolumbar region
Lordosis, unspecified, lumbar region
Lordosis, unspecified, lumbosacral region
Adolescent idiopathic scoliosis, thoracic region
Adolescent idiopathic scoliosis, thoracolumbar region
Adolescent idiopathic scoliosis, lumbar region
Adolescent idiopathic scoliosis, lumbosacral region
Adolescent idiopathic scoliosis, site unspecified
Other idiopathic scoliosis, site unspecified
Other idiopathic scoliosis, thoracic region
Other idiopathic scoliosis, thoracolumbar region
Other idiopathic scoliosis, lumbar region
Other idiopathic scoliosis, lumbosacral region
Thoracogenic scoliosis, site unspecified
Thoracogenic scoliosis, thoracic region
Thoracogenic scoliosis, thoracolumbar region
Neuromuscular scoliosis, site unspecified
Neuromuscular scoliosis, thoracolumbar region
Neuromuscular scoliosis, lumbar region
Neuromuscular scoliosis, lumbosacral region
Other secondarv scoliosis, site unspecified
Other secondarv scoliosis, thoracic region
Other secondarv scoliosis, thoracolumbar region
Other secondarv scoliosis, lumbar region
Other secondarv scoliosis, lumbosacral region
Other forms of scoliosis, thoracic region
Other forms of scoliosis, thoracolumbar region
Other forms of scoliosis, lumbar region
Other forms of scoliosis, lumbosacral region
Adult osteochondrosis of spine, site unspecified
Adult osteochondrosis of spine, thoracic region
Jkt 256001
PO 00000
Frm 00193
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.100
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
48972
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
M42.16
M42.17
M42.18
M42.19
M43.15
M43.16
M43.17
M43.18
M43.19
M43.8X5
M43.8X6
M43.8X7
M43.8X8
M43.8X9
M43.9
M48.26
M48.27
M48.36
M48.37
M53.2X6
M53.2X7
M53.2X8
M53.3
ies,
ies,
ies,
ies,
lumbar re ion
lumbosacral
sacral a
site uns
10n
re 10n
1 disorders, not elsewhere classified
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00194
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.101
khammond on DSKJM1Z7X2PROD with RULES2
For the analysis using 100% of cases,
the applicant identified 2,165 cases
mapping to the following 26 MS–DRGs:
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
S inal Procedures with CC or S inal Neurostimulators
Other Vascular Procedures with MCC
Combined Anterior and Posterior S inal Fusion with MCC
Combined Anterior and Posterior S inal Fusion with CC
Combined Anterior and Posterior S inal Fusion without CC/MCC
Other Musculoskeletal S stem and Connective Tissue O.R. Procedures with MCC
Other Musculoskeletal S stem and Connective Tissue O.R. Procedures with CC
Other Musculoskeletal S stem and Connective Tissue O.R. Procedures without CC/MCC
Other Endocrine, Nutritional and Metabolic O.R. Procedures with MCC
Infectious and Parasitic Diseases with O.R. Procedures with MCC
Infectious and Parasitic Diseases with O.R. Procedures with CC
Posto erative or Post-Traumatic Infections with O.R. Procedures with MCC
Other O.R. Procedures for In"uries with MCC
Other O.R. Procedures for Jn"uries with CC
Other O.R. Procedures for Multiple Significant Trauma with MCC
khammond on DSKJM1Z7X2PROD with RULES2
BILLING CODE 4120–01–C
The applicant then removed 50% of
the charges associated with medical
supplies and implantable devices
(revenue centers 027x and 0624). The
applicant stated that the removal of 50%
of the charges associated with medical
supplies and implantable devices
reflects a conservative estimate as the
iFuse Bedrock Granite Implant System
is used in conjunction with
commercially available pedicle screw
fixation systems as a foundational
element for segmental spinal fusion.
The applicant then standardized the
charges and applied the three-year
inflation factor of 20.4% used to update
the outlier threshold in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45542)
to update the charges from FY 2019 to
FY 2022. The applicant then added
charges for the new technology by
dividing the per-patient anticipated
hospital cost of the iFuse Bedrock
Granite Implant System by the national
average cost-to-charge ratio for
implantable devices (0.239) from the FY
2022 IPPS/LTCH PPS final rule. Under
the analysis based on 100% of identified
claims, the applicant calculated a final
inflated case-weighted average
standardized charge per case of
$254,264 and an average case-weighted
threshold of $159,841.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
For the analysis using 78% of cases,
the applicant identified 1,682 cases
mapping to 4 MS–DRGs. The applicant
conducted the same analysis noted
previously and determined a final
inflated case-weighted average
standardized charge per case of
$253,333 and an average case-weighted
threshold of $164,561. Because the final
inflated case-weighted average
standardized charge per case exceeded
the average case-weighted threshold
amount under both analyses, the
applicant asserted that the technology
meets the cost criterion.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28327), we agreed
with the applicant that iFuse Bedrock
Granite Implant System meets the cost
criterion and therefore we proposed to
approve the iFuse Bedrock Granite
Implant System for new technology addon payments for FY 2023, subject to the
technology receiving FDA marketing
authorization for the indication
corresponding to the Breakthrough
Device designation by July 1, 2022.
Based on preliminary information
from the applicant at the time of the
proposed rule, the per-patient
anticipated hospital cost of the iFuse
Bedrock Granite Implant System was
$15,120. We noted that the cost
information for this technology may be
PO 00000
Frm 00195
Fmt 4701
Sfmt 4700
updated in the final rule based on
revised or additional information CMS
receives prior to the final rule. Under
§ 412.88(a)(2), we limit new technology
add-on payments to the lesser of 65% of
the average cost of the technology, or
65% of the costs in excess of the MS–
DRG payment for the case. As a result,
we proposed that the maximum new
technology add-on payment for a case
involving the use of the iFuse Bedrock
Granite Implant System would be
$9,828 for FY 2023 (that is, 65% of the
average cost of the technology).
We invited public comments on
whether the iFuse Bedrock Granite
Implant System meets the cost criterion
and our proposal to approve new
technology add-on payments for the
iFuse Bedrock Granite Implant System
for FY 2023, subject to the technology
receiving FDA marketing authorization
for the indication corresponding to the
Breakthrough Device designation by
July 1, 2022.
Comment: We received a few
comments supporting CMS’ proposal to
approve the iFuse Bedrock Granite
Implant System for new technology addon payments. One of the commenters
also agreed with CMS that the
technology meets the cost criterion.
Response: We appreciate the input
from the commenters.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.102
252
453
454
455
456
457
458
459
460
496
515
516
517
518
519
628
853
854
856
907
908
957
981
982
48973
48974
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Based on the information provided in
the application for new technology addon payments, and after consideration of
the public comments we received, we
believe the iFuse Bedrock Granite
Implant System meets the cost criterion.
The iFuse Bedrock Granite Implant
System received marketing
authorization from FDA on May 26,
2022 for the indication covered by the
Breakthrough Device designation, for
sacropelvic fixation and as an adjunct
for sacroiliac joint fusion (when used
with commercially available sacroiliac
joint fusion promoting devices) in
conjunction with commercially
available posterior pedicle screw
systems for the treatment of the acute
and chronic instabilities or deformities
of the thoracic, lumbar, and sacral
spine; degenerative disc disease (DDD)
as defined by back pain of discogenic
origin with degeneration of the disc
XNH6358
XNH7058
XNH7358
XRGE058
XRGE358
XRGF058
XRGF358
Insertion of internal fixation device with tulip connector into right pelvic bone, open
a roach, new technolo
rou 8
Insertion of internal fixation device with tulip connector into right pelvic bone,
ercutaneous a roach, new technolo
rou 8
Insertion of internal fixation device with tulip connector into left pelvic bone, open
a roach, new technolo
rou 8
Insertion of internal fixation device with tulip connector into left pelvic bone,
ercutaneous a roach, new technolo
rou 8
Fusion of right sacroiliac joint using internal fixation device with tulip connector,
o en a roach, new technolo
rou 8
Fusion of right sacroiliac joint using internal fixation device with tulip connector,
ercutaneous a roach, new technolo
rou 8
Fusion of left sacroiliac joint using internal fixation device with tulip connector,
o en a roach, new technolo
rou 8
Fusion of left sacroiliac joint using internal fixation device with tulip connector,
ercutaneous a roach, new technolo
rou 8
khammond on DSKJM1Z7X2PROD with RULES2
(4) ThoraflexTM Hybrid Device
Terumo Aortic submitted an
application for new technology-add on
payments for the ThoraflexTM Hybrid
Device for FY 2023. Per the applicant,
the device is a sterile single-use, gelatin
sealed Frozen Elephant Trunk (FET)
surgical medical device. The applicant
explained that the device is deployed
through an opened aortic arch and then
positioned into the descending thoracic
aorta. The applicant further explained
that, once it is completely deployed, the
collar is sutured to the aorta, and graft
anastomoses are then performed in a
manner depending upon the chosen
product design (which the applicant
specified as either the Plexus or the
Ante-Flo). The device includes a
VerDate Sep<11>2014
00:20 Aug 10, 2022
for the indication covered by its
Breakthrough Device designation.
Based on the information at the time
of this final rule, the cost per case of the
iFuse Bedrock Granite Implant System
is $15,120. Under § 412.88(a)(2), we
limit new technology add-on payments
to the lesser of 65% of the average cost
of the technology, or 65% of the costs
in excess of the MS–DRG payment for
the case. As a result, we are finalizing
that the maximum new technology addon payment for a case involving the use
of the iFuse Bedrock Granite Implant
System is $9,828 for FY 2023 (that is,
65% of the average cost of the
technology). Cases involving the use of
the iFuse Bedrock Granite Implant
System that are eligible for new
technology add-on payments will be
identified by one of the following ICD–
10– PCS codes:
Jkt 256001
proximal crimped polyester surgical
graft, central polyester collar, and distal
nitinol ring stents supported by thin
wall polyester fabric. The applicant also
noted that the device has a unique
gelatin sealant that acts as a seal,
preventing blood loss through the
polyester fabric product wall. We note
that Terumo Aortic previously
submitted an application for new
technology add-on payments for the
ThoraflexTM Hybrid Device for FY 2022,
as summarized in the FY 2022 IPPS/
LTCH PPS proposed rule (86 FR 25390)
which was withdrawn prior to the
issuance of the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45127).
According to the applicant, the
ThoraflexTM Hybrid Device received
Breakthrough Device designation on
PO 00000
Frm 00196
Fmt 4701
Sfmt 4700
March 20, 2020 for the open surgical
repair or replacement of damaged or
diseased vessels of the aortic arch and
descending aorta, with or without
involvement of the ascending aorta, in
cases of aneurysm and/or dissection.
The applicant received FDA marketing
authorization on April 19, 2022 for the
same indication as the Breakthrough
Device designation. According to the
applicant, the ICD–10 Coordination and
Maintenance Committee approved the
following ICD–10–PCS codes to
specifically describe the use of the
ThoraflexTM Hybrid Device, effective
October 1, 2021: X2RX0N7
(Replacement of thoracic aorta arch with
branched synthetic substitute with
intraluminal device, new technology
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.103
XNH6058
confirmed by patient history and
radiographic studies; severe
spondylolisthesis (Grades 3 and 4) of
the L5–S1 vertebra in skeletally mature
patients receiving fusions by autogenous
bone graft having implants attached to
the lumbar and sacral spine (L3 to
sacrum) with removal of the implants
after the attainment of a solid fusion;
spondylolisthesis; trauma (that is,
fracture or dislocation); spinal stenosis;
deformities or curvatures (that is,
scoliosis, kyphosis, and/or lordosis);
spinal tumor; pseudarthrosis; and/or
failed previous fusion. Therefore, we are
finalizing our proposal to approve new
technology add-on payments for the
iFuse Bedrock Granite Implant System
for FY 2023, and we consider the
beginning of the newness period to
commence on May 26, 2022, which is
the date on which the technology
received FDA marketing authorization
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
group 7) and X2VW0N7 (Restriction of
thoracic descending aorta with
branched synthetic substitute with
intraluminal device, new technology
group 7).
With respect to the cost criterion, the
applicant conducted two analyses based
on 100% of identified claims and 74%
of identified claims. To identify
potential cases where the ThoraflexTM
Hybrid Device could be utilized, the
applicant searched the FY 2019
MedPAR file for claims reporting the
following ICD–10–PCS codes for
thoracic aortic replacement procedures:
02RX08Z (Replacement of thoracic
aorta, ascending/arch with zooplastic
tissue, open approach), 02RX0JZ
(Replacement of thoracic aorta,
ascending/arch with synthetic tissue,
open approach), and 02RX0KZ
(Replacement of thoracic aorta,
ascending/arch with nonautologous
tissue substitute, open approach).
For the analysis using 100% of cases,
the applicant identified 5,374 cases
mapping to 21 MS–DRGs. The applicant
then removed charges for the technology
being replaced. Per the applicant, the
use of the ThoraflexTM Hybrid device is
expected to replace a portion of prior
technologies. The applicant explained
that because an estimate of the
percentage of these total charges that
would be replaced could not be
determined, it removed 100% of charges
associated with medical/surgical
supplies and devices (revenue centers
027x and 0624). The applicant then
standardized the charges and applied
the 3-year outlier inflation factor of
1.204686 used to update the outlier
threshold in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45542) to update
the charges from FY 2019 to FY 2022.
The applicant then added charges for
the new technology. The applicant
multiplied the cost of the technology by
the national cost-to-charge ratio for
implantable devices from the FY 2022
IPPS/LTCH PPS final rule (0.293) to
calculate estimated average hospital
charges associated with the device.
Under this analysis, based on 100% of
identified claims, the applicant
calculated a final inflated case-weighted
average standardized charge per case of
$420,924 and an average case-weighted
threshold of $230,659.
Under the analysis based on 74% of
cases, the applicant used the same
methodology, which identified 3,980
cases across MS–DRGs 219 and 220. The
applicant determined the average caseweighted threshold of $211,423 and a
final inflated average standardized
charge per case of $373,273. Because the
final inflated case-weighted average
standardized charge per case exceeded
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the average case-weighted threshold
amount under both analyses, the
applicant asserted that the technology
meets the cost criterion.
In the proposed rule, we stated that
we agree with the applicant that the
ThoraflexTM Hybrid Device meets the
cost criterion and therefore proposed to
approve the ThoraflexTM Hybrid Device
for new technology add-on payments for
FY 2023, subject to the technology
receiving FDA marketing authorization
for the open surgical repair or
replacement of damaged or diseased
vessels of the aortic arch and
descending aorta, with or without
involvement of the ascending aorta, in
cases of aneurysm and/or dissection by
July 1, 2022.
Based on preliminary information
from the applicant at the time of the
proposed rule, the cost of the
ThoraflexTM Hybrid Device was $35,000
per patient. We noted that the cost
information for this technology may be
updated in the final rule based on
revised or additional information CMS
receives prior to the final rule. Under
§ 412.88(a)(2), we limit new technology
add-on payments to the lesser of 65% of
the average cost of the technology, or
65% of the costs in excess of the MS–
DRG payment for the case. As a result,
we proposed that the maximum new
technology add-on payment for a case
involving the use of ThoraflexTM Hybrid
Device would be $22,750 per patient for
FY 2023 (that is, 65% of the average cost
of the technology).
We invited public comments on
whether the ThoraflexTM Hybrid Device
meets the cost criterion and our
proposal to approve new technology
add-on payments for the ThoraflexTM
Hybrid Device for FY 2023, subject to
the ThoraflexTM Hybrid Device
receiving FDA marketing authorization
by July 1, 2022 for the open surgical
repair or replacement of damaged or
diseased vessels of the aortic arch and
descending aorta, with or without
involvement of the ascending aorta, in
cases of aneurysm and/or dissection.
Comment: The applicant submitted a
public comment expressing support for
the approval of the ThoraflexTM Hybrid
Device for the new technology add-on
payment for FY 2023. The applicant
emphasized that both X2RX0N7
(Replacement of thoracic aorta arch with
branched synthetic substitute with
intraluminal device, new technology
group 7) and X2VW0N7 (Restriction of
thoracic descending aorta with
branched synthetic substitute with
intraluminal device, new technology
group 7) need to be reported
concurrently to appropriately describe
PO 00000
Frm 00197
Fmt 4701
Sfmt 4700
48975
the implant procedure for the
ThoraflexTM Hybrid Device.
Response: We appreciate the
applicant’s support.
Based on the information provided in
the application for new technology addon payments, and after consideration of
the public comments we received, we
believe the ThoraflexTM Hybrid Device
meets the cost criterion. The
ThoraflexTM Hybrid Device received
marketing authorization from FDA on
April 19, 2022 for the indications
covered by its Breakthrough Device
designation for the open surgical repair
or replacement of damaged or diseased
vessels of the aortic arch and
descending aorta, with or without
involvement of the ascending aorta, in
cases of aneurysm and/or dissection.
Therefore, we are finalizing our
proposal to approve new technology
add-on payments for the ThoraflexTM
Hybrid Device for FY 2023, and we
consider the beginning of the newness
period to commence on April 19, 2022,
which is the date on which the
technology received FDA marketing
authorization for the indication covered
by its Breakthrough Device designation.
Based on the information at the time
of this final rule, the cost per case of the
ThoraflexTM Hybrid Device is $35,000
per patient. Under § 412.88(a)(2), we
limit new technology add-on payments
to the lesser of 65% of the average cost
of the technology, or 65% of the costs
in excess of the MS DRG payment for
the case. As a result, we are finalizing
that the maximum new technology addon payment for a case involving the use
of the ThoraflexTM Hybrid Device is
$22,750 for FY 2023 (that is, 65% of the
average cost of the technology). Cases
involving the use of the ThoraflexTM
Hybrid Device that are eligible for new
technology add-on payments will be
identified by the ICD–10–PCS code
X2RX0N7 (Replacement of thoracic
aorta arch with branched synthetic
substitute with intraluminal device,
new technology group 7) in combination
with the ICD–10–PCS code X2VW0N7
(Restriction of thoracic descending aorta
with branched synthetic substitute with
intraluminal device, new technology
group 7).
(5) ViviStim® Paired VNS System
MicroTransponder, Inc. submitted an
application for new technology add-on
payments for the ViviStim® Paired VNS
System for FY 2023. According to the
applicant, the ViviStim® Paired VNS
System is a paired vagus nerve
stimulation therapy intended to
stimulate the vagus nerve during
rehabilitation therapy to reduce upper
extremity motor deficits and improve
E:\FR\FM\10AUR2.SGM
10AUR2
48976
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
motor function in chronic ischemic
stroke patients with moderate to severe
arm impairment. The applicant stated
that the Vivistim® Paired VNS System is
comprised of an Implantable Pulse
Generator (IPG), an implantable
stimulation Lead, and an external paired
stimulation controller which is
composed of the external Wireless
Transmitter (WT) and the external
Stroke Application and Programming
Software (SAPS). According to the
applicant, the external paired
stimulation controller (SAPS and WT)
enables the implanted components (the
IPG and Lead) to stimulate the vagus
nerve during rehabilitation. The
applicant stated that patients undergo
25–30 hours of in-clinic rehabilitation
over 6 weeks, where the ViviStim®
Paired VNS System is actively paired
with rehabilitation by a therapist. The
applicant further stated that following
this in-clinic rehabilitation period,
when directed by a physician and with
appropriate programming to the IPG, the
patient can initiate at-home use by
swiping a magnet over the IPG implant
site which activates the IPG to deliver
stimulation while rehabilitation
movements are performed.
The applicant stated that the
ViviStim® Paired VNS System was
designated as a Breakthrough Device on
Descri tion
cerebral infarction affectin
cerebral infarction affectin
cerebral infarction affectin
cerebral infarction affectin
cerebral infarction affectin
Hemi
Hemi
Hemi
Hemi
Hemi
cerebral infarction affectin
With respect to the cost criterion, the
applicant presented the following
analysis. The applicant searched the FY
2019 MedPAR claims data set released
with the FY 2022 IPPS/LTCH PPS final
rule for cases representing patients who
may be eligible for the ViviStim® Paired
VNS System. The applicant identified
cases reporting the ICD–10–PCS codes
0JH60BZ and 00HE0MZ in combination
with one of the ICD–10–CM diagnosis
codes, noted previously, describing
moderate to severe upper limb
impairment. The applicant then mapped
the cases to the appropriate MS–DRGs
using MS–DRG Grouper Version 39.0.
After imputing a case count of 11 for
VerDate Sep<11>2014
applicant submitted a request to the
ICD–10 Coordination and Maintenance
Committee for approval of a unique
code for FY 2022 to identify insertion of
the ViviStim® Paired VNS System and
was granted approval for the following
procedure code effective October 1,
2022: X0HQ3R8 (Insertion of
neurostimulator lead with paired
stimulation system into vagus nerve,
percutaneous approach, new technology
group 8).
The applicant also provided the ICD–
10–CM diagnosis codes in the table that
follows. The applicant stated that
moderate to severe upper limb
impairment is described in the ICD–10–
CM as monoplegia (single limb) or
hemiplegia (single laterality, including
upper limb). The applicant stated that
the FY 2021 ICD–10–CM code set 204
includes monoplegia and hemiplegia as
a sequela of infarction (stroke), and
delineates codes based upon stroke type
(hemorrhagic versus ischemic).
Therefore, the applicant stated that the
ICD–10–CM diagnosis codes in the
following table describe chronic
moderate to severe upper arm
impairment as a sequela of ischemic
stroke, and are related to the use of the
ViviStim® Paired VNS System.
00:20 Aug 10, 2022
Jkt 256001
those MS–DRGs with fewer than 11
cases, the applicant identified 285
claims mapping to 12 MS–DRGs, with
65% of cases mapping to MS–DRGs 024
(Craniotomy with Major Device Implant
or Acute Complex CNS Principal
Diagnosis without MCC), 041
(Peripheral Cranial Nerve and Other
Nervous System Procedures with CC or
Peripheral Neurostimulator) and 042
(Peripheral Cranial Nerve and Other
Nervous System Procedures without
CC/MCC).
204 https://www.cms.gov/medicare/icd-10/2021icd-10-cm, effective October 1, 2020 through
September 30, 2021.
PO 00000
Frm 00198
Fmt 4701
Sfmt 4700
The applicant then removed 100% of
charges associated with Medical/
Surgical Supplies and Devices (prior
technology, revenue centers 027X, and
0624). The applicant asserted that the
use of the Vivistim® Paired VNS System
is expected to replace the majority of
existing technologies, although some
devices would still be required to
perform the procedure. The applicant
stated that because it could not
determine the estimated percentage of
the total charges that would be replaced,
it removed 100% of these total charges
to be as conservative as possible. The
applicant did not remove charges
related to the technology being replaced,
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.104
khammond on DSKJM1Z7X2PROD with RULES2
ICD-10-CM
169.331
169.332
169.333
169.334
169.339
169.351
169.352
169.353
169.354
169.359
February 10, 2021 for use in stimulating
the vagus nerve during rehabilitation
therapy in order to reduce upper
extremity motor deficits and improve
motor function in chronic ischemic
stroke patients with moderate to severe
arm impairment. According to the
applicant, the ViviStim® Paired VNS
System received FDA premarket
approval on August 27, 2021 as a Class
III implantable device for the same
indication. The applicant stated that the
technology became commercially
available on April 29, 2022 due to
manufacturing delays.
According to the applicant, there are
no unique ICD–10–PCS procedure codes
to report the implantation of the device.
The applicant noted that together the
following two ICD–10–PCS codes
describe the insertion of the ViviStim®
Paired VNS System: 0JH60BZ (Insertion
of single array stimulator generator into
chest subcutaneous tissue and fascia,
open approach) and 00HE0MZ
(Insertion of neurostimulator lead into
cranial nerve, open approach). The
applicant noted that these codes may be
used for any cranial nerve stimulator
insertion procedure, including VNS
therapy for treatment resistant
depression, VNS therapy for refractory
epilepsy, and upper airway stimulation
to treat obstructive sleep apnea. The
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
stating that the financial impact of
utilizing the Vivistim® Paired VNS
System on hospital resources compared
to prior technologies other than on
Medical Supplies is minimal, and that
100% of charges for Medical/Surgical
Supplies had been removed in the
previous step.
The applicant standardized the
charges by applying the three-year
inflation factor of 1.20469 used in the
FY 2022 IPPS/LTCH PPS final rule and
correction notice to calculate outlier
threshold charges (86 FR 45542). The
applicant then added charges for the
new technology by dividing the cost of
the ViviStim® Paired VNS System by
the national average CCR for
implantable devices which is 0.293 as
published in the FY 2022 IPPS/LTCH
IPPS final rule (86 FR 44966). The
applicant calculated a final inflated
average case-weighted standardized
charge per case of $200,398 which
exceeded the average case-weighted
threshold amount of $107,963. Because
the final inflated average case-weighted
standardized charge per case exceeded
the average case-weighted threshold
amount, the applicant maintained that
the ViviStim® Paired VNS System meets
the cost criterion.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28350), we agreed
with the applicant that the ViviStim®
Paired VNS System meets the cost
criterion and therefore proposed to
approve the ViviStim® Paired VNS
System for new technology add-on
payments for FY 2023.
Based on preliminary information
from the applicant at the time of the
proposed rule, the total cost of the
ViviStim® Paired VNS System to the
hospital was $36,000 per patient.
According to the applicant, this cost
represents the entire per-patient cost of
the system to hospital providers—
specifically for the cost of the
Implantable Pulse Generator and
stimulation lead. Per the applicant,
there is no charge associated with the
external paired stimulation controller
and the magnet/take-home patient
programmer. The applicant stated that
the external paired stimulation
controller may be used on multiple
patients and that it retains a service
agreement with each provider to own,
maintain, and update the hardware and
software that resides on that device
component. The applicant has also
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
stated that they have this service
agreement with providers for the
magnet/take-home patient programmer.
Therefore, as the applicant has stated
they retain and maintain the reusable
hardware components at no charge to
the providers, we stated that it appeared
that capital components were not
included in the cost of the technology.
We welcomed public comment on the
cost information provided by the
applicant for the purpose of calculating
the new technology add-on payment
amount.
We noted that the cost information for
this technology may be updated in the
final rule based on revised or additional
information CMS receives prior to the
final rule. Under § 412.88(a)(2), we limit
new technology add-on payments to the
lesser of 65% of the average cost of the
technology, or 65% of the costs in
excess of the MS–DRG payment for the
case. As a result, we proposed that the
maximum new technology add-on
payment for a case involving the use of
the ViviStim® Paired VNS System
would be $23,400 for FY 2023 (that is,
65% of the average cost of the
technology).
We invited public comments on
whether the ViviStim® Paired VNS
System meets the cost criterion and our
proposal to approve new technology
add-on payments for the ViviStim®
Paired VNS System for FY 2023 for use
in stimulating the vagus nerve during
rehabilitation therapy in order to reduce
upper extremity motor deficits and
improve motor function in chronic
ischemic stroke patients with moderate
to severe arm impairment.
Comment: We received a few
comments supporting our proposal to
approve new technology add-on
payments for FY 2023. The applicant
also noted that the ViviStim® Paired
VNS System received FDA premarket
approval on August 27, 2021; however,
a manufacturing delay prevented market
availability of the device until April 29,
2022. The applicant requested that CMS
begin the newness period for the
Vivistim® Paired VNS System using the
latter market availability date of April
29, 2022. The applicant also supported
our proposed maximum new technology
add-on payment amount.
Response: We thank the commenters
for their support and feedback. We agree
that the newness date for this
technology is the date on which
PO 00000
Frm 00199
Fmt 4701
Sfmt 4700
48977
ViviStim® Paired VNS System became
available on the market, April 29, 2022.
We note that though, generally, our
policy is to begin the newness period on
the date of FDA approval or clearance,
we may consider a documented delay in
the technology’s market availability in
our determination of newness (77 FR
53348 and 70 FR 47341).
Based on the information provided in
the application for new technology addon payments, and after consideration of
the public comments we received, we
believe the ViviStim® Paired VNS
System meets the cost criterion.
Therefore, we are finalizing our
proposal to approve new technology
add-on payments for the ViviStim®
Paired VNS System for FY 2023, and we
consider the beginning of the newness
period to commence on April 29, 2022,
which is when the technology became
commercially available for the
indication covered by its Breakthrough
Device designation, for use in
stimulating the vagus nerve during
rehabilitation therapy in order to reduce
upper extremity motor deficits and
improve motor function in chronic
ischemic stroke patients with moderate
to severe arm impairment.
Based on the information at the time
of this final rule, the cost per case of the
ViviStim® Paired VNS System is
$36,000. According to the applicant,
this cost represents the entire perpatient cost of the system to hospital
providers, specifically for the
implantable pulse generator and
stimulation lead. Under § 412.88(a)(2),
we limit new technology add-on
payments to the lesser of 65% of the
average cost of the technology, or 65%
of the costs in excess of the MS DRG
payment for the case. As a result, we are
finalizing that the maximum new
technology add-on payment for a case
involving the use of the ViviStim®
Paired VNS System would be $23,400
for FY 2023 (that is, 65% of the average
cost of the technology). Cases involving
the use of the ViviStim® Paired VNS
System that are eligible for new
technology add-on payments will be
identified by the ICD–10–PCS procedure
code X0HQ3R8 (Insertion of
neurostimulator lead with paired
stimulation system into vagus nerve,
percutaneous approach, new technology
group 8).
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
b. Alternative Pathways for Qualified
Infectious Disease Products (QIDPs)
(1) DefenCathTM (Solution of
Taurolidine (13.5 mg/mL) and Heparin
(1000 USP Units/mL))
CorMedix Inc. submitted an
application for new technology add-on
payments for DefenCathTM (solution of
taurolidine (13.5 mg/mL) and heparin
(1000 USP Units/mL)) for FY 2023. The
applicant stated that DefenCathTM is a
proprietary formulation of taurolidine, a
thiadiazinane antimicrobial, and
heparin, an anti-coagulant, that is under
development for use as catheter lock
solution, with the aim of reducing the
risk of catheter-related bloodstream
infections (CRBI) from in-dwelling
catheters in patients undergoing
hemodialysis (HD) through a central
venous catheter (CVC). According to the
applicant, in vitro studies of
DefenCathTM indicate broad
antimicrobial activity against grampositive and gram-negative bacteria,
including antibiotic resistant strains as
well as mycobacteria and clinically
relevant fungi. The applicant stated that
DefenCathTM is available in a singledose vial, which is sufficient to fill both
lumens of the HD catheter, and is
instilled into the catheter lumen as a
lock solution at the conclusion of each
dialysis session and aspirated at the
beginning of the next dialysis session.
The applicant noted that DefenCathTM
cannot be flushed or injected into the
patient and that dosing is calibrated to
the volume of the catheter lumens.
Per the applicant, DefenCathTM was
designated by FDA as a QIDP in 2015
for the prevention of CRBSI in patients
with end-stage renal disease (ESRD)
receiving HD through a central venous
catheter, and has been granted FDA Fast
Track status. The applicant indicated
that it is pursuing an NDA under FDA’s
LPAD for the same indication, which
the applicant also stated received
Priority Review. The applicant noted
that FDA issued a Complete Response
Letter in 2021 denying the NDA due to
concerns with the third-party
manufacturing facility. The applicant
stated that the NDA has been
resubmitted and anticipates approval in
the third quarter of CY 2022.205 We note
that, as an application submitted under
the alternative pathway for certain
antimicrobial products at § 412.87(d),
DefenCathTM is eligible for conditional
approval for new technology add-on
payments if it does not receive FDA
khammond on DSKJM1Z7X2PROD with RULES2
ICD-10-CM
N17.0
N17.9
N18.1
N18.2
N18.30
Nl8.31
Nl8.32
Nl8.4
Nl8.5
Nl8.6
N18.9
Description
Acute kidney failure with tubular necrosis
Acute kidney failure, unspecified
Chronic kidney disease, stage 1
Chronic kidney disease, stage 2 (mild)
Chronic kidney disease, stage 3 unspecified
Chronic kidney disease, stage 3a
Chronic kidney disease, stage 3b
Chronic kidney disease, stage 4 (severe)
Chronic kidney disease, stage 5
End stage renal disease
Chronic kidney disease, unspecified
Per the applicant, DefenCathTM will
be used for patients receiving HD
through a CVC. The applicant stated
that coding to identify this population is
difficult because the available CVC
codes only describe the insertion of a
CVC. The applicant asserted that it is
not possible to identify in the MedPAR
file those patients who had previously
received a CVC and are now
hospitalized and receiving HD.
Therefore, the applicant developed two
sets of selection criteria: claims with
codes for HD (Analysis A) and claims
with codes for both HD and CVC
(Analysis B). The applicant asserted that
Analysis A overstates the population of
patients eligible for DefenCathTM
because it includes any patient
receiving HD, regardless of whether a
central venous catheter is used. The
applicant also asserted that Analysis B
undercounts the potential cases because
205 The statement in the proposed rule (87 FR
28350) that the applicant anticipated approval
before July 1, 2022 was in error and has been
corrected here.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
marketing authorization by the July 1
deadline specified in § 412.87(e)(2),
provided that the technology receives
FDA marketing authorization by July 1
of the particular fiscal year for which
the applicant applied for new
technology add-on payments (that is,
July 1, 2023).
The applicant applied for and
received a unique ICD–10–PCS
procedure code to identify cases
involving the administration of
DefenCathTM in 2022. Effective October
1, 2022, DefenCathTM administration
can be identified by ICD–10–PCS
procedure XY0YX28 (Extracorporeal
introduction of taurolidine antiinfective and heparin anticoagulant,
new technology group 8).
With regard to the cost criterion, the
applicant provided two analyses to
demonstrate that DefenCathTM meets the
cost criterion. The applicant first
searched the FY 2019 MedPAR file
released with the FY 2022 IPPS/LTCH
PPS final rule for claims based on the
presence of one of the following ICD–
10–CM diagnosis codes used to identify
ESRD, chronic kidney disease (CKD),
acute kidney injury (AKI) or acute
tubular necrosis (ATN).
PO 00000
Frm 00200
Fmt 4701
Sfmt 4700
CVC codes are not always available on
inpatient claims.
In the first analysis (Analysis A),
which included only claims with codes
for chronic HD, the applicant searched
for claims based on the presence of one
of the ICD–10–CM diagnosis codes
previously listed and then limited the
selection criteria to claims including
ICD–10–CM diagnosis code Z49.31
(encounter for adequacy testing for HD)
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.105
48978
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
48979
or one of the following ICD–10–PCS
procedure codes for HD:
ICD-10-PCS
5AID00Z
5AID60Z
5AID70Z
5AID80Z
5AID90Z
Performance of urin
filtration, intermittent, less than 6 hours
Performance of urin
After imputing a case count of 11 to
any MS–DRG with fewer than 11 cases
in the FY 2019 MedPAR file released
MS-DRG
871
291
640
252
314
682
193
377
853
280
673
189
391
304
246
981
308
286
870
637
with the FY 2022 IPPS final rule, the
applicant identified a total of 490,790
cases mapping to 512 MS–DRGs. The
following table shows the top 20 MS–
DRGs, which account for 57% of all
cases included in Analysis A.
Description
Septicemia or Severe Sepsis without MV >96 Hours with MCC
Heart Failure and Shock with MCC
Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes with MCC
Other Vascular Procedures with MCC
Other Circulatory System Diagnoses with MCC
Renal Failure with MCC
Simple Pneumonia and Pleurisy with MCC
Gastrointestinal Hemorrhage with MCC
Infectious and Parasitic Diseases with O.R. Procedures with MCC
Acute Myocardial Infarction, Discharged Alive with MCC
Other Kidney and Urinary Tract Procedures with MCC
Pulmonary Edema and Respiratory Failure
Esophagitis, Gastroenteritis and Miscellaneous Digestive Disorders with MCC
Hypertension with MCC
Percutaneous Cardiovascular Procedures with Drug-eluting Stent with MCC or 4+ Arteries or Stents
Extensive O.R. Procedures Unrelated to Principal Diaimosis with MCC
Cardiac Arrhythmia and Conduction Disorders with MCC
Circulatory Disorders Except AMI, with Cardiac Catheterization with MCC
Septicemia or Severe Sepsis with MV >96 Hours
Diabetes with MCC
or diagnosis code for HD only) but
further limited cases to those that
include one of the following ICD–10
procedure codes for the insertion of a
CVC.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00201
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.106
ER10AU22.107
For Analysis B, the applicant used the
same case selection criteria as Analysis
A (the presence of an ICD–10-procedure
khammond on DSKJM1Z7X2PROD with RULES2
filtration, sin
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ICD-10-PCS
03130ZD
0JH60WZ
0JH60XZ
0JH63WZ
0JH63XZ
0JHD0WZ
0JHD0XZ
0JHD3WZ
0JHD3XZ
0JHF0WZ
0JHF0XZ
0JHF3WZ
0JHF3XZ
0JHL0WZ
0JHL0XZ
0JHL3WZ
0JHL3XZ
0JHM0WZ
0JHM0XZ
0JHM3WZ
0JHM3XZ
Description
Bypass right subclavian artery to upper arm vein, open approach
Insertion of totally implantable vascular access device into chest subcutaneous tissue and fascia, open approach
Insertion of tunneled vascular access device into chest subcutaneous tissue and fascia, open approach
Insertion of totally implantable vascular access device into chest subcutaneous tissue and fascia, percutaneous approach
Insertion of tunneled vascular access device into chest subcutaneous tissue and fascia, percutaneous approach
Insertion of totally implantable vascular access device into right upper arm subcutaneous tissue and fascia, open approach
Insertion of tunneled vascular access device into right upper arm subcutaneous tissue and fascia, open approach
Insertion of totally implantable vascular access device into right upper arm subcutaneous tissue and fascia, percutaneous approach
Insertion of tunneled vascular access device into right upper arm subcutaneous tissue and fascia, percutaneous approach
Insertion of totally implantable vascular access device into left upper arm subcutaneous tissue and fascia, open approach
Insertion of tunneled vascular access device into left upper arm subcutaneous tissue and fascia, open approach
Insertion of totally implantable vascular access device into left upper arm subcutaneous tissue and fascia, percutaneous approach
Insertion of tunneled vascular access device into left upper arm subcutaneous tissue and fascia, percutaneous approach
Insertion of totally implantable vascular access device into right upper leg subcutaneous tissue and fascia, open approach
Insertion of tunneled vascular access device into right upper leg subcutaneous tissue and fascia, open approach
Insertion of totally implantable vascular access device into right upper leg subcutaneous tissue and fascia, percutaneous approach
Insertion of tunneled vascular access device into right upper leg subcutaneous tissue and fascia, percutaneous approach
Insertion of totally implantable vascular access device into left upper leg subcutaneous tissue and fascia, open approach
Insertion of tunneled vascular access device into left upper leg subcutaneous tissue and fascia, open approach
Insertion of totally implantable vascular access device into left upper leg subcutaneous tissue and fascia, percutaneous approach
Insertion of tunneled vascular access device into left upper leg subcutaneous tissue and fascia, percutaneous approach
The applicant asserted that the patient
population in Analysis B (HD and
central venous catheter) is more likely
to receive DefenCathTM during an
khammond on DSKJM1Z7X2PROD with RULES2
673
314
871
291
252
674
853
870
981
264
907
280
286
640
003
004
246
270
208
377
Description
Other Kidney and Urinary Tract Procedures with MCC
Other Circulatory System Diagnoses with MCC
Septicemia or Severe Sepsis Without MV >96 Hours with MCC
Heart Failure and Shock with MCC
Other Vascular Procedures with MCC
Other Kidney and Urinarv Tract Procedures with CC
Infectious and Parasitic Diseases with O.R. Procedures with MCC
Septicemia or Severe Sepsis with MV >96 Hours
Extensive O.R. Procedures Unrelated to Principal Diagnosis with MCC
Other Circulatory System O.R. Procedures
Other O.R. Procedures for Injuries with MCC
Acute Myocardial Infarction, Discharged Alive with MCC
Circulatory Disorders Except Ami, with Cardiac Catheterization with MCC
Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes with MCC
Ecmo or Tracheostomy with MV >96 Hours or Principal Diagnosis Except Face, Mouth and Neck with Major O.R. Procedures
Tracheostomy with MV >96 Hours or Principal Diagnosis Except Face, Mouth and Neck without Major O.R. Procedures
Percutaneous Cardiovascular Procedures with Drug-eluting Stent with MCC or 4+ Arteries or Stents
Other Major Cardiovascular Procedures with MCC
Respiratory System Diagnosis with Ventilator Support <=96 Hours
Gastrointestinal Hemorrhage with MCC
In both analyses, the applicant did not
remove charges for prior technology
because DefenCathTM would not replace
other therapies a patient may receive
during an inpatient stay. The applicant
standardized the charges using the FY
VerDate Sep<11>2014
MS–DRGs. The following table shows
the top 20 MS–DRGs by case count,
which account for 72% of all cases
included in Analysis B.
00:20 Aug 10, 2022
Jkt 256001
2022 IPPS final rule impact file and
applied a 4-year inflation factor of
1.281834 to update the charges from FY
2019 to FY 2023 based on the inflation
factor used to update the outlier
threshold in the FY 2022 IPPS/LTCH
PO 00000
Frm 00202
Fmt 4701
Sfmt 4700
PPS final rule (86 FR 45542). The
applicant did not add charges for new
technology as the cost of DefenCathTM
has not yet been determined but
believes that the technology meets the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.109
MS-DRG
inpatient stay. After imputing a case
count of 11 to any MS–DRG with fewer
than 11 cases, the applicant identified a
total of 60,679 cases mapping to 408
ER10AU22.108
48980
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
cost criterion without the additional
charges.
The applicant calculated a final
inflated case-weighted average
standardized charge per case of
$116,221 for Analysis A and a final
inflated case-weighted average
standardized charge per case of
$203,746 for Analysis B. The applicant
also determined an average case
weighted threshold amount of $77,290
in Scenario A and $96,645 in Scenario
B. Because the final inflated caseweighted average standardized charge
per case for each scenario exceeded the
average case-weighted threshold amount
for both scenarios, the applicant
asserted that DefenCathTM meets the
cost criterion.
In the proposed rule, we agreed that
the technology meets the cost criterion
and therefore proposed to approve
DefenCathTM for new technology add on
payments for FY 2023. We stated in the
proposed rule that we expected the
applicant to submit its cost per case
information prior to the final rule, and
that we would provide an update
regarding the new technology add-on
payment amount for the technology in
this final rule. We stated that any new
technology add-on payment for
DefenCathTM would be subject to our
policy under § 412.88(a)(2) where we
limit new technology add-on payments
for QIDPs to the lesser of 75% of the
average cost of the technology, or 75%
of the costs in excess of the MS–DRG
payment for the case.
We invited comments on whether
DefenCathTM meets the cost criterion
and our proposal to approve
DefenCathTM for new technology add-on
payments for FY 2023.
Comment: The applicant submitted a
public comment in support of CMS’
proposal to approve new technology
add-on payments for FY 2023 for
DefenCathTM. The applicant requested
that CMS correct erroneous information
from the proposed rule, stating that the
FDA new device approval date is
expected later in the third quarter of
2022, rather than by July 1, 2022, as
stated in the proposed rule. The
applicant also provided the anticipated
cost of DefenCathTM, which the
applicant states is $5,850 to the
hospital, per patient.
Response: We appreciate the
applicant’s support and provision of the
cost information. We appreciate the
applicant’s clarification that the FDA
new device approval date is anticipated
late in the third quarter of CY 2022
rather than by July 1, 2022 as stated in
the proposed rule. This discussion now
accurately reflects the anticipated
timeline for FDA approval.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Comment: A commenter expressed
concern that without information on the
cost of DefenCathTM at the time of the
publication of the proposed rule, it is
difficult to comment positively or
negatively on the cost of the technology.
This commenter also expressed concern
that, without FDA approval at the time
of the publication of the proposed rule,
it is likewise difficult to comment on
the potential impact of the technology.
The commenter raised concerns that
applicants under the Alternative
Pathway for Transformative New
Devices and Alternative Pathway for
Certain Antimicrobial Products do not
have to meet the substantial clinical
improvement criterion under 412.87(d)
and recommend that CMS incorporate
substantial clinical improvement in its
evaluation of applicants under the
alternative pathways.
Response: We thank the commenter
for its input. As discussed in FY 2020
IPPS/LTCH PPS final rule (84 FR 42294
through 42295), we believe that
although there may be less certainty of
clinical benefit or data representing the
Medicare beneficiary population as
compared to the evidence standard for
substantial clinical improvement under
the current new technology add-on
payment policy pathway, the benefits of
providing early access to critical and
life-saving new cures and technologies
that improve beneficiary health
outcomes support the alternative
pathway. We also stated our belief that
the evidence base to demonstrate
substantial clinical improvement may
not be fully developed at the time of
FDA marketing authorization. We refer
the reader to the FY 2020 IPPS/LTCH
PPS final rule for a further discussion of
the development of these alternative
pathways.
With respect to cost information,
consistent with the formula specified in
section 1886(d)(5)(K)(ii)(I) of the Act, we
assess the adequacy of the MS–DRG
prospective payment rate otherwise
applicable to discharges involving the
new medical service or technology by
evaluating whether the charges for cases
involving the new technology exceed
certain threshold amounts. The MS–
DRG threshold amounts used in
evaluating new technology add-on
payment applications for FY 2023 are
presented in a data file that is available,
along with the other data files
associated with the FY 2022 IPPS final
rule on the CMS website at: https://
www.cms.gov/medicare/acute-inpatientpps/fy-2022-ipps-final-rule-home-page.
As discussed in the proposed rule, we
agreed that based on the applicant’s cost
analysis, the final inflated caseweighted average standardized charge
PO 00000
Frm 00203
Fmt 4701
Sfmt 4700
48981
per case for the technology exceeded the
applicable average case-weighted
threshold amount. We also note that
applicants for new technology add-on
payment are not required to have FDA
approval by the time of the publication
of the proposed rule. In addition, and as
discussed in the proposed rule and later
in this final rule, where cost information
is not yet available at the time of the
proposed rule, we note our expectation
is that the applicant will submit cost
information prior to the final rule, and
indicate that we will provide an update
regarding the new technology add-on
payment amount for the technology, if
approved, in the final rule.
Based on the information provided in
the application for new technology addon payments, and after consideration of
the public comments we received, we
believe DefenCathTM (a single dose vial,
solution of Taurolidine (13.5 mg/mL)
and Heparin (1000 USP Units/mL))
meets the cost criterion. Therefore, we
are granting a conditional approval for
DefenCathTM for new technology add-on
payments for FY 2023, subject to the
technology receiving FDA marketing
authorization by July 1, 2023 (that is, by
July 1 of the fiscal year for which the
applicant applied for new technology
add-on payments (2023)). In the
proposed rule we stated that as an
application submitted under the
alternative pathway for certain
antimicrobial products at § 412.87(d),
DefenCathTM is eligible for conditional
approval for new technology add-on
payments if it does not receive FDA
marketing authorization by the July 1
deadline specified in § 412.87(e)(2),
provided that the technology receives
FDA marketing authorization by July 1
of the particular fiscal year for which
the applicant applied for new
technology add-on payments (that is,
July 1, 2023) (87 FR 28350). If
DefenCathTM receives FDA marketing
authorization before July 1, 2023, the
new technology add-on payment for
cases involving the use of this
technology would be made effective for
discharges beginning in the first quarter
after FDA marketing authorization is
granted. If FDA marketing authorization
is received on or after July 1, 2023, no
new technology add-on payments will
be made for cases involving the use of
DefenCathTM for FY 2023.
Based on the information at the time
of this final rule, the cost per case of the
DefenCathTM is $5,850. Under
§ 412.88(a)(2) we limit new technology
add-on payments for QIDPs to the lesser
of 75% of the average cost of the
technology, or 75% of the costs in
excess of the MS–DRG payment for the
case. As a result, we are finalizing that,
E:\FR\FM\10AUR2.SGM
10AUR2
48982
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
subject to DefenCathTM receiving
marketing authorization by July 1, 2023,
the maximum new technology add-on
payment for a case involving the use of
DefenCathTM will be for $4,387.50 for
FY 2023 (that is, 75% of the average cost
of the technology). Cases involving the
use of DefenCathTM that are eligible for
new technology add-on payments will
be identified by ICD–10–PCS procedure
code XY0YX28 (Extracorporeal
introduction of taurolidine antiinfective and heparin anticoagulant,
new technology group 8).
khammond on DSKJM1Z7X2PROD with RULES2
c. Other Comments
We received several public comments
on new technology add-on payment
alternative pathway recommendations
that were outside the scope of the
proposals included in the FY 2023
IPPS/LTCH PPS proposed rule and we
are therefore not addressing them in this
final rule. We appreciate these
comments and may consider them for
possible proposals in future rulemaking.
8. Use of National Drug Codes (NDCs)
To Identify Cases Involving Use of
Therapeutic Agents Approved for New
Technology Add-On Payment
As discussed in the FY 2016 IPPS/
LTCH PPS final rule (80 FR 49434
through 49435), as a part of the
transition to the ICD–10–CM diagnosis
and ICD–10–PCS procedure coding
system from the ICD–9–CM coding
system, CMS established the use of
Section ‘‘X’’ New Technology codes
within the ICD–10–PCS classification to
more specifically identify new
technologies or procedures that have
historically not been captured through
ICD–9–CM codes, or to more precisely
describe information on a specific
procedure or technology than is found
with the other sections of ICD–10–PCS.
However, as noted in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28353
through 28355), CMS continued to
receive comments from interested
parties, including representatives from
hospital associations, software vendors,
professional societies, and coding
professionals, opposing the continued
creation of new ICD–10–PCS (for
example, Section X) procedure codes for
the purpose of administering the new
technology add-on payment for drugs
and biologics. Specifically, public
comments from the ICD–10
Coordination and Maintenance
Committee Meetings have stated that the
ICD–10–PCS classification system was
not intended to represent unique drugs/
therapeutic agents and is not an
appropriate code set for this purpose.
Commenters explained that, since the
implementation of ICD–10, Section X
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
codes have been established for
procedures describing the
administration of a drug/therapeutic
agent, which historically were not
typically coded in the inpatient hospital
setting. Commenters stated their belief
that it was not logical nor should it be
expected for hospital coding
professionals to seek codes for the
administration of drugs within the ICD–
10–PCS classification system. In
addition, we noted that over the past 3
years, the number of applications for
new technology add-on payments has
continued to increase, which has
subsequently resulted in an increasing
number of requests for unique ICD–10–
PCS (for example, Section X) procedure
codes specifically for the purposes of
administering the new technology addon payments.
As discussed in the proposed rule, the
current process of requesting,
proposing, finalizing and assigning new
ICD–10–PCS procedure codes to
identify and describe the administration
of drugs involves several steps, as
described further in this section, and
frequently results in a number of
procedure codes that are created
unnecessarily when the drug/
therapeutic agents do not receive
approval for the new technology add-on
payments, as the administration of
drugs/therapeutic agents is not typically
coded in the inpatient hospital setting.
Applicants seeking a unique ICD–10–
PCS (for example, Section X) procedure
code to identify the use of their
technology for purposes of new
technology add-on payments must
complete the code request process prior
to learning the outcome of their new
technology add-on payment application.
This process involves a number of steps,
including: gathering relevant
information and submitting the ICD–10–
PCS code request; developing a slide
deck for the ICD–10 Coordination and
Maintenance Committee Meeting; and
reviewing the background paper draft
for the ICD–10 Coordination and
Maintenance Committee Meeting
agenda and meeting materials. CMS also
expends significant time, effort, and
resources to administer this process,
which is compounded by the increasing
number of requests for unique ICD–10–
PCS (for example, Section X) procedure
codes. CMS must work with applicants
to review, prepare, and present the code
proposals at ICD–10 Coordination and
Maintenance Committee Meetings, then
review and summarize public comments
received in response to the meetings,
and ultimately make a decision on the
codes requested for new technology
add-on payment policy purposes before
PO 00000
Frm 00204
Fmt 4701
Sfmt 4700
the outcome of the new technology addon payment application (approval or
denial) is known. Following the end of
the three-year timeframe for which a
code was created in connection with a
new technology add-on payment
application, the disposition of the
Section X code is addressed at a later
ICD–10 Coordination and Maintenance
Committee meeting and CMS
subsequently receives public comments
that must be reviewed regarding this
disposition.
We stated that interested parties had
submitted comments that suggested
alternative options to the use of Section
X procedure codes to identify
therapeutic agents for the
administration of the new technology
add-on payment policy. The majority of
commenters supported using National
Drug Codes (NDCs), because it would
avoid creating duplicate codes within
the ICD–10–PCS and NDC code sets to
identify the same technology/product,
which would allow for predictive and
efficient coding. Commenters also stated
that using NDCs would generate product
data on inpatient claims that would
allow for outcomes analyses, thus
providing the same benefit as a unique
ICD–10–PCS code. Some commenters
suggested using the 3E0 Administration
Table within the ICD–10–PCS code set,
as opposed to Section X, as they stated
this would be a more intuitive location
for coders to look for ICD–10–PCS
procedure codes describing the
administration of therapeutic agents.
However, a commenter noted that this
would be unsustainable due to the
potentially large number of new
products coming to market. A few
commenters also suggested using
different drug terminologies, such as
RxNorm, in lieu of using Section X
codes for the time period needed to
administer the new technology add-on
payment. We also noted that we have
previously established the use of NDCs
as an alternative code set for the
purposes of administering the new
technology add-on payment in
circumstances where an ICD–10–PCS
code was not available to uniquely
identify the use of the technology. In the
FY 2013 IPPS/LTCH PPS final rule (77
FR 53351 through 53354), we
established the use of the NDC code set
to identify oral medications where no
inpatient procedure was associated, to
report the oral administration of the
drug DIFICIDTM. We finalized that the
NDC for DIFICIDTM would be used in
conjunction with an ICD–9–CM
diagnosis code to uniquely identify the
indication for which administration of
the drug (technology) was performed for
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
new technology add-on payment
purposes. In the FY 2019 IPPS/LTCH
PPS final rule (83 FR 41311), we stated
that we believed that the circumstances
with respect to the identification of
eligible cases reporting the use of
VABOMERETM, which was
administered by IV infusion, were
similar to those addressed in the FY
2013 IPPS/LTCH PPS final rule with
regard to DIFICIDTM because we also did
not have current ICD–10–PCS code(s) to
uniquely identify the use of
VABOMERETM to make the new
technology add-on payments. Therefore,
consistent with our approach in FY
2013, we stated that we would identify
cases involving the use of
VABOMERETM that were eligible for FY
2019 new technology add-on payments
using its NDCs 65293–0009–01 or
70842–0120–01206 (VABOMERETM
Meropenem-Vaborbactam Vial). At the
time of its new technology add-on
payment application approval,
VABOMERETM was not assigned a
corresponding ICD–10–PCS procedure
or ICD–10–CM diagnosis code along
with its NDCs. In addition, cases
involving the use of two therapeutic
agents that qualify for NCTAP, which is
administered similarly to the new
technology add-on payment, are
identified using the NDCs for these
products for the purposes of the
NCTAP, because there are not currently
ICD–10–PCS procedure codes that
uniquely describe the administration of
these therapies.207
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28353 through
28355), we stated that we believed that
our previous policies regarding the use
of NDCs to identify the administration
of certain therapeutic agents could be
consistently applied toward broader
future usage of the NDCs to identify
therapeutic agents eligible for the new
technology add-on payment.
Additionally, we stated that we believed
that the use of an existing code set to
identify therapeutic agents eligible for
the new technology add-on payment
would address concerns raised by
commenters regarding the use of the
ICD–10–PCS classification system to
identify these agents, and reduce the
need for applicants to seek a unique
ICD–10–PCS code through the ICD–10–
PCS Section X code request process in
advance of a determination on their new
206 We note that these are not the FDA assigned
NDCs, but rather have been converted from 10-digit
NDCs assigned by FDA to the HIPAA compliant 11digit format.
207 New COVID–19 Treatments Add-On Payment
(NCTAP) https://www.cms.gov/medicare/covid-19/
new-covid-19-treatments-add-payment-nctap.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
technology add-on payment
applications.
Therefore, as we discussed further in
this section of the proposed rule and
this final rule, we proposed for FY 2024
to instead use NDCs to identify cases
involving the use of therapeutic agents
approved for the new technology add-on
payment. We stated that we anticipated
that this proposal would reduce work
for hospital coding professionals in
becoming familiar with newly created
ICD–10–PCS Section X codes to
describe the administration of
therapeutic agents and in searching for
these codes within the documentation
and within the classification in what
may be non-intuitive locations. We
stated that we also expected that the
proposed change would address
concerns regarding the creation of
duplicative codes within the ICD–10–
PCS procedure coding system to
describe the administration of
therapeutic agents, which would also
reduce the need for vendors to
incorporate additional procedure codes
into their coding products; for educators
to provide training on these codes; and
for programmers to maintain codes that
may be seldom reported on inpatient
claims but for the purposes of the new
technology add-on payment, in their
databases. We stated it would also
reduce efforts associated with
determining the disposition of
procedure codes describing therapeutic
agents that have reached the end of their
3-year new technology add-on payment
timeframe.
Furthermore, we stated that we
believed that NDCs are a viable
alternative to Section X codes for the
administration of the new technology
add-on payment for therapeutic agents.
We stated that we believed inpatient
hospital staff are familiar with using
NDCs, and as stated earlier, we have
previously utilized NDCs to administer
the new technology add-on payment.
However, to allow for adequate time to
implement this regular usage of NDCs
with the new technology add-on
payment for health care providers and
hospital coding professionals, we
proposed a transitional period for FY
2023. During this transitional period, we
proposed to utilize NDCs to identify the
administration of therapeutic agents for
new technology add-on payment
purposes. However, we also proposed to
utilize ICD–10–PCS Section X codes,
including codes newly created for FY
2023, for therapeutic agents during the
FY 2023 new technology add-on
payment application cycle. Beginning
with the FY 2024 new technology addon payment application cycle, we
proposed to utilize only NDCs to
PO 00000
Frm 00205
Fmt 4701
Sfmt 4700
48983
identify claims involving the
administration of therapeutic agents
approved for the new technology add-on
payment, with the exception of claims
involving therapeutic agents that are not
assigned an NDC by FDA (for example,
blood, blood products, etc.) and are
approved for the new technology add-on
payment. Cases involving the use of
these technologies approved for the new
technology add-on payment would
continue to be identified based on the
assigned ICD–10–PCS procedure code.
A unique ICD–10–PCS procedure code
would also still be needed to identify
cases involving the use of CAR T-cell
and other immunotherapies that may be
assigned to Pre-MDC MS–DRG 018,
because the ICD–10 MS–DRG GROUPER
logic for assignment to Pre-MDC MS–
DRG 018 is comprised of the procedure
codes describing these CAR T-cell and
other immunotherapy products.
Therefore, under the proposal,
beginning with FY 2024 new technology
add-on payment applications submitted
for a therapeutic agent, CMS would
review the information and inform the
applicant, in advance of the deadline for
submitting an ICD–10–PCS procedure
code request to the ICD–10 Coordination
and Maintenance Committee for
consideration at the March meeting, if it
would be necessary to submit such a
code request for purposes of identifying
cases involving the use of the
therapeutic agent for the new
technology add-on payment, if
approved, or if, based on the
information made available with the
application, the NDC could be used to
identify such cases, and therefore, the
applicant would not need to submit an
ICD–10–PCS procedure code request.
For each applicable technology that may
be approved for new technology add-on
payment, we proposed to indicate the
NDC(s) to use to identify cases involving
the administration of the therapeutic
agent for purposes of the new
technology add-on payment.
Specifically, we proposed that, during
the transitional period beginning with
discharges on or after October 1, 2022
(FY 2023), the administration of
therapeutic agents newly approved for
new technology add-on payments
would be uniquely identified using
either their respective NDC(s) or ICD–
10–PCS procedure code(s), in
combination with ICD–10–CM codes
when appropriate. As stated in our FY
2013 IPPS/LTCH PPS final rule, the use
of the NDCs ‘‘does not preclude CMS
from using additional ICD–9–CM
procedure or diagnosis codes to identify
cases for this new technology in
conjunction with this alternative code
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48984
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
set’’ (77 FR 53352). Therefore, we stated
when necessary, we may require the use
of additional ICD–10–PCS procedure
and/or ICD–10–CM diagnosis codes to
uniquely identify cases using these
technologies. We stated that we would
continue the use of the existing ICD–10–
PCS procedure codes to identify the
administration of therapeutic agents
previously approved for the new
technology add-on payment and that
remain eligible for the new technology
add-on payment for FY 2023.
We further proposed that, beginning
with discharges on or after October 1,
2023 (FY 2024), the administration of
therapeutic agents newly approved for
the new technology add-on payments
beginning FY 2024 or a subsequent
fiscal year would be uniquely identified
only by their respective NDC(s), along
with the corresponding existing ICD–10
code(s) required to uniquely identify the
therapeutic agents, when necessary, to
make the new technology add-on
payments. For technologies that were
newly approved for new technology
add-on payments for FY 2023
(beginning with discharges on or after
October 1, 2022) and remain eligible for
the new technology add-on payment for
FY 2024 or a subsequent fiscal year, we
proposed to continue to allow the use of
either the existing ICD–10–PCS
procedure codes or NDCs to identify the
administration of those therapeutic
agents. For technologies that were
newly approved for new technology
add-on payments prior to FY 2023 and
remain eligible for the new technology
add-on payment for FY 2024 or a
subsequent fiscal year, we stated we
would continue to use the existing ICD–
10–PCS procedure codes to identify the
administration of those therapeutic
agents. We invited public comments on
our proposal to utilize NDCs to identify
claims involving the use of therapeutic
agents approved for new technology
add-on payments, including any
potential concerns regarding adoption of
this code set for the identification of
therapeutic agents for purposes of new
technology add-on payments.
Comment: We received multiple
comments related to the proposed
policy. A commenter stated that the
ICD–10–PCS coding system is not
intended to represent unique
therapeutic agents and is not an
appropriate code set for this purpose.
The commenter also stated that ICD–10–
PCS codes have often been created
unnecessarily because the therapeutic
agent was not approved for a new
technology add-on payment, and that in
the absence of a new technology add-on
payment, administration of therapeutic
agents is not typically coded in the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
hospital inpatient setting. The
commenter stated that assignment of
ICD–10–PCS codes by coding
professionals solely for new technology
add-on payment purposes, for services
that would not otherwise be coded in
the inpatient setting, is administratively
burdensome. Another commenter
mentioned that using FDA’s NDCs
would allow for superior data capture
methods and eliminate manual
intervention to complete coding.
Another commenter stated that given
the likelihood of continued therapeutic
innovation, it viewed this proposed
policy as a path toward earlier access to
these therapies by Medicare
beneficiaries. A commenter stated that
as hospitals typically capture all NDCs
related to a patient stay within their
electronic medical record systems, these
codes could easily be included with
claims. The commenter requested that
CMS configure its system to accept all
NDC codes, not just those related to
products eligible to receive new
technology add-on payments, to
significantly reduce administrative
burden for hospitals.
Several commenters also suggested
that if CMS finalizes this policy, we
should establish a process to promote
and educate hospitals on this policy
change to ensure that they are prepared
for billing under the new process,
including clearly indicating which
NDC(s) should be used to identify a
particular therapeutic agent for new
technology add-on payment purposes,
as some therapeutic agents may have
more than one applicable NDC. Multiple
commenters also urged CMS to extend
the proposed transitional process from
one year to two years, that is, through
FY 2024, with NDC utilization
beginning in FY 2025. Some
commenters also suggested that during
this two-year transition period, CMS
should analyze claims data and obtain
feedback from interested parties to
understand hospitals’ usage of NDCs,
prior to eliminating the process for
using ICD–10–PCS codes.
A commenter expressed support for
our proposal to continue use of ICD–10–
PCS codes for cases assigned to PreMDC MS–DRG 018 (Chimeric Antigen
Receptor (CAR) T-cell and Other
Immunotherapies) because hospitals
may not have had experience with
submitting NDCs as part of hospital
inpatient claim forms for such cases.
Another commenter stated that it was
concerned with our proposal to use
NDCs in lieu of ICD–10–PCS codes for
allogeneic HSCT donor sources because
providers, such as hospitals, primarily
report ICD–10–PCS codes and are
unfamiliar with NDCs for these donor
PO 00000
Frm 00206
Fmt 4701
Sfmt 4700
sources. The commenter requested that
CMS expand our proposed exceptions to
the use of NDCs for therapeutic agents
to also include the unique ICD–10–PCS
codes describing the infusion of
therapeutics that begin with the
characters XW1, as well as any future
advanced cell therapy donor sources.
A commenter explained that it
disagreed with creating individual ICD–
10–PCS codes for specific drugs because
it believed that ICD–10–PCS
nomenclature is for surgical procedures
and not specific drugs. The commenter
expressed that coders do not routinely
assign ICD–10–PCS codes for example,
for drugs, radiology procedures, and lab
tests, and that this would be an
administrative burden on coders, as
well as billers, to ensure these drugs are
identified through ICD–10–PCS coding.
The commenter stated that it would be
more cost effective to identify these
specific drugs by their NDC number and
not an ICD–10–PCS code to ensure
adequate reimbursement. Another
commenter recommended that CMS
reevaluate our proposal to transition to
the use of NDCs to identify the
administration of a therapeutic agent for
purposes of new technology add-on
payment because the commenter stated
that it would add undue burden on
coders who typically do not assign ICD–
10–PCS codes for drug administration
for inpatient cases. The commenter also
requested that CMS pursue broader
inpatient claims reporting
improvements.
Response: We appreciate the input
from the commenters on our proposed
use of NDCs to identify cases involving
use of therapeutic agents approved for
new technology add-on payment and
have taken these comments into
consideration, as discussed later in this
section.
Comment: A couple of commenters
were grateful to CMS for listening to
feedback from interested parties and
putting this proposal forward, but had
significant questions about
implementation and existing hospital
resources for CMS to address prior to
finalizing the use of NDCs, and
recommended that CMS retain the ICD–
10–PCS coding for new technology addon payments. Other commenters stated
that CMS does not currently require
NDC reporting on Medicare inpatient
claims, except in rare cases of previous
new technology add-on payments, and
that reporting NDCs for only the
occasional drug, and on an inpatient
claim, would create new operational
burdens for hospitals, especially smaller
and rural hospitals, that do not
currently have a system for concurrent
scanning of NDCs upon administration
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
of therapeutic agents. Another
commenter stated that some hospitals
already have systems that would
provide an automated method of
capturing NDC codes on inpatient
claims, but that other facilities, will face
new and laborious manual processes
despite reporting NDCs on certain
outpatient claims. A commenter noted
that a recent analysis of hospitals by
Deloitte found that incorrect or missing
NDC data had caused inaccurate
billing.208 The commenter further stated
that it believed the process to educate
hospitals and subsequently require the
use of NDCs could possibly create a
greater administrative burden than it
would save. Some commenters also
noted that these burdens would come at
a time when hospitals continue to
address resource and staffing constraints
resulting from the COVID–19 PHE. A
commenter explained that the transition
to NDCs may create complexity in
tracking patient cases, which may make
it difficult to perform further valuable
research on quality of care issues and
health outcomes. Another commenter
stated that it believed any changes to the
current process should be done in a
careful manner to ensure that CMS’
efforts to move to a more streamlined
system do not have any inadvertent
implications on claims data.
A commenter stated that because
there are multiple proposed exceptions
to the use of NDCs, the streamlining and
burden reduction of this policy may be
limited. Another commenter stated that
this proposal would unnecessarily
require two separate standards for
devices and drugs.
A commenter stated that hospitals are
faced with increasingly complex
requirements to report drugs to secure
reimbursement with variations based
upon code sets and patient status. The
commenter stated that for inpatient
claims there are two ways of reporting
drugs for additional payment:
hemophilia products reported with
HCPCS codes and billed units per date
of service (DOS), and new technology
add-on payment-eligible drugs reported
with a single ICD–10–PCS code
independent of number of doses or days
administered. The commenter further
stated that outpatient claims are
reported with HCPCS code and billed
units per DOS, with the exception of
self-administered oral drugs that were
not assigned HCPCS codes, as well as
208 Evaluating Hospital Pharmacy Inventory
Management and Revenue Cycle Processes, White
Paper Guidance for Healthcare Internal Auditors
https://ahia.org/assets/Uploads/pdfUpload/
WhitePapers/EvaluatingHospital
PharmacyInventoryManagementandRevenueCycle
Processes.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
specific new drugs and biologicals
billed under the HCPCS Code C9399
(Unclassified drug or biological) and for
which the commenter stated that CMS
requires that the drug name, dose,
amount of waste and NDC number be
manually added to the remarks section
of the claim. The commenter stated that
hospital pharmacy and billing IT
systems need remediation with complex
maintenance in order to accurately bill
drugs based upon the type of drug,
whether it is eligible for new technology
add-on payment and the status of the
patient, and that many hospitals
currently do not bill some new
technology add-on payment-eligible
drugs due to the cumbersome process
and amount of the anticipated
reimbursement, which the commenter
stated could lead to inadvertent billing
errors or omissions when a business
decision is made that the anticipated
payment will be less than the cost to
remediate IT systems and maintain
these complex billing rules. The
commenter further stated that
inaccurate data could lead to erroneous
future rate-setting by CMS when data is
missing from claims. The commenter
recommended that CMS instead
consider that new technology add-on
payment-eligible drugs be billed on
inpatient claims with the same
instructions as currently used to report
hemophilia products, with HCPCS
codes and billing units by DOS. The
commenter explained that having one
way to bill drugs on inpatient and
outpatient claims would reduce IT
programming expense and reduce errors
with increased standardization. The
commenter requested that the CMS
HCPCS Working Group assign HCPCS
codes to items eligible for new
technology add-on payment, even if
they normally would not be assigned a
HCPCS code. The commenter stated that
as HCPCS codes are assigned quarterly,
this would eliminate the need for
special notification if new NDCs are
marketed after the implementation of
the new technology add-on payment
status and before the next rule-making
cycle. The commenter further
recommended that if CMS were to
finalize its proposal to use NDCs, CMS
should work with the National Uniform
Billing Committee (NUBC) to clarify
how 5010 HIPAA transaction standard
units of measure and billing quantities
should be calculated and reported. The
commenter also recommended that CMS
work with NUBC to require all payers to
accept NDCs on inpatient claims to
avoid payer-specific instructions, which
require complex and expensive IT
programming.
PO 00000
Frm 00207
Fmt 4701
Sfmt 4700
48985
This commenter and several other
commenters also requested CMS
provide additional information in
rulemaking on how NDCs would be
utilized: if a NDC may be reported on
multiple DOS, or if multi-day therapies
must be combined into a single line;
whether units of measures and
quantities would be required to be
reported; if this policy would apply
specifically for therapeutic agents
eligible for new technology add-on
payment or for all therapeutic agents
used in Medicare; how a drug product
with multiple NDCs would be handled;
and how CMS would publish available
NDCs for analysis by interested parties
and update NDCs if the codes were
changed by FDA post-rulemaking.
Several commenters also emphasized
the complexity of information transfer
from the 10-digit FDA-assigned NDC
number format to the 5010 HIPAA
transaction standard required 11-digit
NDC number format used for billing on
claims, especially when trying to
reconstitute the NDC back to its FDA
standard. Other commenters noted
future concerns with potential changes
in FDA assignment of NDC numbers
from 10-digits to a new 16-digit format,
as well as the modifications needed to
the 837I/UB–04 forms to accommodate
this change.
In addition, commenters highlighted
issues regarding a lack of national
standards for correctly coding drugs
using NDCs, as well as a lack of
acceptance of NDCs by all payers, on
inpatient claims. A commenter further
stated that without specific guidance,
current NDC reporting is often
inaccurate, resulting in increasing claim
rejections for an invalid NDC number. A
couple of commenters explained that
currently, Form Locator 43 (FL43) on
the UB–04 form is not unique to only
the NDC number. A commenter stated
that they believed that the proposed
usage of this field may not be allowed
because FL43 is intended for the
reporting of NDCs for Medicaid drug
rebates, but not for the new technology
add-on payment. Some commenters also
stated that there was a potential for
claim line limits to be reached if
multiple NDCs were reported on one
claim. These commenters believed that
this policy change should be considered
as part of broader inpatient claims
reporting improvements, with another
commenter further stating that grouping
together necessary changes to 837I/UB–
04 claim forms, alongside updated
instructions on NDC reporting for
inpatients, would minimize short-term
burden as well as data inaccuracies.
Due to these concerns, a few
commenters suggested that CMS further
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48986
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
study the feasibility of this proposed
policy change though a Technical
Advisory Group (TAG), consisting of
industry experts, before finalizing and
implementing this policy. A commenter
further recommended that other
suggestions noted by CMS, such as the
3E0 Administration Table within ICD–
10–PCS code set and RxNorm, along
with other options, such as the HCPCS
code set or a revision to the process that
allows the ICD–10–PCS code to be
pending assignment until the
finalization of the new technology addon payment determination, should be
explored by the TAG and presented in
an upcoming proposed rule. Another
commenter recommended that CMS
address alignment with timing for U.S.
implementation of ICD–11 codes.
Response: We appreciate the input
from commenters on our proposed use
of NDCs to identify cases involving use
of therapeutic agents approved for new
technology add-on payments. We
acknowledge that interested parties
have continued to share concerns
regarding our current use of the ICD–
10–PCS classification system to identify
therapeutic agents eligible for new
technology add-on payments. As
discussed in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28353
through 28355), we had anticipated that
our proposal to use the NDC, with its
previously established use as an
alternative code set for the purposes of
administering the new technology addon payment, would reduce work for
hospital coding professionals in
becoming familiar with newly created
ICD–10–PCS Section X codes to
describe the administration of
therapeutic agents. We had also
expected that this proposed change
would address concerns regarding the
creation of duplicative codes within the
ICD–10–PCS procedure coding system,
which would also reduce the need for
vendors to incorporate additional
procedure codes into their coding
products; for educators to provide
training on these codes; and for
programmers to maintain codes that
may be seldom reported on inpatient
claims but for the purposes of the new
technology add-on payment in their
databases.
However, as previously summarized,
commenters have shared concerns that
our proposed use of NDCs for this
purpose may impose new
administrative burdens to hospitals. For
example, commenters indicated that
hospital pharmacy and billing IT
systems that are not currently required
to use NDCs for billing on inpatient
Medicare claims may need to use
manual processes to report NDCs for the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
purposes of new technology add-on
payments, because they may not have
existing automated systems in place.
Furthermore, based on review of
comments, it is unclear to us the extent
to which hospitals and health care
providers would utilize NDCs during a
transition period in FY 2023, especially
if they believe adding these manual
processes may result in inadvertent
billing errors for therapeutic agents
eligible for new technology add-on
payments, which commenters state may
be further compounded by staffing
shortages due to the COVID–19
pandemic. This may limit our ability to
obtain comprehensive feedback from
interested parties during the transition
period, as suggested by commenters, or
perform an analysis of claims data to
assess if NDCs are being used, prior to
fully transitioning to using NDCs for
this purpose.
Therefore, after careful consideration
of the concerns raised by commenters,
we are not finalizing this proposed
policy, and will instead reassess this
policy proposal in future rulemaking.
We believe that this will allow for
adequate time to evaluate and consider
the issues raised by commenters. We
understand that commenters would be
interested in further details on how
NDCs would be operationalized for the
purposes of any such policy change,
along with a process to educate
hospitals on these changes to ensure
accurate billing throughout a transition
period. We appreciate that commenters
have raised a number of important
questions on our proposal, and we will
continue to engage the public in these
conversations.
9. Proposal to Publicly Post New
Technology Add-On Payment
Applications
As noted in section II.F.1.f. of the
preamble of this final rule, applicants
for new technology add-on payments for
new medical services or technologies
must submit a formal request, including
a full description of the clinical
applications of the medical service or
technology and the results of any
clinical evaluations demonstrating that
the new medical service or technology
represents a substantial clinical
improvement (unless the application is
under one of the alternative pathways),
along with a significant sample of data
to demonstrate the new medical service
or technology meets the high-cost
threshold (OMB–0938–1347). See
section II.F.1.f. of the preamble of this
final rule for further details on the data
and evidence that can be submitted. We
post complete application information
and final deadlines for submitting a full
PO 00000
Frm 00208
Fmt 4701
Sfmt 4700
application on the CMS website at
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/newtech. We also
post on the same website tracking forms
completed by each applicant, which
include the name of each applicant,
name of the technology, and a brief
description so that interested parties can
identify the new medical services or
technologies under review before the
annual proposed rule. Additionally,
section 1886(d)(5)(K)(viii) of the Act
provides for a mechanism for public
input before the publication of a
proposed rule regarding whether a
medical service or technology
represents a substantial clinical
improvement. Consistent with the Act,
we hold an annual Town Hall meeting,
typically in December following notice
of the meeting in the Federal Register.
As set forth in 42 CFR 412.87(e)(1),
CMS considers whether a technology
meets the criteria for the new
technology add-on payment and
announces the results as part of its
annual updates and changes to the IPPS.
Accordingly, in drafting the proposed
rule, CMS reviews each new technology
add-on payment application it receives
under the pathway specified by the
applicant at the time of application
submission, along with supplemental
information209 obtained from the
applicant, information provided at the
Town Hall meeting, and comments
received in response to the Town Hall
meeting. In the proposed rule, CMS
summarizes the information contained
in the application, including the
applicant’s explanation of what the
technology does, background on the
disease process, information about the
FDA approval/clearance, and the
applicant’s assertions and supporting
data on how the technology meets the
new technology add-on payment criteria
under § 412.87. In summarizing this
information for inclusion in the
proposed rule, CMS restates or
paraphrases information contained in
the application and attempts to avoid
misrepresenting or omitting any of an
applicant’s claims. CMS also tries to
ensure that sufficient information is
provided in the proposed rule to
facilitate public comments on whether
the medical service or technology meets
the new technology add-on payment
criteria. Currently, however, CMS does
not make the applications themselves,
as completed by the applicants, publicly
available. In addition, CMS generally
209 For the FY 2023 new technology add-on
payment applications, the supplemental
information deadline to guarantee inclusion in the
IPPS proposed rule was December 17, 2021.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
does not take into consideration
information that is marked as
confidential when determining whether
a technology meets the criteria for new
technology add-on payments.
We note that in the past, CMS has
received requests from the public to
access and review the new technology
add-on payment applications to further
facilitate comment on whether a
technology meets the new technology
add-on payment criteria. In
consideration of this issue, we stated in
the proposed rule that we agree that
review of the original source
information from the applications for
new technology add-on payments may
help to inform public comment. Further,
making this information publicly
available may foster greater input from
experts in the stakeholder community
based on their review of the completed
application forms and related materials.
Accordingly, as we discuss further in
this section of the proposed rule and
this final rule, we stated that we believe
that providing additional information to
the public by publicly posting the
applications and certain related
materials online may help to further
engage the public and foster greater
input and insights on the various new
medical services and technologies
presented annually for consideration for
new technology add-on payments.
We stated that we also believe that
posting the applications online would
reduce the risk that we may
inadvertently omit or misrepresent
relevant information submitted by
applicants, or are perceived as
misrepresenting such information, in
our summaries in the rules. It also
would streamline our evaluation
process, including the identification of
critical questions in the proposed rule,
particularly as the number and
complexity of the applications have
been increasing over time. That is, by
making the applications available to the
public online, we would afford more
time for CMS to process and analyze the
supporting data and evidence rather
than reiterate parts of the application in
the rule.
Therefore, to increase transparency,
enable increased stakeholder
engagement, and further improve and
streamline our evaluation process, we
proposed in the FY 2023 IPPS/LTCH
PPS proposed rule to publicly post
online future applications for new
technology add-on payments.
Specifically, beginning with the FY
2024 application cycle, we proposed to
post online the completed application
forms and certain related materials (for
example, attachments, uploaded
supportive materials) that we receive
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
from applicants. Additionally, we
proposed to post information acquired
subsequent to the application
submission (for example, comments
received after the New Technology
Town Hall, updated application
information, additional clinical studies,
etc.). We proposed that we would not
post the cost and volume information
the applicant provides in the
application form itself or as attached
materials, or any material included with
the application that the applicant
indicates is not releasable to the public
because the applicant does not own the
copyright or the applicant does not have
the appropriate license to make the
material available to the public, as
further described in the next paragraph.
We proposed that we would publicly
post the completed application forms
and related materials no later than the
issuance of the proposed rule, which
would afford the public the full public
comment period to review the
information provided by the applicant
in its application.
With respect to copyrighted materials,
we proposed that on the application
form itself, the applicant would be
asked to provide a representation that
the applicant owns the copyright or
otherwise has the appropriate license to
make all the copyrighted material
included with its application public
with the exception of those materials
identified by the applicant as not
releasable to the public, as applicable.
For any material included with the
application that the applicant indicates
as copyrighted and/or not otherwise
releasable to the public, we proposed
that the applicant must either provide a
link to where the material can be
accessed or provide an abstract or
summary of the material that CMS can
make public, and CMS will then post
that link or abstract or summary online,
along with the other posted application
materials. We invited comments on this
proposal.
Under our current practice, we
include in the final rule information on
the cost of each technology that is
approved for the new technology add-on
payment for the purposes of calculating
the maximum add-on payment, and
information on the anticipated volume
of the technology for purposes of the
impact analysis. For the proposed rule,
specifically for applications submitted
under the alternative pathway, our
current practice is to propose whether
or not to approve the application based
on the eligibility criteria for the
alternative pathway under 42 CFR
412.87(c) or (d) and, where cost
information is available from the
applicant, to use this information in
PO 00000
Frm 00209
Fmt 4701
Sfmt 4700
48987
proposing a maximum add-on payment
amount. Where cost information is not
yet available, we note our expectation is
that the applicant will submit cost
information prior to the final rule, and
indicate that we will provide an update
regarding the new technology add-on
payment amount for the technology, if
approved, in the final rule. We noted
that we would continue this same
approach with respect to including cost
and volume information in the proposed
and final rules. However, as noted,
under our proposal to post online the
new technology add-on payment
applications, we would not include cost
and volume information for either
traditional or alternative pathway
applications as part of the application
materials that would be posted online.
We noted that at times an applicant
may furnish information marked as
proprietary or trade secret information
along with its application for new
technology add-on payments. Currently,
the application specifies that data
provided in the application or tracking
form may be subject to disclosure and
instructs the applicant to mark any
proprietary or trade secret information
so that CMS can attempt, to the extent
allowed under Federal law, to keep the
information protected from public
view.210 We further stated that this
instruction would change under our
proposal such that information included
in the application, other than cost and
volume information, would be made
publicly available online through
posting of the application. We
emphasized that the applicant should
not submit as part of its application any
such proprietary or trade secret
information that it does not want to be
made publicly available online. As
noted, under our existing practice we
stated that we generally do not consider
information that is marked as
confidential, proprietary, or trade secret
when determining whether a technology
meets the criteria for new technology
add-on payments.
We also stated that this proposal
would not change the current timeline
or evaluation process for new
technology add-on payments, the
criteria used to assess applications, or
the deadlines for various data
submissions. Additionally, we stated
that we do not expect added burdens on
prospective applicants as a result of this
210 See new technology add-on payment
application included in the FY 2023 New
Technology Application Packet, available at:
https://www.cms.gov/files/zip/fy-2023-newtechnology-application-packet.zip; and FY 2023
Tracking Forms, available at: https://www.cms.gov/
files/document/fy-2023-tracking-formsapplicants.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48988
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
proposal since we did not propose to
fundamentally change the information
collected in the application itself or the
supplemental information that would be
furnished to support the application. As
noted, the aim of the proposed policy
change is to increase accuracy,
transparency, and efficiency for both
CMS and stakeholders.
In connection with the proposal to
post the new technology applications
online, we stated that we expect we
would also make changes to the
summaries that appear in the annual
proposed and final rules, given that the
public would have access to the
submitted applications themselves
(excluding certain information and
materials as described previously),
while also continuing to provide
sufficient information in the rules to
facilitate public comments on whether a
medical service or technology meets the
new technology add-on payment
criteria. Specifically, we stated that we
do not anticipate summarizing each
entire application in the Federal
Register as we have in the past, given
the expanded and public access to the
applications under the proposal. In
some instances, such as the discussion
of the substantial clinical improvement
criterion, we stated that we expect to
provide a more concise summary of the
evidence or a more targeted discussion
of the applicant’s claims about how that
criterion is met based on the evidence
and supporting data (although this may
vary depending on the application, new
medical service or technology, and the
nature of supporting materials
provided). We expect that we would
continue to generally include, at a highlevel, the following information in the
proposed and final rules: the technology
and applicant name; a description of
what the technology does; background
on the disease process; the FDA
approval/clearance status; and a
summary of the applicant’s assertions.
We also noted we expect to provide
more succinct information as part of the
summaries in the proposed and final
rules regarding the applicant’s
assertions as to how the medical service
or technology meets the newness, cost,
and substantial clinical improvement
criteria. For example, we would provide
a list of the applicant’s assertions for
whether the technology meets the three
sub-criteria under the substantial
clinical improvement criterion 211 and a
list of the sources of data submitted in
support of the assertions, along with
references to the application in support
211 Sub-criteria referenced are those listed in
Question 36 of the new technology add-on payment
application, specifically Questions 36a–36c.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
of these lists. In the proposed rule, we
stated we would also continue to
provide discussion of the concerns or
issues we identified with respect to
applications submitted under the
traditional pathway, and for an
alternative pathway application, we
intend to continue to propose whether
to approve or disapprove the
application, including noting any
concerns we have identified, and, as
applicable, the maximum add-on
payment amount, where cost
information is available. In the final
rule, we would continue to provide an
explanation of our determination of
whether a medical service or technology
meets the applicable new technology
add-on payment criteria and, for
approved technologies, the final add-on
payment amounts. We stated that as
noted, we believe the proposal to post
online the completed application forms
and other information described
previously would afford greater
transparency during the annual
rulemaking, for purposes of determining
whether a medical service or technology
is eligible for new technology add-on
payments.
We sought public comment on our
proposal to publicly post online the
completed application forms and certain
related materials and updated
application information submitted
subsequent to the initial application
submission for new technology add-on
payments, beginning with applications
for FY 2024.
Comment: We received many public
comments regarding this policy
proposal. Overall, commenters
appreciated the agency’s aims in making
the proposal of fostering greater
transparency and public input, while
mitigating increased burdens and
workloads associated with the rising
complexity and number of new
technology add-on payment
applications submitted annually. A few
commenters were fully supportive of
our proposal, while a majority of the
remaining commenters supported the
proposal, while suggesting
modifications to address concerns about
the disclosure of certain information. In
particular, these commenters were
encouraged by CMS’ proposal not to
include cost and volume information as
part of the application materials that
would be posted online, but stated that
the proposal did not go far enough to
protect potentially confidential,
commercially sensitive information (for
example, biologics license applications
(BLA) or nonpublic studies), and
recommended that CMS modify the
proposal, offering suggestions for
PO 00000
Frm 00210
Fmt 4701
Sfmt 4700
ensuring that such information not be
posted online.
Some commenters requested that
CMS bifurcate the application to allow
a section for information that would not
be posted online, afford applicants the
opportunity to submit a separate file of
confidential information, or allow
information in the application to be
redacted. Other commenters requested
that CMS continue the practice of
allowing the applicant to mark sensitive
proprietary or trade secret information
as confidential and not for posting
online. Commenters stated that if the
full application were posted online,
applicants may refrain from submitting
certain information necessary to support
the application and meet the new
technology add-on payment criteria (for
example, clinical information cited but
not yet in the public domain and prior
to FDA approval and information
concerning newness, such as
engineering specifics), resulting in
applications that are less complete or
robust, and therefore, would
compromise the goals of the new
technology add-on payment process.
Absent protection of this information,
commenters stated that applicants could
apply only after FDA approval, creating
significant delays in new technology
add-on payment approvals and
subsequent beneficiary access.
Commenters also acknowledged that
CMS generally does not consider
confidential or proprietary information
in making a determination whether a
new technology meets the new
technology add-on payment criteria, but
believed there could be circumstances
where such information could
contribute to the agency’s overall
understanding of a technology,
therapeutic area, or other relevant
question that arises during its review
(for example, pre-publication study
results, which are kept from public
release pending their publication in
peer-reviewed scientific publications).
Another commenter asserted that such
data can help CMS better understand
the technology and make a more
informed decision about the
application. The commenters also stated
that, without protection of such
information, companies would no
longer be able to submit such studies
until after publication. Commenters also
stated that the proposed policy puts the
onus on the applicant to not submit this
type of information without recognizing
that a comprehensive application might
require such information.
Additionally, commenters were
generally supportive of our proposal
regarding copyrighted material.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Response: We appreciate the support
for our proposal and our efforts toward
greater transparency, public input, and
streamlining of the new technology addon application process. In making our
proposal, we indicated that applicants
should not submit proprietary or trade
secret information with the application,
to avoid such information being posted
online as part of the application.
Moreover, we proposed not to continue
our practice of allowing applicants to
mark such information to be withheld
from disclosure given that our general
policy is not to consider information
that is marked confidential, proprietary,
or trade secret when determining
whether a technology meets the criteria
for new technology add-on payments
and given the need for the public to
understand the information we are
relying on in making such decisions.
However, in consideration of public
comments, we will provide a
mechanism for applicants to submit
confidential information, including
proprietary or trade secret information,
that will not be posted online. We
anticipate providing a section on the
application where applicants can
submit confidential information
separately from non-confidential
information, or otherwise marking
sections or questions in the application
for which we will not post the
information online. Applicants would
still be required to submit cost and
volume information in the application
since this information is necessary;
however, we will indicate in the
application that cost and volume
information will not be publicly posted
but certain cost and volume information
may still be summarized and discussed
in the proposed rule, as is consistent
with our current practice. Applicants
should expect that, unless otherwise
noted in the application that certain
information will not be posted publicly
(for example, contact information),
everything else may be posted publicly.
We emphasize that it is the applicant’s
responsibility to put confidential
information only in the areas of the
application designated for confidential
information and not elsewhere in the
application. However, as previously
noted, applicants should consider what
they include in a confidential section of
the application given that we generally
do not consider any information that
cannot be made public when
determining whether a technology
meets the new technology add-on
payment criteria. With respect to
copyrighted information, we are
finalizing our proposal without
modification.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Additionally, we note that in the past
we have received applications in which
all the data and information in an
application are marked as proprietary or
confidential, or where certain
information provided in support of the
applicant’s assertions regarding
eligibility for the new technology addon payment, for example a claim of
substantial clinical improvement, is
marked as such. In such cases, we
reiterate that we generally will not be
able to consider that data and
information when determining whether
a technology meets the criteria for new
technology add-on payments. Our
process provides for public input, so it
is important that we provide the
information needed for the public to
meaningfully comment on the new
technology add-on payment
applications, including the applicants’
assertions as to why a technology meets
the new technology add-on payment
criteria.
Comment: A commenter suggested
that CMS further study ways to improve
and streamline the annual review
process. Another commenter requested
that CMS defer a decision until the FY
2025 application cycle, allowing more
time for interested parties and the
agency to more thoroughly consider the
implications and potential options to
improve the efficiency and capacity of
the review process.
Response: As we stated in the
proposed rule, we proposed to publicly
post online applications for new
technology add-on payments to increase
transparency, enable increased
engagement with interested parties, and
improve and streamline our evaluation
process. Through this policy, we also
are attempting to address some of the
downsides and challenges of our current
practice of summarizing the contents of
the applications by restating or
paraphrasing information, ensuring that
sufficient information is provided in the
proposed rule, and avoiding
misrepresenting or omitting any of the
applicants’ claims. Posting the
application and certain related materials
online, subject to certain exceptions as
discussed in this section, is a
straightforward solution and strikes a
balance between affording greater
transparency and streamlining the
application process. Given the reasons
we have noted previously, the overall
support for the proposal, and after
considering the other feedback and
suggestions by commenters, we are
finalizing our proposal to post
applications online, but as previously
discussed, we will provide a mechanism
for applicants to submit confidential
information that would not be included
PO 00000
Frm 00211
Fmt 4701
Sfmt 4700
48989
as part of the application materials
posted online. We also continue to
welcome feedback on the application
and review process, including potential
options for improving the efficiency and
capacity of this process, and we will
continue to consider this issue.
Comment: A few commenters raised
concerns about the timing of when
applications would be posted online. A
commenter questioned whether the
agency planned to post all applications
and related materials online at the same
time, or on a rolling basis as they are
received and deemed complete, noting
that the specific timing of online posting
would be highly relevant to applicants
given that under the current process,
applicants have the opportunity to
amend or withdraw an application prior
to presentation at the New Technology
Town Hall or issuance of the proposed
rule. The commenter believed that any
new online posting process should
preserve an applicant’s ability to
withdraw an application prior to
posting, noting that many applicants
submit materials before certainty that
the technology meets the criteria for a
new technology add-on payment, and
with an intent to either supplement or
withdraw the application during the
cycle, because the annual application
cycle often requires a submission well
in advance of market introduction.
Another commenter noted the fluidity
and frequent updates of the data
collection process in these applications,
which may occur more quickly than the
public notice and comment period and
therefore, the information made
available by CMS may not be current
when it is released.
Response: We agree with the
commenter that additional information
related to the application may be
submitted up until the release of the
proposed rule and understand that
posting the complete application and
supplemental information all at once is
preferable to continually updating the
application information online.
Accordingly, we are clarifying that
under the final policy we are adopting,
we will publicly post the application
and any additional information received
(with the exception of certain
confidential, cost and volume, or
copyrighted information as explained
previously) at the time the proposed
rule is published and no sooner. With
regard to the commenter’s concern
about an applicant’s ability to withdraw
applications during the application
process, we clarify that the policy we
are finalizing would not change an
applicant’s ability to withdraw its
application prior to the proposed rule
being published and, in such cases, we
E:\FR\FM\10AUR2.SGM
10AUR2
48990
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
would not post those applications
online or address them in the proposed
rule. In instances, however, where the
applicant withdraws its application
from consideration after the proposed
rule is issued, the application would
remain posted online (that is,
corresponding to the published
discussion of the application in the
proposed rule).
After considering the comments, and
for the reasons discussed, we are
finalizing our proposal to publicly post
online new technology add-on payment
applications, including the completed
application forms, certain related
materials (as described previously), and
any additional updated application
information submitted subsequent to the
initial application submission (except
certain volume, cost and other
information identified by the applicant
as confidential), beginning with the
application cycle for FY 2024, at the
time the proposed rule is published. We
are finalizing as proposed our proposal
with respect to the treatment of
copyrighted information. We are
finalizing a modification to our proposal
to provide a mechanism for applicants
to submit confidential information that
would not be posted online, such as in
a separate section of the application, or
by identifying particular questions for
which the information submitted would
not be publicly posted. We will not
publicly post cost and volume
information; however, consistent with
our current practice, we will continue to
summarize and discuss certain cost and
volume information for the proposed
rule and will indicate as such in the
application. With the exception of
information included in a confidential
information section of the application,
cost and volume information, and
materials identified by the applicant as
copyrighted and/or not otherwise
releasable to the public, the contents of
the application and related materials
may be posted publicly. We further
clarify that we will post these
application materials at the time of the
proposed rule and no sooner, and that
we will not post applications that are
withdrawn prior to publication of the
proposed rule.
III. Changes to the Hospital Wage Index
for Acute Care Hospitals
khammond on DSKJM1Z7X2PROD with RULES2
A. Background
1. Legislative Authority
Section 1886(d)(3)(E) of the Act
requires that, as part of the methodology
for determining prospective payments to
hospitals, the Secretary adjust the
standardized amounts for area
differences in hospital wage levels by a
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
factor (established by the Secretary)
reflecting the relative hospital wage
level in the geographic area of the
hospital compared to the national
average hospital wage level. We
currently define hospital labor market
areas based on the delineations of
statistical areas established by the Office
of Management and Budget (OMB). A
discussion of the FY 2023 hospital wage
index based on the statistical areas
appears under section III.A.2. of the
preamble of this final rule.
Section 1886(d)(3)(E) of the Act
requires the Secretary to update the
wage index annually and to base the
update on a survey of wages and wagerelated costs of short-term, acute care
hospitals. CMS collects these data on
the Medicare cost report, CMS Form
2552–10, Worksheet S–3, Parts II, III, IV.
The OMB control number for this
information collection request is 0938–
0050, which expired on March 31, 2022.
A 30-day Federal Register notice
published on June 22, 2022 (87 FR
37338) for the reinstatement of the
information collection request. The
comment period closed July 22, 2022.
Section 1886(d)(3)(E) of the Act also
requires that any updates or adjustments
to the wage index be made in a manner
that ensures that aggregate payments to
hospitals are not affected by the change
in the wage index. The adjustment for
FY 2023 is discussed in section II.B. of
the Addendum to this final rule.
As discussed in section III.I. of the
preamble of this final rule, we also take
into account the geographic
reclassification of hospitals in
accordance with sections 1886(d)(8)(B)
and 1886(d)(10) of the Act when
calculating IPPS payment amounts.
Under section 1886(d)(8)(D) of the Act,
the Secretary is required to adjust the
standardized amounts so as to ensure
that aggregate payments under the IPPS
after implementation of the provisions
of sections 1886(d)(8)(B), 1886(d)(8)(C),
and 1886(d)(10) of the Act are equal to
the aggregate prospective payments that
would have been made absent these
provisions. The budget neutrality
adjustment for FY 2023 is discussed in
section II.A.4.b. of the Addendum to
this final rule.
Section 1886(d)(3)(E) of the Act also
provides for the collection of data every
3 years on the occupational mix of
employees for short-term, acute care
hospitals participating in the Medicare
program, in order to construct an
occupational mix adjustment to the
wage index. (The OMB control number
for approved collection of this
information is 0938–0907, which
expires on October 31, 2022. An
extension of the information collection
PO 00000
Frm 00212
Fmt 4701
Sfmt 4700
request is currently being developed.
The public will have an opportunity to
review and submit comments regarding
the extension of this PRA package
through a public notice and comment
period separate from this rulemaking.) A
discussion of the occupational mix
adjustment that we are applying to the
FY 2023 wage index appears under
sections III.E. and F. of the preamble of
this final rule.
2. Core-Based Statistical Areas (CBSAs)
for the FY 2023 Hospital Wage Index
The wage index is calculated and
assigned to hospitals on the basis of the
labor market area in which the hospital
is located. Under section 1886(d)(3)(E)
of the Act, beginning with FY 2005, we
delineate hospital labor market areas
based on OMB-established Core-Based
Statistical Areas (CBSAs). The current
statistical areas (which were
implemented beginning with FY 2015)
are based on revised OMB delineations
issued on February 28, 2013, in OMB
Bulletin No. 13–01. OMB Bulletin No.
13–01 established revised delineations
for Metropolitan Statistical Areas,
Micropolitan Statistical Areas, and
Combined Statistical Areas in the
United States and Puerto Rico based on
the 2010 Census, and provided guidance
on the use of the delineations of these
statistical areas using standards
published in the June 28, 2010, Federal
Register (75 FR 37246 through 37252).
We refer readers to the FY 2015 IPPS/
LTCH PPS final rule (79 FR 49951
through 49963 and 49973 through
49982)) for a full discussion of our
implementation of the OMB statistical
area delineations beginning with the FY
2015 wage index.
Generally, OMB issues major
revisions to statistical areas every 10
years, based on the results of the
decennial census. However, OMB
occasionally issues minor updates and
revisions to statistical areas in the years
between the decennial censuses through
OMB Bulletins. On July 15, 2015, OMB
issued OMB Bulletin No. 15–01, which
provided updates to and superseded
OMB Bulletin No. 13–01 that was issued
on February 28, 2013. The attachment to
OMB Bulletin No. 15–01 provided
detailed information on the update to
statistical areas since February 28, 2013.
The updates provided in OMB Bulletin
No. 15–01 were based on the
application of the 2010 Standards for
Delineating Metropolitan and
Micropolitan Statistical Areas to Census
Bureau population estimates for July 1,
2012, and July 1, 2013. In the FY 2017
IPPS/LTCH PPS final rule (81 FR
56913), we adopted the updates set forth
in OMB Bulletin No. 15–01 effective
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
October 1, 2016, beginning with the FY
2017 wage index. For a complete
discussion of the adoption of the
updates set forth in OMB Bulletin No.
15–01, we refer readers to the FY 2017
IPPS/LTCH PPS final rule. In the FY
2018 IPPS/LTCH PPS final rule (82 FR
38130), we continued to use the OMB
delineations that were adopted
beginning with FY 2015 to calculate the
area wage indexes, with updates as
reflected in OMB Bulletin No. 15–01
specified in the FY 2017 IPPS/LTCH
PPS final rule.
On August 15, 2017, OMB issued
OMB Bulletin No. 17–01, which
provided updates to and superseded
OMB Bulletin No. 15–01 that was issued
on July 15, 2015. The attachments to
OMB Bulletin No. 17–01 provided
detailed information on the update to
statistical areas since July 15, 2015, and
were based on the application of the
2010 Standards for Delineating
Metropolitan and Micropolitan
Statistical Areas to Census Bureau
population estimates for July 1, 2014
and July 1, 2015. In the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41362
through 41363), we adopted the updates
set forth in OMB Bulletin No. 17–01
effective October 1, 2018, beginning
with the FY 2019 wage index. For a
complete discussion of the adoption of
the updates set forth in OMB Bulletin
No. 17–01, we refer readers to the FY
2019 IPPS/LTCH PPS final rule. In the
FY 2020 IPPS/LTCH PPS final rule (84
FR 42300 through 42301), we continued
to use the OMB delineations that were
adopted beginning with FY 2015 (based
on the revised delineations issued in
OMB Bulletin No. 13–01) to calculate
the area wage indexes, with updates as
reflected in OMB Bulletin Nos. 15–01
and 17–01.
On April 10, 2018 OMB issued OMB
Bulletin No. 18–03 which superseded
the August 15, 2017, OMB Bulletin No.
17–01. On September 14, 2018, OMB
issued OMB Bulletin No. 18–04 which
superseded the April 10, 2018 OMB
Bulletin No. 18–03. Historically OMB
bulletins issued between decennial
censuses have only contained minor
modifications to CBSA delineations
based on changes in population counts.
However, OMB’s 2010 Standards for
Delineating Metropolitan and
Micropolitan Statistical Areas to Census
Bureau population estimates created a
larger mid-decade redelineation that
takes into account commuting data from
the American Commuting Survey. As a
result, the September 14, 2018, OMB
Bulletin No. 18–04 included more
modifications to the CBSAs than are
typical for OMB bulletins issued
between decennial censuses.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
In the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58743 through 58755) we
adopted the updates set forth in OMB
Bulletin No. 18–04 effective October 1,
2020, beginning with the FY 2021 wage
index. For a complete discussion of the
adoption of the updates set forth in
OMB Bulletin No. 18–04, we refer
readers to the FY 2021 IPPS/LTCH PPS
final rule.
On March 6, 2020, OMB issued
Bulletin No. 20–01, which provided
updates to and superseded OMB
Bulletin No. 18–04 that was issued on
September 14, 2018. The attachments to
OMB Bulletin No. 20–01 provided
detailed information on the update to
statistical areas since September 14,
2018, and were based on the application
of the 2010 Standards for Delineating
Metropolitan and Micropolitan
Statistical Areas to Census Bureau
population estimates for July 1, 2017,
and July 1, 2018. After reviewing OMB
Bulletin No. 20–01, we determined that
the changes in Bulletin 20–01
encompassed delineation changes that
would not affect the Medicare wage
index for FY 2022. While we adopted
the updates set forth in OMB Bulletin
No. 20–01 in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45163 through
45164) consistent with our general
policy of adopting OMB delineation
updates, we also noted that specific
wage index updates would not be
necessary for FY 2022 as a result of
adopting these updates. In other words,
the updates set forth in OMB Bulletin
No. 20–01 would not affect any
hospital’s geographic area for purposes
of the wage index calculation for FY
2022. For a complete discussion of the
adoption of the updates set forth in
OMB Bulletin No. 20–01, we refer
readers to the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45163 through 45164).
For FY 2023, we are continuing to use
the OMB delineations that were adopted
beginning with FY 2015 (based on the
revised delineations issued in OMB
Bulletin No. 13–01) to calculate the area
wage indexes, with updates as reflected
in OMB Bulletin Nos. 15–01, 17–01, 18–
04 and 20–01.
In connection with our adoption in
FY 2021 of the updates in OMB Bulletin
18–04, we adopted a policy to place a
5-percent cap, for FY 2021, on any
decrease in a hospital’s wage index from
the hospital’s final wage index in FY
2020 so that a hospital’s final wage
index for FY 2021 would not be less
than 95 percent of its final wage index
for FY 2020. We refer the reader to the
FY 2021 IPPS/LTCH PPS final rule (85
FR 58753 through 58755) for a complete
discussion of this transition. As
finalized in the FY 2021 IPPS/LTCH
PO 00000
Frm 00213
Fmt 4701
Sfmt 4700
48991
PPS final rule, this transition was set to
expire at the end of FY 2021. However,
given the unprecedented nature of the
ongoing COVID–19 public health
emergency (PHE), we adopted a policy
in the FY 2022 IPPS/LTCH PPS final
rule to apply an extended transition to
the FY 2022 wage index for hospitals
that received the transition in FY 2021.
Specifically, we continued a wage index
transition for FY 2022 (for hospitals that
received the transition in FY 2021)
under which we applied a 5 percent cap
on any decrease in the hospital’s wage
index compared to its wage index for FY
2021 to mitigate significant negative
impacts of, and provide additional time
for hospitals to adapt to, the CMS
decision to adopt the revised OMB
delineations. We also applied a budget
neutrality adjustment to the
standardized amount so that our
transition in FY 2022 was implemented
in a budget neutral manner under our
authority in section 1886(d)(5)(I) of the
Act. We refer the reader to the FY 2022
IPPS/LTCH PPS final rule (85 FR 45164
through 45165) for a complete
discussion of this transition. We also
refer readers to section III.N. of the
preamble of this final rule which
discusses our permanent policy to apply
a 5-percent cap on any decrease in a
hospital’s wage index compared to its
wage index from the prior fiscal year.
3. Codes for Constituent Counties in
CBSAs
CBSAs are made up of one or more
constituent counties. Each CBSA and
constituent county has its own unique
identifying codes. There are two
different lists of codes associated with
counties: Social Security
Administration (SSA) codes and Federal
Information Processing Standard (FIPS)
codes. Historically, CMS has listed and
used SSA and FIPS county codes to
identify and crosswalk counties to
CBSA codes for purposes of the hospital
wage index. As we discussed in the FY
2018 IPPS/LTCH PPS final rule (82 FR
38129 through 38130), we have learned
that SSA county codes are no longer
being maintained and updated.
However, the FIPS codes continue to be
maintained by the U.S. Census Bureau.
We believe that using the latest FIPS
codes will allow us to maintain a more
accurate and up-to-date payment system
that reflects the reality of population
shifts and labor market conditions.
The Census Bureau’s most current
statistical area information is derived
from ongoing census data received since
2010; the most recent data are from
2020. The Census Bureau maintains a
complete list of changes to counties or
county equivalent entities on the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48992
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
website at https://www.census.gov/
programs-surveys/geography/technicaldocumentation/county-changes.html.
We believe that it is important to use the
latest counties or county equivalent
entities in order to properly crosswalk
hospitals from a county to a CBSA for
purposes of the hospital wage index
used under the IPPS.
In the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38129 through 38130), we
adopted a policy to discontinue the use
of the SSA county codes and began
using only the FIPS county codes for
purposes of cross walking counties to
CBSAs. In addition, in the same rule, we
implemented the latest FIPS code
updates, which were effective October
1, 2017, beginning with the FY 2018
wage indexes. These updates have been
used to calculate the wage indexes in a
manner generally consistent with the
CBSA-based methodologies finalized in
the FY 2005 IPPS final rule and the FY
2015 IPPS/LTCH PPS final rule. We
refer the reader to the FY 2018 IPPS/
LTCH PPS final rule (82 FR 38129
through 38130) for a complete
discussion of our adoption of FIPS
county codes.
Based on the latest information
included in the Census Bureau’s website
at https://www.census.gov/programssurveys/geography/technicaldocumentation/countychanges.2010.html, the Census Bureau
has made the following updates to the
FIPS codes for counties or county
equivalent entities:
• Chugach Census Area, AK (FIPS
State County Code 02–063) and Copper
River Census Area, AK (FIPS State
County Code 02–066), were created
from former Valdez-Cordova Census
Area (02–261) which was located in
CBSA 02. The CBSA code for these two
new county equivalents remains 02.
We believe that it is important to use
the latest counties or county equivalent
entities in order to properly crosswalk
hospitals from a county to a CBSA for
purposes of the hospital wage index
used under the IPPS. In addition, we
believe that using the latest FIPS codes
allows us to maintain a more accurate
and up-to-date payment system that
reflects the reality of population shifts
and labor market conditions. Therefore,
in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28359), we
proposed to implement these FIPS code
updates listed previously, effective
October 1, 2022, beginning with the FY
2023 wage indexes. We proposed to use
these update changes to calculate area
wage indexes in a manner that is
generally consistent with the CBSAbased methodologies finalized in the FY
2005 IPPS final rule (69 FR 49026
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
through 49034) and the FY 2015 IPPS/
LTCH PPS final rule (79 FR 49951
through 49963). We note that while the
county update changes listed previously
changed the county names, the CBSAs
to which these counties map did not
change from the prior counties.
Therefore, we stated that there would be
no impact or change to hospitals in
these counties for purposes of the
hospital wage index as a result of our
implementation of these FIPS code
updates. We invited public comments
on our proposals.
We did not receive any public
comments on our proposals. Therefore,
for the reasons discussed earlier, we are
finalizing our proposal, without
modification, to implement the FIPS
code updates listed previously, effective
October 1, 2022, beginning with the FY
2023 wage indexes. As we proposed, we
will use these update changes to
calculate the area wage indexes in a
manner that is generally consistent with
the CBSA-based methodologies
finalized in the FY 2005 IPPS final rule
and the FY 2015 IPPS/LTCH PPS final
rule. For FY 2023, Tables 2 and 3
associated with this final rule and the
County to CBSA Crosswalk File and
Urban CBSAs and Constituent Counties
for Acute Care Hospitals File posted on
the CMS website reflect these FIPS code
updates.
B. Worksheet S–3 Wage Data for the FY
2023 Wage Index
The FY 2023 wage index values are
based on the data collected from the
Medicare cost reports submitted by
hospitals for cost reporting periods
beginning in FY 2019 (the FY 2022 wage
indexes were based on data from cost
reporting periods beginning during FY
2018).
1. Included Categories of Costs
The FY 2023 wage index includes all
of the following categories of data
associated with costs paid under the
IPPS (as well as outpatient costs):
• Salaries and hours from short-term,
acute care hospitals (including paid
lunch hours and hours associated with
military leave and jury duty).
• Home office costs and hours.
• Certain contract labor costs and
hours, which include direct patient
care, certain top management,
pharmacy, laboratory, and nonteaching
physician Part A services, and certain
contract indirect patient care services
(as discussed in the FY 2008 final rule
with comment period (72 FR 47315
through 47317)).
• Wage-related costs, including
pension costs (based on policies
adopted in the FY 2012 IPPS/LTCH PPS
PO 00000
Frm 00214
Fmt 4701
Sfmt 4700
final rule (76 FR 51586 through 51590)
and modified in the FY 2016 IPPS/
LTCH PPS final rule (80 FR 49505
through 49508)) and other deferred
compensation costs.
2. Excluded Categories of Costs
Consistent with the wage index
methodology for FY 2022, the wage
index for FY 2023 also excludes the
direct and overhead salaries and hours
for services not subject to IPPS payment,
such as skilled nursing facility (SNF)
services, home health services, costs
related to GME (teaching physicians and
residents) and certified registered nurse
anesthetists (CRNAs), and other
subprovider components that are not
paid under the IPPS. The FY 2023 wage
index also excludes the salaries, hours,
and wage-related costs of hospital-based
rural health clinics (RHCs), and
Federally Qualified Health Centers
(FQHCs) because Medicare pays for
these costs outside of the IPPS (68 FR
45395). In addition, salaries, hours, and
wage-related costs of CAHs are excluded
from the wage index for the reasons
explained in the FY 2004 IPPS final rule
(68 FR 45397 through 45398). For FY
2020 and subsequent years, other wagerelated costs are also excluded from the
calculation of the wage index. As
discussed in the FY 2019 IPPS/LTCH
final rule (83 FR 41365 through 41369),
other wage-related costs reported on
Worksheet S–3, Part II, Line 18 and
Worksheet S–3, Part IV, Line 25 and
subscripts, as well as all other wagerelated costs, such as contract labor
costs, are excluded from the calculation
of the wage index.
3. Use of Wage Index Data by Suppliers
and Providers Other Than Acute Care
Hospitals Under the IPPS
Data collected for the IPPS wage
index also are currently used to
calculate wage indexes applicable to
suppliers and other providers, such as
SNFs, home health agencies (HHAs),
ambulatory surgical centers (ASCs), and
hospices. In addition, they are used for
prospective payments to IRFs, IPFs, and
LTCHs, and for hospital outpatient
services. We note that, in the IPPS rules,
we do not address comments pertaining
to the wage indexes of any supplier or
provider except IPPS providers and
LTCHs. Such comments should be made
in response to separate proposed rules
for those suppliers and providers. We
did not receive any comments on the
discussion in this section.
C. Verification of Worksheet S–3 Wage
Data
The wage data for the FY 2023 wage
index were obtained from Worksheet S–
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
3, Parts II, III and IV of the Medicare
cost report, CMS Form 2552–10 for cost
reporting periods beginning on or after
October 1, 2018, and before October 1,
2019. (As noted in section III.A.1 of the
preamble of this final rule, the OMB
control number for this information
collection request is 0938–0050, which
expired on March 31, 2022. A 30-day
Federal Register notice published on
June 22, 2022 (87 FR 37338) for the
reinstatement of the information
collection request. The comment period
closed July 22, 2022). For wage index
purposes, we refer to cost reports
beginning on or after October 1, 2018,
and before October 1, 2019 as the ‘‘FY
2019 cost report,’’ the ‘‘FY 2019 wage
data,’’ or the ‘‘FY 2019 data.’’
Instructions for completing the wage
index sections of Worksheet S–3 are
included in the Provider
Reimbursement Manual (PRM), Part 2
(Pub. 15–2), Chapter 40, Sections 4005.2
through 4005.4. The data file used to
construct the FY 2023 wage index
includes FY 2019 data submitted to us
as of the end of June 2022. As in past
years, we performed an extensive
review of the wage data, mostly through
the use of edits designed to identify
aberrant data.
Consistent with the IPPS and LTCH
PPS ratesettings, our policy principles
with regard to the wage index include
generally using the most current data
and information available which is
usually data on a 4-year lag (for
example, for the FY 2022 wage index we
used cost report data from FY 2018) . In
section I.F. of the preamble of this final
rule, we discuss our analysis of the best
available data for use in the
development of this FY 2023 IPPS/
LTCH PPS final rule given the potential
impact of the public health emergency
(PHE) for the Coronavirus Disease
(COVID–19). For the FY 2023 wage
index, the best available data typically
would be from the FY 2019 wage data.
Our review and analysis of the FY 2019
wage data shows that the data is not
significantly impacted by COVID–19
PHE. A comparison of providers shows
similar trends in those with cost reports
ending during the PHE as compared to
providers without cost reports ending
during the PHE. The data also shows
that changes in the average hourly wage
(AHW) for providers were consistent
between providers with cost reports
ending during the PHE as compared to
providers without cost reports ending
during the PHE. It appears that the
overall impact of the COVID–19 PHE on
the FY 2019 wage data has been
minimal. Additionally, the changes in
the wage data from FY 2018 to FY 2019
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
show similar trends in the change of the
data from FY 2017 to FY 2018.
Therefore, we proposed to use the FY
2019 wage data for the FY 2023 wage
index.
Comment: A commenter expressed
concern that the review and analysis of
the FY 2019 wage data with regard to
the impact by COVID–19 PHE was
unclear. The commenter noted that the
proposed rule did not reference tables or
files for the public to review to confirm
the agency’s conclusion. The
commenter also stated that it is
confusing why CMS stated that the FY
2019 wage data was not impacted by the
PHE given that the PHE did not begin
until March 2020. The commenter
encouraged CMS to share source
information so stakeholders can better
understand the agency’s position,
particularly given the review of data
suggests that the cost of staffing has
increased substantially.
Response: With regard to the
commenter that stated that the PHE did
not begin until March 2020, we note
that the PHE was declared on January
31, 2020 in response to COVID–19. We
also note that in March 2020, the World
Health Organization declared the
COVID–19 outbreak a pandemic.
As previously stated, our review and
analysis of the FY 2019 wage data
shows that the data is not significantly
impacted by COVID–19 PHE. We use
the latest audited data to calculate the
wage index. The latest audited data as
of the FY 2023 rulemaking cycle is cost
reports with a begin date during FY
2019. Because we use audited cost
report data with a begin date in FY 2019
(on or after Oct 1, 2018 through on or
before September 30, 2019), the latest
cost report with a begin date in FY 2019
would be September 30, 2019 which
would end typically 12 months later on
September 30, 2020 (which would
include some months in the PHE). The
earlier the cost report begin date the less
months of data are included in the
period of the PHE. As noted in this
section of this rule, there are 3,136
providers included in the wage index
for FY 2023.
Approximately 1,300 hospitals have
cost report data from FY 2019 that has
some months of data touching the PHE
in the period of January 31, 2020
through September 30, 2020. We note,
while the PHE was declared January 31,
2020, the impact of the PHE began to be
felt by hospitals beginning in March
2020 (which is re-enforced by the
commenter that stated its belief that the
PHE began in March 2020). Of these
1,300 hospitals:
• Approximately 80 hospitals have a
cost reporting period of 04/01/2019
PO 00000
Frm 00215
Fmt 4701
Sfmt 4700
48993
through 03/30/2020 (one month of data
in the period between March 2020
through September 2020).
• Approximately 1,000 hospitals have
a cost reporting period of 07/01/2019
through 06/30/2020 (four months of
data in the period between March 2020
through September 2020).
• Approximately 85 hospitals have a
cost reporting period of 09/01/2019
through 08/30/2020 (six months of data
in the period between April 2020
through September 2020).
Based on the previous, approximately
37 percent of hospitals include data
from the period of March 2020 through
September 2020. The majority of these
hospitals (1,000) have a cost report
begin date of July 1, 2019 which
accounts for approximately 32 percent
of all hospitals cost report data; also, the
majority of the cost report data for these
hospitals (8 months) is not impacted by
the PHE. Therefore, the overwhelming
majority of hospitals data has no data
from the period of March 2020 through
September 2020. While some cost
reports included some months of data
from the period of March 2020 through
September 2020, as previously stated,
the data shows that changes in the
average hourly wage (AHW) for
providers were consistent between
providers with cost reports ending
during the PHE as compared to
providers without cost reports ending
during the PHE. Additionally, the
changes in the wage data from FY 2018
to FY 2019 show similar trends in the
change of the data from FY 2017 to FY
2018. We also note, AHW data by
provider and CBSA is readily available
in our Public Use Files released with
each proposed and final rule each fiscal
year. Therefore, any comparisons that
CMS made within the current year data
and prior year data can easily be
replicated by the public. We did not
receive any comments questioning
whether certain providers or CBSAs
AHW were grossly affected by the PHE.
Therefore, we continue to believe that
the data shows that changes in the
average hourly wage (AHW) for
providers were consistent between
providers with cost reports ending
during the PHE as compared to
providers without cost reports ending
during the PHE.
We also note, in section G.2.c. of
Appendix A of the FY 2023 IPPS/LTCH
proposed rule (87 FR 28709), we
provided a table showing the projected
impact of proposed changes in the area
wage index values for urban and rural
hospitals. Specifically, the table
compares the shifts in wage index
values for hospitals due to proposed
changes in the average hourly wage data
E:\FR\FM\10AUR2.SGM
10AUR2
48994
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
for FY 2023 relative to FY 2022. We
refer the commenter to this table as well
as a similar table that is published in
section G.2.c. of Appendix A in this
final rule.
Finally, CMS will be looking at the
differential effects of the COVID–19 PHE
on the audited wage data in future fiscal
years. We plan to review the audited
wage data, and the impacts of the
COVID–19 PHE on such data and
evaluate these data for future
rulemaking.
We requested that our MACs revise or
verify data elements that result in
specific edit failures. For the proposed
FY 2023 wage index, we identified and
excluded 86 providers with aberrant
data that should not be included in the
wage index. However, we stated that if
data elements for some of these
providers are corrected, we intended to
include data from those providers in the
final FY 2023 wage index. We also
adjusted certain aberrant data and
included these data in the wage index.
For example, in situations where a
hospital did not have documentable
salaries, wages, and hours for
housekeeping and dietary services, we
imputed estimates, in accordance with
policies established in the FY 2015
IPPS/LTCH PPS final rule (79 FR 49965
through 49967). We instructed MACs to
complete their data verification of
questionable data elements and to
transmit any changes to the wage data
no later than March 19, 2022. For the
final FY 2023 wage index, we restored
the data of 23 hospitals to the wage
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
index because their data was either
verified or improved, and removed the
data of 0 hospitals for the first time after
the proposed rule due to its data being
aberrant. We also restored the data of
one provider that we inadvertently
excluded from the proposed rule that
was not on the delete list in the
proposed rule public use file. Thus, 63
hospitals with aberrant data remain
excluded from the FY 2023 wage index
(86¥23 = 63).
In constructing the proposed FY 2023
wage index, we included the wage data
for facilities that were IPPS hospitals in
FY 2019, inclusive of those facilities
that have since terminated their
participation in the program as
hospitals, as long as those data did not
fail any of our edits for reasonableness.
We stated in the proposed rule (87 FR
28630 through 28632) that we believe
that including the wage data for these
hospitals is, in general, appropriate to
reflect the economic conditions in the
various labor market areas during the
relevant past period and to ensure that
the current wage index represents the
labor market area’s current wages as
compared to the national average of
wages. However, we excluded the wage
data for CAHs as discussed in the FY
2004 IPPS final rule (68 FR 45397
through 45398); that is, any hospital that
is designated as a CAH by 7 days prior
to the publication of the preliminary
wage index public use file (PUF) is
excluded from the calculation of the
wage index. For the proposed FY 2023
wage index, we removed 3 hospitals
PO 00000
Frm 00216
Fmt 4701
Sfmt 4700
that converted to CAH status on or after
January 24, 2021, the cut-off date for
CAH exclusion from the FY 2022 wage
index, and through and including
January 21, 2022, the cut-off date for
CAH exclusion from the FY 2023 wage
index. Since the proposed rule, we
learned of 0 more hospitals that
converted to CAH status on or after
January 24, 2021, and through and
including January 21, 2022, the cut-off
date for CAH exclusion from the FY
2023 wage index, for a total of 3
hospitals that were removed from the
FY 2023 wage index due to conversion
to CAH status. In summary, we
calculated the FY 2023 wage index
using the Worksheet S–3, Parts II and III
wage data of 3,136 hospitals.
For the FY 2023 wage index, we
allotted the wages and hours data for a
multicampus hospital among the
different labor market areas where its
campuses are located using campus fulltime equivalent (FTE) percentages as
originally finalized in the FY 2012 IPPS/
LTCH PPS final rule (76 FR 51591).
Table 2, which contains the FY 2023
wage index associated with this final
rule (available via the internet on the
CMS website), includes separate wage
data for the campuses of 26
multicampus hospitals. The following
chart lists the multicampus hospitals by
CSA certification number (CCN) and the
FTE percentages on which the wages
and hours of each campus were allotted
to their respective labor market areas:
BILLING CODE 4120–01–P
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00217
Fmt 4701
Full-Time Equivalent (FTE)
Percenta~es
0.86
0.14
0.96
0.04
0.99
0.01
0.93
0.07
0.53
0.47
0.56
0.44
0.82
0.18
0.89
0.11
0.82
0.18
0.97
0.03
0.89
0.11
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.110
khammond on DSKJM1Z7X2PROD with RULES2
CCN of Multicampus Hospital
050121
05B121
070010
07B010
070022
07B022
070033
07B033
100029
10B029
100167
10B167
140010
14B010
220074
22B074
310069
31B069
310108
31B108
330195
33B195
48995
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
CCN of Multicampus Hospital
330103
33B103
330214
33B214
330234
33B234
340115
34B115
360020
36B020
390006
39B006
390115
39B115
390142
39B142
450033
45B033
450330
45B330
460051
46B051
510022
51B022
520009
52B009
670062
67B062
670107
67B107
khammond on DSKJM1Z7X2PROD with RULES2
BILLING CODE 4120–01–C
We noted that, in past years, in Table
2, we have placed a ‘‘B’’ to designate the
subordinate campus in the fourth
position of the hospital CCN. However,
for the FY 2019 IPPS/LTCH PPS
proposed and final rules and subsequent
rules, we have moved the ‘‘B’’ to the
third position of the CCN. Because all
IPPS hospitals have a ‘‘0’’ in the third
position of the CCN, we believe that
placement of the ‘‘B’’ in this third
position, instead of the ‘‘0’’ for the
subordinate campus, is the most
efficient method of identification and
interferes the least with the other,
variable, digits in the CCN.
Comment: Commenters opposed the
exclusion of hospitals’ wage data. These
commenters stated that excluding
accurate and verified data is
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Full-Time Equivalent (FTE)
Percentages
0.67
0.33
0.74
0.26
0.78
0.22
0.95
0.05
0.96
0.04
0.96
0.04
0.86
0.14
0.84
0.16
0.99
0.01
0.96
0.04
0.78
0.22
0.94
0.06
0.69
0.31
0.69
0.31
0.69
0.31
inconsistent with the extensive process
established by CMS to ensure the
accuracy and reliability of hospital wage
index data. Commenters also raised
concerns about the lawfulness of
excluding wage data for these hospitals,
stating that section 1886(d)(3)(E) of the
Act does not provide the authority for
CMS to delete accurately-reported wage
data, and doing so is arbitrary and
capricious.
Specifically, a commenter opposed
the exclusion of hospitals’ wage data
where hospitals timely submitted
corrections or appeals. The commenter
stated that where hospitals have
available timely-submitted, corrected
and verifiable data CMS is obligated to
use such data in the wage index
calculation. The commenter also stated
PO 00000
Frm 00218
Fmt 4701
Sfmt 4700
that there is no statute or regulation
authorizing CMS to exclude hospital
data based on a unilateral determination
that the data is aberrant.
Response: We responded to similar
comments in the FY 2016 IPPS/LTCH
PPS final rule (80 FR 49490 through
49491) and the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45168 through 45169).
Section 1886(d)(3)(E) of the Act requires
the Secretary to adjust the proportion of
hospitals’ costs attributable to wages
and wage-related costs for area
differences reflecting the relative
hospital wage level in the geographic
area of the hospital compared to the
national average hospital wage level. As
previously stated in those final rules in
response to similar comments, we
believe that, under this section of the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.111
48996
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Act, we have discretion to exclude
aberrant hospital data from the wage
index PUFs to help ensure that the costs
attributable to wages and wage-related
costs in fact reflect the relative hospital
wage level in the hospitals’ geographic
area. We refer commenters to our
previous responses to comments at the
Federal Register pages cited earlier in
this response with regard to the
exclusion of hospitals’ wage data from
the wage index.
Comment: Some commenters urged
CMS to lessen the lag of four years in
hospitals’ cost report data used for the
wage index (for example, FY 2019 cost
report data used for the FY 2023 wage
index) and to consider alternate
methods to collect more accurate data.
Another commenter stated that CMS
should offer short-term assistance to the
hospital community, considering
inflationary updates to the wage index
as necessary to preserve current service
levels, which the commenter believes is
a particular risk point for underserved
populations. The commenter
recommended a more time-sensitive and
layered approach to wage index updates
to account for excess labor costs driven
by increased contract labor and
reimbursement rates to preserve our
critical national hospital system
infrastructure. The commenter stated
that CMS could accomplish this by
leveraging current Medicare cost report
surveys to develop a wage adjustment
until the labor market stabilizes. This
approach would account for regional
disparities and impact, use known and
accepted survey data, create a
standardized and auditable system, and
support hospitals without disrupting the
baseline Medicare wage index.
Response: CMS used the most recent
audited surveys and data to develop the
FY 2023 wage index. We are unclear
what alternative data or which current
surveys and reporting the commenters
are referring to. We note, audited cost
report data from FY 2020 will be used
for FY 2024 and is not available at the
time of this final rule. Therefore, we are
unable to account for regional
differences without audited data. Also,
as previously noted, section
1886(d)(3)(E) of the Act requires that, as
part of the methodology for determining
prospective payments to hospitals, the
Secretary adjust the standardized
amounts for area differences in hospital
wage levels by a factor (established by
the Secretary) reflecting the relative
hospital wage level in the geographic
area of the hospital compared to the
national average hospital wage level.
Uniformly adjusting the salaries and
hours for all areas (which is used to
calculate an areas AHW) would lead to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
a commensurate change to the national
AHW and not the wage index itself.
This is because the wage index is
required to be a relative measure.
Further, we refer the commenter to the
discussion on the market basket in
section V. A. 1. of the preamble of this
final rule for which we now have an
updated forecast of the price proxies
underlying the market basket that
incorporates more recent historical data
and reflects a revised outlook regarding
the U.S. economy (including the more
recent historical CPI growth, impacts of
the Russia/Ukraine war, current
expectations regarding changes to
Federal Reserve interest rates, and tight
labor markets). Additionally, we note
that section 1886(d)(3)(E)(i) of the Act
requires us to make any updates or
adjustments to the wage index in a
manner that ensures that aggregate
payments under section 1886(d) are not
affected by the change in the wage
index. Section 1886(d)(3)(E)(i) of the Act
requires that we implement the wage
index adjustment in a budget neutral
manner. Therefore, since the wage index
is subject to budget neutrality, any
increases or decreases as a result of the
data from one FY to the next FY would
be implemented in a budget neutral
manner.
D. Method for Computing the FY 2023
Unadjusted Wage Index
As stated in the proposed rule (87 FR
28362 through 28365), the method used
to compute the FY 2023 wage index
without an occupational mix adjustment
follows the same methodology that we
used to compute the wage indexes
without an occupational mix adjustment
in the FY 2021 IPPS/LTCH PPS final
rule (see 85 FR 58758 through 58761,
September 18, 2020), and we did not
propose any changes to this
methodology. We have restated our
methodology in this section of this final
rule.
Step 1.—We gathered data from each
of the non-Federal, short-term, acute
care hospitals for which data were
reported on the Worksheet S–3, Parts II
and III of the Medicare cost report for
the hospital’s cost reporting period
relevant to the wage index (in this case,
for FY 2023, these were data from cost
reports for cost reporting periods
beginning on or after October 1, 2018,
and before October 1, 2019). In addition,
we included data from some hospitals
that had cost reporting periods
beginning before October 2018 and
reported a cost reporting period
covering all of FY 2019. These data were
included because no other data from
these hospitals would be available for
the cost reporting period as previously
PO 00000
Frm 00219
Fmt 4701
Sfmt 4700
48997
described, and because particular labor
market areas might be affected due to
the omission of these hospitals.
However, we generally describe these
wage data as FY 2019 data. We note
that, if a hospital had more than one
cost reporting period beginning during
FY 2019 (for example, a hospital had
two short cost reporting periods
beginning on or after October 1, 2018,
and before October 1, 2019), we include
wage data from only one of the cost
reporting periods, the longer, in the
wage index calculation. If there was
more than one cost reporting period and
the periods were equal in length, we
included the wage data from the later
period in the wage index calculation.
Step 2.—Salaries.—The method used
to compute a hospital’s average hourly
wage excludes certain costs that are not
paid under the IPPS. (We note that,
beginning with FY 2008 (72 FR 47315),
we included what were then Lines
22.01, 26.01, and 27.01 of Worksheet S–
3, Part II of CMS Form 2552–96 for
overhead services in the wage index.
Currently, these lines are lines 28, 33,
and 35 on CMS Form 2552–10.
However, we note that the wages and
hours on these lines are not
incorporated into Line 101, Column 1 of
Worksheet A, which, through the
electronic cost reporting software, flows
directly to Line 1 of Worksheet S–3, Part
II. Therefore, the first step in the wage
index calculation is to compute a
‘‘revised’’ Line 1, by adding to the Line
1 on Worksheet S–3, Part II (for wages
and hours respectively) the amounts on
Lines 28, 33, and 35.) In calculating a
hospital’s Net Salaries (we note that we
previously used the term ‘‘average’’
salaries in the FY 2012 IPPS/LTCH PPS
final rule (76 FR 51592), but we now use
the term ‘‘net’’ salaries) plus wagerelated costs, we first compute the
following: Subtract from Line 1 (total
salaries) the GME and CRNA costs
reported on CMS Form 2552–10, Lines
2, 4.01, 7, and 7.01, the Part B salaries
reported on Lines 3, 5 and 6, home
office salaries reported on Line 8, and
exclude salaries reported on Lines 9 and
10 (that is, direct salaries attributable to
SNF services, home health services, and
other subprovider components not
subject to the IPPS). We also subtract
from Line 1 the salaries for which no
hours were reported. Therefore, the
formula for Net Salaries (from
Worksheet S–3, Part II) is the following:
((Line 1 + Line 28 + Line 33 + Line
35)¥(Line 2 + Line 3 + Line 4.01 + Line
5 + Line 6 + Line 7 + Line 7.01 + Line
8 + Line 9 + Line 10)).
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
48998
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
To determine Total Salaries plus
Wage-Related Costs, we add to the Net
Salaries the costs of contract labor for
direct patient care, certain top
management, pharmacy, laboratory, and
nonteaching physician Part A services
(Lines 11, 12 and 13), home office
salaries and wage-related costs reported
by the hospital on Lines 14.01, 14.02,
and 15, and nonexcluded area wagerelated costs (Lines 17, 22, 25.50, 25.51,
and 25.52). We note that contract labor
and home office salaries for which no
corresponding hours are reported are
not included. In addition, wage-related
costs for nonteaching physician Part A
employees (Line 22) are excluded if no
corresponding salaries are reported for
those employees on Line 4. The formula
for Total Salaries plus Wage-Related
Costs (from Worksheet S–3, Part II) is
the following: ((Line 1 + Line 28 + Line
33 + Line 35)¥(Line 2 + Line 3 + Line
4.01 + Line 5 + Line 6 + Line 7 + Line
7.01 + Line 8 + Line 9 + Line 10)) +
(Line 11 + Line 12 + Line 13 + Line
14.01 + 14.02 + Line 15) + (Line 17 +
Line 22 + 25.50 + 25.51 + 25.52).
Step 3.—Hours.—With the exception
of wage-related costs, for which there
are no associated hours, we compute
total hours using the same methods as
described for salaries in Step 2. The
formula for Total Hours (from
Worksheet S–3, Part II) is the following:
((Line 1 + Line 28 + Line 33 + Line
35)¥(Line 2 + Line 3 + Line 4.01 + Line
5 + Line 6 + Line 7 + Line 7.01 + Line
8 + Line 9 + Line 10)) + (Line 11 + Line
12 + Line 13 + Line 14.01 + 14.02 + Line
15).
Step 4.—For each hospital reporting
both total overhead salaries and total
overhead hours greater than zero, we
then allocate overhead costs to areas of
the hospital excluded from the wage
index calculation. First, we determine
the ‘‘excluded rate’’, which is the ratio
of excluded area hours to Revised Total
Hours (from Worksheet S–3, Part II)
with the following formula: (Line 9 +
Line 10)/(Line 1 + Line 28 + Line 33 +
Line 35)—(Lines 2, 3, 4.01, 5, 6, 7, 7.01,
and 8 and Lines 26 through 43). We
then compute the amounts of overhead
salaries and hours to be allocated to the
excluded areas by multiplying the
previously discussed ratio by the total
overhead salaries and hours reported on
Lines 26 through 43 of Worksheet S–3,
Part II. Next, we compute the amounts
of overhead wage-related costs to be
allocated to the excluded areas using
three steps:
• We determine the ‘‘overhead rate’’
(from Worksheet S–3, Part II), which is
the ratio of overhead hours (Lines 26
through 43 minus the sum of Lines 28,
33, and 35) to revised hours excluding
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the sum of lines 28, 33, and 35 (Line 1
minus the sum of Lines 2, 3, 4.01, 5, 6,
7, 7.01, 8, 9, 10, 28, 33, and 35). We note
that, for the FY 2008 and subsequent
wage index calculations, we have been
excluding the overhead contract labor
(Lines 28, 33, and 35) from the
determination of the ratio of overhead
hours to revised hours because hospitals
typically do not provide fringe benefits
(wage-related costs) to contract
personnel. Therefore, it is not necessary
for the wage index calculation to
exclude overhead wage-related costs for
contract personnel. Further, if a hospital
does contribute to wage-related costs for
contracted personnel, the instructions
for Lines 28, 33, and 35 require that
associated wage-related costs be
combined with wages on the respective
contract labor lines. The formula for the
Overhead Rate (from Worksheet S–3,
Part II) is the following: (Lines 26
through 43—Lines 28, 33 and 35)/
((((Line 1 + Lines 28, 33, 35)¥(Lines 2,
3, 4.01, 5, 6, 7, 7.01, 8, and 26 through
43))¥(Lines 9 and 10)) + (Lines 26
through 43¥Lines 28, 33, and 35)).
• We compute overhead wage-related
costs by multiplying the overhead hours
ratio by wage-related costs reported on
Part II, Lines 17, 22, 25.50, 25.51, and
25.52.
• We multiply the computed
overhead wage-related costs by the
previously described excluded area
hours ratio.
Finally, we subtract the computed
overhead salaries, wage-related costs,
and hours associated with excluded
areas from the total salaries (plus wagerelated costs) and hours derived in
Steps 2 and 3.
Step 5.—For each hospital, we adjust
the total salaries plus wage-related costs
to a common period to determine total
adjusted salaries plus wage-related
costs. To make the wage adjustment, we
estimate the percentage change in the
employment cost index (ECI) for
compensation for each 30-day
increment from October 14, 2018,
through April 15, 2020, for private
industry hospital workers from the
Bureau of Labor Statistics’ (BLS’)
Compensation and Working Conditions.
We use the ECI because it reflects the
price increase associated with total
compensation (salaries plus fringes)
rather than just the increase in salaries.
In addition, the ECI includes managers
as well as other hospital workers. This
methodology to compute the monthly
update factors uses actual quarterly ECI
data and assures that the update factors
match the actual quarterly and annual
percent changes. We also note that,
since April 2006 with the publication of
March 2006 data, the BLS’ ECI uses a
PO 00000
Frm 00220
Fmt 4701
Sfmt 4700
different classification system, the North
American Industrial Classification
System (NAICS), instead of the Standard
Industrial Codes (SICs), which no longer
exist. We have consistently used the ECI
as the data source for our wages and
salaries and other price proxies in the
IPPS market basket, and we did not
propose to make any changes to the
usage of the ECI for FY 2023. The factors
used to adjust the hospital’s data are
based on the midpoint of the cost
reporting period, as indicated in this
rule.
Step 6.—Each hospital is assigned to
its appropriate urban or rural labor
market area before any reclassifications
under section 1886(d)(8)(B),
1886(d)(8)(E), or 1886(d)(10) of the Act.
Within each urban or rural labor market
area, we add the total adjusted salaries
plus wage-related costs obtained in Step
5 for all hospitals in that area to
determine the total adjusted salaries
plus wage-related costs for the labor
market area.
Step 7.—We divide the total adjusted
salaries plus wage-related costs obtained
under Step 6 by the sum of the
corresponding total hours (from Step 4)
for all hospitals in each labor market
area to determine an average hourly
wage for the area.
Step 8.—We add the total adjusted
salaries plus wage-related costs obtained
in Step 5 for all hospitals in the Nation
and then divide the sum by the national
sum of total hours from Step 4 to arrive
at a national average hourly wage.
Step 9.—For each urban or rural labor
market area, we calculate the hospital
wage index value, unadjusted for
occupational mix, by dividing the area
average hourly wage obtained in Step 7
by the national average hourly wage
computed in Step 8.
Step 10.—For each urban labor market
area for which we do not have any
hospital wage data (either because there
are no IPPS hospitals in that labor
market area, or there are IPPS hospitals
in that area but their data are either too
new to be reflected in the current year’s
wage index calculation, or their data are
aberrant and are deleted from the wage
index), we finalized in the FY 2020
IPPS/LTCH PPS final rule (84 FR 42305)
that, for FY 2020 and subsequent years’
wage index calculations, such CBSA’s
wage index would be equal to total
urban salaries plus wage-related costs
(from Step 5) in the State, divided by
the total urban hours (from Step 4) in
the State, divided by the national
average hourly wage from Step 8 (see 84
FR 42305 and 42306, August 16, 2019).
We stated that we believe that, in the
absence of wage data for an urban labor
market area, it is reasonable to use a
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
statewide urban average, which is based
on actual, acceptable wage data of
hospitals in that State, rather than
impute some other type of value using
a different methodology. For calculation
of the FY 2023 wage index, we note
there is one urban CBSA for which we
do not have IPPS hospital wage data. In
Table 3 (which is available via the
internet on the CMS website) which
contains the area wage indexes, we
include a footnote to indicate to which
CBSAs this policy applies. These
CBSAs’ wage indexes would be equal to
total urban salaries plus wage-related
costs (from Step 5) in the respective
State, divided by the total urban hours
(from Step 4) in the respective State,
divided by the national average hourly
wage (from Step 8) (see 84 FR 42305 and
42306, August 16, 2019). Under this
step, we also apply our policy with
regard to how dollar amounts, hours,
and other numerical values in the wage
index calculations are rounded, as
discussed in this section of this rule.
We refer readers to section II. of the
Appendix of the final rule for the policy
regarding rural areas that do not have
IPPS hospitals.
Step 11.—Section 4410 of Public Law
105–33 provides that, for discharges on
or after October 1, 1997, the area wage
index applicable to any hospital that is
located in an urban area of a State may
not be less than the area wage index
applicable to hospitals located in rural
areas in that State. The areas affected by
this provision are identified in Table 2
listed in section VI. of the Addendum to
the final rule and available via the
internet on the CMS website.
Following is our policy with regard to
rounding of the wage data (dollar
amounts, hours, and other numerical
values) in the calculation of the
unadjusted and adjusted wage index, as
finalized in the FY 2020 IPPS/LTCH
final rule (84 FR 42306, August 16,
2019). For data that we consider to be
‘‘raw data,’’ such as the cost report data
on Worksheets S–3, Parts II and III, and
the occupational mix survey data, we
use such data ‘‘as is,’’ and do not round
any of the individual line items or
fields. However, for any dollar amounts
within the wage index calculations,
including any type of summed wage
amount, average hourly wages, and the
national average hourly wage (both the
unadjusted and adjusted for
occupational mix), we round the dollar
amounts to 2 decimals. For any hour
amounts within the wage index
calculations, we round such hour
amounts to the nearest whole number.
48999
For any numbers not expressed as
dollars or hours within the wage index
calculations, which could include
ratios, percentages, or inflation factors,
we round such numbers to 5 decimals.
However, we continue rounding the
actual unadjusted and adjusted wage
indexes to 4 decimals, as we have done
historically.
As discussed in the FY 2012 IPPS/
LTCH PPS final rule, in ‘‘Step 5,’’ for
each hospital, we adjust the total
salaries plus wage-related costs to a
common period to determine total
adjusted salaries plus wage-related
costs. To make the wage adjustment, we
estimate the percentage change in the
employment cost index (ECI) for
compensation for each 30-day
increment from October 14, 2018,
through April 15, 2020, for private
industry hospital workers from the BLS’
Compensation and Working Conditions.
We have consistently used the ECI as
the data source for our wages and
salaries and other price proxies in the
IPPS market basket, and we did not
propose any changes to the usage of the
ECI for FY 2023. The factors used to
adjust the hospital’s data were based on
the midpoint of the cost reporting
period, as indicated in the following
table.
After
10/14/2018
11/14/2018
12/14/2018
01/14/2019
02/14/2019
03/14/2019
04/14/2019
05/14/2019
06/14/2019
07/14/2019
08/14/2019
09/14/2019
10/14/2019
11/14/2019
12/14/2019
01/14/2020
02/14/2020
03/14/2020
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Before
11/15/2018
12/15/2018
01/15/2019
02/15/2019
03/15/2019
04/15/2019
05/15/2019
06/15/2019
07/15/2019
08/15/2019
09/15/2019
10/15/2019
11/15/2019
12/15/2019
01/15/2020
02/15/2020
03/15/2020
04/15/2020
Frm 00221
Fmt 4701
Adjustment Factor
1.03404
1.03168
1.02929
1.02694
1.02462
1.02237
1.02026
1.01826
1.01630
1.01429
1.01223
1.01015
1.00808
1.00601
1.00397
1.00196
1.00000
0.99808
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.112
khammond on DSKJM1Z7X2PROD with RULES2
MIDPOINT OF COST REPORTING PERIOD
49000
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
113) amended section 1886(d)(9)(E) of
the Act to specify that the payment
calculation with respect to operating
costs of inpatient hospital services of a
subsection (d) Puerto Rico hospital for
inpatient hospital discharges on or after
January 1, 2016, shall use 100 percent
of the national standardized amount. As
we stated in the FY 2017 IPPS/LTCH
PPS final rule (81 FR 56915 through
56916), because Puerto Rico hospitals
are no longer paid with a Puerto Rico
specific standardized amount as of
January 1, 2016, under section
1886(d)(9)(E) of the Act, as amended by
section 601 of the Consolidated
Appropriations Act, 2016, there is no
longer a need to calculate a Puerto Rico
specific average hourly wage and wage
index. Hospitals in Puerto Rico are now
paid 100 percent of the national
standardized amount and, therefore, are
subject to the national average hourly
wage (unadjusted for occupational mix)
and the national wage index, which is
applied to the national labor-related
share of the national standardized
amount. Therefore, for FY 2023, there is
no Puerto Rico-specific overall average
hourly wage or wage index.
Based on the methodology, as
previously discussed, we stated in the
proposed rule (87 FR 28365) that the
proposed FY 2023 unadjusted national
average hourly wage was $47.77.
We did not receive any comments
regarding the discussion of our method
for computing the FY 2023 unadjusted
wage index. Based on the previously
described methodology, the final FY
2023 unadjusted national average
hourly wage is the following:
I Final FY 2023 Unadjusted National Average Hourly Wage
E. Occupational Mix Adjustment to the
FY 2023 Wage Index
As stated earlier, section 1886(d)(3)(E)
of the Act provides for the collection of
data every 3 years on the occupational
mix of employees for each short-term,
acute care hospital participating in the
Medicare program, in order to construct
an occupational mix adjustment to the
wage index, for application beginning
October 1, 2004 (the FY 2005 wage
index). The purpose of the occupational
mix adjustment is to control for the
effect of hospitals’ employment choices
on the wage index. For example,
hospitals may choose to employ
different combinations of registered
nurses, licensed practical nurses,
nursing aides, and medical assistants for
the purpose of providing nursing care to
their patients. The varying labor costs
associated with these choices reflect
hospital management decisions rather
than geographic differences in the costs
of labor.
khammond on DSKJM1Z7X2PROD with RULES2
1. Use of 2019 Medicare Wage Index
Occupational Mix Survey for the FY
2023 Wage Index
Section 304(c) of the Consolidated
Appropriations Act, 2001 (Pub. L. 106–
554) amended section 1886(d)(3)(E) of
the Act to require CMS to collect data
every 3 years on the occupational mix
of employees for each short-term, acute
care hospital participating in the
Medicare program. As discussed in the
FY 2022 IPPS/LTCH PPS proposed rule
(86 FR 25402 through 25403) and final
rule (86 FR 45173), we collected data in
2019 to compute the occupational mix
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
adjustment for the FY 2022, FY 2023,
and FY 2024 wage indexes. The FY
2023 occupational mix adjustment is
based on the calendar year (CY) 2019
survey. Hospitals were required to
submit their completed 2019 surveys
(Form CMS–10079, OMB Number 0938–
0907, expiration date October 31, 2022)
to their MACs by September 3, 2020. It
should be noted that this collection of
information was approved under OMB
control number 0938–0907 with an
expiration date of October 31, 2022. An
extension of the information collection
request is currently being developed.
The public will have an opportunity to
review and submit comments regarding
the extension of this PRA package
through a public notice and comment
period separate from this rulemaking.
The preliminary, unaudited CY 2019
survey data were posted on the CMS
website on September 8, 2020. As with
the Worksheet S–3, Parts II and III cost
report wage data, as part of the FY 2023
desk review process, the MACs revised
or verified data elements in hospitals’
occupational mix surveys that resulted
in certain edit failures.
2. Calculation of the Occupational Mix
Adjustment for FY 2023
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28366), for FY
2023, we proposed to calculate the
occupational mix adjustment factor
using the same methodology that we
have used since the FY 2012 wage index
(76 FR 51582 through 51586) and to
apply the occupational mix adjustment
to 100 percent of the FY 2023 wage
PO 00000
Frm 00222
Fmt 4701
Sfmt 4700
$47.79
I
index. In the FY 2020 IPPS/LTCH PPS
final rule (84 FR 42308), we modified
our methodology with regard to how
dollar amounts, hours, and other
numerical values in the unadjusted and
adjusted wage index calculation are
rounded, in order to ensure consistency
in the calculation. According to the
policy finalized in the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42308 and
42309), for data that we consider to be
‘‘raw data,’’ such as the cost report data
on Worksheets S–3, Parts II and III, and
the occupational mix survey data, we
continue to use these data ‘‘as is’’, and
not round any of the individual line
items or fields. However, for any dollar
amounts within the wage index
calculations, including any type of
summed wage amount, average hourly
wages, and the national average hourly
wage (both the unadjusted and adjusted
for occupational mix), we round such
dollar amounts to 2 decimals. We round
any hour amounts within the wage
index calculations to the nearest whole
number. We round any numbers not
expressed as dollars or hours in the
wage index calculations, which could
include ratios, percentages, or inflation
factors, to 5 decimals. However, we
continue rounding the actual
unadjusted and adjusted wage indexes
to 4 decimals, as we have done
historically.
Similar to the method we use for the
calculation of the wage index without
occupational mix, salaries and hours for
a multicampus hospital are allotted
among the different labor market areas
where its campuses are located. Table 2
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.113
For example, the midpoint of a cost
reporting period beginning January 1,
2019, and ending December 31, 2019, is
June 30, 2019. An adjustment factor of
1.01630 was applied to the wages of a
hospital with such a cost reporting
period.
Previously, we also would provide a
Puerto Rico overall average hourly
wage. As discussed in the FY 2017
IPPS/LTCH PPS final rule (81 FR
56915), prior to January 1, 2016, Puerto
Rico hospitals were paid based on 75
percent of the national standardized
amount and 25 percent of the Puerto
Rico-specific standardized amount. As a
result, we calculated a Puerto Rico
specific wage index that was applied to
the labor-related share of the Puerto
Rico-specific standardized amount.
Section 601 of the Consolidated
Appropriations Act, 2016 (Pub. L. 114–
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
data of 3,112 hospitals, and we used the
occupational mix surveys of 3,010
hospitals for which we also had
Worksheet S–3 wage data, which
represented a ‘‘response’’ rate of 97
percent (3,010/3,112). For the proposed
FY 2023 wage index, we applied proxy
data for noncompliant hospitals, new
hospitals, or hospitals that submitted
erroneous or aberrant data in the same
manner that we applied proxy data for
such hospitals in the FY 2012 wage
index occupational mix adjustment (76
FR 51586). As a result of applying this
methodology, the proposed FY 2023
occupational mix adjusted national
average hourly wage was $47.71.
We did not receive any comments on
our proposed calculation of the
occupational mix adjustment to the FY
2023 wage index. Thus, for the reasons
discussed in this final rule and in the
FY 2023 IPPS/LTCH PPS proposed rule,
we are finalizing our proposal, without
modification to calculate the
occupational mix adjustment factor
using the same methodology that we
have used since the FY 2012 wage index
and to apply the occupational mix
adjustment to 100 percent of the FY
2023 wage index.
For the final FY 2023 wage index, we
are using the Worksheet S3, Parts II and
III wage data of 3,136 hospitals, and we
are using the occupational mix surveys
of 3,035 hospitals for which we also
have Worksheet S–3 wage data, which
is a ‘‘response’’ rate of 97 percent
(3,035/3,136). For the final FY 2023
wage index, we are applying proxy data
for noncompliant hospitals, new
hospitals, or hospitals that submitted
erroneous or aberrant data in the same
manner that we applied proxy data for
such hospitals in the FY 2012 wage
index occupational mix adjustment (76
FR 51586). As a result of applying this
methodology, the final FY–2023
occupational mix adjusted national
average hourly wage is the following:
I FY 2023 Occupational Mix Adjusted National Average Hourly Wage
Occupational Mix Nursing Subcategory
National RN
National LPN and Surgical Technician
National Nurse Aide, Orderly, and Attendant
National Medical Assistant
National Nurse Category
khammond on DSKJM1Z7X2PROD with RULES2
The national average hourly wage for
the entire nurse category is computed in
Step 5 of the occupational mix
calculation. Hospitals with a nurse
category average hourly wage (as
calculated in Step 4) of greater than the
national nurse category average hourly
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Average Hourly Wage
$44.44
$26.86
$18.54
$19.53
$37.38
wage receive an occupational mix
adjustment factor (as calculated in Step
6) of less than 1.0. Hospitals with a
nurse category average hourly wage (as
calculated in Step 4) of less than the
national nurse category average hourly
wage receive an occupational mix
National Percentage of Hospital Employees in the Nurse Category
National Percentage of Hospital Employees in the All Other
Occupations Category
Range of Percentage of Hospital Employees in the Nurse Category
(CBSA Level)
PO 00000
Frm 00223
Fmt 4701
Sfmt 4725
in the FY 2012 IPPS/LTCH PPS final
rule (76 FR 51582 through 51586).
The FY 2023 national average hourly
wages for each occupational mix
nursing subcategory as calculated in
Step 2 of the occupational mix
calculation are as follows:
adjustment factor (as calculated in Step
6) of greater than 1.0.
Based on the 2019 occupational mix
survey data, we determined (in Step 7
of the occupational mix calculation) the
following:
42%
58%
Low of 20 Percent in one CBSA to a high of 66
percent in another CBSA
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.116
As discussed in section III.E. of the
preamble of this final rule, for FY 2023,
we are applying the occupational mix
adjustment to 100 percent of the FY
2023 wage index. We calculated the
occupational mix adjustment using data
from the 2019 occupational mix survey
data, using the methodology described
ER10AU22.115
F. Analysis and Implementation of the
Proposed Occupational Mix Adjustment
and the FY 2023 Occupational Mix
Adjusted Wage Index
$47.73
ER10AU22.114
associated with this final rule (which is
available via the internet on the CMS
website), which contains the final FY
2023 occupational mix adjusted wage
index, includes separate wage data for
the campuses of multicampus hospitals.
We refer readers to section III.C. of the
preamble of this final rule for a chart
listing the multicampus hospitals and
the FTE percentages used to allot their
occupational mix data.
Because the statute requires that the
Secretary measure the earnings and paid
hours of employment by occupational
category not less than once every 3
years, all hospitals that are subject to
payments under the IPPS, or any
hospital that would be subject to the
IPPS if not granted a waiver, must
complete the occupational mix survey,
unless the hospital has no associated
cost report wage data that are included
in the FY 2023 wage index. For the
proposed FY 2023 wage index, we used
the Worksheet S–3, Parts II and III wage
49001
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
We compared the FY 2023
occupational mix adjusted wage indexes
for each CBSA to the unadjusted wage
indexes for each CBSA. Applying the
occupational mix adjustment to the
wage data resulted in the following:
Comparison of the FY 2023 Occupational Mix Adjusted Wage Indexes
to the Unadjusted Wage Indexes by CBSA
Number of Urban Areas Wage Index Increasing
Number of Rural Areas Wage Index Increasing
Number of Urban Areas Wage Index Increasing by Greater Than or Equal to 1 Percent But Less Than 5 Percent
Number of Urban Areas Wage Index Increasing by 5 percent or More
Number of Rural Areas Wage Index Increasing by Greater Than or Equal to 1 Percent But Less Than 5 Percent
Number of Rural Areas Wage Index Increasing by 5 Percent or More
Number of Urban Areas Wage Index Decreasing
Number of Rural Areas Wage Index Decreasing
Number of Urban Areas Wage Index Decreasing by Greater Than or Equal to 1 Percent But Less Than 5 Percent
Number of Urban Areas Wage Index Decreasing by 5 Percent or More
Number of Rural Areas Wage Index Decreasing by Greater Than or Equal to 1 Percent But Less than 5 Percent
Number of Rural Areas Wage Index Decreasing by 5 Percent or More
Largest Positive Impact for an Urban Area
Largest Positive Impact for a Rural Area
Largest Negative Impact for an Urban Area
Largest Negative Impact for a Rural Area
Urban Areas Unchanged bv Application of the Occupational Mix Adiustment
Rural Areas Unchanged by Application of the Occupational Mix Adjustment
These results indicate that a smaller
percentage of urban areas (53.6 percent)
would benefit from the occupational
mix adjustment than would rural areas
(57.4 percent).
khammond on DSKJM1Z7X2PROD with RULES2
G. Application of the Rural Floor,
Application of the Imputed Floor,
Application of the State Frontier Floor,
Continuation of the Low Wage Index
Hospital Policy, and Budget Neutrality
Adjustment
1. Rural Floor
Section 4410(a) of the Balanced
Budget Act of 1997 (Pub. L. 105–33)
provides that, for discharges on or after
October 1, 1997, the area wage index
applicable to any hospital that is located
in an urban area of a State may not be
less than the area wage index applicable
to hospitals located in rural areas in that
State. This provision is referred to as the
rural floor. Section 3141 of the Patient
Protection and Affordable Care Act
(Pub. L. 111–148) also requires that a
national budget neutrality adjustment be
applied in implementing the rural floor.
In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42332 through 42336), we
removed urban to rural reclassifications
from the calculation of the rural floor to
prevent inappropriate payment
increases under the rural floor due to
rural reclassifications, such that,
beginning in FY 2020, the rural floor
was calculated without including the
wage data of hospitals that have
reclassified as rural under section
1886(d)(8)(E) of the Act (as
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
implemented in the regulations at
§ 412.103). For FY 2023, we proposed to
continue to calculate the rural floor
without the wage data of hospitals that
have reclassified as rural under
§ 412.103 (87 FR 28367–28368). Also,
for the purposes of applying the
provisions of section 1886(d)(8)(C)(iii)
of the Act, effective beginning in FY
2020, we removed the data of hospitals
reclassified from urban to rural under
section 1886(d)(8)(E) of the Act (as
implemented in the regulations at
§ 412.103) from the calculation of ‘‘the
wage index for rural areas in the State
in which the county is located’’ as
referred to in section 1886(d)(8)(C)(iii)
of the Act (84 FR 42333). In the IPPS/
LTCH PPS proposed rule (87 FR 28367
and 28368), we proposed to continue to
apply this policy for FY 2023.
We noted in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28368) that
the FY 2020 rural floor policy and the
related budget neutrality adjustment
were the subject of pending litigation,
including in Citrus HMA, LLC, d/b/a
Seven Rivers Regional Medical Center v.
Becerra, No. 1:20-cv-00707 (D.D.C.)
(hereafter referred to as Citrus). On April
8, 2022, the district court in Citrus
granted in part the plaintiff hospitals’
motion for summary judgment and
denied the Secretary’s cross-motion for
summary judgment. The court found
that the Secretary did not have authority
under section 4410(a) of the Balanced
Budget Act of 1997 to establish a rural
floor lower than the rural wage index for
PO 00000
Frm 00224
Fmt 4701
Sfmt 4700
231 (53.6%)
27 (57.4%
123 (29.9%)
4 (1.0%)
12 (25.5%)
0 (0%)
180 (45.9%)
20 (42.6%)
77 (19.7%)
3 (0.5%)
8 (17.0%)
0 (0%)
7.20%
4.19%
-5.48%
-2.55%
1 (0.5%)
0 (0%)
a state. We stated that while Citrus
involves only FY 2020, the court’s
decision—which is subject to potential
appeal—may have implications for FY
2023 payment rates. We stated that we
were continuing to evaluate the court’s
decision, and although we proposed for
the rural floor wage index policy (and
the related budget neutrality
adjustment) to continue for FY 2023, we
stated we may decide to take a different
approach in the final rule, depending on
public comments or developments in
the court proceedings.
Comments: Several commenters
supported CMS’s policy established
beginning in FY 2020 to exclude the
wage data of § 412.103 hospitals from
the rural floor calculation. Some
commenters specifically stated that this
policy restores fairness in the wage
index by preventing certain states from
manipulating the wage index system to
artificially inflate the wage indexes of
hospitals in the state at the expense of
all other states, due to the rural floor
national budget neutrality adjustment
required by section 3141 of Public Law
111–148.
Many commenters urged CMS to
acquiesce to the district court’s decision
in Citrus, discontinue the policy of
excluding the wage data of § 412.103
hospitals from the rural floor
calculation, and revert to the policy that
existed prior to FY 2020. The
commenters stated their belief that the
court’s analysis was thorough and that
continuing the rural floor policy would
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.117
49002
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
only increase the agency’s exposure to
future lawsuits. Commenters asserted
that the plain language of the statute
does not provide for a free-floating rural
floor that is not linked to the rural wage
index. One of the commenters
advocating for CMS to revert to the
policy that applied prior to FY 2020
requested that if CMS does choose to
continue its current rural floor policy in
FY 2023, it should do so in a nonbudget neutral manner.
Other commenters also suggested that
along with including the wage data of
§ 412.103 hospitals in the rural floor
calculation, CMS should include the
wage data of § 412.103 hospitals for
purposes of the calculation required by
§ 1886(d)(8)(C)(ii) of the Act. Two
commenters specifically asserted that
CMS should include the wage data of
§ 412.103 hospitals that also have an
Medicare Geographic Classification
Review Board (MGCRB) reclassification
for purposes of the calculation required
by § 1886(d)(8)(C)(ii) of the Act.
Specifically, these commenters stated
that when a geographically rural
hospital has an active MGCRB
reclassification to another area, CMS
includes the wage data of the hospital
in calculating the rural wage index of
the state in which that hospital is
located, if not doing so would reduce
the wage index for that rural area, as
described in § 1886(d)(8)(C)(ii) of the
Act. However, the commenters stated
that CMS does not treat the wage data
of hospitals with a § 412.103
reclassification in addition to an
MGCRB reclassification in the same
manner as geographically rural hospitals
with an MGCRB reclassification. A
commenter stated that treating hospitals
with dual § 412.103 and MGCRB
reclassifications in the same manner as
other rural hospitals for the calculation
required by § 1886(d)(8)(C)(ii) would
help address rural floor manipulation by
mitigating the impact that one or two
§ 412.103 hospitals remaining rural for
wage index purposes would have on the
rural wage index and rural floor.
Response: We appreciate the
commenters’ input. In response to the
comments supporting our proposal to
continue our policy of excluding the
wage data of § 412.103 hospitals from
the rural floor calculation for FY 2023,
we appreciate the concern regarding
wage index manipulation, particularly
arising from high wage hospitals in
certain states reclassifying as rural
under § 412.103 to inflate the rural wage
index. However, as noted by a
commenter, a national budget neutrality
adjustment is required by section 3141
of Public Law 111–148. As stated in
response to comments in the FY 2022
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
IPPS/LTCH PPS final rule (86 FR 45175
through 45176) and in the FY 2017
IPPS/LTCH PPS final rule (81 FR
56920), section 3141 requires that
budget neutrality for the rural floor be
applied ‘‘through a uniform, national
adjustment to the area wage index’’
instead of within each State beginning
in FY 2011 (75 FR 50160). Accordingly,
we do not have the authority to
calculate rural floor budget neutrality in
a State-specific manner.
With regard to the comments
concerning the district court’s decision
in Citrus, prior to FY 2020, it was our
policy to have the rural wage index set
the rural floor, resulting in identical
wage index values for a state’s rural area
and rural floor. We changed that policy
in the FY 2020 IPPS/LTCH PPS final
rule to prevent inappropriate payment
increases under the rural floor due to
rural reclassifications under § 412.103
(84 FR 42332 through 42336). We
explained that rather than raising the
payment of some urban hospitals to the
level of the average rural hospital in
their State, as we believed was the
intent of the rural floor policy, the rural
floor calculation prior to FY 2020
enabled urban hospitals to have their
payments raised to the relatively high
level of one or more geographically
urban hospitals reclassified as rural (84
FR 42334). This policy change
beginning in FY 2020 to exclude
§ 412.103 hospitals from the rural floor
calculation created a rural area wage
index separate from the rural floor, with
the rural floor for the state typically
lower than the rural wage index.
We understand that our policy of
setting a rural floor lower than the rural
wage index for a state is inconsistent
with the district court’s decision in
Citrus. Following our review of that
decision and the comments we received
on the proposed rule, we are finalizing
a policy that calculates the rural floor as
it was calculated before FY 2020.
Specifically, for FY 2023 and
subsequent years, we are finalizing a
policy to include the wage data of
hospitals that have reclassified from
urban to rural under section
1886(d)(8)(E) of the Act (as
implemented in the regulations at
§ 412.103) and have no additional form
of reclassification (MGCRB or Lugar) in
the calculation of the rural floor, and to
include the wage data of such hospitals
in the calculation of ‘‘the wage index for
rural areas in the State in which the
county is located’’ as referred to in
section 1886(d)(8)(C)(iii) of the Act.
With regard to the application of the
hold harmless policy that the
commenters referenced at
§ 1886(d)(8)(C)(ii), the statute requires
PO 00000
Frm 00225
Fmt 4701
Sfmt 4700
49003
that a rural area be held harmless from
the effects of hospitals reclassifying
under Lugar or the MGCRB.
Specifically, § 1886(d)(8)(C)(ii) states:
‘‘If the application of subparagraph (B)
or a decision of the Medicare
Geographic Classification Review Board
or the Secretary under paragraph (10),
by treating hospitals located in a rural
county or counties as not being located
in the rural area in a State, reduces the
wage index for that rural area (as
applied under this subsection), the
Secretary shall calculate and apply such
wage index under this subsection as if
the hospitals so treated had not been
excluded from calculation of the wage
index for that rural area.’’
The commenters suggest that CMS
should include the wage data of
§ 412.103 hospitals that also have a
MGCRB reclassification for purposes of
the calculation required by
§ 1886(d)(8)(C)(ii), thereby treating
hospitals with dual § 412.103 and
MGCRB reclassifications no differently
than geographically rural hospitals with
MGCRB reclassifications for the holdharmless comparison at
§ 1886(d)(8)(C)(ii). Specifically, this
would involve calculating the rural area
wage index including the data of all
§ 412.103 hospitals, and then comparing
it to a wage index with the effect of
MGCRB reclassifications and Lugar
hospital statuses applied, in order to
possibly hold the rural area harmless
from the effect of MGCRB
reclassifications and Lugar hospital
statuses.
As we explained in response to a
similar comment in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45181),
CMS continues to treat § 412.103
hospitals as rural as required by the
statute even if such hospitals have an
additional MGCRB reclassification by
affording the hospital the benefits of
rural status, such as 340B program and
RRC eligibility. However, in developing
our policies for how hospitals with dual
reclassifications would be treated in
wage index calculations following our
April 21, 2016 IFC (81 FR 23428
through 23438), CMS discussed the
effect of simultaneous § 412.103 and
MGCRB reclassifications. We stated that
when there is both a § 412.103
reclassification and an MGCRB
reclassification, the MGCRB
reclassification would control for wage
index calculation and payment
purposes. We explained that ‘‘In these
circumstances, we believe it is
appropriate to rely on the urban MGCRB
reclassification to include the hospital’s
wage data in the calculation of the
urban CBSA wage index. Further, we
believe it is appropriate to rely on the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49004
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
urban MGCRB reclassification to ensure
that the hospital be paid based on its
urban MGCRB wage index. While rural
reclassification confers other rural
benefits besides the wage index under
section 1886(d) of the Act, a hospital
that chooses to pursue reclassification
under the MGCRB (while also
maintaining a rural reclassification
under § 412.103) would do so solely for
wage index payment purposes.’’ (81 FR
23434). We continue to believe that
policy, developed through rulemaking,
is appropriate, since MGCRB
reclassifications are solely for wage
index payment purposes. Furthermore,
the approach the commenters suggest
would constitute a significant change to
our current policy for § 412.103
hospitals that also have a MGCRB
reclassification, and would create
numerous downstream effects across
IPPS ratesetting that might not be
favorable to hospitals, contrary to the
commenters’ intent. For example, some
states would experience a decline in
their rural wage index if we were to
treat hospitals with dual § 412.103 and
MGCRB reclassifications no differently
than geographically rural hospitals with
MGCRB reclassifications. In response to
the commenters’ assertion that such
treatment would address rural floor
manipulation, we note that the
commenters’ suggested treatment of
hospitals with dual § 412.103 and
MGCRB reclassifications would
potentially allow for other forms of
wage index manipulation. For example,
high-wage hospitals could obtain
§ 412.103 status, reclassify back to their
home area under the MGCRB, in order
to have their § 412.103 rural
reclassifications raise the rural wage
index via the hold harmless provision at
§ 1886(d)(8)(C)(ii), without lowering the
hospitals’ own wage index. We did not
propose the policy the commenters
suggest, and it would constitute a
significant change with numerous
effects on the IPPS wage index. We do
not think it would be appropriate to
adopt such a policy without describing
it in a proposed rule and obtaining
public comments from all interested
parties. Therefore, in this final rule we
are not adopting the policy the
commenters suggest.
Based on the district court’s decision
in Citrus and the comments we
received, we are not finalizing our rural
floor wage index policy as proposed,
which would have excluded § 412.103
hospitals from the calculation of the
rural floor and from the calculation of
‘‘the wage index for rural areas in the
State in which the county is located’’ as
referred to in section 1886(d)(8)(C)(iii)
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
of the Act. Rather, we are finalizing a
policy that calculates the rural floor as
it was calculated before FY 2020. This
decision follows our review of the
decision in Citrus and the comments
received, including comments urging us
to revert to our pre-2020 policy. For FY
2023 and subsequent years, we are
finalizing a policy to include the wage
data of hospitals that have reclassified
from urban to rural under section
1886(d)(8)(E) of the Act (as
implemented in the regulations at
§ 412.103) and have no additional form
of reclassification (MGCRB or Lugar) in
the calculation of the rural floor, and to
include the wage data of such hospitals
in the calculation of ‘‘the wage index for
rural areas in the State in which the
county is located’’ as referred to in
section 1886(d)(8)(C)(iii) of the Act. We
will apply the same policy as prior to
the FY 2020 final rule for calculating the
rural floor, in which the rural wage
index sets the rural floor. Based on the
FY 2023 wage index associated with
this final rule (which is available via the
internet on the CMS website) and based
on the calculation of the rural floor
including the wage data of hospitals that
have reclassified as rural under
§ 412.103, we estimate that 275
hospitals would receive an increase in
their FY 2023 wage index due to the
application of the rural floor.
2. Imputed Floor
In the FY 2005 IPPS final rule (69 FR
49109 through 49111), we adopted the
imputed floor policy as a temporary 3year regulatory measure to address
concerns from hospitals in all urban
States that have stated that they are
disadvantaged by the absence of rural
hospitals to set a wage index floor for
those States. We extended the imputed
floor policy eight times since its initial
implementation, the last of which was
adopted in the FY 2018 IPPS/LTCH PPS
final rule and expired on September 30,
2018. (We refer readers to further
discussions of the imputed floor in the
IPPS/LTCH PPS final rules from FYs
2014 through 2019 (78 FR 50589
through 50590, 79 FR 49969 through
49971, 80 FR 49497 through 49498, 81
FR 56921 through 56922, 82 FR 38138
through 38142, and 83 FR 41376
through 41380, respectively) and to the
regulations at 42 CFR 412.64(h)(4).) For
FYs 2019, 2020, and 2021, hospitals in
all-urban states received a wage index
that was calculated without applying an
imputed floor, and we no longer
included the imputed floor as a factor in
the national budget neutrality
adjustment.
In computing the imputed floor for an
all-urban State under the original
PO 00000
Frm 00226
Fmt 4701
Sfmt 4700
methodology established beginning in
FY 2005, we calculated the ratio of the
lowest-to-highest CBSA wage index for
each all-urban State as well as the
average of the ratios of lowest-to-highest
CBSA wage indexes of those all-urban
States. We then compared the State’s
own ratio to the average ratio for allurban States and whichever was higher
was multiplied by the highest CBSA
wage index value in the State—the
product of which established the
imputed floor for the State. We adopted
a second, alternative methodology
beginning in FY 2013 (77 FR 53368
through 53369) to address the concern
that the original imputed floor
methodology guaranteed a benefit for
one all-urban State with multiple wage
indexes (New Jersey) but could not
benefit another all-urban State, Rhode
Island, which had only one CBSA.
Under the alternative methodology, we
first determined the average percentage
difference between the post reclassified,
pre-floor area wage index and the postreclassified, rural floor wage index
(without rural floor budget neutrality
applied) for all CBSAs receiving the
rural floor. The lowest post reclassified
wage index assigned to a hospital in an
all-urban State having a range of such
values then was increased by this factor,
the result of which established the
State’s alternative imputed floor. Under
the updated OMB labor market area
delineations adopted by CMS beginning
in FY 2015, Delaware became an allurban State, along with New Jersey and
Rhode Island, and was subject to an
imputed floor as well. In addition, we
adopted a policy, as reflected at
§ 412.64(h)(4)(vi), that, for discharges on
or after October 1, 2012, and before
October 1, 2018, the minimum wage
index value for a State is the higher of
the value determined under the original
methodology or the value determined
under the alternative methodology. The
regulations implementing the imputed
floor wage index, both the original
methodology and the alternative
methodology, were set forth at
§ 412.64(h)(4).
Section 9831 of the American Rescue
Plan Act of 2021 (Pub. L. 117–2) enacted
on March 11, 2021, amended section
1886(d)(3)(E)(i) of the Act (42 U.S.C.
1395ww(d)(3)(E)(i)) and added section
1886(d)(3)(E)(iv) of the Act to establish
a minimum area wage index for
hospitals in all-urban States for
discharges occurring on or after October
1, 2021. Specifically, section
1886(d)(3)(E)(iv)(I) and (II) of the Act
provides that for discharges occurring
on or after October 1, 2021, the area
wage index applicable to any hospital in
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
an all-urban State may not be less than
the minimum area wage index for the
fiscal year for hospitals in that State
established using the methodology
described in § 412.64(h)(4)(vi) as in
effect for FY 2018. Thus, effective
beginning October 1, 2021 (FY 2022),
section 1886(d)(3)(E)(iv) of the Act
reinstates the imputed floor wage index
policy for all-urban States, with no
expiration date, using the methodology
described in 42 CFR 412.64(h)(4)(vi) as
in effect for FY 2018. As discussed
previously, under § 412.64(h)(4)(vi), the
minimum wage index value for
hospitals in an all-urban State is the
higher of the value determined using the
original methodology (as set forth at
§ 412.64(h)(4)(i) through (v)) or the
value determined using alternative
methodology (as set forth at
§ 412.64(h)(4)(vi)(A) and (B)) for
calculating an imputed floor. Therefore,
as provided in § 412.64(h)(4)(vi), we
apply the higher of the value
determined under the original or
alternative methodology for calculating
a minimum wage index, or imputed
floor, for all-urban States effective
beginning with FY 2022. We note that
the rural floor values used in the
alternative methodology at
§ 412.64(h)(4)(vi)(A) and (B) would now
include the wage data of hospitals
reclassified under § 412.103 that have
no additional form of reclassification
(MGCRB or Lugar), according to the
rural floor wage index policy finalized
in this final rule in which we calculate
the rural floor for FY 2023 including the
wage data of such hospitals.
Unlike the imputed floor that was in
effect from FYs 2005 through 2018,
section 1886(d)(3)(E)(iv)(III) of the Act
provides that the imputed floor wage
index shall not be applied in a budget
neutral manner. Specifically, section
9831(b) of Public Law 117–2 amends
section 1886(d)(3)(E)(i) of the Act to
exclude the imputed floor from the
budget neutrality requirement under
section 1886(d)(3)(E)(i) of the Act. In
other words, the budget neutrality
requirement under section
1886(d)(3)(E)(i) of the Act, as amended,
must be applied without taking into
account the imputed floor adjustment
under section 1886(d)(3)(E)(iv) of the
Act. When the imputed floor was in
effect from FY 2005 through FY 2018, to
budget neutralize the increase in
payments resulting from application of
the imputed floor, we calculated the
increase in payments resulting from the
imputed floor together with the increase
in payments resulting from the rural
floor and applied an adjustment to
reduce the wage index. By contrast, for
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
FY 2022 and subsequent years, we
apply the imputed floor after the
application of the rural floor and apply
no reductions to the standardized
amount or to the wage index to fund the
increase in payments to hospitals in allurban States resulting from the
application of the imputed floor
required under section 1886(d)(3)(E)(iv)
of the Act.
The imputed floor under section
1886(d)(3)(E)(iv) of the Act applies to
all-urban States, as defined in new
subclause (IV). Section
1886(d)(3)(E)(iv)(IV) provides that, for
purposes of the imputed floor wage
index under clause (iv), the term allurban State means a State in which
there are no rural areas (as defined in
section 1886(d)(2)(D) of the Act) or a
State in which there are no hospitals
classified as rural under section 1886 of
the Act. Under this definition, given
that it applies for purposes of the
imputed floor wage index, we consider
a hospital to be classified as rural under
section 1886 of the Act if it is assigned
the State’s rural area wage index value.
Therefore, under the definition at
section 1886(d)(3)(E)(iv)(IV) of the Act,
‘‘a State in which there are no hospitals
classified as rural under this section’’
includes a State that has a rural area but
no hospitals that receive the rural area
wage index under section 1886(d) of the
Act. For purposes of this definition,
hospitals redesignated as rural under
section 1886(d)(8)(E) of the Act (412.103
rural reclassifications) are considered
classified as rural if they receive the
rural wage index; however, hospitals
that are deemed urban under section
1886(d)(8)(B) of the Act (in Lugar
counties), or are reclassified to an urban
area under section 1886(d)(10) of the
Act (MGCRB reclassifications) are not
considered classified as rural because
they do not receive the rural wage
index. In contrast, we note that in the
imputed floor policy in effect from FY
2005 through FY 2018, we did not
consider a State to qualify for ‘‘all urban
status’’ if there were one or more
hospitals geographically located in the
rural area of the State, even if all such
hospitals subsequently reclassified to
receive an urban area wage index. There
is one State, Connecticut, that would be
eligible for the imputed floor because
there are currently no hospitals in
Connecticut that are classified as rural
under section 1886(d) for purposes of
the wage index—in other words, there
are no hospitals that receive the rural
wage index. There is currently one rural
county in Connecticut. All hospitals in
this county are either deemed urban
under section 1886(d)(8)(B) of the Act or
PO 00000
Frm 00227
Fmt 4701
Sfmt 4700
49005
receive an MGCRB reclassification
under section 1886(d)(10) of the Act.
While several Connecticut hospitals
were approved for rural reclassification
under section 1886(d)(8)(E) of the Act,
at this point all have received a
subsequent urban reclassification under
section 1886(d)(10) of the Act.
Additionally, under section 1861(x) of
the Act, the term State has the meaning
given to it in section 210(h) of the Act.
Because section 210(h) of the Act
defines the word State to also include
the District of Columbia and the
Commonwealth of Puerto Rico,
Washington, DC and Puerto Rico may
also qualify as all-urban States for
purposes of the imputed floor if the
requirements of section
1886(d)(3)(E)(iv)(IV) of the Act are met.
Based on data available for this final
rule, the following States would be allurban States as defined in section
1886(d)(3)(E)(iv)(IV) of the Act, and thus
hospitals in such States would be
eligible to receive an increase in their
wage index due to application of the
imputed floor for FY 2023: New Jersey,
Rhode Island, Delaware, Connecticut,
and Washington, DC.
In the FY 2022 IPPS/LTCH PPS final
rule, we revised the regulations at
§ 412.64(e)(1) and (4) and (h)(4) and (5)
to implement the imputed floor required
by section 1886(d)(3)(E)(iv) of the Act
for discharges occurring on or after
October 1, 2021. The imputed floor will
be applied for FY 2023 in accordance
with the policies adopted in the FY
2022 IPPS/LTCH PPS final rule. For
more information regarding our
implementation of the imputed floor
required by section 1886(d)(3)(E)(iv) of
the Act, we refer readers to the
discussion in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45176 through
45178).
Comment: Several commenters
supported the application of the
imputed floor wage index policy,
including the policy’s definition of allurban states as well as its non-budget
neutral application as required by
section 9831 of the American Rescue
Plan Act of 2021. A commenter opposed
the imputed floor policy, stating that it
unfairly manipulates the wage index to
benefit a handful of only-urban states
and territories, but acknowledged that
the imputed floor policy is derived from
legislation enacted by Congress.
Response: We appreciate the
commenters’ support of our application
of the statutory imputed floor policy.
Responding to the commenter opposed
to this policy, we underscore that, as the
commenter pointed out, the imputed
floor was established by section 9831 of
the American Rescue Plan Act of 2021.
E:\FR\FM\10AUR2.SGM
10AUR2
49006
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Accordingly, CMS does not have
discretion to not apply the imputed
floor.
After consideration of the public
comments, we will apply the imputed
floor required by section
1886(d)(3)(E)(iv) of the Act for
discharges occurring on or after October
1, 2022 in accordance with our existing
policies.
khammond on DSKJM1Z7X2PROD with RULES2
3. State Frontier Floor for FY 2023
Section 10324 of Public Law 111–148
requires that hospitals in frontier States
cannot be assigned a wage index of less
than 1.0000. (We refer readers to the
regulations at 42 CFR 412.64(m) and to
a discussion of the implementation of
this provision in the FY 2011 IPPS/
LTCH PPS final rule (75 FR 50160
through 50161).) In the FY 2023 IPPS/
LTCH PPS proposed rule, we did not
propose any changes to the frontier floor
policy for FY 2023. In the proposed rule
we stated that 44 hospitals would
receive the frontier floor value of 1.0000
for their FY 2023 proposed wage index.
These hospitals are located in Montana,
North Dakota, South Dakota, and
Wyoming.
We did not receive any public
comments on the application of the
State frontier floor for FY 2023. In this
final rule, 44 hospitals will receive the
frontier floor value of 1.0000 for their
FY 2023 wage index. These hospitals
are located in Montana, North Dakota,
South Dakota, and Wyoming. We note
that while Nevada meets the criteria of
a frontier State, all hospitals within the
State currently receive a wage index
value greater than 1.0000. The areas
affected by the rural and frontier floor
policies for the final FY 2023 wage
index are identified in Table 2
associated with this final rule, which is
available via the internet on the CMS
website.
4. Continuation of the Low Wage Index
Hospital Policy; Budget Neutrality
Adjustment
To help mitigate wage index
disparities, including those resulting
from the inclusion of hospitals with
rural reclassifications under 42 CFR
412.103 in the rural floor, in the FY
2020 IPPS/LTCH PPS final rule (84 FR
42325 through 42339), we finalized
policies to reduce the disparity between
high and low wage index hospitals by
increasing the wage index values for
certain hospitals with low wage index
values and doing so in a budget neutral
manner through an adjustment applied
to the standardized amounts for all
hospitals, as well as by changing the
calculation of the rural floor. We also
provided for a transition in FY 2020 for
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
hospitals experiencing significant
decreases in their wage index values as
compared to their final FY 2019 wage
index, and made these changes in a
budget neutral manner.
We increase the wage index for
hospitals with a wage index value below
the 25th percentile wage index value for
a fiscal year by half the difference
between the otherwise applicable final
wage index value for a year for that
hospital and the 25th percentile wage
index value for that year across all
hospitals (the low wage index hospital
policy). We stated in the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42326
through 42328) our intention that this
policy will be effective for at least 4
years, beginning in FY 2020, in order to
allow employee compensation increases
implemented by these hospitals
sufficient time to be reflected in the
wage index calculation. We noted in the
FY 2023 IPPS/LTCH PPS proposed rule
(87 FR 28369) that the FY 2020 low
wage index hospital policy and the
related budget neutrality adjustment are
the subject of pending litigation,
including in Bridgeport Hospital, et al.,
v. Becerra, No. 1:20–cv–01574 (D.D.C.)
(hereafter referred to as Bridgeport). On
March 2, 2022, the district court in
Bridgeport granted in part the plaintiff
hospitals’ motion for summary
judgment and denied the Secretary’s
cross-motion for summary judgment.
The court found that the Secretary did
not have authority under section
1886(d)(3)(E) or 1886(d)(5)(I)(i) of the
Act to adopt the low wage index
hospital policy and ordered additional
briefing on the appropriate remedy. We
stated that while Bridgeport involves
only FY 2020, the court’s decision—
which is not final at this time and is also
subject to potential appeal—may have
implications for FY 2023 payment rates.
We stated that we were continuing to
evaluate the court’s decision, and
although we proposed the low wage
index hospital policy (and the related
budget neutrality adjustment, discussed
in this section of this rule) to continue
for FY 2023, we stated that we may
decide to take a different approach in
the final rule, depending on public
comments or developments in the court
proceedings. In order to offset the
estimated increase in IPPS payments to
hospitals with wage index values below
the 25th percentile wage index value,
for FY 2023 and for subsequent fiscal
years during which the low wage index
hospital policy is in effect, we proposed
to apply a budget neutrality adjustment
in the same manner as we applied it in
FYs 2020, 2021, and 2022, as a uniform
budget neutrality factor applied to the
PO 00000
Frm 00228
Fmt 4701
Sfmt 4700
standardized amount. We refer readers
to section II.A.4.f. of the addendum to
this final rule for further discussion of
the budget neutrality adjustment for FY
2023. For purposes of the low wage
index hospital policy, based on the data
for this final rule, the table displays the
25th percentile wage index value across
all hospitals for FY 2023. FY 2023 25th
Percentile Wage Index Value 0.8427.
Comment: Many commenters
supported the low wage index hospital
policy. Commenters praised the low
wage index hospital policy for already
beginning to reduce wage index
disparities and urged the agency to
continue with the policy for FY 2023 as
proposed. Commenters described dire
consequences of the policy ending, with
a commenter specifically stating that
Medicare payments to hospitals in
Puerto Rico could fall drastically.
Numerous commenters representing
hospitals in a state with relatively low
wages indicated that they have used the
increased payments resulting from the
low wage index hospital policy as CMS
intended, by raising compensation for
their workers. However, these
commenters stated that the national
average hourly wage increased at an
even higher rate due to COVID–19,
indicating that additional time for the
policy and continued efforts on behalf
of low wage hospitals are required. A
commenter requested that CMS consider
the effects of COVID–19 as CMS decides
how it will appropriately evaluate the
effectiveness of its policy to raise low
wage hospitals’ wage indexes in the
near future, and another commenter
specifically requested that CMS extend
the policy for at least four additional
years due to COVID–19. A commenter
stated that CMS should maintain the
policy until CMS can verify that
increased hospital compensation under
the policy has led to increased wage
indexes, consistent with original intent
of the policy.
Response: We appreciate the many
comments received in support of our
low wage index hospital policy and the
feedback regarding achievement of the
intended policy goal. We appreciate the
commenters’ requests to consider the
impacts of COVID–19, to extend this
policy beyond four years due to COVID–
19, and to extend the policy until the
intended goals of the policy are reached.
We appreciate commenters’ suggestions
on how we might evaluate the
effectiveness of the policy and may
consider those suggestions in future
rulemaking.
Comment: Many commenters
supported increasing the wage index
values of low-wage hospitals, but urged
CMS to do so in a non-budget-neutral
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
manner. Commenters stated that
implementing the policy with a budget
neutrality adjustment merely shifts
funds from one group to another.
Commenters urged CMS to consider
wage index reforms that lift low wage
hospitals’ wage indexes without
reducing the standardized operating rate
for all hospitals, which commenters
indicated already receive Medicare
reimbursement at rates that are less than
the actual cost of care. A commenter
stated that for hospitals between the
22nd and 25th percentile, the reduction
due to the budget neutrality adjustment
is greater than the benefit received from
the quartile adjustment. This
commenter suggested holding hospitals
under the 25th percentile harmless by
slightly reducing the labor-related share
for those hospitals that have a wage
index greater than 1, or via a graduated
reduction to the standardized rate based
on wage index percentile. Other
alternative methodologies and data
suggested by commenters included:
reducing the wage indexes of hospitals
with wage index values above the 75th
percentile through a budget neutrality
adjustment; verifying local labor prices
with wage data audits; working with
Congress to create a new designated
pool of funding; working with Congress
to minimize wage index cliffs;
shortening the lag in hospital wage data
used to construct the wage index; and
setting a national wage index floor of
1.000.
Response: We disagree with the
commenters that the low wage index
hospital policy should be implemented
in a non-budget neutral manner. As we
stated in response to similar comments
in the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42331 and 42332) and the
FY 2022 IPPS/LTCH PPS final rule (86
FR 45180), under section 1886(d)(3)(E)
of the Act, the wage index adjustment
is required to be implemented in a
budget neutral manner. However, even
if the wage index were not required to
be budget neutral under section
1886(d)(3)(E) of the Act, we would
consider it inappropriate to use the
wage index to increase or decrease
overall IPPS spending. As we stated in
the FY 2020 IPPS/LTCH PPS final rule
(84 FR 42331), the wage index is not a
policy tool but rather a technical
adjustment designed to be a relative
measure of the wages and wage-related
costs of subsection (d) hospitals. As a
result, as we explained in the FY 2020
IPPS/LTCH PPS final rule, if it were
determined that section 1886(d)(3)(E) of
the Act does not require the wage index
to be budget neutral, we invoke our
authority at section 1886(d)(5)(I) of the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Act in support of such a budget
neutrality adjustment.
With regard to the commenter’s
assertion about a possible reduction to
overall payment if the amount of benefit
received from the wage index boost is
less than the reduction to the
standardized amount, we believe we
have applied both the quartile policy
and the budget neutrality policy
appropriately, as we explained in
response to comments in the FY 2022
IPPS/LTCH PPS final rule (86 FR
45180). The quartile adjustment is
applied to the wage index, which
resulted in an increase to the wage
index for hospitals below the 25th
percentile. The budget neutrality
adjustment is applied to the
standardized amount in order to ensure
that the low wage index hospital policy
is implemented in a budget neutral
manner. Thus, consistent with our
current methodology for implementing
wage index budget neutrality under
section 1886(d)(3)(E) of the Act and
with how we implemented budget
neutrality for the low wage index
hospital policy in FY 2020, we believe
it is appropriate to continue to apply a
budget neutrality adjustment to the
national standardized amount for all
hospitals so that the low wage index
hospital policy is implemented in a
budget neutral manner for FY 2023.
We appreciate the commenters’ range
of suggested alternatives. Because we
did not propose alternatives with regard
to the low wage index hospital policy,
we consider these comments to be
outside the scope of the FY 2023 IPPS/
LTCH PPS proposed rule. We are not
addressing them in this final rule but
may consider them in future
rulemaking.
Comment: Several commenters
opposed the low wage index hospital
policy, stating that it is inappropriately
redistributive, ineffective, and outside
the agency’s statutory authority under
section 1886(d)(3)(E) of the Act.
Specifically, a commenter stated that
although the policy is intended to help
rural hospitals, rural hospitals in certain
states do not benefit from this policy.
Furthermore, the commenter stated that
the policy undermines the intent of the
wage index by not recognizing real
differences in labor costs.
Response: In response to comments
opposing the low wage index hospital
policy, we believe we addressed the
stated concerns in our responses to
comments when we first finalized the
policy and the related budget neutrality
adjustment in the FY 2020 IPPS/LTCH
PPS final rule (84 FR 42325 through
42332). Concerning the policy’s
redistributive effect, we refer readers to
PO 00000
Frm 00229
Fmt 4701
Sfmt 4700
49007
our response to the comments above
about budget neutrality. With regard to
the policy’s effectiveness, we believe the
comments in support of the policy,
specifically comments from relatively
low-wage hospitals stating that the
increased payments under the policy
have allowed them to raise
compensation for their workers, indicate
that many low wage hospitals are
benefiting from this policy.
Furthermore, we stated in the FY 2020
IPPS/LTCH PPS final rule (84 FR 42326
through 42328) our intention that this
policy will be effective for at least 4
years, until the policy’s effects could be
reflected in the wage index data. In
response to the comment stating that
although the policy is intended to help
rural hospitals, rural hospitals in certain
states do not benefit from this policy,
we refer readers to our response to a
similar comment in the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42328)
regarding the policy’s effect on rural
hospitals.
In response to comments stating the
policy exceeds CMS’s statutory
authority, we refer the commenters to
our prior discussion of the authority for
the policy in the FY 2020 IPPS/LTCH
PPS final rule (84 FR 42326 through
42332).
In response to the commenter who
asserted that the low wage index
hospital policy does not recognize real
differences in labor costs, we continue
to believe, for the reasons stated in the
FY 2020 IPPS/LTCH PPS final rule (84
FR 42327–42328), that by preserving the
rank order in wage index values, our
policy continues to reflect meaningful
distinctions between the employee
compensation costs faced by hospitals
in different geographic areas. Thus,
under the low wage index hospital
policy, we believe the wage index for
low wage index hospitals appropriately
reflects the relative hospital wage level
in those areas compared to the national
average hospital wage level.
Comment: Many commenters noted
that the low wage index hospital policy
is currently the subject of pending
litigation in Bridgeport. A few
commenters urged CMS not to finalize
the policy for FY 2023, or to wait until
a final court decision is reached. One
such commenter suggested CMS should
eliminate the budget neutrality
adjustments for FYs 2020, 2021, and
2022 in light of Bridgeport. Many
commenters urged CMS to appeal the
district court’s decision in Bridgeport.
These commenters stated that the
consequences of halting the policy
would be dire, and that CMS has broad
authority under section 1886(d)(3)(E) to
make policy adjustments, such as the
E:\FR\FM\10AUR2.SGM
10AUR2
49008
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
imputed floor policy implemented in
2005 that was implemented by CMS as
a policy measure to address concerns
from hospitals in all-urban states. These
commenters further stated that this step
towards achieving health equity is
justified, and that CMS implemented
the low wage index hospital policy via
notice-and-comment rulemaking.
Response: We appreciate the
commenters’ input. As we stated in the
proposed rule, the FY 2020 low wage
index hospital policy and the related
budget neutrality adjustment are the
subject of pending litigation, including
in Bridgeport. As Bridgeport is pending
litigation, we are unable to provide
further information at this time. We
disagree with the district court’s
conclusion that the Social Security Act
does not authorize the Secretary to
adopt the low wage index hospital
policy, and we note that its decision
remains subject to potential appeal. We
also note that plaintiffs in Bridgeport
only challenged the low wage index
hospital and associated budget
neutrality adjustment policies for FY
2020.
After consideration of the comments
we received, and for the reasons stated
above and in the proposed rule, we are
finalizing as proposed to continue the
low wage index hospital policy and the
related budget neutrality adjustment for
FY 2023.
khammond on DSKJM1Z7X2PROD with RULES2
H. FY 2023 Wage Index Tables
In the FY 2016 IPPS/LTCH PPS final
rule (80 FR 49498 and 49807 through
49808), we finalized a proposal to
streamline and consolidate the wage
index tables associated with the IPPS
proposed and final rules for FY 2016
and subsequent fiscal years. Effective
beginning FY 2016, with the exception
of Table 4E, we streamlined and
consolidated 11 tables (Tables 2, 3A, 3B,
4A, 4B, 4C, 4D, 4F, 4J, 9A, and 9C) into
2 tables (Tables 2 and 3). In this FY
2023 IPPS/LTCH PPS final rule, as
provided beginning with the FY 2021
IPPS/LTCH PPS final rule, we have
included Table 4A which is titled ‘‘List
of Counties Eligible for the OutMigration Adjustment under Section
1886(d)(13) of the Act’’ and Table 4B
titled ‘‘Counties redesignated under
section 1886(d)(8)(B) of the Act (Lugar
Counties).’’ We refer readers to section
VI. of the Addendum to this final rule
for a discussion of the wage index tables
for FY 2023.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
I. Revisions to the Wage Index Based on
Hospital Redesignations and
Reclassifications
1. General Policies and Effects of
Reclassification and Redesignation
Under section 1886(d)(10) of the Act,
the Medicare Geographic Classification
Review Board (MGCRB) considers
applications by hospitals for geographic
reclassification for purposes of payment
under the IPPS. Hospitals must apply to
the MGCRB to reclassify not later than
13 months prior to the start of the fiscal
year for which reclassification is sought
(usually by September 1). Generally,
hospitals must be proximate to the labor
market area to which they are seeking
reclassification and must demonstrate
characteristics similar to hospitals
located in that area. The MGCRB issues
its decisions by the end of February for
reclassifications that become effective
for the following fiscal year (beginning
October 1). The regulations applicable
to reclassifications by the MGCRB are
located in 42 CFR 412.230 through
412.280. (We refer readers to a
discussion in the FY 2002 IPPS final
rule (66 FR 39874 and 39875) regarding
how the MGCRB defines mileage for
purposes of the proximity
requirements.) The general policies for
reclassifications and redesignations and
the policies for the effects of hospitals’
reclassifications and redesignations on
the wage index are discussed in the FY
2012 IPPS/LTCH PPS final rule for the
FY 2012 final wage index (76 FR 51595
and 51596). We note that rural hospitals
reclassifying under the MGCRB to
another State’s rural area are not eligible
for the rural floor, because the rural
floor may apply only to urban, not rural,
hospitals.
In addition, in the FY 2012 IPPS/
LTCH PPS final rule, we discussed the
effects on the wage index of urban
hospitals reclassifying to rural areas
under 42 CFR 412.103. In the FY 2020
IPPS/LTCH PPS final rule (84 FR 42332
through 42336), we finalized a policy to
exclude the wage data of urban
hospitals reclassifying to rural areas
under 42 CFR 412.103 from the
calculation of the rural floor. In section
III.G.1 of this final rule, for FY 2023 and
subsequent years, we are finalizing a
policy that calculates the rural floor as
it was calculated before FY 2020.
Hospitals that are geographically located
in States without any rural areas are
ineligible to apply for rural
reclassification in accordance with the
provisions of 42 CFR 412.103.
On April 21, 2016, we published an
interim final rule with comment period
(IFC) in the Federal Register (81 FR
23428 through 23438) that included
PO 00000
Frm 00230
Fmt 4701
Sfmt 4700
provisions amending our regulations to
allow hospitals nationwide to have
simultaneous § 412.103 and MGCRB
reclassifications. For reclassifications
effective beginning FY 2018, a hospital
may acquire rural status under § 412.103
and subsequently apply for a
reclassification under the MGCRB using
distance and average hourly wage
criteria designated for rural hospitals. In
addition, we provided that a hospital
that has an active MGCRB
reclassification and is then approved for
redesignation under § 412.103 will not
lose its MGCRB reclassification; such a
hospital receives a reclassified urban
wage index during the years of its active
MGCRB reclassification and is still
considered rural under section 1886(d)
of the Act and for other purposes.
We discussed that when there is both
a § 412.103 redesignation and an
MGCRB reclassification, the MGCRB
reclassification controls for wage index
calculation and payment purposes. We
exclude hospitals with § 412.103
redesignations from the calculation of
the reclassified rural wage index if they
also have an active MGCRB
reclassification to another area. That is,
if an application for urban
reclassification through the MGCRB is
approved, and is not withdrawn or
terminated by the hospital within the
established timelines, we consider the
hospital’s geographic CBSA and the
urban CBSA to which the hospital is
reclassified under the MGCRB for the
wage index calculation. We refer readers
to the April 21, 2016 IFC (81 FR 23428
through 23438) and the FY 2017 IPPS/
LTCH PPS final rule (81 FR 56922
through 56930), in which we finalized
the April 21, 2016 IFC, for a full
discussion of the effect of simultaneous
reclassifications under both the
§ 412.103 and the MGCRB processes on
wage index calculations. For a
discussion on the effects of
reclassifications under § 412.103 on the
rural area wage index and the
calculation of the rural floor for FY 2020
through FY 2022, we refer readers to the
FY 2020 IPPS/LTCH PPS final rule (84
FR 42332 through 42336). For a
discussion of the effects of
reclassifications under § 412.103 on the
rural area wage index and the
calculation of the rural floor for FY 2023
and subsequent years, we refer readers
to section III.G.1 of this final rule.
On May 10, 2021, we published an
IFC in the Federal Register (86 FR
24735 through 24739) that included
provisions amending our regulations to
allow hospitals with a rural
redesignation to reclassify through the
MGCRB using the rural reclassified area
as the geographic area in which the
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
hospital is located. We revised our
regulation so that the redesignated rural
area, and not the hospital’s geographic
urban area, is considered the area a
§ 412.103 hospital is located in for
purposes of meeting MGCRB
reclassification criteria, including the
average hourly wage comparisons
required by § 412.230(a)(5)(i) and
(d)(1)(iii)(C). Similarly, we revised the
regulations to consider the redesignated
rural area, and not the geographic urban
area, as the area a § 412.103 hospital is
located in for the prohibition at
§ 412.230(a)(5)(i) on reclassifying to an
area with a pre-reclassified average
hourly wage lower than the
prereclassified average hourly wage for
the area in which the hospital is located.
Effective for reclassification
applications due to the MGCRB for
reclassification beginning in FY 2023, a
§ 412.103 hospital could apply for a
reclassification under the MGCRB using
the State’s rural area as the area in
which the hospital is located. We refer
readers to the May 10, 2021 IFC (86 FR
24735 through 24739) and the FY 2022
IPPS/LTCH PPS final rule (86 FR 45187
through 45190), in which we finalized
the May 10, 2021 IFC, for a full
discussion of these policies.
khammond on DSKJM1Z7X2PROD with RULES2
2. MGCRB Reclassification and
Redesignation Issues for FY 2023
a. FY 2023 Reclassification Application
Requirements and Approvals
As previously stated, under section
1886(d)(10) of the Act, the MGCRB
considers applications by hospitals for
geographic reclassification for purposes
of payment under the IPPS. The specific
procedures and rules that apply to the
geographic reclassification process are
outlined in regulations under 42 CFR
412.230 through 412.280. At the time
this final rule was drafted, the MGCRB
had completed its review of FY 2023
reclassification requests. Based on such
reviews, there are 383 hospitals
approved for wage index
reclassifications by the MGCRB starting
in FY 2023. Because MGCRB wage
index reclassifications are effective for 3
years, for FY 2023, hospitals reclassified
beginning in FY 2021 or FY 2022 are
eligible to continue to be reclassified to
a particular labor market area based on
such prior reclassifications for the
remainder of their 3-year period. There
were 311 hospitals approved for wage
index reclassifications in FY 2021 that
will continue for FY 2023, and 315
hospitals approved for wage index
reclassifications in FY 2022 that will
continue for FY 2023. Of all the
hospitals approved for reclassification
for FY 2021, FY 2022 and FY 2023,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
based upon the review at the time of the
final rule, 1,009 hospitals are in a
MGCRB reclassification status for FY
2023 (with 166 of these hospitals
reclassified back to their geographic
location).
Under the regulations at 42 CFR
412.273, hospitals that have been
reclassified by the MGCRB are
permitted to withdraw their
applications if the request for
withdrawal is received by the MGCRB
any time before the MGCRB issues a
decision on the application, or after the
MGCRB issues a decision, provided the
request for withdrawal is received by
the MGCRB within 45 days of the date
that CMS’ annual notice of proposed
rulemaking is issued in the Federal
Register concerning changes to the
inpatient hospital prospective payment
system and proposed payment rates for
the fiscal year for which the application
has been filed. For information about
withdrawing, terminating, or canceling
a previous withdrawal or termination of
a 3-year reclassification for wage index
purposes, we refer readers to § 412.273,
as well as the FY 2002 IPPS final rule
(66 FR 39887 through 39888) and the FY
2003 IPPS final rule (67 FR 50065
through 50066). Additional discussion
on withdrawals and terminations, and
clarifications regarding reinstating
reclassifications and ‘‘fallback’’
reclassifications were included in the
FY 2008 IPPS final rule (72 FR 47333)
and the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38148 through 38150).
We note that in the FY 2021 IPPS/
LTCH final rule (85 FR 58771 through
58778), CMS finalized an assignment
policy for hospitals reclassified to
CBSAs from which one or more
counties moved to a new or different
urban CBSA under the revised OMB
delineations based on OMB Bulletin 18–
04. We provided a table in that rule (85
FR 58777 and 58778) which described
the assigned CBSA for all the MGCRB
cases subject to this policy. For such
reclassifications that continue to be
active or are reinstated for FY 2023, the
CBSAs assigned in the FY 2021 IPPS/
LTCH final rule continue to be in effect.
Applications for FY 2024
reclassifications are due to the MGCRB
by September 1, 2022. We note that this
is also the deadline for canceling a
previous wage index reclassification
withdrawal or termination under 42
CFR 412.273(d). Applications and other
information about MGCRB
reclassifications may be obtained
beginning in mid-July 2022, via the
internet on the CMS website at https://
www.cms.gov/RegulationsandGuidance/Review-Boards/MGCRB/
index.html, or by calling the MGCRB at
PO 00000
Frm 00231
Fmt 4701
Sfmt 4700
49009
(410) 786–1174. This collection of
information was previously approved
under OMB Control Number 0938–0573
which expired on January 31, 2021. A
reinstatement of this PRA package is
currently being developed. The public
will have an opportunity to review and
submit comments regarding the
reinstatement of this PRA package
through a public notice and comment
period separate from this rulemaking.
Comment: A commenter requested
that in light of potential actions taken by
CMS in response to the Bridgeport or
Citrus decisions, CMS should allow an
additional 45-day withdrawal/
termination period after the publication
of this final rule to allow hospitals to
select the wage index that would apply
for FY 2023. As an alternative, citing a
FY 2005 policy exception, the
commenter suggested that CMS can
assign hospitals to the geographic area
that is most advantageous to them.
Response: As previously discussed, in
section III.G.4 of this final rule, CMS is
finalizing as proposed to continue the
low wage index hospital policy and the
related budget neutrality adjustment for
FY 2023 and is not implementing any
changes at this time due to Bridgeport.
As previously discussed, in section
III.G.1. of the preamble of this final rule,
we are modifying for FY 2023 and
subsequent years the calculation of the
rural floor and ‘‘the wage index for rural
areas in the State in which the county
is located’’ as referred to in section
1886(d)(8)(C)(iii) of the Act, based on
the Citrus decision. Presumably, the
commenter is requesting that we
provide an additional 45 days for
hospitals with MGCRB reclassifications
to submit MGCRB withdrawal or
termination requests, or rescind such a
request that was already approved. As
previously discussed in the FY 2015
IPPS/LTCH PPS final rule (79 FR 49973)
and the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58769—58770), we maintain
that information provided in the
proposed rule constitutes the best
available data to assist hospitals in
making reclassification decisions. In the
proposed rule, we acknowledged the
district court decisions in Bridgeport
and Citrus, and we stated that we may
decide to take a different approach to
our policies in the final rule, depending
on public comments or developments in
the court proceedings. We believe
hospitals had the ability to make
informed decisions weighing potential
outcomes based on the proposed rule.
In particular, we note that the state
rural wage index published in Table 3
of the FY 2023 IPPS/LTCH PPS
proposed rule would be the rural floor
if we included 412.103 hospitals in the
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
calculation of the rural floor. Therefore,
information with regard to what the
rural floor would have been if we
modified our policy was available in the
proposed rule. Further, looking at the
states and territories in Table 3 of the
proposed rule, 40 states/territories in
the proposed rule had a rural floor that
equals the rural wage index (which
includes Puerto Rico). Four states in the
proposed rule are not eligible for the
khammond on DSKJM1Z7X2PROD with RULES2
02
03
04
15
36
39
46
50
ALASKA
ARIZONA
ARKANSAS
INDIANA
OHIO
PENNSYLVANIA
UTAH
WASHINGTON
In addition, as we discussed in the FY
2021 IPPS/LTCH PPS final rule (85 FR
58769—58770), section 1886(d)(8)(D) of
the Act requires the Secretary to adjust
the standardized amounts to ensure that
the application of certain provisions of
the statute, including a decision of the
MGCRB or the Secretary under section
1886(d)(10), do not result in aggregate
payments under section 1886 that are
greater or less than those that would
otherwise be made. If hospitals were to
withdraw or terminate reclassification
statuses after the publication of the final
rule, as the commenter suggested CMS
permit, any resulting changes in the
wage index would not have been taken
into account when calculating the IPPS
standardized amounts in the final rule
in accordance with the statutory budget
neutrality requirement. Therefore, it is
necessary that the values published in
the final rule represent the final wage
index values reflective of
reclassification decisions.
With regard to the FY 2005 exception
referenced by the commenter, CMS did
provide an exception to the withdrawal
and termination deadline due to the
implementation of special
reclassifications under section 508 of
Pub. L. 108–173 and general concerns
regarding the implementation of revised
OMB labor market delineations based
on the 2000 decennial census (69 FR
VerDate Sep<11>2014
rural floor since they are all urban states
and receive the imputed floor instead.
Using data from Table 3 of the proposed
rule, this leaves the 8 states listed in the
table that follows with a difference
between the state rural floor and state
rural wage index. As demonstrated in
the table that follows, hospitals should
be able to make these MGCRB decisions
based on the data in the proposed rule
as usual as an overwhelming majority of
00:20 Aug 10, 2022
Jkt 256001
02
03
04
15
36
39
46
50
1.1972
0.8560
0.7508
0.8589
0.8112
0.8354
0.9389
1.0659
Frm 00232
Fmt 4701
Sfmt 4700
-0.0092
-0.0009
-0.0231
-0.0220
-0.0029
-0.0280
-0.0723
-0.0479
1.1880
0.8551
0.7277
0.8369
0.8083
0.8074
0.8666
1.0180
49060 and 49061). CMS inferred certain
wage index selections for section 508
hospitals where the preferred option
(depending on the finalization of
proposed wage index policies) was clear
and obvious, and hospitals were granted
a 30 day window after the final rule to
withdraw their reclassification request
or to rescind their previous withdrawal
or termination request. With the
relatively few number of reclassified
hospitals in FY 2005, it was plausible
for CMS to impute or infer the optimal
reclassification status in certain limited
circumstances, and potentially allow for
an additional window of opportunity for
hospitals to review their options to
withdraw or terminate MGCRB status.
However, when factoring the large
number of currently reclassified
hospitals and the iterative and
compounding impacts of various forms
of wage index reclassification policy,
various wage index floor policies, and
other adjustment policies; it does not
support the premise that additional
opportunities to modify MGCRB
reclassification status would be feasible
or would result in more accurate or
consistent results.
Comment: A commenter noted that
the MGCRB issued determinations for
FY 2023 on January 24, 2022. The
commenter stated that this was earlier
than in the past, when the MGCRB
PO 00000
the states/territories show no difference
between the state rural wage index and
state rural floor, and those that do show
a difference show a minimal variance.
Therefore, we do not believe the data
justifies an additional 45 days for
hospitals with MGCRB reclassifications
to submit MGCRB withdrawal or
termination requests or to rescind such
a request that was already approved.
typically issued determinations midFebruary, to meet the statutory
requirement for decisions to be issued
by the end of February. The commenter
requested that CMS limit the MGCRB
from issuing decisions prior to the first
week of February to allow hospitals
ample time to submit documentation of
rural reclassification, SCH and RRC
status to the Board or to submit a
request to withdraw an application
based on review of the January PUF.
The commenter stated that without a
more definitive timeline, hospitals face
uncertainty if their documentation will
be accepted by the MGCRB and could be
adversely affected by an early decision
being issued by the Board.
Response: We disagree with the
commenter that hospitals are
disadvantaged by earlier issuance of
MGCRB decisions. First, we believe
hospitals should submit applications
complete with supporting
documentation at the time MGCRB
applications are due. Hospitals taking
advantage of the MGCRB’s practice of
accepting supporting documentation to
supplement applications until the date
of the MGCRB’s review are aware that
the review is not held on the same date
annually. Furthermore, rural
reclassification may be obtained at any
time, and hospitals seeking benefits of
rural status for MGCRB reclassification
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.118
49010
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
should plan accordingly. Finally, we
note that hospitals dissatisfied with the
MGCRB’s decision may request the
Administrator’s review under § 412.278.
With regard to hospitals requesting to
withdraw a pending reclassification
application following review of the
January PUF, hospitals may withdraw a
reclassification after the MGCRB has
issued decisions, within 45 days of the
date that CMS’ annual notice of
proposed rulemaking is issued in the
Federal Register, per the regulations at
§ 412.273. Therefore, we do not believe
hospitals are disadvantaged by the
earlier timing of MGCRB decisions
because they can submit supporting
documentation timely, obtain a rural
reclassification in advance, request the
Administrator’s review of an MGCRB
decision, and withdraw an unwanted
reclassification.
Comment: A commenter requested
that CMS change the special rule for
RRCs applying for reclassification at the
MGCRB to afford hospitals the same
reclassification opportunities as similar
hospitals competing in the same labor
market area. The commenter specifically
suggested that CMS revise its
regulations to state that if a hospital is
located within five miles of another
acute care hospital in the same CBSA
with a lower average hourly wage, the
hospital may reclassify to the same area
as the lower wage hospital, if the
applicable average hourly wage
requirements are met, rather than to the
area that is closest to the hospital.
Response: We appreciate the
commenter’s input. We did not propose
any changes to the regulation referenced
by the commenter, § 412.230(a)(3), the
special rules for sole community
hospitals and rural referral centers. We
are not finalizing any changes to the
special rule for RRCs applying for
reclassification at the MGCRB in this
final rule.
b. Clarification of Method for
Submission Under § 412.273
The regulations at 42 CFR 412.273 set
forth the procedures for withdrawing an
MGCRB application, terminating an
approved 3-year reclassification, or
canceling a previous withdrawal or
termination (also referred to as a
reinstatement). The timing of such
requests is specified at § 412.273(c) for
terminations and withdrawals and at
paragraph (d)(2) for canceling a previous
withdrawal or termination. However,
the method of submission is not clearly
specified in the regulations, other than
the requirement that a request to cancel
a previous withdrawal or termination (a
reinstatement), or to withdraw an
application or terminate an approved
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
reclassification, be in writing according
to § 412.273(d)(2) and (e). It has come to
our attention that this may be a source
of confusion for hospital representatives
seeking to submit such requests. It is
possible that hospital representatives
would attempt to send such requests to
the MGCRB via mail, email, or fax,
rather than in the manner that the
MGCRB can most efficiently track and
process.
Beginning with applications from
hospitals to reclassify for FY 2020, the
MGCRB requires applications,
supporting documents, and subsequent
correspondence to be filed
electronically through the MGCRB
module of the Office of Hearings Case
and Document Management System
(‘‘OH CDMS’’). The MGCRB issues all of
its notices and decisions via email and
these documents are accessible
electronically through OH CDMS.
Registration instructions and the system
user manual are available at https://
www.cms.gov/Regulations-andGuidance/ReviewBoards/MGCRB/
Electronic-Filing.html.
In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42313), we revised the
regulations at § 412.256(a)(1) to require
applications for reclassification to be
submitted to the MGCRB according to
the method prescribed by the MGCRB.
However, the regulations at § 412.273
for withdrawals, terminations, or
cancelations of a previous withdrawal
or termination (reinstatement) do not
similarly specify a required manner of
submission. Therefore, to eliminate
potential confusion about how to submit
withdrawal, termination, or cancelation
(reinstatement) requests, we proposed to
align the regulations at § 412.273 for
withdrawal, termination, or cancelation
(reinstatement) requests with the
regulations at § 412.256 for new
applications by specifying that
withdrawal, termination, or cancelation
(reinstatement) requests also must be
submitted to the MGCRB according to
the method prescribed by the MGCRB.
Specifically, we proposed to revise
§ 412.273(d)(2) for timing and process of
cancellation requests and § 412.273(e)
for withdrawal and termination
requests. We proposed to revise
§ 412.273(d)(2) to state that cancellation
requests must be submitted in writing to
the MGCRB according to the method
prescribed by the MGCRB no later than
the deadline for submitting
reclassification applications for the
following fiscal year, as specified in
§ 412.256(a)(2). We also proposed to
revise § 412.273(e) by adding that
requests to withdraw an application or
terminate an approved reclassification
must be submitted in writing to the
PO 00000
Frm 00233
Fmt 4701
Sfmt 4700
49011
MGCRB according to the method
prescribed by the MGCRB. We stated
that we believe these proposed revisions
to the regulations would eliminate
potential confusion; align our policy for
withdrawals, terminations, and
cancelations (reinstatements) with our
policy for applications; and ensure
requests are submitted to the MGCRB
through the method for submission that
they can most efficiently process.
Comment: A commenter supported
the proposed changes to § 412.273. The
commenter stated that these changes
will eliminate potential confusion, align
withdrawals, terminations, and
cancellations with the MGCRB
application process, and ensure
submissions can be processed more
efficiently by the MGCRB.
Response: We thank the commenter
for supporting the proposed changes.
After consideration of the public
comment we received, we are finalizing
as proposed without modification our
changes to the regulations at
§ 412.273(d)(2) and (e).
3. Redesignations Under Section
1886(d)(8)(B) of the Act (Lugar Status
Determinations)
In the FY 2012 IPPS/LTCH PPS final
rule (76 FR 51599 through 51600), we
adopted the policy that, beginning with
FY 2012, an eligible hospital that waives
its Lugar status in order to receive the
out-migration adjustment has effectively
waived its deemed urban status and,
thus, is rural for all purposes under the
IPPS effective for the fiscal year in
which the hospital receives the
outmigration adjustment. In addition, in
that rule, we adopted a minor
procedural change that would allow a
Lugar hospital that qualifies for and
accepts the out-migration adjustment
(through written notification to CMS
within 45 days from the publication of
the proposed rule) to waive its urban
status for the full 3-year period for
which its out-migration adjustment is
effective. By doing so, such a Lugar
hospital would no longer be required
during the second and third years of
eligibility for the out-migration
adjustment to advise us annually that it
prefers to continue being treated as rural
and receive the out-migration
adjustment. In the FY 2017 IPPS/LTCH
PPS final rule (81 FR 56930), we further
clarified that if a hospital wishes to
reinstate its urban status for any fiscal
year within this 3-year period, it must
send a request to CMS within 45 days
of publication of the proposed rule for
that particular fiscal year. We indicated
that such reinstatement requests may be
sent electronically to wageindex@
cms.hhs.gov. In the FY 2018 IPPS/LTCH
E:\FR\FM\10AUR2.SGM
10AUR2
49012
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
PPS final rule (82 FR 38147 through
38148), we finalized a policy revision to
require a Lugar hospital that qualifies
for and accepts the out-migration
adjustment, or that no longer wishes to
accept the out-migration adjustment and
instead elects to return to its deemed
urban status, to notify CMS within 45
days from the date of public display of
the proposed rule at the Office of the
Federal Register. These revised
notification timeframes were effective
beginning October 1, 2017. In addition,
in the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38148), we clarified that
both requests to waive and to reinstate
‘‘Lugar’’ status may be sent to
wageindex@cms.hhs.gov. To ensure
proper accounting, we requested that
hospitals include their CCN, and either
‘‘waive Lugar’’ or ‘‘reinstate Lugar’’, in
the subject line of these requests.
In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42314 and 42315), we
clarified that in circumstances where an
eligible hospital elects to receive the
outmigration adjustment within 45 days
of the public display date of the
proposed rule at the Office of the
Federal Register in lieu of its Lugar
wage index reclassification, and the
county in which the hospital is located
would no longer qualify for an outmigration adjustment when the final
rule (or a subsequent correction notice)
wage index calculations are completed,
the hospital’s request to accept the
outmigration adjustment would be
denied, and the hospital would be
automatically assigned to its deemed
urban status under section 1886(d)(8)(B)
of the Act. We stated that final rule
wage index values would be
recalculated to reflect this
reclassification, and in some instances,
after taking into account this
reclassification, the out-migration
adjustment for the county in question
could be restored in the final rule.
However, as the hospital is assigned a
Lugar reclassification under section
1886(d)(8)(B) of the Act, it would be
ineligible to receive the county
outmigration adjustment under section
1886(d)(13)(G) of the Act.
We did not receive any requests to
waive or reinstate an eligible hospital’s
deemed urban status under section
1886(d)(8)(B) of the Act. We did not
receive any public comments on this
policy for FY 2023.
J. Out-Migration Adjustment Based on
Commuting Patterns of Hospital
Employees
In accordance with section
1886(d)(13) of the Act, as added by
section 505 of Public Law 108–173,
beginning with FY 2005, we established
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
a process to make adjustments to the
hospital wage index based on
commuting patterns of hospital
employees (the ‘‘out-migration’’
adjustment). The process, outlined in
the FY 2005 IPPS final rule (69 FR
49061), provides for an increase in the
wage index for hospitals located in
certain counties that have a relatively
high percentage of hospital employees
who reside in the county but work in a
different county (or counties) with a
higher wage index.
Section 1886(d)(13)(B) of the Act
requires the Secretary to use data the
Secretary determines to be appropriate
to establish the qualifying counties.
When the provision of section
1886(d)(13) of the Act was implemented
for the FY 2005 wage index, we
analyzed commuting data compiled by
the U.S. Census Bureau that were
derived from a special tabulation of the
2000 Census journey-to-work data for all
industries (CMS extracted data
applicable to hospitals). These data
were compiled from responses to the
‘‘long-form’’ survey, which the Census
Bureau used at that time and which
contained questions on where residents
in each county worked (69 FR 49062).
However, the 2010 Census was ‘‘short
form’’ only; information on where
residents in each county worked was
not collected as part of the 2010 Census.
The Census Bureau worked with CMS to
provide an alternative dataset based on
the latest available data on where
residents in each county worked in
2010, for use in developing a new
outmigration adjustment based on new
commuting patterns developed from the
2010 Census data beginning with FY
2016.
To determine the out-migration
adjustments and applicable counties for
FY 2016, we analyzed commuting data
compiled by the Census Bureau that
were derived from a custom tabulation
of the American Community Survey
(ACS), an official Census Bureau survey,
utilizing 2008 through 2012 (5-year)
Microdata. The data were compiled
from responses to the ACS questions
regarding the county where workers
reside and the county to which workers
commute. As we discussed in prior
IPPS/LTCH PPS final rules, most
recently in the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45184), we have
applied the same policies, procedures,
and computations since FY 2012. We
proposed to use them again for FY 2023,
as we believe they continue to be
appropriate. We refer readers to the FY
2016 IPPS/LTCH PPS final rule (80 FR
49500 through 49502) for a full
explanation of the revised data source.
PO 00000
Frm 00234
Fmt 4701
Sfmt 4700
For FY 2023, the out-migration
adjustment will continue to be based on
the data derived from the custom
tabulation of the ACS utilizing 2008
through 2012 (5-year) Microdata. For
future fiscal years, we may consider
determining out-migration adjustments
based on data from the next Census or
other available data, as appropriate. For
FY 2023, we did not propose any
changes to the methodology or data
source that we used for FY 2016 (81 FR
25071). (We refer readers to a full
discussion of the out-migration
adjustment, including rules on deeming
hospitals reclassified under section
1886(d)(8) or section 1886(d)(10) of the
Act to have waived the out-migration
adjustment, in the FY 2012 IPPS/LTCH
PPS final rule (76 FR 51601 through
51602).)
We did not receive any public
comments on this proposed policy for
FY 2023. Therefore, for the reasons set
forth in this final rule and in the FY
2023 IPPS/LTCH PPS proposed rule, for
FY 2023, we are finalizing our proposal,
without modification, to continue using
the same policies, procedures, and
computations that were used for the FY
2012 outmigration adjustment and that
were applicable for FYs 2016 through
2022.
Table 2 associated with this final rule
(which is available via the internet on
the CMS website) includes the outmigration adjustments for the FY 2023
wage index. In addition, Table 4A
associated with this final rule, ‘‘List of
Counties Eligible for the Out-Migration
Adjustment under Section 1886(d)(13)
of the Act’’ (also available via the
internet on the CMS website) consists of
the following: A list of counties that are
eligible for the out-migration adjustment
for FY 2023 identified by FIPS county
code, the final FY 2023 out-migration
adjustment, and the number of years the
adjustment will be in effect.
K. Reclassification From Urban to Rural
Under Section 1886(d)(8)(E) of the Act
Implemented at 42 CFR 412.103
Under section 1886(d)(8)(E) of the
Act, a qualifying prospective payment
hospital located in an urban area may
apply for rural status for payment
purposes separate from reclassification
through the MGCRB. Specifically,
section 1886(d)(8)(E) of the Act provides
that, not later than 60 days after the
receipt of an application (in a form and
manner determined by the Secretary)
from a subsection (d) hospital that
satisfies certain criteria, the Secretary
shall treat the hospital as being located
in the rural area (as defined in
paragraph (2)(D)) of the State in which
the hospital is located. We refer readers
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
to the regulations at 42 CFR 412.103 for
the general criteria and application
requirements for a subsection (d)
hospital to reclassify from urban to rural
status in accordance with section
1886(d)(8)(E) of the Act. The FY 2012
IPPS/LTCH PPS final rule (76 FR 51595
through 51596) includes our policies
regarding the effect of wage data from
reclassified or redesignated hospitals.
We refer readers to the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42332
through 42336) for a discussion of our
policy to calculate the rural floor
without the wage data of urban
hospitals reclassifying to rural areas
under 42 CFR 412.103, and to section
III.G.1 of this final rule for a discussion
of our decision, for FY 2023 and
subsequent years, to calculate the rural
floor as it was calculated before FY 2020
by including the wage data of 412.103
hospitals.
In the FY 2019 IPPS/LTCH PPS final
rule (83 FR 41369 through 41374), we
codified certain policies regarding
multicampus hospitals in the
regulations at 42 CFR 412.92, 412.96,
412.103, and 412.108. We stated that
reclassifications from urban to rural
under 42 CFR 412.103 apply to the
entire hospital (that is, the main campus
and its remote location(s)). We also
stated that a main campus of a hospital
cannot obtain an SCH, RRC, or MDH
status, or rural reclassification under 42
CFR 412.103, independently or
separately from its remote location(s),
and vice versa. However, we are aware
that some urban hospitals operate one or
more remote location(s) in a State’s rural
area. In light of this scenario, we wish
to clarify that rural reclassification
under 42 CFR 412.103 applies to the
main campus and any remote location
located in an urban area. Under section
1886(d)(8)(E) of the Act, rural
reclassification is available only to a
hospital that is located in an urban area
and satisfies the criteria specified in the
statute. Thus, a remote location that is
located in a rural area would not qualify
for rural reclassification under section
1886(d)(8)(E) of the Act, as implemented
under 42 CFR 412.103. We proposed to
add 42 CFR 412.103(a)(8) to clarify that
for a multicampus hospital, approved
rural reclassification status applies to
the main campus and any remote
location located in an urban area,
including a main campus or any remote
location deemed urban under section
1886(d)(8)(B) of the Act.
We are also aware that CMS has not
consistently reflected the 412.103 rural
reclassification status in Table 2 of the
annual IPPS/LTCH PPS rulemaking for
certain remote locations of hospitals
that are located in a different CBSA than
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the main campus. If a remote location of
a hospital is located in a different CBSA
than the main campus of the hospital,
it is CMS’s longstanding policy to assign
that remote location a wage index based
on its own geographic area in order to
comply with the statutory requirement
to adjust for geographic differences in
hospital wage levels (section
1886(d)(3)(E) of the Act). Hospitals are
required to identify and allocate wages
and hours based on FTEs for remote
locations located in different CBSA on
Worksheet S–2, Part I, Lines 165 and
166 of form CMS–2552–10. In
calculating wage index values, CMS
identifies the allocated wage data for
these remote locations in Table 2 with
a ‘‘B’’ in the third position of the CCN.
As discussed previously, for a
multicampus hospital, rural
reclassification under 42 CFR 412.103
applies to the main campus and any
remote location located in an urban
area. The wage index implications of
this policy are that, barring another form
of wage index reclassification (for
example, MGCRB reclassification), a
main campus or remote location with
approved 412.103 rural reclassification
status would be assigned the rural wage
index of its State. For FY 2023, we will
list the 412.103 rural reclassification
status for remote locations (a remote
location is listed with a ‘‘B’’ in the third
digit of the CCN) in Table 2 of the
appendix to the final rule. We note that,
as of the date this final rule is issued,
only one ‘‘B’’ location (36B020) would
be assigned its State’s rural wage index
in FY 2023 due to the § 412.103 rural
reclassification status of the main
provider (360020). This location appears
to have ceased inpatient activities, so
we do not expect a negative financial
impact for FY 2023. However, hospitals
with § 412.103 rural reclassification
status and a remote location in a
different CBSA should evaluate
potential wage index outcomes for its
remote location(s) when withdrawing or
terminating MGCRB reclassification, or
canceling 412.103 rural reclassification
status. For example, if a hospital with
412.103 rural reclassification status
withdraws a separate active MGCRB
reclassification for a remote location,
that remote location may be assigned
the State’s rural wage index value,
effective for FY 2023.
Comment: A commenter supported
our proposal to clarify that approved
rural reclassification applies to a main
campus and any remote locations in an
urban area. The commenter stated that
this policy allows for uniform treatment
of all departments and campuses of the
same hospital.
PO 00000
Frm 00235
Fmt 4701
Sfmt 4700
49013
Response: We appreciate the
commenter’s support. Consistent with
our clarification regarding multicampus
hospitals, we are finalizing as proposed
without modification our addition to the
regulations at 42 CFR 412.103(a)(8) to
clarify that for a multicampus hospital,
approved rural reclassification status
applies to the main campus and any
remote location located in an urban
area, including a main campus or any
remote location deemed urban under
section 1886(d)(8)(B) of the Act. Table 2
associated with this FY 2023 IPPS/
LTCH PPS final rule will reflect the
412.103 rural reclassification status for
remote locations of hospitals that are
located in a different CBSA than the
main campus.
L. Process for Requests for Wage Index
Data Corrections
1. Process for Hospitals To Request
Wage Index Data Corrections
The preliminary, unaudited
Worksheet S–3 wage data files and the
CY 2019 occupational mix data files for
the proposed FY 2023 wage index were
made available on May 24, 2021 through
the internet on the CMS website at
https://www.cms.gov/
medicaremedicare-fee-service-payment
acuteinpatientppswage-index-files/
fy2023-wage-index-home-page.
On January 28, 2022, we posted a
public use file (PUF) at https://
www.cms.gov/medicaremedicare-feeservice-paymentacuteinpatientppswageindex-files/fy2023-wage-index-homepage containing FY 2023 wage index
data available as of January 28, 2022.
This PUF contains a tab with the
Worksheet S–3 wage data (which
includes Worksheet S–3, Parts II and III
wage data from cost reporting periods
beginning on or after October 1, 2018
through September 30, 2019; that is, FY
2019 wage data), a tab with the
occupational mix data (which includes
data from the CY 2019 occupational mix
survey, Form CMS–10079), a tab
containing the Worksheet S–3 wage data
of hospitals deleted from the January 28,
2022 wage data PUF, and a tab
containing the CY 2019 occupational
mix data of the hospitals deleted from
the January 28, 2022 occupational mix
PUF. In a memorandum dated January
20, 2022, we instructed all MACs to
inform the IPPS hospitals that they
service of the availability of the January
28, 2022 wage index data PUFs, and the
process and timeframe for requesting
revisions in accordance with the FY
2023 Hospital Wage Index Development
Time Table available at https://
www.cms.gov/files/document/fy2023wi-time-table.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49014
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
In the interest of meeting the data
needs of the public, beginning with the
proposed FY 2009 wage index, we post
an additional PUF on the CMS website
that reflects the actual data that are used
in computing the proposed wage index.
The release of this file does not alter the
current wage index process or schedule.
We notify the hospital community of the
availability of these data as we do with
the current public use wage data files
through our Hospital Open Door Forum.
We encourage hospitals to sign up for
automatic notifications of information
about hospital issues and about the
dates of the Hospital Open Door Forums
at the CMS website at https://
www.cms.gov/Outreach-and-Education/
Outreach/OpenDoorForums.
In a memorandum dated May 11,
2021, we instructed all MACs to inform
the IPPS hospitals that they service of
the availability of the preliminary wage
index data files and the CY 2019
occupational mix survey data files
posted on May 24, 2021, and the process
and timeframe for requesting revisions.
If a hospital wished to request a
change to its data as shown in the May
24, 2021, preliminary wage data files
and occupational mix data files, the
hospital had to submit corrections along
with complete, detailed supporting
documentation to its MAC so that the
MAC received them by September 2,
2021. Hospitals were notified of these
deadlines and of all other deadlines and
requirements, including the requirement
to review and verify their data as posted
in the preliminary wage index data files
on the internet, through the letters sent
to them by their MACs. We note, CMS
issued a waiver due to Hurricane Ida
and modified the September 2, 2021,
deadline specified in the FY 2023
Hospital Wage Index Development Time
Table for certain hospitals. Specifically,
CMS granted an extension until October
4, 2021, for hospitals in the States of
Louisiana and Mississippi to request
revisions to and provide documentation
for their FY 2019 Worksheet S–3 wage
data and CY 2019 occupational mix data
as included in the May 24, 2021
preliminary Public Use Files (PUFs),
respectively. According to the waiver,
MACs must receive the revision
requests and supporting documentation
by October 4, 2021. If hospitals
encountered difficulty meeting the
extended deadline, hospitals were to
communicate their concerns to CMS via
their MAC for CMS to consider an
additional extension if CMS determined
it was warranted. Details regarding this
waiver are available on the CMS website
at https://www.cms.gov/current-noncovid-emergencies, Additional IPPS
Hospital Blanket Waivers (https://
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
www.cms.gov/files/document/hurricanida-additional-ipps-hospital-blanketwaivers.pdf). November 15, 2021, was
the deadline for MACs to complete all
desk reviews for hospital wage and
occupational mix data and transmit
revised Worksheet S–3 wage data and
occupational mix data to CMS.
November 4, 2021, was the date by
when MACs notified State hospital
associations regarding hospitals that
failed to respond to issues raised during
the desk reviews. Additional revisions
made by the MACs were transmitted to
CMS throughout January 2022. CMS
published the wage index PUFs that
included hospitals’ revised wage index
data on January 28, 2022. Hospitals had
until February 15, 2022, to submit
requests to the MACs to correct errors in
the January 28, 2022 PUF due to CMS
or MAC mishandling of the wage index
data, or to revise desk review
adjustments to their wage index data as
included in the January 28, 2022, PUF.
Hospitals also were required to submit
sufficient documentation to support
their requests. Hospitals’ requests and
supporting documentation must be
received by the MAC by the February
deadline (that is, by February 15, 2022,
for the FY 2023 wage index).
After reviewing requested changes
submitted by hospitals, MACs were
required to transmit to CMS any
additional revisions resulting from the
hospitals’ reconsideration requests by
March 18, 2022. Under our current
policy as adopted in the FY 2018 IPPS/
LTCH PPS final rule (82 FR 38153), the
deadline for a hospital to request CMS
intervention in cases where a hospital
disagreed with a MAC’s handling of
wage data on any basis (including a
policy, factual, or other dispute) was
April 1, 2022. Data that were incorrect
in the preliminary or January 28, 2022
wage index data PUFs, but for which no
correction request was received by the
February 15, 2022 deadline, are not
considered for correction at this stage.
In addition, April 1, 2022, was the
deadline for hospitals to dispute data
corrections made by CMS of which the
hospital was notified after the January
28, 2022, PUF and at least 14 calendar
days prior to April 1, 2022 (that is,
March 18, 2022), that do not arise from
a hospital’s request for revisions. The
hospital’s request and supporting
documentation must be received by
CMS (and a copy received by the MAC)
by the April deadline (that is, by April
1, 2022, for the FY 2023 wage index).
We refer readers to the FY 2023 Hospital
Wage Index Development Time Table
for complete details.
Hospitals were given the opportunity
to examine Table 2 associated with the
PO 00000
Frm 00236
Fmt 4701
Sfmt 4700
proposed rule, which is listed in section
VI. of the Addendum to the proposed
rule and available via the internet on the
CMS website at https://www.cms.gov/
medicare/acute-inpatient-pps/fy-2023ipps-proposed-rule-home-page. Table 2
associated with the proposed rule
contained each hospital’s proposed
adjusted average hourly wage used to
construct the wage index values for the
past 3 years, including the proposed FY
2023 wage index which was constructed
from FY 2019 data. We noted in the
proposed rule that the proposed
hospital average hourly wages shown in
Table 2 only reflected changes made to
a hospital’s data that were transmitted
to CMS by early February 2022.
We posted the final wage index data
PUFs on April 29, 2022 on the CMS
website at https://www.cms.gov/
medicaremedicare-fee-service-payment
acuteinpatientppswage-index-files/
fy2023-wage-index-home-page. The
April 2022 PUFs are made available
solely for the limited purpose of
identifying any potential errors made by
CMS or the MAC in the entry of the
final wage index data that resulted from
the correction process previously
described (the process for disputing
revisions submitted to CMS by the
MACs by March 18, 2022, and the
process for disputing data corrections
made by CMS that did not arise from a
hospital’s request for wage data
revisions as discussed earlier).
After the release of the April 2022
wage index data PUFs, changes to the
wage and occupational mix data can
only be made in those very limited
situations involving an error by the
MAC or CMS that the hospital could not
have known about before its review of
the final wage index data files.
Specifically, neither the MAC nor CMS
will approve the following types of
requests:
• Requests for wage index data
corrections that were submitted too late
to be included in the data transmitted to
CMS by the MACs on or before March
18, 2022.
• Requests for correction of errors
that were not, but could have been,
identified during the hospital’s review
of the January 28, 2022, wage index
PUFs.
• Requests to revisit factual
determinations or policy interpretations
made by the MAC or CMS during the
wage index data correction process.
If, after reviewing the April 2022 final
wage index data PUFs, a hospital
believes that its wage or occupational
mix data are incorrect due to a MAC or
CMS error in the entry or tabulation of
the final data, the hospital was given the
opportunity to notify both its MAC and
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
CMS regarding why the hospital
believes an error exists and provide all
supporting information, including
relevant dates (for example, when it first
became aware of the error). The hospital
was required to send its request to CMS
and to the MAC so that it was received
no later than May 27, 2022. May 27,
2022, was also the deadline for hospitals
to dispute data corrections made by
CMS of which the hospital is notified on
or after 13 calendar days prior to April
1, 2022 (that is, March 19, 2022), and at
least 14 calendar days prior to May 27,
2022 (that is, May 13, 2022), that do not
arise from a hospital’s request for
revisions. (Data corrections made by
CMS of which a hospital was notified
on or after 13 calendar days prior to
May 27, 2022 (that is, May 14, 2022),
may be appealed to the Provider
Reimbursement Review Board (PRRB)).
In accordance with the FY 2023
Hospital Wage Index Development Time
Table posted on the CMS website at
https://www.cms.gov/files/document/
fy2023-wi-time-table.pdf, the May
appeals were required to be sent via
mail and email to CMS and the MACs.
We refer readers to the FY 2023 Hospital
Wage Index Development Time Table
for complete details.
Verified corrections to the wage index
data received timely (that is, by May 27,
2022) by CMS and the MACs were
incorporated into the final FY 2023
wage index, which will be effective
October 1, 2022.
We created the processes previously
described to resolve all substantive
wage index data correction disputes
before we finalize the wage and
occupational mix data for the FY 2023
payment rates. Accordingly, hospitals
that do not meet the procedural
deadlines set forth earlier will not be
afforded a later opportunity to submit
wage index data corrections or to
dispute the MAC’s decision with respect
to requested changes. Specifically, our
policy is that hospitals that do not meet
the procedural deadlines as previously
set forth (requiring requests to MACs by
the specified date in February and,
where such requests are unsuccessful,
requests for intervention by CMS by the
specified date in April) will not be
permitted to challenge later, before the
PRRB, the failure of CMS to make a
requested data revision. We refer
readers also to the FY 2000 IPPS final
rule (64 FR 41513) for a discussion of
the parameters for appeals to the PRRB
for wage index data corrections. As
finalized in the FY 2018 IPPS/LTCH
PPS final rule (82 FR 38154 through
38156), this policy also applies to a
hospital disputing corrections made by
CMS that do not arise from a hospital’s
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
request for a wage index data revision.
That is, a hospital disputing an
adjustment made by CMS that did not
arise from a hospital’s request for a wage
index data revision is required to
request a correction by the first
applicable deadline. Hospitals that do
not meet the procedural deadlines set
forth earlier will not be afforded a later
opportunity to submit wage index data
corrections or to dispute CMS’ decision
with respect to changes.
Again, we believe the wage index data
correction process described earlier
provides hospitals with sufficient
opportunity to bring errors in their wage
and occupational mix data to the MAC’s
attention. Moreover, because hospitals
had access to the final wage index data
PUFs by late April 2022, they have an
opportunity to detect any data entry or
tabulation errors made by the MAC or
CMS before the development and
publication of the final FY 2023 wage
index by August 2022, and the
implementation of the FY 2023 wage
index on October 1, 2022. Given these
processes, the wage index implemented
on October 1 should be accurate.
Nevertheless, in the event that errors are
identified by hospitals and brought to
our attention after May 27, 2022, we
retain the right to make midyear
changes to the wage index under very
limited circumstances.
Specifically, in accordance with 42
CFR 412.64(k)(1) of our regulations, we
make midyear corrections to the wage
index for an area only if a hospital can
show that: (1) The MAC or CMS made
an error in tabulating its data; and (2)
the requesting hospital could not have
known about the error or did not have
an opportunity to correct the error,
before the beginning of the fiscal year.
For purposes of this provision, ‘‘before
the beginning of the fiscal year’’ means
by the May deadline for making
corrections to the wage data for the
following fiscal year’s wage index (for
example, May 27, 2022, for the FY 2023
wage index). This provision is not
available to a hospital seeking to revise
another hospital’s data that may be
affecting the requesting hospital’s wage
index for the labor market area. As
indicated earlier, because CMS makes
the wage index data available to
hospitals on the CMS website prior to
publishing both the proposed and final
IPPS rules, and the MACs notify
hospitals directly of any wage index
data changes after completing their desk
reviews, we do not expect that midyear
corrections will be necessary. However,
under our current policy, if the
correction of a data error changes the
wage index value for an area, the
revised wage index value will be
PO 00000
Frm 00237
Fmt 4701
Sfmt 4700
49015
effective prospectively from the date the
correction is made.
In the FY 2006 IPPS final rule (70 FR
47385 through 47387 and 47485), we
revised 42 CFR 412.64(k)(2) to specify
that, effective on October 1, 2005, that
is, beginning with the FY 2006 wage
index, a change to the wage index can
be made retroactive to the beginning of
the Federal fiscal year only when CMS
determines all of the following: (1) The
MAC or CMS made an error in
tabulating data used for the wage index
calculation; (2) the hospital knew about
the error and requested that the MAC
and CMS correct the error using the
established process and within the
established schedule for requesting
corrections to the wage index data,
before the beginning of the fiscal year
for the applicable IPPS update (that is,
by the May 27, 2022, deadline for the
FY 2023 wage index); and (3) CMS
agreed before October 1 that the MAC or
CMS made an error in tabulating the
hospital’s wage index data and the wage
index should be corrected.
In those circumstances where a
hospital requested a correction to its
wage index data before CMS calculated
the final wage index (that is, by the May
27, 2022 deadline for the FY 2023 wage
index), and CMS acknowledges that the
error in the hospital’s wage index data
was caused by CMS’ or the MAC’s
mishandling of the data, we believe that
the hospital should not be penalized by
our delay in publishing or
implementing the correction. As with
our current policy, we indicated that the
provision is not available to a hospital
seeking to revise another hospital’s data.
In addition, the provision cannot be
used to correct prior years’ wage index
data; it can only be used for the current
Federal fiscal year. In situations where
our policies would allow midyear
corrections other than those specified in
42 CFR 412.64(k)(2)(ii), we continue to
believe that it is appropriate to make
prospective-only corrections to the wage
index.
We note that, as with prospective
changes to the wage index, the final
retroactive correction will be made
irrespective of whether the change
increases or decreases a hospital’s
payment rate. In addition, we note that
the policy of retroactive adjustment will
still apply in those instances where a
final judicial decision reverses a CMS
denial of a hospital’s wage index data
revision request.
2. Process for Data Corrections by CMS
After the January 28 Public Use File
(PUF)
The process set forth with the wage
index time table discussed in section
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49016
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
III.L.1. of the preamble of this final rule
allows hospitals to request corrections
to their wage index data within
prescribed timeframes. In addition to
hospitals’ opportunity to request
corrections of wage index data errors or
MACs’ mishandling of data, CMS has
the authority under section
1886(d)(3)(E) of the Act to make
corrections to hospital wage index and
occupational mix data in order to ensure
the accuracy of the wage index. As we
explained in the FY 2016 IPPS/LTCH
PPS final rule (80 FR 49490 through
49491) and the FY 2017 IPPS/LTCH PPS
final rule (81 FR 56914), section
1886(d)(3)(E) of the Act requires the
Secretary to adjust the proportion of
hospitals’ costs attributable to wages
and wage-related costs for area
differences reflecting the relative
hospital wage level in the geographic
areas of the hospital compared to the
national average hospital wage level. We
believe that, under section 1886(d)(3)(E)
of the Act, we have discretion to make
corrections to hospitals’ data to help
ensure that the costs attributable to
wages and wage-related costs in fact
accurately reflect the relative hospital
wage level in the hospitals’ geographic
areas.
We have an established multistep, 15month process for the review and
correction of the hospital wage data that
is used to create the IPPS wage index for
the upcoming fiscal year. Since the
origin of the IPPS, the wage index has
been subject to its own annual review
process, first by the MACs, and then by
CMS. As a standard practice, after each
annual desk review, CMS reviews the
results of the MACs’ desk reviews and
focuses on items flagged during the desk
review, requiring that, if necessary,
hospitals provide additional
documentation, adjustments, or
corrections to the data. This ongoing
communication with hospitals about
their wage data may result in the
discovery by CMS of additional items
that were reported incorrectly or other
data errors, even after the posting of the
January 28 PUF, and throughout the
remainder of the wage index
development process. In addition, the
fact that CMS analyzes the data from a
regional and even national level, unlike
the review performed by the MACs that
review a limited subset of hospitals, can
facilitate additional editing of the data
that may not be readily apparent to the
MACs. In these occasional instances, an
error may be of sufficient magnitude
that the wage index of an entire CBSA
is affected. Accordingly, CMS uses its
authority to ensure that the wage index
accurately reflects the relative hospital
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
wage level in the geographic area of the
hospital compared to the national
average hospital wage level, by
continuing to make corrections to
hospital wage data upon discovering
incorrect wage data, distinct from
instances in which hospitals request
data revisions.
We note that CMS corrects errors to
hospital wage data as appropriate,
regardless of whether that correction
will raise or lower a hospital’s average
hourly wage. For example, as discussed
in section III.C. of the preamble of the
FY 2019 IPPS/LTCH PPS final rule (83
FR 41364), in situations where a
hospital did not have documentable
salaries, wages, and hours for
housekeeping and dietary services, we
imputed estimates, in accordance with
policies established in the FY 2015
IPPS/LTCH PPS final rule (79 FR 49965
through 49967). Furthermore, if CMS
discovers after conclusion of the desk
review, for example, that a MAC
inadvertently failed to incorporate
positive adjustments resulting from a
prior year’s wage index appeal of a
hospital’s wage-related costs such as
pension, CMS would correct that data
error and the hospital’s average hourly
wage would likely increase as a result.
While we maintain CMS’ authority to
conduct additional review and make
resulting corrections at any time during
the wage index development process, in
accordance with the policy finalized in
the FY 2018 IPPS/LTCH PPS final rule
(82 FR 38154 through 38156) and as first
implemented with the FY 2019 wage
index (83 FR 41389), hospitals are able
to request further review of a correction
made by CMS that did not arise from a
hospital’s request for a wage index data
correction. Instances where CMS makes
a correction to a hospital’s data after the
January 28 PUF based on a different
understanding than the hospital about
certain reported costs, for example,
could potentially be resolved using this
process before the final wage index is
calculated. We believe this process and
the timeline for requesting review of
such corrections (as described earlier
and in the FY 2018 IPPS/LTCH PPS
final rule) promote additional
transparency to instances where CMS
makes data corrections after the January
28 PUF, and provide opportunities for
hospitals to request further review of
CMS changes in time for the most
accurate data to be reflected in the final
wage index calculations. These
additional appeals opportunities are
described earlier and in the FY 2023
Hospital Wage Index Development Time
Table, as well as in the FY 2018 IPPS/
LTCH PPS final rule (82 FR 38154
through 38156).
PO 00000
Frm 00238
Fmt 4701
Sfmt 4700
M. Labor-Related Share for the FY 2023
Wage Index
Section 1886(d)(3)(E) of the Act
directs the Secretary to adjust the
proportion of the national prospective
payment system base payment rates that
are attributable to wages and wage
related costs by a factor that reflects the
relative differences in labor costs among
geographic areas. It also directs the
Secretary to estimate from time to time
the proportion of hospital costs that are
labor-related and to adjust the
proportion (as estimated by the
Secretary from time to time) of
hospitals’ costs that are attributable to
wages and wage-related costs of the
DRG prospective payment rates. We
refer to the portion of hospital costs
attributable to wages and wage-related
costs as the labor-related share. The
labor-related share of the prospective
payment rate is adjusted by an index of
relative labor costs, which is referred to
as the wage index.
Section 403 of Public Law 108–173
amended section 1886(d)(3)(E) of the
Act to provide that the Secretary must
employ 62 percent as the labor-related
share unless this would result in lower
payments to a hospital than would
otherwise be made. However, this
provision of Public Law 108–173 did
not change the legal requirement that
the Secretary estimate from time to time
the proportion of hospitals’ costs that
are attributable to wages and wagerelated costs. Thus, hospitals receive
payment based on either a 62-percent
labor-related share, or the labor-related
share estimated from time to time by the
Secretary, depending on which laborrelated share resulted in a higher
payment.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45194 through 45208), we
rebased and revised the hospital market
basket. We established a 2018-based
IPPS hospital market basket to replace
the 2014-based IPPS hospital market
basket, effective October 1, 2021. Using
the 2018-based IPPS market basket, we
finalized a labor-related share of 67.6
percent for discharges occurring on or
after October 1, 2021. In addition, in FY
2022, we implemented this revised and
rebased labor-related share in a budget
neutral manner (86 FR 45529–45530).
However, consistent with section
1886(d)(3)(E) of the Act, we did not take
into account the additional payments
that would be made as a result of
hospitals with a wage index less than or
equal to 1.0000 being paid using a laborrelated share lower than the laborrelated share of hospitals with a wage
index greater than 1.0000.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
The labor-related share is used to
determine the proportion of the national
IPPS base payment rate to which the
area wage index is applied. We include
a cost category in the labor related share
if the costs are labor intensive and vary
with the local labor market. In the FY
2022 IPPS/LTCH PPS final rule (86 FR
45204 through 45207), we included in
the labor-related share the national
average proportion of operating costs
that are attributable to the following cost
categories in the 2018-based IPPS
market basket: Wages and Salaries;
Employee Benefits; Professional Fees:
Labor-Related; Administrative and
Facilities Support Services; Installation,
Maintenance, and Repair Services; and
All Other: Labor-related Services. In the
proposed rule, for FY 2023, we did not
propose to make any further changes to
the labor-related share. For FY 2023, we
proposed to continue to use a laborrelated share of 67.6 percent for
discharges occurring on or after October
1, 2022.
As discussed in section V.A. of the
preamble of this final rule, prior to
January 1, 2016, Puerto Rico hospitals
were paid based on 75 percent of the
national standardized amount and 25
percent of the Puerto Rico-specific
standardized amount. As a result, we
applied the Puerto Rico-specific laborrelated share percentage and nonlaborrelated share percentage to the Puerto
Rico-specific standardized amount.
Section 601 of the Consolidated
Appropriations Act, 2016 (Pub. L. 114–
113) amended section 1886(d)(9)(E) of
the Act to specify that the payment
calculation with respect to operating
costs of inpatient hospital services of a
subsection (d) Puerto Rico hospital for
inpatient hospital discharges on or after
January 1, 2016, shall use 100 percent
of the national standardized amount.
Because Puerto Rico hospitals are no
longer paid with a Puerto Rico-specific
standardized amount as of January 1,
2016, under section 1886(d)(9)(E) of the
Act as amended by section 601 of the
Consolidated Appropriations Act, 2016,
there is no longer a need for us to
calculate a Puerto Rico-specific laborrelated share percentage and nonlaborrelated share percentage for application
to the Puerto Rico-specific standardized
amount. Hospitals in Puerto Rico are
now paid 100 percent of the national
standardized amount and, therefore, are
subject to the national labor-related
share and nonlabor related share
percentages that are applied to the
national standardized amount.
Accordingly, for FY 2023, we did not
propose a Puerto Rico-specific labor-
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
related share percentage or a nonlaborrelated share percentage.
Comment: Some commenters stated
that an analysis comparing hospitals’
average hourly wages calculated from
data reported on schedule S–3 of their
FY 2019 to their 2020 cost reports
shows that the average hourly wage rose
4.14 percent among hospitals with a
wage index greater than 1.0. The
commenters stated that this wage
growth occurred at the same time that
hospital utilization was decreasing due
to the effects of the pandemic, resulting
in a considerable increase in the portion
of overall hospital costs represented by
labor.
In addition to requesting that CMS
update the labor share, the commenters
requested that CMS modify its
methodology to review only the labor
costs of hospitals in areas with a wage
index greater than 1.0 because hospitals
in areas with a wage index lower than
1.0 receive a statutorily defined laborrelated share of 62 percent. The
commenters stated that changes of the
labor share are budget-neutral but
updating the share would ensure that a
more appropriate amount of funds go to
hospitals in areas with a wage index
greater than 1.0, where the greatest
increases in labor costs have been
experienced. The commenters explained
that the same comparison of 2019 and
2020 average hourly wages shows that
hospitals with a wage index of 1.0 or
less experienced an increase of only
2.38 percent during that same period.
For the reasons above, the
commenters requested that CMS
consider raising the labor-related share
for hospitals with wage indexes greater
than 1.0 for FY 2023.
A commenter stated that it strongly
supports continuing to utilize a laborrelated share of 67.6 percent for
discharges. The commenter also stated
that given the extreme increases in labor
costs industry-wide due to the
pandemic over the last three years, the
commenter urged CMS to re-base again
for FY 2023 to reflect a more accurate
labor-related share.
A commenter stated that it
experienced an exponential increase in
the cost of labor as a result of the
COVID–19 pandemic and labor
shortages. The commenter requested
that CMS evaluate the impact of rising
labor costs on wage indices.
Response: We appreciate the
commenters’ concerns regarding how
operating expenses for hospitals may
have been impacted by the PHE.
However, we disagree with the
commenters’ suggestion to update the
labor related share for FY 2023. As
published in the FY 2006 IPPS final rule
PO 00000
Frm 00239
Fmt 4701
Sfmt 4700
49017
(70 FR 47403), in accordance with
section 404 of Public Law 108–173,
CMS determined a new frequency for
rebasing the hospital market basket,
including the labor-related share, of
every four years. Therefore, in the FY
2022 IPPS/LTCH final rule, we finalized
to update the labor related share to
reflect the rebased and revised IPPS
market basket, which is based on 2018
data. The labor-related share is equal to
the national average proportion of
operating costs that are attributable to
the following cost categories in the
2018-based IPPS market basket: Wages
and Salaries, Employee Benefits,
Professional Fees: Labor-Related,
Administrative and Facilities Support
Services, Installation, Maintenance, and
Repair Services, and All Other: LaborRelated Services.
CMS did not propose to rebase and
revise the IPPS market basket, including
the labor-related share, in the FY 2023
IPPS/LTCH proposed rule. However, we
did review the most recent Medicare
cost report data available for IPPS
hospitals submitted as of March 2022,
which includes data for 2019–2020. The
Medicare cost report data showed slight
decreases in the compensation cost
weight (reflecting wages and salaries,
employee benefits, and direct patient
care contract labor costs as a percent of
operating costs) in 2019 and 2020
resulting in a compensation cost weight
that is roughly 1 percentage point less
than the 2018-based IPPS market basket
cost weight. The compensation cost
weight accounts for 53.0 percentage
points of the 67.6 percentage point
labor-related share based on the 2018based IPPS market basket.
We plan to review the 2021 Medicare
cost report data as soon as complete
information is available and evaluate
these data for future rulemaking. We
thank the commenters for their
comments and will consider the
comments regarding the methodology
for deriving the labor-related share for
future rulemaking. After consideration
of the public comments we received, for
the reasons set forth above and in this
final rule and in the FY 2022 IPPS/
LTCH PPS final rule, we are finalizing
our proposals, without modification, to
continue to use a labor-related share of
67.6 percent for discharges occurring on
or after October 1, 2022 for all hospitals
(including Puerto Rico hospitals) whose
wage indexes are greater than 1.0000.
Tables 1A and 1B, which are
published in section VI. of the
Addendum to this FY 2023 IPPS/LTCH
PPS final rule and available via the
internet on the CMS website, reflect the
national labor-related share. Table 1C,
in section VI. of the Addendum to this
E:\FR\FM\10AUR2.SGM
10AUR2
49018
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
FY 2023 IPPS/LTCH PPS final rule and
available via the internet on the CMS
website, reflects the national laborrelated share for hospitals located in
Puerto Rico. For FY 2023, for all IPPS
hospitals (including Puerto Rico
hospitals) whose wage indexes are less
than or equal to 1.0000, we are applying
the wage index to a labor-related share
of 62 percent of the national
standardized amount. For all IPPS
hospitals (including Puerto Rico
hospitals) whose wage indexes are
greater than 1.000, for FY 2023, we are
applying the wage index to a laborrelated share of 67.6 percent of the
national standardized amount.
khammond on DSKJM1Z7X2PROD with RULES2
N. Permanent Cap on Wage Index
Decreases
1. Permanent Cap Policy for the Wage
Index
In the FY 2020 IPPS/LTCH PPS final
rule, CMS implemented a transition
policy for FY 2020 to place a 5 percent
cap on any decrease in a hospital’s wage
index from the hospital’s final wage
index in FY 2019 so that a hospital’s
final wage index for FY 2020 will not be
less than 95 percent of its final wage
index for FY 2019 (84 FR 42336 through
42337). We implemented this transition
due to the combined effect of the policy
changes for the FY 2020 wage index
(including policies to address wage
index disparities between high and low
wage index hospitals), which we
believed could lead to significant
decreases in the wage index values for
some hospitals. We stated that this
transition would allow the effects of our
policies to be phased in over 2 years
with no estimated reduction in the wage
index of more than 5 percent in FY 2020
(that is, no cap would be applied the
second year). We also stated that we
believed 5 percent is a reasonable level
for the cap because it would effectively
mitigate any significant decreases in the
wage index for FY 2020. We applied a
budget neutrality adjustment factor to
the FY 2020 standardized amount for all
hospitals to achieve budget neutrality
for the transition policy (84 FR 42337
through 42338).
In the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58753 through 58755), to
mitigate the effect of our adoption of the
revised OMB delineations in OMB
Bulletin 18–04, we implemented for FY
2021 the same 5 percent cap transition
policy that we had implemented for FY
2020. Specifically, we placed a 5
percent cap on any decrease in a
hospital’s wage index from the
hospital’s final wage index in FY 2020
so that a hospital’s final wage index for
FY 2021 will not be less than 95 percent
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
of its final wage index for FY 2020. We
stated that for FY 2021, we did not
believe it was necessary to implement
the multifaceted transitions (including a
1-year blended wage index) we
established in FY 2015 for the adoption
of the new OMB delineations based on
the new decennial census data. The 5
percent cap transition policy resulted in
some hospitals receiving a transition
adjustment that were not directly
affected by the adoption of the revised
OMB delineations (85 FR 58754). We
applied a budget neutrality adjustment
to the FY 2021 standardized amount to
achieve budget neutrality for the
transition policy (85 FR 58755).
In the FY 2022 IPPS/LTCH PPS
proposed rule (86 FR 25397), given the
unprecedented nature of the ongoing
COVID–19 PHE, we solicited comments
on whether it would be appropriate to
continue to apply a transition to the FY
2022 wage index for hospitals
negatively impacted by our adoption of
the updates in OMB Bulletin 18–04. We
received several comments strongly
recommending CMS extend a transition
policy similar to that implemented in
FY 2020 and FY 2021. Commenters also
recommended CMS consider making a
permanent 5 percent maximum
reduction policy to protect hospitals
from large year-to-year variations in
wage index values as a means to reduce
overall volatility. While we did not
adopt the commenters’ suggestion for a
permanent 5 percent cap policy, we did
finalize a transition policy for FY 2022
in the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45164). Specifically, for
hospitals that received the transition in
FY 2021, we continued a wage index
transition for FY 2022 under which we
apply a 5 percent cap on any decrease
in the hospital’s wage index compared
to its wage index for FY 2021 to mitigate
significant negative impacts of, and
provide additional time for hospitals to
adapt to, the CMS decision to adopt the
revised OMB delineations. We applied a
budget neutrality adjustment to the FY
2022 standardized amount so that the
transition is implemented in a budget
neutral manner (86 FR 45165).
For FY 2023 and subsequent years, we
further considered the comments we
received during the FY 2022 rulemaking
recommending a permanent 5 percent
cap policy to prevent large year-to-year
variations in wage index values as a
means to reduce overall volatility for
hospitals. In the past, we have
established temporary transition
policies (as described above) when there
have been significant changes to wage
index policy, and we have limited the
duration of each transition in order to
phase in the effects of those policy
PO 00000
Frm 00240
Fmt 4701
Sfmt 4700
changes. In taking this temporary
approach in the past, we have sought to
mitigate short-term instability and
fluctuations that can negatively impact
hospitals. We also recognize that, absent
any specific change in wage index
policy, significant year-to-year
fluctuations in an area’s wage index can
occur due to external factors beyond a
hospital’s control, such as the COVID–
19 PHE. For an individual hospital,
these fluctuations can be difficult to
predict. We recognize that predictability
in Medicare payments is important to
enable hospitals to budget and plan
their operations.
In light of these considerations, in the
FY 2023 IPPS/LTCH PPS proposed rule,
we proposed a permanent approach to
smooth year-to-year decreases in
hospitals’ wage indexes (87 FR 28377
through 28380). We proposed a policy
that we believe increases the
predictability of IPPS payments for
hospitals and mitigates instability and
significant negative impacts to hospitals
resulting from changes to the wage
index. We stated that we also believe
our proposed permanent policy would
eliminate the need for temporary and
potentially uncertain transition
adjustments to the wage index in the
future due to specific policy changes or
circumstances outside hospitals’ control
(for example, in the event we adopt any
future OMB revisions to the CBSA
delineations). As a result of this
proposed policy, an otherwise rare but
relatively large year-to-year decrease in
the wage index value for an individual
hospital would be phased in, providing
the hospital with additional time to plan
appropriately and explore potential
reclassification options, if applicable.
For example, if a change in OMB
delineations resulted in a hospital’s
wage index decreasing by more than 10
percent in any given year, this proposed
policy could provide at least one
additional year to phase in the decrease
beyond a single ‘‘transition’’ year
methodology, such as the transition
policy finalized in the FY 2015 IPPS/
LTCH PPS final rule (79 FR 49957
through 49962).
Typical year-to-year variation in the
wage index has historically been within
5 percent, and we stated in the proposed
rule that we expect this will continue to
be the case in future years. Because
hospitals are usually experienced with
this level of wage index fluctuation, we
stated that we believe applying a 5percent cap on all wage index decreases
each year, regardless of the reason for
the decrease, would effectively mitigate
instability in IPPS payments due to any
significant wage index decreases that
may affect hospitals in a year. In
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
addition, we stated that we believe that
the predictability resulting from a 5
percent cap on all wage index decreases
would enable hospitals to more
effectively budget and plan their
operations. Because applying a 5percent cap on all wage index decreases
would represent a small overall impact
on the labor market area wage index
system, we stated that we believe it
would ensure the wage index is a
relative measure of the value of labor in
prescribed labor market areas. In the
proposed rule, we estimated that
applying a 5-percent cap on all wage
index decreases would have a very
small effect on the budget neutrality
factor associated with the cap applied to
the standardized amount for FY 2023
(discussed in section III.N.2 of the
preamble of the proposed rule). Because
the wage index is a measure of the value
of labor (wage and wage-related costs) in
a prescribed labor market area relative
to the national average, we stated that
we anticipate that in the absence of
policy changes most hospitals will not
experience year-to-year wage index
declines greater than 5 percent in any
given year. Therefore, we stated that we
anticipate that the impact to the budget
neutrality factor associated with the cap
in future years would continue to be
minimal. We stated that we also believe
that when the 5-percent cap would be
applied under this proposal, in general
it is likely that it would be applied
similarly to all hospitals in the same
labor market area, as the hospital
average hourly wage data in the CBSA
(and any relative decreases compared to
the national average hourly wage)
would be similar. While in certain
circumstances this policy may result in
some hospitals in a CBSA receiving a
higher wage index than others in the
same area, we stated that we believe the
impact would be temporary.
For the reasons discussed in the
proposed rule, we stated that we believe
a 5-percent cap on wage index decreases
would be appropriate for the IPPS.
Therefore, for FY 2023 and subsequent
years, we proposed to apply a 5-percent
cap on any decrease to a hospital’s wage
index from its wage index in the prior
FY, regardless of the circumstances
causing the decline. That is, we
proposed that a hospital’s wage index
for FY 2023 would not be less than 95
percent of its final wage index for FY
2022, and that for subsequent years, a
hospital’s wage index would not be less
than 95 percent of its final wage index
for the prior FY. This also means that if
a hospital’s prior FY wage index is
calculated with the application of the 5percent cap, the following year’s wage
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
index would not be less than 95 percent
of the hospital’s capped wage index in
the prior FY. For example, if a hospital’s
wage index for FY 2023 is calculated
with the application of the 5-percent
cap, then its wage index for FY 2024
would not be less than 95 percent of its
capped wage index in FY 2023. We
stated that we would reflect the
proposed wage index cap policy at 42
CFR 412.64(h). Specifically, we
proposed to add a new paragraph at 42
CFR 412.64(h)(7) to state that beginning
with fiscal year 2023, if CMS determines
that a hospital’s wage index value for a
fiscal year would decrease by more than
5 percent as compared to the hospital’s
wage index value for the prior fiscal
year, CMS limits the decrease to 5
percent for the fiscal year.
We stated that we have authority to
implement the proposed wage index cap
policy and the associated proposed
budget neutrality adjustment (discussed
in section III.N.2. of the preamble of the
proposed rule) under section
1886(d)(3)(E) of the Act, which gives the
Secretary broad authority to adjust for
area differences in hospital wage levels
by a factor (established by the Secretary)
reflecting the relative hospital wage
level in the geographic area of the
hospital compared to the national
average hospital wage level, and
requires those adjustments to be budget
neutral. We also stated that in addition,
we have authority to implement the
proposed wage index cap policy and the
associated proposed budget neutrality
adjustment (discussed in section III.N.2.
of the preamble of the proposed rule) as
an adjustment under section
1886(d)(5)(I)(i) of the Act, which
similarly gives the Secretary broad
authority to provide by regulation for
such other exceptions and adjustments
to such payment amounts under
subsection (d) as the Secretary deems
appropriate.
We proposed to apply the wage index
cap policy described above for a FY
using the final wage index applicable to
the hospital on the last day of the prior
FY (except for newly opened hospitals,
as discussed below). In general, the final
wage index applicable to the hospital on
the last day of the prior FY would be the
wage index value listed for the hospital
in Table 2 of the IPPS/LTCH PPS final
rule for that prior FY (including any
correction notices, if applicable). We
stated that in rulemaking for a FY, we
intend to relist the wage index values
from Table 2 of the IPPS/LTCH PPS
final rule for the prior FY, with updates
as described below. Under the proposed
wage index cap policy described above,
we would use these values to determine
a hospital’s wage index for a FY by
PO 00000
Frm 00241
Fmt 4701
Sfmt 4700
49019
capping it at 95 percent of the final
wage index applicable to the hospital on
the last day of the prior FY (in general,
the wage index value listed for the
hospital in Table 2 of the IPPS/LTCH
PPS final rule for the prior FY). We
noted in the proposed rule that,
consistent with our past application of
the 5 percent cap transition policy (see
the FY 2020 IPPS/LTCH PPS final rule
(84 FR 42337)), the proposed wage
index cap policy described above would
apply to hospitals whose wage index is
reduced by obtaining a urban to rural
reclassification under 42 CFR 412.103.
Specifically, a hospital that obtains a
rural reclassification under 42 CFR
412.103 may be assigned its State’s rural
wage index.212 While other forms of
wage index reclassification are effective
with the start of a Federal fiscal year,
pursuant to 42 CFR 412.103(d)(1), the
effective date of an approved rural
reclassification is the filing date of the
application. Therefore, the wage index
values for hospitals that obtain rural
reclassification under 42 CFR 412.103
may change in the middle of a Federal
fiscal year and thus may not be reflected
in Table 2 of the IPPS/LTCH PPS final
rule for that year. For example, if a
hospital was assigned its geographic
wage index of 1.0001 in Table 2 of the
FY 2022 IPPS/LTCH PPS final rule, but
obtained a rural reclassification on
December 1, 2021 and was assigned its
state’s rural wage index of 0.9600 for the
remainder of FY 2022; the FY 2023 cap
would be based on the 0.9600 value, not
the 1.0001 value listed in Table 2 of the
FY 2022 IPPS/LTCH PPS final rule. We
stated that as in previous years, we
would instruct hospitals that obtain a
rural reclassification under 42 CFR
412.103 to contact their MAC to ensure
that their assigned wage index does not
result in a greater than 5 percent
decrease from the hospital’s prior year
wage index value (see the FY 2020
IPPS/LTCH PPS final rule (84 FR 42337)
and the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58754)).
In Table 2 associated with this final
rule, which is available via the internet
on the CMS website, we list the FY 2022
final wage index value for all hospitals
in column C. For additional clarity, we
have identified hospitals that have
obtained rural reclassification after the
FY 2022 lock-in date, as described in 42
CFR 412.103(b)(6), and that were
assigned a different wage index than
what was listed in Table 2 associated
212 As discussed in the FY 2016 IFC (81 FR 23428
through 23438), hospitals with simultaneous
reclassifications under 412.103 and either Lugar or
MGCRB reclassification process are not assigned
their State’s rural wage index.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49020
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
with the FY 2022 IPPS/LTCH PPS
correction notice (available on the
internet at https://www.cms.gov/files/
zip/fy-2022-ipps-frtables-2-3-4a-4b.zip).
In Table 2 associated with this final
rule, the FY 2022 wage index column
for these hospitals will not use the
values listed in Table 2 associated with
the FY 2022 IPPS/LTCH PPS correction
notice (available on the internet at
https://www.cms.gov/files/zip/fy2022ipps-fr-tables-2-3-4a-4b.zip), but will
instead be updated with the wage index
value that is currently assigned to the
hospitals. Under our proposal described
above, we would apply the wage index
cap using the actual final wage index
value assigned to the hospital on the last
day of the prior Federal fiscal year
rather than the value listed in Table 2
of the prior FY final rule. In the
proposed rule, we identified in Table 2
(posted on the FY 2023 proposed rule
web page at https://www.cms.gov/
medicare/medicare-fee-for-servicepayment/acuteinpatientpps) all
hospitals that obtained rural
reclassification under 42 CFR 412.103
after the FY 2022 lock-in date and that
have no other form of wage index
reclassification applicable to them at
this time. This column in Table 2 has
been revised for this final rule (posted
on the FY 2023 final rule web page at
https://www.cms.gov/medicare/
medicare-fee-for-service-payment/
acuteinpatientpps) to add additional
hospitals without another form of
reclassification that obtain rural
reclassification under 42 CFR 412.103
before the FY 2023 lock-in date as
described in 42 CFR 412.103(b)(6).
We stated in the proposed rule that
hospitals that obtain rural
reclassification after the FY 2023 lockin date will not be listed as being
reclassified as rural in the FY 2023
IPPS/LTCH PPS final rule. We stated
that if we finalize the proposed wage
index cap policy described above, these
hospitals should contact their MAC to
ensure that the assigned rural wage
index value is not less than 95 percent
of their final wage index value for FY
2022 (that is, the wage index assigned
to the hospital as of September 30,
2022).
For newly opened hospitals, we
proposed to apply the proposed wage
index cap policy for a FY using the
wage index value the hospital was
assigned for the prior FY. A new
hospital would be paid the wage index
for the area in which it is geographically
located for its first full or partial fiscal
year, and it would not receive a cap for
that first year because it would not have
been assigned a wage index in the prior
year. Also, it is possible a new hospital
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
may not be listed in Table 2 for several
years since the hospitals listed in Table
2 are based on historical data. We stated
in the proposed rule that if we finalize
the proposed wage index cap policy
described above, a new hospital may
contact their MAC to ensure that their
assigned wage index value for the
upcoming FY is not less than 95 percent
of the value assigned to them for the
prior Federal fiscal year. For example, if
a hospital begins operations on July 1,
2022, and is assigned its area wage
index of 0.9000 for the remainder of FY
2022, its FY 2023 wage index would be
capped at 95 percent of that value, and
could not be lower than 0.8550 (0.95 ×
0.9000) regardless of whether it was
listed in Table 2 in the FY 2022 IPPS/
LTCH PPS final rule. A hospital that
opens on December 1, 2022 would not
be eligible for a capped wage index in
FY 2023, as it was not assigned a wage
index during FY 2022.
In the proposed rule, we noted that if
we adopt these proposals as final policy,
we would examine the effects of the
policy on an ongoing basis in the future
in order to assess whether it effectively
and appropriately accomplishes the goal
of increasing predictability and stability
in IPPS payments.
We received comments on our
proposals and summarize and respond
to these comments in section III.N.2.
below where we discuss the proposed
budget neutrality adjustment associated
with the proposed wage index cap
policy. As we note below, we are
finalizing our proposals regarding the
wage index cap policy without
modification.
2. Permanent Cap Budget Neutrality
We proposed to implement the
proposed wage index cap policy
(discussed above in section III.N.1 of the
preamble of this final rule) in a budget
neutral manner through a national
adjustment to the standardized amount
each fiscal year as we have
implemented similar past transition
policies involving a cap on wage index
decreases (for example, see the FY 2021
IPPS/LTCH PPS final rule (85 FR 58755)
and the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45164 through 45165)). We
stated that we believe application of the
proposed wage index cap policy should
not increase estimated aggregate
Medicare payments beyond the
payments that would be made had we
never applied the cap.
Specifically, we proposed to apply a
budget neutrality adjustment to ensure
that estimated aggregate payments
under our proposed wage index cap
policy for hospitals that would have a
decrease in their wage indexes for the
PO 00000
Frm 00242
Fmt 4701
Sfmt 4700
upcoming fiscal year of more than 5
percent would equal what estimated
aggregate payments would have been
without the proposed wage index cap
policy. To determine the proposed
associated budget neutrality factor, we
stated that we would compare estimated
aggregate IPPS payments with and
without the proposed wage index cap
policy. As discussed above in section
III.N.1 of the preamble of this final rule,
in the propose rule, we stated that we
have authority to implement this budget
neutrality adjustment under sections
1886(d)(3)(E) and (d)(5)(I)(i) of the Act.
Comment: Commenters were
generally supportive of CMS’s proposal
to limit any decrease in a hospital’s
wage index value to be no greater than
5 percent as compared to the hospital’s
wage index value for the prior fiscal
year. Commenters supported CMS’s goal
of increasing the stability and
predictability of payments under the
IPPS. However, several commenters
contend that contrary to CMS’s past
statements, the statute neither
authorizes nor requires budget
neutrality to offset adjustments made
under section 1886(d)(5)(I)(i). Some
commenters suggested that CMS should
apply the cap in a manner that would
not reduce the wage indexes of other
hospitals, contending this would lead to
less volatility in wage index values.
Several commenters request CMS
review and seek alternatives to the
proposed national budget neutrality
adjustment.
Response: We appreciate commenters’
support of the proposed permanent cap
on wage index decreases. As discussed
above in section III.N.1 of the preamble
of this final rule, we have authority to
implement the proposed budget
neutrality adjustment associated with
the proposed cap under sections
1886(d)(3)(E) and (d)(5)(I)(i) of the Act.
Section 1886(d)(3)(E) gives the Secretary
broad authority to adjust for area
differences in hospital wage levels by a
factor (established by the Secretary)
reflecting the relative hospital wage
level in the geographic area of the
hospital compared to the national
average hospital wage level, and
requires those adjustments to be applied
in a budget neutral manner. However,
even if the wage index were not
required to be budget neutral under
section 1886(d)(3)(E) of the Act, we
would not consider it an appropriate
alternative to use the wage index and
the proposed permanent cap on wage
index decreases to increase or decrease
overall IPPS spending. The wage index
is not a policy tool but rather a technical
adjustment designed to be a relative
measure of the wages and wage-related
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
costs of subsection (d) hospitals in the
United States. Contrary to the
commenters’ assertion, we also have
authority to implement the proposed
budget neutrality adjustment associated
with the proposed cap as an adjustment
under section 1886(d)(5)(I)(i) of the Act,
which similarly gives the Secretary
broad authority to provide by regulation
for such other exceptions and
adjustments to such payment amounts
under subsection (d) as the Secretary
deems appropriate. Furthermore, our
past transition policies involving a 5
percent cap on wage index decreases
implemented in a budget neutral
manner did not result in wage index
volatility, and we expect the same for
the overall budget neutrality
adjustments associated with the
permanent cap policy.
Comment: MedPAC supported the
proposal to cap wage index decreases at
5 percent, but suggested also applying a
cap to increases of more than 5 percent.
Response: We appreciate MedPAC’s
suggestion that the cap on wage index
changes of more than 5 percent should
also be applied to increases in the wage
index. However, as we discussed in the
proposed rule, one purpose of the
proposed policy is to help mitigate the
significant negative impacts of certain
wage index changes. As we discussed in
the proposed rule, we believe applying
a 5-percent cap on all wage index
decreases would support increased
predictability about IPPS payments for
hospitals in the upcoming fiscal year,
enabling them to more effectively
budget and plan their operations. That
is, we proposed to cap decreases
because we believe that a hospital
would be able to more effectively budget
and plan when there is predictability
about its expected minimum level of
IPPS payments in the upcoming fiscal
year. We did not propose to limit wage
index increases because we do not
believe such a policy is needed to
enable hospitals to more effectively
budget and plan their operations.
Therefore, we believe it is appropriate
for hospitals that experience an increase
in their wage index value to receive that
wage index value.
Comment: A commenter suggested
that if CMS discontinues the low wage
index hospital policy, hospitals that
benefitted in the prior year from that
policy should not be subject to a 5
percent cap on any decreases.
Response: We appreciate the
commenter’s suggestion. As discussed
in section III. G. 4 of this final rule, CMS
is continuing the low wage index
hospital policy for FY 2023.
Comment: A commenter did not
support CMS’s proposed policy
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
approach to the wage index cap policy
with regard to newly opened hospitals.
While the commenter stated they
understand the rationale for CMS’s
policy approach, they expressed
concerns that it will create inequity in
Medicare payments for hospitals within
the same market. The commenter
encouraged CMS to apply the same area
wage index value for new and existing
hospitals under this policy.
Response: We understand the
commenter’s concern, but we do not
believe the scenario they are alluding to
(that is, a labor market where existing
hospitals are receiving the cap, and new
hospitals are not) would neither be
common nor require additional
consideration. We believe that on an
ongoing basis, relatively few hospitals
would receive the cap, and even fewer
would receive the cap in consecutive
years. As of this final rule, there will be
126 hospitals receiving the cap in FY
2023, and only 12 that will receive a cap
increase of greater than 5 percent.
Therefore, any potential difference in
the wage index value hospitals in the
same labor market area receive would
likely be minimal and temporary. We
proposed to examine the effects of this
policy on an ongoing basis to assess
whether it effectively and appropriately
accomplishes the goal of increasing
predictability and stability in IPPS
payments, and may reevaluate this issue
in the future. However, at this time, we
do not believe that creating a policy
modification for hospitals that were not
assigned a wage index in the prior year
is necessary.
After consideration of the public
comments we received, for the reasons
discussed in this final rule and in the
proposed rule, we are finalizing as
proposed, without modification, our
wage index cap policy and the
associated budget neutrality adjustment.
We will apply a 5-percent cap on any
decrease to a hospital’s wage index from
its wage index in the prior FY,
regardless of the circumstances causing
the decline. A hospital’s wage index for
FY 2023 will not be less than 95 percent
of its final wage index for FY 2022, and
for subsequent years, a hospital’s wage
index will not be less than 95 percent
of its final wage index for the prior FY.
For example, a hospital that received a
wage index of 1.0000 on September 30,
2022 could not receive a wage index of
less than 0.9500 for FY 2023. If a
hospital’s prior FY wage index is
calculated with the application of the 5percent cap, the following year’s wage
index will not be less than 95 percent
of the hospital’s capped wage index in
the prior FY. Except for newly opened
hospitals, we will apply the cap for a FY
PO 00000
Frm 00243
Fmt 4701
Sfmt 4700
49021
using the final wage index applicable to
the hospital on the last day of the prior
FY. A newly opened hospital would be
paid the wage index for the area in
which it is geographically located for its
first full or partial fiscal year, and it
would not receive a cap for that first
year because it would not have been
assigned a wage index in the prior year.
We are adding a new paragraph at 42
CFR 412.64(h)(7) to state that beginning
with fiscal year 2023, if CMS determines
that a hospital’s wage index value for a
fiscal year would decrease by more than
5 percent as compared to the hospital’s
wage index value for the prior fiscal
year, CMS limits the decrease to 5
percent for the fiscal year.
We will apply the cap in a budget
neutral manner through a national
adjustment to the standardized amount
each fiscal year. Specifically, we will
apply a budget neutrality adjustment to
ensure that estimated aggregate
payments under our wage index cap
policy for hospitals that would have a
decrease in their wage indexes for the
upcoming fiscal year of more than 5
percent would equal what estimated
aggregate payments would have been
without the wage index cap policy. We
note that the budget neutrality
adjustment has been updated based on
the final rule data. We refer readers to
the Addendum of this final rule for
further information regarding the budget
neutrality calculations.
IV. Payment Adjustment for Medicare
Disproportionate Share Hospitals
(DSHs) for FY 2023 (§ 412.106)
A. General Discussion
Section 1886(d)(5)(F) of the Act
provides for additional Medicare
payments to subsection (d) hospitals
that serve a significantly
disproportionate number of low-income
patients. The Act specifies two methods
by which a hospital may qualify for the
Medicare disproportionate share
hospital (DSH) adjustment. Under the
first method, hospitals that are located
in an urban area and have 100 or more
beds may receive a Medicare DSH
payment adjustment if the hospital can
demonstrate that, during its cost
reporting period, more than 30 percent
of its net inpatient care revenues are
derived from State and local
government payments for care furnished
to patients with low incomes. This
method is commonly referred to as the
‘‘Pickle method.’’ The second method
for qualifying for the DSH payment
adjustment, which is the most common,
is based on a complex statutory formula
under which the DSH payment
adjustment is based on the hospital’s
E:\FR\FM\10AUR2.SGM
10AUR2
49022
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
geographic designation, the number of
beds in the hospital, and the level of the
hospital’s disproportionate patient
percentage (DPP). A hospital’s DPP is
the sum of two fractions: the ‘‘Medicare
fraction’’ and the ‘‘Medicaid fraction.’’
The Medicare fraction (also known as
the ‘‘SSI fraction’’ or ‘‘SSI ratio’’) is
A. The Medicaid fraction is computed
by dividing the hospital’s number of
inpatient days furnished to patients
who, for such days, were eligible for
Medicaid, but were not entitled to
benefits under Medicare Part A, by the
hospital’s total number of inpatient days
in the same period.
DSH Eligibility
Qualifying Criteria
Statutory Formula
A hospital that has a disproportionate patient percentage equal to or
exceeding 15 percent, may qualify for the Medicare DSH adjustment.
We refer readers to 42 CFR 412.106 for the specific eligibility criteria
and payment formulas.
"Pickle Method"
A hospital that is located in an urban area and has 100 or more beds
may qualify to receive a Medicare DSH payment adjustment if the
hospital can demonstrate that, during its cost reporting period, more
than 30 percent of its net inpatient care revenues are derived from State
and local government payments for care furnished to patients with low
mcomes
Because the DSH payment adjustment
is part of the IPPS, the statutory
references to ‘‘days’’ in section
1886(d)(5)(F) of the Act have been
interpreted to apply only to hospital
acute care inpatient days. Regulations
located at 42 CFR 412.106 govern the
Medicare DSH payment adjustment and
specify how the DPP is calculated as
well as how beds and patient days are
counted in determining the Medicare
DSH payment adjustment. Under
§ 412.106(a)(1)(i), the number of beds for
the Medicare DSH payment adjustment
is determined in accordance with bed
counting rules for the IME adjustment
under § 412.105(b).
Section 3133 of the Patient Protection
and Affordable Care Act, as amended by
section 10316 of the same Act and
section 1104 of the Health Care and
Education Reconciliation Act (Pub. L.
111–152), added a section 1886(r) to the
Act that modifies the methodology for
computing the Medicare DSH payment
adjustment. (For purposes of this final
rule, we refer to these provisions
collectively as section 3133 of the
Affordable Care Act.) Beginning with
discharges in FY 2014, hospitals that
qualify for Medicare DSH payments
under section 1886(d)(5)(F) of the Act
receive 25 percent of the amount they
previously would have received under
the statutory formula for Medicare DSH
payments. This provision applies
equally to hospitals that qualify for DSH
payments under section
1886(d)(5)(F)(i)(I) of the Act and those
hospitals that qualify under the Pickle
method under section 1886(d)(5)(F)(i)(II)
of the Act.
The remaining amount, equal to an
estimate of 75 percent of what otherwise
would have been paid as Medicare DSH
payments, reduced to reflect changes in
the percentage of individuals who are
uninsured, is available to make
additional payments to each hospital
that qualifies for Medicare DSH
payments and that has uncompensated
care. The payments to each hospital for
a fiscal year are based on the hospital’s
amount of uncompensated care for a
given time period relative to the total
amount of uncompensated care for that
same time period reported by all
hospitals that receive Medicare DSH
payments for that fiscal year.
Since FY 2014, section 1886(r) of the
Act has required that hospitals that are
eligible for DSH payments under section
1886(d)(5)(F) of the Act receive 2
separately calculated payments:
Medicare DSH Uncompensated Care An uncompensated care payment determined as the
Payment product of the 3 factors, as discussed in this section.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00244
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.120
An empirically justified DSH payment equal to
25% of the amount determined under the statutory
formula in section 1886(d)(5)(F) of the Act for
Medicare DSH Payment Medicare DSH payments
ER10AU22.119
khammond on DSKJM1Z7X2PROD with RULES2
computed by dividing the number of the
hospital’s inpatient days that are
furnished to patients who were entitled
to both Medicare Part A and
Supplemental Security Income (SSI)
benefits by the hospital’s total number
of patient days furnished to patients
entitled to benefits under Medicare Part
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
section 1886(r)(1) of the Act for such
fiscal year. Therefore, this factor
amounts to 75 percent of the payments
that would otherwise be made under
section 1886(d)(5)(F) of the Act.
The second factor is, for FY 2018 and
subsequent fiscal years, 1 minus the
percent change in the percent of
individuals who are uninsured, as
determined by comparing the percent of
individuals who were uninsured in
2013 (as estimated by the Secretary,
based on data from the Census Bureau
or other sources the Secretary
determines appropriate, and certified by
the Chief Actuary of CMS), and the
percent of individuals who were
uninsured in the most recent period for
which data are available (as so
estimated and certified), minus a
statutory adjustment of 0.2 percentage
point for FYs 2018 and 2019.
The third factor is a percent that, for
each subsection (d) hospital, represents
the quotient of the amount of
uncompensated care for such hospital
for a period selected by the Secretary (as
estimated by the Secretary, based on
appropriate data), including the use of
alternative data where the Secretary
determines that alternative data are
available which are a better proxy for
the costs of subsection (d) hospitals for
treating the uninsured, and the
aggregate amount of uncompensated
care for all subsection (d) hospitals that
receive a payment under section 1886(r)
of the Act. Therefore, this third factor
represents a hospital’s uncompensated
care amount for a given time period
relative to the uncompensated care
amount for that same time period for all
hospitals that receive Medicare DSH
payments in the applicable fiscal year,
expressed as a percent.
For each hospital, the product of these
three factors represents its additional
payment for uncompensated care for the
applicable fiscal year. We refer to the
additional payment determined by these
factors as the ‘‘uncompensated care
payment.’’ In brief, the uncompensated
care payment for an individual hospital
is determined as the product of the
following 3 factors:
Factor
1
75% of the total amount ofDSH payments that would otherwise made under
section 1886(d)(5)(F) of the Act.
Factor
2
1 minus the percent change in the percent of individuals who are uninsured (minus
0.2 percentage point for FYs 2018 and 2019). For FY 2020 and after, there is no
additional reduction.
Factor
3
The hospital's uncompensated care amount relative to the uncompensated care
amount for all DSH hospitals expressed as a percentage.
Section 1886(r) of the Act applies to
FY 2014 and each subsequent fiscal
year. In the FY 2014 IPPS/LTCH PPS
final rule (78 FR 50620 through 50647)
and the FY 2014 IPPS interim final rule
with comment period (78 FR 61191
through 61197), we set forth our policies
for implementing the required changes
to the Medicare DSH payment
methodology made by section 3133 of
the Affordable Care Act for FY 2014. In
those rules, we noted that, because
section 1886(r) of the Act modifies the
payment required under section
1886(d)(5)(F) of the Act, it affects only
the DSH payment under the operating
IPPS. It does not revise or replace the
capital IPPS DSH payment provided
under the regulations at 42 CFR part
412, subpart M, which was established
through the exercise of the Secretary’s
discretion in implementing the capital
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
IPPS under section 1886(g)(1)(A) of the
Act.
Finally, section 1886(r)(3) of the Act
provides that there shall be no
administrative or judicial review under
section 1869, section 1878, or otherwise
of any estimate of the Secretary for
purposes of determining the factors
described in section 1886(r)(2) of the
Act or of any period selected by the
Secretary for the purpose of determining
those factors. Therefore, there is no
administrative or judicial review of the
estimates developed for purposes of
applying the three factors used to
determine uncompensated care
payments, or the periods selected in
order to develop such estimates.
B. Eligibility for Empirically Justified
Medicare DSH Payments and
Uncompensated Care Payments
As explained earlier, the payment
methodology under section 3133 of the
PO 00000
Frm 00245
Fmt 4701
Sfmt 4700
Affordable Care Act applies to
‘‘subsection (d) hospitals’’ that would
otherwise receive a DSH payment made
under section 1886(d)(5)(F) of the Act.
Therefore, hospitals must receive
empirically justified Medicare DSH
payments in a fiscal year in order to
receive an additional Medicare
uncompensated care payment for that
year. Specifically, section 1886(r)(2) of
the Act states that, in addition to the
payment made to a subsection (d)
hospital under section 1886(r)(1) of the
Act, the Secretary shall pay to such
subsection (d) hospitals an additional
amount. Because section 1886(r)(1) of
the Act refers to empirically justified
Medicare DSH payments, the additional
payment under section 1886(r)(2) of the
Act is limited to hospitals that receive
empirically justified Medicare DSH
payments in accordance with section
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.121
khammond on DSKJM1Z7X2PROD with RULES2
Specifically, section 1886(r)(1) of the
Act provides that the Secretary shall pay
to such subsection (d) hospital
(including a Pickle hospital) 25 percent
of the amount the hospital would have
received under section 1886(d)(5)(F) of
the Act for DSH payments, which
represents the empirically justified
amount for such payment, as
determined by the MedPAC in its March
2007 Report to Congress. We refer to
this payment as the ‘‘empirically
justified Medicare DSH payment.’’
In addition to this empirically
justified Medicare DSH payment,
section 1886(r)(2) of the Act provides
that, for FY 2014 and each subsequent
fiscal year, the Secretary shall pay to
such subsection (d) hospital an
additional amount equal to the product
of three factors. The first factor is the
difference between the aggregate
amount of payments that would be
made to subsection (d) hospitals under
section 1886(d)(5)(F) of the Act if
subsection (r) did not apply and the
aggregate amount of payments that are
made to subsection (d) hospitals under
49023
khammond on DSKJM1Z7X2PROD with RULES2
49024
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
1886(r)(1) of the Act for the applicable
fiscal year.
In the FY 2014 IPPS/LTCH PPS final
rule (78 FR 50622) and the FY 2014
IPPS interim final rule with comment
period (78 FR 61193), we provided that
hospitals that are not eligible to receive
empirically justified Medicare DSH
payments in a fiscal year will not
receive uncompensated care payments
for that year. We also specified that we
would make a determination concerning
eligibility for interim uncompensated
care payments based on each hospital’s
estimated DSH status for the applicable
fiscal year (using the most recent data
that are available). For the proposed
rule, we estimated DSH status for all
hospitals using the most recent available
SSI ratios and information from the
most recent available Provider Specific
File. We noted FY 2019 SSI ratios
available on the CMS website were the
most recent available SSI ratios at the
time of developing the proposed rule. If
more recent data on DSH eligibility
become available before the final rule,
we stated that we would use such data
in the final rule. For this FY 2023 IPPS/
LTCH PPS final rule, the FY 2020 SSI
ratios were available at the time of
developing this final rule. Our final
determination of a hospital’s eligibility
for uncompensated care payments will
be based on the hospital’s actual DSH
status at cost report settlement for FY
2023.
In the FY 2014 IPPS/LTCH PPS final
rule (78 FR 50622) and in the
rulemaking for subsequent fiscal years,
we have specified our policies for
several specific classes of hospitals
within the scope of section 1886(r) of
the Act. In the FY 2023 IPPS/LTCH PPS
proposed rule, we discussed our
specific policies regarding eligibility to
receive empirically justified Medicare
DSH payments and uncompensated care
payments for FY 2023 with respect to
the following hospitals.
Eligible hospitals include the
following:
• Subsection (d) Puerto Rico hospitals
that are eligible for DSH payments also
are eligible to receive empirically
justified Medicare DSH payments and
uncompensated care payments under
section 1886(r) of the Act (78 FR 50623
and 79 FR 50006).
• SCHs that are paid under the IPPS
Federal rate receive interim payments
based on what we estimate and project
their DSH status to be prior to the
beginning of the Federal fiscal year
(based on the best available data at that
time) subject to settlement through the
cost report, and if they receive interim
empirically justified Medicare DSH
payments in a fiscal year, they also will
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
receive interim uncompensated care
payments for that fiscal year on a per
discharge basis, subject as well to
settlement through the cost report. Final
eligibility determinations will be made
at the end of the cost reporting period
at settlement, and both interim
empirically justified Medicare DSH
payments and uncompensated care
payments will be adjusted accordingly
(78 FR 50624 and 79 FR 50007).
• Medicare-dependent, small rural
hospitals (MDHs) are paid based on the
IPPS Federal rate or, if higher, the IPPS
Federal rate plus 75 percent of the
amount by which the Federal rate is
exceeded by the updated hospitalspecific rate from certain specified base
years (76 FR 51684). The IPPS Federal
rate that is used in the MDH payment
methodology is the same IPPS Federal
rate that is used in the SCH payment
methodology. Because MDHs are paid
based on the IPPS Federal rate, they
continue to be eligible to receive
empirically justified Medicare DSH
payments and uncompensated care
payments if their DPP is at least 15
percent, and we apply the same process
to determine MDHs’ eligibility for
interim empirically justified Medicare
DSH and interim uncompensated care
payments as we do for all other IPPS
hospitals.
Section 50205 of the Bipartisan
Budget Act of 2018 (Pub. L. 115–123),
enacted on February 9, 2018, extended
the MDH program for discharges on or
after October 1, 2017, through
September 30, 2022. We note that there
has not been legislation at the time of
development of this final rule that
would extend the MDH program beyond
September 30, 2022. However, if the
MDH program were to be extended
beyond its current expiration date,
similar to how it was extended under
the Bipartisan Budget Act of 2018, we
would continue to make a
determination concerning an MDH’s
eligibility for interim uncompensated
care payments based on the hospital’s
estimated DSH status for the applicable
fiscal year.
• IPPS hospitals that elect to
participate in the Bundled Payments for
Care Improvement Advanced (BPCI
Advanced) model starting October 1,
2018, will continue to be paid under the
IPPS and, therefore, are eligible to
receive empirically justified Medicare
DSH payments and uncompensated care
payments. The BPCI Advanced Model’s
final performance year will end on
December 31, 2023. For further
information regarding the BPCI
Advanced model, we refer readers to the
CMS website at https://
PO 00000
Frm 00246
Fmt 4701
Sfmt 4700
innovation.cms.gov/initiatives/bpciadvanced/.
• IPPS hospitals that participate in
the Comprehensive Care for Joint
Replacement Model (80 FR 73300)
continue to be paid under the IPPS and,
therefore, are eligible to receive
empirically justified Medicare DSH
payments and uncompensated care
payments. We refer the reader to the
interim final rule with request for
comments that appeared in the
November 6, 2020, Federal Register for
a discussion of the Model (85 FR 71167
through 71173). In that interim final
rule, we extended the Model’s
Performance Year 5 to September 30,
2021. In a subsequent final rule that
appeared in the May 3, 2021 Federal
Register (86 FR 23496), we further
extended the Model for an additional
three performance years. The Model’s
Performance Year 8 will end on
December 31, 2024.
Ineligible hospitals include the
following:
• Maryland hospitals are not eligible
to receive empirically justified Medicare
DSH payments and uncompensated care
payments under the payment
methodology of section 1886(r) of the
Act because they are not paid under the
IPPS. As discussed in the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41402
through 41403), CMS and the State have
entered into an agreement to govern
payments to Maryland hospitals under a
new payment model, the Maryland
Total Cost of Care (TCOC) Model, which
began on January 1, 2019. Under the
Maryland TCOC Model, Maryland
hospitals will not be paid under the
IPPS in FY 2023, and will be ineligible
to receive empirically justified Medicare
DSH payments and uncompensated care
payments under section 1886(r) of the
Act.
• Sole community hospitals (SCHs)
that are paid under their hospitalspecific rate are not eligible for
Medicare DSH payments.
• Hospitals participating in the Rural
Community Hospital Demonstration
Program are not eligible to receive
empirically justified Medicare DSH
payments and uncompensated care
payments under section 1886(r) of the
Act because they are not paid under the
IPPS (78 FR 50625 and 79 FR 50008).
The Rural Community Hospital
Demonstration Program was originally
authorized for a 5-year period by section
410A of the Medicare Prescription Drug,
Improvement, and Modernization Act of
2003 (MMA) (Pub. L. 108–173), and
extended for another 5-year period by
sections 3123 and 10313 of the
Affordable Care Act (Pub. L. 114–255).
The period of performance for this 5-
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
year extension period ended December
31, 2016. Section 15003 of the 21st
Century Cures Act (Pub. L. 114–255),
enacted December 13, 2016, again
amended section 410A of Public Law
108–173 to require a 10-year extension
period (in place of the 5-year extension
required by the Affordable Care Act),
therefore requiring an additional 5-year
participation period for the
demonstration program. Section 15003
of Public Law 114–255 also required a
solicitation for applications for
additional hospitals to participate in the
demonstration program. The period of
performance for this 5-year extension
period ended December 31, 2021. The
Consolidated Appropriations Act, 2021
(Pub. L. 116–260) amended section
410A of Public Law 108–173 to extend
the Rural Community Hospital
Demonstration Program for an
additional 5-year period. The period of
participation for the last hospital in the
demonstration under this most recent
legislative authorization would extend
until June 30, 2028, as outlined in
section V.K. of the preamble of this final
rule. Under the payment methodology
that applies during the third 5-year
extension period for the demonstration
program, participating hospitals do not
receive empirically justified Medicare
DSH payments, and they are also
excluded from receiving interim and
final uncompensated care payments. At
the time of development of this final
rule, we believe 26 hospitals may
participate in the demonstration
program at the start of FY 2023.
We received no comments on our
policy of using the best available data
regarding a hospital’s estimated DSH
status for purposes of determining
eligibility for interim uncompensated
care payments for FY 2023. Our final
determination of a hospital’s eligibility
for uncompensated care payments for
FY 2023 will continue to be based on
the hospital’s actual DSH status at cost
report settlement for the payment year.
C. Empirically Justified Medicare DSH
Payments
As we have discussed earlier, section
1886(r)(1) of the Act requires the
Secretary to pay 25 percent of the
amount of the Medicare DSH payment
that would otherwise be made under
section 1886(d)(5)(F) of the Act to a
subsection (d) hospital. Because section
1886(r)(1) of the Act merely requires the
program to pay a designated percentage
of these payments, without revising the
criteria governing eligibility for DSH
payments or the underlying payment
methodology, we stated in the FY 2014
IPPS/LTCH PPS final rule that we did
not believe that it was necessary to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
develop any new operational
mechanisms for making such payments.
Therefore, in the FY 2014 IPPS/LTCH
PPS final rule (78 FR 50626), we
implemented this provision by advising
Medicare Administrative Contractors
(MACs) to simply adjust the interim
claim payments to the requisite 25
percent of what would have otherwise
been paid. We also made corresponding
changes to the hospital cost report so
that these empirically justified Medicare
DSH payments can be settled at the
appropriate level at the time of cost
report settlement. We provided more
detailed operational instructions and
cost report instructions following
issuance of the FY 2014 IPPS/LTCH PPS
final rule that are available on the CMS
website at https://www.cms.gov/
Regulations-and-Guidance/Guidance/
Transmittals/2014-Transmittals-Items/
R5P240.html.
We received public comments that
were outside the scope of this proposed
rule. Many of these comments related to
structural changes to the DSH program.
For example, a commenter
recommended creating new Conditions
of Participation and Conditions of
Coverage related to the DSH program.
Because we consider these public
comments to be outside the scope of the
proposed rule, we are not addressing
them in this final rule.
D. Uncompensated Care Payments
As we discussed earlier, section
1886(r)(2) of the Act provides that, for
each eligible hospital in FY 2014 and
subsequent years, the uncompensated
care payment is the product of three
factors. These three factors represent our
estimate of 75 percent of the amount of
Medicare DSH payments that would
otherwise have been paid, an
adjustment to this amount for the
percent change in the national rate of
uninsurance compared to the rate of
uninsurance in 2013, and each eligible
hospital’s estimated uncompensated
care amount relative to the estimated
uncompensated care amount for all
eligible hospitals. In this section of this
final rule, we discuss the data sources
and methodologies for computing each
of these factors, our final policies for
FYs 2014 through 2022, and our final
policies for FY 2023.
1. Calculation of Factor 1 for FY 2023
Section 1886(r)(2)(A) of the Act
establishes Factor 1 in the calculation of
the uncompensated care payment.
Section 1886(r)(2)(A) of the Act states
that this factor is equal to the difference
between: (1) the aggregate amount of
payments that would be made to
subsection (d) hospitals under section
PO 00000
Frm 00247
Fmt 4701
Sfmt 4700
49025
1886(d)(5)(F) of the Act if section
1886(r) of the Act did not apply for such
fiscal year (as estimated by the
Secretary); and (2) the aggregate amount
of payments that are made to subsection
(d) hospitals under section 1886(r)(1) of
the Act for such fiscal year (as so
estimated).
Therefore, section 1886(r)(2)(A)(i) of
the Act represents the estimated
Medicare DSH payments that would
have been made under section
1886(d)(5)(F) of the Act if section
1886(r) of the Act did not apply for such
fiscal year. Under a prospective
payment system, we would not know
the precise aggregate Medicare DSH
payment amount that would be paid for
a Federal fiscal year until cost report
settlement for all IPPS hospitals is
completed, which occurs several years
after the end of the Federal fiscal year.
Therefore, section 1886(r)(2)(A)(i) of the
Act provides authority to estimate this
amount, by specifying that, for each
fiscal year to which the provision
applies, such amount is to be estimated
by the Secretary. Similarly, section
1886(r)(2)(A)(ii) of the Act represents
the estimated empirically justified
Medicare DSH payments to be made in
a fiscal year, as prescribed under section
1886(r)(1) of the Act. Again, section
1886(r)(2)(A)(ii) of the Act provides
authority to estimate this amount.
Therefore, Factor 1 is the difference
between our estimates of: (1) the amount
that would have been paid in Medicare
DSH payments for the fiscal year, in the
absence of the new payment provision;
and (2) the amount of empirically
justified Medicare DSH payments that
are made for the fiscal year, which takes
into account the requirement to pay 25
percent of what would have otherwise
been paid under section 1886(d)(5)(F) of
the Act. In other words, this factor
represents our estimate of 75 percent
(100 percent minus 25 percent) of our
estimate of Medicare DSH payments
that would otherwise be made, in the
absence of section 1886(r) of the Act, for
the fiscal year.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28383 through
28385), in order to determine Factor 1
in the uncompensated care payment
formula for FY 2023, we proposed to
continue the policy established in the
FY 2014 IPPS/LTCH PPS final rule (78
FR 50628 through 50630) and in the FY
2014 IPPS interim final rule with
comment period (78 FR 61194) of
determining Factor 1 by developing
estimates of both the aggregate amount
of Medicare DSH payments that would
be made in the absence of section
1886(r)(1) of the Act and the aggregate
amount of empirically justified
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49026
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Medicare DSH payments to hospitals
under section 1886(r)(1) of the Act.
Consistent with the policy that has
applied in previous years, we proposed
that these estimates would not be
revised or updated subsequent to the
publication of our final projections in
this FY 2023 IPPS/LTCH PPS final rule.
Therefore, in order to determine the
two elements of proposed Factor 1 for
FY 2023 (Medicare DSH payments prior
to the application of section 1886(r)(1)
of the Act, and empirically justified
Medicare DSH payments after
application of section 1886(r)(1) of the
Act), for this final rule, we used the
most recently available projections of
Medicare DSH payments for the fiscal
year, as calculated by CMS’ Office of the
Actuary (OACT) using the most recently
filed Medicare hospital cost reports with
Medicare DSH payment information and
the most recent Medicare DSH patient
percentages and Medicare DSH payment
adjustments provided in the IPPS
Impact File. The determination of the
amount of DSH payments is partially
based on OACT’s Part A benefits
projection model. One of the results of
this model is inpatient hospital
spending. Projections of DSH payments
require projections for expected
increases in utilization and case-mix.
The assumptions that were used in
making these projections and the
resulting estimates of DSH payments for
FY 2020 through FY 2023 were
discussed in the proposed rule in the
table titled ‘‘Factors Applied for FY
2020 through FY 2023 to Estimate
Medicare DSH Expenditures Using FY
2019 Baseline’’ (87 FR 28384).
For purposes of calculating the
proposed Factor 1 and modeling the
impact of the FY 2023 IPPS/LTCH PPS
proposed rule, we used the Office of the
Actuary’s January 2022 Medicare DSH
estimates, which were based on data
from the September 2021 update of the
Medicare Hospital Cost Report
Information System (HCRIS) and the FY
2022 IPPS/LTCH PPS final rule IPPS
Impact File, published in conjunction
with the publication of the FY 2022
IPPS/LTCH PPS final rule. Because
SCHs that are projected to be paid under
their hospital-specific rate are excluded
from the application of section 1886(r)
of the Act, these hospitals also were
excluded from the January 2022
Medicare DSH estimates. Furthermore,
because section 1886(r) of the Act
specifies that the uncompensated care
payment is in addition to the
empirically justified Medicare DSH
payment (25 percent of DSH payments
that would be made without regard to
section 1886(r) of the Act), Maryland
hospitals, which are not eligible to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
receive DSH payments, were also
excluded from the Office of the
Actuary’s January 2022 Medicare DSH
estimates. The 26 hospitals that are
anticipated to participate in the Rural
Community Hospital Demonstration
Program in FY 2023 were also excluded
from these estimates, because under the
payment methodology that applies
during the third 5-year extension
period, these hospitals are not eligible to
receive empirically justified Medicare
DSH payments or uncompensated care
payments.
For the proposed rule, using the data
sources as previously discussed, the
Office of the Actuary’s January 2022
estimate of Medicare DSH payments for
FY 2023 without regard to the
application of section 1886(r)(1) of the
Act, was approximately $13.266 billion.
Therefore, also based on the January
2022 estimate, the estimate of
empirically justified Medicare DSH
payments for FY 2023, with the
application of section 1886(r)(1) of the
Act, was approximately $3.316 billion
(or 25 percent of the total amount of
estimated Medicare DSH payments for
FY 2023). Under § 412.106(g)(1)(i) of the
regulations, Factor 1 is the difference
between these two OACT estimates.
Therefore, in the proposed rule, we
proposed that Factor 1 for FY 2023
would be $9,949,258,556.56, which was
equal to 75 percent of the total amount
of estimated Medicare DSH payments
for FY 2023 ($13,266 million minus
$3,316 million). In the FY 2023 IPPS/
LTCH PPS proposed rule, we noted that
consistent with our approach in
previous rulemakings, OACT intended
to use more recent data that may
become available for purposes of
projecting the final Factor 1 estimates
for this FY 2023 IPPS/LTCH PPS final
rule.
As we noted in the FY 2023 IPPS/
LTCH PPS proposed rule, the Factor 1
estimates for proposed rules are
generally consistent with the economic
assumptions and actuarial analysis used
to develop the President’s Budget
estimates under current law, and the
Factor 1 estimates for the final rules are
generally consistent with those used for
the Midsession Review of the
President’s Budget. As we have in the
past, for additional information on the
development of the President’s Budget,
we refer readers to the Office of
Management and Budget website at
https://www.whitehouse.gov/omb/
budget. Consistent with historical
practice, we indicated that we expected
that the Midsession Review would have
updated economic assumptions and
actuarial analysis, which would be used
PO 00000
Frm 00248
Fmt 4701
Sfmt 4700
for the development of Factor 1
estimates in the final rule.
For a general overview of the
principal steps involved in projecting
future inpatient costs and utilization,
we refer readers to the ‘‘2021 Annual
Report of the Boards of Trustees of the
Federal Hospital Insurance and Federal
Supplementary Medical Insurance Trust
Funds’’ available on the CMS website at
https://www.cms.gov/research-statisticsdata-and-systems/statistics-trends-andreports/reportstrustfunds under
‘‘Downloads.’’ We note that the annual
reports of the Medicare Boards of
Trustees to Congress represent the
Federal Government’s official
evaluation of the financial status of the
Medicare Program. The actuarial
projections contained in these reports
are based on numerous assumptions
regarding future trends in program
enrollment, utilization and costs of
health care services covered by
Medicare, as well as other factors
affecting program expenditures. In
addition, although the methods used to
estimate future costs based on these
assumptions are complex, they are
subject to periodic review by
independent experts to ensure their
validity and reasonableness.
We also refer readers to the 2018
Actuarial Report on the Financial
Outlook for Medicaid for a discussion of
general issues regarding Medicaid
projections (available at https://
www.cms.gov/Research-Statistics-Dataand-Systems/Research/
ActuarialStudies/MedicaidReport).
Comment: As in previous years, a
concern and/or request expressed by
some commenters was the need for
greater transparency in the methodology
used by CMS and OACT to calculate
Factor 1. Several commenters
specifically requested that a detailed
description of the methodology and the
data behind the assumptions be made
public. Commenters requested that this
information be provided in advance of
the publication of the final rule and in
the IPPS proposed rule each year going
forward, so that the data is available to
replicate CMS’ DSH calculation and
comment sufficiently in future years.
In particular, commenters requested
further explanation regarding the
estimate of the ‘‘Other’’ factor used to
estimate Medicare DSH payments.
Commenters noted that the rule did not
discuss why the ‘‘Other’’ factor varies so
much over successive rule making
cycles.
Additionally, a commenter asserted
that the lack of opportunity afforded to
hospitals to review the data used in
rulemaking is in violation of the
Administrative Procedure Act and
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
expressed concerns about the lack of
transparency in how Factor 1 is
calculated, arguing that hospitals cannot
meaningfully comment on the
methodology given the lack of details. In
particular, this commenter asserted that
the proposed rule neither provided
sufficient details nor an explanation of
the treatment of Medicaid expansions in
the calculation for Factor 1.
Response: We thank the commenters
for their input. We disagree with
commenters’ assertion regarding the
lack of transparency with respect to the
methodology and assumptions used in
the calculation of Factor 1. As explained
in the FY 2023 IPPS/LTCH PPS
proposed rule and in this section of this
final rule, we have been and continue to
be transparent about the methodology
and data used to estimate Factor 1.
Regarding the commenters who
reference the Administrative Procedure
Act, we note that, under the
Administrative Procedure Act, a
proposed rule is required to include
either the terms or substance of the
proposed rule or a description of the
subjects and issues involved. In this
case, the FY 2023 IPPS/LTCH PPS
proposed rule did include a detailed
discussion of our proposed Factor 1
methodology and the data sources that
would be used in making our final
estimate. Accordingly, we believe
interested parties were able to
meaningfully comment on our proposed
estimate of Factor 1.
To provide context, we note that
Factor 1 is not estimated in isolation
from other projections made by OACT.
The Factor 1 estimates for the proposed
rules are generally consistent with the
economic assumptions and actuarial
analyses used to develop the President’s
Budget estimates under current law, and
the Factor 1 estimates for the final rule
are generally consistent with those used
for the Midsession Review of the
President’s Budget. As we have in the
past, for additional information on the
development of the President’s Budget,
we refer readers to the Office of
Management and Budget website at:
https://www.whitehouse.gov/omb/
budget. For additional information on
the specific economic assumptions used
in the Midsession Review of the
President’s FY 2023 Budget, we refer
readers to the ‘‘Midsession Review of
the President’s FY 2023 Budget’’ also
available on the Office of Management
and Budget website at: https://
www.whitehouse.gov/omb/budget. We
recognize that our reliance on the
economic assumptions and actuarial
analyses used to develop the President’s
Budget and the Midsession Review of
the President’s Budget in estimating
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Factor 1 has an impact on hospitals,
health systems, and other impacted
parties who wish to replicate the Factor
1 calculation, such as modeling the
relevant Medicare Part A portion of the
budget. Yet, we believe commenters are
able to meaningfully comment on our
proposed estimate of Factor 1 without
replicating the budget.
For a general overview of the
principal steps involved in projecting
future inpatient costs and utilization,
we refer readers to the ‘‘2022 Annual
Report of the Boards of Trustees of the
Federal Hospital Insurance and Federal
Supplementary Medical Insurance Trust
Funds’’ available on the CMS website at:
https://www.cms.gov/ResearchStatistics-Data-and-Systems/StatisticsTrends-and-Reports/
ReportsTrustFunds/ under
‘‘Downloads.’’ We note that the annual
reports of the Medicare Boards of
Trustees to Congress represent the
Federal Government’s official
evaluation of the financial status of the
Medicare Program. The actuarial
projections contained in these reports
are based on numerous assumptions
regarding future trends in program
enrollment, utilization and costs of
health care services covered by
Medicare, as well as other factors
affecting program expenditures. In
addition, although the methods used to
estimate future costs based on these
assumptions are complex, they are
subject to periodic review by
independent experts to ensure their
validity and reasonableness.
We also refer readers to the 2018
Actuarial Report on the Financial
Outlook for Medicaid which is available
on the CMS website at: https://
www.cms.gov/files/document/2018report.pdf for a discussion of general
issues regarding Medicaid projections.
Additionally, as described in more
detail later in this section, in the FY
2023 IPPS/LTCH PPS proposed rule, we
included information regarding the data
sources, methods, and assumptions
employed by the actuaries in
determining the OACT’s estimate of
Factor 1. In summary, we indicated the
historical HCRIS data update OACT
used to identify Medicare DSH
payments. We explained that the most
recent Medicare DSH payment
adjustments provided in the IPPS
Impact File were used, and we provided
the components of all update factors
that were applied to the historical data
to estimate the Medicare DSH payments
for the upcoming fiscal year, along with
the associated rationale and
assumptions. This discussion also
included a description of the ‘‘Other’’
and ‘‘Discharges’’ assumptions, as well
PO 00000
Frm 00249
Fmt 4701
Sfmt 4700
49027
as additional information regarding how
we address Medicaid and CHIP
expansion.
For further information on our
assumptions regarding Medicaid
expansion in the Factor 1 calculation,
we provide a discussion of more recent
estimates and assumptions regarding the
Medicaid expansion as part of the
discussion of the final Factor 1 for FY
2023. This discussion also incorporates
the estimated impact of the COVID–19
public health emergency (PHE.)
Comment: Many commenters
questioned the proposed rule’s estimate
of the ‘‘Discharge’’ component of the
Factor 1 calculation. Commenters
requested clarity on the Factor 1
calculations, which assume small
increases in discharge volume for FY
2022 and FY 2023.
Commenters noted that they are
seeing trends that indicate that FY 2022
and FY 2023 discharge volumes, even
though lower than pre-PHE levels, will
continue to increase substantially. Some
commenters urged CMS to reflect the
same assumptions that the agency
described in the ‘‘April 2022
Announcement of CY 2023 Medicare
Advantage Capitation Rates and Part C
and Part D Payment Policies,’’ where the
agency made assumptions that Medicare
‘‘utilization will begin to rebound.’’
Other commenters referenced a
Kaufman Hall study, and stated that
adjusted national patient volume has
increased by 18 percent from February
2022 to March 2022. A commenter
referred to their own analysis of
Medicare-Fee-For-service (FFS) claims
data from the Chronic Condition
Warehouse (CCW), which indicated that
non-COVID–19 inpatient hospital
discharge volume increased 22 percent
from February to March 2022. Other
commenters provided anecdotal data
from their own hospitals and service
regions that show continued sustained
volumes in 2022. These commenters
urged CMS to carefully monitor changes
in discharge volume when estimating
Factor 1.
Commenters also urged CMS to use a
later update to the claims data to
capture more of the increases in
utilization that are anticipated for FY
2022. Commenters noted that the
‘‘Discharge’’ factor used by the OACT in
estimating DSH expenditures was based
on the December 2021 update of the
MedPAR file, which includes data
impacted by the PHE from FY 2021 and
the first three months of FY 2022. Some
commenters requested that CMS adjust
the data used in the Factor 1 calculation
for COVID–19 PHE impacts while others
suggested that CMS exclude data from
the latter parts of CY 2021 and early CY
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49028
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
2022. Other commenters urged CMS to
consider excluding FY 2020 and FY
2021 discharges from the FY 2023
Factor 1 calculation, as data from those
years include atypical trends in
Medicare discharges due to the COVID–
19 PHE.
Commenters pointed out that omitting
FY 2020 and FY 2021 data would be
consistent with CMS’ exclusion of FY
2020 data in setting FY 2022 payment
rates and the agency’s proposal to
exclude FY 2020 data from the perdischarge calculation in the FY 2023
IPPS/LTCH PPS proposed rule. Further,
some commenters noted that the
completion factor CMS used to estimate
discharge volumes for FY 2021 and FY
2022 may not fully account for
discharges due to billing delays as a
result of PHE-related staffing shortages.
Finally, two commenters requested
that for the FY 2024 IPPS/LTCH PPS
proposed rule, CMS consider using the
latest available data for the factors used
to estimate Medicare DSH expenditures
for purposes of calculating Factor 1 to
avoid as much change in the estimate of
Factor 1 between the proposed and final
rules for FY 2024.
Some commenters also raised
concerns about the ‘‘Case Mix’’ update
factor used in the proposed FY 2023
Factor 1 calculation. Commenters stated
that the proposed ‘‘Case Mix’’ update
factor underestimates the complexity of
patients returning to seek care following
postponement or deferral of care during
the COVID–19 PHE. Commenters also
stated that CMS was using assumptions
that are inconsistent with those that
were used to develop the 2023 Medicare
Advantage capitation payments, where
the agency indicated an expectation that
utilization will rebound in 2022 and
finalized a risk score increase of 3.5
percentage points with the underlying
assumption that patients put off seeking
medical care throughout the PHE. Other
commenters cited data from Kaufman
Hall that indicate that hospitals are
beginning to see more complex patients
as shown by a nearly 5 percent increase
in the average hospital length of stay in
2022 as compared to 2021.
Response: We thank the commenters
for their input on the impact of the
COVID–19 PHE on the factors used to
estimate DSH payments for FY 2023. In
updating our estimate of Factor 1 for
this final rule, we considered, as
appropriate, the same set of factors that
we used in the proposed rule, which
reflects the impact of the COVID–19
PHE. We then updated estimates for the
‘‘Discharges’’ and ‘‘Case Mix’’ factors to
incorporate the latest available data. We
provide further details on the updated
Factor 1 estimate and data sources as
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
part of the discussion of the final Factor
1 estimate for FY 2023 in this section of
the rule.
Regarding the comments requesting
that we exclude and/or mitigate the
impacts of the COVID–19 PHE when
estimating Factor 1 for FY 2023, we note
that the statute specifies that Factor 1 is
based on the amount of disproportionate
share payments that would otherwise be
made to subsection (d) hospitals for the
fiscal year. As discussed further in this
section, OACT’s estimates of Medicare
DSH payments used in the development
of Factor 1, reflect the estimated impact
of the COVID–19 PHE on DSH payments
during FY 2023.
We also note that, with regard to the
commenters’ questions and concerns
about the use of completion factors to
adjust preliminary data, OACT assumed
a discharge completion factor of 0
percent for FY 2020 and 0 percent for
FY 2021. We believe these assumptions
are consistent with historical patterns of
completion factors that have been
determined for discharges and
appropriately account for incomplete
claims data. We do not believe that
excluding data from certain periods is
necessary to estimate DSH payments
during FY 2023 for purposes of the
Factor 1 calculation, as required by the
statute.
Regarding the comments requesting
that CMS apply the same assumptions
the agency made when setting Medicare
Advantage payment rates, we note that
Medicare Advantage and Medicare FFS
are distinct programs. Accordingly, the
estimates for the ‘‘Discharges’’ and
‘‘Case Mix’’ factors used to estimate
Medicare DSH expenditures incorporate
OACT’s analyses of ‘‘Discharges’’ and
‘‘Case Mix’’ using only claims from the
Medicare FFS program rather than
claims from the Medicare Advantage
program.
In response to commenters’ request
that CMS use the latest available
estimates of historical data to avoid as
much change in the DSH Factor 1
estimate between the proposed and final
rules for FY 2024, we believe that the
use of the most recent available data at
the time of the proposed and final
rulemaking is appropriate to calculate
Factor 1 and consistent with our
approach in previous rulemakings. In
this final rule, OACT has updated the
estimate of Factor 1 with more recent
economic assumptions and actuarial
analyses.
Comment: Commenters expressed
concern regarding the proposed $800
million reduction in the amount
available to make uncompensated care
payments in FY 2023 compared to FY
2022. Commenters stated that this
PO 00000
Frm 00250
Fmt 4701
Sfmt 4700
reduction does not align with CMS’
objective to reduce healthcare inequities
as the reduction disproportionately
impacts safety-net hospitals, which
primarily serve low income and
vulnerable populations.
Response: The statute specifies that
Factor 1 is based on the amount of
disproportionate share payments that
would otherwise be made to subsection
(d) hospitals for the fiscal year. Because
our estimate of Factor 1 is based on the
best available data regarding the amount
of DSH payments that would otherwise
be made during FY 2023, we believe it
is appropriate and consistent with the
requirements of the statute.
After consideration of the public
comments we received, we are
finalizing, as proposed, the
methodology for calculating Factor 1 for
FY 2023. We discuss the resulting
Factor 1 amount for FY 2023 in this
section. For this final rule, OACT used
the most recently submitted Medicare
cost report data from the March 31,
2022, update of HCRIS to identify
Medicare DSH payments and the most
recent Medicare DSH payment
adjustments provided in the Impact File
published in conjunction with the
publication of the FY 2023 IPPS/LTCH
PPS final rule and applied update
factors and assumptions for future
changes in utilization and case-mix to
estimate Medicare DSH payments for
the upcoming fiscal year.
The June 2022 OACT estimate for
Medicare DSH payments for FY 2023,
without regard to the application of
section 1886(r)(1) of the Act, was
approximately $13.949 billion. This
estimate excluded Maryland hospitals
participating in the Maryland All-Payer
Model, hospitals participating in the
Rural Community Hospital
Demonstration, and SCHs paid under
their hospital-specific payment rate.
Therefore, based on this June 2022
estimate, the estimate of empirically
justified Medicare DSH payments for FY
2023, with the application of section
1886(r)(1) of the Act, was approximately
$3.487 billion (or 25 percent of the total
amount of estimated Medicare DSH
payments for FY 2023). Under
§ 412.106(g)(1)(i) of the regulations,
Factor 1 is the difference between these
two OACT estimates. Therefore, the
final Factor 1 for FY 2023 is
$10,461,731,029.40, which is equal to
75 percent of the total amount of
estimated Medicare DSH payments for
FY 2023 ($13,948,974,705.87 minus
$3,487,243,676.47).
The Office of the Actuary’s estimates
of DSH expenditures for FY 2023 for
this final rule began with a baseline of
$13.814 billion in Medicare DSH
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
expenditures for FY 2019. The following
table shows the factors applied to
49029
update this baseline through the current
estimate for FY 2023:
Factors Applied for FY 2020 through FY 2023
to Estimate Medicare DSH Expenditures Using FY 2019 Baseline
Estimated DSH
Payment (in billions)*
Update
Discharges
Case-Mix
Other
Total
1.031
0.862
0.9952
0.9181
12.682
1.038
1.029
0.939
1.029
1.0174
1.0116
12.829
1.025
1.0235
1.0241
0.986
0.99
13.138
1.043
1.0618
13.949
1.050
0.99
0.9793
FY
2020
2021
2022
2023
*Rounded.
2020
2021
2022
2023
Affordable
Care Act
Payment
Reductions
0
0
0
0
Productivity
Adjustment
-0.4
0
-0.7
-0.3
regarding Medicaid enrollment may
change based on actual enrollment in
the States.
For a discussion of general issues
regarding Medicaid projections, we refer
readers to the 2018 Actuarial Report on
the Financial Outlook for Medicaid,
which is available on the CMS website
at https://www.cms.gov/ResearchStatistics-Data-and-Systems/Research/
ActuarialStudies/MedicaidReport. We
note that, in developing their estimates
of the effect of Medicaid enrollment
increases on Medicare DSH
expenditures, our actuaries have
assumed that the increases in the
number of Medicaid enrollees result in
increases in Medicare DSH expenditures
at the same rate as historical
relationships have shown. In the future,
the assumption about the average percapita expenditures of Medicaid
beneficiaries who enrolled due to the
COVID–19 pandemic may change, given
that the pandemic is still ongoing.
The following table shows the factors
that are included in the ‘‘Update’’
column of the previous table:
Documentation
and Coding
0.5
0.5
0.5
0.5
Total
Update
Percentage
3.1
2.9
2.5
4.3
Note: All numbers are the inpatient hospital updates for the applicable year. We refer readers to section V.A. of the
preamble of this fmal rule for a complete discussion of the changes in the inpatient hospital update for FY 2023.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00251
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.123
khammond on DSKJM1Z7X2PROD with RULES2
FY
Market
Basket
Percentage
3.0
2.4
2.7
4.1
assumption based on recent trends
recovering back to the long-term trend.
The case-mix factor figures for FY 2020
to FY 2023 incorporate the actual
impact and estimated future impact of
the COVID–19 pandemic. The ‘‘Other’’
column shows the increase in other
factors that contribute to the Medicare
DSH estimates. These factors include
the difference between the total
inpatient hospital discharges and the
IPPS discharges, and various
adjustments to the payment rates that
have been included over the years but
are not reflected in the other columns
(such as the change in rates for the 2midnight stay policy and the 20 percent
add-on for COVID–19 discharges). In
addition, the ‘‘Other’’ column includes
a factor for the estimated changes in
Medicaid enrollment. We note that this
factor also includes the estimated
impacts on Medicaid enrollment from
the COVID–19 pandemic. We note that,
based on the most recent available data,
Medicaid enrollment is estimated to
change as follows: 2.0 percent in FY
2020, 9.5 percent in FY 2021, 4.2
percent in FY 2022, and -5.7 percent in
FY 2023. In the future, the assumptions
ER10AU22.122
In this table, the discharges column
shows the changes in the number of
Medicare fee-for-service (FFS) inpatient
hospital discharges. The discharge
figures for FY 2020 and FY 2021 are
based on Medicare claims data that have
been adjusted by a completion factor to
account for incomplete claims data. We
note that these claims data reflect the
impact of the pandemic. The discharge
figure for FY 2022 is based on
preliminary data. The discharge figure
for FY 2023 is an assumption based on
recent trends recovering back to the
long-term trend and assumptions related
to how many beneficiaries will be
enrolled in Medicare Advantage (MA)
plans. The discharge figures for FY 2020
to FY 2023 incorporate the actual
impact and estimated future impact of
the COVID–19 pandemic. The case-mix
column shows the estimated change in
case-mix for IPPS hospitals. The casemix figures for FY 2020 and FY 2021 are
based on actual claims data adjusted by
a completion factor. We note that these
claims data reflect the impact of the
pandemic. The case-mix figure for FY
2022 is based on preliminary data and
the case-mix figure for FY 2023 is an
49030
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
2. Calculation of Factor 2 for FY 2023
(a) Background
Section 1886(r)(2)(B) of the Act
establishes Factor 2 in the calculation of
the uncompensated care payment.
Section 1886(r)(2)(B)(ii) of the Act
provides that, for FY 2018 and
subsequent fiscal years, the second
factor is 1 minus the percent change in
the percent of individuals who are
uninsured, as determined by comparing
the percent of individuals who were
uninsured in 2013 (as estimated by the
Secretary, based on data from the
Census Bureau or other sources the
Secretary determines appropriate, and
certified by the Chief Actuary of CMS)
and the percent of individuals who were
uninsured in the most recent period for
which data are available (as so
estimated and certified), minus 0.2
percentage point for FYs 2018 and 2019.
In FY 2020 and subsequent fiscal years,
there is no longer a reduction. We note
that, unlike section 1886(r)(2)(B)(i) of
the Act, which governed the calculation
of Factor 2 for FYs 2014, 2015, 2016,
and 2017, section 1886(r)(2)(B)(ii) of the
Act permits the use of a data source
other than the CBO estimates to
determine the percent change in the rate
of uninsurance beginning in FY 2018. In
addition, for FY 2018 and subsequent
years, the statute does not require that
the estimate of the percent of
individuals who are uninsured be
limited to individuals who are under 65
years of age. We proposed to use a
methodology similar to the one that was
used in FY 2018 through FY 2022 to
determine Factor 2 for FY 2023.
In the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38197 and 38198), we
explained that we determined the data
source for the rate of uninsurance that,
on balance, best meets all of our
considerations and is consistent with
the statutory requirement that the
estimate of the rate of uninsurance be
based on data from the Census Bureau
or other sources the Secretary
determines appropriate, is the
uninsured estimates produced by OACT
as part of the development of the
National Health Expenditure Accounts
(NHEA). The NHEA represents the
government’s official estimates of
economic activity (spending) within the
health sector. The information
contained in the NHEA has been used
to study numerous topics related to the
health care sector, including, but not
limited to, changes in the amount and
cost of health services purchased and
the payers or programs that provide or
purchase these services; the economic
causal factors at work in the health
sector; the impact of policy changes,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
including major health reform; and
comparisons to other countries’ health
spending. Of relevance to the
determination of Factor 2 is that the
comprehensive and integrated structure
of the NHEA creates an ideal tool for
evaluating changes to the health care
system, such as the mix of the insured
and uninsured, because this information
is integral to the well-established NHEA
methodology. A full description of the
methodology used to develop the NHEA
is available on the CMS website at
https://www.cms.gov/files/document/
definitions-sources-and-methods.pdf.
We note that the NHEA estimates of
uninsurance are for the total residentbased U.S. population, including all
people who usually reside in the 50
States or the District of Columbia, but
excluding individuals living in Puerto
Rico and areas under U.S. sovereignty,
members of the U.S. Armed Forces
overseas, and U.S. citizens whose usual
place of residence is outside the U.S.,
plus a small (typically less that 0.2
percent of population) adjustment to
reflect Census undercounts. Thus, the
NHEA estimates of uninsurance are for
U.S. residents of all ages and are not
limited to a specific age cohort, such as
the population under the age of 65. As
we explained in the FY 2018 IPPS/
LTCH PPS proposed and final rules, we
believe it is appropriate to use an
estimate that reflects the rate of
uninsurance in the U.S. across all age
groups. In addition, we continue to
believe that a resident-based population
estimate more fully reflects the levels of
uninsurance in the U.S. that influence
uncompensated care for hospitals than
an estimate that reflects only legal
residents.
The NHEA includes comprehensive
enrollment estimates for total private
health insurance (PHI) (including direct
and employer-sponsored plans),
Medicare, Medicaid, the Children’s
Health Insurance Program (CHIP), and
other public programs, and estimates of
the number of individuals who are
uninsured. Estimates of total PHI
enrollment are available for 1960
through 2020, estimates of Medicaid,
Medicare, and CHIP enrollment are
available for the length of the respective
programs, and all other estimates
(including the more detailed estimates
of direct-purchased and employersponsored insurance) are available for
1987 through 2020. The NHEA data are
publicly available on the CMS website
at https://www.cms.gov/ResearchStatistics-Data-and-Systems/StatisticsTrends-and-Reports/NationalHealth
ExpendData/.
In order to compute Factor 2, the first
metric that is needed is the proportion
PO 00000
Frm 00252
Fmt 4701
Sfmt 4700
of the total U.S. population that was
uninsured in 2013. In developing the
estimates for the NHEA, OACT’s
methodology included using the
number of uninsured individuals for
1987 through 2009 based on the
enhanced Current Population Survey
(CPS) from the State Health Access Data
Assistance Center (SHADAC). The CPS,
sponsored jointly by the U.S. Census
Bureau and the U.S. Bureau of Labor
Statistics (BLS), is the primary source of
labor force statistics for the population
of the United States. (We refer readers
to the website at https://
www.census.gov/programs-surveys/
cps.html.) The enhanced CPS, available
from SHADAC (available at https://
datacenter.shadac.org) accounts for
changes in the CPS methodology over
time. OACT further adjusts the
enhanced CPS for an estimated
undercount of Medicaid enrollees (a
population that is often not fully
captured in surveys that include
Medicaid enrollees due to a perceived
stigma associated with being enrolled in
the Medicaid program or confusion
about the source of their health
insurance).
To estimate the number of uninsured
individuals for 2010 through 2018,
OACT extrapolates from the 2009 CPS
data through 2018 using data from the
National Health Interview Survey
(NHIS). The NHIS is one of the major
data collection programs of the National
Center for Health Statistics (NCHS),
which is part of the Centers for Disease
Control and Prevention (CDC). The 2019
estimate was extrapolated using the
2019/2018 trend from the American
Community Survey (ACS). The 2020
estimate was extrapolated using the
2020/2018 trend from the CPS as
published by the Census Bureau. The
U.S. Census Bureau is the data
collection agent for the NHIS, the ACS,
and the CPS. The results from these data
sources have been instrumental over the
years in providing data to track health
status, health care access, and progress
toward achieving national health
objectives. For further information
regarding the NHIS, we refer readers to
the CDC website at https://
www.cdc.gov/nchs/nhis/index.htm. For
further information regarding the ACS,
we refer readers to the Census Bureau’s
website at https://www.census.gov/
programs-surveys/acs/. For information
regarding the data collection issues
regarding the 2020 ACS, we refer
readers to the Census Bureau’s website
at https://www.census.gov/newsroom/
blogs/random-samplings/2021/10/
pandemic-impact-on-2020-acs-1-yeardata.html. Since the 2020 ACS data
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(b) Factor 2 for FY 2023
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule, using these
data sources and the previously
described methodologies, OACT
estimated that the uninsured rate for the
historical, baseline year of 2013 was 14
percent and for CYs 2022 and 2023 is
8.9 percent and 9.3 percent,
respectively. As required by section
1886(r)(2)(B)(ii) of the Act, the Chief
Actuary of CMS has certified these
estimates. We refer readers to OACT’s
Memorandum on Certification of Rates
of Uninsured prepared for the FY 2023
IPPS/LTCH PPS proposed rule for
further details on the methodology and
assumptions that were used in the
projection of these rates of
uninsurance.213
As with the CBO estimates on which
we based Factor 2 for fiscal years before
FY 2018, the NHEA estimates are for a
calendar year. Under the approach
originally adopted in the FY 2014 IPPS/
LTCH PPS final rule, we have used a
weighted average approach to project
the rate of uninsurance for each fiscal
year. We continue to believe that, in
order to estimate the rate of uninsurance
during a fiscal year accurately, Factor 2
should reflect the estimated rate of
uninsurance that hospitals will
experience during the fiscal year, rather
than the rate of uninsurance during only
one of the calendar years that the fiscal
year spans. Accordingly, we proposed to
continue to apply the weighted average
approach used in past fiscal years in
khammond on DSKJM1Z7X2PROD with RULES2
Proposed FY 2023 Uncompensated Care Amount
In addition, we stated that it had
recently come to our attention that the
provision of the regulations that
addresses Factor 2 inadvertently omits
any reference to the statutory
methodology in section 1886(r)(2)(B)(ii)
of the Act for determining Factor 2 for
FY 2018 and subsequent fiscal years.
Accordingly, we proposed a technical
change to the regulation at § 412.106 to
update paragraph (g)(1)(ii) to reflect the
statutory requirements governing the
determination of Factor 2 for FY 2018
and subsequent fiscal years. We
explained that we have determined
Factor 2 for FY 2018 through FY 2022
consistent with the plain language of
section 1886(r)(2)(B)(ii) of the Act;
therefore, this proposed technical
change is intended merely to update our
regulations to reflect the methodology
for determining Factor 2 that has
applied since FY 2018 and will
continue to apply for FY 2023 and
subsequent fiscal years.
We invited public comments on our
proposed Factor 2 for FY 2023 and on
the proposed technical change to the
regulation at § 412.106(g)(1)(ii).
Comment: The majority of
commenters discussed Factor 2 in the
context of the impact of the temporary
COVID–19 PHE provisions, such as the
Families First Coronavirus Response
Act’s Medicaid continuous coverage
requirement and the American Rescue
Plan’s Marketplace enhanced premium
tax credits, on the uninsured rate for FY
2023. Commenters questioned CMS’
213 OACT Memorandum on Certification of Rates
of Uninsured. March 28, 2022. Available at: https://
www.cms.gov/Medicare/Medicare-Fee-for-ServicePayment/AcuteInPatientPPS/dsh.html.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00253
Fmt 4701
Sfmt 4700
order to estimate the rate of uninsurance
for FY 2023.
The OACT certified the estimate of
the rate of uninsurance for FY 2023
determined using this weighted average
approach to be reasonable and
appropriate for purposes of section
1886(r)(2)(B)(ii) of the Act. In the FY
2023 IPPS/LTCH PPS proposed rule, we
noted that we might also consider the
use of more recent data that might
become available for purposes of
estimating the rates of uninsurance used
in the calculation of the final Factor 2
for FY 2023. In the proposed rule, we
outlined the calculation of the proposed
Factor 2 for FY 2023 as follows:
Percent of individuals without
insurance for CY 2013: 14 percent.
Percent of individuals without
insurance for CY 2022: 8.9 percent.
Percent of individuals without
insurance for CY 2023: 9.3 percent.
Percent of individuals without
insurance for FY 2023 (0.25 times 0.089)
+ (0.75 times 0.093): 9.2 percent.
1¥ |((0.092¥0.14)/0.14)| = 1¥0.3429
= 0.6571 (65.71 percent).
For FY 2020 and subsequent fiscal
years, section 1886(r)(2)(B)(ii) of the Act
no longer includes any reduction to the
previous calculation in order to
determine Factor 2. Therefore, we
proposed that Factor 2 for FY 2023
would be 65.71 percent.
The proposed FY 2023
uncompensated care amount was
$9,949,258,556.56 * 0.6571 =
$6,537,657,797.52.
$6,537,657,797.52
estimates for the FY 2023 uninsured rate
and urged the Office of the Actuary
(OACT) to update its estimate of Factor
2 to account for the projected increases
in the number of uninsured as the
COVID–19 PHE provisions expire. Many
commenters questioned CMS’ estimated
decrease in the uninsured rate from 9.6
percent in the FY 2022 IPPS/LTCH PPS
final rule to 9.2 percent in FY 2023
IPPS/LTCH PPS proposed rule and
stated that they expect increases in the
uninsured rates in their communities.
Further, many commenters noted that
the proposed decrease of $800 million
in uncompensated care payments from
the level in FY 2022 was likely, in part,
driven by the projected uninsured rate.
To that end, commenters cited CMS’
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.124
were not available, the ACS data were
not used for purposes of estimating the
number of uninsured individuals for
2020.
The next metrics needed to compute
Factor 2 for FY 2023 are projections of
the rate of uninsurance in both CY 2022
and CY 2023. On an annual basis, OACT
projects enrollment and spending trends
for the coming 10-year period. The most
recent projections are for 2021 through
2030. Those projections use the latest
NHEA historical data, available at the
time of their construction. The NHEA
projection methodology accounts for
expected changes in enrollment across
all of the categories of insurance
coverage previously listed. The
projected growth rates in enrollment for
Medicare, Medicaid, and CHIP are
developed to be consistent with the
2021 Medicare Trustees Report, updated
where possible with more recent data.
Projected rates of growth in enrollment
for private health insurance and the
uninsured are based largely on OACT’s
econometric models, which rely on a set
of macroeconomic assumptions that are
generally based on the 2021 Medicare
Trustees Report. Greater detail can be
found in OACT’s report titled
‘‘Projections of National Health
Expenditure: Methodology and Model
Specification,’’ which is available on the
CMS website at https://www.cms.gov/
Research-Statistics-Data-and-Systems/
Statistics-Trends-and-Reports/
NationalHealthExpendData/
Downloads/ProjectionsMethodology.pdf.
49031
khammond on DSKJM1Z7X2PROD with RULES2
49032
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
statement in the proposed rule that the
agency might consider more recent data
that may have become available for the
calculation of Factor 2 in FY 2023 and
urged CMS to use more recent data
sources to account for the anticipated
increase in the uninsured rate. One
commenter requested that CMS consider
temporarily changing its methodology
for calculating Factor 2 to better account
for individuals who may lose their
healthcare coverage when various PHE
provisions expire and noted that CMS
has taken similar approaches in other
Medicare payment areas affected by the
COVID–19 PHE.
Many commenters referenced various
data sources and analyses, such as the
Kaiser Family Foundation, the Urban
Institute, and HHS’ Assistant Secretary
for Planning and Evaluation (ASPE)
which project 5 to 16 million
individuals will lose their Medicaid
coverage and another 3 million
additional individuals will lose their
marketplace insurance in FY 2023.
Accordingly, these commenters
requested that CMS increase Factor 2 to
reflect the anticipated increase in the
uninsured population as suggested by
these sources. In addition, one
commenter requested that CMS exclude
FY 2020 and FY 2021 data when
calculating the uninsured rate to
eliminate any irregularities due to the
COVID–19 PHE.
Response: We thank the commenters
for their input regarding the estimate of
Factor 2 for FY 2023 included in the
proposed rule. In response to
commenters who requested that we
update the estimate of the FY 2023
uninsured rate to fully consider any
changes due to the anticipated
expirations of the PHE and the
Marketplace premium tax credits, we
note that the rate of uninsurance used
for the calculation of Factor 2 for the
proposed rule, as well as for this final
rule, reflects CMS’ latest analyses and
projections. The projected enrollment
trends across all insurance types, as
well as for the uninsured, take into
account the expected impacts of current
law including the termination of the
Families First Coronavirus Response
Act’s continuous coverage provision for
Medicaid (assumed to expire when the
PHE ends in 2022 and to be
accompanied by a one-year transition of
disenrollments from the program for
those no longer eligible) and the
conclusion of the enhanced Marketplace
premium tax credits. We believe that
this NHEA projection, on balance, best
meets all of our considerations for
ensuring that the data source that
underlies the Factor 2 calculation of the
uninsured rate meets the statutory
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
requirement that the estimate be based
on data sources that the Secretary
determines to be appropriate, is certified
by CMS’ Chief Actuary, and provides a
reasonable estimate for the rate of
uninsurance that is available in
conjunction with the IPPS rulemaking
cycle. We refer readers to OACT’s
memorandum ‘‘Certification of Rates of
Uninsured’’ and OACT’s report titled
‘‘Projections of National Health
Expenditure: Methodology and Model
Specification’’ for further details on the
methodology and updated assumptions
used in the calculation of the projected
uninsured rate.
We disagree with comments’
suggestions that we exclude FY 2020
and FY 2021 data, or any data from the
COVID–19 PHE period, for purposes of
calculating the uninsured rate for FY
2023. The projections that underlie the
FY 2023 Factor 2 calculation should
take into consideration, and include,
those elements that are expected to
influence health insurance enrollment
trends during FY 2023, and the resulting
rate of uninsured, including the unique
circumstance associated with the
COVID–19 pandemic.
Comment: Some commenters
suggested that CMS use a different
estimate of the uninsured rate to
calculate Factor 2 for FY 2023, while
acknowledging that OACT accounted
for the expiration of the COVID–19 PHE
provisions in its uninsurance estimates.
These commenters indicated that
because the uninsured percent change
serves as a proxy for the change in the
amount of uncompensated care that
hospitals provide, it would be
appropriate for CMS to apply a case-mix
adjuster to the uninsured rate for FY
2023 to account for the rise in resources
that will be used by hospitals to provide
care to uninsured individuals who may
have delayed their care during the
COVID–19 PHE.
A few commenters requested that
CMS maintain the same level of
uncompensated care funding as in FY
2022 ($7.2 billion) while another
commenter requested that CMS consider
delaying any proposed changes to the
uncompensated care payment
calculations until analyses can be
performed to determine the actual
uninsured rate and related costs
following the end of the COVID–19
PHE. Other commenters urged CMS to
be transparent in its calculation of
Factor 2 and how it accounts for
Medicaid expansion populations, while
others urged CMS to be transparent
regarding the data sources used for
calculating Factor 2 and the
assumptions behind the uninsured rate.
PO 00000
Frm 00254
Fmt 4701
Sfmt 4700
Response: Regarding the commenters
that requested modifications to the
uninsured rate, such as multiplying by
a case-mix factor, we note that these
recommendations would not be
consistent with the statutory
requirements in section 1886(r)(2)(B)(ii).
The statute explicitly specifies that
Factor 2 be based on 1 minus the
percent change in the percent of
individuals who are uninsured, as
determined by comparing the percent of
individuals who were uninsured in
2013 and the percent of individuals who
were uninsured in the most recent
period for which data are available.
Regarding the comments
recommending that CMS maintain total
uncompensated care payments at the FY
2022 level or delay any changes to the
amount available to make
uncompensated care payments, we
believe estimating Factor 2 based on the
best available data regarding the
expected rate of uninsurance in FY 2023
is appropriate and consistent with the
statute.
In response to the comments
concerning transparency, we reiterate
that we have been and continue to be
transparent with respect to the
methodology and data used to estimate
Factor 2. The FY 2023 IPPS/LTCH PPS
proposed rule included a detailed
discussion of our proposed Factor 2
methodology, as well as the data sources
that would be used in making our final
estimate. For purposes of this final rule,
we are using projected rates of
uninsurance for CY 2022 and CY 2023,
which account for the effects of the
COVID–19 PHE and any legislative
impacts arising from the end of the
COVID–19 PHE on insurance coverage.
Section 1886(r)(2)(B)(ii) of the Act
permits us to use a data source other
than CBO estimates to determine the
percent change in the rate of
uninsurance beginning in FY 2018. We
continue to believe that the NHEA data
and methodology used to estimate
Factor 2 are transparent and best meet
all of our considerations for ensuring
reasonable estimates for the rate of
uninsurance that are available in
conjunction with the IPPS rulemaking
cycle. Accordingly, we continue to
believe that it is appropriate to calculate
Factor 2 based on the NHEA-based
projection of the FY 2023 rate of
uninsurance as we proposed.
After consideration of the public
comments we received, we are
finalizing, as proposed, the Factor 2
calculation for FY 2023. The estimates
of the percent of uninsured individuals
were produced and certified by OACT
for purposes of the FY 2023 IPPS
proposed rule. Those published CY and
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Percent of individuals without
insurance for CY 2022: 8.9 percent.
Percent of individuals without
insurance for CY 2023: 9.3 percent.
Percent of individuals without
insurance for FY 2023 (0.25 times 0.089)
+ (0.75 times 0.093): 9.2 percent.
Final FY 2023 Uncompensated Care Amount
We did not receive any comments on
our proposed technical change to the
regulation governing the calculation of
Factor 2. We are finalizing the update to
§ 412.106(g)(1)(ii), as proposed.
khammond on DSKJM1Z7X2PROD with RULES2
3. Calculation of Proposed Factor 3 for
FY 2023
(a) General Background
Section 1886(r)(2)(C) of the Act
defines Factor 3 in the calculation of the
uncompensated care payment. As we
have discussed earlier, section
1886(r)(2)(C) of the Act states that Factor
3 is equal to the percent, for each
subsection (d) hospital, that represents
the quotient of: (1) the amount of
uncompensated care for such hospital
for a period selected by the Secretary (as
estimated by the Secretary, based on
appropriate data (including, in the case
where the Secretary determines
alternative data are available that are a
better proxy for the costs of subsection
(d) hospitals for treating the uninsured,
the use of such alternative data)); and
(2) the aggregate amount of
uncompensated care for all subsection
(d) hospitals that receive a payment
under section 1886(r) of the Act for such
period (as so estimated, based on such
data).
Therefore, Factor 3 is a hospitalspecific value that expresses the
proportion of the estimated
uncompensated care amount for each
subsection (d) hospital and each
subsection (d) Puerto Rico hospital with
the potential to receive Medicare DSH
payments relative to the estimated
uncompensated care amount for all
hospitals estimated to receive Medicare
DSH payments in the fiscal year for
which the uncompensated care payment
is to be made. Factor 3 is applied to the
product of Factor 1 and Factor 2 to
determine the amount of the
uncompensated care payment that each
eligible hospital will receive for FY
2014 and subsequent fiscal years. In
order to implement the statutory
requirements for this factor of the
uncompensated care payment formula,
it was necessary to determine: (1) the
definition of uncompensated care or, in
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
other words, the specific items that are
to be included in the numerator (that is,
the estimated uncompensated care
amount for an individual hospital) and
the denominator (that is, the estimated
uncompensated care amount for all
hospitals estimated to receive Medicare
DSH payments in the applicable fiscal
year); (2) the data source(s) for the
estimated uncompensated care amount;
and (3) the timing and manner of
computing the quotient for each
hospital estimated to receive Medicare
DSH payments. The statute instructs the
Secretary to estimate the amounts of
uncompensated care for a period based
on appropriate data. In addition, we
note that the statute permits the
Secretary to use alternative data in the
case where the Secretary determines
that such alternative data are available
that are a better proxy for the costs of
subsection (d) hospitals for treating
individuals who are uninsured.
In the course of considering how to
determine Factor 3 during the
rulemaking process for FY 2014, the
first year for which section 1886(r) of
the Act was in effect, we considered
defining the amount of uncompensated
care for a hospital as the
uncompensated care costs of that
hospital and determined that Worksheet
S–10 of the Medicare cost report would
potentially provide the most complete
data regarding uncompensated care
costs for Medicare hospitals. However,
because of concerns regarding variations
in the data reported on Worksheet S–10
and the completeness of these data, we
did not use Worksheet S–10 data to
determine Factor 3 for FY 2014, or for
FYs 2015, 2016, or 2017. Instead, we
used alternative data on the utilization
of insured low-income patients, as
measured by patient days, which we
believed would be a better proxy for the
costs of hospitals in treating the
uninsured and therefore appropriate to
use in calculating Factor 3 for these
years. Of particular importance in our
decision to use proxy data was the
relative newness of Worksheet S–10,
which went into effect on May 1, 2010.
At the time of the rulemaking for FY
PO 00000
Frm 00255
Fmt 4701
Sfmt 4700
1¥ |((0.092¥0.14)/0.14)| = 1¥0.3429
= 0.6571 (65.71 percent).
Therefore, the final Factor 2 for FY
2023 is 65.71 percent. The final FY 2023
uncompensated care amount is
$10,461,731,029.40* 0.6571 =
$6,874,403,459.42.
$ 6,874,403,459.42
2014, the most recent available cost
reports would have been from FYs 2010
and 2011 and submitted on or after May
1, 2010, when the new Worksheet S–10
went into effect. However, we indicated
our belief that Worksheet S–10 could
ultimately serve as an appropriate
source of more direct data regarding
uncompensated care costs for purposes
of determining Factor 3 once hospitals
were submitting more accurate and
consistent data through this reporting
mechanism.
In the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38202), we stated that we
could no longer conclude that
alternative data to the Worksheet S–10
are available for FY 2014 that are a
better proxy for the costs of subsection
(d) hospitals for treating individuals
who are uninsured. Hospitals were on
notice as of FY 2014 that Worksheet S–
10 could eventually become the data
source for CMS to calculate
uncompensated care payments.
Furthermore, hospitals’ cost reports
from FY 2014 had been publicly
available for some time, and CMS had
analyses of Worksheet S–10, conducted
both internally and by stakeholders,
demonstrating that Worksheet S–10
accuracy had improved over time. We
refer readers to the FY 2018 IPPS/LTCH
PPS final rule (82 FR 38201 through
38203) for a complete discussion of
these analyses.
In the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38206), we recognized
commenters’ concerns that, in
continuing to use Medicaid days as part
of the proxy for uncompensated care, it
would be possible for hospitals in States
that choose to expand Medicaid to
receive higher uncompensated care
payments because they may have more
Medicaid patient days than hospitals in
a State that does not choose to expand
Medicaid. In the FY 2018 IPPS/LTCH
PPS final rule, we finalized a
methodology under which we
calculated Factor 3 for all eligible
hospitals, with the exception of Puerto
Rico hospitals and Indian Health
Service (IHS) and Tribal hospitals, using
Worksheet S–10 data from FY 2014 cost
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.125
estimated FY rates continue to be the
latest available projections.
The calculation of the final Factor 2
for FY 2023 using a weighted average of
OACT’s certified estimates is as follows:
Percent of individuals without
insurance for CY 2013: 14 percent.
49033
khammond on DSKJM1Z7X2PROD with RULES2
49034
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
reports in conjunction with low-income
insured days proxy data based on
Medicaid days and SSI days. The time
period for the Medicaid days data was
FY 2012 and FY 2013 cost reports,
which reflected the most recent
available information regarding these
hospitals’ low-income insured days
before any expansion of Medicaid (82
FR 38208 through 38212).
In the FY 2019 IPPS/LTCH PPS final
rule (83 FR 41414), we stated that with
the additional steps we had taken to
ensure the accuracy and consistency of
the data reported on Worksheet S–10
since the publication of the FY 2018
IPPS/LTCH PPS final rule, we
continued to believe that we could no
longer conclude that alternative data to
the Worksheet S–10 were currently
available for FY 2014 or FY 2015 that
would be a better proxy for the costs of
subsection (d) hospitals for treating
individuals who are uninsured. In the
FY 2019 IPPS/LTCH PPS final rule (83
FR 41428), we advanced the time period
of the data used in the calculation of
Factor 3 forward by 1 year and used
Worksheet S–10 data from FY 2014 and
FY 2015 cost reports in combination
with the low income insured days proxy
for FY 2013 to determine Factor 3 for FY
2019. We note that, as discussed in the
FY 2020 IPPS/LTCH PPS final rule (84
FR 42366), the use of 3 years of data to
determine Factor 3 for FY 2018 and FY
2019 had the effect of smoothing the
transition from the use of low-income
insured days to the use of Worksheet S–
10 data.
As discussed in the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41424), we
received overwhelming feedback from
commenters emphasizing the
importance of audits in ensuring the
accuracy and consistency of data
reported on the Worksheet S–10. We
began auditing the Worksheet S–10 data
for selected hospitals in the Fall of 2018
so that the audited uncompensated care
data from these hospitals would be
available in time for use in the FY 2020
IPPS/LTCH PPS proposed rule.
In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42368), we finalized our
proposal to use a single year of audited
Worksheet S–10 cost report data from
FY 2015 in the methodology for
determining Factor 3 for FY 2020.
Although some commenters expressed
support for the alternative policy of
using the more recent FY 2017
Worksheet S–10 data to determine each
hospital’s share of uncompensated care
costs in FY 2020, given the feedback
from commenters in response to both
the FY 2019 and FY 2020 IPPS/LTCH
PPS proposed rules, emphasizing the
importance of audits in ensuring the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
accuracy and consistency of data
reported on the Worksheet S–10, we
concluded that the FY 2015 Worksheet
S–10 data were the best available
audited data to be used in determining
Factor 3 for FY 2020. We also noted that
we had begun auditing the FY 2017 data
in July 2019, with the goal of having the
FY 2017 audited data available for
future rulemaking.
In the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58823 through 58825), we
finalized our proposal to use the most
recent available single year of audited
Worksheet S–10 data to determine
Factor 3 for FY 2021 and subsequent
fiscal years. We explained our belief
that using the most recent audited data
available before the applicable Federal
fiscal year, will more accurately reflect
a hospital’s uncompensated care costs,
as opposed to averaging multiple years
of data. We explained that mixing
audited and unaudited data for
individual hospitals by averaging
multiple years of data could potentially
lead to a less smooth result. We also
noted that if a hospital has relatively
different data between cost report years,
we potentially would be diluting the
effect of our considerable auditing
efforts and introducing unnecessary
variability into the calculation if we
were to use multiple years of data to
calculate Factor 3. Therefore, we also
believed using a single year of audited
cost report data would be an appropriate
methodology to determine Factor 3 for
FY 2021 and subsequent years, except
for IHS and Tribal hospitals and
hospitals located in Puerto Rico. For
IHS and Tribal hospitals and Puerto
Rico hospitals, we finalized the use of
a low-income insured days proxy to
determine Factor 3 for FY 2021. We did
not finalize a methodology to determine
Factor 3 for IHS and Tribal hospitals
and Puerto Rico hospitals for FY 2022
and subsequent years because we
believed further consideration and
review of these hospitals’ Worksheet S–
10 data was necessary (85 FR 58825).
In the FY 2021 IPPS/LTCH PPS final
rule, we finalized the definition of
‘‘uncompensated care’’ for FY 2021 and
subsequent fiscal years, for purposes of
determining uncompensated care costs
and calculating Factor 3 (85 FR 58825
through 58828). Specifically,
‘‘uncompensated care’’ is defined as the
amount on Line 30 of Worksheet S–10,
which is the cost of charity care (Line
23) and the cost of non-Medicare bad
debt and non-reimbursable Medicare
bad debt (Line 29). This is the same
definition that we initially adopted in
the FY 2018 IPPS/LTCH PPS final rule.
We refer readers to the FY 2021 IPPS/
LTCH PPS rule (85 FR 58825 through
PO 00000
Frm 00256
Fmt 4701
Sfmt 4700
58828) for a discussion of additional
topics related to the definition of
uncompensated care. We noted in the
FY 2021 IPPS/LTCH PPS final rule that
the Paper Reduction Act (PRA) package
for Form CMS–2552–10 would offer an
additional opportunity to comment on
the cost reporting instructions. A PRA
package with comment period appeared
in the November 10, 2020, Federal
Register (85 FR 71653). We thank
stakeholders for their comments on the
PRA package. For further information,
we refer the readers to the following
website. https://www.reginfo.gov/
public/do/PRAViewDocument?ref_
nbr=202206-0938-017.
(b) Background on the Methodology
Used To Calculate Factor 3 for FY 2022
Section 1886(r)(2)(C) of the Act
governs both the selection of the data to
be used in calculating Factor 3, and also
allows the Secretary the discretion to
determine the time periods from which
we will derive the data to estimate the
numerator and the denominator of the
Factor 3 quotient. Specifically, section
1886(r)(2)(C)(i) of the Act defines the
numerator of the quotient as the amount
of uncompensated care for a subsection
(d) hospital for a period selected by the
Secretary. Section 1886(r)(2)(C)(ii) of the
Act defines the denominator as the
aggregate amount of uncompensated
care for all subsection (d) hospitals that
receive a payment under section 1886(r)
of the Act for such period. In the FY
2014 IPPS/LTCH PPS final rule (78 FR
50638), we adopted a process of making
interim payments with final cost report
settlement for both the empirically
justified Medicare DSH payments and
the uncompensated care payments
required by section 3133 of the
Affordable Care Act. Consistent with
that process, we also determined the
time period from which to calculate the
numerator and denominator of the
Factor 3 quotient in a way that would
be consistent with making interim and
final payments. Specifically, we must
have Factor 3 values available for
hospitals that we estimate will qualify
for Medicare DSH payments and for
those hospitals that we do not estimate
will qualify for Medicare DSH payments
but that may ultimately qualify for
Medicare DSH payments at the time of
cost report settlement.
In the FY 2022 IPPS/LTCH PPS final
rule, we continued to apply the
following policies as part of the Factor
3 methodology: (1) the policy regarding
newly merged hospitals that was
initially adopted in the FY 2015 IPPS/
LTCH PPS final rule; (2) the policies
regarding annualization and long cost
reports that were adopted in the FY
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
2018 and FY 2019 IPPS/LTCH PPS final
rules, including a modified policy for
the rare cases where a provider has no
cost report for the fiscal year that is used
in the Factor 3 methodology because the
cost report for the previous fiscal year
spans both years; (3) the modified new
hospital policy that was finalized in the
FY 2020 IPPS/LTCH PPS final rule; (4)
the new merger policy adopted in the
FY 2021 IPPS/LTCH PPS final rule that
accounts for the merger effective date;
and (5) the policies regarding the
application of statistical trim
methodologies to potentially aberrant
CCRs and potentially aberrant
uncompensated care costs reported on
the Worksheet S–10. We discuss these
policies in greater detail in this section.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45244), we continued to
treat hospitals that merge after the
development of the final rule for the
applicable fiscal year similar to new
hospitals. As explained in the FY 2015
IPPS/LTCH PPS final rule, for these
newly merged hospitals, we do not have
data currently available to calculate a
Factor 3 amount that accounts for the
merged hospital’s uncompensated care
burden (79 FR 50021). In the FY 2015
IPPS/LTCH PPS final rule, we finalized
a policy under which Factor 3 for
hospitals that we do not identify as
undergoing a merger until after the
public comment period and additional
review period following the publication
of the final rule or that undergo a merger
during the fiscal year would be
recalculated similar to new hospitals (79
FR 50021 and 50022). Consistent with
past policy, interim uncompensated
care payments for newly merged
hospitals are based only on the data for
the surviving hospital’s CCN available at
the time of the development of the final
rule. However, at cost report settlement,
we will determine the newly merged
hospital’s final uncompensated care
payment based on the uncompensated
care costs reported on its cost report for
the applicable fiscal year. That is, for FY
2022, we will revise the numerator of
Factor 3 for a newly merged hospital to
reflect the uncompensated care costs
reported on the newly merged hospital’s
FY 2022 cost report.
In FY 2022 IPPS/LTCH PPS final rule,
we continued the policy that was
finalized in the FY 2018 IPPS/LTCH
PPS final rule of annualizing
uncompensated care cost data reported
on the Worksheet S–10 if a hospital’s
cost report does not equal 12 months of
data, except in the case of mergers,
which would be subject to the modified
merger policy originally adopted in FY
2021. In addition, we continued the
policies that were finalized in the FY
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
2019 IPPS/LTCH PPS final rule (83 FR
41415) regarding the use of the longest
cost report available within the Federal
fiscal year. We also applied the
modified policy that was adopted in the
FY 2021 IPPS/LTCH PPS final rule (85
FR 58829) for those rare situations
where a hospital has a cost report that
starts in one fiscal year but spans the
entirety of the following fiscal year such
that the hospital has no cost report
starting in that subsequent fiscal year.
Under this modified policy, we use the
cost report that spans both fiscal years
for purposes of calculating Factor 3
when data from the latter fiscal year are
used in the Factor 3 methodology.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 25454), we continued the
modified new hospital policy for new
hospitals that do not have data for the
cost reporting period(s) used in the
Factor 3 calculation (that is, the most
recent cost reporting year for which
audits have been conducted). Under the
modified policy originally adopted for
FY 2020, new hospitals that have a
preliminary projection of being eligible
for Medicare DSH based on their most
recent available disproportionate patient
percentages may receive interim
empirically justified DSH payments
during the fiscal year. However, because
these hospitals do not have a cost report
for the cost reporting period used in the
Factor 3 calculation and the projection
of eligibility for DSH payments is still
preliminary, we are unable to calculate
a prospective Factor 3 for these
hospitals and they do not receive
interim uncompensated care payments.
The MAC will make a final
determination concerning whether the
hospital is eligible to receive Medicare
DSH payments for the fiscal year at cost
report settlement. Thus, for FY 2022, if
a new hospital is ultimately determined
to be eligible for Medicare DSH
payments for FY 2022, the hospital will
receive an uncompensated care payment
calculated using a Factor 3, where the
numerator is the uncompensated care
costs reported on Worksheet S–10 of the
hospital’s FY 2022 cost report, and the
denominator is the same denominator
that was used in the prospective Factor
3 calculation for FY 2022 (that is, the
sum of the uncompensated care costs
reported on Worksheet S–10 of the FY
2018 cost reports for all DSH-eligible
hospitals).
In the FY 2022 IPPS/LTCH PPS final
rule, we continued the new merger
policy that accounts for the merger
effective date, that was originally
adopted in FY 2021. To more accurately
estimate uncompensated care costs
(UCC) for the hospitals involved in a
merger when the merger effective date
PO 00000
Frm 00257
Fmt 4701
Sfmt 4700
49035
occurs partway through the surviving
hospital’s cost reporting period, we
apply a policy of not annualizing the
acquired hospital’s data. Under this
policy, we use only the portion of the
acquired hospital’s unannualized UCC
data that reflects the UCC incurred prior
to the merger effective date, but after the
start of the surviving hospital’s current
cost reporting period. To do this, we
calculate a multiplier to be applied to
the acquired hospital’s UCC. This
multiplier represents the portion of the
UCC data from the acquired hospital
that should be incorporated with the
surviving hospital’s data to determine
UCC for purposes of determining Factor
3 for the surviving hospital. This
multiplier is obtained by calculating the
number of days between the start of the
applicable cost reporting period for the
surviving hospital and the merger
effective date, and then dividing this
result by the total number of days in the
reporting period of the acquired
hospital. Applying this multiplier to the
acquired hospital’s unannualized UCC
data will determine the final portion of
the acquired hospital’s UCC that should
be added to the UCC of the surviving
hospital for purposes of determining
Factor 3 for the merged hospital.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 25454 and 25455), we
continued to apply a CCR trim
methodology similar to the CCR trim
methodology policy that has been used
for purposes of determining
uncompensated care payments since FY
2018. This CCR trim methodology is
consistent with the approach used in
the outlier payment methodology under
§ 412.84(h)(3)(ii), which states that the
Medicare contractor may use a
statewide average CCR for hospitals
whose operating or capital CCR is in
excess of 3 standard deviations above
the corresponding national geometric
mean. We refer readers to the discussion
in the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58831) for a detailed
description of the steps used to
determine the applicable CCR.
In addition, we continued the UCC
data trim methodology for rare
situations where a hospital has
potentially aberrant data that are
unrelated to its CCR (86 FR 45245).
However, because we audit the
Worksheet S–10 data for a number of
hospitals, we no longer believe it is
necessary to apply the trim
methodology for hospitals whose cost
report has been audited. Accordingly,
for FY 2022, we continued the policy
adopted in FY 2021 under which we
exclude hospitals that were part of the
audits for the fiscal year used in the
Factor 3 calculation from the trim
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49036
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
methodology for potentially aberrant
UCC. We also continued to apply a
modified trim methodology for allinclusive rate providers (AIRPs) with
potentially aberrant UCC (86 FR 45235).
Under this modified trim methodology,
when an AIRP’s total UCC are greater
than 50 percent of its total operating
costs when calculated using the CCR
included on its cost report for the most
recent cost reporting year for which
audits have been conducted, we
recalculate the AIRP’s UCC using the
CCR reported on Worksheet S–10, line
1 of the hospital’s most recent available
prior year cost report that does not
result in UCC of over 50 percent of total
operating costs.
In addition, in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45245 and
452456), we finalized an alternative trim
specific to hospitals that are not
projected to be DSH-eligible and that do
not have audited FY 2018 Worksheet S–
10 data for use in determining Factor 3.
We explained that we believe this new
alternative trim more appropriately
addresses potentially aberrant insured
patient charity care costs compared to
the existing trim, because the existing
trim is based solely on the ratio of total
uncompensated care costs to total
operating costs and does not consider
the level of insured patients’ charity
care costs. Specifically, we finalized
that, for the hospitals that would be
subject to the trim, if the hospital is
ultimately determined to be DSHeligible at cost report settlement, then
the MAC would calculate a Factor 3
after reviewing the uncompensated care
information reported on Worksheet S–
10 of the hospital’s FY 2022 cost report.
We stated that we believe if a hospital
subject to this trim is ultimately
determined to be DSH-eligible at cost
report settlement, its uncompensated
care payment should be calculated only
after the hospital’s reporting of insured
charity care costs on its FY 2022
Worksheet S–10 has been reviewed. We
noted that this approach is comparable
to the policy for new hospitals for
which we cannot calculate a prospective
Factor 3 because they do not have
Worksheet S–10 data for the relevant
fiscal year.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45242 and 45243), we
continued the policy we first adopted
for FY 2018 of substituting data
regarding FY 2013 low-income insured
days for the Worksheet S–10 data when
determining Factor 3 for IHS and Tribal
hospitals and subsection (d) Puerto Rico
hospitals that have a FY 2013 cost
report. We stated our belief that this
approach was appropriate as the FY
2013 data reflect the most recent
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
available information regarding these
hospitals’ low-income insured days
before any expansion of Medicaid. In
addition, because we continued to use
1 year of insured low income patient
days as a proxy for uncompensated care
for Puerto Rico hospitals and residents
of Puerto Rico are not eligible for SSI
benefits, we continued to use a proxy
for SSI days for Puerto Rico hospitals
consisting of 14 percent of the hospital’s
Medicaid days, as finalized in the FY
2017 IPPS/LTCH PPS final rule (81 FR
56953 through 56956).
We refer readers to the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45236) for
a discussion of the approach that we
continued to apply in FY 2022 to
determine Factor 3 for new Puerto Rico
hospitals. In brief, Puerto Rico hospitals
that do not have a FY 2013 cost report
were considered new hospitals and
subject to the new hospital policy, as
discussed previously. Specifically, the
numerator of the Factor 3 calculation
will be the uncompensated care costs
reported on Worksheet S–10 of the
hospital’s cost report for the applicable
fiscal year and the denominator is the
same denominator that is determined
prospectively for purposes of
determining Factor 3 for all DSHeligible hospitals.
Consistent with the policy adopted in
the FY 2021 IPPS/LTCH PPS final rule
and codified in the regulations at
§ 412.106(g)(8) for subsequent fiscal
years, in the FY 2022 IPPS/LTCH PPS
final rule we used a single year of
Worksheet S–10 data from FY 2018 cost
reports to calculate Factor 3 for FY 2022
for all eligible hospitals with the
exception of IHS and Tribal hospitals
and Puerto Rico hospitals that have a
cost report for 2013.
Therefore, for FY 2022, we applied
the following methodology to compute
Factor 3 for each hospital:
Step 1: Select the provider’s longest
cost report from its Federal fiscal year
(FFY) 2018 cost reports. (Alternatively,
in the rare case when the provider has
no FFY 2018 cost report because the
cost report for the previous Federal
fiscal year spanned the FFY 2018 time
period, the previous Federal fiscal year
cost report will be used in this step.)
Step 2: Annualize the uncompensated
care costs (UCC) from Worksheet S–10
Line 30, if the cost report is more than
or less than 12 months. (If applicable,
use the statewide average CCR (urban or
rural) to calculate uncompensated care
costs.)
Step 3: Combine adjusted and/or
annualized uncompensated care costs
for hospitals that merged using the
merger policy.
PO 00000
Frm 00258
Fmt 4701
Sfmt 4700
Step 4: Calculate Factor 3 for IHS and
Tribal hospitals and Puerto Rico
hospitals that have a cost report for 2013
using the low-income insured days
proxy based on FY 2013 cost report data
and the most recent available SSI ratio
(or, for Puerto Rico hospitals, 14 percent
of the hospital’s FY 2013 Medicaid
days). The denominator is calculated
using the low-income insured days
proxy data from all DSH eligible
hospitals.
Step 5: Calculate Factor 3 for the
remaining DSH eligible hospitals using
annualized uncompensated care costs
(Worksheet S–10 Line 30) based on FY
2018 cost report data (from Step 1, 2 or
3). New hospitals and the hospitals for
which Factor 3 was calculated in Step
4 are excluded from this calculation.
In the FY 2022 IPPS/LTCH PPS final
rule, we amended the regulation at
§ 412.106 by adding a new paragraph
(g)(1)(iii)(C)(9) to reflect the
methodology for computing Factor 3 for
FY 2022 for IHS and Tribal hospitals
and for Puerto Rico hospitals that have
a 2013 cost report. We also finalized a
conforming change to limit the reference
to Puerto Rico hospitals in
§ 412.106(g)(1)(iii)(C)(8) to those Puerto
Rico hospitals that have a cost report for
2013.
(c) Changes to the Methodology for
Calculating Factor 3 for FY 2023 and
Subsequent Fiscal Years
As described in the FY 2022 IPPS/
LTCH PPS final rule, commenters
expressed concerns that the use of only
1 year of data to determine Factor 3
would lead to significant variations in
year-to-year uncompensated care
payments. Some stakeholders
recommended the use of 2 years of
historical Worksheet S–10 data (86 FR
45237). In the FY 2022 IPPS/LTCH PPS
final rule, we stated that we would
consider using multiple years of data
when the vast majority of providers
have been audited for more than 1 fiscal
year under the revised reporting
instructions. The audits of FY 2019 cost
reports began in 2021 and those audited
reports were available in time for the
development of the FY 2023 IPPS/LTCH
PPS proposed rule. Feedback from
previous audits and lessons learned
were incorporated into the audit process
for the FY 2019 reports.
In consideration of the comments
discussed in the FY 2022 IPPS/LTCH
PPS final rule, in the FY 2023 IPPS/
LTCH PPS proposed rule, we proposed
to determine Factor 3 for FY 2023 using
the average of the audited FY 2018 and
audited FY 2019 reports. We stated our
belief that this proposal would address
concerns from stakeholders regarding
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
year-to-year fluctuations in
uncompensated care payments. In
addition, taking into consideration the
comments recommending that CMS
transition to the use of 3 years of
audited data, we indicated that we
expect FY 2024 will be the first year that
3 years of audited data will be available
at the time of rulemaking. Accordingly,
for FY 2024 and subsequent fiscal years,
we proposed to use a 3-year average of
the uncompensated care data from the 3
most recent fiscal years for which
audited data are available to determine
Factor 3. Specifically, for FY 2024, we
would expect to use data from FY 2018,
FY 2019, and FY 2020 reports to
calculate uncompensated care
payments. In other words, for each of
the 3 most recent fiscal years for which
audited data are available at the time of
rulemaking for the applicable fiscal
year, we would divide a hospital’s
uncompensated care costs for the fiscal
year by the estimated total
uncompensated care costs of all DSH
hospitals for that fiscal year. Then, we
would calculate an average of those
proportions to determine the hospital’s
Factor 3 for the applicable Federal fiscal
year. We explained that we believe the
proposed approach is generally
consistent with our past practice of
using the most recent single year of
audited data from the Worksheet S–10,
while also addressing commenters’
concerns regarding year-to-year
fluctuations in uncompensated care
payments. Consistent with the approach
that we followed when multiple years of
data were previously used in the Factor
3 methodology, we proposed that if a
hospital does not have data for all 3
years used in the Factor 3 calculation,
we would determine Factor 3 based on
an average of the hospital’s available
data.
We invited public comments on our
proposed methodology for calculating
Factor 3 for FY 2023 and subsequent
fiscal years, including, but not limited
to, our proposal to use the most recent
audited Worksheet S–10 data from FY
2018 and FY 2019 cost reports to
determine Factor 3 for FY 2023, and our
proposal to begin using the 3 most
recent years of audited Worksheet S–10
data starting in FY 2024.
Comment: Commenters expressed
continued support for the general use of
Worksheet S–10 data to calculate each
hospital’s share of uncompensated care
costs in FY 2023 and future years. Some
commenters also noted their longstanding support for using audited
Worksheet S–10 data to promote an
accurate and consistent calculation of
uncompensated care costs. One
commenter, who supported using
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Worksheet S–10 data, stressed the
importance of ongoing refinements to
the audit process to ensure data
accuracy, while another recommended
that CMS regularly assess and identify
unusual or irregular trends in the data.
Response: We appreciate the support
for our proposal to use Worksheet S–10
data to calculate Factor 3 for FY 2023
and future years. Regarding those
comments that noted the importance of
ongoing refinements to the Worksheet
S–10 audit process, we reiterate our
commitment to continue working with
the MACs and providers on audit
improvements, including changes to
increase the efficiency of the audit
process and build on the lessons learned
in previous audit years. As noted in the
FY 2023 IPPS/LTCH PPS proposed rule,
we believe that, on balance, Worksheet
S–10 data are the best available data to
use for calculating Factor 3 for FY 2023
and subsequent fiscal years.
Comment: An overwhelming majority
of commenters expressed support for
CMS’ proposal to calculate Factor 3 for
FY 2023 based on a two-year average of
audited FY 2018 and FY 2019
Worksheet S–10 data. These
commenters also expressed support for
the proposal to transition to use of a
three-year average of the most recent
available audited Worksheet S–10 data
for FY 2024 and subsequent fiscal years.
Some commenters explicitly stated that
they agreed with CMS that the use of
only one year of data could lead to
undue fluctuations in year-to-year
uncompensated care payments.
Supporters of these proposals also
specified several benefits from the use
of a multi-year average of Worksheet S–
10 data, such as minimizing year-to-year
volatility, ensuring stability in future
uncompensated care payments, and
mitigating the effect of irregular trends
and data anomalies, like the COVID–19
PHE. One commenter suggested that
CMS consider working with hospitals in
future years to ensure that Worksheet S–
10 data from the COVID–19 PHE period
is reported appropriately, given the
PHE’s significant impact on the
utilization of healthcare services. To
this end, one commenter recommended
that CMS consider incorporating FY
2020 Worksheet S–10 data into the
multi-year average for FY 2023 once the
data has been audited, as this approach
would be more reflective of current
healthcare costs.
In contrast, only a handful of
commenters expressed opposition to
using a two-year average of audited FY
2018 and FY 2019 Worksheet S–10 data
for FY 2023 and a three-year average of
Worksheet S–10 data to calculate
uncompensated care payments moving
PO 00000
Frm 00259
Fmt 4701
Sfmt 4700
49037
forward. One commenter indicated that
using a three-year average to calculate
FY 2024 uncompensated care payments
would dilute the impact of the COVID–
19 PHE on the FY 2020 Worksheet S–
10 data. This commenter asserted that
using a multi-year average would
benefit hospitals that received the
highest amount of Health Resources &
Services Administration (HRSA)
subsidies and hospitals with lower
uncompensated care costs, while
harming hospitals with higher
uncompensated care cost data in FY
2020. The commenter also requested
that CMS provide expedited procedures
for reopening and correcting Worksheet
S–10 data for the cost reporting periods
that will be used to calculate
uncompensated care payments in FY
2024 and future years.
Another commenter noted that the FY
2022 methodology based on one year of
audited Worksheet S–10 data was
adequate and should not be modified to
a multi-year average, indicating that
inconsistencies in the methodology
used to calculate Factor 3 from year to
year add a further burden to hospitals’
ability to understand and predict their
uncompensated care payments. This
commenter also urged CMS to
reexamine the continued use of FY 2018
Worksheet S–10 data to determine
payments for FY 2022, FY 2023, and FY
2024, as it may benefit hospitals that
provided elevated levels of
uncompensated care in FY 2018, and
negatively impact those that provided
less uncompensated care.
Finally, some commenters suggested
alternative approaches to calculating
Factor 3 of the uncompensated care
payment calculation that went beyond
the blending of historical Worksheet S–
10 data for multiple fiscal years.
Response: We thank commenters who
expressed their support for our proposal
to use a two-year average of audited FY
2018 and FY 2019 Worksheet S–10 data
to determine each hospital’s share of
uncompensated care costs in FY 2023
and to use of a 3-year average of audited
Worksheet S–10 data starting in FY
2024. As explained in the FY 2023
IPPS/LTCH PPS proposed rule, we
believe that using a multi-year average
of Worksheet S–10 data will provide
assurance that hospitals’
uncompensated care payments remain
stable and predictable and will not be
subject to unpredictable swings and
anomalies in a hospital’s
uncompensated care costs.
We also believe that our proposal to
use multiple years of data is responsive
to past commenters’ requests for the use
of multiple years of audited data. We
disagree with the commenter who stated
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49038
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
that modifying the uncompensated care
payment methodology to use multiple
years of data would put undue burden
on a hospital’s ability to understand,
budget, and forecast as we believe that
our proposal to use a multi-year average
of Worksheet S–10 data to determine
Factor 3 for FY 2023 and subsequent
fiscal years is responsive to past
recommendations for smoothing
fluctuations.
In relation to the commenter who
noted that the multi-year average will
benefit hospitals that received the
highest amount of HRSA subsidies and
hospitals with lower uncompensated
care costs, we note that cost reporting
data from the COVID–19 PHE time
period is not yet available to be
analyzed. We believe it would be
premature to attempt, in this
rulemaking, to modify the methodology
for determining uncompensated care
payments for a future year, specifically
to address the potential impact of the
PHE-related subsidies.
In response to the request that we
provide expedited procedures for
reopening and correcting Worksheet S–
10 data that will be used in the Factor
3 calculation, we note that we do not
intend to establish fixed timelines for
reopenings across MACs, so we can
retain the flexibility to use our limited
audit resources to address and prioritize
audit needs across all CMS programs
each year. However, we note that MACs
work closely with hospitals regarding
reopenings.
Regarding commenters’ suggestions
for alternative approaches to calculating
Factor 3 beyond the previously
considered methodological concepts for
the blending of historical Worksheet S–
10 data, we appreciate commenters’
input and note that we may consider
these suggestions in future rulemaking.
After consideration of the comments
received, we are finalizing our proposal
to use a two-year average of audited FY
2018 and FY 2019 Worksheet S–10 data
to calculate Factor 3 in FY 2023 and a
three-year average of audited data from
the most recent fiscal years for which
audited data are available to determine
Factor 3 in subsequent years. We also
note that the number of audited
hospitals continues to increase year to
year and, as a result, we believe data
from Worksheet S–10 will improve in
reliability over time. However, we will
continue to audit additional years of the
Worksheet S–10 data and monitor the
stability of uncompensated care
payments as we move forward with
using a multi-year average of audited
Worksheet S–10 data for Factor 3
calculations.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule, we have
determined Factor 3 for IHS and Tribal
hospitals and Puerto Rico hospitals,
based on the low-income insured days
proxy for uncompensated care costs. In
the FY 2022 IPPS/LTCH PPS final rule,
we discussed comments we had
received from IHS/Tribal hospitals and
Puerto Rico hospitals about the
significant challenges they face in
relation to uncompensated care
reporting (86 FR 45242 and 45243). For
example, a commenter stated that the
information technology systems used by
IHS and Tribal hospitals are not
equipped to collect the necessary data
for the Worksheet S–10, noting that
while IHS recently received funding to
upgrade its information technology
system, it will take some time,
potentially years, before it is fully
functional (86 FR 45242). Another
commenter expressed concerns that
Puerto Rico hospitals were understating
the components of uncompensated care
costs, and indicated that technical
education is needed to address the
challenges Puerto Rico hospitals have
regarding charity care and bad debt
reporting, which the commenter stated
would take years to address (86 FR
45243).
In the FY 2023 IPPS/LTCH PPS
proposed rule, we acknowledged that to
the extent commenters have identified
specific challenges for IHS/Tribal
hospitals and Puerto Rico hospitals in
reporting uncompensated care costs on
Worksheet S–10, it is possible that after
a sufficient number of years these
reporting challenges could be
addressed. However, despite the
reporting challenges described by
commenters, we expressed our concern
that the historical 2013-based data on
low-income insured days, which has
been used as an alternative to data on
uncompensated care costs from the
Worksheet S–10 to determine Factor 3
for IHS/Tribal hospitals and Puerto Rico
hospitals, is no longer a good proxy for
the costs of these hospitals in treating
the uninsured, given the time that has
elapsed since 2013. In 2023, this data
will be 10 years old and there is no
obvious way to update the information
given our stated concerns surrounding
the differential impact of state Medicaid
expansions after 2013. In light of these
concerns, we stated that we could no
longer conclude that alternative data to
the data on uncompensated care costs
reported on Worksheet S–10 are
currently available for IHS/Tribal
hospitals and Puerto Rico hospitals that
are a better proxy for the costs of these
hospitals in treating the uninsured.
PO 00000
Frm 00260
Fmt 4701
Sfmt 4700
Accordingly, for FY 2023 and
subsequent fiscal years, we proposed to
discontinue the use of low-income
insured days as a proxy for the
uncompensated care costs of these
hospitals and proposed to use the same
data to determine Factor 3 for IHS and
Tribal hospitals and Puerto Rico
hospitals as for other hospitals.
Specifically, for FY 2023, we would
determine Factor 3 for IHS and Tribal
hospitals and Puerto Rico hospitals
based on the average of the
uncompensated care data reported on
Worksheet S–10 of their FY 2018 and
FY 2019 cost reports. However, we
sought comments on alternatives both to
our proposal to use data on
uncompensated care costs from the
Worksheet S–10 to determine Factor 3
for IHS/Tribal hospitals and Puerto Rico
hospitals and to the continued use of
low-income insured days as a proxy for
the uncompensated care costs of these
hospitals. We also sought comments on
how to best measure and define the
uncompensated care costs associated
with these hospitals that might not
otherwise be captured in Factor 3
calculations based on Worksheet S–10
data. Because we recognized that our
proposal to discontinue the use of the
low-income insured days proxy and to
rely solely on Worksheet S–10 data to
calculate Factor 3 of the uncompensated
care payment methodology for IHS/
Tribal hospitals and Puerto Rico
hospitals could result in a significant
financial disruption for these hospitals,
we also proposed to establish a new
supplemental payment for IHS/Tribal
hospitals and Puerto Rico hospitals,
beginning in FY 2023. We refer readers
to section IV.E. of the preamble of this
final rule for a complete discussion of
this proposed new supplemental
payment.
Prior to the proposed rulemaking for
FY 2023, CMS consulted with IHS and
Tribes regarding our policies for
determining uncompensated care
payments. They expressed that
uncompensated care payments are
critical to the providers and should be
maintained at their current levels, at a
minimum. As we explained in the FY
2023 IPPS/LTCH PPS proposed rule, we
considered this recent input along with
previous input from stakeholders in the
development of our proposed policies.
We also welcomed additional input
from stakeholders regarding the unique
circumstances of IHS/Tribal hospitals
and Puerto Rico hospitals and/or any
mitigating factors, and noted that this
input would inform our considerations
about our proposal to determine Factor
3 for these hospitals using data from
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Worksheet S–10 and the related
proposal to establish a new
supplemental payment for IHS/Tribal
hospitals and Puerto Rico hospitals.
We received comments on our
proposal to discontinue the use of the
low-income insured days proxy and to
rely solely on Worksheet S–10 data to
calculate Factor 3 of the uncompensated
care payment methodology for IHS/
Tribal hospitals and Puerto Rico
hospitals. Due to the close
interrelationship between this proposal
and our proposal to establish a new
supplemental payment for IHS/Tribal
hospitals and Puerto Rico hospitals, we
discuss those comments, along with the
comments received on the proposed
new supplemental payment, and set
forth our final policies in Section IV.E
of this final rule.
For purposes of the FY 2023 proposed
rule, we used the December 2021 HCRIS
extract to calculate Factor 3. We noted
that we intended to use the March 2022
update of HCRIS to calculate Factor 3
for the FY 2023 IPPS/LTCH PPS final
rule. However, we stated that we may
consider the use of more recent data that
may become available after March 2022,
but prior to the development of the final
rule, if appropriate, for purposes of
calculating the final Factor 3 for this FY
2023 IPPS/LTCH PPS final rule.
We received comments regarding the
uncompensated care costs definition
and Worksheet S–10 cost report
instructions.
Comment: With regard to the
definition of uncompensated care,
several commenters urged CMS to
include unreimbursed costs (shortfalls)
from Medicaid in the definition of
uncompensated care. Specifically, some
commenters urged CMS to account for
Medicaid shortfalls and incorporate
Line 31 of Worksheet S–10 along with
already-utilized Line 30. In contrast, one
commenter agreed with CMS that
Medicaid shortfalls, as currently
reported on Worksheet S–10, should not
be included in the estimation of
uncompensated care costs. Instead, the
commenter recommended that the
agency revise Worksheet S–10 so data
on Medicaid shortfalls better resemble
actual shortfalls incurred by hospitals.
The commenter further noted that such
data will be increasingly useful for
informational purposes as previously
uninsured individuals gain access to
Medicaid. Other commenters proposed
incorporating social determinants of
health methodologies into
uncompensated care costs by including
variables that describe socioeconomic
disadvantage such as accounting for
costs incurred by hospitals to improve
access to healthy foods, transportation,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
health screenings, technology
assistance, and similar community
needs. Notably, another commenter
suggested that CMS redefine
uncompensated care to align with the
definitions used to determine
community benefit spending under the
Internal Revenue Code.
Response: We appreciate commenters’
suggestions for revisions and/or
modifications to Worksheet S–10. We
will consider the concerns raised by
commenters as part of future cost report
clarifications and will make
modifications as necessary to further
improve and refine the information that
is reported on Worksheet S–10 to
support collection of the information
necessary to implement section
1886(r)(2) of the Act.
With regard to the comments
requesting that payment shortfalls from
Medicaid be included in
uncompensated care cost calculations,
we continue to believe there are
compelling arguments for excluding
such shortfalls from the definition of
uncompensated care. First, we note that
we did not propose any changes to the
definition of uncompensated care costs,
which was first adopted in the FY 2018
IPPS/LTCH PPS final rule (82 FR 38215
through 38217) as the amount on Line
30 of Worksheet S–10, which is the cost
of charity care (Line 23) and the cost of
non-Medicare bad debt and nonreimbursable Medicare bad debt (Line
29). Additionally, key interested parties
(including MedPAC) do not consider
Medicaid shortfalls in their definition of
uncompensated care. Furthermore, we
continue to believe that it is most
consistent with section 1886(r)(2) of the
Act for Medicare uncompensated care
payments to target hospitals that incur
a disproportionate share of
uncompensated care for patients with
no insurance coverage. We also note
that even if we agreed that it would be
appropriate to adjust the definition of
uncompensated care to include
Medicaid shortfalls, this would not be a
feasible option at this time due to
computational limitations. Specifically,
computing such shortfalls is
operationally problematic because
Medicaid pays hospitals a single DSH
payment that, in part, covers the
hospital’s costs for providing care to the
uninsured and in part covers estimates
of the Medicaid ‘‘shortfalls.’’ Therefore,
it is not clear how CMS would
determine how much of the ‘‘shortfall’’
is left after the Medicaid DSH payment
is made. In addition, in some States,
hospitals return a portion of their
Medicaid revenues to the State via
provider taxes and receive supplemental
payments in return (along with the
PO 00000
Frm 00261
Fmt 4701
Sfmt 4700
49039
federal match), making the computation
of ‘‘shortfalls’’ even more complex.
Regarding the request that we include
costs incurred by hospitals to address
social determinants of health in the
definition of uncompensated care costs,
we have consistently stated in past final
rules (85 FR 58826 and 86 FR 45239) in
response to similar comments that we
believe the purpose of uncompensated
care payments is to provide additional
payment to hospitals for treating the
uninsured, not for other costs incurred,
including costs associated with
addressing social determinants of
health, as commenters have suggested.
Accordingly, we do not believe
changing the calculation of
uncompensated care costs is
appropriate, at this time.
Comment: Commenters requested that
CMS include all patient care costs when
calculating the cost-to-charge ratio
(CCR) used in Worksheet S–10 and
urged CMS to include costs incurred for
graduate medical education (GME),
costs of paying provider taxes associated
with Medicaid revenue, and costs of
providing physician and other
professional services when calculating
the CCR used to determine
uncompensated care costs on Worksheet
S–10 in order to improve the accuracy
of that CCR.
Response: As we have stated in past
rules (84 FR 42378, 85 FR 58826, and
86 FR 45239) in response to similar
requests that we modify the CCR used
on Worksheet S–10, we continue to
believe the CCR calculation that is used
in Worksheet S–10 is appropriate.
Regarding the request that we include
GME costs, costs of paying provider
taxes associated with Medicaid revenue,
and costs of providing physician and
other professional service when
calculating CCR used in Worksheet S–
10, we note that because the CCR on
Line 1 of Worksheet S–10 is obtained
from Worksheet C, Part I, and is also
used in other IPPS rate setting contexts
(such as high-cost outliers and the
calculation of the MS–DRG relative
weights) from which it is appropriate to
exclude the costs associated with
supporting GME costs and the costs of
physician and professional services and
costs of paying provider taxes, we
remain reluctant to adjust CCRs in the
narrower context of calculating
uncompensated care costs. Therefore, as
stated in past final rules, we continue to
believe that it is not appropriate, at this
time, to modify the calculation of the
CCR on Line 1 of Worksheet S–10 to
include any additional costs in the
numerator of the CCR calculation.
Comment: One commenter stated that
large teaching hospitals (with 100+
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49040
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
residents) would experience an even
larger uncompensated care payment
reduction, resulting in underserved and
vulnerable populations having less
access to transplant programs (as these
programs are often operated by large
teaching institutions). Another
commenter expressed concern that
hospitals in Medicaid non-expansion
states depend greatly on uncompensated
care payments for financial support, and
this commenter urged CMS to work
with providers and patient advocates in
non-expansion states to screen patients
for eligibility under either financial
assistance policies or premium support
under the Affordable Care Act before
classifying the case as uncompensated
care. The same commenter noted that
the equal weighting of bad debt and
charity care on the Worksheet S–10
disincentivizes hospitals from ensuring
that eligible patients receive charity
care, as obtaining the qualification for
charity care entails long administrative
processes.
Response: We thank commenters for
their continued concern regarding the
distribution of uncompensated care
payments and the impact of reductions
in uncompensated care payments on
teaching hospitals. However, as stated
previously, the purpose of
uncompensated care payments is to
provide additional payment to hospitals
for treating the uninsured.
Uncompensated payments are not
intended to provide support for other
activities that hospitals may undertake.
We also note that CMS does not set
charity care criteria for hospitals, and
within reason, hospitals can establish
their own criteria of what constitutes
charity care in their financial assistance
policies.
Comment: With regard to Worksheet
S–10 instructions and guidance, a few
commenters commended CMS for its
efforts to provide clearer instructions for
Worksheet S–10. A few commenters
requested that CMS clarify inconsistent
Worksheet S–10 instructions so that
non-Medicare bad debt is not multiplied
by the CCR. These commenters noted
that CMS’ revised instructions indicate
that non-reimbursed Medicare bad debt
is not reduced by the CCR, but that
CMS’ September 2017 transmittal states
that non-Medicare bad debt should be
multiplied by the CCR. One commenter
indicated that such practice is
inconsistent with the way nonreimbursable Medicare bad debt is
treated.
Response: We appreciate commenters’
concerns regarding the need for
clarification of the Worksheet S–10
instructions, as well as their suggestions
for revisions to improve reporting. We
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
reiterate our commitment to continuing
to work with impacted parties to
address their concerns regarding
Worksheet S–10 instructions and
reporting through provider education
and further refinement of the
instructions as appropriate. We also
encourage providers to share with their
respective MAC any questions regarding
clarifications of instructions, reporting,
and submission deadlines.
We continue to believe that, as noted
by a commenter, our efforts to refine the
instructions and guidance have
improved provider understanding of the
Worksheet S–10 and added clarity to the
instructions. We also recognize that
there are continuing opportunities to
further improve the accuracy and
consistency of the information that is
reported on the Worksheet S–10, and to
the extent that commenters have raised
new questions and concerns regarding
the reporting requirements, we will
attempt to address them through future
rulemaking and/or sub-regulatory
guidance and provider outreach.
However, as stated in previous rules, we
continue to believe that the Worksheet
S–10 instructions are now sufficiently
clear and allow hospitals to accurately
complete Worksheet S–10s.
Regarding the commenters’ request
that CMS clarify whether non-Medicare
bad debt is multiplied by CCR, we
believe that the Worksheet S–10
instructions are clear and indicate that
the CCR is multiplied by the nonMedicare bad debt amount on line 28.
Regarding the comments requesting
specific structural changes to Worksheet
S–10 and/or further clarification of the
reporting instructions, we note that
these comments fall outside the scope of
this final rule. We note that a recent
PRA package for hospital cost report is
available at: https://www.cms.gov/
regulations-and-guidancelegislation
paperworkreductionactof1995pralisting/cms-2552-10.
We received comments regarding
Worksheet S–10 data and audits.
Comment: In relation to the accuracy
of the Worksheet S–10 data, one
commenter urged CMS to refine the
instructions for reporting of
uncompensated care costs. The
commenter’s recommendations
included that CMS should mitigate the
effect of anomalies in the cost data for
the COVID–19 PHE period and that
CMS should consider the redistributive
effects of the COVID–19 PHE for
purposes of determining
uncompensated care payments in future
rulemaking. One commenter
recommended that CMS work with
impacted providers in upcoming years
to ensure that the data from the COVID–
PO 00000
Frm 00262
Fmt 4701
Sfmt 4700
19 PHE period is properly understood
and correctly reported. Another
commenter urged CMS to account for
the unpredictability of the COVID–19
PHE, including the emergence of new
variants, in determining uncompensated
care payments for future years.
Response: In regard to requests for
CMS to mitigate the effect of anomalies
in FY 2020 through FY 2022 cost report
data and account for the
unpredictability of the COVID–19 PHE
in determining uncompensated care
payments for future years, we note that
we are finalizing the proposal to use a
three-year average of the most recently
audited cost report data for FY 2024 and
subsequent years. Using the three-year
average will smooth the variation in
year-to-year uncompensated care
payments and lessen the impacts of
COVID–19 PHE and future unforeseen
events. We also note that the
calculations for Factor 1 and Factor 2
reflect the estimated impact of the
COVID–19 PHE on DSH payments.
Further, we anticipate that there will be
less fluctuation in cost report data as the
PHE disruptions on healthcare
utilization fade. We will continue to
monitor the impacts of the PHE and will
consider this issue further in future
rulemaking, as appropriate.
Comment: Some commenters
commended CMS for the agency’s
efforts to develop and improve the audit
process for Worksheet S–10 data.
Specifically, one commenter
commended CMS for its efforts to audit
all hospitals rather than only a portion,
while another commenter recommended
that CMS expend all the necessary
resources to continue to audit
Worksheet S–10 data for all DSH
eligible hospitals.
Echoing concerns expressed in
previous years, commenters encouraged
CMS to work with MACs to make the
audit process clearer, more consistent,
and more complete. The same
commenters provided several
recommendations, including that CMS
establish a standardized process across
auditors, develop uniform standards
regarding information submission and
acceptable documentation to meet audit
requirements, develop a transparent
timeframe with sufficient lead time,
target specific data aspects for the audit,
and develop a process for timely
appeals. Specifically, one commenter
recommended that all hospitals be
audited using the same protocols and
that having only some hospitals subject
to desk reviews is inequitable. A few
commenters cited the Medicare wage
index audit as a model that CMS could
use for Worksheet S–10 audits. One
commenter suggested that CMS ensure
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
that Worksheet S–10 audits impose
minimal burden and are equitable and
uniform across hospitals. The same
commenter also suggested that CMS
consider making the audit process more
transparent by disclosing criteria used
to identify hospitals for audits and
publishing audit protocols in advance to
allow hospitals time and opportunity to
respond to audits and address findings.
Other recommendations from this
commenter included that CMS should
conduct audits in advance of using data
for payment rate setting such that data
are accurate and final, select hospitals
for audits in an equitable and systematic
way, and review audit findings to
ensure that MACs and subcontractors
are consistently performing audits
according to protocols.
Response: We thank commenters for
their feedback on the audits of the FY
2019 Worksheet S–10 data and their
recommendations for future audits. As
we have stated previously in response to
comments regarding audit protocols,
these are provided to the MACs in
advance of the audit so as to assure
consistency and timeliness in the audit
process. We began auditing the FY 2019
Worksheet S–10 data for selected
hospitals last year so that the audited
uncompensated care data for these
hospitals would be available in time for
use in the FY 2023 IPPS/LTCH PPS
proposed rule. We chose to focus the
audit on the FY 2019 cost reports in
order to maximize the available audit
resources. Similarly, as discussed in the
FY 2022 IPPS/LTCH PPS final rule, we
chose to focus the audits on the FY 2018
cost reports in order to maximize the
available audit resources prior to the FY
2022 rulemaking. In response to the
consistent feedback from commenters
emphasizing the importance of audits in
ensuring the accuracy and consistency
of data reported on the Worksheet S–10,
we have also started the process of
auditing FY 2020 Worksheet S–10 data.
We appreciate all commenters’ input
and recommendations on how to
improve our audit process and reiterate
our commitment to continue working
with the MACs and providers on audit
improvements, which include making
changes to increase the efficiency of the
audit process, building on the lessons
learned in previous audit years. We will
take these recommendations into
consideration for future rulemaking.
Regarding commenters’ requests for a
standard audit timeline, we do not
intend to establish a fixed timeline for
audits across MACs at this time such
that we can retain the flexibility to use
our limited audit resources to address
and prioritize audit needs across all
CMS programs each year. We note that
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
MACs collaborate with providers
regarding scheduling dates during the
Worksheet S–10 audit process. We also
note that MACs work closely with
providers to balance the time needed to
complete the Worksheet S–10 audits
and to minimize the burden on
providers and will continue to do so.
Regarding commenters’ requests that
we make public the audit instructions
and criteria, as we previously stated in
the FY 2022 IPPS/LTCH final rule and
in prior rules, we do not make review
protocols public as CMS desk review
and audit protocols are confidential and
are for CMS and MAC use only. We note
that there is no requirement under
either the Administrative Procedure Act
or the Medicare statute that CMS
establish audit protocols through notice
and comment rulemaking. Rather, it is
sufficient that we provide impacted
parties with notice of our proposed
methodology and the data sources that
will be used, so that they may have a
meaningful opportunity to submit their
views on the proposed methodology and
the adequacy of the data for the
intended purpose. Similarly, there is no
requirement that we provide an
opportunity for comment on the actual
findings or audit disallowances
determined for each hospital as these
results are confidential to each hospital.
Concerning commenters’
recommendations that we establish a
timely review and appeals process for
the Worksheet S–10 audits, we do not
plan to introduce such a process at this
time in order to maximize limited audit
resources. However, we will continue to
work with impacted parties to address
their concerns regarding the accuracy
and consistency of data reported on
Worksheet S–10. We will also continue
to work to further improve reporting
through revised instructions, and will
also work with MACs to ensure a more
consistent audit process across
providers and MACs.
Regarding commenters’
recommendations that we establish a
similar process to that of the wage index
audits, at this point we do not plan to
introduce an audit process with such a
structure in order to maximize limited
audit resources.
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28392),
for purposes of determining Factor 3 for
FY 2023 and subsequent fiscal years, we
are continuing to apply the following
policies: (1) the merger policies that
were initially adopted in the FY 2015
IPPS/LTCH PPS final rule (79 FR
50021), as modified in the FY 2021
IPPS/LTCH PPS final rule (85 FR 58828
and 58829) to incorporate the use of a
multiplier to account for merger
PO 00000
Frm 00263
Fmt 4701
Sfmt 4700
49041
effective date; (2) the policy for
hospitals with multiple cost reports,
beginning in the same fiscal year, of
using the longest cost report and
annualizing uncompensated care data if
a hospital’s cost report does not equal
12 months of data; (3) the policy, as
modified in the FY 2021 IPPS/LTCH
PPS final rule (85 FR 58829) and as
further modified as proposed in the FY
2023 IPPS/LTCH PPS proposed rule, for
the rare case where a hospital has a cost
report that starts in one fiscal year and
spans the entirety of the following fiscal
year, such that the hospital has no cost
report for that subsequent fiscal year, of
using the cost report that spans both
fiscal years for the latter fiscal year; (4)
the new hospital policy, as modified in
the FY 2020 IPPS/LTCH PPS final rule
and as further modified as proposed in
this section; (5) the newly merged
hospital policy, with the modifications
proposed in the FY 2023 IPPS/LTCH
PPS proposed rule; and (6) the policies
regarding the application of statistical
trim methodologies to potentially
aberrant CCRs and potentially aberrant
uncompensated care costs reported on
the Worksheet S–10, as modified as
proposed in the FY 2023 IPPS/LTCH
PPS proposed rule.
Because we proposed to use multiple
years of cost reports to determine Factor
3 starting in FY 2023, we determined
that it would also be necessary to make
a further modification to the policy
regarding cost reports that start in one
fiscal year and span the entirety of the
following fiscal year. Specifically, in the
rare cases when we use a cost report
that starts in one fiscal year and spans
the entirety of the subsequent Federal
fiscal year to determine uncompensated
care costs for the subsequent Federal
fiscal year, we would not use the same
cost report to determine the hospital’s
uncompensated care costs for the earlier
fiscal year. We explained that using the
same cost report to determine
uncompensated care costs for both fiscal
years would not be consistent with our
intent to smooth year-to-year variation
in uncompensated care costs. As an
alternative, we proposed to use the
hospital’s most recent prior cost report,
if that cost report spans the applicable
period. In other words, in determining
Factor 3 for FY 2023, we would not use
the same cost report to determine the
hospital’s uncompensated care costs for
both FY 2018 and FY 2019. Rather, we
would use the cost report that spans the
entirety of FY 2019 to determine
uncompensated care costs for FY 2019
and we would use the hospital’s most
recent prior cost report to determine its
uncompensated care costs for FY 2018,
E:\FR\FM\10AUR2.SGM
10AUR2
49042
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
provided that cost report spans some
portion of Federal fiscal year 2018.
We did not receive comments on this
proposed modification. We are
finalizing as proposed.
• Scaling Factor
To address the effects of the
calculating Factor 3 using data from
multiple fiscal years, in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28392) we proposed to apply a scaling
factor to the Factor 3 values calculated
for all DSH eligible hospitals so that
total uncompensated care payments to
hospitals that are projected to be eligible
for DSH for a fiscal year will be
consistent with the estimated amount
available to make uncompensated care
payments for that fiscal year.
Specifically, we proposed to adopt a
policy under which we divide 1 (the
expected sum of all DSH-eligible
hospitals’ Factor 3 values) by the actual
sum of all DSH eligible hospitals’ Factor
3 values and then multiply the quotient
by the uncompensated care payment
determined for each DSH eligible
hospital to obtain a scaled
uncompensated care payment amount
for each hospital. This process is
designed to ensure that the sum of the
scaled uncompensated care payments
for all hospitals that are projected to be
DSH eligible is consistent with the
estimate of the total amount available to
make uncompensated care payments for
the applicable fiscal year. In the
proposed rule, we noted that a similar
scaling factor methodology was
previously used in both FY 2018 (82 FR
38214 and 38215) and FY 2019 (83 FR
41414), when the Factor 3 calculation
also included multiple years of data.
We did not receive comments on this
proposed scaling factor policy. We are
finalizing as proposed.
khammond on DSKJM1Z7X2PROD with RULES2
• Modifications to New Hospital Policy
for Purposes of Factor 3
We proposed to modify the new
hospital policy that was initially
adopted in the FY 2020 IPPS/LTCH PPS
final rule to determine Factor 3 for new
hospitals. Consistent with our proposal
to use multiple years of cost reports to
determine Factor 3, we proposed to
define new hospitals as hospitals that
do not have cost report data for the most
recent year of data being used in the
Factor 3 calculation. In other words, the
cut-off date for the new hospital policy
would be the beginning of the Federal
fiscal year after the most recent year for
which audits of the Worksheet S–10
data have been conducted. For FY 2023,
the FY 2019 cost reports are the most
recent year of cost reports for which
audits of Worksheet S–10 data have
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
been conducted. Thus, hospitals with
CCNs established on or after October 1,
2019, would be subject to the new
hospital policy in FY 2023.
Under the proposed modification to
the new hospital policy, we would
continue the policy established in the
FY 2020 IPPS/LTCH PPS final rule (84
FR 42370) that if a new hospital has a
preliminary projection of being eligible
for DSH payments based on its most
recent available disproportionate patient
percentage, it may receive interim
empirically justified DSH payments.
However, new hospitals would not
receive interim uncompensated care
payments during FY 2023 because we
would have no FY 2018 or FY 2019
uncompensated care data on which to
determine what those interim payments
should be. The MAC will make a final
determination concerning whether the
hospital is eligible to receive Medicare
DSH payments at cost report settlement
based on its FY 2023 cost report.
We also proposed to modify the
methodology used to calculate Factor 3
for new hospitals. Specifically, we
proposed to determine Factor 3 for new
hospitals using a denominator based
solely on uncompensated care costs
from cost reports for the most recent
fiscal year for which audits have been
conducted. For example, if a new
hospital is ultimately determined to be
eligible for Medicare DSH payments for
FY 2023, the hospital will receive an
uncompensated care payment
calculated using a Factor 3, where the
numerator is the uncompensated care
costs reported on Worksheet S–10 of the
hospital’s FY 2023 cost report, and the
denominator is the sum of the
uncompensated care costs reported on
Worksheet S–10 of the FY 2019 cost
reports for all DSH-eligible hospitals. In
addition, we proposed to apply a scaling
factor, as discussed previously, to the
Factor 3 calculation for a new hospital.
We explained that we believe applying
the scaling factor is appropriate for
purposes of calculating Factor 3 for all
hospitals, including new hospitals and
hospitals that are treated as new
hospitals, in order to improve
consistency and predictability across all
hospitals.
• Modifications to the Newly Merged
Hospital Policy
In the FY 2023 IPPS/LTCH PPS rule,
we stated that we will continue to treat
hospitals that merge after the
development of the final rule for the
applicable fiscal year similar to new
hospitals. As explained in the FY 2015
IPPS/LTCH PPS final rule, for these
newly merged hospitals, we do not have
data currently available to calculate a
PO 00000
Frm 00264
Fmt 4701
Sfmt 4700
Factor 3 amount that accounts for the
merged hospital’s uncompensated care
burden (79 FR 50021). In the FY 2015
IPPS/LTCH PPS final rule, we finalized
a policy under which Factor 3 for
hospitals that we do not identify as
undergoing a merger until after the
public comment period and additional
review period following the publication
of the final rule or that undergo a merger
during the fiscal year will be
recalculated similar to new hospitals (79
FR 50021 and 50022). Consistent with
the policy adopted in the FY 2015 IPPS/
LTCH PPS final rule, we will continue
to treat newly merged hospitals in a
similar manner to new hospitals, such
that the newly merged hospital’s final
uncompensated care payment will be
determined at cost report settlement
where the numerator of the newly
merged hospital’s Factor 3 will be based
on the cost report of only the surviving
hospital (that is, the newly merged
hospital’s cost report) for the current
fiscal year. However, if the hospital’s
cost reporting period includes less than
12 months of data, the data from the
newly merged hospital’s cost report will
be annualized for purposes of the Factor
3 calculation. Consistent with the
proposed modification to the
methodology used to determine Factor 3
for new hospitals described previously,
we proposed to determine Factor 3 for
newly merged hospitals using a
denominator that is the sum of the
uncompensated care costs for all DSHeligible hospitals, as reported on
Worksheet S–10 of their cost reports for
the most recent fiscal year for which
audits have been conducted. In
addition, we would apply a scaling
factor, as discussed previously, to the
Factor 3 calculation for a newly merged
hospital. We stated our belief that
applying the scaling factor is
appropriate for purposes of calculating
Factor 3 for all hospitals, including new
hospitals and hospitals that are treated
as new hospitals, in order to improve
consistency and predictability across all
hospitals.
We also explained that consistent
with past policy, interim
uncompensated care payments for the
newly merged hospital will be based
only on the data for the surviving
hospital’s CCN available at the time of
the development of the final rule. In
other words, for FY 2023, the eligibility
of a newly merged hospital to receive
interim uncompensated care payments
and the amount of any interim
uncompensated care payments, would
be based on the uncompensated care
costs from the FY 2018 and FY 2019
cost reports available for the surviving
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
CCN at the time the final rule is
developed. However, at cost report
settlement, we would determine the
newly merged hospital’s final
uncompensated care payment based on
the uncompensated care costs reported
on its FY 2023 cost report. That is, we
would revise the numerator of Factor 3
for the newly merged hospital to reflect
the uncompensated care costs reported
on the newly merged hospital’s FY 2023
cost report. The denominator would be
the sum of the uncompensated care
costs reported on Worksheet S–10 of the
FY 2019 cost reports for all DSH-eligible
hospitals, which is the most recent
fiscal year for which audits have been
conducted.
Comment: A couple of commenters
expressed support for the policy
currently in place for newly merged
hospitals under which interim
uncompensated care payments are
based on the data for the surviving
hospital’s CCN available at the time of
development of the final rule. These
commenters also indicated support for
continuing the policy in place for new
hospitals, under which new hospitals
with a CCN established on or after
October 2019 with a preliminary
projection of being eligible for DSH
payments would receive interim
empirically justified DSH payments.
MACs would then make the final
determination concerning whether a
new hospital is eligible to receive DSH
payments at cost report settlement based
on the new hospital’s FY 2023 cost
report. One commenter requested that
CMS provide clarification regarding
which cost report would be used in the
numerator of the Factor 3 calculation for
a newly merged hospital or new
hospital, and whether the cost report
beginning or ending in FY 2023 would
be used.
Response: We appreciate the support
for our current policies for new and
newly merged hospitals. In response to
the comment asking for clarification on
whether a newly merged hospital or
new hospital would use its cost report
beginning or ending in FY 2023, we
note that the new hospital policy and
the newly merged hospital policy are
based on the start date of the hospital’s
cost reporting period. Specifically, the
Factor 3 calculation for a new hospital
will be based on the hospital’s FY 2023
cost report (that is, a cost report with a
start date on or after October 1, 2022,
and on or before September 30, 2023).
The numerator of the hospital’s Factor
3 will be the hospital’s total
uncompensated care costs from the
Worksheet S–10 Line 30 of its FY 2023
cost report (annualized, if necessary).
The denominator will be the total
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
national uncompensated care costs from
the FY 2019 cost reports as calculated
in this FY 2023 IPPS/LTCH PPS final
rule. In the case of a new hospital or a
newly merged hospital that has a cost
report that spans multiple Federal fiscal
years, if the cost report is a FY 2023 cost
report, there is only one denominator in
the Factor 3 calculation. In addition, the
pro rata calculation (i.e., the hospital’s
cost reporting period spans different
Federal fiscal years) for a new hospital
or a newly merged hospital is calculated
using only the FY2023 total
uncompensated care amount (that is, the
Factor 3 is multiplied by the FY 2023
total uncompensated care amount, as
finalized in this final rule.).
After consideration of the comments
received, we are finalizing the proposed
modifications to the new hospital and
newly merged policies.
• CCR Trim Methodology
The calculation of a hospital’s total
uncompensated care costs on Worksheet
S–10 requires the use of the hospital’s
cost to charge ratio (CCR). Consistent
with the process for trimming CCRs
used in the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58831 and 58832), we
explained in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28393) that
we will apply the following steps to
determine the applicable CCR for FY
2018 reports and FY 2019 reports
separately:
Step 1: Remove Maryland hospitals.
In addition, we will remove allinclusive rate providers because their
CCRs are not comparable to the CCRs
calculated for other IPPS hospitals.
Step 2: Calculate a CCR ‘‘ceiling’’ for
the applicable fiscal year with the
following data: for each IPPS hospital
that was not removed in Step 1
(including non-DSH eligible hospitals),
we use cost report data to calculate a
CCR by dividing the total costs on
Worksheet C, Part I, Line 202, Column
3 by the charges reported on Worksheet
C, Part I, Line 202, Column 8.
(Combining data from multiple cost
reports from the same fiscal year is not
necessary, as the longer cost report will
be selected.) The ceiling is calculated as
3 standard deviations above the national
geometric mean CCR for the applicable
fiscal year. This approach is consistent
with the methodology for calculating
the CCR ceiling used for high-cost
outliers. Remove all hospitals that
exceed the ceiling so that these aberrant
CCRs do not skew the calculation of the
statewide average CCR.
Step 3: Using the CCRs for the
remaining hospitals in Step 2,
determine the urban and rural statewide
average CCRs for the applicable fiscal
PO 00000
Frm 00265
Fmt 4701
Sfmt 4700
49043
year for hospitals within each State
(including non-DSH eligible hospitals),
weighted by the sum of total hospital
discharges from Worksheet S–3, Part I,
Line 14, Column 15.
Step 4: Assign the appropriate
statewide average CCR (urban or rural)
calculated in Step 3 to all hospitals,
excluding all-inclusive rate providers,
with a CCR for the applicable fiscal year
greater than 3 standard deviations above
the national geometric mean for that
fiscal year (that is, the CCR ‘‘ceiling’’).
For purposes of both the proposed rule
and this final rule, the statewide average
CCR was applied to 8 hospitals’ FY 2018
reports, of which 3 hospitals had FY
2018 Worksheet S–10 data. The
statewide average CCR was applied to
14 hospitals’ FY 2019 reports, of which
6 hospitals had FY 2019 Worksheet S–
10 data.
Step 5: For hospitals that did not
report a CCR on Worksheet S–10, Line
1, we assign them the statewide average
CCR for the applicable fiscal year as
determined in step 3.
After completing the previously
described steps, we re-calculate the
hospital’s uncompensated care costs
(Line 30) for the applicable fiscal year
using the trimmed CCR (the statewide
average CCR (urban or rural, as
applicable)).
We did not receive any comments on
the discussion of CCR trim
methodology. We are finalizing as
proposed.
• Modifications to the Uncompensated
Care Data Trim Methodology
After applying the CCR trim
methodology, there are rare situations
where a hospital has potentially
aberrant uncompensated care data for a
fiscal year that are unrelated to its CCR.
Therefore, in the FY 2023 IPPS LTCH/
PPS proposed rule, we explained that
under the trim methodology for
potentially aberrant UCC that was
included as part of the methodology for
purposes of determining Factor 3 in the
FY 2021 IPPS/LTCH PPS final rule (85
FR 58832), if the hospital’s
uncompensated care costs for FY 2018
or FY 2019 are an extremely high ratio
(greater than 50 percent) of its total
operating costs in the applicable fiscal
year, we will determine the ratio of
uncompensated care costs to the
hospital’s total operating costs from
another available cost report, and apply
that ratio to the total operating expenses
for the potentially aberrant fiscal year to
determine an adjusted amount of
uncompensated care costs for the
applicable fiscal year. Specifically, if a
hospital’s FY 2018 cost report is
determined to include potentially
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49044
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
aberrant data, data from its FY 2019 cost
report will be used for the ratio
calculation. Thus, the hospital’s
uncompensated care costs for FY 2018
will be trimmed by multiplying its FY
2018 total operating costs by the ratio of
uncompensated care costs to total
operating costs from the hospital’s FY
2019 cost report to calculate an estimate
of the hospital’s uncompensated care
costs for FY 2018 for purposes of
determining Factor 3 for FY 2023.
Because we proposed to use multiple
years of cost reports in the Factor 3
calculation for FY 2023, we would
apply this same approach to address
potentially aberrant data in the FY 2019
cost report, by trimming based on the
hospital’s FY 2020 cost report.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we noted that we have
audited the FY 2018 and the FY 2019
Worksheet S–10 data for a number of
hospitals. Because the UCC data for
these hospitals have been subject to
audit, we stated our belief that there is
increased confidence that if high
uncompensated care costs are reported
by these audited hospitals, the
information is accurate. Therefore,
consistent with the policy that was
adopted in the FY 2021 IPPS/LTCH PPS
final rule, we stated that it would be
unnecessary to apply the trim
methodology for a fiscal year for which
a hospital’s UCC data have been
audited.
In addition to the UCC trim
methodology, we stated that we would
continue to apply a trim specific to
certain hospitals that do not have
audited FY 2018 Worksheet S–10 data
and/or audited FY 2019 Worksheet S–10
data. We noted that in rare cases,
hospitals that are not currently
projected to be DSH eligible and that do
not have audited Worksheet S–10 data
may have a potentially aberrant amount
of insured patients’ charity care costs
(line 23 column 2). Similar to the
approach initially adopted in the FY
2022 IPPS/LTCH PPS final rule (86 FR
45245 and 45246), we proposed to
continue to use a threshold of t3
standard deviations from the mean ratio
of insured patients’ charity care costs to
total uncompensated care costs (line 23
column 2 divided by line 30) and a
dollar threshold that is the median total
uncompensated care cost reported on
most recent audited cost reports for
hospitals that were projected to be DSHeligible. We stated that we continue to
believe these thresholds are appropriate,
in order to address potentially aberrant
data. However, we proposed to modify
the calculation to include Worksheet S–
10 data from IHS/Tribal hospitals and
Puerto Rico hospitals consistent with
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
our proposal to begin using Worksheet
S–10 data to determine Factor 3 for
these hospitals. We also proposed to
apply the same thresholds to identify
potentially aberrant charity care costs
data for all cost reporting years that are
used in determining Factor 3. We noted
that based on calculations from the FY
2019 reports, the threshold amounts
were similar to FY 2018 reports;
therefore, we explained that we believe
it is reasonable to use the same
thresholds to identify aberrant data for
both years. Thus, under the proposal, in
FY 2023 we would use the same
thresholds to identify potentially
aberrant data for both FY 2018 and FY
2019 reports. In addition, we proposed
to apply the same threshold amounts
originally calculated for the FY 2018
reports to identify potentially aberrant
data for subsequent fiscal years in order
to facilitate transparency and
predictability. Therefore, for FY 2023
and subsequent fiscal years, we
proposed that in the rare case that a
hospital’s insured patients’ charity care
costs are greater than $7 million and the
ratio of the hospital’s cost of insured
patient charity care (line 23 column 2)
to total uncompensated care costs (line
30) is greater than 60 percent, we would
exclude the hospital from the
prospective Factor 3 calculation. We
explained that this trim would only
impact hospitals that are not currently
projected to be DSH-eligible; and
therefore, are not part of the calculation
of the denominator of Factor 3, which
includes only uncompensated care costs
for projected DSH-eligible hospitals.
Consistent with the approach adopted
in the FY 2022 IPPS/LTCH PPS final
rule, if a hospital would be trimmed
under both the UCC trim methodology
and this alternative trim, we would
apply this trim in place of the existing
UCC trim methodology. We stated that
we continue to believe this alternative
trim more appropriately addresses
potentially aberrant insured patient
charity care costs compared to the UCC
trim methodology, because the UCC
trim is based solely on the ratio of total
uncompensated care costs to total
operating costs and does not consider
the level of insured patients’ charity
care costs.
In addition, we proposed to continue
to apply the policy adopted in the FY
2022 IPPS/LTCH PPS final rule, for the
hospitals that would be subject to this
alternative trim and are ultimately
determined to be DSH-eligible at cost
report settlement. We explained that if
a hospital subject to this trim is
ultimately determined to be DSHeligible at cost report settlement, its
PO 00000
Frm 00266
Fmt 4701
Sfmt 4700
uncompensated care payment should be
calculated only after the hospital’s
reporting of insured charity care costs
on its FY 2023 Worksheet S–10 has been
reviewed. Accordingly, the MAC would
calculate a Factor 3 for the hospital only
after reviewing the uncompensated care
information reported on Worksheet S–
10 of the hospital’s FY 2023 cost report.
Then we would calculate Factor 3 for a
hospital subject to this alternative trim
using the same methodology used to
determine Factor 3 for new hospitals.
Specifically, the numerator would
reflect the uncompensated care costs
reported on the hospital’s FY 2023 cost
report, while the denominator would
reflect the sum of the uncompensated
care costs reported on Worksheet S–10
of the FY 2019 cost reports of all DSHeligible hospitals. In addition,
consistent with our proposed approach
for new hospitals, we would apply a
scaling factor, as discussed previously,
to the Factor 3 calculation for these
hospitals. We stated that we believe
applying the scaling factor is
appropriate for purposes of calculating
Factor 3 for all hospitals, including new
hospitals and hospitals that are treated
as new hospitals, in order to improve
consistency and predictability across all
hospitals.
We did not receive any comments on
the proposed modifications to the
uncompensated care data trim
methodology. We are finalizing as
proposed.
• Summary of Methodology
In summary, under the policies we are
finalizing in this FY 2023 IPPS/LTCH
PPS final rule, for FY 2023, we will
compute Factor 3 for each hospital
using the following steps:
Step 1: Select the hospital’s longest
cost report from its Federal fiscal year
(FY) 2018 cost reports and the longest
cost report from its FY 2019 cost
reports. (Alternatively, in the rare case
when the hospital has no cost report for
a particular year because the cost report
for the previous Federal fiscal year
spanned the more recent Federal fiscal
year, the previous Federal fiscal year
cost report will be used in this step. In
the rare case, that using a previous
Federal fiscal year cost report results in
a period without a report, we will use
the prior year report, if that cost report
spanned the applicable period. (For
example, if a hospital does not have a
FY 2019 cost report because the
hospital’s FY 2018 cost report spanned
the FY 2019 time period, then we will
use the FY 2018 cost report that
spanned the FY 2019 time period for
this step. Using the same example,
where the hospital’s FY 2018 report is
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
used for the FY 2019 time period, then
we will use the hospital’s FY 2017
report if it spans some of the FY 2018
time period. In other words, we will not
use the same cost report for both the FY
2019 and the FY 2018 time periods.) In
general, we note that, for purposes of
the Factor 3 methodology, references to
a fiscal year cost report are to the cost
report that spans the relevant Federal
fiscal year period.
Step 2: Annualize the uncompensated
care costs (UCC) from Worksheet S–10
Line 30, if a cost report is more than or
less than 12 months. (If applicable, use
the statewide average CCR (urban or
rural) to calculate uncompensated care
costs.)
Step 3: Combine adjusted and/or
annualized uncompensated care costs
for hospitals that merged using the
merger policy.
Step 4: Calculate Factor 3 for all DSH
eligible hospitals using annualized
uncompensated care costs (Worksheet
S–10 Line 30) based on FY 2018 cost
report data and FY 2019 cost report data
(from Step 1, 2 or 3). New hospitals and
other hospitals that are treated as if they
are new hospitals for purposes of Factor
3 are excluded from this calculation.
Step 5: Average the Factor 3 values
from Step 4; that is, add the Factor 3
values for FY 2018 and FY 2019 for each
hospital, and divide that amount by the
number of cost reporting periods with
data to compute an average Factor 3 for
the hospital. Multiply by a scaling
factor.
For FY 2024 and subsequent fiscal
years, these steps will be calculated
using the most recent 3 years of audited
cost reports. (For example, in FY 2024,
the FY 2018, FY 2019, and FY 2020
reports would be used.)
In the FY 2023 IPPS/LTCH PPS
proposed rule, we proposed to make a
conforming change to the existing
regulation at § 412.106(g)(1)(iii)(C)(8)
and to add a new regulation at
§ 412.106(g)(1)(iii)(C)(10) to reflect our
proposal to calculate Factor 3 based on
the most recent two years of audited
data on uncompensated care costs in FY
2023. We also proposed to add
§ 412.106(g)(1)(iii)(C)(11) to reflect our
proposal to calculate Factor 3 for FY
2024 and subsequent fiscal years based
on a 3-year average of the most recent
available audited data on
uncompensated care costs.
We did not receive any comments on
these proposed changes to regulations.
We are finalizing the proposed changes
with only minor conforming changes for
internal consistency.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
(d) Per Discharge Amount of Interim
Uncompensated Care Payments
Since FY 2014, we have made interim
uncompensated care payments during
the fiscal year on a per discharge basis.
We have used a 3-year average of the
number of discharges for a hospital to
produce an estimate of the amount of
the hospital’s uncompensated care
payment per discharge. Specifically, the
hospital’s total uncompensated care
payment amount for the applicable
fiscal year, is divided by the hospital’s
historical 3-year average of discharges
computed using the most recent
available data to determine the
uncompensated care payment per
discharge for that fiscal year.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45247 and 45248), we
modified this calculation for FY 2022 to
be based on an average of FY 2018 and
FY 2019 historical discharge data, rather
than a 3-year average that included data
from FY 2018, FY 2019, and FY 2020.
We explained our belief that computing
a 3-year average with the FY 2020
discharge data would underestimate
discharges, due to the decrease in
discharges during the COVID–19
pandemic. For the same reason, we
proposed to modify this calculation for
FY 2023 to be based on the average of
FY 2018, FY 2019, and FY 2021
historical discharge data, rather than a
3-year average of the most recent 3 years
of discharge data from FY 2019, FY
2020, and FY 2021. We stated that
computing a 3-year average using the
most recent 3 years would potentially
underestimate the number of discharges
for FY 2023, due to the effects of the
COVID–19 pandemic in FY 2020, which
was the first year of the COVID–19
pandemic. Therefore, we explained our
belief that the proposed modification
may result in a better estimate of the
number of discharges during FY 2023,
for purposes of the interim
uncompensated care payment
calculation. In addition, we noted that
our proposal to include discharge data
from FY 2021 to compute this 3-year
average was consistent with the
proposed use of FY 2021 Medicare
claims in the IPPS ratesetting, as
discussed in section I.F. of the preamble
of the FY 2023 IPPS/LTCH PPS
proposed rule. Under this proposal, the
resulting 3-year average of the number
of discharges would be used to calculate
a per discharge payment amount that
will be used to make interim
uncompensated care payments to each
projected DSH-eligible hospital during
FY 2023. We also explained that the
interim uncompensated care payments
made to a hospital during the fiscal year
PO 00000
Frm 00267
Fmt 4701
Sfmt 4700
49045
will be reconciled following the end of
the year to ensure that the final payment
amount is consistent with the hospital’s
prospectively determined
uncompensated care payment for the FY
2023.
In the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58833 and 58834), we
finalized a voluntary process through
which a hospital may submit a request
to its MAC for a lower per discharge
interim uncompensated care payment
amount, including a reduction to zero,
once before the beginning of the Federal
fiscal year and/or once during the
Federal fiscal year. In conjunction with
this request, the hospital must provide
supporting documentation
demonstrating that there would likely
be a significant recoupment (for
example, 10 percent or more of the
hospital’s total uncompensated care
payment or at least $100,000) at cost
report settlement if the per discharge
amount is not lowered. For example, a
hospital might submit documentation
showing a large projected increase in
discharges during the fiscal year to
support reduction of its per discharge
uncompensated care payment amount.
As another example, a hospital might
request that its per discharge
uncompensated care payment amount
be reduced to zero midyear if the
hospital’s interim uncompensated care
payments during the year have already
surpassed the total uncompensated care
payment calculated for the hospital.
Under the policy we finalized in the
FY 2021 IPPS/LTCH PPS final rule, the
hospital’s MAC would evaluate these
requests and the supporting
documentation before the beginning of
the Federal fiscal year and/or with
midyear requests when the historical
average number of discharges is lower
than the hospital’s projected FY 2023
discharges. If following review of the
request and the supporting
documentation, the MAC agrees that
there likely would be significant
recoupment of the hospital’s interim
Medicare uncompensated care
payments at cost report settlement, the
only change that will be made is to
lower the per discharge amount either to
the amount requested by the hospital or
another amount determined by the MAC
to be appropriate to reduce the
likelihood of a substantial recoupment
at cost report settlement. If the MAC
determines it would be appropriate to
reduce the interim Medicare
uncompensated care payment per
discharge amount, that updated amount
will be used for purposes of the outlier
payment calculation for the remainder
of the Federal fiscal year. We refer
readers to the Addendum to this final
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49046
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
rule for a more detailed discussion of
the steps for determining the operating
and capital Federal payment rate and
the outlier payment calculation. No
change would be made to the total
uncompensated care payment amount
determined for the hospital on the basis
of its Factor 3. In other words, any
change to the per discharge
uncompensated care payment amount
will not change how the total
uncompensated care payment amount
will be reconciled at cost report
settlement.
Comment: A couple of commenters
recommended that CMS use the
traditional payment reconciliation
process to calculate final payments for
uncompensated care costs pursuant to
section 1886(r)(2) of the Act. These
commenters did not object to CMS using
prospective estimates, derived from the
best data available, to calculate interim
payments for uncompensated care costs.
However, the commenters stated that
interim payments should be subject to
later reconciliation based on estimates
derived from actual data from the
federal fiscal year. These same
commenters also asserted that CMS has
failed to provide a meaningful
opportunity to review and comment on
the more recent data used in developing
the final rule before the agency
publishes the final rule.
Response: Consistent with the
position that we have taken in
rulemaking for previous years, we
continue to believe that applying our
best estimates of the three factors used
in the calculation of uncompensated
care payments to determine payments
prospectively is most conducive to
administrative efficiency, finality, and
predictability in payments (78 FR
50628; 79 FR 50010; 80 FR 49518; 81 FR
56949; 82 FR 38195; 84 FR 42373; 85 FR
58833 and 86 FR 45246). We continue
to believe that, in affording the
Secretary the discretion to estimate the
three factors used to determine
uncompensated care payments and by
including a prohibition against
administrative and judicial review of
those estimates in section 1886(r)(3) of
the Act, Congress recognized the
importance of finality and predictability
under a prospective payment system. As
a result, we do not agree with the
commenters’ suggestion that we should
establish a process for reconciling our
estimates of uncompensated care
payments, which would be contrary to
the notion of a prospective payment
system. Furthermore, we note that this
rulemaking has been conducted
consistent with the requirements of the
Administrative Procedure Act and Title
XVIII of the Act. Under the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Administrative Procedure Act, a
proposed rule is required to include
either the terms or substance of the
proposed rule or a description of the
subjects and issues involved. In this
case, the FY 2023 IPPS/LTCH PPS
proposed rule included a detailed
discussion of our proposed
methodology for calculating Factor 3
and the data that would be used. We
made public the best data available at
the time of the proposed rule in order
to allow hospitals to understand the
anticipated impact of the proposed
methodology and submit comments,
and we have considered those
comments in determining our final
policies for FY 2023.
(e) Process for Notifying CMS of Merger
Updates and To Report Upload Issues
As we have done for every proposed
and final rule beginning in FY 2014, in
conjunction with this final rule, we will
publish on the CMS website a table
listing Factor 3 for all hospitals that we
estimate will receive empirically
justified Medicare DSH payments in FY
2023 (that is, those hospitals that will
receive interim uncompensated care
payments during the fiscal year), and for
the remaining subsection (d) hospitals
and subsection (d) Puerto Rico hospitals
that have the potential of receiving an
uncompensated care payment in the
event that they receive an empirically
justified Medicare DSH payment for the
fiscal year as determined at cost report
settlement. However, we note that a
Factor 3 will not be published for new
hospitals and hospitals that are subject
to the alternative trim for hospitals with
potentially aberrant data that are not
projected to be DSH-eligible.
We also will publish a supplemental
data file containing a list of the mergers
that we are aware of and the computed
uncompensated care payment for each
merged hospital. In the DSH
uncompensated care supplemental data
file, we list new hospitals and the 10
hospitals that would be subject to the
alternative trim for hospitals with
potentially aberrant data that are not
projected to be DSH-eligible, with a N/
A in the Factor 3 column.
Hospitals had 60 days from the date
of public display of the FY 2023 IPPS/
LTCH PPS proposed rule in the Federal
Register to review the table and
supplemental data file published on the
CMS website in conjunction with the
proposed rule and to notify CMS in
writing of issues related to mergers and/
or to report potential upload
discrepancies due to MAC mishandling
of Worksheet S–10 data during the
report submission process (for example,
report not reflecting audit results due to
PO 00000
Frm 00268
Fmt 4701
Sfmt 4700
MAC mishandling or most recent report
differs from previously accepted
amended report due to MAC
mishandling). We stated that comments
raising issues or concerns that are
specific to the information included in
the table and supplemental data file
could be submitted by email to the CMS
inbox at Section3133DSH@cms.hhs.gov.
We indicated that we would address
comments related to mergers and/or
reporting upload discrepancies
submitted to the CMS DSH inbox as
appropriate in the table and the
supplemental data file that we publish
on the CMS website in conjunction with
the publication of this FY 2023 IPPS/
LTCH PPS final rule. All other
comments submitted in response to our
proposed policies for determining
uncompensated care payments for FY
2023 must have been submitted in one
of the three ways found in the
ADDRESSES section of the proposed rule
before the close of the comment period
in order to be assured consideration. In
addition, we note that the CMS DSH
inbox is not intended for Worksheet S–
10 audit process related emails, which
should be directed to the MACs.
For FY 2023, we again proposed that
hospitals would have 15 business days
from the date of public display of this
FY 2023 IPPS/LTCH PPS final rule in
the Federal Register to review and
submit comments on the accuracy of the
table and supplemental data file
published in conjunction with the final
rule. Any changes to Factor 3 would be
posted on the CMS website and would
be effective beginning October 1, 2022.
We also explained that we continue to
believe that hospitals have sufficient
opportunity during the comment period
for the proposed rule to provide
information about recent and/or
pending mergers and/or to report
upload discrepancies. Hospitals do not
enter into mergers without advanced
planning. A hospital can inform CMS
during the comment period for the
proposed rule regarding any merger
activity not reflected in supplemental
file published in conjunction with the
proposed rule. As discussed in the
proposed rule, we expected to use data
from the March 2022 HCRIS extract for
the FY 2023 final rule, which
contributed to our increased confidence
that hospitals would have be able to
comment on mergers and report any
upload discrepancies during the
comment period for the FY 2023 IPPS/
LTCH PPS proposed rule. However, we
noted that in the event that there were
any remaining merger updates and/or
upload discrepancies after the final rule,
the 15 business days from the date of
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
public display of the FY 2023 IPPS/
LTCH PPS final rule deadline should
allow for the time necessary to prepare
and make any corrections to Factor 3
calculations before the beginning of the
Federal fiscal year.
We did not receive comments on the
notification process for mergers or data
upload issues. We are finalizing our
proposal to afford hospitals 15 business
days from the public display of this FY
2023 IPPS/LTCH PPS final rule to
submit via email any updated
information on mergers and/or to report
upload discrepancies. We also note that
the historical FY 2018 and FY 2019 cost
reports are publicly available on a
quarterly basis on the CMS website for
analysis and additional review of cost
report data, separate from the
supplemental data file published with
this final rule.
E. Supplemental Payment for Indian
Health Service and Tribal Hospitals and
Puerto Rico Hospitals for FY 2023 and
Subsequent Fiscal Years
In the IPPS/LTCH PPS rulemaking for
several previous fiscal years, Indian
Health Service (IHS) and Tribal
hospitals and hospitals located in
Puerto Rico have commented about the
unique challenges they face with respect
to uncompensated care due to structural
differences in health care delivery and
financing in these areas compared to the
rest of the country. In the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28396),
we referred readers to the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45242 and
45243) and the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58824 and 58825) for
a discussion of these comments. We also
explained that we appreciated the
concerns raised and the input offered by
commenters regarding the methodology
for calculating uncompensated care
payments for IHS/Tribal hospitals and
the Puerto Rico hospitals. After taking
into consideration stakeholders’
longstanding concerns and their input
on potential approaches to address these
concerns, we proposed to establish a
new permanent supplemental payment
under the IPPS for IHS/Tribal hospitals
and hospitals located in Puerto Rico. As
discussed in greater detail in the
proposed rule, we stated our belief that
the proposed new supplemental
payment would mitigate the anticipated
impact on IHS/Tribal hospitals and
hospitals located in Puerto Rico from
our proposal to discontinue the use of
low-income insured days as a proxy for
their uncompensated care costs for
purposes of determining Factor 3 of the
uncompensated care payment
methodology by providing for an
additional payment to these hospitals
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
that would be determined based upon
the difference between the amount of
the uncompensated care payment
determined for the hospital using
Worksheet S–10 data and an
approximation of the amount the
hospital would have received if we had
continued to use low-income insured
days as a proxy for uncompensated care.
As background, beginning in the FY
2018 IPPS/LTCH PPS final rule when
we first included Worksheet S–10 data
in the calculation of Factor 3, and
continuing through the FY 2022 IPPS/
LTCH PPS final rule, we relied on the
authority under section 1886(r)(2)(C)(i)
of the Act to use alternative data that is
a better proxy for the costs of hospitals
for treating the uninsured in order to
determine Factor 3 for IHS/Tribal and
Puerto Rico hospitals using low-income
insured days as a proxy for
uncompensated care costs. Since FY
2019, Factor 3 for these hospitals has
been determined using FY 2013
Medicaid days and the most recent
available data on SSI days. We believed
this approach was appropriate as the FY
2013 Medicaid days data reflect the
most recent available information
regarding these hospitals’ low-income
insured days before any expansion of
Medicaid. In addition, because we
continued to use low-income insured
patient days as a proxy for
uncompensated care for Puerto Rico
hospitals and residents of Puerto Rico
are not eligible for SSI benefits, we
continued to use a proxy for SSI days
for Puerto Rico hospitals consisting of
14 percent of the hospital’s Medicaid
days, as initially adopted in the FY 2017
IPPS/LTCH PPS final rule (81 FR 56953
through 56956). However, we
recognized that our proposal, which we
are finalizing in this final rule, to
discontinue the use of low-income
insured days as a proxy for
uncompensated care costs would result
in a significant financial disruption to
the IHS/Tribal hospitals and hospitals
located in Puerto Rico. We explained
that, for the vast majority of these
hospitals, the proposal to use
uncompensated care data reported on
Worksheet S–10 to determine Factor 3
of the uncompensated care payment
methodology would be expected to
result in an approximately 90 to 100
percent reduction in uncompensated
care payments for FY 2023 compared to
FY 2022. We referred readers to section
I.H. of Appendix A of the proposed rule
for a discussion of the anticipated
impact of the proposal to use
uncompensated care costs from
Worksheet S–10 to determine
uncompensated care payments for IHS/
PO 00000
Frm 00269
Fmt 4701
Sfmt 4700
49047
Tribal hospitals and Puerto Rico
hospitals and the proposal to establish
a new supplemental payment for these
hospitals.
In consideration of the unique
circumstances faced by the hospitals
and the comments received from IHS/
Tribal hospitals and Puerto Rico
hospitals in response to prior
rulemaking, raising concerns regarding
financial stability in the event of a
change in the data used to determine
Factor 3, we proposed to use our
exceptions and adjustments authority
under section 1886(d)(5)(I) of the Act to
establish a new permanent
supplemental payment under the IPPS
for IHS/Tribal hospitals and hospitals
located in Puerto Rico, beginning in FY
2023. Section 1886(d)(5)(I) of the Act
authorizes the Secretary to provide by
regulation for such other exceptions and
adjustments to the payment amounts
under section 1886(d) of the Act as the
Secretary deems appropriate. We have
determined, after taking into
consideration stakeholders’ comments
from prior rulemakings, that the
supplemental payment is necessary so
as not to cause undue long-term
financial disruption to these hospitals as
a result of our proposal to discontinue
the use of low-income insured days as
a proxy for uncompensated care in
determining Factor 3 for IHS/Tribal
hospitals and Puerto Rico hospitals
beginning in FY 2023. In the proposed
rule, we stated our belief that the
proposed supplemental payment would
help to mitigate the anticipated impact
of the proposed changes to the
uncompensated care payment
methodology for these hospitals and
therefore prevent undue long-term
financial disruption for these providers.
We also stated that the proposed new
supplemental payment would not
change in any way the DSH payment
methodology under section
1886(d)(5)(F) of the Act or the
uncompensated care payment
methodology under section 1886(r) of
the Act. Therefore, the total
uncompensated care payment amount
would not be affected by this proposal
to establish a supplemental payment for
IHS/Tribal and hospitals located in
Puerto Rico nor would there be any
impact on the amount of the
uncompensated care payment
determined for each DSH-eligible
hospital under § 412.106(g)(1) of the
regulations.
We proposed that for IHS and Tribal
hospitals and hospitals located in
Puerto Rico for which Factor 3 of the
uncompensated care payment
methodology was determined using the
low-income insured days proxy in FY
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49048
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
2022, we would calculate a
supplemental payment as follows. We
would use the hospital’s FY 2022
uncompensated care payment as the
starting point for this calculation. We
explained that using the FY 2022
uncompensated care payment would be
an appropriate starting point because FY
2022 is the most recent year for which
we used low-income insured days data
in the determination of uncompensated
care payments for IHS/Tribal hospitals
and Puerto Rico hospitals and the
purpose of the proposed supplemental
payment is to avoid undue long-term
financial disruption to these hospitals as
a result of our proposal to discontinue
the use of low-income insured days as
a proxy for uncompensated care
beginning in FY 2023. The base year
amount would be calculated as the
hospital’s FY 2022 uncompensated care
payment adjusted by one plus the
percent change in the total
uncompensated care amount between
the applicable year (for example, FY
2023 for purposes of this rulemaking)
and FY 2022, where the total
uncompensated care amount for a year
is determined as the product of Factor
1 and Factor 2 for the applicable year.
For example, if a hospital’s FY 2022
uncompensated care payment was 1
million, and the percent change
between FY 2023 and FY 2022 total
uncompensated care payments was
negative 9.1 percent, then the hospital’s
FY 2023 base year amount would be 1
million * (1+(¥0.091)), which is
909,000. For the hospitals that were not
projected to be DSH eligible in FY 2022,
we proposed to use the uncompensated
care payment that the hospital would
receive, if the hospital were to be
determined to be DSH eligible in FY
2022 at cost report settlement. For
purposes of the proposed rule, the
percent change between the proposed
FY 2023 uncompensated care amount
and final FY 2022 uncompensated care
amount was projected to be negative 9.1
percent. (This negative 9.1 percent
change was calculated based on the
difference between the proposed FY
2023 uncompensated care amount of
approximately $6.537 billion and the
final FY 2022 uncompensated care
amount of approximately $7.192 billion,
divided by the final FY 2022
uncompensated care amount).
Therefore, we proposed to calculate
each hospital’s base year amount for FY
2023 by multiplying its FY 2022
uncompensated care amount by 0.909
(1–0.091). We note that in order to
determine the base year amount for a
future fiscal year, the calculation would
be the hospital’s FY2022
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
uncompensated care amount multiplied
by one plus the percent change in total
uncompensated care payments between
FY 2022 and the applicable fiscal year.
The hospital’s supplemental payment
for a fiscal year would then be
determined as the difference between
the hospital’s base year amount and its
uncompensated care payment for the
applicable fiscal year as determined
under § 412.106(g). If the base year
amount is equal to or lower than the
hospital’s uncompensated care payment
for the current fiscal year, the hospital
would not receive a supplemental
payment because the hospital would not
be experiencing financial disruption in
that year as a result of the use of
uncompensated care data from the
Worksheet S–10 in determining Factor 3
of the uncompensated care payment
methodology.
We proposed to align the eligibility
and payment processes for the new
supplemental payment with the
processes used to make uncompensated
care payments. Consistent with the
process for determining eligibility to
receive interim uncompensated care
payments adopted in the FY 2014 IPPS/
LTCH final rule, for the supplemental
payment, we proposed to base eligibility
to receive interim supplemental
payments on a projection of DSH
eligibility for the applicable fiscal year.
In addition, consistent with the
approach that is used to calculate
interim uncompensated care payments
on a per discharge basis, for the
supplemental payment, we proposed to
use an average of historical discharges
to calculate a per discharge amount for
interim supplemental payments. We
referred readers to the FY 2014 IPPS/
LTCH PPS final rule for additional
background and discussion of
uncompensated care payment processes
(78 FR 50643 through 50647).
Consistent with our proposal to use 3
years of historical discharges to
determine interim uncompensated care
payments for a fiscal year, we proposed
that the amount of a hospital’s
supplemental payment calculated for a
fiscal year would be divided by the
hospital’s historical 3-year average of
discharges computed using the most
recent available data to determine an
estimated per discharge payment
amount.
For FY 2023, we proposed to use FY
2018, FY 2019, and FY 2021 discharge
data to determine a hospital’s historical
3-year average of discharges, because we
continued to believe the FY 2020
discharge data would underestimate
discharges, due to the effects of the
COVID–19 pandemic in FY 2020. In
addition, consistent with the policy of
PO 00000
Frm 00270
Fmt 4701
Sfmt 4700
including per-discharge uncompensated
care payment amounts in the outlier
calculation, which was initially adopted
in the FY 2014 IPPS/LTCH PPS final
rule, we proposed to use our authority
under section 1886(d)(5)(I) of the Act to
include the per-discharge supplemental
payment in the outlier payment
determination under section
1886(d)(5)(A) of the Act. We referred
readers to the Addendum to the
proposed rule for further discussion of
the outlier payment calculation.
Consistent with the process used to
reconcile interim uncompensated care
payments, we proposed that the MAC
would reconcile the interim
supplemental payments at cost report
settlement to ensure that the hospital
receives the full amount of the
supplemental payment that was
determined prior to the start of the fiscal
year. Consistent with the process used
for cost reporting periods that span
multiple Federal fiscal years, we
proposed that a pro rata supplemental
payment calculation may be made if the
hospital’s cost reporting period differs
from the Federal fiscal year. Thus, the
final supplemental payment amounts
that would be included on a cost report
spanning two Federal fiscal years would
be the pro rata share of the
supplemental payment associated with
each Federal fiscal year. This pro rata
share would be determined based on the
proportion of the applicable Federal
fiscal year that is included in that cost
reporting period. We referred readers to
the FY 2014 interim final rule for
additional background and discussion
of the processes for determining pro rata
uncompensated care payments (78 FR
61191 through 61196).
We proposed that the MAC would
make a final determination with respect
to a hospital’s eligibility to receive the
supplemental payment for a fiscal year,
in conjunction with its final
determination of the hospital’s
eligibility for DSH payments and
uncompensated care payments for that
fiscal year. We noted that if a hospital
is determined not to be DSH eligible for
a fiscal year then the hospital would not
be eligible to receive a supplemental
payment for that fiscal year. In the
proposed rule, we stated our belief that
linking eligibility for the supplemental
payment to eligibility for DSH payments
and the uncompensated care payment is
appropriate because a hospital that is
not eligible to receive an
uncompensated care payment for a
fiscal year would not experience any
financial disruption due to the
discontinuation of the low-income
insured days proxy and the use of
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Worksheet S–10 data in determining
Factor 3 for that fiscal year.
In addition, we proposed that IHS/
Tribal hospitals and Puerto Rico
hospitals that do not have a FY 2022
Factor 3 amount determined under
§ 412.106(g)(1)(iii)(C)(9) using the lowincome insured days proxy or that are
new hospitals that begin participating in
the Medicare program on or after
October 1, 2022, would not be eligible
to receive the supplemental payment.
We explained that these hospitals will
not experience any reduction to their
uncompensated care payments due to
the proposed discontinuation of the
low-income insured days proxy because
they are not currently receiving
uncompensated care payments
determined using the proxy. We
proposed to redesignate the existing
provision at § 412.106(h) as § 412.106(i)
and to add a new provision at
§ 412.106(h) to reflect the methodology
for calculating the supplemental
payment for FY 2023 and subsequent
fiscal years.
We sought comments on our proposal
to establish this new supplemental
payment for IHS/Tribal hospitals and
Puerto Rico hospitals. As discussed in
section IV.D.3. of this final rule, we also
solicited comments on alternatives both
to our proposal to use data on
uncompensated care costs from the
Worksheet S–10 to determine Factor 3
for IHS/Tribal hospitals and Puerto Rico
hospitals and to the continued use of
low-income insured days as a proxy for
the uncompensated care costs of these
hospitals. In addition, we sought
comments on how to best measure and
define the uncompensated care costs
associated with these hospitals that
might not otherwise be captured in
Factor 3 calculations based on
Worksheet S–10 data. Given the close
interrelationship between our proposed
changes to the methodology for
determining Factor 3 of the
uncompensated care payment
methodology for IHS/Tribal hospitals
and Puerto Rico hospitals and the
proposed new supplemental payment
for these hospitals, we discuss the
comments received on both proposals in
this section of this final rule.
Comment: The majority of
commenters expressed appreciation for
CMS’ creativity in devising the
proposed new supplemental payment to
mitigate the anticipated financial impact
from the discontinuation of low-income
insured days as a proxy for
uncompensated care costs for IHS and
Tribal hospitals and hospitals located in
Puerto Rico. Some commenters stated
there are longstanding inequities in DSH
and uncompensated care calculations
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
for Puerto Rico hospitals due to the lack
of an SSI benefit for residents of the U.S.
territories. These commenters also
suggested an alternative methodology
for calculating the supplemental
payment for hospitals in Puerto Rico.
Specifically, the commenters
recommended that CMS calculate the
supplemental payment for Puerto Rico
hospitals using a base year amount
determined from Medicaid days and an
SSI days proxy of at least 40 percent but
no less than 35 percent of Medicaid
days, instead of the current 14 percent.
Commenters further suggested that CMS
determine a second empirical DSH
eligibility threshold for hospitals in
Puerto Rico based on the suggested SSI
days proxy of 40 percent of Medicaid
days, such that if the sum of the
Medicaid fraction and the SSI days
proxy exceeds 15 percent, then the
hospital would be eligible to receive
uncompensated care payments and the
new supplemental payment. A
commenter, in support of this
alternative methodology, noted that,
under the proposed supplemental
payment methodology, Puerto Rico
hospitals would receive an 11.06
percent reduction in Medicare DSH
payments in FY 2023 as compared to FY
2022. The same commenter noted that
the reduction in DSH payments could
also reduce Medicare Advantage (MA)
benchmarks for Puerto Rico in 2024
and, as a result, impact approximately
630,000 Medicare beneficiaries enrolled
in MA plans, including 280,000 dualeligible individuals.
Another commenter expressed
support for the proposed
discontinuation of low-income insured
days as a proxy for uncompensated care
costs for IHS and Tribal hospitals and
hospitals located in Puerto Rico.
However, this commenter recommended
that CMS reduce the size of
supplemental payments to hospitals in
Puerto Rico to an empirically justified
level. This commenter noted that the
continued use of Medicaid days as a
proxy for uncompensated care costs in
Puerto Rico has resulted in a substantial
increase in uncompensated care
payments. Further, this commenter
stated that maintaining the overall
payments at the proposed levels through
the supplemental payment would create
high Medicare profit margins at Puerto
Rico hospitals and distort the MA
benchmarks, as it would increase FFS
spending by more than 25 percent above
what it would have been if Puerto Rico
hospitals received uncompensated care
payments based only on their reported
uncompensated care costs. The
commenter also opposed the
disbursement of the supplemental
PO 00000
Frm 00271
Fmt 4701
Sfmt 4700
49049
payments as an add-on payment to the
IPPS payment rates for hospitals in
Puerto Rico and recommended that
uncompensated care payments not be
factored into MA benchmarks.
A few commenters expressed support
for the proposed supplemental payment
without suggesting enhancements to the
policy. One of these commenters
emphasized the importance of
implementing the supplemental
payment as a permanent policy.
A commenter opposed CMS’ proposal
to discontinue the calculation of
uncompensated care costs using low
income insured days for hospitals in
Puerto Rico without a separate policy in
place for receiving the supplemental
payment. Instead, the commenter
suggested that CMS use a phased
approach such that the agency would
continue to calculate uncompensated
care costs for hospitals in Puerto Rico
using low income insured days until a
future rulemaking. The commenter
further suggested that CMS eventually
phase in payments calculated using
Worksheet S–10 along with the
supplemental payment.
Another commenter specifically
opposed the exclusion of new hospitals
in Puerto Rico from receiving the
supplemental payment. The same
commenter noted that because hospitals
newly established after October 2013
did not have Medicaid days for the
period before the Affordable Care Act
was implemented, the uncompensated
care costs for these hospitals are already
calculated using Worksheet S–10 but
with no supplemental payments. The
commenter also noted that because
hospitals established after October 2013
operate under the same conditions as
hospitals established before October
2013, these hospitals should receive the
proposed supplemental payments in a
manner similar to those hospitals for
which we proposed to transition to the
use of Worksheet S–10 data to
determine uncompensated care costs
starting in FY 2023. Finally, this
commenter requested that CMS consider
calculating uncompensated care costs
for an impacted Puerto Rico hospital
(established after 2013) for the period
from FY 2020 through FY 2022 using
Medicaid days and not Worksheet S–10
data.
Response: We appreciate this input
from commenters regarding the proposal
to establish a new supplement payment
for hospitals in Puerto Rico and IHS and
Tribal hospitals and the concerns raised
regarding the proposed changes to the
data used to determine uncompensated
care costs for these hospitals. We
continue to recognize the unique
financial circumstances and challenges
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49050
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
faced by Puerto Rico hospitals related to
uncompensated care cost reporting on
Worksheet S–10. With regard to the
recommendation to calculate the
supplemental payment using a base year
amount determined using Medicaid
days and an SSI days proxy of at least
40 percent, we note that since FY 2019,
Factor 3 for hospitals in Puerto Rico has
been determined using FY 2013
Medicaid days and the most recent
available data on SSI days and because
residents of Puerto Rico are not eligible
for SSI benefits, we continued to use a
proxy for SSI days for Puerto Rico
hospitals consisting of 14 percent of the
hospital’s Medicaid days, as initially
adopted in the FY 2017 IPPS/LTCH PPS
final rule (81 FR 56953 through 56956).
We also note that we did not receive
comments expressing concerns
regarding this policy when it was
finalized for FY 2019. However, for the
reasons explained in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28391),
we have determined that data on low
income insured days is no longer a good
proxy for the costs of hospitals in
treating the uninsured and that we can
no longer conclude that alternative data
to the data on uncompensated care costs
reported on the Worksheet S–10 are
available for Puerto Rico hospitals that
are a better proxy for the costs of these
hospitals in treating the uninsured.
With respect to the comment
recommending that we adopt a second
eligibility threshold for empirically
justified DSH payments based on the
suggested SSI days proxy of 40 percent
of Medicaid days, we note that in the FY
2023 IPPS/LTCH PPS proposed rule, we
did not propose to adopt a proxy for
Puerto Rico hospitals’ SSI days for
purposes of determining eligibility to
receive DSH payments and calculating
the empirically justified Medicare DSH
payment. Therefore, we consider this
comment to be outside the scope of the
proposed rule. We note, however, that
while section 1886(r)(2)(C)(i) of the Act
allows for the use of alternative data as
a proxy to determine the costs of
subsection (d) hospitals for treating the
uninsured for purposes of determining
uncompensated care payments, section
1886(r)(1) of the Act requires the
Secretary to pay an empirically justified
DSH payment that is equal to 25 percent
of the amount of the Medicare DSH
payment that would otherwise be made
under section 1886(d)(5)(F) of the Act to
a subsection (d) hospital. Section
1886(d)(5)(F)(vi) of the Act, which
prescribes the disproportionate patient
percentage used to determine
empirically justified Medicare DSH
payments, specifically refers to the SSI
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
days in the Medicare fraction and does
not allow the use of alternative data.
Accordingly, we disagree with the
commenter’s assertion that there is legal
support for CMS to use a proxy for
Puerto Rico hospitals’ SSI days in the
calculation of the empirically justified
Medicare DSH payment.
Regarding the comment that hospitals
in Puerto Rico hospitals will receive an
11.06 percent reduction in Medicare
DSH payments in FY 2023 as compared
to FY 2022, we note that, under the
policies we are finalizing in this final
rule, the combined amount of
uncompensated care payments and
supplemental payments for FY 2023
will be less than 11.06 percent below
the amount of uncompensated care
payments for FY 2022. We refer readers
to the discussion of the impact of our
final policies regarding Medicare
uncompensated care payments and the
new supplemental payment in Section
I.H. of Appendix A of this final rule. In
addition, we note that the base year
amount used in calculating the
supplemental payment will change over
time relative to the total uncompensated
care amount. Accordingly, for years in
which there is an increase in the total
uncompensated care total amount, the
hospital’s supplemental payment
calculation would reflect a higher base
year amount, and for the years in which
there is a decrease in the total
uncompensated care total amount, the
hospital’s supplemental payment
calculation would reflect a lower base
year amount.
With regard to the comment that the
supplemental payment would impact
the Medicare Advantage benchmarks,
we believe the combined amount of
empirically justified DSH payments,
uncompensated care payments, and
supplemental payments to IHS/Tribal
hospitals and Puerto Rico hospitals will
be comparable to the amount these
hospitals would have received if CMS
had continued to use the low-income
days proxy to determine Factor 3 of the
uncompensated care payment
methodology. As a result, the new
supplemental payments are expected to
have no impact on MA benchmarks in
Puerto Rico. Given that the MA
capitation calculations are on a different
timeline than the annual rulemaking for
the IPPS (that is, calendar year rather
than Federal fiscal year), the 2024 MA
benchmarks would be the first time any
effects would be reflected.
We disagree with the commenter who
noted that there is no mechanism in
place for receiving the supplemental
payment. We refer readers to the FY
2014 IPPS/LTCH PPS proposed rule for
additional background and discussion
PO 00000
Frm 00272
Fmt 4701
Sfmt 4700
of uncompensated care payment
processes (78 FR 50643 through 50647).
As discussed in the FY 2023 IPPS/LTCH
PPS proposed rule, we proposed to
determine an estimated per discharge
add-on payment amount based on the
amount of a hospital’s supplemental
payment calculated for a fiscal year
divided by the hospital’s historical
three-year average of discharges,
computed using the most recently
available data.
Regarding the concerns raised with
respect to our proposal that hospitals in
Puerto Rico established after October
2013 would be ineligible to receive the
supplemental payment, we note that, as
explained in the FY 2023 IPPS/LTCH
PPS proposed rule, we proposed to
establish the supplemental payment to
mitigate any long-term financial
disruption as a result of our proposal to
discontinue the use of low-income
insured days as a proxy for
uncompensated care costs in
determining Factor 3. Uncompensated
care costs for Puerto Rico hospitals
established after October 2013 are
already determined using Worksheet S–
10 data. As a result, these hospitals will
not experience any reduction to their
uncompensated care payments due to
the proposed discontinuation of the
low-income insured days proxy because
they are not currently receiving
uncompensated care payments
determined using the proxy. Thus, we
do not believe it is appropriate to
modify the proposed eligibility criteria
for the supplemental payment to
include these hospitals at this time.
However, we intend to monitor
uncompensated care payments to these
hospitals and may revisit this issue in
future rulemaking.
Regarding the commenter that
requested that CMS consider calculating
the uncompensated care costs for FY
2020 through FY 2022 for a Puerto Rico
hospital (established after 2013) using
Medicaid days and not Worksheet S–10
data, we believe this comment is out of
scope of this rulemaking. We note that
the policy for new hospitals in Puerto
Rico was initially adopted in the FY
2019 IPPS/LTCH PPS final rule, and we
did not propose any modifications to
this policy in the FY 2023 IPPS/LTCH
PPS proposed rule.
Comment: Commenters expressed
support for CMS’ proposal to establish
a new supplemental payment for IHS
and Tribal hospitals to mitigate the
anticipated impact of the agency’s
proposal to discontinue the use of lowincome insured days as a proxy to
calculate uncompensated care payments
for these hospitals. Commenters
requested that CMS confirm that the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
supplemental payments would result in
an equal or higher uncompensated care
payment amount than in prior years.
Commenters also opposed the exclusion
of new IHS and Tribal hospitals from
receiving the supplemental payment,
with another commenter suggesting that
CMS finalize the supplemental payment
for existing IHS/Tribal hospitals as an
interim measure while the agency
devises an alternate approach that
would be applicable to all IHS/Tribal
hospitals. These commenters also urged
CMS to provide an option for hospitals
to opt out of the new supplemental
payment methodology in the future
years if they preferred payment in a
manner similar to non-Tribal hospitals.
Response: We appreciate the input
from commenters on our proposal to
establish a new supplemental payment
for IHS and Tribal hospitals. We
continue to recognize the unique nature
of these hospitals and the special
circumstances they face.
Regarding commenters’ request that
CMS confirm that the proposed
supplemental payment will result in an
overall payment amount that is equal to
or higher than the uncompensated care
payments for prior years determined
using the low-income days proxy, we
note that the base year amount used to
calculate a hospital’s supplemental
payment will change over time relative
to changes in the total uncompensated
care amount. For years in which there
is an increase in the total
uncompensated care total amount, the
hospital’s supplemental payment
calculation would use a higher base year
amount, and for the years in which
there is a decrease in the total
uncompensated care total amount, the
hospital’s supplemental payment
calculation would use a lower base year
amount.
Regarding the concerns raised by
commenters with respect to our
proposal to limit the new supplemental
payment to existing IHS/Tribal hospitals
that have a Factor 3 amount for FY 2022
determined using the low-income
insured days proxy, we note that, as
explained in the FY 2023 IPPS/LTCH
PPS proposed rule, we proposed to
establish the supplemental payment to
mitigate any long-term financial
disruption as a result of our proposal to
discontinue the use of low-income
insured days as a proxy for
uncompensated care costs in
determining Factor 3. However, new
IHS/Tribal hospitals for which
uncompensated care costs have not
previously been determined using the
low-income insured days proxy will not
experience any reduction to their
uncompensated care payments due to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the proposed discontinuation of the
proxy. Thus, we do not believe it is
appropriate to extend the supplemental
payment to include new IHS/Tribal
hospitals at this time. However, we will
monitor uncompensated care payments
to these hospitals and may revisit this
issue in future rulemaking.
In regard to an option for hospitals to
opt out of the new supplemental
payment methodology in the future
years, we believe that no modification to
our proposed methodology is necessary,
because, under the proposed
supplemental payment methodology,
which we are finalizing in this final
rule, an IHS/Tribal hospital or Puerto
Rico hospital will receive the full
uncompensated care payment
determined using its Worksheet S–10
data. A hospital will only receive the
supplemental payment if it increases the
overall amount payable to the hospital,
so there does not appear to be a clear
reason for a hospital to opt out of the
supplemental payment.
After consideration of the comments
received, we are finalizing both our
proposal to discontinue the use of the
low-income insured days proxy and to
rely solely on Worksheet S–10 data to
calculate Factor 3 of the uncompensated
care payment methodology for IHS/
Tribal hospitals and Puerto Rico
hospitals and our proposal to establish
a new supplemental payment for Puerto
Rico hospitals and IHS/Tribal hospitals,
without modification. We are also
finalizing the proposed provision at
§ 412.106(h) governing the new
supplemental payment without
modification.
The percent change between the final
FY 2023 uncompensated care amount
and final FY 2022 uncompensated care
amount is negative 4.4 percent. (This
negative 4.4 percent change is
calculated based on the difference
between the final FY 2023
uncompensated care amount of
approximately $6.874 billion and the
final FY 2022 uncompensated care
amount of approximately $7.192 billion,
divided by the final FY 2022
uncompensated care amount).
Therefore, consistent with the
methodology in § 412.106(h)(3)(i), we
will calculate each hospital’s base year
amount for FY 2023 by multiplying its
FY 2022 uncompensated care amount
by 0.956 (1¥0.044).
F. Medicare Disproportionate Share
Hospital (DSH) Payments: Counting
Days Associated With Section 1115
Demonstrations in the Medicaid
Fraction (§ 412.106)
In the FY 2023 IPPS/LTCH PPS
proposed rule, we proposed revisions to
PO 00000
Frm 00273
Fmt 4701
Sfmt 4700
49051
the regulation relating to the treatment
of section 1115 demonstration days for
purposes of the DSH adjustment (87 FR
28398 through 28402). The agency
received numerous, detailed comments
on this proposal. We thank the
commenters for their input on the
proposal. Due to the number and nature
of the comments that we received on
our proposal, and after further
consideration of the issue, we have
determined not to move forward with
the current proposal. We expect to
revisit the treatment of section 1115
demonstration days for purposes of the
DSH adjustment in future rulemaking,
and we encourage interested parties to
review any future proposal on this issue
and to submit their comments at that
time.
V. Other Decisions and Changes to the
IPPS for Operating Costs
A. Changes in the Inpatient Hospital
Update for FY 2023 (§ 412.64(d))
1. FY 2023 Inpatient Hospital Update
In accordance with section
1886(b)(3)(B)(i) of the Act, each year we
update the national standardized
amount for inpatient hospital operating
costs by a factor called the ‘‘applicable
percentage increase.’’ For FY 2023, we
stated in the proposed rule that we are
setting the applicable percentage
increase by applying the adjustments
listed in this section in the same
sequence as we did for FY 2022. (We
note that section 1886(b)(3)(B)(xii) of the
Act required an additional reduction
each year only for FYs 2010 through
2019.) Specifically, consistent with
section 1886(b)(3)(B) of the Act, as
amended by sections 3401(a) and
10319(a) of the Affordable Care Act, we
stated that we are setting the applicable
percentage increase by applying the
following adjustments in the following
sequence. The applicable percentage
increase under the IPPS for FY 2023 is
equal to the rate-of-increase in the
hospital market basket for IPPS
hospitals in all areas, subject to all of
the following:
• A reduction of one-quarter of the
applicable percentage increase (prior to
the application of other statutory
adjustments; also referred to as the
market basket update or rate-of-increase
(with no adjustments)) for hospitals that
fail to submit quality information under
rules established by the Secretary in
accordance with section
1886(b)(3)(B)(viii) of the Act.
• A reduction of three-quarters of the
applicable percentage increase (prior to
the application of other statutory
adjustments; also referred to as the
market basket update or rate-of-increase
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49052
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(with no adjustments)) for hospitals not
considered to be meaningful EHR users
in accordance with section
1886(b)(3)(B)(ix) of the Act.
• An adjustment based on changes in
economy-wide multifactor productivity
(MFP) (the productivity adjustment).
Section 1886(b)(3)(B)(xi) of the Act, as
added by section 3401(a) of the
Affordable Care Act, states that
application of the productivity
adjustment may result in the applicable
percentage increase being less than zero.
We note, in compliance with section
404 of the MMA, in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45194
through 45204), we replaced the 2014based IPPS operating and capital market
baskets with the rebased and revised
2018-based IPPS operating and capital
market baskets beginning in FY 2022.
We proposed to base the FY 2023
market basket update used to determine
the applicable percentage increase for
the IPPS on IHS Global Inc.’s (IGI’s)
fourth quarter 2021 forecast of the 2018based IPPS market basket rate-ofincrease with historical data through
third quarter 2021, which was estimated
to be 3.1 percent. We also proposed that
if more recent data subsequently became
available (for example, a more recent
estimate of the market basket update),
we would use such data, if appropriate,
to determine the FY 2023 market basket
update in the final rule.
Comment: Several commenters were
concerned the proposed market basket
update was not accurately reflecting
hospital input inflation citing many
examples including ongoing labor
shortages, supply chain disruptions,
prices for medical equipment, and the
impact of Ukraine/Russia war. They
urged CMS to adjust its market basket
update methodology for FY 2023 to
adjust for more recent data and to
further adjust its estimate to
appropriately capture significant
inflationary trends that will further fuel
rising hospital operating costs but may
not yet be fully captured in IGI’s
updated market basket forecast in the
second quarter of 2022. Commenters
requested CMS recognize that hospital
inflation will generally lag economywide inflation and that the expectations
for sustained inflation should be
recognized in the projection of the
hospital market basket for FY 2023.
Several commenters stated the proposed
market basket update is a time-lagged
estimate that uses historical data to
forecast into the future. The commenters
stated that when historical data is no
longer a good predictor of future
changes, the market basket becomes
inadequate. A commenter stated that the
end of calendar year 2021 into calendar
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
year 2022 should not be considered a
steady-state economic environment that
is a continuance of past trends. A
commenter encouraged CMS to err on
the side of steadily increasing inflation
into 2023 rather than any material
deceleration assumption.
Other commenters urged CMS to rely
on more recent forecasts to determine
the FY 2023 update. A commenter noted
CBO May 2022 baseline projections
which had a market basket increase that
is 1.1 percentage points higher than the
proposed FY 2023 IPPS market basket
percentage increase. Several
commenters requested that CMS review
other inflation data sources such as the
Consumer Price Index (CPI) and the core
Personal Consumption Expenditures
deflator, and suggested that the market
basket increase at least match or exceed
these rates of increases.
Response: Section 1886(b)(3)(B)(iii) of
the Act states the Secretary shall update
IPPS payments based on a market basket
percentage increase that reflects an
index of appropriately weighted
indicators of changes in wages and
prices that are representative of the mix
of goods and services included in such
inpatient hospital services. The 2018based IPPS market basket is a fixedweight, Laspeyres-type price index that
measures the change in price, over time,
of the same mix of goods and services
purchased by hospitals in the base
period. The general inflation measures
cited by the commenters would not
reflect this same mix of goods and
services.
We agree with the commenters that
recent higher inflationary trends have
impacted the outlook for price growth
over the next several quarters. At the
time of the FY 2023 IPPS/LTCH PPS
proposed rule, based on IGI’s fourth
quarter 2021 forecast with historical
data through third quarter 2021, IGI
forecasted the 2018-based IPPS market
basket update of 3.1 percent for FY 2023
reflecting forecasted compensation
prices of 3.8 percent (by comparison,
compensation price growth in the 2018based IPPS market basket averaged 2.2
percent from 2012–2021). As stated
previously, in the FY 2023 IPPS/LTCH
PPS proposed rule, we proposed that if
more recent data became available, we
would use such data, if appropriate, to
derive the final FY 2023 IPPS market
basket update for the final rule. For this
final rule, we now have an updated
forecast of the price proxies underlying
the market basket that incorporates
more recent historical data and reflects
a revised outlook regarding the U.S.
economy (including the more recent
historical CPI growth, impacts of the
Russia/Ukraine war, current
PO 00000
Frm 00274
Fmt 4701
Sfmt 4700
expectations regarding changes to
Federal Reserve interest rates, and tight
labor markets). Based on IGI’s second
quarter 2022 forecast with historical
data through first quarter 2022, we are
projecting a FY 2023 IPPS market basket
update of 4.1 percent (reflecting
forecasted compensation price growth of
4.8 percent) and productivity
adjustment of 0.3 percentage point.
Therefore, as discussed further in this
section and after consideration of the
comments received, for FY 2023, the
final applicable percentage increase for
a hospital that submitted quality data
and is a meaningful EHR user is 3.8
percent (4.1 percent less 0.3 percentage
point), compared to the 2.7 percent that
was proposed. We note that the final FY
2023 IPPS market basket growth rate of
4.1 percent would be the highest market
basket update implemented in an IPPS
final rule going back to FY 1998.
Comment: Several commenters
suggested that CMS use alternative
sources of data that they stated better
reflect input price inflation to calculate
the FY 2023 market basket update. A
commenter stated that in absence of
such data, CMS is urged to consider an
alternative approach to better align the
market basket updates with increases in
the costs needed to care for Medicare
beneficiaries. Several commenters
encouraged CMS to implement a higher
market basket update than proposed,
reflecting alternative sources of cost
data such as the Medicare cost reports.
A commenter requested that CMS
provide a market basket update of at
least 5 percent.
Several commenters proposed that
CMS apply a market basket increase of
approximately 8 percent representing
estimated trends in allowable Medicare
costs per risk-adjusted discharge from
the Medicare cost reports from FY 2019
to FY 2020. To support this method,
commenters provided the language in
the IPPS statute and stated that they
believe that Medicare cost report data
meets the statutory requirement as these
data capture all allowable costs,
including personnel costs and excluding
non-operating costs that comprise
routine, ancillary, and special care unit
inpatient hospital services. The
commenter stated that given that these
data comprise all the costs—on a
volume and risk-adjusted basis—
necessary to deliver hospital care it
represents ‘‘appropriately weighted
indicators of changes in wages and
prices which are representative of the
mix of good and services . . .’’
necessary to provide inpatient hospital
care to Medicare beneficiaries.
Commenters stated their belief that
Medicare cost report data are a more
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
accurate projection of the cost inflation
anticipated by hospitals during FY 2023
than the forecast IGI data used in the
proposed rule. The commenters further
noted that changes in volume and
intensity are accounted for in the market
basket update when CMS rebases or
revises it, which they stated is
infrequent, typically occurring once
every four years. They believe their
proposed methodology of using
Medicare cost report data would fully
account for changes in volume and
acuity annually, thus resulting in a more
accurate proxy.
Another commenter analyzed
Medicare cost report data and found
that compensation costs increased by
more than the IPPS market basket
updates of 3.0 percent and 2.4 percent
for FYs 2020 and 2021, respectively.
The commenter recommended that CMS
adjust the IGI compensation price
indices and the overall inpatient price
indices based on the percent change in
compensation costs as derived from the
Medicare cost reports.
A commenter recommended that CMS
use its exceptions and adjustments
authority to substitute Premier Inc. data
for the IGI forecast to provide hospitals
with an increased payment update in
FY 2023 to accurately reflect labor costs.
Additionally, the commenter
recommended that CMS’ Office of the
Actuary reevaluate the data sources that
it uses for calculating labor costs and
consider adopting new or supplemental
data sources in future rulemaking that
more accurately reflect the cost of labor,
such as more real time data from the
hospital community. While the
commenter stated that they were unable
to forecast a market basket update for
FY 2023, they noted the substantial
impact a 10 percent increase in the labor
components would have on the
historical market basket for FY 2021,
increasing the estimate by several
percentage points under this
hypothetical scenario.
Response: We believe the 2018-based
IPPS market basket increase adequately
reflects the average change in the price
of goods and services hospitals purchase
in order to provide IPPS medical
services, and is technically appropriate
to use as the market basket percentage
increase in accordance with section
1886(b)(3)(B)(iii). As described in the
FY 2022 IPPS/LTCH PPS final rule (86
FR 45194 through 45213), the IPPS
market basket is a fixed-weight,
Laspeyres-type index that measures
price changes over time and would not
reflect increases in costs associated with
changes in the volume or intensity of
input goods and services. As such, the
IPPS market basket increase would
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
reflect the prospective price pressures
described by the commenters as
increasing during a high inflation period
(such as faster wage price growth or
higher energy prices), but would
inherently not reflect other factors that
might increase the level of costs, such
as the quantity of labor used or any
shifts between contract and staff nurses
(which would be reflected in the
Medicare cost report data). We note that
cost changes (that is, the product of
price and quantities) would only be
captured in the market basket weights
when the index is rebased and the base
year is updated to a more recent time
period.
We disagree with the commenters that
costs as reported on the Medicare cost
report are suitable for determining the
trend in compensation prices for the
market basket update. Section
1886(b)(3)(B)(iii) of the Act states the
Secretary shall estimate a market basket
percentage increase based on an index
of appropriately weighted indicators of
changes in wages and prices which are
representative of the mix of goods and
services included in such inpatient
hospital services. While the current
IPPS market basket percentage increase
captures price changes associated with
the goods and services hospitals
purchase in providing care, the
Medicare cost report data also reflects
factors that are beyond those that impact
wage or price growth. For instance,
overall costs as reported by hospitals
would also reflect changes in the mix of
inputs used to provide services; since
2020, observed IPPS case-mix (and
associated higher payments to hospitals)
has increased faster than in prior years
and would likely reflect the use of more
skilled care needed to provide these
services.
Regarding commenters’ request that
CMS consider other methods and data
sources to calculate the final rule market
basket update, we believe the 2018based IPPS market basket continues to
appropriately reflect IPPS cost
structures and we believe the price
proxies used (such as those from BLS
that reflect wage and benefit price
growth) are an appropriate
representation of price changes for the
inputs used by hospitals in providing
services. We further note that we did
not propose to use other methods or
data sources to calculate the final
market basket update for FY 2023.
Consistent with our proposal, we have
used more recent historical data and an
updated forecast (that reflects a revised
inflationary outlook) to calculate a final
IPPS market basket percentage increase
for FY 2023 of 4.1 percent, which is one
percentage point higher than the
PO 00000
Frm 00275
Fmt 4701
Sfmt 4700
49053
proposed market basket percentage
increase of 3.1 percent set forth in the
FY 2023 IPPS/LTCH PPS proposed rule.
Comment: Several commenters also
expressed concerns regarding the use of
BLS’ Employment Cost Index (ECI),
which accounts for 53 percent of the
market basket, stating it did not
accurately reflect hospitals’
compensation costs after the labor
market changes triggered by the PHE. A
commenter stated that this claim can be
evidenced by comparing growth in labor
costs from the Medicare cost report data
to the ECI growth. The commenters also
state that hospitals have faced a shortage
of local labor as the PHE has progressed
and have had to increasingly turn to
contract labor, particularly for the
nursing professions, which in turn has
contributed to increased compensation
costs. The commenters noted that CMS’s
proposed market basket update reflected
a 3.8 percent increase in compensation,
which they believe does not accurately
reflect changes in current labor costs
that they believe are not transitory.
Commenters noted that the ECI does
not capture inflation in contract labor
compensation while the hospital market
basket does include contract labor costs
when calculating the compensation cost
weights and stated that including the
contract labor costs along with other
compensation costs assumes contract
labor compensation growth will grow at
the same rate as non-contract labor
compensation. The commenters stated
that this assumption is not supported by
evidence citing published studies.
Commenters also noted analysis by
Premier Inc., which showed faster
hourly labor rates than the ECI for FY
2021.
Response: As previously discussed,
section 1886(b)(3)(B)(iii) of the Act
states the Secretary shall estimate a
market basket percentage increase based
on an index of appropriately weighted
indicators of changes in wages and
prices which are representative of the
mix of goods and services included in
such inpatient hospital services. The
2018-based IPPS market basket is a
fixed-weight, Laspeyres-type price
index that measures the change in price,
over time, of the same mix of goods and
services purchased in the base period.
Any changes in the quantity or mix of
goods and services (that is, intensity)
purchased over time relative to a base
period are not measured. This type of
IPPS market basket has been in place
since the implementation of the IPPS as
well as used for other CMS market
baskets.
For the compensation cost weight in
the 2018-based IPPS market basket
(which includes salaried and contract
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49054
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
labor employees), we use the ECI for
wages and salaries and benefits for all
civilian hospital workers to proxy the
price increases of labor for IPPS
hospitals. The ECI (published by the
BLS) measures the change in the hourly
labor cost to employers, independent of
the influence of employment shifts
among occupations and industry
categories. We note that the Medicare
cost report data shows contract labor
hours account for about 3 percent of
total compensation hours (reflecting
employed and contract labor staff) for
IPPS hospitals in 2020. Data through
2021 are incomplete at this time.
Therefore, while we acknowledge that
the ECI measures only reflect price
changes for employed staff, we believe
that the ECI for hospital workers is
accurately reflecting the price change
associated with the labor used to
provide hospital care (as employed
workers’ hours account for 97 percent of
hospital compensation hours) and
appropriately does not reflect other
factors that might affect labor costs.
Therefore, we believe it continues to be
an appropriate measure to use in the
IPPS market basket. We also note that
based on IGI’s second quarter 2022
forecast with historical data through
first quarter 2022, compensation price
growth (using the ECIs) for FY 2023 is
now projected to be 4.8 percent, which
is 1.0 percentage point higher than
projected price growth at the time of the
FY 2023 IPPS/LTCH PPS proposed rule
(3.8 percent).
Comment: A commenter encouraged
CMS to consider whether additional
changes are needed regarding the
rebasing and revising of the market
basket, given data from 2018 was relied
upon in the FY 2022 IPPS/LTCH PPS
final rule to determine the appropriate
mix of goods and services, which may
have been impacted by COVID–19. For
example, they stated that during the
pandemic there has been increased use
of personal protective equipment, yet
this utilization would not be captured in
the market basket, which was rebased
and revised in the FY 2022 IPPS/LTCH
PPS final rule.
Response: As described previously,
the IPPS market basket measures price
changes (including changes in the prices
for wages and salaries) over time and
would not reflect increases in costs
associated with changes in the volume
or intensity of input goods and services
until the market basket is rebased. The
IPPS market basket was last rebased in
the FY 2022 IPPS/LTCH PPS final rule
using 2018 Medicare cost reports (86 FR
45194 through 45207), the most recent
year of complete data available at the
time of the rebasing. We note that we
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
did not propose to rebase the IPPS
market basket in the FY 2023 IPPS/
LTCH PPS proposed rule. However, we
did review more recent Medicare cost
report data available for IPPS hospitals
submitted as of March 2022, which
includes data for 2019–2020. The
Medicare cost report data (which does
not allow us to separately identify costs
for-PPE) showed slight decreases in the
compensation cost weight in 2019 and
2020 resulting in a compensation cost
weight that is roughly 1 percentage
point less than the 2018-based IPPS
market basket cost weight. Data through
2021 are incomplete at this time. The
data also showed slight increases over
the 2018 to 2020 time period in the
pharmaceuticals cost weight and home
office cost weight of about 0.3
percentage point each. Based on this
preliminary analysis, the impact on the
cost weights through 2020 are minimal
and it is unclear whether these trends
(particularly the compensation cost
weight) through 2020 are reflective of
sustained shifts in the cost structure for
hospitals or whether they were
temporary as a result of the PHE.
Therefore, we continue to believe it is
premature at this time to use more
recent Medicare cost report data to
derive a rebased and revised IPPS
market basket. We will continue to
monitor these data and any changes to
the IPPS market basket will be proposed
in future rulemaking.
Comment: Several commenters
expressed concerns about the market
basket update calculations. Commenters
stated that CMS calculates the percent
change by dividing the average input
price indices in the most recent four
quarters by the average input price
index in the previous four quarters as
derived from the most recently available
IGI forecast. However, the commenter
stated that CMS does not consider the
difference between the base year
estimates (from the time when prior
year payment rates are finalized) and
updated estimates of the base year
indices since the prior year’s market
basket update calculation. Therefore,
they stated this current update method
does not account for substantial forecast
errors driven by an unusually fast
acceleration of the inflation rate such as
occurred in FY 2021. They urge CMS to
leverage its exceptions and adjustments
authority under section 1886(d)(5)(I)(i)
of the Act to modify its methodology for
FY 2023 to account for the substantial
forecast error in FYs 2021 and 2022. A
commenter added that it believes the
understatement of the hospital market
basket for FY 2021 and FY 2022 and
potentially FY 2023 as well is such an
PO 00000
Frm 00276
Fmt 4701
Sfmt 4700
occasion for using the exceptions and
adjustments authority. The commenter
stated that Premier data collected
directly from hospitals is showing a 10
percent increase in 2022 to date for
hospital compensation (67.6 percent of
the market basket) compared to the 3.8
percent being forecasted by IGI. The
commenter recommended CMS make a
one-time only forecast error correction
on the FY 2021 and FY 2022 market
basket of a combined 1.9 percentage
points for FY 2023 using the exceptions
and adjustments authority. The
commenter also recommended that CMS
use its exceptions and adjustments
authority to substitute Premier data for
the IGI forecast to provide hospitals
with an increased payment update in
FY 2023 to accurately reflect labor costs.
A commenter urged CMS to consider
a one-time adjustment to ensure that the
FY 2023 rate increase is applied to a
base rate that more accurately
incorporates actual inflation during the
pandemic. The commenter cited the
unprecedented nature of the pandemic
and its extraordinary impact on hospital
costs alongside record inflation for the
basis of this one-time adjustment.
Response: Section 1886(b)(3)(B) of the
Act sets forth the update to the
standardized amounts based on the
applicable percentage increase.
Although the statute does not include a
forecast error adjustment, commenters
requested that CMS use its exceptions
and adjustments authority under section
1886(d)(5)(I)(i) of the Act to modify its
methodology to account for the forecast
error in FYs 2021 and 2022. We note
that we did not propose to use our
authority under section 1886(d)(5)(I)(i)
of the Act to apply a forecast correction
in updating the IPPS rates for FY 2023.
While there is no precedent to adjust for
market basket forecast error in the IPPS
operating payment update, the forecast
error for a market basket update is equal
to the actual market basket increase for
a given year less the forecasted market
basket increase. Due to the uncertainty
regarding future price trends, forecast
errors can be both positive and negative.
For example, the FY 2020 IPPS forecast
error was ¥1.0 percentage point, and
the FY 2021 IPPS forecast error was +0.7
percentage point; FY 2022 historical
data are not yet available to calculate a
forecast error for FY 2022. As we have
discussed in past rulemaking, we
believe that an important goal of a PPS
is predictability. For these reasons, we
do not believe it is appropriate to
include adjustments to the market
basket update for future years based on
the difference between the actual and
forecasted market basket increase in
prior years. With regard to the comment
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
recommending the use of the Premier
data, we refer to our response to this
comment as previously discussed earlier
in this section, regarding why we
believe the 2018-based IPPS market
basket increase adequately reflects the
average change in the price of goods and
services hospitals purchase in order to
provide IPPS medical services, and is
technically appropriate to use as the
market basket percentage increase in
accordance with section
1886(b)(3)(B)(iii).
We thank the commenters for their
comments. After consideration of the
comments received and consistent with
our proposal, we are finalizing to use
more recent data to determine the FY
2023 market basket update for the final
rule. Specifically, based on more recent
data available, we determined final
applicable percentage increases to the
standardized amount for FY 2023, as
specified in the table that appears later
in this section.
In the FY 2012 IPPS/LTCH PPS final
rule (76 FR 51689 through 51692), we
finalized our methodology for
calculating and applying the
productivity adjustment. As we
explained in that rule, section
1886(b)(3)(B)(xi)(II) of the Act, as added
by section 3401(a) of the Affordable
Care Act, defines this productivity
adjustment as equal to the 10-year
moving average of changes in annual
economy-wide, private nonfarm
business MFP (as projected by the
Secretary for the 10-year period ending
with the applicable fiscal year, year,
cost reporting period, or other annual
period). The U.S. Department of Labor’s
Bureau of Labor Statistics (BLS)
publishes the official measures of
private nonfarm business productivity
for the U.S. economy. We note that
previously the productivity measure
referenced in section
1886(b)(3)(B)(xi)(II) was published by
BLS as private nonfarm business
multifactor productivity. Beginning
with the November 18, 2021 release of
productivity data, BLS replaced the
term multifactor productivity (MFP)
with total factor productivity (TFP). BLS
noted that this is a change in
terminology only and will not affect the
data or methodology. As a result of the
BLS name change, the productivity
measure referenced in section
1886(b)(3)(B)(xi)(II) is now published by
BLS as private nonfarm business total
factor productivity. However, as
mentioned, the data and methods are
unchanged. Please see www.bls.gov for
the BLS historical published TFP data.
A complete description of IGI’s TFP
projection methodology is available on
the CMS website at https://
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
www.cms.gov/Research-Statistics-Dataand-Systems/Statistics-Trends-andReports/MedicareProgramRatesStats/
MarketBasketResearch. In addition, we
note that beginning with the FY 2022
IPPS/LTCH PPS final rule, we refer to
this adjustment as the productivity
adjustment rather than the MFP
adjustment to more closely track the
statutory language in section
1886(b)(3)(B)(xi)(II) of the Act. We note
that the adjustment continues to rely on
the same underlying data and
methodology.
For FY 2023, we proposed a
productivity adjustment of 0.4 percent.
Similar to the proposed market basket
update, for the proposed rule, the
estimate of the proposed FY 2023
productivity adjustment was based on
IGI’s fourth quarter 2021 forecast. As
noted previously, we proposed that if
more recent data subsequently became
available, we would use such data, if
appropriate, to determine the FY 2023
productivity adjustment for the final
rule.
Comment: Several commenters
requested that CMS use its ‘‘special
exceptions and adjustments’’ authority
under section 1886(d)(5)(I)(i) of the Act
to eliminate the productivity adjustment
for FY 2023. A commenter requested
that CMS work with Congress to
permanently eliminate the productivity
adjustment to the annual hospital
payment updates. Another commenter
stated that, if CMS does not use more
recent figures from BLS on economywide non-farm total factor productivity
when determining the adjustment to the
IPPS market basket update for FY 2023,
then the highly unusual circumstances
of the COVID–19 pandemic are
sufficient reason for the Secretary to
invoke section 1886(d)(5)(I)(i)
‘‘exceptions and adjustments’’ authority
to provide a one-time adjustment that
offsets application of the otherwise
applicable productivity adjustment for
FY 2023.
A commenter requested that CMS use
its ‘‘exceptions and adjustments’’
authority under section 1886(d)(5)(I)(i)
of the Act to remove the productivity
adjustment for any fiscal year that was
covered under PHE determination (for
example, 2020, 2021, and 2022) from
the calculation of market basket update
for FY 2023 and any year thereafter.
A commenter recommended that CMS
withhold the proposed ¥0.4 percent
productivity adjustment until a federal
fiscal year in which hospitals are not
operating under the public health
emergency (PHE).
Response: While we appreciate the
commenters’ concerns, section
1886(b)(3)(B)(xi)(I) of the Act requires
PO 00000
Frm 00277
Fmt 4701
Sfmt 4700
49055
the application of the productivity
adjustment described in section
1886(b)(3)(B)(xi)(II) of the Act to the
IPPS market basket update when
determining the applicable percentage
increase. Section 1886(d)(5)(I)(i) of the
Act authorizes the Secretary to provide
by regulation for such other exceptions
and adjustments to the payment
amounts under section 1886(d) of the
Act as the Secretary deems appropriate.
We further note that we did not
propose to use our authority under
section 1886(d)(5)(I)(i) of the Act in the
FY 2023 IPPS/LTCH PPS proposed rule
to offset the productivity adjustment for
FY 2023. Based on the updated forecast
for this final rule, and as discussed
elsewhere, we are projecting a FY 2023
IPPS market basket update of 4.1
percent and a productivity adjustment
of 0.3 percentage point for this final
rule, as compared to the proposed
market basket update of 3.1 percent and
proposed productivity adjustment of 0.4
percentage point set forth in the
proposed rule. Additionally, we note
Congress has provided other funding to
providers as a result of the COVID–19
PHE. Specifically, the CARES Act
provided additional payments for cases
of COVID–19 under the IPPS and also
created the Provider Relief Fund to
reimburse providers, including IPPS
providers, for increased expenses or lost
revenue attributable to COVID–19.
We thank the commenters for their
comments. However, as previously
noted, section 1886(b)(3)(B)(xi)(II) of the
Act, as added by section 3401(a) of the
Affordable Care Act, requires a
productivity adjustment to the IPPS
market basket update when determining
the applicable percentage increase.
Consistent with our proposal, we are
using more recent data to determine the
FY 2023 productivity adjustment for the
final rule. Specifically, based on IGI’s
second quarter 2022 forecast, we are
projecting a FY 2023 IPPS market basket
update of 4.1 percent and productivity
adjustment of 0.3 percentage point.
Therefore, as discussed further in this
section and after consideration of the
comments received, for FY 2023, the
final IPPS applicable percentage
increase for a hospital that submitted
quality data and is a meaningful EHR
user is 3.8 percent (4.1 percent less 0.3
percentage point).
Comment: Several commenters
expressed concerns about the
productivity adjustment. A commenter
stated that the measure of productivity
used by CMS is intended to ensure
payments more accurately reflect the
true cost of providing patient care and
effectively assumes the hospital field
can mirror productivity gains across the
E:\FR\FM\10AUR2.SGM
10AUR2
49056
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
private nonfarm business sector. Several
commenters stated that this has not
been their experience during the
pandemic. Commenters also stated that
even before the pandemic, CMS Office
of the Actuary questioned the wisdom
of the underlying assumption in their
analysis that compares private non-farm
total factor productivity growth measure
and a hospital-specific measure (https://
www.cms.gov/files/document/
productivity-memo.pdf). Commenters
also stated that the latest data indicates
a decrease in productivity, not gains,
citing the latest BLS release of labor
productivity data. Commenters had
strong concerns about the proposed
productivity adjustment given the
extreme and uncertain circumstances in
which their hospitals and health
systems are currently operating. Several
commenters requested CMS use the
latest BLS data when determining the
productivity adjustment for FY 2023.
Response: Section 1886(b)(3)(B)(xi)(II)
of the Act requires the productivity
adjustment be equal to the 10-year
moving average of changes in annual
economy-wide private nonfarm business
total factor productivity (as projected by
the Secretary for the 10-year period
ending with the applicable fiscal year,
year, cost reporting period, or other
annual period). For the FY 2023 IPPS/
LTCH PPS proposed rule, based on IGI’s
fourth quarter 2021 forecast, the
productivity adjustment was projected
to be 0.4 percentage point for FY 2023.
For this final rule, based on IGI’s second
quarter 2022 forecast, we are updating
the productivity adjustment to reflect
more recent historical data as published
by BLS as well as a revised economic
outlook for FY 2022 and FY 2023. Using
this more recent forecast, the FY 2023
productivity adjustment based on the
10-year moving average growth in
economy-wide total factor productivity
for the period ending FY 2023 is
currently estimated to be 0.3 percent.
We thank the commenters for their
comments. After consideration of the
comments received and consistent with
our proposal, we are finalizing as
proposed to use more recent data to
determine the FY 2023 productivity
adjustment for the final rule.
Based on more recent data available
for this FY 2023 IPPS/LTCH PPS final
rule (that is, IGI’s second quarter 2022
forecast of the 2018-based IPPS market
basket rate-of-increase with historical
data through the first quarter of 2022),
we estimate that the FY 2023 market
basket update used to determine the
applicable percentage increase for the
IPPS is 4.1 percent. Based on more
recent data available for this FY 2023
IPPS/LTCH PPS final rule (that is, IGI’s
second quarter 2022 forecast of the
productivity adjustment), the current
estimate of the productivity adjustment
for FY 2023 is 0.3 percentage point.
As previously discussed, based on the
more recent data available, for this final
rule, we have determined four final
applicable percentage increases to the
standardized amount for FY 2023. For
FY 2023, depending on whether a
hospital submits quality data under the
rules established in accordance with
section 1886(b)(3)(B)(viii) of the Act
(hereafter referred to as a hospital that
submits quality data) and is a
meaningful EHR user under section
1886(b)(3)(B)(ix) of the Act (hereafter
referred to as a hospital that is a
meaningful EHR user), there are four
possible applicable percentage increases
that can be applied to the standardized
amount, as specified in this table.
FY 2023 APPLICABLE PERCENTAGE INCREASES FOR THE IPPS
khammond on DSKJM1Z7X2PROD with RULES2
Market Basket Rate-of-Increase
Adjustment for Failure to Submit Quality Data
under Section 1886(b)(3)(B)(viii) of the Act
Adjustment for Failure to be a Meaningful EHR
User under Section 1886(b)(3)(B)(ix) of the Act
Productivity Adjustment under Section
1886(b)(3)(B)(xi) of the Act
Applicable Percentage Increase Applied to
Standardized Amount
In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42344), we revised our
regulations at 42 CFR 412.64(d) to
reflect the current law for the update for
FY 2020 and subsequent fiscal years.
Specifically, in accordance with section
1886(b)(3)(B) of the Act, we added
paragraph (d)(1)(viii) to § 412.64 to set
forth the applicable percentage increase
to the operating standardized amount
for FY 2020 and subsequent fiscal years
as the percentage increase in the market
basket index, subject to the reductions
specified under § 412.64(d)(2) for a
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Hospital
Submitted
Quality Data
and is NOT a
Meaningful
EHR User
4.1
Hospital Did
NOT Submit
Quality Data
and is a
Meaningful
EHR User
4.1
0
0
-1.025
-1.025
0
-3.075
0
-3.075
-0.3
-0.3
-0.3
-0.3
3.8
0.725
2.775
-0.3
hospital that does not submit quality
data and § 412.64(d)(3) for a hospital
that is not a meaningful EHR user, less
a productivity adjustment. (As
previously noted, section
1886(b)(3)(B)(xii) of the Act required an
additional reduction each year only for
FYs 2010 through 2019.)
Section 1886(b)(3)(B)(iv) of the Act
provides that the applicable percentage
increase to the hospital-specific rates for
SCHs equals the applicable percentage
increase set forth in section
1886(b)(3)(B)(i) of the Act (that is, the
PO 00000
Frm 00278
Fmt 4701
Sfmt 4700
Hospital Did NOT
Submit Quality
Data and is NOT
a Meaningful
EHR User
4.1
same update factor as for all other
hospitals subject to the IPPS). Therefore,
the update to the hospital-specific rates
for SCHs also is subject to section
1886(b)(3)(B)(i) of the Act, as amended
by sections 3401(a) and 10319(a) of the
Affordable Care Act.
Under current law, the MDH program
is effective for discharges on or before
September 30, 2022, as discussed in the
FY 2019 IPPS/LTCH PPS final rule (83
FR 41429 through 41430). Therefore,
under current law, the MDH program
will expire at the end of FY 2022. We
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.126
FY2023
Hospital
Submitted
Quality Data
and is a
Meaningful
EHR User
4.1
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
refer readers to section V.D. of the
preamble of this final rule for further
discussion of the expiration of the MDH
program.
For FY 2023, we proposed the
following updates to the hospitalspecific rates applicable to SCHs: a
proposed update of 2.7 percent for a
hospital that submits quality data and is
a meaningful EHR user; a proposed
update of 0.375 percent for a hospital
that submits quality data and is not a
meaningful EHR user; a proposed
update of 1.925 percent for a hospital
that fails to submit quality data and is
a meaningful EHR user; and a proposed
update of ¥0.4 percent for a hospital
that fails to submit quality data and is
not an meaningful EHR user. We
proposed that if more recent data
subsequently became available (for
example, a more recent estimate of the
market basket update and the
productivity adjustment), we would use
such data, if appropriate, to determine
the update in the final rule.
We did not receive any public
comments on our proposed updates to
hospital-specific rates applicable to
SCHs. The general comments we
received on the proposed FY 2023
update (including the proposed market
basket update and productivity
adjustment) are discussed earlier in this
section. For FY 2023, we are finalizing
the proposal to determine the update to
the hospital specific rates for SCHs in
this final rule using the more recent
available data, as previously discussed.
For this final rule, based on more
recent available data, we are finalizing
the following updates to the hospital
specific rates applicable to SCHs: An
update of 3.8 percent for a hospital that
submits quality data and is a meaningful
EHR user; an update of 0.725 percent for
a hospital that submits quality data and
is not a meaningful EHR user; an update
of 2.775 percent for a hospital that fails
to submit quality data and is a
meaningful EHR user; and an update of
¥0.3 percent for a hospital that fails to
submit quality data and is not a
meaningful EHR user.
2. FY 2023 Puerto Rico Hospital Update
Section 602 of Public Law 114–113
amended section 1886(n)(6)(B) of the
Act to specify that subsection (d) Puerto
Rico hospitals are eligible for incentive
payments for the meaningful use of
certified EHR technology, effective
beginning FY 2016. In addition, section
1886(n)(6)(B) of the Act was amended to
specify that the adjustments to the
applicable percentage increase under
section 1886(b)(3)(B)(ix) of the Act
apply to subsection (d) Puerto Rico
hospitals that are not meaningful EHR
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
users, effective beginning FY 2022.
Accordingly, for FY 2022, section
1886(b)(3)(B)(ix) of the Act in
conjunction with section 602(d) of
Public Law 114–113 requires that any
subsection (d) Puerto Rico hospital that
is not a meaningful EHR user as defined
in section 1886(n)(3) of the Act and not
subject to an exception under section
1886(b)(3)(B)(ix) of the Act will have
‘‘three-quarters’’ of the applicable
percentage increase (prior to the
application of other statutory
adjustments), or three-quarters of the
applicable market basket rate-ofincrease, reduced by 331⁄3 percent. The
reduction to three-quarters of the
applicable percentage increase for
subsection (d) Puerto Rico hospitals that
are not meaningful EHR users increases
to 662⁄3 percent for FY 2023, and, for FY
2024 and subsequent fiscal years, to 100
percent. (We note that section
1886(b)(3)(B)(viii) of the Act, which
specifies the adjustment to the
applicable percentage increase for
‘‘subsection (d)’’ hospitals that do not
submit quality data under the rules
established by the Secretary, is not
applicable to hospitals located in Puerto
Rico.) The regulations at 42 CFR
412.64(d)(3)(ii) reflect the current law
for the update for subsection (d) Puerto
Rico hospitals for FY 2022 and
subsequent fiscal years. In the FY 2019
IPPS/LTCH PPS final rule, we finalized
the payment reductions (83 FR 41674).
For FY 2023, consistent with section
1886(b)(3)(B) of the Act, as amended by
section 602 of Public Law 114–113, we
are setting the applicable percentage
increase for Puerto Rico hospitals by
applying the following adjustments in
the following sequence. Specifically, the
applicable percentage increase under
the IPPS for Puerto Rico hospitals will
be equal to the rate of-increase in the
hospital market basket for IPPS
hospitals in all areas, subject to a 662⁄3
percent reduction to three-fourths of the
applicable percentage increase (prior to
the application of other statutory
adjustments; also referred to as the
market basket update or rate-of-increase
(with no adjustments)) for Puerto Rico
hospitals not considered to be
meaningful EHR users in accordance
with section 1886(b)(3)(B)(ix) of the Act,
and then subject to the productivity
adjustment at section 1886(b)(3)(B)(xi)
of the Act. As noted previously, section
1886(b)(3)(B)(xi) of the Act states that
application of the productivity
adjustment may result in the applicable
percentage increase being less than zero.
Based on IGI’s fourth quarter 2021
forecast of the 2018-based IPPS market
basket update with historical data
through third quarter 2021, in the FY
PO 00000
Frm 00279
Fmt 4701
Sfmt 4700
49057
2023 IPPS/LTCH PPS proposed rule, in
accordance with section 1886(b)(3)(B) of
the Act, as discussed previously, for
Puerto Rico hospitals we proposed a
market basket update of 3.1 percent and
a productivity adjustment of 0.4
percent. Therefore, for FY 2023,
depending on whether a Puerto Rico
hospital is a meaningful EHR user, we
stated there would be two possible
proposed applicable percentage
increases that could be applied to the
standardized amount. Based on these
data, we determined the following
proposed applicable percentage
increases to the standardized amount for
FY 2023 for Puerto Rico hospitals:
• For a Puerto Rico hospital that is a
meaningful EHR user, we proposed an
applicable percentage increase to the FY
2023 operating standardized amount of
2.7 percent (that is, the FY 2023
estimate of the proposed market basket
rate-of-increase of 3.1 percent less an
adjustment of 0.4 percentage point for
the proposed productivity adjustment).
• For a Puerto Rico hospital that is
not a meaningful EHR user, we
proposed an applicable percentage
increase to the operating standardized
amount of 1.15 percent (that is, the FY
2023 estimate of the proposed market
basket rate-of-increase of 3.1 percent,
less an adjustment of 1.55 percentage
point (the proposed market basket rateof-increase of 3.1 percent × 0.75 × (2⁄3)
for failure to be a meaningful EHR user),
and less an adjustment of 0.4 percentage
point for the proposed productivity
adjustment).
We did not receive any public
comments on our proposed updates to
the standardized amount for FY 2023 for
Puerto Rico hospitals. The general
comments we received on the proposed
FY 2023 update (including the proposed
market basket update and productivity
adjustment) are discussed in greater
detail earlier in this section. For FY
2023, we are finalizing the proposal to
determine the update to the
standardized amount for FY 2023 for
Puerto Rico hospitals in this final rule
using the more recent available data, as
previously discussed.
As previously discussed in section
V.A.1, based on more recent data
available for this final rule (that is, IGI’s
second quarter 2022 forecast of the
2018-based IPPS market basket rate-ofincrease with historical data through the
first quarter of 2022), we estimate that
the FY 2023 market basket update used
to determine the applicable percentage
increase for the IPPS is 4.1 percent and
the productivity adjustment is 0.3
percent. For FY 2023, depending on
whether a Puerto Rico hospital is a
meaningful EHR user, there are two
E:\FR\FM\10AUR2.SGM
10AUR2
49058
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
possible applicable percentage increases
that can be applied to the standardized
amount. Based on these data,
accordance with section 1886(b)(3)(B) of
the Act, we determined the following
applicable percentage increases to the
standardized amount for FY 2023 for
Puerto Rico hospitals:
• For a Puerto Rico hospital that is a
meaningful EHR user, an applicable
operating standardized amount of 1.75
percent (that is, the FY 2023 estimate of
the market basket rate-of-increase of 4.1
percent, less an adjustment of 2.05
percentage point (the market basket rateof-increase of 4.1 percent × 0.75 × (2⁄3)
for failure to be a meaningful EHR user),
and less an adjustment of 0.3 percentage
point for the productivity adjustment).
percentage increase to the FY 2023
operating standardized amount of 3.8
percent (that is, the FY 2023 estimate of
the market basket rate-of-increase of 4.1
percent less an adjustment of 0.3
percentage point for the productivity
adjustment).
• For a Puerto Rico hospital that is
not a meaningful EHR user, an
applicable percentage increase to the
FY 2023 APPLICABLE PERCENTAGE INCREASES FOR PUERTO RICO
HOSPITALS PAID UNDER THE IPPS
B. Rural Referral Centers (RRCs) Annual
Updates to Case-Mix Index (CMI) and
Discharge Criteria (§ 412.96)
Under the authority of section
1886(d)(5)(C)(i) of the Act, the
regulations at § 412.96 set forth the
criteria that a hospital must meet in
order to qualify under the IPPS as a
rural referral center (RRC). RRCs receive
special treatment under both the DSH
payment adjustment and the criteria for
geographic reclassification.
Section 402 of Public Law 108–173
raised the DSH payment adjustment for
RRCs such that they are not subject to
the 12-percent cap on DSH payments
that is applicable to other rural
hospitals. RRCs also are not subject to
the proximity criteria when applying for
geographic reclassification. In addition,
they do not have to meet the
requirement that a hospital’s average
hourly wage must exceed, by a certain
percentage, the average hourly wage of
the labor market area in which the
hospital is located.
Section 4202(b) of Public Law 105–33
states, in part, that any hospital
classified as an RRC by the Secretary for
FY 1991 shall be classified as such an
RRC for FY 1998 and each subsequent
fiscal year. In the August 29, 1997, IPPS
final rule with comment period (62 FR
45999), we reinstated RRC status for all
hospitals that lost that status due to
triennial review or MGCRB
reclassification. However, we did not
reinstate the status of hospitals that lost
RRC status because they were now
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Hospital is not a
Meaningful
EHR User
4.1
0
-2.05
-0.3
-0.3
3.8
1.75
urban for all purposes because of the
OMB designation of their geographic
area as urban. Subsequently, in the
August 1, 2000 IPPS final rule (65 FR
47089), we indicated that we were
revisiting that decision. Specifically, we
stated that we would permit hospitals
that previously qualified as an RRC and
lost their status due to OMB
redesignation of the county in which
they are located from rural to urban, to
be reinstated as an RRC. Otherwise, a
hospital seeking RRC status must satisfy
all of the other applicable criteria. We
use the definitions of ‘‘urban’’ and
‘‘rural’’ specified in subpart D of 42 CFR
part 412. One of the criteria under
which a hospital may qualify as an RRC
is to have 275 or more beds available for
use (§ 412.96(b)(1)(ii)). A rural hospital
that does not meet the bed size
requirement can qualify as an RRC if the
hospital meets two mandatory
prerequisites (a minimum case-mix
index (CMI) and a minimum number of
discharges), and at least one of three
optional criteria (relating to specialty
composition of medical staff, source of
inpatients, or referral volume). (We refer
readers to § 412.96(c)(1) through (5) and
the September 30, 1988, Federal
Register (53 FR 38513) for additional
discussion.) With respect to the two
mandatory prerequisites, a hospital may
be classified as an RRC if—
• The hospital’s CMI is at least equal
to the lower of the median CMI for
urban hospitals in its census region,
excluding hospitals with approved
PO 00000
Frm 00280
Fmt 4701
Sfmt 4700
teaching programs, or the median CMI
for all urban hospitals nationally; and
• The hospital’s number of discharges
is at least 5,000 per year, or, if fewer, the
median number of discharges for urban
hospitals in the census region in which
the hospital is located. The number of
discharges criterion for an osteopathic
hospital is at least 3,000 discharges per
year, as specified in section
1886(d)(5)(C)(i) of the Act.
In the FY 2022 final rule (86 FR
45217), in light of the COVID–19 PHE,
we amended the regulations at
§ 412.96(h)(1) to provide for the use of
the best available data rather than the
latest available data in calculating the
national and regional CMI criteria. We
also amended the regulations at
§ 412.96(c)(1) to indicate that the
individual hospital’s CMI value for
discharges during the same Federal
fiscal year used to compute the national
and regional CMI values is used for
purposes of determining whether a
hospital qualifies for RRC classification.
We also amended the regulations
§ 412.96(i)(1) and (2), which describe
the methodology for calculating the
number of discharges criteria, to provide
for the use of the best available data
rather than the latest available or most
recent data when calculating the
regional discharges for RRC
classification.
1. Case-Mix Index (CMI)
Section 412.96(c)(1) provides that
CMS establish updated national and
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.127
khammond on DSKJM1Z7X2PROD with RULES2
FY2023
Market Basket Rate-of-Increase
Adjustment for Failure to be a Meaningful EHR
User under Section 1886(b)(3)(B)(ix) of the Act
Productivity Adjustment under Section
1886(b)(3)(B)(xi) of the Act
Applicable Percentage Increase Applied to
Standardized Amount
Hospital is a
Meaningful
EHR User
4.1
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
1.
2.
3.
4.
5.
6.
7.
8.
9.
3. Discharges
khammond on DSKJM1Z7X2PROD with RULES2
the FY 2023 final rule to reflect the
updated FY 2021 MedPAR file, which
will contain data from additional bills
received through March 2022.
Comment: Commenters supported our
proposal to use FY 2021 data to
calculate the national and regional
median CMI values for FY 2023.
Response: We appreciate the
commenters’ support.
Therefore, based on the best available
data (FY 2021 bills received through
March 2022), in addition to meeting
other criteria, if rural hospitals with
fewer than 275 beds are to qualify for
initial RRC status for cost reporting
periods beginning on or after October 1,
2022, they must have a CMI value for
FY 2021 that is at least:
• 1.8262 (national—all urban); or
• The median CMI value (not
transfer-adjusted) for urban hospitals
(excluding hospitals with approved
teaching programs as identified in
§ 413.75) calculated by CMS for the
census region in which the hospital is
located.
The final CMI values by region are set
forth in the following table.
Case-Mix Index
Value
1.4961
1.59995
1.7062
1.7709
1.68745
1.6754
1.8756
1.896
1.8547
Region
New England (CT, ME, MA, NH, RI, VT)
Middle Atlantic (PA, NJ, NY)
East North Central (IL, IN, MI, OH, WI)
West North Central (IA, KS, MN, MO, NE, ND, SD)
South Atlantic (DE, DC, FL, GA, MD, NC, SC, VA, WV)
East South Central (AL, KY, MS, TN)
West South Central (AR, LA, OK, TX)
Mountain (AZ, CO, ID, MT, NV, NM, UT, WY)
Pacific (AK, CA, HI, OR, WA)
A hospital seeking to qualify as an
RRC should obtain its hospital-specific
CMI value (not transfer-adjusted) from
its MAC. Data are available on the
Provider Statistical and Reimbursement
(PS&R) System. In keeping with our
policy on discharges, the CMI values are
computed based on all Medicare patient
discharges subject to the IPPS MS–DRGbased payment.
Section 412.96(c)(2)(i) provides that
CMS set forth the national and regional
numbers of discharges criteria in each
year’s annual notice of prospective
payment rates for purposes of
determining RRC status. As specified in
section 1886(d)(5)(C)(ii) of the Act, the
national standard is set at 5,000
VerDate Sep<11>2014
section I.F. of the preamble of this final
rule for a complete discussion regarding
our proposal and finalized policy to use
the latest available data (that is, the FY
2021 MedPAR data) as the best available
data for purposes of this FY 2023
rulemaking.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28404), we
proposed that, in addition to meeting
other criteria, if rural hospitals with
fewer than 275 beds are to qualify for
initial RRC status for cost reporting
periods beginning on or after October 1,
2022, they must have a CMI value for
FY 2021 that is at least—
• 1.8251 (national—all urban); or
• The median CMI value (not
transfer-adjusted) for urban hospitals
(excluding hospitals with approved
teaching programs as identified in
§ 413.75) calculated by CMS for the
census region in which the hospital is
located.
The proposed median CMI values by
region were set forth in a table in the
proposed rule (87 FR 28405). We stated
in the proposed rule that we intended
to update the proposed CMI values in
00:20 Aug 10, 2022
Jkt 256001
discharges. In the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28406), for FY
2023, we proposed to update the
regional standards based on discharges
for urban hospitals’ cost reporting
periods that began during FY 2020 (that
is, October 1, 2019 through September
30, 2020). We believe that this is the
best available data for use in calculating
the median number of discharges by
region and is consistent with our
finalized data proposal to use cost
report data from cost reporting periods
beginning during FY 2020 for FY 2023
ratesetting. We refer the reader to
section I.F. of the preamble of this final
rule for a complete discussion regarding
our proposal and finalized policy to use
the latest available data (that is, cost
reports beginning during FY 2020) as
PO 00000
Frm 00281
Fmt 4701
Sfmt 4700
the best available data for purposes of
this FY 2023 rulemaking.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28405), we
proposed that, in addition to meeting
other criteria, a hospital, if it is to
qualify for initial RRC status for cost
reporting periods beginning on or after
October 1, 2022, must have, as the
number of discharges for its cost
reporting period that began during FY
2020, at least—
• 5,000 (3,000 for an osteopathic
hospital); or
• If less, the median number of
discharges for urban hospitals in the
census region in which the hospital is
located. (We refer readers to the table set
forth in the FY 2023 IPPS/LTCH PPS
proposed rule at 87 FR 28406). In the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.128
regional CMI values in each year’s
annual notice of prospective payment
rates for purposes of determining RRC
status. The methodology we used to
determine the national and regional CMI
values is set forth in the regulations at
§ 412.96(c)(1)(ii). The national median
CMI value for FY 2023 is based on the
CMI values of all urban hospitals
nationwide, and the regional median
CMI values for FY 2023 are based on the
CMI values of all urban hospitals within
each census region, excluding those
hospitals with approved teaching
programs (that is, those hospitals that
train residents in an approved GME
program as provided in § 413.75). For
the proposed rule, these values were
based on discharges occurring during
FY 2021 (October 1, 2020 through
September 30, 2021), and include bills
posted to CMS’ records through
December 2021. We believe that this is
the best available data for use in
calculating the national and regional
median CMI values and is consistent
with our finalized proposal to use the
FY 2021 MedPAR claims data for FY
2023 ratesetting. We refer the reader to
49059
49060
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
calculate median number of discharges
by region for FY 2023.
Response: We appreciate the
commenters’ support.
Therefore, based on the best available
discharge data at this time, that is, for
Number of Dischare:es
Ree:ion
1.
2.
3.
4.
5.
6.
7.
8.
9.
New England (CT, ME, MA, NH, RI, VT)
Middle Atlantic (PA, NJ, NY)
East North Central (IL, IN, MI, OH, WI)
West North Central (IA, KS, MN, MO, NE, ND, SD)
South Atlantic (DE, DC, FL, GA, MD, NC, SC, VA, WV)
East South Central (AL, KY, MS, TN)
West South Central (AR, LA, OK, TX)
Mountain (AZ, CO, ID, MT, NV, NM, UT, WY)
Pacific (AK, CA, HI, OR, WA)
We note that because the median
number of discharges for hospitals in
each census region is greater than the
national standard of 5,000 discharges,
under this final rule, 5,000 discharges is
the minimum criterion for all hospitals,
except for osteopathic hospitals for
which the minimum criterion is 3,000
discharges.
C. Payment Adjustment for Low-Volume
Hospitals (§ 412.101)
khammond on DSKJM1Z7X2PROD with RULES2
1. Expiration of Temporary Changes to
Low-Volume Hospital Payment Policy
As discussed in the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41398
through 41399), section 50204 of the
Bipartisan Budget Act of 2018 (Pub. L.
115–123) modified the definition of a
low-volume hospital and the
methodology for calculating the
payment adjustment for low-volume
hospitals under section 1886(d)(12) of
the Act for FYs 2019 through 2022.
Beginning with FY 2023, the lowvolume hospital qualifying criteria and
payment adjustment will revert to the
statutory requirements that were in
effect prior to FY 2011, and the
preexisting low-volume hospital
payment adjustment methodology and
qualifying criteria, as implemented in
FY 2005 and discussed later in this
section of this final rule, will resume.
(For additional information on the
temporary changes to the low-volume
hospital payment policy, we refer
readers to the FY 2019 IPPS/LTCH PPS
final rule (83 FR 41398 through 41401).
We also note, in that same final rule, we
amended the regulations at 42 CFR
412.101 to reflect the provisions of
section 50204 of the Bipartisan Budget
Act of 2018.) We discuss the payment
VerDate Sep<11>2014
cost reporting periods that began during
FY 2020, the final median number of
discharges for urban hospitals by census
region are set forth in the following
table.
00:20 Aug 10, 2022
Jkt 256001
policies for FY 2023 in section V.C.3. of
the preamble of this final rule.
2. Background
Section 1886(d)(12) of the Act
provides for an additional payment to
each qualifying low-volume hospital
under the IPPS beginning in FY 2005.
The additional payment adjustment to a
low-volume hospital provided for under
section 1886(d)(12) of the Act is in
addition to any payment calculated
under section 1886 of the Act.
Therefore, the additional payment
adjustment is based on the per discharge
amount paid to the qualifying hospital
under section 1886 of the Act. In other
words, the low-volume hospital
payment adjustment is based on total
per discharge payments made under
section 1886 of the Act, including
capital, DSH, IME, and outlier
payments. For SCHs and MDHs, the
low-volume hospital payment
adjustment is based in part on either the
Federal rate or the hospital-specific rate,
whichever results in a greater operating
IPPS payment.
As discussed in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45219
through 45221), section 50204 of the
Bipartisan Budget Act of 2018 (Pub. L.
115–123) modified the definition of a
low-volume hospital and the
methodology for calculating the
payment adjustment for low-volume
hospitals for FYs 2019 through 2022.
Specifically, the qualifying criteria for
low-volume hospitals under section
1886(d)(12)(C)(i) of the Act were
amended to specify that, for FYs 2019
through 2022, a subsection (d) hospital
qualifies as a low-volume hospital if it
is more than 15 road miles from another
subsection (d) hospital and has less than
PO 00000
Frm 00282
Fmt 4701
Sfmt 4700
8,713
9,149
7,635
7,298
9,833
9,206
5,747
7,693
8,087
3,800 total discharges during the fiscal
year. Section 1886(d)(12)(D) of the Act
was also amended to provide that, for
discharges occurring in FYs 2019
through 2022, the Secretary determines
the applicable percentage increase using
a continuous, linear sliding scale
ranging from an additional 25 percent
payment adjustment for low-volume
hospitals with 500 or fewer discharges
to a zero percent additional payment for
low-volume hospitals with more than
3,800 discharges in the fiscal year.
Consistent with the requirements of
section 1886(d)(12)(C)(ii) of the Act, the
term ‘‘discharge’’ for purposes of these
provisions refers to total discharges,
regardless of payer (that is, Medicare
and non-Medicare discharges).
Beginning with FY 2023, the lowvolume hospital qualifying criteria and
payment adjustment will revert to the
statutory requirements that were in
effect prior to FY 2011. Section
1886(d)(12)(C)(i) of the Act defines a
low-volume hospital, for FYs 2005
through 2010 and FY 2023 and
subsequent years, as a subsection (d)
hospital that the Secretary determines is
located more than 25 road miles from
another subsection (d) hospital and that
has less than 800 discharges during the
fiscal year. Section 1886(d)(12)(C)(ii) of
the Act further stipulates that the term
‘‘discharge’’ means an inpatient acute
care discharge of an individual,
regardless of whether the individual is
entitled to benefits under Medicare Part
A (except with respect to FYs 2011
through 2018). Therefore, for FYs 2005
through 2010 and FY 2019 and
subsequent years, the term ‘‘discharge’’
refers to total discharges, regardless of
payer (that is, Medicare and nonMedicare discharges), and as such the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.129
proposed rule, we stated that we
intended to update to update these
numbers in the FY 2023 final rule based
on the latest available cost report data.
Comment: Commenters supported our
proposal to use FY 2020 data to
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
term discharge continues to refer to total
discharges for FY 2023 and subsequent
years. Furthermore, section
1886(d)(12)(B) of the Act requires, for
discharges occurring in FYs 2005
through 2010 and FY 2023 and
subsequent years, that the Secretary
determine an applicable percentage
increase for these low-volume hospitals
based on the ‘‘empirical relationship’’
between the standardized cost-per-case
for such hospitals and the total number
of discharges of such hospitals and the
amount of the additional incremental
costs (if any) that are associated with
such number of discharges. The statute
thus mandates that the Secretary
develop an empirically justifiable
adjustment based on the relationship
between costs and discharges for these
low-volume hospitals. Section
1886(d)(12)(B)(iii) of the Act limits the
applicable percentage increase
adjustment to no more than 25 percent.
Based on an analysis we conducted
for the FY 2005 IPPS final rule (69 FR
49099 through 49102), a 25-percent lowvolume adjustment to all qualifying
hospitals with less than 200 discharges
was found to be most consistent with
the statutory requirement to provide
relief to low-volume hospitals where
there is empirical evidence that higher
incremental costs are associated with
low numbers of total discharges. In the
FY 2006 IPPS final rule (70 FR 47432
through 47434), we stated that
multivariate analyses supported the
existing low-volume adjustment
implemented in FY 2005. Accordingly,
under the existing regulations, in order
for a hospital to continue to qualify as
a low-volume hospital on or after
October 1, 2022, it must have fewer than
200 total discharges during the fiscal
year and be located more than 25 road
miles from the nearest ‘‘subsection (d)’’
hospital (see § 412.101(b)(2)(i)). (For
additional information on the lowvolume hospital payment adjustment
prior to FY 2018, we refer readers to the
FY 2017 IPPS/LTCH PPS final rule (81
FR 56941 through 56943). For
additional information on the lowvolume hospital payment adjustment for
FY 2018, we refer readers to the FY
2018 IPPS notice (CMS–1677–N) that
appeared in the April 26, 2018, Federal
Register (83 FR 18301 through 18308).
For additional information on the lowvolume hospital payment adjustment for
FY 2019 through FY 2022, we refer
readers to the FY 2019 IPPS/LTCH PPS
final rule (83 FR 41398 through 41399).)
3. Payment Adjustment for FY 2023 and
Subsequent Fiscal Years
In accordance with section
1886(d)(12) of the Act, beginning with
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
FY 2023, the low-volume hospital
definition and payment adjustment
methodology will revert back to the
statutory requirements that were in
effect prior to the amendments made by
the Affordable Care Act and subsequent
legislation. Therefore, effective for FY
2023 and subsequent years, under
current policy at § 412.101(b), in order
to qualify as a low-volume hospital, a
subsection (d) hospital must be more
than 25 road miles from another
subsection (d) hospital and have less
than 200 discharges (that is, less than
200 discharges total, including both
Medicare and non-Medicare discharges)
during the fiscal year. For FY 2023 and
subsequent years, the statute specifies
that a low-volume hospital must have
less than 800 discharges during the
fiscal year. However, as required by
section 1886(d)(12)(B)(i) of the Act and
as discussed earlier, the Secretary has
developed an empirically justifiable
payment adjustment based on the
relationship, for IPPS hospitals with less
than 800 discharges, between the
additional incremental costs (if any) that
are associated with a particular number
of discharges. Based on an analysis we
conducted for the FY 2005 IPPS final
rule (69 FR 49099 through 49102), a 25percent low-volume adjustment to all
qualifying hospitals with less than 200
discharges was found to be most
consistent with the statutory
requirement to provide relief for lowvolume hospitals where there is
empirical evidence that higher
incremental costs are associated with
low numbers of total discharges. (Under
the policy we established in that same
final rule, hospitals with between 200
and 799 discharges do not receive a lowvolume hospital adjustment.)
For FYs 2005 through 2010 and FY
2018 and subsequent years, the
discharge determination is made based
on the hospital’s number of total
discharges, that is, Medicare and nonMedicare discharges. The hospital’s
most recently submitted cost report is
used to determine if the hospital meets
the discharge criterion to receive the
low-volume payment adjustment in the
current year (§ 412.101(b)(2)(i)). We use
cost report data to determine if a
hospital meets the discharge criterion
because this is the best available data
source that includes information on
both Medicare and non-Medicare
discharges. We note that, for FYs 2011
through 2018, we used the most recently
available MedPAR data to determine the
hospital’s Medicare discharges because
only Medicare discharges were used to
determine if a hospital met the
discharge criterion for those years.
PO 00000
Frm 00283
Fmt 4701
Sfmt 4700
49061
In addition to the discharge criterion,
a hospital must also meet the mileage
criterion to qualify for the low-volume
payment adjustment. As specified by
section 1886(d)(12)(C)(i) of the Act, a
low-volume hospital must be more than
25 road miles (or 15 road miles for FYs
2011 through 2022) from another
subsection (d) hospital. Accordingly, for
FY 2023 and for subsequent fiscal years,
in addition to the discharge criterion,
the eligibility for the low-volume
payment adjustment is also dependent
upon the hospital meeting the mileage
criterion at § 412.101(b)(2)(i), which
specifies that a hospital must be located
more than 25 road miles from the
nearest subsection (d) hospital,
consistent with section 1886(d)(12)(C)(i)
of the Act. We define, at § 412.101(a),
the term ‘‘road miles’’ to mean ‘‘miles’’
as defined at § 412.92(c)(1) (75 FR 50238
through 50275 and 50414).
Comment: Several commenters
opposed the change to the low-volume
hospital policy in FY 2023. Many of
those commenters stated that they are
concerned about the financial impact
resulting from the decrease in payments
due to the expiration of the temporary
changes to the low-volume hospital
payment policy. Some commenters
requested that CMS use its authority to
extend the use of the modified
definition of a low-volume hospital and
the methodology for calculating the
payment adjustment for low-volume
hospitals. Some commenters stated their
belief that CMS has the authority to not
allow the temporary changes to expire.
A commenter requested CMS use its
discretion under the Emergency
Pandemic Declarations to extend the
low-volume hospital payment policy.
Response: We appreciate the
commenters’ sharing their concerns
regarding the financial impact resulting
from the expiration of the temporary
changes to the low-volume hospital
payment policy. As previously
discussed, section 1886(d)(12) of the Act
sets forth the applicable low-volume
hospital policy beginning FY 2023. In
response to the comment that requested
the temporary changes to the lowvolume hospital policy be extended
using the discretion under the
Emergency Pandemic Declarations, we
believe the commenter is referring to the
use of waivers under Section 1135 of the
Act. While this provision authorizes
certain Medicare (and other) program
requirements and conditions of
participation to be waived during
certain emergencies, this authority
cannot be used to waive provisions of
payment.
Comment: Several commenters
support legislative action through the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49062
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Rural Hospital Support Act (H.R. 1887/
S. 4009) to extend or make permanent
the modifications to the low-volume
hospital payment policy enacted by
section 50204 of the Bipartisan Budget
Act of 2018. Many commenters urged
CMS to collaborate with Congress to
extend or make permanent the
modifications to the low-volume
hospital payment policy. Other
commenters stated that it is not the
intent of Congress for the low-volume
hospital payment policy to revert back
to the historical statutory requirements.
Some of these commenters believe that
CMS is ignoring the congressional intent
of this policy and denying a group of
IPPS providers low-volume hospital
payments with the reversion to the
policy that was originally established
for FY 2005. These commenters
requested expanding eligibility for the
discharge criteria to match the statutory
requirement to include IPPS providers
with 200–799 discharges. These
commenters did not provide any data
analysis in support of their comments to
expand the low-volume hospital
adjustment to qualifying hospitals that
have more than 200 and less than 800
total discharges. A commenter requested
that CMS update its regression analysis.
The commenter stated that empirical
justification used by CMS to determine
the discharge criteria of less than 200
discharges is dated and that no rationale
to support the ongoing validity of the
previous analysis was provided in the
proposed rule. The commenter also
noted that even if the low-volume
hospital discharge criteria were
expanded to less than 800 total
discharges, there would still only be a
small number of hospitals to qualify for
low-volume payment adjustment.
Response: We appreciate the
commenters sharing their support for
legislative action. We disagree that is
contrary to the congressional intent for
the low-volume hospital policy to revert
back to the policy established under the
original historical statutory
requirements. As noted earlier in the
preamble of this final rule and as
discussed in response to public
comments in the FY 2013 IPPS/LTCH
PPS final rule (77 FR 53408 through
53409), the FY 2014 IPPS/LTCH PPS
final rule (78 50612 through 50613), and
the FY 2018 IPPS/LTCH PPS final rule
(82 FR 38184 through 38189) to
implement the original low-volume
hospital payment adjustment provision,
and as mandated by statute, we
developed an empirically justified
adjustment based on the relationship
between costs and total discharges of
hospitals with less than 800 total
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
(Medicare and non-Medicare)
discharges. Specifically, we performed
several regression analyses to evaluate
the relationship between hospitals’ costs
per case and discharges, and found that
an adjustment for hospitals with less
than 200 total discharges is most
consistent with the statutory
requirement to provide for additional
payments to low-volume hospitals
where there is empirical evidence that
higher incremental costs are associated
with lower numbers of discharges (69
FR 49101 through 49102). Based on
these analyses, we established a lowvolume hospital policy under which
qualifying hospitals with less than 200
total discharges receive a payment
adjustment of an additional 25 percent.
(Section 1886(d)(12)(B)(iii) of the Act
limits the applicable percentage
increase adjustment to no more than 25
percent.) In the future, we may
reevaluate the low-volume hospital
adjustment policy; that is, the definition
of a low-volume hospital and the
payment adjustment. However, we are
not aware of any analysis or empirical
evidence that would support expanding
the originally established low-volume
hospital adjustment policy and we did
not make any proposals regarding the
low-volume hospital payment
adjustment for FY 2023. For these
reasons, we are not making any changes
to the low-volume hospital payment
adjustment policy in this final rule.
Comment: Some commenters urged
CMS to expedite any changes to the
definition of a low-volume hospital and
the methodology for calculating the
payment adjustment for low-volume
hospitals, should Congress extend the
current policy. They requested that lowvolume hospital payments be restored
quickly so that impacted providers are
able to continue to provide quality care.
Response: We appreciate the
commenters’ request and, as in the past,
we will make every effort to implement
any extension of the low-volume
payment policy as expeditiously as
possible.
Comment: A commenter questioned
how a hospital would qualify for lowvolume payments while also adhering to
the inpatient hospitals Conditions of
Participation (CoP) since only hospitals
with less than 200 total discharges
would be eligible for the low-volume
hospital adjustment beginning in FY
2023. The commenter argues that IPPS
hospitals cannot adhere to the average
daily census (ADC) and average length
of stay (ALOS) thresholds in the
discussion of the factors for state
agencies to consider when certifying a
facility as an inpatient hospital in the
PO 00000
Frm 00284
Fmt 4701
Sfmt 4700
State Operations Manual (SOM).214
Specifically, the commenter cites ‘‘the
ALOS of two midnights’’ benchmark
and the expectation ‘‘to maintain an
average daily census (ADC) of two
patients.’’
Response: While we appreciate the
commenter’s concern regarding
compliance with the COPs and
hospitals’ certification as an inpatient
hospital, it is not clear to us why a lowvolume hospital payment adjustment
criterion of less than 200 discharges
would prevent a hospital from meeting
‘‘the ADC and ALOS thresholds
required for maintaining its certification
and status as an inpatient facility.’’ The
low-volume payment adjustment
provides an additional payment to
hospitals that meet the low-volume
hospital qualifying criteria and does not
directly impact a hospital’s ADC or
ALOS. We also note that CMS considers
multiple factors when determining
certification for inpatient hospitals.
ADC and ALOS are factors in
determining a hospital’s eligibility for
specialized payment categories.
Hospitals are not required to have any
specific number of inpatients for
certification. A hospital’s ability to
adhere to the inpatient hospital CoPs is
not relevant to the reversion to the lowvolume hospital payment requirements
that were in effect prior to FY 2011.
After consideration of the public
comments we received, we are
finalizing our proposals, without
modification. Consistent with current
law, effective beginning FY 2023, the
low-volume hospital definition and
payment adjustment methodology will
revert back to the policy established
under statutory requirements that were
in effect prior to the amendments made
by the Affordable Care Act and
extended through subsequent legislation
(most recently the Bipartisan Budget Act
of 2018).
4. Process for Requesting and Obtaining
the Low-Volume Hospital Payment
Adjustment
In the FY 2011 IPPS/LTCH PPS final
rule (75 FR 50238 through 50275 and
50414) and subsequent rulemaking,
most recently in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45219
through 45221), we discussed the
process for requesting and obtaining the
low-volume hospital payment
adjustment.
Under this previously established
process, a hospital makes a written
214 https://www.cms.gov/Medicare/ProviderEnrollment-and-Certification/SurveyCertification
GenInfo/Downloads/Survey-and-Cert-Letter-17-44Revised-102717.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
request for the low-volume payment
adjustment under § 412.101 to its MAC.
This request must contain sufficient
documentation to establish that the
hospital meets the applicable mileage
and discharge criteria. The MAC will
determine if the hospital qualifies as a
low-volume hospital by reviewing the
data the hospital submits with its
request for low-volume hospital status
in addition to other available data.
Under this approach, a hospital will
know in advance whether or not it will
receive a payment adjustment under the
low-volume hospital policy. The MAC
and CMS may review available data
such as the number of discharges, in
addition to the data the hospital submits
with its request for low-volume hospital
status, to determine whether or not the
hospital meets the qualifying criteria.
(For additional information on our
existing process for requesting the lowvolume hospital payment adjustment,
we refer readers to the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41399
through 41401).)
As explained earlier, for FY 2019 and
subsequent fiscal years, the discharge
determination is made based on the
hospital’s number of total discharges,
that is, Medicare and non-Medicare
discharges, as was the case for FYs 2005
through 2010. Under § 412.101(b)(2)(i)
and (iii), a hospital’s most recently
submitted cost report is used to
determine if the hospital meets the
discharge criterion to receive the lowvolume payment adjustment in the
current year. As discussed in the FY
2019 IPPS/LTCH PPS final rule (83 FR
41399 and 41400), we use cost report
data to determine if a hospital meets the
discharge criterion because this is the
best available data source that includes
information on both Medicare and nonMedicare discharges. (For FYs 2011
through 2018, the most recently
available MedPAR data were used to
determine the hospital’s Medicare
discharges because non-Medicare
discharges were not used to determine
if a hospital met the discharge criterion
for those years.) Therefore, a hospital
must refer to its most recently submitted
cost report for total discharges
(Medicare and non-Medicare) to decide
whether or not to apply for low-volume
hospital status for a particular fiscal
year.
As also discussed in the FY 2019
IPPS/LTCH PPS final rule, in addition
to the discharge criterion, for FY 2019
and for subsequent fiscal years,
eligibility for the low-volume hospital
payment adjustment is also dependent
upon the hospital meeting the
applicable mileage criterion specified in
§ 412.101(b)(2)(i) or (iii) for the fiscal
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
year. Specifically, to meet the mileage
criterion to qualify for the low-volume
hospital payment adjustment for FY
2023, a hospital must be located more
than 25 road miles from the nearest
subsection (d) hospital. (We define in
§ 412.101(a) the term ‘‘road miles’’ to
mean ‘‘miles’’ as defined in
§ 412.92(c)(1) (75 FR 50238 through
50275 and 50414).) For establishing that
the hospital meets the mileage criterion,
the use of a web-based mapping tool as
part of the documentation is acceptable.
The MAC will determine if the
information submitted by the hospital,
such as the name and street address of
the nearest hospitals, location on a map,
and distance from the hospital
requesting low-volume hospital status,
is sufficient to document that it meets
the mileage criterion. If not, the MAC
will follow up with the hospital to
obtain additional necessary information
to determine whether or not the hospital
meets the applicable mileage criterion.
In accordance with our previously
established process, a hospital must
make a written request for low-volume
hospital status that is received by its
MAC by September 1 immediately
preceding the start of the Federal fiscal
year for which the hospital is applying
for low-volume hospital status in order
for the applicable low-volume hospital
payment adjustment to be applied to
payments for its discharges for the fiscal
year beginning on or after October 1
immediately following the request (that
is, the start of the Federal fiscal year).
For a hospital whose request for low
volume hospital status is received after
September 1, if the MAC determines the
hospital meets the criteria to qualify as
a low-volume hospital, the MAC will
apply the applicable low-volume
hospital payment adjustment to
determine payment for the hospital’s
discharges for the fiscal year, effective
prospectively within 30 days of the date
of the MAC’s low-volume status
determination.
Consistent with this previously
established process, for FY 2023, we
proposed that a hospital must submit a
written request for low-volume hospital
status to its MAC that includes
sufficient documentation to establish
that the hospital meets the applicable
mileage and discharge criteria (as
described earlier). Specifically, for FY
2023, a hospital must make a written
request for low-volume hospital status
that is received by its MAC no later than
September 1, 2022, in order for the 25percent, low-volume, add-on payment
adjustment to be applied to payments
for its discharges beginning on or after
October 1, 2022. If a hospital’s written
request for low-volume hospital status
PO 00000
Frm 00285
Fmt 4701
Sfmt 4700
49063
for FY 2023 is received after September
1, 2022, and if the MAC determines the
hospital meets the criteria to qualify as
a low-volume hospital, the MAC would
apply the low-volume hospital payment
adjustment to determine the payment
for the hospital’s FY 2023 discharges,
effective prospectively within 30 days of
the date of the MAC’s low-volume
hospital status determination.
Under this process, a hospital that
qualified for the low-volume hospital
payment adjustment for FY 2022 may
continue to receive a low-volume
hospital payment adjustment for FY
2023 without reapplying if it meets both
the discharge criterion and the mileage
criterion applicable for FY 2023. As
discussed previously, for FY 2023 the
discharge and the mileage criteria are
reverting to the statutory requirements
that were in effect prior to FY 2011, and
to the preexisting low-volume hospital
qualifying criteria, as implemented in
FY 2005 and specified in the existing
regulations at § 412.101(b)(2)(i). As in
previous years, we proposed that such
a hospital must send written verification
that is received by its MAC no later than
September 1, 2022, stating that it meets
the mileage criterion applicable for FY
2023 (that is, is located more than 25
road miles from the nearest ‘‘subsection
(d)’’ hospital). For FY 2023, we further
proposed that this written verification
must also state, based upon the most
recently submitted cost report, that the
hospital meets the discharge criterion
applicable for FY 2023 (that is, less than
200 discharges total, including both
Medicare and non-Medicare discharges).
If a hospital’s request for low-volume
hospital status for FY 2023 is received
after September 1, 2022, and if the MAC
determines the hospital meets the
criteria to qualify as a low-volume
hospital, the MAC will apply the 25percent, low-volume, add-on payment
adjustment to determine the payment
for the hospital’s FY 2023 discharges,
effective prospectively within 30 days of
the date of the MAC’s low-volume
hospital status determination.
We received no comments on our
proposed process for requesting and
obtaining the low-volume hospital
payment adjustment for FY 2023 and
therefore are finalizing this proposal
without modification.
We note, in the FY 2019 IPPS/LTCH
PPS final rule (83 FR 41398 through
41401 and 41702), in accordance with
the provisions of section 50204 of the
Bipartisan Budget Act of 2018, for FY
2023 and subsequent fiscal years, we
made conforming changes to the
regulations at 42 CFR 412.101 to reflect
that the low-volume payment
adjustment policy in effect for these
E:\FR\FM\10AUR2.SGM
10AUR2
49064
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
years is the same low-volume hospital
payment adjustment policy in effect for
FYs 2005 through 2010. Under these
revisions, beginning with FY 2023,
consistent with current law, the lowvolume hospital qualifying criteria and
payment adjustment methodology will
return to the criteria and methodology
that were in effect prior to the
amendments made by the Affordable
Care Act (that is, the low-volume
hospital payment policy in effect for
FYs 2005 through 2010). Therefore, no
further revisions to the policy or to the
regulations at § 412.101 are required to
conform them to the statutory
requirement that the low-volume
hospital policy in effect prior to the
Affordable Care Act will again be in
effect for FY 2023 and subsequent years.
khammond on DSKJM1Z7X2PROD with RULES2
D. Changes in the Medicare-Dependent,
Small Rural Hospital (MDH) Program
(§ 412.108)
1. Background for the MDH Program
Section 1886(d)(5)(G) of the Act
provides special payment protections,
under the IPPS, to a Medicaredependent, small rural hospital (MDH).
(For additional information on the MDH
program and the payment methodology,
we refer readers to the FY 2012 IPPS/
LTCH PPS final rule (76 FR 51683
through 51684).) As discussed in section
V.B. of the preamble of this final rule,
the MDH program provisions at section
1886(d)(5)(G) of the Act will expire at
the end of FY 2022. Beginning with
discharges occurring on or after October
1, 2022, all hospitals that previously
qualified for MDH status will be paid
based on the Federal rate.
Since the extension of the MDH
program through FY 2012 provided by
section 3124 of the Affordable Care Act,
the MDH program had been extended by
subsequent legislation as follows:
section 606 of the ATRA (Pub. L. 112–
240) extended the MDH program
through FY 2013 (that is, for discharges
occurring before October 1, 2013).
Section 1106 of the Pathway for SGR
Reform Act of 2013 (Pub. L. 113–67)
extended the MDH program through the
first half of FY 2014 (that is, for
discharges occurring before April 1,
2014). Section 106 of the PAMA (Pub.
L. 113–93) extended the MDH program
through the first half of FY 2015 (that is,
for discharges occurring before April 1,
2015). Section 205 of the MACRA (Pub.
L. 114–10) extended the MDH program
through FY 2017 (that is, for discharges
occurring before October 1, 2017).
Section 50205 of the Bipartisan Budget
Act (Pub. L. 115– 123) extended the
MDH program through FY 2022 (that is
for discharges occurring before October
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
1, 2022). For additional information on
the extensions of the MDH program after
FY 2012, we refer readers to the
following Federal Register documents:
• The FY 2013 IPPS/LTCH PPS final
rule (77 FR 53404 through 53405 and
53413 through 53414).
• The FY 2013 IPPS notice (78 FR
14689).
• The FY 2014 IPPS/LTCH PPS final
rule (78 FR 50647 through 50649).
• The FY 2014 interim final rule with
comment period (79 FR 15025 through
15027).
• The FY 2014 notice (79 FR 34446
through 34449).
• The FY 2015 IPPS/LTCH PPS final
rule (79 FR 50022 through 50024).
• The August 2015 interim final rule
with comment period (80 FR 49596).
• The FY 2017 IPPS/LTCH PPS final
rule (81 FR 57054 through 57057).
• The FY 2018 notice (83 FR 18303
through 18305).
• The FY 2019 IPPS/LTCH PPS final
rule (83 FR 41429).
2. Expiration of the MDH Program
Because section 50205 of the
Bipartisan Budget Act extended the
MDH program through FY 2022 only,
beginning October 1, 2022, the MDH
program will no longer be in effect.
Because the MDH program is not
authorized by statute beyond September
30, 2022, beginning October 1, 2022, all
hospitals that previously qualified for
MDH status under section 1886(d)(5)(G)
of the Act will no longer have MDH
status and will be paid based on the
IPPS Federal rate.
When the MDH program was set to
expire at the end of FY 2012, in the FY
2013 IPPS/LTCH PPS final rule (77 FR
53404 through 53405), we revised our
sole community hospital (SCH) policies
to allow MDHs to apply for SCH status
in advance of the expiration of the MDH
program and be paid as such under
certain conditions. We codified these
changes in the regulations at
§ 412.92(b)(2)(i) and (v). Specifically,
the existing regulations at
§ 412.92(b)(2)(v) allow for an effective
date of an approval of SCH status that
is the day following the expiration date
of the MDH program. We note that these
same conditions apply to MDHs that
intend to apply for SCH status with the
expiration of the MDH program on
September 30, 2022. Therefore, in order
for an MDH to receive SCH status
effective October 1, 2022, the MDH must
apply for SCH status at least 30 days
before the expiration of the MDH
program; that is, the MDH must apply
for SCH status by September 1, 2022.
The MDH also must request that, if
approved as an SCH, the SCH status be
PO 00000
Frm 00286
Fmt 4701
Sfmt 4700
effective with the expiration of the MDH
program; that is, the MDH must request
that the SCH status, if approved, be
effective October 1, 2022, immediately
after its MDH status expires with the
expiration of the MDH program on
September 30, 2022. We emphasize that
an MDH that applies for SCH status in
anticipation of the expiration of the
MDH program would not qualify for the
October 1, 2022, effective date for SCH
status if it does not apply by the
September 1, 2022, deadline. If the
MDH does not apply by the September
1, 2022, deadline, the hospital would
instead be subject to the usual effective
date for SCH classification; that is, as of
the date the MAC receives the complete
application as specified at
§ 412.92(b)(2)(i).
We note that the regulations
governing the MDH program are found
at § 412.108 and the MDH program is
also cited in the general payment rules
in the regulations at § 412.90. As stated
earlier, under current law, the MDH
program will expire at the end of FY
2022, which is already reflected in
§§ 412.108 and 412.90(j). As such, we
did not propose specific amendments to
the regulations at § 412.108 or § 412.90
to reflect the expiration of the MDH
program. However, we proposed that if
the MDH program were to be extended
by law, similar to how it was extended
through FY 2013, by the ATRA (Pub. L.
112–240); through March 31, 2014, by
the Pathway for SGR Reform Act of 2013
(Pub. L. 113–167); through March 31,
2015, by the PAMA (Pub. L. 113–93);
through FY 2017, by the MACRA (Pub.
L. 114–10); and most recently through
FY 2022, by the Bipartisan Budget Act
of 2018 (Pub. L. 115–123), we would
make conforming changes to the
regulations governing the MDH program
at § 412.108(a)(1) and (c)(2)(iii) and the
general payment rules at § 412.90(j) to
reflect such an extension of the MDH
program. We stated that these
conforming changes would only be
made if the MDH program were to be
extended by statute beyond September
30, 2022. As of the time of the
development of this final rule, there has
been no change in law to extend the
MDH program beyond FY 2022.
Therefore, in this final rule, we are not
making any additional changes to the
regulations governing the MDH program
at § 412.108 or the general payment
rules at § 412.90.
Comment: Many commenters
expressed support for extending the
MDH program or making the MDH
program permanent and noted that they
would continue supporting
congressional efforts to protect the MDH
program. Some commenters also
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
expressed support for an additional base
year for calculating MDH payments. A
commenter urged CMS to remove the
MDH program expiration proposal from
the final rule. Several state hospital
associations expressed their concern
that hospitals in their states would
experience significant payment
decreases as a result of the expiration of
the MDH program. A few commenters
urged for action to be taken to ensure
that the MDH program is extended,
while other commenters urged CMS to
explore alternatives and make
immediate adjustments within its
authority to provide relief and mitigate
negative impacts to rural hospitals
should Congress not act.
Response: While we appreciate the
commenters’ concerns about the
expiration of the MDH program and the
financial impact to affected providers if
the MDH program is not extended
beyond FY 2022, CMS does not have the
authority under current law to extend
the MDH program beyond the
September 30, 2022 statutory expiration
date. Similarly, Section 1886(b)(3)(D) of
the Act specifies the applicable base
years or ‘‘target amounts’’ for hospitals
classified as MDHs. These comments are
similar to comments we received
previously, prior to the statutory
extension of the MDH program for FY
2018 through FY 2022 provided by
subsequent legislation, and discussed in
the FY 2018 IPPS/LTCH PPS final rule
(82 FR 38220 through 38221). In
response to the comment urging CMS to
explore other relief options should
Congress not act, we will consider this
for future rulemaking and explore
potential ways to provide support to
this subset of rural providers.
Comment: Several commenters
expressed support for CMS’ policy that
allows MDHs to apply for SCH status in
advance of the expiration of the MDH
program and be paid as such under
certain conditions. Some commenters
also requested that CMS also provide
former MDHs with the ability to rescind
their newly acquired SCH status and
reinstate their MDH status in a seamless
manner, if a retroactive extension to the
MDH program is made.
Response: We appreciate the
commenters’ support of our policy
allowing MDHs to apply for SCH status
in advance of the expiration of the MDH
program and to be paid as such under
certain conditions and allow for a
seamless transition from MDH
classification to SCH classification. In
response to the suggestion that CMS
provide former MDHs with ability to
rescind their newly acquired SCH status
and reinstate their MDH status in a
seamless manner if a retroactive
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
extension to the MDH program is made,
we understand the desire on the part of
hospitals for certainty in the face of
MDH program expiration and will
consider for future rulemaking any
potential mechanisms to further
streamline such transitions in
connection with legislative extensions
of the MDH program. We note that
under the current regulations at
§ 412.108(b)(4), the effective date for
MDH classification is as of the date the
MAC receives the complete application.
A MDH that applied for and was
classified as an SCH in advance of the
MDH expiration per the regulations at
§ 412.92(b)(2)(v) could request a
cancellation of its SCH status and
simultaneously re-apply for MDH status
if the MDH program were to be
extended, and the MDH classification
would be effective as of the date that the
MAC receives the complete application.
This would allow a former MDH to
maintain special payment status as an
SCH and then as an MDH generally
without interruption in the event the
MDH program is extended.
Comment: Commenters urged CMS to
expedite restoration of MDH status,
should Congress act to extend these
programs, stating that past retroactive
restorations have seen delays that
caused significant cash flow problems to
affected hospitals. They requested that
CMS move expeditiously to restore
payments so that these rural facilities
are able to continue to provide quality
care to their communities and that CMS
clarify how it might handle program
extensions, should Congress enact
legislation to extend them.
Response: We appreciate the
commenters’ sharing their concerns
relating to a retroactive restoration of
the MDH program. As with past
extensions, CMS will evaluate enacted
legislation to determine the most
appropriate approach to implement
changes to the law, including
instructions to the MACs to reinstate
MDH status to eligible hospitals. As in
the past, we will make every effort to
implement any extension of the MDH
program as expeditiously as possible.
In summary, under current law,
beginning October 1, 2022, all hospitals
that previously qualified for MDH status
will no longer have MDH status.
E. Indirect Medical Education (IME)
Payment Adjustment Factor (§ 412.105)
Under the IPPS, an additional
payment amount is made to hospitals
with residents in an approved graduate
medical education (GME) program in
order to reflect the higher indirect
patient care costs of teaching hospitals
relative to nonteaching hospitals. The
PO 00000
Frm 00287
Fmt 4701
Sfmt 4700
49065
payment amount is determined by use
of a statutorily specified adjustment
factor. The regulations regarding the
calculation of this additional payment,
known as the IME adjustment, are
located at § 412.105. We refer readers to
the FY 2012 IPPS/LTCH PPS final rule
(76 FR 51680) for a full discussion of the
IME adjustment and IME adjustment
factor. Section 1886(d)(5)(B)(ii)(XII) of
the Act provides that, for discharges
occurring during FY 2008 and fiscal
years thereafter, the IME formula
multiplier is 1.35.
Accordingly, for discharges occurring
during FY 2023, the formula multiplier
is 1.35. We estimate that application of
this formula multiplier for the FY 2023
IME adjustment will result in an
increase in IPPS payment of 5.5 percent
for every approximately 10 percent
increase in the hospital’s resident-to-bed
ratio.
We did not receive any comments
regarding the IME adjustment factor,
which, as noted earlier, is statutorily
required. Accordingly, for discharges
occurring during FY 2023, the IME
formula multiplier is 1.35.
F. Payment for Indirect and Direct
Graduate Medical Education Costs
(§§ 412.105 and 413.75 Through 413.83)
1. Background
Section 1886(h) of the Act, as added
by section 9202 of the Consolidated
Omnibus Budget Reconciliation Act
(COBRA) of 1985 (Pub. L. 99–272) and
as currently implemented in the
regulations at 42 CFR 413.75 through
413.83, establishes a methodology for
determining payments to hospitals for
the direct costs of approved graduate
medical education (GME) programs.
Section 1886(h)(2) of the Act sets forth
a methodology for the determination of
a hospital-specific base-period per
resident amount (PRA) that is calculated
by dividing a hospital’s allowable direct
costs of GME in a base period by its
number of full-time equivalent (FTE)
residents in the base period. The base
period is, for most hospitals, the
hospital’s cost reporting period
beginning in FY 1984 (that is, October
1, 1983 through September 30, 1984).
The base year PRA is updated annually
for inflation. In general, Medicare direct
GME payments are calculated by
multiplying the hospital’s updated PRA
by the weighted number of FTE
residents working in all areas of the
hospital complex (and at nonprovider
sites, when applicable), and the
hospital’s Medicare share of total
inpatient days.
Section 1886(d)(5)(B) of the Act
provides for a payment adjustment
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49066
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
known as the indirect medical
education (IME) adjustment under the
IPPS for hospitals that have residents in
an approved GME program, in order to
account for the higher indirect patient
care costs of teaching hospitals relative
to nonteaching hospitals. The
regulations regarding the calculation of
this additional payment are located at
42 CFR 412.105. The hospital’s IME
adjustment applied to the DRG
payments is calculated based on the
ratio of the hospital’s number of FTE
residents training in either the inpatient
or outpatient departments of the IPPS
hospital (and, for discharges occurring
on or after October 1, 1997, at nonprovider sites, when applicable) to the
number of inpatient hospital beds.
The calculation of both direct GME
payments and the IME payment
adjustment is affected by the number of
FTE residents that a hospital is allowed
to count. Generally, the greater the
number of FTE residents a hospital
counts, the greater the amount of
Medicare direct GME and IME payments
the hospital will receive. In an attempt
to end the implicit incentive for
hospitals to increase the number of FTE
residents, Congress, through the
Balanced Budget Act of 1997 (Pub. L.
105–33), established a limit on the
number of allopathic and osteopathic
residents that a hospital could include
in its FTE resident count for direct GME
and IME payment purposes. Under
section 1886(h)(4)(F) of the Act, for cost
reporting periods beginning on or after
October 1, 1997, a hospital’s
unweighted FTE count of residents for
purposes of direct GME may not exceed
the hospital’s unweighted FTE count for
direct GME in its most recent cost
reporting period ending on or before
December 31, 1996. Under section
1886(d)(5)(B)(v) of the Act, a similar
limit based on the FTE count for IME
during that cost reporting period is
applied, effective for discharges
occurring on or after October 1, 1997.
Dental and podiatric residents are not
included in this statutorily mandated
cap.
As mentioned previously, Medicare
direct GME payments are calculated by
multiplying the hospital’s updated PRA
by the weighted number of FTE
residents working in all areas of the
hospital complex (and at nonprovider
sites, when applicable), and the
hospital’s Medicare share of total
inpatient days. Section 1886(h)(4) of the
Act specifies the methodology for
determining the amount of FTE
residents to be included in a hospital’s
direct GME payment formula. That is,
the number of FTE residents training at
a hospital (or in non-provider sites as
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
applicable) would not necessarily equal
the sum of those FTE residents used in
the hospital’s direct GME payment
formula, since certain rules and factors
are applied to adjust the count of FTE
residents for direct GME payment
purposes. First, section 1886(h)(4)(C) of
the Act requires that a ‘‘weighting
factor’’ of either 1.0 or 0.5 be applied to
each FTE resident, as follows: In
calculating the number of FTE residents
in an approved residency program on or
after July 1, 1987, for a resident who is
not in the resident’s initial residency
period, the weighting factor is 0.50.
Section 1886(h)(5)(F) of the Act defines
the term ‘‘initial residency period’’ as
the ‘‘period of board eligibility,’’ with
certain exceptions. Finally, section
1886(h)(4)(G) of the Act states that the
term ‘‘period of board eligibility’’
means, for a resident, the minimum
number of years of formal training
necessary to satisfy the requirements for
initial board eligibility in the particular
specialty for which the resident is
training. The direct GME calculation
and our policy on applying the
weighting factors to each FTE resident
based on the FTE resident’s status
within or beyond the initial residency
period (IRP) was established in the
September 29, 1989, Federal Register
(54 FR 40287, 40292, 40305 and 40306),
and implemented in the regulations at
42 CFR 413.86(f) (now 42 CFR 413.79(a)
and (b)).
Thus, the FTE count used in the
direct GME payment formula must be a
weighted FTE count when a hospital is
training residents beyond their IRPs.
However, the direct GME FTE cap is an
unweighted number. That is, under
section 1886(h)(4)(F) of the Act, for cost
reporting periods beginning on or after
October 1, 1997, a hospital’s unweighted
FTE count of residents for purposes of
direct GME may not exceed the
hospital’s unweighted FTE count for
direct GME in its most recent cost
reporting period ending on or before
December 31, 1996 (that is the hospital’s
unweighted 1996 FTE cap or FTE cap).
Regulations regarding the FTE caps and
unweighted FTE counts were first
published in the August 29, 1997,
Federal Register (62 FR 45966). To
address situations where a hospital’s
weighted FTE count exceeds its
unweighted 1996 FTE cap, we
established a policy effective for cost
reporting periods beginning on or after
October 1, 1997, to bring the weighted
FTE count within the unweighted FTE
cap using the following ratio on the
Medicare cost report: ((1996 unweighted
FTE cap/current year unweighted FTE
count) × (current year total weighted
PO 00000
Frm 00288
Fmt 4701
Sfmt 4700
FTE count)) (see 62 FR 46005 and 63 FR
26,330 (May 12, 1998)). In the August 1,
2001, Federal Register (66 FR 39893
through 39896), we modified this ratio
effective for cost reporting periods
beginning on or after October 1, 2001, to
separately account for a hospital’s
current year weighted primary care and
obstetrics/gynecology (OB/GYN) FTE
count and primary care and OB/GYN
PRA, and current year weighted other
FTE count and other PRA, as follows:
(FTE cap/unweighted total FTEs in the
cost reporting period) × (weighted
primary care and OB/GYN FTEs in the
cost reporting period) plus (FTE cap/
unweighted total FTEs in the cost
reporting period) × (weighted
nonprimary care FTEs in the cost
reporting period). The sum of the
products is the current year allowable
weighted FTE count. In addition,
effective for cost reporting periods
beginning on or after October 1, 2001,
the direct GME payment is calculated
using two separate rolling averages, one
for primary care and OB/GYN FTE
residents, and one for nonprimary care
FTE residents. These calculations were
implemented at 42 CFR 413.86(g)(4) and
(5) respectively, currently 42 CFR
413.79(c)(2)(iii) and (d)(3).
2. Milton S. Hershey Medical Center, et
al. v. Becerra Litigation
On May 17, 2021, the U.S. District
Court for the District of Columbia ruled
against CMS’s method of calculating
direct GME payments to teaching
hospitals when those hospitals’
weighted FTE counts exceed their direct
GME FTE cap. In Milton S. Hershey
Medical Center, et al. v. Becerra (Slip.
Op., 2021 WL 1966572, May 17, 2021),
the court ordered CMS to recalculate
reimbursement owed, holding that
CMS’s regulation impermissibly
modified the statutory weighting factors
discussed previously. The plaintiffs in
these consolidated cases alleged that as
far back as 2005, the proportional
reduction that CMS applied to the
weighted FTE count when the weighted
FTE count exceeded the FTE cap
conflicted with the Medicare statute,
and it was an arbitrary and capricious
exercise of agency discretion under the
Administrative Procedure Act. The
Court held that the proportional
reduction methodology improperly
modified the weighting factors
statutorily assigned to residents and
fellows. The court ordered CMS to pay
the plaintiffs according to a more
favorable method.
For example, a hospital has a direct
GME cap of 100, trains 90 FTE residents
weighted at 1.0 and 10 FTE fellows
weighted at 0.5, for a total unweighted
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
count of 100, and a total weighted FTE
count of 95. Under current
methodology, the proportional
reduction is: (100 cap/100 current year
unweighted count) × 95 (current year
weighted count) = 95.
If that hospital adds 10 more fellows
and exceeds the cap with an
unweighted total of 110 (90 residents
and 20 fellows), its weighted FTE count
of 100 is reduced as follows: (100 cap/
110 current year unweighted count) ×
100 (current year weighted count) =
90.91.
The plaintiffs stated that CMS’s
proportional reduction method
unlawfully reduced the weighting factor
of 0.5 to an amount less than that,
thereby reducing the capped weighted
FTE amount (100 reduced to 90.91 in
the example) to which they were
entitled for direct GME payment
purposes. The court granted the
plaintiffs’ motion for summary
judgment, denied defendant’s, and
remanded to the Agency so that it could
recalculate plaintiffs’ reimbursement
payments consistent with the court’s
opinion. The court held that CMS’s
proportional reduction methodology,
enacted at 42 CFR 413.79(c)(2)(iii), was
inconsistent with the statutory
weighting factors. In response to the
court’s decision, in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28410
through 28412), we proposed to
implement a modified policy applicable
to all teaching hospitals, effective as of
October 1, 2001, which would replace
the existing policy at 42 CFR
413.79(c)(2)(iii). While the proportional
reduction method struck down in
Hershey was first effective for cost
reports beginning on or after October 1,
1997, we are unaware of any open or
reopenable NPRs for the 1997–2001
period where the proportional reduction
method caused a provider’s payments to
be lower than they would be under our
proposed new policy, but we welcomed
comments alerting us of such NPRs. The
proportional reduction method was
amended to its present form effective for
cost reporting periods beginning on or
after October 2001. (See current 42 CFR
413.79(c)(2)(ii) and (iii).) Therefore, we
proposed to modify the policy
embodied in 42 CFR 413.79(c)(2)(iii),
which the Court found in Hershey was
inconsistent with the statute.
The Court’s decision in Hershey held
that our prior rule governing
‘‘computation of the approved number
of full-time equivalent residents in an
approved medical residency training
program’’ (§ 1886(h)(4) of the Act) was
inconsistent with the statute. That
statute further requires us to ‘‘establish
rules consistent with this paragraph’’ for
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the computation of FTEs. Following our
review of the district court’s reasoning
in Hershey and the statute, we
concluded that our existing formula for
computing the number of FTEs was
inconsistent with the statutory
requirements. It is also our view that the
combination of the statutory
requirement to ‘‘establish rules’’ and the
Hershey court’s conclusion that our
existing rules are inconsistent with
statutory requirements necessitates a
new rulemaking. We further note that
the Hershey decision does not mandate
an alternative payment method, and we
do not believe that the decision—or our
independent conclusion that the
formula should be modified—forecloses
alternatives to the calculation method
we finalize here. In the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28411),
we stated our belief that, in order to
comply with the statutory requirement
to make rules governing the
computation of FTEs, it is necessary to
engage in a retroactive rulemaking to
modify the statutorily-required rule
effective for cost reporting periods
beginning on or after October 1, 2001.
While Hershey itself does not mandate
this conclusion, we believe it would be
inconsistent with the statute to calculate
past payments for open cost reports
based on a rule inconsistent with the
law, particularly where a court ordered
us to recalculate payments to plaintiffs.
Doing so via notice-and-comment
rulemaking is in the public interest
because it will permit interested
stakeholders to comment on the
proposed approach, allow the agency to
have the benefit of those comments in
the development of a final rule, and
calculate payments for past open cost
years in a transparent, consistent, and
efficient manner. This is particularly
true in this situation, where the existing
policy was promulgated via an interim
final rule with comment period, and the
agency received no comments on the
policy the court found unlawful.
In the proposed rule, we noted that
because we proposed to establish this
policy retroactively, it would cover cost
reporting periods for which many NPRs
have already been settled. Consistent
with § 405.1885(c)(2), any final rule
retroactively adopting the proposed new
policy would not be the basis for
reopening final settled NPRs.
After reviewing the statutory language
regarding the direct GME FTE cap and
the court’s reasoning, we decided to
propose a modified policy to be applied
for cost reporting periods beginning on
October 1, 2001, as described
previously. The proposed modified
policy would address situations for
applying the FTE cap when a hospital’s
PO 00000
Frm 00289
Fmt 4701
Sfmt 4700
49067
weighted FTE count was greater than its
FTE cap, but would not reduce the
weighting factor of residents that are
beyond their IRP by an amount less than
0.5. Section 1886(h)(4)(F) of the Act
states that for purposes of a cost
reporting period beginning on or after
October 1, 1997, the total number of
FTE residents before application of
weighting factors may not exceed the
number of such FTEs for the hospital’s
most recent cost reporting period ending
on or before December 31, 1996. Under
current policy, we interpreted this to
mean that only a hospital’s unweighted
(before application of weighting factors)
allopathic and osteopathic FTE count
was compared to its FTE cap, and if the
unweighted allopathic and osteopathic
FTE count exceeded the FTE cap, then
the proportional reduction is made to
the weighted FTE counts. Under this
modified proposed policy, in the
instance where a hospital’s unweighted
allopathic and osteopathic FTE count
exceeds its FTE cap, we proposed to add
a step to also compare the total weighted
allopathic and osteopathic FTE count to
the FTE cap. If the total weighted
allopathic and osteopathic FTE count is
equal to or less than the FTE cap, then
no adjustments would be made to the
respective primary care & OB/GYN
weighted FTE counts or the other
weighted FTE counts. If the total
weighted allopathic and osteopathic
FTE count exceeds the FTE cap, then we
would adjust the respective primary
care & OB/GYN weighted FTE counts or
the other weighted FTE counts to make
the total weighted FTE count equal the
FTE cap, as follows:
((primary care & OB/GYN weighted
FTEs/total weighted FTEs) × FTE
cap)) + ((other weighted FTEs/total
weighted FTEs) × FTE cap)).
The sum would be the current year
total allowable weighted FTE count,
which would be reported on Worksheet
E–4, line 9, column 3.
More specific to the Medicare cost
report, we proposed to revise the
instructions to Worksheet E–4, line 9 to
state: If line 6 is less than or equal to
line 5, enter the amounts from line 8,
columns 1 and 2, in columns 1 and 2,
of this line. Otherwise, if the total
weighted FTE count from line 8, column
3 is greater than the amount on line 5,
then enter in column 1 the result of
((primary care & OBGYN weighted
FTEs/total weighted FTEs) × FTE cap)).
Enter in column 2 the result of ((other
weighted FTEs/total weighted FTEs) ×
FTE cap)). Enter in column 3 the sum
of
((primary care & OBGYN weighted
FTEs/total weighted FTEs) × FTE
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49068
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
cap)) + ((other weighted FTEs/total
weighted FTEs) × FTE cap)).
Example : [Note—see the comments
and responses later in this section for a
revised version of this Example 1]
Hospital with an FTE cap of 100 trains
120 FTEs with a weight of 1.0, and 105
FTEs with a weight of 0.5, consisting of
70 weighted primary care & OBGYN
FTEs and 35 weighted other FTEs. Since
the total weighted count of 105
(Worksheet E–4, line 8, column 3)
exceeds the FTE cap of 100 (Worksheet
E–4, line 5), the Hospital reports the
following adjusted weighted FTE counts
on Worksheet E–4:
Line 9, column 1: ((70 weighted
primary care & OBGYN FTEs/105 total
weighted FTEs) × 100 cap)) = 66.67.
Line 9, column 2: ((35 weighted other
FTEs/105 total weighted FTEs) × 100
cap)) = 33.33.
Line 9, column 3: 66.67 FTEs + 33.33
FTEs = 100.
Example 2: Hospital with an FTE cap
of 100 trains 102 unweighted FTEs,
equating to 96 weighted FTEs. This 96weighted count consists of 30 weighted
primary care & OBGYN FTEs, and 66
weighted other FTEs. Since the total
weighted count of 96 (Worksheet E–4,
line 8, column 3) is less than the FTE
cap of 100 (Worksheet E–4, line 5), then
no further adjustment is needed; enter
the amounts from line 8, columns 1 and
2, in columns 1 and 2, of line 9.
Example 3: Hospital with a cap of 100
FTEs trains 90 FTEs with a weight of
1.0, and 20 FTEs with a weight of 0.5.
Since the total weighted count is 100
(90 + (20 × 0.5)), then no further
adjustment is needed. Enter the
amounts from line 8, columns 1 and 2,
in columns 1 and 2 of line 9.
Comment: We received many
comments supporting our proposed
revision to the weighted count
methodology and to the Medicare cost
reporting instructions. Commenters
urged CMS to finalize the proposed
revision, asserting it is required by the
law and the court’s order, and to
recalculate payments immediately, as
over a year has passed since the court
order.
Response: We appreciate the
commenters’ support, and upon
issuance of this final rule, we will work
with the MACs and other impacted
parties to recalculate and issue adjusted
payments as soon as possible.
Comment: Many commenters urged
CMS to abandon the proposal to use
retroactive rulemaking as the means of
complying with the decision of the
Hershey court. These commenters stated
that retroactive rulemaking is strongly
disfavored under the Medicare statute
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
and permitted only under limited
circumstances as specified in section
1871(e)(1)(A) of the Act, namely, when
it is either necessary to comply with
statutory requirements
(§ 1871(e)(1)(A)(i)) of the Act); or when
failure to apply the change retroactively
would be contrary to the public interest
(§ 1871(e)(1)(A)(ii) of the Act).
Commenters asserted that neither of
these exceptions applies in the present
case.
With respect to the exception at
section 1871(e)(1)(A)(i) of the Act,
commenters stated that retroactive
rulemaking is not necessary for CMS to
comply with statutory requirements.
Commenters said that the Medicare
statute is unambiguous with respect to
the weighting of residents and fellows,
and that the proposed revision to the
methodology is the only way for CMS to
comply with the statutory directive and
the Hershey decision, neither of which
requires any interpretation by the
agency. Commenters also stated that the
exception at section 1871(e)(1)(A)(ii)
does not apply, since it does not serve
the public interest for CMS to engage in
retroactive rulemaking and to entertain
public comments on actions that the
agency is required to take under a
legally binding court order. According
to a commenter, engaging in retroactive
rulemaking in this instance implicitly
contradicts the court’s decision, while
others expressed concern that it would
create a precedent whereby CMS might
invoke public interest in receiving
comments as a justification for virtually
any retroactive rule change.
Commenters also stated that it is not
necessary for CMS to engage in
retroactive rulemaking to benefit from
public comments, pointing out that in
the past the agency has made retroactive
policy changes via program instruction
and only submitted the policies to
public comment for purposes of
prospective application.
Commenters also rejected the
argument that retroactive rulemaking in
this instance is necessary to comply
with the Supreme Court’s ruling in Azar
v. Allina Health Services. Commenters
observed that the Allina ruling
established the need for notice-andcomment rulemaking to change a
substantive legal standard governing
payment where the agency engages in
‘‘gap-filling’’ an ambiguous statute.
However, as previously stated,
commenters believed that the statute is
unambiguous with regard to the
weighting of residents and fellows, and
that therefore there are no gaps for the
agency to fill. In other words, as stated
by a commenter, the proposed policy is
already dictated by the statute as
PO 00000
Frm 00290
Fmt 4701
Sfmt 4700
explained in Hershey, and there is no
room for CMS to substantively change
the policy enacted by Congress.
Furthermore, commenters disagreed
with CMS’s position, as originally stated
in the FY 2023 IPPS/LTCH proposed
rule, that retroactive rulemaking is
necessary in the wake of the Hershey
ruling since the Secretary ‘‘has no
promulgated rule governing’’ direct
GME payments to teaching hospitals
over the cap for cost reporting periods
beginning on or after October 1, 2001
(87 FR 28411). A number of commenters
stated that the Hershey court did not
leave CMS with a regulatory void to fill,
but merely ruled ‘‘that the regulation is
unlawful as applied to the Plaintiffs’’;
even if the court had vacated the
existing regulation, these commenters
asserted that notice-and-comment
rulemaking would not be required or
appropriate to acquiesce to the vacatur.
By contrast, another commenter stated
that the existing regulation is a ‘‘legal
nullity’’ in light of the Hershey decision,
but nevertheless stated that the statutory
payment directive requires no
substantive change in policy and can be
properly effectuated without
rulemaking.
Citing a number of examples,
commenters observed that historically,
both before and after Allina, CMS has
implemented policy changes to resolve
appeals or comply with court decisions
without engaging in retroactive
rulemaking, and invoked its retroactive
rulemaking authority only under
particular circumstances, such as in
response to a natural disaster or when
a rule is published after a statute’s
effective date. Only more recently,
according to commenters, has CMS
inappropriately begun to engage in
retroactive rulemaking in response to
litigation. Rather than engage in
retroactive rulemaking to comply with
the Hershey decision, commenters
urged CMS to make the change in
regulation prospectively and to employ
other appropriate means, such as
program instruction to the MACs or
settlement with hospitals, to implement
the proposed correction for past years.
While urging CMS to abandon
retroactive rulemaking as the means of
complying with the Hershey decision,
commenters stated that, if CMS does
engage in retroactive rulemaking, it
should specify exactly which hospitals
and past cost reporting periods will be
eligible for relief under the revised
policy. In particular, commenters
pointed out that CMS proposed that
‘‘certain other providers’’ will be
eligible for relief in addition to the
plaintiffs in Hershey, but the preamble
does not make it clear who those
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
providers will be. These commenters
stated that CMS should reopen all cost
reports within the three-year reopening
period and recalculate direct GME
payments consistent with the statute. At
a minimum, however, the ‘‘certain other
providers’’ should include any provider
that, if applicable, has an appeal
pending with the Provider
Reimbursement Review Board or in
federal court on the same issue as
Hershey. In addition, if CMS does not
reopen all cost reports that are within
the three-year reopening period, it
should nonetheless apply the
methodology any time a cost report is
reopened and the direct GME payment
is altered. Other commenters likewise
stated that hospitals should be
permitted to reopen their cost reports
for the purpose of recalculating their
direct GME payments according to the
revised weighting methodology, and
that CMS should not finalize any
ongoing cost report audits until the final
rule has been issued.
Some commenters expressed concern
that CMS’s proposal to extend relief to
only certain providers is inconsistent
with concept of retroactive rulemaking.
Another commenter objected to CMS’s
statement that under 42 CFR
405.1885(c)(2), any final rule
retroactively adopting the proposed new
policy would not be the basis for
reopening final settled NPRs (87 FR
28411). This commenter asserted that
§ 405.1885(c)(2) does not apply to
retroactive rulemaking, and that CMS’s
proposal has ‘‘no real retroactive effect’’
if it does not serve as the basis for
reopening settled cost reports. Another
commenter similarly recommended that
CMS make the new policy ‘‘fully
retroactive’’ so that even final settled
NPRs subject to reopening may be
reopened for the purpose of applying
the revised methodology. This
commenter stated that withholding
relief from certain providers would be
arbitrary and capricious and result in
CMS not fully complying with the
statute.
Response: We appreciate the
comments regarding our proposal to
implement the court’s decision in
Hershey retroactively, but for the
reasons that follow (as well as those
stated in the proposed rule), we are
finalizing our policy as proposed,
retroactive to 2001.
We agree with commenters who
objected to our statement that there is
‘‘no promulgated rule governing’’ direct
GME payments to over-the-cap
hospitals. The Hershey court did not
vacate the rule. We further agree that the
Hershey decision itself does not require
us to engage in retroactive rulemaking.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
However, the statute at issue states that
‘‘[t]he Secretary shall establish rules
consistent with this paragraph for the
computation of the number of full-time
equivalent residents in an approved
medical residency training program.’’
Section1886(h)(4)(A) of the Act
(emphasis added). And the Hershey
court did say that the rules at issue were
not consistent with the statute.
Following our review of the Hershey
court’s reasoning and the statutory
requirements, we decided that our
method for computing FTEs was not
consistent with statutory requirements.
We therefore conclude that our existing
rule, which does not comply with the
statute, should be modified retroactively
such that our FTE computation rules are
consistent with the statute and
payments, including payments for open
cost years in past, are calculated
pursuant to regulation.
Several commenters state that no rule
is necessary because of an express
statutory mandate that fellows be
counted as 0.5 FTE. We disagree, for
two reasons. First, there are two express
statutory mandates in the section cited
by commenters: that the Secretary
promulgate rules, and that those rules
weight fellows at 0.5 FTE (see sections
1886(h)(4)(A) and 1886(h)(4)(C)(iv) of
the Act). In other words, the statutory
language cited by commenters describes
the content of the rules the Secretary is
required to promulgate, rather than
setting an independent statutory
benchmark. Second, we disagree with
the commenters’ position that the rule
we proposed was the only possible way
to compute FTE counts in light of
Hershey. Section 1886(h)(4)(C) is not the
only relevant statutory provision
governing the content of the rule;
section 1886(h)(4)(F)(i) of the Act
requires the rules to cap the number of
unweighted residents based on a
hospital’s FY 1996 FTE count. In
Hershey itself, the court did not
mandate a particular method of
calculation or require CMS to adopt the
plaintiffs’ proposed calculation method.
We believe that there is more than one
way to comply with the statutory
requirements and the court’s order. Our
decision in this rule does not mean that
all other alternatives were foreclosed by
the Hershey decision. The Hershey court
decision held that the prior regulation
governing FTE counting for over-the-cap
hospitals was unlawful. It did not
mandate any particular alternative
approach. We further disagree with
commenters to the extent they suggest
that we compute FTE counts without a
rule in place for doing so. As discussed
PO 00000
Frm 00291
Fmt 4701
Sfmt 4700
49069
elsewhere, the statute at issue requires
the Secretary to establish a rule.
Even if the Hershey decision did
mandate a single method of computing
FTE counts, it was silent on how to
incorporate that computation into the
three-year rolling average. Without a
rule for determining the inputs to the
three-year-rolling average, which we
proposed and are now finalizing, it is
impossible to calculate a given
provider’s dollar reimbursement.
Therefore, even if we agreed with
commenters that the Hershey decision
provided sufficient guidance for
computing FTE counts and that no
further rulemaking on that issue is
required, we would nonetheless
consider it necessary to undergo
rulemaking to implement our response
to the decision, that is, use its
requirements to develop a method for
calculating reimbursement. For these
reasons, we disagree with commenters
who believe that notice-and-comment
rulemaking is unnecessary to implement
the Hershey decision, including for past
cost years.
We appreciate the comments about
retroactive rulemaking here being
inconsistent with CMS’s historical
practice. Many of the examples raised
by commenters do not involve judicial
decisions calling into question agency
rules, which is a key factor here, as we
noted in the proposed rule. The
governing statute requires the Secretary
to promulgate rules governing
reimbursement that are consistent with
statutory requirements, and the court’s
decision in Hershey concluded that our
existing rule was not consistent with
those requirements. We do not believe
that using retroactive rulemaking in this
instance is inconsistent with our past
practice.
We acknowledge that our statutory
authority to engage in retroactive
rulemaking is limited by section
1871(e)(1)(A) of the Act. As previously
discussed, we believe that the explicit
statutory requirement that the Secretary
promulgate a rule governing GME
reimbursement renders retroactive
application here ‘‘necessary to comply
with statutory requirements.’’
1871(e)(1)(A)(i). If we promulgated this
rule prospectively only, a necessary
result would be that some hospitals
would receive GME reimbursement
based on a computation of FTE
equivalents that was not established by
rule. We emphasize again that the rule
at issue in Hershey and the rule we
promulgate here are not merely
statutory gap-fillers. The statute
affirmatively requires us to promulgate
a rule.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49070
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
In the alternative, and even if it were
permissible to compute the number of
FTEs without a rule governing the
methodology for doing so, we believe
that retroactive rulemaking here is in
the public interest (section
1871(e)(1)(A)(ii) of the Act). In response
to comments, we want to make clear
that we believe that public notice-andcomment will benefit the rulemaking
process generally. As we noted in the
preamble, there was limited public
comment on the key provisions of the
original rulemaking that the Hershey
court found inconsistent with statutory
requirements. And we acknowledge—
and we do not believe that commenters
disagree—that it is necessary to
recalculate past payments in light of the
Hershey decision. The public interest
will be served by having past payments
calculated in the same way as future
payments, and given our view that it is
necessary to engage in notice-andcomment rulemaking to implement the
Hershey decision, we believe it is
sensible and efficient to calculate past
payments based on a formula
promulgated with the benefit of noticeand-comment rulemaking. We do not
mean to imply that the public interest
requires consistency between past
payments and future payments in all
conceivable situations. However,
where—as here— payment was set by a
regulation that a court held inconsistent
with substantive statutory requirements
and the agency engages in new noticeand-comment rulemaking to implement
that judicial ruling, there is a public
benefit in having past payments
calculated via the same method as
future payments. This is particularly
true where the statute at issue requires
that payments be calculated pursuant to
a rule. We therefore believe that this is
a case where the public interest in
having a rule applicable to all payments,
both past and future, justifies retroactive
rulemaking. It would be contrary to the
public interest for plaintiffs in Hershey
and other judicial challenges to have
their payments calculated by a different
methodology (whether more or less
generous than the methodology
established by regulation) than other
providers that are otherwise similarly
situated. Retroactive rulemaking in this
situation, benefits the public interest by
achieving parity in payment among
similarly situated hospitals.
We also believe that the public
interest is served by having payments
for past open cost years calculated in a
transparent, efficient, and not
administratively burdensome fashion,
an interest that is served by
promulgating a rule (following notice-
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
and-comment) that applies to those cost
years. This rule will allow us to
calculate payments to hospitals with
open cost reports based on a universal
and transparent formula, and it will
allow many hospitals (and MACs) to
avoid the administrative expense of
calculating payments based on a
formula that the agency has concluded
should not be applied. The public
interest is further served by reducing the
need for hospitals to file administrative
appeals in order to obtain the benefit of
the new payment formula.
We appreciate comments regarding
the applicability of 42 CFR
405.1885(c)(2) to this rule. We disagree
that 405.1885(c)(2) does not apply to
retroactive rules. The text of the
regulation does not support that
proposed carve-out. The rule we
proposed—and finalize here—is a
‘‘change of legal interpretation or policy
by CMS in a regulation . . . made in
response to judicial precedent,’’ and
thus it is ‘‘not a basis for reopening a
CMS or contractor determination.’’
Some commenters urged us to apply 42
CFR 405.1885(c)(1) to direct contractors
to reopen cost reports, but we note that
paragraph (c)(1) allows CMS to do so
(‘‘CMS may direct a contractor . . . to
reopen and revise’’) subject to the
prohibited reopening’s in paragraph
(c)(2). We disagree that this rule will
have no ‘‘real retroactive effect,’’ as a
number of hospitals will receive
increased reimbursement for past cost
reporting years.
We further disagree that it is arbitrary
and capricious to apply 405.1885(c)(2)
here. This is not the first time that we
have made a policy change that could
potentially affect closed cost reports,
and we have previously declined to
direct reopening of closed cost reports
consistent with the policy favoring
finality embedded in 405.1885(c)(2). For
example, we permitted qualifying
hospitals to request application of a
policy change made in the FY 2020 IPPS
rule to FYs 2011 through 2017, ‘‘subject
to the reopening rules at 42 CFR
405.1885.’’ (84 FR 42349) We believe
that the policy we finalize here is
consistent with our past practice and
our general approach toward finality.
Comment: Many commenters
appreciated that CMS proposed that ‘‘If
the number of FTE residents weighted
in accordance with paragraph (b) of this
section does not exceed [the FTE cap],
then the allowable weighted FTE count
is the actual weighted FTE count.’’
However, some commenters pointed out
that CMS’s proposed change to the
instructions for line 9 of Worksheet E–
4 does not contain language reflecting
this scenario and requested that CMS
PO 00000
Frm 00292
Fmt 4701
Sfmt 4700
add a third sentence to the proposed
changes to the instructions for line 9.
The sentence should state as follows: ‘‘If
the total weighted FTE count from line
8, column 3 is less than or equal to the
amount on line 5, then enter the
amounts from line 8, columns 1 and 2,
in columns 1 and 2 of this line.’’
Response: We agree with the
commenters’ request and will revise the
proposed instructions to Worksheet E–
4, line 9 to address the commenters’
request. However, since we are adding
the sentence requested by the
commenters, then we are removing the
following: ‘‘If line 6 is less than or equal
to line 5, enter the amounts from line 8,
columns 1 and 2, in columns 1 and 2,
of this line.’’ This latter sentence is not
necessary, since if line 6 is less than or
equal to line 5, then by default line 8,
column 3 will also be less than or equal
to line 5. We are revising the
instructions to Worksheet E–4, line 9 to
state: If the total weighted FTE count
from line 8, column 3 is less than or
equal to the amount on line 5, then
enter the amounts from line 8, columns
1 and 2, in columns 1 and 2 of this line
(emphasis added). Otherwise, if the total
weighted FTE count from line 8, column
3 is greater than the amount on line 5,
then enter in column 1 the result of
((primary care & OBGYN weighted
FTEs/total weighted FTEs) × FTE cap)).
Enter in column 2 the result of ((other
weighted FTEs/total weighted FTEs) ×
FTE cap)). Enter in column 3 the sum
of columns 1 and 2.
Under section 1886(h)(4)(G)(i) and 42
CFR 413.79(d)(3), a hospital’s weighted
FTE count for payment purposes is the
3-year average of its current year
weighted FTEs, prior year weighted
FTEs, and penultimate year FTEs (for
primary care & OBGYN FTEs and other
FTEs respectively). Effective for cost
reporting periods beginning on or after
October 1, 2001, we proposed to
implement this modified methodology
for the purpose of determining the prior
year weighted FTE count on line 12 of
Worksheet E–4, and for the purpose of
determining the penultimate year’s
weighted FTE count on line 13 of
Worksheet E–4, even though the prior
and penultimate years’ FTE counts
would be from cost reporting periods
prior to October 1, 2001. In this manner,
the modified methodology would be
fully applied to determining the direct
GME payment for cost reporting periods
beginning on or after October 1, 2001.
Therefore, we proposed to modify the
cost report instructions on Worksheet
E–4, lines 12 and 13, respectively to
state that effective for cost reporting
periods beginning on or after October 1,
2001, if subject to the cap in the prior
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
year or penultimate year respectively, if
the prior/penultimate year total
weighted FTE count from line 8, column
3 is greater than the amount on line 5
from the prior/penultimate year, then
enter in column 1 the result of ((primary
care & OBGYN weighted FTEs/total
weighted FTEs) × FTE cap)). Enter in
column 2 the result of ((other weighted
FTEs/total weighted FTEs) × FTE cap))
plus the amount on line 10, column 2.
These instructions do not in any way
modify or reopen final-settled prior and
penultimate year NPRs.
Comment: Some commenters
supported CMS’s proposal to update the
cost report instructions for lines 12 and
13 of Worksheet E–4 to ensure that the
weighted resident FTE counts from the
prior and penultimate years will be
updated to reflect the new direct GME
payment formula. However, the
commenters pointed out that the
proposed language for lines 12 and 13
does not specify how to calculate the
weighted FTE count for the prior and/
or penultimate years when the
unweighted FTE count from those years
exceeds the FTE cap, but the weighted
FTE count from those years does not,
and requested that CMS add a sentence
to the instructions for lines 12 and 13
stating: ‘‘If the prior/penultimate year
total weighted FTE count from line 8,
column 3 is less than or equal to line 5
from the prior/penultimate year, then
enter the amounts from line 8, columns
1 and 2, in columns 1 and 2 of this
line.’’
Response: We agree with the
commenters’ request and are revising
the instructions on Worksheet E–4 lines
12 and 13 to state: Effective for cost
reporting periods beginning on or after
October 1, 2001, if the prior/penultimate
year total weighted FTE count from line
8, column 3 is less than or equal to line
5 from the prior/penultimate year, then
enter the amounts from line 8, columns
1 and 2, in columns 1 and 2 of this line
(emphasis added). If subject to the cap
in the prior year or penultimate year
respectively, if the prior/penultimate
year total weighted FTE count from line
8, column 3 is greater than the amount
on line 5 from the prior/penultimate
year, then enter in column 1 the result
of ((primary care & OBGYN weighted
FTEs/total weighted FTEs) × FTE cap)).
Enter in column 2 the result of ((other
weighted FTEs/total weighted FTEs) ×
FTE cap)) plus the amount on line 10,
column 2.
Comment: Several commenters
observed that CMS should have also
proposed to apply the revised direct
GME weighting methodology to the socalled ‘‘section 422 MMA (Medicare
Modernization Act) cap slots’’ as well.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Specifically, many teaching hospitals
received additional FTE caps following
a redistribution of unused FTE cap slots
mandated by section 422 of the MMA.
Similar to the fellowship penalty, CMS
applies a proportional methodology
when determining payment for section
422 cap FTEs. The commenters
suggested that CMS calculate the
‘‘Section 422 Allowable Direct GME
FTE Resident Count’’ on Worksheet E–
4, line 22 as follows:
• If the weighted FTEs on line 8 are
less than or equal to the adjusted FTE
cap on line 5, the hospital would have
entered the weighted FTEs from line 8
on line 9. In this instance, the additional
section 422 cap slots are unnecessary,
and the hospital would enter zero on
line 22.
• If the weighted FTEs on line 8 are
greater than the adjusted FTE cap on
line 5, the hospital would have entered
the adjusted FTE cap on line 9. In this
instance, the hospital would subtract
line 9 from line 8 and proceed as
follows:
Æ If line 9 minus line 8 equals or
exceeds the ‘‘Section 422 Direct GME
FTE Cap’’ on line 20, then the hospital
would enter the amount from line 20 on
line 22.
Æ If line 9 minus line 8 is less than
line 20, the hospital would enter line 9
minus line 8 on line 20.
Response: We agree with the
commenters’ observation that the
revised methodology should apply to
the MMA section 422 FTE cap, as the
mathematical cap concept is the same
for the 422 FTE cap as it is for the
regular FTE cap. Accordingly, for
portions of cost reporting periods
beginning on or after July 1, 2005, the
effective date of section 422 under 42
CFR 413.79(c)(4), we will revise
Worksheet E–4, line 22, as follows:
For portions of cost reporting periods
beginning on or after July 1, 2005, if the
weighted FTE count on line 8 is less
than or equal to the adjusted FTE cap
on line 5, the hospital would have
entered the weighted FTEs from line 8
on line 9. In this instance, the additional
§ 422 cap slots are unnecessary; do not
complete lines 22 through 24. If the
weighted FTE count on line 8 is greater
than the adjusted FTE cap on line 5, the
hospital would have entered the
adjusted FTE cap on line 9. In this
instance, subtract line 9 from line 8. If
line 9 minus line 8 equals or exceeds
the ‘‘Section 422 Direct GME FTE Cap’’
on line 20, then enter the amount from
line 20 on line 22. If line 9 minus line
8 is less than line 20, enter line 9 minus
line 8 on line 22. (We note the
commenters indicated ‘‘enter line 9
PO 00000
Frm 00293
Fmt 4701
Sfmt 4700
49071
minus line 8 on line 20,’’ but we believe
they meant to say ‘‘on line 22’’).
We proposed to amend the
regulations text at 42 CFR
413.79(c)(2)(iii) to state that, effective
for cost reporting periods beginning on
or after October 1, 2001, if the hospital’s
unweighted number of FTE residents
exceeds the limit described in this
section of the final rule, and the number
of weighted FTE residents in accordance
with § 413.79(b) also exceeds that limit,
the respective primary care and
obstetrics and gynecology weighted FTE
counts and other weighted FTE counts
are adjusted to make the total weighted
FTE count equal the limit. If the number
of FTE residents weighted in accordance
with § 413.79(b) does not exceed that
limit, then the allowable weighted FTE
count is the actual weighted FTE count.
Comment: A commenter requested
that CMS make conforming changes to
the three-year rolling average regulation
at. § 413.79(d)(3) to clarify that the
weighted FTE counts for the ‘‘preceding
two cost reporting periods’’ must be
calculated in accordance with the
revised payment formula at
§ 413.79(c)(2)(iii).
Response: We agree to add a
parenthetical to the regulations at
§ 413.79(d)(3) to state, ‘‘For cost
reporting periods beginning on or after
October 1, 2001, the hospital’s weighted
FTE counts for the preceding two cost
reporting periods are calculated in
accordance with the payment formula at
42 CFR 413.79(c)(2)(iii)).’’
Comment: A commenter stated they
would like to see the three-year rolling
average eliminated retroactive to
October 1, 2001, as it would delay
implementation of CMS’s proposed
payment formula.
Response: Under section
1886(h)(4)(G)(i) and 42 CFR
413.79(d)(3), a hospital’s weighted FTE
count for payment purposes is the 3year average of its current year weighted
FTEs, prior year weighted FTEs, and
penultimate year weighted FTEs (for
primary care & OBGYN FTEs and other
FTEs respectively). Our proposed
interpretation of section 1886(h)(4)(F) of
the Act regarding application of
weighting factors does not change this
portion of the statute regarding
application of the 3-year rolling average.
Therefore, we are not adopting the
commenter’s request to eliminate
application of the rolling average under
our proposed payment formula.
Comment: Some commenters
requested that CMS correct or clarify
certain misstatements in the FY 2023
IPPS/LTCH PPS proposed rule regarding
the Hershey case. First, CMS should be
clearer about the position of the Hershey
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49072
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
plaintiffs. CMS described the position of
the Hershey plaintiffs as follows: ‘‘The
plaintiffs in these consolidated cases
alleged that as far back as 2005, the
proportional reduction that CMS
applied to the weighted FTE count
when the weighted FTE count exceeded
the FTE cap conflicted with the
Medicare statute’’ (87 FR 28410).
According to the commenters, this is an
incomplete description of the plaintiffs’
position. The commenters stated that
CMS’s proportional reduction also
impermissibly reduces the weighted
FTE count when the weighted FTE
count is less than unweighted FTE cap.
Second, the commenters believed that
‘‘Example 1’’ in the preamble is
misstated. In that example, a ‘‘Hospital
with an FTE cap of 100 trains 120 FTEs
with a weight of 1.0 and 105 FTEs with
a weight of 0.5, consisting of 70
weighted primary care & OBGYN FTEs
and 35 weighted other FTEs’’ (87 FR
28411). The ‘‘total weighted count’’ is
‘‘105.’’ The commenters noted that if the
hospital trained 120 FTEs with a weight
of 1.0 and 105 FTEs with a weight of
0.5, its unweighted FTE count would be
225 (120 + 105), and its weighted FTE
count would be 172.5 ((120 × 1.0) + (105
× 0.5)), not 105. The commenters
believed that CMS intended this
example to say that the hospital had an
unweighted FTE count of 120 and a
weighted FTE count of 105. The 105
weighted FTEs would consist of 90
FTEs weighted at 1.0 and 30 FTEs
weighted at 0.5.
Response: Regarding the first point
about not fully capturing Plaintiffs’
position, we acknowledge the
commenters’ assertion that the plaintiffs
in Hershey argued that CMS’s
proportional reduction impermissibly
reduced the weighted FTE count when
the weighted FTE count was less than
unweighted FTE cap.
Regarding the second point that the
commenters believe that Example 1 is
misstated, we acknowledge the
confusing wording, and we are
providing a corrected Example 1 as
follows:
Example 1 Revised: Hospital with an
FTE cap of 100 trains 120 unweighted
FTEs, consisting of 105 weighted FTEs
(90 FTEs weighted at 1.0 and 30 FTEs
weighted at 0.5 = 105 weighted FTEs).
The 105 weighted FTEs further consists
of 70 weighted primary care & OBGYN
FTEs and 35 weighted other FTEs. Since
the total weighted count of 105
(Worksheet E–4, line 8, column 3)
exceeds the FTE cap of 100 (Worksheet
E–4, line 5), the Hospital reports the
following adjusted weighted FTE counts
on Worksheet E–4:
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Line 9, column 1: ((70 weighted
primary care & OBGYN FTEs/105 total
weighted FTEs) × 100 cap)) = 66.67.
Line 9, column 2: ((35 weighted other
FTEs/105 total weighted FTEs) × 100
cap)) = 33.33.
Line 9, column 3: 66.67 FTEs + 33.33
FTEs = 100.
Comment: A commenter requested
clarification on the implications of the
Medicare direct GME formula change
for hospitals that participate in the
Children’s Hospitals Graduate Medical
Education (CHGME) program
administered by HRSA.
Response: Since the CHGME program
is administered by HRSA and not by
CMS, we defer to HRSA to determine
the implications of CMS’s change to the
Medicare direct GME payment formula.
After consideration of comments
received, we are finalizing our proposed
policy and regulations text at 42 CFR
413.79(c)(2)(iii) to state that, effective
for cost reporting periods beginning on
or after October 1, 2001, if the hospital’s
unweighted number of FTE residents
exceeds the limit described in this
section of the final rule, and the number
of weighted FTE residents in accordance
with § 413.79(b) also exceeds that limit,
the respective primary care and
obstetrics and gynecology weighted FTE
counts and other weighted FTE counts
are adjusted to make the total weighted
FTE count equal the limit. If the number
of FTE residents weighted in accordance
with § 413.79(b) does not exceed that
limit, then the allowable weighted FTE
count is the actual weighted FTE count.
In response to comments, we are also
making a conforming change to the
regulations text at 42 CFR 413.79(d)(3)
regarding application to the 3-year
rolling average to state that for cost
reporting periods beginning on or after
October 1, 2001, the hospital’s weighted
FTE counts for the preceding two cost
reporting periods are calculated in
accordance with the payment formula at
§ 413.79(c)(2)(iii). In addition, in
response to comments, we are applying
the new payment methodology to the
MMA section 422 FTE cap.
3. Reasonable Cost Payment for Nursing
and Allied Health Education Programs
a. General
Under section 1861(v) of the Act,
Medicare has historically paid providers
for Medicare’s share of the costs that
providers incur in connection with
approved educational activities.
Approved nursing and allied health
(NAH) education programs are those
that are, in part, operated by a provider,
and meet State licensure requirements,
or are recognized by a national
PO 00000
Frm 00294
Fmt 4701
Sfmt 4700
accrediting body. The costs of these
programs are excluded from the
definition of inpatient hospital
operating costs and are not included in
the calculation of payment rates for
hospitals or hospital units paid under
the IPPS, IRF PPS, or IPF PPS, and are
excluded from the rate-of-increase
ceiling for certain facilities not paid on
a PPS. These costs are separately
identified and ‘‘passed through’’ (that is,
paid separately on a reasonable cost
basis). Existing regulations on NAH
education program costs are located at
§ 413.85. The most recent rulemakings
on these regulations were in the January
12, 2001 final rule (66 FR 3358 through
3374), and in the August 1, 2003, final
rule (68 FR 45423 and 45434).
b. Medicare+Choice Nursing and Allied
Health Education Payments
Section 541 of the Balanced Budget
Refinement Act (BBRA) of 1999
provides for additional payments to
hospitals for costs of nursing and allied
health education associated with
services to Medicare+Choice (now
called Medicare Advantage (MA))
enrollees. Hospitals that operate
approved nursing or allied health
education programs and receive
Medicare reasonable cost
reimbursement for these programs
would receive additional payments from
MA organizations. Section 541 of the
BBRA limits total spending under the
provision to no more than $60 million
in any calendar year (CY). (In this
document, we refer to the total amount
of $60 million or less as the payment
‘‘pool’’.) Section 541 of the BBRA also
provides that direct graduate medical
education (GME) payments for
Medicare+Choice utilization are
reduced to the extent that these
additional payments are made for
nursing and allied health education
programs. This provision was effective
for portions of cost reporting periods
occurring in a CY, on or after January 1,
2000.
Section 512 of the Benefits
Improvement and Protection Act (BIPA)
of 2000 changed the formula for
determining the additional amounts to
be paid to hospitals for MA nursing and
allied health costs. Under section 541 of
the BBRA, the additional payment
amount was determined based on the
proportion of each individual hospital’s
nursing and allied health education
payment to total nursing and allied
health education payments made to all
hospitals. However, this formula did not
account for a hospital’s specific MA
utilization. Section 512 of the BIPA
revised this payment formula to
specifically account for each hospital’s
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
MA utilization. This provision was
effective for portions of cost reporting
periods occurring in a calendar year,
beginning with CY 2001, and was
implemented in the August 1, 2001 IPPS
final rule (66 FR 39909 and 39910).
The regulations at 42 CFR 413.87
codified both statutory provisions. We
first implemented the BBRA NAH MA
provision in the August 1, 2000 IPPS
interim final rule with comment period
(IFC) (65 FR 47036 through 47039). In
that IFC, we outlined the qualifying
conditions for a hospital to receive the
NAH MA payment, how we would
calculate the NAH MA payment pool,
and how a qualifying hospital would
calculate its ‘‘share’’ of payment from
that pool. Determining a hospital’s NAH
MA payment essentially involves
applying a ratio of the hospital-specific
NAH Part A payments, total inpatient
days, and MA inpatient days, to
national totals of those same amounts,
from cost reporting periods ending in
the fiscal year that is 2 years prior to the
current calendar year. The formula is as
follows:
(((Hospital NAH pass-through payment/
Hospital Part A Inpatient Days) *
Hospital MA Inpatient Days)/
((National NAH pass-through
payment/National Part A Inpatient
Days) * National MA Inpatient
Days)) * Current Year Payment
Pool.
With regard to determining the total
national amounts for NAH pass-through
payment, Part A inpatient days, and MA
inpatient days, we note that section
1886(l) of the Act, as added by section
541 of the BBRA, gives the Secretary the
discretion to ‘‘estimate’’ the national
components of the formula noted
previously. For example, section
1886(l)(2)(A) of the Act states that the
Secretary would estimate the ratio of
payments for all hospitals for portions
of cost reporting periods occurring in
the year under subsection 1886(h)(3)(D)
to total direct GME payments estimated
for the same portions of periods under
subsection 1886(h)(3) of the Act.
Accordingly, we made the following
statements in the August 1, 2000 IFC:
• Each year, we would determine and
publish in a final rule and a final rule
the total amount of nursing and allied
health education payments made across
all hospitals during the fiscal year that
is 2 years prior to the current calendar
year (65 FR 47038). We would use the
best available cost reporting data for the
applicable hospitals from the Hospital
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Cost Report Information System (HCRIS)
for cost reporting periods in the fiscal
year that is 2 years prior to the current
calendar year (65 FR 47038).
• To calculate the pool, in accordance
with section 1886(l) of the Act, we
would ‘‘estimate’’ a total amount for
each calendar year, not to exceed $60
million (65 FR 47038).
• To calculate the proportional
reduction to Medicare+Choice (now
MA) Direct GME payments, we stated
that the percentage is estimated by
calculating the ratio of the
Medicare+Choice nursing and allied
health payment ‘‘pool’’ for the current
calendar year to the projected total
Medicare+Choice direct GME payments
made across all hospitals for the current
calendar year. We stated that the
projections of Medicare+Choice direct
GME and Part A direct GME are based
on the best available cost report data
from the HCRIS (for example, for
calendar year 2000, the projections are
based on the best available cost report
data from HCRIS 1998), and these
payment amounts were increased using
the increases allowed by section 1886(h)
of the Act for these services (using the
percentage applicable for the current
calendar year for Medicare+Choice
direct GME and the Consumer Price
Index (CPI) increases for Part A direct
GME). We also stated that we would
publish the applicable percentage
reduction each year in the IPPS
proposed and final rules (65 FR 47038).
Thus, in the August 1, 2000, IFC, we
described our policy regarding the
timing and source of the national data
components for the NAH MA add-on
payment and the percent reduction to
the direct GME MA payments, and we
stated that we would publish the rates
for each calendar year in the IPPS
proposed and final rules. While the
rates for CY 2000 were published in the
August 1, 2000, IFC (see 65 FR 47038
and 47039), the rates for subsequent CYs
were only issued through Change
Requests (CRs) (CR 2692, CR 11642, CR
12407). After recent issuance of the CY
2019 rates in CR 12407 on August 19,
2021, we reviewed our update
procedures, and were reminded that the
August 1, 2000 IFC states that we would
publish the NAH MA rates and direct
GME percent reduction every year in the
IPPS rules. Accordingly, for CY 2020
and forward, the NAH MA add-on rates
will be proposed and included in the
IPPS proposed and final rules, and we
PO 00000
Frm 00295
Fmt 4701
Sfmt 4700
49073
are also reiterating the data sources we
would use.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we proposed the NAH
MA add-on rates as well as the direct
GME MA percent reductions for CYs
2020 and 2021. We proposed to issue
the rates for CYs 2020 and 2021 because
we believe we have sufficient HCRIS
data to develop the rates for these years,
and these rate years are most needed to
ensure accurate and timely cost report
settlements of cost reports with portions
overlapping with CYs 2020 and 2021.
We expect to propose to issue the rates
for CY 2022 in the FY 2024 IPPS/LTCH
PPS proposed rule, and the rates for CY
2023 in the FY 2025 IPPS/LTCH PPS
proposed rule, and so forth.
Consistent with the use of HCRIS data
for past calendar years, for CY 2020, we
proposed to use data from cost reports
ending in FY 2018 HCRIS (the fiscal
year that is 2 years prior to CY 2020) to
compile these national amounts: NAH
pass-through payment, Part A Inpatient
Days, MA Inpatient Days. We proposed
to use data from cost reports ending in
FY 2019 HCRIS (the fiscal year that is
2 years prior to CY 2021) to compile the
same national amounts for CY 2021.
For the proposed rule, we accessed
the HCRIS data from the fourth
quarterly HCRIS update of 2021.
However, to calculate the ‘‘pool’’ and
the direct GME MA percent reduction,
we ‘‘project’’ Part A direct GME
payments and MA direct GME payments
for the current calendar years, which in
this final rule, are CYs 2020 and 2021,
based on the ‘‘best available cost report
data from the HCRIS’’ (65 FR 47038).
Next, consistent with the method we
described previously from the August 1,
2000 IFC, we increased these payment
amounts from midpoint to midpoint of
the appropriate calendar year using the
increases allowed by section 1886(h) of
the Act for these services (using the
percentage applicable for the current
calendar year for MA direct GME, and
the Consumer Price Index–Urban (CPI–
U) increases for Part A direct GME. For
CY 2020, the direct GME projections are
based on FY 2019 HCRIS. For CY 2021,
the direct GME projections are based on
FY 2019 HCRIS. For CYs 2020 and 2021,
the proposed national rates and
percentages, and their data sources are
set forth in this table. We stated in the
proposed rule that we intend to update
these numbers in the FY 2023 final rule
based on the latest available cost report
data.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
SOURCE
CY2020
$272,775,476
Cost reports ending in
FY 2018 HCRIS
Cost reports ending in
FY 2018 HCRIS
Cost reports ending in
FY 2018 HCRIS
NAH Pass-Through
64,510,859
Part A Inpatient Days
9,481,755
MA Inpatient Days
Part A Direct GME
$2,770,987,049
MA Direct GME
$1,617,557,770
Pool (not to exceed $60
million)
Percent Reduction to
MA DGME Payments
$60,000,000
khammond on DSKJM1Z7X2PROD with RULES2
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
66,521,096
10,705,665
$2,749,561,756
CY 2019 HCRIS + CPI-U
CY 2019 HCRIS + CPI-U
((Part A DGME/MA
DGME) * (NAH Passthrough))
(Pool/MA direct GME)
$1,862,798,849
CY 2019 HCRIS + CPI-U
$60,000,000
((Part A DGME/MA DGME)
* (NAH Pass-through))
3.22%
(Pool/MA direct GME)
payment. That is, hospitals that are both
teaching hospitals receiving direct GME
payments and that operate approved
NAH programs may be affected by both
aspects of these laws; such hospitals
may receive both a payment for MA
NAH, while also receiving a reduced
direct GME MA payment. Hospitals that
only operate NAH programs may only
receive the MA NAH payment;
conversely, teaching hospitals with no
approved NAH programs would only
receive the reduced direct GME MA
payment.
We received numerous comments
regarding various aspects of the MA
NAH add-on and the direct GME MA
percent reduction, expressing
opposition to reconciliation of
overpayments, voicing concerns
regarding reimbursement that does not
adequately reflect current costs and
nursing and healthcare workforce
shortages, and opposing reductions to
direct GME payments to fund NAH
programs. While concerns expressed in
these comments may be important, we
did not specifically make proposals
related to those concerns. These
comments are out of scope, and
therefore, we are not responding to them
at this time.
For this final rule, consistent with the
use of HCRIS data for past calendar
years, for CY 2020, we use data from
cost reports ending in FY 2018 HCRIS
(the fiscal year that is 2 years prior to
PO 00000
SOURCE
Cost reports ending in FY
2019 HCRIS
Cost reports ending in FY
2019 HCRIS
Cost reports ending in FY
2019 HCRIS
CY 2019 HCRIS + CPI-U
3.71%
We did not propose any changes to
the regulations text at 42 CFR 413.87, as
our proposal to include the nursing and
allied health MA rates in the IPPS
rulemaking was consistent with current
regulations.
Comment: A commenter requested
clarification on the calculation of the
direct GME MA percent reduction and
questioned if it is separate from the
allocation of funds used for the NAH
pass-through payment.
Response: We appreciate the
commenter’s request for clarification. As
explained previously in the background
section, under sections 541 of the BBRA
and 512 of BIPA, hospitals that operate
approved nursing or allied health
education programs and receive
Medicare reasonable cost
reimbursement for these programs
would receive additional payments for
services associated with MA enrollees.
Section 541 of the BBRA limits total
spending under the provision to no
more than $60 million in any calendar
year (CY). Section 541 of the BBRA also
provides for estimated reductions in
direct GME MA payments, which are to
equal the estimated total additional MA
NAH payments. Thus, nationally, the
estimated reductions to direct GME MA
payments would not be more than $60
million in any CY. However, on a
hospital-specific basis, the direct GME
MA percent reduction is not necessarily
tied to receipt of the MA NAH add-on
CY2021
$277,240,471
Frm 00296
Fmt 4701
Sfmt 4700
CY 2020) to compile these national
amounts: NAH pass-through payment,
Part A Inpatient Days, MA Inpatient
Days. We use data from cost reports
ending in FY 2019 HCRIS (the fiscal
year that is 2 years prior to CY 2021) to
compile the same national amounts for
CY 2021. For this final rule, we accessed
the HCRIS data from the first quarterly
HCRIS update of 2022. However, to
calculate the ‘‘pool’’ and the direct GME
MA percent reduction, we ‘‘project’’
Part A direct GME payments and MA
direct GME payments for the current
calendar years, which in this final rule,
are CYs 2020 and 2021 as the best
available cost report data. Next,
consistent with the method we
described previously from the August 1,
2000 IFC, we increased these payment
amounts from midpoint to midpoint of
the appropriate calendar year using the
increases allowed by section 1886(h) of
the Act for these services (using the
percentage applicable for the current
calendar year for MA direct GME, and
the Consumer Price Index–Urban (CPI–
U) increases for Part A direct GME. For
CY 2020, the direct GME projections are
based on FY 2019 HCRIS. For CY 2021,
the direct GME projections are based on
FY 2019 HCRIS. For CYs 2020 and 2021,
the final national rates and percentages,
and their data sources are set forth in
this table.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.130
49074
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
SOURCE
Cost reports ending in FY 2018 HCRIS
CY2021
$276,790,522
64,285,989
Cost reports ending in FY 2018 HCRIS
66,512,964
9,473,935
Cost reports ending in FY 2018 HCRIS
10,702,732
NAH Pass-Throul!;h
Part A Inoatient Davs
MA lnoatient Davs
Part A Direct GME
MA Direct GME
$2,772,451,903
$1,608,018,609
Pool (not to exceed $60 million)
Percent Reduction to MA DGME
Pavments
$ 60,000,000
khammond on DSKJM1Z7X2PROD with RULES2
4. Allowance of Medicare GME
Affiliation Agreements Within Certain
Rural Track FTE Limitations
Sections 1886(h)(4)(F) and
1886(d)(5)(B)(v) of the Act established
limits on the number of allopathic and
osteopathic residents that hospitals may
count for purposes of calculating direct
GME payments and the IME adjustment,
respectively, thereby establishing
hospital-specific direct GME and IME
full-time equivalent (FTE) resident caps.
However, under the authority granted
by section 1886(h)(4)(H)(ii) of the Act,
the Secretary may issue rules to allow
institutions that are members of the
same affiliated group to apply their
direct GME and IME FTE resident caps
on an aggregate basis through a
Medicare GME affiliation agreement.
The Secretary’s regulations permit
hospitals, through a Medicare GME
affiliation agreement, to increase or
decrease their IME and direct GME FTE
resident caps to reflect the rotation of
residents among affiliated hospitals for
agreed-upon academic years. Consistent
with the broad authority conferred by
the statute, we established criteria for
defining an ‘‘affiliated group’’ and an
‘‘affiliation agreement’’ in both the
August 29, 1997, final rule (62 FR
45966, 46006) and the May 12, 1998,
final rule (63 FR 26318). In the August
1, 2002, IPPS final rule (67 FR 50069),
we amended our regulations to require
that each Medicare GME affiliation
agreement must have a shared rotational
arrangement. The term ‘‘Medicare GME
affiliation agreement’’ is defined at 42
00:20 Aug 10, 2022
CY 2019 HCRIS + CPI-U
((Part A DGME/MA DGME)
Pass-throul!;h))
(Pool/MA direct GME)
$ 1,840,934,928
* (NAH
$ 60,000,000
3.71%
In summary, after consideration of the
public comments received, we are
finalizing our proposal to use NAH MA
add-on rates as well as the direct GME
MA percent reductions for CYs 2020
and 2021, based on sufficient HCRIS
data to develop the rates for these years.
We expect to propose to issue the rates
for CY 2022 in the FY 2024 IPPS/LTCH
PPS proposed rule, and the rates for CY
2023 in the FY 2025 IPPS/LTCH PPS
proposed rule, and so forth.
VerDate Sep<11>2014
$2,732,276,287
CY 2019 HCRIS + CPI-U
Jkt 256001
3.22%
CFR 413.75(b) as a written, signed, and
dated agreement by responsible
representatives of each respective
hospital in a Medicare GME affiliated
group, as defined in § 413.75(b), that
specifies—
• The term of the Medicare GME
affiliation agreement (which, at a
minimum is 1 year), beginning on July
1 of a year;
• Each participating hospital’s direct
and indirect GME FTE caps in effect
prior to the Medicare GME affiliation;
• The total adjustment to each
hospital’s FTE caps in each year that the
Medicare GME affiliation agreement is
in effect, for both direct GME and IME,
that reflects a positive adjustment to one
hospital’s direct and indirect FTE caps
that is offset by a negative adjustment to
the other hospital’s (or hospitals’) direct
and indirect FTE caps of at least the
same amount;
• The adjustment to each
participating hospital’s FTE counts
resulting from the FTE resident’s (or
residents’) participation in a shared
rotational arrangement at each hospital
participating in the Medicare GME
affiliated group for each year the
Medicare GME affiliation agreement is
in effect. This adjustment to each
participating hospital’s FTE count is
also reflected in the total adjustment to
each hospital’s FTE caps (in accordance
with in accordance with paragraph (3)
of this definition); and
• The names of the participating
hospitals and their Medicare provider
numbers.
We also define the term ‘‘Shared
Rotational Arrangement’’ in that section
of our rules as a residency training
program under which a resident(s)
participates in training at two or more
hospitals in that program.
To encourage the training of residents
in rural areas, section 407(c) of the
Medicare, Medicaid, and SCHIP
Balanced Budget Refinement Act of
1999 (Pub. L. 106–113) (BBRA)
amended section 1886(h)(4)(H) of the
Act to add a provision (subsection (iv))
stating that, in the case of a hospital that
PO 00000
Frm 00297
Fmt 4701
Sfmt 4700
SOURCE
Cost reports ending in FY 2019
HCRIS
Cost reports ending in FY 2019
HCRIS
Cost reports ending in FY 2019
HCRIS
CY 2019 HCRIS + CPI-U
CY 2019 HCRIS + CPI-U
((Part A DGME/MA DGME)
(NAH Pass-throul!;h))
*
(Pool/MA direct GME)
is not located in a rural area (an urban
hospital) that establishes separately
accredited approved medical residency
training programs (or rural tracks) in a
rural area, or has an accredited training
program with an integrated rural track,
the Secretary shall adjust the urban
hospital’s cap on the number of FTE
residents under section 1886(h)(4)(F) of
the Act, in an appropriate manner in
order to encourage training of
physicians in rural areas. Historically,
the Accreditation Council for Graduate
Medical Education (ACGME) has
separately accredited family medicine
programs in the ‘‘1–2 format’’ (meaning,
residents in the 1–2 format receive their
first year experience at a core family
medicine program, and their second and
third year experiences at another site,
which may or may not be rural). Section
407(c) of Public Law 106–113 was
effective for direct GME payments to
hospitals for cost reporting periods
beginning on or after April 1, 2000, and
for IME payments applicable to
discharges occurring on or after April 1,
2000. We refer readers to the August 1,
2000, interim final rule with comment
period (65 FR 47025, 47033 through
47037) and the FY 2002 IPPS final rule
(66 FR 39828, 39902 through 39909)
where we implemented section 407(c) of
Public Law 106–113. The regulations for
establishing rural track FTE limitations
are located at 42 CFR 413.79(k) for
direct GME and at 42 CFR
412.105(f)(1)(x) for IME. (We note that
additional legislative and regulatory
changes were made to Rural Track
Programs in the December 27, 2021 final
rule, 86 FR 73445.)
When we first implemented the rural
track regulations in the August 1, 2000
IFC, we specified that the caps
associated with rural tracks are separate
and distinct from a hospital’s general
FTE caps. Specifically, we defined Rural
track FTE limitation at 42 CFR 413.75(b)
as the maximum number of residents
training in a rural track residency
program that an urban hospital may
include in its FTE count and that is in
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.131
CY2020
$264,332,386
49075
khammond on DSKJM1Z7X2PROD with RULES2
49076
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
addition to the number of FTE residents
already included in the hospital’s FTE
cap (emphasis added). As a result, the
rural track FTE limitations are not part
of the regular FTE caps that hospitals
may aggregate in Medicare GME
affiliation agreements.
The rural track FTE limitations are
calculated in the same manner as the
adjustments to any allowable new
program, in accordance with 42 CFR
413.79(e)(1). That is, at the end of the 5year cap building window for the rural
track program, the urban hospital’s and
rural hospital respective IME and direct
GME rural track FTE limitations are
calculated as the product of three factors
(limited to the number of accredited
slots for each program):
• The highest total number of FTE
residents trained in any program year
during the fifth year of the first new
program’s existence at all of the
hospitals to which the residents in the
program rotate.
• The number of years in which
residents are expected to complete the
program, based on the minimum
accredited length for each type of
program.
• The ratio of the number of FTE
residents in the new program that
trained at the hospital over the entire 5year period to the total number of FTE
residents that trained at all hospitals
over the entire 5-year period.
Thus, while the calculated rural track
FTE limitations calculated at the end of
the 5-year window may reflect the
division of the rotations between the
urban and rural hospitals over the 5
initial years of the program, the future
rotations amounts may change
somewhat (albeit adhering to greater
than 50 percent of the duration of the
training occurring in the rural hospital/
rural area). As rotations shift to meet
patient care needs, the respective rural
track FTE limitations may not quite
match the amount of FTEs actually
training in the urban and rural
hospitals. There has been request that
the same flexibility with cap sharing
afforded to teaching hospitals to share
general FTE cap slots via Medicare GME
affiliation agreements also be afforded to
urban and rural teaching hospitals that
together train residents in a rural track
program. This flexibility would allow
the urban and rural hospitals to share
their rural track FTE limitations in a
manner that best matches the rotations
occurring in the urban and rural
hospitals. Stakeholders representing
urban-rural training partnerships
specifically raised this request with
regard to separately accredited 1–2
family medicine programs that have
existed for a number of years, and either
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
already have established their rural
track FTE limitations, or have just
recently reached or will reach the end
of their 5-year cap building windows.
We have considered this request and
agree it would be equitable to allow an
urban and rural hospital jointly training
residents in a 1–2 separately accredited
family medicine program to aggregate
their respective IME and direct GME
rural track FTE limitations and enter
into a ‘‘Rural Track Medicare GME
Affiliation Agreement’’ to share those
cap slots, and facilitate the crosstraining of residents. We proposed to
allow urban and rural hospitals that
participate in the same separately
accredited 1–2 family medicine rural
track program and have rural track FTE
limitations to enter into ‘‘Rural Track
Medicare GME Affiliation Agreements.’’
We proposed that programs that are not
separately accredited in the 1–2 format
and are not in family medicine would
not be permitted to enter into ‘‘Rural
Track Medicare GME Affiliation
Agreements’’ under this proposal. These
Rural Track Medicare GME Affiliation
Agreements, which we proposed to
define in this final rule, will be
structured similarly to regular Medicare
GME affiliation agreements, but we
proposed two distinct requirements.
First, in an effort to ensure that
regular FTE caps and FTE residents in
non-rural track programs are not
commingled with the rural track FTE
residents, and that rural track FTE
limitations are not being used to provide
additional cap slots for non-rural track
FTE residents, we proposed that the
responsible representatives of each
urban and rural hospital entering into
the Rural Track Medicare GME
Affiliation Agreement must attest in that
written agreement that each
participating hospital’s FTE counts and
rural track FTE limitations in the
agreement do not reflect FTE residents
nor FTE caps associated with programs
other than the rural track program. We
noted this attestation is important for
both the urban and rural hospital, as
both urban and rural hospitals may have
regular FTE caps that could be part of
regular Medicare GME affiliation
agreements (see 42 CFR 413.79(e)(1)(iv)
and (v) and 413.79(f)). Second, we
proposed to only allow urban and rural
hospitals to participate in Rural Track
Medicare GME Affiliated Groups if they
are separately accredited 1–2 family
medicine programs that have rural track
FTE limitations in place prior to
October 1, 2022. We proposed to choose
these criteria and this date of October 1,
2022, as the date by which eligible
hospitals must have rural track FTE
limitations in place because the
PO 00000
Frm 00298
Fmt 4701
Sfmt 4700
effective date of section 127 of the
Consolidated Appropriations Act (CAA)
is cost reporting periods beginning on or
after October 1, 2022, and we proposed
to limit this proposal to only rural track
FTE limitations established under the
BBRA of 1999 that are unaffected by
section 127 of the CAA. In this final
rule, we are distinguishing between
rural track programs with rural track
FTE limitations associated with the
BBRA of 1999 in effect prior to October
1, 2022, and Rural Track Programs
(RTPs, defined at 42 CFR 413.75(b))
started or expanded to new participating
sites under the authority of section 127
of the CAA. We explain this distinction
later in this section of the final rule.
First, we refer readers to the
December 27, 2021, final rule (86 FR
73445) for details about section 127 of
the CAA. Generally, that provision
removes the requirement that rural track
programs be separately accredited,
places in statute (previously in
regulation) the requirement that rural
track residents must spend greater than
50 percent of their training time in a
rural area, and allows urban and rural
hospitals to receive adjustments to their
rural track FTE limitations for adding
new rural training sites to an existing
rural track program. In that December
27, 2021, final rule, we addressed a
comment (86 FR 73456) that requested
whether multiple rural hospital training
sites added under the new section 127
authority may share their rural track
FTE limitations via a Medicare GME
affiliation agreement. We responded
that effective October 1, 2022, we are
not permitting the formation of
Medicare GME affiliated groups for the
purpose of aggregating and crosstraining RTP FTE limitations. First, we
explained that we believe Medicare
GME affiliated groups for RTPs would
be premature, as only starting October 1,
2022, would hospitals have the first
opportunity to add additional
participating sites. Subsequently, there
would be the 5-year cap building period
in which Medicare GME affiliations are
not permitted, even under existing
Medicare GME affiliation agreement
rules (42 CFR 413.79(f)). Second, we
stated that before we create Medicare
GME affiliation agreements unique to
RTPs, we believe it would be best to
first modify the Medicare cost report
form to add spaces for the hospitals to
indicate the number of any additional
RTP FTEs, and the caps applicable to
those FTEs. We also stated that we wish
to assess flexibility within a hospital’s
own total RTP FTE limitation, before
sharing those slots with other hospitals.
We would need to be vigilant to ensure
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
that the RTP FTE limitations are not
comingled with regular FTE cap
adjustments currently used in Medicare
GME affiliation agreements. Therefore,
we concluded with our belief that it is
best to reassess allowing Medicare GME
affiliation agreements for RTP FTE
limitations at some point in the future.
For these same reasons, at this time, we
believe it is appropriate to only propose
to allow rural track Medicare GME
affiliation agreements with urban and
rural hospitals that have a rural track
FTE limitation in place prior to October
1, 2022. We will assess allowing these
agreements with RTP FTE limitations
established after October 1, 2022, in the
future.
We proposed the following new
definitions and requirements at 42 CFR
413.75(b):
• ‘‘Rural track Medicare GME
affiliated group’’ is an urban hospital
and a rural hospital that participates in
a rural track program defined in 42 CFR
413.75(b), and that have rural track FTE
limitations in effect prior to October 1,
2022, and that comply with 42 CFR
413.79(f)(1) through (6) for Medicare
GME affiliated groups.
• ‘‘Rural track Medicare GME
affiliation agreement’’ is a written,
signed, and dated agreement by
responsible representatives of each
respective hospital in a rural track
Medicare GME affiliated group, as
defined in 42 CFR 413.75(b), that
specifies—
++ A statement attesting that each
participating hospital’s FTE counts and
rural track FTE limitations in the
agreement do not reflect FTE residents
nor FTE caps associated with programs
other than the rural track program.
++ The term of the rural track
Medicare GME affiliation agreement
(which, at a minimum is 1 year),
beginning on July 1 of a year;
++ Each participating hospital’s direct
and indirect GME rural track FTE
limitations in effect prior to the rural
track Medicare GME affiliation;
++ The total adjustment to each
hospital’s rural track FTE limitations in
each year that the rural track Medicare
GME affiliation agreement is in effect,
for both direct GME and IME, that
reflects a positive adjustment to one
hospital’s direct and indirect rural track
FTE limitations that is offset by a
negative adjustment to the other
hospital’s (or hospitals’) direct and
indirect rural track FTE limitations of at
least the same amount;
++ The adjustment to each
participating hospital’s FTE counts
resulting from the FTE resident’s (or
residents’) participation in a shared
rotational arrangement at each hospital
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
participating in the rural track Medicare
GME affiliated group for each year the
Medicare GME affiliation agreement is
in effect. This adjustment to each
participating hospital’s FTE count is
also reflected in the total adjustment to
each hospital’s rural track FTE
limitations (in accordance with
paragraph (iii) of the definition
(regarding the total adjustment to each
hospital’s rural track FTE limitations
previously noted)); and
++ The names of the participating
hospitals and their Medicare provider
numbers.
In addition, we proposed to require
that no later than July 1 of the residency
year during which the rural track
Medicare GME affiliation agreement
will be in effect, the urban and rural
hospital must submit the signed
agreement to the CMS contractor or
MAC servicing the hospital and send a
copy to the CMS Central Office. The
hospitals may submit amendments to
the adjustments to their respective rural
track FTE limitations to the MAC with
a copy to CMS by June 30 of the
residency year that the agreement is in
effect. We proposed that eligible urban
and rural hospitals may enter into rural
track Medicare GME affiliation
agreements effective with the July 1,
2023, academic year.
With regard to how the rural track
Medicare GME affiliation adjustments
would be reported on the Medicare cost
report, first, for background, we noted in
the proposed rule that on the previous
Medicare cost report CMS–Form–2552–
96, the rural track FTE limitation was
combined, together with the ‘‘cap’’ addon for new (non-rural track) programs
on Worksheet E, Part A, line 3.05, and
on Worksheet E–3, Part IV, line 3.02. On
the current cost report CMS–Form–
2552–10, the rural track FTE limitation
is, likewise, combined together with the
‘‘cap’’ add-on for new (non-rural track)
programs on Worksheet E, Part A, line
6, and on Worksheet E–4, line 2. We
stated in the proposed rule that going
forward, we intend to add lines to the
cost report to accommodate separate
reporting of urban or rural hospital rural
track FTE limitations, and the positive
or negative adjustments made to the
rural track FTE limitations, including
those applicable to the affiliated
agreements.
In summary, we proposed to allow
urban and rural hospitals that
participate in the same separately
accredited 1–2 family medicine rural
track program and have rural track FTE
limitations to enter into ‘‘Rural Track
Medicare GME Affiliation Agreements’’.
We proposed that programs that are not
separately accredited in the 1–2 format
PO 00000
Frm 00299
Fmt 4701
Sfmt 4700
49077
and are not in family medicine would
not be permitted to enter into ‘‘Rural
Track Medicare GME Affiliation
Agreements’’ under this proposal. We
proposed to add new definitions at 42
CFR 413.75(b) of rural track Medicare
GME affiliated group and rural track
Medicare GME affiliation agreement. We
also proposed to require that the
responsible representatives of each
urban and rural hospital entering into
the rural track Medicare GME affiliation
agreement must attest in that agreement
that each participating hospital’s FTE
counts and rural track FTE limitations
in the agreement do not reflect FTE
residents nor FTE caps associated with
programs other than the rural track
program. In addition, we proposed to
only allow urban and rural hospitals to
participate in rural track Medicare GME
affiliated groups if they have rural track
FTE limitations in place prior to
October 1, 2022. We proposed that
eligible urban and rural hospitals may
enter into rural track Medicare GME
affiliation agreements effective with the
July 1, 2023, academic year.
Comment: The majority of
commenters strongly supported CMS’s
proposal to enable rural training
flexibilities through Medicare GME
affiliation agreements between urban
and rural hospitals that have rural track
programs. Some commenters
‘‘applauded’’ CMS for its attention to
rural GME training, and appreciated
additional options for cap flexibilities
afforded to rural hospitals. A
commenter stated that the proposal will
assist urban hospitals in providing
flexibilities needed to address
disparities affected by geography and
other social determinants of care. Some
commenters stated that the proposal
will help provide care to Medicare
beneficiaries and may create interest for
future physicians to practice in rural
settings. Many commenters who
supported the proposal also added that
CMS should engage in future
rulemaking that will allow any RTP, not
just those separately accredited in
family medicine that were established
prior to October 1, 2022, to also engage
in affiliation agreements following the
conclusion of the cap-building period.
Response: We thank the commenters
for their feedback and support. As we
stated in the proposed rule, we
proposed to only allow urban and rural
hospitals to participate in Rural Track
Medicare GME Affiliated Groups if they
are separately accredited 1–2 family
medicine programs that have rural track
FTE limitations in place prior to
October 1, 2022. We stated that we are
distinguishing between rural track
programs with rural track FTE
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49078
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
limitations associated with the BBRA of
1999 in effect prior to October 1, 2022,
and Rural Track Programs (RTPs,
defined at 42 CFR 413.75(b)) started or
expanded to new participating sites
under the authority of section 127 of the
CAA effective on or after October 1,
2022. We explained that we are not
permitting the formation of Medicare
GME affiliated groups for the purpose of
aggregating and cross-training RTP FTE
limitations effective on or after October
1, 2022, because we believe Medicare
GME affiliated groups for RTPs would
be premature, as only starting October 1,
2022, would hospitals have the first
opportunity to add additional
participating sites. Subsequently, there
would be the 5-year cap building period
in which Medicare GME affiliations
would not be permitted, even under
existing Medicare GME affiliation
agreement rules (42 CFR 413.79(f)). In
addition, we stated that before we
created Medicare GME affiliation
agreements unique to RTPs, we believe
it would be best to first modify the
Medicare cost report form to add spaces
for the hospitals to indicate the number
of any additional RTP FTEs, and the
caps applicable to those FTEs. We also
stated that we wished to assess
flexibility within a hospital’s own total
RTP FTE limitation, before sharing
those slots with other hospitals. We
would need to be vigilant to ensure that
the RTP FTE limitations were not
comingled with regular FTE cap
adjustments currently used in Medicare
GME affiliation agreements. We
concluded with our belief that it would
be best to reassess allowing Medicare
GME affiliation agreements for RTP FTE
limitations at some point in the future.
For these same reasons, at this time, we
believe it is appropriate to only propose
to allow rural track Medicare GME
affiliation agreements with urban and
rural hospitals that have a separately
accredited rural track program and rural
track FTE limitation in place prior to
October 1, 2022. We will assess
allowing these agreements with RTP
FTE limitations established after
October 1, 2022, in the future.
Comment: A commenter representing
a group of organizations opposed CMS’s
proposal to allow Medicare GME
affiliation agreements for rural track
programs with FTE limitations prior to
October 1, 2022, and did not believe the
use of affiliation agreements resolves
concerns over the inequity of the
current method for determining a cap to
be applied to rural track programs. The
commenter was concerned that the
proposal establishes additional barriers
to many programs. The commenter
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
believed that the proposal is too narrow,
limited only to family medicine
training, and only to separately
accredited training tracks established
prior to the CAA 2021. Specifically, the
commenter observed that currently,
CMS counts the time residents spend
training at the rural site, across five
years, and the time spent in the urban
setting, and then counts the highest
number (in any program year) during
the fifth year of the cap-setting window
across all participating hospitals.
Because a rural track program typically
has its residents train in the urban
hospital in year one, rather than in the
rural setting, the urban hospital gets
more than its fair share of the cap, and
the rural site gets less than the actual
number of FTEs training in that site.
When apportioned this way, rural sites
are disadvantaged compared to urban
hospital sites. The commenter noted
that a mechanism already exists for
Medicare affiliated groups to aggregate
caps other than ‘‘rural FTE limitations,’’
and stated that they ‘‘are aware of
multiple occasions where such
aggregation has occurred between urban
and rural hospitals, always to the
disadvantage of the rural hospital that
has, for example, been acquired by the
larger urban health system. It seems
unlikely that urban hospitals would give
up ‘‘rural FTE limitation’’ slots to
benefit a participating rural hospital’s
cap . . .’’ The commenter stated that
CMS has the authority to make changes
to the calculation of rural cap
limitations as section 127 of the CAA
states that the Secretary shall ‘‘adjust in
an appropriate manner the limitation
under subparagraph (F) for such
hospital and each such hospital located
in a rural area that participates in such
a training’’ (emphasis added). As such,
beginning with cost reporting periods
on or after October 1, 2022, CMS is not
restricted to only sharing positions
through an affiliation agreement but
should set appropriate caps associated
with these training programs for the
future, rather than institute affiliation
agreements. This commenter and
another commenter recommended that
the solution is to count the highest year,
rather than using all five years when
determining the ratio for cap
apportionment.
Response: We appreciate the concerns
raised by the commenter and
acknowledge the commenter’s unique
perspective on rural GME training. We
certainly want to initiate a payment
mechanism that is inherently equitable,
and believe that a policy that we finalize
should encourage, rather than hinder,
GME training in rural areas. However,
PO 00000
Frm 00300
Fmt 4701
Sfmt 4700
we note that the vast majority of
commenters, including others with
close ties to rural GME training, have
submitted comments in support of our
proposal, generally stating that this
proposal will facilitate training in rural
settings.
With regard to the commenter’s point
that CMS’s current methodology of
looking at all 5 years to apportion FTE
caps disadvantages the rural hospital in
a RTP because the method gives more
than the fair share of FTE cap to the
urban hospital, we acknowledge that
there might be other mathematical
apportionment methods that, if tailormade for RTPs, would result in higher
caps for the rural hospital. However, we
note that this current mathematical
apportionment in the regulations at 42
CFR 413.79(e)(1) and (3) was first
implemented for all hospitals in the
August 1, 2012 LTCH PPS/IPPS final
rule (77 FR 53416 through 53424). Then
in the August 22, 2016 LTCH PPS/IPPS
final rule, we adopted this same cap
apportionment methodology for rural
track FTE limitations (81 FR 57026
through 57031), without any objection
from commenters. Thus, we have
established a single, national policy for
calculating FTE caps for new programs
and RTPs, and we have not proposed a
change to this national method in the
proposed rule. While a ‘‘one-size-fitsall’’ method may not be optimal in all
situations, we do not believe it is
advisable to alter the cap calculation for
RTPs at this time. With the advent of
CAA section 127, and the expectation
that RTPs will develop not only in 3year family medicine programs, but also
in many other specialties of differing
lengths, it is not the right time to
establish an RTP cap calculation
method, before we even understand
what the RTP landscape will be like
over the next 5 or more years. At this
point, allowing Medicare GME
affiliation agreements between the
urban and rural hospitals participating
in the same RTP may be the better
solution, as it would allow the hospitals
to customize their individual caps,
rather than CMS instituting yet another
national cap calculation methodology.
Furthermore, because the majority of
commenters supported our proposal to
allow Rural Track Medicare GME
Affiliation Agreements, we believe it is
fair and appropriate to finalize our
policy as proposed. In the December 27,
2021 final rule (86 FR 73456), and as
reiterated in the proposed rule and in
response to other comments in this final
rule, we already stated that we expect to
reassess allowing Medicare GME
affiliation agreements for RTP FTE
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
limitations established after October 1,
2022 at some point in the future. For
these same reasons, and in conjunction
with observing what we hope will be
robust growth and development of RTPs
in many specialties, not just family
medicine, we are open to reassessing at
the appropriate time the viability of
Rural Track Medicare GME Affiliation
Agreements for appropriate payment for
urban and rural hospitals participating
in RTPs.
Comment: Another commenter who
supported our proposal added that they
believe CMS’s concerns about hospitals
taking advantage of affiliated
agreements and comingled caps are
misguided, and that placing this
limitation on affiliated agreements
within RTPs is inappropriate. The
commenter asserted that urban and rural
hospitals participating in any RTP
program for the benefit of rural
communities should be permitted this
flexibility, as it would promote the
adoption of the model partnerships.
Response: As we stated in the
proposed rule, when we first
implemented the rural track regulations
in the August 1, 2000 IFC, we specified
that the caps associated with rural
tracks are separate and distinct from a
hospital’s general FTE caps.
Specifically, we defined the ‘‘rural track
FTE limitation’’ at 42 CFR 413.75(b) as
the maximum number of residents
training in a rural track residency
program that an urban hospital may
include in its FTE count and that is in
addition to the number of FTE residents
already included in the hospital’s FTE
cap (emphasis added). As a result, the
rural track FTE limitations are not part
of the regular FTE caps that hospitals
may aggregate in Medicare GME
affiliation agreements. In the proposed
rule, we proposed that the responsible
representatives of each urban and rural
hospital entering into the Rural Track
Medicare GME Affiliation Agreement
attest in that written agreement that
each participating hospital’s FTE counts
and rural track FTE limitations in the
agreement do not reflect FTE residents
nor FTE caps associated with programs
other than the rural track program. We
noted this attestation is important for
both the urban and rural hospital, as
both urban and rural hospitals may have
regular FTE caps that could be part of
regular Medicare GME affiliation
agreements (see 42 CFR 413.79(e)(1)(iv)
and (v) and 413.79(f)). Accordingly, as
long as it is possible for a hospital to
have both regular FTE caps and rural
track FTE limitations, we believe it is
appropriate to have mechanisms in
place to ensure those caps are not
inadvertently comingled. We do not
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
believe these mechanisms limit the
flexibility of rural hospitals seeking to
create model partnerships, as the
commenter asserts.
Comment: A commenter offered one
minor suggestion on language used to
describe the programs encompassed in
the proposal to allow Medicare GME
affiliation agreements within certain
rural track FTE limitations. The
commenter offered these suggestions in
the interest of accurate references to
ACGME terminology and processes. The
commenter suggested eliminating use of
the outdated term ‘‘1–2’’ when referring
to separately accredited family medicine
programs. CMS could instead consider
phrasing such as ‘‘separately accredited
family medicine programs with caps in
place as of October 1, 2022.’’
Response: We appreciate the
commenter’s suggestion, and in this
final rule, we are finalizing our policy
with respect to ‘‘separately accredited
family medicine programs with rural
track FTE limitations in place as of
October 1, 2022.’’
After consideration of the public
comments we received, we are
finalizing our proposal, without
modification, to allow urban and rural
hospitals that participate in the same
separately accredited family medicine
RTP and have rural track FTE
limitations to enter into ‘‘Rural Track
Medicare GME Affiliation Agreements’’.
We are finalizing the following new
definitions at 42 CFR 413.75(b) and
requirements:
• Rural track Medicare GME affiliated
group is an urban hospital and a rural
hospital that participates in a rural track
program defined in 42 CFR 413.75(b),
and that have rural track FTE
limitations in effect prior to October 1,
2022, and that comply with 42 CFR
413.79(f)(1) through (6) for Medicare
GME affiliated groups.
• Rural track Medicare GME
affiliation agreement is a written,
signed, and dated agreement by
responsible representatives of each
respective hospital in a rural track
Medicare GME affiliated group, as
defined in 42 CFR 413.75(b), that
specifies—
++ A statement attesting that each
participating hospital’s FTE counts and
rural track FTE limitations in the
agreement do not reflect FTE residents
nor FTE caps associated with programs
other than the rural track program.
++ The term of the rural track
Medicare GME affiliation agreement
(which, at a minimum is 1 year),
beginning on July 1 of a year;
++ Each participating hospital’s direct
and indirect GME rural track FTE
PO 00000
Frm 00301
Fmt 4701
Sfmt 4700
49079
limitations in effect prior to the rural
track Medicare GME affiliation;
++ The total adjustment to each
hospital’s rural track FTE limitations in
each year that the rural track Medicare
GME affiliation agreement is in effect,
for both direct GME and IME, that
reflects a positive adjustment to one
hospital’s direct and indirect rural track
FTE limitations that is offset by a
negative adjustment to the other
hospital’s (or hospitals’) direct and
indirect rural track FTE limitations of at
least the same amount;
++ The adjustment to each
participating hospital’s FTE counts
resulting from the FTE resident’s (or
residents’) participation in a shared
rotational arrangement at each hospital
participating in the rural track Medicare
GME affiliated group for each year the
Medicare GME affiliation agreement is
in effect. This adjustment to each
participating hospital’s FTE count is
also reflected in the total adjustment to
each hospital’s rural track FTE
limitations (in accordance with
paragraph (iii)); and
++ The names of the participating
hospitals and their Medicare provider
numbers.
In addition, we are requiring that no
later than July 1 of the residency year
during which the rural track Medicare
GME affiliation agreement will be in
effect, the urban and rural hospital must
submit the signed agreement to the CMS
contractor or MAC servicing the
hospital and send a copy to the CMS
Central Office. The hospitals may
submit amendments to the adjustments
to their respective rural track FTE
limitations to the MAC with a copy to
CMS by June 30 of the residency year
that the agreement is in effect. Eligible
urban and rural hospitals may enter into
rural track Medicare GME affiliation
agreements effective with the July 1,
2023, academic year.
With regard to how the rural track
Medicare GME affiliation adjustments
would be reported on the Medicare cost
report, first, for background, we note
that on the previous Medicare cost
report CMS–Form–2552–96, the rural
track FTE limitation was combined,
together with the ‘‘cap’’ add-on for new
(non-rural track) programs on
Worksheet E, Part A, line 3.05, and on
Worksheet E–3, Part IV, line 3.02. On
the current cost report CMS–Form–
2552–10, the rural track FTE limitation
is, likewise, combined together with the
‘‘cap’’ add-on for new (non-rural track)
programs on Worksheet E, Part A, line
6, and on Worksheet E–4, line 2. Going
forward, we intend to add lines to the
cost report to accommodate separate
reporting of urban or rural hospital rural
E:\FR\FM\10AUR2.SGM
10AUR2
49080
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
track FTE limitations, and the positive
or negative adjustments made to the
rural track FTE limitations, including
those applicable to the affiliated
agreements.
G. Payment Adjustment for Certain
Clinical Trial and Expanded Access Use
Immunotherapy Cases (§§ 412.85 and
412.312)
Effective for FY 2021, we created MS–
DRG 018 for cases that include
procedures describing CAR T-cell
therapies, which were reported using
ICD–10–PCS procedure codes XW033C3
or XW043C3 (85 FR 58599 through
58600). Effective for FY 2022, we
revised MS–DRG 018 to include cases
that report the procedure codes for CAR
T-cell and non-CAR T-cell therapies and
other immunotherapies (86 FR 44798
through 448106). We refer the reader to
section II.D.17. of the preamble of this
final rule for discussion of the agenda
items for the March 8–9, 2022 ICD–10
Coordination and Maintenance
Committee meeting relating to new
procedure codes to describe the
administration of a CAR T-cell or
another type of gene or cellular therapy
product, as well as our established
process for determining the MS–DRG
assignment for codes approved at the
March meeting.
Effective for FY 2021, we modified
our relative weight methodology for
MS–DRG 018 in order to develop a
relative weight that is reflective of the
typical costs of providing CAR T-cell
therapies relative to other IPPS services.
Specifically, under our finalized policy
we do not include claims determined to
be clinical trial claims that group to
MS–DRG 018 when calculating the
average cost for MS–DRG 018 that is
used to calculate the relative weight for
this MS–DRG, with the additional
refinements that: (a) when the CAR Tcell therapy product is purchased in the
usual manner, but the case involves a
clinical trial of a different product, the
claim will be included when calculating
the average cost for MS DRG 018 to the
extent such claims can be identified in
the historical data; and (b) when there
is expanded access use of
immunotherapy, these cases will not be
included when calculating the average
cost for MS–DRG 018 to the extent such
claims can be identified in the historical
data (85 FR 58600). The term ‘‘expanded
access’’ (sometimes called
‘‘compassionate use’’) is a potential
pathway for a patient with an
immediately life-threatening condition
or serious disease or condition to gain
access to an investigational medical
product (drug, biologic, or medical
device) for treatment outside of clinical
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
trials when no comparable or
satisfactory alternative therapy options
are available.215
Effective FY 2021, we also finalized
an adjustment to the payment amount
for applicable clinical trial and
expanded access immunotherapy cases
that group to MS–DRG 018 using the
same methodology that we used to
adjust the case count for purposes of the
relative weight calculations (85 FR
58842 through 58844). (As previously
noted, effective beginning FY 2022, we
revised MS–DRG 018 to include cases
that report the procedure codes for CAR
T-cell and non-CAR T-cell therapies and
other immunotherapies (86 FR 44798
through 448106).) Specifically, under
our finalized policy we apply a payment
adjustment to claims that group to MS–
DRG 018 and include ICD–10–CM
diagnosis code Z00.6, with the
modification that when the CAR T-cell,
non-CAR T-cell, or other
immunotherapy product is purchased in
the usual manner, but the case involves
a clinical trial of a different product, the
payment adjustment will not be applied
in calculating the payment for the case.
We also finalized that when there is
expanded access use of immunotherapy,
the payment adjustment will be applied
in calculating the payment for the case.
This payment adjustment is codified at
42 CFR 412.85 (for operating IPPS
payments) and 42 CFR 412.312 (for
capital IPPS payments), for claims
appropriately containing Z00.6, as
described previously, and reflects that
the adjustment is also applied for cases
involving expanded access use
immunotherapy, and that the payment
adjustment only applies to applicable
clinical trial cases; that is, the
adjustment is not applicable to cases
where the CAR T-cell, non-CAR T-cell,
or other immunotherapy product is
purchased in the usual manner, but the
case involves a clinical trial of a
different product. The regulations at 42
CFR 412.85(c) also specify that the
adjustment factor will reflect the
average cost for cases to be assigned to
MS–DRG 018 that involve expanded
access use of immunotherapy or are part
of an applicable clinical trial to the
average cost for cases to be assigned to
MS–DRG 018 that do not involve
expanded access use of immunotherapy
and are not part of a clinical trial (85 FR
58844).
For FY 2023, we proposed to continue
to apply an adjustment to the payment
amount for expanded access use of
immunotherapy and applicable clinical
215 https://www.fda.gov/news-events/expandedaccess/expanded-access-keywords-definitions-andresources.
PO 00000
Frm 00302
Fmt 4701
Sfmt 4700
trial cases that would group to MS–DRG
018 using the same methodology
adopted in the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58842), which is the
same methodology we proposed to use
to adjust the case count for purposes of
the relative weight calculations:
• Calculate the average cost for cases
to be assigned to MS–DRG 018 that
contain ICD–10–CM diagnosis code
Z00.6 or contain standardized drug
charges of less than $373,000.
• Calculate the average cost for all
other cases to be assigned to MS–DRG
018.
• Calculate an adjustor by dividing
the average cost calculated in step 1 by
the average cost calculated in step 2.
• Apply this adjustor when
calculating payments for expanded
access use of immunotherapy and
applicable clinical trial cases that group
to MS–DRG 018 by multiplying the
relative weight for MS–DRG 018 by the
adjustor.
Additionally, we proposed to
continue to use our finalized
methodology for calculating this
payment adjustment, such that: (a)
when the CAR T-cell, non-CAR T-cell,
or other immunotherapy product is
purchased in the usual manner, but the
case involves a clinical trial of a
different product, the claim will be
included when calculating the average
cost for cases not determined to be
clinical trial cases; and (b) when there
is expanded access use of
immunotherapy, these cases will be
included when calculating the average
cost for cases determined to be clinical
trial cases. However, we continue to
believe to the best of our knowledge
there are no claims in the historical data
(FY 2021 MedPAR) used in the
calculation of the adjustment for cases
involving a clinical trial of a different
product, and to the extent the historical
data contain claims for cases involving
expanded access use of immunotherapy
we believe those claims would have
drug charges less than $373,000. We
note that we are in the process of
making modifications to the MedPAR
files to include information for claims
with the payer-only condition code
‘‘ZC’’ in the future. Payer-only condition
code ‘‘ZC’’ is used by the IPPS Pricer to
identify a case where the CAR T-cell,
non-CAR T-cell, or other
immunotherapy product is purchased in
the usual manner, but the case involves
a clinical trial of a different product so
that the payment adjustment is not
applied in calculating the payment for
the case (for example, see Change
Request 11879, available at https://
www.cms.gov/files/document/
r10571cp.pdf).
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Consistent with our calculation of the
proposed adjustor for the relative weight
calculations, and our proposal to use the
FY 2021 data for the FY 2023
ratesetting, for the proposed rule we
proposed to calculate this adjustor
based on the December 2021 update of
the FY 2021 MedPAR file for purposes
of establishing the FY 2023 payment
amount. Specifically, in accordance
with 42 CFR 412.85 (for operating IPPS
payments) and 42 CFR 412.312 (for
capital IPPS payments), we proposed to
multiply the FY 2023 relative weight for
MS–DRG 018 by a proposed adjustor of
0.20 as part of the calculation of the
payment for claims determined to be
applicable clinical trial or expanded use
access immunotherapy claims that
group to MS–DRG 018, which includes
CAR T-cell and non-CAR T-cell
therapies and other immunotherapies.
We also proposed to update the value of
the adjustor based on more recent data
for the final rule.
We note that a commenter requested
that CMS consider allowing hospitals to
use expanded access condition code 90
instead of the remarks field, which
would remove a layer of manual work
required by the MACs, which would
decrease the opportunity for errors. As
discussed more fully in our response to
this comment in section II.E.2.b. of this
final rule, we agree with the
commenter’s request, and effective
October 1, 2022, providers should
submit condition code 90 to identify
expanded access claims that group to
MS–DRG 018, rather than the remarks
field. We did not receive any comments
specifically relating to the proposed
payment adjustment for applicable
clinical trial and expanded access use
immunotherapy cases.
After consideration of the comment
we received, we are finalizing our
proposal regarding the calculation of
this payment adjustment for FY 2023, as
described previously. We are also
finalizing our proposal to update the
value of this adjustor based on more
recent data for this final rule. Therefore,
using the March 2022 update of the FY
2021 MedPAR data, we are finalizing an
adjustor of 0.21 for FY 2023, which will
be multiplied by the final FY 2023
relative weight for MS–DRG 018 as part
of the calculation of the payment for
claims determined to be applicable
clinical trial or expanded use access
immunotherapy claims that group to
MS–DRG 018.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
H. Hospital Readmissions Reduction
Program: Updates and Changes
(§§ 412.150 Through 412.154)
1. Statutory Basis for the Hospital
Readmissions Reduction Program
Section 1886(q) of the Act, as
amended by section 15002 of the 21st
Century Cures Act, establishes the
Hospital Readmissions Reduction
Program. Under the Hospital
Readmissions Reduction Program,
Medicare payments under the acute
inpatient prospective payment system
(IPPS) for discharges from an applicable
hospital, as defined under section
1886(d) of the Act, may be reduced to
account for certain excess readmissions.
Section 15002 of the 21st Century Cures
Act requires the Secretary to compare
hospitals with respect to the proportion
of beneficiaries who are dually eligible
for Medicare and full-benefit Medicaid
(also known as ‘‘dually eligible
beneficiaries’’) in determining the extent
of excess readmissions. We refer readers
to the FY 2016 IPPS/LTCH PPS final
rule (80 FR 49530 through 49531) and
the FY 2018 IPPS/LTCH PPS final rule
(82 FR 38221 through 38240) for a
detailed discussion of and additional
information on the statutory history of
the Hospital Readmissions Reduction
Program.
2. Regulatory Background
We refer readers to the following final
rules for detailed discussions of the
regulatory background and descriptions
of the current policies for the Hospital
Readmissions Reduction Program:
• FY 2012 IPPS/LTCH PPS final rule
(76 FR 51660 through 51676).
• FY 2013 IPPS/LTCH PPS final rule
(77 FR 53374 through 53401).
• FY 2014 IPPS/LTCH PPS final rule
(78 FR 50649 through 50676).
• FY 2015 IPPS/LTCH PPS final rule
(79 FR 50024 through 50048).
• FY 2016 IPPS/LTCH PPS final rule
(80 FR 49530 through 49543).
• FY 2017 IPPS/LTCH PPS final rule
(81 FR 56973 through 56979).
• FY 2018 IPPS/LTCH PPS final rule
(82 FR 38221 through 38240).
• FY 2019 IPPS/LTCH PPS final rule
(83 FR 41431 through 41439).
• FY 2020 IPPS/LTCH PPS final rule
(84 FR 42380 through 42390).
• FY 2021 IPPS/LTCH PPS final rule
(85 FR 58844 through 58847.
• FY 2022 IPPS/LTCH PPS final rule
(86 FR 45249 through 45266).
We have also codified certain
requirements of the Hospital
Readmissions Reduction Program at 42
CFR 412.152 through 412.154.
PO 00000
Frm 00303
Fmt 4701
Sfmt 4700
49081
3. Current Measures
The Hospital Readmissions Reduction
Program currently includes six
applicable conditions/procedures:
Acute myocardial infarction (AMI);
heart failure (HF); pneumonia (PN);
elective primary total hip arthroplasty/
total knee arthroplasty (THA/TKA);
chronic obstructive pulmonary disease
(COPD); and coronary artery bypass
graft (CABG) surgery.
We continue to believe the measures
we have adopted adequately meet the
goals of the Hospital Readmissions
Reduction Program. In the FY 2022
IPPS/LTCH PPS final rule, we finalized
suppression of the CMS 30-Day
Pneumonia Readmission Measure (NQF
#0506) for purposes of payment
adjustment for the FY 2023 program
year due to the impact of the COVID–
19 PHE (86 FR 45254 through 45256). In
this final rule, we are finalizing
resumption of use of this measure in the
Hospital Readmissions Reduction
Program beginning with the FY 2024
program year, with an exclusion of
patients with principal or secondary
COVID–19 diagnoses from both the
denominator (cohort) and the numerator
(outcome). We are also providing
information on technical specification
updates for all of the condition/
procedure-specific readmission
measures in the Hospital Readmissions
Reduction Program to include a
covariate adjustment for patients with a
clinical history of COVID–19 in the 12
months prior to the index admission.
We refer readers to the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41431
through 41439) for more information
about how the Hospital Readmissions
Reduction Program supports CMS’ goal
of bringing quality measurement,
transparency, and improvement together
with value-based purchasing to the
hospital inpatient care setting through
the Meaningful Measures Framework.
4. Flexibility for Changes That Affect
Quality Measures During a Performance
Period in the Hospital Readmissions
Reduction Program
In the FY 2022 IPPS/LTCH PPS final
rule, we adopted a policy for the
duration of the COVID–19 PHE that has
allowed us to suppress the use of
quality measures via adjustment to the
Hospital Readmissions Reduction
Program’s program calculations if we
determine that circumstances caused by
the COVID–19 PHE significantly
affected those measures and the
associated ‘‘excess readmissions’’
calculations (86 FR 45250 through
45253). As described under that
finalized policy, if we were to determine
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49082
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
that the suppression of a Hospital
Readmissions Reduction Program
measure was warranted for an
applicable period, we would calculate
the measure’s rates for that program year
but then suppress the use of those rates
to make changes to hospitals’ Medicare
payments. In the Hospital Readmissions
Reduction Program, this policy would
have the effect of temporarily weighting
the affected measure at zero percent in
the program’s scoring methodology until
adjustments were made, the affected
portion of the performance period for
the measure was made no longer
applicable to program calculations, or
the measure was removed entirely
through rulemaking. We also explained
that we would provide feedback reports
to hospitals as part of program activities,
including to inform their quality
improvement activities, and to ensure
that they were made aware of the
changes in performance rates that we
observed (86 FR 45251). We stated that
we would publicly report a suppressed
measure’s data with appropriate caveats
noting the limitations of the data due to
the COVID–19 PHE (86 FR 45251). To
provide stakeholders an opportunity to
review this final rule prior to release of
the Hospital Specific Reports (HSRs)
that incorporate updates to the CMS 30Day Pneumonia Readmission Measure
(NQF #0506), we are postponing
incorporation of the CMS 30-Day
Pneumonia Readmission Measure (NQF
#0506), which would typically be
included in the July update of the
Compare website hosted by HHS
(https://www.medicare.gov/carecompare/).
In the FY 2022 IPPS/LTCH PPS final
rule, we also adopted Measure
Suppression Factors to guide our
determination of whether to suppress a
Hospital Readmissions Reduction
Program measure for one or more
program years that include discharges
during the COVID–19 PHE (86 FR
45251). We adopted these Measure
Suppression Factors for use in the
Hospital Readmissions Reduction
Program, and for consistency, the
following other value-based purchasing
programs: Hospital Value-Based
Purchasing, HAC Reduction Program,
Skilled Nursing Facility Value-Based
Purchasing Program, and End-Stage
Renal Disease Quality Incentive
Program. We stated our belief that these
Measure Suppression Factors will help
us evaluate the Hospital Readmissions
Reduction Program’s measures and that
their adoption in the other value-based
purchasing programs, as previously
noted, would help ensure consistency in
our measure evaluations across
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
programs. The previously adopted
Measure Suppression Factors are as
follows:
• Significant deviation in national
performance on the measure during the
PHE for COVID–19, which could be
significantly better or significantly
worse compared to historical
performance during the immediately
preceding program years.
• Clinical proximity of the measure’s
focus to the relevant disease, pathogen,
or health impacts of the PHE for
COVID–19.
• Rapid or unprecedented changes
in—
++ Clinical guidelines, care delivery
or practice, treatments, drugs, or related
protocols, or equipment or diagnostic
tools or materials; or
++ The generally accepted scientific
understanding of the nature or
biological pathway of the disease or
pathogen, particularly for a novel
disease or pathogen of unknown origin.
• Significant national shortages or
rapid or unprecedented changes in—
++ Healthcare personnel;
++ Medical supplies, equipment, or
diagnostic tools or materials; or
++ Patient case volumes or facilitylevel case mix.
We stated our belief that we view this
measure suppression policy as
necessary to ensure that the Hospital
Readmissions Reduction Program did
not penalize hospitals based on factors
that the program’s measures were not
designed to accommodate (86 FR
45252).
In the FY 2023 IPPS/LTCH PPS
proposed rule, we did not propose any
changes to this policy. We did not
receive any comments on our previously
finalized flexibilities in response to the
COVID–19 PHE or our previously
finalized Measure Suppression Factors.
5. Provisions That Address the Impact
of COVID–19 on Current Hospital
Readmissions Reduction Program
Measures
a. Background
As described in V.H.4 of the preamble
of this final rule, in the FY 2022 IPPS/
LTCH PPS final rule, we adopted a
measure suppression policy and
Measure Suppression Factors to ensure
that the Hospital Readmissions
Reduction Program did not penalize
hospitals based on factors that the
program’s measures were not designed
to accommodate (86 FR 45252).
Additionally, in the FY 2022 IPPS/
LTCH PPS final rule, we finalized
suppression of the CMS 30-Day
Pneumonia Readmissions Measure
(NQF #0506) for the FY 2023 program
PO 00000
Frm 00304
Fmt 4701
Sfmt 4700
year (86 FR 45254 through 45256). We
expressed the belief that the second
Measure Suppression Factor (clinical
proximity of the measure’s focus to the
relevant disease, pathogen, or health
impacts of the COVID–19 PHE) applied
to the CMS 30-Day Pneumonia
Readmissions Measure (NQF #0506). In
our analysis of the impacts of the
COVID–19 PHE on the measures in the
Hospital Readmissions Reduction
Program, we observed that pneumonia
has been identified as a typical
characteristic of individuals infected
with COVID–19 (86 FR 45254). Using
data available during and subsequent to
the preparation of the FY 2022 IPPS/
LTCH PPS final rule, we found that a
substantial portion of the CMS 30-Day
Pneumonia Readmissions Measure
(NQF #0506) denominator (cohort)
included admissions with a COVID–19
diagnosis, ranging from 13.3 percent in
April 2020 to a high of 27.1 percent in
December 2020.216 Furthermore, we
noted that at the beginning of the
pandemic, the 30-day observed
readmission rate for pneumonia patients
with a secondary diagnosis of COVID–
19 present on admission was lower than
the observed readmissions rate for
pneumonia patients without a diagnosis
of COVID–19 (12.4 percent versus 15.8
percent) because patients with a
secondary diagnosis of COVID–19
present on admission had a higher risk
of mortality than patients without a
COVID–19 diagnosis (86 FR 45254
through 45255).
Additionally, we provided
information on technical specification
updates for the remaining five
condition/procedure-specific
readmission measures to exclude
patients with a principal or secondary
COVID–19 diagnosis present on
admission from the measures’
numerators (outcomes) and
denominators (cohorts) beginning in
fiscal year (FY) 2023 (86 FR 45256
through 45258). In the FY 2015 IPPS/
LTCH PPS final rule, we finalized a
subregulatory process to incorporate
technical measure specification updates
into the measure specifications adopted
for the Hospital Readmissions
Reduction Program (79 FR 50039). In
the FY 2022 IPPS/LTCH PPS final rule,
we noted that to continue to account for
readmissions as intended, we would use
our subregulatory process to update the
specifications to exclude patients with a
principal or secondary diagnosis of
216 While data prior to April 1, 2020 are available,
these data used a different method to identify
COVID–19 diagnoses. To improve consistency of
analysis we began our analysis on April 1, 2020
with the introduction of the COVID–19 ICD–10
codes.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
COVID–19 present on admission from
the denominators (cohorts) and the
numerators (outcomes) of the following
five condition/procedure-specific
readmission measures: (1) Hospital 30Day All-Cause RSRR Following AMI
Hospitalization (NQF #0505); (2) the
Hospital 30-Day, All-Cause, Unplanned,
RSRR Following CABG Surgery (NQF
#2515); (3) the Hospital 30-Day, AllCause, RSRR Following COPD
Hospitalization (NQF #1891); (4) the
Hospital 30-Day, All-Cause RSRR
Following Heart Failure Hospitalization
(NQF #0330); and (5) the Hospital-Level
30-Day, RSRR Following Elective
Primary Total Hip Arthroplasty (THA)
and/or Total Knee Arthroplasty (TKA)
(NQF #1551) beginning in FY 2023 (86
FR 45256).
In the FY 2023 IPPS/LTCH PPS
proposed rule, we did not propose any
changes to these policies.
b. Resumption of the CMS 30-Day
Pneumonia Readmission Measure (NQF
#0506) for the FY 2024 Program Year
Our measure suppression policy,
described in section V.H.4 of the
preamble of this final rule, focuses on a
short-term, equitable approach during
this unprecedented PHE, and was not
intended for indefinite application.
While we recognize that performance on
some measures may not immediately
return to levels seen prior to the PHE,
we want to emphasize the long-term
importance of value-based care and
incentivizing quality care by linking
provider performance to program
payment. The Hospital Readmissions
Reduction Program is an example of our
long-standing effort to link payments to
healthcare quality in the inpatient
hospital setting as well as crosscontinuum care. Our goal has been to
resume the use of measure data for
scoring and payment adjustment
purposes. We note that in the FY 2022
IPPS/LTCH PPS final rule, we finalized
the suppression of the CMS 30-Day
Pneumonia Readmission Measure (NQF
#0506) for the FY 2023 Program Year
and stated that we would continue to
monitor the claims that form the basis
for this measure’s calculations to
evaluate the effect of the circumstances
on quality measurement and to
determine the appropriate policies for
the future. Additionally, we recognized
that it is important to continue tracking
the impact of the COVID–19 PHE on the
CMS 30-Day Pneumonia Readmission
Measure (NQF #0506), as these data will
inform our considerations regarding
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
whether future measure suppression is
necessary beyond FY 2023. We noted
that the measure is important to
improving patient safety and quality of
care and stated that we would continue
to monitor measure data to determine
when it may be considered sufficiently
reliable such that resuming full
implementation of the CMS 30-Day
Pneumonia Readmission Measure (NQF
#0506) is appropriate (86 FR 45256).
Following publication of the FY 2022
IPPS/LTCH PPS final rule, we have
continued to monitor the claims that
form the basis for this measure’s
calculations. While pneumonia
continues to be a typical characteristic
of individuals infected with COVID–19,
we believe that coding practices
enhanced by the availability of COVID–
19–related ICD–10–CM and ICD–10–
PCS codes, effective since January 1,
2021, have enabled us to differentiate
patients with COVID–19 from
pneumonia patients without COVID–19
within certain data periods.
In this final rule, we are finalizing
that beginning in FY 2024, the
Pneumonia Readmission Measure (NQF
#0506) will no longer be suppressed
under the Hospital Readmissions
Reduction Program. We will resume the
use of the pneumonia readmission
measure for FY 2024 because of the
following differences between the FY
2023 and FY 2024 performance periods:
(1) the improved coding practices; (2)
decreased proportion of COVID–19
admissions in the pneumonia
readmission measure for this
performance period; and (3) sufficient
available data to make technical updates
to the measure specifications in order to
further account for how patients with a
COVID–19 diagnosis might impact the
quality of care assessed by this measure.
These differences lead us to believe that
the clinical proximity of the measure’s
focus is no longer sufficiently close to
the health impacts of the COVID–19
PHE for the suppression factor to
continue to apply. Specifically, effective
January 2021, the ICD–10 code J12.82,
pneumonia due to coronavirus disease
2019, was added for use as a secondary
diagnosis present on admission, along
with a principal diagnosis of COVID–19
(U07.1) present on admission, to
identify patients with COVID–19
pneumonia. J12.82 is not included
within the denominator (cohort) of the
pneumonia readmission measure,
therefore readmission rates for patients
with an index admission of COVID–19
pneumonia (J12.82) are not captured by
PO 00000
Frm 00305
Fmt 4701
Sfmt 4700
49083
this measure as of January 1, 2021.
Whenever new codes are introduced,
changes in coding practices are difficult
to predict. At the time of the FY 2022
IPPS final rule, we did not have
sufficient data to determine the effects
of these coding changes on the
proportion of COVID–19 patients and
readmission rates with pneumonia due
to COVID–19 in the pneumonia
readmission measure. As additional
months of data have become available
since early 2021, we have now seen
increased use of these codes. Secondly,
as these coding changes have occurred
and as the COVID–19 PHE has evolved,
more recent data show the proportion of
COVID–19 admissions in the
pneumonia readmission measure have
decreased compared to 2020 data.
Finally, with the availability of
additional data and the decrease in the
proportion of COVID–19 admissions in
the pneumonia readmission measure,
we are now able to make technical
updates to the measure specifications in
alignment with the technical updates to
the five other readmission measures. All
of these factors have led us to conclude
that the suppression factor no longer
applies to the CMS 30-Day Pneumonia
Readmissions Measure (NQF #0506)
measure.
As previously discussed, we observed
that in 2020, following the declaration
of the COVID–19 PHE for COVID–19 a
substantial proportion of the CMS 30Day Pneumonia Readmissions Measure
(NQF #0506) denominator (cohort)
included admissions with a COVID–19
diagnosis present on admission.
Specifically, the proportion ranged from
13.3 percent when the COVID–19 ICD–
10 diagnosis code became available in
April 2020 to a high of 27.1 percent in
December 2020. After the J12.82 code
was implemented in January 2021, the
proportion of patients with COVID–19
diagnosis present on admission in the
pneumonia measure dropped to 9.8
percent. Data on the proportion of
patients with COVID–19 diagnosis
present on admission from April 2020
through December 2020 are detailed in
Table V.H.-01. The most recently
available data at the time of the
proposed rule on the proportion of
patients with COVID–19 diagnosis
present on admission for January
through September 2021, which do not
include patients with pneumonia due to
coronavirus disease 2019 per ICD–10
code J12.82, are detailed in Table V.H–
02.
E:\FR\FM\10AUR2.SGM
10AUR2
49084
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE V.H.-01: PERCENT OF PRINCIPAL OR SECONDARY COVID-19
DIAGNOSES IN READMISSION MEASURE COHORTS APRIL 2020 - DECEMBER
2020
April
2020
13.3%
0.3%
0.5%
0.4%
0.3%
0.1%
Measure
Cohort
Pneumonia
COPD
AMI
HF
THA/TKA
CABG
May
2020
11.2%
0.2%
0.6%
0.6%
0.1%
0.2%
June
2020
6.7%
0.2%
0.5%
0.6%
0.1%
0.2%
July
2020
15.6%
0.4%
1.0%
0.7%
0.1%
0.4%
Aue:ust
2020
14.5%
0.5%
1.1%
0.8%
0.1%
0.4%
September
2020
7.5%
0.4%
0.8%
0.6%
0.1%
0.3%
October
2020
9.5%
0.4%
0.9%
0.7%
0.2%
0.3%
November
2020
17.9%
0.9%
2.2%
1.3%
0.3%
0.5%
December
2020
27.1%
1.4%
3.6%
2.1%
0.5%
1.5%
TABLE V.H.-02: PERCENT OF PRINCIPAL OR SECONDARY COVID-19
DIAGNOSES IN READMISSION MEASURE COHORTS JANUARY 2021 SEPTEMBER 2021
Measure Cohort
Pneumonia
COPD
AMI
HF
THA/TKA
CABG
January
2021
9.8%
1.4%
3.7%
2.4%
0.6%
1.4%
February
2021
5.6%
0.9%
2.3%
1.8%
0.4%
1.1%
We note that the surge of COVID–19–
related hospitalizations had begun to
subside with the rollout of the U.S.
vaccination program in early 2021,
although hospitalizations began
increasing again during late summer
2021 with the COVID–19 Delta variant
and increased over the fall and winter
with the COVID–19 Omicron variant.
We also note that updated data show
that the proportion of admissions with
a COVID–19 diagnosis present on
admission for the CMS 30-Day
March
2021
2.5%
0.5%
1.2%
1.0%
0.2%
0.5%
April
2021
1.9%
0.3%
0.8%
0.7%
0.2%
0.4%
May
2021
1.2%
0.3%
0.6%
0.6%
0.1%
0.3%
June
2021
0.8%
0.2%
0.4%
0.3%
0.1%
0.2%
Pneumonia Readmission Measure (NQF
#0506) between April 2020 and
December 2020 was 13.1 percent,
whereas the proportion between January
2021 and September 2021 was
substantially lower, at 3.1 percent.
Analyzing data available for the FY
2022 IPPS/LTCH PPS final rule (April
2020 through June 2020), we noted that
the 30-day observed readmissions rate
for patients with a secondary diagnosis
of COVID–19 present on admission at
the index admission were lower than
July
2021
0.7%
0.2%
0.3%
0.3%
0.1%
0.1%
Aue:ust
2021
2.1%
0.6%
1.4%
0.9%
0.2%
0.5%
September
2021
3.5%
0.7%
2.0%
1.1%
0.2%
0.6%
the observed readmissions rates for
patients without a diagnosis of COVID–
19 (12.4 percent versus 15.8 percent). In
more recent data, we have found that
the observed readmission rate for
admissions with a COVID–19 diagnosis
present on admission were similar to
observed readmission rates for
admissions without a COVID–19
diagnosis (17.3 percent vs. 17.2 percent,
respectively) as depicted in Table V.H.–
03.
TABLE V.H.-03: OBSERVED READMISSION RA TE FOR ADMISSIONS
WITH/WITHOUT SECONDARY DIAGNOSIS OF COVID-19 PRESENT ON
ADMISSION*
22,967
3,972
17.3%
757,517
130,067
17.2%
*For the Pneumonia Readmission measure, based on data from July I, 2018-February 28, 2021, excluding admissions from
December 2, 2019-June 30, 2020 reflecting application of the nationwide ECE in response to the COVID-19 ECE.
Because updated data show that
following the January 2021 coding
update patients with a diagnosis of
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
COVID–19 now make up a smaller
proportion of the population of
pneumonia admissions than in the
PO 00000
Frm 00306
Fmt 4701
Sfmt 4700
analysis described in the FY 2022 IPPS/
LTCH PPS final rule, and because
observed 30-day readmission rates are
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.134
khammond on DSKJM1Z7X2PROD with RULES2
Admissions without a Diae:nosis ofCOVID-19
Observed 30-Day
Readmission Rate
ER10AU22.133
Admissions with Secondary Diagnosis of
COVID-19 present on admission
Number of
Readmissions
ER10AU22.132
Number of
Admissions
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
similar between admissions for patients
with a COVID–19 diagnosis present on
admission and patients without a
COVID–19 diagnosis present on
admission, we believe that resuming the
CMS 30-Day Pneumonia Readmission
Measure (NQF #0506) with a
modification to exclude patients with a
primary or secondary diagnosis of
COVID–19 present on admission
beginning with the FY 2024 program
year would be appropriate. As described
in more detail in section V.H.5.c of the
preamble of this final rule, we will also
add a covariate to adjust for history of
COVID–19 diagnosis in the 12 months
prior to the index admission as a
technical update to the measure
specifications.
In our analysis, measure scores
calculated with the numerator
(outcome) and denominator (cohort)
exclusions and addition of the covariate
for history of COVID–19 diagnosis in the
12 months prior resulted in mean
measure scores that were closer to the
prior non-COVID–19 affected period
compared with the unchanged measure.
We note that these measure-specific
modifications are in addition to
application of the nationwide ECE
granted in response to the COVID–19
PHE, which precludes the use of data
from January 1, 2020 through June 30,
2020 from measure score calculations.
Because these updates are to minimize
the effect of COVID–19 on the
pneumonia measure, which was not
developed to account for COVID–19
diagnosed patients, we believe that
these changes do not fundamentally
change the measure such that it is no
longer the same measure that we
originally adopted, and therefore we
believe that these are non-substantive
updates. We note that in the FY 2015
IPPS/LTCH PPS final rule, we finalized
a subregulatory process to incorporate
technical measure specification updates
into the measure specifications we have
adopted for the Hospital Readmissions
Reduction Program (79 FR 50039). We
reiterated this policy in the FY 2020
IPPS/LTCH PPS final rule, stating our
continued belief that the subregulatory
process is the most expeditious manner
possible to ensure that quality measures
remain fully up to date while preserving
the public’s ability to comment on
updates that so fundamentally change a
measure that it is no longer the same
measure that we originally adopted (84
FR 42385). We believe that excluding
COVID–19 patients from the measure
denominator (cohort) and numerator
(outcome) and adding a covariate to
adjust for history of a COVID–19
diagnosis in the 12 months prior to an
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
admission (discussed in section V.H.5.c.
of the preamble of this final rule), will
ensure that this condition-specific
readmission measure continues to
account for readmissions as intended
and meets the goals of incentivizing
patient safety and better care
coordination of the Hospital
Readmissions Reduction Program. We
note that the readmission measure uses
three years of data. The performance
period for the FY 2023 program year
includes admissions from July 1, 2018
through June 30, 2021, with data from
January 1, 2020 through June 30, 2020
excluded due to the implementation of
the nationwide ECE waiver. Therefore,
we continue to believe it is appropriate
to suppress the currently implemented
measure for use in payment reduction
calculations 217 for FY 2023 as finalized
in the FY 2022 IPPS/LTCH PPS final
rule.
Additional resources about the
current measure technical specifications
and methodology for the hospital
technical specification of the current
readmission measures are provided at
our website in the Measure
Methodology Reports (posted on the
QualityNet website at https://
qualitynet.cms.gov/inpatient/measures/
readmission/methodology). Hospital
Readmissions Reduction Program
resources are located at the Resources
web page of the QualityNet website
(available at https://qualitynet.cms.gov/
inpatient/hrrp/resources).
We welcomed public comment on our
proposal to resume use of the CMS 30Day Pneumonia Readmissions Measure
(NQF #0506) beginning with the FY
2024 program year. The comments we
received, and our responses are set forth
in this section of this rule.
Comment: Several commenters
supported suppressing the CMS 30-Day
Pneumonia Readmission Measure (NQF
#0506) from the Hospital Readmissions
Reduction Program for the FY 2023
program year.
Response: We thank these
commenters for their support.
Comment: A few commenters
recommended that in addition to
suppressing the CMS 30-Day
Pneumonia Readmission Measure (NQF
#0506) data from payment adjustments
for FY 2023, CMS should also suppress
these data from public reporting to
avoid presenting information that could
potentially confuse consumers regarding
the quality of care. Some of these
217 We note that in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28421) this referred to
‘‘payment calculations,’’ for accuracy we have
revised that here to read ‘‘payment reduction
calculations’’ as payments are not calculated by the
Hospital Readmissions Reduction Program.
PO 00000
Frm 00307
Fmt 4701
Sfmt 4700
49085
commenters noted their continued
support for hospital-specific
confidential reporting. A commenter
recommended that CMS calculate
measure information both with and
without the exclusion for patients with
a diagnosis of COVID–19 present on
admission and provide the measure
results from both calculations in
hospital-specific reports.
Response: We understand the
commenters’ concern about publicly
reporting measure data from the
COVID–19 PHE. However, we will make
clear in the public presentation of the
data that the measure has been
suppressed for FY 2023 for purposes of
payment adjustments because of the
effects of the COVID–19 PHE. We
believe that displaying this information
will promote transparency on the
impacts of the PHE due to COVID–19,
and we will appropriately caveat the
data in order to mitigate public
confusion. Additionally, the Hospital
Readmissions Reduction Program
Hospital-Specific Report that is sent to
hospitals provides discharge-level data
for each condition/procedure. The
discharge-level data shows whether, and
why, a stay was excluded from the
numerator (outcome) or denominator
(cohort), including stays that are
excluded due to a qualifying COVID–19
diagnosis.
Comment: Some commenters
recommended that CMS continue
reporting all measure results, regardless
of whether the measure was being
included in program calculations
because these commenters believe this
supports transparency and
accountability. Some of these
commenters specifically recommended
public and confidential reporting.
Response: We agree with commenters
that public reporting of measure results,
regardless of whether the measure
results were used for payment
adjustments, supports transparency and
accountability. Therefore, we will
continue to report all data with
appropriate caveats for the measure
results impacted by the COVID–19 PHE.
We will also continue to confidentially
report these data to hospitals prior to
publicly reporting in accordance with
our review and correction process
detailed in the FY 2013 IPPS/LTCH PPS
final rule (77 FR 53399 through 53401).
Comment: Several commenters
recommended suppressing the HospitalLevel 30-Day, RSRR Following Elective
Primary Total Hip Arthroplasty (THA)
and/or Total Knee Arthroplasty (TKA)
(NQF #1551) measure from payment
calculations due to the higher
complexity, higher acuity patient
population undergoing these procedures
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49086
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
on an inpatient basis during the COVID–
19 PHE.
Response: We acknowledge that the
COVID–19 PHE has impacted the
healthcare system in unprecedented
ways. However, our analyses of
available data to date have found only
minimal impacts of COVID–19 on the
Hospital-Level 30-Day RSRR Following
Elective Primary THA/TKA (NQF
#1551) measure results. Furthermore,
we believe that the COVID–19
exclusions we have adopted combined
with the covariate adjustment for
patient history of COVID–19 within 12
months prior to admission described in
Section V.H.5.c of this final rule account
for the impacts of COVID–19 diagnosed
patients. Our analyses have shown that
for the FY 2023 program year (that is
July 1, 2018 through June 30, 2021 with
January 1, 2020 through June 30, 2020
data excluded as a result of
implementing the nationwide ECE due
to the COVID–19 PHE) reporting results
using the updated measure generate
very similar measure score distributions
compared with FY 2022 program year
(that is July 1, 2017 through December
1, 2019) reporting results of the original
measure. Additionally, we note that the
existing clinical risk adjustments for
this measure (available in the Measures
Methodology Report at https://
qualitynet.cms.gov/inpatient/measures/
readmission/methodology) are designed
to account for the complexity and acuity
of the patient population. Finally, we
believe that hospitals which perform
fewer of these procedures due to the
shift to outpatient settings may no
longer meet the 25-case threshold for
inclusion of the measure in the Hospital
Readmissions Reduction Program. We
will, however, continue to monitor the
volume of index admissions for the
conditions and procedures that the
Hospital Readmissions Reduction
Program measures address to ensure
that the measures remain appropriate.
Comment: Many commenters
supported resuming use of the CMS 30Day Pneumonia Readmission Measure
(NQF #0506) in the Hospital
Readmissions Reduction Program. Some
of these commenters observed that
publishing hospital quality data allows
trending over time and that public
information is vital for consumers.
Response: We thank commenters for
their support.
Comment: Several commenters who
supported resuming use of the CMS 30Day Pneumonia Readmission Measure
(NQF #0506) recommended monitoring
to evaluate additional effects of COVID–
19 on providers and patients. One of
these commenters stated that there may
be significant changes in Hospital
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Readmissions Reduction Program
penalties for individual providers
because of the effects of COVID–19.
Response: We agree with commenters
that we should monitor the COVID–19
PHE’s ongoing effects carefully and we
will work with measure developers to
refine measure specifications as
circumstances warrant. We will also
assess performance periods,
performance, and other effects of the
COVID–19 PHE carefully, and we will
monitor the policy’s effects as we
implement it.
Comment: Many commenters
recommended postponing resumption
of the CMS–30 Day Pneumonia
Readmission Measure (NQF #0506).
Some of these commenters suggested
postponing finalization of our proposal
to resume use of the pneumonia
readmission measure until the FY 2024
IPPS/LTCH PPS rule to provide at least
a full year of use of the new ICD–10
codes. A few commenters recommended
postponing resumption until the
performance period does not include
time prior to the adoption of the new
ICD–10 codes, specifically until the
performance period does not include
any dates prior to January 1, 2021. Other
commenters recommended postponing
resumption until the COVID–19 PHE
has ended because many patients have
delayed care, resulting in higher acuity
when they received care, which affects
the case mix.
Response: We recognize that the
COVID–19 PHE continues to affect
communities and healthcare systems
and understand commenters’ concerns
that data used in the analysis for the
proposed rule may not be representative
of the prevalence of COVID–19 and
associated changes to admissions
patterns after September 2021. However,
we believe that the CMS 30-Day
Pneumonia Readmission Measure (NQF
#0506) is an important aspect of our
goal to improve patient safety and
quality of care and wish to resume the
use of this measure in the Hospital
Readmissions Reduction Program at the
earliest point that allows for a valid and
comparable measure. Based on our
analysis of data from the start of the
PHE through September 2021, we
believe that the measure will be valid
and comparable beginning with the FY
2024 program year.
More recent data through March 2022
show that across all Hospital
Readmissions Reduction Program
measures, less than 3 percent of the
cohorts have a COVID–19 diagnosis.
Commenters are correct that the FY
2024 program year does include six
months after the declaration of the PHE
for COVID–19 prior to the adoption of
PO 00000
Frm 00308
Fmt 4701
Sfmt 4700
the new ICD–10 codes for COVID–19
(specifically July 1, 2020 through
December 31, 2020). However, in our
analysis, measure scores calculated
based on data which include this period
using the numerator (outcome) and
denominator (cohort) exclusions and
addition of the covariate for history of
COVID–19 diagnosis in the 12 months
prior to the index admission resulted in
mean measure scores that were closer to
the prior non-COVID–19 affected period
compared with the unchanged measure.
Therefore, we believe that the measure
is sufficiently valid and comparable to
resume use in the FY 2024 program
year, despite the six months of data not
affected by updated coding practices.
Additionally, we note that the existing
clinical risk adjustments for this
measure (available in the Measures
Methodology Report at https://
qualitynet.cms.gov/inpatient/measures/
readmission/methodology) are designed
to account for the complexity and acuity
of the patient population. Because it is
our goal to make hospitals aware of our
intent to resume use of the measure as
early as feasible, we do not believe it
would be appropriate to wait until the
FY 2024 IPPS/LTCH PPS final rule to
finalize resumption of this measure.
After consideration of the public
comments we received, we are
finalizing our proposal to resume use of
the CMS 30-Day Pneumonia
Readmission Measure (NQF #0506) for
payment adjustments beginning with
the FY 2024 program year.
c. Technical Measure Specification
Update To Include a Covariate
Adjustment for COVID–19 Beginning
with FY 2023
As discussed in section V.H.5.b of the
preamble of this final rule, we have
previously finalized a subregulatory
process to incorporate technical
measure specification updates into the
measure specifications we have adopted
for the Hospital Readmissions
Reduction Program (79 FR 50039) and
reiterated this policy in the FY 2020
IPPS/LTCH PPS final rule (84 FR 42385)
and the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45256). As we continue to
evaluate the effects of the COVID–19
PHE on our programs, and the effects of
COVID–19 on our measures, we have
observed that for some patients COVID–
19 continues to have lasting effects,
including fatigue, cough, palpitations,
and others potentially related to organ
damage, post-viral syndrome, postcritical care syndrome or other
reasons.218 These clinical conditions
218 Raveendran, A.V., Jayadevan, R. and
Sashidharan, S., Long COVID: An overview.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
could affect a patient’s risk factors for
being readmitted following an index
admission for any of the six conditions/
procedures included in the Hospital
Readmissions Reduction Program.
Therefore, we are modifying the
technical measure specifications of each
of our six condition/procedure specific
risk-standardized readmission measures
to include a covariate adjustment for
patient history of COVID–19 in the 12
months prior to the admission
beginning with the FY 2023 program
year. This inclusion of the covariate
adjustment for patient history of
COVID–19 in the 12 months prior to the
admission will be effective beginning
with the FY 2023 program year and for
subsequent years for the five nonpneumonia condition- and procedurespecific readmission measures. As
described in V.H.5.b, the pneumonia
readmission measure remains
suppressed from scoring and payment
adjustments for the FY 2023 program
year and will be resumed for the FY
2024 program year. However, this
update will be reflected in the
confidential and public reporting of the
pneumonia readmission measure for FY
2023.219 For more information on the
application of covariate adjustments,
please see the Measure Methodology
Reports (posted on the QualityNet
website at https://qualitynet.cms.gov/
inpatient/measures/readmission/
methodology).
Although we did not solicit comments
on the technical measure specification
updates to apply a covariate adjustment
for patients with a history of COVID–19
in the 12 months prior to the index
hospitalization, we received several
comments and have summarized them
here. We have also included the
comments on our technical measure
specification update to exclude COVID–
19 patients from the measure
denominator (cohort) and numerator
(outcome) for the CMS 30-Day
Pneumonia Readmission Measure (NQF
#0506) here.
Comment: Many commenters
supported both the technical update to
adopt a covariate adjustment for
patients who have had COVID–19 in the
Available at https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC8056514/. Accessed on December 15,
2021.
219 We note that the pneumonia readmission
measure would typically be included in the July
update of the Compare website. However, to
provide stakeholders an opportunity to provide
comment on these updates, we are postponing
incorporation of the pneumonia readmission
measure to the January 2023 refresh of the Compare
website. (In the proposed rule we stated that the
pneumonia measure would be included in the
October refresh, however we are correcting that
here to the January 2023 refresh).
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
12 months prior to the index admission
for each of the six condition/procedure
specific readmission measures in the
Hospital Readmissions Reduction
Program and the technical update to
exclude patients with a COVID–19
diagnosis present on admission from the
numerator (outcome) and denominator
(cohort) of the pneumonia readmission
measure.
Response: We thank these
commenters for their support.
Comment: Many commenters
expressed concern that many patients
with a history of COVID–19 would not
be captured in ICD–10–CM codes,
specifically mentioning the possibility
of these patients being diagnosed
through at-home or pharmacy-based
tests and then receiving care in visits
billed with other codes for resulting
conditions. These commenters noted
that a covariate adjustment based on
data that are inconsistently captured
could impact the reliability and validity
of the measure results and therefore the
fairness of the program. Some of these
commenters recommended review by a
Technical Expert Panel (TEP) convened
by the NQF to ensure that COVID–19
adjustments are sufficiently
comprehensive and include all
appropriate codes. Some commenters
recommended further data analysis to
ensure appropriate data sources are
available for this adjustment.
Response: We understand the
commenters’ concerns regarding the
prevalence of at-home or pharmacybased testing for COVID–19 and the
potential effects on the validity of the
covariate adjustment. The history of
COVID–19 variable 220 is defined as
U07.1 (COVID–19) or Z86.16 (personal
history of COVID–19) in the 12 months
prior to the admission, or Z86.16 at the
index admission. Therefore, the history
of COVID–19 variable does not rely
solely on the COVID–10 specific ICD–10
code, U07.1, but also includes the
‘‘personal history of COVID–19’’ code
(Z86.16) which hospitals can code, even
during the index encounter. However,
we will consider these concerns and
recommendations as we continue to
evaluate and update our measure
specifications, especially with respect to
the ongoing changes to the COVID–19
PHE. We thank commenters for their
suggestion of having a special NQF
convened TEP review the covariate
adjustment methodology to ensure that
the adjustments are comprehensive
220 The history of COVID–19 variable is used as
part of our risk adjustment model which accounts
for risk factors such as beneficiary age and other
clinical risk factors. This variable has been added
as a clinical risk factor due to effects of patient
history of COVID–19 on readmission risk.
PO 00000
Frm 00309
Fmt 4701
Sfmt 4700
49087
enough to capture the long-term impacts
of COVID–19. Any permanent changes
to the measure will be submitted for
NQF review during the endorsement
maintenance process.
Comment: Many commenters
observed that the extended effects of
COVID–19 on patients are still not
known. These commenters
recommended continued monitoring to
ensure that the 12-month period is
appropriate for the covariate
adjustment. A commenter
recommended adopting a 24-month
period as opposed to a 12-month period.
A commenter expressed that the effects
of the pandemic changing over time
may decrease the ability to identify
appropriate adjustments, including both
the covariate adjustment for patients
with a history of COVID–19 in the 12
months prior to index admission and
the update to the CMS 30-Day
Pneumonia Readmission Measure to
exclude patients who have a diagnosis
of COVID–19 present at admission from
the numerator (outcome) and
denominator (cohort). A commenter
observed that COVID–19 will likely
become an endemic disease. A
commenter recommended analyzing
cohort-specific risk adjustment and
analyses for the COVID–19 patient
population due to differences in
utilization, infection risk, and
readmission risk among these patients.
Response: We thank these
commenters for the recommendations.
We agree that the extended effects of
COVID–19 on patients are still not
known. We will consider these
recommendations as we continue to
evaluate and update our measure
specifications, especially with respect to
the ongoing changes to the COVID–19
PHE. We note, however, that hospitals
can use the ‘‘personal history of COVID’’
code (Z86.16) on the index admission
which is not affected by a look-back
period. We also note that patients who
are admitted with a diagnosis of
COVID–19 present on admission are
excluded from all measures within the
Hospital Readmissions Reduction
Program. We will continue to monitor
and analyze the appropriateness of this
exclusion using available data.
Comment: A commenter observed that
the measure methodology reports
published on CMS’s website in May
2022 demonstrate that history of
COVID–19 is negatively correlated to
readmissions (that is, patients with
history of COVID–19 are less likely to be
readmitted) for four out of the of five
conditions analyzed and recommended
to only include the covariate adjustment
for conditions where patient history of
COVID–19 is a positive risk variable
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49088
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(that is, patients with history of COVID–
19 are more likely to be readmitted) for
the performance period.
Response: We thank the commenter
for this input. Analyses using data from
July 1, 2020 through February 28, 2021
showed that for most of the
readmissions measures, observed
(unadjusted) 30-day readmission rates
for patients without an index admission
of COVID–19, but with a history of
COVID–19 (defined as U07.1 or Z86.16
in the 12 months prior to the admission,
or Z86.16 at the index admission), were
higher than patients without a history of
COVID–19. Based on the higher odds of
readmission for these patients, we
decided to add the covariate across all
of the readmission measures in the
Hospital Readmissions Reduction
Program. We are now providing updated
information.
Results using more recent data
spanning the entire 3-year reporting
period (July 1, 2018 through June 30,
2021) showed that for patients without
an index admission of COVID–19, those
with a history of COVID–19 (defined in
the previous paragraph) in the
pneumonia and heart failure cohorts
have much higher frequencies of some
model risk variables compared with
patients without a history of COVID–19,
suggesting they are sicker. At the same
time, in a multivariable model, we
found, as the commenter notes, that
unlike the bivariate relationship, the
adjusted odds ratios for 30-day
readmission for the history of COVID–
19 variable (the odds ratios in the
context of all the variables in the model)
were less than one (for all but the
Hospital 30-day RSSR following COPD
hospitalization measure—NQF #1891).
Therefore, in these patients without
COVID–19 at the time of admission, but
with a history of COVID–19, the nonCOVID–19 clinical comorbidities in the
risk model are lessening or reversing the
effect size of the history of COVID–19
variable. We have decided, however, to
keep the history of COVID covariate in
the model for reasons of face validity
and to account for any future risk
adjustment for long COVID that may not
be accounted for in the measures’
baseline risk models. However, we will
consider this recommendation as we
continue to evaluate and update our
measure specifications
Comment: A commenter opposed
updates to measure specifications (that
is, inclusion of a covariate adjustment to
account for patient history of COVID–19
in the 12 months prior to the index
admission and excluding patients with
a diagnosis of COVID–19 present on
admission from the pneumonia
readmission measure) because these
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
patients are vulnerable. This commenter
stated that hospitals should be
incentivized to care for this patient
population.
Response: We agree with the
commenter that it is important that
these patients receive high quality care
when hospitalized. However, we note
that the measures in the Hospital
Readmissions Reduction Program were
developed and adopted to identify
excess readmissions for patients
hospitalized for specific conditions or
procedures. Because COVID–19 did not
exist when these measures were
developed, the measures are neither
intended nor specified to address the
clinical needs of patients with a history
of COVID–19. We will continue to
assess specifications of the measures in
the Hospital Readmissions Reduction
Program to identify whether further
updates to account for care provided to
COVID–19 patients are appropriate.
Comment: A commenter requested
clarification regarding whether the
updates to the measure specifications,
specifically inclusion of a covariate
adjustment for patients who have had
COVID–19 in the 12 months prior to the
index admission for each of the six
condition/procedure specific
readmissions measures in the Hospital
Readmissions Reduction Program and
updating the CMS 30-Day Pneumonia
Readmission Measure (NQF #0506) to
exclude patients with a diagnosis of
COVID–19 present on admission from
the measure denominator (cohort) and
numerator (outcome), will be in effect
after the end of the PHE or if this is a
form of data suppression associated
with the PHE.
Response: We have adopted this
update as an update to the measure
specifications, not as suppression of
data related to the COVID–19 PHE.
Therefore, the updated measure
specifications will not necessarily
change with the end of the PHE.
However, we will continue to monitor
the effects of COVID–19 on each of our
measures and on the overall program to
ensure that the measure specifications
remain appropriate for evolving clinical
practices.
Comment: A commenter expressed
concern that the measure specifications
are not publicly available and therefore
commenters were unable to assess the
impact of measure updates.
Response: We regret that the
commenter was unable to find the
measure specification information to
assess the impact of measure updates.
As described in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28421), the
measure specifications, which were
posted in May 2022, are available at
PO 00000
Frm 00310
Fmt 4701
Sfmt 4700
https://qualitynet.cms.gov/inpatient/
measures/readmission/methodology.
Because of the CMS 30 Day
Pneumonia Readmission Measure (NQF
#0506) being paused from program
calculations for FY 2023, the
methodology report for FY 2023 is not
yet available. However, we believe that
past methodology reports provide
sufficient information on the measure’s
specifications that commenters were
able to assess the impact of updates on
this measure.
Comment: A commenter
recommended risk adjusting for COVID–
19 during an encounter instead of
suppressing data for reporting periods
or populations.
Response: We believe this commenter
is recommending developing a risk
adjustment methodology for patients
admitted with a primary or secondary
diagnosis of COVID–19 present at
admission instead of excluding these
patients from the numerator (outcome)
and denominator (cohort). We thank the
commenter for this suggestion. We will
consider this option in the future as we
continue to evaluate the effectiveness of
our COVID–19 updates for the measures
in the Hospital Readmissions Reduction
Program.
Comment: Several commenters
recommended that CMS publicly report
the results of analyses that show that the
data being used to capture patients with
a history of COVID–19 in the 12 months
prior to the index admission are
sufficiently reliable. A commenter
recommended that CMS publicly report
analyses of the impact of COVID–19
patients on measure results to support
public understanding of the results of
measure updates.
Response: We agree with the
commenters that publicly reporting
analyses that support our updates to
measure specifications advances our
objective of transparency in program
operations. We note that we have
published our analyses to date in the FY
2023 IPPS/LTCH PPS proposed rule (87
FR 28419 through 28421) and in
response to public comments in this
final rule.
6. Definition of ‘‘Applicable Period’’
We refer readers to the FY 2012 IPPS/
LTCH PPS final rule (76 FR 51671) and
the FY 2013 IPPS/LTCH PPS final rule
(77 FR 53375) for discussion of our
previously finalized policy for defining
‘‘applicable period.’’ The definition of
‘‘applicable period’’ is also specified at
42 CFR 412.152. The ‘‘applicable
period’’ is the 3-year period from which
data are being collected in order to
calculate excess readmission ratios
(ERRs) and payment adjustment factors
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
7. Identification of Aggregate Payments
for Each Condition/Procedure and All
Discharges
When calculating the numerator
(aggregate payments for excess
readmissions), we determine the base
operating DRG payment amount for an
individual hospital for the applicable
period for each condition/procedure
using Medicare inpatient claims from
the MedPAR file with discharge dates
that are within the applicable period.
Under our established methodology, we
use the update of the MedPAR file for
each Federal fiscal year, which is
updated 6 months after the end of each
Federal fiscal year within the applicable
period, as our data source.
In identifying discharges for the
applicable conditions/procedures to
calculate the aggregate payments for
excess readmissions, we apply the same
exclusions to the claims in the MedPAR
file as are applied in the measure
methodology for each of the applicable
conditions/procedures. For the FY 2023
applicable period, this includes the
discharge diagnoses for each applicable
condition/procedure based on a list of
specific ICD–10–CM and ICD–10–PCS
code sets, as applicable, for that
condition/procedure.
We identify Medicare fee-for-service
(FFS) claims that meet the criteria as
previously described for each applicable
condition/procedure to calculate the
aggregate payments for excess
readmissions. This means that services
covered by Medicare Advantage are not
included in this calculation. This policy
is consistent with the methodology to
calculate ERRs based solely on
admissions and readmissions for
Medicare FFS patients.
In the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38232), we stated that we
would determine the neutrality modifier
using the most recently available full
year of MedPAR data. For the purpose
of modeling the estimated FY 2023
readmissions payment adjustment
factors for this final rule, we would use
the proportion of dually eligible
beneficiaries, excess readmission ratios,
and aggregate payments for each
condition/procedure and all discharges
for applicable hospitals from the FY
2023 Hospital Readmissions Reduction
Program applicable period (July 1, 2018
through June 30, 2021).222
For the FY 2023 program year,
applicable hospitals will have the
opportunity to review and correct
calculations based on the FY 2023
applicable period of July 1, 2018 to June
30, 2021, before they are made public
under our policy regarding reporting of
hospital-specific information. Again, we
reiterate that this period is intended to
review the program calculations, and
not the underlying data. For more
information on the review and
corrections process, we refer readers to
the FY 2013 IPPS/LTCH PPS final rule
(77 FR 53399 through 53401).
We did not propose any changes to
our policies for the identification of
aggregate payments for each condition/
procedure in the FY 2023 IPPS/LTCH
PPS proposed rule.
221 Although the FY 2023 applicable period
would be July 1, 2018 through June 30, 2021, we
note that the first and second quarter data from CY
2020 is excluded from consideration for program
calculation purposes due to nationwide ECE that
was granted in response to the COVID–19 PHE.
222 Although the FY 2023 applicable period is
July 1, 2018, through June 30, 2021, we note that
first and second quarter data from CY 2020 is
excluded from consideration for program
calculation purposes due to the nationwide ECE
that was granted in response to the COVID–19 PHE.
khammond on DSKJM1Z7X2PROD with RULES2
for the fiscal year; this includes
aggregate payments for excess
readmissions and aggregate payments
for all discharges used in the calculation
of the payment adjustment. The
‘‘applicable period’’ for dually eligible
beneficiaries is the same as the
‘‘applicable period’’ that we otherwise
adopt for purposes of the Hospital
Readmissions Reduction Program.
In order to provide greater certainty
around future ‘‘applicable periods’’ for
the Hospital Readmissions Reduction
Program, in the FY 2021 IPPS/LTCH
PPS final rule (85 FR 58845 through
58846), we finalized the automatic
adoption of ‘‘applicable periods’’ for FY
2023 and all subsequent program years
for the Hospital Readmissions
Reduction Program.
Beginning in FY 2023, the ‘‘applicable
period’’ for the Hospital Readmissions
Reduction Program will be the 3-year
period beginning 1 year advanced from
the previous program fiscal year’s start
of the ‘‘applicable period.’’ 221 Under
this policy, for all subsequent years, we
will advance this 3-year period by 1
year unless otherwise specified by the
Secretary, which we would convey
through notice and comment
rulemaking. Similarly, the ‘‘applicable
period’’ for dual eligibility will continue
to correspond to the ‘‘applicable period’’
for the Hospital Readmissions
Reduction Program, unless otherwise
specified by the Secretary. We refer
readers to the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58845 through 58846)
for a more detailed discussion of this
topic.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we did not propose any
updates to this policy.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00311
Fmt 4701
Sfmt 4700
49089
8. Use of MedPAR Data Corresponding
to the Applicable Period
We refer readers to the FY 2013 IPPS/
LTCH PPS final rule (77 FR 53387
through 53390) for discussion of our
previously finalized policy for the use of
MedPAR claims data as our data source
for determining aggregate payments for
each condition/procedure and aggregate
payments for all discharges during
applicable periods. Most recently, in the
FY 2022 IPPS/LTCH PPS final rule (86
FR 45258), we finalized our policy on
the continued use of the MedPAR data
corresponding to the applicable period
for the Hospital Readmissions
Reduction Program calculations for the
FY 2022 applicable period.
In addition, in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45259), we
expressed our continued belief that the
use of MedPAR claims data is the
appropriate source for identifying
aggregate payments for each condition/
procedure and all discharges during the
corresponding applicable period for the
Hospital Readmissions Reduction
Program. Therefore, we finalized our
proposal to automatically adopt the use
of MedPAR data corresponding to the
applicable period (the 3-year period
beginning 1 year advanced from the
previous program fiscal year’s MedPAR
data) 223 for Hospital Readmissions
Reduction Program calculations for FY
2023 and all subsequent program years.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we did not propose any
changes to this policy.
9. Calculation and Application of
Payment Adjustment Factors
As we discussed in the FY 2018 IPPS/
LTCH PPS final rule (82 FR 38226),
section 1886(q)(3)(D) of the Act requires
the Secretary to group hospitals and
apply a methodology that allows for
separate comparisons of hospitals
within peer groups, based on the
proportion of dually eligible
beneficiaries served by each hospital, in
determining a hospital’s adjustment
factor for payments applied to
discharges beginning in FY 2019.
Section 1886(q)(3)(D) of the Act also
states that this methodology could be
223 Although the FY 2023 applicable period is
July 1, 2018, through June 30, 2021, we note that
first and second quarter data from CY 2020 is
excluded from consideration for program
calculation purposes due to the nationwide ECE
that was granted in response to the COVID–19 PHE.
Taking into consideration the 30-day window to
identify readmissions, the period for calculating
DRG payments would be adjusted to July 1, 2018
through December 1, 2019 and July 1, 2020 through
June 30, 2021. Further information will be found in
the FY 2023 Hospital Specific Report (HSR) User
Guide located on QualityNet website at https://
qualitynet.cms.gov/inpatient/hrrp/reports.
E:\FR\FM\10AUR2.SGM
10AUR2
49090
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
replaced through the application of
subclause (E)(i), which states that the
Secretary may take into account the
studies conducted and the
recommendations made by the reports
required by section 2(d)(1) of the
IMPACT Act of 2014 (Pub. L. 113–185;
42 U.S.C. 1395 note) with respect to risk
adjustment methodologies.
Additionally, section 1886(q)(3)(A) of
the Act defines the payment adjustment
factor for an applicable hospital for a
fiscal year as ‘‘equal to the greater of: (i)
the ratio described in subparagraph (B)
for the hospital for the applicable period
(as defined in paragraph (5)(D)) for such
fiscal year; or (ii) the floor adjustment
factor specified in subparagraph (C).’’
Section 1886(q)(3)(B) of the Act, in turn,
describes the ratio used to calculate the
adjustment factor. Specifically, it states
that the ratio is equal to 1 minus the
ratio of aggregate payments for excess
readmissions to aggregate payments for
all discharges, scaled by the neutrality
modifier. The calculation of this ratio is
codified at 42 CFR 412.154(c)(l) and the
floor adjustment factor is codified at 42
CFR 412.154(c)(2). Section 1886(q)(3)(C)
of the Act specifies the floor adjustment
factor at 0.97 for FY 2015 and
subsequent fiscal years.
Consistent with section 1886(q)(3) of
the Act, and codified in our regulations
at 42 CFR 412.154(c)(2), for FY 2023, the
payment adjustment factor will be either
the greater of the ratio or the floor
adjustment factor of 0.97. Under our
established policy, the ratio is rounded
to the fourth decimal place. In other
words, for FY 2023, a hospital subject to
the Hospital Readmissions Reduction
Program would have an adjustment
factor that is between 1.0 (no reduction)
and 0.9700 (greatest possible reduction).
We refer readers to the FY 2018 IPPS/
LTCH PPS final rule (82 FR 38226
through 38237) for a detailed discussion
of the payment adjustment
methodology. For additional
information on Hospital Readmissions
Reduction Program payment
calculations, we refer readers to the
Hospital Readmissions Reduction
Program information and resources
available on our QualityNet website.
We did not propose any changes to
our calculation of payment methodology
in the FY 2023 IPPS/LTCH PPS
proposed rule.
10. Extraordinary Circumstance
Exception (ECE) Policy for the Hospital
Readmissions Reduction Program
In the FY 2016 IPPS/LTCH PPS final
rule (80 FR 49542 through 49543), we
adopted an ECE policy for the Hospital
Readmissions Reduction Program,
which recognized that there may be
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
periods of time during which a hospital
is not able to submit data (from which
readmission measures data are derived)
in an accurate or timely fashion due to
an extraordinary circumstance beyond
its control. When adopting this policy,
we noted that we considered the
feasibility and implications of excluding
data for certain measures for a limited
period of time from the calculations for
a hospital’s excess readmission ratios
for the applicable performance period.
By minimizing the data excluded from
the program, the policy enabled affected
hospitals to continue to participate in
the Hospital Readmissions Reduction
Program for a given fiscal year if they
otherwise continued to meet applicable
measure minimum threshold
requirements. We expressed the belief
that this approach would help alleviate
the burden for a hospital that might be
adversely impacted by a natural disaster
or other extraordinary circumstance
beyond its control, while enabling the
hospital to continue to participate in the
Hospital Readmissions Reduction
Program. We further observed that
section 1886(q)(5)(D) of the Act permits
the Secretary to determine the
applicable period for readmissions data
collection, and we interpreted the
statute to allow us to determine that the
period not include times when hospitals
may encounter extraordinary
circumstances. In the FY 2018 IPPS/
LTCH PPS final rule (82 FR 38239
through 38240), we modified the
requirements for the Hospital
Readmissions Reduction Program ECE
policy to further align with the
processes used by other quality
reporting and VBP programs for
requesting an exception from program
reporting due to an extraordinary
circumstance not within a provider’s
control.
In response to COVID–19, we
announced relief for clinicians,
providers, hospitals, and facilities
participating in Medicare quality
reporting and value-based purchasing
programs. On September 2, 2020, we
published the interim final rule with
comment period (IFC), ‘‘Medicare and
Medicaid Programs, Clinical Laboratory
Improvement Amendments (CLIA), and
Patient Protection and Affordable Care
Act; Additional Policy and Regulatory
Revisions in Response to the COVID–19
Public Health Emergency’’ (85 FR
54820). The IFC updated the ECE we
granted in response to the COVID–19
PHE, for the Hospital Readmissions
Reduction Program and several other
quality reporting programs (85 FR 54827
through 54837). In the IFC, we updated
the previously announced application of
PO 00000
Frm 00312
Fmt 4701
Sfmt 4700
our ECE policy for the Hospital
Readmissions Reduction Program (85
FR 54832 through 54833) to the COVID–
19 PHE to exclude any data submitted
regarding care provided during the first
and second quarters of CY 2020 from
our calculation of performance for FY
2022, FY 2023, and FY 2024.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45260 through 45262), we
clarified our ECE policy to highlight that
an ECE granted under the Hospital
Readmissions Reduction Program would
exclude claims data during the
corresponding ECE period. We stated
that although we had considered the
feasibility and implications of excluding
data under the ECE policy for the
Hospital Readmissions Reduction
Program, we had never specified the
types of data that would be excluded
under an ECE granted to an individual
hospital. Considering that the Hospital
Readmissions Reduction Program only
uses claims data, we clarified our ECE
policy to specify that claims data will be
excluded from calculations of measure
performance under an approved ECE for
the Hospital Readmissions Reduction
Program. We further clarified that
although an approved ECE for the
Hospital Readmissions Reduction
Program would exclude excepted data
from Hospital Readmissions Reduction
Program payment reduction
calculations, we did not waive the data
submission requirements of a hospital
for claims data (86 FR 45261 through
45262). For example, for claims data, we
require a hospital to submit claims to
receive payments for the services they
provided to patients. Although an
individual ECE approval under the
Hospital Readmissions Reduction
Program would except data submitted
by a hospital from Hospital
Readmissions Reduction Program
calculations, a hospital would still need
to submit its claims in order to receive
payment outside the scope of the
Hospital Readmissions Reduction
Program for services provided.
Finally, in the FY 2022 IPPS/LTCH
PPS final rule, we clarified that,
although an approved ECE for the
Hospital Readmissions Reduction
Program would exclude excepted data
from Hospital Readmissions Reduction
Program payment reduction
calculations, such an ECE does not
exempt hospitals from payment
reductions under the Hospital
Readmissions Reduction Program (86
FR 45262).
We did not propose any changes to
our previously finalized ECE Policy in
the FY 2023 IPPS/LTCH PPS proposed
rule.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
11. Request for Public Comment on
Possible Future Inclusion of Health
Equity Performance in the Hospital
Readmissions Reduction Program
We are committed to achieving equity
in healthcare outcomes for our
beneficiaries by supporting providers’
quality improvement activities to reduce
health inequities, by enabling them to
make more informed decisions, and by
promoting provider accountability for
healthcare disparities.224 As described
in section IX.B. of the preamble of this
final rule, we discussed and sought
comment on overarching principles for
measuring health care quality
disparities to provide more actionable
and comprehensive information on
health care disparities across multiple
social risk factors and demographic
variables. As part of this request for
information, we also discussed different
approaches for identifying meaningful
performance differences and guiding
principles for reporting disparity
measures.
As previously discussed in the FY
2018 IPPS/LTCH PPS final rule (82 FR
38226), section 1886(q)(3)(D) of the Act
requires the Secretary to group hospitals
and apply a methodology that allows for
separate comparisons of hospitals with
differing proportions of dually eligible
beneficiaries in determining a hospital’s
adjustment factor for payments applied
to discharges beginning in FY 2019. To
implement this provision, in the FY
2018 IPPS/LTCH PPS final rule (82 FR
38226 through 38237), we finalized a
number of changes to the payment
reduction methodology, including our
policy to stratify hospitals into
quintiles, or peer groups, based on their
proportion of dually eligible
beneficiaries (82 FR 38229 through
38231) and our policy to use the median
excess readmission ratio for the
hospital’s peer group in place of 1.0 in
the payment reduction formula (82 FR
38231 through 38237). In this peer
grouping methodology, dual eligibility
status is used as it is an indicator of
beneficiaries’ social risk. The peer
grouping methodology mitigates against
disproportionate payment reductions for
hospitals serving socially at-risk
populations. However, this peer
grouping methodology does not directly
measure or account for disparities in
health care quality between beneficiary
groups with heightened social risk and
groups with less social risk.
In the FY 2018 IPPS/LTCH PPS final
rule, we introduced confidential
224 https://www.cms.gov/Medicare/QualityInitiatives-Patient-Assessment-Instruments/Quality
initiativesgeninfo/downloads/cms-qualitystrategy.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
reporting of hospital quality measure
data stratified by social risk factors (82
FR 38403 through 38409). We have
created two complementary methods to
calculate disparities in condition/
procedure-specific readmission
measures (the CMS Disparity Methods).
The first method (the Within-Hospital
disparity method) promotes quality
improvement by calculating differences
in outcome rates across beneficiary
groups within a hospital while
accounting for their clinical risk factors.
This method also allows for comparison
of those differences, or disparities,
across hospitals, so hospitals could
assess how well they are closing
disparity gaps compared to other
hospitals. The second methodological
approach (the Across-Hospital method)
assesses hospitals’ outcome rates for
subgroups of beneficiaries across
hospitals, allowing for a comparison
across hospitals on their performance
serving beneficiaries with social risk
factors. We refer readers to the FY 2018
IPPS/LTCH PPS final rule (82 FR 38405
through 38407) and the Disparity
Methods technical report and Updates
and Specifications Report posted on the
QualityNet website for additional
details. The CMS Disparity Methods
more directly measure disparities in
health care quality between dually
eligible and non-dually eligible
beneficiary groups than the Hospital
Readmissions Reduction Program’s peer
grouping methodology. For example,
when considering the CMS Disparity
Methods results calculated using data
for the FY 2022 Hospital Readmissions
Reduction Program performance period,
measures showed not only a range
between low and high disparity rates
within hospitals, but also worse overall
outcome rates for beneficiaries with
social risk using beneficiary dual
eligibility status as the stratification
variable. Of these measures, the most
actionable for hospitals were measures
that showed overall high readmission
rates for dually eligible beneficiaries
across hospitals, or a large difference in
readmission rates between dually
eligible and non-dually eligible
beneficiaries. These gaps in care
indicated that there is potential for
improvement, or a reduction in
disparity at poorly performing hospitals
if they were able to emulate the
performance of strongly performing
hospitals.
The Hospital Readmissions Reduction
Program currently groups hospitals into
one of five peer groups based on their
proportion of beneficiaries who are
dually eligible for Medicare and full
Medicaid benefits. Beneficiaries’ dual
PO 00000
Frm 00313
Fmt 4701
Sfmt 4700
49091
eligibility for Medicare and Medicaid is
a widely used proxy for a beneficiary’s
financial risk. Medicaid enrollees have
incomes and overall wealth below a
certain threshold and thus, Medicaid
eligibility may be used as a proxy for
low socioeconomic status. The use of
beneficiaries’ dual eligibility in social
risk factor analyses was supported by
ASPE’s First Report to Congress.225 This
report found that in the context of
value-based purchasing programs such
as the Hospital Readmissions Reduction
Program, dual eligibility, as an indicator
of social risk, was among the most
powerful predictors of poor health
outcomes among those social risk
factors that ASPE examined and tested.
In alignment with the current program,
we are considering the use of the
beneficiary’s dual eligibility status as a
measure of beneficiaries’ social risk that
could be used to incorporate hospitals’
performance for socially at-risk
populations in the Hospital
Readmissions Reduction Program.
As part of our broader goal of
achieving equity in healthcare outcomes
for our beneficiaries, we are interested
in encouraging providers to improve
health equity and reduce health care
disparities through the Hospital
Readmissions Reduction Program. We
sought comment on approaches to
updating the Hospital Readmissions
Reduction Program to incorporate
performance for socially at-risk
populations. For example, we are
considering approaches that would
account for a hospital’s performance on
readmissions for socially at-risk
beneficiaries compared to all other
hospitals, or its performance in treating
socially at-risk beneficiaries compared
to other beneficiaries within the
hospital, or combinations of these
approaches. We acknowledge that
updating the Hospital Readmissions
Reduction Program to encourage
improved performance for socially atrisk populations can take many forms,
and we sought to explore different
approaches so we can find an approach
that satisfies our goals without
unintended consequences.
In exploring approaches to
incorporate performance for socially atrisk populations in the Hospital
Readmissions Reduction Program, our
objective is to encourage providers to
improve health equity and reduce
health care disparities without
225 Office of the Assistant Secretary for Planning
and Evaluation. (2016). Social risk factors and
performance under Medicare’s value-based
purchasing programs. Available at: https://
aspe.hhs.gov/reports/report-congress-social-riskfactors-performance-under-medicares-value-basedpurchasing-programs.
E:\FR\FM\10AUR2.SGM
10AUR2
49092
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
disincentivizing hospitals to treat
socially at-risk beneficiaries or
disproportionately penalizing hospitals
that treat a large proportion of socially
at-risk beneficiaries. We sought
comment on approaches that would
achieve this objective.
As also discussed in our request for
information on overarching principles
for measuring health care quality
disparities, as described in section IX.C
of the preamble of this final rule, many
non-clinical drivers of health are known
to impact beneficiary outcomes,
including social risk factors such as
socioeconomic status, housing security
and adequacy, and food security. The
Hospital Readmissions Reduction
Program currently uses beneficiaries’
dual eligibility for Medicare and
Medicaid as a proxy for a beneficiary’s
social risk and uses dual eligibility, as
required by the statute, to divide
hospitals into peer groups for
comparison under the program. We
sought comment on variables associated
with or measures of social risk and
beneficiary demographics that are
already collected, as well as broader
definitions of dual eligibility, such as
those who are enrolled in a Medicare
Savings Program or the Medicare Part D
Low Income Subsidy, that could be
included in the Hospital Readmissions
Reduction Program in addition to dual
eligibility. We note initially we would
use such variables to stratify results
within Hospital Specific Reports (HSRs)
as confidential feedback to hospitals.
Measures of social risk could also
include indices developed for the
purpose of identifying socially at-risk
populations and measuring the degree
of risk. For example, as described in
section IX.B, we are considering the
University of Wisconsin School of
Medicine and Public Health and Health
Resources and Services
Administration’s Area Deprivation
Index (ADI),226 Agency for Healthcare
Research and Quality Socioeconomic
Status Index,227 and the Centers for
Disease Control and Prevention’s Social
Vulnerability Index.228 For example, the
226 Center for Health Disparities Research. About
the Neighborhood Atlas. Available at: https://
www.neighborhoodatlas.medicine.wisc.edu/.
227 Bonito A., Bann C., Eicheldinger C., Carpenter
L. (2008). Creation of New Race-Ethnicity Codes
and Socioeconomic Status (SES) Indicators for
Medicare Beneficiaries. Final Report, Sub-Task 2.
(Prepared by RTI International for the Centers for
Medicare & Medicaid Services through an
interagency agreement with the Agency for
Healthcare Research and Policy, under Contract No.
500–00–0024, Task No. 21) AHRQ Publication No.
08–0029–EF. Rockville, MD, Agency for Healthcare
Research and Quality.
228 Flanagan, B.E., Gregory, E.W., Hallisey, E.J.,
Heitgerd, J.L., Lewis, B. (2011). A social
vulnerability index for disaster management.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
ADI allows for rankings of
neighborhoods by socioeconomic
disadvantage in a region of interest
(such as at the state or national level),
and includes factors for income,
education, employment, and housing
quality and is used in our Everyone
with Diabetes Counts program in order
to target seniors in the most
disadvantaged neighborhoods for
diabetes education.229 In addition to
individual variables or sets of variables
we sought comment on the addition of
one or more of these indices or
proposals for other indices or modified
indices that capture multiple
dimensions of social risk and that have
demonstrated relations to health
outcomes or access to health care
resources, that can be added to the
Program along with dual eligibility as
factors for stratifying data. We requested
commenters to include information on
the availability of public data sources
and documentation of the methods and
testing that establish their applicability
and provide supporting information
about availability and methods when
suggesting variables or indices to
measure social risk. Support from a
national-level assessment of the impact
of social risk can be particularly useful
to demonstrate the relevance of a
proposed indicator.
Before any changes to the Hospital
Readmissions Reduction Program are
implemented, we plan to assess the
extent to which they address our
objective as well as their financial
impact on the Hospital Readmissions
Reduction Program. Any proposals to
update the Hospital Readmissions
Reduction Program to account for the
extent to which a hospital is able to
provide high quality and equitable care
for beneficiaries with social risk factors,
as previously described, would be made
through future rulemaking.
We invited public comment on the
following: (1) the benefit and potential
risks, unintended consequences, and
costs of incorporating hospital
performance for beneficiaries with
social risk factors in the Hospital
Readmissions Reduction Program; (2)
the approach of linking performance in
caring for socially at-risk populations
and payment reductions by calculating
the reductions based on readmission
outcomes for socially at-risk
beneficiaries compared to other
hospitals or compared to performance
Journal of Homeland Security and Emergency
Management, 8(1). Available at: https://
www.atsdr.cdc.gov/placeandhealth/svi/img/pdf/
Flanagan_2011_SVIforDisasterManagement508.pdf.
229 https://www.neighborhoodatlas.medicine.
wisc.edu/.
PO 00000
Frm 00314
Fmt 4701
Sfmt 4700
for other beneficiaries within the
hospital; and (3) measures or indices of
social risk, in addition to dual
eligibility, that should be used to
measure hospitals’ performance in
achieving equity in the Hospital
Readmissions Reduction Program.
We received comments in response to
this request for information and have
summarized them here.
Comment: Several commenters
provided general comments regarding
equity in the Hospital Readmissions
Reduction Program. Some of these
commenters expressed concern that
current disparity methods lack
actionable information. A commenter
recommended providing financial
support to prevent readmissions related
to social needs, for example, by
supporting hospitals’ efforts to monitor
post discharge outcomes and connect
patients with necessary services. A
commenter observed that hospitals are
still experiencing the effects of the
COVID–19 PHE and recommended that
CMS wait until these effects have
subsided to introduce new payment
calculations both to ensure that any
calculations are based on reliable data
and to prevent further overwhelming
hospitals.
Many commenters responded to our
request for input on the benefit and
potential risks, unintended
consequences, and costs of
incorporating hospital performance for
beneficiaries with social risk factors in
the Hospital Readmissions Reduction
Program. Several commenters expressed
that the potential benefits of
incorporating equity in the Hospital
Readmissions Reduction Program are
improved care for at-risk patients,
improved understanding of the effects of
the social risk factors, and improved
care for all patients. A commenter stated
that readmissions are a metric for
healthcare equity because patients who
receive high quality care are generally
not readmitted. This commenter
expressed that improving healthcare
equity could reduce readmissions.
Many commenters expressed the
concern that linking payment to
performance on equity measures may
disproportionately penalize safety net
hospitals or other providers that treat
high complexity patients which could
impact access and quality for these
patients. Some of these commenters
recommended using bonus points or
incentives to avoid penalizing hospitals
that treat at-risk patients. A commenter
observed that addressing disparities will
require a long-term systemic approach.
Many commenters expressed concern
that incorporating performance for
beneficiaries with social risk factors in
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
the Hospital Readmissions Reduction
Program could lead hospitals to be held
accountable for factors outside of their
control. These commenters specifically
noted that there are numerous factors
outside of a hospitals’ control that affect
readmission rates, including community
and patient level factors. Some of these
commenters recommended developing a
mechanism for adjusting for
confounding influences to ensure public
reporting and payment are based
exclusively on the quality of care
provided; one of these commenters
specifically recommended adopting a
risk adjustment for patients who do not
take responsibility for their post
discharge care. Other commenters
recommended against public reporting
on stratified or other equity data
because this publication could imply
that hospitals are solely responsible for
30-day readmissions.
Several commenters observed that
analyzing data does not address the
underlying disparities, it only allows
the extent of the issue to be understood.
A commenter stated that publicly
reporting all data, both as trend reports
and as raw data, allows advocates and
other interested parties to perform
analyses and evaluate equity.
Several commenters observed that the
current peer grouping and stratified
reporting are recent changes to the
Hospital Readmissions Reduction
Program, and that much of the recent
data for the Program has been affected
by the COVID–19 PHE. These
commenters recommended leaving the
payment structure unchanged for at
least three more years to analyze the
effects of the current program prior to
modifying the payment structure. A
commenter stated the belief that the
Hospital Readmissions Reduction
Program methodology is flawed because
it uses point estimates of riskstandardized readmission rates without
respect to the margin of error for each
estimate. This commenter requested
clarification regarding the expectations
for hospitals prior to including care for
at-risk patients into the Hospital
Readmission Reduction Program
methodology. Another commenter
observed that the current payment
calculations are already complex and
expressed concern that further
modification to a complex system could
lead to unintended consequences.
Several commenters stated that
linking payment to equity is
inconsistent with the statutory
requirements for calculating payment
reductions. Some of these commenters
observed that the payment system was
designed to ensure equitable payments
for hospitals that treat high risk patients,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
not to advance patient level equity in
outcomes. Several commenters observed
that tracking drivers of health data may
increase the burden for providers. A
commenter expressed concern that
linking payment to performance on
equity measures would change
hospitals’ focus to factors outside of
each patient’s medical diagnosis,
thereby decreasing the quality of care. A
commenter expressed concern that the
measures in the Hospital Readmissions
Reduction Program already require three
years of data to ensure sufficient sample
sizes, therefore this commenter is
concerned that stratification of these
measures could lead to samples too
small to be reliable.
A commenter stated that without
uniformly collected patient-reported
sociodemographic data there is not a
data source sufficiently reliable for
inclusion in payment adjustments. This
commenter observed that the NQF is
preparing to release guidance on using
ADI and other social risk factor data for
quality measurement which may
provide useful information for the
Hospital Readmissions Reduction
Program to consider. Another
commenter recommended rigorous
statistical testing prior to adopting any
health equity methodologies.
Several commenters responded to our
request for input on the approach of
linking performance in caring for
socially at-risk populations and
payment reductions by calculating the
reductions based on readmission
outcomes for socially at-risk
beneficiaries compared to other
hospitals or compared to performance
for other beneficiaries within the
hospital. Several of these commenters
recommended that any use of the
Across-Hospital Disparity method
comparison should only compare
hospitals within similar communities
because community resources are an
important factor in readmission risk. A
commenter recommended starting with
the Across-Hospital Disparity method
because this is more likely to account
for factors outside of a hospital’s control
that affect readmission rates. Another
commenter recommended starting with
Within-Hospital Disparity method
because these data will be easier for
CMS to calculate and easier for
hospitals to understand.
Several commenters supported
providing both Within- and AcrossHospital Disparity methods, but only in
confidential reports for hospitals. One of
these commenters stated that CMS does
not have the statutory authority to
include these data in Hospital
Readmissions Reduction Program
payment calculations. Other
PO 00000
Frm 00315
Fmt 4701
Sfmt 4700
49093
commenters observed that including
Within- and Across-Hospital Disparity
method performance in a hospital’s
readmission score (as opposed to in the
measures’ risk adjustment
methodologies) is inconsistent with
CMS’s approach to clinical risk factors,
specifically noting that for clinical risk
factors CMS recognizes that these
factors are largely beyond a hospital’s
control and therefore includes them in
the risk adjustment methodology.
Many commenters provided input to
our request for potential measures or
indices of social risk, in addition to dual
eligibility, that should be used to
measure hospitals’ performance in
achieving equity in the Hospital
Readmissions Reduction Program. Many
commenters observed that the Hospital
IQR Program has proposed a Screen
Positive Rate for Social Drivers of
Health (SDOH) measure in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28503 through 87 28506). These
commenters observed that the patientlevel data collected by hospitals for
these measures may be appropriate for
stratification or other analysis in the
Hospital Readmissions Reduction
Program.
Several commenters expressed
concern regarding the use of dual
eligibility for Medicare and Medicaid
coverage as a proxy variable. These
commenters observed that Medicaid
eligibility requirements vary from state
to state and therefore is not a nationally
comparable metric. One of these
commenters supported including
eligibility for the Medicare Savings
Program or the Medicare Part D Low
Income Subsidy in analyses. Another
commenter expressed concern that
disability may be another aspect of dual
eligibility that influences readmissions,
and that using dual eligibility as a proxy
for income may hinder analysis of the
effects of disability.
Many commenters supported the use
of proxy measures (including dual
eligible status, the ADI, the Social
Vulnerability Index, the Neighborhood
Deprivation Index, the
Multidimensional Deprivation Index, or
a custom developed index specifically
related to health equity) as a short term
solution until CMS can report data
based on clearly and consistently
defined patient-level, patient-collected
data (including race, age, disability, sex,
sexual orientation, and gender identity,
limited English proficiency, primary
language, housing instability, and
marital status). Several commenters
observed that there may be challenges to
patient-level data collection, including
technological challenges and patient
discomfort with sharing sensitive
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49094
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
information. A few commenters
recommended including the ADI with
other, patient-level data in analyses to
ensure that use of the ADI does not
further disparities such as by providing
data indicating specific communities
need greater support, but not providing
data regarding the subpopulations
within those communities that require
the most support. A commenter
observed that available indices do not
account for the role of segregation,
gentrification, and hypersegregation in
health outcomes. A commenter
expressed concern that use of multiple
factors or indices could create
contradictory analytical findings.
Without detailed explanation for these
contradictory results, there could be
stakeholder confusion. A commenter
recommended considering how to
incorporate data collected on claims
using z-codes to analyze readmissions
in the Hospital Readmissions Reduction
Program. Another commenter
recommended combining the analysis of
social and clinical data to identify gaps
in care. A commenter observed that the
factors that affect disparities are
systemic, community, institutional,
interpersonal, and intrapersonal and
recommended that CMS consider all
factors.
Several commenters agreed that nonclinical factors may affect readmissions
and recommended conducting analyses
to determine which factors and to what
degree prior to incorporating these
factors into the Hospital Readmissions
Reduction Program. Several commenters
recommended using patient-level social
risk variables (such as race, age,
disability, sex, sexual orientation, and
gender identity, limited English
proficiency, primary language, housing
instability, and marital status) for peer
grouping. A commenter recommended
using stratification for analysis. A
commenter recommended that CMS
evaluate hospitals’ community
investments.
Response: We appreciate all of the
comments and interest in this topic. We
believe that this input is very valuable
in the continuing development of the
CMS health equity efforts. We will
continue to take all concerns,
comments, and suggestions into account
for future development and expansion
of our health equity efforts. For more
information on our ongoing effort we
refer readers to our recently released
CMS National Quality Strategy (https://
www.cms.gov/Medicare/QualityInitiatives-Patient-AssessmentInstruments/Value-Based-Programs/
CMS-Quality-Strategy) and the CMS
Framework for Health Equity (https://
www.cms.gov/About-CMS/Agency-
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Information/OMH/equity-initiatives/
framework-for-health-equity) in which
we describe our five priorities for
advancing health equity.
I. Hospital Value-Based Purchasing
(VBP) Program: Policy Changes
Section 1886(o) of the Act requires the
Secretary to establish a hospital valuebased purchasing program (the Hospital
VBP Program) under which value-based
incentive payments are made in a fiscal
year (FY) to hospitals that meet
performance standards established for a
performance period for such fiscal year.
Both the performance standards and the
performance period for a fiscal year are
to be established by the Secretary.
For more of the statutory background
and descriptions of our current policies
for the Hospital VBP Program, we refer
readers to our codified requirements for
the Hospital VBP Program at 42 CFR
412.160 through 412.168.
1. Flexibilities for the Hospital VBP
Program in Response to the Public
Health Emergency (PHE) Due to COVID–
19
a. Measure Suppression Policy for the
Duration of the COVID–19 PHE
In the FY 2022 IPPS/LTCH PPS final
rule, we finalized a measure
suppression policy and several Measure
Suppression Factors for the duration of
the COVID–19 PHE (86 FR 45266
through 45269). We stated that we had
previously identified the need for
flexibility in our quality programs to
account for the impact of changing
conditions that are beyond participating
hospitals’ control. We identified this
need because we would like to ensure
that participants in our programs are not
affected negatively when their quality
performance suffers not due to the care
provided, but due to external factors,
such as the COVID–19 PHE.
Specifically, we finalized a policy for
the duration of the COVID–19 PHE that
enables us to suppress the use of data
for a number of measures if we
determine that circumstances caused by
the COVID–19 PHE have affected those
measures and the resulting Total
Performance Scores (TPSs) significantly.
We also finalized the adoption of
Measure Suppression Factors which
will guide our determination of whether
to suppress a Hospital VBP Program
measure for one or more program years
where the baseline or performance
period of the measure overlaps with the
COVID–19 PHE. The finalized Measure
Suppression Factors are as follows:
• Measure Suppression Factor 1:
Significant deviation in national
performance on the measure during the
PO 00000
Frm 00316
Fmt 4701
Sfmt 4700
PHE for COVID–19, which could be
significantly better or significantly
worse compared to historical
performance during the immediately
preceding program years.
• Measure Suppression Factor 2:
Clinical proximity of the measure’s
focus to the relevant disease, pathogen,
or health impacts of the PHE for
COVID–19.
• Measure Suppression Factor 3:
Rapid or unprecedented changes in—
++ Clinical guidelines, care delivery
or practice, treatments, drugs, or related
protocols, or equipment or diagnostic
tools or materials; or
++ The generally accepted scientific
understanding of the nature or
biological pathway of the disease or
pathogen, particularly for a novel
disease or pathogen of unknown origin.
• Measure Suppression Factor 4:
Significant national shortages or rapid
or unprecedented changes in—
++ Healthcare personnel;
++ Medical supplies, equipment, or
diagnostic tools or materials; or
++ Patient case volumes or facilitylevel case mix.
We also note that, as part of this
measure suppression policy, we stated
that we would still provide confidential
feedback reports to hospitals on their
measure rates on all measures to ensure
that they are made aware of the changes
in performance rates that we have
observed. We also stated that we would
publicly report suppressed data with
appropriate caveats noting the
limitations of the data due to the
COVID–19 PHE. We continue to
strongly believe that publicly reporting
these data will balance our
responsibility to provide transparency
to consumers and uphold safety while
ensuring that hospitals are not unfairly
scored or penalized through payment
under the Hospital VBP Program. We
also note that, due to operational
complications associated with the
proposed changes to the scoring
methodology, and in order to allow
enough time for the appropriate notice
and comment period process, we may
not be able to provide hospitals with the
feedback reports for FY 2023 until after
August 1, 2022. We intend to provide
hospitals with these feedback reports for
FY 2023 as soon as possible and
estimate that we will be able to provide
reports before the end of 2022.
We did not propose any changes to
the measure suppression policy.
b. Suppression of Specific Measures for
the FY 2023 Program Year
(1) Background and Overview
COVID–19 has had significant
negative health effects—on individuals,
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
communities, nations, and globally.
Consequences for individuals who have
COVID–19 include morbidity,
hospitalization, mortality, and postCOVID–19 related conditions (also
known as long COVID). As of June 2022,
over 86 million COVID–19 cases, 4.8
million new COVID–19 related
hospitalizations, and 1 million COVID–
19 deaths have been reported in the
U.S.230 One analysis projected that
COVID–19 would reduce life
expectancy in 2020 by 1.13 years
overall, with the estimated impact
disproportionately affecting minority
communities. According to this
analysis, the estimated life expectancy
reduction for Black and Latino
populations is 3 to 4 times the estimate
when comparing to the white
population.231 With a death toll
surpassing that of the 1918 influenza
pandemic, COVID–19 is the deadliest
disease in American history.232
Additionally, impacts of the COVID–
19 pandemic have continued to
accelerate in 2021 as compared with
2020. The Delta variant of COVID–19
(B.1.617.2) surfaced in the United States
in early-to-mid 2021. Studies have
shown that the Delta variant is up to 60
percent more transmissible than the
previously dominant Alpha variant in
2020.233 Further, in November 2021, the
number of COVID–19 deaths for 2021
surpassed the total deaths for 2020.
According to CDC data, the total number
of deaths involving COVID–19 reached
385,453 in 2020 and 451,475 in 2021.234
With this increased transmissibility and
morbidity associated with the Delta
variant as well as new variants like
Omicron which have impacted
2021 235 236 and worsening staffing
shortages in Q3 and Q4 2021 associated
230 https://www.cdc.gov/coronavirus/2019-ncov/
cases-updates/.
231 Andrasfay, T., & Goldman, N. (2021).
Reductions in 2020 US life expectancy due to
COVID–19 and the disproportionate impact on the
Black and Latino populations. Proceedings of the
National Academy of Sciences of the United States
of America, 118(5), e2014746118. https://
www.pnas.org/content/118/5/e2014746118.
232 Covid overtakes 1918 Spanish flu as deadliest
disease in U.S. history (statnews.com).
233 Allen H., Vusirikala A., Flannagan J., et al.
Increased Household Transmission of COVID–19
cases associated with SARS–CoV–2 Variant of
Concern B.1.617.2: a national case-control study.
Public Health England. 2021.
234 https://www.cdc.gov/nchs/nvss/vsrr/covid19/
index.htm.
235 https://www.cdc.gov/coronavirus/2019-ncov/
science/forecasting/mathematical-modelingoutbreak.html.
236 https://www.cdc.gov/coronavirus/2019-ncov/
variants/omicron-variant.html?s_
cid=11734:omicron%20variant:
sem.ga:p:RG:GM:gen:PTN:FY22.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
with the ongoing PHE,237 we remain
concerned about using measure data
that is significantly impacted by
COVID–19 for scoring and payment
purposes for the FY 2023 program year.
As noted in section V.H.1.a., in the FY
2022 IPPS/LTCH PPS final rule, we
finalized a measure suppression policy
and several Measure Suppression
Factors for the duration of the COVID–
19 PHE (86 FR 45266 through 45269). In
addition, under that policy, we
suppressed the following measures for
the FY 2022 program year:
• Hospital Consumer Assessment of
Healthcare Providers and Systems
(HCAHPS) (NQF #0166)
• Medicare Spending per
Beneficiary—Hospital (MSPB) (NQF
#2158)
• National Healthcare Safety Network
(NHSN) Catheter-Associated Urinary
Tract Infection (CAUTI) Outcome
Measure (NQF #0138)
• National Healthcare Safety Network
(NHSN) Central Line-Associated
Bloodstream Infection (CLABSI)
Outcome Measure (NQF #0139)
• American College of SurgeonsCenters for Disease Control and
Prevention Harmonized Procedure
Specific Surgical Site Infection (SSI)
Outcome Measure (NQF #0753)
• National Healthcare Safety Network
(NHSN) Facility-wide Inpatient
Hospital-onset Methicillin-resistant
Staphylococcus aureus (MRSA)
Bacteremia Outcomes Measure (NQF
#1716)
• National Healthcare Safety Network
(NHSN) Facility-wide Inpatient
Hospital-onset Clostridium difficile
Infection (CDI) Outcome Measure (NQF
#1717)
Since the publication of the FY 2022
IPPS/LTCH PPS final rule, we have
conducted analyses on all Hospital VBP
Program measures to determine whether
and how COVID–19 has impacted the
validity of the data used to calculate
these measures for the FY 2023 program
year. Our discussion of the findings
from these analyses follows. Based on
those analyses, in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28426
through 28445), we proposed to
suppress the following measures for the
FY 2023 program year:
• Hospital Consumer Assessment of
Healthcare Providers and Systems
(HCAHPS) (NQF #0166)
• National Healthcare Safety Network
(NHSN) Catheter-Associated Urinary
237 Bloomberg, U.S. Hospital Staff Shortages Hit
Most in a Year on Covid Surge, https://
www.bloomberg.com/news/articles/2022-01-05/onein-five-u-s-hospitals-face-staffing-shortages-most-inyear (citing HHS data).
PO 00000
Frm 00317
Fmt 4701
Sfmt 4700
49095
Tract Infection (CAUTI) Outcome
Measure (NQF #0138)
• National Healthcare Safety Network
(NHSN) Central Line-Associated
Bloodstream Infection (CLABSI)
Outcome Measure (NQF #0139)
• American College of SurgeonsCenters for Disease Control and
Prevention Harmonized Procedure
Specific Surgical Site Infection (SSI)
Outcome Measure (NQF #0753)
• National Healthcare Safety Network
(NHSN) Facility-wide Inpatient
Hospital-onset Methicillin-resistant
Staphylococcus aureus (MRSA)
Bacteremia Outcome Measure (NQF
#1716)
• National Healthcare Safety Network
(NHSN) Facility-wide Inpatient
Hospital-onset Clostridium difficile
Infection (CDI) Outcome Measure (NQF
#1717)
We also note that in the FY 2022
IPPS/LTCH PPS final rule, we finalized
our proposal to suppress the Hospital
30-Day, All Cause, Risk Standardized
Mortality Rate Following Pneumonia
(PN) Hospitalization measure (NQF
#0468) (MORT–30–PN) for the FY 2023
program year (86 FR 45274 through
45276).
(2) Suppression of the Hospital
Consumer Assessment of Healthcare
Providers and Systems (HCAHPS)
Survey Measure (NQF #0166) for the FY
2023 Hospital VBP Program Year
As noted in section V.H.1.b. of the
preamble of this final rule, in the FY
2022 IPPS/LTCH PPS final rule, we
finalized the suppression of the
HCAHPS measure for the FY 2022
program year under Measure
Suppression Factor 1, significant
deviation in national performance on
the measures, which could be
significantly better or significantly
worse compared to historical
performance during the immediately
preceding program years. We refer
readers to the FY 2022 IPPS/LTCH PPS
final rule for additional details and a
summary of public comments we
received related to that finalized policy
(86 FR 45270 through 45271).
In the FY 2023 IPPS/LTCH PPS
proposed rule, we proposed to suppress
the HCAHPS measure for the FY 2023
program year under Measure
Suppression Factor 1, significant
deviation in national performance on
the measure during the COVID–19 PHE,
which could be significantly better or
significantly worse as compared to
historical performance during the
immediately preceding program years,
and Measure Suppression Factor 4,
significant national shortages or rapid or
unprecedented changes in healthcare
E:\FR\FM\10AUR2.SGM
10AUR2
49096
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
personnel (87 FR 28427 through 28429).
We would calculate hospitals’ HCAHPS
measure rates, but we would not use
these measure rates to generate
achievement, improvement, or
consistency points for this measure.
Additionally, because the HCAHPS
measure is the only measure included in
the Person and Family Engagement
domain, we would not calculate
hospitals’ FY 2023 domain scores for
the Person and Family Engagement
domain. Participating hospitals would
continue to report the measure data to
CMS so that we can monitor the effect
of the circumstances on quality
measurement and consider appropriate
policies in the future. We would
continue to provide confidential
feedback reports to hospitals as part of
program activities to allow hospitals to
track the changes in performance rates
that we observe. We also intend to
publicly report CY 2021 measure rate
data where feasible and appropriately
caveated. As noted in section V.I.1.a. of
the preamble of this final rule, we
believe that publicly reporting
suppressed measure data is an
important step in providing
transparency and upholding the quality
of care and safety for consumers.
Based on our analysis of HCAHPS
data from Q1 2019 to Q3 2021, we
continue to observe a sustained decline
in hospital-level HCAHPS scores
beginning in Q2 2020. This decline is
associated with the COVID–19 PHE in
2020 and 2021. HCAHPS measure
results are publicly reported as ‘‘topbox’’, ‘‘bottom-box’’, and ‘‘middle-box’’
scores, with ‘‘top-box’’ being the most
positive response to HCAHPS Survey
items.238
In order to determine whether the
COVID–19 PHE impacted the HCAHPS
measure for the FY 2023 program year
and to what extent, we conducted an
analysis that compared the Q1 2021, Q2
2021, and Q3 2021 HCAHPS data to the
Q1 2019, Q2 2019, and Q3 2019
HCAHPS data.239 This analysis was
similar to the analysis we conducted
last year when we compared Q1 2020
and Q2 2020 HCAHPS data to Q1 2019
and Q2 2019 HCAHPS data.240 As
reflected in Table V.I.–01, this analysis
showed that HCAHPS measure top-box
scores in Q1, Q2, and Q3 2021
compared to the same quarter in preCOVID–19 2019 were almost always
lower. The relatively steady decline in
HCAHPS top-box scores that began in
Q2 2020 became sharper in Q3 2021.
Compared to Q3 2019, HCAHPS scores
in Q3 2021 were lower by 1 to 4 topbox points. These changes were
statistically significant for all HCAHPS
measures in Q2 2021 and Q3 2021 at the
p<0.0001 level, meaning that changes
were too large to occur by chance more
than one time in 10,000.241 These
changes stand in sharp contrast to the
pattern of generally small improvements
prior to Q2 2020.
We believe that the analysis of Q1,
Q2, and Q3 2021 HCAHPS scores
indicates a pattern of significant
negative changes in hospital
performance from the immediately
preceding pre-COVID–19 quarters where
HCAHPS scores generally changed by
less than 1 top-box point, sometimes
increasing and sometimes decreasing,
compared to the same quarter one year
earlier.
TABLE V.1.-01: CHANGE IN HCAHPS TOP-BOX SCORES IN MATCHED
QUARTERS FROM Ql 2020 VS. Ql 2019, TO Q3 2021 VS. Q3 2019
We also proposed to suppress the
HCAHPS measure for the FY 2023
program year under Measure
Suppression Factor 4, significant
national shortage or rapid or
unprecedented changes in healthcare
personnel. During the course of the
PHE, an unprecedented number of
healthcare personnel have left the
workforce or ended their employment in
hospitals.242 This healthcare personnel
shortage worsened in 2021, with
hospitals across the United States
reporting 296,466 days of critical
staffing shortages, an increase of 86
percent from the 159,320 days of critical
staffing shortage hospitals reported in
238 Summary Analyses (hcahpsonline.org):
https://www.hcahpsonline.org/en/summaryanalyses/.
239 We note that the COVID–19 PHE was declared
on January 31, 2020: https://www.phe.gov/
emergency/news/healthactions/phe/Pages/2019nCoV.aspx.
240 As described further in the FY 2022 IPPS/
LTCH PPS final rule, in order to detect the possible
impact of the COVID–19 PHE on patients’
experience of hospital care, we previously
conducted an ‘‘apples-to-apples’’ analysis in which
we compared hospitals’ HCAHPS measure top-box
scores for each quarter between Q1 2019 and Q4
2020 to their top-box scores for each of the same
quarters one year earlier (86 FR 45270 through
45271). We refer readers to the FY 2022 IPPS/LTCH
PPS final rule for additional details on that analysis
(86 FR 45270 through 45271).
241 Comparisons for this analysis are based on
hospitals with at least 25 completed surveys in each
of the two matched quarters.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00318
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.135
khammond on DSKJM1Z7X2PROD with RULES2
COVID-19 QUARTERS
Chanee in HCAHPS Top-Box Points
HCAHPS Measnre used in the Hospital
Ql 2020vs.
Q2 2020vs.
Q3 2020vs. Q4 2020vs. Ql 2021 vs.
Q2 2021 vs. Q3 2021 vs.
Ql 2019
Q2 2019
Q3 2019
Q4 2019
Ql 2019
Q2 2019
Q3 2019
VBPProeram
Communication with Nurses
-0.04
-1.15***
-1.40***
-1.09***
-1.41***
-1.30***
-2.04***
-1.67***
Communication with Doctors
-0.91 ***
-1.06***
-0.78***
-0.90***
-1.02***
0.00
Staff Responsiveness
-0.82*
-2.06***
-2.54***
-2.99***
-2.79***
-4.39***
-2.61 ***
Communication About Medicine
-1.23***
-3.27***
-3.05***
-2.12***
-2.68***
-2.67***
-3.84***
Cleanliness
-0.63***
-0.92***
-2.44***
-2.70***
-2.02***
-3.70***
-2.21 ***
Quietness
0.54***
-0.20*
0.46***
-0.87***
-1.34***
0.17
0.41 **
Discharge Information
0.20**
-0.79***
-0.69***
-0.76***
-0.52***
-0.59***
-1.02***
Care Transition
0.25**
-2.00***
-1.96***
-1.63***
-1.42***
-1.26***
-2.06***
Overall Rating
0.77***
-0.19
-1.41***
-0.70***
-0.80***
-1.56***
-2.64***
Number of hospitals in each pair of matched Quarters
1606
1701
3074
3117
3129
3084
3084
*Significant at p<0.05; **Significant at p<0.005; ***Significant at p<0.0001. All bolded values are statistically significant.
Notes: Approximately 90% of hospitals in the Q3 2021 vs. Q3 2019 comparison are IPPS hospitals. Standard HCAHPS scoring, including
survey mode and patient-mix adjustment, has been applied. Each column compares data from the named quarter (Ql 2020 to Q3 2021) to
data from the same hospitals in the same quarter of 2019, thus accounting for seasonal effects and patient-mix adjustment.
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
2020.243 Healthcare workers, especially
those in areas with higher infection
rates, have reported serious
psychological symptoms, including
anxiety, depression, and burnout.244 245
Shortages in hospital healthcare
personnel have been shown to affect
quality of care and patient satisfaction.
Studies have shown that hospitals with
greater numbers of hospitalists treating
general-medicine patients and greater
availability of nursing unit support
services have been associated with
higher levels of patient
satisfaction.246 247 Conversely, nurse
burnout has been linked to lower nurseassessed quality of care 248 and lower
patient satisfaction.249 Nursing
shortages have also been linked with
negative patient perceptions of care.250
Therefore, we believe this significant
national change in healthcare personnel
due to the COVID–19 PHE has
significantly impacted hospitals’ scores
on the HCAHPS measure, which
measures patient experience of hospital
care, including staff responsiveness,
communication with hospital staff, and
cleanliness of the hospital environment.
242 Health Affairs, COVID–19’s Impact on Nursing
Shortages, The Rise of Travel Nurses, and Price
Gouging (Jan. 28, 2022), https://
www.healthaffairs.org/do/10.1377/
forefront.20220125.695159/.
243 https://healthdata.gov/Hospital/COVID-19Reported-Patient-Impact-and-Hospital-Capa/g62hsyeh.
244 Kriti Prasad, Colleen McLoughlin, Martin
Stillman, Sara Poplau, Elizabeth Goelz, Sam Taylor,
Nancy Nankivil, Roger Brown, Mark Linzer, Kyra
Cappelucci, Michael Barbouche, Christine A.
Sinsky. Prevalence and correlates of stress and
burnout among U.S. healthcare workers during the
COVID–19 pandemic: A national cross-sectional
survey study. EClinicalMedicine, Volume 35. 2021.
100879. ISSN 2589–5370. https://doi.org/10.1016/
j.eclinm.2021.100879.
245 Vizheh, M., Qorbani, M., Arzaghi, S.M. et al.
The mental health of healthcare workers in the
COVID–19 pandemic: A systematic review. J
Diabetes Metab Disord 19, 1967–1978 (2020).
https://doi.org/10.1007/s40200-020-00643-9.
246 Chen L, Birkmeyer J, Saint S, Jha A. 2013.
Hospitalist Staffing and Patient Satisfaction in the
National Medicare Population. Journal of Hospital
Medicine, https://doi.org/10.1002/jhm.2001.
247 Bacon, C.T., & Mark, B. (2009). Organizational
effects on patient satisfaction in hospital medicalsurgical units. The Journal of nursing
administration, 39(5), 220–227. https://doi.org/
10.1097/NNA.0b013e3181a23d3f.
248 Aiken L, Clarke S, Sloane D. Hospital staffing,
organization, and quality of care: cross-national
findings. International Journal for Quality in Health
Care. Int J Qual Health Care. 2002.10.1093/intqhc/
14.1.5.
249 Jeannie P. Cimiotti, et al., Nurse staffing,
burnout, and health care–associated infection,
American Journal of Infection Control, Volume 40,
Issue 6, 2012, Pages 486–490, https://doi.org/
10.1016/j.ajic.2012.02.029 (citing Vahey DC, et al.,
Nurse burnout and patient satisfaction. Med Care
2004;42:II–57–66 and Leiter MP, Harvie P, Frizzell
C. The correspondence of patient satisfaction and
nurse burnout. Soc Sci Med 1998;47:1611–7).
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Additionally, reports of hospital staff
shortages have varied widely
geographically. In January 2021, half of
the hospitals in New Mexico and over
40 percent of the hospitals in Vermont,
Rhode Island, West Virginia, and
Arizona reported staffing shortages.251
Conversely, in that same week, less than
10 percent of hospitals in Washington,
DC, Connecticut, Alaska, Illinois, New
York, Maine, Montana, Idaho, Texas,
South Dakota and Utah reported staffing
shortages. Given the wide variance in
reported staffing shortages, and the
impact staffing shortages has had on
HCAHPS scores, we believe our
proposal to suppress the HCAHPS
measure fairly addresses the geographic
disparity in the impact of the COVID–
19 PHE on participating hospitals.
Due to the emergence of COVID–19
variants, such as the Delta variant,
which worsened staffing shortages in Q3
and Q4 2021,252 we anticipate that Q4
2021 data will continue to demonstrate
a deviation in national performance
such that scoring this measure would
not be representative of national or
individual hospital quality of care.
Additionally, we believe that
suppressing the HCAHPS measure is
appropriate because the impact of
COVID–19 on the measure cannot be
addressed through risk adjustment for
two reasons. First, we cannot risk adjust
the measure to exclude patients whose
admissions were related to COVID–19
because this measure does not capture
patient-level diagnosis data. Second,
even if we could exclude patients whose
admissions were related to COVID–19
from the measure, we believe the
HCAHPS calculations would still be
impacted because hospital staffing and
resource issues affect a hospital’s entire
patient population. Therefore, we
believe that suppressing this measure
for the FY 2023 program year will
address concerns about the potential
unintended consequences of penalizing
hospitals that treated COVID–19
diagnosed patients.
For these reasons, we proposed to
suppress the HCAHPS measure for the
FY 2023 Hospital VBP Program year for
purposes of scoring and payment under
Measure Suppression Factors 1 and 4.
We welcomed public comment on
this proposal.
250 Aiken
LH, Sloane DM, Ball J, et al., Patient
satisfaction with hospital care and nurses in
England: an observational study, https://
bmjopen.bmj.com/content/8/1/e019189.
251 U.S. News, States With the Biggest Hospital
Staffing Shortages (Jan. 13, 2022), https://
www.usnews.com/news/health-news/articles/202201-13/states-with-the-biggest-hospital-staffingshortages (citing data from the HHS, CDC, and
PO 00000
Frm 00319
Fmt 4701
Sfmt 4700
49097
Comment: Many commenters
supported our proposal to suppress the
HCAHPS measure, agreeing with our
goal of ensuring that hospitals are not
penalized or rewarded for quality
measurement that was impacted by the
COVID–19 PHE.
Response: We thank commenters for
their support in suppressing the
HCAHPS measure for scoring and
payment purposes.
Comment: Several commenters did
not support suppressing HCAHPS
calculations because they believe that
the need for transparency was more
important. Commenters noted that
patients should be aware of changes in
the natural environment including due
to the COVID–19 PHE.
Response: We appreciate and agree
with commenters’ concern about the
need for transparency. As discussed in
this final rule, although the HCAHPS
measure is suppressed for the purposes
of scoring and payment adjustments, we
will make the data publicly available
where feasible and appropriately
caveated, recognizing the importance of
transparency. We believe that publicly
reporting these data will balance our
responsibility to provide transparency
to consumers, while ensuring hospitals
are not unfairly scored or penalized.
Comment: A few commenters did not
support our proposal to suppress the
HCAHPS measure for the FY 2023
program year because they believe that
suppressing measures does not
incentivize resilience, noting that
hospitals have had two years to adapt to
the pandemic.
Response: Although we agree that
building a more resilient health care
system is necessary to avoid future
threats to patient safety,253 we believe
that suppressing the HCAHPS measure
for the FY 2023 program year offers
hospitals the flexibility to focus on
delivery of care while also accounting
for the changing conditions during a
PHE that are beyond hospitals’ control.
As we note previously, our goal is to
resume the use of measure data for
scoring and payment adjustment
purposes beginning with the FY 2024
program year.
Comment: A commenter did not
support suppressing entire data and
reporting periods, noting widespread
suppression, and instead recommended
253 Fleisher et al. (2022). ‘‘Health Care Safety
during the Pandemic and Beyond—Building a
System That Ensures Resilience’’. New England
Journal of Medicine. Article available here: https://
www.nejm.org/doi/full/10.1056/
NEJMp2118285?utm_
source=STAT+Newsletters&utm_
campaign=8933b7233e-MR_COPY_01&utm_
medium=email&utm_term=0_8cab1d79618933b7233e-151759045.
E:\FR\FM\10AUR2.SGM
10AUR2
49098
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
that in the absence of rigorous statistical
testing we risk-adjust for COVID–19
diagnosis during an encounter. A
commenter did not support suppression
of the HCAHPS measure out of concern
that measure suppression may worsen
health inequities if performance is
masked.
Response: As noted in section
V.I.1.b.2 of the preamble of this final
rule, we cannot risk-adjust the HCAHPS
measure to exclude patients whose
admissions were related to COVID–19
because this measure does not capture
patient-level diagnosis data. However,
we share the commenter’s concern
about how measure suppression may
impact health equity. We believe that
our proposal to continue publicly
reporting suppressed measure data will
provide important information that
could assist in addressing health
inequities caused or exacerbated by the
COVID–19 PHE and maintain
transparency for consumers while
ensuring hospitals are not unfairly
scored or penalized based on CY 2021
HCAHPS data. We note our intention to
resume normal scoring for FY 2024
given the widespread availability of
vaccines in CY 2022 as well advances in
the treatment of COVID–19.
After consideration of the public
comments we received, we are
finalizing our proposal to suppress the
HCAHPS measure for FY 2023 for
scoring and payment purposes as
proposed. We will continue to make the
HCAHPS data publicly available,
recognizing the importance of
transparency.
(3) Suppression of the Five HealthcareAssociated Infection (HAI) Safety
Measures for the FY 2023 Hospital VBP
Program Year
khammond on DSKJM1Z7X2PROD with RULES2
As noted in section V.H.1.b. of the
preamble of this final rule, in the FY
2022 IPPS/LTCH PPS final rule, we
finalized the suppression of the five HAI
Safety measures (CAUTI, CLABSI,
Colon and Hysterectomy SSI, MRSA,
and CDI) for the FY 2022 program year
under Measure Suppression Factor 1,
significant deviation in national
performance on the measures, which
could be significantly better or
significantly worse compared to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
historical performance during the
immediately preceding program years.
We refer readers to the FY 2022 IPPS/
LTCH PPS final rule for additional
details on that policy and a summary of
public comments we received related to
that finalized policy (86 FR 45272
through 45274).
In the FY 2023 IPPS/LTCH PPS
proposed rule, we proposed to suppress
the five HAI Safety measures (CAUTI,
CLABSI, Colon and Hysterectomy SSI,
MRSA, and CDI) for the FY 2023
program year under Measure
Suppression Factor 1, significant
deviation in national performance on
the measures, which could be
significantly better or significantly
worse compared to historical
performance during the immediately
preceding program years; Measure
Suppression Factor 3, rapid or
unprecedented changes in clinical
guidelines, care delivery or practice,
treatments, drugs, or related protocols,
or equipment or diagnostic tools or
materials; and Measure Suppression
Factor 4, significant national shortages
or rapid or unprecedented changes in
healthcare personnel and patient case
volumes (87 FR 28429 through 28431).
We are concerned that the COVID–19
PHE affected measure performance on
the HAI measures in 2021 such that we
will not be able to score hospitals fairly
or reliably for national comparison and
payment adjustment purposes. As part
of this proposal, we would calculate
hospitals’ five HAI measure rates, but
we would not use these measure rates
to generate achievement or
improvement points for these measures.
Additionally, because these five
measures make up the entirety of the
Safety domain, we would not calculate
hospitals’ FY 2023 Safety domain score.
Participating hospitals would continue
to report the measure data to the CDC
and CMS so that we can monitor the
effect of the circumstances on quality
measurement and consider appropriate
policies for the future. We would
continue to provide confidential
feedback reports to hospitals as part of
program activities to ensure that they
are made aware of the changes in
performance rates that we observe.
Though we are concerned that the
PO 00000
Frm 00320
Fmt 4701
Sfmt 4700
COVID–19 PHE has affected measure
performance on the HAI measures in
2021, patient safety remains a priority in
our value-based purchasing programs.
Therefore, we also intend to publicly
report CY 2021 data where feasible and
appropriately caveated. As noted in
section V.I.1.a. of the preamble of this
final rule, we believe that publicly
reporting suppressed measure data is an
important step in providing
transparency and upholding quality of
care and safety for consumers.
We proposed to suppress three of the
five CDC NHSN HAI measures (CLABSI,
CAUTI, and MSRA bacteremia) under
Measure Suppression Factor 1,
significant deviation in national
performance on the measures, which
could be significantly better or
significantly worse compared to
historical performance during the
immediately preceding program years.
We refer readers to the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45272
through 45274) for previous analysis on
the HAI Safety measures that showed
that measure rates for the CLABSI,
CAUTI, and MRSA measures increased
during the CY 2020 pandemic year as
compared to the pre-COVID–19 CY 2019
year immediately preceding the COVID–
19 PHE. To determine whether the
CLABSI, CAUTI, and MRSA measure
rates would continue to show increases
for CY 2021, the CDC analyzed changes
in standardized infection ratios (SIRs)
for Q1 and Q2 of CY 2021 as compared
to the SIRs in Q1 and Q1 of CY 2019.
This analysis found that the CLASBI,
CAUTI, and MSRA measures had
statistically significant measure rate
increases during Q1 and Q2 of CY 2021
as compared to pre-pandemic levels in
Q1 and Q2 of CY 2019. For Q1 2021, the
national SIR increased by approximately
45 percent for the CLABSI measure,
approximately 12 percent for the CAUTI
measure, and approximately 39 percent
for the MRSA measure as compared to
Q1 2019. For Q2 2021, the national SIR
increased by approximately 15 percent
for the CLABSI measure and
approximately 8 percent for the MRSA
measure. The SIRs for the CAUTI
measure showed no statistically
significant difference for Q2 2021 as
compared to Q2 2019.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49099
TABLE V.I.-02: PERCENT CHANGES IN SIRS COMPARED TO RESPECTIVE
2019 QUARTERS
CLABSI
2020 Ql
-11.8
2020 Q2
27.9
2020 Q3
46.4
2020 Q4
47.0
2021 Ql
45.3
2021 Q2
14.6
Preliminary 2021
Q3*
48.6
CAUTI
-21.3
No change
12.7
18.8
11.5
No change
13.3
SSI: Colon surgery
-9.1
No change
-6.9
SSI: Abdominal hysterectomy
-16.0
No change No change
MRSA bacteremia
-7.2
12.2
-17.5
-10.3
CDI
-8.3
No change
No change
-6.6
-13.1
No change
No change
No change
22.5
33.8
39.2
8.3
44.5%
-8.8
-5.5
-15.6
-14.1
-14.5%
For the CDI measure, the national SIR
decreased by approximately 16 percent
for Q1 2021 as compared to Q1 2019
and by approximately 14 percent for Q2
2021 as compared to Q2 2019. The SSI
measure showed no significant increase
or decrease during Q1 2021 and Q2
2021 as compared to Q1 2019 and Q2
2019. Though the changes in the
national SIRs for SSI and CDI were not
as large as compared to the other Safety
domain measures, we proposed to
suppress these measures under Measure
Suppression Factor 4, significant
national shortages or rapid or
unprecedented changes in patient case
volumes and Measure Suppression
Factor 3, rapid or unprecedented
changes in clinical guidelines, care
delivery or practice, treatments, drugs,
or related protocols, or equipment or
diagnostic tools or materials,
respectively. Specifically, for the SSI
measure, we proposed to suppress the
measure for FY 2023 under Measure
Suppression Factor 4, rapid or
unprecedented changes in patient case
volumes. We note that the SSI measure
has historically had a low procedure
volume for many hospitals, which
impacts our ability to produce SIRs for
that measure. For CY 2019, 2,087
hospitals (61 percent) did not have
sufficient procedure-level data needed
to calculate SSI SIRs for abdominal
hysterectomy, and 1,262 hospitals (37
percent) did not have sufficient data to
calculate SIRs for colon surgery.
However, nationally, procedure
volumes declined even further during
the COVID–19 PHE in 2020, compared
to 2019, with decreases of up to 23
percent for colon procedures and 39
percent for abdominal hysterectomy
procedures.254 As of July 2021,
abdominal hysterectomy procedures
254 Weiner-Lastinger, L, et al,. The impact of
coronavirus disease 2019 (COVID–19) on
healthcare-associated infections in 2020: A
summary of data reported to the National
Healthcare Safety Network. Infection Control &
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
were still 6 percent below predicted
levels.255 These changes in patient
volumes for the SSI measure limit our
ability to calculate SSI SIRs for hospitals
that do not have sufficient data in FY
2023, which may impact the accuracy
and reliability of overall national
comparison on performance for this
measure.
For the CDI measure, we proposed to
suppress the measure under Measure
Suppression Factor 3, rapid or
unprecedented changes in clinical
guidelines, care delivery or practice,
related protocols, or equipment or
diagnostic tools or materials. Pandemicrelated improvements to typical CDI
prevention practices such as hand
hygiene, PPE practices, and
environmental cleaning could have
contributed to the declines seen in the
CDI SIR in 2021 compared to 2019.256
In addition, a decline in outpatient
antibiotic prescribing was observed
starting in 2020 as healthcare utilization
decreased during the COVID–19
pandemic.257 This, combined with the
continued use of inpatient antibiotic
stewardship programs in hospitals, may
also have contributed to the decline in
the national CDI SIRs, as reducing
patient antibiotic exposure is a
recommended strategy for CDI
prevention. More information about CDI
prevention strategies can be found at
Hospital Epidemiology (2022), 43, 12–25.
doi:10.1017/ice.2021.362.
255 https://epicresearch.org/articles/electivesurgeries-approach-pre-pandemic-volumes.
256 Weiner-Lastinger LM, et al. (2021). The impact
of coronavirus disease 2019 (COVID–19) on
healthcare-associated infections in 2020: A
summary of data reported to the National
Healthcare Safety Network. Infection Control &
Hospital Epidemiology, https://doi.org/10.1017/
ice.2021.362.
257 The intersection of antibiotic resistance (AR),
antibiotic use (AU), and COVID–19. Department of
Health and Human Services website. https://
www.hhs.gov/sites/default/files/antibioticresistance-antibiotic-use-covid-19-paccarb.pdf.
Published February 10, 2021. Accessed June 28,
2021.
PO 00000
Frm 00321
Fmt 4701
Sfmt 4700
https://www.cdc.gov/cdiff/clinicians/
cdi-prevention-strategies.html.
Additionally, because we cannot
identify all potential elements that
could be impacting the overall HAI
experience at facilities during an
unprecedented PHE as well as potential
geographic disparities in the impact of
the PHE that could cause uneven impact
on facilities based on their location, and
in order to reduce bias toward only
those measures that are performing well
at the national level, we believe all five
CDC NHSN HAI measures should be
suppressed. Therefore, we believe it is
appropriate to suppress all five HAI
measures in the Safety domain to ensure
an accurate and reliable national
comparison of performance on hospital
safety.
We also proposed to suppress the five
CDC NHSN HAI measures for the FY
2023 program year under Measure
Suppression Factor 4, significant
national shortage or rapid or
unprecedented changes in healthcare
personnel. As discussed in section
V.I.1.b.(2). Of the preamble of this final
rule, during the course of the COVID–
19 PHE, an unprecedented number of
healthcare personnel have left the
workforce or ended their employment in
hospitals.258 This healthcare personnel
shortage worsened in 2021, with
hospitals across the United States
reporting 296,466 days of critical
staffing shortages, an increase of 86
percent from the 159,320 days of critical
staffing shortage hospitals reported in
2020.259 Healthcare workers, especially
those in areas with higher infection
rates, have reported serious
258 Health Affairs, COVID–19’s Impact on Nursing
Shortages, The Rise of Travel Nurses, and Price
Gouging (Jan. 28, 2022), https://
www.healthaffairs.org/do/10.1377/
forefront.20220125.695159/.
259 https://healthdata.gov/Hospital/COVID-19Reported-Patient-Impact-and-Hospital-Capa/g62hsyeh.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.136
khammond on DSKJM1Z7X2PROD with RULES2
*This data is preliminary as of the time of the FY 2023 IPPS/L TCH PPS final rule publication. The Q3 2021 HAI measure data submission
deadline was February 15, 2022 and the SIR for Q3 2021 has not yet been finalized.
49100
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
psychological symptoms, including
anxiety, depression, and burnout.260 261
Healthcare personnel staffing
shortages and burnout has been shown
to be significantly associated with
hospital-associated infections, including
urinary tract infections and surgical site
infections.262 263 Along with being
shown to impact quality of care,264
healthcare staffing shortages impact a
hospital’s ability to investigate
infections and take corrective action.265
As discussed in section V.I.1.b.(2). Of
the preamble of this final rule, reports
of hospital staff shortages have varied
widely geographically, ranging from 10
to 50 percent of hospitals in any
particular state reporting staffing
shortages. Given the wide variance in
reported staffing shortages, and the
impact staffing shortages may have on
CDC NHSN HAI scores, we believe our
proposal to suppress the CDC NHSN
HAI measures fairly addresses the
geographic disparity in the impact of the
COVID–19 PHE on participating
hospitals.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45272 through 45274), we
stated our belief that the distortion in
measure performance may be due to
circumstances unique to the effects of
the pandemic such as staffing shortages
and turnover, patients that are more
susceptible to infections due to
increased hospitalization stays, and
longer indwelling catheters and central
lines. We believe that the continued
distortion in measure performance is
impacted by similar circumstances
260 Kriti Prasad, Colleen McLoughlin, Martin
Stillman, Sara Poplau, Elizabeth Goelz, Sam Taylor,
Nancy Nankivil, Roger Brown, Mark Linzer, Kyra
Cappelucci, Michael Barbouche, Christine A.
Sinsky. Prevalence and correlates of stress and
burnout among U.S. healthcare workers during the
COVID–19 pandemic: A national cross-sectional
survey study. EClinicalMedicine, Volume 35. 2021.
100879. ISSN 2589–5370. https://doi.org/10.1016/
j.eclinm.2021.100879.
261 Vizheh, M., Qorbani, M., Arzaghi, S.M. et al.
The mental health of healthcare workers in the
COVID–19 pandemic: A systematic review. J
Diabetes Metab Disord 19, 1967–1978 (2020).
https://doi.org/10.1007/s40200-020-00643-9.
262 Jeannie P. Cimiotti, et al., Nurse staffing,
burnout, and health care-associated infection,
American Journal of Infection Control, Volume 40,
Issue 6, 2012, Pages 486–490, https://doi.org/
10.1016/j.ajic.2012.02.029.
263 Jinjin Shang, et al., Nurse staffing and
Healthcare Associated Infection, Unit-level
Analysis, https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC6478399/.
264 Aiken L., Clarke S., Sloane D. Hospital
staffing, organization, and quality of care: crossnational findings. International Journal for Quality
in Health Care. Int J Qual Health Care.
2002.10.1093/intqhc/14.1.5.
265 Healthcare-Associated Infections Increase
Dramatically During Pandemic, https://
www.reliasmedia.com/articles/148560-healthcareassociated-infections-increase-dramatically-duringpandemic.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
unique to the effects of the COVID–19
PHE as hospitals and researchers have
investigated the impact of COVID–19 on
HAIs and found that COVID–19 is
associated with increases in HAIs, with
changes in the SIR varying
geographically and over
time.266 267 268 269 270 Additionally, we
believe that suppressing the HAI
measures is appropriate because the
impact of COVID–19 on the measure
cannot be addressed through riskadjustment. Under current collection
requirements for the CDC NHSN HAI
measures, the data used for risk
adjustment are collected at the ward or
facility level, meaning that the hospital
submits infection data for a given ward
or the entire facility rather than at the
individual patient level. Accordingly,
we are not able to identify the number
of patients with HAIs who also had
COVID–19 and therefore cannot riskadjust for or otherwise account for
COVID–19 diagnoses. In order to
address the impact of the ongoing
COVID–19 PHE on HAI incidence, we
proposed to suppress the CY 2021 HAI
measure data.
We welcomed public comment on our
proposal to suppress the five HAI Safety
domain measures for the FY 2023
program year for purposes of scoring
and payment.
Comment: Many commenters
supported suppression of the HAI
measures and expressed appreciation
that suppression would ensure that
hospitals are not penalized for
challenges brought on by the pandemic
which are not representative of the care
generally provided.
266 Fakih M.G., et al. (2021). Coronavirus disease
2019 (COVID–19) pandemic, central-line-associated
bloodstream infection (CLABSI), and catheterassociated urinary tract infection (CAUTI): The
urgent need to refocus on hardwiring prevention
efforts. Infection Control & Hospital Epidemiology,
https://doi.org/10.1017/ice.2021.70.
267 Palmore T.N. and Henderson D.K. (2021).
Healthcare-associated infections during the
coronavirus disease 2019 (COVID–19) pandemic.
Infection Control & Hospital Epidemiology, https://
doi.org/10.1017/ice.2021.377.
268 Weiner-Lastinger L.M., et al. (2021). The
impact of coronavirus disease 2019 (COVID–19) on
healthcare-associated infections in 2020: A
summary of data reported to the National
Healthcare Safety Network. Infection Control &
Hospital Epidemiology, https://doi.org/10.1017/
ice.2021.362.
269 Baker, Meghan A. et al. ‘‘The Impact of
COVID–19 on Healthcare-Associated Infections.’’
Clinical infectious diseases: an official publication
of the Infectious Diseases Society of America,
ciab688. 9 Aug. 2021, doi:10.1093/cid/ciab688.
270 Advani, Sonali D. et al. ‘‘The impact of
coronavirus disease 2019 (COVID–19) response on
hospital infection prevention programs and
practices in the southeastern United States.’’
Infection control and hospital epidemiology, 1–4. 2
Nov. 2021, doi:10.1017/ice.2021.460.
PO 00000
Frm 00322
Fmt 4701
Sfmt 4700
Response: We thank the commenters
for their support of the HAI measure
suppression proposals and we agree that
suppressing these measures for scoring
and payment purposes will ensure that
hospitals are not penalized for impacts
outside of their control.
Comment: A few commenters
recommended we continue analyzing
data to determine whether suppressions
may be necessary in future fiscal years.
A commenter also recommended careful
reintroduction of the measures at an
appropriate time.
Response: We thank the commenters
for their recommendations, and we will
continue to monitor the COVID–19
PHE’s ongoing effects. As discussed in
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28433) and section V.I.2 of
this final rule, we believe that 2022 has
a more promising outlook in the fight
against COVID–19 as we enter the third
year of the pandemic. Our goal is to
resume the use of measure data for
scoring and payment adjustment
purposes beginning with the FY 2024
program year, given the widespread
availability of vaccines and
improvement in the treatment of
COVID–19, but we will continue to
analyze data.
Comment: A commenter supported
hospitals continuing to report the
measure data to CDC and CMS to ensure
ongoing quality improvement
monitoring and further recommended
that we use those data to assess whether
variability in reporting (for example due
to relief extended to providers during
implicated COVID–19 reporting periods)
versus variability in actual performance
could be driving variability in HAI rates.
Response: We appreciate the
commenter’s recommendation and agree
that it is essential that hospitals
continue to report data. The FY 2023
program year uses data from CY 2021
for the HAI measures. There were no
widespread data submission exceptions
in CY 2021 like there were for Q1 and
Q2 of 2020 (85 FR 54820).271 Therefore,
we believe our analysis of CY 2021 data
shows actual variability in performance.
With that noted, the COVID–19 PHE has
caused a variety of factors to impact
hospital performance on the HAI
measures, including but not limited to
wide variation in case rates by
geographic area at different points in
time. Therefore, we believe the best
271 Centers for Medicare and Medicaid Services.
(2020). CMS Announces Relief for Clinicians,
Providers, Hospitals and Facilities Participating in
Quality Reporting Programs in Response to COVID–
19. Available at: https://www.cms.gov/newsroom/
press-releases/cms-announces-relief-cliniciansproviders-hospitals-and-facilities-participatingquality-reporting.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
approach for the FY 2023 Hospital VBP
Program is measure suppression for
purposes of scoring and payment.
However, in collaboration with the CDC,
we will continue to collect, monitor,
and analyze the HAI data, as well as
continue publicly reporting the data
with appropriate caveats as necessary.
Comment: Several commenters did
not support suppression of the HAI
measures, stating their belief that
hospitals should be held accountable for
their quality of care. A commenter did
not support suppression of infection
rates because of concerns around
transparency.
Response: As discussed in section
V.I.1.a of this final rule, although we are
finalizing our proposals to suppress the
HAI measures for the purposes of
scoring and payment adjustments for
the FY 2023 program year, we are also
finalizing that we will make the data
publicly available, recognizing the
importance of transparency. We believe
that continuing to make the data
publicly available ensures transparency
for consumers as they decide where to
obtain care. We will also continue to
provide confidential feedback reports to
hospitals through the previously
established processes as part of program
activities to ensure that hospitals are
made aware of the changes in
performance rates that we observe and
to inform their quality improvement
activities.
Comment: A commenter did not
support suppressing entire data and
reporting periods, noting concerns about
the consequences of widespread
suppression and that, in the absence of
rigorous statistical testing, instead
recommended we risk-adjust for
COVID–19 diagnosis during an
encounter.
Response: We appreciate the
recommendation to risk adjust for
COVID–19 diagnosis, but we cannot risk
adjust the HAI measures to exclude
patients whose admissions were related
to COVID–19 because the HAI measures
do not capture patient-level diagnosis
data. Additionally, we believe the HAI
rates would still be impacted even with
COVID–19 risk adjustment because the
PHE has affected hospital staffing and
resource issues which impact a
hospital’s entire patient population,
regardless of a COVID–19 diagnosis.
Comment: A commenter did not
support suppressing HAI measures
because of the belief that it weakens
hospitals’ resilience, given that the
Measure Suppression Factors justify
suppression for a wide variety of
environmental shifts, including changes
in national performance, guidelines, and
case mix. The commenter holds the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
belief that suppressing payment
incentive programs when the
environment shifts does not strengthen
hospital resilience.
Response: We agree that building a
more resilient health care system is
necessary to avoid future threats to
patient safety.272 However, we also
believe that suppressing the HAI
measures for purposes of scoring and
payment for FY 2023 balances the need
to provide hospitals with the flexibility
to focus on delivery of care without
penalizing them for the changing
conditions of the COVID–19 PHE during
the 2021 performance period that were
beyond hospitals’ control and to
maintain access to care for patients. As
we noted previously, our goal is to
resume the use of measure data for
scoring and payment adjustment
purposes beginning with the FY 2024
program year.
Comment: A commenter did not
support the HAI suppression proposal
and expressed concern about the
Measure Suppression Factors lacking
sufficient definition, and thus
transparency, thereby suppressing
critically important data on hospitalacquired infection measures. A
commenter did not support HAI
suppression because it was concerned
about CMS adhering to, interpreting,
and operationalizing the Measure
Suppression Factors given that an everchanging landscape can be tied to most
measures.
Response: We appreciate the
commenter’s concern regarding the
definitions of the Measure Suppression
Factors. We note that the Measure
Suppression Factors we are employing
to suppress the HAI measures for FY
2023 in this final rule were finalized in
the FY 2022 IPPS/LTCH PPS final rule,
and we did not propose any changes to
those Measure Suppression Factors in
the FY 2023 IPPS/LTCH PPS proposed
rule (86 FR 45266 through 45269). We
also note that these Measure
Suppression Factors were developed to
specifically address challenges that
arose due to the COVID–19 PHE, and we
considered what circumstances caused
by the COVID–19 PHE would affect a
quality measure significantly enough to
warrant its suppression in the Hospital
VBP Program. Although the landscape is
ever-changing, the COVID–19 PHE
272 Fleisher et al. (2022). ‘‘Health Care Safety
during the Pandemic and Beyond—Building a
System That Ensures Resilience’’. New England
Journal of Medicine. Available at: https://
www.nejm.org/doi/full/10.1056/
NEJMp2118285?utm_
source=STAT+Newsletters&utm_
campaign=8933b7233e-MR_COPY_01&utm_
medium=email&utm_term=0_8cab1d79618933b7233e-151759045.
PO 00000
Frm 00323
Fmt 4701
Sfmt 4700
49101
presented unique and unprecedented
experiences that challenged hospitals in
new ways beyond their control,
particularly in 2020 when the virus was
initially identified as a global pandemic
and then in 2021 as new COVID–19
variants increased infection rates to
higher levels than 2020 for many parts
of the U.S. Due to these unique
challenges, we believe that it would be
unfair to score or penalize hospitals
based on CY 2021 data for the HAI
measures. We note our intention to
resume normal scoring for FY 2024
given the widespread availability of
vaccines in CY 2022 as well advances in
the treatment of COVID–19.
Comment: A commenter did not
support HAI suppression because of the
belief that being unable to determine the
causes of changes in HAI rates is not a
rationale for suppression. The
commenter stated that, in light of the
numerous factors that can potentially
impact improvement on a given HAI or
other outcome of interest, the
commenter believes that CMS is
focusing too much on the statistical
analysis rather than protecting the lives
and health of Medicare beneficiaries
and the public at large. The commenter
questioned whether these statistical
analysis concerns could be used to
suppress virtually all measures in
virtually all circumstances. A
commenter did not support HAI
suppression because of the belief that
the rationale exceeds CMS authority and
recommended CMS retract its stated
rationale for the suppression of NHSN
CDC HAIs in the FY 2022 IPPS/LTCH
PPS final rule.
Response: We believe that, in the face
of evolving circumstances of the
COVID–19 PHE, the level of detail in the
Measure Suppression Factors, which
were developed and finalized in the FY
2022 IPPS/LTCH PPS final rule to
specifically address challenges that
arose due to the COVID–19 PHE, is
sufficient and applicable in suppressing
the HAI measures. In deciding which
measures to suppress, and as discussed
in the proposed rule and this final rule,
we examined each measure and
determined that the evidence showed
significant deviation in the individual
measure’s performance data associated
with the COVID–19 PHE. We believe
hospitals’ experiences during the
COVID–19 PHE in 2021 with the rise of
new COVID–19 variants have been
uniquely challenging, thus warranting
the use of Measure Suppression Factors.
We note our measure-by-measure
assessment in determining the impacts
of COVID–19 on each measure and
whether we should propose to suppress
a measure for scoring and payment
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49102
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
purposes in a pay-for-performance
program or not. Ultimately, we
determined to propose to suppress the
HCAHPS and HAI measures for FY 2023
scoring and payment purposes as
discussed previously, but we did not
propose to suppress the Medicare
Spending per Beneficiary or Clinical
Outcome measures (mortality and
complications), especially if there were
technical refinements that could be
made to address COVID–19 impacts on
a measure.
Comment: A commenter did not
support HAI measure suppression
because of a concern that suppression
policies may worsen health inequities.
Response: We are committed to
addressing health inequities, and we
believe that our continued requirements
for the collection and reporting by
hospitals of the HAI data to CMS via the
CDC’s National Healthcare Safety
Network and proposal that we are
finalizing to publicly report the FY 2023
program year HAI measure data will
provide important performance
information that could assist in
addressing health inequities caused by
the COVID–19 PHE while maintaining
transparency for consumers and
ensuring hospitals are not unfairly
scored or penalized. We also believe
that suppressing the HAI measures for
purposes of scoring and payment for FY
2023 balances the need to provide
hospitals with the flexibility to focus on
delivery of care without penalizing
them for the changing conditions of the
COVID–19 PHE during the 2021
performance period that were beyond
hospitals’ control and to maintain
access to care for patients. We note that
it is our intent to resume normal scoring
for FY 2024 given the widespread
availability of vaccines in CY 2022 as
well advances in the treatment of
COVID–19.
Comment: A commenter expressed
concern over inconsistency in the
citation of Measure Suppression Factors
across the HAC Reduction Program and
the Hospital VBP Program for the same
measures, noting that it appeared to be
an uneven application of the Measure
Suppression Factor policy. The
commenter recommended we find ways
to adapt the Measure Suppression
Factor policy across the programs in
order to use the critical safety measures
discussed in transparency and valuebased purchasing.
Response: We appreciate the
commenter’s concern regarding
consistency. We believe that the
Measure Suppression Factors which
were applied for the same set of HAI
measures used in the Hospital VBP
Program and the HAC Reduction
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Program are relevant and aligned across
both programs. We continue to believe
that suppressing the HAI measures for
purposes of FY 2023 scoring and
payment under both the Hospital VBP
Program and the HAC Reduction
Program will continue to provide
flexibility for providers to focus on
delivering quality of care to patients
during the COVID–19 PHE.
After consideration of the public
comments we received, we are
finalizing our proposal to suppress the
HAI measures for purposes of scoring
and payment for FY 2023 as proposed.
We will continue to make the HAI data
publicly available, recognizing the
importance of transparency.
c. Scoring and Payment Methodology
for the FY 2023 Program Year Due to the
COVID–19 PHE
As described in section V.I.1.b. of the
preamble of this final rule, we proposed
to suppress six measures in the Hospital
VBP Program for FY 2023 and use a
special rule for FY 2023 scoring, which
we would codify in our regulations at 42
CFR 412.168. Specifically, we proposed
that we would calculate measure rates
for all measures in the FY 2023 program
year. For measures for which we have
finalized suppression, we will not use
the measure rates to generate
achievement and improvement points
within the Hospital VBP Program’s
current scoring methodology. We
further proposed under this special rule
that we would only calculate
achievement and improvement points,
as well as a domain score, for remaining
measures in the Clinical Outcomes
domain and the Efficiency and Cost
Reduction domain that have not been
proposed for suppression and that,
because no other domains receive scores
for the FY 2023 program year, we would
not award TPSs to any hospital for FY
2023.
Because no hospital would receive a
TPS for FY 2023, we will reduce each
hospital’s base-operating DRG payment
amount by two percent, as required
under section 1886(o)(7)(B) of the Act,
and then assign to each hospital a valuebased incentive payment amount that
matches the two percent reduction to
the base operating DRG payment
amount. The net result of these payment
adjustments will be neutral for
hospitals. We have stated that valuebased payment systems should rely on
a mix of standards, processes, outcomes,
and patient experience measures (76 FR
26491). As such, the Hospital VBP
Program scoring methodology was
developed to be used with several
measures across multiple domains and
aims to score hospitals on their overall
PO 00000
Frm 00324
Fmt 4701
Sfmt 4700
achievement relative to national
benchmarks. Unlike other hospital
value-based purchasing programs that
are intentionally designed to focus on
specific aspects of quality, such as the
HAC Reduction Program and the
Hospital Readmissions Reduction
Program, the Hospital VBP Program is
uniquely designed to address a
comprehensive set of quality and
efficient metrics that evaluate multiple
facets of quality. However, as discussed
in the measure suppression proposals in
section V.I.1.b. of the preamble of this
final rule, the data from several
measures has been significantly
impacted by the COVID–19 PHE.
Awarding negative or positive incentive
payment adjustment percentages using
TPSs calculated using the current
scoring methodology would not provide
a representative score of a hospitals’
overall performance in providing
quality of care during a pandemic. We
believe that the current scoring
methodology remains a balanced and
comprehensive approach for tying
payment to hospitals for their
performance on a set of diverse
measures that depict quality of care
provided. However, we understand that
the COVID–19 PHE has led to sudden
and unexpected changes to healthcare
systems. Our measure suppression
policy was designed as a non-permanent
approach to provide flexibility for
changing conditions outside of
participating hospitals’ control and to
avoid penalizing hospitals on measure
scores that we believe are distorted by
the COVID–19 PHE and are thus not
truly reflective of quality of care. As we
enter the third year of the pandemic, we
believe that the updated knowledge of
the virus and access to various
treatment and mitigation efforts in place
have provided hospitals with various
tools to adapt to this virus. Therefore, as
we discuss further in section V.I.2. of
the preamble of this final rule, our goal
is to continue resuming the use of
measure data for scoring and payment
adjustment purposes beginning with the
FY 2024 program year.
In order to ensure that hospitals are
aware of changes in their performance
rates that we have observed, in the FY
2023 IPPS/LTCH PPS proposed rule, we
proposed to provide FY 2023
confidential feedback reports that
contain the measure rates we have
calculated for the FY 2023 program
year, along with achievement and
improvement scores for all the measures
in the Cost and Efficiency Reduction
domain and the Clinical Outcomes
domain that have not been finalized for
suppression and a Cost and Efficiency
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Reduction domain and a Clinical
Outcomes domain score (87 FR 28431
through 28434). However, as previously
discussed, we would not calculate TPSs
for the purpose of adjusting hospital
payments under the FY 2023 Hospital
VBP Program. We note that the
proposed special scoring methodology
for FY 2023 generally aligns with the
special scoring methodology finalized in
for FY 2022 in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45295 through
45296).
In the proposed rule, we also stated
our understanding that, if finalized, the
FY 2023 special scoring and payment
policy proposal for the Hospital VBP
Program would have implications for
the Merit-Based Incentive Payment
System (MIPS) program (87 FR 28432).
Under the facility-based measurement
option within MIPS described at 42 CFR
414.1380I, clinicians eligible for facilitybased measurement may have their
MIPS quality and cost performance
category scores based on the Total
Performance Score of the applicable
hospital from the Hospital VBP Program
as determined under 42 CFR
414.1380(e)(5). As described at 42 CFR
414.1380(e)(1)(ii) and in the CY 2019
PFS final rule, the scoring methodology
applicable for MIPS eligible clinicians
scored with facility-based measurement
is the Total Performance Score
methodology adopted for the Hospital
VBP Program, for the fiscal year for
which payment begins during the
applicable MIPS performance period.
Thus, for the CY 2022 MIPS
performance period/CY 2024 MIPS
payment year, the Total Performance
Score under the Hospital VBP Program
for the FY 2023 program year would be
applied. If a hospital does not have a
Total Performance Score under the
Hospital VBP Program for FY 2023,
facility-based measurement would not
be available for the MIPS eligible
clinicians to whom that hospital’s Total
Performance Score would be applicable.
If our proposed special scoring policy
for the Hospital VBP Program for FY
2023 is finalized, hospitals would not
have a FY 2023 Total Performance
Score, and the clinicians who would
normally be assessed through facilitybased measurement would need to
identify another method of participating
in MIPS for the CY 2022 MIPS
performance period/CY 2024 MIPS
payment year or submit an application
for reweighting a performance category
or categories, if applicable.
We invited public comment on these
proposals.
Comment: Many commenters
supported our proposed scoring and
payment methodology for the FY 2023
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
program year. Commenters noted that
they believe our approach is proactive
and noted that this policy will help
ensure providers are not penalized for
impacts outside of their control.
Commenters also expressed
appreciation that we are accounting for
the on-going effects of the COVID–19
PHE in hospitals. A commenter noted
that they believe we struck the right
balance by ensuring transparency of
quality performance data, while at the
same time, not penalizing hospitals
when their performance scores are
highly related to the COVID–19 PHE. A
few commenters thanked us for
recognizing that COVID–19 has
significantly impacted quality measures
and expressed support for our efforts to
prevent skewed payment incentives and
inequitable payments in the Hospital
VBP Program. Commenters also
expressed appreciation for our
engagement with hospitals to gauge the
impact of COVID–19 on individual
measures and programs, and for using a
data-driven approach to inform
proposals. A few commenters noted that
this proposed policy would provide
important relief and stability for
providers, especially rural providers,
regarding compliance concerns so they
can focus on the unique challenges of
providing care during the COVID–19
PHE.
Response: We thank commenters for
their support, and we agree that the
policy will help ensure that providers
are not penalized for impacts outside of
their control. We also agree that our
proposed suppression, scoring, and
payment policies for the FY 2023
program year were developed using
data-driven approaches and are
intended to balance the importance of
patient safety through data collection,
transparency, and public reporting
while allowing hospitals to focus on
maintaining access and providing
quality health care to patients during
the COVID–19 PHE.
Comment: Several commenters urged
us to continue to carefully review the
impact of the COVID–19 PHE and
revised technical specifications on
measure performance prior to
establishing a policy for Hospital VBP
Program payment adjustments in future
years. A commenter encouraged us to
resume full implementation of hospital
quality programs as soon as reliable data
are available for evaluating hospital
performance because the measures used
in those programs are intended to
promote improvements in critical
patient safety and quality of care. A few
commenters also encouraged us to
engage interested parties in developing
a permanent suppression policy that
PO 00000
Frm 00325
Fmt 4701
Sfmt 4700
49103
could be used for future PHEs and to
include lessons learned from the
COVID–19 PHE. A commenter urged us
to continue the suppression policy
through the end of the PHE and noted
their belief that data through at least Q2
2022 should not be used to inform
penalties under any of the quality
programs. A commenter recommended
we ignore all data from CY 2020 and CY
2021.
Response: We thank commenters for
these suggestions. We note that the
current measure suppression policy, as
finalized in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45266 through
45269), has been adopted for the
duration of the COVID–19 PHE.
Therefore, we may continue to propose
to suppress measures through the end of
the COVID–19 PHE if we determine that
the Measure Suppression Factor criteria
have been met and that quality measure
data continue to be significantly
impacted by the COVID–19 PHE. We
note that we did not want to take a
blanket approach to the suppression of
CY 2020 or CY 2021 data and instead
have analyzed CY 2020 and CY 2021
data on a measure-by-measure basis for
the measures used in the Hospital VBP
Program, and have finalized specific
policies based on the data and technical
specifications for each particular
measure (such as specific measure
suppressions and updated baseline
periods) to appropriately address any
COVID–19 impacted data from those
time periods. For example, for certain
measures we determined that the data
did not warrant proposing to suppress
for FY 2023, such as the Medicare
Spending per Beneficiary measure.
Comment: Many commenters
expressed support for providing
suppressed measure data on hospital
performance in hospital confidential
feedback reports. Commenters noted
that it is helpful to continue receiving
these reports with measure rates, which
allows hospitals to analyze their
performance and continue focusing on
performance improvements.
Response: We thank commenters for
their support and agree that providing
hospitals with information related to
measure rates for suppressed measures
can be a useful tool in evaluating and
improving quality of care provided. We
will continue to provide confidential
reporting of all measures, including
those that are suppressed from scoring
calculations, via the Payment
Percentage Summary Report (PPSR),
though we will not calculate domain or
Total Performance Scores. Providing
confidential measure results to hospitals
also serves as an opportunity to preview
the data before they are publicly
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49104
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
reported on the Compare tool hosted by
HHS.
Comment: Several commenters
supported publicly reporting
suppressed measure data. A few
commenters noted that it is important
for the public to have access to key
hospital safety data. A commenter noted
that timely, accurate, comprehensive,
and clear public reporting of quality
measure data is meaningful for patients.
Commenters encouraged us to include
information on the Care Compare
website explaining the appropriate use
and interpretation of the publicly
reported data so that others, who might
intend to use the data for other
purposes, also can consider whether
their intended use needs to be adjusted
or suppressed for a time period due to
COVID–19 impacts.
Response: We appreciate commenters’
support and agree that it is important for
the public to have access to Hospital
VBP Program data through resources
such as the Compare tool to continue to
make informed health care decisions. As
noted in the preamble of the final rule
and proposed rule, we intend to
publicly report suppressed data with
appropriate caveats that explain that
performance information has been
impacted due to the COVID–19 PHE.
Comment: A few commenters
expressed concern with the proposed
scoring methodology for the FY 2023
program year because of the
implications it would have for the
Medicare Incentive Payment System
(MIPS) Program for eligible clinicians.
Specifically, commenters were
concerned that clinicians eligible for
facility-based measurement will not be
able to base their MIPS quality and cost
performance category scores on the
Total Performance Score of the
applicable hospital from the Hospital
VBP Program if we finalize the special
scoring methodology for FY 2023 as
proposed. A commenter noted that some
clinicians may not have the resources or
technology to report quality measures
through an electronic health record,
registry, or quality clinical data registry
(QCDR) and suggested that we award
TPSs for FY 2023, use TPSs from prior
years, or create a hold harmless
provision to ensure that hospital-based
clinicians are not penalized and do not
receive a downward payment
adjustment under the MIPS Program. A
commenter requested that we align the
scoring and payment policies between
the Hospital VBP Program and the MIPS
Programs such that facility-based
providers would receive net neutral
payment adjustments under the MIPS
program as well. Another commenter
suggested that we offer an automatic
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Extreme and Uncontrollable
Circumstances (EUC) exception to
facility-based providers for FY 2022 to
avoid impacting their cost and quality
scores under MIPS.
Response: We understand
commenters’ concerns around the
implications the special scoring
methodology for FY 2023 under the
Hospital VBP Program would have for
clinicians under MIPS. However,
because no hospitals will have a FY
2023 Total Performance Score, the
clinicians who are normally assessed
through facility-based measurement will
need to identify another method of
participating in MIPS for the CY 2022
MIPS performance period/CY 2024
MIPS payment year or submit an EUC
application 273 to request the
reweighting of one or more performance
categories, if applicable. With regard to
the commenter’s suggestion that we
award TPSs for FY 2023 or use TPSs
from prior years, we do not believe it
would be an appropriate or meaningful
indication of quality to award hospitals
TPSs under the Hospital VBP Program
based only on the unsuppressed
measures in the Efficiency and Cost
Reduction and the Clinical Outcomes
domains for the FY 2023 program year
because we do not believe it would
result in nationally comparable
assessment of quality of care for overall
hospital performance without the
inclusion of the suppressed measures.
Further, we believe that awarding TPSs
under the Hospital VBP Program from
prior years would not be useful,
equitable, or meaningful as it would not
be new information and could
potentially cause confusion for some
hospitals around their actual
performance during the COVID–19 PHE
as it would be re-using data from prior
to the COVID–19 PHE. Additionally,
any changes to the previously
established policies for MIPS, such as
commenters’ suggestions to create a
hold harmless provision to ensure that
hospital-based clinicians are not
penalized and do not receive a
downward payment adjustment under
the MIPS Program or to offer an
automatic EUC exception, would be
determined by and communicated
through the appropriate channels for
MIPS.
Comment: Some commenters did not
support the proposed payment
methodology for the FY 2023 program
year. A commenter expressed concern
that the proposed special payment
policy for FY 2023 that would result in
net neutral payments for hospitals does
273 EUC Application available at: https://
qpp.cms.gov/mips/exception-applications.
PO 00000
Frm 00326
Fmt 4701
Sfmt 4700
not recognize investments in and ongoing costs of quality infrastructure
made by hospitals that maintained
strong performance on measures prior to
the COVID–19 pandemic. This
commenter suggested that we consider
establishing alternate performance
periods, such as CY 2019 or a blend of
prior performance periods, in order to
score hospitals for the FY 2023 program
year. A few commenters requested that
we explore the authority to allow
payment adjustments for hospitals that
would have earned a positive payment
adjustment for the FY 2023 program to
reward hospitals that have
demonstrated positive performance
under the Hospital VBP Program
throughout the COVID–19 PHE.
Response: We recognize that many
hospitals have made important
investments in infrastructure and
processes to improve quality of care
both before the COVID–19 PHE and
during the PHE, and we encourage
hospitals to continue investing in
quality infrastructure that improves
delivery of care. care. Though we
recognize that some hospitals have
maintained strong performance on
measures throughout the COVID–19
PHE, we believe COVID–19 has
interfered with the ability to accurately
compare measure performance of
hospitals side-by-side on a national
level due to the variation in the impacts
of the COVID–19 PHE in 2021 across
time and across geographies, and
whether that performance was positive
or negative. Additionally, to reward
hospitals that have improved quality of
care during the PHE would require
penalizing hospitals with negative
payment adjustments based on measure
scores, which we believe to be
inappropriate given that we believe
these scores are distorted by the
COVID–19 PHE during 2021 and, thus,
not reflective of the quality of care that
the measures in the Hospital VBP
Program were designed to assess. As
noted previously in this section, we
believe that awarding TPSs to hospitals
based on prior performance periods
would not be useful or meaningful as it
would not be new information and
could potentially cause confusion for
some hospitals around their actual
performance during the COVID–19 PHE
as it would be re-using data from prior
to the COVID–19 PHE. However, the
measure data will continue to be
publicly reported, which will provide
transparency regarding performance
during the COVID–19 PHE.
Comment: Several commenters
expressed opposition to suppressing
measure data from public reporting. A
commenter noted that it was firmly
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
against eliminating the reporting of
patient safety measures, including HAI
and mortality rates, because they are
crucial to performance comparisons
across healthcare facilities. A few
commenters expressed that suppressing
measure data from the public would
thwart the public’s ability to evaluate
the strength and resilience of the health
care system and make informed
decisions regarding health care and
public policy. A commenter expressed
their belief that the public has a right to
know hospital infection rates and other
complication rates for hospitals
receiving federal funding, regardless of
the impact of the COVID–19 PHE. A few
commenters noted that the suppressed
measure data are important to keep
public and could be used to inform
future improvements in delivery of care.
Response: We agree with commenters
that hospitals should continue
collecting and reporting suppressed
measure data and that we should
continue publicly reporting suppressed
measure data, and we will continue to
do so under the policy we are finalizing
for the FY 2023 program year. As noted
in section V.I.1.a. of the preamble of this
final rule, we believe that publicly
reporting suppressed measure data is an
important step in providing
transparency.
Comment: Several commenters did
not support our proposal to continue
publicly reporting suppressed measure
data. A commenter noted its belief that
the general public does not understand
the complex methodology behind the
publicly posted data, and the uneven
impacts of the COVID–19 PHE across
geographical area might further skew
how the public interprets the measure
data. This commenter also noted that
enterprising organizations might
continue to use the publicly reported
data without considering the effects of
the COVID–19 PHE on that data and
unfairly penalize hospitals. Several
commenters noted that displaying
suppressed measure data will have
limited value and would likely cause
confusion or misinterpretation of
quality, even with caveats attached. A
few commenters suggested that we
provide hospitals with the option to optin to public reporting as part of their
confidential feedback review. A
commenter noted that publicly
reporting data is an additional stressor
that detracts from hospitals focusing on
other priority areas during the COVID–
19 PHE. A commenter expressed its
belief that interested parties should
have the opportunity to provide public
comments on the public reporting
determination in any future suppression
policies.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Response: We understand
commenters’ concerns with publicly
reporting suppressed measure data.
However, we disagree that publicly
reporting suppressed measure data is
not useful for interested parties. We
continue to place significant value on
being as transparent as possible with the
data we collect, and we will make clear
with caveats that performance data were
affected by the COVID–19 PHE, which
impacts occurred in different ways and
at different times of the year that we
believe impact their national
comparability for payment purposes.
However, we believe the measures
themselves remain reliable and useful
for quality improvement purposes.
Further, we disagree with the suggestion
to allow hospitals the option to opt-in
to public reporting. We believe that
hospitals would choose to opt-in based
on how well they performed, which
could cause confusion, distorting the
data and providing an incomplete
picture of the impact of COVID–19 on
performance. We acknowledge there
may be limitations of these data, but
believe this policy will balance our
responsibility to provide transparency
to consumers while ensuring that
hospitals are not unfairly scored or
penalized through FY 2023 payment.
We encourage hospitals to continue
focusing on providing quality care,
using any insight they might gain from
their measure rates to inform their own
priority areas for improvement.
Comment: A commenter urged us to
consider the implications of exempting
quarters of data from reporting on
measure reliability and accuracy in
future public reporting. This commenter
urged us to perform measure reliability
analyses, using shortened performance
periods to ensure CMS has sufficient
data to calculate performance
accurately, and to make public the
results of those analyses.
Response: We thank the commenter
for their feedback, and we wish to
clarify that we have not proposed to
exempt any quarters of measure data or
to shorten performance periods for any
measures from current or future
reporting under the Hospital VBP
Program in this rule beyond the
exception for Q1 and Q2 of 2020 (85 FR
54820).274 The only measures still
affected by the nationwide COVID–19
related Extraordinary Circumstances
274 Centers for Medicare and Medicaid Services.
(2020). CMS Announces Relief for Clinicians,
Providers, Hospitals and Facilities Participating in
Quality Reporting Programs in Response to COVID–
19. Available at: https://www.cms.gov/newsroom/
press-releases/cms-announces-relief-cliniciansproviders-hospitals-and-facilities-participatingquality-reporting.
PO 00000
Frm 00327
Fmt 4701
Sfmt 4700
49105
Exception (ECE) that CMS issued in
March 2020 are the mortality and
complications measures. These
measures use a 36-month performance
period, and our analyses show these
measures continue to perform with good
reliability even when calculated with 30
months of data. We agree that reporting
reliable and accurate data are important,
and any future policies that might
impact measure reliability and accuracy
would be accompanied by relevant and
comprehensive analyses.
After consideration of the public
comments we received, we are
finalizing the scoring and payment
methodology for the FY 2023 program
year as proposed.
2. FY 2023 Program Year Payment
Details
Section 1886(o)(7)(B) of the Act
instructs the Secretary to reduce the
base operating DRG payment amount for
a hospital for each discharge in a fiscal
year by an applicable percent. Under
section 1886(o)(7)(A) of the Act, the sum
of these reductions in a fiscal year must
equal the total amount available for
value-based incentive payments for all
eligible hospitals for the fiscal year, as
estimated by the Secretary. We finalized
details on how we would implement
these provisions in the FY 2013 IPPS/
LTCH PPS final rule (77 FR 53571
through 53573), and we refer readers to
that rule for further details. We note that
in section V.I.1.b. of the preamble of this
final rule, we are finalizing our proposal
to suppress several measures in the
Hospital VBP Program for the FY 2023
program year, and in section V.I.1.c. of
the preamble of this final rule, we are
finalizing our proposal to apply special
scoring and payment adjustment
policies for the FY 2023 program year.
Because we are finalizing these policies,
each hospital will receive the payment
reduction for the Hospital VBP Program
as required by statute, but every hospital
will receive a value-based incentive
payment amount that matches the
payment reduction amount.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we stated that if our
proposals to suppress measures and
award each hospital a value-based
payment amount that matches the
reduction to the base operating DRG
payment amount are finalized, we
would not update Table 16 as Table 16A
in the final rule. We stated in the FY
2023 IPPS/LTCH PPS proposed rule that
if our proposals to suppress measures
and award each hospital a value-based
payment amount that matches the
reduction to the base operating DRG
payment amount are finalized, we
would also not post Table 16B (which
E:\FR\FM\10AUR2.SGM
10AUR2
49106
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
we typically do to display the actual
value-based incentive payment
adjustment factors, exchange function
slope, and estimated amount available
for the applicable program year, after
hospitals have been given an
opportunity to review and correct their
actual TPSs). Because we are finalizing
our proposed measure suppression and
scoring and payment policies in
response to the COVID–19 PHE, we will
not post a Table 16A or a Table 16B.
We continue to be concerned about
the impact of the COVID–19 PHE, but
we also remain encouraged by the
rollout of COVID–19 vaccinations to
more age groups and new antiviral
treatments for those diagnosed with
COVID–19. We also believe that
hospitals are better prepared to treat
patients with COVID–19 than they were
two years ago. Our measure suppression
policy focuses on a short-term, equitable
approach during this unprecedented
PHE, and was not intended for
indefinite application. Additionally, we
want to emphasize the long-term
importance of value-based care and
incentivizing quality care tied to
payment. The Hospital VBP Program is
an example of our long-standing effort
to link payments to healthcare quality in
the inpatient hospital setting.275
We understand that the COVID–19
PHE is ongoing and unpredictable in
nature, however, we believe that 2022
has a more promising outlook in the
fight against COVID–19. As we enter the
third year of the pandemic, healthcare
providers have gained experience
managing the disease, surges of COVID–
19 infection, and adjusting to supply
chain fluctuations.276 In 2022 and the
upcoming years, we anticipate
continued availability and increased
uptake in the use of vaccinations,277
including the availability and use of
vaccination for young children ages 5–
11, who were not eligible for
vaccination for the majority of 2021 and
for whom only 36 percent had received
275 CMS has also partnered with the CDC in a
joint Call to Action on safety, which is focused on
our core goal to keep patients safe. Fleisher et al.
(2022). New England Journal of Medicine. Article
available here: https://www.nejm.org/doi/full/
10.1056/NEJMp2118285?utm_
source=STAT+Newsletters&utm_
campaign=8933b7233e-MR_COPY_01&utm_
medium=email&utm_term=0_8cab1d7961-8933b
7233e-151759045.
276 McKinsey and Company. (2021). How COVID–
19 is Reshaping Supply Chains. Available at:
https://www.mckinsey.com/business-functions/
operations/our-insights/how-covid-19-is-reshapingsupply-chains.
277 Schneider, E. et al. (2022). The
Commonwealth Fund. Responding to Omicron:
Aggressively Increasing Booster Vaccinations Now
Could Prevent Many Hospitalizations and Deaths.
Available at: https://www.commonwealthfund.org/
blog/2022/responding-omicron.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
at least one dose as of June 29, 2022.
278 279 On June 17, 2022, the Food and
Drug Administration (FDA) also
authorized emergency use of the
COVID–19 vaccine for children as
young as 6 months old, which has
opened up eligibility to 18 million
children. 280 281
Additionally, the FDA has expanded
availability of at-home COVID–19
treatment, having issued the first
emergency use authorizations (EUAs)
for two oral antiviral drugs for the
treatment of COVID–19 in December
2021.282 283 Finally, the Biden-Harris
Administration has mobilized efforts to
distribute home test kits,284 N–95
masks,285 and increase COVID–19
testing in schools,286 providing more
278 KFF, Update on COVID–19 Vaccination of 5–
11 Year Olds in the U.S., https://www.kff.org/
coronavirus-covid-19/issue-brief/update-on-covid19-vaccination-of-5-11-year-olds-in-the-u-s/.
279 American Academy of Pediatrics. (2022).
Summary of data publicly reported by the Centers
for Disease Control and Prevention. Available at:
https://www.aap.org/en/pages/2019-novel-corona
virus-covid-19-infections/children-and-covid-19vaccination-trends/.
280 Food and Drug Administration. (2022).
Coronavirus (COVID–19) Update: FDA Authorizes
Moderna and Pfizer-BioNTech COVID–19 Vaccines
for Children Down to 6 Months of Age. Available
at: https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fdaauthorizes-moderna-and-pfizer-biontech-covid-19vaccines-children.
281 MacMillan, C. (2022) COVID–19 Vaccines for
Kids Under 5: What Parents Need To Know.
Available at: https://www.yalemedicine.org/news/
covid-19-vaccines-kids-under-5.
282 U.S. Food and Drug Administration. (2021).
Coronavirus (COVID–19) Update: FDA Authorizes
First Oral Antiviral for Treatment of COVID–19.
Available at: https://www.fda.gov/news-events/
press-announcements/coronavirus-covid-19update-fda-authorizes-first-oral-antiviral-treatmentcovid-19.
283 U.S. Food and Drug Administration. (2021).
Coronavirus (COVID–19) Update: FDA Authorizes
Additional Oral Antiviral for Treatment of COVID–
19 in Certain Adults. Available at: https://
www.fda.gov/news-events/press-announcements/
coronavirus-covid-19-update-fda-authorizesadditional-oral-antiviral-treatment-covid-19-certain
#:∼:text=Today%2C%20the%20U.S.%20Food%20
and,progression%20to%20severe%20COVID
%2D19%2C.
284 The White House. (2022). Fact Sheet: The
Biden Administration to Begin Distributing AtHome, Rapid COVID-19 Tests to Americans for
Free. Available at: https://www.whitehouse.gov/
briefing-room/statements-releases/2022/01/14/factsheet-the-biden-administration-to-begindistributing-at-home-rapid-covid-19-tests-toamericans-for-free/.
285 Miller, Z. 2021. The Washington Post. Biden
to give away 400 million N95 masks starting next
week Available at: https://
www.washingtonpost.com/politics/biden-to-giveaway-400-million-n95-masks-starting-next-week/
2022/01/19/5095c050-;7915-11ec-9dce7313579de434_story.html.
286 The White House. (2022). FACT SHEET:
Biden-Harris Administration Increases COVID-19
Testing in Schools to Keep Students Safe and
Schools Open. Available at: https://
www.whitehouse.gov/briefing-room/statementsreleases/2022/01/12/fact-sheet-biden-harris-
PO 00000
Frm 00328
Fmt 4701
Sfmt 4700
treatment and testing to the American
people. Therefore, we note that our goal
is to continue resuming the use of
measure data for scoring and payment
adjustment purposes beginning with the
FY 2024 program year. That is, for FY
2024, for each hospital, we would plan
to calculate measure scores for the
measures in the Hospital VBP Program
for which the hospital reports the
minimum measure requirements, as
well as domain scores for the Hospital
VBP Program domains for which the
hospital reports the minimum number
of measures. We would then calculate a
TPS for each eligible hospital and use
the established methodology for
converting the TPSs to value-based
incentive payments for the given fiscal
year.
3. Retention and Removal of Quality
Measures
a. Retention of Previously Adopted
Hospital VBP Program Measures and
Relationship Between the Hospital IQR
and Hospital VBP Program Measure Sets
In the FY 2013 IPPS/LTCH PPS final
rule (77 FR 53592), we finalized a policy
to retain measures from prior program
years for each successive program year,
unless otherwise proposed and
finalized. In the FY 2019 IPPS/LTCH
PPS final rule (83 FR 41440 through
41441), we finalized a revision to our
regulations at 42 CFR 412.164(a) to
clarify that once we have complied with
the statutory prerequisites for adopting
a measure for the Hospital VBP
Program, the statute does not require
that the measure continue to remain in
the Hospital IQR Program. We did not
propose any changes to these policies in
the proposed rule.
b. Measure Removal Factors for the
Hospital VBP Program
In the FY 2019 IPPS/LTCH PPS final
rule (83 FR 41441 through 41446), we
finalized measure removal factors for
the Hospital VBP Program, and we refer
readers to that final rule for details. We
did not propose any changes to these
policies in the proposed rule.
c. Technical Measure Specification
Updates To Include Covariate
Adjustment for COVID–19 Beginning
With the FY 2023 Program Year
In the FY 2022 IPPS/LTCH PPS final
rule, we stated that we were updating
the Hospital 30-Day, All-Cause, Risk
-Standardized Mortality Rate Following
Acute Myocardial Infarction (AMI)
Hospitalization (MORT–30–AMI),
Hospital 30-Day, All-Cause, Riskadministration-increases-covid-19-testing-inschools-to-keep-students-safe-and-schools-open/.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Standardized Mortality Rate Following
Coronary Artery Bypass Graft (CABG)
Surgery (MORT–30–CABG), Hospital
30-Day, All-Cause, Risk-Standardized
Mortality Rate Following Chronic
Obstructive Pulmonary Disease (COPD)
Hospitalization (MORT–30 COPD),
Hospital 30-Day, All-Cause, RiskStandardized Mortality Rate Following
Heart Failure (HF) Hospitalization
(MORT–30–HF), and Hospital-Level
Risk-Standardized Complication Rate
Following Elective Primary Total Hip
Arthroplasty (THA) and/or Total Knee
Arthroplasty (TKA) (COMP–HIP–KNEE)
measures to exclude admissions with
either a principal or secondary
diagnosis of COVID–19 present on
admission from the measure
denominators beginning in FY 2023 (86
FR 45256 through 45258). We stated
that we were making these updates
pursuant to the technical updates policy
we finalized in the FY 2015 IPPS/LTCH
PPS final rule. Under this policy, we use
a subregulatory process to incorporate
technical measure specification updates
into the measure specifications we have
adopted for the Hospital VBP Program
(79 FR 50077 through 50079). As we
stated in the FY 2022 IPPS/LTCH PPS
final rule, we continue to believe that
this subregulatory process is the most
expeditious manner possible to ensure
that quality measures remain fully up to
date while preserving the public’s
ability to comment on updates that so
fundamentally change a measure that it
is no longer the same measure that we
originally adopted (84 FR 42385).
As we continue to evaluate the effects
of COVID–19 on the Hospital VBP
Program measure set, we have observed
that for some patients COVID–19
continues to have lasting effects,
including fatigue, cough, palpitations,
and others potentially related to organ
damage, post viral syndrome, postcritical care syndrome or other
reasons.287 These clinical conditions
could affect a patient’s risk of mortality
or complications following an index
admission and, as a result, impact a
hospital’s performance on one or more
of the four condition-specific mortality
measures or the procedure-specific
complication measure included in the
Hospital VBP Program. In order to
account for case mix among hospitals,
the current risk adjustment approach for
these measures include covariates for
clinical comorbidities present on
admission (POA) and in the 12 months
287 Raveendran, A.V., Jayadevan, R. and
Sashidharan, S., Long COVID: An overview.
Available at https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC8056514/. Accessed on December 15,
2021.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
prior to the index admission that are
relevant and have relationships with the
outcome, for example patient history of
coronary artery bypass (CABG) surgery
or history of mechanical ventilation. In
accordance with the principles used
during measure development and to
adequately account for patient case mix,
we are further modifying the technical
measure specifications for the MORT–
30–AMI, MORT–30–CABG, MORT–30–
COPD, MORT–30–HF, and COMP–HIP–
KNEE measures to include a covariate
adjustment for patient history of
COVID–19 in the 12 months prior to the
admission.
This inclusion of the covariate
adjustment for patient history of
COVID–19 in the 12 months prior to the
admission will be effective beginning
with the FY 2023 program year for the
MORT–30–AMI, MORT–30–CABG,
MORT–30–COPD, MORT–30–HF, and
COMP–HIP–KNEE measures. We will
also include the covariate adjustment
for patient history of COVID–19 in the
12 months prior to the admission for the
Hospital 30-Day, All-Cause, RiskStandardized Mortality Rate Following
Pneumonia Hospitalization (MORT–30–
PN) measure. We note that, even though
we previously finalized that we would
suppress the MORT–30–PN measure for
the FY 2023 program year, we would
still publicly report the measure, and
therefore, the inclusion of the covariate
adjustment for patient history of
COVID–19 in the 12 months prior to the
admission will still be effective
beginning with the FY 2023 program
year. We will delay sending MORT–30–
PN confidential hospital feedback
reports until October 2022 and delay
public reporting until January 2023 to
allow time for hospitals to become
informed about this measure update and
their hospital-level results. We will
resume including hospital performance
on the MORT–30–PN measure in the
payment adjustment calculations, using
the updated MORT–30–PN measure,
beginning in FY 2024. We believe that
making these updates to the MORT–30–
PN measure for FY 2023 in hospitals’
confidential feedback reports will allow
hospitals the opportunity to preview
these updates to the measure
specifications in FY 2023 before they
are used as part of payment adjustments
for the FY 2024 program year.
For more information on the
application of covariate adjustments,
including the technical updates we are
announcing in this final rule, please see
the Measure Updates and Specifications
Reports (available at https://
www.cms.gov/Medicare/QualityInitiatives-Patient-Assessment-
PO 00000
Frm 00329
Fmt 4701
Sfmt 4700
49107
Instruments/HospitalQualityInits/
Measure-Methodology).
Comment: Many commenters strongly
supported the inclusion of patient
history of COVID–19 in the 12 months
prior to the index hospitalization as a
covariate in the measures’ risk
adjustment models for the Hospital VBP
Program mortality and complication
measures starting in FY 2023. One of
these commenters specifically agreed
that a history of COVID–19 could affect
a patient’s risk for readmission and
mortality. Another commenter added
that the covariate for history of COVID–
19 infection could allow tracking and
better understanding of the effect of
‘long COVID’ on hospital performance
and inform other potential pay for
performance program changes, if
indicated by the data. A few
commenters stated that this update to
risk-adjust measures for COVID–19 will
be helpful to their healthcare
organizations in particular, to prevent
being unfairly penalized for caring for a
high volume of COVID–19 patients.
Response: We thank the commenters
for their support for the inclusion of a
covariate adjustment for patient history
of COVID–19 in the 12 months prior to
the admission for the mortality and
complication measures included in the
Hospital VBP Program.
Comment: Among commenters who
supported the technical update to the
measure specifications for MORT–30–
AMI, MORT–30–CABG, MORT–30–
COPD, MORT–30–HF, MORT–30 PN
and COMP–HIP–KNEE measures to
include a covariate adjustment for
patient history of COVID–19 in the 12
months prior to the admission, several
commenters also strongly encouraged us
to continue monitoring and evaluating
the data to assess the full impact of
COVID–19 on hospital operations,
quality measures, and most importantly
on patient health and outcomes, as the
impact of ‘long COVID’ is still
unknown. A few commenters urged us
to continue to assess the measures’ risk
adjustment to determine if a 12-month
period fully accounts for the impacts of
‘long COVID–19’ on these mortality
measures. Another commenter noted
that the most recent measure
methodology reports show that history
of COVID–19 is negatively correlated for
outcomes measured for the five
conditions in the domain for FY 2023.
This commenter recommended that we
only include the covariate adjustment
for measures where it is a positive risk
variable for the performance period in
line with the proposal’s intended
recognition that history of COVID–19
could affect a patient’s risk of mortality
or complications.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49108
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Response: With regard to the rationale
for adding the history of COVID–19
covariate to the model, analyses using
data from 7/1/2020–2/28/2021 showed
that for most of the mortality measures
observed (unadjusted), 30-day mortality
for patients without an index admission
of COVID–19, but with a history of
COVID–19 (defined as U07.1 or Z86.16
in the 12 months prior to the admission,
or Z86.16 at the index admission), were
higher than patients without a history of
COVID–19. Based on the higher odds of
death for these patients we decided to
add the covariate across all of the
condition- and procedure-specific
mortality and complications measures
in Hospital VBP Program. In the months
since the publication of the FY 2023
IPPS/LTCH PPS proposed rule, we have
analyzed newly available data and are
providing updated information in this
final rule. Specifically, results using
more recent data spanning the entire 3year reporting period (7/1/2018–6/30/
2021) showed that for patients without
an index admission of COVID–19, those
with a history of COVID–19 (as defined
in technical update) in the pneumonia
and heart failure cohorts have much
higher frequencies of some model risk
variables compared with patients
without a history of COVID–19,
suggesting they are sicker.
We also found that the adjusted odds
ratios for 30-day mortality for the
history of COVID–19 variable (the odds
ratios in the context of all of the
variables in the model) are less than one
(for all but the pneumonia mortality
measure, where the odds of mortality
are not statistically significant). In other
words, in these patients without
COVID–19, but with a history of
COVID–19, the non-COVID–19 clinical
comorbidities in the risk model are
lessening or reversing the effect size of
the history of COVID–19 variable.
Nonetheless, we have decided to keep
the history of COVID–19 covariate in the
model along with the model’s baseline
risk factors in order to account for
hospital case mix differences more
effectively and for potential future
impacts of long COVID–19 that the
current measure does not currently
account for.
Comment: Several commenters, while
supportive of the technical update to
incorporate a history of COVID–19 into
the measures’ risk adjustment models,
raised concerns about the adequacy of
the current codes and reliability of the
existing data. A few of them specifically
expressed concern that the covariate
adjustment methodology which relies
on the U07.1 or Z86.16 ICD–10–CM
codes may not fully capture all patients
who have had a history of COVID–19
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
and recommended further evaluation of
additional codes or claims data. The
commenters also suggested that the
covariate adjustment methodology be
reviewed by a special NQF Technical
Expert Panel (TEP) to ensure that the
adjustments are comprehensive enough
to capture the long-term impacts of
COVID–19.
Response: We appreciate commenters’
concern about the adequacy of the
current codes, and the implementation
of the covariate in the model. Regarding
coding adequacy, the history of COVID–
19 variable is defined as U07.1 (COVID–
19) or Z86.16 (personal history of
COVID–1) in the 12 months prior to the
admission, or Z86.16 at the index
admission. Therefore, the history of
COVID–19 variable does not rely solely
on the COVID–19-specific ICD–10 code,
U07.1, but also includes the ‘‘personal
history of COVID’’ code (Z86.16) which
hospitals can code even during the
index encounter. With regard to
additional variables related to a prior
COVID–19 infection, we note that on
October 1, 2021, the ICD–10 code U09.9
(Post COVID–19 condition, unspecified)
was approved for implementation,
which is another code that can be
examined for future use in risk
adjustment.
We thank commenters for their
suggestion that a special NQF TEP
review the covariate adjustment
methodology to ensure that the
adjustments are comprehensive enough
to capture the long-term impacts of
COVID–19. These changes to the
measure, if permanent, will be reviewed
by the NQF during the endorsement
maintenance process. We will also
continue to monitor the claims data and
review the covariate adjustment
methodology to evaluate the effect of
history of COVID–19 on these quality
measures and to determine appropriate
policies in the future.
Comment: A few commenters
supported the inclusion of patient
history of COVID–19 in the 12 months
prior to the index hospitalization as a
covariate in the measures’ risk
adjustment models for the Hospital VBP
Program mortality and complication
measures starting in FY 2023 but urged
us to conduct further analysis before
implementing this change to ensure
prior COVID–19 data are captured
across hospitals in a complete,
consistent, and equitable way. The
commenters specifically urged us to
examine and share publicly any data on
variation in how prior COVID–19 is
being captured in claims data. They also
encouraged us to explore to what extent
history of COVID–19 codes are
capturing COVID–19 self-testing that
PO 00000
Frm 00330
Fmt 4701
Sfmt 4700
patients may perform at home, and how
frequently those codes are being used.
The commenters also expressed concern
that relying on the history of COVID–19
code could leave out a substantial
portion of patients that may have had
COVID–19, but did not get tested in an
inpatient or ambulatory setting in the
prior 12 months. Lastly, they
recommended we continue to monitor
the evolving evidence around post
COVID–19 conditions to determine
whether the 12-month timeframe should
be lengthened or shortened. As the field
continues to learn more about the ways
in which ‘long COVID’ manifests itself,
and the duration of its impacts, these
commenters stated that our current
approach may need to change.
Response: We appreciate commenters’
recommendations regarding conducting
further analysis to ensure prior COVID–
19 data are captured across hospitals in
a complete, consistent, and equitable
way. The history of COVID–19 variable
is defined as U07.1 (COVID–19) or
Z86.16 (personal history of COVID–1) in
the 12 months prior to the admission, or
Z86.16 at the index admission.
Therefore, the history of COVID–19
variable does not rely solely on the
COVID–19-specific ICD–10 code, U07.1,
but also includes the ‘‘personal history
of COVID’’ code (Z86.16) which
hospitals can code even during the
index encounter. With regard to
additional variables related to a prior
COVID–19 infection, we note that on
October 1, 2021, the CDC’s National
Center for Health Statistics
implemented the ICD–10 code U09.9
(Post COVID–19 condition,
unspecified), which is another code that
can be examined for future use in risk
adjustment. We will continue
monitoring and evaluating additional
data as they become available to
understand the full impact of COVID–19
on healthcare organizations and patients
to inform future program decisions.
Comment: A few commenters did not
support risk adjusting for COVID–19
diagnosis within the condition- and
procedure-specific mortality and
complication Hospital VBP Program
measures. They recommended adjusting
the benchmarks instead for the
achievement thresholds as well as
reestablishing baselines inclusive of
COVID–19 diagnosis. They also stated
that the COVID–19 virus became a part
of normal infection prevention care, and
therefore its inclusion would inherently
risk adjust the 2022 baseline for 2024
outcome data, effectively and
appropriately leveling the playing field
to the new normal.
Response: We interpret the
commenter’s statement to be referring to
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
adjustment of an index admission of
COVID–19 and not a history of COVID–
19, and therefore, we note that COVID–
19 admissions have been excluded from
the cohorts of these measures as
outlined in the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45256 through 45258).
We thank commenters for their
feedback. We will implement the
inclusion of the covariate adjustment for
patient history of COVID–19 in the 12
months prior to the admission effective
beginning with the FY 2023 program
year for the MORT–30–AMI, MORT–30–
CABG, MORT–30–COPD, MORT–30–
HF, MORT–30–PN and COMP–HIP–
KNEE measures.
d. Technical Updates to the
Specifications for the MORT–30–PN
Measure Beginning With the FY 2024
Program Year
In the FY 2022 IPPS/LTCH PPS final
rule, pursuant to the measure
suppression policy finalized in that rule
and described in section V.I.1. of the
preamble of this final rule, we finalized
suppression of the MORT–30–PN
measure (NQF #0468) for the FY 2023
program year (86 FR 45274 through
45276), and we refer readers to that final
rule for additional information.
Since the publication of the FY 2022
IPPS/LTCH PPS final rule, we have
continued to monitor the MORT–30–PN
measure and have found that several
factors, such as improved coding
practices and decreased proportion of
COVID–19 admissions for the MORT–
30–PN cohort, have mitigated some of
the impact of COVID–19 on this
measure within certain data periods.
Beginning in FY 2024 the MORT–30–PN
measure will no longer be suppressed
under the Hospital VBP Program. We
are resuming the use of the MORT–30–
PN measure for FY 2024 because of the
following differences between the FY
2023 and FY 2024 performance periods:
(1) the improved coding practices; (2)
decreased proportion of COVID–19
admissions in the MORT–30–PN
measure for this performance period;
and (3) sufficient available data to make
technical updates to the measure
specifications in order to further
account for how patients with a COVID–
19 diagnosis might impact the quality of
care assessed by this measure.
Specifically, effective January 2021 the
ICD10 code J12.82, Pneumonia due to
coronavirus disease 2019, was added for
use as a secondary diagnosis, along with
a principal diagnosis of COVID–19
(U07.1), to identify patients with
COVID–19 pneumonia. J12.82 is not
included within the cohort of the
MORT–30–PN measure, therefore
mortality rates with pneumonia due to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
COVID–19 are not captured by this
measure as of January 1, 2021.
Whenever new codes are introduced,
changes in coding practices are difficult
to predict. At the time of the FY 2022
IPPS/LTCH PPS final rule, we did not
have sufficient data to determine the
effects of these coding changes on the
proportion of COVID–19 patients and
mortality rates with pneumonia due to
COVID–19 in the MORT–30–PN
measure. As additional months of data
have become available since early 2021,
we have now seen increased use of
these codes. Secondly, as these coding
changes have occurred and as the
COVID–19 PHE has evolved, more
recent data show the proportion of
COVID–19 admissions in the MORT–
30–PN measure have decreased
compared to 2020 data. Finally, with the
availability of additional data and the
decrease in the proportion COVID–19
admissions in the MORT–30–PN
measure, we are now able to make
technical updates to the measure
specifications in alignment with the
technical updates we are making to four
other mortality measures and one
complication measure. Specifically, we
are updating the technical specifications
for the MORT–30–PN measure to
exclude patients with either principal or
secondary diagnoses of COVID–19 from
the measure denominator beginning
with the FY 2024 program year.
We are also updating the technical
specifications for the MORT–30–PN
measure to add a covariate that adjusts
the measure outcome for a history of
COVID–19 diagnosis in the 12 months
prior to the admission (as discussed in
section V.I.3.c. of the preamble of this
final rule) and ensures alignment with
the other four mortality and one
complication measures. In our analysis,
hospital-level MORT–30–PN measure
scores calculated with the cohort and
denominator exclusions and the
addition of the covariate for a history of
COVID–19 diagnosis in the 12 months
prior (using data from July 1, 2018
through June 30, 2021, excluding
admissions from December 2, 2019
through June 30, 2020 to apply the
nationwide ECE granted due to the
COVID–19 PHE (85 FR 54833 through
54835)), resulted in mean measure
scores that were closer to the prior preCOVID–19 period (July 1, 2017- through
December 2, 2019) compared with the
unchanged measure. We believe that
excluding COVID–19 patients from the
measure denominator, in addition to
adjusting for a prior infection with
COVID–19, will mitigate the impact of
COVID–19 on this measure as much as
is currently feasibly possible given the
PO 00000
Frm 00331
Fmt 4701
Sfmt 4700
49109
unpredictable nature of the pandemic,
and ensure that this measure continues
to reflect mortality rates as intended and
meet the goals of the Hospital VBP
Program beginning in FY 2024. We note
that the MORT–30–PN measure uses
three years of data. The performance
period for the FY 2023 program year
includes admissions from July 1, 2018
through June 30, 2021, exclusive of
January 1, 2020 through June 30, 2020
data excluded due to the ECE waiver.
Therefore, we continue to believe it is
appropriate to suppress the currently
implemented measure for use in
payment calculations as finalized in the
FY 2022 IPPS/LTCH PPS final rule (86
FR 45274 through 45276). The MORT–
30–PN measure is also included in
confidential feedback reports and public
reporting on CMS’ Care Compare
website separate from the Hospital VBP
Program use of the measure. Technical
specifications of the Hospital VBP
Program measures are provided on our
website under the Measure
Methodology Reports section (available
at https://www.cms.gov/Medicare/
Quality-Initiatives-Patient-AssessmentInstruments/HospitalQualityInits/
Measure-Methodology.html). Additional
resources about the measure technical
specifications and methodology for the
Hospital VBP Program are on the
QualityNet website (available at https://
qualitynet.cms.gov/inpatient/hvbp).
Comment: Many commenters
supported the technical updates to the
MORT–30–PN measure to exclude
admissions with either a principal or
secondary diagnosis of COVID–19
present on admission from the measure
denominator and to include a covariate
for history of COVID–19 in the 12
months prior to admission. A
commenter supported resuming the
MORT–30–PN measure in the Hospital
VBP Program in FY 2024. A few
commenters also applauded our
decision to publicly report the measure
in January 2023 (2022 reporting period),
even though the measure will be
suppressed for FY 2023.
Response: We appreciate commenters’
support. We note that the MORT–30–PN
measure is suppressed in the Hospital
VBP Program for FY 2023 and will
resume in FY 2024. The October 2022
confidential reporting and January 2023
public reporting of the updated measure
is to provide transparency and
information to providers and patients on
this important measure.
Comment: Many commenters
supported the technical updates to the
MORT–30–PN measure but urged us not
to resume the use of this measure in the
Hospital VBP Program for FY 2024 and
to further evaluate the impact of
E:\FR\FM\10AUR2.SGM
10AUR2
49110
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
COVID–19 prior to resuming this
measure. A commenter added that with
these technical updates, the measure
when considered in isolation appears to
be structured appropriately to return to
use in the Hospital VBP Program for FY
2024. However, we should consider the
combined effects of the multiple
program adjustments that have been
made that would affect FY 2024
payment year determinations. The
commenter recommended that we
seriously consider the combined effects
of data suppression and shortened
performance period, along with any
lingering impacts of COVID–19 that are
uncovered by our monitoring in the
interval prior to FY 2024 proposed
rulemaking, in determining whether to
again apply scoring and payment
adjustments for FY 2024 payment
determinations.
A few commenters recommended we
conduct further analysis to ensure it has
minimized the overlap between this
measure and COVID–19-related
pneumonia. The commenters also agree
that these specification changes are
directionally appropriate, and data
included in the proposed rule shows a
decline in the percentage of pneumonia
patients with COVID–19 from January–
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
July 2021. However, the commenters
noted there were upticks in these
percentages in August and September
2021 and suggested we run the same
data for the entirety of 2021 to ensure
these increases are anomalies rather
than trends before re-introducing the
MORT–30–PN measure into the
Hospital VBP Program. This would
enable agencies and the hospitals to
determine whether additional education
on the new codes is necessary, or if
further measure specification tweaks
may be required.
Response: We thank commenters for
their feedback to conduct further
evaluation of data and monitor the
impact of COVID–19 before resuming
the MORT–30–PN measure. Admissions
for patients with a COVID–19 diagnosis
will be removed from the measure,
which means that the ‘‘upticks’’ in the
percentage of COVID–19 admissions in
the unmodified measure will not impact
the cohort for the revised MORT–30–PN
measure. As previously stated, our goal
is to resume the use of measure data for
scoring and payment adjustment
purposes beginning with the FY 2024
program year. The October 2022
confidential reporting and January 2023
public reporting of the updated measure
PO 00000
Frm 00332
Fmt 4701
Sfmt 4700
is to provide transparency and
information to providers and patients on
this important measure. Additionally,
while we shortened the performance
period for certain measures under the
nationwide COVID–19 ECE, analyses
show that the measures have a good
reliability even when using a 30-month
period versus a 36-month period.
e. Summary of Previously Adopted
Measures for FY 2023 Through FY 2026
Program Years
We refer readers to the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45281
through 45284) for summaries of
previously adopted measures for the FY
2024 and FY 2025 program years, and
to Table V.I.-03 in this section of the
final rule showing summaries of
previously adopted measures for the FY
2024, FY 2025, and FY 2026 program
years. We proposed to suppress the
HCAHPS and HAI measures for the FY
2023 program year. We did not propose
to add new measures at this time. The
Hospital VBP Program measure set for
the FY 2023, FY 2024, FY 2025, and FY
2026 program years would contain the
following measures:
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49111
TABLE V.I.-03: SUMMARY OF PREVIOUSLY ADOPTED MEASURES FOR
THE FY 2023, FY 2024, FY 2025, FY 2026 PROGRAM YEARS
Measure Short Name
HCAHPS*
CAUTI*
CLABSI*
Colon and Abdominal
Hysterectomy SSI*
MRSA Bacteremia*
CDI*
MORT-30-AMI
MORT-30-HF
MORT-30-PN (updated
cohort)**
MORT-30-COPD
MORT-30-CABG
COMP-HIP-KNEE
MSPB
Domain/Measure Name
Person and Community Engagement Domain
Hospital Consumer Assessment of Healthcare Providers and Systems
(HCAHPS) (including Care Transition measure)
Safety Domain
National Healthcare Safety Network (NHSN) Catheter-Associated Urinary
Tract Infection (CAUTI) Outcome Measure
National Healthcare Safety Network (NHSN) Central Line-Associated
Bloodstream Infection (CLABSI) Outcome Measure
American College of Surgeons - Centers for Disease Control and Prevention
(ACS-CDC) Harmonized Procedure Specific Surgical Site Infection (SSI)
Outcome Measure
National Healthcare Safety Network (NHSN) Facility-wide Inpatient
Hospital-onset Methicillin-resistant Staphylococcus aureus (MRSA)
Bacteremia Outcome Measure
National Healthcare Safety Network (NHSN) Facility-wide Inpatient
Hospital-onset Clostridium difficile Infection (CDI) Outcome Measure
Clinical Outcomes Domain
Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following
Acute Myocardial Infarction (AMI) Hospitalization
Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following
Heart Failure (HF) Hosoitalization
Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following
Pneumonia Hosoitalization
Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following
Chronic Obstructive Pulmonarv Disease (COPD) Hospitalization
Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following
Coronarv Artery Bypass Graft (CABG) Surgery
Hospital-Level Risk-Standardized Complication Rate Following Elective
Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty
(TKA)
Efficiency and Cost Reduction Domain
Medicare Spending Per Beneficiary (MSPB) - Hospital
NQF#
0166
(0228)
0138
0139
0753
1716
1717
0230
0229
0468
1893
2558
1550
2158
(86 FR 45284 through 45290) for
additional previously adopted baseline
and performance periods for the FY
2024 and subsequent program years.
4. Previously Adopted Baseline and
Performance Periods
khammond on DSKJM1Z7X2PROD with RULES2
a. Background
Section 1886(o)(4) of the Act requires
the Secretary to establish a performance
period for the Hospital VBP Program
that begins and ends prior to the
beginning of such fiscal year. We refer
readers to the FY 2017 IPPS/LTCH PPS
final rule (81 FR 56998 through 57003)
for a previously finalized schedule for
all future baseline and performance
periods for previously adopted
measures. We refer readers to the FY
2018 IPPS/LTCH PPS final rule (82 FR
38256 through 38261), the FY 2019
IPPS/LTCH PPS final rule (83 FR 41466
through 41469), the FY 2020 IPPS/LTCH
PPS final rule (84 FR 42393 through
42395), the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58850 through 58854),
and FY 2022 IPPS/LTCH PPS final rule
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
b. Updated Baseline Periods for Certain
Measures Due to the COVID–19 PHE
(1) Background
We previously finalized baseline
periods for the FY 2024, 2025, 2026,
2027, and 2028 program years for all the
measures included in the Hospital VBP
Program, and we refer readers to Tables
V.I.–04 through V.I.–08 for those
previously adopted baseline periods.
However, subsequent to finalizing those
baseline periods and, as described
further in section V.I.1.b. of the
preamble of this final rule, we proposed
to suppress the HCAHPS and five HAI
measures for the purposes of scoring
and payment for FY 2023. Because these
baseline periods are used to determine
PO 00000
Frm 00333
Fmt 4701
Sfmt 4700
achievement thresholds and are used in
awarding improvement scores to
hospitals, we are concerned with using
COVID–19 impacted data for the FY
2025 baseline periods for scoring and
payment purposes.
Accordingly, to ensure that we have
reliable data that are not unfairly
affected by the COVID–19 PHE for
baselining purposes, we proposed
several updates to the baseline periods
in this final rule for the FY 2025
program year.
We note that we proposed to update
the baseline periods for certain
measures under the Hospital VBP
Program that have a 1-year baseline
period. However, for measures that have
baseline periods that span across
multiple years, we believe the
previously established baseline periods
provide enough data from before and
after CY 2021 to still calculate baseline
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.137
* Per section V.1.1.b. of the preamble of this final rule, we are finalizing our proposal to suppress the HCAHPS
and five HAI measures for the FY 2023 program year.
** In the FY 2022 IPPS/L TCH PPS final rule, we finalized our proposal to suppress the MORT-30-PN
measure for the FY 2023 program year (86 FR 45274 through 45276).
49112
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
scores that would be reliable for scoring
and payment purposes. Specifically, for
the measures in the Clinical Outcomes
domain (MORT–30–AMI, MORT–30–
CABG, MORT–30–COPD, MORT–30–
HF, MORT–30–PN, and COMP–HIP–
KNEE), which have 36-month baseline
periods, we did not propose any
changes to the previously established
baseline periods for FY 2025.
(2) Updated FY 2025 Baseline Period for
the Person and Community Engagement
Domain Measure (HCAHPS Survey)
In the FY 2017 IPPS/LTCH PPS final
rule, we finalized that the baseline
period for Person and Community
Engagement Domain Measure (HCAHPS
Survey) for the FY 2025 program year
would be January 1, 2021 through
December 31, 2021 (81 FR 56998).
However, as more fully described in
section V.I.1.b. of the preamble of this
final rule, we have determined that the
top-box scores for hospitals are
significantly lower in Q1 and Q2 of CY
2021 than they were in Q1 and Q2 of CY
2019 (pre-pandemic), demonstrating the
impact of COVID–19 on hospital
performance for this measure.
Therefore, in order to best mitigate the
impact of using measure data affected
by the COVID–19 PHE when
determining achievement thresholds or
awarding improvement points, we
proposed to use a baseline period of
January 1, 2019 through December 31,
2019 for the FY 2025 program year. This
baseline period would be paired with a
performance period of January 1, 2023
through December 31, 2023. We believe
using data from this period will provide
sufficiently reliable data for evaluating
hospital performance that can be used
for FY 2025 scoring. We are selecting
this revised data period because it
would provide the most consistency for
hospitals in terms of the comparable
length to previous program years and
the performance period, and it would
capture a full year of data, including any
seasonal effects.
Comment: Many commenters
supported our proposal to establish new
baseline periods for the HCAHPS
measure, which has been impacted by
the COVID–19 PHE. Commenters
appreciated that our proposal would
allow us to use a full-year of data
unaffected by the COVID–19 PHE to
compare to the CY 2023 performance
period.
Response: We thank the commenters
for their support of our proposal to
update the baseline period for the
HCAHPS measure for the FY 2025
program year.
Comment: A few commenters
recommended that we continue to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
evaluate the impact of the pandemic as
they set future policy and program
adjustments related to baseline periods
and performance standards.
Response: We appreciate the
commenters’ suggestions and note that
we will continue to monitor the impact
of the COVID–19 PHE on Hospital VBP
Program data.
Comment: A commenter did not
support our proposal for the HCAHPS
2019 baseline period, stating its belief
that the proposed baseline is not
reflective of current operations, safety
protocols, and staffing. Instead, the
commenter recommended we explore
using alternative baseline periods, such
as using all or part of CY 2021 or CY
2022 performance data as the baseline
or using CY 2023 as both the baseline
period and the performance period. The
commenter also urged us to consider
ways to modify the scoring policies for
FY 2025 to incentivize improvement
over achievement.
Response: We thank the commenter
for the recommendation and note that
we have chosen the 2019 baseline
period to ensure that we have reliable
data that are not unfairly affected by the
COVID–19 PHE. We believe using data
from this period will provide
sufficiently reliable data for evaluating
hospital performance that can be used
for FY 2025 scoring and because it
would provide the most consistency for
hospitals in terms of the comparable
length to previous program years and
the performance period. Because the
pandemic has impacted hospitals and
health systems in many different ways,
and at different times, using an
alternative baseline may unfairly
penalize certain hospitals for
circumstances out of their control. We
do not believe it would be appropriate
to use CY 2021 data as the baseline
period because, as noted in section
V.I.1.b.(2). of this final rule, we are
finalizing the suppression the FY 2022
HCAHPS performance period, which
uses CY 2021 data, because we believe
that data has been impacted by the
COVID–19 PHE. We note that we would
not be able to use CY 2022 or CY 2023
data as the baseline period for the FY
2025 program year due to the
operational time it takes to calculate
performance standards and we would
not be able to notify hospitals of the
performance standards 60 days prior to
the beginning of the performance
period. Further, we believe that the
current scoring methodology, which
takes the higher of the improvement and
achievement scores for a given measure,
incentivizes hospitals to improve, while
also incentivizing hospitals to continue
PO 00000
Frm 00334
Fmt 4701
Sfmt 4700
striving for standards of care that would
result in high quality of care.
Comment: A commenter did not
support the proposed baseline period
for the HCAHPS measure for the FY
2025 program year because it excludes
COVID–19 data. The commenter
recommended adjusting benchmarks
and baselines to include COVID–19
diagnoses in the measure data, noting its
belief that the COVID–19 virus has
become part of normal infection
prevention care and its inclusion would
inherently risk adjust the 2022 baseline
for 2024 outcome data.
Response: We appreciate the
commenter’s recommendation, but we
believe it is not appropriate to use 2021
as the baseline because conditions
related to the COVID–19 PHE in 2021
were not alike across the country, with
some hospitals experiencing more staff
shortages than others and geographic
disparities in COVID–19 cases, with
certain parts of the country experiencing
more cases and greater strains on their
health systems than others. Such
conditions may have been out of their
control and using a 2021 baseline would
thus unfairly penalize the hospitals
disproportionately impacted. Our
proposed suppression, scoring,
payment, and updated baseline policies
have been developed to provide as
much flexibility as we can for providers
to focus on delivering care during the
COVID–19 PHE. We intend to continue
to consider the evolving COVID–19 PHE
while also evaluating future policies so
as to continue incentivizing hospitals to
prioritize high quality of care for
patients.
After consideration of the public
comments we received, we are
finalizing our proposal to update the
baseline period for the HCAHPS
measure for FY 2025 as proposed.
(3) Updated FY 2025 Baseline Period for
the Safety Domain Measures
In the FY 2017 IPPS/LTCH PPS final
rule (81 FR 57000), we finalized the
performance period for all measures in
the Safety domain to run on the
calendar year two years prior to the
applicable program year and a baseline
period that runs on the calendar year
four years prior to the applicable
program year for the FY 2019 program
year and subsequent program years. For
FY 2025, the baseline period for the
Safety domain measures would be
January 1, 2021 through December 31,
2021. However, as more fully described
in section V.I.1.b. of the preamble of this
final rule, we have determined that the
national measure rates for the HAI
measures have significantly deviated in
national performance in CY 2021,
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
indicating that the COVID–19 PHE has
impacted performance on this measure.
Therefore, in order to mitigate the
impact of using measure data affected
by the COVID–19 PHE when
determining achievement thresholds or
awarding improvement points, we
proposed to use a baseline period of
January 1, 2019 through December 31,
2019 for the FY 2025 program year. This
baseline period would be paired with a
performance period of January 1, 2023
through December 31, 2023. We believe
using data from this period will provide
sufficiently reliable data for evaluating
hospital performance that can be used
for FY 2025 scoring. We are selecting
this revised data period because it
would provide the most consistency for
hospitals in terms of the comparable
length to previous program years and
the performance period, and it would
capture a full year of data, including any
seasonal effects.
Comment: Many commenters
supported our proposal to use updated
baseline periods for the Safety Domain
measures due to the COVID–19
pandemic, noting that it would allow us
to use a full-year of data unaffected by
the COVID–19 PHE to compare to the
CY 2023 performance period. A few
commenters recommended that we
consider the impact of COVID–19 in
future policies.
Response: We thank the commenters
for their support of the updated baseline
periods for the Safety Domain measures.
We will continue to monitor the impact
of the PHE on program data and will
take commenters’ concerns and
recommendations under consideration
for future rulemaking.
Comment: A commenter did not
support our proposal to use CY 2019 as
the updated baseline period for each of
the Safety Domain measures because the
commenter believes the updated
baseline periods are not reflective of
current operations and recommended
we explore alternative baseline periods.
A commenter did not support our
proposal because the baseline periods
exclude COVID–19 data and the
commenter believes that the pandemic
has become a part of normal infection
prevention care and should thus be
included in the 2022 baseline period for
2024 outcome data.
Response: We appreciate the
commenter’s recommendation, but we
believe it is not appropriate to use a
more recent baseline period inclusive of
COVID–19 data because conditions
related to the COVID–19 PHE are not
alike across the country, with some
49113
hospitals experiencing more staff
shortages than others and geographic
disparities in COVID–19 cases. Such
conditions may have been out of their
control and using a more recent baseline
inclusive of COVID–19 data would thus
unfairly penalize the hospitals
disproportionately impacted. Our
proposed suppression, scoring,
payment, and updated baseline policies
have been developed to provide as
much flexibility as we can for providers
to focus on delivering care during the
COVID–19 PHE. We intend to continue
to consider the evolving COVID–19 PHE
while also evaluating future policies so
as to continue incentivizing and
prioritizing high quality of care for
patients.
After consideration of the public
comments we received, we are
finalizing our proposal to use updated
baseline periods for the 5 HAI measures
for FY 2025 as proposed.
c. Summary of Previously Adopted and
Newly Baseline and Performance
Periods for the FY 2024 Through FY
2028 Program Years Tables V.I.–04
Through 08 Summarize the Baseline
and Performance Periods That We Have
Previously Adopted and Those That We
Are Finalizing
TABLE V.I.-04: PREVIOUSLY ADOPTED BASELINE AND PERFORMANCE
PERIODS FOR THE FY 2024 PROGRAM YEAR
Measures
HCAHPS
Mortality measures (MORT-30-AMI,
MORT-30-HF, MORT-30-COPD,
MORT-30-CABG, MORT-30-PN
(undated cohort))
COMP-HIP-KNEE
Baseline Period
Performance Period
Person and Community Engagement Domain
Januarv 1, 2019-December 31 2019*
Januarv 1, 2022 - December 31 2022
Clinical Outcomes Domain
July 1, 2014-June 30, 2017
July 1, 2019-June 30, 2022**
April 1, 2019 - March 31, 2022**
Safety Domain
January 1, 2019 - December 31 2019*
January 1, 2022 - December 31 2022
Efficiency and Cost Reduction Domain
Januarv 1, 2022 - December 31 2022
MSPB
Januarv 1, 2019-December 31 2019*
*In the FY 2022 IPPS/LTCH PPS final rule, we finalized that these baseline periods would be January 1, 2019 through
December 31, 2019 (86 FR 45284 through 45285).
**In accordance with the ECE granted in response to the COVID-19 PHE and the policies finalized in the September 2, 2020
interim final rule with comment titled "Medicare and Medicaid Programs, Clinical Laboratory Improvement Amendments
(CLIA), and Patient Protection and Affordable Care Act; Additional Policy and Regulatory Revisions in Response to the
COVID-19 Public Health Emergency," (85 FR 54820), we will not use QI and Q2 2020 data that was voluntarily submitted for
scoring purposes under the Hospital VBP Program.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00335
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.138
khammond on DSKJM1Z7X2PROD with RULES2
NHSN measures (CAUTI, CLABSI,
Colon and Abdominal Hysterectomy SSI,
CDI, MRSA Bacteremia)
April 1, 2014 -March 31, 2017
49114
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE V.I.-05: PREVIOUSLY ADOPTED AND BASELINE AND PERFORMANCE
PERIODS FOR THE FY 2025 PROGRAM YEAR
Measures
HCAHPS
Mortality measures (MORT-30-AMI,
MORT-30-HF, MORT-30-COPD,
MORT-30-CABG, MORT-30-PN
(updated cohort))
COMP-HIP-KNEE
Baseline Period
Performance Period
Person and Communitv Ene:ae:ement Domain
Januarv 1, 2019-December 31 2019*
J anuarv 1, 2023 - December 31 2023
Clinical Outcomes Domain
July 1, 2015 - June 30, 2018
July 1, 2020 - June 30, 2023
April 1, 2015 - March 31, 2018
Safetv Domain
January 1, 2019 - December 31 2019*
NHSN measures (CAUTI, CLABSI,
Colon and Abdominal Hysterectomy SSI,
CDI, MRSA Bacteremia)
April 1, 2020-March 31, 2023**
January 1, 2023 - December 31 2023
Efficiency and Cost Reduction Domain
J anuarv 1, 2023 - December 31 2023
MSPB
Januarv 1, 2021 -December 31 2021
*As described more fully in section V.I.4.b. of the preamble of this final rule, we are finalizing our proposals to update the
baseline periods for the measures included in the Person and Community Engagement and Safety domains for FY 2025.
**In accordance with the ECE granted in response to the COVID-19 PHE and the policies finalized in the September 2, 2020
interim final rule with comment titled "Medicare and Medicaid Programs, Clinical Laboratory Improvement Amendments
(CLIA), and Patient Protection and Affordable Care Act; Additional Policy and Regulatory Revisions in Response to the
COVID-19 Public Health Emergency," (85 FR 54820), we will not use Ql and Q2 2020 data that was voluntarily submitted for
scoring purposes under the Hospital VBP Program.
TABLE V.1.-06: PREVIOUSLY ADOPTED BASELINE AND PERFORMANCE
PERIODS FOR THE FY 2026 PROGRAM YEAR
Measures
HCAHPS
Mortality measures (MORT-30-AMI,
MORT-30-HF, MORT-30-COPD,
MORT-30-CABG, MORT-30-PN
(undated cohort))
COMP-HIP-KNEE
Baseline Period
Performance Period
Person and Community Ene:ae:ement Domain
J anuarv 1, 2024 - December 31 2024
Januarv 1, 2022-December 31 2022
Clinical Outcomes Domain
July 1, 2016 - June 30, 2019
July 1, 2021 - June 30, 2024
NHSN measures (CAUTI, CLABSI,
Colon and Abdominal Hysterectomy SSI,
CDI, MRSA Bacteremia)
Safetv Domain
January 1, 2022 - December 31 2022
January 1, 2024 - December 31 2024
Efficiency and Cost Reduction Domain
Januarv 1, 2022 - December 31 2022
J anuarv 1, 2024 - December 31 2024
ER10AU22.140
April 1, 2021 - March 31, 2024
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00336
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.139
khammond on DSKJM1Z7X2PROD with RULES2
MSPB
April 1, 2016 -March 31, 2019
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49115
TABLE V.I.-07: PREVIOUSLY ADOPTED BASELINE AND PERFORMANCE
PERIODS FOR THE FY 2027 PROGRAM YEAR
Measures
HCAHPS
Mortality measures (MORT-30-AMI,
MORT-30-HF, MORT-30-COPD,
MORT-30-CABG, MORT-30-PN
(updated cohort))
COMP-HIP-KNEE
Baseline Period
Performance Period
Person and Communitv En2a2ement Domain
J anuarv 1, 2025 - December 31 2025
Januarv 1, 2023 -December 31 2023
Clinical Outcomes Domain
July 1, 2017 -June 30, 2020**
July 1, 2022 - June 30, 2025
NHSN measures (CAUTI, CLABSI,
Colon and Abdominal Hysterectomy SSI,
CDI, MRSA Bacteremia)
April 1, 2017-March 31, 2020**
April 1, 2022 - March 31, 2025
Safety Domain
January 1, 2023 - December 31 2023
January 1, 2025 - December 31 2025
Efficiencv and Cost Reduction Domain
MSPB
Januarv 1, 2023 - December 31 2023
J anuarv 1, 2025 - December 31 2025
**These baseline periods are impacted by the ECE granted by CMS on March 22, 2020. For more detailed information, we refer
readers to the FY 2022 IPPS/L TCH PPS final rule (86 FR 45297 through 45299).
TABLE V.1.-08: PREVIOUSLY ADOPTED BASELINE AND PERFORMANCE
PERIODS FOR THE FY 2028 PROGRAM YEAR
Measures
HCAHPS
Mortality measures (MORT-30-AMI,
MORT-30-HF, MORT-30-COPD,
MORT-30-CABG, MORT-30-PN
(updated cohort))
COMP-HIP-KNEE
Baseline Period
Performance Period
Person and Community En2a2ement Domain
Januarv 1, 2024-December 31 2024
J anuarv 1, 2026 - December 31 2026
Clinical Outcomes Domain
July 1, 2023 - June 30, 2026
July 1, 2018-June 30, 2021 **
NHSN measures (CAUTI, CLABSI,
Colon and Abdominal Hysterectomy SSI,
CDI, MRSA Bacteremia)
MSPB
April 1, 2018 -March 31, 2021 **
April 1, 2023 - March 31, 2026
Safetv Domain
January 1, 2024 - December 31 2024
January 1, 2026 - December 31 2026
Efficiencv and Cost Reduction Domain
Januarv 1, 2024 - December 31 2024
J anuarv 1, 2026 - December 31 2026
**These baseline periods are impacted by the ECE granted by CMS on March 22, 2020. For more detailed
information, we refer readers to the FY 2022 IPPS/L TCH PPS final rule (86 FR 45297 through 45299).
We refer readers to sections
1886(o)(3)(A) through 1886(o)(3)(D) of
the Act for the statutory provisions
governing performance standards under
the Hospital VBP Program. We refer
readers to the Hospital Inpatient VBP
Program final rule (76 FR 26511 through
26513) for further discussion of
achievement and improvement
standards under the Hospital VBP
Program. We refer readers to the FY
2013 IPPS/LTCH PPS final rule, FY
2014 IPPS/LTCH PPS final rule, and FY
2015 IPPS/LTCH PPS final rule (77 FR
53599 through 53605; 78 FR 50694
through 50699; and 79 FR 50077
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00337
Fmt 4701
Sfmt 4700
discussion on performance standards for
which the measures are calculated with
lower values representing better
performance (85 FR 58855).
b. Previously Established and Estimated
Performance Standards for the FY 2025
Program Year
In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42398 through 42399), we
established performance standards for
the FY 2025 program year for the
Clinical Outcomes domain measures
(MORT–30–AMI, MORT–30–HF,
MORT–30–PN (updated cohort),
MORT–30–COPD, MORT–30–CABG,
and COMP–HIP–KNEE) and for the
Efficiency and Cost Reduction domain
measure (MSPB). We note that the
performance standards for the MSPB
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.142
khammond on DSKJM1Z7X2PROD with RULES2
a. Background
through 50081, respectively) for a more
detailed discussion of the general
scoring methodology used in the
Hospital VBP Program. We refer readers
to the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45290 through 45292) for
previously established performance
standards for the FY 2024 program year.
We note that the measure suppression
proposals for the FY 2023 program year,
discussed more fully in section V.I.1.b.
of this final rule, will not affect the
performance standards for the FY 2023
program year. However, as discussed in
section V.I.1.c. of this final rule, we
proposed to not generate achievement or
improvement points for any suppressed
measures for FY 2023.
We refer readers to the FY 2021 IPPS/
LTCH PPS final rule for further
ER10AU22.141
5. Performance Standards for the
Hospital VBP Program
49116
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
measure are based on performance
period data. Therefore, we are unable to
provide numerical equivalents for the
standards at this time. As discussed in
section V.I.4.b. of this final rule, we
proposed to update the FY 2025
program year baseline periods for the
measures included in the Safety domain
and Person and Community Engagement
domain, and we have finalized these
baseline periods as proposed. In the
proposed rule, we stated that if these
proposals are finalized, we would use
data from January 1, 2019 through
December 31, 2019 to calculate
performance standards for the FY 2025
program year for these measures.
In accordance with our methodology
for calculating performance standards
discussed more fully in the Hospital
Inpatient VBP Program final rule (76 FR
26511 through 26513) and codified at 42
CFR 412.160, we are estimating
additional performance standards for
the FY 2024 program year. We note that
the numerical values for the
performance standards for the Safety
domain and Person and Community
Engagement domain for the FY 2025
program year in Tables V.I.–09 and V.I.–
10 were calculated using data from
January 1, 2019 through December 31,
2019. Therefore, in the FY 2023 IPPS/
LTCH PPS proposed rule, we stated that
if our proposed updates to the baseline
periods for these measures are finalized,
we will not update the numerical values
in the FY 2023 IPPS/LTCH PPS final
rule. As stated in section V.I.4.c. of this
final rule, we are finalizing the
proposed updates to the baseline period
for these measures as proposed.
The previously established and
estimated performance standards for the
measures in the FY 2025 program year
have been updated and are set out in
Tables V.I.–09 and V.I.–10.
TABLE V.1.-09: PREVIOUSLY ESTABLISHED AND NEWLY ESTIMATED
PERFORMANCE STANDARDS FOR THE FY 2025 PROGRAM YEAR
Measure Short Name
Achievement Threshold
Safety Domain•
CAUTI*
CLABSI*
CDI*
MRSA Bacteremia*
Colon and Abdominal Hysterectomy SSI*
Benchmark
0.735
0.918
0.427
0.969
0.716
0.824
0
0.013
0
0.026
0
0
Clinical Outcomes Domain
MORT-30-AMI#
MORT-30-HF#
MORT-30-PN (updated cohort)#
MORT-30-COPD#
MORT-30-CABG#
COMP-HIP-KNEE*#
0.872624
0.889994
0.910344
0.883990
0.841475
0.874425
0.915127
0.932236
0.970100
0.979775
0.025332
0.017946
Efficiency and Cost Reduction Domain
MSPB*#
Median Medicare Spending per Beneficiary ratio Mean of the lowest decile Medicare
Spending per Beneficiary ratios across all
across all hospitals during the performance
period.
nospitals during the performance period.
• As discussed in section V.I.4.b. of this fmal rule, we proposed to update the FY 2025 baseline periods for measures included in the Person and
Community Engagement and Safety domains to use CY 2019 data. Therefore, the performance standards displayed in this table for the Safety
domain measures were calculated using CY 2019 data.
* Lower values represent better performance.
#Previously established performance standards.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Points are then calculated, which range
from 0 to 20 points. The Consistency
Points take into consideration the scores
of all eight Person and Community
Engagement dimensions. The final
element of the scoring formula is the
summation of the HCAHPS Base Score
and the HCAHPS Consistency Points,
which results in the Person and
Community Engagement domain score
that ranges from 0 to 100 points. As
discussed in section V.I.4.b.(2). of this
PO 00000
Frm 00338
Fmt 4701
Sfmt 4700
final rule, we proposed to update the FY
2025 program year baseline period for
the measure included in the Person and
Community Engagement domain. We
are finalizing that proposal and,
according to our established
methodology for calculating
performance standards, we will use data
from January 1, 2019 through December
31, 2019 to calculate performance
standards for the FY 2025 program year
for this measure.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.143
khammond on DSKJM1Z7X2PROD with RULES2
The HCAHPS Base Score is calculated
using the eight dimensions of the
HCAHPS measure. For each of the eight
dimensions, Achievement Points (0–10
points) and Improvement Points (0–9
points) are calculated, the larger of
which is then summed across the eight
dimensions to create the HCAHPS Base
Score (0–80 points). Each of the eight
dimensions is of equal weight; therefore,
the HCAHPS Base Score ranges from 0
to 80 points. HCAHPS Consistency
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49117
TABLE V.I.-10: ESTIMATED PERFORMANCE STANDARDS FOR THE FY
2025 PROGRAMYEAR: PERSON AND COMMUNITY ENGAGEMENT DOMAIN±
Floor
Achievement Threshold
Benchmark
(minimum)
(501h oercentile)
(mean of too decile)
HCAHPS Survev Dimension
Communication with Nurses
53.50
79.42
87.71
Communication with Doctors
62.41
79.83
87.97
Responsiveness of Hospital Staff
40.40
65.52
81.22
Communication about Medicines
39.82
63.11
74.05
Hospital Cleanliness & Quietness
45.94
79.64
65.63
Discharge Information
66.92
87.23
92.21
Care Transition
25.64
51.84
63.57
Overall Rating of Hospital
36.31
71.66
85.39
± As discussed in section V.I.4.b.(2). of this final rule, we are finalizing our proposal to update the FY 2025 baseline periods for
measures included in the Person and Community Engagement and Safety domains to use CY 2019 data. Therefore, the
performance standards displayed in this table for the Person and Community Engagement domain measures were calculated
using CY 2019 data.
c. Previously Established Performance
Standards for Certain Measures for the
FY 2026 Program Year
We have adopted certain measures for
the Safety domain, Clinical Outcomes
domain, and Efficiency and Cost
Reduction domain for future program
years in order to ensure that we can
adopt baseline and performance periods
of sufficient length for performance
scoring purposes. In the FY 2021 IPPS/
LTCH PPS final rule (85 FR 58858
through 58859), we established
performance standards for the FY 2026
program year for the Clinical Outcomes
domain measures (MORT–30–AMI,
MORT–30–HF, MORT–30–PN (updated
cohort), MORT–30–COPD, MORT–30–
CABG, and COMP–HIP–KNEE) and the
Efficiency and Cost Reduction domain
measure (MSPB). We note that the
performance standards for the MSPB
measure are based on performance
period data. Therefore, we are unable to
provide numerical equivalents for the
standards at this time. The previously
established performance standards for
these measures are set out in the Table
V.I.–11.
TABLE V.I.-11: PREVIOUSLY ESTABLISHED PERFORMANCE STANDARDS
FOR THE FY 2026 PROGRAM YEAR
Measure Short Name
Achievement Threshold
Benchmark
Clinical Outcomes Domain
0.87442(
0.890687
0.88594 1
0.91287~
0.84336 1
0.877097
0.914691
0.932157
0.97056E
0.980473
0.02401S
0.016873
Efficiencv and Cost Reduction Domain
Median Medicare Spending per
Mean of the lowest decile Medicare
!Beneficiary ratio across all hospitals Spending per Beneficiary ratios
across all hospitals during the
~uring the performance period.
performance period.
MORT-30-AMI
MORT-30-HF
MORT-30-PN (undated cohort)
MORT-30-COPD
MORT-30-CABG
COMP-HIP-KNEE*
MSPB*
We have adopted certain measures for
the Safety domain, Clinical Outcomes
domain, and the Efficiency and Cost
Reduction domain for future program
years in order to ensure that we can
adopt baseline and performance periods
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
of sufficient length for performance
scoring purposes. In the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45294
through 45295), we established
performance standards for the FY 2027
program year for the Clinical Outcomes
domain measures (MORT–30–AMI,
MORT–30–HF, MORT–30–PN (updated
cohort), MORT–30–COPD, MORT–30–
CABG, and COMP–HIP–KNEE) and the
PO 00000
Frm 00339
Fmt 4701
Sfmt 4700
Efficiency and Cost Reduction domain
measure (MSPB). We note that the
performance standards for the MSPB
measure are based on performance
period data. Therefore, we are unable to
provide numerical equivalents for the
standards at this time. The previously
established performance standards for
these measures are set out in Table V.I.–
12.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.144
khammond on DSKJM1Z7X2PROD with RULES2
d. Previously Established Performance
Standards for Certain Measures for the
FY 2027 Program Year
ER10AU22.145
* Lower values represent better performance.
49118
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE V.1.-12: PREVIOUSLY ESTABLISHED PERFORMANCE STANDARDS
FOR THE FY 2027 PROGRAM YEAR
Measure Short Name
Achievement Threshold
Clinical Outcomes Domain**
0.877824
0.887571
0.844826
0.917395
0.971149
0.023322
Efficiency and Cost Reduction Domain
Median Medicare Spending per
Beneficiary ratio across all
hospitals during the performance
period.
MORT-30-AMI
MORT-30-HF
MORT-30-PN (updated cohort)
MORT-30-COPD
MORT-30-CABG
COMP-HIP-KNEE*
MSPB*
Benchmark
0.893133
0.913388
0.877204
0.932640
0.980752
0.017018
Mean of the lowest decile
Medicare Spending per
Beneficiary ratios across all
hospitals during the performance
period.
* Lower values represent better performance.
** As discussed in the FY 2022 IPPS/LTCH PPS final rule (86 FR 5297 through 45299), we did not include data from QI
and Q2 of CY 2020 in the calculation of these performance standards.
e. Newly Established Performance
Standards for Certain Measures for the
FY 2028 Program Year
As discussed previously, we have
adopted certain measures for the
Clinical Outcomes domain (MORT–30–
AMI, MORT–30–HF, MORT–30–PN
(updated cohort), MORT–30–COPD,
MORT–30–CABG, and COMP–HIP–
KNEE) and the Efficiency and Cost
Reduction domain (MSPB) for future
program years in order to ensure that we
can adopt baseline and performance
periods of sufficient length for
performance scoring purposes. In
accordance with our methodology for
calculating performance standards
discussed more fully in the Hospital
Inpatient VBP Program final rule (76 FR
26511 through 26513), which is codified
at 42 CFR 412.160, we are establishing
the following performance standards for
the FY 2028 program year for the
Clinical Outcomes domain and the
Efficiency and Cost Reduction domain.
We note that the performance standards
for the MSPB measure are based on
performance period data. Therefore, we
are unable to provide numerical
equivalents for the standards at this
time. The newly established
performance standards for these
measures are set out in Table V.I.–13.
TABLE V.1.-13 NEWLY ESTABLISHED PERFORMANCE STANDARDS FOR
THE FY 2027 PROGRAM YEAR
Measure Short Name
Achievement Threshold
Benchmark
Clinical Outcomes Domain**
0.893229
0.877260
0.885427
0.910649
0.831776
0.866166
0.913752
0.929652
0.971052
0.980570
0.029758
0.022002
Efficiencv and Cost Reduction Domain
Median Medicare Spending per
Mean of the lowest decile Medicare
!Beneficiary ratio across all hospitals Spending per Beneficiary ratios
across all hospitals during the
kluring the performance period.
performance period.
IMORT-30-AMI
IMORT-30-HF
IMORT-30-PN (updated cohort)
IMORT-30-COPD
MORT-30-CABG
COMP-HIP-KNEE*
MSPB*
a. Domain Weighting for Hospitals That
Receive a Score on All Domains
In the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38266), we finalized our
proposal to retain the equal weight of 25
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
percent for each of the four domains in
the Hospital VBP Program for the FY
2020 program year and subsequent years
for hospitals that receive a score in all
domains. We did not propose any
changes to these domain weights.
PO 00000
Frm 00340
Fmt 4701
Sfmt 4700
b. Domain Weighting for Hospitals
Receiving Scores on Fewer Than Four
Domains
In the FY 2015 IPPS/LTCH PPS final
rule (79 FR 50084 through 50085), we
adopted a policy that hospitals must
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.147
6. Data Requirements
ER10AU22.146
khammond on DSKJM1Z7X2PROD with RULES2
* Lower values represent better performance.
** We note that these performance standards are calculated using some data from CY 2020 and CY 2021, which are
included the COVID-19 PHE. However, these performance standards have been calculated using the updated
technical specifications described in sections V.1.3.c. and V.1.3.d. of this fmal rule, which excludes patients
diagnosed with COVID-19 and risk-adjusts for history of COVID-19 for these measures.
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
receive domain scores on at least three
of four quality domains in order to
receive a TPS, for the FY 2017 program
year and subsequent years. Hospitals
with sufficient data on only three
domains will have their TPSs
proportionately reweighted (79 FR
50084 through 50085). We did not
propose any changes to these domain
weights.
c. Minimum Numbers of Measures for
Hospital VBP Program Domains
We refer readers to the FY 2018 IPPS/
LTCH PPS final rule (82 FR 38266) for
our previously finalized requirements
for the minimum numbers of measures
for hospitals to receive domain scores.
We did not propose any changes to
these policies.
d. Minimum Numbers of Cases for
Hospital VBP Program Measures
(1) Background
Section 1886(o)(1)(C)(ii)(IV) of the Act
requires the Secretary to exclude for the
fiscal year hospitals that do not report
a minimum number (as determined by
the Secretary) of cases for the measures
that apply to the hospital for the
performance period for the fiscal year.
For additional discussion of the
previously finalized minimum numbers
of cases for measures under the Hospital
VBP Program, we refer readers to the
49119
Hospital Inpatient VBP Program final
rule (76 FR 26527 through 26531); the
CY 2012 OPPS/ASC final rule (76 FR
74532 through 74534); the FY 2013
IPPS/LTCH PPS final rule (77 FR 53608
through 53610); the FY 2015 IPPS/LTCH
PPS final rule (79 FR 50085 through
50086); the FY 2016 IPPS/LTCH PPS
final rule (80 FR 49570); and the FY
2018 IPPS/LTCH PPS final rule (82 FR
38266 through 38267). We did not
propose any changes to these policies.
(2) Summary of Previously Adopted
Minimum Numbers of Cases
The previously adopted minimum
numbers of cases for these measures are
set forth in Table V.I.–14.
TABLE V.I.-14: PREVIOUSLY ADOPTED MINIMUM CASE NUMBER
REQUIREMENTS FOR HOSPITAL VBP PROGRAM
HCAHPS
MORT-30-AMI
MORT-30-HF
MORT-30-PN (updated cohort)
MORT-30-COPD
MORT-30-CABG
COMP-HIP-KNEE
CAUTI
CLABSI
Colon and Abdominal Hysterectomy SSI
MRSA Bacteremia
CDI
khammond on DSKJM1Z7X2PROD with RULES2
MSPB
e. Summary of Previously Adopted
Administrative Policies for NHSN
Healthcare-Associated Infection (HAI)
Measure Data
In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42400 through 42402), we
finalized our proposal to use the same
data to calculate the CDC NHSN HAI
measures for the Hospital VBP Program
that the HAC Reduction Program uses
for purposes of calculating the measures
under that program, beginning on
January 1, 2020 for CY 2020 data
collection, which would apply to the
Hospital VBP Program starting with data
for the FY 2022 program year
performance period. In the FY 2020
IPPS/LTCH PPS final rule (84 FR
42402), we also finalized our proposal
for the Hospital VBP Program to use the
same processes adopted by the HAC
Reduction Program for hospitals to
review and correct data for the CDC
NHSN HAI measures and to rely on
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Minimum Number of Cases
Person and Community Engagement Domain
Hospitals must report a minimum number of 100 completed HCAHPS survevs.
Clinical Outcomes Domain
Hospitals must report a minimum number of 25 cases.
Hospitals must report a minimum number of 25 cases.
Hospitals must report a minimum number of 25 cases.
Hospitals must report a minimum number of 25 cases.
Hospitals must report a minimum number of 25 cases.
Hospitals must report a minimum number of 25 cases.
Safety Domain
Hospitals have a minimum of 1.000 predicted infections as calculated by the CDC.
Hospitals have a minimum of 1.000 predicted infections as calculated bv the CDC.
Hospitals have a minimum of 1.000 predicted infections as calculated by the CDC.
Hospitals have a minimum of 1.000 predicted infections as calculated by the CDC.
Hospitals have a minimum of 1.000 predicted infections as calculated by the CDC.
Efficiency and Cost Reduction Domain
Hospitals must report a minimum number of 25 cases.
HAC Reduction Program validation to
ensure the accuracy of CDC NHSN HAI
measure data used in the Hospital VBP
Program. We did not propose any
changes to these policies.
7. Extraordinary Circumstance
Exception (ECE) Policy for the Hospital
VBP Program
We refer readers to the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45298
through 45299) for additional details
related to the Hospital VBP Program
ECE policy. We did not propose any
changes to the Hospital VBP Program
ECE policy.
8. References to Requests for
Information
future adoption of the National
Healthcare Safety Network (NHSN)
Healthcare-Associated Clostridioides
difficile Infection Outcome Measure and
the National Healthcare Safety Network
(NHSN) Hospital-Onset Bacteremia &
Fungemia Outcome Measure into the
Hospital IQR Program. In addition, we
requested information on the potential
future inclusion of these digital CDC
NHSN measures in the Hospital VBP
Program. This request for information
supports our goal of moving fully to
digital quality measurement in CMS
quality reporting and value-based
purchasing programs, including the
Hospital VBP Program.
a. NHSN Digital Quality Measures
We also refer readers to section
IX.E.9.a. of this final rule, where we
received comments in response to our
request for information on the potential
PO 00000
Frm 00341
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.148
Measure Short Name
49120
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
b. Reference to the Request for
Information: Overarching Principles for
Measuring Healthcare Quality
Disparities Across CMS Quality
Programs
We refer readers to section IX.B. of
this final rule where we received input
on overarching principles in measuring
healthcare quality disparities in hospital
quality and value-based purchasing
programs.
J. Hospital-Acquired Condition (HAC)
Reduction Program: Updates and
Changes (42 CFR 412.170)
1. Regulatory Background
We refer readers to the FY 2014 IPPS/
LTCH PPS final rule (78 FR 50707
through 50708) for a general overview of
the HAC Reduction Program and to the
same final rule (78 FR 50708 through
50709) for a detailed discussion of the
statutory basis for the Program. For
additional descriptions of our
previously finalized policies for the
HAC Reduction Program, we also refer
readers to the following final rules:
• The FY 2014 IPPS/LTCH PPS final
rule (78 FR 50707 through 50729);
• The FY 2015 IPPS/LTCH PPS final
rule (79 FR 50087 through 50104);
• The FY 2016 IPPS/LTCH PPS final
rule (80 FR 49570 through 49581);
• The FY 2017 IPPS/LTCH PPS final
rule (81 FR 57011 through 57026);
• The FY 2018 IPPS/LTCH PPS final
rule (82 FR 38269 through 38278);
• The FY 2019 IPPS/LTCH PPS final
rule (83 FR 41472 through 41492);
• The FY 2020 IPPS/LTCH PPS final
rule (84 FR 42402 through 42411);
• The FY 2021 IPPS/LTCH PPS final
rule (85 FR 58860 through 58865); and
• The FY 2022 IPPS/LTCH PPS final
rule (86 FR 45300 through 45310).
We have also codified certain
requirements of the HAC Reduction
Program at 42 CFR 412.170 through
412.172.
khammond on DSKJM1Z7X2PROD with RULES2
2. Flexibility for Changes That Affect
Quality Measures During a Performance
or Measurement Period in the HAC
Reduction Program
a. Measure Suppression Policy for the
Duration of the COVID–19 PHE
In the FY 2022 IPPS/LTCH PPS final
rule, we adopted a policy for the
duration of the COVID–19 PHE enabling
us to suppress a number of measures
from the Total HAC Score calculations
for the HAC Reduction Program if we
determine that circumstances caused by
the COVID–19 PHE have affected these
measures and the resulting Total HAC
Scores significantly (86 FR 45301
through 45304). We refer readers to the
FY 2022 IPPS/LTCH PPS final rule for
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
further details on our measure
suppression policy (86 FR 45301
through 45304).
In the FY 2022 IPPS/LTCH PPS final
rule, we also adopted Measure
Suppression Factors to guide our
determination of whether to propose to
suppress HAC Reduction Program
measures for one or more program years
that overlap with the PHE for COVID–
19 (86 FR 45302). We adopted these
Measure Suppression Factors for use in
the HAC Reduction Program, and, for
consistency, in the following other
value-based purchasing programs:
Hospital Value-Based Purchasing
Program, Hospital Readmissions
Reduction Program, Skilled Nursing
Facility Value-Based Purchasing
Program, and End-Stage Renal Disease
Quality Incentive Program. We continue
to believe that these Measure
Suppression Factors will help us
evaluate the HAC Reduction Program’s
measures, and that their adoption in the
other value-based purchasing programs
will help ensure consistency in our
measure evaluations across programs.
The previously adopted Measure
Suppression Factors are as follows:
• Significant deviation in national
performance on the measure during the
COVID–19 PHE, which could be
significantly better or significantly
worse compared to historical
performance during the immediately
preceding program years.
• Clinical proximity of the measure’s
focus to the relevant disease, pathogen,
or health impacts of the COVID–19 PHE.
• Rapid or unprecedented changes
in—
++ Clinical guidelines, care delivery
or practice, treatments, drugs, or related
protocols, or equipment or diagnostic
tools or materials; or
++ The generally accepted scientific
understanding of the nature or
biological pathway of the disease or
pathogen, particularly for a novel
disease or pathogen of unknown origin.
• Significant national shortages or
rapid or unprecedented changes in—
++ Healthcare personnel;
++ Medical supplies, equipment, or
diagnostic tools or materials; or
++ Patient case volumes or facilitylevel case mix.
We stated that we view this measure
suppression policy as necessary to
ensure that the HAC Reduction Program
does not reward or penalize facilities
based on factors that the Program’s
measures were not designed to
accommodate (86 FR 45302).
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28446 through
28449), we proposed changes to this
PO 00000
Frm 00342
Fmt 4701
Sfmt 4700
measure suppression policy, which we
discuss in section V.J.2.b.(2).
b. Proposals To Apply the Measure
Suppression Policy to FY 2023 and FY
2024 HAC Reduction Program Years
(1) Background
Through memoranda released in
March 2020 288 and an interim final rule
with comment (IFC) published in
September 2020 (85 FR 54830 through
54832), in response to the COVID–19
PHE, we excluded, by application of our
Extraordinary Circumstances Exception
(ECE) policy, all data submitted
regarding care provided during the first
and second quarters of CY 2020 from
our performance calculations for FY
2022 and FY 2023. We excluded such
data because of our concerns about the
national comparability of these data due
to the geographic differences of COVID–
19 incidence rates and hospitalizations,
along with different impacts resulting
from different State and local laws and
policy changes implemented in
response to COVID–19.
Additionally, in the FY 2022 IPPS/
LTCH PPS final rule, we finalized our
policy suppressing the third and fourth
quarters of CY 2020 289 CDC NHSN HAI
and the CMS Patient Safety and Adverse
Events Composite measure (CMS PSI
90) data from our performance
calculations for FY 2022, FY 2023, and
FY 2024 under the proposed Measure
Suppression Factor 1, ‘‘significant
deviation in national performance on
the measure, which could be
significantly better or significantly
worse compared to historical
performance during the immediately
preceding program years’’; and the
Measure Suppression Factor 4 subfactor,
‘‘significant national or regional
shortages or rapid or unprecedented
changes in patient case volumes or case
mix’’ (86 FR 45304 through 45307). We
explained that although Q3 and Q4 2020
data would be suppressed from the
Total HAC Score calculation, hospitals
would still be required to submit such
288 Centers for Medicare and Medicaid Services.
(2020). Exceptions and Extensions for Quality
Reporting Requirements for Acute Care Hospitals,
PPS-Exempt Cancer Hospitals, Inpatient Psychiatric
Facilities, Skilled Nursing Facilities, Home Health
Agencies, Hospices, Inpatient Rehabilitation
Facilities, Long-Term Care Hospitals, Ambulatory
Surgical Centers, Renal Dialysis Facilities, and
MIPS Eligible Clinicians Affected by COVID–19
Available at: https://www.cms.gov/files/document/
guidance-memo-exceptions-and-extensions-qualityreporting-and-value-based-purchasingprograms.pdf.
289 In the FY 2022 IPPS/LTCH PPS final rule, we
finalized the suppression of the third and fourth
quarters of CY 2020, which is July 1, 2020 through
September 30, 2020 (Q3 2020) and October 1, 2020
through December 31, 2020 (Q4 2020).
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
data and such data would be used for
public reporting purposes.
These policies resulted in the
following applicable periods for
calculating Total HAC Scores for FY
49121
2022, FY 2023, and FY 2024 HAC
Reduction Programs:
In sections V.J.2.b.(2). and (3), of this
final rule, we are finalizing the proposal
to further modify some of these
applicable periods.
khammond on DSKJM1Z7X2PROD with RULES2
(2) Updates to the FY 2023 HAC
Reduction Program
In the FY 2023 IPPS/LTCH proposed
rule, we discussed two updates for the
FY 2023 HAC Reduction Program’s
measure suppression policy: (1) We
proposed to suppress the CMS PSI 90
measure and the five CDC NHSN HAI
measures from the calculation of
measure scores and the Total HAC
Score, thereby not penalizing any
hospital under the FY 2023 HAC
Reduction Program; and (2) For the CMS
PSI 90 measure, we proposed to not
calculate or report measure results for
the FY 2023 HAC Reduction Program.
COVID–19 has had significant
negative health effects—on individuals,
communities, and the nation as a whole.
Consequences for individuals who have
COVID–19 include morbidity,
hospitalization, mortality, and postCOVID conditions (also known as long
COVID). As of mid-December 2021, over
50 million COVID–19 cases, three
million new COVID–19 related
hospitalizations, and over 800,000
COVID–19 deaths have been reported in
the U.S.290 291 One analysis projected
that COVID–19 would reduce life
expectancy in 2020 by 1.13 years
overall, with the estimated impact
disproportionately affecting members of
historically underserved and underresourced communities. According to
this analysis, the estimated life
expectancy reduction for Black and
Latino populations is three to four times
the estimate when comparing to the
290 Centers for Disease Control and Prevention.
(2021). COVID Data Tracker, https://covid.cdc.gov/
covid-data-tracker/#datatracker-home.
291 As of mid-June 2022, over 86 million COVID–
19 cases, 15,000 new COVID–19 related
hospitalizations, and over a million COVID–19
deaths have been reported in the U.S.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
white population.292 Indeed, COVID–19
has overtaken the 1918 influenza
pandemic as the deadliest disease event
in American history.293 Impacts of the
pandemic have continued to accelerate
in 2021. The Delta variant of COVID–19
(B.1.617.2), which was first identified in
India, surfaced in the United States in
early-to-mid 2021. It was found that the
Delta variant is 60 percent more
transmissible compared to the
previously dominant Alpha variant.294
Further, in November 2021, the number
of COVID–19 deaths for 2021 surpassed
the total deaths for 2020. According to
CDC data, the total number of deaths
involving COVID–19 reached 385,453 in
2020 and 451,475 in 2021.295 We
continue to monitor and evaluate the
measures in the HAC Reduction
Program for impacts due to COVID–19
and the emergence of COVID–19
variants, such as Delta and Omicron
variants, and elaborate further later in
the section.
As described in section V.J.2.b.(1). of
this final rule, we previously excluded
or suppressed all quarters of CY 2020
data from the calculation of the Total
HAC Score, in part, because of concerns
about the national comparability of
these data and significant deviation in
national performance on the measure
compared to historical performance. We
292 Andrasfay, T., & Goldman, N. (2021).
Reductions in 2020 US life expectancy due to
COVID–19 and the disproportionate impact on the
Black and Latino populations. Proceedings of the
National Academy of Sciences of the United States
of America, 118(5), e2014746118. https://
www.pnas.org/content/118/5/e2014746118.
293 STAT News. (2021). Covid-19 overtakes 1918
Spanish flu as deadliest disease in American
history, https://www.statnews.com/2021/09/20/
covid-19-set-to-overtake-1918-spanish-flu-asdeadliest-disease-in-american-history/.
294 Allen H., Vusirikala A., Flannagan J., et al.
Increased Household Transmission of COVID–19
cases associated with SARS–CoV–2 Variant of
Concern B.1.617.2: a national case-control study.
Public Health England. 2021.
295 Centers for Disease Control. (2022). COVID–19
Death Data and Resources. Available at: https://
www.cdc.gov/nchs/nvss/covid-19.htm.
PO 00000
Frm 00343
Fmt 4701
Sfmt 4700
acknowledge that facilities were still
adapting to the demands of the PHE and
that subsequently national performance
deviated from previous performance
during CY 2021. Therefore, we proposed
to suppress all HAC Reduction Program
measures (CMS PSI 90, CAUTI, CLABSI,
Colon and Hysterectomy SSI, MRSA,
and CDI) from the calculation of the
Total HAC Score for the FY 2023 HAC
Reduction Program under Measure
Suppression Factor 1 significant
deviation in national performance on
the measure, which could be
significantly better or significantly
worse compared to historical
performance during the immediately
preceding program years; Measure
Suppression Factor 3, rapid or
unprecedented changes in clinical
guidelines, care delivery or practice,
treatments, drugs, or related protocols,
or equipment or diagnostic tools or
materials; and Measure Suppression
Factor 4, significant national or regional
shortages or rapid or unprecedented
changes in patient case volumes or case
mix.
We are concerned that the COVID–19
PHE resulted in changes in HAC
Reduction Program measure
performance such that we would not be
able to score hospitals fairly. We refer
readers to the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45304 through 45305)
for previous analysis on the HAC
Reduction Program measures that
showed that measure rates for the
CLABSI, CAUTI, and MRSA measures
increased during the CY 2020 pandemic
year as compared to the pre-COVID CY
2019 year immediately preceding the
COVID–19 PHE.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we proposed to suppress
three of the five CDC NSHN HAI
measures (CLABSI, CAUTI, and MRSA)
under Measure Suppression Factor 1,
significant deviation in national
performance on the measures, which
could be significantly better or
significantly worse compared to
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.149
Aoolicable Periods for FY 2022, FY 2023, and FY 2024 for the HAC Reduction Prouam
Current Applicable Periods that Resulted from
Fiscal Year
Measure Set
ECE and Measure Suooression Policies
CDCNHSNHAI
Januarv 1, 2019 through December 31, 2019
FY 2022
July 1, 2018 through December 31, 2019
CMS PSI 90
CDCNHSNHAI
Januarv 1, 2021 through December 31, 2021
FY 2023
CMS PSI 90
July 1, 2019 through December 31, 2019 and
Januarv 1, 2021 through June 30, 2021
CDCNHSNHAI
Januarv 1, 2021 through December 31, 2022
FY 2024
Januarv 1, 2021 through June 30, 2022
CMS PSI 90
49122
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
historical performance during the
immediately preceding program years.
To determine whether the CLABSI,
CAUTI, and MRSA measure rates would
continue to show increases for CY 2021,
the CDC analyzed changes in
standardized infection ratios (SIRs) for
Q1 and Q2 of CY 2021 as compared to
the SIRs in Q1 and Q2 of CY 2019. This
analysis found that the CLASBI, CAUTI,
and MSRA measures had statistically
significant measure rate increases
during Q1 and Q2 of CY 2021 as
compared to pre-pandemic levels in Q1
and Q2 of CY 2019. For Q1 2021, the
national SIR increased by approximately
45 percent for the CLABSI measure,
approximately 12 percent for the CAUTI
measure, and approximately 39 percent
for the MRSA measure as compared to
Q1 2019. For Q2 2021, the national SIR
increased by approximately 15 percent
for the CLABSI measure and
approximately 8 percent for the MRSA
measure. The SIRs for the CAUTI
measure showed no statistically
significant difference for Q2 2021 as
compared to Q2 2019.
For the CDI measure, the national SIR
decreased by approximately 16 percent
for Q1 2021 as compared to Q1 2019
and by approximately 14 percent for Q2
2021 as compared to Q2 2019. The SSI
measure showed no significant increase
or decrease in SIRs during Q1 2021 and
Q2 2021 as compared to Q1 2019 and
Q2 2019, however there has been an
CLABSI
appreciable decrease in procedure
volume for the measure. We proposed to
suppress the SSI and CDI measures
under Measure Suppression Factor 4,
significant national shortages or rapid or
unprecedented changes in patient case
volumes and Measure Suppression
Factor 3, rapid or unprecedented
changes in clinical guidelines, care
delivery or practice, treatments, drugs,
or related protocols, or equipment or
diagnostic tools or materials,
respectively. Specifically, for the SSI
measure, we proposed to suppress the
measure for FY 2023 under Measure
Suppression Factor 4, rapid or
unprecedented changes in patient case
volumes. We note that the SSI measure
has had a low procedure volume for
many hospitals during the PHE, which
impacts our ability to produce SIRs for
that measure. For CY 2019, 2,087
hospitals (61 percent) did not have
sufficient procedure-level data needed
to calculate an SSI SIR for abdominal
hysterectomy, and 1,262 hospitals (37
percent) did not have sufficient data to
calculate an SIR for colon surgery.
However, nationally, procedure
volumes declined even further during
the COVID–19 PHE in 2020, compared
to 2019, with decreases of up to 23
percent for colon procedures and 39
percent for abdominal hysterectomy
procedures.296 As of July 2021,
abdominal hysterectomy procedures
were still 6 percent below predicted
levels.297 These changes in patient
volumes for the SSI measure limit our
ability to calculate SSI SIRs for hospitals
that don’t have sufficient data in FY
2023, which may impact the accuracy
and reliability of overall national
comparison on performance for this
measure.
For the CDI measure, we proposed to
suppress the measure under Measure
Suppression Factor 3, rapid or
unprecedented changes in clinical
guidelines, care delivery or practice,
related protocols, or equipment or
diagnostic tools or materials. Pandemicrelated improvements to typical CDI
prevention practices such as hand
hygiene, PPE practices, and
environmental cleaning could have
contributed to the declines seen in the
CDI SIR in 2021 compared to 2019.298
In addition, a decline in outpatient
antibiotic prescribing was observed
starting in 2020 as healthcare utilization
decreased during the COVID–19
pandemic.299 This, combined with the
continued use of inpatient antibiotic
stewardship programs in hospitals, may
also have contributed to the decline in
the national CDI SIRs, as reducing
patient antibiotic exposure is a
recommended strategy for CDI
prevention. More information about CDI
prevention strategies can be found at
https://www.cdc.gov/cdiff/clinicians/
cdi-prevention-strategies.html.
PERCENT CHANGES IN SIRS COMPARED TO RESPECTIVE 2019 QUARTERS
2020 Q2
2020 Q3
2020 Q4
2021 Ql
2021 Q2
2020 Ql
-11.8
27.9
46.4
47.0
45.3
14.6
2021 Q3*
48.6
CAUTI
-21.3
No change
12.7
18.8
11.5
No change
12.7
SSI: Colon surgery
-9.1
No change
-6.9
-8.3
No change
No change
No change
No change
SSI: Abdominal hysterectomy
-16.0
No change
No change
-13.1
No change
No change
IMRSA bacteremia
-7.2
12.2
22.5
33.8
39.2
8.3
40.7
CDI
-17.5
-10.3
-8.8
-5.5
-15.6
-14.1
-15.8
Additionally, because we cannot
identify all potential elements that
could be impacting the overall HAI
experience at hospitals during an
unprecedented PHE as well as potential
geographic disparities in the impact of
the PHE that could cause uneven impact
on facilities based on their location, like
shortages of healthcare personnel, we
believe all five CDC NHSN HAI
measures should be suppressed.
Therefore, we believe it is appropriate to
suppress all five HAI measures from the
HAC Reduction Program for the FY
2023 program year, to ensure an
accurate and reliable national
comparison of performance on hospital
safety.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45304 through 45305), we
observed that the skewed measure
296 Weiner-Lastinger, L., et al,. The impact of
coronavirus disease 2019 (COVID–19) on
healthcare-associated infections in 2020: A
summary of data reported to the National
Healthcare Safety Network. Infection Control &
Hospital Epidemiology (2022), 43, 12–25.
doi:10.1017/ice.2021.362.
297 Butler, S., et al. (2021). Epic Research. Elective
Surgeries Approach Pre-Pandemic Volumes.
Available at: https://epicresearch.org/articles/
elective-surgeries-approach-pre-pandemic-volumes.
298 Weiner-Lastinger L.M., et al. (2021). The
impact of coronavirus disease 2019 (COVID–19) on
healthcare-associated infections in 2020: A
summary of data reported to the National
Healthcare Safety Network. Infection Control &
Hospital Epidemiology, https://doi.org/10.1017/
ice.2021.362.
299 The intersection of antibiotic resistance (AR),
antibiotic use (AU), and COVID–19. (2021).
Department of Health and Human Services website.
https://www.hhs.gov/sites/default/files/antibioticresistance-antibiotic-use-covid-19-paccarb.pdf.
Published February 10, 2021. Accessed June 28,
2021.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00344
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.150
khammond on DSKJM1Z7X2PROD with RULES2
* The Q3 2021 HAI measure data has been finalized since the publication of the FY 2023 IPPS/L TCH proposed rule. In this final rule, we have
updated the table to reflect the final figures.
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
performance may be due to
circumstances unique to the effects of
the pandemic such as staffing shortages
and turnover, patients who are more
susceptible to infections due to
increased hospitalization stays, and
longer indwelling catheters and central
lines. We believe that the continued
skewed measure performance is
impacted by similar circumstances
unique to the effects of the COVID–19
PHE. We further believe that our
proposal to suppress the HAI measure
data from CY 2021 was appropriate
because the impact of the COVID–19
PHE on the measures cannot be
addressed through risk-adjustment.
Under current data collection
requirements for the CDC NHSN HAI
measures the data are collected at each
hospital’s ward level, meaning that the
hospital submits infection data for a
given ward rather than at the individual
patient level. Accordingly, we are not
able to identify the number of patients
with HAIs who also had COVID–19, and
therefore cannot risk-adjust for or
otherwise account for COVID–19
diagnoses. Modifying CDC’s risk
adjustment methodology is a multi-year
process that requires substantial time to
review, analyze, and implement
updated methodology for the
calculation of the SIR. In order to
address the impact of the ongoing
COVID–19 PHE on HAI incidence, as
reported to CDC NHSN, we believe
suppression of the CY 2021 measure
data is the best path forward for
participating hospitals. Therefore, we
proposed to suppress all five HAI
measures in the HAC Reduction
Program for the FY 2023 program year.
In accordance with the previously
adopted measure suppression policy (86
FR 45301 through 45304), we proposed
to suppress the CMS PSI 90 measure
and the five CDC NHSN HAI measures
for the HAC Reduction Program FY
2023 program year. We will continue to
provide the measure results for the CDC
NHSN HAI measures to hospitals via
their hospital-specific reports (HSRs).
We will also continue providing
information regarding hospital
performance to hospitals and other
interested persons via the Care Compare
tool hosted by Health and Human
Services, currently available at https://
www.medicare.gov/care-compare, and
the Provider Data Catalog. As previously
noted, under this policy, we would
continue to use claims data for the CMS
PSI 90 measure and participating
hospitals would continue to report CDC
NHSN HAI measure data to the CDC, so
that we can monitor the effect of the
circumstances on quality measurement
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
and determine appropriate policies in
the future.
Similarly, our analysis of the CMS PSI
90 measure suggested that comparability
of performance on the measure has also
been impacted by the PHE.
Additionally, after the nationwide ECE
(85 FR 54827 through 54828) and the FY
2022 IPPS/LTCH PPS final rule measure
suppression policies (86 FR 45304
through 45307) the CMS PSI 90 measure
reference period for the FY 2023
program year does not include data
affected by the COVID–19 PHE.
Conversely, the applicable period for
the CMS PSI 90 measure does include
data affected by COVID–19 PHE. Due to
the fact that the reference period for this
measure does not include data affected
by the COVID–19 PHE and the
applicable period does include such
data, this would result in risk
adjustment parameters that do not
account for the impact of COVID–19 on
affected patients. We believe that this
misalignment would produce distorted
measure results and potentially yield
biased CMS PSI 90 measure results
among hospitals highly impacted by the
COVID–19 PHE. Therefore, for the FY
2023 program year we proposed to not
calculate measure results for CMS PSI
90, to not provide the measure results
for the CMS PSI 90 measure to hospitals
via their hospital-specific reports
(HSRs), and to not publicly report those
measure results on the Care Compare
tool hosted by Health and Human
Services and the Provider Data Catalog.
We refer readers to section V.J.3.c.(1).
and (2) of this final rule where we
discuss the impact of the COVID–19
PHE on the CMS PSI 90 measure and a
technical update to the measure
specifications to risk-adjust for COVID–
19 diagnoses.
For the remaining measures,
specifically the CDC NHSN HAI
measures, we would use the previously
finalized applicable periods 300 to
calculate measure results (that is, SIRs
for each of the CDC NHSN HAI
measures) the FY 2023 program year.
We would use those measure results in
feedback reports to hospitals and as part
of program activities, fulfilling our
obligation under section 1886(p)(5) of
the Act to provide confidential reports
to applicable hospitals with information
on their performance on measures with
respect to hospital-acquired conditions.
Consumers may continue to access
information on hospital performance
with regards to hospital-acquired
300 In the FY 2022 IPPS/LTCH PPS final rule, we
finalized that the applicable periods for the FY 2023
HAC Reduction Program are for the CDC NHSN HAI
measures the 12-month period from January 1, 2021
through December 31, 2021.
PO 00000
Frm 00345
Fmt 4701
Sfmt 4700
49123
conditions through several channels,
including the Care Compare tool hosted
by Health and Human Services,
currently available at https://
www.medicare.gov/care-compare, the
Provider Data Catalog, available at
https://data.cms.gov/provider-data/.
Ultimately, we stated in the proposed
rule that if we finalize our proposals, all
hospitals would receive a Total HAC
Score of zero, and no hospitals would
receive a penalty for FY 2023. We
would report the measure scores of ‘‘N/
A’’, Total HAC Score of zero and
payment reduction indicators of ‘‘no
penalty’’ for all hospitals for the FY
2023 program year after confidentially
reporting via HSRs and a 30-day
preview period and then publicly
reporting on the Care Compare tool
hosted by Health and Human Services
and the Provider Data Catalog. For the
five CDC NHSN HAI measures, we
would also report the measure results,
both via HSRs and public reporting
methods. For the CMS PSI 90 measure
results, we would not calculate or report
on the measure results and would
indicate ‘N/A’ in confidential and
public reporting. We would resume
calculating measure scores in the FY
2024 program year, as discussed in
section V.J.2.b.(3). of this final rule.
In determining how to address the
impact of the COVID–19 PHE on
hospital performance and calculating
Total HAC Scores for FY 2023, we also
considered suppressing some CY 2021
quality measure data as an alternative to
suppressing all measures. Under this
alternative, we considered suppressing
the CY 2021 data for the CLABSI,
CAUTI, and MRSA measures on the
basis that performance on those
measures continued to be affected by
the COVID–19 PHE. We considered
scoring hospitals based solely on their
performance on SSI, CDI, and CMS PSI
90; however, we had concerns about
running the HAC Reduction Program on
only half of the program’s measures as
this may result in measure scores that
are significantly better or worse than in
immediately preceding years. In
addition, a Total HAC Score based on
only three program measures would be
less reliable, with more random noise in
identification of bottom quartile
hospitals, than a score based on six
program measures. Therefore, we
believe it is appropriate to suppress all
five CDC NSHN HAI measures and the
CMS PSI 90 measure from the
calculation of measure scores and Total
HAC Scores for the FY 2023 program
year.
We also considered making no
modifications to the program and
suppressing no additional measure data
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49124
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
from the FY 2023 Total HAC Scores
rather than extending the measure
suppression policy. As discussed, when
considering this approach in the FY
2022 IPPS/LTCH PPS final rule (86 FR
45305), this alternative would be
operationally easier to implement, but
would mean assessing participating
hospitals using quality measure data
that have been distorted by the COVID–
19 PHE without additional adjustments
to the measure. Additionally, given the
geographic disparities in the COVID–19
PHE’s effects, this policy could place
hospitals in regions that were hit harder
by the pandemic in CY 2021 at a
disadvantage compared to hospitals in
regions that were more heavily affected
in CY 2020. Ultimately, we believe that
our proposal to suppress all measures
from the FY 2023 HAC Reduction
Program more fairly addresses the
impact of the COVID–19 PHE for
participating hospitals.
Finally, we considered reusing a
previous fiscal year’s applicable period
to serve as the applicable period for FY
2023. Although this option would
enable us to continue operating the
program, it has the disadvantage of
double penalizing hospitals that were in
a prior fiscal year’s worst performing
quartile even if the hospital had
implemented policy and operational
changes to improve their performance in
future program years. Under this option,
no new quality data would be used to
inform hospitals or drive quality
improvement.
We continue to be concerned about
the pandemic, but are encouraged by the
development and rollout of prevention
techniques like COVID–19 vaccinations
and treatment for those diagnosed with
COVID–19. Our measure suppression
policy focuses on a short-term, equitable
approach during this unprecedented
PHE, and was not intended for
indefinite application. We also
recognize that measure performance for
some measures may not immediately
return to levels seen prior to the PHE,
particularly for the CDC NHSN HAI
measures for which we do not receive
patient-level data. Additionally, we
wanted to emphasize the long-term
importance of value-based care and
incentivizing quality care tied to
payment. The HAC Reduction Program
is an example of our long-standing effort
to link payments to healthcare quality in
the inpatient hospital setting
payment.301 Therefore, we note that our
301 CMS has also partnered with the CDC in a
joint Call to Action on safety, which is focused on
our core goal to keep patients safe. Fleisher et al.
(2022). New England Journal of Medicine. Article
available here: https://www.nejm.org/doi/full/
10.1056/NEJMp2118285?utm_
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
goal is to continue resuming the use of
measure data for the purposes of scoring
and payment adjustment beginning with
the FY 2024 program year.
We understand that the COVID–19
PHE is ongoing and unpredictable in
nature, however, we believe that CY
2022 has a more promising outlook in
the fight against COVID–19. As we enter
the third year of the pandemic,
healthcare providers and systems have
gained experience managing the disease,
surges of COVID–19 infection, and
adjusting to supply chain
fluctuations.302 In CY 2022 and the
upcoming years, we anticipate
continued availability and increased
uptake in the use of vaccinations and
the associated boosters,303 including
vaccination for children ages 5–11, who
were not eligible for vaccination for the
majority of 2021 and of whom only 36
percent had received at least one dose
as of June 29, 2022.304 305 Additionally,
the FDA issued emergency use
authorizations (EUAs) for the first oral
antiviral COVID–19 pill on December
22, 2021, and later approved a second
the following day, expanding access to
at-home COVID–19 treatment
options.306 307 Finally, the Biden-Harris
Administration has mobilized efforts to
source=STAT+Newsletters&utm_
campaign=8933b7233e-MR_COPY_01&utm_
medium=email&utm_term=0_8cab1d79618933b7233e-151759045.
302 Schneider, E. et al. (2022). The
Commonwealth Fund. Responding to Omicron:
Aggressively Increasing Booster Vaccinations Now
Could Prevent Many Hospitalizations and Deaths.
Available at: https://www.commonwealthfund.org/
blog/2022/responding-omicron.
303 Schneider, E. et al. (2022). The
Commonwealth Fund. Responding to Omicron:
Aggressively Increasing Booster Vaccinations Now
Could Prevent Many Hospitalizations and Deaths.
Available at: https://www.commonwealthfund.org/
blog/2022/responding-omicron.
304 KFF, Update on COVID–19 Vaccination of 5–
11 Year Olds in the U.S., https://www.kff.org/
coronavirus-covid-19/issue-brief/update-on-covid19-vaccination-of-5-11-year-olds-in-the-u-s/.
305 American Academy of Pediatrics. (2022).
Summary of data publicly reported by the Centers
for Disease Control and Prevention. Available at:
https://www.aap.org/en/pages/2019-novelcoronavirus-covid-19-infections/children-andcovid-19-vaccination-trends/.
306 U.S. Food and Drug Administration. (2021).
Coronavirus (COVID–19) Update: FDA Authorizes
First Oral Antiviral for Treatment of COVID–19.
Available at: https://www.fda.gov/news-events/
press-announcements/coronavirus-covid-19update-fda-authorizes-first-oral-antiviral-treatmentcovid-19.
307 U.S. Food and Drug Administration. (2021).
Coronavirus (COVID–19) Update: FDA Authorizes
Additional Oral Antiviral for Treatment of COVID–
19 in Certain Adults. Available at: https://
www.fda.gov/news-events/press-announcements/
coronavirus-covid-19-update-fda-authorizesadditional-oral-antiviral-treatment-covid-19certain#:∼:text=
Today%2C%20the%20U.S.%20Food
%20and,progression
%20to%20severe%20COVID%2D19%2C.
PO 00000
Frm 00346
Fmt 4701
Sfmt 4700
distribute home test kits,308 N–95
masks,309 and increase COVID–19
testing in schools,310 providing more
treatment and testing to the American
people. Given these developments, we
will continue to assess the impact of the
PHE on measure data used for the HAC
Reduction Program.
We invited public comments on our
proposals. We received a large volume
of input from the public regarding these
proposals. We first address the
comments related to our proposal to
suppress the CMS PSI 90 measure and
the five CDC NHSN HAI measures from
the calculation of measure scores and
the Total HAC Score, thereby not
penalizing any hospital under the FY
2023 HAC Reduction Program, for the
purposes of scoring and payment. Next,
we address the proposal to suppress
calculation and public reporting of
measure results for CMS PSI 90 for FY
2023.
Comment: Many commenters
supported the proposal to suppress the
CMS PSI 90 measure and the five CDC
NHSN HAI measures from the
calculation of measure scores and the
Total HAC Score, thereby not penalizing
any hospital under the FY 2023 HAC
Reduction Program. Several commenters
agreed that this policy would help
ensure hospitals are not penalized for
conditions beyond the control of
hospitals and providers that may
negatively impact hospital performance.
Several supported the proposal due to
the significant impact of the COVID–19
PHE on quality measures. A few
commenters noted that this proposed
policy would provide important relief
and stability for providers, especially
rural providers, regarding compliance
concerns so they can focus on the
unique challenges of providing care
during the COVID–19 PHE. Several
commenters supported the proposal
because it addresses the significant
308 The White House. (2022). Fact Sheet: The
Biden Administration to Begin Distributing AtHome, Rapid COVID–19 Tests to Americans for
Free. Available at: https://www.whitehouse.gov/
briefing-room/statements-releases/2022/01/14/factsheet-the-biden-administration-to-begindistributing-at-home-rapid-covid-19-tests-toamericans-for-free/.
309 Miller, Z. (2021). The Washington Post. Biden
to give away 400 million N95 masks starting next
week. Available at: https://
www.washingtonpost.com/politics/biden-to-giveaway-400-million-n95-masks-starting-next-week/
2022/01/19/5095c050-7915-11ec-9dce7313579de434_story.html.
310 The White House. (2022). FACT SHEET:
Biden–Harris Administration Increases COVID–19
Testing in Schools to Keep Students Safe and
Schools Open. Available at: https://
www.whitehouse.gov/briefing-room/statementsreleases/2022/01/12/fact-sheet-biden-harrisadministration-increases-covid-19-testing-inschools-to-keep-students-safe-and-schools-open/.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
deviation in national performance
across all program measures due to the
COVID–19 PHE. Many commenters
supported the proposal due to the belief
that the COVID–19 PHE negatively
impacted hospitals and patients through
a number of factors including quickly
changing clinical practices, operational
changes, increased clinical acuity,
staffing and supply shortages, and care
capacity concerns. Several commenters
supported the proposal because of the
disproportionate impacts of the COVID–
19 PHE on hospital performance given
geographic and temporal variation in
surges of cases. A commenter supported
the proposal due to the belief that this
will provide hospitals more time to
focus on training and education rather
than public reporting of measure scores.
A commenter supported the proposal
due to the belief that this will help
alleviate hospital administrative burden.
Response: We thank commenters for
their support. We agree that the
proposed suppression, scoring, and
payment policies for the FY 2023
program year were developed using
data-driven approaches and are
intended to balance the importance of
patient safety through transparency and
public reporting while allowing
hospitals to maintain access to care and
focus on providing quality health care to
patients during the COVID–19 PHE.
Additionally, we agree that suppressing
these measures for scoring and payment
purposes will ensure hospitals are not
penalized for impacts outside of their
control and note that hospitals will still
be required to report measure data for
the five CDC NSHN HAI measures and
CMS PSI 90 will be calculated through
claims data, so hospital administrative
burden will remain unchanged.
Comment: A few commenters
expressed support for the proposal to
suppress the HAI measures from scoring
and payment because they believe that
CMS could not feasibly use either risk
adjustment or exclusions to account for
COVID–19 diagnoses in calculating
performance.
Response: We thank commenters for
their support and agree that the HAI
measures cannot be risk-adjusted due to
the reasons described in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28449 through 28450) and in this final
rule.
Comment: Many commenters did not
support the proposal to suppress the
CMS PSI 90 measure and the five CDC
NHSN HAI measures from the
calculation of measure scores and the
Total HAC Score. Many commenters
recommended that instead of finalizing
the proposal to not score or penalize
hospitals for their performance, CMS
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
should penalize the worst performing
hospitals to incentivize quality
improvement. A few commenters
requested that CMS explore the
authority to provide payment bonuses
for hospitals to create a reward for
improved patient care. Many
commenters did not support the
proposal due to the belief that not
instituting payment penalties would not
hold hospitals accountable for care
delivered to patients. Many commenters
did not support the proposal because
they believe that suspending payment
reduction would be poor financial
stewardship of the Medicare Trust Fund
and ultimately not help beneficiaries.
Response: We thank the commenters
for their feedback. Throughout the
COVID–19 PHE, we have prioritized
access to safe, comprehensive
healthcare, and we continue to make
patient safety our primary concern. As
part of this dedicated commitment to
patient safety, we ensure public access
to the highest quality data regarding the
performance of health care facilities. We
continue to collect and closely monitor
performance to ensure safety, and will
continue to share that data with the
public. We understand commenters’
concerns; though we recognize that
some hospitals have maintained strong
performance on measures throughout
the COVID–19 PHE, we do not believe
it is appropriate to penalize any
hospitals based on measure data that we
believe were distorted by the COVID–19
PHE, the impacts of which were
geographically and temporally varied
during 2021, and, thus, would not
ensure an accurate and reliable national
comparison of performance on hospital
safety for penalty purposes. Meanwhile,
we note the HAC Reduction Program
statute does not grant the authority to
award payment bonuses or incentive
payments to hospitals with favorable
performance and measure outcomes.
Interested parties can view the HAC
Reduction Program statute at § 412.172
for more details on the payment
requirements. Additionally, we note
that the suppression, scoring, and
payment policies for the FY 2023
program year were developed using
data-driven approaches that are
intended to balance the importance of
patient safety through transparency and
public reporting while allowing
hospitals to maintain access to care and
focus on providing quality health care to
patients during the COVID–19 PHE.
Comment: A commenter expressed
concern over the misalignment of the
Measure Suppression Factors used
across the Hospital VBP and HAC
Reduction Programs for the HAI
measures.
PO 00000
Frm 00347
Fmt 4701
Sfmt 4700
49125
Response: We appreciate the
commenter’s concern regarding
consistency. To promote alignment
across our value-based purchasing
programs, in both the Hospital VBP and
HAC Reduction Programs, we proposed
to suppress three of the five CDC NSHN
HAI measures (CLABSI, CAUTI, and
MRSA) under Measure Suppression
Factor 1, significant deviation in
national performance on the measures,
which could be significantly better or
significantly worse compared to
historical performance during the
immediately preceding program years;
to suppress the SSI measure under
Measure Suppression Factor 4,
significant national shortages or rapid or
unprecedented changes in patient case
volumes; and to suppress the CDI
measure under Measure Suppression
Factor 3, rapid or unprecedented
changes in clinical guidelines, care
delivery or practice, related protocols,
or equipment or diagnostic tools or
materials. We applied these measure
suppression factors with both programspecific considerations in mind as well
as cross-program alignment. We
continue to believe that suppressing the
HAI measures under the HAC Reduction
Program and the Hospital VBP Program
for purposes of scoring and payment
will provide flexibility for providers to
focus on delivering quality of care to
patients during the COVID–19 PHE. We
refer readers to the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45301 through
45304) for more information on the HAC
Reduction Program’s measure
suppression factors and the FY 2022
IPPS/LTCH PPS final rule (86 FR 45266
through 45269) for more information on
the Hospital VBP Program’s measure
suppression factors.
Comment: Many commenters
recommended that we not suppress
future measures without seeking public
comment which gives the public an
opportunity to provide feedback.
Response: We appreciate the
commenters’ recommendation.
Consistent with our previously finalized
measure suppression policy in the FY
2022 IPPS/LTCH PPS final rule (86 FR
45301 through 45304), we intend to
provide interested parties with the
opportunity to comment on future
suppression through the rulemaking
process.
Comment: A commenter did not
support the proposal to suppress the
HAI measures from scoring and
payment and recommended that we
evaluate whether the HAC Reduction
Program is sufficiently committed to
ensuring a deeply embedded safety
culture.
E:\FR\FM\10AUR2.SGM
10AUR2
49126
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Response: We thank the commenter
for sharing their input, and we agree on
the importance of safety culture. We
also believe building a more resilient
health care system is necessary to avoid
future threats to patient safety.311
Specifically, as to the use of 2021 HAI
data for assessing HAC Reduction
Program penalties, based on data
analyses by the CDC, we believe that
suppressing the HAI measure for the FY
2023 program year offers hospitals and
health systems the flexibility to focus on
delivery of care while also accounting
for the changing conditions during a
PHE that are beyond hospitals’ control.
In addition, we are committed to the
continued collection, reporting, and
public availability of the HAI measure
data, focusing on transparency,
upholding quality care, and helping
patients make informed decisions about
their care. As we note previously, our
goal is to resume the use of 2022 HAI
measure data for scoring and payment
adjustment purposes beginning with the
FY 2024 program year as we believe that
2022 has a more promising outlook in
the fight against COVID–19 as we enter
the third year of the pandemic.
Comment: Many commenters
supported our proposal to continue to
publicly and confidentially report HAI
measure results. Several commenters
supported our proposal because they
believe it would promote transparency
in reporting of HAI measure data to help
interested parties understand the
healthcare landscape and the impact of
the COVID–19 PHE. A few commenters
supported our proposal because of their
belief that the public access to the HAI
data would allow them to make
informed decisions about care. A
commenter supported our proposal and
recommended that we provide hospitals
the option to opt-in to public reporting
of the HAI measures.
Response: We thank the commenters
for their support and agree that it is
important for the public to have access
to the HAI measure data to continue to
make informed health care decisions. As
noted in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28448) and in this
final rule, we intend to publicly report
HAI measure results with appropriate
caveats that explain that performance
information has been impacted due to
the COVID–19 PHE. We continue to
311 Fleisher et al. (2022). ‘‘Health Care Safety
during the Pandemic and Beyond—Building a
System That Ensures Resilience’’. New England
Journal of Medicine. Article available here: https://
www.nejm.org/doi/full/10.1056/
NEJMp2118285?utm_
source=STAT+Newsletters&utm_
campaign=8933b7233e-MR_COPY_01&utm_
medium=email&utm_term=0_8cab1d79618933b7233e-151759045.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
place significant value on being as
transparent as possible with the
performance information that we
collect, and we will make clear with
caveats that performance information
was affected by the COVID–19 PHE.
We disagree with the commenter’s
suggestion to allow hospitals the option
to opt-in to public reporting. We believe
this may cause greater confusion and
would provide an incomplete picture of
the impact of COVID–19 on
performance data since mostly only
hospitals that performed well might
choose to opt-in. Additionally, we
believe that providing transparent
performance information to the public
throughout the COVID–19 PHE and
beyond is a priority, and we do not
believe publicly reporting suppressed
measure data places additional burden
on providers above the processes
providers already have in place that are
used to collect and report the data to
CMS and the CDC. We encourage
hospitals to continue focusing on
providing quality care, and we believe
that the continued collection and public
reporting of performance information
can be a useful tool to inform future
quality improvements for health care
providers.
Comment: Many commenters did not
support suppression of the CDC NHSN
HAI measures from the calculation of
measure scores and the Total HAC Score
for the FY 2023 HAC Reduction
Program out of concerns relating to
access to publicly reported measure
data. Many commenters expressed their
belief that the proposal to suppress the
CDC NHSN HAI measures from the
calculation of measure scores and the
Total HAC Score would prevent patients
from making informed decisions on
where to receive care, especially those
at high risk for the measure. Similarly,
several commenters did not support the
proposal because they believe it violates
CMS’ commitment to public safety by
not granting the public access to
hospital performance data. Several
commenters stated that the proposal
would not hold hospitals accountable
for patient safety and the level and
quality of care delivered. A few
commenters stated that suppressing the
HAI measures would create the
perception that the government is not
disclosing information, reducing public
trust and transparency.
Response: We thank the commenters
for expressing their concerns. As
discussed in section V.J.2.b.(2)., we
wish to clarify that we are continuing to
publicly report the CDC NSHN HAI
measure results—the suppression
proposal related to the five CDC NHSN
HAI measure results was limited to
PO 00000
Frm 00348
Fmt 4701
Sfmt 4700
suppression of the measures from the
calculation of measure scores and the
Total HAC Score for purposes of
assessing HAC Reduction Program
penalties for FY 2023. As discussed in
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28448) and section
V.J.2.b.(2). of this final rule, we intend
to publicly report the suppressed CDC
NHSN HAI measure data with
appropriate caveats, as we recognize the
importance of transparency, promoting
public trust, and empowering
individuals to make data-informed
decisions using the publicly reported
HAI measure data. We will also
continue to provide confidential
feedback reports to hospitals through
the previously established processes,
including the information available to
hospitals via the CDC’s National
Healthcare Safety Network, as part of
program activities to ensure that
hospitals are made aware of the changes
in performance rates that we observe.
We believe that continuing to make the
data publicly available ensures that
hospitals are still held accountable for
their quality of care as consumers
decide where to obtain care based on
the publicly available data on hospital
performance.
Comment: A commenter did not
support HAI suppression out of concern
that we might have difficulty adhering
to, interpreting, and operationalizing the
Measure Suppression Factors, given the
ever-changing landscape. A commenter
did not support HAI suppression,
believing that being unable to determine
the causes of changes in HAI rates is not
a rationale for suppression. A
commenter did not support HAI
suppression, stating that the rationale
exceeds program authority and
recommending that CMS retract its
stated rationale for the suppression of
NHSN CDC HAIs in this final rule.
Response: We appreciate the concern
surrounding the operationalizing of the
measure Suppression Factors. We
believe that, in the face of evolving
circumstances of the COVID–19 PHE,
the level of detail in the Suppression
Factors, which were developed and
finalized in the FY 2022 IPPS/LTCH
PPS final rule to specifically address
challenges that arose due to the COVID–
19 PHE, is sufficient and applicable in
suppressing the HAI measures. In
deciding which measures to suppress,
and as discussed in the proposed rule
and this final rule, we examined each
measure and determined that the
evidence showed significant deviation
in the individual measure performance
data associated with the COVID–19 PHE
and/or a low reporting volume.
Additionally, the COVID–19 PHE in
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
2021 presented unique and
unprecedented experiences that
challenged hospitals in new ways
beyond their control. We believe that it
would be unfair to score or penalize
hospitals through payment during these
unique challenges, thus warranting the
use of Measure Suppression Factors. We
do not anticipate implementing the
Measure Suppression Factors in other
instances outside of such an
unprecedented and unique
circumstance as the COVID–19
pandemic.
Comment: A commenter questioned
whether we would be publicly reporting
the HAI measure results in the aggregate
form (that is, deidentified).
Response: We appreciate the
commenter’s question. CDC collects
data for the HAI measures at the ward
level rather than the patient level, and
then provides aggregate results at the
individual hospital CCN level.
Therefore, the data reported publicly
will not have patient identifiable
information, but will be identifiable by
hospital aggregated to the same CCN.
Comment: A commenter did not
support publicly reporting the HAI
measure results until the HAI measures
can be risk adjusted for COVID–19.
Response: We appreciate the
commenter’s recommendation.
However, due to the nature of the HAI
measure data being collected at the
ward level rather than the patient level,
we cannot feasibly risk adjust or
exclude for COVID–19 diagnoses in
calculating hospital performance on the
HAI measures. Additionally, we believe
the HAI rates could potentially still be
impacted even with COVID–19 risk
adjustment because pandemic-related
hospital staffing and resource issues
affect a hospital’s entire patient
population. We continue to place
significant value on being as transparent
as possible with the performance
information that we collect, and we will
make clear with caveats that
performance information was affected
by the COVID–19 PHE.
Comment: A few commenters
recommended that the HAI measures
continue to be suppressed until the end
of the COVID–19 PHE. A few
commenters recommended that we
continue to evaluate the impact of the
COVID–19 PHE on the data as the PHE
subsides. A commenter recommended
that we suppress CY 2020 and CY 2021
data from the HAI measure to address
the impact of the COVID–19 PHE. A few
commenters expressed concern about
publicly reporting the HAI measure
results because the data will be
distorted and of little value to the
public. Several commenters believed
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
that publicly reporting the data would
cause confusion or be misinterpreted by
consumers due to the impacts of the
COVID–19 PHE outside of facilities
control. A commenter recommended
that we delay public reporting of the
HAI measures so that we can evaluate
how to best communicate the impacts of
the COVID–19 PHE to consumers.
Response: We thank the commenters
for their recommendations and will
continue to monitor the PHE’s ongoing
effects carefully on the measures within
the HAC Reduction Program. In the
September 2, 2020 IFC,312 we finalized
exclusion of data submitted regarding
care provided during the first and
second quarters of CY 2020 from
calculation of scoring and payment
adjustments in the HAC Reduction
Program. In the FY 2022 IPPS/LTCH
final rule (86 FR 45307 through 45307),
we finalized suppression of the third
and fourth quarters of CY 2020 CDC
NSHN HAI data for purposes of scoring
and payment adjustments. In the FY
2023 IPPS/LTCH proposed rule (87 FR
28446 through 28450), we proposed to
suppress CY 2021 CDC NHSN HAI
measure data from the FY 2024 HAC
Reduction Program for purposes of
scoring and payment adjustments.
Therefore, we have suppressed CY 2020
and CY 2021 HAI measure data from the
HAC Reduction Program for scoring and
payment purposes.
We understand commenters’ concerns
with publicly reporting measure data
that were suppressed for purposes of
calculating the measure scores and Total
HAC Score. However, we disagree that
publicly reporting suppressed measure
data is not useful for consumers and
interested parties. We continue to place
significant value on being as transparent
as possible with the performance
information that we collect, and we will
make clear with caveats that that
performance information was affected
by the COVID–19 PHE. We encourage
hospitals to continue focusing on
providing quality care, and we believe
that the continued collection and public
reporting of performance information
can be a useful tool to inform future
quality improvements for health care
providers.
312 Centers for Medicare and Medicaid Services.
(2020). Exceptions and Extensions for Quality
Reporting Requirements for Acute Care Hospitals,
PPS-Exempt Cancer Hospitals, Inpatient Psychiatric
Facilities, Skilled Nursing Facilities, Home Health
Agencies, Hospices, Inpatient Rehabilitation
Facilities, Long-Term Care Hospitals, Ambulatory
Surgical Centers, Renal Dialysis Facilities, and
MIPS Eligible Clinicians Affected by COVID–19.
Available at: https://www.cms.gov/files/document/
guidance-memo-exceptions-and-extensionsqualityreporting-and-value-basedpurchasingprograms.pdf.
PO 00000
Frm 00349
Fmt 4701
Sfmt 4700
49127
Comment: Many commenters
supported the proposal to suppress the
calculating and reporting of CMS PSI 90
measure results for the FY 2023 HAC
Reduction Program. Several commenters
supported the proposal because they
believe the impacts of the COVID–19
PHE affected the accuracy of the data.
Several commenters supported the
proposal due to the potential for
distorted measure results because of
discrepancies in the reference and
applicable periods among hospitals
impacted by COVID–19. A few
commenters supported the proposal,
noting their belief that because hospitals
are seeing COVID–19 hospitalizations
increase again, hospital care will likely
be substantially impacted by these
trends for the foreseeable future. A
commenter recommended suppressing
CMS PSI 90 through at least Q2 2022.
Response: We thank the commenters
for their support, and we understand
and acknowledge commenter’s concerns
regarding the impact of the COVID–19
PHE on the CMS PSI 90 measure. In
light of the comments received and in
alignment with our continued
commitment to transparency, we are not
finalizing our proposal to suppress the
calculating and public reporting of CMS
PSI 90 measure results for the FY 2023
HAC Reduction Program. Additional
detail on how the measure will be
adjusted to exclude patients with a
diagnosis of COVID–19 is discussed at
the end of this section in this rule. In
public and confidential reporting, we
intend to annotate measure data to
indicate that performance was affected
by the COVID–19 PHE. We thank the
commenters for their recommendations,
and we will continue to monitor the
PHE’s ongoing effects carefully.
Comment: A few commenters
expressed support for the proposal to
suppress the calculating and public
reporting of CMS PSI 90 measure results
for the FY 2023 HAC Reduction
Program, noting that consumers may not
fully understand the caveats on Care
Compare and that third party
organizations may misuse the data. A
commenter expressed their belief that
public reporting is not of any value,
even with the appropriate caveats on
data limitations.
Response: We appreciate the
commenters’ support and concerns. We
have always believed that public
reporting of measure data is an
invaluable tool for patients, providers,
and the public. Public reporting of
measure data fosters transparency and
provides safety information to the
public in order to assist them with their
healthcare decisions. While we
proposed to not calculate or publicly
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49128
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
report the CMS PSI 90 measure
unadjusted for any impacts of COVID–
19, since the publication of the
proposed rule, we have been able to
determine a method for excluding
patients with a diagnosis of COVID–19
that will allow us to calculate and
publicly report valid and reliable
measure results. Therefore, based on
this measure adjustment and
stakeholder support for continued
public reporting, we are not finalizing
our proposal to suppress the calculating
and public reporting of CMS PSI 90
measure results for the FY 2023 HAC
Reduction Program. We believe that
publicly reporting the CMS PSI 90
measure data with these adjustments is
of value and an important step in
providing transparency and upholding
quality of care and safety for consumers.
Additional detail is discussed later in
this rule.
Comment: A few commenters
recommended three methods we could
employ to preserve the integrity of the
CMS PSI 90 measure for the FY 2023
program year including: applying a
measure exclusion for COVID–19
diagnosis, excluding cases with a
COVID–19 diagnosis 12 months prior to
admission, or including a COVID–19
diagnosis at admission variable in the
risk adjustment methodology. A
commenter recommended that for
version 12 of the CMS PSI 90 software
CMS extend the applicable period to
include more data from 2021 to increase
the number of hospitals measured and
increase measure reliability. Several
commenters recommended that we
should continue to report CMS PSI 90
measure data on Care Compare with the
caveat that the values are not adjusted
for COVID–19 diagnosis.
Response: We appreciate commenters’
recommendations regarding alternatives
to suppressing CMS PSI 90 measure
results for the FY 2023 program year.
We note that for the FY 2023 program
year, we will be applying an exclusion
to CMS PSI 90 for patients with a
diagnosis of COVID–19 as a few of the
commenters suggested. Since the
publication of the proposed rule, we
have been able to determine a method
for excluding patients with a diagnosis
of COVID–19 that will allow us to
calculate and publicly report valid and
reliable measure results. We refer
readers to section V.J.3.c.(2) of this final
rule for more detail on the updates to
the measure specifications being made
for the FY 2024 to risk-adjust for
COVID–19 diagnoses (in any position)
present on admission. We note that risk
adjustment details are released to the
public when each version of the
software is completed and made
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
available. The Risk Adjustment
methodology report will be posted on
the QualityNet website for CMS PSI 90
Resources at https://qualitynet.cms.gov/
inpatient/measures/psi/resources. The
risk adjustment methodology is part of
the routine annual process to update the
CMS PSI 90 measure, where the
measure developer will submit an
annual update to NQF that includes
updates to the risk adjustment model.313
We appreciate the commenters’
recommendation to extend the
applicable period to include more data
from 2021 to increase the measure
reliability and will consider it as we
continue to assess the impact of the
COVID–19 PHE on our measure data.
Comment: A number of commenters
did not support the proposal to suppress
the calculating and public reporting of
CMS PSI 90 measure results for the FY
2023 HAC Reduction Program. Many
commenters did not support the
proposal because they believe the data
should remain publicly available in
order for patients to make informed
decisions on where to receive care.
Several commenters did not support the
proposal because they believe it would
reduce the usefulness of the data
displayed on Care Compare.
Response: We thank the commenters
for sharing their concerns. As discussed,
since the publication of the proposed
rule, we have been able to determine a
method for excluding COVID–19
patients from program calculations that
will allow us to calculate and publicly
report valid and reliable measure
results. This exclusion method uses
fields available in the claims form to
identify patients with a diagnosis of
COVID–19. After identifying these
patients, we will exclude them from our
measure calculation for our CMS PSI 90
measure. We agree that we should
continue publicly reporting the CMS
PSI 90 measure so patients can make
informed decisions about where they
receive care. Ultimately, we believe that
publicly reporting this measure data
with these exclusions is of value and an
important step in providing
transparency and upholding quality of
care and safety for consumers. In light
of the comments received and in
alignment with our continued
commitment to transparency, we are not
finalizing our proposal to suppress the
calculating and public reporting of CMS
PSI 90 measure results for the FY 2023
program year. Additional detail is
discussed at the end of this section in
313 National Quality Forum. (2022). Maintenance
of NQF-Endorsed Performance Measures. Available
at: https://www.qualityforum.org/measuring_
performance/endorsed_performance_measures_
maintenance.aspx.
PO 00000
Frm 00350
Fmt 4701
Sfmt 4700
this rule. We intend to confidentially
report and publicly report the measure
results, annotated to identify where
performance was affected by the
COVID–19 PHE.
Comment: Many commenters did not
support the proposal to suppress the
calculating and public reporting of CMS
PSI 90 measure results for the FY 2023
HAC Reduction Program because they
believe the proposal violates the public
trust in both CMS and the medical
community and also reduces
transparency in the Medicare program.
Commenters also suggested that this
proposal could erode patient safety
infrastructure and ultimately hurt
patients. Many commenters did not
support the proposal and expressed
concern about public awareness of
potentially increasing rates of medical
errors and infections. A few commenters
did not support the proposal due to the
belief that suppression of these data
from reporting will not improve staffing
shortages or clinical training, which
have been critical contributors to poor
hospital performance on the measures.
Response: We thank the commenters
for sharing their concerns. As discussed,
since the publication of the proposed
rule, we have been able to determine a
method for excluding COVID–19
patients from program calculations that
will allow us to calculate and publicly
report valid and reliable measure
results. This exclusion method uses
fields available in the claims form to
identify patients with a diagnosis of
COVID–19. After identifying these
patients, we will exclude them from our
measure calculation for our CMS PSI 90
measure. We agree with commenters
that we should continue publicly
reporting measure data for CMS PSI 90.
Therefore, we note, that after
consideration of the public comments
we received, we are not finalizing our
proposal to suppress the calculating and
public reporting of CMS PSI 90 measure
results for the FY 2023 HAC Reduction
Program. Additional details are
discussed later in this section of the
rule. Ultimately, we believe that
publicly reporting suppressed measure
data is an important step in providing
transparency and upholding quality of
care and safety for consumers.
We also believe that publicly
reporting CMS PSI 90 will help enforce
patient safety infrastructure and benefit
the patient-provider relationship.
Additionally, we believe that
confidentially reporting these measure
data will help empower hospitals to
better understand their performance and
make improvements to staffing,
education, and training.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Comment: Many commenters did not
support the proposal to suppress the
calculating and public reporting of CMS
PSI 90 measure results for the FY 2023
HAC Reduction Program due to the
belief that there is no other publicly
available source for data on the
complications included in PSI 90 and if
we do not publicly report this data
interested parties will not have access to
the data to inform their decisions. Many
commenters did not support the
proposal because they believe that
public reporting of CMS PSI 90 measure
data helps interested parties understand
the patient safety landscape and prevent
more adverse events from occurring.
Many commenters did not support the
proposal due to the belief that public
reporting of the CMS PSI 90 measure
helps employers and health plans
analyze care delivery and promote
robust health plan networks. Several
commenters recommended that CMS
report CMS PSI 90 measure data so that
regulators and researchers can learn
from the COVID–19 PHE and develop an
action plan to improve hospital
performance. Many commenters
recommended that CMS report the PSI
90 measure data to align with the
recommendations focused on expanding
focus and resources on patient safety
contained in the 2018 Office of the
Inspector General Report on Adverse
Events in Hospitals.314
Response: We agree with the
commenters concerns and
recommendations regarding the public
and confidential reporting of the CMS
PSI 90 measure and recognize that
interested parties should have access to
this data to make data-informed
decisions. Therefore, we note, that since
we were able to determine a method for
excluding COVID–19 patients from
program calculations that will allow us
to calculate and publicly report valid
and reliable measure result, we are not
finalizing our proposal to suppress the
calculating and reporting of CMS PSI 90
measure results for the FY 2023 HAC
Reduction Program. This exclusion
method uses fields available in the
claims form to identify patients with a
diagnosis of COVID–19. After
identifying these patients, we will
exclude them from our measure
calculation for our CMS PSI 90 measure.
Additional detail is discussed at the end
of this section in this rule. We
encourage hospitals to continue
maintaining access and focusing on
314 Department of Health and Human Services,
Office of the Inspector General. (2018). Adverse
Events in Hospitals: A Quarter of Medicare Patients
Experienced Harm in October 2018. Available at:
https://oig.hhs.govAd/oei/reports/OEI-06-1800400.asp.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
providing quality care, and we believe
that the continued collection, analysis,
and public reporting of patient safety
performance information can be a useful
tool to inform future quality
improvement for health care systems,
maintain focus on patient safety, and
ultimately improve patient care.
Comment: Many commenters did not
support the proposal to suppress the
calculating and public reporting of CMS
PSI 90 measure results for the FY 2023
HAC Reduction Program due to their
belief that CMS PSI 90 data provides
essential information about significant
health care disparities that exist in
patient safety. These commenters stated
that not reporting on the CMS PSI 90
measure will perpetuate these health
inequities and prevent quality
improvement efforts to decrease
disparities. Many commenters noted
that the suppression of the CMS PSI 90
measure would impede decision-making
specifically for those populations that
are high-risk for adverse patient safety
events.
Response: We share the commenters’
concern about health equity and highrisk patients and note that as discussed,
we are not finalizing our proposal to
suppress the calculating and reporting
of CMS PSI 90 measure results for the
FY 2023 HAC Reduction Program.
Additional detail is discussed at the end
of this section in this rule.
We believe that by continuing to
publish the data for these measures, in
a way that is accessible to consumers
and researchers, patients can make
informed decisions about their care.
Additionally, we refer readers to section
IX.B. focused on our Request for
Information, Overarching Principles for
Measuring Quality Disparities Across
CMS Quality Programs, where we
requested information on healthcare
quality disparities in hospital quality
and value-based purchasing programs,
which will inform our Equity Plan for
Improving Quality in Medicare. We are
committed to promoting health equity
through our CMS National Quality
Strategy 315 and CMS Framework for
Health Equity 2022–2032,316 which
focuses on advancing health equity and
addressing the health disparities that
underlie our health system.
Comment: A few commenters did not
support the proposal to suppress CMS
315 Centers for Medicare and Medicaid Services.
(2022). CMS Strategic Plan: Health Equity.
Available at: https://www.cms.gov/files/document/
cms-national-quality-strategy-fact-sheet-april2022.pdf.
316 Center for Medicare and Medicaid Services.
(2022). CMS Framework for Health Equity 2022–
2032. Available at: https://www.cms.gov/files/
document/cms-framework-health-equity.pdf.
PO 00000
Frm 00351
Fmt 4701
Sfmt 4700
49129
PSI 90 because they believe that we did
not justify suppression based on any of
the measure suppression factors in the
FY 2023 IPPS/LTCH PPS proposed rule.
Response: We acknowledge the
commenters’ concerns, however, in the
FY 2023 IPPS/LTCH proposed rule, we
discussed our rationale that our analysis
of the CMS PSI 90 measure suggested
that comparability of performance on
the measure has also been impacted by
the PHE and our analysis found that
there was a decrease in volume across
all component PSI measures, especially
those related to surgical procedures. We
stated that this rationale falls under
Measure Suppression Factor 4,
‘‘significant national or regional
shortages or rapid or unprecedented
changes in patient case volumes or case
mix’’ (87 FR 28446 through 28447; and
28452). Additionally, we stated that the
CMS PSI 90 reference period does not
include data affected by the COVID–19
PHE and the applicable period does
include such data. We stated that this
misalignment would produce distorted
measure results and potentially yield
biased CMS PSI 90 measure results
among hospitals highly impacted by the
COVID–19 PHE (87 FR 28448). We
believe we have appropriately applied
the Measure Suppression Factors in this
rulemaking to address the impacts of the
COVID–19 PHE on the HAC Reduction
Program measures.
Comment: A few commenters did not
support the proposal to suppress CMS
PSI 90 and not calculate or report CMS
PSI 90 measure results for the FY 2023
HAC Reduction Program due to their
belief that the proposal does not align
with our priorities outlined in the 2022
CMS Strategic Framework.317 A few
commenters did not support the
proposal because they believed that
hospitals do not want outdated data to
represent their performance especially
since some facilities have made quality
improvements during the COVID–19
PHE.
Response: We acknowledge the
commenters’ concerns regarding
alignment with our 2022 CMS Strategic
Framework as well as outdated measure
data representing hospital performance.
We note, however, that after
consideration of the public comments
we received, we are not finalizing our
proposal to suppress the calculating and
reporting of CMS PSI 90 measure results
for the FY 2023 HAC Reduction
Program. Additional detail is discussed
at the end of this section in this rule. We
317 Centers for Medicare and Medicaid Services.
(2022). 2022 CMS Strategic Framework. Available
at: https://www.cms.gov/files/document/2022-cmsstrategic-framework.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49130
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
strongly believe that publicly reporting
these data aligns with our Strategic Plan
and will balance our responsibility to
provide transparency to consumers
while ensuring hospitals are not
unfairly scored or penalized. Also, since
we will calculate updated measure
results for CMS PSI 90, hospitals will
not have outdated information
representing performance on the
measure.
Comment: A commenter
recommended that if the CMS PSI 90
measure is suppressed from the FY 2023
HAC Reduction Program that we instead
report the PSI 03 measure as a standalone measure because this will help
maintain hospital focus on pressure
ulcers and injuries and would lead to
better reporting and improved patient
care since the measure has a sole focus.
Response: We agree with the
commenter on the importance of
measuring pressure ulcers and injuries
which is the intent of the PSI 03
measure. Because we are not finalizing
the proposal to suppress the calculating
and public reporting of CMS PSI 90
measure results for the FY 2023 HAC
Reduction Program, data on pressure
ulcers and injuries will continue to be
reported publicly and confidentially as
part of the PSI 90 measure results. We
also note that PSI 03 will be publicly
available in the Provider Data Catalog.
Comment: Many commenters
recommend that we continue to report
CMS PSI 90 data and publish previous
CMS PSI 90 data since it is important
that interested parties have access to all
previous CMS PSI 90 data from CY 2019
and past years. A few commenters
recommended that we consider
continuing to publicly report the CMS
PSI 90 measure using hospital’s prepandemic data. A few commenters
recommended that we report CMS PSI
90 measure data on the Provider Data
Catalog since this is valuable data for
health systems to learn from but not on
Care Compare because the data
impacted by the COVID–19 PHE should
not be used for scores, grades, or ratings.
Response: We acknowledge the
commenters’ recommendations
regarding public reporting of CMS PSI
90. We note, that after consideration of
the public comments we received and
because we identified a method for
excluding COVID–19 patients from
program calculations that will allow us
to calculate and publicly report valid
and reliable measure results, we are not
finalizing our proposal to suppress the
calculating and reporting of CMS PSI 90
measure results for the FY 2023 HAC
Reduction Program. Although we will
not calculate or report CMS PSI 90
measure results for use in the HAC
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Reduction Program scoring calculations
for the program year, we will still
calculate and publicly report the CMS
PSI 90 measure displayed on the main
pages of the Care Compare tool hosted
by HHS after confidentially reporting
these results to hospitals via CMS PSI
90-specific HSRs and a 30-day preview
period. We will also be reporting these
results on the Provider Data Catalog. We
strongly believe that publicly reporting
these data will balance our
responsibility to provide transparency
to consumers while ensuring hospitals
are not unfairly penalized.
We acknowledge the commenter’s
recommendation to continue public
reporting of CMS PSI 90 using hospital’s
pre-pandemic data and understand that
hospitals have been impacted by the
pandemic. For this reason, for the FY
2023 HAC Reduction Program, we are
not assessing payment penalties for
hospitals which report HAC Reduction
Program measures. This policy in
combination with calculating and
publicly reporting CMS PSI 90 ensures
that interested parties can access the
measure data but hospitals are not
penalized for the differential effects of
the COVID–19 PHE outside of their
control.
We also acknowledge the commenters
recommendation to report historic CMS
PSI 90 data, and note that CMS PSI 90
data is available from the last seven
years on the Provider Data Catalog’s
Data Archive at this website: https://
data.cms.gov/provider-data/archiveddata/hospitals.
Comment: A few commenters
recommended that we begin to resume
normal reporting of the CMS PSI 90
measure publicly and confidentially
when hospitals are less burdened by the
impacts of the COVID–19 PHE. A few
commenters recommended that we not
publicly report PSI 90 measure data but
calculate the measure and report the
data confidentially so hospitals can gain
insight into their performance.
Response: We appreciate the
commenters’ recommendation to not
publicly report CMS PSI 90 until the
COVID–19 PHE recedes, and to report
the CMS PSI 90 measure confidentially
so that hospitals can understand their
performance. We note, that after
consideration of the public comments
we received and because we identified
a method for excluding COVID–19
patients from program calculations that
will allow us to calculate and publicly
report valid and reliable measure
results, we are not finalizing our
proposal to suppress the calculating and
reporting of CMS PSI 90 measure results
for the FY 2023 HAC Reduction
Program. Additional detail is discussed
PO 00000
Frm 00352
Fmt 4701
Sfmt 4700
at the end of this section in this rule. We
will ensure the appropriate caveats are
applied to public reporting of the
measure so that interested parties
understand the data was impacted by
the COVID–19 PHE. We also will be
confidentially reporting these results to
hospitals via CMS PSI 90-specific HSRs
so that hospitals can evaluate their
performance on the measure.
We reiterate that ensuring patient
safety, and access to safe, equitable,
quality health care is high priority and
a primary concern. We continue to place
significant value on being as transparent
as possible with the performance
information that we collect to support
the decision making of consumers,
healthcare providers, researcher, and
other interested parties. After
consideration of the public comments
we received, and because since the
publication of the proposed rule, we
have determined a methodology to
exclude COVID–19 patients from the
CMS PSI 90 measure that will allow us
to calculate and publicly report valid
and reliable measure results, we are not
finalizing our proposal to suppress the
calculating and reporting of CMS PSI 90
measure results for the FY 2023 HAC
Reduction Program. Although we will
not calculate or report CMS PSI 90
measure results for use in the HAC
Reduction Program scoring calculations
for the program year, we will still
calculate and report the measure
displayed on the main pages of the Care
Compare tool hosted by HHS after
confidentially reporting these results to
hospitals via CMS PSI 90-specific HSRs
and a 30-day preview period. We will
continue to calculate and report
measure results for the five CDC NSHN
HAI measures. Further, we are finalizing
our proposal to suppress the CMS PSI
90 measure and the five CDC NHSN HAI
measures from the calculation of
measure scores and Total HAC Scores
for the FY 2023 program year, thereby
not penalizing any hospital under the
FY 2023 HAC Reduction Program. We
thank the commenters for their
comments and suggestions, which we
will take into consideration when
assessing potential future measure
reporting and scoring decisions.
(3) Proposal To Suppress CY 2021 CDC
NHSN HAI Measure Data From the FY
2024 HAC Reduction Program Year
As described in section V.J.2.b.(1). of
this final rule, we previously excluded
or suppressed all quarters of CY 2020
data for all the program measures from
the calculation of the Total HAC Score,
in part, because of concerns about the
national comparability of these data and
significant deviation in national
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
performance on the measure compared
to historical performance. The exclusion
and suppression of those data resulted
in a shortened applicable period for the
CMS PSI 90 measure for the FY 2024
HAC Reduction Program, specifically
the 18-month period of January 1, 2021
through June 30, 2022. The applicable
period for the CDC NHSN HAI measures
for the FY 2024 program year was
unaffected and remained as the 24month period of January 1, 2021,
through December 31, 2022.
As described previously, we continue
to be concerned about measure
performance and the national
comparability of such performance
during CY 2021. We therefore are
proposing to suppress CY 2021 CDC
NHSN HAI data from the FY 2024 HAC
Reduction Program under Measure
Suppression Factor 1, ‘‘significant
deviation in national performance on
the measure, which could be
significantly better or significantly
worse compared to historical
performance during the immediately
preceding program years’’; and the
Measure Suppression Factor 4 subfactor,
‘‘significant national or regional
shortages or rapid or unprecedented
changes in patient case volumes or case
mix.’’ Under current data collection
processes for the CDC NHSN HAI
measures, we are not able to risk-adjust
for or otherwise account for COVID–19
diagnoses and therefore must suppress
the CY 2021 data in order to account for
COVID–19 diagnoses in the CDC NHSN
HAI data. For the FY 2024 program year,
the resulting applicable period for CDC
NHSN HAI measures would be the 12month period of January 1, 2022, to
December 31, 2022.
To account for the impact of the
COVID–19 PHE on CY 2021 data in the
CMS PSI 90 measure, we are updating
the measure specifications to risk-adjust
for COVID–19 diagnoses, as described in
section V.J.3.c.(2). of this final rule,
beginning with the FY 2024 program
year. Our analysis of the COVID–19 PHE
49131
impacts on CY 2021 data found that the
decrease in volume continued in CY
2021 across nearly all component
Patient Safety Indicator (PSI) measures,
especially those related to surgical
procedures (for which the denominator
volume was 8 percent to 45 percent
lower in the first two quarters of CY
2021 than in the corresponding quarters
of CY 2019). Our analysis also found
that unadjusted rates continued to be
high in CY 2021 for patients with a
COVID–19 diagnosis compared to
patients without a COVID–19 diagnosis.
We refer readers to section V.J.3.c.(2).
for more information about COVID–19
impacts on the CMS PSI 90 measure.
For the CMS PSI 90 measure, the
applicable period remains unchanged
from January 1, 2021, through June 30,
2022.318 If finalized, these policies
would result in the following applicable
periods for FY 2023, FY 2024, and FY
2025 HAC Reduction Programs:
We invited public comments on this
proposal to suppress CY 2021 CDC
NHSN HAI Measure data from the FY
2024 HAC Reduction Program.
Comment: Many commenters
supported the proposal to suppress the
CY 2021 data from the five CDC NHSN
HAI measures for the FY 2024 program
year. A few commenters supported the
proposal due to the belief that
suppression of the CY 2021 data from
the five CDC NHSN HAI measures
would address significant deviation in
national performance due to continued
disruptions in the health care system
and care delivery process caused by the
COVID–19 PHE, including staffing and
supply shortages. A few commenters
supported the proposal due to the belief
that it would prevent hospitals from
being penalized and incentivized based
on measure data impacted by the
COVID–19 PHE. A few commenters
suggested to monitor the CDC NHSN
HAI measures for fluctuations in
performance due to the suppression of
the CY 2021 data and ensure continued
measure reliability.
Response: We thank commenters for
their support, and we agree that
suppressing the CY 2021 data from
these measures will ensure that
hospitals are not penalized for the
impacts of the COVID–19 PHE on the
healthcare delivery system and
subsequently the HAI measure data. We
will continue to monitor performance in
the CDC NHSN HAI measures and will
consider any such issues we identify for
future rulemaking.
Comment: Several commenters did
not support the suppression of the CY
2021 data from the five CDC NHSN HAI
measures for FY 2024. A few
commenters did not support the
proposal due to the belief that
suppressing the CY 2021 data from the
five CDC NHSN HAI measures would
prevent patients from assessing hospital
performance and making informed
decisions on where to receive care.
Response: We acknowledge the
commenters concern about suppression
of the CY 2021 data from the CDC
NHSN HAI measure for FY 2024.
However, we continue to be concerned
about measure performance and the
national comparability of such
performance during CY 2021. Under the
current data collection processes for the
CDC NHSN HAI measures, we are not
able to risk-adjust for or otherwise
account for COVID–19 diagnoses and
therefore must suppress the CY 2021
data in order to account for COVID–19
diagnoses in the CDC NHSN HAI data.
Further, we understand commenters’
concern regarding patients’ ability to
make informed decisions on where to
receive care. We continue to place
significant value on being transparent as
possible with the performance
318 For the FY 2025 HAC Reduction Program year,
there is no CY 2021 data included in the applicable
period for the HAI measures so the applicable
period remains unchanged and would be January 1,
2022, to December 31, 2023. For the CMS PSI 90
measure, the applicable period is July 1, 2021,
through June 30, 2023. As discussed, to account for
the impact of the COVID–19 PHE on CY 2021 CMS
PSI 90 measure data, we are updating the measure
specifications to risk-adjust for COVID–19
diagnoses.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00353
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.151
khammond on DSKJM1Z7X2PROD with RULES2
Annlicable Periods for FY 2023, FY 2024, and FY 2025 for the HAC Reduction Pro2ram
Current Applicable Periods that Resulted from ECE and Measure
Measure Set
Fiscal Year
Sunnression Policies
CDCNHSNHAI
Januarv 1, 2021, through December 31, 2021
FY2023
CMS PSI 90
July 1, 2019, through December 31, 2019; and January 1, 2021, through June
30,2021
Januarv 1, 2022, through December 31, 2022
CDCNHSNHAI
FY2024
Januarv 1, 2021, through June 30, 2022
CMS PSI 90
CDCNHSNHAI
Januarv 1, 2022, through December 31, 2023
FY2025
CMS PSI 90
July 1, 2021, through June 30, 2023
khammond on DSKJM1Z7X2PROD with RULES2
49132
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
information that we collect with caveats
of the performance information
impacted by the COVID–19 PHE. As
discussed in section V.J.2.b.(3) of this
final rule, for the FY 2024 program year,
we will continue to report the measure
data for CY 2021, both in confidential
reporting via HSR’s and public reporting
methods on Care Compare, as part of
program activities to ensure that
consumers and interested parties are
able to assess facility performance and
quality of care.
Comment: A commenter did not
support the proposal because of the
concern regarding hospital
accountability, asserting that hospitals
utilize the data to improve the patient
treatment delivery process and
eliminate preventable medical error. A
commenter believed that despite the
impacts from the COVID–19 PHE this
emergency only increases the need to
collect and measure the HAI measure
data. A commenter recommended to
continue to report CY 2021 data
including notations of mitigating
circumstances and data abnormalities.
Response: We thank commenters for
expressing concerns regarding holding
facilities accountable for the standard
and quality of care of services furnished
and the urgency of retaining this
requirement during the COVID–19 PHE.
We agree that the PHE underscored the
importance of measuring hospital
acquired infections to promote patient
safety. We believe that although the
collection, monitoring, and public
reporting of COVID–19 impacted data
with the appropriate caveats is
important, such data should not be used
to assess hospital performance and
utilized for payment determination or
penalties. Under current data collection
processes for the CDC NHSN HAI
measures, we are not able to risk-adjust
for or otherwise account for COVID–19
diagnoses, thus we proposed to
suppress the CY 2021 data in order to
account for COVID–19 diagnoses in the
CDC NHSN HAI data. We agree that the
HAI measure data should be
confidentially reported and made
available to facilities to support
improvement initiatives within the
patient delivery process, and we will
report the measure results, both in
confidential reporting via HSR’s and
public reporting methods on Care
Compare, to ensure hospitals are made
aware of the changes in performance
rates that we observe, as discussed in
section V.J.2.b.(2) of this final rule.
We thank the commenter for the
suggestion to report the CY 2021 data
including notations of data
abnormalities. As noted in the preamble
of the final rule, we intend to publicly
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
report suppressed data with appropriate
caveats that explain that performance
information has been impacted due to
the COVID–19 PHE.
Comment: A commenter questioned if
CMS intends to continue the policy of
not assessing payment penalties for the
FY 2024 program year. Several
commenters recommended that we
extend this payment and scoring policy
to the FY 2024 program year to account
for the continued impact of the COVID–
19 PHE. A few commenters
recommended that CMS provide
additional outreach and educational
materials to understand the data-related
changes and scoring impacts. Another
commenter recommended that CMS
provide HAI measure scores to hospitals
to allow for evaluation of hospital
performance.
Response: In the FY 2023 IPPS/LTCH
proposed rule (87 FR 28446 through
28450), we did not propose to not assess
payment penalties in the FY 2024
program year, but we understand
commenters’ concerns regarding the
impact of the COVID–19 PHE and will
ensure that we monitor and evaluate the
data to determine if further suppression
is warranted in the future. We want to
emphasize the long-term importance of
value-based care and incentivizing
quality care tied to payment. Therefore,
we note that our goal is to continue
resuming the use of measure data for the
purposes of scoring and payment
adjustment beginning with the FY 2024
program year. Additionally, we will
work to ensure that hospitals and
providers receive additional outreach
and educational material that clearly
communicates the updates and changes
to the HAC Reduction Program. Finally,
hospitals will be able to evaluate their
performance using the HAI measure
results that they receive in their
Hospital Specific Reports which we will
provide for the FY 2023 program year.
Comment: A commenter did not
support the proposal due to belief that
it would create the perception that the
government is not disclosing
information, reducing public trust and
transparency.
Response: We understand
commenters’ concerns regarding public
reporting of the HAI measure data to
promote public trust and transparency.
We continue to place significant value
on being transparent as possible with
the performance information that we
collect with caveats of the performance
information impacted by the COVID–19
PHE. Therefore, to address challenges in
national comparability of these data and
to retain transparency with consumers
and interested parties, we proposed to
suppress the CY 2021 data for program
PO 00000
Frm 00354
Fmt 4701
Sfmt 4700
calculations for payment purposes, but
continue to report, both in confidential
reporting via HSR’s and public reporting
methods on Care Compare, the five HAI
measures for the FY 2024 program year
with the resulting applicable 12-month
period of January 1, 2022 to December
31, 2022. Under the current data
collection processes for the CDC NHSN
HAI measures, we are not able to riskadjust for or otherwise account for
COVID–19 diagnoses and therefore we
proposed to suppress the CY 2021 data
in order to account for COVID–19
diagnoses and ensure that hospitals are
not unfairly scored or penalized through
payment due to the COVID–19 PHE.
Comment: Many commenters did not
support the proposal due to the belief
that the program would be heavily
reliant on CMS PSI 90 if the CY 2021
data from the CDC NHSN HAI measures
are suppressed. A few commenters
recommended to include some limited
data for the CDC NHSN HAI measures
or to suppress all the measures for FY
2024. A few commenters suggested that
CMS evaluate the impacts on hospital
performance if hospitals are only scored
on CMS PSI 90 for the FY 2024 program
year.
Response: We understand the
commenters’ concern about the program
being heavily reliant on CMS PSI 90 for
FY 2024 due to the proposed
suppression of the CY 2021 data for the
CDC NHSN HAI measure. However, we
disagree that FY 2024 program year
performance will be too heavily
dependent on the PSI 90 measures. We
intend to continue to report all five HAI
measures for the FY 2024 program year
with the resulting applicable 12-month
period of January 1, 2022 to December
31, 2022 and to report CMS PSI 90 risk
adjusted for COVID–19. We will
continue to monitor the impacts of these
policies and will consider any such
issues we identify for future rulemaking.
After consideration of the public
comments we received, we are
finalizing our proposal to suppress CY
2021 CDC NHSN HAI measure data
from the FY 2024 HAC Reduction
Program.
3. Measures for FY 2023 and
Subsequent Years
We refer readers to the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41472
through 41474) for more information
about how the HAC Reduction Program
supports our goal of bringing quality
measurement, transparency, and
improvement together with value-based
purchasing to the hospital inpatient care
setting through the Meaningful
Measures Framework.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
The HAC Reduction Program has
adopted six measures to date. In the FY
2014 IPPS/LTCH PPS final rule (78 FR
Short Name
CMSPSI90
CAUTI
CDI
CLABSI
Colon and Abdominal
Hysterectomy SSI
MRSA Bacteremia
b. Measure Removal Factors Policy
We refer readers to the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42404
through 42406) for information about
our measure removal and retention
factors for the HAC Reduction Program.
In this final rule, we did make any
measure removal and retention factor
policy changes.
c. Technical Measure Specification
Updates to the CMS PSI 90 Measure
khammond on DSKJM1Z7X2PROD with RULES2
LTCH PPS final rule (81 FR 57014), we
finalized the use of the CMS PSI 90
measure. These previously finalized
measures, with their full measure
names, are shown in this table.
HAC Reduction Program Measures for FY 2023 and Subsequent Years
Measure Name
CMS Patient Safety and Adverse Events Composite (CMS PSI 90)
CDC NHSN Catheter-associated Urinarv Tract Infection (CAUTI) Outcome Measure
CDC NHSN Facility-wide Inpatient Hospital-onset Clostridium difficile Infection (CDI)
Outcome Measure
CDC NHSN Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure
k<\merican College of Surgeons - Centers for Disease Control and Prevention (ACS-CDC)
aarmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure
CDC NHSN Facility-wide Inpatient Hospital-onset Methicillin-resistant Staphylococcus
'{lureus (MRSA) Bacteremia Outcome Measure
Technical specifications for the CMS
PSI 90 measure can be found on the
QualityNet website at https://
qualitynet.cms.gov/inpatient/measures/
psi/resources. Technical specifications
for the CDC NHSN HAI measures can be
found at CDC’s NHSN website at https://
www.cdc.gov/nhsn/acute-care-hospital/
index.html. Both websites provide
measure updates and other information
necessary to guide hospitals
participating in the collection of HAC
Reduction Program data.
In this final rule, we did not add or
remove any measures. However, we
discuss our proposal to suppress all of
the measures for the FY 2023 program
year, as discussed in section V.J.2.b.(2)
of the preamble of this final rule, and
our proposal to suppress CY 2021 CDC
NHSN HAI data from the FY 2024
program year, as discussed in section
V.J.2.b.(3). Of the preamble of this final
rule.
(1) Technical Measure Specification
Update to the Minimum Volume
Threshold for the CMS PSI 90 Measure
Beginning With the FY 2023 Program
Year
In the FY 2015 IPPS/LTCH PPS final
rule (79 FR 50100 through 50101), we
finalized a subregulatory process to
incorporate technical measure
specification updates into the measure
specifications we have adopted for the
VerDate Sep<11>2014
50717), we finalized the use of five CDC
NHSN HAI measures: (1) CAUTI; (2)
CDI; (3) CLABSI; (4) Colon and
Abdominal Hysterectomy SSI; and (5)
MRSA bacteremia. In the FY 2017 IPPS/
00:20 Aug 10, 2022
Jkt 256001
HAC Reduction Program. We stated our
belief that this policy adequately
balances our need to incorporate
updates to HAC Reduction Program
measures in the most expeditious
manner possible while preserving the
public’s ability to comment on updates
that so fundamentally change an
endorsed measure that it is no longer
the same measure that we originally
adopted.
Currently, the minimum volume
threshold for the CMS PSI 90 measure
requires hospitals to have three or more
eligible discharges for at least one
component indicator in order to receive
a CMS PSI 90 measure score for the
HAC Reduction Program (81 FR 57012).
Although the CMS PSI 90 measure
surpasses the accepted reliability
standard, based on an Intracluster
Correlation Coefficient (ICC) for
hospital-level reporting of at least 0.60
(in a standard 24-month performance
period, the CMS PSI 90 measure
demonstrated median reliability of
0.74), a small subset of hospitals have a
reliability close to zero for their CMS
PSI 90 composite score due to the
current minimum volume threshold for
the measure.
To address this subset of hospitals
with a CMS PSI 90 composite score with
reliability close to zero, we are
instituting a stricter minimum volume
threshold for the measure, which would
prevent those small hospitals from
receiving a CMS PSI 90 composite score.
Consistent with the current minimum
volume threshold policy, hospitals that
do not meet the threshold criteria would
not receive a measure result or,
subsequently, a measure score (that is.,
a Winsorized z-score) for the CMS PSI
90 measure and it would not factor into
the calculation of their Total HAC
Score. Accordingly, in this final rule, we
are announcing an increased minimum
PO 00000
Frm 00355
Fmt 4701
Sfmt 4700
NQF#
0531
0138
1717
0139
0753
1716
volume threshold for the CMS PSI 90
measure, under which hospitals would
be required to meet both of the
following criteria in order to receive a
CMS PSI 90 composite score:
• One or more component PSI
measure with at least 25 eligible
discharges; and
• Seven or more component PSI
measures with at least three eligible
discharges.
We note that this change to the CMS
PSI 90 minimum volume threshold
criteria will be applied to both the
version of the measure used in HAC
Reduction Program scoring calculations
as well as the version of the measure
displayed on the main pages of the Care
Compare tool hosted by the U.S.
Department of Health and Human
Services, currently available at https://
www.medicare.gov/care-compare, via
updates to the next version of the CMS
PSI 90 software. Additional information
regarding the technical specifications
for the CMS PSI 90 measure can be
found on the QualityNet website at
https://qualitynet.cms.gov/inpatient/
measures/psi/resources.
An analysis of the impact of this
threshold change on HAC Reduction
Program results indicates that it would
impact the scoring of a small number of
low-volume hospitals. As a result of this
threshold change, approximately five
percent of hospitals would no longer
receive a CMS PSI 90 composite score
(and, subsequently, a CMS PSI 90
measure score) and approximately half
of those hospitals, or 2.5 percent of all
hospitals, would no longer receive a
Total HAC Score. Accordingly, there
will be a decrease in the number of
hospitals in the worst-performing
quartile. We anticipate that the majority
of the hospitals no longer receiving a
Total HAC Score will be small hospitals
with fewer than 100 beds. Rural
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.152
A. Current Measures
49133
khammond on DSKJM1Z7X2PROD with RULES2
49134
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
hospitals, which tend to have lower
capacity, are also more impacted by the
change than urban hospitals. The
threshold change only impacts a small
number of hospitals in the HAC
Reduction Program while improving
overall measure reliability.
While we did not solicit comments on
this technical measure specification
update, we received some comments,
which are summarized in this final rule.
Comment: Several commenters
supported the technical measure
specification update to the minimum
volume threshold for CMS PSI 90
beginning with the FY 2023 HAC
Reduction Program. A commenter
expressed its belief that the update will
minimize the unintended consequence
of penalizing smaller or low volume
hospitals based on scores that that may
not demonstrate sufficient reliability.
Response: We thank commenters for
their support of the technical measure
specification update to increase the
minimum volume threshold for CMS
PSI 90 beginning with the FY 2023
program year.
Comment: A commenter expressed
concern that the updated minimum
volume threshold might omit many
hospitals from being rated on CMS PSI
90 and would remove these hospitals
from accountability.
Response: We appreciate commenter’s
position, however, as discussed in the
FY 2023 IPPS/LTCH PPS proposed rule
(87 FR 28451) the impact analysis of the
threshold change indicated that it
would impact the scoring of a small
number of low-volume hospitals who
have a CMS PSI 90 measure reliability
close to zero. Approximately just five
percent of hospitals included in the
HAC Reduction Program would no
longer receive a CMS PSI 90 composite
score (and, subsequently, a CMS PSI 90
measure score) and approximately just
2.5 percent of all hospitals would no
longer receive a Total HAC Score. It
should be noted CMS PSI 90 is
unreliable for these very low-volume
hospitals, as their computed scores from
prior program years are tightly clustered
around one (that is, the mean value for
all hospitals).
Comment: A commenter suggested
that we obtain all-payer claims to drive
up the denominators, increase
reliability, and reduce the number of
hospitals who do not qualify for a score.
Another commenter recommended that
we examine the ICC at minimum
threshold rather than at the median and
set the minimum volume at a number
that will produce an ICC of 0.6 or
higher.
Response: We appreciate commenters’
recommendations for additional
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
refinements to the technical measure
specification update to the minimum
volume threshold for CMS PSI 90
beginning with the FY 2023 program
year. We will consider the feedback we
received for future rulemaking.
Comment: A commenter
recommended that since the update to
the minimum volume threshold would
yield approximately 5 percent of
hospitals no longer receiving a CMS PSI
90 score and half of those hospitals
would no longer receive a Total HAC
Score, CMS should reduce the number
of hospitals penalized by a similar
factor. The commenter also
recommended given these changes to
the measure specifications, CMS PSI 90
should be suppressed for the FY 2024
program year to allow time to evaluate
the impacts of these specification
updates.
Response: We appreciate the
suggestion to reduce the number of
hospitals penalized for the FY 2024
HAC Reduction Program. We note that
the HAC Reduction Program is
statutorily required to penalize the
worst-performing quartile (that is, the
worst-performing 25 percent) of
hospitals based on their Total HAC
Score in a given program year. Hospitals
that do not receive a Total HAC Score
are not included in the distribution of
hospitals used to determine the 75th
percentile. Therefore, a decrease in the
number of hospitals receiving a Total
HAC Score will also lead to a decrease
in the number of hospitals in the worstperforming quartile. We note that we
did acknowledge this impact in the FY
2023 IPPS/LTCH proposed rule where
we stated that this increase to the
minimum volume threshold for CMS
PSI 90 would likely yield a reduction in
the number of hospitals in the worstperforming quartile for the HAC
Reduction Program (87 FR 28451).
We thank the commenter for their
suggestion to suppress CMS PSI 90 for
the FY 2024 program year. Impact
analyses have shown that this update to
CMS PSI 90 measure specifications
improves overall measure reliability,
which in turn improves comparison
between hospitals’ CMS PSI 90 scores
for HAC Reduction Program scoring
purposes. Because this measure
specification update improves the
overall scoring process, we will not
suppress CMS PSI 90 for the FY 2024
program year.
PO 00000
Frm 00356
Fmt 4701
Sfmt 4700
(2) Technical Measure Specification
Update to Risk-Adjust for COVID–19
Diagnoses in the CMS PSI 90 Measure
Beginning With the FY 2024 HAC
Reduction Program Year
We refer readers to the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45305) for
previous analysis on the impact of the
COVID–19 PHE on the CMS PSI 90
measure. Our analysis found that the
decrease in volume continued in CY
2021 across all component PSI
measures, especially those related to
surgical procedures for which the
denominator volume was 8 percent to
45 percent lower in the first two
quarters of CY 2021 than in the
corresponding quarters of CY 2019. Our
analysis also found that unadjusted
rates continued to be high in CY 2021
for patients with a COVID–19 diagnosis
compared to patients without a COVID–
19 diagnosis, across most of the 10
component measures in CMS PSI 90.
However, PSI 90 component rates
among patients without COVID–19 were
virtually unchanged through the
COVID–19 PHE. CMS has found that
adjusting for COVID–19 at the patient
level entirely removes the incremental
risk associated with this diagnosis. After
risk-adjustment for COVID–19, PSI
component rates appear consistently flat
across the first two quarters of 2021.
In the FY 2015 IPPS/LTCH PPS final
rule (79 FR 50100 through 50101), we
finalized a subregulatory process to
make nonsubstantive updates to
measures used for the HAC Reduction
Program. To address the impact of the
COVID–19 PHE on the CMS PSI 90
measure, we are announcing a technical
update to the CMS PSI 90 software to
include COVID–19 diagnosis as a riskadjustment parameter for the FY 2024
program year and subsequent years.
While we did not solicit comments on
this technical measure specification
update, we received some comments,
which are summarized in this final rule.
Comment: Many commenters
supported the technical measure
specification update to risk-adjust for
COVID–19 diagnosis in CMS PSI 90
beginning with the FY 2024 program
year. Several commenters believed that
the update will help address the
lingering impacts of the COVID–19 PHE.
Response: We thank commenters for
their support of the technical measure
specification update to risk-adjust for
COVID–19 diagnosis present on
admission in CMS PSI 90 beginning
with the FY 2024 program year.
Comment: A commenter
recommended that CMS continue to
monitor whether the PHE would
necessitate additional measure changes.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Another commenter recommended that
CMS review model performance before
reinstituting payment penalties.
Response: We agree with commenters’
recommendations regarding continued
monitoring of the effects of the COVID–
19 PHE. We intend to work with
measure developers to refine measure
specifications as necessary and feasible
for future rulemaking. We appreciate the
commenter’s feedback regarding
reinstituting payment penalties under
the HAC Reduction Program. As noted
in section V.J.2.b.(2), we understand
commenters’ concerns regarding the
impact of the COVID–19 PHE and will
ensure that we monitor and evaluate the
data to determine if further suppression
is warranted in the future. Though, we
note that our goal is to continue
resuming the use of measure data for the
purposes of scoring and payment
adjustment beginning with the FY 2024
HACRP Program. Any proposal to
suppress payment penalties for
additional program years would be
made through future notice-andcomment rulemaking.
Comment: A commenter does not
support the technical measure
specification update to risk-adjust for
COVID–19 diagnosis in CMS PSI 90
beginning with the FY 2024 program
year and instead recommended that
patients diagnosed with COVID–19 be
included in measurement of preventable
harms.
Response: We appreciate the
commenter’s concern, however, as
discussed in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45305) where we
conducted an analysis on the impacts of
the COVID–19 PHE on CMS PSI 90, we
found that unadjusted rates continued
to be high in CY 2021 for patients with
a COVID–19 diagnosis compared to
patients without a COVID–19 diagnosis,
across most of the 10 component
measures in CMS PSI 90. In order to
address the impact of the COVID–19
PHE on CMS PSI 90, we are
implementing the technical measure
specification update to risk adjusts for
the COVID–19 to mitigate the impacts
on measure results and ensure that
hospitals are not unfairly scored or
penalized through payment due to the
COVID–19 PHE.
Comment: A few commenters
recommended that CMS release
additional details on the CMS PSI 90
risk-adjustment methodology like
whether risk-adjustment of COVID–19
diagnosis pertains to a patient’s primary
or secondary diagnosis. Several
commenters recommended that CMS
further assess CMS PSI 90 COVID–19
risk adjustment methodology and
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
convene an NQF Technical Expert Panel
to evaluate the methodology.
Response: We seek to clarify that riskadjustment details are released to the
public when each version of the
software is completed and made
available. The first software version that
would incorporate COVID–19 riskadjustment would be version 13. The
Risk Adjustment methodology report
will be posted on the QualityNet site for
CMS PSI 90 Resources at https://
qualitynet.cms.gov/inpatient/measures/
psi/resources. We appreciate
commenters’ recommendations
regarding the technical measure
specification update to risk-adjust for
COVID–19 diagnosis present on
admission in CMS PSI 90 beginning
with the FY 2024 program year. We note
that the update to the risk adjustment
methodology is part of the routine
annual process to update CMS PSI 90.
As part of that process, the measure
developer will submit an annual update
to NQF that includes updates to the risk
adjustment model.319
Comment: A few commenters
recommended that CMS implement the
COVID–19 risk-adjustment as well as
suppress CMS PSI 90 for the first two
quarters of CY 2021 of the FY 2024
program year due to the impact of the
COVID–19 PHE on hospitals.
Response: We appreciate the
commenter’s recommendations to risk
adjust for COVID–19 and suppress CMS
PSI 90 in FY 2024. We will monitor
performance in CMS PSI 90 and will
consider any issues we identify for
future rulemaking.
Comment: A commenter suggested
that CMS consider suppression of CMS
PSI 90 for the FY 2024 program year
based on the evaluation of the technical
update impacts as well as impacts from
the COVID–19 PHE.
Response: We appreciate the
commenter’s recommendations to
suppress CMS PSI 90 for the FY 2024
program year based on evaluation of the
CMS PSI 90 risk adjustment for COVID–
19. We will monitor performance in
CMS PSI 90 and will consider any
issues we identify for future rulemaking.
Comment: A few commenters
expressed concern that CMS PSI 90
COVID–19 risk adjustment would
reduce the amount of attention and
monitoring for patients diagnosed with
COVID–19. A commenter recommended
that CMS not risk adjust for COVID–19
to address this concern.
319 National Quality Forum. (2022). Maintenance
of NQF-Endorsed Performance Measures. Available
at: https://www.qualityforum.org/measuring_
performance/endorsed_performance_measures_
maintenance.aspx.
PO 00000
Frm 00357
Fmt 4701
Sfmt 4700
49135
Response: We appreciate the
commenters concern that CMS PSI 90
COVID–19 risk adjustment would
reduce the amount of attention and
monitoring for patients diagnosed with
COVID–19. However, in the FY 2023
IPPS/LTCH proposed rule, we stated
that our analysis of CMS PSI 90 found
that unadjusted rates continued to be
high in CY 2021 for patients with a
COVID–19 diagnosis compared to
patients without a COVID–19 diagnosis,
across most of the 10 component
measures. We note that rates for the
component PSI 90 measures among
patients without COVID–19 were
virtually unchanged through the
COVID–19 PHE. We have found that
adjusting for COVID–19 at the patient
level entirely removes the incremental
risk associated with this diagnosis
(87FR 28450). In order to address the
impact of the COVID–19 PHE on CMS
PSI 90, we are implementing this
technical measure specification update
to ensure that hospitals are not unfairly
scored or penalized through payment
due to the COVID–19 PHE.
Additionally, due to the potentially
geographically disparate impacts of the
COVID–19 PHE, we believe that riskadjusting CMS PSI 90 is appropriate to
ensure hospitals are not unevenly
penalized due to their location.
Comment: A commenter
recommended that CMS only
confidentially report, without publicly
reporting, CMS PSI 90 due to the
impacts of COVID–19 for the FY 2024
program year.
Response: We appreciate the
commenter’s recommendation to not
publicly report data for CMS PSI 90 in
the FY 2024 program year. To account
for the impact of the COVID–19 PHE on
CY 2021 data in CMS PSI 90, however,
we are updating the measure
specifications to risk-adjust for COVID–
19 diagnoses present on admission. As
discussed in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28450), our
analysis of the COVID–19 PHE impacts
on CY 2021 data found that the decrease
in volume continued in CY 2021 across
nearly all component PSI measures,
especially those related to surgical
procedures (for which the denominator
volume was 8 percent to 45 percent
lower in the first two quarters of CY
2021 than in the corresponding quarters
of CY 2019). Our analysis also found
that unadjusted rates continued to be
high in CY 2021 for patients with a
COVID–19 diagnosis compared to
patients without a COVID–19 diagnosis.
We believe that modifying our proposal
to publicly report the CMS PSI 90
measure data for the FY 2023 HAC
Reduction Program and continuing to
E:\FR\FM\10AUR2.SGM
10AUR2
49136
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
publicly report measure data for the FY
2024 HAC Reduction Program will
maintain transparency and support
consumers in making informed
decisions on where to receive care.
Comment: A commenter expressed
concern that the modified PSI 90
measure and the partially suppressed
HAI measure will not allow for
equitable and meaningful Total HAC
Scores for FY 2024.
Response: We appreciate the
commenters’ concern about the
meaningfulness of the Total HAC Score
for FY 2024 due to the proposed
measure suppression and technical
measure specification updates. As
discussed in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28450), we
continue to be concerned about measure
performance and the national
comparability of such performance
during the CY 2021 (87 FR 28450). We
believe national comparability of
hospital performance is very significant,
so we are pursuing suppression of the
CY 2021 data of the CDC NHSN HAI
measures and risk adjustment for
COVID–19 diagnosis in CMS PSI 90 to
account for COVID–19 diagnosis in the
CY 2021.
Comment: A commenter suggested
that the COVID–19 risk adjustment may
not accurately capture COVID–19
diagnosis due to at-home testing and
absence of diagnosis codes.
Response: We acknowledge the
commenter’s concern about the
accuracy of risk adjusting for COVID–19
in CMS PSI 90. Although COVID–19
diagnoses may be under-reported to
public health authorities due to at-home
testing, this concern does not apply to
inpatient hospitals that routinely repeat
at-home test results.
d. HAC Reduction Program Requests for
Information
khammond on DSKJM1Z7X2PROD with RULES2
(1) Digital CDC NHSN Measures
We refer readers to section IX.E.9.a. of
this final rule, for a discussion of the
comments received regarding this crossprogram request for information on the
potential future adoption of two digital
NHSN measures, the NHSN Healthcareassociated Clostridioides difficile
Infection Outcome Measure and the
NHSN Hospital-Onset Bacteremia &
Fungemia Outcome Measure, into the
Hospital IQR Program, PCHQR Program,
and the LTCH QRP. In addition, we
requested information on the potential
inclusion of these digital CDC NHSN
measures in the HAC Reduction
Program. This request for information
supports our goal of moving fully to
digital quality measurement in CMS
quality reporting and value-based
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
purchasing programs, including the
HAC Reduction Program.
(2) Overarching Principles for
Measuring Healthcare Quality
Disparities Across CMS Quality
Programs
We refer readers to section IX.B. of
this final rule where we sought input on
overarching principles in measuring
healthcare quality disparities in hospital
quality and value-based purchasing
programs.
4. Proposal To Update the CDC NHSN
HAI Data Submission Requirements for
Newly Opened Hospitals Beginning in
the FY 2023 HAC Reduction Program
Year
In the FY 2017 IPPS/LTCH PPS final
rule (81 FR 57013), we finalized CDC
NHSN HAI data submission
requirements for newly-opened
hospitals under the HAC Reduction
Program that referred to the date that a
hospital filed a notice of participation
(NOP) with the Hospital IQR Program.
At the time, the HAC Reduction
Program obtained measure results that
hospitals submitted to the CDC NHSN
from the Hospital IQR Program.
However, in the FY 2019 IPPS/LTCH
PPS final rule (83 FR 41545 through
41553), we transferred our collection of
the CDC NHSN HAI measures from the
Hospital IQR Program to the HAC
Reduction Program beginning with CY
2020 data. Given the transition from the
Hospital IQR Program, the NOP
requirements noted in the FY 2017
IPPS/LTCH PPS final rule do not apply.
We proposed to update the definition
of ‘‘newly-opened hospitals’’ for the
CDC NHSN HAI measures to include
hospitals with a Medicare Accept Date
within the last 12 months of the
performance period.320 Under the HAC
Reduction Program scoring
methodology, hospitals that are defined
as newly-opened hospitals for the CDC
NHSN HAI measures would not receive
a measure score for any of the CDC
NHSN HAI measures.
The number of hospitals impacted by
this change in criteria is small, less than
one-quarter percent of hospitals.
Hospitals with a Medicare Accept Date
between the 12th and the 6th month
before the end of the HAI performance
period (January 1, 2021 to June 30, 2021
for the FY 2023 program year) do not
meet the current criteria for newlyopened hospitals for the CDC NHSN
HAI measures, but would meet the
320 Because the CMS PSI 90 measure requires at
least 12 months of measure data (81 FR 50712),
hospitals that open during the final 12 months of
the performance period would also not receive a
CMS PSI 90 measure score.
PO 00000
Frm 00358
Fmt 4701
Sfmt 4700
updated criteria.321 In addition, all of
these hospitals do not have 12 months
of CMS PSI 90 data and because of this
already do not receive a measure score
for that measure. Therefore, all
impacted hospitals would not receive a
Total HAC Score for the program year
and could not be subject to the one
percent payment reduction. As per the
measure suppression policy discussed
in section V.J.2.b.(2). we proposed to
suppress all six measures in the
program for the FY 2023 program year,
so no hospitals will be impacted by this
change for the FY 2023 program year.
An analysis of the number of
hospitals not meeting the current
definition of ‘‘new hospitals’’ that
would meet the criteria under this new
proposed definition indicate that 0.22
percent of hospitals would have been
affected by this definition change in the
FY 2021 program year and 0.09 percent
in the FY 2020 program year.
We invited public comments on this
proposal to update the newly-opened
hospital definition for CDC NHSN HAI
measures beginning in the FY 2023
program year.
Comment: A commenter supported
the proposal to update the CDC NHSN
HAI data submission requirements for
newly opened hospitals beginning in
the FY 2023 HAC Reduction Program
and recommended that CMS ensure the
proposal does not increase hospital
compliance burden.
Response: We thank the commenter
for its support and note that the
proposal does not affect requirements
for data submission, but only affects
which hospitals receive a measure
score.
After consideration of the public
comments we received, we are
finalizing our proposal to update the
‘‘newly-opened hospital’’ definition for
CDC NHSN HAI measures beginning in
the FY 2023 program year.
5. HAC Reduction Program Scoring
Methodology and Scoring Review and
Corrections Period
In the FY 2019 IPPS/LTCH PPS final
rule (83 FR 41484 through 41489), we
adopted the Equal Measure Weights
approach to scoring and clarified the
Scoring Calculations Review and
321 There is a small subset of hospitals with a
Medicare Accept Date between the 6th and 9th
month before the end of the HAI performance
period (April 1, 2021, to June 30, 2021 for the FY
2023 program year) and a Hospital IQR Program
Notice of Participation Date during the last quarter
of the HAI performance period (before October 1,
2021 or after December 31, 2021 for the FY 2023
program year), that are also currently defined as
newly-opened hospitals. These hospitals’ newlyopened status would not be impacted by this
criteria change.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Correction Period (83 FR 41484) for the
HAC Reduction Program. Hospitals
must register for a QualityNet website’s
secure portal account in order to access
their annual hospital-specific reports. In
this final rule we are not making any
changes to the Scoring Calculations
Review and Correction Period process.
We note that in the FY 2023 IPPS/
LTCH PPS proposed rule, we proposed
to temporarily suppress all measures
from the FY 2023 HAC Reduction
Program. We proposed to calculate the
measure results for the five CDC NHSN
HAI measures for the FY 2023 HAC
Reduction Program, but to not use those
measure results to calculate measure
scores (that is, Winsorized z-scores) for
any of the measures because of our
concerns regarding the comparability of
measure results. Additionally, we
proposed to not calculate measure
results for the CMS PSI 90 measure nor
publicly report the measure on the Care
Compare tool hosted by Health and
Human Services and the Provider Data
Catalog. We also proposed that all
hospitals would receive a Total HAC
Score of zero, and no hospitals would
receive a penalty for FY 2023. We
intend to resume the previously adopted
HAC Reduction Program scoring
methodology in FY 2024 (with the
proposed suppression of CY 2021 CDC
NHSN HAI data as discussed in section
V.J.2.b.(3).) and for subsequent years. In
section V.J.2.b.(2)., we invited public
comment on the proposal to temporarily
suppress all measures from the FY 2023
HAC Reduction Program.
6. Validation of HAC Reduction
Program Data
In the FY 2019 IPPS/LTCH PPS final
rule (83 FR 41478 through 41484), we
adopted processes to validate the CDC
NHSN HAI measure data used in the
HAC Reduction Program, because the
Hospital IQR Program finalized its
proposals to remove CDC NHSN HAI
measures from its program. In the FY
2020 IPPS/LTCH PPS final rule (84 FR
42406 through 42410), we provided
additional clarification to the validation
selection and scoring methodology. We
also refer readers to the QualityNet
website for more information regarding
chart-abstracted data validation of
measures. In the FY 2020 IPPS/LTCH
PPS final rule (85 FR 58862 through
58865), we finalized our policy to align
the HAC Reduction Program validation
process with that of the Hospital IQR
Program. Specifically, we aligned the
hospital selection and submission
quarters beginning with CY 2021 data
for the FY 2024 Hospital IQR and HAC
Reduction Programs validation so that
we only require one pool of hospitals to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
49137
submit data for validation. Additionally,
we finalized a policy requiring hospitals
to submit digital files when submitting
medical records for validation of HAC
Reduction Program measures, for the FY
2024 program year and subsequent
years.
In the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58862 through 58865), we
finalized our policy that for the FY 2024
program year and subsequent years, we
will use measure data from all of CY
2021 for both the HAC Reduction
Program and the Hospital IQR Program,
which must be reported using the
validation schedule posted on the
QualityNet Secure Portal (also referred
to as the Hospital Quality Reporting
(HQR) System.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we proposed to suppress
all measures from the FY 2023 program
and CY 2021 CDC NHSN HAI data from
the FY 2024 HAC Reduction Program,
respectively. As discussed in those
sections, hospitals are still required to
submit such data and such data will be
used for validation purposes. If
hospitals do not submit measure data
for validation during the FY 2024
program year, then those hospitals will
automatically receive the maximum
Winsorized z-score for the measure in
the FY 2024 program year payment
calculation. We therefore are not making
any changes to the policies regarding
measure validation in this final rule.
Locations (NML) policy. The CDC has
confirmed that the NML exemption does
not indicate that a hospital does not
need to report data, and that hospitals
requesting to be exempt from reporting
for CMS quality programs including the
HAC Reduction Program, should submit
an IPPS Measure Exception Form on the
QualityNet website at https://
qualitynet.cms.gov/files/
5e3459aa152a7d001f93d36c?
filename=IPPS_
MeasureExceptionForm_CY2020.pdf.
Therefore, we want to clarify that
beginning in FY 2023 and subsequent
years, the NML designation will no
longer apply, and hospitals will be
required to appropriately submit data to
the NHSN or, if hospitals do not have
the applicable locations for the CLABSI
and CAUTI measures, the hospital must
submit an IPPS Measure Exception
Form to be exempt from CLABSI and
CAUTI reporting for CMS programs. If
the hospitals do not submit an IPPS
Measure Exception Form and continue
to not submit data to the NHSN, these
hospitals would receive the maximum
measure score (that is., Winsorized zscore) under the HAC Reduction
Program for not reporting data. In the
FY 2020 IPPS/LTCH PPS final rule, we
instructed hospitals that do not have
adequate locations for CLABSI or
CAUTI reporting to submit the IPPS
Measure Exception Form to the HAC
Reduction Program beginning on
January 1, 2020 (84 FR 42406), and the
7. Clarification of the Removal of the
removal of the NML policy has
‘‘No Mapped Locations’’ Policy
previously been communicated in the
Beginning With the FY 2023 Program
FY 2022 HAC Reduction Program
Year
Frequently Asked Questions 325 and the
Under the HAC Reduction Program,
FY 2022 HAC Reduction Program HSR
hospitals have historically been able to
User Guide.326 Additionally, because
receive a ‘‘no mapped locations (NML)’’ NML only applies to a small subset of
exemption 322 for the CLABSI and
hospitals, we plan to execute targeted
CAUTI measures.323 This exemption has outreach via email to those hospitals
been applied when hospitals do not
that had received the exception in the
map an applicable ward (that is,
past two program years notifying them
Intensive Care Units (ICUs), surgical,
of the removal of the NML policy.
medical, and medical-surgical wards) in
For more details on the NML
the NHSN system, do not submit data
designation and policy, we refer readers
for the measures, and do not submit an
to the FY 2022 Hospital Specific Report
IPPS Measure Exception Form.324
(HSR) User Guide located on QualityNet
In this final rule we would like to
website at https://qualitynet.cms.gov/
clarify the removal of the No Mapped
files/61152cf0a248cb001efce449?
filename=FY_2022_HACRP_HSR_User_
322 Prior to FY 2018, the program used the term
Guide.pdf and the FY 2022 HAC
No Facilities Waiver for this same situation. Centers
Reduction Program Frequently Asked
for Medicare & Medicaid Services. (2017). HACRP
Questions website at https://
HAI Webinar Slides Final. Available at: https://
www.qualityreportingcenter.com/globalassets/
migrated-pdf/vbp-iqr-hacrp_hai_webinar_slides_
vfinal508.pdf.
323 Centers for Medicare and Medicaid Services.
(2021). FY 2022 HACRP HSR User Guide. Available
at: https://qualitynet.cms.gov/files/
61152cf0a248cb001efce449?filename=FY_2022_
HACRP_HSR_User_Guide.pdf.
324 The valid OMB control number for the IPPS
Measure Exception Form is 0938–1022.
PO 00000
Frm 00359
Fmt 4701
Sfmt 4700
325 Centers for Medicare and Medicaid Services.
(2021). FY 2022 HACRP FAQs. Available at: https://
qualitynet.cms.gov/files/61152d1252b92
f00229e9717?filename=FY_2022_HACRP_FAQ.pdf.
326 Centers for Medicare and Medicaid Services.
(2021). FY 2022 HACRP HSR User Guide. Available
at: https://qualitynet.cms.gov/files/
61152cf0a248cb001efce449?filename=FY_2022_
HACRP_HSR_User_Guide.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
49138
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
qualitynet.cms.gov/files/
61152d1252b92f00229e9717?
filename=FY_2022_HACRP_FAQ.pdf.
While we did not solicit comments on
this clarification, we received some
comments, which are summarized later
in this section.
Comment: A commenter supported
the clarification of the removal of the No
Mapped Locations policy and
recommended that targeted outreach to
affected hospitals be expanded beyond
email.
Response: We thank the commenter
for its support for the removal of the No
Mapped Locations policy and we will
take into consideration the
recommendation to expand targeted
outreach to additional modalities
beyond email correspondence.
Comment: A commenter did not
support the requirement for hospitals to
submit an IPPS Measure Exception
Form to be exempt from CLABSI and
CAUTI reporting for our programs when
they have no applicable locations.
Response: We appreciate the
commenter’s concern; however, we
believe that this requirement is
necessary to maintain alignment with
the CDC’s recommendations as well as
ensure clear and transparent hospital
reporting.
8. Extraordinary Circumstances
Exception (ECE) Policy for the HAC
Reduction Program
We refer readers to the FY 2016 IPPS/
LTCH PPS final rule (80 FR 49579
through 49581) and the FY 2018 IPPS/
LTCH PPS final rule (82 FR 38276
through 38277) for discussion of our
Extraordinary Circumstances Exception
(ECE) policy. In the FY 2016 IPPS/LTCH
PPS final rule (80 FR 49579 through
49581), we adopted an ECE policy for
the HAC Reduction Program, which
recognized that there may be periods of
time during which a hospital is not able
to submit data in an accurate or timely
fashion due to an extraordinary
circumstance beyond its control. When
adopting this policy, we noted that we
considered the feasibility and
implications of excluding data for
certain measures for a limited period of
time from the calculations for a
hospital’s measure results or Total HAC
Score for the applicable performance
period. By minimizing the data
excluded from the program, the policy
enabled affected hospitals to continue to
participate in the HAC Reduction
Program for a given fiscal year if they
otherwise continued to meet applicable
measure minimum threshold
requirements. We expressed the belief
that this approach would help alleviate
the burden for a hospital that might be
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
adversely impacted by a natural disaster
or other extraordinary circumstance
beyond its control, while enabling the
hospital to continue to participate in the
HAC Reduction Program. In developing
this policy, we considered a policy and
process similar to that for the Hospital
IQR Program, as finalized in the FY
2012 IPPS/LTCH PPS final rule (76 FR
51651), modified by the FY 2014 IPPS/
LTCH PPS final rule (78 FR 50836)
(designation of a non-CEO hospital
contact), and further modified in the FY
2015 IPPS/LTCH PPS final rule (79 FR
50277) (amended § 412.40(c)(2)) to refer
to ‘‘extension or exemption’’ instead of
the former ‘‘extension or waiver’’). We
also considered how best to align an
extraordinary circumstance exception
policy for the HAC Reduction Program
with existing extraordinary
circumstance exception policies for
other IPPS quality reporting and
payment programs, such as the Hospital
Value-Based Purchasing (VBP) Program,
to the extent feasible. In the FY 2018
IPPS/LTCH PPS final rule (82 FR 38276
through 38277), we modified the
requirements for the HAC Reduction
Program ECE policy to further align
with the processes used by other quality
reporting and value-based purchasing
programs for requesting an exception
from program reporting due to an
extraordinary circumstance not within a
provider’s control.
In response to the COVID–19 PHE, we
announced relief for clinicians,
providers, hospitals, and facilities
participating in Medicare quality
reporting and value-based purchasing
programs. On September 2, 2020, we
published the interim final rule with
comment period (IFC), ‘‘Medicare and
Medicaid Programs, Clinical Laboratory
Improvement Amendments (CLIA), and
Patient Protection and Affordable Care
Act; Additional Policy and Regulatory
Revisions in Response to the COVID–19
Public Health Emergency’’ (85 FR
54820). The IFC updated the ECE we
granted in response to the COVID–19
PHE, for the HAC Reduction Program
and several other quality reporting
programs (85 FR 54827 through 54838).
In the IFC, we updated the previously
announced application of our ECE
policy for the HAC Reduction Program
(85 FR 54830 through 54832) to the
COVID–19 PHE to exclude any CDC
NHSN HAI data submitted regarding
care provided during the first and
second quarters of CY 2020 from our
calculation of performance for FY 2022
and FY 2023.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45308 through 45310), we
clarified our ECE policy to highlight that
an ECE granted under the HAC
PO 00000
Frm 00360
Fmt 4701
Sfmt 4700
Reduction Program may allow an
exception from quality data reporting
requirements and may grant a request to
exclude any data submitted (whether
submitted for claims purposes or to the
CDC NHSN) from the calculation of a
hospital’s measure results or Total HAC
Score for the applicable period,
depending on the exact circumstances
under which the request was made.
Finally, in the FY 2022 IPPS/LTCH
PPS final rule we clarified that,
although an approved ECE for the HAC
Reduction Program would exclude
excepted data and grant an exception
with respect to data reporting
requirements for the period during
which performance or ability to submit
data was impacted or both, a hospital
would still be evaluated for the
remainder of the applicable period
during which performance and ability to
submit data was not impacted (to the
extent that enough data are available to
ensure that the calculation is
statistically sound) or both. We clarified
that an approved ECE for the HAC
Reduction Program does not exempt
hospitals from payment reductions
under the HAC Reduction Program (86
FR 45309 through 45310).
We have not made any changes to our
previously finalized ECE Policy in this
final rule.
K. Rural Community Hospital
Demonstration Program
1. Introduction
The Rural Community Hospital
Demonstration was originally
authorized by section 410A of the
Medicare Prescription Drug,
Improvement, and Modernization Act of
2003 (MMA) (Pub. L. 108–173). The
demonstration has been extended three
times since the original 5-year period
mandated by the MMA, each time for an
additional 5 years. These extensions
were authorized by sections 3123 and
10313 of the Affordable Care Act (ACA)
(Pub. L. 111–148), section 15003 of the
21st Century Cures Act (Pub. L. 114–
255) (Cures Act) enacted in 2016, and
most recently, by section 128 of the
Consolidated Appropriations Act of
2021 (Pub. L. 116–260). In this final
rule, we follow upon the FY 2023 IPPS
proposed rule, and summarize the status
of the demonstration program, and the
ongoing methodologies for
implementation and budget neutrality.
We are also stating the finalized
amount to be applied to the national
IPPS payment rates to account for the
costs of the demonstration in FY 2023,
and, in addition, the reconciled amount
of demonstration costs for FY 2017, the
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
most recent year for which finalized
cost reports have become available.
khammond on DSKJM1Z7X2PROD with RULES2
2. Background
Section 410A(a) of Public Law 108–
173 required the Secretary to establish
a demonstration program to test the
feasibility and advisability of
establishing rural community hospitals
to furnish covered inpatient hospital
services to Medicare beneficiaries. The
demonstration pays rural community
hospitals under a reasonable cost-based
methodology for Medicare payment
purposes for covered inpatient hospital
services furnished to Medicare
beneficiaries. A rural community
hospital, as defined in section
410A(f)(1), is a hospital that—
• Is located in a rural area (as defined
in section 1886(d)(2)(D) of the Act) or is
treated as being located in a rural area
under section 1886(d)(8)(E) of the Act;
• Has fewer than 51 beds (excluding
beds in a distinct part psychiatric or
rehabilitation unit) as reported in its
most recent cost report;
• Provides 24-hour emergency care
services; and
• Is not designated or eligible for
designation as a CAH under section
1820 of the Act.
3. Policies for Implementing the 5-Year
Extension Period Authorized by Public
Law 116–260
Our policy for implementing the 5year extension period authorized by
Public Law 116–260 (the Consolidated
Appropriations Act of 2021) follows
upon that for the previous extensions,
under the ACA (Pub. L. 111–148) and
the Cures Act (Pub. L.114–255).
Section 410A of Public Law 108–173
(MMA) initially required a 5-year period
of performance. Subsequently, sections
3123 and 10313 of Pub. L. 111–148
(ACA) required the Secretary to conduct
the demonstration program for an
additional 5-year period, to begin on the
date immediately following the last day
of the initial 5-year period. Public Law
111–148 required the Secretary to
provide for the continued participation
of rural community hospitals in the
demonstration program during this 5year extension period, in the case of a
rural community hospital participating
in the demonstration program as of the
last day of the initial 5-year period,
unless the hospital made an election to
discontinue participation. In addition,
Public Law 111–148 limited the number
of hospitals participating to no more
than 30.
Section 15003 of the Cures Act
required the Secretary to conduct the
demonstration for a 10-year extension
period (in place of the 5-year extension
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
period required by Public Law 111–148
(ACA)). Specifically, section 15003 of
Public Law 114–255 (Cures Act)
amended section 410A(g)(4) of Public
Law 108–173 (MMA) to require that, for
hospitals participating in the
demonstration as of the last day of the
initial 5-year period, the Secretary
would provide for continued
participation of such rural community
hospitals in the demonstration during
the 10-year extension period, unless the
hospital made an election, in such form
and manner as the Secretary may
specify, to discontinue participation. In
addition, section 15003 of Public Law
114–255 added subsection (g)(5) to
section 410A of Public Law 108–173 to
require that, during the second 5 years
of the 10-year extension period, the
Secretary would apply the provisions of
section 410A(g)(4) of Public Law 108–
173 to rural community hospitals not
described in subsection (g)(4) but that
were participating in the demonstration
as of December 30, 2014, in a similar
manner as such provisions apply to
hospitals described in subsection (g)(4).
In the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38280), we finalized our
policy with regard to the effective date
for the application of the reasonable
cost-based payment methodology under
the demonstration for those previously
participating hospitals choosing to
participate in the second 5-year
extension period. According to our
finalized policy, each previously
participating hospital began the second
5 years of the 10-year extension period
and payment for services provided
under the cost-based payment
methodology under section 410A of
Public Law 108–173 (as amended by
section 15003 of Pub. L. 114–255) on the
date immediately after the period of
performance ended under the first 5year extension period.
Seventeen of the 21 hospitals that
completed their periods of participation
under the extension period authorized
by Public Law 111–148 (ACA) elected to
continue in the 5-year extension period
authorized by Public Law 114–255
(Cures Act). Therefore, for these
hospitals, this third 5-year period of
participation started on dates ranging
from May 1, 2015 through January 1,
2017, depending on when they had
initially started.
On November 20, 2017, we
announced that 13 additional hospitals
were selected to participate in the
demonstration in addition to these 17
hospitals continuing participation from
the first 5-year extension period. (These
two groups are referred to as ‘‘newly
participating’’ and ‘‘previously
participating’’ hospitals, respectively.)
PO 00000
Frm 00361
Fmt 4701
Sfmt 4700
49139
We announced that each of these newly
participating hospitals would begin its
5-year period of participation effective
with the start of the first cost-reporting
period on or after October 1, 2017. One
of the newly participating hospitals
withdrew from the demonstration
program prior to beginning participation
in the demonstration on July 1, 2018. In
addition, one of the previously
participating hospitals closed effective
January 2019, and another withdrew
effective October 1, 2019. Therefore, 27
hospitals were participating in the
demonstration as of October 1, 2019—15
previously participating and 12 newly
participating.
Each hospital has had its own end
date applicable to this third five-year
period for the demonstration. For four of
the previously participating hospitals,
this end date fell within FY 2020, while
for 11 of the previously participating
hospitals, the end date fell within CY
2021. (One of the hospitals within this
group chose in February of 2020 to
withdraw effective September of the
previous year). The newly participating
hospitals were all scheduled to end
their participation either at the end of
FY 2022 or during FY 2023.
Section 128 of the Consolidated
Appropriations Act of 2021 (CAA),
Public Law 116–260 requires a 15-year
extension period, to begin on the date
immediately following the last day of
the initial 5-year period, instead of the
10-year extension period mandated by
the Public Law 114–255 (Cures Act). In
addition, the statute provides for
continued participation for all hospitals
participating in the demonstration
program as of December 30, 2019.
Therefore, in the FY 2022 IPPS final
rule (86 FR 45314), we stated our
interpretation of the statute as providing
for an additional 5-year period under
the reasonable cost-based
reimbursement methodology for the
demonstration for the 26 hospitals
whose effective participation extended
back to December 30, 2019.
Given that four hospitals ended the 5year period authorized by the Cures Act
during FY 2020, we finalized the policy
from previous extensions, that is, to
apply the cost-based reimbursement
methodology to the date following the
last day of this previous period for each
hospital that elects to continue
participation. Likewise, each of the 22
hospitals with a scheduled end date
during 2021, 2022, or 2023 is eligible for
an additional 5-year period starting from
the day after the specified end date.
Accordingly, the period of participation
for the last hospital in the
demonstration under this most recent
E:\FR\FM\10AUR2.SGM
10AUR2
49140
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
legislative authorization would extend
until June 30, 2028.
4. Budget Neutrality
a. Statutory Budget Neutrality
Requirement
Section 410A(c)(2) of Public Law 108–
173 requires that, in conducting the
demonstration program under this
section, the Secretary shall ensure that
the aggregate payments made by the
Secretary do not exceed the amount that
the Secretary would have paid if the
demonstration program under this
section was not implemented. This
requirement is commonly referred to as
‘‘budget neutrality.’’ Generally, when
we implement a demonstration program
on a budget neutral basis, the
demonstration program is budget
neutral on its own terms; in other
words, the aggregate payments to the
participating hospitals do not exceed
the amount that would be paid to those
same hospitals in the absence of the
demonstration program. We note that
the payment methodology for this
demonstration, that is, cost-based
payments to participating small rural
hospitals, makes it unlikely that
increased Medicare outlays will
produce an offsetting reduction to
Medicare expenditures elsewhere.
Therefore, in the 12 IPPS final rules
spanning the period from FY 2005
through FY 2016, we adjusted the
national inpatient PPS rates by an
amount sufficient to account for the
added costs of this demonstration
program, thus applying budget
neutrality across the payment system as
a whole rather than merely across the
participants in the demonstration
program. (A different methodology was
applied for FY 2017.) As we discussed
in the FYs 2005 through 2017 IPPS/
LTCH PPS final rules (69 FR 49183; 70
FR 47462; 71 FR 48100; 72 FR 47392;
73 FR 48670; 74 FR 43922, 75 FR 50343,
76 FR 51698, 77 FR 53449, 78 FR 50740,
77 FR 50145; 80 FR 49585; and 81 FR
57034, respectively), we believe that the
statutory language of the budget
neutrality requirements permits the
agency to implement the budget
neutrality provision in this manner.
khammond on DSKJM1Z7X2PROD with RULES2
b. General Budget Neutrality
Methodology
We have generally incorporated two
components into the budget neutrality
offset amounts identified in the final
IPPS rules in previous years. First, we
have estimated the costs of the
demonstration for the upcoming fiscal
year, generally determined from
historical, ‘‘as submitted’’ cost reports
for the hospitals participating in that
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
year. Update factors representing
nationwide trends in cost and volume
increases have been incorporated into
these estimates, as specified in the
methodology described in the final rule
for each fiscal year. Second, as finalized
cost reports became available, we
determined the amount by which the
actual costs of the demonstration for an
earlier, given year differed from the
estimated costs for the demonstration
set forth in the final IPPS rule for the
corresponding fiscal year, and
incorporated that amount into the
budget neutrality offset amount for the
upcoming fiscal year. If the actual costs
for the demonstration for the earlier
fiscal year exceeded the estimated costs
of the demonstration identified in the
final rule for that year, this difference
was added to the estimated costs of the
demonstration for the upcoming fiscal
year when determining the budget
neutrality adjustment for the upcoming
fiscal year. Conversely, if the estimated
costs of the demonstration set forth in
the final rule for a prior fiscal year
exceeded the actual costs of the
demonstration for that year, this
difference was subtracted from the
estimated cost of the demonstration for
the upcoming fiscal year when
determining the budget neutrality
adjustment for the upcoming fiscal year.
We note that we have calculated this
difference for FYs 2005 through 2016
between the actual costs of the
demonstration as determined from
finalized cost reports once available,
and estimated costs of the
demonstration as identified in the
applicable IPPS final rules for these
years.
c. Budget Neutrality Methodology for
the Extension Period Authorized by
Public Law 116–260
For the newly enacted extension
period, under the CAA, we continue
upon the general budget neutrality
methodology used in previous years,
and to specifically follow upon the
determinations for the previous
extension period, under the Cures Act.
(1) Budget Neutrality Methodology for
Previous Extension Period Under the
Cures Act
We finalized our budget neutrality
methodology for periods of participation
under this previous 5-year extension
period in the FY 2018 IPPS/LTCH PPS
final rule (82 FR 38285 through 38287).
Similar to previous years, we stated in
this rule, as well as in the FY 2019 and
FY 2020 IPPS/LTCH PPS proposed and
final rules (83 FR 20444 and 41503, and
84 FR 19452 and 42421, respectively)
that we would incorporate an estimate
PO 00000
Frm 00362
Fmt 4701
Sfmt 4700
of the costs of the demonstration,
generally determined from historical,
‘‘as submitted’’ cost reports for the
participating hospitals, and appropriate
update factors, into a budget neutrality
offset amount to be applied to the
national IPPS rates for the upcoming
fiscal year. In addition, we stated that
we would continue to apply our general
policy from previous years of including,
as a second component to the budget
neutrality offset amount, the amount by
which the actual costs of the
demonstration for an earlier, given year
(as determined from finalized cost
reports, when available) differed from
the estimated costs for the
demonstration set forth in the final IPPS
rule for the corresponding fiscal year.
In these proposed and final rules, we
described several distinct components
to the budget neutrality offset amount
for the specific fiscal years of the
extension period authorized by Public
Law 114–255 (Cures Act).
We included a component to our
overall methodology similar to previous
years, according to which an estimate of
the costs of the demonstration for both
previously and newly participating
hospitals for the upcoming fiscal year is
incorporated into a budget neutrality
offset amount to be applied to the
national IPPS rates for the upcoming
fiscal year. In the FY 2019 IPPS final
rule (83 FR 41506), we included such an
estimate of the costs of the
demonstration for each of FYs 2018 and
2019 into the budget neutrality offset
amount for FY 2019. In the FY 2020
IPPS final rule (84 FR 42421), we
included an estimate of the costs of the
demonstration for FY 2020 for 28
hospitals. In the FY 2021 IPPS final rule
(85 FR 58873), we included an estimate
of the costs of the demonstration for FY
2021 for the 22 hospitals for which the
cost-based reimbursement methodology
was to apply for all or part of FY 2021.
In the FY 2022 IPPS final rule (86 FR
45316), we included an estimate of the
costs of the demonstration for FY 2022
for the 26 hospitals expected to
participate in that fiscal year.
Similar to previous years, we
continued to implement the policy of
determining the difference between the
actual costs of the demonstration as
determined from finalized cost reports
for a given fiscal year and the estimated
costs indicated in the corresponding
year’s final rule, and including that
difference as a positive or negative
adjustment in the upcoming year’s final
rule. (For each previously participating
hospital that decided to participate in
the 5-year extension period under the
Cures Act, the cost-based payment
methodology under the demonstration
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
began on the date immediately
following the end date of its period of
performance for the still previous
extension period (under the ACA). In
addition, for previously participating
hospitals that converted to CAH status
during the time period of the second 5year extension period, the
demonstration payment methodology
was applied to the date following the
end date of its period of performance for
the first extension period to the date of
conversion). In the FY 2020 final rule,
we included the difference between the
amount determined for the cost of the
demonstration in each of FYs 2014 and
2015 and the estimated amount
included in the budget neutrality offset
in the final rule for each of these
respective fiscal years. In the FY 2022
final rule, we included the difference
between the amount determined for the
cost of the demonstration in FY 2016
and the estimated amount included in
the budget neutrality offset in the final
rule for that fiscal year.
(2) Methodology for Estimating
Demonstration Costs for FY 2022
We are using a methodology similar to
previous years, according to which an
estimate of the costs of the
demonstration for the upcoming fiscal
year is incorporated into a budget
neutrality offset amount to be applied to
the national IPPS rates for the upcoming
fiscal year, that is, FY 2023. We are
conducting this estimate for FY 2023
based on the 26 hospitals that are
continuing participation in
demonstration for the fiscal year. The
methodology for calculating this amount
for FY 2023 proceeds according to the
following steps:
Step 1: For each of these 26 hospitals,
we identify the reasonable cost amount
calculated under the reasonable costbased methodology for covered
inpatient hospital services, including
swing beds, as indicated on the ‘‘as
submitted’’ cost report for the most
recent cost reporting period available.
For each of these hospitals, the ‘‘as
submitted’’ cost report is that with cost
report period end date in CY 2020. We
sum these hospital-specific amounts to
arrive at a total general amount
representing the costs for covered
inpatient hospital services, including
swing beds, across the total 26 hospitals
eligible to participate during FY 2023.
Then, we multiply this amount by the
FYs 2021, 2022 and 2023 IPPS market
basket percentage increases, which are
calculated by the CMS Office of the
Actuary. (Unlike in the proposed rule,
where used the proposed market basket
percentage increase for FY 2023, for this
final rule, we use the final market basket
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
percentage increase, which can be found
at section X.XX of the preamble to this
final rule). The result for the 26
hospitals is the general estimated
reasonable cost amount for covered
inpatient hospital services for FY 2022.
Consistent with our methods in
previous years for formulating this
estimate, we are applying the IPPS
market basket percentage increases for
FYs 2021 through 2023 to the applicable
estimated reasonable cost amount
(previously described) in order to model
the estimated FY 2023 reasonable cost
amount under the demonstration. We
believe that the IPPS market basket
percentage increases appropriately
indicate the trend of increase in
inpatient hospital operating costs under
the reasonable cost methodology for the
years involved.
Step 2: For each of the participating
hospitals, we identify the estimated
amount that would otherwise be paid in
FY 2023 under applicable Medicare
payment methodologies for covered
inpatient hospital services, including
swing beds (as indicated on the same set
of ‘‘as submitted’’ cost reports as in Step
1), if the demonstration were not
implemented. We sum these hospitalspecific amounts, and, in turn, multiply
this sum by the FYs 2021, 2022 and
2023 IPPS applicable percentage
increases. (For FY 2023, we are using
the final applicable percentage increase
for FY 2023, per section X.XX of the
preamble of this final rule). This
methodology differs from Step 1, in
which we apply the market basket
percentage increases to the hospitals’
applicable estimated reasonable cost
amount for covered inpatient hospital
services. We believe that the IPPS
applicable percentage increases are
appropriate factors to update the
estimated amounts that generally would
otherwise be paid without the
demonstration. This is because IPPS
payments constitute the majority of
payments that would otherwise be made
without the demonstration and the
applicable percentage increase is the
factor used under the IPPS to update the
inpatient hospital payment rates.
Step 3: We subtract the amount
derived in Step 2 from the amount
derived in Step 1. According to our
methodology, the resulting amount
indicates the total difference for the 26
hospitals (for covered inpatient hospital
services, including swing beds), which
will be the general estimated amount of
the costs of the demonstration for FY
2023.
For this final rule, the resulting
amount is $72,449,896, which we are
incorporating into the budget neutrality
offset adjustment for FY 2023. This
PO 00000
Frm 00363
Fmt 4701
Sfmt 4700
49141
estimated amount is based on the
specific assumptions regarding the data
sources used, that is, recently available
‘‘as submitted’’ cost reports and
historical update factors for cost and
payment. In the proposed rule, we
stated that if updated data become
available prior to the final rule, we
would use them as appropriate to
estimate the costs for the demonstration
program for FY 2023 in accordance with
our methodology for determining the
budget neutrality estimate. Accordingly,
we are using the specific market basket
and applicable percentage increases
identified in this final rule in estimating
the budget neutrality offset amount for
FY 2023. In future years, we will also
incorporate any statutory change that
might affect the methodology for
determining hospital costs either with
or without the demonstration.
(3) Reconciling Actual and Estimated
Costs of the Demonstration for Previous
Years
As described earlier, we have
calculated the difference for FYs 2005
through 2016 between the actual costs
of the demonstration, as determined
from finalized cost reports once
available, and estimated costs of the
demonstration as identified in the
applicable IPPS final rules for these
years. As we stated in the FY 2023
proposed rule, all of the finalized cost
reports are available for the 17 hospitals
that completed cost report periods
beginning in FY 2017 under the
demonstration payment methodology;
these cost reports show the actual costs
of the demonstration for this fiscal year
to be $35,989,928. This amount is
unchanged from the proposed rule.
We note that the FY 2017 IPPS final
rule included no budget neutrality offset
amount for that fiscal year. The final
rule for FY 2017 preceded the reauthorization of the demonstration
under the Cures Act. Anticipating that
the demonstration would end in 2016,
we projected no demonstration cost
estimate for the upcoming fiscal year,
FY 2017, while we stated our plan to
continue to reconcile actual costs when
all finalized cost reports for previous
fiscal years under the demonstration
became available (81 FR 57037).
Thus, keeping with past practice, as
described in the proposed rule, we are
including the actual costs of the
demonstration as determined from
finalized cost reports for FY 2017 within
the budget neutrality offset amount for
this upcoming fiscal year.
E:\FR\FM\10AUR2.SGM
10AUR2
49142
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
(4) Total Proposed Budget Neutrality
Offset Amount for FY 2023
Therefore, for this FY 2023 IPPS/
LTCH PPS final rule, the budget
neutrality offset amount for FY 2023 is
based on the sum of two amounts:
(a) the amount determined under
section X.4.c.(2) of the preamble of this
final rule, representing the difference
applicable to FY 2023 between the sum
of the estimated reasonable cost
amounts that would be paid under the
demonstration for covered inpatient
services to the 26 hospitals participating
in the fiscal year and the sum of the
estimated amounts that would generally
be paid if the demonstration had not
been implemented. This estimated
amount is $72,449,896.
(b) the amount determined under
section X.4.c.(3) of the preamble of this
final rule, indicating the amount by
which the actual costs of the
demonstration in FY 2017 as shown by
finalized cost reports from that fiscal
year exceed the estimated amount
identified in the FY 2017. Since no
budget neutrality offset was conducted
in FY 2017, the amount of this
difference is the actual cost amount for
FY 2017 ($35,989,928)
Thus, we are subtracting the sum of
these amounts ($108,439,824) from the
national IPPS rates for FY 2023.
Comment: The parent company for
two of the participating hospitals
expressed support for the continuation
of the Rural Community Hospital
Demonstration program, but noted that
it does not offer long-term financial
stability needed to maintain health care
access in rural areas. The commenter
requests that the demonstration be made
a permanent program, and, in addition,
requests several technical modifications
to how payment is conducted and costs
are audited under the demonstration:
Response: We appreciate the first
comment. We have conducted the
demonstration program in accordance
with Congressional mandates. Title
XVIII does not extend authority to make
the demonstration a permanent
program. With regard to the further
comments, we will work with the entire
group of hospitals participating in the
demonstration in examining the
relevant policy and administrative
issues.
VI. Changes to the IPPS for Capital
Related Costs
A. Overview
Section 1886(g) of the Act requires the
Secretary to pay for the capital-related
costs of inpatient acute hospital services
in accordance with a prospective
payment system established by the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Secretary. Under the statute, the
Secretary has broad authority in
establishing and implementing the IPPS
for acute care hospital inpatient capitalrelated costs. We initially implemented
the IPPS for capital-related costs in the
FY 1992 IPPS final rule (56 FR 43358).
In that final rule, we established a 10year transition period to change the
payment methodology for Medicare
hospital inpatient capital-related costs
from a reasonable cost-based payment
methodology to a prospective payment
methodology (based fully on the Federal
rate).
FY 2001 was the last year of the 10year transition period that was
established to phase in the IPPS for
hospital inpatient capital-related costs.
For cost reporting periods beginning in
FY 2002, capital IPPS payments are
based solely on the Federal rate for
almost all acute care hospitals (other
than hospitals receiving certain
exception payments and certain new
hospitals). (We refer readers to the FY
2002 IPPS final rule (66 FR 39910
through 39914) for additional
information on the methodology used to
determine capital IPPS payments to
hospitals both during and after the
transition period.)
The basic methodology for
determining capital prospective
payments using the Federal rate is set
forth in the regulations at 42 CFR
412.312. For the purpose of calculating
capital payments for each discharge, the
standard Federal rate is adjusted as
follows:
(Standard Federal Rate) × (DRG
Weight) × (Geographic Adjustment
Factor (GAF) × (COLA for hospitals
located in Alaska and Hawaii) × (1 +
Capital DSH Adjustment Factor +
Capital IME Adjustment Factor, if
applicable).
In addition, under § 412.312(c),
hospitals also may receive outlier
payments under the capital IPPS for
extraordinarily high-cost cases that
qualify under the thresholds established
for each fiscal year.
B. Additional Provisions
1. Exception Payments
The regulations at 42 CFR 412.348
provide for certain exception payments
under the capital IPPS. The regular
exception payments provided under
§ 412.348(b) through (e) were available
only during the 10-year transition
period. For a certain period after the
transition period, eligible hospitals may
have received additional payments
under the special exceptions provisions
at § 412.348(g). However, FY 2012 was
the final year hospitals could receive
PO 00000
Frm 00364
Fmt 4701
Sfmt 4700
special exceptions payments. For
additional details regarding these
exceptions policies, we refer readers to
the FY 2012 IPPS/LTCH PPS final rule
(76 FR 51725).
Under § 412.348(f), a hospital may
request an additional payment if the
hospital incurs unanticipated capital
expenditures in excess of $5 million due
to extraordinary circumstances beyond
the hospital’s control. Additional
information on the exception payment
for extraordinary circumstances in
§ 412.348(f) can be found in the FY 2005
IPPS final rule (69 FR 49185 and 49186).
2. New Hospitals
Under the capital IPPS, the
regulations at 42 CFR 412.300(b) define
a new hospital as a hospital that has
operated (under previous or current
ownership) for less than 2 years and
lists examples of hospitals that are not
considered new hospitals. In accordance
with § 412.304(c)(2), under the capital
IPPS, a new hospital is paid 85 percent
of its allowable Medicare inpatient
hospital capital related costs through its
first 2 years of operation, unless the new
hospital elects to receive full
prospective payment based on 100
percent of the Federal rate. We refer
readers to the FY 2012 IPPS/LTCH PPS
final rule (76 FR 51725) for additional
information on payments to new
hospitals under the capital IPPS.
3. Payments for Hospitals Located in
Puerto Rico
In the FY 2017 IPPS/LTCH PPS final
rule (81 FR 57061), we revised the
regulations at 42 CFR 412.374 relating to
the calculation of capital IPPS payments
to hospitals located in Puerto Rico
beginning in FY 2017 to parallel the
change in the statutory calculation of
operating IPPS payments to hospitals
located in Puerto Rico, for discharges
occurring on or after January 1, 2016,
made by section 601 of the Consolidated
Appropriations Act, 2016 (Pub. L. 114–
113). Section 601 of Public Law 114–
113 increased the applicable Federal
percentage of the operating IPPS
payment for hospitals located in Puerto
Rico from 75 percent to 100 percent and
decreased the applicable Puerto Rico
percentage of the operating IPPS
payments for hospitals located in Puerto
Rico from 25 percent to zero percent,
applicable to discharges occurring on or
after January 1, 2016. As such, under
revised § 412.374, for discharges
occurring on or after October 1, 2016,
capital IPPS payments to hospitals
located in Puerto Rico are based on 100
percent of the capital Federal rate.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
C. Annual Update for FY 2023
The annual update to the national
capital Federal rate, as provided for in
42 CFR 412.308(c), for FY 2023 is
discussed in section III. of the
Addendum to this FY 2023 IPPS/LTCH
PPS final rule.
In section II.C. of the preamble of this
FY 2023 IPPS/LTCH PPS final rule, we
present a discussion of the MS–DRG
documentation and coding adjustment,
including previously finalized policies
and historical adjustments, as well as
the adjustment to the standardized
amount under section 1886(d) of the Act
that we are making for FY 2023, in
accordance with the amendments made
to section 7(b)(1)(B) of Public Law 110–
90 by section 414 of the MACRA.
Because these provisions require us to
make an adjustment only to the
operating IPPS standardized amount, we
are not making a similar adjustment to
the national capital Federal rate (or to
the hospital-specific rates).
VII. Changes for Hospitals Excluded
From the IPPS
khammond on DSKJM1Z7X2PROD with RULES2
A. Rate-of-Increase in Payments to
Excluded Hospitals for FY 2023
Certain hospitals excluded from a
prospective payment system, including
children’s hospitals, 11 cancer
hospitals, and hospitals located outside
the 50 States, the District of Columbia,
and Puerto Rico (that is, hospitals
located in the U.S. Virgin Islands,
Guam, the Northern Mariana Islands,
and American Samoa) receive payment
for inpatient hospital services they
furnish on the basis of reasonable costs,
subject to a rate-of-increase ceiling. A
per discharge limit (the target amount,
as defined in § 413.40(a) of the
regulations) is set for each hospital
based on the hospital’s own cost
experience in its base year, and updated
annually by a rate-of-increase
percentage. For each cost reporting
period, the updated target amount is
multiplied by total Medicare discharges
during that period and applied as an
aggregate upper limit (the ceiling as
defined in § 413.40(a)) of Medicare
reimbursement for total inpatient
operating costs for a hospital’s cost
reporting period. In accordance with
§ 403.752(a) of the regulations, religious
nonmedical health care institutions
(RNHCIs) also are subject to the rate-ofincrease limits established under
§ 413.40 of the regulations discussed
previously. Furthermore, in accordance
with § 412.526(c)(3) of the regulations,
extended neoplastic disease care
hospitals also are subject to the rate-ofincrease limits established under
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
§ 413.40 of the regulations discussed
previously.
As explained in the FY 2006 IPPS
final rule (70 FR 47396 through 47398),
beginning with FY 2006, we have used
the percentage increase in the IPPS
operating market basket to update the
target amounts for children’s hospitals,
the 11 cancer hospitals, and RNHCIs.
Consistent with the regulations at
§§ 412.23(g) and 413.40(a)(2)(ii)(A) and
(c)(3)(viii), we also have used the
percentage increase in the IPPS
operating market basket to update target
amounts for short-term acute care
hospitals located in the U.S. Virgin
Islands, Guam, the Northern Mariana
Islands, and American Samoa. In the FY
2018 IPPS/LTCH PPS final rule, we
rebased and revised the IPPS operating
basket to a 2014 base year, effective for
FY 2018 and subsequent fiscal years (82
FR 38158 through 38175), and finalized
the use of the percentage increase in the
2014-based IPPS operating market
basket to update the target amounts for
children’s hospitals, the 11 cancer
hospitals, RNHCIs, and short-term acute
care hospitals located in the U.S. Virgin
Islands, Guam, the Northern Mariana
Islands, and American Samoa for FY
2018 and subsequent fiscal years.
As discussed in section IV. of the
preamble of the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45194 through
45207), we rebased and revised the IPPS
operating basket to a 2018 base year.
Therefore, we used the percentage
increase in the 2018-based IPPS
operating market basket to update the
target amounts for children’s hospitals,
the 11 cancer hospitals, RNHCIs, and
short-term acute care hospitals located
in the U.S. Virgin Islands, Guam, the
Northern Mariana Islands, and
American Samoa for FY 2022 and
subsequent fiscal years.
For the FY 2023 IPPS/LTCH PPS
proposed rule, based on IGI’s 2021
fourth quarter forecast, we estimated
that the 2018-based IPPS operating
market basket update for FY 2023 would
be 3.1 percent (that is, the estimate of
the market basket rate-of-increase).
However, we proposed that if more
recent data became available for the FY
2023 IPPS/LTCH PPS final rule, we
would use such data, if appropriate, to
calculate the final IPPS operating
market basket update for FY 2023. We
did receive updated data. Therefore, for
this FY 2023 IPPS/LTCH PPS final rule,
based on IGI’s 2022 second quarter
forecast, we estimate that the 2018based IPPS operating market basket
update for FY 2023 is 4.1 percent. Based
on this estimate, the FY 2023 rate-ofincrease percentage that will be applied
to the FY 2022 target amounts in order
PO 00000
Frm 00365
Fmt 4701
Sfmt 4700
49143
to calculate the FY 2023 target amounts
for children’s hospitals, the 11 cancer
hospitals, RNCHIs, and short-term acute
care hospitals located in the U.S. Virgin
Islands, Guam, the Northern Mariana
Islands, and American Samoa will be
4.1 percent, in accordance with the
applicable regulations at 42 CFR 413.40.
In addition, payment for inpatient
operating costs for hospitals classified
under section 1886(d)(1)(B)(vi) of the
Act (which we refer to as ‘‘extended
neoplastic disease care hospitals’’) for
cost reporting periods beginning on or
after January 1, 2015, is to be made as
described in 42 CFR 412.526(c)(3), and
payment for capital costs for these
hospitals is to be made as described in
42 CFR 412.526(c)(4). (For additional
information on these payment
regulations, we refer readers to the FY
2018 IPPS/LTCH PPS final rule (82 FR
38321 through 38322).)
Section 412.526(c)(3) provides that
the hospital’s Medicare allowable net
inpatient operating costs for that period
are paid on a reasonable cost basis,
subject to that hospital’s ceiling, as
determined under § 412.526(c)(1), for
that period. Under § 412.526(c)(1), for
each cost reporting period, the ceiling
was determined by multiplying the
updated target amount, as defined in
§ 412.526(c)(2), for that period by the
number of Medicare discharges paid
during that period. Section
412.526(c)(2)(i) describes the method for
determining the target amount for cost
reporting periods beginning during FY
2015. Section 412.526(c)(2)(ii) specifies
that, for cost reporting periods
beginning during fiscal years after FY
2015, the target amount will equal the
hospital’s target amount for the previous
cost reporting period updated by the
applicable annual rate-of-increase
percentage specified in § 413.40(c)(3) for
the subject cost reporting period (79 FR
50197).
For FY 2023, in accordance with
§§ 412.22(i) and 412.526(c)(2)(ii) of the
regulations, for cost reporting periods
beginning during FY 2023 the proposed
update to the target amount for
extended neoplastic disease care
hospitals (that is, hospitals described
under § 412.22(i)) is the applicable
annual rate-of-increase percentage
specified in § 413.40(c)(3) for FY 2023,
which would be equal to the percentage
increase in the hospital market basket,
which is estimated to be the percentage
increase in the 2018-based IPPS
operating market basket (that is, the
estimate of the market basket rate-ofincrease). Accordingly, the proposed
update to an extended neoplastic
disease care hospital’s target amount for
FY 2023 was 3.1 percent, which was
E:\FR\FM\10AUR2.SGM
10AUR2
49144
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
B. Report on Adjustment (Exception)
Payments
Section 4419(b) of Public Law 105–33
requires the Secretary to publish
annually in the Federal Register a
report describing the total amount of
adjustment payments made to excluded
Class of Hospital
Cancer Hospitals
Children's
Hospitals
RNHCis
Total
Excess Cost Over Ceilin2
$48,831,338
$1,774,147
Adjustment Payments
$24,623,016
$1,015,213
4
13
$330,405
$51,935,890
$312,463
$25,950,692
1. Background
Section 1820 of the Act provides for
the establishment of Medicare Rural
Hospital Flexibility Programs
(MRHFPs), under which individual
States may designate certain facilities as
critical access hospitals (CAHs).
Facilities that are so designated and
meet the CAH conditions of
participation under 42 CFR part 485,
subpart F, will be certified as CAHs by
CMS. Regulations governing payments
to CAHs for services to Medicare
beneficiaries are located in 42 CFR part
413.
2. Frontier Community Health
Integration Project Demonstration
khammond on DSKJM1Z7X2PROD with RULES2
a. Introduction
The Frontier Community Health
Integration Project Demonstration was
originally authorized by section 123 of
the Medicare Improvements for Patients
and Providers Act of 2008 (Pub. L. 110–
275). The demonstration has been
extended by section 129 of the
Consolidated Appropriations Act, 2021
00:20 Aug 10, 2022
request applications are incomplete and
additional information must be
requested in order to have a completed
request application. However, in an
attempt to provide interested parties
with data on the most recent adjustment
payments for which we have data, we
are publishing data on adjustment
payments that were processed by the
MAC or CMS during FY 2021.
The table that follows includes the
most recent data available from the
MACs and CMS on adjustment
payments that were adjudicated during
FY 2021. As indicated previously, the
adjustments made during FY 2021 only
pertain to cost reporting periods ending
in years prior to FY 2020. Total
adjustment payments made to IPPSexcluded hospitals during FY 2021 are
$25,950,692. The table depicts for each
class of hospitals, in the aggregate, the
number of adjustment requests
adjudicated, the excess operating costs
over the ceiling, and the amount of the
adjustment payments.
Number
7
2
C. Critical Access Hospitals (CAHs)
VerDate Sep<11>2014
hospitals and hospital units by reason of
section 1886(b)(4) of the Act during the
previous fiscal year.
The process of requesting, adjusting,
and awarding an adjustment payment is
likely to occur over a 2-year period or
longer. First, generally, an excluded
hospital must file its cost report for the
fiscal year in accordance with
§ 413.24(f)(2) of the regulations. The
MAC reviews the cost report and issues
a notice of provider reimbursement
(NPR). Once the hospital receives the
NPR, if its operating costs are in excess
of the ceiling, the hospital may file a
request for an adjustment payment.
After the MAC receives the hospital’s
request in accordance with applicable
regulations, the MAC or CMS,
depending on the type of adjustment
requested, reviews the request and
determines if an adjustment payment is
warranted. This determination is
sometimes not made until more than
180 days after the date the request is
filed because there are times when the
Jkt 256001
(Pub. L. 116–260) for an additional 5
years. In this final rule, we are
summarizing the status of the
demonstration program, and the
ongoing methodologies for
implementation and budget neutrality
for the demonstration extension period.
b. Background and Overview
As discussed in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45323
through 45328), section 123 of the
Medicare Improvements for Patients and
Providers Act of 2008, as amended by
section 3126 of the Affordable Care Act,
authorized a demonstration project to
allow eligible entities to develop and
test new models for the delivery of
health care services in eligible counties
in order to improve access to and better
integrate the delivery of acute care,
extended care and other health care
services to Medicare beneficiaries. The
demonstration was titled
‘‘Demonstration Project on Community
Health Integration Models in Certain
Rural Counties,’’ and commonly known
as the Frontier Community Health
PO 00000
Frm 00366
Fmt 4701
Sfmt 4700
Integration Project (FCHIP)
Demonstration.
The authorizing statute stated the
eligibility criteria for entities to be able
to participate in the demonstration. An
eligible entity, as defined in section
123(d)(1)(B) of Public Law 110–275, as
amended, is a Medicare Rural Hospital
Flexibility Program (MRHFP) grantee
under section 1820(g) of the Act (that is,
a CAH); and is located in a state in
which at least 65 percent of the counties
in the state are counties that have 6 or
less residents per square mile.
The authorizing statute stipulated
several other requirements for the
demonstration. In addition, section
123(g)(1)(B) of Pub. L. 110–275 required
that the demonstration be budget
neutral. Specifically, this provision
stated that, in conducting the
demonstration project, the Secretary
shall ensure that the aggregate payments
made by the Secretary do not exceed the
amount which the Secretary estimates
would have been paid if the
demonstration project under the section
were not implemented. Furthermore,
section 123(i) of Public Law 110–275
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.153
based on IGI’s fourth quarter 2021
forecast. Furthermore, we proposed that
if more recent data became available for
the FY 2023 IPPS/LTCH PPS final rule,
we would use such data, if appropriate,
to calculate the IPPS operating market
basket update for FY 2023. For this FY
2023 IPPS/LTCH PPS final rule, based
on IGI’s second quarter 2022 forecast,
we estimate that the 2018-based IPPS
operating market basket update for FY
2023 is 4.1 percent.
We received no comments on this
proposal and therefore are finalizing
this provision without modification.
Incorporating more recent data available
for this final rule, as we proposed, we
are adopting a 4.1 percent update for FY
2023.
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
stated that the Secretary may waive
such requirements of titles XVIII and
XIX of the Act as may be necessary and
appropriate for the purpose of carrying
out the demonstration project, thus
allowing the waiver of Medicare
payment rules encompassed in the
demonstration. CMS selected CAHs to
participate in four interventions, under
which specific waivers of Medicare
payment rules would allow for
enhanced payment for telehealth,
skilled nursing facility/nursing facility
beds, ambulance services, and home
health services. These waivers were
formulated with the goal of increasing
access to care with no net increase in
costs.
Section 123 of Public Law 110–275
initially required a 3-year period of
performance. The FCHIP Demonstration
began on August 1, 2016, and concluded
on July 31, 2019 (referred to in this
section of the final rule as the ‘‘initial
period’’). Subsequently, section 129 of
the Consolidated Appropriations Act,
2021 (Pub. L. 116–260) extended the
demonstration by 5 years (referred to in
this section of the final rule as the
‘‘extension period’’). The Secretary is
required to conduct the demonstration
for an additional 5-year period. CAHs
participating in the demonstration
project during the extension period
shall begin such participation in the
cost reporting year that begins on or
after January 1, 2022.
As described in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45323
through 45328), 10 CAHs were selected
for participation in the demonstration
initial period. The selected CAHs were
located in three states—Montana,
Nevada, and North Dakota—and
participated in three of the four
interventions identified in the FY 2017
IPPS/LTCH PPS final rule (81 FR 57064
through 57065), the FY 2018 IPPS/LTCH
PPS final rule (82 FR 38294 through
38296), and the FY 2019 IPPS/LTCH
PPS final rule (83 FR 41516 through
41517), the FY 2020 IPPS/LTCH PPS
final rule (84 FR 42427 through 42428)
and the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58894 through 58896) and
the FY 2022 IPPS/LTCH PPS final rule
(86 FR 45323 through 45328). Each CAH
was allowed to participate in more than
one of the interventions. None of the
selected CAHs were participants in the
home health intervention, which was
the fourth intervention.
In the FY 2022 IPPS/LTCH PPS final
rule, CMS concluded that the initial
period of the FCHIP Demonstration
(covering the performance period of
August 1, 2016, to July 31, 2019) had
satisfied the budget neutrality
requirement described in section
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
123(g)(1)(B) of Public Law 110–275.
Therefore, CMS did not apply a budget
neutrality payment offset policy for the
initial period of the demonstration.
Section 129 of Public Law 116–260,
stipulates that only the 10 CAHs that
participated in the initial period of the
FCHIP Demonstration are eligible to
participate during the extension period.
Among the eligible CAHs, six have
elected to participate in the extension
period. The selected CAHs are located
in two states—Montana and North
Dakota—and are implementing three of
the four interventions. The eligible CAH
participants elected to change the
number of interventions and payment
waivers they would participate in
during the extension period. CMS
accepted and approved the CAHs
intervention and payment waiver
updates. For the extension period, five
CAHs are participants in the telehealth
intervention, four CAHs are participants
in the skilled nursing facility/nursing
facility bed intervention, and three
CAHs are participants in the ambulance
services intervention. As with the initial
period, each CAH was allowed to
participate in more than one of the
interventions during the extension
period. None of the selected CAHs are
participants in the home health
intervention, which was the fourth
intervention.
c. Intervention Payment and Payment
Waivers
As described in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45323
through 45328), CMS waived certain
Medicare rules for CAHs participating
in the demonstration initial period to
allow for alternative reasonable costbased payment methods in the three
distinct intervention service areas:
telehealth services, ambulance services,
and skilled nursing facility/nursing
facility (SNF/NF) beds expansion. The
payments and payment waiver
provisions only apply if the CAH is a
participant in the associated
intervention. Given updates to Medicare
payment rules and regulations, CMS has
modified and/or updated the
Intervention Payment and Payment
Waivers for the extension period. The
FCHIP payment waivers for the
demonstration extension period consist
of the following:
(1) Telehealth Services Intervention
Payments
CMS waives section 1834(m)(2)(B) of
the Act, which specifies the facility fee
to the originating site. CMS modifies the
facility fee payment specified under
section 1834(m)(2)(B) of the Act to make
reasonable cost-based reimbursement to
PO 00000
Frm 00367
Fmt 4701
Sfmt 4700
49145
the participating CAH where the
participating CAH serves as the
originating site for a telehealth service
furnished to an eligible telehealth
individual, as defined in section
1834(m)(4)(B) of the Act. CMS would
reimburse the participating CAH serving
as the originating site at 101 percent of
its reasonable costs for overhead,
salaries and fringe benefits associated
with telehealth services at the
participating CAH. CMS would not fund
or provide reimbursement to the
participating CAH for the purchase of
new telehealth equipment.
CMS waives section 1834(m)(2)(A) of
the Act, which specifies the payment
made for a telehealth service furnished
by the distant site practitioner. CMS
modifies the distant site payment
specified under section 1834(m)(2)(A) of
the Act to make reasonable cost-based
reimbursement to the participating CAH
for telehealth services furnished by a
physician or practitioner located at
distant site that is a participating CAH
that is billing for the physician or
practitioner professional services.
Whether the participating CAH has or
has not elected Optional Payment
Method II for outpatient services, CMS
would pay the participating CAH 101
percent of reasonable costs for
telehealth services when a physician or
practitioner has reassigned their billing
rights to the participating CAH and
furnishes telehealth services from the
participating CAH as a distant site
practitioner. This means that
participating CAHs that are billing
under the Standard Method on behalf of
employees who are physicians or
practitioners (as defined in section
1834(m)(4)(D) and (E) of the Act,
respectively) would be eligible to bill for
distant site telehealth services furnished
by these physicians and practitioners.
Additionally, CAHs billing under the
Optional Method would be reimbursed
based on 101 percent of reasonable
costs, rather than paid based on the
Medicare physician fee schedule, for the
distant site telehealth services furnished
by physicians and practitioners who
have reassigned their billing rights to
the CAH. For distant site telehealth
services furnished by physicians or
practitioners who have not reassigned
billing rights to a participating CAH,
payment to the distant site physician or
practitioner would continue to be made
as usual under the Medicare physician
fee schedule. Currently these services
are eligible to be furnished and paid in
this way due to a waiver issued during
the PHE. Except as described herein,
CMS does not waive any other
provisions of section 1834(m) of the Act
E:\FR\FM\10AUR2.SGM
10AUR2
49146
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
for purposes of the telehealth services
intervention payments, including the
scope of Medicare telehealth services as
established under section 1834(m)(4)(F)
of the Act. We received no comments on
this proposal and therefore are
finalizing this provision without
modification.
khammond on DSKJM1Z7X2PROD with RULES2
(2) Ambulance Services Intervention
Payments
CMS waives 42 CFR 413.70(b)(5)(D)
and section 1834(l)(8) of the Act, which
provides that payment for ambulance
services furnished by a CAH, or an
entity owned and operated by a CAH, is
101 percent of the reasonable costs of
the CAH or the entity in furnishing the
ambulance services, but only if the CAH
or the entity is the only provider or
supplier of ambulance services located
within a 35-mile drive of the CAH,
excluding ambulance providers or
suppliers that are not legally authorized
to furnish ambulance services to
transport individuals to or from the
CAH. The participating CAH would be
paid 101 percent of reasonable costs for
its ambulance services regardless of
whether there is any provider or
supplier of ambulance services located
within a 35-mile drive of the
participating CAH or participating CAHowned and operated entity. CMS would
not make cost-based payment to the
participating CAH for any new capital
(for example, vehicles) associated with
ambulance services. This waiver does
not modify any other Medicare rules
regarding or affecting the provision of
ambulance services. We received no
comments on this proposal and
therefore are finalizing this provision
without modification.
(3) SNF/NF Beds Expansion
Intervention Payments
CMS waives 42 CFR 485.620(a), 42
CFR 485.645(a)(2), and section
1820(c)(2)(B)(iii) of the Act which limit
CAHs to maintaining no more than 25
inpatient beds, including beds available
for acute inpatient or swing bed
services. CMS waives 1820(f) of the Act
permitting designating or certifying a
facility as a critical access hospital for
which the facility at any time is
furnishing inpatient beds which exceed
more than 25 beds. Under this waiver,
if the participating CAH has received
swing bed approval from CMS, the
participating CAH may maintain up to
ten additional beds (for a total of 35
beds) available for acute inpatient or
swing bed services; however, the
participating CAH may only use these
10 additional beds for nursing facility or
skilled nursing facility level of care.
CMS would pay the participating CAH
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
101 percent of reasonable costs for its
SNF/NF services furnished in the 10
additional beds. We received no
comments on this proposal and
therefore are finalizing this provision
without modification.
d. Budget Neutrality
(1) Budget Neutrality Requirement
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45323 through 45328), we
finalized a policy to address the budget
neutrality requirement for the
demonstration initial period. We also
discussed this policy in the FY 2017
IPPS/LTCH PPS final rule (81 FR 57064
through 57065), the FY 2018 IPPS/LTCH
PPS final rule (82 FR 38294 through
38296), the FY 2019 IPPS/LTCH PPS
final rule (83 FR 41516 through 41517),
the FY 2020 IPPS/LTCH PPS final rule
(84 FR 42427 through 42428) and the FY
2021 IPPS/LTCH PPS final rule (85 FR
58894 through 58996). As explained in
the FY 2022 IPPS/LTCH PPS final rule,
we based our selection of CAHs for
participation in the demonstration with
the goal of maintaining the budget
neutrality of the demonstration on its
own terms meaning that the
demonstration would produce savings
from reduced transfers and admissions
to other health care providers, offsetting
any increase in Medicare payments as a
result of the demonstration. However,
because of the small size of the
demonstration and uncertainty
associated with the projected Medicare
utilization and costs, the policy we
finalized for the demonstration initial
period of performance in the FY 2022
IPPS/LTCH PPS final rule provides a
contingency plan to ensure that the
budget neutrality requirement in section
123 of Public Law 110–275 is met.
For the FY 2023 proposed rule, we
proposed to adopt the same budget
neutrality policy contingency plan used
during the demonstration initial period
to ensure that the budget neutrality
requirement in section 123 of Public
Law 110 275 is met during the
demonstration extension period. If
analysis of claims data for Medicare
beneficiaries receiving services at each
of the participating CAHs, as well as
from other data sources, including cost
reports for the participating CAHs,
shows that increases in Medicare
payments under the demonstration
during the 5-year extension period are
not sufficiently offset by reductions
elsewhere, we would recoup the
additional expenditures attributable to
the demonstration through a reduction
in payments to all CAHs nationwide.
As explained in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45323
PO 00000
Frm 00368
Fmt 4701
Sfmt 4700
through 45328), because of the small
scale of the demonstration, we indicated
that we did not believe it would be
feasible to implement budget neutrality
for the demonstration initial period by
reducing payments to only the
participating CAHs. Therefore, in the
event that this demonstration extension
period is found to result in aggregate
payments in excess of the amount that
would have been paid if this
demonstration extension period were
not implemented, CMS policy is to
comply with the budget neutrality
requirement finalized in the FY 2022
IPPS/LTCH PPS final rule, by reducing
payments to all CAHs, not just those
participating in the demonstration
extension period.
In the FY 2022 IPPS/LTCH PPS final
rule, we stated that we believe it is
appropriate to make any payment
reductions across all CAHs because the
FCHIP Demonstration was specifically
designed to test innovations that affect
delivery of services by the CAH
provider category. We explained our
belief that the language of the statutory
budget neutrality requirement at section
123(g)(1)(B) of Public Law 110–275
permits the agency to implement the
budget neutrality provision in this
manner. The statutory language merely
refers to ensuring that aggregate
payments made by the Secretary do not
exceed the amount which the Secretary
estimates would have been paid if the
demonstration project was not
implemented, and does not identify the
range across which aggregate payments
must be held equal.
Under the policy finalized in the FY
2022 IPPS/LTCH PPS final rule, we
adopted the policy finalized in the FY
2017 IPPS/LTCH PPS final rule, in the
event the demonstration initial period
was found not to have been budget
neutral, any excess costs would be
recouped over a period of 3 cost
reporting years. In the FY 2023 IPPS/
LTCH PPS proposed rule, we sought
public comment on this proposal, since
we were revising an aspect of the policy
finalized in the FY 2022 IPPS/LTCH
PPS final rule. Our new proposed policy
is in the event the demonstration
extension period is found not to have
been budget neutral, any excess costs
would be recouped within one fiscal
year. We believe our new policy is a
more efficient timeframe for the
government to conclude the
demonstration operational requirements
(such as analyzing claims data, cost
report data and/or other data sources) to
adjudicate the budget neutrality
payment recoupment process due to any
excess cost that occurred as result of the
demonstration extension period. We
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
received no comments on this proposal
and therefore are finalizing this
provision without modification.
(2) FCHIP Budget Neutrality
Methodology and Analytical Approach
As explained in the FY 2022 IPPS/
LTCH PPS final rule, we finalized a
policy to address the demonstration
budget neutrality methodology and
analytical approach for the initial period
of the demonstration. In the FY 2023
IPPS/LTCH PPS proposed rule, we
proposed to adopt the budget neutrality
methodology and analytical approach
used during the demonstration initial
period to ensure budget neutrality for
the extension period. The analysis of
budget neutrality during the initial
period of the demonstration identified
both the costs related to providing the
intervention services under the FCHIP
Demonstration and any potential
downstream effects of the interventionrelated services, including any savings
that may have accrued.
The budget neutrality analytical
approach for the demonstration initial
period incorporated two major data
components: (1) Medicare cost reports;
and (2) Medicare administrative claims.
As described in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45323 through
45328), CMS computed the cost of the
demonstration for each fiscal year of the
demonstration initial period using
Medicare cost reports for the
participating CAHs, and Medicare
administrative claims and enrollment
data for beneficiaries who received
demonstration intervention services.
In addition, in order to capture the
full impact of the interventions, CMS
developed a statistical modeling,
Difference-in-Difference (DiD)
regression analysis to estimate
demonstration expenditures and
compute the impact of expenditures on
the intervention services by comparing
cost data for the demonstration and nondemonstration groups using Medicare
administrative claims across the
demonstration period of performance
under the initial period of the
demonstration. The DiD regression
analysis would compare the direct cost
and potential downstream effects of
intervention services, including any
savings that may have accrued, during
the baseline and performance period for
both the demonstration and comparison
groups.
Second, the Medicare administrative
claims analysis would be reconciled
using data obtained from auditing the
participating CAHs’ Medicare cost
reports. We would estimate the costs of
the demonstration using ‘‘as submitted’’
cost reports for each hospital’s financial
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
fiscal year participation within each of
the demonstration extension period
performance years. Each CAH has its
own Medicare cost report end date
applicable to the 5-year period of
performance for the demonstration
extension period. The cost report is
structured to gather costs, revenues and
statistical data on the provider’s
financial fiscal period. As a result, we
would determine the final budget
neutrality results for the demonstration
extension once complete data is
available for each CAH for the
demonstration extension period. We
received no comments on this proposal
and therefore are finalizing this
provision without modification.
d. Policies for Implementing the 5-Year
Extension and Provisions Authorized By
Section 129 of the Consolidated
Appropriations Act, 2021 (Pub. L. 116–
260)
As stated in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45323 through
45328), our policy for implementing the
5-year extension period for section 129
of Public Law 116–260 follows same
budget neutrality methodology and
analytical approach as the
demonstration initial period
methodology. While we expect to use
the same methodology that was used to
assess the budget neutrality of the
FCHIP Demonstration during initial
period of the demonstration to assess
the financial impact of the
demonstration during this extension
period, upon receiving data for the
extension period, we may update and/
or modify the FCHIP budget neutrality
methodology and analytical approach to
ensure that the full impact of the
demonstration is appropriately
captured. In the FY 2023 IPPS/LTCH
PPS proposed rule, we proposed to
adopt the same budget neutrality
methodology and analytical approach
used during the demonstration initial
period to be used for the demonstration
extension period.
Comment: A commenter expressed
support of CMS implementation of the
FCHIP demonstration initial period of
performance, the demonstration
intervention payment waivers and of the
budget neutrality methodology for the
extension period. The commenter urged
CMS to continue implementing the fiveyear extension period of the
demonstration project with the same
budget neutrality and analytical
approach as it used in the
demonstration initial period. In
addition, the commenter requested that
CMS increase the number of CAHs
participating in the demonstration
extension period. The commenter
PO 00000
Frm 00369
Fmt 4701
Sfmt 4700
49147
explained that several other CAH
service areas have unique topography
that could benefit by participation in the
demonstration extension period,
specifically, special consideration
should be granted to allow additional
participants within the demonstration
ambulance service intervention.
Response: We appreciate the
commenter’s support of the
demonstration project and the budget
neutrality methodology. We
acknowledge the commenter’s request
for CMS to expand the number of CAHs
participating in the demonstration
extension period. However, we note that
section 129(b)(C) of Public Law 116–
260, stipulates ‘‘[a]n entity shall only be
eligible to participate in the
demonstration project under this section
during the extension period if the entity
participated in the demonstration
project under this section during the
initial period.’’ As such, expanding the
number of CAHs participating within
the demonstration extension period
would require legislative action to the
eligible entities, as defined in section
129(b)(C) of Public Law 116–260. After
consideration of the public comments
we received, we are finalizing our
proposal to adopt the same budget
neutrality methodology and analytical
approach used during the
demonstration initial period to be used
for the demonstration extension period
without modification.
e. Total Budget Neutrality Offset
Amount for FY 2023
At this time, for the FY 2023 IPPS/
LTCH PPS proposed rule, while this
discussion represents our anticipated
approach to assessing the financial
impact of the demonstration extension
period based on upon receiving data for
the full demonstration extension period,
we may update and/or modify the
FCHIP Demonstration budget neutrality
methodology and analytical approach to
ensure that the full impact of the
demonstration is appropriately
captured.
Therefore, we did not propose to
apply a budget neutrality payment offset
to payments to CAHs in FY 2023. This
policy will have no impact for any
national payment system for FY 2023.
We received no comments on this
proposal and therefore are finalizing
this provision without modification.
E:\FR\FM\10AUR2.SGM
10AUR2
49148
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
VIII. Changes to the Long-Term Care
Hospital Prospective Payment System
(LTCH PPS) for FY 2023
A. Background of the LTCH PPS
khammond on DSKJM1Z7X2PROD with RULES2
1. Legislative and Regulatory Authority
Section 123 of the Medicare,
Medicaid, and SCHIP (State Children’s
Health Insurance Program) Balanced
Budget Refinement Act of 1999 (BBRA)
(Pub. L. 106–113), as amended by
section 307(b) of the Medicare,
Medicaid, and SCHIP Benefits
Improvement and Protection Act of
2000 (BIPA) (Pub. L. 106–554), provides
for payment for both the operating and
capital-related costs of hospital
inpatient stays in long-term care
hospitals (LTCHs) under Medicare Part
A based on prospectively set rates. The
Medicare prospective payment system
(PPS) for LTCHs applies to hospitals
that are described in section
1886(d)(1)(B)(iv) of the Act, effective for
cost reporting periods beginning on or
after October 1, 2002.
Section 1886(d)(1)(B)(iv)(I) of the Act
originally defined an LTCH as a hospital
that has an average inpatient length of
stay (as determined by the Secretary) of
greater than 25 days. Section
1886(d)(1)(B)(iv)(II) of the Act also
provided an alternative definition of
LTCHs (‘‘subclause II’’ LTCHs).
However, section 15008 of the 21st
Century Cures Act (Pub. L. 114–255)
amended section 1886 of the Act to
exclude former ‘‘subclause II’’ LTCHs
from being paid under the LTCH PPS
and created a new category of IPPSexcluded hospitals, which we refer to as
‘‘extended neoplastic disease care
hospitals,’’ to be paid as hospitals that
were formally classified as ‘‘subclause
(II)’’ LTCHs (82 FR 38298).
Section 123 of the BBRA requires the
PPS for LTCHs to be a ‘‘per discharge’’
system with a diagnosis-related group
(DRG) based patient classification
system that reflects the differences in
patient resource use and costs in
LTCHs.
Section 307(b)(1) of the BIPA, among
other things, mandates that the
Secretary shall examine, and may
provide for, adjustments to payments
under the LTCH PPS, including
adjustments to DRG weights, area wage
adjustments, geographic reclassification,
outliers, updates, and a disproportionate
share adjustment.
In the August 30, 2002 Federal
Register, we issued a final rule that
implemented the LTCH PPS authorized
under the BBRA and BIPA (67 FR
55954). For the initial implementation
of the LTCH PPS (FYs 2003 through
2007), the system used information from
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
LTCH patient records to classify
patients into distinct long-term carediagnosis-related groups (LTCDRGs)
based on clinical characteristics and
expected resource needs. Beginning in
FY 2008, we adopted the Medicare
severity-long-term care-diagnosis related
groups (MS–LTC–DRGs) as the patient
classification system used under the
LTCH PPS. Payments are calculated for
each MS–LTC–DRG and provisions are
made for appropriate payment
adjustments. Payment rates under the
LTCH PPS are updated annually and
published in the Federal Register.
The LTCH PPS replaced the
reasonable cost-based payment system
under the Tax Equity and Fiscal
Responsibility Act of 1982 (TEFRA)
(Pub. L. 97248) for payments for
inpatient services provided by an LTCH
with a cost reporting period beginning
on or after October 1, 2002. (The
regulations implementing the TEFRA
reasonable-cost-based payment
provisions are located at 42 CFR part
413.) With the implementation of the
PPS for acute care hospitals authorized
by the Social Security Amendments of
1983 (Pub. L. 98–21), which added
section 1886(d) to the Act, certain
hospitals, including LTCHs, were
excluded from the PPS for acute care
hospitals and paid their reasonable costs
for inpatient services subject to a per
discharge limitation or target amount
under the TEFRA system. For each cost
reporting period, a hospital specific
ceiling on payments was determined by
multiplying the hospital’s updated
target amount by the number of total
current year Medicare discharges.
(Generally, in this section of the
preamble of this final rule, when we
refer to discharges, we describe
Medicare discharges.) The August 30,
2002 final rule further details the
payment policy under the TEFRA
system (67 FR 55954).
In the August 30, 2002 final rule, we
provided for a 5-year transition period
from payments under the TEFRA system
to payments under the LTCH PPS.
During this 5-year transition period, an
LTCH’s total payment under the PPS
was based on an increasing percentage
of the Federal rate with a corresponding
decrease in the percentage of the LTCH
PPS payment that is based on
reasonable cost concepts, unless an
LTCH made a one-time election to be
paid based on 100 percent of the Federal
rate. Beginning with LTCHs’ cost
reporting periods beginning on or after
October 1, 2006, total LTCH PPS
payments are based on 100 percent of
the Federal rate. In addition, in the
August 30, 2002 final rule, we presented
an in-depth discussion of the LTCH
PO 00000
Frm 00370
Fmt 4701
Sfmt 4700
PPS, including the patient classification
system, relative weights, payment rates,
additional payments, and the budget
neutrality requirements mandated by
section 123 of the BBRA. The same final
rule that established regulations for the
LTCH PPS under 42 CFR part 412,
subpart O, also contained LTCH
provisions related to covered inpatient
services, limitation on charges to
beneficiaries, medical review
requirements, furnishing of inpatient
hospital services directly or under
arrangement, and reporting and
recordkeeping requirements. We refer
readers to the August 30, 2002 final rule
for a comprehensive discussion of the
research and data that supported the
establishment of the LTCH PPS (67 FR
55954).
In the FY 2016 IPPS/LTCH PPS final
rule (80 FR 49601 through 49623), we
implemented the provisions of the
Pathway for Sustainable Growth Rate
(SGR) Reform Act of 2013 (Pub. L. 113–
67), which mandated the application of
the ‘‘site neutral’’ payment rate under
the LTCH PPS for discharges that do not
meet the statutory criteria for exclusion
beginning in FY 2016. For cost reporting
periods beginning on or after October 1,
2015, discharges that do not meet
certain statutory criteria for exclusion
are paid based on the site neutral
payment rate. Discharges that do meet
the statutory criteria continue to receive
payment based on the LTCH PPS
standard Federal payment rate. For
more information on the statutory
requirements of the Pathway for SGR
Reform Act of 2013, we refer readers to
the FY 2016 IPPS/LTCH PPS final rule
(80 FR 49601 through 49623) and the FY
2017 IPPS/LTCH PPS final rule (81 FR
57068 through 57075).
In the FY 2018 IPPS/LTCH PPS final
rule, we implemented several
provisions of the 21st Century Cures Act
(‘‘the Cures Act’’) (Pub. L. 114–255) that
affected the LTCH PPS. (For more
information on these provisions, we
refer readers to 82 FR 38299.)
In the FY 2019 IPPS/LTCH PPS final
rule (83 FR 41529), we made
conforming changes to our regulations
to implement the provisions of section
51005 of the Bipartisan Budget Act of
2018 (Pub. L. 115–123), which extends
the transitional blended payment rate
for site neutral payment rate cases for an
additional 2 years. We refer readers to
section VII.C. of the preamble of the FY
2019 IPPS/LTCH PPS final rule for a
discussion of our final policy. In
addition, in the FY 2019 IPPS/LTCH
PPS final rule, we removed the 25percent threshold policy under 42 CFR
412.538, which was a payment
adjustment that was applied to
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
payments for Medicare patient LTCH
discharges when the number of such
patients originating from any single
referring hospital was in excess of the
applicable threshold for given cost
reporting period.
In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42439), we further revised
our regulations to implement the
provisions of the Pathway for SGR
Reform Act of 2013 (Pub. L. 113–67)
that relate to the payment adjustment
for discharges from LTCHs that do not
maintain the requisite discharge
payment percentage and the process by
which such LTCHs may have the
payment adjustment discontinued.
2. Criteria for Classification as an LTCH
khammond on DSKJM1Z7X2PROD with RULES2
a. Classification as an LTCH
Under the regulations at
§ 412.23(e)(1), to qualify to be paid
under the LTCH PPS, a hospital must
have a provider agreement with
Medicare. Furthermore, § 412.23(e)(2)(i),
which implements section
1886(d)(1)(B)(iv) of the Act, requires
that a hospital have an average Medicare
inpatient length of stay of greater than
25 days to be paid under the LTCH PPS.
In accordance with section 1206(a)(3) of
the Pathway for SGR Reform Act of 2013
(Pub. L. 113–67), as amended by section
15007 of Public Law 114–255, we
amended our regulations to specify that
Medicare Advantage plans’ and site
neutral payment rate discharges are
excluded from the calculation of the
average length of stay for all LTCHs, for
discharges occurring in cost reporting
period beginning on or after October 1,
2015.
b. Hospitals Excluded From the LTCH
PPS
The following hospitals are paid
under special payment provisions, as
described in § 412.22(c) and, therefore,
are not subject to the LTCH PPS rules:
• Veterans Administration hospitals.
• Hospitals that are reimbursed under
State cost control systems approved
under 42 CFR part 403.
• Hospitals that are reimbursed in
accordance with demonstration projects
authorized under section 402(a) of the
Social Security Amendments of 1967
(Pub. L. 90–248) (42 U.S.C. 1395b–1),
section 222(a) of the Social Security
Amendments of 1972 (Pub. L. 92–603)
(42 U.S.C. 1395b1 (note)) (Statewide-all
payer systems, subject to the rate-of
increase test at section 1814(b) of the
Act), or section 3201 of the Patient
Protection and Affordable Care Act
(Pub. L. 111–148) (42 U.S.C. 1315a).
• Nonparticipating hospitals
furnishing emergency services to
Medicare beneficiaries.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
3. Limitation on Charges to Beneficiaries
In the August 30, 2002 final rule, we
presented an in-depth discussion of
beneficiary liability under the LTCH
PPS (67 FR 55974 through 55975). This
discussion was further clarified in the
RY 2005 LTCH PPS final rule (69 FR
25676). In keeping with those
discussions, if the Medicare payment to
the LTCH is the full LTC–DRG payment
amount, consistent with other
established hospital prospective
payment systems, § 412.507 currently
provides that an LTCH may not bill a
Medicare beneficiary for more than the
deductible and coinsurance amounts as
specified under §§ 409.82, 409.83, and
409.87, and for items and services
specified under § 489.30(a). However,
under the LTCH PPS, Medicare will
only pay for services furnished during
the days for which the beneficiary has
coverage until the short-stay outlier
(SSO) threshold is exceeded. If the
Medicare payment was for a SSO case
(in accordance with § 412.529), and that
payment was less than the full LTC–
DRG payment amount because the
beneficiary had insufficient coverage as
a result of the remaining Medicare days,
the LTCH also is currently permitted to
charge the beneficiary for services
delivered on those uncovered days (in
accordance with § 412.507). In the FY
2016 IPPS/LTCH PPS final rule (80 FR
49623), we amended our regulations to
expressly limit the charges that may be
imposed upon beneficiaries whose
LTCHs’ discharges are paid at the site
neutral payment rate under the LTCH
PPS. In the FY 2017 IPPS/LTCH PPS
final rule (81 FR 57102), we amended
the regulations under § 412.507 to
clarify our existing policy that blended
payments made to an LTCH during its
transitional period (that is, an LTCH’s
payment for discharges occurring in cost
reporting periods beginning in FYs 2016
through 2019) are considered to be site
neutral payment rate payments.
4. Best Available Data
We refer readers to section I.F. of the
preamble of this final rule for our
discussion on our use of the most recent
data available for the FY 2023 LTCH
PPS ratesetting, including the FY 2021
MedPAR claims and FY 2020 cost report
data. In section I.F. of the preamble of
this final rule we also discuss our
modification of our ratesetting
methodology for FY 2023 to account for
the ongoing COVID–19 PHE.
Comment: We received several
comments unrelated to LTCH PPS
proposals included in the proposed
rule. For example, some commenters
requested changes to the structure of the
PO 00000
Frm 00371
Fmt 4701
Sfmt 4700
49149
site neutral payment policy or the
calculation of the average length of stay.
Response: We appreciate the
commenters’ feedback and will keep
these comments in mind for future
rulemaking.
B. Medicare Severity Long-Term Care
Diagnosis-Related Group (MS–LTC–
DRG) Classifications and Relative
Weights for FY 2023
1. Background
Section 123 of the BBRA required that
the Secretary implement a PPS for
LTCHs to replace the cost-based
payment system under TEFRA. Section
307(b)(1) of the BIPA modified the
requirements of section 123 of the BBRA
by requiring that the Secretary examine
the feasibility and the impact of basing
payment under the LTCH PPS on the
use of existing (or refined) hospital
DRGs that have been modified to
account for different resource use of
LTCH patients.
Under both the IPPS and the LTCH
PPS, the DRG-based classification
system uses information on the claims
for inpatient discharges to classify
patients into distinct groups (for
example, DRGs) based on clinical
characteristics and expected resource
needs. When the LTCH PPS was
implemented for cost reporting periods
beginning on or after October 1, 2002,
we adopted the same DRG patient
classification system utilized at that
time under the IPPS. We referred to this
patient classification system as the
‘‘long-term care diagnosis-related groups
(LTC–DRGs).’’ As part of our efforts to
better recognize severity of illness
among patients, in the FY 2008 IPPS
final rule with comment period (72 FR
47130), we adopted the MS–DRGs and
the Medicare severity long-term care
diagnosis-related groups (MS–LTC–
DRGs) under the IPPS and the LTCH
PPS, respectively, effective beginning
October 1, 2007 (FY 2008). For a full
description of the development,
implementation, and rationale for the
use of the MS–DRGs and MS–LTC–
DRGs, we refer readers to the FY 2008
IPPS final rule with comment period (72
FR 47141 through 47175 and 47277
through 47299). (We note that, in that
same final rule, we revised the
regulations at § 412.503 to specify that
for LTCH discharges occurring on or
after October 1, 2007, when applying
the provisions of 42 CFR part 412,
subpart O, applicable to LTCHs for
policy descriptions and payment
calculations, all references to LTC–
DRGs would be considered a reference
to MS–LTC–DRGs. For the remainder of
this section, we present the discussion
E:\FR\FM\10AUR2.SGM
10AUR2
49150
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
in terms of the current MS–LTC–DRG
patient classification system unless
specifically referring to the previous
LTC–DRG patient classification system
that was in effect before October 1,
2007.)
Consistent with section 123 of the
BBRA, as amended by section 307(b)(1)
of the BIPA, and § 412.515 of the
regulations, we use information derived
from LTCH PPS patient records to
classify LTCH discharges into distinct
MS–LTC–DRGs based on clinical
characteristics and estimated resource
needs. As noted previously, we adopted
the same DRG patient classification
system utilized at that time under the
IPPS. The MS–DRG classifications are
updated annually, which has resulted in
the number of MS–DRGs changing over
time. For FY 2023, there will be 767
MS–DRG, and by extension, MS–LTC–
DRG, groupings based on the changes,
as discussed in section II.E. of the
preamble of this final rule.
Although the patient classification
system used under both the LTCH PPS
and the IPPS are the same, the relative
weights are different. The established
relative weight methodology and data
used under the LTCH PPS result in
relative weights under the LTCH PPS
that reflect the differences in patient
resource use of LTCH patients,
consistent with section 123(a)(1) of the
BBRA. That is, we assign an appropriate
weight to the MS–LTC–DRGs to account
for the differences in resource use by
patients exhibiting the case complexity
and multiple medical problems
characteristic of LTCH patients.
2. Patient Classifications Into MS–LTC–
DRGs
khammond on DSKJM1Z7X2PROD with RULES2
a. Background
The MS–DRGs (used under the IPPS)
and the MS–LTC–DRGs (used under the
LTCH PPS) are based on the CMS DRG
structure. As noted previously in this
section, we refer to the DRGs under the
LTCH PPS as MS–LTC–DRGs although
they are structurally identical to the
MS–DRGs used under the IPPS.
The MS–DRGs are organized into 25
major diagnostic categories (MDCs),
most of which are based on a particular
organ system of the body; the remainder
involve multiple organ systems (such as
MDC 22, Burns). Within most MDCs,
cases are then divided into surgical
DRGs and medical DRGs. Surgical DRGs
are assigned based on a surgical
hierarchy that orders operating room
(O.R.) procedures or groups of O.R.
procedures by resource intensity. The
GROUPER software program does not
recognize all ICD–10–PCS procedure
codes as procedures affecting DRG
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
assignment. That is, procedures that are
not surgical (for example, EKGs) or are
minor surgical procedures (for example,
a biopsy of skin and subcutaneous
tissue (procedure code 0JBH3ZX)) do
not affect the MS–LTC–DRG assignment
based on their presence on the claim.
Generally, under the LTCH PPS, a
Medicare payment is made at a
predetermined specific rate for each
discharge that varies based on the MS–
LTC–DRG to which a beneficiary’s
discharge is assigned. Cases are
classified into MS–LTC–DRGs for
payment based on the following six data
elements:
• Principal diagnosis.
• Additional or secondary diagnoses.
• Surgical procedures.
• Age.
• Sex.
• Discharge status of the patient.
Currently, for claims submitted using
the version ASC X12 5010 format, up to
25 diagnosis codes and 25 procedure
codes are considered for an MS–DRG
assignment. This includes one principal
diagnosis and up to 24 secondary
diagnoses for severity of illness
determinations. (For additional
information on the processing of up to
25 diagnosis codes and 25 procedure
codes on hospital inpatient claims, we
refer readers to section II.G.11.c. of the
preamble of the FY 2011 IPPS/LTCH
PPS final rule (75 FR 50127).)
Under the HIPAA transactions and
code sets regulations at 45 CFR parts
160 and 162, covered entities must
comply with the adopted transaction
standards and operating rules specified
in subparts I through S of part 162.
Among other requirements, on or after
January 1, 2012, covered entities are
required to use the ASC X12 Standards
for Electronic Data Interchange
Technical Report Type 3—Health Care
Claim: Institutional (837), May 2006,
ASC X12N/005010X223, and Type 1
Errata to Health Care Claim:
Institutional (837) ASC X12 Standards
for Electronic Data Interchange
Technical Report Type 3, October 2007,
ASC X12N/005010X233A1 for the
health care claims or equivalent
encounter information transaction (45
CFR 162.1102(c)).
HIPAA requires covered entities to
use the applicable medical data code
sets when conducting HIPAA
transactions (45 CFR 162.1000).
Currently, upon the discharge of the
patient, the LTCH must assign
appropriate diagnosis and procedure
codes from the International
Classification of Diseases, 10th
Revision, Clinical Modification (ICD–
10–CM) for diagnosis coding and the
International Classification of Diseases,
PO 00000
Frm 00372
Fmt 4701
Sfmt 4700
10th Revision, Procedure Coding
System (ICD–10–PCS) for inpatient
hospital procedure coding, both of
which were required to be implemented
October 1, 2015 (45 CFR 162.1002(c)(2)
and (3)). For additional information on
the implementation of the ICD–10
coding system, we refer readers to
section II.F.1. of the preamble of the FY
2017 IPPS/LTCH PPS final rule (81 FR
56787 through 56790) and section II.E.1.
of the preamble of this final rule.
Additional coding instructions and
examples are published in the AHA’s
Coding Clinic for ICD–10–CM/PCS.
To create the MS–DRGs (and by
extension, the MS–LTC–DRGs), base
DRGs were subdivided according to the
presence of specific secondary
diagnoses designated as complications
or comorbidities (CCs) into one, two, or
three levels of severity, depending on
the impact of the CCs on resources used
for those cases. Specifically, there are
sets of MS–DRGs that are split into 2 or
3 subgroups based on the presence or
absence of a CC or a major complication
or comorbidity (MCC). We refer readers
to section II.D. of the preamble of the FY
2008 IPPS final rule with comment
period for a detailed discussion about
the creation of MS–DRGs based on
severity of illness levels (72 FR 47141
through 47175).
MACs enter the clinical and
demographic information submitted by
LTCHs into their claims processing
systems and subject this information to
a series of automated screening
processes called the Medicare Code
Editor (MCE). These screens are
designed to identify cases that require
further review before assignment into a
MS–LTC–DRG can be made. During this
process, certain types of cases are
selected for further explanation (74 FR
43949).
After screening through the MCE,
each claim is classified into the
appropriate MS–LTC–DRG by the
Medicare LTCH GROUPER software on
the basis of diagnosis and procedure
codes and other demographic
information (age, sex, and discharge
status). The GROUPER software used
under the LTCH PPS is the same
GROUPER software program used under
the IPPS. Following the MS–LTC–DRG
assignment, the MAC determines the
prospective payment amount by using
the Medicare PRICER program, which
accounts for hospital-specific
adjustments. Under the LTCH PPS, we
provide an opportunity for LTCHs to
review the MS–LTC–DRG assignments
made by the MAC and to submit
additional information within a
specified timeframe as provided in
§ 412.513(c).
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
The GROUPER software is used both
to classify past cases to measure relative
hospital resource consumption to
establish the MS–LTC–DRG relative
weights and to classify current cases for
purposes of determining payment. The
records for all Medicare hospital
inpatient discharges are maintained in
the MedPAR file. The data in this file
are used to evaluate possible MS–DRG
and MS–LTC–DRG classification
changes and to recalibrate the MS–DRG
and MS–LTC–DRG relative weights
during our annual update under both
the IPPS (§ 412.60(e)) and the LTCH PPS
(§ 412.517), respectively.
b. Changes to the MS–LTC–DRGs for FY
2023
As specified by our regulations at
§ 412.517(a), which require that the MS–
LTC–DRG classifications and relative
weights be updated annually, and
consistent with our historical practice of
using the same patient classification
system under the LTCH PPS as is used
under the IPPS, in this final rule, as
proposed, we updated the MS–LTC–
DRG classifications effective October 1,
2022 through September 30, 2023 (FY
2023) consistent with the changes to
specific MS–DRG classifications
presented in section II.D. of the
preamble of this final rule. Accordingly,
the MS–LTC–DRGs for FY 2023 are the
same as the MS–DRGs being used under
the IPPS for FY 2023. In addition,
because the MS–LTC–DRGs for FY 2023
are the same as the MS–DRGs for FY
2023, the other changes that affect MS–
DRG (and, by extension, MS–LTC–DRG)
assignments under GROUPER Version
40, as discussed in section II.D. of the
preamble of this final rule, including the
changes to the MCE software and the
ICD–10–CM/PCS coding system, are
also applicable under the LTCH PPS for
FY 2023.
khammond on DSKJM1Z7X2PROD with RULES2
3. General Summary of the FY 2023
MS–LTC–DRG Relative Weights
Methodology
In this section of this final rule, we
provide a general summary of our
modifications to the methodology for
determining the FY 2023 MS–LTC–DRG
relative weights under the LTCH PPS.
a. Averaging of Relative Weights for FY
2023
In section I.F. of the preamble to this
final rule, we discuss our use of FY
2021 claims data for the FY 2023 LTCH
PPS ratesetting. As we discussed in the
FY 2023 IPPS/LTCH PPS proposed rule
(87 FR 28466), we recognize the impact
COVID–19 cases in the FY 2021 claims
data have on the relative weight
calculations for a few COVID–19-related
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
MS–LTC–DRGs. Specifically, we have
determined that the COVID–19 cases
grouped to a few MS–LTC–DRGs have,
on average, meaningfully different costs
than the non-COVID–19 cases grouped
to these MS–LTC–DRGs. As a result, for
these MS–LTC–DRGs, the relative
weights calculated using all cases will
be meaningfully different than the
relative weights calculated excluding
COVID–19 cases. For example, using the
FY 2021 MedPAR data, the relative
weight for MS–LTC–DRG 870
(Septicemia or severe sepsis with MV
>96 hours) is approximately 3.1 percent
higher when the relative weights are
calculated including COVID–19 cases
compared to when the relative weights
are calculated excluding COVID–19
cases.
In section I.F. of the preamble to this
final rule, we also discuss that we
believe it is reasonable to assume there
will be fewer COVID–19
hospitalizations among Medicare
beneficiaries in LTCHs in FY 2023 than
there were in FY 2021, although we
cannot know the actual number of
COVID–19 hospitalizations among
Medicare beneficiaries in LTCHs in FY
2023. In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28466), we
proposed to modify our relative weight
methodology for FY 2023 to align with
an assumption that there will be fewer,
but not zero, COVID–19 cases in FY
2023 compared to FY 2021. To account
for this assumption, we proposed an
averaging approach to determine the
MS–LTC–DRG relative weights for FY
2023. Specifically, we proposed to
calculate the relative weights both
including and excluding COVID–19
cases, and then average the two sets of
relative weights together. We stated our
belief that this would be appropriate as
it would reduce, but not remove
entirely, the effect of COVID–19 cases
on the relative weight calculations,
particularly given the uncertainty in the
number of COVID–19 cases in FY 2023.
By averaging the relative weights in this
manner, we stated our belief that the
result would reflect a reasonable
estimation of the mix of cases for FY
2023 based on the information available
at the time on the trajectory of the
COVID–19 PHE (as discussed in section
I.F. of the preamble to this final rule),
and a more accurate estimate of the
relative resource use for cases treated in
FY 2023. We believe the relative
weights calculated using our modified
methodology would be more accurate
than if we applied our standard
methodology, that is, with relative
weights calculated based on 100 percent
of the relative weights calculated using
PO 00000
Frm 00373
Fmt 4701
Sfmt 4700
49151
all applicable LTCH cases. As discussed
in section I.O of Appendix A of the
proposed rule, as an alternative to our
proposed approach, we considered
following our historical approach for
calculating the relative weights and not
proposing this modification. That is, we
considered determining the FY 2023
MS–LTC–DRG weights using all
applicable LTCH cases without any
modifications to account for COVID–19
cases.
Comment: We received comments
that were supportive of our proposal to
use FY 2021 data when determining the
FY 2023 MS–LTC–DRG relative weights.
We also received comments that were
supportive of our proposal to calculate
the relative weights both including and
excluding COVID–19 cases, and then
averaging the two sets of relative
weights together. A commenter stated
that this is a sensible approach to
account for the effects of COVID–19 on
the data CMS uses for ratesetting.
Some commenters disagreed with the
proposed approach for determining the
FY 2023 MS–LTC–DRG relative weights.
These commenters believe a more
appropriate approach would be to
determine the relative weights based on
an average of the relative weights
calculated using FY 2019 data and FY
2021 data. These commenters stated that
COVID–19 has not only influenced
LTCH costs of care through higher direct
input costs, but also through other
factors such as challenges in discharging
patients. Since it is uncertain whether
these factors will remain in FY 2023,
these commenters believe their
suggested approach, which blends
claims data prior to the PHE with claims
data during the PHE, better reflects the
overall uncertainty of the future impact
of COVID–19.
We did not receive any comments in
support of the alternative approach that
we discussed in section I.O of Appendix
A of the proposed rule.
Response: We thank the commenters
for their support. With respect to the
commenters who suggested we
determine the relative weights based on
an average of the relative weights
calculating using FY 2019 and FY 2021
data, we recognize that there is
uncertainty regarding the utilization and
costs that LTCHs will experience in FY
2023. While the commenters’ approach
for addressing this uncertainty is not
unreasonable, we believe that our
proposed approach will result in a more
accurate reflection of the types of cases
expected to be treated by LTCHs in FY
2023. Specifically, we believe that the
mix and resource use of non-COVID–19
cases is better represented by more
recent MedPAR claims data than is
E:\FR\FM\10AUR2.SGM
10AUR2
49152
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
reflected in the cases in the FY 2019
data. Therefore, while we considered
this alternative approach, we continue
to believe that the relative weights
determined as an average of the relative
weights calculated with and without the
COVID–19 cases reflected in the FY
2021 MedPAR data are a more
reasonable estimation of the mix and
relative resource use of cases that will
be treated at LTCHs in FY 2023.
Therefore, after consideration of the
public comments we received, we are
finalizing our proposal to use FY 2021
MedPAR claims data to calculate the FY
2023 MS–LTC–DRG relative weights.
We also are finalizing our proposal to
establish the FY 2023 MS–LTC–DRG
relative weights as an average of the
relative weights calculated both
including and excluding COVID–19
cases identified in the FY 2021 MedPAR
claims. The technical details of the
relative weight calculations are
discussed in section VIII.B.4. of the
preamble to this final rule. We note this
averaging approach for the calculation
of the FY 2023 MS–LTC–DRG relative
weights is consistent with the approach
being adopted under the IPPS for FY
2023, as discussed in section II.E.c. of
the preamble to this final rule.
b. Cap on Relative Weight Decreases
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28466 through
28467), we discussed comments we
have received in recent years about
significant fluctuations in the relative
weights for some MS–LTC–DRGs. We
stated that some commenters have
requested that CMS establish a
transition policy to mitigate the negative
effects of significant year-to-year
reductions to relative weights. We stated
that predictability and stability of rates
is one of the fundamental principles of
a prospective payment system.
Instability in the relative weights for
MS–LTC–DRGs can reduce the
predictability and stability of an
individual LTCH’s Medicare payments
from year to year. Therefore, given the
concerns commenters have raised about
the financial impacts of significant yearto-year fluctuations in MS–LTC–DRGs
relative weights, we proposed a policy
to address these concerns.
Consistent with the broad authority
conferred upon the Secretary by section
123 of the BBRA, as amended by section
307(b) of the BIPA, to determine
appropriate payment adjustments under
the LTCH PPS, including adjustments to
DRG weights, in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28466
through 28467), we proposed to
establish a permanent 10-percent cap on
the reduction to a MS–LTC–DRG’s
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
relative weight in a given year,
beginning in FY 2023. We proposed that
this 10-percent cap would be applied to
the relative weights for MS–LTC–DRGs
with applicable LTCH cases. Under this
policy, the 10-percent cap would not
apply to no-volume MS–LTC–DRGs
(that is, an MS–LTC–DRG with no
applicable LTCH cases) whose relative
weight was determined by a cross-walk
to another MS–LTC–DRG’s relative
weight. We stated our belief that it is not
necessary to apply the 10-percent cap to
no-volume MS–LTC–DRGs because the
financial impact of fluctuations in the
relative weights for these no-volume
MS–LTC–DRGs is extremely small, as
evident by there being zero applicable
LTCH cases grouped to these MS–LTC–
DRGs in the MedPAR claims data.
We also proposed that the 10-percent
cap on the reduction in a MS–LTC–
DRG’s relative weight in a given year be
budget neutral, meaning we would
apply a budget neutrality adjustment to
the MS–LTC–DRG relative weights, after
application of the 10-percent cap, to
ensure that our proposed 10-percent cap
on relative weight reductions policy
results in no change in aggregate LTCH
PPS standard Federal rate payments. We
stated that our application of the
proposed 10-percent cap on the
reduction in a MS–LTC–DRG’s relative
weight in a given year in a budget
neutral manner is consistent with the
existing budget neutrality requirement
for annual MS–LTC–DRG
reclassification and recalibration, which
we adopted to mitigate estimated
fluctuations in estimated aggregate
LTCH PPS payments (72 FR 26881–
26882).
In the proposed rule, we stated our
belief that the impact of the application
of a cap on relative weight reductions
on an LTCH’s total LTCH PPS payments
in a given year would be relatively small
because a change in the relative weight
would be applied to a single MS–LTC–
DRG, unlike the impact of the wage
index adjustment, which adjusts the
payment for each discharge and impacts
approximately two-thirds of an LTCH’s
total LTCH PPS payments in a given
year. In considering the amount of the
cap for our proposal, we explained that
we balanced the number of MS–LTC–
DRGs that would receive the cap with
the magnitude of the budget neutrality
factor that would be applied to all MS–
LTC–DRGs, while also maintaining an
accurate reflection of the relative
resource use across the MS–LTC–DRG
weights overall. We considered that a
higher cap, such as 20-percent cap,
would limit declines in the relative
weights for fewer MS–LTC–DRGs while
a lower cap, such as a 5-percent cap,
PO 00000
Frm 00374
Fmt 4701
Sfmt 4700
would limit declines in the relative
weights for more MS–LTC–DRGs, but
would also result in a larger budget
neutrality adjustment. We stated our
belief that on balance, a 10-percent cap
would mitigate financial impacts
resulting from fluctuations in the
relative weights, particularly for lowvolume MS–LTC–DRGs, without the
larger budget neutrality adjustment
associated with a smaller cap, and
without distorting the integrity of the
MS–LTC–DRG relative weights overall
as a reflection of relative resource use.
We noted that this proposed 10percent cap on reductions to a MS–
LTC–DRG’s relative weight would apply
only to a given MS–LTC–DRG with its
current MS–LTC–DRG number. In cases
where CMS creates new MS–LTC–DRGs
or modifies existing MS–LTC–DRGs as
part of its annual reclassifications
resulting in renumbering of one or more
MS–LTC–DRGs, we proposed that this
limit on the reduction in the relative
weight would not apply to any MS–
LTC–DRGs affected by the renumbering
(that is, the 10-percent cap would not
apply to the relative weight for any new
or renumbered MS–LTC–DRGs for the
fiscal year).
Comment: Commenters generally
agreed with our proposal to cap MS–
LTC–DRG relative weights decreases at
90 percent of the value of the MS–LTC–
DRG relative weight in the previous
year. However, several commenters
questioned the appropriateness of
applying a budget neutrality adjustment
to the 10-percent cap on relative weight
reductions. These commenters
expressed concern that the budget
neutrality adjustment could result in a
decrease to the relative weights for the
most commonly used MS–LTC–DRGs
(the ’’high-volume’’ MS–LTC–DRGs).
Although none of the proposed
relative weights for the top five high
volume MS–LTC–DRGs would decrease
by more than 10-percent in FY 2023,
commenters noted, the proposed budget
neutrality adjustment to offset the 10percent cap on relative weight decreases
for other MS–LTC–DRGs will reduce the
relative weights for these five most
commonly used MS–LTC–DRGs. A
commenter stated that ‘‘high-volume’’
MS–LTC–DRGs are less likely than
‘‘low-volume’’ MS–LTC–DRGs to
decrease more than 10-percent, in
which case applying the proposed 10percent cap in a budget neutral manner
would generally result in increases to
the relative weights of low-volume MS–
LTC–DRGs at the expense of decreases
to the relative weights of high-volume
MS–LTC–DRGs. A commenter
recommended that CMS should only
apply the 10-percent cap to an MS–
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
LTC–DRG relative weight if it is one of
the top five MS–LTC–DRGs, by volume,
of LTCH discharges. This, the
commenter stated, would target
payment relief where it is most needed
and would have more of a beneficial
effect on payment stability from year to
year.
A number of commenters who
disagreed with applying a budget
neutrality adjustment to relative weights
after application of the 10-percent cap
maintained that CMS has the statutory
authority to make adjustments,
including waiving the budget neutrality
adjustment to the cap, under section 123
of the BBRA, as amended by section
BIPA 307(b)(1).
Response: We appreciate the
comments in support of the proposed
10-percent cap on MS–LTC–DRG
relative weight decreases. We agree that
CMS has the statutory authority to
implement this policy in a non-budget
neutral manner. However, we continue
to believe it is appropriate to implement
this policy in a budget neutral manner,
consistent with the existing budget
neutrality requirement for annual MS–
LTC–DRG reclassification and
recalibration, which we adopted to
mitigate estimated fluctuations in
estimated aggregate LTCH PPS
payments (72 FR 26881–26882).
However, we understand commenters’
concerns regarding potential negative
impacts of the budget neutrality
adjustment on the highest volume MS–
LTC–DRG relative weights. We
recognize, as commenters stated, that
the application of a 10-percent cap on
decreases in MS–LTC–DRG relative
weights, applied in a budget neutral
manner, may inadvertently partially
negate our stated intent to stabilize and
increase predictability to LTCH
payments. In response to these
concerns, we conducted additional
analysis regarding the cap on MS–LTC–
DRG weights and the impact of the
budget neutrality adjustment. Based on
the March 2022 update of the FY 2021
MedPAR file used for calculating the
MS–LTC–DRG relative weights in this
final rule, under our proposal, 139 MS–
LTC–DRGs would be subject to the 10percent cap in FY 2023.
These 139 MS–LTC–DRGs accounted
for approximately 5.1 percent of all
standard Federal payment rate cases in
FY 2021. After application of the cap to
these 139 MS–LTC–DRGs, the budget
neutrality adjustment, based on the data
used for this final rule, would have
reduced the relative weights of all MS–
LTC–DRGs by 0.34 percent. We note
that the proposed budget neutrality
adjustment we calculated in the
proposed rule was similar in magnitude
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
and reduced the proposed relative
weights by 0.33 percent. When
developing this policy for the proposed
rule, we considered the magnitude of
the proposed budget neutrality
adjustment against the overall benefits
of our stated policy goal. As discussed
in the proposed rule and noted
previously, we believed the proposed
policy would provide LTCHs more
predictable and stable MS–LTC–DRG
relative weights from year to year. When
we made our proposal, it was our belief
that the overall benefits of the policy
would outweigh the effect of the
corresponding budget neutrality
adjustment on the MS–LTC–DRG
relative weights. However, based on
public comments received, it clear that
not all commenters share this belief.
Therefore, we have explored whether
placing a limit on MS–LTC–DRGs
subject to the cap, similar to the
approach suggested by a commenter,
would reduce both the number of MS–
LTC–DRGs capped and the size of the
budget neutrality adjustment. We found
that limiting the application of the 10percent cap to MS–LTC–DRGs with at
least 25 cases resulted in a significant
decrease to the number of MS–LTC–
DRGs subject to the cap, from 139 to 25.
The MS–LTC–DRGs capped under such
policy accounted for 3.9 percent of all
standard Federal payment rate cases in
FY 2021, and the associated budget
neutrality adjustment for this cap would
result in a much smaller reduction to
the relative weights of all MS–LTC–
DRGs (that is, ¥0.13 percent).
We believe that modifying our
proposed policy so that the 10-percent
cap on MS–LTC–DRG relative weight
decreases only applies to MS–LTC–
DRGs with 25 or more cases addresses
commenters’ concerns about the
destabilizing impact of the budget
neutrality adjustment, as the budget
neutrality adjustment associated with
this more limited cap policy (¥0.13
percent reduction to the relative
weights) is meaningfully less than the
budget neutrality adjustment associated
with our proposed cap policy. We
believe that 25 cases is an appropriate
threshold since that threshold is already
used in establishing the low-volume
MS–LTC–DRGs that are grouped into
quintiles for purposes of calculating the
MS–LTC–DRG relative weights (As
discussed in section VIII.B.4. of the
preamble to this final rule, for purposes
of calculating the MS–LTC–DRG relative
weights, we group low-volume MS–
LTC–DRGs, that is those MS–LTC–DRGs
that contain between 1 and 24
applicable LTCH cases, into five
categories (quintiles) based on average
charges). We also believe that modifying
PO 00000
Frm 00375
Fmt 4701
Sfmt 4700
49153
our proposed policy to limit the
application of the 10-percent cap to
MS–LTC–DRGs with 25 or more cases
will still result in more predictable and
stable MS–LTC–DRG relative weights
from year to year, especially for highvolume MS–LTC–DRGs that generally
have the largest financial impact on an
LTCH’s operations. We note that this
modification to our 10-percent cap
policy will treat MS–LTC–DRGs with 1–
24 cases (low-volume MS–LTC–DRGs)
the same as we proposed to treat novolume MS–LTC–DRGs. That is, the 10percent cap will not apply to either MS–
LTC–DRGs with 1–24 cases (lowvolume) or no-volume MS–LTC–DRGs.
Comment: MedPAC, while agreeing
with the proposal to cap decreases in
MS–LTC–DRG weights at 90 percent of
the MS–LTC–DRG relative weight from
the previous year, recommended
extending this policy to MS–LTC–DRG
relative weights increasing by more than
10 percent, as well.
Response: We appreciate the
suggestion that the cap should apply to
increases in MS–LTC–DRG relative
weights as well as decreases. However,
as we discussed in the proposed rule,
our goal in smoothing year-to-year
changes in MS–LTC–DRG relative
weights is to increase predictability for
LTCHs to enable them to better plan;
when hospitals have more time to adjust
to significant changes to relative
weights, they can mitigate financial
impacts. We did not propose to limit
increases in MS–LTC–DRG relative
weights because we do not believe such
a policy is needed to enable hospitals to
more effectively budget and plan their
operations.
In this final rule, after consideration
of public comments received, we are
finalizing our proposed policy to cap
decreases in MS–LTC–DRG relative
weights to 10 percent of the previous
year’s relative weight, with a
modification that limits the application
of the cap to only MS–LTC–DRGs with
at least 25 applicable LTCH cases in the
claims data used to calculate the relative
weights for the fiscal year. We also are
finalizing our proposal that the 10percent cap on the reduction in a MS–
LTC–DRG’s relative weight in a given
year will be budget neutral. As an
example, if the relative weight for an
MS–LTC–DRG with at least 25
applicable LTCH cases was 1.100 in FY
2022 and the relative weight for FY
2023 would otherwise be 0.9350, which
would represent a decrease of 15
percent from FY 2022, the reduction
would be limited to 10 percent such that
the relative weight for FY 2023 would
be 0.9900 (that is, 0.90 × FY 2022 weight
of 1.100) prior to the application of the
E:\FR\FM\10AUR2.SGM
10AUR2
49154
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
budget neutrality adjustment (as
described later in this section in Step 13
of our methodology). In cases where
CMS creates new MS–LTC–DRGs or
modifies the MS–LTC–DRGs as part of
its annual reclassifications resulting in
renumbering of one or more MS–LTC–
DRGs, we are finalizing our proposal
that this the 10-percent cap will not
apply to the relative weight for any new
or renumbered MS–LTC–DRGs for the
fiscal year.
Consequently, we are amending our
proposed regulation at 42 CFR 412.515
to reflect the modification we are
adopting in this final rule to limit the
application of the 10-percent cap on
MS–LTC–DRG relative weight
reductions to only MS–LTC–DRGs with
at least 25 applicable LTCH cases in the
claims data used to calculate the relative
weights for the fiscal year. The technical
details of this provision are discussed in
section VIII.B.4. of the preamble to this
final rule. We note that this provision is
similar to the permanent 10-percent cap
on decreases to a MS–DRG relative
weight being adopted under the IPPS, as
discussed in section II.E.d. of the
preamble of this final rule.
c. Conforming Changes to Other
Components of the FY 2023 MS–LTC–
DRG Relative Weights Methodology
In general, for FY 2023, we continue
to apply the other components of our
existing methodology for determining
the MS–LTC–DRG relative weights (as
discussed in greater detail in section
VIII.B.4. of the preamble of this final
rule) that are not impacted by our
previously described modifications to
our methodology. As discussed
previously, we are establishing the FY
2023 MS–LTC–DRG relative weights
using an average of the relative weights
calculated both including and excluding
the COVID–19 claims to align with an
assumption that there will be fewer, but
not zero, COVID–19 cases in FY 2023
compared to FY 2021. We note that in
conjunction with this modification, we
applied the MS–LTC–DRG relative
weights methodology, described later in
this section, twice—once to determine
the relative weights based on claims
data that include COVID–19 cases and
again to determine the relative weights
based on claims data that exclude
COVID–19 cases. Specifically, in
determining the relative weights based
on both sets of claims, we applied our
established policies related to the
hospital-specific relative value
methodology, the treatment of severity
levels in the MS LTC DRGs, low-volume
and no-volume MS LTC DRGs, and
adjustments for nonmonotonicity, only
using data from applicable LTCH cases
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
(which includes our policy of only
using cases that would meet the criteria
for exclusion from the site neutral
payment rate). We discuss all
components of our MS–LTC–DRG
relative weight methodology in greater
detail in section VIII.B.4.g. of the
preamble of this final rule.
4. Development of the FY 2023 MS–
LTC–DRG Relative Weights
a. General Overview of the MS–LTC–
DRG Relative Weights
One of the primary goals for the
implementation of the LTCH PPS is to
pay each LTCH an appropriate amount
for the efficient delivery of medical care
to Medicare patients. The system must
be able to account adequately for each
LTCH’s case-mix to ensure both fair
distribution of Medicare payments and
access to adequate care for those
Medicare patients whose care is costlier
(67 FR 55984). To accomplish these
goals, we have annually adjusted the
LTCH PPS standard Federal prospective
payment rate by the applicable relative
weight in determining payment to
LTCHs for each case. Under the LTCH
PPS, relative weights for each MS–LTC–
DRG are a primary element used to
account for the variations in cost per
discharge and resource utilization
among the payment groups (§ 412.515).
To ensure that Medicare patients
classified to each MS–LTC–DRG have
access to an appropriate level of services
and to encourage efficiency, we
calculate a relative weight for each MS–
LTC–DRG that represents the resources
needed by an average inpatient LTCH
case in that MS–LTC–DRG. For
example, cases in an MS–LTC–DRG
with a relative weight of 2 would, on
average, cost twice as much to treat as
cases in an MS–LTC–DRG with a
relative weight of 1.
The established methodology to
develop the MS–LTC–DRG relative
weights is generally consistent with the
methodology established when the
LTCH PPS was implemented in the
August 30, 2002 LTCH PPS final rule
(67 FR 55989 through 55991). However,
there have been some modifications of
our historical procedures for assigning
relative weights in cases of zero volume
or nonmonotonicity or both resulting
from the adoption of the MS–LTC–
DRGs, along with the change made in
conjunction with the implementation of
the dual rate LTCH PPS payment
structure beginning in FY 2016 to use
LTCH claims data from only LTCH PPS
standard Federal payment rate cases (or
LTCH PPS cases that would have
qualified for payment under the LTCH
PPS standard Federal payment rate if
PO 00000
Frm 00376
Fmt 4701
Sfmt 4700
the dual rate LTCH PPS payment
structure had been in effect at the time
of the discharge). (For details on the
modifications to our historical
procedures for assigning relative
weights in cases of zero volume and
nonmonotonicity or both, we refer
readers to the FY 2008 IPPS final rule
with comment period (72 FR 47289
through 47295) and the FY 2009 IPPS
final rule (73 FR 48542 through 48550).)
For details on the change in our
historical methodology to use LTCH
claims data only from LTCH PPS
standard Federal payment rate cases (or
cases that would have qualified for such
payment had the LTCH PPS dual
payment rate structure been in effect at
the time) to determine the MS–LTC–
DRG relative weights, we refer readers
to the FY 2016 IPPS/LTCH PPS final
rule (80 FR 49614 through 49617).
For purposes of determining the MS–
LTC–DRG relative weights, under our
historical methodology, there are three
different categories of MS–LTC–DRGs
based on volume of cases within
specific MS–LTC–DRGs: (1) MS–LTC–
DRGs with at least 25 applicable LTCH
cases in the data used to calculate the
relative weight, which are each assigned
a unique relative weight; (2) low-volume
MS–LTC–DRGs (that is, MS–LTC–DRGs
that contain between 1 and 24
applicable LTCH cases that are grouped
into quintiles (as described later in this
section in Step 3 of our methodology)
and assigned the relative weight of the
quintile); and (3) no-volume MS–LTC–
DRGs that are cross-walked to other
MS–LTC–DRGs based on the clinical
similarities and assigned the relative
weight of the cross-walked MS–LTC–
DRG (as described later in this section
in Step 8 of our methodology). For FY
2023, we are continuing to use
applicable LTCH cases to establish the
same volume-based categories to
calculate the FY 2023 MS–LTC–DRG
relative weights.
As discussed in section VIII.B.3.a. of
the preamble to this final rule, for FY
2023, we are establishing the MS–LTC–
DRG relative weights as an average of
the relative weights calculated both
including and excluding the COVID–19
claims. As discussed in section
VIII.B.3.b. of the preamble to this final
rule, we also are establishing a 10percent cap on the reduction in a MSLTC–DRG’s relative weight, beginning
in FY 2023 for MS–LTC–DRGs with at
least 25 applicable LTCH cases in the
claims data used to calculate the relative
weights for the fiscal year.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
b. Development of the MS–LTC–DRG
Relative Weights for FY 2023
In this section, we present our
methodology for determining the MS–
LTC–DRG relative weights for FY 2023.
In general, we are continuing to apply
the components of our existing
methodology that are not impacted by
our modifications to use an average of
the relative weights calculated both
including and excluding the COVID–19
claims and the application of a 10percent cap on the reduction in a MS–
LTC–DRG’s relative weight, as
discussed in section VIII.B.3 of the
preamble to this final rule. For example,
we are continuing with the application
of established policies related to the
hospital-specific relative value
methodology, the treatment of severity
levels in the MS–LTC–DRGs, lowvolume and no-volume MS–LTC–DRGs,
adjustments for nonmonotonicity, and
only using data from applicable LTCH
cases (which includes our policy of only
using cases that would meet the criteria
for exclusion from the site neutral
payment rate). We note that in our
establishment of MS–LTC–DRG relative
weights using an average of the relative
weights calculated both including and
excluding the COVID–19 claims,
particular components of our existing
relative weight methodology are
performed twice (once when
determining relative weights based on
claims data that include COVID–19
cases and again when determining
relative weights based on claims data
that exclude COVID–19 cases). Later in
this section we list and provide a brief
description of our steps for determining
the FY 2023 MS–LTC–DRG relative
weights. Each step is discussed in
greater detail later in this section.
• Step 1—Prepare data for MS–LTC–
DRG relative weight calculation. In this
step, we select and group the applicable
claims data used in the development of
the MS–LTC–DRG relative weights. For
FY 2023, we are preparing two sets of
claims: a claims dataset that includes
COVID–19 cases and a claims dataset
that excludes COVID–19 cases.
• Step 2—Remove cases with a length
of stay of 7 days or less. In this step, we
trim the applicable claims data to
remove cases with a length of stay 7
days or less. For FY 2023, we are
performing this step on each set of
claims data (claims dataset that includes
COVID–19 cases and claims dataset that
excludes COVID–19 cases).
• Step 3—Establish low-volume MS–
LTC–DRG quintiles. In this step, we
employ our established quintile
methodology for low-volume MS–LTC–
DRGs (that is, MS–LTC–DRGs with less
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
than 25 cases). For FY 2023, we are
performing this step on each set of
claims data (claims dataset that includes
COVID–19 cases and claims dataset that
excludes COVID–19 cases).
• Step 4—Remove statistical outliers.
In this step, we trim the applicable
claims data to remove statistical outlier
cases. For FY 2023, we are performing
this step on each set of claims data
(claims dataset that includes COVID–19
cases and claims dataset that excludes
COVID–19 cases).
• Step 5—Adjust charges for the
effects of Short Stay Outliers (SSOs). In
this step, we adjust the number of
applicable cases in each MS–LTC–DRG
(or low-volume quintile) for the effect of
SSO cases. For FY 2023, we are
performing this step on each set of
claims data (claims dataset that includes
COVID–19 cases and claims dataset that
excludes COVID–19 cases).
• Step 6—Calculate the relative
weights on an iterative basis using the
hospital-specific relative weights
methodology. In this step, we use our
established hospital-specific relative
value (HSRV) methodology, which is an
iterative process, to calculate the
relative weights. For FY 2023, we are
using the HSRV methodology to
calculate relative weights using the
claims that include COVID–19 cases and
again using the claims that exclude the
COVID–19 cases.
• Step 7— Adjust the relative weights
to account for nonmonotonically
increasing relative weights. In this step,
we make adjustments that ensure that
within each base MS–LTC–DRG, the
relative weights increase by MS–LTC–
DRG severity. For FY 2023, we are
adjusting each set of relative weights
(that is, the relative weights calculated
including COVID–19 cases and the
relative weights calculated excluding
COVID–19 cases).
• Step 8—Determine a relative weight
for MS–LTC–DRGs with no applicable
LTCH cases. In this step, we cross-walk
each no-volume MS–LTC–DRG to
another MS–LTC–DRG for which we
calculated a relative weight. For FY
2023, we are cross-walking no-volume
MS–LTC–DRGs in each set of relative
weights (that is, the set of relative
weights calculated including COVID–19
cases and the set of relative weights
calculated excluding COVID–19 cases).
• Step 9—Normalize each set of
relative weights. In this step, we make
a normalization adjustment so that the
recalibration of the MS–LTC–DRG
relative weights (that is, the process
itself) neither increases nor decreases
the average case-mix index. For FY
2023, we are normalizing the set of
relative weights calculated including
PO 00000
Frm 00377
Fmt 4701
Sfmt 4700
49155
COVID–19 cases and the set relative
weights calculated excluding COVID–19
cases.
• Step 10—Average the two sets of
normalized relative weights. In this step,
we average the set of normalized
relative weights calculated including
COVID–19 cases and the set of
normalized relative weights calculated
excluding COVID–19 cases. In addition
to the relative weights, we also average
the geometric mean length of stays and
arithmetic mean length of stays.
• Step 11—Budget neutralize the
averaged relative weights. In this step, to
ensure budget neutrality in the annual
update to the MS–LTC–DRG
classifications and relative weights, we
adjust the relative weights by a
normalization factor and budget
neutrality factor that ensures estimated
aggregate LTCH PPS payments will be
unaffected by the updates to the MS–
LTC–DRG classifications and relative
weights. This step is performed prior to
applying the 10-percent cap.
• Step 12—Apply the 10-percent cap
to decreases in MS–LTC–DRG relative
weights. In this step we limit the
reduction of the relative weight for a
MS–LTC–DRG to 10 percent of its prior
year value. This 10-percent cap does not
apply to zero-volume MS–LTC–DRGs or
low-volume MS–LTC–DRGs.
• Step 13—Calculate the MS–LTC–
DRG cap budget neutrality factor. In this
step, to ensure budget neutrality in the
application of the MS–LTC–DRG cap
policy, we adjust the relative weights by
a budget neutrality factor that ensures
estimated aggregate LTCH PPS
payments will be unaffected by our
application of the cap to the MS–LTC–
DRG relative weights.
Later in this section we describe each
of the 13 steps for calculating the FY
2023 MS–LTC–DRG relative weights in
greater detail. In this discussion, we
note when the step was performed twice
under our provisions for averaging
relative weights calculated including
COVID–19 cases and relative weights
calculated excluding COVID–19 cases.
Step 1—Prepare data for MS–LTC–
DRG relative weight calculation.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28469), consistent
with our proposals regarding the
calculation of the proposed MS–LTC–
DRG relative weights for FY 2023, we
obtained total charges from FY 2021
Medicare LTCH claims data from the
December 2021 update of the FY 2021
MedPAR file, which was the best
available data at that time, and we
proposed to use Version 40 of the
GROUPER to classify LTCH cases.
Consistent with our historical practice,
we proposed that if better data became
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49156
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
available, we would use those data and
the finalized Version 40 of the
GROUPER in establishing the FY 2023
MS–LTC–DRG relative weights in the
final rule. Accordingly, for this final
rule, we are establishing the FY 2023
MS–LTC–DRG relative weights based on
updated FY 2021 Medicare LTCH
claims data from the March 2022 update
of the FY 2021 MedPAR file, which is
the best available data at the time of
development of this final rule, and the
finalized Version 40 of the GROUPER to
classify LTCH cases.
To calculate the FY 2023 MS–LTC–
DRG relative weights under the dual
rate LTCH PPS payment structure, as we
proposed, we continue to use applicable
LTCH data, which includes our policy
of only using cases that meet the criteria
for exclusion from the site neutral
payment rate (or would have met the
criteria had they been in effect at the
time of the discharge) (80 FR 49624).
Specifically, we began by first
evaluating the LTCH claims data in the
March 2022 update of the FY 2021
MedPAR file to determine which LTCH
cases would meet the criteria for
exclusion from the site neutral payment
rate under § 412.522(b) or had the dual
rate LTCH PPS payment structure
applied to those cases at the time of
discharge. We identified the FY 2021
LTCH cases that were not assigned to
MS–LTC–DRGs 876, 880, 881, 882, 883,
884, 885, 886, 887, 894, 895, 896, 897,
945, and 946, which identify LTCH
cases that do not have a principal
diagnosis relating to a psychiatric
diagnosis or to rehabilitation; and that
either—
• The admission to the LTCH was
‘‘immediately preceded’’ by discharge
from a subsection (d) hospital and the
immediately preceding stay in that
subsection (d) hospital included at least
3 days in an ICU, as we define under the
ICU criterion; or
• The admission to the LTCH was
‘‘immediately preceded’’ by discharge
from a subsection (d) hospital and the
claim for the LTCH discharge includes
the applicable procedure code that
indicates at least 96 hours of ventilator
services were provided during the LTCH
stay, as we define under the ventilator
criterion. Claims data from the FY 2021
MedPAR file that reported ICD–10–PCS
procedure code 5A1955Z were used to
identify cases involving at least 96
hours of ventilator services in
accordance with the ventilator criterion.
We note that we have previously
addressed the treatment of cases that
would have been excluded from the site
neutral payment rate under the statutory
provisions that provided for temporary
exception from the site neutral payment
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
rate under the LTCH PPS for certain
spinal cord specialty hospitals or for
certain severe wound care discharges
from certain LTCHs provided by
sections 15009 and 15010 of Public Law
114–255, respectively. These statutory
provisions were not in effect for any
discharges occurring in FY 2021 (or
beyond), so it is no longer necessary to
address their treatment for purposes of
developing the MS–LTC–DRG relative
weights. We also note that section
3711(b)(2) of the CARES Act, which
provided a waiver of the application of
the site neutral payment rate for LTCH
cases admitted during the COVID–19
PHE period, was in effect for the
entirety of FY 2021. Therefore, all LTCH
PPS cases in FY 2021 were paid the
LTCH PPS standard Federal rate
regardless of whether the discharge met
the statutory patient criteria. However,
for purposes of setting rates for LTCH
PPS standard Federal rate cases for FY
2023 (including MS–LTC–DRG relative
weights), we used FY 2021 cases that
meet the statutory patient criteria
without consideration to how those
cases were paid in FY 2021.
Furthermore, consistent with our
historical methodology, we excluded
any claims in the resulting data set that
were submitted by LTCHs that were allinclusive rate providers and LTCHs that
are paid in accordance with
demonstration projects authorized
under section 402(a) of Public Law 90–
248 or section 222(a) of Public Law 92–
603. In addition, consistent with our
historical practice and our policies, we
excluded any Medicare Advantage (Part
C) claims in the resulting data. Such
claims were identified based on the
presence of a GHO Paid indicator value
of ‘‘1’’ in the MedPAR files.
In addition, as discussed in section
VIII.B.3.a. of this final rule, for FY 2023,
we are establishing the MS–LTC–DRG
relative weights as an average of the
relative weights calculated both
including and excluding the COVID–19
claims. To calculate the set of relative
weights based on claims that excluded
COVID–19 cases, we performed an
additional trim to remove COVID–19
cases. We identified COVID–19 cases as
any claim in the FY 2021 MedPAR file
with a principal or secondary diagnosis
of COVID–19 (ICD–10–CM diagnosis
code U07.1).
In summary, in general, we identified
the claims data used in the development
of the FY 2023 MS–LTC–DRG relative
weights in this final rule by trimming
claims data that would have been paid
the site neutral payment rate had the
provisions of the CARES Act not been
in effect. We trimmed the claims data of
all-inclusive rate providers reported in
PO 00000
Frm 00378
Fmt 4701
Sfmt 4700
the March 2022 update of the FY 2021
MedPAR file and any Medicare
Advantage claims data. There were no
data from any LTCHs that are paid in
accordance with a demonstration
project reported in the March 2022
update of the FY 2021 MedPAR file, but,
had there been any, we would have
trimmed the claims data from those
LTCHs as well, in accordance with our
established policy.
We used the remaining data (that is,
the applicable LTCH data) in the
subsequent steps to calculate the set of
relative weights based on claims that
include COVID–19 cases. In addition,
we performed a trim to remove COVID–
19 cases based on a principal or
secondary diagnosis of COVID–19. We
used these data in the subsequent steps
to calculate the set of relative weights
based on claims that exclude COVID–19
cases.
Step 2—Remove cases with a length of
stay of 7 days or less.
The next step in our calculation of the
FY 2023 MS–LTC–DRG relative weights
is to remove cases with a length of stay
of 7 days or less. The MS–LTC–DRG
relative weights reflect the average of
resources used on representative cases
of a specific type. Generally, cases with
a length of stay of 7 days or less do not
belong in an LTCH because these stays
do not fully receive or benefit from
treatment that is typical in an LTCH
stay, and full resources are often not
used in the earlier stages of admission
to an LTCH. If we were to include stays
of 7 days or less in the computation of
the FY 2023 MS–LTC–DRG relative
weights, the value of many relative
weights would decrease and, therefore,
payments would decrease to a level that
may no longer be appropriate. We do
not believe that it would be appropriate
to compromise the integrity of the
payment determination for those LTCH
cases that actually benefit from and
receive a full course of treatment at an
LTCH by including data from these very
short stays. Therefore, as we proposed,
consistent with our existing relative
weight methodology, in determining the
FY 2023 MS–LTC–DRG relative weights,
we removed LTCH cases with a length
of stay of 7 days or less from applicable
LTCH cases for both sets of claims (that
is the applicable LTCH claims that
include COVID–19 cases and the
applicable LTCH claims that exclude
COVID–19 cases). (For additional
information on what is removed in this
step of the relative weight methodology,
we refer readers to 67 FR 55989 and 74
FR 43959.)
Step 3—Establish low-volume MS–
LTC–DRG quintiles.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
To account for MS–LTC–DRGs with
low-volume (that is, with fewer than 25
applicable LTCH cases), consistent with
our existing methodology, as we
proposed, we are continuing to employ
the quintile methodology for lowvolume MS–LTC–DRGs, such that we
grouped the ‘‘low-volume MS–LTC–
DRGs’’ (that is, MS–LTC–DRGs that
contain between 1 and 24 applicable
LTCH cases into one of five categories
(quintiles) based on average charges (67
FR 55984 through 55995; 72 FR 47283
through 47288; and 81 FR 25148)).
Under our provision in section
VIII.B.3.a. of the preamble to this final
rule to establish the FY 2023 MS–LTC–
DRG relative weights as an average of
the relative weights calculated both
including and excluding the COVID–19
claims, we employed our quintile
methodology when calculating the
relative weights for each set of claims
(that is the claims that include COVID–
19 cases and the claims that exclude
COVID–19 cases).
In this final rule, based on the best
available data (that is, the March 2022
update of the FY 2021 MedPAR files),
we identified 233 MS–LTC–DRGs that
contained between 1 and 24 applicable
LTCH cases in the claims data that
included COVID–19 cases, and 232 MS
LTC–DRGs that contained between 1
and 24 applicable LTCH cases in the
claims data that excluded COVID–19
cases. These lists of MS–LTC–DRGs
were then divided into 1 of the 5 lowvolume quintiles. We assigned the lowvolume MS–LTC–DRGs to specific lowvolume quintiles by sorting the lowvolume MS–LTC–DRGs in ascending
order by average charge in accordance
with our established methodology.
Based on the data available for this final
rule, the number of MS–LTC–DRGs with
less than 25 applicable LTCH cases in
each set of claims was not evenly
divisible by 5. The quintiles based on
the claims data that included COVID–19
cases each contained at least 46 MS–
LTC–DRGs (233/5 = 46 with a
remainder of 3). Meanwhile, the
quintiles based on the claims data that
excluded COVID-cases also each
contained at least 46 MS–LTC–DRGs
(232/5 = 46 with a remainder of 2). We
employed our historical methodology of
assigning each remainder low-volume
MS–LTC–DRG to the low-volume
quintile that contains an MS–LTC–DRG
with an average charge closest to that of
the remainder low-volume MS–LTC–
DRG.
For the claims that include COVID–19
cases, the application of our quintile
methodology resulted in 2 low-volume
quintiles containing 46 MS–LTC DRGs
(Quintiles 1 and 5) and 3 low-volume
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
quintiles containing 47 MS–LTC–DRGs
(Quintiles 2, 3, and 4). For the claims
that excluded COVID–19 cases, the
application of our quintile methodology
resulted in 3 low-volume quintiles
containing 46 MS–LTC DRGs (Quintiles
1, 3, and 5) and 2 low-volume quintiles
containing 47 MS–LTC–DRGs (Quintiles
2 and 4). In cases where these initial
assignments of low-volume MS–LTC–
DRGs to quintiles results in
nonmonotonicity within a base-DRG, we
are making adjustments to the resulting
low-volume MS–LTC–DRGs to preserve
monotonicity, as discussed in Step 7 of
our methodology.
To determine the FY 2023 relative
weights for the low-volume MS–LTC–
DRGs, consistent with our historical
practice, we used the five low-volume
quintiles from each set of claims
described previously. We determined a
relative weight and (geometric) average
length of stay for each of the five lowvolume quintiles using the methodology
described in Step 6 of our methodology.
We assigned the same relative weight
and average length-of-stay to each of the
low-volume MS–LTC–DRGs that make
up an individual low-volume quintile.
These calculations were performed
separately for the relative weight set
based on claims that include COVID–19
cases and the relative weight set based
on claims that exclude COVID–19 cases.
We note that, as this system is dynamic,
it is possible that the number and
specific type of MS–LTC–DRGs with a
low-volume of applicable LTCH cases
would vary in the future.
Furthermore, we note that we
continue to monitor the volume (that is,
the number of applicable LTCH cases)
in the low-volume quintiles to ensure
that our quintile assignments used in
determining the MS–LTC–DRG relative
weights result in appropriate payment
for LTCH cases grouped to low-volume
MS–LTC–DRGs and do not result in an
unintended financial incentive for
LTCHs to inappropriately admit these
types of cases. In the proposed rule, we
noted our description in previous rules
did not specify the point in our
methodology when the low-volume
MS–LTC–DRG quintiles are established.
We stated that although we are now
including this step explicitly, this is not
a change to our historical methodology
for determining the MS–LTC–DRG
relative weights.
For this final rule, we are providing
the lists of the composition of the lowvolume quintiles for low-volume MS–
LTC–DRGs in a supplemental data file
for public use posted via the internet on
the CMS website for this final rule at
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
PO 00000
Frm 00379
Fmt 4701
Sfmt 4700
49157
AcuteInpatientPPS/ to
streamline the information made
available to the public that is used in
the annual development of Table 11.
This supplemental data file includes the
composition of low-volume quintiles for
low-volume MS–LTC–DRGs based on
the claims that include COVID–19 cases
and the composition of the low-volume
quintiles for low-volume MS–LTC–
DRGs based on the claims that exclude
COVID–19 cases.
Step 4—Remove statistical outliers.
The next step in our calculation of the
FY 2023 MS–LTC–DRG relative weights
is to remove statistical outlier cases
from the LTCH cases with a length-ofstay of at least 8 days. Consistent with
our existing relative weight
methodology, as we proposed, we are
continuing to define statistical outliers
as cases that are outside of 3.0 standard
deviations from the mean of the log
distribution of both charges per case and
the charges per day for each MS–LTC–
DRG. These statistical outliers are
removed prior to calculating the relative
weights because we believe that they
may represent aberrations in the data
that distort the measure of average
resource use.
Including those LTCH cases in the
calculation of the relative weights could
result in an inaccurate relative weight
that does not truly reflect relative
resource use among those MS–LTC–
DRGs. (For additional information on
what is removed in this step of the
relative weight methodology, we refer
readers to 67 FR 55989 and 74 FR
43959.) This step was performed on
both sets of claims (that is the
applicable LTCH claims that include
COVID–19 cases and the applicable
LTCH claims that exclude COVID–19
cases). After removing cases with a
length of stay of 7 days or less and
statistical outliers, in each set of claims,
we were left with applicable LTCH
cases that have a length of stay greater
than or equal to 8 days. In this final
rule, we refer to these cases as ‘‘trimmed
applicable LTCH cases.’’
Step 5—Adjust charges for the effects
of Short Stay Outliers (SSOs).
As the next step in the calculation of
the FY 2023 MS–LTC–DRG relative
weights, consistent with our historical
approach, as we proposed, we adjusted
each LTCH’s charges per discharge for
those remaining cases in each set of
claims (that is, trimmed applicable
LTCH cases that include COVID–19
cases and the trimmed applicable LTCH
cases that exclude COVID–19 cases) for
the effects of SSOs (as defined in
§ 412.529(a) in conjunction with
§ 412.503). Specifically, as we proposed,
we made this adjustment by counting an
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49158
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
SSO case as a fraction of a discharge
based on the ratio of the length of stay
of the case to the average length of stay
of all cases grouped to the MS–LTC–
DRG. This has the effect of
proportionately reducing the impact of
the lower charges for the SSO cases in
calculating the average charge for the
MS–LTC–DRG. This process produces
the same result as if the actual charges
per discharge of an SSO case were
adjusted to what they would have been
had the patient’s length of stay been
equal to the average length of stay of the
MS–LTC–DRG.
Counting SSO cases as full LTCH
cases with no adjustment in
determining the FY 2023 MS–LTC–DRG
relative weights would lower the
relative weight for affected MS–LTC–
DRGs because the relatively lower
charges of the SSO cases would bring
down the average charge for all cases
within a MS–LTC–DRG. This would
result in an ‘‘underpayment’’ for nonSSO cases and an ‘‘overpayment’’ for
SSO cases. Therefore, we are continuing
to adjust for SSO cases under § 412.529
in this manner because it would result
in more appropriate payments for all
LTCH PPS standard Federal payment
rate cases. (For additional information
on this step of the relative weight
methodology, we refer readers to 67 FR
55989 and 74 FR 43959.)
Step 6—Calculate the relative weights
on an iterative basis using the hospitalspecific relative value (HSRV)
methodology.
By nature, LTCHs often specialize in
certain areas, such as ventilatordependent patients. Some case types
(MS–LTC–DRGs) may be treated, to a
large extent, in hospitals that have, from
a perspective of charges, relatively high
(or low) charges. This nonrandom
distribution of cases with relatively high
(or low) charges in specific MS–LTC–
DRGs has the potential to
inappropriately distort the measure of
average charges. To account for the fact
that cases may not be randomly
distributed across LTCHs, consistent
with the methodology we have used
since the implementation of the LTCH
PPS, in this FY 2023 IPPS/LTCH PPS
final rule, as we proposed, we are
continuing to use a hospital-specific
relative value (HSRV) methodology to
calculate the MS–LTC–DRG relative
weights for FY 2023. We believe that
this method removes this hospitalspecific source of bias in measuring
LTCH average charges (67 FR 55985).
Specifically, under this methodology,
we reduced the impact of the variation
in charges across providers on any
particular MS–LTC–DRG relative weight
by converting each LTCH’s charge for an
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
applicable LTCH case to a relative value
based on that LTCH’s average charge for
such cases.
Under the HSRV methodology, we
standardize charges for each LTCH by
converting its charges for each
applicable LTCH case to hospitalspecific relative charge values and then
adjusting those values for the LTCH’s
case-mix. The adjustment for case-mix
is needed to rescale the hospital-specific
relative charge values (which, by
definition, average 1.0 for each LTCH).
The average relative weight for an LTCH
is its case-mix; therefore, it is reasonable
to scale each LTCH’s average relative
charge value by its case-mix. In this
way, each LTCH’s relative charge value
is adjusted by its case-mix to an average
that reflects the complexity of the
applicable LTCH cases it treats relative
to the complexity of the applicable
LTCH cases treated by all other LTCHs
(the average LTCH PPS case-mix of all
applicable LTCH cases across all
LTCHs). In other words, by multiplying
an LTCH’s relative charge values by the
LTCH’s case-mix index, we account for
the fact that the same relative charges
are given greater weight at an LTCH
with higher average costs than they
would at an LTCH with low average
costs, which is needed to adjust each
LTCH’s relative charge value to reflect
its case-mix relative to the average casemix for all LTCHs. By standardizing
charges in this manner, we count
charges for a Medicare patient at an
LTCH with high average charges as less
resource-intensive than they would be
at an LTCH with low average charges.
For example, a $10,000 charge for a case
at an LTCH with an average adjusted
charge of $17,500 reflects a higher level
of relative resource use than a $10,000
charge for a case at an LTCH with the
same case-mix, but an average adjusted
charge of $35,000. We believe that the
adjusted charge of an individual case
more accurately reflects actual resource
use for an individual LTCH because the
variation in charges due to systematic
differences in the markup of charges
among LTCHs is taken into account.
Consistent with our historical relative
weight methodology, as we proposed,
we calculated the FY 2023 MS–LTC–
DRG relative weights using the HSRV
methodology, which is an iterative
process. Under our provision in section
VIII.B.3.a. of the preamble to this final
rule to establish the FY 2023 MS–LTC–
DRG relative weights as an average of
the relative weights calculated both
including and excluding the COVID–19
claims, we applied the HSRV
methodology when calculating the
relative weights for each sets of claims
(that is the claims that include COVID–
PO 00000
Frm 00380
Fmt 4701
Sfmt 4700
19 cases and the claims that exclude
COVID–19 cases).
Therefore, in accordance with our
established methodology, for FY 2023,
we continued to standardize charges for
each applicable LTCH case by first
dividing the adjusted charge for the case
(adjusted for SSOs under § 412.529 as
described in Step 5 of our methodology)
by the average adjusted charge for all
applicable LTCH cases at the LTCH in
which the case was treated. The average
adjusted charge reflects the average
intensity of the health care services
delivered by a particular LTCH and the
average cost level of that LTCH. The
average adjusted charge was then
multiplied by the LTCH’s case-mix
index to produce an adjusted hospitalspecific relative charge value for the
case. We used an initial case-mix index
value of 1.0 for each LTCH.
For each MS–LTC–DRG, we
calculated the FY 2023 relative weight
by dividing the SSO-adjusted average of
the hospital-specific relative charge
values for applicable LTCH cases for the
MS–LTC–DRG (that is, the sum of the
hospital-specific relative charge value,
as previously stated, divided by the sum
of equivalent cases from Step 5 for each
MS–LTC–DRG) by the overall SSOadjusted average hospital-specific
relative charge value across all
applicable LTCH cases for all LTCHs
(that is, the sum of the hospital-specific
relative charge value, as previously
stated, divided by the sum of equivalent
applicable LTCH cases from Step 5 for
each MS–LTC–DRG). Using these
recalculated MS–LTC–DRG relative
weights, each LTCH’s average relative
weight for all of its SSO-adjusted
trimmed applicable LTCH cases (that is,
its case-mix) was calculated by dividing
the sum of all the LTCH’s MS–LTC–
DRG relative weights by its total number
of SSO-adjusted trimmed applicable
LTCH cases. The LTCHs’ hospitalspecific relative charge values (from
previous) are then multiplied by the
hospital-specific case-mix indexes. The
hospital-specific case-mix adjusted
relative charge values were then used to
calculate a new set of MS–LTC–DRG
relative weights across all LTCHs. This
iterative process continued until there
was convergence between the relative
weights produced at adjacent steps, for
example, when the maximum difference
was less than 0.0001.
Step 7—Adjust the relative weights to
account for nonmonotonically
increasing relative weights.
The MS–DRGs contain base DRGs that
have been subdivided into one, two, or
three severity of illness levels. Where
there are three severity levels, the most
severe level has at least one secondary
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
diagnosis code that is referred to as an
MCC (that is, major complication or
comorbidity). The next lower severity
level contains cases with at least one
secondary diagnosis code that is a CC
(that is, complication or comorbidity).
Those cases without an MCC or a CC are
referred to as ‘‘without CC/MCC.’’ When
data do not support the creation of three
severity levels, the base MS–DRG is
subdivided into either two levels or the
base MS–DRG is not subdivided. The
two-level subdivisions may consist of
the MS–DRG with CC/MCC and the
MS–DRG without CC/MCC.
Alternatively, the other type of twolevel subdivision may consist of the
MS–DRG with MCC and the MS–DRG
without MCC.
In those base MS–LTC–DRGs that are
split into either two or three severity
levels, cases classified into the ‘‘without
CC/MCC’’ MS–LTC–DRG are expected
to have a lower resource use (and lower
costs) than the ‘‘with CC/MCC’’ MS–
LTC–DRG (in the case of a two-level
split) or both the ‘‘with CC’’ and the
‘‘with MCC’’ MS–LTC–DRGs (in the
case of a three-level split). That is,
theoretically, cases that are more severe
typically require greater expenditure of
medical care resources and would result
in higher average charges. Therefore, in
the three severity levels, relative
weights should increase by severity,
from lowest to highest. If the relative
weights decrease as severity increases
(that is, if within a base MS–LTC–DRG,
an MS–LTC–DRG with CC has a higher
relative weight than one with MCC, or
the MS–LTC–DRG ‘‘without CC/MCC’’
has a higher relative weight than either
of the others), they are nonmonotonic.
We continue to believe that utilizing
nonmonotonic relative weights to adjust
Medicare payments would result in
inappropriate payments because the
payment for the cases in the higher
severity level in a base MS–LTC–DRG
(which are generally expected to have
higher resource use and costs) would be
lower than the payment for cases in a
lower severity level within the same
base MS–LTC–DRG (which are generally
expected to have lower resource use and
costs). Therefore, in determining the FY
2023 MS–LTC–DRG relative weights
based on each set of claims (that is
claims that include COVID–19 cases and
the claims that exclude COVID–19
cases), consistent with our historical
methodology, as we proposed, we
continued to combine MS–LTC–DRG
severity levels within a base MS–LTC–
DRG for the purpose of computing a
relative weight when necessary to
ensure that monotonicity is maintained.
For a comprehensive description of our
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
existing methodology to adjust for
nonmonotonicity, we refer readers to
the FY 2010 IPPS/RY 2010 LTCH PPS
final rule (74 FR 43964 through 43966).
For both sets of weights, the one based
on claims that include COVID–19 cases
and the one based on claims that
exclude COVID–19 cases, any
adjustments for nonmonotonicity that
were made in determining the FY 2023
MS–LTC–DRG relative weights by
applying this methodology are denoted
in Table 11, which is listed in section
VI. of the Addendum to this final rule
and is available via the internet on the
CMS website.
Step 8—Determine a relative weight
for MS–LTC–DRGs with no applicable
LTCH cases.
Using the trimmed applicable LTCH
cases, consistent with our historical
methodology, we identified the MS–
LTC–DRGs for which there were no
claims in the March 2022 update of the
FY 2021 MedPAR file and, therefore, for
which no charge data was available for
these MS–LTC–DRGs. Because patients
with a number of the diagnoses under
these MS–LTC–DRGs may be treated at
LTCHs, consistent with our historical
methodology, we generally assign a
relative weight to each of the no-volume
MS–LTC–DRGs based on clinical
similarity and relative costliness (with
the exception of ‘‘transplant’’ MS–LTC–
DRGs, ‘‘error’’ MS–LTC–DRGs, and MS–
LTC–DRGs that indicate a principal
diagnosis related to a psychiatric
diagnosis or rehabilitation (referred to as
the ‘‘psychiatric or rehabilitation’’ MS–
LTC–DRGs), as discussed later in this
section of this final rule). (For
additional information on this step of
the relative weight methodology, we
refer readers to 67 FR 55991 and 74 FR
43959 through 43960.)
Consistent with our existing
methodology, as we proposed, we crosswalked each no-volume MS–LTC–DRG
to another MS–LTC–DRG for which we
calculated a relative weight (determined
in accordance with the methodology as
previously described). Then, the ‘‘novolume’’ MS–LTC–DRG was assigned
the same relative weight (and average
length of stay) of the MS–LTC–DRG to
which it was cross-walked (as described
in greater detail in this section of this
final rule).
For this final rule, there was only one
claim grouped to MS–LTC–DRG 273
(Percutaneous and other intracardiac
procedures with MCC) in the March
2022 update of the FY 2021 MedPAR
file. This claim had a COVID–19
diagnosis code. Therefore, when
determining relative weights based on
all applicable LTCH claims, a relative
weight was computed for MS–LTC–DRG
PO 00000
Frm 00381
Fmt 4701
Sfmt 4700
49159
273. However, when determining
relative weights based on the set of
claims that excluded COVID–19 cases, a
relative was not computed for MS–LTC–
DRG 273. When establishing the relative
weights based on claims that exclude
COVID–19 cases, instead of assigning a
cross-walked relative weight for MS–
LTC–DRG 273, as we proposed, we
assigned MS–LTC–DRG 273 the relative
weight calculated using all applicable
LTCH cases. In the absence of a nonCOVID–19 claim for this MS–LTC–DRG,
we believe the relative weight based on
a COVID–19 claim grouped to this same
MS–LTC–DRG would more accurately
reflect the relative resource use of this
MS–LTC–DRG than a relative weight
based on a cross-walked MS–LTC–DRG.
Of the 767 MS–LTC–DRGs for FY
2023, we identified 427 MS–LTC–DRGs
for which there were no trimmed
applicable LTCH cases. We do not
include MS–LTC–DRG 273, discussed
previously, in this count. The 427 MS
LTC DRGs for which there were no
trimmed applicable LTCH cases
includes the 11 ‘‘transplant’’ MS–LTC–
DRGs, the 2 ‘‘error’’ MS–LTC–DRGs,
and the 15 ‘‘psychiatric or
rehabilitation’’ MS–LTC–DRGs, which
are discussed in this section of this rule,
such that we identified 399 MS–LTC–
DRGs that for which, we assigned a
relative weight using our existing ‘‘novolume’’ MS–LTC–DRG methodology
(that is, 427¥11¥2¥15 = 399). As we
proposed, we assigned relative weights
to each of the 399 no-volume MS–LTC–
DRGs based on clinical similarity and
relative costliness to 1 of the remaining
340 (767¥427 = 340) MS–LTC–DRGs
for which we calculated relative weights
based on the trimmed applicable LTCH
cases in the FY 2021 MedPAR file data
using the steps described previously.
(For the remainder of this discussion,
we refer to the ‘‘cross-walked’’ MS–
LTC–DRGs as one of the 340 MS–LTC–
DRGs to which we cross-walked each of
the 399 ‘‘no-volume’’ MS–LTC–DRGs.)
Then, in general, we assigned the 399
no-volume MS–LTC–DRGs the relative
weight of the cross-walked MS–LTC–
DRG (when necessary, we made
adjustments to account for
nonmonotonicity).
We cross-walked the no-volume MS–
LTC–DRG to a MS–LTC–DRG for which
we calculated relative weights based on
the March 2022 update of the FY 2021
MedPAR file, and to which it is similar
clinically in intensity of use of resources
and relative costliness as determined by
criteria such as care provided during the
period of time surrounding surgery,
surgical approach (if applicable), length
of time of surgical procedure,
postoperative care, and length of stay.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49160
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(For more details on our process for
evaluating relative costliness, we refer
readers to the FY 2010 IPPS/RY 2010
LTCH PPS final rule (73 FR 48543).) We
believe in the rare event that there
would be a few LTCH cases grouped to
one of the no-volume MS–LTC–DRGs in
FY 2023, the relative weights assigned
based on the cross-walked MS–LTC–
DRGs would result in an appropriate
LTCH PPS payment because the
crosswalks, which are based on clinical
similarity and relative costliness, would
be expected to generally require
equivalent relative resource use.
Then we assigned the relative weight
of the cross-walked MS–LTC–DRG as
the relative weight for the no-volume
MS–LTC–DRG such that both of these
MS–LTC–DRGs (that is, the no-volume
MS–LTC–DRG and the cross-walked
MS–LTC–DRG) have the same relative
weight (and average length of stay) for
FY 2023. We note that, if the crosswalked MS–LTC–DRG had 25
applicable LTCH cases or more, its
relative weight (calculated using the
methodology as previously described in
Steps 1 through 4) is assigned to the novolume MS–LTC–DRG as well.
Similarly, if the MS–LTC–DRG to which
the no-volume MS–LTC–DRG was crosswalked had 24 or less cases and,
therefore, was designated to 1 of the
low-volume quintiles for purposes of
determining the relative weights, we
assigned the relative weight of the
applicable low-volume quintile to the
no-volume MS–LTC–DRG such that
both of these MS–LTC–DRGs (that is,
the no-volume MS–LTC–DRG and the
cross-walked MS–LTC–DRG) have the
same relative weight for FY 2023. (As
we noted previously, in the infrequent
case where nonmonotonicity involving
a no-volume MS–LTC–DRG resulted,
additional adjustments are required to
maintain monotonically increasing
relative weights.)
For this final rule, we are providing
the list of the no-volume MS–LTC–
DRGs and the MS–LTC–DRGs to which
each was cross-walked (that is, the
cross-walked MS–LTC–DRGs) for FY
2023 in a supplemental data file for
public use posted via the internet on the
CMS website for this final rule at
https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/ to
streamline the information made
available to the public that is used in
the annual development of Table 11.
To illustrate this methodology for
determining the relative weights for the
FY 2023 MS–LTC–DRGs with no
applicable LTCH cases, we are
providing the following example.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Example: There were no trimmed
applicable LTCH cases in the FY 2021
MedPAR file that we are using for this
final rule for MS–LTC–DRG 061
(Ischemic stroke, precerebral occlusion
or transient ischemia with thrombolytic
agent with MCC). We determined that
MS–LTC–DRG 070 (Nonspecific
cerebrovascular disorders with MCC) is
similar clinically and based on resource
use to MS–LTC–DRG 061. Therefore, we
assigned the same relative weight (and
average length of stay) of MS–LTC–DRG
70 of 0.837 for FY 2023 to MS–LTC–
DRG 061 (we refer readers to Table 11,
which is listed in section VI. of the
Addendum to this final rule and is
available via the internet on the CMS
website).
Again, we note that, as this system is
dynamic, it is entirely possible that the
number of MS–LTC–DRGs with no
volume would vary in the future.
Consistent with our historical practice,
as we proposed, we used the best
available claims data to identify the
trimmed applicable LTCH cases from
which we determined the relative
weights in the final rule.
For FY 2023, consistent with our
historical relative weight methodology,
as we proposed, we are establishing a
relative weight of 0.0000 for the
following transplant MS–LTC–DRGs:
Heart Transplant or Implant of Heart
Assist System with MCC (MS–LTC–DRG
001); Heart Transplant or Implant of
Heart Assist System without MCC (MS–
LTC–DRG 002); Liver Transplant with
MCC or Intestinal Transplant (MS–LTC–
DRG 005); Liver Transplant without
MCC (MS–LTC–DRG 006); Lung
Transplant (MS–LTC–DRG 007);
Simultaneous Pancreas/Kidney
Transplant (MS–LTC–DRG 008);
Simultaneous Pancreas/Kidney
Transplant with Hemodialysis (MS–
LTC–DRG 019); Pancreas Transplant
(MS–LTC–DRG 010); Kidney Transplant
(MS–LTC–DRG 652); Kidney Transplant
with Hemodialysis with MCC (MS–
LTC–DRG 650), and Kidney Transplant
with Hemodialysis without MCC (MS
LTC DRG 651). This is because
Medicare only covers these procedures
if they are performed at a hospital that
has been certified for the specific
procedures by Medicare and presently
no LTCH has been so certified. At the
present time, we include these 11
transplant MS–LTC–DRGs in the
GROUPER program for administrative
purposes only. Because we use the same
GROUPER program for LTCHs as is used
under the IPPS, removing these MS–
LTC–DRGs would be administratively
burdensome. (For additional
information regarding our treatment of
transplant MS–LTC–DRGs, we refer
PO 00000
Frm 00382
Fmt 4701
Sfmt 4700
readers to the RY 2010 LTCH PPS final
rule (74 FR 43964).) In addition,
consistent with our historical policy, we
are establishing a relative weight of
0.0000 for the 2 ‘‘error’’ MS–LTC–DRGs
(that is, MS–LTC–DRG 998 (Principal
Diagnosis Invalid as Discharge
Diagnosis) and MS–LTC–DRG 999
(Ungroupable)) because applicable
LTCH cases grouped to these MS–LTC–
DRGs cannot be properly assigned to an
MS–LTC–DRG according to the
grouping logic.
Additionally, we are establishing a
relative weight of 0.0000 for the
following ‘‘psychiatric or rehabilitation’’
MS–LTC–DRGs: MS–LTC–DRG 876
(O.R. Procedure with Principal
Diagnoses of Mental Illness); MS–LTC–
DRG 880 (Acute Adjustment Reaction &
Psychosocial Dysfunction); MS–LTC–
DRG 881 (Depressive Neuroses); MS–
LTC–DRG 882 (Neuroses Except
Depressive); MS–LTC–DRG 883
(Disorders of Personality & Impulse
Control); MS–LTC–DRG 884 (Organic
Disturbances & Mental Retardation);
MS–LTC–DRG 885 (Psychoses); MS–
LTC–DRG 886 (Behavioral &
Developmental Disorders); MS–LTC–
DRG 887 (Other Mental Disorder
Diagnoses); MS–LTC–DRG 894
(Alcohol/Drug Abuse or Dependence,
Left Ama); MS–LTC–DRG 895 (Alcohol/
Drug Abuse or Dependence, with
Rehabilitation Therapy); MS–LTC–DRG
896 (Alcohol/Drug Abuse or
Dependence, without Rehabilitation
Therapy with MCC); MS–LTC–DRG 897
(Alcohol/Drug Abuse or Dependence,
without Rehabilitation Therapy without
MCC); MS–LTC–DRG 945
(Rehabilitation with CC/MCC); and MS–
LTC–DRG 946 (Rehabilitation without
CC/MCC). We are establishing a relative
weight 0.0000 for these 15 ‘‘psychiatric
or rehabilitation’’ MS–LTC–DRGs
because the blended payment rate and
temporary exceptions to the site neutral
payment rate would not be applicable
for any LTCH discharges occurring in
FY 2023, and as such payment under
the LTCH PPS would be no longer be
made in part based on the LTCH PPS
standard Federal payment rate for any
discharges assigned to those MS–LTC–
DRGs.
Step 9—Normalize the two sets of
relative weights.
The next step in our calculation of the
FY 2023 MS–LTC–DRG relative weights
is to normalize the set of relative
weights that were calculated using
claims that include COVID–19 cases and
to normalize the set of relative weights
that were calculated using claims that
excluded COVID–19 cases. The
normalization adjustment is intended to
ensure that the recalibration of the MS–
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
LTCH cases from each set of claims
using the FY 2022 GROUPER Version 39
and MS–LTC–DRG relative weights and
calculated the average CMI for each set;
and computed the ratio by dividing the
average CMI for each set for FY 2022 by
the average CMI for each set for FY
2023. These ratios are the normalization
factors that were applied to each
respective set of unnormalized weights.
Because the calculation of the
khammond on DSKJM1Z7X2PROD with RULES2
Claims used in Calculation
All applicable LTCH cases, including COVID-19 cases
All annlicable LTCH cases, excluding COVID-19 cases
Step 10—Average the two sets of
normalized relative weights.
After each set of relative weights was
normalized, we computed a simple
average of the normalized relative
weights and geometric mean length of
stays from each set, by using 50 percent
of the relative weights calculated using
applicable LTCH cases that include
COVID–19 cases and 50 percent of the
relative weights calculated using
applicable LTCH cases that exclude
COVID–19 cases.
Step 11— Budget neutralize the
averaged relative weights.
In accordance with the regulations at
§ 412.517(b) (in conjunction with
§ 412.503), the annual update to the
MS–LTC–DRG classifications and
relative weights is done in a budget
neutral manner such that estimated
aggregate LTCH PPS payments would be
unaffected, that is, would be neither
greater than nor less than the estimated
aggregate LTCH PPS payments that
would have been made without the MS–
LTC–DRG classification and relative
weight changes. (For a detailed
discussion on the establishment of the
budget neutrality requirement for the
annual update of the MS–LTC–DRG
classifications and relative weights, we
refer readers to the RY 2008 LTCH PPS
final rule (72 FR 26881 and 26882).
To achieve budget neutrality under
the requirement at § 412.517(b), under
our established methodology, for each
annual update the MS–LTC–DRG
relative weights are uniformly adjusted
to ensure that estimated aggregate
payments under the LTCH PPS would
not be affected (that is, decreased or
increased). Consistent with that
provision, as we proposed, we
continued to apply budget neutrality
adjustments in determining the FY 2023
MS–LTC–DRG relative weights so that
our update the MS–LTC–DRG
classifications and relative weights for
FY 2023 are made in a budget neutral
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Normalization Factor
1.33569
1.33224
manner. In addition, as discussed in
section VIII.B.3.b. of the preamble to
this final rule, we are finalizing our
proposal that the 10-percent cap on the
reduction in a MS–LTC–DRG’s relative
weight in a given year be budget neutral.
Therefore, for FY 2023, we are applying
two budget neutrality factors to
determine the MS–LTC–DRG relative
weights. In this step, we describe the
determination of the budget neutrality
adjustment that accounts for the update
of the MS–LTC–DRG classifications and
relative weights prior to the application
of the 10-percent cap. In steps 12 and
13, we describe the application of the
10-percent cap policy (step 12) and the
determination of the budget neutrality
factor that accounts for the application
of the 10-percent cap policy (step 13).
As described previously, the relative
weights constructed up to this point in
our methodology were calculated based
on two different set of claims (the
applicable LTCH cases that included
COVID–19 cases and the applicable
LTCH cases that excluded COVID–19
cases) and then averaged together.
However, in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28475), when
modeling payments for determining the
budget neutrality factors, we proposed
to use the set of LTCH cases that include
COVID–19 cases. In the absence of a set
of MedPAR claims that reflect our
expectation that there will be fewer (but
not zero) COVID–19 cases in FY 2023 as
compared to the COVID–19 cases in the
FY 2021 claims data, we stated our
belief that this is the best data available
for determining the budget neutrality
factors. We solicited feedback from
commenters on alternative ways to use
the FY 2021 claims data for purposes of
calculating the FY 2023 budget
neutrality factors. We received no
comments on this proposal and are
finalizing this proposal without
modification. Therefore, for this final
rule, when modeling payments for
PO 00000
Frm 00383
Fmt 4701
Sfmt 4700
normalization factor involves the
relative weights for the MS–LTC–DRGs
that contained applicable LTCH cases to
calculate the average CMIs, any lowvolume MS–LTC–DRGs are included in
the calculation (and the MS–LTC–DRGs
with no applicable LTCH cases are not
included in the calculation). The table
displays the normalization factors that
were calculated and applied for each set
of relative weights.
determining the budget neutrality
factors we used the set of LTCH cases
that include COVID–19 cases.
In this final rule, to ensure budget
neutrality for the update to the MS–
LTC–DRG classifications and relative
weights prior to the application of the
10-percent cap (that is, uncapped
relative weights), under § 412.517(b), we
continued to use our established twostep budget neutrality methodology.
Therefore, in the first step of our MS–
LTC–DRG update budget neutrality
methodology, for FY 2023, we
calculated and applied a normalization
factor to the recalibrated relative
weights (the result of Steps 1 through 10
discussed previously) to ensure that
estimated payments are not affected by
changes in the composition of case
types or the changes to the classification
system. That is, the normalization
adjustment is intended to ensure that
the recalibration of the MS–LTC–DRG
relative weights (that is, the process
itself) neither increases nor decreases
the average case-mix index.
To calculate the normalization factor
for FY 2023, we used the following
three steps: (1.a.) use the applicable
LTCH cases from the best available data
(that is, LTCH discharges from the FY
2021 MedPAR file, including the
COVID–19 cases as discussed
previously) and group them using the
FY 2023 GROUPER (that is, Version 40
for FY 2023) and the recalibrated FY
2023 MS–LTC–DRG uncapped relative
weights (determined in Steps 1 through
10 discussed previously) to calculate the
average case-mix index; (1.b.) group the
same applicable LTCH cases (as are
used in Step 1.a.) using the FY 2022
GROUPER (Version 39) and FY 2022
MS–LTC–DRG relative weights and
calculate the average case-mix index;
and (1.c.) compute the ratio of these
average case-mix indexes by dividing
the average case-mix index for FY 2022
(determined in Step 1.b.) by the average
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.154
LTC–DRG relative weights (that is, the
process itself) neither increases nor
decreases the average case-mix index.
To calculate the normalization factors,
we grouped applicable LTCH cases from
each set of claims using the FY 2023
Version 40 GROUPER, and used the FY
2023 MS–LTC–DRG relative weights
associated with each set to calculate the
average case-mix index (CMI) for each
set; we grouped the same applicable
49161
khammond on DSKJM1Z7X2PROD with RULES2
49162
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
case-mix index for FY 2023 (determined
in Step 1.a.). As a result, in determining
the MS–LTC–DRG relative weights for
FY 2023, each recalibrated MS–LTC–
DRG uncapped relative weight was
multiplied by the normalization factor
of 0.99884 (determined in Step 1.c.) in
the first step of the budget neutrality
methodology, which produces
‘‘normalized relative weights.’’
In the second step of our MS–LTC–
DRG update budget neutrality
methodology, we calculated a budget
neutrality adjustment factor consisting
of the ratio of estimated aggregate FY
2023 LTCH PPS standard Federal
payment rate payments for applicable
LTCH cases (the sum of all calculations
under Step 1.b. stated previously) before
reclassification and recalibration to
estimated aggregate payments for FY
2023 LTCH PPS standard Federal
payment rate payments for applicable
LTCH cases after reclassification and
recalibration (that is, the sum of all
calculations under Step 1.a. stated
previously).
That is, for this final rule, for FY
2023, we determined the budget
neutrality adjustment factor using the
following three steps: (2.a.) simulate
estimated total FY 2023 LTCH PPS
standard Federal payment rate
payments for applicable LTCH cases
using the uncapped normalized relative
weights for FY 2023 and GROUPER
Version 40 (as described previously);
(2.b.) simulate estimated total FY 2023
LTCH PPS standard Federal payment
rate payments for applicable LTCH
cases using the FY 2022 GROUPER
(Version 39) and the FY 2022 MS–LTC–
DRG relative weights in Table 11 of the
FY 2022 IPPS/LTCH PPS final rule; and
(2.c.) calculate the ratio of these
estimated total payments by dividing
the value determined in Step 2.b. by the
value determined in Step 2.a. In
determining the FY 2023 MS–LTC–DRG
relative weights, each uncapped
normalized relative weight was then
multiplied by a budget neutrality factor
of 0.9937739 (the value determined in
Step 2.c.) in the second step of the
budget neutrality methodology.
Step 12—Apply the 10-percent cap to
decreases in MS–LTC–DRG relative
weights.
As discussed in section VIII.B.3.b. of
the preamble to this final rule, we are
establishing a 10-percent cap on the
reduction in a MS–LTC–DRG’s relative
weight in a given year, beginning in FY
2023. Specifically, in cases where the
relative weight for a MS–LTC–DRG
would decrease by more than 10-percent
in a given year, we are limiting the
reduction to 10-percent for that year.
Under this provision, this 10-percent
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
cap will only be applied to the relative
weights for MS–LTC–DRGs with 25 or
more applicable LTCH cases and will
not be applied to the low-volume MS–
LTC–DRGs identified in Step 3 or the
no-volume MS–LTC–DRGs identified in
Step 8. Therefore, in this step, for each
FY 2023 MS–LTC–DRG with 25 or more
applicable LTCH cases (excludes lowvolume and zero-volume MS–LTC–
DRGs) we compared its FY 2023 relative
weight (after application of the
normalization and budget neutrality
factors determined in Step 11), to its FY
2022 MS–LTC–DRG relative weight. For
any MS–LTC–DRG where the FY 2023
relative weight would otherwise have
declined more than 10 percent, we
established a capped FY 2023 MS–LTC–
DRG relative weight that would be equal
to 90 percent of that MS–LTC–DRG’s FY
2022 relative weight (that is, we set the
FY 2023 relative weight equal to the FY
2022 weight × 0.90).
Step 13—Calculate the MS–LTC–DRG
cap budget neutrality factor.
As discussed in section VIII.B.3.b. of
the preamble to this final rule, we also
are applying a budget neutrality
adjustment to the MS–LTC–DRG
relative weights so that the 10-percent
cap on relative weight reductions is
implemented in a budget neutral
manner. Therefore, we are determining
the budget neutrality adjustment factor
for our 10-percent cap on relative
weight reductions using the following
three steps: (a) simulate estimated total
FY 2023 LTCH PPS standard Federal
payment rate payments for applicable
LTCH cases using the capped relative
weights for FY 2023 (determined in Step
12) and GROUPER Version 40; (b)
simulate estimated total FY 2023 LTCH
PPS standard Federal payment rate
payments for applicable LTCH cases
using the uncapped relative weights for
FY 2023 (determined in Step 11) and
GROUPER Version 40; and (c) calculate
the ratio of these estimated total
payments by dividing the value
determined in step (b) by the value
determined in step (a). In determining
the FY 2023 MS–LTC–DRG relative
weights, each capped relative weight
was then multiplied by a budget
neutrality factor of 0.998734 (the value
determined in step (c)) to achieve the
budget neutrality requirement.
Table 11, which is listed in section VI.
of the Addendum to this final rule and
is available via the internet on the CMS
website, lists the MS–LTC–DRGs and
their respective relative weights,
geometric mean length of stay, and fivesixths of the geometric mean length of
stay (used to identify SSO cases under
§ 412.529(a)) for FY 2023. We also are
making available on our website the two
PO 00000
Frm 00384
Fmt 4701
Sfmt 4700
sets of relative weights that were
averaged together in determining the FY
2023 MS–LTC–DRG relative weights.
That is, the set of relative weights based
on applicable LTCH cases that included
COVID–19 cases and the set of relative
weights based on applicable LTCH cases
that excluded COVID–19 cases. We also
are making available on the website the
MS–LTC–DRG relative weights prior to
the application of the 10-percent cap on
MS–LTC–DRG relative weight
reductions and corresponding cap
budget neutrality factor.
C. Changes to the LTCH PPS Payment
Rates and Other Changes to the LTCH
PPS for FY 2023
1. Overview of Development of the
LTCH PPS Standard Federal Payment
Rates
The basic methodology for
determining LTCH PPS standard
Federal payment rates is currently set
forth at 42 CFR 412.515 through 412.533
and 412.535. In this section of the final
rule, we discuss the factors that we used
to update the LTCH PPS standard
Federal payment rate for FY 2023, that
is, effective for LTCH discharges
occurring on or after October 1, 2022
through September 30, 2023. Under the
dual rate LTCH PPS payment structure
required by statute, beginning with
discharges in cost reporting periods
beginning in FY 2016, only LTCH
discharges that meet the criteria for
exclusion from the site neutral payment
rate are paid based on the LTCH PPS
standard Federal payment rate specified
at 42 CFR 412.523. (For additional
details on our finalized policies related
to the dual rate LTCH PPS payment
structure required by statute, we refer
readers to the FY 2016 IPPS/LTCH PPS
final rule (80 FR 49601 through 49623).)
Prior to the implementation of the
dual payment rate system in FY 2016,
all LTCH discharges were paid similarly
to those now exempt from the site
neutral payment rate. That legacy
payment rate was called the standard
Federal rate. For details on the
development of the initial standard
Federal rate for FY 2003, we refer
readers to the August 30, 2002 LTCH
PPS final rule (67 FR 56027 through
56037). For subsequent updates to the
standard Federal rate from FYs 2003
through 2015, and LTCH PPS standard
Federal payment rate from FY 2016
through present, as implemented under
42 CFR 412.523(c)(3), we refer readers to
the FY 2020 IPPS/LTCH PPS final rule
(84 FR 42445 through 42446).
In this FY 2023 IPPS/LTCH PPS final
rule, we present our policies related to
the annual update to the LTCH PPS
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
standard Federal payment rate for FY
2023.
The update to the LTCH PPS standard
Federal payment rate for FY 2023 is
presented in section V.A. of the
Addendum to this final rule. The
components of the annual update to the
LTCH PPS standard Federal payment
rate for FY 2023 are discussed in this
section of the final rule, including the
statutory reduction to the annual update
for LTCHs that fail to submit quality
reporting data for FY 2023 as required
by the statute (as discussed in section
VIII.C.2.c. of the preamble of this final
rule). As we proposed in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28476), we also made an adjustment to
the LTCH PPS standard Federal
payment rate to account for the
estimated effect of the changes to the
area wage level for FY 2023 on
estimated aggregate LTCH PPS
payments, in accordance with 42 CFR
412.523(d)(4) (as discussed in section
V.B. of the Addendum to this final rule).
2. FY 2023 LTCH PPS Standard Federal
Payment Rate Annual Market Basket
Update
khammond on DSKJM1Z7X2PROD with RULES2
a. Overview
Historically, the Medicare program
has used a market basket to account for
input price increases in the services
furnished by providers. The market
basket used for the LTCH PPS includes
both operating and capital-related costs
of LTCHs because the LTCH PPS uses a
single payment rate for both operating
and capital-related costs. We adopted
the 2017-based LTCH market basket for
use under the LTCH PPS beginning in
FY 2021 (85 FR 58907 through 58909).
For additional details on the historical
development of the market basket used
under the LTCH PPS, we refer readers
to the FY 2013 IPPS/LTCH PPS final
rule (77 FR 53467 through 53476), and
for a complete discussion of the LTCH
market basket and a description of the
methodologies used to determine the
operating and capital-related portions of
the 2017-based LTCH market basket, we
refer readers to the FY 2021 IPPS/LTCH
PPS final rule (85 FR 58909 through
58926).
Section 3401(c) of the Affordable Care
Act provides for certain adjustments to
any annual update to the LTCH PPS
standard Federal payment rate and
refers to the timeframes associated with
such adjustments as a ‘‘rate year.’’ We
note that, because the annual update to
the LTCH PPS policies, rates, and
factors now occurs on October 1, we
adopted the term ‘‘fiscal year’’ (FY)
rather than ‘‘rate year’’ (RY) under the
LTCH PPS beginning October 1, 2010, to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
conform with the standard definition of
the Federal fiscal year (October 1
through September 30) used by other
PPSs, such as the IPPS (75 FR 50396
through 50397). Although the language
of sections 3004(a), 3401(c), 10319, and
1105(b) of the Affordable Care Act refers
to years 2010 and thereafter under the
LTCH PPS as ‘‘rate year,’’ consistent
with our change in the terminology used
under the LTCH PPS from ‘‘rate year’’ to
‘‘fiscal year,’’ for purposes of clarity,
when discussing the annual update for
the LTCH PPS standard Federal
payment rate, including the provisions
of the Affordable Care Act, we use
‘‘fiscal year’’ rather than ‘‘rate year’’ for
2011 and subsequent years.
b. Annual Update to the LTCH PPS
Standard Federal Payment Rate for FY
2023
As previously noted, we adopted the
2017-based LTCH market basket for use
under the LTCH PPS beginning in FY
2021. The 2017-based LTCH market
basket is primarily based on the
Medicare cost report data submitted by
LTCHs and, therefore, specifically
reflects the cost structures of only
LTCHs. (For additional details on the
development of the 2017-based LTCH
market basket, we refer readers to the
FY 2021 IPPS/LTCH PPS final rule (85
FR 58909 through 58926).) We continue
to believe that the 2017-based LTCH
market basket appropriately reflects the
cost structure of LTCHs for the reasons
discussed when we adopted its use in
the FY 2021 IPPS/LTCH PPS final rule.
Therefore, in this final rule, as we
proposed in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28476), we
used the 2017-based LTCH market
basket to update the LTCH PPS standard
Federal payment rate for FY 2023.
Section 1886(m)(3)(A) of the Act
provides that, beginning in FY 2010,
any annual update to the LTCH PPS
standard Federal payment rate is
reduced by the adjustments specified in
clauses (i) and (ii) of subparagraph (A),
as applicable. Clause (i) of section
1886(m)(3)(A) of the Act provides for a
reduction, for FY 2012 and each
subsequent rate year, by ‘‘the
productivity adjustment’’ described in
section 1886(b)(3)(B)(xi)(II) of the Act.
Clause (ii) of section 1886(m)(3)(A) of
the Act provided for a reduction, for
each of FYs 2010 through 2019, by the
‘‘other adjustment’’ described in section
1886(m)(4)(F) of the Act; therefore, it is
not applicable for FY 2023.
Section 1886(m)(3)(B) of the Act
provides that the application of
paragraph (3) of section 1886(m) of the
Act may result in the annual update
being less than zero for a rate year, and
PO 00000
Frm 00385
Fmt 4701
Sfmt 4700
49163
may result in payment rates for a rate
year being less than such payment rates
for the preceding rate year.
c. Adjustment to the LTCH PPS
Standard Federal Payment Rate Under
the Long-Term Care Hospital Quality
Reporting Program (LTCH QRP)
In accordance with section 1886(m)(5)
of the Act, the Secretary established the
Long-Term Care Hospital Quality
Reporting Program (LTCH QRP). The
reduction in the annual update to the
LTCH PPS standard Federal payment
rate for failure to report quality data
under the LTCH QRP for FY 2014 and
subsequent fiscal years is codified under
42 CFR 412.523(c)(4). The LTCH QRP,
as required for FY 2014 and subsequent
fiscal years by section 1886(m)(5)(A)(i)
of the Act, applies a 2.0 percentage
points reduction to any update under 42
CFR 412.523(c)(3) for an LTCH that does
not submit quality reporting data to the
Secretary in accordance with section
1886(m)(5)(C) of the Act with respect to
such a year (that is, in the form and
manner and at the time specified by the
Secretary under the LTCH QRP) (42 CFR
412.523(c)(4)(i)). Section
1886(m)(5)(A)(ii) of the Act provides
that the application of the 2.0
percentage points reduction may result
in an annual update that is less than 0.0
for a year, and may result in LTCH PPS
payment rates for a year being less than
such LTCH PPS payment rates for the
preceding year. Furthermore, section
1886(m)(5)(B) of the Act specifies that
the 2.0 percentage points reduction is
applied in a noncumulative manner,
such that any reduction made under
section 1886(m)(5)(A) of the Act shall
apply only with respect to the year
involved, and shall not be taken into
account in computing the LTCH PPS
payment amount for a subsequent year.
These requirements are codified in the
regulations at 42 CFR 412.523(c)(4). (For
additional information on the history of
the LTCH QRP, including the statutory
authority and the selected measures, we
refer readers to section VIII.C. of the
preamble of this final rule.)
d. Annual Market Basket Update Under
the LTCH PPS for FY 2023
Consistent with our historical
practice, we estimate the market basket
increase and the productivity
adjustment based on IGI’s forecast using
more recent available data. Based on
IGI’s fourth quarter 2021 forecast, the
proposed FY 2023 market basket update
for the LTCH PPS using the 2017-based
LTCH market basket was 3.1 percent.
The proposed productivity adjustment
for FY 2023 based on IGI’s fourth
quarter 2021 forecast was 0.4 percent.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49164
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
For FY 2023, section 1886(m)(3)(A)(i) of
the Act requires that any annual update
to the LTCH PPS standard Federal
payment rate be reduced by the
productivity adjustment, described in
section 1886(b)(3)(B)(xi)(II) of the Act.
Consistent with the statute, we
proposed in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28477), to
reduce the FY 2023 market basket
increase by the FY 2023 productivity
adjustment. To determine the proposed
market basket increase for LTCHs for FY
2023, as reduced by the proposed
productivity adjustment, consistent
with our established methodology, we
subtracted the proposed FY 2023
productivity adjustment from the FY
2023 market basket increase. (For
additional details on our established
methodology for adjusting the market
basket increase by the productivity
adjustment, we refer readers to the FY
2012 IPPS/LTCH PPS final rule (76 FR
51771).)
For FY 2023, section 1886(m)(5) of the
Act requires that, for LTCHs that do not
submit quality reporting data as
required under the LTCH QRP, any
annual update to an LTCH PPS standard
Federal payment rate, after application
of the adjustments required by section
1886(m)(3) of the Act, shall be further
reduced by 2.0 percentage points.
Therefore, for LTCHs that fail to submit
quality reporting data under the LTCH
QRP, the proposed 3.1 percent market
basket update to the LTCH PPS standard
Federal payment rate for FY 2023 would
be reduced by the 0.4 percentage point
productivity adjustment as required
under section 1886(m)(3)(A)(i) of the
Act and by the additional 2.0 percentage
points reduction required by section
1886(m)(5) of the Act.
In the FY 2023 IPPS/LTCH PPS
proposed rule, in accordance with the
statute, we proposed to reduce the
proposed FY 2023 market basket update
of 3.1 percent (based on IGI’s fourth
quarter 2021 forecast of the 2017-based
LTCH market basket) by the proposed
FY 2023 productivity adjustment of 0.4
percentage point (based on IGI’s fourth
quarter 2021 forecast). Therefore, under
the authority of section 123 of the BBRA
as amended by section 307(b) of the
BIPA, consistent with 42 CFR
412.523(c)(3)(xvii), we proposed to
establish an annual market basket
update to the LTCH PPS standard
Federal payment rate for FY 2023 of 2.7
percent (that is, more recent estimate of
the LTCH PPS market basket increase of
3.1 percent less the productivity
adjustment of 0.4 percentage point). For
LTCHs that fail to submit quality
reporting data under the LTCH QRP,
under 42 CFR 412.523(c)(3)(xvii) in
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
conjunction with 42 CFR 412.523(c)(4),
we proposed to further reduce the
annual update to the LTCH PPS
standard Federal payment rate by 2.0
percentage points, in accordance with
section 1886(m)(5) of the Act.
Accordingly, we proposed to establish
an annual update to the LTCH PPS
standard Federal payment rate of 0.7
percent (that is, 2.7 percent minus 2.0
percentage points) for FY 2023 for
LTCHs that fail to submit quality
reporting data as required under the
LTCH QRP. Consistent with our
historical practice, we proposed in the
FY 2023 IPPS/LTCH PPS proposed rule
(86 FR 28477) to use a more recent
estimate of the market basket and the
productivity adjustment, if appropriate,
in the final rule to establish an annual
update to the LTCH PPS standard
Federal payment rate for FY 2023. We
note that, consistent with historical
practice, we also proposed to adjust the
FY 2023 LTCH PPS standard Federal
payment rate by an area wage level
budget neutrality factor in accordance
with 42 CFR 412.523(d)(4) (as discussed
in section V.B.5. of the Addendum to
the proposed rule).
Comment: A number of commenters
expressed concern that the proposed
2017-based LTCH market basket growth
rate of 3.1 percent was inadequate and
did not reflect current inflationary
trends. These commenters cited several
reasons why they believe the proposed
market basket was underestimated,
including significant rises in hospital
labor costs (especially contract nursing
costs), as well as rises in other hospital
costs (such as equipment and supplies).
Several commenters cited recent growth
in the Bureau of Labor Statistics (BLS)
Consumer Price Index (CPI) as evidence
of the inflationary pressures inflicted
upon hospitals.
Several commenters expressed that,
since the market basket is a time-lagged
estimate that uses historical data to
forecast into the future, it is most
suitable for forecasting changes in a
steady-state economy with small and
stable changes in inflation and costs.
However, these commenters believe the
current inflationary environment is not
a typical economic environment and
therefore the resulting market basket
estimates are inadequate. A commenter
stated that the construction of the
market basket itself does not allow it to
fully capture unexpected shocks
because it is a time-lagged rolling
average estimate.
Commenters requested CMS to ensure
that the market basket and update factor
reflect the actual experiences of LTCHs
and be modified accordingly. Several
commenters urged CMS to identify more
PO 00000
Frm 00386
Fmt 4701
Sfmt 4700
accurate and up-to-date data inputs to
calculate a market basket update that
better represents the inflationary
pressures that hospitals are facing.
Response: CMS has historically used
a market basket to account for input
price increases in the services furnished
by fee-for-service providers. The market
basket used for the LTCH PPS includes
both operating and capital-related costs
of LTCHs because the LTCH PPS uses a
single payment rate for both operating
and capital-related costs. We adopted
the 2017-based LTCH market basket for
use under the LTCH PPS beginning in
FY 2021 (85 FR 58907 through 58909).
We believe the 2017-based LTCH market
basket increase adequately reflects the
average change in the price of goods and
services hospitals purchase in order to
provide LTCH medical services, and is
appropriate to use as the market basket
percentage increase. As described in the
FY 2021 final rule (86 FR 45194 through
45213), the LTCH market basket is a
fixed-weight, Laspeyres-type index that
measures price changes over time and
would not reflect increases in costs
associated with changes in the volume
or intensity of input goods and services.
As such, the LTCH market basket
increase would reflect the prospective
price pressures described by the
commenters as increasing during a high
inflation period (such as faster wage
price growth or higher energy prices),
but would inherently not reflect other
factors that might increase the level of
costs, such as the quantity of labor used
or any shifts between contract and staff
nurses. We note that cost changes (that
is, the product of price and quantities)
would only be captured in the market
basket weights when the index is
rebased and the base year is updated to
a more recent time period. Comments
requesting that CMS rebase the LTCH
market basket and our response are
discussed later in this section.
We agree with the commenters that
recent higher inflationary trends have
impacted the outlook for price growth
over the next several quarters. At the
time of the FY 2023 IPPS/LTCH
proposed rule, based on IGI’s fourth
quarter 2021 forecast with historical
data through the third quarter of 2021,
IGI forecasted the 2017-based LTCH
market basket update of 3.1 percent for
FY 2023 reflecting forecasted
compensation prices of 3.9 percent (by
comparison, compensation price growth
in the 2017-based LTCH market basket
averaged 2.1 percent from 2012–2021).
In the FY 2023 IPPS/LTCH proposed
rule, we proposed that if more recent
data became available, we would use
such data, if appropriate, to derive the
final FY 2023 LTCH market basket
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
update for the final rule. For this final
rule, we now have an updated forecast
of the price proxies underlying the
market basket that incorporates more
recent historical data and reflects a
revised outlook regarding the U.S.
economy (including the more recent
historical CPI growth, impacts of the
Russia/Ukraine war, current
expectations regarding changes to
Federal Reserve interest rates, and tight
labor markets). Based on IGI’s second
quarter 2022 forecast with historical
data through the first quarter of 2022,
we are projecting a FY 2023 LTCH
market basket update of 4.1 percent
(reflecting forecasted compensation
price growth of 4.8 percent) and
productivity adjustment of 0.3
percentage point. Therefore, for FY
2023, we are finalizing an LTCH update
of 3.8 percent (4.1 percent less 0.3
percentage point), compared to 2.7
percent that we had proposed. We note
that the final FY 2023 LTCH market
basket growth rate of 4.1 percent would
be the highest market basket update
implemented in an IPPS/LTCH final
rule going back to RY 2004.
Comment: Some commenters
maintained that, in consideration of
rapidly increasing labor costs, it would
be appropriate for CMS to implement a
temporary payment adjustment increase
or add-on payment to LTCH payments
for FY 2023. The commenters stated
their belief that CMS has the authority
to determine appropriate adjustments to
the LTCH PPS under section 123 of the
BBRA as amended by section 307(b)(1)
of the BIPA. A commenter requested
that such a payment adjustment
continue to be applied until CMS
rebases the LTCH PPS market basket.
Response: We disagree with the
commenters that CMS should apply a
temporary payment adjustment or addon payment to the LTCH PPS to account
for the increases in labor costs at LTCHs
that they believe were not being
captured in the market basket. As
discussed earlier, we believe the LTCH
market basket increase appropriately
reflects the input price growth
(including compensation price growth)
that LTCHs incur in providing medical
services. As also described earlier, we
are using an updated forecast of the
price proxies underlying the market
basket that incorporates more recent
historical data and reflects a revised
outlook regarding the U.S. economy
(including the more recent historical
CPI growth, impacts of the Russia/
Ukraine war, current expectations
regarding changes to Federal Reserve
interest rates, and tight labor markets).
As a result, the update for FY 2023 of
3.8 percent is 1.1 percentage points
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
higher than the proposed update of 2.7
percent.
Comment: Several commenters
requested that CMS apply a
retrospective payment adjustment that
accounts for the difference between the
2.6 percent market basket increase that
was implemented in FY 2022 and what
the market basket is currently projected
to be for FY 2022. Several commenters
stated that the FY 2022 market basket
increase that was used to determine the
annual update did not capture
significant increases in labor expenses
that occurred in FY 2022.
Response: Under the law, the LTCH
PPS is a per-discharge prospective
payment system that uses a market
basket increase to set the annual update
prospectively. This means that the
update relies on a mix of both historical
data for part of the period for which the
update is calculated and forecasted data
for the remainder. For instance, the
2017-based LTCH market basket growth
rate for FY 2023 in this final rule is
based on IGI’s second quarter 2022
forecast with historical data through the
first quarter of 2022. While there is
currently no mechanism to adjust for
market basket forecast error in the LTCH
payment update, the forecast error for a
market basket update is equal to the
actual market basket increase for a given
year less the forecasted market basket
increase. Due to the uncertainty
regarding future price trends, forecast
errors can be both positive and negative.
We note that FY 2022 historical data are
not yet available to calculate a forecast
error for FY 2022. For this final rule, we
have incorporated more recent historical
data and forecasts to capture the price
and wage pressures facing LTCHs and
believe the market basket increase that
we are finalizing is the best available
projection of inflation to determine the
applicable percentage increase for the
LTCH payments in FY 2023. For these
reasons we are not adopting the
commenters’ suggestion to adjust for the
difference between the currently
projected market basket increase for FY
2022 and the forecasted market basket
increase used in determining the FY
2022 update.
Comment: We received numerous
comments about our proposed
productivity adjustment to the FY 2023
LTCH market basket update.
Commenters generally stated that a
negative productivity adjustment is
inappropriate because evidence suggests
that productivity for LTCHs has
decreased, rather than increased over
the past year. Commenters requested
CMS to use its existing statutory
authority to remove the productivity
adjustment for FY 2023. A commenter
PO 00000
Frm 00387
Fmt 4701
Sfmt 4700
49165
requested that we remove the
productivity adjustment for FY 2023,
and any fiscal year during which the
PHE for COVID–19 was in effect.
A subset of these commenters also
requested that CMS reconsider the
appropriateness of the productivity
adjustment to LTCHs more broadly.
They stated that the productivity
adjustment, based on a 10-year moving
average of changes in the annual
economy-wide private nonfarm business
total factor productivity, is not
representative of the cost structure of
LTCHs. These commenters expressed
concern that hospital work is extremely
dependent on human capital and that
increased operational efficiencies are
relatively limited for LTCHs compared
with industries that are able to produce
greater efficiencies through automation.
Commenters specifically cited evidence
for why they believe it is unrealistic for
hospitals to achieve the same
productivity gains as the private
nonfarm business sector in FY 2023. For
example, a commenter cited the
significant decrease in hospital
employment levels that have occurred
during the pandemic and the resulting
reliance on contract staffing firms to
address staffing shortages as a reason
why they believe hospitals are
experiencing declines in productivity
during the pandemic.
Response: Section 1886(m)(3)(A)(i) of
the Act requires that any annual update
to the LTCH PPS standard Federal
payment rate be reduced by the
productivity adjustment, described in
section 1886(b)(3)(B)(xi) of the Act;
therefore, we do not have the authority
to eliminate the productivity
adjustment. In section V.A.1. of this
preamble, in response to similar
comments, we explained that we do not
believe it is appropriate to eliminate the
productivity adjustment for FY 2023 in
this final rule. In that same section, we
discuss the methodology for calculating
and applying the productivity
adjustment required by section
1886(b)(3)(B)(xi) of the Act that we
finalized in the FY 2012 IPPS/LTCH
PPS final rule (76 FR 51689 through
51692). As we explained in that rule,
section 1886(b)(3)(B)(xi)(II) of the Act
defines this productivity adjustment as
equal to the 10-year moving average of
changes in annual economy-wide,
private nonfarm business multi-factor
productivity (as projected by the
Secretary for the 10-year period ending
with the applicable fiscal year, year,
cost reporting period, or other annual
period) and BLS publishes the official
measures of private nonfarm business
productivity for the U.S. economy. (We
note, beginning with the November 18,
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49166
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
2021 release of productivity data, BLS
replaced the term multifactor
productivity (MFP) with total factor
productivity (TFP), and beginning with
the FY 2022 IPPS/LTCH PPS final rule,
we refer to this adjustment as the
productivity adjustment rather than the
MFP adjustment. The adjustment
continues to rely on the same
underlying data and methodology.)
For the FY 2023 IPPS/LTCH proposed
rule, based on IGI’s fourth quarter 2021
forecast, the productivity adjustment
was projected to be 0.4 percentage point
for FY 2023. For this final rule, based on
IGI’s second quarter 2022 forecast, we
are updating the productivity
adjustment to reflect more recent
historical data as published by BLS as
well as a revised economic outlook for
FY 2022 and FY 2023. Using this more
recent forecast, the FY 2023
productivity adjustment based on the
10-year moving average growth in
economy-wide total factor productivity
for the period ending FY 2023 is 0.3
percent.
Comment: Several commenters
requested that CMS rebase and revise
the 2017-based LTCH market basket for
FY 2023 using the most recent LTCH
data on labor costs in order for the FY
2023 market basket estimate to
accurately reflect recent inflationary
trends. A commenter stated that the
unprecedented COVID–19 pandemic
has drastically changed hospital
operations and the costs associated with
operating a hospital. This commenter
also stated its view that the market
basket update that CMS applies each
year is simply unable to account for
many of the changes to hospital
operations and costs since the
pandemic.
Response: As described previously,
the LTCH market basket measures price
changes (including changes in the prices
for wages and salaries) over time and
would not reflect increases in costs
associated with changes in the volume
or intensity of input goods and services
until the market basket is rebased. The
LTCH market basket was last rebased in
the FY 2021 IPPS/LTCH PPS final rule
using 2017 Medicare cost reports (85 FR
58909 through 58926), the most recent
year of complete data available at the
time of the rebasing. We note that we
did not propose to rebase the LTCH
market basket in the FY 2023 IPPS/
LTCH proposed rule; however, we did
review the most recent Medicare cost
report data available for LTCHs
submitted as of March 2022, which
includes data for 2018–2020. The
Medicare cost report data showed that
between 2017 and 2019 the
compensation cost weight (which
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
reflects expenses for wages and salaries,
employee benefits, and contract labor)
was relatively unchanged, decreasing by
roughly 1.2 percentage points relative to
the 2017-based LTCH market basket
compensation cost weight. We note that
data through 2021 are incomplete at this
time and therefore, we are not able to
estimate a compensation cost share
weight for 2021 at this time. We have
concluded that based on this
preliminary analysis it is unclear
whether these trends through 2020 are
reflective of sustained shifts in the cost
structure for long-term care hospitals or
whether they were temporary as a result
of the COVID–19 PHE. Therefore, we
believe it is premature at this time to
use more recent Medicare cost report
data to derive a rebased and revised
LTCH market basket. We will continue
to monitor these data and any changes
to the LTCH market basket will be
proposed in future rulemaking.
Comment: A few commenters
expressed concern that the 2023 rate
increase CMS finalized for Medicare
Advantage plans was significantly
higher than the proposed FY 2023
update for LTCH PPS payments. These
commenters believe this difference
supports their view that the proposed
FY 2023 update for LTCH PPS payments
was inadequate.
Response: As stated previously, the
Medicare program has historically used
a market basket to account for input
price increases in the services furnished
by fee-for-service providers; in most
instances, basing these updates on input
price indexes is statutorily required. For
the LTCH PPS we adopted a similar
approach of using a market basket to
update PPS payments, and beginning in
FY 2021 this update reflected the
percentage change in the 2017-based
LTCH market basket (85 FR 58907
through 58909). For this FY 2023 IPPS/
LTCH final rule, based on a more recent
forecast than was used for the proposed
rule, the LTCH market basket increase is
4.1 percent (one percentage point higher
than the estimated market basket
increase published in the FY 2023 IPPS/
LTCH proposed rule).
After consideration of public
comments, we are finalizing the LTCH
payment update using more recent
forecast of the market basket and
productivity adjustment. As such, based
on IGI’s second quarter 2022 forecast,
the FY 2023 market basket update for
the LTCH PPS using the 2017-based
LTCH market basket is 4.1 percent. The
current estimate of the productivity
adjustment for FY 2023 based on IGI’s
second quarter 2022 forecast is 0.3
percent. Therefore, under the authority
of section 123 of the BBRA as amended
PO 00000
Frm 00388
Fmt 4701
Sfmt 4700
by section 307(b) of the BIPA, consistent
with 42 CFR 412.523(c)(3)(xvii), we are
establishing an annual market basket
update to the LTCH PPS standard
Federal payment rate for FY 2023 of 3.8
percent (that is, more recent estimate of
the LTCH PPS market basket increase of
4.1 percent less the productivity
adjustment of 0.3 percentage point).
For LTCHs that fail to submit quality
reporting data under the LTCH QRP,
under § 412.523(c)(3)(xvii) in
conjunction with 42 CFR 412.523(c)(4),
as we proposed, we further reduced the
annual update to the LTCH PPS
standard Federal payment rate by 2.0
percentage points, in accordance with
section 1886(m)(5) of the Act.
Accordingly, we are establishing an
annual update to the LTCH PPS
standard Federal payment rate of 1.8
percent (that is, 3.8 percent minus 2.0
percentage points) for FY 2023 for
LTCHs that fail to submit quality
reporting data as required under the
LTCH QRP.
IX. Quality Data Reporting
Requirements for Specific Providers
and Suppliers
In section IX. of the preamble of the
FY 2023 IPPS/LTCH PPS proposed rule
(87 FR 28477 through 28612), we sought
public comment on the following focus
areas and proposed changes to the
Medicare quality reporting programs:
• In section IX.A., assessment of the
impact of climate change and health
equity.
• In section IX.B., overarching
principles in measuring healthcare
quality disparities in hospital quality
programs.
• In section IX.C., advancement of
digital quality measurement and use of
Fast Healthcare Interoperability
Resources (FHIR) in hospital quality
programs.
• In section IX.D., advancing the
Trusted Exchange Framework and
Common Agreement (TEFCA).
• In section IX.E., the Hospital IQR.
• In section IX.F., the PCHQR
Program.
• In section IX.G., the LTCH QRP.
• In section IX.H. the Medicare
Promoting Interoperability Program for
Eligible Hospitals and Critical Access
Hospitals (CAHs) (previously known as
the Medicare EHR Incentive Program).
A. Current Assessment of Climate
Change Impacts on Outcomes, Care,
and Health Equity—Request for
Information
1. Background
A recent consensus statement signed
by more than 200 medical journals
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
noted climate change represents the
greatest threat to global public health of
the coming century.327 Pollution
associated with the burning of fossil
fuels is known to cause serious harm
and loss in productivity, and resultant
climate instability introduces a
combination of catastrophic weather
events and chronic disease impacts that
create serious burdens on organizations
providing health care.328 There is also
evidence that climate change
disproportionately harms underserved
populations (for example, racial and
ethnic minority groups, indigenous
people, members of religious minorities,
people with disabilities, sexual and
gender minorities, individuals with
limited English proficiency, older
adults, and rural populations).329 Longterm discrimination and disparities
based on social determinants of health
mean that these groups are often less
equipped to withstand climate threats
and are more susceptible to associated
harm.330 For example, Black Americans
are much likelier to experience
premature mortality as a result of
extreme heat, and childhood asthma
rates related to warming temperatures
will be much higher in minority
communities, as well.331 Out of concern
for the health of individuals, and to
maintain uninterrupted operations in
service of patients, we believe the
healthcare sector more fully explore
how to effectively prepare for climate
threats. Because healthcare facilities
also emit greenhouse gases (GHGs) that
contribute to climate change and its
impacts, we believe that they study how
best to reduce those emissions, as well.
khammond on DSKJM1Z7X2PROD with RULES2
2. Solicitation of Comments on the
Current State of Health System Climate
Change Efforts
In the Request for Information (RFI) in
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28478 through 28479), we
sought comment on how hospitals,
327 Atwoli, L., Banqui A., Benfield T., et al.
(2021). Call for emergency action to limit global
temperature increases, restore biodiversity, and
protect health. Lancet, 398(10304):939–41.
328 Eckelman, M., Huang K., et al. (2020). Health
Care Pollution and Public Health Damage in the
United States: An Update. Health Affairs, 39:12.
329 U.S. Environmental Protection Agency. (2021).
Climate Change and Social Vulnerability in the
United States: A Focus on Six Impacts. U.S.
Environmental Protection Agency, EPA 430–R–21–
003.
330 U.S. Environmental Protection Agency. (2021).
Climate Change and Social Vulnerability in the
United States: A Focus on Six Impacts. U.S.
Environmental Protection Agency, EPA 430–R–21–
003.
331 U.S. Environmental Protection Agency. (2021).
Climate Change and Social Vulnerability in the
United States: A Focus on Six Impacts. U.S.
Environmental Protection Agency, EPA 430–R–21–
003.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
nursing homes, hospices, home health
agencies, and other providers can better
prepare for the harmful impacts of
climate change on their patients, and
how we can support them in doing so.
Because research has shown that
climate change causes harm to
individuals (through both catastrophic
events and chronic disease)332 and
because there is evidence to show that
climate change will disproportionately
harm underserved populations,333 we
believe that it is critical to study and
prepare for these impacts.
Generally, we sought input on what
the U.S. Department of Health and
Human Services (HHS) and CMS can do
to support hospitals, nursing homes,
hospices, home health agencies, and
other providers in more effectively: (a)
Determining likely climate impacts (that
is, both immediate impacts associated
with climate-related disasters and longterm chronic disease implications of
climate change) on their patients,
residents and consumers so that they
can develop plans to mitigate those
impacts; (b) understanding exceptional
threats that climate-related emergencies
(for example., storms, floods, extreme
heat, wildfires) present to continuous
facility operations (including potential
disruptions in patient services
associated with catastrophic events as a
result of power loss, limited
transportation, evacuation challenges,
etc.) so they can better address those;
and (c) understanding how to take
action on reducing their emissions and
tracking their progress in this regard.
We believe this will inform the
development and updating of policies
that can assist providers in responding
to climate-related challenges (for
example, policies related to emergency
preparedness) as well as the updating of
HHS climate-health tools and resources.
We also invited public comments on
the following topics (understanding that
some provider types might have done
more work in this area than others):
• The availability of information,
such as analyses of climate change
impacts (whether developed internally
or collected from outside sources), that
hospitals, nursing homes, hospices,
home health agencies, and other
providers can access to better
understand climate threats to their
patients, community, and staff.
332 Eckelman, M., Huang K., et al. (2020). Health
Care Pollution and Public Health Damage in the
United States: An Update. Health Affairs, 39:12.
333 U.S. Environmental Protection Agency. (2021).
Climate Change and Social Vulnerability in the
United States: A Focus on Six Impacts. U.S.
Environmental Protection Agency, EPA 430–R–21–
003.
PO 00000
Frm 00389
Fmt 4701
Sfmt 4700
49167
• The degree to which different
provider types currently complete
comprehensive climate change risk
assessments to better understand risks
to their patient populations and the
costs incurred due to catastrophic
climate events and climate-related
chronic disease.
• The degree to which facility efforts
to prepare for climate impacts overlap
with the work they already complete to
meet CMS’s Emergency Preparedness
Requirements for Medicare and
Medicaid Participating Providers and
Suppliers, and the degree to which
related CMS requirements sufficiently
(or insufficiently) prepare them for the
threats created by climate change and
help or hinder these efforts.
• The degree to which hospitals,
nursing homes, hospices, home health
agencies, and other providers measure
and share performance associated with
their response to climate-related
catastrophes (for example, measuring
harm to vulnerable populations as a
result of such events, or extent of
disruption in service).
• The nature of facility plans for
assisting the community and patients to
prepare for and recover from climaterelated events, as well as the nature of
plans for evacuating patients with
differing needs, including those with
disabilities.
• The degree to which climate
change, and climate change linked to
health equity, is publicly addressed in
strategic plans and objectives in your
facility or system, and the degree to
which hospital leadership regularly
reviews progress on goals related to
climate preparedness and mitigation
and invests in health professional
training on this topic.
• Whether health systems and
facilities have time-bound, public aims
for GHG emissions reduction, and, if
yes, whether those aims relate to direct
facility emissions, emissions associated
with purchased energy, emissions
associated with supply chain or some
combination of these.
• The measures that health systems
and facilities use to track their progress
on GHG emissions reduction and use of
renewable energy, as well as the data
collection tools that they may use
support this tracking.
• The tools and supports that health
systems and facilities most heavily rely
on to support their efforts to reduce
GHG emissions.
• How HHS and CMS can support
hospitals, nursing homes, hospices,
home health agencies, and other
providers in their efforts to more fully
prepare for climate change’s
catastrophic and chronic impacts on
E:\FR\FM\10AUR2.SGM
10AUR2
49168
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
their operations and the people they
serve, as well as what incentives (for
example, recognition, payment,
reporting) might assist them in taking
more action on climate readiness and
emissions reduction.
• Whether accrediting organizations
assess facilities’ readiness for climaterelated threats and their efforts to
reduce GHG emissions.
We received comments on these
topics.
Comment: We received many
comments expressing support for this
request for information on health
impacts due to climate change and how
we could potentially support hospitals,
nursing homes, hospices, home health
agencies, and other providers to more
effectively determine and plan for
climate impacts. Many commenters
underscored the impacts of climate
change, particularly on specific disease
and services lines, as well as on
underserved populations. Many
commenters provided sources of public
data and analyses that depict
healthcare’s impact on climate. Many
commenters also identified pledges to
which they committed in pursuit of
reducing their climate impact.
The vast majority of commenters
suggested that we incentivize and
provide funding for participation in
climate change initiatives. Several
commenters proposed a value-based
purchasing program as a potential
format for such participation. A
commenter suggested projects that
reduce climate footprint could count
towards community benefit.
Many commenters provided feedback
and insights regarding how we can
assess the impact of climate change on
patients. Many commenters
recommended undertaking additional
analysis as the first step towards helping
the healthcare industry understand and
impact climate change. A commenter
recommended hospitals study their
internal patient level data to identify
climate impacts on patients. A few
commenters also recommended
updating screening tools to include
climate change health impact topics.
Commenters identified many
initiatives and projects they are
pursuing to reduce their footprint.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Commenters recommended that we
develop a repository of data and projects
that have addressed climate change;
highlight the impact of single use
products versus reprocessing medical
equipment and forced device
obsolescence; encourage the reduction
and recycling of anesthesia gases;
leverage lessons learned from the
reduction of highly enriched uranium;
understand data storage and its impact
on the environment; update aging
healthcare infrastructure and building
codes, especially on temperature
regulation requirements; update
guidance for on-site alternative energy
sources and micro-grids; and add
education on climate topics for
clinicians. Many commenters also
identified the need to update hospital
emergency preparedness plans to
include responses to climate-related
disasters, including short-term, longterm, and post-disaster responses.
Commenters emphasized that climate
change is not just a hospital issue. They
recommended the that we engage with
relevant groups including suppliers,
advocacy groups, and other government
agencies. A few commenters suggested
that we work with interested parties to
perform a life cycle analysis to identify
high emission, low value clinical
devices or services. A few commenters
suggested that we continue to consider,
and perhaps expand, the definition of
climate change.
A few commenters cautioned us about
considering new initiatives against the
backdrop of the challenges stemming
from the COVID–19 pandemic. A
commenter specifically encouraged us
to ensure that our work on addressing
climate change does not detract from the
mission of improving health. A
commenter shared that climate related
initiatives are funded through taxexemption, which is not available to
non-profit healthcare entities.
Furthermore, A commenter questioned
whether HHS has the authority to
impose climate-change requirements.
Finally, a commenter advised that any
expansion of emergency preparedness
requirements be non-burdensome.
In summary, the organizations and
individuals that submitted comments
almost uniformly embraced the
PO 00000
Frm 00390
Fmt 4701
Sfmt 4700
importance of setting goals for reduced
emissions and increased climate
resilience but also repeatedly requested
the following:
• More timely data to understand
threats and health impacts associated
with climate change, especially for
vulnerable and marginalized
populations, as well as information on
cost impacts for care providers.
• Financing supports and incentives
to help deepen their work in this area
(with attention to the needs of different
provider types).
• Technical assistance tools to assist
operational and clinical improvements
in this area (with attention to frontline
specialties whose work intersects with
climate health).
• Standardized measures and
measurement frameworks to help with
progress tracking and reporting (with
mixed views on whether such reporting
be mandatory or voluntary).
• Updates to/simplification of
emergency preparedness requirements,
conditions of participation and other
regulations to help all provider and
supplier types to be more responsive to
climate-related challenges.
• Attention to the challenges different
provider types, already under strain
from the pandemic, must address to take
on this work and ensure no compromise
in the quality of care delivery.
• Attention to the importance of
engaging supply chain stakeholders in
order to fully address the challenge of
reducing emissions.
Response: We thank the commenters
for their input, recommendations, and
many ideas. We will consider all the
feedback received as we continue to
understand how hospitals, nursing
homes, hospices, home health agencies,
and other providers can better prepare
for the harmful impacts of climate
change on their patients, and how we
can support them in doing so. We
additionally appreciate the many
commenters who would like to
volunteer to be a part of groups to help
develop any future policies on this
topic. We will continue to engage all
interested parties via multiple avenues
including future notice-and-comment
rulemaking.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
B. Overarching Principles for Measuring
Healthcare Quality Disparities Across
CMS Quality Programs—Request for
Information
khammond on DSKJM1Z7X2PROD with RULES2
1. Background
Significant and persistent inequities
in healthcare outcomes exist in the
United States (U.S.). Belonging to a
racial or ethnic minority group; being a
member of a religious minority; living
with a disability; being a member of the
lesbian, gay, bisexual, transgender, and
queer (LGBTQ+) community; living in a
rural area; or being near or below the
poverty level, are often associated with
worse health
outcomes.334 335 336 337 338 339 340 341 342 343
We are committed to achieving equity in
healthcare outcomes for our
beneficiaries by supporting healthcare
providers’ quality improvement
activities to reduce health disparities,
enabling beneficiaries to make more
informed decisions, and promoting
334 Joynt KE, Orav E, Jha AK. (2011). Thirty-day
readmission rates for Medicare beneficiaries by race
and site of care. JAMA, 305(7): 675–681.
335 Vu M. et al. (2016). Predictors of Delayed
Healthcare Seeking Among American Muslim
Women, Journal of Women’s Health 26(6). doi:
10.1089/jwh.2015.5517.
336 Nadimpalli SB, Cleland CM, Hutchinson MK,
Islam N, Barnes LL, Van Devanter N. (2016) The
Association between Discrimination and the Health
of Sikh Asian Indians. Health Psychology, 35(4),
351–355. https://doi.org/10.1037/hea0000268.
337 Lindenauer PK, Lagu T, Rothberg MB, et al.
(2013). Income inequality and thirty-day outcomes
after acute myocardial infarction, heart failure, and
pneumonia: Retrospective cohort study. British
Medical Journal, 346.
338 Trivedi AN, Nsa W, Hausmann LRM, et al.
(2014). Quality and equity of care in U.S. hospitals.
New England Journal of Medicine, 371(24): 2298–
2308.
339 Polyakova, M., et al. (2021). Racial disparities
in excess all-cause mortality during the early
COVID–19 pandemic varied substantially across
states. Health Affairs, 40(2): 307–316.
340 Rural Health Research Gateway. (2018). Rural
communities: age, income, and health status. Rural
Health Research Recap. Available at: https://
www.ruralhealthresearch.org/assets/2200-8536/
rural-communities-age-income-health-statusrecap.pdf.
341 HHS Office of Minority Health. (2020).
Progress Report to Congress: 2020 Update on the
Action Plan to Reduce Racial and Ethnic Health
Disparities. Available at: https://
www.minorityhealth.hhs.gov/omh/
browse.aspx?lvl=2&lvlid=57.
342 Heslin, KC, Hall, JE. (2021). Sexual
Orientation Disparities in Risk Factors for Adverse
COVID–19-Related Outcomes, by Race/Ethnicity—
Behavioral Risk Factor Surveillance System, United
States, 2017–2019. MMWR Morb Mortal Wkly Rep
2021;70:149–154. Available at: https://
www.cdc.gov/mmwr/volumes/70/wr/
mm7005a1.htm.
343 Poteat TC, Reisner SL, Miller M, Wirtz AL.
(2020). COVID–19 vulnerability of transgender
women with and without HIV infection in the
Eastern and Southern U.S. preprint. medRxiv.
2020;2020.07.21. 20159327. doi:10.1101/
2020.07.21.20159327. Available at: https://
pubmed.ncbi.nlm.nih.gov/32743608/.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
healthcare provider accountability for
healthcare disparities.344
Health equity is an important
component of an equitable society.
Equity, as defined in Executive Order
13985, is ‘‘the consistent and systematic
fair, just, and impartial treatment of all
individuals, including individuals who
belong to underserved communities that
have been denied such treatment, such
as Black, Latino, and Indigenous and
Native American persons, Asian
Americans and Pacific Islanders and
other persons of color; members of
religious minorities; LGBTQ+ persons;
persons with disabilities; persons who
live in rural areas; and persons
otherwise adversely affected by
persistent poverty or inequality.’’ 345 We
define health equity as the attainment of
the highest level of health for all people,
where everyone has a fair and just
opportunity to attain their optimal
health regardless of race, ethnicity,
disability, sexual orientation, gender
identity, religion, socioeconomic status,
geography, preferred language, or other
factors that affect access to care and
health outcomes. We are working to
advance health equity by designing,
implementing, and operationalizing
policies and programs that support
health for all the people served by our
programs, eliminating avoidable
differences in health outcomes
experienced by people who are
disadvantaged or underserved, and
providing the care and support that our
beneficiaries need to thrive.346
Advancing health equity will require
a variety of efforts across the healthcare
system. The reduction in healthcare
disparities is one aspect of improving
equity that we have prioritized. In a RFI
that we included in the FY 2022 IPPS/
LTCH PPS final rule, titled ‘‘Closing the
Health Equity Gap in CMS Hospital
Quality Programs’’ (86 FR 45349
through 45360), we described programs
and policies we have implemented over
the past decade with the aim of
identifying and reducing healthcare
disparities, including: the CMS
Mapping Medicare Disparities Tool 347
344 Centers for Medicare and Medicaid Services.
(2016). CMS Quality Strategy. Available at: https://
www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/Qualityinitiativesgeninfo/
downloads/cms-quality-strategy.pdf.
345 Federal Register. (2021). Advancing Racial
Equity and Support for Underserved Communities
Through the Federal Government. Available at:
https://www.federalregister.gov/documents/2021/
01/25/2021-01753/advancing-racial-equity-andsupport-for-underserved-communities-through-thefederal-government.
346 Centers for Medicare & Medicaid Services.
(2022). Health Equity. Available at: https://
www.cms.gov/pillar/health-equity.
347 Centers for Medicare and Medicaid Services.
(2021). CMS Office of Minority Health. Available at:
PO 00000
Frm 00391
Fmt 4701
Sfmt 4700
49169
and the CMS Disparity Methods
stratified reporting.348 CMS has also
supported HHS’ efforts to implement
the National Standards for Culturally
and Linguistically Appropriate Services
(CLAS) in Health and Health Care (78
FR 58539); 349 as well as improvement
of the collection of drivers of health in
standardized patient assessment data in
four post-acute care settings and the
collection of health-related social need
data by model participants in the
Accountable Health Communities
Model.350 351 352
Measuring healthcare disparities and
reporting these results to healthcare
providers is a cornerstone of our
approach to advancing healthcare
equity. It is important to consistently
measure differences in care received by
different groups of our beneficiaries,
and this can be achieved by methods to
stratify quality measures. Measure
stratification is defined for this purpose
as calculating measure results for
specific groups or subpopulations of
patients. Assessing healthcare
disparities through stratification is only
one method for using healthcare quality
measurement to address health equity,
but it is an important approach that
allows healthcare providers to tailor
quality improvement initiatives,
decrease disparity, track improvement
over time, and identify opportunities to
evaluate upstream drivers of health. The
use of measure stratification to assess
disparities has been identified by our
Office of Minority Health as a critical
component of an organized response to
health disparities.353 To date, we have
https://www.cms.gov/About-CMS/AgencyInformation/OMH/OMH-Mapping-MedicareDisparities.
348 Centers for Medicare and Medicaid Services.
Disparity Methods Confidential Reporting.
Available at: https://qualitynet.cms.gov/inpatient/
measures/disparity-methods.
349 Federal Register. (2013). National Standards
for Culturally and Linguistically Appropriate
Services (CLAS) in Health and Health Care.
Available at: https://www.federalregister.gov/
documents/2013/09/24/2013-23164/nationalstandards-for-culturally-and-linguisticallyappropriate-services-clas-in-health-and-health.
350 Centers for Medicare and Medicaid Services.
(2021). Accountable Health Communities Model.
Available at: https://innovation.cms.gov/
innovation-models/ahcm.
351 Centers for Medicare and Medicaid Services.
The Accountable Health Communities HealthRelated Social Needs Screening Tool. Available at:
https://innovation.cms.gov/files/worksheets/ahcmscreeningtool.pdf.
352 Centers for Medicare and Medicaid Services.
(2021). IMPACT Act Standardized Patient
Assessment Data Elements. Available at: https://
www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/Post-Acute-Care-QualityInitiatives/IMPACT-Act-of-2014/-IMPACT-ActStandardized-Patient-Assessment-Data-Elements.
353 Centers for Medicare & Medicaid Services.
(2021). Building an Organizational Response to
E:\FR\FM\10AUR2.SGM
Continued
10AUR2
49170
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
performed analyses of disparities in our
quality programs by using a series of
stratification methodologies identifying
quality of care for patients with
heightened social risk or with
demographic characteristics with
associations to poorer outcomes. In
2015, we began providing entity-level
quality and member experience data to
all Medicare Part C/D health plans
stratified by race and ethnicity. In 2018,
we introduced confidential reporting of
hospital quality measure data stratified
by dual eligibility in the Hospital IQR
Program (81 FR 25199; 82 FR 38403
through 38409).354
We are continuing to evaluate
opportunities to expand our measure
stratification reporting initiatives using
existing sources of data. Our goal is to
provide comprehensive and actionable
information on health disparities to
healthcare providers participating in our
quality programs to support quality
improvement efforts. We are doing this,
in part, by starting with confidential
reporting of stratified measure results
that highlight potential gaps in care
between groups of patients. This
includes examining the possibility of
reporting disparities in care based on
additional social risk factors and
demographic variables associated with
historic disadvantage in the healthcare
system, and examining disparities
through the use of stratified healthcare
quality measures across a variety of care
settings. As we consider expanding our
disparity measurement initiatives
through the use of measure
stratification, we believe that we model
these efforts on existing best practices,
such as considering feedback and
making use of lessons learned through
the development of our existing
disparity reporting efforts.
There are several key elements that
we intend to take into account as we
consider advancing the use of
measurement and stratification as tools
to address healthcare disparities and
advance healthcare equity. In the FY
2023 IPPS/LTCH PPS proposed rule, we
sought input on key considerations in
five specific areas that could inform our
approach (87 FR 28479 through 28486).
Each is described in more detail later in
this section:
• Identification of Goals and
Approaches for Measuring Healthcare
Health Disparities [Fact Sheet]. U.S. Department of
Health and Human Services. Available at: https://
www.cms.gov/About-CMS/Agency-Information/
OMH/Downloads/Health-Disparities-Guide.pdf.
354 Centers for Medicare & Medicaid Services,
Office of Minority Health. Racial, Ethnic, & Gender
Disparities in Health Care in Medicare Advantage.
(2021). Available at: https://www.cms.gov/files/
document/racial-ethnic-gender-disparities-healthcare-medicare-advantage.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Disparities and Using Measure
Stratification Across CMS Quality
Programs—This section identifies
potential approaches for measuring
healthcare disparities through measure
stratification in CMS quality reporting
programs.
• Guiding Principles for Selecting and
Prioritizing Measures for Disparity
Reporting Across CMS Quality
Reporting Programs—This section
describes considerations that could
inform the selection of healthcare
quality measures to prioritize for
stratification.
• Principles for Social Risk Factor
and Demographic Data Selection and
Use—This section describes several
types of social risk factor and
demographic data that could be used in
stratifying measures for healthcare
disparity measurement.
• Identification of Meaningful
Performance Differences—This section
reviews several strategies for identifying
meaningful differences in performance
when measure results are stratified.
• Guiding Principles for Reporting
Disparity Results—This section reviews
considerations we could take into
account in determining how quality
programs will report measure results
stratified by social risk factors and
demographic variables to healthcare
providers, as well as the ways different
reporting strategies could hold
healthcare providers accountable for
identified disparities.
2. Identification of Goals and
Approaches for Measuring Healthcare
Disparities and Using Measure
Stratification Across CMS Quality
Programs
One of our goals in developing
methods to measure disparities in care
for beneficiaries is to provide actionable
and useful results to healthcare
providers. By quantifying healthcare
disparities (for example, through quality
measure stratification), we aim to
provide useful tools for healthcare
providers to drive improvements. We
hope that these results support
healthcare provider efforts to examine
the underlying drivers of disparities in
their patients’ care and to develop their
own innovative and targeted quality
improvement interventions. With
stratified disparity information
available, it may be possible to drive
system-wide advancement through
incremental, provider-level
improvement.
There are multiple conceptual
approaches to stratifying measures.
Since 2018, we have focused on
illuminating healthcare disparities by
reporting stratified results of existing
PO 00000
Frm 00392
Fmt 4701
Sfmt 4700
quality measures by dual eligible status
in two complementary ways.355 First,
after stratification by dual eligible
status, measure results for subgroups of
patients served by an individual
healthcare provider can be directly
compared. This type of comparison
identifies such disparities, or gaps in
care or outcomes between groups at a
hospital. This approach is sometimes
referred to as ‘‘within-provider’’
disparity and can be done for most
measures that include patient-level data
for most care settings. ‘‘Withinprovider’’ disparities are a helpful
means by which to quantitatively
express disparities in care at the
provider level.356 Second, a healthcare
provider’s performance on a measure for
only dual eligible patients is compared
to other healthcare providers’
performance for that same subgroup of
patients (sometimes referred to as
‘‘across-provider’’ disparities
measurement). This type of comparison
illuminates the healthcare provider’s
performance for only the dual eligible
subgroup, allowing comparisons for
specific performance to be better
understood and compared to peers, or
against state and national benchmarks.
Taken separately, each approach may
provide an incomplete picture of
disparities in care for a particular
measure, but when reported together
with overall quality performance, these
results can give detailed information
about where differences in care exist.
Using dual eligibility as an example, a
healthcare provider may underperform
when compared to national averages for
their dual eligible population (‘‘acrossprovider’’ disparity), but if they also
underperform for patients who are not
dual eligible, the measured difference,
or ‘‘within-provider’’ disparity, could be
negligible even though performance for
the group that has been historically
marginalized remains poor. In this case,
simply providing stratified withinprovider results could show little
difference in care between patient
groups seen by the provider but the
combined results show the provider is
underperforming on care for some
patients compared to other providers.
Similar approaches have been
recommended by the Assistant
Secretary of Planning and Evaluation
(ASPE) as ways to measure health
355 QualityNet. Disparity Methods Confidential
Reporting Overview. Available at: https://
qualitynet.cms.gov/inpatient/measures/disparitymethods.
356 Centers for Medicare & Medicaid Services.
(2015). Risk Adjustment Fact Sheet. Available at:
https://www.cms.gov/Medicare/Medicare-Fee-forService-Payment/PhysicianFeedbackProgram/
Downloads/Risk-Adjustment-Fact-Sheet.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
equity in their 2020 Report to
Congress.357 In their report, ASPE
suggested measuring and reporting
quality specifically for beneficiaries
with social risk factors, stratifying
measures by social risk factors, and
encouraging the development of health
equity measures such as these for
incorporation into quality reporting
programs.
We are especially sensitive to the
need to ensure all disparity reporting
avoids measurement bias. Stratified
results must be carefully examined for
potential measurement or algorithmic
bias 358 that is introduced through
stratified reporting. Furthermore, results
of stratified reporting must be evaluated
for any type of selection bias that fails
to capture disparity due to inadequate
representation of subgroups of patients
in measure cohorts. As part of the
implementation of any type of measure
stratification, we would carefully
examine stratified results and methods
to mitigate the potential for drawing
incorrect conclusion from results.
3. Guiding Principles for Selecting and
Prioritizing Measures for Disparity
Reporting Across CMS Quality
Reporting Programs
khammond on DSKJM1Z7X2PROD with RULES2
We are considering expanding our
efforts to provide stratified reporting for
additional clinical quality measures,
provided they offer meaningful and
valid feedback to healthcare providers
on their care for populations that may
face social disadvantage or other forms
of discrimination or bias. Further
development of stratified reporting of
healthcare quality measures can provide
healthcare providers with more granular
results that support targeting resources
and initiatives to improve health equity
as a means to improving the overall
quality of care. We are mindful that it
may not be possible to calculate
stratified results for all quality
measures, or that there may be
situations where stratified reporting
may not be desired. To help inform
prioritization of the next generation of
candidate measures for stratified
reporting, we solicited feedback on
several systematic principles under
consideration that we believe will help
357 ASPE. (2020). Social Risk Factors and
Performance in Medicare’s Value-Based Purchasing
Program: The Second of Two Reports Required by
the Improving Medicare Post-Acute Care
Transformation (IMPACT) Act of 2014. Available at:
https://aspe.hhs.gov/sites/default/files/migrated_
legacy_files//195191/Second-IMPACT-SES-Reportto-Congress.pdf.
358 Obermeyer Z, Powers B, Vogeli C,
Mullainathan S. Dissecting racial bias in an
algorithm used to manage the health of populations.
Science. 2019;366(6464):447–53.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
us prioritize measures for disparity
reporting across quality programs.
These considerations would help
guide the use of stratified measure
results to provide information on
healthcare disparities broadly across our
quality programs. While we aim to
standardize approaches where possible,
disparity identification requires an
understanding of the specific context
and measures used by each program. To
ensure that results provide the most
actionable data possible, and to limit the
potential for the introduction of bias, we
believe decisions about how to identify
and prioritize measures for possible
stratification be made at the program
level.
• Prioritize Existing Clinical Quality
Measures—When considering disparity
reporting of stratified quality measures,
there are several advantages to focusing
on measures that we have already,
through notice and comment
rulemaking, adopted for one or more
CMS quality programs. These measures
assess the quality of care on agreed
upon topics for quality measurement
specific to a quality program setting.
These measures have gone through an
extensive development process and
validation testing with significant
opportunity for public input. Adapting
these existing quality measures to
measure disparity through stratification
maintains adherence to the
measurement priorities identified
through expert review and validation
completed through measure
development and testing. The
application of measure stratification to
these measures would also minimize
any new reporting burden on healthcare
providers.
• Prioritize Measures with Identified
Disparity in Treatment or Outcomes for
the Selected Social or Demographic
Factor—Candidate measures for
stratification be supported by evidence
of underlying healthcare disparities in
the procedure, condition, or outcome
being measured. A review of peerreviewed research studies be conducted
to identify disparities related to
treatment, procedure, or outcome
associated with the measure, and
carefully consider both social risk
factors and patient demographics. In
addition, analysis of Medicare-specific
data be done to demonstrate evidence of
disparity in care among the Medicare
population. In addition, consideration
also be given to conditions that have
highly disproportionate prevalence in
certain populations.
• Prioritize Measures with Sufficient
Sample Size to Allow for Reliable and
Representative Comparisons—Sample
size holds specific significance for
PO 00000
Frm 00393
Fmt 4701
Sfmt 4700
49171
statistical calculations; however, it
holds additional importance in the
context of disparity reporting. Candidate
measures for stratification will need to
have sufficient cohort sample size to
ensure that reported results of the
disparity calculation are reliable and
representative of the healthcare
provider’s patient population. This may
be challenging if cohorts with a given
social risk factor are small.
Carefully establishing reliability and
representation standards for measure
reporting is important for considering
measures to stratify. Reliability, in this
case, refers to the minimum case count
needed to achieve reliable results.
Metrics for reliability are used in nonstratified quality measure reporting,
such as when measures require a certain
number of procedures for their rates to
be considered reliable. The use of a
reliability standard for disparity
reporting will ensure consistently
reliable results are calculated.
Representation standards are also
important and may involve requiring a
minimum number or percent of
healthcare providers or patients to be
eligible to receive stratified results with
reliable estimates before a measure is
considered for disparity reporting. This
requirement aims to ensure that
meaningful comparisons can be made.
As we noted previously, when only a
small proportion of healthcare providers
can receive statistically significant
results, it may not be prudent for quality
programs to pursue stratified reporting
for that particular measure. Doing so can
create challenges when generalizing
rates of disparity for conditions or
procedures when only a small
proportion of a healthcare provider’s
results are considered. If, for example,
only 10 percent of healthcare providers
can report results, results must be
clearly presented to ensure they are not
understood to represent disparity in
care for the measurement taking place in
all care settings, as shown in this
example, where 90 percent of them
would not be included in reporting.
Quality programs may further
consider measures for disparity
reporting based on the size of the
calculated disparity by prioritizing
measures for stratification that show
large differences in care between patient
groups. Large differences in care for
patients along social or demographic
lines may indicate high potential that
targeted initiatives could be effective.
However, measures with disparities of
smaller magnitude but with large
cohorts affect many patients because
they may have very large aggregate
impacts on the national scale.
E:\FR\FM\10AUR2.SGM
10AUR2
49172
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
• Prioritize Outcome Measures and
Measures of Access and
Appropriateness of Care— Quality
measurement in CMS programs often
focus on outcomes of care, such as
mortality or readmission. Outcomes
measures remain a priority in the
context of disparities measurement.
However, measures that focus on access
to care, when available, are also critical
tools for addressing healthcare
disparities. Measures that address
healthcare access can counterbalance
the risk of creating perverse incentives.
If only differences in care between
groups are measured, performance on a
measure of disparity could be improved
by limiting access to care for high-risk
patients in the populations that are
historically underserved or
marginalized.
To complement stratification of
measures focused on clinical outcomes,
quality programs may consider
prioritizing measures with a focus on
access to or the appropriateness of care.
These measures, when reported in
tandem with clinical outcomes, would
provide a broader picture of care
provided by a healthcare provider,
illuminate potential drivers of
performance, and highlight
organizations that fail to address
barriers in access to care for groups that
have been historically marginalized. We
acknowledge that the measurement of
access and appropriateness of care is a
growing field, and that there are
currently a limited number of developed
quality measures on these topics.
However, as our ability to measure these
facets of healthcare improves, we expect
that they will be high priority for
measure stratification.
4. Principles for Social Risk Factor and
Demographic Data Selection and Use
khammond on DSKJM1Z7X2PROD with RULES2
There are a wide array of non-clinical
drivers of health known to impact
patient outcomes, including social risk
factors such as socioeconomic status,
housing availability, and nutrition, as
well as marked inequity in outcomes
based on patient demographics such as
race and ethnicity, being a member of a
minority religious group, geographic
location, sexual orientation, and gender
identity, religion, and disability
status.359 360 361 362 363 364 365 366 367 The
359 Joynt
KE, Orav E, Jha AK. (2011). Thirty-day
readmission rates for Medicare beneficiaries by race
and site of care. JAMA, 305(7):675–681.
360 Lindenauer PK, Lagu T, Rothberg MB, et al.
(2013). Income inequality and thirty-day outcomes
after acute myocardial infarction, heart failure, and
pneumonia: retrospective cohort study. British
Medical Journal, 346.
361 Trivedi AN, Nsa W, Hausmann LRM, et al.
(2014). Quality and equity of care in U.S. hospitals.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
World Health Organization (WHO)
defines social risk factors as ‘‘nonmedical factors that influence health
outcomes. They are the conditions in
which people are born, grow, work, live,
and age, and the wider set of forces and
systems shaping the conditions of daily
life.’’368 These include factors such as
income, education, job security, food
security, housing, social inclusion and
non-discrimination, access to affordable
health services, and any others.
Research has indicated that these social
factors may have as much or more
impact on health outcomes as clinical
care itself.369 370 Additionally,
differences in outcomes based on
patient race and ethnicity have been
identified as significant, persistent, and
of high priority for CMS and other
federal agencies.371
New England Journal of Medicine, 371(24):2298–
2308.
362 Polyakova, M., et al. (2021). Racial disparities
in excess all-cause mortality during the early
COVID–19 pandemic varied substantially across
states. Health Affairs, 40(2): 307–316.
363 Rural Health Research Gateway. (2018). Rural
communities: Age, income, and health status. Rural
Health Research Recap. Available at: https://
www.ruralhealthresearch.org/assets/2200-8536/
rural-communities-age-income-health-statusrecap.pdf.
364 HHS Office of Minority Health (2020). 2020
Update on the Action Plan to Reduce Racial and
Ethnic Health Disparities. Available at: https://
www.minorityhealth.hhs.gov/assets/PDF/Update_
HHS_Disparities_Dept-FY2020.pdf.
365 Poteat TC, Reisner SL, Miller M, Wirtz AL.
(2020). COVID–19 vulnerability of transgender
women with and without HIV infection in the
Eastern and Southern U.S. medRxiv [Preprint].
2020.07.21.20159327. doi: 10.1101/
2020.07.21.20159327. PMID: 32743608; PMCID:
PMC7386532.
366 Vu M. et al. (2016). Predictors of Delayed
Healthcare Seeking Among American Muslim
Women, Journal of Women’s Health 26(6). doi:
10.1089/jwh.2015.5517.
367 Nadimpalli SB, Cleland CM, Hutchinson MK,
Islam N, Barnes LL, Van Devanter N. (2016) The
Association between Discrimination and the Health
of Sikh Asian Indians. Health Psychology, 35(4),
351–355. https://doi.org/10.1037/hea0000268.
368 World Health Organization. Social
Determinants of Health. Available at: https://
www.who.int/health-topics/social-determinants-ofhealth#tab=tab_1.
369 Hood, C., Gennuso K., Swain G., Catlin B.
(2016). County Health Rankings: Relationships
Between Determinant Factors and Health
Outcomes. Am J Prev Med. 50(2):129–135.
doi:10.1016/j.amepre.2015.08.024.
370 Chepaitis, A.E., Bernacet, A., Kordomenos, C.,
Greene, A.M., Walsh, E.G. (2020). Addressing social
determinants of health in demonstrations under the
financial alignment initiative. RTI International.
Available at: https://innovation.cms.gov/data-andreports/2021/fai-sdoh-issue-brief.
371 White House. (2021). Executive Order On
Advancing Racial Equity and Support for
Underserved Communities Through the Federal
Government. Available at: https://
www.whitehouse.gov/briefing-room/presidentialactions/2021/01/20/executive-order-advancingracial-equity-and-support-for-underservedcommunities-through-the-federal-government/.
PO 00000
Frm 00394
Fmt 4701
Sfmt 4700
Identifying and prioritizing specific
indicators of social risk or demographic
variables to consider for stratified
analyses and measure reporting can be
challenging due to the large number of
variables identified in the literature as
potential risk factors for disparities in
health care and poorer health outcomes.
And yet, the limited availability of data
for many self-reported social risk factors
and demographic factors across the
healthcare sector further complicates
our ability to choose effective metrics to
evaluate disparity.
Disparity reporting in the Hospital
IQR Program has focused on
stratification by dual eligibility for
Medicare and Medicaid. Dual eligibility
has been used in this and other CMS
quality programs as an indicator of
financial risk, as the majority of
Medicaid beneficiaries are eligible based
on meeting thresholds for low patient
income and/or assets. The use of dual
eligibility is consistent with
recommendations from ASPE’s First
Report to Congress which was required
by the Improving Medicare Post-Acute
Care Transformation (IMPACT) Act of
2014 (Pub. L. 113–185).372 This report
found that, in the context of value-based
purchasing (VBP) programs, dual
eligibility, as an indicator of social risk,
was among the most powerful
predictors of poor health outcomes
among those social risk factors that
ASPE examined and tested.
Financial risk is only one metric of
social risk, and stratification of quality
measures by additional social risk
factors and demographics (such as race,
ethnicity, language, religion, sexual
orientation, and gender identity) or
disability, is important to provide more
granular information for healthcare
providers to act upon. As we consider
prioritizing and expanding the variables
used for measure stratification, we will
carefully consider both social risk
factors and patient demographics as
well as other variables associated with
historic disadvantage in healthcare,
such as disability status.
As noted previously, a growing body
of literature identifies the association
between social risk factors and
demographic variables with poorer
health outcomes.373 374 375 While social
372 Office of the Assistant Secretary For Planning
and Evaluation. (2016). Report to Congress: Social
Risk Factors and Performance Under Medicare’s
Value-Based Purchasing Programs. Available at:
https://aspe.hhs.gov/reports/report-congress-socialrisk-factors-performance-under-medicares-valuebased-purchasing-programs.
373 National Academies of Sciences, Engineering,
and Medicine. (2016). Accounting for social risk
factors in Medicare payment: Identifying social risk
factors. Washington, DC: The National Academies
Press. https://doi.org/10.17226/21858. Available at:
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
risk factors and demographic variables
are both associated with worse
healthcare outcomes and experiences,
they are distinct constructs, and be
identified, measured, and reported as
such. Patient demographic variables
such as race and ethnicity are often
identified as indicators of social risk
driven by the differences in care
received by persons who belong to
minority racial and ethnic groups. The
disparity in outcomes can be attributed
to many factors, including
discrimination in the healthcare system,
challenges accessing quality healthcare,
and societal inequity in other factors
connected to social risk. Attributing
differences in outcomes to race may
inappropriately place the driver of
poorer health outcomes on the patient,
rather than on structural factors, such as
racism in society and the healthcare
system that drive the provision of lower
quality care.376 It is important, in
identification of non-clinical drivers of
health, to identify that race and
ethnicity are not the social risk factor,
but markers of exposure to other factors.
In prioritizing among social risk
factors and demographic variables,
disability, and other markers of
disadvantage for stratified reporting, we
anticipate that each individual quality
program would design an approach
appropriate to their care setting. We
strive to operationalize our programs
consistently where possible to decrease
the burden on healthcare providers,
however, the deeply contextual nature
of this type of reporting may require the
development of an approach specific to
the quality programs based on care
setting, patient population, and data
availability.
The availability of data is a crucial
consideration when examining data
sources for use in stratified quality
reporting. In many cases, the lack of
available patient-reported data on
patient social risk or demographic
https://www.nap.edu/catalog/21858/accountingfor-social-risk-factors-in-medicare-paymentidentifying-social.
374 Office of the Assistant Secretary For Planning
and Evaluation. (2016). Report to Congress: Social
Risk Factors and Performance Under Medicare’s
Value-Based Purchasing Programs. Available at:
https://aspe.hhs.gov/reports/report-congress-socialrisk-factors-performance-under-medicares-valuebased-purchasing-programs.
375 Office of the Assistant Secretary For Planning
and Evaluation. (2020). Report to Congress: Social
Risk Factors and Performance Under Medicare’s
Value-Based Purchasing Programs. Available at:
https://aspe.hhs.gov/reports/second-reportcongress-social-risk-medicares-value-basedpurchasing-programs.
376 Gee G.C., Ford C.L. (2011). Structural Racism
and health inequities: Old Issues, New Directions.
Du Bois Review: Social science research on race,
8(1), 115–132. Available at: https://doi.org/10.1017/
S1742058X11000130.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
variables limits the ability to conduct
disparity analyses. While improving the
collection of patient-reported
demographic information and
information on social risk is an ongoing
goal, other methods and data sources for
estimating social risk (as described
further in this section) could potentially
fill in gaps in existing data sets, and
could include area-based indicators or
imputation techniques that use existing
information about patient populations
to estimate approximations about
related population information. Each of
these types of data sources have
advantages and disadvantages.
Patient-reported data are considered
to be the gold standard for evaluating
care for patients with social risk factors
or who belong to certain demographic
groups as this is an accurate and
preferred way to attribute social risk.377
Currently, there are many efforts
underway to further develop data
standards for collection for self-reported
patient social risk and demographic
variables. Yet, given that national data
sources of reliable, self-reported data are
not yet available, we also intend to
consider other options for social risk
factor data. We note efforts to
standardize the collection of
demographic and social risk factor data
include prior work done by both CMS
and the Office of the National
Coordinator for Health Information
Technology (ONC) with federal and
private partners to better collect and
leverage data on social risk. This work
includes: (1) The development of an
Inventory of Resources for Standardized
Demographic and Language Data
Collection; 378 379 (2) CMS’ work to
support specialized International
Classification of Diseases, (ICD) 10th
Revision, Clinical Modification (ICD–
10–CM) codes for describing the
socioeconomic, cultural, and
environmental drivers of health; 380 and
377 Jarrı
´n OF, Nyandege AN, Grafova IB, Dong X,
Lin H. (2020). Validity of race and ethnicity codes
in Medicare administrative data compared with
gold-standard self-reported race collected during
routine home health care visits. Med Care, 58(1):e1–
e8. doi: 10.1097/MLR.0000000000001216. PMID:
31688554; PMCID: PMC6904433.
378 Centers for Medicare & Medicaid Services.
(2020). Building an Organizational Response to
Health Disparities Inventory of Resources for
Standardized Demographic and Language Data
Collection. Available at: https://www.cms.gov/
About-CMS/Agency-Information/OMH/Downloads/
Data-Collection-Resources.pdf.
379 The Office of the National Coordinator for
Health Information Technology (ONC). Health IT
Standards Bulletin. HealthIT.gov: 2021. URL:
https://www.healthit.gov/sites/default/files/page/
2021-05/Standards_Bulletin_2021-2.pdf.
380 Centers for Medicare & Medicaid Services
(2019). Utilization of Z Codes for Social
Determinants of Health among Medicare Fee-forService Beneficiaries, 2019. Available at: https://
PO 00000
Frm 00395
Fmt 4701
Sfmt 4700
49173
(3) the CMS sponsorship of several
initiatives to statistically estimate race
and ethnicity information when it is
absent.381 382
One example of improving sources of
data come from the certified health IT
utilized by hospitals to meet the
requirements of the Promoting
Interoperability program. This includes
health IT certified to the
‘‘demographics’’ certification criterion
(45 CFR 170.315(a)(5)), which provides
for the capability to record race and
ethnicity at a detailed level of
granularity consistent with the Centers
for Disease Control and Prevention’s
(CDC) Race & Ethnicity—CDC code
system. This code system includes more
than 900 concepts for race and
ethnicity, which gives patients very
specific options for self-identifying their
demographic information. The 900
concepts are organized in a way to
eventually ‘‘roll up’’ to the Office of
Management and Budget’s (OMB)
minimum categories for race and
ethnicity,383 which can support
aggregation and reporting needs when
the OMB standard is necessary. It also
includes social, psychological, and
behavioral standards in health IT
certification criteria (80 FR 62601),
providing interoperability standards
(LOINC [Logical Observation Identifiers
Names and Codes] and SNOMED CT
[Systematized Nomenclature of
Medicine—Clinical Terms]) for financial
strain, education, social connection and
isolation, and others. The Agency for
Healthcare Research and Quality
(AHRQ) has also worked with the
Gravity Project which is a
multistakeholder effort to expand
capabilities to capture additional drivers
of health data elements, to identify and
harmonize social risk factor data for
interoperable electronic health
information exchange for electronic
health record (EHR) fields,384 and make
recommendations on the expansion of
www.cms.gov/files/document/z-codes-datahighlight.pdf.
381 Centers for Medicare & Medicaid Services
(2021). A New Method to Improve measurement of
Race-and-Ethnicity in CMS Data and Applications
to Inequities in Quality of Care. Available at:
https://www.cms.gov/files/document/new-methodimprove-measurement-race-and-ethnicity-cms-dataand-applications-inequalities-quality.pptx.
382 Eicheldinger, C., & Bonito, A. (2008). More
accurate racial and ethnic codes for Medicare
administrative data. Health Care Financing Review,
29(3), 27–42.
383 Federal Register. (1997). Revisions to the
Standards for the Classification of Federal Data on
Race and Ethnicity. Available at: https://
www.federalregister.gov/documents/1997/10/30/9728653/revisions-to-the-standards-for-theclassification-of-federal-data-on-race-and-ethnicity.
384 Gravity Project. Available at: https://
thegravityproject.net/.
E:\FR\FM\10AUR2.SGM
10AUR2
49174
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
the ICD–10 (International Classification
of Diseases, 10th Revision) Z-codes, the
alphanumeric codes used worldwide to
represent diagnoses, to include
additional social risk diagnoses.385
We expect to continue evaluating
patient-reported sources of social risk
and demographic information. We are
also considering three sources of social
risk and demographic data that would
allow us to report stratified measure
results:
• Billing and Administrative Data—
The majority of quality measurement
tools used in our quality programs focus
on utilizing existing claims and
administrative data for Medicare
beneficiaries. Using these existing data
to assess disparity, for example by the
use of dual enrollment for Medicare and
Medicaid, allows for high impact
analyses with negligible healthcare
provider burden. There are, however,
limitations in these data’s usability for
stratification analysis. CMS’s current
administrative race and ethnicity data
have been shown to have historical
inaccuracies due to limited collection
classifications and attribution
techniques, and are generally
considered not to be accurate enough for
stratification and disparity analyses.386
International Classification of Diseases,
10th Revision (ICD–10) codes for
socioeconomic and psychosocial
circumstances (‘‘Z codes’’ Z55 to Z65)
represent an important opportunity to
document patient-level social risk
factors in Medicare beneficiaries,
however, they are rarely used in clinical
practice, limiting their usability in
disparities measurement.387 If the
collection of social risk factor data
improves in administrative data, we will
continue to evaluate its applicability for
stratified reporting in the future.
Dual eligibility is a widely used proxy
for low socioeconomic status and is an
exception to the previously discussed
limitations, making it an effective
indicator for worse outcomes due to low
socioeconomic status. The use of dual
eligibility in social risk factor analyses
385 Centers for Medicare and Medicaid Services.
(2020). Z Codes Utilization among Medicare Feefor-Service (FFS) Beneficiaries in 2017. Available
at: https://www.cms.gov/files/document/cms-omhjanuary2020-zcode-data-highlightpdf.pdf.
386 Jarrı
´n OF, Nyandege AN, Grafova IB, Dong X,
Lin H. (2020). Validity of race and ethnicity codes
in Medicare administrative data compared with
gold-standard self-reported race collected during
routine home health care visits. Med Care, 58(1):e1–
e8. doi: 10.1097/MLR.0000000000001216. PMID:
31688554; PMCID: PMC6904433.
387 Centers for Medicare & Medicaid Services,
Office of Minority Health. (2021). Utilization of Z
codes for social determinants of health among
Medicare fee-for-service beneficiaries, 2019.
Available at: https://www.cms.gov/files/document/
z-codes-data-highlight.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
was supported by ASPE’s First and
Second Reports to Congress.388 389 These
reports found that in the context of VBP
programs, dual eligibility, as an
indicator of social risk, was among the
most powerful predictor of poor health
outcomes among those social risk
factors that ASPE examined and tested.
• Area-based Indicators of Social
Risk Information and Patient
Demographics—Area-based indicators
pool area-level information to create
approximations of patient risk or
describe the neighborhood or context
that a patient resides in. Popular among
them are the use of the American
Community Survey (ACS), which is
commonly used to attribute social risk
to populations at the ZIP code or
Federal Information Processing
Standards (FIPS) county level. Several
indices, such as the Agency for
Healthcare Research and Quality
(AHRQ) Socioeconomic Status (SES)
Index,390 Centers for Disease Control
and Prevention/Agency for Toxic
Substances and Disease Registry Social
Vulnerability Index (CDC/ATSDR
SVI),391 and Health Resources and
Services Administration Area
Deprivation Index,392 combine multiple
indicators of social risk into a single
score which can be used to provide
multifaceted contextual information
about an area and may be considered as
an efficient way to stratify measures that
include many social risk factors.
• Imputed Sources of Social Risk
Information and Patient
388 Office of the Assistant Secretary for Planning
and Evaluation. (2016). Social risk factors and
performance under Medicare’s value-based
purchasing programs. Available at: https://
aspe.hhs.gov/reports/report-congress-social-riskfactors-performance-under-medicares-value-basedpurchasing-programs.
389 Office of the Assistant Secretary For Planning
and Evaluation. (2020). Report to Congress: Social
Risk Factors and Performance Under Medicare’s
Value-Based Purchasing Programs. Available at:
https://aspe.hhs.gov/reports/second-reportcongress-social-risk-medicares-value-basedpurchasing-programs.
390 Bonito A., Bann C., Eicheldinger C., Carpenter
L. (2008). Creation of New Race-Ethnicity Codes
and Socioeconomic Status (SES) Indicators for
Medicare Beneficiaries. Final Report, Sub-Task 2.
(Prepared by RTI International for the Centers for
Medicare & Medicaid Services through an
interagency agreement with the Agency for
Healthcare Research and Policy, under Contract No.
500–00–0024, Task No. 21) AHRQ Publication No.
08–0029–EF. Rockville, MD, Agency for Healthcare
Research and Quality.
391 Flanagan, B.E., Gregory, E.W., Hallisey, E.J.,
Heitgerd, J.L., Lewis, B. (2011). A social
vulnerability index for disaster management.
Journal of Homeland Security and Emergency
Management, 8(1). Available at: https://
www.atsdr.cdc.gov/placeandhealth/svi/img/pdf/
Flanagan_2011_SVIforDisasterManagement508.pdf.
392 Center for Health Disparities Research. About
the Neighborhood Atlas. Available at: https://
www.neighborhoodatlas.medicine.wisc.edu/.
PO 00000
Frm 00396
Fmt 4701
Sfmt 4700
Demographics—Imputed data sources
use statistical techniques to estimate
patient-reported factors, including race
and ethnicity. In the case of race and
ethnicity, indirect estimation improves
upon imperfect and incomplete data by
drawing on information about a person’s
name and address and the linkage of
those variables to race and ethnicity.
One such tool is the Medicare Bayesian
Improved Surname Geocoding (MBISG)
method (currently in version 2.1), which
combines information from
administrative data, surname, and
residential location to estimate patient
race and ethnicity.393 We have
customized this tool for the Medicare
population to improve our existing
administrative data on race and
ethnicity.
The MBISG 2.1 method does not
assign a single race and ethnicity to an
individual; instead, it generates a set of
six probabilities, each estimating how
the individual would self-identify if
provided with a set of racial and ethnic
groups to choose from including:
American Indian or Alaska Native,
Asian or Pacific Islander, Black,
Hispanic, Multiracial, and White. In no
case would the estimated probability be
used for making inferences about a
specific beneficiary; only self-reported
data on race and ethnicity be used for
that purpose. However, in aggregate,
these results can provide insight and
accurate information at the population
level, such as the patients of a given
hospital, or the members of a given
plan. MBISG 2.1 is currently used by
our Office of Minority Health (OMH) to
undertake various analyses, such as
comparing scores on clinical quality of
care measures from the Healthcare
Effectiveness Database and Information
Set (HEDIS) by race and ethnicity for
Medicare Part C/D health plans, and in
developing a Health Equity Summary
Score (HESS) for Medicare Advantage
(MA) health plans.394
While the use of area-based indicators
and imputed data sources are not meant
to replace efforts to improve patientlevel data collection, we are considering
how they might be used to begin
393 Haas A., Elliott M.N., Dembosky J.W., Adams
J.L., Wilson-Frederick S.M., Mallett J.S. et al. (2019).
Imputation of race/ethnicity to enable measurement
of HEDIS performance by race/ethnicity. Health
Serv Res, 54(1):13–23. doi: 10.1111/1475–
6773.13099. Epub 2018 Dec 3. PMID: 30506674;
PMCID: PMC6338295. Available at: https://
pubmed.ncbi.nlm.nih.gov/30506674/.
394 Agniel D., Martino S.C., Burkhart Q.,
Hambarsoomian K., Orr N., Beckett M.K, et al.
(2021). Incentivizing excellent care to at-risk groups
with a health equity summary score. J Gen Intern
Med, 36(7):1847–1857. doi: 10.1007/s11606–019–
05473–x. Epub 2019 Nov 11. PMID: 31713030;
PMCID: PMC8298664. Available at: https://
pubmed.ncbi.nlm.nih.gov/31713030/.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
population-level disparity reporting of
stratified measure results while being
conscientious about data limitations.
Imputed data sources, particularly
when used to identify patient
populations for measurement, must be
carefully evaluated for their potential to
negatively affect the populations being
studied. For this reason, imputed data
sources only be considered after a
significant validation study has been
completed, including evaluation by key
stakeholders for face validity, and any
calculations that incorporate these
methods be continuously evaluated for
the accuracy of their results and the
necessity of their use. While neither
imputed nor area-level geographic data
be considered a replacement for
improved data collection, researchers
have found their use to be a simple and
cost-efficient way to make general
estimations of social risk at a
community level.395 In place of patientlevel information when it is not
available, the combination of several
sources of imputed or area-level data
can provide actionable estimations of
social risk of a population.
5. Identification of Meaningful
Performance Differences
In examining potential ways to report
healthcare disparity data, that is, the
results of quality measure stratification,
we expect to consider different
approaches to identifying meaningful
differences in performance. Stratified
results can be presented in several ways
to describe to providers how well or
poorly they are performing, or how they
perform when compared to other care
facilities. For this reason, it is important
to identify how best to present
meaningful differences in performance
for measures of disparity reporting.
While we aim to use standardized
approaches where possible, we also
expect that decisions about how to
identify meaningful differences in
performance would ultimately be
tailored to each individual program. We
welcomed feedback on the benefits and
limitations of the possible disparity
reporting approaches we described in
this RFI.
• Statistical Differences—When
aiming to examine differences in
disparities results among healthcare
providers, the use of statistical testing
can be helpful. There are many
statistical approaches that can be used
to reliably group results, such as using
395 Bi, Q., He, F., Konty, K., Gould, L.H.,
Immerwahr, S., & Levanon Seligson, A. (2020). ZIP
code-level estimates from a local health survey:
Added value and limitations. Journal of Urban
Health: Bulletin of the New York Academy of
Medicine, 97(4), 561–567.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
confidence intervals, creating cut points
based on standard deviations, or using
a clustering algorithm. Importantly,
these approaches may result in
groupings that are statistically different,
but not meaningfully different
depending on the distribution of results.
• Rank Ordering and Percentiles—
Ordering healthcare providers in a
ranked system is another option for
reporting disparity results in a
meaningful way. In this system,
healthcare providers could be ranked
based on their performance on disparity
measures to quickly allow them to
compare their performance to other
similar healthcare providers. We may
consider using an ordered system to
report healthcare provider results by
categorizing healthcare providers into
groups, for example, into quintile or
decile groups. This approach works well
as a way for healthcare providers to
easily compare their own performance
against others; however, a potential
drawback is that it does not identify the
overall magnitude of disparity. For
example, if a measure shows large
disparity in care for patients based on a
given factor, and that degree of disparity
has very little variation between
healthcare providers, the difference
between the top and bottom ranked
healthcare providers would be very
small even if the overall disparity is
large.
• Threshold Approach—A
categorization system could also be
considered for reporting disparity
results. In this system, healthcare
providers could be grouped based on
their performance using defined
metrics, such as fixed intervals of
results of disparity measures, indicating
different levels of performance. Using a
categorized system may be more easily
understood by stakeholders by giving a
clear indication that outcomes are not
considered equal. However, this method
does not convey the degree of disparity
between healthcare providers or the
potential for improvement based on the
performance of other healthcare
providers. Furthermore, it requires a
determination of what is deemed
‘acceptable disparity’ when developing
categories.
• Benchmarking—Benchmarking, or
comparing individual results to, for
example, state or national averages, is
another potential reporting strategy.
This type of approach could be done,
especially in combination with a ranked
or threshold approach, to give
healthcare providers more information
about how they compare to the average
care for a patient group.
Another consideration for each of
these approaches is grouping similar
PO 00000
Frm 00397
Fmt 4701
Sfmt 4700
49175
care settings together for comparison
through a peer grouping step, especially
if a ranked system is used to compare
healthcare providers. Some stakeholders
have stated that comparisons between
healthcare providers have limited
meaning if the healthcare providers are
not similar, and that peer grouping
would improve their ability to interpret
results. Overall, the value of peer
grouping must be weighed against the
potential to set different standards of
meaningful disparity among different
care settings.
6. Guiding Principles for Reporting
Disparity Results
Confidential reporting for a short
period that is not followed by public
reporting of the same measure data is
one approach we have used for newly
adopted measures in a CMS quality
program to give healthcare providers an
opportunity to become more familiar
with calculation methods and to begin
improvement activities before their
measure results are publicly reported.
Providing early results to healthcare
providers is an important way to
provide healthcare providers the
information they need to design
impactful strategies to reduce disparity.
Public reporting is a statutory
requirement in all of our quality
programs. Public reporting provides all
stakeholders with important
information on healthcare provider
quality, and in turn, relies on market
forces to incentivize healthcare
providers to improve and become more
competitive in their markets.
Payment accountability for
performance is also statutorily required
in some of our quality programs.
Payment accountability refers to tying
payment to the results of quality
measure performance, and in general
rewards better performance with higher
payment rates. Payment accountability
allows us to reward healthcare
providers for having low disparity rates
and performing well for vulnerable
patient groups.
We are exploring whether it would be
prudent to first confidentially report all
stratified measure results, where
adopted into a quality reporting
program, to give healthcare providers an
opportunity to understand those results
so they can begin to implement
programs to reduce disparities before we
report the results publicly.
We also believe it is important to
report stratified measure data alongside
overall measure results. Review of both
overall measure results along with
stratified results can illuminate greater
levels of detail about quality of care for
subgroups of patients, providing
E:\FR\FM\10AUR2.SGM
10AUR2
49176
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
important information to drive quality
improvement. Unstratified quality
measure results address general
differences in quality of care between
healthcare providers and promote
improvement for all patients, but unless
stratified results are available, it may be
unclear whether there are subgroups of
patients that would benefit most from
targeted quality improvement
initiatives. Notably, even if overall
quality measure scores were to improve,
without identifying and measuring
differences in outcomes between groups
of patients, it could be impossible to
track progress in reducing disparity
between patients with and without
heightened risk of poor outcomes due to
social factors.
7. Solicitation of Comments
The goal of this RFI was to describe
key considerations in determining how
to develop future policies around the
use of measure stratification as one
quality measurement tool to address
healthcare disparities and advance
health equity across our quality
programs. This is important as a means
of setting priorities and expectations for
the use of stratified measure results.
We invited general comments on the
principles and approaches listed
previously, as well as additional
recommendations about disparity
measurement or stratification guidelines
suitable for overarching consideration
across our quality programs.
Specifically, we invited comment on:
• Overarching goals for measuring
disparity that be considered across CMS
quality programs, including the
importance of pairing stratified results
with overall measure results to evaluate
gaps in care among groups of patients
attributed to a given healthcare provider
and comparison of care for a subgroup
of patients across healthcare providers.
• Principles to consider for
prioritization of measures for disparity
reporting, including prioritizing
stratification for: valid clinical quality
measures; measures with established
disparities in care; measures that have
adequate sample size and representation
among healthcare providers; and,
measures that consider access and
appropriateness of care.
• Principles to be considered for the
selection of social risk factors and
demographic data for use measuring
disparities, include the importance of
identifying new social risk factor and
demographic variables to use to stratify
measures. We also sought comment on
the use of imputed and area-based social
risk and demographic indicators for
measure stratification when patient
reported data are unavailable.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
• Preferred ways that meaningful
differences in disparity results can be
identified or be considered.
• Guiding principles for the use and
application of the results of disparity
measurement such as providing
confidential reporting initially.
We received comments on these
topics.
Comment: Many commenters
responded to the overarching goals for
measuring disparity across CMS quality
programs described in the RFI. In
general, commenters supported the
goals of measure stratification set out in
the proposed rule and suggested that
these efforts could lead to a better
understanding of longitudinal,
geographic and provider disparity
trends. Commenters noted that
stratification of applicable measures by
social risk factors will support hospital
decision making and encourage CMS to
be more explicit in describing the
relationship between stratification
methods and the concept of ‘‘health
equity,’’ as well as the implications of
those views for the specific proposals
being made. Commenters also suggested
that these methods be designed to have
the greatest impact possible on patient
care and experience.
Many commenters supported
considering multiple approaches to
measuring healthcare disparities,
specifically, using the existing ‘‘withinprovider’’ and ‘‘across-provider’’
approaches included in the CMS
Disparity Methods. Commenters
supported the current use of dualeligibility for Medicare and Medicaid as
a stratification variable, but suggested
stratification by additional social risk
factors and noted that appropriate
considerations for confounding factors
be accounted for.
Many commenters urged that CMS
consider any additional provider burden
associated with disparity measurement
and that CMS acknowledge the need to
provide actionable, useful, consistent,
valid, reliable, comparable, and robust
measures and data. A commenter
recommended that CMS establish
consistent measures across CMS’s
various quality programs to reduce
reporting burden and to enhance
robustness of the data collected;
however, other commenters agreed that
approaches may need to be tailored to
individual settings. Commenters
expressed that there are many
challenges in the implementation of
stratified measure reporting and offered
several comments and suggestions.
Commenters noted the need for CMS to
contextualize disparity results, the need
for more resources for providers to
address disparity results, and the
PO 00000
Frm 00398
Fmt 4701
Sfmt 4700
potential utility of peer grouping
especially when using approaches that
compare performance across providers
to allow for more ‘like to like’
comparisons.
A commenter suggested using
performance thresholds and
benchmarking for the entire patient
population instead of performance
threshold by subgroup like the ‘‘acrossprovider’’ approach.’’ Another
commenter suggested that, in order not
to reward low-quality care, reductions
in disparities be measured against total
quality of care.
A commenter noted that the inclusion
of health equity as a strategic goal in the
FY 2023 IPPS/LTCH PPS proposed rule
assumes a meaningful relationship
between the processes and outcomes of
care at the inpatient hospital level and
the broad measures of population health
that are generally subsumed under the
concept of ‘‘health equity.’’ The
commenter encouraged CMS to be more
explicit in describing its views of this
relationship, and the implications of
those views for the specific proposals
being made.
A few commenters opposed measure
stratification or the direction of CMS’s
health equity efforts noting that ranking
and comparing provider performance
may lead to performance competition
and gaming but may not result in
improved care for patients. Another
commenter noted that CMS could
potentially create a healthcare provider
ranking system based on the results of
the nonmedical, social risk factors
included in the stratification method
but that this would be an unacceptable
and inappropriate use of the healthcare
system’s resources.
Response: We appreciate the feedback
and suggestions provided by the
commenters regarding overarching goals
for measuring disparity across CMS
quality programs; particularly, the
importance of balancing the pursuit of
meaningful impact with burden
reduction in implementation. We will
take commenters’ feedback into
consideration in future policy
development.
Comment: Several commenters
emphasized the importance of avoiding
measurement bias as a key goal for
measuring disparity. Commenters
expressed concerns that stratification,
specifically when combined with the
use of imputed data to identify
demographic and social risk factors and
variables, could lead to measurement
bias, and potentially deepen inequities.
Commenters recommended that CMS
disclose methods and algorithms for
imputed data to maintain consumer
trust and confidence.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Several commenters suggested that
methods be introduced to adjust quality
measures and measurement tools for
patient social risk or race and ethnicity.
These commenters noted that this is
important to ensure that providers, such
as safety-net hospitals, who care for
large proportions of patients with social
risk factors are not unfairly penalized
under these performance metrics.
Response: We appreciate the feedback
and suggestions provided by the
commenters regarding attention to the
importance of avoiding measurement
bias when stratifying measures in CMS
programs. We will take commenters’
feedback into consideration in future
policy development.
We would also like to clarify that the
RFI does not directly address risk
adjustment for patient social factors or
demographic variables within measures,
which may set different expected
quality results for persons with certain
social risk factors, but rather discusses
approaches to distinguish performance
between groups to highlight underlying
disparities.
Comment: Commenters responding to
principles for the prioritization of
measures for disparity reporting
supported using existing clinical quality
measures, particularly outcome
measures and measures of access and
appropriateness of care, as a guiding
principle in selecting and prioritizing
measures for quality reporting across
CMS quality reporting programs.
A commenter expressed support for
the proposed prioritization of existing
clinical quality measures for disparity
stratification, particularly those
classified as outcomes measures and
measures of access and appropriateness
of care, rather than developing entirely
new disparity-focused measures. The
commenter stated that this will limit
any additional administrative burden
for facilities to understand, implement,
and report new quality measures while
focusing on the most meaningful results
for patients.
A commenter appreciated CMS’s
efforts to test and validate these
measures, though others cautioned the
agency to balance reducing the burden
of developing purpose-fit measures with
potential problems or limitations in
many existing measures and
recommended that existing clinical
measures be further reviewed and
validated prior to implementation
within CMS’s reporting programs. Other
commenters cautioned that individual
measures’ risk-adjustment methods
must be assessed for their impact on
disparity results.
Many commenters supported using
measures with identified disparity in
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
treatment or outcomes for the selected
social or demographic factor as a
guiding principle in selecting and
prioritizing measures for quality
reporting across CMS quality reporting
programs. A commenter urged CMS to
prioritize measures that relate to the
conditions in which the inequities are
starkest. Another commenter cautioned
that measures with known disparities in
care be judged carefully—that is, that
reporting disparity results must be
actionable, and not just be descriptive of
large disparities. Several additional
topics and conditions were suggested
for disparity measurement, including
maternal morbidity and mortality, sickle
cell disease, cancer, cardiovascular
disease, chronic kidney disease and
End-Stage Renal Disease.
Response: We appreciate the feedback
and suggestions provided by the
commenters regarding the prioritization
of quality measures for stratification;
again, with particular appreciation for
the importance of reducing burden in
implementation. We will take
commenters’ feedback into
consideration in future policy
development.
Comment: Many commenters
commented on priorities for selecting
measures for stratification particularly
related to sample size and reliability of
measures. They supported using
measures with sufficient sample size to
allow for reliable and representative
comparisons to be made.
Commenters noted that focusing on
statistical reliability and representation
meets two important criteria. First, the
reportability and reliability of a measure
will have an impact on how appropriate
different types of reporting will be, and
second, not reporting results for all
providers due to statistical
considerations risks drawing
conclusions about disparity from an
incomplete set of results. For example,
disparity in hospitals with low sample
sizes may not be calculated and
reported, even if differences in care in
this setting are the greatest. The
commenters stated that unintended
consequences of this approach could
allow for disparities to go unnoticed in
communities already historically
disadvantaged and marginalized by the
healthcare system.
Commenters suggested that CMS
consider innovative applications of
statistical methodologies for the design
and analysis of small sample data
including: (1) Research designs and
analytic methods that can maximize
statistical power for analyses of
interventions conducted with small,
culturally distinct samples—including
dynamic wait list research designs,
PO 00000
Frm 00399
Fmt 4701
Sfmt 4700
49177
Bayesian approaches, matching,
imputation, or increasing look back
periods, (2) strategies for reducing error
and bias in measures applied in studies
with culturally distinct samples such as
the Rasch Measurement Model, and (3)
use of qualitative methods and mixed
methods combining qualitative and
quantitative data.
A commenter noted that statistical
reliability and representative sampling
are important but could prove difficult
(depending on census composition) for
facilities to maintain with fluctuating
demographics and recommended that
any representation standards be applied
over the duration of the performance
year to maximize the chance of
capturing data on individuals with
social risk factors.
A commenter noted that while
blending performance across years also
encourages sustained high quality,
pooling data across years could dampen
a provider’s drive to improve if their
recent better results are blended with
older, poorer performance. The
commenter noted that in such a case,
the provider’s improved performance
would not be fully recognized in its
payment incentive payment for several
years and suggested that, in order to
counter this disincentive, CMS could
consider weighting the more recent
years more heavily or CMS could also
pool data across years only for lowvolume providers, while reporting just
the most recent year’s performance for
providers that meet a minimum count in
a single year.
Response: We appreciate the feedback
and suggestions provided by the
commenters regarding sample size and
representation in disparity analyses. We
will take commenters’ feedback into
consideration in future policy
development.
Comment: Commenters on principles
for prioritizing measurement suggested
that measures be prioritized for
stratification based on many criteria,
such as identifying measures that: target
the most high-value and impactful
measures; meaningfully advance health
equity or reduce healthcare disparities;
provide a person-centered and holistic
view of quality, including consideration
of Social Drivers of Health (SDOH) and
experience of care; provide meaningful
and usable information, or are linked to
an intervention; are tailored to specific
community needs and socioeconomic
circumstances that focus on
improvements within those populations
rather than exist as flat standards to
meet; and, incentivize work on
disparities reduction and improvement
rather than penalize providers and
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49178
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
payers who serve more patients that are
socially-disadvantaged.
A commenter stated that CMS not
prioritize measures for stratification
based on the type of measure (for
example, structure, process, outcome,
access), but that CMS instead prioritize
measures for stratification if disparities
exist in these measures and they can be
measured accurately and reliably. This
commenter noted that while the trend
has been towards prioritizing outcome
and access measures, these measures are
also highly susceptible to factors outside
a provider’s control.
Response: We appreciate the feedback
and suggestions provided by the
commenters regarding prioritization of
measures for disparity reporting. We
will take commenters’ feedback into
consideration in future policy
development.
Comment: Commenters offered a
variety of views regarding principles for
social risk factor and demographic data
selection and use in stratification. A
commenter expressed support for CMS’s
ongoing work to collect and make data
publicly available related to social risk
factors that affect patient outcomes.
Commenters agreed with the
examples of social risk factors in the
proposed rule (88 FR 28482 through
28483), including our current use of
dual eligibility for Medicare and
Medicaid as a social risk factor.
Commenters also recommended that
CMS use other financial risk factors in
addition to dual eligibility, because the
commenters believed that dual
eligibility is better understood as a
proxy for extreme financial risk.
Commenters suggested that CMS work
to enhance the use of SDOH Z-codes for
use in disparity reporting. that CMS
work to enhance the capture of
standardized data sets, and that CMS
conduct research to identify the factors
that have disproportionate impact on
health outcomes and prioritize their
collection. Commenters also suggested
CMS review tools used to capture
patient demographic and social risk
factors that are validated and widely
used but noted that ideally providers
have the ability to choose the tool that
best suit their patient population. Other
commenters recommended that CMS
explore using existing data, such as
SSDOH Z-codes, before imposing new
data reporting requirements.
Commenters suggested the use of
additional social risk factors such as
broadband internet access, social
isolation, vision, mental health status,
immigration status, and health literacy.
Commenters suggested using gender as
a social risk factor (as well as a
demographic variable).
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Commenters recommended that CMS
explore using existing data before
imposing new data reporting
requirements.
Response: We appreciate the feedback
and suggestions provided by the
commenters regarding selection of
social risk factors to use for measure
stratification. We will take commenters’
feedback into consideration in future
policy development.
In addition we want to note that
conceptually, equity related terms, such
as ‘‘health related social needs’’, ‘‘social
determinants of health’’, and ‘‘social
risk factors’’ are all used to describe
upstream factors that can adversely
affect the health of individuals and
communities (87 FR 28497). These
terms are often conflated and used
interchangeably and the variety of terms
can create confusion, prompting some
leaders in the field to adopt ‘‘drivers of
health’’ instead. In the future, CMS is
considering using ‘‘drivers of health’’
terminology to more holistically capture
aforementioned and related concepts,
while minimizing potential
misinterpretation or negative
connotation.
Comment: Several commenters
addressed the identification of new
demographic variables. Many
commenters agreed that the collection of
race and ethnicity data as well as data
regarding the other demographic
variables discussed in the preamble of
the proposed rule was needed and will
be essential for tracking disparities as
well as guiding the design and
application of culturally specific public
health approaches. A commenter
suggested that CMS add tribal
membership as a variable.
Other comments suggested using
current OMB race and ethnicity
standards. A few commenters believed
that CMS ensure collection of data on
race and ethnicity, as well as certain
other demographic data including
patients’ disability status, sexual
orientation, gender identity, and
physical and cogitative disabilities.
A commenter believed that ‘‘race’’
and ‘‘ethnicity’’ are so overly broad,
vague, and ill-defined that, even in
combination with other indicators, they
are unlikely to provide useful
information and may even obscure
individual experience to the detriment
of individualized patient care.
Some commenters supported using
imputation, or estimation, methods for
demographic variables. A commenter
stated that CMS use strong, vetted
algorithms for indirect/imputed data
attribution. Another commenter noted
that the indirect estimations as
described in the proposed rule have
PO 00000
Frm 00400
Fmt 4701
Sfmt 4700
very high predictiveness statistics and
are often used in other facets of health
research and analysis, including the
annual report on Racial, Ethnic, &
Gender Disparities in Health Care in
Medicare Advantage. The commenter
believed that these estimations are
largely built on assumptions and that
such algorithms often have issues with
how race and ethnicity is defined and
how the data are collected. Because selfreported race and ethnicity data are the
gold standard and not be replaced with
less reliable estimations, this
commenter recommended that CMS
move away from utilizing indirect
estimations to collect race and ethnicity
data and rather focus on efforts to
promote collection of self-reported data
in hospital settings.
Some commenters did not support
using estimated patient race and
ethnicity. Several commenters believed
that estimating an individual’s race or
ethnicity based on name and geography
is inappropriate. A commenter
expressed several specific concerns
regarding CMS’s potential use of the
Medicare Bayesian Improved Surname
Geocoding (MBISG) model to estimate
race and ethnicity for the purpose of
risk stratification, and recommended
CMS review the Urban Institute’s Design
Thinking Workshop on the Ethics of
Imputation and Related Methods and
subsequent report, ‘‘Five Ethical Risks
to Consider before Filling Missing Race
and Ethnicity Data.’’
Response: We appreciate the feedback
and suggestions provided by the
commenters regarding selection of
demographic variables to use for
measure stratification, and acknowledge
the complexities involved in accurately
capturing race, ethnicity, and other
nuanced demographic information.
While we will continue to explore
rigorous estimation methods, we are
committed to improving the collection
and reporting of self-reported data as
well as its use for risk stratification and
other quality measurement purposes.
We will take commenters’ feedback into
consideration in future policy
development.
Comment: Several commenters
expressed appreciation for CMS’s
identification of systemic racism as a
driver of inequitable health. A
commenter believed that data analysis
include proactive steps to explicitly
name racism and longstanding
structural racism as root causes of
inequities when interpreting and
communicating findings, and whenever
possible, make clear that observed
health inequities are not due to
biological traits, gender identities or
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
other characteristics of ethnically and
racially diverse individuals or groups.
Commenters suggested CMS be wary
of quality adjustment policies based on
race or ethnicity due to the potential of
measurement bias or other unintended
consequences related to the
implementation of well-intentioned
models that may be biased.
Commenters believed that regular and
ongoing implicit and explicit bias
training for all healthcare team members
is critical to addressing disparities and
pursuing equity, and additional training
will be necessary to support collecting
patient-reported social risk and
demographic data.
Response: We appreciate the feedback
and suggestions provided by the
commenters regarding the identification
of structural racism as a driver of
inequitable health, and agree that
addressing the impact of racism, bias,
and other forms of discrimination must
be centered in the pursuit of health
equity across CMS quality programs. We
will take commenters’ feedback into
consideration in future policy
development.
Comment: Commenters agreed with
CMS that the availability of data on
patient demographics and social risk
factors is a crucial consideration when
choosing variables to use for stratifying
quality measures. Commenters agreed
that patient self-reported data are
preferred and are the gold standard
because they are the most accurate and
reflect a patient-centered focus;
however, many clinicians already find it
difficult to collect this information from
their patients due to workflow issues,
resource constraints, and the reluctance
of some patients to self-report
demographic and social risk data.
Commenters offered suggestions
regarding how to improve data selfreporting. Commenters suggested CMS
consider opportunities for consumer
education and notification on the
importance of self-reported data, and
that any entities that will be collecting
and using these data also be prepared to
address the privacy and security of the
data.
Commenters noted the difficulty in
collecting patient data. A commenter
recommended that CMS consider how it
can support hospitals and other
providers to improve the collection of
patient self-reported social risk and
demographic data, potentially by
working with stakeholders to identify
and share best practices on consumercentered data collection approaches and
workflows to expand and improve
available options for demographic and
social risk data collection. The
commenter also recommended that CMS
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
make efforts to ensure the data can be
collected and reported efficiently and
without undue burden.
A commenter stated that while that
patient-level data remain the gold
standard, depending on the proposed
application, imputed data could have
some potential utility to fill gaps in
availability. The commenter expressed
reluctance to support the use of imputed
indices with approaches like risk
adjustment, peer grouping, and other
comparative performance applications
unless CMS tests their use on specific
measures and scoring methodologies.
Several commenters expressed some
support for the use of the Health
Resources and Services Administration
Area Deprivation Index (ADI). A
commenter stated that tools like the ADI
have shown some utility and are worth
consideration, but that the literature is
less clear on the validity and utility of
imputing individual race, ethnicity, or
other variables. Commenters suggested
that CMS avoid public reporting of
disparity reports that use imputed data
sources because this could
unintentionally introduce measurement
bias or discourage patients from
selecting providers that care for patients
in communities that have been
marginalized.
Commenters urged that CMS adopt
and endorse the Office of the National
Coordinator for Health Information
Technology’s (ONC’s) 2015 Edition
standards for collecting disaggregated
data for all hospitals and for all CMS
quality programs. A commenter noted
that the ONC’s 2015 Edition Health
Information Technology Certification
Criteria Final Rule, the ‘‘2015 Edition’’
establishes HIT certification
requirements that include full
disaggregation of race and ethnicity,
language, sexual orientation, gender
identity, and social and behavioral risk
factors.
Response: We appreciate the feedback
and suggestions provided by the
commenters regarding the availability of
social risk and demographic data for use
in stratified reporting. We especially
recognize the importance of establishing
and sustaining trust in the collection of
such data to ensure both patients and
providers understand intentions for its
use and opportunities for impact. We
will take commenters’ feedback into
consideration in future policy
development.
Comment: Commenters had
significant feedback on ways to identify
meaningful performance differences in
stratified disparity results. Commenters
suggested that CMS work to develop
metrics for measuring specific
disparities and requested that CMS
PO 00000
Frm 00401
Fmt 4701
Sfmt 4700
49179
perform analyses with various reporting
approaches—including statistical
differences, rank ordering and
percentiles, threshold, and
benchmarking. A commenter also stated
that the field needs to develop science
and analytics to understand if a
difference in performance on a given
measure is a true disparity in care that
is statistically significant. A commenter
recommended that CMS conduct
analyses to compare the results of
different methods for identifying
meaningful differences and publish the
results of these analyses for stakeholder
review and public comment.
A commenter stated that the
identification of ‘‘meaningful,’’ included
at least two major concepts—one is
clinical importance (including lives
saved, quality-adjusted life years gained,
numbers of patients affected) and the
other is size of disparity. The
commenter suggested that not all
available healthcare ‘‘performance’’
measures truly reflect performance by
the measured entities in a clear and
meaningful way and that this is
particularly the case for many outcome
measures that focus on endpoints
removed both in time and location from
the hospital providing care.
A few commenters recommended that
CMS create a minimum threshold of
acceptability from a statistical
standpoint that defines what would
constitute a disparity. More specifically,
a commenter suggested that CMS adopt
and use metrics for which success is not
solely based on percentage point
improvement as this may incentivize
bias in the selection of members and
inappropriately reward efforts that have
minimal actual impact on populationlevel disparities in care.
The majority of commenters did not
support rank orderings and percentiles,
while a commenter cautioned that
particular care is required with these
approaches to avoid unintentional harm
and another commenter agreed with
CMS’s recommendation that many
approaches be considered. A commenter
stated that rankings, or ordering,
particularly when it impacts
reimbursement, may lead to unintended
consequences specifically when these
are in large part due to factors outside
the provider’s control. These
commenters believe that using these
approaches will likely defeat the
purpose of an evolving disparity effort
in a quality program.
Commenters had mixed feedback on
the threshold approach. Some
commenters supported it because it uses
statistical testing as to whether a
hospital is significantly better, no
different, or worse than a national
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49180
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
threshold or benchmark, while other
commenters suggested it will not
adequality highlight differences
between groups that do not account for
the error associated with performance
estimates. A commenter stated that this
approach may identify differences that
are not practically meaningful, and it
also places significant burden on CMS
to determine an appropriate or
acceptable level of performance.
A commenter recommended that CMS
prioritize methods for the identification
of meaningful performance differences
that include a combination of
approaches, such as peer grouping,
benchmarking, and using a measure of
statistical significance.
A commenter noted that
benchmarking, depending on how it is
applied, may also be effective and that
relying on statistical differences is not
enough. A commenter noted that with
time, and maturity, national or state
benchmarking could become a key tool
for helping providers understand and
contextualize their own performance in
relation to that of their peers. A
commenter recommended that if
benchmarking is pursued, that it not be
done using national or state averages,
but rather comparing like facilities or
communities. Another commenter noted
that benchmarking may mask local or
regional differences in patient
populations and resource access,
inadvertently penalizing providers
serving communities that are some of
the most under-resourced and
historically marginalized across the
country.
Several commenters suggested that
across-hospital comparisons and
comparisons of within-hospital results
be done individually by hospital types
or peer groups, to give more fair
comparisons. A commenter suggested
that peer hospitals could be identified
based on patient demographic profile,
payer mix, dual-eligible percentage,
geographic location (urban vs. rural),
and/or bed size.
Response: We appreciate the feedback
and suggestions provided by the
commenters regarding the availability of
social risk and demographic data for use
in stratified reporting, and particularly
acknowledge the implications
stratification approaches may have on
provider responsibility and
accountability. We will take
commenters’ feedback into
consideration in future policy
development.
Comment: Many commenters
provided feedback on the proposed
guiding principles for the use and
application of the results of disparity
measurement on reporting strategies for
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
stratified measure results. In general,
commenters supported confidential
reporting for a short period, although
they provided mixed feedback on the
appropriateness of public reporting.
Commenters offered several
suggestions concerning whether public
reporting occur. Some commenters
urged CMS to refrain from public
reporting measures with stratified data.
A commenter suggested that some
measures may be important for internal
quality improvement but may not be
appropriate for public reporting. Other
commenters suggested that stratified
measures that contained imputed data,
or area-based data, not be publicly
reported while others expressed
concerns about whether the data would
be misunderstood by patients and the
public. Some commenters noted that
public reporting could lead to
unintended consequences, for example,
the perpetuation of stereotypes about
the type of care provided by the hospital
or its providers to certain groups of
patients or patient selection bias.
A commenter stated that in its
modeling of value incentive programs, it
concluded that there is a need for better
measures of patient social risk than are
currently available. This commenter
also recognized that another approach to
capture beneficiary social risk would be
to use area-level measures of social risk.
A commenter outlined another
potential unintended consequence as
discouraging more resourced patients
from receiving care at hospitals with
poor disparity scores, which may not
necessarily be indicative of the quality
of care the hospital provides. The
commenter noted that this could
contribute to deepening resource
inequity for patients who rely on safety
net hospitals. Another commenter
requested that CMS provide resources
and support to help hospitals and
providers interpret, understand, and act
upon any stratified data provided to
them, which may support less resourced
hospitals and discourage this type of
gaming.
Other commenters agreed with a
period of confidential reporting,
followed by public reporting, and
offered several suggestions as to when
public reporting begin. Several
commenters suggested that public
reporting not begin until: complete,
accurate and up-to-date data become
available; there is a review and
correction period; disparity reports are
validated; or, there are risk adjustments.
Many commenters supported moving
to public reporting of stratified measure
results. They noted that public reporting
enable comparisons of individual
providers with state and national
PO 00000
Frm 00402
Fmt 4701
Sfmt 4700
averages to give consumers meaningful
reference points and that quality
improvement activities, through public
reporting, would allow patients and
their family members to make more
informed health care decisions and
health care provider choices. A few
commenters noted that if information
about disparities is made public, health
insurance providers and health plans
would be better able to understand
which health care providers in their
networks were taking meaningful action
to improve health equity.
Commenters expressed concerns that
public reporting, which included
demographic data derived using
imputed methodology, was less accurate
than self-reported data and therefore
could lead to measure bias. A
commenter expressed concerns
regarding the privacy implications
under the HIPAA of public disclosure of
self-reported data and how it might
affect patients’ willingness to self-report
these data. Other commenters believed
that stratified measures not be publicly
reported because, in their view, public
reporting of stratified measures would
not add value for consumers, who
generally select providers based on
proximity, insurance coverage, provider
referral, and recommendations from
family and friends, among other criteria.
Response: We appreciate the feedback
and suggestions proposed guiding
principles for the use and application of
the results of disparity measurement on
reporting strategies for stratified
measure results, including the
importance of ensuring that both
patients and providers are given the
tools and resources to adequately
interpret these results. We will take
commenters’ feedback into
consideration in future policy
development.
Comment: Many commenters
supported CMS’s goal of advancing
health equity. Many commenters also
supported CMS’s efforts to measure
healthcare disparities and report these
results to healthcare providers and to
use quality measures stratified by
demographic variables and social risk
factors as a part of these efforts.
Commenters also supported CMS’s
efforts to improve data collection as a
part of its health equity efforts.
Commenters suggested that CMS
establish feedback loops to ensure
health equity quality measures keep up
with evolving practices in the field and
measurement science, consider using a
Technical Expert Panel or other
mechanism to advise it on this process,
and partner with other organizations as
it continues to refine its principles so
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
that any unintended consequences of
this work are identified and avoided.
A commenter recommended
expanding health equity efforts to other
settings such as outpatient hospital and
ambulatory surgical centers.
Commenters also suggested measures be
selected and prioritized that: can be
impacted by an intervention; protect the
safety net; are within the locus of
control of the measured entity;
minimize burden; and, strike a balance
between innovation and feasibility.
Response: We appreciate the general
feedback and suggestions provided by
the commenters regarding stratified
reporting. We are committed to
continued transparency in the reporting
of performance, particularly with
regards to achievement on health equity
goals, to providers and to the patients
they serve. This commitment extends
across hospitals and to all other
providers and care settings participating
in CMS quality programs. We will take
commenters’ feedback into
consideration in future policy
development.
C. Continuing To Advance to Digital
Quality Measurement and the Use of
Fast Healthcare Interoperability
Resources (FHIR) in Hospital Quality
Programs—Request for Information
In the FY 2022 IPPS/LTCH PPS final
rule, we stated the aim to move fully to
digital quality measurement in CMS
quality reporting and value-based
purchasing programs (86 FR 45342). As
part of this modernization of our quality
measurement enterprise, we issued this
RFI to gather broad public input on the
transition to digital quality
measurement. Any updates to specific
program requirements related to
providing data for quality measurement
and reporting provisions would be
addressed through future notice-andcomment rulemaking. In the FY 2023
IPPS/LTCH PPS proposed rule, we
discussed this RFI which contains five
parts (87 FR 28486 through 28489):
• Background. This part provides an
overview of our goals and strategies to
achieve digital quality measurement,
and notes input and learnings relevant
to these goals and strategies.
• Refined definition of Digital Quality
Measures (dQMs). This part outlines
potential revisions for a future
definition for dQMs.
• Data Standardization Activities to
Leverage and Advance Standards for
Digital Data. This part discusses data
standardization strategies and potential
venues for advancing data
standardization.
• Approaches to Achieve FHIR®
eCQM Reporting. This part describes
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
activities we are undertaking and
considering to achieve FHIR-based
electronic clinical quality measure
(eCQM) reporting (for example, via
FHIR APIs) as our initial
implementation of dQMs.
• Solicitation of Comments. This part
lists all requests for input included in
the sections of this RFI.
1. Background
In the FY 2022 IPPS/LTCH PPS final
rule, we noted the continued focus on
use of digital data and advancements in
technology and technical standards to
improve interoperability of healthcare
data which creates opportunity to
significantly improve our quality
measurement systems (86 FR 45342). In
a learning health system, standardized
and interoperable digital data from a
single point of collection can support
multiple use cases, including quality
measurement, quality improvement
efforts, clinical decision support,
research, and public health. We believe
data used for quality measurement, as
well as these other use cases, be a
seamless outgrowth of data generation
from routine workflows. Data sharing be
standards-based to maximize
interoperability, minimize burden, and
facilitate the development and use of
common tooling across use cases. This
approach supports data analysis, rapidcycle feedback, and quality
measurement that are aligned for
continuous improvement in patientcentered care.
We are continuing to define how we
can leverage existing policy to transform
all CMS quality measurement to digital
reporting, such as policy finalized in the
ONC 21st Century Cures Act final rule
(85 FR 25642). In that rule, ONC
finalized a ‘‘Standardized API for
Patient and Population Services’’
certification criterion (45 CFR
170.315(g)(10)) for certified health
information technology (IT) requiring
the use of FHIR Release 4 and several
other implementation specifications.
Health IT certified to this criterion will
offer single patient and multiple patient
services that can be accessed by third
party applications (85 FR 25742). The
ONC 21st Century Cures Act final rule
(85 FR 25642) also required health IT
developers to update their certified
health IT to support the United States
Core Data for Interoperability (USCDI)
standard, Version 1.396 By aligning
technology requirements for payers,
healthcare providers, and health IT
developers, HHS can advance an
interoperable health IT infrastructure
396 https://www.healthit.gov/isa/united-statescore-data-interoperability-uscdi.
PO 00000
Frm 00403
Fmt 4701
Sfmt 4700
49181
that ensures providers and patients have
access to health data when and where
it is needed.
In the FY 2022 IPPS/LTCH PPS final
rule, we outlined actions in four areas
to transition to digital quality measures:
(1) leverage and advance standards for
digital data and obtain all electronic
health record (EHR) data required for
quality measures via provider FHIRbased application programming
interfaces (APIs); (2) redesign our
quality measures to be self-contained
tools; (3) better support data
aggregation; and (4) work to align
measure requirements across our
reporting programs, other Federal
programs and agencies, and the private
sector where appropriate (86 FR 45342).
The actions are further described in
CMS’ Digital Quality Measurement
Strategic Roadmap available at: https://
ecqi.healthit.gov/dQM. In this RFI, we
focused on data standardization
activities related to leveraging and
advancing standards for digital data and
approaches to transition to FHIR eCQM
reporting in the future, as initial steps
in our transition to digital quality
measurement.
In the FY 2022 IPPS/LTCH PPS final
rule, we also stated our goal of moving
to digital quality measurement for all
CMS quality reporting and value-based
purchasing programs (86 FR 45342). In
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28487), we further clarified
that we plan to transition incrementally,
beginning with the uptake of FHIR API
technology and shifting to eCQM
reporting using FHIR standards as
described subsequently in section
IX.C.4. of the preamble of the proposed
rule. We aim to achieve a quality
measurement system fully based on
digital measures. The goals of a fully
digital measurement system include:
Reduced burden of reporting; provision
of multi-dimensional data in a timely
fashion, rapid feedback, and transparent
reporting of quality measures; digital
measures leveraged for advanced
analytics to define, measure, and predict
key quality issues; and quality measures
that support development of a learning
health system, which uses key data that
are also used for care, quality
improvement, public health, research,
etc.
2. Refined Definition of Digital Quality
Measures (dQMs)
In the FY 2022 IPPS/LTCH PPS final
rule, we sought to define a dQM as
software that processes digital data to
produce a measure score or measure
scores (86 FR 45342). In the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28487), based on feedback regarding
E:\FR\FM\10AUR2.SGM
10AUR2
49182
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
confusion by the term ‘‘software,’’ we
further clarified that dQMs are quality
measures, organized as self-contained
measure specifications and code
packages, that use one or more sources
of health information that is captured
and can be transmitted electronically
via interoperable systems. We continue
to note data sources for dQMs may
include administrative systems,
electronically submitted clinical
assessment data, case management
systems, EHRs, laboratory systems,
prescription drug monitoring programs
(PDMPs), instruments (for example,
medical devices and wearable devices),
patient portals or applications (for
example, for collection of patientgenerated data such as a home blood
pressure monitor, or patient-reported
health data), health information
exchanges (HIEs) or registries, and other
sources. We are currently considering
how eCQMs, which use EHR data, can
be refined or repackaged to fit within
the dQM umbrella. While eCQMs meet
the definition for dQMs in many
respects, limitations in data standards,
requirements, and technology have
limited their interoperability. In the
current state, there are multiple
standards that must be supported (for
example, Health Quality Measurement
Format (HQMF) 397 and Quality
Reporting Document Architecture
(QRDA) 398) for eCQM data collection
and reporting. Mapping EHR data can be
challenging and burdensome for
providers as there is often novel data
collection occurring to support quality
measurement. For example, eCQMs
require steps to map data elements from
the EHR to the appropriate format.
Future dQMs would leverage
interoperability standards to decrease
mapping burden and align standards for
quality measurement with
interoperability standards used in other
healthcare exchange methods.
We sought comment on this refined
definition of dQMs and feedback on
potential considerations or challenges
related to non-EHR data sources.
3. Data Standardization Activities To
Leverage and Advance Standards for
Digital Data
As noted in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45342), we are
considering implementing eCQM
quality reporting via FHIR-based APIs
based on standardized, interoperable
data. Advancing data standardization is
a critical step for this implementation,
and for long-term digital measurement
397 https://www.hl7.org/implement/standards/
product_brief.cfm?product_id=97.
398 https://ecqi.healthit.gov/qrda.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
strategies. Utilizing standardized data
for EHR-based measurement (based on
the FHIR standard) and aligning where
possible with other interoperability
requirements can reduce the data
collection burden incurred by providers
for the purpose of reporting quality
measures and supports achieving the
goals of transitioning to a fully digital
quality measurement system identified
in section IX.C.1. previously, including
provision of timely feedback, leveraging
the same data for multiple use cases,
and contributing to a learning health
system.
We intend to utilize standardized data
for quality measurement as one use case
of digital data in a learning health
system. In a learning health system,
standardized digital data can support
multiple use cases, including quality
measurement, quality improvement
efforts, clinical decision support,
research, and public health. We believe
that standardization across data
elements and data models is necessary
to ensure data are accessible across use
cases and enable the transmission of
data through each stage of the health
system’s learning process. Standardized
data and FHIR APIs are important for
advancing interoperability; the goal is
for data to be sent and received via
trusted exchanges, and for patients to
have access to their data. Operations
activities (for example, prior
authorization) are also dependent on
standardized, interoperable data.
Additionally, standardization is
necessary across implementation
guides, or rules for how a particular
interoperability standard be used,399
and across value sets that organize the
specific terminologies and codes that
define clinical concepts.400
Commenters on the RFI in the FY
2022 IPPS/LTCH PPS proposed rule
encouraged the use of data elements for
quality measurement that are consistent
with ONC’s USCDI standard,401 where
possible. We agree with this approach.
To advance the use of standardized
data, models, implementation guides,
and value sets in quality measurement,
we continue to focus on leveraging the
interoperability data requirements for
standardized APIs in certified health IT,
set by the ONC 21st Century Cures Act
final rule and any future updates made
in rulemaking, as a vehicle to support
modernization of CMS quality measure
399 Resource Implementation Guide—Content.
Available at: https://www.hl7.org/fhir/
implementationguide.html.
400 National Library of Medicine, Value Set
Authority Center. Available at: https://
vsac.nlm.nih.gov/.
401 https://www.healthit.gov/isa/united-statescore-data-interoperability-uscdi.
PO 00000
Frm 00404
Fmt 4701
Sfmt 4700
reporting. These API requirements are
being implemented as part of a series of
updates to certified health IT (85 FR
84825), and include availability of data
included in the USCDI via standardsbased APIs. In the CY 2021 Physician
Fee Schedule final rule, we finalized
that eligible clinicians and eligible
hospitals and CAHs participating in the
Merit-based Incentives Payment System
(MIPS) and the Medicare Promoting
Interoperability Program, respectively,
must transition to use of certified
technology updated consistent with the
2015 Edition Cures Update by 2023 (85
FR 84825). We aim to align with these
standardized data requirements as the
basis for data used in quality
measurement.
We are collaborating with federal
agencies to define and prioritize
additional data standardization needs
and develop consensus with federal
partners on recommendations for future
versions of the USCDI. We are also
directly collaborating with ONC to build
requirements to support data
standardization and alignment with
requirements for quality measurement.
ONC recently launched the USCDI+
initiative focused on supporting
identification and establishment of
domain specific datasets that build on
the USCDI foundation.402 A USCDI+
quality measurement domain currently
being explored could support defining
additional data specifications for quality
measurement that harmonize, where
possible, with other federal agency data
needs and inform supplemental
standards necessary to support quality
measurement.
We also received feedback on the RFI
in the FY 2022 IPPS/LTCH PPS
proposed rule that the use of Health
Level Seven (HL7®) Implementation
Guides are foundational to FHIR
measure reporting. To advance
implementation of standardized data,
we continue to collaborate with
consensus standards-setting bodies such
as HL7. We are considering how best to
leverage existing implementation guides
that are routinely updated and
maintained by HL7 to define data
standards and exchange mechanisms for
FHIR-based dQMs, in a fashion that
supports the learning health system and
alignment across use cases, including
the following existing HL7
Implementation Guides:
• US Core Implementation Guide; 403
402 USCDI+. Available at: https://
www.healthit.gov/topic/interoperability/uscdi-plus.
403 HL7 FHIR US Core Implementation Guide.
Available at: https://hl7.org/fhir/us/core/.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
• Quality Improvement Core (QI
Core) Implementation Guide; 404
• Data Exchange for Quality Measures
(DEQM) Implementation Guide; 405 and
• Quality Measure (QM)
Implementation Guide.406
We are also considering what, if any,
additional CMS-specific
implementation guides may be
necessary to support future digital
quality measurement such as guidance
on aggregation mechanisms for
reporting.
We recognize the importance of
considering how implementation guides
used across quality measurement and
other use cases (for example, public
health reporting, clinical decision
support) work together to support a
learning health system. For example, the
Clinical Guidelines (CPG)
Implementation Guide 407 connects
computable guidelines, clinical decision
support, quality reporting, and case
reporting. The mechanisms for reporting
across use cases are also critical to
consider, as each time a different
mechanism for reporting is needed
across different use cases, it creates
more burden. We are collaborating
closely with federal partners, such as
the Centers for Disease Control and
Prevention (CDC), to align where
possible.
We believe developing appropriately
defined implementation guides will be
a key component of supporting
standardized FHIR APIs that enable
access to standardized data elements for
particular use cases, such as quality
measurement.
We sought comment on the specific
Implementation Guides noted
previously, additional implementation
guides to consider, and other data and
reporting components (for example, data
vocabulary/terminology, alignment with
other types of reporting) where
standardization may be considered to
advance data standardization for a
learning health system.
khammond on DSKJM1Z7X2PROD with RULES2
4. Approaches to Achieve FHIR eCQM
Reporting
We previously noted in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45342)
activities we are conducting to begin
structuring and reporting eCQMs using
FHIR. eCQMs are a subset of dQMs. We
consider the transition to FHIR-based
eCQM reporting the first step to dQM
404 HL7 FHIR QI Core Implementation Guide.
Available at: https://hl7.org/fhir/us/qicore/.
405 HL7 Data Exchange For Quality Measures.
Available at: https://hl7.org/fhir/us/davinci-deqm/.
406 HL7 Quality Measure Implementation Guide.
Available at: https://hl7.org/fhir/us/cqfmeasures/.
407 HL7 FHIR Clinical Guidelines Implementation
Guide. Available at: https://hl7.org/fhir/uv/cpg/.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
reporting, and a potential model for how
future digital reporting can occur.
To support the transition, we
continue to undertake and consider
activities necessary for reporting of
FHIR-based eCQMs and future dQMs:
• In the near term, we plan to
continue to convert current Quality Data
Model (QDM)-based eCQMs to the FHIR
standard and test the implementation of
measures respecified to FHIR and
submission of data elements represented
in FHIR through ongoing HL7
Connectathons.
• In the near term, we also plan to
develop a unified CMS FHIR receiving
system. This system would allow for a
singular point of data receipt to be used
for quality reporting requirements, and
modernization of programmatic data
receiving systems to leverage
opportunities related to digital data.
• We are committed to working with
implementers and partners to optimize
interoperable data exchange to support
FHIR-based eCQM reporting (for
example, via FHIR APIs) and eventually
other dQMs, while ensuring solutions
and implementations that require
patients to engage with technology that
also support health equity.
• In the near term, we plan to identify
opportunities for the public to provide
feedback on FHIR-based measure
specifications prior to implementation,
such as during measure development/
conversion activities.
• We also plan to identify
opportunities for collaboration with
vendors and implementers via systems
testing of FHIR-based eCQM reporting to
ensure involvement in systems
development.
• Finally, we are exploring venues for
continued feedback on CMS future
measurement direction and data
aggregation approaches in anticipation
of FHIR-based API reporting of eCQMs.
• To support both near term FHIRbased eCQMs and other future dQMs, as
noted in section IX.C.3., we intend to
continue engaging with standards
development organizations to advance
and maintain implementation guides to
support the FHIR standard and API
reporting of quality measures.
• We also anticipate that prior to the
implementation of any mandatory FHIRbased eCQM reporting requirements
within our quality programs, it would
be necessary to undertake voluntary
reporting of FHIR-based eCQMs to allow
time to learn and enhance systems and
processes, both internally and among
providers and vendors.
We also continue to consider how
best to leverage the FHIR API
technology implemented to meet ONC’s
interoperability requirements to access
PO 00000
Frm 00405
Fmt 4701
Sfmt 4700
49183
and electronically transmit
interoperable data for quality
measurement. Based on feedback on the
FY 2022 IPPS/LTCH PPS proposed rule
RFI, many supported the use of FHIR
APIs, while others expressed concern
around infrastructure readiness. We
continue to explore how to leverage
FHIR APIs to decrease reporting burden
and support implementor readiness. We
sought comment on approaches to
optimize data flows for quality
measurement to retrieve data from EHRs
via FHIR APIs, and to combine data
needed for measure score calculation for
measures that require aggregating data
across multiple providers (for example,
risk-adjusted outcome measures) and
multiple data sources (for example,
hybrid claims-EHR measures). We were
interested in data flows that support
using the same data for measurement
and to provide feedback to providers at
multiple levels of accountability, such
as at the individual clinician, group,
accountable care organization and
health plan levels, as are used for
patient care and other use cases (for
example, public health reporting).
We sought comment on additional
venues to engage with implementors
during the transition to digital quality
measurement, and other critical
considerations during the transition. We
also sought comment on data flow
options to support FHIR-based eCQM
reporting.
5. Solicitation of Comments
As noted previously, we sought input
on the following:
• Refined potential future Definition
of dQMs. We sought feedback on the
following as described in section
IX.C.2.:
++ Do you have feedback on the
potential refined definition of digital
quality measures (dQMs)?
++ Do you have feedback on potential
considerations or challenges related to
non-EHR data sources?
• Data Standardization Activities to
Leverage and Advance Standards for
Digital Data. We sought feedback on the
following as described in section
IX.C.3.:
++ Do you have feedback on the
specific implementation guides we are
considering, additional FHIR
implementation guides we consider, or
other data and reporting components
where standardization be considered to
advance data standardization for a
learning health system?
• Approaches to Achieve FHIR eCQM
Reporting. We sought feedback on the
following as described in section
IX.C.4.:
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49184
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
++ Are there additional venues to
engage with implementors during the
transition to digital quality
measurement?
++ What data flow options we
consider for FHIR-based eCQM
reporting, including retrieving data from
EHRs via FHIR APIs and other
mechanisms?
++ Are there other critical
considerations during the transition?
We received several comments on
these topics.
Comment: There was widespread
support among commenters for CMS’
efforts to transition to digital quality
measurement and support for leveraging
the FHIR standard and FHIR APIs. A
couple of commenters pointed out that
improved electronic health record (EHR)
interoperability for the exchange and
use of electronic health data holds great
promise to not only improve quality
measurement and patient outcomes, but
also to reduce burden on providers. A
commenter noted that dQMs are a
critical component of a fully
interoperable learning health system
that generates knowledge beyond the
quality reporting use case, and
suggested CMS make this clear in its
transition plans. A commenter
supported CMS’s iterative approach to
transition quality reporting programs to
the use of dQMs and the FHIR standard.
Another commenter noted that
leveraging EHRs for dQM must not
interfere, delay, or hinder patient care.
While there was general support for use
of the FHIR standard, a few commenters
noted the standard was not yet fully
mature, and a commenter recommended
allowing for flexibility in standards
used, focusing on a set of standards
rather than using only FHIR.
Additionally, a commenter stated that
the FHIR standard is not broad enough
to support all potential use cases, and
that some EHR data does not map to the
standard. The commenter recommended
CMS work with ONC to advance the
adoption and consistent implementation
of data and interoperability standards,
so that provider data collection and
reporting requirements are enabled by
health IT.
Commenters differed in their input on
the time to transition to dQMs.
Although CMS did not indicate
transition by 2025 in the RFI in the FY
2023 IPPS/LTCH PPS proposed rule,
some commenters noted feasibility to
transition by 2025, whereas some
expressed concerns regarding the
timeline for dQM rollout. Some
commenters noted it would be feasible
to submit EHR data by 2025, and many
commenters agreed with beginning the
transition with EHR-based APIs and
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
expand into other data sources, as
technology development and testing
allows. A commenter noted if the data
submission requirements extend beyond
EHR data, there would need to be
changes to infrastructure which would
be burdensome. Many commenters
requested the transition be delayed
beyond 2025, until the technology
evolves further. A commenter suggested
CMS account for at least two to three
years to accommodate EHR vendor
development, budget considerations,
and testing, implementation, and
validation activities as it transitions to
dQMs.
Another commenter recommended
CMS provide at least three to four years
between finalizing any policies around
the transition timeline to requiring
FHIR-based API functionality for health
IT products/systems that are not already
going through ONC’s Health IT
Certification Program (Certification
Program). A few commenters requested
CMS provide transparency and more
detailed plans about the transition to
dQMs, or suggested CMS be flexible
with the deadline for launching dQMs.
Several commenters recommended
CMS use the Trusted Exchange
Framework and Common Agreement
(TEFCA) or CareQuality, which are
interoperability frameworks, through
the beginning of this transition. The
commenters suggested that CMS move
ahead in this transition using data tools
that CMS already has access to and are
already in use. They also requested CMS
release more information regarding the
current system capabilities. Conversely,
a commenter suggested that CMS not
use preexisting tools, but instead use
new and innovative data tools.
Several commenters stated that while
the transition to dQMs occurs, it is
imperative that quality measurement
continues, and that quality of care is not
affected by the transition. A commenter
stated that there are still current eCQM
operational challenges that must be
addressed prior to the transition to
dQMs. Commenters also questioned
which dQMs would be implemented
first. Several commenters suggested
dQMs rolled out first be clinically
relevant and useful.
Response: We appreciate all of the
comments on and interest in this topic.
This input is very valuable in our
continuing planning for the transition to
the digital quality measurement in CMS
quality reporting and value-based
purchasing programs. We continue to
take all input into account as we
develop future regulatory proposals for
our digital quality measurement
transition efforts.
PO 00000
Frm 00406
Fmt 4701
Sfmt 4700
Comment: Many commenters
supported the refined dQM definition
noting it provides a ‘‘good overview of
the intent behind dQMs’’ and it captures
‘‘the full range of evolving healthcare
information sources.’’ Some
commenters noted the definition is still
too broad and requested clarification on
components of the definition and
examples of dQMs. A commenter
encouraged CMS to continue with
refinement of its dQMs definition and
set clear, specific parameters for what it
hopes to achieve and what it expects of
hospitals. A commenter requested CMS
clarify what would make a successful
dQM interoperable or conversely not
interoperable. Another commenter
noted that establishing dQMs as freestanding software, as defined, may
disincentivize the use of clinical data
registries, which add additional value to
the healthcare ecosystem.
A commenter stated that not all data
sources identified for use in dQMs are
ready for inclusion in quality
measurement. As an example, the
commenter stated that wearable devices
and patient-generated health data have
not been vetted as valid and reliable
interoperable data sources or as usable
data for clinical quality improvement
and assessment, and wearable devices,
such as smartwatches and fitness
trackers are not universally adopted and
may introduce bias or inequities.
Another commenter suggested the
definition include the potential for
dQMs to be developed in a way that
allows their components to support a
variety of use cases, such as decision
support and quality improvement.
Several commenters noted the
ambiguity around eCQMs compared to
dQMs and requested for further
distinction. A commenter requested
clarification as to whether eCQMs will
be separate and distinct from dQMs or
incorporated into dQMs. Some
commenters expressed concern around
the introduction of new eCQMs if CMS
is transitioning to dQMs given the
resources and investments necessary for
supporting new measures.
Response: We appreciate all of the
comments on and interest in this topic.
We believe that this input is very
valuable in the continuing development
of our transition to digital quality
measurement in CMS quality reporting
and value-based purchasing programs.
We will continue to take all comments
into account as we refine the digital
quality measure definition.
Comment: Commenters were divided
on the use of non-EHR data sources for
dQMs. Several commenters indicated
non-EHR data sources could enhance
the accuracy and completeness of data
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
to determine hospital quality
performance. A commenter encouraged
CMS to continue to leverage a broad set
of data sources for digital quality
measurement rather than relying solely
on EHR-derived, standardized data,
which would limit the completeness,
accuracy, and timeliness of the data
used to determine hospital quality
performance. Commenters
recommended CMS align with other
federal initiatives such as the FDA’s use
of non-EHR data sources such as
patient-generated health data. Other
commenters expressed concern that
hospitals and clinicians may be unable
to calculate or understand their
performance internally if other data
sources are incorporated into dQMs.
Some commenters stated that because
non-EHR data are often not standardized
or not yet standardized, non-EHR data
sources could increase mapping burden,
and that platforms are not yet available
to support electronic capture,
extraction, and access from non-EHR
data sources. A commenter noted CMS
would need to address unintended
consequences of inadequate data quality
for non-EHR data sources. Some
commenters noted that patient matching
must be considered when aggregating or
combining data from disparate systems
or sources. A commenter suggested that
CMS’ initial focus of dQMs remain on
measures that emphasize the use of data
available in EHRs. Another commenter
requested CMS to provide specific
details for how hospitals are expected to
make data from non-EHR sources
available. A commenter noted that other
health IT are not required to certify to
ONC’s Health IT Certification program
and that there are no FHIR-based API
requirements for other health IT, which
poses challenges for integrating nonEHR data sources. The commenter
suggested CMS will need to establish
specific requirements on its own, or in
collaboration with ONC, to require other
health IT systems/products to develop
and maintain FHIR-based APIs that
CMS could leverage to query the data
necessary for dQMs.
Several commenters noted additional
burden when considering non-EHR data
for interoperability and data
standardization. A couple of
commenters noted requiring data
capture beyond what clinicians
document in their typical workflows
would add development and
documentation burden and require
infrastructure changes. A commenter
expressed concern with CMS’ vision for
an ecosystem with a broad set of data
sources when the calculation of existing
quality measures using data from source
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
EHRs still uncovers gaps in data which
hinder quality measure calculations.
A few commenters noted that as CMS
moves toward dQMs that use data
sources across various non-EHR health
IT, that EHRs not be the data aggregator
or be expected to capture, store, and
share information that would not be
routinely captured in an EHR.
Commenters recommended CMS aim to
obtain data from the data’s source
system when possible.
Commenters requested more specific
transition plans for the incorporation of
non-EHR data sources into dQMs, and a
commenter strongly suggested CMS
consider how the use of non-EHR data
would impact dQM development and
timelines.
Response: We appreciate all of the
comments on and interest in this topic.
We believe that this input is very
valuable in the continuing development
of our transition to digital quality
measurement in CMS quality reporting
and value-based purchasing programs.
We will continue to take all comments
into account as we refine the dQM
definition and consider the use of nonEHR data sources for digital quality
measurement.
Comment: Many commenters
expressed support for the
implementation guides CMS is
considering using for digital quality
measurement, including the Quality
Improvement (QI) Core and the Data
Exchange for Quality Measures (DEQM)
Implementation Guides. Several
commenters also specifically supported
the use of the Da Vinci Implementation
Guide and the C–CDA Implementation
Guide. A commenter also supported
standardization across implementation
guides as CMS outlined in this RFI.
Commenters also recommended CMS
consider the following additional IGs:
the Clinical Guidelines (CPG)
Implementation Guide, the FHIR Bulk
Data Access Implementation Guide,
Carequality’s FHIR-Based Exchange
Implementation Guide, and specialtyspecific implementation guides. A
commenter noted it could provide more
effective feedback when CMS clarifies
what data elements and APIs the agency
intends to use, and from where they
intend to access data. The commenter
provided the example that if CMS
would like to access health information
typically stored in a financial or billing
product along with clinical health
information for a dQM, the
implementation guidance would likely
be different than if CMS is looking to
use clinical data only for a dQM.
Several commenters encouraged CMS
to continue testing and validating the
implementation guides, recommending
PO 00000
Frm 00407
Fmt 4701
Sfmt 4700
49185
implementation guides be fully
developed and sufficiently tested for
successful implementation of truly
interoperable sharing and transparency.
Several commenters recommended that
implementation guides be mature,
defined by a commenter as broad
adoption and completion of the
balloting process. A commenter
recommended CMS seek input from
stakeholders through Connectathons
and public comment to further refine
the implementation guides.
Several commenters expressed
concerns that alignment, testing, and
maturity of the standards need to be
completed before the implementation
guides can be used for CMS programs.
One of these commenters specifically
noted alignment of definitions of
common quality measurement concepts
across implementation guides still must
be accomplished. A commenter noted
they could not provide feedback on the
specific implementation guides until
CMS communicates decisions on what
dQMs CMS intends to implement, what
data elements and APIs CMS intends to
use, and where CMS is intending to pull
the data from. Several commenters also
encouraged CMS to provide
implementers sufficient time after
implementation guides are completed
before initiating program requirements.
Several commenters expressed
concerns about the limitations of the
currently available implementation
guides, such as the DEQM defining
methods for exchange at the individual
resource or data element level, while
data are currently exchanged at the
measure document level and enabling
EHRs to push quality reporting data via
FHIR APIs only at the aggregate level,
but not at the patient level. Another
commenter expressed the need for
specialty-specific implementation
guides.
Several commenters recommended
CMS develop further implementation
guidance, including clarifying which
exchange methods will be required for
use in FHIR eCQM reporting,
aggregation of data across interoperable
systems for the purpose of quality
measurement, and methods for
collection of social determinants of
health data for measure stratification
and risk adjustment. A commenter
suggested bucketing guidance into two
categories: (1) content or context IGs
(such as measures specifications) and
(2) operational IGs (such as for data
aggregation or CMS reporting).
Regarding aggregation guidance,
commenters noted the importance of
aggregation activities including
normalizing, standardizing, and quality
assurance activities via valid methods.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49186
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Some commenters also noted that some
data, for example EHR notes, are free
text and in their current state cannot be
extrapolated and therefore require
manual abstraction. An additional
commenter recommended optimizing
these resources for better care that is
safe, affordable, and equitable,
prioritizing which IGs are being built to
align with the goals for quality
improvement programs. A commenter
noted that in terms of guidelines and
standardization of data within the
implementation guides, CMS avoid a
‘‘one size fits all’’ approach. Another
commenter suggested the importance of
consistency of data definitions, as they
believe this is fundamentally critical to
ensure analysis and interpretations can
be applied across the healthcare system.
Commenters also supported
alignment with ONC’s USCDI and
development of USCDI+ for quality
measurement. A commenter specifically
supported replacing the Common
Clinical Data Set (CCDS) for information
exchange with the more robust USCDI.
These commenters noted that the USCDI
may not include all data elements
necessary for quality measurement, and
that the USCDI+ must still be defined.
Therefore, additional standards may
still be required to support quality
measurement. A commenter suggested
the USCDI+ be incorporated into
certified EHR technology requirements
to support implementation. Another
commenter noted the importance of
federal and commercial alignment on
data needs included in USCDI and
USCDI+. Another commenter pointed
out that a holistic approach is needed
for data standards whereby standards
are developed and adopted for use
across care settings. The commenter
added that there are at present a limited
number of common data elements
across inpatient, outpatient, and postacute care; however, these elements
could serve as a starting point for crosscontinuum patient assessment.
Response: We appreciate all of the
comments and suggestions on this topic.
We believe that this input is very
valuable in the continuing development
of our transition to digital quality
measurement in CMS quality reporting
and value-based purchasing programs
underpinned by data standardization
activities. We will continue to take all
comments into account as we refine
implementation guides and additional
guidance for dQM reporting.
Comment: Several commenters
provided input on additional venues to
engage with implementors and other
stakeholders during the transition to
digital quality measurement. Several
commenters requested CMS continue to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
solicit feedback from the public and
other agencies on the transition to
dQMs. Many commenters suggested
CMS continue to participate in and host
events, such as Connectathons,
conferences, webinars, and the CMS
Quality Conference to further explain
CMS’ plans to advance digital quality
measures and to solicit feedback.
Commenters also suggested CMS
collaborate with and solicit feedback
from a variety of other stakeholders
including, but not limited to: the Core
Quality Measures Collaborative
(CQMC), the National Quality Forum
(NQF), the National Committee for
Quality Assurance (NCQA), technical
expert panels, health insurers,
clinicians, EHR Association, hospitals,
clinical registries, and health IT
developers. Commenters also suggested
CMS work with health information
exchanges (HIEs) and regional health
information exchanges (RHIEs), which
have experience with data flow options
and dQM data collection and exchange.
Some commenters also offered to
provide CMS with additional feedback
as the agency works on transitioning to
dQMs.
Commenters also recommended CMS
work with ONC to update certification
criteria if FHIR-based dQMs require the
implementation of additional FHIR
APIs. A commenter expressed concern
that development and documentation
burden would increase, if CMS would
require data capture beyond what
clinicians document in their typical
workflows.
Regarding testing of dQMs, several
commenters recommended CMS
conduct sufficient large-scale testing
and consult with multi-stakeholder
groups such as the Health Information
Technology Advisory Committee
(HITAC) and NQF prior to wide-spread
adoption. Several commenters also
noted the utility of Connectathons for
testing.
Response: We thank commenters for
their suggestions for soliciting feedback.
CMS will continue to solicit feedback
from the implementers and other
stakeholders throughout the transition
planning and implementation of dQMs.
Comment: Regarding data flow
options, several commenters supported
CMS’ overall direction towards using
Clinical Quality Language (CQL), FHIR,
and FHIR-based APIs for digital quality
measurement, as common language and
data source availability would promote
data consistency across health IT
systems.
Several commenters expressed
concerns and suggestions regarding data
privacy and security. Some commenters
expressed concerns regarding privacy of
PO 00000
Frm 00408
Fmt 4701
Sfmt 4700
the non-EHR data sources, noting that
non-EHR data sources do not have to
abide by the Health Insurance
Portability and Accountability Act of
1996 (HIPAA) and expressed concerns
about the security of Protected Health
Information (PHI) in non-EHR
environments. Commenters also
expressed concerns about privacy of
data accessed via FHIR APIs. A
commenter requested clarification about
whether FHIR receiving systems will
hold PHI, and if so for how long and
how PHI would be secured.
Commenters inquired whether patients
would have the ability to opt-out of
their information being transferred.
Another commenter expressed concern
about private information being shared
with entities that are not covered by
HIPAA and requested CMS work with
Congress to fill the gap in the national
privacy framework by developing robust
federal privacy laws and regulations
applicable to organizations that obtain
healthcare data but are not subject to
HIPAA. In addition, the commenter
suggested HHS and the Federal Trade
Commission (FTC) work together to find
an effective stop-gap measure that can
be implemented to protect potentially
personally identifiable information that
could be shared via APIs.
While several commenters supported
CMS’s vision in accelerating the use of
the FHIR standard and FHIR APIs to
improve the exchange of health
information to improve patient
satisfaction and care, some commenters
noted they do not themselves guarantee
data quality, accuracy, or completeness.
Commenters suggested CMS clarify how
data integrity would be maintained for
CMS dQM reporting and consider
unintended consequences if the data
quality is inadequate. A commenter
noted using existing FHIR US Corebased APIs may not be an ideal
approach for CMS dQM reporting,
depending on the volume of data being
considered and the frequency of data
access. The commenter also stated that
the FHIR resources needed to calculate
dQMs may go beyond those available
through FHIR US Core-based APIs.
Another commenter stated concern
about the variation of FHIR versions,
and lack of version requirements. A
commenter noted there are limitations
on a provider’s ability to connect to
certain applications to submit data with
multiple versions of FHIR and no
version requirements.
A few commenters expressed concern
that API data providers, healthcare
systems and provider practices may be
unfairly burdened by fees and costs
incurred from API technology providers.
A commenter expressed concern that
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
payers or providers could be required to
purchase certain software or be forced to
pay to join registries or HIEs. A
commenter expressed an additional
concern that the API implementation
costs would be shifted onto healthcare
systems and physician practices, which
could have a significant deleterious
effect on smaller practices.
Several commenters provided input
on other considerations.
A couple of commenters provided
input on CMS’ vision for the FHIRbased measure calculation tool,
described in CMS’s Digital Quality
Measurement Strategic Roadmap,
although CMS did not request comment
on the tool in this RFI. CMS previously
requested comment on the tool in the
FY 2022 IPPS/LTCH PPS proposed rule.
A commenter requested clarification
about whether measure calculation tools
that would be created by CMS would
enable real-time performance
monitoring and about the frequency of
measure calculation tool queries. The
same commenter noted validation
would need to be redone to verify that
accurate measure outcomes were
calculated by a measure calculation tool
after measures are expressed in FHIR.
Another commenter recognized the
promise of an end-to-end measure
calculation tool for distributing digital
quality measures from a measure
calculation tool to end users.
A commenter requested CMS provide
information on the CMS FHIR receiving
system to be used for digital quality
measurement. The commenter requested
clarification on the CMS FHIR receiving
system’s attributes including how the
system would know which APIs to
query for which information, and if the
CMS FHIR receiving system would rely
on querying APIs or publication/
subscription functionality not currently
required by ONC or CMS.
Many commenters raised concern
with burden. Several commenters noted
CMS consider the burden of
transitioning to dQMs and ensure dQMs
do not increase overall quality reporting
burden. A commenter acknowledged the
potential of dQMs as an end-to-end
reporting solution and stated their belief
that dQMs could enable a true learning
health system in which real-time
feedback from dQMs could be shared
with providers for clinical decision
support at the point-of-care.
Commenters noted that while FHIRbased quality collection and reporting
may potentially reduce the effort
involved in measurement in the longer
term, there are several precursor steps
that need to be taken as setting up this
capability will be burdensome for health
IT vendors and providers.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
As noted previously, several
commenters provided input on the
timeline for transition and timeline
feasibility. Commenters requested
clarity from CMS on the transition
timelines, including timelines for the
phase-out of or addition of eCQMs, the
use of USCDI+, the use of FHIR-based
API, and when CMS would publish the
required data elements and
specifications for required dQMs.
Several commenters noted the
timeline to transition to dQMs is the
biggest challenge and that period would
significantly increase burden on
providers, with even greater concerns
noted for LTCHs and small rural
hospitals. Commenters noted the longterm benefit of the transition to dQMs
and FHIR however acknowledged the
up-front burden. While beyond the
scope of concern for the Hospital IQR
Program or this RFI, commenters
expressed similar concerns for other
Medicare payment systems and other
provider types that use non-certified
health IT that also would have little
historical reason for adoption of FHIRbased APIs. These commenters stated
that if CMS is considering adoption of
dQMs for the quality reporting programs
for post-acute care, home health or other
provider types, they believe it will be
challenging to incentivize these other
provider types to adopt updates to their
health IT and to push health IT vendors
and developers to develop those
capabilities.
Many commenters also noted data
mapping challenges and associated
burden. Some commenters noted they
do not anticipate less mapping burden
than current state with the transition to
FHIR. Other commenters noted that data
mapping guidance is necessary to
ensure that the underlying data being
accessed via FHIR APIs is accurate,
valid, and consistent across providers. A
commenter suggested CMS publish a
deliberative roadmap that focuses on
how source systems can generate the
relevant source data set into an agreedupon FHIR-based format mapping to the
source health IT’s internal data
structures, before attempting to access
such data directly through data element
level FHIR-based APIs. The commenter
noted the approach would also enable
more focus initially on data mapping,
quality, and completeness, and on
patient matching across health IT to
ensure data is properly correlated for
dQMs beyond EHRs.
Some commenters identified FHIR
bulk data as a critical component to
using FHIR for eCQMs. Commenters
noted bulk FHIR transactions simplify
and speed transmission and reduce risk
of overtaxing source APIs depending on
PO 00000
Frm 00409
Fmt 4701
Sfmt 4700
49187
the volume of data and frequency of
access required for dQMs. A few
commenters noted bulk FHIR would be
required for providers to support FHIR
implementation.
A few commenters suggested the
current method of pulling and
submitting files yearly to the HQR portal
is burdensome and often encounters
issues with data validation. The
commenters noted that a direct
connection for data submission and
validation would reduce burden,
because providers would not need to do
anything more than initiate data
retrieval and authorize data submission
once it has been processed. Several
commenters explained that due to the
burden this transition would put on care
facilities, CMS provide financial,
technical, and educational support to
these facilities during the transition.
Commenters also stated that patient data
may not be complete until weeks after
the patient encounter, and therefore
providers be able to resubmit data for
calculations at any point.
A few commenters requested CMS
consider mechanisms that would
provide resource support to assist and
incentives for FHIR eCQM reporting. A
commenter noted resource support is
especially important for providers who
care for underserved and vulnerable
populations to ensure all providers can
successfully transition to FHIR-based
eCQM reporting and that no providers
are left behind. A commenter suggested
ensuring availability of free education
sessions on FHIR-based digital quality
measure development, and the
provision of user-friendly measure
authoring and testing tools. Another
commenter suggested monetary
incentives to participating in dQM
testing.
A commenter recommended
participation in standards development
processes will continue to provide CMS
with the best channels to engage with
the health IT developer community
during the transition to digital quality
measurement. The commenter noted the
processes used in standards
development give developers an
opportunity to provide technical
feedback on implementation guides
based on their knowledge of how
hospitals and clinicians use their
software and their experience
supporting users’ participation in
quality reporting programs. The
commenter recommended CMS also
provide developers access to test
submission portals and other testing
tools, even if the developer does not
submit on behalf of its clients, because
testing tools will allow developers to
validate that data captured during
E:\FR\FM\10AUR2.SGM
10AUR2
49188
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
clinical workflows is accurately
retrieved via FHIR APIs when used for
quality reporting. The commenter stated
that FHIR-based eCQM reporting will
need to support push flows for data
correction and revision because
hospitals and clinicians may not finalize
the clinical or billing documentation for
an encounter until weeks after
discharge. If the measure calculation
tool has already retrieved data for that
encounter, hospitals will need a way to
re-trigger retrieval so that revised/final
data is reflected in the measure outcome
calculation. The commenter expressed
concern that the DEQM Implementation
Guide enables EHRs to push quality
reporting data via FHIR APIs, but only
at the aggregate level, meanwhile
pushing patient level quality reporting
outcomes would be required to
reconcile discrepancies between quality
measure reports before and after
revisions took place.
Several commenters recommended
real-time, bi-directional data exchange
between organizations and CMS, and
across the healthcare system, to increase
the value of this effort to patients and
providers. Commenters noted that data
collected and analyzed for dQMs could
provide significant benefit for clinical
decision support, shared and
coordinated care across providers and
facilities, and increased ability to track
patients’ outcomes. A commenter
recommended that if dQM calculation is
conducted outside of the EHR, it will be
essential for those tools to engage in bidirectional data exchange with EHRs to
allow users to have actionable insight
into their quality measure performance.
A commenter emphasized the need for
bi-directional exchange of SDOH data
with all members of the care team in
real-time to support communication
around the patients’ goals and enable
high-quality care for all patients. A
commenter questioned whether the
measure calculation tools introduced in
CMS’s Digital Quality Measurement
Strategic Roadmap would enable realtime performance monitoring for
currently admitted patients.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Response: We appreciate all of the
comments on and interest in this topic.
This input is very valuable in our
continuing planning for the transition to
the digital quality measurement in CMS
quality reporting and value-based
purchasing programs. We continue to
take all input into account as we
develop future regulatory proposals for
our digital quality measurement
transition efforts.
D. Advancing the Trusted Exchange
Framework and Common Agreement—
Request for Information
Section 4003(b) of the 21st Century
Cures Act (Pub. L. 114–255), enacted in
2016, amended section 3001(c) of the
Public Health Service Act (42 U.S.C.
300jj–11(c)), and required HHS to take
steps to advance interoperability for the
purposes of ensuring full network-tonetwork exchange of health information.
Specifically, Congress directed the
National Coordinator to ‘‘develop or
support a trusted exchange framework,
including a common agreement among
health information networks
nationally.’’ Since the enactment of the
21st Century Cures Act, HHS has
pursued development of a Trusted
Exchange Framework and Common
Agreement (TEFCA). ONC’s goals for
TEFCA are as follows:
Goal 1: Establish a universal policy
and technical floor for nationwide
interoperability.
Goal 2: Simplify connectivity for
organizations to securely exchange
information to improve patient care,
enhance the welfare of populations, and
generate health care value.
Goal 3: Enable individuals to gather
their health care information.408
On January 18, 2022, ONC announced
a significant TEFCA milestone by
releasing the Trusted Exchange
Framework 409 and Common Agreement
Version 1.410 The Trusted Exchange
408 See https://www.healthit.gov/buzz-blog/
interoperability/321tefca-is-go-for-launch.
409 Trusted Exchange Framework (Jan. 2022),
https://www.healthit.gov/sites/default/files/page/
2022-01/Trusted_Exchange_Framework_0122.pdf.
410 Common Agreement for Nationwide Health
Information Interoperability Version 1 (Jan. 2022),
PO 00000
Frm 00410
Fmt 4701
Sfmt 4700
Framework is a set of non-binding
principles for health information
exchange, and the Common Agreement
for Nationwide Health Information
Interoperability Version 1 (also referred
to as Common Agreement) is a contract
that advances those principles. The
Common Agreement and the
incorporated by reference Qualified
Health Information Network (QHIN)
Technical Framework Version 1
(QTF) 411 establish the technical
infrastructure model and governing
approach for different health
information networks and their users to
securely share clinical information with
each other, all under commonly agreed
to terms. The Common Agreement is a
legal contract that QHINs 412 sign with
the ONC Recognized Coordinating
Entity (RCE),413 a private-sector entity
that implements the Common
Agreement and ensures QHINs comply
with its terms.
https://www.healthit.gov/sites/default/files/page/
2022-01/Common_Agreement_for_Nationwide_
Health_Information_Interoperability_Version_1.pdf.
411 Qualified Health Information Network (QHIN)
Technical Framework (QTF) Version 1.0 (Jan. 2022),
https://rce.sequoiaproject.org/wp-content/uploads/
2022/01/QTF_0122.pdf.
412 The Common Agreement defines a QHIN as
‘‘to the extent permitted by applicable SOP(s), a
Health Information Network that is a U.S. Entity
that has been Designated by the RCE and is a party
to the Common Agreement countersigned by the
RCE.’’ See Common Agreement for Nationwide
Health Information Interoperability Version 1, at 10
(Jan. 2022), https://www.healthit.gov/sites/default/
files/page/2022-.
413 In August 2019, ONC awarded a cooperative
agreement to The Sequoia Project to serve as the
initial RCE. The RCE will operationalize and
enforce the Common Agreement, oversee QHINfacilitated network operations, and ensure
compliance by participating QHINs. The RCE will
also engage stakeholders to create a roadmap for
expanding interoperability over time. See ONC
Awards The Sequoia Project a Cooperative
Agreement for the Trusted Exchange Framework
and Common Agreement to Support Advancing
Nationwide Interoperability of Electronic Health
Information (September 3, 2019), https://
sequoiaproject.org/onc-awards-the-sequoia-projecta-cooperative-agreement-for-the-trusted-exchangeframework-and-common-agreement-to-supportadvancing-nationwide-interoperability-ofelectronic-health-information.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
The technical and policy architecture
of how exchange occurs under TEFCA
follows a network-of-networks structure,
which allows for connections at
different levels and is inclusive of many
different types of entities at those
different levels, such as health
information networks, care practices,
hospitals, public health agencies, and
Individual Access Services (IAS) 414
Providers.415 QHINs connect directly to
each other to facilitate nationwide
interoperability, and each QHIN can
connect Participants, which can connect
Subparticipants.416 Compared to most
nationwide exchange today, the
Common Agreement includes an
expanded set of Exchange Purposes
beyond Treatment to include Individual
Access Services, Payment, Health Care
Operations, Public Health, and
Government Benefits
Determination 417—all built upon
common technical and policy
requirements to meet key needs of the
U.S. health care system. This flexible
structure allows stakeholders to
participate in the way that makes most
sense for them, while supporting
simplified, seamless exchange.
The QTF,418 which was developed
and released by the RCE, describes the
414 The Common Agreement defines Individual
Access Services (IAS) as ‘‘with respect to the
Exchange Purposes definition, the services
provided utilizing the Connectivity Services, to the
extent consistent with Applicable Law, to an
Individual with whom the QHIN, Participant, or
Subparticipant has a Direct Relationship to satisfy
that Individual’s ability to access, inspect, or obtain
a copy of that Individual’s Required Information
that is then maintained by or for any QHIN,
Participant, or Subparticipant.’’ See Common
Agreement for Nationwide Health Information
Interoperability Version 1, at 7 (Jan. 2022), https://
www.healthit.gov/sites/default/files/page/2022-01/
Common_Agreement_for_Nationwide_Health_
Information_Interoperability_Version_1.pdf.
415 The Common Agreement defines ‘‘IAS
Provider’’ as: ‘‘Each QHIN, Participant, and
Subparticipant that offers Individual Access
Services.’’ See Common Agreement for Nationwide
Health Information Interoperability Version 1, at 7
(Jan. 2022), https://www.healthit.gov/sites/default/
files/page/2022-01/Common_Agreement_for_
Nationwide_Health_Information_Interoperability_
Version_1.pdf.
416 For the Common Agreement definitions of
QHIN, Participant, and Subparticipant, see
Common Agreement for Nationwide Health
Information Interoperability Version 1, at 8–12 (Jan.
2022), https://www.healthit.gov/sites/default/files/
page/2022-01/Common_Agreement_for_
Nationwide_Health_Information_Interoperability_
Version_1.pdf.
417 For the Common Agreement definitions of
Payment, Health Care Operations, Public Health,
and Government Benefits Determination, see
Common Agreement for Nationwide Health
Information Interoperability Version 1, at 6–10 (Jan.
2022), https://www.healthit.gov/sites/default/files/
page/2022-01/Common_Agreement_for_
Nationwide_Health_Information_Interoperability_
Version_1.pdf.
418 Qualified Health Information Network (QHIN)
Technical Framework (QTF) Version 1.0 (Jan. 2022),
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
functional and technical requirements
that a Health Information Network
(HIN) 419 must fulfill to serve as a QHIN
under the Common Agreement. The
QTF specifies the technical
underpinnings for QHIN-to-QHIN
exchange and certain other
responsibilities described in the
Common Agreement. The technical and
functional requirements described in
the QTF enable different types of
information exchange, including
querying and message delivery across
participating entities.
In 2022, prospective QHINs are
anticipated to begin signing the
Common Agreement and applying for
designation. The RCE will then begin
onboarding and designating QHINs to
share information. In 2023, HHS expects
stakeholders across the care continuum
to have increasing opportunities to
enable exchange under TEFCA.
Specifically, this would mean such
stakeholders would be: (1) signatories to
either the Common Agreement or an
agreement that meets the flow-down
requirements of the Common Agreement
(called a Framework Agreement 420
under the Common Agreement), (2) in
good standing (that is, not suspended)
under that agreement, and (3) enabling
secure, bi-directional exchange of
information to occur, in production.
TEFCA is expected to give individuals
and entities easier, more efficient,
access to more health information while
requiring strong privacy and security
protections.
We believe that exchange of health
information enabled by the Common
Agreement can advance CMS policy and
program objectives related to care
coordination, cost efficiency, and
patient-centeredness in a variety of
ways. We also believe that CMS policy
and programs can help to accelerate
nationwide connectivity through
TEFCA by health care providers as well
as other stakeholders.
We are considering other ways that
available CMS policy and program
levers can advance information
https://rce.sequoiaproject.org/wp-content/uploads/
2022/01/QTF_0122.pdf.
419 ‘‘Health Information Network’’ under TEFCA
has the meaning assigned to the term ‘‘Health
Information Network or Health Information
Exchange’’ in the information blocking regulations
at 45 CFR 171.102.
420 The Common Agreement defines ‘‘Framework
Agreement(s)’’ as: ‘‘any one or combination of the
Common Agreement, a Participant-QHIN
Agreement, a Participant-Subparticipant
Agreement, or a Downstream Subparticipant
Agreement, as applicable.’’ See Common Agreement
for Nationwide Health Information Interoperability
Version 1, at 6 (Jan. 2022) https://www.healthit.gov/
sites/default/files/page/2022-01/Common_
Agreement_for_Nationwide_Health_Information_
Interoperability_Version_1.pdf.
PO 00000
Frm 00411
Fmt 4701
Sfmt 4700
49189
exchange under TEFCA. For instance,
similar to the proposal in the current
rule, there may be opportunities for
CMS to incentivize exchange under
TEFCA through other programs that
incentivize high quality care, or through
program features in value-based
payment models that encourage certain
activities that can improve care
delivery.
In addition to programs focused on
providers, we are interested in
opportunities to encourage exchange
under TEFCA through CMS regulations
for certain health care payers, including
Medicare Advantage, Medicaid
Managed Care, and CHIP issuers. For
instance, we believe there may be
opportunities to encourage information
exchange under TEFCA to support
recently finalized requirements for these
payers to make information available to
patients and to make patient
information available to other payers as
beneficiaries transition between plans in
the ‘‘Medicare and Medicaid Programs;
Patient Protection and Affordable Care
Act; Interoperability and Patient Access
for Medicare Advantage Organization
and Medicaid Managed Care Plans,
State Medicaid Agencies, CHIP
Agencies and CHIP Managed Care
Entities, Issuers of Qualified Health
Plans on the Federally-Facilitated
Exchanges, and Health Care Providers’’
final rule (85 FR 25510). Finally, we are
considering future opportunities to
encourage information exchange under
TEFCA for payment and operations
activities such as submission of clinical
documentation to support claims
adjudication and prior authorization
processes.
We are requesting input from the
public on the ideas described previously
and related concepts for future
exploration, as well as the following
questions:
• What are the most important use
cases for different stakeholder groups
that could be enabled through
widespread information exchange under
TEFCA? What key benefits would be
associated with effectively
implementing these use cases, such as
improved care coordination, reduced
burden, or greater efficiency in care
delivery?
• What are key ways that the
capabilities of TEFCA can help to
advance the goals of CMS programs?
Should CMS explore policy and
program mechanisms to encourage
exchange between different
stakeholders, including those in rural
areas, under TEFCA? In addition to the
ideas discussed previously, are there
other programs CMS should consider in
E:\FR\FM\10AUR2.SGM
10AUR2
49190
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
order to advance exchange under
TEFCA?
• How should CMS approach
incentivizing or encouraging
information exchange under TEFCA
through CMS programs? Under what
conditions would it be appropriate to
require information exchange under
TEFCA by stakeholders for specific use
cases?
• What concerns do commenters have
about enabling exchange under TEFCA?
Could enabling exchange under TEFCA
increase burden for some stakeholders?
Are there other financial or technical
barriers to enabling exchange under
TEFCA? If so, what could CMS do to
reduce these barriers?
Comment: We received a wide range
of comments on this request for
information. Many did not recommend
requiring TEFCA participation at this
time. Some stated that there was
confusion about TEFCA in the provider
community. A commenter stated that
there are difficulties in managing
readmissions management under
TEFCA that would create productivity
decreases and recommended the
creation of TECFA billing codes so that
hospitals can be compensated. Many
commenters raised concerns about the
costs associated with participation
noting that the costs may be a barrier for
many health care providers.
A commenter stated that data sharing
for purposes of use beyond medical
treatment holds tremendous possibility
for advancing the goals of CMS
programs and healthcare delivery.
Others requested that we provide
additional education on the benefits of
TEFCA and why it remains essential
when there are others ways to
accomplish the objective of exchanging
information. Another commenter
suggested that CMS align any TEFCA
Use Cases with the required Exchange
Purposes: Treatment; Payment; Health
Care Operations; Public Health; Benefits
Determination; and Individual Access
Services (IAS).
Response: We appreciate the feedback
and suggestions provided by the
commenters regarding TEFCA. We plan
to share all the input with ONC and will
take commenters’ feedback into
consideration in future policy
development.
E. Hospital Inpatient Quality Reporting
(IQR) Program
1. Background and History of the
Hospital IQR Program
Through the Hospital IQR Program,
we strive to put patients first by
ensuring they are empowered to make
decisions about their own healthcare
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
along with their clinicians by using
information from data-driven insights
that are increasingly aligned with
meaningful quality measures. We
support technology that reduces burden
and allows clinicians to focus on
providing high-quality healthcare for
their patients. We also support
innovative approaches to improve
quality, accessibility, and affordability
of care, while paying particular
attention to improving clinicians’ and
beneficiaries’ experiences when
interacting with CMS programs. In
combination with other efforts across
HHS, we believe the Hospital IQR
Program incentivizes hospitals to
improve healthcare quality and value,
while giving patients the tools and
information needed to make the best
decisions for themselves.
We seek to promote higher quality
and more efficient healthcare for
Medicare beneficiaries. The adoption of
widely agreed upon quality and cost
measures supports this effort. We work
with relevant stakeholders to define
measures in almost every care setting
and currently measure some aspect of
care for almost all Medicare
beneficiaries. These measures assess
clinical processes, patient safety and
adverse events, patient experiences with
care, care coordination, and clinical
outcomes, as well as cost of care. We
have implemented quality measure
reporting programs for multiple settings
of care. To measure the quality of
hospital inpatient services, we
implemented the Hospital IQR Program,
previously referred to as the Reporting
Hospital Quality Data for Annual
Payment Update (RHQDAPU) Program.
We refer readers to the following final
rules for detailed discussions of the
history of the Hospital IQR Program,
including statutory history, and for the
measures we have previously adopted
for the Hospital IQR Program measure
set:
• The FY 2010 IPPS/LTCH PPS final
rule (74 FR 43860 through 43861);
• The FY 2011 IPPS/LTCH PPS final
rule (75 FR 50180 through 50181);
• The FY 2012 IPPS/LTCH PPS final
rule (76 FR 51605 through 61653);
• The FY 2013 IPPS/LTCH PPS final
rule (77 FR 53503 through 53555);
• The FY 2014 IPPS/LTCH PPS final
rule (78 FR 50775 through 50837);
• The FY 2015 IPPS/LTCH PPS final
rule (79 FR 50217 through 50249);
• The FY 2016 IPPS/LTCH PPS final
rule (80 FR 49660 through 49692);
• The FY 2017 IPPS/LTCH PPS final
rule (81 FR 57148 through 57150);
• The FY 2018 IPPS/LTCH PPS final
rule (82 FR 38326 through 38328 and 82
FR 38348);
PO 00000
Frm 00412
Fmt 4701
Sfmt 4700
• The FY 2019 IPPS/LTCH PPS final
rule (83 FR 41538 through 41609);
• The FY 2020 IPPS/LTCH PPS final
rule (84 FR 42448 through 42509);
• The FY 2021 IPPS/LTCH PPS final
rule (85 FR 58926 through 58959); and
• The FY 2022 IPPS/LTCH PPS final
rule (86 FR 45360 through 45426).
We also refer readers to 42 CFR
412.140 for Hospital IQR Program
regulations.
2. Retention of Previously Adopted
Hospital IQR Program Measures for
Subsequent Payment Determinations
We refer readers to the FY 2013 IPPS/
LTCH PPS final rule (77 FR 53512
through 53513) for our finalized
measure retention policy. Pursuant to
this policy, when we adopt measures for
the Hospital IQR Program beginning
with a particular payment
determination, we automatically
readopt these measures for all
subsequent payment determinations
unless a different or more limited time
period is proposed and finalized.
Measures are also retained unless we
propose to remove, suspend, or replace
the measures. We did not propose any
changes to these policies in the
proposed rule.
3. Removal Factors for Hospital IQR
Program Measures
We refer readers to the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41540
through 41544) for a summary of the
Hospital IQR Program’s removal factors.
We did not propose any changes to
these policies in the proposed rule.
4. Considerations in Expanding and
Updating Quality Measures
We refer readers to the FY 2013 IPPS/
LTCH PPS final rule (77 FR 53510
through 53512) for a discussion of the
previous considerations we have used to
expand and update quality measures
under the Hospital IQR Program. We
also refer readers to the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41147
through 41148), in which we describe
the Meaningful Measures Framework,
our objectives under this Framework for
quality measurement, and the quality
topics that we have identified as highimpact measurement areas that are
relevant and meaningful to both patients
and providers. In 2021, we launched
Meaningful Measures 2.0 to promote
innovation and modernization of all
aspects of quality, and to address a wide
variety of settings, stakeholders, and
measure requirements (we note that
Meaningful Measures 2.0 is still under
development).421 We did not propose
421 Centers for Medicare and Medicaid Services.
(2021). Meaningful Measures 2.0: Moving from
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
any changes to these policies in the
proposed rule.
We also note that the Hospital IQR
Program must first adopt measures and
publicly report them on the Compare
tool hosted by HHS, currently available
at: https://www.medicare.gov/carecompare, or its successor website, for at
least one year before the Hospital ValueBased Purchasing (VBP) Program is able
to adopt them. We view the value-based
purchasing programs, including the
Hospital VBP Program, as the next step
in promoting higher quality care for
Medicare beneficiaries by transforming
Medicare from a passive payer of claims
into an active purchaser of quality
healthcare for its beneficiaries.
khammond on DSKJM1Z7X2PROD with RULES2
5. New Measures for the Hospital IQR
Program Measure Set
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28491 through
29535), we proposed to adopt 10 new
measures, including four electronic
clinical quality measures (eCQMs): (1)
Hospital Commitment to Health Equity
measure, beginning with the CY 2023
reporting period/FY 2025 payment
determination; (2) Screening for Social
Drivers of Health measure, beginning
with voluntary reporting in the CY 2023
reporting period and mandatory
reporting beginning with the CY 2024
reporting period/FY 2026 payment
determination; (3) Screen Positive Rate
for Social Drivers of Health measure,
beginning with voluntary reporting in
the CY 2023 reporting period and
mandatory reporting beginning with the
CY 2024 reporting period/FY 2026
payment determination; (4) Cesarean
Birth eCQM, beginning with the CY
2023 reporting period/FY 2025 payment
determination and mandatory reporting
beginning with the CY 2024 reporting
period/FY 2026 payment determination;
(5) Severe Obstetric Complications
eCQM, beginning with the CY 2023
reporting period/FY 2025 payment
determination and mandatory reporting
beginning with the CY 2024 reporting
period/FY 2026 payment determination;
(6) Hospital-Harm—Opioid-Related
Adverse Events eCQM, beginning with
the CY 2024 reporting period/FY 2026
payment determination; (7) Global
Malnutrition Composite Score eCQM,
Measure Reduction to Modernization. Available at:
https://www.cms.gov/meaningful-measures-20moving-measure-reduction-modernization. We note
that Meaningful Measures 2.0 is still under
development.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
beginning with the CY 2024 reporting
period/FY 2026 payment determination;
(8) Hospital-Level, Risk Standardized
Patient-Reported Outcomes Performance
Measure (PRO–PM) Following Elective
Primary Total Hip Arthroplasty (THA)
and/or Total Knee Arthroplasty (TKA),
beginning with two voluntary reporting
periods followed by mandatory
reporting for the reporting period which
runs from July 1, 2025 through June 30,
2026, impacting the FY 2028 payment
determination; (9) Medicare Spending
Per Beneficiary (MSPB) Hospital
measure beginning with the FY 2024
payment determination; and (10)
Hospital-Level Risk-Standardized
Complication Rate (RSCR) Following
Elective Primary Total THA/TKA
measure beginning with the FY 2024
payment determination.
We provide more details on each of
these proposals in the subsequent
sections.
a. Hospital Commitment to Health
Equity Measure Beginning With the CY
2023 Reporting Period/FY 2025
Payment Determination and for
Subsequent Years
(1) Background
Significant and persistent disparities
in healthcare outcomes exist in the U.S.
For example, belonging to a racial or
ethnic minority group, living with a
disability, being a member of the
lesbian, gay, bisexual, transgender, and
queer (LGBTQ+) community, being a
member of a religious minority, living in
a rural area, having a disability, or being
near or below the poverty level, is often
associated with worse health
outcomes.422 423 424 425 426 427 428 429 430 431
422 Joynt KE, Orav E, Jha AK. (2011). Thirty-Day
Readmission Rates for Medicare Beneficiaries by
Race and Site of Care. JAMA, 305(7), 675–681.
Available at: doi:10.1001/jama.2011.123.
423 Lindenauer PK, Lagu T, Rothberg MB, et al.
(2013). Income Inequality and Thirty-Day Outcomes
After Acute Myocardial Infarction, Heart Failure,
and Pneumonia: Retrospective Cohort Study. BMJ,
346. Available at: https://doi.org/10.1136/bmj.f521.
424 Trivedi AN, Nsa W, Hausmann LRM, et al.
(2014). Quality and Equity of Care in U.S. Hospitals.
N Engl J Med, 371(24), 2298–2308. Available at: doi:
10.1056/NEJMsa1405003.
425 Polyakova, M, Udalova V, Kocks, G, Genadek
K, Finlay K, Finkelstein AN. (2021). Racial
Disparities In Excess All-Cause Mortality During
The Early COVID–19 Pandemic Varied
Substantially Across States. Health Affairs, 40(2),
307–316. Available at: https://doi.org/10.1377/
hlthaff.2020.02142.
426 Rural Health Research Gateway. (2018). Rural
Communities: Age, Income, and Health Status.
PO 00000
Frm 00413
Fmt 4701
Sfmt 4700
49191
Numerous studies have shown that
among Medicare beneficiaries, racial
and ethnic minority individuals often
receive lower quality of hospital care,
report lower experiences of care, and
experience more frequent hospital
readmissions and procedural
complications.432 433 434 435 436 437
Rural Health Research Recap. Available at: https://
www.ruralhealthresearch.org/assets/2200-8536/
rural-communities-age-income-health-statusrecap.pdf.
427 HHS Office of Minority Health. (2020).
Progress Report to Congress, 2020 Update on the
Action Plan to Reduce Racial and Ethnic Health
Disparities. Department of Health and Human
Services. Available at: https://www.minorityhealth.
hhs.gov/assets/PDF/Update_HHS_Disparities_DeptFY2020.pdf.
428 Heslin KC, Hall JE. (2021). Sexual Orientation
Disparities in Risk Factors for Adverse COVID–19–
Related Outcomes, by Race/Ethnicity—Behavioral
Risk Factor Surveillance System, United States,
2017–2019. MMWR Morb Mortal Wkly Rep, 70(5),
149. doi: 10.15585/mmwr.mm7005a1.
429 Poteat TC, Reisner SL, Miller M, Wirtz AL.
(2020). COVID–19 Vulnerability of Transgender
Women With and Without HIV Infection in the
Eastern and Southern U.S. medRxiv. doi: 10.1101/
2020.07.21.20159327.
430 Vu M, Azmat A, Radejko T, Padela AI. (2016).
Predictors of Delayed Healthcare Seeking Among
American Muslim Women. Journal of Women’s
Health, 25(6), 586–593. doi: 10.1089/jwh.2015.5517
431 Nadimpalli SB, Cleland CM, Hutchinson MK,
Islam N, Barnes LL, Van Devanter N. (2016). The
Association Between Discrimination and the Health
of Sikh Asian Indians. Health Psychology, 35(4),
351–355. https://doi.org/10.1037/hea0000268.
432 CMS Office of Minority Health. (2020). Racial,
Ethnic, and Gender Disparities in Healthcare in
Medicare Advantage. Baltimore, MD: Centers for
Medicare & Medicaid Services. Available at: https://
www.cms.gov/files/document/2020-national-levelresults-race-ethnicity-and-gender-pdf.pdf.
433 CMS Office of Minority Health. (Updated
August 2018). Guide to Reducing Disparities in
Readmissions. Baltimore, MD: Centers for Medicare
& Medicaid Services. Available at: https://
www.cms.gov/About-CMS/Agency-Information/
OMH/Downloads/OMH_Readmissions_Guide.pdf.
434 Singh JA, Lu X, Rosenthal GE, Ibrahim S,
Cram P. (2014). Racial Disparities in Knee and Hip
Total Joint Arthroplasty: An 18-year analysis of
national Medicare data. Ann Rheum Dis., 73(12),
2107–15. Available at: doi:10.1136/annrheumdis2013-203494.
435 Rivera-Hernandez M, Rahman M, Mor V,
Trivedi AN. (2019). Racial Disparities in
Readmission Rates among Patients Discharged to
Skilled Nursing Facilities. J Am Geriatr Soc., 67(8),
1672–1679. Available at: https://doi.org/10.1111/
jgs.15960.
436 Joynt KE, Orav E, Jha AK. (2011). Thirty-Day
Readmission Rates for Medicare Beneficiaries by
Race and Site of Care. JAMA, 305(7), 675–681.
Available at: doi:10.1001/jama.2011.123.
437 Tsai TC, Orav EJ, Joynt KE. (2014). Disparities
in Surgical 30-day Readmission Rates for Medicare
Beneficiaries by Race and Site of Care. Ann Surg.,
259(6), 1086–1090. Available at: doi: 10.1097/SLA.
0000000000000326.
E:\FR\FM\10AUR2.SGM
10AUR2
49192
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Readmission rates in the Hospital
Readmission Reduction Program have
shown to be higher among Black and
Hispanic Medicare beneficiaries with
common conditions, including
congestive heart failure and acute
myocardial infarction.438 439 440 441 442
Data indicate that, even after accounting
for factors such as socioeconomic
conditions, members of racial and
ethnic minority groups reported
experiencing lower quality of
healthcare.443 Evidence of differences in
quality of care received among racial
and ethnic minority groups show worse
health outcomes including diabetes
complications such as retinopathy.444
Additionally, inequities in the social
determinants of health affecting these
groups, such as poverty and healthcare
access, are interrelated and influence a
wide range of health and quality-of-life
outcomes and risks.445
In the FY 2022 IPPS/LTCH PPS
proposed rule (86 FR 25592), we
identified potential opportunities
specific to the Hospital IQR Program by
which we could leverage current
measures or develop new measures to
address the gap in healthcare
disparities. In that rule, we sought
public comment on addressing this gap,
438 Rodriguez F, Joynt KE, Lopez L, Saldana F, Jha
AK. (2011). Readmission Rates for Hispanic
Medicare Beneficiaries with Heart Failure and
Acute Myocardial Infarction. Am Heart J., 162(2),
254–261 e253. Available at: https://doi.org/10.1016/
j.ahj.2011.05.009.
439 Centers for Medicare & Medicaid Services.
(2014). Medicare Hospital Quality Chartbook:
Performance Report on Outcome Measures.
Available at: https://www.hhs.gov/guidance/
document/medicare-hospital-quality-chartbookperformance-report-outcome-measures.
440 CMS Office of Minority Health. (Updated
August 2018). Guide to Reducing Disparities in
Readmissions. Baltimore, MD: Centers for Medicare
& Medicaid Services. Available at: https://
www.cms.gov/About-CMS/Agency-Information/
OMH/Downloads/OMH_Readmissions_Guide.pdf.
441 Prieto-Centurion V, Gussin HA, Rolle AJ,
Krishnan JA. (2013). Chronic Obstructive
Pulmonary Disease Readmissions at MinorityServing Institutions. Ann Am Thorac Soc., 10(6),
680–684. Available at: https://doi.org/10.1513/
AnnalsATS.201307-223OT.
442 Joynt KE, Orav E, Jha AK. (2011). Thirty-Day
Readmission Rates for Medicare Beneficiaries by
Race and Site of Care. JAMA, 305(7), 675–681.
Available at: doi:10.1001/jama.2011.123.
443 Nelson AR. (2003). Unequal Treatment: Report
of the Institute of Medicine on Racial and Ethnic
Disparities in Healthcare. The Annals of Thoracic
Surgery, 76(4), S1377–S1381. doi: 10.1016/s0003–
4975(03)01205–0.
444 Peek, ME, Odoms-Young, A, Quinn, MT,
Gorawara-Bhat, R, Wilson, SC, & Chin, MH. (2010).
Race and Shared Decision-Making: Perspectives of
African-Americans with diabetes. Social Science &
Medicine, 71(1), 1–9. Available at: doi:10.1016/
j.socscimed.2010.03.014.
445 Department of Health and Human Services.
(2021). Healthy People 2020: Disparities. Available
at: www.healthypeople.gov/2020/about/foundationhealth-measures/Disparities.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
specifically requesting input on the
inclusion of a structural measure to
assess the degree of hospital leadership
commitment to collecting and
monitoring health equity performance
data. We sought feedback on conceptual
and measurement priorities to better
illuminate organizational efforts to
improve health equity, and on an
appropriate measure regarding
organizational commitment to health
equity and accessibility for individuals
with intellectual and developmental
disabilities (86 FR 25593). In the FY
2022 IPPS/LTCH PPS final rule (86 FR
45414 through 45416), we summarized
the public comments we received,
including support for the development
and implementation of a health equity
structural measure. We refer readers to
the ‘‘Closing the Health Equity Gap in
CMS Quality Programs—Request for
Information’’ (86 FR 45349) and
‘‘Potential Future Efforts to Address
Health Equity in the Hospital IQR
Program’’ (86 FR 45414) in the FY 2022
IPPS/LTCH PPS final rule for more
details.
We note that the Agency for
Healthcare Research and Quality
(AHRQ) and The Joint Commission
identified that hospital leadership plays
an important role in promoting a culture
of quality and safety.446 447 AHRQ
research shows that hospital boards can
influence quality and safety in a variety
of ways; not only through strategic
initiatives, but also through more direct
interactions with frontline workers.448
Because we are working toward the goal
of all patients receiving high quality
healthcare when hospitalized,
regardless of individual characteristics,
we are committed to supporting
healthcare organizations in building a
culture of equity that focuses on
educating and empowering their
workforce to recognize and eliminate
health disparities. This includes
patients receiving the right care, at the
right time, in the right setting for their
condition(s), regardless of those
characteristics.
We believe that strong and committed
leadership from hospital executives and
board members is essential and can play
446 Agency for Healthcare Research and Quality.
Leadership Role in Improving Patient Safety.
Patient Safety Primer, September 2019. Available at:
https://psnet.ahrq.gov/primer/leadership-roleimproving-safety.
447 Joint Commission on Accreditation of
Healthcare Organizations, USA. Leadership
Committed to Safety. Sentinel Event Alert. 2009
Aug 27;(43):1–3. PMID: 19757544.
448 Agency for Healthcare Research and Quality.
Leadership Role in Improving Patient Safety.
Patient Safety Primer, September 2019: Available at:
https://psnet.ahrq.gov/primer/leadership-roleimproving-safety.
PO 00000
Frm 00414
Fmt 4701
Sfmt 4700
a role in shifting organizational culture
and advancing equity goals.
Additionally, studies demonstrate that
hospital leadership can positively
influence culture for better quality,
patient outcomes, and experience of
care.449 450 451 A systematic review of 122
published studies showed that strong
leadership that prioritized safety,
quality, and the setting of clear guidance
with measurable goals for improvement
resulted in a high-performing hospital
with better patient outcomes.452 We
believe leadership commitment to
health equity will have a parallel effect
in contributing to a reduction in health
disparities.
The Institute of Healthcare
Improvement’s (IHI’s) research of 23
health systems throughout the U.S. and
Canada also shows that health equity
must be a priority championed by
leadership teams to improve both
patient access to needed healthcare
services and outcomes among
disadvantaged populations.453 This IHI
study specifically identified concrete
actions to make health equity a core
strategy, including making health equity
a leader-driven priority alongside
organizational development structures
and processes that support equity.454
Based upon these findings, we believe
that hospital leadership can be
instrumental in setting specific,
measurable, attainable, realistic, and
time-based (SMART) goals to assess
progress towards achieving equity
priorities and ensuring high-quality care
is equally accessible to all individuals.
Therefore, in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28492
through 28497), we proposed to adopt
an attestation-based structural measure,
449 Bradley EH, Brewster AL, McNatt Z, et al.
(2018) How Guiding Coalitions Promote Positive
Culture Change in Hospitals: A Longitudinal Mixed
Methods Interventional Study. BMJ Qual Saf., 27(3),
218–225. doi:10.1136/bmjqs-2017-006574.
450 Smith SA, Yount N, Sorra J. (2017). Exploring
Relationships Between Hospital Patient Safety
Culture and Consumer Reports Safety Scores. BMC
Health Services Research, 17(1), 143. doi:10.1186/
s12913-017-2078-6.
451 Keroack MA, Youngberg BJ, Cerese JL, Krsek
C, Prellwitz LW, Trevelyan EW. (2007).
Organizational Factors Associated with High
Performance in Quality and Safety in Academic
Medical Centers. Acad Med., 82(12), 1178–86. doi:
10.1097/ACM.0b013e318159e1ff.
452 Millar R, Mannion R, Freeman T, et al. (2013).
Hospital Board Oversight of Quality and Patient
Safety: A Narrative Review and Synthesis of Recent
Empirical Research. The Milbank Quarterly, 91(4),
738–70. doi:10.1111/1468–0009.12032.
453 Mate KS and Wyatt R. (2017). Health Equity
Must Be a Strategic Priority. NEJM Catalyst.
Available at: https://catalyst.nejm.org/doi/full/
10.1056/CAT.17.0556.
454 Mate KS and Wyatt R. (2017). Health Equity
Must Be a Strategic Priority. NEJM Catalyst.
Available at: https://catalyst.nejm.org/doi/full/
10.1056/CAT.17.0556.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Hospital Commitment to Health Equity,
beginning with the CY 2023 reporting
period/FY 2025 payment determination
and for subsequent years.
The first pillar of our strategic
priorities 455 reflects our deep
commitment to improvements in
healthcare equity by addressing the
health disparities that underly our
health system. We developed this
structural measure to assess hospital
commitment to health equity across five
domains (see Table IX.E–01. in the
subsequent section) using a suite of
organizational competencies aimed at
achieving health equity for racial and
ethnic minority groups, people with
disabilities, members of the LGBTQ+
community, individuals with limited
English proficiency, rural populations,
religious minorities, and people facing
socioeconomic challenges. We believe
these elements are actionable focus
areas, and assessment of hospital
leadership commitment to them is
foundational. We also believe this
measure will incentivize providers to
collect and utilize data to identify
critical equity gaps, implement plans to
address said gaps, and ensure that
resources are dedicated toward
addressing healthcare equity initiatives.
While many factors contribute to health
equity, we believe this measure is an
important step toward assessing
hospital leadership commitment, and a
fundamental step toward closing the gap
in equitable care for all populations. We
note that this measure is not intended
C. (2021). My First 100 Days
and Where We Go From Here: A Strategic Vision
for CMS. Centers for Medicare & Medicaid.
Available at: https://www.cms.gov/blog/my-first100-days-and-where-we-go-here-strategic-visioncms.
khammond on DSKJM1Z7X2PROD with RULES2
455 Brooks-LaSure,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
to encourage hospitals to take action on
any one given element of collected data,
but instead encourages hospitals to
analyze their own data to understand
many factors, including race, ethnicity,
and various social drivers of health,
such as housing status and food
security, in order to deliver more
equitable care.
We believe this measure builds on
current health disparities reporting,
supports hospitals in quality
improvement, promotes efficient and
effective use of resources, and leverages
available data. The five questions of the
proposed structural measure are
adapted from the CMS Office of
Minority Health’s Building an
Organizational Response to Health
Disparities framework, which focuses
on data collection, data analysis, culture
of equity, and quality improvement.456
This measure also aligns with our
efforts under the Meaningful Measures
Framework, which identifies highpriority areas for quality measurement
and improvement to assess core issues
most critical to high-quality healthcare
and improving patient outcomes.457 In
2021, we launched Meaningful
Measures 2.0 to promote innovation and
modernization of all aspects of quality,
and to address a wide variety of settings,
stakeholders, and measure
456 Centers for Medicare & Medicaid Services.
(2021). Building an Organizational Response to
Health Disparities [Fact Sheet]. U.S. Department of
Health and Human Services. Available at: https://
www.cms.gov/About-CMS/Agency-Information/
OMH/Downloads/Health-Disparities-Guide.pdf.
457 Centers for Medicare & Medicaid Services.
Meaningful Measures Framework. Available at:
https://www.cms.gov/Medicare/Quality-InitiativesPatient-Assessment-Instruments/QualityInitiatives
GenInfo/CMS-Quality-Strategy.
PO 00000
Frm 00415
Fmt 4701
Sfmt 4700
49193
requirements.458 We plan to address
healthcare priorities and gaps with
Meaningful Measures 2.0 by leveraging
quality measures to promote equity and
close gaps in care. The Hospital
Commitment to Health Equity measure
supports these efforts and is aligned
with the Meaningful Measures Area of
‘‘Equity of Care’’ and the Meaningful
Measures 2.0 goal to ‘‘Leverage Quality
Measures to Promote Equity and Close
Gaps in Care.’’ This measure also
supports the Meaningful Measures 2.0
objective to ‘‘Commit to a patientcentered approach in quality measure
and value-based incentives programs to
ensure that quality and safety measures
address healthcare equity.’’
(2) Overview of Measure
The Hospital Commitment to Health
Equity measure assesses hospital
commitment to health equity using a
suite of equity-focused organizational
competencies aimed at achieving health
equity for racial and ethnic minority
groups, people with disabilities,
members of the LGBTQ+ community,
individuals with limited English
proficiency, rural populations, religious
minorities, and people facing
socioeconomic challenges. Table IX.E–
01. includes the five attestation domains
and the elements within each of those
domains that a hospital must
affirmatively attest to for the hospital to
receive credit for that domain.
458 Centers for Medicare & Medicaid Services.
(2021). Meaningful Measures 2.0: Moving from
Measure Reduction to Modernization. Available at:
https://www.cms.gov/meaningful-measures-20moving-measure-reduction-modernization. We note
that Meaningful Measures 2.0 is still under
development.
E:\FR\FM\10AUR2.SGM
10AUR2
49194
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE IX.E-01. THE HOSPITAL COMMITMENT TO HEALTH EQUITY
MEASURES FIVE ATTESTATIONS
Attestation
Elements: Select all that apply
(Note: Affirmative attestation of all elements within a
domain will be required for the hospital to receive a point
for the domain in the numerator)
Domain 1: Equity is a Strategic Priority
Hospital commitment to reducing healthcare disparities is
strengthened when equity is a key organizational priority. Please
attest that your hospital has a strategic plan for advancing
healthcare equity and that it includes all the following elements.
(A) Our hospital strategic plan identifies priority
populations who currently experience health disparities.
(B) Our hospital strategic plan identifies healthcare equity
goals and discrete action steps to achieving these goals.
(C) Our hospital strategic plan outlines specific resources
which have been dedicated to achieving our equity goals.
(D) Our hospital strategic plan describes our approach for
engaging key stakeholders, such as community-based
organizations.
Domain 2: Data Collection
Collecting valid and reliable demographic and social determinant
(A) Our hospital collects demographic information,
of health data on patients served in a hospital is an important step
including self-reported race and ethnicity and/or social
in identifying and eliminating health disparities. Please attest that
determinant of health information on the majority of our
your hospital engages in the following activities.
patients.
(B) Our hospital has training for staff in culturally sensitive
collection of demographic and/or social determinant of
health information.
(C) Our hospital inputs demographic and/or social
determinant of health information collected from patients
into structured, interoperable data elements using a
certified EHR technology.
Domain 3: Data Analysis
Effective data analysis can provide insights into which factors
(A) Our hospital stratifies key performance indicators by
demographic and/or social determinants of health variables
contribute to health disparities and how to respond. Please attest
that your hospital engages in the following activities.
to identify equity gaps and includes this information on
hospital performance dashboards.
The Hospital Commitment to Health
Equity measure was included in the
publicly available ‘‘List of Measures
Under Consideration for December 1,
2021’’ (MUC List), a list of measures
under consideration for use in various
Medicare programs.459 The National
459 Centers
for Medicare & Medicaid Services.
(2021). List of Measures Under Consideration for
December 1, 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96464.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Quality Forum (NQF) Measure
Applications Partnership (MAP) Rural
Health Advisory Group reviewed the
MUC List and the Hospital Commitment
to Health Equity measure (MUC 2021–
106) in detail on December 8, 2021.460
460 National Quality Forum. (2021). Measure
Applications Partnership Rural Health Advisory
Group Virtual Review Meeting: Meeting Summary
for December 8, 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96571.
PO 00000
Frm 00416
Fmt 4701
Sfmt 4700
The MAP Rural Health Workgroup
initially raised concerns that this
measure may cause undue burden to
rural hospitals that may not yet be
directing resources or have available
resources to dedicate toward
implementing the measure. We
acknowledge that for some hospitals,
the implementation of this structural
measure may impose additional data
collection efforts. However, we believe
this measure builds on hospitals’
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.155
khammond on DSKJM1Z7X2PROD with RULES2
Domain 4: Quality Improvement
Health disparities are evidence that high-quality care has not been
(A) Our hospital participates in local, regional, or national
delivered equally to all patients. Engagement in quality
quality improvement activities focused on reducing health
disparities.
improvement activities can improve quality of care for all patients.
Domain 5: Leadership Engagement
Leaders and staff can improve their capacity to address disparities
(A) Our hospital senior leadership, including chief
by demonstrating routine and thorough attention to equity and
executives and the entire hospital board of trustees,
annually reviews our strategic plan for achieving health
setting an organizational culture of equity. Please attest that your
hospital engages in the following activities.
equity.
(B) Our hospital senior leadership, including chief
executives and the entire hospital board of trustees,
annually reviews key performance indicators stratified by
demographic and/or social factors.
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
current quality improvement activities
through participation in the Hospital
IQR Program. Additionally, we believe
the activities outlined in the previous
table are foundational best practices for
advancing health equity for patients and
communities. The Rural Health
Workgroup agreed that this is an
important measure and for that reason
should be added to the Hospital IQR
Program measure set as the intent of the
measure is to identify these gaps and
make the needed investments in
workforce training, leadership
development, and other related areas to
improve equity.461 The MAP Rural
Health Workgroup’s recommendation
was majority support for the Hospital
Commitment to Health Equity
measure.462
In addition, on December 9, 2021, the
MAP Health Equity Advisory Group
reviewed the 2021 MUC List.463 The
MAP Health Equity Advisory Group was
convened at the request of CMS to
provide input on the MUC List with the
goal of reducing health disparities
closely linked with social, economic, or
environmental disadvantages.464 The
MAP Health Equity Advisory Group is
charged with providing feedback related
to the relative priority of each measure
in advancing health equity, and input
on potential data, reporting, and/or
methodological concerns on reporting
measures adjusting for healthcare
disparities.465 The MAP Health Equity
Advisory Group provided input on
potential unintended consequences or
measurement gap areas related to health
disparities.466 After discussion of each
461 National Quality Forum. (2021). Measure
Applications Partnership Rural Health Advisory
Group Virtual Review Meeting: Meeting Summary
for December 8, 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96571.
462 National Quality Forum. (2021). Measure
Applications Partnership Rural Health Advisory
Group Virtual Review Meeting: Meeting Summary
for December 8, 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96571.
463 Centers for Medicare & Medicaid Services.
(2021). List of Measures Under Consideration for
December 1, 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96464.
464 National Quality Forum. (2022). Measure
Applications Partnership Health Equity Advisory
Group Virtual Review Meeting: Meeting Summary
for December 9, 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96599.
465 National Quality Forum. (2022). Measure
Applications Partnership Health Equity Advisory
Group Virtual Review Meeting: Meeting Summary
for December 9, 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96599.
466 National Quality Forum. (2022). Measure
Applications Partnership Health Equity Advisory
Group Virtual Review Meeting: Meeting Summary
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
measure under consideration, the
Workgroup was polled on the potential
impact on health disparities if the
measure were to be included in a
specific program. Like the MAP Rural
Health Advisory Group, the MAP Health
Equity Advisory Group agreed this is an
important measure for advancing
healthcare equity in the Hospital IQR
Program and a fundamental first step
toward future measure development and
innovation.467 The MAP Health Equity
Advisory Group’s feedback was
supportive of this measure and its
potential to decrease health
disparities.468
The MUC List, including this measure
(MUC2021–106), was also reviewed by
the MAP Hospital Workgroup on
December 15, 2021.469 MAP
stakeholders expressed concerns about
whether measure data will be actionable
and how improvements in clinical
healthcare equity outcomes will be
measured.470 The MAP Hospital
Workgroup had concerns about how this
measure would be publicly reported,
specifically, how it would be and
interpreted by patients/consumers.471
For these reasons, the MAP Hospital
Workgroup recommended that the MAP
not support the measure for
rulemaking.472 In response to this
feedback, we wish to explain that we
will publicly report the numerator
indicating how many of the
for December 9, 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96599.
467 National Quality Forum. (2022). Measure
Applications Partnership Health Equity Advisory
Group Virtual Review Meeting: Meeting Summary
for December 9, 2021. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?Link
Identifier=id&ItemID=96599.
468 National Quality Forum. (2022). Measure
Applications Partnership Health Equity Advisory
Group Virtual Review Meeting: Meeting Summary
for December 9, 2021. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96599.
469 National Quality Forum. (2022). Measure
Applications Partnership Hospital Workgroup Web
Review Meeting: Meeting Summary for December
15, 2021. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96629.
470 National Quality Forum. (2022). Measure
Applications Partnership Hospital Workgroup Web
Review Meeting: Meeting Summary for December
15, 2021. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96629.
471 National Quality Forum. (2022). Measure
Applications Partnership Hospital Workgroup Web
Review Meeting: Meeting Summary for December
15, 2021. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96629.
472 National Quality Forum. (2022). Measure
Applications Partnership Hospital Workgroup Web
Review Meeting: Meeting Summary for December
15, 2021. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96629.
PO 00000
Frm 00417
Fmt 4701
Sfmt 4700
49195
competencies hospitals attest to, and we
refer readers to section IX.E.5.a.(3). for
our proposed measure calculation
methodology and section IX.E.5.a.(4).
for the proposed public reporting.
Thereafter, the MAP Coordinating
Committee deliberated and ultimately
voted to conditionally support this
measure for rulemaking given its
importance in being a first step towards
the future development of outcomebased measures.473 We agree that this
measure is an important foundation of
a comprehensive quality reporting
program. Our approach to developing
health equity measures is incremental
and will evolve over time to capture
healthcare equity outcomes in the
Hospital IQR Program. We additionally
believe this measure to be a building
block that lays the groundwork for a
future meaningful suite of measures that
would assess progress in providing
high-quality healthcare for all patients
regardless of social risk factors or
demographic characteristics.
We have not submitted this measure
for NQF endorsement at this time. We
note that under section
1866(b)(3)(B)(viii)(IX)(aa) of the Act,
each measure specified by the Secretary
shall be endorsed by the entity with a
contract under section 1890(a) of the
Act (the NQF is the entity that currently
holds this contract). Under section
1886(b)(3)(B)(viii)(IX)(bb) of the Act, in
the case of a specified area or medical
topic determined appropriate by the
Secretary for which a feasible and
practical measure has not been endorsed
by the entity with a contract under
section 1890(a) of the Act, the Secretary
may specify a measure that is not so
endorsed as long as due consideration is
given to a measure that has been
endorsed or adopted by a consensus
organization identified by the Secretary.
We reviewed NQF-endorsed measures
and were unable to identify any other
NQF-endorsed measures on this topic,
and, therefore we believe the exception
in section 1886(b)(3)(B)(viii)(IX)(bb) of
the Act applies.
(3) Measure Calculation
The Hospital Commitment to Health
Equity measure consists of five
domains, and a hospital will need to
evaluate and determine whether it can
affirmatively attest to each domain.
Some of these domains have multiple
elements to which a hospital must
attest. For a hospital to affirmatively
attest to a domain, and receive credit for
473 National Quality Forum. (2022). Measure
Applications Partnership (MAP) 2021–2022 Final
Recommendations. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96698.
E:\FR\FM\10AUR2.SGM
10AUR2
49196
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
that domain, the hospital will evaluate
and determine whether it engages in
each of the elements that comprise the
domain. Each of the domains will be
represented in the denominator as a
point, for a total of 5 points (one per
domain).
For example, for Domain 1 (‘‘Hospital
commitment to reducing healthcare
disparities is strengthened when equity
is a key organizational priority’’), a
hospital will evaluate and determine
whether its strategic plan meets each of
the elements described in (A) through
(D) (see Table IX.E–01.). If the hospital’s
plan meets all four of these elements,
the hospital will affirmatively attest to
Domain 1 and will receive a point for
that attestation. A hospital will not be
able to receive partial credit for a
domain. In other words, if a hospital’s
strategic plan meets elements (A) and
(B) but not (C) and (D), the hospital will
not be able to affirmatively attest to
Domain 1 and will not receive a point
for that attestation.
The numerator will capture the total
number of domain attestations that the
hospital is able to affirm. For example,
a hospital that affirmatively attests each
element of the 5 domains will receive
the maximum 5 points.
khammond on DSKJM1Z7X2PROD with RULES2
(4) Data Submission and Reporting
Specifications for the measure are
available on the CMS Measure
Methodology page with the file name
‘‘Hospital Commitment to Health Equity
Structural Measure Specifications’’ at:
https://qualitynet.cms.gov/inpatient/iqr/
resources. Hospitals are required to
submit information for structural
measures once annually using a CMSapproved web-based data collection tool
available within the Hospital Quality
Reporting (HQR) System. Hospitals will
follow established submission and
reporting requirements as previously
finalized for structural measures and
refer readers to section IX.E.10.i. of the
preamble of this final rule for more
details on our previously finalized data
submission and deadline requirements
for structural measures.
We proposed this measure for the CY
2023 reporting period/FY 2025 payment
determination and for subsequent years.
In developing this proposal, we
considered proposing an incremental
approach to the implementation of this
measure. However, we ultimately
decided to propose mandatory reporting
given the importance of this measure
and how it aligns with our healthcare
quality goal of closing the racial and
ethnic disparity gaps.
We invited public comment on this
proposal.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Comment: Many commenters
supported the addition of the Hospital
Commitment to Health Equity measure
beginning with the CY 2023 reporting
period/FY 2025 payment determination
and for subsequent years. Commenters
supported this measure as a first step
towards robust measurement of
equitable healthcare delivery.
Commenters believed this measure
would help increase awareness for the
importance of improving healthcare
equity and send an important signal to
hospital leadership. Additionally,
commenters supported this measure,
citing its importance for addressing
disparities in healthcare outcomes and
experience among populations that have
been disadvantaged and/or underserved
by the healthcare system. Others
supported this measure because they
believed it would assess commitment to
establishing a culture of equity and help
identify and address institutional biases.
A commenter supported adoption of
this measure because it highlights the
importance of developing strategic
initiatives, collecting data, and
incorporating learnings in to care
delivery and quality improvement
initiatives. A commenter supported this
measure because it presents the
opportunity to address the lack of data
that are comprehensive, consistent, and
accurate to improve access and include
participants from communities that
have been disadvantaged and/or
underserved by the healthcare system. A
few commenters supported this measure
as proposed.
Response: We thank commenters for
their support of our proposal to adopt
the Hospital Commitment to Health
Equity measure and agree that adopting
this measure is in line with our goal of
improving healthcare equity.
Comment: A few commenters
believed that starting with a structural
measure is a good policy before
proposing future process or outcome
measures. A few commenters noted that
the Hospital Commitment to Health
Equity structural measure is strong for a
structural measure. A few commenters
agreed that this measure is actionable
and will incentivize providers to collect
and use data to close equity gaps. A
commenter believed it would encourage
hospitals to be more accountable for
health disparities and help drive local
commitment to health equity and
advance health equity goals in the
nation overall.
Response: We thank commenters for
their support to adopt this measure into
the Hospital IQR Program measure set.
Comment: A few commenters did not
support this measure and recommended
the measure should be further refined or
PO 00000
Frm 00418
Fmt 4701
Sfmt 4700
alternative measure concepts should be
developed. A commenter did not
support and recommended hospitals be
required to provide evidence in meeting
each question. A few commenters did
not support adopting the measure, citing
concerns about whether the data will be
meaningful and lead to progress or
change.
Response: We appreciate commenters’
recommendations to further refine or
develop alternative measure concepts.
We wish to note this measure has been
reviewed by the Measure Application
Partnership (MAP) Coordinating
Committee, which voted to
conditionally support the measure given
its importance in being a first step
towards the future development of
outcome-based measures. We also
acknowledge concerns related to
whether this measure will lead to
meaningful change. However, we
respectfully disagree that data from this
measure will not lead to progress or
change. As previously stated, our
approach to developing health equity
measures is incremental and will evolve
over time to capture healthcare equity
outcomes in the Hospital IQR Program.
We additionally believe this measure to
be a building block that lays the
groundwork for a more comprehensive
suite of measures in the future that
would assess progress in providing
high-quality healthcare for all patients
regardless of social risk factors or
demographic characteristics (87 FR
28496). We will monitor the data and
any unintended consequences of the
measure as part of standard measure
maintenance.
Comment: A few commenters did not
support this measure because of
concerns that public reporting could be
misleading to the public by failing to
recognize other steps hospitals are
taking to advance health equity. A few
commenters expressed concern about
public reporting and requested
additional guidance on interpreting
partial scores as to not mislead patients
and communities. A commenter
recommended alternative public
reporting options including reporting
the data as a part of a publicly available
dataset instead of on the Care Compare
website. A commenter requested
clarification on how this measure will
be publicly reported.
Response: We acknowledge
commenters’ concern about public
reporting of this measure and
interpretation by the public. We refer
readers to sections IX.E.5.(a).(3). and
IX.E.5.(a).(4). (Measure Calculation and
Data Submission and Reporting,
respectively) of this final rule for
detailed descriptions of how we
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
calculate and publicly report this
measure on the Compare tool hosted by
HHS, currently available at: https://
www.medicare.gov/care-compare. This
measure includes five attestation-based
questions, each representing a separate
domain of commitment. Hospitals
receive one point for each domain to
which they attest ‘‘yes,’’ stating they are
meeting the required competencies. For
each domain there are between one and
four associated yes/no sub-questions for
related structures or activities within
the hospital. Hospitals will only receive
a point for each domain if they attest
‘‘yes’’ to all related sub-questions. A
hospital’s score can be a total of zero to
five points.474 This measure will be
publicly reported on the Compare tool
hosted by HHS, currently available at
https://www.medicare.gov/carecompare, or its successor website (87 FR
28562). We believe this measure will
provide insightful information to
healthcare providers and the public on
the number of hospitals currently
participating in health equity strategic
planning, collecting data, using this data
to identify equity gaps, establishing key
performance indicators, and reviewing
them with hospital senior leaders. We
intend to provide educational materials
as part of our outreach and public
reporting of this measure to ensure
understanding and interpretation of
publicly reported data.
Comment: A few commenters did not
support measure adoption due to
resource constraints and timing of
mandatory reporting and recommended
delaying reporting to allow time for
hospitals to build and deploy processes.
A few commenters expressed concern
that all hospitals will not have
capabilities within their EHR to meet
the criteria set forth by this measure. A
few commenters expressed concern
about the burden this may place on
hospitals and systems, particularly
those that are under resourced.
Specifically, commenters noted
attestation to this measure would be
difficult for small rural hospitals.
Response: We acknowledge
commenters’ concerns regarding
resources and timing of mandatory
reporting; however, we believe
achieving health equity is an issue,
which deserves serious focus and rapid
action for improvement. Although
measure results will be publicly posted,
we note that hospitals will receive
credit for the reporting of their measure
474 Centers for Medicare & Medicaid Services.
(2022). Hospital Commitment to Health Equity
Structural Measure Specifications. Available at:
https://qualitynet.cms.gov/files/
62629ee35e40610016f30140?filename=Hosp_
Commit_HlthEqStrct_Meas.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
results regardless of their responses to
the attestation questions because the
Hospital IQR Program is a pay-forreporting program.
With regard to comments about EHR
capabilities, we are sensitive to the
potential for increased administrative
burden associated with adding new
capabilities within EHR to meet the
criteria set forth in this measure and
will take commenters’ feedback into
consideration in future policy
development. Furthermore, we
acknowledge that facilitating quality
improvement for rural hospitals and
small hospitals can present unique
challenges and is a high priority under
the Meaningful Measures Framework.
We continue to consider ways to
support small and rural hospital efforts
toward achieving health equity.
Comment: A few commenters
expressed concern about this measure
not being NQF endorsed.
Response: We thank commenters for
their recommendations. While we
recognize the value of measures
undergoing NQF endorsement review,
given the urgency of achieving health
equity and, as there are currently no
NQF-endorsed measures that address
hospital commitment to health equity,
we believe it is important to implement
this measure as soon as possible. We
note that under section
1866(b)(3)(B)(viii)(IX)(aa) of the Act,
each measure specified by the Secretary
shall be endorsed by the entity with a
contract under section 1890(a) of the
Act (the NQF is the entity that currently
holds this contract). Under section
1886(b)(3)(B)(viii)(IX)(bb) of the Act, in
the case of a specified area or medical
topic determined appropriate by the
Secretary for which a feasible and
practical measure has not been endorsed
by the entity with a contract under
section 1890(a) of the Act, the Secretary
may specify a measure that is not so
endorsed as long as due consideration is
given to a measure that has been
endorsed or adopted by a consensus
organization identified by the Secretary.
We reviewed NQF-endorsed measures
and were unable to identify any other
NQF-endorsed measures on this topic,
and, therefore we believe the exception
in section 1886(b)(3)(B)(viii)(IX)(bb) of
the Act applies.
Comment: A commenter requested
clarification on whether this measure
would be a pay-for-reporting measure
since it is part of the Hospital IQR
Program, or if affirmation in each of the
five attestation domains would have a
performance value.
Response: We note that the Hospital
IQR Program is a pay-for-reporting
program, and hospitals’ payments are
PO 00000
Frm 00419
Fmt 4701
Sfmt 4700
49197
not based on their performance on
measures. We note that hospitals will
receive credit for the reporting of their
measure results regardless of their
responses to the attestation questions.
Comment: A commenter requested
clarification on how this measure will
be validated.
Response: We thank the commenter
for their question. We wish to clarify
that this measure will not be included
in the Hospital IQR Program validation
at this time. We require all hospitals
participating in the Hospital IQR
Program to complete the Data Accuracy
and Completeness Agreement (DACA)
each year which requires attestation that
all of the information reported to CMS
is accurate and complete (77 FR 53554).
Comment: A few commenters
indicated that hospitals are not yet
uniformly collecting disaggregated
sociodemographic data and suggested
that as a first step, we encourage
hospitals to collect disaggregated data
since it leads to a more complete data
set. A commenter recommended
changing the language to require
hospitals to stratify performance
indicators by demographic variables and
state which demographic variables
hospitals must use when stratifying
quality data.
Response: We appreciate commenters’
recommendations to uniformly collect
disaggregated data and interest
regarding the collection and
standardization of sociodemographic
data. We believe this measure allows for
significant flexibility in the approach to
data collection and believe this is an
appropriate first step for this structural
measure and our first health equityrelated quality measure. Though we will
not be revising the measure to require
stratification of performance indicators
by identified demographic variables at
this time, we will take commenters’
feedback into consideration for future
policy development. Additionally, we
refer readers to our Overarching
Principles for Measuring Healthcare
Quality Disparities Across CMS Quality
Programs—Request for Information in
section IX.B. for more information about
potential future measure stratification.
Comment: A commenter suggested
that for purposes of the Hospital IQR
Program, we focus on assessing clinical
quality rather than the quality of data
collection.
Response: We appreciate the
commenters’ feedback. We intend to
continue research and assessments on
improving clinical quality through
quality measurement reporting to
achieve health equity and have
evaluated research, existing frameworks,
and various tools in the development of
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49198
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
this measure as described in section
IX.E.5.a. As discussed in the proposed
rule, the five domains of this measure
were adapted from the CMS Office of
Minority Health’s Building and
Organizational Response to Health
Disparities framework, which focuses
on data collection, data analysis, culture
of equity, and quality improvement (87
FR 28492). Further, we believe this
measure is an important first step
toward development of a more
comprehensive suite of measures in the
future (87 FR 28496). Additionally, the
MAP Rural Health Workgroup agreed
that this is an important measure and
that the intent of the measure is to
identify gaps and make the needed
investments in workforce training,
leadership development, and other
related areas to improve equity (87 FR
28496).
Comment: A commenter
recommended that if we move forward
with the Z codes and social drivers of
health screening quality measures, there
is no need to attest to data collection
and analysis.
Response: We thank the commenter
for their recommendation regarding
minimizing provider reporting burden
by removing data collection and
analysis (Domain 2 and Domain 3)
attestation questions if we move forward
with finalization of other proposals such
as Z codes (discussed as a RFI in section
II.D.13.d. of this final rule) and social
drivers of health screening quality
measures such as the Screening for
Social Drivers of Health and Screen
Positive Rate both discussed in section
IX.E.5.b. of this final rule. We agree that
any future measures or measure
refinements should carefully consider
alignment with other quality measure
reporting requirements and efforts in a
manner that minimizes provider
reporting burden. We will take
commenters’ feedback into
consideration in future policy
development.
Comment: A few commenters raised
concerns that the measure is potentially
duplicative of other measure reporting
requirements such as eCQMs. A
commenter questioned the need for this
measure given that there are equity
standards that are already developed. A
commenter recommended a complete
environment scan, listening sessions,
focus groups, and/or a technical expert
panel to catalogue what hospitals are
doing to identify and address health
disparities and ensure there is no
redundancy in reporting requirements.
Another commenter stated that a
requirement of the Hospital
Readmissions Reduction Program is to
provide hospitals with risk-stratified
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
reports, thus, requiring stratified reports
in Domain 3 in this structural measure
is duplicative. A few commenters
recommended considering
opportunities for alignment with
existing tools to reduce reporting
burden.
Response: We thank the commenter
for their recommendations, and we will
continue to engage interested parties as
we continue to build on our efforts to
address unmet needs. Additionally, we
wish to refer readers to our thorough
discussion and RFIs on our ongoing
evaluation of appropriate initiatives to
reduce health disparities (see section
IX.B., ‘‘Closing the Health Equity Gap in
CMS Hospital Quality Programs—
Request for Information,’’ in the FY
2022 IPPS/LTCH PPS final rule (86 FR
45349)) as well as section IX.B. of this
final rule). We additionally appreciate
commenter concerns related to
potentially duplicative efforts and
continually look for ways to minimize
provider reporting burden. We will take
this into consideration for future
program years. We wish to reiterate that
our approach to developing health
equity measures is incremental and will
evolve over time to capture healthcare
equity outcomes in the Hospital IQR
Program. We additionally believe this
measure to be a building block that lays
the groundwork for a more
comprehensive suite of measures that
would assess progress in providing
high-quality healthcare for all patients
regardless of social risk factors or
demographic characteristics.
Additionally, we continually look for
ways to minimize provider reporting
burden and do not believe that this
measure is duplicative of other efforts or
currently available eCQMs in the
Hospital IQR Program at this time. With
regard to the commenters
recommending alignment, we interpret
the commenters to mean that they have
existing tools integrated into their EHRs
or similar systems that assess the
domains evaluated by this measure. We
agree and encourage hospitals to utilize
existing tools in their assessment of
meeting reporting requirements of this
measure.
In regard to the comment on the
Hospital Readmissions Reduction
Program, while the Hospital
Readmissions Reduction Program does
provide hospitals with reports stratified
by dual-eligibility, these reports are
specific to the six condition/procedure
specific readmissions measures within
that program. Therefore, we believe that
the data collected regarding Hospital
Commitment to Health Equity will be
complementary to the stratified data
provided to hospitals within the
PO 00000
Frm 00420
Fmt 4701
Sfmt 4700
Hospital Readmissions Reduction
Program.
Comment: Several commenters
recommended that we broaden the
scope of this measure to address more
health equity factors and indicators. A
few commenters believed that we
should require collection of more
granular and more specific data in order
to thoroughly assess a hospital’s
commitment to equity. A commenter
recommended inclusion of the elderly
and veterans. Another commenter
expressed concern this measure will not
provide specific enough information to
identify equity gaps and determine
where improvements are most needed.
Response: We appreciate commenters
recommendations. At this time, this
measure is a hospital-level measure that
is assessing hospital commitment to
health equity. We believe that the
domains covered by this measure are
inclusive of a hospital’s commitment to
the care of the population they serve,
inclusive of the elderly and veterans.
We refer readers to section IX.E.5.b. for
discussion of the Social Drivers of
Health measures and section IX.E.5.f. for
discussion of the Global Malnutrition
Composite Score eCQM which we
believe address further the health equity
factors. With regard to commenter
concerns about sufficient measure
specificity to identify equity gaps, as
stated in the proposed rule, we
encourage providers to analyze their
own data to understand many factors,
including race, ethnicity, and various
drivers of health, such as housing
stability and food security, in order to
deliver more equitable care (87 FR
28493). The five domains of this
measure were adapted from the CMS
Office of Minority Health’s Building an
Organizational Response to Health
Disparities framework, which focuses
on data collection, data analysis, culture
of equity, and quality improvement, and
we encourage its use for data analysis to
further understand the factors we have
highlighted.475 Additionally, we wish to
highlight the recently published CMS
Framework for Health Equity 2022–2032
that provides guidance on designing,
implementing, and operationalizing
policies and programs.476
475 Centers for Medicare & Medicaid Services.
(2021). Building an Organizational Response to
Health Disparities [Fact Sheet]. U.S. Department of
Health and Human Services. Available at: https://
www.cms.gov/About-CMS/Agency-Information/
OMH/Downloads/Health-Disparities-Guide.pdf.
476 Centers for Medicare & Medicaid Services.
(2022). CMS Framework for Health Equity 2022–
2032. Available at: https://www.cms.gov/files/
document/cms-framework-health-equity.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Comment: A commenter
recommended we remove the
requirement to collect data relating to
race and ethnicity out of concern that
collecting the data might worsen patient
care and trust. Another commenter
recommended removal of references to
drivers of health data to maintain focus
on healthcare related actions.
Response: We appreciate commenters’
concern and recognize the importance
of establishing and maintaining patient
trust in health equity initiatives. We
wish to clarify that this measure does
not require the collection of race and
ethnicity data as a part of reporting.
Rather, the measure assesses hospital
commitment to health equity using a
suite of equity-focused organizational
competencies aimed at achieving health
equity for racial and ethnic minority
groups, people with disabilities,
members of the LGBTQ+ community,
individuals with limited English
proficiency, rural populations, religious
minorities, and people facing
socioeconomic challenges. We believe
this measure is an important
foundational measure for improving
health equity among those that have
been disadvantaged and/or underserved
by the healthcare system, and there is
substantial research showing differences
in care and experiences among these
populations (87 FR 28492 through
28493). We encourage providers to
analyze their own data to understand
the many factors, including race,
ethnicity, and various drivers of health,
such as housing stability and food
security, in order to deliver more
equitable care. Further, we note that
although measure results will be
publicly posted, hospitals will receive
credit for the reporting of their measure
results regardless of their responses to
the attestation questions.
Comment: A few commenters
expressed concern about the need for
training and education on implementing
and structuring a program to engage
leadership in improving health equity.
Response: We appreciate commenters’
concerns and agree that training and
education is important for establishing
and implementing any new measures in
the Hospital IQR Program. We wish to
highlight the various resources available
through the CMS Office of Minority
Health’s Building an Organizational
Response to Health Disparities
framework, from which this measure
was adapted, and the recently published
CMS Framework for Health Equity
2022–2032 that provides guidance on
designing, implementing, and
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
operationalizing policies and
programs.477 478
Comment: A commenter expressed
concern about including Domain 3: Data
Analysis in this attestation-based
measure and recommended removing
attestation to a performance dashboard
that stratifies findings from this
proposal as this activity is viewed as a
next step. Another commenter
expressed concerns that Domain 4
would be resource intensive as
described. Instead, the commenter
recommended this should be optional
with a requirement to attest whether
equity is embedded in the hospital’s
quality improvement processes and
workflows or attest to having initiatives
focused on addressing an inequity
identified in hospital data analysis. A
commenter recommended revising
specifications for Domains 2, 3, and 4 as
attestations to the inclusion of hospitals’
strategic plans, timelines for
implementation, and specific steps for
achieving all five domains. A
commenter recommended adding
attestations regarding community and
patient perspectives related to health
equity and ongoing education to the
leadership domain.
Response: We appreciate the
commenter’s recommendations
regarding domains. As we noted in the
FY 2023 IPPS/LTCH PPS proposed rule,
we believe all the activities outlined in
the five domains of this attestation
measure are foundational best practices
for advancing health equity for patients
and communities (87 FR 28496). We
acknowledge not all hospitals will be
engaged in all activities outlined across
the five domains. Further, we wish to
reiterate that hospitals will receive
credit for the reporting of their measure
results regardless of their responses to
the attestation questions. As previously
stated, our approach to developing
health equity measures is incremental
and will evolve over time to capture
healthcare equity outcomes in the
Hospital IQR Program. We additionally
believe that a hospital’s attestation to
the action of the elements of the
domains and not just the inclusion of
the elements is important. Moreover, we
do not anticipate that every hospital
will be able to affirmatively attest to
each domain. We note that this measure
477 Centers for Medicare & Medicaid Services.
(2021). Building an Organizational Response to
Health Disparities [Fact Sheet]. U.S. Department of
Health and Human Services. Available at: https://
www.cms.gov/About-CMS/Agency-Information/
OMH/Downloads/Health-Disparities-Guide.pdf.
478 Centers for Medicare & Medicaid Services.
(2022). CMS Framework for Health Equity 2022–
2032. Available at: https://www.cms.gov/files/
document/cms-framework-health-equity.pdf.
PO 00000
Frm 00421
Fmt 4701
Sfmt 4700
49199
will be included in the Hospital IQR
Program beginning with the CY 2023
reporting period/FY 2025 payment
determination and for subsequent years.
With each additional year, we hope to
see that each hospital is able to attest to
more domains as part of their growth
strategy and commitment to equityfocused organizational improvements.
We expect variability across hospitals
and we believe this is important as part
of our long-term strategy to improve
health equity.
Comment: Many commenters
expressed concern about the scoring of
this structural measure, citing it as an
‘‘all or nothing’’ approach, and
recommended awarding partial credit
within each domain. Specifically, many
requested to receive a point for each
element within a domain, resulting in a
denominator of 11 rather than 5. A
commenter recommended scoring
collection of social drivers of health
information separately from
demographic data, suggesting this
would highlight the importance of
capturing both sets of data.
Response: We thank the commenters
for their feedback. We believe the five
domains of this measure are actionable
focus areas, and assessment of hospital
leadership commitment to them is
foundational. We also believe this
measure will incentivize providers to
collect and utilize data to identify
critical equity gaps, implement plans to
address said gaps, and ensure that
resources are dedicated toward
addressing healthcare equity initiatives
(87 FR 28493). The five questions of the
proposed structural measure are
adapted from the CMS Office of
Minority Health’s Building an
Organizational Response to Health
Disparities framework, which focuses
on data collection, data analysis, culture
of equity, and quality improvement (87
FR 28494). We believe that each element
within a domain is important together to
help hospitals identify, prioritize, and
take action on health disparities.
Additionally, we wish to note that the
Hospital IQR Program is a pay-forreporting program, and hospitals are not
scored based on their performance on
measures.
Comment: A commenter requested
clarification on whether providers
would receive a special designation for
attesting to all five domains.
Response: We appreciate the
commenter’s request for clarification.
We wish to clarify that we are not
proposing a hospital designation related
to health equity at this time. We
commend and encourage hospitals to
establish the necessary suite of equity-
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49200
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
focused organizational competencies
aimed at achieving health equity.
Comment: Many commenters
recommended CMS provide guidance to
ensure attestations are meaningful,
accurate, complete, and applied
consistently across hospitals.
Specifically, commenters requested we
provide a standard set of definitions and
key terms. Several commenters
recommended establishing guidelines or
minimum benchmarks for each domain
to create a more standardized
methodology to reduce ambiguity.
Commenters expressed concerns that
the lack of clear definitions and
benchmarks limit data from being truly
actionable with respect to illuminating
equity gaps, as the elements allow a
large degree of ambiguity on how
hospitals are evaluating whether they
have met the requirements. A
commenter requested clarification for
which instances a hospital’s
participation in a regional framework
(such as an HIE and related use cases),
would constitute evidence of data
collection, data analysis, and quality
improvement. A commenter requested
clarification on the intent by leaving the
questions subject to interpretation.
Response: We thank commenters for
their feedback. Regarding a more
standardized measure methodology, we
note that the measure specifications as
proposed (87 FR 28497) are available on
the CMS Measure Methodology page
with the file name ‘‘Hospital
Commitment to Health Equity Structural
Measure Specifications’’ at: https://
qualitynet.cms.gov/inpatient/iqr/
resources. As stated in the proposed
rule, the five domains of this measure
were adapted from the CMS Office of
Minority Health’s Building an
Organizational Response to Health
Disparities framework, which focuses
on data collection, data analysis, culture
of equity, and quality improvement, and
we encourage its use for data analysis to
further understand the factors we have
highlighted (87 FR 28492). Further, we
stated that this measure is an important
foundation and the MAP Coordinating
Committee supported the measure for
rulemaking given its importance in
being a first step towards the future
development of outcome-based
measures (87 FR 28496). Additionally,
we wish to highlight the recently
published CMS Framework for Health
Equity 2022–2032 that provides
guidance on designing, implementing,
and operationalizing policies and
programs.479 We encourage providers to
analyze their own data to understand
many factors, including race, ethnicity,
and various drivers of health, such as
housing stability and food security, and
encourage hospitals to use these data to
set specific, measurable, attainable, and
realistic, and time-based (SMART) goals
that support delivery of equitable care
(87 FR 28493).
We wish to clarify that we will
provide educational and training
materials to help with consistent
implementation which will be conveyed
through routine communication
channels to hospitals, vendors, and
QIOs, including, but not limited to,
issuing memos, emails, and notices on
the QualityNet website.
Regarding the request for benchmarks
and clarification on which instances a
hospital’s participation in a regional
framework would constitute evidence of
data collection, data analysis, and
quality improvement, we remind
readers that the Hospital IQR Program is
a pay-for-reporting program, and
therefore, there are no set performance
targets. We refer readers to the measure
specifications at https://
qualitynet.cms.gov/inpatient/iqr/
resources for more details.
Comment: Many commenters
recommended starting with voluntary
reporting beginning with the CY 2023
reporting period. A commenter
recommended voluntary reporting to
allow for time to refine measure
elements and direct educational and
technical assistance resources
appropriately. A commenter
recommended delaying mandatory
reporting until at least CY 2024 to allow
to allow additional time to allocate the
necessary resources to fully implement
the measure elements. Several
commenters recommended delaying
mandatory reporting until additional
testing and greater specificity is further
developed.
Response: We appreciate commenters’
concerns about mandatory reporting;
however, we believe that achieving
health equity is a pressing issue which
deserves serious focus and rapid action.
We note that hospitals will receive
credit for the reporting of their measure
results regardless of their responses to
the attestation questions. We emphasize
that the measure was proposed for
inclusion beginning in the CY 2023
reporting period/FY 2025 payment
determination, which will allow
hospitals time during the remainder of
CY 2022 to begin assessing their
activities and levels of engagement in
the identified domains. We additionally
479 Centers for Medicare & Medicaid Services.
(2022). CMS Framework for Health Equity 2022–
2032. Available at: https://www.cms.gov/files/
document/cms-framework-health-equity.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00422
Fmt 4701
Sfmt 4700
believe this measure to be a building
block that lays the groundwork for a
more comprehensive suite of measures
that would assess progress in providing
high-quality healthcare for all patients
regardless of social risk factors or
demographic characteristics.
Comment: A commenter requested
allowing hospitals to report as a system
to reduce burden and duplicative
reporting.
Response: We thank the commenter
for their request. We interpret the
commenter to mean that they want a
hospital system to report as one instead
of separately by hospital. We wish to
clarify that as part of the measure
reporting, a hospital would be required
to report under their CMS certification
number (CCN) as part of their normal
Hospital IQR Program reporting
operations.
Comment: A commenter
recommended focusing on hospitallevel practices and data, promoting
collaboration between hospitals,
ensuring measures are appropriately
specified and tested before
implementation, establishing feedback
loops, fostering alignment and
standardized approaches to data
collection, and prioritizing the use of
existing data. A commenter
recommended enhanced coordination
with local public health systems and
sharing the measure data in the
Community Health Needs Assessment
(CHNA) processes, which are shared
with local public health systems to
guide public and private resource
allocation.
Response: We appreciate the
commenter’s recommendations. We
agree that these are all important
elements to monitoring and evaluating a
quality reporting program. We believe
this measure, the other measures we are
proposing for adoption in the Hospital
IQR Program, and our current measure
set address a range of priorities. We are
consistently committed to developing,
adopting, assessing, and maintaining
appropriate measures to put patients
first and ensure they are empowered to
make decisions about their own
healthcare along with their clinicians by
using information from data-driven
insights. We equally encourage
hospitals to collaborate, both with other
hospitals and with local, state, and
regional partners to align where possible
to help supplement our efforts. We will
continue to take these recommendations
into consideration for future policy
development.
Comment: Another commenter
recommended robust evaluation and
monitoring of the measure.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Response: We thank the commenter
for their feedback. We will monitor
measure implementation and data
reporting as part of standard program
and measure review. After consideration
of the public comments we received, we
are finalizing the proposal as proposed.
b. Adoption of Two Social Drivers of
Health Measures Beginning With
Voluntary Reporting in the CY 2023
Reporting Period and Mandatory
Reporting Beginning With the CY 2024
Reporting Period/FY 2026 Payment
Determination and for Subsequent Years
Health-related social needs (HRSNs),
which we have previously defined as
individual-level, adverse social
conditions that negatively impact a
person’s health or healthcare, are
significant risk factors associated with
worse health outcomes as well as
increased healthcare utilization.480 We
believe that consistently pursuing
identification of HRSNs will have two
significant benefits. First, because social
risk factors disproportionately impact
historically 481 Second, these measures
could support ongoing hospital quality
improvement initiatives by providing
data with which to stratify patient risk
and organizational performance.
Further, we believe collecting patientlevel HRSN data through screening is
essential in the long-term in
encouraging meaningful collaboration
between healthcare providers and
community-based organizations and in
implementing and evaluating related
innovations in health and social care
delivery. We note that advancing health
equity by addressing the health
disparities that underlie the country’s
health system is one of our strategic
khammond on DSKJM1Z7X2PROD with RULES2
480 Centers for Medicare & Medicaid Services.
(2021). A Guide to Using the Accountable Health
Communities Health-Related Social Needs
Screening Tool: Promising Practices and Key
Insights. June 2021. Available at: https://
innovation.cms.gov/media/document/ahcmscreeningtool-companion. Accessed: November 23,
2021.
481 American Hospital Association. (2020). Health
Equity, Diversity & Inclusion Measures for
Hospitals and Health System Dashboards. December
2020. Accessed: January 18, 2022. Available at:
https://ifdhe.aha.org/system/files/media/file/2020/
12/ifdhe_inclusion_dashboard.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
pillars 482 and a Biden-Harris
Administration priority.
As a first step towards addressing the
role of HRSNs in closing the health
equity gap, we have developed two
evidence-based measures—Screening
for Social Drivers of Health and Screen
Positive Rate for Social Drivers of
Health. These two Social Drivers of
Health measures will support
identification of specific risk factors for
inadequate healthcare access and
adverse health outcomes among
patients. We note that these measures
will enable systematic collection of
HRSN data which aligns with our other
efforts, including the CY 2023 Medicare
Advantage and Part D proposed rule in
which we proposed that all Special
Needs Plans (SNPs) complete health risk
assessments (HRAs) of enrollees that
include specific standardized questions
on housing stability, food security, and
access to transportation (87 FR 1858).
(We also note that this proposal was
finalized with modification in the CY
2023 Medicare Advantage and Part D
final rule (87 FR 27726). We finalized
that all SNPs include one or more
questions on housing stability, food
security, and access to transportation in
their HRA using questions from a list of
screening instruments specified in subregulatory guidance instead of the
proposed use of the same standardized
questions (82 FR 27726)).
These standardized measures will
identify patients with HRSNs, who are
known to experience the greatest risk of
poor health outcomes, thereby
improving the accuracy of high-risk
prediction calculations. Improvement in
risk prediction has the potential to
reduce healthcare access barriers,
address the disproportionate
expenditures attributed to high-risk
population groups, and improve the
hospital’s quality of care.483 484 485 486
482 Brooks-LaSure, C. (2021). My First 100 Days
and Where We Go From Here: A Strategic Vision
for CMS. Centers for Medicare & Medicaid.
Available at: https://www.cms.gov/blog/my-first100-days-and-where-we-go-here-strategic-visioncms.
483 Baker, M.C., Alberti, P.M., Tsao, T.Y., Fluegge,
K., Howland, R.E., & Haberman, M. (2021). Social
PO 00000
Frm 00423
Fmt 4701
Sfmt 4700
49201
Further, these data could guide future
public and private resource allocation to
promote targeted collaboration between
hospitals and health systems and
appropriate community-based
organizations and ultimately contribute
to improved patient outcomes following
inpatient hospitalization.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28497 through
28506), we proposed voluntary
reporting of these two measures
beginning with the CY 2023 reporting
period and mandatory reporting
beginning with the CY 2024 reporting
period/FY 2026 payment determination
and for subsequent years. We believe
incremental implementation of these
measures beginning with one year of
voluntary reporting will allow hospitals
who are not yet screening patients for
HRSNs to get experience with the
measure and equally allow hospitals
who already undertake screening efforts
to report data already being collected.
We provide further details on both
measures in the subsequent discussion.
Additionally, consistent with our
strategy to incorporate social drivers of
health factors into Medicare quality
reporting and payment, we refer readers
to section II.D.13.(d). where we sought
comment on how the reporting of
diagnosis codes may improve our ability
to advance health equity.
Determinants Matter for Hospital Readmission
Policy: Insights From New York City. Health
Affairs, 40(4), 645–654. Available at: https://
doi.org/10.1377/hlthaff.2020.01742.
484 Hammond, G., Johnston, K., Huang, K., Joynt
Maddox, K. (2020). Social Determinants of Health
Improve Predictive Accuracy of Clinical Risk
Models for Cardiovascular Hospitalization, Annual
Cost, and Death. Circulation: Cardiovascular
Quality and Outcomes, 13 (6) 290–299. Available at:
https://doi.org/10.1161/CIRCOUTCOMES.
120.006752.
485 Hill-Briggs, F. (2021, January 1). Social
Determinants of Health and Diabetes: A Scientific
Review. Diabetes Care. Available at: https://
pubmed.ncbi.nlm.nih.gov/33139407/.
486 Jaffrey, J.B., Safran, G.B., Addressing Social
Risk Factors in Value-Based Payment: Adjusting
Payment Not Performance to Optimize Outcomes
and Fairness. Health Affairs Blog, April 19, 2021.
Available at: https://www.healthaffairs.org/do/
10.1377/forefront.20210414.379479/full/.
E:\FR\FM\10AUR2.SGM
10AUR2
49202
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(1) Screening for Social Drivers of
Health Measure
(a) Background
khammond on DSKJM1Z7X2PROD with RULES2
In the FY 2022 IPPS/LTCH PPS final
rule, we sought feedback on the
development of new measures that
could address the gap in existing health
disparities, focusing on social risk
factors for which providers should
screen (85 FR 45414). As a result, we
identified the Screening for Social
Drivers of Health measure, which
assesses the percent of patients admitted
to the hospital who are 18 years or older
at time of admission and are screened
for food insecurity, housing instability,
transportation needs, utility difficulties,
and interpersonal safety.
Health disparities manifest primarily
as worse health outcomes in population
groups where access to care is
inequitable.487 488 489 490 491 Such
differences persist across geography and
healthcare settings irrespective of
improvements in quality of care over
time.492 493 494 Assessment of HRSNs is
an essential mechanism for capturing
the interaction between social,
487 Seligman, H.K., & Berkowitz, S.A. (2019).
Aligning Programs and Policies to Support Food
Security and Public Health Goals in the United
States. Annual Review of Public Health, 40(1), 319–
337. Available at: https://pubmed.ncbi.nlm.nih.gov/
30444684/.
488 The Physicians Foundation. (2020). Survey of
America’s Patients, Part Three. Available at: https://
physiciansfoundation.org/wp-content/uploads/
2020/10/2020-Physicians-Foundation-SurveyPart3.pdf.
489 Office of the Assistant Secretary for Planning
and Evaluation (ASPE) (2020). Report to Congress:
Social Risk Factors and Performance Under
Medicare’s Value-Based Purchasing Program
(Second of Two Reports). Available at: https://
aspe.hhs.gov/pdf-report/second-impact-report-tocongress.
490 Trivedi AN, Nsa W, Hausmann LRM, et al.
Quality and Equity of Care in U.S. Hospitals. New
England Journal of Medicine. 2014; 371(24):2298–
2308.
491 Billioux, A., Verlander, K., Anthony, S., &
Alley, D. (2017). Standardized Screening for HealthRelated Social Needs in Clinical Settings: The
Accountable Health Communities Screening Tool.
NAM Perspectives, 7(5). Available at: https://
doi.org/10.31478/201705b.
492 Office of the Assistant Secretary for Planning
and Evaluation (ASPE) (2020). Report to Congress:
Social Risk Factors and Performance Under
Medicare’s Value-Based Purchasing Program
(Second of Two Reports). Available at: https://
aspe.hhs.gov/pdf-report/second-impact-report-tocongress.
493 Hill-Briggs, F. (2021, January 1). Social
Determinants of Health and Diabetes: A Scientific
Review. Diabetes Care. Available at: https://
pubmed.ncbi.nlm.nih.gov/33139407/.
494 Khullar, D., MD. (2020, September 8).
Association Between Patient Social Risk and
Physician Performance American academy of
Family Physicians. Addressing Social Determinants
of Health in Primary Care team-based approach for
advancing health equity. Available at: https://
www.aafp.org/dam/AAFP/documents/patient_care/
everyone_project/team-based-approach.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
community, and environmental factors
associated with health status and health
outcomes.495 496 497 While widespread
interest in addressing HRSNs exists,
action is inconsistent, with 92 percent
of hospitals screening for one or more of
the five HRSNs—food insecurity,
housing instability, transportation
needs, utility difficulties, and
interpersonal safety—specified in the
proposed measures, but only 24 percent
of hospitals screening for all five
HRSNs.498
Growing evidence demonstrates that
specific social risk factors are directly
associated with patient health outcomes
as well as healthcare utilization, costs,
and performance in quality-based
payment programs.499 500 In 2017, CMS’
Center for Medicare and Medicaid
Innovation (CMMI) launched the
Accountable Health Communities
(AHC) Model to test the impact of
systematically identifying and
addressing the HRSNs of Medicare and
Medicaid beneficiaries (through
screening, referral, and community
navigation on their health outcomes and
related healthcare utilization and
costs).501 502 503 504 Although there are
495 Institute of Medicine. (2014). Capturing Social
and Behavioral Domains and Measures in
Electronic Health Records: Phase 2. Washington,
DC: The National Academies Press. Available at:
https://doi.org/10.17226/18951.
496 Alley, D.E., C.N. Asomugha, P.H. Conway, and
D.M. Sanghavi. (2016). Accountable Health
Communities—Addressing Social Needs through
Medicare and Medicaid. The New England Journal
of Medicine 374(1):8–11. Available at: https://
doi.org/10.1056/NEJMp1512532.
497 Centers for Disease Control and Prevention.
CDC COVID–19 Response Health Equity Strategy:
Accelerating Progress Towards Reducing COVID–19
Disparities and Achieving Health Equity. July 2020.
Available at: https://www.cdc.gov/coronavirus/
2019-ncov/community/health-equity/cdcstrategy.html. Accessed November 17, 2021.
498 TK Fraze, AL Brewster, VA Lewis, LB Beidler,
GF Murray, CH Colla. Prevalence of screening for
food insecurity, housing instability, utility needs,
transportation needs, and interpersonal violence by
US physician practices and hospitals. JAMA
Network Open 2019; 2:e1911514.10.1001/
jamanetworkopen.2019.11514.31532515.
499 Zhang Y, Li J, Yu J, Braun RT, Casalino LP
(2021). Social Determinants of Health and
Geographic Variation in Medicare per Beneficiary
Spending. JAMA Network Open.
2021;4(6):e2113212. doi:10.1001/
jamanetworkopen.2021.13212.
500 Khullar, D., Schpero, W.L., Bond, A.M., Qian,
Y., & Casalino, L.P. (2020). Association Between
Patient Social Risk and Physician Performance
Scores in the First Year of the Merit-based Incentive
Payment System. JAMA, 324(10), 975–983. https://
doi.org/10.1001/jama.2020.13129.
501 Centers for Medicare & Medicaid Services.
(2021). A Guide to Using the Accountable Health
Communities Health-Related Social Needs
Screening Tool: Promising Practices and Key
Insights. June 2021. Accessed: November 23, 2021.
Available at: https://innovation.cms.gov/media/
document/ahcm-screeningtool-companion.
502 Alley, D.E., C.N. Asomugha, P.H. Conway, and
D.M. Sanghavi. 2016. Accountable Health
PO 00000
Frm 00424
Fmt 4701
Sfmt 4700
models that address HRSNs, the AHC
Model is one of the first federal pilots
to systematically test whether
identifying and addressing core HRSNs
improves healthcare costs, utilization,
and outcomes.505 It also tested the
ability of hospitals and health systems
to implement HRSN screening, referral,
and community navigation in over 600
clinical sites in 21 states.506 The AHC
Model has a 5-year period of
performance that began in May 2017
and will end in April 2022, with
beneficiary screening beginning in the
summer of 2018 following an
implementation period.507 508
While social risk factors account for
50 to 70 percent of health outcomes, the
mechanisms by which this connection
emerges are complex and
multifaceted.509 510 511 512 The persistent
Communities—Addressing Social Needs through
Medicare and Medicaid. The New England Journal
of Medicine 374(1):8–11. Available at: https://
doi.org/10.1056/NEJMp1512532.
503 Billioux, A., Verlander, K., Anthony, S., &
Alley, D. (2017). Standardized Screening for HealthRelated Social Needs in Clinical Settings: The
Accountable Health Communities Screening Tool.
NAM Perspectives, 7(5). Available at: https://
doi.org/10.31478/201705b.
504 Centers for Medicare & Medicaid Services.
(2021). Accountable Health Communities Model.
Accountable Health Communities Model | CMS
Innovation Center. Accessed November 23, 2021.
Available at: https://innovation.cms.gov/
innovation-models/ahcm.
505 RTI International. (2020). Accountable Health
Communities (AHC) Model Evaluation. Available
at: https://innovation.cms.gov/data-and-reports/
2020/ahc-first-eval-rpt.
506 RTI International. (2020). Accountable Health
Communities (AHC) Model Evaluation. Available
at: https://innovation.cms.gov/data-and-reports/
2020/ahc-first-eval-rpt.
507 RTI International. (2020). Accountable Health
Communities (AHC) Model Evaluation. Available
at: https://innovation.cms.gov/data-and-reports/
2020/ahc-first-eval-rpt.
508 We note that the model officially concluded in
April 2022 but many awardees are continuing with
no-cost extensions to continue utilizing unspent
cooperative agreement funding and all awardees
will conclude by April 2023.
509 Kaiser Family Foundation. (2021). Racial and
Ethnic Health Inequities and Medicare. Available
at: https://www.kff.org/medicare/report/racial-andethnic-health-inequities-and-medicare/. Accessed
November 23, 2021.
510 Khullar, D., MD. (2020, September 8).
Association Between Patient Social Risk and
Physician Performance American academy of
Family Physicians. (2020). Addressing Social
Determinants of Health in Primary Care team-based
approach for advancing health equity.
511 Hammond, G., Johnston, K., Huang, K., Joynt
Maddox, K. (2020). Social Determinants of Health
Improve Predictive Accuracy of Clinical Risk
Models for Cardiovascular Hospitalization, Annual
Cost, and Death. Circulation: Cardiovascular
Quality and Outcomes, 13 (6) 290–299. Available at:
https://doi.org/10.1161/CIRCOUTCOMES.
120.006752.
512 The Physicians Foundation. (2021).
Viewpoints: Social Determinants of Health.
Available at: https://physiciansfoundation.org/wpcontent/uploads/2019/08/The-PhysiciansFoundation-SDOH-Viewpoints.pdf. Accessed
December 8, 2021.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
interactions between individuals’
HRSNs, medical providers’ practices/
behaviors, and community resources
significantly impact healthcare access,
quality, and ultimately costs, as
described in the CMS Equity Plan for
Improving Quality in Medicare.513 514 In
their 2018 survey of 8,500 physicians,
The Physicians Foundation found
almost 90 percent of physician
respondents reported their patients had
a serious health problem linked to
poverty or other social conditions.515
Additionally, associations between
disproportionate health risk,
hospitalization, and adverse health
khammond on DSKJM1Z7X2PROD with RULES2
513 Centers for Medicare & Medicaid Services.
(2021). Paving the Way to Equity: A Progress
Report. Accessed January 18, 2022. Available at:
https://www.cms.gov/files/document/paving-wayequity-cms-omh-progress-report.pdf.
514 Centers for Medicare & Medicaid Services
Office of Minority Health. (2021). The CMS Equity
Plan for Improving Quality in Medicare. 2015–2021.
Available at: https://www.cms.gov/About-CMS/
Agency-Information/OMH/OMH_Dwnld-CMS_
EquityPlanforMedicare_090615.pdf#:∼:
text=The%20Centers%20for
%20Medicare%20%26%20Medicaid%20
Services%20%28CMS%29,evidence%20base
%2C%20identifying%20opportunities%2C%20and
%20gathering%20stakeholder%20input.
515 The Physicians Foundation. (2019).
Viewpoints: Social Determinants of Health.
Available at: https://physiciansfoundation.org/wpcontent/uploads/2019/08/The-PhysiciansFoundation-SDOH-Viewpoints.pdf. Accessed
December 8, 2021.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
outcomes have been highlighted and
magnified by the COVID–19
pandemic.516 517
516 Centers for Disease Control and Prevention.
(2020). CDC COVID–19 Response Health Equity
Strategy: Accelerating Progress Towards Reducing
COVID–19 Disparities and Achieving Health Equity.
July 2020. Available at: https://www.cdc.gov/
coronavirus/2019-ncov/community/health-equity/
cdc-strategy.html. Accessed November 17, 2021.
517 Kaiser Family Foundation. (2021). Racial and
Ethnic Health Inequities and Medicare. Available
at: https://www.kff.org/medicare/report/racial-andethnic-health-inequities-and-medicare/. Accessed
November 23, 2021.
518 Billioux, A., Verlander, K., Anthony, S., &
Alley, D. (2017). Standardized Screening for HealthRelated Social Needs in Clinical Settings: The
Accountable Health Communities Screening Tool.
NAM Perspectives, 7(5). Available at: https://
doi.org/10.31478/201705b.
519 Billioux, A., Verlander, K., Anthony, S., &
Alley, D. (2017). Standardized Screening for HealthRelated Social Needs in Clinical Settings: The
Accountable Health Communities Screening Tool.
NAM Perspectives, 7(5). Available at: https://
doi.org/10.31478/201705b.
520 Centers for Medicare & Medicaid Services.
(2021). Accountable Health Communities Model.
Accountable Health Communities Model | CMS
Innovation Center. Accessed November 23, 2021.
Available at: https://innovation.cms.gov/
innovation-models/ahcm.
521 Kamyck, D., Senior Director of Marketing.
(2019). CMS releases standardized screening tool
for health-related social needs. Activate Care.
Available at: https://blog.activatecare.com/
standardized-screening-for-health-related-socialneeds-in-clinical-settings-the-accountable-healthcommunities-screening-tool/.
PO 00000
Frm 00425
Fmt 4701
Sfmt 4700
49203
In developing this measure, we
identified core HRSN domains based on
the following criteria: (1) The
availability of high-quality scientific
evidence linking a given HRSN to
adverse health outcomes and increased
healthcare utilization, including
hospitalizations, and associated costs;
(2) the HRSNs can be screened and
identified in the inpatient setting prior
to hospital discharge, addressed by
community-based services, and
potentially improve healthcare
outcomes, including reduced hospital
re-admission; and (3) the HRSNs are not
systematically addressed by healthcare
providers.518 Based on those criteria, the
following five domains were selected to
screen for social risk factors in Medicare
and Medicaid beneficiaries under the
AHC Model: (1) Food insecurity; (2)
housing instability; (3) transportation
needs; (4) utility difficulties; and (5)
interpersonal safety. In addition to
established evidence of their association
with health status, risk, and outcomes,
these five domains were selected
because they can be assessed across the
broadest spectrum of individuals in a
variety of settings.519 520 521 The five core
HRSN domains are described in Table
IX.E–02.
E:\FR\FM\10AUR2.SGM
10AUR2
49204
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE IX.E-02. THE FIVE CORE HRSN DOMAINS TO SCREEN FOR SOCIAL
DRIVERS OF HEALTH
Housing Instability
khammond on DSKJM1Z7X2PROD with RULES2
Transportation Needs
Descriution
Food insecurity is defined as limited or uncertain access to adequate quality and
quantity of food at the household level. It is associated with diminished mental and physical health
and increased risk for chronic conditions. 522•523 Individuals experiencing food insecurity often have
inadequate access to healthier food options which can impede self-management of chronic diseases
like diabetes and heart disease, and require individuals to make personal trade-offs between food
purchases and medical needs, including prescription medication refills and preventive health
services. 524 •525 Food insecurity is associated with high-cost healthcare utilization including emergency
deoartment (ED) visits and hosoitalizations. 526,527 ,528
Housing instability encompasses multiple conditions ranging from inability to pay rent or mortgage,
frequent changes in residence including temporary stays with friends and relatives, living in crowded
conditions, and actual lack of sheltered housing in which an individual does not have a personal
residence. 529•530 Population surveys consistently show that people from some racial and etlmic
minority groups constitute the largest proportion of the U.S. population experiencing unstable
housing. 531 Housing instability is associated with higher rates of chronic illnesses, injuries, and
complications and more frecrnent utilization of high-cost healthcare services. 532 •533
Unmet transportation needs include limitations that impede transportation to destinations required for
all aspects of daily living. 534 Groups disproportionately affected include older adults (aged >65
years), people with lower incomes, people with impaired mobility, residents of rural areas, and people
from some racial and etlmic minority groups. Transportation needs contribute to postponement of
routine medical care and preventive services which ultimately lead to chronic illness exacerbation and
522 Berkowitz SA, Seligman HK, Meigs JB, Basu
S. Food insecurity, healthcare utilization, and high
cost: a longitudinal cohort study. Am J Managed
Care. 2018 Sep;24(9):399–404. PMID: 30222918;
PMCID: PMC6426124.
523 Hill-Briggs, F. (2021, January 1). Social
Determinants of Health and Diabetes: A Scientific
Review. Diabetes Care. Available at: https://
pubmed.ncbi.nlm.nih.gov/33139407/.
524 Seligman, H.K., & Berkowitz, S.A. (2019).
Aligning Programs and Policies to Support Food
Security and Public Health Goals in the United
States. Annual Review of Public Health, 40(1), 319–
337. Available at: https://pubmed.ncbi.nlm.nih.gov/
30444684/.
525 National Academies of Sciences, Engineering,
and Medicine 2006. Executive Summary: CostBenefit Analysis of Providing Non-Emergency
Medical Transportation. Washington, DC: The
National Academies Press. Available at: https://
doi.org/10.17226/23285.
526 Hill-Briggs, F. (2021, January 1). Social
Determinants of Health and Diabetes: A Scientific
Review. Diabetes Care. Available at: https://
pubmed.ncbi.nlm.nih.gov/33139407/.
527 Berkowitz SA, Seligman HK, Meigs JB, Basu
S. Food insecurity, healthcare utilization, and high
cost: a longitudinal cohort study. Am J Managed
Care. 2018 Sep;24(9):399–404. PMID: 30222918;
PMCID: PMC6426124.
528 Dean, E.B., French, M.T., & Mortensen, K.
(2020a). Food insecurity, health care utilization,
and health care expenditures. Health Services
Research, 55(S2), 883–893. Available at: https://
doi.org/10.1111/1475-6773.13283.
529 Larimer, M.E. (2009). Health Care and Public
Service Use and Costs Before and After Provision
of Housing for Chronically Homeless Persons with
Severe Alcohol Problems. JAMA, 301(13), 1349.
Available at: https://doi.org/10.1001/
jama.2009.414.
530 Hill-Briggs, F. (2021). Social Determinants of
Health and Diabetes: A Scientific Review. Diabetes
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Care. Available at: https://
pubmed.ncbi.nlm.nih.gov/33139407/.
531 Henry, M., de Sousa, T., Roddey, C., Gayen,
S., Bednar, T.; Abt Associates. The 2020 Annual
Homeless Assessment Report (AHAR) to Congress;
Part 1: Point-in-Time Estimates of Homelessness,
January 2021. U.S. Department of Housing and
Urban Development. Accessed November 24, 2021.
Available at: https://www.huduser.gov/portal/sites/
default/files/pdf/2020-AHAR-Part-1.pdf.
532 Larimer, M.E. (2009). Health Care and Public
Service Use and Costs Before and After Provision
of Housing for Chronically Homeless Persons with
Severe Alcohol Problems. JAMA, 301(13), 1349.
Available at: https://doi.org/10.1001/
jama.2009.414.
533 Baxter, A., Tweed, E., Katikireddi, S.,
Thomson, H. (2019). Effects of Housing First
approaches on health and well-being of adults who
are homeless or at risk of homelessness: systematic
review and meta-analysis of randomized controlled
trials. Journal of Epidemiology and Community
Health, 73; 379–387. Available at: https://
jech.bmj.com/content/jech/73/5/379.full.pdf.
534 National Academies of Sciences, Engineering,
and Medicine 2006. Executive Summary: CostBenefit Analysis of Providing Non-Emergency
Medical Transportation. Washington, DC: The
National Academies Press. Available at: https://
doi.org/10.17226/23285.
535 National Academies of Sciences, Engineering,
and Medicine 2006. Executive Summary: CostBenefit Analysis of Providing Non-Emergency
Medical Transportation. Washington, DC: The
National Academies Press. Available at: https://
doi.org/10.17226/23285.
536 Hill-Briggs, F. (2021, January 1). Social
Determinants of Health and Diabetes: A Scientific
Review. Diabetes Care. Available at: https://
pubmed.ncbi.nlm.nih.gov/33139407/.
537 Billioux, A., Verlander, K., Anthony, S., &
Alley, D. (2017). Standardized Screening for HealthRelated Social Needs in Clinical Settings: The
PO 00000
Frm 00426
Fmt 4701
Sfmt 4700
Accountable Health Communities Screening Tool.
NAM Perspectives, 7(5). Available at: https://
doi.org/10.31478/201705b.
538 Shier, G., Ginsburg, M., Howell, J., Volland, P.,
& Golden, R. (2013). Strong Social Support Services,
Such as Transportation And Help For Caregivers,
Can Lead To Lower Health Care Use And Costs.
Health Affairs, 32(3), 544–551. Available at: https://
doi.org/10.1377/hlthaff.2012.0170.
539 Baxter, A., Tweed, E., Katikireddi, S.,
Thomson, H. (2019). Effects of Housing First
approaches on health and well-being of adults who
are homeless or at risk of homelessness: systematic
review and meta-analysis of randomized controlled
trials. Journal of Epidemiology and Community
Health, 73; 379–387. Available at: https://
jech.bmj.com/content/jech/73/5/379.full.pdf.
540 Wright, B.J., Vartanian, K.B., Li, H.F., Royal,
N., & Matson, J.K. (2016). Formerly Homeless
People Had Lower Overall Health Care
Expenditures After Moving into Supportive
Housing. Health Affairs, 35(1), 20–27. Available at:
https://doi.org/10.1377/hlthaff.2015.0393.
541 Billioux, A., Verlander, K., Anthony, S., &
Alley, D. (2017). Standardized Screening for HealthRelated Social Needs in Clinical Settings: The
Accountable Health Communities Screening Tool.
NAM Perspectives, 7(5). Available at: https://
doi.org/10.31478/201705b.
542 Henry M., de Sousa, T., Roddey, C., Gayen, S.,
Bednar, T.; Abt Associates. The 2020 Annual
Homeless Assessment Report (AHAR) to Congress;
Part 1: Point-in-Time Estimates of Homelessness,
January 2021. U.S. Department of Housing and
Urban Development. Accessed November 24, 2021.
Available at: https://www.huduser.gov/portal/sites/
default/files/pdf/2020-AHAR-Part-1.pdf.
543 Larimer, M.E. (2009). Health Care and Public
Service Use and Costs Before and After Provision
of Housing for Chronically Homeless Persons with
Severe Alcohol Problems. JAMA, 301(13), 1349.
Available at: https://doi.org/10.1001/
jama.2009.414.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.156
Domain
Food Insecurity
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Utility Difficulties
Interpersonal Safety
Description
more frequent utilization of high-cost healthcare services including emergency medical services, EDs,
and hosoitalizations. 535 ,536,537•538
Inconsistent availability of electricity, water, oil, and gas services is directly associated with housing
instability and food insecurity. 539 Specifically, interventions that increase or maintain access to such
services have been associated with individual and population-level health improvements. 540
Interpersonal safety affects individuals across the lifespan, from birth to old age, and is directly linked
to mental and physical health. Assessment for this domain includes screening for exposure to intimate
partner violence, child abuse, and elder abuse. 541 Exposure to violence and social isolation are
reflective of individual-level social relations and living conditions that are directly associated with
iniurv, psychological distress, and death in all age groups. 542,543
khammond on DSKJM1Z7X2PROD with RULES2
Utilization of screening tools to
identify the burden of unmet HRSNs
can be a helpful first step in identifying
necessary community partners and
connecting individuals to resources in
their communities. We believe
collecting data across the same five
HRSN domains that were screened
under the AHC Model will illuminate
their impact on health outcomes and
disparities and the care-cost burden for
hospitals, and in particular for hospitals
that serve patients with
disproportionately high levels of social
risk factors. This data collection could
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
inform meaningful and sustainable
solutions for other provider-types
through similar collections in other
quality reporting
programs.544 545 546 547 548
544 The Physicians Foundation: 2020 Survey of
America’s Patients, Part Three. Available at: https://
physiciansfoundation.org/wp-content/uploads/
2020/10/2020-Physicians-Foundation-SurveyPart3.pdf.
545 Office of the Assistant Secretary for Planning
and Evaluation (ASPE) (2020). Report to Congress:
Social Risk Factors and Performance Under
Medicare’s Value-Based Purchasing Program
(Second of Two Reports). Available at: https://
aspe.hhs.gov/pdf-report/second-impact-report-tocongress.
PO 00000
Frm 00427
Fmt 4701
Sfmt 4700
546 Billioux, A., Verlander, K., Anthony, S., &
Alley, D. (2017). Standardized Screening for HealthRelated Social Needs in Clinical Settings: The
Accountable Health Communities Screening Tool.
NAM Perspectives, 7(5). Available at: https://
doi.org/10.31478/201705b.
547 Baker, M.C., Alberti, P.M., Tsao, T.Y., Fluegge,
K., Howland, R.E., & Haberman, M. (2021). Social
Determinants Matter for Hospital Readmission
Policy: Insights From New York City. Health
Affairs, 40(4), 645–654. Available at: https://
doi.org/10.1377/hlthaff.2020.01742.
548 De Marchis, E., Knox, M., Hessler, D., WillardGrace, R., Oliyawola, JN, et al. (2019). Physician
Burnout and Higher Clinic Capacity to Address
Patients’ Social Needs. The Journal of the American
Board of Family Medicine, 32 (1), 69–78.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.157
Domain
49205
49206
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
For data collection of this measure,
providers could use a self-selected
screening tool and collect these data in
multiple ways, which can vary to
accommodate the population they serve
and their individual needs.549 550 One
example of such data collection is the
AHC Model, which uses the standard
10-item AHC Health-Related Social
Needs Screening Tool to enable
providers to identify HRSNs in the five
core domains (described in Table IX.E–
02.) of community-dwelling Medicare,
Medicaid, and dually eligible
beneficiaries.551 Since its inception, the
AHC Model has been implemented
across many care delivery sites in
diverse geographic locations across the
U.S.552 More than one million Medicare
and Medicaid beneficiaries have been
screened using the AHC Health-Related
Social Needs Screening Tool, which has
been evaluated psychometrically and
demonstrated evidence of both
reliability and validity, including interrater reliability and concurrent and
predictive validity.553 Moreover, the
screening instrument can be
implemented in a variety of clinical
settings, including primary care, EDs,
labor and delivery units, inpatient units
(including mental and behavioral health
settings), and other places where
patients seek healthcare.554
The intent of this measure is to
promote adoption of HRSN screening by
hospitals. We encourage hospitals to use
the screening as a basis for developing
their own individual action plans
549 Social Interventions Research & Evaluation
Network. (2019). Social Needs Screening Tool
Comparison Table. Available at: https://
sirenetwork.ucsf.edu/tools-resources/resources/
screening-tools-comparison. Accessed January 18,
2021.
550 Centers for Medicare & Medicaid Services.
(2021). A Guide to Using the Accountable Health
Communities Health-Related Social Needs
Screening Tool: Promising Practices and Key
Insights (June 2021). Available at: https://
innovation.cms.gov/media/document/ahcmscreeningtool-companion. Accessed January 18,
2021.
551 More information on the HRSN Screening
Tool is available at: https://innovation.cms.gov/
files/worksheets/ahcm-screeningtool.pdf.
552 RTI International. (2020). Accountable Health
Communities (AHC) Model Evaluation. Available
at: https://innovation.cms.gov/data-and-reports/
2020/ahc-first-eval-rpt.
553 Lewis C., Wellman R., Jones S., Walsh-Bailey
C., Thompson E., Derus A., Paolino A., Steiner J.,
De Marchis E., Gottlieb L., and Sharp A. (2020).
Comparing the Performance of Two Social Risk
Screening Tools in a Vulnerable Subpopulation. J
Family Med Prim Care. 2020 Sep; 9(9): 5026–5034.
Available at: https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC7652127/.
554 CMS. A Guide to Using the Accountable
Health Communities Health-Related Social Needs
Screening Tool: Promising Practices and Key
Insights. June 2021. Accessed: November 23, 2021.
Available at: https://innovation.cms.gov/media/
document/ahcm-screeningtool-companion.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
(which could include navigation
services), as well as opportunities for
initiating and improving partnerships
between healthcare delivery and
community-based services. This effort
will yield actionable information to
close the disparity gap by encouraging
hospitals to identify patients with
HRSNs, with a reciprocal goal of
partnering with community-based
organizations to connect those
individuals to community support to
help address those risks.
Under our Meaningful Measures
Framework,555 the Screening for Social
Drivers of Health measure addresses the
quality priority of ‘‘Work with
Communities to Promote Best Practices
of Healthy Living’’ through the
Meaningful Measures Area of ‘‘Equity of
Care.’’ Additionally, pursuant to
Meaningful Measures 2.0, this measure
addresses the ‘‘healthcare equity’’
priority area and aligns with our
commitment to introduce plans to close
health equity gaps and promote equity
through quality measures, including to
‘‘develop and implement measures that
reflect social and economic
determinants.’’ 556 Development and
proposal of this measure also aligns
with our strategic pillar to advance
health equity by addressing the health
disparities that underlie our health
system.557
This measure (alongside the Screen
Positive Rate for Social Drivers of
Health measure) will be the first patientlevel measurement of social drivers of
health in the Hospital IQR Program. We
believe this measure is appropriate for
the measurement of the quality of care
furnished by hospitals in inpatient
settings. Screening during inpatient
hospitalization will allow healthcare
providers to identify and potentially
help address HRSNs as part of discharge
planning and contribute to long-term
improvements in patient outcomes. This
will have a direct and positive impact
on hospital quality performance.
Collecting baseline data via this
measure is crucial in informing design
of future measures that could enable us
555 Centers for Medicare & Medicaid Services.
Meaningful Measures Framework. Available at:
https://www.cms.gov/Medicare/Quality-InitiativesPatient-Assessment-Instruments/
QualityInitiativesGenInfo/CMS-Quality-Strategy.
556 Centers for Medicare & Medicaid Services.
Meaningful Measures 2.0: Moving from Measure
Reduction to Modernization. Available at: https://
www.cms.gov/meaningful-measures-20-movingmeasure-reduction-modernization. We note that
Meaningful Measures 2.0 is still under
development.
557 Brooks-LaSure, C. (2021). My First 100 Days
and Where We Go From Here: A Strategic Vision
for CMS. Available at: https://www.cms.gov/blog/
my-first-100-days-and-where-we-go-here-strategicvision-cms.
PO 00000
Frm 00428
Fmt 4701
Sfmt 4700
to set appropriate performance targets
for hospitals.
(b) Overview of Measure
The Screening for Social Drivers of
Health measure assesses whether a
hospital implements screening for all
patients that are 18 years or older at
time of admission for food insecurity,
housing instability, transportation
needs, utility difficulties, and
interpersonal safety. To report on this
measure, hospitals will provide: (1) The
number of inpatients admitted to the
hospital who are 18 years or older at
time of admission and who are screened
for all 558 of the five HRSNs: Food
insecurity, housing instability,
transportation needs, utility difficulties,
and interpersonal safety; and (2) the
total number of patients who are
admitted to the hospital who are 18
years or older on the date they are
admitted.
The Screening for Social Drivers of
Health (MUC21–136) measure was
included in the publicly available ‘‘List
of Measures Under Consideration for
December 1, 2021’’ (MUC List).559 The
MAP Rural Health Workgroup and the
Health Equity Advisory Group reviewed
the measure on December 8, 2021, and
December 9, 2021, respectively. Both
groups indicated that screening for
social risk factors would inform future
efforts to expand capabilities to capture
data that demonstrate the extent to
which improvements in healthcare
quality contribute to reductions in
health disparities and the impact of
serving patients at higher risk for
adverse health outcomes on healthcare
quality at the organization level.
Although MAP stakeholders expressed
concerns regarding standardization and
the need to emphasize the link between
the measure and better healthcare
outcomes for patients, the measure
developer stated that the focus at this
point was to establish standard social
drivers of health screening measures
and not to dictate to hospitals and
providers which tool they use or how to
address the needs of their patients,
citing that multiple CMS models have
demonstrated the feasibility of
implementing HRSN screening.
However, we acknowledge the value
and importance of tools which support
558 In the FY 2023 IPPS/LTCH PPS proposed rule
(87 FR 28502), we stated ‘‘for each of the five
HRSNs.’’ We have updated the preamble of the final
rule to state ‘‘for all five HRSNs’’ as per the measure
specifications and in alignment with the language
throughout the preamble.
559 Centers for Medicare & Medicaid Services.
(2021). List of Measures Under Consideration for
December 1, 2021. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96464.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
the interoperability of HRSN data and
encourage the use of health IT-enabled
assessment instruments with coded
questions. We also refer readers to
sections IX.E.5.b.(1).(g). where we
discuss measure reporting. The MAP
Health Equity Advisory Group majority
voted that this measure has potential or
high potential to have a positive impact
by decreasing health disparities. The
MAP Rural Health Workgroup majority
voted agreement or strong agreement
that this measure is suitable for use with
rural providers.
On December 15, 2021, the MAP
Hospital Workgroup reviewed the MUC
List, including the Screening for Social
Drivers (MUC21–136) measure. The
MAP Hospital Workgroup discussion
was similar to that of the MAP Health
Equity Advisory Group and MAP Rural
Health Workgroup, and ultimately voted
to conditionally support the measure
pending NQF endorsement. On January
19, 2022, the MAP Coordinating
Committee reviewed the MUC List
including the Screening for Social
Drivers of Health (MUC21–136) measure
and voted to uphold the MAP Hospital
Workgroup recommendation of
conditional support for rulemaking.560
We intend to submit this measure in
future for NQF endorsement. We note
that under section
1866(b)(3)(B)(viii)(IX)(aa) of the Act,
each measure specified by the Secretary
shall be endorsed by the entity with a
contract under section 1890(a) of the
Act (the NQF is the entity that currently
holds this contract). Under section
1886(b)(3)(B)(viii)(IX)(bb) of the Act, in
the case of a specified area or medical
topic determined appropriate by the
Secretary for which a feasible and
practical measure has not been endorsed
by the entity with a contract under
section 1890(a) of the Act, the Secretary
may specify a measure that is not so
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary.
We reviewed NQF-endorsed measures
and were unable to identify any other
NQF-endorsed measures on this this
topic, and, therefore we believe the
exception in section
1886(b)(3)(B)(viii)(IX)(bb) of the Act
applies.
Measure specifications for this
measure are available on the QualityNet
website at: https://qualitynet.cms.gov
(or other successor CMS designated
websites).
560 National Quality Forum. (2022). Measure
Applications Partnership (MAP) 2021–2022 Final
Recommendations. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96698.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
49207
(g) Data Submission and Reporting
We are finalizing voluntary reporting
of the Screening for Social Drivers of
Health measure beginning with the CY
2023 reporting period, followed by
mandatory reporting on an annual basis
beginning with the CY 2024 reporting
period/FY 2026 payment determination
and for subsequent years.
Due to variability across hospital
settings and the populations they serve,
we are allowing hospitals flexibility
with selection of tools to screen patients
for food insecurity, housing instability,
transportation needs, utility difficulties,
and interpersonal safety.
Potential sources of these data could
include, for example, administrative
claims data, electronic clinical data,
standardized patient assessments, or
patient-reported data and surveys.
Multiple screening tools exist and many
hospitals already have screening tools
integrated into their electronic health
records (EHRs). We suggest hospitals
refer to the Social Interventions
Research and Evaluation Network
(SIREN) website, for example, for
comprehensive information about the
most widely used HRSN screening
tools.563 564 SIREN contains descriptions
of the content and characteristics of
various tools, including information
about intended populations, completion
time, and number of questions.
We note that providers participating
in the Hospital IQR Program must use
certified EHR technology (CEHRT) that
has been certified to the 2015 Edition of
health IT certification criteria under the
Office of the National Coordinator for
Health Information Technology (ONC)
Health IT Certification Program, and
extraction of structured data from a
certified EHR can make the data more
accessible for utilization and
submission for quality measurement
reporting (86 FR 45383). Use of certified
health IT can also support capture of
HRSN information in an interoperable
fashion so that this data can be shared
across the care continuum to support
coordinated care. For instance, in the
2020 ONC 21st Century Cures Act final
rule, ONC adopted a new framework for
the core data set which certified health
IT products must exchange, called the
United States Core Data for
Interoperability (USCDI) (85 FR 25669).
Version 2 of the USCDI, published in
July 2021, included new data classes for
social determinants of health (SDOH).
These include standards to capture
561 In the FY 2023 IPPS/LTCH PPS proposed rule
(87 FR 28502), we stated ‘‘one or all of the following
five HRSNs.’’ We have updated the preamble of the
final rule in this instance to state ‘‘all five HRSNs’’
as per the measure specifications and in alignment
with the language throughout the preamble.
562 In the FY 2023 IPPS/LTCH PPS proposed rule
(87 FR 28502), we stated ‘‘one or all of the following
five HRSNs.’’ We have updated the preamble of the
final rule in this instance to state ‘‘all five HRSNs’’
as per the measure specifications and in alignment
with the language throughout the preamble.
563 Social Interventions Research & Evaluation
Network. (2019). Social Needs Screening Tool
Comparison Table. Available at: https://
sirenetwork.ucsf.edu/tools-resources/resources/
screening-tools-comparison. Accessed January 18,
2021.
564 The Social Interventions Research and
Evaluation Network (SIREN) at University of
California San Francisco was launched in the spring
of 2016 to synthesize, disseminate, and catalyze
research on the social determinants of health and
healthcare delivery.
(c) Cohort
The Screening for Social Drivers of
Health measure assesses the total
number of patients, aged 18 years and
older, screened for social risk factors
(specifically, food insecurity, housing
instability, transportation needs, utility
difficulties, and interpersonal safety)
during a hospital inpatient stay. The
measure cohort includes patients who
are admitted to an inpatient hospital
stay and are 18 years or older on the
date of admission.
(d) Numerator
The numerator consists of the number
of patients admitted to an inpatient
hospital stay who are 18 years or older
on the date of admission and are
screened for all 561 of the following five
HRSNs: Food insecurity, housing
instability, transportation needs, utility
difficulties, and interpersonal safety
during their hospital inpatient stay.
(e) Denominator
The denominator consists of the
number of patients who are admitted to
a hospital inpatient stay and who are 18
years or older on the date of admission.
The following patients will be excluded
from the denominator: (1) Patients who
opt-out of screening; and (2) patients
who are themselves unable to complete
the screening during their inpatient stay
and have no legal guardian or caregiver
able to do so on the patient’s behalf
during their inpatient stay.
(f) Measure Calculation
The Screening for Social Drivers of
Health measure will be calculated as the
number of patients admitted to an
inpatient hospital stay who are 18 years
or older on the date of admission
screened for all 562 five HRSNs (food
insecurity, housing instability,
transportation needs, utility difficulties,
and interpersonal safety) divided by the
total number of patients 18 years or
older on the date of admission admitted
to the hospital.
PO 00000
Frm 00429
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
49208
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
SDOH Problems/Health Concerns,
SDOH Interventions, SDOH Goals, and
SDOH Assessments. ONC recently
published USCDI Version 3, which
maintains the SDOH elements in
Version 2 while adding additional data
elements.565 While adoption of USCDI
Version 2 is not a requirement for ONC
Health IT Certification at this time,
under ONC’s Standards Version
Advancement Process,566 developers of
certified health IT may upgrade their
certified health IT products to USCDI
Version 2 to support the availability of
information about social drivers of
health. Version 3 will also be
considered under the SVAP process.
Additional stakeholder efforts are
underway to expand capabilities to
capture additional social determinants
of health data elements include
initiatives such as the Gravity Project 567
to identify and harmonize social risk
factor data for interoperable electronic
health information exchange. We note
these various efforts and encourage use
of tools that will meet information
exchange standards and facility
interoperability. We also encourage
providers to identify and utilize tools
that rely on standards-based approaches
to data collection and utilization to
support interoperability of these data.
Hospitals are required to submit
information for structural measures
once annually using a CMS-approved
web-based data collection tool available
within the Hospital Quality Reporting
(HQR) System (previously referred to as
the QualityNet Secure Portal). We refer
readers to section IX.E.10. of the
preamble of this final rule (Form,
Manner, and Timing of Quality Data
Submission) for more details on our
previously finalized data submission
and deadline requirements across
measure types, and specifically, section
IX.E.10.i. for our data and submission
requirements for structural measures.
We invited public comment on this
proposal.
We note to readers that due to the
complementary nature of the Screening
for Social Drivers of Health and the
Screen Positive Rate for Social Drivers
of Health, most of the public comments
received were indicated as applicable
for both measures. We are summarizing
and responding to those comments
565 Office of the National Coordinator for Health
IT. (2022). United States Core Data for
Interoperability, Version 3 (July 2022). Available at:
https://www.healthit.gov/isa/sites/isa/files/2022-07/
USCDI-Version-3-July-2022-Final.pdf.
566 Office of the National Coordinator for Health
IT. (2022). Standards Version Advancement
Process. Available at: https://www.healthit.gov/
topic/standards-version-advancement-process-svap.
567 See https://thegravityproject.net/.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
relevant to the Screening for Social
Drivers of Health first and then
providing a summary and responses to
both measures afterwards. Comments
specifically about the Screen Positive
Rate for Social Drivers of Health
measure are in the subsequent section.
Comment: Many commenters
emphasized support for requiring
screening and reporting for all five
HRSN domains, including housing
instability, food insecurity,
transportation needs, utility difficulties,
and interpersonal safety. A few
commenters expressed support for the
measure but requested that we confirm
their understanding that the measure as
specified requires hospitals to screen for
all five HRSNs.
Response: We thank the commenters
for their support and confirm that
hospitals would screen for all five
HRSN domains. We note that there were
two instances in the preamble of the FY
2023 IPPS/LTCH PPS proposed rule in
which we made a technical error by
inconsistently stating screening for ‘‘one
or all’’ of the five HRSNs (87 FR 28502
and 87 FR 28503; sections
IX.E.7.b.(1).(d). and IX.E.7.b.(1).(f).). The
language should have indicated that this
measure requires screening for all five
HRSNs as per the measure
specifications that we referred to
throughout the preamble of the
proposed rule (87 FR 28497) and as
reviewed as part of the MUC review
process.568 We have now updated and
footnoted these two instances in the
preamble of this final rule and clarify
here that this measure requires that
patients be screened for all five HRSNs.
Comment: Many commenters
supported our proposal to adopt the
Screening for Social Drivers of Health
measure beginning with voluntary
reporting for the CY 2023 reporting
period and mandatory reporting
beginning with the CY 2024 reporting
period/FY 2026 payment determination
and for subsequent years. Specifically,
many commenters applauded this
proposal as one of the first patientcentered quality measures that will
allow health systems and care providers
to use a data-driven approach to account
for the impact of drivers of health on
patient health outcomes and healthcare
access, including illness complexity,
variations in severity, and resource
utilization. Several commenters
expressed their belief that adoption of
this measure, together with the Screen
Positive Rate for Social Drivers of
568 National Quality Forum. Measure
Applications Partnership Hospital Workgroup
(2021). Virtual Review Meeting Summary available
at: https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96629.
PO 00000
Frm 00430
Fmt 4701
Sfmt 4700
Health measure, will improve health
outcomes and healthcare costs. Some
commenters stated that adopting both
Social Drivers of Health measures could
lay the foundation for future policy
initiatives that will increase equitable
access to healthy foods, safe and
affordable housing, safe physical
environments, and affordable
healthcare.
Response: We thank commenters for
their support of the Screening for Social
Drivers of Health measure. We
appreciate all of the comments and
interest in this important topic. Public
input is very valuable in the continuing
development of our health equity
quality measurement efforts and broader
commitment to health equity. We agree
that this measure, in combination with
the Screen Positive Rate for Social
Drivers of Health measure, will be a
significant first step towards addressing
the role of HRSNs in improving health
equity, one of our quality improvement
goals.
Comment: Many commenters
expressed support for the measure and
applauded what they believe is a
necessary step towards accounting for
the role of drivers of health in persistent
health disparities that perpetuate the
health equity gap and inflate healthcare
costs for populations that have been
historically underserved. Many
commenters supported the adoption of
the measure, noting it would enable
healthcare providers and other
healthcare professionals to take a datadriven approach to identifying
important social risk factors and unmet
needs among under-resourced
populations across settings. Several
commenters referenced the role the
COVID–19 pandemic has played in
magnifying pre-existing disparities in
drivers of health and their impact on
health outcomes and healthcare access
among historically underserved
populations in the U.S. Some
commenters identified specific
opportunities for drivers of health data
to enhance care continuity that is
essential for under-resourced
population groups. A commenter
recommended we start drivers of health
screening in vulnerable populations
first.
Response: We thank the commenters
for their support of the measure and the
input shared on its utility. We agree
with commenters that drivers of health
data are a critical first step towards
accounting for the profound influence
these factors have on health outcomes,
especially in patient groups that
experienced the disproportionate effects
of the COVID–19 pandemic, healthcare
providers who deliver care to groups
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
who have been historically underserved
by the healthcare system, and
ultimately, the costs associated with
health disparities. We are committed to
closing the health equity gap and this
measure is a step towards that goal. The
five HRSN domains are derived from a
robust evidence base that has
demonstrated over time both direct
correlations between these drivers of
health and patient outcomes and
significant benefits associated with
relevant interventions (87 FR 24898).
We expect the data captured by this
measure will inform meaningful and
sustainable solutions for other providertypes through similar data collection in
other quality reporting programs. While
we appreciate the recommendation to
address screening in populations who
have been historically underserved by
the healthcare system first, we believe
national implementation of this measure
in conjunction with the Screen Positive
Rate for Social Drivers of Health
measure will allow us to more
accurately identify those hospital
communities where there may be higher
rates of patients who indicate one or
more of the five HRSNs.
Comment: Several commenters
supported our proposal, noting their
belief that the measure will advance
CMS’ strategic pillars, specifically
relative to advancing health equity.
Some commenters viewed adoption of
this measure as an initial, necessary,
and logical outgrowth from CMS’
strategic pillar around health equity
because it will address the interactions
between social conditions and health
outcomes on a broad scale and facilitate
true care continuity for patients
experiencing the impact of drivers of
health. Some commenters noted the
measure presents opportunity for
alignment across public and private
quality performance measurement,
potential to inform healthcare benefit
design across systems of care and
payment programs, and alignment with
the CY 2023 Medicare Advantage and
Part D rule and the Accountable Care
Organization Realizing Equity, Access,
and Community Health (ACO REACH)
Model, both of which they note include
requirements for including drivers of
health in enrollee health risk
assessments.
Response: We thank the commenters
for their support and appreciate their
input. We agree that drivers of health
data will account for critical factors that
impact patient outcomes and,
consequently, quality performance. We
believe HRSN screening will help
healthcare professionals to explain the
direct relationship between HRSNs and
poor health outcomes and also
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
49209
strengthen collaboration between
hospitals and community-based service
providers. Further, we believe this data
collection will inform meaningful and
sustainable solutions for other provider
types through similar collections in
other quality reporting programs (87 FR
28501). We also agree that this measure
aligns with proposals included in the
CY 2023 Medicare Advantage and Part
D rule (82 FR 27726) and the ACO
REACH Model 569 as they both included
proposals with a focus on inclusion of
drivers of health and promotion of
health equity.
Comment: Many commenters
supported our proposal to adopt this
measure, noting it would help support
efforts to connect patients with relevant
community resources, which in turn
could interrupt the downstream effects
of poor health outcomes and ultimately
generate cost savings associated with
healthcare delivery. Several commenters
emphasized that adoption of the two
Social Drivers of Health measures will
support hospitals and health systems in
addressing health disparities by
encouraging meaningful collaboration
with existing community-based
organizations and guiding future public
and private resource allocation to
enhance these partnerships. Many
commenters acknowledged that the
measure data can be leveraged to
support investments in and linkage to
community resources; for example,
building closed-loop referrals that link
patients, healthcare providers, and
community resources. A commenter
identified community-based
organizations and federally qualified
health centers (FQHCs) as priority
recipients of referral capacity-building
resources from CMS. A commenter
noted that the proposal will contribute
to innovations in health and social care
delivery.
Response: We thank the commenters
for their feedback and support. We agree
with commenters that availability of
drivers of health quality data will
potentially identify innovative
opportunities to support enhanced
availability of community resources to
meet the needs identified by both these
Social Drivers of Health quality
measures. We share the commenters’
belief that this measure could support
efforts to connect patients in need with
community resources.
Comment: Some commenters
identified promotion and support for
healthy aging as a potential benefit of
adopting this measure. A few
commenters described how the burdens
experienced by patients with HRSNs
often extend to caregivers. Some
commenters expressed particular
support for the emphasis this measure
would place on food insecurity, given
the direct association between food
insecurity and chronic disease risk,
healthcare utilization, and adverse
health outcomes.
Response: We agree and thank the
commenters for their support. We agree
that HRSNs often extend to caregivers
and other household members. We refer
readers to our Caregiver Partners
Workgroup which works to build
bridges with caregiver organizations,
both federal and non-federal, to better
serve Americans in need with national
and local resources to assist in their
caregiving efforts.570 We also refer
readers to section IX.E.5.f. of the
preamble of this final rule in which we
discuss our proposal to adopt the Global
Malnutrition Composite Score eCQM.
Comment: Many commenters noted
that physicians are held clinically and
financially accountable for patient
outcomes without consideration of the
extensive toll that HRSNs take on health
outcomes over time. Several
commenters believed the COVID–19
pandemic was instrumental in revealing
the impact of health disparities on
physician burnout, especially among
providers who primarily deliver
healthcare in communities that have
been historically under-resourced.
Several commenters supported our
proposal to adopt the measure believing
it could provide data that could be used
to modify risk adjustment performance
and payment standards to reflect more
accurately the role of HRSNs in
contributing to poor health outcomes
and associated costs. A commenter
described the dilemma of providing care
to patients with significant unmet
HRSNs and subsequent financial
penalization for poor health outcomes
as ‘‘psychic risk’’ that contributes to
physician burnout. Some commenters
noted their expectation that by
facilitating investments in community
resources, adoption of both Social
Drivers of Health measures may reduce
healthcare provider burden.
Response: We appreciate the
commenters’ feedback and acknowledge
the burden that many healthcare
providers experience in providing care
to patients with significant drivers of
health needs. Healthcare providers face
569 Centers for Medicare & Medicaid Services.
ACO REACH. (Accessed July 19, 2022). Available
at: https://innovation.cms.gov/innovation-models/
aco-reach.
570 Centers for Medicare & Medicaid Services.
(2022). Caregiver Partners. Available at: https://
www.cms.gov/Outreach-and-Education/Outreach/
Partnerships/Caregiver.
PO 00000
Frm 00431
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49210
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
the challenges of trying to meet complex
patient needs while being tasked with
achieving quality performance
standards that inevitably are impacted
by their patients’ unmet needs. We are
committed to developing a better
understanding of the role that drivers of
health play in patient outcomes and
hospital and physician quality
performance. This measure is a first step
towards achieving greater health equity
and we recognize the central roles that
hospitals and healthcare providers will
continue to play in creating sustainable
improvements in our quality programs.
Comment: Several commenters
expressed support for the measure but
requested we extend the proposed
voluntary reporting period and delay
mandatory reporting. Commenters cited
a number of specific reasons, including:
Operational complexity of developing
new data collection and reporting
protocols as well as revising workflows
and training staff, ongoing constraints
related to the COVID–19 PHE, and other
resource limitation challenges such as
addressing the numerous EHR-related
reporting requirements. A commenter
recommended we implement the
measures over a longer period of time to
ensure that resources to support health
equity advancement result in improved
health outcomes and avoid eroding
patient trust in the healthcare system.
A commenter recommended further
measure development prior to
implementation to allow time for
determination of data collection
requirements. Several commenters did
not support adoption of the measure,
noting their belief that the CY 2024
reporting period/FY 2026 payment
determination timeline for mandatory
reporting would be too soon for
generating reliable baseline data, and
instead recommended extending the
voluntary reporting period and delaying
the mandatory reporting period. A
commenter believed the proposed
timeline for implementation will be
inadequate for hospitals despite the
proposed flexibilities.
Response: We thank the commenters
for their support and feedback. We
appreciate their concerns about the
operational complexity of introducing
drivers of health quality measures into
existing clinical workflows and EHR
systems. While we agree
implementation of these two Social
Drivers of Health measures will be a
major undertaking for some providers,
especially given the ongoing COVID–19
PHE, we also recognize that the COVID–
19 PHE magnified the disproportionate
burden of drivers of health on
communities who have been historically
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
under-resourced.571 Beginning to collect
the data remains imperative as we
continue to build on our strategic pillar
to advance health equity by addressing
the health disparities that underlie our
health system. We have therefore
determined that the proposed voluntary
and mandatory reporting periods
prioritize the urgency of capturing
drivers of health data and taking
actionable steps towards closing the
health equity gap. As stated in the
proposed rule, potential sources of these
data could include, for example,
administrative claims data, electronic
clinical data, standardized patient
assessments, or patient-reported data
and surveys (87 FR 28503).
Additionally, we note that 92 percent of
hospitals already screen for one or more
of the five HRSNs—food insecurity,
housing instability, transportation
needs, utility difficulties, and
interpersonal safety—specified in the
proposed measures (87 FR 28498). We
believe that this is a strong indication
that hospitals have processes in place to
conduct the screening required.
Comment: A commenter
recommended we require mandatory
reporting without delay to encourage
hospitals with existing screening
capabilities to start data collection.
Response: We thank the commenter
for this feedback. We believe the
voluntary reporting period will be
necessary for some hospitals as they
integrate this measure specifications
into their workflow. We encourage
hospitals that already have such
capacity and processes in place to
initiate screening at the start of the
voluntary period.
Comment: A few commenters
supported the measure but
recommended it not be included in the
Hospital IQR Program. A commenter
believed the measure would achieve its
intended purpose in the Hospital
Outpatient Quality Reporting (OQR)
Program instead. A commenter was
concerned about the inclusion of this
structural measure in quality
performance programs.
Response: We thank the commenters
for their recommendation, but we
respectfully disagree that the proposed
measure is not suited for the Hospital
IQR Program. We believe this measure,
alongside the Screen Positive Rate for
Social Drivers of Health measure, serves
571 Centers for Disease Control and
Prevention.(2020). CDC COVID–19 Response Health
Equity Strategy: Accelerating Progress Towards
Reducing COVID–19 Disparities and Achieving
Health Equity. July 2020. Available at: https://
www.cdc.gov/coronavirus/2019-ncov/community/
health-equity/cdc-strategy.html. Accessed
November 17, 2021.
PO 00000
Frm 00432
Fmt 4701
Sfmt 4700
as a key first step in measuring and
promoting quality improvement in the
care delivered by hospitals in inpatient
settings and will additionally encourage
hospitals to collaborate with
community-based organizations as part
of discharge planning and implement
closed-loop referrals that will more
adequately address unmet social needs
that drive hospital readmissions and
diminished health outcomes following
hospitalization. Given that individuals
with high HRSNs also have greater
healthcare needs that result in
hospitalization, we believe the proposed
Screening for Social Drivers of Health
measure is appropriate for the
measurement of the quality of care
furnished by hospitals in inpatient
settings. Moreover, hospital
accountability for screening is a critical
step towards eliminating health
disparities in health outcomes among
populations that have been historically
underserved by the healthcare system.
Comment: A commenter requested
clarification of how hospitals will report
the Screening for Social Drivers of
Health data.
Response: We appreciate the
commenter’s request for clarification. In
the proposed rule, we describe the
measure specifications and data
submission requirements, which can be
found at https://qualitynet.cms.gov/
inpatient/iqr/resources (87 FR 28502).
Hospitals are required to submit
information for structural measures
once annually using a CMS-approved
web-based data collection tool available
within the HQR System (87 FR 28503).
We also refer readers to section IX.E.10.
of the preamble of this final rule (Form,
Manner, and Timing of Quality Data
Submission) for more details on our
previously finalized data submission
and deadline requirements across
measure types, and specifically, section
IX.E.10.i. for our data and submission
requirements for structural measures.
Comment: Several commenters
commented on our flexibility with
screening tool selection. Several
commenters supported this flexibility.
Several commenters recommended we
require hospitals take a standardized
screening approach to implementing
drivers of health assessments. A
commenter believed that requiring
standardized screenings would allow for
more valid comparisons between
hospitals.
A commenter supported the measure
and emphasized the importance of
allowing flexibility in screening tool
selection until more is understood about
data capture. A few commenters
recommended we encourage hospitals
to use validated, widely-accepted
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
screening instruments to ensure data
reliability and comparability to inform
risk adjustment and further policy
development. A commenter
recommended we prioritize high-quality
screening over volume of screening and
track the number of patients who are
linked to community-based resources to
promote capacity-building for
collaboration. A commenter
recommended we clearly define
screening to ensure active screening of
drivers of health directly with the
patient. Some commenters supported
establishment of drivers of health
screening but did not support the
proposed approach of allowing
hospitals flexibility with tool selection.
A few commenters believed this
flexibility will produce results that are
not reliable and questioned whether
there would be adequate denominator
sizes to calculate reliable and valid
comparisons.
Response: We appreciate all the
commenters’ support and input on the
use of a screening tool. We share the
enthusiasm of many of the commenters
about the potential for improving
quality of care and advancing health
equity by addressing the unmet social
needs of hospital patients. We agree that
allowing hospitals flexibility with tool
selection is a tradeoff, but, as we
discussed previously, we believe it is
necessary to allow hospitals flexibility
because this measure is the first step in
what we see as a longer journey to
address unmet needs. This is the first
time we will be collecting drivers of
health screening data as part of quality
performance measurement and we want
to ensure that all hospitals are working
towards initial screening, in a form that
works for them. As we indicated
previously, health equity is a key
priority and we intend to continue to
develop relevant measures. We
recognize that hospitals often employ
different strategies for screening for
social needs across their patient
populations. As such, in the FY 2023
IPPS/LTCH PPS proposed rule, we
noted that hospitals pursuing this
quality measure may use a self-selected
screening instrument, which can vary to
accommodate the population they serve
and their individual needs, and that
social needs data collected to satisfy this
quality measure could include, for
example, administrative claims data,
electronic clinical data, standardized
patient assessments, or patient-reported
data and surveys (87 FR 28501). We also
encouraged standards-based approaches
to data collection and utilization to
support interoperability of these data
(87 FR 28503).
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
We are sensitive to the concerns
raised by some commenters about the
lack of standardization across screening
instruments or data collection practices,
and the challenges this may introduce
in the consistency of the information
collected across hospitals. While we
acknowledge the potential benefits of a
single screening instrument or
prescribed set of standards, we also
recognize the benefits of providing
hospitals with flexibility to customize
screening and data collection to their
local community contexts and patient
populations, especially in the initial
stages of implementing screening
protocols.
Currently, we intend to continue
providing hospitals with flexibility
regarding the selection of tools to screen
patients. However, we anticipate
additional emphasis on standardized
and validated screening instruments in
future versions of this measure. We
encourage hospitals to prioritize
screening tools that have undergone
adequate testing to ensure they are
accurate and reliable. We believe that
this measure should promote highquality screening practices which,
among other things, ensure accurate
identification of unmet social needs. We
look forward to additional input from
stakeholders on this topic.
We also recognize that digital data
collection is a necessary path for
effective and efficient measurement. As
part of our Meaningful Measures 2.0
Framework 572 we aim to further shape
the entire ecosystem of quality measures
that promote innovation and
modernization of all aspects of quality.
A priority of the Meaningful Measure
2.0 Framework is transforming measures
to improve quality measure efficiency
by transitioning to digital measures and
using advanced data analytics. We aim
to transform to all digital quality
measures, accelerate development of
and testing electronic clinical quality
measures using FHIR API technology for
transmitting and receiving quality
measurement, transform data collection
to use FHIR API technology, and
leverage centralized data analytic tools
to examine programs and measures.
Currently, to the extent possible, we
encourage hospitals to use certified
health IT that can also support capture
and exchange of drivers of health
information in a structured and
interoperable fashion so that these data
can be shared across the care continuum
to support coordinated care. We
anticipate additional emphasis on data
collection using certified health IT in
572 We note that Meaningful Measures 2.0 is still
under development.
PO 00000
Frm 00433
Fmt 4701
Sfmt 4700
49211
future versions of this measure. We will
continue to take all concerns,
comments, and suggestions into account
for future development and expansion
of this measure. We agree that allowing
hospitals flexibility with tool selection
is a tradeoff. This is the first time we
will be collecting drivers of health
screening data as part of quality
performance measurement. We believe
allowing hospitals flexibility during this
initial first step will further enable them
to adopt solutions that use structured
EHR data elements to reflect patients’
drivers of health status. We are taking
commenters’ recommendations under
consideration to inform future noticeand-comment rulemaking.
We are taking commenters’
recommendations under consideration
to inform future notice-and-comment
rulemaking.
Comment: Several commenters
supported screening for drivers of
health but expressed concerns regarding
individual patient rights and
transparency. A commenter
recommended that patients be granted
flexibility with timing of screening
completion and adequate privacy is
provided to the patient in the process.
A commenter noted patients and
families should be clearly informed that
they can opt-out of screening and that
their decision would not affect their
care. A commenter recommended that
the language and documentation of
HRSNs in patient health records be nonstigmatizing and free of bias.
Specifically, the commenter noted
screening should not be included in
hospital visit charges and that patients
should be informed of the right to optout of screening. A commenter
recommended we consider providing
hospitals with comparative opt-out rates
to provide benchmarks for individual
hospitals to understand their own optout rates.
Response: We thank the commenters
for their input. We underscore that
patients and families will be able to optout of screening. Specifically, the
measure specifications as proposed state
that the following patients would be
excluded from the denominator: (1)
Patients who opt-out of screening; and
(2) patients who are themselves unable
to complete the screening during their
inpatient stay and have no legal
guardian or caregiver able to do so on
the patient’s behalf during their
inpatient stay (87 FR 28502). As
discussed earlier, this measure does not
require use of a specific screening tool.
During measure development, we gave
commenters’ concerns significant
consideration. As we noted in the FY
2023 IPPS/LTCH PPS proposed rule, we
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49212
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
recommend that hospitals incorporate
inclusive language in their screening
activities to address this potential
concern among patient and caregiver
respondents (87 FR 28505). We strongly
recommend that hospitals incorporate
inclusive language in their screening
activities to reassure patients that
whether they choose to opt-out or
answer the screenings, the information
provided would not be used to
stigmatize patients or reduce their
healthcare benefits. We defer to
hospitals to make the appropriate
disclosures to their patients regarding
how the collected data are used as well
as ensuring that the patient and their
caregiver(s) are informed of their option
to opt-out of screening. Commenters’
input is very valuable to our continuing
development of health equity quality
measurement and our aims to address
the impact of HRSNs on healthcare
access, utilization, outcomes, and costs.
Comment: A few commenters
expressed concern regarding hospital
staff training, recommending that staff
members who conduct screening and
follow-up on the results are adequately
trained. A few commenters
recommended delegating screening
duties to frontline hospital workers who
may have demographic congruence with
patients.
Response: We thank the commenters
for their input and agree that staff
training on culturally sensitive
engagement and trauma-centered care
would be helpful. Throughout the FY
2023 IPPS/LTCH PPS proposed rule (87
FR 25498 through 25504), we referred to
the performance evaluation of the AHC
Model which reported utilization of
multiple staffing models that could be
adapted to meet the specific workflow
needs of participating providers, which
allowed providers to optimize resources
to complete screening, navigation, and
reporting requirements.573 AHC Model
organizations developed and provided
structured, systematic training for staff
in screening, referral, and navigation
roles.574 Most used routine training
approaches that included presentations
(in person or online), experienced staff
shadowing, role-playing of routine and
challenging activities, staff performance
reviews, and coaching. Quality was
ensured through observing screening or
navigation encounters, monitoring
number of screenings completed, and
tracking navigation follow-up. Many
organizations also used innovative
573 RTI International. (2020). Accountable Health
Communities (AHC) Model Evaluation. Available
at: https://innovation.cms.gov/data-and-reports/
2020/ahc-first-eval-rpt.
574 Ibid.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
training strategies they believed were
particularly effective. The training
strategies included trauma-informed
care, racial inequity and cultural
competency training, motivational
interviewing, and patient engagement.
Based on the experiences of AHC
Model participating providers, we
believe staff training is feasible, tools
and resources are available, and the
benefits of such trainings could apply
beyond the activity of screening for
HRSNs. As we discussed in the FY 2023
IPPS/LTCH PPS proposed rule, 92
percent of hospitals are already
screening for one or more of the five
HRSNs (87 FR 28498). And while only
24 percent are screening for all five
HRSNs (87 FR 28498), we believe this
data is a strong indication that screening
is occurring in the inpatient hospital
setting. We encourage hospitals to
ensure staff are adequately trained to
conduct screenings.
Comment: Some commenters
expressed concerns about the timeline
for screening in the hospital setting. A
commenter requested clarification on
whether screening must take place
during each hospital admission,
especially if screening has already been
completed and data captured in the EHR
during outpatient visits that occurred
during the measure performance period.
A few commenters noted that screening
at the time of admission may not be
feasible due to the patient’s physical
state and medical staff members’ focus
on stabilization. Some commenters
noted screening may introduce undue
burden to patients. A commenter
recommended annual distinct patient
screening. A few commenters
recommended we permit hospitals to
utilize drivers of health screening data
previously documented in patient EHRs
from care provided in ambulatory
settings.
Response: We thank the commenters
for their feedback, questions, and
recommendations. We wish to clarify
for stakeholders that screening should
occur during the hospital stay as noted
in the Cohort section of the preamble of
the proposed rule in which we explain
that the measure assesses the total
number of patients 18 years and older,
screened for social risk factors during a
hospital inpatient stay (87 FR 28502).
We refer readers to the Data Submission
and Reporting section of the preamble of
the proposed rule in which we explain
that hospitals will have flexibility with
screening and that potential sources of
the drivers of health data could include,
for example, administrative claims data,
electronic clinical data, standardized
patient assessments, or patient-reported
data and surveys (87 FR 28503). For
PO 00000
Frm 00434
Fmt 4701
Sfmt 4700
patients frequently admitted to the
hospital due to chronic health
conditions which are exacerbated by
HRSNs, hospitals could confirm the
current status of any previously
reported drivers of health and inquire
about others not previously reported.
However, if this information has been
captured in the EHR in the outpatient
setting prior to repeat hospital
admission, it could be included in
hospital reporting of numerator and
denominator data, during the
performance measurement period. We
will continue evaluating screening
requirements in future notice-andcomment rulemaking.
Comment: Several commenters
expressed support for the measure but
recommended modifications and
refinements related to the proposed five
HRSN domains. Some commenters
recommended adding more domains in
addition to the five domains. A
commenter suggested eight additional
domains including financial strain,
employment status, family and
community support, education, physical
activity, substance use, mental health,
and disabilities. A commenter suggested
we allow for optional reporting of
additional domains to inform hospital
discharge planning and facilitate
linkages to community resources. A
commenter questioned whether the
utility difficulties domain would be
redundant and better suited as a
component of the housing instability
domain. A few commenters
recommended removal of the
interpersonal safety domain due to
uniquely sensitive considerations
associated with interpersonal safety
compared to the other four domains. A
commenter recommended CMS not
specify screening domains at all. A
commenter believed health systems
should be allowed to select additional
non-essential domains and their own
specific questions. A commenter
expressed concern that hospitals might
focus on domains and questions that
align with existing resources that are
already offered to patients with given
HRSNs. A commenter supported the
measure and recommended CMS
prioritize collection of self-reported
drivers of health data.
Response: We thank the commenters
for their support and appreciate their
acknowledgement of the relevance of
other drivers of health that influence
health outcomes and contribute to
persistent health disparities. We have
prioritized selection of the proposed
five HRSN domains based on existing
evidence from both the AHC Model,
including recommendations from a TEP
that informed the initial selection, and
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
emerging evidence of correlations
between given drivers of health and
worse health outcomes and/or drivers of
health for which interventions have
shown marked improvements in health
outcomes and healthcare utilization (87
FR 28498). We remind stakeholders that
the proposed measure is a first step
towards development of a long-term
strategy to integrate drivers of health
data into hospital quality performance
measurement and our broader
commitment to health equity. We
believe it is imperative that hospitals
screen for all five domains, irrespective
of resource availability.
Additionally, regarding the concern
that hospitals will focus on domains
that align with their existing resources,
we believe that each hospital best
understands the patient population they
serve. As they collect these data, we
hope that they can then best discern
whether they have existing resources to
meet their populations’ unmet needs or
dedicate further resources to a domain
beyond the five required HRSNs for
which they knew a need exists and now
have evidence of the extent that
resource allocation is necessary. In
addition, we highlight that the Hospital
IQR Program is a pay-for-reporting
program, and hospitals are not scored
based on their performance on
measures.
We thank the commenters for the
additional domain suggestions and we
will consider them as part of any
potential future modifications to these
measures or potential new measure
development in future notice-andcomment rulemaking.
Comment: Several commenters
expressed concern about the lack of
current NQF endorsement of the
proposed measure at the time of
proposed rule display. A few
commenters recommended we delay
adoption of the measure until NQF
endorsement is obtained.
Response: We have submitted this
measure for NQF review and the
decision is currently pending. Under
section 1886(b)(3)(B)(viii)(IX)(bb) of the
Act, in the case of a specified area or
medical topic determined appropriate
by the Secretary for which a feasible and
practical measure has not been endorsed
by the entity with a contract under
section 1890(a) of the Act, the Secretary
may specify a measure that is not so
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary.
We reviewed NQF-endorsed measures
and were unable to identify any other
NQF-endorsed measures on this topic,
and, therefore we believe the exception
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
49213
in section 1886(b)(3)(B)(viii)(IX)(bb) of
the Act applies. We note that the MAP
also voted to conditionally support this
measure for rulemaking (87 FR 28502).
Comment: Several commenters
recommended we use consistent
terminology when describing social risk
factors related to health outcomes.
Response: We thank the commenters
for this feedback. HRSNs, which we
have previously defined as individuallevel, adverse social conditions that
negatively impact a person’s health or
healthcare, are significant risk factors
associated with worse health outcomes
as well as increased healthcare
utilization (87 FR 28502). Conceptually,
HRSNs exist along a continuum with
other equity-related terms—such as
‘‘social determinants of health’’ and
‘‘social risk factors’’—used to describe
upstream factors that can adversely
affect the health of individuals and
communities (87 FR 28497).575 We agree
these terms are often conflated and even
used interchangeably, and the variety of
terms has created both confusion as well
as concern, prompting leaders in the
field to adopt ‘‘drivers of health’’
instead.576 In the future, we intend to
utilize ‘‘drivers of health’’ terminology
to more holistically capture
aforementioned and related concepts,
while minimizing potential
misinterpretation or negative
connotation.
Comment: Several commenters
expressed concerns regarding follow-on
resources not being readily available to
address the drivers of health for which
patients might screen positive. A few
commenters noted screening should not
occur for resources that are not easily
obtained.
Response: We thank the commenters
for their input and appreciate the
concerns noted. During development of
both proposed Social Drivers of Health
measures, we gave this topic significant
consideration. The intent of the two
measures is to promote adoption of
HRSNs screening by hospitals as well as
taking action to connect patients who
identify one or more HRSNs with
available resources (87 FR 28501).
Evaluation of the AHC Model concluded
that universal screening may identify
needs that would otherwise remain
undetected.577 While broad availability
of community-based resources that
address patients’ health-related social
needs would be ideal, we believe that
one of the benefits of screening data will
be identification of opportunities to
enable meaningful action, including
prioritizing and investing in such
resources (87 FR 28505). Beginning to
collect the data remains imperative and
such data collection has already allowed
some entities to reallocate resources to
address particular HRSNs that
disproportionately affect a given patient
population or geographic region.578
As we noted in the FY 2023 IPPS/
LTCH PPS proposed rule, this data
collection could inform meaningful and
sustainable solutions for other providertypes through similar collections in
other quality reporting programs (87 FR
28501). We believe this input is very
valuable in the continuing development
of the CMS health equity quality
measurement efforts and our aims to
acknowledge the impact of HRSNs on
healthcare access, utilization, outcomes,
and costs. We will continue to take all
concerns, comments, and suggestions
into account for any potential future
development and expansion of our
health equity quality measurement
efforts.
Comment: Several commenters
recommended we ensure alignment
with Project Gravity standards and
promote interoperability standards for
data collection. A few commenters
expressed concerns about
implementation due to existence of
other CMS initiatives that address social
drivers of health in patient assessments
and that this can create duplicative
performance measures, cause confusion,
and waste resources. A commenter
recommended harmonization of drivers
of health assessment approaches
between CMS and the National
Committee for Quality Assurance
(NCQA).
Response: We thank the commenters
for this feedback. We believe this data
collection will inform meaningful and
sustainable solutions for other provider
types through similar collections in
other quality reporting programs (87 FR
28501). We will continue identifying
opportunities for collaboration with
other stakeholders to align drivers of
health assessment across CMS
575 Institute of Medicine 2014. Capturing Social
and Behavioral Domains and Measures in
Electronic Health Records: Phase 2. Washington,
DC: The National Academies Press. Available at:
https://doi.org/10.17226/18951. https://
innovation.cms.gov/media/document/ahcmscreeningtool-companion.
576 https://www.healthaffairs.org/do/10.1377/
forefront.20210429.335599/.
577 RTI International. (2020). Accountable Health
Communities (AHC) Model Evaluation. Available
at: https://innovation.cms.gov/data-and-reports/
2020/ahc-first-eval-rpt.
578 National Quality Forum (2022). Measure
Applications Partnership. MAP 2021–2022
Considerations for Implementing Measures Final
Report—Clinicians, Hospitals, and PAC–LTC.
Available at: https://www.qualityforum.org/
Publications/2022/03/MAP_2021-2022_
Considerations_for_Implementing_Measures_Final_
Report_-_Clinicians,_Hospitals,_and_PACLTC.aspx.
PO 00000
Frm 00435
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49214
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
programs. We commend additional
stakeholder efforts currently underway
to expand capabilities to capture
additional drivers of health data
elements, including the Gravity
Project.579 We support harmonization of
social risk factor data for interoperable
electronic health information exchange
that will meet information exchange
standards (87 FR 28503).
We will continue building the
overarching strategy for integrating
social drivers of health screening into
hospital quality improvement and
future rulemaking, where appropriate.
We note that hospitals and CAHs
participating in the Hospital IQR and
Medicare Promoting Interoperability
Programs must use CEHRT that has been
certified to the 2015 Edition of health IT
certification criteria under the ONC
Health IT Certification Program, and
extraction of structured data from a
certified EHR can make the data more
accessible for utilization and
submission for quality measurement
reporting (86 FR 45383). Use of certified
health IT can also support capture of
HRSN information in an interoperable
fashion so that these data can be shared
across the care continuum to support
coordinated care. We note these various
efforts and encourage use of tools that
will meet information exchange
standards and facility interoperability
(87 FR 28503). We also encourage
providers to identify and utilize tools
that rely on standards-based approaches
to data collection and utilization to
support interoperability of these data.
Comment: Several commenters
recommended that we take an
incremental approach to using the
Screening for Social Drivers of Health
measure data.
Response: We thank the commenters
for their feedback and recommendations
for an incremental approach. In the
proposed rule, we stated that collecting
these baseline data via this measure
would be crucial in informing design of
future measures (87 FR 28502). If we
add any data use for risk adjustment of
the measure, we would do so in future
notice-and-comment rulemaking. As
noted previously, it would be ideal if
there were broad availability of
community-based resources that address
patients’ HRSNs such that we could
evaluate their impact on health
outcomes. However, the COVID–19 PHE
revealed the significant and
disproportionate burden of drivers of
health in historically underserved
communities. We believe that one of the
benefits of screening data will be
identification of opportunities to enable
579 https://thegravityproject.net/.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
meaningful action, including
prioritizing and investing in such
resources (87 FR 28505). We remain
hopeful that these actions will enhance
patient trust in the healthcare system
and trustworthiness of the system itself.
Comment: A commenter requested
that future public reporting and
payment adjustments correlate with care
delivered to avoid bias stemming from
local community sociodemographic
characteristics. A commenter
recommended that instead of requiring
low-resourced hospitals report on this
measure (who may not be able to
implement data collection and
workflow requirements), that we
consider incentivizing screening
instead.
Response: We note that the Hospital
IQR Program is a pay-for-reporting
program, and hospitals’ payments are
not based on their performance on
measures. We note that hospitals will
receive credit for the reporting of their
measure results regardless of patients’
responses to the questions. We refer
readers to section IX.E.5.b.(1).(g). of this
final rule for information on the
submission and reporting requirements
for this measure and to section IX.B. for
our request for information on the
Overarching Principles for Measuring
Healthcare Quality Disparities Across
CMS Quality Reporting Programs.
Comment: A commenter stated that
interpretation of the proposed measure
is challenging due to the absence of a
meaningful goal or benchmark for the
measure. The commenter believed if a
hospital reports very low positive screen
rates, this may indicate very low HRSNs
among the patient population, or, a high
level of mistrust and discomfort of
patients to disclose sensitive needs to
clinical staff.
Response: We thank the commenter
for this feedback, but we respectfully
disagree. We refer readers to the
Overview section in the preamble of the
proposed rule where we state, the
measure is intended to provide
information to hospitals on the level of
unmet social needs among patients
served and the extent to which these
factors impact quality measure
performance in the hospital inpatient
setting (87 FR 28505). The Screening for
Social Drivers of Health and Screen
Positive Rate for Social Drivers of
Health measures are closely related but
inform distinct measure results,
meaning it would be possible for a
hospital to have a high screening rate
and a lower screen positive rate, or a
low screening rate and higher screen
positive rate, in one or more of the five
domains.
PO 00000
Frm 00436
Fmt 4701
Sfmt 4700
Comment: Commenters offered
recommendations for future
consideration for our drivers of health
strategy. A commenter recommended
including the measure in other CMS
quality performance programs including
the Merit-based Incentive Payment
System (MIPS) and Outpatient Quality
Reporting programs, such as the
Hospital OQR Program. A commenter
recommended we conduct outreach
with voluntary reporters to assess data
collection processes and identify
potential challenges and determine the
extent to which the screening
information supports health equity
improvements. A commenter
recommended we conduct outreach to
hospitals to provide education on
available screening methods.
Response: We thank the commenters
for these recommendations and will
consider their input. The Social Drivers
of Health measures are the first of their
kind in CMS quality programs. Through
adoption of these measures in the
Hospital IQR Program, we encourage
hospitals to initiate screening if they
have not already done so. In the CY
2023 Physician Fee Schedule proposed
rule, we are also proposing to adopt the
Screening for Social Drivers of Health
measure for MIPS.580 Further, we
believe this data collection will inform
meaningful and sustainable solutions
for other provider types through similar
collections in other quality reporting
programs (87 FR 28501).
Comment: A commenter stated there
was a lack of evidence to support a
direct relationship between drivers of
health screening and positive impact on
hospital quality performance because
this was not tested in the AHC Model.
Response: We appreciate the
commenter’s concern, but we
respectfully disagree. The two Social
Drivers of Health measures are derived
from existing evidence from both the
AHC Model 581 and emerging evidence
of correlations between the designated
drivers of health and higher healthcare
utilization of emergency departments
and hospitals, worse health outcomes
and/or drivers of health for which
interventions have shown marked
improvements in health outcomes and
health care utilization (87 FR 28498).
580 Currently on display at: https://
www.federalregister.gov/public-inspection/202214562/medicare-and-medicaid-programs-calendaryear-2023-payment-policies-under-the-physicianfee-schedule.
581 RTI International. (2020). Accountable Health
Communities (AHC) Model Evaluation. Available
at: https://innovation.cms.gov/data-and-reports/
2020/ahc-first-eval-rpt.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
(2) Screen Positive Rate for Social
Drivers of Health Measure
khammond on DSKJM1Z7X2PROD with RULES2
(a) Background
The impact of social risk factors on
health outcomes has been wellestablished in the literature.
582 583 584 585 586 The Physicians
Foundation reported that 73 percent of
the physician respondents to their
annual survey agreed that social risk
factors like housing instability and food
insecurity would drive health services
demand in 2021.587 As noted in the FY
2023 IPPS/LTCH PPS proposed rule (87
FR 28497 through 28506), recognizing
the need for a more comprehensive
approach to eliminating the health
equity gap, we have prioritized
development and implementation of
quality measures that will capture social
risk factors and facilitate assessment of
their impact on health outcomes and
disparities and healthcare utilization
and costs.588 589 590 Specifically, in the
582 Institute of Medicine 2014. Capturing Social
and Behavioral Domains and Measures in
Electronic Health Records: Phase 2. Washington,
DC: The National Academies Press. Available at:
https://doi.org/10.17226/18951.
583 Centers for Medicare & Medicaid Services.
(2021). Accountable Health Communities Model.
Accountable Health Communities Model | CMS
Innovation Center. Available at: https://
innovation.cms.gov/innovation-models/ahcm.
Accessed November 23, 2021.
584 Kaiser Family Foundation. (2021). Racial and
Ethnic Health Inequities and Medicare. Available
at: https://www.kff.org/medicare/report/racial-andethnic-health-inequities-and-medicare/. Accessed
November 23, 2021.
585 Milkie Vu et al. Predictors of Delayed
Healthcare Seeking Among American Muslim
Women, Journal of Women’s Health 26(6) (2016) at
58; Nadimpalli SB, Cleland CM, Hutchinson MK,
Islam N, Barnes LL, Van Devanter N. (2016) The
Association between Discrimination and the Health
of Sikh Asian Indians. Health Psychology, 35(4),
351–355. https://doi.org/10.1037/hea0000268.
586 Office of the Assistant Secretary for Planning
and Evaluation (ASPE). (2020). Report to Congress:
Social Risk Factors and Performance Under
Medicare’s Value-Based Purchasing Program
(Second of Two Reports). Available at: https://
aspe.hhs.gov/pdf-report/second-impact-report-tocongress.
587 The Physicians Foundation. (2020) 2020
Survey of America’s Patients, Part Three. Available
at: https://physiciansfoundation.org/wp-content/
uploads/2020/10/2020-Physicians-FoundationSurvey-Part3.pdf.
588 Alley, D.E., C.N. Asomugha, P.H. Conway, and
D.M. Sanghavi. 2016. Accountable Health
Communities–Addressing Social Needs through
Medicare and Medicaid. The New England Journal
of Medicine 374(1):8–11. Available at: https://
doi.org/10.1056/NEJMp1512532.
589 Centers for Medicare & Medicaid Services.
(2021). Accountable Health Communities Model.
Accountable Health Communities Model | CMS
Innovation Center. Available at: https://
innovation.cms.gov/innovation-models/ahcm.
Accessed November 23, 2021.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
inpatient setting, we aim to identify
patient HRSNs as part of discharge
planning with the intention of
promoting linkages with relevant
community-based services that will
address those needs and support
improvements in health outcomes
following hospitalization.
While the Screening for Social Drivers
of Health process measure (discussed
previously in section IX.E.5.b.(1).)
enables identification of individuals
with HRSNs, use of the Screen Positive
Rate for Social Drivers of Health
structural measure will allow us to
estimate the impact of individual-level
HRSNs on healthcare utilization,
including hospitalizations, when
evaluating quality of care.591 592 593 The
Screen Positive Rate for Social Drivers
of Health structural measure will
require the reporting of the resulting
screen positive rates for each domain.
Reporting the social drivers of health
screen positive rate for each domain
will inform actionable planning by
hospitals towards closing health equity
gaps and enable the development of
individual patient action plans
(including navigation and referral). We
believe this effort could yield actionable
information to close the health equity
gap in CMS programs and policies.
In the FY 2022 IPPS/LTCH PPS final
rule, we discussed ongoing
consideration of potential approaches
that could be implemented to address
health equity through the Hospital IQR
Program (85 FR 45414). As a result of
the feedback we received, we identified
the Screen Positive Rate for Social
Drivers of Health measure to help
inform efforts to address health equity.
This structural measure assesses the
percent of patients admitted to the
hospital who are 18 years or older at
time of admission who were screened
590 Billioux, A., Verlander, K., Anthony, S., &
Alley, D. (2017). Standardized Screening for HealthRelated Social Needs in Clinical Settings: The
Accountable Health Communities Screening Tool.
NAM Perspectives, 7(5). Available at: https://
doi.org/10.31478/201705b.
591 Baker, M.C., Alberti, P.M., Tsao, T.Y., Fluegge,
K., Howland, R.E., & Haberman, M. (2021). Social
Determinants Matter for Hospital Readmission
Policy: Insights From New York City. Health
Affairs, 40(4), 645–654. Available at: https://
doi.org/10.1377/hlthaff.2020.01742.
592 CMS. Accountable Health Communities
Model. Accountable Health Communities Model |
CMS Innovation Center. Available at: https://
innovation.cms.gov/innovation-models/ahcm.
Accessed November 23, 2021.
593 Hammond, G., Johnston, K., Huang, K., Joynt
Maddox, K. (2020). Social Determinants of Health
Improve Predictive Accuracy of Clinical Risk
Models for Cardiovascular Hospitalization, Annual
Cost, and Death. Circulation: Cardiovascular
Quality and Outcomes, 13 (6) 290–299. Available at:
https://doi.org/10.1161/
CIRCOUTCOMES.120.006752.
PO 00000
Frm 00437
Fmt 4701
Sfmt 4700
49215
for HRSNs and who screen positive for
one or more of the core HRSNs,
including food insecurity, housing
instability, transportation needs, utility
difficulties, or interpersonal safety
(reported as five separate rates).594 We
refer readers to section IX.E.5.b.(1).(a).
of the preamble of this final rule where
we previously discussed the CMS
identification process resulting in the
selection of these five domains.
The COVID–19 pandemic
underscored the overwhelming impact
that these five core domains have on
disparities, health risk, healthcare
access, and health outcomes, including
premature mortality.595 596 Adoption of
the Screen Positive Rate for Social
Drivers of Health structural measure
will encourage hospitals to track
prevalence of specific HRSNs among
patients over time and use the data to
stratify risk as part of quality
performance improvement efforts. This
measure may also prove helpful for
patients by providing data transparency
and signifying hospitals’ familiarity,
expertise, and commitment regarding
these issues. Evaluation of AHC Model
participation demonstrated positive
feedback and enhanced trust among
patients.597 This measure also has the
potential to reduce healthcare provider
burnout by systematically
acknowledging patients’ social needs
that contribute to adverse health
outcomes and linking providers with
community-based organizations to
enhance patient-centered treatment and
discharge planning.598 599 600 Finally, we
594 Billioux, A., Verlander, K., Anthony, S., &
Alley, D. (2017). Standardized Screening for HealthRelated Social Needs in Clinical Settings: The
Accountable Health Communities Screening Tool.
NAM Perspectives, 7(5). Available at: https://
doi.org/10.31478/201705b.
595 Kaiser Family Foundation. (2021). Racial and
Ethnic Health Inequities and Medicare. Available
at: https://www.kff.org/medicare/report/racial-andethnic-health-inequities-and-medicare/. Accessed
November 23, 2021.
596 Centers for Disease Control and Prevention.
(2019). CDC COVID–19 Response Health Equity
Strategy: Accelerating Progress Towards Reducing
COVID–19 Disparities and Achieving Health Equity.
July 2020. Available at: https://www.cdc.gov/
coronavirus/2019-ncov/community/health-equity/
cdc-strategy.html. Accessed November 17, 2021.
597 RTI International. (2020). Accountable Health
Communities (AHC) Model Evaluation. Available
at: https://innovation.cms.gov/data-and-reports/
2020/ahc-first-eval-rpt.
598 The Physicians Foundation. (2020). Survey of
America’s Patients, Part Three. Available at: https://
physiciansfoundation.org/wp-content/uploads/
2020/10/2020-Physicians-Foundation-SurveyPart3.pdf.
599 De Marchis, E., Knox, M., Hessler, D., WillardGrace, R., Oliyawola, JN, et al. (2019). Physician
Burnout and Higher Clinic Capacity to Address
Patients’ Social Needs. The Journal of the American
Board of Family Medicine, 32 (1), 69–78.
E:\FR\FM\10AUR2.SGM
Continued
10AUR2
49216
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
believe there is a potential further value
of this measure to facilitate datainformed collaboration with
community-based services and targeted
community investments, and enable
quality improvement activities and
efforts to address disparities, including
the development of pathways and
infrastructure to connect patients to
community resources.
Underserved communities are
disproportionately impacted by HRSNs,
such as food insecurity, that impact
health outcomes and cost.601 602 Unmet
HRSNs have been directly associated
with healthcare utilization, including
hospitalization, especially for hospitals
that serve such communities.603 In
pursuit of eliminating health equity
gaps, we are focused on supporting
effective and sustainable collaboration
between healthcare delivery and
community-based services organizations
to meet the unmet needs of historically
underserved populations. Reporting
data from both the Screening for Social
Drivers of Health measure and the
proportion of admitted patients who
screen positive for HRSNs across the
five domains (via this complementary
measure) will enable quantification of
the levels of HRSNs in local
communities served by a hospital and
greater visibility into the interaction
between HRSNs and health status,
healthcare utilization, and quality of
care. These measures harmonize, as it is
important to know both if a hospital or
health system is using a screening tool
and the results from the screening.
Ultimately, we believe that, together,
these two social drivers of health
measures could enhance collaboration
to meet the needs of historically
underserved populations by identifying
high-risk individuals who will benefit
from engagement with communitybased service providers. As with the
theory of change for the AHC Model, we
would expect such collaboration, and
600 Kung, A., Cheung, T., Knox, M., WillardGrace, R., Halpern, J., et.al, (2019). Capacity to
Address Social Needs Affect Primary Care Clinician
Burnout. Annals of Family Medicine. 17 (6), 487–
494. Available at: https://doi.org/10.1370/afm.2470.
601 RTI International. (2020). Accountable Health
Communities (AHC) Model Evaluation. Available
at: https://innovation.cms.gov/data-and-reports/
2020/ahc-first-eval-rpt.
602 U.S. Department of Agriculture Economic
Research Service (2021). Food Security in the U.S.
Accessed January 18, 2022. Available at: https://
www.ers.usda.gov/topics/food-nutrition-assistance/
food-security-in-the-us/key-statistics-graphics.aspx.
Accessed January 18, 2022.
603 Office of the Assistant Secretary for Planning
and Evaluation (ASPE) (2020). Report to Congress:
Social Risk Factors and Performance Under
Medicare’s Value-Based Purchasing Program
(Second of Two Reports). Available at: https://
aspe.hhs.gov/pdf-report/second-impact-report-tocongress.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
associated increase in capacity and
community investments, to yield a net
reduction in costly healthcare
utilization, such as ED visits and
avoidable hospitalizations and promote
more appropriate healthcare service
consumption.604
Pursuant to Meaningful Measures 2.0,
this measure addresses the ‘‘healthcare
equity’’ priority area and aligns with our
commitment to introduce plans to close
health equity gaps and promote equity
through quality measures, including to
‘‘develop and implement measures that
reflect social and economic
determinants.’’ 605 Under CMS’
Meaningful Measures Framework, the
Screen Positive Rate for Social Drivers
of Health structural measure addresses
the quality priority of ‘‘Work with
Communities to Promote Best Practices
of Healthy Living’’ through the
Meaningful Measures Area of ‘‘Equity of
Care.’’ 606 Development of this measure
also aligns with our strategic pillar to
advance health equity by addressing the
health disparities that underlie our
health system.607
(b) Overview of Measure
The Screen Positive Rate for Social
Drivers of Health structural measure is
intended to enhance standardized data
collection that can identify high-risk
individuals who will benefit from
connection via the hospital to targeted
community-based services.608 The
measure will identify the proportion of
patients who screened positive on the
date of hospital admission for one or
more of the following five HRSNs: Food
insecurity, housing instability,
604 Centers for Medicare & Medicaid Services.
(2021). Accountable Health Communities Model.
Accountable Health Communities Model | CMS
Innovation Center. Available at: https://
innovation.cms.gov/innovation-models/ahcm.
Accessed November 23, 2021.
605 Centers for Medicare & Medicaid Services.
Meaningful Measures 2.0: Moving from Measure
Reduction to Modernization. Available at: https://
www.cms.gov/meaningful-measures-20-movingmeasure-reduction-modernization. We note that
Meaningful Measures 2.0 is still under
development.
606 Centers for Medicare & Medicaid Services.
(2021). CMS Measures Management System
Blueprint (Blueprint v 17.0). Available at: https://
www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/MMS/MMS-Blueprint.
607 Brooks-LaSure, C. (2021). My First 100 Days
and Where We Go From Here: A Strategic Vision
for CMS. Available at: https://www.cms.gov/blog/
my-first-100-days-and-where-we-go-here-strategicvision-cms.
608 Centers for Medicare & Medicaid Services.
(2021). A Guide to Using the Accountable Health
Communities Health-Related Social Needs
Screening Tool: Promising Practices and Key
Insights (June 2021). Available at: https://
innovation.cms.gov/media/document/ahcmscreeningtool-companion. Accessed November 23,
2021.
PO 00000
Frm 00438
Fmt 4701
Sfmt 4700
transportation needs, utility difficulties,
and interpersonal safety. Hospitals will
report this measure as five separate
rates. We note that this measure is
intended to provide information to
hospitals on the level of unmet social
needs among patients served, and not
for comparison between hospitals.
The Screen Positive Rate for Social
Drivers of Health (MUC21–134) measure
was included in the publicly available
‘‘List of Measures Under Consideration
for December 1, 2021’’ (MUC List), a list
of measures under consideration for use
in various Medicare and Medicaid
programs.609 The MAP Rural Health
Advisory Group and the Health Equity
Advisory Group reviewed the measure
on December 8, 2021, and December 9,
2021, respectively. Both groups
expressed concerns about
standardization of the measure and
operationalization approaches that will
yield real solutions for patients and
clinicians. We intend to prioritize
consideration of potential
standardization approaches in future
rulemaking. The MAP Health Equity
Advisory Group members emphasized
the importance of explaining to patients
that self-report of HRSNs will not be
used to stigmatize them or reduce
healthcare benefits. We recommend that
hospitals incorporate inclusive language
in their screening activities to address
this potential concern among patient
and caregiver respondents. The measure
developer stated that the focus of this
measure is to establish standard social
drivers of health screening measures,
referencing data from the AHC Model as
having demonstrated the feasibility of
implementing HRSN screening and how
essential the screening results are to
enable action. Stakeholders’ support for
the measure was attributed, in part, to
potential for hospitals, health systems,
and community-based organizations to
use the data to identify and prioritize
opportunities for investment in
community resources to address these
HRSNs. Likewise, discussants reported
that screening for HRSNs has allowed
payors to enhance their understanding
of the scope of such challenges among
their patients, target resource
investments, initiate changes in benefits
designs, and prioritize community
partnerships. We expect that hospitals
will report similar findings and use the
data to enhance resource allocation that
will support referrals to relevant
609 Centers for Medicare & Medicaid Services.
(2021). List of Measures Under Consideration for
December 1, 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96464.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
community-based services
organizations.
On December 15, 2021, the MAP
Hospital Workgroup met and reviewed
the MUC List, including the Screen
Positive Rate for Social Drivers of
Health (MUC21–134) measure. Similar
concerns and support as raised during
the MAP Health Equity Advisory Group
and MAP Rural Health Workgroup were
also discussed during the MAP Hospital
Workgroup meeting. The MAP Hospital
Workgroup voted to conditionally
support the measure for rulemaking
pending NQF endorsement. On January
19, 2022, the MAP Coordinating
Committee met and reviewed the MUC
List including the Screen Positive Rate
for Social Drivers of Health (MUC21–
134) measure. The Coordinating
Committee upheld the vote of the MAP
Hospital Workgroup.610
We intend to submit this measure in
future for NQF endorsement. We note
that under section 1866
(b)(3)(B)(viii)(IX)(aa) of the Act, each
measure specified by the Secretary shall
be endorsed by the entity with a
contract under section 1890(a) of the
Act (the NQF is the entity that currently
holds this contract). Under section
1886(b)(3)(B)(viii)(IX)(bb) of the Act, in
the case of a specified area or medical
topic determined appropriate by the
Secretary for which a feasible and
practical measure has not been endorsed
by the entity with a contract under
section 1890(a) of the Act, the Secretary
may specify a measure that is not so
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary.
We reviewed NQF-endorsed measures
and were unable to identify any other
NQF-endorsed measures on this topic,
and, therefore we believe the exception
in section 1886(b)(3)(B)(viii)(IX)(bb) of
the Act applies.
This measure (alongside the
Screening for Social Drivers of Health)
will be the first patient-level
measurement of social drivers of health.
We believe this is an important measure
to include because of the connection
between HRSNs and patient health.
When patients are admitted to hospital
for inpatient care, there is substantial
opportunity to screen for HRSNs and
include relevant community services
referrals as part of discharge planning.
Providers will be able to identify if
patients have unmet health-related
social needs and the rate will help gauge
610 National Quality Forum. (2022). Measure
Applications Partnership (MAP) 2021–2022 Final
Recommendations. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96698.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
what percentage of the population they
serve (who are screened) indicate they
need help, by HRSN domain. We
envision that hospitals could implement
and assess their quality improvement
efforts to address patients’ unmet social
needs such as by connecting admitted
patients identified with unmet social
needs to local community resources.
These efforts could include referring
patients to services available through
the hospital or the community. The
information from this structural
measure may serve as a baseline in the
future to assess the proportion of
admitted patients whose unmet social
needs were addressed by the hospital
during the hospital stay to support safe
discharge and improved health
outcomes.
Measure specifications for this
measure are available on the QualityNet
website at: https://qualitynet.cms.gov
(or other successor CMS designated
websites).
(c) Cohort
The Screen Positive Rate for Social
Drivers of Health is a structural measure
that provides information on the percent
of patients admitted for an inpatient
hospital stay and who are 18 years or
older on the date of admission, were
screened for an HRSN, and who screen
positive for one or more of the following
five HRSNs: Food insecurity, housing
instability, transportation needs, utility
difficulties, or interpersonal safety.
(d) Numerator
The numerator consists of the number
of patients admitted for an inpatient
hospital stay who are 18 years or older
on the date of admission, who were
screened for an HRSN, and who screen
positive for having a need in one or
more of the following five HRSNs
(calculated separately): Food insecurity,
housing instability, transportation
needs, utility difficulties or
interpersonal safety.
(e) Denominator
The denominator consists of the
number of patients admitted for an
inpatient hospital stay who are 18 years
or older on the date of admission and
are screened for an HRSN (food
insecurity, housing instability,
transportation needs, utility difficulties
and interpersonal safety) during their
hospital inpatient stay. The following
patients will be excluded from the
denominator: (1) Patients who opt-out of
screening; and (2) patients who are
themselves unable to complete the
screening during their inpatient stay
and have no caregiver able to do so on
PO 00000
Frm 00439
Fmt 4701
Sfmt 4700
49217
the patient’s behalf during their
inpatient stay.
(f) Measure Calculation
The result of this measure will be
calculated as five separate rates. Each
rate is derived from the number of
patients admitted for an inpatient
hospital stay and who are 18 years or
older on the date of admission, screened
for an HRSN, and who screen positive
for each of the five HRSNs—food
insecurity, housing instability,
transportation needs, utility difficulties,
or interpersonal safety—divided by the
total number of patients 18 years or
older on the date of admission screened
for all five HRSNs.
(g) Data Submission and Reporting
We are finalizing voluntary reporting
of the Screen Positive Rate for Social
Drivers of Health measure beginning
with the CY 2023 reporting period,
followed by mandatory reporting on an
annual basis, beginning with the CY
2024 reporting period/FY 2026 payment
determination and for subsequent years.
Hospitals are required to submit
information for structural measures
once annually using a CMS-approved
web-based data collection tool available
within the HQR System. We refer
readers to section IX.E.10. (Form,
Manner, and Timing of Quality Data
Submission) of the preamble of this
final rule for more details on our
previously finalized data submission
and deadline requirements across
measure types, and specifically, section
IX.E.10.i. for our data and submission
requirements for structural measures.
We invited public comment on this
proposal.
Comment: Many commenters
supported the proposal to adopt the
Screen Positive Rate for Social Drivers
of Health measure beginning with
voluntary reporting for the CY 2023
reporting period and mandatory
reporting beginning with the CY 2024
reporting period/FY 2026 payment
determination and for subsequent years.
Those commenters agreed with our
described rationale for the proposal.
Commenters believed the Screen
Positive Rate for Social Drivers of
Health measure would advance CMS’
strategic pillar to advance health equity
by providing data about the impact of
drivers of health on patients’ health
outcomes, health disparities, physician
quality performance, and health care
costs. Several commenters applauded
the proposal of the first drivers of health
measures in hospital quality
performance measurement. A
commenter referenced recent studies
that have quantified the significant
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49218
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
impact of drivers of health on physician
performance and Medicare spending. A
commenter referenced recent research
reports of approximately 80 percent of
health outcomes being directly
associated with drivers of health and
many physicians reporting that such
factors influence patients’ health and
health outcomes. Several commenters
stated the measure would improve
healthcare transparency, promote datadriven community resource
investments, and inform and strengthen
quality improvement efforts addressing
health equity.
Response: We thank commenters for
their support of the measure and agree
that it, in combination with the
Screening for Social Drivers of Health
measure, will be a first step towards
addressing drivers of health to improve
health equity, which is one of our
strategic pillars.
Comment: Many commenters
supported the measure because it would
provide data needed to identify factors
that perpetuate health disparities. A
commenter stated the measure would
provide data on key contributors to poor
physical and mental health outcomes. A
few commenters noted the measure
would provide additional data on the
specific drivers of health challenges
faced by patients in complement to the
Screening for Social Drivers of Health
measure. A few commenters believed
the measure would highlight variability
in drivers of health prevalence across
hospitals, thereby reflecting the
challenges faced by hospitals that
disproportionately serve patients with
higher HRSN burden. Several
commenters believed the measure
would allow CMS to account for HRSNs
in risk adjustment for quality
performance scoring and support
targeted quality improvement activities.
A few commenters noted the measure
would promote data transparency and
build credibility for hospitals engaging
in social drivers of health screening and
intervention activities. A few
commenters emphasized the measure
would be person- or patient-level which
will support enhanced evaluation of the
economic implications of HRSNs on
healthcare billing, risk adjustment, and
cost benchmarks. A commenter noted
the measure would be especially
important for practicing physicians and
their patients because it would
accelerate quality improvement
activities that address health disparities.
A few commenters believed the measure
would enable public and private
institutions to make strategic
investments that will strengthen
capacity-building for addressing
patients’ HRSNs.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Response: We thank commenters for
their support of the measure and the
multiple ways in which the data could
potentially be used to inform evidencebased decision making. We believe this
measure is the next logical step after
screening for HRSNs. We agree with
commenters that data from the measure
will contribute to efforts to close the
health equity gap. Specifically, for the
Hospital IQR Program, we recognize that
drivers of health contribute significantly
to unplanned hospital re-admissions
and other patient outcomes in the
hospital inpatient setting which impacts
hospitals and healthcare providers that
serve patients who are
disproportionately burdened with
unmet HRSNs. We intend for the two
measures to encourage hospitals’
accountability for addressing health
disparities and, specifically, that the
Screen Positive Rate for Social Drivers
of Health will enable identification of
specific unmet needs among patients.
Comment: Several commenters did
not support adoption of the Screen
Positive Rate for Social Drivers of
Health measure. A commenter did not
support adoption of the Screen Positive
Rate for Social Drivers of Health
measure because they believed the
measure would be inappropriate for
CMS quality measurement.
Response: We thank the commenters
for their input, but respectfully disagree.
The intent of both measures is to
promote adoption of HRSN screening by
hospitals as part of a larger long-term
strategy to improve patient outcomes
and eliminate health equity gaps in the
hospital inpatient setting. We refer
readers to the Overview section in the
proposed rule (87 FR 28505) where we
state that the measure is intended to
provide information to hospitals on the
level of unmet social needs among
patients served. We also refer the reader
to our definition of quality measures as
noted in our Measure Management
System.611 We believe the Screen
Positive Rate for Social Drivers of
Health measure will function as tools to
help us measure and quantify healthcare
processes and patient outcomes in the
hospital inpatient setting.
Comment: A few commenters stated
the measure lacks comparability across
hospitals.
Response: We thank the commenters
for their input. We refer readers to the
Overview section in the proposed rule
where we state that the measure is
intended to provide information to
hospitals on the level of unmet social
needs among patients served, and not
611 https://mmshub.cms.gov/about-quality/newto-measures/what-is-a-measure.
PO 00000
Frm 00440
Fmt 4701
Sfmt 4700
for comparison between hospitals (87
FR 28505).
Comment: A few commenters
believed the measure would be difficult
to interpret. Specifically, a commenter
believed the Screen Positive Rate for
Social Drivers of Health measure
interpretation would be extremely
difficult because the denominator will
not be specific to the numerator’s
drivers of health domains. A few
commenters expressed concern about
potential confusion among patients and
unclear interpretation that could lead to
data misuse.
Response: We thank the commenters
for their input. We appreciate the
concerns noted and we will take them
into consideration for our future
outreach efforts aimed at enhancing
understanding of the measures and how
the data will be used. We do not agree
with the commenters that the measure
may lack specificity or clarity or create
confusion. We refer readers to the
explanation of the measure
specifications and specifically, the
Measure Calculation section (IX.
E.5.b.(2).(f).), in which we discuss the
relationship between the numerator and
denominator.
Comment: A few commenters stated
the measure does not capture response
to screening or whether intervention
occurred and was effective.
Response: We thank the commenters
for their input. We stated in the
proposed rule that utilization of
screening tools to identify the burden of
unmet HRSNs can be a helpful first step
in identifying necessary community
partners connecting individuals to
resources in their communities (87 FR
28500). The measure does not currently
include measurement of intervention
efficacy, and we will consider this in
future rulemaking.
Comment: A commenter questioned
the value of public reporting of the
Screen Positive Rate for Social Drivers
of Health measure data.
Response: We thank the commenter
for their input. Collecting healthcare
quality data related to social drivers can
promote transparency in delivery of care
by increasing involvement of leadership
in healthcare quality improvement,
increasing a sense of accountability,
helping to focus organizational
priorities and providing a means of
delivering important healthcare
information to patients. We believe this
will be especially important as we
advance the aims of our strategic pillar
to improve health equity in general and
address the disproportionate impact that
drivers of health have on hospital
quality performance for organizations
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
that serve patient populations with high
HRSN levels.
Comment: Several commenters stated
the proposed timeline for voluntary and
mandatory reporting is inadequate. A
commenter stated the work required to
make the measures meaningful and
establish effective workflows would
take many years to develop.
Response: We thank the commenters
for their feedback. We appreciate the
concerns about the operational
complexity of introducing drivers of
health quality measures into existing
clinical workflows. While the
implementation of these two Social
Drivers of Health measures may be a
major undertaking for some providers,
especially given the ongoing COVID–19
PHE, we also recognize that the COVID–
19 PHE magnified the disproportionate
burden of drivers of health on
communities who have been historically
under-resourced.612 We have therefore
determined that the proposed voluntary
and mandatory reporting periods
balance the time needed to implement
these measures with the urgency of
capturing drivers of health data and
taking actionable steps towards closing
the health equity gap. As stated in the
proposed rule, potential sources of these
data could include, for example,
administrative claims data, electronic
clinical data, standardized patient
assessments, or patient-reported data
and surveys (87 FR 28503).
Additionally, we note that 92 percent of
hospitals already screen for one or more
of the five HRSNs—food insecurity,
housing instability, transportation
needs, utility difficulties, and
interpersonal safety—specified in the
proposed measures (87 FR 28498). We
believe that this is a strong indication
that hospitals have processes in place to
conduct the screening required.
Comment: A commenter identified
inadequate measure design and lack of
measure specification and testing to
support adoption as challenges to
implementation of the proposed
measures; the commenter recommended
an attestation-based data collection
approach.
Response: We thank the commenters
for their input. We respectfully disagree
with the commenter that the measures
lack specification and testing. We
appreciate the concerns noted and we
refer readers to the Overview of Measure
section in the proposed rule (and
612 Centers for Disease Control and Prevention.
(2020). CDC COVID–19 Response Health Equity
Strategy: Accelerating Progress Towards Reducing
COVID–19 Disparities and Achieving Health Equity.
July 2020. Available at: https://www.cdc.gov/
coronavirus/2019-ncov/community/health-equity/
cdc-strategy.html. Accessed November 17, 2021.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
section E.5.b.(2).(b). of this final rule)
where we provide the measure
specifications (87 FR 28506).
Specifically, we explain the numerator,
denominator, and measure calculation
for both measures. Moreover, evidence
from the AHC Model evaluation
supports adoption of the measure as
proposed because it demonstrated the
ability of drivers of health screening to
identify higher cost and utilization
patients in the hospital inpatient setting.
The measures were reviewed by the
MAP Hospital Workgroup, MAP Health
Equity Workgroup, and the MAP Rural
Health Workgroup and all supported
inclusion of the measures in the
Hospital IQR Program. We expect this
will advance efforts for hospitals to
reduce unplanned readmission rates.
Comment: A commenter was
concerned about the appropriateness of
including the measure in the Hospital
IQR Program. The commenter believed
the measure is a hospital ‘‘case-mix’’
measure instead of a structural measure.
The commenter believed the measure
does not reflect hospital quality
performance because hospitals are not
resourced to address the problems
identified in HRSN screening.
Response: We thank the commenter
for this input. We define a structural
quality measure, also known as a
structure measure, in the CMS
Measurement Management System
Blueprint as a measure that ‘‘assesses
features of a healthcare organization or
clinician relevant to its capacity to
provide healthcare.’’ 613 This is
particularly relevant in the hospital
patient setting where patients with high
levels of HRSNs tend to have higher
utilization and costs related to care
delivery. While case mix reflects the
diversity, complexity, and severity of
patient illnesses treated at a given
hospital, patients’ HRSNs and the levels
of unmet need among screened patients
have not previously been measured or
publicly reported on a national scale.
Moreover, while HRSNs contribute to
case mix components such as illness
severity and complexity, our initial aim
with these measures centers on using
drivers of health screening to
understand the precursors of patient
illnesses and disparities in health
outcomes over time. We aim to
encourage hospitals to address patientlevel HRSNs in care delivery because
patient characteristics greatly influence
healthcare organizations’ and healthcare
professionals’ capacity to deliver
613 Centers for Medicare & Medicaid Services.
Measure Management System (MMS): Glossary.
Available at: https://mmshub.cms.gov/glossary.
Accessed July 22, 2022.
PO 00000
Frm 00441
Fmt 4701
Sfmt 4700
49219
healthcare. We emphasize that
screening for and reporting of HRSN
prevalence among patients are intended
to be initial steps towards more robust
accounting of the impact of HRSNs on
patient health and related outcomes
during and following hospitalization.
Hospitals will not be expected to
address the problems identified by
screening but instead will be expected
to facilitate linkage to community
resources that can assist patients in
meaningful ways.
Comment: A few commenters
recommended against publicly reporting
the data for this measure. A few
commenters specifically recommended
against reporting data on the Compare
tool due to risk of misinterpretation by
consumers. A few commenters were
concerned that public reporting of the
data might suggest that hospitals serving
communities with high HRSNs are
under-performing. A commenter
believed that public reporting the data
would discourage hospitals from
screening patients with higher risk. A
commenter recommended we ensure the
measures are implemented consistently
to allow fair comparisons across
providers and regions due to differences
in capacity for screening and making
follow-on services available. Several
commenters recommended we provide
outreach and education to patients and
providers to address the meaning,
reasons, and interpretation of the
measures. A commenter recommended
developing guidance on effective
education on the measures for patients
and providers. A commenter
recommended we evaluate the ability of
consumers to interpret the measure
rate(s) accurately.
Response: We appreciate the
commenters’ concerns. We wish to
remind readers that the measure is
intended to provide information to
hospitals on the level of unmet need
among their patients, and not for
comparison between hospitals (87 FR
28505). We intend to conduct outreach
and education in conjunction with
public reporting of the data for the two
Social Drivers of Health measures. We
believe public reporting of healthcare
quality data promotes transparency in
the delivery of care by increasing the
involvement of leadership in healthcare
quality improvement, creating a sense of
accountability, helping to focus
organizational priorities, and providing
a means of delivering important
healthcare information to consumers.614
614 Centers for Medicare & Medicaid Services
Quality Net. Public Reporting Overview. Available
E:\FR\FM\10AUR2.SGM
Continued
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49220
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
We intend to conduct outreach and
education with providers and patients
to share information about the two
Social Drivers of Health measures in
conjunction with public reporting.
Comment: A commenter believed the
name of the measure is misleading and
recommending changing the name
because patients may misinterpret
‘‘screening positive’’ as a positive event.
Response: We thank the commenter
for their input about potential
misinterpretation of the measure name.
While we are not changing the measure
name at this time, we appreciate this
feedback and will consider it in
outreach and education in conjunction
with public reporting of the data and
potential future development of this and
other related measures.
Comment: A commenter
recommended considering a minimum
level of cross-cultural validation of the
measures and/or demonstration of how
community members and patients
participated in domain prioritization.
Response: We appreciate the
commenters recommendations. We will
consider this input as part of future
measure maintenance analyses as well
as future policy development.
Comment: A commenter
recommended modifying the measure so
that in addition to capturing the five
separate rates, one for each of the HRSN
domains, the measure would ‘‘drill
down’’ into sub-components to include
three options for each: Screen positive,
screen negative, and did not screen. A
commenter recommended
reconsideration of the measure
specifications to reduce risk of small
denominator sizes that would impede
calculation and/or interpretation.
Response: We thank the commenter
for their input. We will consider this
input as part of future measure
maintenance analyses as well as policy
development.
Comment: A commenter
recommended consolidating the two
Screening for Social Drivers measures
into a single measure and adding a
component that would capture
screening follow-up. The commenter
believed that one single measure then
could be stratified by whether an
individual screened positive or
negative.
Response: We thank the commenter
for their input. We will consider this
input as part of future measure
maintenance analyses as well as policy
development.
at: https://qualitynet.cms.gov/inpatient/publicreporting/public-reporting.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
c. Cesarean Birth eCQM Beginning With
the CY 2023 Reporting Period/FY 2025
Payment Determination With
Mandatory Reporting Beginning With
the CY 2024 Reporting Period/FY 2026
Payment Determination and for
Subsequent Years
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28506 through
28510), we proposed to adopt the
Cesarean Birth eCQM as one of the
eCQMs in the Hospital IQR Program
measure set that hospitals can self-select
to report for the CY 2023 reporting
period/FY 2025 payment determination.
We also proposed to make reporting of
this eCQM mandatory beginning with
the CY 2024 reporting period/FY 2026
payment determination and for
subsequent years.
(1) Background
A Cesarean section (C-section) is the
use of surgery to deliver a baby (or
babies) in lieu of vaginal delivery. The
procedure entails surgical and
anesthesia risks and requires mothers to
undergo several days of inpatient, postoperative recovery. A C-section may
occur on an elective or nonelective
basis.615 Elective C-sections may be
planned due to the presence of a
complicating medical condition,
abnormal positioning of the baby, or
other medical indications.616 Elective Csections may also occur for non-medical
reasons, including maternal preference
(in consultation with their healthcare
provider), local practice patterns,
malpractice risk, or other
factors.617 618 619 C-sections that occur
upon a mother’s request are rare, but
615 National Quality Forum. Quality Measure PC–
02 (Cesarean Birth). Available at: https://
www.qualityforum.org/QPS/0471.
616 Xu, X., Yan, J.Y., Chen, L.C. (2021). Risk
factors and maternal-fetal outcomes of pregnancies
complicated by pre-eclampsia, following cesarean
section after a trial vaginal birth. Chin Med J (Engl).
2021;134(18):2249–2251. doi:10.1097/
CM9.0000000000001452.
617 Caughey AB, Cahill AG, Guise JM, Rouse DJ.
(2014). Safe prevention of the primary cesarean
delivery. Am J Obstet Gynecol. 2014
Mar;210(3):179–93. doi: 10.1016/j.ajog.2014.01.026.
618 Schifrin BS, Cohen WR. (2013). The effect of
malpractice claims on the use of caesarean section.
Best Pract Res Clin Obstet Gynaecol. 2013
Apr;27(2):269–83. doi: 10.1016/
j.bpobgyn.2012.10.004. Epub 2012 Dec 1. Review.
619 Chen CS, Liu TC, Chen B, Lin CL. (2014). The
failure of financial incentive? The seemingly
inexorable rise of cesarean section. Soc Sci Med.
2014 Jan;101:47–51. doi: 10.1016/
j.socscimed.2013.11.010. Epub 2013 Nov 15.
PO 00000
Frm 00442
Fmt 4701
Sfmt 4700
occur after consultation with a
clinician.620
The total rate of (elective and
nonelective) C-sections has risen in the
U.S. since the 1990s.621 C-sections
accounted for 31.8 percent of U.S. live
births in 2020,622 and there is a
considerable amount of variation in the
rates based on U.S. region, state, and
healthcare institution.623 There is also
substantial variability across races and
ethnicities; the rate of C-sections is: 30.8
percent among Non-Hispanic White
women, 36.3 percent among Black
women, 28.8 percent among American
Indian or Alaska Native women, 32.6
among Asian women, and 31.4 percent
among Hispanic women.624 U.S.
practice guidelines have not indicated
an optimal rate of C-section or an
appropriate variance rate; while
international studies suggest a
preference for a lower range than
current U.S. rates.625 626 627
When medically indicated, a Csection can effectively prevent maternal
and neonatal morbidity and
mortality.628 However, clinicians and
consensus groups agree that increased
C-section rates have not improved
overall perinatal outcomes and that Csections are overused.629 630
620 Committee on Obstetric Practice. (2019)
Cesarean Delivery on Maternal Request. The
American College of Obstetricians and
Gynecologists, 133(1). Available at: https://
www.acog.org/clinical/clinical-guidance/
committee-opinion/articles/2019/01/cesareandelivery-on-maternal-request.
621 Osterman, M.J.K., Martin, J.A. (2014). Trends
in Low-risk Cesarean Delivery in the United States,
1990–2013. National Vital Statistics Reports, 63(6):
1–16.
622 Hamilton, B.E., Martin, J.A., Osterman, M.J.K.
(2020). Births: Provisional Data for 2020. National
Vital Statistics Rapid Release, no 12. DOI: https://
doi.org/10.15620/cdc:104993.
623 Kozhimannil, K.B., Law, M.R. & Virnig, B.A.
(2013). Cesarean delivery rates vary tenfold among
US hospitals; reducing variation may address
quality and cost issues. Health Affairs, 32(3): 527–
35.
624 Hamilton, B.E., Martin, J.A., Osterman, M.J.K.
(2020). Births: Provisional Data for 2020. National
Vital Statistics Rapid Release, no 12. DOI: https://
doi.org/10.15620/cdc:104993.
625 National Collaborating Centre for Women’s
and Children’s Health. (2011). Caesarean Section:
NICE Clinical Guideline (commissioned by the
United Kingdom National Institute for Health and
Clinical Excellence).
626 Caughey AB, Cahill AG, Guise JM, Rouse DJ.
(2014). Safe prevention of the primary cesarean
delivery. Am J Obstet Gynecol, 210(3): 179–93. doi:
10.1016/j.ajog.2014.01.026.
627 Keag, O.E., Norman, J.E. & Stock, S.J. (2018).
Long-term risks and benefits associated with
cesarean delivery for mother, baby, and subsequent
pregnancies: Systematic review and meta-analysis.
Plos Med, 15(1): e1002494.
628 Caughey AB, Cahill AG, Guise JM, Rouse DJ.
(2014). Safe prevention of the primary cesarean
delivery. Am J Obstet Gynecol, 210(3): 179–93. doi:
10.1016/j.ajog.2014.01.026.
629 Caughey AB, Cahill AG, Guise JM, Rouse DJ.
(2014). Safe prevention of the primary cesarean
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Additionally, low risk C-sections—
defined as deliveries by nulliparous,
term, or singleton vertex (NTSV)
women—have seen an increase.
‘‘Nulliparous’’ women are those who
have never given birth to a live baby but
may have had a miscarriage, stillbirth,
or elective abortion. They have a lower
risk of maternal morbidity and mortality
during vaginal birth than do women
who have undergone a previous Csection.631,632 ‘‘Term’’ indicates a term
birth (that is on or after 37 weeks’
gestation), which has better outcomes
than a preterm birth, and ‘‘singleton’’
refers to the birth of a single child
during one delivery. Vertex
presentations, which are those where
the child is positioned headfirst, carry
less risk than breech or transverse
presentations.633 The rate of low-risk Csection deliveries also varies by race
and ethnicity; low-risk C-section births
in 2020 were: 24.9 percent among NTSV
Non-Hispanic White women, 30.6
percent among NTSV Non-Hispanic
Black women, 23.6 percent among
NTSV American Indian or Alaska
Native women, 27.7 percent among
NTSV Asian women, and 25.2 percent
among NTSV Hispanic women.634 A
majority of which are still higher than
the Centers for Disease Control and
Prevention’s (CDC’s) Healthy People
2020 goal to reduce C-section births
among NTSV women to 23.9 percent by
2020.635
C-sections have higher morbidity and
mortality (9.2 percent) than vaginal
deliveries (8.6 percent).636 Existing
literature largely does not distinguish
delivery. Am J Obstet Gynecol, 210(3): 179–93. doi:
10.1016/j.ajog.2014.01.026.
630 National Collaborating Centre for Women’s
and Children’s Health. (2011). Caesarean Section:
NICE Clinical Guideline (commissioned by the
United Kingdom National Institute for Health and
Clinical Excellence).
631 Caughey AB, Cahill AG, Guise JM, Rouse DJ.
(2014). Safe prevention of the primary cesarean
delivery. Am J Obstet Gynecol, 210(3): 179–93. doi:
10.1016/j.ajog.2014.01.026.
632 National Quality Forum. (2016). Perinatal and
Reproductive Health 2015–2016 Final Report.
Available at: https://www.qualityforum.org/
Publications/2016/12/Perinatal_and_Reproductive_
Health_2015-2016_Final_Report.aspx.
633 Caughey AB, Cahill AG, Guise JM, Rouse DJ.
(2014). Safe prevention of the primary cesarean
delivery. Am J Obstet Gynecol, 210(3): 179–93. doi:
10.1016/j.ajog.2014.01.026.
634 Hamilton, B.E., Martin, J.A., Osterman, M.J.K.
(2020). Births: Provisional Data for 2020. National
Vital Statistics Rapid Release, no 12. DOI: https://
doi.org/10.15620/cdc:104993.
635 Centers for Disease Control and Prevention,
Maternal Child and Infant Health. Healthy People
2020. Available at: https://www.cdc.gov/nchs/data/
hpdata2020/HP2020MCR-C26–MICH.pdf.
636 Caughey AB, Cahill AG, Guise JM, Rouse DJ.
(2014). Safe prevention of the primary cesarean
delivery. Am J Obstet Gynecol, 210(3): 179–93. doi:
10.1016/j.ajog.2014.01.026.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
49221
whether inferior outcomes derive from
cause (higher-risk patients undergo Csection) or effect (surgery carries
inherent risks due to anesthesia,
bleeding, infection, post-operative
recovery, etc.).637 However, taking an
aggregate view of multiple studies over
time, it appears that C-sections carry a
higher risk of subsequent miscarriage,
placental abnormalities, and repeat Csection.638 The rates of transfusions,
ruptured uteri, unplanned
hysterectomies, and intensive care unit
(ICU) admissions are higher among
women who deliver via C-section for the
first time than those who deliver
vaginally for the first time across all
races and ethnicities. However, nonHispanic Black women who deliver via
C-section for the first time had the
highest rates of uterine rupture and ICU
admission compared with all other races
and ethnicities.639
In terms of neonatal outcomes, Csections have higher respiratory
morbidity (1 percent to 4 percent) than
vaginal births (<1 percent).640 Again, it
is unclear whether this is because of
cause (high-risk fetuses are more likely
to be delivered by C-section) or effect
(surgery carries inherent risks due to
anesthesia, bleeding, infection, postoperative recovery, etc.). The medical
indications for a C-section entail broad
provider discretion because of the need
to: (1) Balance any conflicting medical
conditions of mother versus fetus; and
(2) balance the C-section against any
other competing clinical considerations
or external constraints (for example,
availability of operation room,
personnel, and/or blood). It should also
be noted that reducing the rate of Csections does not result in worse
outcomes for the mother or newborn,
with newborn complications even
declining in some hospitals with
significant C-section reductions.641
Furthermore, C-sections receive
higher reimbursement than vaginal
deliveries (typically about 50 percent
more). The prevalence of non-medically
indicated C-sections carries economic
impacts because C-sections are more
expensive than vaginal deliveries and
may be accompanied by adverse
outcomes and complications, which
similarly have substantial cost
implications.642
We believe this eCQM will help
further our goal of addressing maternal
health outcomes in the Hospital IQR
Program. Currently, the Hospital IQR
Program includes two measures that
address improving maternal health: The
Elective Delivery measure (PC–01) (77
FR 53530) and the Maternal Morbidity
Structural measure (86 FR 45361
through 45365). However, neither of
these measures directly address the
factors contributing to maternal
mortality, such as the high rates of Csections in the U.S. We believe adopting
measures like the Cesarean Birth eCQM
presents unique opportunities for largescale quality measurement and activities
that can improve the short- and longterm health outcomes for mothers and
children.643 We also refer readers to
section IX.E.5.d. of the preamble of this
final rule, where we also finalized the
adoption of the Severe Obstetric
Complications eCQM as part of the
Hospital IQR Program measure set.
In response to increases in low-risk Csections, HHS has included a goal of
reducing low-risk C-sections by 25
percent in the next five years as part of
the Maternal Action Plan.644 To build
on the previously established HHS
Maternal Health Action Plan, the Vice
President’s nationwide call to action to
reduce maternal morbidity and
mortality, and ongoing efforts with HHS
and across the federal government,645
637 Keag, O.E., Norman, J.E. & Stock, S.J. (2018).
Long-term risks and benefits associated with
cesarean delivery for mother, baby, and subsequent
pregnancies: Systematic review and meta-analysis.
Plos Med, 15(1): e1002494.
638 Keag, O.E., Norman, J.E. & Stock, S.J. (2018).
Long-term risks and benefits associated with
cesarean delivery for mother, baby, and subsequent
pregnancies: Systematic review and meta-analysis.
Plos Med, 15(1): e1002494.
639 Curtin, S.C., Gregory, K.D., Korst, L.M., Uddin,
S.F.G. (2015) Maternal Morbidity for Vaginal and
Cesarean Deliveries, According to Previous
Cesarean History: New Data from the Birth
Certificate, 2013. National Vital Statistics Reports.
Volume 64, Number 4. Available at: https://
www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_
04.pdf.
640 Caughey AB, Cahill AG, Guise JM, Rouse DJ.
(2014). Safe prevention of the primary cesarean
delivery. Am J Obstet Gynecol, 210(3): 179–93. doi:
10.1016/j.ajog.2014.01.026.
641 Main, E.K., Chang, S.C., Cape, V., Sakowski,
C. Smith, H., Vasher, J. (2019) Safety Assessment of
a Large-Scale Improvement Collaborative to Reduce
Nulliparous Cesarean Delivery Rates. Obstetrics &
Gynecology, 133(4):613–623. doi: 10.1097/
AOG.0000000000003109.
642 Kozhimannil, K.B., Law, M.R. & Virnig, B.A.
(2013). Cesarean delivery rates vary tenfold among
US hospitals; reducing variation may address
quality and cost issues. Health Affairs, 32(3): 527–
35. doi: 10.1377/hlthaff.2012.1030.
643 Department of Health and Human Services.
(2020). Healthy Women, Healthy Pregnancies,
Health Futures: Action Plan to Improve Maternal
Health in America. Available at: https://
aspe.hhs.gov/sites/default/files/private/aspe-files/
264076/healthy-women-healthy-pregnancieshealthy-future-action-plan_0.pdf.
644 Department of Health and Human Services.
HHS Initiative to Improve Maternal Health.
Available at: https://aspe.hhs.gov/topics/publichealth/hhs-initiative-improve-maternal-health.
645 Department of Health and Human Services.
HHS Initiative to Improve Maternal Health.
Available at: https://aspe.hhs.gov/topics/publichealth/hhs-initiative-improve-maternal-health.
PO 00000
Frm 00443
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
49222
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
the Biden-Harris Administration seeks
to use a whole-of-government approach
for improving maternal health and
advancing maternal health equity that
reduces maternal mortality and
morbidity, reduces persistent
disparities, and among other activities,
increases hospital participation in HHSsponsored maternal health quality
improvement initiatives. A critical focus
is reducing existing disparities in
maternal health outcomes across race,
ethnicity, and geographic area. The
Cesarean Birth eCQM is intended to
facilitate safer patient care by assessing
the rate of NTSV C-sections to
ultimately reduce the occurrence of
non-medically indicated C-sections,
promoting adherence to recommended
clinical guidelines, and encouraging
hospitals to track and improve their
practices of appropriate monitoring and
maternity care delivery for pregnant and
postpartum patients. The 2020
performance measurement data for the
Cesarean Birth eCQM indicates a 27.5
percent average rate of C-section birth
for NTSV women (across 15 hospitals,
N=933). A group of subject matter
experts for NQF noted that decreasing
the rate of non-medically indicated Csections can result in increased patient
safety, decreased maternal and neonatal
morbidity, and substantial savings in
healthcare costs.646 Additionally,
considering that Non-Hispanic Black
women have the highest rate of low-risk
C-sections along with the highest rates
of uterine ruptures and ICU admissions
as a result of C-sections, reducing lowrisk C-section rates could improve
maternal health outcomes for this
population in particular by reducing the
excess maternal morbidity they
experience.647 648 649
646 National Quality Forum. (2008) Perinatal and
Reproductive Health Project NQF #0471 PC–02
Cesarean Section: Measure Submission and
Evaluation Worksheet 5.0. Available at: https://
www.qualityforum.org/Projects/n-r/Perinatal_Care_
Endorsement_Maintenance_2011/0471.aspx.
647 Department of Health and Human Services.
(2020). Healthy Women, Healthy Pregnancies,
Health Futures: Action Plan to Improve Maternal
Health in America. Available at: https://
aspe.hhs.gov/sites/default/files/private/aspe-files/
264076/healthy-women-healthy-pregnancieshealthy-future-action-plan_0.pdf.
648 Curtin, S.C., Gregory, K.D., Korst, L.M., Uddin,
S.F.G. (2015) Maternal Morbidity for Vaginal and
Cesarean Deliveries, According to Previous
Cesarean History: New Data from the Birth
Certificate, 2013. National Vital Statistics Reports.
Volume 64, Number 4. https://www.cdc.gov/nchs/
data/nvsr/nvsr64/nvsr64_04.pdf.
649 Debbink, M.P. Ugwu, L.G. Grobman, W.A. et
al. (2022) Racial and Ethnic Inequities in Cesarean
Birth and Maternal Morbidity in a Low-Risk,
Nulliparous Cohort. Obstetrics &
Gynecology;139(1): 73–82. doi: 10.1097/
AOG.0000000000004620.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Under CMS’ Meaningful Measures
Framework,650 the Cesarean Birth eCQM
addresses the quality priority of ‘‘Make
Care Safer by Reducing Harm Caused in
the Delivery of Care’’ through the
Meaningful Measures Area of
‘‘Preventable Healthcare Harm.’’ 651
Additionally, pursuant to Meaningful
Measures 2.0,652 this measure addresses
the ‘‘Safety’’ priority area and aligns
with our commitment to a patientcentered approach in quality
measurement to ensure that patients are
safe and receive the highest quality
care.653 Finally, this measure aligns
with our strategic priorities including
the pillar to advance health equity by
addressing the health disparities that
underlie our health system.654
Therefore, in the proposed rule, we
proposed the adoption of the Cesarean
Birth eCQM beginning with the CY 2023
reporting period/FY 2025 payment
determination. As part of the currently
finalized eCQM reporting and
submission requirements, hospitals
must report on three self-selected
eCQMs and the Safe Use of Opioids—
Concurrent Prescribing eCQM, for a
total of four eCQMs (85 FR 58939).
Hospitals may choose to report it as one
of the three self-selected eCQMs for the
CY 2023 reporting period/FY 2025
payment determination. After which,
beginning with the CY 2024 reporting
period/FY 2026 payment determination
and for subsequent years, the Cesarean
Birth eCQM would be required to be
reported by all hospitals, except those
hospitals that do not have an obstetrics
department and do not perform
deliveries. We also refer readers to
section IX.E.10.e. of the preamble of this
final rule for our policy to modify the
eCQM reporting and submission
650 Centers for Medicare & Medicaid Services.
Meaningful Measures Framework. Available at:
https://www.cms.gov/Medicare/Quality-InitiativesPatient-Assessment-Instruments/
QualityInitiativesGenInfo/CMS-Quality-Strategy.
651 CMS’ Meaningful Measures Framework can be
found at: https://www.cms.gov/Medicare/QualityInitiatives-Patient-Assessment-Instruments/
QualityInitiativesGenInfo/MMF/General-info-SubPage.
652 Centers for Medicare & Medicaid Services.
Meaningful Measures 2.0: Moving from Measure
Reduction to Modernization. Available at: https://
www.cms.gov/meaningful-measures-20-movingmeasure-reduction-modernization. We note that
Meaningful Measures 2.0 is still under
development.
653 Centers for Medicare & Medicaid Services.
(2021) CMS Quality Measurement Action Plan.
Available at: https://www.cms.gov/files/document/
2021-cms-quality-conference-cms-qualitymeasurement-action-plan-march-2021.pdf.
654 Brooks-LaSure, C. (2021). My First 100 Days
and Where We Go From Here: A Strategic Vision
for CMS. Centers for Medicare & Medicaid.
Available at: https://www.cms.gov/blog/my-first100-days-and-where-we-go-here-strategic-visioncms.
PO 00000
Frm 00444
Fmt 4701
Sfmt 4700
requirements beginning with the CY
2024 reporting period/FY 2026 payment
determination.
(2) Overview of Measure
This measure assesses the rate of
NTSV pregnancies delivered via Csection. Determining the NTSV Csection rate permits a hospital to
compare its outcomes to other hospitals
while focusing only on the NTSV
population which can impact the rates
of first time and possibly subsequent Csection rates. We note that the NQF has
endorsed the chart-abstracted form of
this measure (PC–02: Cesarean Birth,
NQF #0471) as a voluntary consensus
standard since 2008 and continuously
renewed its endorsement (most recently
in 2020).655 The Rural Health
Workgroup of the NQF’s MAP also
identified the chart-abstracted version
as a measure that holds particular
relevance for rural hospitals, noting how
important it is to focus on best practices
in obstetric care in rural areas.656 We
acknowledge that there are instances
where C-sections are medically
indicated, and we emphasize that this
measure is not intended to discourage
practitioners from performing C-sections
when they are medically indicated. We
believe that assessing the rate of NTSV
C-sections may ultimately reduce the
occurrence of non-medically indicated
C-sections. We encourage hospitals
whose measure rates are higher than
rates at other hospitals to explore and
evaluate differences in the clinical
management of women in labor.657
Further, this measure will help ensure
that the Hospital IQR Program includes
measures which are applicable to rural
hospitals.
The Cesarean Birth eCQM was
included in a publicly available
document entitled ‘‘List of Measures
Under Consideration for December 1,
2018’’ (MUC List).658 The MAP’s Final
Report on February 15, 2019
655 National Quality Forum. Quality Measure PC–
02 (Cesarean Birth). Available at: https://
www.qualityforum.org/QPS/0471.
656 National Quality Forum, Measure
Applications Partnership. (2018). A Core Set of
Rural-Relevant Measures and Measuring and
Improving Access to Care: 2018 Recommendations
from the MAP Rural Health Workgroup. Available
at: https://www.qualityforum.org/Publications/2018/
08/MAP_Rural_Health_Final_Report_-_2018.aspx.
657 Centers for Medicare & Medicaid Services.
(2015). Cesarean Birth (PC–02) Measure Public
Comment Summary. Available at: https://
www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/MMS/Downloads/PC-02Public-Comment-Summary-Memo.pdf?msclkid=
a582dfc0b52411ecbab8ba3255a5b678.
658 Centers for Medicare & Medicaid Services.
(2018). List of Measures Under Consideration for
December 1, 2018. Available at: https://
www.cms.gov/files/document/2018rmuc-list
clearancerpt.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
conditionally supported the eCQM for
rulemaking pending NQF evaluation
and endorsement.659 The MAP
suggested further feasibility testing,
consultation with multiple stakeholders,
and examination of unintended
consequences.
Given the importance of this measure,
we sought stakeholder input on the
potential future inclusion of this
measure in the FY 2020 IPPS/LTCH PPS
proposed rule (84 FR 19491 through
19494). Many stakeholders supported
inclusion of the measure, though some
stakeholders shared similar concerns as
the MAP (84 FR 42493 through 42496).
Thereafter, the measure steward
conducted further reliability and
validity testing in 2021 and submitted
the measure to the NQF for
consideration of endorsement in Spring
2022. Given the additional testing
performed and feedback provided, we
proposed this measure in the proposed
rule.
We also note that in 2020, the
measure steward introduced the
Cesarean Birth eCQM as one of the
available eCQMs hospitals can choose
for data submission to meet The Joint
Commission’s ORYX® requirements.660
The ORYX initiative integrates
performance measurement data into The
Joint Commission’s accreditation
process.661 Currently, we understand
that The Joint Commission uses both the
chart-abstracted (PC–02) and the eCQM
versions. A total of 15 hospitals
(representing 6 sites) submitted
production data for one quarter of
calendar year 2020. We note that the
measure steward reached out to all 15
hospitals to recruit sites willing to
participate in reliability testing on the
data submitted. Seven hospitals
(representing 2 sites) volunteered. One
site is a system representing six
hospitals. The seventh hospital is a
stand-alone facility that uses a different
EHR system. During the third quarter of
2021, feasibility scorecards were
completed, and the feasibility rate was
found to be 98 percent across the two
EHR systems. Reliability and validity
testing revealed the Cesarean Births
659 National Quality Forum.(2019). Measure
Applications Partnership, MAP 2019
Considerations for Implementing Measures in
Federal Programs: Hospitals Final Report. Available
at: https://www.qualityforum.org/Publications/
2019/02/MAP_2019_Considerations_for_
Implementing_Measures_Final_Report_-_
Hospitals.aspx.
660 The Joint Commission. (2020). 2020 ORYX
Performance Measure Reporting Requirements.
Available at: https://www.jointcommission.org/-/
media/tjc/documents/measurement/oryx/cy2020oryx-reporting-requirements_.pdf.
661 The Joint Commission. Accreditation-ORYX.
Available at: https://www.jointcommission.org/
measurement/reporting/accreditation-oryx/.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
eCQM to have a measure outcome
agreement rate of 83.7 percent with a
kappa score of .750 indicating
substantial agreement. Overall, the data
element agreement rate for all hospitals
was 92.2 percent.
As mentioned previously, the NQF
has endorsed the chart-abstracted form
of this measure. Additionally, the
measure steward submitted the eCQM to
the NQF for consideration of
endorsement during Spring 2022. We
note that section
1866(b)(3)(B)(viii)(IX)(aa) of the Act
requires that any measure specified by
the Secretary must have been endorsed
by the entity with a contract under
section 1890(a) of the Act (the NQF is
the entity that currently holds this
contract). Under section
1886(b)(3)(B)(viii)(IX)(bb) of the Act, in
the case of a specified area or medical
topic determined appropriate by the
Secretary for which a feasible and
practical measure has not been endorsed
by the entity with a contract under
section 1890(a) of the Act, the Secretary
may specify a measure that is not
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary.
We reviewed NQF-endorsed measures
and note that while the chart-abstracted
version is endorsed, we were unable to
identify any other NQF-endorsed
measures on this topic, and, therefore
we believe the exception in section
1886(b)(3)(B)(viii)(IX)(bb) of the Act
applies.
The measure specifications for the
Cesarean Birth eCQM can be found on
the eCQI Resource Center website,
available at: https://ecqi.healthit.gov/
pre-rulemaking-eh-cah-ecqms.
(3) Data Sources
The eCQM uses data collected
through hospitals’ EHRs. The measure is
designed to be calculated by the
hospitals’ CEHRT using the patient-level
data and then submitted by hospitals to
CMS.
(4) Measure Calculation
This eCQM assesses the rate of
nulliparous women with a term,
singleton baby in a vertex position
delivered by C-section birth.662 The
eCQM uses one of the following:
Nulliparous defined as Parity = 0,
Gravidity = 0, or Preterm and Term both
= 0. Parity is the number of completed
662 The Joint Commission. (2021). eCQM
Specifications 2022 Reporting Period. Available at:
https://www.jointcommission.org/-/media/tjc/
documents/measurement/specification-manuals/
2022-reporting-period/january-2022/ecqm_
specifications_reportingperiod_2022.zip.
PO 00000
Frm 00445
Fmt 4701
Sfmt 4700
49223
pregnancies reaching 20 weeks gestation
regardless of the number of fetuses or
outcome of the pregnancy. Gravidity is
the number of pregnancies, current and
past, regardless of the pregnancy
outcome. Preterm is less than 37 weeks
and 0 days, and Term is greater than or
equal to 37 weeks and 0 days using best
Estimated Due Delivery (EDD).
(5) Outcome
The outcome of interest is the number
of C-sections to NTSV women divided
by all live, term (≥37 weeks gestation)
singleton deliveries to NTSV women.
(6) Cohort
The cohort consists of all patients in
the denominator: Nulliparous women
with a singleton, vertex fetus at ≥37
weeks of gestation who deliver a
liveborn infant. The cohort includes all
pertinent patients regardless of payer
(for example, Medicare, Medicaid, other
public programs, private insurance, selfpay, or charity care) or admission source
(for example, home, ED, nursing home,
hospice, another hospital, or law
enforcement).
(7) Numerator
The measure numerator consists of
the subset of patients delivering by Csection.
(8) Denominator
The measure denominator consists of
the number of nulliparous women with
a singleton, vertex fetus at ≥37 weeks of
gestation who deliver a liveborn infant.
(9) Exclusion Criteria
The measure excludes patients with
abnormal presentations or placenta
previa.
(10) Risk Adjustment
This measure is not currently risk
adjusted. When developing the measure,
the exclusion criteria were chosen to
ensure that the focus population will be
women with NTSV pregnancies.
Nulliparous women are those
experiencing their first birth. These
women have a lower risk of maternal
morbidity and mortality during a
vaginal birth delivery than do women
who have undergone a previous Csection.663 The population of women in
the denominator as a result of the
exclusions allow the measure to focus
on a more homogeneous group of
women where the greatest improvement
opportunity exists as evidenced by
variation in rates of NTSV C-sections,
663 Caughey AB, Cahill AG, Guise JM, Rouse DJ.
(2014). Safe prevention of the primary cesarean
delivery. Am J Obstet Gynecol, 210(3): 179–93. doi:
10.1016/j.ajog.2014.01.026.
E:\FR\FM\10AUR2.SGM
10AUR2
49224
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
indicating clinical practice patterns may
affect this rate.664 Lowering the Csection rate in NTSV pregnancies is
important because C-sections may carry
a higher risk of subsequent miscarriage,
placental abnormalities, and repeat Csection.665 The rates of ruptured uteri,
unplanned hysterectomies, and ICU
admission are higher among women
who deliver via C-section for the first
time than those who deliver vaginally
for the first time across all races and
ethnicities. However, non-Hispanic
Black women who deliver via C-section
for the first time had the highest rates
of uterine rupture and ICU admission
compared with all other races.666
Focusing on the NTSV population
aligns with the measure intent to have
a significant effect on cesarean birth
rates. We believe this could encourage
a decrease in C-section rates in the
NTSV population, which will in turn
have a meaningful impact on future
pregnancies and maternal health.
Including a comprehensive set of
maternal medical exclusions will add
data collection burdens without
commensurate benefit.
khammond on DSKJM1Z7X2PROD with RULES2
(11) Data Submission and Reporting
We refer readers to: Section IX.E.10.e.
of the preamble of this final rule for a
discussion of our previously finalized
eCQM reporting and submission
policies; and section IX.E.13.b. for the
public reporting of eCQM data.
Additionally, we refer readers to section
IX.E.10.e.(4). where we discuss the use
of the zero denominator declarations
and case threshold exemption policies
for hospitals.
We also refer readers to four related
proposals discussed in the preamble of
this final rule: (1) Section IX.E.10.e.
where we discuss modifications to our
reporting and submission requirements
for eCQMs, including a discussion of
our policy to require hospitals to report
on the Cesarean Birth eCQM; (2) section
IX.E.5.d. for our policy to adopt the
Severe Obstetric Complications eCQM;
(3) section IX.H.10.a.(2).of the preamble
of this final rule for a discussion of
similar policies to adopt these two
664 Caughey AB, Cahill AG, Guise JM, Rouse DJ.
(2014). Safe prevention of the primary cesarean
delivery. Am J Obstet Gynecol, 210(3): 179–93. doi:
10.1016/j.ajog.2014.01.026.
665 Keag, O.E., Norman, J.E. & Stock, S.J. (2018).
Long-term risks and benefits associated with
cesarean delivery for mother, baby, and subsequent
pregnancies: Systematic review and meta-analysis.
Plos Med, 15(1): e1002494.
666 Curtin, S.C., Gregory, K.D., Korst, L.M., Uddin,
S.F.G. (2015) Maternal Morbidity for Vaginal and
Cesarean Deliveries, According to Previous
Cesarean History: New Data from the Birth
Certificate, 2013. National Vital Statistics Reports,
64(4). Available at: https://www.cdc.gov/nchs/data/
nvsr/nvsr64/nvsr64_04.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
perinatal eCQMs in the Medicare
Promoting Interoperability Program for
Eligible Hospitals and Critical Access
Hospitals (CAHs); and (4) section IX.E.8.
where we are establishing a publiclyreported hospital designation to capture
the quality and safety of maternity care
and other related activities in advancing
maternal health equity.
We invited public comment on this
proposal.
Comment: Many commenters
supported adoption of the Cesarean
Birth eCQM beginning with the CY 2023
reporting period/FY 2025 payment
determination and mandatory reporting
beginning with the CY 2024 reporting
period/FY 2026 payment determination
and for subsequent years. Commenters
agreed with our rationale in the
preamble of the FY 2023 IPPS/LTCH
PPS proposed rule and underscored
their beliefs that the measure could
support the provision of high- quality
maternity care, that this data is
necessary for addressing the maternal
health crisis, and that the measure could
lead to improved clinical practices.
Additionally, a few commenters
indicated that their support was tied to
the measure’s alignment with their
state’s or The Joint Commission’s
reporting practices.
Response: We thank the commenters
for their support of the Cesarean Birth
eCQM and agree that measure is in line
with best practices for reducing low-risk
C-sections. As we noted in the preamble
of the FY 2023 IPPS/LTCH PPS
proposed rule, we believe the measure
addresses a key priority area and will
further our goal of addressing maternal
health outcomes in the Hospital IQR
Program (87 FR 28507).
Comment: A few commenters
supported the proposal, but
recommended staggered
implementation, extending the
voluntary reporting period for an
additional year, or making the measure
voluntary permanently.
Response: We thank commenters for
their input on the timeline of adoption
and implementation of the Cesarean
Birth eCQM. We believe adopting
measures like the Cesarean Birth eCQM
presents unique opportunities for largescale quality measurement and activities
that can improve the short- and longterm health outcomes for mothers and
children (87 FR 28508). As a result, we
believe the proposed timeline of
inclusion of this eCQM into the Hospital
IQR Program measure set beginning in
CY 2023 reporting period/FY 2025
payment determination (in which
hospitals can choose to self-select
reporting of this measure) followed by
mandatory reporting beginning with the
PO 00000
Frm 00446
Fmt 4701
Sfmt 4700
CY 2024 reporting period/FY 2026
payment determination and for
subsequent years is sufficient for EHR
vendors and hospitals to incorporate,
adopt, and implement this measure.
Comment: A few commenters
supported the proposal and
recommended monitoring the measures
in the future to track performance or to
modify or expand the exclusion criteria
as needed.
Response: We thank commenters for
their support and agree that continued
monitoring of the measures is
important. We believe collecting data
and reporting results will provide a
critical baseline and we will monitor the
data and any unintended consequences
of the measure as part of standard
measure maintenance.
Comment: A commenter supported
the measure and requested clarification
on how non-birthing hospitals would be
affected by the adoption of this eCQM.
Response: We thank the commenter
for their requested clarification on how
hospitals which do not provide labor
and delivery services would be affected.
As stated in the FY 2023 IPPS/LTCH
PPS proposed rule, the Cesarean Birth
eCQM would be reported by all
hospitals participating in the Hospital
IQR Program, except those hospitals that
do not have an obstetrics department
and do not perform deliveries (87 FR
28507). We also refer readers to section
IX.E.10.e.(4). of this final rule where we
discuss the Hospital IQR Program’s zero
denominator declarations and case
threshold exemption policies for
eCQMs. Zero denominator declarations
allow a hospital whose EHR is capable
of reporting eCQM data to submit a zero
in the denominator for the reporting of
an eCQM if the hospital does not have
patients that meet the denominator
criteria of that hybrid measure (82 FR
38387). Similarly, the case threshold
exemptions policy allows for a hospital
with five or fewer inpatient discharges
per quarter or 20 or fewer inpatient
discharges per year in a given
denominator declaration be exempted
from reporting on that individual eCQM
(82 FR 38387). We refer readers to the
FY 2016 IPPS/LTCH PPS final rule (80
FR 49705 through 49708) and the FY
2017 IPPS/LTCH PPS final rule (81 FR
57170) for our previously adopted
eCQM file format requirements.
Hospitals can continue to meet the
reporting requirements by submitting
data via QRDA I files, zero denominator
declaration, or case threshold
exemption (82 FR 38387).
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Comment: Many commenters did not
support the adoption of the Cesarean
Birth eCQM. Several commenters
believed the measure is misaligned with
factors that contribute to negative
outcomes, or that testing and validation
of the eCQM has been insufficient to
establish that the measure is
appropriately aligned. Several
commenters did not support the
measure because it does not have NQF
endorsement. A few commenters
recommended the adoption of
alternative measures which they
believed would more appropriately
align with the equity goal. A few
commenters did not support the
measure because they believed there is
no ideal rate of C-sections. A commenter
did not support because they believed
that diverting natural birth from Csection begins earlier than when a
patient seeks hospital labor and delivery
services, which the measure does not
capture.
Response: We thank the commenters
for their input. As stated in the FY 2023
IPPS/LTCH PPS proposed rule, the NQF
has endorsed the chart-abstracted
version of this measure and the measure
steward has submitted the eCQM to
NQF for consideration of endorsement
(87 FR 28509). We also note that section
1886(b)(3)(B)(viii)(IX)(bb) offers an
exception in the case of a specified area
or medical topic determined appropriate
by the Secretary for which a feasible and
practical measure has not been endorsed
by the entity under contract under
section 1890(a) of the Act, and the
Secretary may specify a measure that is
not endorsed as long as due
consideration is given to measures that
have been endorsed or adopted by a
consensus organization identified by the
Secretary. We reviewed NQF-endorsed
measures and note that while the chartabstracted measure is endorsed, we
were unable to identify any other NQFendorsed measures on this topic and
therefore believe the exception at
1886(b)(3)(B)(viii)(IX)(bb) applies. Given
the severity of the maternal morbidity
crisis and as there are currently no NQFendorsed measures that address
Cesarean birth we believe it is important
to implement this measure as soon as
possible. We appreciate the suggestions
of alternative measures and will
consider them for potential future
rulemaking.
Regarding commenter concerns about
testing and validation, the measure
steward conducted additional testing in
2021. The reliability and validity testing
found the measure to have an overall
data element agreement rate of 92.2
percent and we therefore believe the
measure to be reliable and valid for use
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
in the Hospital IQR Program. We believe
that this measure serves as a key first
step in measuring and promoting
quality improvement in maternity care
by encouraging hospitals to track their
rate of low- risk C-sections and practices
that may be contributing to trends in
low-risk C-sections in the United States.
While we agree that there is no ideal
rate of low-risk C-sections, we noted in
the FY 2023 IPPS/LTCH PPS proposed
rule, the Cesarean Birth eCQM is
intended to facilitate safer patient care
by assessing the rate of NTSV C-sections
to ultimately reduce the occurrence of
non-medically indicated C-sections,
promoting adherence to recommended
clinical guidelines, and encouraging
hospitals to track and improve their
practices in caring for pregnant and
postpartum patients (87 FR 28508).
Additionally, we acknowledged that
there are instances where C-sections are
medically indicated and continue to
emphasize that this measure is not
intended to discourage practitioners
from performing C-sections writ large
(87 FR 28508). A group of subject matter
experts for NQF noted that decreasing
the rate of non-medically indicated Csections can result in increased patient
safety, decreased maternal and neonatal
morbidity, and substantial savings in
healthcare costs.667
Comment: A commenter did not
support adoption and expressed
concern that the time to implement the
measure was insufficient.
Response: We thank the commenter
for their input and respectfully disagree
that the timeline for adoption is not
appropriate. We emphasize that as
proposed, hospitals may choose to
report the Cesarean Birth eCQM as one
of the three self-selected eCQMs for the
CY 2023 reporting period/FY 2025
payment determination. After which,
beginning with the CY 2024 reporting
period/FY 2026 payment determination
and for subsequent years, the Cesarean
Birth eCQM would be required to be
reported by all hospitals, except those
hospitals that do not have an obstetrics
department and do not perform
deliveries. This timeline will allow
hospitals at least one year to prepare
and implement the measure before they
are required to report it.
Comment: A few commenters did not
support the proposal because they
believed the exclusion criteria are not
broad enough and should be risk
adjusted. A few commenters did not
667 National
Quality Forum. (2008) Perinatal and
Reproductive Health Project NQF #0471 PC–02
Cesarean Section: Measure Submission and
Evaluation Worksheet 5.0. Available at: https://
www.qualityforum.org/Projects/n-r/Perinatal_Care_
Endorsement_Maintenance_2011/0471.aspx.
PO 00000
Frm 00447
Fmt 4701
Sfmt 4700
49225
support adoption of the measure
because it does not distinguish between
medically necessary and non-medically
necessary procedures. A commenter
requested that CMS clarify that the
measure is not intended to discourage
medically necessary C-sections.
Response: We thank the commenters
for their input. While we agree that
there are many ways to track data
related to the C-section rate in the
United States, and ultimately reduce
excess non-medically indicated
C-sections, the standards and
comprehensiveness of initiatives can
vary widely, and we do not believe
broadening exclusion criteria or risk
adjustment is necessary at this time. As
we noted in the FY 2023 IPPS/LTCH
PPS proposed rule, when developing
the measure, the exclusion criteria were
chosen to ensure that the focus
population would be women with
NTSV pregnancies (86 FR 28510).
Barring the presence of other comorbidities, such women often have a
lower risk of maternal morbidity and
mortality at the time of delivery than
their counterparts who have undergone
a previous C-section (87 FR 28510). As
a result of the existing exclusion
criteria, the population denominator
allows the measure to focus on a more
homogeneous group where the greatest
improvement opportunity exists. As
evidenced by variation in rates of NTSV
C-sections, clinical practice patterns in
particular may affect this rate (87 FR
28510). Lowering the C-section rate in
NTSV pregnancies is important because
C-sections may carry a higher risk of
subsequent miscarriage, placental
abnormalities, and repeat C-section (87
FR 28510). The rates of ruptured uteri,
unplanned hysterectomies, and ICU
admission are higher among women
who deliver via C-section for the first
time than those who deliver vaginally
for the first time across all races and
ethnicities (87 FR 28507). However,
non-Hispanic Black women who deliver
via C-section for the first time had the
highest rates of uterine rupture and ICU
admission compared with all other
races.668 Including a comprehensive set
of maternal medical exclusions would
add data collection burdens without
commensurate benefit. Regarding
commenters’ concerns based on a lack
of distinction between medically
indicated and non-medically indicated
procedures, the measure is designed to
668 Curtin, S.C., Gregory, K.D., Korst, L.M., Uddin,
S.F.G. (2015) Maternal Morbidity for Vaginal and
Cesarean Deliveries, According to Previous
Cesarean History: New Data from the Birth
Certificate, 2013. National Vital Statistics Reports,
64(4). Available at: https://www.cdc.gov/nchs/data/
nvsr/nvsr64/nvsr64_04.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49226
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
track C-section prevalence in the lowestrisk population, and we believe that any
reduction in the rate will inherently
overburden non-medically indicated
C-sections.
Comment: A few commenters did not
support the eCQM because they
believed the chart-abstracted version of
the measure was acceptable.
Response: We thank the commenters
for their input. We note that the NQF
has endorsed the chart-abstracted form
of this measure (PC–02: Cesarean Birth,
NQF #0471) as a voluntary consensus
standard since 2008 and continuously
renewed its endorsement (most recently
in 2020) (87 FR 28508). Additionally,
the measure steward introduced the
Cesarean Birth eCQM as one of the
available eCQMs hospitals can choose
for data submission to meet The Joint
Commission’s ORYX® requirements (87
FR 28509). We believe that the proposal
for use of the eCQM version continues
our approach to collect data derived
from EHRs and make progress toward a
transition to fully digital measurement.
We refer readers to section IX.C. of the
preamble of this final rule—‘‘Continuing
to Advance to Digital Quality
Measurement and the Use of Fast
Healthcare Interoperability Resources
(FHIR) in Hospital Quality Programs—
Request for Information’’—where we
outlined and solicited comments on
ongoing efforts to advance digital
quality measurement.
Comment: Many commenters
recommended delaying adoption of the
measure because they requested we
conduct additional testing for validity
and reliability testing.
Response: We thank commenters for
their input and feedback on this
measure. As we noted in the FY 2023
IPPS/LTCH PPS proposed rule, the
measure steward submitted the eCQM to
the NQF for consideration of
endorsement during Spring 2022 (87 FR
28509). As part of that process, it has
gone through the Scientific Methods
Panel and no major issues were raised
around measure reliability. Regarding
reliability concerns, we refer readers to
the discussion in FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28509) and in
section IX.E.5.c. of the preamble of this
final rule where we discuss the validity
and reliability testing which found that
this measure has a measure outcome
agreement rate of 83.7 percent with a
kappa score of .750 indicating
substantial agreement. Overall, the data
element agreement rate for all hospitals
was 92.2 percent. Additionally, the
measure developer notes that the
Cesarean Birth eCQM rates for the 13
hospitals who submitted both eCQM
and chart-abstracted measure results to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the measure developer for 2020
discharges were correlated. A
correlation of 0.1–0.3 is considered
weak, 0.3–0.5 is considered moderate,
and over 0.5 is considered strong. The
measure developer also clarified that the
eCQM and the chart-based (NQFendorsed) versions of the measure
correlate at 0.88 which is strong and is
statistically significant (p<0.01). Given
the severity of the maternal morbidity
crisis we believe it is important to
implement this measure as soon as
possible.
Comment: A few commenters
suggested additions to the measure to
increase alignment with the measure’s
goals. The comments included
recommendations that the measure: (1)
track efforts taken to eliminate
disparities in maternal health outcomes;
(2) track unexpected complications in
term newborns; (3) data be
disaggregated; (4) track how social
drivers of health contribute to C-section
rates; (5) exclusion criteria be
broadened; and (6) be monitored closely
to determine if the measure is tracking
useful data.
Response: We thank commenters for
their recommendations on changes to
the measure specifications. We note the
current scope of the exclusion criteria
are selected based on the most up-todate literature and then were rigorously
tested by the measure steward. While
we agree that there are many ways to
track data related to the C-section rate
in the United States, the standards and
comprehensiveness of initiatives can
vary widely. We will keep the
recommendations in mind in the future
if any changes to the eCQM are
necessary as part of our regular measure
maintenance. Regarding monitoring of
the measure’s impact, we note that, as
with all Hospital IQR Program
measures, we will monitor the data as
part of the standard measure
maintenance.
Comment: A commenter
recommended that the specifications for
the measure be published concurrently
with the final rule.
Response: As part of notice-andcomment rulemaking, we publish
measure specifications on a CMS
website for interested parties to review.
As we noted in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28509),
measure specifications for eCQMs,
including the Cesarean Birth eCQM, can
be found on the eCQI Resource Center
website, available at: https://
ecqi.healthit.gov.
Comment: A commenter
recommended that CMS clarify that the
measure tracks all procedures,
regardless of payer.
PO 00000
Frm 00448
Fmt 4701
Sfmt 4700
Response: As we noted in the FY 2023
IPPS/LTCH PPS proposed rule that the
cohort includes all pertinent patients
regardless of payer (87 FR 28509).
Comment: A few commenters
expressed concerns about the
consistency of performance data
extraction from clinical data or patient
charts or requested clarification on
extracting data from clinical notes.
Specifically, a commenter expressed
concern that not all components of the
proposed measure are identifiable using
standard coding data.
Response: We thank the commenters
for their feedback. We interpret the
commenters to mean that they have
concerns about extracting clinical data
from paper charts or notes. We refer
readers to the FY 2016 IPPS/LTCH PPS
final rule (80 FR 49705 through 49708)
and the FY 2017 IPPS/LTCH PPS final
rule (81 FR 57169 through 57170) for
our previously adopted eCQM file
format requirements. Under these
requirements, hospitals: (1) Must submit
eCQM data via the Quality Reporting
Document Architecture Category I
(QRDA I) file format as was previously
required; (2) may use third parties to
submit QRDA I files on their behalf; and
(3) may either use abstraction or pull the
data from noncertified sources in order
to then input these data into CEHRT for
capture and reporting QRDA I files.
Hospitals can continue to meet the
reporting requirements by submitting
data via QRDA I files, zero denominator
declaration, or case threshold
exemption (82 FR 38387). We encourage
hospitals to continue to work with their
EHR vendors to refine their processes
optimally.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
d. Severe Obstetric Complications
eCQM Beginning With the CY 2023
Reporting Period/FY 2025 Payment
Determination With Mandatory
Reporting Beginning With the CY 2024
Reporting Period/FY 2026 Payment
Determination and for Subsequent Years
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28510 through
28515), we proposed to adopt the Severe
Obstetric Complications eCQM as one of
the eCQMs in the Hospital IQR Program
measure set on which hospitals can selfselect to report for the CY 2023
reporting period/FY 2025 payment
determination. We also proposed to
make reporting of this eCQM mandatory
beginning with the CY 2024 reporting
period/FY 2026 payment determination
and for subsequent years.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
(1) Background
Severe maternal morbidity (SMM)
refers to unexpected outcomes due to
complications at labor and delivery that
result in significant consequences to a
woman’s health, and includes, but is not
limited to, hemorrhage, embolism,
severe hypertension, stroke, and other
serious complications.669 Despite the
highest rate of spending on maternity
care, totaling $1.4 billion dollars in FY
2021,670 the U.S. ranks worse than most
other developed nations in pregnancyrelated deaths and the rate of SMM is
continuing to steadily increase.671 672 As
reported by the CDC, the overall rate of
SMM increased almost 200 percent,
from 49.5 per 10,000 delivery
hospitalizations in 1993 to 144 per
10,000 delivery hospitalizations in
2014.673 674 675 Increasing rates of SMM
are resulting in increased healthcare
costs, longer hospitalization stays, and
short- and long-term negative outcomes
to women’s health.676 677 678 679
669 Centers for Disease Control and Prevention.
(2021). Severe Maternal Morbidity in the United
States. Available at: https://www.cdc.gov/
reproductivehealth/maternalinfanthealth/
severematernalmorbidity.html.
670 Kaiser Family Foundation. (2021). The U.S.
Government and Global Maternal and Child Health
Efforts. Available at: https://www.kff.org/globalhealth-policy/fact-sheet/the-u-s-government-andglobal-maternal-and-child-health-efforts/.
671 Centers for Disease Control and Prevention.
(2021). Severe Maternal Morbidity in the United
States. Available at: https://www.cdc.gov/
reproductivehealth/maternalinfanthealth/
severematernalmorbidity.html.
672 Maternal Health Task Force. (2015). Maternal
Health in the United States. Available at: https://
www.mhtf.org/topics/maternal-health-in-theunited-states/.
673 Centers for Disease Control and Prevention.
(2021). Severe Maternal Morbidity in the United
States. Available at: https://www.cdc.gov/
reproductivehealth/maternalinfanthealth/
severematernalmorbidity.html.
674 Leonard SA et al. (2019). Racial and ethnic
disparities in severe maternal morbidity prevalence
and trends. Annals of epidemiology. 2019;33:30–36.
675 Petersen EE, Davis NL, Goodman D, et al.
(2019). Vital signs: pregnancy-related deaths,
United States, 2011–2015, and strategies for
prevention, 13 states, 2013–2017. Morbidity and
Mortality Weekly Report. 68(18):423.
676 Vesco KK et al. (2020). Costs of Severe
Maternal Morbidity During Pregnancy in U.S.
Commercially Insured and Medicaid Populations:
An Observational Study. Maternal and Child Health
Journal,24(1):30–38.
677 Chen HY, Chauhan SP, Blackwell SC. (2018).
Severe Maternal Morbidity and Hospital Cost
among Hospitalized Deliveries in the United States.
Am J Perinatol. 2018 Nov;35(13):1287–1296. doi:
10.1055/s-0038–1649481. Epub 2018 May 3. PMID:
29723900.
678 Lin, Ching-Ching Claire, et al. (2020). ‘‘Rural–
urban differences in delivery hospitalization costs
by severe maternal morbidity status.’’ Annals of
Internal Medicine 173.11_Supplement: S59–S62.
679 Premier Inc. (2019). Report 2: The Added Cost
of Complications During and After Delivery.
Available at: https://explore.premierinc.com/
Global/FileLib/Quick_Start_Cloud/19250_
BudleofJoyReport_Report2_v7_digital.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Without proper treatment and
awareness surrounding SMM, such
complications can lead to mortality.680
While partially attributed to changes in
reporting standards, the maternal
mortality rate has also risen in the U.S.
from 17 deaths per 100,000 live births
in 1990 to 26 deaths per 100,000 live
births in 2015.681 Recent maternal
mortality data from 2018 reveal that 658
women died from pregnancy-related
complications, resulting in a rate of 17.4
deaths per 100,000 live births, with 77
percent of the deaths attributed to direct
obstetric causes like hemorrhage,
preeclampsia, obstetric embolism, and
other complications.682 683 Researchers
have found that the presence of select
maternal morbidities such as chronic
hypertension, preeclampsia, and sepsis
were strongly associated with increased
odds of mortality at the time of
delivery.684 685 Similar to maternal
mortality, the existing literature on
maternal morbidity indicates that a
significant proportion of maternal
morbidity is highly preventable.686
Therefore, timely and appropriate
treatment of maternal morbidities is
imperative to prevent complications
that can lead to maternal mortality.687
Additionally, racial and ethnic
disparities are significant; non-Hispanic
Black women are at considerably higher
risk for developing these maternal
complications than are non-Hispanic
White women.688 689 Maternal death rate
680 Kilpatrick, S.K., Ecker, J.L. (2016). Severe
Maternal Morbidity: Screening and Review.
American Journal of Obstetrics and Gynecology,
215(3):B17–B22.
681 Maternal Health Task Force. (2015). Maternal
Health in the United States. Available at: https://
www.mhtf.org/topics/maternal-health-in-theunited-states/.
682 Hoyert, D. L., & Minin
˜ o, A. M. (2020).
Maternal mortality in the United States: changes in
coding, publication, and data release, 2018.
683 St Pierre A, Zaharatos J, Goodman D,
Callaghan WM. Challenges and Opportunities in
Identifying, Reviewing, and Preventing Maternal
Deaths. Obstet Gynecol. 2018 Jan;131(1):138–142.
doi: 10.1097/AOG.0000000000002417. PMID:
29215526; PMCID: PMC6511983.
684 Campbell, K. H. et al. (2013). Maternal
Morbidity and Risk of Death at Delivery
Hospitalization. Obstetrics and Gynecology, 122(3):
627–633. Available at: https://journals.lww.com/
greenjournal/fulltext/2013/09000/Maternal_
Morbidity_and_Risk_of_Death_at_Delivery.20.aspx.
685 Mocumbi, A. O., Sliwa, K., & Soma-Pillay, P.
(2016). Medical disease as a cause of maternal
mortality: the pre-imminence of cardiovascular
pathology: review articles. Cardiovascular journal of
Africa, 27(2), 84–88.
686 Kilpatrick, S.K., Ecker, J.L. (2016). Severe
Maternal Morbidity: Screening and Review.
American Journal of Obstetrics and Gynecology,
215(3): B17.
687 Kilpatrick, S.K., Ecker, J.L. (2016). Severe
Maternal Morbidity: Screening and Review.
American Journal of Obstetrics and Gynecology.
215(3): B17.
688 Leonard, S.A., Main, E.K., Scott, K.A., Profit,
J., & Carmichael, S.L. (2019). Racial and ethnic
PO 00000
Frm 00449
Fmt 4701
Sfmt 4700
49227
data indicate wide ethnic and racial
gaps exist in maternal healthcare and
outcomes. The maternal death rate for
Black women is more than double that
of White women—37.1 deaths per
100,000 live births compared to 14.7—
and almost three times the rate
compared to Hispanic women—11.8
deaths per 100,000 live births.690
As stated in the HHS Action Plan to
Improve Maternal Health in America,691
we are pursuing a vision for improving
maternal health by focusing on: (1)
Reducing maternal mortality, including
disparities by race, ethnicity, and
geography, in 5 years; (2) reducing
SMM, including disparities by race and
ethnicity, in five years; and (3)
increasing hospital participation in
HHS-sponsored maternal health quality
improvement initiatives. As reflected in
these goals, a critical focus of our
maternal health efforts is reducing
existing disparities in maternal health
outcomes across race, ethnicity, and
geographic area. This is further reflected
in the Biden-Harris Administration’s
first ever Presidential Proclamation
recognizing Black Maternal Health
Week.692 CMS is also interested in
promoting policies that ensure
Americans who live in rural areas have
access to high quality care, particularly
in the area of maternal health where
residents in rural settings have a 9
percent greater probability of SMM and
mortality, compared with urban
residents.693 Ultimately, driving the
development and execution of evidencebased best practices in maternity care,
improving overall maternal health, and
closing the racial and ethnic disparity
gaps in outcomes are among our
disparities in severe maternal morbidity prevalence
and trends. Annals of epidemiology, 33, 30–36.
689 Petersen, E.E. et al. (2019). Vital signs:
pregnancy-related deaths, United States, 2011–
2015, and strategies for prevention, 13 states, 2013–
2017. Morbidity and Mortality Weekly Report,
68(18), 423.
690 Centers for Disease Control and Prevention.
(2020). First Data Released on Maternal Mortality in
Over a Decade. Available at: https://www.cdc.gov/
nchs/pressroom/nchs_press_releases/2020/202001_
MMR.htm.
691 U.S. Department of Health and Human
Services. Healthy Women, Healthy Pregnancies,
Healthy Futures: Action Plan to Improve Maternal
Health in America. Available at: https://
aspe.hhs.gov/sites/default/files/private/aspe-files/
264076/healthy-women-healthy-pregnancieshealthy-future-action-plan_0.pdf.
692 White House. (2021). A Proclamation on Black
Maternal Health Week. Available at: https://
www.whitehouse.gov/briefing-room/presidentialactions/2021/04/13/a-proclamation-on-blackmaternal-health-week-2021/.
693 Kozhimannil, K.B., Interrante, J.D., HenningSmith, C., & Admon, L.K. (2019). Rural-urban
differences in severe maternal morbidity and
mortality in the US, 2007–15. Health affairs, 38(12),
2077–2085.
E:\FR\FM\10AUR2.SGM
10AUR2
49228
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
agency’s top healthcare quality and
safety goals.694
Currently, the Hospital IQR Program
includes two measures that address
improving maternal health: The Elective
Delivery measure (PC–01) (77 FR 53530)
and the Maternal Morbidity Structural
measure (86 FR 45361 through 45365).
In section IX.E.5.c. of the preamble of
this final rule, we are finalizing the
adoption of the Cesarean Birth eCQM as
part of the Hospital IQR Program
measure set. However, there are
currently no maternal morbidity or
obstetric complications outcome-based
measures in the Hospital IQR Program.
The Severe Obstetric Complications
eCQM has been developed to focus on
the high maternal morbidity and
mortality rates in the U.S., which we
believe will present important
opportunities for large-scale quality
measurement and improvement
activities in the Hospital IQR
Program.695 Statistics on preventability
vary but suggest that a considerable
proportion of maternal morbidity and
mortality events could be
prevented.696 697 This measure is
intended to facilitate safer patient care
by increasing awareness of the danger of
obstetric complications, promoting
adherence to recommended clinical
guidelines, and encouraging hospitals to
track and improve their practices of
appropriate monitoring and care
delivery for pregnant and postpartum
patients.
Under CMS’ Meaningful Measures
Framework, the Severe Obstetric
Complications eCQM addresses the
quality priority of ‘‘Make Care Safer by
Reducing Harm Caused in the Delivery
of Care’’ through the Meaningful
Measures Area of ‘‘Preventable
Healthcare Harm.’’ Additionally,
pursuant to Meaningful Measures 2.0,
this measure addresses the ‘‘Safety’’
priority area and aligns with our
commitment to a patient-centered
approach in quality measurement to
694 Centers for Medicare & Medicaid Services.
(2021). Evidence-based best practices for hospitals
in managing obstetric emergencies and other key
contributors to maternal health disparities.
Available at: https://www.cms.gov/files/document/
qso-22-05-hospitals.pdf.
695 National Quality Forum. (2022). Measure
Applications Partnership (MAP) 2021–2022 Final
Recommendations. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96698.
696 Davis, N.L., Smoots, A.N., & Goodman, D.A.
(2019). Pregnancy-Related Deaths: Data from 14 US
Maternal Mortality Review Committees. Education,
40(36), 8–2.
697 Geller SE, Rosenberg D, Cox SM, et al. (2004).
The continuum of maternal morbidity and
mortality: factors associated with severity.
American journal of obstetrics and gynecology,
191(3):939–944.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
ensure that patients are safe and receive
the highest quality care.698
Therefore, in the proposed rule, we
proposed the adoption of the Severe
Obstetric Complications eCQM
beginning with the CY 2023 reporting
period/FY 2025 payment determination.
We previously finalized that hospitals
must report on three self-selected
eCQMs and the Safe Use of Opioids—
Concurrent Prescribing eCQM, for a
total of four eCQMs in the CY 2023
reporting period/FY 2025 payment
determination (85 FR 58939). In the
proposed rule, we proposed to include
this measure as part of the measure set
in the Hospital IQR Program which
hospitals will be able to self-select for
the CY 2023 reporting period/FY 2025
payment determination. After which,
beginning with the CY 2024 reporting
period/FY 2026 payment determination
and for subsequent years, we proposed
to require reporting of the Severe
Obstetric Complications eCQM by all
hospitals except those hospitals that do
not perform deliveries or have an
obstetrics department. We refer readers
to section IX.E.10.e. of preamble of this
final rule for our related policy to
modify the eCQM reporting and
submission requirements beginning
with the CY 2024 reporting period/FY
2026 payment determination.
(2) Overview of Measure
This measure assesses the proportion
of patients with severe obstetric
complications which occur during the
inpatient delivery hospitalization. The
Severe Obstetric Complications eCQM
was included in the publicly available
‘‘List of Measures Under Consideration
for December 1, 2021’’ (MUC List).699
The MAP Rural Health Advisory Group
reviewed the MUC List and the Severe
Obstetric Complications eCQM (MUC
2021–104) on December 8, 2021.700 The
MAP Rural Health Advisory Workgroup
discussed questions regarding the
specifications of the measure. First,
there was discussion about the use of
blood transfusions as an intervention
and concern that blood transfusions
698 Centers for Medicare & Medicaid Services.
Meaningful Measures 2.0: Moving from Measure
Reduction to Modernization. Available at: https://
www.cms.gov/meaningful-measures-20-movingmeasure-reduction-modernization. We note that
Meaningful Measures 2.0 is still under
development.
699 Centers for Medicare & Medicaid Services.
(2021). List of Measures Under Consideration for
December 1, 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96464.
700 National Quality Forum. (2022). Measure
Applications Partnership Rural Health Advisory
Group Virtual Review Meeting. Available at:
https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96571.
PO 00000
Frm 00450
Fmt 4701
Sfmt 4700
would be excluded and/or delayed
when clinical evidence indicates that
patients would benefit from transfusions
as an earlier intervention. The measure
developer provided clarification that
this measure reports two outcomes, one
that includes all patients that meet the
numerator criteria, and one that
excludes patients whose only
qualification for the numerator is a
transfusion.701 This is as a recognition
that transfusions may be necessary for a
number of reasons and for less severe
complications. Second, the MAP Rural
Health Advisory Workgroup discussed
that rural settings have high maternal
morbidity and mortality and that this
measure would help improve maternal
health outcomes, and that since the
measure is risk adjusted for the presence
of economic/housing instability the
measure has a focus on accounting for
potential disparities. The measure
developer added that as an EHR-based
measure, these data are patient-specific
and the measure was tested in both rural
and urban settings.702 The Workgroup
voted majority support in agreement of
the applicability of the Severe Obstetric
Complications eCQM to rural health
settings.703
The Severe Obstetric Complications
eCQM (MUC2021–104) was also
reviewed by the NQF MAP Hospital
Workgroup on December 15, 2021, and
received conditional support pending
NQF endorsement.704 Some MAP
stakeholders expressed concerns about
the minimum sample size and low case
volumes as well as the risk adjustment
methodology. The measure developer
underscored for the MAP that this
measure was tested in ten health
systems which represented 28 hospitals
and tested over 60,000 delivery
encounters, and there was no concern
701 National Quality Forum. (2022). Measure
Applications Partnership Rural Health Advisory
Group Virtual Review Meeting. Available at:
https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96571.
702 National Quality Forum. (2022). Measure
Applications Partnership Rural Health Advisory
Group Virtual Review Meeting. Available at:
https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96571.
703 National Quality Forum. (2022). Measure
Applications Partnership Rural Health Advisory
Group Virtual Review Meeting. Available at:
https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96571.
704 National Quality Forum. (2022). Measure
Applications Partnership 2021–2022 Considerations
for Implementing Measures in Federal Programs:
Clinician, Hospital, and Post-Acute Care Long-Term
Care: Final Report. Available at: https://
www.qualityforum.org/Publications/2022/03/MAP_
2021-2022_Considerations_for_Implementing_
Measures_Final_Report_-_Clinicians,_Hospitals,_
and_PAC-LTC.aspx.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
about case volumes.705 The measure
developer also clarified that testing was
underway to evaluate the ideal risk
adjustment methodology to determine
approaches that would consider
stratification based on
sociodemographic factors, such as race
and ethnicity, pre- and post-risk
adjustment. We emphasized the
importance of this measure and its role
in helping hospitals to understand the
disparities existent in maternal health
outcomes.706 Ultimately, MAP Hospital
Workgroup stakeholders supported this
measure and recommended conditional
support because it would assist in
surveillance on maternal morbidity, a
clinical area that needs further
measurement.707 The MAP
Coordinating Committee, which
provides direction to the MAP
workgroups, reviewed the Severe
Obstetric Complications eCQM
(MUC2021–104) on January 19, 2022,
and voted to uphold the MAP Hospital
Workgroup recommendation for
conditional support pending NQF
endorsement.708
In January 2022, the Severe Obstetric
Complications eCQM was submitted for
endorsement by NQF, and is currently
under review. We note that section
1866(b)(3)(B)(viii)(IX)(aa) of the Act
requires that any measure specified by
the Secretary must have been endorsed
by the entity with a contract under
section 1890(a) of the Act (the NQF is
the entity that currently holds this
contract). Under section
1886(b)(3)(B)(viii)(IX)(bb) of the Act, in
the case of a specified area or medical
topic determined appropriate by the
Secretary for which a feasible and
practical measure has not been endorsed
by the entity with a contract under
section 1890(a) of the Act, the Secretary
705 National Quality Forum. (2022). Meeting
Transcript—Virtual Review Meeting. Available at:
https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96632.
706 National Quality Forum. (2022). Meeting
Transcript—Virtual Review Meeting. Available at:
https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96632.
707 National Quality Forum. (2022). Measure
Applications Partnership 2021–2022 Considerations
for Implementing Measures in Federal Programs:
Clinician, Hospital, and Post-Acute Care Long-Term
Care: Final Report. Available at: https://
www.qualityforum.org/Publications/2022/03/MAP_
2021-2022_Considerations_for_Implementing_
Measures_Final_Report_-_Clinicians,_Hospitals,_
and_PAC-LTC.aspx.
708 National Quality Forum. (2022). Measure
Applications Partnership 2021–2022 Considerations
for Implementing Measures in Federal Programs:
Clinician, Hospital, and Post-Acute Care Long-Term
Care: Final Report. Available at: https://
www.qualityforum.org/Publications/2022/03/MAP_
2021-2022_Considerations_for_Implementing_
Measures_Final_Report_-_Clinicians,_Hospitals,_
and_PAC-LTC.aspx.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
may specify a measure that is not so
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary.
We reviewed NQF-endorsed measures
and were unable to identify any other
NQF-endorsed measures on this topic,
and, therefore, we believe the exception
in section 1886(b)(3)(B)(viii)(IX)(bb) of
the Act applies.
To evaluate the validity, feasibility,
and reliability of the measure, in 2021,
the measure developer, conducted pilot
testing in a total of 10 sites, consisting
of 28 hospitals. The measure developer
conducted alpha testing (formative
testing) 709 and beta testing (field
testing) 710 on the measure. Feasibility
testing was conducted to assess data
collection and accessibility, and
included nine sites in the analysis,
which consisted of 27 hospitals and
three different EHR systems.711 Using
NQF’s eCQM Feasibility Scorecard
template,712 the measure developer
calculated results which indicated high
feasibility of data elements defining the
measure specifications (98 percent),
clinical and documentation workflows
compared to measure intent (99
percent), data element availability (95
percent) and accuracy (98 percent), and
use of data standards (96 percent).
Following feasibility testing, one site
representing two hospitals withdrew
from the project, one site representing
one hospital was unable to submit beta
testing data in the timeline requested,
and one site representing one hospital
was added; as a result, the measure
developer conducted beta testing in
eight healthcare test sites and 25
hospitals, representing three different
EHR systems. The measure developer
709 Centers for Medicare & Medicaid Services.
(2018). Alpha tests include methods to determine
if individual data elements are available and if the
form in which they exist is consistent with the
intent of the measure. Measure Testing NMS
Newsletter. Available at: https://www.cms.gov/
Medicare/Quality-Initiatives-Patient-AssessmentInstruments/MMS/Downloads/Measure_Testing_
MMS_Newsletter_April_2018.pdf.
710 Centers for Medicare & Medicaid Services.
(2018). Beta tests serve as the primary means to
assess scientific acceptability and usability of a
measure including gathering further information
about feasibility. Measure Testing NMS Newsletter.
Available at: https://www.cms.gov/Medicare/
Quality-Initiatives-Patient-Assessment-Instruments/
MMS/Downloads/Measure_Testing_MMS_
Newsletter_April_2018.pdf.
711 Centers for Medicare & Medicaid Services.
(2018). eCQM Feasibility: How Stakeholders Inform
Measure Development. Available at: https://
www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/MMS/Downloads/eCQMFeasibility.pdf.
712 National Quality Forum. (2022). NQF eCQM
Feasibility Scorecard. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=89036.
PO 00000
Frm 00451
Fmt 4701
Sfmt 4700
49229
pulled data for delivery hospital
encounters discharged from January 1 to
December 31, 2020. During measure
testing, the measure score reliability was
assessed, which is the degree to which
repeated measurements of the same
entity agree with each other.713 The
measure developer estimated the
measure score reliability using a signalto-noise ratio to assess the values
according to conventional standards.
They assessed signal-to-noise reliability
that describes how well the measure can
distinguish the performance of one
hospital from another. The signal is the
proportion of the variability in
measured performance that can be
explained by real differences in
performance. Scores can range from zero
to one, where a score of zero implies
that all the variability in a measure is
attributable to measurement error, and a
score of one implies that all the
variability is attributable to real
difference in performance. The
reliability analysis yielded a median
reliability score of 0.991 (range: 0.983–
0.997) for any severe obstetric
complication and 0.957 (range: 0.918–
0.984) for severe obstetric complications
excluding blood transfusion-only cases.
The measure developer completed
validity testing on six sites representing
15 hospitals, which was a statistically
relevant sample of electronically
submitted inpatient encounters selected
for re-abstraction for reliability testing
and clinical adjudication from six of the
beta testing sites. Validity testing of the
measure refers to the correctness of
conclusions about the quality of
measured entities that can be made
based on the measure scores (that is a
higher score on a quality measure
reflects higher quality).714 Overall, the
data element agreement rate for all six
sites was 90.4 percent. Further, validity
testing of the measure showed a
performance score agreement rate of
91.2 percent with a kappa score of .881
indicating good agreement. Measure
score validity testing revealed a high
positive predictive value (rate of
agreement) of 94.7 percent, and a
713 Centers for Medicare & Medicaid Services.
(2018). CMS Measures Management System (MNS)
Testing Scientific Acceptability for de novo
eCQMS. Available at: https://www.cms.gov/
Medicare/Quality-Initiatives-Patient-AssessmentInstruments/MMS/Downloads/CMS-MMS-WebinarBP101-%E2%80%93-Scientific-Acceptability-ofeCQMs.pptx.
714 National Quality Forum. (2011). Guidance for
Measure Testing and Evaluating Scientific
Acceptability of Measure Properties. Available at:
https://www.qualityforum.org/Measuring_
Performance/Improving_NQF_Process/Measure_
Testing_Task_Force_Final_Report.aspx#:∼:
text=Validity%20of%20the%20measure%20score,
quality%20measure%20reflects%20higher
%20quality.
E:\FR\FM\10AUR2.SGM
10AUR2
49230
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
negative predictive value of 100 percent.
Likewise, sensitivity (responsiveness to
change) and specificity (accuracy)
across test sites for the measure score
were high, at 100 percent and 90.5
percent, respectively.
The measure developer conducted
testing of the Severe Obstetric
Complications eCQM and found that
across 60,184 delivery encounters at 8
different sites, the current observed rate
of any severe obstetric complications
was 244 and the mean risk-standardized
rate across test sites was 247 (per 10,000
delivery hospitalizations). The severe
obstetric complications rate excluding
blood transfusion-only cases was 50 for
both the observed rate and the mean
risk-standardized rate across test sites
(per 10,000 delivery hospitalizations).
Through rigorous testing, the measure
developer found that the measure was
feasible, reliable, and valid.
The measure specifications for the
Severe Obstetric Complications eCQM
can be found on the eCQI Resource
Center website, available at: https://
ecqi.healthit.gov/pre-rulemaking-ehcah-ecqms.
(3) Data Sources
The eCQM uses data collected
through hospitals’ EHRs. The measure is
designed to be calculated by the
hospitals’ CEHRT using the patient-level
data and then submitted by hospitals to
CMS.
(4) Outcome
The outcome of interest (numerator)
for the Severe Obstetric Complications
eCQM is the number of inpatient
hospitalizations for patients with severe
obstetric complications occurring
during the delivery hospitalization, not
present on admission, which include
the following: Severe maternal
morbidity diagnoses (we refer readers to
the subsequent table); severe maternal
morbidity procedures, including blood
transfusion, conversion of cardiac
rhythm, hysterectomy, temporary
tracheostomy, and ventilation; or a
discharge disposition of expired.715 716
Table IX.E–03. summarizes the severe
maternal morbidity categories along
with their corresponding diagnoses:
TABLE IX.E-03. SEVERE MATERNAL MORBIDITY DIAGNOSIS SPECIFIED IN
THE NUMERATOR DEFINITION
Hemorrhage
Renal
Respiratory
Sepsis
Other Obstetric Complications
(OB)
Other Medical Complications
This measure is intended to report
two outcomes: (1) Severe obstetric
complications; and (2) severe obstetric
complications, but excluding delivery
hospitalizations for which blood
transfusion was the only numerator
event.
khammond on DSKJM1Z7X2PROD with RULES2
(5) Cohort
The measure cohort (denominator)
consists of inpatient hospitalizations for
patients between eight years of age and
less than 65 years of age admitted to the
hospital for inpatient acute care who
undergo a delivery procedure for a
stillbirth or livebirth greater than or
715 eCQI Resource Center. (2022). Eligible
Hospital/Critical Access Hospital Pre-rulemaking
eCQMs. Available at: https://ecqi.healthit.gov/prerulemaking-eh-cah-ecqms.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Severe Maternal Morbidity Diagnoses
Acute heart failure
Acute myocardial infarction
Aortic aneurysm
Cardiac arrest/ventricular fibrillation
Heart failure/arrest during procedure or surgery
Disseminated intravascular coagulation
Shock
Acute renal failure
Adult respiratory distress syndrome
Pulmonarv edema
Sepsis
Air and thrombotic embolism
Amniotic fluid embolism
Eclamosia
Severe anesthesia complications
Puerperal cerebrovascular disease
Sickle cell disease with crisis
equal to 20 weeks’ gestation, with a
discharge date that ends during the
measurement period. Patients with
confirmed diagnosis of COVID–19 with
COVID–19-related respiratory condition
or patients with confirmed diagnosis of
COVID–19-related respiratory procedure
are excluded from the measure
calculation.717
(6) Risk Adjustment
The Severe Obstetric Complications
eCQM is a risk-adjusted measure. The
measure developer identified candidate
risk variables for severe obstetric
complications for consideration in the
716 The Joint Commission. (2021). eCQM
Specifications 2022 Reporting Period. Available at:
https://www.jointcommission.org/-/media/tjc/
documents/measurement/specification-manuals/
2022-reporting-period/january-2022/ecqm_
specifications_reportingperiod_2022.zip.
PO 00000
Frm 00452
Fmt 4701
Sfmt 4700
measure risk adjustment model by
utilizing literature and research
findings, consulting with an expert
clinical consultant, and by soliciting
input from a technical expert panel
(TEP). Following the identification of
candidate risk adjustment variables, the
measure developer developed risk
models for the outcomes of severe
obstetric complications and severe
obstetric complications excluding blood
transfusion-only encounters. The
measure developer then utilized the
variables included in the final risk
models for use as the risk adjustment
variables when calculating the risk
717 eCQI Resource Center. (2022). Eligible
Hospital/Critical Access Hospital Pre-rulemaking
eCQMs. Available at: https://ecqi.healthit.gov/prerulemaking-eh-cah-ecqms.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.158
Severe Maternal Morbidity
Diaenoses Cateeorv
Cardiac
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
standardized severe obstetric
complication rates for the two versions
of the measure outcome (with and
without transfusion-only encounters).
Variables included in the measure’s
risk adjustment are: patient age; several
preexisting conditions that are present
on admission defined by ICD–10 codes
(listed later in the section); pregnancy
characteristics; laboratory tests and vital
signs upon hospital arrival (hematocrit,
white blood cell (WBC) count, heart
rate, systolic blood pressure); long term
anticoagulant medication use; and
social risk measured by the presence of
economic/housing instability.
The following preexisting conditions
and pregnancy characteristics, defined
by ICD–10 codes, are included in the
measure’s risk adjustment: Anemia,
asthma, autoimmune disease, bariatric
surgery, bleeding disorder, Body Mass
Index (BMI), cardiac disease,
gastrointestinal disease, gestational
diabetes, Human Immunodeficiency
Virus (HIV), Hypertension, mental
health disorder, multiple pregnancy,
neuromuscular disease, obstetric venous
thromboembolism (VTE), other preeclampsia, placental accreta spectrum,
placental abruption, placenta previa,
preexisting diabetes, preterm birth,
previous cesarean, pulmonary
hypertension, renal disease, severe preeclampsia, substance abuse, and
thyrotoxicosis.
khammond on DSKJM1Z7X2PROD with RULES2
(7) Measure Calculation
The measure is an outcome measure
that assesses the risk-standardized
proportion of eligible patients with
severe obstetric complications, and the
risk-standardized proportion of eligible
patients with severe obstetric
complications excluding transfusiononly hospital delivery encounters,
which occur during the inpatient
delivery hospitalization. The measure
calculates the proportion of inpatient
hospitalizations with severe obstetric
complications occurring during the
delivery hospitalization out of the total
number of inpatient hospitalizations for
patients delivering stillborn or live birth
with greater than or equal to least 20
weeks and 0 days of gestation
completed. The measure score will be
reported as a rate per 10,000 deliveries.
(8) Data Submission and Reporting
We refer readers to: Section IX.E.10.e.
of the preamble of this final rule for
discussion of our previously finalized
eCQM reporting and submission
policies; and section IX.E.13.b. for the
public reporting of eCQM data.
Additionally, we refer readers to section
IX.E.10.e.(4). where we discuss the use
of the zero denominator declarations
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
and case threshold exemption policies
for hospitals.
We also refer readers to four related
proposals discussed in the preamble of
this final rule: (1) Section IX.E.10.e.
where we discuss modifications to our
reporting and submission requirements
for eCQMs, including a discussion of
our policy to require hospitals to report
on the Severe Obstetric Complications
eCQM; (2) section IX.E.5.c. for our
policy to adopt the Cesarean Birth
eCQM; (3) section IX.H.10.a.(2). of the
preamble of this final rule for a
discussion of similar policies to adopt
these two perinatal eCQMs in the
Medicare Promoting Interoperability
Program for Eligible Hospitals and
CAHs; and (4) section IX.E.8. where we
are establishing a publicly-reported
hospital designation to capture the
quality and safety of maternity care and
other related activities in advancing
maternal health equity.
We invited public comment on this
proposal.
Comment: Many commenters support
the proposed adoption of the Severe
Obstetric Complications eCQM
beginning with the CY 2023 reporting
period/FY 2025 payment determination
and mandatory reporting beginning with
the CY 2024 reporting period/FY 2026
payment determination and for
subsequent years. A few commenters
indicated that they supported the
measure because the measure aligns
with existing state or Joint Commission
reporting practices.
Response: We thank the commenters
for their support and agree that the
measure is in line with best practices for
improving maternal morbidity and
mortality rates.
Comment: A few commenters
expressed support for the measure but
had recommendations for how the
measure should be implemented. A
commenter recommended that COVID–
19 patients not be excluded. A
commenter recommended monitoring
the measure in the future to determine
whether modifications would be
appropriate.
Response: We thank commenters for
their recommendations. Regarding
ongoing monitoring of the measure’s
performance, impact on reporters, and
alignment with the measure’s goals, we
will monitor the data for any
unintended consequences as part of the
standard measure maintenance.
Regarding the COVID–19 exclusions, at
this time patients with confirmed
diagnosis of COVID–19, with COVID–
19-related respiratory condition or with
COVID–19-related respiratory procedure
are excluded from the measure
calculation (87 FR 28514). The measure
PO 00000
Frm 00453
Fmt 4701
Sfmt 4700
49231
currently excludes COVID–19 patients
from the measure cohort due to
potential concerns of the COVID–19
impact on maternal health. We will
continue to monitor the impact of
COVID–19 on the measure’s
performance and alignment with the
measure’s goals as part of the standard
measure maintenance.
Comment: A few commenters either
expressed concern about the impact that
public reporting may have on low
volume hospitals or requested
clarification on how non-birthing
hospitals would be affected by the
adoption of the measure.
Response: We thank the commenter
for their requested clarification on how
hospitals without birthing programs
would be affected. In the FY 2023 IPPS/
LTCH PPS proposed rule, we stated the
Severe Obstetric Complications eCQM
would be reported by all hospitals
participating in the Hospital IQR
Program except those hospitals that do
not have an obstetrics department (87
FR 28512). We refer readers to section
IX.E.10.e.(4). of this final rule where we
discuss the Hospital IQR Program’s zero
denominator declarations and case
threshold exemption policies for
eCQMs. Zero denominator declarations
allow a hospital whose EHR is capable
of reporting eCQM data to submit a zero
in the denominator for the reporting of
an eCQM if the hospital does not have
patients that meet the denominator
criteria of that measure. Similarly, the
case threshold exemptions policy allows
for a hospital with five or fewer
inpatient discharges per quarter or 20 or
fewer inpatient discharges per year in a
given denominator declaration be
exempted from reporting on that
individual eCQM. We refer readers to
the FY 2016 IPPS/LTCH PPS final rule
(80 FR 49705 through 49708) and the FY
2017 IPPS/LTCH PPS final rule (81 FR
57170) for our previously adopted
eCQM file format requirements.
Hospitals can continue to meet the
reporting requirements by submitting
data via QRDA I files, zero denominator
declaration, or case threshold
exemption (82 FR 38387).
Comment: A commenter requested
clarification on the definition and
appropriate documentation of ‘‘housing
instability.’’
Response: Housing instability is
included in the risk adjustment for this
measure due to evidence for its
inclusion and availability in the EHR.718
718 Centers for Medicare & Medicaid Services.
(2021). Severe Obstetric Complications Electronic
Clinical Quality Measure (eCQM) Methodology
Report: Version 1. Available at: https://
E:\FR\FM\10AUR2.SGM
Continued
10AUR2
49232
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
available on the eCQI Resource Center
website at: https://ecqi.healthit.gov/,
economic housing instability is defined
by the National Library of Medicine
(NLM) value set 719
(2.16.840.1.113762.1.4.1029.292)
comprising the following ICD–10 Z
codes:
259.0
Homelessness
259.1
Inadequate housing
259.2
Discord with neighbors, lodgers and landlord
259.3
Problems related to living in residential institution
259.4
Lack of adequate food
259.5
Extreme poverty
259.6
Low income
259.7
Insufficient social insurance and welfare support
259.8
Other problems related to housing and economic circumstances
259.9
Problem related to housing and economic circumstances, unspecified
Comment: Several commenters did
not support the measure because they
believed it does not provide a
meaningful measure for driving
improvements in maternal health
disparities and would not encourage
hospitals to take the desired actions to
mitigate severe maternal morbidity.
Response: We appreciate the
commenters’ concerns and respectfully
disagree that the proposed measure does
not provide a meaningful measure for
driving improvements in maternal
health disparities. We believe that this
measure serves as a key activity in
measuring and promoting quality
improvement in maternity care by
incentivizing hospitals to track and
report severe obstetric complications
and to publicly report measure data for
transparency.
Comment: A commenter believed the
measure may not be feasible.
Response: The measure developer’s
testing established the feasibility of the
measure, first in 25 hospitals across
eight healthcare sites and then in an
additional hospital unaffiliated with the
first 25, and across several different
electronic health record systems. Based
on the testing performed, we
respectfully disagree that the measure is
not feasible. All numerator indicators
and 30 of 34 risk factors use easily
mapped ICD–10 codes.720 The two
laboratory and two vital sign risk factors
were chosen in part because of their
availability and high rates of
extractability from the medical record.
Comment: Several commenters either
did not support the measure or
expressed concerns about the proposed
eCQM due to perceived resource
limitations or because they believed the
adoption timeline is too rapid.
Response: We acknowledge
commenters’ concerns and believe that
the maternal health crisis requires
urgent action without delay. In addition,
we refer readers to section XII.B.4. for
information on measure burden and
note that, as with all Hospital IQR
Program measures, we will monitor the
data and any unintended consequences
of the measure as part of the standard
measure maintenance.
Comment: Many commenters
recommended that the measure be
adopted only once it is NQF endorsed.
A few commenters recommended that
the measure be risk adjusted or the
exclusion criteria broadened. A few
commenters recommended
disaggregated or stratified data
reporting. A commenter recommended
that the measure be finalized with
voluntary reporting and believed
facilities are better positioned to set
clinical priorities. A commenter
recommended making the measure
modifiable in case new risk factors are
identified.
Response: We acknowledge
commenters’ recommendations that we
seek NQF endorsement for the measure.
As we stated in the FY 2023 IPPS/LTCH
PPS proposed rule that the Severe
Obstetric Complication eCQM was
submitted to NQF in January 2022 and
is currently under review (87 FR 28512).
As there are currently no NQF-endorsed
measures that address severe obstetric
complications, we believe the exception
at section 1886(b)(3)(B)(viii)(IX)(bb) of
the Act applies.
We further thank commenters for
their recommendations on changes to
the measure specifications. We note that
the measure is risk adjusted by several
variables including patient age, several
preexisting conditions, pregnancy
characteristics, laboratory test results,
long term anticoagulant medication use,
and social risk (87 FR 28514). In the FY
2023 IPPS/LTCH PPS proposed rule, we
also stated that the measure developer is
currently conducting testing to
determine approaches that would
consider stratification based on
sociodemographic factors (87 FR 28512).
We also refer readers to section IX.B.
(Overarching Principles for Measuring
Healthcare Quality Disparities Across
CMS Quality Programs—Request for
Information) for additional discussion
on CMS’ potential use of measure
stratification in the future. We also
regularly conduct measure maintenance
and evaluate whether any modifications
to measures are necessary. Any
substantive changes to measures would
be proposed in future notice-andcomment rulemaking.
In regard to voluntary reporting and
prioritization, we believe that the
maternal health crisis is urgent,
maternal health inequities are
unacceptable, and this persistent
problem requires prompt action.
Therefore, we believe allowing hospitals
to self-select reporting beginning with
the CY 2023 reporting period/FY 2025
payment determination and require
www.cms.gov/files/document/measuremethodology-report.pdf.
719 https://vsac.nlm.nih.gov/valueset/
2.16.840.1.113762.1.4.1029.292/expansion/Latest.
720 eCQI Resource Center. (2022). Eligible
Hospital/Critical Access Hospital Pre-rulemaking
eCQMs. Available at: https://ecqi.healthit.gov/prerulemaking-eh-cah-ecqms.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00454
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.159
khammond on DSKJM1Z7X2PROD with RULES2
While not explained in the proposed
ruled, we are clarifying here that for
purposes of this measure consistent
with the measure specifications
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
reporting beginning with the CY 2024
reporting period/FY 2026 payment
determination is imperative.
Comment: A commenter
recommended that the measure only
report the second outcome of the Severe
Obstetric Complications eCQM (the
outcome of severe complications
excluding transfusion-only encounters)
because the commenter believes it
would be inappropriate to publicly
report the outcome of the severe
obstetric complications with transfusion
as the measure does not place a
threshold on the number of units of
blood involved in the transfusion. A
commenter expressed concern that there
may be negative unintended
consequences.
Response: We appreciate commenters’
concerns. As proposed, this measure is
intended to report two outcomes: (1)
Severe obstetric complications; and (2)
severe obstetric complications but
excluding delivery hospitalizations for
which blood transfusion was the only
numerator event (87 FR 28512, 28514).
We believe that reporting on both
outcomes is necessary to advance the
goals of this eCQM. We note that we do
not anticipate any unintended
consequences, but as with all Hospital
IQR Program measures, we will monitor
the data for any unintended
consequences as part of the standard
measure maintenance.
Comment: A commenter expressed
concern about the complexity of
documenting the procedures and
outcomes indicated in this measure and
suggested that CMS assess whether the
procedures reportable in the measures
are documented in medical records
(specifically, ventilation and
transfusion).
Response: We thank the commenter
for their recommendation. We
appreciate the commenter’s
recommendation about evaluating the
accuracy and applicability of the
procedures reported under this measure.
We note that these procedures are
currently defined with ICD–10
procedure codes in the measure
specifications, which can be found at
https://ecqi.healthit.gov/ (87 FR 28513
through 28514). The measure developer
conducted medical record reviews to
test the validity of the procedure codes
and found high positive predictive
value for both ventilation and
transfusion.
Comment: A few commenters raised
concerns that conditions accounted for
in the numerator may not be
predictable, preventable, or indicators of
the quality of care provided. A
commenter raised concerns that the
eCQM data requirement is not aligned
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
with current clinical practice guides on
data collected, meaning that standards
of practice will be negatively affected. A
commenter raised concerns that the
non-birthing hospitals may score
disproportionately high if the measure
is adopted because they may have zerodenominator measures. A few
commenters requested clarification on
how rates would be reportable if the
volume of delivery hospitalizations was
so low as to make only one rate
reportable.
Response: We appreciate the
commenters’ concerns about measure
data. As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule, the measure
developer conducted rigorous testing
and found the measure to be valid,
feasible, and reliable (87 FR 28513).
With regard to concerns about low rates,
we note that the measure developer
conducted measure score reliability
testing in both rural and urban settings,
and that the thresholds for
consideration for implementation of
public reporting were found to be
appropriate due to the risk-adjustment
for the presence of economic/housing
instability, the measure has a focus on
accounting for potential disparities; the
measure was tested in ten health
systems with varying case volumes and
no concerns were identified for lowvolume hospitals (87 FR 28512).
Regarding potential zero-denominator
reporting hospitals, we believe this will
not be a problem because, as stated
previously, in the FY 2023 IPPS/LTCH
PPS proposed rule that the Severe
Obstetric Complications eCQM would
be reported by all hospitals except those
hospitals that do not have an obstetrics
department and therefore zerodenominator hospitals would be exempt
(87 FR 28512).
We refer readers to section
IX.E.10.e.(4). of this final rule where we
discuss the Hospital IQR Program’s zero
denominator declarations and case
threshold exemption policies for
eCQMs. Zero denominator declarations
allow a hospital whose EHR is capable
of reporting eCQM data to submit a zero
in the denominator for the reporting of
an eCQM if the hospital does not have
patients that meet the denominator
criteria of that hybrid measure (82 FR
38387). Similarly, the case threshold
exemptions policy allows for a hospital
with five or fewer inpatient discharges
per quarter or 20 or fewer inpatient
discharges per year in a given
denominator declaration be exempted
from reporting on that individual eCQM
(82 FR 38387).
Comment: A commenter requested
guidance on extrapolating data from
clinical notes and patient records.
PO 00000
Frm 00455
Fmt 4701
Sfmt 4700
49233
Response: We reiterate that this is an
eCQM in which the data is collected
through hospitals’ EHR and designed to
be calculated by the hospital’s CEHRT
(87 FR 28513). For more information
regarding data submission, we refer
readers to section IX.E.10.a. for
discussion of our previously finalized
eCQM reporting and submission
requirements and to the measure
specifications, which can be found at
https://ecqi.healthit.gov.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
e. Hospital-Harm—Opioid-Related
Adverse Events eCQM (NQF #3501e)
Beginning With the CY 2024 Reporting
Period/FY 2026 Payment Determination
and for Subsequent Years
(1) Background
Opioids are among the most
frequently implicated medications in
adverse drug events among hospitalized
patients.721 The most serious opioidrelated adverse events include those
involving respiratory depression, which
can lead to brain damage and
death.722 723 724 Opioid-related adverse
events have both a negative impact on
patients and financial implications.
Patients who experience adverse events
due to opioid administration have been
noted to have 55 percent longer lengths
of stay, 47 percent higher costs, 36
percent higher risk of 30-day
readmission, and 3.4 times higher
payments than patients without these
adverse events.725 While noting that
data are limited, The Joint Commission
suggested that opioid-induced
respiratory arrest may contribute
721 Davies EC, Green CF, Taylor S, Williamson
PR, Mottram DR, et al. (2009) Adverse Drug
Reactions in Hospital In-Patients: A Prospective
Analysis of 3695 Patient-Episodes. PLoS ONE 4(2):
e4439. doi:10.1371/journal.pone.0004439.
722 Jungquist CR, Quinlan-Colwell A, Vallerand
A, et al. (2020). American Society for Pain
Management Nursing Guidelines on Monitoring for
Opioid-Induced Advancing Sedation and
Respiratory Depression: Revisions. Pain Manag
Nurs.21(1):7–25. Epub 2019 Jul 31.
723 Ramachandran SK, Haider N, Saran KA, et al.
(2011). Life-threatening critical respiratory events: a
retrospective study of postoperative patients found
unresponsive during analgesic therapy. Journal of
Clinical Anesthesia. 23(3):207–213.
724 Dahan A, Aarts L, Smith TW. (2010).
Incidence, Reversal, and Prevention of Opioidinduced Respiratory Depression. Anesthesiology.
112(1):226–238.
725 Kessler, E.R., Shah, M., Gruschkkus, S.K., et
al. (2013). Cost and quality implications of opioidbased postsurgical pain control using
administrative claims data from a large health
system: opioid-related adverse events and their
impact on clinical and economic outcomes.
Pharmacotherapy, 33(4): 383–91.
E:\FR\FM\10AUR2.SGM
10AUR2
49234
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
substantially to the 350,000 to 750,000
in-hospital cardiac arrests annually.726
Most opioid-related adverse events
are preventable.727 Of the opioid-related
adverse drug events reported to The
Joint Commission’s Sentinel Event
database, 47 percent were due to a
wrong medication dose, 29 percent due
to improper monitoring, and 11 percent
due to other causes (for example,
medication interactions and/or drug
reactions).728 In addition, in a review of
cases from a malpractice claims
database in which there was opioidinduced respiratory depression among
post-operative surgical patients, 97
percent of these adverse events were
judged preventable with better
monitoring and response.729
While hospital quality interventions
such as proper dosing, adequate
monitoring, and attention to potential
drug interactions that can lead to
overdose are key to prevention of
opioid-related adverse events, the use of
these practices can vary substantially
across hospitals.730 731 732 In addition,
administration of opioids also varies
widely by hospital, ranging from 5
percent in the lowest-use hospital to 72
percent in the highest-use hospital.733
Notably, hospitals that use opioids most
frequently have increased adjusted risk
of severe opioid-related adverse
events.734 The measure developer,
726 Overdyk, F.J. (2009). Postoperative Respiratory
Depression and Opioids. Initiatives in Safe Patient
Care. Available at: https://www.initiativespatientsafety.org/_files/ugd/ba15f5_
d52da446e2f141d7be95d3a99b538a42.pdf.
727 Lee LA, Caplan RA, Stephens LS, et al.
Postoperative opioid-induced respiratory
depression: a closed claims analysis.
Anesthesiology. 2015;122(3):659–665.
728 The Joint Commission. (2012.) Safe Use of
Opioids in Hospitals. The Joint Commission
Sentinel Event Alert, 49:1–5. Available at: https://
www.jointcommission.org/-/media/deprecatedunorganized/imported-assets/tjc/system-folders/
topics-library/sea_49_opioids_8_2_12_
finalpdf.pdf?db=web&hash=0135F306FCB10D919
CF7572ECCC65C84.
729 Lee, L.A., Caplan, R.A., Stephens, L.S., et al.
(2015). Postoperative opioid-induced respiratory
depression: a closed claims analysis.
Anesthesiology, 122(3): 659–65.
730 Willens JS, Jungquist CR, Cohen A, Polomano
R. (2013). ASPMN survey—nurses’ practice patterns
related to monitoring and preventing respiratory
depression. Pain Management Nursing. 14(1):60–65.
731 Meisenberg B, Ness J, Rao S, Rhule J, Ley C.
(2017). Implementation of solutions to reduce
opioid-induced oversedation and respiratory
depression. Am J Health Syst Pharm. 74:162–169.
732 Jungquist CR, Correll DJ, Fleisher LA, et al.
(2016). Avoiding Adverse Events Secondary to
Opioid-Induced Respiratory Depression:
Implications for Nurse Executives and Patient
Safety. Journal of Nursing Administration. 46(2):87–
94.
733 Herzig, S.J., Rothberg, M.B., Cheung, M., et al.
(2014). Opioid utilization and opioid-related
adverse events in nonsurgical patients in US
hospitals. Journal of Hospital Medicine, 9(2): 73–81.
734 Ibid.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
under contract with CMS, developed the
Hospital Harm–Opioid-Related Adverse
Events eCQM to assess the rates of
adverse events as well as the variation
in rates among hospitals.
(2) Overview of Measure
The Hospital Harm—Opioid-Related
Adverse Events eCQM is an outcome
measure focusing specifically on opioidrelated adverse events during an
admission to an acute care hospital by
assessing the administration of
naloxone. Naloxone is a lifesaving
emergent therapy with clear and
unambiguous applications in the setting
of opioid overdose.735 736 737 738 Naloxone
administration has also been used in a
number of studies as an indicator of
opioid-related adverse events to indicate
harm to a patient during inpatient
admission to a hospital.739 740 The
intent of this measure is for hospitals to
track and improve their monitoring and
response to patients administered
opioids during hospitalization, and to
avoid harm, such as respiratory
depression, which can lead to brain
damage and death. This measure
focuses specifically on in-hospital
opioid-related adverse events, rather
than opioid overdose events that
happen in the community and may
bring a patient into the ED.
The goal of this measure is to
incentivize hospitals to closely monitor
patients who receive opioids during
their hospitalization to prevent serious
adverse events. The measure requires
evidence of hospital opioid
administration prior to the naloxone
735 Surgeon General’s Advisory on Naloxone and
Opioid Overdose. (2018). Available at: https://
www.surgeongeneral.gov/priorities/opioidoverdose-prevention/naloxone-advisory.html.
736 Agency for Healthcare Research and Quality
(AHRQ). (2017). Management of Suspected Opioid
Overdose with Naloxone by Emergency Medical
Services Personnel. Comparative Effectiveness
Review No. 193. Available at: https://effective
healthcare.ahrq.gov/topics/emt-naloxon/
systematic-review.
737 Substance Abuse and Mental Health Services
Administration (SAMHSA). (2018). Opioid
Overdose Prevention Toolkit: Information for
Prescribers. Available at: https://store.samhsa.gov/
product/Opioid-Overdose-Prevention-Toolkit/
SMA18-4742.
738 Harm Reduction Coalition. (2020). Guide To
Developing and Managing Overdose Prevention and
Take-Home Naloxone Projects. Available at: https://
harmreduction.org/issues/overdose-prevention/
developing-overdose-prevention-and-naloxoneprojects/.
739 Eckstrand, J.A., Habib, A.S., Williamson, A., et
al. (2009). Computerized surveillance of opioidrelated adverse drug events in perioperative care: a
cross-sectional study. Patient Safety Surgery, 3:18.
740 Nwulu, U., Nirantharakumar, K., Odesanya,
R., et al. (2013). Improvement in the detections of
adverse drug events by the use of electronic health
and prescription records: an evaluation of two
trigger tools. European Journal of Clinical
Pharmacology, 69(2): 255–59.
PO 00000
Frm 00456
Fmt 4701
Sfmt 4700
administration during the first 24 hours
after hospital arrival to ensure that the
harm was hospital acquired and not due
to an overdose that happened outside of
the hospital.741 This measure does not
identify preventability of an individual
harm instance or whether each instance
of harm was an error, but rather, it
assesses the overall rate of harm within
a hospital by incorporating a definition
of harm that is likely to be reduced as
a result of hospital best practice.
The Hospital Harm—Opioid-Related
Adverse Events eCQM was included as
a measure undergoing field testing in
the publicly available ‘‘List of Measures
Under Consideration for December 1,
2017’’ (MUC List).742 The measure was
reviewed by the NQF MAP Hospital
Workgroup in December 2017, and
received the recommendation to refine
and resubmit with completed test
results demonstrating reliability and
validity prior to rulemaking, as
referenced in the ‘‘2017–2018
Spreadsheet of Final Recommendations
to HHS and CMS.’’ 743
This measure was submitted for
endorsement consideration to NQF’s
Patient Safety Standing Committee for
the Spring 2019 cycle. NQF reviewed
the measure on June 21, 2019, but did
not proceed with full endorsement
consideration due to concerns with the
performance gap criterion. In the FY
2020 IPPS/LTCH PPS proposed rule (84
FR 19477), we proposed but did not
finalize the adoption of the HospitalHarm—Opioid-Related Adverse Events
eCQM. Commenters provided measure
suggestions and refinements, as outlined
in the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42459), and we decided to
further assess the measure and the
suggested considerations with intent to
re-propose the measure. The main areas
of suggestions were to better establish
the connection between naloxone
administration and an opioid-related
event and consider narrowing the broad
denominator that, as specified, may
result in the calculation of very low
rates of adverse events.
In response to the feedback received,
the measure developer refined and
retested the measure specifications. The
measure developer limited the
741 #3501e Hospital Harm—Opioid-Related
Adverse Events, Apr 02, 2021. Measure Information
Form. https://nqfappservices
storage.blob.core.windows.net/proddocs/27/Spring/
2021/measures/3501e/shared/3501e.zip.
742 National Quality Forum. (2017). List of
Measures Under Consideration for December 1,
2017. Available at: https://www.qualityforum.org/
ProjectMaterials.aspx?projectID=75369.
743 National Quality Forum. 2017–2018
Spreadsheet of Final Recommendations to HHS and
CMS. Available at: https://www.qualityforum.org/
ProjectMaterials.aspx?projectID=75369.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
denominator to encounters where
patients received at least one opioid
during the hospitalization. The measure
developer constrained the numerator to
those patients with an opioid
administration that preceded the
subsequent naloxone administration by
no more than a 12-hour time window,
to ensure that a hospital administered
opioid was the cause for the naloxone
administration. The measure developer
also updated the value sets to ensure
that the most current codes for hospital
administered opioids and naloxone are
used and that the codes harmonize
across other current eCQMs in our
quality reporting programs. Finally, the
measure was re-tested by the measure
developer for feasibility at 23 hospital
test sites using four different EHR
vendor systems and for the scientific
acceptability of the measure’s properties
including reliability and validity at six
beta implementation test sites.744
Participant test sites varied by EHR
vendor systems, bed size, geographic
location, teaching/non-teaching status,
and urban/rural representation.
The Hospital Harm—Opioid-Related
Adverse Events eCQM (NQF #3501e)
was then re-submitted to the NQF for
the Spring 2021 review cycle and
received NQF endorsement on
December 7, 2021.745 The MAP Rural
Health Advisory Group also reviewed
the MUC List and Hospital Harm—
Opioid-Related Adverse Events eCQM
(MUC2021–084) on December 8, 2021
and voted majority support in
agreement on the applicability of the
eCQM to rural health settings.746 The
refined and retested eCQM was also reconsidered by the MAP Hospital
Workgroup on December 15, 2021,
which voted to support the measure for
rulemaking.747 The MAP Coordinating
Committee, which provides direction to
the MAP workgroups, then reviewed the
measure on January 19, 2022 748 and
744 National Quality Forum. #3501e Hospital
Harm—Opioid-Related Adverse Events. Available
at: https://www.qualityforum.org/ProjectTemplate
Download.aspx?SubmissionID=3501e.
745 National Quality Forum. (2021). Hospital
Harm—Opioid Related Adverse Events. Available
at: https://www.qualityforum.org/QPS/3501e.
746 National Quality Forum. (2022). Measure
Applications Partnership Rural Health Advisory
Group Virtual Review Meeting Summary, December
8, 2021. Available at: https://www.qualityforum.org/
WorkArea/linkit.aspx?LinkIdentifier=
id&ItemID=96571.
747 Measure Applications Partnership Hospital
Workgroup Web Review Meeting: Meeting
Summary. December 15, 2021. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96629.
748 Measure Applications Partnership
Coordinating Committee 2021–2022 Review Web
Meeting: Meeting Summary. January 19, 2022.
Available at: https://www.qualityforum.org/
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
upheld the MAP Hospital Workgroup
recommendation to support the measure
for rulemaking.749
We believe this measure will provide
hospitals with reliable and timely
measurement of their opioid-related
adverse event rates, which is a highpriority measurement area. We believe
implementation of this measure can
lead to safer patient care by
incentivizing hospitals to implement or
refine clinical workflows that facilitate
evidence-based use and monitoring
when administering opioids. We also
believe implementation of this measure
may result in fewer patients
experiencing adverse events associated
with the administration of opioids, such
as respiratory depression, which can
lead to brain damage and death. This
measure addresses the quality priority
of ‘‘Making Care Safer by Reducing
Harm Caused in the Delivery of Care’’
through the Meaningful Measures Area
of ‘‘Preventable Healthcare Harm.’’750
For detailed information on the
Hospital Harm—Opioid-Related
Adverse Events eCQM, we refer readers
to the measure specifications, available
at: https://ecqi.healthit.gov/prerulemaking-eh-cah-ecqms.
(3) Data Sources
The eCQM uses data collected
through hospitals’ EHRs. The measure is
designed to be calculated by the
hospitals’ CEHRT using the patient-level
data and then submitted by hospitals to
CMS.
As with all quality measures we
develop, testing was performed to
confirm the feasibility of the measure,
data elements, and validity of the
numerator, using clinical adjudicators
who validated the EHR data compared
with medical chart-abstracted data.
Testing demonstrated no missing or
erroneous data (0 percent) for all six
implementation test sites. These results
suggest that all critical data elements are
reliably and consistently captured in
patient EHRs, and that measure
implementation is feasible. Testing also
showed that the positive predictive
WorkArea/linkit.aspx?LinkIdentifier=
id&ItemID=96709.
749 Measure Applications Partnership 2021–2022
Considerations for Implementing Measures in
Federal Programs: Clinician, Hospital, and PostAcute Care Long-Term Care Final Report. March 3,
2022. Available at: https://www.qualityforum.org/
Publications/2022/03/MAP_2021-2022_
Considerations_for_Implementing_Measures_Final_
Report_-_Clinicians,_Hospitals,_and_PACLTC.aspx.
750 More information on CMS’ Meaningful
Measures Framework is available at: https://
www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/QualityInitiativesGenInfo/
MMF/General-info-Sub-Page.html.
PO 00000
Frm 00457
Fmt 4701
Sfmt 4700
49235
value (PPV),751 which describes the
probability that a patient with a positive
result (numerator case) identified by the
EHR data was also a positive result
verified by review of the patient’s
medical record done by a clinical
adjudicator, was high at all hospital
testing sites (98 percent in one hospital
to 100 percent in the five other
hospitals). Testing was completed using
output from the Measure Authoring
Tool (MAT) in 23 hospitals using four
different EHR systems for feasibility and
six different hospitals for
implementation testing for reliability
and validity.
(4) Outcome
This measure assesses the proportion
of inpatient hospital encounters where
patients 18 years of age or older have
been administered an opioid
medication, subsequently suffer the
harm of an opioid-related adverse event,
and are administered an opioid
antagonist (naloxone) within 12 hours.
This measure excludes opioid
antagonist (naloxone) administration
occurring in the operating room setting.
(5) Cohort
This measure’s cohort includes all
patients ages 18 years and older at the
start of the encounter, and for whom at
least one opioid medication was
administered during the encounter. An
inpatient hospitalization includes time
spent in the ED or in observation status
when the patients are ultimately
admitted to inpatient status.
(6) Inclusion and Exclusion Criteria
This measure excludes opioid
antagonist (naloxone) administration
occurring in the operating room setting.
There are no denominator exclusions.
(7) Risk Adjustment
This measure is not risk adjusted for
chronic opioid use, as most instances of
opioid-related adverse events should be
preventable for all patients regardless of
prior exposure to opioids or chronic
opioid use.
Generally, patient characteristics,
including gender, age, race/ethnicity,
reasons for hospitalization, clinical
status when patients arrive at the
hospital, or comorbidities can influence
the risk of harm occurring during a
hospitalization.752 Therefore, if
hospitals care for patients with different
751 ‘‘Predictive Value.’’ Farlex Partner Medical
Dictionary. Available at: https://medical-dictionary.
thefreedictionary.com/predictive+value.
752 National Quality Forum. Glossary of Terms.
Available at: https://www.qualityforum.org/
WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=73681.
E:\FR\FM\10AUR2.SGM
10AUR2
49236
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
degrees of risk, then it may be important
to account for such case mix to compare
hospital performance.753 However,
opioid-related adverse events should be
avoidable regardless of patient risk,
particularly when the opioid was given
after patients have arrived at the
hospital.754 During measure
development, in evaluating whether this
measure needed to be risk adjusted, the
measure developer considered the
following in determining whether risk
adjustment is warranted for this
measure: Patients are at risk of the harm
regardless of their demographic and
clinical characteristics; most incidents
of harm are linkable to care provision
under the hospital control, for example,
harms caused by excessive or
inappropriate medication dosing; and
there is evidence that the risk of harm
can be largely reduced by following best
care practices independent of patient
inherent risks. For example, patients
with multiple risk factors can still avoid
the harm event when providers adhere
to care guidelines.
Opioid-related adverse events should
be avoidable regardless of patient risk,
particularly when the opioid was given
after patients have arrived at the
hospital.755 While certain patients may
require higher doses to achieve pain
control or are more sensitive to opioids
(depending on their age, sex, and
weight), the most common cause is
hospital administration of excessive
doses and inadequate monitoring.756
Because the dosing of opioids and the
intensity of patient monitoring is
entirely under the control of providers
in hospitals, the risk of an opioidrelated adverse event can be reduced by
following best practices.757 758 759
753 National Quality Forum. Developing and
Testing Risk Adjustment Models for Social and
Functional Status-Related Risk Within Healthcare
Performance Measurement: Final Technical
Guidance—Version 4. August 30, 2021. Available
at: https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96087.
754 The Joint Commission. (2012). Safe Use of
Opioids in Hospitals. The Joint Commission
Sentinel Event Alert, 49:1–5. Available at: https://
www.jointcommission.org/-/media/deprecatedunorganized/imported-assets/tjc/system-folders/
topics-library/sea_49_opioids_8_2_12_
finalpdf.pdf?db=web&hash=0135F306FCB10D919
CF7572ECCC65C84.
755 Ibid.
756 Dahan A, Aarts L, Smith TW. Incidence,
Reversal, and Prevention of Opioid-induced
Respiratory Depression. Anesthesiology.
2010;112(1):226–238.
757 Practice Guidelines for the Prevention,
Detection, and Management of Respiratory
Depression Associated with Neuraxial Opioid
Administration: An Updated Report by the
American Society of Anesthesiologists Task Force
on Neuraxial Opioids and the American Society of
Regional Anesthesia and Pain Medicine.
Anesthesiology. 2016 Mar;124(3):535–52.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Therefore, the measure developer did
not think risk adjustment is warranted
for this measure.
To provide supportive evidence of the
clinical rationale for not risk adjusting,
the measure developer examined the
measure performance rate in various
subgroups of population. All these
analyses demonstrated no pattern in
measure performance rates across
subgroups.760 During measure
development, TEP members gave
feedback on whether the measure
required risk adjustment and agreed
with this rationale. Subsequently the
NQF Scientific Methods Panel (SMP),
the Patient Safety Standing Committee,
and the Consensus Standards Advisory
Committee (CSAC) also agreed with this
approach.761 762 763
(8) Measure Calculation
The Hospital Harm—Opioid-Related
Adverse Events eCQM is an outcome
measure that defines the indication of a
harm for an opioid-related adverse event
by assessing administration of an opioid
antagonist (naloxone). The numerator is
the number of inpatient hospitalizations
where an opioid antagonist (naloxone)
was administered outside of the
operating room and within 12 hours
following administration of an opioid
medication. Only one numerator event
is counted per encounter. The
denominator includes inpatient
hospitalizations for patients 18 years or
older during which at least one opioid
medication was administered. An
inpatient hospitalization includes time
spent in the ED or in observation status
when the patients are ultimately
admitted to inpatient status.
758 Jungquist CR, Quinlan-Colwell A, Vallerand
A, et al. American Society for Pain Management
Nursing Guidelines on Monitoring for OpioidInduced Advancing Sedation and Respiratory
Depression: Revisions. Pain Manag Nurs. 2020
Feb;21(1):7–25. Epub 2019 Jul 31.
759 Dahan A, Aarts L, Smith TW. Incidence,
Reversal, and Prevention of Opioid-induced
Respiratory Depression. Anesthesiology.
2010;112(1):226–238.
760 #3501e Hospital Harm—Opioid-Related
Adverse Events, Apr 02, 2021. Measure Information
Form. https://nqfappservicesstorage.blob.
core.windows.net/proddocs/27/Spring/2021/
measures/3501e/shared/3501e.zip.
761 National Quality Forum. Scientific Methods
Panel Measure Evaluation Web Meeting—Spring
2021 Meeting Summary. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=95246.
762 National Quality Forum. Patient Safety Spring
2021 Cycle. Memo: Consensus Standards Approval
Committee (CSAC). November 30, 2021. Available
at: https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96423.
763 National Quality Forum. Consensus Standards
Approval Committee (CSAC) Voting Results and
Decisions for Spring 2021 Measures. November 30,
2021. Available at: https://www.qualityforum.org/
WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96528.
PO 00000
Frm 00458
Fmt 4701
Sfmt 4700
To calculate the hospital-level
measure result, divide the total
numerator events by the total number of
qualifying inpatient encounters
(denominator). Qualifying inpatient
encounters include all patients 18 years
of age or older at the start of the
encounter with at least one opioid
medication administered during the
encounter. The measure does not
include naloxone use in the operating
room where it could be part of the
sedation plan as administered by an
anesthesiologist or nurse anesthetist.
Uses of naloxone for procedures outside
of the operating room (such as bone
marrow biopsy) are counted in the
numerator as its use will indicate the
patient was over sedated.764 The
measure numerator identifies a harm
using the administration of naloxone,
and purposely does not include any
medications that combine naloxone
with other agents.
(9) Data Submission and Reporting
We proposed the adoption of the
Hospital-Harm—Opioid-Related
Adverse Events eCQM as part of the
Hospital IQR Program for which
hospitals can self-select beginning with
the CY 2024 reporting period/FY 2026
payment determination and for
subsequent years. We refer readers to
section IX.E.10.e. of the preamble of this
final rule for a discussion of our
previously finalized eCQM reporting
and submission policies, as well as our
proposal to modify these eCQM
reporting and submission requirements.
Additionally, we refer readers to section
IX.H.10.a.(2). of the preamble of this
final rule for a discussion of a similar
proposal to adopt this measure in the
Medicare Promoting Interoperability
Program for Eligible Hospitals and
CAHs.
We invited public comment on this
proposal.
Comment: Many commenters
supported adoption of the Hospital
Harm—Opioid-Related Adverse Events
eCQM (NQF #3501e) beginning with the
CY 2024 reporting period/FY 2026
payment determination and for
subsequent years. Several commenters
believed that measure implementation
will result in fewer adverse events
associated with the administration of
opioids (for example, respiratory
depression) and will lead to safer
patient care and saved lives. A few
commenters agreed that the measure
764 Nwulu, U., Nirantharakumar, K., Odesanya,
R., McDowell, S.E., & Coleman, J.J. Improvement in
the detection of adverse drug events by the use of
electronic health and prescription records: an
evaluation of two trigger tools. Eur J Clin
Pharmacol. 2013;69(2), 255–259.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
will incentivize hospitals to implement
or refine clinical workflows and
implement continual monitoring
protocols when administering opioids.
Several commenters recognized and
appreciated the refinements made to the
measure since its earlier proposal in the
FY 2020 IPPS/LTCH PPS proposed rule
(84 FR 19477). A few commenters
applauded CMS for expanding the
choices of available eCQMs for reporting
in the Hospital IQR Program.
A few commenters highlighted the
potential positive impact measure
reporting may have on vulnerable
populations. A commenter noted that
opioid use is a serious concern in rural
health and appreciated the transparency
this measure will bring. Another
commenter noted this measure will help
to track and improve quality for older
adult patients and a commenter stated
that the measure will help to address
the disproportionate overdose deaths
occurring among racial and ethnic
minorities.
Response: We thank commenters for
their support and input on the inclusion
of the measure. We agree that this
measure captures important quality
information that is critical to patient
safety and improving patient outcomes.
Comment: A few commenters did not
support the inclusion of the measure
due to concerns that implementation
could lead to unintended consequences
for care delivery, as the potential for
lower performance could lead to
hesitancy in hospitals’ or clinicians’ use
of naloxone in clinically appropriate,
rapid-response situations. These
commenters also noted that
implementation could lead to
undertreatment of pain after surgery. A
commenter recommended that a more
robust methodology be developed for
identifying the cause of the event as
opioid-related. Another commenter
suggested we consider ways to
distinguish appropriate use of naloxone
in the measure specifications.
Response: We thank commenters for
their input and feedback on this
measure. We acknowledge that some
stakeholders have expressed concern
that implementation of the measure
could result in deterring or delaying
clinically appropriate administration of
naloxone or under-prescribing of
opioids for pain control when clinically
necessary. We reiterate that naloxone is
a life-saving emergent therapy with
clear and unambiguous applications in
the setting of opioid
overdose,765 766 767 768 and we outline
765 Surgeon General’s Advisory on Naloxone and
Opioid Overdose. Available at: https://
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
below the methodology deployed to
ascertain that numerator cases flagged
by the measure are true positives.
During testing at six sites, the measure
developer examined whether numerator
cases identified by the measure were
true positives and found that in 98
percent of cases naloxone was
administered for respiratory depression
or reduced arousal or for opioid reversal
and resulted in improvement in the
patient’s level of consciousness.769 To
examine if the numerator cases
identified by the quality reporting
engine are true positives, clinical
abstractors pulled additional
information regarding the indication for
and subsequent reaction to the naloxone
administration from the nurse notes and
physician orders. We also found that
some, but not all, test sites also used the
Pasero Opioid-induced Sedation Scale
(POSS) 770 in recording the
appropriateness of opioid dosage, which
is a 5 point scale as follows:
• S = Sleep, easy to arouse;
acceptable; no action necessary; may
increase opioid dose if needed.
• 1 = Awake and alert: acceptable; no
action necessary; may increase opioid
dose if needed.
• 2 = Slightly drowsy, easily aroused;
acceptable; no action necessary; may
increase opioid dose if needed.
• 3 = Frequently drowsy, arousable,
drifts off to sleep during conversation;
unacceptable; monitor respiratory status
www.surgeongeneral.gov/priorities/opioidoverdoseprevention/naloxone-advisory.html.
766 Agency for Healthcare Research and Quality
(AHRQ). (2017). Management of Suspected Opioid
Overdose with Naloxone by Emergency Medical
Services Personnel. Comparative Effectiveness
Review No. 193. Available at: https://
effectivehealthcare.ahrq.gov/topics/emt-naloxon/
systematic-review.
767 Substance Abuse and Mental Health Services
Administration (SAMHSA). (2018). Opioid
Overdose Prevention Toolkit: Information for
Prescribers. Available at: https://store.samhsa.gov/
product/Opioid-Overdose-Prevention-Toolkit/
SMA18-4742.
768 Harm Reduction Coalition. (2020). Guide To
Developing and Managing Overdose Prevention and
Take-Home Naloxone Projects. Available at: https://
harmreduction.org/issues/overdose-prevention/
developing-overdose-prevention-and-naloxoneprojects/.
769 #3501e Hospital Harm—Opioid-Related
Adverse Events, Apr 02, 2021. Testing Attachment.
https://
nqfappservicesstorage.blob.core.windows.net/
proddocs/27/Spring/2021/measures/3501e/shared/
3501e.zip.
770 Davis, C., Geik, C., Arthur, K., Fuller, J.,
Johnston, E., Levitt, F., Leung, E., McCart, G.,
McMichael, D., Painter, J., Staublin, T., & Walroth,
T. (2017). A Multisite Retrospective Study
Evaluating the Implementation of the Pasero
Opioid-Induced Sedation Scale (POSS) and Its
Effect on Patient Safety Outcomes. Pain
management nursing: official journal of the
American Society of Pain Management Nurses,
18(4), 193–201. https://doi.org/10.1016/
j.pmn.2017.03.006.
PO 00000
Frm 00459
Fmt 4701
Sfmt 4700
49237
and sedation level closely until sedation
level is stable at less than 3 and
respiratory status is satisfactory;
decrease opioid dose 25 percent to 50
percent or notify prescriber or
anesthesiologist for orders; consider
administering a non-sedating, opioidsparing nonopioid, such as
acetaminophen or a NSAID, if not
contraindicated.
• 4 = Somnolent, minimal or no
response to verbal and physical
stimulation; unacceptable; stop opioid;
consider administering naloxone; notify
prescriber or anesthesiologist; monitor
respiratory status and sedation level
closely until sedation level is stable at
less than 3 and respiratory status is
satisfactory.
The POSS is a valid, reliable tool used
to assess sedation when administering
opioid medications to manage pain. The
POSS is endorsed by The Joint
Commission and the American Society
for Pain Management Nursing to help
prevent adverse opioid-related
respiratory events.771 Of the identified
numerator cases where POSS were used,
most showed an initial POSS of 3 or 4.
After the naloxone administration,
patients’ POSS decreased to 1 or 2. We
also note that patients showing no
immediate responses may be due to the
inadequate dosage of naloxone, as there
were some instances identified during
the manual abstraction where patients
became responsive only after the second
naloxone. Overall, the developer found
that the use of naloxone in the absence
of opioid toxicity was rare.772 We are
confident that hospitals and clinicians
will continue to administer naloxone
when it is clinically necessary and will
monitor for evidence of unintended
consequences as we do for all Hospital
IQR Program measures.
Comment: A few commenters raised
concerns about implementation burden.
Two commenters highlighted that there
is a substantial cost and time burden
faced by hospitals when adopting new
eCQMs. A commenter also reported they
are already collecting a similar opioid
measure.
771 Davis, C., Geik, C., Arthur, K., Fuller, J.,
Johnston, E., Levitt, F., Leung, E., McCart, G.,
McMichael, D., Painter, J., Staublin, T., & Walroth,
T. (2017). A Multisite Retrospective Study
Evaluating the Implementation of the Pasero
Opioid-Induced Sedation Scale (POSS) and Its
Effect on Patient Safety Outcomes. Pain
management nursing: official journal of the
American Society of Pain Management Nurses,
18(4), 193–201. https://doi.org/10.1016/
j.pmn.2017.03.006.
772 #3501e Hospital Harm—Opioid-Related
Adverse Events, Apr 02, 2021. Testing Attachment.
https://nqfappservicesstorage.
blob.core.windows.net/proddocs/27/Spring/2021/
measures/3501e/shared/3501e.zip.
E:\FR\FM\10AUR2.SGM
10AUR2
49238
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Response: We thank commenters for
their feedback. We highlight that this
measure is one of the available (not
required) eCQMs hospitals may selfselect for submission beginning with the
CY 2024 reporting period. The addition
of this eCQM further advances CMS’
goal of transitioning to a fully digital
quality measures landscape, promoting
interoperability that will help decrease
burden.
We also recognize there is an opioid
measure in the Hospital IQR Program,
Safe Use of Opioids—Concurrent
Prescribing (NQF #3316e) (84 FR
42598). While both measures are
designed to reduce adverse events or
harms associated with opioid use, the
main focus of each measure is different.
The Safe Use of Opioids—Concurrent
Prescribing eCQM focuses on
concurrent prescriptions of opioids and
benzodiazepines at discharge, an area of
high-risk prescribing (84 FR 42598). The
Hospital Harm—Opioid-Related
Adverse Events eCQM is designed to
reduce adverse events associated with
the administration of opioids in the
hospital setting by assessing the
administration of naloxone as an
indicator of harm (87 FR 28516). We
believe implementation of the Hospital
Harm—Opioid-Related Adverse Events
eCQM can lead to safer patient care by
incentivizing hospitals to track and
improve their monitoring of patients
who receive opioids during
hospitalization.
Comment: A few commenters offered
recommendations to augment the
measure’s exclusions; for example, by
excluding patients who receive
naloxone for indications other than
over-sedation (for example, pruritis).
Response: We thank commenters for
their input and recommendations
regarding potential measure exclusions.
We note the exclusions as presented in
the measure specifications in the
proposed rule (87 FR 28516) were
evaluated and endorsed by the NQF
Scientific Methods Panel (SMP),773 the
Patient Safety Standing Committee,774
and the Consensus Standards Advisory
Committee (CSAC).775 This eCQM was
773 National Quality Forum. Scientific Methods
Panel Measure Evaluation Web Meeting—Spring
2021 Meeting Summary. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=95246. 1096.
774 National Quality Forum. Patient Safety Spring
2021 Cycle. Memo: Consensus Standards Approval
Committee (CSAC). November 30, 2021. Available
at: https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96423. 1097.
775 National Quality Forum. Consensus Standards
Approval Committee (CSAC) Voting Results and
Decisions for Spring 2021 Measures. November 30,
2021. Available at: https://www.qualityforum.org/
WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96528.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
also evaluated by the MAP Hospital
Workgroup and the MAP Coordinating
Committee,776 777 778 who both supported
the measure for rulemaking. We aim to
be as inclusive as possible in defining
a measure cohort to ensure the measure
will have the most impact on important
subgroups of patients. We will take
these suggestions into consideration and
are assessing the feasibility of capturing
the indication(s) for administration of
naloxone.
Comment: Two commenters requested
clarifications on the measure. A
commenter requested if CMS has target
data for hospitals to compare their own
results to and whether zero events is an
attainable target. Another commenter
requested more information about
which opioids would be included in the
calculations of ‘‘opioid-related adverse
events’’ and if the measure is based on
prescription history within a provider’s
electronic health record.
Response: We thank commenters for
their questions. Regarding the
commenter’s question on benchmarks,
we note that the Hospital IQR Program
does not implement benchmarks or
target levels of performance for its
measures as it is a pay-for-reporting
quality program. Moreover, the intent of
this measure is not to reduce clinically
appropriate use of naloxone, nor to
bring the measure rate to zero, but to
identify if hospitals have particularly
high rates of naloxone use as an
indicator of high rates of overadministration of opioids in the
inpatient setting, and thereby
incentivize improved clinical practices
when administering opioids (87 FR
28516).
Regarding which opioids are included
in the calculation of opioid-related
adverse events, the opioid value set
includes all formulations of opioids that
may be administered in an inpatient or
outpatient setting regardless of intended
use (87 FR 28516). It also includes
776 Measure Applications Partnership Hospital
Workgroup Web Review Meeting: Meeting
Summary. December 15, 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96629.
777 Measure Applications Partnership
Coordinating Committee 2021–2022 Review Web
Meeting: Meeting Summary. January 19, 2022.
Available at: https://www.qualityforum.org/
WorkArea/linkit.aspx?LinkIdentifier=id&
ItemID=96709.
778 Measure Applications Partnership 2021–2022
Considerations for Implementing Measures in
Federal Programs: Clinician, Hospital, and PostAcute Care Long-Term Care Final Report. March 3,
2022. Available at: https://www.qualityforum.org/
Projects/i-/MAP/MAP_2021-2022_Considerations_
for_Implementing_Measures_Final_Report.aspx#
onclick=%E2%80%9D_gaq.push.%E2%80%98_
trackEvent%E2%80%99,%E2%80%99Download
%E2%80%99,%E2%80%99PDF%E2%80
%99,this.href;%E2%80%9D.
PO 00000
Frm 00460
Fmt 4701
Sfmt 4700
combination medications that contain
both an opioid and another class of
medication, as it is possible to overdose
on these combination medications (87
FR 28516).
Comment: A few commenters were
generally supportive of the measure but
questioned whether the adoption will be
impactful (especially given the
resources and time needed for hospitals
to implement the measure) as they
noted the overall number of inpatient
naloxone rescue events is small. A
commenter did not support measure
adoption noting it focused on rare
events in the inpatient setting rather
than targeting the primary drivers of the
opioid epidemic. A commenter
recommended additional testing in a
broader range of hospitals and vendor
systems to further assess variation in
performance scores. A few commenters
requested we collect and analyze several
years of data before adding this measure
to a pay-for-performance program.
Response: We acknowledge that some
stakeholders have expressed concern
regarding the measure’s impact given
the small number of overall events.
However, our overall analysis during
testing demonstrated the rate of ORAE
ranged from 1.1 to 6.1 per 1,000
qualified inpatient encounters, signaling
there is still opportunity for
improvement. As noted in the proposed
rule, we tested feasibility at 23 hospital
test sites using four different EHR
vendor systems and for the scientific
acceptability of the measure’s properties
including reliability and validity at six
beta implementation test sites (87 FR
28516). Participant test sites varied by
EHR vendor systems, bed size,
geographic location, teaching/nonteaching status, and urban/rural
representation. This far exceeds NQF
measure evaluation criteria for testing
eCQMs, which requires testing using at
least two EHR vendor systems (87 FR
28516). We will monitor the
performance gap as hospitals begin to
report this measure. Future potential
use of the measure for a pay-forperformance program would be through
notice-and-comment rulemaking.
Comment: A few commenters
supported inclusion of the measure into
the Hospital IQR Program but requested
changes to the reporting schedule and
requirements. A commenter stated the
measure should not impact hospital
payment until the CY 2025 reporting
period/FY 2027 payment determination,
while another commenter suggested
mandating opioid-related adverse event
reporting by all hospitals in the
program.
Response: We thank commenters for
their support and input. This measure
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
was proposed for inclusion as one of the
eCQMs hospitals can self-select for
reporting beginning with the CY 2024
reporting period/FY 2026 payment
determination, which we believe allows
sufficient time for hospitals to prepare
and implement the measure. The
addition of this eCQM further advances
CMS’ goal of transitioning to a fully
digital quality measures landscape, and
we will take the commenter’s suggestion
to make this eCQM mandatory under
consideration for future rulemaking.
Comment: A few commenters
requested we monitor clinical literature
and hospital administration practices in
the coming years to determine if the
measurement area remains of critical
importance.
Response: We thank the commenters
for their feedback. We will continue to
evaluate and refine the measure through
implementation as necessary.
Comment: A commenter suggested
considering the potential value of risk
adjustment for the measure.
Response: We thank the commenter
for their feedback to consider risk
adjusting this measure. We did not
apply risk adjustment in the measure,
given strong evidence that most
instances of severe over-sedation
requiring naloxone for reversal can be
avoided by following best practices; and
given that opioid dosing and patient
monitoring are under the control of
providers in hospitals, such that risk
can be minimized by following best
practices.779 780
We will continue to evaluate and
refine the measure through
implementation as necessary.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
f. Global Malnutrition Composite Score
eCQM (NQF #3592e) Beginning With
the CY 2024 Reporting Period/FY 2026
Payment Determination and for
Subsequent Years
(1) Background
khammond on DSKJM1Z7X2PROD with RULES2
From 1960 until the start of the
COVID–19 pandemic,781 life expectancy
779 Practice Guidelines for the Prevention,
Detection, and Management of Respiratory
Depression Associated with Neuraxial Opioid
Administration: An Updated Report by the
American Society of Anesthesiologists Task Force
on Neuraxial Opioids and the American Society of
Regional Anesthesia and Pain Medicine.
Anesthesiology. 2016 Mar;124(3):535–52.
780 Lee LA, Caplan RA, Stephens LS, et al.
Postoperative opioid-induced respiratory
depression: a closed claims analysis.
Anesthesiology. 2015;122(3):659–665.
781 Islam N, Jdanov D A, Shkolnikov V M, Khunti
K, Kawachi I, White M et al. (2021). Effects of covid19 pandemic on life expectancy and premature
mortality in 2020: time series analysis in 37
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
for the total population in the U.S.
increased by almost 10 years.782 While
adults are living longer lives, the
amount of time spent in poor health at
the end of life is similarly increasing.783
Studies found that healthy nutrition is
indeed more important for healthy aging
than generally recognized.784
Malnutrition includes undernutrition
(wasting, stunting, underweight),
inadequate vitamins or minerals,
overweight, and obesity, and can result
in diet-related noncommunicable
diseases.785 The developmental,
economic, social, and medical impacts
of the global burden of malnutrition are
serious and lasting, for individuals and
their families, for communities, and for
countries.786 Malnutrition is complex
and may be both associated with and
exacerbated by chronic conditions, agerelated cognitive or physical changes,
medication side effects, and poverty.787
Evidence shows that healthy eating
contributes to prevention and risk
reduction of many common chronic
health conditions prevalent in older
adults including hypertension, heart
disease, heart failure, diabetes, obesity,
certain cancers, and osteoporosis.788
While it is estimated that sixty percent
of older adults manage two or more
chronic health conditions, many
underuse preventive services, including
those related to nutrition.789 Research
indicates that preventive screening and
interventions may reduce risk of
countries. BMJ 375:e066768 doi:10.1136/bmj-2021–
066768.
782 United States Census Bureau. (2020). Living
Longer: Historical and Projected Life Expectancy in
the United States, 1960 to 2060. Available at:
https://www.census.gov/content/dam/Census/
library/publications/2020/demo/p25-1145.pdf.
783 Roberts SB, Silver RE, Das SK, Fielding RA,
Gilhooly CH, Jacques PF, et al. (2021) Healthy
Aging-Nutrition Matters: Start Early and Screen
Often. Adv Nutr. 12(4):1438–1448. doi: 10.1093/
advances/nmab032.
784 Ibid.
785 World Health Organization. (2021).
Malnutrition. Available at: https://www.who.int/
news-room/fact-sheets/detail/malnutrition.
786 World Health Organization. (2021).
Malnutrition. Available at: https://www.who.int/
news-room/fact-sheets/detail/malnutrition.
787 Barker CA, Gout BS, et al. (2011). Hospital
malnutrition prevalence, identification, and impact
on patients and the healthcare system. International
Journal of Environmental Research and Public
Health.8:514–527.
788 Wright NC, Looker AC, Saag KG, et al. (2014).
The recent prevalence of osteoporosis and low bone
mass in the United States based on bone mineral
density at the femoral neck or lumbar spine. J Bone
Miner Res. 29(11):2520–2526. https://
onlinelibrary.wiley.com/doi/10.1002/jbmr.2269/
epdf.
789 US Department of Health and Human
Services. (2020). Office of Disease Prevention and
Health Promotion. Older Adults: Overview. Healthy
People 2020 website. Available at: https://
www.healthypeople.gov/2020/topics-objectives/
topic/older-adults.
PO 00000
Frm 00461
Fmt 4701
Sfmt 4700
49239
malnutrition in older adults and
improve quality of life, particularly for
individuals with chronic conditions.790
While disease-related malnutrition is
not limited to older adults, it is more
frequent among those with higher age,
and the consequences appear to be more
severe in older persons due to their
impaired regenerative capacity,
inflammation, and other factors.791
Malnutrition remains a challenge for
older adults in the U.S. as
approximately 7.7 percent of seniors, or
5.5 million, are food insecure annually
with reports of reduced quality, variety,
or desirability of diet while 3.1 percent,
or 2.1 million are very low food
insecure with reports of multiple
indications of disrupted eating patterns
and reduced food intake.792 793 From late
September through mid-October 2021,
U.S. Census Bureau data indicates that
more than 2.5 million adults ages 65
and older responded ‘‘sometimes’’ or
‘‘often’’ when questioned about the
frequency of not having enough food to
eat in the past seven days.794 As our
population continues to age, it is
expected that 1 in 5 residents will be 65
years or older by the year 2030 795 and
malnutrition risk among seniors is likely
to increase.796
One factor contributing to the burden
of malnutrition is health disparity
across racial and ethnic groups. Black,
Hispanic, and other non-White older
adult populations have higher hunger
790 Mangels, AR. (2018). Malnutrition in Older
Adults. American Journal of Nursing. 118(3):34–41.
doi: 10.1097/01.NAJ.0000530915.26091.be.
791 Norman K, Ha+ U, Pirlich M. (2021).
Malnutrition in Older Adults—Recent Advances
and Remaining Challenges. Nutrients. 13, 2764.
Available at: https://doi.org/10.3390/nu13082764.
792 Feeding America. (2019). The State of Senior
Hunger in America in 2017: An Annual Report.
Available at: https://www.feedingamerica.org/sites/
default/files/2019-05/state-of-senior-hunger-2017_
full-report.pdf.
793 United States Department of Agriculture
Economic Research Service. (2021). Definitions of
Food Security. Available at: https://
www.ers.usda.gov/topics/food-nutrition-assistance/
food-security-in-the-us/definitions-of-foodsecurity.aspx.
794 United States Census Bureau. (2021). Week 39
Household Pulse Survey: September 29—October
11. Available at: https://www.census.gov/data/
tables/2021/demo/hhp/hhp39.html.
795 United States Census Bureau. (2018). Older
People Projected to Outnumber Children for First
Time in U.S. History. Available at: https://
www.census.gov/newsroom/press-releases/2018/
cb18-41-population-projections.html.
796 Haines J, LeVan D, Roth-Kauffman MM.
(2020). Malnutrition in the Elderly:
Underrecognized and Increasing in Prevalence.
Clinical Advisor. Available at: https://
www.clinicaladvisor.com/home/topics/geriatricsinformation-center/malnutrition-in-the-elderlyunderrecognized-and-increasing-in-prevalence/.
E:\FR\FM\10AUR2.SGM
10AUR2
49240
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
rates than White populations.797 Black
Americans and Hispanic Americans are
nearly 2.5 times and 1.4 times as likely
as White Americans, respectively, to
lack access to a full-service grocery
store; this contributes to higher rates of
food insecurity and can increase risk of
malnutrition.798 Black, Hispanic, and
other non-White Americans are also at
higher risk for many chronic diseases,
emphasizing the importance of
addressing nutrition through both
prevention and management of these
condition—especially when they cannot
access healthy food.799
Patients over 65 comprise more than
one-third of all discharges and nearly 13
million seniors are hospitalized each
year.800 801 While federal data indicate
that approximately 8 percent of all
hospitalized adults have a diagnosis of
malnutrition,802 803 additional research
finds that malnutrition and malnutrition
risk can be found in 20 to 50 percent of
hospitalized adults.804 805 This indicates
that between 910,000 and 6.5 million
hospitalized seniors may experience
malnutrition.806 Hospitalized adults
797 United States Department of the Treasury
CDFI Fund Capacity Building Initiative. (2012). A
Summary of Searching for Markets: The Geography
of Inequitable Access to Healthy & Affordable Food
in the United States. Available at: https://
www.reinvestment.com/wp-content/uploads/2015/
12/Searching_For_Markets-Summary_2011.pdf.
798 Ibid.
799 Dawson MD, Blancato B. (2021). To Advance
Health Equity, Measure Hospital Malnutrition Care.
Health Affairs. Available at: https://
www.healthaffairs.org/do/10.1377/
hblog20210930.667648/full/.
800 Gorman A. (2016). Elderly Hospital Patients
Arrive Sick, Often Leave Disabled. Kaiser Health
Network. Available at: https://khn.org/news/
elderly-hospital-patients-arrive-sick-often-leavedisabled/.
801 Mattison M. (2021). Hospital Management of
Older Adults. Available at: https://
www.uptodate.com/contents/hospital-managementof-older-adults.
802 United States Agency for Healthcare Research
and Quality. (2016). Non-maternal and nonneonatal inpatient stays in the United States
involving malnutrition, 2016. Available at: https://
hcup-us.ahrq.gov/reports/ataglance/
HCUPMalnutritionHospReport_083018.pdf.
803 Valladares AF, McCauley SM, Khan M,
D’Andrea C, Kilgore K, Mitchell K. (2021).
Development and Evaluation of a Global
Malnutrition Composite Score. Journal of the
Academy of Nutrition and Dietetics. doi: https://
doi.org/10.1016/j.jand.2021.02.002.
804 Pereira GF., Bulik CM, Weaver MA, Holland
WC, Platts-Mills TF. (2015). Malnutrition among
cognitively intact, noncritically ill older adults in
the emergency department. Ann Emerg Med. 65:
85–91.
805 Barker CA, Gout BS, et al. (2011). Hospital
malnutrition prevalence, identification, and impact
on patients and the healthcare system. International
Journal of Environmental Research and Public
Health. 8:514–527.
806 United States Government Accountability
Office. (2019). Report to Congressional Requestors.
Nutrition Assistance Programs: Agencies Could Do
More to Help Address the Nutritional Needs of
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
with a diagnosis of malnutrition have a
longer length of stay, higher costs, more
comorbidities, five times the likelihood
of death, and greater risk of infectious
disease and injury compared with other
adult inpatients without
malnutrition.807 808 Malnutrition may
also contribute to post-hospital
syndrome—described as ‘‘an acquired,
transient period of vulnerability’’
following hospitalization809—which
may dramatically increase the risk of
readmission.810 811
Partly due to the substantial impacts
on clinical outcomes,812 malnutrition
imposes a serious burden on the
healthcare system.813 Hospitalized
patients with poor nutrition have been
estimated to incur approximately 300
percent higher healthcare costs than
those who are adequately nourished.814
Reports indicate that the average cost for
an individual hospital stay (including
both direct and indirect costs) for a
malnourished patient is $25,600 while it
is only $13,900 for a well-nourished
patient; 815 further, malnutritionassociated diseases among older adults
in the US has been estimated to cost
$51.3 billion annually.816
Older Adults. Available at: https://www.gao.gov/
assets/gao-20-18.pdf.
807 United States Agency for Healthcare Research
and Quality. (2016). Healthcare Cost and Utilization
Project: Non-maternal and Non-Neonatal Inpatient
Stays in the United States Involving Malnutrition
2016. Available at: https://hcup-us.ahrq.gov/
reports/ataglance/HCUPMalnutritionHospReport_
083018.pdf.
808 United States Agency for Healthcare Research
and Quality. (2013). Characteristics of Hospital
Stays Involving Malnutrition, 2013. HCUP
Statistical Brief #210. Available at: https://
www.hcup-us.ahrq.gov/reports/statbriefs/sb210Malnutrition-Hospital-Stays-2013.jsp.
809 Krumholz, HM. (2013). Post-hospital
syndrome—an acquired, transient condition of
generalized risk. New England Journal of Medicine.
368(2):100–2.
810 Sauer, A, Luo M. (2015) Role of Malnutrition
in Increasing Risk of Hospital Readmissions. Abbott
Nutrition Health Institute. Available at: https://
static.abbottnutrition.com/cms-prod/anhi.org/img/
Role-Of-Malnutrition-In-Increasing-RiskOfHospital-Readmissions-article.pdf.
811 Guenter P, Jensen G, Patel V, Miller S,
Mogensen KM, Malone A, et al. (2015). Addressing
disease-related malnutrition in hospitalized
patients: a call for a national goal. Joint Commission
Journal on Quality and Patient Safety.41(10):469–
73.
812 Norman K., Pichard C., Lochs H., Pirlich M.
(2008). Prognostic impact of disease-related
malnutrition. Clin. Nutr. 27, 5–15.
813 Khalatbari-Soltani S., Marques-Vida, P. (2015).
The economic cost of hospital malnutrition in
Europe; a narrative review. Clin. Nutr. ESPEN. 10,
e89–e94.
814 Correia M.I., Waitzberg D.L. (2003). The
impact of malnutrition on morbidity, mortality,
length of hospital stay and costs evaluated through
a multivariate model analysis. Clin Nutr. 22(3):235–
9.
815 Ibid.
816 Snider J.T., Linthicum M.T., Wu Y., et al.
(2014). Economic burden of community-based
PO 00000
Frm 00462
Fmt 4701
Sfmt 4700
Hospitals have an opportunity to
identify malnutrition during the patient
admission process and to address it
efficiently and effectively with
individualized interventions that could
optimize outcomes including reduced
readmissions and lengths of stay.817
Research demonstrates that there is
significant room to improve
identification, diagnosis, and treatment
of malnutrition in hospitalized
patients.818 819 Nutrition screening is the
first step in optimal malnutrition care
and triggers a nutrition assessment for
patients found to be at risk.820 821
We have consistently received
stakeholder input requesting the
addition of nutrition measures to the
Hospital IQR Program measure set to
address malnutrition of hospitalized
patients, including comments described
in the FY 2012 IPPS/LTCH PPS final
rule (76 FR 51639), the FY 2013 IPPS/
LTCH PPS final rule (77 FR 53535), the
FY 2014 IPPS/LTCH PPS final rule (78
FR 50810), the FY 2015 IPPS/LTCH PPS
final rule (79 FR 50056), and the FY
2016 IPPS/LTCH PPS final rule (80 FR
49561). In the FY 2018 IPPS/LTCH PPS
proposed rule, we solicited public
comments on potential future inclusion
of malnutrition eCQMs in the Hospital
IQR Program (82 FR 20060 through
20061), and in the FY 2018 IPPS/LTCH
PPS final rule we provided a summary
of these comments (82 FR 38379
through 38380). Commenters expressed
support and stated that Medicare
beneficiaries would benefit from the
adoption of malnutrition eCQMs that
support prompt malnutrition screening,
assessment, diagnosis, and development
of a care plan (82 FR 38379). In
addition, the commenters stated that
eCQMs specifically designed and tested
to be used with patient data
documented directly in the EHR would
likely impose minimal data collection
disease-associated malnutrition in the United
States. JPEN. 38(2 Suppl):77s–85s.
817 Ibid.
818 Kabashneh S., Alkassis S., Shanah L., Ali H..
(2020). A Complete Guide to Identify and Manage
Malnutrition in Hospitalized Patients. Cureus. doi:
10.7759/cureus.8486.
819 Fitall E., Jones Pratt K., McCauley S.M.,
Astrauskas G., Heck T., Hernandez B., et al. (2019).
Improving Malnutrition in Hospitalized Older
Adults: The Development, Optimization, and Use of
a Supportive Toolkit. Journal of the Academy of
Nutrition and Dietetics. 119(9):S25–S31 Available
at: https://www.sciencedirect.com/science/article/
pii/S2212267219305039.
820 Skipper A. (2008). Nutrition care process and
model part I: the 2008 update. J Am Diet
Assoc.108(7):1113–7.
821 Swan W., Vivanti A., Hakel-Smith N.A.,
Trostler N., Beck Howarter N., Papoutsakis C.
(2017). Nutrition Care Process and Model Update:
Toward Realizing People-Centered Care and
Outcomes Management. Journal of the Academy of
Nutrition and Dietetics. 117(12):2003–2014.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
and reporting burden (82 FR 38379
through 38380). The commenters further
stated that the inclusion of malnutrition
eCQMs in the Hospital IQR Program
measure set could help improve
outcomes and quality of life for patients,
especially for seniors and the
disadvantaged (82 FR 38380). We
believe adopting a malnutrition measure
will address several priority areas
identified in the CMS Equity Plan for
Medicare, including evaluating impacts
of disparities, integrating equity
solutions across CMS programs, and
increasing the ability of the healthcare
workforce to meet the needs of 822 823
Therefore, in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28518
through 28523) rule, we proposed to
adopt the Global Malnutrition
Composite Score eCQM (NQF #3592e)
beginning with the CY 2024 reporting
period/FY 2026 payment determination
and for subsequent years. At this time,
CMS quality reporting programs do not
include quality measures that
specifically address malnutrition. In the
CY 2022 Physician Fee Schedule (PFS)
final rule (86 FR 65970 through 65971),
we adopted the Implement Food
Insecurity and Nutrition Risk
Identification and Treatment Protocols
Improvement Activity (IA) as part of the
Merit-based Incentives Payment System
(MIPS), which incentivizes MIPSeligible clinicians to create or improve,
and then implement, protocols for
identifying and providing appropriate
support to: a) Patients with or at risk for
food insecurity, and b) patients with or
at risk for poor nutritional status.824 In
conjunction with adopting the IA under
MIPS, we believe adoption of the Global
Malnutrition Composite Score eCQM in
the Hospital IQR Program has the
potential to improve care delivery in the
inpatient setting and is likely to
ameliorate food insecurity and
malnutrition and lead to better health
outcomes.
Under the CMS Meaningful Measures
Framework,825 the Global Malnutrition
Composite Score eCQM addresses the
quality priority of ‘‘Promote Effective
Communication & Coordination of
Care’’ as well as ‘‘Promote Effective
823 Centers for Medicare & Medicaid Services.
CMS Equity Plan for Medicare. Available at: https://
www.cms.gov/About-CMS/Agency-Information/
OMH/equity-initiatives/equity-plan.
824 Centers for Medicare & Medicaid Services.
Quality Payment Program. Improvement Activities
Performance Category: Traditional MIPS
Requirements. Available at: https://qpp.cms.gov/
mips/improvement-activities.
825 Centers for Medicare & Medicaid Services.
Meaningful Measures Framework. Available at:
https://www.cms.gov/Medicare/Quality-InitiativesPatient-Assessment-Instruments/
QualityInitiativesGenInfo/CMS-Quality-Strategy.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Prevention and Treatment of Chronic
Disease.’’ Under the CMS Meaningful
Measures 2.0 Initiative, the Global
Malnutrition Composite Score eCQM
addresses the quality priority of
‘‘Affordability and Efficiency.’’ 826
(2) Overview of Measure
The Global Malnutrition Composite
Score eCQM assesses adults 65 years of
age and older admitted to inpatient
hospital service who received care
appropriate to their level of
malnutrition risk and malnutrition
diagnosis, if properly identified. Best
practices for malnutrition care
recommend inpatients be screened for
malnutrition risk, assessed to confirm
findings of malnutrition if found at-risk,
and have the proper severity of
malnutrition indicated in their
diagnosis along with a corresponding
nutrition care plan that addresses the
respective severity of malnutrition.827 828
The malnutrition composite measure
includes four component measures,
which are first scored separately, and
then integrated into an overall
composite score. The overall composite
score is derived from averaging the
individual performance scores of the
following four component measures:
• Screening for malnutrition risk at
admission;
• Completing a nutrition assessment
for patients who screened for risk of
malnutrition;
• Appropriate documentation of
malnutrition diagnosis in the patient’s
medical record if indicated by the
assessment findings; and
• Development of a nutrition care
plan for malnourished patients
including the recommended treatment
plan.
Together, the four component
measures represent the key processes of
care of malnutrition associated with the
risk identification, diagnosis, and
treatment of malnutrition in older
hospitalized adults as supported by
826 Centers for Medicare & Medicaid Services.
Meaningful Measures 2.0: Moving from Measure
Reduction to Modernization. Available at: https://
www.cms.gov/meaningful-measures-20-movingmeasure-reduction-modernization. We note that
Meaningful Measures 2.0 is still under
development.
827 Nepple K.G., Tobert C.M., Valladares A.F.,
Mitchell K., Yadrick M. (2019). Enhancing
Identification and Management of Hospitalized
Patients Who Are Malnourished: A Pilot Evaluation
of Electronic Quality Improvement Measures.
Journal of the Academy of Nutrition and Dietetics.
119(9):S32–S39.
828 McCauley S.M., Barrocas A., Malone A.
(2019). Hospital Nutrition Care Betters Patient
Clinical Outcomes and Reduces Costs: The
Malnutrition Quality Improvement Initiative Story.
Journal of the Academy of Nutrition and Dietetics.
119(9):S11–S14.
PO 00000
Frm 00463
Fmt 4701
Sfmt 4700
49241
clinical guidelines and submitted
evidence.829
The four component measures were
initially submitted for endorsement as
individual process measures in the NQF
2015–2017 Health and Well-Being
Project.830 The NQF declined to endorse
any of the individual component
measures based on evidence, provider
burden concern (including timing of
malnutrition screening and assessment),
and the unavailability of necessary data
elements to report the eCQMs.831 The
2015–2017 Health and Well-Being
Standing Committee recommended
combining individual measures or all
measures into a composite measure to
make the measure more meaningful by
including both the screening and the
development of a nutrition care plan
into one measure.832
Based on these recommendations, the
measure developer conducted
additional testing. The four component
measures were piloted as a single
composite measure at a large hospital in
the Midwest and the testing results
demonstrated that the measures were
usable for identifying key improvement
areas in malnutrition care related to
identifying risk, assessing for
malnutrition, developing the
appropriate care plan, and ensuring the
diagnosis of malnutrition was
documented to support follow-up
care.833 Subsequently, a group of 27
hospitals adopted and reported on the
use of the four component measures to
guide various projects focused on
improving care provided to hospitalized
patients who were malnourished or at
risk of malnutrition.834 The
829 Valladares A.F., McCauley S.M., Khan M.,
D’Andrea C., Kilgore K., Mitchell K. (2021).
Development and Evaluation of a Global
Malnutrition Composite Score. Journal of the
Academy of Nutrition and Dietetics. 122(2):P251–
P253.
830 National Quality Forum. Health and WellBeing Project 2015–2017. Available at: https://
www.qualityforum.org/
ProjectDescription.aspx?projectID=80741.
831 National Quality Forum. Prevention and
Population Health, Fall 2020 Cycle: CDP Report.
Available at: https://www.qualityforum.org/
ProjectMaterials.aspx?projectID=86178.
832 National Quality Forum. Health and WellBeing 2015–2017 Final Report. Available at: https://
www.qualityforum.org/Publications/2017/04/
Health_and_Well-Being_2015-2017_Final_
Report.aspx.
833 Nepple K.G., Tobert C.M., Valladares A.F.,
Mitchell K., Yadrick M. (2019). Enhancing
identification and management of hospitalized
patients who are malnourished: a pilot evaluation
of electronic quality improvement measures.
Journal of the Academy of Nutrition and Dietetics.
119: S32–S39.
834 Valladares A.F., Kilgore K.M., Partridge J.,
Sulo S., Kerr K.W., McCauley S. (2021). How a
malnutrition quality improvement initiative
furthers malnutrition measurement and care: results
E:\FR\FM\10AUR2.SGM
Continued
10AUR2
49242
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
participating hospitals reported changes
in measure performance based on
implementation of cyclical quality
improvement initiatives at their
respective institutions. Multivariate
analyses were then conducted to
identify the relationships between
performance on the four component
measures with patient outcomes of 30day readmission and length of stay. The
study results concluded that the four
component measures could be
implemented in a cohort of diverse
hospitals and lead to meaningful
improvements in measure performance
as all four components of the composite
measure were significantly associated
with improved outcomes for 30-day
readmissions.835 836 Prior analyses also
reported early nutrition interventions
were associated with reduced patient
length of stay.837 838 839 840 841 Following
measure testing, the measure developer
returned to NQF with the composite
eCQM for consideration in the Fall 2020
measure cycle.
The Global Malnutrition Composite
Score eCQM (MUC20–0032) was
included in the publicly available ‘‘List
of Measures Under Consideration for
December 21, 2020’’ (MUC List).842 The
measure was voted on and approved by
the Scientific Methods Panel in October
from a hospital learning collaborative. JPEN J
Parenter Enteral Nutr. 45: 366–371.
835 Ibid.
836 Anghel S., Kerr K.W., Valladares A.F., Kilgore
K.M., Sulo S. (2021). Identifying patients with
malnutrition and improving use of nutrition
interventions: A quality study in four US hospitals.
Nutrition. 91–92; 111360.
837 Silver H.J., Pratt K.J., Bruno M., Lynch J.,
Mitchell K., McCauley S.M. (2018). Effectiveness of
the malnutrition quality improvement initiative on
practitioner malnutrition knowledge and screening,
diagnosis, and timeliness of malnutrition-related
care provided to older adults admitted to a tertiary
care facility: a pilot study. Journal of the Academy
of Nutrition and Dietetics. 118(1): 101–109.
838 Meehan A., Loose C., Bell J., Partridge J.,
Nelson J., Goates S. (2017). Health system quality
improvement: impact of prompt nutrition care on
patient outcomes and health care costs. J Nurs Care
Qual. 2016; 31(3): 217–223.
839 Sriram K., Sulo S., VanDerBosch G., et al. A
comprehensive nutrition-focused Quality
Improvement Program reduces 30-day readmissions
and length of stay in hospitalized patients. JPEN J
Parenter Enteral Nutr. 41(3): 384–391.
840 Somanchi M., Tao X., Mullin G.E. (2011). The
facilitated early enteral and dietary management
effectiveness trial in hospitalized patients with
malnutrition. JPEN J Parenter Enteral Nutr. 35(2):
209–216.
841 Deutz N.E., Matheson E.M., Matarese L.E., et
al. (2016). Readmission and mortality in
malnourished, older, hospitalized adults treated
with a specialized oral nutritional supplement: A
randomized clinical trial. Clin Nutr. 35(1): 18–26.
842 Centers for Medicare & Medicaid Services. List
of Measures Under Consideration for December 21,
2020. Available at: https://www.cms.gov/files/
document/measures-under-consideration-list-2020report.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
2020.843 The MAP Rural Health
Advisory Group reviewed the measure
during its January 2021 meeting and
agreed that this measure was suitable for
use with rural providers in the Hospital
IQR Program.844 The MAP subsequently
offered conditional support for
rulemaking, pending NQF endorsement
of the measure.845
The composite measure was initially
reviewed by the NQF Prevention and
Population Health (PPH) Standing
Committee for endorsement suitability
during its February 2021 measure
evaluation meeting 846 and the full
review of the measure was detailed in
the NQF Prevention and Population
Health Fall 2020 Consensus
Development Process (CDP) Report.847
The NQF PPH Standing Committee
members agreed malnutrition is a
significant contributor to infections and
pressure ulcers requiring treatment,
especially for patients transferred to
other care facilities (such as an inpatient
rehabilitation hospital), and held a
robust discussion with most members
supporting the presented evidence and
topic area importance that assigns
accountability to the hospital team.848
Some PPH Standing Committee
members questioned the lack of
validated and standardized screening
and assessment tools specified in the
first two components. The measure
developer along with the measure
steward stated that objective, validated
screening tools 849 and standardized
843 National
Quality Forum. MAP 2020–2021
Considerations for Implementing Measures in
Federal Programs: Clinician, Hospital & PAC/LTC.
Available at: https://www.qualityforum.org/
Publications/2021/03/MAP_2020-2021_
Considerations_for_Implementing_Measures_Final_
Report_-_Clinicians,_Hospitals,_and_PACLTC.aspx.
844 National Quality Forum. Measure
Applications Partnership Rural Health Workgroup
Virtual Review Meeting Summary. January 2021.
Available at: https://www.qualityforum.org/
WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=94656.
845 National Quality Forum. MAP 2020–2021
Considerations for Implementing Measures Final
Report—Clinicians, Hospitals, and PAC–LTC.
March 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=94894.
846 National Quality Forum. Measure Evaluation
Web Meeting #1: Prevention and Population Health.
February 2021. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=94816.
847 National Quality Forum. Prevention and
Population Health Fall 2020 CDP Report. October
2021. Available at: https://www.qualityforum.org/
WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96457.
848 National Quality Forum. Measure
Worksheet—3592—Fall 2020 Cycle. Available at:
https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=95961.
849 Skipper A., Coltman A., Tomesko J., Piemonte
T.A., Handu D., Cheng F.W., et al. Position of the
PO 00000
Frm 00464
Fmt 4701
Sfmt 4700
assessment tools 850 can be implemented
to capture variables from structured
EHR data fields, such as BMI, dietary
history, recent weight loss, illness
severity, laboratory values, and age.
After further discussion on performance
gaps and the ability to discern
differences within and between
populations, many PPH Standing
Committee members stated they wanted
to review additional performance data
for the eCQM.851 The measure
developer submitted the requested
performance data for the PPH NQF
Standing Committee to review, discuss,
and revote at the NQF Standing
Committee post-comment meeting on
June 3, 2021.852 At that time, the NQF
PPH Standing Committee voted on the
overall suitability for endorsement and
the NQF Consensus Standards Approval
Committee (CSAC) subsequently
endorsed the measure (NQF #3592e).853
The measure specifications for the
Global Malnutrition Composite Score
eCQM can be found on the eCQI
Resource Center website, available at:
https://ecqi.healthit.gov/prerulemaking-eh-cah-ecqms.
(3) Data Sources
The eCQM uses data collected
through hospitals’ EHRs. The measure is
designed to be calculated by the
hospitals’ CEHRT using the patient-level
data and then submitted by hospitals to
CMS.
(4) Measure Calculation
The Global Malnutrition Composite
Score eCQM consists of four component
measures, which are first scored
separately.854 855 The overall composite
Academy of Nutrition and Dietetics: Malnutrition
(Undernutrition) Screening Tools for All Adults.
Journal of the Academy of Nutrition and Dietetics.
120(4):709–713.
850 White J.V., Guenter P., Jensen G., Malone A.,
Schofield M. Consensus Statement of the Academy
of Nutrition and Dietetics/American Society for
Parenteral and Enteral Nutrition: Characteristics
Recommended for the Identification and
Documentation of Adult Malnutrition
(Undernutrition). J Am Diet Assoc;112(5):730–738.
851 National Quality Forum. Post-Comment Web
Meeting (Fall 2020 Cycle) Comments Received.
Available at: https://www.qualityforum.org/
WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=95422.
852 National Quality Forum. Post-Comment Web
Meeting (Fall 2020 Cycle) Memo. Available at:
https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=95421.
853 National Quality Forum. Consensus Standards
Approval Committee Prevention and Population
Health Fall 2020 Review. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=95602.
854 Valladares A.F., McCauley S.M., Khan M.,
D’Andrea C., Kilgore K., Mitchell K. (2021).
Development and Evaluation of a Global
Malnutrition Composite Score. Journal of the
Academy of Nutrition and Dietetics. Available at:
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
score is derived from averaging the
individual performance scores of the
four component measures. The
malnutrition component measures are
all fully specified for use in EHRs. Table
IX.E–04. outlines the data
49243
specification(s) and data sources for
each of the four components.
TABLE IX.E-04. GLOBAL MALNUTRITION COMPOSITE SCORE ECQM
COMPONENTS AND DATA SOURCES
Component
Completion of a Malnutrition Screening
Description
Patients age 65 years aud older who were
screened for malnutrition
Completion of a
Nutrition Assessment
for Patients Identified
as At-Risk for Malnutrition
Patients age 65 years aud older identified
as at-risk for malnutrition based on a
malnutrition screening
who have a nutrition assessment
documented in the medical record
Appropriate Documentation of a
Malnutrition Diagnosis
Patients age 65 years aud older aud found
to be malnourished based on a completed
nutrition assessment who have
documentation of a malnutrition diagnosis
Nutrition Care Plau for Patients
Identified as
Malnourished after a Completed
Nutrition Assessment
Patients age 65 years aud older aud found
to be malnourished based on a completed
nutrition assessment who have a
documented nutrition care plau in the
medical record.
(5) Measure Numerator
The Global Malnutrition Composite
Score eCQM numerator is comprised of
Data Sources
- Inpatient Admission Time
- Inpatient Discharge Time
- Birthdate
- Completed Malnutrition Screening
- Completed Malnutrition Screening Time Stamp
- Inpatient Admission Time
- Inpatient Discharge Time
- Birthdate
- Completed Malnutrition Screening
- Malnutrition Screening Result
- Completed Nutrition Assessment
- Completed Nutrition Assessment Time Stamp
- Inpatient Admission Time
- Inpatient Discharge Time
- Birthdate
- Completed Nutrition Assessment
- Nutrition Assessment Result
- Malnutrition Diagnosis
- Inpatient Admission Time
- Inpatient Discharge Time
- Birthdate
- Completed Nutrition Assessment
- Nutrition Assessment Result
- Documented Nutrition Care Plau
the four component measures, that are
individually scored for patients 65 years
of age and older who are admitted to an
acute inpatient hospital. Details on the
numerator for each component are
specified in Table IX.E–05.
TABLE IX.E-05. GLOBAL MALNUTRITION COMPOSITE SCORE ECQM
COMPONENTS' NUMERATOR DESCRIPTIONS
Nutrition Care Plau for Patients Identified as
Malnourished after a Completed Nutrition Assessment
(6) Measure Denominator
khammond on DSKJM1Z7X2PROD with RULES2
The measure denominator is the
composite, or total, of the four
https://www.jandonline.org/article/S22122672(21)00075-7/fulltext.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
component measures for patients aged
65 years and older who are admitted to
an acute inpatient hospital. Details on
the denominator (and any exclusions)
for each component are specified in
Table IX.E–06.
855 National Quality Forum. #3592e Global
Malnutrition Composite Score. Available at: https://
www.qualityforum.org/ProjectTemplate
Download.aspx?SubmissionID=3592e.
PO 00000
Frm 00465
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.161
Completion of a Nutrition Assessment for Patients Identified as AtRisk for Malnutrition
Appropriate Documentation of a Malnutrition Diagnosis
Numerator
Patients in the denominator who have a malnutrition screening
documented in the medical record
Patients in the denominator who have a nutrition assessment
documented in the medical record
Patients in the denominator with a diagnosis of malnutrition
documented in the medical record
Patients in the denominator who have a nutrition care plau
documented in the medical record
ER10AU22.160
Component
Completion of a Malnutrition Screening
49244
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE IX.E-06. GLOBAL MALNUTRITION COMPOSITE SCORE ECQM
COMPONENTS' DENOMINATOR DESCRIPTIONS AND EXCLUSIONS
Completion of a Nutrition Assessment for Patients
Identified as At-Risk for Malnutrition
Appropriate Documentation of a Malnutrition
Diagnosis
Nutrition Care Plan for Patients Identified as
Malnourished after a Completed Nutrition
Assessment
khammond on DSKJM1Z7X2PROD with RULES2
Each measure component is a
proportion with a possible performance
score of 0 to 100 percent. After each
component score is calculated
individually, an unweighted average of
all four scores is completed to
determine the final composite score
with a total score ranging from 0 to 100
percent.856
(7) Data Submission and Reporting
We are proposed the adoption of the
Global Malnutrition Composite Score
eCQM as part of the Hospital IQR
Program measure set for which hospitals
can self-select beginning with the CY
2024 reporting period/FY 2026 payment
determination and for subsequent years.
We refer readers to section IX.E.10.e. of
this final rule for our previously
finalized eCQM reporting and
submission requirements, as well as
proposed modifications for these
requirements. We also refer readers to
section IX.H.10.a.(2). of the preamble of
this final rule for discussion of a similar
proposal to adopt this measure in the
Medicare Promoting Interoperability
Program for Eligible Hospitals and
CAHs.
We invited public comment on this
proposal.
Comment: Many commenters
supported our proposal to adopt the
Global Malnutrition Composite Score
eCQM beginning with the CY 2024
reporting period/FY 2026 payment
determination and for subsequent years.
Many commenters supported our
proposal to adopt this measure,
856 Valladares A.F., McCauley S.M., Khan M.,
D’Andrea C., Kilgore K., and Mitchell K. (2021).
Development and Evaluation of a Global
Malnutrition Composite Score. Journal of the
Academy of Nutrition and Dietetics. 122(2): p251–
253.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Denominator
Patients age 65 years and older at time of
admission who are admitted to an inpatient
hospital
Patients age 65 years and older at time of
admission who are admitted to an inpatient
hospital and were identified as at-risk for
malnutrition upon completing a
malnutrition screening
Patients age 65 years and older at time of
admission who are admitted to an inpatient
hospital with findings of malnutrition upon
completing a nutrition assessment
Patients age 65 years and older at time of
admission who are admitted to an inpatient
hospital with findings of malnutrition upon
completing a nutrition assessment.
expressing their beliefs that the measure
will provide valuable information and
insights to providers, patients, families,
communities, as well as policymakers.
Many commenters supported this
measure because of its positive
implications for healthcare, including
improving care coordination and the
quality of life after hospitalization,
providing timely interventions and
connections to community resources,
and reducing issues like costly
outcomes, readmissions, lengths of stay,
complications, and mortality. Many
commenters appreciated that this
measure may help close the gap
between identification of and
intervention for malnutrition. Several
commenters indicated appreciation that
this measure may help raise awareness
and support for screening for
malnutrition by clinicians, helping to
ensure that hospitals are consistently
screening patients. Many commenters
supported our proposal because they
believe that malnutrition is a significant
issue for aging populations and is tied
to health outcomes. Several commenters
appreciated that this measure is a step
toward improving and standardizing
care for malnutritioned older adults.
Several commenters appreciated our
proposal, noting that it will fill a
measurement gap because malnutrition
is otherwise unaddressed by our other
quality reporting and value-based
purchasing programs. A few
commenters suggested that we should
focus on whether patients received
appropriate nutrition while in the
hospital, or whether their nutritional
needs were met after discharge. A
commenter noted that operationalizing
this measure may be more challenging
for rural hospitals without full-time
dietician support. A commenter
PO 00000
Frm 00466
Fmt 4701
Sfmt 4700
Denominator Exclusions
Patients with a length of stay of less than 24
hours
Patients with a length of stay of less than 24
hours
Patients with a length of stay of less than 24
hours
Patients with a length of stay of less than 24
hours
suggested we consider trying to assess
upstream flagging measures for nutrition
prior to hospitalization.
Response: We thank the commenters
for their support of our proposal to
adopt the Global Malnutrition
Composite Score eCQM. The
developmental, economic, social, and
medical impacts of the global burden of
malnutrition are serious and lasting, for
individuals and their families, for
communities, and for countries (87 FR
28518). We agree that this measure may
provide valuable information and may
help us begin to address the serious
burden that malnutrition imposes on the
healthcare system. We agree that
disease-related malnutrition, while not
limited to older adults, is more frequent
among those with higher age, and the
consequences appear to be more severe
in older persons (87 FR 28518). This
measure will capture important
information that may be critical to
improving care for aging people with
malnutrition. Further, we believe that
adoption of the Global Malnutrition
Composite Score eCQM has the
potential to improve care delivery in the
inpatient setting and is likely to
ameliorate food insecurity and
malnutrition and lead to better health
outcomes by delivering necessary
attention and resources to hospitalized
individuals with nutrition needs that
can improve their quality of care. With
regard to dietician support, while we
acknowledge that hospitals have
different staffing levels, we believe that
nutrition screening is an important
aspect of a patient’s holistic health and
it is the responsibility of all clinicians
to support appropriate nutrition,
particularly in inpatient settings where
hospitalized individuals can receive
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.162
Component
Completion of a Malnutrition Screening
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
resources, education, and appropriate
nutrition to address their needs.
Comment: Many commenters
supported our proposal because it aligns
with our health equity priorities for
reducing disparities in healthcare. Many
commenters supported our proposal
because they believe that malnutrition
disproportionately affects vulnerable
populations and anticipate this measure
may be important to advancing health
equity. Several commenters appreciated
that the measure will help provide a
safety net for vulnerable patients and
historically underserved populations. A
few commenters noted that malnutrition
disproportionately impacts rural
residents and emphasized that this
measure may be particularly helpful for
rural communities.
Response: We thank the commenters
for their support. We agree that adopting
a malnutrition measure may help
address several priority areas identified
in the CMS Framework for Health
Equity,857 including evaluating impacts
of disparities, integrating equity
solutions across CMS programs, and
increasing the ability of the healthcare
workforce to meet the needs of
underserved populations (87 FR 28520).
We also note that addressing nutrition
disparities is a priority for the BidenHarris administration, which has set a
goal of ending hunger and increasing
healthy eating so fewer Americans
experience diet-related diseases.858 We
agree that health disparities are one
factor that contributes to the burden of
malnutrition across racial and ethnic
groups and inpatient hospitals have an
opportunity to identify malnutrition and
optimize outcomes for patients
including reduced readmissions, which
are significantly higher for Black and
Hispanic Americans as well as
American Indian and Alaskan
Natives.859 860 This measure may help
857 Centers for Medicare & Medicaid Services.
CMS Framework for Health Equity. Available at:
https://www.cms.gov/About-CMS/AgencyInformation/OMH/equity-initiatives/framework-forhealth-equity.
858 The White House. White House Announces
Conference on Hunger, Nutrition, and Health in
September. May 4, 2022. Available at: https://
www.whitehouse.gov/briefing-room/statementsreleases/2022/05/04/white-house-announcesconference-on-hunger-nutrition-and-health-inseptember/.
859 Rodriguez-Gutierrez R., Herrin J., Lipska K.J.
Racial and Ethnic Differences in 30-Day Hospital
Readmissions Among US Adults With Diabetes.
(2019). JAMA Network Open. 2019;2(10):e1913249.
Available at: https://jamanetwork.com/journals/
jamanetworkopen/fullarticle/2752820.
860 Centers for Medicare & Medicaid Services
Office of Minority Health. Medicare Hospital
Readmissions Among Minority Populations. (2015).
Available at: https://www.cms.gov/About-CMS/
Agency-Information/OMH/Downloads/OMH_
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
underscore the importance of
addressing nutrition for the health of
vulnerable patients in historically
underserved populations (87 FR 28519).
We also note that the MAP Rural Health
Advisory Group reviewed this measure
and determined it would be suitable for
use with rural providers in the Hospital
IQR Program (87 FR 28521).
Comment: A commenter requested
that we provide a direction score to help
hospitals better understand their
performance.
Response: We appreciate the
commenter’s suggestion and will
consider it as part of our educational
materials and outreach during
implementation of this measure. We
note that the Hospital IQR Program does
not implement benchmarks or target
levels of performance for its measures as
it is a pay-for-reporting program.
However, a higher score on the Global
Malnutrition Composite Score eCQM
represents better quality of care.
Comment: A commenter
recommended that we refine the
exclusion criteria to give more time for
sufficient nutrition assessments.
Response: We thank the commenter
for their feedback. We note that the NQF
assessed and endorsed this measure
with the current exclusion criteria.861
We will continue to evaluate the
appropriateness of refinements to the
exclusion criteria upon implementation
of the measure.
Comment: A commenter expressed
concern that the measure could be
overly subjective and noted that
providers do not control patient choices
regarding the management of their own
health.
Response: We acknowledge the
commenter’s concern that providers do
not control patient choices; however, we
respectfully disagree that the measure is
overly subjective. The four component
measures that make up this composite
eCQM represent the key processes of
care of malnutrition associated with the
risk and identification, diagnosis, and
treatment of malnutrition in older
hospitalized adults as supported by
clinical guidelines and submitted
evidence (87 FR 28520). Measure testing
across a group of 27 hospitals found that
the four component measures could be
implemented in a cohort of diverse
hospitals and lead to meaningful
improvements in measure performance
as all four components of the composite
Dwnld-MedicareHospitalReadmissions
AmongMinorityPopulations.pdf.
861 National Quality Forum. Consensus Standards
Approval Committee Prevention and Population
Health Fall 2020 Review. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=95602.
PO 00000
Frm 00467
Fmt 4701
Sfmt 4700
49245
measure were significantly associated
with improved outcomes for 30-day
readmissions (87 FR 28521). Based on
the measure testing and ultimate NQF
endorsement of this measure, we believe
that adoption of the Global Malnutrition
Composite Score eCQM has the
potential to improve the quality of care
delivery in the inpatient setting and is
likely to ameliorate food insecurity and
malnutrition and lead to better health
outcomes, particularly in inpatient
settings where hospitalized individuals
can receive resources, education, and
appropriate nutrition to address their
needs.
Comment: A few commenters
expressed concern that this measure
may be duplicative of the food
insecurity attestation proposed in the
Screening for Social Drivers of Health
measure. A commenter did not support
our proposal to adopt this measure for
that same concern.
Response: We acknowledge the
commenters’ concern, however we
believe that the measures, while related,
are not duplicative. The Screening for
Social Drivers of Health measure,
discussed in section IX.E.5.b.(1). of the
preamble of this final rule, and the
Global Malnutrition Composite Score
eCQM both speak to nutrition as a
driver of health because it is an
important contributor to a healthful
population. However, the measures
address different but related goals. The
Screening for Social Drivers of Health
measure focuses on incentivizing the
screening and identifying of patients for
food insecurity, defined as limited or
uncertain access to adequate quality and
quantity of food (87 FR 28500), while
the Global Malnutrition Composite
Score eCQM focuses not only on
screening for malnutrition risk (of
which food insecurity may be a
contributing factor), but also the
performance of a nutrition assessment
and development of a care plan for
identified malnourished patients (87 FR
28520). We believe these two measures
are equally important and
complementary, but not duplicative as
they measure different aspects of quality
care processes.
Comment: Several commenters
addressed requiring reporting of this
measure. A few commenters suggested
we require reporting on this eCQM. A
few commenters specifically supported
the measure as a measure that hospitals
can choose to self-select. A few
commenters expressed their belief that
this measure may not be relatively
important for the Hospital IQR Program
and recommended that we not require
reporting of it in the future. A
commenter suggested that we not
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49246
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
require reporting of this measure until
after several years’ worth of the measure
data have been validated.
Response: We appreciate the
commenters’ feedback on our proposal
to adopt, but not yet require, reporting
on this eCQM. We believe that our
proposal is balanced so as to provide
hospitals with the option of reporting on
this new eCQM. The addition of this
eCQM further advances CMS’ goal of
transitioning to a fully digital quality
measures landscape, and we will take
the commenters’ suggestion to make this
eCQM mandatory under consideration
as we begin to collect data. We note that
any proposal to require reporting this
eCQM would be made through future
notice-and-comment rulemaking.
Comment: Several commenters
expressed concern about implementing
and operationalizing this measure given
the detailed and complex nature of the
measure specification and because of
competing EHR-related proposals and
reporting requirements. They believe
that implementation would require
updates to EHRs and workflows. A
commenter requested additional
implementation guidance to support
standardized implementation across
hospitals.
Response: We appreciate the
commenters’ concerns about
implementation of the measure and note
that the measure uses data collected
through hospital’s EHRs and is designed
to be calculated by the hospital’s
CEHRT, thereby reducing reporting
burden and complexity. Regarding
resource commitments and the
proposed adoption schedule, we believe
that the design of the measure is
balanced to provide hospitals sufficient
information for driving healthful
outcomes by quickly identifying and
addressing patients’ nutrition needs and
additional resource allocations to
support reporting for this eCQM,
particularly in the hospital inpatient
older adult population of which up to
6.5 million patients experience
malnutrition (87 FR 28519). We also
remind hospitals that they may selfselect to report on this eCQM; it is not
a required eCQM for the CY 2024
reporting period/FY 2026 performance
period. As we noted in the FY 2023
IPPS/LTCH PPS proposed rule, the
measure developer conducted testing on
this measure across a group of 27
hospitals and concluded that the four
component measures could be
implemented in a cohort of diverse
hospitals and lead to meaningful
improvements in measure performance
(87 FR 28521). For implementation
guidance, we refer readers to the
measure specifications, implementation
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
guide, and other resources, which can
be found on the eCQI Resource Center
website, available at: https://
ecqi.healthit.gov.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
g. Hospital-Level, Risk Standardized
Patient-Reported Outcomes Following
Elective Primary Total Hip Arthroplasty
(THA) and/or Total Knee Arthroplasty
(TKA) (NQF #3559), Beginning With
Two Voluntary Reporting Periods in
CYs 2025 and 2026, Followed by
Mandatory Reporting for Eligible
Elective Procedures Occurring July 1,
2025 Through June 30, 2026, Impacting
the FY 2028 Payment Determination
and for Subsequent Years
(1) Background
Approximately six million adults
aged 65 or older suffer from
osteoarthritis in the U.S.862
Osteoarthritis accounts for more than
half of all arthritis-related
hospitalizations,863 and in 2013 there
were approximately 1,023,000
hospitalizations for osteoarthritis.864
Hip and knee osteoarthritis is one of the
leading causes of disability among noninstitutionalized adults,865 and roughly
80 percent of patients with osteoarthritis
have some limitation in mobility.866
Elective total hip arthroplasty (THA)
and total knee arthroplasty (TKA) are
most commonly performed for
degenerative joint disease or
osteoarthritis, which affects more than
30 million Americans.867 THA and TKA
offer significant improvement in quality
of life by decreasing pain and improving
862 Arthritis Foundation. Arthritis By the
Numbers Book of Trusted Facts and Figures. 2018:
https://www.arthritis.org/getmedia/e1256607-fa874593-aa8a-8db4f291072a/2019-abtn-final-march2019.pdf. Accessed March 8, 2019.
863 Levit K., Stranges E., Ryan K., Elixhauser A.
HCUP Facts and Figures, 2006: Statistics on
Hospital-based Care in the United States. 2008.
Available at: https://www.hcup-us.ahrq.gov/
reports.jsp.
864 Torio C.M., B.J., National inpatient hospital
costs: the most expensive conditions by payer,
2013. HCUP statistical brief #204. Healthcare Cost
and Utilization Project (HCUP) Statistical Briefs.
Rockville, MD, Agency for Healthcare Research and
Quality. https://www.hcup-us.ahrq.gov/reports/
statbriefs/sb204-Most-Expensive-HospitalConditions.pdf. Accessed February 2021.
865 Guccione A.A., Felson D.T., Anderson J.J., et
al. The effects of specific medical conditions on the
functional limitations of elders in the Framingham
Study. American journal of public health.
1994;84(3):351–358.
866 Michaud C.M., McKenna M.T., Begg S., et al.
The burden of disease and injury in the United
States 1996. Population health metrics. 2006;4:11.
doi: 10.1186/1478–7954–4–11.
867 Centers for Disease Control and Prevention
(CDC). Osteoarthritis (OA). Accessed March 8, 2019.
Available at: https://www.cdc.gov/arthritis/basics/
osteoarthritis.htm.
PO 00000
Frm 00468
Fmt 4701
Sfmt 4700
function in a majority of patients,
without resulting in a high risk of
complications or death.868 869 870 871
However, not all patients experience
benefit from these procedures.872 Many
patients note that their pre-operative
expectations for functional
improvement have not been
met.873 874 875 876 In addition, clinical
practice variation has been well
documented in the U.S.,877 878 879
readmission and complication rates vary
across hospitals,880 881 and international
868 Rissanen P., Aro S., Slatis P., Sintonen H.,
Paavolainen P. Health and quality of life before and
after hip or knee arthroplasty. The Journal of
arthroplasty. 1995;10(2):169–175.
869 Wiklund I., Romanus B. A comparison of
quality of life before and after arthroplasty in
patients who had arthrosis of the hip joint. The
Journal of bone and joint surgery. American
volume. 1991;73(5):765–769.
870 Laupacis A., Bourne R., Rorabeck C., et al. The
effect of elective total hip replacement on healthrelated quality of life. The Journal of bone and joint
surgery. American volume. 1993;75(11):1619–1626.
871 Ritter M.A., Albohm M.J., Keating E.M., Faris
P.M., Meding J.B. Comparative outcomes of total
joint arthroplasty. The Journal of arthroplasty.
1995;10(6):737–741.
872 National Joint Registry. National Joint Registry
for England and Wales 9th Annual Report 2012.
Available at: https://www.hqip.org.uk/wp-content/
uploads/2018/02/national-joint-registry-9th-annualreport-2012.pdf.
873 Suda A.J., Seeger J.B., Bitsch R.G., Krueger M.,
Clarius M. Are patients’ expectations of hip and
knee arthroplasty fulfilled? A prospective study of
130 patients. Orthopedics. 2010;33(2):76–80.
874 Ghomrawi H.M., Franco Ferrando N., Mandl
L.A., Do H., Noor N., Gonzalez Della Valle A. How
Often are Patient and Surgeon Recovery
Expectations for Total Joint Arthroplasty Aligned?
Results of a Pilot Study. HSS journal: The
musculoskeletal journal of Hospital for Special
Surgery. 2011;7(3):229–234.
875 Harris I.A., Harris A.M., Naylor J.M., Adie S.,
Mittal R., Dao A.T. Discordance between patient
and surgeon satisfaction after total joint
arthroplasty. The Journal of arthroplasty.
2013;28(5):722–727.
876 Jourdan C., Poiraudeau S., Descamps S., et al.
Comparison of patient and surgeon expectations of
total hip arthroplasty. PloS one. 2012;7(1):e30195.
877 Roos E.M. Effectiveness and practice variation
of rehabilitation after joint replacement. Current
opinion in rheumatology. 2003;15(2):160–162.
878 Anderson F.A, Jr., Huang W., Friedman R.J.,
Kwong L.M., Lieberman J.R., Pellegrini V.D., Jr.
Prevention of venous thromboembolism after hip or
knee arthroplasty: findings from a 2008 survey of
US orthopedic surgeons. The Journal of
arthroplasty. 2012;27(5):659–666 e655.
879 American Academy of Orthopaedic Surgeons
(AAOS). Preventing Venous Thromboembolic
Disease in Patients Undergoing Elective Hip and
Knee Arthroplasty: Evidence-Based Guideline and
Evidence Report. 2011.
880 Suter L.G., Grady J.N., Lin Z., et al. 2013
Measure Updates and Specifications: Elective
Primary Total Hip Arthroplasty (THA) And/OR
Total Knee Arthroplasty (TKA) All-Cause
Unplanned 30-Day Risk-Standardized Readmission
Measure (Version 2.0). March 2013.
881 Suter L.G., Parzynski C.S., Grady J.N., et al.
2013 Measures Update and Specifications: Elective
Primary Total Hip Arthroplasty (THA) AND/OR
Total Knee Arthroplasty (TKA) Risk-Standardized
Complication Measure (Version 2.0). March 2013;
Available at: https://qualitynet.org/.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
experience documents wide hospitallevel variation in patient-reported
outcome measure results following THA
and TKA.882
For example, data from the United
Kingdom demonstrate that there is a
greater than 15 percent difference across
hospitals in the proportion of patients
showing improvement after
surgery.883 884
Peri-operative care and care
coordination across provider groups and
specialties have important effects on
clinical outcomes.885 886 The goal of a
hospital-level outcome measure is to
capture the full spectrum of care to
incentivize collaboration and shared
responsibility for improving patients’
health and reducing the burden of their
disease. THA and TKA procedures
provide a suitable environment for
optimizing care, as there are many
studies indicating how hospitals and
providers can improve outcomes of their
patients by addressing aspects of pre-,
peri-, and post-operative
care.887 888 889 890 891 892
882 Rolfson O. Patient-reported Outcome
Measures and Health-economic Aspects of Total
Hip Arthroplasty: A study of the Swedish Hip
Arthroplasty Register. (2010). https://
gupea.ub.gu.se/bitstream/handle/2077/23722/
gupea_2077_23722_1.pdf?sequence=1. Accessed
July 20, 2013.
883 National Health System: The Information
Centre for Health and Social Care. HESonline
Hospital Episode Statistics: Proms Data. https://
www.hesonline.nhs.uk/Ease/ ContentServer?siteID=
1937&categoryID=1295, 2012.
884 Neuburger J., Hutchings A., van der Meulen J.,
Black N. Using patient-reported outcomes (PROs) to
compare the providers of surgery: Does the choice
of measure matter? Medical care. 2013;51(6):517–
523.
885 Feng J., Novikov D., Anoushiravani A.,
Schwarzkopf R. Total knee arthroplasty: improving
outcomes with a multidisciplinary approach. J
Multidiscip Healthc. 2018;11:63–73.
886 Saufl N., Owens A., Kelly I., Merrill B.,
Freyaldenhouen L. A multidisciplinary approach to
total joint replacement. Journal of Perianesthesia
Nursing. 2007;22(3):195.
887 Monticone M., Ferrante S., Rocca B., et al.
Home-based functional exercises aimed at
managing kinesiophobia contribute to improving
disability and quality of life of patients undergoing
total knee arthroplasty: a randomized controlled
trial. Archives of physical medicine and
rehabilitation. 2013;94(2):231–239.
888 Brown K., Topp R., Brosky J.A., Lajoie A.S.
Prehabilitation and quality of life three months after
total knee arthroplasty: A pilot study. Perceptual
and motor skills. 2012;115(3):765–774.
889 Choong P.F., Dowsey M.M., Stoney J.D. Does
accurate anatomical alignment result in better
function and quality of life? Comparing
conventional and computer-assisted total knee
arthroplasty. The Journal of arthroplasty.
2009;24(4):560–569.
890 Galea M.P., Levinger P., Lythgo N., et al. A
targeted home- and center-based exercise program
for people after total hip replacement: A
randomized clinical trial. Archives of physical
medicine and rehabilitation. 2008;89(8):1442–1447.
891 McGregor A.H., Rylands H., Owen A., Dore
C.J., Hughes S.P. Does preoperative hip
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Due to the absence of large scale and
uniformly collected patient-reported
outcome (PRO) data available from
patients undergoing elective primary
THA/TKA, in November 2015 we
established an incentivized, voluntary
PRO data collection opportunity within
the Comprehensive Care for Joint
Replacement (CJR) model 893 to support
measure development. Requirements for
successful submission of PRO data for
eligible elective primary THA/TKA
procedures were set forth in the 2015
CJR final rule (80 FR 73274). This
Hospital-Level, Risk-Standardized
Patient-Reported Outcomes Following
Elective Primary Total Hip and/or Total
Knee Arthroplasty (THA/TKA)
performance measure (THA/TKA PRO–
PM) was developed and tested using
PRO instruments and risk variable data
collected and submitted by CJR
participant hospitals. PRO data from the
first few performance years for the CJR
model revealed hospital-level variation
in these outcomes across U.S. hospitals,
although the full degree and extent of
variation is unknown.
In October 2017, we launched the
Meaningful Measures Framework to
identify high priority areas for quality
measurement that improve patient
outcomes while also reducing burden
on providers.894 The initiative captures
the agency’s vision in evaluating and
streamlining regulations with a goal to
reduce unnecessary cost and burden,
increase efficiencies, and improve
beneficiary experience. The scope of the
Meaningful Measures Framework
continues to evolve as the healthcare
environment continues to change.
Meaningful Measures 2.0 895 is currently
underway and aims to promote better
collection and integration of patients’
voices by incorporating patient reported
outcome measures that are embedded
into the clinical workflow, are easy to
rehabilitation advice improve recovery and patient
satisfaction? The Journal of arthroplasty. 2004;19(4):
464–468.
892 Moffet H, Collet J.P., Shapiro S.H., Paradis G.,
Marquis F., Roy L. Effectiveness of intensive
rehabilitation on functional ability and quality of
life after first total knee arthroplasty: A single-blind
randomized controlled trial. Archives of physical
medicine and rehabilitation. 2004;85(4):546–556.
893 Centers for Medicare & Medicaid Services.
Comprehensive Care for Joint Replacement Model.
Available at: https://innovation.cms.gov/
innovation-models/cjr.
894 CMS’ Meaningful Measures Framework can be
found at: https://www.cms.gov/Medicare/QualityInitiatives-Patient-Assessment-Instruments/Quality
InitiativesGenInfo/MMF/General-info-Sub-Page.
895 Centers for Medicare & Medicaid Services.
Meaningful Measures 2.0: Moving from Measure
Reduction to Modernization. Available at: https://
www.cms.gov/meaningful-measures-20-movingmeasure-reduction-modernization. We note that
Meaningful Measures 2.0 is still under
development.
PO 00000
Frm 00469
Fmt 4701
Sfmt 4700
49247
use, and reduce reporting burden.896
The THA/TKA PRO–PM is fully
developed and aligns with these future
Meaningful Measures 2.0 goals, which
are still under development.
Elective THA/TKAs are important,
effective procedures performed on a
broad population, and the patient
outcomes for these procedures (such as
pain, mobility, and quality of life) can
be measured in a scientifically
soundway,
897 898 899 900 901 902 903 904 905 906 907 908 909
are influenced by a range of
896 https://www.cms.gov/meaningful-measures20-moving-measure-reduction-modernization.
897 Alviar M.J., Olver J., Brand C., Hale T., Khan
F. Do patient-reported outcome measures used in
assessing outcomes in rehabilitation after hip and
knee arthroplasty capture issues relevant to
patients? Results of a systematic review and ICF
linking process. J. Rehabil Med. 2011;43(5):374–
381.
898 Alviar M.J., Olver J., Brand C., et al. Do
patient- reported outcome measures in hip and knee
arthroplasty rehabilitation have robust
measurement attributes? A systematic review. J
Rehabil Med. 2011;43(7):572–583.
899 Bauman S., Williams D., Petruccelli D., Elliott
W., de Beer J. Physical activity after total joint
replacement: a cross-sectional survey. Clin J Sport
Med. 2007;17(2):104–108.
900 Collins N.J., Roos E.M. Patient-reported
outcomes for total hip and knee arthroplasty:
Commonly used instruments and attributes of a
‘‘good’’ measure. Clin Geriatr Med. 2012;28(3):367–
394.
901 Jones C.A., Beaupre L.A., Johnston D.W.,
Suarez-Almazor M.E. Total joint arthroplasties:
Current concepts of patient outcomes after surgery.
Rheum Dis Clin North Am. 2007;33(1):71–86.
902 Lau R.L., Gandhi R., Mahomed S., Mahomed
N. Patient satisfaction after total knee and hip
arthroplasty. Clin Geriatr Med. 2012;28(3):349–365.
903 Liebs T.R., Herzberg W., Ruther W., Russlies
M., Hassenpflug J., Multicenter Arthroplasty
Aftercare Project M. Quality-adjusted life years
gained by hip and knee replacement surgery and its
aftercare. Archives of physical medicine and
rehabilitation. 2016;97(5):691–700.
904 Montin L., Leino-Kilpi H., Suominen T.,
Lepisto J. A systematic review of empirical studies
between 1966 and 2005 of patient outcomes of total
hip arthroplasty and related factors. J Clin Nurs.
2008;17(1):40–45.
905 Papalia R., Del Buono A., Zampogna B.,
Maffulli N., Denaro V. Sport activity following joint
arthroplasty: A systematic review. Br Med Bull.
2012;101:81–103.
906 Rolfson O., Rothwell A., Sedrakyan A., et al.
Use of patient-reported outcomes in the context of
different levels of data. J Bone Joint Surg Am.
2011;93 Suppl 3:66–71.
907 Suter L.G., Potteiger J., Cohen D.B., Lin Z.,
Drye E.E., Bernheim S.M. Environmental Scan/
Literature Review: Total Hip and Total Knee
Arthroplasty Patient-Reported Outcome Measure.
Report prepared for Centers for Medicare &
Medicaid Services. 2012.
908 Thorborg K., Roos E.M., Bartels E.M., Petersen
J., Holmich P. Validity, reliability and
responsiveness of patient-reported outcome
questionnaires when assessing hip and groin
disability: A systematic review. BJSM online.
2010;44(16):1186–1196.
909 White D., Master H. Patient Reported
Measures of Physical Function in Knee
Osteoarthritis. Rheum Dis Clin North Am.
2016;42(2):239–252.
E:\FR\FM\10AUR2.SGM
10AUR2
49248
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
improvements in
care,910 911 912 913 914 915 916 917 and
demonstrate hospital-level variation
even after patient case mix
adjustment.918 919 Further, THA/TKA
procedures are specifically intended to
improve function and reduce pain,
making patient reported outcomes a
meaningful outcome metric to assess.920
Several stakeholder groups were
engaged throughout the development
process of the THA/TKA PRO–PM, as
recommended in the Measures
Management System (MMS)
Blueprint,921 including a Technical
Advisory Group (TAG), a Patient
Working Group, and a national, multistakeholder TEP consisting of a diverse
910 Brown K., Topp R., Brosky J.A., Lajoie A.S.
Prehabilitation and quality of life three months after
total knee arthroplasty: A pilot study. Perceptual
and motor skills. 2012;115(3):765–774.
911 Choong P.F., Dowsey M.M., Stoney J.D. Does
accurate anatomical alignment result in better
function and quality of life? Comparing
conventional and computer-assisted total knee
arthroplasty. The Journal of arthroplasty.
2009;24(4):560–569.
912 Galea M.P., Levinger P., Lythgo N., et al. A
targeted home- and center-based exercise program
for people after total hip replacement: A
randomized clinical trial. Arch Phys Med Rehabil.
2008;89(8):1442–1447.
913 Kim K., Anoushiravani A., Chen K., et al.
Perioperative Orthopedic Surgical Home:
Optimizing Total Joint Arthroplasty Candidates and
Preventing Readmission. Journal of Arthroplasty.
2019;34(7):S91–S96.
914 McGregor A.H., Rylands H., Owen A., Dore
C.J., Hughes S.P. Does preoperative hip
rehabilitation advice improve recovery and patient
satisfaction? The Journal of arthroplasty. 2004;19(4):
464–468.
915 Moffet H., Collet J.P., Shapiro S.H., Paradis G.,
Marquis F., Roy L. Effectiveness of intensive
rehabilitation on functional ability and quality of
life after first total knee arthroplasty: A single-blind
randomized controlled trial. Arch Phys Med
Rehabil. 2004;85(4):546–556.
916 Monticone M., Ferrante S., Rocca B., et al.
Home-based functional exercises aimed at
managing kinesiophobia contribute to improving
disability and quality of life of patients undergoing
total knee arthroplasty: A randomized controlled
trial. Arch Phys Med Rehabil. 2013;94(2):231–239.
917 Walters M., Chambers M., Sayeed Z.,
Anoushiravani A., El-Othmani M., Saleh K.
Reducing Length of Stay in Total Joint Arthroplasty
Care. Orthopedic Clinics of North America.
2016;47(4):653–660.
918 Bozic K.J., Grosso L.M., Lin Z., et al. Variation
in hospital-level risk-standardized complication
rates following elective primary total hip and knee
arthroplasty. JBJS. 2014;96(8):640–647.
919 Ma kela K.T., Peltola M., Sund R, Malmivaara
A., Ha kkinen U., Remes V.. Regional and hospital
variance in performance of total hip and knee
replacements: A national population-based study.
Annals of medicine. 2011;43(sup1):S31–S38.
920 Liebs T., Herzberg W., Gluth J., et al. Using the
patient’s perspective to develop function short
forms specific to total hip and knee replacement
based on WOMAC function items. Bone Joint J.
2013;95(B):239–243.
921 Centers for Medicare & Medicaid Services.
(2021). CMS Measures Management System
Blueprint (Blueprint v 17.0). Available at: https://
www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/MMS/MMS-Blueprint.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
set of stakeholders, including providers
and patients. These groups were
convened by the measure developer
under contract with CMS and provided
feedback on the measure concept,
outcome, cohort, risk model variables,
reporting results, and data collection.
We received feedback from patients and
providers that they had a desire for a
flexible data collection approach. For
example, providers wanted the option to
choose to collect their own data or have
data collected through an external
entity, such as a vendor. Patients
wanted to choose from multiple modes
of data collection, such as telephone,
paper, and/or electronic. We also
received feedback from patients and
providers that they would like to utilize
their patient reported outcome results as
part of the shared decision-making
process. Patients were more willing to
report data if they knew the survey was
from their provider, they understood the
importance and use of the survey, and
they had access to their own survey
responses. In response to this feedback,
we did not propose a specific mode for
data collection for the THA/TKA PRO–
PM. Rather, we proposed that hospitals
may determine a data collection mode
that accommodates their clinical
workflow. We also received multiple
public comments as summarized in the
2015 CJR final rule (80 FR 73274) that
we used to support the development of
this measure.
The THA/TKA PRO–PM (MUC20–
0003) was included in the publicly
available ‘‘2020 Measures Under
Consideration List.’’ 922 The MAP
Coordinating Committee supported the
measure, as referenced in the 2020–2021
Final Recommendations report to HHS
and CMS.923 The NQF endorsed the
THA/TKA PRO–PM (NQF #3559) in
November 2020.924
In the FY 2022 IPPS/LTCH PPS
proposed rule (86 FR 25588 through
25592), we requested public comment
on the potential future inclusion of the
THA/TKA PRO–PM in the Hospital IQR
Program. Many commenters expressed
support for the measure, with many
commending joint-specific PRO–PMs as
an effective way to provide insights to
quality improvement opportunities,
PRO–PMs for assessing results of
surgery as interpreted by patients, and
describing the measure as essential for
922 2020 Measures Under Consideration List.
Available at https://www.cms.gov/media/492911.
923 MAP 2020–2021 Considerations for
Implementing Measures Final Report—Clinicians,
Hospitals, and PAC–LTC. NQF. 2021. Available at:
https://www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=94894.
924 NQF Quality Positioning System. Available at
https://www.qualityforum.org/QPS.
PO 00000
Frm 00470
Fmt 4701
Sfmt 4700
value-based payment models (86 FR
45411 through 45414). Many
commenters recommended that the
measure be implemented in a phased
approach, with voluntary reporting
occurring prior to public reporting (86
FR 45411 through 45414). In response to
these comments, we proposed a phased
implementation approach, with two
voluntary reporting periods in CY 2025
and 2026 reporting periods prior to
mandatory reporting beginning with the
CY 2027 reporting period/FY 2028
payment determination, as described in
further detail in our discussion on data
submission in section IX.E.5.g.(9).
Furthermore, many commenters
recommended that we offer multiple
options for data submission, including
through the hospital directly or by an
external vendor engaged by a hospital
for this purpose, to ensure hospitals
have the flexibility needed to
implement the measure (86 FR 45411
through 45414). In response to those
comments, in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28526
through 28529), we proposed flexible
options for data submission as
discussed in more detail in subsequent
section. For a more detailed description
of the public comments received, we
refer readers to the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45411 through
45414).
Additionally, we note that many
hospitals have already incorporated
PRO data collection into their
workflows. While we did not propose to
require how hospitals collect data,
hospitals new to collecting PRO data
have multiple options for when and
how they will collect this data and can
best determine the mode of data
collection that works for their patient
population.
(2) Overview of Measure
The THA/TKA PRO–PM reports the
hospital-level risk-standardized
improvement rate (RSIR) in patient
reported outcomes following elective
primary THA/TKA for Medicare FFS
beneficiaries aged 65 years and older.
Substantial clinical improvement will
be measured by achieving a pre-defined
improvement in score on joint-specific
PRO instruments measuring hip or knee
pain and functioning, from the preoperative assessment (data collected 90
to 0 days before surgery) to the postoperative assessment (data collected 300
to 425 days following surgery). For
additional details regarding the measure
specifications, we refer readers to the
Patient-Reported Outcomes (PROs)
Following Elective Primary Total Hip
and/or Total Knee Arthroplasty:
Hospital-Level Performance Measure—
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Measure Methodology Report, available
at: https://www.cms.gov/Medicare/
Quality-Initiatives-Patient-AssessmentInstruments/HospitalQualityInits/
Measure-Methodology.
khammond on DSKJM1Z7X2PROD with RULES2
(3) Data Sources
The THA/TKA PRO–PM uses four
sources of data for the calculation of the
measure: (1) PRO data; (2) claims data;
(3) Medicare enrollment and beneficiary
data; and (4) U.S. Census Bureau survey
data. The measure uses PRO data
collected by hospitals pre-operatively
and post-operatively (described in
section IX.E.5.g.(9).) and limited patientlevel risk factor data collected with PRO
data and identified in claims. The
measure includes PRO data collected
with several PRO instruments, among
them are two joint-specific PRO
instruments—the Hip dysfunction and
Osteoarthritis Outcome Score for Joint
Replacement (HOOS, JR) 925 for
completion by THA recipients and the
Knee injury and Osteoarthritis Outcome
Score for Joint Replacement (KOOS,
JR) 926 for completion by TKA
recipients—from which scores are used
to assess substantial clinical
improvement. For risk adjustment by
pre-operative mental health score,
hospitals will submit one of two
additional PRO instruments, either all of
the items in the Patient-Reported
Outcomes Measurement Information
System (PROMIS)-Global Mental Health
subscale or all of the items in the
Veterans RAND 12-Item Health Survey
(VR–12) Mental Health subscale.927 928
The risk model also includes a onequestion patient-reported assessment of
health literacy—the Single Item Literacy
Screener questionnaire.
Furthermore, the following data are
collected for identification of the
measure cohort, outcome and for risk
adjustment purposes. Claims data are
used to identify eligible elective primary
THA/TKA procedures for the measure
cohort to which submitted PRO data can
925 Lyman S., Lee Y–Y., Franklin P.D., Li W.,
Mayman D.J., Padgett D.E. Validation of the HOOS,
JR: A Short-form Hip Replacement Survey. Clinical
Orthopaedics and Related Research®.
2016;474(6):1472–1482.
926 Lyman S., Lee Y–Y., Franklin P.D., Li W.,
Cross M.B., Padgett D.E. Validation of the KOOS,
JR: A Short-form Knee Arthroplasty Outcomes
Survey. Clinical Orthopaedics and Related
Research®. 2016;474(6):1461–1471.
927 National Institutes of Health (NIH). (Patient
Reported Outcomes Measurement Information
Systems) PROMIS Instrument Details. Available at:
https://www.healthmeasures.net/exploremeasurement-systems/promis.
928 Iqbal U.S., Rogers W., Selim A., et al. The
Veterans Rand 12 Item Health Survey (VR–12):
What It Is and How It Is Used. https://
www.hosonline.org/globalassets/hos-online/
publications/veterans_rand_12_item_health_
survey_vr-12_2007.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
be matched, and to identify additional
variables for risk adjustment and in the
statistical approach to accounting for
response bias, including patient
demographics and clinical
comorbidities up to 12 months prior to
surgery. The Medicare Enrollment
Database (EDB) identifies Medicare FFS
enrollment and race, and the Master
Beneficiary Summary File allows for
determination of Medicare and
Medicaid dual eligibility enrollment
status. Demographic information from
the U.S. Census Bureau’s American
Community Survey 929 allows for
derivation of the AHRQ SES Index
score. Race, dual eligibility, and AHRQ
SES Index score are used in the
statistical approach to accounting for
non-response bias. We refer readers to
section IX.E.5.g.(9). for further details
regarding the variables required for data
collection and submission.
(4) Outcome
The measure outcome (numerator) is
the risk-standardized proportion of
patients undergoing elective primary
THA/TKA who meet or exceed a
substantial clinical improvement
threshold between pre-operative and
post-operative assessments on two jointspecific PRO instruments. The measure
outcome will assess patient
improvement in PROs using the HOOS,
JR following elective primary THA and
the KOOS, JR following elective primary
TKA. PRO data will be collected 90 to
zero days prior to surgery and 300 to
425 days following surgery. These PRO
collection periods align with typical
patient visits prior to and following
surgery.
The measure outcome defines patient
improvement as a binary outcome
(‘‘Yes’’/‘‘No’’) of meeting or exceeding
the pre-defined improvement threshold
between pre-operative and postoperative assessments on the jointspecific PRO instruments: Specifically,
for THA patients, meeting or exceeding
the threshold of 22 points on the HOOS,
JR and, for TKA patients, meeting or
exceeding the threshold of 20 points on
the KOOS, JR.
(5) Cohort
The measure cohort (denominator) is
Medicare FFS beneficiaries aged 65
years and older undergoing elective
primary THA/TKA procedures as
inpatients in acute care hospitals. We
are aware that elective primary THA/
TKA procedures are increasingly
occurring in hospital outpatient and
ambulatory surgical center settings and
929 American Community Survey, available at:
https://www.census.gov/programs-surveys/acs.
PO 00000
Frm 00471
Fmt 4701
Sfmt 4700
49249
we will be evaluating options to address
measurement of those procedures and
settings.
For additional details regarding the
measure cohort, we refer readers to the
Patient-Reported Outcomes (PROs)
Following Elective Primary Total Hip
and/or Total Knee Arthroplasty:
Hospital-Level Performance Measure—
Measure Methodology Report, available
in Hip and Knee Arthroplasty PatientReported Outcomes folder at: https://
www.cms.gov/Medicare/QualityInitiatives-Patient-AssessmentInstruments/HospitalQualityInits/
Measure-Methodology.
(6) Inclusion and Exclusion Criteria
The THA/TKA PRO–PM includes
patients who are:
• Enrolled in Medicare FFS Part A
and Part B for the 12 months prior to the
date of the index admission and
enrolled in Part A during the index
admission;
• Aged 65 or older; and
• Discharged alive from a non-Federal
short-term acute care hospital.
The measure includes only elective
primary THA/TKA procedures (patients
with fractures and revisions are not
included). The measure excludes
patients with staged procedures, defined
as more than one elective primary THA
or TKA performed on the same patient
during distinct hospitalizations during
the measurement period, and patients
who leave the hospital against medical
advice following the procedure.
(7) Risk Adjustment
The risk model was developed with
clinically relevant risk variables
identified by public comment in the
2015 CJR final rule (80 FR 73274), the
TEP, and expert orthopedic consultants,
and supported by empirical analyses.
The risk model includes some of the
same risk variables collected with PRO
data by hospitals in the CJR model as
well as risk variables identified in
claims. The pre-operative score of the
Mental Health subscale from one of two
global PRO instruments (the PROMISGlobal or the VR–12) is included as a
risk variable. In addition, the risk model
includes a validated, one-question
patient-reported assessment of health
literacy—the Single Item Literacy
Screener questionnaire.
Furthermore, poorly or incompletely
collected PRO data may be
asymmetrically distributed across lower
socioeconomic or disadvantaged
populations, potentially affecting
measure scores. Research on PRO–PM
response has indicated that patients of
non-White race, patients of lower socioeconomic status, and patients with
E:\FR\FM\10AUR2.SGM
10AUR2
49250
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Medicare and Medicaid coverage have
lower response rates.930 931 932 Therefore,
the measure developer used empirical
analyses and stakeholder input to
develop an approach to account for
response bias in the measure
calculation. The approach uses
comorbidities, social drivers of health,
and demographic variables (such as
non-White individuals, dual eligibility,
and AHRQ SES index lowest quartile) to
predict response to the PRO survey.
Weighting the responders based on their
likelihood of response (given their
patient characteristics) helps reduce
non-response bias when calculating the
RSIR.
For additional details regarding the
approach to risk adjustment and the full
risk model, we refer readers to the
Patient-Reported Outcomes (PROs)
Following Elective Primary Total Hip
and/or Total Knee Arthroplasty:
Hospital-Level Performance Measure—
Measure Methodology Report, available
in Hip and Knee Arthroplasty PatientReported Outcomes folder at: https://
www.cms.gov/Medicare/QualityInitiatives-Patient-AssessmentInstruments/HospitalQualityInits/
Measure-Methodology.
khammond on DSKJM1Z7X2PROD with RULES2
(8) Measure Calculation
The hospital-level THA/TKA PRO–
PM measure result is calculated by
aggregating all patient-level results
across the hospital. At the hospital
level, this measure will be calculated
and presented as a RSIR, producing a
performance measure per hospital
which accounts for patient case mix,
addresses potential non-response bias,
and represents a measure of quality of
care following elective primary THA
and TKA. Response rates for PRO data
will be calculated as the percentage of
elective primary THA or TKA
procedures for which complete and
matched pre-operative and postoperative PRO data have been submitted
930 Hutchings A., Neuburger J., Frie K., Black N.,
van der Meulen J. Factors associated with
nonresponse in routine use of patient reported
outcome measures after elective surgery in England.
Health and Quality of Life Outcomes. 2012;10(34).
931 Schamber E., Takemoto S., Chenok K., Bozic
K. Barriers to completion of patient reported
outcome measures. The Journal of arthroplasty.
2013;28:1449–1453.
932 Patel J., Lee J., Zhongmin L., SooHoo N., Bozic
K., Huddleston J. Predictors of low patient-reported
outcomes response rates in the California Joint
Replacement Registry. The Journal of arthroplasty.
2015;30:2071–2075.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
divided by the total number of eligible
THA or TKA procedures performed at
each hospital.
(9) Data Submission
Comments submitted on a request for
information in the FY 2022 IPPS/LTCH
PPS proposed rule and summarized in
the FY 2022 IPPS/LTCH PPS final rule
(86 FR 45411 through 45414)
recommended CMS provide multiple
options for data submission
mechanisms to ensure flexibility,
including through qualified clinical data
registries, as well as through the
hospital.
In response to ongoing stakeholder
feedback and public comments in the
FY 2022 IPPS/LTCH PPS final rule (86
FR 45411 through 45414), we proposed
in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28527) to adopt
the THA/TKA PRO–PM in the Hospital
IQR Program utilizing multiple
submission approaches. For example,
hospitals may choose to: (1) Send their
data to CMS for measure calculation
directly; or (2) utilize an external entity,
such as through a vendor or registry, to
submit data on behalf of the hospital to
CMS for measure calculation.
Furthermore, hospitals or vendors will
use the HQR System as part of data
submission for the THA/TKA PRO–PM.
Use of the HQR System leverages
existing CMS infrastructure already
utilized for other quality measures (such
as the Hospital Consumer Assessment of
Healthcare Providers and Systems
(HCAHPS) Survey). The HQR System
allows for data submission using
multiple file formats (such as CSV,
XML) and a manual data entry option,
allowing hospitals and vendors
additional flexibility in data
submission. We will provide hospitals
with more detailed instructions and
information regarding data submission
through CMS’ existing website
QualityNet, and through list servs. This
data submission approach is consistent
with stakeholder input received by the
measure developer during measure
development and comments as
summarized in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45411 through
45414) which recommended CMS
provide multiple options for data
submission mechanisms to ensure
flexibility.
Hospitals will submit the following
pre-operative assessment variables
PO 00000
Frm 00472
Fmt 4701
Sfmt 4700
collected between 90 and zero days
prior to the THA/TKA procedure:
Medicare provider number, Medicare
health insurance claim (HIC) number/
Medicare beneficiary identifier (MBI),
date of birth, date of procedure, date of
PRO data collection, procedure type,
mode of collection, person completing
the survey, date of admission to anchor
hospitalization, generic patient reported
outcome measure version, PROMISGlobal (mental health subscale items) or
VR–12 (mental health subscale items),
HOOS, JR (for THA patients), KOOS, JR
(for TKA patients), Single-Item Health
Literacy Screening (SILS2)
questionnaire, BMI or weight (kg)/height
(cm), chronic (≥ 90 day) narcotic use,
total painful joint count (patientreported in non-operative lower
extremity joint), and quantified spinal
pain (patient-reported back pain,
Oswestry index question933 934).
Hospitals will submit the following
post-operative assessment variables
collected between 300 and 425 days
following the THA/TKA procedure:
Medicare provider number, Medicare
health insurance claim number/
Medicare beneficiary identifier, date of
birth, procedure date, date of PRO data
collection, procedure type, mode of
collection, person completing the
survey, date of admission to anchor
hospitalization, KOOS, JR (TKA
patients), and HOOS, JR (THA patients).
The data submission period for the
THA/TKA PRO–PM will also serve as
the review and correction period. Data
will not be able to be corrected
following the submission deadline.
For additional details we refer readers
to the Patient-Reported Outcomes
(PROs) Following Elective Primary Total
Hip and/or Total Knee Arthroplasty:
Hospital-Level Performance Measure—
Measure Methodology Report, available
in Hip and Knee Arthroplasty PatientReported Outcomes folder at: https://
www.cms.gov/Medicare/QualityInitiatives-Patient-AssessmentInstruments/HospitalQualityInits/
Measure-Methodology.
(a) Voluntary Reporting Period
933 Fairbank J.C., Pynsent P.B. The Oswestry
Disability Index. Spine (Phila Pa 1976). 2000 Nov
15;25(22):2940–52; discussion 2952. doi: 10.1097/
00007632–200011150–00017. PMID: 11074683.
934 The Oswestry Disability Index is in the public
domain and available for all hospitals to use.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
We proposed a phased
implementation approach for adoption
of this measure to the Hospital IQR
Program, with two voluntary reporting
periods prior to mandatory reporting in
the Hospital IQR Program. Voluntary
reporting prior to mandatory reporting
will allow time for hospitals to
incorporate the THA/TKA PRO–PM
data collection into their clinical
workflows and is responsive to
stakeholder comments as summarized
in the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45411 through 45414). For
each voluntary and subsequent
mandatory reporting period, we will
collect data on the THA/TKA PRO–PM
in accordance with, and to the extent
permitted by, the HIPAA Privacy and
Security Rules (45 CFR parts 160 and
164, subparts A, C, and E), and other
applicable law.
We proposed that the first voluntary
reporting period for CY 2025 would
include pre-operative PRO data
collection from October 3, 2022 through
June 30, 2023 (for eligible elective
primary THA/TKA procedures
performed from January 1, 2023 through
June 30, 2023) and post-operative PRO
data collection from October 28, 2023 to
August 28, 2024. Hospitals will submit
pre-operative data in 2023 and postoperative data in 2024, and we intend
to provide hospitals with their results in
confidential feedback reports in 2025.
We refer readers to section IX.E.10.k.,
where we discuss the form, manner, and
timing for PRO–PMs, including
submission deadlines.
The second voluntary reporting
period for CY 2026 will include preoperative PRO data collection from
April 2, 2023 through June 30, 2024 (for
eligible elective primary THA/TKA
procedures performed from July 1, 2023
through June 30, 2024) and postoperative PRO data collection from
April 26, 2024 to August 29, 2025.
Hospitals will submit pre-operative data
49251
in 2024 and post-operative data in 2025,
and we intend to provide hospitals with
their results in confidential feedback
reports in 2026. We refer readers to
section IX.E.10.k., where we discuss the
form, manner, and timing for PRO–PMs,
including submission deadlines.
Hospitals that voluntarily submit data
for this measure will receive
confidential feedback reports that detail
submission results from the reporting
period. If feasible, we will calculate and
provide each participating hospital with
their risk-standardized improvement
rate as part of the confidential feedback
reports. This will provide each hospital
with an indication of their performance
relative to the other hospitals that
participate in the voluntary reporting
period. We refer readers to Table IX.E–
07. for an overview of the pre- and postoperative performance periods, data
collection windows, and data
submission deadlines during voluntary
reporting.
TABLE IX.E-07. PRE-OPERATIVE AND POST-OPERATIVE PERIODS FOR
THA/TKA PRO-PM FOR VOLUNTARY REPORTING
Performance Period Pre-operative Data
Collection Window
Reporting
Period
Voluntary
Reporting 1
(2025)
Voluntary
Reporting2
(2026)
Pre-operative Data Post-operative
Post-operative Data
Submission Deadline Data Collection
Submission Deadline
Window
January l, 2023
October 3, 2022 through October 2, 2023
October 28, 2023 to September 30, 2024
throughJune30,2023 June 30, 2023
August 28, 2024
April 2, 2023 through
July 1, 2023
throughJune30,2024 June 30, 2024
(b) Mandatory Reporting
Following the two voluntary reporting
periods, we proposed that mandatory
reporting of the THA/TKA PRO–PM
would begin with eligible elective
primary THA/TKA procedures from July
1, 2024 through June 30, 2025 with
affecting the FY 2028 payment
determination. Hospitals’ data reporting
requirements will be based on preoperative PRO data collection from
April 2, 2024 through June 30, 2025 (for
September 30, 2024
April 26, 2024 to
August 29, 2025
eligible elective THA/TKA procedures
from July 1, 2024 through June 30, 2025)
and post-operative PRO data collection
from April 27, 2025 to August 29, 2026.
Pre-operative data submission will
occur in 2025 and post-data submission
in 2026 and we intend to provide
hospitals with their results in 2027
before publicly reporting results on the
Compare tool hosted by HHS, currently
available at: https://www.medicare.gov/
care-compare, or its successor website.
For this first mandatory reporting
September 30, 2025
period, hospitals that fail to timely meet
the reporting requirements will receive
a reduction of their Annual Payment
Update (APU) in FY 2028. We refer
readers to the section IX.E.10.k., where
we discuss the form, manner, and
timing for PRO–PMs, including
submission deadlines. We refer readers
to Table IX.E–08. for an overview of the
pre- and post-operative performance
periods, data collection windows, and
data submission deadlines during
mandatory reporting.
Performance Period Pre-operative data
Collection Window
Pre-operative Data
Submission Deadline
Mandatory
Reporting
(2027)
July 1, 2024
April 2, 2024 through
through June 30, 2025 June 30, 2025
September 30, 2025
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00473
Fmt 4701
Sfmt 4725
Post-operative
Data Collection
Window
April 27, 2025 to
August 29, 2026
E:\FR\FM\10AUR2.SGM
10AUR2
Post-operative Data
Submission Deadline
September 30, 2026
ER10AU22.164
Reporting
Period
ER10AU22.163
khammond on DSKJM1Z7X2PROD with RULES2
TABLE IX.E-08. PRE-OPERATIVE AND POST-OPERATIVE PERIODS FOR
THA/TKA PRO-PM FOR MANDATORY REPORTING
49252
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(10) Public Reporting
khammond on DSKJM1Z7X2PROD with RULES2
(a) Voluntary Reporting Periods
We proposed to provide hospitals
with their THA/TKA PRO–PM results in
confidential feedback reports during the
two voluntary reporting periods
occurring in 2025 and 2026. While we
did not propose to publicly report
voluntary THA/TKA PRO–PM hospitallevel risk-standardized improvement
rates (RSIR) during this period, to
acknowledge the efforts of stakeholders
who choose to participate in voluntary
reporting, and to support their efforts to
improve quality in this important area,
we proposed to publicly report which
hospitals choose to participate in
voluntary reporting and/or the percent
of pre-operative data submitted by
participating hospitals for the first
voluntary reporting period, and their
percent of pre-operative and postoperative matched PRO data submitted
for subsequent voluntary reporting
periods. For example, if out of 100
eligible procedures a hospital submits
45 pre-operative cases that match to
post-operative cases, then we will report
that hospital submitted 45 percent of
matched pre-operative and postoperative PRO surveys during voluntary
reporting
(b) Mandatory Reporting
The THA/TKA PRO–PM results and
response rates will be publicly reported
on the Compare tool hosted by HHS,
currently available at: https://
www.medicare.gov/care-compare, or its
successor website, beginning with the
first mandatory reporting period for the
FY 2028 payment determination.
Reporting will be based on pre-operative
PRO data April 2, 2024 through June 30,
2025 (for eligible elective THA/TKA
procedures from July 1, 2024 through
June 30, 2025) and post-operative PRO
data collection from April 27, 2025 to
August 29, 2026. Hospitals will receive
confidential feedback reports prior to
public reporting that detail results from
the reporting period. If feasible,
confidential feedback reports will
include the risk-standardized
improvement rate as well as other
results that support understanding of
their performance.
We invited public comment on this
proposal.
Comment: Many commenters
expressed support for the adoption of
the THA/TKA PRO–PM in the Hospital
IQR Program. A commenter strongly
supported the adoption of the measure
as it provides patients with valuable
information on the quality of joint care
provided by hospitals, as well as
information on post-operative
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
functional improvements. Another
commenter strongly supported the
adoption of the measure as it assesses
the success of procedures based on
outcomes that are important to patients
while also supplying clinical teams with
information essential to a patient’s
recovery. The commenter noted this
information is useful to other patients
seeking care and should be publicly
posted. A commenter stated patientreported outcomes for elective primary
THA and TKA procedures are critical to
ensure the procedure quality is
accurately captured. Another
commenter supported the measure’s
adoption as it incentivizes collaboration
in patient care between hospitals and
providers, both pre- and postoperatively, which improves patient
outcomes. Many commenters expressed
support for the collection of PRO data
for hospital quality improvement efforts,
and use of PRO–PMs in CMS programs,
generally. A commenter stated that THA
and TKA procedures offer the majority
of patients significant improvement in
quality of life by decreasing pain and
improving function without high risk of
complication or death and, therefore,
supported collection of PRO data for
total joint replacements. A commenter
supported adoption of the measure for
Critical Access Hospitals that provide
THA and TKA services. A commenter
supported the adoption of the measure
and requested more information on the
mechanism for data collection for
providers and patients.
Response: We thank commenters for
their support and agree with the
importance of measuring patientreported outcomes for elective primary
THA and TKA procedures, particularly
to measure functional improvement
following the applicable surgical
procedure. We will conduct education
and outreach activities for hospitals and
other stakeholders with detailed
information, including data collection
and reporting processes for the THA/
TKA PRO–PM to support preparation
for the voluntary reporting periods in
the Hospital IQR Program.
Comment: Many commenters did not
support the proposed adoption of the
THA/TKA PRO–PM to the Hospital IQR
Program because of the volume of newly
proposed quality measures and EHRrelated reporting requirements proposed
by CMS for the Hospital IQR Program.
Many commenters expressed concern
that the adoption of the THA/TKA
PRO–PM to the Hospital IQR Program
would be burdensome to hospitals.
Many commenters stated that the
financial, resource, and labor costs
required to collect, track, and submit
data would burden hospitals and make
PO 00000
Frm 00474
Fmt 4701
Sfmt 4700
successful implementation of the
measure difficult, even if hospitals opt
to use a third-party vendor for data
collection and submission. A
commenter expressed concern about the
burden specifically for small and rural
hospitals. A few commenters noted that
data are not collected in a standardized
way and EHRs are not integrated with
patient portals that would allow
hospitals to collect patient-reported
information, adding manual burden to
extrapolate data or infrastructure
investments. A commenter noted their
belief that the measure is counter to
CMS’s efforts to reduce administrative
burden for hospitals and detracts from
their primary mission of direct patient
care. A few commenters urged CMS to
work with stakeholders to develop a less
burdensome measure or reassess the
burden compared to the value of this
measure following voluntary reporting.
A few commenters expressed
concerns regarding the burden of
tracking patients pre- and postoperatively to collect PRO data, stating
that data are not centrally housed,
patients receive post-operative care
outside the hospital, and the tracking of
patients for the duration of the postoperative data collection timeframe of
300 to 425 days would be expensive and
burdensome. Additionally, a few
commenters stated that reaching out to
patients to collect surveys in multiple
modes would be expensive; however,
other commenters encouraged having
multiple modes of survey collection.
Response: We acknowledge
commenters’ concerns with the volume
of measures and reporting requirements
proposed for the Hospital IQR Program.
We will continue to evaluate the
Hospital IQR Program measure set and
take this feedback into consideration.
However, we believe that measuring
patient-reported outcomes is an
important aspect of patient-centered
healthcare and continue to emphasize,
as highlighted in our Meaningful
Measures 2.0 Framework,935 that the
patient voice should be prioritized
across healthcare systems and
providers. Our aim is to promote better
collection and integration of patients’
voices by incorporating PROMs that are
embedded into clinical workflow, easy
to use, and as minimally burdensome to
patients and providers as possible.
We thank commenters for their
feedback regarding the financial, labor,
and resource burdens associated with
adopting the THA/TKA PRO–PM to the
Hospital IQR Program. We acknowledge
935 https://www.cms.gov/medicare/meaningfulmeasures-framework/meaningful-measures-20moving-measure-reduction-modernization.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
that while PROMs and PRO–PMs may
involve more burden and initial
implementation resources compared to
some other types of quality measures,
we believe the benefit of collecting
direct functional improvement
information from the patients outweighs
the burden. We are carefully
considering public comments and are
seeking to advance patient-centered
measurement with as little burden as
possible to both providers and patients.
While PRO–PMs require providers to
integrate data collection into clinical
workflows, this integration provides an
important opportunity for patientreported outcomes to inform clinical
decision making and benefit patients by
engaging them in discussions about
potential outcomes. To provide more
flexibility, we are not requiring
hospitals to collect data in a
standardized way. In fact, we
acknowledge hospitals may use a
variety of data collection, storage, and
submission approaches, and we
encourage hospitals to use processes
best suited to them. Instead, we are
standardizing the specific data elements
that need to be collected and reported
to CMS. Further, we believe that
clinicians, providers, and hospitals
should determine practices that avoid
duplication across care settings. We will
continue to monitor data collection
burden and duplication during the
voluntary reporting period.
The PRO instruments used to
calculate pre- and post-operative scores
for this THA/TKA PRO–PM were
carefully considered, with extensive
stakeholder input, including from
clinicians, to be low burden and are
non-proprietary for free use. We will
evaluate data collection burden and
response rates associated with the THA/
TKA PRO–PM and will also consider
this information in future measure
reevaluation.
Comment: A few commenters
expressed concern about the data
collection burden for patients, with a
commenter specifically citing survey
fatigue as patients are already
responding to the HCAHPS survey
measure. Another commenter expressed
concern that completion of surveys for
the measure beyond only the HOOS, JR
and KOOS, JR would burden patients
resulting in lower completion rates.
Response: This measure was
developed with extensive input from
patients, who indicated strong support
for a PRO–PM following elective
primary THA and TKA. We anticipate
data collection for this measure to
present a low burden to patients.
Regarding survey fatigue, we designed
the measure to illuminate a patient’s
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
pain and functional status before and
after a THA or TKA, which is different
than other surveys such as HCAHPS
that capture patient experience.
Regarding the comment that the THA/
TKA PRO–PM may have a reporting
impact on other measures, such as
HCAHPS, we anticipate a minimal
impact to other measures as the THA/
TKA PRO–PM’s eligible population is
procedure-specific which reduces the
likelihood of the same patient receiving
the HCAHPS and a PRO survey.
Additionally, the THA/TKA PRO–PM
pre-operative assessment (90 to 0 days
before surgery) and post-operative
assessment (300 to 425 days following
surgery) timeframe is different than
HCAHPS, which is two weeks after a
hospital visit.
Comment: Another commenter
requested CMS assess survey
completion rates during voluntary
reporting of the measure as part of the
Hospital IQR Program compared to the
CJR Model. A few commenters
requested CMS not adopt the THA/TKA
PRO–PM in the Hospital IQR Program
until operational challenges identified
by CJR participating hospitals are shared
publicly, independently analyzed, and
addressed. Commenters expressed
concern that reporting of the THA/TKA
PRO–PM as part of the CJR Model has
been challenging and burdensome,
potentially impacting completion rates.
Response: We appreciate commenters’
request for information about use of the
measure in the CJR Model. We have
collected feedback from CJR
participating hospitals and applied
lessons learned to the THA/TKA PRO–
PM proposal for adoption into the
Hospital IQR Program. These lessons
learned include requiring hospitals to
collect and submit fewer variables,
allowing hospitals flexibility in data
collection options to better integrate
into their workflows, and influenced the
decision to set the reporting threshold to
a moderate rate of 50 percent. We
highlight that our proposal includes two
voluntary reporting periods in which we
will gather feedback from participating
hospitals on their experience collecting
and submitting data and apply any
lessons learned prior to mandatory
reporting.
We thank commenters for their
feedback. We will continue to evaluate
feedback on challenges with data
collection during voluntary reporting
and consider them prior to mandatory
reporting.
Comment: A few commenters
suggested ways to reduce data collection
and submission burden for hospitals
and providers. A commenter suggested
CMS align THA/TKA PRO–PM data
PO 00000
Frm 00475
Fmt 4701
Sfmt 4700
49253
collection with The Joint Commission
Advanced Hip and Knee certification
requirements. Another commenter
suggested data collection should occur
through registries, specifically the
American Academy of Orthopedic
Surgeons American Joint Replacement
registry. A few commenters
recommended CMS only use claims
data or develop a new measure using
Medicare claims to assess total joint
arthroplasty revisions and mortality
rates. A commenter recommended CMS
directly collect post-operative surveys
because CMS has access to current
beneficiary information, could collect
surveys for different surgeries across
care settings, and reduce burden on
providers.
Response: We thank commenters for
their recommendations to reduce
burden of data collection and
submission associated with adoption of
the THA/TKA PRO–PM to the Hospital
IQR Program. We confirm that the
measure as proposed notes registries as
an acceptable form of data collection for
the measure (87 FR 28527 through
28528). We agree with use of registries
to reduce data collection burden for
hospitals. Regarding alignment of the
THA/TKA PRO–PM with The Joint
Commission Advanced Hip and Knee
certification requirements, we note that
alignment exists in the PRO
instruments, specifically the HOOS, JR
and KOOS, JR (collected for the measure
outcome for the THA/TKA PRO–PM) as
well as the PROMIS–10 or VR–12
(collected for the risk model of the
THA/TKA PRO–PM).936 We will
continue to monitor potential areas for
alignment, as appropriate. We will also
consider commenter suggestions about
CMS’s role in post-operative data
collection, and the development of
claims-based joint arthroplasty
measures.
Comment: Many commenters
expressed concerns with the 300
through 425 days post-operative data
collection window related to
appropriateness, feasibility, and burden
to hospitals and other care settings,
though a commenter supported
assessment of longer-term outcomes
generally. A few commenters stated that
the proposed post-operative data
collection window is not aligned with
clinical practice where patients receive
follow up care from their surgeons
ranging between three to eight weeks
post-operatively. A few commenters
936 The Joint Commission. R3 Report Issue 26:
Advanced Total Hip and Total Knee Replacement
Certification Standards; 2020. https://
www.jointcommission.org/-/media/tjc/documents/
standards/r3-reports/thkr-standards-r3-final-copy1_17_20.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49254
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
added that most improvement is
demonstrated before the 300 through
425 post-operative data collection
windows: for example, within 80 or 90
days. A commenter stated the proposed
post-operative data collection window
will introduce unnecessary health care
encounters which add risk to patients.
A few commenters noted challenges
with tracking patients during the postoperative data collection window,
stating beneficiaries do not always
return for follow up care or may
relocate. A commenter was concerned
the post-operative data collection
window was too far removed from the
surgery and patient survey responses
could be inaccurate. Several
commenters recommended CMS shorten
the post-operative data collection
window. Commenters offered the
following suggestions: 3 months, 3
through 6 months, and 8 through 12
months.
Response: We appreciate commenters’
concerns with the 300 through 425-day
post-operative data collection window;
however, we disagree that the proposed
post-operative window should be
changed at this time. In development of
the THA/TKA PRO–PM, the measure
developer conducted extensive
stakeholder engagement, a thorough
literature review, and reviewed registry
data capture to inform the postoperative assessment window (initially
270 to 365 days) for capture of full
recovery from both THA and TKA and
alignment with the typically scheduled
one-year post-surgery appointments so
that the collection of the post-operative
data collection would not require an
additional appointment. Following
several years of PRO data collection
through the CJR Model, clinical experts
expressed concern that the initial 365day upper limit missed patients who
were scheduled or rescheduled for this
one-year follow-up beyond 365 days,
and they strongly advocated for shifting
the post-operative data collection
window to better align with clinical
practice and increase PRO data
collection. For additional details we
refer readers to the Patient-Reported
Outcomes (PROs) Following Elective
Primary Total Hip and/or Total Knee
Arthroplasty: Hospital-Level
Performance Measure—Measure
Methodology Report, available in Hip
and Knee Arthroplasty Patient-Reported
Outcomes folder at: https://
www.cms.gov/Medicare/QualityInitiatives-Patient-AssessmentInstruments/HospitalQualityInits/
Measure-Methodology.
Comment: Many commenters
provided feedback on the proposed
voluntary and mandatory reporting
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
timelines for the THA/TKA PRO–PM
adoption into the Hospital IQR Program
but expressed a mix of support and
recommended changes. A few
commenters supported the proposed
voluntary and mandatory reporting
timelines, noting they give hospitals an
opportunity to incorporate data
collection into clinical workflows.
However, a few commenters supported
only the voluntary reporting timeline
without mandatory reporting. A few
commenters requested CMS extend the
voluntary reporting timeline and delay
mandatory reporting to support
hospitals learning and their
incorporation of data collection into
clinical workflows; to allow CMS to
assess the success, value, and burden of
the measure; and to allow time for data
collection challenges to be reduced. A
commenter suggested four years of
voluntary reporting. Another
commenter recommended CMS use
multiple six- month reporting periods
before requiring a full year of reporting
data.
Response: We thank commenters for
their support of the phased approach of
adopting the THA/TKA PRO–PM in the
Hospital IQR Program. We have
considered commenters’
recommendations regarding voluntary
and mandatory reporting timelines. We
believe the proposed voluntary and
mandatory reporting implementation
approach will allow hospitals sufficient
time to make the necessary
enhancements to their clinical workflow
to successfully report this measure. We
highlight that our proposal includes two
voluntary reporting periods prior to
mandatory reporting which balances the
need to allow hospitals time to prepare
for mandatory reporting with the need
to make this information public for
patient use. We will carefully consider
feedback received during voluntary
reporting to inform improvements that
may be made for mandatory reporting.
We also refer readers to section
IX.E.10.k. of this final rule where we
discuss in more detail the form, manner,
and timing of reporting the THA/TKA
PRO–PM.
Comment: A few commenters did not
support the adoption of the THA/TKA
PRO–PM into the Hospital IQR Program
as proposed. A commenter expressed
that physician performance cannot be
differentiated using patient-reported
outcomes, noting many factors that
influence an outcome are beyond an
individual physician’s influence, such
as those related to patient factors and
quality of care received overall.
Response: We acknowledge
commenters’ concerns regarding the
adoption of the THA/TKA PRO–PM and
PO 00000
Frm 00476
Fmt 4701
Sfmt 4700
patient-reported outcomes generally.
However, we believe that PRO–PMs are
an important aspect of patient-centered
healthcare and continue to emphasize
our position in our Meaningful
Measures 2.0 Framework 937 that the
patient voice is prioritized across
healthcare systems and providers. Our
aim is to promote better collection and
integration of patients’ voices by
incorporating PRO–PMs that are
embedded into clinical workflow, easy
to use, and reduce reporting burden. We
agree with the commenter that many
factors influence a patient’s outcome
after a THA or TKA procedure, many of
which are related to the overall quality
of care the patient received at the
hospital. As such, we are beginning to
measure patient reported outcomes for
these procedures at the hospital level
but believe future measurement in other
care settings, such as for HOPDs, ASCs,
or at the clinician level, is important to
understanding quality of care across
settings.
Comment: Many commenters
discussed the appropriateness of CMS’
use of the THA/TKA PRO–PM in the
hospital setting. A few commenters
recommended CMS expand use of the
measure across other care settings where
THA/TKA procedures are performed.
Many commenters noted the transition
of THA/TKA procedures from the
inpatient hospital setting to the
outpatient setting and encouraged use of
the measure in the Hospital Outpatient
Quality Reporting (OQR) Program or the
Ambulatory Surgical Center Quality
Reporting (ASCQR) Program, and at the
clinician level, with a few commenters
recommending CMS monitor shifts in
volume of procedures between settings
during the voluntary reporting period. A
few commenters expressed concern that,
given the shift of procedures to the
outpatient setting, only the sickest and
most complex patients would undergo
THA/TKA procedures in the hospital,
and this could skew hospital results on
the measure. A few commenters
suggested that CMS consider risk
adjusting to account for trends in greater
acuity of inpatient patients undergoing
THA/TKA procedures. A few
commenters had concerns attributing
outcomes to hospitals because surgeons’
offices or other settings commonly
administer PRO surveys. Another
commenter requested CMS consider its
future public reporting approach to
ensure inappropriate comparisons
cannot be made between hospital and
outpatient THA/TKA PRO–PM results.
937 https://www.cms.gov/medicare/meaningfulmeasures-framework/meaningful-measures-20moving-measure-reduction-modernization.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
A commenter suggested CMS consider
efficiencies gained by linking hospital
data with MIPS data for providers.
Response: We thank commenters for
their support for expanding this
measure to other programs and settings.
We agree that monitoring trends and
transition of THA/TKA procedures to
outpatient settings is also important. We
appreciate commenter insights on the
differences in patient complexity across
care settings and will continue to
monitor this during reevaluation of the
measure’s risk adjustment model. We
disagree that the measure is not
appropriate for the inpatient hospital
setting at this time. We note that the
proposed THA/TKA PRO–PM measure
is case mix adjusted for patient
comorbidities and is a relative
performance measure for hospitals
performing these elective THA and TKA
procedures (87 FR 28527).938 As such,
we believe that this measure accurately
reflects hospital performance even if
patients receiving these procedures in
the inpatient setting tend to be sicker,
on average, than those treated in an
outpatient setting.
Given the relatively recent removal of
TKA and THA from the Inpatient Only
(IPO) list (82 FR 52521 through 52526)
(84 FR 61352 through 61355), we expect
that the volume of THA and TKA
procedures will continue to increase in
HOPDs and ASCs, and that significant
numbers of Medicare beneficiaries 65
and older will potentially undergo these
procedures in the outpatient setting in
future years. We recognize that potential
future adoption and implementation of
a respecified version of the THA/TKA
PRO–PM in the Hospital OQR Program
would require sufficient numbers of
procedures for each measured HOPD
and ASC to ensure a reliable measure
score. We proposed the measure in the
inpatient setting at this time and will
consider potential expansion to other
outpatient settings. We refer readers to
the CY 2022 OPPS final rule for a
summary of comments on the request
for comment on the potential future
adoption of the measure into the
Hospital OQR and ASCQR Programs (86
FR 63851 through 63854 and 63896
through 63898). We also agree that there
is value in measurement at the clinician
level, however, the hospital level
measure helps capture the quality of
care provided during a patient’s stay
and provides the opportunity for more
entities to have sufficient case volume
to be included in the measure. A
938 Patient-Reported
Outcomes (PROs) Following
Elective Primary Total Hip and/or Total Knee
Arthroplasty: Hospital-Level Performance Measure
(Version 1.0 Methodology Report). March 2021.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
respecified version of the measure at the
clinician level, the Clinician-Level and
Clinician Group-Level Total Hip and/or
Total Knee Arthroplasty PatientReported Outcome-Based Performance
Measure, was included on the 2021
Measures Under Consideration List. For
additional details we refer readers to the
List of Measures Under Consideration
for December 1, 2021 at: https://
www.cms.gov/files/document/measuresunder-consideration-list-2021report.pdf. Any proposal to implement
the measure in other CMS programs
would be announced through future
rulemaking.
Comment: A few commenters
provided recommendations on
reimbursement and incentives for
adopting the THA/TKA PRO–PM in the
Hospital IQR Program. A commenter
stated CMS should not use the measure
in determining hospital reimbursement
due to limits in risk stratification.
Another commenter stated it is too early
to compare hospital scores to determine
reimbursement as PRO scores are not
fully understood at the patient level.
Another commenter urged CMS not to
impose penalties if the measure is
adopted. A few commenters
recommended CMS provide incentives
for hospitals to report the measure.
Another commenter stated rural
hospitals that are burdened by the
measure would benefit from incentives
similar to the facility bonus used in the
Quality Payment Program (QPP). A few
commenters encouraged CMS to
consider reimbursing hospitals for data
collection, such as using a CPT code
with a bonus, similar to QPP. Another
commenter recommended a quality
bonus payment similar to the CJR Model
or Bundled Payments for Care
Improvement Initiative.
Response: We thank commenters for
their recommendations about
reimbursement and incentives for
reporting the THA/TKA PRO–PM. We
are not able to provide incentive
payments under the Hospital IQR
Program. We note that the Hospital IQR
Program is a pay-for-reporting program,
and hospitals’ payments are not based
on their performance on measures;
hospitals will receive credit for the
reporting of their measure data
regardless of their measure score.
Comment: A few commenters
provided recommendations regarding
the measure specifications. A
commenter supported the risk
adjustment approach for the measure.
However, another commenter
recommended CMS include social
determinants of health, body mass
index, and smoking as risk variables and
a third commenter requested CMS also
PO 00000
Frm 00477
Fmt 4701
Sfmt 4700
49255
consider variables that are outside of
providers’ influence that impact
outcomes, such as patient adherence to
surgical instructions or comorbidities. A
few commenters recommended
separating THA and TKA into their own
procedure specific measures, stating
that THA procedures have a higher
success rate for improvement while the
same level of improvement is not
reached for TKA procedures. A few
commenters suggested CMS calculate
the change in PRO survey scores for
individual patients pre- and postoperatively rather than the measure
calculation approach as currently
proposed. A commenter requested CMS
exclude patients with history of
prosthetic knee joint infections for
reimplantation of knee arthroplasty and
arthroplasties where the medical record
includes a diagnosis of nonunion where
the surgery is performed on a joint
previously fractured that failed to heal.
The commenter expressed concern that
these surgeries are highly complex and
dissimilar to other procedures captured
in the THA/TKA PRO–PM’s cohort as
proposed.
Response: We thank commenters for
their input on the THA/TKA PRO–PM’s
specifications for the cohort, risk
adjustment, and measure calculation.
We note that the measure is risk
adjusted for several risk variables
including but not limited to health
literacy, body mass index, and several
comorbidities (87 FR 28527). The
threshold improvement approach to
measure score calculation was strongly
supported by clinical experts and
patients during measure development
and preferred to averaging patient
change scores. We note that the National
Quality Forum endorsed the THA/TKA
PRO–PM as proposed.939 For additional
details we refer readers to the PatientReported Outcomes (PROs) Following
Elective Primary Total Hip and/or Total
Knee Arthroplasty: Hospital-Level
Performance Measure—Measure
Methodology Report, available in Hip
and Knee Arthroplasty PatientReported Outcomes folder at https://
www.cms.gov/Medicare/QualityInitiatives-Patient-AssessmentInstruments/HospitalQualityInits/
Measure-Methodology. We will review
these recommendations and consider
any adjustments to the measure as
appropriate as part of normal ongoing
measure reevaluation.
Comment: A few commenters
provided input on the PRO instruments
939 National Quality Forum. Patient Experience
and Function Final Report—Spring 2020 Cycle;
2021. Available at: https://www.qualityforum.org/
Publications/2021/03/Patient_Experience_and_
Function_Final_Report_-_Spring_2020_Cycle.aspx.
E:\FR\FM\10AUR2.SGM
10AUR2
49256
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
selected for the THA/TKA PRO–PM. A
commenter requested CMS clarify
rationale for collecting quantified spinal
pain in the Oswestry Disability index.
Another commenter opposed limiting
the THA/TKA PRO–PM to just HOOS,
JR and KOOS, JR instruments and
suggested CMS allow communities to
decide which validated PRO instrument
to use for their patient population. The
commenter noted the HOOS, JR and
KOOS, JR lack cross cultural validation
and suggested use of HOOS and KOOS
full forms, Joint Replacement
Shortforms, Physical Function
Shortform, or PROMIS Physical
Function.
Response: We thank commenters for
their feedback on the selected PRO
instruments. Use of the HOOS, JR and
KOOS, JR instruments to calculate preand post-operative scores for this THA/
TKA PRO–PM were carefully
considered, with extensive stakeholder
input from clinicians, and found to be
low burden. The clinicians also
believed, and data demonstrated, that
joint-specific functional status tools
such as the HOOS, JR and KOOS, JR are
more relevant for clinical decision
making and are more responsive than
other PROMs that are not as specific.
We believe the use of different PRO
instruments by different facilities would
prevent a valid comparison of hospital
performance and quality. In response to
the commenter’s objection to collection
of Quantified Spinal Pain as part of the
Oswestry Disability index,940 941 we note
that variable was identified as a clinical
risk variable supported by the Technical
Expert Panel and orthopedic experts as
relevant and important for risk
adjustment of outcomes following
elective primary THA and TKA
procedures. We note that the National
Quality Forum endorsed the THA/TKA
PRO–PM as proposed.942 For additional
details we refer readers to the PatientReported Outcomes (PROs) Following
Elective Primary Total Hip and/or Total
Knee Arthroplasty: Hospital-Level
Performance Measure—Measure
Methodology Report, available in Hip
and Knee Arthroplasty Patient-Reported
Outcomes folder at: https://
www.cms.gov/Medicare/QualityInitiatives-Patient-Assessment940 Fairbank JC, Pynsent PB. The Oswestry
Disability Index. Spine (Phila Pa 1976). 2000 Nov
15;25(22):2940–52; discussion 2952. doi: 10.1097/
00007632–200011150–00017. PMID: 11074683.
941 The Oswestry Disability Index is in the public
domain and available for all hospitals to use.
942 National Quality Forum. Patient Experience
and Function Final Report—Spring 2020 Cycle;
2021. https://www.qualityforum.org/Publications/
2021/03/Patient_Experience_and_Function_Final_
Report_-_Spring_2020_Cycle.aspx.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Instruments/HospitalQualityInits/
Measure-Methodology.
Comment: A few commenters
discussed concerns with the THA/TKA
PRO–PM’s impact on health disparities
and response bias. A few commenters
stated that surveys may only provide a
limited sample of patient data,
introducing bias and masking lower
completion rates among marginalized
groups. Surveys administered through
technologies such as Epic, text, or thirdparty vendors could worsen racial
disparities, introduce barriers, and limit
a hospital’s ability to collect a
representative sample of patients from
all races, socioeconomic statuses, and
languages. A commenter questioned
whether the THA/TKA PRO–PM as
proposed adjusts for non-response bias
for patients with limited English
language proficiency, as such patients
would be challenged to complete
surveys, and hospitals with a high
proportion of patients with limited
English proficiency may have a lower
response rate. A commenter suggested
CMS provide reimbursement to
hospitals to overcome these challenges
in data collection. Another commenter
encouraged stratification and reporting
of results to hospitals for
underrepresented populations.
Response: We thank commenters for
their input regarding health disparities
and response bias. We agree with
commenters that considering the unique
experience of populations with social
risk factors is important. As proposed,
the measure accounts for potential nonresponse bias (inverse probability
weighting) and considers patient
characteristics, including non-White
race, dual eligibility, and the AHRQ SES
index score (87 FR 28527). The AHRQ
SES index score is computed using US
census data and considers factors
including zip code, median household
income, percentage of persons below the
Federal poverty line, unemployment,
education, property value, and
percentage of persons in crowded
households.943 Although preferred
language spoken is not a variable
currently included in the non-response
bias approach, the measure as proposed
includes health literacy in the risk
model. For additional details we refer
readers to the Patient-Reported
Outcomes (PROs) Following Elective
Primary Total Hip and/or Total Knee
Arthroplasty: Hospital-Level
Performance Measure—Measure
Methodology Report, available in Hip
943 Bonito A, Bann C, Eicheldinger C, Carpenter
L. Creation of new race-ethnicity codes and
socioeconomic status (SES) indicators for Medicare
beneficiaries. Final Report, Sub-Task. 2008;2.
PO 00000
Frm 00478
Fmt 4701
Sfmt 4700
and Knee Arthroplasty Patient-Reported
Outcomes folder at: https://
www.cms.gov/Medicare/QualityInitiatives-Patient-AssessmentInstruments/HospitalQualityInits/
Measure-Methodology. We appreciate
the comments regarding the importance
of considering disadvantaged
populations within the measure
specifications and implementation, and
we will continue to assess any impact
of social risk factors on the measure and
response rates over time.
Regarding non-response bias and the
measure results, we encourage hospitals
to consider a variety of PRO data
collection methods to support responses
from all eligible patients. We also
recognize that addressing health
disparities and response bias are
complex issues. We are firmly
committed to addressing health
disparities and response bias for patient
reported outcomes. We believe
finalizing the Hospital Commitment to
Health Equity structural measure and
the two Social Drivers of Health
screening measures, discussed in
sections IX.E.5.a. and IX.E.5.b. of this
final rule, respectively, supports
addressing these issues and incentivizes
structural quality improvement. We
believe it will take a complementary set
of quality measures focused on health
equity to see significant improvements.
Comment: A few commenters
expressed concern about reporting
thresholds as well as the pre- and postoperative survey matching
requirements. A commenter suggested
CMS lower the reporting threshold for
the measure and study response rates
before finalizing a threshold. Another
commenter urged CMS to use the
voluntary reporting periods to set
realistic matching percentages between
pre- and post-operative surveys. A
commenter noted the transition from
performing THA and TKA procedures
from hospitals to outpatient settings
may affect hospital’s ability to meet
reporting thresholds. A commenter
noted that the CJR Model uses an 80%
reporting threshold which is
challenging for hospitals to meet. The
commenter encouraged CMS to analyze
response rates from CJR participating
hospitals and identify ways to increase
pre- and post-operative survey
responses. Another commenter
questioned if hospitals will be penalized
for not meeting reporting thresholds due
to low response rates.
Response: We selected the 50 percent
reporting threshold after considering
numerous factors and the experience of
CJR Model participants. The proposed
reporting threshold is based on average
response rates for both pre-operative
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
and post-operative surveys collected by
participating hospitals in the CJR
Model. The proposed reporting
threshold for adoption of the measure
into the Hospital IQR Program is lower
than that currently used in the CJR
Model (50 percent versus 80 percent).
Additionally, hospitals are not held to
reporting thresholds until mandatory
reporting; therefore, we believe
hospitals will have time to develop their
data collection and reporting processes.
Lastly, the proposed thresholds for the
Hospital IQR Program are percentages
based on the number of eligible
inpatient procedures performed by a
hospital; therefore, we do not expect
any potential future transition of
procedures to outpatient settings to
impact a hospital’s ability to meet
reporting thresholds (87 FR 28559
through 28560).
We will continue to consider the
appropriate pre- and post-operative
matched survey response rate, as well as
reporting thresholds. We will evaluate
our proposed approach during
voluntary reporting and consider
adjustments based on feedback prior to
mandatory reporting.
Comment: A few commenters
requested CMS adjust the threshold of
functional improvement of 20 and 22
points for KOOS, JR and HOOS, JR,
respectively. A commenter requested
CMS to adopt an average functional gain
for HOOS, JR and KOOS, JR scores to
better capture the extent of patientreported post-operative improvement,
stating that the proposed approach sets
the quality bar too low and is not
aligned with the literature.
Response: The substantial clinical
benefit thresholds of a 20-point
improvement on the KOOS, JR and a 22point improvement on the HOOS, JR
were selected based on our analyses of
published literature and measure
development data and with
considerable stakeholder input to
capture variation in patient outcomes
among hospitals that reflect differences
in care quality among hospitals. During
measure development, these
improvement thresholds were
supported by the Technical Expert
Panel and patients. For additional
details, we refer readers to the PatientReported Outcomes (PROs) Following
Elective Primary Total Hip and/or Total
Knee Arthroplasty: Hospital-Level
Performance Measure—Measure
Methodology Report, available in the
Hip and Knee Arthroplasty PatientReported Outcomes folder at: https://
www.cms.gov/Medicare/QualityInitiatives-Patient-AssessmentInstruments/HospitalQualityInits/
Measure-Methodology. We thank
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
commenters for their recommendations
and will consider this feedback during
routine measure reevaluation.
After consideration of the public
comments we received, we are
finalizing the proposal as proposed.
h. Medicare Spending per Beneficiary
(MSPB) Hospital Measure (NQF #2158)
Beginning With the FY 2024 Payment
Determination
For the purpose of continuing to
assess hospitals’ efficiency and resource
use and to meet statutory requirements
under section 1886(o)(2)(B)(ii) of the
Act, in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28529 through
28532) we proposed the adoption of the
re-evaluated version of the MSPB
Hospital measure in the Hospital IQR
Program. We plan to subsequently
propose this for the Hospital VBP
Program measure set under the
Efficiency and Cost Reduction Domain
sometime in the future.
(1) Background
In the FY 2012 IPPS/LTCH PPS final
rule, we adopted a prior version of the
MSPB Hospital measure in both the
Hospital IQR Program (76 FR 51618)
and the Hospital VBP Program (under
the Efficiency and Cost Reduction
Domain) (76 FR 51654). The original
MSPB Hospital measure was
subsequently removed from the Hospital
IQR Program beginning with the FY
2020 payment determination, under the
proposed removal Factor 8, the costs
associated with a measure outweigh the
benefit of its continued use in the
program (83 FR 41559). The original
version of the MSPB Hospital measure
that was removed from the Hospital IQR
Program was identical to the version
that was concurrently, and continues to
be used in the Hospital VBP Program.
For more information on the removal of
the original MSPB Hospital measure
from the Hospital IQR Program, please
see section VIII.A.4.b of the FY 2019
IPPS/LTCH PPS final rule (83 FR 41540
through 41544). We note that adding the
updated MSPB Hospital measure with
the refinements outlined previously to
the Hospital IQR Program would follow
the process associated with adopting
new measures into the Hospital VBP
Program, as specified under section
1889(o)(2)(C)(i) of the Act, and provide
beneficiaries, hospitals, and other
stakeholders with an opportunity to
familiarize themselves with this
updated version of the measure before
we propose to replace the original
MSPB Hospital measure in the Hospital
VBP Program and calculate incentive
payment adjustments for eligible
hospitals. Given that the proposed
PO 00000
Frm 00479
Fmt 4701
Sfmt 4700
49257
updated MSPB Hospital measure is
different from the original MSPB
Hospital measure currently in use in the
Hospital VBP Program, we believe that
including the updated MSPB Hospital
measure in the Hospital IQR Program
will not incur costs that justified the
removal of the original MSPB Hospital
measure from the Hospital IQR Program
in the FY 2019 IPPS/LTCH PPS final
rule.
The original MSPB Hospital measure
evaluated hospitals’ efficiency relative
to the efficiency of the national median
hospital. Specifically, it assessed the
cost to Medicare during an episode of
care, which is composed of the period
three days prior to an IPPS hospital
admission through 30 days after
discharge. The measure included
Medicare Part A and B payments for
services provided to a Medicare
beneficiary during an episode. The costs
included in this measure were payment
standardized to remove sources of
variation not directly related to
hospitals’ care decisions, such as
geographic differences in practice
expenses. The measure was risk
adjusted to account for factors outside of
hospitals’ influence. The details of the
original MSPB Hospital episode
construction and measure calculation
can be found in the FY 2012 IPPS/LTCH
PPS final rule (76 FR 51618 through
51627).
As part of our measure maintenance
process (as required in section 8 of the
Blueprint for the CMS Measures
Management System Version 17.0
available at: https://www.cms.gov/
Medicare/Quality-Initiatives-PatientAssessment-Instruments/MMS/
Downloads/Blueprint.pdf), we
comprehensively re-evaluated the
original MSPB Hospital measure in
2020, after it was removed from the
Hospital IQR Program beginning with
the FY 2020 payment determination
period. The re-evaluation was informed
by feedback received on this measure
through prior public comment
periods 944 and the literature.
Specifically, regarding the all-cost
nature of the measure, some
stakeholders raised concerns that an allcost approach may result in the measure
capturing services that are not under the
influence of the facilities or
practitioners, while others noted that
there is a need for all-cost/condition
measures such as the MSPB Hospital
944 We received feedback during the public
comment periods of the FY 2012 and FY 2013 IPPS/
LTCH PPS proposed rules. We refer readers to the
FY 2012 IPPS/LTCH PPS final rule (76 FR 51619
through 51627) and the FY 2013 IPPS/LTCH PPS
final rule (77 FR 53584 through 53592) for a
summary of the comments received.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49258
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
measure to promote broad incentives for
care coordination. Regarding
readmissions triggering new episodes,
commenters noted that potentially high
cost services occurring after an inpatient
readmission are not fully captured
under the current methodology that
does not allow readmissions to initiate
new episodes, and that the correlation
between the MSPB Hospital measure
and the Hospital Readmission
Reduction Program’s readmission
measures is weak. Finally, some
commenters suggested potential need
for social risk factor (SRF)
adjustments.945 Relatedly, the literature
has identified dual enrollment in
Medicare and Medicaid as a potentially
meaningful SRF to adjust for in the VBP
programs.946
In the process of evaluating this
feedback, the TEP reviewed four main
topics to explore as potential changes to
the specifications, including:
(1) Narrowing the all-cost approach
through service inclusion and exclusion
rules;
(2) Including SRFs in the measure’s
risk adjustment model;
(3) Allowing readmissions to trigger a
new episode and include an indicator
variable in the risk adjustment model
for whether there was an inpatient stay
in the 30 days prior to episode start
date; and
(4) Changing the measure calculation
from the sum of observed costs divided
by the sum of expected costs to the
mean of observed costs divided by
expected costs.
After reviewing the analyses prepared
by the measure development contractor
and discussed during the February 2020
meeting, the TEP members provided
feedback on each of the potential
refinements during the process of reevaluation. In brief, the TEP believed
that the current all-cost methodology
approach appropriately reflected the
broad scope of a hospital’s
responsibility of care, and that this was
needed to promote broad incentive for
care coordination. TEP members
highlighted the need for further testing
around the impact of including SRF
variables in the risk adjustment model.
The TEP supported the refinement to
allow readmissions to trigger new
episodes, as they believed it was
clinically appropriate to hold the
hospital responsible for these costs. The
members also agreed that the slight
945 FY 2012 IPPS/LTCH PPS final rule (76 FR
51624 through 51625) and FY 2013 IPPS/LTCH PPS
final rule (77 FR 53586 through 53587).
946 Johnston, K.J. & Maddox, K.E.J. (2019). The
Role of Social, Cognitive, And Functional Risk
Factors In Medicare Spending For Dual And
Nondual Enrollees.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
change to the measure calculation
would reduce the impact of outliers on
the final measure scores. The summary
of the TEP’s discussions of the MSBP
Hospital measure is in the February
2020 Physician Cost Measures and
Patient Relationship Codes TEP
Summary Report.947
Through the re-evaluation process
and the feedback that was provided by
the TEP, we identified three refinements
to the measure which will ensure a
more comprehensive and consistent
reflection of hospital performance by
capturing more episodes and adjusting
the measure calculation. First, we
refined the measure to include all
readmissions to trigger new episodes to
account for episodes and costs that are
currently not included in the measure
but that could be within the hospital’s
reasonable influence. Second, we added
an indicator variable in the risk
adjustment model for whether there was
an inpatient stay in the 30 days prior to
episode start date. And third, we revised
the measure to change one step in the
measure calculation from the sum of
observed costs divided by the sum of
expected costs (ratio of sums) to the
mean of observed costs divided by
expected costs (mean of ratios). Based
on our measure development
contractor’s recommendations, informed
by the guidance from the TEP and the
additional testing of the potential
refinements suggested by the TEP, we
believe that these changes will benefit
the MSPB Hospital measure’s relevance
and statistical stability as well as ensure
a more comprehensive and consistent
reflection of hospital performance by
capturing more episodes and adjusting
the measure calculation. We describe
these changes in a summary of the
measure re-evaluation on the CMS
QualityNet website posted in July
2020.948
We proposed the updated MSPB
Hospital measure for the Hospital IQR
Program that incorporates the three
changes, which are detailed in the
subsequent discussion. We note that
aside from these three described
refinements, all other aspects of the
updated measure are the same as
compared to the original measure.
947 Physician Cost Measures and Patient
Relationship Codes TEP Summary Report. (2020).
Available at: https://www.cms.gov/files/zip/
physician-cost-measures-and-patient-relationshipcodes-pcmp.zip.
948 Medicare Spending Per Beneficiary (MSPB)
Measure Methodology. Available at: https://
qualitynet.cms.gov/inpatient/measures/mspb/
methodology.
PO 00000
Frm 00480
Fmt 4701
Sfmt 4700
(a) Update To Allow Readmissions To
Trigger New Episodes
First, we refined the measure to allow
readmissions to trigger new episodes to
account for episodes and costs that are
currently not included in the measure
but that could be within the hospital’s
reasonable influence. It is clinically
appropriate to hold the hospital
responsible for the costs that are
associated with the readmissions (that
is, from 3 days prior to the readmission
through 30 days post-discharge) to
encourage care transitions and
coordination in improving patient care
and reducing unnecessary readmissions.
Under the previously adopted measure
methodology, the measure only
included episodes that are triggered by
initial hospital admissions, and
inpatient readmissions occurring in the
30-day post-discharge period of an
existing episode are excluded from
initiating new episodes (76 FR 51620
through 51624). Allowing readmissions
to trigger new episodes will increase the
number of episodes for which a
provider can be scored and align the
incentives of the measure during
readmissions, by encouraging hospitals
to provide cost efficient care and
improve care coordination not only
during initial hospitalizations, but also
during readmissions. This refinement
will also ensure that the measure
captures potentially high-cost services
that would otherwise be excluded.
To illustrate this refinement, take for
example a beneficiary who is admitted
to an inpatient hospital for a spinal
procedure with major complication or
comorbidity (MS–DRG 028). This
hospital admission triggers an episode
(Episode 1), where the episode window
starts three days prior to the admission
date and ends 30 days after discharge.
Episode 1 is attributed to the hospital
where the inpatient stay occurs. Fifteen
days after being discharged from the
hospital, the beneficiary needs to
receive additional inpatient hospital
care for pneumonia (MS–DRG 194). This
readmission occurs within the 30-day
post-discharge period of Episode 1 (that
is, the episode triggered by the initial
hospitalization), and will trigger a new
episode (Episode 2). Episode 2’s
window will start three days prior to
this readmission and end 30 days after
discharge. Episode 2 will be attributed
to the hospital managing this
readmission. Under the previous
methodology, the readmission would
not be calculated under the measure as
a new episode because it occurred
during the 30-day post-discharge period
of Episode 1. However, under the
proposed new methodology, the
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
readmission will trigger a new episode
(Episode 2), and the episode will be
included in the MSPB rate for the
hospital managing the readmission.
Episode 2 will include the costs in the
post-discharge period of the
readmission that would not be
previously captured. Additionally, the
costs where Episode 1 and Episode 2
overlap will be counted towards each
episode. We note that the services being
assigned to these episodes will only be
counted once per episode. In other
words, costs will not be double-counted.
The revised measure calculation
compares each hospital’s observed
episode costs to predicted episode costs
among their peers for patients with the
same observable characteristics, rather
than to a pre-defined standard. By
comparing hospitals to other hospitals
that are all attributed in the same way,
we expect this comparison to be fair.
This also helps to maintain care
coordination incentives of the MSPB
Hospital measure.
(b) New Indicator Variable in the Risk
Adjustment Model
Additionally, to account for the
differences in expected costs for
episodes that are triggered by
readmissions, the updated methodology
includes an indicator variable in the risk
adjustment model showing whether
there was an inpatient stay in the 30
days prior to episode start date. The
previous methodology does not include
this indicator variable, given that all
episodes with an inpatient stay in the 30
days prior to the episode start date (that
is, episodes that are based on a hospital
readmission) are excluded from the
measure calculation (76 FR 51620
through 51624). Continuing with the
example used earlier, given that Episode
2 is based on a hospital readmission and
there was an inpatient stay within 30
days prior to its episode start date, the
risk adjustor indicator will be turned on
for Episode 2. This means that when we
calculate predicted spending for
Episode 2, the risk adjustment model
will take into account the fact that this
episode was triggered by a readmission,
and not an initial admission. This will
ensure that the hospital is not unfairly
penalized for providing care to the
patient during the episode that could be
more high cost due to its readmission
status.
An illustration of this refinement that
compares the previously adopted
methodology where a readmission does
not trigger a new episode and the
proposed new methodology where a
readmission does trigger a new episode,
is available in Appendix B of the
Measure Information Form (MIF)
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
document available at: https://
qualitynet.cms.gov/files/5f1b3bd
12bd4670021abc1b4?filename=MSPB_
Hospital_MIF_2020.pdf.
(c) Updated MSPB Amount Calculation
Methodology
The third refinement changes one step
in the measure calculation from the sum
of observed costs divided by the sum of
expected costs (ratio of sums) to the
mean of observed costs divided by
expected costs (mean of ratios). Under
the previously adopted methodology,
we calculated the MSPB Amount as
follows: ((Sum of Observed Costs//# of
Attributed Episodes)/(Sum of Expected
Costs/# of Attributed Episodes)) *
Average Observed Cost Nationally (76
FR 51626). The revised methodology
calculates the MSPB Amount instead as
follows: (Sum (Observed Costs/Expected
Costs)/# of Attributed Episodes) *
Average Observed Cost Nationally.
Under this refinement, changing the
measure calculation will: (a) Slightly
increase measure reliability with
minimal score changes; and (b) evenly
weight attributed episodes in the final
performance score, where previously
good or poor performance on more
expensive episodes will have more
weight in the provider’s final score.
Specifically, by changing the measure
calculation, the impact of outlier
episodes on a measure score will be
reduced (under the previously adopted
calculation methodology, most costly
episodes are weighted proportionately,
which will make the measure slightly
more sensitive to outlier episodes).
Additionally, the updated MSPB
Hospital measure will further align with
MSPB cost measures in other settings,
including the MSPB Clinician measure
in MIPS (84 FR 62974 through 62977),
and the MSPB-Post Acute Care (PAC)
measures, including MSPB–PAC for
Inpatient Rehabilitation Facilities (81
FR 52087 through 52095), Long-Term
Care Hospitals (81 FR 57199 through
57207), Skilled Nursing Facilities (81 FR
52014 through 52021), and Home Health
Agencies (81 FR 76757 through 76765).
The updated MSPB Hospital measure
will also align with the acute inpatient
medical condition episode-based cost
measures in MIPS (83 FR 59767 through
59773, 84 FR 62962 through 62968. and
86 FR 65446 through 65453). We note
that while the scope of care is different
for clinician, hospital, and post-acute
care level measures, we believe aligning
these measures will help to ensure
consistent care coordination incentives
between the hospital, post-acute care
facility, and the clinician(s) providing
care in those settings.
PO 00000
Frm 00481
Fmt 4701
Sfmt 4700
49259
(2) NQF Re-Endorsement
This original MSPB Hospital measure
was first endorsed by the NQF in
2013 949 and then again in 2017.950 We
presented the updated MSPB Hospital
measure (NQF ID #2158) with these
three refinements to NQF in the Fall
2020 cycle for measure re-endorsement.
During the Fall 2020 NQF endorsement
cycle, the updated MSPB Hospital
measure was reviewed by the Scientific
Methods Panel (SMP), Cost and
Efficiency Standing Committee, and
Consensus Standards Approval
Committee (CSAC) during the 11-month
endorsement process.951 The updated
measure passed on the reliability and
validity criteria when reviewed by the
SMP. The Cost and Efficiency Standing
Committee reviewed each aspect of the
updated measure in detail across three
meetings. They also closely reviewed
our testing around the impact of social
risk factors. Specifically, we had tested
whether the inclusion of sex, dual
eligibility status, race/ethnicity, the
AHRQ SES index, components of the
AHRQ SES index, and the Area
Deprivation Index could meaningfully
be incorporated into the measure, so as
not to penalize the hospital for the
patients they treat, while also not setting
a lower standard of care for hospitals
with patients that have social risk
factors. Results showed that the
inclusion of these social risk factors had
a limited and inconsistent effect on
measure scores, and some of the
variation that was captured by tested
covariates was attributable to the
hospital in which the episodes were
initiated. Therefore, social risk factors
continue to not be included in the
measure’s risk adjustment model. The
CSAC approved the Standing
Committee’s endorsement
recommendation unanimously, meaning
that the updated MSPB Hospital
measure (NQF #2158) was re-endorsed
in June 2021 with the three refinements
discussed.952
949 The NQF Cost and Resource Use—Phase 3
Final Report is available at: https://
www.qualityforum.org/Publications/2015/02/Cost_
and_Resource_Use_-_Phase_3_Final_Report.aspx,
and the 2013 NQF measure evaluation form is
available at: https://www.qualityforum.org/Projects/
c-d/Cost_and_Resource_Project/2158.aspx.
950 NQF. (2017). Cost and Resource Use 2016–
2017 Final Technical Report. Available at: https://
www.qualityforum.org/Publications/2017/08/Cost_
and_Resource_Use_2016–2017_Final_Technical_
Report.aspx.
951 The submission materials, including the
testing results, are available at: https://
www.qualityforum.org/ProjectMeasures.aspx?
projectID=86056&cycleNo=2&cycleYear=2020.
952 NQF. (2020). Cost and Efficiency Final
Report—Fall 2020 Cycle. Available at: https://
www.qualityforum.org/Publications/2021/09/
E:\FR\FM\10AUR2.SGM
Continued
10AUR2
49260
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(3) Measure Applications Partnership
Review
khammond on DSKJM1Z7X2PROD with RULES2
Following NQF re-endorsement, the
updated measure was included in
CMS’s ‘‘List of Measures Under
Consideration for December 1,
2021.’’ 953 The updated MSPB Hospital
measure (MUC2021–131) underwent
MAP review during the 2021–2022
cycle. On December 15, 2021, the MAP
Hospital Workgroup supported the
updated measure for rulemaking. On
January 19, 2022, the MAP Coordinating
Committee upheld the MAP Hospital
Workgroup’s preliminary
recommendation to support the updated
measure for rulemaking. More detail on
the discussion is available in the MAP’s
final report.954
We proposed the updated MSPB
Hospital measure (NQF #2158) for the
Hospital IQR Program beginning with
the FY 2024 payment determination and
for subsequent years. This will allow us
to assess hospitals’ efficiency and
resource use and meet statutory
requirements for future adoption in the
Hospital VBP Program.955
We invited public comment on this
proposal.
Comment: Several commenters
supported the proposed revisions to the
MSPB Hospital measure, and the
measure’s adoption in the Hospital IQR
Program in general. Some commenters
expressed specific support for the
refinement to allow readmissions to
trigger a new episode, with a commenter
stating that this refinement would
encourage greater care coordination and
shared accountability for avoidable
readmissions. A commenter supported
the refinement to add an indicator in the
risk adjustment model for a previous
inpatient stay within 30 days of the
episode start date. A few commenters
were also appreciative that the revised
measure was NQF-endorsed prior to its
proposal to be included in the Hospital
IQR Program.
Response: We appreciate the
commenters’ support for inclusion of
Cost_and_Efficiency_Final_Report_-_Fall_2020_
Cycle.aspx.
953 Centers for Medicare & Medicaid Services.
(2021). List of Measures Under Consideration for
December 1, 2021. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96464.
954 National Quality Forum, (2022) Measure
Applications Partnership 2021–2022 Considerations
for Implementing Measures in Federal Programs:
Clinician, Hospital, and Post-Acute Care Long-Term
Care (https://www.qualityforum.org/Publications/
2022/03/MAP_2021-2022_Considerations_for_
Implementing_Measures_Final_Report_-_
Clinicians,_Hospitals,_and_PAC-LTC.aspx).
955 Sections 1886(o)(2)(B)(ii) and 1886(o)(2)(C)(i)
of the Social Security Act (https://www.ssa.gov/OP_
Home/ssact/title18/1886.htm).
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the revised MSPB Hospital measure in
the Hospital IQR Program.
Comment: While some commenters
supported the proposed revisions to the
MSPB Hospital measure, a few
commenters urged that we share
information on the impact of proposed
refinements on the measure. A few
commenters requested that we provide
example calculations under the revised
and original measure versions to
illustrate the potential effects of the
proposed measure calculation changes
and their impact on hospitals. A
commenter noted that they would be
interested to see how the revised
version of the MSPB Hospital measure
and the measure scores compare to
those of the current version of the
measure that is currently used in the
Hospital VBP Program. The commenter
further noted that they would be
interested in how the refinement of the
measure calculation would affect
Hospital VBP Program scores and
outcomes. Finally, a commenter urged
that we closely monitor the results for
both versions of the measure in the
Hospital IQR and Hospital VBP
Programs for any unintended
consequences, especially during the
period of time when the measure
specifications are not aligned.
Response: We thank the commenters
for their feedback. We note that as part
of the NQF endorsement process, we
provided statistics on the impacts of the
proposed refinements to the measure.
For example, Table 3.b of the testing
appendix that was submitted to NQF
contains an analysis of changes in
MSPB Hospital measure scores between
the current version of the measure and
the version of the measure with
proposed refinements implemented. In
addition, Table 3.a includes testing
results on the MSPB Hospital measure
episodes stratified by whether an
episode was triggered by an original
hospitalization or a readmission. The
submission materials that include these
testing results are available at: https://
www.qualityforum.org/ProjectMeasures.
aspx?projectID=86056&cycleNo=
2&cycleYear=2020. Additional
information on the impact of the
refinements and the TEP’s discussion on
each refinement is also available in the
February 2020 Physician Cost Measures
and Patient Relationship Codes TEP
Summary Report available at: https://
www.cms.gov/files/zip/physician-costmeasures-and-patient-relationshipcodes-pcmp.zip. In order to evaluate the
impact of the refinements on the
Hospital VBP Program scores (that is,
the Total Performance Scores that are
used to adjust hospital payments) and
outcomes, the measure would need to
PO 00000
Frm 00482
Fmt 4701
Sfmt 4700
be implemented in the Hospital VBP
Program, so that hospital performance
on the measure can be aggregated with
hospital performance on measures in
other domains. We will continue
monitoring the results for both versions
of the measure in each program for any
unintended consequences in the future.
Comment: Some commenters
expressed concerns that for a period of
time, there would be two slightly
different versions of the measure used to
assess hospital performance in the
Hospital IQR and the Hospital VBP
Programs, respectively. Commenters
noted that this could make it difficult
for hospitals to interpret performance
results and could lead to additional
burden on providers who would need to
track two different reporting rates. Some
commenters also expressed concerns
about publicly reporting two versions of
the MSPB Hospital measure, with a
commenter requesting clarification on
how these measures would be
distinguished for the public. Some
commenters recommended that we
suppress one set of measures from
public reporting, but maintain both
results in downloadable files. To reduce
any confusion caused by having two
version of the measures being
simultaneously reported publicly, a few
commenters recommended only
publicly reporting the current measure
that is used in Hospital VBP Program,
while waiting for at least one year before
starting to publicly report the revised
version of the measure. Another
commenter recommended suppressing
the version used in Hospital VBP
Program if the revised version is used in
the Hospital IQR Program and made
publicly available.
Response: We thank the commenters
for raising these concerns. As we have
previously stated (87 FR 28529), a
couple of goals of adopting the revised
version of the measure in the Hospital
IQR Program is to publicly report it for
at least a year in order to meet
requirements for potential future use in
the Hospital VBP Program (as required
by the Hospital VBP Program statute at
section 1886(o) of the Act) as well as to
provide interested parties with an
opportunity to become familiar with the
new version of the measure and provide
feedback. Therefore, we do not want to
delay the public reporting of the
measure by one year, as suggested by
the commenters. Additionally, by
statute, there must be a cost measure in
the Hospital VBP Program, which is the
MSPB Hospital measure, so we are
unable to remove the current version of
the measure from Hospital VBP
Program, as it is the only cost measure
under the Efficiency and Cost Reduction
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
domain and we believe this domain is
an essential part of assessing value in
addition to quality in the program. We
will work to clearly identify the version
of the measure when publicly reporting
the revised MSPB Hospital measure and
help address any potential confusion.
The updated version of the measure will
be posted with other Hospital IQR
Program data on the Compare tool,
which displays data in a consumerfocused way. Hospital VBP Program
data will continue to be posted to
data.cms.gov which presents the data as
downloadable files and is targeted more
towards data analysts and researchers
rather than consumers. We also plan to
publicly post educational materials and
provide support via help desk to
respond to stakeholder inquiries.
Comment: Several commenters did
not support the measure and expressed
concerns that allowing readmissions to
trigger a new episode in the revised
MSPB Hospital measure could lead to
the same costs being attributed to
hospitals twice and potentially result in
a misleading portrayal of hospital
performance. Another commenter
expressed concern that a facility would
be penalized twice related to
readmissions, once through in the
Hospital IQR Program based on their
performance on the revised MSPB
Hospital measure, and again through the
Hospital Readmissions Reduction
Program.
Response: We thank the commenters
for raising these concerns. As previously
stated in the proposed rule(87 FR
28530), the refinement allows
readmissions to trigger new episodes
which would result in some services
being assigned to multiple episodes.
These services, however, would only be
counted once per episode, so the cost of
these services would not be counted
twice within the same episode.
Additionally, the presence of an
inpatient admission within 30 days
before the start date of an episode based
on a readmission is controlled for in the
risk adjustment model to account for the
additional complexity that readmissions
may entail.956 Further, the inclusion of
episodes triggered by readmissions does
not necessarily result in a worse
measure score for the provider. Such
episodes still use the observed over
expected cost ratios, where it is possible
for the observed cost to be lower than
expected cost, if the hospital performed
better on the episode than expected.
Additionally, we do not agree with the
956 Medicare Spending Per Beneficiary (MSPB)
Measure Methodology. Available at: https://
qualitynet.cms.gov/inpatient/measures/mspb/
methodology.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
commenter’s statement that this
refinement would result in hospitals
being penalized twice. The revised
MSPB Hospital measure, whether used
in the Hospital IQR Program or Hospital
VBP Program, and the condition- and
procedure-specific readmission
measures used in the Hospital
Readmissions Reduction Program assess
readmissions for different purposes (for
example, assess hospitals’ cost
efficiency on readmissions and reduce
avoidable readmissions, respectively) to
help encourage hospitals to provide
higher value care to their patients; thus,
it is beneficial to have this alignment.
Additionally, allowing readmissions to
trigger new MSPB Hospital episodes
does not impact a hospital’s
readmissions rates, given that it merely
captures episodes that are based on
existing readmissions so that those
episodes can be used to assess hospital
performance.
Comment: Several commenters did
not support the measure, expressing
concerns that the reliability and validity
of the revised MSPB Hospital measure
are low.
Response: We respectfully disagree
with the comments that the reliability
and validity of the revised MSPB
Hospital measure are low. The NQF
rated reliability as high when endorsing
the measure. The average reliability
score of hospitals with at least 25
episodes was 0.92,957 958 which far
exceeds the standard generally
considered as ‘high’ reliability. The
NQF rated validity as moderate when
endorsing the measure.959 960 As part of
the NQF endorsement submission, we
undertook three approaches to
empirically examine the extent to which
the revised MSPB Hospital measure
captures what it intends to capture.
Firstly, we examined the relationship
between risk adjusted episode cost
ratios and episodes with and without
post-admission events that are known
957 The submission materials, including the
testing results, are available at: https://
www.qualityforum.org/
ProjectMeasures.aspx?projectID=86056&cycle
No=2&cycleYear=2020.
958 NQF’s Cost and Efficiency Final Report with
the summary of the Scientific Methods Panel’s and
Standing Committee’s discussion is available here:
https://www.qualityforum.org/Publications/2021/
09/Cost_and_Efficiency_Final_Report_-_Fall_2020_
Cycle.aspx.
959 The submission materials, including the
testing results, are available at: https://
www.qualityforum.org/
ProjectMeasures.aspx?projectID=86056&
cycleNo=2&cycleYear=2020.
960 NQF’s Cost and Efficiency Final Report with
the summary of the Scientific Methods Panel’s and
Standing Committee’s discussion is available here:
https://www.qualityforum.org/Publications/2021/
09/Cost_and_Efficiency_Final_Report_-_Fall_2020_
Cycle.aspx.
PO 00000
Frm 00483
Fmt 4701
Sfmt 4700
49261
indicators of high cost or intensive care.
Secondly, we examined the relationship
between a hospital’s average expected
episode cost and average episode rates
of several service use categories, to test
whether the risk adjustment model can
predict patient need for certain services.
Thirdly, we examined the relationship
between the revised MSPB Hospital
measure and other cost-specific
measures, efficiency-related measures,
and measures in other Hospital VBP
Program domains. For all three types of
validity testing, we observed results that
were in line with our expectations,
demonstrating that the measure is
functioning as intended.
Comment: Some commenters raised
concerns about the risk adjustment
approach for the revised MSPB Hospital
measure. Specifically, a few
commenters were concerned that the
measure does not adjust for social risk
factors. A commenter stated that social
risk factors should not be considered
supplementary to clinical risk factors in
risk adjustment models. Additionally, a
commenter did not believe that the risk
adjustment model’s fit with the
unadjusted and adjusted R-squared
(ranging from 0.11 to 0.67) was
sufficiently addressed. Finally, a
commenter requested for additional
clarification on whether the revised
MSPB Hospital measure takes into
account patient acuity, impact of patient
social drivers of health, supply chain
impact, COVID–19 impacts, and short
staffing as variables that could impact
Medicare spending per beneficiary.
Response: We thank the commenters
for their feedback. As noted previously,
as part of the NQF endorsement
submission we assessed the impact of
social drivers of health on the measure,
conducting testing based on NQF
precedents, as well as supplemented
with novel testing and in response to
specific stakeholder feedback. The
NQF’s Scientific Methods Panel
carefully reviewed the testing results on
the impacts of social risk factors on the
measure and our recommendation to
continue not including them in the
measure’s risk adjustment model, and
passed the measure on validity
criterion. Additionally, as part of
normal measure maintenance, we plan
to continue to conduct testing and
monitoring of the impact of social risk
factors on the measure.
Regarding the commenter’s note about
the measure’s low R-squared metrics
that were included in the NQF
endorsement submission materials, we
would like to clarify that R-squared
metrics, which are calculated to analyze
the proportion of cost variation
explained by the risk adjustment model,
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49262
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
should be interpreted within the context
of the measure construction, what it is
intended to capture, and its use. A low
R-squared is conceptually neither
required nor expected for a ‘‘valid’’
measure, so some valid measures will
have low R-squared metrics, while
others will have high R-squared metrics.
We also note that extensive testing
demonstrates the validity of the risk
adjustment models for the revised
MSPB Hospital measure, with model
discrimination and calibration results
demonstrating predictive ability across
the full range of episodes, from low to
high spending risk. There was no
evidence of excessive under- or overestimation at the extremes of episode
risk.
Given that the revised MSPB Hospital
measure is calculated using
administrative claims data, the measure
is unable to directly account for supply
chain impacts and short staffing.
Regarding the commenter’s note on the
impact of COVID–19 on the measure,
given that the measure uses a risk
adjustment model that is run separately
for each Major Diagnostic Category
(MDC), and COVID–19 diagnoses are
mapped to particular Diagnosis-Related
Groups (DRGs), the measure would
adjust for COVID–19 when risk
adjusting by the DRG of the
hospitalization. We also observed that
COVID–19 hospitalizations are highly
concentrated within MDC 4 (Respiratory
System), which further improves
comparability of COVID–19 episodes to
non-COVID–19 episodes. We will
continue monitoring the effects of
COVID–19 on both the current and
revised versions of the MSPB Hospital
measure, however, because of the ways
the measure already accounts for
COVID–19 hospitalizations as
described, we do not believe any
additional adjustments for COVID–19
are needed at this time.
Finally, the measure’s risk adjustment
methodology accounts for patient casemix and other factors by adjusting for
patient age and severity of illness.
Specifically, the risk adjustment
methodology includes 12 age categorical
variables, 79 hierarchical condition
category (HCC) indicators, status
indicator variables for whether the
beneficiary qualifies for Medicare
through disability or age and End-Stage
Renal Disease (ESRD), indicators to
account for disease interactions, an
indicator of whether the beneficiary
recently required long-term care, and
the Medicare Severity-Diagnosis Related
Group (MS–DRG) of the index
hospitalization. We believe this
provides adequate adjustment for
patient acuity.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Comment: A few commenters raised
concerns about a lack of alignment
between the revised MSPB Hospital
measure and relevant quality data, and
stated that without this alignment or the
incorporation of these data into the
revised MSPB Hospital measure, it
cannot accurately assess efficiency. The
commenters believe that efficiency of
care must be a measure of cost of care
associated with a specified level of
quality of care. They also believe
measures should be grounded in current
best evidence, should evaluate clinical
outcomes concurrently with resource
use, and should be interpretable based
on outcomes achieved with resources
expended. The commenter added that to
fully interpret cost measure data,
relevant quality data must also be
available. The inclusion of cost
measures alone could discourage the
provision of needed care or innovative
treatments to reduce costs. As a result,
the commenter encouraged that we
investigate alternative frameworks for
efficiency measurement to properly
align the evaluation of cost and quality.
Response: We thank the commenters
for their feedback. For the purposes of
the Hospital IQR Program, we determine
the quality of care provided by hospitals
to their patients by using a variety of
measures that include both cost and
quality measures, thus ensuring
alignment between cost and quality.
Specifically, such measures include
payment measures (including four
condition-specific measures and the
revised MSPB Hospital measure being
proposed), patient safety, morality
outcome, patient experience of care
survey, and others. Similarly, in the
Hospital VBP Program, the revised
MSPB Hospital measure would be used
in alignment with several quality
measures that span Clinical Outcomes,
Person and Community Engagement,
and Safety measure domains, so
together these measures would facilitate
profiling hospital value, from both the
cost and quality perspectives. In
addition, to ensure that hospitals are
able to understand their performance on
the revised MSPB Hospital measure and
identify areas for improvement, eligible
hospitals will receive Hospital-Specific
Reports (HSRs) that contain different
breakdowns of the hospital’s
performance on the measure. Providing
these files to hospitals would also allow
them to provide informed feedback on
the measure to the measure developer
and CMS.
We also add that the measure itself
safeguards against potential care stinting
by including the costs of consequences
of care. For example, if the attributed
hospital attempts to reduce costs by
PO 00000
Frm 00484
Fmt 4701
Sfmt 4700
discharging a patient too early, it could
result in higher post-acute care costs, rehospitalization for complications, or
emergency department visits soon after
the discharge, which would be captured
by the measure, resulting in worse
performance. Testing submitted as part
of the NQF endorsement cycle
demonstrated that the measure
accurately reflects high-cost adverse
outcomes, confirming that the measure
can appropriately distinguish that better
providers tend to have fewer
downstream re-hospitalizations and
post-acute care use.961 Thus, by being
able to differentiate between good and
poor performance, the measure is able to
accurately assess a hospital’s efficiency
as compared to other hospitals.
Finally, to address a commenter’s
feedback that the measure should be
grounded in current best evidence and
practices, we note that prior to being
proposed in the FY 2023 IPPS/LTCH
PPS proposed rule, the NQF and MAP
reviewed the revised MSPB Hospital
measure against the measure evaluation
criteria, which include importance to
measure and report, scientific
acceptability of measure properties,
feasibility, usability and use, and
related/competing measures, to ensure
the measure’s suitability, and
subsequently recommended the
measure for endorsement and
implementation in the Hospital IQR
Program.
Comment: A commenter
recommended that CMS delay adopting
the revised MSPB Hospital measure in
the Hospital IQR Program until the FY
2025 payment determination due the
impact that COVID–19 could have on
measure calculations.
Response: We appreciate the
commenter’s concern that the impact of
COVID–19 on the healthcare system has
been profound. We intend to closely
monitor the effect of COVID–19 on the
revised MSPB Hospital measure and the
Hospital IQR Program. As noted
previously, by construction the revised
MSPB Hospital measure adjusts for
COVID–19 when risk adjusting by the
DRG of the hospitalization.
Additionally, for the MSPB Hospital
measure currently used in the Hospital
VBP Program, our analyses using data
from the first three quarters of 2021
showed that admission volumes
returned to near pre-COVID–19 levels,
while cost ratios were not significantly
different for episodes with and without
COVID–19. Based on the findings
961 The submission materials, including the
testing results, are available at: https://www.quality
forum.org/ProjectMeasures.aspx?projectID=86056&
cycleNo=2&cycleYear=2020.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
indicating that COVID–19 had a small
impact on the measure in 2021, we did
not propose to suppress the measure for
the purposes of Hospital VBP Program
scoring. We disagree about delaying the
implementation of the measure in the
Hospital IQR Program as this would
prevent stakeholders from familiarizing
themselves with the revised version of
the measure and would further delay
the potential future implementation of
the measure in the Hospital VBP
Program.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
khammond on DSKJM1Z7X2PROD with RULES2
i. Hospital-Level Risk-Standardized
Complication Rate (RSCR) Following
Elective Primary Total Hip Arthroplasty
(THA) and/or Total Knee Arthroplasty
(TKA) Measure (NQF#1550) Beginning
With the FY 2024 Payment
Determination
(1) Background
In the FY 2013 IPPS/LTCH PPS final
rule (77 FR 53516 through 53521) and
the FY 2015 IPPS/LTCH PPS final rule
(79 FR 50062 through 50063), we
adopted the Hospital-Level RSCR
Following Elective Primary THA/TKA
(hereinafter referred to as the THA/TKA
Complication measure) for use in both
the Hospital IQR and Hospital VBP
Programs, respectively. We refer readers
to the FY 2016 IPPS/LTCH PPS final
rule (80 FR 49674) for information on
the previously adopted measure
specifications. Although the measure is
still included in the Hospital VBP
Program and measure results are still
publicly reported, in the FY 2018 IPPS/
LTCH PPS final rule (83 FR 41150) we
finalized the removal of the measure
from the Hospital IQR Program as part
of agency-wide efforts to reduce
provider burden since the measure was
also being reported under the Hospital
VBP Program. We, however, believe it is
important to assess the quality of care
provided to Medicare beneficiaries who
undergo one or both of these
procedures. In the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28532
through 28534), we proposed to adopt
the re-evaluated form of the THA/TKA
Complication measure with an
expanded measure outcome. Since the
measure was removed from the Hospital
IQR Program, it has been revised to
include 26 additional mechanical
complication ICD–10 codes which were
identified during measure maintenance.
The statutory requirements of the
Hospital VBP Program are set forth in
section 1886(o) of the Social Security
Act. As noted at 42 CFR 412.164(b)
measures must be publicly reported for
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
one year prior to the beginning of the
performance period in the Hospital VBP
Program. Therefore, we proposed to
adopt this measure into the Hospital
IQR Program with the intention to
eventually propose the updated measure
into the Hospital VBP Program after the
required year of public reporting in
Hospital IQR Program.
THA and TKA are commonly
performed procedures for the Medicare
population that improve quality of life.
From 2016 to 2019, there were
1,012,190 THA and TKA procedures
performed on Medicare fee-for-service
(FFS) patients 65 years and older. 962
The number of procedures being
performed has steadily increased over
the last decade and is projected to reach
over four million by 2030. 963 964 While
these procedures can dramatically
improve a person’s quality of life, they
are costly. Based on projections of the
annual demand for THA and TKA
procedures, researchers estimate that
Medicare expenditures on Total Joint
Arthroplasty (TJA) could climb from
$3.95 billion and $7.42 billion for both
primary THA and TKA, respectively, in
2005, 965 to $50 billion by 2030. 966
Complications following elective THA
and TKA procedures are rare, but the
results can be devastating. Evidence
shows that periprosthetic joint infection
rates following THA and TKA range
from 0.7 percent to 1.6 percent
depending upon the population. 967 968
Reported 30- and 90-day death rates
following THA range from 0.4 percent to
0.7 percent. 969 Rates for pulmonary
962 Triche, E., J.N. Grady, and J.e.a. Debuhr,
Procedure Specific Complication Measure Updates
and Specifications Report: Elective Primary Total
Hip Arthroplasty (THA) and/or Total Knee
Arthroplasty (TKA) Risk-Standardized
Complication Measure (Version 9.0). 2020.
963 Kurtz, S., et al., Projections of primary and
revision hip and knee arthroplasty in the United
States from 2005 to 2030. J Bone Joint Surg Am,
2007. 89(4): p. 780–5.
964 Kurtz, S.M., et al., Impact of the economic
downturn on total joint replacement demand in the
United States: updated projections to 2021. J Bone
Joint Surg Am, 2014. 96(8): p. 624–30.
965 Kurtz, S.M., et al., Future clinical and
economic impact of revision total hip and knee
arthroplasty. J Bone Joint Surg Am, 2007. 89 Suppl
3: p. 144–51.
966 Wilson, N.A., et al., Hip and knee implants:
current trends and policy considerations. Health Aff
(Millwood), 2008. 27(6): p. 1587–98.
967 Kurtz S, Ong K, Lau E, Bozic K, Berry D,
Parvizi J. Prosthetic joint infection risk after TKA
in the Medicare population. Clin Orthop Relat Res.
2010; 468:5.
968 Bozic KJ, Grosso LM, Lin Z, et al. Variation in
hospital-level risk-standardized complication rates
following elective primary total hip and knee
arthroplasty. J Bone Joint Surg Am.
2014;96(8):640-647. doi:10.2106/JBJS.L.01639.
969 Soohoo NF, Farng E, Lieberman JR, Chambers
L, Zingmond DS. Factors That Predict Short-term
Complication Rates After Total Hip Arthroplasty.
Clin Orthop Relat Res. Sep 2010;468(9):2363–2371.
PO 00000
Frm 00485
Fmt 4701
Sfmt 4700
49263
embolism following THA range from 0.5
percent to 1.22 percent 970 and range
from 0.5 percent to 0.9 percent 971
following TKA. Rates for wound
infection in Medicare population-based
studies vary between 0.21 percent and
1.0 percent. 972 Rates for sepsis/
septicemia range from 0.09 percent
during the index admission to 0.3
percent 90 days following discharge for
primary TKA. Rates for bleeding and
hematoma following TKA range from
0.94 percent to 1.7 percent.973
The updated THA/TKA Complication
measure was listed in the publicly
available document entitled ‘‘List of
Measures Under Consideration for
December 1, 2021’’ 974 (MUC List) with
identification number MUC2021–118.
The MAP reviewed the updated
measure and voted to conditionally
support the measure for rulemaking for
use in the Hospital IQR Program
pending NQF review and endorsement
of the measure update. The MAP Rural
Health Advisory Group reviewed this
updated measure on December 8, 2021
and voted to majority support the
measure given that there would be no
undue consequences for rural
hospitals.975
The NQF re-endorsed the original
measure in July of 2021; and we intend
to submit the updated measure to NQF
for endorsement in Fall 2024.976 We
note that section
1866(b)(3)(B)(viii)(IX)(aa) of the Act
requires that any measure specified by
the Secretary must have been endorsed
by the entity with a contract under
section 1890(a) of the Act (the NQF is
the entity that currently holds this
970 Arshi A, Leong NL, Wang C, Buser Z, Wang
JC, SooHoo NF. Outpatient total hip arthroplasty in
the United States: A population-based comparative
analysis of complication rates. J Am Acad Orthop
Surg. 2019;27(2):61–7.
971 Khatod M, Inacio M, Paxton EW, et al. Knee
replacement: epidemiology, outcomes, and trends
in Southern California: 17,080 replacements from
1995 through 2004. Acta Orthop. Dec
2008;79(6):812–819.
972 Browne J, Cook C, Hofmann A, Bolognesi M.
Postoperative morbidity and mortality following
total knee arthroplasty with computer navigation.
Knee. Mar 2010;17(2):152–156.
973 Huddleston JI, Maloney WJ, Wang Y, Verzier
N, Hunt DR, Herndon JH. Adverse Events After
Total Knee Arthroplasty: A National Medicare
Study. The Journal of Arthroplasty. 2009;24(6,
Supplement 1):95–100.
974 https://www.cms.gov/files/document/
measures-under-consideration-list-2021-report.pdf.
975 https://www.qualityforum.org/Publications/
2022/03/MAP_2021–2022_Considerations_for_
Implementing_Measures_Final_Report_-_
Clinicians,_Hospitals,_and_PAC–LTC.aspx.
976 National Quality Forum. Hospital-level riskstandardized complication rate (RSCR) following
elective primary total hip arthroplasty (THA) and/
or total knee arthroplasty (TKA) Measure
Specifications. 2021. https://www.qualityforum.org/
QPS/1550.
E:\FR\FM\10AUR2.SGM
10AUR2
49264
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
contract). Under section
1886(b)(3)(B)(viii)(IX)(bb) of the Act, in
the case of a specified area or medical
topic determined appropriate by the
Secretary for which a feasible and
practical measure has not been endorsed
by the entity with a contract under
section 1890(a) of the Act, the Secretary
may specify a measure that is not so
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary.
We reviewed NQF-endorsed measures
and were unable to identify any other
NQF-endorsed measures on this topic,
and, therefore, we believe the exception
in section 1886(b)(3)(B)(viii)(IX)(bb) of
the Act applies.
khammond on DSKJM1Z7X2PROD with RULES2
(2) Overview of Measure
The original THA/TKA Complication
measure (NQF # 1550) was previously
removed from the Hospital IQR
Program, but is currently implemented
in the Hospital VBP Program (79 FR
50062 through 50063). Adopting the
newly refined version of this measure
into the Hospital IQR Program will
expand the measure outcome to include
26 additional mechanical complication
ICD–10 codes. We note that aside from
the additional ICD–10 codes, measure
specifications align with the version of
the measure currently in use in the
Hospital VBP Program.
(3) Data Sources
The updated THA/TKA Complication
measure uses index admission
diagnoses and in-hospital comorbidity
data from Medicare Part A claims.
Additional comorbidities prior to the
index admission are assessed using Part
A inpatient, outpatient, and Part B office
visit Medicare claims in the 12 months
prior to index (initial) admission.
Enrollment status is obtained from the
Medicare Enrollment Database which
contains beneficiary demographic,
benefit/coverage, and vital status
information. We proposed to use claims
data with admission dates beginning
from April 1, 2019–March 31, 2022
(excluding data from the period covered
by the ECE granted by CMS related to
the COVID–19 Public Health Emergency
(PHE)) that is associated with the FY
2024 payment determination. As a
claims-based measure, hospitals will not
be required to submit additional data for
calculating the measure.
(4) Outcome
The outcome for the updated THA/
TKA Complication measure is any
complication occurring during the index
admission (not coded as present on
admission (POA)) to 90 days post-date
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
of the index admission. Complications
are counted in the measure only if they
occur during the index hospital
admission or during a readmission. The
complication outcome is a dichotomous
(yes/no) outcome. If a patient
experiences one or more of these
complications in the applicable time
period, the complication outcome for
that patient is counted in the measure
as a ‘‘yes.’’
The updated measure includes the
following 26 additional clinically vetted
mechanical complication ICD–10 codes:
• M96.65 Fracture of pelvis following
insertion of orthopedic implant, joint
prosthesis, or bone plate;
• M96.661 Fracture of femur
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
right leg;
• M96.662 Fracture of femur
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
left leg;
• M96.669 Fracture of femur
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
unspecified leg;
• M96.671 Fracture of tibia or fibula
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
right leg;
• M96.672 Fracture of tibia or fibula
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
left leg;
• M96.679 Fracture of tibia or fibula
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
unspecified leg;
• M97.01XA Periprosthetic fracture
around internal prosthetic right hip
joint, initial encounter;
• M97.01XD Periprosthetic fracture
around internal prosthetic right hip
joint, subsequent encounter;
• M97.01XS Periprosthetic fracture
around internal prosthetic right hip
joint, sequela;
• M97.02XA Periprosthetic fracture
around internal prosthetic left hip joint,
initial encounter;
• M97.02XD Periprosthetic fracture
around internal prosthetic left hip joint,
subsequent encounter;
• M97.02XS Periprosthetic fracture
around internal prosthetic left hip joint,
sequela;
• M97.11XA Periprosthetic fracture
around internal prosthetic right knee
joint, initial encounter;
• M97.11XD Periprosthetic fracture
around internal prosthetic right knee
joint, subsequent encounter;
• M97.11XS Periprosthetic fracture
around internal prosthetic right knee
joint, sequela;
PO 00000
Frm 00486
Fmt 4701
Sfmt 4700
• M97.12XA Periprosthetic fracture
around internal prosthetic left knee
joint, initial encounter;
• M97.12XD Periprosthetic fracture
around internal prosthetic left knee
joint, subsequent encounter;
• M97.12XS Periprosthetic fracture
around internal prosthetic left knee
joint, sequela;
• M97.8XXA Periprosthetic fracture
around other internal prosthetic joint,
initial encounter;
• M97.8XXD Periprosthetic fracture
around other internal prosthetic joint,
subsequent encounter;
• M97.8XXS Periprosthetic fracture
around other internal prosthetic joint,
sequela;
• M97.9XXA Periprosthetic fracture
around unspecified internal prosthetic
joint, initial encounter;
• M97.9XXD Periprosthetic fracture
around unspecified internal prosthetic
joint, subsequent encounter;
• M97.9XXS Periprosthetic fracture
around unspecified internal prosthetic
joint, sequela; and
• M96.69 Fracture of other bone
following insertion of orthopedic
implant, joint prosthesis, or bone plate.
During routine measure maintenance,
our analyses showed the addition of
these clinically relevant codes
contributed to an increase in the THA/
TKA national observed complication
rate. Findings demonstrated an increase
of approximately 0.5 percent (from 2.42
percent to 2.93 percent) in the THA/
TKA national observed complication
rate when evaluated for the FY 2021
performance period (April 1, 2016
through March 30, 2019). These findings
suggest that the expanded outcome will
allow the updated THA/TKA
Complication measure to capture a more
complete outcome.
The updated THA/TKA Complication
measure as with the version of measure
currently implemented in the Hospital
VBP Program (86 FR 45279 through
45281), excludes admissions with a
principal or secondary COVID–19
diagnosis, POA, from the measure
outcome, as outcomes for patients with
COVID–19 who are receiving THA/TKA
surgery may differ from patients without
COVID–19. The four medical
complication outcomes that this applies
to are:
(1) Acute myocardial infarction (AMI)
during a subsequent inpatient
admission that occurs within seven days
from the start of the index admission;
(2) pneumonia or other acute respiratory
complication during a subsequent
inpatient admission that occurs within
seven days from the start of the index
admission, (3) sepsis/septicemia/shock
during a subsequent inpatient
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
admission that occurs within seven days
from the start of the index admission,
and (4) pulmonary embolism during the
index admission or a subsequent
inpatient admission within 30 days
from the start of the index admission. In
these cases, readmissions with a
principal or secondary diagnosis POA of
COVID–19 (U07.1) will be removed
from the numerator.
We refer readers to the Hip and Knee
Arthroplasty Complications (ZIP) folder
on the CMS.gov Measure Methodology
website at: https://www.cms.gov/
Medicare/Quality-Initiatives-PatientAssessment-Instruments/
HospitalQualityInits/MeasureMethodology for measure specification
details on this newly restructured
measure.
(5) Cohort
The updated THA/TKA Complication
measure continues to include Medicare
FFS beneficiaries, aged 65 years or
older, having a qualifying elective
primary THA or TKA procedure during
the index admission. Beneficiaries must
be enrolled in Medicare FFS Part A and
Part B for the 12 months prior to the
date of admission and enrolled in Part
A during the index admission. We also
note that the updated THA/TKA
Complication measure excludes
admissions with a principal or
secondary COVID–19 diagnosis, POA,
from the measure cohort.
khammond on DSKJM1Z7X2PROD with RULES2
(6) Risk Adjustment
The updated THA/TKA Complication
measure is risk adjusted using clinically
relevant risk variables identified from
inpatient and outpatient claims in the
12 months prior to the procedure. We
will also include a covariate adjustment
for patient history of COVID–19 in the
12 months prior to the admission.
(7) Measure Calculation
The updated THA/TKA Complication
measure will be calculated using a
hospital risk-standardized complication
rate by producing a ratio of the number
of ‘‘predicted’’ complications (that is,
the adjusted number of complications at
a specific hospital based on its patient
population) to the number of
‘‘expected’’ complications (that is, the
number of complications if an average
quality hospital treated the same
patients) for each hospital and then
multiplying the ratio by the national
observed complication rate. For each
hospital, the numerator of the ratio is
the number of complications within the
specified time period (up to 90 days)
predicted on the basis of the hospital’s
performance with its observed case mix,
and the denominator is the number of
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
complications expected based on the
nation’s performance with that
hospital’s case mix. This approach is
analogous to a ratio of ‘‘observed’’ to
‘‘expected’’ used in other types of
statistical analyses. It conceptually
allows for a comparison of a particular
hospital’s performance given its case
mix to an average hospital’s
performance with the same case mix.
We proposed to adopt the newly
restructured version of the THA/TKA
Complication measure beginning with
admission dates from April 1, 2019–
March 31, 2022 (excluding data from the
period covered by the ECE granted by
CMS related to the COVID–19 Public
Health Emergency (PHE)) affecting the
FY 2024 payment determination.
(8) Public Reporting
We will also publicly report the
updated THA/TKA Complication
measure on the Compare tool hosted by
HHS, currently available at: https://
www.medicare.gov/care-compare, or its
successor website, beginning in 2023.
We invited public comment on this
proposal.
Comment: Many commenters
expressed their support for the proposed
adoption into the Hospital IQR Program
of the updated THA/TKA Complication
measure beginning with the FY 2024
payment determination. A commenter
noted that they believe the additional
complications codes are clinically
appropriate to be paired with
arthroplasty and will improve the
measure’s accuracy. A few commenters
noted that they believe measuring and
reporting risk-standardized
complications rates will inform health
care providers about opportunities to
improve care, strengthen incentives for
quality improvement, and promote
improvements in the quality of care
received by patients and the outcomes
they experience. A few commenters
reiterated that they believe this measure
will provide patients with beneficial
information that could guide their
choices regarding where they seek care
for these procedures, increase
transparency for consumers and that it
has the potential to lower health care
costs by decreasing the likelihood of
costly readmissions associated with
these complications.
Response: We thank the commenters
for their support.
Comment: A few commenters did not
support the proposed adoption of the
updated THA/TKA Complication
measure. A commenter expressed
concern that, because they believe that
the majority of these procedures take
place in outpatient settings, hospitals
subject to this measure will be caring for
PO 00000
Frm 00487
Fmt 4701
Sfmt 4700
49265
the sickest patients and therefore subject
to improper penalties. A commenter did
not support the proposed adoption of
the updated the THA/TKA
Complication measure because they did
not believe the updated measure
accurately reflects hospital performance.
Specifically, they expressed concern
that the ICD–10 codes proposed to be
included reflect falls and fractures since
THA/TKA patients are at a greater risk
for falls regardless of the level of care
provided at the hospital. A commenter
recommended that using the ratio of
observed to expected would be an easier
concept to understand than the
currently used ratio of predicted to
expected.
Response: We thank the commenters
for their feedback and acknowledge
their concerns. We are monitoring the
shifts of THA/TKA from the inpatient to
outpatient setting as well as the
potential impacts on this inpatient only
measure. The proposed updated THA/
TKA Complication measure is case mix
adjusted for patient comorbidities and is
a relative performance measure for
hospitals performing these elective
THA/TKA procedures.977 As such, we
believe that this measure accurately
reflects hospital performance even if
patients receiving these procedures in
the inpatient setting tend to be sicker,
on average, than those treated in an
outpatient setting.
We believe this updated measure
provides an accurate representation of
hospital performance. As noted in the
FY 2023 IPPS/LTCH PPS proposed rule
(87 FR 28532 through 28534), during
routine measure maintenance, our
internal analyses showed the addition of
these clinically relevant codes
contributed to an increase in the THA/
TKA national observed complication
rate. Findings demonstrated an increase
of approximately 0.5 percent (from 2.42
percent to 2.93 percent) in the THA/
TKA national observed complication
rate when evaluated for the FY 2021
performance period (April 1, 2016
through March 30, 2019). These findings
suggest that the expanded outcome will
allow the updated THA/TKA
Complication measure to capture a more
complete assessment of complications.
We note while conducting these
analyses, orthopedic surgeons and
clinical coding experts vetted the
additional 26 mechanical complication
ICD–10 codes and agreed they should be
included. Thus, these additions are
977 For more detailed measure specifications, we
refer readers to the ‘‘2022 Procedure-Specific
Complication Measure Updates and Specifications:
THA/TKA’’ at the CMS.gov QualityNet website at:
https://qualitynet.cms.gov/inpatient/measures/
complication/methodology.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49266
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
directly responsive to input from
stakeholders, including hospitals.
Lastly, we thank the commenter for
their recommendation related to the
reporting ratio. We reiterate that, as
proposed in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28532
through 28534), the proposed updated
THA/TKA Complication measure is
calculated using a hospital riskstandardized complication rate by
producing a ratio of the number of
‘‘predicted’’ complications (that is, the
adjusted number of complications at a
specific hospital based on its patient
population) to the number of
‘‘expected’’ complications (that is, the
number of complications if an average
quality hospital treated the same
patients) for each hospital and then
multiplying the ratio by the national
observed complication rate. For each
hospital, the numerator of the ratio is
the number of complications within the
specified time period (up to 90 days)
predicted on the basis of the hospital’s
performance with its observed case mix,
and the denominator is the number of
complications expected based on the
nation’s performance with that
hospital’s case mix.978 This approach is
analogous to a ratio of ‘‘observed’’ to
‘‘expected’’ used in other types of
statistical analyses, and it conceptually
allows for a comparison of a particular
hospital’s performance given its case
mix to an average hospital’s
performance with the same case mix.
Further details on the predicted/
expected calculation approach are
provided within the THA/TKA
Complication Measure Methodology
Report and other publicly available
resources on our QualityNet website,
available at: https://qualitynet.cms.gov/
inpatient/measures/complication/
methodology.
Comment: A few commenters
expressed concern that the required data
collection will be burdensome to
hospitals.
Response: We respectfully disagree
that the proposed updated THA/TKA
Complication measure with the
additional 26 complication codes will
cause significant data collection burden.
Hospitals will not be required to submit
additional data for calculating the
measure as it is a claims-based measure.
As stated in the in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28532
through 28534), the proposed updated
THA/TKA Complication measure uses
index admission diagnoses and inhospital comorbidity data from
Medicare Part A claims. Additional
comorbidities prior to the index
admission are assessed using Part A
inpatient, outpatient, and Part B office
visit Medicare claims in the 12 months
prior to index (initial) admission.
Enrollment status is obtained from the
Medicare Enrollment Database which
contains beneficiary demographic,
benefit/coverage, and vital status
information.979
Comment: A few commenters
expressed concern that the proposed
updates to the THA/TKA Complication
measure would result in two similar,
but not identical, measures in the
Hospital IQR Program and the Hospital
VBP Program. The commenters believe
that public reporting of both measures,
which could yield different results, has
the potential to be misleading or
confusing for providers and patients. A
commenter requested clarification on
how the versions of the measure will be
distinguished in public reporting and
which version of the measure will be in
use for the Overall Hospital Quality Star
Ratings.
Response: We acknowledge the
commenters’ concerns that two slightly
different versions of the measure would
be in use in the Hospital IQR and
Hospital VBP Programs simultaneously.
However, the statutory requirements of
the Hospital VBP Program, as set forth
in section 1886(o) of the Act and at 42
CFR 412.164(b), state that measures
must be publicly reported for one year
prior to the beginning of the
performance period in the Hospital VBP
Program. Therefore, we proposed to
adopt this updated version of the THA/
TKA Complication measure into the
Hospital IQR Program with the intention
to consider proposing the updated
measure for use in the Hospital VBP
Program in the future. As proposed in
the FY 2023 IPPS/LTCH PPS proposed
rule, the proposed updated THA/TKA
Complication measure would be
publicly reported on the Compare tool
hosted by HHS, currently available at:
https://www.medicare.gov/carecompare, or its successor website,
beginning in 2023 (87 FR 28532 through
28534). Overall Hospital Quality Star
Ratings utilize the publicly reported
version of the measure on the Compare
tool, as finalized in the CY 2021 OPPS/
ASC final rule (85 FR 86202). That is,
those ratings would use the proposed
978 For more detailed measure specifications, we
refer readers to the ‘‘2022 Procedure-Specific
Complication Measure Updates and Specifications:
THA/TKA’’ at the CMS.gov QualityNet website at:
https://qualitynet.cms.gov/inpatient/measures/
complication/methodology.
979 For more detailed measure specifications, we
refer readers to the ‘‘2022 Procedure-Specific
Complication Measure Updates and Specifications:
THA/TKA’’ at the CMS.gov QualityNet website at:
https://qualitynet.cms.gov/inpatient/measures/
complication/methodology.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00488
Fmt 4701
Sfmt 4700
updated THA/TKA Complication
measure with the additional 26
complication codes once it is publicly
reported beginning in 2023. Results for
the THA/TKA Complication measure
currently implemented in the Hospital
VBP Program will continue to be
available according to program policies
(for example, on the Provider Data
Catalog) as noted in the FY 2015 IPPS/
LTCH PPS final rule (79 FR 50062
through 50063).
Comment: A commenter expressed
interest in obtaining detailed
information about all relevant
complications, including the 26 newly
added complications, so they can
prepare for potential implementation of
the new measure.
Response: We thank the commenter
for their interest in obtaining the
detailed information on the newly
added mechanical complication ICD–10
codes. We refer the commenter to the
measure specifications as proposed in
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28532 through 28534) and
ICD–10 resources provided publicly
here: https://www.cms.gov/medicare/
icd-10/2023-icd-10-pcs. The annual
Procedure-Specific Complication
Measure Updates and Specifications
Report will be posted during the 2023
spring preview period and will contain
any further details related to the added
codes. This is expected to be available
on our QualityNet website at: https://
qualitynet.cms.gov/inpatient/measures/
complication/methodology.
Comment: A commenter was
concerned by the lack of inclusion of
social risk factors in the measure.
Response: We appreciate commenter’s
feedback. We are committed to
measuring and improving health equity
and addressing social risk factors in
quality measurement. During the last
NQF endorsement maintenance
submission for the original THA/TKA
Complication measure prior to 2022,
comprehensive testing was completed
which included an assessment of the
impact of social risk as captured by dual
eligibility and the AHRQ SES Index.980
The AHRQ SES Index score considers
aspects of socioeconomic status and is
computed using U.S. census data, and
considers factors including median
household income, percentage of
persons below the Federal poverty line,
unemployment, education, property
value, and percentage of persons in
crowded households at the 9-digit zip
code level.981 We found wide variation
981 Bonito A, Bann C, Eicheldinger C, Carpenter
L. Creation of new race-ethnicity codes and
socioeconomic status (SES) indicators for Medicare
beneficiaries. Final Report, Sub-Task. 2008;2.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
in the prevalence of the two social risk
factors we examined, with a large
proportion of hospitals treating zero
patients with these risk factors. We also
found that both had some association
with complication risk. However,
adjustment for these factors did not
have a material impact on hospital
RSCRs.982 Our decisions about which
risk factors should be included in each
measure’s risk adjustment model are
based on whether inclusion of such
variables is likely to make the measures
more successful at illuminating quality
differences and motivating quality
improvement. Given these empiric
findings and program considerations,
we chose not to include these two social
risk factors in the final risk model. In
presenting these results and
interpretation, the NQF re-endorsed the
original measure (NQF #1550) in June of
2021 without adjustment for patientlevel social risk factors.983 We
acknowledge the importance of
balancing these competing
considerations and we plan to continue
to reevaluate this risk adjustment model
and available risk factors on an ongoing
basis, with the goal of producing the
most accurate and fair risk adjustment
models for assessing provider
performance. Further details related to
social risk testing for this measure can
be found from downloading the measure
specifications from NQF’s Surgery Fall
Cycle 2020 project here: https://
nqfappservicesstorage.blob.
core.windows.net/proddocs/22/Fall/
2020/measures/1550/shared/1550.zip.
Comment: A few commenters
encouraged CMS to seek NQF
endorsement of this measure.
Response: We thank the commenters
for their feedback. The NQF re-endorsed
the original measure (NQF #1550) in
June of 2021; 984 and we intend to
submit the updated measure to the NQF
for endorsement maintenance in Fall
2024.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
982 National Quality Forum. Surgery Fall Cycle
2020. Measure Testing (subcriteria 2a2, 2b1–2b6)
Document. November 3, 2020. Available at: https://
nqfappservicesstorage.blob.core.windows.net/
proddocs/22/Fall/2020/measures/1550/shared/
1550.zip.
983 National Quality Forum. Consensus Standards
Approval Committee—Measure Evaluation Web
Meeting, June 2021. Available at: https://
www.qualityforum.org/WorkArea/linkit.
aspx?LinkIdentifier=id&ItemID=95862.
984 National Quality Forum. Consensus Standards
Approval Committee—Measure Evaluation Web
Meeting, June 2021. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=95862.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
6. Refinements to Current Measures in
the Hospital IQR Program Measure Set
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28534), we
proposed refinements to two measures
currently in the Hospital IQR Program
measure set—Hospital-Level, RiskStandardized Payment Associated with
an Episode-of-Care for Primary Elective
THA and/or TKA and Excess Days in
Acute Care (EDAC) After
Hospitalization for Acute Myocardial
Infarction (AMI)—beginning with the
FY 2024 payment determination. We
provide more details on our proposals
in the subsequent discussion.
a. Refinement of the Hospital-Level,
Risk-Standardized Payment Associated
With an Episode of Care for Primary
Elective Total Hip Arthroplasty (THA)
and/or Total Knee Arthroplasty (TKA)
Measure (NQF #3474) Beginning With
the FY 2024 Payment Determination
and for Subsequent Years
(1) Background
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28534 through
28536), we proposed a refinement to the
Hospital-Level, Risk-Standardized
Payment Associated with an Episode of
Care for Primary Elective THA and/or
TKA Measure (NQF #3474) (hereinafter
referred to as the THA/TKA Payment
measure), which expands the measure
outcome to include 26 clinically vetted
mechanism complication ICD–10 codes,
for the FY 2024 payment determination
and subsequent years. For the purposes
of describing the refinement of this
measure, we note that the ‘‘outcome’’ is
defined as hospital-level, riskstandardized payment associated with a
90-day episode-of-care for primary
elective THA and/or TKA.
The THA/TKA Payment measure was
first adopted into the Hospital IQR
Program in the FY 2016 IPPS/LTCH PPS
final rule (80 FR 49680) for the FY 2018
payment determination and subsequent
years. Prior to adopting the measure, the
MAP conditionally supported it on
December 10, 2014, pending a timely
review by the NQF Cost and Resource
Use Standing Committee.985 The MAP
recommended harmonizing and
determining the most parsimonious
approach to measure the costs of hip
and knee replacements to minimize the
burden and confusion of competing
methodologies.986 The original measure
985 https://www.qualityforum.org/Publications/
2014/01/MAP_Pre-Rulemaking_Report__2014_
Recommendations_on_Measures_for_More_than_
20_Federal_Programs.aspx.
986 https://www.qualityforum.org/Publications/
2014/01/MAP_Pre-Rulemaking_Report__2014_
PO 00000
Frm 00489
Fmt 4701
Sfmt 4700
49267
was initially NQF endorsed in June
2019 and will be submitted for the first
re-endorsement in Fall 2022.987
The proposed refined measure was
included on a publicly available
document entitled ‘‘List of Measures
Under Consideration for December 1,
2021’’ 988 (MUC List) with identification
number MUC2021–120. The refined
measure was reviewed by the MAP and
conditionally supported for rulemaking
pending NQF review and endorsement
of the measure update.989
As noted earlier we intend to submit
the revised measure for the first NQF reendorsement in the Fall of 2022. We
note that section
1866(b)(3)(B)(viii)(IX)(aa) of the Act
requires that any measure specified by
the Secretary must have been endorsed
by the entity with a contract under
section 1890(a) of the Act (the NQF is
the entity that currently holds this
contract). Under section
1886(b)(3)(B)(viii)(IX)(bb) of the Act, in
the case of a specified area or medical
topic determined appropriate by the
Secretary for which a feasible and
practical measure has not been endorsed
by the entity with a contract under
section 1890(a) of the Act, the Secretary
may specify a measure that is not so
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary.
We reviewed NQF-endorsed measures
and were unable to identify any other
NQF-endorsed measures on this topic,
and, therefore, we believe the exception
in section 1886(b)(3)(B)(viii)(IX)(bb) of
the Act applies.
(2) Overview of Measure
The proposed measure refinement
will expand the measure outcome to
include 26 mechanical complication
ICD–10 codes to the outcome. This
refinement is in alignment with the
refinement of the updated THA/TKA
Complication measure in section
IX.E.5.i. of this final rule. The data
sources, cohort, inclusion and exclusion
criteria, and risk adjustment remain
substantively unchanged. We proposed
this measure refinement for the FY 2024
payment determination and subsequent
years, reflecting data collected
beginning from April 1, 2019 through
March 31, 2022 admissions (excluding
data from the period covered by the ECE
Recommendations_on_Measures_for_More_than_
20_Federal_Programs.aspx.
987 https://www.qualityforum.org/QPS/QPSTool.
aspx.
988 https://www.qualityforum.org/Publications/
2022/03/MAP_2021-2022_Considerations_for_
Implementing_Measures_Final_Report_-_
Clinicians,_Hospitals,_and_PAC-LTC.aspx.
E:\FR\FM\10AUR2.SGM
10AUR2
49268
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
granted by CMS related to the COVID–
19 PHE).
(3) Data Sources
We did not propose any changes to
the data sources for the THA/TKA
Payment measure. The measure uses
Part A and Part B Medicare
administrative claims data that contain
payments for Medicare FFS
beneficiaries who were hospitalized and
underwent an elective THA/TKA. This
measure uses three years of data.
khammond on DSKJM1Z7X2PROD with RULES2
(4) Outcome
The primary outcome of this measure
is the hospital-level risk-standardized
payment for an elective primary THA/
TKA episode-of-care. This measure
captures payments for Medicare FFS
patients across multiple care settings,
services, and supplies (inpatient,
outpatient, skilled nursing facility,
home health, hospice, physician/
clinical laboratory/ambulance services,
and durable medical equipment,
prosthetics/orthotics, and supplies).
This measure includes patient
copayments as well as payments from
coinsurance.
This measure uses the index
admission for an elective primary THA/
TKA to 90 days postadmission. The
measurement includes all payments for
the first 30 days after admission and
only certain payments based on a predefined set of care settings and services
for days 31–90. Payments in the 31–90day window include readmissions for
complications as defined in the THA/
TKA Complication measure
(Mechanical Complications and
Periprosthetic Joint Infection/Wound
Infection and Other Wound
Complications) (see section IX.E.5.i. of
this final rule for discussion on this
measure), therefore, the expansion of
the definition of mechanical
complications impacts this measure as
well.
As we did not propose any changes
besides the addition of the 26
mechanical complication codes, we
refer readers to the FY 2016 IPPS/LTCH
PPS final rule (80 FR 49674) for
information on the previously adopted
measure specifications. We refer readers
to Hip and Knee Arthroplasty Payment
(ZIP) folder on the CMS.gov
Methodology website at: https://
www.cms.gov/Medicare/QualityInitiatives-Patient-AssessmentInstruments/HospitalQualityInits/
Measure-Methodology for updated
specifications on this measure.
The proposed additional 26
mechanical complication ICD–10 codes
are the following:
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
• M96.65 Fracture of pelvis following
insertion of orthopedic implant, joint
prosthesis, or bone plate;
• M96.661 Fracture of femur
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
right leg;
• M96.662 Fracture of femur
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
left leg;
• M96.669 Fracture of femur
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
unspecified leg;
• M96.671 Fracture of tibia or fibula
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
right leg;
• M96.672 Fracture of tibia or fibula
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
left leg;
• M96.679 Fracture of tibia or fibula
following insertion of orthopedic
implant, joint prosthesis, or bone plate,
unspecified leg;
• M97.01XA Periprosthetic fracture
around internal prosthetic right hip
joint, initial encounter;
• M97.01XD Periprosthetic fracture
around internal prosthetic right hip
joint, subsequent encounter;
• M97.01XS Periprosthetic fracture
around internal prosthetic right hip
joint, sequela;
• M97.02XA Periprosthetic fracture
around internal prosthetic left hip joint,
initial encounter;
• M97.02XD Periprosthetic fracture
around internal prosthetic left hip joint,
subsequent encounter;
• M97.02XS Periprosthetic fracture
around internal prosthetic left hip joint,
sequela;
• M97.11XA Periprosthetic fracture
around internal prosthetic right knee
joint, initial encounter;
• M97.11XD Periprosthetic fracture
around internal prosthetic right knee
joint, subsequent encounter;
• M97.11XS Periprosthetic fracture
around internal prosthetic right knee
joint, sequela;
• M97.12XA Periprosthetic fracture
around internal prosthetic left knee
joint, initial encounter;
• M97.12XD Periprosthetic fracture
around internal prosthetic left knee
joint, subsequent encounter;
• M97.12XS Periprosthetic fracture
around internal prosthetic left knee
joint, sequela;
• M97.8XXA Periprosthetic fracture
around other internal prosthetic joint,
initial encounter;
• M97.8XXD Periprosthetic fracture
around other internal prosthetic joint,
subsequent encounter;
PO 00000
Frm 00490
Fmt 4701
Sfmt 4700
• M97.8XXS Periprosthetic fracture
around other internal prosthetic joint,
sequela;
• M97.9XXA Periprosthetic fracture
around unspecified internal prosthetic
joint, initial encounter;
• M97.9XXD Periprosthetic fracture
around unspecified internal prosthetic
joint, subsequent encounter;
• M97.9XXS Periprosthetic fracture
around unspecified internal prosthetic
joint, sequela; and
• M96.69 Fracture of other bone
following insertion of orthopedic
implant, joint prosthesis, or bone plate.
We proposed the addition of these
codes as proposed refinements to the
THA/TKA Payment measure in
response to recent analyses during
routine measure maintenance showing
that the addition of these codes will
increase the national observed
complication rate within the proposed
THA/TKA Complication measure (NQF
#1550) discussed earlier in this final
rule. This demonstrates that the
exclusion of these codes could result in
missed complications. A number of
clinicians in the field of orthopedics
vetted the proposed addition of the new
ICD–10 codes to identify the
complications of care. As described in
section IX.E.5.i. of the preamble of this
final rule, we anticipate the inclusion of
these additional complication codes
will increase the national observed
complication rate and therefore may
impact payments. Payments in the 31–
90-day window are included
readmissions for complications as
defined in the proposed THA/TKA
Complication measure (Mechanical
Complications and Periprosthetic Joint
Infection/Wound Infection and Other
Wound Complications), therefore, the
expansion of the definition of
mechanical complications impacts the
THA/TKA Payment measure as well.
Since the payment measure uses these
codes for payment included in the post30-day window, we also anticipate an
increase in total payments.
These refinements to the measure will
be effective for admissions from April 1,
2019 through March 31, 2022 (excluding
data from the period covered by the ECE
granted by CMS related to the COVID–
19 PHE) and impacting the FY 2024
payment determination and subsequent
years.
We invited public comment on this
proposal.
Comment: Several commenters
expressed their support for adoption of
refinements to the THA/TKA Payment
measure beginning with the FY 2024
payment determination.
Response: We thank the commenters
for their support.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Comment: A few commenters
recommended we update the testing and
achieve endorsement of the proposed
refinements from NQF before
implementation in the Hospital IQR
Program. They additionally
recommended we consider delaying
measure adoption until NQF
endorsement is achieved, if unable to be
endorsed prior to the proposed
implementation timeline. A commenter
expressed that they do believe the
refined measure to be an improvement
over the current version, and while they
agreed that it would capture
complications being missed by the
current measure version, they noted a
concern about overlap between this
episode payment measure and the
MSPB Hospital measure that we are also
proposing to adopt into to the Hospital
IQR Program beginning with the FY
2024 payment determination.
Response: We thank the commenters
for their feedback. As noted in the FY
2023 IPPS/LTCH PPS proposed rule (87
FR 28534 through 28536), we intend to
submit the revised measure for the first
NQF re-endorsement cycle in the Fall of
2022. Under section
1886(b)(3)(B)(viii)(IX)(bb) of the Act, in
the case of a specified area or medical
topic determined appropriate by the
Secretary for which a feasible and
practical measure has not been endorsed
by the entity with a contract under
section 1890(a) of the Act, the Secretary
may specify a measure that is not so
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary.
We reviewed NQF-endorsed measures
and were unable to identify any other
NQF-endorsed measures on this topic,
and, therefore, we believe the exception
in section 1886(b)(3)(B)(viii)(IX)(bb) of
the Act applies.
We acknowledge the commenters
concerns about overlap between the
episode payment measure and the
revised MSPB Hospital measure
discussed in section IX.E.5.h. of the
preamble of this final rule. Although the
revised MSPB Hospital and THA/TKA
Payment measures are aligned in how
the outcome is determined by using the
same claim standardization process, the
revised MSBP Hospital measure cohort
includes most, if not all inpatient
admissions at a hospital (that is, it is
broader) while the cohort of the THA/
TKA Payment measure is more narrow
and aligns with the THA/TKA
Complication measure. The THA/TKA
Payment measure was developed to be
viewed in combination with the THA/
TKA Complication measure as an
indicator of value of care. Therefore, the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
revised MSPB Hospital and THA/TKA
Payment measures serve different
purposes.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
b. Refinement of the Excess Days in
Acute Care (EDAC) After
Hospitalization for Acute Myocardial
Infarction (AMI) Measure (NQF #2881)
Beginning With the FY 2024 Payment
Determination and for Subsequent Years
(1) Background
The EDAC After Hospitalization for
AMI (hereinafter referred to as AMI
EDAC) measure was initially adopted in
the Hospital IQR Program in the FY
2016 IPPS/LTCH PPS final rule (FR 80
49660 through 49690) beginning with
the FY 2018 payment determination.
The measure is intended to capture the
quality-of-care transitions provided to
discharged patients hospitalized with
AMI by collectively measuring a set of
adverse acute care outcomes that can
occur post-discharge: (1) ED visits, (2)
observation stays, and (3) unplanned
readmissions at any time during the 30
days post-discharge. Safely transitioning
patients from hospital to home requires
a complex series of tasks including
timely and effective communication
between providers, prevention of and
response to complications, patient
education about post-discharge care and
self-management, timely follow-up, and
more. Suboptimal transitions contribute
to a variety of adverse events postdischarge, including ED evaluation,
need for observation, and readmission.
Within the Hospital IQR Program’s
measure set, the AMI EDAC measure
illuminates post-discharge outcomes
that are important to patients, better
informs consumers about care quality,
and incentivizes improvement in
transitional care.
(2) Overview of Measure
We proposed to refine this measure by
increasing the minimum case count for
reporting. The NQF Scientific Methods
Panel Committee and stakeholder
feedback indicated that the measure’s
reliability was not adequate. Therefore,
we proposed to increase the reporting
threshold to 50 cases in an effort to
balance the need to include as many
hospitals as possible while maintaining
acceptable measure reliability.990 The
remainder of the AMI EDAC measure
specifications, including the data
990 National Quality Forum. Scientific Methods
Panel: Spring 2021 Measure Evaluation Meeting
Transcript. March 30, 2021. https://
www.qualityforum.org/Measuring_Performance/
Scientific_Methods_Panel/Docs/Transcript_
03302021.aspx.
PO 00000
Frm 00491
Fmt 4701
Sfmt 4700
49269
sources, outcome, cohort, exclusion
criteria, risk adjustment approach, and
measure calculation will remain
unchanged as compared to what is
currently adopted in the Hospital IQR
Program.
For more detailed measure
specifications, we refer readers to the
‘‘2017 Condition-Specific Measures
Updates and Specifications Report
Hospital-Level 30-Day RiskStandardized Excess Days in Acute Care
Measures: Acute Myocardial
Infarction—Version 2.0’’ available in the
AMI, HF Excess Days in Acute Care
folder on the CMS.gov Measure
Methodology website at: https://
www.cms.gov/Medicare/QualityInitiatives-Patient-AssessmentInstruments/HospitalQualityInits/
Measure-Methodology and the CMS.gov
QualityNet website at: https://
qualitynet.cms.gov/inpatient/measures/
complication/methodology.
(3) Update to Minimum Case Count
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28536), we
proposed a refinement to the currently
adopted version of the AMI EDAC
measure to increase the minimum case
count of 25 to a minimum case count of
50 during the measurement period. The
increase to the minimum case count
will improve the measure’s reliability.
Based on internal analyses using the
reporting period July 1, 2016 through
June 30, 2019, the split-sample
intraclass correlation (ICC) with
Spearman Brown Adjustment increased
when we increased the minimum case
count from .384 with 25 admissions to
.402 with 50 admissions. Based on our
analysis, the mean performance rate for
all hospitals was 3.6 excess days per 100
discharges, with a standard deviation of
26.3. For hospitals with at least 50
admissions in the same performance
period, the mean performance rate was
6.9 per 100 discharges, with a standard
deviation of 22. Additionally, 1,805
hospitals of 4,074 hospitals (or 44.3
percent) meet the minimum case count
of 50 admissions for the same
performance period.
Based on this improvement in
reliability, we proposed to increase the
AMI EDAC measure’s minimum case
count reporting threshold from 25 to 50
beginning with the FY 2024 payment
determination using the reporting
period July 1, 2019 through June 30,
2022 (excluding data from the period
covered by the ECE granted by CMS
related to the COVID–19 PHE), for
which public display of the measure
results will occur as part of a 2023
Compare website refresh (or as soon as
operationally feasible thereafter), and
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49270
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
for subsequent years. Hospitals with
fewer than 50 cases for the AMI EDAC
measure will continue to receive
confidential feedback reports containing
measure results to understand their
performance. Public reporting of
measure results on the Compare tool
hosted by HHS, currently available at:
https://www.medicare.gov/carecompare, or its successor website, will
only occur for hospitals meeting the 50
minimum cases required for reporting.
Hospitals will not need to submit
additional data as the AMI EDAC
measure is calculated using
administrative claims submitted to CMS
for payment purposes.
We invited public comment on this
proposal.
Comment: Several commenters
expressed their support for the proposed
refinements to the AMI EDAC measure
beginning with the FY 2024 payment
determination. A few commenters noted
that they believe increasing the
minimum denominator for the AMI
EDAC measure from 25 to 50 cases
improves measure reliability.
Response: We thank the commenters
for their support of our proposal to
increase the AMI EDAC measure’s
minimum case count reporting
threshold from 25 to 50 cases.
Comment: A few commenters
recommended that the AMI EDAC
measure be removed from the Hospital
IQR Program. A commenter stated they
do not believe the measure adds value
to the Hospital IQR Program. Other
commenters expressed concerns with
the measure outcome being a
combination of readmissions,
observation stays, and ED visits into a
single category, stating their belief that
each of these settings reflect widely
different approaches to patient-centered
care and cannot be meaningfully
interpreted from a single number of
days. Commenters added that they
believe CMS added the AMI EDAC
measure with the assumption that the
then-new readmission measures would
increase use of observation stays and ED
visits and stated that evidence to
support that assumption is not
available.
Response: We thank the commenters
for their input but we respectfully
disagree that the measure does not add
value to the Hospital IQR Program or
that it should be removed. We believe
the measure adds value to the Hospital
IQR Program because the measure
illuminates additional post-discharge
outcomes that are important to patients
beyond readmissions only, better
informs consumers about care quality,
and incentivizes improvement in
transitional care. Regarding the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
commenters’ concern about combining
the count of days for readmissions,
observation stays or ED visits, we
believe this single count can be
meaningfully interpreted because, from
a patient perspective, it is the count of
total days that is most meaningful and
representative of the disruption, cost, or
risk. This measure is meant to provide
patients with a complete picture of
potential post-discharge acute care use.
For this reason, the AMI EDAC
measure’s outcome is expressed in days,
and we combine day counts for each
type of event and do not publicly report
rates of each type of event. Further
information on the public reporting of
the measure can be accessed here:
https://data.cms.gov/provider-data/
topics/hospitals/unplanned-hospitalvisits/. Regarding the commenters’
concern related to different approaches
to patient centered care, we note that
the measure developer’s discussions
with patients and the TEP, as well as
published literature, indicate that acute
care utilization after discharge (that is,
return to the ED, observation stay, and
readmission), for any reason, is
disruptive to patients and caregivers,
costly to the healthcare system, and puts
patients at additional risk of hospitalacquired infections and complications.
We are confident that for most patients,
remaining home or remaining in a nonacute setting rather than returning to the
hospital indicates a better outcome.
Although some hospital returns are
unavoidable, others may result from
poor quality of care, overutilization of
care, or inadequate transitional care.
Transitional care includes effective
discharge planning, transfer of
information at the time of discharge,
patient assessment and education, and
coordination-of-care and monitoring in
the post-discharge period. When
appropriate care transition processes are
in place (for example, a patient is
discharged to a suitable location,
communication occurs between
clinicians, medications are correctly
reconciled, timely follow-up is
arranged), fewer patients return to an
acute care setting, either for an ED visit,
observation stay, or hospital
readmission during the 30 days postdischarge. Numerous studies have
found an association between quality of
inpatient or transitional care and early
(typically 30-day) readmission
rates 991 992 993 994 995 996 997 998 999 and
991 Corrigan JM, Martin JB. Identification of
factors associated with hospital readmission and
development of a predictive model. Health Serv
Res. Apr 1992;27(1):81–101.
992 Oddone EZ, Weinberger M, Horner M, et al.
Classifying general medicine readmissions. Are
they preventable? Veterans Affairs Cooperative
PO 00000
Frm 00492
Fmt 4701
Sfmt 4700
ED visits 1000 1001 1002 1003 1004 for a wide
range of conditions including AMI.
In response to the commenters’ stated
assumption that the AMI EDAC measure
may have been developed out of
concern for the use of observation stays
and ED visits in lieu of readmission
without evidence that either are being
substituted for readmissions, we
reiterate that we developed the measure
to provide a broad perspective on postdischarge events. The goal of the
measure is not to prevent hospitals from
keeping patients in the ED or
observation units; it is to help patients
and providers understand variation
among hospitals in the days that are
spent by patients in acute care settings
Studies in Health Services Group on Primary Care
and Hospital Readmissions. Journal of General
Internal Medicine. 1996;11(10):597–607.
993 Benbassat J, Taragin M. Hospital readmissions
as a measure of quality of health care: advantages
and limitations. Arch Intern Med. Apr 24
2000;160(8):1074–1081.
994 Frankl SE, Breeling JL, Goldman L.
Preventability of emergent hospital readmission.
Am J Med. Jun 1991;90(6):667–674.
995 Halfon P, Eggli Y, Pr, et al. Validation of the
potentially avoidable hospital readmission rate as a
routine indicator of the quality of hospital care.
Medical Care. Nov 2006;44(11):972–981.
996 Hernandez AF, Greiner MA, Fonarow GC, et
al. Relationship between early physician follow-up
and 30-day readmission among Medicare
beneficiaries hospitalized for heart failure. JAMA:
the journal of the American Medical Association.
May 5 2010;303(17):1716–1722.
997 Courtney EDJ, Ankrett S, McCollum PT. 28Day emergency surgical re-admission rates as a
clinical indicator of performance. Ann R Coll Surg
Engl. Mar 2003;85(2):75–78.
998 Hernandez AF, Greiner MA, Fonarow GC, et
al. Relationship between early physician follow-up
and 30-day readmission among Medicare
beneficiaries hospitalized for heart failure. JAMA:
the journal of the American Medical Association.
May 5 2010;303(17):1716–1722.
999 Ashton CM, Del Junco DJ, Souchek J, Wray
NP, Mansyur CL. The association between the
quality of inpatient care and early readmission: a
meta-analysis of the evidence. Med Care. Oct
1997;35(10):1044–1059.
1000 Baer RB, Pasternack JS, Zwemer FL, Jr.
Recently discharged inpatients as a source of
emergency department overcrowding. Academic
emergency medicine: official journal of the Society
for Academic Emergency Medicine. Nov
2001;8(11):1091–1094.
1001 Kuo YF, Goodwin JS. Association of
hospitalist care with medical utilization after
discharge: evidence of cost shift from a cohort
study. Annals of internal medicine. Aug
22011;155(3):152–159.
1002 Nunez S, Hexdall A, Aguirre-Jaime A.
Unscheduled returns to the emergency department:
an outcome of medical errors? Quality & safety in
health care. Apr 2006;15(2):102–108.
1003 Balaban RB, Weissman JS, Samuel
PA,Woolhandler S. Redefining and redesigning
hospital discharge to enhance patient care: a
randomized controlled study. J Gen Intern Med.Aug
2008;23(8):1228–1233.
1004 Koehler BE, Richter KM, Youngblood L, et al.
Reduction of 30-day postdischarge hospital
readmission or emergency department (ED) visit
rates in high-risk elderly medical patients through
delivery of a targeted care bundle. J Hosp Med. Apr
2009;4(4):211–218.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
following a discharge for AMI, as
discussed in the FY 2016 IPPS/LTCH
PPS proposed rule (80 FR 24574
through 24576).
Comment: A commenter noted they
appreciate our responsiveness to the
concerns of the NQF’s Scientific
Methods Panel and thereby increased
the case minimum to 50 patients to
improve the intraclass correlation
coefficient (ICC) result but suggested
that measures should have a minimum
ICC reliability threshold of 0.6 or higher.
The commenter noted that reaching 0.6
or higher for this measure would require
a minimum of 300 cases, which would
in turn exclude too many hospitals from
the measure and therefore believe it is
not appropriate for use in the Hospital
IQR Program.
Response: We thank the commenter
for their feedback. We agree that is it
important to balance the need to include
as many hospitals as possible while
maintaining acceptable measure
reliability. We would like to further
clarify that during the NQF Spring 2021
Measure Evaluation Meeting, the NQF
Scientific Methods Panel Committee
indicated that a split-sample ICC
threshold of around 0.4 or higher is
considered acceptable measure
reliability.1005 As noted previously in
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28536), the proposed
refinement of increasing the minimum
case count from 25 to 50 will increase
the ICC with Spearman Brown
Adjustment from 0.384 to 0.402,
therefore improving the measure’s
reliability and meeting an acceptable
threshold as determined by the NQF
Scientific Methods Panel Committee’s
guidance at that time. As guidance on
acceptable reliability is often changing,
we will continue to take this into
consideration as we conduct routine
measure maintenance.
Comment: A few commenters offered
recommendations for ongoing
reevaluation of the AMI EDAC measure.
A commenter recommended we
consider how the COVID–19 pandemic
may pose challenges to timely
discharge, as hospitals may face
constraints due to other health care
settings (for example, a skilled nursing
facility) being unable to promptly accept
patients. Another commenter
recommended that we should identify
methods to address the issue of fewer
1005 National Quality Forum. Scientific Methods
Panel: Spring 2021 Measure Evaluation Meeting
Transcript. March 30, 2021. Available at: https://
www.qualityforum.org/Measuring_Performance/
Scientific_Methods_Panel/Docs/Transcript_
03302021.aspx.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
hospitals meeting the proposed
increased minimum case count and
suggested that we could remedy this
issue by using all-payer claims data to
increase the denominator, improve
reliability, include additional risk
factors, and increase the relevancy of
the measure to a broader base of
providers and consumers.
Response: We thank the commenter
for their feedback to consider the impact
of the COVID–19 pandemic on timely
discharge, specifically the concern that
the pandemic has presented novel
circumstances that might extend the
length of a patient’s stay in situations in
which a hospital is ready to discharge
a patient to another healthcare setting
but is unable to do so because the other
setting, for instance, is unable or
unwilling to accept new patients due to
issues related to COVID–19. The
following COVID–19 adjustments have
been made to the AMI EDAC measure
for 2022 public reporting as technical
updates: (1) Exclusion of COVID–19
patients (ICD–10–CM U07.1) from the
cohort; (2) claims for ED visits,
observation stays, and readmissions
with COVID–19 coding (ICD–10–CM
U07.1) are not eligible for the AMI
EDAC outcome and are excluded; and
(3) addition of a new ‘‘History of
COVID–19’’ risk variable for risk
adjustment. The COVID–19 pandemic
continues to have significant and
enduring effects on the provision of
medical care in the country and around
the world. It affects care decisions,
including readmissions to the hospital.
National or regional shortages or
changes in healthcare personnel,
medical supplies, equipment, diagnostic
tools, and patient case volumes or
facility-level case mix may affect quality
measurement data.1006 Adjustments to
public reporting methodologies and
specifications for 2022 help to ensure
the intent of the measures is
maintained. Further details of COVID–
19 adjustment can be accessed by
viewing the 2022 Condition-Specific
Excess Days in Acute Care Measures
Updates and Specifications Report:
AMI, HF, and the Pneumonia and 2022
AMI EDAC Measure Code Specifications
Supplemental File, both available on the
QualityNet website here: https://
qualitynet.cms.gov/inpatient/measures/
edac/methodology.
We appreciate the suggestion of
utilizing all-payer claims data to
1006 The
Centers for Medicare and Medicaid. 2022
Condition-Specific Excess Days in Acute Care
Measures Updates and Specifications Report: AMI,
HF. Available at: https://qualitynet.cms.gov/
inpatient/measures/edac/methodology.
PO 00000
Frm 00493
Fmt 4701
Sfmt 4700
49271
increase the number of hospitals with at
least 50 cases, and we will take this into
consideration when planning ongoing
measure maintenance analyses.
Hospitals with fewer than 50 cases for
the AMI EDAC measure will continue to
receive confidential feedback reports
containing measure results to
understand their performance.
Comment: A commenter requested
that CMS explain their rationale for
proposing the case minimum
refinements based on reliability
concerns for only the AMI EDAC
measure and not including the Excess
Days in Acute Care after Hospitalization
for Pneumonia (NQF #2882)
(Pneumonia EDAC) and Excess Days in
Acute Care after Hospitalization for
Heart Failure (NQF #2880) (Heart
Failure EDAC) measures for
consistency. The commenter expressed
an assumption that the Pneumonia
EDAC and Heart Failure EDAC
measures would also be affected by the
same reliability concerns as the AMI
EDAC measure and would therefore
need to adopt the same minimum case
count to improve reliability.
Response: We thank the commenter
for sharing these concerns. We would
like to clarify that the NQF Scientific
Methods Panel Committee did not raise
concerns with reliability regarding the
Pneumonia EDAC or Heart Failure
EDAC measures, therefore, refinements
for these measures were not proposed
alongside those for the AMI EDAC
measure. During the Spring 2021 project
cycle, NQF’s Scientific Methods Panel
Committee reviewed and passed both
Pneumonia EDAC and Heart Failure
EDAC measures on reliability with a
rating of moderate, and NQF’s All-Cause
Admissions and Readmissions Standing
Committee voted to uphold the
Scientific Methods Panel Committee’s
rating on reliability. Thus, as both
Pneumonia EDAC and Heart Failure
EDAC measures were found to have met
the NQF’s Scientific Acceptability
criteria, we did not propose reliability
related refinements to these measures at
this time.1007 Further details regarding
NQF’s ratings on reliability for these
measures can be accessed here: https://
www.qualityforum.org/Publications/
2022/02/All-Cause_Admissions_and_
Readmissions_Final_Report_-_Spring_
2021_Cycle.aspx.
1007 National Quality Forum. All-Cause
Admissions and Readmissions, Spring 2021 Cycle:
CDP Report February 14, 2022. Available at: https://
www.qualityforum.org/Publications/2022/02/AllCause_Admissions_and_Readmissions_Final_
Report_-_Spring_2021_Cycle.aspx.
E:\FR\FM\10AUR2.SGM
10AUR2
49272
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
7. Summary of Previously Finalized and
New Hospital IQR Program Measures
IQR Program measure set for the FY
2024 payment determination:
a. Summary of Previously Finalized and
New Hospital IQR Program Measures for
the FY 2024 Payment Determination
BILLING CODE 4120–01–P
khammond on DSKJM1Z7X2PROD with RULES2
This table summarizes the previously
finalized and newly finalized Hospital
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00494
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49273
TABLE IX.E-09. MEASURES FOR THE FY 2024 PAYMENT DETERMINATION
Short Name
HCP Influenza
Vaccination
HCP COVID-19
Vaccination
Measure Name
National Healthcare Safetv Network Measures
NQF#
Influenza Vaccination Coverage Among Healthcare Personnel
0431
..
• In this final rule, we are finahzmg adoptrnn ofa refined Hospital-Level R1sk-Standard1zed Comphcatrnn Rate (RSCR) Followmg Eleclive
Primary THA and/or TKA measure beginning with the FY 2024 payment determination and for subsequent years. We refer readers to section
IX.E.5.i. for more detailed discussion.
•• In the FY 2020 IPPS/LTCH PPS final rule, we removed the claims-only Hospital-Wide All-Cause Unplanned Readmission (HWR claimsonly) measure (NQF # 1789) and replaced it with the Hybrid HWR measure (NQF #2879), beginning with the FY 2026 payment determination
(84 FR 42465 through 42481). The removal of the HWR claims-only measure was contingent on our finalizing our proposal to adopt the Hybrid
HWR measure. We finalized our proposal to align the removal of the HWR clainls only measure such that its removal aligns with the end of the
finalized 2-year voluntary reporting period and the beginning of the fmalized mandatory data submission and public reporting of the Hybrid
HWR measure.
••• In this final rule, we are finalizing refinements to two current Hospital !QR Program measures-Hospital-Level, Risk-Standardized Payment
Associated with an Episode-of-Care for Primary Elective THA/TKA and Excess Days in Acute Care (EDAC) after Hospitalization for Acute
Myocardial Infarction (AMI}-beginning with the FY 2024 payment determination. We refer readers to sections IX.E.6.a. and IX.E.6.b,
respectively, for more detailed discussion.
•••• In this final rule, we are fmalizing adoption of a refmed the MSPB Hospital measure beginning with the FY 2024 payment determination.
We refer readers to section IX.E.5.h. for more detailed discussion.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00495
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.165
khammond on DSKJM1Z7X2PROD with RULES2
COVID-19 Vaccination Coverage Among Health Care Personnel
NIA
Claims-Based Patient Safety Measures
Death Rate among Surgical Inpatients with Serious Treatable
Complications (CMS Recalibrated Death Rate among Surgical Inpatients
with Serious Treatable Complications)
CMS PSI-04
0351
Claims-Based Outcome Measures
Hospital 30-Day, All-Cause, Risk Standardized Mortality- Rate Following
MORT-30-STK
Acute Ischemic Stroke
NIA
Hospital-Level Risk-Standardized Complication Rate (RSCR) Following
COMP-HIP-KNEE*
Elective Primarv THA and/or TKA
1550
Claims-Based Coordination of Care Measures
Hospital-Wide All-Cause Unplanned Readmission Measure (HWR)
READM-30-HWR**
1789
Excess Days in Acute Care after Hospitalization for Acute Myocardial
AMI Excess Days***
Infarction
2881
HF Excess Days
Excess Days in Acute Care after Hospitalization for Heart Failure
2880
Excess Davs in Acute Care after Hospitalization for Pneumonia
PN Excess Davs
2882
Claims-Based Pavment Measures
Hospital-Level, Risk-Standardized Payment Associated with a 30-Day
AMI Payment
Episode-of-Care for Acute Myocardial Infarction (AMI)
2431
Hospital-Level, Risk-Standardized Payment Associated with a 30-Day
HFPavment
Episode-of-Care For Heart Failure (HF)
2436
Hospital-Level, Risk-Standardized Payment Associated with a 30-day
Episode-of-Care For Pneumonia
2579
PNPavment
Hospital-Level, Risk-Standardized Payment Associated with an Episodeof-Care for Primary Elective Total Hip Arthroplasty and/or Total Knee
THA/TKA Pavment***
Arthroplastv
3474
Medicare Spending Per Beneficiarv rMSPB)-Hospital
MSPB****
2158
Claims and Electronic Data Measures
HvbridHWR**
Hybrid Hospital-Wide All-Cause Readmission Measure (HWR)
2879
Chart-Abstracted Clinical Process of Care Measures
PC-01
Elective Deliverv
0469
Severe Sepsis and Septic Shock: Management Bundle (Composite
Sepsis
Measure)
0500
Structural Measures
Maternal Morbiditv
Maternal Morbiditv Structural Measure
NIA
EHR-based Clinical Process of Care Measures (that is, Electronic Clinical Quality Measures (eCQMs))
ED-2
Admit Decision Time to ED Departure Time for Admitted Patients
0497
Exclusive Breast Milk Feeding
PC-05
0480
Safe Use ofOpioids
Safe Use of Opioids - Concurrent Prescribing
3316e
STK-02
Discharged on Antithrombotic Therapy
0435
Anticoalllilation TheraPv for Atrial Fibrillation/Flutter
0436
STK-03
Antithrombotic Therapy bv the End of Hospital Dav Two
STK-05
0438
STK-06
Discharged on Statin Medication
0439
VTE-1
Venous Thromboembolism ProPhvlaxis
0371
VTE-2
Intensive Care Unit Venous Thromboembolism Prophvlaxis
0372
Patient Experience of Care Survev Measures
Hospital Consumer Assessment of Healthcare Providers and Systems
0166
(0228)
HCAHPS
Survey (including Care Transition Measure)
49274
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
b. Summary of Previously Finalized and
New Hospital IQR Program Measures for
the FY 2025 Payment Determination
IQR Program measure set for the FY
2025 payment determination:
khammond on DSKJM1Z7X2PROD with RULES2
This table summarizes the previously
finalized and newly finalized Hospital
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00496
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
49275
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE IX.E-10. MEASURES FOR THE FY 2025 PAYMENT DETERMINATION
Measure Name
National Healthcare Safety Network Measures
HCP Influenza Vaccination
Influenza Vaccination Coverage Among Healthcare Personnel
COVID-19 Vaccination Coverage Among Health Care Personnel
HCP COVID-19 Vaccination
Claims-Based Patient Safety Measures
Death Rate among Surgical Inpatients with Serious Treatable Complications (CMS
Recalibrated Death Rate among Surgical Inpatients with Serious Treatable
CMS PSI-04
Complications)
Claims-Based Mortality/Complications Measures
Hospital 30-Day, All-Cause, Risk Standardized Mortality- Rate Following Acute
MORT-30-STK
Ischemic Stroke
Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective
COMP-HIP-KNEE*
Primarv THA and/or TKA
Claims-Based Coordination of Care Measures
READM-30-HWR**
Hospital-Wide All-Cause Unplanned Readmission Measure (HWR)
AMI Excess Days***
Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction
HF Excess Days
Excess Days in Acute Care after Hospitalization for Heart Failure
PN Excess Days
Excess Days in Acute Care after Hospitalization for Pneumonia
Claims-Based Payment Measures
Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care
AMI Payment
for Acute Myocardial Infarction (AMI)
Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care
HF Payment
For Heart Failure (HF)
Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-of-Care
PNPayment
For Pneumonia
Hospital-Level, Risk-Standardized Payment Associated with an Episode-of-Care for
THA/TKA Payment***
Primarv Elective Total Hip Arthroplasty and/or Total Knee Arthroplasty
Medicare Spending Per Beneficiary (MSPB}-Hospital
MSPB****
Claims and Electronic Data Measures
HybridHWR**
Hybrid Hospital-Wide All-Cause Readmission Measure (HWR)
Hybrid HWM*****
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Measure (HWM)
Chart-Abstracted Clinical Process of Care Measures
Elective Delivery
PC-01
Sepsis
Severe Sepsis and Septic Shock: Management Bundle (Composite Measure)
Structural Measures
Maternal Morbidity
Maternal Morbidity Structural Measure
Hospital Commitment to Health Eauity
HCHE******
EHR-based Clinical Process of Care Measures (that is, Electronic Clinical Quality Measures (eCQMs))
ED-2
Admit Decision Time to ED Departure Time for Admitted Patients
PC-05
Exclusive Breast Milk Feeding
Safe Use ofOpioids
Safe Use of Opioids - Concurrent Prescribing
Discharged on Antithrombotic Therapy
STK-02
Anticowulation Therapy for Atrial Fibrillation/Flutter
STK-03
STK-05
Antithrombotic Therapv bv the End of Hospital Dav Two
STK-06
Discharged on Statin Medication
VTE-1
Venous Thromboembolism Prophylaxis
VTE-2
Intensive Care Unit Venous Thromboembolism Prophylaxis
Hospital Harm-Severe Hypoglycemia Measure
HH-01
Hospital Harm-Severe Hyperglycemia Measure
HH-02
ePC-02*******
Cesarean Birth
Severe Obstetric Complications
ePC-07ISMM*******
Patient Experience of Care Survey Measures
Hospital Consumer Assessment of Healthcare Providers and Systems Survey (including
HCAHPS
Care Transition Measure)
Process Measures
SDOH-1 ********
Screening for Social Drivers of Health
SDOH-2********
Screen Positive Rate for Social Drivers of Health
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00497
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
NQF#
0431
NIA
0351
NIA
1550
1789
2881
2880
2882
2431
2436
2579
3474
2158
2879
3502
0469
0500
NIA
NIA
0497
0480
3316e
0435
0436
0438
0439
0371
0372
3503e
3533e
NIA
NIA
0166
(0228)
NIA
NIA
ER10AU22.166
khammond on DSKJM1Z7X2PROD with RULES2
Short Name
49276
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
* In this final rule, we are finalizing adoption of a refined Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective
Primary THA and/or TKA measure beginning with the FY 2024 payment determination and for subsequent years. We refer readers to section
IX.E.5 .i. for more detailed discussion.
** In the FY 2020 IPPS/L TCH PPS final rule, we removed the claims-only Hospital-Wide All-Cause Unplanned Readmission (HWR claimsonly) measure (NQF # 1789) and replaced it with the Hybrid HWR measure (NQF #2879), beginning with the FY 2026 payment determination
(84 FR 42465 through 42481). The removal of the HWR claims-only measure was contingent on our fmalizing our proposal to adopt the Hybrid
HWR measure. We finalized our proposal to align the removal of the HWR claims only measure such that its removal aligns with the end of the
finalized 2-year voluntary reporting period and the beginning of the finalized mandatory data submission and public reporting of the Hybrid
HWR measure.
*** In this final rule, we are finalizing refinements to two current Hospital IQR Program measures-Hospital-Level, Risk-Standardized Payment
Associated with an Episode-of-Care for Primary Elective THA/TKA and Excess Days in Acute Care (EDAC) after Hospitalization for Acute
Myocardial Infarction (AMI}--beginning with the FY 2024 payment determination. We refer readers to sections IX.E.6.a. and IX.E.6.b,
respectively, for more detailed discussion.
**** In this final rule, we are finalizing adoption of a refined MSPB Hospital measure beginning with the FY 2024 payment determination. We
refer readers to section IX.E.5.h. for more detailed discussion.
***** In the FY 2022 IPPS/L TCH PPS final rule (86 FR 45365), we finalized adoption of the Hybrid HWM measure beginning with one
voluntary reporting period (July 1, 2023-June 30, 2023), followed by mandatory reporting beginning with the July 1, 2023- June 30, 2024
reporting period, impacting the FY 2026 payment determination.
****** In this final rule, we are finalizing the adoption of the Hospital Commitment to Health Equity measure beginning with the CY 2023
reporting period/FY 2025 payment determination and for subsequent years. We refer readers to section IX.E.5.a. for more detailed discussion.
******* In this final rule, we are finalizing two eCQMs beginning with the CY 2023 reporting period/FY 2025 payment determination: Cesarean
Birth and Severe Obstetric Complications. We are finalizing mandatory reporting of these two measures beginning with the CY 2024 reporting
period/FY 2026 payment determination and for subsequent years. We refer readers to sections IX.E.5.c. and IX.E.5.d., respectively, for more
detailed discussion. We also refer readers to section IX.E.10.e. for changes to our eCQM reporting and submission requirements beginning with
the CY 2024 reporting period/FY 2026 payment determination and for subsequent years.
******** In this final rule, we are finalizing adoption of the Screening for Social Drivers of Health measure and the Screen Positive Rate for
Social Drivers of Health measure beginning with voluntary reporting in the CY 2023 reporting period and mandatory reporting in the CY 2024
reporting period/FY 2026 payment determination and for subsequent years. We refer readers to sections IX.E.5.b.(1). and IX.E.5.b.(2),
respectively, for more detailed discussion.
c. Summary of Previously Finalized and
New Hospital IQR Program Measures for
the FY 2026 Payment Determination
IQR Program measure set for the FY
2026 payment determination:
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00498
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.167
khammond on DSKJM1Z7X2PROD with RULES2
This table summarizes the previously
finalized and newly finalized Hospital
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49277
TABLE IX.E-11. MEASURES FOR THE FY 2026 PAYMENT DETERMINATION
Short Name
Measure Name
National Healthcare Safety Network Measures
Influenza Vaccination Coverage Among Healthcare Personnel
HCP Influenza Vaccination
COVID-19 Vaccination Coverage Among Health Care Personnel
HCP COVID-19 Vaccination
Claims-Based Patient Safety Measures
Death Rate among Surgical Inpatients with Serious Treatable Complications (CMS
Recalibrated Death Rate among Surgical Inpatients with Serious Treatable
CMS PSI-04
Complications)
Claims-Based Mortality/Complications Measures
Hospital 30-Day, All-Cause, Risk Standardized Mortality- Rate Following Acute
MORT-30-STK
Ischemic Stroke
Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective
COMP-HIP-KNEE*
Primarv THA and/or TKA
Claims-Based Coordination of Care Measures
AMI Excess Days**
Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction
HF Excess Days
Excess Days in Acute Care after Hospitalization for Heart Failure
PN Excess Days
Excess Days in Acute Care after Hospitalization for Pneumonia
Claims-Based Payment Measures
Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-ofAMI Payment
Care for Acute Myocardial Infarction (AMI)
Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-ofHF Payment
Care For Heart Failure (HF)
Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-ofPNPayment
Care For Pneumonia
Hospital-Level, Risk-Standardized Payment Associated with an Episode-of-Care for
THA/TKA Payment**
Primarv Elective Total Hip Arthroplasty and/or Total Knee Arthroplasty
Medicare Spending Per Beneficiarv (MSPB)-Hospital Measure
MSPB***
Claims and Electronic Data Measures
Hybrid HWM****
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Measure (HWM)
HybridHWR*****
Hybrid Hospital-Wide All-Cause Readmission Measure (HWR)
Chart-Abstracted Clinical Process of Care Measures
PC-01
Elective Delivery
Sepsis
Severe Sepsis and Septic Shock: Management Bundle (Composite Measure)
Structural Measures
Maternal Morbidity
Maternal Morbidity Structural Measure
HCHE******
Hospital Commitment to Health Equity
EHR-based Clinical Process of Care Measures (that is, Electronic Clinical Qualitv Measures (eCQMs)
Safe Use ofOpioids
Safe Use of Opioids - Concurrent Prescribing
Discharged on Antithrombotic Therapy
STK-02
Anticoagulation Therapy for Atrial Fibrillation/Flutter
STK-03
STK-05
Antithrombotic Therapy bv the End of Hospital Dav Two
VTE-1
Venous Thromboembolism Prophylaxis
Intensive Care Unit Venous Thromboembolism Prophylaxis
VTE-2
Hospital Harm-Severe Hypoglycemia Measure
HH-01
Hospital Harm-Severe Hyperglycemia Measure
HH-02
ePC-02*******
Cesarean Birth
d. Summary of Previously Finalized and
New Hospital IQR Program Measures for
the FY 2027 Payment Determination
NQF#
0431
NIA
0351
NIA
1550
2881
2880
2882
2431
2436
2579
3474
2158
3502
2879
0469
0500
NIA
NIA
3316e
0435
0436
0438
0371
0372
3503e
3533e
NIA
IQR Program measure set for the FY
2027 payment determination:
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00499
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.168
khammond on DSKJM1Z7X2PROD with RULES2
This table summarizes the previously
finalized and newly finalized Hospital
49278
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Short Name
ePC-07/SMM*******
HH-ORAE********
GMCS********
HCAHPS
THA/TKA PRO-PM*********
SDOH-1 **********
SDOH-2*********
Measure Name
Severe Obstetric Comolications
Hospital-Harm-Opioid Related Adverse Events
Global Malnutrition Composite Score
Patient Experience of Care Survev Measures
Hospital Consumer Assessment of Healthcare Providers and Systems Survey
(including Care Transition Measure)
Patient-Reported Outcome Performance Measures
Hospital-Level Total Hip Arthroplasty and/or Total Knee Arthroplasty PatientReported Outcome-Based Performance Measure (PRO-PM)
Process Measures
Screening for Social Drivers of Health
Screen Positive Rate for Social Drivers of Health
NQF#
NIA
3501e
3592e
0166
(0228)
3559
NIA
NIA
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00500
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.169
khammond on DSKJM1Z7X2PROD with RULES2
* In this final rule, we are finalizing adoption of a refined Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective
Primary THA and/or TKA measure beginning with FY 2024 payment determination and for subsequent years. We refer readers to section
IX.E.5 .i. for more detailed discussion.
** In this final rule, we are finalizing refinements to two current Hospital IQR Program measures-Hospital-Level, Risk-Standardized Payment
Associated with an Episode-of-Care for Primary Elective THA/TKA and Excess Days in Acute Care (EDAC) after Hospitalization for Acute
Myocardial Infarction (AMI}--beginning with the FY 2024 payment determination. We refer readers to sections IX.E.6.a. and IX.E.6.b,
respectively, for more detailed discussion.
*** In this final rule, we are finalizing adoption of a refined MSPB Hospital measure beginning with the FY 2024 payment determination. We
refer readers to section IX.E.5.h. for more detailed discussion.
**** In the FY 2022 IPPS/L TCH PPS final rule 86 FR 45365, we finalized adoption of the Hybrid HWM measure beginning with one voluntary
reporting period (July I, 2023-June 30, 2023), followed by mandatory reporting beginning with the July I, 2023- June 30, 2024 reporting period,
impacting the FY 2026 payment determination.
***** In the FY 2020 IPPS/L TCH PPS final rule, we removed the claims-only Hospital-Wide All-Cause Unplanned Readmission (HWR claimsonly) measure (NQF # 1789) and replaced it with the Hybrid HWR measure (NQF #2879), beginning with the FY 2026 payment determination
(84 FR 42465 through 42481). The removal of the HWR claims-only measure was contingent on our finalizing our proposal to adopt the Hybrid
HWR measure. We finalized our proposal to align the removal of the HWR claims only measure such that its removal aligns with the end of the
finalized 2-year voluntary reporting period and the beginning of the finalized mandatory data submission and public reporting of the Hybrid
HWR measure.
****** In this final rule, we are finalizing the adoption of the Hospital Commitment to Health Equity measure beginning with the CY 2023
reporting period/FY 2025 payment determination and for subsequent years. We refer readers to section IX.E.5 .a. for more detailed discussion.
******* In this final rule, we are finalizing adoption of two eCQMs beginning with the CY 2023 reporting period/FY 2025 payment
determination: Cesarean Birth and Severe Obstetric Complications. We are finalizing mandatory reporting of these two measures beginning with
the CY 2024 reporting period/FY 2026 payment determination and for subsequent years. We refer readers to sections IX.E.5.c. and IX.E.5.d.,
respectively, for more detailed discussion. We also refer readers to section IX.E.10.e. for changes to our eCQM reporting and submission
requirements beginning with the CY 2024 reporting period/FY 2026 payment determination and for subsequent years.
******** In this final rule, we are finalizing the adoption of two eCQMs beginning with the CY 2024 reporting period/FY 2026 payment
determination and for subsequent years: Hospital-Harm-Opioid-Related Adverse Events and Global Malnutrition Composite Score. We refer
readers to sections IX.E.5.e. and IX.E.5.f., respectively for more detailed discussion. We also refer readers to section IX.E.10.e. for changes to
our eCQM reporting and submission requirements beginning with the CY 2024 reporting period/FY 2026 payment determination and for
subsequent years.
********* In this final rule, we are finalizing adoption of the Hospital-Level THA/TKA PRO-PM measure. We are finalizing voluntary
reporting of the measure across two periods-July 1, 2023 through June 30, 2024 and July I, 2024 through June 30, 2025-followed by
mandatory reporting for the reporting period which runs from July I, 2025 through June 30, 2026, impacting the FY 2028 payment determination
and for subsequent years. We refer readers to section IX.E.5.g. for more detailed discussion.
********** In this final rule, we are finalizing adoption of the Screening for Social Drivers of Health measure and the Screen Positive Rate for
Social Drivers of Health measure beginning with voluntary reporting in the CY 2023 reporting period and mandatory reporting in the CY 2024
reporting period/FY 2026 payment determination and for subsequent years. We refer readers to sections IX.E.5.b.(1). and IX.E.5.b.(2).,
respectively, for more detailed discussion.
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49279
TABLE IX.E-12. MEASURES FOR THE FY 2027 PAYMENT DETERMINATION
khammond on DSKJM1Z7X2PROD with RULES2
HCP Influenza
Vaccination
HCP COVID-19
Vaccination
Measure Name
National Healthcare Safetv Network Measures
NQF#
Influenza Vaccination Coverage Among Healthcare Personnel
0431
COVID-19 Vaccination Coverage Among Health Care Personnel
Claims-Based Patient Safety Measures
Death Rate among Surgical Inpatients with Serious Treatable
Complications (CMS Recalibrated Death Rate among Surgical Inpatients
CMS PSI-04
with Serious Treatable Complications)
Claims-Based Mortalitv/Complications Measures
Hospital 30-Day, All-Cause, Risk Standardized Mortality- Rate Following
MORT-30-STK
Acute Ischemic Stroke
Hospital-Level Risk-Standardized Complication Rate (RSCR) Following
COMP-HIP-KNEE*
Elective Primarv THA and/or TKA
Claims-Based Coordination of Care Measures
Excess Days in Acute Care after Hospitalization for Acute Myocardial
AMI Excess Days**
Infarction
HF Excess Davs
Excess Davs in Acute Care after Hospitalization for Heart Failure
PN Excess Days
Excess Days in Acute Care after Hospitalization for Pneumonia
Claims-Based Payment Measures
Hospital-Level, Risk-Standardized Payment Associated with a 30-Day
Episode-of-Care for Acute Myocardial Infarction (AMI)
AMIPavment
Hospital-Level, Risk-Standardized Payment Associated with a 30-Day
HFPavment
Episode-of-Care For Heart Failure (HF)
Hospital-Level, Risk-Standardized Payment Associated with a 30-day
Episode-of-Care For Pneumonia
PNPavment
Hospital-Level, Risk-Standardized Payment Associated with an Episodeof-Care for Primary Elective Total Hip Arthroplasty and/or Total Knee
Arthroplastv
THA/TKA Pavment**
MSPB***
Medicare Spending Per Beneficiarv (MSPB)-Hospital Measure
Claims and Electronic Data Measures
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Measure
(HWM)
Hybrid HWM****
Hvbrid Hospital-Wide All-Cause Readmission Measure (HWR)
Hvbrid HWR*****
Chart-Abstracted Clinical Process of Care Measures
PC-01
Elective Delivery
Severe Sepsis and Septic Shock: Management Bundle (Composite
Sepsis
Measure)
Structural Measures
Maternal Morbidity
Maternal Morbidity Structural Measure
Hospital Commitment to Health Eauitv
HCHE******
EHR-based Clinical Process of Care Measures (that is, Electronic Clinical Quality Measures
Safe Use ofOpioids
Safe Use of Opioids - Concurrent Prescribing
STK-02
Discharged on Antithrombotic Therapy
STK-03
Anticoagulation Therapy for Atrial Fibrillation/Flutter
STK-05
Antithrombotic Therapy by the End of Hospital Day Two
VTE-1
Venous Thromboembolism Prophy!axis
VTE-2
Intensive Care Unit Venous Thromboembolism Prophylaxis
HH-01
Hospital Harm-Severe Hypoglycemia Measure
Hospital Harm-Severe Hyperglycemia Measure
HH-02
ePC-02*******
Cesarean Birth
ePC-07/SMM*******
Severe Obstetric Complications
HH-ORAE********
Hospital-Harm-Opioid Related Adverse Events
GMCS********
Global Malnutrition Composite Score
Patient Experience of Care Survey Measures
Hospital Consumer Assessment of Healthcare Providers and Systems
HCAHPS
Survey (including Care Transition Measure)
Patient-Reported Outcome Performance Measures
THA/TKA PROHospital-Level Total Hip Arthroplasty and/or Total Knee Arthroplasty
Patient-Reported Outcome-Based Performance Measure (PRO-PM)
PM*********
Process Measures
Screening for Social Drivers of Health
SDOH-1 **********
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00501
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
NIA
0351
NIA
1550
2881
2880
2882
2431
2436
2579
3474
2158
3502
2879
0469
0500
NIA
NIA
eCQMs))
3316e
0435
0436
0438
0371
0372
3503e
3533e
NIA
NIA
3501e
3592e
0166
(0228)
3559
NIA
ER10AU22.170
Short Name
49280
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Short Name
SDOH-2**********
NQF#
NIA
Measure Name
Screen Positive Rate for Social Drivers of Health
* In this final rule, we are finalizing adoption of the Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary
THA and/or TKA measure beginning with the FY 2024 payment determination and for subsequent years. We refer readers to section IX.E.5.i. for
more detailed discussion.
** In this final rule, we are finalizing refinements to two current Hospital IQR Program measures-Hospital-Level, Risk-Standardized Payment
Associated with an Episode-of-Care for Primary Elective THA!fKA and Excess Days in Acute Care (EDAC) after Hospitalization for Acute
Myocardial Infarction (AMI)--beginning with the FY 2024 payment determination. We refer readers to sections IX.E.6.a. and IX.E.6.b,
respectively, for more detailed discussion.
*** In this final rule, we are finalizing adoption of a refined MSPB-Hospital measure beginning with the FY 2024 payment determination. We
refer readers to section IX.E.5.h. for more detailed discussion.
**** In the FY 2022 IPPS/L TCH PPS fmal rule 86 FR 45365, we finalized adoption of the Hybrid HWM measure beginning with one voluntary
reporting period (July I, 2023-June 30, 2023), followed by mandatory reporting beginning with the July I, 2023- June 30, 2024 reporting period,
impacting the FY 2026 payment determination.
***** In the FY 2020 IPPS/L TCH PPS final rule, we removed the claims-only Hospital-Wide All-Cause Unplanned Readmission (HWR claimsonly) measure (NQF # 1789) and replaced it with the Hybrid HWR measure (NQF #2879), beginning with the FY 2026 payment determination
(84 FR 42465 through 42481). The removal of the HWR claims-only measure was contingent on our finalizing our proposal to adopt the Hybrid
HWR measure. We finalized our proposal to align the removal of the HWR claims only measure such that its removal aligns with the end of the
finalized 2-year voluntary reporting period and the beginning of the finalized mandatory data submission and public reporting of the Hybrid
HWR measure.
****** In this final rule, we are finalizing adoption of the Hospital Commitment to Health Equity measure beginning with the CY 2023 reporting
period/FY 2025 payment determination and for subsequent years. We refer readers to section IX.E.5.a. for more detailed discussion.
******* In this final rule, we are finalizing adoption of two eCQMs beginning with the CY 2023 reporting period/FY 2025 payment
determination: Cesarean Birth and Severe Obstetric Complications. We are finalizing mandatory reporting of these two measures beginning with
the CY 2024 reporting period/FY 2026 payment determination and for subsequent years. We refer readers to sections IX.E.5.c. and IX.E.5.d.,
respectively, for more detailed discussion. We also refer readers to section IX.E.10.e. for changes to our eCQM reporting and submission
requirements beginning with the CY 2024 reporting period/FY 2026 payment determination and for subsequent years.
******** In this fmal rule, we are finalizing the adoption of two eCQMs beginning with the CY 2024 reporting period/FY 2026 payment
determination and for subsequent years: Hospital-Harm-Opioid-Related Adverse Events and Global Malnutrition Composite Score. We refer
readers to sections IX.E.5.e. and IX.E.5.f., respectively for more detailed discussion. We also refer readers to section IX.E.10.e. for changes to
our eCQM reporting and submission requirements beginning with the CY 2024 reporting period/FY 2026 payment determination and for
subsequent years
********* In this final rule, we are finalizing adoption of the Hospital-Level THA!IKA PRO-PM measure. We are finalizing voluntary
reporting of the measure across two periods-July I, 2023 through June 30, 2024 and July 1, 2024 through June 30, 2025-followed by
mandatory reporting for the reporting period which runs from July 1, 2025 through June 30, 2026, impacting the FY 2028 payment determination
and for subsequent years. We refer readers to section IX.E.5.g. for more detailed discussion.
********** In this final rule, we are finalizing adoption of the Screening for Social Drivers of Health measure and the Screen Positive Rate for
Social Drivers of Health measure beginning with voluntary reporting in the CY 2023 reporting period and mandatory reporting in the CY 2024
reporting period/FY 2026 payment determination and for subsequent years. We refer readers to sections IX.E.5.b.(1) and IX.E.5.b.(2).,
respectively, for more detailed discussion.
e. Summary of Previously Finalized and
New Hospital IQR Program Measures for
the FY 2028 Payment Determination
and for Subsequent Years
IQR Program measure set for the FY
2028 payment determination and for
subsequent years:
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00502
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.171
khammond on DSKJM1Z7X2PROD with RULES2
This table summarizes the previously
finalized and newly finalized Hospital
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49281
TABLE IX.E-13. MEASURES FOR THE FY 2028 PAYMENT DETERMINATION AND
FOR SUBSEQUENT YEARS
Measure Name
National Healthcare Safety Network Measures
Influenza Vaccination Coverage Among Healthcare Personnel
HCP Influenza Vaccination
HCP COVID-19 Vaccination
COVID-19 Vaccination Coverage Among Health Care Personnel
Claims-Based Patient Safety Measures
Death Rate among Surgical Inpatients with Serious Treatable Complications (CMS
CMS PSI-04
Recalibrated Death Rate among Surgical Inpatients with Serious Treatable Complications)
Claims-Based Mortality/Complications Measures
Hospital 30-Day, All-Cause, Risk Standardized Mortality- Rate Following Acute Ischemic
MORT-30-STK
Stroke
Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary
COMP-HIP-KNEE*
THA and/or TKA
Claims-Based Coordination of Care Measures
AMI Excess Days**
Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction
HF Excess Davs
Excess Davs in Acute Care after Hospitalization for Heart Failure
PN Excess Days
Excess Days in Acute Care after Hospitalization for Pneumonia
Claims-Based Pavment Measures
Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for
AMI Payment
Acute Myocardial Infarction (AMI)
Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care For
Heart Failure (HF)
HFPavment
Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-of-Care For
PNPayment
Pneumonia
Hospital-Level, Risk-Standardized Payment Associated with an Episode-of-Care for Primary
THA/TKA Pavment**
Elective Total Hip Arthroplastv and/or Total Knee Arthroplastv
MSPB***
Payment-Standardized Medicare Spending Per Beneficiarv (MSPB)
Claims and Electronic Data Measures
Hybrid HWM* ***
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Measure (HWM)
Hybrid Hospital-Wide All-Cause Readmission Measure (HWR)
HybridHWR*****
Chart-Abstracted Clinical Process of Care Measures
PC-01
Elective Deliverv
Sepsis
Severe Sepsis and Septic Shock: Management Bundle (Composite Measure)
Structural Measures
Maternal Morbidity
Maternal Morbidity Structural Measure
HCHE******
Hospital Commitment to Health Eauitv
EHR-based Clinical Process of Care Measures (that is, Electronic Clinical Quality Measures (eCQMs))
Safe Use ofOpioids
Safe Use of Opioids - Concurrent Prescribing
STK-02
Discharged on Antithrombotic Therapy
STK-03
Anticoagulation Therapy for Atrial Fibrillation/Flutter
STK-05
Antithrombotic Therapy by the End of Hospital Day Two
VTE-1
Venous Thromboembolism Prophylaxis
VTE-2
Intensive Care Unit Venous Thromboembolism Prophylaxis
Hospital Harm-Severe Hypoglycemia Measure
HH-01
Hospital Harm-Severe Hyperglycemia Measure
HH-02
ePC-02*******
Cesarean Birth
ePC-07ISMM* ** ** **
Severe Obstetric Complications
Hospital-Harm-Opioid Related Adverse Events
HH-ORAE********
Global Malnutrition Composite Score
GMCS********
Patient Experience of Care Survev Measures
Hospital Consumer Assessment of Healthcare Providers and Systems Survey (including Care
Transition Measure)
HCAHPS
Patient-Reported Outcome Performance Measures
THA/TKA PROHospital-Level Total Hip Arthroplasty and/or Total Knee Arthroplasty Patient-Reported
Outcome-Based Performance Measure (PRO-PM)
PM*********
Process Measures
Screening for Social Drivers of Health
SDOH-1 **********
SDOH-2**********
Screen Positive Rate for Social Drivers of Health
..
• In thJS final rule, we are final1zmg adoption of a refined Hospital-Level R1sk-Standard1zed Comphcatmn Rate (RSCR) Followmg Elective
Primary THA and/or TKA measure beginning with the CY 2022 reporting period/FY 2024 payment determination. We refer readers to section
IX.E.5.i. for more detailed discussion.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00503
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
NOF#
0431
NIA
0351
NIA
1550
2881
2880
2882
2431
2436
2579
3474
2158
NIA
2879
0469
0500
NIA
NIA
3316e
0435
0436
0438
0371
0372
3503e
3533e
NIA
NIA
350le
3592e
0166
(0228)
3559
NIA
NIA
ER10AU22.172
khammond on DSKJM1Z7X2PROD with RULES2
Short Name
49282
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
** In this final rule, we are finalizing refinements to two current Hospital IQR Program measures-Hospital-Level, Risk-Standardized Payment
Associated with an Episode-of-Care for Primary Elective THA/TKA and Excess Days in Acute Care (EDAC) after Hospitalization for Acute
Myocardial Infarction (AMI}---beginning with the FY 2024 payment determination. We refer readers to sections IX.E.6.a. and IX.E.6.b,
respectively, for more detailed discussion.
*** In this final rule, we are finalizing adoption ofa refined MSPB Hospital measure beginning with the /FY 2024 payment determination. We
refer readers to section IX.E.5.h. for more detailed discussion.
**** In the FY 2022 IPPS/L TCH PPS final rule 86 FR 45365, we finalized adoption of the Hybrid HWM measure beginning with one voluntary
reporting period (July I, 2023-June 30, 2023), followed by mandatory reporting beginning with the July I, 2023- June 30, 2024 reporting period,
impacting the FY 2026 payment determination.
***** In the FY 2020 IPPS/L TCH PPS final rule, we removed the claims-only Hospital-Wide All-Cause Unplanned Readmission (HWR claimsonly) measure (NQF # 1789) and replaced it with the Hybrid HWR measure (NQF #2879), beginning with the FY 2026 payment determination
(84 FR 42465 through 42481). The removal of the HWR claims-only measure was contingent on our finalizing our proposal to adopt the Hybrid
HWR measure. We finalized our proposal to align the removal of the HWR claims only measure such that its removal aligns with the end of the
finalized 2-year voluntary reporting period and the beginning of the finalized mandatory data submission and public reporting of the Hybrid
HWR measure.
****** In this final rule, we are finalizing the adoption of the Hospital Commitment to Health Equity measure beginning with the CY 2023
reporting period/FY 2025 payment determination and for subsequent years. We refer readers to section IX.E.5 .a. for more detailed discussion.
******* In this final rule, we are finalizing the adoption of two eCQMs beginning with the CY 2023 reporting period/FY 2025 payment
determination: Cesarean Birth and Severe Obstetric Complications. We are finalizing mandatory reporting of these two measures beginning with
the CY 2024 reporting period/FY 2026 payment determination and for subsequent years. We refer readers to sections IX.E.5.c and IX.E.5.d,
respectively, for more detailed discussion. We also refer readers to section IX.E.10.e. for changes to our eCQM reporting and submission
requirements beginning with the CY 2024 reporting period/FY 2026 payment determination and for subsequent years.
******** In this final rule, we are finalizing the adoption of two eCQMs beginning with the CY 2024 reporting period/FY 2026 payment
determination and for subsequent years: Hospital-Harm-Opioid-Related Adverse Events and Global Malnutrition Composite Score. We refer
readers to sections IX.E.5.e. and IX.E.5.f., respectively for more detailed discussion. We also refer readers to section IX.E.10.e. for changes to
our eCQM reporting and submission requirements beginning with the CY 2024 reporting period/FY 2026 payment determination and for
subsequent years.
********* In this final rule, we are finalizing adoption of the Hospital-Level THA/TKA PRO-PM measure. We are finalizing voluntary
reporting of the measure across two periods-July 1, 2023 through June 30, 2024 and July 1, 2024 through June 30, 2025-, followed by
mandatory reporting for the reporting period which runs from July 1, 2025 through June 30, 2026, impacting the FY 2028 payment determination
and for subsequent years We refer readers to section IX.E.5.g. for more detailed discussion.
********** In this final rule, we are finalizing adoption of the Screening for Social Drivers of Health measure and the Screen Positive Rate for
Social Drivers of Health measure beginning with a voluntary reporting in the CY 2023 reporting period and mandatory reporting in the CY 2024
reporting period/FY 2026 payment determination and for subsequent years. We refer readers to sections IX.E.5.b.(1). and IX.E.5.b.(2).,
respectively, for more detailed discussion.
khammond on DSKJM1Z7X2PROD with RULES2
8. Establishment of a Publicly-Reported
Hospital Designation To Capture the
Quality and Safety of Maternity Care
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28547 through
28550), we proposed to establish a
hospital quality designation that we
would publicly report on a CMS website
beginning in Fall 2023. We proposed
this designation would be awarded to
hospitals based on their attestation of
submission of the Maternal Morbidity
Structural measure, which we believe
will reflect their commitment to the
quality and safety of maternity care they
furnish. This will be the first-ever
hospital quality designation by HHS or
CMS that specifically focuses on
maternal health. We proposed this
policy in conjunction with Vice
President Harris’ ‘‘Maternal Health Day
of Action’’ announcement 1008 which
also signaled CMS’ intent to establish
this proposed ‘‘birthing-friendly’’
hospital designation. Additionally, we
1008 The White House. (2021). Fact Sheet: Vice
President Kamala Harris Announces Call to Action
to Reduce Maternal Mortality and Morbidity.
Accessed January 26, 2022. Available at: https://
www.whitehouse.gov/briefing-room/statementsreleases/2021/12/07/fact-sheet-vice-presidentkamala-harris-announces-call-to-action-to-reducematernal-mortality-and-morbidity/.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
requested feedback on potential
additional activities that we could
undertake to advance maternal health
equity.
a. The U.S. Maternal Health Crisis
Despite the highest rate of spending
on maternity care, maternal mortality
rates in the U.S. are among the highest
in the developed world. Every year,
approximately 700 women die of
complications related to pregnancy and
childbirth, and over 25,000 women
experience severe complications of
pregnancy (severe maternal morbidity).
1009 1010 Approximately one-third of all
pregnancy-related deaths occur at the
time of delivery and immediately
postpartum, with nearly 20 percent
occurring between one and six days
postpartum.1011 Yet, three out of five
1009 Petersen EE et al. Vital Signs: PregnancyRelated Deaths, United States, 2011–2015, and
Strategies for Prevention, 13 States, 2013–2017.
MMWR Morbidity and Mortality Weekly Report
2019;68:423–29.
1010 Maternal and Child Health Bureau. Federally
Available Data (FAD) Resource Document. Health
Resources and Services Administration. Available
at: https://mchb.tvisdata.hrsa.gov/Admin/File
Upload/DownloadContent?fileName=FadResource
Document.pdf&isForDownload=False.
1011 Davis N.L., Smoots A.N., and Goodman D.A.
(2019). Pregnancy-Related Deaths: Data from 14
U.S. Maternal Mortality Review Committees, 2008–
2017. Available at: https://www.cdc.gov/
PO 00000
Frm 00504
Fmt 4701
Sfmt 4700
pregnancy-related deaths are considered
preventable.1012
Racial, ethnic, disability, and
geographic disparities intensify the U.S.
maternal health crisis. Adverse maternal
health outcomes vary considerably by
race and ethnicity, and are highest
among Black and American Indian/
Alaskan Native women, regardless of
their income or education levels.1013 1014
Black and American Indian/Alaskan
Native women die from pregnancyrelated causes at a rate two to three
times higher 1015 and experience severe
maternal morbidity at a rate nearly two
reproductivehealth/maternal-mortality/erase-mm/
MMR-Data-Brief_2019-h.pdf.
1012 The Centers for Disease Control and
Prevention. Pregnancy-Related Deaths in the United
States. September 2021. Available at: https://
www.cdc.gov/hearher/pregnancy-related-deaths/
index.html.
1013 Hoyert DL and Minin
˜ o AM. Maternal
Mortality in the United States: Changes in Coding,
Publication, and Data Release. National Vital
Statistics Report. Vol 69, No. 2 (Jan. 2020): 1–18.
1014 Centers for Disease Control and Prevention.
Racial/Ethnic Disparities in Pregnancy-Related
Deaths — United States, 2007–2016. September 6,
2019. Vol. 68, No. 35. Available at: https://
www.cdc.gov/mmwr/volumes/68/wr/pdfs/mm
6835a3-H.pdf.
1015 Centers for Disease Control and Prevention.
Pregnancy Mortality Surveillance System. Available
at: https://www.cdc.gov/reproductivehealth/
maternal-mortality/pregnancy-mortalitysurveillance-system.htm. Accessed November 10,
2021.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.173
BILLING CODE 4120–01–C
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
times higher than their White, Asian
Pacific Islander, and Hispanic
counterparts.1016 The COVID–19
pandemic in the U.S. has exacerbated
such racial and ethnic disparities in
maternal outcomes, likely associated
with Black and Hispanic women facing
higher rates of economic hardship and
reporting higher rates of mental health
concerns compared to their White
counterparts.1017 1018 1019 1020 Women
with disabilities have a higher mortality
risk and significantly higher risk in
almost all adverse maternal outcomes
compared with women without
disabilities.1021 Finally, geographic
disparities in maternal outcomes also
exist. Pregnant women who live in rural
communities are at higher risk for
severe maternal morbidity and about 60
percent more likely to die before,
during, or after delivery than those
living in urban settings.1022
b. HHS Focus on Improving Maternal
Health in the U.S.
khammond on DSKJM1Z7X2PROD with RULES2
To build on the previously
established HHS Maternal Health
Action Plan, the Vice President’s
nationwide call to action to reduce
maternal morbidity and mortality, and
ongoing efforts with HHS and across the
1016 US Government Accountability Office.
MATERNAL MORTALITY Trends in PregnancyRelated Deaths and Federal Efforts to Reduce Them.
March 2020. Available at: https://www.gao.gov/
assets/gao-20-248.pdf.
1017 Raman S. COVID–19 Amplifies Racial
Disparities in Maternal Health. Roll Call. May 14,
2020. Available at: https://www.rollcall.com/2020/
05/14/covid-19-amplifies-racial-disparities-inmaternal-health/.
1018 National Partnership for Women & Families.
Black Women’s Maternal Health: A Multifaceted
Approach to Addressing Persistent and Dire Health
Disparities. April 2018. Available at: https://
www.nationalpartnership.org/our-work/health/
reports/black-womens-maternal-health.html.
1019 Bion X–S. Efforts to Reduce Black Maternal
Mortality Complicated by COVID–19. California
Health Care Foundation. April 2020. Available at:
https://www.chcf.org/blog/efforts-reduce-blackmaternal-mortality-complicated-covid-19/.
1020 Getachew Y et al. Beyond the Case Count:
The Wide-Ranging Disparities of COVID–19 in the
United States The Commonwealth Fund. September
2020. Available at: https://www.commonwealth
fund.org/publications/2020/sep/beyond-case-countdisparities-covid-19-united-states.
1021 Brown, Hilary K, ‘‘Disparities in Severe
Maternal Morbidity and Mortality—A Call for
Inclusion of Disability in Obstetric Research and
Health Care Professional Education,’’ JAMA Netw
Open. 2021;4(12):e2138910. doi:10.1001/jamanet
workopen.2021.38910. Online at: https://
jamanetwork.com/journals/jamanetworkopen/full
article/2787181.
1022 White House Fact Sheet: Vice President
Kamala Harris Announces Call to Action to Reduce
Maternal Mortality and Morbidity. https://
www.whitehouse.gov/briefing-room/statementsreleases/2021/12/07/fact-sheet-vice-presidentkamala-harris-announces-call-to-action-to-reducematernal-mortality-and-morbidity/.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
federal government,1023 the
Administration seeks to use a whole-ofgovernment approach for improving
maternal health and advancing maternal
health equity that reduces maternal
mortality and morbidity, reduces
persistent disparities, and among other
activities, increases hospital
participation in HHS-sponsored
maternal health quality improvement
initiatives. A critical focus is reducing
existing disparities in maternal health
outcomes across race, ethnicity, and
geographic area. This targeted strategy is
further embodied by other efforts
spearheaded by the Biden-Harris
Administration, including the first-ever
Presidential Proclamation in recognition
of Black Maternal Health Week in April
2021, as well as the first-ever federal
‘‘Maternal Health Day of Action’’ on
December 7, 2021. 1024 1025
As part of the ‘‘Day of Action,’’ Vice
President Harris issued a nationwide
call to action to reduce maternal
mortality and morbidity and made
several key announcements, including
CMS’ intention to establish the
proposed hospital designation.1026
Additionally, we released a quality,
safety, and oversight memorandum
(QSO–22–05-Hospitals) to state survey
agencies. In that memorandum, we
encourage hospitals to consider
implementation of evidence-based best
practices for the management of
obstetric emergencies, along with
interventions to address other key
contributors to maternal health
disparities, to support the delivery of
equitable, high-quality care for all
pregnant and postpartum
individuals.1027 Such best practices
include participation in local/regional
perinatal quality collaboratives,
application of early warning sign tools,
and the use of patient safety ‘‘bundles.’’
We encourage hospitals to review the
1023 HHS Initiative to Improve Maternal Health.
https://aspe.hhs.gov/topics/public-health/hhsinitiative-improve-maternal-health.
1024 A Proclamation on Black Maternal Health
Week, 2021. Available at: https://
www.whitehouse.gov/briefing-room/presidentialactions/2021/04/13/a-proclamation-on-blackmaternal-health-week-2021/.
1025 The White House. (2021). Fact Sheet: Vice
President Kamala Harris Announces Call to Action
to Reduce Maternal Mortality and Morbidity.
Accessed January 26, 2022. Available at: https://
www.whitehouse.gov/briefing-room/statementsreleases/2021/12/07/fact-sheet-vice-presidentkamala-harris-announces-call-to-action-to-reducematernal-mortality-and-morbidity/.
1026 Ibid.
1027 Centers for Medicare & Medicaid Services.
Evidence-Based Best Practices for Hospitals in
Managing Obstetric Emergencies and Other Key
Contributors to Maternal Health Disparities.
Accessed December 20, 2021. Available at: https://
www.cms.gov/files/document/qso-22-05hospitals.pdf.
PO 00000
Frm 00505
Fmt 4701
Sfmt 4700
49283
guidance and resources provided in the
memorandum to assess their own
capacity to provide optimal
management of obstetric emergencies
and to combat maternal health
disparities.
As part of our commitment to
reducing high maternal morbidity and
mortality rates, the Hospital IQR
Program adopted the Maternal
Morbidity Structural measure in the FY
2022 IPPS/LTCH PPS final rule (86 FR
45361 through 45365). This measure is
designed to determine hospital
participation in a state or national
Perinatal Quality Improvement (QI)
Collaborative and implementation of
patient safety practices or bundles
through that QI initiative. As noted in
the FY 2022 IPPS/LTCH PPS final rule
(86 FR 45361 through 45365), hospital
participation in QI collaboratives has
been shown to be effective in improving
the infrastructure surrounding
management of obstetric conditions that
may lead to severe maternal morbidity
or mortality.1028 Additionally, hospital
implementation of related QI efforts has
been associated with both enhanced
quality and safety of care as well as a
reduction in the maternal health
disparity gap.
The Maternal Morbidity Structural
measure is specified to capture whether
hospitals are: (1) Currently participating
in a structured state or national
Perinatal QI Collaborative; and (2)
implementing patient safety practices or
bundles as part of these QI initiatives.
In reporting on this measure, hospitals
respond ‘‘Yes,’’ ‘‘No,’’ or ‘‘N/A (our
hospital does not provide inpatient
labor/delivery care)’’ to a two-part
question assessing these two topic
areas.1033 Data collection began with
1028 Main, E.K., Cape, V., Abreo, A., Vasher, J.,
Woods, A., Carpenter, A., Gould, J.B. (2017).
Reduction of Severe Maternal Morbidity from
Hemorrhage Using a State Perinatal Quality
Collaborative. American Journal of Obstetrics and
Gynecology, 216(3): 298.e1. Available at: https://
www.ncbi.nlm.nih.gov/pubmed/28153661.
1029 Callaghan-Koru JA et al. Implementation of
the Safe Reduction of Primary Cesarean Births
safety bundle during the first year of a statewide
collaborative in Maryland. Obstet Gynecol
2019;134:109–19.
1030 Main EK et al. Reduction of severe maternal
morbidity from hemorrhage using a state perinatal
quality collaborative. Am J Obstet Gynecol
2017;216(3):298.e1–298.e11.
1031 King PL et al. Reducing time to treatment for
severe maternal hypertension through statewide
quality improvement. Am J Obstet Gynecol
2018;218:S4.
1032 Main EK et al. Reduction in racial disparities
in severe maternal morbidity from hemorrhage in a
large-scale quality improvement collaborative. Am
J Obstet Gynecol 2020;223:123.e1–14.
1033 To report on this measure, hospitals will
respond to a two-part question: ‘‘Does your hospital
E:\FR\FM\10AUR2.SGM
Continued
10AUR2
49284
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
fourth quarter 2021 data, which
hospitals must have reported by May
2022. We refer readers to the FY 2022
IPPS/LTCH PPS final rule (86 FR 45361
through 45365) for more details on the
measure.
khammond on DSKJM1Z7X2PROD with RULES2
c. Establishment of a Publicly-Reported
Hospital Designation To Capture the
Quality and Safety of Maternity Care
In alignment with the announcement
made during the ‘‘Maternal Health Day
of Action’’1034 we proposed to establish
a hospital designation to be publicly
reported on a CMS website beginning in
Fall 2023. We will give this designation
to hospitals that report ‘‘Yes’’ to both
questions in the Maternal Morbidity
Structural measure. This designation
will initially be based only on data from
hospitals reporting an affirmative
attestation to the Maternal Morbidity
Structural measure. This will allow us
to initially award the designation based
on the data hospitals are currently
reporting on the Maternal Morbidity
Structural measure under the Hospital
IQR Program. In future notice and
comment rulemaking, we intend to
propose a more robust set of metrics for
awarding the designation that may
include other maternal health-related
measures that may be finalized for the
Hospital IQR Program measure set in the
future. We note that in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28506 through 28515), we proposed to
adopt two new electronic clinical
quality measures (eCQMs) for the
Hospital IQR Program—the Cesarean
Birth (ePC–02) and Severe Obstetric
Complications (ePC–07)—in sections
IX.E.5.c. and IX.E.5.d, respectively,
which are discussed in sections IX.E.5.c.
and IX.E.5.d., respectively, of this final
rule.
Section 1886(b)(3)(B)(viii)(VII) of the
Social Security Act requires that the
Secretary establish procedures for
making information regarding Hospital
IQR Program measures available to the
public (74 FR 43864; 75 FR 50184
or health system participate in a Statewide and/or
National Perinatal Quality Improvement
Collaborative Program aimed at improving maternal
outcomes during inpatient labor, delivery and postpartum care, and has it implemented patient safety
practices or bundles related to maternal morbidity
to address complications, including, but not limited
to, hemorrhage, severe hypertension/preeclampsia
or sepsis?.’’ Further details on this measure can be
found in the FY 2022 IPPS/LTCH PPS final rule at
86 FR 45361 through 45365.
1034 The White House. (2021). Fact Sheet: Vice
President Kamala Harris Announces Call to Action
to Reduce Maternal Mortality and Morbidity.
Accessed January 26, 2022. Available at: https://
www.whitehouse.gov/briefing-room/statementsreleases/2021/12/07/fact-sheet-vice-presidentkamala-harris-announces-call-to-action-to-reducematernal-mortality-and-morbidity/.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
through 50815). We believe adding this
designation to a consumer-facing CMS
website will allow patients and families
to choose hospitals that have
demonstrated a commitment to
improving maternal health through their
participation in related perinatal QI
collaboratives and their implementation
of best practices that support the
delivery of high-quality maternity care.
We invited public comment on this
proposal.
Comment: Many commenters
supported the creation of a public
designation related to maternity care.
Response: We thank commenters for
their support of our proposal to
establish a maternity care hospital
designation to be publicly reported on a
CMS website beginning in Fall 2023. We
believe that adoption of this designation
represents a first step in informing the
public in a meaningful and consumerfriendly manner about hospitals’
commitment to the provision of highquality maternity care and it will
empower the public to make more
informed decisions as to where they
choose to obtain care during pregnancy
and postpartum (87 FR 28549). We also
note that since the publication of the FY
2023 IPPS/LTCH PPS proposed rule, the
White House has published the ‘‘White
House Blueprint for Addressing the
Maternal Health Crisis’’ which further
outlines how the hospital designation
will fit in with the HHS’ maternal health
strategy.1035
Comment: While many commenters
supported the creation of the
designation, many of these commenters
also stated that they believe the
attestation-based Maternal Morbidity
Structural measure is not sufficient in
fully addressing maternal health. The
commenters encouraged CMS to, in the
near future, push beyond the use of an
attestation by incorporating more
rigorous quality reporting components
that incentivize hospitals to deliver
high-quality care and provide
consumers with more detailed, reliable
data on hospital results in improving
maternal health. Several commenters
emphasized the importance of including
clear, consistent, patient-centered, and
evidence-based measures on maternal
health and encouraged our engagement
with hospitals, clinicians, and
consumers to design and apply a
maternal health designation. A few
commenters expressed support for the
designation’s potential to increase
participation in perinatal quality
1035 White House Blueprint for Addressing the
Maternal Health Crisis. (2022). Available at: https://
www.whitehouse.gov/wp-content/uploads/2022/06/
Maternal-Health-Blueprint.pdf.
PO 00000
Frm 00506
Fmt 4701
Sfmt 4700
collaboratives and other quality
improvement initiatives. A couple of
commenters noted the proposal builds
off an existing Hospital IQR Program
measure and will therefore mitigate
administrative burden for hospitals. A
commenter supported the designation’s
potential to address the issue of
maternal hemorrhage and facilitate
timely initiation of interventions.
Response: We appreciate commenters’
feedback and support for the maternity
care hospital designation. We
acknowledge and agree that this
iteration of the proposed designation is
a first step towards informing the public
in a meaningful and consumer-friendly
manner about maternity care quality,
and advancing maternal health equity
more broadly, using a measure that was
already finalized in the Hospital IQR
Program. As we stated in the FY 2023
IPPS/LTCH PPS proposed rule, we
intend to propose a more robust set of
criteria for awarding the designation in
future notice-and-comment rulemaking
(87 FR 28549). We thank the
commenters for their support and agree
that the designation could support
greater participation in perinatal quality
improvement collaboratives and
implementation of best practices. We
are committed to engaging with
interested parties as we continue to
improve upon this designation in future
notice-and-comment rulemaking.
Comment: Many commenters did not
support the proposal as currently
proposed, indicating that the attestation
of participation in a perinatal quality
improvement collaborative (as captured
by the Maternal Morbidity Structural
measure) is insufficient to demonstrate
hospital maternity care quality. The
commenters suggested that participation
in quality improvement collaboratives
and initiatives should be considered the
floor for acceptable maternity care
rather than the ceiling. A few of these
commenters noted that participation in
such collaboratives varies and using it
as the basis for the designation may not
be meaningful. A few commenters noted
that the designation will be particularly
unhelpful in states where the vast
majority of birthing facilities participate
in perinatal quality improvement
collaboratives because the designation
would not offer distinction in quality
among hospitals. Another commenter
questioned whether the designation as
proposed meaningfully informs patients
beyond the information that is currently
available and publicly reported. A few
commenters stated further concern that,
as proposed, the designation will
mislead consumers who believe it
indicates an exceptional level of quality
when it reflects a less stringent
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
criterion. A commenter noted that some
state perinatal quality improvement
collaboratives have had to suspend
initiatives due to the COVID–19
pandemic and introduction of a
designation based on measures or
initiatives that are unattainable for
many hospitals is not appropriate at this
time. Relatedly, a commenter noted that
they used to participate in perinatal
quality improvement collaboratives but
found the cost of paid membership to be
a barrier.
Response: We appreciate the
commenters’ feedback and acknowledge
their concerns. As we stated in the FY
2023 IPPS/LTCH PPS proposed rule, at
this time we will base the designation
only on data from hospitals reporting an
affirmative attestation to the Maternal
Morbidity Structural measure under the
Hospital IQR Program (87 FR 28549).
This measure is already reported as part
of the Hospital IQR Program measure set
(as finalized in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45361)) and we
believe using an existing measure will
reduce burden for hospitals during the
first year of the designation which is
particularly critical in light of the
ongoing public health emergency. This
is a first step. In future notice-andcomment rulemaking, we intend to
propose a more robust set of metrics for
awarding the designation that may
include other maternal health-related
measures that may be finalized for the
Hospital IQR Program measure set (87
FR 28549). In the Biden-Harris
Administration Blueprint to Address the
Maternal Health Crisis (hereto referred
to as the Blueprint), we acknowledge
that full-scale adoption of perinatal
quality improvement collaboratives has
not happened for several reasons: Not
all states have been funded to support
this key infrastructure; hospitals are not
required to adopt these best practices
and therefore may struggle to procure
the resources needed to implement
them; and, hospitals are not externally
incentivized to do so.1036 In the
Blueprint, we state our intent to explore
opportunities to advance equitable,
high-quality maternity care provided by
hospitals in several ways, including
through this hospital designation and
through the FY 2023 President’s Budget
which, would support a perinatal
quality collaborative in every state.1037
1036 The White House. White House Blueprint for
Addressing the Maternal Health Crisis. June 2022.
Available at: https://www.whitehouse.gov/wpcontent/uploads/2022/06/Maternal-HealthBlueprint.pdf.
1037 The White House. Budget of the U.S.
Government Fiscal Year 2023. Accessed June 24,
2022. Available at: https://www.whitehouse.gov/wpcontent/uploads/2022/03/budget_fy2023.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
We believe this will further support
hospitals in areas where perinatal
quality collaboratives have not been
available due to resource or access
issues. We acknowledge commenters’
concerns that participation in perinatal
quality improvement collaboratives may
vary. However, as stated in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28548) and the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45361 through 45365),
hospital participation in quality
improvement collaboratives has been
shown to be effective in improving the
infrastructure surrounding management
of obstetric conditions that may lead to
severe maternal morbidity or mortality,
and hospital implementation of quality
improvement efforts has been associated
with both enhanced quality and safety
of maternity care as well as a reduction
in the maternal health disparity gap. We
believe supporting hospital
participation in such efforts is critical to
addressing maternal health. In addition,
we believe that while the Maternal
Morbidity Structural measure and the
hospital designation do not directly
mandate participation in perinatal
quality collaboratives and other quality
improvement initiatives, they create
strong incentives to the over 3,000
participating hospitals and CAHs that
voluntarily participate in the Hospital
IQR Program to begin active
participation if they have not yet done
so or to continue participation in such
activities that are an important part of
improving the quality of maternity care
offered in hospitals.
Comment: Several commenters
recommended that hospitals that
participate in any state, national, or
regional quality improvement activities
or collaboratives be considered for the
designation. A few commenters noted
this flexibility is particularly important
for rural hospitals, safety net hospitals,
and hospitals in states or regions where
a perinatal quality improvement
collaborative is not available. A
commenter suggested that state
Medicaid programs may use national or
state Alliance for Innovation on
Maternal Health (AIM) or other quality
improvement initiatives and these
should be considered for the
designation. A couple of commenters
encouraged us to consider recognizing
hospitals that already participate in
maternal health designation programs as
recipients of the CMS designation.
Response: We thank the commenters
for their recommendations. We
recognize that hospitals are involved in
a variety of quality improvement
activities. As stated in the FY 2022
IPPS/LTCH PPS final rule, for purposes
of the Maternal Morbidity Structural
PO 00000
Frm 00507
Fmt 4701
Sfmt 4700
49285
measure in the Hospital IQR Program,
we define a State or national perinatal
quality improvement collaborative as a
Statewide or a multi-State network
working to improve women’s health and
maternal health outcomes by addressing
the quality and safety of maternity care
(86 FR 45362). (Specifications for the
measure are available on the CMS
Measure Methodology page under the
file name ‘Maternal Morbidity
Structural Measure Specifications,’
available at: https://www.cms.gov/
Medicare/Quality-Initiatives-PatientAssessment-Instruments/
HospitalQualityInits/MeasureMethodology.) We believe this provides
hospitals with some flexibility to
identify a perinatal quality
improvement collaborative, of which
the HRSA-funded AIM Program is one
example, in their state or region in
addition to national options.1038
However, we acknowledge that some
hospitals, and especially those in rural
areas, may lack immediate access to a
collaborative. We continue to consider
additional measures for future years of
the designation. In the interim, we
direct commenters and providers to the
December 2021 quality, safety, and
oversight memo that provides
information on a variety of maternity
care quality improvement resources.1039
Comment: A few commenters stated
that the Maternal Morbidity Structural
measure has yet to receive NQF
endorsement and therefore should not
be the only metric used to designate
maternity care quality.
Response: We stated in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45364)
that section 1886(b)(3)(B)(viii)(IX)(bb) of
the Act provides an exception for NQF
endorsement that, in the case of a
specified area or medical topic
determined appropriate by the Secretary
for which a feasible and practical
measure has not been endorsed by the
entity with a contract under section
1890(a) of the Act, the Secretary may
specify a measure that is not so
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary.
1038 Health Resources & Services Administration.
Alliance for Innovation on Maternal Health (AIM)
and Alliance for Innovation on Maternal Health
Community Care Initiative (AIM CCI). 2022.
Available at: https://mchb.hrsa.gov/programsimpact/programs/alliance-innovation-maternalhealth-aim-community-care-aim-cci.
1039 Centers for Medicare & Medicaid Services.
Evidence-Based Best Practices for Hospitals in
Managing Obstetric Emergencies and Other Key
Contributors to Maternal Health Disparities.
Accessed December 20, 2021. Available at: https://
www.cms.gov/files/document/qso-22-05hospitals.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49286
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
We reviewed NQF-endorsed measures
and were unable to identify any other
NQF-endorsed measures that addressed
maternal morbidity through hospital
participation in perinatal quality
improvement initiatives and the
implementation of associated bundles or
patient safety practices. We found no
other feasible and practical measures on
the topic of maternal health; therefore,
we believe the exception in section
1886(b)(3)(B)(viii)(IX)(bb) of the Act
applies. In future notice-and-comment
rulemaking, we intend to propose a
more robust set of measures for the
designation. We believe that the
maternal health crisis is urgent,
maternal health inequities are
unacceptable, and this persistent
problem requires prompt action. We
will consider commenter suggestions
received as part of the related request
for comment included in the FY 2023
IPPS/LTCH PPS proposed rule.
Comment: Many commenters
questioned the intent and purpose of the
designation. A few commenters
disagreed with the designation’s narrow
focus on maternal health. A commenter
stated that a ‘‘birthing-friendly’’
designation without neonatal health
components is inadequate and
suggested that a designation that
includes maternal and neonatal health
care would be most appropriate for such
a designation.
Response: We thank the commenters
for their feedback. As previously stated,
the proposed designation is intended as
a first step in our efforts to adopt
policies that address maternal health. In
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28549), we expressed our
intent to propose a more robust set of
criteria for awarding the designation,
such as other maternal health-related
measures that may be finalized for the
Hospital IQR Program in the future;
which could include two maternal
health eCQMs–Cesarean Birth and
Severe Obstetric Complications– that we
are finalizing in this final rule (in
sections IX.E.5.c. and IX.E.5.d.,
respectively). We acknowledge that
there may be other measures that could
be candidates for the designation, and
we reiterate our intention to continue
exploring opportunities across future
notice-and-comment rulemaking to
continue refining the designation so that
it remains meaningful and useful for
patients and hospitals.
Comment: A few commenters noted
that patients often have limited choice
in their delivery location, due to, for
example, insurance coverage or provider
admitting privileges, and questioned
whether this designation could therefore
be impactful when considering where to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
deliver. A commenter stated that
because Medicare beneficiaries tend to
produce relatively few claims for
services related to maternity care, the
desired impact with the designation is
unclear.
Response: We thank these
commenters for their feedback. We
acknowledge that for some patients,
including those in emergent situations,
there may not be opportunities to
choose the hospital in which they
deliver. However, for many patients,
there is an opportunity for some choice
and we believe it is important to
provide meaningful and user-friendly
information to help inform those
choices. We also note that there are
other important uses for collecting and
publishing the data, including
transparency to incentivize continuous
improvement. We appreciate the
commenter’s feedback that Medicare
claims would likely be less useful as
sources of quality data for a maternity
care quality designation, which is why
we have focused on the use of an
attestation measure to begin, and will
explore potential EHR-based and other
quality measure data to base future
iterations of the designation.
Comment: Many commenters
expressed concern about potential
consequences of evolving the
designation over time. Several
commenters noted that changing the
criteria for the designation without
properly educating and informing
consumers is likely to impact the
integrity of the initiative and the
perception of care delivered in hospitals
with birthing facilities that may gain
and then lose designation. A few
commenters stated that hospitals may
lose their designation, but continue to
prominently feature their previous
recognition and create a false assurance
of quality to consumers. A commenter
expressed concern that CMS could
choose to add criteria or metrics to the
designation from outside of the Hospital
IQR Program or quality measures that
have not been reviewed or endorsed
through the NQF process, both of which
they believe could negatively impact the
integrity and accuracy of the
designation.
Response: We thank the commenters
for their feedback, and we acknowledge
commenters’ concerns about potential
evolution of the designation. We
understand many public-facing quality
indicators and summary scores, such as
star ratings, rankings, or grades, undergo
revisions over time rather than remain
static to continuously improve the data
quality, reliability, and validity, as well
as to ensure information remain
meaningful to users and align with the
PO 00000
Frm 00508
Fmt 4701
Sfmt 4700
state of the field. We do not believe that
such revisions jeopardize the integrity
of the designation. In addition, as
participating facilities continue to
provide quality data for the Maternal
Morbidity Structural measure each year,
the designation will be accordingly
refreshed to reflect the most current
data. We believe that future refinements
to the designation will be needed in
order to continue to provide hospitals
and consumers the opportunity to
access timely quality and safety data to
inform decision-making. We encourage
hospitals to routinely and accurately
update public-facing materials related to
the designation to provide the most upto-date information and avoid
misleading the public. We additionally
intend to provide additional outreach,
communication, and educational
materials as we rollout and improve
upon this designation. We also note that
interested parties may review any future
new measures included for the
designation as they would be proposed
through notice-and-comment
rulemaking. With regard to concerns
about future adoption of measures for
the designation that may lack NQF
endorsement, while we prioritize
measures that are endorsed when
available, we reiterate that section
1886(b)(3)(B)(viii)(IX)(bb) of the Act
provides an exception that, in the case
of a specified area or medical topic
determined appropriate by the Secretary
for which a feasible and practical
measure has not been endorsed by the
entity with a contract under section
1890(a) of the Act, the Secretary may
specify a measure that is not so
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary.
As noted earlier, we believe the
maternal health crisis is urgent,
maternal health inequities are
unacceptable, and this persistent
problem requires immediate action.
Comment: Several commenters
requested additional support or
consideration for certain hospital and
facility types. Several commenters
expressed concern that the designation
would have unintended consequences
for small and rural hospitals as well as
hospitals, including Indian Health
Service (IHS) hospitals, caring for
populations that have been historically
underserved. Commenters cautioned
that such a designation could
potentially exacerbate disparities and
limit access in areas where hospitals
struggle to maintain labor and delivery
units due to low volume. Commenters
worried that patients with the means to
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
seek care elsewhere could bypass local
undesignated hospitals due to a
perception of low-value care, further
reducing the availability and provision
of maternity care in those communities.
A few commenters requested CMS
consider exempting IHS providers from
the designation.
A few commenters recommended the
designation consider hospital capacity
and offer special consideration to lowvolume hospitals to avoid penalizing
those hospitals by withholding a
designation that could improve access
to quality maternity care. The
commenters noted that rural hospitals
may lack the resources to participate in
perinatal quality improvement
collaboratives. The commenters
suggested providing incentives and
resources to rural hospitals to
collaborate with any nearby hospital to
achieve collective designation, thereby
allowing more pregnant individuals to
seek care at a local hospital. Similarly,
another commenter requested CMS set
aside funding for technical assistance
for rural hospitals and other facilities to
fill in gaps in training and workforce
shortages that limit a hospital from
participating in a perinatal quality
improvement collaborative.
A commenter requested clarification
on whether IPPS-exempt, self-governing
children’s hospitals would be eligible
for the designation.
Response: We appreciate commenters
sharing their concerns. As stated in the
FY 2023 IPPS/LTCH PPS proposed rule,
geographic disparities in maternal
outcomes persist and we recognize the
challenges faced by small and rural
hospitals that offer maternity care in
these areas, as well as poor maternal
health outcomes disproportionately
affecting rural communities of color,
including American Indian/Alaska
Native people (87 FR 28548). We
additionally appreciate commenters’
concerns regarding the resources
required to participate in a perinatal
quality improvement collaborative and
subsequently affirmatively attest to the
Maternal Morbidity Structural measure
in order to earn the designation. We
recognize that rural and low-volume
hospitals may face challenges achieving
the designation. We intend to work with
HRSA to explore approaches that could
support maternity care quality
improvement in those facilities in the
future. In the Blueprint, the BidenHarris Administration states its intent to
improve rural obstetric readiness at
hospitals and IHS facilities by
developing guidelines and standards so
that facilities without obstetric units are
still ‘‘obstetric ready,’’ expanding
HRSA’s Rural Maternity and Obstetrics
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Management Strategies (RMOMS)
Program to enhance access to maternal
and obstetric care in rural communities,
and providing free readily-accessible
online obstetrical trainings to HRSAfunded health centers and free clinics to
support the delivery of competent
preconception, prenatal, intrapartum,
and postpartum care.1040
With regard to the recommendation to
offer financial or technical assistance,
we note that the Hospital IQR Program
statute does not authorize incentive
payments based on performance as it is
a pay-for-reporting program. However,
with our federal partners, we will
explore opportunities to offer technical
and other resources to providers. With
regard to considerations for hospital
capacity, we will consider the
suggestions for potential modifications
to the designation in the future and
explore additional variables that can
affect quality of maternity care,
including but not limited to delivery
volume, staffing capabilities, and levels
of risk-appropriate care. Any additional
changes would be made through future
rulemaking. Regarding a commenter
requesting clarification on IPPS-exempt
children’s hospitals, we note that we
use data from participating subsection
(d) hospitals and CAHs that voluntarily
participate in the Hospital IQR Program
for the designation, which means IPPSexempt children’s hospitals are
excluded. We further wish to clarify that
subsection (d) hospitals participating in
the Hospital IQR Program receive credit
under the Hospital IQR Program for the
reporting of their Maternal Morbidity
Structural measure results, whether they
attest to the affirmative or not because
it is a pay-for-reporting program (86 FR
45365). This designation is in addition
to, but separate from, the reporting of
the Maternal Morbidity Structural
measure. We continue to assess
opportunities to improve maternity care
quality, safety, and equity through this
designation and will consider strategies
focused on rural and low-volume
hospitals in future notice-and-comment
rulemaking.
Comment: Several commenters
requested that any measures used to
inform the designation be risk-adjusted.
Some commenters also requested that
publicly reported measure data be
disaggregated and stratified across
drivers of health. A few commenters
requested that publicly reported data
from the designation should include
indicators for consumers when a
1040 The White House. White House Blueprint for
Addressing the Maternal Health Crisis. June 2022.
Available at: https://www.whitehouse.gov/wpcontent/uploads/2022/06/Maternal-HealthBlueprint.pdf.
PO 00000
Frm 00509
Fmt 4701
Sfmt 4700
49287
hospital delivers care primarily to
populations that are disadvantaged and/
or underserved by the healthcare
system.
Response: We thank the commenters
for their feedback. The initial
implementation of the designation
would be based on the Maternal
Morbidity Structural measure, which is
an attestation-based measure that is not
risk-adjusted or stratified. We will
consider the feasibility, applicability,
and appropriateness of risk-adjustment
and stratification of measures as we
continue to develop this designation in
future years. We refer readers to the
Overarching Principles for Measuring
Healthcare Quality Disparities Across
CMS Quality Programs—Request for
Information in section IX.B. of the
preamble of this final rule for more
information on CMS’ potential use of
measure stratification in the future.
Comment: A few commenters
recommended CMS develop a
monitoring program to inform
consumers on the efficacy of the
designation, both for hospitals that
receive the designation and those that
do not. The commenters recommended
hospitals that did not receive the
designation should be monitored to
determine whether a lack of designation
may contribute to a reduction in
maternity care access and/or quality,
including the closure of obstetric units.
Response: We thank commenters for
this recommendation and as we monitor
hospital performance on the Maternal
Morbidity Structural measure and the
new designation, we will consider
mechanisms to assess the
implementation and impact of the
designation.
Comment: Several commenters
emphasized the importance of engaging
interested parties at state, local, and
national levels prior to implementing
the designation and in advance of
making any modifications to the
qualification requirements for the
designation. Some commenters noted
that the designation is likely to lack
value to hospitals, patients, and
communities without engagement with
relevant interested parties across the
spectrum of maternal health. Several
commenters also expressed
disappointment and concern that more
outreach was not done prior to the
creation of the designation and
requested a delay in implementation so
that hospitals have time to allocate the
resources required to qualify for the
designation. A commenter noted that
labor and resource shortages resulting
from the ongoing COVID–19 PHE
continue to impact hospitals and a delay
in implementation is needed.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49288
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Response: We appreciate feedback
from interested parties and the value it
adds to proposals set forth for the
Hospital IQR Program. We finalized the
adoption of the Maternal Morbidity
Structural measure for the Hospital IQR
Program in the FY 2022 IPPS/LTCH PPS
final rule with a reporting period
starting October 1, 2021 (86 FR 45361).
We additionally indicated our
commitment to a serious focus and
rapid action for maternal health
improvement (86 FR 45365). We seek to
use a whole-of-government approach for
improving maternal health and
advancing maternal health equity to
reduce maternal mortality and
morbidity, reduce persistent disparities,
and increase hospital participation in
evidence-based maternal health quality
improvement initiatives. As mentioned
earlier, we signaled our intent for this
designation in December 2021 alongside
Vice President Harris’ ‘‘Maternal Health
Day of Action.’’ It is our intention to
consider ongoing opportunities for
engagement with interested parties as
we continue to improve upon the
designation across future years. While
we recognize that hospitals may
participate in a variety of quality
improvement activities with a focus on
maternal health and that many hospitals
face challenges due to the COVID–19
PHE, we believe that the maternal
health crisis is urgent, maternal health
inequities are unacceptable, and this
persistent problem requires prompt
action. Thus, we do not believe delaying
the fall 2023 implementation timeframe
to launch the hospital designation
information to the public is sufficiently
responsive nor appropriate.
Comment: A few commenters
expressed concern about the
reputational impact to birth centers and
other non-hospital birthing facilities
that may provide especially high-quality
care but will be excluded from the
designation as they do not participate in
the Hospital IQR Program.
Response: We thank the commenters,
and we recognize that people may
receive maternity care in a non-hospital
birthing facility for a variety of reasons.
Birth centers, for example, are not
subsection (d) hospitals, so they cannot
participate in the Hospital IQR Program,
and would therefore not be eligible for
a designation. We encourage consumers
to utilize publicly reported quality
information to better understand the
quality of maternity services and care
available in their communities. We also
intend to provide additional outreach,
communication, and educational
materials as we launch the designation.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
d. Solicitation of Comments on
Designation Name and Additional Data
Sources To Consider for Purposes of
Awarding This Publicly-Reported
Hospital Designation
While our ultimate goal is to
designate hospitals with demonstrated
commitment to the provision of highquality, safe, and equitable maternity
care, we wish to do so in a way that is
meaningful and useful to patients and
their families as well as clinicians and
hospitals. Therefore, we solicited
comments on a name for this
designation for future years.
In addition as noted previously, we
proposed to designate hospital
commitment to maternity care quality
and safety based initially on data
collected on the Maternal Morbidity
Structural measure. Our intent is to
expand the criteria we use to award this
designation so that it more
comprehensively captures the quality
and safety of the maternity care
delivered by hospitals. Other future
sources of data potentially include data
collected on the two eCQMs we
proposed to add to the Hospital IQR
Program measure set, or data on other
Hospital IQR Program maternal health
measures, should such measures be
adopted in the future. We also
considered the feasibility of including
other quality measurement data sources.
In particular, we welcomed comments
about patient experience measures that
could be relevant for this designation,
including patient experience measures
that are currently in use in other care
settings, patient experience measures
that have been developed but require
additional testing in pilot settings, or
other measures of patient experience
that would be appropriate for inclusion
in the designation.
We invited public comment on these
and other potential quality
measurement data sources that would
be appropriate to include in a
designation that captures the quality
and safety of maternity care furnished
by hospitals, including quality measures
used in other quality reporting programs
or care delivery settings. In the previous
section IX.E.8.c., we address related
comments in the discussion of the
maternity care hospital designation.
This section of this document contains
additional comments received related to
the designation name and additional
sources of data to consider.
Comment: Many commenters shared
other recommendations related to
potential future iterations of the
PO 00000
Frm 00510
Fmt 4701
Sfmt 4700
designation. Many commenters urged
CMS to use evidence-based outcome
measures to inform a designation
instead of the attestation-based Maternal
Morbidity Structural measure. Several
commenters recommended inclusion of
existing levels of maternal care
(LoMC) 1041 in the designation,
including those already promoted and
endorsed by national stakeholder
groups, accrediting bodies, and
commissions, as an alternative to
participation in a perinatal quality
improvement collaborative. Another
commenter suggested CMS consider
other payment models, including
trauma activation or a maternal and fetal
health disproportionate share
reimbursement model that combines
U.S. Census indices with Healthcare
Effectiveness Data and Information Set
(HEDIS) and CCO data. A commenter
suggested designated hospitals be
required to offer remote patient
monitoring to high-risk patients. One
commenter believes that the designation
would be better managed by an
accreditation agency rather than CMS.
Response: We appreciate commenters’
suggestions. We note that the Hospital
IQR Program specifically uses quality
measures to improve the quality of care
as a pay-for-reporting program. As
previously stated, we intend to continue
exploring opportunities to refine the
designation for the future based on
measures that are meaningful and useful
for patients and hospitals.
Comment: A few commenters urged
CMS to dedicate sufficient resources to
clearly and deliberately communicate
with and educate consumers so they are
easily able to understand what the
designation does and does not indicate.
A couple of commenters recommended
a consumer-focused campaign with
details about the designation and where
to find information on which hospitals
are designated. The commenters also
recommended that such a campaign
include resources on safe and healthy
birth for consumers who may not have
access to a designated facility or may
not have a provider with clinical
privileges in a designated hospital. A
commenter suggested we partner with
local health departments and Medicaid
offices to share information in multiple
formats and languages with consumers.
Response: We agree with commenters
about the importance of clear
communication, and are dedicated to
communicate in a way that is culturally
and linguistically appropriate and
1041 American College of Obstetricians and
Gynecologists. Levels of Maternal Care. 2021.
Available at: https://www.acog.org/clinical/clinicalguidance/obstetric-care-consensus/articles/2019/
08/levels-of-maternal-care.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
accessible by people with disabilities,
with consumers. We intend to work
with hospitals and other interested
parties to make information about the
designation available and accessible to
patients, their families, and
communities in a way that clearly
describes what the designation means
and where they can find additional
information and resources.
Comment: Commenters had varying
recommendations on whether other
maternal health measures proposed for
the Hospital IQR Program would be
appropriate for inclusion in the
designation. Several commenters
supported the future inclusion of the
Cesarean Birth eCQM and Severe
Obstetrics Complications eCQM in the
designation. Conversely, a few
commenters opposed the potential
inclusion of these two eCQMs into the
designation citing potential burden
concerns. A few commenters
specifically noted that they would not
support the inclusion of the Cesarean
Birth eCQM as part of the designation
until it receives NQF endorsement.
Response: We thank commenters for
their recommendations on the potential
future inclusion of the Cesarean Birth
eCQM and Severe Obstetrics
Complications eCQM as part of the
designation. We will consider these
measures as we continue to develop this
designation. Any additional measures or
data sources would undergo notice-andcomment rulemaking before inclusion
in the designation. In regard to NQF
endorsement, we remind readers that
both of these eCQMs are currently
undergoing NQF review and refer
readers to our response in sections
IX.E.5.c. and IX.E.5.d. to similar
comments. While we prioritize
measures that are endorsed when
available, we reiterate that section
1886(b)(3)(B)(viii)(IX)(bb) of the Act
provides an exception that, in the case
of a specified area or medical topic
determined appropriate by the Secretary
for which a feasible and practical
measure has not been endorsed by the
entity with a contract under section
1890(a) of the Act, the Secretary may
specify a measure that is not so
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary.
We further reiterate, as stated in the FY
2022 IPPS/LTCH PPS final rule (86 FR
45365) that, given the severity of the
maternal morbidity crisis and as there
are currently no NQF-endorsed
measures that address maternal
morbidity through hospital participation
in Statewide or national Perinatal QI
Collaboratives, we believe it is
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
important to implement this measure as
soon as possible.
Comment: Many commenters
suggested other measures for inclusion
in the designation requirements. Several
commenters recommended
breastfeeding measures. Several
commenters recommended that the
designation include a requirement to
demonstrate the provision of respectful
maternity care, which could include
training on cultural competency,
implicit bias, and antiracism. A few
commenters suggested demonstration of
hiring practices that are culturally and
community representative. A couple of
commenters recommended maternity
adaptations of the sixth CAHPS
development cycle to track disrespect
and related forms of provider behavior.
The commenters also suggested Patient
Reported Outcome Measures (PROMs)
and Patient-Reported Outcome-based
Performance Measures (PRO–PMs)
measuring the various dimensions of
respect and experience of care. Several
commenters emphasized the importance
of a designation that highlights hospitals
providing access to a diverse maternity
care workforce. Commenters cited
certified nurse midwives and certified
midwives, doulas, certified lactation
consultants, community health workers,
mental health professionals, and
substance use treatment clinicians as
vital members of the team. Some
commenters recommended the
designation include a requirement for
hospitals to report whether or not they
provide access to such providers. A
commenter recommended CMS adopt a
sufficient minimum staffing rate as a
designation criterion to ensure quality
and safety in maternity care delivery.
One commenter recommended hospitals
seeking the designation conduct
simulations of urgent or emergency
obstetric scenarios, attest that they have
regional transport agreements in place,
and that emergency department staff are
trained in neonatal resuscitation.
Another commenter recommended a
measure of postpartum patients with
new medical conditions who are
discharged with at least seven days of
medication. Another commenter
recommended requiring implementation
of the AIM Postpartum Discharge
Transition Patient Safety Bundle.1042
Another commenter suggested a
structural measure of hospital
participation in Maternal Early Warning
1042 American College of Obstetrics and
Gynecology. Alliance for Innovation on Maternal
Health (AIM). 2014. Available at: https://
www.acog.org/practice-management/patient-safetyand-quality/partnerships/alliance-for-innovationon-maternal-health-aim.
PO 00000
Frm 00511
Fmt 4701
Sfmt 4700
49289
System (MEWS) programs.1043 Another
commenter recommended measurement
of the rate of completion of two-week
postpartum visits. Another commenter
recommended a measure of access to a
certified lactation consultant. Another
commenter suggested a measure of skinto-skin rates. Another commenter
recommended a measure of access to
postpartum contraception (NQF #2902)
as well as a measure of unexpected
complications of the healthy newborn
(NQF #0716). A couple of commenters
recommended CMS include the
establishment of a hemorrhage protocol
as a requirement of the designation.
Another commenter recommended
implementation of a triage acuity tool
specifically designed for obstetric units
as a component of the designation.
Several commenters expressed
concern about the rights of patients and
their ability to access medically
necessary care. A couple of commenters
recommended that any hospitals that
receive the designation be required to
transparently report any non-medical
restrictions on care, including bans on
postpartum tubal ligations, offering
other forms of postpartum
contraception, and treatments for
ectopic pregnancy or premature rupture
of membranes. The commenters also
requested a commitment from
designated hospitals to publicly report
the number of patients who are denied
those forms of care each year.
Additionally, the commenters
recommended that designated hospitals
not be allowed to send away patients
with emergency medical conditions and
should be required to comply with
Emergency Medical Treatment and
Labor Act (EMTALA). The commenters
further encouraged CMS to utilize
Beneficiary and Family Care Quality
Improvement Organizations (BFCC–
QIOs) and Quality Innovation Network
(QIN) QIOs to help patients better
understand the quality of care to which
they are entitled, work with hospitals to
improve delivery of care, assist patients
with complaint processes, and help
patients understand their rights and
hospitals their obligations under
EMTALA.
Response: We thank the commenters
for their feedback and appreciate their
robust recommendations. We note that
we recently communicated with
hospitals regarding their existing
obligations to comply with EMTALA
and refer readers to https://
www.cms.gov/files/document/qso-221043 TCHMB. Maternal Early Warning System.
Available at: https://www.tchmb.org/maternalearly-warning-system#:∼:text=The%20Maternal
%20Early%20Warning%20System,avoiding
%20major%20morbidity%20and%20mortality.
E:\FR\FM\10AUR2.SGM
10AUR2
49290
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
22-hospitals.pdf for more details.1044
We further reaffirm our ongoing
commitment to improving maternal
health and note that actions related to
many suggestions from commenters are
discussed in more detail in the BidenHarris Administration’s Blueprint for
Addressing the Maternal Health Crisis,
including the call to eliminate coverage
gaps for postpartum women by
encouraging states to extend Medicaid
coverage from 60 days to a full 12
months postpartum.1045 The Blueprint
also discusses plans to address the gaps
in our perinatal workforce, including
increasing the number of physicians,
licensed midwives, doulas, and
community health workers in
communities that are historically
underserved and under-resourced by the
healthcare system; providing guidance
to states to help them expand access to
licensed midwives, doulas, and
freestanding birth centers in Medicaid;
and encouraging insurance companies
to improve reimbursement for and
coverage of licensed midwives and
perinatal supports, such as doulas and
nurse home visits.1046 Additionally, the
FY 2023 President’s Budget allocates
funds to help train providers on implicit
biases as well as culturally and
linguistically appropriate care and to
educate and empower more pregnant
women and families to know the early
warning signs of pregnancy-related
complications and behavioral health
needs.1047 We appreciate these
recommendations as we consider future
direction and policy related to the
designation for future notice-andcomment rulemaking.
Comment: A commenter
recommended future measures be
submitted through the Measures Under
Consideration (MUC) process.
Response: We thank the commenter
for the suggestion and note that
measures adopted for the Hospital IQR
Program are required to go through the
1044 Centers for Medicare & Medicaid Services
Center for Clinical Standards and Quality. QSO–22–
22-Hospitals. Reinforcement of EMTALA
Obligations specific to Patients who are Pregnant or
are Experiencing Pregnancy Loss (QSO–21–22HospitalsUPDATED JULY 2022). July 2022.
Available at: https://www.cms.gov/files/document/
qso-22-22-hospitals.pdf.
1045 The White House. White House Blueprint for
Addressing the Maternal Health Crisis. June 2022.
Available at: https://www.whitehouse.gov/wpcontent/uploads/2022/06/Maternal-HealthBlueprint.pdf.
1046 The White House. White House Blueprint for
Addressing the Maternal Health Crisis. June 2022.
Available at: https://www.whitehouse.gov/wpcontent/uploads/2022/06/Maternal-HealthBlueprint.pdf.
1047 The White House. Budget of the U.S.
Government Fiscal Year 2023. Accessed June 24,
2022. Available at: https://www.whitehouse.gov/wpcontent/uploads/2022/03/budget_fy2023.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
pre-rulemaking process (which includes
the MUC process and review of the
MAP) in compliance with section
1890A of the Act.
Comment: Another commenter
cautioned that hospitals should not be
penalized through components in the
designation that fail to account for
patients who choose to receive care
from non-physician practitioners and
are then transferred to physician care
late in pregnancy due to an advanced
complication. The commenter stated
that many factors remain outside of the
control of the hospital or treating
physician and designation components
should take this into account. A few
commenters urged CMS to maintain
facility-level measures under the
designation and cautioned against the
adoption of physician-level measures.
Response: We acknowledge the
commenter’s concern and understand
the commenter to mean that hospitals
may provide care to pregnant patients in
labor or delivery who have not
previously received care at that hospital
and the commenter is concerned about
the impact such situations may have on
a hospital’s ability to earn the
designation. At this time, the
designation is based solely on
affirmative attestation to the Maternal
Morbidity Structural measure and we do
not believe that situations such as those
described by the commenter would
negatively affect a hospital’s ability to
attest to that measure. We further
recognize that there are factors beyond
the control of hospitals when treating
pregnant women, but we believe that
the maternal health crisis requires
urgent action, and that this designation
can support hospital action on maternal
health quality improvement activities.
Comment: Several commenters
suggested names for the new maternity
care hospital designation. A few
commenters suggested ‘‘Quality Birthing
Hospital’’ as a possible name. A
commenter recommended use of ‘‘Birth
Star Hospital’’ or ‘‘Better Birthing
Hospital’’ to reflect the quality of
birthing care. Another commenter
suggested ‘‘Quality Care for Birthing
People’’ while another commenter
recommended ‘‘Quality Care and Birth
Equity’’ or ‘‘Excellence in Birthing
Outcomes.’’ Another commenter
suggested ‘‘Birthing-Conscious
Hospital’’ to reflect the maternal and
neonatal process. Another commenter
suggested ‘‘Center of Excellence in
Maternity Care.’’
Several commenters stated that the
designation name should reflect the data
it is measuring and meaningfully
represent the population of interest. A
commenter recommended that the name
PO 00000
Frm 00512
Fmt 4701
Sfmt 4700
emphasize our commitment to
excellence. Another commenter
cautioned against a name that could be
mistaken for marketing.
Several commenters were concerned
that use of ‘‘birthing-friendly’’ was too
similar to the Baby-Friendly Hospital
Initiative, a program developed by the
World Health Organization (WHO) and
the United Nations International
Children’s Emergency Fund (UNICEF).
The commenters encouraged moving
away from use of ‘‘birthing-friendly’’ to
avoid any potential confusion.
Response: We thank commenters for
their suggestions and will take them
into consideration for a future name for
the designation.
e. Additional Activities To Advance
Maternal Health Equity—Request for
Information
We are committed to advancing
equity for all, including those in
historically underserved and underresourced communities (American
Indian or Alaska Native, Asian or
Pacific Islander, Black, Hispanic, and
other persons of color; members of
religious minorities; lesbian, gay,
bisexual, transgender, and queer
(LGBTQ+) persons; persons with
disabilities; persons who live in rural
areas and others who have been
historically underserved, marginalized,
and adversely affected by persistent
poverty and inequality).
We specifically sought to explore how
we can address the U.S. maternal health
crisis through policies and programs,
including, but not limited to, the
Conditions of Participation (CoPs) and
through measures in our quality
reporting programs. The CoPs are the
health and safety standards that
Medicare-certified providers and
suppliers must meet to receive Medicare
and Medicaid payment. CMS has broad
statutory authority to establish health
and safety regulations for various
providers and suppliers; that statutory
authority is usually found within the
statutory definition of each provider and
supplier type. In the case of hospitals,
for instance, section 1861(e)(1) through
(8) of the Act sets out specified
requirements that hospitals must meet;
in addition, section 1861(e)(9) of the Act
requires hospitals to ‘‘meet[ ] such other
requirements as the Secretary finds
necessary in the interest of the health
and safety of individuals who are
furnished services in the institution.’’
We invited public comment on the
following:
• CMS outlines best practices in the
memorandum to state survey agencies
entitled ‘‘Evidence-Based Best Practices
for Hospitals in Managing Obstetric
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
emergencies and Other Key Contributors
to Maternal Health Disparities.’’ 1048
What other additional effective best
practices or quality improvement
initiatives are currently being utilized
by hospitals? How else can hospitals
improve maternal health outcomes,
enhance their quality of maternity care,
and reduce maternal health disparities?
• For hospitals that offer inpatient
maternity services, including labor and
delivery care, how could the CoPs be
modified to improve maternity care and
address disparities in maternal health
outcomes? How would hospitals focus
their governance, provider and staff
training, and care-delivery activities to
effectively demonstrate compliance
with CoPs related to improving maternal
health outcomes? What types of
measurable activities targeting maternal
health outcomes might demonstrate a
reduction in maternal health care
disparities or improvement in maternal
health care delivery?
• Are there new requirements that
could be established in the CoPs that
would require hospitals to address and
improve the quality of postpartum care
and support provided to patients? How
can the CoPs specifically address the
need to improve behavioral health
services and monitoring offered during
prenatal and postpartum care?
• Might the potential additional
maternal health-focused CoPs have
unintended consequences on providers
with certain characteristics (such as
being located in a rural area or having
low-volume)? Please provide details on
how certain providers might be
differentially affected by potential
maternal health CoPs. Are there barriers
or facilitators that would influence rural
hospital achievement of a publiclyreported maternal health designation
that may not relate directly to the
quality of services provided? How might
maternal health CoPs impact providers
considering whether it is feasible or
viable to offer labor and delivery
services in their area?
• What services and staff training
should hospitals without inpatient
maternity services have in place in
preparation for patients in labor?
• What are the best practices that
hospitals are utilizing to educate and
conduct outreach to patients in
underserved communities to increase
access to timely maternity care?
1048 Evidence-based best practices for hospitals in
managing obstetric emergencies and other key
contributors to maternal health disparities. U.S.
Department of Health and Human Services. https://
www.hhs.gov/guidance/document/evidence-basedbest-practices-hospitals-managing-obstetricemergencies-and-other-key.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
• What are best practices for hospitals
to actively engage with patients and
their families, community-based
organizations, and others within their
local community to obtain information
on ways to improve maternity care? Are
there barriers to such engagement (if so,
what are the barriers)?
• Do hospitals provide preventionrelated education and community
outreach on the specific maternal health
conditions that have the greatest impact
on disadvantaged and underserved
communities?
• How can hospitals review and
monitor aggregate data on the maternal
health risks of the patient population
that they serve? What data should
hospitals review related to the maternal
health risks of the patient population
they serve? What data sharing best
practices are required for hospitals to
share data with external entities,
including local and state health
departments, community-based
organizations, or other health care
providers? How can hospitals connect
data collected for mothers and their
babies after delivery to support research
and evaluation of maternal health care
after delivery?
• What challenges are there to
collecting data on patients with specific
maternal health risks? Can these data be
stratified by demographics (for example,
race and ethnicity)? In addition, how
can these data be used in a hospital’s
quality improvement efforts, and
specifically, in their quality assurance
and performance improvement (QAPI)
program, to improve maternal health
outcomes and advance health equity
and reduce disparities within their
facility? How can maternity care can be
incorporated into an ongoing QAPI
program?
• How do hospitals conduct reviews
of maternal deaths that have occurred
within the facility?
• Are hospitals currently utilizing
community health needs assessments to
determine the specific maternity care
needs and social determinants of health
of the patient population that they
serve? For those hospitals that are
utilizing community health needs
assessments, are there certain best
practices or examples of ways that this
assessment can be used to reduce
disparities in maternal outcomes?
• Do hospitals have reporting
relationships or mechanisms among
primary care physicians, obstetriciangynecologists, and other health care
providers such as nurses and certified
nurse midwives, and community-based
perinatal workers, such as doulas, for
optimal coordination of care?
PO 00000
Frm 00513
Fmt 4701
Sfmt 4700
49291
• Do hospitals have readily available
referral relationships and points of
contact with community resources or
community-based organizations to
address additional services that a
postpartum patient may need upon
discharge? This could include the
consideration of behavioral and mental
health services or resources to address
health-related social needs, such as food
insecurity, housing instability, and
transportation challenges. If hospitals
do not have readily available referral
relationships and points of contact
within the community, what barriers
and facilitators impact hospital
relationships with community resources
or community-based organizations?
• How do hospitals evaluate their
perinatal customer experience? What
are best practices that are currently
being utilized for getting robust input
from patients on their perinatal
experience?
• What best practices exist for
ensuring systemic racism and biases,
including implicit bias, are not
perpetuated in maternity care?
We received comments on this topic.
Comment: Commenters provided
many recommendations for additional
maternal health considerations. These
included suggestions on how to
effectively disseminate best practices in
maternity care, the potential
applicability of CoPs related to maternal
health outcomes, staff training on
antiracism and implicit bias in
maternity care, approaches for riskadjustment and stratification of
maternal health data, frameworks for
implementing maternal health safety
monitoring programs, integration of
comprehensive clinical and communitybased maternity care delivery systems,
opportunities for hospitals to build
referral relationships with communitybased providers, staffing crossfunctional and holistic maternity care
teams, and designing customer
experience and evaluation tools for
maternity care patients and families.
Commenters additionally shared
examples from state, local, and regional
groups as well as individual hospitals
working to improve maternity care.
Commenters also urged our pursuit of
meaningful, continuous outreach with
interested parties to ensure that future
maternal health actions are effective and
add value to hospitals, patients, and
communities.
Response: We appreciate learning
about the many meaningful programs
and practices hospitals are utilizing
across our nation and the commitment
to implementation of evidence-based
practices to improve maternal health
and maternity care delivery. We also
E:\FR\FM\10AUR2.SGM
10AUR2
49292
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
thank commenters for the range of
recommendations and measure
suggestions. As noted in the Blueprint,
every person should have a safe,
dignified pregnancy and birth and
equitable access to health care before,
during, and after pregnancy.1049 We will
consider all input as we continue to
develop and make progress in strategies
that address maternity care quality,
safety, and equity in the Hospital IQR
Program, through potential new CoPs,
and other CMS activities, and will
continue outreach to interested parties
on future maternal health actions.
khammond on DSKJM1Z7X2PROD with RULES2
9. Future Considerations
We seek to develop a comprehensive
set of quality measures to be available
for widespread use for informed
decision-making and quality and cost
improvements through the inpatient
hospital setting. We have identified
potential future measures for future
development, which we believe address
areas that are important to stakeholders,
but which are not currently covered in
the Hospital IQR Program. Therefore, in
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28550) we sought comment
on these potential future considerations,
as detailed later in the section.
We also refer readers to the following
sections: (1) section IX.A. where we
sought comments from stakeholders on
the health impacts due to climate
change, especially on underserved
populations, and how we could
potentially support hospitals and health
systems to more effectively determine
and plan for climate impacts, reduce
greenhouse gas emissions, and track
progress; (2) section IX.B. where we
sought input on overarching principles
in measuring healthcare quality
disparities in hospital quality programs
and value-based purchasing programs;
and (3) section IX.C. where we sought
input on ongoing ways we can advance
digital quality measurement and use of
Fast Healthcare Interoperability
Resources (FHIR) in quality reporting
programs.
a. Potential Future Inclusion of Two
Digital National Healthcare Safety
Network (NHSN) Measures
The Hospital IQR Program previously
included NHSN measures that were
finalized for removal from the measure
set in the FY 2019 IPPS/LTCH PPS final
rule (83 FR 4157 through 41553), and
retained in the Hospital-Acquired
Condition (HAC) Reduction Program (83
1049 The White House. White House Blueprint for
Addressing the Maternal Health Crisis. June 2022.
Available at: https://www.whitehouse.gov/wpcontent/uploads/2022/06/Maternal-HealthBlueprint.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
FR 41474 through 41477; 83 FR 41449
through 41452) and the Hospital VBP
Program (83 FR 41449 through 41452).
We have recently identified two new
potential measures that utilize EHRderived data to help address hospitalbased adverse events, specifically,
hospital-onset infections.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28550 through
28554), we discussed these two
measures in more detail and sought
public comment on the future inclusion
of these measures in the Hospital IQR
Program. We also invited public
comment on other aspects of these two
measures related to future
implementation. In addition, we sought
public comment on the application of
one or both of these measures in other
quality reporting programs, including
the HAC Reduction Program, the
Hospital VBP Program, the PCHQR
Program, and the LTCH QRP.
(1) National Healthcare Safety Network
(NHSN) Healthcare-Associated
Clostridioides difficile Infection
Outcome Measure
(a) Background
Clostridioides difficile 1050 is a
bacterium that causes diarrhea,
pseudomembranous colitis, and toxic
megacolon which can lead to sepsis or
death.1051 1052 1053 Clostridioides difficile
infections (CDI) can be reduced in
healthcare settings using a multi-faceted
approach, including development of an
infrastructure for monitoring CDI,
implementation of effective antibiotic
stewardship to reduce the use of
unnecessary antibiotics, isolation and
contact precautions for patients with
CDI, performance of environmental
cleaning with sporicidal agents, and
other measures.1054 CDI is one of the
most common healthcare-associated
infections (HAIs) in the U.S.1055 1056 At
1050 The Clostridioides difficile bacterium was
previously called clostridium difficile. The naming
was updated in 2016 due to taxonomic updates.
1051 Centers for Disease Control and Prevention
(CDC). What is C. diff? Available at: https://
www.cdc.gov/cdiff/what-is.html.
1052 Centers for Disease Control and Prevention
(CDC). Clostridioides difficile Infection (CDI)
Tracking. Available at: https://www.cdc.gov/hai/
eip/cdiff-tracking.html.
1053 Centers for Medicare & Medicaid Services
National Healthcare Safety Network (NHSN)
Facility-wide Inpatient Hospital-onset Clostridium
difficile Infection (CDI) Outcome Measure.
Available at: https://cmit.cms.gov/cmit/#/
MeasureView?variantId=606§ionNumber=1.
1054 Centers for Disease Control and Prevention
(CDC) CDI Prevention Strategies. Available at:
https://www.cdc.gov/cdiff/clinicians/cdiprevention-strategies.html.
1055 Kwon, J.H., Olsen, M.A., Dubberke, E.R.
(2015). The Morbidity, Mortality, and Costs
Associated with Clostridium difficile Infection.
PO 00000
Frm 00514
Fmt 4701
Sfmt 4700
any given time, 1 in 31 patients has an
HAI in the U.S., and over a million
cases of HAIs are reported every year,
making HAIs one of the most common
adverse events that occurs in a
healthcare setting.1057 1058
As one of the most common HAIs,
CDIs are a significant contributor to
inpatient morbidity and mortality,
particularly among older adults.1059
Incidence of CDI is higher among White
patients, female patients, and patients
over 65 years of age.1060 CDIs result in
an estimated 500,000 cases annually
and between 15,000 and 20,000
deaths.1061 Additionally, costs
associated with CDIs average about
$11,400 per case and can have a
significant impact on the U.S.
healthcare system.1062 More broadly,
HAIs cost over $9.8 billion dollars
annually with CDIs contributing to 15.4
percent, or about $1.5 billion dollars of
these total annual costs.1063 Therefore,
we currently require reporting of CDI
outcomes, along with other HAIs, in
value-based purchasing programs like
the Hospital VBP Program and HAC
Infect Dis Clin North Am. 29(1):123–34. Available
at: https://www.sciencedirect.com/science/article/
abs/pii/S0891552014000804?via%3Dihub.
1056 Magil, S.S., O’Leary, E., Janelle, S.J.,
Thompson, D.L., Ghinwa, D., Nadle, J., et al. (2018).
Changes in Prevalence of Health Care-Associated
Infections in U.S. Hospitals. N Engl J Med.
379:1732–1744. DOI: 10.1056/NEJMoa1801550.
1057 Magil, S.S., O’Leary, E., Janelle, S.J.,
Thompson, D.L., Ghinwa, D., Nadle, J., et al. (2018).
Changes in Prevalence of Health Care-Associated
Infections in U.S. Hospitals. N Engl J Med.
379:1732–1744. DOI: 10.1056/NEJMoa1801550.
1058 Haque M, Sartelli M, McKimm J, Abu Bakar
M. (2018). Health care-associated infections—an
overview. Infect Drug Resist. 11:2321–2333.
doi:10.2147/IDR.S177247.
1059 Centers for Disease Control and Prevention.
(2018). Analysis and Recommendations on the
NHSN Clostridioides difficile Outcome. Available
at: https://www.cdc.gov/hicpac/pdf/NHSN-C-diff-H.
pdf#:∼:text=NHSN%20is%20the%20most
%20widely%20used%20secure%2C%20internetbased,decreasing%20in%20contrast%20to
%20other%20healthcare-associated%20infections.
%202.
1060 Lessa FC, Mu Y, Bamberg WM, et al. (2015).
Burden of Clostridium difficile infection in the
United States. N Engl J Med. 372(9):825–34. doi:
10.1056/NEJMoa1408913.
1061 Zaver, H.B., Moktan, V.P, Harper, E.P., et al.
(2021). Reduction in Health Care Facility—Onset
Clostridioides difficile Infection: A Quality
Improvement Initiative. Mayo Clin Proc Innov Qual
Outcomes. 5(6):1066–1074. doi: 10.1016/
j.mayocpiqo.2021.09.004.
1062 Zimlichman E, Henderson D, Tamir O, et al.
(2013). Health care-associated infections: a metaanalysis of costs and financial impact on the US
health care system. JAMA Intern Med.
173(22):2039–46. doi: 10.1001/
jamainternmed.2013.9763.
1063 Zimlichman E, Henderson D, Tamir O, et al.
(2013). Health care-associated infections: a metaanalysis of costs and financial impact on the US
health care system. JAMA Intern
Med.173(22):2039–46. doi: 10.1001/
jamainternmed.2013.9763.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Reduction Program, in order to connect
performance on HAI measures with
payment adjustments.1064
The CDC has developed the National
Healthcare Safety Network (NHSN)
Healthcare-Associated Clostridioides
difficile Infection Outcome measure that
utilizes EHR-derived data. The goal of
this measure is to drive an increase in
prevention practices, which would
result in fewer CDI cases and reduced
morbidity and mortality in patients. We
believe this would be especially useful
given that most cases of CDIs may be
prevented or stopped from spreading to
other patients when inpatient facilities
utilize infection control steps
recommended by the CDC. We believe
utilizing the CDC’s NHSN reporting and
submission infrastructure will impose
less administrative burden related to
data collection and submission for this
measure.
Previously, the Hospital IQR Program
included a CDI measure which only
required CDI facility-wide Lab-ID event
reporting (we refer readers to the FY
2012 IPPS/LTCH PPS final rule, 76 FR
51630 through 51631).1065 The newly
developed version of the measure would
improve on the original version of the
measure by requiring both microbiologic
evidence of CDI in stool and evidence
of antimicrobial treatment, whereas the
original measure only required CDI
facility-wide Lab-ID event reporting.
The addition of anti-microbial treatment
evidence may provide further validity in
the reporting of CDIs, as it serves as a
surrogate for test results that were
clinically interpreted as true infections.
The NHSN Healthcare-Associated
Clostridioides difficile Infection
Outcome measure addresses the quality
priority of ‘‘Make Care Safer by
Reducing Harm Caused in the Delivery
of Care’’ through the Meaningful
Measures Area of ‘‘Healthcare
Associated Infections.’’ 1066
1064 Centers for Disease Control and Prevention.
(2018). Analysis and Recommendations on the
NHSN Clostridioides difficile Outcome. Available
at: https://www.cdc.gov/hicpac/pdf/NHSN-C-diffH.pdf#:∼:text=NHSN%20is%20the%20most
%20widely%20used%20secure%2C%20internetbased,decreasing%20in%20contrast%20to
%20other%20healthcare-associated
%20infections.%202.
1065 In the FY 2019 IPPS/LTCH PPS final rule (83
FR 41547 through 41553) we removed the NHSN
Facility-Wide Inpatient Hospital-Onset Clostridium
difficile Infection (CDI) Outcome measure (NQF
#1717) from the Hospital IQR Program measure set
but retained it in the HAC Reduction Program and
Hospital VBP Program where it is reported via the
CDC NHSN portal (83 FR 41474 through 41477; 83
FR 41449 through 41452). We removed this
measure under removal Factor 8, the costs
associated with a measure outweigh the benefit of
its continued use in the program (83 FR 41547).
1066 Centers for Medicare & Medicaid Services.
(2021). Meaningful Measures Hub. Available at:
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
49293
Additionally, pursuant to Meaningful
Measures 2.0, this measure addresses
the ‘‘Safety’’ and ‘‘Wellness and
Prevention’’ priority areas and aligns
with our commitment to a patientcentered approach in quality
measurement to ensure that patients are
safe and receive the highest quality
care.1067
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28551 through
28552), we requested feedback on the
potential future inclusion of the NHSN
Healthcare-Associated Clostridioides
difficile Infection Outcome measure into
the Hospital IQR Program measure set to
aid in disease monitoring, provide
hospitals and patients with more
information to inform care delivery, and
improve patient outcomes.
under consideration for use in various
Medicare programs. The NHSN
Healthcare-Associated Clostridioides
difficile Infection Outcome measure
(MUC2021–098) was reviewed by the
NQF MAP Hospital Workgroup on
December 15, 2021, and received
conditional support pending NQF
review and re-endorsement once the
revised measure is fully tested.1070 The
MAP Coordinating Committee, which
provides direction to the MAP
workgroups, concurred with the
recommendations of the MAP Hospital
Workgroup.1071 We understand that the
CDC intends to submit the measure in
the future for NQF review and
endorsement.
(b) Overview of Measure
The NHSN Healthcare-Associated
Clostridioides difficile Infection
Outcome measure would track the
development of new CDIs among
patients already admitted to healthcare
facilities, using algorithmic
determinations from data sources
widely available in EHRs. Both the
original and new measure employ the
Standardized Infection Ratio (SIR), a
statistic used to track HAIs over time.
Along with the SIR, this new measure
would also use the Adjusted Ranking
Metric (ARM) of hospital-onset CDIs
among hospitalized patients. The SIR is
a primary summary statistic used by the
NHSN to track HAIs, and ARM is a new
statistic available for acute care
hospitals that accounts for differences in
the volume of exposure (specifically,
denominator) between facilities. ARM
provides complementary information to
the SIR as ARM provides the reliabilityadjusted number of events and allows
for ranking facilities.1068
The measure was previously endorsed
by MAP on June 11, 2019. The CDC
submitted the measure for reendorsement and it was included in the
publicly available ‘‘List of Measures
Under Consideration for December 1,
2021’’ (MUC List),1069 a list of measures
Hospitals would provide data for this
measure from their EHRs. The primary
sources of data for determining
numerator events include microbiology
data (CDI test), medication
administration data (CDI antimicrobial
treatment), and patient encounter,
demographic, and location information.
To facilitate rapid, automated, and
secure data exchange, the CDC’s NHSN
is planning to enable and promote
reporting of this measure using FHIR.
However, as FHIR capabilities are
evolving and not yet uniform across
healthcare systems, the CDC is also
planning on enabling reporting using
the existing Health Level 7 (HL7)
Clinical Document Architecture (CDA),
and potentially other formats as well to
provide all facilities with an option for
reporting. We are also working with the
CDC and ONC to consider how certified
health IT can support reporting of data
for this measure.
We invited public comment on
potential reporting formats for this
measure.
https://www.cms.gov/Medicare/Quality-InitiativesPatient-Assessment-Instruments/
QualityInitiativesGenInfo/MMF/General-info-SubPage.
1067 Centers for Medicare & Medicaid Services.
(2021). Quality Measurement Action Plan.
Available at: https://www.cms.gov/files/document/
2021-cms-quality-conference-cms-qualitymeasurement-action-plan-march-2021.pdf. We note
that Meaningful Measures 2.0 is still under
development.
1068 More information on how ARM and SIR
compare can be found at: https://www.cdc.gov/
nhsn/ps-analysis-resources/arm/.
1069 Centers for Medicare & Medicaid Services.
(2021). List of Measures Under Consideration for
December 1, 2021. Available at: https://
PO 00000
Frm 00515
Fmt 4701
Sfmt 4700
(c) Data Sources
(d) Outcome
The outcome of interest is the number
of new CDIs among patients already
admitted to healthcare facilities.
www.cms.gov/files/document/measures-underconsideration-list-2021-report.pdf.
1070 National Quality Forum. (2022). Measure
Applications Partnership (MAP) 2021–2022 Final
Recommendations. Available at: https://
www.qualityforum.org/WorkArea/linkit.aspx?
LinkIdentifier=id&ItemID=96698.
1071 National Quality Forum. (2022). Measure
Applications Partnership 2021–2022 Considerations
for Implementing Measures in Federal Programs:
Clinician, Hospital, and Post-Acute Care Long-Term
Care: Final Report. Available at: https://
www.qualityforum.org/Publications/2022/03/MAP_
2021-2022_Considerations_for_Implementing_
Measures_Final_Report_-_Clinicians,_Hospitals,_
and_PAC-LTC.aspx.
E:\FR\FM\10AUR2.SGM
10AUR2
49294
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(e) Cohort
The measure cohort consists of all
patients in the denominator: the
expected number of hospital-acquired
CDIs based on predictive models using
facility- and patient- care location data
as predictors.
(f) Exclusion Criteria
The measure excludes patients in the
denominator who are not assigned to an
inpatient bed in an applicable location,
including outpatient clinics and ED
visits. Patients <365 days old will also
be excluded. As an aside, inpatient
rehabilitation locations and inpatient
psychiatric locations that have their
own CMS Certification Number (CCN)
are also excluded from the denominator.
(g) Risk adjustment
The risk adjustment was developed
with a statistical risk model. The SIR is
risk adjusted for each facility, and the
ARM adjusts for volume of exposure
between facilities as well as risk
adjustment.
khammond on DSKJM1Z7X2PROD with RULES2
(h) Measure Calculation
The measure assesses the
development of new CDI among patients
already admitted to healthcare facilities.
(i) Numerator and Denominator
The measure’s denominator consists
of the expected number of hospitalassociated CDIs based on predictive
models using facility and patient care
location data as predictors. The
numerator consists of the total observed
number of observed CDIs among all
inpatients in the facility based on the
combination of laboratory test for CDIs
plus a therapeutic administered within
a window period around the specimen
date.
We received comments on this topic.
Comment: Many commenters
supported the potential inclusion of the
NHSN Healthcare-Associated
Clostridioides difficile Infection
Outcome measure in the Hospital IQR
Program, stating that it is an
improvement over the previously
developed CDC NHSN Facility-wide
Inpatient Hospital-onset Clostridium
difficile Outcome Measure and will
prevent hospital-acquired infections. A
few commenters suggested that we use
a phased adoption timeline to give
hospitals time to familiarize themselves
with reporting measure data. A
commenter supported the measure on
the condition that certified health IT
systems can support data reporting for
this measure.
Response: We thank the commenters
for their support and suggestions to
improve the measure. We will continue
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
to collaborate with the CDC and take the
feedback into account for future noticeand-comment rulemaking.
Comment: Several commenters did
not support potential inclusion of the
NHSN Healthcare-Associated
Clostridioides difficile Infection
Outcome measure into the Hospital IQR
Program. A commenter opposed
adoption because the measure has not
received NQF endorsement yet, while
another cited uncertainties in the
measure definitions. A commenter
stated that the measure does not take
into account patient factors that increase
the risk of developing CDIs. A
commenter believed that the technology
to report this measure is currently not
ready for use. Another commenter did
not support providing evidence of
antimicrobial treatment for CDI.
Response: We thank the commenters
for their feedback and for sharing their
concerns. We will continue to
collaborate with the CDC and consider
this feedback during future notice-andcomment rulemaking.
Comment: Many commenters
requested that we postpone adopting the
NHSN Healthcare-Associated
Clostridioides difficile Infection
Outcome measure until it has been fully
tested for validity and reliability and
receives NQF endorsement. Several
commenters recommended that the
measure exclude immunocompromised
patients or include risk adjustment
based on patients’ vulnerability to
infections. A commenter recommended
that the measure include an exclusion
for infections following the use of
antibiotics and expressed concern about
the measure’s impact on rural and lowvolume hospitals. A few commenters
requested additional clarification and
guidance on the measure definitions.
Response: We appreciate the
commenters’ recommendations. We
note that the CDC is still refining the
measure specifications. We will take
this feedback into consideration as part
of future notice-and-comment
rulemaking.
Comment: Several commenters were
concerned that the NHSN HealthcareAssociated Clostridioides difficile
Infection Outcome measure might have
unintended side effects, such as
hospitals discouraging health care
practitioners from testing or treating
patients for CDIs to reduce the number
of patients reported in the numerator.
To prevent this, a few suggested that we
consider working with the CDC to
monitor for such practices, or conduct
parallel monitoring of complementary
metrics. A few commenters expressed
concern over the administrative burden
of reporting the measure, especially
PO 00000
Frm 00516
Fmt 4701
Sfmt 4700
while Fast Healthcare Interoperability
Resources (FHIR) and other electronic
reporting capabilities are still evolving.
A few others suggested that CMS delay
mandatory reporting to provide
hospitals with enough time to develop
their digital reporting capabilities. A
commenter recommended that the
measure include incentives to hire
infection prevention staff given that
existing staff are already overworked.
Response: We thank commenters for
their feedback and share their concern
for avoiding any negative effects on
patient care arising from adoption of
this measure. We note that this measure
is not being proposed for adoption at
this time and we requested input as we
consider its future inclusion into quality
reporting and value-based programs. We
will take these comments into
consideration as part of future noticeand-comment rulemaking.
Comment: Several commenters shared
their feedback on including the NHSN
Healthcare-Associated Clostridioides
difficile Infection Outcome measure in
the Hospital VBP and HAC Reduction
Programs. A few commenters were
supportive of including the measure in
the value-based purchasing programs,
with a commenter noting that including
this potential future measure in the
Hospital VBP and HAC Reduction
Programs could improve quality of care,
especially for the most vulnerable
patients. A few commenters expressed
concern that the new digital measure is
not yet ready for the value-based
purchasing programs because it lacks
baseline testing data, the measure
definitions need refinement, and the
risk adjustment methodology does not
account for patient factors that increase
the risk of developing CDIs. They urged
that this measure be fully defined,
validated, and NQF endorsed prior to
implementation. A commenter
expressed their belief that CMS should
not adopt this measure for the Hospital
VBP Program or HAC Reduction
Program until hospitals can consistently
report using FHIR or testing confirms
comparable results using different
reporting methods. A commenter sought
clarification on how this potential
future measure would be weighted in
the Hospital VBP and HAC Reduction
Programs and how CMS would establish
baseline data from which to determine
percentiles and rankings that would
impact Hospital VBP and HAC
Reduction Program payments. Another
commenter recommended that the CDC
NHSN MRSA and CLABSI measures be
maintained in their current programs
because they are more specific and
better understood by consumers. A
commenter stated that CMS should
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
match the measure definition with the
one utilized in the CDI project as part
of the CDC’s Emerging Infections
Program (EIP) and consider general
measure alignment with EIP.
Response: We thank commenters for
their feedback on the potential future
inclusion of this measure in the
Hospital VBP and HAC Reduction
Programs, and we will consider it for
future notice-and-comment rulemaking.
We note that specifics about weighting
and scoring of any future measures
would be proposed in future notice and
comment rulemaking.
Comment: A commenter supported
the potential inclusion of the NHSN
Healthcare-Associated Clostridioides
difficile Infection Outcome measure in
the PCHQR Program pending removal of
the previously adopted NHSN Facilitywide Inpatient Hospital-onset
Clostridium difficile Infection (CDI)
Outcome Measure. The commenter also
requested that the measure take into
consideration that cancer hospitals
using PCR testing for CDIs may be
penalized unfairly because of the test’s
higher sensitivity than other testing
options. Another commenter supported
the measure once it has been fully
refined and receives NQF endorsement,
stating that the measure would protect
patients at cancer hospitals, who as a
population are at a higher risk of
contracting HAIs.
Response: We thank the commenters
for their support and will take their
feedback into consideration.
(2) National Healthcare Safety Network
(NHSN) Hospital-Onset Bacteremia &
Fungemia Outcome Measure
khammond on DSKJM1Z7X2PROD with RULES2
(a) Background
HAIs are the most frequent adverse
event in the delivery of healthcare
globally.1072 Incidence rates for most
types of HAIs had been declining for
several years in the U.S., but the
COVID–19 pandemic reversed these
trends.1073 Central line-associated
bloodstream infections (CLABSI)
declined 31 percent between 2015 and
2019.1074 Despite this initial trend, the
1072 Hongsuwan M, Srisamang P, Kanoksil M, et
al. (2014). Increasing incidence of hospital-acquired
and healthcare-associated bacteremia in northeast
Thailand: a multicenter surveillance study. PLoS
One. 2014;9(10):e109324. doi:10.1371/
journal.pone.0109324.
1073 Weiner-Lastinger, L., Pattabiraman, V.,
Konnor, R., Patel, P., Wong, E., Xu, S., Dudeck, M.
(2022). The impact of coronavirus disease 2019
(COVID–19) on healthcare-associated infections in
2020: A summary of data reported to the National
Healthcare Safety Network. Infection Control &
Hospital Epidemiology, 43(1), 12–25. doi:10.1017/
ice.2021.362.
1074 Centers for Disease Control and Prevention.
Central Line-Associated Bloodstream Infections.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
SIR for CLABSI increased in 2020
compared to 2019 in the later quarters
due to the pandemic. The NHSN found
a 47 percent increase in CLABSI in
Quarter 4 of 2020 compared to Quarter
4 of 2019. Overall, CLABSI increased by
24 percent from 2019 to 2020, with the
largest increase (50 percent) being found
in the ICU. Other types of infections
also rose during this period, including
hospital-onset MRSA by 15 percent, and
Ventilator-Associated Events (VAE) by
35 percent.1075
One likely reason for this reversal was
the staffing and institutional challenges
of caring for COVID–19 patients, which
led to a breakdown in previous
standards of care. In qualitative studies,
infection prevention teams have
reported that the pandemic made it
difficult to maintain routine CLABSI
prevention practices in the ICU.1076
Another possible reason is that many
hospitals underwent large staffing
changes, leading to more workers who
were not accustomed to the hospital’s
standard HAI prevention practices.1077
The NHSN Hospital-Onset Bacteremia
& Fungemia Outcome measure was
developed to help further our goal of
addressing patient safety outcomes in
the hospital care setting. The frequency
of hospital fungemia and bacteremia
infection rates in the U.S. present
unique opportunities for large-scale
quality measurement and improvement
activities. Statistics on preventability
vary but suggest that a considerable
proportion of fungemia and bacteremia
could be prevented.1078 The NHSN
Accessed on Available at: https://arpsp.cdc.gov/
profile/infections/clabsi?year-selectreport=year2019&year-select-hai-statelist=year2019.
1075 Centers for Disease Control and Prevention.
2020 National and State Healthcare-Associated
Infections Progress Report. Available at: https://
www.cdc.gov/hai/pdfs/progress-report/2020Progress-Report-Executive-Summary-H.pdf.
1076 Fakih, M., Bufalino, A., Sturm, L., Huang, R.,
Ottenbacher, A., Saake, K. Cacchione, J. (2021).
Coronavirus disease 2019 (COVID–19) pandemic,
central-line–associated bloodstream infection
(CLABSI), and catheter-associated urinary tract
infection (CAUTI): The urgent need to refocus on
hardwiring prevention efforts. Infection Control &
Hospital Epidemiology, 1–6. doi:10.1017/
ice.2021.70.
1077 Fakih, M., Bufalino, A., Sturm, L., Huang, R.,
Ottenbacher, A., Saake, K. Cacchione, J. (2021).
Coronavirus disease 2019 (COVID–19) pandemic,
central-line–associated bloodstream infection
(CLABSI), and catheter-associated urinary tract
infection (CAUTI): The urgent need to refocus on
hardwiring prevention efforts. Infection Control &
Hospital Epidemiology, 1–6. doi:10.1017/
ice.2021.70.
1078 Dantes RB, Rock C, Milstone AM, Jacob JT,
Chernetsky-Tejedor S, Harris AD, Leekha S. (2019).
Preventability of hospital onset bacteremia and
fungemia: A pilot study of a potential healthcareassociated infection outcome measure. Infect
Control Hosp Epidemiol, 40(3):358–361. doi:
10.1017/ice.2018.339.
PO 00000
Frm 00517
Fmt 4701
Sfmt 4700
49295
Hospital-Onset Bacteremia & Fungemia
Outcome measure is intended to
facilitate safer patient care by increasing
awareness of the dangers of fungemia
and bacteremia, promoting adherence to
recommended clinical guidelines, and
encouraging hospitals to track and
improve their practices of appropriate
monitoring and care delivery for
patients. For these reasons, we
requested feedback on the potential
future inclusion of this measure into the
Hospital IQR Program measure set to aid
in disease monitoring, provide hospitals
and patients with more information to
inform care delivery, and improve
patient outcomes.
Under CMS’ Meaningful Measures
Framework, the NHSN Hospital-Onset
Bacteremia & Fungemia Outcome
measure addresses the quality priority
of ‘‘Make Care Safer by Reducing Harm
Caused in the Delivery of Care’’ through
the Meaningful Measures Area of
‘‘Healthcare Associated Infection.’’ 1079
Additionally, pursuant to Meaningful
Measures 2.0, this measure addresses
the ‘‘Safety’’ priority area and aligns
with our commitment to a patientcentered approach in quality
measurement to ensure that patients are
safe and receive the highest quality
care.1080
While the HAC Reduction Program
and Hospital VBP Program use several
HAI measures, we believe that the
NHSN Hospital-Onset Bacteremia &
Fungemia Outcome measure may be
necessary to build upon previous efforts
to reduce HAIs because it encompasses
all types of bacteremia and fungemia
that occur among already hospitalized
patients. Meanwhile, the NHSN Central
Line-Associated Bloodstream Infection
(CLABSI) Outcome measure and NHSN
Facility-wide Inpatient Hospital-onset
Methicillin-resistant Staphylococcus
aureus (MRSA) Bacteremia Outcome
measure only capture specific types of
HAIs.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28553), we invited
public comment on the potential use of
this measure in the Hospital IQR
Program. We are also considering its use
in the PCHQR Program and the
possibility of replacing the current
CLABSI and MRSA measures in the
1079 Centers for Medicare & Medicaid Services.
Meaningful Measures 2.0: Moving from Measure
Reduction to Modernization. Available at: https://
www.cms.gov/meaningful-measures-20-movingmeasure-reduction-modernization. We note that
Meaningful Measures 2.0 is still under
development.
1080 Centers for Medicare & Medicaid Services.
(2021). CMS Quality Measurement Action Plan.
Available at: https://www.cms.gov/files/document/
2021-cms-quality-conference-cms-qualitymeasurement-action-plan-march-2021.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
49296
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
HAC Reduction Program and Hospital
VBP Program with the NHSN HospitalOnset Bacteremia & Fungemia Outcome
measure.
(b) Overview of Measure
This measure captures the
development of new bacteremia and
fungemia among patients already
admitted to acute care hospitals, using
algorithmic determinations from data
sources widely available in EHRs.
The NHSN Hospital-Onset Bacteremia
& Fungemia Outcome measure was
previously endorsed by MAP on June
11, 2019. The CDC submitted the
measure for re-endorsement and it was
included in the publicly available ‘‘List
of Measures Under Consideration for
July 15, 2021’’ (MUC List),1081 a list of
measures under consideration for use in
various Medicare programs. The NHSN
Hospital-Onset Bacteremia & Fungemia
Outcome measure (MUC2021–100) was
reviewed by the NQF MAP Hospital
Workgroup on December 15, 2021 and
received conditional support pending
NQF review and re-endorsement once
the revised measure is fully tested.1082
The MAP Coordinating committee,
which provides direction to the MAP
workgroups, concurred with the
recommendations of the MAP Hospital
Workgroup. We understand that the
CDC intends to submit the measure in
the future for NQF review and
endorsement.
khammond on DSKJM1Z7X2PROD with RULES2
(c) Data Sources
The data submission and reporting
standard procedures for the NHSN
Hospital-Onset Bacteremia & Fungemia
Outcome measure have been set forth by
the CDC for NHSN participation in
general and for submission of measure
data. Although the NHSN HospitalOnset Bacteremia & Fungemia Outcome
measure is not specified as an eCQM,
manual data entry is not available. The
primary sources of data for determining
numerator events include microbiology
data (blood culture) and patient
encounter, demographic, and location
information often located in AdmissionDischarge-Transfer data (Fast Healthcare
Interoperability Resources (FHIR):
Encounter, Patient, Observation,
Location).
To facilitate rapid, automated, and
secure data exchange, the CDC’s NHSN
1081 Centers for Medicare & Medicaid Services.
(2021). List of Measures Under Consideration for
December 1, 2021. Available at: https://
www.cms.gov/files/document/measures-underconsideration-list-2021-report.pdf.
1082 National Quality Forum. (2022). Measure
Applications Partnership (MAP) 2021–2022 Final
Recommendations. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96698.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
is planning to enable and promote
reporting of this measure using FHIR.
However, as FHIR capabilities are
evolving and not uniform across
healthcare systems, the CDC is also
planning on enabling reporting using
the existing Health Level 7 (HL7)
Clinical Document Architecture (CDA),
and potentially other formats as well to
provide all facilities with an option for
reporting. We are also working with the
CDC and ONC to consider how certified
health IT can support reporting of data
for this measure.
We invited public comment on
potential reporting formats for this
measure.
(d) Outcome
The measures outcome (numerator) is
defined as the observed number of HOB
events. This is defined as growth of a
recognized bacterial or fungal pathogen
from a blood culture specimen collected
on the 4th calendar day of admission or
later (where the date of admission to an
inpatient location is calendar day 1).
(e) Cohort
The measures outcome (numerator) is
defined as the observed number of
hospital-onset bacteremia and fungemia
(HOB) events based on predictive
models using facility-level factors
(community-onset incidence of
bacteremia and fungemia, blood culture
utilization rates), patient care location,
and potentially other data as predictors.
(f) Exclusion Criteria
The measure has two numerator
exclusions for patients with previous
matching POA bacteremia or fungemia.
The first numerator exclusion is HOB
infections in which the pathogen is the
same species or genus level as the one
identified from a blood specimen by
culture that the hospital collected in the
POA window (defined as hospital
calendar day three or earlier).
Additionally, if multiple pathogens are
identified from the same blood culture,
then a match of any of those pathogens
to a POA blood pathogen is sufficient to
exclude the event from the HOB
measure. The measure also excludes
patients with a previous HOB event who
experience additional HOB events
during the same hospital admission. We
understand that the CDC may consider
additional exclusion criteria for patients
with significant risk factors for
bacteremia or fungemia infections that
are judged not likely to be preventable
in rigorous studies.
The measure has one denominator
exclusion for data from patients who are
not assigned to an inpatient bed in an
applicable location. As an aside,
PO 00000
Frm 00518
Fmt 4701
Sfmt 4700
denominator counts exclude data from
inpatient rehabilitation units and
inpatient psychiatric units with a
unique CCN from the acute care facility.
(g) Measure Calculation
The measure is an outcome measure
that assesses the observed number of
HOB events. The measure calculates the
ratio of the observed number of HOB
events out of the expected number of
HOB events based on predictive models
using facility and patient care location
data as predictors.
We received comments on this topic.
Comment: Many commenters
supported the potential inclusion of the
NHSN Hospital-Onset Bacteremia &
Fungemia Outcome measure to the
Hospital IQR Program. Numerous
commenters stated that the measure
would improve patient safety by
preventing hospital-acquired infections.
Several commenters supported the
digital reporting aspect of the measure,
expressing their belief that it would
make reporting less subjective, make
data more traceable, and reduce the
administrative burden on hospital staff.
A commenter specifically supported the
flexibility of reporting via either FHIR or
HL7. A commenter supported the
measure for adoption in the Hospital
IQR Program prior to adding the
measure to other quality programs to
determine the measure’s validity.
Response: We thank the commenters
for their support. We will continue to
collaborate with the CDC and keep this
feedback in mind as part of future
notice-and-comment rulemaking.
Comment: Many commenters did not
support the potential inclusion of the
NHSN Hospital-Onset Bacteremia &
Fungemia Outcome measure in the
Hospital IQR Program. Numerous
commenters opposed adoption because
the measure has not received NQF
endorsement and has yet to be fully
tested, while a few others stated that
hospitals would incur a significant
burden to prepare for reporting
electronically sourced data. Several
commenters opposed adoption of this
measure because it does not take into
account patient factors that can increase
their risk of developing CDIs. Some
expressed concern over potential
unintended side effects of this measure,
such as the overuse of antibiotics and
placing major teaching hospitals at a
disadvantage. A commenter cited the
uncertainties in measure definitions.
Response: We thank the commenters
for their feedback and acknowledge
their concerns. We will continue to
collaborate with the CDC and consider
this feedback as we determine the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
potential future inclusion of this
measure.
Comment: Many commenters
expressed their belief that the measure
specifications need to be further refined.
Several commenters suggested that the
measure exclude immunocompromised
patients or include risk adjustment
based on patients’ vulnerability to
infections, to account for factors outside
of hospitals’ control. Several other
commenters posed questions about the
measure definitions and requested
additional clarification. A commenter
recommended that the measure account
for the type of vascular access device
used in patients with HOBs. Several
commenters recommended that we
postpone adoption of the measure to the
Hospital IQR Program until the measure
has been validated and NQF endorsed.
Response: We appreciate the
recommendations and requests for
information. We note that the CDC is
still refining the measure specifications.
We will take this feedback into
consideration as part of future noticeand-comment rulemaking.
Comment: Many commenters were
concerned that collecting, reviewing,
and reporting data for the NHSN
Hospital-Onset Bacteremia & Fungemia
Outcome measure would be a major
burden to hospital staff. Several stated
that preparing for digital reporting
would be time- and resource-intensive
for hospitals while a few others
expressed their belief that the measure
would be overly burdensome to
infection control staff. To improve the
measure implementation process, a few
commenters recommended that we
implement voluntary reporting until the
measure has been fully refined,
hospitals have time to prepare for
reporting, and the technology for data
submission is mature.
A few other commenters were
concerned about unintended
consequences for patient care, including
that hospitals might use antimicrobials
inappropriately or reduce blood culture
orders. To prevent this, A commenter
recommended that we consider another
measure focused on specific types of
bacteremia and fungemia instead. A few
commenters recommended that we
monitor additional sources of data for
surveillance in addition to the NHSN
Hospital-Onset Bacteremia & Fungemia
Outcome measure, such as
complementary NHSN metrics.
Response: We appreciate commenters
sharing their concerns. We will consider
the recommendations for improving the
measure and preventing unintended
consequences as we consider the
potential future inclusion of this
measure.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Comment: Several commenters
provided feedback on including the
NHSN Hospital-Onset Bacteremia &
Fungemia Outcome measure in the
Hospital VBP and HAC Reduction
Programs. A few commenters supported
the inclusion of this measure in the
value-based purchasing programs, with
a commenter noting it was a step in the
right direction. A few commenters
expressed concern that the new digital
measure is not yet ready for adoption
because it lacks baseline testing data,
the measure definitions need
refinement, and the risk adjustment
methodology does not account for
patient factors that increase the risk of
developing CDIs. They urged that we
ensure that this measure is fully
defined, validated, and NQF endorsed
prior to implementation. A commenter
stated that CMS should not adopt this
measure for the Hospital VBP Program
or HAC Reduction Program until
hospitals can consistently report using
FHIR or testing confirms comparable
results using different reporting
methods. A commenter recommended
that the HOB measure replace the CDC
NHSN MRSA and CLABSI measures.
Another commenter suggested that the
CDC NHSN MRSA and CLABSI
measures be maintained in the Hospital
VBP and HAC Reduction Programs
because they are more specific and
better understood by consumers. A
commenter recommended peer
baselining the measure to account for
institutional differences in
demographics and size.
Response: We thank commenters for
their feedback on the potential future
inclusion of this measure in the
Hospital VBP and HAC Reduction
Programs. We will consider all input
and note that any future proposal to
implement such a measure would be
announced through future notice-andcomment rulemaking.
10. Form, Manner, and Timing of
Quality Data Submission
a. Background
Sections 1886(b)(3)(B)(viii)(I) and
(b)(3)(B)(viii)(II) of the Act state that the
applicable percentage increase for FY
2015 and each subsequent year shall be
reduced by one-quarter of such
applicable percentage increase
(determined without regard to sections
1886(b)(3)(B)(ix), (xi), or (xii) of the Act)
for any subsection (d) hospital that does
not submit data required to be
submitted on measures specified by the
Secretary in a form and manner, and at
a time, specified by the Secretary. To
successfully participate in the Hospital
Inpatient Quality Reporting (IQR)
PO 00000
Frm 00519
Fmt 4701
Sfmt 4700
49297
Program, hospitals must meet specific
procedural, data collection, submission,
and validation requirements.
Previously, the applicable percentage
increase for FY 2007 and each
subsequent fiscal year until FY 2015
was reduced by 2.0 percentage points
for subsection (d) hospitals failing to
submit data in accordance with the
previous description. In accordance
with the statute, the FY 2023 payment
determination will begin the ninth year
that the Hospital IQR Program will
reduce the applicable percentage
increase by one-quarter of such
applicable percentage increase.
b. Maintenance of Technical
Specifications for Quality Measures
For each Hospital IQR Program
payment determination, we require that
hospitals submit data on each specified
measure in accordance with the
measure’s specifications for a particular
period of time. We refer readers to the
FY 2019 IPPS/LTCH PPS final rule (83
FR 41538), in which we summarized
how the Hospital IQR Program
maintains the technical measure
specifications for quality measures and
the subregulatory process for
incorporation of nonsubstantive updates
to the measure specifications to ensure
that measures remain up-to-date. We
did not propose any changes to these
policies in the proposed rule.
The data submission requirements,
Specifications Manual, and submission
deadlines are posted on the QualityNet
website at: https://qualitynet.cms.gov
(or other successor CMS designated
websites). The CMS Annual Update for
the Hospital Quality Reporting Programs
(Annual Update) contains the technical
specifications for electronic clinical
quality measures (eCQMs). The Annual
Update contains updated measure
specifications for the year prior to the
reporting period. For example, for the
CY 2022 reporting period/FY 2024
payment determination, hospitals are
collecting and will submit eCQM data
using the May 2021 Annual Update and
any applicable addenda. The Annual
Update and implementation guidance
documents are available on the
Electronic Clinical Quality
Improvement (eCQI) Resource Center
website at: https://ecqi.healthit.gov/.
Hospitals must register and submit
quality data through the Hospital
Quality Reporting (HQR) System
(previously referred to as the QualityNet
Secure Portal) (86 FR 45520). The HQR
System is safeguarded in accordance
with the HIPAA Privacy and Security
Rules to protect submitted patient
information. See 45 CFR parts 160 and
164, subparts A, C, and E.
E:\FR\FM\10AUR2.SGM
10AUR2
49298
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
We also refer readers to section IX.C.
of the preamble of the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28486
through 28491) where we requested
information on potential actions that
would continue to transform the
Hospital IQR Program’s quality
measurement enterprise toward the use
of the FHIR standard for data
submission.
c. Procedural Requirements
The Hospital IQR Program’s
procedural requirements are codified in
regulation at 42 CFR 412.140. We refer
readers to these codified regulations for
participation requirements, as further
explained by the FY 2014 IPPS/LTCH
PPS final rule (78 FR 50810 through
50811) and the FY 2017 IPPS/LTCH PPS
final rule (81 FR 57168). The previously
finalized requirements, including
setting up a QualityNet account and the
associated timelines, are described at 42
CFR 412.140(a)(2), 42 CFR
412.140(e)(2)(iii), and in the FY 2012
IPPS/LTCH PPS final rule (76 FR 51639
through 51640). In the FY 2022 IPPS/
LTCH PPS final rule, we finalized the
following changes to the Hospital IQR
Program regulation text: (1) Update
references to the QualityNet website at
42 CFR 412.140(a)(1) and 42 CFR
412.140(c)(2)(i); and (2) use the term
‘‘QualityNet security official’’ instead of
‘‘QualityNet Administrator’’ at 42 CFR
412.140(a)(2). We did not propose any
changes to these policies in the
proposed rule.
d. Data Submission Requirements for
Chart-Abstracted Measures
We refer readers to the FY 2012 IPPS/
LTCH PPS final rule (76 FR 51640
through 51641), the FY 2013 IPPS/LTCH
PPS final rule (77 FR 53536 through
53537), and the FY 2014 IPPS/LTCH
PPS final rule (78 FR 50811) for details
on the Hospital IQR Program data
submission requirements for chartabstracted measures. We did not
propose any changes to these policies in
the proposed rule.
e. Reporting and Submission
Requirements for eCQMs
(1) Background
For a discussion of our previously
finalized eCQMs and policies, we refer
readers to the FY 2014 IPPS/LTCH PPS
final rule (78 FR 50807 through 50810;
50811 through 50819), the FY 2015
IPPS/LTCH PPS final rule (79 FR 50241
through 50253; 50256 through 50259;
and 50273 through 50276), the FY 2016
IPPS/LTCH PPS final rule (80 FR 49692
through 49698; and 49704 through
49709), the FY 2017 IPPS/LTCH PPS
final rule (81 FR 57150 through 57161;
and 57169 through 57172), the FY 2018
IPPS/LTCH PPS final rule (82 FR 38355
through 38361; 38386 through 38394;
38474 through 38485; and 38487
through 38493), the FY 2019 IPPS/LTCH
PPS final rule (83 FR 41567 through
41575; 83 FR 41602 through 41607), the
FY 2020 IPPS/LTCH PPS final rule (84
FR 42501 through 42506), the FY 2021
IPPS/LTCH PPS final rule (85 FR 58932
through 58940), and the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45417
through 45421).
In the FY 2018 IPPS/LTCH PPS final
rule, we finalized eCQM reporting and
submission requirements such that
hospitals were required to report only
one, self-selected calendar quarter of
data for four self-selected eCQMs for the
CY 2018 reporting period/FY 2020
payment determination (82 FR 38358
through 38361). Those reporting
requirements were extended to the CY
2019 reporting period/FY 2021 payment
determination through the CY 2021
reporting period/FY 2023 payment
determination (83 FR 41603 through
41604; 84 FR 42501 through 42503). In
the FY 2020 IPPS/LTCH PPS final rule,
we finalized that for the CY 2022
reporting period/FY 2024 payment
determination, hospitals would be
required to report one, self-selected
calendar quarter of data for: (a) Three
self-selected eCQMs; and (b) the Safe
Use of Opioids—Concurrent Prescribing
eCQM, for a total of four eCQMs (84 FR
42503 through 42505).
In the FY 2021 IPPS/LTCH PPS final
rule, we finalized a progressive increase
in the number of required reported
quarters of eCQM data, from one selfselected quarter of data to four quarters
of data over a three-year period (85 FR
58932 through 58939). Specifically, for
the CY 2021 reporting period/FY 2023
payment determination, hospitals were
required to report two self-selected
calendar quarters of data for each of the
four self-selected eCQMs (85 FR 58939).
For the CY 2022 reporting period/FY
2024 payment determination, hospitals
are required to report three self-selected
calendar quarters of data for each
eCQM: (a) Three self-selected eCQMs,
and (b) the Safe Use of Opioids—
Concurrent Prescribing eCQM (85 FR
58939). We clarified in the FY 2021
IPPS/LTCH PPS final rule that until
hospitals are required to report all four
quarters of data beginning with the CY
2023 reporting period/FY 2025 payment
determination, they may submit
consecutive or non-consecutive selfselected quarters of data (85 FR 58939).
In the FY 2022 IPPS/LTCH PPS final
rule, we did not propose any changes to
these policies, and we clarified that the
self-selected eCQMs must be the same
eCQMs across quarters in a given
reporting year (86 FR 45418). We did
not propose any changes to these
policies in the proposed rule. The
following Table IX.E–14. summarizes
our finalized policy:
TABLE IX.E-14. eCQM DATA PUBLIC REPORTING REQUIREMENTS
eCQM Data Publicly Reported
Two Quarters of Data
Three Quarters of Data
For the CY 2023 reporting period/FY
2025 payment determination and
subsequent years, hospitals are required
to report four calendar quarters of data
for each eCQM: (a) Three self-selected
eCQMs, and (b) the Safe Use of OpioidsConcurrent Prescribing eCQM (85 FR
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Four Quarters of Data
58939). We did not propose any changes
to the eCQM reporting or submission
requirements for the CY 2023 reporting
period/FY 2025 payment determination.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28555 through
28556), we proposed to modify eCQM
PO 00000
Frm 00520
Fmt 4701
Sfmt 4700
reporting and submission requirements
beginning with the CY 2024 reporting
period/FY 2026 payment determination
and for subsequent years.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.174
khammond on DSKJM1Z7X2PROD with RULES2
Reportin2 Period / Payment Determination
CY 2021 / FY 2023
CY 2022 I FY 2024
CY 2023 I FY 2025
( and for subsequent years)
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(2) Reporting and Submission
Requirements for eCQMs for the CY
2024 Reporting Period/FY 2026
Payment Determination and for
Subsequent Years
eCQM reporting and submission
requirements, such that beginning with
the CY 2024 reporting period/FY 2026
payment determination hospitals would
be required to report four calendar
quarters of data for each required eCQM:
(1) Three self-selected eCQMs; (2) the
Safe Use of Opioids—Concurrent
Prescribing eCQM; (3) the proposed
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28555 through
28556), we proposed to modify the
49299
Cesarean Birth eCQM; and (4) the
proposed Severe Obstetric
Complications eCQM; for a total of six
eCQMs. We refer readers to Table IX.E–
15. which represents the progressive
increase in eCQM reporting
requirements, including our proposed
changes.
TABLE IX.E-15. CURRENT AND PROPOSED eCQM REPORTING AND
SUBMISSION REQUIREMENTS FOR THE CY 2022 REPORTING PERIOD/FY 2024
PAYMENT DETERMINATION AND FOR SUBSEQUENT YEARS
eCQM Data Publicly
Reported
Total
Number of
eCQMs
Reported
CY 2022 I FY 2024
Three Quarters of Data
Four
CY 2023 I FY 2025
Four Quarters of Data
Four
Proposed:
CY 2024 I FY 2026
(and for subsequent years)
Four Quarters of Data
Six
khammond on DSKJM1Z7X2PROD with RULES2
This proposal is made in conjunction
with our proposals discussed in sections
IX.E.5.c. and IX.E.5.d. of the preamble of
this final rule, in which we are adopting
the Cesarean Birth eCQM and Severe
Obstetric Complications eCQM,
respectively. Addressing the maternal
health crisis, improving maternal
health, and closing any gaps that exist
as a result of health disparities are
among our top goals for quality
improvement. The high maternal
mortality and morbidity rates in the U.S.
necessitate large-scale quality
measurement and improvement
activities. As part of the effort to reduce
maternal mortality and morbidity, we
believe it to be important to receive data
from all hospitals that provide perinatal
care and not to limit data to just
hospitals that may self-select those
eCQMs. Requiring these eCQMs will
also aid in the surveillance of maternal
morbidity, mortality, and associated
comorbidities and complications as we
1083 In the FY 2023 IPPS/LTCH PPS proposed rule
(87 FR 28556), we stated in Table IX.E–15. ‘‘Four
self-selected eCQMs’’ for the eCQMs required to be
reported for the CY 2022 reporting period/FY 2024
payment determination. We correct this error in
table IX.E–15 of this final rule to ‘‘Three selfselected eCQMs; and Safe Use of Opioids—
Concurrent Prescribing eCQM’’ in alignment with
the language throughout the preamble and as
finalized in previous policy.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
eCQMs Required to be Reported
• Three self-selected eCQMs; and
• Safe Use ofOpioids----Concurrent
Prescribing eCQM 1083
• Three self-selected eCQMs; and
• Safe Use of Opioids----Concurrent
Prescribing eCQM
• Three self-selected eCQMs; and
• Safe Use ofOpioids----Concurrent
Prescribing eCQM; and
• Proposed Cesarean Birth eCQM; and
• Proposed Severe Obstetric Complications
eCQM
collect data from all of the hospitals
participating in the Hospital IQR
Program. Additionally, no maternal
morbidity or obstetric complications
outcome-based measures exist in
national reporting programs, and we
believe these measures have the
potential to reduce preventable harm
and costs associated with adverse events
related to perinatal care.
Accordingly, after consideration of
public comments and as we are
finalizing to adopt the Cesarean Birth
eCQM and the Severe Obstetric
Complications eCQM, all hospitals
participating in the Hospital IQR
Program will also be required to report
these two eCQMs, increasing the total
number of eCQMs reported from four to
six beginning with the CY 2024
reporting period/FY 2026 payment
determination and for subsequent years
as discussed further below.
At the start of required eCQM
reporting, we stated that increasing the
reporting requirements over time is
consistent with our goal of reporting on
all eCQMs in the Hospital IQR Program
in a stepwise manner while being
responsive to hospitals’ concerns about
timing, readiness, and burden
associated with the increased number of
measures required to be reported (81 FR
57151 through 57152). With the
PO 00000
Frm 00521
Fmt 4701
Sfmt 4700
addition of new measures to the eCQM
measure set and increasing the quarters
of eCQM data to be reported, our
approach to eCQM reporting
requirements has supported the goal to
incrementally increase eCQM reporting
requirements as hospitals continue to
gain experience with eCQMs (84 FR
42502). After several years of a steady
eCQM reporting requirement, we
believe a proposed change to the
reporting requirement is timely. We
believe that allowing hospitals to
continue self-selection of three eCQMs
from the measure set for the CY 2024
reporting period/FY 2026 payment
determination while requiring reporting
of three additional eCQMs provides
sufficient flexibility to report on eCQMs
applicable to a hospital’s quality
improvement priorities while also
reporting on measures that address the
opioid and maternal health crises and
that advance health equity.
Additionally, we believe that our
proposal for hospitals to submit data
from three self-selected eCQMs and
three required eCQMs continues our
approach to collect data derived from
EHRs and make progress toward a
transition to fully digital quality
measurement (86 FR 45345).
We invited public comment on our
proposal to increase the number of
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.175
Reporting Period /
Payment Determination
khammond on DSKJM1Z7X2PROD with RULES2
49300
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
mandatory measures to be reported from
one to three, as described previously,
and thereby increase the total number of
required eCQMs from four to six.
We refer readers to section IX.H.10.b.
of the preamble of this final rule for a
discussion of a similar proposal by the
Medicare Promoting Interoperability
Program for Eligible Hospitals and
Critical Access Hospitals (CAHs).
Comment: Several commenters
supported our proposal to modify the
reporting and submission requirements
for eCQMs such that beginning with the
CY 2024 reporting period/FY 2026
payment determination hospitals would
be required to submit four calendar
quarters of data and three required
eCQMs. Commenters cited improved
transparency and oversight over eCQM
submissions, increased data ensuring
comparison of quality on priority topics,
and enabling hospitals to leverage
electronic data collection and reporting
to the greatest extent possible.
Response: We thank commenters for
their support.
Comment: A commenter supported
the proposal to modify eCQM reporting
and submission requirements and
requested two years of voluntary
reporting for the Severe Obstetric
Complications eCQM before mandatory
reporting.
Response: We thank the commenter
for its support of our proposal.
Regarding the recommendation to
increase the voluntary reporting period
from one year to two years, which
would delay the start of mandatory
reporting of these two finalized
perinatal eCQMs, we reiterate that
addressing the maternal health crisis,
improving maternal health, and closing
any gaps that exist as a result of health
disparities are among our top goals for
quality improvement. By proposing a
one-year voluntary reporting period, we
sought to balance the need for hospitals
and their vendors to prepare for
reporting the new eCQMs with the
urgency of measuring at a national scale
and addressing the high maternal
mortality and morbidity rates in the U.S.
by requiring mandatory reporting of
both the Severe Obstetric Complications
eCQM and the Cesarean Birth eCQM
beginning with the CY 2024 reporting
period/FY 2026 payment determination.
Comment: Several commenters did
not support the proposal to modify
eCQM reporting and submission
requirements, expressing concerns
about the pace of change in eCQM
reporting and submission proposals,
including the amount of time for
hospital workflow changes, measure
validation, and EHR vendor readiness
for eCQM changes. A few commenters
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
recommended a longer timeframe prior
to increased requirements for eCQM
reporting, including two years of
optional reporting prior to mandatory
reporting of an eCQM due to the need
to address current eCQM challenges
before additional eCQMs are required to
be reported. Specifically, commenters
noted difficulties extracting data from
production ready eCQM products
delivered by developers, the cost and
time associated with eCQM adoption,
the demands on hospital resources to
meet COVID–19 PHE needs, other CMS
quality reporting requirements, and
federal EHR requirements given the
competing demands on limited hospital
quality and health IT resources.
Response: We appreciate commenters’
concerns related to additions to the
eCQM measure set when some hospitals
are experiencing challenges with eCQM
reporting and submission. We establish
program requirements considering all
hospitals that participate in the Hospital
IQR Program at a national level, which
involves a wide spectrum of capabilities
and resources with respect to eCQM
reporting. In establishing our eCQM
policies, we must balance the needs of
hospitals with variable preferences and
capabilities. We believe our finalized
policy to modify the eCQM reporting
and submission requirements will offer
opportunities for hospitals that are
prepared to voluntarily report the two
perinatal eCQMs—Cesarean Birth and
Severe Obstetric Complications—to do
so for the CY 2023 reporting period/
FY2025 payment determination, while
providing more than one year for other
hospitals to prepare and implement the
two perinatal eCQMs for the CY 2024
reporting period/FY 2026 payment
determination and for subsequent years.
We believe the long-term benefits
associated with reporting a full year of
data for six eCQMs will outweigh the
burdens and that increasing the number
of eCQMs for which hospitals are
required to report will produce more
comprehensive and reliable quality
information for patients and providers.
Hospitals have had several years to
gain experience reporting eCQM data. In
the FY 2021 IPPS/LTCH PPS final rule,
we stated that, after holding eCQM
reporting and submission policies
constant for a number of years in order
to give hospitals and their vendors
additional time to improve eCQM
reporting capabilities, we intended to
transition to more robust reporting (85
FR 58934). We reiterate our intention to
continue a transition toward more
robust eCQM reporting (82 FR 38356
and 84 FR 42502). We believe that
increasing the amount of eCQM data
reported is in line with our goals to
PO 00000
Frm 00522
Fmt 4701
Sfmt 4700
increase electronic reporting of clinical
quality measures. We add that eCQM
reporting and submission will be
supported by technology certified to the
2015 Edition Cures Update that
hospitals have had several years to
possess, implement, and use in advance
of the December 31, 2022 deadline (86
FR 45418). We recognize the cost and
time associated with eCQM adoption
and refer readers to section XII.B.4.f. of
the preamble of this final rule
(information collection requirements)
for a detailed discussion of our burden
estimates associated with the
modification of our eCQM reporting and
submission requirements.
We acknowledge the commenters’
concern that modifying the eCQM
reporting and submission requirement
for the CY 2024 reporting period/FY
2026 payment determination will
require hospital quality and health IT
resources to support Hospital IQR
Program and other CMS quality
reporting requirements and federal EHR
requirements, however, we point to the
alignment between Hospital IQR
Program’s reporting requirements and
other quality programs, such as the
Medicare Promoting Interoperability
Program for hospitals and critical access
hospitals (CAHs). We refer readers to
the FY 2016 IPPS/LTCH PPS final rule
(80 FR 49705 through 49708) and the FY
2017 IPPS/LTCH PPS final rule (81 FR
57170) for our previously adopted
eCQM file format requirements, zero
denominator declaration, and case
threshold exemption policies, and the
FY 2018 IPPS/LTCH PPS final rule (81
FR 57255 through 57257) where we
stated the finalized successful
submission requirements in the Hospital
IQR Program align with the CQM
electronic reporting requirements of
Medicare Promoting Interoperability
Program for eligible hospitals and
CAHs. We will continue to look across
all quality programs to identify areas for
further streamlining of quality reporting
requirements. As referenced in section
IX.C., in the ‘‘Continuing to Advance
Digital Quality Measurement and Use of
Fast Healthcare Interoperability
Resources (FHIR) in Hospital Quality
Programs—Request for Information,’’ we
also believe utilizing standardized data
for EHR-based measurement (based on
the FHIR standard) and aligning where
possible with other interoperability
requirements can reduce the data
collection burden incurred by providers
for the purpose of reporting quality
measures. We appreciate the comments
on, and interest in, opportunities to
reduce reporting burden and we will
continue to take all comments into
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
account as we develop future regulatory
proposals or other guidance for our
quality measurement policies.
We also recognize the burden that the
COVID–19 PHE has had on the
healthcare system and will continue to
monitor the impact that the COVID–19
PHE has on hospitals, including small,
rural hospitals. Additionally, if, due to
COVID–19 or any other extraordinary
circumstance, we emphasize that
hospitals may be eligible for an
extraordinary circumstances exception
(ECE). Hospitals may request an ECE if
they are unable to fulfill program
requirements due to extraordinary
circumstances beyond their control. We
refer readers to section IX.E.15 of this
final rule, the eCQM ECE resources on
the QualityNet website (available at:
https://qualitynet.cms.gov/inpatient/
measures/ecqm/participation#tab2),
and 42 CFR 412.140(c)(2) for more
information about the Hospital IQR
Program’s Extraordinary Circumstances
Exceptions policy.
Comment: A few commenters did not
support the proposal to revise eCQM
reporting and submission requirements
due to concerns with vendors’ timelines
to complete upgrades and programming.
Response: We appreciate the
commenters’ concern, and we urge
hospitals to continue to work with their
vendor to secure timely delivery of their
products. We acknowledge the effort
required for hospitals to adopt and
implement updated technology to meet
the eCQM reporting and submission
requirements. However, we respectfully
disagree that our proposal would not
permit adequate time for product
implementation and use. We believe our
finalized policy to modify the eCQM
reporting and submission requirements
will offer opportunities for hospitals
that are prepared to voluntarily report
the two perinatal eCQMs to do so for the
CY 2023 reporting period while
providing more than one year for other
hospitals to prepare and implement the
two perinatal eCQMs for the CY 2024
reporting period/FY 2026 payment
determination.
Comment: A few commenters did not
support our proposal to modify eCQM
reporting and submission requirements
due to the cost and time required for
EHR changes and updates for small and
rural hospitals with limited IT and
staffing resources. A commenter
requested clarification for hospitals
without obstetric departments or who
do not perform deliveries and the
proposal to require reporting of the two
perinatal eCQMs, inquiring if such
hospitals replace the measures or omit
the perinatal measures.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Response: We acknowledge that
facilitating quality improvement for
small or rural hospitals can present
unique challenges. When selecting
eCQMs for inclusion in the measure set
we have, and will continue to, consider
the recommendations from the rural
stakeholders to ensure eCQMs are
meaningful to quality improvement for
small, rural hospitals (85 FR 58935). As
stated in sections IX.E.5.c. and IX.E.5.d.,
a critical focus in the national approach
for improving maternal health and
advancing maternal health equity is
reducing existing disparities in maternal
health outcomes by race, ethnicity, and
geography. If a hospital does not have
an obstetrics department or has few or
no deliveries during a reporting period,
the hospital would submit a zero
denominator declaration for the
measure that allows a hospital to meet
the reporting requirements for a
particular eCQM if a hospital does not
have patients that meet the denominator
criteria. We refer readers to the FY 2015
IPPS/LTCH PPS final rule (79 FR
50258), the FY 2016 IPPS/LTCH PPS
final rule (80 FR 49705 through 49708),
and the FY 2017 IPPS/LTCH PPS final
rule (81 FR 57170) for our previously
adopted eCQM file format requirements.
A QRDA Category I file with patients
meeting the initial patient population of
the applicable measures, a zero
denominator declaration, and/or a case
threshold exemption all count toward a
successful submission for eCQMs for the
Hospital IQR Program (82 FR 38387).
Comment: A few commenters did not
support the proposal to modify eCQM
reporting and submission requirements
due to the as yet determined benefit
relative to the administrative costs and
the need for more comprehensive,
frequent, and actionable eCQM
performance feedback.
Response: We thank the commenters
for their input and we appreciate their
concern, but reiterate our eCQM policies
further advance our goal of
incrementally increasing the use of EHR
data for quality measurement and
improvement and is responsive to the
feedback of some interested parties
urging a faster transition to full
electronic reporting (84 FR 42503). We
also use a validation process to address
concerns about reliability and validity
of eCQM data. As stated in the FY 2021
IPPS/LTCH PPS final rule (85 FR
58935), we have conducted an eCQM
validation pilot (OMB Control #0938–
1022) and completed eCQM data
validation from the CY 2017 reporting
period and the CY 2018 reporting
period. Based on our internal review of
the CY 2017 and CY 2018 eCQM data
submitted for validation, over half of the
PO 00000
Frm 00523
Fmt 4701
Sfmt 4700
49301
measures validated had agreement rates
of 80 percent or better. As discussed in
section IX.E.11.b. of this final rule, we
have an ongoing goal of continuing to
assess the accuracy of eCQM measure
data (81 FR 57155). Through the
finalized modifications to the existing
processes for validation of Hospital IQR
Program eCQM data discussed in
section IX.E.11.b. of this final rule and
our finalized policy to modify eCQM
reporting and submission requirements
we expect to gain a better understanding
of how to increase the accuracy of
eCQM data by continuing to analyze the
validation process and the results (85
FR 58935). We appreciate commenters’
statements in support of comprehensive,
frequent, and actionable eCQM
performance feedback. The
implementation of the updated HQR
System has provided a more
comprehensive platform for eCQM
performance feedback as compared to
the legacy system. The new HQR
System provides various reports and
user interfaces to be used by the
hospitals to validate their submissions
and overall performance. Overall
measure outcomes, including the ability
to review individual measure outcomes,
are available on the eCQM user interface
in near real time. Users of the HQR
System for eCQM reporting can generate
reports real time instead of waiting on
the system refresh. This enhanced
functionality in the HQR System allows
submitters to export a downloadable
report for rejected files providing
details, including the associated
conformance number of the error to
make it easier for the submitter to
troubleshoot, correct and resubmit the
file to achieve the expected outcome.
Comment: A few commenters did not
support the proposal to increase the
number of mandatory measures, citing
concerns about the two proposed
perinatal eCQMs and the support for
self-selection as an appropriate
approach to achieving quality
improvement goals. They recommended
continuation of the current reporting
and submission requirements to provide
time for hospitals and the CMS platform
to acclimate to the existing requirement
to report four quarters of eCQM data.
Response: We appreciate commenters’
position regarding mandatory reporting
of the two perinatal eCQMs, but note
our longstanding view that electronic
reporting of quality measure data
derived from the EHR will, over time,
reduce the burden on hospitals to
collect and submit data for the Hospital
IQR Program (78 FR 50956). We believe
that mandatory reporting of the two
perinatal eCQMs in order to gain
comprehensive, national measure data
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49302
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
are important tools in addressing the
maternal health crisis, as no maternal
morbidity or obstetric complications
outcome-based measures exist in
national reporting programs.
Regarding comments about the CMS
platform, we launched the HQR System
for reporting quality data (beginning
with the CY 2019 reporting period) to
improve the experience for program
participants (82 FR 38390 and 85 FR
58958). After several years of requiring
only one quarter of eCQM data for
reporting, at the end of March 2022, we
successfully completed the submission
period for two quarters of CY 2021
eCQM data. Three quarters of CY 2022
eCQM data will be due by February 28,
2023, and four quarters of CY 2023
eCQM data will not be due until
February 29, 2024. We believe this
progressive increase in the quarters of
data to be reported allows sufficient
time for system readiness. In addition,
we plan to continue to make changes to
improve the system’s usability as
needed.
Comment: A commenter requested
clarification on the proposals for new
eCQMs in the Hospital IQR Program
given the stated intent to transition to
FHIR-based quality measures.
Response: We appreciate the
commenter’s request for clarification.
We consider eCQMs to be a type of
digital quality measure (87 FR 28487).
As we stated in section IX.C., in the
‘‘Continuing to Advance Digital Quality
Measurement and Use of Fast
Healthcare Interoperability Resources
(FHIR) in Hospital Quality Programs—
Request for Information,’’ while eCQMs
meet the definition for dQMs in many
respects, limitations in data standards,
requirements, and technology have
limited their interoperability. We
appreciate the comments on, and
interest in, this topic and we will
continue to take all comments into
account as we develop future regulatory
proposals or other guidance for our
digital quality measurement efforts.
Comment: A commenter noted an
error in Table IX.E–15 of the preamble
of the FY 2023 IPPS/LTCH PPS
proposed rule indicating the number of
eCQMs required to be reported for the
CY 2022 reporting period/FY 2024
payment determination.
Response: We thank the commenter
for the comment. In the FY 2023 IPPS/
LTCH PPS proposed rule(87 FR 28556),
Table IX.E.15, first row, erroneously
stated ‘‘Four self-selected eCQMs’’ for
the eCQMs required to be reported for
the CY 2022 reporting period/FY 2024
payment determination. We correct this
error in Table IX.E–15 of this final rule
to state ‘‘Three self-selected eCQMs; and
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Safe Use of Opioids—Concurrent
Prescribing eCQM’’ in alignment with
the language throughout the preamble
and as finalized in previous policy. To
be clear, this was an inadvertent
technical error. As finalized in the FY
2020 IPPS/LTCH PPS final rule, four
eCQMs are required to be reported for
the CY 2022 reporting period/FY 2024
payment determination of which three
are self-selected and the Safe Use of
Opioids—Concurrent Prescribing eCQM
is required (84 FR 42505). In this final
rule, we have revised Table IX. E–15 to
correct the error.
Comment: A commenter supported
the proposal to modify eCQM reporting
and submission requirements if CMS
mandates the specific eCQMs to be
reported, removing the ability of
facilities to self-select eCQMs.
Response: We thank the commenter
for their input. For the present state,
particularly before the implementation
of the FHIR standard for eCQM
reporting, we believe it is beneficial for
hospitals to have the flexibility to selfselect eCQMs for reporting and
submission in addition to submitting
data from high priority eCQMs that are
mandatory for reporting. However, as
we continue to transition toward more
robust eCQM reporting, we will
consider the commenter’s feedback in
future rulemaking.
Comment: A commenter cautioned
that public reporting before four
quarters of data are reported for a
reporting period may not show correct
trends or patterns within the quality of
care being provided by the organization.
Response: We appreciate the
commenter’s concern and refer readers
to the FY 2020 IPPS/LTCH PPS final
rule where we finalized eCQM reporting
and submission requirements for the CY
2023 reporting period/FY 2025 payment
determination to require hospitals to
report four calendar quarters of data for
each required eCQM: (a) Three selfselected eCQMs; and (b) the Safe Use of
Opioids—Concurrent Prescribing eCQM
(85 FR 58974 through 58975). In the FY
2020 IPPS/LTCH PPS final rule, we also
finalized public reporting requirements
of eCQMs for the CY 2021 reporting
period/FY 2023 payment determination
and subsequent years, specifically
publicly reporting two quarters of data
for the CY 2021 reporting period/FY
2023 payment determination, three
quarters of data for the CY 2022
reporting period/FY 2024 payment
determination, and for the CY 2023
reporting period/FY 2025 payment
determination and subsequent years, we
will publicly report four quarters of
eCQM data (85 FR 58956). We believe
that, beginning with the CY 2023
PO 00000
Frm 00524
Fmt 4701
Sfmt 4700
reporting period, the four quarters of
data reported will provide more robust
insight on the trends and patterns in the
quality of care.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
(3) Continuation of Certification
Requirements for eCQM Reporting
(a) Requiring Use of the 2015 Edition
and 2015 Edition Cures Update
Certification Criteria
In the CY 2021 Physician Fee
Schedule (PFS) final rule (85 FR 84825
through 84828), we expanded flexibility
under the Hospital IQR Program for the
CY 2020 reporting period/FY 2022
payment determination and for
subsequent years to allow hospitals to
use either: (1) Technology certified to
the 2015 Edition criteria as was
previously finalized for reporting
eCQMs in the FY 2019 IPPS/LTCH PPS
final rule (83 FR 41537 through 41608),
or (2) certified technology updated
consistent with the 2015 Edition Cures
Update as finalized in the ONC 21st
Century Cures Act final rule (85 FR
25642 through 25961). We adopted this
flexible approach to encourage hospitals
to be early implementers of the 2015
Edition Cures Update while remaining
in compliance with Hospital IQR
Program data submission requirements
and maintaining alignment with
requirements in the Medicare Promoting
Interoperability Program for Eligible
Hospitals and CAHs.
In the FY 2022 IPPS/LTCH PPS final
rule, beginning with the CY 2023
reporting period/FY 2025 payment
determination and subsequent years, we
finalized the requirement for hospitals
to use only certified technology updated
consistent with the 2015 Edition Cures
Update to submit data for the Hospital
IQR Program data (86 FR 45418). We
refer readers to the ONC 21st Century
Cures Act final rule for additional
information about the updates included
in the 2015 Edition Cures Update (85 FR
25665). We did not propose any changes
to this policy.
(b) Requiring EHR Technology To Be
Certified to All Available eCQMs
In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42505 through 42506), we
finalized the requirement that EHRs be
certified to all available eCQMs used in
the Hospital IQR Program for the CY
2020 reporting period/FY 2022 payment
determination and subsequent years. In
the FY 2022 IPPS/LTCH PPS final rule
(86 FR 45418), we finalized the
requirement for hospitals to use the
2015 Edition Cures Update beginning
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
with the CY 2023 reporting period/FY
2025 payment determination, then all
available eCQMs used in the Hospital
IQR Program for the CY 2023 reporting
period/FY 2025 payment determination
and subsequent years would need to be
reported using certified technology
updated to the 2015 Edition Cures
Update. We did not propose any
changes to this policy.
khammond on DSKJM1Z7X2PROD with RULES2
(4) File Format for EHR Data, Zero
Denominator Declarations, and Case
Threshold Exemptions
We refer readers to the FY 2016 IPPS/
LTCH PPS final rule (80 FR 49705
through 49708) and the FY 2017 IPPS/
LTCH PPS final rule (81 FR 57170) for
our previously adopted eCQM file
format requirements. Under these
requirements, hospitals: (1) Must submit
eCQM data via the Quality Reporting
Document Architecture Category I
(QRDA I) file format, (2) may use third
parties to submit QRDA I files on their
behalf, and (3) may either use
abstraction or pull the data from noncertified sources to then input these
data into Certified EHR Technology
(CEHRT) for capture and reporting
QRDA I. Hospitals can continue to meet
the reporting requirements by
submitting data via QRDA I files, zero
denominator declaration, or case
threshold exemption (82 FR 38387).
More specifically regarding the use of
QRDA I files, we refer readers to the FY
2017 IPPS/LTCH PPS final rule (81 FR
57169 through 57170) and the FY 2020
IPPS/LTCH PPS final rule (85 FR
58940), in which we stated that we
expect QRDA I files to reflect data for
one patient per file per quarter, and
identified the five key elements that are
utilized to identify the file:
• CMS Certification Number (CCN);
• CMS Program Name;
• EHR Patient ID;
• Reporting period specified in the
Reporting Parameters Section per the
CMS Implementation Guide for the
applicable reporting year, which is
published on the eCQI Resource Center
website at: https://ecqi.healthit.gov/
QRDA; and
• EHR Submitter ID (beginning with
the CY 2021 reporting period/FY 2023
payment determination).
We did not propose any changes to
this policy.
(5) Submission Deadlines for eCQM
Data
We refer readers to the FY 2015 IPPS/
LTCH PPS final rule (79 FR 50256
through 50259), the FY 2016 IPPS/LTCH
PPS final rule (80 FR 49705 through
49709), and the FY 2017 IPPS/LTCH
PPS final rule (81 FR 57169 through
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
57172) for our previously adopted
policies to align eCQM data reporting
periods and submission deadlines for
both the Hospital IQR Program and the
Medicare Promoting Interoperability
Program for Eligible Hospitals and
CAHs. In the FY 2017 IPPS/LTCH PPS
final rule (81 FR 57172), we finalized
the alignment of the Hospital IQR
Program eCQM submission deadline
with that of the Medicare Promoting
Interoperability Program for Eligible
Hospitals and CAHs—the end of two
months following the close of the
calendar year—for the CY 2017
reporting period/FY 2019 payment
determination and subsequent years. We
note the submission deadline will be
moved to the next business day if it falls
on a weekend or Federal holiday. We
did not propose any changes to this
policy.
f. Data Submission and Reporting
Requirements for Hybrid Measures
(1) Background
The Hospital IQR Program recently
adopted hybrid measures into the
program’s measure set. In the FY 2018
IPPS/LTCH PPS final rule (82 FR 38350
through 38355), we finalized voluntary
reporting of the Hybrid Hospital-Wide
Readmission (Hybrid HWR) measure for
the CY 2018 reporting period. In the FY
2020 IPPS/LTCH PPS final rule, we
finalized the adoption of the Hybrid
HWR measure for the Hospital IQR
Program (84 FR 42465 through 42481)
such that, beginning with the FY 2026
payment determination, hospitals are
required to report on the Hybrid HWR
measure (84 FR 42479). In the FY 2022
IPPS/LTCH PPS final rule, we also
finalized the adoption of the Hybrid
Hospital-Wide All-Cause Risk
Standardized Mortality (Hybrid HWM)
measure in a stepwise fashion,
beginning with a voluntary reporting
period from July 1, 2022 through June
30, 2023, and followed by mandatory
reporting from July 1, 2023 through June
30, 2024, affecting the FY 2026 payment
determination and for subsequent years
(86 FR 45365). We also finalized several
requirements related to data submission
and reporting requirements for hybrid
measures under the Hospital IQR
Program (84 FR 42506 through 42508).
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28557 through
28558), we proposed changes specific to
the zero denominator declarations and
case threshold exemptions policies for
hybrid measures, as discussed further in
the subsequent section.
PO 00000
Frm 00525
Fmt 4701
Sfmt 4700
49303
(2) Certification and File Format
Requirements
We refer readers to the FY 2020 IPPS/
LTCH PPS final rule (84 FR 19498
through 19499), the FY 2021 IPPS/LTCH
PPS final rule (85 FR 58941), and the CY
2021 PFS final rule (85 FR 84472) for
our previously adopted policies
regarding certification and file format
requirements for hybrid measures in the
Hospital IQR Program.
In the CY 2021 PFS final rule (85 FR
84825 through 84828), we finalized
flexibility to allow hospitals to use
either: (1) Technology certified to the
2015 Edition criteria as was previously
finalized in the FY 2019 IPPS/LTCH
PPS final rule (83 FR 41537 through
41608) or (2) certified technology
updated consistent with the 2015
Edition Cures Update as finalized in the
ONC 21st Century Cures Act final rule
(85 FR 25642 through 25961, 85 FR
50271), beginning with the CY 2020
reporting period/FY 2022 payment
determination and subsequent years.
The Hospital IQR Program offers
flexibility to meet hybrid measure
submission requirements to facilitate
successful reporting during the period
of transition as providers are updating
certified technology to be consistent
with the 2015 Edition Update. This
flexibility applies to all Hospital IQR
Program measures which use EHR data
elements to calculate measure rates,
including eCQMs and hybrid measures.
In the FY 2022 IPPS/LTCH PPS final
rule, to align with the health IT
certification requirements for eCQM
reporting, we finalized to require
hospitals to use only certified
technology that has been updated
consistent with the 2015 Edition Cures
Update to submit hybrid measure data
beginning with the CY 2023 reporting
period/FY 2025 payment determination
and for subsequent years (86 FR 45421).
We did not propose any changes to
these policies in the proposed rule.
(3) Additional Submission
Requirements
In the FY 2020 IPPS/LTCH PPS final
rule, we finalized allowing hospitals to
meet the hybrid measure reporting and
submission requirements by submitting
any combination of data via QRDA I
files, zero denominator declarations,
and case threshold exemptions (84 FR
42507). We also finalized applying
similar zero denominator declaration
and case threshold exemption policies
to hybrid measure reporting as we allow
for eCQM reporting (84 FR 42507
through 42508).
We note that the ONC 21st Century
Cures Act final rule revises the clinical
E:\FR\FM\10AUR2.SGM
10AUR2
49304
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
quality measurement criterion at 45 CFR
170.315(c)(3) to refer to CMS QRDA IGs
and remove the HL7® QRDA standard
requirements (85 FR 25645). We
encourage all hospitals and their health
IT vendors to submit QRDA I files early,
and to use one of the pre-submission
testing tools for electronic reporting,
such as submitting test files to the HQR
System, to allow additional time for
testing and make sure all required data
files are successfully submitted by the
deadline.
khammond on DSKJM1Z7X2PROD with RULES2
(4) Modification of the Zero
Denominator Declarations Policy and
Case Threshold Exemptions Policy for
Hybrid Measures
As stated in the previous section
(section IX.E.10.f.(3).), in the FY 2020
IPPS/LTCH PPS final rule, we finalized
applying the zero denominator
declarations policy and case threshold
exemptions policy to hybrid measure
reporting (84 FR 42507 through 42508).
Additionally, in the FY 2020 IPPS/
LTCH PPS final rule, we indicated that
zero denominator declarations and case
threshold exemptions would not be
necessary during the voluntary
reporting periods for hybrid measures
but would be an option for hospitals to
utilize when hybrid measure reporting
became mandatory (84 FR 42508).
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28558), we
proposed to remove zero denominator
declarations and case threshold
exemptions as an option for the
reporting of hybrid measures beginning
with the FY 2026 payment
determination for reasons discussed in
the subsequent section. We note that the
FY 2026 payment determination is the
first year for which hybrid measures,
finalized as part of the Hospital IQR
Program measure set, will become
mandatory for reporting.
Zero denominator declarations allow
a hospital whose EHR is capable of
reporting hybrid measure data to submit
a zero in the denominator for the
reporting of a measure if the hospital
does not have patients that meet the
denominator criteria of that hybrid
measure (84 FR 42507). Similarly, the
case threshold exemptions policy allows
for a hospital with five or fewer
inpatient discharges per quarter or 20 or
fewer inpatient discharges per year in a
given denominator declaration be
exempted from reporting on that
individual hybrid measure (84 FR
42507). These policies were originally
developed for eCQMs and were
extended to hybrid measures to ensure
hospitals were not penalized for the
absence of patients that meet the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
denominator criteria in the reporting of
those measures.
Upon further analysis, however, we
do not believe that these policies are
applicable for hybrid measures due to
the process of reporting the measure
data. Hybrid measures do not require
that hospitals report a traditional
denominator as is required for the
submission of eCQMs. Instead, hybrid
measures utilize the Initial Patient
Population (IPP), as per their measure
specifications, that identifies the
patients for which hospitals need to
extract the EHR data and annual claims
data. Additionally, we calculate hybrid
measures by merging both the claims
and EHR data received. Therefore, since
we will confirm the measure cohort to
determine whether a hospital has met
the denominator criteria, both the zero
denominator declaration and the case
threshold exemption for hybrid
measures will not be applicable to
hospitals.
We invited public comment on this
proposal.
Comment: A commenter supported
our proposal to remove the zero
denominator declarations and case
threshold exemptions policies for
hybrid measures beginning with the FY
2026 payment determination.
Response: We thank the commenter
for the support.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
(5) Submission Deadlines for Hybrid
Measures
We refer readers to the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42508),
where we finalized submission
deadlines for hybrid measures. We did
not propose any changes to these
policies in the proposed rule.
g. Sampling and Case Thresholds for
Chart-Abstracted Measures
We refer readers to the FY 2011 IPPS/
LTCH PPS final rule (75 FR 50221), the
FY 2012 IPPS/LTCH PPS final rule (76
FR 51641), the FY 2013 IPPS/LTCH PPS
final rule (77 FR 53537), the FY 2014
IPPS/LTCH PPS final rule (78 FR
50819), and the FY 2016 IPPS/LTCH
PPS final rule (80 FR 49709) for details
on our sampling and case thresholds for
the FY 2016 payment determination and
subsequent years. We did not propose
any changes to these policies in the
proposed rule.
h. HCAHPS Administration and
Submission Requirements
We refer readers to the FY 2011 IPPS/
LTCH PPS final rule (75 FR 50220), the
FY 2012 IPPS/LTCH PPS final rule (76
PO 00000
Frm 00526
Fmt 4701
Sfmt 4700
FR 51641 through 51643), the FY 2013
IPPS/LTCH PPS final rule (77 FR 53537
through 53538), and the FY 2014 IPPS/
LTCH PPS final rule (78 FR 50819
through 50820) for details on
previously-adopted HCAHPS
submission requirements. We also refer
hospitals and HCAHPS Survey vendors
to the official HCAHPS website at
https://www.hcahpsonline.org for new
information and program updates
regarding the HCAHPS Survey, its
administration, oversight, and data
adjustments. We did not propose any
changes to these policies in the
proposed rule.
i. Data Submission Requirements for
Structural Measures
We refer readers to the FY 2012 IPPS/
LTCH PPS final rule (76 FR 51643
through 51644) and the FY 2013 IPPS/
LTCH PPS final rule (77 FR 53538
through 53539) for details on the data
submission requirements for structural
measures. Hospitals are required to
submit information for structural
measures once annually using a CMSapproved web-based data collection tool
available within the HQR System. The
data submission period for structural
measures begins in April and has the
same submission deadline as the fourth
calendar quarter chart-abstracted
measure deadline. For example, for the
FY 2025 payment determination,
hospitals would be required to submit
the required information between April
1, 2024 and May 15, 2024, with respect
to the time period of January 1, 2023
through December 31, 2023.
We note that, in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45361), for
the Maternal Morbidity Structural
Measure and the CY 2021 reporting
period/FY 2023 payment determination
only, we finalized a shortened reporting
period from October 1, 2021 through
December 31, 2021, while retaining the
standard data submission period.
Specifically, for the shortened reporting
period hospitals will be required to
submit the data between April 1, 2022
and May 16, 2022 (we note that May 15,
2022 falls on a weekend and therefore
the close of this data submission period
is moved to May 16, 2022). Thereafter,
we finalized that the reporting period
for the Maternal Morbidity Structural
Measure will run from: January 1
through December 31 on an annual
basis, and that the data submission
period will continue to be consistent
with our current policy (beginning in
April until the same submission
deadline as for the fourth calendar
quarter of the chart-abstracted measures
with respect to the reporting period for
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
the previous calendar year) (86 FR
45361).
We did not propose any changes to
these policies in the proposed rule.
j. Data Submission and Reporting
Requirements for CDC NHSN Measures
For details on the data submission
and reporting requirements for measures
reported via the CDC’s National
Healthcare Safety Network (NHSN), we
refer readers to the FY 2012 IPPS/LTCH
PPS final rule (76 FR 51629 through
51633; 51644 through 51645), the FY
2013 IPPS/LTCH PPS final rule (77 FR
53539), the FY 2014 IPPS/LTCH PPS
final rule (78 FR 50821 through 50822),
and the FY 2015 IPPS/LTCH PPS final
rule (79 FR 50259 through 50262). The
data submission deadlines are posted on
the QualityNet website.
We note that in the FY 2022 IPPS/
LTCH PPS final rule, we finalized the
adoption of the COVID–19 Vaccination
Among Health Care Personnel measure,
beginning in October 2021 for the
October 1, 2021 through December 31,
2021 reporting period affecting the FY
2023 payment determination and
continuing for each quarter in
subsequent years (86 FR 45374).
Specific details on data submission for
this measure can be found in the CDC’s
Overview of the Healthcare Safety
Component, available at: https://
www.cdc.gov/nhsn/PDFs/slides/NHSNOverview-HPS_Aug2012.pdf. We did
not propose any changes to these
policies in the proposed rule.
k. Data Submission and Reporting
Requirements for Patient-Reported
Outcome-Based Performance Measures
(PRO–PMs)
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28559 through
28560), in section IX.E.5.g., we
proposed the adoption of the hospitallevel THA/TKA PRO–PM into the
Hospital IQR Program measure set. In
this section of the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28559
through 28560), we proposed the
reporting and submission requirements
for PRO–PM measures as a new type of
measure to the Hospital IQR Program.
(1) Submission of PRO–PM Data
khammond on DSKJM1Z7X2PROD with RULES2
(a) Data Submission
In section IX.E.5.g. of the preamble of
this final rule, we discuss adoption of
the THA/TKA PRO–PM in the Hospital
IQR Program. In the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28527),
we proposed that hospitals would have
the choice of selecting from multiple
submission approaches.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
First hospitals may choose to: (1)
Send their data to CMS for measure
calculation directly; or (2) utilize an
external entity, such as through a
vendor or registry, to submit their data
on behalf of the hospital to CMS for
measure calculation. This data
submission approach is consistent with
stakeholder input received by the
measure developer during measure
development and comments as
summarized in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45411 through
45414) which recommended CMS
provide multiple options for data
submission mechanisms to ensure
flexibility.
Whether a hospital chooses to submit
the data itself or via a vendor, we would
allow a range of file formats. Both
hospitals and vendors would use the
HQR System for data submission for the
THA/TKA PRO–PM. Use of the HQR
System leverages existing CMS
infrastructure already utilized for other
quality measures (such as, HCAHPS or
the Sepsis measure). The HQR System
allows for data submission using the
following file formats: CSV, XML, and a
manual data entry option; allowing
hospitals and vendors flexibility in data
submission. We would provide
hospitals with additional detailed
information and instructions for
submitting data using the HQR System
through CMS’ existing websites, such as
on QualityNet, and through listservs or
both.
(b) Data Submission Reporting
Requirements
(1) Voluntary Reporting Requirements
for the Proposed THA/TKA PRO–PM
As discussed earlier, we proposed a
phased implementation approach for
adoption of the THA/TKA PRO–PM,
with two voluntary reporting periods for
the CY 2025 and 2026 reporting periods
prior to mandatory reporting beginning
with the FY 2028 payment
determination. Voluntary reporting
prior to mandatory reporting would
allow time for hospitals to incorporate
the THA/TKA PRO–PM data collection
into their clinical workflows and is
responsive to stakeholder comments
summarized in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45411 through
45414). For each voluntary and
subsequent mandatory reporting
periods, we would collect data on the
THA/TKA PRO–PM in accordance with,
and to the extent permitted by, the
HIPAA Privacy and Security Rules (45
CFR parts 160 and 164, Subparts A, C,
and E), and other applicable federal law.
PO 00000
Frm 00527
Fmt 4701
Sfmt 4700
49305
For hospitals participating in
voluntary reporting, hospitals would
submit pre-operative PRO data, as well
as matching post-operative PRO data for
at least 50 percent of their eligible
elective primary THA/TKA procedures.
The first voluntary reporting period for
CY 2025 would include pre-operative
PRO data collection from October 3,
2022 through June 30, 2023 (for eligible
elective THA/TKA procedures
performed from January 1, 2023 through
June 30, 2023) and post-operative PRO
data collection from October 28, 2023 to
August 28, 2024. Hospitals would
submit pre-operative data in 2023 and
post-operative data in 2024, and we
intend to provide hospitals with their
results in confidential feedback reports
in 2025. Hospitals would submit preoperative data for the first voluntary
reporting three months following the
end of the performance period. For postoperative data, hospitals would be
required to submit data one month
following the end of the performance
period. If that day falls on a weekend,
submissions will be due the following
Monday. For example, for procedures
performed between January 1, 2023 and
June 30, 2023, pre-operative data will
need to be submitted by October 2,
2023. After the initial submission of preoperative data in the first voluntary
period, hospitals would submit both
pre-operative and post-operative data by
the same day, but for different time
periods. For example, hospitals would
need to submit: (1) Post-operative data
for the first voluntary reporting (for
procedures performed between January
1, 2023 and June 30, 2023); and (2) preoperative data for the second voluntary
reporting (for procedures performed
between July 1, 2023 and June 30, 2024)
of the THA/TKA PRO–PM by September
30, 2024.
The second voluntary reporting
period will include pre-operative PRO
data collection from April 2, 2023
through June 30, 2024 (for eligible
elective THA/TKA procedures
performed from July 1, 2023 through
June 30, 2024) and post-operative PRO
data collection from April 26, 2024 to
August 29, 2025. Hospitals would
submit pre-operative data in 2024 and
post-operative data in 2025, and we
noted our intention to provide hospitals
with their results in confidential
feedback reports in 2026.
We refer readers to Table IX.E–16. for
an overview of the proposed
performance period, pre- and postoperative data collection timeframes,
and data submission deadlines during
voluntary reporting.
E:\FR\FM\10AUR2.SGM
10AUR2
49306
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE IX.E-16. VOLUNTARY REPORTING OF PRE-OPERATIVE AND POSTOPERATIVE PERIODS FOR THA/TKA PRO-PM
'iPerformance Period 'iPre-Operative Data
'iPre-Operative Data Post-Operative Data
Collection
Submission Deadline Collection
Voluntmy Reporting Janumy 1, 2023
October 3, 2022 through October 2, 2023
October 28, 2023 to
1 (2025)
through
June 30, 2023
August 28, 2024
June 30, 2023
Voluntmy Reporting July 1, 2023 through April 2, 2023 through September 30, 2024 April 26, 2024 to
2 (2026)
June 30, 2024
June 30, 2024
August 29, 2025
Reporting Period
(2) Mandatory Reporting
Following the two voluntary reporting
periods, we proposed the mandatory
reporting of the THA/TKA PRO–PM
would begin with reporting PRO data
for eligible elective THA/TKA
procedures from July 1, 2024 through
June 30, 2025 (performance period),
impacting the FY 2028 payment
determination. This initial mandatory
reporting would include pre-operative
PRO data collection from three months
preceding the applicable performance
period and from 10 to 14 months after
the performance period. For example,
pre-operative data from April 2, 2024
through June 30, 2025 (for eligible
elective primary THA/TKA procedures
from July 1, 2024 through June 30, 2025)
and post-operative PRO data collection
from April 27, 2025 to August 29, 2026.
Pre-operative data submission would
occur in 2025 and post-operative data
submission in 2026 and we noted our
intention to provide hospitals with their
results in 2027 before publicly reporting
results on the Compare tool hosted by
HHS, currently available at: https://
Post-Operative Data
Submission deadline
September 30, 2024
September 30, 2025
www.medicare.gov/care-compare, or its
successor website. Hospitals would be
required to submit 50 percent of
eligible, complete pre-operative data
with matching eligible, complete postoperative data as a minimum amount of
data for mandatory reporting in the
Hospital IQR Program.
We refer readers to Table IX.E–17. for
an overview of the proposed
performance period, pre- and postoperative data collection timeframes,
and data submission deadlines during
the mandatory reporting period.
TABLE IX.E-17. MANDATORY REPORTING OF PRE-OPERATIVE AND
POST-OPERATIVE PERIODS FOR THA/TKA PRO-PM
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
specifically supported the adoption of
the THA/TKA PRO–PM to the Hospital
IQR Program stating it enables patient
voices to be heard throughout all phases
of their care and recovery, and the
measure is important as it includes the
patient voice in assessment of outcomes
which should be reflected in quality and
safety performance.
Response: We thank commenters for
their support.
Comment: Several commenters
discussed the data collection approach
and burden associated with the
adoption of the THA/TKA PRO–PM into
the Hospital IQR Program. A few
commenters supported having multiple
modes for data collection and
submission of PRO data, including the
use of registries. A commenter
supported the use of Medicare
enrollment data as the source to identify
dual eligibility status and variables for
risk adjustment.
Many commenters stated specifically
that the financial, resource, and labor
costs required to collect, track, and
PO 00000
Frm 00528
Fmt 4701
Sfmt 4700
submit data would burden hospitals and
make successful implementation of the
measure difficult. A commenter
encouraged delayed adoption for several
years to give health systems time to
recover resources and staffing impacted
by the COVID–19 pandemic. Another
commenter expressed concern about
small hospitals’ ability to collect and
report data and suggested we institute
technical support as well as financial
bonuses for them to utilize. A
commenter urged us to consider
technical difficulties of adopting a PRO–
PM and noted limitations in data
infrastructure and EHR systems, and a
lack of integration between PRO data.
The commenter expressed that progress
in this area will require adoption of
newer technologies such as machine
learning and artificial intelligence to
advance the healthcare system.
Response: We thank commenters for
their feedback regarding data collection
and burden. We agree that having
multiple modes of data collection,
including use of registries, would be
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.177
We invited public comment on this
proposal.
Comment: Several commenters
supported the adoption of the HospitalLevel, Risk Standardized PatientReported Outcomes Performance
Measure (PRO–PM) Following Elective
Primary Total Hip Arthroplasty (THA)
and/or Total Knee Arthroplasty (TKA)
(THA/TKA PRO–PM), beginning with
two voluntary reporting periods
followed by mandatory reporting for the
reporting period which runs from July 1,
2025, through June 30, 2026, impacting
the FY 2028 payment determination. A
commenter specifically supported
patient-reported outcome measures as a
way to assess quality of care and
effectiveness from the patient
perspective. A commenter generally
supported the addition of PRO–PMs
into quality programs for clinical
scenarios where reliable PRO
instruments are available for patients to
complete. A commenter supported CMS
beginning PRO–PMs using elective
procedures. A few commenters
'iPre-operative Data Post-Operative Data Post-Operative Data
Submission Deadline Collection
Submission Deadline
September 30, 2025 April 27, 2025 to
September 30, 2026
August 29, 2026
ER10AU22.176
khammond on DSKJM1Z7X2PROD with RULES2
!Reporting Period Performance Period Pre-operative Data
Collection
Mandatory
July 1, 2024
April 2, 2024 through
Reporting (2027) through June 30,
June 30, 2025
2025
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
beneficial to hospitals and reduce
burden. We acknowledge the concerns
regarding financial, labor, and resource
burdens associated with adopting the
THA/TKA PRO–PM into the Hospital
IQR Program and are seeking to advance
patient-centered measurement with as
little burden as possible to both
providers and patients. While PRO–PMs
require providers to integrate data
collection into clinical workflows, this
integration provides an opportunity for
patient-reported outcomes to inform
clinical decision making and benefits
patients by engaging them in
discussions about potential outcomes.
The PRO instruments used to
calculate pre- and post-operative scores
for this THA/TKA PRO–PM were
carefully considered, with extensive
stakeholder input from clinicians, to be
low burden and are non-proprietary for
free use. We will evaluate data
collection burden and response rates
associated with the THA/TKA PRO–PM.
Any feedback on data collection will be
considered in future measure
development and reevaluation.
We thank commenters for their
feedback, and will provide hospitals
and other interested parties with more
information on data collection and
reporting for the THA/TKA PRO–PM
through education and outreach
activities prior to implementation. We
will continue to evaluate feedback on
challenges with data collection during
voluntary reporting and consider them
prior to mandatory reporting.
Comment: A commenter encouraged
us to minimize data collection burden to
patients by leveraging technology and
considering other surveys they are
requested to complete, such as
HCAHPS. Another commenter
requested additional research to
understand the burden of the measure
on hospitals and patients, including
patient survey fatigue, impact of new
PRO–PMs on established survey
measures like HCAHPS, and acceptable
level of burden for use of the measure.
Response: This measure was
developed with extensive input from
patients, who indicated strong support
for a PRO–PM following elective
primary THA and TKA. We anticipate
data collection for this measure to
present a low burden to patients.
Regarding survey fatigue, we designed
the measure to illuminate a patient’s
pain and functional status before and
after a THA or TKA, which is different
than other surveys such as HCAHPS
that capture patient experience.
Regarding the comment that the THA/
TKA PRO–PM may have a reporting
impact on other measures, such as
HCAHPS, we anticipate a minimal
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
impact to other measures as the THA/
TKA PRO–PM’s eligible population is
procedure-specific which reduces the
likelihood of the same patient receiving
the HCAHPS and PRO survey.
Additionally, the THA/TKA PRO–PM
pre-operative assessment (90 to 0 days
before surgery) and post-operative
assessment (300 to 425 days following
surgery) timeframe is different than
HCAHPS, which is two weeks after a
hospital visit.
Comment: A commenter requested we
not adopt the THA/TKA PRO–PM in the
Hospital IQR Program until operational
challenges identified by CJR
participating hospitals are shared
publicly, independently analyzed, and
addressed. Commenters expressed
concern that reporting of the THA/TKA
PRO–PM as part of the CJR Model has
been challenging and burdensome,
resulting in potentially impacting
completion rates. A commenter
expressed concern response rates will
be insufficient to calculate reliable and
valid results for comparison of hospital
performance. Another commenter stated
hospitals have not been able to meet
high reporting thresholds and have
challenges with survey response rates
for the THA/TKA PRO–PM as part of
the CJR Model. The commenter
recommended CMS analyze pre- and
post-operative response rates in the CJR
Model and consider ways to support
hospitals in increasing responsiveness.
Another commenter requested CMS
lower the 50 percent submission
requirement proposal until it is clear
hospitals can produce this.
Response: We appreciate commenters’
request for information about use of the
measure in the CJR Model. We have
gathered feedback from several years of
PRO data collection by CJR participating
hospitals and applied lessons learned to
the THA/TKA PRO–PM proposal for
adoption in the Hospital IQR Program,
including requiring hospitals to collect
and submit fewer variables, allowing
hospitals flexibility in data collection
options to better integrate into their
workflows, and influenced the decision
to set the initial reporting threshold to
a moderate rate of 50 percent reporting
threshold. We highlight that our
proposal included two voluntary
reporting periods in which we would
gather additional feedback from
participating hospitals on their
experience collecting and submitting
data and apply any lessons learned prior
to mandatory reporting.
The proposed reporting threshold is
based on average response rates for both
pre-operative and post-operative
surveys collected by participating
hospitals in the CJR Model. The
PO 00000
Frm 00529
Fmt 4701
Sfmt 4700
49307
proposed reporting threshold for
adoption of the measure to the Hospital
IQR Program is lower than that
currently used in the CJR Model.
Additionally, hospitals are not held to
reporting thresholds until mandatory
reporting. We believe hospitals will
therefore have time to develop their data
collection and reporting processes. We
will continue to consider the
appropriate pre- and post-operative
matched survey response rate, as well as
reporting thresholds. We will evaluate
this approach during voluntary
reporting and consider adjustments
based on feedback prior to mandatory
reporting.
Comment: A few commenters
supported the proposed phased
implementation timeline. A few
commenters requested CMS delay
mandatory reporting of the measure to
allow hospitals time to enhance
interoperability and develop processes
for successful data collection and
submission. A commenter stated the
proposed voluntary and mandatory
reporting timeline does not provide
hospitals sufficient time to gain
experience or use results to improve
data collection processes. A commenter
requested three years of voluntary
reporting.
Response: We thank commenters for
their support of the phased approach of
adopting the THA/TKA PRO–PM in the
Hospital IQR Program. We have
considered commenters’
recommendations regarding voluntary
and mandatory reporting timelines. We
believe the proposed voluntary and
mandatory reporting implementation
approach allows hospitals time and
notice to make the necessary
enhancements to their clinical workflow
to successfully report this measure. We
highlight that our proposal included
two voluntary reporting periods prior to
mandatory reporting which balances the
need to allow hospitals time to prepare
for mandatory reporting with the
importance of measuring patients’
functional status for these common
surgical procedures and the need to
make this information publicly available
for patient use and quality improvement
(87 FR 28528 through 28529). We also
note that the proposed first voluntary
reporting period uses just six months of
data to allow hospitals an opportunity
to receive feedback more quickly on,
and improve, their data collection and
submission processes (87 FR 28528). We
intend to carefully consider feedback
received during voluntary reporting to
inform improvements that may be made
for mandatory reporting.
Comment: A commenter requested
reimbursement to incentivize reporting
E:\FR\FM\10AUR2.SGM
10AUR2
49308
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
of the THA/TKA PRO–PM and
suggested we create a G code for near
term use, and a CPT code for permanent
use.
Response: We acknowledge
commenters’ feedback on
reimbursement incentives. The Hospital
IQR Program statutory authority in
section 1886(b)(3)(B)(viii) of the Act
does not provide for the ability to award
incentive payments for meeting program
requirements as it is a pay-for-reporting
quality program.
Comment: Another commenter
requested CMS share performance
results with hospitals transparently and
in real time for use in shared decision
making.
Response: We confirm that hospitals
will receive performance results
confidentially as part of both voluntary
and mandatory reporting. We encourage
hospitals to use these results as part of
shared decision making with their
patients.
Comment: A commenter expressed
concern with response bias and noted
accounting for patient socioeconomic
status, race, or dual eligibility in the risk
model is not adequate to address lack of
response.
Response: We thank the commenter
for their input regarding health
disparities and response bias. We agree
that considering the unique experience
of populations with social risk factors is
important. The measure as proposed
accounts for potential non-response bias
through inverse probability weighting
and considers patient characteristics,
including non-white race, dual
eligibility, and the AHRQ SES index
score.1084 The AHRQ SES index score is
computed using US census data and
considers factors including zip code,
median household income, percentage
of persons below the Federal poverty
line, unemployment, education,
property value, and percentage of
persons in crowded households.1085 The
measure also includes health literacy in
the risk model.1086 We encourage
hospitals to consider a variety of PRO
data collection methods to support
responses from all eligible patients. We
will continue to assess the impact of
1084 Patient-Reported Outcomes (PROs) Following
Elective Primary Total Hip and/or Total Knee
Arthroplasty: Hospital-Level Performance Measure
(Version 1.0 Methodology Report). March 2021.
1085 Bonito A, Bann C, Eicheldinger C, Carpenter
L. Creation of new race-ethnicity codes and
socioeconomic status (SES) indicators for Medicare
beneficiaries. Final Report, Sub-Task. 2008;2.
1086 Patient-Reported Outcomes (PROs) Following
Elective Primary Total Hip and/or Total Knee
Arthroplasty: Hospital-Level Performance Measure
(Version 1.0 Methodology Report). March 2021.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
social risk factors on the measure and
response rates over time.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
11. Validation of Hospital IQR Program
Data
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28560 through
28562), we proposed to update our
eCQM validation process. Specifically,
we proposed to update our validation
requirements for eCQMs from our
current requirement that hospitals
submit timely and complete data for 75
percent of requested records to
submission of timely and complete data
for 100 percent of requested records
beginning with CY 2022 eCQM data
affecting the FY 2025 payment
determination and for subsequent years.
We note that this will not affect
finalized policies with respect to
validation of chart-abstracted measures.
a. Background
We refer readers to the FY 2013 IPPS/
LTCH PPS final rule (77 FR 53539
through 53553), the FY 2014 IPPS/LTCH
PPS final rule (78 FR 50822 through
50835), the FY 2015 IPPS/LTCH PPS
final rule (79 FR 50262 through 50273),
the FY 2016 IPPS/LTCH PPS final rule
(80 FR 49710 through 49712), the FY
2017 IPPS/LTCH PPS final rule (81 FR
57173 through 57181), the FY 2018
IPPS/LTCH PPS final rule (82 FR 38398
through 38403), the FY 2019 IPPS/LTCH
PPS final rule (83 FR 41607 through
41608), the FY 2020 IPPS/LTCH PPS
final rule (84 FR 42509), the FY 2021
IPPS/LTCH PPS final rule (85 FR 58942
through 58953), and the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45423
through 45426) for detailed information
on and previous changes to chartabstracted and eCQM validation
requirements for the Hospital IQR
Program.
In the FY 2017 IPPS/LTCH PPS final
rule, we finalized our policy to require
submission of at least 75 percent of
sampled eCQM medical records in a
timely and complete manner for
validation (81 FR 57181). To ensure we
have adequate data to assess and
validate eCQMs, we finalized a
requirement that hospitals submit at
least 75 percent of sampled eCQM
medical records (81 FR 57173 through
57175). In the FY 2021 IPPS/LTCH PPS
final rule, we combined the validation
processes for eCQMs and chartabstracted measures, but did not update
the threshold submission percent for
eCQM medical records (85 FR 58952
through 58944). In that rule, we adopted
a policy to remove the separate process
PO 00000
Frm 00530
Fmt 4701
Sfmt 4700
for eCQM validation, beginning with the
validation affecting the FY 2024
payment determination (for validation
commencing in CY 2022 using data
from the CY 2021 reporting period) (85
FR 58942 through 58953). Beginning
with validation affecting the FY 2024
payment determination and subsequent
years, we finalized a policy to
incorporate eCQMs into the existing
validation process for chart-abstracted
measures such that there would be one
pool of hospitals selected through
random selection and one pool of
hospitals selected using targeting
criteria, for both chart-abstracted
measures and eCQMs (85 FR 58942
through 58953). Under the aligned
validation process, a single hospital
could be selected for validation of both
eCQMs and chart-abstracted measures
and is expected to submit data for both
chart-abstracted measures and eCQMs
(85 FR 58942 through 58953). We refer
readers to the FY 2017 IPPS/LTCH PPS
final rule (81 FR 57179 through 57180)
for details on the Hospital IQR Program
data submission requirements for chartabstracted measures. We did not
propose any changes to finalized
policies for validation of chartabstracted measures.
b. Modifications to the Existing
Processes for Validation of Hospital IQR
Program eCQM Data
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28561), we
proposed to update our eCQM
validation requirement to require that
hospitals selected for validation submit
timely and complete data for 100
percent of requested records for eCQM
validation beginning with CY 2022
eCQM data, affecting the FY 2025
payment determination and for
subsequent years. Hospitals selected for
eCQM validation are required to submit
timely and sufficient medical records.
As finalized in the FY 2017 IPPS/LTCH
PPS final rule (81 FR 57178 through
57179), hospitals must submit timely
medical records—within 30 days of the
records request—to meet eCQM
validation requirements. To meet the
eCQM validation requirement for
sufficient medical records, we proposed
to increase the submission threshold
from 75 percent to 100 percent
beginning with validation of CY 2022
eCQM data affecting the FY 2025
payment determination and for
subsequent years.
Ever since validation of eCQMs
commenced with CY 2017 data (81 FR
57173 through 57181), all hospitals
selected for eCQM validation have
successfully submitted at least 75
percent of eCQM medical records
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
requested by the Clinical Data
Abstraction Center (CDAC).
Additionally, 95 percent of hospitals
selected for participation in eCQM
validation for the FY 2020 and FY 2021
payment determinations, which are the
most recently available periods,
voluntarily and successfully submitted
100 percent of requested records. We
believe that increasing the submission
threshold from 75 percent to 100
percent of the requested records will
support our ongoing goal of continuing
to assess the accuracy of eCQM measure
data (81 FR 57155). Also, given the high
rate of hospitals voluntarily submitting
100 percent of records, we believe
updating the submission threshold to
100 percent will be feasible for
hospitals.
We note that under our current
policy, the accuracy of eCQM data (the
extent to which data abstracted for
validation matches the data submitted
in the QRDA I file) submitted for
validation does not affect a hospital’s
validation score as described in the FY
2017 IPPS/LTCH PPS final rule (81 FR
57180 through 57181) and will not be
impacted by this finalized update to the
submission threshold. We also note that
hospitals that fail to submit timely and
complete medical records will not meet
the eCQM validation requirement and
will be subject to payment reduction as
described in our previously finalized
policy (81 FR 57180). Chart-abstracted
data continue to be weighted at 100
percent for payment determination as
finalized in the FY 2021 IPPS/LTCH
49309
PPS final rule (85 FR 58942 through
58953) and will not be impacted by our
proposed modification to the eCQM
validation.
The previously finalized eCQM
validation requirements, including data
submission requirements, are described
at 42 CFR 412.140(d)(2)(ii). We also
proposed to update the references to ‘‘at
least 75 percent’’ in this Hospital IQR
Program regulation text. Specifically, we
proposed to remove the phrase ‘‘at least
75 percent’’ and add in its place the
phrase ‘‘100 percent.’’ We continue to
evaluate data submitted for validation
for potential future policy changes.
Our previously finalized and newly
proposed validation scoring changes are
summarized in Table IX.E–18.
TABLE IX.E-18. SUMMARY OF PREVIOUSLY FINALIZED AND PROPOSED eCQM
VALIDATION SCORING
Quarters of Data
Reauired for Validation
Scorine
Previously Finalized Validation Scorine for the FY 2023 Payment Determination (81 FR 57179 throueh 57181)
At least 75% validation score
3Q 2020
Chart-Abstracted Measures Validation: 400 Random
Hospitals + up to 200 Targeted Hospitals
4Q 2020
Successful submission of at least 75% of requested
medical records
Previously Finalized Validation Scorine for the FY 2024 Payment Determination (85 FR 58942 throueh 58953)
Chart-Abstracted Measures: at least 75% validation
COMBINED Process (Chart-Abstracted Measures and
score (weighted at 100%)
IQ 2021-4Q 2021
eCQM Validation): up to 200 Random Hospitals+ up
And
to 200 Targeted Hospitals
eCQMs: Successful submission of75% ofrequested
medical records
Proposed Update to eCQM Validation Scorine for the FY 2025 Payment Determination and Subsequent Years
Chart-Abstracted Measures: at least 75% validation
COMBINED Process (Chart-Abstracted Measures and
score (weighted at 100%)
1Q 2022 - 4Q 2022
eCQM Validation): up to 200 Random Hospitals+ up
And
eCQMs: Successful submission of 100% of
to 200 Targeted Hospitals
requested medical records
We invited public comment on this
proposal.
Comment: Several commenters
supported our proposal to increase the
requested medical records for eCQM
validation from 75 percent to 100
percent. A commenter emphasized its
belief that the vast majority of hospitals
already provide 100 percent of
requested medical records for eCQM
validation.
Response: We thank the commenters
for their support.
Comment: A few commenters did not
support our proposal. A commenter
requested that the 75 percent threshold
be maintained until after the end of the
COVID–19 PHE. A commenter did not
support this modification requesting the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
1Q 2020 - 4Q 2020
current requirement be maintained until
scoring is satisfactory enough to score
based on performance. Another
commenter recommended focusing on
accuracy and quality for eCQM
validation.
Response: We thank the commenters
for their feedback. We acknowledge that
hospitals continue to be affected by
COVID–19 and we do not wish to
further burden these hospitals, but
respectfully disagree that we should
delay this requirement. As we noted in
the FY 2023 IPPS/LTCH PPS proposed
rule, ever since validation of eCQMs
commenced with CY 2017 data (81 FR
57173 through 57181), all hospitals
selected for eCQM validation have
successfully submitted at least 75
PO 00000
Frm 00531
Fmt 4701
Sfmt 4700
percent of eCQM medical records
requested by the Clinical Data
Abstraction Center (CDAC) (86 FR
28561). Additionally, 95 percent of
hospitals selected for participation in
eCQM validation for the FY 2020 and
FY 2021 payment determinations,
which are the most recently available
periods, voluntarily and successfully
submitted 100 percent of requested
records (86 FR 28561). Given the high
rate of hospitals voluntarily submitting
100 percent of records, we believe
updating the submission threshold to
100 percent will be feasible for hospitals
(86 FR 28561). We note that under our
current policy, the accuracy of eCQM
data (the extent to which data abstracted
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.178
khammond on DSKJM1Z7X2PROD with RULES2
eCQM Validation: Up to 200 Random Hospitals
49310
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
for validation matches the data
submitted in the QRDA I file) submitted
for validation does not affect a hospital’s
validation score as described in the FY
2017 IPPS/LTCH PPS final rule (81 FR
57180 through 57181). We will consider
the commenters’ feedback for future
notice-and-comment rulemaking as we
continue to improve our current
requirements.
Comment: A few commenters shared
concerns about vendor-related issues. A
commenter requested that hospitals not
be penalized for vendor delays. Another
commenter requested that vendor
systems be thoroughly vetted before
these changes are implemented. A
commenter noted concerns about the
timeliness and value of validation
results that they have received back
from the validation vendor.
Response: We thank the commenters
for their feedback. We encourage
hospitals to work closely with their
vendors to ensure they are up-to-date
with previous and newly finalized
requirements. We note that hospitals
have had several years to meet the
functional and operational demands of
eCQM reporting and validation (81 FR
57173 through 57181). We wish to
clarify that the accuracy of eCQM data
submitted for validation currently does
not affect a hospital’s payment
determination as described in the FY
2017 IPPS/LTCH PPS final rule (81 FR
57181).
We did not receive any comments on
our proposal to update the regulatory
language at 42 CFR 412.140(d)(2)(ii) to
reflect this change in our validation
policy.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
a. Background
b. Public Reporting of eCQM Data
We direct readers to the FY 2021
IPPS/LTCH PPS final rule (85 FR 58954
through 58959) where we finalized
public reporting requirements of eCQM
data reported by hospitals for the CY
2021 reporting period/FY 2023 payment
determination and for subsequent years.
We note that this policy incrementally
increases the eCQM data publicly
reported to four quarters of data for the
CY 2023 reporting period/FY 2025
payment determination and subsequent
years. We did not propose any changes
to these policies in the proposed rule.
Section 1886(b)(3)(B)(viii)(VII) of the
Act requires the Secretary to report
quality measures of process, structure,
outcome, patients’ perspectives on care,
efficiency, and costs of care that relate
to services furnished in inpatient
settings in hospitals on the internet
website of CMS. Section
1886(b)(3)(B)(viii)(VII) of the Act also
requires that the Secretary establish
procedures for making information
c. Overall Hospital Star Ratings
In the CY 2021 OPPS/ASC final rule
with comment period and interim final
rule with comment period (85 FR 86193
through 86236), we finalized a
methodology to calculate the Overall
Hospital Quality Star Rating (Overall
Star Ratings). The Overall Star Ratings
utilizes data collected on hospital
inpatient and outpatient measures that
are publicly reported on a CMS website,
12. Data Accuracy and Completeness
Acknowledgement (DACA)
Requirements
We refer readers to the FY 2013 IPPS/
LTCH PPS final rule (77 FR 53554) for
previously adopted details on DACA
requirements. We did not propose any
changes to this policy.
13. Public Display Requirements
khammond on DSKJM1Z7X2PROD with RULES2
regarding measures available to the
public after ensuring that a hospital has
the opportunity to review its data before
they are made public. Our current
policy is to report data from the
Hospital IQR Program as soon as it is
feasible on CMS websites such as the
Compare tool hosted by HHS, currently
available at: https://www.medicare.gov/
care-compare, or its successor website,
after a 30-day preview period (78 FR
50776 through 50778). We refer readers
to the FY 2008 IPPS/LTCH PPS final
rule (72 FR 47364), the FY 2011 IPPS/
LTCH PPS final rule (75 FR 50230), the
FY 2012 IPPS/LTCH PPS final rule (76
FR 51650), the FY 2013 IPPS/LTCH PPS
final rule (77 FR 53554), the FY 2014
IPPS/LTCH PPS final rule (78 FR
50836), the FY 2015 IPPS/LTCH PPS
final rule (79 FR 50277), the FY 2016
IPPS/LTCH PPS final rule (80 FR 49712
through 49713), the FY 2018 IPPS/LTCH
PPS final rule (82 FR 38403 through
38409), the FY 2019 IPPS/LTCH PPS
final rule (83 FR 41538 through 41539),
and the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58953) for details on public
display requirements. The Hospital IQR
Program quality measures are typically
reported on the Compare tool hosted by
HHS, currently available at: https://
www.medicare.gov/care-compare.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we also proposed a
publicly-reported hospital designation
on a public-facing website to capture the
quality and safety of maternity care. We
refer readers to section IX.E.8. of the
preamble of this final rule for more
details.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00532
Fmt 4701
Sfmt 4700
including data from the Hospital IQR
Program. We refer readers to section
XVI. of the CY 2021 OPPS/ASC final
rule with comment period for details (85
FR 86193 through 86236). We did not
propose any changes to these policies in
the proposed rule. However, we refer
readers to the CY 2023 OPPS/ASC
proposed rule 1087 where we proposed
to amend the language of 42 CFR
412.190(c) to state that we would use
publicly available measure results on
Hospital Compare or its successor
websites from a quarter within the prior
twelve months (instead of the ‘‘prior
year’’).
14. Reconsideration and Appeal
Procedures
We refer readers to the FY 2012 IPPS/
LTCH PPS final rule (76 FR 51650
through 51651), the FY 2014 IPPS/LTCH
PPS final rule (78 FR 50836), and 42
CFR 412.140(e) for details on
reconsideration and appeal procedures
for the FY 2017 payment determination
and subsequent years. We did not
propose any changes to these policies in
the proposed rule.
15. Hospital IQR Program Extraordinary
Circumstances Exceptions (ECE) Policy
We refer readers to the FY 2012 IPPS/
LTCH PPS final rule (76 FR 51651
through 51652), the FY 2014 IPPS/LTCH
PPS final rule (78 FR 50836 through
50837), the FY 2015 IPPS/LTCH PPS
final rule (79 FR 50277), the FY 2016
IPPS/LTCH PPS final rule (80 FR
49713), the FY 2017 IPPS/LTCH PPS
final rule (81 FR 57181 through 57182),
the FY 2018 IPPS/LTCH PPS final rule
(82 FR 38409 through 38411), and 42
CFR 412.140(c)(2) for details on the
current Hospital IQR Program ECE
policy. We also refer readers to the
QualityNet website at: https://
qualitynet.cms.gov for our current
requirements for submission of a request
for an exception. As finalized in the FY
2017 IPPS/LTCH PPS final rule, if a
hospital is granted an Extraordinary
Circumstances Exception with respect
to eCQM reporting for the applicable
eCQM reporting period, the hospital
would be excluded from the eCQM
validation sample due to its inability to
supply data for validation (81 FR
57181). We did not propose any changes
to these policies in the proposed rule.
1087 Federal Register unpublished display version
available at: https://www.federalregister.gov/publicinspection/2022-15372/medicare-program-hospitaloutpatient-prospective-payment-and-ambulatorysurgical-center-payment
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
F. Updates to the PPS-Exempt Cancer
Hospital Quality Reporting (PCHQR)
Program
1. Background
The PPS-Exempt Cancer Hospital
Quality Reporting (PCHQR) Program is
authorized by section 1866(k) of the Act
and applies to hospitals described in
section 1886(d)(1)(B)(v) (referred to as
‘‘PPS-Exempt Cancer Hospitals’’ or
‘‘PCHs’’). For additional background
information, including previously
finalized measures and other policies
for the PCHQR Program, we refer
readers to all of the following final
rules:
• The FY 2013 IPPS/LTCH PPS final
rule (77 FR 53555 through 53567).
• The FY 2015 IPPS/LTCH PPS final
rule (79 FR 50277 through 50286).
• The FY 2016 IPPS/LTCH PPS final
rule (80 FR 49713 through 49723).
• The FY 2017 IPPS/LTCH PPS final
rule (81 FR 57182 through 57193).
• The FY 2018 IPPS/LTCH PPS final
rule (82 FR 38411 through 38425).
• The FY 2019 IPPS/LTCH PPS final
rule (83 FR 41609 through 41624).
• The CY 2019 OPPS/ASC final rule
with comment period (83 FR 59149
through 59154).
• The FY 2020 IPPS/LTCH PPS final
rule (84 FR 42509 through 42524).
• The FY 2021 IPPS/LTCH PPS final
rule (85 FR 58959 through 58966).
• The FY 2022 IPPS/LTCH PPS final
rule (86 FR 45426 through 45437).
We also refer readers to 42 CFR
412.23(f) and 412.124 for the PCHQR
Program regulations.
2. Measure Retention and Removal
Factors for the PCHQR Program
khammond on DSKJM1Z7X2PROD with RULES2
a. Current Measure Retention and
Removal Factors
For a detailed discussion regarding
our retention and removal factors, we
refer readers to the FY 2017 IPPS/LTCH
PPS final rule (81 FR 57182 through
57183), where we adopted policies for
measure retention and removal, and the
FY 2019 IPPS/LTCH PPS final rule (83
FR 41609 through 41611), where we
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
updated our measure removal factors.
We did not propose any changes to our
measure retention policy. We describe
our proposal to update our measure
removal policy in the following section.
b. Adoption of a Patient Safety
Exception to the Measure Removal
Policy
To further align with the measure
removal policies adopted in other
quality programs such as the Hospital
IQR Program (74 FR 43864), Hospital
VBP Program (83 FR 41446), and HAC
Reduction Program (84 FR 42404 to
42406), we proposed that if we believe
continued use of a measure in the
PCHQR Program raises specific patient
safety concerns, we may promptly
remove the measure from the program
without rulemaking and notify hospitals
and the public of the removal of the
measure, along with the reasons for its
removal through routine
communication channels to hospitals,
vendors, and QIOs, including, but not
limited to, issuing memos, emails, and
notices on the QualityNet website. We
would then provide notice of the
removal in the Federal Register. In
circumstances where we do not believe
that continued use of a measure raises
specific patient safety concerns, we
would use the regular rulemaking
process to remove a measure. We stated
that the proposed policy mirrors that of
the Hospital IQR Program, Hospital VBP
Program, and HAC Reduction Program,
and we continue to believe that a
mechanism to immediately remove a
quality measure that is causing specific
and unintended patient harm aligns
with our patient-centered focus.
We further proposed to add this
patient safety exception to our
regulations by revising 42 CFR
412.24(d)(3) to add a new paragraph
(d)(3)(iii). We invited public comment
on these proposals.
Comment: Commenters supported the
proposal to adopt a patient safety
exception to the measure removal policy
and revise 42 CFR 412.24(d)(3) to add a
new paragraph (d)(3)(iii).
PO 00000
Frm 00533
Fmt 4701
Sfmt 4700
49311
Response: We appreciate the
commenters’ support.
After consideration of the public
comments we received, we are
finalizing our proposal to adopt a
patient safety exception to the measure
removal policy and revise 42 CFR
412.24(d)(3) to add a new paragraph
(d)(3)(iii) beginning in FY 2023.
3. Potential Adoption of Two National
Healthcare Safety Network (NHSN)
Measures—Request for Information
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28563), we sought
comment on a potential future proposal
to adopt the NHSN Healthcareassociated Clostridioides difficile
Infection Outcome measure and NHSN
Hospital-Onset Bacteremia & Fungemia
Outcome measure into the PCHQR
Program. We refer readers to section
IX.E.9.a. of the preamble of the
proposed rule, where we requested
information on potentially adopting
them for the Hospital IQR Program, and
we noted that we are also considering
proposing them for the HAC Reduction
Program. With respect to the PCHQR
Program, we stated that we were
considering proposing these measures
because cancer patients are often
immunosuppressed and therefore more
vulnerable to healthcare-associated
infections (HAIs). We stated that we
believed these measures will drive an
increase in prevention practices, which
may lead to a reduction in the number
of HAI cases, morbidity, and mortality.
We refer readers to section IX.E.9.a. of
the preamble of this final rule for a
discussion of the comments received
regarding this cross-program RFI.
4. Summary of PCHQR Program
Measures for the FY 2024 Program Year
and Subsequent Years
Table IX.F.–01 summarizes the
PCHQR Program measure set for the FY
2024 program year and subsequent
years. We did not propose any changes
to the PCHQR Program measure set.
E:\FR\FM\10AUR2.SGM
10AUR2
49312
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE IX.F.-01: FY 2024 PCHQR PROGRAM MEASURE SET AND SUBSEQUENT
YEARS
Short Name
INQFNumber
Measure Name
Safetv and Healthcare-Associated Infection ffiAI) Measures
National Healthcare Safety Network (NHSN) Catheter-associated Urinary Tract
K:AUTI
0138
Infection (CAUTI) Outcome Measure
(:LABSI
0139
National Healthcare Safety Network (NHSN) Central line-associated
a1oodstream Infection (CLABSI) Outcome Measure
0431
Influenza Vaccination Coverage Among Healthcare Personnel
!HCP
k'\merican College of Surgeons - Centers for Disease Control and Prevention
(:olon and Abdominal
Kl753
!Hysterectomy SSI
(ACS-CDC) Harmonized Procedure Specific Surgical Site Infection (SSI)
Outcome Measure [currently includes SSis following Colon Surgery and
~bdominal Hvsterectomv Surgery l
1716
National Healthcare Safety Network (NHSN) Facility-wide Inpatient HospitalMRSA
onset Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia
Outcome Measure
1717
National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospitalonset Clostridium difficile Infection (CDI) Outcome Measure
(:OVID-19 HCP Vaccination
COVID-19 Vaccination Coverage Among HCP
WA
(:linical Process/Oncology Care Measures
IEOL-Chemo
0210
!Proportion of Patients Who Died from Cancer Receiving Chemotherapy in the
!Last 14 Days of Life
K)215
~roportion of Patients Who Died from Cancer Not Admitted to Hospice
~OL-Hospice
lntermediate Clinical Outcome Measures
0213
~roportion of Patients Who Died from Cancer Admitted to the ICU in the Last
~OL-ICU
30 Days of Life
IEOL-3DH
0216
!Proportion of Patients Who Died from Cancer Admitted to Hospice for Less
Than Three Days
ratient Engagement/Experience of Care Measure
CARPS (Hospital Consumer Assessment of Healthcare Providers and
0166
IHCAHPS
Systems) Survey
K;laims Based Outcome Measures
~dmissions and Emergency Department (ED) Visits for Patients Receiving
WA
WA
Outpatient Chemotherapy
3188
30-Day Unolanned Readmissions for Cancer Patients
IN/A
Surgical Treatment Complications for Localized Prostate Cancer
WA
WA
rm
6. Public Display Requirements
a. Background
Under section 1866(k)(4) of the Act,
we are required to establish procedures
for making the data submitted under the
PCHQR Program available to the public.
Such procedures must ensure that a
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PCH has the opportunity to review its
data before they are made public. We
are specifically required to report
quality measures of process, structure,
outcome, patients’ perspective on care,
efficiency, and costs of care that relate
to services furnished by PCHs on the
CMS website.
In the FY 2017 IPPS/LTCH PPS final
rule (81 FR 57191 through 57192), we
finalized that although we would
continue to use rulemaking to establish
what year we first publicly report data
on each measure, we would publish the
data as soon as feasible during that year.
We also stated that our intent is to make
the data available on at least a yearly
basis, and that the time period for PCHs
to review their data before the data are
made public would be approximately 30
days in length. We announce the exact
data review and public reporting
timeframes on a CMS website and our
applicable Listservs. Currently, the
PCHQR measures’ performance data are
PO 00000
Frm 00534
Fmt 4701
Sfmt 4700
made publicly available on the Provider
Data Catalog available at https://
data.cms.gov/provider-data/.
We recognize the importance of being
transparent and keeping the public
abreast of any changes that arise with
the PCHQR Program measure set. As
such, in this final rule, we are finalizing
our proposals to begin public display of
the four end-of-life measures with
modification and the 30-Day Unplanned
Readmissions for Cancer Patients
measure.
b. Public Display of the End-of-Life
(EOL) Measures
We proposed to begin public display
of the EOL-Chemo, EOL-Hospice, EOL–
ICU, and EOL–3DH measures
(collectively, the ‘‘EOL measures’’)
beginning with FY 2024 program year
data. We adopted these measures for the
PCHQR measure set beginning with FY
2020 program year data (82 FR 38414
through 38420). In the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42523
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.179
khammond on DSKJM1Z7X2PROD with RULES2
5. Maintenance of Technical
Specifications for Quality Measures
We maintain and periodically update
technical specifications for the PCHQR
Program measures. The specifications
may be found on the QualityNet website
at https://qualitynet.cms.gov/pch. We
also refer readers to the FY 2015 IPPS/
LTCH PPS final rule (79 FR 50281),
where we adopted a policy to use a
subregulatory process to make
nonsubstantive updates to measures
used for the PCHQR Program. We did
not propose any changes to our
processes for maintaining technical
specifications for PCHQR Program
measures.
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
through 42524), we finalized that we
would confidentially report PCH
performance on these measures to
individual PCHs, and we indicated that
we would propose to publicly display
PCH performance on the measures after
this initial confidential reporting period.
We stated that we anticipated providing
confidential reports on the data
collected on the measures for the FY
2022 and FY 2023 program years, which
correspond to data collected from July 1,
2019, to June 30, 2020 and July 1, 2020,
to June 30, 2021, respectively, within
calendar year 2022. We also stated that
under our current policy, the measures
are calculated on a yearly basis based on
data collected from July 1 of the year 3
years prior to the program year to June
30 of the year 2 years prior to the
program year. Therefore, we proposed to
begin public reporting of these measures
beginning with the FY 2024 program
year data, which corresponds to data
collected from July 1, 2021 through June
30, 2022. We stated that we would make
these data publicly available following a
30-day period in which PCHs would
have an opportunity to review the data.
Public display would occur during the
July 2023 refresh cycle or as soon as
feasible thereafter. We further stated
that we would announce the exact
timeframe on a CMS website and our
applicable listservs.
We invited public comment on the
proposal to begin public display of the
four EOL measures beginning with the
FY 2024 program year data.
Comment: A few commenters
supported the proposal to begin public
display of the four EOL measures,
stating that this public display will
provide valuable information about
hospital performance to patients.
Another commenter specifically
supported public display of the EOLChemo and EOL–ICU measures, stating
that the data from these measures would
complement the ADCC Serious Illness
project.
Response: We thank the commenters
for their support of publicly displaying
the four EOL measures. We also thank
the commenter who supported public
display of the EOL-Chemo and EOL–
ICU measures.
Comment: Several commenters
requested that CMS delay public
reporting of the EOL measures until
hospitals can review their FY 2022
confidential reports, the release of
which was delayed by one year.
Response: We thank the commenters
for their feedback. The FY 2022
confidential feedback reports were made
available to PCHs in June 2022. We
anticipate the FY 2023 confidential
reports will be made available to PCHs
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
in August 2022 or as soon as feasible
thereafter. We agree that the delay in
releasing the FY 2022 and FY 2023
confidential feedback reports
necessitates a delay in public reporting
in order to provide PCHs with sufficient
time to gain familiarity with the
measure calculation and results. We
believe a one-year delay, which is the
minimum delay possible due to measure
reporting timelines, will be sufficient to
provide PCHs with additional time
while balancing the importance of
transparency of the EOL measure data.
Comment: Another commenter
expressed concern about the lack of
context for publicly displayed measure
data such as individual patients’
preferences and needs, which may lead
to misrepresentation of the quality of
cancer care.
Response: We thank the commenter
for sharing their concern. The measure
information will initially be available
only via the Provider Data Catalog
(PDC), and we are in the process of
making this data available via Care
Compare for public display. We would
like to reiterate that PCHs will have a
30-day review period to confirm
accuracy of the measure data before
public display, and measures rates will
be displayed with any appropriate
context for ease of understanding the
results.
After consideration of the public
comments we received, we are
finalizing our proposal to begin public
reporting of the four EOL measures,
with modification. Specifically, we are
finalizing to begin public reporting
beginning with FY 2025 program year
data, which corresponds to data
collected from July 1, 2022, through
June 30, 2023, to provide hospitals with
enough time to review their confidential
reports. Public display will occur during
the July 2024 refresh cycle or as soon as
feasible thereafter. We will announce
the exact timeframe on a CMS website
and PCHQR Program listservs.
c. Public Display of the 30-Day
Unplanned Readmissions for Cancer
Patients Measure Beginning With the FY
2024 Program Year Data
We proposed to begin public display
of the 30-Day Unplanned Readmissions
for Cancer Patients measure beginning
with FY 2024 program year data. We
adopted this measure for the PCHQR
measure set beginning with FY 2021
program year data (83 FR 41613 through
41616). In the FY 2020 IPPS/LTCH PPS
final rule (84 FR 42523 through 42524),
we finalized that we would
confidentially report this measure to
individual PCHs, and we indicated that
we would propose public display after
PO 00000
Frm 00535
Fmt 4701
Sfmt 4700
49313
this initial confidential reporting period.
We provided confidential reports on the
data collected on this measure for the
FY 2022 program year in July 2021. In
addition, we stated that we anticipated
confidentially reporting data collected
on the measure for the FY 2023 program
year, which corresponds to data
collected from October 1, 2020 to
September 30, 2021, in July 2022.
Under our current policy, the measure
is calculated on a yearly basis based on
data collected from October 1 of the year
3 years prior to the program year to
September 30 of the year 2 years prior
to the program year. We proposed to
begin public reporting of this measure
beginning with the FY 2024 program
year data, which corresponds to data
collected from October 1, 2021 through
September 30, 2022. We stated that we
would make these data publicly
available following a 30-day period in
which PCHs would have an opportunity
to review the data. Public display would
occur during the October 2023 refresh
cycle or as soon as feasible thereafter.
We stated that we would announce the
exact timeframe on a CMS website and
our applicable listservs.
We invited public comment on the
proposal to begin public display of the
30-Day Unplanned Readmissions for
Cancer Patients measure beginning with
the FY 2024 program year data.
Comment: Several commenters
supported the proposal to begin public
display of the 30-Day Unplanned
Readmissions for Cancer Patients
measure beginning with the FY 2024
program year data. A few commenters
noted that that the FY 2021 confidential
reports were reflective of measure
specifications. A few commenters
applauded CMS’ early release of the
confidential reports, allowing for
proactive review prior to reporting
periods. A commenter stated their belief
that the measure will provide valuable
information about hospital performance
to patients.
Response: We thank the commenters
for their support.
After consideration of the public
comments we received, we are
finalizing our proposal to begin public
display of the 30-Day Unplanned
Readmissions for Cancer Patients
measure beginning with the FY 2024
program year data.
d. Summary of Previously Finalized and
Newly Finalized Public Display
Requirements for the PCHQR Program
Our previously finalized and newly
finalized public display requirements
for the PCHQR Program measures are
shown in the following Table IX.F.–02:
E:\FR\FM\10AUR2.SGM
10AUR2
49314
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE IX.F-02: PREVIOUSLY FINALIZED AND NEWLY FINALIZED PUBLIC
DISPLAY REQUIREMENTS FOR THE PCHQR PROGRAM
Summarv of Previouslv Finalized and Newlv Finalized Public Disulav Reauirements
Public Reuortine
Measures
• HCAHPS (NQF #0166)
2016 and subsequent years
• Oncology: Plan of Care for Pain-Medical Oncology and Radiation Oncology (NQF #0383)*
• American College of Surgeons - Centers for Disease Control and Prevention (ACS-CDC)
Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure [currently includes
SSis following Colon Surgery and Abdominal Hysterectomy Surgery] (NQF #0753)
2019 and subsequent years
• National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Methicillinesistant Staphylococcus aureus Bacteremia Outcome Measure (NQF #1716)
• National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Clostridium
difficile Infection (CDI) Outcome Measure (NQF #1717)
• National Healthcare Safety Network (NHSN) Influenza Vaccination Coverage Among Healthcare
Personnel (NQF #0431)
• COVID-19 Vaccination Coverage Among Healthcare Personnel
October 2022 and subsequent years
• Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient
Chemotherapy
• CAUTI (NQF #0138)
April 2020 and subsequent years
Deferred until October 2022
• CLABSI (NQF #0139)
• Proportion of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of
._jfe (NQF #0210)**
• Proportion of Patients Who Died from Cancer Not Admitted to Hospice (NQF #0215)**
• Proportion of Patients Who Died from Cancer Admitted to the ICU in the Last 30 Days of
~ife (NQF #0213)**
July 2024 or as soon as feasible
thereafter
• Proportion of Patients Who Died from Cancer Admitted to Hospice for Less Than Three
Days (NQF #0216)**
• 30-day Unplanned Readmissions for Cancer Patients (NQF #3188)* **
October 2023 or as soon as feasible
thereafter
khammond on DSKJM1Z7X2PROD with RULES2
7. Form, Manner, and Timing of Data
Submissions
We refer readers to the FY 2013 IPPS/
LTCH PPS final rule (77 FR 53563
through 53567) for our previously
finalized procedural requirements for
the PCHQR Program. Data submission
requirements and deadlines for the
PCHQR Program are posted on the
QualityNet website. We did not propose
any updates to our previously finalized
data submission requirements and
deadlines.
8. Extraordinary Circumstances
Exceptions (ECE) Policy Under the
PCHQR Program
We refer readers to the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41623
through 41624), for a discussion of the
Extraordinary Circumstances Exceptions
(ECE) policy under the PCHQR Program.
We did not propose any changes to this
policy.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
G. Long-Term Care Hospital Quality
Reporting Program (LTCH QRP)
1. Background and Statutory Authority
The Long-Term Care Hospital Quality
Reporting Program (LTCH QRP) is
authorized by section 1886(m)(5) of the
Act, and it applies to all hospitals
certified by Medicare as Long-Term Care
Hospitals (LTCHs). Section
1886(m)(5)(C) of the Act requires LTCHs
to submit to the Secretary quality
measure data specified under section
1886(m)(5)(D) in a form and manner,
and at a time, specified by the Secretary.
In addition, section 1886(m)(5)(F) of the
Act requires LTCHs to submit data on
quality measures under section
1899B(c)(1) of the Act, resource use or
other measures under section
1899B(d)(1) of the Act, and standardized
patient assessment data required under
section 1899B(b)(1) of the Act. LTCHs
must submit the data required under
PO 00000
Frm 00536
Fmt 4701
Sfmt 4700
section 1886(m)(5)(F) of the Act in the
form and manner, and at the time,
specified by the Secretary. Under the
LTCH QRP, the Secretary must reduce
by 2 percentage points the annual
update to the LTCH PPS standard
Federal rate for discharges for an LTCH
during a fiscal year if the LTCH has not
complied with the LTCH QRP
requirements specified for that fiscal
year. For more information on the
background for the LTCH QRP, we refer
readers to the FY 2012 IPPS/LTCH PPS
final rule (76 FR 51743 through 51744),
the FY 2013 IPPS/LTCH PPS final rule
(77 FR 53614), the FY 2014 IPPS/LTCH
PPS final rule (78 FR 50853), the FY
2015 IPPS/LTCH PPS final rule (79 FR
50286), the FY 2016 IPPS/LTCH PPS
final rule (80 FR 49723 through 49725),
the FY 2017 IPPS/LTCH PPS final rule
(81 FR 57193), the FY 2018 IPPS/LTCH
PPS final rule (82 FR 38425 through
38426), the FY 2019 IPPS/LTCH PPS
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.180
*Measure finalized for removal, beginning with the FY 2024 program year.
**Measure finalized for public display beginning with FY 2025 program year data.
***Measure finalized for public display beginning with FY 2024 program year data.
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
final rule (83 FR 41624 through 41634),
the FY 2020 IPPS/LTCH PPS final rule
(84 FR 42524 through 42591), and the
FY 2022 IPPS/LTCH PPS final rule (86
FR 45438 through 45446). For more
information on the requirements under
the LTCH QRP, we refer readers to 42
CFR 412.560.
2. General Considerations Used for the
Selection of Quality Measures for the
LTCH QRP
For a detailed discussion of the
considerations we historically use for
the selection of LTCH QRP quality,
resource use, and other measures, we
refer readers to the FY 2016 IPPS/LTCH
PPS final rule (80 FR 49728).
49315
3. Quality Measures Currently Adopted
for the FY 2023 LTCH QRP
The LTCH QRP currently has 18
measures for the FY 2023 LTCH QRP,
which are set out in the following Table
IX.G.-01. For a discussion of the factors
used to evaluate whether a measure
should be removed from the LTCH QRP,
we refer readers to the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41624
through 41634) and to the regulations at
42 CFR 412.560(b)(3).
TABLE IX.G.-01. QUALITY MEASURES CURRENTLY ADOPTED FOR THE FY 2023
LTCHQRP
Short Name
Pressure Ulcer/Injury
Application of Falls
Functional Assessment
Functional Outcome Measure: Change in Mobility Among Long-Term Care Hospital
(L TCH) Patients Requiring Ventilator Suooort (NQF #2632)
DRR
Drug Regimen Review Conducted With Follow-Up for Identified Issues-Post Acute Care
(PAC) Long-Term Care Hospital (LTCH) Quality Reporting Program (QRP)
Compliance with SBT
Compliance with Spontaneous Breathing Trial (SBT) by Day 2 of the LTCH Stay
Ventilator Liberation
Ventilator Liberation Rate
TOH-Provider*
Transfer of Health Information to the Provider Post-Acute Care (PAC)
TOH-Patient*
Transfer of Health Information to the Patient Post-Acute Care (PAC)
NHSN
CAUTI
National Healthcare Safety Network (NHSN) Catheter-Associated Urinary Tract Infection
(CAUTI) Outcome Measure (NQF #0138)
CLABSI
National Healthcare Safety Network (NHSN) Central Line-associated Bloodstream Infection
(CLABSI) Outcome Measure (NQF #0139)
CDI
National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset
Clostridium difficile Infection (CDI) Outcome Measure (NQF #1717)
Influenza Vaccination Coverage among Healthcare Personnel (NQF #0431)
HCP Influenza Vaccine
HCP COVID-19 Vaccine
COVID-19 Vaccination Coverage among Healthcare Personnel (HCP)
Claims-Based
Medicare Spending Per Beneficiary (MSPB}-Post Acute Care (PAC) Long-Term Care
MSPBLTCH
Hospital (LTCH) Quality Reporting Program (QRP) (NQF #3562)
DTC
Discharge to Community (DTC)-Post Acute Care (PAC) Long-Term Care Hospital (L TCH)
Quality Reporting Program (QRP) (NQF #3480)
PPR
Potentially Preventable 30-Day Post-Discharge Readmission Measure for Long-Term Care
Hospital (L TCH) Quality Reporting Program (QRP)
*In response to the COVID-19 public health emergency (PHE), we released an interim fmal rule (85 FR 27595
through 27597) which delayed the compliance date for the collection and reporting of the Transfer of Health
Information measures. The compliance date for the collection and reporting of the Transfer of Health Information
measures was revised to October 1, 2022 in the CY 2022 Home Health Prospective Payment System Rate Update
fmal rule (86 FR 62386 through 62390).
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00537
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.181
khammond on DSKJM1Z7X2PROD with RULES2
Application of Functional
Assessment/
Care Plan
Change in Mobility
Measure Name & Data Source
L TCH CARE Data Set
Changes in Skin Integrity Post-Acute Care: Pressure Ulcer/Injury
Application of Percent of Residents Experiencing One or More Falls with Major Injury
(Long Stay) (NQF #0674)
Percent of Long-Term Care Hospital (L TCH) Patients with an Admission and Discharge
Functional Assessment and a Care Plan That Addresses Function (NQF #2631)
Application of Percent of Long-Term Care Hospital (LTCH) Patients with an Admission and
Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631)
49316
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
There were no proposals in the
proposed rule for new measures for the
LTCH QRP.
4. LTCH QRP Quality Measure Concepts
Under Consideration for Future Years:
Request for Information (RFI) Included
in the FY 2023 IPPS/LTCH PPS
Proposed Rule
In the FY 2023 IPPS/LTCH PPS
proposed rule, we sought input on the
importance, relevance, and applicability
of the concepts under consideration
listed in Table IX.G.-02 for future years
in the LTCH QRP. More specifically, we
sought input on a cross-setting
functional measure that would
incorporate the domains of self-care and
mobility. Our measure development
contractor for the cross-setting
functional outcome measure convened a
Technical Expert Panel (TEP) on June 15
and June 16, 2021 to obtain expert input
on the development of a functional
outcome measure for PAC. During this
meeting, the possibility of creating one
measure to capture both self-care and
mobility was discussed. We also sought
input on measures of health equity,
such as structural measures that assess
an organization’s leadership in
advancing equity goals or assess
progress towards achieving equity
priorities. Finally, we sought input on
the value of a COVID–19 Vaccination
Coverage measure that would assess
whether LTCH patients were up to date
on their COVID–19 vaccine.
TABLE IX.G.-02: FUTURE MEASURE CONCEPTS UNDER CONSIDERATION FOR
THELTCHQRP
Comment: Commenters were
generally supportive of a cross-setting
functional outcome measure, although
some commenters expressed concern
over the potential burden of collecting
additional information. Some
commenters emphasized that the
measure should provide meaningful
information to patients, caregivers,
discharge planners, providers, and
payers, and noted that LTCH patients
often have different levels of acuity and
treatment needs so a future measure
must be able to differentiate LTCHs
from one another. Two commenters
stated that since LTCH patients have
different levels of acuity and treatment
needs, it may make comparisons to
other ‘‘PAC’’ settings not appropriate,
even when risk adjustment is used.
These commenters urged CMS to
consider measures that incorporate
improvement in function, but also
recognize that some patients may not
demonstrate improvement due to their
medical condition(s). A commenter
stated they preferred separate quality
measures for self-care and mobility, but
would support the initial use of a
composite measure reflecting both selfcare and mobility function. Another
commenter opposed the inclusion of a
measure that was based on providerreported assessment data.
We received mixed comments
regarding a health equity measure in the
LTCH QRP. Two commenters were
concerned with how accurate a health
equity measure could be for LTCHs
given their small sample sizes, and
whether LTCHs would be able to
meaningfully improve a measure of
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
health equity. Other commenters were
strongly supportive of including health
equity measures in the LTCH QRP in a
future year.
Commenters stated they understood
why CMS was considering a COVID–19
Vaccination Coverage among Patients
measure, but noted CMS should
postpone considering this measure since
the definition of ‘‘fully vaccinated’’ is
evolving.
We also received comments
suggesting CMS consider other measure
concepts for the LTCH QRP, including
malnutrition and patient-reported
outcomes. A commenter urged CMS to
consider a measure of malnutrition
screening since malnutrition is a risk
factor for several clinical events,
including falls and delayed healing.
Another commenter suggested measures
of patient experience, patient and
workforce safety and reliability, clinical
quality, and caregiver engagement that
are evidence-based, targeted, and
meaningful to patients and caregivers.
Response: As discussed in the
proposed rule, we are not responding to
specific comments submitted in
response to this RFI in this final rule,
but we intend to use this input to
inform our future measure development
efforts.
PO 00000
Frm 00538
Fmt 4701
Sfmt 4700
5. Inclusion of the National Healthcare
Safety Network (NHSN) HealthcareAssociated Clostridioides difficile
Infection Outcome Measure in the LTCH
QRP—Request for Information (RFI)
Included in the FY 2023 IPPS/LTCH
PPS Proposed Rule
a. Solicitation of Public Comment
In the FY 2023 IPPS/LTCH PPS
proposed rule, we requested stakeholder
input on the potential electronic
submission of quality data from LTCHs
via their electronic health records
(EHRs) under the LTCH QRP. We
specifically sought public comment on
the future inclusion of the NHSN
Healthcare-Associated Clostridioides
difficile Infection Outcome measure
(HA–CDI) (MUC2021–098) as a digital
quality measure in the LTCH QRP.
Specifically, we sought public
comment on the following:
• Would you support utilizing LTCH
EHRs as the mechanism of data
collection and submission for LTCH
QRP measures?
• Would your EHR support exposing
data via HL7 Fast Healthcare
Interoperability Resources (FHIR) to a
locally installed Measure Calculation
Tool (MCT)? For LTCHs using certified
health IT systems, how can existing
certification criteria under the Office of
the National Coordinator (ONC) Health
Information Technology (IT)
Certification Program support reporting
of these data? What updates, if any, to
the Certification Program would be
needed to better support capture and
submission of these data?
• Is a transition period between the
current method of data submission and
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.182
khammond on DSKJM1Z7X2PROD with RULES2
Quality Measure Concepts
Cross-Setting Function
Health Equity Measures
PAC - COVID-19 Vaccination Coverage among Patients
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
an electronic submission method
necessary? If so, how long of a transition
would be necessary, and what specific
factors are relevant in determining the
length of any transition?
• Would vendors, including those
that service LTCHs, be interested in or
willing to participate in pilots or
voluntary electronic submission of
quality data?
• Do LTCHs anticipate challenges,
other than the adoption of EHR, to
adopting the NHSN HA–CDI measure,
and if so, what are potential solutions
for those challenges?
We received several comments on this
RFI, which are summarized in this
section of this document:
Comment: Commenters were mixed in
their support of utilizing LTCH EHRs as
the mechanism for data collection and
submission for LTCH QRP measures.
While all commenters supported the
concept of reducing provider burden
through using fully digital measures,
commenters did note several barriers. A
commenter noted that the transition
would take time and staffing hours away
from other clinical initiatives. Most
commenters raised concerns about the
cost associated with LTCHs t adopting
EHR systems that are equipped to
collect and exchange digital quality
measure (dQM) data. They stated that
EHR adoption has been slower and less
uniform than it was in acute care
hospitals, due to the lack of incentive
payments available to LTCHs. They
urged CMS to provide incentive
payments to LTCHs as they did for acute
care hospitals through the Health
Information Technology for Economic
and Clinical Health (HITECH) Act prior
to requiring LTCHs’ transition to dQMs.
A commenter stated that their EHR
would support exposing data via HL7
FHIR to a locally installed MCT.
Another commenter stated they had
concerns about the definition of
treatment, as well as potential gaming of
the measure that could lead to the
untended consequences of overuse of
antimicrobials or the undertreatment of
patients with CDI. This commenter also
suggested CMS to work with CMS to
determine whether risk adjustment
based on hospital characteristics is
needed. Finally, they cautioned that
electronic reporting is evolving and they
requested CMS work with the Office of
the National Coordinator for Health
Information Technology (ONC) and
other EHR vendors to fully integrate
electronic reporting options before
implementation.
Commenters universally agreed that a
transition period would be necessary to
set up processes capable of electronic
submission of data. They stressed that
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
LTCHs would need significant lead time
to ensure they could be compliant with
new digital reporting requirements, and
estimated it would take a minimum of
2 years to transition to digital reporting.
Another commenter stated that a switch
to dQMs would involve a number of
different workflows, and that sufficient
testing would be important since LTCHs
could be penalized 2% for an entire year
if they were found non-compliant.
A commenter urged CMS to allow
LTCH provider organizations, in
addition to vendors, to participate in
any pilots or testing of dQMs before
implementation.
Response: We will consider all input
as we develop future regulatory
proposals. Any updates to specific
program requirements related to quality
measurement and reporting provisions
would be addressed through separate
and future notice-and-comment
rulemaking, as necessary.
6. Overarching Principles for Measuring
Equity and Healthcare Quality
Disparities Across CMS
a. Solicitation of Public Comment
The goal of this request for
information was to describe some key
principles and approaches that we will
consider when advancing the use of
quality measure development and
stratification to address healthcare
disparities and advance health equity
across our programs.
We invited general comments on the
principles and approaches described
previously in this section of the rule, as
well as additional thoughts about
disparity measurement guidelines
suitable for overarching consideration
across CMS’s QRP programs.
Specifically, we invited comment on the
following:
• Identification of Goals and
Approaches for Measuring Healthcare
Disparities and Using Measure
Stratification Across CMS Quality
Reporting Programs
++ The use of the within- and
between-hospital disparity methods in
LTCHs to present stratified measure
results.
++ The use of decomposition
approaches to explain possible causes of
measure performance disparities.
++ Alternative methods to identify
disparities and the drivers of disparities.
• Guiding Principles for Selecting and
Prioritizing Measures for Disparity
Reporting
++ Principles to consider for
prioritization of health equity measures
and measures for disparity reporting,
including prioritizing stratification for
validated clinical quality measures,
PO 00000
Frm 00539
Fmt 4701
Sfmt 4700
49317
those measures with established
disparities in care, measures that have
adequate sample size and representation
among healthcare providers and
outcomes, and measures of appropriate
access and care.
• Principles for Social Risk Factor
(SRF) and Demographic Data Selection
and Use
++ Principles to be considered for the
selection of SRFs and demographic data
for use in collecting disparity data
including the importance of expanding
variables used in measure stratification
to consider a wide range of SRFs,
demographic variables, and other
markers of historic disadvantage. In the
absence of patient-reported data we will
consider use of administrative data,
area-based indicators, and imputed
variables as appropriate.
• Identification of Meaningful
Performance Differences
++ Ways that meaningful difference
in disparity results should be
considered.
• Guiding Principles for Reporting
Disparity Measures
++ Guiding principles for the use and
application of the results of disparity
measurement.
• Measures Related to Health Equity
++ The usefulness of a Health Equity
Summary Score (HESS) for LTCHs, both
in terms of provider actionability to
improve health equity, and in terms of
whether this information would support
Care Compare website users in making
informed healthcare decisions.
++ The potential for a structural
measure assessing an LTCH’s
commitment to health equity, the
specific domains that should be
captured, and options for reporting
these data in a manner that would
minimize burden.
++ Options to collect facility-level
information that could be used to
support the calculation of a structural
measure of health equity.
++ Other options for measures that
address health equity.
We received several comments on the
RFI for Overarching Principles for
Measuring Equity and Healthcare
Quality Disparities Across CMS Quality
Programs. While we will not be
responding to specific comments
submitted in response to this RFI, the
following is a summary of some
comments received:
Comment: Many commenters
provided feedback on the use of the
within-provider and between provider
disparity methods to present stratified
measure results. Overall, comments
were generally supportive of
implementing both methods in order to
provide a more complete picture of the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49318
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
quality of care provided to beneficiaries
with SRFs.
In terms of specific feedback related
to the implementation of these
stratification approaches, a few
commenters stated CMS should
prioritize expansion of the withinprovider method over the betweenprovider method due to the fact that the
latter method might provide an
incomplete picture of disparity and
would not inform a LTCH’s an
understanding of its own performance.
Other commenters suggested CMS
consider using peer groups for betweenprovider comparisons, such as peer
LTCHs identified based patient
demographic profile, geographic
location, or bed size. A commenter
noted concern that within-provider
methods may place excessive
responsibility on providers to mitigate
the disparities without providing the
resources to take action. Another
commenter stated the feedback would
be more actionable and useful if the
results included information beyond
what hospitals already collect. Finally,
a commenter recommended feedback
methods should be carefully considered
for each type of measure, and
specifically pointed out that patient
experience measures may not be
appropriate to compare between
subgroups since it could lend itself to
misinterpretation and labeling of certain
subgroups of patients.
Several commenters responded to the
disparity decomposition approach
presented in the proposed rule. A
commenter noted the decomposition
approach described could be a
promising method to identify specific
drivers of performance disparities,
which would increase the actionability
of stratified measure information while
adding no additional burden to
providers. Other commenters supported
the method, but a commenter did
caution that LTCHs would be limited in
their ability to address patients’ needs
while under their care. A few
commenters opposed the use of
decomposition techniques, citing their
concern that if statistical methods are
poorly chosen, some LTCHs may be
labeled discriminatory unintentionally,
causing harm to beneficiaries, providers
and the Medicare program.
Commenters were overwhelmingly
supportive of prioritizing existing
quality measures for disparity reporting,
and most commenters were also
supportive of prioritizing measures with
identified disparities in treatment or
outcomes, or conditions that have
highly disproportionate prevalence in
certain populations. Many commenters
stated CMS should focus on: (1)
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
outcome measures over process
measures; (2) use existing collected
patient data and prevent additional
reporting burdens on providers; and (3)
have a meaningful and quantifiable
impact on overall patient health and
system cost. For those reasons, these
commenters suggested measures such as
hospital readmissions, mortality
associated with certain health
conditions, and potentially avoidable
events. Support for prioritizing
measures with adequate sample sizes
and measures that seek to determine
patient access to care and the
appropriate use of care were suggested
by many commenters as well.
Commenter also suggested additional
guiding principles. A commenter
recommended the measures should
have essential characteristics such as
being data-driven, actionable, feasible,
have utility and be constructed such
that providers have prompt feedback.
Another commenter suggested CMS
should focus on the areas of clinical
quality, clinical safety and patient
experience, while still another stressed
alignment with other programs and
agencies, where possible and
appropriate.
We received a number of other
comments on the guiding principles for
selecting and prioritizing measures for
disparity reporting. A commenter
suggested the only criteria that should
be used is whether the measure
highlights disparities in care. Another
commenter requested CMS clarify how
it defines ‘‘industry standards for
measure reliability and validity.’’
Finally, another commenter cautioned
CMS against using this information to
single out healthcare providers and take
punitive action against them.
A number of commenters provider
feedback on considerations for the
selection of SRFs and demographic data
for use in collecting disparity data. A
majority of commenters supported using
race and ethnicity, although a
commenter recommended using any
SRFs other than dual eligibility, race
and ethnicity. Several commenters
suggested using disability status, and
two of these commenters also suggested
using primary language. Other data
points were suggested, including sexual
orientation, gender identity, age, and
health literacy. Finally, a commenter
recommended CMS use a standard
definition of the term ‘‘disparity’’ that
can be used as a measurable benchmark
across programs.
The feedback received on methods for
determining meaningful performance
differences in disparity results was
mixed. First, we summarize the
comments regarding the four possible
PO 00000
Frm 00540
Fmt 4701
Sfmt 4700
reporting approaches discussed in
section IX.E.6.1.4 the proposed rule, and
then summarize comments
recommending other approaches.
While several commenters were
generally supportive of benchmarking,
one provider stated the data was too
limited at the current time to apply
benchmarks and another commenter
noted it could mask local or regional
differences in patient populations and
thus inadvertently penalize providers. A
commenter provided feedback specific
to using statistical differences to
identifying meaningful performance
differences, and the commenter
recommended that if this approach were
used the measure, along with an
estimate of its variability, such as a
confidence interval, be displayed with it
to aid in its interpretation. Several
commenters did not support ranked
orderings and percentiles and cautioned
they could lead to significant
unintended consequences, and two of
these commenters noted that they do
not necessarily translate to meaningful
clinical differences. Finally we received
two comments supporting the use of
defined thresholds, such as fixed
intervals of results of disparity
reporting, but several commenters did
not support this method. The most
notable reason given was their concern
this method created an artificial cutoff
where small performance differences are
either acceptable or unacceptable, and it
could result in inappropriately
characterizing some LTCHs as
practicing discrimination. We also
received one comment recommending
CMS use a combination of peer group
benchmarking and statistical
significance.
Commenters also recommended other
approaches. A commenter
recommended CMS conduct analyses to
compare the results of different methods
and publish the results of these analyses
for stakeholder review and public
comment. Other commenters urged
CMS not to apply a one-size-fits-all
approach, and suggested CMS may need
to tailor the approaches to the
individual patient populations and
quality program. A few commenters
noted that before any analyses are
completed, CMS will need to define a
statistically acceptable minimum
threshold for determining a disparity
exists as well as a high reliability
standard for determining the minimum
number of observations required for a
provider’s performance to be stratified
and reported.
Several commenters responded to
CMS’ request for information about
measures CMS could develop to assess
and encourage health equity, including
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
comments regarding the usefulness and
actionability of HESS and the potential
for a structural measure to assess SNFs’
commitment to health equity. We first
summarize the comments regarding the
HESS, then summarize comments
related to a structural measure to assess
commitment to equity.
Several commenters specifically
addressed the HESS. A commenter
simply encouraged CMS to clarify that
the HESS would assess individual SNFs
as a whole, as opposed to the individual
clinicians within each SNF. The two
remaining commenters either supported
or appreciated the HESS score in
concept, but raised several concerns
pertaining to technical barriers,
ambiguity in the methodology, and
usability of the measure. In terms of
technical concerns, a commenter noted
that the availability of a standardized set
of demographic data elements must be
available for each patient, and stated
that demographic data elements are not
yet standardized across healthcare
setting and organizations. Regarding
methodological concerns, a commenter
questioned how one could combine
within-facility disparities and
disparities across facilities into a single
summary score in a manner that would
accurately reflect both the individual
and potentially independent factors that
may result in these different types of
disparities. Other commenters raised
similar concerns about the usability the
HESS, primarily stemming from the
extent to which disparities across
multiple measures and SRFs are
aggregated into a single score.
Specifically, commenters noted that one
SRF included in the HESS could mask
the effects of other SRFs, which could
potentially lead to misinterpretation of
the overall score. Another commenter
stated the measure was vague and
therefore would not be actionable by
their members or meaningful to the
public.
Several commenters addressed the
potential for a structural measures to
assess health equity. A commenter
stated that a structural measure would
have a low level of burden, while
signaling to the LTCH community the
importance of focusing improvement
efforts on health equity and prompting
the healthcare organization to consider
their ongoing or needed efforts to
address each domain. Another
commenter noted that the development
of a structural measure to assess
engagement and commitment of
leadership toward advancing health
equity should be included as one of
several guiding principles to address
health disparities and achieve health
equity. Another commenter cautioned
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
against the development of structural
measures, suggesting that such measures
would only demonstrate whether an
organization is ‘‘good at checking the
box’’ for the purpose of meeting the
requirements of a measure.
Response: We appreciate all of the
comments and interest in this important
topic. Public input is very valuable in
the continuing development of CMS’s
health equity quality measurement
efforts and broader commitment to
health equity, a key pillar of our
strategic vision as well as a core agency
function. Thus, we will continue to take
all concerns, comments, and suggestions
into account for future development and
expansion of policies to advance health
equity across the LTCH QRP, including
by supporting LTCHs in their efforts to
ensure equity for all of their patients,
and to identify opportunities for
improvements in health outcomes. Any
updates to specific program
requirements related to quality
measurement and reporting provisions
would be addressed through separate
and future notice-and-comment
rulemaking, as necessary.
7. Form, Manner, and Timing of Data
Submission Under the LTCH QRP
We refer readers to the regulatory text
at 42 CFR 412.560(b) for information
regarding the current policies for
reporting LTCH QRP data.
For more details about the required
reporting periods of measures or
standardized patient assessment data
during the first and subsequent years
upon adoption, please refer to the FY
2020 IPPS/LTCH PPS final rule (84 FR
24588 through 24590).
We did not propose any new policies
regarding the form, manner, and timing
of data submission under the LTCH
QRP.
8. Policies Regarding Public Display of
Measure Data for the LTCH QRP
We did not propose any new policies
regarding the public display of LTCH
QRP measure data.
H. Changes to the Medicare Promoting
Interoperability Program
1. Statutory Authority for the Medicare
Promoting Interoperability Program for
Eligible Hospitals and Critical Access
Hospitals (CAHs)
The Health Information Technology
for Economic and Clinical Health Act
(HITECH Act) (Title IV of Division B of
the American Recovery and
Reinvestment Act of 2009 (ARRA),
together with Title XIII of Division A of
the ARRA) authorized incentive
payments under Medicare and
PO 00000
Frm 00541
Fmt 4701
Sfmt 4700
49319
Medicaid, as well as downward
payment adjustments under Medicare,
for the adoption and meaningful use of
certified electronic health record
technology (CEHRT). Incentive
payments under Medicare were
available to eligible hospitals and CAHs
for certain payment years (as authorized
under sections 1886(n) and 1814(l) of
the Act, respectively) if they
successfully demonstrated meaningful
use of CEHRT, which included
reporting on clinical quality measures
using CEHRT. In accordance with the
timeframe set forth in the statute, these
incentive payments under Medicare are
no longer available. Sections
1886(b)(3)(B)(ix) and 1814(l)(4) of the
Act authorize downward payment
adjustments under Medicare, beginning
with Federal fiscal year (FY) 2015 (and
beginning with FY 2022 for subsection
(d) Puerto Rico hospitals), for eligible
hospitals and CAHs that do not
successfully demonstrate meaningful
use of CEHRT for certain associated
electronic health record (EHR) reporting
periods.
2. EHR Reporting Period
Under the definition of ‘‘EHR
reporting period for a payment
adjustment year’’ at 42 CFR 495.4, for
eligible hospitals and CAHs that are
new or returning participants in the
Medicare Promoting Interoperability
Program, the EHR reporting period in
calendar year (CY) 2023 is a minimum
of any continuous 90-day period within
CY 2023, and the EHR reporting period
in CY 2024 is a minimum of any
continuous 180-day period within CY
2024. For more information, we refer
readers to the discussion in the FY 2022
Hospital Inpatient Prospective Payment
Systems for Acute Care Hospitals and
the Long-Term Care Hospital (IPPS/
LTCH) Prospective Payment System
(PPS) final rule (86 FR 45460 through
45462).
a. CEHRT Requirements
The Promoting Interoperability
Program and the Quality Payment
Program (QPP) require the use of
CEHRT as defined at 42 CFR 495.4 and
414.1305, respectively. Since 2019, in
general, this has consisted of EHR
technology (which could include
multiple technologies) certified under
the Office of the National Coordinator
for Health Information Technology
(ONC) Health Information Technology
(IT) Certification Program that meets the
2015 Edition Base EHR definition (as
defined at 45 CFR 170.102) and has
been certified to certain other 2015
Edition health IT certification criteria as
specified in the definition.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49320
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
The ‘‘21st Century Cures Act:
Interoperability, Information Blocking,
and the ONC Health IT Certification
Program’’ final rule (also referred to as
the ‘‘ONC 21st Century Cures Act final
rule’’), published in the May 1, 2020,
Federal Register (85 FR 25642 through
25961), finalized a number of updates to
the 2015 Edition of health IT
certification criteria (also referred to as
the 2015 Edition Cures Update) and
introduced new 2015 Edition
certification criteria. In connection with
these updates, ONC also finalized that
health IT developers have 24 months
from the publication date of the final
rule (until May 2, 2022) to make
technology available that is certified to
the updated, or new criteria. In response
to additional calls for flexibility in
response to the Public Health
Emergency (PHE) for COVID–19, ONC
published an interim final rule with
comment period on November 4, 2020
entitled, ‘‘Information Blocking and the
ONC Health IT Certification Program:
Extension of Compliance Dates and
Timeframes in Response to the COVID–
19 Public Health Emergency’’
(hereinafter the ‘‘ONC interim final
rule’’) (85 FR 70064). In this interim
final rule, ONC finalized extended
compliance dates for certain 2015
Edition certification criteria.
Specifically, where the ONC 21st
Century Cures Act final rule provided
that developers of certified health IT
have 24 months from the publication
date of the final rule to make technology
certified to new or updated criteria
available, ONC extended the timeline
until December 31, 2022 (and until
December 31, 2023, for 45
CFR 170.315(b)(10), ‘‘electronic health
information (EHI) export’’).
In the CY 2021 Physician Fee
Schedule (PFS) final rule (85 FR 84815
through 84825), we finalized that the
technology used by health care
providers to satisfy the definitions of
CEHRT at 42 CFR 495.4 and 414.1305
must be certified under the ONC Health
IT Certification Program, in accordance
with the updated 2015 Edition
certification criteria as finalized in the
ONC 21st Century Cures Act final rule
(85 FR 25642). We further finalized
aligning the transition period during
which health care providers
participating in the Promoting
Interoperability Program or QPP may
use technology certified to either the
existing or updated 2015 Edition
certification criteria, with the December
31, 2022, date established in the ONC
interim final rule for health IT
developers to make updated certified
health IT available. After this date,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
health care providers will be required to
use only certified technology updated to
the 2015 Edition Cures Update for an
EHR reporting period or performance
period in CY 2023. We did not propose
any changes to this policy.
We remind readers that health care
providers would not be required to
demonstrate that they are using updated
technology to meet the CEHRT
definitions immediately upon the
transition date of December 31, 2022. In
accordance with the EHR reporting
period and performance period
established for the Promoting
Interoperability Program and the Meritbased Incentive Payment System (MIPS)
Promoting Interoperability performance
category, participants are only required
to use technology meeting the CEHRT
definitions during a self-selected EHR
reporting period or performance period
of a minimum of any consecutive 90
days in CY 2023, including the final 90
days of 2023 (86 FR 45460 through
45462 and 86 FR 65466, respectively).
The eligible hospital, CAH, or MIPS
eligible clinician is not required to
demonstrate meaningful use of
technology meeting the 2015 Edition
Cures Update until the EHR reporting
period or performance period they have
selected.
3. Electronic Prescribing Objective:
Changes to the Query of Prescription
Drug Monitoring Program Measure and
Technical Update to the E-Prescribing
Measure
a. Query of Prescription Drug
Monitoring Program Measure
Background
We have adopted the Query of
Prescription Drug Monitoring Program
(PDMP) measure under the Electronic
Prescribing Objective. For background
on this measure, we refer readers to the
FY 2019 IPPS/LTCH PPS final rule (83
FR 41648 through 41653), the FY 2020
IPPS/LTCH PPS final rule (84 FR 42593
through 42595), the FY 2021 IPPS/LTCH
PPS final rule (85 FR 58967 through
58969), and the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45462 through
45464). In the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58967 through 58969),
we finalized that the Query of PDMP
measure will remain optional and
eligible for 5 bonus points for EHR
reporting periods in CY 2021. In the FY
2022 IPPS/LTCH PPS final rule (86 FR
45464), we finalized that the Query of
PDMP measure will remain optional
and increased the eligible bonus points
to 10 points for CY 2022.
In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42593 through 42596), FY
2021 IPPS/LTCH PPS final rule (85 FR
PO 00000
Frm 00542
Fmt 4701
Sfmt 4700
58967 through 58969), and FY 2022
IPPS/LTCH PPS final rule (86 FR 45462
through 45464), we described the
concern expressed by interested parties
who believed it was premature for the
Medicare Promoting Interoperability
Program to require the Query of PDMP
measure and to score it based on
performance. We heard extensive
feedback from EHR developers that
effectively incorporating the ability to
count the number of PDMP queries in
the EHR would require more robust
measurement specifications. These
interested parties stated that EHR
developers may face significant cost
burdens if they fully develop numerator
and denominator calculations and are
then required to change the
specification at a later date. Interested
parties stated that the costs of additional
development would likely be passed on
to health care providers without
additional benefit, as this development
would be solely for the purpose of
calculating the measure, rather than
furthering the clinical goal of the
measure. While we recognize that a
numerator/denominator-based measure
remains challenging, we also note (as
discussed in more detail later in this
section of the final rule) that the
widespread availability of PDMPs across
the country, and recent progress toward
solutions for connecting PDMPs with
provider EHR systems, has made use of
PDMPs feasible through a wide variety
of approaches.
b. Current Status of PDMP Adoption
Today, all 50 states and several
localities host PDMPs.1088 The final
state to establish a PDMP, the state of
Missouri, passed legislation to address
this issue in 2021, and is currently
working to make its PDMP operational.
A 2021 American Medical Association
report found that physicians and others
used state PDMPs more than 910
million times in 2020.1089 An
assessment of PDMPs conducted by the
PDMP Training and Technical
Assistance Center (TTAC) at the
Institute for Intergovernmental Research
(IIR) found an increase in the number of
PDMPs that are integrated with Health
Information Exchanges (HIEs), EHRs,
and/or Pharmacy Dispensing Systems
(PDSs), with 44 PDMPs integrated in
1088 Prescription Drug Monitoring Program
Training and Technical Assistance Center, PDMP
Policies and Capabilities: Results From 2021 State
Assessment, September 2021, https://
www.pdmpassist.org/pdf/PDMP%20Policies
%20and%20Capabilities%202021
%20Assessment%20Results_20210921.pdf.
1089 American Medical Association, 2021
Overdose Epidemic Report, https://www.amaassn.org/system/files/ama-overdose-epidemicreport.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
2021 reflecting an increase from 28
PDMPs with at least one type of
integration in 2017. We refer readers to
Table IX.H.-01. for the report’s findings
on the type of integration and the
number of PDMPs that have
49321
implemented that type of integration in
2021.
TABLE IX.H.-01.: PDMP INTEGRATION - TYPE AND NUMBER OF PDMPS 1090
Type of Inte2ration
# of PD MPs
EHRandPDS
HIE and EHR
HIE, EHR, and PDS
EHR only
HIE only
PDS only
35
1090 PDMP Policies and Capabilities: Results From
2021 State Assessment, September 2021, https://
www.pdmpassist.org/pdf/PDMP%20
Policies%20and%20
Capabilities%202021%20Assessment%20Results_
20210921.pdf.
1091 Government Accountability Office. GAO–21–
22, PRESCRIPTION DRUG MONITORING
PROGRAMS: Views on Usefulness and Challenges
of Programs.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
18
5
1
1
The SUPPORT for Patients and
Communities Act included new
requirements for PDMP enhancement
and integration, to help reduce opioid
misuse and overprescribing and
promote the effective prevention and
treatment of opioid use disorder
beginning in October of 2021. Enhanced
Federal matching funds were available
to states to support related PDMP
design, development, and
implementation activities during fiscal
years 2019 and 2020.
c. Changes to the Query of PDMP
Measure and Related Policies
(1) Changes to the Query of PDMP
Measure Description
The description of the Query of PDMP
measure provides that for at least one
Schedule II opioid electronically
prescribed using CEHRT during the EHR
reporting period, the eligible hospital or
CAH uses data from CEHRT to conduct
a query of a PDMP for prescription drug
history, except where prohibited and in
accordance with applicable law (42 CFR
495.24(e)(5)(iii)(B)). In the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28579), beginning with the EHR
reporting period in CY 2023, we
proposed to require the Query of PDMP
measure for eligible hospitals and CAHs
participating in the Medicare Promoting
Interoperability Program. We also noted
that should we finalize our proposal to
require the Query of PDMP measure
beginning with the EHR reporting
period in CY 2023, we proposed two
exclusions beginning with the EHR
reporting period in CY 2023: (1) Any
eligible hospital or CAH that does not
have an internal pharmacy that can
accept electronic prescriptions for
controlled substances that include drugs
from Schedules II, III, and IV, and is not
located within 10 miles of any
pharmacy that accepts electronic
prescriptions for controlled substances
PO 00000
Frm 00543
Fmt 4701
Sfmt 4700
at the start of their EHR reporting
period; and (2) any eligible hospital or
CAH that cannot report on this measure
in accordance with applicable law (87
FR 28581). We also noted in the FY
2023 IPPS/LTCH PPS proposed rule that
should we finalize the proposals to
require the Query of PDMP measure and
the associated exclusions, we believe
the inclusion of the phrase ‘‘except
where prohibited and in accordance
with applicable law’’ in the description
of the Query of PDMP measure and the
inclusion of the phrase ‘‘in accordance
with applicable law’’ in the second
proposed exclusion for the Query of
PDMP measure would be duplicative
and potentially cause confusion (87 FR
28578). Therefore, we proposed to
remove the phrase ‘‘except where
prohibited and in accordance with
applicable law’’ from the description of
the Query of PDMP measure should our
proposals to require the Query of PDMP
measure and the associated exclusions
be finalized. For additional information
on proposed changes to the Query of
PDMP measure, we referred readers to
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28580).
We also stated in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28579)
that should our proposal to remove
associated regulatory text related to
measures and objectives for the
Medicare Promoting Interoperability
Program not be finalized, we propose to
update the regulatory text to reflect
these proposed changes at 42 CFR
495.24(e)(5). We invited public
comment on these proposals.
Comment: A few commenters
expressed support for our proposal to
change the Query of PDMP measure
description.
Response: We thank commenters for
their support.
After consideration of the public
comments we received, we are
finalizing our proposal to change the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.183
khammond on DSKJM1Z7X2PROD with RULES2
Moreover, a number of enhancements
to PDMPs and related initiatives are
occurring across the country, including
enhancements to RxCheck, which is a
free, federally supported interstate
exchange hub for PDMP data. RxCheck
is connected to 50 out of 54 PDMPs in
states and territories and does not
require providers to pay to have access
to PDMP data from other states and
territories that are also live on RxCheck.
The CDC, in partnership with ONC and
other industry stakeholders, have been
working to connect RxCheck to the
eHealth Exchange as an alternative
pathway for providers to conduct
interstate queries of patient medication
histories. The goal of the project is to
allow any health care provider who is
live on the eHealth Exchange to use that
existing connection to query a patient’s
record through the RxCheck Hub, which
routes the query to individual State
PDMPs that are also live on RxCheck.
This solution enables health care
providers to query PDMPs via existing
connections to health information
exchange networks. Most states use
either RxCheck or Prescription
Monitoring Program (PMP) InterConnect
or both to facilitate the sharing of PDMP
information between states, allowing
health care providers to query other
states’ PDMP.1091
We also note that the Substance UseDisorder Prevention that Promotes
Opioid Recovery and Treatment
(SUPPORT) for Patients and
Communities Act (Pub. L. 115–271),
enacted in 2018, has focused on ways to
address the nation’s opioid epidemic.
20
49322
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Query of PDMP measure description to
remove the phrase ‘‘except where
prohibited and in accordance with
applicable law’’; we refer the reader to
section IX.H.3.c.(3) for the finalized
measure description. In section IX.H.8.
of this final rule, we are finalizing our
proposal to remove the associated
regulatory text related to measures and
objectives for the Medicare Promoting
Interoperability Program, and therefore,
we will not be updating 42 CFR
495.24(e)(5) with our finalized changes
to the Query of PDMP measure
description.
khammond on DSKJM1Z7X2PROD with RULES2
(2) Changes To Require the Query of
PDMP Measure
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45462), we noted that the
decision to maintain the Query of PDMP
as an optional measure for EHR
reporting periods in CY 2022 considered
the current efforts to improve the
technical foundation for EHR–PDMP
integration, the continued
implementation of the SUPPORT for
Patients and Communities Act, our
ongoing review of alternative measure
approaches, and interested party
concerns about the current readiness
across states for implementation of the
existing measure. We also noted that
this measure can play an important role
in helping health care providers to
improve clinical decision making by
utilizing this information to identify
potential opioid use disorders, inform
the development of care plans, and
develop effective interventions (86 FR
45463); maintaining it as an optional
measure with bonus points signals to
the hospital and vendor community that
this is an important measure which can
help spur development and innovation
to reduce barriers and challenges (86 FR
45463).
We continue to believe that PDMPs
play an important role in patient safety
by assisting in the identification of
patients who have multiple
prescriptions for controlled substances
or may be misusing or overusing them.
Querying the PDMP is important for
tracking dispensed controlled
substances and improving prescribing
practices. Efforts to expand the use of
PDMPs and integrate PMDPs with
health information technology systems
are supported by Federal agencies
including ONC, the Centers for Disease
Control and Prevention (CDC), the
Department of Justice (DOJ), and the
Substance Abuse and Mental Health
Services Administration (SAMHSA).
The Query of PDMP measure offers a
way to reward health care providers
who participate in current PDMP
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
initiatives that are supported by Federal
partners.
While work continues to improve
standardized approaches to PDMP and
EHR interoperability, we believe that it
is feasible at this time to require health
care providers to report the current
Query of PDMP measure requiring a
‘‘yes/no’’ response. Given our policies
for the Query of PDMP measure that
included increasing the eligible bonus
points to reward eligible hospitals and
CAHs that could report the measure, as
well as the recent progress in the
availability of PDMPs in all fifty states,
and solutions which support
accessibility of PDMPs to health care
providers, we believe eligible hospitals
and CAHs have had time to grow
familiar with what this measure requires
of them, even as technical approaches to
the use of PDMPs continue to advance.
By requiring a ‘‘yes/no’’ response the
current measure allows health care
providers to use a variety of technical
solutions to conduct a query of the
PDMP and receive credit for the
measure.
Therefore, beginning with the EHR
reporting period in CY 2023, we
proposed to require the current Query of
PDMP measure requiring a ‘‘yes/no’’
response for eligible hospitals and CAHs
participating in the Medicare Promoting
Interoperability Program. We stated that
we would maintain the associated
points at 10 points and referred readers
to section IX.H.6. of the proposed rule
for a discussion of our scoring
methodology and proposed concurrent
changes. As a result of this proposal, the
maximum total points available for the
Electronic Prescribing Objective would
remain at 20 points for EHR reporting
periods in CY 2023. We also stated in
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28579) that should our
proposal to remove associated
regulatory text related to measures and
objectives for the Medicare Promoting
Interoperability Program not be
finalized, we propose to update the
regulatory text to reflect these proposed
changes at 42 CFR 495.24(e)(5)(iii)(B).
We invited public comment on these
proposals.
Comment: Many commenters
expressed support for requiring the
Query of PDMP measure because it
remains a ‘‘yes/no’’ attestation-based
measure; they noted that it allows for
use of a variety of technical solutions to
report the measure, and includes
exclusions. Several commenters
supported requiring the measure
because querying a PDMP is critical to
understanding a patient’s medication
history to inform effective, quality care,
particularly when Schedule II opioids
PO 00000
Frm 00544
Fmt 4701
Sfmt 4700
and Schedules III and IV drugs are
prescribed and dispensed. They further
stated that it is important for future
public health initiatives and drug abuse
prevention efforts.
Response: We would like to thank the
commenters for their support. We agree
that the Query of PDMP measure is an
important tool for clinicians, and for
improving prescribing practices geared
towards overall patient safety.
Comment: Several commenters
expressed their support stating that
eligible hospitals and CAHs have had
ample time to prepare for this change.
For eligible hospitals and CAHs with
continued challenges, a commenter
shared that there are technological
solutions available to make this
requirement feasible. Last, commenters
shared that the benefits of the measure
outweigh concerns with implementation
of improved systems to support access
to PDMP data health IT system design,
and that requiring the measure will
continue to promote data exchange and
more advanced EHR workflows.
Response: We appreciate the
commenters’ support for requiring the
Query of PDMP measure. We agree that
eligible hospitals and CAHs have had
ample time to prepare for this
requirement, and have had time to grow
familiar with what this measure requires
of them. As states continue to improve
the accessibility of PDMPs through
technical advances, we believe eligible
hospitals and CAHs have an increasing
number of solutions available to
effectively query PDMPs.
Comment: Several commenters
offered suggestions and
recommendations for our consideration.
A commenter recommended that CMS
ensure that requiring the Query of
PDMP measure would not create a
barrier for clinicians appropriately
prescribing opioids for patients.
Another commenter recommended that
CMS consider accounting for state laws
that already require PDMP queries, and
adjusting for known challenges,
including state variability of PDMP
requirements and processes and the
availability of interstate data. A
commenter recommended that CMS
require States to work with EHR
vendors to continue the integration
process, thereby improving clinician
workflow. A commenter recommended
that CMS monitor the ability of CAHs
and small rural hospitals to comply
with the Query of PDMP measure and
provide flexibility, support and
technical assistance if disparities in
capacity and ability to use IT systems
are identified.
Response: We appreciate the
commenters’ support, including their
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
recommendations for our proposal. We
agree it is important that the measure
not create barriers for appropriate
prescribing or create additional
administrative burden, and believe that
maintaining the measure as requiring a
‘‘yes/no’’ response allows eligible
hospitals and CAHs to report while
minimizing burden. Regarding the
recommendation that CMS require
states to work with EHR vendors and
continuously monitor for known
challenges, we thank commenters for
this suggestion. CMS maintains
communication with ONC, and together,
we assess and monitor challenges that
eligible hospitals and CAHs face with
vendors and state-specific PDMPs. We
appreciate commenters’ concerns about
the impact of requiring the Query of
PDMP measure on CAHs and small rural
hospitals. The Query of PDMP measure
requires a ‘‘yes/no’’ response, and we
believe this helps to minimize potential
burden for small rural hospitals. We
also refer readers to the finalized
measure description for the Query of
PDMP measure of this final rule at
section IX.H.3.c.(3), where we state that
we require a minimum of ‘‘at least one’’
query of the PDMP and that no
maximum or suggested number of
queries have been established. Last,
CMS, as well as other HHS agencies, are
supporting a number of initiatives to
enable better integration between
PDMPs and health IT systems used by
health care providers. We refer readers
to the FY 2023 IPPS/LTCH PPS
proposed rule for further discussion (87
FR 28577 through 28578).
Comment: A few commenters
expressed support for making the Query
of PDMP measure required, so long as
it is delayed until CY 2024. A few
commenters have requested a delay in
requiring the measure until every state
has an operational statewide PDMP, or
until there is an exclusion for those
eligible hospitals and CAHs without a
statewide PDMP. A few commenters
cited the need for additional time for
network development and nationwide
integration between EHRs and PDMPs.
A commenter noted that EHR vendors
require a minimum of 24 months to
complete development and deployment
of any new functionality.
Response: We disagree that requiring
the Query of PDMP measure should be
delayed until CY 2024. While we
appreciate the importance of ongoing
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
work to improve interoperability of
PDMP data and integration systems, we
also believe that at this time, there is
sufficient technical capacity across the
country to support finalizing the
measure in its current form, requiring a
‘‘yes/no’’ attestation. We also
understand that there is currently only
one state without an operational
statewide PDMP, and that this
remaining state is moving towards an
operational status. Last, we note that we
are not finalizing any new technology
requirements to support the completion
of the actions associated with this
measure.
Comment: Many commenters did not
support requiring the Query of PDMP
measure citing inconsistencies across
state lines with regard to
interoperability standards, varying
degrees of implementation, and the
complexities resulting from inconsistent
state laws and licensing requirements.
Some commenters did not support
requiring the Query of PDMP measure
due to a lack of standardized privacy
and security protocols.
Response: CMS recognizes the work
required to improve integration between
PDMPs and health care provider health
IT systems, as well as the efforts
required to standardize data sharing
between the systems that may include
consideration of privacy and security
protocols, and that these efforts are
ongoing across the country. While we
believe that the importance of querying
the PDMP, and the widespread
availability of PDMPs at this time is
sufficient to finalize requiring the
current measure requiring a ‘‘yes/no’’
response, we will continue to support
efforts to improve the technical
approaches supporting data exchange
between systems. As these approaches
mature, we will work with ONC to
consider whether these approaches
should be incorporated into the ONC
Health IT Certification Program and the
Medicare Promoting Interoperability
Program.
After consideration of the public
comments we received, we are
finalizing our proposal to require the
Query of PDMP measure beginning with
the EHR reporting period in CY 2023. In
section IX.H.8. of this final rule, we are
finalizing our proposal to remove the
associated regulatory text related to
measures and objectives for the
Medicare Promoting Interoperability
PO 00000
Frm 00545
Fmt 4701
Sfmt 4700
49323
Program, and therefore, we will not be
updating 42 CFR 495.24(e)(5) with our
finalized changes to the Query of PDMP
measure.
(3) Changes to the Query of PDMP
Measure To Include Schedule II Opioids
and Schedule III and IV Drugs
Under 42 CFR 495.24(e)(5)(iii)(B), the
Query of PDMP measure provides that
for at least one Schedule II opioid
electronically prescribed using CEHRT
during the EHR reporting period, the
eligible hospital or CAH uses data from
CEHRT to conduct a query of a PDMP
for prescription drug history, except
where prohibited and in accordance
with applicable law. The Query of
PDMP measure was adopted in the FY
2019 IPPS/LTCH PPS final rule as one
of two measures under the Electronic
Prescribing Objective intended to
support HHS initiatives related to the
treatment of opioid and substance use
disorders by helping health care
providers avoid inappropriate
prescriptions, improving coordination
of prescribing amongst health care
providers, and focusing on the advanced
use of CEHRT (83 FR 41648 through
41653).
Under the Controlled Substances Act
(CSA),1092 the Drug Enforcement
Administration classifies drugs,
substances, and certain chemicals used
to make drugs into five distinct
categories or schedules depending upon
the drug’s acceptable medical use and
the drug’s abuse or dependency
potential. A drug’s abuse rate is a factor
used to determine its classification; for
example, Schedule I medications have
the highest abuse potential while
medications in Schedule V have a low
abuse potential. We refer readers to
Table IX. H.-02. for information on each
Schedule, including abuse potential,
medicinal use, if any, and drug
examples. For additional information,
we refer readers to the listing of drugs
and their schedule located at CSA
Scheduling at https://
www.deadiversion.usdoj.gov/schedules/
orangebook/c_cs_alpha.pdf.1093
1092 Public Law 91–513, tit. II, 84 Stat. 1236,
1242–84 (1970); codified, as amended, at 21 U.S.C.
801 et seq.
1093 See also https://www.dea.gov/sites/default/
files/2020-04/Drugs%20of%20Abuse%202020Web%20Version-508%20compliant-4-24-20_0.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
49324
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE IX.H.-02.: CONTROLLED SUBSTANCE SCHEDULES, DESCRIPTIONS, AND
EXAMPLES 1094
Schedule II
Schedule III
Schedule IV
Schedule V
Description
No accepted medical use, are unsafe, and
hold a high potential for abuse.
Accepted medical use, high potential for
abuse, abuse could lead to severe
psychological or physical dependence.
Accepted medical use, less potential for
abuse than schedule I or II substances, abuse
may lead to moderate or low physical
dependence or high psychological
dependence.
Accepted medical use, low potential for
abuse relative to schedule III substances,
abuse may lead to limited physical or
psychological dependence relative to
schedule III substances.
Accepted medical use, low potential for
abuse relative to schedule IV substances,
abuse may lead to limited physical or
psychological dependence relative to
schedule IV substances.
khammond on DSKJM1Z7X2PROD with RULES2
PDMPs are operated at the state level
and individual state requirements for
reporting and use differ from state to
state.1095 Currently, every state collects
data on schedules II, III, and IV
drugs.1096 Some states collect
information about certain noncontrolled substances that are
potentially subject to abuse or on all
prescription drugs.1097 While state laws
vary, we note that most state PDMPs
require physicians and dispensing
pharmacists to review a patient’s
prescribing information for the past
twelve months prior to prescribing or
dispensing any Schedule II, III, and IV
drugs.1098
PDMPs play an important role in
patient safety by assisting in the
1094 GAO–21–22, Prescription Drug Monitoring
Programs: Views on Usefulness and Challenges of
Programs; 21 U.S.C. 812, and the U.S. Drug
Enforcement Administration.
1095 For additional information, we refer readers
to https://www.cdc.gov/drugoverdose/pdf/
Leveraging-PDMPs-508.pdf; https://www.ncbi.nlm.
nih.gov/pmc/articles/PMC4605194/; and https://
www.pdmpassist.org/Policies/Legislative/
StatutesAndRegulations.
1096 https://www.pdmpassist.org/State.
1097 GAO report, GAO–21–22 Prescription Drug
Monitoring Programs.
1098 https://www.pdmpassist.org/State.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Examples
Heroin and LSD
Hydrocodone, methadone,
Demerol, OxyContin,
Percocet, morphine, codeine,
and amphetamine
Tylenol with Codeine and
anabolic steroids
Xanax, Klonopin, Valium,
and Ativan
Cough syrups containing
codeine
identification of patients who have
multiple prescriptions for controlled
substances or may be misusing or
overusing them. We believe that
expanding the requirements of the
Query of PDMP measure to include not
only Schedule II opioids, and but also
Schedule III and IV drugs, this would
further support HHS initiatives related
to the treatment of opioid and substance
use disorders by expanding the types of
drugs included in the Query of PDMP
measure while aligning with the PDMP
requirements in a majority of states. We
also believe this expansion to include
additional Scheduled drugs would
facilitate more informed prescribing
practices and improve patient outcomes.
Therefore, in the FY 2023 IPPS/LTCH
PPS proposed rule, we proposed to
expand the Query of PDMP measure to
include Schedule II opioids, and
Schedule III and IV drugs beginning
with the EHR reporting period in CY
2023 (87 FR 28579 through 28581).
Proposed Measure Description: For at
least one Schedule II opioid or Schedule
III or IV drug electronically prescribed
using CEHRT during the EHR reporting
period, the eligible hospital or CAH uses
data from CEHRT to conduct a query of
a PDMP for prescription drug history.
PO 00000
Frm 00546
Fmt 4701
Sfmt 4700
To align with the policy for the Query
of PDMP measure with regard to
Schedule II opioids, we proposed in the
FY 2023 IPPS/LTCH PPS proposed rule
that the query of the PDMP for
prescription drug history must occur
prior to the electronic transmission of
an electronic prescription for a
Schedule II opioid or Schedule III or IV
drug (87 FR 28580). We also proposed
that this measure would include all
permissible prescriptions and
dispensing of Schedule II opioids, and
Schedule III or IV drugs, no matter how
small the dose prescribed during an
encounter. This would allow eligible
hospitals and CAHs to identify multiple
health care provider episodes (physician
shopping), prescriptions of dangerous
combinations of drugs, and controlled
substances prescribed in high quantities
(87 FR 28580). We also proposed that
multiple prescriptions for Schedule II
opioids or Schedule III and IV drugs
prescribed on the same date, by the
same eligible hospital or CAH would
not require multiple queries of the
PDMP, and at least one query would
have to be performed for this measure.
We proposed that eligible hospitals and
CAHs would have flexibility to query
the PDMP using data from CEHRT in
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.184
Schedule
Schedule I
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
any manner allowed under state law (87
FR 28580). We also stated in the FY
2023 IPPS/LTCH PPS proposed rule (87
FR 28580 through 28581) that should
our proposal to remove associated
regulatory text related to measures and
objectives for the Medicare Promoting
Interoperability Program not be
finalized, we proposed to update the
regulatory text to reflect these proposed
changes at 42 CFR 495.24(e)(5)(iii)(B).
We invited public comment on these
proposals. We also invited public
comment on whether to expand this
measure to include Schedule V or other
drugs with the potential for abuse.
Comment: Many commenters
expressed support to expand the Query
of PDMP measure to include Schedule
III and IV drugs. A commenter
expressed their belief that
understanding a patient’s medication
history is critical to safe, effective,
quality care, particularly when
Schedule II opioids and Schedule III
and IV drugs are prescribed and
dispensed. A commenter expressed its
belief that the proposed expansion
makes sense because many states also
require similar queries.
Response: We thank commenters for
their support, and agree that in
expanding our measure to also include
Schedule III and IV drugs, this will offer
eligible hospitals and CAHs a broader
clinical picture, aimed at overall patient
safety efforts, and agree that expanding
these schedules will support better
alignment with state regulations.
Comment: A commenter expressed
support to include Schedule III and IV
drugs, and further recommended that
CMS consider similar state laws that
require PDMP queries, and how those
requirements differ from CMS’s
requirements.
Response: We thank the commenter
for their support. While state laws do
vary, we generally understand that
many states’ PDMPs require physicians
and dispensing pharmacists to review
each patient’s prescribing information
for twelve months prior to prescribing
or dispensing any Schedule II opioids or
Schedule III and IV controlled
substances. We may consider the
additional feedback in future
rulemaking.
Comment: A few commenters did not
support expanding the Query of PDMP
measure to include Schedule III and IV
drugs citing the lack of harmony
between state requirements, the
potential for confusion, and that some
states do not have an operational
statewide PDMP.
Response: We disagree with the
commenter that expanding the Query of
PDMP measure to include Schedule III
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
and IV drugs would contribute to a lack
of harmony between state requirements,
thereby causing potential confusion. We
note that currently, every state collects
data on Schedule II opioids, and
Schedule III and IV drugs. We believe
that in collecting similar data this
would minimize the potential for
confusion, and instead, promote
harmony.
Comment: A few commenters
requested clarification on whether the
expansion includes all Schedule II
drugs.
Response: We proposed expanding
the Query of PDMP measure to include
Schedule III and IV drugs, but did not
propose any changes to the language in
the measure description that references
Schedule II opioids, and clarify that the
Query of PDMP measure does not
include or apply to Schedule II drugs
that are not opioids (for example,
central nervous system stimulants).
Comment: A few commenters
recommended furthering the expansion
of the Query of PDMP measure to also
include Schedule V drugs if there would
be value in doing so.
Response: We appreciate the
commenters’ feedback. While we are not
including Schedule V drugs at this time
due to the current low potential for
abuse in that category, we may consider
this in future rulemaking.
After consideration of the public
comments we received, we are
finalizing our proposals related to the
expansion of the Query of PDMP
measure to include Schedule II opioids,
and Schedule III and IV drugs beginning
with the EHR reporting period in CY
2023, as well as the proposed Query of
PDMP measure description, and our
proposals related to requiring that the
query of the PDMP for prescription drug
history must occur prior to the
electronic transmission of an electronic
prescription for a Schedule II opioid or
Schedule III or IV drug; that the measure
would include all permissible
prescriptions and dispensing of
Schedule II opioids, and Schedule III or
IV drugs, no matter how small the dose
prescribed during an encounter; that
multiple prescriptions for Schedule II
opioids or Schedule III and IV drugs
prescribed on the same date, by the
same eligible hospital or CAH would
not require multiple queries of the
PDMP, and at least one query would
have to be performed for this measure;
and that eligible hospitals and CAHs
would have flexibility to query the
PDMP using data from CEHRT in any
manner allowed under state law . In
section IX.H.8. of this final rule, we are
finalizing our proposal to remove the
associated regulatory text related to
PO 00000
Frm 00547
Fmt 4701
Sfmt 4700
49325
measures and objectives for the
Medicare Promoting Interoperability
Program, and therefore, we will not be
updating 42 CFR 495.24(e)(5) with our
finalized changes to the Query of PDMP
measure.
(4) Exclusions
In FY 2019 IPPS/LTCH PPS final rule,
we finalized exclusions for eligible
hospitals and CAHs from reporting the
Query of PDMP measure beginning with
EHR reporting period in CY 2020 when
the measure would have been required
by the Medicare Promoting
Interoperability Program (83 FR 41653).
The finalized exclusions included: (1)
Any eligible hospital or CAH that does
not have an internal pharmacy that can
accept electronic prescriptions for
controlled substances and is not located
within 10 miles of any pharmacy that
accepts electronic prescriptions for
controlled substances at the start of their
EHR reporting period; and (2) any
eligible hospital and CAH that could not
report on this measure in accordance
with applicable law. We also finalized
that beginning with EHR reporting
period in CY 2020, an eligible hospital
or CAH that qualifies for the ePrescribing measure exclusion is also
excluded from reporting on the Query of
PDMP measure (83 FR 41649). We noted
our intention to propose a third
exclusion where integration with a
statewide PDMP was not yet feasible or
widely available (83 FR 41652).
In FY 2020 IPPS/LTCH PPS final rule
(84 FR 42595), we finalized the removal
of the exclusions associated with the
Query of PDMP measure, noting that
exclusions were not necessary because
we finalized the Query of PDMP
measure as optional for the EHR
reporting period in CY 2020. We also
finalized the Query of the PDMP
measure as an optional measure for EHR
reporting periods in CY 2021 and CY
2022 in FY 2021 IPPS/LTCH PPS final
rule (85 FR 58969) and the FY 2022
IPPS/LTCH PPS final rule (86 FR
45464), respectively.
In the FY 2023 IPPS/LTCH PPS
proposed rule, beginning with the EHR
reporting period in CY 2023, we
proposed to require the Query of PDMP
measure for eligible hospitals and CAHs
participating in the Medicare Promoting
Interoperability Program (87 FR 28581).
We noted that should we finalize our
proposal to require the Query of PDMP
measure beginning with CY 2023, we
believed that exclusions for the measure
would be necessary (87 FR 28581). We
revisited the exclusions established in
the FY 2019 IPPS/LTCH PPS final rule
and subsequently removed in the FY
2020 IPPS/LTCH PPS final rule because
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49326
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
the Query of PDMP measure would
continue to be an optional measure. In
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28581), we stated that if we
finalize our proposal to require the
Query of PDMP measure, we proposed
the following exclusions beginning with
the EHR reporting period in CY 2023:
(1) Any eligible hospital or CAH that
does not have an internal pharmacy that
can accept electronic prescriptions for
controlled substances that include drugs
from Schedules II, III, and IV, and is not
located within 10 miles of any
pharmacy that accepts electronic
prescriptions for controlled substances
at the start of their EHR reporting
period; and (2) any eligible hospital or
CAH that cannot report on this measure
in accordance with applicable law. We
also referred readers to our proposed
policy to redistribute points to the ePrescribing measure under the
Electronic Prescribing Objective should
an eligible hospital or CAH claim an
exclusion for the Query of PDMP
measure for an EHR reporting period (87
FR 28589 through 28592). We also
stated in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28581) that should
our proposal to remove associated
regulatory text related to measures and
objectives for the Medicare Promoting
Interoperability Program not be
finalized, we proposed to update the
regulatory text to reflect these proposed
changes at 42 CFR 495.24(e)(5).
In the FY 2019 IPPS/LTCH PPS final
rule (83 FR 41652), we signaled our
intention to propose an additional
exclusion beginning in CY 2020 for
health care providers in states where
integration with a statewide PDMP is
not yet feasible or not yet widely
available. In the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28581), we
expressed our belief that this exclusion
is no longer needed given the flexibility
of the Query PDMP measure, which
requires a ‘‘yes/no’’ response, as well as
the implementation of PDMPs in all 50
states and several localities and the
increasing number of PDMPs offering
some degree of integration with EHRs
(from 28 PDMPs with at least one type
of integration in 2017 to 44 PDMPs that
are integrated with HIEs, EHRs, and/or
PDSs in 2021 1099). We also expressed
our belief that broadly requiring this
measure across health care providers
who may access PDMPs in different
ways would help to continue to drive
development of improved solutions for
1099 PDMP Policies and Capabilities: Results From
2021 State Assessment, September 2021, https://
www.pdmpassist.org/pdf/PDMP%20
Policies%20and%20Capabilities%202021%20
Assessment%20Results_20210921.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PDMP access. In addition, we stated that
while we believe the Query of PDMP
measure is achievable for eligible
hospitals and CAHs and that the
proposed exclusions offer significant
flexibilities such that most health care
providers would be able to meet the
measure or claim an exclusion, we
welcomed public comment on other
barriers, including barriers related to
technology solutions, cost, and
workflow, that should be considered.
We also requested comment on any
additional exclusions that we should
consider for this measure and may
propose in the future.
We invited public comment on these
proposals.
Comment: Several commenters
expressed support for our proposed
exclusions.
Response: We thank commenters for
their support.
Comment: Several commenters
recommended that CMS consider
additional exclusions. Suggestions
included allowing an exclusion for
eligible hospitals and CAHs in states
where EHR–PDMP integration is
limited, not possible, or where there is
no operational statewide PDMP. A few
commenters recommended an
exclusion, waiver, or discretion
enforcement for the Query of PDMP
measure noting it could be burdensome
on clinician workflows to compile
supporting documentation for
attestation using multiple systems, and
that this is not the time to put additional
burden on clinicians until states have
improved their technologies to enable
more efficient inquiries. Other
commenters recommended that CMS
consider exclusions for eligible
hospitals and CAHs that are required by
the state to use their PDMP outside of,
and independent from, their CEHRT,
and may not be able to meet the
requirements of the Query of PDMP
measure.
Response: We thank commenters for
their recommendations to include
additional exclusions. After reviewing
the comments, we agree with
commenters that an additional
exclusion is needed for eligible
hospitals and CAHs for one year. We
understand that, for some, accessing
state PDMPs can be time-consuming and
disruptive to clinical workflow, if
technology requires exiting the hospital
medical record, connecting with the
state PDMP, then compiling supporting
documentation for attestation using
multiple systems. We also understand
that while most states have an
operational statewide PDMP, for those
eligible hospitals and CAHs located in
a state that does not have an operational
PO 00000
Frm 00548
Fmt 4701
Sfmt 4700
statewide PDMP, they would need to
check a limited county-level PDMP to
meet the requirements of the Query of
PDMP measure, and we agree, that
could interrupt workflows for providers.
We believe that this additional, and
temporary, exclusion would address
concerns raised by CAHs and small
rural hospitals where disparities in
capacity, and the ability to use IT
systems, make meeting the requirements
of the Query of PDMP measure costly or
burdensome.
We believe that offering an additional
exclusion for the CY 2023 EHR
reporting period for eligible hospitals or
CAHs would provide more time for
technologies to improve and for
increased EHR–PDMP integration to
enable more efficient queries of the
PDMP. This exclusion would be
available for a limited time (CY 2023),
because we believe that one year would
offer eligible hospitals and CAHs time to
become familiar with new technologies,
processes and make necessary
adjustments to their workflow with
minimal burden and allow for improved
readiness.
We appreciate the commenter’s
recommendation for an exclusion to
address when state laws may not allow
for an eligible hospital or CAH to meet
the requirements of the Query of PDMP
measure, and believe the proposed
exclusion for ‘‘any eligible hospital or
CAH that cannot report on this measure
in accordance with applicable law’’
would address that scenario.
After consideration of the public
comments we received, we are
finalizing our proposals with
modification to include the following
three exclusions for the Query of PDMP
measure: (1) Any eligible hospital or
CAH that does not have an internal
pharmacy that can accept electronic
prescriptions for controlled substances
that include Schedule II, III and IV
drugs, and is not located within 10
miles of any pharmacy that accepts
electronic prescriptions for controlled
substances at the start of their EHR
reporting period; (2) Any eligible
hospital or CAH that cannot report on
this measure in accordance with
applicable law; and (3) Any eligible
hospital or CAH for which querying a
PDMP would impose an excessive
workflow or cost burden prior to the
start of the EHR reporting period they
select in CY 2023. We note that we are
finalizing this third exclusion related to
workflow and cost burden on a timelimited basis for those eligible hospitals
and CAHs that believe they would face
significant burden associated with
querying a PDMP at least once when
reporting the measure during an EHR
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
reporting period in CY 2023. This
exclusion will no longer be available for
EHR reporting periods after CY 2023.
We expect that those eligible hospitals
and CAHs claiming this exclusion in
2023 will be able to utilize the
additional time provided by this timelimited exclusion to resolve any
remaining barriers to reporting the
measure. In section IX.H.8. of this final
rule, we are finalizing our proposal to
remove the associated regulatory text
related to measures and objectives for
the Medicare Promoting Interoperability
Program, and therefore, we will not be
updating 42 CFR 495.24(e)(5) with our
finalized changes to the Query of PDMP
measure.
khammond on DSKJM1Z7X2PROD with RULES2
d. Future Direction
While we believe that finalizing our
proposals for the Query of PDMP
measure are feasible and appropriate at
this time, we continue to work with
industry and Federal partners to
advance common standards for the
exchange of information between
PDMPs, EHRs, pharmacy information
systems, and exchange networks. We
believe this work will ultimately allow
us to achieve our ideal state, where we
would further modify the Query of
PDMP measure to be numerator/
denominator-based, and require use of
standardized functionality within
CEHRT to support the actions associated
with the measure while reporting on a
numerator and denominator. We will
continue to collaborate with ONC to
monitor developments across the
industry, efforts made toward advancing
relevant standards, and plan to revisit
this measure in the future to explore
further specifying health IT
requirements if they become available
and are incorporated into the ONC
Health IT Certification Program.
Federally supported activities
continue to focus on developing and
refining standards-based approaches to
enable effective integration into clinical
workflows; exploring emerging
technical solutions to enhance access to
and use of PDMP data; and providing
technical resources to a variety of
interested parties to advance and scale
the interoperability of health IT systems
and PDMPs. Moreover, updates to
certified health IT systems incorporating
application programming interfaces
(APIs) based on HL7® FHIR® standard
version Release 4 (85 FR 25642) can
help support future technical
approaches that enable more seamless
exchange of data between CEHRT and
PDMP systems. For more information
about current and emerging standards
related to PDMP data capture and
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
exchange, we refer readers to the ONC
Interoperability Standards Advisory.1100
e. Technical Update to the E-Prescribing
Measure
The ONC 21st Century Cures Act final
rule (85 FR 25642; 85 FR 25660 through
25661) retired the ‘‘drug-formulary and
preferred drug list checks’’ certification
criterion at 45 CFR 170.315(a)(10) which
was associated with measures under the
Electronic Prescribing Objective for the
Medicare Promoting Interoperability
Program and the MIPS Promoting
Interoperability performance category
(80 FR 62882 and 83 FR 59817). ONC
retired this criterion after January 1,
2022 (85 FR 26661).
In the CY 2021 PFS final rule, we
finalized that the ‘‘drug-formulary and
preferred drug list checks’’ criterion will
no longer be associated with measures
under the Electronic Prescribing
Objective and will no longer be required
to meet the CEHRT definition for the
Medicare Promoting Interoperability
Program and the MIPS Promoting
Interoperability performance category,
beginning with CY 2021 EHR reporting
and performance periods (85 FR 84815
through 84825).
In the FY 2022 IPPS/LTCH PPS final
rule, we inadvertently omitted a
revision to TABLE IX.F.-02.: Objectives
and Measures for the Medicare
Promoting Interoperability Program in
2022 to reflect this change and included
the text ‘‘queried for a drug formulary’’
in the measure description and in the
numerator of the e-Prescribing measure
(86 FR 45484). In an effort to more
clearly capture the previously
established policy finalized in the CY
2021 PFS final rule with respect to the
e-Prescribing measure, we proposed in
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28582) to revise the measure
description in TABLE 56 to read, ‘‘For
at least one hospital discharge,
medication orders for permissible
prescriptions (for new and changed
prescriptions) are transmitted
electronically using CEHRT’’ and the
numerator will be updated to read to
indicate ‘‘[t]he number of prescriptions
in the denominator generated and
transmitted electronically’’ to reflect the
removal of the health IT certification
criterion ‘‘drug-formulary and preferred
drug list checks’’ (86 FR 65478).
We invited comment on our proposal.
Comment: A few commenters
supported our proposal.
Response: We thank commenters for
their support. After consideration of the
1100 https://www.healthit.gov/isa/allows-aprovider-request-a-patients-medication-history-astate-prescription-drug-monitoring.
PO 00000
Frm 00549
Fmt 4701
Sfmt 4700
49327
public comments we have received, we
are finalizing our proposal to revise the
measure description in [TABLE XX] to
read ‘‘For at least one hospital
discharge, medication orders for
permissible prescriptions (for new and
changed prescriptions) are transmitted
electronically using CEHRT,’’ and the
numerator will be updated to read to
indicate ‘‘[t]he number of prescriptions
in the denominator generated and
transmitted electronically’’ to reflect the
removal of the health IT certification
criterion ‘‘drug-formulary and preferred
drug list checks’’.
4. Health Information Exchange (HIE)
Objective: Addition of An Alternative
Measure for Enabling Exchange Under
the Trusted Exchange Framework and
Common Agreement (TEFCA)
a. Background on the Health
Information Exchange Objective
The Health Information Exchange
(HIE) Objective and its associated
measures for eligible hospitals and
CAHs hold particular importance
because of the role they play within the
care continuum. In addition, these
measures encourage and leverage
interoperability on a broader scale and
promote health IT-based care
coordination. The Health Information
Exchange Objective currently includes
three measures: Support Electronic
Referral Loops by Sending Health
Information, Support Electronic Referral
Loops by Receiving and Reconciling
Health Information, and Health
Information Exchange Bi-Directional
Exchange. For background on this
objective and its associated measures,
we refer readers to the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41656
through 41661), the FY 2020 IPPS/LTCH
PPS final rule (84 FR 42596 through
42597), the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58969), and the FY
2022 IPPS/LTCH PPS final rule (86 FR
45465 through 45470).
In the FY 2022 IPPS/LTCH PPS final
rule, we finalized the HIE Bi-Directional
Exchange measure, under the Health
Information Exchange Objective (86 FR
45465 through 45470). The HIE BiDirectional Exchange measure is worth
40 points, the maximum number of
points of the Health Information
Exchange Objective, and was finalized
as an alternative to reporting on the two
existing Health Information Exchange
Objective measures: The Support
Electronic Referral Loops by Sending
Health Information measure (42 CFR
495.24(e)(6)(ii)(A)) and the Support
Electronic Referral Loops by Receiving
and Reconciling Health Information
measure (42 CFR 495.24(e)(6)(ii)(B)). To
E:\FR\FM\10AUR2.SGM
10AUR2
49328
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
meet the measure requirements, eligible
hospitals and CAHs must attest to the
following statements:
• Statement 1: Participating in an HIE
to enable secure, bi-directional
exchange of information to occur for all
unique patients discharged from the
eligible hospital or CAH inpatient or
emergency department (POS 21 or 23),
and all unique patient records stored or
maintained in the EHR for these
departments, during the EHR reporting
period in accordance with applicable
law and policy.
• Statement 2: Participating in an HIE
that is capable of exchanging
information across a broad network of
unaffiliated exchange partners including
those using disparate EHRs, and not
engaging in exclusionary behavior when
determining exchange partners.
• Statement 3: Using the functions of
CEHRT to support bi-directional
exchange with an HIE.
We stated that, by enabling bidirectional exchange of information
between health care providers and
aggregating data across health care
providers with disparate systems, HIEs
(including a wide range of organizations
facilitating health information
exchange) can bring together the
information needed to create a true
longitudinal care record and support
improved care coordination by
facilitating timely access to robust
health information across care settings
(86 FR 45465). We further described
how participation in HIEs can amplify
health care providers’ capacity to share
information beyond what a health care
provider can achieve through the
sending and receiving actions described
in the existing measures under the
Health Information Exchange Objective,
for instance, by facilitating information
exchange when a health care provider is
unaware of another health care
provider’s need to receive information
about a patient (86 FR 45466). By
finalizing this measure for eligible
hospitals and CAHs, we sought to
ensure that eligible hospitals and CAHs
participating in the Medicare Promoting
Interoperability Program would be
rewarded for connecting to exchange
arrangements that can enable this type
of robust information sharing.
b. Background on TEFCA
Section 4003(b) of the 21st Century
Cures Act (Pub. L. 114–255), enacted in
2016, amended section 3001(c) of the
Public Health Service Act (42 U.S.C.
300jj–11(c)), and required HHS to take
steps to advance interoperability for the
purpose of ensuring full network-tonetwork exchange of health information.
Specifically, Congress directed the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
National Coordinator to ‘‘develop or
support a trusted exchange framework,
including a common agreement among
health information networks
nationally.’’ Since the enactment of the
21st Century Cures Act, HHS has
pursued development of a Trusted
Exchange Framework and Common
Agreement, or TEFCA. ONC’s goals for
TEFCA are: 1101
Goal 1: Establish a universal policy
and technical floor for nationwide
interoperability.
Goal 2: Simplify connectivity for
organizations to securely exchange
information to improve patient care,
enhance the welfare of populations, and
generate health care value.
Goal 3: Enable individuals to gather
their health care information.
In the FY 2019 IPPS/LTCH PPS
proposed rule (83 FR 20537), we
requested comment on whether eligible
hospital or CAH participation in TEFCA
should be considered a health IT
activity that could count for credit
within the Health Information Exchange
Objective in lieu of reporting on
measures for this objective. We received
comments in support of this concept,
although some commenters disagreed
indicating that they were concerned
about adding additional burden (83 FR
41669).
In the FY 2022 IPPS/LTCH PPS
proposed rule (86 FR 25631 through
25634), in which we proposed the HIE
Bi-Directional Exchange measure for
eligible hospitals and CAHs, we noted
that the proposed attestation statements
for the measure did not explicitly refer
to participation in a health information
network or partnering with a health
information network that enables
exchange under TEFCA. However, we
stated TEFCA was likely to be an
important way for eligible hospitals and
CAHs to enable bi-directional health
information exchange in the future and
that we would continue to explore ways
to provide further guidance or update
this measure to align with the use of
health information networks that enable
exchange under TEFCA in the future (86
FR 25634). In the final rule, we noted
that several commenters were
encouraged to see our acknowledgement
that this measure could align with the
efforts on TEFCA (86 FR 45468).
Since the publication of the FY 2022
IPPS/LTCH PPS final rule, important
additional developments have occurred
with respect to TEFCA.1102 On January
18, 2022, ONC announced a significant
1101 See https://www.healthit.gov/buzz-blog/
interoperability/321tefca-is-go-for-launch.
1102 For more information on current
developments related to TEFCA, we refer readers to
www.HealthIT.gov/TEFCA.
PO 00000
Frm 00550
Fmt 4701
Sfmt 4700
TEFCA milestone by releasing the
Trusted Exchange Framework 1103 and
Common Agreement Version 1.1104 The
Trusted Exchange Framework is a set of
non-binding principles for health
information exchange, and the Common
Agreement for Nationwide Health
Information Interoperability Version 1
(also referred to as Common Agreement)
is a contract that advances those
principles. The Common Agreement
and the incorporated by reference
Qualified Health Information Network
(QHIN) Technical Framework Version 1
(QTF) 1105 establish the technical
infrastructure model and governing
approach for different health
information networks and their users to
securely share clinical information with
each other—all under commonly
agreed-to terms. The Common
Agreement is a legal contract that
QHINs 1106 sign with the ONC
Recognized Coordinating Entity
(RCE),1107 a private-sector entity that
implements the Common Agreement
and ensures QHINs comply with its
terms.
The technical and policy architecture
of how exchange occurs under TEFCA
follows a network-of-networks structure,
which allows for connections at
different levels and is inclusive of many
different types of entities at different
levels, such as health information
networks, care practices, hospitals,
public health agencies, and Individual
1103 Trusted Exchange Framework (Jan. 2022),
https://www.healthit.gov/sites/default/files/page/
2022-01/Trusted_Exchange_Framework_0122.pdf.
1104 Common Agreement for Nationwide Health
Information Interoperability Version 1 (Jan. 2022),
https://www.healthit.gov/sites/default/files/page/
2022-01/Common_Agreement_for_Nationwide_
Health_Information_Interoperability_Version_1.pdf.
1105 Qualified Health Information Network
(QHIN) Technical Framework (QTF) Version 1.0
(Jan. 2022), https://rce.sequoiaproject.org/wpcontent/uploads/2022/01/QTF_0122.pdf.
1106 The Common Agreement defines a QHIN as
‘‘to the extent permitted by applicable SOP(s), a
Health Information Network that is a U.S. Entity
that has been Designated by the RCE and is a party
to the Common Agreement countersigned by the
RCE.’’ See Common Agreement for Nationwide
Health Information Interoperability Version 1, at 10
(Jan. 2022), https://www.healthit.gov/sites/default/
files/page/2022-01/Common_Agreement_for_
Nationwide_Health_Information_Interoperability_
Version_1.pdf.
1107 In August 2019, ONC awarded a cooperative
agreement to The Sequoia Project to serve as the
initial RCE. The RCE will operationalize and
enforce the Common Agreement, oversee QHINfacilitated network operations, and ensure
compliance by participating QHINs. The RCE will
also engage interested parties to create a roadmap
for expanding interoperability over time. https://
sequoiaproject.org/onc-awards-the-sequoia-projecta-cooperative-agreement-for-the-trusted-exchangeframework-and-common-agreement-to-supportadvancing-nationwide-interoperability-ofelectronic-health-information/.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Access Services (IAS) 1108 Providers.1109
QHINs connect directly to each other to
facilitate nationwide interoperability,
and each QHIN can connect
Participants, which can connect
Subparticipants.1110 Compared to most
nationwide exchange today, the
Common Agreement includes an
expanded set of Exchange Purposes
beyond Treatment to include Individual
Access Services, Payment, Health Care
Operations, Public Health, and
Government Benefits
Determination 1111—all built upon
common technical and policy
requirements to meet key needs of the
U.S. health care system.1112 This
1108 The Common Agreement defines Individual
Access Services (IAS) as ‘‘with respect to the
Exchange Purposes definition, the services
provided utilizing the Connectivity Services, to the
extent consistent with Applicable Law, to an
Individual with whom the QHIN, Participant, or
Subparticipant has a Direct Relationship to satisfy
that Individual’s ability to access, inspect, or obtain
a copy of that Individual’s Required Information
that is then maintained by or for any QHIN,
Participant, or Subparticipant.’’ See Common
Agreement for Nationwide Health Information
Interoperability Version 1, at 7 (Jan. 2022), https://
www.healthit.gov/sites/default/files/page/2022-01/
Common_Agreement_for_Nationwide_Health_
Information_Interoperability_Version_1.pdf.
1109 The Common Agreement defines ‘‘IAS
Provider’’ as: ‘‘Each QHIN, Participant, and
Subparticipant that offers Individual Access
Services.’’ See Common Agreement for Nationwide
Health Information Interoperability Version 1, at 7
(Jan. 2022), https://www.healthit.gov/sites/default/
files/page/2022-01/Common_Agreement_for_
Nationwide_Health_Information_Interoperability_
Version_1.pdf.
1110 For the Common Agreement definitions of
QHIN, Participant, and Subparticipant, see
Common Agreement for Nationwide Health
Information Interoperability Version 1, at 8–12 (Jan.
2022), https://www.healthit.gov/sites/default/files/
page/2022-01/Common_Agreement_for_
Nationwide_Health_Information_Interoperability_
Version_1.pdf.
1111 For the Common Agreement definitions of
Payment, Health Care Operations, Public Health,
and Government Benefits Determination, see
Common Agreement for Nationwide Health
Information Interoperability Version 1, at 6–10 (Jan.
2022), https://www.healthit.gov/sites/default/files/
page/2022-01/Common_Agreement_for_
Nationwide_Health_Information_Interoperability_
Version_1.pdf.
1112 Exchange Purpose(s): means the reason, as
authorized by [the] Common Agreement including
the Exchange Purposes SOP, for a Request, Use,
Disclosure, or Response transmitted via QHIN-toQHIN exchange as one step in the transmission.
Authorized Exchange Purposes are: Treatment,
Payment, Health Care Operations, Public Health,
Government Benefits Determination, Individual
Access Services, and any other purpose authorized
as an Exchange Purpose by the Exchange Purposes
SOP, each to the extent permitted under Applicable
Law, under all applicable provisions of [the]
Common Agreement, and, if applicable, under the
implementation SOP for the applicable Exchange
Purpose. Definitions for each of these exchange
purposes can be found in the Common Agreement
for Nationwide Health Information Interoperability
Version 1, at 6 (Jan. 2022), https://
www.healthit.gov/sites/default/files/page/2022-01/
Common_Agreement_for_Nationwide_Health_
Information_Interoperability_Version_1.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
flexible structure allows interested
parties to participate in the way that
makes the most sense for them, while
supporting simplified, seamless
exchange.
The QTF,1113 which was developed
and released by the RCE, describes the
functional and technical requirements
that a Health Information Network
(HIN) 1114 must fulfill to serve as a QHIN
under the Common Agreement. The
QTF specifies the technical
underpinnings for QHIN-to-QHIN
exchange and certain other
responsibilities described in the
Common Agreement. The technical and
functional requirements described in
the QTF enable information exchange
modalities, including querying and
message delivery across participating
entities.
In general, the information to be
exchanged within the TEFCA ecosystem
allows for the use of the Health Level
Seven (HL7®) Implementation Guide for
Clinical Document Architecture (CDA®)
Release 2: Consolidated CDA Templates
for Clinical Notes (US Realm) Draft
Standard for Trial Use Release 2.1 (C–
CDA 2.1) document format, including
data defined as part of U.S. Core Data
for Interoperability (USCDI), with
allowance for flexibility to further
expand the content to support a
multitude of use cases.1115 The
Common Agreement and the QTF do
not require HL7® Fast Healthcare
Interoperability Resource (FHIR®)-based
exchange. TEFCA allows for the
optional exchange of FHIR content
using more traditional, established
standards to enable the transport of that
content. However, TEFCA can
nonetheless be a strong catalyst for
network enablement of FHIR
maturation. To that end, the RCE
released a three-year FHIR Roadmap for
TEFCA Exchange, which lays out a
deliberate strategy to add FHIR-based
exchange under TEFCA in the near
future.1116
1113 Qualified Health Information Network
(QHIN) Technical Framework (QTF) Version 1.0
(Jan. 2022), https://rce.sequoiaproject.org/wpcontent/uploads/2022/01/QTF_0122.pdf.
1114 ‘‘Health Information Network’’ under TEFCA
has the meaning assigned to the term ‘‘Health
Information Network or Health Information
Exchange’’ in the information blocking regulations
at 45 CFR 171.102.
1115 User’s Guide to the Trusted Exchange
Framework and Common Agreement—TEFCA (Jan
2022), https://rce.sequoiaproject.org/wp-content/
uploads/2022/01/Common-Agreement-UsersGuide.pdf.
1116 FHIR® Roadmap for TEFCA Exchange
Version 1 (Jan. 2022), https://rce.sequoiaproject.org/
wp-content/uploads/2022/01/FHIR-Roadmap-v1.0_
updated.pdf.
PO 00000
Frm 00551
Fmt 4701
Sfmt 4700
49329
c. New Enabling Exchange Under
TEFCA Measure
In 2022, prospective QHINs are
anticipated to begin signing the
Common Agreement and applying for
designation. The RCE will then begin
onboarding and designating QHINs to
share information. In 2023, HHS expects
interested parties across the care
continuum to have increasing
opportunities to enable exchange under
TEFCA. Specifically, this would mean
such interested parties would be: (1)
signatories to either the Common
Agreement or an agreement that meets
the flow-down requirements of the
Common Agreement (called a
Framework Agreement 1117 under the
Common Agreement), (2) in good
standing (that is not suspended) under
that agreement, and (3) enabling secure,
bi-directional exchange of information
to occur, in production. TEFCA is
expected to give individuals and entities
easier, more efficient access to more
health information. The Common
Agreement will require strong privacy
and security protections for all entities
who elect to participate, including
entities not covered by the Health
Insurance Portability and
Accountability Act (HIPAA).1118
By connecting to an entity that
connects to a QHIN or connecting
directly to a QHIN, an eligible hospital
or CAH can share health information in
the same manner as described in the
attestation statements previously
finalized for the HIE Bi-Directional
Exchange measure (42 CFR
495.24(e)(6)(ii)(C)). By connecting to an
entity that connects to a QHIN, or
connecting directly to a QHIN, that
supports sharing information on
patients as part of a Framework
Agreement,1119 an eligible hospital or
1117 The Common Agreement defines
‘‘Framework Agreement(s)’’ as: ‘‘any one or
combination of the Common Agreement, a
Participant-QHIN Agreement, a ParticipantSubparticipant Agreement, or a Downstream
Subparticipant Agreement, as applicable.’’ See
Common Agreement for Nationwide Health
Information Interoperability Version 1, at 6 (Jan.
2022) https://www.healthit.gov/sites/default/files/
page/2022-01/Common_Agreement_for_
Nationwide_Health_Information_Interoperability_
Version_1.pdf.
1118 Common Agreement for Nationwide Health
Information Interoperability Version 1 (Jan. 2022),
https://www.healthit.gov/sites/default/files/page/
2022-01/Common_Agreement_for_Nationwide_
Health_Information_Interoperability_Version_1.pdf.
1119 The Common Agreement defines
‘‘Framework Agreement(s)’’ as: ‘‘any one or
combination of the Common Agreement, a
Participant-QHIN Agreement, a ParticipantSubparticipant Agreement, or a Downstream
Subparticipant Agreement, as applicable.’’ See
Common Agreement for Nationwide Health
Information Interoperability Version 1, at 6 (Jan.
E:\FR\FM\10AUR2.SGM
Continued
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49330
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
CAH would be thereby enabling bidirectional exchange with other health
care providers as described in Statement
1 of the HIE Bi-Directional Exchange
measure. Since participation in a
Framework Agreement as a QHIN,
Participant, or Sub-participant will be
open to all qualifying entities and will
not be restricted by use of a single
vendor, a connection via a Framework
Agreement would also satisfy the
requirements of Statement 2 of the HIE
Bi-Directional Exchange measure.
Finally, as discussed previously, the
technical requirements for exchanging
information by entities through the
Common Agreement and Framework
Agreements utilize standards included
in certified technology referenced under
the CEHRT definition (see 42 CFR
495.4), including the ability to exchange
and receive data using the C–CDA
standard (see certification criteria at 45
CFR 170.315(b)(1) and (2)), thus health
care providers participating in a
Framework Agreement can use the
functions of CEHRT to support bidirectional exchange with an HIE.
To offer health care providers more
opportunities to earn credit for the
Health Information Exchange Objective,
and given the alignment between
enabling exchange under TEFCA and
the existing HIE Bi-Directional
Exchange measure, in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28582
through 28585), we proposed to add an
additional measure through which an
eligible hospital or CAH could earn
credit for the Health Information
Exchange Objective by connecting to an
entity that connects to a QHIN or
connecting directly to a QHIN.
Specifically, we proposed to add the
following new measure to the Health
Information Exchange Objective
beginning with the EHR reporting
period in CY 2023: Enabling Exchange
Under TEFCA measure. We proposed
that eligible hospitals and CAHs would
have three reporting options for the
Health Information Exchange Objective:
(1) report on both the Support
Electronic Referral Loops by Sending
Health Information measure and the
Support Electronic Referral Loops by
Receiving and Reconciling Health
Information measure, (2) report on the
HIE Bi-Directional Exchange measure,
or (3) report on the proposed Enabling
Exchange Under TEFCA measure.
We proposed that the Enabling
Exchange Under TEFCA measure would
be worth the total amount of points
2022) https://www.healthit.gov/sites/default/files/
page/2022-01/Common_Agreement_for_
Nationwide_Health_Information_Interoperability_
Version_1.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
available for the Health Information
Exchange Objective. Under the current
scoring methodology finalized in the FY
2022 IPPS/LTCH PPS final rule, the
Health Information Exchange Objective
is worth a total of 40 points (86 FR
45466). We noted in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28589)
that we were proposing changes to the
scoring methodology beginning with the
EHR reporting period in CY 2023 such
that the Health Information Exchange
Objective would be worth no more than
30 points. Therefore, under our
proposal, the proposed Enabling
Exchange Under TEFCA measure would
be worth 30 points. We proposed this
change to the scoring methodology as a
result of our proposal in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28579) to make the Query of PDMP
measure required and worth 10 points.
However, we stated that should we not
finalize the Query of PDMP measure
proposal, we proposed that the Enabling
Exchange Under TEFCA measure would
be worth 40 points (the current total
point value of the Health Information
Exchange Objective). In no case could
more than 40 points total be earned for
the Health Information Exchange
Objective. In the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28593
through 28594), we proposed to remove
text for the objectives and measures
from paragraph (e) under 42 CFR 495.24
beginning in CY 2023. We stated that if
we do not finalize that proposal, we
would revise 42 CFR 495.24(e) to reflect
the addition of the proposed Enabling
Exchange Under TEFCA measure.
We stated that we believe the new
measure for enabling exchange under
TEFCA that we proposed would
incentivize eligible hospitals and CAHs
to exchange information by connecting
directly or indirectly to a QHIN and
support health information exchange at
a national level. We believe that
fulfillment of this measure is an
extremely high value action. The overall
TEFCA goal of establishing a universal
floor of interoperability across the
country aligns with our commitment to
promoting and prioritizing
interoperability and exchange of
healthcare data. Incentivizing providers
to enable exchange under TEFCA is a
critical component to advancing
healthcare data exchange nationwide.
We proposed that eligible hospitals and
CAHs would report the Enabling
Exchange Under TEFCA measure by
attestation, and the measure would
require a ‘‘yes/no’’ response. A ‘‘yes’’
response would enable eligible hospitals
and CAHs to earn the proposed 30
points allotted to the Health Information
PO 00000
Frm 00552
Fmt 4701
Sfmt 4700
Exchange Objective. Further, we
proposed that this measure may be
calculated by reviewing only the actions
for patients whose records are
maintained using CEHRT. A patient’s
record is maintained using CEHRT if
sufficient data were entered in the
CEHRT to allow the record to be saved,
and not rejected due to incomplete data.
We proposed that eligible hospitals
and CAHs would attest to the following:
• Participating as a signatory to a
Framework Agreement (as that term is
defined by the Common Agreement for
Nationwide Health Information
Interoperability as published in the
Federal Register and on ONC’s website)
(in good standing, that is, not
suspended) and enabling secure, bidirectional exchange of information to
occur, in production, for all unique
patients discharged from the eligible
hospital or CAH inpatient or emergency
department (POS 21 or 23), and all
unique patient records stored or
maintained in the EHR for these
departments, during the EHR reporting
period in accordance with applicable
law and policy.
• Using the functions of CEHRT to
support bi-directional exchange of
patient information, in production,
under this Framework Agreement.
Similar to the HIE Bi-Directional
Exchange measure, to successfully attest
to this measure, we proposed the
eligible hospital or CAH must use the
capabilities of CEHRT to support bidirectional exchange under a
Framework Agreement, which includes
capabilities that support exchanging the
clinical data within the Common
Clinical Data Set (CCDS) or the United
States Core Data for Interoperability
(USCDI). This is consistent with the
other measures under the Health
Information Exchange Objective, which
point to the use of CEHRT to support
the exchange of the clinical data within
the CCDS or the USCDI. We note that,
beginning in 2023, when this measure
would be available for eligible hospitals
and CAHs to report eligible hospitals
and CAHs must use certified health IT
that has been updated consistent with
the 2015 Edition Cures Update,
including updates to relevant
certification criteria to reference the
USCDI instead of the CCDS (85 FR
25642).
We stated that we believe there are
numerous certified health IT
capabilities that can support bidirectional exchange under a
Framework Agreement. For instance,
participants may exchange information
under a Framework Agreement by using
technology certified to the criterion at
45 CFR 170.315(b)(1), ‘‘Care
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
coordination—Transitions of care,’’ to
transmit C–CDAs across a network.
Where supported, participants could
also utilize API technology certified to
either the criterion at 45 CFR
170.315(g)(8), ‘‘Design and
performance—Application access—data
category request,’’ or (g)(10), ‘‘Design
and performance—Standardized API for
patient and population services,’’ as
finalized in the ONC 21st Century Cures
Act final rule (85 FR 25742), to enable
exchange of data in the USCDI from a
participant’s EHR. Additional certified
health IT modules may also support
exchange of information under a
Framework Agreement for transitions of
care, including modules certified to
certification criteria at 45 CFR
170.315(g)(7), ‘‘Design and
performance—Application access—
patient selection,’’ and (g)(9), ‘‘Design
and performance—Application access—
all data request,’’ which support
information exchange via API; the
certification criterion at 45 CFR
170.315(e)(1), ‘‘Patient engagement—
View, download, and transmit to 3rd
party,’’ which supports patient access to
their information; and the certification
criterion at 45 CFR 170.315(g)(6),
‘‘Design and performance—
Consolidated CDA creation
performance,’’ which supports creation
of a summary of care record. We
recognize that entities that will connect
directly or indirectly to a QHIN are
currently interacting with health care
providers using certified health IT in a
variety of ways, and, as with the HIE BiDirectional Exchange measure, believe
that we should allow for substantial
flexibility in how health care providers
use certified health IT to exchange data
under a Framework Agreement.
We stated that the Enabling Exchange
Under TEFCA measure could offer
health care providers an alternative to
earn credit for the Health Information
Exchange Objective. The Enabling
Exchange Under TEFCA measure would
not require an eligible hospital or CAH
to assess whether they participate in a
health information exchange that meets
the attributes of attestation Statement 2
under the HIE Bi-Directional Exchange
measure regarding exchange across a
broad network of unaffiliated exchange
partners including those using disparate
EHRs. These attributes are key to the
goals of TEFCA, which aims to offer
health care providers a uniform set of
expectations around information
sharing regardless of which network for
information exchange they participate
in.
We invited public comment on these
proposals.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Comment: Many commenters
expressed support for the proposal. A
few commenters believed the measure
would allow health care providers to
have options to meet this objective that
enable more broad-based data exchange
across the health ecosystem and utilize
TEFCA when appropriate. Many
commenters expressed support for the
adoption of the Enabling Exchange
Under TEFCA measure as a means to
advance health information exchange
and interoperability on a national level.
A commenter suggested that this
improved means toward interoperability
would help optimize patient care.
Another commenter believed the
measure would support compliance
with the regulations finalized in the
ONC 21st Cures Act Final Rule. Several
commenters noted the measure would
promote capabilities for bi-directional
exchange, which they believed would
be critical to advancing effective
interoperability. A few commenters
noted the measure would help improve
health care provider reporting. A few
commenters thanked CMS for a flexible
model that would allow newly created
programs to mature and reduce burdens
associated with participation
requirements, all while incentivizing
participation in TEFCA.
Response: We thank commenters for
their support and feedback. We agree
that adding a third measure under the
Health Information Exchange Objective
to offer an additional path to earn credit
and accelerate the bi-directional
exchange of health information is
consistent with the goals of the HIE
Objective and aligns with the overall
goal to promote nationwide
interoperability.
Comment: A few commenters
expressed specific support for CMS’ and
ONC’s collaboration in making TEFCA a
key pillar in the nationwide strategy to
establish a ‘‘floor’’ and framework for
health data interoperability and
exchange.
Response: We thank commenters for
recognizing our continued efforts
toward alignment and inter-agency
collaboration. CMS and ONC will
continue to collaborate and work with
interested parties on TEFCA
implementation to support
advancements in health information
exchange.
Comment: A few commenters
expressed support for the Enabling
Exchange under TEFCA measure as a
means to position TEFCA to be a more
effective mechanism for data delivery
for a range of important use cases, such
as patient access and patient-centered
care.
PO 00000
Frm 00553
Fmt 4701
Sfmt 4700
49331
Response: We thank commenters for
their support. We believe that
widespread adoption of the Common
Agreement will facilitate patients,
health care providers, payers, HINs,
health IT developers, and other
interested parties having access to data
when and where it is needed to better
support patient care.
Comment: Many commenters
expressed support around the optional
or alternative nature of this measure,
specifically citing concerns around the
technical maturity and functionality of
TEFCA. Several commenters cautioned
against requiring this measure without
first confirming that the infrastructure is
mature and widespread enough to
support the requirements. For example,
a few commenters expressed concern
around whether there would be an
available QHIN in which to participate
in time for the 2023 reporting period.
Response: We thank the commenters
for their support and acknowledge these
concerns. We note that TEFCA will be
operationalized in 2022 before the start
of the EHR reporting period in CY 2023,
and that the Enabling Exchange under
TEFCA measure was proposed as an
optional alternative for the HIE
Objective beginning with the EHR
reporting period in CY 2023. We
anticipate that TEFCA will provide a
valuable pathway for health care
providers to access information needed
to support value-based care, care
management, and population health. By
connecting a set of nationwide, trusted
health information networks and
creating baseline legal and technical
requirements that would enable secure
information sharing across different
networks nationwide, TEFCA has the
potential to significantly reduce the
need for duplicative network
connectivity interfaces, which are
costly, complex to create and maintain,
and an inefficient use of health care
provider and health IT developer
resources. As more eligible hospitals
and CAHs enable exchange under
TEFCA and are able to report on this
new measure, we believe technical
maturity and functionality of health
information exchange will also continue
to significantly improve.
Comment: A commenter suggested
CMS should consider the impact on
eligible hospitals and CAHs if TEFCA
participation were to become unstable
due to entities that facilitate exchange
not meeting relevant terms and
conditions and offer a hardship
exception if a health care provider’s
ability to exchange information under
TEFCA were to be limited or terminated
due to suspension/termination of an
entity which a provider relies upon in
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49332
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
order to exchange information under
TEFCA. Another commenter expressed
related concerns and stated that CMS
should add exceptions to the Enabling
Exchange under TEFCA measure to
allow for potential trickle-down effect
disruptions that are beyond the control
of eligible hospitals and CAHs.
Response: We understand that there
could be a scenario in which an eligible
hospital or CAH is unable to exchange
information under the Common
Agreement or a Framework Agreement
for the duration of a reporting period
using a specific entity due to that entity
being terminated or suspended under
the terms of the Common Agreement or
an associated Framework Agreement. In
such cases, an eligible hospital or CAH
could explore connecting to a different
QHIN, Participant, or Subparticipant,
which could enable the exchange of
health information by the eligible
hospital or CAH, limit the disruption,
and potentially allow the eligible
hospital or CAH to continue to attest to
the statements required for the measure.
If the eligible hospital or CAH is not
able to connect to a different QHIN,
Participant, or Subparticipant, the
eligible hospital or CAH would likely no
longer be able to attest ‘‘yes’’ to the
statements required for the measure. In
such cases, the eligible hospital or CAH
could select one or more of the other
measures that are included under the
HIE Objective (for instance, the HIE Bidirectional measure could still be
relevant if an eligible hospital or CAH
can continue to use a network
previously connected under TEFCA).
We do not believe a hardship exception
would be necessary for the Enabling
Exchange Under TEFCA measure
because it is an optional measure.
Comment: Several commenters, in
addition to expressing support for the
proposed measure, offered additional
recommendations for future efforts. A
few commenters suggested continued
collaboration among CMS, ONC and
other entities to support TEFCA
implementation. A commenter
recommended CMS consider future
measures that would further support
health care provider interactions with
payers for processes such as coverage
requirements discovery and submission
of prior authorization requests. Another
commenter noted there are similar,
already existing private sector solutions
that seek to accomplish the same goals
as this measure. This commenter
recommended government participation
in those efforts to expand impact of this
measure. A commenter recommended
CMS consider innovative technologies
like blockchain within TEFCA.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Response: We appreciate these
recommendations. ONC and CMS will
continue to work together to explore
how TEFCA can support a wide range
of CMS programs and activities.
Furthermore, we note that ONC and
CMS invite collaboration around TEFCA
by all private sector solutions that are
seeking to accomplish the same goal of
advancing interoperability nationwide.
Comment: Several commenters did
not support the proposed measure.
These commenters suggested CMS
proceed with caution when adding a
new measure related to TEFCA before
additional TEFCA milestones are
achieved, citing uncertainties around
how TEFCA will function and the lack
of details around participation to fully
understand all of its implications. A
commenter suggested CMS wait to
implement the measure until TEFCA
transitions from the ‘‘TEFCA
Transitional Council’’ advisory group to
the full ‘‘TEFCA Governing Council,’’
which, according to the commenter,
would signal that the QHINs are
operational and ready to govern the
Common Agreement themselves.
Another commenter cited the lack of
standard operating procedures released
by the RCE. This commenter believed
that the measure could encourage
eligible hospitals and CAHs to shift
from more mature and interoperable
networks, leading to an overall decrease
in interoperability. Another commenter
suggested CMS postpone this measure
until at least CY 2024, after data
exchange under TEFCA has been
initiated.
Response: We thank the commenters
for their feedback and acknowledge
these concerns. The Trusted Exchange
Framework and the Common Agreement
Version 1 were published in January
2022, and entities will soon be able to
apply to be designated as QHINs. By
proposing this as an optional measure,
hospitals may opt into reporting if they
are ready to exchange information under
TEFCA, but including this optional
measure does not create any
requirement for eligible hospitals and
CAHs to exchange information under
TEFCA if they choose not to at this time
due to concerns such as those expressed
by commenters around postponing the
measure. We are hopeful that the
finalization of this proposal will help
incentivize readiness as well as increase
participation in exchange under TEFCA.
We disagree with commenters that this
measure should be postponed, or that
the measure would pose a threat to
current progress towards
interoperability.
Comment: A few commenters did not
support the measure because they
PO 00000
Frm 00554
Fmt 4701
Sfmt 4700
believed it duplicates the HIE BiDirectional Exchange measure and
therefore may be confusing to health
care providers. These commenters state
that the current HIE Bi-Directional
measure would allow participants in
TEFCA to claim credit for the objective.
A commenter recommended a step-wise
approach for facilities to allow a ramp
up to compliance while meeting other
interoperability requirements
simultaneously.
Response: We thank the commenters
for their feedback and acknowledge this
concern. We disagree that the Enabling
Exchange under TEFCA measure is
duplicative of the HIE Bi-Directional
Exchange measure. Instead, we believe
the optional Enabling Exchange under
TEFCA measure would complement the
HIE Bi-Directional Exchange measure by
providing a convenient option for those
who enable exchange under TEFCA to
claim credit for the HIE objective. At
this time, we believe, it is unclear what
a step-wise approach would look like,
given the binary nature of TEFCA
participation, and do not believe a stepwise approach would more effectively
support participation. We expect that
many eligible hospitals and CAHs will
already be participating in health
information networks that will enable
exchange under the TEFCA and would
not need to engage in an incremental
process in order to begin attesting to this
measure in 2023.
Comment: Several commenters
offered recommendations for CMS with
regard to this measure. A few
commenters suggested CMS should add
this optional measure for eligible
clinicians to report under the Promoting
Interoperability performance category of
MIPS. Several commenters suggested
CMS provide resources on the benefits
of TEFCA and reasons why eligible
hospitals and CAHs should invest in
exchanging information under TEFCA,
including how eligible hospitals or
CAHs can justify additional investments
to hospital boards and communities for
exchange under TEFCA.
Response: We appreciate this
feedback and will take these comments
into consideration for future
rulemaking. Regarding a complementary
proposal for eligible clinicians in MIPS,
we refer readers to the 2023 PFS NPRM,
in which we have proposed a similar
measure for inclusion in the Promoting
Interoperability performance
category.1120
1120 See https://www.federalregister.gov/publicinspection/2022-14562/medicare-and-medicaidprograms-calendar-year-2023-payment-policiesunder-the-physician-fee-schedule.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Regarding resources on the benefits of
TEFCA and reasons why eligible
hospitals and CAHs should invest in
exchanging information under TEFCA,
we note that some resources are already
available on this topic, including an
information resource developed by the
RCE entitled ‘‘The Nationwide Network
Based on the Common Agreement
Benefits for Health Care Providers
Across the Continuum.’’ 1121 However,
we will continue to collaborate with
ONC and other partners to identify
resources that can help providers to
better understand the benefits of
TEFCA, and invite public comment on
what kinds of resources would be most
useful to stakeholders.
Comment: Commenters recommended
that the alternative measure require
eligible hospitals and CAHs to attest to
facilitating exchange for all required
Exchange Purposes, including
Individual Access Services. A
commenter recommended that CMS
should increase incentives for the use of
HIEs for Exchange Purposes beyond
Treatment, so as not to go against
information blocking rules, furthering
the need for HIEs to facilitate data
exchange for a broad range of purposes
authorized by law. Another commenter
suggested that CMS and ONC coordinate
to ensure measures that reference
TEFCA include measurement of
participation in the Individual Access
Services Exchange Purpose in addition
to Treatment, Payment, and Health Care
Operations Exchange Purposes.
Response: For this Enabling Exchange
under TEFCA measure, we have focused
on aligning with the goals of the HIE
Objective which pertains to care
coordination and exchange between
health care providers. However, we will
consider whether this model can be
applied to other Promoting
Interoperability objectives that may
align with other TEFCA Exchange
Purposes, such as IAS, in the future. We
do believe that HIEs can support other
Exchange Purposes beyond Treatment
and will continue to explore ways to
incentivize these use cases. Finally, we
do not believe there is any conflict
between incentives for care
coordination under this proposal and
the information blocking rules. We refer
readers to the resources around TEFCA
cited in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28582 through
28585).1122 1123 1124 1125 1126 1127 CMS
1121 See https://rce.sequoiaproject.org/wpcontent/uploads/2022/01/RCE_LeveragingNationwide-Exchange_Providers_1.2-RCE-Final.pdf.
1122 Blog post, 3...2...1...TEFCA is Go for Launch.
Published: January 19, 2022. https://
www.healthit.gov/buzz-blog/interoperability/
321tefca-is-go-for-launch.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
will continue to explore additional
opportunities to provide further
education and outreach regarding
TEFCA.
Comment: A commenter requested
clarification from CMS on requirements
for health care providers participating in
multiple state HIEs, including hospitals
near state borders.
Response: For health care providers
near state borders, there is no specific
requirement that an eligible hospital or
CAH must ensure that exchange enabled
under TEFCA includes health care
providers in a neighboring state with
which a health care provider may need
to share information. However, we
believe that by enabling exchange across
networks nationwide, providers
exchanging information under TEFCA
will be more likely to be able to
effectively exchange information across
state lines.
Comment: A commenter suggested
CMS should clarify that the exchange of
patient summaries or other patient data
need not occur for all unique patients
but only as needed or requested. A
commenter requested clarity on the
definition of ‘‘enable’’ in the context of
this measure.
Response: We thank commenters for
their feedback. The first attestation
statement, as proposed, would require
an eligible hospital or CAH to enable
secure, bi-directional exchange of
information to occur under a
Framework Agreement. As we noted in
our discussion of the final policy for the
HIE Bi-Directional Measure (86 FR
45468), enabling bi-directional exchange
does not mean that an eligible hospital
or CAH would be required to conduct
1123 Website, Trusted Exchange Framework and
Common Agreement (TEFCA), January 2022.
https://www.HealthIT.gov/TEFCA.
1124 Policy document, The Trusted Exchange
Framework (TEF): Principles for Trusted Exchange,
January 2022. Available at https://
www.healthit.gov/sites/default/files/page/2022-01/
Trusted_Exchange_Framework_0122.pdf.
1125 Policy document, Common Agreement for
Nationwide Health Information Interoperability
Version 1, January 2022. Available at https://
www.healthit.gov/sites/default/files/page/2022-01/
Common_Agreement_for_Nationwide_Health_
Information_Interoperability_Version_1.pdf.
1126 Policy document, Qualified Health
Information Network (QHIN) Technical Framework
(QTF) Version 1.0, January 2022. Available at
https://rce.sequoiaproject.org/wp-content/uploads/
2022/01/QTF_0122.pdf.
1127 Press release, ONC Awards The Sequoia
Project a Cooperative Agreement for the Trusted
Exchange Framework and Common Agreement to
Support Advancing Nationwide Interoperability of
Electronic Health Information. Published
September 4, 2019. Available at https://
sequoiaproject.org/onc-awards-the-sequoia-projecta-cooperative-agreement-for-the-trusted-exchangeframework-and-common-agreement-to-supportadvancing-nationwide-interoperability-ofelectronic-health-information/.
PO 00000
Frm 00555
Fmt 4701
Sfmt 4700
49333
information transactions that are not
clinically necessary. Rather, it means
that an eligible hospital or CAH has
established the capabilities necessary to
complete exchanges of information for
its patients at the appropriate time. In
the case of the Enabling Exchange under
TEFCA measure, this means the
capabilities to exchange information
under a Framework Agreement.
Comment: Commenters requested
clarity around what data is to be
exchanged and whether there is an
expectation to incorporate any of the
exchanged information into the patient
chart as with the current HIE Objective
measure ‘‘Support Electronic Referral
Loops by Receiving and Reconciling
Health Information,’’ for instance,
through reconciliation of parsed data
from received C–CDAs.
Response: We note that, at a
minimum, TEFCA requires the
exchange of all available data elements
from USCDI Version 1.1128 Health care
providers participating in a Framework
Agreement and attesting to this measure
would be required to exchange data
according to the terms of the Framework
Agreement. Regarding reconciliation of
information, the requirements for the
measure are limited to attesting to the
statements related to engaging in bidirectional exchange under a
Framework Agreement using the
functions of CEHRT. There are no
additional explicit requirements related
to how the health care provider must
incorporate information received under
the Framework Agreement into the
patient’s record.
Comment: Another commenter
requested clarity on the definition of
‘‘calculated’’ in the context of this
measure.
Response: Thank you for the
comment. We wish to clarify that the
proposed attestation statements do not
require an eligible hospital or CAH to
perform calculations, as part of this
measure, such as those necessary for
measures that are based on reporting of
a numerator and denominator and count
unique patients or actions. Therefore,
we are not finalizing our proposal that
this measure may be calculated by
reviewing only the actions for patients
whose records are maintained using
CEHRT, as this proposal is not relevant
to the measure.
Comment: A commenter requested
CMS provide further clarity on how to
document completion of this measure
and what would suffice as a
1128 See QHIN Technical Framework, at QTF–047
and QTF–092, available at https://
rce.sequoiaproject.org/wp-content/uploads/2022/
01/QTF_0122.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49334
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
demonstration of the capacity to
exchange information with others
efficiently and effectively.
Response: In order to successfully
‘‘complete’’ this measure, eligible
hospitals and CAHs must attest to the
required statements. Completion of the
measure would be limited to attesting to
the required statements. For audit
purposes, eligible hospitals and CAHs
should retain evidence of their
agreement with a QHIN, Participant, or
Subparticipant that includes the terms
of a Framework Agreement.
Comment: A few commenters who
supported the measure also expressed
some concerns regarding this measure.
A commenter believed CMS is adding
technical requirements without
confirming that the functionality of
vendor systems is useful with regard to
system integration, user interface, or
workflow of the technology, placing this
burden on eligible hospitals and CAHs.
This commenter requested that CMS
and ONC reassess measurement of
compliance for vendor systems. Another
commenter cautioned CMS against
offering a measure based on enabling
information exchange under TEFCA
because they believed TEFCA
implementation will be slow and
additional milestones should be
confirmed and achieved first.
Response: We appreciate commenters’
feedback and acknowledge these
concerns. In order to attest to this
measure, the eligible hospital or CAH
must use the functions of CEHRT to
connect directly or indirectly to a QHIN.
As noted in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28585) and
reiterated above, there are currently a
number of certified health IT
capabilities that support the technical
requirements for exchange under
TEFCA, thus these capabilities would be
useful for participation in exchange
under TEFCA and earning credit under
this measure. We believe that by
finalizing this measure as optional,
eligible hospitals and CAHs can opt in
to reporting it once they are ready to
enable exchange under TEFCA and are
confident in the infrastructure.
After consideration of the public
comments we received, we are
finalizing our proposal to add an
additional measure through which an
eligible hospital or CAH could earn
credit for the Health Information
Exchange Objective by connecting to an
entity that connects to a QHIN or
connecting directly to a QHIN. We are
finalizing our proposal to add this
measure to the Health Information
Exchange Objective beginning with the
EHR reporting period in CY 2023:
Enabling Exchange Under TEFCA
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
measure. We are finalizing our proposal
that eligible hospitals and CAHs will
now have three reporting options for the
Health Information Exchange Objective:
(1) Report on both the Support
Electronic Referral Loops by Sending
Health Information measure and the
Support Electronic Referral Loops by
Receiving and Reconciling Health
Information measure, (2) report on the
HIE Bi-Directional Exchange measure,
or (3) report on the Enabling Exchange
Under TEFCA measure. We are
finalizing our proposal that the Enabling
Exchange Under TEFCA measure would
be worth the total amount of points
available for the Health Information
Exchange Objective. We are finalizing
our proposal in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28589
through 28591) to change the scoring
methodology beginning with the EHR
reporting period in CY 2023, such that
the Health Information Exchange
Objective would be worth no more than
30 points, therefore we are finalizing
our proposal that the Enabling Exchange
Under TEFCA measure would be worth
30 points. We are finalizing our
proposal that eligible hospitals and
CAHs would report the Enabling
Exchange Under TEFCA measure by
attestation, and that the measure would
require a ‘‘yes/no’’ response. We are not
finalizing our proposal that this measure
be calculated by reviewing only the
actions for patients whose records are
maintained using CEHRT as
calculations are not necessary for this
measure, which instead requires
attestation to the specified statements.
We are finalizing our proposal that
eligible hospitals and CAHs would
attest to the following: Participating as
a signatory to a Framework Agreement
(as that term is defined by the Common
Agreement for Nationwide Health
Information Interoperability as
published in the Federal Register and
on ONC’s website) (in good standing
that is, not suspended) and enabling
secure, bi-directional exchange of
information to occur, in production, for
all unique patients discharged from the
eligible hospital or CAH inpatient or
emergency department (POS 21 or 23),
and all unique patient records stored or
maintained in the EHR for these
departments, during the EHR reporting
period in accordance with applicable
law and policy; and using the functions
of CEHRT to support bi-directional
exchange of patient information in
production, under this Framework
Agreement. We refer readers to the FY
2023 IPPS/LTCH PPS proposed rule for
additional information on certified
health IT capabilities that can support
PO 00000
Frm 00556
Fmt 4701
Sfmt 4700
bi-directional exchange under a
Framework Agreement (87 FR 28582
through 28585). Additionally, we are
finalizing our proposal in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28593 through 28594) to remove
associated regulatory text, therefore, we
will not be updating 42 CFR 495.24(e)
to reflect the addition of the Enabling
Exchange Under TEFCA measure.
5. Public Health and Clinical Data
Exchange Objective
a. Background
The Medicare Promoting
Interoperability Program for eligible
hospitals and CAHs has been an
important mechanism for encouraging
healthcare data exchange for public
health purposes through the Public
Health and Clinical Data Exchange
Objective. Effective responses to public
health events, such as the COVID–19
PHE, require fast, accurate exchange of
data between health care providers and
Federal, state, and local public health
agencies (PHAs). Health care providers
collect these data for patient care, and
PHAs need them to protect the public,
whether to track an outbreak, initiate
contact tracing, find gaps in vaccine
coverage, or pinpoint the source of a
foodborne outbreak.
There are six measures under the
Public Health and Clinical Data
Exchange Objective: Immunization
Registry Reporting, Syndromic
Surveillance Reporting, Electronic Case
Reporting, Electronic Reportable
Laboratory (ELR) Result Reporting,
Public Health Registry Reporting, and
Clinical Data Registry Reporting. For
background on this objective and its
associated measures, we refer readers to
the FY 2019 IPPS/LTCH PPS final rule
(83 FR 41665 through 41667), and the
FY 2022 IPPS/LTCH PPS final rule (86
FR 45470 through 45479). In the FY
2022 IPPS/LTCH PPS final rule (86 FR
45470 through 45479), we finalized the
requirement for eligible hospitals and
CAHs to report four of the six of the
measures associated with the Public
Health and Clinical Data Exchange
Objective, beginning with the EHR
reporting period in CY 2022: Syndromic
Surveillance Reporting; Immunization
Registry Reporting; Electronic Case
Reporting; and Electronic Reportable
Laboratory Result Reporting. These four
measures will put PHAs on better
footing for future health threats and a
long-term COVID–19 pandemic recovery
by strengthening three important public
health functions: (1) early warning
surveillance, (2) case surveillance, and
(3) vaccine uptake. Requiring these
measures will enable nationwide
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
syndromic surveillance for early
warning of emerging outbreaks and
threats; automated case and laboratory
reporting for fast public health response;
and local and national visibility on
immunization uptake so PHAs can tailor
vaccine distribution strategies.
khammond on DSKJM1Z7X2PROD with RULES2
b. Modifications to the Reporting
Requirements for the Public Health and
Clinical Data Exchange Objective:
Antimicrobial Use and Resistance
(AUR) Surveillance Measure
Antimicrobial-resistant (AR)
infections are caused by pathogens that
no longer respond to the drugs designed
to kill them and directly threaten
patient and population health. An
effective national response to the threat
presented by antimicrobial resistant
bacteria requires robust systems for
systematically collecting, analyzing, and
using antimicrobial use and resistance
data to direct action.
Each year in the United States, more
than three million people are infected
by an antimicrobial-resistant pathogen
or C. difficile (an opportunistic
pathogen associated with antimicrobial
use), and nearly 50,000 people die.1129
As more pathogens become resistant to
available antimicrobials, options for
reliably and rapidly treating
infections—including pneumonias,
foodborne illnesses, and healthcareassociated infections—become
increasingly limited, more expensive
and, in some cases, nonexistent. The
CDC has found that one-third to onehalf of all antimicrobials used in
inpatient and outpatient settings are
either unnecessary or prescribed
incorrectly.1130 The misuse and overuse
of antimicrobials both facilitates the
emergence of drug-resistant pathogens
and exposes patients to needless risk for
adverse effects. AR infections can also
complicate the response to and recovery
from other serious health risks, such as
COVID–19. Rates of AR infections have
increased in healthcare settings since
the beginning of the COVID–19
pandemic, reversing previous
prevention successes such as declines of
AR infections by as much as 30 percent
prior to the pandemic.1131 Additionally,
Methicillin-resistant Staphylococcus
aureus (MRSA) infections increased five
consecutive quarters from 2020 to 2021,
1129 CDC. Antibiotic Resistance Threats in the
United States, 2019. Atlanta, GA: U.S. Department
of Health and Human Services, CDC; 2019.
1130 CDC. Antibiotic Use in the United States,
2018 Update: Progress and Opportunities. Atlanta,
GA: US Department of Health and Human Services,
CDC; 2019.
1131 CDC. 2020 National and State HealthcareAssociated Infections Progress Report. Atlanta, GA:
U.S. Department of Health and Human Services,
CDC; 2021.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
including some quarter over quarter
increases of 39 percent.1132
Strengthening of infection prevention
and control and antibiotic stewardship
is needed to address these challenges
and ensure a solid foundation for future
public health emergencies.
As outlined in the National Action
Plan for Combating Antibiotic-Resistant
Bacteria (CARB), 2020–2025,1133 an
effective national response to the threat
presented by AR bacteria and fungi
depends in part on slowing the
emergence of new resistant threats and
preventing the spread of existing
resistant infections. Successfully
meeting this goal, in turn, requires
robust systems for collecting, analyzing,
and using AUR data to direct action.
Systematically collecting AUR data also
helps inform the availability and
potential need for new antibiotics to
address emerging forms of resistance.
Antimicrobial use (AU) data delivered
to antimicrobial stewardship programs
(ASPs) enable stewards to develop,
select, and assess interventions aimed at
optimizing antimicrobial prescribing.
These interventions, in turn, serve to
improve antimicrobial treatment
effectiveness, protect patients from
harms caused by unnecessary
antimicrobial exposure, and curb
antimicrobial resistance associated with
prophylactic and therapeutic excess.
Studies have shown that ASPs can help
slow the emergence of antimicrobial
resistance while optimizing treatment
and minimizing costs—all in support of
safe and appropriate care for patients.
Antimicrobial resistance data can aid
in clinical decision making (hospital
cumulative antibiograms) and direct
transmission prevention and
antimicrobial stewardship efforts. With
timely and complete reporting, these
data can also facilitate rapid
identification and control of potential
outbreaks, as well as longer term
assessment of progression or
improvement to guide public health
response efforts. Currently, acute care
hospitals and CAHs voluntarily report
to CDC’s National Healthcare Safety
Network’s (NHSN) AUR Module with
approximately 2000 eligible hospitals
and 1000 CAHS reporting on AUR
1132 Weiner-Lastinger, Lindsey M., et al. ‘‘The
Impact of Coronavirus Disease 2019 (COVID–19) on
Healthcare-Associated Infections in 2020: A
Summary of Data Reported to the National
Healthcare Safety Network.’’ Infection Control &
Hospital Epidemiology, vol. 43, no. 1, 2022, pp. 12–
25., doi:10.1017/ice.2021.362.
1133 Office of the Assistant Secretary for Planning
and Evaluation (ASPE). (2020). National Action
Plan for Combatting Antibiotic-Resistant Bacteria,
2020–2025. Available at: https://aspe.hhs.gov/
reports/national-action-plan-combating-antibioticresistant-bacteria-2020-2025.
PO 00000
Frm 00557
Fmt 4701
Sfmt 4700
49335
NHSN. Compared to the hospitals that
have not reported AUR data, those that
reported were more likely to be larger
and teaching hospitals.
The extensive voluntary participation
in NHSN’s AUR surveillance, which
calls for hospitals to buy or build an
AUR reporting solution, indicates that
thousands of hospitals see value in
NHSN’s AUR surveillance. However,
incomplete participation in NHSN’s
AUR surveillance limits the
generalizability of the AUR data: The
data are subject to selection bias and do
not provide a comprehensive national
picture. Other comparable NHSN
reporting pathways—such as those used
to report data on blood stream
infections, urinary tract infections, and
other healthcare-associated infections—
are required under CMS quality
reporting and value-based payment
programs, including the Hospital ValueBased Purchasing (VBP) and HospitalAcquired Condition (HAC) Reduction
Programs. In the Hospital VBP and HAC
Reduction Programs, the reporting
coverage and compliance with NHSN
measures is routinely approximately 97
percent. The benefits of monitoring
AUR data for patient care and public
health are most likely to be achieved
when data collection and analysis are
systematic, standardized, and achieve
complete coverage across eligible
facilities. In fact, as more hospitals
participate, the system becomes better at
detecting emerging threats as the
network for data collection grows.
We believe that requiring an AUR
measure under the Medicare Promoting
Interoperability Program would enable
the development of a true national
picture of the threat posed by
antimicrobial overuse and resistance.
Requiring AUR reporting through CDC’s
NHSN would produce inpatient AU and
AR benchmarks that can be used to
guide clinical and public health action
and enable a true national picture of the
threat posed by antimicrobial overuse
and resistance. In the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28586
through 28587), we proposed the
following new AUR Surveillance
measure under the Public Health and
Clinical Data Exchange Objective:
AUR Surveillance measure: The
eligible hospital or CAH is in active
engagement with CDC’s National
Healthcare Safety Network (NHSN) to
submit antimicrobial use and resistance
(AUR) data for the EHR reporting period
and receives a report from NHSN
indicating their successful submission
of AUR data for the EHR reporting
period.
We proposed to require eligible
hospitals and CAHs to report this
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49336
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
measure beginning with the EHR
reporting period in CY 2023. Eligible
hospitals and CAHs that report a ‘‘yes’’
response or an exclusion for which they
are eligible would receive credit for
reporting the measure. Eligible hospitals
and CAHs that report a ‘‘no’’ response
or fail to report any response would not
receive credit for reporting the measure
and would fail to satisfy the Public
Health and Clinical Data Exchange
Objective. No additional points would
be associated with the reporting of this
measure, but it would be one of five
required measures required to satisfy
the Public Health and Clinical Data
Exchange Objective. See the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28589) for further detail on the
proposals and section IX.H.6 of this
final rule for the finalized modification
of the scoring of this objective.
For purposes of this proposed
measure, we proposed eligible hospitals
and CAHs must use technology certified
to the criterion at 45 CFR 170.315(f)(6),
‘‘Transmission to public health
agencies—antimicrobial use and
resistance reporting.’’ We also stated we
were aware of an updated version of the
standard referenced in the criterion 1134
and that we would work with our
partners at CDC and ONC to consider
avenues for addressing use of this
specification within the ONC Health IT
Certification program. We provide
additional information on use of this
updated version below.
We proposed three exclusions for the
AUR Surveillance measure as follows:
the eligible hospital or CAH: (1) Does
not have any patients in any patient care
location for which data are collected by
NHSN during the EHR reporting period;
(2) Does not have electronic medication
administration records (eMAR)/
barcoded medication administration
(BCMA) records or an electronic
admission discharge transfer (ADT)
system during the EHR reporting period;
or (3) Does not have an electronic
laboratory information system (LIS) or
electronic ADT system during the EHR
reporting period (87 FR 28587). We
anticipate reevaluating exclusions #2
and #3 for future EHR reporting periods.
The AUR Surveillance measure would
leverage the standards and functionality
included in certified technology
referenced under the CEHRT definition,
including the ability to transmit to
PHAs for antimicrobial use and
resistance reporting.
We invited public comment on these
proposals. We also invited comments on
the feasibility of the timeline and any
1134 https://www.hl7.org/implement/standards/
product_brief.cfm?product_id=426.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
additional exclusions that we should
consider for this measure for proposal in
future rulemaking.
Comment: Many commenters
supported the proposal to add the AUR
Surveillance measure agreeing on the
critical role this measure would play in
improving antibiotic use and reducing
antibiotic resistance, facilitating
targeting areas for improvement,
providing data critical to tracking
threats and identifying trends
nationwide, informing clinicians, public
health agencies, government, and
policymakers alike. Several commenters
noted the importance of this measure to
provide a much needed national,
generalizable comparison and
benchmarks. A few commenters noted
the utility of this data to potentially
drive increased investment from
Congress to address the rising threat of
adverse events such as antibiotic
resistance.
Response: We appreciate commenters’
support of the proposal to require the
AUR Surveillance measure under the
Public Health and Clinical Data
Exchange Objective. We believe that this
measure will help produce inpatient AU
and AR benchmarks that can be used to
guide clinical and public health action
and enable a true national picture of the
threat posed by antimicrobial overuse
and resistance.
Comment: Many commenters did not
support the proposal to add the AUR
Surveillance measure. Several
commenters stated that the
implementation timeline was too
ambitious and that the financial burden
on health care providers was
substantial. A commenter pointed out
that it is already too late to include this
in the budget for CY 2023 which has, at
the time of the FY 2023 IPPS/LTCH PPS
proposed rule being published, already
been approved. A few commenters
highlighted that the majority of CAHs
will not be ready and thus find
themselves at a substantial
disadvantage. A few commenters noted
that eligible hospitals are still dealing
with burden related to the PHE and
these proposals overwhelm systems
already tasked with substantial COVID–
19 related reporting and clinical
requirements. Many commenters offered
recommendations to delay the adoption
of the AUR Surveillance measure to the
Public Health and Data Exchange
Objective with most recommending a
delay of at least one year and several
recommending alternative periods of
delay. A commenter requested that the
adoption of the measure be delayed
until CEHRT criteria are adopted and
vendors and hospitals have sufficient
time to implement the CEHRT criteria.
PO 00000
Frm 00558
Fmt 4701
Sfmt 4700
A few commenters requested adoption
be delayed until the end of the PHE.
Several commenters recommend making
the measure optional to allow time for
implementation. A commenter noted
that smaller and resource-limited
facilities may need a phase in time not
to exceed two years and another
commenter recommended a phase-in
time with stronger incentives.
Response: We thank the commenters
for their feedback. We believe that the
AUR Surveillance measure is critical to
stem AR infections nationwide, by
providing the necessary AUR data to
direct action. However, we also heard
very clearly from commenters that
eligible hospitals and CAHs continue to
face enormous operational challenges as
a result of the ongoing PHE.
We understand that many
commenters believe that more time may
be needed for health care providers and
EHR vendors to implement the
necessary changes in workflows,
infrastructure and functionality to
report the AUR Surveillance measure.
We recognize more time may be
beneficial for eligible hospitals and
CAHs to implement the necessary
infrastructure. Therefore, we are
delaying our adoption of this measure
by one year, so that it will be included
in the Public Health and Clinical Data
Exchange Objective and will be a
required measure beginning with the
EHR reporting period in CY 2024.
Regarding the concern over a lack of
applicable certification criteria
referenced in the CEHRT definition, we
inform readers that the applicable
criteria is available in ‘‘Transmission to
public health agencies—antimicrobial
use and resistance reporting’’ in 45 CFR
170.315(f)(6), and was finalized in the
‘‘2015 Edition Health Information
Technology (Health IT) Certification
Criteria, 2015 Edition Base Electronic
Health Record (EHR) Definition, and
ONC Health IT Certification Program
Modifications’’ final rule published on
October 16, 2015 (80 FR 62668).
Comment: A few commenters
recommended adding exceptions for
hospitals when they encounter
situations related to bi-directional
exchange that are outside their control
such as encountering deficiencies in the
state/local public health agency. A
commenter recommended adding an
exclusion for eligible hospitals and
CAHs using CEHRT that does not
include technology certified per
§ 170.315(f)(6) at the beginning of the
EHR reporting period. This type of
exclusion would be similar to the one
year exclusion that is available for MIPS
eligible clinicians for the Electronic
Case Reporting measure under the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Public Health and Clinical Data
Exchange Objective for those clinicians
in CY 2022 using CEHRT that does not
include technology certified to the
electronic case reporting certification
criterion. Some commenters expressed
concern that their ability to successfully
fulfill this measure is limited based on
dependence their health IT vendor
team, and potentially by delays at the
state level.
Response: We thank commenters for
their feedback.
We do not believe that additional
exclusions related to state and local
readiness to engage in bi-directional
exchange are necessary, as data within
the AUR measure are reported directly
to CDC through NHSN. We believe that
granting eligible hospitals and CAHs an
additional year to prepare to report on
this measure will alleviate the concerns
that the commenters have raised. Any
health IT vendors that have not yet
certified under 45 CFR 170.315(f)(6)
‘‘Transmission to public health
agencies—antimicrobial use and
resistance reporting,’’ will have
sufficient time to update their product
and complete certification due to the
one year delay.
Comment: A few commenters
requested clarification around the
specific standards submitters are
required to use, additional information
on a minimum period for hospitals to
transmit data, and technical assistance
and support during the implementation
period.
Response: As noted in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28587), for purposes of this measure, we
proposed that eligible hospitals and
CAHs must use technology certified to
the criterion at 45 CFR 170.315(f)(6),
‘‘Transmission to public health
agencies—antimicrobial use and
resistance reporting.’’ This certification
criterion references the ‘‘HL7®
Implementation Guide for CDA®
Release 2—Level 3: Healthcare
Associated Infection (HAI) Reports,
Release 1, U.S. Realm, August 2013’’
implementation specification, adopted
at § 170.205(r)(1).
We note that an updated version of
this this implementation specification
has been approved under ONC’s
Standards Version Advancement
Process. The Standards Version
Advancement Process (SVAP) permits
health IT developers to voluntarily
update health IT products certified
under the ONC Health IT Certification
Program to newer versions of adopted
standards and implementation
specifications (85 FR 25775).
Specifically, as part of the 2022 SVAP
cycle, ONC has approved the use of
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
‘‘HL7 CDA® R2 Implementation Guide:
Healthcare Associated Infection (HAI)
Reports, Release 3—US Realm,
December 2020’’ for the ‘‘Transmission
to public health agencies—antimicrobial
use and resistance reporting’’ at 45 CFR
170.315(f)(6). Health IT developers may
begin voluntarily incorporating this
specification into Certified Health IT
Modules beginning August 29, 2022.
Our experience with NHSN has
shown that reporting is not just broadly
feasible but also highly valuable for
hospitals and their state/local public
health partners. As previously noted,
over 2000 hospitals currently submit
AU and/or AR data through CDC’s
NHSN. Eligible hospitals and CAHs that
do encounter challenges submitting,
reviewing, interpreting and using their
AU and AR data have access to a robust
suite of training and technical assistance
resources, as well as one-on-one
assistance from subject matter experts
via a help desk system. NHSN gives
eligible hospitals and CAHs the ability
to see and analyze their data in realtime, as well as share that information
with clinicians and facility leadership,
as well as with other facilities (for
example, a multi-hospital system) and
partners such as health departments or
quality improvement organizations. The
measure must be fulfilled during the
eligible hospital or CAH’s EHR reporting
period but it is hoped that once they are
able to submit data that they will do so
throughout the year.
Comment: Several commenters
offered suggestions to support health
care provider implementation and
reduce participant burden associated
with validation. A commenter
recommended NHSN and CMS
validation reports be aligned to reduce
burden on health care providers. A
commenter recommended that RxNorm
codes be used. Finally, a commenter
recommended that CMS allow health
care providers to alternatively report on
any 5 of the 7 available measures in the
Public Health and Clinical Data
Exchange Objective to achieve the 10
points.
Response: We thank them for their
comments and agree with the
importance of ensuring eligible
hospitals and CAHs have the resources
and support they need to meet
requirements without undue reporting
burden. CDC already offers a wide array
of tools and resources to support
onboarding, testing and validation, and
data submission (see https://
www.cdc.gov/nhsn/pdfs/cda/PHDIFacility-Guidance-508.pdf). And CDC
and CMS will work together to build
upon these resources as needed to
support health care provider
PO 00000
Frm 00559
Fmt 4701
Sfmt 4700
49337
participation. Similarly, CDC and CMS
will work together to align and
streamline accountability processes (for
example, reporting validation; (letters
from the NHSN to the hospitals to serve
as proof of their active engagement).
With respect to the commenter’s
suggestion that the AUR measure
support the use of RxNorm codes, the
CDC has confirmed that the measure
already does so. Finally, as we have
previously discussed, we believe that
requiring reporting for specific measures
under the Public Health and Clinical
Data Exchange objective is necessary to
better prepare for and support public
health responses to health threats. For a
thorough discussion of our reasoning for
selecting each required measure we
refer readers to the FY 2022 IPPS/LTCH
final rule (86 FR 45470 through 45479).
After consideration of the public
comments we received, we are
finalizing our proposal to require
eligible hospitals and CAHs to report
the AUR surveillance measure, with the
modification that it will be required
beginning with the EHR reporting
period in CY 2024. Eligible hospitals
and CAHs that report a ‘‘yes’’ response
or an exclusion for which they are
eligible will receive credit for reporting
the measure. Eligible hospitals and
CAHs must use technology certified to
the criterion at 45 CFR 170.315(f)(6),
‘‘Transmission to public health
agencies—antimicrobial use and
resistance reporting.’’ We are adopting
three exclusions as proposed for the
AUR Surveillance measure as follows:
the eligible hospital or CAH: (1) Does
not have any patients in any patient care
location for which data are collected by
NHSN during the EHR reporting period;
(2) Does not have electronic medication
administration records (eMAR)/
barcoded medication administration
(BCMA) records or an electronic
admission discharge transfer (ADT)
system during the EHR reporting period;
or (3) Does not have an electronic
laboratory information system (LIS) or
electronic ADT system during the EHR
reporting period.
c. Revisions to Active Engagement
(1) Background
The Medicare Promoting
Interoperability Program has been an
important mechanism for encouraging
data exchange between health care
providers and PHAs through the Public
Health and Clinical Data Exchange
Objective. In the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45470 through
45479), we finalized beginning with the
EHR reporting period in CY 2022,
eligible hospitals and CAHs must report
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49338
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
on the four required measures to obtain
points under the Public Health and
Clinical Data Exchange Objective: (1)
Syndromic Surveillance Reporting; (2)
Immunization Registry Reporting; (3)
Electronic Case Reporting; and, (4)
Electronic Reportable Laboratory Result
Reporting. We believe these required
measures will motivate health IT
vendors to implement the necessary
capabilities in their products and
encourage eligible hospitals and CAHs
to engage in the reporting activities
described in the measures.
Despite these gains, ensuring the
nation’s thousands of hospitals
implement and initiate data production
for these vital public health capabilities
remains an ongoing and important
effort. The Medicare Promoting
Interoperability Program provides an
opportunity to continue strengthening
the incentives for eligible hospitals and
CAHs to engage in these essential
reporting activities. Without adequate
incentives, it will be difficult to attain
the comprehensive data exchange
needed to ensure fast, complete,
actionable data in response to future
public health threats.
In the EHR Incentive Program Stage 3
final rule (80 FR 62862 through 62864),
beginning with the EHR reporting
period in 2016, we established a
definition for active engagement under
the Public Health and Clinical Data
Registry Reporting Objective. Active
engagement is defined as when an
eligible hospital or CAH is in the
process of moving towards sending
‘‘production data’’ to a public health
agency or clinical data registry, or is
sending production data to a public
health agency or clinical data registry.
We noted that the term ‘‘production
data’’ refers to data generated through
clinical processes involving patient care
and it is used to distinguish between
this data and ‘‘test data’’ which may be
submitted for the purposes of enrolling
in and testing electronic data transfers.
We established the following three
options for eligible hospitals and CAHs
to demonstrate active engagement:
Option 1—Completed registration to
submit data: The eligible hospital or
CAH registered to submit data with the
PHA or, where applicable, the clinical
data registry (CDR) to which the
information is being submitted;
registration was completed within 60
days after the start of the EHR reporting
period; and the eligible hospital or CAH
is awaiting an invitation from the PHA
or CDR to begin testing and validation.
Eligible hospitals or CAHs that have
registered in previous years do not need
to submit an additional registration to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
meet this requirement for each EHR
reporting period.
Option 2—Testing and validation:
The eligible hospital or CAH is in the
process of testing and validation of the
electronic submission of data. Eligible
hospitals or CAHs must respond to
requests from the PHA or, where
applicable, the CDR within 30 days;
failure to respond twice within an EHR
reporting period would result in that
health care provider not meeting the
measure.
Option 3—Production: The eligible
hospital or CAH has completed testing
and validation of the electronic
submission and is electronically
submitting production data to the PHA
or CDR. For more information about the
current options for active engagement,
we refer readers to the EHR Incentive
Program Stage 3 final rule (80 FR 62862
through 62864).
(2) Revision to Options for Active
Engagement
The three active engagement options
provided flexibility for eligible hospitals
and CAHs to meet the measures under
the Public Health and Clinical Data
Exchange Objective in a variety of ways,
but they did not provide an incentive to
move through the options and get to
option 3, production, where there is the
ongoing electronic submission of data.
Option 1, completed registration to
submit data, was an important option in
2016 as many PHAs and CDRs were
starting to come online, and thus the
provision of this option recognized that
many eligible hospitals and CAHs were
just beginning to engage in electronic
data exchange with PHAs and CDRs.
Now many years have passed, and we
believe that eligible hospitals and CAHs
have had ample time to complete option
1.
Thus, in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28588), we
proposed to consolidate current options
1 and 2 into one option beginning with
the EHR reporting period in CY 2023.
We did not propose any substantive
changes to the individual options or
requirements for selecting the
individual options; rather, we would
combine current options 1 and 2 into a
single option, as follows:
1. Proposed Option 1. Pre-production
and Validation (a combination of
current option 1, completed registration
to submit data, and current option 2,
testing and validation);
2. Proposed Option 2. Validated Data
Production (current option 3,
production).
Eligible hospitals and CAHs must
demonstrate their level of active
engagement as either proposed Option 1
PO 00000
Frm 00560
Fmt 4701
Sfmt 4700
(pre-production and validation) or
proposed Option 2 (validated data
production) to fulfill each measure. We
invited public comment on these
proposed changes to the options for
active engagement.
Comment: Many commenters
supported the proposal to modify the
active engagement options under the
Public Health and Clinical Data
Exchange Objective.
Response: We thank commenters for
their support of our proposal to modify
the options of active engagement under
the Public Health and Clinical Data
Exchange Objective.
Comment: A commenter requested
clarification on the consolidation of
options 1 and 2 for the levels of active
engagement with regard to eligible
hospitals and CAHs that have
completed registration but not yet begun
testing and validation.
Response: The proposed active
engagement option 1: Pre-Production
and Validation includes both the
completion of registration to submit
data with the PHA or CDR, as
applicable, and being in the process of
testing and validation of the electronic
submission of data. Upon receiving an
invitation from the PHA or CDR to begin
testing and validation, the eligible
hospital or CAH should begin testing
and validation, as we understand the
validation process can take some time.
If, at any point in the process, an
eligible hospital or CAH encounters a
lack of readiness on the part of the PHA
or CDR, the eligible hospital or CAH
could consider whether it could report
an exclusion for one or more of the
measures associated with the Public
Health and Clinical Data Exchange
Objective.
Comment: A few commenters
expressed concern that eligible hospitals
and CAHs are determining their active
engagement status without input from
the appropriate public health agency.
These commenters requested that CMS
provide further guidance to define the
active engagement option 2 criteria, and
identify at what point an eligible
hospital or CAH can move from active
engagement option 1 to active
engagement option 2.
Response: To move from Active
Engagement Option 1: Pre-production
and Validation, to Active Engagement
Option 2: Validated Data Production,
the eligible hospital or CAH must finish
validation. Validation is an effort to
ensure that the data exchanged with a
public health agency is high quality and
useful, and meets the appropriate HL7
implementation guide standard. Only
the PHA or CDR can confirm validation
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
has been completed and a ‘‘production’’
state has been reached.
Comment: Several commenters did
not support the proposal, stating that
the reduction of levels obscures the
necessary granularity of where hospitals
are in the onboarding process. The
commenters stated that since eligible
hospitals and CAHs do not control the
onboarding process, and that this varies
based on the resources at the public
health departments, it is important to
distinguish between those who are
waiting to begin testing and validation
from those who are actively engaged in
testing and validation.
Response: CMS does not agree that it
is important to differentiate between
those who are registered and those who
have begun testing and validation. CMS
has collaborated with the PHA
community and has received comments
that PHAs currently do not have any
waitlists, and the eligible hospitals or
CAHs who register are immediately
invited to begin testing and validation.
CMS agrees that eligible hospitals and
CAHs should not be held accountable
for actions outside of their control.
However, at this time, registration is no
longer a meaningful status, as PHAs are
ready to begin testing and validation
with those who register right away. CMS
is not concerned with the loss of
granularity, and we believe that this will
facilitate easier reporting from our
partners.
Additionally, we do not believe that
allowing eligible hospitals and CAHs to
remain at the registration stage fulfills
the intent of the public health measures.
Validation is critical as it ensures that
the data from eligible hospitals and
CAHs meets the needs of public health
for both routine and emergency
reporting. This is true across the
Electronic Case Reporting measure, the
Electronic Reportable Laboratory Result
Reporting measure, the Syndromic
Surveillance Reporting measure, the
Immunization Registry Reporting
measure, and in the future, the AUR
Surveillance measure. In addition,
public health capabilities for
onboarding may have been delayed at
the state level due to the COVID–19
pandemic. As such, CDC is providing
funding for PHAs to improve and
modernize their data infrastructure,
which will result in more rapid testing
and validation.
After consideration of the public
comments we received, we are
finalizing our proposal to consolidate
current options 1 and 2 into a new
combined option called Pre-production
and Validation and renaming the
current option 3 as Validated Data
Production beginning with EHR
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
reporting periods in CY 2023. Our goal
continues to be that all eligible hospitals
and CAHs will be at the Validated Data
Production option as successful
exchange of data is needed because that
is where that data can be utilized to
combat current and future PHEs.
(3) Reporting Requirement for Level of
Engagement
Although we established the active
engagement options, eligible hospitals
and CAHs currently are not required to
report their level of active engagement
for any of the measures associated with
the Public Health and Clinical Data
Exchange Objective. During the recent
COVID–19 PHE, we recognized the
importance of public health reporting,
as discussed further in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28585 through 28586), and we believe
that knowing the level of active
engagement that an eligible hospital or
CAH selects would provide information
on the types of registries and geographic
areas with health care providers in the
Pre-production and Validation stage.
Our goal is for all health care providers
nationwide to be at the Validated Data
Production stage so that data will be
actively flowing and public health
threats can be monitored. Therefore, as
proposed in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28588), for
the Public Health and Clinical Data
Exchange Objective, in addition to
submitting responses for the required
measures and any optional measures an
eligible hospital or CAH chooses to
report, we proposed to require eligible
hospitals and CAHs to submit their level
of active engagement, either Preproduction and Validation or Validated
Data Production) for each measure they
report beginning with the EHR reporting
period in CY 2023. We believe that this
information regarding the level of active
engagement would be helpful as it
would enable HHS to identify registries
and PHAs which may be having
difficulty onboarding eligible hospitals
and CAHs and moving them to the
Validated Data Production level. If we
can identify the PHAs with which
eligible hospitals and CAHs are
encountering difficulties, we believe we
will be able to identify the barriers that
prevent them from moving to the
Validated Data Production level and
work to develop solutions to overcome
the barriers.
We invited public comment on the
proposal to require submission of the
level of active engagement.
Comment: Many commenters
supported the proposal to require
eligible hospitals and CAHs to report
level of active engagement on measures
PO 00000
Frm 00561
Fmt 4701
Sfmt 4700
49339
in the Public Health and Clinical Data
Exchange Objective. Many commenters
cited that bi-directional data exchange is
integral to achieve meaningful impacts
in health care delivery and the
importance of reporting the level of
active engagement to promote
transparency of active engagement
status at a national level.
Response: We thank the commenters
for their support of our proposal to
require eligible hospitals and CAHs to
report their level of active engagement
on measures in the Public Health and
Clinical Data Exchange Objective. We
agree with commenters that bidirectional data exchange is integral in
health care delivery.
Comment: A commenter requested
that hospitals be required to provide
proof from a public health agency of
their active engagement status through a
letter or other forms of
acknowledgement as through HL7
messages and emails indicating
confirmation.
Response: At this time, eligible
hospitals and CAHs attest to CMS. PHAs
have no role in the attestation process.
Many eligible hospitals and CAHs
request documentation from the PHA to
support their active engagement status,
which is used in case of an audit by
CMS. CMS agrees that this is a best
practice. CMS does acknowledge the
desire of PHAs to become more engaged
in the attestation process for eligible
hospitals and CAHs but to date we have
not established what that relationship
might be. However, eligible hospitals
and CAHs will be required to report
their level of active engagement for the
first time. If CMS learns that there is a
mismatch between the active
engagement records at PHAs and the
active engagement status provided
through attestation, CMS may consider
making a future change to the attestation
process. No change will be made until
CMS has more evidence about eligible
hospitals’ and CAHs’ self-reported
active engagement status.
Comment: A few commenters did not
support the proposal to require
reporting the Active Engagement option
selected under the Public Health and
Clinical Data Exchange Objective and
requested this not be required until the
technology can facilitate the reporting.
Some raised concerns that PHAs may
not be able to offer documentation of
level of active engagement in a
reasonable amount of time to support
compliance with a 90-day reporting
period. Commenters also recommended
active engagement be demonstrated
with information provided either by the
eligible hospital or CAH, or the PHA, or
that CMS incentivize PHAs to turn
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49340
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
around this information in a timely
manner. A few commenters requested
that CMS provide further guidance
illustrating expectations for completion
of active engagement options and how
eligible hospitals and CAHs can prove
their active engagement status. A
commenter requested that CMS allow
eligible hospitals and CAHs at least one
year of stable reporting of public health
measures without implementing this
active engagement reporting
requirement. Many commenters
supported an exclusion for situations in
which the state or public health
department has not declared readiness
or lacks resources for timely
onboarding.
Response: We acknowledge
commenters’ concerns regarding our
proposal to require eligible hospitals
and CAHs to report their level of active
engagement for each Public Health and
Clinical Data Exchange measure.
However, we believe that this
information will be extremely valuable
to better understand progress with
reporting over time and readiness for
public health emergencies.
We offer the following examples as
ways an eligible hospital or CAH may
demonstrate their level of active
engagement:
• A dated report or screenshot from
CEHRT that documents successful
submission to the registry or PHA. The
report should include evidence to
support that it was generated for that
eligible hospital’s or CAH’s system (for
example, identified by CMS certification
number [CCN] and eligible hospital or
CAH) name or;
• A dated report or screenshot of
successful registration or electronic
transmission (for example, screenshot
from another system, etc.). The report
should include evidence to support that
it was generated for that eligible
hospital or CAH (for example, identified
by CMS certification number [CCN] and
eligible hospital or CAH name) or;
• A letter or email from a registry or
PHA confirming registration.
With respect to the recommendation
to include an exclusion, we refer readers
to the existing exclusions for each
measure within the Public Health and
Clinical Data Exchange Objective (See
Table IX.H.-07.). For instances when
there is an issue with the ability of a
PHA or CDR to receive the data in the
specific standards required to meet the
CEHRT definition or where no PHA has
declared readiness to receive data from
eligible hospitals or CAHs, there are
exclusions available for eligible
hospitals and CAHs (42 CFR 495.24
(e)(8)(iii)). While we recognize that there
may be variability in ability to quickly
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
test and validate state to state, PHAs
have been requiring transmission of
electronic laboratory reporting,
immunization registry reporting, and
syndromic surveillance reporting for
many years. To help address the
existing variability, CDC is providing
funding for PHAs to improve and
modernize their data infrastructure,
which will result in more rapid testing
and validation. In addition, most
eligible hospitals and CAHs are
successfully reporting these measures.
Comment: A few commenters
requested that CMS provide further
guidance on whether the previous EHR
Incentive Program registration satisfies
current program requirements. A few
commenters requested that CMS address
concerns over lack of vendor readiness.
A few commenters requested that CMS
provide more clarity on how active
engagement status is impacted by
eligible hospitals and CAHs that
registered with PHAs in the past but
will only now be engaging in data
exchange with the PHA.
Response: If an eligible hospital or
CAH has previously registered and has
not received an invitation to proceed to
testing and validation, we recommend
that they reach out to the PHA to
confirm that they remain actively
engaged and to discuss their timeline for
moving into testing and validation.
After consideration of the public
comments we received, we are
finalizing our proposal for the Public
Health and Clinical Data Exchange
Objective to require that in addition to
submitting responses for the required
measures and any optional measures an
eligible hospital or CAH chooses to
report, that they submit their level of
active engagement, either Option 1: Preproduction and Validation or Option 2:
Validated Data Production (as finalized
in section H.5.c(2)), for each measure
they report beginning with the EHR
reporting period in CY 2023.
(4) Changes to the Duration of Active
Engagement Options
As discussed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28588),
eligible hospitals and CAHs currently
are not required to report their level of
active engagement, or advance from one
option to the next option within a
certain period of time. As we proposed
requiring eligible hospitals and CAHs to
submit their level of active engagement
for each measure they report, we also
proposed, beginning with the EHR
reporting period in CY 2023, that
eligible hospitals and CAHs may spend
only one EHR reporting period at the
Option 1: Pre-production and Validation
level of active engagement per measure,
PO 00000
Frm 00562
Fmt 4701
Sfmt 4700
and that they must progress to the
Option 2: Validated Data Production
level for the next EHR reporting period
for which they report a particular
measure. For example, under this
proposal, if an eligible hospital or CAH
submits a level of active engagement at
the proposed option 1 level (Preproduction and Validation) for the
Syndromic Surveillance Reporting
measure for the EHR reporting period in
CY 2023, the eligible hospital must
report a level of active engagement at
the proposed option 2 level (Validated
Data Production) for the next EHR
reporting period for which it reports the
Syndromic Surveillance Reporting
measure, or it would fail to satisfy the
Public Health and Clinical Data
Exchange Objective for its next EHR
reporting period. The options for active
engagement assume the same PHA or
CDR is used by the hospital. In the event
an eligible hospital or CAH chooses to
switch between one or more CDRs or
PHAs, we proposed they would be
permitted to spend an additional EHR
reporting period at the Option 1: Preproduction and Validation level to assist
with onboarding to the new CDR or
PHA. As electronic transmission of
high-quality data is achieved at the
Option 2: Validated Data Production
level, we want all eligible hospitals and
CAHs to reach this level.
We invited public comments on these
proposed changes to the duration of the
active engagement options.
Comment: Many commenters
supported the proposal to limit the
amount of time an eligible hospital or
CAH may spend at the pre-production
and validation level of active
engagement to one EHR reporting
period. Many commenters noted the
importance of eligible hospitals and
CAHs exchanging data with public
health agencies, as highlighted by the
COVID–19 PHE, as well as how this
limit on duration in the pre-production
and validation level promotes and
incentivizes progress through the levels
of active engagement and data exchange.
Response: We thank the commenters
for their support of our proposal to limit
the amount of time an eligible hospital
or CAH may spend in the preproduction and validation level of
active engagement. We agree on the
importance of data exchange between
eligible hospitals and public health
agencies and clinical registries,
particularly in light of the ongoing
COVID–19 PHE, and thus have
prioritized efforts to promote data
exchange with public health agencies
and clinical registries.
Comment: While offering support,
several commenters expressed concern
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
about the readiness of state and local
public health agencies and registries to
accept production data and urged CMS
to implement changes to the duration of
active engagement levels in a phased
approach or offer exclusions for
circumstances that are out of the control
of the eligible hospital or CAH.
Response: We appreciate commenters’
recommendations regarding including
exclusions for when state and local
jurisdictions may not be ready or
capable of accepting production data, or
are slow to onboard, and refer readers to
the existing exclusions for each Public
Health and Clinical Data Exchange
measure. For instance, when there is an
issue with the ability of a PHA or CDR
to receive the data in the specific
standards required to meet the CEHRT
definition or where no PHA has
declared readiness to receive data from
eligible hospitals or CAHs, there are
exclusions available for eligible
hospitals and CAHs (42 CFR 495.24
(e)(8)(iii)).
Comment: Many commenters did not
support the proposal to limit the
duration of Pre-production and
Validation level of active engagement to
one EHR reporting period citing that
progression out of this level is often not
under hospital control and depends on
the resources available from a given
PHA and their technical capabilities and
timeliness in communications. A few
commenters recommended adding an
exclusion to allow for when public
health agencies have limited resources
to validate and onboard. A few
commenters suggested this could lead to
rushed validation and poor data quality,
particularly with a move to a 180-day
EHR reporting period. A few
commenters stated concerns that EHR
vendors may not be ready for testing in
2023 or 2024 and suggested CMS allow
hospitals multiple reporting years under
the Pre-Production and Validation level.
A commenter requested that CMS allow
hospitals at least one year of stable
reporting of public health measures
without implementing this active
engagement reporting requirement.
Another commenter did not support the
proposal because the commenter stated
CMS lacks a baseline as it has never
collected eligible hospitals or CAHs
active engagement level.
Response: We acknowledge
commenters’ concerns regarding the
lack of control that eligible hospitals or
CAHs may have when moving through
the levels of active engagement. In
particular, we recognize that an eligible
hospital’s or CAH’s successful
progression through the levels of active
engagement is partially dependent on
the readiness, resources, and technical
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
capabilities of the PHAs to which it
reports. We further recognize that public
health capacity remains somewhat
variable and constrained—particularly
as PHAs continue to direct substantial
resources to the COVID–19 PHE
response efforts. Accordingly, we agree
with the commenter who suggested
allowing at least one year of stable
reporting of public health measures
before instituting limits on the length of
time eligible hospitals and CAHs can
spend in the pre-production and
validation level of active engagement.
For these reasons, we are delaying the
implementation of this requirement by
one year, such that it will apply
beginning with the EHR reporting
period in CY 2024. This delay balances
the urgent need to move eligible
hospitals and CAHs into data
production with the need identified by
the commenters for additional time for
public health agencies and health care
providers to prepare for this change.
Without this requirement, facilities can
linger in registration, testing or
validation for years, which provides
little benefit to the public in a PHE or
to address health threats. Moreover,
existing data PHAs have shared with
CDC indicate that registration, testing
and validation completion rates are
already fairly rapid—typically less than
3 months in many cases. Admittedly,
there are exceptions—in particular, the
validation stage can take longer, as it
depends on PHA readiness, as well as
the quality of the data a provider is
sending and the CEHRT product being
used. However, we anticipate that
testing and validation cycle times will
continue to shrink over the next year as
public health agencies use CDC funding
to modernize their data infrastructures.
Nonetheless, we appreciate and agree
with commenters’ recommendations
regarding the need for exclusions when
state and local jurisdictions are not
ready or capable of accepting
production data, or are slow to onboard
facilities (for example, an eligible
hospital is unable to complete testing
and validation in a single EHR reporting
period because the PHA has a backlog
of validation requests). We believe an
eligible hospital or CAH could consider
whether the existing exclusions for each
measure associated with the Public
Health and Clinical Data Exchange
Objective could be claimed in these
cases and refer readers to these
exclusions at 42 CFR 495.24 (e)(8)(iii).
However, we will continue to examine
this issue in collaboration with CDC
and, if additional exclusions are
warranted, we may address them and
any other changes warranted in future
rulemaking.
PO 00000
Frm 00563
Fmt 4701
Sfmt 4700
49341
Comment: A few commenters had
questions regarding allowances for
when hospitals need to migrate from
testing/validation to production and
back if the public health department
performs systems updates, for
unforeseen outages, or if hospitals move
to a different vendor and their testing
does not line up well to be in
production during their next reporting
period. A few commenters expressed
concern over the lack of control
hospitals have in moving from one level
to another, or in receiving
documentation that proves they have
achieved a certain level of active
engagement. A commenter requested
that CMS work with other agencies to
support state organizations in providing
the technical support necessary and
suggested including an exclusion for
situations in which a state has limited
capacity for engagement.
Response: We appreciate commenters’
feedback on the proposal to limit the
time spent in the Pre-production and
Validation level of active engagement to
one EHR reporting period. With respect
to the concern about moving to different
vendors, PHAs, or CDRs, the options for
active engagement assume the same
PHA or CDR is used by the hospital. In
the event an eligible hospital or CAH
chooses to switch between one or more
CDRs or PHAs, we proposed they would
be permitted to spend an additional
EHR reporting period at the Preproduction and Validation level to assist
with onboarding to the new CDR or
PHA (87 FR 28588). As we have
previously stated, we acknowledge
commenters’ concerns regarding the
lack of control that eligible hospitals or
CAHs may have when moving through
the levels of active engagement and the
dependency on resources and technical
capabilities at public health
departments and registries. We refer
readers to the existing exclusions for
each Public Health and Clinical Data
Exchange measure. For instances when
there is an issue with the ability of a
PHA or CDR to receive the data in the
specific standards required to meet the
CEHRT definition or where no PHA has
declared readiness to receive data from
eligible hospitals or CAHs, there are
exclusions available for eligible
hospitals and CAHs (42 CFR 495.24
(e)(8)(iii)).
Comment: A commenter expressed
concern for smaller hospitals who may
need more time to progress to
production and stated that establishing
a time limit should be based on a solid
understanding of the barriers hospitals
face to moving between levels of active
engagement. A commenter
recommended that CMS incentivize
E:\FR\FM\10AUR2.SGM
10AUR2
49342
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
health care organizations (HCOs) and
vendors to continue to engage with
PHAs once initial validated production
data are flowing to ensure that accurate,
complete, and timely data for reportable
conditions are available to PHAs as
required by jurisdictional laws and
regulations and for effective public
health response activities. A commenter
recommended CMS create a list of states
where certain types of public health and
clinical data exchange is immature to
identify potential scoring issues.
Response: We appreciate commenters’
feedback regarding the impact of this
policy on smaller hospitals and
recommendations to provide incentives
for continued engagement with PHAs as
well as developing resources to identify
where public health and clinical data
exchange is immature. We will monitor
implementation and consider future
changes if necessary.
Comment: Several commenters noted
that local and state health departments
have limitations and offer variable
levels of technical capacity to support
this type of data exchange and that CMS
should follow and support development
efforts at the state and local levels of
PHAs and registries.
Response: We agree with the
importance of ensuring health care
providers and PHAs have the ability to
set up data exchange within a
reasonable timeframe. Our goal is that
all parties continue to move towards
validated production, which will
prepare the nation for a more effective
response to public health emergencies.
As we discussed above, given the many
challenges identified in the comments,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
we are delaying the implementation of
this requirement until the beginning of
the EHR reporting period in CY 2024.
Additionally, among the core
objectives of CDC’s DMI are seamless
reporting to public health agencies and
interoperability among core public
health surveillance strategies. As such,
CDC is providing funding to public
health agencies to improve and
modernize their data infrastructure. We
are working closely with CDC to
coordinate healthcare program
requirements and public health
modernization investments to foster comaturation and readiness for bidirectional data exchange.
After consideration of the public
comments we received, we are
finalizing the proposals to limit the
amount of time an eligible hospital or
CAH may spend at the pre-production
and validation level of active
engagement to one EHR reporting period
with the modification that this
limitation will apply beginning with the
EHR reporting period in CY 2024.
(5) Public Health Reporting and
Information Blocking
The ONC 21st Century Cures Act final
rule (85 FR 25642) implemented
policies related to information blocking
as authorized under section 4004 of the
21st Century Cures Act, as discussed
further in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28588 through
28589).
PO 00000
Frm 00564
Fmt 4701
Sfmt 4700
6. Changes to Scoring Methodology for
the EHR Reporting Period in CY 2023
In the FY 2019 IPPS/LTCH PPS final
rule (83 FR 41636 through 41645), we
adopted a new performance-based
scoring methodology for eligible
hospitals and CAHs attesting under the
Medicare Promoting Interoperability
Program beginning with the EHR
reporting period in CY 2019, which
included a minimum scoring threshold
of a total score of 50 points or more
which eligible hospitals and CAHs must
meet to satisfy the requirement to report
on the objectives and measures of
meaningful use under 42 CFR 495.24. In
the FY 2022 IPPS/LTCH PPS final rule
(86 FR 45491 through 45492), we
increased the minimum scoring
threshold from 50 points to 60 points
beginning with the EHR reporting
period in CY 2022. As shown in Table
IX.H.-03, the points associated with the
required measures sum to 100 points,
and the optional measures may add
additional bonus points. The scores for
each of the measures are added together
to calculate a total score of up to 100
possible points for each eligible hospital
or CAH (83 FR 41636 through 41645).
We note in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28589), we
erroneously stated that we calculate a
total score of up to 105 possible points,
but we want to clarify that we cap the
number of points at 100.
Table IX.H.–03 reflects the objectives
and measures for the EHR reporting
period in CY 2022 and was included in
the FY 2022 IPPS/LTCH PPS final rule
(86 FR 45492).
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49343
TABLE IX.H.-03: PERFORMANCE-BASED SCORING METHODOLOGY
EHR REPORTING PERIOD IN CY 2022
Measure
Maximum Points
e-Prescribing
10 Points
10 points (bonus)*
Bonus: Query of POMP
Health Information Exchange
Support Electronic Referral Loops by Sending Health
20 points
Information
Support Electronic Referral Loops by Receiving and
20 points
Reconciling Health Information
-ORHealth Information Exchange Bi-Directional Exchange*
40 points*
Provider to Patient Exchange
Provide Patients Electronic Access to Their Health
40 points
Information
Report the following four measures: *
• Syndromic Surveillance Reporting
10 points
• Immunization Registry Reporting
Public Health and Clinical Data
Electronic
Case
Reporting
•
Exchange
• Electronic Reportable Laboratory Result
Reporting
Report one of the following measures:
5 points (bonus)*
• Public Health Registry Reporting
• Clinical Data Registry Reporting
Notes: The Security Risk Analysis measure, SAFER Guides measure, and attestations required by section
106(b)(2)(B) ofMACRA are required, but will not be scored. Electronic clinical quality measures (eCQM)
measures are required, but will not be scored.
*Signifies a final policy adopted in the FY 2022 IPPS/L TCH PPS final rule.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28590), we noted
that in proposing to make the Query of
PDMP measure required, we would
retain the 10 points associated with it,
which are allocated as bonus points for
the EHR reporting period in CY 2022. If
finalized, we proposed to reduce the
points associated with the Health
Information Exchange Objective
measures from the current 40 points to
30 points beginning with the CY 2023
EHR reporting period. The Public
Health and Clinical Data Exchange
Objective, with its current four required
measures, is currently worth 10 points.
Despite increasing the number of
required measures from two to four to
make the objective more effective in
promoting public health data electronic
exchange, the total number of points did
not change between CY 2021 and CY
2022. We believe that increasing the
point value of the Public Health and
Clinical Data Exchange Objective would
create a more meaningful incentive for
eligible hospitals and CAHs to engage in
the electronic reporting of public health
information and recognize the
importance of public health systems
affirmed by the COVID–19 pandemic.
Increasing the point value would make
the Public Health and Clinical Data
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Exchange Objective a more central piece
of the Promoting Interoperability
Program, and better incentivize eligible
hospitals and CAHs to implement these
essential public health data exchange
capabilities. Without adequate
incentives, there remains a risk that
eligible hospitals and CAHs will simply
not prioritize implementing these
capabilities, which are essential to
ongoing efforts to address COVID–19
and will be indispensable for
responding to future public health
threats and emergencies. Increasing the
point value would more appropriately
incentivize eligible hospitals and CAHs
to engage in the electronic reporting of
public health information, and would
align the value of the objective with the
objective’s importance and the effort
necessary to meet the required
measures.
Thus, we proposed to increase the
points allocated to the Public Health
and Clinical Data Exchange Objective
from 10 to 25 points to better align with
the true value of this objective
beginning with the EHR reporting
period in CY 2023. This proposal was
independent of our proposal to add the
AUR Surveillance measure to the
objective, and we considered increasing
the points regardless of whether the
PO 00000
Frm 00565
Fmt 4701
Sfmt 4700
proposal to add the AUR Surveillance
measure to the objective was finalized.
We believe assigning 25 points to the
objective reflects the importance of
comprehensive, nationwide health care
data exchange between eligible
hospitals and CAHs and public health
agencies. Nationwide health care data
exchange would provide immense value
to the public by improving the speed
and effectiveness of public health
responses, as well as to eligible
hospitals and CAHs, since better public
health response reduces pressure on
hospitals, which can be overwhelmed in
a public health crisis. To balance the
increase in the points associated with
the Public Health and Clinical Data
Exchange Objective, we also proposed
to reduce the points associated with the
Provide Patients Electronic Access to
Their Health Information measure from
the current 40 points to 25 points
beginning with the EHR reporting
period in CY 2023.
We included Table IX.H.–04. in the
FY 2023 IPPS/LTCH PPS proposed rule,
which reflects the objectives, measures,
and maximum points available for the
EHR reporting period in CY 2023, if the
proposals discussed (87 FR 28598) are
finalized.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.185
khammond on DSKJM1Z7X2PROD with RULES2
Obiective
Electronic Prescribing
49344
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE IX.H.-04: PROPOSED PERFORMANCE-BASED SCORING
METHODOLOGY FOR EHR REPORTING PERIOD IN CY 2023
Ob_jective
Electronic
Prescribing
Health Information
Exchange
Provider to Patient
Exchange
Public Health and
Clinical Data
Exchange
Measure
e-Prescribing
Query of PDMP*
Support Electronic Referral Loops by Sending Health
Information
Support Electronic Referral Loops by Receiving and
Reconciling Health Information
-ORHealth Information Exchange Bi-Directional Exchange
-OREnabling Exchange under TEFCA *
Provide Patients Electronic Access to Their Health
Information
Report the following five measures:*
• Syndromic Surveillance Reporting
• Immunization Registry Reporting
• Electronic Case Reporting
• Electronic Reportable Laboratory Result
Reporting
• AUR Surveillance Reporting*
Maximum
Points
10 points
10 points*
Required/Optional
Required
Required
15 points*
15 points*
30 points*
30 points*
25 points*
Required (eligible
hospital or CAHs
choice of one of the
three reporting
options)
Required
Required
25 points*
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00566
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.186
khammond on DSKJM1Z7X2PROD with RULES2
Optional
Report one of the following measures:
5 points (bonus)
• Public Health Registry Reporting
• Clinical Data Registry Reporting
Notes: The Security Risk Analysis measure, SAFER Guides measure, and attestations required by section
106(b)(2)(B) ofMACRA are required, but will not be scored. eCQM measures are required, but will not be
scored.
*Signifies a proposal made in the FY 2023 IPPS/L TCH PPS proposed rule.
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
The maximum points available in
Table [IX.H.–04.] do not include the
points that would be redistributed in the
event an exclusion is claimed. For ease
of reference, in the FY 2023 IPPS/LTCH
PPS proposed rule, we included Table
[IX.H.–054 at 87 FR 28592] which
shows the point redistribution among
the objectives and measures for the EHR
reporting period in CY 2023 in the event
49345
an eligible hospital or CAH claims an
exclusion, if the proposals made in the
FY 2023 IPPS/LTCH PPS proposed rule
are finalized.
TABLE IX.H.-05.: PROPOSED EXCLUSION REDISTRIBITION FOR
EHR REPORTING PERIOD IN CY 2023
Objective
e-Prescribing
Query of PDMP*
Electronic Prescribing
Health Information Exchange
Provider to Patient Exchange
Public Health and Clinical
Data Exchange
Redistribution if exclusion is
claimed
10 points to HIE Objective
10 points to e-Prescribing
measure
Measure
Support Electronic Referral Loops by Sending Health
Information
Support Electronic Referral Loops by Receiving and
Reconciling Health Information
-ORHealth Information Exchange Bi-Directional Exchange
-OREnabling Exchange under TEFCA *
Provide Patients Electronic Access to Their Health Information
Report the following five measures:*
• Syndromic Surveillance Reporting
• Immunization Registry Reporting
• Electronic Case Reporting
• Electronic Reportable Laboratory Result Reporting
• AUR Surveillance Reporting*
No exclusion
No exclusion
No exclusion
No exclusion
No exclusion
If an exclusion is claimed for
each of the five measures, 25
points are redistributed to the
Provide Patients Electronic
Access to their Health
Information measure
We invited public comment on these
proposed changes to our scoring
methodology.
Comment: A few commenters
expressed support for the proposed
changes to the scoring methodology. A
commenter expressed support for
increasing the points associated with
the Electronic Prescribing Objective
from 10 to 20 to further incentivize
electronic prescribing. A few
commenters supported the proposed
reduction in points of the HIE Objective
from 40 to 30 points. Many commenters
supported the adjustment of the Public
Health and Clinical Data Exchange
Objective from 10 to 25 points. Several
agreed with the importance of
incentivizing efforts related to the
COVID–19 pandemic.
Response: We thank the commenters
for their support.
Comment: A few commenters did not
support our proposal to reduce the
number of points assigned to the HIE
Objective citing that the current point
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
allocation reflects the push for the
continued adoption and expansion of
clinical data exchange. A few
commenters did not support the point
reduction of the Provider to Patient
Exchange Objective citing that such a
reduction would signal that CMS
devalues the exchange of data between
patients and health care providers. A
few commenters did not support our
proposal to increase the total score of
the Public Health and Clinical Data
Exchange Objective citing the lack of
readiness of, and variability among,
states and public health agencies to
receive and process data.
Response: We thank commenters for
their concerns and feedback. Point
changes across objectives reflect the
importance of shifting priorities,
especially during the COVID–19
pandemic. Thus we are reducing the
points associated with the Provider to
Patient Exchange Objective so we can
increase the points associated with the
Public Health and Clinical Data
PO 00000
Frm 00567
Fmt 4701
Sfmt 4700
Exchange Objective due to the
importance of public health data during
PHEs. The reduction to the HIE
Objective was to accommodate the
requirement of the Query of PDMP
measure which increased the points
associated with the Electronic
Prescribing Objective.
Comment: A commenter
recommended increasing the number of
points that hospitals can earn to
accommodate the necessary point
increases.
Response: While we appreciate this
suggestion, we believe that increasing
the number of points may inflate scores
and would not reflect the priorities that
are conveyed through the reallocation of
points.
After consideration of the public
comments we received, we are
finalizing our proposals for changes to
the scoring methodology for the EHR
reporting period in CY 2023 without
modification.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.187
khammond on DSKJM1Z7X2PROD with RULES2
Notes: The Security Risk Analysis measure, SAFER Guides measure, and attestations required by section
106(b)(2)(B) ofMACRA are required, but will not be scored. eCQM measures are required, but will not be
scored.
*Signifies a proposal made in the FY 2023 IPPS/L TCH PPS proposed rule.
khammond on DSKJM1Z7X2PROD with RULES2
49346
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
7. Public Reporting of Medicare
Promoting Interoperability Program Data
Section 1886(n)(4)(B) of the Act
requires the Secretary to post in an
easily understandable format a list of
the names and other relevant data, as
determined appropriate by the
Secretary, of eligible hospitals and
CAHs who are meaningful EHR users
under the Medicare FFS program, on a
CMS website. In addition, that section
requires the Secretary to ensure that an
eligible hospital or CAH has the
opportunity to review the other relevant
data that are to be made public with
respect to the eligible hospital or CAH
prior to such data being made public.
As the Medicare Promoting
Interoperability Program has evolved
over the years, we have continued to
expand the scope of relevant data points
across the Medicare Promoting
Interoperability Program. For example,
we post information on a CMS website
available to the public regarding those
eligible hospitals and CAHs who attest
to limiting or restricting the
compatibility or interoperability of
CEHRT under 42 CFR 495.40(b)(2)(i)(I),
as established in the 2020 Patient
Access and Interoperability final rule
(85 FR 25578 through 25580).
Additionally, in alignment with the
Hospital IQR Program, we finalized
proposals to begin publicly reporting
eCQM data beginning with the CY 2021
reporting period, and subsequent years
(85 FR 58975 through 58976).
To date, we have not publicly
reported eligible hospitals’ and CAHs’
total scores for the Medicare Promoting
Interoperability Program. We calculate a
total score of up to 100 possible points
by adding together the points earned for
each required measure and any optional
measures reported by an eligible
hospital or CAH (83 FR 41636 through
41645). In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28592 through
28593), we proposed to post the eligible
hospital’s or CAH’s actual score, up to
105 possible points, so that consumers
can clearly see the high performing
hospitals. We wish to clarify in this
final rule that although we cap the total
score at 100 points, the actual score
includes the addition of any bonus
points earned by the eligible hospital or
CAH that could total up to 105 possible
points. We believe an eligible hospital’s
or CAH’s actual score for the Medicare
Promoting Interoperability Program
measures, which includes any bonus
points earned, could constitute other
relevant data because it would help
consumers make informed decisions
regarding their health care team, such as
knowing whether and to what extent
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
their health care provider is involved in
health information exchange or
providing patients with electronic
access to their health information. We
believe that publicly reporting
additional Medicare Promoting
Interoperability Program data
demonstrates our commitment to
providing data to patients, consumers,
and health care providers, to assist them
in their decision-making; promoting
enhanced health information exchange
processes across eligible hospitals and
CAHs; and continually aligning
processes and policies with the Hospital
IQR Program and the MIPS Promoting
Interoperability performance category.
For example, for the MIPS Promoting
Interoperability performance category,
individual measure scores and the total
performance score across all measures
reported by eligible clinicians are
posted on a CMS website available to
the public.
Therefore, in alignment with our goals
to encourage interoperability and
transparency, in the FY 2023 IPPS/
LTCH PPS proposed rule, we proposed
to publicly report certain Medicare
Promoting Interoperability Program data
submitted by eligible hospitals and
CAHs beginning with the EHR reporting
period in CY 2023 (87 FR 28592 through
28593). In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28592 through
28593), we used the term ‘‘total score’’
within the public reporting proposals
and wish to clarify that we were
referring to the ‘‘actual score’’ that
includes bonus points that could add up
to 105 possible points. The language in
this final rule has been updated to
reflect the distinction and clarification.
Specifically, as a first step, we proposed
to publish on a CMS website available
to the public, the actual score of up to
105 points for each eligible hospital and
CAH, and the CMS EHR certification ID
that represents the CEHRT used by the
eligible hospital or CAH, beginning with
the scores and CMS EHR certification
IDs for the EHR reporting period in CY
2023. We did not propose to publish
individual measure scores at this time,
but we will continue to evaluate that
possibility for future rulemaking. For
example, under our proposal, if an
eligible hospital scored a total of 75
points for the EHR reporting period in
CY 2023, we would publish the score of
75 points, and not the number of points
earned for each individual measure
within the score.
We stated that if our proposal is
finalized, the actual score and CMS EHR
certification ID data could be made
available to the public as early as the
Fall of CY 2024, or as soon as
operationally feasible. In addition, as
PO 00000
Frm 00568
Fmt 4701
Sfmt 4700
required by section 1886(n)(4)(B) of the
Act, we proposed that eligible hospitals
and CAHs would have the opportunity
to review their data that we would
publish, during a 30-day preview period
before the data are made public. We
proposed to follow our current policy
and operational process that eligible
hospitals and CAHs are already familiar
with for the Hospital IQR Program and
use the Hospital Quality Reporting
(HQR) system (formerly, the QualityNet
Secure Portal) for eligible hospitals and
CAHs to access and review their
Medicare Promoting Interoperability
Program data during a 30-day preview
period before publication. We proposed
to post the Medicare Promoting
Interoperability Program data using the
Compare tool hosted by Health and
Human Services currently available at
https://www.medicare.gov/carecompare.
We invited public comments on these
proposals. Specifically, we are
interested in comments that provide
information on how these proposals
might affect existing incentives and
burdens under the Medicare Promoting
Interoperability Program, as well as the
benefit and utility of such data being
publicly available. We also sought
comments on which Medicare
Promoting Interoperability Program data
points to publish in future years,
including specific objective or measure
performance rates.
Comment: A few commenters
expressed general support for our
proposal to publicly report Medicare
Promoting Interoperability Program
actual scores because they believe it will
promote data transparency and help
consumers make informed decisions.
Response: We thank commenters for
their support of our proposal and agree
that it will help promote data
transparency and help consumers make
informed decisions.
Comment: A few commenters noted
their support for allowing a 30-day
review and dispute period prior to
publicly posting data. A commenter
recommended CMS notify eligible
hospitals and CAHs prior to the 30-day
review, and another commenter
suggested that CMS not publish data
until any concerns or disputes that arise
during the 30-day review are resolved.
Response: We appreciate commenters’
feedback regarding CMS notifying
eligible hospitals and CAHs prior to the
30-day review period, and the request
that CMS address and resolve any
disputes prior to publication. As stated
previously, we proposed to follow our
current policy and operational process
for the 30-day review period that
eligible hospitals and CAHs are already
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
familiar with for the Hospital IQR
Program. We proposed to use the
Hospital Quality Reporting (HQR)
system (formerly, the QualityNet Secure
Portal) for eligible hospitals and CAHs
to access and review their Medicare
Promoting Interoperability Program data
during a 30-day preview period before
publication.
Comment: Many commenters did not
support the proposal to publicly report
data stating they do not believe the data
would be of interest, hold meaning, or
be understandable to consumers; thus, it
would not help consumers make
informed health care decisions. A few
commenters cited that given the
complexity of the Medicare Promoting
Interoperability Program, the actual
score may not accurately reflect eligible
hospitals’ or CAHs’ levels of
interoperability, such as supporting
patient access to health information. A
commenter did not support the proposal
to publicly report the EHR Certification
ID, stating that health IT vendors do not
have control over which functionality
eligible hospitals or CAHs choose to
implement, therefore this information
should not be publicly reported.
Response: We appreciate commenters’
feedback and concerns regarding
whether the Medicare Promoting
Interoperability Program data would be
of interest, meaningful, or
understandable to consumers, especially
as a tool used to help make informed
decisions about their health care. As we
have previously stated, we believe
public reporting demonstrates our
commitment to transparency and
providing data to consumers, and that
these data would help consumers make
informed decisions regarding their
health care team. This would extend to
knowing whether, and to what extent,
their health care provider is involved in
health information exchange or
providing patients with electronic
access to their health information. We
believe these data depict levels of health
IT adoption and functionality across
eligible hospitals and CAHs.
Additionally, we believe it is important
to align policies across CMS programs,
and this proposal to publicly report
Medicare Promoting Interoperability
Program data for eligible hospitals and
CAHs aligns with the current policy for
the MIPS Promoting Interoperability
performance category, wherein
individual measure scores and the total
performance score across all measures
reported by eligible clinicians are
posted on a CMS website available to
the public.
Comment: Several commenters
provided recommendations for CMS to
consider if the proposal to publicly
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
report Medicare Promoting
Interoperability Program data is
finalized. These recommendations
include providing explanations of what
the Medicare Promoting Interoperability
Program score indicates, what the EHR
Certification ID is, and the process for
searching for the information within the
CHLP site. This would allow consumers
to understand and determine how the
actual score is calculated, emphasizing
the importance of presenting data in a
format that is both valuable and
understandable to multiple audiences.
A few commenters recommended CMS
include the data in the CMS Provider
Data Catalog so it is available to
researchers and others seeking to
understand the current variability and
performance within the Medicare
Promoting Interoperability Program. A
commenter suggested implementing a
‘‘star rating’’ program based on national
benchmarks to provide more meaningful
information to patients and another
commenter urged CMS to ensure any
publicly reported data will not have
unintended impacts on health care
providers or the health care system. A
few commenters recommended aligning
with the Hospital IQR Program’s policy
for publicly reporting performance data
to ensure information is easily
understood. A commenter
recommended, if CMS finalizes the
proposal, to publish points available
and points earned along with the yes
and no attestations for measures within
the Medicare Promoting Interoperability
Program.
Response: We appreciate commenters’
recommendations to include
explanations of what the Medicare
Promoting Interoperability score
indicates, as well as recommendations
for the specific data points to publish in
the future. We also appreciate
commenters’ recommendations to align
with the Hospital IQR Program’s policy
for publicly reporting. As we have
previously stated, we proposed to
publicly report these data to align with
the Hospital IQR Program and the MIPS
Promoting Interoperability performance
category public reporting policies. We
also appreciate the recommendation to
include a key for consumers alongside
the publicly reported data allowing
consumers to better understand the
data. We may consider this feedback in
future rulemaking.
After consideration of the public
comments we received, we are
finalizing our proposal to publicly
report certain Medicare Promoting
Interoperability program data submitted
by eligible hospitals and CAHs
beginning with the EHR reporting
period in CY 2023. We are finalizing our
PO 00000
Frm 00569
Fmt 4701
Sfmt 4700
49347
proposal to publish, on a CMS website
available to the public, the actual score
of up to 105 points for each eligible
hospital and CAH, and the CMS EHR
certification ID that represents the
CEHRT used by the eligible hospital or
CAH, beginning with the EHR reporting
period in CY 2023. Additionally, and as
required by section 1886(n)(4)(B) of the
Act, we are finalizing our proposal that
eligible hospitals and CAHs would have
the opportunity to review their data that
we would publish, during a 30-day
preview period before the data are made
public. We finalized our proposal to
follow our current policy and
operational process that eligible
hospitals are already familiar with for
the Hospital IQR Program and use the
Hospital Quality Reporting (HQR)
system (formerly, the QualityNet Secure
Portal) for eligible hospitals and CAHs
to access and review their Medicare
Promoting Interoperability Program data
during a 30-day preview period before
publication. We are also finalizing our
proposal to post the Medicare
Promoting Interoperability Program data
using the Compare tool hosted by
Health and Human Services currently
available at: https://www.medicare.gov/
care-compare.
8. Modifications and Additions to the
Regulatory Text
In the FY 2019 IPPS/LTCH PPS final
rule (83 FR 41636 through 41668), we
finalized the objectives, measures,
exclusion criteria, and scoring
methodology for eligible hospitals and
CAHs attesting under the Medicare
Promoting Interoperability Program
beginning with the EHR reporting
period in CY 2019 and codified these
policies in paragraph (e) under 42 CFR
495.24. We have updated the regulatory
text to reflect policy changes in the FY
2020 IPPS/LTCH PPS final rule (84 FR
42616), the FY 2021 IPPS/LTCH PPS
final rule (85 FR 59026), and the FY
2022 IPPS/LTCH PPS final rule (86 FR
45522).
We note that historically, the
objectives, measures, exclusion criteria,
and associated scoring methodology for
the Medicare Promoting Interoperability
Program have been included in both the
preamble and associated regulatory text
under 42 CFR part 495 (see, for
example, the Medicare and Medicaid
EHR Incentive Programs Stage 1 final
rule (75 FR 44314)). We also note that
many CMS quality reporting and
performance-based programs, including,
but not limited to, the Hospital VBP
Program, Hospital IQR Program, the
End-Stage Renal Disease Quality
Incentive Program (ESRD QIP), and
Quality Payment Program/MIPS, do not
E:\FR\FM\10AUR2.SGM
10AUR2
49348
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
include the text of the measures (also
referred to as the measure
specifications) adopted for those
programs in the Code of Federal
Regulations. Instead, the measure
specifications generally are included in
the rulemaking preamble or maintained
by measure stewards outside of CMS
and referenced in the preamble. For
example, the specifications for the
objectives and measures for the
Promoting Interoperability performance
category of MIPS are not included in the
regulatory text for the program under 42
CFR part 414 and instead appear in the
preamble only (for example, see CY
2022 PFS final rule (86 FR 65466
through 65485)).
We believe that aligning with the
approach taken by other CMS programs
to include measures only in the
preamble would simplify the Medicare
Promoting Interoperability Program and
minimize confusion by ensuring
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
consistency across similar CMS
programs. We also believe taking this
approach for the Medicare Promoting
Interoperability Program would reduce
burden on regulated parties, CMS, and
the general public both during and
outside of the rulemaking process.
Ensuring the objectives and measures
are described consistently in the
preamble and regulation text can
involve significant effort in terms of
time and resources, and inconsistency
has the potential to create confusion for
regulated parties and the general public.
For these reasons, we proposed to
remove the text of the objectives and
measures for the Medicare Promoting
Interoperability Program from paragraph
(e) under 42 CFR 495.24 beginning in
CY 2023 (87 FR 28593 through 28594).
We noted that this proposal does not
include any changes in policy for the
Medicare Promoting Interoperability
Program, including changes to the
PO 00000
Frm 00570
Fmt 4701
Sfmt 4700
objectives and measures (87 FR 285593).
We referred readers to the proposed
changes in policies related to objectives
and measures in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28579
through 28581). We also emphasized
that this proposal does not change our
view that the objectives and measures
are rules intended to bind regulated
parties, nor does it change our intention
to enforce the objectives and measures.
Specifically, we proposed to modify the
introductory paragraph to 42 CFR
495.24 and paragraph (e) and to
establish a new paragraph (f), under 42
CFR 495.24 as described in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR
28593 through 28594). In the event that
our proposals are not finalized, we
proposed that we would update the
regulatory text to reflect those policy
changes to the objectives and measures
in this final rule.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49349
TABLE IX.H.-06: PROPOSED MODIFICATIONS AND ADDITIONS TO THE
REGULATORY TEXT UNDER 42 CFR 495.24
Regulatory Text
Objectives and Measures
Proposed Regulatory Text Modifications and Additions
Impacted
§ 495.24 Stage 3 meaningful use
objectives and measures for EPs,
eligible hospitals and CAHs for
2019 and subsequent years
§ 495.24 --{Introductory
text)
Modification--To remove "for 2019 and subsequent years" and
add "for 2019 through 2022.
Stage 3 objectives and measures
for eligible hospitals and CAHs
attesting to CMS for 2019 and
subsequent vears
General rule
§ 495.24(e)- (Heading)
Modification--In paragraph heading: delete "for 2019 and
subsequent years" and to add "for 2019 through 2022."
§ 495.24(e)(l)(i)(C)
Modification--Delete "In 2022 and subsequent years, earn" and to
add "In 2022, earn" at§ 495.24(e)(l)(i)(C).
Protect Patient Health Information
§ 495.24(e)(4)(ii)
Modification--Remove "In 2022 and subsequent years" and to add
"In 2022" at§ 495.24(e)(4)(ii).
Electronic Prescribing
§ 495.24(e)(5)(ii)(B)*
Modification--Delete "In 2020 and subsequent years" and to add
"In 2020 through 2022" at§ 495.24(e)(5)(ii)(B).
Electronic Prescribing
§ 495.24(e)(5)(iii)(A)*
Modification--Delete "in CY 2019 and subsequent years" and to
add "in CY 2019 through CY 2022".
Electronic Prescribing
§ 495.24(e)(5)(v)*
Modification--Delete "Beginning with the EHR reporting period
in CY 2019" and to add "For the EHR reporting periods in CY
2019 through CY 2022".
Provider to Patient Exchange
§ 495 .24(e)(7)(ii)
Modification--Delete "beginning in CY 2019" and to add "for CY
2019 through CY 2022." at§ 495.24(e)(7)(ii).
Public Health and Clinical Data
Exchange
§ 495.24(e)(8)
Modification--Delete "For CY 2022 and subsequent years" and to
add "For CY 2022" at§ 495.24(e)(8)(ii) introductory text;
(e)(8)(ii)(A); (e)(8)(iii) introductory text; (e)(8)(iii)(A)(2);
(e)(8)(iii)(D)(2); and (e)(8)(iii)(E)(2).
Stage 3 objectives and measures
for eligible hospitals and CAHs
attesting to CMS for 2023 and
subsequent years
§ 495.24(f)-
Addition-- Adds new paragraph (f) that would set forth the Stage
3 objectives and measures for eligible hospitals and CAHs
attesting to CMS for 2023 and subsequent years. (See § 495.24(f)
of the regulations text for the proposed requirements.)
Addition-Add the following sentence to the end of the
introductory paragraph: "The criteria specified in paragraph (f) of
this section are applicable for eligible hospitals and CAHs
attesting to CMS for 2023 and subsequent years."
We invited public comment on our
proposed modifications and additions to
the regulatory text at 42 CFR 495.24
beginning in CY 2023.
We received no comments on this
proposal, and for the reasons stated in
the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28593 through 28594), we
are finalizing our proposal without
modification.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
9. Overview of Objectives and Measures
for the Medicare Promoting
Interoperability Program for the EHR
Reporting Period in CY 2023
For ease of reference, Table [IX.H.-07.]
lists the objectives and measures for the
Medicare Promoting Interoperability
Program for the EHR reporting period in
CY 2023 as revised to reflect the final
policies established in this final rule.
Due to our modifications to the
PO 00000
Frm 00571
Fmt 4701
Sfmt 4700
regulatory text at 42 CFR 495.24(e)
(described in section [IX.H.8.] of the
preamble of this final rule), we are
adding a column to Table [IX.H.-07.]
indicating whether the measures that
count unique patients or actions may be
calculated by reviewing only the actions
for patients whose records are
maintained using CEHRT or must be
calculated by reviewing all patient
records, which is intended to reflect the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.188
khammond on DSKJM1Z7X2PROD with RULES2
* The FY 2023 IPPS/L TCH PPS proposed rule inadvertently included an incorrect numerical
reference that has been corrected in this table.
49350
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
policy codified at 42 CFR 495.24(e)(3).
Table [IX.H.-08.] lists the 2015 Edition
certification criteria required to meet the
objectives and measures.
TABLE IX.H.-07.: SUMMARY OF OBJECTIVES AND MEASURES FOR THE
MEDICARE PROMOTING INTEROPERABILITY PROGRAM FOR THE EHR
REPORTING PERIOD IN CY 2023
Electronic
Prescribing
e-Prescribing: *
The number of
prescriptions in the
At least one hospital denominator
discharge
generated, queried for
medication order for a drug formulary, and
permissible
transmitted
prescriptions (for
electronically.
new and changed
prescriptions) is
queried for a drug
formulary and
transmitted
electronically using
certified electronic
health record
technology
CEHRT.
Query of
NIA (measure is YIN)
Prescription Drug
Monitoring Program
(PDMP):*
The number of new or
changed prescriptions
written for drugs
requiring a prescription
in order to be dispensed
other than controlled
substances for patients
discharged during the
EHR reporting period.
Any eligible hospital or
CAH that does not have
an internal pharmacy
that can accept
electronic prescriptions
and there are no
pharmacies that accept
electronic prescriptions
within 10 miles at the
start of their EHR
reporting period.
NIA (measure is YIN)
Any eligible hospital or
CAH that does not have
an internal pharmacy
that can accept
electronic prescriptions
for controlled
substances and is not
located within 10 miles
of any pharmacy that
accepts electronic
prescriptions for
controlled substances at
the start of their EHR
reporting period.
For at least one
Schedule II opioid
or Schedule III or IV
drug electronically
prescribed using
CEHRT during the
EHR reporting
period, the eligible
hospital or CAH
uses data from
CEHRT to conduct a
query of a PDMP for
prescription drug
history.
khammond on DSKJM1Z7X2PROD with RULES2
Health
Information
Exchange
VerDate Sep<11>2014
Support Electronic
Referral Loops by
00:20 Aug 10, 2022
Jkt 256001
Measure may be
calculated by
reviewing only
actions for patients
whose records are
maintained using
CEHRT for which
sufficient data were
entered in the CEHRT
to allow the record to
be saved and not
rejected due to
incomplete data.
Measure may be
calculated by
reviewing only
actions for patients
whose records are
maintained using
CEHRT for which
sufficient data were
entered in the
CEHRT to allow the
record to be saved
and not rejected due
to incomplete data.
Any eligible hospital or
CAH that could not
report on this measure
in accordance with
applicable law.
Number of transitions Number of transitions of
of care and referrals in care and referrals during
NIA
the denominator
the EHR reporting
PO 00000
Frm 00572
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
Measure may be
calculated by
reviewing only
10AUR2
ER10AU22.189
Electronic
Prescribing
Sending Health
Information:
For at least one
transition of care or
referral, the eligible
hospital or CAIi that
transitions or refers
its patient to another
setting of care or
provider of care: ( 1)
Creates a summary
of care record using
CEHRT; and (2)
Electronically
exchanges the
summary of care
record.
Health
Information
Exchange
Support Electronic
Referral Loops by
Receiving and
Reconciling Health
Information:
For at least one
electronic summary
of care record
received using
CEHRT for patient
encounters during
the EHR reporting
period for which an
eligible hospital or
CAHwasthe
receiving party of a
transition of care or
referral, or for
patient encounters
during the EHR
reporting period in
which the eligible
hospital or CAH has
never before
encountered the
patient, the eligible
hospital or CAH
conducts clinical
information
reconciliation for
medication,
medication allergy,
and current problem
list using CEHRT.
khammond on DSKJM1Z7X2PROD with RULES2
Health
Information
Exchange
HIE Bi-Directional
Exchange
where a summary of
care record was
created using CEHRT
and exchanged
electronically.
period for which the
eligible hospital or CAH
inpatient or emergency
department (POS 21 or
23) was the transitioning
or referring provider.
actions for patients
whose records are
maintained using
CEHRT for which
sufficient data were
entered in the
CEHRT to allow the
record to be saved
and not rejected due
to incomplete data.
Number of electronic
summary of care
records in the
denominator for
which clinical
information
reconciliation is
completed using
CEHRT for the
following three
clinical information
sets: (I) Medication Review of the
patient's medication,
including the name,
dosage, frequency,
and route of each
medication; (2)
Medication Allergy Review of the
patient's known
medication allergies;
and (3) Current
Problem List Review of the
patient's current and
active diagnoses.
Number of electronic
NIA
summary of care records
received using certified
electronic health record
technology (CEHRT)
for patient encounters
during the EHR
reporting period for
which an eligible
hospital or CAH was the
reconciling party of a
transition of care or
referral, and for patient
encounters during the
EHR reporting period in
which the eligible
hospital or CAH has
never before
encountered the patient.
Measure may be
calculated by
reviewing only
actions for patients
whose records are
maintained using
CEHRT for which
sufficient data were
entered in the CEHRT
to allow the record to
be saved and not
rejected due to
incomplete data.
NIA (measure is YIN)
NIA (measure is YIN)
Measure may be
calculated by
reviewing only actions
for patients whose
records are maintained
using CEHRT for
which sufficient data
were entered in the
CEHRT to allow the
NIA (measure is YIN)
The eligible hospital
or CAH must attest
to the following:
(/) Participating in
an HIE in order to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
49351
PO 00000
Frm 00573
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.190
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49352
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
enable secure, bidirectional exchange
of information to
occur for all unique
patients discharged
from the eligible
hospital or CAH
inpatient or
emergency
department (POS 21
or 23 ), and all
unique patient
records stored or
maintained in the
EHR for these
departments, during
the EHR reporting
period in accordance
with applicable law
and policy.
record to be saved and
not rejected due to
incomplete data.
(2) Participating in
an HIE that is
capable of
exchanging
information across a
broad network of
unaffiliated
exchange partners
including those
using disparate
EHRs, and not
engaging in
exclusionary
behavior when
determining
exchange partners.
(3) Using the
functions ofCEHRT
to support bidirectional exchange
with an HIE.
Health
Information
Exchange
Enabling Exchange
under TEFCA*
NIA (measure is YIN)
NIA (measure is YIN)
NIA (measure is YIN)
NIA
(1) Participating as
a signatory to a
Framework
Agreement (as that
term is defined by
the Common
Agreement for
Nationwide Health
Information
Interoperability as
published in the
Federal Register and
on ONC's website)
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00574
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.191
khammond on DSKJM1Z7X2PROD with RULES2
The eligible hospital
or CAH must attest
to the following:
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49353
in good standing
(that is not
suspended) and
enabling secure, bidirectional exchange
of information to
occur, in production,
for all unique
patients discharged
from the eligible
hospital or CAH
inpatient or
emergency
department (POS 21
or 23 ), and all
unique patient
records stored or
maintained in the
EHR for these
departments, during
the EHR reporting
period in accordance
with applicable law
and policy.
(2) Using the
functions ofCEHRT
to support bidirectional exchange
of patient
information, in
production, under
this Framework
Agreement.
Provider to
Patient
Exchange
Provide Patients
Electronic Access to
Their Health
Information:
For at least one
unique patient
discharged from the
eligible hospital or
CAH inpatient or
emergency
department (POS
2lor 23):
The number of unique
patients discharged from
an eligible hospital or
CAR inpatient or
emergency department
(POS 21 or 23) during
the EHR reporting
period.
NIA
Measure must be
calculated by
reviewing all patient
records, not just those
maintained using
CEHRT.
(2) the eligible
hospital or CAH
ensures the patient's
health information is
available for the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00575
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.192
khammond on DSKJM1Z7X2PROD with RULES2
(I) the patient (or
patient-authorized
representative) is
provided timely
access to view
online, download,
and transmit his or
her health
information; and
The number of
patients in the
denominator (or
patient authorized
representative) who
are provided timely
access to health
information to view
online, download and
transmit to a third
party and to access
using an application
of their choice that is
configured to meet the
technical
specifications of the
APT in the eligible
hospitals or CAH's
CEHRT.
49354
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Public Health
and Clinical
Data Exchange
Immunization
Registry Reporting:
NIA (measure is YIN)
NIA (measure is YIN)
Any eligible hospital or
CAH meeting one or
more of the following
criteria may be excluded
from the immunization
registry reporting
measure if the eligible
hospital or CAH: (1)
Does not administer any
immunizations to any of
the populations for
which data is collected
by their jurisdiction's
immunization registry
or IIS during the EHR
reporting period; (2)
Operates in a
jurisdiction for which
no immunization
registry or 11S is capable
of accepting the specific
standards required to
meet the certified
electronic health record
technology (CEHRT)
definition at the start of
the EHR reporting
period; or (3) Operates
in a jurisdiction where
no immunization
registry or ITS has
declared readiness to
receive immunization
data as of six months
prior to the start of the
EHR reporting period.
Measure may be
calculated by
reviewing only
actions for patients
whose records are
maintained using
CEHRT for which
sufficient data were
entered in the CEHRT
to allow the record to
be saved and not
rejected due to
incomplete data.
NIA (measure is YIN)
NIA (measure is YIN)
Any eligible hospital or
CAH meeting one or
more of the following
criteria may be excluded
from the syndromic
surveillance reporting
measure if the eligible
hospital or CAH: (1)
Does not have an
emergency department;
(2) Operates in a
Measure may be
calculated by
reviewing only
actions for patients
whose records are
maintained using
CEHRT for which
sufficient data were
entered in the CEHRT
to allow the record to
be saved and not
The eligible hospital
or CAH is in active
engagement with a
public health agency
(PHA) to submit
immunization data
and receive
immunization
forecasts and
histories from the
public health
immunization
registrylimmunizatio
n information
system (IIS).
khammond on DSKJM1Z7X2PROD with RULES2
Public Health
and Clinical
Data Exchange
Syndromic
Surveillance
Reporting:
The eligible hospital
or CAH is in active
engagement with a
public health agency
(PHA) to submit
syndromic
surveillance data
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00576
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.193
patient (or patientauthorized
representative) to
access using any
application of their
choice that is
configured to meet
the technical
specifications of the
application
programming
interface (API) in
the eligible hospital
or CAH's CEHRT.
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Public Health
and Clinical
Data Exchange
Electronic Case
Reporting:
jurisdiction for which
rejected due to
no PHA is capable of
incomplete data.
receiving electronic
syndromic surveillance
data from eligible
hospitals or CAHs in the
specific standards
required to meet the
certified electronic
health record
technology (CEHRT)
definition at the start of
the EHR reporting
period; or (3) Operates
in ajurisdiction where
no PHA has declared
readiness to receive
syndromic surveillance
data from eligible
hospitals or CAHs as of
six months prior to the
start of the EHR
reporting period.
NIA (measure is YIN)
NIA (measure is YIN)
Any eligible hospital or
CAH meeting one or
more of the following
criteria may be excluded
from the case reporting
measure if the eligible
hospital or CAH: (1)
Docs not treat or
diagnose any reportable
diseases for which data
is collected by their
jurisdiction's reportable
disease system during
the EHR reporting
period; (2) Operates in a
jurisdiction for which
no PHA is capable of
receiving electronic case
reporting data in the
specific standards
required to meet the
certified electronic
health record
technology (CEHRT)
definition at the start of
the EHR reporting
period; or (3) Operates
in a jurisdiction where
no PHS has declared
readiness to receive
electronic case reporting
data as of six months
prior to the start of the
EHR reporting period.
Measure may be
calculated by
reviewing only
actions for patients
whose records are
maintained using
CEHRT for which
sufficient data were
entered in the CEHRT
to allow the record to
be saved and not
rejected due to
incomplete data.
NIA (measure is YIN)
NIA (measure is YIN)
Any eligible hospital or
CAH meeting one or
more of the following
criteria may be excluded
Measure may be
calculated by
reviewing only
actions for patients
khammond on DSKJM1Z7X2PROD with RULES2
The eligible hospital
or CAH is in active
engagement with a
public health agency
(PHA) to submit
case reporting of
reportable
conditions.
Public Health
and Clinical
Data Exchange
VerDate Sep<11>2014
Electronic
Reportable
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00577
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.194
from an emergency
department (POS
23).
49355
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Laboratory (ELR)
Result Reporting:
The eligible hospital
or CAH is in active
engagement with a
public health agency
(PHA) to submit
ELR results.
Public Health
and Clinical
Data Exchange
Public Health
Registry Reporting:
from the case reporting
measure if the eligible
hospital or CAH: (1)
Does not perform or
order laboratory tests
that are reportable in
their jurisdiction during
(EHR reporting period;
(2) Operates in a
jurisdiction for which
no PHA is capable of
accepting the specific
ELR standards required
to meet the certified
electronic health record
technology (CEHRT)
definition at the start of
the EHR reporting
period; or (3) Operates
in a jurisdiction where
no PHA has declared
readiness to receive
ELR results from an
eligible hospital or CAH
as of 6 months prior to
the start of the EHR
reporting period.
whose records are
maintained using
CEHRT for which
sufficient data were
entered in the CEHRT
to allow the record to
be saved and not
rejected due to
incomplete data.
NIA (measure is YIN)
NIA (measure is YIN)
None
Measure may be
calculated by
reviewing only
actions for patients
whose records are
maintained using
CEHRT for which
sufficient data were
entered in the CEHRT
to allow the record to
be saved and not
rejected due to
incomplete data.
NIA (measure is YIN)
NIA (measure is YIN)
None
Measure may be
calculated by
reviewing only
actions for patients
whose records are
maintained using
CEHRT for which
sufficient data were
entered in the CEHRT
to allow the record to
be saved and not
rejected due to
incomplete data.
NIA (measure is YIN)
NIA (measure is YIN)
None
Measure may be
calculated by
reviewing only
actions for patients
whose records are
The eligible hospital
or CAH is in active
engagement with a
public health agency
(PHA) to submit
data to public health
registries.
Public Health
and Clinical
Data Exchange
Clinical Data
Registry Reporting:
khammond on DSKJM1Z7X2PROD with RULES2
The eligible hospital
or CAH is in active
engagement to
submit data to a
clinical data registry
(CDR).
Protect Patient
Health
Information
Security Risk
Analysis
Conduct or review a
security risk analysis
in accordance with
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00578
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.195
49356
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
the requirements
under45 CFR
164.308(a)(l),
including addressing
the security
(including
encryption) of data
created or
maintained by
CEHRTin
accordance with
requirements under
45CFR
164.312(a)(2)(iv)
and 45 CFR
164.306(d)(3),
implement security
updates as
necessary, and
correct identified
security deficiencies
as part of the
provider's risk
management
process. Actions
included in the
security risk analysis
measure may occur
any time during the
calendar year in
which the EHR
reporting period
occurs.
Safety Assurance
Factors for EHR
Resilience Guides
(SAFER Guides)
maintained using
CEHRT for which
sufficient data were
entered in the CEHRT
to allow the record to
be saved and not
rejected due to
incomplete data.
NIA (measure is YIN)
NIA (measure is YIN)
None
Measure may be
calculated by
reviewing only
actions for patients
whose records are
maintained using
CEHRT for which
sufficient data were
entered in the CEHRT
to allow the record to
be saved and not
rejected due to
incomplete data.
khammond on DSKJM1Z7X2PROD with RULES2
Conduct an annual
self- assessment
using all nine
SAFER Guides at
any point during the
calendar year in
which the EHR
reporting period
occurs.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00579
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.196
Protect Patient
Health
Information
49357
49358
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE IX.H.-08: MEDICARE PROMOTING INTEROPERABILITY PROGRAM
OBJECTIVES AND MEASURES AND 2015 EDITION CERTIFICATION CRITERIA
Objecth e
Electronic
Prescribing
Health
Information
Exchange
2015 Edition (CY 2023 EHR Reporting Period)1'
Measure
e-Prescribing
§ l 70.315(b)(3) Electronic prescribing
Query of PDMP
§ l 70.3 l 5(b)(3) Electronic prescribing
Support electronic referral loops by
sending health information
§ 170.315(b)(l) Transitions of care
Support electronic referral loops by
receiving and reconciling health
information
§ 170.315(b)(l) Transitions of care
§ l 70.3 l 5(b)(2) Clinical information reconciliation and
incorporation
Examples of certified health IT capabilities to support the actions
of this measure may include but are not limited to technology
certified to the following criteria:
§ 170.315(b)(l) Transitions of care
Health
Information
Exchange
(alternative)
Health Information Exchange (HIE
Bi-Directional Exchange
§ 170.3 l 5(b)(2) Clinical information reconciliation and
incorporation
§ l 70.3 l 5(g)(7) Application access -
patient selection
§ l 70.3 l 5(g)(8) Application access -
data category request
§ 170.315(g)(9) Application access -
all data request
§ 170.3 l 5(g)(10) Application access - standardized API for
patient and population services
Examples of certified health IT capabilities to support the actions
of this measure may include but are not limited to technology
certified to the following criteria:
§ 170.315(b)(l) Transitions of care
Health
Information
Exchange
(alternative)
§ l 70.3 l 5(b)(2) Clinical information reconciliation and
incorporation
Enabling Exchange Under TEFCA
§ l 70.3 l 5(g)(7) Application access -
patient selection
§ 170.3 l 5(g)(8) Application access -
data category request
§ 170.3 l 5(g)(9) Application access -
all data request
§ 170.3 l 5(g)(l 0) Application access patient and population services
standardized API for
§ 170.315(e)(1) View, download, and transmit to 3rd party
Provide patients electronic access
to their health information
patient selection
§ l 70.3 l 5(g)(8) Application access -
data category request
§ l 70.3 l 5(g)(9) Application access -
all data request
khammond on DSKJM1Z7X2PROD with RULES2
§ 170.3 l 5(g)(l 0) Application access patient and population services
Public Health
and Clinical
Data Exchange
VerDate Sep<11>2014
standardized API for
Immunization registry reporting
§ 170.315(£)(1) Transmission to immunization registries
Syndromic surveillance reporting
§ 170.315(£)(2) Transmission to public health agencies syndromic surveillance
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00580
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.197
§ 170.3 l 5(g)(7) Application access Provider to
Patient
Exchange
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
§ 170.315(f)(5) Transmission to public health agencies electronic case reporting
Electronic case reporting
Public health registry reporting
Electronic
Clinical Quality
Measures
(eCQMs)
Protect Patient
Health
Information
49359
§ 170.315(f)(6) Transmission to public health agencies antimicrobial use and resistance reporting
§ 170.315(f)(7) Transmission to public health agencies -health
care surveys
Clinical data registry reporting
No 2015 health IT certification criteria at this time.
Electronic reportable laboratory
result reporting
§ 170.315(f)(3) Transmission to public health agencies reportable laboratory tests and value/results
AUR Surveillance Reporting (for
2024)
§ 170.315(f)(6) Transmission to public health agencies antimicrobial use and resistance reporting
§ 170.315(c)(l)
eCQMs for eligible hospitals and
CAHs
§ 170.315(c)(2)
§ 170.315(c)(3)(i) and (ii)
§ 170.315(c)(4) (optional)
Security Risk Assessment
The requirements are a part of CEHRT specific to each
certification criterion.
Safety Assurance Factors for EHR
Resilience Guides (SAFER
Guides)
No 2015 health IT certification criteria at this time.
*The ONC Cures Act final rule made changes to the existing 2015 Edition Health IT Certification Criteria by introducing new
criteria, and revising and removing existing criteria (85 FR 25667 through 25668). These changes are required for the CY2023
EHR reporting period.
10. Clinical Quality Measurement for
Eligible Hospitals and CAHs
Participating in the Medicare Promoting
Interoperability Program
a. Changes to Clinical Quality Measures
in Alignment With the Hospital IQR
Program
(1) Background
khammond on DSKJM1Z7X2PROD with RULES2
Under sections 1814(l)(3)(A) and
1886(n)(3)(A) of the Act and the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
definition of ‘‘meaningful EHR user’’
under 42 CFR 495.4, eligible hospitals
and CAHs must report on clinical
quality measures selected by CMS using
CEHRT (also referred to as electronic
clinical quality measures, or eCQMs), as
part of being a meaningful EHR user
under the Medicare Promoting
Interoperability Program.
Tables IX.H.-09. through IX.H.-11.
summarize the previously finalized
eCQMs available for eligible hospitals
and CAHs to report under the Medicare
PO 00000
Frm 00581
Fmt 4701
Sfmt 4700
Promoting Interoperability Program for
the CY 2022 reporting period, the CY
2023 reporting period, and the CY 2024
reporting period and subsequent years
(86 FR 45496 through 45497). The tables
include the Safe Use of Opioids—
Concurrent Prescribing measure (NQF
#3316e), which we finalized as
mandatory for reporting beginning with
the CY 2022 reporting period (84 FR
42598 through 42600).
BILLING CODE 4120–01–P
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.198
BILLING CODE 4120–01–C
49360
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE IX.H.-09: PREVIOUSLY FINALIZED ECQMS FOR ELIGIBLE HOSPITALS
AND CAHS FOR THE CY 2022 REPORTING PERIOD
Short Name
ED-2
PC-05
STK-02
STK-03
STK-05
STK-06
VTE-1
VTE-2
Safe Use of Opioids*
Measure Name
Admit Decision Time to ED Departure Time for Admitted Patients
Exclusive Breast Milk Feeding
Discharged on Antithrombotic Theraov
Anticoagulation Therapy for Atrial Fibrillation/Flutter
Antithrombotic Therapy by the End of Hospital Day Two
Discharged on Statin Medication
Venous Thromboembolism Prophylaxis
Intensive Care Unit Venous Thromboembolism Prophylaxis
Safe Use of Opioids - Concurrent Prescribing
NQFNo.
0497
0480
0435
0436
0438
0439
0371
0372
3316e
*Reporting the Safe Use ofOpioids-Concurrent Prescribing eCQM is mandatory beginning with the CY 2022
reporting period.
TABLE IX.H.-10.: PREVIOUSLY FINALIZED ECQMS FOR ELIGIBLE
HOSPITALS AND CAHS FOR THE CY 2023 REPORTING PERIOD
Short Name
ED-2
HH-02
HH-01
PC-05
STK-02
STK-03
STK-05
STK-06
VTE-1
VTE-2
Safe Use of Opioids*
Measure Name
Admit Decision Time to ED Departure Time for Admitted Patients
Hospital Harm--Severe Hyperglycemia Measure
Hospital Harm-Severe Hypoglycemia Measure
Exclusive Breast Milk Feeding
Discharged on Antithrombotic Therapy
Anticoagulation Therapy for Atrial Fibrillation/Flutter
Antithrombotic Therapy by the End of Hospital Day Two
Discharged on Statin Medication
Venous Thromboembolism Prophylaxis
Intensive Care Unit Venous Thromboembolism Prophylaxis
Safe Use of Opioids - Concurrent Prescribing
NQFNo.
0497
3533e
3503e
0480
0435
0436
0438
0439
0371
0372
3316e
*Reporting the Safe Use of Opioids-Concurrent Prescribing eCQM is mandatory beginning with the CY 2022
reporting period.
NQFNo.
3533e
3503e
0435
0436
0438
0371
0372
3316e
*Reporting the Safe Use ofOpioids-Concurrent Prescribing eCQM is mandatory beginning with the CY 2022
reporting period.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00582
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.201
Measure Name
Hospital Harm-Severe Hyperglycemia Measure
Hospital Harm-Severe Hypoglycemia Measure
Discharged on Antithrombotic Theraov
Anticoagulation Therapy for Atrial Fibrillation/Flutter
Antithrombotic Therapy bv the End of Hospital Dav Two
Venous Thromboembolism Prophylaxis
Intensive Care Unit Venous Thromboembolism Prophylaxis
Safe Use of Opioids - Concurrent Prescribing
ER10AU22.200
Short Name
HH-02
HH-01
STK-02
STK-03
STK-05
VTE-1
VTE-2
Safe Use of Opioids*
ER10AU22.199
khammond on DSKJM1Z7X2PROD with RULES2
TABLE IX.H.11: PREVIOUSLY FINALIZED ECQMS FOR ELIGIBLE HOSPITALS
AND CAHS FOR THE CY 2024 REPORTING PERIOD AND SUBSEQUENT YEARS
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(2) eCQM Adoptions
As we have stated previously in
rulemaking (82 FR 38479), we intend to
continue to align the eCQM reporting
requirements for the Medicare
Promoting Interoperability Program
with similar requirements under the
Hospital IQR Program to the extent
feasible. Section 1886(n)(3)(B)(i)(I) of
the Act provides in part that in selecting
clinical quality measures for the
Medicare Promoting Interoperability
Program, the Secretary shall provide
preference to such measures that have
been selected for purposes of the
Hospital IQR Program (section
1886(b)(3)(B)(viii) of the Act). In
addition, section 1886(n)(3)(B)(iii) of the
Act provides that in selecting clinical
quality measures for the Medicare
Promoting Interoperability Program, and
in establishing the form and manner for
reporting, the Secretary shall seek to
avoid redundant or duplicative
reporting with reporting otherwise
required, including reporting under the
Hospital IQR Program. To minimize
redundant or duplicative reporting,
while maintaining a set of meaningful
clinical quality measures that continue
to incentivize improvement in the
quality of care provided to patients, we
proposed to adopt four new eCQMs for
the Medicare Promoting Interoperability
Program in alignment with the Hospital
IQR Program, as further discussed in
this section of the final rule.
In alignment with proposals for the
Hospital IQR Program eCQM measure
set, we proposed two new eCQMs that
address factors contributing to maternal
mortality and morbidity, beginning with
the CY 2023 reporting period.
Specifically, we proposed to add the
following eCQMs in the Medicare
Promoting Interoperability Program
eCQM measure set beginning with the
CY 2023 reporting period: (1) Severe
Obstetric Complications eCQM (NQF
NA); and (2) Cesarean Birth eCQM (NQF
NA) (87 FR 28609). We also proposed to
require mandatory reporting of the
Severe Obstetric Complications eCQM
and Cesarean Birth eCQM for the CY
2024 reporting period and for
subsequent years. We refer readers to
the discussion of the same proposals for
the Hospital IQR Program in sections
IX.E.5.d. and IX.E.5.c. of the preamble of
this final rule for more information
about these proposed measures.
We invited public comments on these
proposed measures for the Medicare
Promoting Interoperability Program.
Comment: Several commenters
support our proposal to adopt the
Severe Obstetric Complications eCQM
in alignment with the Hospital IQR
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Program. A few commenters requested a
delay in mandatory reporting until the
CY 2025 reporting period, or until the
measure receives NQF endorsement. A
commenter recommended optional
reporting if NQF endorsement is
received.
Response: We thank commenters for
their support. We disagree with
commenters who have suggested
delaying reporting until the CY 2025
reporting period. Addressing factors
contributing to maternal mortality and
morbidity is one of our priorities. The
Severe Obstetric Complications eCQM
has been developed to focus on the high
maternal morbidity and mortality rates
in the U.S. which we believe will
present important opportunities for
large-scale quality measurement and
improvement activities.1135 The Severe
Obstetric Complications eCQM was also
reviewed by the NQF Measure
Applications Workgroup (MAP)
Hospital Workgroup on December 15,
2021 and received conditional support
pending NQF endorsement.1136 The
MAP Coordinating Committee, which
provides direction to the MAP
workgroups, reviewed the Severe
Obstetric Complications eCQM on
January 19, 2022, and voted to uphold
the MAP Hospital Workgroup
recommendation for conditional
support pending NQF endorsement.1137
We acknowledge commenters’
recommendations that we seek NQF
endorsement for the measure; the Severe
Obstetric Complication eCQM was
submitted to NQF in January 2022 and
is currently under review (87 FR 28512).
Comment: Several commenters
supported the proposal to add the
Cesarean Birth eCQM and mandatory
reporting of this measure. A commenter
supported the adoption of the measure
for self-selection rather than mandatory
reporting. A commenter supported
adoption and mandatory reporting and
recommended identification of
community partners such as HIEs for
1135 National Quality Forum. (2022). Measure
Applications Partnership (MAP) 2021–2022 Final
Recommendations. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=96698.
1136 National Quality Forum. (2022). Measure
Applications Partnership 2021–2022 Considerations
for Implementing Measures in Federal Programs:
Clinician, Hospital, and Post-Acute Care Long-Term
Care: Final Report. Available at: https://
www.qualityforum.org/Publications/2022/03/MAP_
2021-.
1137 National Quality Forum. (2022). Measure
Applications Partnership 2021–2022 Considerations
for Implementing Measures in Federal Programs:
Clinician, Hospital, and Post-Acute Care Long-Term
Care: Final Report. Available at: https://
www.qualityforum.org/Publications/2022/03/MAP_
2021-2022_Considerations_for_Implementing_
Measures_Final_Report_-_Clinicians,_Hospitals,_
and_PAC-LTC.aspx.
PO 00000
Frm 00583
Fmt 4701
Sfmt 4700
49361
data capture and sharing. A few
commenters supported the measure
adoption and requested an adoption
delay until NQF endorsement is
received. A commenter supported the
proposal and requested clarifications on
the reporting requirements for nonbirthing eligible hospitals and CAHs.
Response: We thank commenters for
their support of the Cesarean Birth
eCQM. We believe adopting the
Cesarean Birth eCQM addresses a
priority area.1138 We also believe
adopting measures like the Cesarean
Birth eCQM presents unique
opportunities for large-scale quality
measurement and activities that can
improve the short- and long-term health
outcomes for mothers and children (87
FR 28508). As a result, we believe that
the timeline should not be further
delayed as the urgency of the quality
issues necessitates making the measure
mandatory for data collection from all
participating hospitals, not just those
hospitals that self-select to report on the
measure. We also believe the voluntary
reporting in the CY 2023 reporting
period before mandatory reporting
beginning with the CY 2024 reporting
period balances the urgency of the
measure with the need for EHR vendors
and hospitals to incorporate, adopt, and
implement this measure. We
acknowledge the comment regarding
community partners such as HIEs for
data capture and sharing and refer
readers to the FY 2016 IPPS/LTCH PPS
final rule (80 FR 49705 through 49708)
and the FY 2017 IPPS/LTCH PPS final
rule (81 FR 57170) for our previously
adopted eCQM file format requirements.
Under these requirements, hospitals: (1)
Must submit eCQM data via the Quality
Reporting Document Architecture
Category I (QRDA I) file format, (2) may
use third parties to submit QRDA I files
on their behalf, and (3) may either use
abstraction or pull the data from
noncertified sources in order to then
input these data into CEHRT for capture
and reporting QRDA I. However, we do
not currently have a policy to publicly
identify any such third parties. We
acknowledge commenters’
recommendations that we seek NQF
endorsement for the measure. As stated
in the FY 2023 IPPS/LTCH PPS
proposed rule, the NQF has endorsed
the chart-abstracted version of this
measure and the measure steward has
submitted the eCQM to NQF for
1138 Department of Health and Human Services.
(2020). Healthy Women, Healthy Pregnancies,
Health Futures: Action Plan to Improve Maternal
Health in America. Available at: https://
aspe.hhs.gov/sites/default/files/private/aspe-files/
264076/healthy-women-healthy-pregnancieshealthy-future-action-plan_0.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49362
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
consideration of endorsement (87 FR
28509). We also note that the measure
steward submitted this measure for
endorsement in the Spring of 2022.
Non-birthing eligible hospitals and
CAHs that do not perform deliveries
would submit a zero denominator
declaration that allows a hospital to
meet the reporting requirements for an
eCQM if the hospital does not have
patients that meet the denominator
criteria of the measure. We refer readers
to the FY 2017 IPPS/LTCH PPS final
rule (81 FR 57153) where we stated that
utilization of the zero denominator
declaration and case threshold
exemptions are considered as part of the
criteria for successful submissions when
reporting eCQMs (81 FR 57170).
Hospitals can continue to meet the
reporting requirements by submitting
data via QRDA I files, zero denominator
declaration, or case threshold
exemption (82 FR 38387). We also refer
readers to the FY 2018 IPPS/LTCH PPS
final rule (81 FR 57255 through 57257)
where we stated the finalized successful
submission requirements in the Hospital
IQR Program align with the CQM
electronic reporting requirements of the
Medicare Promoting Interoperability
Program for eligible hospitals and
CAHs. For additional information about
the requirements for successful
submission of eCQMs, we refer readers
to our QualityNet website (https://
qualitynet.cms.gov/inpatient/measures/
ecqm/participation).
Comment: Several commenters did
not support the proposal to adopt the
Severe Obstetric Complications eCQM
in the measure set, expressing concerns
about feasibility and reliability and the
lack of NQF endorsement, the proposal
for mandatory reporting, vendors’
ability to support the measure, and the
measure’s achievement of its stated goal.
A few commenters offered
recommendations about the proposal
including securing NQF endorsement
before requiring reporting in the
Medicare Promoting Interoperability
Program. A commenter encouraged CMS
to collaborate with eligible hospitals
and CAHs, and connect the
measurement to community-involved
initiatives to reduce complications.
Response: We appreciate commenters’
concerns and believe that this measure
serves as a key activity in measuring
and promoting quality improvement in
maternity care by incentivizing eligible
hospitals and CAHs to track and report
severe obstetric complications and to
publicly report the measure data for
transparency. As with the Cesarean
Birth eCQM, due to the priority on
improving maternity care particularly to
reduce morbidity and mortality during
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
inpatient births, we believe the timeline
for reporting the Severe Obstetric
Complications eCQM is appropriate and
should not be further delayed. We
acknowledge commenters’
recommendations that we seek NQF
endorsement for the measure; the Severe
Obstetric Complication eCQM was
submitted to NQF in January 2022 and
is currently under review (87 FR 28512).
Testing established the feasibility of the
measure, first in 25 hospitals across
eight healthcare sites and then in
additional hospitals unaffiliated with
the first 25. The data elements were
feasible to collect across three different
electronic health record systems.1139 All
numerator indicators and 30 of 34 risk
factors use easily mapped ICD–10 codes.
The two laboratory and two vital sign
risk factors were chosen in part because
of their availability and high rates of
extractability from the medical record.
Using NQF’s eCQM Feasibility
Scorecard template,1140 the measure
developer calculated results which
indicated high feasibility of data
elements defining the measure
specifications (98 percent), clinical and
documentation workflows compared to
measure intent (99 percent), data
element availability (95 percent) and
accuracy (98 percent), and use of data
standards (96 percent).
Comment: Several commenters did
not support the proposal to adopt the
Cesarean Birth eCQM due to concerns
about feasibility and validity, the
adequacy of the adoption timeline for
hospitals and vendors, and the measure
as an indicator of quality performance.
A few commenters recommended that
CMS consider further refining the
measure exclusions.
Response: We thank commenters for
sharing their concerns and their input
on the timeline of adoption, and
implementation of the Cesarean Birth
eCQM. With regard to feasibility and
validity, the measure steward conducted
additional measure testing in 2021. The
reliability and validity testing found the
measure to have an overall data element
agreement rate of 92.2 percent and we
therefore believe the measure to be
reliable and valid for use. As we noted
in the preamble of the FY 2023 IPPS/
LTCH PPS proposed rule, we are
proposing eCQMs that address factors
1139 Centers for Medicare & Medicaid Services.
(2018). eCQM Feasibility: How Stakeholders Inform
Measure Development. Available at: https://
www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/MMS/Downloads/eCQMFeasibility.pdf.
1140 National Quality Forum. (2022). NQF eCQM
Feasibility Scorecard. Available at: https://
www.qualityforum.org/WorkArea/
linkit.aspx?LinkIdentifier=id&ItemID=89036.
PO 00000
Frm 00584
Fmt 4701
Sfmt 4700
contributing to maternal mortality and
morbidity (87 FR 28609) in alignment
with proposals for the Hospital IQR
Program that address maternal health
outcomes. We believe the proposed
timeline of inclusion of this eCQM into
the Medicare Promoting Interoperability
Program measure set beginning with the
CY 2023 EHR reporting period, followed
by mandatory reporting beginning with
the CY 2024 reporting period and for
subsequent years, provides sufficient
time for EHR vendors and hospitals to
incorporate, adopt, and implement the
measure. We believe one year of
voluntary reporting is sufficient because
as noted in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28509), in 2020,
the measure steward introduced the
Cesarean Birth eCQM as one of the
available eCQMs hospitals can choose
for data submission to meet The Joint
Commission’s ORYX® requirements.
We agree that continued monitoring
of the measure is important. We believe
collecting data and reporting results will
provide a critical baseline and we will
monitor the data and any unintended
consequences of the measure. While we
agree that there are many ways to track
data related to the C-section rate in the
United States, and ultimately reduce
excess non-medically indicated Csections, the standards and
comprehensiveness of initiatives can
vary widely and we do not believe
broadening exclusion criteria or risk
adjustment is necessary at this time. As
we noted in the FY 2023 IPPS/LTCH
PPS proposed rule, when developing
the measure, the exclusion criteria were
chosen to ensure that the focus
population would be women with
NTSV pregnancies (86 FR 28510).
Barring the presence of other comorbidities, such women often have a
lower risk of maternal morbidity and
mortality at the time of delivery than
their counterparts who have undergone
a previous C-section (87 FR 28510). As
a result of the existing exclusion
criteria, the population denominator
allows the measure to focus on a more
homogeneous group where the greatest
improvement opportunity exists. As
evidenced by variation in rates of NTSV
C-sections, clinical practice patterns in
particular may affect this rate (87 FR
28510). Lowering the C-section rate in
NTSV pregnancies is important because
C-sections may carry a higher risk of
subsequent miscarriage, placental
abnormalities, and repeat C-section (87
FR 28510). The rates of ruptured uteri,
unplanned hysterectomies, and ICU
admission are higher among women
who deliver via C-section for the first
time than those who deliver vaginally
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
for the first time across all races and
ethnicities. However, non-Hispanic
Black women who deliver via C-section
for the first time had the highest rates
of uterine rupture and ICU admission
compared with all other races.1141
Including a comprehensive set of
maternal medical exclusions would add
data collection burdens without
commensurate benefit. After
consideration of the public comments
we received, we are finalizing our
proposal to add the following eCQMs in
the Medicare Promoting Interoperability
Program eCQM measure set beginning
with the CY 2023 reporting period: (1)
Severe Obstetric Complications eCQM
(NQF NA); and (2) Cesarean Birth eCQM
(NQF NA), and we are finalizing our
proposal to require mandatory reporting
49363
of the Severe Obstetric Complications
eCQM and the Cesarean Birth eCQM for
the CY 2024 reporting period and for
subsequent years. We refer readers to
the discussion of the same proposals for
the Hospital IQR Program in sections
IX.E.5.d. and IX.E.5.c. of the preamble of
this final rule for more information
about these finalized policies.
TABLE IX.H.-12.: ECQMS FOR ELIGIBLE HOSPITALS AND CAHS FOR THE CY
2023 REPORTING PERIOD
Short Name
ED-2
HH-02
HH-01
PC-05
STK-02
STK-03
STK-05
STK-06
VTE-1
VTE-2
Safe Use of Opioids*
ePC-07 /SMM**
ePC-02**
Measure Name
Admit Decision Time to ED Departure Time for Admitted Patients
Hospital Harm-Severe Hyperglycemia Measure
Hospital Harm-Severe Hypoglycemia Measure
Exclusive Breast Milk Feeding
Discharged on Antithrombotic Therapy
Anticoagulation Therapy for Atrial Fibrillation/Flutter
Antithrombotic Therapy by the End of Hospital Day Two
Discharged on Statin Medication
Venous Thromboembolism Prophylaxis
Intensive Care Unit Venous Thromboembolism Prophylaxis
Safe Use of Opioids - Concurrent Prescribing
Severe Obstetric Complications
Cesarean Birth
NQFNo.
0497
3533e
3503e
0480
0435
0436
0438
0439
0371
0372
3316e
NA
NA
We also proposed, in alignment with
the proposals for the Hospital IQR
Program eCQM measure set, to adopt
two new eCQMs which eligible
hospitals and CAHs can self-select to
report on for the CY 2024 reporting
period and subsequent years. These
eCQMs focus on opioid-related adverse
events during an admission to an acute
care hospital, and malnutrition.
Specifically, we proposed to add the
following two additional eCQMs to the
Medicare Promoting Interoperability
Program eCQM measure set on which
hospitals can self-select to report
beginning with the CY 2024 reporting
period: Hospital Harm-Opioid-Related
Adverse Event eCQM (NQF #3501e) and
Global Malnutrition Composite Score
eCQM (NQF #3592e). Table IX.H.-13
summarizes the finalized eCQMs in the
Medicare Promoting Interoperability
Program for the CY 2024 reporting
period and subsequent years. We refer
readers to the discussion of the same
proposals for the Hospital IQR Program
in sections IX.E.5.e. and IX.E.5.f. of the
preamble of this final rule for more
information about these measures and
our policy reasons for proposing them.
We invited public comments on these
proposed measures for the Medicare
Promoting Interoperability Program.
Comment: Many commenters
expressed support for our proposal to
adopt the Hospital Harm—Opioid
Related Adverse Events eCQM (NQF
#3501e), stating that its implementation
will incentivize opioid adverse event
monitoring and reporting, which
commenters believe may also address a
disproportionate number of inpatient
overdose deaths among racial and
ethnic minorities. A commenter
supported the measure and requested
information about performance and
what the intended action with the
collected data would be.
Response: We thank commenters for
their support of the measure. The intent
of the measure is to identify if hospitals
have particularly high rates of naloxone
use, as an indicator of high rates of overadministration of opioids in the
inpatient setting, and thereby
incentivize improved clinical practices
when administering opioids.
Comment: A commenter did not
support the proposed adoption of the
Hospital Harm—Opioid Related
Adverse Events eCQM (NQF #3501e),
because the measure focuses on a rare
event rather than large populationbased approaches and could create
unintended consequences and
recommended CMS consider or create
an alternative measure. A commenter
suggested considering a re-specification
of the measure for the outpatient setting.
A commenter expressed concern that
the Hospital Harm—Opioid-Related
Adverse Event eCQM does not focus on
undertreatment of pain or other
symptoms for which opioids may be
appropriately prescribed.
1141 Curtin, S.C., Gregory, K.D., Korst, L.M.,
Uddin, S.F.G. (2015) Maternal Morbidity for
Vaginal and Cesarean Deliveries, According to
Previous Cesarean History: New Data from the Birth
Certificate, 2013. National Vital Statistics Reports,
64(4). Available at: https://www.cdc.gov/nchs/data/
nvsr/nvsr64/nvsr64_04.pdf.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00585
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.202
khammond on DSKJM1Z7X2PROD with RULES2
*Reporting the Safe Use of Opioids-Concurrent Prescribing eCQM is mandatory beginning with the CY 2022
reporting period.
** eCQM available for reporting in the CY 2023 reporting period.
49364
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Response: We thank commenters for
their support of the measure. The intent
of the measure is not to reduce
clinically appropriate use of naloxone,
nor to bring the measure rate to zero, but
to identify if hospitals have particularly
high rates of naloxone use as an
indicator of high rates of overadministration of opioids in the
inpatient setting, and thereby
incentivize improved clinical practices
when administering opioids. We
acknowledge that some interested
parties have expressed concern
regarding the measure’s impact given
the small number of overall events.
However, our overall analysis during
testing demonstrated the rate of ORAE
ranged from 1.1 to 6.1 per 1,000
qualified inpatient encounters, signaling
there is still opportunity for
improvement. We also acknowledge that
some interested parties have expressed
concern that implementation of the
measure could result in deterring or
delaying clinically appropriate
administration of naloxone or underprescribing of opioids for pain control
when clinically necessary. However, we
reiterate that naloxone is a life-saving
emergent therapy with clear and
unambiguous applications in the setting
of opioid overdose and we note that it
would be unethical to withhold
lifesaving medication.
Comment: Many commenters
expressed support for our proposal to
adopt the Global Malnutrition
Composite Score eCQM as there is a gap
between performance measures focused
on nutrition care and malnutrition. With
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
malnutrition contributing to increased
lengths of stay, complications and
mortality, commenters believe this
measure will benefit patients, families,
caregivers and health care providers.
Response: We thank the commenters
for their support of our proposal and
agree that the adoption of the Global
Malnutrition Composite Score eCQM
may help address several priority areas
identified in the CMS Equity Plan for
Medicare. This would allow us to
further evaluate the impact of
disparities, while integrating equity
solutions across CMS programs, and
increasing the ability of the healthcare
workforce to meet the needs of
populations that have been
disadvantaged and/or underserved by
the healthcare system.
Comment: A commenter did not
support our proposal to adopt the
Global Malnutrition Composite Score
due to the practicality of translating a
complex multi-step measure into an
eCQM, and have instead requested
delaying its adoption for one additional
year. A few commenters expressed
concern about operationalizing and
implementing the measure, its value,
and potential duplication with the CMS
proposed Health Related Social Needs
screening measure.
Response: We appreciate the
commenters’ concerns about our
proposed measure. The Screening for
Social Drivers of Health measure,
discussed in section IX.E.5.b. of the
preamble of this final rule, and the
Global Malnutrition Composite Score
eCQM both speak to nutrition as a
PO 00000
Frm 00586
Fmt 4701
Sfmt 4700
driver of health because it is an
important contributor to a healthful
population. However, the measures
address different but related goals. The
Screening for Social Drivers of Health
measure focuses on incentivizing the
screening and identifying of patients for
food insecurity, defined as limited or
uncertain access to adequate quality or
quantity of food (87 FR 28500). The
Global Malnutrition Composite Score
eCQM focuses not only on screening for
malnutrition risk (of which food
insecurity may be a contributing factor)
but also the performance of a nutrition
assessment and development of a care
plan for identified malnourished
patients (87 FR 28520). We believe these
two measures are equally important and
complementary, but not duplicative as
they measure different aspects of the
care process. We also appreciate the
recommendation to delay adoption for
one additional year, however we
disagree because we have proposed to
adopt this as a self-select eCQM.
Additionally, we have not yet
determined future plans with respect to
requiring reporting of this measure. Any
proposal to mandate reporting this
eCQM would be made through future
notice-and-comment rulemaking.
After consideration of the public
comments we received, we are
finalizing our proposals as proposed.
We refer readers to the discussion of the
same proposals for the Hospital IQR
Program in sections IX.E.5.e. and
IX.E.5.f. of the preamble of this final
rule for more information about these
finalized policies.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49365
TABLE IX.H.-13: ECQMS FOR ELIGIBLE HOSPITALS AND CAHS FOR THE CY
2024 REPORTING PERIOD AND SUBSEQUENT YEARS
Short Name
HH-02
HH-01
STK-02
Measure Name
Hospital Harm-Severe Hyperglycemia Measure
Hospital Harm-Severe Hypoglycemia Measure
Discharged on Antithrombotic Therapy
NQFNo.
3533e
3503e
0435
STK-03
STK-05
VTE-1
VTE-2
Safe Use of Opioids*
ePC-07 /SMM***
ePC-02***
HH-ORAE****
GMCS****
Anticoagulation Therapy for Atrial Fibrillation/Flutter
Antithrombotic Therapy by the End of Hospital Day Two
Venous Thromboembolism Prophylaxis
Intensive Care Unit Venous Thromboembolism Prophylaxis
Safe Use of Opioids - Concurrent Prescribing
Severe Obstetric Complications
Cesarean Birth
Hospital Harm-Opioid Related Adverse Event
Global Malnutrition Composite Score
0436
0438
0371
0372
3316e
NA
NA
3501e
3592e
b. eCQM Reporting and Submission
Requirements for the CY 2024 Reporting
Period and Subsequent Years
Consistent with our goal to align the
eCQM reporting periods and criteria in
the Medicare Promoting Interoperability
Program and the Hospital IQR Program,
we previously finalized the requirement
that eligible hospitals and CAHs
reporting eCQMs for the Medicare
Promoting Interoperability Program
must report four calendar quarters of
data from CY 2023 and each subsequent
year for: (a) Three self-selected eCQMs
from the set of available eCQMs for CY
2023 and each subsequent year, and (b)
the Safe Use of Opioids-Concurrent
Prescribing eCQM (NQF #3316e), for a
total of four eCQMs (85 FR 58975). We
did not propose to change the data
reporting and submission requirements
for the CY 2023 reporting period.
In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28610), in
alignment with proposals for the
Hospital IQR Program, we proposed to
modify the eCQM reporting and
submission requirements under the
Medicare Promoting Interoperability
Program for eligible hospitals and CAHs
beginning with the CY 2024 reporting
period such that hospitals would be
required to report four calendar quarters
of data for each required eCQM: (1)
Three self-selected eCQMs; (2) the Safe
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Use of Opioids—Concurrent Prescribing
eCQM; (3) the proposed Severe
Obstetric Complications eCQM; and (4)
the proposed Cesarean Birth eCQM, for
a total of six eCQMs, beginning with the
CY 2024 reporting period and for
subsequent years. We noted that the
number of calendar quarters of data
required and the number of self-selected
eCQMs would remain the same, but we
proposed to increase the number of
eCQMs that all eligible hospitals and
CAHs would be required to report from
one to three. This proposal was made in
conjunction with our proposals
discussed in the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28609), in
which we proposed to adopt the Severe
Obstetric Complications eCQM and
Cesarean Birth eCQM, respectively. We
stated that we believe by 2024, eligible
hospitals and CAHs will have had
sufficient experience with eCQM
reporting to propose an increase in the
number of required eCQMs from four to
six eCQMs. In addition, we stated that
we believe in light of the maternal
health crisis as described in sections
IX.E.5.d.(1) and IX.E.5.c.(1) of this final
rule, and our commitment to reducing
unacceptably high maternal morbidity
and mortality rates, it is important to
collect and utilize quality measure data
focused on maternal health to incentive
improved quality of care.
PO 00000
Frm 00587
Fmt 4701
Sfmt 4700
As detailed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28610),
we proposed that if our proposals to
adopt the Severe Obstetric
Complications eCQM and the Cesarean
Birth eCQM are finalized, these
measures would be available for eligible
hospitals and CAHs to select as one of
their three self-selected eCQMs for the
CY 2023 reporting period, and then
beginning with the CY 2024 reporting
period, all eligible hospitals and CAHs
would be required to report these two
eCQMs. We referred readers to the FY
2023 IPPS/LTCH PPS proposed rule (87
FR 28555) for the reporting and
submission requirements associated
with the proposal to modify the eCQM
reporting requirements for the Hospital
IQR Program. We invited public
comments on these proposed eCQM
reporting requirements.
Comment: A few commenters
supported our proposal to modify the
reporting and submission requirements
for eCQMs such that beginning with the
CY 2024 reporting period/FY 2026
payment determination hospitals would
be required to submit four calendar
quarters of data from three self-selected
eCQMs and three required eCQMs.
Response: We thank commenters for
their support.
Comment: A commenter supported
the proposal to modify eCQM reporting
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.203
khammond on DSKJM1Z7X2PROD with RULES2
*Reporting the Safe Use ofOpioids-Concurrent Prescribing eCQM is mandatory beginning with the CY 2022
reporting period.
*** Reporting the Severe Obstetric Complications eCQM (ePC-07) and Cesarean Birth (ePC-02) is mandatory
beginning with the CY 2024 reporting period.
****Hospital Harm-Opioid Related Adverse Event eCQM and Global Malnutrition Composite Score eCQM
available for reporting beginning with the CY 2024 reporting period.
khammond on DSKJM1Z7X2PROD with RULES2
49366
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
and submission requirements and
requested two years of voluntary
reporting for the Severe Obstetric
Complications eCQM before mandatory
reporting.
Response: We thank the commenter
for their support of our proposal but,
regarding a delay in mandatory
reporting of our two finalized perinatal
eCQMs, reiterate that addressing the
maternal health crisis, improving
maternal health, and closing any gaps
that exist as a result of health disparities
are among our top goals and mandatory
reporting of the Severe Obstetric
Complications eCQM beginning with
the CY 2024 reporting period advances
that goal.
Comment: Many commenters did not
support the proposal to modify eCQM
reporting and submission requirements
due to current eCQM challenges such as
the lack of frequent and actionable
eCQM performance feedback,
difficulties extracting data from
production ready eCQM products
delivered by developers, insufficient
time for vendor design and development
and for hospitals to complete testing,
validation, staff education before
required reporting, and the costly and
prolonged process of eCQM health care
provider adoption. A few commenters
recommended a delayed and phase
implementation of modified reporting
and submission requirements as clinical
quality measure reporting is moving
from eCQMs to dQMs.
Response: We appreciate commenters’
concerns related to modifications of the
eCQM reporting and submission
requirements due to eCQM reporting
challenges experienced by hospitals. We
urge hospitals to continue to work with
their vendor to secure timely delivery of
their products and we believe our
finalized policy will offer opportunities
for hospitals that are prepared to
voluntarily report the two perinatal
eCQMs to do so for the CY 2023
reporting period while providing more
than one year for other hospitals to
prepare and implement the two
perinatal eCQMs for the CY 2024
reporting period.
With respect to the challenges of
extracting eCQM data, we believe that
our proposal to modify the eCQM
reporting and submission requirements
advances our goal of increasing the use
of EHR data for quality measurement
and improvement. We also believe the
implementation of the production ready
product supports feasible data
extraction processes, and we will be
considerate of this feedback in future
rulemaking.
We understand commenters’ concerns
related to the effort by hospitals to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
customize their health IT and to
potentially update workflows and train
staff following vendor delivery of their
product; however, we expect the burden
for hospitals to be no greater than that
already required to comply with CMS
annual updates which includes the
eCQM specifications, educational
materials, value sets, code systems
direct reference codes, and terminology
that are posted on the eCQI Resource
Center.1142
We recognize the process of hospital
adoption of eCQMs can be costly and
prolonged. We refer readers to section
XII.B.9.e. of the preamble of this final
rule (information collection
requirements) for a detailed discussion
of our burden estimates associated with
the modification of our eCQM reporting
and submission requirements. We
believe the long-term benefits associated
with reporting a full year of data for six
eCQMs will outweigh the burdens and
that increasing the number of eCQMs for
which hospitals are required to report
will produce more comprehensive and
reliable quality information for patients
and health care providers. We will
continue to look across CMS programs
to identify areas for further streamlining
of reporting requirements. Also, as
referenced in section IX.C. of the
preamble of this final rule, in the
‘‘Continuing to Advance Digital Quality
Measurement and Use of Fast
Healthcare Interoperability Resources
(FHIR) in Hospital Quality Programs—
Request for Information,’’ we also
believe utilizing standardized data for
EHR-based measurement (based on the
FHIR standard) and aligning where
possible with other interoperability
requirements can reduce the data
collection burden incurred by health
care providers.
For the purpose of reporting quality
measures and alleviating the concern
about the costly and prolonged process
of eCQM adoption. We appreciate the
comments and interest in opportunities
to reduce reporting burden, and we will
continue to take all under consideration
as we develop future regulatory
proposals.
Comment: A commenter did not
support due to the cost, time and
limited IT resources barriers faced by
small rural hospitals for EHR changes
and updates.
Response: We appreciate the
commenter’s concern regarding the cost,
time and IT resources required to in
eCQM reporting and submission. We
establish program requirements
considering all hospitals and CAHs that
participate in the Medicare Promoting
1142 https://ecqi.healthit.gov/.
PO 00000
Frm 00588
Fmt 4701
Sfmt 4700
Interoperability Program for eligible
hospitals and CAHs, which involves a
wide spectrum of capabilities and
resources with respect to eCQM
reporting. We acknowledge that
advancing quality improvement
supported by health IT can present
unique challenges for small or rural
hospitals. We believe our finalized
policy to modify the eCQM reporting
and submission requirements will offer
opportunities for hospitals that are
prepared to voluntarily report the two
perinatal eCQMs—Cesarean Birth and
Severe Obstetric Complications—to do
so for the CY 2023 reporting period,
while providing more than one year for
other hospitals to prepare and
implement the two perinatal eCQMs for
mandatory reporting in the CY 2024
reporting period and subsequent years.
We recognize the cost and time
associated with eCQM adoption and
refer readers to section XII.B.9.k. of the
preamble of this final rule (information
collection requirements) for a
discussion of our burden estimates
associated with the modification of our
eCQM reporting and submission
requirements. When considering
modifications to program requirements,
we have, and may continue to, consider
the recommendations from the rural
health care providers to ensure eCQMs
policies are meaningful to quality
improvement for small, rural hospitals.
Comment: A few commenters did not
support the proposal to modify eCQM
reporting and submission requirements
and recommended a phased and
incremental timeline for increasing the
number of required eCQMs. A
commenter recommended financial
incentives to support hospitals with
changing eCQM requirements.
Response: We thank the commenters
and acknowledge the concerns about the
pace of change in eCQM reporting and
submission policy. However, we believe
that hospitals have had several years to
report eCQM data. After holding eCQM
reporting and submission policies
constant for a number of years in order
to give hospitals and their vendors
additional time to improve eCQM
reporting capabilities, we intended to
transition to more robust reporting.
Comment: Several commenters
offered recommendations such as
alignment of eCQM data submissions
with the quarterly timeline for
submission of Hospital IQR Program’s
chart-based measure data, an analysis of
required measures and a proposal to
remove measures less impactful to
improved health outcomes, limit eCQMs
to self-selection until hospitals gain
experience to confirm feasibility and
reliability, delay of public reporting
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
until one year of data is reported and a
proposal for a quarter exception rather
than a full year hardship exception for
eCQM reporting in future rulemaking. A
commenter recommended
reconsideration of the proposal.
Response: We thank commenters for
their comments. Concerning the eCQM
data submission timeline, the data
submission deadline for eCQM data
under the Medicare Promoting
Interoperability Program for eligible
hospitals and CAHs continues to be the
end two months following the close of
the calendar year. We note the
submission deadline may be moved to
the next business day if it falls on a
weekend or Federal holiday. We did not
propose any changes to this policy in
the FY 2023 IPPS/LTCH proposed rule.
We plan to monitor the implementation
of the finalized eCQM data reporting
and submission requirements and
welcome continued feedback from
stakeholders through webinars,
listservs, and help desk questions.
We utilize principles and frameworks
to assess clinical quality measures
included in our programs including the
CMS National Quality Strategy 1143 and
the Meaningful Measures Initiative,1144
which identifies high-priority areas for
quality measurement and improvement
to assess core issues most critical to
high-quality healthcare and improving
patient outcomes. In 2021, we launched
Meaningful Measures 2.0 to promote
innovation and modernization of all
aspects of quality, and to address a wide
variety of settings, stakeholders, and
measure requirements.1145 We will
continue to utilize this approach.
We believe the Cesarean Birth eCQM
and Severe Obstetric Complications
eCQM present unique opportunities for
large-scale quality measurement and
activities that can improve the shortand long-term health outcomes for
mothers and children (87 FR 28508) and
self-selection of these measures would
not advance us toward our short-and
long-term goals.
We acknowledge commenters’
concern about public reporting and refer
readers to the FY2021 IPPS/LTCH PPS
final rule (85 FR 58976) for a discussion
1143 https://www.cms.gov/Medicare/QualityInitiatives-Patient-Assessment-Instruments/ValueBased-Programs/CMS-Quality-Strategy.
1144 https://www.cms.gov/Medicare/QualityInitiatives-Patient-Assessment-Instruments/
QualityInitiativesGenInfo/MMF/General-info-SubPage.
1145 Centers for Medicare & Medicaid Services.
(2021). Meaningful Measures 2.0: Moving from
Measure Reduction to Modernization. Available at:
https://www.cms.gov/meaningful-measures-20moving-measure-reduction-modernization. We note
that Meaningful Measures 2.0 is still under
development.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
of our previously finalized public
reporting of eCQM data policy.
Additionally, we would like to remind
readers that the Medicare Promoting
Interoperability Program allows
hardship exception applications for
extreme and uncontrollable
circumstances, including vendor issues.
Additional information on this process
is available at: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
EHRIncentivePrograms/PaymentAdj_
Hardship. We did not propose any
changes to this policy in the FY 2023
IPPS/LTCH PPS proposed rule. We
thank commenters for their
recommendations. We acknowledge
commenters’ recommendations, and we
may continue to take all comments into
account as we develop future regulatory
proposals.
Comment: A commenter requested
clarification for hospitals without
obstetric departments or providing labor
and delivery services. A commenter
expressed concern that hospitals could
be penalized due to hospital or vendor
inability to meet reporting and
submission requirements.
Response: If a hospital does not have
an obstetrics department or has few or
no deliveries during a reporting period,
the hospital may submit a zerodenominator declaration or a case
threshold exemption for an eCQM that
is being reported. A QRDA Category I
file with patients meeting the initial
patient population of the applicable
measures, a zero-denominator
declaration and/or a case threshold
exemption all count toward a successful
submission for eCQMs for the Medicare
EHR Incentive Program (now called the
Promoting Interoperability Program) (82
FR 38482). Hospitals may request a
hardship exception if they are unable to
fulfill program requirements due to
extreme and uncontrollable
circumstances, including vendor issues.
Additional information on this process
is available at: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
EHRIncentivePrograms/PaymentAdj_
Hardship.
After consideration of the public
comments we received, we are
finalizing our proposal as proposed.
11. Patient Access to Health Information
Measure—Request for Information (RFI)
Patient use of portals to access their
health information has been tied to
benefits such as improvements in
access, quality of care, and health
outcomes, and reductions in healthcare
expenditures.1146 In particular, access to
1146 Ronda MC, Dijkhorst-Oei LT, Rutten GE.
Reasons and barriers for using a patient portal:
PO 00000
Frm 00589
Fmt 4701
Sfmt 4700
49367
health information has been shown to
enable the discovery of medical errors,
to improve medication adherence, and
to promote communication between the
patient and health care provider.1147
However, despite the fact that surveyed
patients experiencing shared access to
notes with health care providers has
been largely positive,1148 voluntary
uptake and use of patient portals has
been low, with nearly two-thirds of
hospitals having less than 25 percent of
patients activate access to the hospital’s
patient portal in 2017.1149 Health care
provider encouragement (and other
facilitating conditions), perceived
usefulness, ease of use, control of health
information, and enhanced
communication are demonstrated as
facilitators, while concerns of privacy,
security, and lack of awareness have
been tied to barriers of use.1150 1151
The Health Information National
Trends Survey (HINTS), a large,
nationally representative survey
operated by the National Cancer
Institute (with support from ONC), is
conducted routinely and contains key
utilization data on consumer access and
use of their online medical record
through patient portals. The HINTS
results showed the rates of individuals
being offered and subsequently using
their health information through a
patient portal, as well as use of mobile
health applications (apps) and the role
health care providers play in
survey among patients with diabetes mellitus. J
Med internet Res. 2014 Nov 25;16(11):e263. doi:
10.2196/jmir.3457. PMID: 25424228; PMCID:
PMC4260081.
1147 Wildenbos GA, Peute L, Jaspers M.
Facilitators and Barriers of Electronic Health Record
Patient Portal Adoption by Older Adults: A
Literature Study. Stud Health Technol Inform.
2017;235:308–312. PMID: 28423804.
1148 Walker J, Leveille S, Bell S, Chimowitz H,
Dong Z, Elmore JG, Fernandez L, Fossa A, Gerard
M, Fitzgerald P, Harcourt K, Jackson S, Payne TH,
Perez J, Shucard H, Stametz R, DesRoches C,
Delbanco T. OpenNotes After 7 Years: Patient
Experiences With Ongoing Access to Their
Clinicians’ Outpatient Visit Notes. J Med internet
Res.
1149 Henry J, Barker W, Kachay L. Office of the
National Coordinator for Health Information
Technology (ONC) Data Brief No. 45 (April 2019).
Electronic Capabilities for Patient Engagement
among U.S. Non-Federal Acute Care Hospitals:
2013–2017. Available at: https://www.healthit.gov/
sites/default/files/page/2019–04/
AHApatientengagement.pdf.
1150 Powell KR. Patient-Perceived Facilitators of
and Barriers to Electronic Portal Use: A Systematic
Review. Comput Inform Nurs. 2017
Nov;35(11):565–573. doi: 10.1097/
CIN.0000000000000377. PMID: 28723832.
1151 Alaa A. Abd-alrazaq, Bridgette M. Bewick,
Tracey Farragher, Peter Gardner, Factors that affect
the use of electronic personal health records among
patients: A systematic review, International Journal
of Medical Informatics, Volume 126, 2019, Pages
164–175, ISSN 1386–5056, https://doi.org/10.1016/
j.ijmedinf.2019.03.014.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49368
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
encouraging use.1152 Results showed
that health care providers and staff have
a substantial role in influencing patient
use of the portal.
In the past for the Medicare
Promoting Interoperability Program, we
attempted to promote patient access to
their health information through
measuring the number of patients who
actively engaged with the electronic
health record through the View,
Download, or Transmit (VDT) measure
at 42 CFR 495.24(c)(6)(ii)(A). In the FY
2019 IPPS/LTCH PPS final rule (83 FR
41636 through 41668), we renamed the
Patient Electronic Access Objective to
the Provider to Patient Exchange
Objective and updated the measures
within the Provider to Patient Exchange
Objective. Specifically, we removed the
standalone VDT measure from the
Medicare Promoting Interoperability
Program in response to interested party
feedback, including hospitals and
hospital associations detailing the
significant challenges they faced in
implementing measures that require
patient action (83 FR 41665). These
challenges included, but were not
limited to, patients who have limited
knowledge of, proficiency with, or
access to information technology;
patients declining to access the portals
provided by the eligible hospital or CAH
to view, download, and transmit their
health information via this platform; as
well as the lack of availability of userfriendly portals and the immaturity of
the health IT infrastructure needed to
facilitate useful access and use of their
own health information. We also noted
that data analysis of the VDT measure
showed low percentages of patients
taking action to view, download, and
transmit their health information (83 FR
41665). Additionally, in the FY 2019
IPPS/LTCH PPS final rule (83 FR 41661
through 41663) we changed the name of
the Provide Patient Access measure at
42 CFR 495.24(c)(5)(ii)(A) to Provide
Patients Electronic Access to Their
Health Information at 42 CFR
495.24(e)(7)(ii) and finalized changes to
the measure description. These measure
changes included a requirement for
eligible hospitals or CAHs to provide
timely access for viewing, downloading
or transmitting their health information
for at least one unique patient
discharged using any application of the
patient’s choice (83 FR 41661 through
41663). This change emphasized timely
electronic access of patient health
1152 Johnson C, Richwine C, Patel V. Office of the
National Coordinator for Health Information
Technology (ONC) Data Brief, No. 57 (September
2021). Individuals’ Access and Use of Patient
Portals and Smartphone Health Apps, 2020.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
information rather than requiring health
care providers to be accountable for
patient actions.
Through the current Provide Patients
Electronic Access to Their Health
Information measure in the Provider to
Patient Exchange Objective, we are
ensuring that patients have access to
their health information through any
application of their choice that is
configured to meet the technical
specifications of the Application
Programing Interface (API) in the
CEHRT of the eligible hospital or CAH.
Promoting the use of API-enabled
applications that provide timely access
to updated information whenever the
patient needs that information is an
integral step in enhancing patient access
and use of their health information.
These API-enabled applications should
be configured using standardized
technology and contain the information
the patient needs to make informed
decisions about their care in a way the
patient understands, and that recognizes
the community’s level of access to
devices and internet connectivity. While
we removed the VDT measure holding
eligible hospitals and CAHs responsible
for patient action (83 FR 41665), we still
require that the technical capabilities be
in place within an eligible hospital’s or
CAH’s CEHRT through the Provide
Patients Electronic Access to Their
Health Information measure should
patients choose to access and use their
health information (83 FR 41661
through 41663).
We continue to believe in the
importance of taking a patient-centered
approach to health information access
and moving to a system in which
patients have immediate access to their
electronic health information and can be
assured that their health information
will follow them as they move
throughout the health care system.
Recognizing the concerns and barriers
with the previous VDT measure
discussed previously, but
acknowledging the advancements made
within the health IT industry over the
past few years, this request for
information (RFI) sought a broad array
of public comments regarding how to
further promote equitable patient access
and use of their health information
without adding unnecessary burden on
the hospital or health care provider.
Specifically, we sought public comment
on the following questions:
• Moving beyond providing the
information and technical capabilities to
access their data, are there additional
approaches to promote patient access
and use of their health information? Are
there examples of successful approaches
or initiatives that have enhanced patient
PO 00000
Frm 00590
Fmt 4701
Sfmt 4700
access and use of their health
information?
++ Would allowing patients to add
information to their records be useful in
promoting patient access and
utilization? Are there other incentives
that would promote patient access?
++ Are there potential unintended
consequences in allowing patients to
add information to their records? What
could be done to mitigate any potential
unintended consequences?
++ Are there certain tools found to be
useful in promoting patient access and
use of their health information?
• Recent studies have raised concerns
about the presence of racial bias and
stigmatizing language within EHRs that
could lead to unintended consequences
if patients were to obtain disparaging
notes regarding their medical
care.1153 1154
++ What policy, implementation
strategies, or other considerations are
necessary to address existing racial bias
or other biases and prevent use of
stigmatizing language?
• Additional analysis of HINTS data
provides insights into common barriers
to patient portal access and use as well
as characteristics that can help predict
which individuals are more likely to
experience certain barriers (for example,
preference for in-person communication
with their health care provider is one of
the most prevalent barriers experienced
more often by older adults and
women).1155
++ What are the most common
barriers to patient access and use of
their health information that have been
observed? Are there differences by
populations or individual
characteristics?
• Patients’ health information may be
found in multiple patient portals. How
could CMS or HHS facilitate
individuals’ ability to access all their
health information in one place?
++ If patient portals connected to a
network participating in the recently
launched TEFCA,1156 1157 would this
1153 Sun M, Oliwa T, Peek ME, Tung EL. Negative
Patient Descriptors: Documenting Racial Bias in the
Electronic Health Record. Health Affairs 41, No. 2
(2022): 203–211. doi:10.1377/hlthaff.2021.01423.
1154 Himmelstein G, Bates D, Zhou L.
Examination of Stigmatizing Language in the
Electronic Health Record. JAMA Netw Open.
2022;5(1):e2144967. doi:10.1001/
jamanetworkopen.2021.44967.
1155 Turner K, Clary A, Hong Y, Alishahi Tabriz
A, Shea CM. Patient Portal Barriers and Group
Differences: Cross-Sectional National Survey Study.
J Med internet Res 2020;22(9):e18870.
1156 The Trusted Exchange Framework (TEF):
Principles for Trusted Exchange. ONC January
2022: https://www.healthit.gov/sites/default/files/
page/2022–01/Trusted_Exchange_Framework_
0122.pdf.
1157 Common Agreement for Nationwide Health
Information Interoperability V1. ONC. January
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
enable more seamless access to
individual health information across
various patient portals?
• With the advancement of HIT, EHRs
and other health-related communication
technologies, there are concerns of
equity to health outcomes and access
with populations who could receive
greater benefits from these technologies
but are less likely to adopt them.1158 1159
What policy, governance and
implementation strategies or other
considerations are necessary to ensure
equal access to patient portals, equitable
portal implementation, appropriate
design and encouragement of use?
• What challenges do eligible
hospitals and CAHs face when
addressing patient questions and
requests resulting from patient access of
patient portals or access of data through
use of a mobile app? What can be done
to mitigate potential burden?
• For patients who access their health
information, how could CMS, HHS, and
health care providers help patients
manage their health through the use of
their personal health information?
• Do you believe the API and app
ecosystem is at the point where it would
be beneficial to revisit adding a measure
of patient access to their health
information which assesses health care
providers on the degree to which their
patients actively access their health
information?
* What should be considered when
designing a measure of patient access of
their health information through portals
or apps?
We welcomed input on how we can
encourage and enable patient access to
and use of their health information to
manage and improve their care across
the care continuum. We thank the
interested parties who submitted
comments for our review and
consideration.
Comment: Many commenters
provided input on additional
approaches to promote patient access
and use of patient health information.
Several commenters supported
individuals contributing to their own
records as an approach to promote
2022: https://www.healthit.gov/sites/default/files/
page/2022–01/Common_Agreement_for_
Nationwide_Health_Information_Interoperability_
Version_1.pdf.
1158 Sarkar U, Karter AJ, Liu JY, et al. The literacy
divide: health literacy and the use of an internetbased patient portal in an integrated health
system—results from the diabetes study of Northern
California (DISTANCE). J Health Commun 2010; 15
(Suppl 2): 183–96.
1159 Ackerman SL, Sarkar U, Tieu L, et al.
Meaningful use in the safety net: a rapid
ethnography of patient portal implementation at
five community health centers in California. J Am
Med Inform Assoc 2017; 24 (5): 903–12.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
patient access to and engagement with
their health information. These
commenters offered a number of
successful suggestions for individuals to
contribute to their records, as well as
important considerations regarding
potentially duplicative or erroneous
information being added, and the need
for clinical review of information
entered by individuals before inclusion
in the medical record. A commenter
recommended CMS work with ONC to
develop certification criteria and
technical capabilities to amend or
update their records. Several
commenters recommended including
beneficial capabilities within the patient
portal to promote patient access, such as
appointment scheduling, prescription
refills, immediate release of lab results,
push notifications to patients, and
secure physician messaging. Many
commenters provided support for
TEFCA implementation and the use of
HIEs as an approach to promote a
standard nationwide method of
collecting patient health data and
consolidating into one view for seamless
patient access. Commenters stated that
TEFCA has a lot of potential to improve
patient access to health information, but
CMS should monitor the progress of
TEFCA implementation.
Many commenters provided input on
potential unintended consequences and
concerns around increasing patient
access to their health information
related to racial bias and stigmatizing
language. A few commenters stated the
importance of developing educational
materials for health care providers to
reduce stigmatizing language, including
providing guidance on the information
blocking regulations so health care
providers are aware of requirements for
patient access to clinical notes, and
provide patient-facing resources to
address questions when reviewing
records. A few commenters stated the
importance of accurate translation of
health information from other languages
and how technology can provide
reliable real-time translation of
information contained in a portal. A
commenter recommended
implementing a policy to permit
patients to complete sexual orientation,
and gender identity fields within the
patient portal.
Many commenters provided input on
the potential barriers to patient access
including those associated with
individuals having limited access to
technology or insufficient
understanding of how to use health
technology who encounter difficulties
navigating portals. Several commenters
stated that racial and ethnic minority
groups, socioeconomically
PO 00000
Frm 00591
Fmt 4701
Sfmt 4700
49369
disadvantaged, rural, elderly, and
people who are at risk of poor health
outcomes lack physical tools including
computers, email addresses,
smartphones, and inconsistent internet
access. Commenters discussed the
absence of technical assistance to help
patients access information as well as
the lack of understanding of their rights
under the Health Insurance Portability
and Accountability Act of 1996 (HIPAA)
Privacy Rule, including the right to
access an electronic copy when their
health information is stored
electronically. A commenter stated the
success of publishing health care
provider compliance rates with patient
access requirements under HIPAA and
recommended similar approaches to
help improve patient access. A few
commenters discussed the
complications and potential barriers
regarding proxy access to patient portals
and patient applications. Additionally,
commenters stated the lack of a unique
patient identifier or identity proofing
and authentication creates a barrier to
access health information.
Many commenters provided input on
challenges and burdens faced by
hospitals including cumbersome and
decentralized processes for requesting
records as well as the manual workflows
for health information professionals
fulfilling requests. Commenters
recommended CMS continue to monitor
challenges related to patient access of
data and solicit feedback from interested
parties, particularly health information
professionals who field patient
questions and concerns related to the
access of data.
Many commenters provided input
and recommendations on policy,
governance, and implementation
considerations for promoting patient
access and the role of CMS and HHS.
Commenters recommended continued
collaboration with OCR and ONC to
develop guidance regarding HIPAA
requirements, particularly in the context
of health information exchanges and
networks, as well as guidance regarding
the lack of HIPAA protections when
data moves to third-party applications.
Commenters recommended CMS remain
actively engaged in the work of
standards development organizations to
determine the best avenue for regulatory
alignment. Commenters also
recommended CMS work with ONC to
improve patient matching and
identification to promote longitudinal
records, and further advance and ensure
adoption of standards. Many
commenters recommended providing
funding for equipment and studying the
optimal use of digital technology
including wearable devices. A few
E:\FR\FM\10AUR2.SGM
10AUR2
49370
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
commenters recommended CMS use
their authority and exercise enforcement
to ensure health plans subject to CMS
oversight facilitate patient access and
implement APIs.
Many commenters provided input on
the prospect of adding a measure of
patient access. A few commenters
supported adding a measure for patient
access to their health information but
several commenters did not support
adding a new measure of patient access
stating many reasons including lack of
control, unnecessary burden, and
existing patient access barriers.
Response: We appreciate the
comments and suggestions we have
received. While we will not be
responding to specific comments
submitted in response to this RFI, we
believe that this input is valuable in our
efforts to continue to promote patient
access to their health information. We
may consider these suggestions in future
rulemaking.
X. Changes for Hospitals and Other
Providers
khammond on DSKJM1Z7X2PROD with RULES2
A. Codification of the Costs Incurred for
Qualified and Non-Qualified Deferred
Compensation Plans
1. Background
Currently, certain costs incurred on
behalf of Deferred Compensation Plans
may be allowable costs under Medicare
to the extent such costs are related to
the reasonable and necessary cost of
providing patient care and represent
costs actually incurred. Reasonable cost
reimbursement is addressed in section
1861(v)(1)(A) of the Act. Section
1861(v)(1)(A) of the Act defines
‘‘reasonable cost,’’ in part, as the cost
actually incurred, excluding costs found
to be unnecessary in the efficient
delivery of needed health services.
Section 1861(v)(1)(A) of the Act does
not specifically address the
determination of reasonable costs, but
authorizes the Secretary to promulgate
regulations and principles to be applied
in determining reasonable costs.
We have issued regulations
implementing this provision of the Act,
including 42 CFR 413.9(a), which
provides that the payments ‘‘must be
based on the reasonable cost of services
covered under Medicare and related to
the care of beneficiaries.’’ In addition,
§ 413.9(c)(2) states that ‘‘[t]he provision
in Medicare for payment of reasonable
cost of services is intended to meet the
actual costs.’’ Further, § 413.9(c)(3)
provides that ‘‘[r]easonable cost
includes all necessary and proper
expenses incurred in furnishing services
. . . .’’ Therefore, in accordance with
the statute, the regulations include two
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
principles that help guide the
determination of which expenses may
be considered allowable reasonable
costs that can be paid under Medicare;
that is, such costs must be ‘‘related’’ to
the care of Medicare beneficiaries, and
such costs must actually be ‘‘incurred.’’
Consistent with these provisions, we
have issued instructions in sections
2140 through 2142 of the Medicare
Provider Reimbursement Manual, Part I
(PRM–I) for determining and reporting
the policies that govern how providers
of services are to determine and report
the allowable costs of Deferred
Compensation Plans. Section 2140.1 of
PRM–I defines Deferred Compensation
as ‘‘remuneration currently earned by an
employee but which is not received
until a subsequent period, usually after
retirement. Accordingly, a Deferred
Compensation Plan defers the receipt of
income beyond the year in which it is
earned.’’ The policies for Deferred
Compensation plans that we have
established in sections 2140 through
2142 of PRM–I vary depending on
whether a plan is funded using an
allowable funding mechanism or
unfunded, and whether a plan is a
Defined Contribution plan or a Defined
Benefit plan. The term funded
essentially means that funds are set
aside to protect payment of future
benefits for plan participants, and not
simply paid out of current revenues, as
is the case with unfunded plans.
Allowable Non-Qualified Deferred
Compensation Plan costs that are
considered unfunded are based on
reasonable benefits that providers of
services paid to participating
employees.
Allowable Defined Contribution plan
costs are based on reasonable
contributions made by providers of
services to Defined Contribution
accounts. Prior to August 2011,
allowable funded Defined Benefit plan
costs were based on Employee
Retirement Income Security Act of 1974
(ERISA) components of accrued pension
costs (for example, Normal Cost,
Actuarial Accrued Liability, Actuarial
Value of Assets) if the resulting
computation of costs was funded into an
approved account. In August 2011, the
FY 2012 IPPS/LTCH PPS final rule (76
FR 51693 through 51697), established
regulations for reporting costs of
Qualified Defined Benefit plans for
Medicare cost-finding purposes.
Specifically, for cost reporting periods
beginning on or after October 1, 2011, a
provider of services cost equals the cash
basis contribution deposits plus any
carry forward contributions, subject to a
limitation (§ 413.100(c)(2)(vii)(D)(1)).
Providers of services with current
PO 00000
Frm 00592
Fmt 4701
Sfmt 4700
contributions and carry forward
contributions that exceed the limit may
request approval of excess
contributions, which are reviewed by
the contractor on a case-by-case basis
(§ 413.100(c)(2)(vii)(D)(3)).
At the time the FY 2012 IPPS/LTCH
final rule was issued, the regulations at
§§ 413.24 and 413.100 specified that
pension costs of Qualified Defined
Benefit plans were reported on an
accrual basis of accounting method. To
conform this accrual requirement in the
regulations with the cash-basis
methodology for reporting pension costs
finalized in the FY 2012 IPPS/LTCH
PPS final rule, in the FY 2013 IPPS/
LTCH PPS final rule (77 FR 53448), we
amended the general cost reporting
rules under §§ 413.24(a)(2) and
413.100(c)(2)(vii)(D) to note the
exception for recognizing actual
contributions funded during the cost
reporting period on a cash basis.
In the FY 2023 IPPS/LTCH proposed
rule (87 FR 28612 through 28618), we
proposed to codify and clarify
additional policies relating to Deferred
Compensation in a new section in part
413, subpart F. We did not propose to
change our current policies for
allowable Deferred Compensation costs
associated with Qualified and NonQualified Deferred Compensation Plans
(the plans) that are included in
Medicare cost reports. Nor did we
propose to change the way in which
Deferred Compensation costs are to be
audited by the Medicare Administrative
Contractors (MACs).
In the paragraphs that follow, we
discuss our proposals in the FY 2023
IPPS/LTCH proposed rule. We received
no comments on these proposals and are
finalizing our proposals without
modification.
2. Qualified and Funded Non-Qualified
Deferred Compensation Plans (§ 413.99)
In accordance with section
1861(v)(1)(A) of the Act, in the FY 2023
IPPS/LTCH proposed rule (87 FR
28613), we proposed to add a new
§ 413.99 in subpart F of part 413 of title
42, titled ‘‘Qualified and Funded NonQualified Deferred Compensation
Plans,’’ to establish rules for allowable
and non-allowable costs incurred for the
plans, by providers of services, under
the program. Our proposals, which we
discuss in more detail throughout this
section of this final rule, set forth
general requirements; definitions;
requirements for costs of the plans to be
allowable under the program; additional
requirements for payments to funded
defined benefit plans; data and
documentation requirements to support
payments/contributions to the plans;
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
and allowable administrative and other
costs associated with the plans,
including costs related to the Pension
Benefit Guaranty Corporation (PBGC).
We received no comments on these
proposals and are finalizing our
proposals without modification.
3. Statutory Basis, Scope, and
Definitions (§ 413.99(a))
In accordance with section
1861(v)(1)(A) of the Act, in the FY 2023
IPPS/LTCH proposed rule (87 FR
28613), we proposed to establish the
‘‘Basis,’’ ‘‘Scope,’’ and ‘‘Definitions’’ of
these regulations that determine the
allowable and non-allowable costs of
the plans under the program at
proposed new § 413.99(a)(1), (2), and
(3), respectively. Specifically, we
proposed at new § 413.99(a)(1) to
specify that all payments to providers of
services must be based on the
‘‘reasonable cost’’ of services covered
under Title XVIII in accordance with
section 1861(v) of the Act and the
regulations in 42 CFR part 413. In
addition, we proposed at new
§ 413.99(a)(2) to specify that this section
and § 413.100(c)(2)(vii) will apply to
Medicare’s treatment of the costs
incurred for Qualified and NonQualified Deferred Compensation Plans.
CMS has previously defined certain
terms related to the program’s policies
on Deferred Compensation and the
plans in sections 2140 through 2142 of
PRM–I. In the FY 2023 IPPS/LTCH
proposed rule (87 FR 28613), we
proposed to codify these definitions,
with clarifications where appropriate, at
new § 413.99(a)(3). We also proposed to
add definitions for several new terms to
ensure clarity and consistent
application. Specifically, we proposed
at new § 413.99(a)(3) to establish, for
purposes of § 413.99, definitions for the
following terms: Deferred
Compensation, Employee Retirement
Income Security Act of 1974 (ERISA),
Funded Plan, Non-Qualified Deferred
Compensation Plan (NQDC), NonQualified Defined Benefit Plan (NQDB),
Pension Benefit Guaranty Corporation
(PBGC), Qualified Defined Benefit Plan
(QDBP), Qualified Defined Contribution
or Individual Account Plan (QDCP), and
Unfunded plan. The specific definitions
we proposed to codify at § 413.99(a)(3)
appear in the proposed rule at 87 FR
28648 through 28649.
We received no comments on this
proposal and are finalizing this proposal
without modification.
4. Principle Requirements (§ 413.99(b))
In the FY 2023 IPPS/LTCH proposed
rule (87 FR 28613 through 28614), we
proposed to establish at new § 413.99(b)
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the ‘‘Principle requirements’’ that must
be satisfied by all Deferred
Compensation Plans in order for costs
incurred by a provider of services in
connection with such plans to be
allowable under the program. A formal
Deferred Compensation Plan is an
agreement between the provider of
services and its participating employees,
in which the agreeing parties can make
contributions to the plan for the
exclusive benefit of its participating
employees. Proposed § 413.99(b)(1)
would specify that amounts be
contributed by a provider of services, or
an employee of the provider of services,
to a Qualified or Non-Qualified Deferred
Compensation Plan, established and
maintained by the provider of services
to provide retirement income to
employees or to result in the deferral of
income by employees for periods
extending to the termination of covered
employment or beyond. Contributions
or payments made by a provider of
services for the benefit of its employees
to a Qualified or Non-Qualified Deferred
Compensation Plan are allowable when,
and to the extent that, such costs are
actually incurred by the provider of
services and found to be reasonable and
necessary under the principles of
reasonable cost.
Contracts or agreements between
hospital-based physicians and hospitals
involve a variety of arrangements under
which the physician is compensated by
the hospital for the full range of services
within the institution. We proposed to
include requirements for recognition of
the costs incurred to fund the plans for
hospital-based physician patient care
services and guarantee arrangements for
physician emergency room services.
Deferred compensation paid for
physician services to hospitals and
SNFs is part of physician compensation
under § 415.60(a) and is directly
attributable to an employee’s salary.
Deferred compensation is salary earned
in the current period that is not received
until a subsequent period, usually after
retirement. Defined Contribution plans
and Defined Benefit plans generally
specify contributions and benefits as a
percentage of employee salary. Deferred
compensation based on unallowable
compensation is also unallowable.
Consistent with the policies in PRM–I,
we proposed in § 413.99(b)(2) to specify
that costs incurred by a hospital or SNF
to fund a Qualified or Non-Qualified
Deferred Compensation Plan for a
provider-based physician must meet
certain requirements to be allowable.
These proposed requirements at
§ 413.99(b)(2)(i) through (iii) would
establish that: (i) the allocation of
PO 00000
Frm 00593
Fmt 4701
Sfmt 4700
49371
physician compensation costs required
under § 415.60 does not attribute the
provider-based physician’s Deferred
Compensation entirely to one category
of service and his current compensation
to another; (ii) contributions or
payments toward the Qualified or NonQualified Deferred Compensation Plan
do not include any cost excluded from
the definition of physician
compensation at § 415.60(a); and (iii)
the amount of Deferred Compensation
does not exceed the amount specified in
the agreement required by § 415.60(g).
In situations where the provider is
merely acting as the billing agent for the
physician whose remuneration is
derived from billing for patient care
services, the Medicare program will not
recognize such remuneration. As a
result, these proposed requirements
would also specify that an arrangement
between a physician and a provider of
services under which the physician is
reimbursed for patient charges, but the
provider of services does the billing as
a Deferred Compensation agreement, is
not allowed. We proposed to codify this
policy at § 413.99(b)(2)(iv).
We proposed to codify at
§ 413.99(b)(2)(v) that the costs incurred
for physician guarantee arrangements
for hospital emergency room availability
services must also meet the additional
requirements that: (1) the terms of both
the guarantee arrangement and the
Deferred Compensation plan establish
the amounts to be included at the
beginning of the hospital’s cost
reporting period; (2) the amount of
Deferred Compensation is included in
the guaranteed amount; (3) the hospital
contributes to the fund established
under the Deferred Compensation Plan
from its own funds; (4) the amount of
Deferred Compensation that is allowable
is limited to the amount by which the
guarantee, including Deferred
Compensation, exceeds the total billed
by the hospital to all patients for the
physician’s patient care services; and (5)
when the physician’s charges to all
patients equal or exceed the amount
guaranteed by the hospital, the program
does not recognize a Deferred
Compensation contribution/payment.
We received no comments on the
proposed principle requirements of
§ 413.99(c) and are finalizing this
proposal without modification.
5. Requirements for Non-Qualified and
Qualified Deferred Compensation Plans
(§ 413.99(c))
In the FY 2023 IPPS/LTCH proposed
rule (87 FR 28614 through 28615), we
proposed to codify the guidance from
sections 2140 through 2142 of PRM–I
regarding the requirements that must be
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49372
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
met in order for costs incurred by
providers of services to be allowable for
inclusion as Deferred Compensation in
the Medicare cost report. The
requirements vary based on the type of
plan established by the provider of
services. The plans currently recognized
by the program include Deferred
Compensation Plans, currently set forth
in section 2140 of PRM–I, Qualified
Defined Contribution Deferred
Compensation Plans set forth in section
2141 of PRM–I, and Qualified Defined
Benefit Pension Plans set forth in
section 2142 of PRM–I. As discussed
previously in section X.A.1. of this final
rule, we proposed to codify the
definitions of these types of plans and
related terms, with clarifications where
appropriate, in proposed new
§ 413.99(a)(3). We proposed to establish
at new § 413.99(c) the plan-specific
requirements that each type of Qualified
or Non-Qualified Deferred
Compensation Plan must meet in order
for a provider of servicers contributions
or payments to the plan to be allowable
under the program.
Employer contributions for the benefit
of employees under a Deferred
Compensation Plan are allowable when,
and to the extent that, such costs are
actually incurred by the provider or
services. Contributions to a funded
Deferred Compensation Plan are
allowable costs when they are made to
the plan, to the extent they fall under
the computed limit. Benefits paid for an
unfunded Deferred Compensation Plans
are allowable costs only when actually
paid to the participating employees (or
their beneficiaries), and only to the
extent considered reasonable.
First, we proposed to codify at
§ 413.99(c)(1) the requirements for
NQDCs, which can be funded or
unfunded. Proposed § 413.99(c)(1)(i)
would establish that an NQDC must
meet the requirements for document
compliance and operational compliance
set forth in Internal Revenue Code (IRC)
section 409A. Proposed paragraph
(c)(1)(ii) would specify that a funded
NDQC must meet the proposed
definition of a Funded Plan in
§ 413.99(a)(3) and comply with the
requirements in proposed § 413.99(c)(5)
(discussed later in this section of this
final rule). Proposed paragraph (c)(1)(iii)
would provide that an unfunded NQDC
must meet the definition of an
Unfunded Plan as proposed in
§ 413.99(a)(3), and there must be no
constructive receipt of income for
employees from the NQDC as a result of
contributions made by a provider of
services.
Second, we proposed to codify at
§ 413.99(c)(2) the requirements for
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
QDCPs. Consistent with our existing
policies for Defined Contribution
Deferred Compensation Plans found in
section 2141.1 of PRM–I, proposed
paragraph (c)(2)(i) would specify that a
QDCP must meet the applicable
requirements of ERISA, as amended,
and the requirements set forth in IRC
section 401(a), and, if applicable,
section 401(k). In addition, proposed
paragraph (c)(2)(ii) would specify that a
QDCP must meet the proposed
definition for a Funded Plan in
§ 413.99(a)(3) and comply with the
requirements in proposed § 413.99(c)(5).
Third, we proposed to codify at
§ 413.99(c)(3) the requirements for
QDBPs. Specifically, proposed
§ 413.99(c)(3)(i) would establish that a
QDBP must meet the applicable
requirements of ERISA, as amended,
and the requirements for a QDBP under
IRC section 401(a). Proposed paragraph
(c)(3)(ii) would specify that a QDBP
must meet the definition of a Funded
Plan as proposed in § 413.99(a)(3) and
comply with the requirements in
proposed § 413.99(c)(5).
Fourth, we proposed to codify at
§ 413.99(c)(4) the requirements for
NQDBs, which may be funded or
unfunded. Proposed § 413.99(c)(4)(i)
would establish that an NQDB must
meet the requirements for document
compliance and operational compliance
set forth in Internal Revenue Code (IRC)
section 409A. Proposed paragraph
(c)(4)(ii) would specify that a funded
NQDB must meet the definition of a
Funded Plan as proposed in
§ 413.99(a)(3) and comply with the
requirements in proposed § 413.99(c)(5).
Proposed paragraph (c)(4)(iii) would
provide that an unfunded NQDB must
meet the definition of an Unfunded Plan
as proposed in § 413.99(a)(3), and there
must be no constructive receipt of
income for employees from the NQDC
as a result of contributions made by a
provider of services.
We proposed to codify at
§ 413.99(c)(5) certain requirements for
Funded Plans. We proposed to establish
at paragraph (c)(5)(i) the types of
funding mechanisms that Funded Plans
must use in order for provider of
services contributions and employee
contributions to such plans to be
included in allowable costs.
Specifically, a Funded Plan would be
required to use either to purchase an
insured plan with a commercial
insurance company, to establish a
custodial bank account, or to establish
a trust fund administered by a trustee.
Proposed paragraph (c)(5)(ii) would
codify our longstanding policy, set forth
in section 2140.3.B of PRM–I,
disallowing the use of an ordinary life
PO 00000
Frm 00594
Fmt 4701
Sfmt 4700
insurance contract as a funding
mechanism for a Funded Plan.
Specifically, proposed paragraph
(c)(5)(ii) would specify that the
purchase of an ordinary life insurance
contract (for example, whole life,
straight life, or other) is not a deferral of
compensation and is not recognized as
a funding mechanism, even where it is
convertible at the normal retirement
date specified in the policy to an
annuity payable over the remaining life
of the employee. Proposed paragraph
(c)(5)(iii) would establish that,
regardless of the funding mechanism
utilized, all provider of services and
employee contributions to the fund
established under the Deferred
Compensation Plan and income
therefrom must be used for the sole
benefit of the participating employees.
The proposed requirements for a
Funded Plan are based on the generally
accepted definition of a Funded Plan,
along with existing CMS policies on the
funding of Deferred Compensation Plans
found in section 2140.3 of PRM–I.
We received no comments on the
proposed requirements of § 413.99(c) for
Non-Qualified and Qualified Deferred
Compensation plans and are finalizing
this proposal without modification.
6. Recognition of Contributions or
Payments to Qualified and NonQualified Deferred Compensation Plans
(§ 413.99(d))
In the FY 2023 IPPS/LTCH proposed
rule (87 FR 28615 through 28616), at
proposed § 413.99(d), we proposed to
codify rules and requirements that
determine when payments or
contributions by a provider to Qualified
or Non-Qualified Deferred
Compensation Plans that meet the
applicable plan-specific requirements at
proposed § 413.99(c) are recognized and
included in allowable costs under the
program. In general, the rules in
proposed § 413.99(d) vary depending on
whether a plan is qualified or nonqualified. In addition, certain special
rules apply to contributions to QDBPs
and NQDBs that are deposited into
trusts.
First, for unfunded Deferred
Compensation Plans (which include
unfunded NQDBs), we proposed to
codify at proposed § 413.99(d)(1)(ii) that
payments made to such plans are
included in allowable costs only during
the cost reporting period in which an
actual payment is made to the
participating employees (or their
beneficiaries) and only to the extent
considered reasonable in accordance
with § 413.100(c)(2)(vii)(A). This
proposed requirement incorporates the
existing regulatory requirement for
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
payments to unfunded Deferred
Compensation Plans at
§ 413.100(c)(2)(vii)(A), to aid the reader
in understanding related policies that
appear in other sections of this part that
affect unfunded NQDCs and unfunded
NQDBs.
Second, regarding certain funded
Deferred Compensation Plans
(specifically funded Defined
Contribution Plans, but excluding
QDBPs and funded NQDBs), we
proposed to include at § 413.99(d)(1)(ii)
a cross reference to
§ 413.100(c)(2)(vii)(B), which requires
that accrued costs related to matching or
non-elective contributions to a funded
Deferred Compensation Plan must be
liquidated within 1 year after the end of
the cost reporting period in which the
liability is incurred. Under
§ 413.100(c)(2)(viii)(B), an extension,
not to exceed 3 years beyond the end of
the cost reporting year in which the
liability was incurred, may be granted
for good cause if the provider of
services, within the 1-year time limit,
furnishes to the contractor sufficient
written justification for non-payment of
the liability. Applying this requirement
to QDCPs is consistent with
§ 413.100(c)(2)(vii)(B) and with policies
established in section 2141.2 of PRM–I.
Third, contributions into a protected
trust for QDBPs and funded NQDBs are
allowable. We require that these assets
be protected solely for the plan
participants and to pay reasonable plan
administrative expenses. Contributions
or payments must be made by the
provider into a protected trust and
accounted for on a cash basis. For these
plans, we proposed to establish at
§ 413.99(d)(1)(iii) that contributions by
providers must satisfy the following
four requirements to be allowable: first,
the contributions must be paid to the
plan participants or the plan trust;
second, contributions are accounted for
on a cash basis; third, money refunded
from a plan must be treated as a
negative contribution; and fourth, the
allowable cost must be computed in
accordance with the calculation defined
in § 413.100(c)(2)(vii)(D). We described
each of these proposed requirements in
greater detail in the paragraphs that
follow.
First, we proposed to establish at
§ 413.99(d)(1)(iii)(A) that QDBP or
funded NQDB contributions are found
to have been incurred only if paid
directly to participants or beneficiaries
under the terms of the plan or to the
QDBP or NQDB. Proposed paragraph
(d)(1)(iii)(A) codifies our existing policy,
which is described in section 2142.6.A
of PRM–I. Section 2142.6 states that
provider contributions or payments
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
made to a defined benefit pension plan
are allowable only to the extent that
costs are actually incurred by the
provider. Such costs are found to have
been incurred only if paid directly to
participants or beneficiaries under the
terms of the plan or paid to a pension
fund which meets the applicable tax
qualification requirements under IRC
section 401(a).
Second, we proposed to codify at
§ 413.99(d)(1)(iii)(B) the existing
regulatory requirement at
§ 413.100(c)(2)(vii)(D) for contributions
to a QDBP or funded NQDB.
Specifically, proposed
§ 413.99(d)(1)(iii)(B) would require that
payments to a QDBP or funded NQDB
for a cost reporting period be measured
on a cash basis. A contribution or
payment would be deemed to occur on
the date it is credited to the fund
established for the QDBP or funded
NQDB, or for provider of services
payments made directly to a plan
participant or beneficiary, on the date
the provider of services account is
debited.
Third, we proposed to clarify the
treatment of pension contributions
when a QDBP or funded NQDB is
terminated at § 413.99(d)(1)(iii)(C) as
payments/contributions made to fully
fund a terminating QDBP or funded
NQDB are to be included as funding on
the date they are paid. Excess assets
withdrawn from a QDBP or funded
NQDB are to be treated as negative
contributions on the date that they are
withdrawn. We believe our proposal to
recognize negative contributions by
reference to the date of withdrawal
provides greater clarity than the
standard under our current guidance
under section 2140.3 of PRM–I, which
refers to the ‘‘year of plan termination,’’
which is less specific and subject to
interpretation.
Fourth, we proposed to specify at
§ 413.99(d)(1)(iii)(D) that QDBP and
funded NQDB costs and limits are
computed in accordance with the
existing regulatory requirements at
§ 413.100(c)(2)(vii)(D). For purposes of
determining the QDBP or funded NQDB
cost limit under
§ 413.100(c)(2)(vii)(D)(2), we propose
that provider of services contribution
payments for each applicable cost
reporting period shall be determined on
a cash basis in accordance with
proposed § 413.99(d)(1)(iii)(B), without
regard to any limit determined for the
period during which the contributions
were made, and excluding any
contributions deposited in a prior
period and treated as carry forward
contributions. We proposed that the
averaging period used to determine the
PO 00000
Frm 00595
Fmt 4701
Sfmt 4700
49373
QDBP or funded NQDB cost limit shall
be determined without regard to a
provider of services period of
participation in the Medicare program.
Periods that are not Medicare cost
reporting periods (for example, periods
prior to the hospital’s participation in
the Medicare program) shall be defined
as consecutive twelve-month periods
ending immediately prior to the
provider of services initial Medicare
cost reporting period. We proposed that
the averaging period used to determine
the QDBP or funded NQDB cost limit
shall exclude all periods ending prior to
the initial effective date of the plan (or
a predecessor plan in the case of a
merger). Lastly, we proposed that in
general, the current period defined
benefit cost and limit shall be computed
and applied separately for each QDBP or
funded NQDB offered by a provider of
services. In the case of a plan merger,
the contribution payments made by a
provider of services to a predecessor
QDBP or funded NQDB and reflected in
the assets subsequently transferred to a
successor plan shall be treated as
contribution payments made to the
successor plan.
In the FY 2012 IPPS/LTCH PPS final
rule, we established separate
methodologies for measuring pension
costs for Medicare cost-finding purposes
(76 FR 51693 through 51697) and for
purposes of updating the hospital wage
index (76 FR 51586 through 51590).
Under the methodology we established
for the wage index, the pension costs
that are to be included in the wage
index equal a hospital’s average cash
contributions deposited to its defined
benefit pension plan over a 3-year
period or, if less than a 3-year period,
the number of years that the hospital
has sponsored a defined benefit plan.
The 3-year average was centered on the
base cost reporting period for the wage
index. For example, the FY 2013 wage
index is based on Medicare cost
reporting periods beginning during
Federal FY 2009 and reflects the average
pension contributions made in
hospitals’ cost reporting periods
beginning during Federal FYs 2008,
2009, and 2010. In the FY 2016 IPPS/
LTCH PPS final rule (80 FR 49505
through 49508), we modified the policy
such that the 3-year average is based on
pension contributions made during the
base cost reporting period plus the prior
2 cost reporting years. For example, the
FY 2017 wage index is based on
Medicare cost reporting periods
beginning during Federal FY 2013.
Therefore, the FY 2017 wage index
reflects the average pension
contributions made in hospitals’ cost
E:\FR\FM\10AUR2.SGM
10AUR2
49374
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
reporting periods beginning during
Federal FYs 2011, 2012, and 2013
(rather than Federal FYs 2012, 2013,
and 2014 under the prior policy
established in the FY 2012 IPPS/LTCH
PPS final rule (76 FR 51586 through
51590)). While the QDBP cost for costfinding purposes is computed using the
cost period annual contributions limited
by a cap (as codified in
§ 413.100(c)(2)(vii)(D)), the wage index
QDBP cost is a 3-year average of annual
plan contributions without adjustment
or cap.
We received no comments on the
proposed recognition under § 413.99(d)
of contributions or payments to
Qualified and Non-Qualified Deferred
Compensation Plans and are finalizing
this proposal without modification.
7. Documentation Requirements
(§ 413.99(e))
In the FY 2023 IPPS/LTCH proposed
rule (87 FR 28616 through 28617), we
proposed to codify at § 413.99(e) that a
provider of services must maintain and
make available upon request
documentation to substantiate the costs
incurred for the plans included in its
Medicare cost report. These proposed
requirements for documentation are
based on the existing regulatory
requirements at § 413.20, which require
providers of services to maintain
sufficient financial records and
statistical data for proper determination
of costs payable under the program.
In addition, these requirements are
based in part on the policy established
when CMS revised the calculation for a
QDBP and funded NQDB in the FY 2012
IPPS/LTCH PPS final rule (76 FR 51693
through 51697). Section 2142.5.F of
PRM–I states that the provider must
have available data to show the
amount(s) and date(s) of contribution
payments made to a defined benefit
pension plan during the current
reporting period and any applicable
prior periods. If the pension costs
included in the cost report for a period
differ from the pension contribution
payments made during the reporting
period (for example, as a result of carry
forward contributions), the provider
must also have data available to track
and reconcile the difference.
Specifically, we proposed at
§ 413.99(e) that documentation must be
maintained by the provider of services
in accordance with § 413.20 to
substantiate the allowability of the
payments or contributions to Qualified
or Non-Qualified Deferred
Compensation Plans (or both) that it has
included in its cost reports. With
respect to required documentation, we
proposed to specify at § 413.99(e)(1) that
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the provider of services must maintain
and make available, upon request from
the contractor or CMS, certain specified
documentation, to substantiate the
allowability of payments or
contributions made by the provider of
services to a Qualified or Non-Qualified
Deferred Compensation Plan. Under
proposed § 413.99(e)(1), the following
documentation would be required:
documentation that demonstrates that
the provider of services is in compliance
with IRC section 409A and IRC section
409A(a), and if applicable IRC section
457; ledger accounts/account statements
for each plan participant noting current
year deferrals, distributions, and loans,
including any deferral election forms
completed by employees, any change
requests, and the approval of such
requests; documentation that
demonstrates the amount(s) and date(s)
of actual payment/contributions made
to the Non-Qualified or Qualified
Deferred Compensation Plan during the
current cost reporting period; Schedule
SB of Form 5500 (tri-agency form
(Department of Labor (DOL), Internal
Revenue Service (IRS), PBGC) that plans
file with the DOL’s ‘‘EFAST’’ electronic
filing system. The ‘‘Form 5500’’ is the
Annual Return/Report of Employee
Benefit Plan for a QDBP for the current
cost reporting period, or any applicable
prior periods; and, in the case of a
system wide (multiple employer) plan,
the home office shall identify the
contributions attributed to each
participating provider of services. If the
costs included in the cost report for a
period differ from the contributions
made during the reporting period (for
example, as a result of carry forward
contributions), the provider of services
must also have data available to track
and reconcile the difference.
We also proposed to establish at
§ 413.99(e)(2) that the following
additional documentation must be made
available, upon request by the
contractor or CMS, to substantiate the
allowability of payments or
contributions made by a provider of
services to a Qualified or Non-Qualified
Deferred Compensation Plan: the plan
document, the trust document and all
amendments related to the current cost
reporting period; if applicable, any
Form 5330, Return of Excise Taxes
Related to Employee Benefit Plans, for
the cost reporting period; supporting
documents for all plan assets and
liabilities, such as broker’s statements,
bank statements, insurance contracts,
loan documents, deeds, etc., and
verification of how assets are valued;
trustee or administrator reports; ledgers;
journals; trustee, administrator and
PO 00000
Frm 00596
Fmt 4701
Sfmt 4700
investment committee minutes; certified
audit report; and other financial reports
for the trust. Any other financial reports,
including receipt and disbursement
statements, a detailed income statement
and a detailed balance sheet; and, for
each covered QDBP, documentation of
the certified premium information and
payments to the PBGC.
We received no comments on the
proposed documentation requirements
of § 413.99(e) and are finalizing this
proposal without modification.
8. Administrative and Other Costs
Associated With Qualified and NonQualified Deferred Compensation Plans
(§ 413.99(f))
In the FY 2023 IPPS/LTCH proposed
rule (87 FR 28617), in proposed
§ 413.99(f), we proposed to codify our
current policies, as set forth in sections
2140, 2141, and 2142 of PRM–I,
regarding the treatment of certain
administrative and other costs related to
Deferred Compensation Plans as
allowable or non-allowable under the
program. In the paragraphs that follow,
we discuss our proposed treatment of
various administrative costs related to
Deferred Compensation Plans. First, we
proposed to establish at § 413.99(f) that
the provider of services shall file a cost
report required under §§ 413.20 and
413.24(f) that is consistent with the
proposed policies set forth in proposed
§ 413.99.
We received no comments on this
proposal and are finalizing this proposal
without modification.
a. Trustee and Custodial Fees
In the FY 2023 IPPS/LTCH proposed
rule (87 FR 28617), we proposed to
codify at § 413.99(f)(1) that reasonable
trustee or custodial fees, including
PBGC premiums, paid by the provider
of services are allowed as an
administrative cost, except where the
plan provides that such fees are paid out
of the corpus or earnings of the fund.
Fees paid out of the corpus or earnings
of the fund would not be allowed, based
on the rationale that, because
contributions into the plan trust pay for
benefits and expenses that are paid from
the trust, that means administrative
costs paid out of the plan trust have
already been accounted for through the
allowance of contributions made by the
provider of services. This proposed
provision would codify our current
policy, which is set forth in section
2140.3.B.1.d of PRM–I.
We received no comments on this
proposal and are finalizing this proposal
without modification.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
b. Vested Benefits
In the FY 2023 IPPS/LTCH proposed
rule (87 FR 28617), we proposed to
codify at § 413.99(f)(2) that the forfeiture
of an employee’s benefits for cause (as
defined in the plan) is recognized as an
allowable cost provided that such
forfeited amounts are used to reduce the
provider of services contributions or
payments to the plan during the cost
reporting period in which the forfeiture
occurs. This proposed provision would
codify our policy on the effects of a
forfeiture of vested benefits on the plan
costs that are allowable under the
program, as set forth at section 2140.3.D
of PRM–I, with the added clarification
that the reduction must occur in the cost
reporting period in which the forfeiture
occurs.
We proposed to codify at
§ 413.99(f)(3) our existing policy on the
effects of employees’ termination of
participation in a plan before their
rights are vested in the contributions/
payments to the plan that are allowable
under the program. Specifically,
proposed § 413.99(f)(3) would specify
that if an employee terminates
participation in the Deferred
Compensation Plan before their rights
are vested, the applicable non-vested
contributions/payments cannot be
applied to increase the benefits of the
surviving participants. Instead, the nonvested contributions/payments should
be used to reduce the provider of
services contributions/payments to the
Deferred Compensation Plan, in the cost
reporting period wherein the employee
terminated participation in the Deferred
Compensation Plan. Otherwise, the
contributions/payments made by the
provider of services must be applied to
reduce the subsequent contributions/
payments to the Deferred Compensation
Plan in the next cost reporting period.
If subsequent provider of services
contributions/payments to the Deferred
Compensation Plan are not made, then
provider of services costs will be
reduced by the contractor to the extent
of such non-vested funds.
We received no comments on this
proposal and are finalizing this proposal
without modification.
khammond on DSKJM1Z7X2PROD with RULES2
c. DOL, IRS, and PBGC Penalties
Providers of services who maintain a
Deferred Compensation Plan are
required to comply with regulatory
requirements related to the plan that are
established by the Department of Labor
(DOL), the IRS and the PBGC. Where
providers of services fail to follow these
requirements, a penalty may be levied.
For example, the IRS levies an excise
tax when payments are not timely filed.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Section 1861(v)(8) of the Act sets forth
items unrelated to patient care that are
not considered reasonable under the
program. In other words, these items are
unallowable, and therefore cannot be
included in the allowable costs of the
provider of services. One of these items
is the cost for fines and penalties
resulting from violations of Federal,
State, or local laws. Accordingly, in the
FY 2023 IPPS/LTCH proposed rule (87
FR 28617), we proposed at § 413.99(f)(4)
to specify that if the provider of services
is assessed an excise tax or other
remedy by DOL or IRS or PBGC for
failure to follow the DOL, IRS, or PBGC
requirements under ERISA, or any other
penalty fee or penalty interest
applicable to its Deferred Compensation
Plan, the associated cost is unallowable,
in accordance with section
1861(v)(8)(iv) of the Act.
We received no comments on this
proposal and are finalizing this proposal
without modification.
d. Loans Made From a Deferred
Compensation Plan
Under our current policy, as set forth
in section 2140.3.C of PRM–I providers
of services are able to make a loan to
themselves out of either corpus or
income from their Qualified or NonQualified Deferred Compensation Plan
on the conditions that the fund receive
adequate security and a reasonable rate
of interest on the loan. This existing
policy is inconsistent with ERISA
section 406 (29 U.S.C. 1106(1)(B)) which
specifically prohibits lending of money
or other extension of credit between the
plan and a party in interest, unless
found to be excepted under 29 U.S.C.
1108. The definition of a ‘‘party in
interest’’ includes an employer any of
whose employees are covered by such
plan. The same provision exists in the
IRC at 26 U.S.C. 4975. We believe that
the policy we proposed to codify in new
§ 413.99 should reflect these provisions
in ERISA and the IRS rules that are
designed to protect Deferred
Compensation Plans and the plans’
participants and beneficiaries.
Accordingly, in the FY 2023 IPPS/LTCH
proposed rule (87 FR 28617), we
proposed at § 413.99(f)(5) to specify that
a provider of services cannot make a
loan to itself from a Deferred
Compensation Plan where ERISA or IRS
rules prohibit such a transaction, except
where specifically excepted. In cases
where an exception applies, our existing
policy on allowable interest expense at
§ 413.153 continues to apply.
We received no comments on this
proposal and are finalizing this proposal
without modification.
PO 00000
Frm 00597
Fmt 4701
Sfmt 4700
49375
e. Termination/Discontinuation of a
Deferred Compensation Plan
Sections 2140.3.D and 2141.3.D of
PRM–I set forth CMS’s policy on the
effect of a provider of services declining
to vest its outstanding required
contributions/payments as a result of a
termination, in full or in part, or a
discontinuation of contributions or
payments to a Deferred Compensation
Plan. Under this policy, we proposed n
the FY 2023 IPPS/LTCH proposed rule
(87 FR 28617 through 28618), to codify
at § 413.99(f)(6), where the provider of
services declines to vest its outstanding
required contributions/payments (that
is, matching and non-elective or both) to
a Deferred Compensation Plan, as a
result of a termination, in full or in part,
or a discontinuation of contributions or
payments to a Deferred Compensation
Plan, then the provider of services total
outstanding required contributions or
payments to the Deferred Compensation
Plan during the cost reporting period
wherein such termination is initiated
cannot be included in the provider of
services allowable cost for the cost
reporting period in which the
termination is initiated, nor any future
period.
We received no comments on this
proposal and are finalizing this proposal
without modification.
f. Required Offset Against Interest
Expense
In section 2140.3.D of PRM–I, CMS
has established a policy that investment
income earned on a fund after its
termination but prior to liquidation of
the fund’s assets and distribution to the
provider is offset against the provider’s
allowable interest expense. In the FY
2023 IPPS/LTCH proposed rule (87 FR
28618), we proposed to adopt the
current policy in section 2140.3 of
PRM–I at proposed § 413.99(f)(7), which
would state that investment income
earned on a Deferred Compensation
Plan after its termination but prior to
liquidation of the plan’s assets and
distribution to the provider of services
must be offset against the provider of
services allowable interest expense
under § 413.153.
We received no comments on this
proposal and are finalizing this proposal
without modification.
g. Treatment of Residual Assets
Following Termination of a Funded
Plan
In section 2140.3.D of PRM–I, CMS
has established a policy describing how
residual assets arising from the
termination of a funded plan are to be
handled on the Medicare cost report. In
E:\FR\FM\10AUR2.SGM
10AUR2
49376
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
the FY 2023 IPPS/LTCH proposed rule
(87 FR 28618), we proposed to adopt the
current policy, as it appears in section
2140.3.D of PRM–I, at new
§ 413.99(f)(8). Specifically, we proposed
that § 413.99(f)(8) would specify that
residual assets arising from the
termination of a funded plan must be
recouped in the year of the plan
termination only against the cost
center(s) in which the provider of
services reported its plan contributions/
payments, usually the administrative
and general cost center. Residual assets
exceeding the amount in the
administrative and general (or other)
cost center are not further offset in the
current or subsequent years. The
Medicare share of the reversion is based
on the Medicare utilization rate in the
year the reversion occurs (or the year
the actuarial surplus is determined), and
not Medicare’s utilization in the years
the contributions to the plan were made.
We received no comments on this
proposal and are finalizing this proposal
without modification.
9. Treatment of Costs Associated With
the Pension Benefit Guaranty
Corporation (PBGC) (§ 413.99(g))
Since 1974, the PBGC has protected
retirement security and the retirement
incomes of over 33 million American
workers, retirees, and their families in
private sector defined benefit pension
plans. A Qualified Defined Benefit Plan
(defined previously as a QDBP) provides
a specified monthly benefit at
retirement, often based on a
combination of salary and years of
service. The PBGC was created by
ERISA to encourage the continuation
and maintenance of private sector
defined benefit pension plans, provide
timely and uninterrupted payment of
pension benefits, and keep pension
insurance premiums at a minimum.
General tax revenues do not fund the
PBGC Single-Employer Program. The
PBGC collects insurance premiums from
employers that sponsor insured pension
plans, earns money from investments,
and receives funds from pension plans
it takes over (see https://www.pbgc.gov/
about/how-pbgc-operates).
Providers of services who offer a
QDBP may incur costs related to the
PBGC premiums. The proposed
regulations outlined in this section of
this final rule establish which costs
incurred by providers of services who
maintain a QDBP and pay premiums for
basic benefits to the PBGC are allowable
under the program. We proposed to
include these provisions on the
treatment of costs associated with the
PBGC in paragraph (g) of proposed
§ 413.99.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
In 29 U.S.C. 1306 the schedule for the
premium rates, and the bases for
application of those rates are set forth.
Under 29 U.S.C. 1306, premiums are
established for basic benefits, non-basic
benefits, and reimbursement for
uncollectible withdrawal liability. In the
FY 2023 IPPS/LTCH proposed rule (87
FR 28618), we proposed at § 413.99(g)(1)
that PBGC premiums and costs paid out
of the corpus or earnings of the trust are
included in the contributions allowed
by § 413.99(d)(3)(ii), and therefore are
not allowable as separate costs. We note,
in the proposed rule we inadvertently
made a typographical error and referred
to § 413.99(d)(3)(ii) when we intended
to refer to § 413.99(d)(1)(iii)(A). We also
proposed at § 413.99(g)(2) that the
amount of PBGC premiums paid for
basic benefits (that is, flat rate or
variable, excluding amounts paid out of
the corpus or earnings of the trust) by
a provider of services who sponsors a
QDBP are allowable under the program.
Similar to allowance of Administrative
Costs as stated in proposed
§ 413.99(f)(1), while PBGC premiums
are an allowable cost, they are not
allowed if they are paid from the plan
trust.
In 29 CFR part 4050, the rules for
PBGC’s program that holds retirement
benefits for missing participants and
beneficiaries of terminated retirement
plans and pays those benefits to
participants and beneficiaries when
found, are provided. A Missing
Participant is a former employee of a
provider of services who has a liability
remaining with the plan but cannot be
located or is unresponsive when the
plan terminates and closes out.
Transfers of funds to the PBGC by the
provider of services to cover this
liability under the PBGC Missing
Participant Program are allowable as
long as they are not paid out of the
corpus or earnings of the trust. In the FY
2023 IPPS/LTCH proposed rule (87 FR
28618), we proposed at new
§ 413.99(g)(3) that the total amount paid
to the PBGC by a provider of services
who sponsors a QDBP (excluding
amounts paid out of the corpus or
earnings of the trust) of the benefit
transfer amount (see 29 CFR
4050.103(d)) for all missing participants
or beneficiaries of the QDBP is
allowable under the program.
After entering into a trusteeship
agreement with the employer or after
receiving an order issued by a U.S.
district court approving termination, the
PBGC guarantees employee plan
benefits will be paid up to a certain
limit if the QDBP has insufficient assets
as part of a Distress Termination (as
described in 29 CFR part 4041) or as
PO 00000
Frm 00598
Fmt 4701
Sfmt 4700
part of a PBGC-initiated termination
under 29 U.S.C. 1342. In the FY 2023
IPPS/LTCH proposed rule (87 FR
28618), we proposed at § 413.99(g)(4)
that for terminated plans with
insufficient assets to pay all of the plan
benefits, where the PBGC guarantees the
payment of vested benefits up to limits
defined by law, only contributions to
the QDBP made by a provider of
services are allowable. Benefits paid to
the participants and beneficiaries of the
QDBP by the PBGC are unallowable.
In 29 CFR part 4047, PBGC is given
the authority to restore a plan from
terminated status to ongoing.
Contributions and benefits paid by the
provider of services to the PBGC or the
plan or its participants and beneficiaries
are allowable in this situation. In the FY
2023 IPPS/LTCH proposed rule (87 FR
28618), we proposed at § 413.99(g)(5)
that where the PBGC issues or has
issued a plan restoration order as
described in 29 CFR part 4047, the
amounts that the provider of services
repays to the PBGC for guaranteed
benefits and related expenses under the
plan while the plan was in terminated
status, and any administrative costs
assessed by the PBGC, excluding
penalties, are allowable.
We received no comments on the
proposed treatment of costs associated
with the PBGC under § 413.99(g) and are
generally finalizing this proposal
without modification, except we are
revise the proposed regulation text at
§ 413.99(g)(1) so that the erroneous
reference to § 413.99(d)(3)(ii) is
corrected in the finalized regulation text
and instead refers to
§ 413.99(d)(1)(iii)(A).
B. Condition of Participation (CoP)
Requirements for Hospitals and CAHs
To Continue Reporting Data for COVID–
19 and Influenza After the PHE Ends as
Determined by the Secretary
Under sections 1866 and 1902 of the
Act, providers of services seeking to
participate in the Medicare or Medicaid
program, or both, must enter into an
agreement with the Secretary or the
state Medicaid agency, as appropriate.
Hospitals (all hospitals to which the
requirements of 42 CFR part 482 apply,
including short-term acute care
hospitals, LTC hospitals, rehabilitation
hospitals, psychiatric hospitals, cancer
hospitals, and children’s hospitals) and
CAHs seeking to be Medicare and
Medicaid providers of services under 42
CFR part 485, subpart F, must be
certified as meeting Federal
participation requirements. Our
conditions of participation (CoPs),
conditions for coverage (CfCs), and
requirements set out the patient health
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
and safety protections established by the
Secretary for various types of providers
and suppliers. The specific statutory
authority for hospital CoPs is set forth
in section 1861(e) of the Act; section
1820(e) of the Act provides similar
authority for CAHs. The hospital
provision at section 1861(e)(9) of the
Act authorizes the Secretary to issue any
regulations he or she deems necessary to
protect the health and safety of patients
receiving services in those facilities; the
CAH provision at section 1820(e)(3) of
the Act authorizes the Secretary to issue
such other criteria as he or she may
require. The CoPs are codified in the
implementing regulations at part 482 for
hospitals, and at 42 CFR part 485,
subpart F, for CAHs.
Our CoPs at § 482.42 for hospitals and
§ 485.640 for CAHs require that
hospitals and CAHs, respectively, have
active facility-wide programs, for the
surveillance, prevention, and control of
healthcare-associated infections (HAIs)
and other infectious diseases and for the
optimization of antibiotic use through
stewardship. Additionally, the programs
must demonstrate adherence to
nationally recognized infection
prevention and control guidelines, as
well as to best practices for improving
antibiotic use where applicable, and for
reducing the development and
transmission of HAIs and antibioticresistant organisms. Infection
prevention and control problems and
antibiotic use issues identified in the
required hospital and CAH programs
must also be addressed in coordination
with facility-wide quality assessment
and performance improvement (QAPI)
programs.
Infection prevention and control is a
primary goal of hospitals and CAHs in
their normal day-to-day operations, and
these programs have been at the center
of initiatives taking place in hospitals
and CAHs during the PHE for COVID–
19. Our regulations at §§ 482.42(a)(3)
and 485.640(a)(3) require infection
prevention and control program policies
to address any infection control issues
identified by public health authorities.
We proposed to revise the hospital and
CAH infection prevention and control
and antibiotic stewardship programs
CoPs to extend the current COVID–19
reporting requirements and to establish
new reporting requirements for any
future PHEs related to a specific
infectious disease or pathogen.
Specifically, we proposed to revise
the COVID–19 and Seasonal Influenza
reporting standards for hospitals and
CAHs (at §§ 482.42(e) and (f); and
485.640(d) and (e), respectively) to
require that, beginning at the conclusion
of the current COVID–19 PHE
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
declaration and continuing until April
30, 2024, a hospital (or a CAH) must
electronically report information about
COVID–19 and seasonal influenza in a
standardized format specified by the
Secretary. In addition, we proposed
additional requirements to address
future PHEs related to infectious
diseases at §§ 482.42(g) and 485.640(f),
for hospitals and CAHs respectively.
Specifically, when the Secretary has
declared a PHE, we proposed to require
hospitals and CAHs to report specific
data elements to the CDC’s National
Health Safety Network (NHSN), or other
CDC-supported surveillance systems, as
determined by the Secretary. We noted
that the proposed requirements of this
section would apply to local, state, and
national PHEs as declared by the
Secretary.
In the proposed rule, we highlighted
the various interim final rules with
comment (IFC) that currently require
hospitals and CAHs to report important
data critical to support the fight against
COVID–19 and noted that these
requirements are both tied to the current
PHE (meaning they would no longer be
required post-PHE) and emphasized that
COVID–19 reporting, by all hospitals
and CAHs, have been, and continue to
be, important in supporting surveillance
of, and response to, the PHE for COVID–
19. We stressed that such reporting
requirements are necessary for CMS to
monitor whether individual hospitals
and CAHs are appropriately tracking,
responding to, and mitigating the spread
and impact of viral and bacterial
pathogens and infectious diseases of
pandemic or epidemic potential on
patients, the staff who care for them,
and the general public and the
important role that such reporting plays
when considering future planning.
Additionally, we noted our concern that
current reporting, while appropriately
focused on the current COVID–19
pandemic, are too limited in scope for
potential future use and noted that we
are considering ways to ensure a more
flexible regulatory framework to
promote a nimble and informed
response to the next potential pandemic
or epidemic, so that we are able to
immediately respond to the situation at
hand. We refer readers to the FY 2023
IPPS proposed rule for this detailed
discussion (87 FR 28618–28622).
In response to the proposed rule, we
received approximately 757 public
comments that specifically addressed
the proposals to continue COVID–19related data reporting and to establish
reporting in the event of a future PHE
declaration involving an infectious
disease. Commenters included
individuals, health care professionals
PO 00000
Frm 00599
Fmt 4701
Sfmt 4700
49377
and corporations, national associations,
health department and emergency
management professionals, and
individual facilities that would be
impacted by the regulation. We have
organized our responses to the
comments as follows: (1) general
comments, (2) comments focused on the
proposals for continued COVID–19related data reporting, and (3) comments
pertaining to the proposals for data
reporting in the event of a future PHE
declaration. We note that for many
comments, CMS was unable to discern
if the content was applicable to both
proposals or specific to either the
proposals for continued COVID–19related reporting or future data reporting
for a declared PHE involving an
infectious diseases. We address these
comments as general comments. To the
extent possible, in those instances
where commenters clearly referenced
specific requirements in the proposals
for either continued COVID–19-related
reporting or reporting in the event of a
future PHE, we address those comments
in the applicable section. Comments
related to the collection of information
requirements and burden estimates are
addressed in sections XII.B.10 and
XII.H.11, ‘‘Collection of Information
Requirements’’ and ‘‘Regulatory Impact
Analysis’’ of this final rule, as
appropriate.
A. General Comments
Comment: Several commenters agreed
with our goal to ensure patient health
and safety by continuing and
establishing a flexible framework for
data-driven surveillance and response
for COVID–19 and future PHEs
involving infectious diseases,
respectively. Commenters stated that
although collecting and reporting data
may consume resources and increase
demands on staff, such data are
important for establishing and
maintaining situational awareness
during a PHE and beyond. They noted
that these data are critical and used in
decision making at the local, state, and
federal levels. In addition, while these
commenters noted the increased
demands experienced by health care
facilities and their staff during the
COVID–19 PHE, they shared that efforts
to recover and resume normal
operations are well under way and reenforced their commitment to providing
the highest quality and safe level of care
to patients at all times.
Response: We appreciate the support
from commenters. We agree that data
are critical for monitoring the spread of
infectious diseases, informing research
and guidance development by
government and non-governmental
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49378
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
entities, and responding during and
after a public health emergency. We
commend health care facilities and their
staff for their efforts throughout the
COVID–19 pandemic and recovery, and
we are also committed to ensuring high
quality and safe care to patients.
Comment: While several commenters
supported the overall policy goal, many
commenters disagreed with our
approach to achieve a flexible regulatory
framework for data-driven surveillance
and response for COVID–19 and future
infectious diseases in the event of a PHE
declaration. Commenters noted that
these proposals would place undue
burden on facilities, and particularly
during and/or directly after PHEs, when
patient care demands and stress and
burnout among staff are increased. Some
commenters stated the proposed data
categories reflected a high level of detail
that would be burdensome to collect
and report thereby negatively impacting
the accuracy of the data and taking time
away from patient care, infection
prevention and control, and quality
improvement activities. Commenters
also raised concerns regarding
duplicative reporting and encouraged
increased coordination at the local,
state, and federal level to ease the
burden on providers and limit the need
to report the same information through
multiple streams. Commenters also
suggested reviewing the use case for
each data category and eliminating
those that are not providing valuable
information. A few commenters stated
that more reimbursement would be
needed to support any additional
reporting requirements. Others
suggested that incentives for reporting
data would be helpful.
Response: We understand the burden
concerns expressed by commenters. As
indicated in the proposed rule, CMS
recognizes that the health and safety
benefits associated with any reporting
requirements must be carefully weighed
against the potential burden they
impose on facility operations—
particularly in situations, like a public
health emergency, where staff resources
are stretched. We appreciate the
comments about reimbursement and
incentives; however, reimbursement
and incentives are outside of the scope
of the CoPs. As suggested by the
commenters, we reviewed the use case
for each data category, and we discuss
this in greater detail in sections B and
C. As with the current COVID–19
reporting required during the ongoing
PHE, CDC and ASPR are working with
states and other jurisdictions for the
continuation of COVID–19-related
reporting to ensure that states have
access to the data reported directly to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the federal government and that
jurisdictions so inclined can continue to
report on behalf of the hospitals within
their jurisdictions. According to ASPR,
approximately half of the states
currently submit data on behalf of the
hospitals in their jurisdictions and
many have expressed their interest in
continuing this capability. CDC, CMS,
and ASPR concur and will continue to
leverage this capability—where desired
by jurisdictions—so that they may
receive the data directly from hospitals
to fulfill local jurisdictional reporting
requirements and then pass the data to
the federal government to alleviate the
burden of hospitals reporting to both
state health departments and the federal
government.
Comment: Many commenters noted
the significant administrative burden
associated with manual entry,
configuration, and submission of
required data elements, and most agreed
that greater automation of the reporting
enterprise would be critical to
minimizing future hospital burden. A
few of these commenters also believed
that, given widespread adoption of
certified EHR technologies and
associated interoperability standards,
such automation was within reach for
most hospitals. The majority, however,
shared concern about the extent to
which the technical and technological
architecture to support automated,
electronic reporting was in place—or
would be soon, given the complex array
of systems from which hospitals have to
pull and assemble required data. These
commenters noted that small, rural
hospitals and CAHs in particular often
lack the resources and IT expertise to
establish and maintain the necessary
system interfaces. Most commenters
focused more on the capabilities
necessary for automated data reporting,
while some commenters focused on
specific systems for data reporting.
Specifically, some commenters
recommended use of NHSN as a single
pathway for data reporting and
indicated that this would streamline
reporting guidance and the systems for
submitting data. Some commenters
suggested that the data reporting
pathways currently in place for the
COVID–19 PHE should remain available
for continued COVID–19-related
reporting after the PHE ends and for
reporting in the event of a future PHE
declaration. These commenters noted
that changing reporting systems requires
modifying workflows and making these
changes would increase burden.
Response: We thank commenters for
their feedback and agree that greater
automation of the reporting enterprise
will greatly reduce burden on providers.
PO 00000
Frm 00600
Fmt 4701
Sfmt 4700
We expect reporting to become
increasingly automated and real-time as
data systems and standards continue to
mature and become more interoperable.
As noted in the proposed rule, the CDC
is investing in increasing the
automation capabilities of surveillance
systems, like the NHSN, and their
ability to connect with other data
submission techniques, vendors, and
systems (87 FR 28622). We look forward
to continuing the work in this space and
are excited about the future possibilities
as we continue efforts to protect and
ensure the health and safety of patients.
Comment: Some commenters stated
there was a lack of transparency in why
CMS would need the data, who would
use the data, and how the data would
be used. These commenters also
indicated that there should be a bidirectional flow of the information
reported and that the data should be
accessible to all health partners to both
increase transparency and inform
emergency management efforts.
Response: As CMS noted in the
proposals, the proposed rule aimed to
minimize data reporting while
maintaining transparency 1160 and
ensuring that public health agencies,
researchers, and the public have
sufficient awareness 1161 of overall
health system capacity amid evolving
epidemiological conditions in order to
rapidly direct preventive and response
actions. In addition, NHSN provides
ready access to data to state and many
local public health agencies for the
facilities in their jurisdictions via their
NHSN accounts and contributes
aggregate data to multiple public-facing
platforms, including HHS Protect and
CMS Care Compare. For example, the
COVID–19-related data pertaining to
bed census and occupancy, vaccination
of staff, and PPE supplies reported by
hospitals and CAHs throughout the
COVID–19 PHE has been publicly
posted in aggregate on a regular basis on
HHS Protect and/or NHSN websites.
Requiring the collection of the data
supports our responsibility and
commitment to protect the health and
safety of hospital and CAH patients.
These data would allow CMS to monitor
whether individual hospitals and CAHs
were appropriately tracking, responding
to, and mitigating the impact on
patients, the staff who care for them,
and the general public. A streamlined
approach will greatly assist government
leaders in tracking, identifying new
1160 https://obamawhitehouse.archives.gov/thepress-office/2013/05/09/executive-order-makingopen-and-machine-readable-new-defaultgovernment1161 https://digital.gov/open-data-policy-m-13-13/
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
threats, and ultimately inform decisionmaking, resource allocation, and the
ability to inform a coordinated response
effort across the nation. For example,
during the COVID–19 PHE, the data
collected and reported by hospitals and
CAHs enabled CMS, in partnership with
CDC and ASPR, to monitor the ability of
facilities to provide safe care for patients
by determining the number of COVID–
19 patients being cared for in facilities;
the amount of resources facilities were
using; and facilities’ continued capacity
to provide safe care based on these
factors. Throughout the COVID–19
pandemic, HHS and state and local
agencies used these data to provide
resources (such as PPE, staffing, strike
teams, financial resources) to hospitals
to ensure safe care and used these data
to update guidance on the provision of
care to patients during periods of scarce
staffing, scarce PPE, and limited
hospital capacity.
Comment: In response to our request
for strategies to support a smooth
transition, several commenters
suggested implementation approaches
that CMS could take to support
compliance with the proposed reported
policies. Commenters emphasized that
the data definitions across facility types
and different reporting organizations
need to be clearly defined and
consistent. These commenters noted
that as an example, for healthcare
worker COVID–19 vaccination data, the
definition of a ‘‘week’’ is different
depending on to which organization the
data are being reported. Commenters
stated that providing education to
facilities on the context for data requests
and usage would improve the quality,
timeliness, and participation of
reporting. Some commenters stated that
data reporting requirements and
relevant interpretative guidance should
be clearly communicated with adequate
lead time so that facilities could
develop, implement, and update
workflows and procedures for collecting
and reporting the necessary data, as well
as any changes in the data they are
required to report. A few commenters
suggested that facilities would need this
interpretive guidance with a minimum
notice of 30 to 60 days to prepare data
reporting workflows and procedures.
Response: We appreciate the feedback
and suggestions provided regarding
strategies to help support
implementation and a smooth
transition. As stated in the proposed
rule, facilities will be notified of the
specific reporting requirements (start
date, data elements and definitions,
frequency, etc.) and subsequent changes
in guidance, such as a Quality, Safety,
and Oversight (QSO) memorandum,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
consistent with the notification methods
used previously for COVID–19-related
reporting (87 FR 28620); (see QSO–21–
03-Hospitals/CAHs at https://
www.cms.gov/files/document/qso-2103-hospitalscahs.pdf-0). We will
consider these comments when
developing the interpretive guidance for
this final rule.
B. Comments Focused on the Proposals
for Continued COVID–19-Related Data
Reporting
Comment: A few commenters stated
that the proposal for continued COVID–
19-related data was unclear, because the
proposal indicated that hospitals and
CAHs would report data in a
standardized format specified by the
Secretary. These commenters
recommended that the rule clearly
identify the systems by which hospitals
and CAHs would be able to report data,
to include HHS Protect.
Response: We agree that the rule does
not identify specific systems for data
reporting by hospitals and CAHs.
Current regulations for COVID–19
reporting and reporting of acute
respiratory illness, including seasonal
influenza virus, influenza-like illness,
and severe acute respiratory infection at
§ 482.42(e) and (f) (hospitals) and
§ 485.640(d) and (e) (CAHs) state that
hospitals and CAHs must report
information in a standardized format
specified by the Secretary. We adopted
that approach because it affords
flexibility to adapt data reporting
requirements in response to changing
circumstances. In this rule, we maintain
this regulatory language (in a
standardized format as specified by the
Secretary) thereby ensuring a sustained,
flexible approach for continued COVID–
19-related data reporting after the PHE
ends. As indicated in the proposed rule,
throughout the COVID–19 PHE, CMS
notified hospitals and CAHs of the
reporting requirements with QSO
memorandums (for example, see QSO–
21–03-Hospitals/CAHs at https://
www.cms.gov/files/document/qso-2103-hospitalscahs.pdf-0.) We anticipate a
similar model of notification for the
continued COVID–19-related data
reporting requirements finalized in this
rule.
Comment: A few commenters stated
that it was difficult to understand the
purpose of continuing COVID–19related reporting beyond the current
PHE declaration. The commenters stated
that the data is of questionable value
given the current state of the pandemic.
Some commenters recommended that
the COVID–19-related reporting
requirements end when the current PHE
PO 00000
Frm 00601
Fmt 4701
Sfmt 4700
49379
expires and restart in the event another
PHE is declared.
Response: We acknowledge the
concerns raised by commenters,
however disagree that there is no value
in continued COVID–19 reporting
beyond the current PHE. Due to the
unpredictable nature of the novel SARSCoV–2 virus that causes COVID–19, we
believe that continuing COVID–19related data reporting is necessary to
protect the health and safety of hospital
and CAH patients as well as the
communities in which the hospitals and
CAHs are located. The COVID–19related data reported by all hospitals
and CAHs, have been, and continue to
be, important in supporting surveillance
of, and response to, COVID–19 and
other respiratory illnesses. These data
play an important role in evaluating
spread of respiratory viruses and
infections, including but not limited to
COVID–19 and influenza. Retaining the
data reporting requirements after the
end of the current COVID–19 PHE is an
important element of maintaining
effective surveillance of this novel virus.
Timely and actionable surveillance will
enable CMS to continue to respond to
facilities in need of additional technical
support and oversight, should they
experience increased cases or outbreaks
of COVID–19 and/or influenza.
Furthermore, we note that these
requirements will sunset April 2024,
unless the Secretary establishes an
earlier end date, based upon the
statutory authority in the Social
Security Act that authorizes the
Secretary to issue any regulations
deemed necessary to protect the health
and safety of patients receiving services
in hospitals (section 1861(e)(9) of the
Act) and CAHs (section 1820(e)(3) of the
Act).
Comment: Some commenters stated
that our proposal to continue COVID–
19-related data reporting beyond the
current PHE declaration was
burdensome and labor intensive,
especially for infection preventionists
and nurses who have worked additional
hours and taken on additional duties
since the start of the COVID–19
pandemic in March 2020. These
commenters indicated that the
proposals would add to an already high
level of stress among health care
personnel, prompting individuals to
leave their positions and thereby
exacerbating staffing shortages. Some
commenters offered suggestions for
reducing the data categories required to
mitigate concerns regarding burden,
particularly those pertaining to
suspected cases, staff vaccination, and
staffing shortages as these have already
been made optional or retired from
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49380
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
current reporting requirements under
the PHE (available at https://
www.hhs.gov/sites/default/files/covid19-faqs-hospitals-hospital-laboratoryacute-care-facility-data-reporting.pdf).
In addition, a few commenters
suggested reducing or changing specific
data elements for health care worker
vaccination status, including but not
limited to those elements for vaccine
manufacturer and first and second doses
in a series. Some commenters suggested
that we reevaluate the data categories
and reduce where necessary without
identifying specific data categories to
remove. Other commenters stated that
the proposed data categories were
reasonable and represented a balance
between burden on facilities and patient
health and safety considerations
associated with COVID–19.
Response: We understand the burden
concerns shared by commenters and
appreciate the suggestions offered to
mitigate those concerns. As noted
previously, we believe this information
collection and record is vital to ensure
the health and safety of patients and the
communities in which they live.
However, we agree that in a post-PHE
posture that certain COVID–19 specific
data categories may not provide
additional value to inform our
surveillance and mitigation efforts.
Therefore, as further discussed in this
section, we have re-evaluated the
proposed data elements in consideration
of the feedback shared by commenters
and the evolving state of the current
PHE and are modifying our proposal to
remove the following from the list of
required data categories to report:
• Suspected COVID–19 infections
among patients and staff—Although
data pertaining to suspected cases were
valuable throughout the COVID–19
PHE, particularly in instances when
testing supplies were limited and cases
were often identified based on clinical
signs and symptoms, this information is
less meaningful now that testing
supplies are readily available to confirm
the presence of infection. Thus, we do
not believe suspected COVID–19
infection data would be necessary to
collect from hospitals and CAHs once
the PHE declaration ends, and therefore,
we removed this data category.
• Confirmed COVID–19 and influenza
infections among staff, confirmed comorbid influenza and COVID–19
infections among staff, and COVID–19
and influenza deaths among staff—The
data categories for staff (suspected
infections among staff; confirmed
COVID–19, influenza, and co-morbid
infections among staff; COVID–19 and
influenza deaths among staff) have not
been among the information that
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
hospitals and CAHs were required to
report throughout the COVID–19 PHE.
Hospitals and CAHs were required to
report suspected, confirmed, and
comorbid infections, as well as deaths,
for patients only. Upon reflection, we do
not believe collecting these data for staff
from hospitals and CAHs post-PHE is
necessary.
While beneficial during an active PHE
and the specific circumstances of the
COVID–19 PHE, we believe the data
categories previously noted are not
necessary to provide the most valuable
information during a post-PHE state for
continued monitoring, and as such we
are removing these data categories to be
responsive to commenter concerns
regarding increased burden on facilities
and staff, while also attempting to
provide quality care for patients.
The data categories that we are
finalizing in this rule that hospitals and
CAHs will be required to report relevant
to COVID–19, to the extent as
determined by the Secretary, are as
follows: Confirmed infections among
patients; Total deaths among patients;
Personal protective equipment and
testing supplies; Ventilator use,
capacity, and supplies; Total bed and
intensive care unit bed census and
capacity; Staffing shortages; Vaccine
administration data of patients and staff;
and Relevant therapeutic inventories or
usage, or both. The data categories that
we are finalizing in this rule that
hospitals and CAHs will be required to
report relevant to influenza, to the
extent as determined by the Secretary,
are as follows: Confirmed infections
among patients; Total deaths among
patients; and Confirmed co-morbid
influenza and COVID–19 infections
among patients. We believe these data
will offer the most valuable information
during a post-PHE state by continuing to
capture critical data on COVID–19 for
ongoing surveillance and to inform any
potential action to protect patient health
and safety. As previously discussed,
these data will enable the federal
government to monitor the ability of
facilities to provide safe care for patients
by determining the number of COVID–
19 and influenza infections being
treated by facilities; the quantity of
resources available to facilities and the
volume of resources they are using; and
facilities’ continued capacity to provide
safe patient care. In addition, as done
throughout the COVID–19 pandemic,
local, state, and federal authorities will
continue to use these data to identify
possible resurgence in cases and
outbreaks, for resource allocation
purposes, and to update guidance
pertaining to the safe provision of
patient care.
PO 00000
Frm 00602
Fmt 4701
Sfmt 4700
As indicated in the proposal, we do
not expect continued daily reporting for
COVID–19 or influenza outside of a
declared PHE. Moreover, the rule allows
for the scope of data categories and
frequency of data collection and
reporting to be reduced and limited, as
determined by the Secretary, responsive
to evolving clinical and epidemiology
circumstances. This approach to
reducing the proposed set of required
data categories will provide a path
towards winding down the overall
reporting of COVID–19-related data
between the end of the current PHE and
April 2024, when these requirements
will sunset. These requirements will not
be implemented and enforced until the
current COVID–19 PHE declaration
concludes, and CMS will issue guidance
indicating such a transition. As
discussed previously, we expect the
method of notification to follow a model
similar to that which we used to inform
regulated entities at the beginning of the
COVID–19 PHE (see QSO–21–03Hospitals/CAHs at https://
www.cms.gov/files/document/qso-2103-hospitalscahs.pdf-0).
C. Comments Pertaining to the
Proposals for Data Reporting in the
Event of a Future PHE Declaration
Comment: In the proposed rule, we
solicited comment on the potential that
long-term data collection in the event of
a future PHE may duplicate elements
already reported elsewhere and on the
feasibility of such a requirement. Many
commenters acknowledged the hard
work of the hospital system during the
COVID–19 PHE and the many efforts
taken by facilities to quickly adapt and
respond to both the demands of the PHE
and the requirements to report critical
data for monitoring and surveillance.
When considering the feasibility of
maintaining these efforts long-term, a
few commenters questioned the
appropriateness of requiring its
collection as a CoP (noting that many
hospitals provided such data voluntarily
prior to mandating its collection),
especially within the CoPs for infection
prevention and control and antibiotic
stewardship. Specifically, these
commenters indicated that the COVID–
19 data do not directly or indirectly
reflect a facility’s infection control
policies or practices, but rather, are
descriptive of public health information
(such as, infection rate, bed capacity,
supplies, etc.). With regard to
duplication, some commenters raised
concerns about accessibility and the
flow of reported information across
various government entities and
response partners. Many noted that,
throughout the COVID–19 PHE,
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
hospitals have been required to report
similar (but not necessarily
standardized) data elements to multiple
agencies (federal, state, local) and
through multiple platforms. Likewise,
commenters also reiterated that various
reporting requirements already exist
such as requirements to report quality
measures and shared concerns that the
new requirements proposed would
perpetuate, if not exacerbate, reporting
redundancies that tax already limited
facility and staff time and resources—
particularly if state and local public
health and emergency management
agencies do not have timely or complete
access to data reported through federal
systems. Nearly all of these commenters
called for CMS and other HHS agencies
to work closely with facilities, as well
as state and local agencies, to align and
streamline future reporting
requirements.
Response: We appreciate this
informative feedback regarding the
challenges and often redundant efforts
associated with current reporting. As
noted in the proposed rule, CMS does
not intend to supplant or duplicate
existing state and local requirements
and mechanisms for reporting of public
health and disease surveillance data (87
FR 28622). We believe that the reporting
requirements proposed for health care
facilities in these CoPs are distinct from
and serve a different purpose than case
surveillance of notifiable diseases and
conditions that is conducted by state
and local health departments. State and
local authorities define their own
reporting requirements and data
definitions, but differences among these
data neither enable comparisons across
states and local jurisdictions nor
provide a national perspective.
Moreover, HHS does not have easy
access to the data reported to state and
local authorities; these authorities are
not required to report the data to the
federal government, and, unless such
authorities are also directly providing
health services, CMS has no authority to
require state and local authorities to
collect certain data, standardize the data
collected, and report such data to the
federal government. However, as
discussed previously in this rule, during
the COVID–19 PHE, HHS worked with
states and other jurisdictions to ensure
they had access to the data reported by
hospitals and CAHs directly to the
federal government, and several states
submitted data to the federal
government on behalf of hospitals and
CAHs within their jurisdictions. HHS
will continue to partner with state and
local jurisdictions, health care facilities,
and stakeholders to coordinate data
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
collection, sharing, and accessibility in
a streamlined fashion that satisfies the
needs of all stakeholders while reducing
duplicative reporting requirements, to
the extent possible. Also as previously
discussed, data collected and reported
by hospitals and CAHs during the
COVID–19 PHE enabled the federal
government to monitor the ability of
facilities to provide safe care to patients,
and these date were used by local, state,
and federal government agencies to
allocate resources (such as PPE, staff,
strike teams, funding) to hospitals and
to update guidance on the provision of
care, which was particularly important
during periods of staffing and PPE
scarcity and limited capacity. Therefore,
we continue to see the value in creating
long-term opportunities to activate the
collection of this data and the need for
increased preparedness across the
health care system in the event of a
future PHE. Lessons learned from the
COVID–19 PHE have also highlighted
the need for and importance of
community engagement and
collaboration amongst hospitals and
CAHs, but also across provider types.
Throughout the COVID–19 pandemic,
it has been imperative for facilities to
have the ability to both assess and
communicate their needs and to
monitor their ability to continue to
provide safe care. While we can
appreciate the concerns shared by
commenters regarding the burden and
appropriateness of including a
requirement for surveillance reporting
as a long-term CoP in a facility’s
infection control and prevention
standards, we disagree that such
reporting is not appropriate for the CoPs
in an effort to protect patient health and
safety. However, we agree that
additional consideration is necessary to
fully establish a long-term solution for
ensuring the preparedness of the
healthcare system in the event of
another PHE. Therefore, we are
withdrawing our proposal to require
future infectious disease reporting in the
event of a declared PHE. We agree that
continued collaboration across
government partners and engagement
with interested parties to standardize
and streamline reporting efforts would
be beneficial. We also echo commenters
encouragement to continue efforts to
further enhance the infrastructure used
to support the submission of data for the
long-term in hopes of mitigating many
of the burden concerns raised by
comments. We appreciate the
commenters who have acknowledged
the ongoing efforts by facilities to meet
the current reporting requirements and
the willingness of many hospitals to
PO 00000
Frm 00603
Fmt 4701
Sfmt 4700
49381
report the information voluntarily.
While CMS considers a longer-term
solution for ensuring overall
preparedness as previously noted, it is
our expectation that hospitals and CAHs
will continue increasing their readiness
and will be prepared to report data in
the event of a future declared PHE.
Comment: We received a mixed
response to our proposal to require
facilities to report person-level data
during a pandemic. Commenters who
supported the proposal noted that
person-level data would provide
information about how different groups
are affected by an infectious disease
thereby supporting efforts focused on
advancing health equity and suggested
this data should include socioeconomic
status. Commenters who disagreed
noted concerns related to burden and
indicated that such reporting would be
unreasonable, particularly for larger
facilities or those facilities lacking
automated processes to collect and
report such data. These commenters
also questioned the use of and need for
person-level data. Other commenters
acknowledged our efforts to limit any
directly or potentially individually
identifiable person-level data, but noted
the that local health departments
currently use information such as name,
date of birth, and patient addresses to
link case and exposure data to identify
clusters and inform infection prevention
and control efforts by local jurisdictions.
Response: We thank commenters for
their feedback. We believe that personlevel data elements, such as race,
ethnicity, age, sex residential county
and zip code, and relevant
comorbidities for affected patients, will
help to inform response management
and address health equity issues. In the
absence of these data, it is challenging
to take actions to reduce disparities in
disease incidence and severity, access,
and effectiveness of relevant preventive
and therapeutic services (for example,
vaccines) among vulnerable or
otherwise marginalized populations. As
noted in the proposed rule, the lack of
individual data elements was an
important gap raised during the COVID–
19 PHE and we are seeking ways to
increase our ability to follow patients
through the health care system to
provide actionable information on
outcomes and health care facility
capacities. We will consider all of the
feedback received as we continue to
explore issues of if and when personlevel data may be warranted in the
context of future PHE reporting
requirements.
Comment: Many commenters
supported our proposal to require
facilities to report the required data to
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49382
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
the NHSN or some other CDCsupported surveillance system.
Commenters acknowledged the CDC’s
NHSN as a leader for data collection and
reporting in health care settings and
supported our goal of promoting a
standardized and streamlined
framework for data reporting. However,
while supporting the use of NHSN
commenters emphasized that its usage
must complement, not replace, existing
data collection efforts that provide
awareness and inform health care
practices, especially those at the local
level. Commenters noted that local
health departments are increasingly
called to facilitate coordination between
health care facilities, provide leadership
in response efforts, and often leverage
their jurisdictional data to establish
trends for their jurisdiction, and target
stewardship and infection prevention
and control initiatives. These
commenters shared concerns regarding
the likelihood that critical data would
continue to be reported to both NHSN
and any local surveillance systems
given the resource burden that would be
placed on providers. Specifically,
commenters noted systems such as
those used for case reporting, laboratory
data, and vaccination registries.
Response: We appreciate the feedback
and the additional comments noted
previously regarding additional
reporting streams and data collection
efforts. In the proposed rule, we noted
that we proposed reporting the CDC’s
NHSN because it is a vendor-neutral,
federally owned system and as such
provides ready access to data to state
and many local public health agencies
and can accept data submitted by
outside vendors contracted either by
hospitals, jurisdictions, or other Federal
entities to submit data on behalf of
providers (87 FR 28622). Additionally,
as previously noted in the proposed
rule, through resources provided by the
American Rescue Plan Act and its Data
Modernization Initiative, CDC is
investing in increasing the automation
capabilities of surveillance systems, like
NHSN, and its ability to connect with
other data submission techniques,
vendors, and systems to further
automate data collection, reduce
provider burden, and increase data
accessibility for stakeholders. In the
proposed rule, CMS also noted the
existing requirement for eligible
hospitals and CAHs participating in the
Promoting Interoperability Program to
report four of the six of the measures
associated with the Public Health and
Clinical Data Exchange Objective
(Syndromic Surveillance Reporting,
Immunization Registry Reporting,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Electronic Case Reporting, and
Electronic Reportable Laboratory Result
Reporting), and that to take advance of
other reporting streams, CMS would
consider other CDC-supported
surveillance systems, as determined by
the Secretary, for data reporting to allow
for flexibility in the designation of
future systems that are most capable of
meeting these needs. We will consider
all of these comments as we continue to
seek opportunities to work with
interested parties to explore the most
effective approaches for data reporting
that informs the success of our response
efforts, incentivizes and encourages
preparedness among providers in the
event of a future PHE, and ensures
health and safety for patients and
communities served by providers.
Final Rule Action: After consideration
of the public comments, we are
finalizing our proposal with the
following changes—
1. We are modifying our proposal at
§§ 482.42(e) and (f) for hospitals and
§§ 485.640(d) and (e) for CAHs, to
decrease the scope of data categories
required for continued COVID–19 and
seasonal influenza reporting.
2. We are withdrawing our proposal
to add new paragraphs at 482.42(g)
(hospitals) and 485.640(f) (CAHs), to
establish reporting requirements for an
infectious disease in the event of a PHE
declaration. CMS believes that
additional consideration is necessary to
establish a longer-term solution for data
collection and reporting that ensures the
ongoing preparedness of the entire
health care system in the event of
another PHE involving an infectious
disease or a PHE resulting from natural
or human-made factors. We also believe
that continued collaboration among
government and interested parties
would be beneficial to standardize and
streamline data reporting to the extent
possible thereby reducing burden on
facilities, particularly during
emergencies when resources are
stretched and patient care-related work
demands are elevated. As previously
discussed, while CMS considers a
longer-term solution for ensuring overall
preparedness in the event of future
emergencies, it is our expectation that
hospitals and CAHs will continue
assessing and improving their readiness
to report data in the event of a future
declared PHE, consistent with their
existing requirements for emergency
preparedness.
PO 00000
Frm 00604
Fmt 4701
Sfmt 4700
C. Public Comments Requested on IPPS
and OPPS Payment Adjustments for
Wholly Domestically Made NIOSHApproved Surgical N95 Respirators
In the FY 2023 IPPS/LTCH PPS
proposed rule, we requested public
comments on potential IPPS and OPPS
payment adjustments for wholly
domestically made National Institute for
Occupational Safety & Health (NIOSH)approved surgical N95 respirators (87
FR 28622 through 28625). Given the
importance of NIOSH-approved surgical
N95 respirators in protecting hospital
personnel and beneficiaries from the
SARS–CoV–2 virus and future
respiratory pandemic illnesses, we
indicated we were considering whether
it might be appropriate to provide
payment adjustments to hospitals to
recognize the additional resource costs
they incur to acquire NIOSH-approved
surgical N95 respirators that are wholly
domestically made. We stated that
NIOSH-approved surgical N95
respirators, which faced severe shortage
at the onset of the COVID–19 pandemic,
are essential for the protection of
patients and hospital personnel that
interface with patients. We indicated
that procurement of NIOSH-approved
surgical N95 respirators that are wholly
domestically made, while critical to
pandemic preparedness and protecting
health care workers and patients, can
result in additional resource costs for
hospitals.
We stated we were interested in
feedback and comments on the
appropriateness of payment adjustments
that would account for these additional
resource costs. We stated that we
believed such payment adjustments
could help achieve a strategic policy
goal, namely, sustaining a level of
supply resilience for NIOSH-approved
surgical N95 respirators that is critical
to protect the health and safety of
personnel and patients in a public
health emergency. We stated we were
considering such payment adjustments
for 2023 and potentially subsequent
years.
We received many comments that
were helpful in developing the payment
adjustment that we proposed in the CY
2023 OPPS/ASC proposed rule. For
instance, many commenters were
supportive of a payment adjustment,
acknowledging the importance of
surgical N95 respirators in keeping
health care workers and patients safe
and attesting to the difficulties of
procuring surgical N95 respirators
during the height of the COVID–19
pandemic. The majority of commenters
supported an approach of CMS making
biweekly interim lump-sum payments
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
that would be reconciled at cost report
settlement, although some commenters
preferred a claims-based approach.
Many commenters urged CMS to
minimize the administrative burden on
hospitals in the development of any N95
payment policy. We also acknowledge
the comments of MedPAC and others
stating that Medicare payment policy is
not the most appropriate mechanism to
support domestic manufacturing of
medical supplies.
In the CY 2023 OPPS/ASC proposed
rule, we proposed to make a payment
adjustment under the OPPS and IPPS
for the additional resource costs of
domestic NIOSH-approved surgical N95
respirators for cost reporting periods
beginning on or after January 1, 2023.
We refer the reader to the CY 2023
OPPS/ASC proposed rule for the
complete discussion on this proposal.
XI. MedPAC Recommendations
Under section 1886(e)(4)(B) of the
Act, the Secretary must consider
MedPAC’s recommendations regarding
hospital inpatient payments. Under
section 1886(e)(5) of the Act, the
Secretary must publish in the annual
proposed and final IPPS rules the
Secretary’s recommendations regarding
MedPAC’s recommendations. We have
reviewed MedPAC’s March 2022
‘‘Report to the Congress: Medicare
Payment Policy’’ and have given the
recommendations in the report
consideration in conjunction with the
policies set forth in this final rule.
MedPAC recommendations for the IPPS
for FY 2023 are addressed in Appendix
B to this final rule.
For further information relating
specifically to the MedPAC reports or to
obtain a copy of the reports, contact
MedPAC at (202) 653–7226, or visit
MedPAC’s website at https://
www.medpac.gov.
XII. Other Required Information
khammond on DSKJM1Z7X2PROD with RULES2
A. Publicly Available Files
IPPS-related data are available on the
internet for public use. The data can be
found on the CMS website at https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
AcuteInpatientPPS/index. We listed the
data files available in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28625
through 28627).
Commenters interested in discussing
any data files used in construction of
this final rule should contact Michael
Treitel at (410) 786–4552.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
B. Collection of Information
Requirements
1. Statutory Requirement for Solicitation
of Comments
Under the Paperwork Reduction Act
(PRA) of 1995, we are required to
provide 60-day notice in the Federal
Register and solicit public comment
before a collection of information
requirement is submitted to the Office of
Management and Budget (OMB) for
review and approval. In order to fairly
evaluate whether an information
collection should be approved by OMB,
section 3506(c)(2)(A) of the PRA of 1995
requires that we solicit comment on the
following issues:
• The need for the information
collection and its usefulness in carrying
out the proper functions of our agency.
• The accuracy of our estimate of the
information collection burden.
• The quality, utility, and clarity of
the information to be collected.
• Recommendations to minimize the
information collection burden on the
affected public, including automated
collection techniques.
In the FY 2023 IPPS/LTCH PPS
proposed rule, we solicited public
comment on each of these issues for the
following sections of this document that
contain information collection
requirements (ICRs).
2. ICRs for the Hospital Wage Index for
Acute Care Hospitals
Section III.E.1. of the preamble of this
final rule, use of 2019 Medicare wage
index occupational mix survey for the
FY 2023 wage index, references the
information collection request currently
approved under 0938–0907. There were
no proposed changes to the currently
approved information collection request
associated with this rulemaking;
however, we note that the information
collection expires October 31, 2022. An
extension of the information collection
request is currently being developed.
The public will have an opportunity to
review and submit comments regarding
the extension of this PRA package
through a public notice and comment
period separate from this rulemaking.
Section III.I.2.a. of the preamble of
this final rule, FY 2023 Reclassification
Application Requirements and
Approvals, references the information
collection request 0938–0573 which
expired on January 31, 2021. A
reinstatement of the information
collection request is currently being
developed. The public will have an
opportunity to review and submit
comments regarding the reinstatement
of this PRA package through a public
PO 00000
Frm 00605
Fmt 4701
Sfmt 4700
49383
notice and comment period separate
from this rulemaking.
We did not receive comments
regarding the ICRs for the hospital wage
index for acute care hospitals.
3. ICRs for Payments for Low-Volume
Hospitals
As discussed in section V.C. of this
final rule, in accordance with section
1886(d)(12) of the Act, beginning with
FY 2023, the low-volume hospital
definition and payment adjustment
methodology will revert back to the
statutory requirements that were in
effect prior to the amendments made by
the Affordable Care Act and subsequent
legislation. Therefore, effective for FY
2023 and subsequent years, under
current policy at § 412.101(b), in order
to qualify as a low-volume hospital, a
subsection (d) hospital must be more
than 25 road miles from another
subsection (d) hospital and have less
than 200 discharges during the fiscal
year. In that section we also discuss the
process for requesting and obtaining the
low-volume hospital payment
adjustment under § 412.101.
Specifically, a hospital makes a written
request to its MAC that contains
sufficient documentation to establish
that the hospital meets the applicable
statutory mileage and discharge criteria.
While this information collection
requirement would normally be subject
to the PRA, we believe in this instance
it is exempt. Based on historical data,
we estimated there are fewer than 5
hospitals among all subsection (d)
hospitals that will meet the applicable
mileage and discharge criteria for FY
2023. In accordance with the
implementing regulations of the PRA at
5 CFR 1320.3(c)(4), the requirement will
be exempt as it affects less than 10
entities in a 12-month period.
We did not receive comments
regarding the ICRs for payments for lowvolume hospitals.
4. ICRs Relating to the Hospital
Readmissions Reduction Program
In section V.H of the preamble of this
final rule, we discuss requirements for
the Hospital Readmissions Reduction
Program. In this rule, we are not
removing or adopting any new measures
into the Hospital Readmissions
Reduction Program for FY 2023. All six
of the current Hospital Readmissions
Reduction Program’s measures are
claims-based measures. We believe that
continuing to use these claims-based
measures would not create or reduce
any information collection burden for
hospitals because they will continue to
be collected using Medicare FFS claims
that hospitals are already submitting to
E:\FR\FM\10AUR2.SGM
10AUR2
49384
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
the Medicare program for payment
purposes.
khammond on DSKJM1Z7X2PROD with RULES2
5. ICRs for the Hospital Value—Based
Purchasing (VBP) Program
In section V.I. of the preamble of this
final rule, we discuss new requirements
we are finalizing for the Hospital VBP
Program. Specifically, in this final rule,
with respect to quality measures, we are
finalizing our proposals to suppress the
Hospital Consumer Assessment of
Healthcare Providers and Systems
(HCAHPS) Survey and the five
Healthcare—Associated Infection (HAI)
measures for the FY 2023 program year.
We are also finalizing our proposal to
continue requiring hospitals to report
data for all measures, including
measures we are suppressing for FY
2023. Because the FY 2023 Hospital
VBP Program will use data that are also
used to calculate quality measures in
other programs and Medicare FFS
claims data that hospitals are already
submitting to CMS for payment
purposes, we do not anticipate any
change in burden associated with this
final rule.
6. ICRs Relating to the HospitalAcquired Condition (HAC) Reduction
Program
In this final rule, we are not removing
any measures, adopting any new
measures into the HAC Reduction
Program, or updating our validation
procedures.1162 The HAC Reduction
Program has previously adopted six
measures: the CMS PSI 90 measure and
five CDC NHSN HAI measures. We are
not finalizing our proposal to not
calculate measure results for PSI 90 and
thus will be calculating measure results
for the FY 2023 HAC Reduction
program. We do not believe that the
claims-based CMS PSI 90 measure in
the HAC Reduction Program creates
additional burden for hospitals because
the measure is calculated using the
Medicare FFS claims that hospitals have
submitted to the Medicare program for
payment purposes. Accordingly, we do
not believe that our finalized policy in
sections V.J.3.c.(1). to increase the
minimum volume threshold for the
CMS PSI 90 measure changes any
information collection burden for
hospitals.
We note the burden associated with
collecting and submitting data for the
HAI measures (CAUTI, CLABSI, Colon
and Abdominal Hysterectomy SSI,
MRSA bacteremia, and CDI) via the
CDC’s NHSN system is captured under
1162 Burden associated with the validation
procedures in the HAC Reduction Program are
accounted for under OMB Control Number 0938–
1352.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
a separate OMB control number, 0920–
0666 (expiration January 1, 2025). As
discussed in sections V.J.2.b.(2). and
V.J.2.b.(3). of the preamble of this final
rule, we are suppressing the five NHSN
measures from the FY 2023 HAC
Reduction Program. We are also
suppressing CY 2021 CDC NHSN HAI
data from the FY 2024 program year.
Because hospitals would continue to
report data for the HAI measures, this
policy does not change information
collection burden for hospitals as
accounted for under CDC’s OMB control
number 0920–1066.
In section V.J.7. of the preamble of
this final rule, we clarify the removal of
the No Mapped Locations (NML) policy
beginning in FY 2023. Hospitals will be
required to appropriately submit data to
the NHSN or, if hospitals do not have
the applicable locations for the CLABSI
and CAUTI measures, the hospital must
submit an IPPS Measure Exception
Form to be exempt from CLABSI and
CAUTI reporting for CMS programs. The
burden for all hospitals to submit data
to the NHSN is already accounted for
under OMB control number 0920–0666,
therefore there is no increase in burden
for hospitals which submit data as a
result of this clarification. In addition,
the burden associated with completion
of forms (including the IPPS Measure
Exception Form) is already accounted
for under OMB control number 0938–
1022 (expiration date December 31,
2022), therefore there is no increase in
burden for hospitals which elect to
submit this form as a result of this
clarification. This clarification does not
necessitate substantive changes to the
IPPS Measure Exception Form, therefore
any change in burden is negligible and
our currently approved burden
estimates under OMB control number
0938–1022 are conservative enough to
accommodate the change. Revisions to
the IPPS Measure Exception Form, will
be submitted for approval under OMB
control number 0938–1022.
We did not receive comments
regarding the ICRs for the HAC
Reduction Program.
7. ICRs for the Hospital Inpatient
Quality Reporting (IQR) Program
a. Background
The Hospital IQR Program (formerly
referred to as the Reporting Hospital
Quality Data for Annual Payment
Update (RHQDAPU) Program) was
originally established to implement
section 501(b) of the MMA, Public Law
108–173. OMB has currently approved
1,572,810 hours of burden and
approximately $65 million under OMB
control number 0938–1022 (expiration
PO 00000
Frm 00606
Fmt 4701
Sfmt 4700
date December 31, 2022), accounting for
information collection burden
experienced by approximately 3,300
IPPS hospitals and 1,100 non-IPPS
hospitals for the FY 2024 payment
determination. In the proposed rule (87
FR 28627 through 28635) and this final
rule, we describe the burden changes
regarding collection of information
under OMB control number 0938–1022
(expiration date December 31, 2022) for
IPPS hospitals.
For more detailed information on our
finalized policies for the Hospital IQR
Program, we refer readers to section
IX.E. of the preamble of this final rule.
We are adopting four measures that we
expect to affect our collection of
information burden estimates: (1) The
Hospital Commitment to Health Equity
structural measure, beginning with the
CY 2023 reporting period/FY 2025
payment determination and for
subsequent years; (2) the Screening for
Social Drivers of Health measure,
beginning with voluntary reporting for
the CY 2023 reporting period and
mandatory reporting beginning with the
CY 2024 reporting period/FY 2026
payment determination; (3) the Screen
Positive Rate for Social Drivers of
Health measure, beginning with
voluntary reporting for the CY 2023
reporting period and mandatory
reporting beginning with the CY 2024
reporting period/FY 2026 payment
determination; and (4) the Hospitallevel THA/TKA PRO–PM, beginning
with voluntary reporting across two
periods, followed by mandatory
reporting of the measure for the
reporting period which runs from July 1,
2025 through June 30, 2026, impacting
the FY 2028 payment determination. We
are also modifying our eCQM reporting
and submission requirements which
will increase the total number of eCQMs
to be reported from four to six eCQMs
beginning with the CY 2024 reporting
period/FY 2026 payment determination,
which will additionally affect our
collection of information burden. The
estimated collection of burden
associated with our finalized proposals
is discussed in this section of this final
rule.
We are also finalizing policies which
will not affect the information collection
burden associated with the Hospital IQR
Program. As discussed in section IX.E.
of the preamble of this final rule, we are
adopting four eCQMs: (1) Cesarean Birth
electronic clinical quality measure
(eCQM), with inclusion in the eCQM
measure set beginning with the CY 2023
reporting period/FY 2025 payment
determination, followed by mandatory
reporting beginning with the CY 2024
reporting period/FY 2026 payment
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
determination; (2) Severe Obstetric
Complications eCQM, with inclusion in
the eCQM measure set beginning with
the CY 2023 reporting period/FY 2025
payment determination, followed by
mandatory reporting beginning with the
CY 2024 reporting period/FY 2026
payment determination; (3) HospitalHarm—Opioid-Related Adverse Events
eCQM, beginning with inclusion in the
eCQM measure set in the CY 2024
reporting period/FY 2026 payment
determination; and (4) Global
Malnutrition Composite Score eCQM,
beginning with inclusion in the eCQM
measure set in the CY 2024 reporting
period/FY 2026 payment determination.
We are also adopting two claims-based
measures beginning with the FY 2024
payment determination: (1) MSPB
Hospital; and (2) the Hospital-Level
RSCR Following Elective Primary THA/
TKA. We are refining two current
Hospital IQR Program claims-based
measures beginning with the FY 2024
payment determination: (1) HospitalLevel, Risk-Standardized Payment
Associated with an Episode of Care for
Primary Elective THA/TKA; and (2) The
Acute Myocardial Infarction (AMI)
Excess Days in Acute Care (EDAC).
Lastly, we are: (1) Establishing a
hospital designation related to patient
care to be publicly-reported on a publicfacing website beginning in Fall 2023;
(2) modifying our case threshold
exemptions and zero denominator
declaration policies for hybrid measures
as we believe they are not applicable for
this measure type beginning with the FY
2026 payment determination; and (3)
modifying our eCQM validation policy
to increase the reporting of medical
requests from 75 percent of records to
100 percent of records, beginning with
the validation of CY 2022 eCQM data
affecting the FY 2025 payment
determination.
The most recent data from the Bureau
of Labor Statistics reflects a median
hourly wage of $21.20 per hour for a
medical records and health information
technician professional.1163 We
calculated the cost of overhead,
including fringe benefits, at 100 percent
of the median hourly wage, consistent
with previous years. This is necessarily
a rough adjustment, both because fringe
benefits and overhead costs vary
significantly by employer and methods
of estimating these costs vary widely in
the literature. Nonetheless, we believe
that doubling the hourly wage rate
1163 U.S.
Bureau of Labor Statistics. Occupational
Outlook Handbook, Medical Records and Health
Information Technicians. Accessed on January 13,
2022. Available at: https://www.bls.gov/ooh/
healthcare/medical-records-and-healthinformation-technicians.htm.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
($21.20 × 2 = $42.40) to estimate total
cost is a reasonably accurate estimation
method. Accordingly, unless otherwise
specified, we will calculate cost burden
to hospitals using a wage plus benefits
estimate of $42.40 per hour throughout
the discussion in this section of this rule
for the Hospital IQR Program.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45507), our burden
estimates were based on an assumption
of approximately 3,300 IPPS hospitals.
For this final rule, we are updating our
assumption to 3,150 IPPS hospitals
based on recent data from the FY 2022
Hospital IQR Program payment
determination which reflects a closer
approximation of the total number of
hospitals reporting data to the Hospital
IQR Program.
b. Information Collection Burden
Estimate for the Hospital Commitment
to Health Equity Structural Measure
Beginning With the CY 2023 Reporting
Period/FY 2025 Payment Determination
In section IX.E.5.a. of the preamble of
this final rule, we are finalizing
adoption of the Hospital Commitment to
Health Equity structural measure
beginning with the CY 2023 reporting
period/FY 2025 payment determination.
Hospitals will report data through the
Hospital Quality Reporting (HQR)
System.
Hospitals will submit the response on
an annual basis during the submission
period. We estimate the information
collection burden associated with this
structural measure to be, on average
across all 3,150 IPPS hospitals, no more
than 10 minutes per hospital per year,
as it involves attesting to as many as five
questions one time per year for a given
reporting period. While we understand
some hospitals may require more than
10 minutes to research the information
needed to respond, we believe that the
majority of hospitals will have the
information readily available to respond
to the questions listed in section
IX.E.5.a. of the preamble of this final
rule and will require less than 10
minutes. In addition, we believe that
many hospitals will be able to submit
similar responses in future years,
thereby reducing the actual time to
respond in subsequent reporting
periods. Using the estimate of 10
minutes (or 0.167 hours) per hospital
per year, and the updated wage estimate
as described previously, we estimate
that this policy will result in a total
annual burden increase of 525 hours
across all participating IPPS hospitals
(0.167 hours × 3,150 IPPS hospitals) at
a cost of $22,260 (525 hours × $42.40).
With respect to any costs/burdens
unrelated to data submission, we refer
PO 00000
Frm 00607
Fmt 4701
Sfmt 4700
49385
readers to the Regulatory Impact
Analysis (section I.K. of Appendix A of
this final rule).
c. Information Collection Burden
Estimate for the Screening for Social
Drivers of Health Measure Beginning
With Voluntary Reporting in the CY
2023 Reporting Period and Mandatory
Reporting in the CY 2024 Reporting
Period/FY 2026 Payment Determination
In section IX.E.5.b.(1). of the preamble
of this final rule, we are adopting the
Screening for Social Drivers of Health
measure beginning with voluntary
reporting in the CY 2023 reporting
period and mandatory reporting
beginning with the CY 2024 reporting
period/FY 2026 payment determination.
Hospitals will report data through the
HQR System.
As discussed in the preamble of this
final rule, hospitals will be able to
collect data and report the measure via
multiple methods. We believe that most
hospitals will likely collect data through
a screening tool incorporated into their
electronic health record (EHR) or other
patient intake process.
We believe the Outcome and
Assessment Information Set (OASIS),
which is currently used in the Home
Health Quality Reporting Program, is a
reasonable comparison for estimating
the information collection burden for
the Screening for Social Drivers of
Health measure due to analogous
assessment of patient-level need. The
OASIS is a core standard assessment
data set home health agencies integrate
into their own patient-specific,
comprehensive assessment to identify
each patient’s need for home care that
meets the patient’s medical, nursing,
rehabilitative, social, and discharge
planning needs. For OASIS, the
currently approved information
collection burden under OMB 0938–
1279 (expiration date November 30,
2024) is estimated to be 0.3 minutes per
data element (18 seconds). For the five
HRSN domains screened for by the
Social Drivers of Health measure under
the Hospital IQR Program, we estimate
a total of 2 minutes (0.033 hours) per
patient to conduct this screening. The
most recent data from the Bureau of
Labor Statistics reflects an Average
Hourly Earnings of $31.31.1164 Based on
information collected by the American
Hospital Association,1165 we estimate
1164 U.S. Bureau of Labor Statistics. Economy at
a Glance, Average Hourly Earnings. Accessed on
January 24, 2022; available at: https://www.bls.gov/
eag/eag.us.htm.
1165 https://www.aha.org/system/files/media/file/
2020/01/2020-aha-hospital-fast-facts-new-Jan2020.pdf.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49386
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
approximately 21,000,000 patients
(34,251,159 total admissions in U.S.
community hospitals × 3,150 IPPS
hospitals ÷ 5,198 total U.S. community
hospitals) will be screened annually
across all participating IPPS hospitals.
For the purposes of calculating burden,
we estimate that during the voluntary
period, 50 percent of hospitals will
survey 50 percent of patients. We
estimate during the mandatory period,
hospitals would submit for 100 percent
of patients. For the CY 2023 voluntary
reporting period, we estimate a total
burden of 175,000 hours (21,000,000
respondents × 50 percent of patients ×
50 hospitals of hospitals × 0.033 hours)
at a cost of $5,479,250 (175,000 hours ×
$31.31) across all participating IPPS
hospitals. For the CY 2024 reporting
period and subsequent years, we
estimate a total annual burden of
700,000 hours (21,000,000 respondents
× 0.033 hours) at a cost of $21,917,000
(700,000 hours × $31.31) across all
participating IPPS hospitals.
Measure data will be submitted via
the HQR System annually. Similar to
the currently approved data submission
and reporting burden estimate for
eCQMs in the Hospital IQR Program and
web-based measures for the Ambulatory
Surgical Center Quality Reporting
(ASCQR) Program (OMB control number
0938–1270; expiration date July 31,
2024) reported via the HQR System, we
estimate a burden of 10 minutes per
hospital response to transmit the
measure data. Therefore, we estimate
that each participating facility will
spend 10 minutes (0.1667 hours)
annually to collect and submit the data
via this portal. For the purposes of
calculating burden, we estimate that
during the voluntary period, 50 percent
of hospitals will submit data. For the CY
2023 voluntary reporting period, we
estimate a total burden of 263 hours
(0.1667 hours × 3,150 hospitals × 50
percent of hospitals) at a cost of $11,151
(263 hours × $42.40) across all
participating IPPS hospitals. For the CY
2024 reporting period and subsequent
years, we estimate a total annual burden
for all participating IPPS hospitals of
525 hours (0.1667 hours × 3,150
hospitals) at a cost of $22,260 (525
hours × $42.40).
With respect to any costs/burdens
unrelated to data submission, we refer
readers to the Regulatory Impact
Analysis (section I.K. of Appendix A of
this final rule).
d. Information Collection Burden
Estimate for the Screen Positive Rate for
Social Drivers of Health Process
Measure Beginning With Voluntary
Reporting in the CY 2023 Reporting
Period and Mandatory Reporting
Beginning With the CY 2024 Reporting
Period/FY 2026 Payment Determination
In section IX.E.5.b.(2). of the preamble
of this final rule, we are adopting the
Screen Positive Rate for Social Drivers
of Health measure beginning with
voluntary reporting in the CY 2023
reporting period and mandatory
reporting beginning with the CY 2024
reporting period/FY 2026 payment
determination. Hospitals will report
data through the HQR System. For this
measure, hospitals will be required to
report on an annual basis the number of
patients who screen positive for one or
more of the five domains (reported as
five separate rates) divided by the total
number of patients screened.
We previously included the burden
associated with screening patients in
our discussion of the Screening for
Social Drivers of Health measure. For
this measure, we estimate only the
additional burden for a hospital
reporting via the HQR System since
patients would not need to provide any
additional information for this measure.
We estimate that each participating
facility will spend 10 minutes (0.1667
hours) annually to collect and submit
the data. For the purposes of calculating
burden, we estimate that during the
voluntary period, 50 percent of
hospitals would submit data. For the CY
2023 voluntary reporting period, we
estimate a total burden of 263 hours
(0.1667 hours × 3,150 hospitals × 50
percent of hospitals) at a cost of $11,130
(263 hours × $42.40) across all
participating IPPS hospitals. For the CY
2024 reporting period and subsequent
years, we estimate a total annual burden
estimate for all IPPS hospitals of 525
hours (0.1667 hours × 3,150 hospitals) at
a cost of $22,260 (525 hours × $42.40).
e. Information Collection Burden
Estimate for the Hospital-Level, Risk
Standardized Patient-Reported
Outcomes Performance Measure (PRO–
PM) Following Elective Primary Total
Hip Arthroplasty (THA) and/or Total
Knee Arthroplasty (TKA) Beginning
With Two Voluntary Reporting Periods
Followed by Mandatory Reporting for
Eligible Elective Procedures Occurring
July 1, 2025 Through June 30, 2026,
Impacting the FY 2028 Payment
Determination, and for Subsequent
Years
In section IX.E.5.g. of the preamble of
this final rule, we are adopting the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00608
Fmt 4701
Sfmt 4700
THA/TKA PRO–PM beginning with
voluntary reporting across two periods
(July 1, 2023 through June 30, 2024 and
July 1, 2024 through June 30, 2025),
followed by mandatory reporting of the
measure beginning with the reporting
period which runs from July 1, 2025
through June 30, 2026, impacting the FY
2028 payment determination.
The THA/TKA PRO–PM uses four
sources of data for the calculation of the
measure: (1) PRO data; (2) claims data;
(3) Medicare enrollment and beneficiary
data; and (4) U.S. Census Bureau survey
data. We estimate no additional burden
associated with claims data, Medicare
enrollment and beneficiary data, and
U.S. Census Bureau survey data as these
data are already collected via other
mechanisms.
Many hospitals have already
incorporated patient-reported outcome
(PRO) data collection into their
workflows. While we are not requiring
how hospitals collect data, hospitals
new to collecting PRO data have
multiple options for when and how they
would collect this data so they can best
determine the mode and timing of
collection that works best for their
patient population. The possible patient
touchpoints for pre-operative PRO data
collection include the doctor’s office,
pre-surgical steps such as education
classes, or medical evaluations that can
occur in an office or at the hospital. The
modes of PRO data collection can
include completion of the pre-operative
surveys using electronic devices (such
as an iPad or tablet), pen and paper,
mail, phone call, or through the
patient’s portal. Post-operative PRO data
collection modes are similar to preoperative modes. The possible patient
touchpoints for post-operative data
collection can occur before the followup appointment, at the doctor’s office,
or after the follow-up appointment. The
potential modes of PRO data collection
for post-operative data are the same as
for pre-operative data. If the patient
does not or cannot attend a follow-up
appointment, the modes of collection
can include completion of the postoperative survey using email, mail,
phone, or through the patient portal.
Use of multiple modes will increase
response rates as it allows for different
patient preferences.
For the THA/TKA PRO–PM data,
hospitals will be able to submit data
during two voluntary periods, followed
by mandatory reporting for eligible
elective procedures occurring July 1,
2025 through June 30, 2026, impacting
the FY 2028 payment determination and
for subsequent years. Hospitals will
need to submit data twice (pre-operative
data and post-operative data). For the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
purposes of calculating burden, we
estimate that during the voluntary
periods, 50 percent of hospitals that
perform at least one THA/TKA
procedure would submit data, and will
do so for 50 percent of THA/TKA
patients. We estimate during the
mandatory period, hospitals will submit
for 100 percent of patients. While we are
requiring hospitals to submit, at
minimum, 50 percent of eligible,
complete pre-operative data with
matching eligible, complete postoperative data, we are conservative in
our estimate for the mandatory period in
case hospitals exceed this threshold.
Under OMB control number 0938–
0981 (expiration date September 30,
2024), the currently approved burden
per respondent to complete the Hospital
Consumer Assessment of Healthcare
Providers and Systems (HCAHPS)
Survey measure is 7.25 minutes
(0.120833 hours). We estimate that the
time to complete both the preoperative
and post-operative surveys is analogous
to completing the HCAHPS Survey
once. The most recent data from the
Bureau of Labor Statistics reflects an
Average Hourly Earnings of $31.31.1166
For burden estimating purposes, we
assume that most hospitals will likely
undertake PRO data collection through
a screening tool incorporated into their
EHR or other patient intake process. We
estimate that approximately 330,000
THA/TKA procedures occur in the
inpatient setting each year, and that
many patients could complete both the
pre-operative and postoperative
questionnaires, although from our
experience with using this measure in
the Comprehensive Joint Replacement
model, we are also aware that not all
patients who complete the pre-operative
questionnaire would complete the postoperative questionnaire. Due to the
performance period for the first
voluntary reporting period being 6
months, we assume 41,250 patients will
complete the survey (165,000 patients ×
0.50 × 0.50 of hospitals) for a total of
4,984 hours annually (41,250
respondents × 0.120833 hours) at a cost
of $156,049 (4,984 hours × $31.31)
across all IPPS hospitals. For the second
voluntary reporting periods, we assume
82,500 patients will complete the survey
(330,000 patients × 0.50 × 0.50
hospitals) for a total of 9,969 hours
annually (82,500 respondents ×
0.120833 hours) at a cost of $312,122
1166 U.S. Bureau of Labor Statistics. Economy at
a Glance, Average Hourly Earnings. Accessed on
January 24, 2022; available at: https://www.bls.gov/
eag/eag.us.htm.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
(9,969 hours × $31.31) across all IPPS
hospitals. Beginning with mandatory
reporting for the FY 2028 payment
determination, we estimate a total of
39,875 hours (330,000 patients ×
0.120833 hours) at a cost of $1,248,486
(39,875 hours × $31.31) across all IPPS
hospitals.
For the data submission, which will
be reported via the HQR System, we
estimate a burden of 10 minutes per
response. For each of the two voluntary
reporting periods, we estimate that each
hospital will spend 20 minutes (0.33
hours) annually (10 minutes × 2
surveys) to collect and submit the data
via this tool. We estimate a resulting
burden for all participating IPPS
hospitals of 525 hours (0.33 hours ×
3,150 hospitals × 50 percent) at a cost
of $22,260 (525 hours × $42.40).
Beginning with mandatory reporting for
the FY 2028 payment determination, we
estimate a total of 1,050 hours (0.33
hours × 3,150 hospitals) at a cost of
$44,520 (1,050 hours × $42.40).
With respect to any costs/burdens
unrelated to data submission, we refer
readers to the Regulatory Impact
Analysis (section I.K. of Appendix A of
this final rule).
f. Information Collection Burden
Estimate for the Modification of the
eCQM Reporting and Submission
Requirements Beginning With the CY
2024 Reporting Period/FY 2026
Payment Determination
In section IX.E.10.e. of the preamble
of this final rule, we are modifying our
eCQM reporting and submission
requirements whereby we are increasing
the total number of eCQMs to be
reported from four to six eCQMs
beginning with the CY 2024 reporting
period/FY 2026 payment determination.
We previously finalized in the FY
2020 IPPS/LTCH PPS final rule that, for
the CY 2021 reporting period/FY 2023
payment determination, hospitals are
required to submit data for four selfselected eCQMs each year (84 FR
42503). Additionally, for the CY 2022
reporting period/FY 2024 payment
determination, hospitals are required to
submit data for three self-selected
eCQMs and the Safe Use of OpioidsConcurrent Prescribing eCQM for a total
of four eCQMs (84 FR 42505). We also
finalized in the FY 2021 IPPS/LTCH
PPS final rule to require hospitals to
submit four quarters of eCQM data
beginning in the CY 2023 reporting
period/FY 2025 payment determination
(85 FR 59008 through 59009). We
continue to estimate the information
collection burden associated with the
PO 00000
Frm 00609
Fmt 4701
Sfmt 4700
49387
eCQM reporting and submission
requirements to be 10 minutes per
measure per quarter. For the increase in
submission from four to six eCQMs, we
estimate a total of 20 minutes or 0.33
hours (10 minutes × 2 eCQMs) per
hospital per quarter. We estimate a total
burden increase of 1,050 hours across
all participating IPPS hospitals (0.33
hour × 3,150 IPPS hospitals) for each
quarter of eCQM data or 4,200 hours
annually (1,050 hours × 4 quarters) at a
cost of $178,080 (4,200 hours × $42.40).
g. Information Collection Burden
Estimate for the Adoption of Four
eCQMs: Two Perinatal eCQMs
Beginning With the CY 2023 Reporting
Period/FY 2025 Payment Determination;
One Opioid-Related Hospital-Harm
eCQM and One Malnutrition eCQM
Beginning With the CY 2024 Reporting
Period/FY 2026 Payment Determination
In sections IX.E.5.c. and IX.E.5.d. of
the preamble of this final rule, we are
adopting two perinatal eCQMs—
Cesarean Birth and Severe Obstetric
Complications—beginning with the CY
2023 reporting period/FY 2025 payment
determination, followed by mandatory
reporting beginning with the CY 2024
reporting period/FY 2026 payment
determination and for subsequent years.
Also, in sections IX.E.5.e. and IX.E.5.f.
of the preamble of this final rule, we are
adopting the Hospital-Harm—OpioidRelated Adverse Events eCQM and the
Global Malnutrition Composite Score
eCQM, respectively, beginning with the
CY 2024 reporting period/FY 2026
payment determination and for
subsequent years.
The addition of these four eCQMs do
not affect the information collection
burden of submitting eCQMs under the
Hospital IQR Program. Current Hospital
IQR Program policy requires hospitals to
select four eCQMs from the eCQM
measure set on which to report (84 FR
42503 through 4250). In other words,
although these new eCQMs are being
added to the eCQM measure set,
hospitals are not required to report more
than a total of six eCQMs, as finalized
in section IX.E.10.e. of the preamble of
this final rule. In the previous section
XII.B.4.f. (of the Collection of
Information section of this final rule),
we account for the burden of reporting
six eCQMs.
With respect to any costs/burdens
unrelated to data submission, we refer
readers to the Regulatory Impact
Analysis (section I.K. of Appendix A of
this final rule).
E:\FR\FM\10AUR2.SGM
10AUR2
49388
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
h. Information Collection Burden
Estimate for the Adoption or Refinement
of Four Claims-Based Measures
In sections IX.E.5.h., IX.E.5.i.,
IX.E.6.a., and IX.E.6.b. of the preamble
of this final rule, we are adopting two
claims-based measures—MSPB Hospital
and Hospital-Level RSCR Following
Elective Primary THA/TKA—and
refining two claims-based measures
currently in the Hospital IQR Program
measure set—Hospital-Level, RiskStandardized Payment Associated with
an Episode of Care for Primary Elective
THA/TKA and AMI EDAC. We are
adopting the Hospital MSPB measure
and the Hospital-Level RSCR Following
Elective Primary THA/TKA beginning
with the FY 2024 payment
determination and are refining the other
two measures beginning with the FY
2024 payment determination and for
subsequent years. Because these
measures are calculated using data that
are already reported to the Medicare
program for payment purposes,
adopting and refining these measures
does not result in a change to the
burden estimates provided in the FY
2022 IPPS/LTCH PPS final rule (86 FR
45507 through 45512).
i. Information Collection Burden
Estimate for Addition of the PubliclyReported Hospital Designation To
Capture Hospital Commitment to the
Quality and Safety of Maternal Health
Beginning Fall 2023
khammond on DSKJM1Z7X2PROD with RULES2
In section IX.E.8. of the preamble of
this final rule, we are establishing the
publicly-reported hospital designation
to capture hospital commitment to the
quality and safety of maternity care on
a CMS website, for hospitals who
qualify for the designation, beginning in
Fall 2023. In the FY 2022 IPPS/LTCH
PPS final rule, we finalized adoption of
the Maternal Morbidity Structural
measure (86 FR 45365) and accounted
for that burden under OMB control
number 0938–1022 (expiration date
December 31, 2022). We expect that our
policy will not yield a change in burden
as it does not require any additional
information collection nor affect the
requirements for data submission for
hospitals.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
j. Information Collection Burden
Estimate for the Modification of the
Case Threshold Exemptions and Zero
Denominator Declaration Policies for
Hybrid Measures Beginning With the FY
2026 Payment Determination
In section IX.E.10.f.(4). of the
preamble of this final rule, we are
modifying our case threshold
exemptions and zero denominator
declaration policies for hybrid measures
as we believe they are not applicable for
those measure types, beginning with the
FY 2026 payment determination and for
subsequent years.
In the FY 2020 IPPS/LTCH PPS final
rule, we finalized the adoption of the
Hybrid Hospital-Wide Readmission
Measure with Claims and Electronic
Health Record Data (Hybrid HWR) (84
FR 42505 through 42508) and in the FY
2022 IPPS/LTCH PPS final rule, we
finalized the Hybrid Hospital-Wide
Mortality Measure with Claims and
Electronic Health Record Data (Hybrid
HWM) (86 FR 45508). For each hybrid
measure, all IPPS hospitals are required
to submit one of three things: Data via
QRDA I file, a zero denominator
declaration, or a case threshold
exemption. Of these three options,
submission of data via QRDA I file is the
most burden-intensive. For both hybrid
measures, our currently approved
burden estimates assume data
submission via QRDA I file for all IPPS
hospitals; therefore, we do not believe
this modification results in an increase
in burden.
k. Information Collection Burden
Estimate for the Modification of the
eCQM Validation Policy Medical Record
Requests Beginning With the FY 2025
Payment Determination
In section IX.E.11.b. of the preamble
of this final rule, we are modifying our
eCQM validation policy to increase the
reporting of medical requests from at
least 75 percent of records to 100
percent of records beginning with the
FY 2025 payment determination and for
subsequent years.
In the FY 2017 IPPS/LTCH PPS final
rule, we finalized to require submission
of at least 75 percent of sampled eCQM
medical records in a timely and
complete manner (81 FR 57181). While
we adopted a policy to require
submission of at least 75 percent of
sampled records, we estimated the
PO 00000
Frm 00610
Fmt 4701
Sfmt 4700
burden associated with this finalized
policy with the assumption that
hospitals would submit 100 percent of
sampled eCQM medical records (81 FR
57261). Based on this estimate, we
believe the currently approved burden
already encompasses burden associated
with our finalized policy.
l. Information Collection Burden
Estimate To Add Reporting and
Submission Requirements for PRO–PMs
Beginning With the FY 2026 Payment
Determination
In section IX.E.10.k. of the preamble
of this final rule, we are adopting
reporting and submission requirements
for PRO–PMs beginning with the FY
2026 payment determination. Our
policy does not yield a change in
burden beyond that which is discussed
in section X.B.6.e. of the preamble of
this final rule for the THA/TKA PRO–
PM.
m. Summary of Information Collection
Burden Estimates for the Hospital IQR
Program
In summary, under OMB control
number 0938–1022 (expiration date
December 31, 2022), we estimate that
the policies promulgated in this final
rule will result in a total increase of
746,300 hours annually for 3,150 IPPS
hospitals from the CY 2023 reporting
period/FY 2025 payment determination
through the CY 2026 reporting period/
FY 2028 payment determination. The
total cost increase related to this
information collection is approximately
$23,437,906. The subsequent tables
summarize the total burden changes for
each respective FY payment
determination compared to our
currently approved information
collection burden estimates (the table
for the FY 2028 payment determination
reflects the total burden change
associated with all proposals). For the
THA/TKA PRO–PM, only one survey
will be administered during the CY
2023 reporting period due to the start of
reporting occurring in 3Q and the
beginning of mandatory reporting would
take place in 3Q of the CY 2025
reporting period. We will submit the
revised information collection estimates
to OMB for approval under OMB control
number 0938–1022 which expires
December 31, 2022.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
VerDate Sep<11>2014
Jkt 256001
PO 00000
Frm 00611
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
Activity
Add Hospital Commitment to Health
Equity Structural Measure
Add Screening for Social Drivers of Health
Measure (Survey)
Add Screening for Social Drivers of Health
Measure
khammond on DSKJM1Z7X2PROD with RULES2
49390
VerDate Sep<11>2014
Jkt 256001
PO 00000
Frm 00612
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.205
Activity
Add Hospital Commi1ment to Health
Equity Structural Measure
Add Screening for Social Drivers of
Health Measure (Survev)
Add Screening for Social Drivers of
Health Measure (Reporting)
Add Screen Positive Rate for Social
Drivers of Health
Add THA!TKA PRO-PM Measure
(Survey)
Add THA!TKA PRO-PM Measure
(Reporting)
Modify eCQM Reporting
Annual Recordkeeping and Reporting Requirements Under 0MB Control Number 0938-1022 for the CY 2024
Reoortinl! Period I FY 2026 Pavment Determination
Previously
Newly
finalized
Average
Annual
Finalized
annual
Net
Estimated
Number
number
burden
burden
burden
difference
records per
(hours)
(hours)
(hours)
in annual
time per
reporting
Number of
record
quarters
respondents
respondent
per
across
across
burden
(minutes)
per year
per quarter
reportin2
hospital
respondent
respondent
hours
10
1
3,150
1
.167
525
NIA
+525
2
NIA
21,000,000
NIA
222.2
700,000
NIA
+700,000
10
1
3,150
1
0.167
525
NIA
+525
10
1
3,150
1
0.167
,525
NIA
+525
7.25
NIA
1,575
NIA
4.75
7,477
NIA
+7,477
10
60
2
4
1,575
3,150
1
1
0.33
1
525
12,600
NIA
8,800
+525
+3,800
Total Chan2e in Information Collection Burden Hours: +713,377
Total Cost Estimate: Updated Hourly Wage (Varies) x Change in Burden Hours (+713,377) = +$22,401,251
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
SUMMARY OF HOSPITAL IQR PROGRAM ESTIMATED INFORMATION
COLLECTION BURDEN CHANGE FOR THE CY 2024 REPORTING PERIOD/FY 2026
PAYMENT DETERMINATION
khammond on DSKJM1Z7X2PROD with RULES2
VerDate Sep<11>2014
Jkt 256001
PO 00000
Frm 00613
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
Activity
Add Hospital Commitment to
Health Euuitv Structural Measure
Add Screening for Social Drivers
of Health Measure (Survey)
Add Screening for Social Drivers
of Health Measure (Reporting)
Add Screen Positive Rate for
Social Drivers of Health
Add THA/IKA PRO-PM Measure
- Voluntarv Reporting (Survev)
Add THA/IKA PRO-PM Measure
- Voluntarv Reporting (Reporting)
Add THA/IKA PRO-PM Measure
- Mandatorv Reporting (Survev)
Add THA/IKA PRO-PM Measure
- Mandatory Reporting
(Reporting)
Modifv eCOM Reporting
Annual Recordkeeping and Reporting Requirements Under 0MB Control Number 0938-1022 for the CY 2025
Reoortin2 Period / FY 2027 Pavment Determinations
Average
Newly
Previously
number
finalized
finalized
records
Annual
annual
annual
Net
Estimated
Number
per
burden
burden
burden
difference
time per
reporting
Number of
responden
(hours)
(hours)
(hours)
in annual
record
quarters
respondents
t per
per
across
across
burden
quarter
hospital
respondent
oeryear
respondent
hours
(minutes)
reoortin2
10
1
3,150
1
.167
525
NIA
+525
2
NIA
21,000,000
NIA
222.2
700,000
NIA
+700,000
10
1
3,150
1
0.167
525
NIA
+525
10
1
3,150
1
0.167
525
NIA
+525
7.25
NIA
1 575
NIA
3.16
4 984
NIA
+4984
10
1
1,575
1
0.167
262.5
NIA
+262.5
7.25
NIA
3,150
NIA
6.33
19,938
NIA
+19,938
10
60
1
4
3 150
3,150
1
1
0.33
1
525
12,600
NIA
8,800
+525
+3,800
Total Chan2e in Information Collection Burden Hours: +731,084
Total Cost Estimate: Updated Hourly Wage (Varies) x Change in Burden Hours (+ 731,084) = +$22,958,594
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
SUMMARY OF HOSPITAL IQR PROGRAM ESTIMATED INFORMATION
COLLECTION BURDEN CHANGE FOR THE CY 2025 REPORTING PERIOD/FY 2027
PAYMENT DETERMINATION
49391
ER10AU22.206
khammond on DSKJM1Z7X2PROD with RULES2
49392
Jkt 256001
10
1
3,150
1
.167
525
NIA
+525
2
NIA
21,000,000
NIA
222.2
700,000
NIA
+700,000
10
1
3,150
1
0.167
525
NIA
+525
10
I
3,150
I
0.167
525
NIA
+525
7.25
NIA
3,150
NIA
12.66
39,875
NIA
+39,875
10
60
2
4
3,150
3,150
1
1
0.33
1
1,050
12,600
NIA
8,800
+1,050
+3,800
PO 00000
Frm 00614
Fmt 4701
Sfmt 4700
Total Cost Estimate: Undated Hourlv Wage (Varies) x Change in Burden Hours (+746,300) = +$23,437,906
a. Historical Background
9. ICRs for the Medicare Promoting
Interoperability Program
Total Chan11:e in Information Collection Burden Hours: +746,300
10AUR2
In section IX.H. of the preamble of
this final rule, we discussed several
policies for the Medicare Promoting
Interoperability Program. An
information collection request under
OMB control number 0938–1278
(expiration date July 31, 2022) reflecting
program policies finalized in the FY
2022 IPPS/LTCH PPS final rule (86 FR
45514) is pending approval, which
E:\FR\FM\10AUR2.SGM
measure removal policy; (2) beginning
public display of the End-of-Life (EOL)
measures with modification to begin
with FY 2025 program year data; and (3)
beginning public display of the 30-Day
Unplanned Readmissions for Cancer
Patients measure beginning with FY
2024 program year data. These new
requirements do not impact our
currently approved information
collection burden estimates.
We did not receive comments
regarding the ICRs for the PCHQR
Program.
Activitv
Add Hospital Commitment to Health
Eauitv Structural Measure
Add Screening for Social Drivers of
Health Measure (Survey)
Add Screening for Social Drivers of
Health Measure (Reporting)
Add Screen Positive Rate for Social
Drivers of Health
Add THA/IKA PRO-PM Measure
(Survey)
Add THA/IKA PRO-PM Measure
(Reporting)
Modify eCQM Reporting
Annual Recordkeeping and Reporting Requirements Under 0MB Control Number 0938-1022 for the CY 2026
Reportine Period I FY 2028 Payment Determinations
Average
Previously
New
finalized
number
finalized
records
Annual
annual
annual
Net
Number
per
burden
burden
burden
difference
Estimated
reporting
Number of
responden
(hours)
(hours)
(hours)
in annual
time per
record
quarters
respondents
t per
per
across
across
burden
hospital
(minutes)
respondent
respondent
pervear
reportin11:
hours
auarter
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
8. ICRs for PPS-Exempt Cancer Hospital
Quality Reporting (PCHQR) Program
OMB has currently approved 0 hours
of burden under OMB control number
0938–1175 (expiration date January 31,
2025), accounting for the information
collection requirements for 11 PCHs for
the FY 2024 program year.
For more detailed information on our
finalized policies for the PCHQR
Program, we refer readers to section
IX.F. of the preamble of this final rule.
We are: (1) adopting and codifying a
patient safety exemption for the
VerDate Sep<11>2014
ER10AU22.207
SUMMARY OF HOSPITAL IQR PROGRAM ESTIMATED INFORMATION
COLLECTION BURDEN CHANGE FOR THE CY 2026 REPORTING PERIOD/FY 2028
PAYMENT DETERMINATION
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
includes an estimated total burden of
21,450 hours and $879,450, accounting
for information collection burden
experienced by approximately 3,300
eligible hospitals that attest to CMS
under the Medicare Promoting
Interoperability Program. We will be
submitting an updated information
collection request under OMB control
number 0938–1278 in connection with
this FY 2023 IPPS/LTCH PPS final rule
that will reflect the inclusion of CAHs
and additional new information
pertinent to the collection requirements.
The collection of information burden
analysis in this final rule focuses on all
eligible hospitals and CAHs that could
participate in the Medicare Promoting
Interoperability Program and attest to
the objectives and measures, and report
eCQMs, under the Medicare Promoting
Interoperability Program for the EHR
reporting periods in CY 2023, CY 2024,
and CY 2025.
For more detailed information on our
finalized policies for the Medicare
Promoting Interoperability Program, we
refer readers to section IX.H. of the
preamble of this final rule. We are
finalizing the following changes for
eligible hospitals and CAHs that attest
to CMS under the Medicare Promoting
Interoperability Program that we expect
to affect our collection of information
burden estimates: (1) requiring the
Electronic Prescribing Objective’s Query
of Prescription Drug Monitoring
Program (PDMP) measure beginning in
the CY 2023 electronic health record
(EHR) reporting period while
maintaining its associated points at 10
points and with the two exclusions that
we proposed and an additional
exclusion based on public comment; (2)
adopting a new Antimicrobial Use and
Resistance (AUR) Surveillance measure
that will be required for eligible
hospitals and CAHs under the Medicare
Promoting Interoperability Program’s
Public Health and Clinical Data
Exchange Objective with associated
exclusions beginning with the CY 2024
EHR reporting period, and (3) requiring
eligible hospitals and CAHs to submit
their level of active engagement in
addition to submitting responses for the
Public Health and Clinical Data
Exchange Objective required measures
and the optional measures beginning
with the CY 2023 EHR reporting period.
We are also modifying our eCQM
reporting and submission requirements
whereby we are increasing the total
number of eCQMs to be reported from
four to six eCQMs beginning with the
CY 2024 reporting period. Details on
these policies and associated burden
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
changes are discussed further in this
section of this final rule.
We are also finalizing several policies
which will not affect the information
collection burden associated with the
Medicare Promoting Interoperability
Program. As discussed in section
IX.H.10.a.(2) of the preamble to this
final rule, we are adopting four eCQMs:
(1) Severe Obstetric Complications
eCQM with inclusion in the eCQM
measure set beginning with the CY 2023
reporting period, followed by
mandatory reporting beginning with the
CY 2024 reporting period; (2) Cesarean
Birth (ePC–02) eCQM with inclusion in
the eCQM measure set beginning with
the CY 2023 reporting period, followed
by mandatory reporting beginning with
the CY 2024 reporting period; (3)
Hospital-Harm—Opioid-Related
Adverse Events eCQM with inclusion in
the eCQM measure set beginning with
the CY 2024 reporting period; and (4)
Global Malnutrition Composite Score
eCQM with inclusion in the eCQM
measure set beginning with the CY 2024
reporting period. We are also: (1)
expanding the Query of PDMP measure
to include not only Schedule II opioids,
but also Schedule III and IV drugs,
beginning with the EHR reporting
period in CY 2023; (2) adding the
Enabling Exchange Under TEFCA
measure to the Health Information
Exchange Objective as an optional
alternative to the three existing
measures and updating the scoring
methodology for the Health Information
Exchange Objective beginning with EHR
reporting period in CY 2023; (3)
reducing the active engagement options
for the Public Health and Clinical Data
Exchange Objective from three to two
options beginning with the CY 2023
EHR reporting period; (4) modifying the
scoring methodology for the Medicare
Promoting Interoperability Program
beginning with EHR reporting period in
CY 2023; (5) instituting public reporting
of certain Medicare Promoting
Interoperability Program data beginning
with data from EHR reporting period in
CY 2023; and (6) removing regulation
text for the objectives and measures
under 42 CFR 495.24(e) and adding new
paragraph (f) beginning in CY 2023.
The most recent data from the Bureau
of Labor Statistics reflects a median
hourly wage of $21.20 per hour for a
medical records and health information
technician professional.1167 We
calculated the cost of overhead,
1167 U.S. Bureau of Labor Statistics. Occupational
Outlook Handbook, Medical Records and Health
Information Technicians. Accessed on January 13,
2022. Available at: https://www.bls.gov/ooh/
healthcare/medical-records-and-healthinformation-technicians.htm.
PO 00000
Frm 00615
Fmt 4701
Sfmt 4700
49393
including fringe benefits, at 100 percent
of the median hourly wage, consistent
with previous years. This is necessarily
a rough adjustment, both because fringe
benefits and overhead costs vary
significantly by employer and methods
of estimating these costs vary widely in
publicly available literature.
Nonetheless, we believe that doubling
the hourly wage rate ($21.20 × 2 =
$42.40) to estimate total cost is a
reasonably accurate estimation method
and is consistent with OMB guidance.
Accordingly, we will calculate cost
burden to hospitals using a wage plus
benefits estimate of $42.40 per hour
throughout the discussion in this
section of this rule for the Medicare
Promoting Interoperability Program.
In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45514), our burden
estimates were based on an assumption
of 3,300 eligible hospitals and CAHs.
We have determined that our
assumption was in error as we
inadvertently omitted the number of
CAHs in our estimate. For this final
rule, we are updating our assumption to
3,150 eligible hospitals and 1,350 CAHs
based on data from the CY 2020 EHR
reporting period, for a total number of
4,500 respondents. These estimates
differ from those of the information
collection request under OMB control
number 0938–1278 as they are based on
updated data from the CY 2020 EHR
reporting period and reflect the addition
of the number of CAHs. As indicated
earlier, an updated information
collection request will be submitted
with updated numbers inclusive of
CAHs. We are making this adjustment to
reflect the total number of potential
eligible hospitals and CAHs that could
report under the Medicare Promoting
Interoperability Program.
b. Information Collection Burden
Estimate for the Electronic Prescribing
Objective’s Query of PDMP Measure
Beginning with the CY 2023 EHR
Reporting Period
In section IX.H.3.c.(2) of the preamble
of this final rule, we are requiring the
Query of PDMP measure for eligible
hospitals and CAHs participating in the
Medicare Promoting Interoperability
Program beginning in CY 2023 and
maintain the associated points at 10
points.
In the FY 2020 IPPS/LTCH PPS final
rule, we estimated the burden
associated with reporting the Electronic
Prescribing Objective and associated
measures to be 10 minutes (84 FR
42608) coinciding with the finalized
change to the Query of PDMP measure
to require a ‘‘yes/no’’ response instead
of a numerator/denominator calculation.
E:\FR\FM\10AUR2.SGM
10AUR2
49394
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
However, the burden associated with
the Query of PDMP measure was not
accounted for in the burden estimate of
10 minutes for the Electronic
Prescribing Objective in the FY 2020
IPPS/LTCH PPS final rule (84 FR 42608
through 42609), the FY 2021 IPPS/LTCH
PPS final rule (85 FR 59014), or the FY
2022 IPPS/LTCH PPS final rule (86 FR
45516). In the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45464), we finalized
that the Query of PDMP measure will
remain optional. As a result of the
finalized policy to require the Query of
PDMP measure beginning with the EHR
reporting period in CY 2023, and
considering the burden estimate of 30
seconds (0.5 minutes) for similar ‘‘yes/
no’’ response measures for the Public
Health and Clinical Data Exchange
Objective as reflected in the FY 2022
IPPS/LTCH PPS final rule (86 FR
45515), we have updated our burden
estimate for the Electronic Prescribing
Objective to 10.5 minutes to reflect the
additional burden of reporting the
Query of PDMP measure. Therefore, we
estimate a total increase in burden of 38
hours across all eligible hospitals and
CAHs (0.5 minutes × 4,500 eligible
hospitals and CAHs) annually at a cost
of $1,590 (38 hours × $42.40).
In addition, in section IX.H.3.c.(3) of
the preamble of this final rule, we are
refining the Query of PDMP measure to
include not only Schedule II opioids,
but also Schedule III and IV drugs,
beginning with EHR reporting period in
CY 2023. Our policy will not yield a
change in burden as it does not affect
the requirements for data submission for
eligible hospitals or CAHs as we
continue to assume all eligible hospitals
and CAHs will report this measure once
per year.
c. Information Collection Burden
Estimate for the Antimicrobial Use and
Resistance (AUR) Surveillance Measure
Beginning With the CY 2024 EHR
Reporting Period
In section IX.H.5.b. of the preamble of
this final rule, we are finalizing the
requirement to report a new
Antimicrobial Use and Resistance
(AUR) Surveillance measure for eligible
hospitals and CAHs under the Medicare
Promoting Interoperability Program’s
Public Health and Clinical Data
Exchange Objective with a modification
to delay the beginning of reporting until
the EHR reporting period in CY 2024
instead of the EHR reporting period in
CY 2023. Eligible hospitals and CAHs
will be required to attest to active
engagement with CDC’s National
Healthcare Safety Network (NHSN) to
submit AUR data and receive a report
from NHSN indicating their successful
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
submission of AUR data for the EHR
reporting period.
In the FY 2022 IPPS/LTCH PPS final
rule, we finalized that eligible hospitals
and CAHs are required to report four
measures for the Public Health and
Clinical Data Exchange Objective with a
total estimated burden of 2 minutes
annually (30 seconds × 4 measures) (86
FR 45516). Therefore, we estimate the
burden associated with this new
measure to be 30 seconds, or 0.5
minutes, per eligible hospital or CAH
annually. We estimate a total increase in
burden of 38 hours across all eligible
hospitals and CAHs (0.5 minutes ×
4,500 eligible hospitals and CAHs)
annually at a cost of $1,611 (38 hours
× $42.40).
While the burden associated with
attesting to active engagement for the
AUR Surveillance measure will be
accounted for under OMB control
number 0938–1278 (expiration date July
31, 2022), the burden associated with
the actual submission of AUR data to
NHSN is accounted for under OMB
control number 0920–0666 (expiration
date January 31, 2025).
d. Information Collection Burden
Estimate for the Policy To Require
Eligible Hospitals and CAHs To Submit
Their Level of Active Engagement for
the Public Health and Clinical Data
Exchange Objective
In section IX.H.5.c.(3) of the preamble
of this final rule, we are requiring
eligible hospitals and CAHs to submit
their level of engagement for the
measures under the Public Health and
Clinical Data Exchange Objective, either
Pre-production and Validation or
Validated Data Production. This
requirement is in addition to submitting
responses for the required measures and
the optional measures, if applicable.
The burden associated with this
requirement is similar to the burden
associated with the attestation that
eligible hospitals and CAHs must
complete for the four previously
finalized measures under this objective
and the finalized AUR Surveillance
measure. Therefore, we estimate the
burden associated with this new
requirement to be 30 seconds, or 0.5
minutes, per eligible hospital or CAH
annually. We estimate a total increase in
burden of 38 hours across all eligible
hospitals and CAHs (0.5 minutes/
hospital × 4,500 eligible hospitals and
CAHs) annually at a cost of $1,611 (38
hours × $42.40).
In addition, in section IX.H.c.(2) of
the preamble of this final rule, we are
reducing the active engagement options
for the Public Health and Clinical Data
Exchange Objective from three to two
PO 00000
Frm 00616
Fmt 4701
Sfmt 4700
options beginning with EHR reporting
period in CY 2023. We are delaying the
requirement that eligible hospitals and
CAHs may spend only one EHR
reporting period at the pre-production
and validation phase until the EHR
reporting period in CY 2024. Our policy
will not yield a change in burden as it
does not affect the requirements for data
submission for eligible hospitals or
CAHs but instead will motivate health
IT vendors to implement these
capabilities in their products and
encourage healthcare organizations to
engage in these reporting activities.
e. Information Collection Burden
Estimate for the Modification of the
eCQM Reporting and Submission
Requirements Beginning With the CY
2024 Reporting Period
In section IX.H.10.b of the preamble
of this final rule, we are modifying our
eCQM reporting and submission
requirements whereby we are increasing
the total number of eCQMs to be
reported from four to six eCQMs
beginning with the CY 2024 reporting
period. In addition, the six eCQMs must
be comprised of: (1) Three self-selected
eCQMs; (2) the Safe Use of Opioids—
Concurrent Prescribing eCQM; (3) the
finalized Severe Obstetric
Complications eCQM; and (4) the
finalized Cesarean Birth eCQM, for a
total of six eCQMs.
We previously finalized in the FY
2021 IPPS/LTCH PPS final rule that, for
the CY 2023 reporting period, eligible
hospitals and CAHs are required to
submit data for three self-selected
eCQMs each year and the Safe Use of
Opioids-Concurrent Prescribing eCQM
for a total of four eCQMs (85 FR 58975).
We also finalized in the FY 2021 IPPS/
LTCH PPS final rule to require eligible
hospitals and CAHs to submit four
quarters of eCQM data beginning in the
CY 2023 reporting period (85 FR 58975).
We continue to estimate the information
collection burden associated with the
eCQM reporting and submission
requirements to be 10 minutes per
measure per quarter. As discussed in the
section IX.E.4.f. of the preamble of this
final rule, we already account for the
burden associated with the reporting of
eCQM measures for eligible hospitals as
part of the Hospital Inpatient Quality
Reporting Program, therefore the burden
for the 3,150 eligible hospitals is
included there. For the submission of
six eCQM measures for CAHs, we
estimate a total of 1 hour (0.167 hours/
eCQM × 6 eCQMs) per CAH per quarter.
We estimate a total burden of 1,350
hours across all CAHs (1 hour × 1,350
CAHs) for each quarter of eCQM data or
5,400 hours annually (1,350 hours × 4
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
quarters) at a cost of $228,960 (5,400
hours × $42.40/).
khammond on DSKJM1Z7X2PROD with RULES2
f. Information Collection Burden
Estimate for the Adoption of Two
eCQMs Beginning With the CY 2023
Reporting Period and Two eCQMs
Beginning With the CY 2024 Reporting
Period
In section IX.H.10.a. of the preamble
of this final rule, we are adopting four
eCQMs: (1) Severe Obstetric
Complications eCQM beginning with
the CY 2023 reporting period, followed
by mandatory reporting beginning with
the CY 2024 reporting period; (2)
Cesarean Birth (ePC–02) eCQM
beginning with the CY 2023 reporting
period, followed by mandatory
reporting beginning with the CY 2024
reporting period; (3) Hospital-Harm—
Opioid-Related Adverse Events eCQM
beginning with the CY 2024 reporting
period; and (4) Global Malnutrition
Composite Score eCQM beginning with
the CY 2024 reporting period.
The addition of these four eCQMs do
not affect the information collection
burden of submitting eCQMs under the
Medicare Promoting Interoperability
Program beyond the burden described
in section IX.B.4.f. of the preamble of
this final rule. Current Medicare
Promoting Interoperability Program
policy requires hospitals to submit data
for three self-selected eCQMs each year
and the Safe Use of Opioids-Concurrent
Prescribing eCQM for a total of four
eCQMs (85 FR 58975). In other words,
although these new eCQMs are being
added to the eCQM measure set,
hospitals are not required to report more
than a total of six eCQMs as discussed
in section IX.10. of the preamble of this
final rule.
With respect to any costs unrelated to
data submission, we refer readers to
section I.K. of Appendix A of this final
rule.
g. Information Collection Burden
Estimate To Add the Enabling Exchange
Under TEFCA Measure to the Health
Information Exchange Objective
Beginning With the CY 2023 EHR
Reporting Period
In section IX.H.4.c. of the preamble of
this final rule, we are adding the
Enabling Exchange Under TEFCA
measure to the Health Information
Exchange Objective as an optional
alternative to the three existing
measures (Support Electronic Referral
Loops by Sending Health Information
measure and the Support Electronic
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Referral Loops by Receiving and
Reconciling Health Information
measure, or the HIE Bi-Directional
Exchange measure) and updating the
scoring methodology for the Health
Information Exchange Objective
beginning with EHR reporting period in
the CY 2023. Our policy does not yield
a change in burden as eligible hospitals
and CAHs may choose to report the two
Support Electronic Referral Loop
measures, or may choose to report the
HIE Bi-Directional Exchange measure,
or may choose to report the new
Enabling Exchange Under TEFCA
measure.
h. Information Collection Burden
Estimate To Modify the Scoring
Methodology for the Medicare
Promoting Interoperability Program
Beginning With the CY 2023 EHR
Reporting Period
In section IX.H.6. of the preamble of
this final rule, we are finalizing the
following changes to the scoring
methodology:
• Increasing the points allocated to
the Public Health and Clinical Data
Exchange Objective from 10 points to 25
points,
• Increasing the points allocated to
the Electronic Prescribing Objective
from 10 points to 20 points,
• Decreasing the points allocated to
the Health Information Exchange
Objective from 40 points to 30 points,
and
• Decreasing the points allocated to
the Provide to Patient Exchange
Objective from 40 points to 25 points.
Our policy does not yield a change in
burden as it does not affect the
requirements for data submission for
eligible hospitals or CAHs but only
changes the scoring methodology.
i. Information Collection Burden
Estimate To Institute Public Reporting
of Medicare Promoting Interoperability
Program Data Beginning With Data
From the CY 2023 EHR Reporting
Period
In section IX.H.7. of the preamble of
this final rule, we are finalizing to
publicly report certain Medicare
Promoting Interoperability Program data
submitted by eligible hospitals and
CAHs beginning with EHR reporting
period in CY 2023. Specifically, we are
finalizing that we will publish eligible
hospitals’ and CAHs’ actual scores and
their CMS EHR certification ID,
beginning with data submitted for the
CY 2023 EHR reporting period. Our
PO 00000
Frm 00617
Fmt 4701
Sfmt 4700
49395
policy does not yield a change in
burden as it does not affect the
requirements for data submission for
eligible hospitals or CAHs.
j. Information Collection Burden
Estimate for Modifications to Regulatory
Text
In section IX.H.8. of the preamble of
this final rule, we are removing
references to objectives and measures
and making modifications to regulatory
text at 42 CFR 495.24 beginning in CY
2023. Our policy does not yield a
change in burden as it does not affect
the requirements for data submission for
eligible hospitals or CAHs since the
changes only modify regulatory text.
k. Summary of Estimates Used To
Calculate the Collection of Information
Burden
In summary, under OMB control
number 0938–1278 (expiration date July
31, 2022), we estimate that the policies
in this final rule result in a total
increase in burden of 5,513 hours
through the CY 2024 EHR reporting
period. The total cost increase related to
this information collection is
approximately $233,730 (5,513 hours ×
$42.40) across 4,500 eligible hospitals
and CAHs. The tables summarize the
total burden changes for the CY 2023
and for CY 2024 EHR reporting periods
compared to our currently approved
information collection burden estimates
(the table for the CY 2024 EHR reporting
period reflects the total burden change
associated with all policies being
finalized).
In the FY 2022 IPPS/LTCH PPS final
rule, we estimated each eligible hospital
and CAH would require 6.5 hours
annually to participate in the Medicare
Promoting Interoperability Program (86
FR 45517). As a result of the policies in
this final rule, we estimate the new total
annual burden to be 6.6 hours per
eligible hospital and CAH as well as an
additional 4 hours annually for CAHs to
report eCQMs. Therefore, we estimate
the adjustment in the number of eligible
hospitals and CAHs from 3,300 to 4,500
results in an increase of approximately
+13,290 hours ((6.6 hours × ¥150
eligible hospitals) + (10.6 hours × 1,350
CAHs)) at a cost of +$563,496 (+13,290
hours × $42.40).
We will submit the revised
information collection estimates to OMB
for approval under OMB control number
0938–1278 (expiration date July 31,
2022).
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49396
VerDate Sep<11>2014
Jkt 256001
PO 00000
Frm 00618
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.208
Activity
Require Query of PDMP measure
Require Active Engagement Reporting
Annual Recordkeepin2 and Reportin2 Requirements Under 0MB Control Number 0938-1278
Average
Newly
number
Finalized
records
Annual
annual
per
burden
burden
Net
eligible
(hours)
(hours)
Previously
differen
Estimated
Number
Number of
hospital
per
across
finalized annual
ce in
reporting
eligible
orCAH
eligible
eligible
burden (hours)
annual
time per
record
quarters
hospitals/CAHs
per
hospital/
hospitals/C
across eligible
burden
(minutes)
per year
quarter
hospitals/CAHs
reportin2
CAH
AHs
hours
+37.5
0.5
1
4,500
1
0.0083
37.5
NIA
+37.5
0.5
1
4,500
1
0.0083
37.5
NIA
Total Chan2e in Information Collection Burden Hours: +75
Total Cost Estimate: Updated Hourly Wage ($42.40) x Change in Burden Hours (+75) = +$3,180
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
SUMMARY OF ANNUAL MEDICARE PROMOTING INTEROPERABILITY PROGRAM INFORMATION
COLLECTION BURDEN CHANGES FOR THE CY 2023 EHR REPORTING PERIOD
khammond on DSKJM1Z7X2PROD with RULES2
VerDate Sep<11>2014
Jkt 256001
PO 00000
Frm 00619
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
Activitv
Require Query of PDMP measure
Add Antimicrobial Use and Resistance
(AUR) Surveillance measure
Require Active Engagement Reporting
Modify eCQM Reoorting
Estimated
time per
record
(minutes)
0.5
0.5
0.5
20
Annual Recordkeeoinl! and Reoortinl! Reauirements Under 0MB Control Number 0938-1278
Average
number
Annual
records
burden
Previously
per
(hours)
Newly Finalized
finalized
Number
Number of
hospital
per
annual burden
annual burden
reporting
eligible
orCAH
eligible
(hours) across
(hours) across
quarters
hospitals/CAB
per
hospital/
eligible
eligible
oervear
s reoortin2
quarter
CAH
hosoitals/CAHs
hosoitals/CAHs
1
4,500
1
0.0083
37.5
NIA
l
l
4
4,500
4,500
1,350
l
1
1
0.0083
0.0083
1.33
37.5
37.5
5,400
Total Chan2e in Information Collection Burden Hours: +5,513
Total Cost Estimate: Updated Hourly Wage ($42.40) x Change in Burden Hours (+5,513) = +$233,730
NIA
NIA
NIA
Net
difference in
annual
burden
hours
+37.5
+37.5
+37.5
+5,400
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
SUMMARY OF ANNUAL MEDICARE PROMOTING INTEROPERABILITY PROGRAM INFORMATION
COLLECTION BURDEN CHANGE FOR THE CY 2024 EHR REPORTING PERIOD
49397
ER10AU22.209
49398
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
We did not receive comments
regarding the ICRs for the Medicare
Promoting Interoperability Program.
10. ICRs for the Codification of the Costs
Incurred for Qualified and NonQualified Deferred Compensation Plans
As discussed in section X.A. of the
preamble of this final rule, we are
finalizing proposed codifications and
clarifications for certain policies relating
to Deferred Compensation. This
finalized provision will not change our
current policies for allowable Deferred
Compensation costs associated with
Qualified and Non-Qualified Deferred
Compensation Plans that are included
in Medicare cost reports. The
documentation requirements will
require that a provider of services must
maintain and make available to its
contractor and CMS, documentation to
substantiate the costs incurred for the
plans included in its Medicare cost
report. These documentation
requirements are based on the
recordkeeping requirements at current
§ 413.20, which require providers of
services to maintain sufficient financial
records and statistical data for proper
determination of costs payable under
Medicare. The OMB control number for
this information collection request is
0938–0050, which expired on March 31,
2022. A 30-day Federal Register notice
published on June 22, 2022 (87 FR
37338) for the reinstatement of the
information collection request. The
comment period closed July 22, 2022.
We did not receive comments
regarding the ICRs for the codification of
the costs incurred for qualified and nonqualified deferred compensation plans.
11. ICRs for Condition of Participation
(CoP) Requirements for Hospitals and
CAHs To Continue Reporting Data for
COVID–19 and Influenza After the PHE
Ends as Determined by the Secretary
khammond on DSKJM1Z7X2PROD with RULES2
a. Continued COVID–19 and Seasonal
Influenza Reporting
We are finalizing proposed revisions
the regulations by adding provisions to
the CoPs (§ 482.42 for hospitals and
§ 485.640 for CAHs) requiring hospitals
and CAHs, after the conclusion of the
current COVID–19 PHE, to continue
COVID–19 and seasonal influenzarelated reporting. The revisions will
continue to apply upon conclusion of
the COVID–19 Public Health Emergency
(PHE) and would continue until April
30, 2024, unless the Secretary
establishes an earlier ending date. The
data elements align closely with those
COVID–19 reporting requirements for
long-term care (LTC) facilities that were
finalized on November 9, 2021 (86 FR
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
62421) and are representative of the
guidance provided to hospitals and
CAHs for reporting. Therefore, we do
not expect that these categories of data
elements will require hospitals and
CAHs to report any information beyond
that which they have already been
reporting. Furthermore, similar to the
requirements for LTC facilities, this
provision will also allow for the scope
and frequency of data collection to be
reduced and limited responsive to the
evolving clinical and epidemiological
circumstances.
Specifically, as discussed in section
XX.B.2 of the preamble of this final rule,
we have re-evaluated the proposed data
elements in consideration of the
feedback shared by commenters and the
evolving state of the current PHE and
are modifying our proposal to remove
the following from the list of required
data categories to report:
• Suspected COVID–19 infections
among patients and staff
• Confirmed COVID–19 and influenza
infections among staff
• COVID–19 and influenza deaths
among staff
• Confirmed co-morbid influenza and
COVID–19 infections among staff
Although data pertaining to suspected
cases were valuable throughout the
COVID–19 PHE, particularly in
instances when testing supplies were
limited and cases were often identified
based on clinical signs and symptoms,
this information is less meaningful now
that testing supplies are readily
available to confirm the presence of
infection. Thus, we do not believe
suspected COVID–19 infection data
would be necessary to collect from
hospitals and CAHs once the PHE
declaration ends, and therefore, we
removed this data category.
The data categories for staff
(suspected infections among staff;
confirmed COVID–19, influenza, and
co-morbid infections among staff;
COVID–19 and influenza deaths among
staff) have not been among the
information that hospitals and CAHs
were required to report throughout the
COVID–19 PHE. Hospitals and CAHs
were required to report suspected,
confirmed, and comorbid infections, as
well as deaths, for patients only. In the
proposed rule, CMS did not intend to
extend these data categories to include
staff. The inclusion of staff in the
proposed rule for these data categories
was a technical error; therefore, we
removed these data categories.While
beneficial during an active PHE and the
specific circumstances of the COVID–19
PHE, we believe the above data
categories are not necessary to provide
PO 00000
Frm 00620
Fmt 4701
Sfmt 4700
the most valuable information during a
post-PHE state for continued monitoring
and as such we are removing these data
categories to be responsive to
commenter concerns regarding
increased burden on facilities and staff,
while also attempting to provide quality
care for patients.
The data categories that we are
finalizing in this rule that hospitals and
CAHs will be required to report relevant
to COVID–19, to the extent as
determined by the Secretary, are as
follows: Confirmed infections among
patients; Total deaths among patients;
Personal protective equipment and
testing supplies; Ventilator use,
capacity, and supplies; Total bed and
intensive care unit bed census and
capacity; Vaccine administration data of
patients and staff; and Relevant
therapeutic inventories or usage, or
both. The data categories that we are
finalized in this rule that hospitals and
CAHs will be required to report relevant
to influenza, to the extend as
determined by the Secretary, are as
follows: Confirmed infections among
patients; Total deaths among patients;
and Confirmed co-morbid influenza and
COVID–19 infections among patients.
We believe these data will offer the most
valuable information during a post-PHE
state by continuing to capture critical
information on COVID–19 and seasonal
influenza for ongoing surveillance and
to inform any potential action to protect
patient health and safety. As previously
discussed, these data will enable the
federal government to monitor the
ability of facilities to provide safe care
for patients by determining the number
of COVID–19 and influenza infections
being treated by facilities; the quantity
of resources available to facilities and
the volume of resources they are using;
and facilities’ continued capacity to
provide safe patient care. In addition, as
done throughout the COVID–19
pandemic, local, state, and federal
authorities will continue to use these
data to identify possible resurgence in
cases and outbreaks, for resource
allocation purposes, and to update
guidance pertaining to the safe
provision of patient care.
As indicated in the proposal, we do
not expect continued daily reporting for
COVID–19 or influenza outside of a
declared PHE. Moreover, the rule allows
for the scope of data categories and
frequency of data collection and
reporting to be reduced and limited, as
determined by the Secretary, responsive
to evolving clinical and epidemiology
circumstances. This approach to
reducing the proposed set of required
data categories will provide a path
towards winding down the overall
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
reporting of COVID–19-related data
between the end of the current PHE and
April 2024 when these requirements
will sunset. These requirements will not
be implemented and enforced until the
current COVID–19 PHE declaration
concludes, and CMS will issue guidance
indicating such a transition. As
discussed previously, we expect the
method of notification to follow a model
similar to that which we used to inform
regulated entities at the beginning of the
COVID–19 PHE (see QSO–21–03–
Hospitals/CAHs at https://
www.cms.gov/files/document/qso-2103-hospitalscahs.pdf-0). The data that
hospitals and CAHs will be required to
report are consistent with the
information they have already been
reporting throughout the COVID–19
PHE (OMB control numbers 0938–0328
for hospitals and 0938–1043 for CAHs).
For purposes of burden estimates, we
do not differentiate among hospitals and
CAHs as they all will complete the same
data collection.
For the estimated costs contained in
the analysis that follows, we used data
from the U.S. Bureau of Labor Statistics
(BLS) to determine the mean hourly
wage for the staff member responsible
for reporting the required information
for a hospital (or a CAH).1168 Based on
our experience with hospitals and CAHs
and the current COVID–19 and related
reporting requirements, we believe that
this will primarily be the responsibility
of a registered nurse and we have used
this position in this analysis at an
average hourly salary of $39.27. For the
total hourly cost, we doubled the mean
hourly wage for a 100 percent increase
to cover overhead and fringe benefits,
according to standard HHS estimating
procedures. If the total cost after
doubling resulted in 0.50 or more, the
cost was rounded up to the next dollar.
If it was 0.49 or below, the total cost was
rounded down to the next dollar.
Therefore, we estimated the total hourly
cost for a registered nurse to perform
these duties would be $79.
According to the most recent COVID–
19 hospital reporting guidance
(available at https://www.hhs.gov/sites/
default/files/covid-19-faqs-hospitalshospital-laboratory-acute-care-facilitydata-reporting.pdf), hospitals are
reporting COVID–19 and influenzarelated data on a daily basis, with
backdating permitted for weekends and
holidays, except psychiatric and
rehabilitation hospitals who report
weekly. Some data element reporting
fields are inactive for data collection,
and therefore, hospitals can optionally
report data for these fields. The inactive
fields and active fields together reflect
what is listed in this final rule for
continued COVID–19 and influenzarelated reporting as well as future
reporting in the event of a declared PHE,
which we discuss next. We do not
expect, nor did we propose, continued
daily reporting for COVID–19 or
influenza outside of a declared PHE. If
we were to assume a weekly reporting
frequency, we would anticipate that
there are reduced cases and fewer data
elements (with no line level patient
data) being reported. Based on these
assumptions, we estimated that total
annual burden hours for all
participating hospitals and CAHs to
comply with these requirements would
be 483,600 hours based on weekly
reporting of the required information by
approximately 6,200 hospitals and
CAHs × 52 weeks per year and at an
average weekly response time of 1.5
49399
hours for a registered nurse with an
average hourly salary of $79. Therefore,
the estimate for total annual costs for all
hospitals and CAHs to comply with the
required reporting provisions weekly
would be $38,204,400 or approximately
$6,162 per facility annually. We
acknowledge that the data elements and
reporting frequency could increase or
decrease over the next 2 years, and
those changes would impact this burden
estimate.
We note that this estimate is assumed
to be a 1-day snapshot of reporting
information as opposed to a cumulative
weekly report accounting for
information based on each day of that
week. If we assumed a cumulative
weekly account, we can assume reduced
burden related to the actual reporting
time, but anticipate that the estimate
would be slightly higher to account for
the need to track closely to daily
reporting. We also acknowledged that
respondents may have to track and
invest in infrastructure in order to
timely and accurately report on the
specified frequency. Thus, respondents
may face ongoing burdens associated
with this collection even in the case of
reduced frequency of submissions. We
solicited comment on this potentiality.
Furthermore, we note that this
estimate likely overestimates the costs
associated with reporting because it
assumes that all hospitals and CAHs
will report manually. Efforts are
underway to automate hospital and
CAH reporting that have the potential to
significantly decrease reporting burden
and improve reliability. Our preliminary
estimates for these reporting activities
(OMB control numbers 0938–0328 for
hospitals and 0938–1043 for CAHs) can
be found in the tables that follow.
ESTIMATED ANNUALIZED BURDEN HOURS
Form Name
Standardized format as
determined bv the Secretarv
00:20 Aug 10, 2022
Total Burden Hours
(low range - high
rane:e)
483,600
483,600
1168 BLS. May 2020 National Occupational
Employment and Wage Estimates United States.
VerDate Sep<11>2014
Number of
Respondents
6,200
Average
Burden per
Response
(in hours)
1.5
Jkt 256001
United States Department of Labor. Accessed at
PO 00000
Frm 00621
Fmt 4701
Sfmt 4725
https://www.bls.gov/oes/current/oes_nat.htm.
Accessed on August 25, 2021.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.210
khammond on DSKJM1Z7X2PROD with RULES2
Type of
Respondent
Hospitals and
CAHs
Total
Number of
Responses
per
Respondent
(low rangehhi:h rane:e)
52
49400
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
ESTIMATED ANNUALIZED RESPONDENT BURDEN COSTS
khammond on DSKJM1Z7X2PROD with RULES2
b. Future Reporting in the Event of a
PHE Declaration
In addition, we proposed to establish
reporting requirements for future PHEs
related to infectious diseases by
requiring hospitals and CAHs to
electronically report information on
Acute Respiratory Illness (including, but
not limited to, Seasonal Influenza Virus,
Influenza-like Illness, and Severe Acute
Respiratory Infection), SARS–CoV–2/
COVID–19, and other viral and bacterial
pathogens or infectious diseases of
pandemic or epidemic potential only
when the Secretary has declared a PHE
directly related to such specific
pathogens and infectious diseases.
Specifically, we proposed that when the
Secretary has declared a PHE, hospitals
and CAHs would be required to report
specific data elements to the CDC’s
National Health Safety Network
(NHSN), or other CDC-supported
surveillance systems, as determined by
the Secretary.
We also proposed to require that a
hospital (or a CAH) would be required
to report each applicable infection
(confirmed and suspected) and the
applicable vaccination data in a format
that provides person-level information,
to include medical record identifier,
race, ethnicity, age, sex, residential
county and zip code, and relevant
comorbidities for affected patients,
unless the Secretary specifies an
alternative format by which the hospital
(or CAH) would be required to report
these data elements. Lastly, we
proposed that a hospital (or a CAH)
would provide the information specified
on a daily basis, unless the Secretary
specifies a lesser frequency, to the
Centers for Disease Control and
Prevention’s National Healthcare Safety
Network (NHSN) or other CDCsupported surveillance systems as
determined by the Secretary. We noted
that in this final rule, we have
withdrawn this proposal to establish
requirements for hospitals and CAHs to
report certain data in the event of a
future PHE declaration.
We solicited comment on the burden
associated with these proposed
requirements given the intended
flexibility provided in reducing or
limiting the scope and frequency of
reporting based on the state of the PHE
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Total Burden
Hours
483,600
Hourly
Wa2e Rate
* $79
and ongoing circumstances, requested
comment on the potential burden
associated with the proposed reporting
requirements as they might relate to any
differences in the public health
response to one specific pathogen or
infectious disease versus another that
would be directly related to the declared
PHE, and requested public comments
addressing burden estimates (and the
potential differences in those estimates)
for variations in the required reporting
response for a local PHE versus a
regional PHE versus a national PHE that
might be declared by the Secretary
based on the specific circumstances at
the time of the declaration.
Comment: A few commenters
indicated that our cost estimate for
continued COVID–19-related data
reporting was inaccurate and
underestimated. The commenters stated
that collecting and reporting these data
involves multiple staff from nursing,
human resources, medical staff,
infection prevention and control,
laboratory, respiratory, materials,
pharmacy, and information technology
departments, and these staff have had to
repeatedly adjust how they collect and
report data in response to changes in
guidance throughout the COVID–19
PHE while also performing their other
duties. Likewise, a few commenters
indicated that data collection and
reporting was solely performed by
infection prevention and control staff,
while and other commenters stated that
quality staff solely compiled and
reported the data. One commenter also
noted that lost revenue due to nursing
staffing having to devote time and
resources to non-direct care activities,
such as manual data collection/
reporting, and the current staffing
shortages, should also be considered in
the burden estimate acknowledging that
this is an opportunity cost that is
difficult to quantify.
Response: We agree that data
collection and reporting procedures,
including but not limited to the number
and type of staff involved (job title,
direct care or non-direct care) vary
among hospitals and CAHs. After
reviewing these comments and other
feedback we received, we also believe
the method of collecting the data
(automated or manual) varies among
hospitals and CAHs. As discussed in
PO 00000
Frm 00622
Fmt 4701
Sfmt 4700
Total Respondent Costs
$38,204,400
$38,204,400
detail in section X.B. of this final rule,
we modified our proposal to decrease
the amount of data categories required
for continued COVID–19-related
reporting beginning at the conclusion of
the current PHE. Specifically, we are
finalizing the proposed revisions at
§ 482.42(e) and (f) and § 485.640(d) and
(e) for hospitals and CAHs, respectively,
with the following information no
longer required to be reported: (1)
Suspected COVID–19 infections among
patients and staff, (2) Confirmed
COVID–19 and influenza infections
among staff, (3) COVID–19 and
influenza deaths among staff, and (4)
Confirmed co-morbid influenza and
COVID–19 infections among staff. Given
that this final rule decreases the scope
of data categories and that the data
collecting and reporting procedures
among hospitals and CAHs varies, we
believe the estimate reflects an accurate
average burden.
Comment: With regard to reporting
frequency and the burden associated,
commenters provided various
suggestions for the appropriate
frequency of reporting including
weekly, Mondays through Fridays only,
while excluding holidays, and
Mondays, Wednesdays, and Fridays
only. One commenter noted that even if
reporting were reduced from a daily
requirement to once per week the
burden would still be far greater than
1.5 hours per week. However, other
commenters emphasized that, while
more burdensome, standardized data
reporting on a daily basis is necessary
to detect trends and outbreaks in a
timely manner and improves accuracy
of real-time models developed to
forecast spread of infectious diseases.
Some commenters also noted the
proposal as an unfunded mandate and
indicated that CMS payment rates do
not keep up with inflation rates.
Response: As noted in the proposed
rule, we do not expect, nor did we
propose, continued daily reporting for
COVID–19 or seasonal influenza data
outside of a declared PHE (87 FR
28642). We appreciate the suggestions
from commenters and will consider
them as decisions are made over the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.211
Type of Respondent
Hospital and CAH Staff-Registered Nurses
Total
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
next two years until this requirement
sunsets in April 2024. Ultimately, the
scope and frequency of reporting will be
informed by the ongoing circumstances
and evolving state of the public health
response efforts.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
13. Summary of All Burden in This
Final Rule
presented in this section of this final
rule.
The following chart reflects the total
burden and associated costs for the ICRs
PO 00000
Frm 00623
Fmt 4701
Sfmt 4700
49401
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49402
Jkt 256001
Frm 00624
Medicare & Medicaid Services,
PO 00000
Fmt 4701
Sfmt 4700
10AUR2
approved this document on July 22,
2022.
E:\FR\FM\10AUR2.SGM
Hospital Wage Index
Pavment for Low-Volume Hosoitals
Hosoital lnoatient Qualitv Reoorting Program
PPS-Exemot Cancer Hospital Qualitv Reporting Program
Hospital Value-Based Purchasing Program
Hospital-Acquired Condition Reduction Program
Hospital Readmissions Reduction Program
Medicare Promoting Interoperabilitv Program
Long Term Care Hospital Qualitv Reporting Program
Costs Incurred for Qualified and Non-Qualified Deferred Compensation Plans
CoP Requirements for Hospitals and CAHs to Continue Reporting Data for COVID-19 and Influenza After the PHE ends as Determined by the Secretary
Cost
(+/-)*
$0
$0
+$23 437,906
$0
$0
$0
$0
+$563,496
$0
$0
$38,204,400
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
Chiquita Brooks-LaSure,
Administrator of the Centers for
VerDate Sep<11>2014
ER10AU22.212
Information Collection Requests
Burden Hours
Increase/Decrease
(+/-)*
0
0
+746 300
0
0
0
0
+13,290
0
0
+483,600
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
List of Subjects
42 CFR Part 412
Administrative practice and
procedure, Health facilities, Medicare,
Puerto Rico, Reporting and
recordkeeping requirements.
42 CFR Part 413
Diseases, Health facilities, Medicare,
Puerto Rico, Reporting and
recordkeeping requirements.
42 CFR Part 482
Grant programs—health, Hospitals,
Medicaid, Medicare, Reporting and
recordkeeping requirements.
42 CFR Part 485
Grant programs—health, Health
facilities, Medicaid, Privacy, Reporting
and recordkeeping requirements.
42 CFR Part 495
Administrative practice and
procedure, Health facilities, Health
maintenance organizations (HMO),
Health professions, Health records,
Medicaid, Medicare, Penalties, Privacy,
Reporting and recordkeeping
requirements.
For the reasons set forth in the
preamble, the Centers for Medicare and
Medicaid Services amends 42 CFR
chapter IV as set forth below:
PART 412—PROSPECTIVE PAYMENT
SYSTEMS FOR INPATIENT HOSPITAL
SERVICES
1. The authority citation for part 412
continues to read as follows:
■
2. Section 412.24 is amended by
adding paragraph (d)(3)(iii) to read as
follows:
■
§ 412.24 Requirements under the PPSExempt Cancer Hospital Quality Reporting
(PCHQR) Program.
khammond on DSKJM1Z7X2PROD with RULES2
*
*
*
*
*
(d) * * *
(3) * * *
(iii) Patient safety exception. Upon a
determination by CMS that the
continued requirement for PCHs to
submit data on a measure raises specific
patient safety concerns, CMS may elect
to immediately remove the measure
from the PCHQR measure set. CMS will,
upon removal of the measure—
(A) Provide notice to PCHs and the
public at the time CMS removes the
measure, along with a statement of the
specific patient safety concerns that
would be raised if PCHs continued to
submit data on the measure; and
(B) Provide notice of the removal in
the Federal Register.
*
*
*
*
*
00:20 Aug 10, 2022
Jkt 256001
§ 412.60
factors.
DRG classification and weighting
*
*
*
*
*
(b) DRG weighting factors. CMS
assigns, for each DRG, an appropriate
weighting factor that reflects the
estimated relative cost of hospital
resources used with respect to
discharges classified within that group
compared to discharges classified
within other groups, subject to a
maximum ten percent reduction to the
weighting factor for a DRG as compared
to the weighting factor for the same DRG
for the prior fiscal year.
*
*
*
*
*
■ 4. Section 412.64 is amended by
adding paragraph (h)(7) to read as
follows:
§ 412.64 Federal rates for inpatient
operating costs for Federal fiscal year 2005
and subsequent fiscal years.
*
*
*
*
*
(h) * * *
(7) Beginning with fiscal year 2023, if
CMS determines that a hospital’s wage
index value for a fiscal year would
decrease by more than 5 percent as
compared to the hospital’s wage index
value for the prior fiscal year, CMS
limits the decrease to 5 percent for the
fiscal year.
*
*
*
*
*
■ 5. Section 412.103 is amended by
adding paragraph (a)(8) to read as
follows:
§ 412.103 Special treatment: Hospitals
located in urban areas and that apply for
reclassification as rural.
Authority: 42 U.S.C. 1302 and 1395hh.
VerDate Sep<11>2014
3. Section 412.60 is amended by
revising paragraph (b) to read as follows:
■
(a) * * *
(8) For a hospital with a main campus
and one or more remote locations under
a single provider agreement where
services are provided and billed under
the inpatient hospital prospective
payment system and that meets the
provider-based criteria at § 413.65 of
this chapter as a main campus and a
remote location of a hospital, approved
rural reclassification status applies to
the main campus and any remote
location located in an urban area (as
defined in § 412.64(b) and including a
main campus or any remote location
deemed urban under section
1886(d)(8)(B) of the Act).
*
*
*
*
*
■ 6. Section 412.106 is amended by—
■ a. Revising paragraph (g)(1)(ii);
■ b. In paragraph (g)(1)(iii)(C)(8),
removing the phrase ‘‘For each
subsequent fiscal year,’’ and adding in
its place the phrase ‘‘For fiscal year
2022,’’;
PO 00000
Frm 00625
Fmt 4701
Sfmt 4700
49403
c. Adding paragraphs (g)(1)(iii)(C)(10)
and (11);
■ d. Redesignating paragraph (h) as
paragraph (i); and
■ e. Adding a new paragraph (h).
The revisions and additions read as
follows:
■
§ 412.106 Special treatment: Hospitals that
serve a disproportionate share of lowincome patients.
*
*
*
*
*
(g) * * *
(1) * * *
(ii) Factor 2. (A) For each of fiscal
years 2014, 2015, 2016, and 2017, a
factor equal to 1 minus the percent
change in the percent of individuals
under the age of 65 who are uninsured
(and subtracting from the factor 0.1
percentage point for fiscal year 2014 and
0.2 percentage point for each of fiscal
years 2015, 2016, and 2017), as
determined by comparing—
(1) 18 percent, the percent of such
individuals who are uninsured in 2013,
based on the March 20, 2010, estimate
of the ‘‘Insured Share of the Nonelderly
Population Including All Residents’’ by
the Congressional Budget Office.
(2) The percent of such individuals
who are uninsured in the applicable
fiscal year, based on the most recent
estimate of the ‘‘Insured Share of the
Nonelderly Population Including All
Residents’’ by the Congressional Budget
Office available at the time of
development of the annual final rule for
the hospital inpatient prospective
payment system.
(B) For FY 2018 and subsequent fiscal
years, a factor equal to 1 minus the
percent change in the percent of
individuals who are uninsured (and
subtracting from the factor 0.2
percentage point for each of fiscal years
2018 and 2019), as determined by
comparing the percent of individuals
who are uninsured in—
(1) 2013 (as estimated by the
Secretary, based on data from the
Census Bureau or other sources the
Secretary determines appropriate, and
certified by the Chief Actuary of the
CMS); and
(2) The most recent period for which
data is available (as so estimated and
certified).
(iii) * * *
(C) * * *
(10) For fiscal year 2023, for all
eligible hospitals, CMS will base its
estimates of the amount of hospital
uncompensated care on data on
uncompensated care costs, defined as
charity care costs plus non-Medicare
and non-reimbursable Medicare bad
debt costs from cost reports from the
two most recent cost reporting years for
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49404
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
which audits have been conducted. If a
hospital is a new hospital (that is, a
hospital that began participation in the
Medicare program after the two most
recent cost reporting years for which
audits have been conducted) or if the
hospital is treated as a new hospital for
purposes of Factor 3, the Medicare
administrative contractor (MAC) will
determine Factor 3 as the ratio of the
hospital’s uncompensated care costs
from its FY 2023 cost report to the sum
of uncompensated care costs for all
DSH-eligible hospitals as estimated by
CMS from the most recent cost reporting
year for which audits have been
conducted.
(11) For fiscal year 2024 and
subsequent fiscal years, for all eligible
hospitals, CMS will base its estimates of
the amount of hospital uncompensated
care on data on uncompensated care
costs, defined as charity care costs plus
non-Medicare and non-reimbursable
Medicare bad debt costs from cost
reports from the three most recent cost
reporting years for which audits have
been conducted. If a hospital is a new
hospital (that is, a hospital that began
participation in the Medicare program
after the three most recent cost reporting
years for which audits have been
conducted) or if the hospital is treated
as a new hospital for purposes of Factor
3, the Medicare administrative
contractor (MAC) will determine Factor
3 as the ratio of the hospital’s
uncompensated care costs from its cost
report for the applicable fiscal year to
the sum of uncompensated care costs for
all disproportionate share hospital
(DSH)-eligible hospitals as estimated by
CMS from the most recent cost reporting
year for which audits have been
conducted.
(h) Supplemental payment for Indian
Health Service and Tribal hospitals and
Puerto Rico hospitals. (1) For fiscal year
2023 and each subsequent fiscal year,
Indian Health Service and Tribal
Hospitals and Puerto Rico hospitals that
qualify for an additional payment for
uncompensated care under paragraph
(g) of this section for the applicable
fiscal year may also qualify to receive a
supplemental payment.
(2) Indian Health Service and Tribal
Hospitals and Puerto Rico hospitals that
do not have a Factor 3 amount for fiscal
year 2022 determined under paragraph
(g)(1)(iii)(C)(9) of this section are not
eligible to receive a supplemental
payment under this paragraph (h).
(3) The amount of the supplemental
payment for a fiscal year is determined
as the difference between the following:
(i) A base year amount defined as the
FY 2022 uncompensated care payment
determined for the hospital, in
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
accordance with paragraph (g)(1) of this
section, adjusted by 1 plus the percent
change in the aggregate amount of
uncompensated care payments as
estimated by CMS in accordance with
paragraphs (g)(1)(i) and (ii) of this
section between fiscal year 2022 and the
applicable fiscal year. If the hospital did
not qualify for an additional payment
for uncompensated care under
paragraph (g) of this section for fiscal
year 2022, CMS uses the Factor 3
determined for the hospital under
paragraph (g)(1)(iii)(C)(9) of this section
to estimate the amount of the additional
payment for uncompensated care that
the hospital would have received in
fiscal year 2022 if the hospital had
qualified for an additional payment for
uncompensated care under paragraph
(g)(1) of this section for that fiscal year.
(ii) The additional payment for
uncompensated care determined for the
hospital for the applicable fiscal year, in
accordance with paragraph (g)(1) of this
section.
(4) If the base year amount under
paragraph (h)(3)(i) of this section is
equal to or lower than the additional
payment for uncompensated care
determined for the hospital for the
applicable fiscal year in accordance
with paragraph (g)(1) of this section, the
hospital will not receive a supplemental
payment under paragraph (h) of this
section for that fiscal year.
*
*
*
*
*
§ 412.140
[Amended]
7. Section 412.140 is amended in
paragraph (d)(2)(ii) by removing the
phrase ‘‘at least 75 percent’’ and adding
in its place the phrase ‘‘100 percent’’.
■ 8. Section 412.168 is amended by—
■ a. Revising the section heading;
■ b. In paragraph (a), removing the
phrase ‘‘for the fiscal year 2022’’ and
adding in its place ‘‘for each of fiscal
years 2022 and 2023’’; and
■ c. By adding paragraphs (g) through
(k).
The revision and additions read as
follows:
■
§ 412.168
2023.
Special rules for FY 2022 and FY
*
*
*
*
*
(g) CMS calculates a measure rate for
all measures selected under § 412.164(a)
for fiscal year 2023 but only applies
§ 412.165(a) to the measures included in
the Clinical Outcomes Domain and the
Efficiency and Cost Reduction Domain
for that fiscal year, which are the
following:
(1) Hospital 30-Day, All-Cause, RiskStandardized Mortality Rate Following
Acute Myocardial Infarction (AMI)
Hospitalization (MORT–30–AMI).
PO 00000
Frm 00626
Fmt 4701
Sfmt 4700
(2) Hospital 30-Day, All-Cause, RiskStandardized Mortality Rate Following
Heart Failure (HF) Hospitalization
(MORT–30–HF).
(3) Hospital 30-Day, All-Cause, RiskStandardized Mortality Rate Following
Pneumonia Hospitalization (MORT–30–
PN (updated cohort)).
(4) Hospital 30-Day, All-Cause, RiskStandardized Mortality Rate Following
Chronic Obstructive Pulmonary Disease
(COPD) Hospitalization (MORT–30–
COPD).
(5) Hospital 30-Day, All-Cause, RiskStandardized Mortality Rate Following
Coronary Artery Bypass Graft (CABG)
Surgery (MORT–30–CABG).
(6) Hospital-Level Risk-Standardized
Complication Rate Following Elective
Primary Total Hip Arthroplasty (THA)
and/or Total Knee Arthroplasty (TKA)
(COMP–HIP–KNEE).
(7) Medicare Spending Per
Beneficiary (MSPB)—Hospital.
(h) CMS calculates—
(1) A Clinical Outcomes Domain score
for fiscal year 2023 for hospitals that
report the minimum number of cases
and measures with respect to the
measures described in paragraphs (g)(1)
through (6) of this section; and
(2) An Efficiency and Cost Reduction
Domain score for fiscal year 2023 for
hospitals that report the minimum
number of cases with respect to the
measure described in paragraph (g)(7) of
this section.
(i) CMS does not award a Total
Performance Score to any hospital for
fiscal year 2023.
(j) The total amount available for
value-based incentive payments for
fiscal year 2023 is equal to the total
amount of base-operating DRG payment
reductions for that fiscal year, as
estimated by the Secretary.
(k) CMS awards a value-based
incentive payment percentage (as
defined in § 412.160) for fiscal year 2023
to all hospitals to ensure that each
hospital receives a value-based
incentive payment amount equal to the
amount of the reduction made to its
base-operating DRG payment amounts.
■ 9. Section 412.273 is amended by
revising paragraphs (d)(2) and (e) to read
as follows:
§ 412.273 Withdrawing an application,
terminating an approved 3-year
reclassification, or canceling a previous
withdrawal or termination.
*
*
*
*
*
(d) * * *
(2) Timing and process of cancellation
request. Cancellation requests must be
submitted in writing to the MGCRB
according to the method prescribed by
the MGCRB no later than the deadline
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
for submitting reclassification
applications for the following fiscal
year, as specified in § 412.256(a)(2).
*
*
*
*
*
(e) Written request only. (1) A request
to withdraw an application must be
submitted in writing to the MGCRB
according to the method prescribed by
the MGCRB by all hospitals that are
party to the application.
(2) A request to terminate an
approved reclassification must be
submitted in writing to the MGCRB
according to the method prescribed by
the MGCRB by an individual hospital or
by an individual hospital that is party
to a group classification.
*
*
*
*
*
■ 10. Section 412.515 is revised to read
as follows:
§ 412.515
LTC–DRG weighting factors.
(a) For each LTC–DRG, CMS assigns
an appropriate weight that reflects the
estimated relative cost of hospital
resources used within that group
compared to discharges classified
within other groups.
(b)(1) Beginning FY 2023, each LTC–
DRG weight is subject to a maximum 10
percent reduction as compared to the
weight for the same LTC–DRG for the
prior fiscal year, except as provided in
paragraph (b)(2) of this section.
(2) The limitation described in
paragraph (b)(1) of this section does not
apply to LTC–DRGs with less than 25
applicable LTCH cases in the data used
to determine the relative weights for the
fiscal year.
■ 11. Section 412.525 is amended by
revising paragraph (c)(1) to read as
follows:
§ 412.525 Adjustments to the Federal
prospective payment.
khammond on DSKJM1Z7X2PROD with RULES2
*
*
*
*
*
(c) * * *
(1) The labor portion of a long-term
care hospital’s Federal prospective
payment is adjusted to account for
geographical differences in the area
wage levels using an appropriate wage
index (established by CMS), which
reflects the relative level of hospital
wages and wage-related costs in the
geographic area (that is, urban or rural
area as determined in accordance with
the definitions set forth in § 412.503) of
the hospital compared to the national
average level of hospital wages and
wage-related costs.
(i)(A) The appropriate wage index that
is established by CMS is updated
annually.
(B) Beginning in fiscal year 2023, if
CMS determines that an LTCH’s wage
index value for a fiscal year would
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
decrease by more than 5 percent as
compared to the LTCH’s wage index
value for the prior fiscal year, CMS
limits the decrease to 5 percent for the
fiscal year.
(ii) The labor portion of a long-term
care hospital’s Federal prospective
payment is established by CMS and is
updated annually.
*
*
*
*
*
49405
PART 413—PRINCIPLES OF
REASONABLE COST
REIMBURSEMENT; PAYMENT FOR
END-STAGE RENAL DISEASE
SERVICES; PROSPECTIVELY
DETERMINED PAYMENT RATES FOR
SKILLED NURSING FACILITIES;
PAYMENT FOR ACUTE KIDNEY
INJURY DIALYSIS
■
13. The authority citation for part 413
continues to read as follows:
§ 412.529 Special payment provision for
short-stay outliers.
Authority: 42 U.S.C. 1302, 1395d(d),
1395f(b), 1395g, 1395l(a), (i), and (n),
1395x(v), 1395hh, 1395rr, 1395tt, and
1395ww.
12. Section 412.529 is amended by
revising paragraphs (d)(4)(ii)(B) and
(d)(4)(iii)(B) to read as follows:
*
*
*
*
*
(d) * * *
(4) * * *
(ii) * * *
(B)(1) Is adjusted for different area
wage levels based on the geographic
classifications set forth at § 412.503 and
the applicable hospital inpatient
prospective payment system (IPPS)
labor-related share, using the applicable
hospital inpatient prospective payment
system wage index value for
nonreclassified hospitals (an LTCH’s
applicable IPPS wage index).
(2) Beginning in fiscal year 2023, if
CMS determines that an LTCH’s
applicable IPPS wage index value for a
fiscal year would decrease by more than
5 percent as compared to the LTCH’s
applicable IPPS wage index value for
the prior fiscal year, CMS limits the
decrease to 5 percent for the fiscal year.
(3) For LTCHs located in Alaska and
Hawaii, the amount specified in
paragraph (d)(4)(ii) of this section is also
adjusted by the applicable hospital
inpatient prospective payment system
cost of living adjustment factors.
*
*
*
*
*
(iii) * * *
(B)(1) Is adjusted for the applicable
geographic adjustment factors,
including local cost variation based on
the geographic classifications set forth at
§ 412.503 and the applicable full
hospital inpatient prospective payment
system (IPPS) wage index value for
nonreclassified hospitals (an LTCH’s
applicable IPPS wage index) and
applicable cost of living adjustment
factors for LTCHs in Alaska and Hawaii.
(2) Beginning in fiscal year 2023, if
CMS determines that an LTCH’s
applicable IPPS wage index value for a
fiscal year would decrease by more than
5 percent as compared to the LTCH’s
applicable IPPS wage index value for
the prior fiscal year, CMS limits the
decrease to 5 percent for the fiscal year.
*
*
*
*
*
PO 00000
Frm 00627
Fmt 4701
Sfmt 4700
■
14. Section 413.75 is amended in
paragraph (b) by adding in alphabetical
order the definitions of ‘‘Rural track
Medicare GME affiliated group’’ and
‘‘Rural track Medicare GME affiliation
agreement’’ to read as follows:
■
§ 413.75 Direct GME payments: General
requirements.
*
*
*
*
*
(b) * * *
Rural track Medicare GME affiliated
group means an urban hospital and a
rural hospital that—
(i) Participate in a rural track program
defined in this paragraph (b);
(ii) Have rural track FTE limitations in
effect prior to October 1, 2022; and
(iii) Comply with the regulations at
§ 413.79(f)(1) through (6) for Medicare
GME affiliated groups.
Rural track Medicare GME affiliation
agreement means a written, signed, and
dated agreement by responsible
representatives of each respective
hospital in a rural track Medicare GME
affiliated group, as defined in this
paragraph (b), that specifies all of the
following:
(i) A statement attesting that each
participating hospital’s FTE counts and
rural track FTE limitations in the
agreement do not reflect FTE residents
nor FTE caps associated with programs
other than the rural track program.
(ii) The term of the rural track
Medicare GME affiliation agreement
(which, at a minimum is 1 year),
beginning on July 1 of a year.
(iii) Each participating hospital’s
direct and indirect GME rural track FTE
limitations in effect prior to the rural
track Medicare GME affiliation.
(iv) The total adjustment to each
hospital’s rural track FTE limitations in
each year that the rural track Medicare
GME affiliation agreement is in effect,
for both direct GME and indirect
medical education (IME), that reflects a
positive adjustment to one hospital’s
direct and indirect rural track FTE
limitations that is offset by a negative
adjustment to the other hospital’s (or
E:\FR\FM\10AUR2.SGM
10AUR2
49406
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
hospitals’) direct and indirect rural track
FTE limitations of at least the same
amount.
(v) The adjustment to each
participating hospital’s FTE counts
resulting from the FTE resident’s (or
residents’) participation in a shared
rotational arrangement at each hospital
participating in the rural track Medicare
GME affiliated group for each year the
Medicare GME affiliation agreement is
in effect. This adjustment to each
participating hospital’s FTE count is
also reflected in the total adjustment to
each hospital’s rural track FTE
limitations (in accordance with
paragraph (iii) of this definition).
(vi) The names of the participating
hospitals and their Medicare provider
numbers.
*
*
*
*
*
■ 15. Section 413.79 is amended by
revising paragraphs (c)(2)(iii) and
adding a sentence at the end of
paragraph (d)(3) to read as follows:
§ 413.79 Direct GME payments:
Determination of the weighted number of
FTE residents.
khammond on DSKJM1Z7X2PROD with RULES2
*
*
*
*
*
(c) * * *
(2) * * *
(iii) Effective for cost reporting
periods beginning on or after October 1,
2001, if the hospital’s unweighted
number of FTE residents exceeds the
limit described in this section, and the
number of weighted FTE residents in
accordance with paragraph (b) of this
section also exceeds that limit, the
respective primary care and obstetrics
and gynecology weighted FTE counts
and other weighted FTE counts are
adjusted to make the total weighted FTE
count equal the limit. If the number of
FTE residents weighted in accordance
with paragraph (b) of this section does
not exceed that limit, then the allowable
weighted FTE count is the actual
weighted FTE count.
*
*
*
*
*
(d) * * *
(3) * * * For cost reporting periods
beginning on or after October 1, 2001,
the hospital’s weighted FTE counts for
the preceding two cost reporting periods
are calculated in accordance with the
payment formula in paragraph (c)(2)(iii)
of this section.
■ 16. Subpart F is amended by adding
§ 413.99 to read as follows:
§ 413.99 Qualified and Non-Qualified
Deferred Compensation Plans.
(a) Statutory basis, scope, and
definitions—(1) Basis. All payments to
providers of services must be based on
the reasonable cost of services covered
under Title XVIII in accordance with
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
section 1861(v) of the Act and the
regulations in this part.
(2) Scope. This section and
§ 413.100(c)(2)(vii) apply to Medicare’s
treatment of the costs incurred for
Qualified and Non-Qualified Deferred
Compensation Plans.
(3) Definitions. As used in this section
the following definitions apply:
Deferred Compensation means
remuneration currently earned by an
employee that is not received until a
subsequent period, usually after
retirement.
Employee Retirement Income Security
Act of 1974 (ERISA) is a Federal law
that sets standards of protection for
individuals in most voluntarily
established, private-sector retirement
plans. The law is set forth in Title 29,
Chapter 18 of the U.S. Code.
Funded Plan means a plan in which
assets have been irrevocably and
unconditionally set aside with a third
party for the payment of plan benefits
(for example, in a trust or escrow
account), and those assets are beyond
the reach of the employer or its general
creditors.
Non-Qualified Deferred
Compensation Plan (NQDC) means an
elective or non-elective plan, agreement,
method, or arrangement between an
employer and an employee to pay the
employee compensation in the future. In
comparison with qualified plans,
nonqualified plans do not provide
employers and employees with the tax
benefits associated with qualified plans
because NQDC plans do not satisfy all
the requirements of 26 U.S.C. 401(a).
Non-Qualified Defined Benefit Plan
(NQDB) means a type of NQDC that is
established and maintained by the
employer primarily to provide definitely
determinable benefits to its employees
usually over a period of years, or for life,
after retirement. Such benefits are
generally measured by, and based on,
such factors as age of employees, years
of service, and compensation received
by the employees.
Pension Benefit Guaranty Corporation
(PBGC) is a Federal agency created by
ERISA to protect benefits in privatesector QDBP plans described in section
3(35) of ERISA.
Qualified Defined Benefit Plan
(QDBP) means a type of Qualified
Deferred Compensation Plan that is
established and maintained by the
employer primarily to provide definitely
determinable benefits to its employees
usually over a period of years, or for life,
after retirement. Such benefits are
generally measured by, and based on,
such factors as age of employees, years
of service, and compensation received
by the employees. A QDBP meets the
PO 00000
Frm 00628
Fmt 4701
Sfmt 4700
applicable requirements of ERISA, as
amended, and the requirements for a
QDBP under 26 U.S.C. 401(a). Under a
qualified plan, employers are entitled to
deduct expenses in the year the
employer makes contributions even
though employees will not recognize
income until the receipt of distributions.
Qualified Defined Contribution or
Individual Account Plan (QDCP) means
a type of Deferred Compensation Plan in
which the employee, the employer, or
both, contribute to an employee’s
individual account under the plan. The
amount in the account at distribution
includes the contributions and
investment gains or losses, minus any
investment and administrative fees. The
value of the account changes based on
contributions and the value and
performance of the investments. A
QDCP meets the applicable
requirements of ERISA, as amended,
and the requirements set forth in 26
U.S.C. 401(a), and, if applicable 26
U.S.C. 401(k).
Unfunded Plan means a plan in
which benefits are supported by assets
that have not been set aside (that is, a
‘‘pay as you go’’ plan), or by assets that
have been set aside, but remain subject
to the claims of the employer’s general
creditors.
(b) Principle requirements—(1)
General. Deferred Compensation
contributions or payments must be
made by a provider of services, or an
employee of the provider of services, to
a Qualified or Non-Qualified Deferred
Compensation Plan, established and
maintained by the provider of services
to provide retirement income to
employees or to result in the deferral of
income by employees for periods
extending to the termination of covered
employment or beyond. Contributions
or payments made by a provider of
services for the benefit of its employees
to a Qualified or Non-Qualified Deferred
Compensation Plan are allowable,
when, and to the extent that, such costs
are actually incurred by the provider of
services and found to be reasonable and
necessary under the principles of
reasonable cost.
(2) Deferred Compensation for
provider-based physicians services in a
hospital or SNF. Costs incurred by a
hospital or SNF to fund a Qualified or
Non-Qualified Deferred Compensation
Plan for a provider-based physician
must meet the following requirements to
be allowable under the program:
(i) The allocation of physician
compensation costs required under
§ 415.60 of this chapter does not
attribute the provider-based physician’s
Deferred Compensation entirely to one
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
category of service and his current
compensation to another.
(ii) Contributions or payments toward
the Qualified or Non-Qualified Deferred
Compensation Plan do not include any
cost excluded from the definition of
physician compensation at § 415.60(a)
of this chapter.
(iii) The amount of Deferred
Compensation does not exceed the
amount specified in the agreement
required by § 415.60(g) of this chapter.
(iv) An arrangement between a
physician and a provider of services
under which the physician is
reimbursed for patient charges, but the
provider of services does the billing as
a Deferred Compensation agreement, is
not allowed.
(v) The costs incurred for physician
guaranteed arrangements for hospital
emergency room availability services,
must meet the following additional
requirements:
(A) The terms of both the guarantee
arrangements and the Deferred
Compensation Plan establish the
amounts to be included at the beginning
of the hospital’s cost reporting period.
(B) The amount of Deferred
Compensation is included in the
guaranteed amount.
(C) The hospital contributes to the
Deferred Compensation Plan from its
own funds.
(D) The amount of Deferred
Compensation that is allowable is
limited to the amount by which the
guarantee, including Deferred
Compensation, exceeds the total billed
by the hospital to all patients for the
physician’s patient care services.
(E) When the physician’s charges to
all patients equal or exceed the amount
guaranteed by the hospital, the program
does not recognize a Deferred
Compensation contribution/payment.
(c) Requirements for Non-Qualified
and Qualified Deferred Compensation
Plans—(1) NQDC requirements. In order
for contributions or payments by a
provider of services to an NQDC as
defined at paragraph (a)(3) of this
section to be allowable under the
program, the NQDC must meet the
general requirements at paragraph
(c)(1)(i) of this section, and it must
either meet the requirements for a
funded NQDC at paragraph (c)(1)(ii) of
this section or the requirements for an
unfunded NQDC at paragraph (c)(1)(iii)
of this section, as applicable.
(i) General requirements. An NQDC
must satisfy the requirements for
document compliance and operational
compliance set forth in 26 U.S.C. 409A.
(ii) Funded NQDCs. A funded NQDC
must meet the definition of a Funded
Plan in paragraph (a)(3) of this section
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
and comply with the requirements in
paragraph (c)(5) of this section.
(iii) Unfunded NQDCs. An NQDC that
is unfunded must meet the definition of
an Unfunded Plan in paragraph (a)(3) of
this section, and there must be no
constructive receipt of income for
employees from a NQDC as a result of
contributions made by a provider of
services.
(2) QDCP requirements. A QDCP must
meet the applicable requirements of
ERISA, as amended, and the
requirements set forth in 26 U.S.C.
401(a), and if applicable 26 U.S.C.
401(k). A QDCP must meet the
definition of a Funded Plan in
paragraph (a)(3) of this section and
comply with the requirements in
paragraph (c)(5) of this section.
(3) QDBP requirements. A QDBP must
meet the applicable requirements of
ERISA, as amended, and the
requirements for a defined benefit plan
under 26 U.S.C. 401(a). A QDBP must
meet the definition of a Funded Plan in
paragraph (a)(3) of this section and
comply with the requirements in
paragraph (c)(5) of this section.
(4) NQDB requirements. In order for
contributions or payments by a provider
of services to an NQDB as defined at
paragraph (a)(3) of this section to be
allowable under the program, the NQDB
must meet the general requirements at
paragraph (c)(4)(i) of this section, and it
must either meet the requirements for a
funded NQDB at paragraph (c)(4)(ii) of
this section or the requirements for an
unfunded NQDB at paragraph (c)(4)(iii)
of this section, as applicable.
(i) General requirements. An NQDB
must satisfy the requirements for
document compliance set forth in 26
U.S.C. 409A and operational
compliance set forth in 26 U.S.C.
409A(a).
(ii) Funded NQDBs. An NQDB that is
funded must meet the definition of a
Funded Plan in paragraph (a)(3) of this
section and comply with the
requirements in paragraph (c)(5) of this
section.
(iii) Unfunded NQDBs. An NQDB that
is unfunded must meet the definition of
an Unfunded Plan in paragraph (a)(3) of
this section, and there must be no
constructive receipt of income for
employees from a NQDB as a result of
contributions made by a provider of
services.
(5) Funded Plan requirements—(i)
Acceptable funding mechanism. Both
provider of services contributions and
employee contributions must be used
either to purchase an insured plan with
a commercial insurance company, to
establish a custodial bank account, or to
PO 00000
Frm 00629
Fmt 4701
Sfmt 4700
49407
establish a trust fund administered by a
trustee.
(ii) Life insurance contracts. The
purchase of an ordinary life insurance
contract (for example, whole life,
straight life, or other) is not a deferral of
compensation and is not recognized as
a funding mechanism, even where it is
convertible at the normal retirement
date specified in the policy to an
annuity payable over the remaining life
of the employee.
(iii) Sole benefit of participating
employees. Regardless of the funding
mechanism utilized, all provider of
services and employee contributions to
the fund established under the Deferred
Compensation Plan and income
therefrom must be used for the sole
benefit of the participating employees.
(d) Recognition of contributions or
payments to Qualified and NonQualified Deferred Compensation
Plans—(1) General rule. Except as
provided for in paragraph (c)(1)(iii) of
this section with respect to QDBPs and
funded NQDBs, contributions to
Qualified Deferred Compensation Plans
or payments to plan participants from
Non-Qualified Deferred Compensation
Plans are recognized as allowable costs
in accordance with paragraph (c)(1)(i) of
this section (in the case of Unfunded
Plans) and paragraph (c)(1)(ii) of this
section (in the case of Funded Plans).
(i) Unfunded Plans. Contributions or
payments made to an unfunded
Deferred Compensation Plans (including
unfunded NQDBs) by a provider of
services on behalf of its employees are
included in allowable costs only during
the cost reporting period in which an
actual payment is made to the
participating employees (or their
beneficiaries) and only to the extent
considered reasonable, in accordance
with § 413.100(c)(2)(vii)(A).
(ii) Funded Plans. Reasonable
provider of services payments made
under funded Deferred Compensation
Plans (specifically, funded Defined
Contribution Plans, but excluding
QDBPs and funded NQDBs) are
included in allowable costs in
accordance with § 413.100(c)(2)(vii)(B).
(iii) Exception for QDBPs and funded
NQDBs. (A) QDBP and NQDB
contributions are found to have been
incurred only if paid directly to
participants or beneficiaries under the
terms of the plan or to the QDBP or
NQDB.
(B) Payments to a QDBP or funded
NQDB for a cost reporting period must
be measured on a cash basis. A
contribution or payment is deemed to
occur on the date it is credited to the
fund established for the QDBP or
funded NQDB, or for provider of
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49408
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
services payments made directly to a
plan participant or beneficiary, on the
date the provider of services account is
debited.
(C) Payments or contributions made to
fully fund a terminating QDBP or
funded NQDB are to be included as
funding on the date they are paid.
Excess assets withdrawn from a QDBP
or funded NQDB are to be treated as
negative contributions on the date that
they are withdrawn.
(D) QDBP and funded NQDB annual
allowable costs are computed as
follows:
(1) QDBP and funded NQDB costs and
limits are computed in accordance with
§ 413.100(c)(2)(vii)(D).
(2) For purposes of determining the
QDBP or funded NQDB cost limit under
§ 413.100(c)(2)(vii)(D)(2), provider of
services contribution payments for each
applicable cost reporting period must be
determined on a cash basis without
regard to any limit determined for the
period during which the contributions
were made, and excluding any
contributions deposited in a prior
period and treated as carry forward
contributions.
(3) The averaging period used to
determine the QDBP or funded NQDB
cost limit must be determined without
regard to a provider of services period
of participation in the Medicare
program. Periods that are not Medicare
cost reporting periods (for example,
periods prior to the hospital’s
participation in the Medicare program)
must be defined as consecutive 12month periods ending immediately
prior to the provider of services initial
Medicare cost reporting period.
(4) The averaging period used to
determine the QDBP or funded NQDB
cost limit must exclude all periods
ending prior to the initial effective date
of the plan (or a predecessor plan in the
case of a merger).
(5) In general, the current period
defined benefit cost and limit is
computed and applied separately for
each QDBP or funded NQDB offered by
a provider of services. In the case of a
plan merger, the contributions or
payments made by a provider of
services to a predecessor QDBP or
funded NQDB and reflected in the assets
subsequently transferred to a successor
plan are treated as contribution
payments made to the successor plan.
(2) [Reserved]
(e) Documentation requirements.
Documentation must be maintained by
the provider of services in accordance
with § 413.20 to substantiate the
allowability of contributions or
payments to Qualified and NonQualified Deferred Compensation
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Plan(s) that it has included in its cost
reports.
(1) Required documentation. The
provider of services must maintain and
make available, upon request by the
contractor or CMS, certain specified
documentation, to substantiate the
allowability of the contributions or
payments to its Qualified or NonQualified Deferred Compensation
Plan(s), or both:
(i) Documentation that demonstrates
that the provider of services is in
compliance with 26 U.S.C. 409A and
409A(a), and, if applicable, 26 U.S.C.
457.
(ii) Ledger accounts/account
statements for each plan participant
noting current year deferrals,
distributions and loans, including any
deferral election forms completed by
employees, any change requests, and the
approval of such requests.
(iii) Documentation that demonstrates
the amount(s) and date(s) of actual
contributions or payments made to the
Qualified or Non-Qualified Deferred
Compensation Plan during the current
cost reporting period.
(iv) Schedule SB of Form 5500 (triagency form (Department of Labor
(DOL), Internal Revenue Service (IRS),
and PBGC) that plans file with the
DOL’s ‘‘EFAST’’ electronic filing
system) for a QDBP for the current cost
reporting period, or any applicable prior
periods.
(v) In the case of a system-wide
(multiple employer) plan, the home
office shall identify the contributions
attributed to each participating provider
of services. If the costs included in the
cost report for a period differ from the
contributions made during the reporting
period (that is, as a result of carry
forward contributions), the provider of
services must also have data available to
track and reconcile the difference.
(2) Additional documentation. The
following additional documentation
must be made available, upon request
by the contractor or CMS, to
substantiate the allowability of the
payments/contributions by a provider of
services to a Qualified or Non-Qualified
Deferred Compensation Plan:
(i) The plan document, the trust
document and all amendments related
to the current cost reporting period.
(ii) If applicable, any Form 5330,
Return of Excise Taxes Related to
Employee Benefit Plans, for the cost
reporting period.
(iii)(A) Supporting documents for all
plan assets and liabilities, such as
broker’s statements, bank statements,
insurance contracts, loan documents,
deeds, etc.
PO 00000
Frm 00630
Fmt 4701
Sfmt 4700
(B) Verification of how assets are
valued.
(iv)(A) Trustee or administrator
reports.
(B) Ledgers.
(C) Journals.
(D) Trustee, administrator, and
investment committee minutes.
(E) Certified audit report and other
financial reports for the trust.
(F) Any other financial reports,
including receipt and disbursement
statements, a detailed income statement,
and a detailed balance sheet.
(v) For each covered QDBP,
documentation of the certified premium
information and payments to the PBGC.
(f) Administrative and other costs
associated with Deferred Compensation
Plans. The provider of services shall file
a cost report required under §§ 413.20
and 413.24(f) that is consistent with the
policies set forth in this section.
(1) Trustee and custodial fees.
Reasonable trustee or custodial fees,
including PBGC premiums, paid by the
provider of services are allowed as an
administrative cost except where the
plan provides that such fees are paid out
of the corpus or earnings of the fund.
(2) Vested benefits. The forfeiture of
an employee’s benefits for cause (as
defined in the plan) is recognized as an
allowable cost provided that such
forfeited amounts are used to reduce the
provider of services contributions or
payments to the plan during the cost
reporting period in which the forfeiture
occurs.
(3) Benefits to be paid. If an employee
terminates participation in the Deferred
Compensation Plan before their rights
are vested, the applicable non-vested
contributions/payments cannot be
applied to increase the benefits of the
surviving participants. Instead the nonvested contributions or payments
should be used to reduce the provider
of services contributions or payments to
the Deferred Compensation Plan, in the
cost reporting period in which the
employee terminated participation in
the Deferred Compensation Plan.
Otherwise, the contributions/payments
made by the provider of services must
be applied to reduce the subsequent
contributions or payments to the
Deferred Compensation Plan in the next
cost reporting period. If subsequent
provider of services contributions/
payments to the Deferred Compensation
Plan are not made, then the provider of
services costs are reduced by the
contractor to the extent of such nonvested funds.
(4) DOL, IRS, or PBGC penalties. If the
provider of services is assessed an
excise tax or other remedy by the DOL,
IRS, or PBGC for failure to follow DOL,
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
IRS, or PBGC requirements under ERISA
or any other penalty fee or penalty
interest applicable to its Deferred
Compensation Plan, the cost is
unallowable in accordance with section
1861(v)(8) of the Act.
(5) Loans made from a Deferred
Compensation Plan. A provider of
services cannot make a loan to itself
from a Deferred Compensation Plan
where ERISA or IRS rules prohibit such
a transaction, except where specifically
excepted.
(6) Termination/discontinuation of a
Deferred Compensation Plan. If the
provider of services declines to vest its
outstanding required contributions or
payments (that is, matching or nonelective) to a Deferred Compensation
Plan as a result of a termination in full
or in part or a discontinuation of
contributions or payments to a Deferred
Compensation Plan, then the provider of
services total outstanding required
contributions or payments to the
Deferred Compensation Plan during the
cost reporting period wherein such
termination is initiated cannot be
included in the provider of services
allowable cost for the cost reporting
period in which the termination is
initiated, nor any future period.
(7) Required offset against interest
expense. Investment income earned on
a Deferred Compensation Plan after its
termination but prior to liquidation of
the plan’s assets and distribution to the
provider of services must be offset
against the provider of services
allowable interest expense under
§ 413.153.
(8) Treatment of residual assets
following termination of a Funded Plan.
(i) Residual assets arising from the
termination of a funded Deferred
Compensation Plan must be recouped in
the year of the plan termination only
against the cost center(s) in which the
provider of services reported its plan
contributions or payments, usually the
administrative and general cost center.
(ii) Residual assets exceeding the
amount in the administrative and
general (or other) cost center are not
further offset in the current or
subsequent years.
(iii) The Medicare share of the
reversion is based on the Medicare
utilization rate in the year the reversion
occurs (or the year the actuarial surplus
is determined), and not Medicare’s
utilization in the years the contributions
to the plan were made.
(g) Treatment of costs associated with
the PBGC. Costs associated with the
requirements set forth in ERISA and by
the PBGC and incurred by a provider of
services who sponsors a QDBP are
allowable or unallowable under the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
program as provided for in this
paragraph (g).
(1) Costs paid out of the plan trust.
PBGC premiums and costs paid out of
the corpus or earnings of the trust are
included in the contributions allowed
under paragraph (d)(1)(iii)(A) of this
section, and are not allowable as
separate costs.
(2) Premium payments for single- and
multi-employer plans. The amount of
PBGC premiums paid for basic benefits
(flat rate or variable, excluding amounts
paid out of the corpus or earnings of the
trust) by a provider of services who
sponsors a QDBP are allowable under
the program.
(3) Liability for missing participants
or beneficiaries. The total amount paid
to the PBGC by a provider of services
who sponsors a QDBP (excluding
amounts paid out of the corpus or
earnings of the trust) of the benefit
transfer amount (as described in 29 CFR
4050.103(d)) for all missing participants
or beneficiaries of the QDBP, is
allowable under the program.
(4) Plan termination due to distress.
For a defined benefit plan that
terminated with insufficient assets to
pay all of the plan benefits, which
resulted in the PBGC making payment
of vested benefits up to limits defined
by law in accordance with 29 CFR part
4022, such amounts contributed to the
QDBP by the provider of services who
sponsors the QDBP are allowable.
Benefits paid to the participants and
beneficiaries of the QDBP by the PBGC
are unallowable.
(5) Restored plan payments. If the
PBGC issues or has issued a plan
restoration order as described in 29 CFR
part 4047, the amounts that the provider
of services repays to the PBGC for
guaranteed benefits and related
expenses under the plan while the plan
was in terminated status, and any
administrative costs assessed by the
PBGC, excluding penalties, are
allowable.
PART 482—CONDITIONS OF
PARTICIPATION FOR HOSPITALS
17. The authority citation for part 482
continues to read as follows:
■
Authority: 42 U.S.C. 1302, 1395hh, and
1395rr, unless otherwise noted.
18. Section 482.42 is amended by
revising paragraphs (e) and (f) to read as
follows:
■
§ 482.42 Condition of participation:
Infection prevention and control and
antibiotic stewardship programs.
*
*
*
*
*
(e) COVID–19 reporting. (1) During
the Public Health Emergency, as defined
PO 00000
Frm 00631
Fmt 4701
Sfmt 4700
49409
in § 400.200 of this chapter, the hospital
must report information in accordance
with a frequency as specified by the
Secretary on COVID–19 in a
standardized format specified by the
Secretary. This report must include, but
not be limited to, the following data
elements:
(i) The hospital’s current inventory
supplies of any COVID–19-related
therapeutics that have been distributed
and delivered to the hospital under the
authority and direction of the Secretary.
(ii) The hospital’s current usage rate
for any COVID–19-related therapeutics
that have been distributed and delivered
to the hospital under the authority and
direction of the Secretary.
(2) Beginning at the conclusion of the
COVID–19 Public Health Emergency, as
defined in § 400.200 of this chapter, and
continuing until April 30, 2024, except
when the Secretary specifies an earlier
end date for the requirements of this
paragraph (e)(2), the hospital must
electronically report information about
COVID–19 in a standardized format
specified by the Secretary. To the extent
as required by the Secretary, this report
must include the following data
elements:
(i) Confirmed COVID–19 infections
among patients.
(ii) Total deaths among patients.
(iii) Personal protective equipment
and testing supplies.
(iv) Ventilator use, capacity, and
supplies.
(v) Total bed and intensive care unit
bed census and capacity.
(vi) Staffing shortages.
(vii) COVID–19 vaccine
administration data of patients and staff.
(viii) Relevant therapeutic inventories
or usage, or both.
(f) Standard: Reporting of acute
respiratory illness, including seasonal
influenza virus, influenza-like illness,
and severe acute respiratory infection.
(1) During the Public Health Emergency,
as defined in § 400.200 of this chapter,
the hospital must report information, in
accordance with a frequency as
specified by the Secretary, on Acute
Respiratory Illness (including, but not
limited to, Seasonal Influenza Virus,
Influenza-like Illness, and Severe Acute
Respiratory Infection) in a standardized
format specified by the Secretary.
(2) Beginning at the conclusion of the
COVID–19 Public Health Emergency, as
defined in § 400.200 of this chapter, and
continuing until April 30, 2024, except
when the Secretary specifies an earlier
end date for the requirements of this
paragraph (f)(2), the hospital must
electronically report information about
seasonal influenza in a standardized
format specified by the Secretary. To the
E:\FR\FM\10AUR2.SGM
10AUR2
49410
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
extent as required by the Secretary, this
report must include the following data
elements:
(i) Confirmed influenza infections
among patients.
(ii) Total deaths among patients.
(ii) Confirmed co-morbid influenza
and COVID–19 infections among
patients.
PART 485—CONDITIONS OF
PARTICIPATION: SPECIALIZED
PROVIDERS
19. The authority citation for part 485
is revised to read as follows:
■
Authority: 42 U.S.C. 1302 and 1395(hh).
20. Section 485.640 is amended by
revising paragraphs (d) and (e) to read
as follows:
■
§ 485.640 Condition of participation:
Infection prevention and control and
antibiotic stewardship programs.
khammond on DSKJM1Z7X2PROD with RULES2
*
*
*
*
*
(d) COVID–19 reporting. (1) During
the Public Health Emergency, as defined
in § 400.200 of this chapter, the CAH
must report information in accordance
with a frequency as specified by the
Secretary on COVID–19 in a
standardized format specified by the
Secretary. This report must include, but
not be limited to, the following data
elements:
(i) The CAH’s current inventory
supplies of any COVID–19-related
therapeutics that have been distributed
and delivered to the CAH under the
authority and direction of the Secretary;
and
(ii) The CAH’s current usage rate for
any COVID–19-related therapeutics that
have been distributed and delivered to
the CAH under the authority and
direction of the Secretary.
(2) Beginning at the conclusion of the
COVID–19 Public Health Emergency, as
defined in § 400.200 of this chapter, and
continuing until April 30, 2024, except
when the Secretary specifies an earlier
end date for the requirements of this
paragraph (d)(2), the CAH must
electronically report information about
COVID–19 in a standardized format
specified by the Secretary. To the extent
as required by the Secretary, this report
must include the following data
elements:
(i) Confirmed COVID–19 infections
among patients.
(ii) Total deaths among patients.
(iii) Personal protective equipment
and testing supplies.
(iv) Ventilator use, capacity, and
supplies.
(v) Total bed and intensive care unit
bed census and capacity.
(vi) Staffing shortages.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
(vii) COVID–19 vaccine
administration data of patients and staff.
(viii) Relevant therapeutic inventories
or usage, or both.
(e) Standard: Reporting of acute
respiratory illness, including seasonal
influenza virus, influenza-like illness,
and severe acute respiratory infection.
(1) During the Public Health Emergency,
as defined in § 400.200 of this chapter,
the CAH must report information, in
accordance with a frequency as
specified by the Secretary, on Acute
Respiratory Illness (including, but not
limited to, Seasonal Influenza Virus,
Influenza-like Illness, and Severe Acute
Respiratory Infection) in a standardized
format specified by the Secretary.
(2) Beginning at the conclusion of the
COVID–19 Public Health Emergency, as
defined in § 400.200 of this chapter, and
continuing until April 30, 2024, except
when the Secretary specifies an earlier
end date for the requirements of this
paragraph (e)(2), the CAH must
electronically report information about
seasonal influenza in a standardized
format specified by the Secretary. To the
extent as required by the Secretary, this
report must include the following data
elements:
(i) Confirmed influenza infections
among patients.
(ii) Total deaths among patients.
(iii) Confirmed co-morbid influenza
and COVID–19 infections among
patients.
*
*
*
*
*
PART 495—STANDARDS FOR THE
ELECTRONIC HEALTH RECORD
TECHNOLOGY INCENTIVE PROGRAM
21. The authority citation for part 495
continues to read as follows:
■
Authority: 42 U.S.C. 1302 and 1395hh.
22. Section § 495.24 is amended—
a. In the introductory text, by revising
the last sentence and adding a new
sentence at the end of the paragraph;
■ b. In paragraph (e), in the paragraph
heading by removing the phrase ‘‘for
2019 and subsequent years’’ and adding
in its place the phrase ‘‘for 2019 through
2022.’’;
■ c. In paragraph (e)(1)(i)(C), by
removing the phrase ‘‘In 2022 and
subsequent years, earn’’ and adding in
its place the phrase ‘‘In 2022, earn’’;
■ d. In paragraph (e)(4)(ii), by removing
the phrase ‘‘In 2022 and subsequent
years’’ and adding in its place the
phrase ‘‘In 2022’’;
■ e. In paragraph (e)(5)(ii)(B), by
removing the phrase ‘‘In 2020 and
subsequent years’’ and adding in its
place the phrase ‘‘In 2020 through
2022’’;
■
■
PO 00000
Frm 00632
Fmt 4701
Sfmt 4700
f. In paragraph (e)(5)(iii)(A), by
removing the phrase ‘‘in CY 2019 and
subsequent years’’ and adding in its
place ‘‘in CY 2019 through CY 2022.’’;
■ g. In paragraph (e)(5)(v), by removing
the phrase ‘‘Beginning with the EHR
reporting period in CY 2019’’ and
adding in its place ‘‘For the EHR
reporting periods in CY 2019 through
CY 2022’’;
■ h. In paragraph (e)(7)(ii) introductory
text, by removing the phrase ‘‘beginning
in CY 2019’’ and adding in its place the
phrase ‘‘for CY 2019 through CY 2022’’;
■ i. In paragraph (e)(8)(ii), by removing
the phrase ‘‘For CY 2022 and
subsequent years’’ and adding in its
place ‘‘For CY 2022’’;
■ j. In paragraph (e)(8)(ii)(A), by
removing the phrase ‘‘For CY 2022 and
subsequent years’’ and adding in its
place ‘‘For CY 2022’’;
■ k. In paragraphs (e)(8)(iii)
introductory text, by removing the
phrase ‘‘For CY 2022 and subsequent
years’’ and adding in its place ‘‘For CY
2022’’;
■ l. In paragraph (e)(8)(iii)(A)(2), by
removing the phrase ‘‘For CY 2022 and
subsequent years’’ and adding in its
place ‘‘For CY 2022’’;
■ m. In paragraph (e)(8)(iii)(D)(2), by
removing the phrase ‘‘For CY 2022 and
subsequent years’’ and adding in its
place ‘‘For CY 2022’’;
■ n. In paragraph (e)(8)(iii)(E)(2), by
removing the phrase ‘‘For CY 2022 and
subsequent years’’ and adding in its
place ‘‘For CY 2022’’; and
■ o. Adding paragraph (f).
The revision and addition read as
follows:
■
§ 495.24 Stage 3 meaningful use
objectives and measures for EPs, eligible
hospitals and CAHs for 2019 and
subsequent years.
* * * The criteria specified in
paragraph (e) of this section are
applicable for eligible hospitals and
CAHs attesting to CMS for 2019 through
2022. The criteria specified in paragraph
(f) of this section are applicable for
eligible hospitals and CAHs attesting to
CMS for 2023 and subsequent years
*
*
*
*
*
(f) Stage 3 objectives and measures for
eligible hospitals and CAHs attesting to
CMS for 2023 and subsequent years. (1)
General rule. (i) Except as specified in
paragraph (f)(2) of this section, eligible
hospitals and CAHs must do all of the
following as part of meeting the
definition of a meaningful EHR user
under § 495.4:
(A) Meet all objectives and associated
measures selected by CMS under
section 1886(n)(3) of the Act for an EHR
reporting period.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(B) In 2023 and subsequent years,
earn a total score of at least 60 points.
(ii) The numerator and denominator
of the measures increment based on
actions occurring during the EHR
reporting period selected by the eligible
hospital or CAH, unless otherwise
indicated.
(2) Exclusion for nonapplicable
measures. (i) Exclusion of a particular
measure. An eligible hospital or CAH
may exclude a particular measure that
includes an option for exclusion if the
eligible hospital or CAH meets the
following requirements:
(A) Meets the criteria in the
applicable measure that would permit
the exclusion.
(B) Attests to the exclusion.
(ii) Distribution of points for
nonapplicable measures. For eligible
hospitals or CAHs that claim such
exclusion, the points assigned to the
excluded measure are distributed to
other measures as specified by CMS for
an EHR reporting period.
Dated: July 27, 2022.
Xavier Becerra,
Secretary, Department of Health and Human
Services.
Note: The following Addendum and
Appendixes will not appear in the Code of
Federal Regulations.
Addendum—Schedule of Standardized
Amounts, Update Factors, Rate-ofIncrease Percentages Effective With
Cost Reporting Periods Beginning on or
After October 1, 2022, and Payment
Rates for LTCHs Effective for
Discharges Occurring on or After
October 1, 2022
khammond on DSKJM1Z7X2PROD with RULES2
I. Summary and Background
In this Addendum, we are setting forth a
description of the methods and data we used
to determine the prospective payment rates
for Medicare hospital inpatient operating
costs and Medicare hospital inpatient capitalrelated costs for FY 2023 for acute care
hospitals. We also are setting forth the rateof-increase percentage for updating the target
amounts for certain hospitals excluded from
the IPPS for FY 2023. We note that, because
certain hospitals excluded from the IPPS are
paid on a reasonable cost basis subject to a
rate-of-increase ceiling (and not by the IPPS),
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
these hospitals are not affected by the
proposed figures for the standardized
amounts, offsets, and budget neutrality
factors. Therefore, in this final rule, we are
setting forth the rate-of-increase percentage
for updating the target amounts for certain
hospitals excluded from the IPPS that will be
effective for cost reporting periods beginning
on or after October 1, 2022. In addition, we
are setting forth a description of the methods
and data we used to determine the LTCH PPS
standard Federal payment rate that will be
applicable to Medicare LTCHs for FY 2023.
In general, except for SCHs, for FY 2023,
each hospital’s payment per discharge under
the IPPS is based on 100 percent of the
Federal national rate, also known as the
national adjusted standardized amount. This
amount reflects the national average hospital
cost per case from a base year, updated for
inflation. Under current law, the MDH
program is effective for discharges on or
before September 30, 2022. Therefore, under
current law, the MDH program will expire at
the end of FY 2022.
Sole Community Hospitals (SCHs) are paid
based on whichever of the following rates
yields the greatest aggregate payment: the
Federal national rate (including, as discussed
in section IV.G. of the preamble of this final
rule, uncompensated care payments under
section 1886(r)(2) of the Act); the updated
hospital-specific rate based on FY 1982 costs
per discharge; the updated hospital-specific
rate based on FY 1987 costs per discharge;
the updated hospital-specific rate based on
FY 1996 costs per discharge; or the updated
hospital-specific rate based on FY 2006 costs
per discharge.
As discussed in section V.A.2. of the
preamble of this final rule, section
1886(n)(6)(B) of the Act was amended to
specify that the adjustments to the applicable
percentage increase under section
1886(b)(3)(B)(ix) of the Act apply to
subsection (d) Puerto Rico hospitals that are
not meaningful EHR users, effective
beginning FY 2022. In general, Puerto Rico
hospitals are paid 100 percent of the national
standardized amount and are subject to the
same national standardized amount as
subsection (d) hospitals that receive the full
update. Accordingly, our discussion later in
this section does not include references to
the Puerto Rico standardized amount or the
Puerto Rico-specific wage index.
As discussed in section II. of this
Addendum, we are making changes in the
determination of the prospective payment
rates for Medicare inpatient operating costs
for acute care hospitals for FY 2023. In
section III. of this Addendum, we discuss our
policy changes for determining the
PO 00000
Frm 00633
Fmt 4701
Sfmt 4700
49411
prospective payment rates for Medicare
inpatient capital-related costs for FY 2023. In
section IV. of this Addendum, we are setting
forth the rate-of-increase percentage for
determining the rate-of-increase limits for
certain hospitals excluded from the IPPS for
FY 2023. In section V. of this Addendum, we
discuss policy changes for determining the
LTCH PPS standard Federal rate for LTCHs
paid under the LTCH PPS for FY 2023. The
tables to which we refer in the preamble of
this final rule are listed in section VI. of this
Addendum and are available via the internet
on the CMS website.
II. Changes to Prospective Payment Rates for
Hospital Inpatient Operating Costs for Acute
Care Hospitals for FY 2023
The basic methodology for determining
prospective payment rates for hospital
inpatient operating costs for acute care
hospitals for FY 2005 and subsequent fiscal
years is set forth under § 412.64. The basic
methodology for determining the prospective
payment rates for hospital inpatient
operating costs for hospitals located in Puerto
Rico for FY 2005 and subsequent fiscal years
is set forth under §§ 412.211 and 412.212. In
this section, we discuss the factors we are
using for determining the proposed
prospective payment rates for FY 2023. In
summary, the standardized amounts set forth
in Tables 1A, 1B, and 1C that are listed and
published in section VI. of this Addendum
(and available via the internet on the CMS
website) reflect—
• Equalization of the standardized
amounts for urban and other areas at the
level computed for large urban hospitals
during FY 2004 and onward, as provided for
under section 1886(d)(3)(A)(iv)(II) of the Act.
• The labor-related share that is applied to
the standardized amounts to give the hospital
the highest payment, as provided for under
sections 1886(d)(3)(E) and 1886(d)(9)(C)(iv)
of the Act. For FY 2023, depending on
whether a hospital submits quality data
under the rules established in accordance
with section 1886(b)(3)(B)(viii) of the Act
(hereafter referred to as a hospital that
submits quality data) and is a meaningful
EHR user under section 1886(b)(3)(B)(ix) of
the Act (hereafter referred to as a hospital
that is a meaningful EHR user), there are four
possible applicable percentage increases that
can be applied to the national standardized
amount. We refer readers to section IV.A. of
the preamble of this final rule for a complete
discussion on the FY 2023 inpatient hospital
update. The table that follows shows these
four scenarios:
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
FY 2023 APPLICABLE PERCENTAGE INCREASES FOR THE IPPS
Hospital
Hospital
Hospital Did
Submitted
Submitted
NOT Submit
Quality Data
Quality Data
Quality Data
and is a
and is NOT a
and is a
Meaningful
Meaningful
Meaningful
FY2023
EHR User
EHR User
EHR User
Adjustment for Failure to Submit Quality Data under
Section 1886(b)(3)ffi)(viii) of the Act
-1.025
0
0
Adjustment for Failure to be a Meaningful EHR User
under Section 1886(b)(3)(B)(ix) of the Act
-3.075
0
0
Productivity Adjustment under Section
1886(b)(3)(B)(xi) of the Act
-0.3
-0.3
-0.3
Applicable Percentage Increase Applied to
Standardized Amount
0.725
2.775
3.8
We note that section 1886(b)(3)(B)(viii) of
the Act, which specifies the adjustment to
the applicable percentage increase for
‘‘subsection (d)’’ hospitals that do not submit
quality data under the rules established by
the Secretary, is not applicable to hospitals
located in Puerto Rico.
In addition, section 602 of Public Law 114–
113 amended section 1886(n)(6)(B) of the Act
to specify that Puerto Rico hospitals are
eligible for incentive payments for the
meaningful use of certified EHR technology,
effective beginning FY 2016, and also to
apply the adjustments to the applicable
percentage increase under section
1886(b)(3)(B)(ix) of the Act to subsection (d)
Puerto Rico hospitals that are not meaningful
EHR users, effective beginning FY 2022.
Accordingly, for FY 2022, section
1886(b)(3)(B)(ix) of the Act in conjunction
with section 602(d) of Public Law 114–113
requires that any subsection (d) Puerto Rico
hospital that is not a meaningful EHR user (as
defined in section 1886(n)(3) of the Act) and
not subject to an exception under section
1886(b)(3)(B)(ix) of the Act will have ‘‘threequarters’’ of the applicable percentage
increase (prior to the application of other
statutory adjustments), or three-quarters of
the applicable market basket update, reduced
by 331⁄3 percent. The reduction to threequarters of the applicable percentage increase
for subsection (d) Puerto Rico hospitals that
are not meaningful EHR users increases to
662⁄3 percent for FY 2023, and, for FY 2024
and subsequent fiscal years, to 100 percent.
In the FY 2019 IPPS/LTCH PPS final rule, we
finalized the payment reductions (83 FR
41674). The regulations at 42 CFR
412.64(d)(3)(ii) reflect the current law for the
update for subsection (d) Puerto Rico
hospitals for FY 2023 and subsequent fiscal
years.
• An adjustment to the standardized
amount to ensure budget neutrality for DRG
recalibration and reclassification, as provided
for under section 1886(d)(4)(C)(iii) of the Act.
• An adjustment to the standardized
amount to ensure budget neutrality for our
permanent 10-percent cap on the reduction
in a MS–DRG’s relative weight in a given
fiscal year beginning FY 2023, as discussed
in section II.E.2.d. of the preamble of this
final rule, consistent with our current
methodology for implementing DRG
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
recalibration and reclassification budget
neutrality under section 1886(d)(4)(C)(iii) of
the Act.
• An adjustment to ensure the wage index
and labor-related share changes (depending
on the fiscal year) are budget neutral, as
provided for under section 1886(d)(3)(E)(i) of
the Act (as discussed in the FY 2006 IPPS
final rule (70 FR 47395) and the FY 2010
IPPS final rule (74 FR 44005)). We note that
section 1886(d)(3)(E)(i) of the Act requires
that when we compute such budget
neutrality, we assume that the provisions of
section 1886(d)(3)(E)(ii) of the Act (requiring
a 62-percent labor-related share in certain
circumstances) had not been enacted.
• An adjustment to ensure the effects of
geographic reclassification are budget
neutral, as provided for under section
1886(d)(8)(D) of the Act, by removing the FY
2022 budget neutrality factor and applying a
revised factor.
• A positive adjustment of 0.5 percent in
FYs 2019 through 2023 as required under
section 414 of the MACRA.
• An adjustment to the standardized
amount to implement in a budget neutral
manner the increase in the wage index values
for hospitals with a wage index value below
the 25th percentile wage index value across
all hospitals (as described in section III.N. of
the preamble of this final rule).
• An adjustment to the standardized
amount to implement in a budget neutral
manner our permanent wage index cap
policy, as discussed in section III. N of the
preamble of this final rule.
• An adjustment to ensure the effects of
the Rural Community Hospital
Demonstration program required under
section 410A of Public Law 108–173 (as
amended by sections 3123 and 10313 of
Public Law 111–148; section 15003 of Public
Law 114–255; and Division CC, section 128
of Public Law 116–260, which extended the
program), are budget neutral, as required
under section 410A(c)(2) of Public Law 108–
173.
• An adjustment to remove the FY 2022
outlier offset and apply an offset for FY 2023,
as provided for in section 1886(d)(3)(B) of the
Act.
For FY 2023, consistent with current law,
we are applying the rural floor budget
neutrality adjustment to hospital wage
PO 00000
Frm 00634
Fmt 4701
Sfmt 4700
Hospital Did
NOT Submit
Quality Data
and is NOT a
Meaningful
EHR User
-1.025
-3.075
-0.3
-0.3
indexes. Also, consistent with section 3141
of the Affordable Care Act, instead of
applying a State-level rural floor budget
neutrality adjustment to the wage index, we
are applying a uniform, national budget
neutrality adjustment to the FY 2023 wage
index for the rural floor.
For FY 2023, we proposed to not remove
the Stem Cell Acquisition Budget Neutrality
Factor from the prior year’s standardized
amount and to not apply a new factor. If we
removed the prior year’s adjustment, we
would not satisfy budget neutrality. We
believe this approach ensures the effects of
the reasonable cost-based payment for
allogeneic hematopoietic stem cell
acquisition costs under section 108 of the
Further Consolidated Appropriations Act,
2020 (Pub. L. 116–94) are budget neutral as
required under section 108 of Public Law
116–94. For a discussion of Stem Cell
Acquisition Budget Neutrality Factor, we
refer the reader to the FY 2021 IPPS/LTCH
PPS final rule (85 FR 59032 and 59033).
When cost report data regarding reasonable
cost of acquisition become available, we
intend to consider using that reasonable cost
data in future rulemaking for budget
neutrality.
We did not receive comments on stem cell
acquisition budget neutrality. We are
finalizing as proposed without modification.
A. Calculation of the Adjusted Standardized
Amount
1. Standardization of Base-Year Costs or
Target Amounts
In general, the national standardized
amount is based on per discharge averages of
adjusted hospital costs from a base period
(section 1886(d)(2)(A) of the Act), updated
and otherwise adjusted in accordance with
the provisions of section 1886(d) of the Act.
The September 1, 1983, interim final rule (48
FR 39763) contained a detailed explanation
of how base-year cost data (from cost
reporting periods ending during FY 1981)
were established for urban and rural
hospitals in the initial development of
standardized amounts for the IPPS.
Sections 1886(d)(2)(B) and 1886(d)(2)(C) of
the Act require us to update base-year per
discharge costs for FY 1984 and then
standardize the cost data in order to remove
the effects of certain sources of cost
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.213
49412
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
variations among hospitals. These effects
include case-mix, differences in area wage
levels, cost-of-living adjustments for Alaska
and Hawaii, IME costs, and costs to hospitals
serving a disproportionate share of lowincome patients.
For FY 2023, as we proposed, we are
continuing to use the national labor-related
and nonlabor-related shares (which are based
on the 2018-based IPPS market basket) that
were used in FY 2022. Specifically, under
section 1886(d)(3)(E) of the Act, the Secretary
estimates, from time to time, the proportion
of payments that are labor-related and adjusts
the proportion (as estimated by the Secretary
from time to time) of hospitals’ costs which
are attributable to wages and wage-related
costs of the DRG prospective payment rates.
We refer to the proportion of hospitals’ costs
that are attributable to wages and wagerelated costs as the ‘‘labor-related share.’’ For
FY 2023, as discussed in section III.M. of the
preamble of this final rule, as we proposed,
we are using a labor-related share of 67.6
percent for the national standardized
amounts for all IPPS hospitals (including
hospitals in Puerto Rico) that have a wage
index value that is greater than 1.0000.
Consistent with section 1886(d)(3)(E) of the
Act, as proposed, we are applying the wage
index to a labor-related share of 62 percent
of the national standardized amount for all
IPPS hospitals (including hospitals in Puerto
Rico) whose wage index values are less than
or equal to 1.0000.
The standardized amounts for operating
costs appear in Tables 1A, 1B, and 1C that
are listed and published in section VI. of the
Addendum to this final rule and are available
via the internet on the CMS website.
2. Computing the National Average
Standardized Amount
Section 1886(d)(3)(A)(iv)(II) of the Act
requires that, beginning with FY 2004 and
thereafter, an equal standardized amount be
computed for all hospitals at the level
computed for large urban hospitals during FY
2003, updated by the applicable percentage
update. Accordingly, as proposed, we are
calculating the FY 2023 national average
standardized amount irrespective of whether
a hospital is located in an urban or rural
location.
3. Updating the National Average
Standardized Amount
Section 1886(b)(3)(B) of the Act specifies
the applicable percentage increase used to
update the standardized amount for payment
for inpatient hospital operating costs. We
note that, in compliance with section 404 of
the MMA, we are using the 2018-based IPPS
operating and capital market baskets for FY
2023. As discussed in section IV.B. of the
preamble of this final rule, in accordance
with section 1886(b)(3)(B) of the Act, as
amended by section 3401(a) of the Affordable
Care Act, we are reducing the FY 2023
applicable percentage increase (which for
this final rule is based on IGI’s second
quarter 2022 forecast of the 2018-based IPPS
market basket) by the productivity
adjustment, as discussed elsewhere in this
final rule.
Based on IGI’s second quarter 2022 forecast
(as discussed in Appendix B of this final
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
rule), the forecast of the IPPS market basket
increase for FY 2023 for this final rule is 4.1
percent. As discussed earlier, for FY 2023,
depending on whether a hospital submits
quality data under the rules established in
accordance with section 1886(b)(3)(B)(viii) of
the Act and is a meaningful EHR user under
section 1886(b)(3)(B)(ix) of the Act, there are
four possible applicable percentage increases
that can be applied to the standardized
amount. We refer readers to section V.B. of
the preamble of this final rule for a complete
discussion on the FY 2023 inpatient hospital
update to the standardized amount. We also
refer readers to the previous table for the four
possible applicable percentage increases that
would be applied to update the national
standardized amount. The standardized
amounts shown in Tables 1A through 1C that
are published in section VI. of this
Addendum and that are available via the
internet on the CMS website reflect these
differential amounts.
Although the update factors for FY 2023
are set by law, we are required by section
1886(e)(4) of the Act to recommend, taking
into account MedPAC’s recommendations,
appropriate update factors for FY 2023 for
both IPPS hospitals and hospitals and
hospital units excluded from the IPPS.
Section 1886(e)(5)(A) of the Act requires that
we publish our recommendations in the
Federal Register for public comment. Our
recommendation on the update factors is set
forth in Appendix B of this final rule.
4. Methodology for Calculation of the
Average Standardized Amount
The methodology we used to calculate the
FY 2023 standardized amount is as follows:
• To ensure we are only including
hospitals paid under the IPPS in the
calculation of the standardized amount, we
applied the following inclusion and
exclusion criteria: include hospitals whose
last four digits fall between 0001 and 0879
(section 2779A1 of Chapter 2 of the State
Operations Manual on the CMS website at
https://www.cms.gov/Regulations-andGuidance/Guidance/Manuals/Downloads/
som107c02.pdf); exclude CAHs at the time of
this final rule; exclude hospitals in Maryland
(because these hospitals are paid under an all
payer model under section 1115A of the Act);
and remove PPS excluded-cancer hospitals
that have a ‘‘V’’ in the fifth position of their
provider number or a ‘‘E’’ or ‘‘F’’ in the sixth
position.
• As in the past, we are adjusting the FY
2023 standardized amount to remove the
effects of the FY 2022 geographic
reclassifications and outlier payments before
applying the FY 2023 updates. We then
applied budget neutrality offsets for outliers
and geographic reclassifications to the
standardized amount based on FY 2023
payment policies.
• We do not remove the prior year’s budget
neutrality adjustments for reclassification
and recalibration of the DRG relative weights
and for updated wage data because, in
accordance with sections 1886(d)(4)(C)(iii)
and 1886(d)(3)(E) of the Act, estimated
aggregate payments after updates in the DRG
relative weights and wage index should equal
estimated aggregate payments prior to the
changes. If we removed the prior year’s
PO 00000
Frm 00635
Fmt 4701
Sfmt 4700
49413
adjustment, we would not satisfy these
conditions.
Budget neutrality is determined by
comparing aggregate IPPS payments before
and after making changes that are required to
be budget neutral (for example, changes to
MS–DRG classifications, recalibration of the
MS–DRG relative weights, updates to the
wage index, and different geographic
reclassifications). We include outlier
payments in the simulations because they
may be affected by changes in these
parameters.
• Consistent with our methodology
established in the FY 2011 IPPS/LTCH PPS
final rule (75 FR 50422 through 50433),
because IME Medicare Advantage payments
are made to IPPS hospitals under section
1886(d) of the Act, we believe these
payments must be part of these budget
neutrality calculations. However, we note
that it is not necessary to include Medicare
Advantage IME payments in the outlier
threshold calculation or the outlier offset to
the standardized amount because the statute
requires that outlier payments be not less
than 5 percent nor more than 6 percent of
total ‘‘operating DRG payments,’’ which does
not include IME and DSH payments. We refer
readers to the FY 2011 IPPS/LTCH PPS final
rule for a complete discussion on our
methodology of identifying and adding the
total Medicare Advantage IME payment
amount to the budget neutrality adjustments.
• Consistent with the methodology in the
FY 2012 IPPS/LTCH PPS final rule, in order
to ensure that we capture only fee-for-service
claims, we are only including claims with a
‘‘Claim Type’’ of 60 (which is a field on the
MedPAR file that indicates a claim is an FFS
claim).
• Consistent with our methodology
established in the FY 2017 IPPS/LTCH PPS
final rule (81 FR 57277), in order to further
ensure that we capture only FFS claims, we
are excluding claims with a ‘‘GHOPAID’’
indicator of 1 (which is a field on the
MedPAR file that indicates a claim is not an
FFS claim and is paid by a Group Health
Organization).
• Consistent with our methodology
established in the FY 2011 IPPS/LTCH PPS
final rule (75 FR 50422 through 50423), we
examine the MedPAR file and remove
pharmacy charges for anti-hemophilic blood
factor (which are paid separately under the
IPPS) with an indicator of ‘‘3’’ for blood
clotting with a revenue code of ‘‘0636’’ from
the covered charge field for the budget
neutrality adjustments. We are removing
organ acquisition charges, except for cases
that group to MS–DRG 018, from the covered
charge field for the budget neutrality
adjustments because organ acquisition is a
pass-through payment not paid under the
IPPS. Revenue centers 081X–089X are
typically excluded from ratesetting. However,
we are not removing revenue center 891
charges from MS–DRG 018 claims during
ratesetting, because those revenue 891
charges were included in the relative weight
calculation for MS–DRG 018, which is
consistent with the policy finalized in FY
2021 final rule (85 FR 58600). We note that
a new MedPAR variable for revenue code 891
charges was introduced in April 2020.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49414
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
• For FY 2023, we are continuing to
remove allogeneic hematopoietic stem cell
acquisition charges from the covered charge
field for budget neutrality adjustments. As
discussed in the FY 2021 IPPS/LTCH PPS
final rule, payment for allogeneic
hematopoietic stem cell acquisition costs is
made on a reasonable cost basis for cost
reporting periods beginning on or after
October 1, 2020 (85 FR 58835 through
58842).
• The participation of hospitals under the
BPCI (Bundled Payments for Care
Improvement) Advanced model started on
October 1, 2018. The BPCI Advanced model,
tested under the authority of section 3021 of
the Affordable Care Act (codified at section
1115A of the Act), is comprised of a single
payment and risk track, which bundles
payments for multiple services beneficiaries
receive during a Clinical Episode. Acute care
hospitals may participate in the BPCI
Advanced model in one of two capacities: as
a model Participant or as a downstream
Episode Initiator. Regardless of the capacity
in which they participate in the BPCI
Advanced model, participating acute care
hospitals would continue to receive IPPS
payments under section 1886(d) of the Act.
Acute care hospitals that are Participants also
assume financial and quality performance
accountability for Clinical Episodes in the
form of a reconciliation payment. For
additional information on the BPCI
Advanced model, we refer readers to the
BPCI Advanced web page on the CMS Center
for Medicare and Medicaid Innovation’s
website at https://innovation.cms.gov/
initiatives/bpci-advanced/.
For FY 2023, consistent with how we
treated hospitals that participated in the BPCI
Advanced Model in the FY 2021 IPPS/LTCH
PPS final rule (85 FR 59029 and 59030), as
we proposed, we are including all applicable
data from subsection (d) hospitals
participating in the BPCI Advanced model in
our IPPS payment modeling and ratesetting
calculations. We believe it is appropriate to
include all applicable data from the
subsection (d) hospitals participating in the
BPCI Advanced model in our IPPS payment
modeling and ratesetting calculations
because these hospitals are still receiving
IPPS payments under section 1886(d) of the
Act. For the same reasons, as we proposed,
we included all applicable data from
subsection (d) hospitals participating in the
Comprehensive Care for Joint Replacement
(CJR) Model in our IPPS payment modeling
and ratesetting calculations.
• Consistent with our methodology
established in the FY 2013 IPPS/LTCH PPS
final rule (77 FR 53687 through 53688), we
believe that it is appropriate to include
adjustments for the Hospital Readmissions
Reduction Program and the Hospital VBP
Program (established under the Affordable
Care Act) within our budget neutrality
calculations.
Both the hospital readmissions payment
adjustment (reduction) and the hospital VBP
payment adjustment (redistribution) are
applied on a claim-by-claim basis by
adjusting, as applicable, the base-operating
DRG payment amount for individual
subsection (d) hospitals, which affects the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
overall sum of aggregate payments on each
side of the comparison within the budget
neutrality calculations.
In order to properly determine aggregate
payments on each side of the comparison,
consistent with the approach we have taken
in prior years, for FY 2023, we are continuing
to apply a proxy based on the prior fiscal
year hospital readmissions payment
adjustment (for FY 2023 this would be FY
2022 final adjustment factors from Table 15
of the FY 2022 IPPS/LTCH PPS final rule)
and a proxy based on the prior fiscal year
hospital VBP payment adjustment (for FY
2023, this proxy would be an adjustment
factor of 1 to reflect our policy for the FY
2022 program year to suppress measures and
award each hospital a value-based payment
amount that matches the reduction to the
base operating DRG payment amount) on
each side of the comparison, consistent with
the methodology that we adopted in the FY
2013 IPPS/LTCH PPS final rule (77 FR 53687
through 53688). That is, we are applying a
proxy readmissions payment adjustment
factor from the prior final rule and a proxy
hospital VBP payment adjustment factor from
the prior final rule on both sides of our
comparison of aggregate payments when
determining all budget neutrality factors
described in section II.A.4. of this
Addendum.
• The Affordable Care Act also established
section 1886(r) of the Act, which modifies
the methodology for computing the Medicare
DSH payment adjustment beginning in FY
2014. Beginning in FY 2014, IPPS hospitals
receiving Medicare DSH payment
adjustments receive an empirically justified
Medicare DSH payment equal to 25 percent
of the amount that would previously have
been received under the statutory formula set
forth under section 1886(d)(5)(F) of the Act
governing the Medicare DSH payment
adjustment. In accordance with section
1886(r)(2) of the Act, the remaining amount,
equal to an estimate of 75 percent of what
otherwise would have been paid as Medicare
DSH payments, reduced to reflect changes in
the percentage of individuals who are
uninsured and any additional statutory
adjustment, would be available to make
additional payments to Medicare DSH
hospitals based on their share of the total
amount of uncompensated care reported by
Medicare DSH hospitals for a given time
period. In order to properly determine
aggregate payments on each side of the
comparison for budget neutrality, prior to FY
2014, we included estimated Medicare DSH
payments on both sides of our comparison of
aggregate payments when determining all
budget neutrality factors described in section
II.A.4. of this Addendum.
To do this for FY 2023 (as we did for the
last 9 fiscal years), as we proposed, we are
including estimated empirically justified
Medicare DSH payments that would be paid
in accordance with section 1886(r)(1) of the
Act and estimates of the additional
uncompensated care payments made to
hospitals receiving Medicare DSH payment
adjustments as described by section
1886(r)(2) of the Act. That is, we considered
estimated empirically justified Medicare DSH
payments at 25 percent of what would
PO 00000
Frm 00636
Fmt 4701
Sfmt 4700
otherwise have been paid, and also the
estimated additional uncompensated care
payments for hospitals receiving Medicare
DSH payment adjustments on both sides of
our comparison of aggregate payments when
determining all budget neutrality factors
described in section II.A.4. of this
Addendum.
• When calculating total payments for
budget neutrality, to determine total
payments for SCHs, we model total hospitalspecific rate payments and total Federal rate
payments and then include whichever one of
the total payments is greater. As discussed in
section IV.G. of the preamble to this final rule
and later in this section, we are continuing
to use the FY 2014 finalized methodology
under which we take into consideration
uncompensated care payments in the
comparison of payments under the Federal
rate and the hospital-specific rate for SCHs.
Therefore, we are including estimated
uncompensated care payments in this
comparison.
• As we proposed, we included an
adjustment to the standardized amount for
those hospitals that are not meaningful EHR
users in our modeling of aggregate payments
for budget neutrality for FY 2023. Similar to
FY 2022, we are including this adjustment
based on data on the prior year’s
performance. Payments for hospitals will be
estimated based on the applicable
standardized amount in Tables 1A and 1B for
discharges occurring in FY 2023.
• In our determination of all budget
neutrality factors described in section II.A.4.
of this Addendum, we used transfer-adjusted
discharges. Specifically, we calculated the
transfer-adjusted discharges using the
statutory expansion of the postacute care
transfer policy to include discharges to
hospice care by a hospice program as
discussed in section IV.A.2. of the preamble
of the FY 2020 IPPS/LTCH PPS final rule (84
FR 45239 through 42342).
We note that prior to FY 2020, the Rural
Community Hospital (RCH) Demonstration
budget neutrality factor was typically applied
to the standardized amount after all wage
index and other budget neutrality factors
were applied. In the past we completed all
the wage index budget neutrality factors and
then applied the RCH Demonstration budget
neutrality factor. Beginning with FY 2020, we
finalized and implemented additional
policies in a budget neutral manner such as
the increase in the wage index values for
hospitals with a wage index value below the
25th percentile wage index value across all
hospitals and the transitional wage indexes.
When these new policies were implemented
beginning with FY 2020, the associated
budget neutrality adjustments were applied
to the standardized amount after the RCH
Demonstration budget neutrality factor was
applied. Taking into consideration that we
are placing a permanent cap on wage index
decreases beginning FY 2023, we believe the
RCH Demonstration budget neutrality factor
should revert to the order prior to FY 2020
and be applied after all wage index and other
budget neutrality adjustments. Therefore, in
the FY 2023 IPPS/LTCH proposed rule (87
FR 28659), beginning in FY 2023 we
proposed to change the ordering of budget
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
neutrality factors with the RCH
Demonstration budget neutrality factor
applied after all wage index and other budget
neutrality factors. We stated that we believe
this re-ordering of applying the RCH
Demonstration budget neutrality factor after
all wage index and other budget neutrality
factors will have a minimal impact and
minor interactive affects.
We received no comments on our proposal
and therefore are finalizing as proposed
without modification to change the ordering
of budget neutrality factors with the RCH
Demonstration budget neutrality factor
applied after all wage index and other budget
neutrality factors.
a. Reclassification and Recalibration of MS–
DRG Relative Weights Before Cap
Section 1886(d)(4)(C)(iii) of the Act
specifies that, beginning in FY 1991, the
annual DRG reclassification and recalibration
of the relative weights must be made in a
manner that ensures that aggregate payments
to hospitals are not affected. As discussed in
section II.E of this final rule, we are
determining the MS DRG relative weights for
FY 2023 by averaging the relative weights as
calculated with and without COVID–19 cases
in the FY 2021 data. We refer the reader to
section II.E.2.c for complete details. As
discussed in section II.E. of the preamble of
this final rule, we normalized the
recalibrated MS–DRG relative weights by an
adjustment factor so that the average case
relative weight after recalibration is equal to
the average case relative weight prior to
recalibration. However, equating the average
case relative weight after recalibration to the
average case relative weight before
recalibration does not necessarily achieve
budget neutrality with respect to aggregate
payments to hospitals because payments to
hospitals are affected by factors other than
average case relative weight. Therefore, as we
have done in past years, we are making a
budget neutrality adjustment to ensure that
the requirement of section 1886(d)(4)(C)(iii)
of the Act is met.
For this FY 2023 final rule, as we
proposed, to comply with the requirement
that MS–DRG reclassification and
recalibration of the relative weights be budget
neutral for the standardized amount and the
hospital-specific rates, we used FY 2021
discharge data to simulate payments and
compared the following:
• Aggregate payments using the FY 2022
labor-related share percentages, the FY 2022
relative weights, and the FY 2022 prereclassified wage data, and applied the
estimated FY 2023 hospital readmissions
payment adjustments and estimated FY 2023
hospital VBP payment adjustments; and
• Aggregate payments using the FY 2022
labor-related share percentages, the FY 2023
relative weights before applying the 10percent cap, and the FY 2022 pre-reclassified
wage data, and applied the estimated FY
2023 hospital readmissions payment
adjustments and estimated FY 2023 hospital
VBP payment adjustments applied
previously.
Because this payment simulation uses the
FY 2023 relative weights (before application
of the 10-percent cap), consistent with our
policy in section IV.I. of the preamble to this
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
final rule, we applied the adjustor for certain
cases that group to MS–DRG 018 in our
simulation of these payments. We note that
because the simulations of payments for all
of the budget neutrality factors discussed in
this section also use the FY 2023 relative
weights, we are applying the adjustor for
certain MS–DRG 18 cases in all simulations
of payments for the budget neutrality factors
discussed later in this section. We refer the
reader to section IV.I. of the preamble of this
final rule for a complete discussion on the
adjustor for certain cases that group to MS–
DRG 018 and to section II.E.2.b. of the
preamble of this final rule, for a complete
discussion of the adjustment to the FY 2023
relative weights to account for certain cases
that group to MS–DRG 018.
Based on this comparison, we computed a
budget neutrality adjustment factor and
applied this factor to the standardized
amount. As discussed in section IV. of this
Addendum, as we proposed, we are applying
the MS–DRG reclassification and
recalibration budget neutrality factor to the
hospital-specific rates that are effective for
cost reporting periods beginning on or after
October 1, 2022. Please see the table later in
this section setting forth each of the FY 2023
budget neutrality factors.
b. Budget Neutrality Adjustment for
Reclassification and Recalibration of MS–
DRG Relative Weights With Cap
As discussed in section II.E.2.d of this final
rule, as proposed we are establishing a
permanent 10-percent cap on the reduction
in a MS–DRG’s relative weight in a given
fiscal year, beginning in FY 2023. As
discussed in section II.E.2.d of this final rule,
and consistent with our current methodology
for implementing budget neutrality for MS–
DRG reclassification and recalibration of the
relative weights under section
1886(d)(4)(C)(iii) of the Act, we are applying
a budget neutrality adjustment to the
standardized amount for all hospitals so that
this 10-percent cap on relative weight
reductions does not increase estimated
aggregate Medicare payments beyond the
payments that would be made had we never
applied this cap. We refer the reader to
section II.E.2.d of this final rule for further
discussion on our permanent 10-percent cap
on the reduction in a MS–DRG’s relative
weight in a given fiscal year, including the
budget neutrality adjustment to the
standardized amount.
To calculate this budget neutrality
adjustment factor for FY 2023, we used FY
2021 discharge data to simulate payments
and compared the following:
• Aggregate payments using the FY 2022
labor-related share percentages, the FY 2023
relative weights before applying the 10percent cap, and the FY 2022 pre-reclassified
wage data, and applied the estimated FY
2023 hospital readmissions payment
adjustments and estimated FY 2023 hospital
VBP payment adjustments.
• Aggregate payments using the FY 2022
labor-related share percentages, the FY 2023
relative weights with the 10-percent cap, and
the FY 2022 pre-reclassified wage data, and
applied the estimated FY 2023 hospital
readmissions payment adjustments and
PO 00000
Frm 00637
Fmt 4701
Sfmt 4700
49415
estimated FY 2023 hospital VBP payment
adjustments applied previously.
Because this payment simulation uses the
FY 2023 relative weights, consistent with our
policy in section IV.I. of the preamble to this
final rule, we applied the adjustor for certain
cases that group to MS–DRG 018 in our
simulation of these payments. We note that
because the simulations of payments for all
of the budget neutrality factors discussed in
this section also use the FY 2023 relative
weights, we are applying the adjustor for
certain MS–DRG 18 cases in all simulations
of payments for the budget neutrality factors
discussed later in this section. We refer the
reader to section IV.I. of the preamble of this
final rule for a complete discussion on the
adjustor for certain cases that group to MS–
DRG 018 and to section II.E.2.b. of the
preamble of this final rule, for a complete
discussion of the adjustment to the FY 2023
relative weights to account for certain cases
that group to MS–DRG 018.
In addition, we applied the MS–DRG
reclassification and recalibration budget
neutrality adjustment factor before the cap
(derived in the first step) to the payment rates
that were used to simulate payments for this
comparison of aggregate payments from FY
2022 to FY 2023. Based on this comparison,
we computed a budget neutrality adjustment
factor and applied this factor to the
standardized amount. As discussed in
section IV. of this Addendum, we are
applying this budget neutrality factor to the
hospital-specific rates that are effective for
cost reporting periods beginning on or after
October 1, 2022. Please see the table later in
this section setting forth each of the FY 2023
budget neutrality factors.
c. Updated Wage Index—Budget Neutrality
Adjustment
Section 1886(d)(3)(E)(i) of the Act requires
us to update the hospital wage index on an
annual basis beginning October 1, 1993. This
provision also requires us to make any
updates or adjustments to the wage index in
a manner that ensures that aggregate
payments to hospitals are not affected by the
change in the wage index. Section
1886(d)(3)(E)(i) of the Act requires that we
implement the wage index adjustment in a
budget neutral manner. However, section
1886(d)(3)(E)(ii) of the Act sets the laborrelated share at 62 percent for hospitals with
a wage index less than or equal to 1.0000,
and section 1886(d)(3)(E)(i) of the Act
provides that the Secretary shall calculate the
budget neutrality adjustment for the
adjustments or updates made under that
provision as if section 1886(d)(3)(E)(ii) of the
Act had not been enacted. In other words,
this section of the statute requires that we
implement the updates to the wage index in
a budget neutral manner, but that our budget
neutrality adjustment should not take into
account the requirement that we set the
labor-related share for hospitals with wage
indexes less than or equal to 1.0000 at the
more advantageous level of 62 percent.
Therefore, for purposes of this budget
neutrality adjustment, section 1886(d)(3)(E)(i)
of the Act prohibits us from taking into
account the fact that hospitals with a wage
index less than or equal to 1.0000 are paid
using a labor-related share of 62 percent.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49416
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Consistent with current policy, for FY 2023,
as we proposed, we are adjusting 100 percent
of the wage index factor for occupational
mix. We describe the occupational mix
adjustment in section III.E. of the preamble
of this final rule.
To compute a budget neutrality adjustment
factor for wage index and labor-related share
percentage changes, we used FY 2021
discharge data to simulate payments and
compared the following:
• Aggregate payments using the FY 2023
relative weights and the FY 2022 prereclassified wage indexes, applied the FY
2022 labor-related share of 67.6 percent to all
hospitals (regardless of whether the
hospital’s wage index was above or below
1.0000), and applied the FY 2023 hospital
readmissions payment adjustment and the
estimated FY 2023 hospital VBP payment
adjustment.
• Aggregate payments using the FY 2023
relative weights and the FY 2023 prereclassified wage indexes, applied the laborrelated share for FY 2023 of 67.6 percent to
all hospitals (regardless of whether the
hospital’s wage index was above or below
1.0000), and applied the same FY 2023
hospital readmissions payment adjustments
and estimated FY 2023 hospital VBP
payment adjustments applied previously.
In addition, we applied the MS–DRG
reclassification and recalibration budget
neutrality adjustment factor before the cap
(derived in the first step) and the 10-percent
cap on relative weight reductions adjustment
factor (derived from the second step) to the
payment rates that were used to simulate
payments for this comparison of aggregate
payments from FY 2022 to FY 2023. Based
on this comparison, we computed a budget
neutrality adjustment factor and applied this
factor to the standardized amount for changes
to the wage index. Please see the table later
in this section for a summary of the FY 2023
budget neutrality factors.
d. Reclassified Hospitals—Budget Neutrality
Adjustment
Section 1886(d)(8)(B) of the Act provides
that certain rural hospitals are deemed urban.
In addition, section 1886(d)(10) of the Act
provides for the reclassification of hospitals
based on determinations by the MGCRB.
Under section 1886(d)(10) of the Act, a
hospital may be reclassified for purposes of
the wage index.
Under section 1886(d)(8)(D) of the Act, the
Secretary is required to adjust the
standardized amount to ensure that aggregate
payments under the IPPS after
implementation of the provisions of sections
1886(d)(8)(B) and (C) and 1886(d)(10) of the
Act are equal to the aggregate prospective
payments that would have been made absent
these provisions.
As discussed in section III.G.1. of the
preamble of this final rule, for FY 2023 and
subsequent years, we are finalizing a policy
to include the wage data of hospitals that
have reclassified from urban to rural under
section 1886(d)(8)(E) of the Act (as
implemented in the regulations at § 412.103)
and have no additional form of
reclassification (MGCRB or Lugar) in the
calculation of the rural floor, and to include
the wage data of such hospitals in the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
calculation of ‘‘the wage index for rural areas
in the State in which the county is located’’
as referred to in section 1886(d)(8)(C)(iii) of
the Act. We refer the reader to the FY 2015
IPPS final rule (79 FR 50371 and 50372) for
a complete discussion regarding the
requirement of section 1886(d)(8)(C)(iii) of
the Act. We further note that the wage index
adjustments provided for under section
1886(d)(13) of the Act are not budget neutral.
Section 1886(d)(13)(H) of the Act provides
that any increase in a wage index under
section 1886(d)(13) of the Act shall not be
taken into account in applying any budget
neutrality adjustment with respect to such
index under section 1886(d)(8)(D) of the Act.
To calculate the proposed budget neutrality
adjustment factor for FY 2023, we used FY
2021 discharge data to simulate payments
and compared the following:
• Aggregate payments using the FY 2023
labor-related share percentage, the FY 2023
relative weights, and the FY 2023 wage data
prior to any reclassifications under sections
1886(d)(8)(B) and (C) and 1886(d)(10) of the
Act, and applied the estimated FY 2023
hospital readmissions payment adjustments
and the estimated FY 2023 hospital VBP
payment adjustments.
• Aggregate payments using the FY 2023
labor-related share percentage, the FY 2023
relative weights, and the FY 2023 wage data
after such reclassifications, and applied the
same estimated FY 2023 hospital
readmissions payment adjustments and the
estimated FY 2023 hospital VBP payment
adjustments applied previously.
We note that the reclassifications applied
under the second simulation and comparison
are those listed in Table 2 associated with
this final rule, which is available via the
internet on the CMS website. This table
reflects reclassification crosswalks for FY
2023, and applies the policies explained in
section III. of the preamble of this final rule.
Based on this comparison, we computed a
budget neutrality adjustment factor and
applied this factor to the standardized
amount to ensure that the effects of these
provisions are budget neutral, consistent
with the statute. Please see the table later in
this section for a summary of the FY 2023
budget neutrality factors.
The FY 2023 budget neutrality adjustment
factor was applied to the standardized
amount after removing the effects of the FY
2022 budget neutrality adjustment factor. We
note that the FY 2023 budget neutrality
adjustment reflects FY 2023 wage index
reclassifications approved by the MGCRB or
the Administrator at the time of development
of this final rule.
e. Rural Floor Budget Neutrality Adjustment
Under § 412.64(e)(4), we make an
adjustment to the wage index to ensure that
aggregate payments after implementation of
the rural floor under section 4410 of the BBA
(Pub. L. 105–33) is equal to the aggregate
prospective payments that would have been
made in the absence of this provision.
Consistent with section 3141 of the
Affordable Care Act and as discussed in
section III.G. of the preamble of this final rule
and codified at § 412.64(e)(4)(ii), the budget
neutrality adjustment for the rural floor is a
national adjustment to the wage index.
PO 00000
Frm 00638
Fmt 4701
Sfmt 4700
Similar to our calculation in the FY 2015
IPPS/LTCH PPS final rule (79 FR 50369
through 50370), for FY 2023, as we proposed,
we calculated a national rural Puerto Rico
wage index. Because there are no rural Puerto
Rico hospitals with established wage data,
our calculation of the FY 2023 rural Puerto
Rico wage index is based on the policy
adopted in the FY 2008 IPPS final rule with
comment period (72 FR 47323). That is, we
use the unweighted average of the wage
indexes from all CBSAs (urban areas) that are
contiguous (share a border with) to the rural
counties to compute the rural floor (72 FR
47323; 76 FR 51594). Under the OMB labor
market area delineations, except for Arecibo,
Puerto Rico (CBSA 11640), all other Puerto
Rico urban areas are contiguous to a rural
area. Therefore, based on our existing policy,
the FY 2023 rural Puerto Rico wage index is
calculated based on the average of the FY
2023 wage indexes for the following urban
areas: Aguadilla-Isabela, PR (CBSA 10380);
Guayama, PR (CBSA 25020); Mayaguez, PR
(CBSA 32420); Ponce, PR (CBSA 38660); San
German, PR (CBSA 41900); and San JuanCarolina-Caguas, PR (CBSA 41980).
We also note, as discussed in section
III.G.1. of the preamble of this final rule,
based on the district court’s decision in
Citrus and the comments we received, we are
not finalizing our rural floor wage index
policy as proposed, which would have
excluded § 412.103 hospitals from the
calculation of the rural floor and from the
calculation of ‘‘the wage index for rural areas
in the State in which the county is located’’
as referred to in section 1886(d)(8)(C)(iii) of
the Act. Rather, we are finalizing a policy
that calculates the rural floor as it was
calculated before FY 2020. For FY 2023 and
subsequent years, we are finalizing a policy
to include the wage data of hospitals that
have reclassified from urban to rural under
section 1886(d)(8)(E) of the Act (as
implemented in the regulations at § 412.103)
and have no additional form of
reclassification (MGCRB or Lugar) in the
calculation of the rural floor, and to include
the wage data of such hospitals in the
calculation of ‘‘the wage index for rural areas
in the State in which the county is located’’
as referred to in section 1886(d)(8)(C)(iii) of
the Act.
To calculate the national rural floor budget
neutrality adjustment factor, we used FY
2021 discharge data to simulate payments,
and the post-reclassified national wage
indexes and compared the following:
• National simulated payments without
the rural floor.
• National simulated payments with the
rural floor.
Based on this comparison, we determined
a national rural floor budget neutrality
adjustment factor. The national adjustment
was applied to the national wage indexes to
produce rural floor budget neutral wage
indexes. Please see the table later in this
section for a summary of the FY 2023 budget
neutrality factors.
As further discussed in section III.G.2. of
the preamble of this final rule, we note that
section 9831 of the American Rescue Plan
Act of 2021 (Pub. L. 117–2), enacted on
March 11, 2021 amended section
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
1886(d)(3)(E)(i) of the Act (42 U.S.C.
1395ww(d)(3)(E)(i)) and added section
1886(d)(3)(E)(iv) of the Act to establish a
minimum area wage index (or imputed floor)
for hospitals in all-urban States for
discharges occurring on or after October 1,
2021. Unlike the imputed floor that was in
effect from FY 2005 through FY 2018, section
1886(d)(3)(E)(iv)(III) of the Act provides that
the imputed floor wage index shall not be
applied in a budget neutral manner.
Specifically, section 9831(b) of Public Law
117–2 amends section 1886(d)(3)(E)(i) of the
Act to exclude the imputed floor from the
budget neutrality requirement under section
1886(d)(3)(E)(i) of the Act. In the past, we
budget neutralized the estimated increase in
payments each year resulting from the
imputed floor that was in effect from FY 2005
through FY 2018. For FY 2022 and
subsequent years, in applying the imputed
floor required under section 1886(d)(3)(E)(iv)
of the Act, we are applying the imputed floor
after the application of the rural floor and
applying no reductions to the standardized
amount or to the wage index to fund the
increase in payments to hospitals in all-urban
States resulting from the application of the
imputed floor. We refer the reader to section
III.G.2. of the preamble of this final rule for
a complete discussion regarding the imputed
floor.
f. Continuation of the Low Wage Index
Hospital Policy—Budget Neutrality
Adjustment
As discussed in section III.G.3. of the
preamble of this final rule, we are continuing
for FY 2023 the wage index policy finalized
in the FY 2020 IPPS/LTCH PPS final rule to
address wage index disparities by increasing
the wage index values for hospitals with a
wage index value below the 25th percentile
wage index value across all hospitals (the
low wage index hospital policy). As
discussed in section III.G.3. of this final rule,
consistent with our current methodology for
implementing wage index budget neutrality
under section 1886(d)(3)(E) of the Act, we are
making a budget neutrality adjustment to the
national standardized amount for all
hospitals so that the increase in the wage
index for hospitals with a wage index below
the 25th percentile wage index, is
implemented in a budget neutral manner.
To calculate this budget neutrality
adjustment factor for FY 2023, we used FY
2021 discharge data to simulate payments
and compared the following:
• Aggregate payments using the FY 2023
labor-related share percentage, the FY 2023
relative weights, and the FY 2023 wage index
for each hospital before adjusting the wage
indexes under the low wage index hospital
policy, and applied the estimated FY 2023
hospital readmissions payment adjustments
and the estimated FY 2023 hospital VBP
payment adjustments, and the operating
outlier reconciliation adjusted outlier
percentage discussed later in this section.
• Aggregate payments using the FY 2023
labor-related share percentage, the FY 2023
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
relative weights, and the FY 2023 wage index
for each hospital after adjusting the wage
indexes under the low wage index hospital
policy, and applied the same estimated FY
2023 hospital readmissions payment
adjustments and the estimated FY 2023
hospital VBP payment adjustments applied
previously, and the operating outlier
reconciliation adjusted outlier percentage
discussed later in this section.
This FY 2023 budget neutrality adjustment
factor was applied to the standardized
amount.
g. Permanent Cap Policy for the Wage
Index—Budget Neutrality Adjustment
As noted previously, in section III.N. of the
preamble of this final rule, for FY 2023 and
subsequent years, we are finalizing as
proposed to apply a 5-percent cap on any
decrease to a hospital’s wage index from its
wage index in the prior FY, regardless of the
circumstances causing the decline. That is, a
hospital’s wage index for FY 2023 would not
be less than 95 percent of its final wage index
for FY 2022, and that for subsequent years,
a hospital’s wage index would not be less
than 95 percent of its final wage index for the
prior FY. In section III.N.2. of this final rule,
we are also applying this wage index cap
policy in a budget neutral manner through an
adjustment to the standardized amount to
ensure that estimated aggregate payments
under our wage index cap policy for
hospitals that will have a decrease in their
wage indexes for the upcoming fiscal year of
more than 5 percent will equal what
estimated aggregate payments would have
been without the wage index cap policy. We
refer readers to sections III.N.1 and III.N.2 of
the preamble of this final rule for a complete
discussion regarding this policy.
To calculate a wage index cap budget
neutrality adjustment factor for FY 2023, we
used FY 2021 discharge data to simulate
payments and compared the following:
• Aggregate payments without the 5percent cap using the FY 2023 labor-related
share percentages, the FY 2023 relative
weights, the FY 2023 wage index for each
hospital after adjusting the wage indexes
under the low wage index hospital policy
with the associated budget neutrality
adjustment to the standardized amount, and
applied the estimated FY 2023 hospital
readmissions payment adjustments and the
estimated FY 2023 hospital VBP payment
adjustments, and the operating outlier
reconciliation adjusted outlier percentage
discussed later in this section.
• Aggregate payments with the 5-percent
cap using the FY 2023 labor-related share
percentages, the FY 2023 relative weights,
the FY 2023 wage index for each hospital
after adjusting the wage indexes under the
low wage index hospital policy with the
associated budget neutrality adjustment to
the standardized amount, and applied the
same estimated FY 2023 hospital
readmissions payment adjustments and the
estimated FY 2023 hospital VBP payment
PO 00000
Frm 00639
Fmt 4701
Sfmt 4700
49417
adjustments applied previously, and the
operating outlier reconciliation adjusted
outlier percentage discussed later in this
section.
We note, Table 2 associated with this final
rule contains the wage index by provider
before and after applying the low wage index
hospital policy and the cap.
h. Rural Community Hospital Demonstration
Program Adjustment
In section V.K. of the preamble of this final
rule, we discuss the Rural Community
Hospital (RCH) Demonstration program,
which was originally authorized for a 5-year
period by section 410A of the Medicare
Prescription Drug, Improvement, and
Modernization Act of 2003 (MMA) (Pub. L.
108–173) and extended for another 5-year
period by sections 3123 and 10313 of the
Affordable Care Act (Pub. L. 111–148).
Subsequently, section 15003 of the 21st
Century Cures Act (Pub. L. 114–255), enacted
December 13, 2016, amended section 410A of
Pub. L. 108–173 to require a 10-year
extension period (in place of the 5-year
extension required by the Affordable Care
Act, as further discussed later in this
section). Finally, Division CC, section 128(a)
of the Consolidated Appropriations Act of
2021 (Pub. L. 116–260) again amended
section 410A to require a 15-year extension
period in place of the 10-year period. We
make an adjustment to the standardized
amount to ensure the effects of the RCH
Demonstration program are budget neutral as
required under section 410A(c)(2) of Public
Law 108–173. We refer readers to section
V.K. of the preamble of this final rule for
complete details regarding the Rural
Community Hospital Demonstration.
With regard to budget neutrality, as
mentioned earlier, we make an adjustment to
the standardized amount to ensure the effects
of the Rural Community Hospital
Demonstration are budget neutral, as
required under section 410A(c)(2) of Public
Law 108–173. For FY 2023, based on the
latest data for this final rule, the total amount
that we will apply to make an adjustment to
the standardized amounts to ensure the
effects of the Rural Community Hospital
Demonstration program are budget neutral is
$108,439,824. Accordingly, using the most
recent data available to account for the
estimated costs of the demonstration
program, for FY 2023, we computed a factor
for the Rural Community Hospital
Demonstration budget neutrality adjustment
that will be applied to the standardized
amount. Please see the table later in this
section for a summary of the FY 2023 budget
neutrality factors. We refer readers to section
V.K. of the preamble of this final rule for
complete details regarding the calculation of
the amount we will apply to make an
adjustment to the standardized amounts.
The following table is a summary of the FY
2023 budget neutrality factors, as discussed
in the previous sections.
E:\FR\FM\10AUR2.SGM
10AUR2
49418
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
1.000509
0.999764
1.000968
0.984399
0.991909
0.998146
0.999689
0.998935
As discussed in section II.A. of this final
rule, we are using the FY 2021 data for FY
2023 ratesetting, with certain modifications
to our relative weight and outlier
methodologies. As discussed elsewhere in
this final rule and in this Addendum, we
solicited comments on, as an alternative to
our proposed approach, the use of the FY
2021 MedPAR claims for purposes of FY
2023 ratesetting without these proposed
modifications to our usual methodologies. In
order to facilitate comments on this
alternative approach, we made available
budget neutrality and other ratesetting
adjustments calculated under this alternative
approach, which can be found on the CMS
website at https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/index. We refer the
reader to section I.O. of Appendix A of this
final rule for further discussion of the files
that we made available with regard to our
alternative approach.
i. Adjustment for FY 2023 Required Under
Section 414 of Public Law 114–10 (MACRA)
As stated in the FY 2017 IPPS/LTCH PPS
final rule (81 FR 56785), once the
recoupment required under section 631 of
the ATRA was complete, we had anticipated
making a single positive adjustment in FY
2018 to offset the reductions required to
recoup the $11 billion under section 631 of
the ATRA. However, section 414 of the
MACRA (which was enacted on April 16,
2015) replaced the single positive adjustment
we intended to make in FY 2018 with a 0.5
percent positive adjustment for each of FYs
2018 through 2023. (As noted in the FY 2018
IPPS/LTCH PPS proposed and final rules,
section 15005 of the 21st Century Cures Act
(Pub. L. 114–255), which was enacted
December 13, 2016, reduced the adjustment
for FY 2018 from 0.5 percentage points to
0.4588 percentage points.) Therefore, for FY
2023, we are implementing the required +0.5
percent adjustment to the standardized
amount. This is a permanent adjustment to
the payment rates.
j. Outlier Payments
Section 1886(d)(5)(A) of the Act provides
for payments in addition to the basic
prospective payments for ‘‘outlier’’ cases
involving extraordinarily high costs. To
qualify for outlier payments, a case must
have costs greater than the sum of the
prospective payment rate for the MS–DRG,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
any IME and DSH payments, uncompensated
care payments, any new technology add-on
payments, and the ‘‘outlier threshold’’ or
‘‘fixed-loss’’ amount (a dollar amount by
which the costs of a case must exceed
payments in order to qualify for an outlier
payment). We refer to the sum of the
prospective payment rate for the MS–DRG,
any IME and DSH payments, uncompensated
care payments, any new technology add-on
payments, and the outlier threshold as the
outlier ‘‘fixed-loss cost threshold.’’ (As
discussed later in this section, we are also
including the supplemental payment for
eligible IHS/Tribal hospitals and Puerto Rico
hospitals in the computation of the outlier
fixed-loss cost threshold beginning in FY
2023.) To determine whether the costs of a
case exceed the fixed-loss cost threshold, a
hospital’s CCR is applied to the total covered
charges for the case to convert the charges to
estimated costs. Payments for eligible cases
are then made based on a marginal cost
factor, which is a percentage of the estimated
costs above the fixed-loss cost threshold. The
marginal cost factor for FY 2023 is 80
percent, or 90 percent for burn MS–DRGs
927, 928, 929, 933, 934 and 935. We have
used a marginal cost factor of 90 percent
since FY 1989 (54 FR 36479 through 36480)
for designated burn DRGs as well as a
marginal cost factor of 80 percent for all other
DRGs since FY 1995 (59 FR 45367).
In accordance with section
1886(d)(5)(A)(iv) of the Act, outlier payments
for any year are projected to be not less than
5 percent nor more than 6 percent of total
operating DRG payments (which does not
include IME and DSH payments) plus outlier
payments. When setting the outlier
threshold, we compute the percent target by
dividing the total operating outlier payments
by the total operating DRG payments plus
outlier payments. As discussed in the next
section, for FY 2023, we are incorporating an
estimate of outlier reconciliation when
setting the outlier threshold. We do not
include any other payments such as IME and
DSH within the outlier target amount.
Therefore, it is not necessary to include
Medicare Advantage IME payments in the
outlier threshold calculation. Section
1886(d)(3)(B) of the Act requires the
Secretary to reduce the average standardized
amount by a factor to account for the
estimated proportion of total DRG payments
made to outlier cases. More information on
PO 00000
Frm 00640
Fmt 4701
Sfmt 4700
outlier payments may be found on the CMS
website at https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/outlier.html.
(1) Methodology To Incorporate an Estimate
of Outlier Reconciliation in the FY 2023
Outlier Fixed-Loss Cost Threshold
The regulations in 42 CFR 412.84(i)(4) state
that any outlier reconciliation at cost report
settlement will be based on operating and
capital cost-to-charge ratios (CCRs) calculated
based on a ratio of costs to charges computed
from the relevant cost report and charge data
determined at the time the cost report
coinciding with the discharge is settled. We
have instructed MACs to identify for CMS
any instances where: (1) A hospital’s actual
CCR for the cost reporting period fluctuates
plus or minus 10 percentage points compared
to the interim CCR used to calculate outlier
payments when a bill is processed; and (2)
the total outlier payments for the hospital
exceeded $500,000.00 for that cost reporting
period. If we determine that a hospital’s
outlier payments should be reconciled, we
reconcile both operating and capital outlier
payments. We refer readers to section
20.1.2.5 of Chapter 3 of the Medicare Claims
Processing Manual (available on the CMS
website at https://www.cms.gov/Regulationsand-Guidance/Guidance/Manuals/
Downloads/clm104c03.pdf) for complete
details regarding outlier reconciliation. The
regulation at § 412.84(m) further states that at
the time of any outlier reconciliation under
§ 412.84(i)(4), outlier payments may be
adjusted to account for the time value of any
underpayments or overpayments. Section
20.1.2.6 of Chapter 3 of the Medicare Claims
Processing Manual contains instructions on
how to assess the time value of money for
reconciled outlier amounts.
If the operating CCR of a hospital subject
to outlier reconciliation is lower at cost
report settlement compared to the operating
CCR used for payment, the hospital would
owe CMS money because it received an
outlier overpayment at the time of claim
payment. Conversely, if the operating CCR
increases at cost report settlement compared
to the operating CCR used for payment, CMS
would owe the hospital money because the
hospital outlier payments were underpaid.
In the FY 2020 IPPS/LTCH PPS final rule
(84 FR 42623 through 42635), we finalized a
methodology to incorporate outlier
reconciliation in the FY 2020 outlier fixed
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.214
khammond on DSKJM1Z7X2PROD with RULES2
*The rural floor budget neutrality factor is applied to the national wage indexes while the rest of the budget
neutrality adjustments are applied to the standardized amounts.
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
loss cost threshold. As discussed in the FY
2020 IPPS/LTCH PPS proposed rule (84 FR
19592), we stated that rather than trying to
predict which claims and/or hospitals may
be subject to outlier reconciliation, we
believe a methodology that incorporates an
estimate of outlier reconciliation dollars
based on actual outlier reconciliation
amounts reported in historical cost reports
would be a more feasible approach and
provide a better estimate and predictor of
outlier reconciliation for the upcoming fiscal
year. We also stated that we believe the
methodology addresses stakeholder’s
concerns on the impact of outlier
reconciliation on the modeling of the outlier
threshold. For a detailed discussion of
additional background regarding outlier
reconciliation, we refer the reader to the FY
2020 IPPS/LTCH PPS final rule.
(a) Incorporating a Projection of Outlier
Payment Reconciliations for the FY 2023
Outlier Threshold Calculation
Based on the methodology finalized in the
FY 2020 IPPS/LTCH PPS final rule (84 FR
42623 through 42625), for FY 2023, as we
proposed, we are continuing to incorporate
outlier reconciliation in the FY 2023 outlier
fixed loss cost threshold.
As discussed in the FY 2020 IPPS/LTCH
PPS final rule, for FY 2020, we used the
historical outlier reconciliation amounts from
the FY 2014 cost reports (cost reports with
a begin date on or after October 1, 2013, and
on or before September 30, 2014), which we
believed would provide the most recent and
complete available data to project the
estimate of outlier reconciliation. We refer
the reader to the FY 2020 IPPS/LTCH PPS
final rule (84 FR 42623 through 42625) for a
discussion on the use of the FY 2014 cost
report data for purposes of projecting outlier
payment reconciliations for the FY 2020
outlier threshold calculation. For FYs 2021
and 2022, we applied the same methodology
finalized in FY 2020, using the historical
outlier reconciliation amounts from the FY
2015 cost reports (cost reports with a begin
date on or after October 1, 2014, and on or
before September 30, 2015) and the FY 2016
cost reports (cost reports with a begin date on
or after October 1, 2015, and on or before
September 30, 2016), respectively.
Similar to the FY 2022 methodology, in
this final rule, we are determining a
projection of outlier payment reconciliations
for the FY 2023 outlier threshold calculation,
by advancing the methodology by 1 year.
Specifically, we are using FY 2017 cost
reports (cost reports with a begin date on or
after October 1, 2016, and on or before
September 30, 2017).
For FY 2023, as we proposed, we are using
the same methodology from FY 2020 to
incorporate a projection of operating outlier
payment reconciliations for the FY 2023
outlier threshold calculation. The following
steps are the same as those finalized in the
FY 2020 final rule but with updated data for
FY 2023:
Step 1.—Use the Federal FY 2017 cost
reports for hospitals paid under the IPPS
from the most recent publicly available
quarterly HCRIS extract available at the time
of development of the proposed and final
rules, and exclude sole community hospitals
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
(SCHs) that were paid under their hospitalspecific rate (that is, if Worksheet E, Part A,
Line 48 is greater than Line 47). We note that
when there are multiple columns available
for the lines of the cost report described in
the following steps and the provider was
paid under the IPPS for that period(s) of the
cost report, then we believe it is appropriate
to use multiple columns to fully represent
the relevant IPPS payment amounts,
consistent with our methodology for the FY
2020 final rule.
Step 2.—Calculate the aggregate amount of
historical total of operating outlier
reconciliation dollars (Worksheet E, Part A,
Line 2.01) using the Federal FY 2017 cost
reports from Step 1.
Step 3.—Calculate the aggregate amount of
total Federal operating payments using the
Federal FY 2017 cost reports from Step 1.
The total Federal operating payments consist
of the Federal payments (Worksheet E, Part
A, Line 1.01 and Line 1.02, plus Line 1.03
and Line 1.04), outlier payments (Worksheet
E, Part A, Line 2 and Line 2.02), and the
outlier reconciliation payments (Worksheet
E, Part A, Line 2.01). We note that a negative
amount on Worksheet E, Part A, Line 2.01 for
outlier reconciliation indicates an amount
that was owed by the hospital, and a positive
amount indicates this amount was paid to the
hospital.
Step 4.—Divide the amount from Step 2 by
the amount from Step 3 and multiply the
resulting amount by 100 to produce the
percentage of total operating outlier
reconciliation dollars to total Federal
operating payments for FY 2017. This
percentage amount would be used to adjust
the outlier target for FY 2023 as described in
Step 5.
Step 5.—Because the outlier reconciliation
dollars are only available on the cost reports,
and not in the Medicare claims data in the
MedPAR file used to model the outlier
threshold, we are targeting 5.1 percent minus
the percentage determined in Step 4 in
determining the outlier threshold. Using the
FY 2017 cost reports based on the December
2021 HCRIS extract, because the aggregate
outlier reconciliation dollars from Step 2 are
negative, we are targeting an amount higher
than 5.1 percent for outlier payments for FY
2023 under our methodology.
In the FY 2023 proposed rule, we used the
December 2021 HCRIS extract of the cost
report data to calculate the proposed
percentage adjustment for outlier
reconciliation. For the FY 2023 final rule, we
proposed to use the latest quarterly HCRIS
extract that is publicly available at the time
of the development of that rule which, for FY
2023, would be the March 2022 extract.
Similar to the FY 2022 final rule, we stated
that we may also consider the use of more
recent data that may become available for
purposes of projecting the estimate of
operating outlier reconciliation used in the
calculation of the final FY 2023 outlier
threshold.
In the FY 2023 proposed rule, based on the
December 2021 HCRIS, 10 hospitals had an
outlier reconciliation amount recorded on
Worksheet E, Part A, Line 2.01 for total
operating outlier reconciliation dollars of
negative $11,939,505 (Step 2). The total
PO 00000
Frm 00641
Fmt 4701
Sfmt 4700
49419
Federal operating payments based on the
December 2021 HCRIS was $88,388,722,611
(Step 3). The ratio (Step 4) is a negative
0.013508 percent, which, when rounded to
the second digit, is ¥0.01 percent. Therefore,
for FY 2023, we proposed to incorporate a
projection of outlier reconciliation dollars by
targeting an outlier threshold at 5.11 percent
[5.1 percent¥(¥0.01 percent)].
When the percentage of operating outlier
reconciliation dollars to total Federal
operating payments rounds to a negative
value (that is, when the aggregate amount of
outlier reconciliation as a percent of total
operating payments rounds to a negative
percent), the effect is a decrease to the outlier
threshold compared to an outlier threshold
that is calculated without including this
estimate of operating outlier reconciliation
dollars. In section II.A.4.i.(2). of the
Addendum to the proposed rule, we
provided the proposed FY 2023 outlier
threshold as calculated for the proposed rule
both with and without including this
percentage estimate of operating outlier
reconciliation.
As explained in the FY 2020 IPPS/LTCH
PPS final rule, we finalized the continued
use a 5.1 percent target (or an outlier offset
factor of 0.949) in calculating the outlier
offset to the standardized amount. In the
past, the outlier offset was six decimals
because we targeted and set the threshold at
5.1 percent by adjusting the standardized
amount by the outlier offset until operating
outlier payments divided by total operating
Federal payments plus operating outlier
payments equaled approximately 5.1 percent
(this approximation resulted in an offset
beyond 3 decimals). However, under our
methodology, we believe a 3-decimal offset of
0.949 reflecting 5.1 percent is appropriate
rather than the unrounded 6-decimal offset
that we have calculated for prior fiscal years.
Specifically, as discussed in section II.A.5. of
this Addendum, we proposed to determine
an outlier adjustment by applying a factor to
the standardized amount that accounts for
the projected proportion of total estimated
FY 2023 operating Federal payments paid as
outliers. Our proposed modification to the
outlier threshold methodology is designed to
adjust the total estimated outlier payments
for FY 2023 by incorporating the projection
of negative outlier reconciliation. That is,
under this proposal, total estimated outlier
payments for FY 2023 would be the sum of
the estimated FY 2023 outlier payments
based on the claims data from the outlier
model and the estimated FY 2023 total
operating outlier reconciliation dollars. We
stated that we believe the proposed
methodology would more accurately estimate
the outlier adjustment to the standardized
amount by increasing the accuracy of the
calculation of the total estimated FY 2023
operating Federal payments paid as outliers.
In other words, the net effect of our proposal
to incorporate a projection for outlier
reconciliation dollars into the threshold
methodology would be that FY 2023 outlier
payments (which included the proposed
estimated recoupment percentage for FY
2023 of 0.01 percent) would be 5.1 percent
of total operating Federal payments plus total
outlier payments. Therefore, the proposed
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49420
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
operating outlier offset to the standardized
amount is 0.949 (1¥0.051).
We invited public comment on our
proposed methodology for projecting an
estimate of outlier reconciliation and
incorporating that estimate into the modeling
for the fixed-loss cost outlier threshold for FY
2023.
We did not receive any comments on the
proposed methodology, and for the reasons
discussed in the proposed rule and in this
final rule, we are finalizing the methodology
described previously for incorporating the
outlier reconciliation in the outlier threshold
calculation. Therefore, for this final rule we
used the same steps described previously and
in the proposed rule to incorporate a
projection of operating outlier payment
reconciliations for the calculation of the FY
2023 outlier threshold calculation. The
March 2022 HCRIS contained data for 15
hospitals. As stated previously, while we
proposed to use the March 2022 HCRIS
extract to calculate the reconciliation
adjustment for this FY 2023 IPPS final rule,
we also stated that similar to the FY 2022
final rule, we may also consider the use of
more recent data that may become available
for purposes of projecting the estimate of
operating outlier reconciliation used in the
calculation of the final FY 2023 outlier
threshold. Data for 2 additional outlier
reconciliations were made available to CMS
outside of the March 2022 HCRIS update.
Similar to our discussion of the estimated
operating outlier reconciliation for FY 2021
in the FY 2021 IPPS/LTCH PPS final rule (85
FR 59036) and FY 2022 in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45535), we
believe supplementing with 2 hospitals’
outlier reconciliation data will lend
additional accuracy to project the estimate of
operating outlier reconciliation used in the
calculation of the outlier threshold.
Therefore, in order to use the most complete
data for FY 2017 cost reports, we are using
the March 2022 HCRIS extract, supplemented
by these 2 additional hospitals’ data for this
FY 2023 IPPS final rule. Based on March
2022 HCRIS and supplemental data for 2
hospitals, a total of 17 hospitals had an
outlier reconciliation amount recorded on
Worksheet E, Part A, Line 2.01 for total
operating outlier reconciliation dollars of
negative $17,153,313 (Step 2). The total
Federal operating payments based on the
March 2022 HCRIS and supplemental data
for 2 hospitals is $ 88,414,357,653 (Step 3).
The ratio (Step 4) is a negative 0.019401
percent, which, when rounded to the second
digit, is negative 0.02 percent. Therefore, for
FY 2023, using the finalized methodology,
we incorporated a projection of operating
IPPS outlier reconciliation dollars by
targeting an outlier threshold at 5.12 percent
[5.1 percent¥(¥0.02 percent)]. As noted
previously, when the percentage of operating
outlier reconciliation dollars to total Federal
operating payments is negative (such is the
case when the aggregate amount of outlier
reconciliation is negative), the effect is a
decrease to the outlier threshold compared to
an outlier threshold that is calculated
without including this estimate of operating
outlier reconciliation dollars.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
(b) Reduction to the FY 2023 Capital
Standard Federal Rate by an Adjustment
Factor To Account for the Projected
Proportion of Capital IPPS Payments Paid as
Outliers
We establish an outlier threshold that is
applicable to both hospital inpatient
operating costs and hospital inpatient capital
related costs (58 FR 46348). Similar to the
calculation of the adjustment to the
standardized amount to account for the
projected proportion of operating payments
paid as outlier payments, as discussed in
greater detail in section III.A.2. of this
Addendum, we proposed to reduce the FY
2023 capital standard Federal rate by an
adjustment factor to account for the projected
proportion of capital IPPS payments paid as
outliers. The regulations in 42 CFR
412.84(i)(4) state that any outlier
reconciliation at cost report settlement would
be based on operating and capital CCRs
calculated based on a ratio of costs to charges
computed from the relevant cost report and
charge data determined at the time the cost
report coinciding with the discharge is
settled. As such, any reconciliation also
applies to capital outlier payments.
For FY 2023, we proposed to use the same
methodology from FY 2020 to adjust the FY
2023 capital standard Federal rate by an
adjustment factor to account for the projected
proportion of capital IPPS payments paid as
outliers. Similar to FY 2020, as part of our
proposal for FY 2023 to incorporate into the
outlier model the total outlier reconciliation
dollars from the most recent and most
complete fiscal year cost report data, we also
proposed to adjust our estimate of FY 2023
capital outlier payments to incorporate a
projection of capital outlier reconciliation
payments when determining the adjustment
factor to be applied to the capital standard
Federal rate to account for the projected
proportion of capital IPPS payments paid as
outliers (that is, the capital outlier payment
adjustment factor). To do so, we proposed to
use the following methodology, which
generally parallels the proposed methodology
to incorporate a projection of operating
outlier reconciliation payments for the FY
2023 outlier threshold calculation.
Step 1.—Use the Federal FY 2017 cost
reports for hospitals paid under the IPPS
from the most recent publicly available
quarterly HCRIS extract available at the time
of development of the proposed and final
rules, and exclude SCHs that were paid
under their hospital-specific rate (that is, if
Worksheet E, Part A, Line 48 is greater than
Line 47). We note that when there are
multiple columns available for the lines of
the cost report described in the following
steps and the provider was paid under the
IPPS for that period(s) of the cost report, then
we believe it is appropriate to use multiple
columns to fully represent the relevant IPPS
payment amounts, consistent with our
methodology for the FY 2020 final rule. We
used the December 2021 HCRIS extract for
the proposed rule and we stated that we
expect to use the March 2022 HCRIS extract
for the FY 2023 final rule. Similar to the FY
2022 final rule, we stated that we may also
consider the use of more recent data that may
become available for purposes of projecting
PO 00000
Frm 00642
Fmt 4701
Sfmt 4700
the estimate of capital outlier reconciliation
used in the calculation of the final FY 2023
adjustment to the FY 2023 capital standard
Federal rate.
Step 2.—Calculate the aggregate amount of
the historical total of capital outlier
reconciliation dollars (Worksheet E, Part A,
Line 93, Column 1) using the Federal FY
2017 cost reports from Step 1.
Step 3.—Calculate the aggregate amount of
total capital Federal payments using the
Federal FY 2017 cost reports from Step 1.
The total capital Federal payments consist of
the capital DRG payments, including capital
indirect medical education (IME) and capital
disproportionate share hospital (DSH)
payments (Worksheet E, Part A, Line 50,
Column 1) and the capital outlier
reconciliation payments (Worksheet E, Part
A, Line 93, Column 1). We note that a
negative amount on Worksheet E, Part A,
Line 93 for capital outlier reconciliation
indicates an amount that was owed by the
hospital, and a positive amount indicates this
amount was paid to the hospital.
Step 4.—Divide the amount from Step 2 by
the amount from Step 3 and multiply the
resulting amount by 100 to produce the
percentage of total capital outlier
reconciliation dollars to total capital Federal
payments for FY 2017. This percentage
amount would be used to adjust the estimate
of capital outlier payments for FY 2023 as
described in Step 5.
Step 5.—Because the outlier reconciliation
dollars are only available on the cost reports,
and not in the specific Medicare claims data
in the MedPAR file used to estimate outlier
payments, we proposed that the estimate of
capital outlier payments for FY 2023 would
be determined by adding the percentage in
Step 4 to the estimated percentage of capital
outlier payments otherwise determined using
the shared outlier threshold that is applicable
to both hospital inpatient operating costs and
hospital inpatient capital-related costs. (We
note that this percentage is added for capital
outlier payments but subtracted in the
analogous step for operating outlier
payments. We have a unified outlier payment
methodology that uses a shared threshold to
identify outlier cases for both operating and
capital payments. The difference stems from
the fact that operating outlier payments are
determined by first setting a ‘‘target’’
percentage of operating outlier payments
relative to aggregate operating payments
which produces the outlier threshold. Once
the shared threshold is set, it is used to
estimate the percentage of capital outlier
payments to total capital payments based on
that threshold. Because the threshold is
already set based on the operating target,
rather than adjusting the threshold (or
operating target), we adjust the percentage of
capital outlier to total capital payments to
account for the estimated effect of capital
outlier reconciliation payments. This
percentage is adjusted by adding the capital
outlier reconciliation percentage from Step 4
to the estimate of the percentage of capital
outlier payments to total capital payments
based on the shared threshold.) Because the
aggregate capital outlier reconciliation
dollars from Step 2 are negative, the estimate
of capital outlier payments for FY 2023 under
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
our proposed methodology would be lower
than the percentage of capital outlier
payments otherwise determined using the
shared outlier threshold.
Similarly, for the FY 2023 proposed rule,
we used the December 2021 HCRIS extract of
the cost report data to calculate the proposed
percentage adjustment for outlier
reconciliation. For this FY 2023 final rule, we
proposed to use the latest quarterly HCRIS
extract that is publicly available at the time
of the development of that rule which, for FY
2023, would be the March 2022 extract. As
previously noted, we stated that may also
consider the use of more recent data that may
become available for purposes of projecting
the estimate of capital outlier reconciliation
used in the calculation of the final FY 2023
adjustment to the FY 2023 capital standard
Federal rate.
For the FY 2023 proposed rule, the
estimated percentage of FY 2023 capital
outlier payments otherwise determined using
the shared outlier threshold was 5.56 percent
(estimated capital outlier payments of
$394,593,407 divided by (estimated capital
outlier payments of $394,593,407 plus the
estimated total capital Federal payment of
$6,707,033,365)). Based on the December
2021 HCRIS, 9 hospitals had an outlier
reconciliation amount recorded on
Worksheet E, Part A, Line 93 for total capital
outlier reconciliation dollars of negative
$759,945 (Step 2). The total Federal capital
payments based on the December 2021
HCRIS was $7,992,953,494 (Step 3) which
results in a ratio (Step 4) of -0.01 percent.
Therefore, for FY 2023, taking into account
projected capital outlier reconciliation
payments under our proposed methodology
would decrease the estimated percentage of
FY 2023 aggregate capital outlier payments
by 0.01 percent.
As discussed in section III.A.2. of this
Addendum, we proposed to incorporate the
capital outlier reconciliation dollars from
Step 5 when applying the outlier adjustment
factor in determining the capital Federal rate
based on the estimated percentage of capital
outlier payments to total capital Federal rate
payments for FY 2023.
We invited public comment on our
proposed methodology for projecting an
estimate of capital outlier reconciliation and
incorporating that estimate into the modeling
of the estimate of FY 2023 capital outlier
payments for purposes of determining the
capital outlier adjustment factor.
We did not receive comments about the
proposed capital outlier reconciliation
methodology. Therefore, we are finalizing the
methodology for projecting an estimate of
capital outlier reconciliation as previously
described. We stated in the proposed rule
that while we expect to use the March 2022
HCRIS extract for the FY 2023 final rule,
similar to the FY 2022 final rule, we may also
consider the use of more recent data that may
become available for purposes of projecting
the estimate of capital outlier reconciliation
used in the calculation of the final FY 2023
adjustment to the FY 2023 capital standard
Federal rate. For this final rule, for projecting
the estimate of capital outlier reconciliation,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
similar to our projection of the estimate of
operating outlier reconciliation, we are using
cost report data of 12 hospitals from the
March 2022 HCRIS supplemented for 2
hospitals for a total of 14 hospitals, which we
believe will lend additional accuracy to the
projection of estimated capital outlier
reconciliation for FY 2023. We note that a
difference in the number of cost reports for
the operating and capital outlier
reconciliation projections is possible and
may be due to new hospitals defined in the
regulations at 42 CFR 412.300(b) that may
receive capital cost-based payments (in lieu
of Federal rate payments), and therefore
would not receive capital outlier payments.
As a result, capital outlier reconciliation is
not applicable to such hospitals since there
is no capital outlier payment.
Based on the March 2022 HCRIS and
supplemental data for 2 hospitals, 14
hospitals had an outlier reconciliation
amount recorded on Worksheet E, Part A,
Line 93 for total capital outlier reconciliation
dollars of negative $1,101,225 (Step 2). The
total Federal capital payments based on the
March 2022 HCRIS is approximately
$7,995,731,783 (Step 3). The ratio (Step 4) is
a negative 0.013773 percent, which, when
rounded to the second digit, is negative 0.01
percent (Step 4). Therefore, for FY 2023,
taking into account projected capital outlier
reconciliation payments under our
methodology will decrease the estimated
percentage of FY 2023 aggregate capital
outlier payments by 0.01 percent.
Accordingly, under our methodology as
previously discussed, we are applying the
0.01 percent adjustment to our estimate of
the capital outlier percentage (described
below).
To determine the FY 2023 IPPS fixed-loss
amount (shared threshold) in this final rule
(as discussed in greater detail later in this
section), after consideration of public
comments we are incorporating
modifications to our proposed methodology.
Specifically, one of the modifications we are
making is to determine the shared threshold
as an average of the thresholds calculated
when including and excluding COVID–19
cases. Because of this averaging, it is
necessary to make a minor modification to
the proposed methodology for incorporating
the estimate of capital outlier reconciliation
into the modeling of the estimate of FY 2023
capital outlier payments for purposes of
determining the capital outlier adjustment
factor. (We refer the reader to the discussion
below in section II.A.4.j.(2). of this
Addendum for complete details regarding the
calculation of the shared threshold for FY
2023 based on the averaging of the thresholds
as calculated including and excluding
COVID–19 cases.)
Therefore, to incorporate the estimate of
capital outlier reconciliation, after
calculating the shared threshold based on the
average of the thresholds as calculated with
and without COVID–19 cases, for this final
rule we are using the same steps as described
in the proposed rule to reduce the FY 2023
capital standard Federal rate by an
adjustment factor to account for the projected
PO 00000
Frm 00643
Fmt 4701
Sfmt 4700
49421
proportion of capital IPPS payments paid as
outliers. However, with regard to Step 5
above, as discussed in more detail below, for
this final rule we are determining the
estimate of capital outlier payments for FY
2023 by adding the percentage in Step 4 to
the estimated percentage of capital outlier
payments calculated by averaging the
estimated percentage of capital outlier
payments including and excluding COVID–
19 cases.
As explained previously, once a shared
threshold is set, it is used to estimate the
percentage of capital outlier payments to
total capital payments based on that
threshold. Therefore, our modified
methodology produces two separate
estimates of the percentage of capital outlier
payments to total capital payments. One
estimate is based on the shared threshold that
was determined using all cases in the FY
2021 claims data, including COVID–19 cases.
The other estimate is based on the shared
threshold that was determined using FY 2021
claims data excluding COVID–19 cases. We
then averaged these two estimates of capital
outlier payments to total capital payments to
estimate the percentage of capital outlier
payments in FY 2023 using the final FY 2023
shared outlier threshold. This approach is
also consistent with our belief that it is
reasonable to assume there will be fewer
COVID–19 cases in FY 2023 as compared to
FY 2021 (as discussed later in this section
and in section I.F of the preamble to this final
rule).
For this final rule, we first determined a
capital outlier percentage of 5.66 percent
(estimated capital outlier payments of
$406,733,862 divided by $7,190,928,057
(estimated capital outlier payments of
$406,733,862 plus the estimated total capital
Federal payment of $6,784,194,195)) based
on the shared threshold that was calculated
using all claims, including COVID–19 cases.
We next determined a capital outlier
percentage of 5.40 percent (estimated capital
outlier payments of $346,066,050 divided by
$6,412,816,596 (estimated capital outlier
payments of $346,066,050 plus the estimated
total capital Federal payment of
$6,066,750,547)) based on the shared
threshold that was calculated excluding
COVID–19 cases. Therefore, taking the
average of these two estimates, we estimate
capital outlier payments to be 5.53 percent of
total capital payments prior to incorporating
the estimate of capital outlier reconciliation.
Finally, under our methodology for
accounting for capital outlier reconciliation
as discussed previously, we are applying the
0.01 percent adjustment to this estimate of
the capital outlier percentage as calculated
using the average of the two estimates based
on the shared thresholds including and
excluding COVID–19 data of 5.53 percent, as
previously described. Therefore, accounting
for estimated capital outlier reconciliation,
we estimate outlier payments for capitalrelated PPS payments will equal 5.52 percent
(5.53 percent—0.01 percent) of inpatient
capital-related payments based on the capital
Federal rate in FY 2023.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49422
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(2) FY 2023 Outlier Fixed-Loss Cost
Threshold
In the FY 2014 IPPS/LTCH PPS final rule
(78 FR 50977 through 50983), in response to
public comments on the FY 2013 IPPS/LTCH
PPS proposed rule, we made changes to our
methodology for projecting the outlier fixedloss cost threshold for FY 2014. We refer
readers to the FY 2014 IPPS/LTCH PPS final
rule for a detailed discussion of the changes.
As we have done in the past, to calculate
the FY 2023 outlier threshold, we simulated
payments by applying FY 2023 payment rates
and policies using cases from the FY 2021
MedPAR file. As noted in section II.C. of this
Addendum, we specify the formula used for
actual claim payment which is also used by
CMS to project the outlier threshold for the
upcoming fiscal year. The difference is the
source of some of the variables in the
formula. For example, operating and capital
CCRs for actual claim payment are from the
PSF while CMS uses an adjusted CCR (as
described later in this section) to project the
threshold for the upcoming fiscal year. In
addition, charges for a claim payment are
from the bill while charges to project the
threshold are from the MedPAR data with an
inflation factor applied to the charges (as
described earlier).
In order to determine the proposed FY
2023 outlier threshold, we inflated the
charges on the MedPAR claims by 2 years,
from FY 2021 to FY 2023. Consistent with
the FY 2020 IPPS/LTCH PPS final rule (84 FR
42626 and 42627), we proposed to use the
following methodology to calculate the
charge inflation factor for FY 2023:
• Include hospitals whose last four digits
fall between 0001 and 0899 (section 2779A1
of Chapter 2 of the State Operations Manual
on the CMS website at https://www.cms.gov/
Regulations-and-Guidance/Guidance/
Manuals/Downloads/som107c02.pdf);
include CAHs that were IPPS hospitals for
the time period of the MedPAR data being
used to calculate the charge inflation factor;
include hospitals in Maryland; and remove
PPS-excluded cancer hospitals who have a
‘‘V’’ in the fifth position of their provider
number or a ‘‘E’’ or ‘‘F’’ in the sixth position.
• Include providers that are in both
periods of charge data that are used to
calculate the 1-year average annual rate ofchange in charges per case. We note this is
consistent with the methodology used since
FY 2014.
• We excluded Medicare Advantage IME
claims for the reasons described in section
I.A.4. of this Addendum. We refer readers to
the FY 2011 IPPS/LTCH PPS final rule for a
complete discussion on our methodology of
identifying and adding the total Medicare
Advantage IME payment amount to the
budget neutrality adjustments.
• In order to ensure that we capture only
FFS claims, we included claims with a
‘‘Claim Type’’ of 60 (which is a field on the
MedPAR file that indicates a claim is an FFS
claim).
• In order to further ensure that we capture
only FFS claims, we excluded claims with a
‘‘GHOPAID’’ indicator of 1 (which is a field
on the MedPAR file that indicates a claim is
not an FFS claim and is paid by a Group
Health Organization).
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
• We examined the MedPAR file and
removed pharmacy charges for antihemophilic blood factor (which are paid
separately under the IPPS) with an indicator
of ‘‘3’’ for blood clotting with a revenue code
of ‘‘0636’’ from the covered charge field. We
also removed organ acquisition charges from
the covered charge field because organ
acquisition is a pass-through payment not
paid under the IPPS. As noted previously, we
are removing allogeneic hematopoietic stem
cell acquisition charges from the covered
charge field for budget neutrality
adjustments. As discussed in the FY 2021
IPPS/LTCH PPS final rule, payment for
allogeneic hematopoietic stem cell
acquisition costs is made on a reasonable cost
basis for cost reporting periods beginning on
or after October 1, 2020 (85 FR 58835–
58842).
• Because this payment simulation uses
the FY 2023 relative weights, consistent with
our policy discussed in section IV.I. of the
preamble to this final rule, we applied the
proposed adjustor for certain cases that group
to MS–DRG 018 in our simulation of these
payments. As discussed in section II.E.2.b. of
the preamble of this final rule, we are
applying an adjustment to account for certain
cases that group to MS–DRG 018 in
calculating the FY 2023 relative weights and
for purposes of budget neutrality and outlier
simulations.
Our general methodology to inflate the
charges computes the 1-year average annual
rate-of-change in charges per case which is
then applied twice to inflate the charges on
the MedPAR claims by 2 years since we
typically use claims data for the fiscal year
that is 2 years prior to the upcoming fiscal
year.
In the FY 2020 IPPS/LTCH PPS final rule
(84 FR 42627), we modified our charge
inflation methodology. We stated that we
believe balancing our preference to use the
latest available data from the MedPAR files
and stakeholders’ concerns about being able
to use publicly available MedPAR files to
review the charge inflation factor can be
achieved by modifying our methodology to
use the publicly available Federal fiscal year
period (that is, for FY 2020, we used the
charge data from Federal fiscal years 2017
and 2018), rather than the most recent data
available to CMS which, under our prior
methodology, was based on calendar year
data. We refer the reader to the FY 2020
IPPS/LTCH PPS final rule for a complete
discussion regarding this change.
For FY 2023, under our policy of
computing the charge inflation factor using
the publicly available Federal fiscal year
period, we would ordinarily use charge data
from the MedPAR files for Federal fiscal
years 2020 and 2021 to compute the 1-year
average annual rate-of-change in charges per
case. Specifically, for the proposed rule, we
would ordinarily use the December 2020
MedPAR file of FY 2020 (October 1, 2019,
through September 30, 2020) charge data and
the December 2021 MedPAR file of FY 2021
(October 1, 2021, through September 30,
2021) charge data to compute the proposed
charge inflation factor. However, based on
our analysis, the charge inflation factors
calculated using these two most recently
PO 00000
Frm 00644
Fmt 4701
Sfmt 4700
available years of MedPAR claims data (FY
2020 and FY 2021) are abnormally high as
compared to recent historical levels prior to
the COVID–19 PHE period. Specifically, in
the proposed rule we stated that we
calculated a 1-year average annual rate-ofchange in charges per case of approximately
10 percent based on the FY 2020 and FY
2021 MedPAR claims data, as compared to
approximately 6 percent based on the FY
2018 and 2019 MedPAR claims data for the
two most recent Federal fiscal year time
periods prior to the PHE. We stated that we
believe this abnormally high charge inflation
as compared to historical levels was partially
due to the high number of COVID–19 cases
with higher charges that were treated in IPPS
hospitals in FY 2021. As discussed in section
I.F of the preamble of this final rule, we
believe there will be fewer COVID–19 cases
in FY 2023 than in FY 2021. Therefore, we
do not believe it is reasonable to assume
charges will continue to increase at these
abnormally high rates.
Therefore, in the FY 2023 IPPS/LTCH
proposed rule (87 FR 28667), we proposed
for FY 2023 to use the same methodology as
FY 2020, with a proposed modification to use
the most recent 1-year average annual rate-ofchange in charges per case for the period
prior to the COVID–19 PHE, and based on the
same data used in the FY 2021 IPPS/LTCH
PPS final rule to determine the charge
inflation factor for the proposed rule. We
further noted that this is the same data used
to determine the charge inflation factor for
the FY 2022 IPPS/LTCH PPS rulemaking.
Specifically, for FY 2023, we proposed to use
the MedPAR files for the two most recent
available Federal fiscal year time periods
prior to the COVID–19 PHE to calculate the
charge inflation factor. Specifically, for the
proposed rule we proposed to use the March
2019 MedPAR file of FY 2018 (October 1,
2017, to September 30, 2018) charge data
(released for the FY 2020 IPPS/LTCH PPS
final rule) and the March 2020 MedPAR file
of FY 2019 (October 1, 2018, to September
30, 2019) charge data (released for the FY
2021 IPPS/LTCH PPS final rule) to compute
the proposed charge inflation factor. We
proposed that for the FY 2023 IPPS/LTCH
PPS final rule, we would continue to use the
charge inflation estimate from the FY 2021
IPPS/LTCH PPS final rule. Under this
proposed methodology, to compute the 1year average annual rate-of-change in charges
per case for FY 2023, we compared the
average covered charge per case of
$61,578.82 ($584,618,863,834/9,493,830
cases) from October 1, 2017, through
September 31, 2018, to the average covered
charge per case of $65,522.10
($604,209,834,327/9,221,466 cases) from
October 1, 2018, through September 31, 2019.
This rate-of-change was 6.4 percent (1.06404)
or 13.2 percent over 2 years (1.13218).
Because we proposed to use the FY 2021
MedPAR for the FY 2023 ratesetting, we
applied a factor of 13.2 percent over 2 years.
The billed charges are obtained from the
claim from the MedPAR file and inflated by
the inflation factor specified previously.
In the FY 2023 IPPS/LTCH proposed rule
(87 FR 28667–28668), we also solicited
comments on the alternative approach of
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
using the data we would ordinarily use to
determine the charge inflation factor for
purposes of this FY 2023 rule (that is, charge
data from FYs 2020 and 2021 to compute the
1-year average annual rate of change in
charges per case), and noted that under this
alternative approach, if finalized, we would
anticipate using more recently updated data
from FYs 2020 and 2021 for purposes of the
FY 2023 IPPS/LTCH PPS final rule. As
previously noted, in order to facilitate
comments on our alternative approach of
using the FY 2021 MedPAR claims for
purposes of FY 2023 ratesetting but without
the proposed modifications to our usual
methodologies, including use of the same
data that we would ordinarily use for
purposes of determining the charge inflation
factor for this FY 2023 rulemaking, and
which we stated we may consider finalizing
for FY 2023 based on consideration of
comments received, we made available
budget neutrality and other ratesetting
adjustments, including the charge inflation
factor, calculated under this alternative
approach, which can be found on the CMS
website at https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/index. We included in a
supplemental data file the following: budget
neutrality factors, charge inflation factor, the
CCR adjustment factors, an impact file and
outlier threshold based on this alternative
approach. Consistent with historical practice,
we stated that if we were to finalize this
alternative approach, we would use the most
recent available data for the final rule, as
appropriate.
As discussed previously, in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR 28668),
we proposed to establish the FY 2023 outlier
threshold using hospital CCRs from the
December 2021 update to the ProviderSpecific File (PSF), the most recent available
data at the time of developing the proposed
rule. We proposed to apply the following
edits to providers’ CCRs in the PSF. We
stated that we believe these edits are
appropriate in order to accurately model the
outlier threshold. We first searched for
Indian Health Service providers and those
providers assigned the statewide average CCR
from the current fiscal year. We then
replaced these CCRs with the statewide
average CCR for the upcoming fiscal year. We
also assigned the statewide average CCR (for
the upcoming fiscal year) to those providers
that have no value in the CCR field in the
PSF or whose CCRs exceed the ceilings
described later in this section (3.0 standard
deviations from the mean of the log
distribution of CCRs for all hospitals). We did
not apply the adjustment factors described
later in this section to hospitals assigned the
statewide average CCR. For FY 2023, we also
proposed to continue to apply an adjustment
factor to the CCRs to account for cost and
charge inflation (as explained further in this
section).
In the FY 2014 IPPS/LTCH PPS final rule
(78 FR 50979), we adopted a new
methodology to adjust the CCRs. Specifically,
we finalized a policy to compare the national
average case-weighted operating and capital
CCR from the most recent update of the PSF
to the national average case-weighted
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
operating and capital CCR from the same
period of the prior year.
In the FY 2023 IPPS/LTCH proposed rule
(87 FR 28668) we stated that ordinarily, for
the proposed rule, we would apply a
proposed adjustment factor to adjust the
CCRs from the December 2021 update of the
PSF by comparing the percentage change in
the national average case-weighted operating
CCR and capital CCR from the December
2020 update of the PSF to the national
average case-weighted operating CCR and
capital CCR from the December 2021 update
of the PSF. However, the operating and
capital CCR adjustment factors based on the
data we ordinarily would use are above 1.0.
Since the implementation of our new
methodology to adjust the CCRs in the FY
2014 IPPS/LTCH PPS final rule (78 FR
50979), the operating and capital CCR
adjustment factors have typically been below
1.0 (for example, operating and capital CCR
adjustment factors of approximately 1.03 and
1.03, respectively, based on the December
2020 and December 2021 updates to the PSF
as compared to operating and capital CCR
adjustment factors of approximately 0.97 and
0.96, respectively, based on the March 2019
and March 2020 updates to the PSF). As
stated in section I.F. of the preamble to this
final rule, we believe this abnormally high
CCR adjustment factor as compared to
historical levels is partially due to the high
number of COVID–19 cases with higher
charges that were treated in IPPS hospitals in
FY 2021. As we previously stated, we believe
there will be fewer COVID–19 cases in FY
2023 than in FY 2021. Therefore, we stated
that we do not believe it is reasonable to
assume CCRs will continue to increase at
these abnormally high rates. Therefore, we
proposed to adjust the CCRs from the
December 2021 update of the PSF by
comparing the percentage change in the
national average case-weighted operating
CCR and capital CCR from the March 2019
update of the PSF to the national average
case-weighted operating CCR and capital
CCR from the March 2020 update of the PSF,
which is the last update of the PSF prior to
the PHE. We noted that this is the same data
used to adjust the CCRs for the FY 2022
IPPS/LTCH PPS rulemaking. We stated that
we believe using these data for the latest
available period prior to the PHE, for which
the percentage change in the national average
case weighted operating CCR and capital CCR
is below 1.0, is appropriate in light of our
expectation that the CCRs will not continue
to increase at these abnormally high rates for
FY 2023. We noted that we used total
transfer-adjusted cases from FY 2019 to
determine the national average case-weighted
CCRs for both sides of the comparison. As
stated in the FY 2014 IPPS/LTCH PPS final
rule (78 FR 50979), we believe that it is
appropriate to use the same case count on
both sides of the comparison, because this
would produce the true percentage change in
the average case-weighted operating and
capital CCR from 1 year to the next without
any effect from a change in case count on
different sides of the comparison.
Using the proposed methodology, for the
proposed rule, we calculated a March 2019
operating national average case-weighted
PO 00000
Frm 00645
Fmt 4701
Sfmt 4700
49423
CCR of 0.254027 and a March 2020 operating
national average case-weighted CCR of
0.247548. We then calculated the percentage
change between the two national operating
case-weighted CCRs by subtracting the March
2019 operating national average caseweighted CCR from the March 2020 operating
national average case-weighted CCR and then
dividing the result by the March 2019
national operating average case-weighted
CCR. This resulted in a proposed 1-year
national operating CCR adjustment factor of
0.974495. In the proposed rule, we noted that
because we proposed to use CCRs from the
December 2021 update of the PSF for FY
2023, we applied a 1-year proposed national
operating CCR adjustment.
We used this same proposed methodology
to adjust the capital CCRs. Specifically, we
calculated a March 2019 capital national
average case-weighted CCR of 0.02073 and a
March 2020 capital national average caseweighted CCR of 0.019935. We then
calculated the percentage change between the
two national capital case-weighted CCRs by
subtracting the March 2019 capital national
average case-weighted CCR from the March
2020 capital national average case-weighted
CCR and then dividing the result by the
March 2019 capital national average caseweighted CCR. This resulted in a proposed 1year national capital CCR adjustment factor
of 0.96165. Because we proposed to use CCRs
from the December 2021 update of the PSF
for FY 2023, we applied a 1-year proposed
national capital CCR adjustment.
As discussed in section I.F. of the proposed
rule and in section I.O. of Appendix A of the
proposed rule, we solicited comments on an
alternative approach of using the data that we
would ordinarily use for purposes of
adjusting the CCRs for this FY 2023
rulemaking, which we stated we may
consider finalizing for FY 2023 based on
consideration of comments received. As
previously noted, in order to facilitate
comments on our alternative approach of
using the FY 2021 MedPAR claims for
purposes of FY 2023 ratesetting but without
the proposed modifications to our usual
methodologies, we made available
supplemental data files, including the
following: budget neutrality factors, charge
inflation factor, the CCR adjustment factors,
and outlier threshold based on this
alternative approach. Consistent with
historical practice, we stated in the proposed
rule if we were to finalize this alternative
approach, we would use the most recent
available data for the final rule, as
appropriate.
For purposes of estimating the proposed
outlier threshold for FY 2023, we used a
wage index that reflects the policies
discussed in the proposed rule. This includes
all of the following:
• The proposed frontier State floor
adjustments in accordance with section
10324(a) of the Affordable Care Act.
• The proposed out-migration adjustment
as added by section 505 of Public Law 108–
173.
• Incorporating the proposed FY 2023 low
wage index hospital policy (described in
section III. G. 4 of the FY 2023 IPPS/LTCH
proposed rule (87 FR 28369)) for hospitals
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49424
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
with a wage index value below the 25th
percentile, where the increase in the wage
index value for these hospitals would be
equal to half the difference between the
otherwise applicable final wage index value
for a year for that hospital and the 25th
percentile wage index value for that year
across all hospitals.
• Incorporating our proposed policy
(described in section III.N. of the preamble of
the proposed rule) to apply a 5-percent cap
on any decrease to a hospital’s wage index
from its wage index in the prior FY,
regardless of the circumstances causing the
decline.
If we did not take the aforementioned into
account, our estimate of total FY 2023
payments would be too low, and, as a result,
our proposed outlier threshold would be too
high, such that estimated outlier payments
would be less than our projected 5.1 percent
of total payments (which includes outlier
reconciliation).
As described in sections V.K. and V.L.,
respectively, of the preamble of this final
rule, sections 1886(q) and 1886(o) of the Act
establish the Hospital Readmissions
Reduction Program and the Hospital VBP
Program, respectively. We stated in the
proposed rule that we do not believe that it
is appropriate to include the proposed
hospital VBP payment adjustments and the
hospital readmissions payment adjustments
in the proposed outlier threshold calculation
or the proposed outlier offset to the
standardized amount. Specifically, consistent
with our definition of the base operating DRG
payment amount for the Hospital
Readmissions Reduction Program under
§ 412.152 and the Hospital VBP Program
under § 412.160, outlier payments under
section 1886(d)(5)(A) of the Act are not
affected by these payment adjustments.
Therefore, outlier payments would continue
to be calculated based on the unadjusted base
DRG payment amount (as opposed to using
the base-operating DRG payment amount
adjusted by the hospital readmissions
payment adjustment and the hospital VBP
payment adjustment). Consequently, we
proposed to exclude the estimated hospital
VBP payment adjustments and the estimated
hospital readmissions payment adjustments
from the calculation of the proposed outlier
fixed-loss cost threshold.
We noted in the proposed rule that, to the
extent section 1886(r) of the Act modifies the
DSH payment methodology under section
1886(d)(5)(F) of the Act, the uncompensated
care payment under section 1886(r)(2) of the
Act, like the empirically justified Medicare
DSH payment under section 1886(r)(1) of the
Act, may be considered an amount payable
under section 1886(d)(5)(F) of the Act such
that it would be reasonable to include the
payment in the outlier determination under
section 1886(d)(5)(A) of the Act. As we have
done since the implementation of
uncompensated care payments in FY 2014,
for FY 2023, we proposed to allocate an
estimated per-discharge uncompensated care
payment amount to all cases for the hospitals
eligible to receive the uncompensated care
payment amount in the calculation of the
outlier fixed-loss cost threshold
methodology. We stated that we continue to
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
believe that allocating an eligible hospital’s
estimated uncompensated care payment to
all cases equally in the calculation of the
outlier fixed-loss cost threshold would best
approximate the amount we would pay in
uncompensated care payments during the
year because, when we make claim payments
to a hospital eligible for such payments, we
would be making estimated per-discharge
uncompensated care payments to all cases
equally. Furthermore, we stated that we
continue to believe that using the estimated
per-claim uncompensated care payment
amount to determine outlier estimates
provides predictability as to the amount of
uncompensated care payments included in
the calculation of outlier payments.
Therefore, consistent with the methodology
used since FY 2014 to calculate the outlier
fixed-loss cost threshold, for FY 2023, we
proposed to include estimated FY 2023
uncompensated care payments in the
computation of the proposed outlier fixedloss cost threshold. Specifically, we proposed
to use the estimated per-discharge
uncompensated care payments to hospitals
eligible for the uncompensated care payment
for all cases in the calculation of the
proposed outlier fixed-loss cost threshold
methodology.
In addition, as discussed in section IV.E. of
the preamble of the proposed rule, we
proposed to establish a supplemental
payment for eligible IHS/Tribal hospitals and
Puerto Rico hospitals, beginning in FY 2023.
We proposed to make interim payments of
this proposed new supplement payment on
a per-discharge basis. Consistent with the
policy of including estimated
uncompensated care payments in the
computation of the proposed outlier fixedloss cost threshold, as previously
summarized, we proposed to use our
authority under section 1886(d)(5)(I) of the
Act to include the estimated supplemental
payments in the computation of the proposed
outlier fixed-loss cost threshold. Specifically,
we proposed to use the estimated perdischarge supplemental payments to
hospitals eligible for the supplemental
payment for all cases in the calculation of the
proposed outlier fixed-loss cost threshold
methodology.
Using this methodology, we used the
formula described in section I.C.1. of this
Addendum to simulate and calculate the
Federal payment rate and outlier payments
for all claims. In addition, as described in the
earlier section to this Addendum, we
proposed to incorporate an estimate of FY
2023 outlier reconciliation in the
methodology for determining the outlier
threshold. As noted previously, for the FY
2023 proposed rule, the ratio of outlier
reconciliation dollars to total Federal
Payments (Step 4) is a negative 0.013508
percent, which, when rounded to the second
digit, is ¥0.01 percent. Therefore, for FY
2023, we proposed to incorporate a
projection of outlier reconciliation dollars by
targeting an outlier threshold at 5.11 percent
[5.1 percent¥(¥.01 percent)]. Under this
proposed approach, we determined a
proposed threshold of $43,214 and calculated
total outlier payments of $4,709,906,314 and
total operating Federal payments of
PO 00000
Frm 00646
Fmt 4701
Sfmt 4700
$88,837,735,468. We then divided total
outlier payments by total operating Federal
payments plus total outlier payments and
determined that this threshold matched with
the 5.11 percent target, which reflected our
proposal to incorporate an estimate of outlier
reconciliation in the determination of the
outlier threshold (as discussed in more detail
in the previous section of this Addendum).
We noted that, if calculated without applying
our proposed methodology for incorporating
an estimate of outlier reconciliation in the
determination of the outlier threshold, the
proposed threshold would be $43,292. We
proposed an outlier fixed-loss cost threshold
for FY 2023 equal to the prospective payment
rate for the MS–DRG, plus any IME,
empirically justified Medicare DSH
payments, estimated uncompensated care
payment, proposed estimated supplemental
payment for eligible IHS/Tribal hospitals and
Puerto Rico hospitals, and any add-on
payments for new technology, plus $43,214.
As previously noted, and as discussed
further in section I.O of the Appendix A of
this final rule, we also considered an
alternative approach of using the FY 2021
MedPAR claims for purposes of FY 2023
ratesetting but without the proposed
modifications to our usual methodologies,
including use of the same data we would
ordinarily use for purposes of this FY 2023
rulemaking to compute the charge inflation
factors and CCR adjustment factors in
determining the FY 2023 outlier fixed-loss
amount for IPPS cases. Under this alternative
approach, we estimated an outlier threshold
of $58,798 rather than the proposed
threshold of $43,214 noted previously.
Comment: Commenters expressed concern
about the increase to the fixed-loss threshold
for FY 2023. Several commenters
acknowledged the steps CMS took to account
for some of the COVID–19 pandemic-related
factors that have driven the increase, which
may not continue in FY 2023. Specifically,
many commenters supported the use of prePHE data for charge inflation and CCR
adjustment factors.
Several other commenters opposed the use
of the charge inflation data and CCR
adjustment factors from the period preceding
the PHE for the following reasons.
• A commenter stated that the use of pre
COVID–19 data for the charge inflation does
not appear to consider the unusually high
inflation currently facing hospitals. The
commenter encouraged CMS to recognize
that hospitals continue to experience atypical
costs from COVID–19 care, along with
historic inflation levels, continued labor
shortages, and supply chain disruptions and
to fully reflect these costs in the data and
methodologies used for FY 2023.
• Another commenter believes that the
charge inflation that has occurred during the
PHE will continue as this trend has been
consistent since before the pandemic.
• Another commenter stated that it does
not support the use of an inflation factor
preceding the COVID–19 PHE as this does
not accurately reflect today’s environment.
The commenter stated that providers are
experiencing the rise of inflation and
additional costs that are not likely to resolve
within the next fiscal year and while COVID–
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
19 hospitalizations may continue to decline,
providers are also seeing higher acuity
patients, many who delayed care and are
now sicker and costlier to treat. The
commenter recommended that CMS
reevaluate the use of a pre-COVID–19
inflation factor and instead use 2021 data.
Some commenters supported the use of the
FY 2021 claims data. Another commenter
opposed the use of unadjusted FY 2021
claims data, stating that more recent data
suggests that there should be far fewer highcost COVID–19 cases in FY 2023 relative to
FY 2021. This commenter suggested that
CMS trim COVID–19 cases with costs that are
more than three standard deviations from the
geometric mean. Several other commenters
suggested that CMS remove high-cost cases
in MS–DRGs identified as COVID–19 related,
while others suggested that CMS remove all
COVID–19 cases. Other commenters
suggested using a blend of FY 2019 and FY
2021 data, using a blend of FY 2019 and FY
2020 data with COVID–19 cases removed,
reducing the weight of COVID–19 cases in
the FY 2021 data by 50 percent, using claims
data from prior to the PHE, or using an
average of the current FY 2022 threshold
with the newly proposed threshold. MedPAC
suggested calculating the FY 2023 fixed-loss
amount as an average of the outlier fixed-loss
amounts calculated with and without
COVID–19 cases in the FY 2021 data.
MedPAC believes that this approach would
be consistent with the approach CMS
proposed for calculating the MS–DRG
relative weights and would reflect the
assumption that there will be fewer COVID–
19 cases in FY 2023 as compared to FY 2021.
A commenter suggested that CMS model
the inclusion of NCTAP payments and the
increased payments for COVID–19 cases
provided by the CARES Act in the FY 2021
claims data when calculating the fixed-loss
threshold. This commenter stated that
conservatively, the PHE is anticipated to end
no earlier than mid-October 2022, which
means that NCTAP payments will continue
for all of FY 2023. This commenter stated
that in using the FY 2021 MedPAR data, CMS
is assuming that COVID–19 hospitalizations
in FY 2023 will mirror those in FY 2021,
which implies that the PHE will be further
renewed, and that the increased payments for
COVID–19 cases provided by the CARES Act
will continue in FY 2023. (Section 3710 of
the CARES Act provides for an increase in
the MS–DRG weighting factor of 20 percent
for an individual diagnosed with COVID–19
discharged during the period of the PHE for
COVID–19.)
Some commenters suggested that CMS
phase in the large proposed increase to the
fixed-loss threshold over time. Many
commenters suggested that CMS reexamine
its methodology more closely and adopt
additional changes to offset substantial
increases in the outlier threshold. A
commenter suggested that CMS better
account for the data anomalies created by the
pandemic until patient mix becomes more
predictable and the data used for ratesetting
reflects a more stable healthcare
environment.
A commenter stated they believe that
inadequate market basket updates in prior
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
years and for the upcoming fiscal year do not
accurately capture increases in costs which
also drive increases to the outlier threshold.
The commenter stated that smaller market
basket adjustments leave IPPS payments too
low, pushing the costs of too many claims
above the MS–DRG payment amount and
driving untenable growth in the fixed loss
threshold. The commenter requested that
CMS calculate the final rule outlier threshold
using a higher market basket percentage
increase.
Response: We appreciate commenters’
support regarding the use of pre-PHE data for
charge inflation and CCR adjustment factors.
With respect to those commenters that
opposed the use of this data, it appears that
these commenters believe that the charge
inflation factor is a measure of cost inflation,
and that a higher charge inflation factor
would more accurately account for the costs
of providing medical care. The charge
inflation factor is typically a 1-year average
annual rate-of-change in charges which is
applied to inflate the charges on the MedPAR
claims by 2 years since we typically use
claims data for the fiscal year that is 2 years
prior to the upcoming fiscal year. For the
reasons discussed in the proposed rule, we
continue to believe that use of the pre-PHE
data for the FY 2023 charge inflation and
CCR adjustment factors is most appropriate
given our belief that there will be fewer
COVID–19 cases in FY 2023 than in FY 2021,
based on the information available at this
time. As mentioned in the proposed rule, the
charge inflation factors calculated using the
two most recently available years of MedPAR
claims data (FY 2020 and FY 2021) are
abnormally high as compared to recent
historical levels prior to the COVID–19 PHE
period. With regard to the CCR adjustment
factors, the operating and capital CCR
adjustment factors based on the data we
ordinarily would use are above 1.0 while the
operating and capital CCR adjustment factors
have typically been below 1.0. We also
continue to believe that these abnormal
charges were partially due to the high
number of COVID–19 cases with higher
charges. Because we anticipate that there will
be fewer COVID–19 cases in FY 2023 as
compared to FY 2021, based on the
information available at this time and as
explained previously, we believe the use of
the most recent available data prior to the
COVID–19 PHE is appropriate for FY 2023.
We also note that lower charges per case due
to a lower charge inflation factor and lower
CCRs based on a CCR adjustment factor
below 1 will result in lower costs per case
and will result in a lower threshold in order
to ensure outlier payments are 5.1 percent of
total payments. As discussed in the proposed
rule, under the alternative approach of using
the same data we would ordinarily use for
purposes of this FY 2023 rulemaking to
compute the charge inflation factors and CCR
adjustment factors in determining the FY
2023 outlier fixed-loss amount for IPPS cases,
we estimated an outlier threshold of $58,798
rather than the proposed threshold of
$43,214.
With respect to commenters’
recommendations of various approaches to
modify the data or methodology to calculate
PO 00000
Frm 00647
Fmt 4701
Sfmt 4700
49425
the fixed-loss threshold, we continue to
recognize that there is uncertainty regarding
the utilization and costs that hospitals will
experience in FY 2023. However, based on
the information available at this time on the
trajectory of the COVID–19 PHE, consistent
with the discussion in section I.F. of the
preamble to this final rule, we believe
averaging the outlier-fixed loss thresholds
calculated using FY 2021 data including and
excluding COVID–19 claims, as suggested by
MedPAC, would best reflect our belief that it
is reasonable to assume there will be fewer
COVID–19 hospitalizations among Medicare
beneficiaries in FY 2023 than there were in
FY 2021 (as discussed in section I.F of the
preamble to this final rule). While another
commenter recommended to reduce the
weight of COVID–19 cases in the FY 2021
data by 50 percent, we believe that averaging
the outlier-fixed loss thresholds as calculated
with and without COVID–19 claims in the FY
2021 data as described would be most
consistent with the approach we proposed
and are finalizing for calculating the MS–
DRG relative weights for FY 2023, as
discussed in section II.E.2.c of the preamble
to this final rule. As discussed below, we are
adopting the approach suggested by MedPAC
when determining the FY 2023 outlier fixed
loss amount.
With regard to averaging the data with
claims pre COVID–19 for modeling the fixed
loss threshold, we note that the FY 2021 and
FY 2022 thresholds used claims from FY
2019 to set the fixed loss threshold. The
thresholds in FY 2021 and FY 2022 were
$29,064 and $30,988 respectively. As noted
in the proposed rule, if we made no
modifications to our methodology to set the
FY 2023 fixed loss threshold, the proposed
fixed loss threshold would have been
$58,798. Even with our modifications to the
methodology that we proposed in the FY
2023 IPPS/LTCH proposed rule, the proposed
threshold was lowered from $58,798 to
$43,214. Because of this large variance in the
thresholds as determined using pre and post
COVID–19 data, we do not believe it would
be appropriate to average the data used to
calculate the threshold with pre COVID–19
data (including, as suggested by the
commenters, by using a blend of FY 2019 and
FY 2021 data, or using a blend of FY 2019
and FY 2020 data with COVID–19 cases
removed) as we do not believe this approach
would provide a reasonable estimate of
outlier payments for FY 2023 as 5.1 percent
of estimated total payments for FY 2023.
We also agree with the commenter that
suggested that we include the increase in
payments for COVID–19 cases provided by
the CARES Act, based on the information
available at this time on the trajectory of the
COVID–19 PHE. Therefore, we incorporating
these two suggested modifications to our
proposed methodology for determining the
FY 2023 outlier fixed-loss amount.
Specifically, we calculated two fixed-loss
thresholds, one using FY 2021 claims data
including COVID–19 cases that reflect the
payment increase provided by the CARES
Act and one using FY 2021 claims data
excluding COVID–19 cases, and then
averaged these two fixed-loss thresholds to
determine the final fixed-loss threshold for
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49426
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
FY 2023. We believe these adjustments to our
proposed methodology will best reflect a
reasonable estimation of the case mix and
relative resource use of FY 2023 cases based
on the information available at this time.
With respect to the comment that we
should include NCTAP payments in the
COVID–19 cases in the FY 2021 claims data,
we note that, as stated in the Interim Final
Rule Additional Policy and Regulatory
Revisions in Response to the COVID–19
Public Health Emergency (85 FR 71142), the
NCTAP will not be included as part of the
calculation of the operating outlier payments.
Therefore, including the NCTAP payments in
the COVID–19 cases would not impact the
calculation of the outlier threshold.
With respect to the comment that CMS
phase in the large proposed increase to the
fixed-loss threshold over time, if we used a
phase in approach then the fixed loss
threshold for FY 2023 would not meet the
requirement that outlier payments result in
5.1 percent of estimated total payments.
In response to the commenters that
suggested that CMS reexamine its
methodology more closely and adopt
additional changes to offset substantial
increases in the outlier threshold, in addition
to the proposed modifications in the
proposed rule, we are making additional
changes to the methodology for FY 2023 in
this final rule in response to comments,
specifically the averaging of the two fixedloss thresholds and accounting for the
payment increase provided by the CARES
Act.
With respect to the commenter that
suggested that CMS better account for the
data anomalies created by the pandemic until
patient mix becomes more predictable and
the data used for ratesetting reflects a more
stable healthcare environment, as previously
discussed, we recognize that there is
uncertainty regarding the utilization and
costs that hospitals will experience in FY
2023. Therefore, we believe that based on the
information available at this time on the
trajectory of the COVID–19 PHE, our
averaging of the outlier-fixed loss thresholds
as previously described represents the best
estimate of the fixed loss threshold for FY
2023.
With respect to commenters who expressed
concerns regarding the effect of the market
basket update on the calculation of the fixedloss threshold, we refer readers to section
V.A of the preamble of this final rule for our
response to comments about the market
basket update. We note, for this final rule, we
now have an updated forecast of the price
proxies underlying the market basket that
incorporates more recent historical data and
reflects a revised outlook regarding the U.S.
economy (which incorporates more recent
historical CPI growth, estimated impacts of
the Russia/Ukraine war, expectations
regarding changes to Federal Reserve interest
rates, and the estimated impacts of continued
tight labor markets).
Comment: A commenter requested that
CMS consider whether it is appropriate to
include extreme cases when calculating the
threshold. This commenter explained that
high charge cases have a significant impact
on the threshold. The commenter stated that
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
it examined the data to understand the
factors that drove an increase of over $7,000
in the threshold between FY 2017 and FY
2022 and stated that it observed that the
inclusion of extreme cases in the calculation
of the threshold, the rate of which are
increasing over time, significantly impacts
CMS’ determination of the fixed-loss
threshold. If this trend continues (that is, if
the number (and proportion) of extreme cases
continues to increase each year), the
commenter stated that the impact of this
population of cases on the threshold will
likewise increase. Thus, the commenter
recommended that CMS carefully consider
what is causing this trend, whether the
inclusion of these cases in the calculation of
the threshold is appropriate, or whether a
separate outlier mechanism should apply to
these cases that more closely hews outlier
payments to marginal costs. The commenter
believes this is consistent with the
calculation process used for IPPS rate setting
generally and that a 2013 OIG Report,
Medicare Hospital Outlier Payments Warrant
Increased Scrutiny, https://oig.hhs.gov/oei/
reports/oei-06-10-00520.asp, concurs with
this view. Another commenter suggested that
CMS take steps to ensure that the outlier
threshold approximates the FY 2022 outlier
threshold.
Response: As we explained when
responding to a similar comment in the FY
2018 IPPS/LTCH PPS final rule (82 FR
38526), the methodology used to calculate
the outlier threshold includes all claims in
order to account for all different types of
cases, including high charge cases, to ensure
that CMS meets the 5.1 percent target. As the
commenter pointed out, the volume of these
cases continues to rise, making their impact
on the threshold significant. We believe
excluding these cases would artificially
lower the threshold. We believe it is
important to include all cases in the
calculation of the threshold no matter how
high or low the charges. Including these
cases with high charges lends more accuracy
to the threshold, as these cases have an
impact on the threshold and continue to rise
in volume. Therefore, we believe the
inclusion of the high-cost outlier cases in the
calculation of the outlier threshold is
appropriate.
Also, with regard to the 2013 OIG report
that the commenter references, this report
studied the distribution of outlier payments
and made recommendations based on the
OIG findings, but did not mention concerns
or make any recommendations with regard to
the calculation of the outlier threshold.
Therefore, we do not agree with the
commenter that the OIG report concurs with
its view.
Comment: A commenter stated that it
believes that ordinarily it is important to the
process for setting the outlier threshold that
CMS accurately calculate prior year actual
payment comparisons to the 5.1 percent
target. Without doing so, the commenter
stated it is impossible for CMS to
appropriately modify its methodology to
achieve an accurate result. The commenter
also noted that CMS’ estimates of past outlier
payments also routinely exceed the
calculations of outlier payments based on
PO 00000
Frm 00648
Fmt 4701
Sfmt 4700
HCRIS cost report data. The commenter
emphasized the importance of CMS using the
most recent data available to more accurately
assess the outlier payment level. The
commenter stated that CMS has generally
fallen short of its 5.1 percent outlier target
virtually every FY since at least 2013 (the
exceptions being meeting it in FY 2019 and
exceeding it during the PHE) and yet is still
proposing a significant increase in the
threshold this year with no rationale offered
to explain the prior years’ shortfalls in outlier
payments. Another commenter stated that to
the extent an increase in the fixed loss
threshold is necessary, it should be limited
to the market basket increase.
Response: As noted previously, section
1886(d)(5)(A)(iv) of the Act states that outlier
payments may not be not less than 5 percent
nor more than 6 percent of the total payments
projected or estimated to be made based on
DRG prospective payment rates for
discharges in that year. With regard to the
comment that CMS has generally fallen short
of its 5.1% outlier target virtually every FY
since at least 2013 (the exceptions being
meeting it in FY 2019 and exceeding it
during the PHE) and yet is still proposing a
significant increase in the threshold this year
with no rationale offered to explain the prior
year shortfalls in payment, as we have
previously stated in the FY 2015 IPPS/LTCH
PPS final rule (79 FR 50379) and the FY 2016
IPPS/LTCH PPS final rule (80 FR 49783),
when we conduct our modeling to determine
the outlier threshold, we generally factor in
all payments and policies that would affect
actual payments for the current year in order
to estimate that outlier payments are 5.1
percent of total MS–DRG payments. While
we recognize that outlier payments
sometimes are below the 5.1 percent target in
prior fiscal years, we do not believe that
these lower payouts are relevant to the
current fiscal year because they do not lend
greater accuracy to the estimate of payments
that are 5.1 percent of total MS–DRG
payments for the upcoming fiscal year for FY
2023. We also note that in response to
concerns such as the commenters’, over the
years we have modified our outlier threshold
calculation by changing the way we adjust
the CCRs, changing the measure of inflation
and incorporating an adjustment for outlier
reconciliation. While the commenter has
expressed their concern, we note they have
not provided any suggestions for how CMS
can improve the calculation of the outlier
threshold (based on the concerns expressed
by this commenter). As in prior years, CMS
will continue to evaluate our methodology of
calculating the fixed loss threshold and
consider any suggestions made by the
commenters to improve the accuracy of the
calculation of the outlier threshold.
We did not receive comments on our
proposal to use the estimated per-discharge
supplemental payments for eligible IHS/
Tribal hospitals and Puerto Rico hospitals to
hospitals eligible for the supplemental
payment for all cases in the calculation of the
proposed outlier fixed-loss cost threshold
methodology. Therefore, we are finalizing as
proposed without modification to include the
estimated per-discharge supplemental
payments to hospitals eligible for the
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
supplemental payment for all cases in the
calculation of the proposed outlier fixed-loss
cost threshold methodology.
After consideration of the public comments
we received, we are finalizing the
methodology we proposed to calculate the
final outlier threshold with the two
modifications described previously. That is,
we are using the same methodology as
proposed, which includes the use of charge
inflation data and the CCR adjustment factors
from the period preceding the PHE, with the
modification that we calculated two fixedloss thresholds using this methodology, one
using FY 2021 claims data including COVID–
19 cases that reflect the payment increase
provided by the CARES Act and one using
FY 2021 claims data excluding COVID–19
cases, and then averaged these two fixed-loss
thresholds to determine the final fixed-loss
threshold for FY 2023.
As discussed previously, we are finalizing
as proposed to calculate charge inflation
using the publicly available FY 2018 and FY
2019 claims data and to incorporate a
projection of outlier payment reconciliations
for the FY 2023 outlier threshold calculation.
For the FY 2023 final outlier threshold, we
used the March 2019 MedPAR file of FY
2018 (October 1, 2017 through September 30,
2018) charge data (released in conjunction
with the FY 2020 IPPS/LTCH PPS final rule)
and the March 2020 MedPAR file of FY 2019
(October 1, 2018 through September 30,
2019) charge data (released in conjunction
with the FY 2021 IPPS/LTCH PPS final rule)
to determine the charge inflation factor. To
compute the 1 year average annual rate of
change in charges per case, we compared the
average covered charge per case of
$61,578.82 ($584,618,863,834/9,493,830
cases) from October 1, 2017 through
September 31, 2018, to the average covered
charge per case of $65,522.10
($604,209,834,327/9,221,466 cases) from
October 1, 2018 through September 31, 2019.
This rate-of-change was 6.4 percent (1.06404)
or 13.2 percent over 2 years (1.13218) .
Because are using the FY 2021 MedPAR for
the FY 2023 ratesetting, we applied a factor
of 13.2 percent over 2 years. The billed
charges are obtained from the claim from the
MedPAR file and inflated by the inflation
factor specified previously.
For FY 2023, as we have done in the past,
we are establishing the FY 2023 outlier
threshold using hospital CCRs from the
March 2022 update to the Provider-Specific
File (PSF); the most recent available data at
the time of the development of the final rule.
We applied the following edits to providers’
CCRs in the PSF. We believe these edits are
appropriate in order to accurately model the
outlier threshold. We first search for Indian
Health Service providers and those providers
assigned the statewide average CCR from the
current fiscal year. We then replaced these
CCRs with the statewide average CCR for the
upcoming fiscal year. We also assigned the
statewide average CCR (for the upcoming
fiscal year) to those providers that have no
value in the CCR field in the PSF or whose
CCRs exceed the ceilings described later in
this section (3.0 standard deviations from the
mean of the log distribution of CCRs for all
hospitals). We did not apply the adjustment
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
factors described below to hospitals assigned
the statewide average CCR. For FY 2023, we
also are continuing to apply an adjustment
factor to the CCRs to account for cost and
charge inflation (as explained below).
As previously discussed, ordinarily, for the
final rule, using the latest available data at
the time of this final rule, we would apply
an adjustment factor to adjust the CCRs from
the March 2022 update of the PSF by
comparing the percentage change in the
national average case-weighted operating
CCR and capital CCR from the March 2021
update of the PSF to the national average
case-weighted operating CCR and capital
CCR from the March 2022 update of the PSF.
However, for the reasons as previously
discussed, we are finalizing as proposed to
adjust the CCRs from the March 2022 update
of the PSF by comparing the percentage
change in the national average case-weighted
operating CCR and capital CCR from the
March 2019 update of the PSF to the national
average case-weighted operating CCR and
capital CCR from the March 2020 update of
the PSF, which is the last update of the PSF
prior to the PHE. We note that this is the
same data used to adjust the CCRs for the FY
2022 IPPS/LTCH PPS rulemaking. As
previously stated, we believe using these data
for the latest available period prior to the
PHE, for which the percentage change in the
national average case weighted operating
CCR and capital CCR is below 1.0, is
appropriate in light of our expectation that
the CCRs will not continue to increase at
these abnormally high rates for FY 2023. We
note that we used total transfer-adjusted
cases from FY 2019 to determine the national
average case-weighted CCRs for both sides of
the comparison. As stated in the FY 2014
IPPS/LTCH PPS final rule (78 FR 50979), we
believe that it is appropriate to use the same
case count on both sides of the comparison,
because this would produce the true
percentage change in the average caseweighted operating and capital CCR from 1
year to the next without any effect from a
change in case count on different sides of the
comparison.
Using this methodology, for this final rule,
we calculated a March 2019 operating
national average case-weighted CCR of
0.254027 and a March 2020 operating
national average case-weighted CCR of
0.247548. We then calculated the percentage
change between the two national operating
case-weighted CCRs by subtracting the March
2019 operating national average caseweighted CCR from the March 2020 operating
national average case-weighted CCR and then
dividing the result by the March 2019
national operating average case-weighted
CCR. This resulted in a 1-year national
operating CCR adjustment factor of 0.974495.
Similar to the proposed rule, because we are
using CCRs from the March 2022 update of
the PSF for FY 2023, we applied a 1-year
national operating CCR adjustment.
We used this same methodology to adjust
the capital CCRs. Specifically, we calculated
a March 2019 capital national average caseweighted CCR of 0.02073 and a March 2020
capital national average case-weighted CCR
of 0.019935. We then calculated the
percentage change between the two national
PO 00000
Frm 00649
Fmt 4701
Sfmt 4700
49427
capital case-weighted CCRs by subtracting
the March 2019 capital national average caseweighted CCR from the March 2020 capital
national average case-weighted CCR and then
dividing the result by the March 2019 capital
national average case-weighted CCR. This
resulted in a 1-year national capital CCR
adjustment factor of 0.96165. Similar to the
proposed rule, because we use CCRs from the
March 2022 update of the PSF for FY 2023,
we applied a 1-year national capital CCR
adjustment.
As discussed previously, consistent with
the proposed rule, for FY 2023, we applied
the following policies (as discussed in more
detail earlier):
• We used a wage index based on the FY
2023 wage index that hospitals will be paid.
This included our final policy to include the
wage data of hospitals that have reclassified
from urban to rural under section
1886(d)(8)(E) of the Act (as implemented in
the regulations at § 412.103) in the
calculation of the rural floor (see section
III.G.1. of the preamble of this final rule for
a complete discussion on this policy);
application of the imputed floor adjustment,
the frontier State floor adjustment in
accordance with section 10324(a) of the
Affordable Care Act, and the out migration
adjustment as added by section 505 of Public
Law 108–173; and application of our wage
index policies to: (1) increase the wage index
values for hospitals with a wage index value
below the 25th percentile wage index value
across all hospitals, and (2) apply a 5-percent
cap on any decrease to a hospital’s wage
index from its wage index in the prior FY,
regardless of the circumstances causing the
decline (described in section III. N of the
preamble of this final rule). As stated
previously, if we did not take the above into
account, our estimate of total FY 2023
payments would be too low, and, as a result,
our outlier threshold would be too high, such
that estimated outlier payments would be
less than our projected 5.12 percent of total
payments (which reflects the estimate of
outlier reconciliation calculated for this final
rule).
• We excluded the hospital VBP payment
adjustments and the hospital readmissions
payment adjustments from the calculation of
the outlier fixed-loss cost threshold.
• We used the estimated per-discharge
uncompensated care payments to hospitals
eligible for the uncompensated care payment
for all cases in the calculation of the outlier
fixed-loss cost threshold methodology.
• Based on the policy finalized, as
previously described, we used the estimated
per-discharge supplemental payments to
hospitals eligible for the supplemental
payment for all cases in the calculation of the
proposed outlier fixed-loss cost threshold
methodology.
Using this methodology, we used the
formula described in section I.C.1 of this
Addendum to simulate and calculate the
Federal payment rate and outlier payments
for all claims. In addition, as described in the
earlier section to this Addendum, we are
finalizing to incorporate an estimate of FY
2023 outlier reconciliation in the
methodology for determining the outlier
threshold. As noted previously, for this FY
E:\FR\FM\10AUR2.SGM
10AUR2
49428
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
2023 final rule, the ratio of outlier
reconciliation dollars to total Federal
Payments (Step 4) is a negative 0.019401
percent, which when rounded to the second
digit, is 0.02 percent. Therefore, for FY 2023,
we incorporated a projection of outlier
reconciliation dollars by targeting an outlier
threshold at 5.12 percent [5.1 percent¥(0.02
percent)].
As previously discussed, after
consideration of the comments we received,
we are modifying elements of our calculation
of the fixed-loss threshold by averaging the
fixed-loss thresholds calculated including
and excluding COVID–19 cases in the FY
2021 claims data. We also agreed with the
commenter’s suggestion that we include the
payment increase for COVID–19 cases
provided by the CARES Act. As discussed
previously, we calculated two fixed-loss
thresholds, one using FY 2021 claims data
including COVID–19 cases that reflect the
payment increase provided by the CARES
Act and one using FY 2021 claims data
excluding COVID–19 cases, and then
averaged these two fixed-loss thresholds to
determine the final fixed-loss threshold for
FY 2023.
Based on this finalized averaging approach,
the following are the steps we used to
determine the final fixed-loss threshold for
FY 2023 using FY 2021 claims data.
Step 1: Using all claims, which included
COVID–19 cases and incorporating the
payment increase provided by the CARES
Act, we determined a threshold of $39,389
and calculated total outlier payments of
$4,658,400,549 and total operating Federal
payments of $86,325,462,972. We then
divided total outlier payments by total
operating Federal payments plus total outlier
payments and determined that this threshold
matched with the 5.12 percent target, which
reflects our methodology to incorporate an
estimate of outlier reconciliation in the
determination of the outlier threshold (as
discussed in more detail in the previous
section of this Addendum).
Step 2: Excluding COVID–19 cases, we
determined a threshold of $38,328 and
National
calculated total outlier payments of
$4,073,729,554 and total operating Federal
payments of $75,488,568,943. We then
divided total outlier payments by total
operating Federal payments plus total outlier
payments and determined that this threshold
matched with the 5.12 percent target, which
reflects our methodology to incorporate an
estimate of outlier reconciliation in the
determination of the outlier threshold (as
discussed in more detail in the previous
section of this Addendum).
Step 3: We averaged the two fixed-loss
thresholds from steps 1 and 2 to determine
a final fixed-loss threshold for FY 2023 of
$38,859 (($39,389 + $38,328)/2)).
We are finalizing an outlier fixed-loss cost
threshold for FY 2023 equal to the
prospective payment rate for the MS–DRG,
plus any IME, empirically justified Medicare
DSH payments, estimated uncompensated
care payment, estimated supplemental
payment for eligible IHS/Tribal hospitals and
Puerto Rico hospitals and any addon
payments for new technology, plus $38,859.
Comment: A commenter stated that the
COVID–19 PHE increased case acuity and
payments due to the suspension of the 2%
sequestration. Therefore, the commenter
recommended that payments should be
adjusted from the FY 2022 estimated outlier
threshold because of the temporal nature of
these additional payments.
Response: We appreciate the commenter’s
input. The sequestration reduction is a 2percent reduction to overall payments and is
applied after calculating individual payments
such as outlier payments. Therefore, CMS
has not made any adjustments that consider
the 2-percent reduction in our modeling of
outlier payments. As a result, no change to
the outlier model for FY 2023 is necessary.
With regard to the commenter noting the
increased case acuity, we refer the reader to
section I.F. of this FY 2023 IPPS/LTCH final
rule for a discussion of our final policy .
(3) Other Changes Concerning Outliers
As stated in the FY 1994 IPPS final rule (58
FR 46348), we establish an outlier threshold
Operating Standardized Amounts
0.949
that is applicable to both hospital inpatient
operating costs and hospital inpatient
capital-related costs. When we modeled the
combined operating and capital outlier
payments, we found that using a common
threshold resulted in a higher percentage of
outlier payments for capital-related costs
than for operating costs. We project that the
threshold for FY 2023 (which reflects our
methodology to incorporate an estimate of
operating outlier reconciliation) would result
in operating outlier payments that would
equal 5.1 percent of operating DRG
payments. As discussed previously, once an
outlier threshold is set, it is used to estimate
the percentage of capital outlier payments to
total capital payments based on that
threshold. Therefore, our modified
methodology produces two separate
estimates of the percentage of capital outlier
payments to total capital payments. One
estimate is based on the shared threshold that
was determined using all cases in the FY
2021 data. The other estimate is based on the
shared threshold that was determined
excluding COVID–19 cases in the FY 2021
data. As stated, we averaged these two
estimates together to establish the final
estimate of capital outlier payments to total
capital payments for FY 2023. Therefore,
based on this finalized methodology to
average these two estimates, we estimate that
capital outlier payments would equal 5.52
percent of capital payments based on the
Federal rate (which reflects our methodology
discussed previously to incorporate an
estimate of capital outlier reconciliation).
In accordance with section 1886(d)(3)(B) of
the Act and as discussed previously, we are
reducing the FY 2023 standardized amount
by 5.1 percent to account for the projected
proportion of payments paid as outliers.
The outlier adjustment factors that would
be applied to the operating standardized
amount and capital Federal rate based on the
FY 2023 outlier threshold are as follows:
Capital Federal Rate*
0.944837
We are applying the outlier adjustment
factors to the FY 2023 payment rates after
removing the effects of the FY 2022 outlier
adjustment factors on the standardized
amount.
To determine whether a case qualifies for
outlier payments, we currently apply
hospital-specific CCRs to the total covered
charges for the case. Estimated operating and
capital costs for the case are calculated
separately by applying separate operating
and capital CCRs. These costs are then
combined and compared with the outlier
fixed-loss cost threshold.
Under our current policy at § 412.84, we
calculate operating and capital CCR ceilings
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
and assign a statewide average CCR for
hospitals whose CCRs exceed 3.0 standard
deviations from the mean of the log
distribution of CCRs for all hospitals. Based
on this calculation, for hospitals for which
the MAC computes operating CCRs greater
than 1.224 or capital CCRs greater than 0.134
or hospitals for which the MAC is unable to
calculate a CCR (as described under
§ 412.84(i)(3) of our regulations), statewide
average CCRs are used to determine whether
a hospital qualifies for outlier payments.
Table 8A listed in section VI. of this
Addendum (and available via the internet on
the CMS website) contains the statewide
average operating CCRs for urban hospitals
PO 00000
Frm 00650
Fmt 4701
Sfmt 4700
and for rural hospitals for which the MAC is
unable to compute a hospital-specific CCR
within the range previously specified. These
statewide average ratios would be effective
for discharges occurring on or after October
1, 2022, and would replace the statewide
average ratios from the prior fiscal year.
Table 8B listed in section VI. of this
Addendum (and available via the internet on
the CMS website) contains the comparable
statewide average capital CCRs. As
previously stated, the CCRs in Tables 8A and
8B would be used during FY 2023 when
hospital-specific CCRs based on the latest
settled cost report either are not available or
are outside the range noted previously. Table
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.215
khammond on DSKJM1Z7X2PROD with RULES2
*The adjustment factor for the capital Federal rate reflects this final rule's modified calculation and includes an adjustment to the
estimated percentage of FY 2023 capital outlier payments for capital outlier reconciliation, as discussed previously and in section
III. A. 2 in the Addendum of this final rule.
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
8C listed in section VI. of this Addendum
(and available via the internet on the CMS
website) contains the statewide average total
CCRs used under the LTCH PPS as discussed
in section V. of this Addendum.
We finally note that section 20.1.2 of
chapter three of the Medicare Claims
Processing Manual (on the internet at https://
www.cms.gov/Regulations-and-Guidance/
Guidance/Manuals/Downloads/
clm104c03.pdf) covers an array of topics,
including CCRs, reconciliation, and the time
value of money. We encourage hospitals that
are assigned the statewide average operating
and/or capital CCRs to work with their MAC
on a possible alternative operating and/or
capital CCR as explained in the manual. Use
of an alternative CCR developed by the
hospital in conjunction with the MAC can
avoid possible overpayments or
underpayments at cost report settlement,
thereby ensuring better accuracy when
making outlier payments and negating the
need for outlier reconciliation. We also note
that a hospital may request an alternative
operating or capital CCR at any time as long
as the guidelines of the manual are followed.
In addition, the manual outlines the outlier
reconciliation process for hospitals and
Medicare contractors. We refer hospitals to
the manual instructions for complete details
on outlier reconciliation.
(4) FY 2021 Outlier Payments
Our current estimate, using available FY
2021 claims data, is that actual outlier
payments for FY 2021 were approximately
5.66 percent of actual total MS–DRG
payments. Therefore, the data indicate that,
for FY 2021, the percentage of actual outlier
payments relative to actual total payments is
higher than we projected for FY 2021.
Consistent with the policy and statutory
interpretation we have maintained since the
inception of the IPPS, we do not make
retroactive adjustments to outlier payments
to ensure that total outlier payments for FY
2021 are equal to 5.1 percent of total MS–
DRG payments. As explained in the FY 2003
Outlier final rule (68 FR 34502), if we were
to make retroactive adjustments to all outlier
payments to ensure total payments are 5.1
percent of MS–DRG payments (by
retroactively adjusting outlier payments), we
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
would be removing the important aspect of
the prospective nature of the IPPS. Because
such an across-the-board adjustment would
either lead to more or less outlier payments
for all hospitals, hospitals would no longer
be able to reliably approximate their payment
for a patient while the patient is still
hospitalized. We believe it would be neither
necessary nor appropriate to make such an
aggregate retroactive adjustment.
Furthermore, we believe it is consistent with
the statutory language at section
1886(d)(5)(A)(iv) of the Act not to make
retroactive adjustments to outlier payments.
This section states that outlier payments be
equal to or greater than 5 percent and less
than or equal to 6 percent of projected or
estimated (not actual) MS–DRG payments.
We believe that an important goal of a PPS
is predictability. Therefore, we believe that
the fixed-loss outlier threshold should be
projected based on the best available
historical data and should not be adjusted
retroactively. A retroactive change to the
fixed-loss outlier threshold would affect all
hospitals subject to the IPPS, thereby
undercutting the predictability of the system
as a whole.
We note that, because the MedPAR claims
data for the entire FY 2022 period would not
be available until after September 30, 2022,
we are unable to provide an estimate of
actual outlier payments for FY 2022 based on
FY 2022 claims data in the proposed rule and
this final rule. We will provide an estimate
of actual FY 2022 outlier payments in the FY
2024 IPPS/LTCH PPS proposed rule.
5. FY 2023 Standardized Amount
The adjusted standardized amount is
divided into labor-related and nonlaborrelated portions. Tables 1A and 1B listed and
published in section VI. of this Addendum
(and available via the internet on the CMS
website) contain the national standardized
amounts that we are applying to all hospitals,
except hospitals located in Puerto Rico, for
FY 2023. The standardized amount for
hospitals in Puerto Rico is shown in Table 1C
listed and published in section VI. of this
Addendum (and available via the internet on
the CMS website). The amounts shown in
Tables 1A and 1B differ only in that the
labor-related share applied to the
PO 00000
Frm 00651
Fmt 4701
Sfmt 4700
49429
standardized amounts in Table 1A is 67.6
percent, and the labor-related share applied
to the standardized amounts in Table 1B is
62 percent. In accordance with sections
1886(d)(3)(E) and 1886(d)(9)(C)(iv) of the Act,
we are applying a labor-related share of 62
percent, unless application of that percentage
would result in lower payments to a hospital
than would otherwise be made. In effect, the
statutory provision means that we would
apply a labor-related share of 62 percent for
all hospitals whose wage indexes are less
than or equal to 1.0000.
In addition, Tables 1A and 1B include the
standardized amounts reflecting the
applicable percentage increases for FY 2023.
The labor-related and nonlabor-related
portions of the national average standardized
amounts for Puerto Rico hospitals for FY
2023 are set forth in Table 1C listed and
published in section VI. of this Addendum
(and available via the internet on the CMS
website). Similarly, section 1886(d)(9)(C)(iv)
of the Act, as amended by section 403(b) of
Public Law 108–173, provides that the laborrelated share for hospitals located in Puerto
Rico be 62 percent, unless the application of
that percentage would result in lower
payments to the hospital.
The following table illustrates the changes
from the FY 2022 national standardized
amounts to the FY 2023 national
standardized amounts. The second through
fifth columns display the changes from the
FY 2022 standardized amounts for each
applicable FY 2023 standardized amount.
The first row of the table shows the updated
(through FY 2022) average standardized
amount after restoring the FY 2022 offsets for
outlier payments, geographic reclassification,
rural demonstration, lowest quartile, and
transition budget neutrality. The MS–DRG
reclassification and recalibration, wage
index, and stem cell acquisition budget
neutrality factors are cumulative (that is, we
have not restored the offsets). Accordingly,
those FY 2022 adjustment factors have not
been removed from the base rate in the
following table. Additionally, for FY 2023 we
have applied the budget neutrality factors for
the lowest quartile hospital policy, described
previously.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49430
VerDate Sep<11>2014
Jkt 256001
PO 00000
Frm 00652
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
FY 2023 Base Rate after removing: 1. FY 2022
Geographic Reclassification Budget Neutrality
(0.986741)
2. FY 2022 Operating Outlier Offset (0.949)
3. FY 2022 Rural Demonstration Budget Neutrality
Factor (0.999361)
4. FY 2022 Lowest Quartile Budget Neutrality Factor
(0.998029)
5. FY 2022 Transition Budget Neutrality Factor
(0 999859)
FY 2023 Uodate Factor
FY 2023 MS-DRG Reclassification and Recalibration
Budqet Neutrality Factor Before Cao
FY 2023 Cap Policy MS-DRG Weight Budget Neutrality
Factor
FY 2023 Waae Index Budaet Neutrality Factor
FY 2023 Reclassification Budaet Neutrality Factor
FY 2023 Lowest Quartile Budqet Neutrality Factor
FY 2023 Cap Policy Wage Index Budget Neutrality
Factor
FY 2023 RCH Demonstration Budaet Neutrality Factor
FY 2023 Operatinq Outlier Factor
Adjustment for FY 2023 Required under Section 414 of
Pub. L. 114-10 (MACRAl
National Standardized Amount for FY 2023 if Wage
Index is Greater Than 1.0000; Labor/Non-Labor
Share Percentaae (67 .6/32.4)
National Standardized Amount for FY 2023 if Wage
Index is Less Than or Equal to 1.0000; Labor/NonLabor Share Percentaae (62/38)
If Wage Index is less Than or Equal to
1.0000:
Labor (62%): $4,064.31
Nonlabor (38%): $ 2,491.03
Hospital Did NOT Submit Quality
Data and is a Meaningful EHR
User
If Wage Index is Greater Than
1.0000:
Labor(67.6%): $4,431.41
Nonlabor (32.4%): $2,123.93
If Wage Index is less Than or Equal
to 1.0000:
Labor (62%): $ 4,064.31
Nonlabor (38%): $ 2,491.03
If Wage Index is less Than or Equal to
1.0000:
Labor (62%): $4,064.31
Non labor (38%): $2,491.03
1.038
1.00725
1.02775
0.9970
1.000509
1.000509
1.000509
1.000509
0.999764
1.000968
0.984399
0.998146
0.999764
1.000968
0.984399
0.998146
0.999764
1.000968
0.984399
0.998146
0.999764
1.000968
0.984399
0.998146
0.999689
0.998935
0.949
0.999689
0.998935
0.949
0.999689
0.998935
0.949
0.999689
0.998935
0.949
1.005
1.005
1.005
1.005
Labor: $4,310.00
Non labor $2 065. 74
Labor: $4,182.32
Nonlabor: $2 004.54
Labor: $4,267.44
Nonlabor: $2 045.34
Labor: $4,139.76
Nonlabor: $1 984.15
Labor: $3,952.96
Nonlabor: $2,422.78
Labor: $3,835.85
Non labor: $2,351.01
Labor: $3,913.92
Non labor: $2,398.86
Labor: $3,796.82
Non labor: $2,327.09
Hospital Submitted Quality Data and
is a Meaningful EHR User
If Wage Index is Greater Than 1.0000:
Labor (67.6%): $4,431.41
Nonlabor (32.4%): $2,123.93
Hospital Submitted Quality Data and is
NOT a Meaningful EHR User
If Wage Index is Greater Than 1.0000:
Labor (67.6%): $4,431.41
Nonlabor (32.4%): $2,123.93
If Wage Index is less Than or Equal to
1.0000:
Labor (62%): $4,064.31
Nonlabor (38%): $ 2,491.03
Hospital Did NOT Submit Quality
Data and is NOT a Meaningful EHR
User
If Wage Index is Greater Than 1.0000:
Labor (67.6%): $4,431.41
Non labor (32.4%): $2,123.93
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
ER10AU22.216
CHANGES FROM FY 2022 STANDARDIZED AMOUNTS TO THE FY 2023 STANDARDIZED AMOUNTS
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
B. Adjustments for Area Wage Levels and
Cost-of-Living
Tables 1A through 1C, as published in
section VI. of this Addendum (and available
via the internet on the CMS website), contain
the labor-related and nonlabor-related shares
that we are using to calculate the prospective
payment rates for hospitals located in the 50
States, the District of Columbia, and Puerto
Rico for FY 2023. This section addresses two
types of adjustments to the standardized
amounts that are made in determining the
prospective payment rates as described in
this Addendum.
1. Adjustment for Area Wage Levels
Sections 1886(d)(3)(E) and
1886(d)(9)(C)(iv) of the Act require that we
make an adjustment to the labor-related
portion of the national prospective payment
rate to account for area differences in
hospital wage levels. This adjustment is
made by multiplying the labor-related
portion of the adjusted standardized amounts
by the appropriate wage index for the area in
which the hospital is located. For FY 2023,
as discussed in section IV.B.3. of the
preamble of this final rule, we are applying
a labor-related share of 67.6 percent for the
national standardized amounts for all IPPS
hospitals (including hospitals in Puerto Rico)
that have a wage index value that is greater
than 1.0000. Consistent with section
1886(d)(3)(E) of the Act, we are applying the
wage index to a labor-related share of 62
percent of the national standardized amount
for all IPPS hospitals (including hospitals in
Puerto Rico) whose wage index values are
less than or equal to 1.0000. In section III. of
the preamble of this final rule, we discuss the
data and methodology for the FY 2023 wage
index.
2. Adjustment for Cost-of-Living in Alaska
and Hawaii
Section 1886(d)(5)(H) of the Act provides
discretionary authority to the Secretary to
make adjustments as the Secretary deems
appropriate to take into account the unique
circumstances of hospitals located in Alaska
and Hawaii. Higher labor-related costs for
these two States are taken into account in the
adjustment for area wages described
previously. To account for higher non-labor
related costs for these two States, we
multiply the nonlabor-related portion of the
standardized amount for hospitals in Alaska
and Hawaii by an adjustment factor.
49431
In the FY 2013 IPPS/LTCH PPS final rule,
we established a methodology to update the
COLA factors for Alaska and Hawaii that
were published by the U.S. Office of
Personnel Management (OPM) every 4 years
(at the same time as the update to the labor
related share of the IPPS market basket),
beginning in FY 2014. We refer readers to the
FY 2013 IPPS/LTCH PPS proposed and final
rules for additional background and a
detailed description of this methodology (77
FR 28145 through 28146 and 77 FR 53700
through 53701, respectively). For FY 2022, in
the FY 2022 IPPS/LTCH PPS final rule (86 FR
45546 through 45547), we updated the COLA
factors published by OPM for 2009 (as these
are the last COLA factors OPM published
prior to transitioning from COLAs to locality
pay) using the methodology that we finalized
in the FY 2013 IPPS/LTCH PPS final rule.
Based on the policy finalized in the FY 2013
IPPS/LTCH PPS final rule, we are continuing
to use the same COLA factors in FY 2023 that
were used in FY 2022 to adjust the nonlaborrelated portion of the standardized amount
for hospitals located in Alaska and Hawaii.
The following table lists the COLA factors for
FY 2023.
FY 2023 Cost-of-Living Adjustment Factors (COLA):
Alaska and Hawaii Hospitals
Area
FY 2022 - FY 2025
Alaska:
City of Anchorage and 80-kilometer (50-mile) radius by road
City of Fairbanks and 80-kilometer (50-mile) radius by road
Citv ofJuneau and 80-kilometer (50-mile) radius bv road
Rest of Alaska
Hawaii:
City and County of Honolulu
County of Hawaii
County of Kauai
County of Maui and County of Kalawao
C. Calculation of the Prospective Payment
Rates
khammond on DSKJM1Z7X2PROD with RULES2
1. General Formula for Calculation of the
Prospective Payment Rates for FY 2023
In general, the operating prospective
payment rate for all hospitals (including
hospitals in Puerto Rico) paid under the
IPPS, except SCHs, for FY 2023 equals the
Federal rate (which includes uncompensated
care payments). Under current law, the MDH
program is effective for discharges on or
before September 30, 2022. Therefore, under
current law, the MDH program will expire at
the end of FY 2022.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
SCHs are paid based on whichever of the
following rates yields the greatest aggregate
payment: the Federal national rate (which, as
discussed in section VI.G. of the preamble of
this final rule, includes uncompensated care
payments); the updated hospital-specific rate
based on FY 1982 costs per discharge; the
updated hospital-specific rate based on FY
1987 costs per discharge; the updated
hospital-specific rate based on FY 1996 costs
per discharge; or the updated hospitalspecific rate based on FY 2006 costs per
discharge to determine the rate that yields
the greatest aggregate payment.
The prospective payment rate for SCHs for
FY 2022 equals the higher of the applicable
Federal rate, or the hospital-specific rate as
described later in this section.
2. Operating and Capital Federal Payment
Rate and Outlier Payment Calculation
Note: The formula specified in this section
is used for actual claim payment and is also
PO 00000
Frm 00653
Fmt 4701
Sfmt 4700
1.25
1.22
1.25
1.25
used by CMS to project the outlier threshold
for the upcoming fiscal year. The difference
is the source of some of the variables in the
formula. For example, operating and capital
CCRs for actual claim payment are from the
PSF while CMS uses an adjusted CCR (as
described previously) to project the threshold
for the upcoming fiscal year. In addition,
charges for a claim payment are from the bill
while charges to project the threshold are
from the MedPAR data with an inflation
factor applied to the charges (as described
earlier). We note that the formula specified
below reflects our finalized policy to include
the estimated supplemental payment for
eligible IHS/Tribal hospitals and Puerto Rico
hospitals in the computation of the outlier
fixed-loss cost threshold.
Step 1—Determine the MS–DRG and MS–
DRG relative weight (from Table 5) for each
claim based on the ICD–10–CM diagnosis
and ICD–10–PCS procedure codes on the
claim.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.217
Lastly, as we finalized in the FY 2013
IPPS/LTCH PPS final rule (77 FR 53700 and
53701), we intend to update the COLA
factors based on our methodology every 4
years, at the same time as the update to the
labor-related share of the IPPS market basket.
1.22
1.22
1.22
1.24
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Step 2—Select the applicable average
standardized amount depending on whether
the hospital submitted qualifying quality data
and is a meaningful EHR user, as described
previously.
Step 3—Compute the operating and capital
Federal payment rate:
— Federal Payment Rate for Operating Costs
= MS–DRG Relative Weight × [(LaborRelated Applicable Standardized
Amount × Applicable CBSA Wage Index)
+ (Nonlabor-Related Applicable
Standardized Amount × Cost-of-Living
Adjustment)] × (1 + IME + (DSH * 0.25))
— Federal Payment for Capital Costs = MS–
DRG Relative Weight × Federal Capital
Rate × Geographic Adjustment Fact × (l
+ IME + DSH)
Step 4—Determine operating and capital
costs:
— Operating Costs = (Billed Charges ×
Operating CCR)
— Capital Costs = (Billed Charges × Capital
CCR).
Step 5—Compute operating and capital
outlier threshold (CMS applies a geographic
adjustment to the operating and capital
outlier threshold to account for local cost
variation):
— Operating CCR to Total CCR = (Operating
CCR)/(Operating CCR + Capital CCR)
— Operating Outlier Threshold = [Fixed Loss
Threshold × ((Labor-Related Portion ×
CBSA Wage Index) + Nonlabor-Related
portion)] × Operating CCR to Total CCR
+ Federal Payment with IME, DSH +
Uncompensated Care Payment +
Supplemental Payment for IHS/Tribal
hospitals and Puerto Rico hospitals +
New Technology Add-On Payment
Amount
— Capital CCR to Total CCR = (Capital CCR)/
(Operating CCR + Capital CCR)
— Capital Outlier Threshold = (Fixed Loss
Threshold × Geographic Adjustment
Factor × Capital CCR to Total CCR) +
Federal Payment with IME and DSH
Step 6—Compute operating and capital
outlier payments:
— Marginal Cost Factor = 0.80 or 0.90
(depending on the MS–DRG)
— Operating Outlier Payment = (Operating
Costs—Operating Outlier Threshold) ×
Marginal Cost Factor
— Capital Outlier Payment = (Capital Costs—
Capital Outlier Threshold) × Marginal
Cost Factor
The payment rate may then be further
adjusted for hospitals that qualify for a lowvolume payment adjustment under section
1886(d)(12) of the Act and 42 CFR
412.101(b). The base-operating DRG payment
amount may be further adjusted by the
hospital readmissions payment adjustment
and the hospital VBP payment adjustment as
described under sections 1886(q) and 1886(o)
of the Act, respectively. Payments also may
be reduced by the 1-percent adjustment
under the HAC Reduction Program as
described in section 1886(p) of the Act. We
also make new technology add-on payments
in accordance with section 1886(d)(5)(K) and
(L) of the Act. In addition, we add the
uncompensated care payment to the total
claim payment amount. As noted in the
previous formula, we take uncompensated
care payments and new technology add-on
payments into consideration when
calculating outlier payments. Finally, as
previously discussed, we are finalizing,
beginning in FY 2023, to take into
consideration the supplemental payment for
eligible IHS/Tribal hospitals and Puerto Rico
hospitals when calculating outlier payments.
3. Hospital-Specific Rate (Applicable Only to
SCHs and MDHs)
a. Calculation of Hospital-Specific Rate
Section 1886(b)(3)(C) of the Act provides
that SCHs are paid based on whichever of the
khammond on DSKJM1Z7X2PROD with RULES2
FY2023
Market Basket Rate-of-Increase
Adjustment for Failure to Submit Quality Data under section
1886(b)(3)(B)(viii) of the Act
Adjustment for Failure to be a Meaningful EHR User under section
1886(b)(3)(B)(ix) of the Act
Productivity Adjustment under section 1886(b)(3)(B)(xi) of the Act
Annlicable Percentae:e Increase Annlied to Standardized Amount
For a complete discussion of the applicable
percentage increase applied to the hospitalspecific rates for SCHs, we refer readers to
section V.B. of the preamble of this final rule.
In addition, because SCHs use the same
MS–DRGs as other hospitals when they are
paid based on the hospital-specific rate, the
hospital-specific rate is adjusted by a budget
neutrality factor to ensure that changes to the
MS–DRG classifications and the recalibration
of the MS–DRG relative weights are made in
a manner so that aggregate IPPS payments are
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Hospital
Submitted
Quality Data
and is a
Meaningful
EHR User
Frm 00654
Fmt 4701
b. Updating the FY 1982, FY 1987, FY 1996,
FY 2002 and FY 2006 Hospital-Specific Rate
for FY 2023
Section 1886(b)(3)(B)(iv) of the Act
provides that the applicable percentage
increase applicable to the hospital-specific
rates for SCHs equals the applicable
percentage increase set forth in section
1886(b)(3)(B)(i) of the Act (that is, the same
update factor as for all other hospitals subject
to the IPPS). Because the Act sets the update
factor for SCHs equal to the update factor for
all other IPPS hospitals, the update to the
hospital-specific rates for SCHs is subject to
the amendments to section 1886(b)(3)(B) of
the Act made by sections 3401(a) and
10319(a) of the Affordable Care Act.
Accordingly, the proposed applicable
percentage increases to the hospital-specific
rates applicable to SCHs are the following:
Hospital
Submitted
Quality Data
and is NOT a
Meaningful
EHR User
Hospital Did
NOT Submit
Quality Data
and is a
Meaningful
EHR User
Hospital Did
NOT Submit
Quality Data
and is NOT a
Meaningful EHR
User
4.1
4.1
4.1
4.1
0
0
-1.025
-1.025
0
-0.3
3.8
-3.075
-0.3
0.725
0
-0.3
2.775
-3.075
-0.3
-0.3
unaffected. Therefore, the hospital specificrate for an SCH is adjusted by the MS–DRG
reclassification and recalibration budget
neutrality factor, as discussed in section III.
of this Addendum and listed in the table in
section II. of this Addendum. In addition, as
discussed in section II.E.2.d of this final rule,
we are establishing a permanent 10-percent
cap on the reduction in a MS–DRG’s relative
weight in a given fiscal year, beginning in FY
2023. As discussed in section II.E.2.d of this
final rule, and consistent with our current
PO 00000
following rates yields the greatest aggregate
payment: the Federal rate; the updated
hospital-specific rate based on FY 1982 costs
per discharge; the updated hospital-specific
rate based on FY 1987 costs per discharge;
the updated hospital-specific rate based on
FY 1996 costs per discharge; or the updated
hospital-specific rate based on FY 2006 costs
per discharge to determine the rate that
yields the greatest aggregate payment. (We
note, under current law, the MDH program is
effective for discharges on or before
September 30, 2022. Therefore, under current
law, the MDH program will expire at the end
of FY 2022.)
For a more detailed discussion of the
calculation of the hospital-specific rates, we
refer readers to the FY 1984 IPPS interim
final rule (48 FR 39772); the April 20, 1990
final rule with comment period (55 FR
15150); the FY 1991 IPPS final rule (55 FR
35994); and the FY 2001 IPPS final rule (65
FR 47082).
Sfmt 4700
methodology for implementing budget
neutrality for DRG reclassification and
recalibration of the relative weights, we are
applying a budget neutrality adjustment to
the standardized amount for all hospitals so
that this 10-percent cap on relative weight
reductions does not increase estimated
aggregate Medicare payments beyond the
payments that would be made had we never
applied this cap. As mentioned previously,
SCHs use the same MS–DRGs as other
hospitals when they are paid based on the
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.218
49432
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
hospital-specific rate. Therefore, we are
establishing that the hospital specific-rate for
an SCH would be adjusted by the MS–DRG
10-percent cap budget neutrality factor. The
resulting rate is used in determining the
payment rate that an SCH would receive for
its discharges beginning on or after October
1, 2022. We note that, in this final rule, for
FY 2023, we are not making a documentation
and coding adjustment to the hospital
specific-rate. We refer readers to section II.D.
of the preamble of this final rule for a
complete discussion regarding our policies
and previously finalized policies (including
our historical adjustments to the payment
rates) relating to the effect of changes in
documentation and coding that do not reflect
real changes in case mix. We note, as
mentioned previously, under current law, the
MDH program is effective for discharges on
or before September 30, 2022. Therefore,
under current law, the MDH program will
expire at the end of FY 2022.
III. Changes to Payment Rates for Acute Care
Hospital Inpatient Capital-Related Costs for
FY 2023
The PPS for acute care hospital inpatient
capital-related costs was implemented for
cost reporting periods beginning on or after
October 1, 1991. The basic methodology for
determining Federal capital prospective rates
is set forth in the regulations at 42 CFR
412.308 through 412.352. In this section of
this Addendum, we discuss the factors that
we used to determine the capital Federal rate
for FY 2023, which would be effective for
discharges occurring on or after October 1,
2022.
All hospitals (except ‘‘new’’ hospitals
under § 412.304(c)(2)) are paid based on the
capital Federal rate. We annually update the
capital standard Federal rate, as provided in
§ 412.308(c)(1), to account for capital input
price increases and other factors. The
regulations at § 412.308(c)(2) also provide
that the capital Federal rate be adjusted
annually by a factor equal to the estimated
proportion of outlier payments under the
capital Federal rate to total capital payments
under the capital Federal rate. In addition,
§ 412.308(c)(3) requires that the capital
Federal rate be reduced by an adjustment
factor equal to the estimated proportion of
payments for exceptions under § 412.348.
(We note that, as discussed in the FY 2013
IPPS/LTCH PPS final rule (77 FR 53705),
there is generally no longer a need for an
exceptions payment adjustment factor.)
However, in limited circumstances, an
additional payment exception for
extraordinary circumstances is provided for
under § 412.348(f) for qualifying hospitals.
Therefore, in accordance with
§ 412.308(c)(3), an exceptions payment
adjustment factor may need to be applied if
such payments are made. Section
412.308(c)(4)(ii) requires that the capital
standard Federal rate be adjusted so that the
effects of the annual DRG reclassification and
the recalibration of DRG weights and changes
in the geographic adjustment factor (GAF) are
budget neutral.
Section 412.374 provides for payments to
hospitals located in Puerto Rico under the
IPPS for acute care hospital inpatient capital-
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
related costs, which currently specifies
capital IPPS payments to hospitals located in
Puerto Rico are based on 100 percent of the
Federal rate.
A. Determination of the Federal Hospital
Inpatient Capital-Related Prospective
Payment Rate Update for FY 2023
In the discussion that follows, we explain
the factors that we used to determine the
capital Federal rate for FY 2023. In
particular, we explain why the FY 2023
capital Federal rate would increase
approximately 2.36 percent, compared to the
FY 2022 capital Federal rate. As discussed in
the impact analysis in Appendix A to this
final rule, we estimate that capital payments
per discharge will increase approximately 0.6
percent during that same period. Because
capital payments constitute approximately 10
percent of hospital payments, a 1-percent
change in the capital Federal rate yields only
approximately a 0.1 percent change in actual
payments to hospitals.
As discussed in section I.F. of the preamble
to this final rule, we are finalizing our
proposal to use FY 2021 data for purposes of
FY 2023 IPPS ratesetting. Consistent with
this policy, for this final rule we are
finalizing our proposal to use claims from the
March 2022 update of the FY 2021 MedPAR
file for purposes of calculating the budget
neutrality adjustment factors for changes
resulting from the annual DRG
reclassification and recalibration and changes
in the GAF. However, as we also discuss in
section I.F. of the preamble to this final rule,
we are finalizing certain modifications to our
usual methodologies to account for the
anticipated decline in COVID–19
hospitalizations of Medicare beneficiaries at
IPPS hospitals in FY 2023 as compared to FY
2021. First, we are modifying the calculation
of the FY 2023 MS–DRG relative weights by
first calculating two sets of weights, one
including and one excluding COVID–19
claims in the FY 2021 data, and then
averaging the two sets of relative weights to
determine the FY 2023 MS–DRG relative
weight values (as described in greater detail
in section II.E. of the preamble to this final
rule). Second, we are modifying our
methodology for determining the FY 2023
outlier fixed-loss amount for IPPS cases by
using charge inflation factors and CCR
adjustment factors based on the last 1-year
period prior to the COVID–19 PHE. We also
are modifying our methodology for
determining the FY 2023 outlier fixed-loss
amount for IPPS cases by establishing the
fixed-loss amount as an average of fixed-loss
amounts calculated including and excluding
COVID–19 claims in the FY 2021 data.
Lastly, we are modifying our methodology for
determining the FY 2023 outlier fixed-loss
amount for IPPS cases by including the
increases in payments to COVID–19 cases
provided by the CARES Act in the
calculation of the fixed-loss amount. The
modifications we have made to our
methodology for determining the FY 2023
outlier fixed-loss amount for IPPS cases are
discussed in greater detail in section II.A.4.
of the Addendum to this final rule.
PO 00000
Frm 00655
Fmt 4701
Sfmt 4700
49433
1. Projected Capital Standard Federal Rate
Update
Under § 412.308(c)(1), the capital standard
Federal rate is updated on the basis of an
analytical framework that takes into account
changes in a capital input price index (CIPI)
and several other policy adjustment factors.
Specifically, we adjust the projected CIPI rate
of change, as appropriate, each year for casemix index-related changes, for intensity, and
for errors in previous CIPI forecasts. The
update factor for FY 2023 under that
framework is 2.5 percent based on a
projected 2.5 percent increase in the 2018based CIPI, a 0.0 percentage point adjustment
for intensity, a 0.0 percentage point
adjustment for case-mix, a 0.0 percentage
point adjustment for the DRG reclassification
and recalibration, and a forecast error
correction of 0.0 percentage point. As
discussed in section III.C. of this Addendum,
we continue to believe that the CIPI is the
most appropriate input price index for
capital costs to measure capital price changes
in a given year. We also explain the basis for
the FY 2023 CIPI projection in that same
section of this Addendum. In this final rule,
we describe the policy adjustments that we
applied in the update framework for FY
2023.
The case-mix index is the measure of the
average DRG weight for cases paid under the
IPPS. Because the DRG weight determines
the prospective payment for each case, any
percentage increase in the case-mix index
corresponds to an equal percentage increase
in hospital payments.
The case-mix index can change for any of
several reasons—
• The average resource use of Medicare
patient changes (‘‘real’’ case-mix change);
• Changes in hospital documentation and
coding of patient records result in higherweighted DRG assignments (‘‘coding
effects’’); or
• The annual DRG reclassification and
recalibration changes may not be budget
neutral (‘‘reclassification effect’’).
We define real case-mix change as actual
changes in the mix (and resource
requirements) of Medicare patients, as
opposed to changes in documentation and
coding behavior that result in assignment of
cases to higher-weighted DRGs, but do not
reflect higher resource requirements. The
capital update framework includes the same
case-mix index adjustment used in the
former operating IPPS update framework (as
discussed in the May 18, 2004 IPPS proposed
rule for FY 2005 (69 FR 28816)). (We no
longer use an update framework to make a
recommendation for updating the operating
IPPS standardized amounts, as discussed in
section II. of Appendix B to the FY 2006 IPPS
final rule (70 FR 47707).)
For FY 2023, we project a 1.0 percent total
increase in the case-mix index. We estimated
that the real case-mix increase would equal
1.0 percent for FY 2023. The net adjustment
for change in case-mix is the difference
between the projected real increases in case
mix and the projected total increase in case
mix. Therefore, as proposed, the net
adjustment for case-mix change in FY 2023
is 0.0 percentage point.
The capital update framework also
contains an adjustment for the effects of DRG
E:\FR\FM\10AUR2.SGM
10AUR2
49434
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
reclassification and recalibration. This
adjustment is intended to remove the effect
on total payments of prior year’s changes to
the DRG classifications and relative weights,
to retain budget neutrality for all case-mix
index-related changes other than those due to
patient severity of illness. Due to the lag time
in the availability of data, there is a 2-year
lag in data used to determine the adjustment
for the effects of DRG reclassification and
recalibration. For example, for this FY 2023
IPPS/LTCH PPS final rule, we have the FY
2021 MedPAR claims data available to
evaluate the effects of the FY 2021 DRG
reclassification and recalibration as part of
our update for FY 2023. We assume for
purposes of this adjustment, that the estimate
of FY 2021 DRG reclassification and
recalibration would result in no change in
the case-mix when compared with the case
mix index that would have resulted if we had
not made the reclassification and
recalibration changes to the DRGs. Therefore,
as proposed, we are making a 0.0 percentage
point adjustment for reclassification and
recalibration in the update framework for FY
2023.
The capital update framework also
contains an adjustment for forecast error. The
input price index forecast is based on
historical trends and relationships
ascertainable at the time the update factor is
established for the upcoming year. In any
given year, there may be unanticipated price
fluctuations that may result in differences
between the actual increase in prices and the
forecast used in calculating the update
factors. In setting a prospective payment rate
under the framework, we make an
adjustment for forecast error only if our
estimate of the change in the capital input
price index for any year is greater than 0.25
percentage point in absolute terms. There is
a 2-year lag between the forecast and the
availability of data to develop a measurement
of the forecast error. Historically, when a
forecast error of the CIPI is greater than 0.25
percentage point in absolute terms, it is
reflected in the update recommended under
this framework. A forecast error of ¥0.1
percentage point was calculated for the FY
2021 update, for which there are historical
data. That is, current historical data indicated
that the forecasted FY 2021 CIPI (1.1 percent)
used in calculating the FY 2021 update factor
is 0.1 percentage point higher than actual
realized price increases (1.0 percent). As this
does not exceed the 0.25 percentage point
threshold, as proposed we are not making an
adjustment for forecast error in the update for
FY 2023.
Under the capital IPPS update framework,
we also make an adjustment for changes in
intensity. Historically, we calculate this
adjustment using the same methodology and
data that were used in the past under the
framework for operating IPPS. The intensity
factor for the operating update framework
reflects how hospital services are utilized to
produce the final product, that is, the
discharge. This component accounts for
changes in the use of quality-enhancing
services, for changes within DRG severity,
and for expected modification of practice
patterns to remove noncost-effective services.
Our intensity measure is based on a 5-year
average.
We calculate case-mix constant intensity as
the change in total cost per discharge,
adjusted for price level changes (the CPI for
hospital and related services) and changes in
real case-mix. Without reliable estimates of
the proportions of the overall annual
intensity changes that are due, respectively,
to ineffective practice patterns and the
combination of quality-enhancing new
technologies and complexity within the DRG
system, we assume that one-half of the
annual change is due to each of these factors.
Thus, the capital update framework provides
an add-on to the input price index rate of
increase of one-half of the estimated annual
increase in intensity, to allow for increases
within DRG severity and the adoption of
quality-enhancing technology.
In this final rule, as proposed, we are
continuing to use a Medicare-specific
intensity measure that is based on a 5-year
adjusted average of cost per discharge for FY
2023 (we refer readers to the FY 2011 IPPS/
LTCH PPS final rule (75 FR 0436) for a full
description of our Medicare-specific intensity
measure). Specifically, for FY 2023, we are
using an intensity measure that is based on
an average of cost-per-discharge data from
the 5-year period beginning with FY 2016
and extending through FY 2020. Based on
these data, we estimated that case-mix
constant intensity declined during FYs 2016
through 2020. In the past, when we found
intensity to be declining, we believed a zero
(rather than a negative) intensity adjustment
was appropriate. Consistent with this
approach, because we estimated that
intensity would decline during that 5-year
period, we believe it is appropriate to
continue to apply a zero-intensity adjustment
for FY 2023. Therefore, as proposed, we are
making a 0.0 percentage point adjustment for
intensity in the update for FY 2023.
Earlier, we described the basis of the
components we used to develop the 2.5
percent capital update factor under the
capital update framework for FY 2023, as
shown in the following table.
FY 2023 UPDATE FACTOR TO THE CAPITAL FEDERAL RATE
Capital Input Price Index*
Intensity:
Case-Mix Adjustment Factors:
Projected Case-Mix Change
Real Across DRG Change
Subtotal
Effect of FY 2021 Reclassification and Recalibration
Forecast Error Correction
Total Update
2.5
0.0
-1.0
1.0
0.0
0.0
0.0
2.5
khammond on DSKJM1Z7X2PROD with RULES2
2. Outlier Payment Adjustment Factor
Section 412.312(c) establishes a unified
outlier payment methodology for inpatient
operating and inpatient capital-related costs.
A shared threshold is used to identify outlier
cases for both inpatient operating and
inpatient capital-related payments. Section
412.308(c)(2) provides that the standard
Federal rate for inpatient capital-related costs
be reduced by an adjustment factor equal to
the estimated proportion of capital-related
outlier payments to total inpatient capital-
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
related PPS payments. The outlier threshold
is set so that operating outlier payments are
projected to be 5.1 percent of total operating
IPPS DRG payments. For FY 2023, we have
incorporated the estimated outlier
reconciliation payment amounts into the
outlier threshold model, as we did for FY
2022. (For more details on our incorporation
of the estimated outlier reconciliation
payment amounts into the outlier threshold
model, please see section II.A. of this
Addendum to this final rule.)
PO 00000
Frm 00656
Fmt 4701
Sfmt 4700
For FY 2022, we estimated that outlier
payments for capital-related PPS payments
would equal 5.29 percent of inpatient capitalrelated payments based on the capital
Federal rate. As discussed previously and in
section II.A.4.j. of the Addendum to this final
rule, we are modifying our methodology for
determining the FY 2023 outlier threshold for
IPPS cases. For FY 2023, this threshold is
being determined as an average of the
thresholds calculated when including and
excluding COVID–19 cases in the FY 2021
claims data. As also discussed in section
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.219
*The capital input price index represents the 2018-based CIPI.
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
II.A., this modification results in two
separate estimates of outlier payments for
capital related costs as a percentage of
inpatient capital-related payments (prior to
taking into account projected capital outlier
reconciliation payments). One estimate is
based on the outlier threshold that was
calculated using all cases (that is including
COVID–19 cases). The other estimate is based
on the outlier threshold that was calculated
excluding COVID–19 cases. Consistent with
our modification to average the outlier
thresholds in determining the final FY 2023
outlier threshold, we are estimating the
capital outlier percentage for FY 2023 as the
average of these two estimates. Accordingly,
as discussed in more detail in section II.A.4.j.
of the Addendum to this final rule, we
estimate that prior to taking into account
projected capital outlier reconciliation
payments, outlier payments for capitalrelated costs will equal 5.53 percent of
inpatient capital-related payments based on
the capital Federal rate in FY 2023.
Using the methodology outlined in section
II.A.4.j.(2). of this Addendum, we estimate
that taking into account projected capital
outlier reconciliation payments will decrease
FY 2023 aggregate estimated capital outlier
payments by 0.01 percent. Therefore,
accounting for estimated capital outlier
reconciliation, the estimated outlier
payments for capital-related PPS payments
would equal 5.52 percent (5.53 percent—0.01
percent) of inpatient capital-related payments
based on the capital Federal rate in FY 2023.
Accordingly, we applied an outlier
adjustment factor of 0.9448 in determining
the capital Federal rate for FY 2023. Thus, we
estimate that the percentage of capital outlier
payments to total capital Federal rate
payments for FY 2023 will be higher than the
percentage for FY 2022.
The outlier reduction factors are not built
permanently into the capital rates; that is,
they are not applied cumulatively in
determining the capital Federal rate. The FY
2023 outlier adjustment of 0.9448 is a ¥0.24
percent change from the FY 2022 outlier
adjustment of 0.9471. Therefore, the net
change in the outlier adjustment to the
capital Federal rate for FY 2023 is 0.9976
(0.9448/0.9471) so that the outlier adjustment
will decrease the FY 2023 capital Federal rate
by approximately ¥0.24 percent compared to
the FY 2022 outlier adjustment.
3. Budget Neutrality Adjustment Factor for
Changes in DRG Classifications and Weights
and the GAF
Section 412.308(c)(4)(ii) requires that the
capital Federal rate be adjusted so that
aggregate payments for the fiscal year based
on the capital Federal rate, after any changes
resulting from the annual DRG
reclassification and recalibration and changes
in the GAF, are projected to equal aggregate
payments that would have been made on the
basis of the capital Federal rate without such
changes.
As discussed in section III.G.3. of the
preamble of this final rule, in the FY 2020
IPPS/LTCH PPS final rule (84 FR 42325
through 42339), we finalized a policy to help
reduce wage index disparities between high
and low wage index hospitals by increasing
the wage index values for hospitals with a
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
wage index value below the 25th percentile
wage index. We stated our intention that this
policy will be effective for at least 4 years,
beginning in FY 2020. As discussed in
section III.G.3 of the preamble of this final
rule, this policy was applied in FYs 2020,
2021, and 2022, and will continue to apply
in FY 2023 as we proposed. In addition, in
FYs 2020 and 2021, we placed a 5-percent
cap on any decrease in a hospital’s wage
index from the hospital’s final wage index in
the prior fiscal year (see (84 FR 42336
through 42338) and (85 FR 58753 through
58755)). In FY 2022, we finalized a policy
that for hospitals that received the transition
in FY 2021 (that is hospitals that received a
5 percent cap on their FY 2021 wage index),
we continued a wage index transition for FY
2022 under which we applied a 5-percent
cap on any decrease in the hospital’s wage
index compared to its wage index for FY
2021 (86 FR 45164 through 45165).
Beginning in FY 2023, as discussed in
section III.N. of the preamble to this final
rule, we finalized a permanent 5-percent cap
on any decrease to a hospital’s wage index
from its wage index in the prior FY,
regardless of the circumstances causing the
decline. That is, a hospital’s wage index will
not be less than 95 percent of its final wage
index for the prior FY.
As we discussed in the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42638 through
42639), we augmented our historical
methodology for computing the budget
neutrality factor for changes in the GAFs in
light of the effect of those wage index
changes on the GAFs. Specifically, we
established a 2-step methodology, under
which we first calculate a factor to ensure
budget neutrality for changes to the GAFs
due to the update to the wage data, wage
index reclassifications and redesignations,
and application of the rural floor policy,
consistent with our historical GAF budget
neutrality factor methodology. In the second
step, we calculate a factor to ensure budget
neutrality for changes to the GAFs due to our
policy to increase the wage index for
hospitals with a wage index value below the
25th percentile wage index and our policy to
place a 5-percent cap on any decrease in a
hospital’s wage index from the hospital’s
final wage index in the prior fiscal year. In
this section of this Addendum, we refer to
these two policies as the lowest quartile
hospital wage index adjustment and the 5percent cap on wage index decreases. We
further note that in this section of this
Addendum, for this final rule, we also refer
to the permanent cap on wage index
decreases beginning in FY 2023 as the 5percent cap on wage index decreases policy.
The budget neutrality factors applied for
changes to the GAFs due to the update to the
wage data, wage index reclassifications and
redesignations, and application of the rural
floor policy are built permanently into the
capital Federal rate; that is, they are applied
cumulatively in determining the capital
Federal rate. In the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45552), we finalized our
proposal to not permanently apply the
budget neutrality factor for the lowest
quartile hospital wage index adjustment and
the 5 percent cap on wage index decreases
PO 00000
Frm 00657
Fmt 4701
Sfmt 4700
49435
such that they would not be applied
cumulatively in determining the capital
Federal rate. We believe this is more
technically appropriate because the GAFs
with the lowest quartile hospital wage index
adjustment and the 5-percent cap on wage
index decreases policies applied from the
previous year are not used in the budget
neutrality factor calculations for the current
year. Accordingly, and consistent with this
approach, prior to calculating the GAF
budget neutrality factors for FY 2023, we
removed from the capital Federal rate the
budget neutrality factor applied in FY 2022
for the lowest quartile hospital wage index
adjustment and the 5-percent cap on wage
index decreases. Specifically, we divided the
capital Federal rate by the FY 2022 budget
neutrality factor of 0.9974 (86 FR 45552). We
refer the reader to the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45552) for additional
discussion on our policy of removing the
prior year budget neutrality factor for the
lowest quartile hospital wage index
adjustment and the 5 percent cap on wage
index decreases from the capital Federal rate.
In light of the changes to the wage index
and other wage index policies for FY 2023
discussed previously, which directly affect
the GAF, we continue to compute a budget
neutrality adjustment for changes in the
GAFs in two steps. We discuss our 2-step
calculation of the GAF budget neutrality
factors for FY 2023 as follows.
To determine the GAF budget neutrality
factors for FY 2023, we first compared
estimated aggregate capital Federal rate
payments based on the FY 2022 MS–DRG
classifications and relative weights and the
FY 2022 GAFs to estimated aggregate capital
Federal rate payments based on the FY 2022
MS–DRG classifications and relative weights
and the FY 2023 GAFs without incorporating
the lowest quartile hospital wage index
adjustment and the 5-percent cap on wage
index decreases policy. To achieve budget
neutrality for these changes in the GAFs, we
calculated an incremental GAF budget
neutrality adjustment factor of 1.0008 for FY
2023. Next, we compared estimated aggregate
capital Federal rate payments based on the
FY 2023 GAFs with and without the lowest
quartile hospital wage index adjustment and
the 5 percent cap on wage index decreases
policy. For this calculation, estimated
aggregate capital Federal rate payments were
calculated using the FY 2023 MS–DRG
classifications and relative weights (after
application of the 10-percent cap discussed
later in this section of the Addendum) and
the FY 2023 GAFs (both with and without
the lowest quartile hospital wage index
adjustment and the 5-percent cap on wage
index decreases policy). (We note, for this
calculation the GAFs included the imputed
floor, out-migration and Frontier state
adjustments.) To achieve budget neutrality
for the effects of the lowest quartile hospital
wage index adjustment and the 5-percent cap
on wage index decreases policy on the FY
2023 GAFs, we calculated an incremental
GAF budget neutrality adjustment factor of
0.9972. As discussed earlier in this section of
the Addendum, the budget neutrality factor
for the lowest quartile hospital wage index
adjustment factor and the 5-percent cap on
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49436
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
wage index decreases is not permanently
built into the capital Federal rate. Consistent
with this, we present the budget neutrality
factor for the lowest quartile hospital wage
index adjustment and the 5-percent cap on
wage index decreases calculated under the
second step of this 2-step methodology
separately from the other budget neutrality
factors in the discussion that follows, and
this factor is not included in the calculation
of the combined GAF/DRG adjustment factor
described later in this section of the
Addendum.
In section II.E.2. of the preamble to this
final rule, we finalized our proposal to apply
a permanent 10-percent cap on the reduction
in a MS–DRG’s relative weight in a given
year. Consistent with our current
methodology for adjusting the capital
standard Federal rate to ensure that the
effects of the annual DRG reclassification and
the recalibration of DRG weights are budget
neutral under § 412.308(c)(4)(ii), as we
proposed, we are applying an additional
budget neutrality factor to the capital
standard Federal rate so that the 10-percent
cap on decreases in an MS–DRG’s relative
weight is implemented in a budget neutral
manner. Specifically, in light of this
provision, as proposed, we are augmenting
our historical methodology for computing the
budget neutrality factor for the annual DRG
reclassification and recalibration by
computing a budget neutrality adjustment for
the annual DRG reclassification and
recalibration in two steps. We first calculate
a budget neutrality factor to account for the
annual DRG reclassification and recalibration
prior to the application of the 10-percent cap
on MS–DRG relative weight decreases. Then
we calculate an additional budget neutrality
factor to account for the application of the
10-percent cap on MS–DRG relative weight
decreases.
To determine the DRG budget neutrality
factors for FY 2023, we first compared
estimated aggregate capital Federal rate
payments based on the FY 2022 MS–DRG
classifications and relative weights to
estimated aggregate capital Federal rate
payments based on the FY 2023 MS–DRG
classifications and relative weights prior to
the application of the 10-percent cap. For
these calculations, estimated aggregate
capital Federal rate payments were
calculated using the FY 2023 GAFs without
the lowest quartile hospital wage index
adjustment and the 5-percent cap on wage
index decreases. The incremental adjustment
factor for DRG classifications and changes in
relative weights prior to the application of
the 10-percent cap is 1.0006. Next, we
compared estimated aggregate capital Federal
rate payments based on the FY 2023 MS–
DRG classifications and relative weights prior
to the application of the 10-percent cap to
estimated aggregate capital Federal rate
payments based on the FY 2023 MS–DRG
classifications and relative weights after the
application of the 10-percent cap. For these
calculations, estimated aggregate capital
Federal rate payments were also calculated
using the FY 2023 GAFs without the lowest
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
quartile hospital wage index adjustment and
the 5-percent cap on wage index decreases.
The incremental adjustment factor for the
application of the 10-percent cap on relative
weight decreases is 0.9998. Therefore, to
achieve budget neutrality for the FY 2023
MS–DRG reclassification and recalibration
(including the 10-percent cap), based on the
calculations described previously, we are
applying an incremental budget neutrality
adjustment factor of 1.0004 (1.0006 × 0.9998)
for FY 2023 to the capital Federal rate. We
note that all the values are calculated with
unrounded numbers.
The incremental adjustment factor for the
FY 2023 MS–DRG reclassification and
recalibration (1.0004) and for changes in the
FY 2023 GAFs due to the update to the wage
data, wage index reclassifications and
redesignations, and application of the rural
floor policy (1.0008) is 1.0012 (1.0004 ×
1.0008). This incremental adjustment factor
is built permanently into the capital Federal
rates. To achieve budget neutrality for the
effects of the lowest quartile hospital wage
index adjustment and the 5-percent cap on
wage index decreases policy on the FY 2023
GAFs, as described previously, we calculated
a budget neutrality adjustment factor of
0.9972 for FY 2023. We refer to this budget
neutrality factor for the remainder of this
section as the lowest quartile/cap adjustment
factor.
We applied the budget neutrality
adjustment factors described previously to
the capital Federal rate. This follows the
requirement under § 412.308(c)(4)(ii) that
estimated aggregate payments each year be
no more or less than they would have been
in the absence of the annual DRG
reclassification and recalibration and changes
in the GAFs.
The methodology used to determine the
recalibration and geographic adjustment
factor (GAF/DRG) budget neutrality
adjustment is similar to the methodology
used in establishing budget neutrality
adjustments under the IPPS for operating
costs. One difference is that, under the
operating IPPS, the budget neutrality
adjustments for the effect of updates to the
wage data, wage index reclassifications and
redesignations, and application of the rural
floor policy are determined separately. Under
the capital IPPS, there is a single budget
neutrality adjustment factor for changes in
the GAF that result from updates to the wage
data, wage index reclassifications and
redesignations, and application of the rural
floor policy. In addition, there is no
adjustment for the effects that geographic
reclassification, the lowest quartile hospital
wage index adjustment, or the 5-percent cap
on wage index decreases policy described
previously have on the other payment
parameters, such as the payments for DSH or
IME.
The incremental GAF/DRG adjustment
factor of 1.0012 accounts for the MS–DRG
reclassifications and recalibration (including
application of the 10-percent cap on relative
weight decreases) and for changes in the
GAFs that result from updates to the wage
PO 00000
Frm 00658
Fmt 4701
Sfmt 4700
data, the effects on the GAFs of FY 2023
geographic reclassification decisions made by
the MGCRB compared to FY 2022 decisions,
and the application of the rural floor policy.
The lowest quartile/cap adjustment factor of
0.9972 accounts for changes in the GAFs that
result from our policy to increase the wage
index values for hospitals with a wage index
value below the 25th percentile wage index
and the 5-percent cap on wage index
decreases policy. However, these factors do
not account for changes in payments due to
changes in the DSH and IME adjustment
factors.
4. Capital Federal Rate for FY 2023
For FY 2022, we established a capital
Federal rate of $472.59 (86 FR 45553, as
corrected in 86 FR 58026). We are
establishing an update of 2.5 percent in
determining the FY 2023 capital Federal rate
for all hospitals. As a result of this update
and the budget neutrality factors discussed
earlier, we are establishing a national capital
Federal rate of $483.76 for FY 2023. The
national capital Federal rate for FY 2023 was
calculated as follows:
• The FY 2023 update factor is 1.025; that
is, the update is 2.5 percent.
• The FY 2023 GAF/DRG budget neutrality
adjustment factor that is applied to the
capital Federal rate for changes in the MS–
DRG classifications and relative weights
(including application of the 10-percent cap
on relative weight decreases) and changes in
the GAFs that result from updates to the
wage data, wage index reclassifications and
redesignations, and application of the rural
floor policy is 1.0012.
• The FY 2023 lowest quartile/cap budget
neutrality adjustment factor that is applied to
the capital Federal rate for changes in the
GAFs that result from our policy to increase
the wage index values for hospitals with a
wage index value below the 25th percentile
wage index and the 5-percent cap on wage
index decreases policy is 0.9972.
• The FY 2023 outlier adjustment factor is
0.9448.
We are providing the following chart that
shows how each of the factors and
adjustments for FY 2023 affects the
computation of the FY 2023 national capital
Federal rate in comparison to the FY 2022
national capital Federal rate. The FY 2023
update factor has the effect of increasing the
capital Federal rate by 2.5 percent compared
to the FY 2022 capital Federal rate. The GAF/
DRG budget neutrality adjustment factor has
the effect of increasing the capital Federal
rate by 0.12 percent. The FY 2023 lowest
quartile/cap budget neutrality adjustment
factor has the effect of decreasing the capital
Federal rate by 0.02 percent compared to the
FY 2022 capital Federal rate. The FY 2023
outlier adjustment factor has the effect of
decreasing the capital Federal rate by 0.24
percent compared to the FY 2022 capital
Federal rate. The combined effect of all the
changes will increase the national capital
Federal rate by approximately 2.36 percent,
compared to the FY 2022 national capital
Federal rate.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49437
COMPARISON OF FACTORS AND ADJUSTMENTS: FY 2022 CAPITAL FEDERAL
RATE AND THE FY 2023 CAPITAL FEDERAL RATE
FY2022
1.0080
1.0004
0.9974
0.9471
$472.59
Update Factor 1
GAF/DRG Adjustment Factor1
Quartile/Cap Adjustment Factor2
Outlier Adjustment Factor3
Capital Federal Rate
FY2023
1.0250
1.0012
0.9972
0.9448
$483.76
Change
1.0250
1.0012
0.9998
0.9976
1.0236
Percent Change
2.50
0.12
-0.02
-0.24
2.36 4
B. Calculation of the Inpatient CapitalRelated Prospective Payments for FY 2023
For purposes of calculating payments for
each discharge during FY 2023, the capital
Federal rate is adjusted as follows: (Standard
Federal Rate) × (DRG weight) × (GAF) ×
(COLA for hospitals located in Alaska and
Hawaii) × (1 + DSH Adjustment Factor + IME
Adjustment Factor, if applicable). The result
is the adjusted capital Federal rate.
Hospitals also may receive outlier
payments for those cases that qualify under
the threshold established for each fiscal year.
Section 412.312(c) provides for a shared
threshold to identify outlier cases for both
inpatient operating and inpatient capitalrelated payments. The outlier threshold for
FY 2023 is in section II.A. of this Addendum.
For FY 2023, a case will qualify as a cost
outlier if the cost for the case is greater than
the prospective payment rates for the MS–
DRG plus IME and DSH payments (including
the empirically justified Medicare DSH
payment and the estimated uncompensated
care payment), any add-on payments for new
technology, and, as we finalized beginning in
FY 2023, the estimated supplemental
payment for eligible IHS/Tribal hospitals and
Puerto Rico hospitals (as discussed in section
IV.E. of the preamble of this final rule), plus
the fixed-loss amount of $38,859.
Currently, as provided under
§ 412.304(c)(2), we pay a new hospital 85
percent of its reasonable costs during the first
2 years of operation, unless it elects to
receive payment based on 100 percent of the
capital Federal rate. Effective with the third
year of operation, we pay the hospital based
on 100 percent of the capital Federal rate
(that is, the same methodology used to pay
all other hospitals subject to the capital PPS).
capital, which is the acquisition and use of
capital over time. Capital expenses in any
given year are determined by the stock of
capital in that year (that is, capital that
remains on hand from all current and prior
capital acquisitions). An index measuring
capital price changes needs to reflect this
vintage nature of capital. Therefore, the CIPI
was developed to capture the vintage nature
of capital by using a weighted-average of past
capital purchase prices up to and including
the current year.
We periodically update the base year for
the operating and capital input price indexes
to reflect the changing composition of inputs
for operating and capital expenses. For this
final rule, we are using the IPPS operating
and capital market baskets that reflect a 2018
base year. For a complete discussion of this
rebasing, we refer readers to the FY 2022
IPPS/LTCH PPS final rule (86 FR 45194
through 45213).
2. Forecast of the CIPI for FY 2023
Based on IHS Global Inc.’s second quarter
2022 forecast, for this final rule, we are
forecasting the 2018-based CIPI to increase
2.5 percent in FY 2023. This reflects a
projected 2.9 percent increase in vintageweighted depreciation prices (building and
fixed equipment, and movable equipment),
and a projected 6.7 percent increase in other
capital expense prices in FY 2023, partially
offset by a projected 1.7 percent decline in
vintage-weighted interest expense prices in
FY 2023. The weighted average of these three
factors produces the forecasted 2.5 percent
increase for the 2018-based CIPI in FY 2023.
As proposed, we are using the more recent
data available for this final rule to determine
the FY 2023 increase in the 2018-based CIPI
for this final rule.
C. Capital Input Price Index
1. Background
Like the operating input price index, the
capital input price index (CIPI) is a fixedweight price index that measures the price
changes associated with capital costs during
a given year. The CIPI differs from the
operating input price index in one important
aspect—the CIPI reflects the vintage nature of
IV. Changes to Payment Rates for Excluded
Hospitals: Rate-of-Increase Percentages for
FY 2023
Payments for services furnished in
children’s hospitals, 11 cancer hospitals, and
hospitals located outside the 50 States, the
District of Columbia and Puerto Rico (that is,
short-term acute care hospitals located in the
U.S. Virgin Islands, Guam, the Northern
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00659
Fmt 4701
Sfmt 4700
Mariana Islands, and American Samoa) that
are excluded from the IPPS are made on the
basis of reasonable costs based on the
hospital’s own historical cost experience,
subject to a rate-of-increase ceiling. A per
discharge limit (the target amount, as defined
in § 413.40(a) of the regulations) is set for
each hospital, based on the hospital’s own
cost experience in its base year, and updated
annually by a rate-of-increase percentage
specified in § 413.40(c)(3). In addition, as
specified in the FY 2018 IPPS/LTCH PPS
final rule (82 FR 38536), effective for cost
reporting periods beginning during FY 2018,
the annual update to the target amount for
extended neoplastic disease care hospitals
(hospitals described in § 412.22(i) of the
regulations) also is the rate-of-increase
percentage specified in § 413.40(c)(3). (We
note that, in accordance with § 403.752(a),
religious nonmedical health care institutions
(RNHCIs) are also subject to the rate-ofincrease limits established under § 413.40 of
the regulations.)
In the FY 2023 IPPS/LTCH PPS proposed
rule, based on IGI’s 2021 fourth quarter
forecast, we estimated the 2018-based IPPS
operating market basket update for FY 2023
to be 3.1 percent (that is, the estimate of the
market basket rate-of-increase). However, we
proposed that if more recent data
subsequently became available (for example,
a more recent estimate of the market basket
update), we would use such data, if
appropriate, to calculate the IPPS operating
market basket update for FY 2023. More
recent data did subsequently become
available. Thus, for this FY 2023 IPPS/LTCH
PPS final rule, based on IGI’s second quarter
2022 forecast, the FY 2023 rate-of-increase
percentage that will be applied to the FY
2022 target amounts in order to calculate the
FY 2023 target amounts for children’s
hospitals, the 11 cancer hospitals, RNCHIs,
short-term acute care hospitals located in the
U.S. Virgin Islands, Guam, the Northern
Mariana Islands, and American Samoa, and
extended neoplastic disease care hospitals is
4.1 percent, in accordance with the
applicable regulations at 42 CFR 413.40.
IRFs and rehabilitation distinct part units,
IPFs and psychiatric units, and LTCHs are
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.220
khammond on DSKJM1Z7X2PROD with RULES2
1 The update factor and the GAF/DRG budget neutrality adjustment factors are built permanently into the capital Federal rate. Thus, for
example, the incremental change from FY 2022 to FY 2023 resulting from the application of the 1.0012 GAF/DRG budget neutrality adjustment
factor for FY 2023 is a net change of0.0012 (or 0.12 percent).
2 The lowest quartile/cap budget neutrality adjustment factor is not built permanently into the capital Federal rate; that is, the factor is not
applied cumulatively in determining the capital Federal rate. Thus, for example, the net change resulting from the application of the FY 2023
lowest quartile/cap budget neutrality adjustment factor is 0.9972/0.9974 or 0.9998 (or -0.02 percent).
3 The outlier reduction factor is not built permanently into the capital Federal rate; that is, the factor is not applied cumulatively in determining
the capital Federal rate. Thus, for example, the net change resulting from the application of the FY 2023 outlier adjustment factor is
0.9448/0.9471 or 0.9976 (or -0.24 percent).
4 Percent change may not sum due to rounding.
49438
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
excluded from the IPPS and paid under their
respective PPSs. The IRF PPS, the IPF PPS,
and the LTCH PPS are updated annually. We
refer readers to section VIII. of the preamble
and section V. of the Addendum of this final
rule for the changes to the Federal payment
rates for LTCHs under the LTCH PPS for FY
2023. The annual updates for the IRF PPS
and the IPF PPS are issued by the agency in
separate Federal Register documents.
We received no comments on this proposal
and therefore are finalizing this provision
without modification.
khammond on DSKJM1Z7X2PROD with RULES2
V. Changes to the Payment Rates for the
LTCH PPS for FY 2023
A. LTCH PPS Standard Federal Payment Rate
for FY 2023
1. Overview
In section VIII. of the preamble of this final
rule, we discuss our annual updates to the
payment rates, factors, and specific policies
under the LTCH PPS for FY 2023.
Under § 412.523(c)(3) of the regulations, for
FY 2012 and subsequent years, we updated
the standard Federal payment rate by the
most recent estimate of the LTCH PPS market
basket at that time, including additional
statutory adjustments required by sections
1886(m)(3) (citing sections
1886(b)(3)(B)(xi)(II) and 1886(m)(4) of the Act
as set forth in the regulations at
§ 412.523(c)(3)(viii) through (xvii)). (For a
summary of the payment rate development
prior to FY 2012, we refer readers to the FY
2018 IPPS/LTCH PPS final rule (82 FR 38310
through 38312) and references therein.)
Section 1886(m)(3)(A) of the Act specifies
that, for rate year 2012 and each subsequent
rate year, any annual update to the standard
Federal payment rate shall be reduced by the
productivity adjustment described in section
1886(b)(3)(B)(xi)(II) of the Act as discussed in
section VIII.C.2. of the preamble of this final
rule. This section of the Act further provides
that the application of section 1886(m)(3)(B)
of the Act may result in the annual update
being less than zero for a rate year, and may
result in payment rates for a rate year being
less than such payment rates for the
preceding rate year. (As noted in section
VIII.C.2. of the preamble of this final rule, the
annual update to the LTCH PPS occurs on
October 1 and we have adopted the term
‘‘fiscal year’’ (FY) rather than ‘‘rate year’’
(RY) under the LTCH PPS beginning October
1, 2010. Therefore, for purposes of clarity,
when discussing the annual update for the
LTCH PPS, including the provisions of the
Affordable Care Act, we use the term ‘‘fiscal
year’’ rather than ‘‘rate year’’ for 2011 and
subsequent years.)
For LTCHs that fail to submit the required
quality reporting data in accordance with the
LTCH QRP, the annual update is reduced by
2.0 percentage points as required by section
1886(m)(5) of the Act.
2. Development of the FY 2023 LTCH PPS
Standard Federal Payment Rate
Consistent with our historical practice and
§ 412.523(c)(3)(xvii), for FY 2023, as we
proposed, we are applying the annual update
to the LTCH PPS standard Federal payment
rate from the previous year. Furthermore, in
determining the LTCH PPS standard Federal
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
payment rate for FY 2023, we are also making
certain regulatory adjustments, consistent
with past practices. Specifically, in
determining the FY 2023 LTCH PPS standard
Federal payment rate, as we proposed, we are
applying a budget neutrality adjustment
factor for the changes related to the area wage
level adjustment (that is, changes to the wage
data and labor-related share) as discussed in
section V.B.5. of this Addendum to this final
rule.
In this final rule, we are establishing an
annual update to the LTCH PPS standard
Federal payment rate of 3.8 percent (that is,
the most recent estimate of the LTCH PPS
market basket increase of 4.1 percent less the
productivity adjustment of 0.3 percentage
point). Therefore, in accordance with
§ 412.523(c)(3)(xvii), we are applying an
update factor of 1.038 to the FY 2022 LTCH
PPS standard Federal payment rate of
$44,713.67 to determine the FY 2023 LTCH
PPS standard Federal payment rate. Also, in
accordance with § 412.523(c)(3)(xvii) and
(c)(4), we are required to reduce the annual
update to the LTCH PPS standard Federal
payment rate by 2.0 percentage points for
LTCHs that fail to submit the required quality
reporting data for FY 2023 as required under
the LTCH QRP. Therefore, we are
establishing an annual update to the LTCH
PPS standard Federal payment rate of 1.8
percent (that is, an update factor of 1.018) for
FY 2023 for LTCHs that fail to submit the
required quality reporting data for FY 2023
as required under the LTCH QRP. Consistent
with § 412.523(d)(4), we are applying an area
wage level budget neutrality factor to the FY
2023 LTCH PPS standard Federal payment
rate of 1.0004304, based on the best available
data at this time, to ensure that any changes
to the area wage level adjustment (that is, the
annual update of the wage index (including
application of the 5-percent cap on wage
index decreases, discussed later in this
section of this final rule), and labor-related
share) will not result in any change (increase
or decrease) in estimated aggregate LTCH
PPS standard Federal payment rate
payments. Accordingly, we are establishing
an LTCH PPS standard Federal payment rate
of $46,432.77 (calculated as $44,713.67 ×
1.038 × 1.0004304) for FY 2023. For LTCHs
that fail to submit quality reporting data for
FY 2023, in accordance with the
requirements of the LTCH QRP under section
1866(m)(5) of the Act, we are establishing an
LTCH PPS standard Federal payment rate of
$45,538.11 (calculated as $44,713.67 × 1.018
× 1.0004304) for FY 2023.
B. Adjustment for Area Wage Levels Under
the LTCH PPS for FY 2023
1. Background
Under the authority of section 123 of the
BBRA, as amended by section 307(b) of the
BIPA, we established an adjustment to the
LTCH PPS standard Federal payment rate to
account for differences in LTCH area wage
levels under § 412.525(c). The labor-related
share of the LTCH PPS standard Federal
payment rate is adjusted to account for
geographic differences in area wage levels by
applying the applicable LTCH PPS wage
index. The applicable LTCH PPS wage index
is computed using wage data from inpatient
PO 00000
Frm 00660
Fmt 4701
Sfmt 4700
acute care hospitals without regard to
reclassification under section 1886(d)(8) or
section 1886(d)(10) of the Act.
The FY 2023 LTCH PPS standard Federal
payment rate wage index values that will be
applicable for LTCH PPS standard Federal
payment rate discharges occurring on or after
October 1, 2022, through September 30, 2023,
are presented in Table 12A (for urban areas)
and Table 12B (for rural areas), which are
listed in section VI. of the Addendum to this
final rule and available via the internet on
the CMS website.
2. Geographic Classifications (Labor Market
Areas) for the LTCH PPS Standard Federal
Payment Rate
In adjusting for the differences in area
wage levels under the LTCH PPS, the laborrelated portion of an LTCH’s Federal
prospective payment is adjusted by using an
appropriate area wage index based on the
geographic classification (labor market area)
in which the LTCH is located. Specifically,
the application of the LTCH PPS area wage
level adjustment under existing § 412.525(c)
is made based on the location of the LTCH—
either in an ‘‘urban area,’’ or a ‘‘rural area,’’
as defined in § 412.503. Under § 412.503, an
‘‘urban area’’ is defined as a Metropolitan
Statistical Area (MSA) (which includes a
Metropolitan division, where applicable), as
defined by the Executive OMB, and a ‘‘rural
area’’ is defined as any area outside of an
urban area (75 FR 37246).
The geographic classifications (labor
market area definitions) currently used under
the LTCH PPS, effective for discharges
occurring on or after October 1, 2014, are
based on the Core Based Statistical Areas
(CBSAs) established by OMB, which are
based on the 2010 decennial census data. In
general, the current statistical areas (which
were implemented beginning with FY 2015)
are based on revised OMB delineations
issued on February 28, 2013, in OMB
Bulletin No. 13–01. (We note we have
adopted minor revisions and updates in the
years between the decennial censuses.) We
adopted these labor market area delineations
because they were at that time based on the
best available data that reflect the local
economies and area wage levels of the
hospitals that are currently located in these
geographic areas. We also believed that these
OMB delineations would ensure that the
LTCH PPS area wage level adjustment most
appropriately accounted for and reflected the
relative hospital wage levels in the
geographic area of the hospital as compared
to the national average hospital wage level.
We noted that this policy was consistent with
the IPPS policy adopted in FY 2015 under
§ 412.64(b)(1)(ii)(D) (79 FR 49951 through
49963). (For additional information on the
CBSA-based labor market area (geographic
classification) delineations currently used
under the LTCH PPS and the history of the
labor market area definitions used under the
LTCH PPS, we refer readers to the FY 2015
IPPS/LTCH PPS final rule (79 FR 50180
through 50185).)
In general, it is our historical practice to
update the CBSA-based labor market area
delineations annually based on the most
recent updates issued by OMB. Generally,
OMB issues major revisions to statistical
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
areas every 10 years, based on the results of
the decennial census. However, OMB
occasionally issues minor updates and
revisions to statistical areas in the years
between the decennial censuses. OMB
Bulletin No. 17–01, issued August 15, 2017,
established the delineations for the Nation’s
statistical areas, and the corresponding
changes to the CBSA-based labor market
areas were adopted in the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41731). A copy
of this bulletin may be obtained on the
website at https://www.whitehouse.gov/wpcontent/uploads/legacy_drupal_files/omb/
bulletins/2017/b-17-01.pdf.
On April 10, 2018, OMB issued OMB
Bulletin No. 18–03, which superseded the
August 15, 2017 OMB Bulletin No. 17–01. On
September 14, 2018, OMB issued OMB
Bulletin No. 18–04, which superseded the
April 10, 2018 OMB Bulletin No. 18–03.
Historically OMB bulletins issued between
decennial censuses have only contained
minor modifications to CBSA delineations
based on changes in population counts.
However, OMB’s 2010 Standards for
Delineating Metropolitan and Micropolitan
Standards created a larger mid-decade
redelineation that takes into account
commuting data from the American
Commuting Survey. As a result, the
September 14, 2018 OMB Bulletin No. 18–04
included more modifications to the CBSAs
than are typical for OMB bulletins issued
between decennial censuses. We adopted the
updates set forth in OMB Bulletin No. 18–04
in the FY 2021 IPPS/LTCH PPS final rule (85
FR 59050 through 59051). A copy of the
September 14, 2018 OMB Bulletin No. 18–04,
may be obtained at https://
www.whitehouse.gov/wp-content/uploads/
2018/09/Bulletin-18-04.pdf.
On March 6, 2020, OMB issued Bulletin
No. 20–01, which provided updates to and
superseded OMB Bulletin No. 18–04, which
was issued on September 14, 2018. The
attachments to OMB Bulletin No. 20–01
provided detailed information on the update
to statistical areas since September 14, 2018.
(For a copy of this bulletin, we refer readers
to the following website: https://
www.whitehouse.gov/wp-content/uploads/
2020/03/Bulletin-20-01.pdf.) In OMB Bulletin
No. 20–01, OMB announced one new
Micropolitan Statistical Area and one new
component of an existing Combined
Statistical Area. After reviewing OMB
Bulletin No. 20–01, we determined that the
changes in Bulletin 20–01 encompassed
delineation changes that would not affect the
CBSA-based labor market area delineations
used under the LTCH PPS. Therefore, we
adopted the updates set forth in OMB
Bulletin No. 20–01 in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45556 through
45557) consistent with our general policy of
adopting OMB delineation updates; however,
the LTCH PPS area wage level adjustment
was not altered as a result of adopting the
updates because the CBSA-based labor
market area delineations were the same as
the CBSA-based labor market area
delineations adopted in the FY 2021 IPPS/
LTCH PPS final rule based on OMB Bulletin
No. 18–04 (85 FR 59050 through 59051).
We believe the CBSA-based labor market
area delineations, as established in OMB
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Bulletin 20–01, ensure that the LTCH PPS
area wage level adjustment most
appropriately accounts for and reflects the
relative hospital wage levels in the
geographic area of the hospital as compared
to the national average hospital wage level
based on the best available data that reflect
the local economies and area wage levels of
the hospitals that are currently located in
these geographic areas (81 FR 57298).
Therefore, for FY 2023, we did not propose
any changes to the CBSA-based labor market
area delineations as established in OMB
Bulletin 20–01 and adopted in the FY 2022
IPPS/LTCH final rule.
CBSAs are made up of one or more
constituent counties. Each CBSA and
constituent county has its own unique
identifying codes. The Census Bureau
maintains a complete list of changes to
counties or county equivalent entities on
their website at https://www.census.gov/
programs-surveys/geography/technicaldocumentation/county-changes.html. We
believe that it is important to use the latest
counties or county equivalent entities to
properly crosswalk LTCHs from a county to
a CBSA for purposes of the wage indexes
used under the LTCH PPS. Based on the
latest information included in the Census
Bureau’s website at https://www.census.gov/
programs-surveys/geography/technicaldocumentation/county-changes.2010.html,
the Census Bureau has made the following
updates to the Federal Information
Processing Series (FIPS) codes for counties or
county equivalent entities:
• Chugach Census Area, AK (FIPS State
County Code 02–063) and Copper River
Census Area, AK (FIPS State County Code
02–066) were created from former ValdezCordova Census Area (02–261) which was
located in CBSA 02. The CBSA code for these
two new county equivalents remains 02.
We believe using the latest FIPS codes
allows us to maintain a more accurate and
up-to-date payment system that reflects
population shifts and labor market
conditions. Therefore, we are adopting these
FIPS code updates listed previously, effective
October 1, 2022. We note that while the
county update changes listed previously
changed the county names, the CBSAs to
which these counties map did not change
from the prior counties. We also note that
there are currently no LTCHs located in these
counties. However, if an LTCH were to open
in one of these counties, there would be no
impact or change to the LTCH for purposes
of the LTCH PPS wage indexes as a result of
our implementation of these FIPS code
updates. We are publishing, as a
supplemental file to this final rule, an
updated county-to-CBSA crosswalk that
reflects this provision.
3. Labor-Related Share for the LTCH PPS
Standard Federal Payment Rate
Under the payment adjustment for the
differences in area wage levels under
§ 412.525(c), the labor-related share of an
LTCH’s standard Federal payment rate is
adjusted by the applicable wage index for the
labor market area in which the LTCH is
located. The LTCH PPS labor-related share
currently represents the sum of the laborrelated portion of operating costs and a labor-
PO 00000
Frm 00661
Fmt 4701
Sfmt 4700
49439
related portion of capital costs using the
applicable LTCH market basket. Additional
background information on the historical
development of the labor-related share under
the LTCH PPS can be found in the RY 2007
LTCH PPS final rule (71 FR 27810 through
27817 and 27829 through 27830) and the FY
2012 IPPS/LTCH PPS final rule (76 FR 51766
through 51769 and 51808).
For FY 2013, we rebased and revised the
market basket used under the LTCH PPS by
adopting a 2009-based LTCH market basket.
In addition, for FY 2013 through FY 2016, we
determined the labor-related share annually
as the sum of the relative importance of each
labor-related cost category of the 2009-based
LTCH market basket for the respective fiscal
year based on the best available data. (For
more details, we refer readers to the FY 2013
IPPS/LTCH PPS final rule (77 FR 53477
through 53479).) For FY 2017, we rebased
and revised the 2009-based LTCH market
basket to reflect a 2013 base year. In addition,
for FY 2017 through FY 2020, we determined
the labor-related share annually as the sum
of the relative importance of each laborrelated cost category of the 2013-based LTCH
market basket for the respective fiscal year
based on the best available data. (For more
details, we refer readers to the FY 2017 IPPS/
LTCH PPS final rule (81 FR 57085 through
57096).) Then, effective for FY 2021, we
rebased and revised the 2013-based LTCH
market basket to reflect a 2017 base year and
determined the labor-related share annually
as the sum of the relative importance of each
labor-related cost category in the 2017-based
LTCH market basket using the most recent
available data. (For more details, we refer
readers to the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58909 through 58926).)
In the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28683 through 26864), consistent
with our historical practice, we proposed that
the LTCH PPS labor-related share for FY
2023 is the sum of the FY 2023 relative
importance of each labor-related cost
category in the LTCH market basket using the
most recent available data. Specifically, we
proposed that the labor-related share for FY
2023 would continue to include the sum of
the labor-related portion of operating costs
from the 2017-based LTCH market basket
(that is, the sum of the FY 2023 relative
importance shares of Wages and Salaries;
Employee Benefits; Professional Fees: LaborRelated; Administrative and Facilities
Support Services; Installation, Maintenance,
and Repair Services; All Other: Labor-related
Services) and a portion of the relative
importance of Capital-Related cost weight
from the 2017-based LTCH market basket.
The relative importance reflects the different
rates of price change for these cost categories
between the base year (2017) and FY 2023.
Based on IHS Global Inc.’s fourth quarter
2021 forecast of the 2017-based LTCH market
basket, the sum of the FY 2023 relative
importance for Wages and Salaries; Employee
Benefits; Professional Fees: Labor-Related;
Administrative and Facilities Support
Services; Installation, Maintenance, & Repair
Services; and All Other: Labor-Related
Services was 64.0 percent. The portion of
capital-related costs that is influenced by the
local labor market is estimated to be 46
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49440
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
percent (that is, the same percentage applied
to the 2009-based and 2013-based LTCH
market baskets). Since the FY 2023 relative
importance for capital-related costs was 9.2
percent based on IHS Global Inc.’s fourth
quarter 2021 forecast of the 2017-based LTCH
market basket, we took 46 percent of 9.2
percent to determine the labor-related share
of capital-related costs for FY 2023 of 4.2
percent. Therefore, in the IPPS/LTCH PPS
proposed rule (87 FR 28684), we proposed a
total labor-related share for FY 2023 of 68.2
percent (the sum of 64.0 percent for the
operating costs and 4.2 percent for the laborrelated share of capital-related costs). We also
proposed that if more recent data became
available after the publication of the
proposed rule and before the publication of
the final rule (for example, a more recent
estimate of the relative importance of each
labor-related cost category of the 2017-based
LTCH market basket), we would use such
data, if appropriate, to determine the FY 2023
LTCH PPS labor-related share.
Comment: A commenter opposed the
increase in labor-related share for LTCHs for
FY 2023. The commenter noted that the
increase in labor-related share adversely
impacts any LTCH with a wage index of less
than 1.0. According to the commenter,
limiting the increase would help mitigate the
growing disparity between high-wage and
low-wage states.
Response: We thank the commenter for the
feedback. As noted previously, effective for
FY 2021, we rebased and revised the 2013based LTCH market basket to reflect a 2017
base year and determined the labor-related
share annually as the sum of the relative
importance of each labor-related cost
category in the 2017-based LTCH market
basket using the most recent available data
(85 FR 58909 through 58926). We continue
to believe that this approach is the most
appropriate methodology for determining the
labor-related portion of the LTCH PPS
standard Federal payment rate. We note that
the proposed labor related share of 68.2
percent, which was based on IHS Global Inc’s
fourth quarter 2021 forecast of the 2017based LTCH market basket, has been updated
to reflect IHS Global Inc’s second quarter
2022 forecast, and that this update, resulting
in a labor related share of 68.0 percent, is a
slightly smaller increase over the labor share
from FY 2022, which was 67.9 percent.
After consideration of public comments,
we are finalizing the FY 2023 labor-related
share using the most recently available data.
Based on IHS Global Inc.’s second quarter
2022 forecast of the 2017-based LTCH market
basket, the sum of the FY 2023 relative
importance for Wages and Salaries; Employee
Benefits; Professional Fees: Labor-Related;
Administrative and Facilities Support
Services; Installation, Maintenance, & Repair
Services; and All Other: Labor-Related
Services is 63.8 percent. The portion of
capital-related costs that is influenced by the
local labor market is estimated to be 46
percent (that is, the same percentage applied
to the 2009-based and 2013-based LTCH
market baskets). Since the FY 2023 relative
importance for capital-related costs is 9.1
percent based on IHS Global Inc.’s second
quarter 2022 forecast of the 2017-based LTCH
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
market basket, we took 46 percent of 9.1
percent to determine the labor-related share
of capital-related costs for FY 2023 of 4.2
percent. Therefore, we are finalizing a total
labor-related share for FY 2023 of 68.0
percent (the sum of 63.8 percent for the
operating costs and 4.2 percent for the laborrelated share of capital-related costs).
4. Wage Index for FY 2023 for the LTCH
PPS Standard Federal Payment Rate
Historically, we have established LTCH
PPS area wage index values calculated from
acute care IPPS hospital wage data without
taking into account geographic
reclassification under sections 1886(d)(8) and
1886(d)(10) of the Act (67 FR 56019). The
area wage level adjustment established under
the LTCH PPS is based on an LTCH’s actual
location without regard to the ‘‘urban’’ or
‘‘rural’’ designation of any related or
affiliated provider. As with the IPPS wage
index, wage data for multicampus hospitals
with campuses located in different labor
market areas (CBSAs) are apportioned to each
CBSA where the campus (or campuses) are
located. We also employ a policy for
determining area wage index values for areas
where there are no IPPS wage data.
Consistent with our historical
methodology, to determine the applicable
area wage index values for the FY 2023 LTCH
PPS standard Federal payment rate, under
the broad authority of section 123 of the
BBRA, as amended by section 307(b) of the
BIPA, as we proposed, we are continuing to
employ our historical practice of using the
same data we used to compute the FY 2023
acute care hospital inpatient wage index, as
discussed in section III. of the preamble of
this final rule (that is, wage data collected
from cost reports submitted by IPPS hospitals
for cost reporting periods beginning during
FY 2019) because these data are the most
recent complete data available.
In addition, as we proposed, we computed
the FY 2023 LTCH PPS standard Federal
payment rate area wage index values
consistent with the ‘‘urban’’ and ‘‘rural’’
geographic classifications (that is, the
proposed labor market area delineations as
previously discussed in section V.B. of this
Addendum) and our historical policy of not
taking into account IPPS geographic
reclassifications under sections 1886(d)(8)
and 1886(d)(10) of the Act in determining
payments under the LTCH PPS. As we
proposed, we also continued to apportion the
wage data for multicampus hospitals with
campuses located in different labor market
areas to each CBSA where the campus or
campuses are located, consistent with the
IPPS policy. Lastly, consistent with our
existing methodology for determining the
LTCH PPS wage index values, for FY 2023
as we proposed, we continued to use our
existing policy for determining area wage
index values for areas where there are no
IPPS wage data. Under our existing
methodology, the LTCH PPS wage index
value for urban CBSAs with no IPPS wage
data is determined by using an average of all
of the urban areas within the State, and the
LTCH PPS wage index value for rural areas
with no IPPS wage data is determined by
using the unweighted average of the wage
indices from all of the CBSAs that are
contiguous to the rural counties of the State.
PO 00000
Frm 00662
Fmt 4701
Sfmt 4700
Based on the FY 2019 IPPS wage data that
we used to determine the FY 2023 LTCH PPS
area wage index values in this final rule,
there are no IPPS wage data for the urban
area of Hinesville, GA (CBSA 25980).
Consistent with our existing methodology,
we calculated the FY 2023 wage index value
for CBSA 25980 as the average of the wage
index values for all of the other urban areas
within the State of Georgia (that is, CBSAs
10500, 12020, 12060, 12260, 15260, 16860,
17980, 19140, 23580, 31420, 40660, 42340,
46660 and 47580), as shown in Table 12A,
which is listed in section VI. of the
Addendum to this final rule.
Based on the FY 2019 IPPS wage data that
we used to determine the FY 2023 LTCH PPS
standard Federal payment rate area wage
index values in this final rule, there are no
rural areas without IPPS hospital wage data.
Therefore, it is not necessary to use our
established methodology to calculate a LTCH
PPS wage index value for rural areas with no
IPPS wage data for FY 2023. We note that,
as IPPS wage data are dynamic, it is possible
that the number of rural areas without IPPS
wage data will vary in the future.
5. Permanent Cap on Wage Index Decreases
a. Permanent Cap on LTCH PPS Wage Index
Decreases
In the past, we have proposed and
finalized temporary transition policies to
mitigate significant changes to payments due
to changes to the LTCH PPS wage index,
particularly when adopting changes that have
large negative impacts on an LTCH’s
payments. In the FY 2021 IPPS/LTCH final
rule (85 FR 59052), we implemented a 5percent cap on any decrease in an LTCH’s
wage index from the LTCH’s final wage index
in FY 2020, so that the hospital’s final wage
index for FY 2021 would not be less than 95
percent of its final wage index for FY 2020.
We implemented this policy to mitigate
potential negative consequences of finalizing
the adoption of revised CBSA delineations
announced in OMB Bulletin 18–04 for FY
2021. In particular, we acknowledged that a
significant portion of Medicare LTCH PPS
payments are adjusted by the wage index and
that some changes in OMB delineations
destabilized payments to LTCHs. We stated
our belief that applying the 5-percent cap to
all wage index decreases for FY 2021
provided an adequate safeguard against
significant payment reductions related to the
adoption of the revised CBSAs and that it
would improve stability and predictability in
payment levels to LTCHs. We applied a
budget neutrality adjustment to the FY 2021
standard Federal payment rate to achieve
budget neutrality for this policy (85 FR
59053).
Although we did not propose or implement
a cap on wage index decreases for LTCH’s in
FY 2022, we acknowledged that some
commenters requested that we extend the FY
2021 transition policy, citing the continuing
impact of changes related to the OMB
updates and the unprecedented nature of the
ongoing COVID–19 PHE. In response to those
comments, we reiterated that our policy
principles with regard to the wage index
include generally using the most current data
and information available and providing that
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
data and information, as well as addressing
significant year-over-year variations in
Medicare payments in notice and comment
rulemaking.
For FY 2023, we further considered
comments received during the FY 2022
rulemaking, including requests for a broader,
permanent wage index policy to mitigate
unpredictable changes in payments to LTCHs
resulting from large wage index decreases.
We recognize that changes to the wage index
have the potential to create instability and
significant negative impacts on certain
providers even when we have not adopted
specific changes to wage index policy. That
is, year to year fluctuations in an area’s wage
index can occur due to external factors that
can be difficult for an LTCH to predict and
are often outside an LTCH’s ability to directly
control, such as the COVID–19 PHE. We
recognize that predictability in Medicare
payments is important to enable hospitals to
budget and plan their operations. For LTCHs,
in particular, we further recognize that a
significant portion of Medicare LTCH PPS
payments are adjusted by the wage index and
that a large decrease from one year to the
next can have significant implications for
LTCH payments.
For these reasons, under the broad
authority of section 123 of the BBRA, as
amended by section 307(b) of the BIPA, in
the FY 2023 IPPS/LTCH PPS proposed rule
(87 FR 28684 through 28685), we proposed,
beginning with FY 2023, to apply a
permanent 5-percent cap on any decrease to
an LTCH’s wage index from its wage index
in the prior year. In the proposed rule, we
stated our belief that a 5-percent reduction is
an appropriate threshold to mitigate large
negative financial impacts on hospitals and
limit the magnitude of the associated
proposed budget neutrality adjustment
(discussed later in section V.A.5. of the
Addendum). Typical year-to-year variations
in the LTCH wage index have historically
been within 5 percent, and we expect this
will continue to be the case in future years.
Because providers typically experience some
level of wage index fluctuation, we stated our
belief that applying a 5-percent cap on all
wage index decreases each year, regardless of
the reason for the decrease, would effectively
mitigate instability and increase
predictability in LTCH PPS payments due to
any significant wage index decreases.
In the proposed rule, we stated our belief
that this proposed policy of applying a
permanent cap to wage index decreases
would provide greater predictability to
LTCHs. That is, the policy would smooth
year-to-year changes in LTCHs’ wage indexes
and provide for increased predictability in
their wage index and thus their LTCH PPS
payments. We also stated our belief that our
proposed permanent policy would mitigate
significant payment reductions due to
changes in wage index policy, such as the
adoption of the revised CBSAs in FY 2021,
thereby eliminating the need for one-off
temporary transition adjustments to wage
index levels in the future. Because applying
a 5-percent cap on all wage index decreases
would generally represent a small overall
impact on the adjustment for area wage
levels, we stated our belief that the 5-percent
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
cap would not distort the integrity of the
wage index as a relative measure of the value
of labor in a labor market area.
Furthermore, consistent with the
requirement at § 412.525(c)(2), that changes
to area wage level adjustments are made in
a budget neutral manner, we proposed that
the 5-percent cap on the decrease on an
LTCH’s wage index would not result in any
change in estimated aggregate LTCH PPS
payments by including the application of this
policy in the determination of the area wage
level budget neutrality factor that is applied
to the standard Federal payment rate, as is
discussed later in section V.B.6. of the
Addendum to the final rule.
We proposed that an LTCH’s wage index
cap adjustment would be determined based
on the wage index value applicable to the
LTCH on the last day of the prior Federal
fiscal year. We proposed that new LTCHs
that became operational during the prior
Federal fiscal year would be subject to the
LTCH PPS wage index cap. For example, if
an LTCH begins operations on July 1, 2022
and is paid its area wage index of 0.9000 for
the remainder of FY 2022, its FY 2023 wage
index would be capped at 95 percent of that
value and could not be lower than 0.8550
(0.95 × 0.9000). However, for newly opened
LTCHs that become operational on or after
the first day of the fiscal year to which this
final rule would apply, we proposed that
these LTCHs would not be subject to the
LTCH PPS wage index cap since they were
not paid under the LTCH PPS in the prior
year. These LTCHs would receive the
calculated wage index for the area in which
they are geographically located, even if other
LTCHs in the same geographic area are
receiving a wage cap. For example, a hospital
that opens on December 1, 2022 would not
be eligible for a capped wage index in FY
2023, as it was not paid a wage index during
FY 2022.
Comment: We received several comments
expressing support for our proposed
permanent 5-percent cap on any decrease to
an LTCH’s wage index from its wage index
in the prior year beginning with FY 2023.
Commenters generally agreed that the cap
would help mitigate significant payment
decreases and provide stability and
predictability to LTCH payments. Some
commenters encouraged CMS to apply this
general principle of increasing stability to
other aspects of LTCH payment policies.
Response: We appreciate the support for
our proposal. We agree with commenters
about the importance of stability and
predictability in LTCH PPS payments. We
will continue to consider additional policy
options to achieve this objective in future
rulemaking.
Comment: MedPAC supported our
proposal to cap LTCH’s wage index decreases
at 5 percent, but suggested also applying a
cap to increases of more than 5 percent.
Response: We appreciate MedPAC’s
suggestion that CMS should apply a cap on
wage index increases greater than 5 percent.
However, as we discussed in the proposed
rule, the purpose of the proposed policy is
to help mitigate the significant negative
impacts of certain wage index changes. We
believe applying a 5-percent cap on all wage
PO 00000
Frm 00663
Fmt 4701
Sfmt 4700
49441
index decreases would support increased
predictability about LTCH PPS payments for
providers, enabling them to more effectively
budget and plan their operations. That is, we
believe that a provider would be able to more
effectively budget and plan when there is
predictability about its expected minimum
level of LTCH PPS payments in the
upcoming fiscal year. We did not propose to
limit wage index increases because we do not
believe such a policy is needed to enable
LTCHs to more effectively budget and plan
their operations. So, we believe it is
appropriate for providers that would
experience an increase in their wage index
value to receive the wage index value that
most accurately reflects the labor costs in that
area.
Comment: A number of commenters
disagreed with our proposal to implement
the proposed 5-percent cap on wage index
decreases in a budget neutral manner and
maintained that CMS has the statutory
authority to implement the proposed policy
in a non-budget neutral manner. Some of
these commenters indicated that their
support of the cap was conditional on CMS
not implementing the cap in a budget neutral
manner.
Response: While CMS’s statutory authority
is broad, we continue to believe it is
appropriate to implement this policy in a
budget neutral manner which is consistent
with the requirement at § 412.525(c)(2) that
changes to area wage level adjustments are
made in a budget neutral manner. That is, we
continue to believe that changes to area wage
level adjustments, including the proposed 5percent cap on the decrease on an LTCH’s
wage index, should not result in any change
in estimated aggregate LTCH PPS payments.
We also anticipate that in the absence of
proposed policy changes most LTCHs will
not experience year-to-year wage index
declines greater than 5 percent in any given
year and that the overall budget neutrality
adjustments associated with the policy will
be relatively small and would not create
volatility in LTCH PPS payments.
Comment: A commenter recommended
that CMS retroactively apply the 5-percent
cap policy to the FY 2022 wage index for
LTCHs that experienced wage index
decreases due to their transition to a new
CBSA based on the new OMB delineations
that were finalized for FY 2021.
Response: As noted previously, in FY
2021, we implemented a transition to
mitigate any negative effects of wage index
changes by applying a 5-percent cap on any
decrease in an LTCH’s wage index from the
LTCH’s final wage index in FY 2020; we
indicated that no cap would be applied to the
reduction in the second year, FY 2022. In the
FY 2023 IPPS/LTCH PPS proposed rule, we
did not propose to modify that transition
policy to extend the transition period for FY
2022. We have historically implemented
transitions of limited duration to address
CBSA changes due to substantial updates to
OMB delineations. In accordance with our
policy principles that we use the most
updated data and information available with
regard to the wage index, we proposed that
the FY 2023 5-percent cap wage index policy
would be prospective to mitigate any
significant decreases beginning in FY 2023.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49442
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Comment: Some commenters disagreed
with our proposal to apply the 5-percent cap
on decreases to an LTCH’s wage index only
to existing hospitals; that is, hospitals that
were already operational on the last day of
the prior Federal fiscal year. The commenters
stated that this policy would create
unnecessary inequity in Medicare payments
for hospitals in the same market. They
encouraged CMS to apply the same area wage
index value for new and existing hospitals.
Response: We appreciate the commenters’
concerns about equity and fairness. As we
have stated, however, the primary purpose of
applying a 5-percent cap on decreases to an
LTCH’s wage index is to support
predictability about LTCH payments,
mitigate financial instability from one year to
the next, and enable LTCHs to more
effectively budget and plan their operations.
LTCHs that were not operational on the last
day of the prior Federal fiscal year could not
experience LTCH PPS payment decreases
relative to the prior year since they would
have received no LTCH PPS payments in the
prior year. In addition, we do not expect that
there would be many LTCHs in this situation.
There are few newly created LTCHs, in
general, and even fewer that will open in an
area that is receiving an adjustment under the
policy. Finally, we note that any differential
in the wage index related to a newly
operational LTCH and an existing LTCH in
the same labor market area will generally be
limited to a single year, since typical year-toyear variations in the LTCH wage index have
historically been, and we expect will
continue to be, within 5 percent.
Comment: A commenter, while supportive
of the proposed 5-percent cap on wage index
decreases, believes it does not correct for an
ongoing problem with the range in wage
index values amongst LTCHs. This
commenter believes the range in wage index
values is too large and that CMS should
establish an annual cap that would be placed
on CBSAs with high wage index values.
Furthermore, the same commenter believes
that LTCHs should have the option to
reclassify to a different CBSA as is permitted
for IPPS hospitals.
Response: We disagree with the
commenters’ suggestion that we establish a
cap for CBSAs with high wage index values.
We believe the LTCH PPS wage index
accurately reflects the relative labor costs in
areas with both high wage index and low
wage index values. In reference to the
comment on LTCHs having an option to
reclassify to a different CBSA, we did not
propose this specific policy suggested by the
commenters, but we will take this comment
into consideration to potentially inform
future rulemaking.
After consideration of the public comments
we received, we are finalizing as proposed,
that, beginning in FY 2023, we will apply a
permanent 5-percent cap on any decrease to
an LTCH’s wage index from its wage index
in the prior year. Also, after consideration of
the public comments we received, we are
establishing that this wage index cap policy
will be implemented in a budget neutral
manner by including the application of this
policy in the area wage level budget
neutrality factor that is applied to the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
standard Federal payment rate. We believe
that this policy appropriately mitigates
instability and significant negative impacts to
LTCHs resulting from significant changes to
the wage index and increases predictability
of LTCH payments. We note that this
provision is similar to our provision
establishing a permanent 5-percent cap on
annual wage index decreases for IPPS
hospitals, as discussed in section III.N. of the
preamble to this final rule.
We received no comments about our
proposal to modify text at § 412.525(c)(1) to
reflect the permanent cap on wage index
decreases. Therefore, as we proposed, we are
reflecting the permanent cap on wage index
decreases at § 412.525(c)(1) by adding
paragraphs (c)(1)(i) and (ii) to specify that
CMS updates the wage index for LTCHs
annually and that, beginning in FY 2023, if
CMS determines that an LTCH’s wage index
value for a fiscal year would decrease by
more than 5 percent as compared to the
LTCH’s wage index value for the prior year,
we will limit the decrease to 5 percent for the
fiscal year.
For each LTCH we identify in our
rulemaking data, we are including in a
supplemental data file the wage index values
from both fiscal years used in determining its
capped wage index. This includes the
LTCH’s final prior year wage index value, the
LTCH’s uncapped current year wage index
value, and the LTCH’s capped current year
wage index value. Due to the lag in
rulemaking data, a new LTCH may not be
listed in this supplemental file for a few
years. For this reason, a newly opened LTCH
could contact their MAC to ensure that its
wage index value is not less than 95 percent
of the value paid to it for the prior Federal
fiscal year. This supplemental data file for
public use will be posted on the CMS website
for this final rule at https://www.cms.gov/
Medicare/Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/.
b. Permanent Cap on IPPS Comparable Wage
Index Decreases
Determining LTCH PPS payments for
short-stay-outlier cases (reflected in
§ 412.529) and site neutral payment rate
cases (reflected in § 412.522(c)) requires
calculating an ‘‘IPPS comparable amount.’’
For information on this ‘‘IPPS comparable
amount’’ calculation, we refer the reader to
the FY 2016 IPPS/LTCH PPS final rule (80 FR
49608 through 49610). Determining LTCH
PPS payments for LTCHs that do not meet
the applicable discharge payment percentage
(reflected in § 412.522(d)) requires
calculating an ‘‘IPPS equivalent amount.’’ For
information on this ‘‘IPPS equivalent
amount’’ calculation, we refer the reader to
the FY 2020 IPPS/LTCH PPS final rule (84 FR
42439 through 42445).
Calculating both the ‘‘IPPS comparable
amount’’ and the ‘‘IPPS equivalent amount’’
requires adjusting the IPPS operating and
capital standardized amounts by the
applicable IPPS wage index for
nonreclassified IPPS hospitals. That is, the
standardized amounts are adjusted by the
IPPS wage index for nonreclassified IPPS
hospitals located in the same geographic area
as the LTCH. Consistent with our proposal to
apply a 5-percent cap on decreases in the
PO 00000
Frm 00664
Fmt 4701
Sfmt 4700
LTCH PPS wage index and under the broad
authority of section 123 of the BBRA, as
amended by section 307(b) of the BIPA, in
the FY 2023 IPPS/LTCH PPS proposed rule
(87 FR 28685 through 28686), we also
proposed, beginning with FY 2023 to apply
a permanent 5-percent cap on decreases in an
LTCH’s applicable IPPS comparable wage
index from its applicable IPPS comparable
wage index in the prior year. As with our
proposed policy to apply a cap on decreases
in the LTCH PPS wage index each year, we
stated our belief that a permanent cap on
applicable IPPS comparable wage index
decreases would provide greater
predictability to LTCHs by mitigating
instability and significant negative impacts to
LTCHs resulting from significant changes to
the wage index and increase predictability of
LTCH payments. Historically, we have not
budget neutralized changes to LTCH PPS
payments that result from the annual update
of the IPPS wage index for nonreclassified
IPPS hospitals. Consistent with this
approach, we proposed that the cap on
decreases in an LTCH’s applicable IPPS
comparable wage index not be applied in a
budget neutral manner.
We proposed that an LTCH’s applicable
IPPS comparable wage index cap adjustment
would be determined based on the wage
index value assigned to the LTCH on the last
day of the prior Federal fiscal year. We also
proposed that new LTCHs that became
operational during the prior Federal fiscal
year be subject to the applicable IPPS
comparable wage index cap. However, for
newly opened LTCHs that become
operational on or after the first day of the
fiscal year to which this final rule applies, we
proposed that these LTCHs would not be
subject to the applicable IPPS comparable
wage index cap since they were not paid
under the LTCH PPS in the prior year.
We received no comments on our proposal
to apply a permanent 5-percent cap on
decreases in an LTCH’s applicable IPPS
comparable wage index from its applicable
IPPS comparable wage index in the prior
year. Therefore, we are finalizing this
proposal without modification.
We received no comments about our
proposal to modify text at
§ 412.529(d)(4)(ii)(B) and
§ 412.529(d)(4)(iii)(B) to reflect the
permanent cap on IPPS comparable wage
index decreases. Similarly, we received no
comments on our proposal to remove the
reference in § 412.529(d)(4)(iii)(B) related to
the applicable large urban location
adjustment. Therefore, as proposed, we are
reflecting the permanent cap on IPPS
comparable wage index decreases at
§ 412.529(d)(4)(ii)(B) to state that, beginning
in FY 2023, an LTCH’s applicable IPPS wage
index used to adjust the IPPS operating
standardized amount is subject to a 5-percent
cap on decreases to an LTCH’s applicable
IPPS wage index value from the prior fiscal
year. We also are reflecting the permanent
cap on IPPS comparable wage index
decreases at § 412.529(d)(4)(iii)(B) to state
that, beginning in FY 2023, an LTCH’s
applicable IPPS wage index used to adjust
the IPPS capital Federal rate is subject to a
5-percent cap on decreases to an LTCH’s
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
applicable IPPS wage index value from the
prior fiscal year. In addition, we are
finalizing our proposal to remove the
reference in § 412.529(d)(4)(iii)(B) related to
the applicable large urban location
adjustment because this policy is no longer
applicable under the IPPS effective with
discharges occurring on or after October 1,
2007 (72 FR 47400).
Similar to the information we made
available for the cap on the LTCH PPS wage
index values (described previously), for each
LTCH we identify in our rulemaking data, we
are including in a supplemental data file the
wage index values from both fiscal years
used in determining its capped applicable
IPPS comparable wage index. Due to the lag
in rulemaking data, a new LTCH may not be
listed in this supplemental file for a few
years. For this reason, a newly opened LTCH
could contact its MAC to ensure that its
applicable IPPS comparable wage index
value is not less than 95 percent of the value
paid to them for the prior Federal fiscal year.
This supplemental data file for public use
will be posted on the CMS website for this
final rule at https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/.
6. Budget Neutrality Adjustments for
Changes to the LTCH PPS Standard Federal
Payment Rate Area Wage Level Adjustment
Historically, the LTCH PPS wage index and
labor-related share are updated annually
based on the latest available data. Under
§ 412.525(c)(2), any changes to the area wage
index values or labor-related share are to be
made in a budget neutral manner such that
estimated aggregate LTCH PPS payments are
unaffected; that is, will be neither greater
than nor less than estimated aggregate LTCH
PPS payments without such changes to the
area wage level adjustment. Under this
policy, we determine an area wage level
adjustment budget neutrality factor that is
applied to the standard Federal payment rate
to ensure that any changes to the area wage
level adjustments are budget neutral such
that any changes to the area wage index
values or labor-related share would not result
in any change (increase or decrease) in
estimated aggregate LTCH PPS payments.
Accordingly, under § 412.523(d)(4), we have
applied an area wage level adjustment budget
neutrality factor in determining the standard
Federal payment rate, and we also
established a methodology for calculating an
area wage level adjustment budget neutrality
factor. (For additional information on the
establishment of our budget neutrality policy
for changes to the area wage level
adjustment, we refer readers to the FY 2012
IPPS/LTCH PPS final rule (76 FR 51771
through 51773 and 51809).)
For FY 2023, in accordance with
§ 412.523(d)(4), as we proposed, we applied
an area wage level budget neutrality factor to
adjust the LTCH PPS standard Federal
payment rate to account for the estimated
effect of the adjustments or updates to the
area wage level adjustment under
§ 412.525(c)(1) on estimated aggregate LTCH
PPS payments, consistent with the
methodology we established in the FY 2012
IPPS/LTCH PPS final rule (76 FR 51773). As
discussed in section V.B.5. of the Addendum
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
to this final rule, for each year, beginning
with FY 2023, we are limiting a hospital’s
LTCH PPS wage index value for the coming
year by capping it at 95 percent of its prior
year value. As also discussed previously, we
are applying the 5-percent cap on wage index
decreases, consistent with § 412.525(c)(2), in
a budget neutral manner.
Specifically, as we proposed, we
determined an area wage level adjustment
budget neutrality factor that is applied to the
LTCH PPS standard Federal payment rate
under § 412.523(d)(4) for FY 2023 using the
following methodology, which will
incorporate our 5-percent cap on decreases in
a hospital’s wage index:
Step 1—Simulate estimated aggregate
LTCH PPS standard Federal payment rate
payments using the FY 2022 wage index
values and the FY 2022 labor-related share of
67.9 percent.
Step 2—Simulate estimated aggregate
LTCH PPS standard Federal payment rate
payments using the FY 2023 wage index
values (including application of the 5-percent
cap on wage index decreases) and the FY
2023 labor-related share of 68.0 percent. (As
noted previously, the changes to the wage
index values based on updated hospital wage
data are discussed in section V.B.4. of this
Addendum to this final rule and the laborrelated share is discussed in section V.B.3. of
this Addendum to this final rule.)
Step 3—Calculate the ratio of these
estimated total LTCH PPS standard Federal
payment rate payments by dividing the
estimated total LTCH PPS standard Federal
payment rate payments using the FY 2022
area wage level adjustments (calculated in
Step 1) by the estimated total LTCH PPS
standard Federal payment rate payments
using the FY 2023 updates to the area wage
level adjustment (calculated in Step 2) to
determine the budget neutrality factor for
updates to the area wage level adjustment for
FY 2023 LTCH PPS standard Federal
payment rate payments.
Step 4—Apply the FY 2023 updates to the
area wage level adjustment budget neutrality
factor from Step 3 to determine the FY 2023
LTCH PPS standard Federal payment rate
after the application of the FY 2023 annual
update.
In section I.F. of the preamble to this final
rule, we discuss our use of FY 2021 claims
data for the FY 2023 LTCH PPS ratesetting.
We also state our belief that it is reasonable
to assume that there will be fewer COVID–
19 hospitalizations among Medicare
beneficiaries at LTCHs in FY 2023 than there
were in FY 2021. For this reason, we are
making modifications in our determination of
the FY 2023 MS–LTC–DRG relative weights
and outlier fixed-loss amount for LTCH PPS
standard Federal payment rate cases. We
believe that these modifications will account
for an anticipated decline in, but not
elimination of, COVID–19 hospitalizations at
LTCHs in FY 2023. However, in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR 28687),
when modeling payments for determining
the area wage level adjustment budget
neutrality factor, we proposed to use the full
set of LTCH PPS standard Federal payment
rate cases (including all COVID–19 cases)
identified in the FY 2021 claims data. We
PO 00000
Frm 00665
Fmt 4701
Sfmt 4700
49443
stated that in the absence of a set of MedPAR
claims that reflect our expectation that there
will be fewer (but not zero) COVID–19 cases
in FY 2023 as compared to the COVID–19
cases in the FY 2021 claims data, we believe
this is the best data available for determining
the budget neutrality factors. We also
solicited feedback from commenters on
alternative ways to use the FY 2021 claims
data for purposes of calculating the FY 2023
budget neutrality factors. We received no
comments on this proposal or our request for
feedback on alternatives and are finalizing
this proposal without modification.
Therefore, for this final rule, when modeling
payments for determining the budget
neutrality factors, we used the full set of
standard Federal payment rate cases
(including all COVID–19 cases) identified in
the FY 2021 claims data. We note this is
consistent with the calculation of the budget
neutrality factors for changes to the MS–
LTC–DRG classifications and relative weights
(including the 10-percent cap) discussed in
section VIII.B.4.b. (Step 11) of the preamble
of this final rule. We also note this is
consistent with the approach under the IPPS
as discussed in section II.A.4. of the
Addendum of this final rule.
We note that, because the area wage level
adjustment under § 412.525(c) is an
adjustment to the LTCH PPS standard
Federal payment rate, consistent with
historical practice, we only used data from
claims that qualified for payment at the
LTCH PPS standard Federal payment rate
under the dual rate LTCH PPS to calculate
the FY 2023 LTCH PPS standard Federal
payment rate area wage level adjustment
budget neutrality factor. For this final rule,
using the steps in the methodology
previously described, we determined a FY
2023 LTCH PPS standard Federal payment
rate area wage level adjustment budget
neutrality factor of 1.0004304. Accordingly,
in section V.A. of the Addendum to this final
rule, we applied the area wage level
adjustment budget neutrality factor of
1.0004304 to determine the FY 2023 LTCH
PPS standard Federal payment rate, in
accordance with § 412.523(d)(4).
C. Cost-of-Living Adjustment (COLA) for
LTCHs Located in Alaska and Hawaii
Under § 412.525(b), a cost-of-living
adjustment (COLA) is provided for LTCHs
located in Alaska and Hawaii to account for
the higher costs incurred in those States.
Specifically, we apply a COLA to payments
to LTCHs located in Alaska and Hawaii by
multiplying the nonlabor-related portion of
the standard Federal payment rate by the
applicable COLA factors established annually
by CMS. Higher labor-related costs for LTCHs
located in Alaska and Hawaii are taken into
account in the adjustment for area wage
levels previously described. The
methodology used to determine the COLA
factors for Alaska and Hawaii is based on a
comparison of the growth in the Consumer
Price Indexes (CPIs) for Anchorage, Alaska,
and Honolulu, Hawaii, relative to the growth
in the CPI for the average U.S. city as
published by the Bureau of Labor Statistics
(BLS). It also includes a 25-percent cap on
the CPI-updated COLA factors. Under our
E:\FR\FM\10AUR2.SGM
10AUR2
49444
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
current policy, we update the COLA factors
using the methodology as previously
described every 4 years (at the same time as
the update to the labor-related share of the
IPPS market basket) and we last updated the
COLA factors for Alaska and Hawaii
published by OPM for 2009 in FY 2022 (86
FR 45559 through 45560).
We continue to believe that determining
updated COLA factors using this
methodology would appropriately adjust the
nonlabor-related portion of the LTCH PPS
standard Federal payment rate for LTCHs
located in Alaska and Hawaii. Therefore, in
this final rule, for FY 2023, under the broad
authority conferred upon the Secretary by
section 123 of the BBRA, as amended by
section 307(b) of the BIPA, to determine
appropriate payment adjustments under the
LTCH PPS, as we proposed, we are
continuing to use the COLA factors based on
the 2009 OPM COLA factors updated through
2020 by the comparison of the growth in the
CPIs for Anchorage, Alaska, and Honolulu,
Hawaii, relative to the growth in the CPI for
the average U.S. city as established in the FY
2022 IPPS/LTCH PPS final rule. (For
additional details on our current
methodology for updating the COLA factors
for Alaska and Hawaii and for a discussion
on the FY 2022 COLA factors, we refer
readers to the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45559 through 45560).)
COST-OF-LIVING ADJUSTMENT FACTORS (COLA):
ALASKA AND HAWAIi UNDER THE LTCH PPS FOR FY 2023
FY2023
D. Adjustment for LTCH PPS High Cost
Outlier (HCO) Cases
1. HCO Background
From the beginning of the LTCH PPS, we
have included an adjustment to account for
cases in which there are extraordinarily high
costs relative to the costs of most discharges.
Under this policy, additional payments are
made based on the degree to which the
estimated cost of a case (which is calculated
by multiplying the Medicare allowable
covered charge by the hospital’s overall
hospital CCR) exceeds a fixed-loss amount.
This policy results in greater payment
accuracy under the LTCH PPS and the
Medicare program, and the LTCH sharing the
financial risk for the treatment of
extraordinarily high-cost cases.
We retained the basic tenets of our HCO
policy in FY 2016 when we implemented the
dual rate LTCH PPS payment structure under
section 1206 of Public Law 113–67. LTCH
discharges that meet the criteria for exclusion
from the site neutral payment rate (that is,
LTCH PPS standard Federal payment rate
cases) are paid at the LTCH PPS standard
Federal payment rate, which includes, as
applicable, HCO payments under
§ 412.523(e). LTCH discharges that do not
meet the criteria for exclusion are paid at the
site neutral payment rate, which includes, as
applicable, HCO payments under
§ 412.522(c)(2)(i). In the FY 2016 IPPS/LTCH
PPS final rule, we established separate fixedloss amounts and targets for the two different
LTCH PPS payment rates. Under this
bifurcated policy, the historic 8-percent HCO
target was retained for LTCH PPS standard
Federal payment rate cases, with the fixedloss amount calculated using only data from
LTCH cases that would have been paid at the
LTCH PPS standard Federal payment rate if
that rate had been in effect at the time of
those discharges. For site neutral payment
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
1.22
1.22
1.22
1.24
1.25
1.22
1.25
1.25
rate cases, we adopted the operating IPPS
HCO target (currently 5.1 percent) and set the
fixed-loss amount for site neutral payment
rate cases at the value of the IPPS fixed-loss
amount. Under the HCO policy for both
payment rates, an LTCH receives 80 percent
of the difference between the estimated cost
of the case and the applicable HCO
threshold, which is the sum of the LTCH PPS
payment for the case and the applicable
fixed-loss amount for such case.
To maintain budget neutrality, consistent
with the budget neutrality requirement at
§ 412.523(d)(1) for HCO payments to LTCH
PPS standard Federal rate payment cases, we
also adopted a budget neutrality requirement
for HCO payments to site neutral payment
rate cases by applying a budget neutrality
factor to the LTCH PPS payment for those
site neutral payment rate cases. (We refer
readers to § 412.522(c)(2)(i) of the regulations
for further details.) We note that, during the
4-year transitional period, the site neutral
payment rate HCO budget neutrality factor
did not apply to the LTCH PPS standard
Federal payment rate portion of the blended
payment rate at § 412.522(c)(3) payable to site
neutral payment rate cases. (For additional
details on the HCO policy adopted for site
neutral payment rate cases under the dual
rate LTCH PPS payment structure, including
the budget neutrality adjustment for HCO
payments to site neutral payment rate cases,
we refer readers to the FY 2016 IPPS/LTCH
PPS final rule (80 FR 49617 through 49623).)
2. Determining LTCH CCRs Under the LTCH
PPS
a. Background
As noted previously, CCRs are used to
determine payments for HCO adjustments for
both payment rates under the LTCH PPS and
also are used to determine payments for site
neutral payment rate cases. As noted earlier,
PO 00000
Frm 00666
Fmt 4701
Sfmt 4700
in determining HCO and the site neutral
payment rate payments (regardless of
whether the case is also an HCO), we
generally calculate the estimated cost of the
case by multiplying the LTCH’s overall CCR
by the Medicare allowable charges for the
case. An overall CCR is used because the
LTCH PPS uses a single prospective payment
per discharge that covers both inpatient
operating and capital-related costs. The
LTCH’s overall CCR is generally computed
based on the sum of LTCH operating and
capital costs (as described in Section 150.24,
Chapter 3, of the Medicare Claims Processing
Manual (Pub. 100–4)) as compared to total
Medicare charges (that is, the sum of its
operating and capital inpatient routine and
ancillary charges), with those values
determined from either the most recently
settled cost report or the most recent
tentatively settled cost report, whichever is
from the latest cost reporting period.
However, in certain instances, we use an
alternative CCR, such as the statewide
average CCR, a CCR that is specified by CMS,
or one that is requested by the hospital. (We
refer readers to § 412.525(a)(4)(iv) of the
regulations for further details regarding CCRs
and HCO adjustments for either LTCH PPS
payment rate and § 412.522(c)(1)(ii) for the
site neutral payment rate.)
The LTCH’s calculated CCR is then
compared to the LTCH total CCR ceiling.
Under our established policy, an LTCH with
a calculated CCR in excess of the applicable
maximum CCR threshold (that is, the LTCH
total CCR ceiling, which is calculated as 3
standard deviations from the national
geometric average CCR) is generally assigned
the applicable statewide CCR. This policy is
premised on a belief that calculated CCRs in
excess of the LTCH total CCR ceiling are most
likely due to faulty data reporting or entry,
and CCRs based on erroneous data should
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.221
khammond on DSKJM1Z7X2PROD with RULES2
Area
Alaska:
City of Anchorage and SO-kilometer (5O-mile) radius by road
City of Fairbanks and SO-kilometer (5O-mile) radius by road
City of Juneau and SO-kilometer (5O-mile) radius by road
Rest of Alaska
Hawaii:
City and County of Honolulu
County of Hawaii
County of Kauai
County of Maui and County of Kalawao
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
not be used to identify and make payments
for outlier cases.
b. LTCH Total CCR Ceiling
Consistent with our historical practice, as
we proposed, we used the best available data
to determine the LTCH total CCR ceiling for
FY 2023 in this final rule. Specifically, in
this final rule, we used our established
methodology for determining the LTCH total
CCR ceiling based on IPPS total CCR data
from the March 2022 update of the Provider
Specific File (PSF), which is the most recent
data available. Accordingly, we are
establishing an LTCH total CCR ceiling of
1.312 under the LTCH PPS for FY 2023 in
accordance with § 412.525(a)(4)(iv)(C)(2) for
HCO cases under either payment rate and
§ 412.522(c)(1)(ii) for the site neutral
payment rate. (For additional information on
our methodology for determining the LTCH
total CCR ceiling, we refer readers to the FY
2007 IPPS final rule (71 FR 48117 through
48119).)
We did not receive any public comments
on our proposals. Therefore, we are finalizing
our proposals as described previously,
without modification.
c. LTCH Statewide Average CCRs
Our general methodology for determining
the statewide average CCRs used under the
LTCH PPS is similar to our established
methodology for determining the LTCH total
CCR ceiling because it is based on ‘‘total’’
IPPS CCR data. (For additional information
on our methodology for determining
statewide average CCRs under the LTCH PPS,
we refer readers to the FY 2007 IPPS final
rule (71 FR 48119 through 48120).) Under the
LTCH PPS HCO policy at
§ 412.525(a)(4)(iv)(C), the SSO policy at
§ 412.529(f)(4)(iii), and the site neutral
payment rate at § 412.522(c)(1)(ii), the MAC
may use a statewide average CCR, which is
established annually by CMS, if it is unable
to determine an accurate CCR for an LTCH
in one of the following circumstances: (1)
New LTCHs that have not yet submitted their
first Medicare cost report (a new LTCH is
defined as an entity that has not accepted
assignment of an existing hospital’s provider
agreement in accordance with § 489.18); (2)
LTCHs whose calculated CCR is in excess of
the LTCH total CCR ceiling; and (3) other
LTCHs for whom data with which to
calculate a CCR are not available (for
example, missing or faulty data). (Other
sources of data that the MAC may consider
in determining an LTCH’s CCR include data
from a different cost reporting period for the
LTCH, data from the cost reporting period
preceding the period in which the hospital
began to be paid as an LTCH (that is, the
period of at least 6 months that it was paid
as a short-term, acute care hospital), or data
from other comparable LTCHs, such as
LTCHs in the same chain or in the same
region.)
Consistent with our historical practice of
using the best available data, in this final
rule, we are using our established
methodology for determining the LTCH
statewide average CCRs, based on the most
recent complete IPPS ‘‘total CCR’’ data from
the March 2022 update of the PSF. As we
proposed, we are establishing LTCH PPS
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
statewide average total CCRs for urban and
rural hospitals that will be effective for
discharges occurring on or after October 1,
2022, through September 30, 2023, in Table
8C listed in section VI. of the Addendum to
this final rule (and available via the internet
on the CMS website). Consistent with our
historical practice, as we also proposed, we
used the best available data to determine the
LTCH PPS statewide average total CCRs for
FY 2023 in the final rule.
Under the current LTCH PPS labor market
areas, all areas in Delaware, the District of
Columbia, New Jersey, and Rhode Island are
classified as urban. Therefore, there are no
rural statewide average total CCRs listed for
those jurisdictions in Table 8C. This policy
is consistent with the policy that we
established when we revised our
methodology for determining the applicable
LTCH statewide average CCRs in the FY 2007
IPPS final rule (71 FR 48119 through 48121)
and is the same as the policy applied under
the IPPS. In addition, although Connecticut
has areas that are designated as rural, in our
calculation of the LTCH statewide average
CCRs, there were no short-term, acute care
IPPS hospitals classified as rural or LTCHs
located in these rural areas as of March 2022.
Therefore, consistent with our existing
methodology, we used the national average
total CCR for rural IPPS hospitals for rural
Connecticut in Table 8C. While
Massachusetts also has rural areas, the
statewide average CCR for rural areas in
Massachusetts is based on one IPPS provider
whose CCR is an atypical 1.205. Because this
is much higher than the statewide urban
average (0.484) and furthermore implies costs
greater than charges, as with Connecticut, we
used the national average total CCR for rural
IPPS hospitals for rural Massachusetts in
Table 8C. Furthermore, consistent with our
existing methodology, in determining the
urban and rural statewide average total CCRs
for Maryland LTCHs paid under the LTCH
PPS, as we proposed, we are continuing to
use, as a proxy, the national average total
CCR for urban IPPS hospitals and the
national average total CCR for rural IPPS
hospitals, respectively. We are using this
proxy because we believe that the CCR data
in the PSF for Maryland hospitals may not
be entirely accurate (as discussed in greater
detail in the FY 2007 IPPS final rule (71 FR
48120)).
We did not receive any public comments
on our proposals. Therefore, we are finalizing
our proposals as described previously,
without modification.
d. Reconciliation of HCO Payments
Under the HCO policy at
§ 412.525(a)(4)(iv)(D), the payments for HCO
cases are subject to reconciliation (regardless
of whether payment is based on the LTCH
standard Federal payment rate or the site
neutral payment rate). Specifically, any such
payments are reconciled at settlement based
on the CCR that was calculated based on the
cost report coinciding with the discharge. For
additional information on the reconciliation
policy, we refer readers to sections 150.26
through 150.28 of the Medicare Claims
Processing Manual (Pub. 100–4), as added by
Change Request 7192 (Transmittal 2111;
PO 00000
Frm 00667
Fmt 4701
Sfmt 4700
49445
December 3, 2010), and the RY 2009 LTCH
PPS final rule (73 FR 26820 through 26821).
3. High-Cost Outlier Payments for LTCH PPS
Standard Federal Payment Rate Cases
a. High-Cost Outlier Payments for LTCH PPS
Standard Federal Payment Rate Cases
Under the regulations at § 412.525(a)(2)(ii)
and as required by section 1886(m)(7) of the
Act, the fixed-loss amount for HCO payments
is set each year so that the estimated
aggregate HCO payments for LTCH PPS
standard Federal payment rate cases are
99.6875 percent of 8 percent (that is, 7.975
percent) of estimated aggregate LTCH PPS
payments for LTCH PPS standard Federal
payment rate cases. (For more details on the
requirements for high-cost outlier payments
in FY 2018 and subsequent years under
section 1886(m)(7) of the Act and additional
information regarding high-cost outlier
payments prior to FY 2018, we refer readers
to the FY 2018 IPPS/LTCH PPS final rule (82
FR 38542 through 38544).)
b. Fixed-Loss Amount for LTCH PPS
Standard Federal Payment Rate Cases for FY
2023
When we implemented the LTCH PPS, we
established a fixed-loss amount so that total
estimated outlier payments are projected to
equal 8 percent of total estimated payments
(that is, the target percentage) under the
LTCH PPS (67 FR 56022 through 56026).
When we implemented the dual rate LTCH
PPS payment structure beginning in FY 2016,
we established that, in general, the historical
LTCH PPS HCO policy would continue to
apply to LTCH PPS standard Federal
payment rate cases. That is, the fixed-loss
amount for LTCH PPS standard Federal
payment rate cases would be determined
using the LTCH PPS HCO policy adopted
when the LTCH PPS was first implemented,
but we limited the data used under that
policy to LTCH cases that would have been
LTCH PPS standard Federal payment rate
cases if the statutory changes had been in
effect at the time of those discharges.
To determine the applicable fixed-loss
amount for LTCH PPS standard Federal
payment rate cases, we estimate outlier
payments and total LTCH PPS payments for
each LTCH PPS standard Federal payment
rate case (or for each case that would have
been an LTCH PPS standard Federal payment
rate case if the statutory changes had been in
effect at the time of the discharge) using
claims data from the MedPAR files. In
accordance with § 412.525(a)(2)(ii), the
applicable fixed-loss amount for LTCH PPS
standard Federal payment rate cases results
in estimated total outlier payments being
projected to be equal to 7.975 percent of
projected total LTCH PPS payments for LTCH
PPS standard Federal payment rate cases.
In the FY 2022 IPPS/LTCH PPS final rule
(86 FR 45562 through 45566), we finalized a
number of technical changes to the
methodology for determining the charge
inflation factor and the CCR used when
calculating the fixed-loss amount, while
maintaining estimated HCO payments at the
projected 7.975 percent of total estimated
LTCH PPS payments for LTCH PPS standard
Federal payment rate cases. First, we
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49446
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
finalized a technical change to the
methodology for determining the charge
inflation factor applied to the charges on the
MedPAR claims when calculating the fixedloss amount for each FY. Second, we
finalized a technical change to the
methodology for determining the CCRs used
when calculating the fixed-loss amount for
each FY. These methodologies are described
in greater detail later in this section of this
Addendum.
(1) Charge Inflation Factor for Use in
Determining the Fixed-Loss Amount for
LTCH PPS Standard Federal Payment Rate
Cases for FY 2023
Under the LTCH PPS, the cost of each
claim is estimated by multiplying the charges
on the claim by the provider’s CCR. Due to
the lag time in the availability of claims data,
when estimating costs for the upcoming
payment year we typically inflate the charges
from the claims data by a uniform factor.
For greater accuracy in calculating the
fixed-loss amount, in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45562 through
45566), we finalized a technical change to
our methodology for determining the charge
inflation factor. Similar to the method used
under the IPPS hospital payment
methodology (as discussed in section
II.A.4.h.(2) of the Addendum to this final
rule), our methodology determines the LTCH
charge inflation factor based on the historical
growth in charges for LTCH PPS standard
Federal payment rate cases, calculated using
historical MedPAR claims data. In this
section of this Addendum, we describe our
charge inflation factor methodology using the
most recently available data. However, as
discussed in further detail later in this
section, we did not propose to use the charge
inflation factor derived from the most
recently available data. Rather, we proposed
using the charge inflation factor used in the
FY 2022 IPPS/LTCH PPS final rule that was
based on the growth in charges that occurred
between FY 2018 and FY 2019.
Step 1—Identify LTCH PPS Standard
Federal Payment Rate Cases
The first step in our methodology is to
identify LTCH PPS standard Federal payment
rate cases from the MedPAR claim files for
the two most recently available Federal fiscal
year time periods. For both fiscal years,
consistent with our historical methodology
for determining payment rates for the LTCH
PPS, we remove any claims submitted by
LTCHs that were all-inclusive rate providers
as well as any Medicare Advantage claims.
For both fiscal years, we also remove claims
from providers that only had claims in one
of the fiscal years.
Step 2—Remove Statistical Outliers
The next step in our methodology is to
remove all claims from providers whose
growth in average charges was a statistical
outlier. We remove these statistical outliers
prior to calculating the charge inflation factor
because we believe they may represent
aberrations in the data that would distort the
measure of average charge growth. To
perform this statistical trim, we first calculate
each provider’s average charge in both fiscal
years. Then, we calculate a charge growth
factor for each provider by dividing its
average charge in the most recent fiscal year
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
by its average charge in the prior fiscal year.
Then we remove all claims for providers
whose calculated charge growth factor was
outside 3 standard deviations from the mean
provider charge growth factor.
Step 3—Calculate the Charge Inflation
Factor
The final step in our methodology is to use
the remaining claims to calculate a national
charge inflation factor. We first calculate the
average charge for those remaining claims in
both fiscal years. Then we calculate the
national charge inflation factor by dividing
the average charge in the more recent fiscal
year by the average charge in the prior fiscal
year.
Following the methodology described
previously, in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28690 through 28691),
we computed a charge inflation factor based
on the most recently available data.
Specifically, we used the December 2021
update of the FY 2021 MedPAR file and the
December 2020 update of the FY 2020
MedPAR as the basis of the LTCH PPS
standard Federal payment rate cases for the
two most recently available Federal fiscal
year time periods, as described previously in
our methodology. Therefore, we trimmed the
December 2021 update of the FY 2021
MedPAR file and the December 2020 update
of the FY 2020 MedPAR file as described in
steps 1 and 2 of our methodology. To
compute the 1-year average annual rate-ofchange in charges per case, we compared the
average covered charge per case of $239,245
($14,013,531,722/58,574 cases) from FY 2020
to the average covered charge per case of
$266,358 ($13,426,298,925/50,407 cases)
from FY 2021. This rate-of-change was
11.3327 percent, which results in a 1-year
charge inflation factor of 1.113327, and a 2year charge inflation factor of 1.239497
(calculated by squaring the 1-year factor).
In the proposed rule, we recognized that
this LTCH charge inflation factor calculated
using the established methodology was
abnormally high compared to recent
historical levels prior to the COVID–19 PHE.
We stated our belief that this abnormally
high charge inflation factor is partially due to
the high number of COVID–19 cases that
were treated in LTCHs in FY 2021. We also
stated our belief that there will be fewer
COVID–19 cases in FY 2023 than in FY 2021
and therefore do not believe it is reasonable
to assume charges will continue to increase
at this abnormally high rate. Consequently,
when determining the proposed fixed-loss
amount for LTCH PPS standard Federal
payment rate cases for FY 2023, we did not
propose to use this charge inflation factor,
which was based on the growth in charges
that occurred between FY 2020 and FY 2021.
Rather, we proposed to use the charge
inflation factor determined in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45565),
which was based on the growth in charges
that occurred between FY 2018 and FY 2019
(the last 1-year period prior to the COVID–
19 PHE).
The rate of LTCH charge growth
determined in the FY 2022 IPPS/LTCH PPS
final rule, based on the growth in charges
that occurred between FY 2018 and FY 2019,
was 6.0723 percent. This results in a 1-year
PO 00000
Frm 00668
Fmt 4701
Sfmt 4700
charge inflation factor of 1.060723, and a 2year charge inflation factor of 1.125133
(calculated by squaring the 1-year factor).
Therefore, we proposed to inflate the billed
charges obtained from the FY 2021 MedPAR
file by this 2-year charge inflation factor of
1.125133 when determining the fixed-loss
amount for LTCH PPS standard Federal
payment rate cases for FY 2023.
Comment: Nearly all commenters were
appreciative of CMS’s efforts to account for
some of the pandemic-related factors in
calculating the fixed-loss amount by applying
the final FY 2022 charge inflation factor
rather than the calculated amounts using our
previously established methodology.
Response: We appreciate the support for
this modification to our methodology in
determining the charge inflation factor. We
are finalizing our proposal to use the 2-year
charge inflation factor of 1.125133
determined in the FY 2022 IPPS/LTCH PPS
final rule, which was based on the growth in
charges that occurred between FY 2018 and
FY 2019 (the last 1-year period prior to the
COVID–19 PHE) in calculating the fixed-loss
amount. We note that using our ordinary data
for this final rule, we calculated a 2-year
charge inflation of 1.241308.
(2) CCRs for Use in Determining the FixedLoss Amount for LTCH PPS Standard Federal
Payment Rate Cases for FY 2023
For greater accuracy in calculating the
fixed-loss amount, in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45562 through
45566), we finalized a technical change to
our methodology for determining the CCRs
used to calculate the fixed-loss amount.
Similar to the methodology used for IPPS
hospitals (as discussed in section II.A.4.h.(2).
of the Addendum to this final rule), our
methodology adjusts CCRs obtained from the
best available PSF data by an adjustment
factor that is calculated based on historical
changes in the average case-weighted CCR for
LTCHs. We believe these adjusted CCRs more
accurately reflect CCR levels in the upcoming
payment year because they account for
historical changes in the relationship
between costs and charges for LTCHs. In this
section of this Addendum, we describe our
CCR adjustment factor methodology using
the most recently available data. However, as
discussed in further detail later in this
section of this Addendum, we did not
propose to use the CCR adjustment factor
derived from the most recently available
data. Rather, we proposed using the CCR
adjustment factor that was derived in the FY
2022 IPPS/LTCH PPS final rule, which is
based on the change in CCRs that occurred
between the March 2019 PSF and the March
2020 PSF.
Step 1—Assign Providers Their Historical
CCRs
The first step in our methodology is to
identify providers with LTCH PPS standard
Federal payment rate cases in the most recent
MedPAR claims file (excluding all-inclusive
rate providers and providers with only
Medicare Advantage claims). For each of
these providers, we then identify the CCR
from the most recently available PSF. For
each of these providers we also identify the
CCR from the PSF that was made available
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
one year prior to the most recently available
PSF.
Step 2—Trim Providers With Insufficient
CCR Data
The next step in our methodology is to
remove from the CCR adjustment factor
calculation any providers for which we
cannot accurately measure changes to their
CCR using the PSF data. We first remove any
provider whose CCR was missing in the most
recent PSF or prior year PSF. We next
remove any provider assigned the statewide
average CCR for their State in either the most
recent PSF or prior year PSF. We lastly
remove any provider whose CCR was not
updated between the most recent PSF and
prior year PSF (determined by comparing the
effective date of the records).
Step 3—Remove Statistical Outliers
The next step in our methodology is to
remove providers whose change in their CCR
is a statistical outlier. To perform this
statistical trim, for those providers remaining
after application of Step 2, we calculate a
provider-level CCR growth factor by dividing
the provider’s CCR from the most recent PSF
by its CCR in the prior year’s PSF. We then
remove any provider whose CCR growth
factor was outside 3 standard deviations from
the mean provider CCR growth factor. These
statistical outliers are removed prior to
calculating the CCR adjustment factor
because we believe that they may represent
aberrations in the data that would distort the
measure of average annual CCR change.
Step 4—Calculate a CCR Adjustment Factor
The final step in our methodology is to
calculate, across all remaining providers after
application of Step 3, an average caseweighted CCR from both the most recent PSF
and prior year PSF. The provider case counts
that we use to calculate the case-weighted
average are determined from claims for LTCH
standard Federal rate cases from the most
recent MedPAR claims file. We note when
determining these case counts, consistent
with our historical methodology for
determining the MS–LTC–DRG relative
weights, we do not count short-stay outlier
claims as full cases but instead as a fraction
of a case based on the ratio of covered days
to the geometric mean length of stay for the
MS–LTC–DRG grouped to the case. We
calculate the national CCR adjustment factor
by dividing the case-weighted CCR from the
most recent PSF by the case-weighted CCR
from the prior year PSF.
Following the methodology described
previously, in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28691 through 28692)
we computed a CCR adjustment factor based
on the most recently available data.
Specifically, we used the December 2021 PSF
as the most recently available PSF and the
December 2020 PSF as the PSF that was
made available one year prior to the most
recently available PSF, as described in our
methodology. In addition, we used claims
from the December 2021 update of the FY
2021 MedPAR file in our calculation of
average case-weighted CCRs described in
Step 4 of our methodology. Specifically,
following the methodology described
previously and, for providers with LTCH PPS
standard Federal payment rate cases in the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
December 2021 update of the FY 2021
MedPAR file, we identified their CCRs from
both the December 2020 PSF and December
2021 PSF. After performing the trims
outlined in our methodology, we used the
LTCH PPS standard Federal payment rate
case counts from the FY 2021 MedPAR file
(classified using proposed Version 40 of the
GROUPER) to calculate case-weighted
average CCRs. Based on this data, we
calculated a December 2020 national average
case-weighted CCR of 0.244856 and a
December 2021 national average caseweighted CCR of 0.234409. We then
calculated a national CCR adjustment factor
by dividing the December 2021 national
average case-weighted CCR by the December
2020 national average case-weighted CCR.
This results in a 1-year national CCR
adjustment factor of 0.957334.
Unlike the charge inflation factor
calculated using the most recently available
data, the CCR adjustment factor calculated
previously is not significantly different from
historical levels. However, consistent with
our proposal to derive our proposed charge
inflation factor for FY 2023 based on data
from the last 1-year period prior to the
COVID–19 PHE, we proposed using the CCR
adjustment factor determined in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45565),
which was based on the change in CCRs that
occurred between the March 2019 PSF and
the March 2020 PSF (the last 1-year period
prior to the COVID–19 PHE). We note that
the CCR adjustment factor of 0.961554
determined in the FY 2022 IPPS/LTCH PPS
final rule is close to the CCR adjustment
factor we calculated previously using the
most recently available data.
Comment: Nearly all commenters were
appreciative of CMS’s efforts to account for
some of the pandemic-related factors in
calculating the fixed-loss amount by applying
the final FY 2022 CCR adjustment factor
rather than the calculated amounts using our
previously established methodology.
Response: We appreciate the support for
our modified methodology for determining
the CCR adjustment factor. We are finalizing
our proposal to use the CCR adjustment
factor of 0.961554 determined in the FY 2022
IPPS/LTCH PPS final rule, which was based
on the change in CCRs that occurred between
the March 2019 PSF and the March 2020 PSF
(the last 1-year period prior to the COVID–
19 PHE) in calculating the fixed loss amount.
When calculating the fixed-loss amount for
FY 2023, consistent with our proposal, we
assigned the statewide average CCR for the
upcoming fiscal year to all providers who
were assigned the statewide average in the
March 2022 PSF or whose CCR was missing
in the March 2022 PSF. For all other
providers, we multiplied their CCR from the
March 2022 PSF by the 1-year national CCR
adjustment factor of 0.961554. We note that
using our ordinary data for this final rule, we
calculated a 1-year national CCR adjustment
factor of 0.959468.
(3) Fixed-Loss Amount for LTCH PPS
Standard Federal Payment Rate Cases for FY
2023
In the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28123 through 28125), we
discussed our proposed use of FY 2021
PO 00000
Frm 00669
Fmt 4701
Sfmt 4700
49447
claims data for the FY 2023 LTCH PPS
ratesetting. In the proposed rule, we stated
our belief that it is reasonable to assume that
there will be fewer COVID–19
hospitalizations among Medicare
beneficiaries at LTCHs in FY 2023 than there
were in FY 2021. For this reason, as
discussed previously, we proposed
modifications to the charge inflation and CCR
adjustment factors used in determining the
outlier fixed-loss amount for LTCH PPS
standard Federal payment rate cases.
However, when modeling payments for the
outlier fixed-loss amount for LTCH PPS
standard Federal payment rate cases, we
proposed to use the full set of LTCH PPS
standard Federal payment rate cases
(including all COVID–19 cases) identified in
the FY 2021 claims data. In the absence of
a set of MedPAR claims that reflect our
expectation that there will be fewer (but not
zero) COVID–19 cases in FY 2023 as
compared to the COVID–19 cases in the FY
2021 claims data, we stated our belief that
this is the best data available for determining
the outlier fixed-loss amount for LTCH PPS
standard Federal payment rate cases. In the
proposed rule, we solicited feedback from
commenters on alternative ways to use the
FY 2021 claims data for purposes of
calculating the FY 2023 outlier fixed-loss
amount for LTCH PPS standard Federal
payment rate cases.
In the proposed rule, for FY 2023, using
the best available data, we calculated a fixedloss amount that would maintain estimated
HCO payments at the projected 7.975 percent
of total estimated LTCH PPS payments for
LTCH PPS standard Federal payment rate
cases (based on the payment rates and
policies for these cases presented in the final
rule). Therefore, based on LTCH claims data
from the December 2021 update of the FY
2021 MedPAR file adjusted for charge
inflation and adjusted CCRs from the
December 2021 update of the PSF, under the
broad authority of section 123(a)(1) of the
BBRA and section 307(b)(1) of the BIPA, we
proposed a fixed-loss amount for LTCH PPS
standard Federal payment rate cases for FY
2023 of $44,182 that would result in
estimated outlier payments projected to be
equal to 7.975 percent of estimated FY 2023
payments for such cases. We also proposed
to continue making an additional HCO
payment for the cost of an LTCH PPS
standard Federal payment rate case that
exceeds the HCO threshold amount that is
equal to 80 percent of the difference between
the estimated cost of the case and the outlier
threshold (the sum of the adjusted LTCH PPS
standard Federal payment rate payment and
the fixed-loss amount for LTCH PPS standard
Federal payment rate cases of $44,182).
Consistent with our historical practice, we
proposed to use the best available LTCH
claims data and CCR data, if applicable,
when determining the fixed-loss amount for
LTCH PPS standard Federal payment rate
cases for FY 2023. In the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28740 through
28741), we also considered as an alternative,
to use the FY 2021 data without any of our
methodological changes that account for an
anticipated decline in COVID–19 cases in FY
2023. We noted in the proposed rule that,
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49448
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
under this alternative, the fixed-loss amount
for LTCH PPS standard Federal payment rate
cases would be $61,842
Comment: We received numerous
comments objecting to our proposed fixedloss amount of $44,182 for standard Federal
payment rate cases. Commenters stated that
the increase over last year’s fixed-loss
amount of $33,015, particularly on top of the
increase to the FY 2021 threshold of $27,195,
would have a significant financial impact on
LTCHs. Moreover, commenters stated their
belief that the proposed fixed-loss amount
would result in underpayments to LTCHs
treating high-cost patients, hindering the
ability of LTCHs to provide care to the sickest
beneficiaries. Some commenters stated that
CMS should lower the outlier fixed-loss
amount in response to rising costs that have
and will continue to impact LTCHs.
Several commenters expressed concern
about our proposed use of FY 2021 claims
data in determining the outlier fixed-loss
amount for LTCH PPS standard Federal
payment rate cases. Commenters
recommended several alternative data
sources or methodologies for calculating the
outlier fixed-loss amount that they believed
would more accurately reflect the impact of
the COVID–19 pandemic on utilization in FY
2023.
The most commonly recommended
approach by commenters was to determine
the outlier fixed-loss amount as an average of
the outlier fixed-loss amounts calculated
using both FY 2019 and FY 2021 claims data,
thereby incorporating data from one year
before the COVID–19 PHE and one year
during the COVID–19 PHE. Some
commenters believed that this approach
would better account for the uncertainty on
whether the abnormal levels of charges and
costs reflected in the FY 2021 claims data
caused by the COVID–19 pandemic will
normalize in FY 2023. Another commenter,
while suggesting this alternative
methodology, expressed its belief that costs
in FY 2023 will more closely resemble prepandemic costs than what was experienced
in FY 2021. Some commenters stated that
this approach would be consistent with other
FY 2023 proposals aimed to institute stability
and predictability in payments from year to
year.
Some commenters suggested that CMS use
its regulatory authority under the PHE to
establish the FY 2023 outlier fixed-loss
amount for LTCH PPS standard Federal
payment rate cases at the FY 2022 level.
Other commenters, while expressing
concerns that the FY 2021 claims were
atypical, requested CMS to reexamine its
methodology and better account for data
anomalies.
In its comment letter, MedPAC presented
an alternative approach for CMS to consider
in which the FY 2023 fixed-loss amount
would be established by averaging the outlier
fixed-loss amounts calculated with and
without COVID–19 cases in the FY 2021 data.
MedPAC believes that this approach would
be consistent with the approach CMS
proposed for calculating the MS–LTC–DRG
relative weights and would reflect the
assumption that there will be fewer COVID–
19 cases in FY 2023 as compared to FY 2021.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Commenters strongly objected to the
alternative fixed loss amount we considered
in section I.O. of Appendix A of the proposed
rule which was calculated using FY 2021
data without any of the methodological
changes to account for anticipated declines
in COVID–19 cases in FY 2023.
Response: We thank commenters for their
feedback. In response to commenters’
concerns, we considered recommendations
made by commenters on how we could better
account for the impact of the COVID–19 PHE
on the data used for determining the outlier
fixed-loss amount.
We do not agree with commenters who
recommend that CMS use it regulatory
authority under the PHE to establish an
alternative outlier fixed-loss amount or
commenters who suggested that CMS lower
the outlier-fixed loss amount in response to
rising costs at LTCHs. We note that in
accordance with § 412.525(a)(2)(ii), which
implements section 1886(m)(7)(B) of the Act,
CMS must determine a fixed-loss amount for
LTCH PPS standard Federal payment rate
cases that we project will result in total
outlier payments for FY 2023 being equal to
7.975 percent of projected total LTCH PPS
payments for LTCH PPS standard Federal
payment rate cases. We do not believe that
CMS has the statutory authority to establish
an outlier fixed-loss amount that does not
meet this requirement.
With respect to the commenters who
suggested we determine the outlier fixed-loss
amount based on an average of the fixed-loss
amounts calculated using FY 2019 and FY
2021 data, we continue to recognize that
there is uncertainty regarding the utilization
and costs that LTCHs will experience in FY
2023. However, based on the information
available at this time on the trajectory of the
COVID–19 PHE, consistent with the
discussion in section I.F. of the preamble to
this final rule, we do not believe averaging
the fixed-loss amounts calculated using FY
2019 and FY 2021 data is the best approach
for determining an outlier fixed-loss amount
that will reflect a reasonable estimation of the
mix and relative resource use of cases that
will be treated at LTCHs in FY 2023. Rather,
we believe averaging the outlier-fixed loss
thresholds calculated using FY 2021 data
including and excluding COVID–19 claims,
as suggested by MedPAC, better reflects our
belief that it is reasonable to assume there
will be fewer COVID–19 hospitalizations
among Medicare beneficiaries in LTCHs in
FY 2023 than there were in FY 2021 (as
discussed in section I.F of the preamble to
this final rule). In addition, we agree this
approach would be most consistent with the
approach we proposed and are finalizing for
calculating the MS–LTC–DRG relative
weights, as discussed in section VIII.B.3.a. of
the preamble to this final rule. As discussed
later in this section, we are adopting the
approach suggested by MedPAC when
determining the FY 2023 outlier fixed loss
amount.
With respect to commenters’ concerns
about data anomalies contributing to a higher
outlier fixed-loss amount, we note we
recently became aware of an anomaly in the
data that contributed to the increase in the
proposed outlier fixed-loss amount. Under
PO 00000
Frm 00670
Fmt 4701
Sfmt 4700
our existing outlier policy, in general, the
CCR from an LTCH’s latest settled or
tentatively settled cost report is used in
determining its outlier payments. In the case
of one LTCH, in particular, we observed that
its rate-of-charge increases greatly exceed
their rate-of-cost increases. In other words,
the charges reported on its claims were
increasing at a significantly faster pace than
their reported costs. Because there is a time
lag between the CCR from the latest settled
or tentatively settled cost report and current
charges, this sizable differential in the rateof-increases for charges and costs results in
CCRs that are too high relative to the actual
relationship between the LTCH’s charges and
costs at the time of the discharge. This in
turn results in an overestimation of the
LTCH’s current costs per case at the time of
the discharge, and high amounts of HCO
payments. In FY 2021, this LTCH’s charges
per case increased to extreme levels. In the
FY 2021 MedPAR file, we identified over 50
LTCH PPS standard Federal payment rate
cases for this LTCH with charges that exceed
$9 million. In addition, this LTCH received
outlier payments for over 80 percent of its
LTCH PPS standard Federal payment rate
cases identified in the FY 2021 MedPAR file.
As discussed previously, under the HCO
policy at § 412.525(a)(4)(iv)(D), the payments
for HCO cases are subject to reconciliation
(regardless of whether payment is based on
the LTCH standard Federal payment rate or
the site neutral payment rate). Specifically,
any such payments are reconciled at cost
report settlement based on the CCR that was
calculated for the cost reporting period
coinciding with the discharge. Based on
information from the provider, we believe
that these extreme levels of charges will not
persist into FY 2023. For this reason, we do
not believe it would be appropriate to
include cases for this LTCH (CCN 312024) in
our model for determining the FY 2023
outlier fixed-loss amount. Therefore, as
discussed later in this section, we are
excluding them from our calculations of the
FY 2023 outlier fixed-loss amount.
After consideration of all comments
received, we are modifying our proposed
approach for determining the FY 2023 outlier
fixed-loss amount. As discussed, we are
adopting the suggested approach to establish
the FY 2023 outlier fixed-loss amount based
on the average of the outlier-fixed loss
thresholds calculated using FY 2021 data
including and excluding COVID–19 claims.
As discussed, we are also excluding claims
from CCN 312024 from the FY 2021 claims
data used in determining the FY 2023 outlier
fixed-loss amount. As discussed previously,
we also are finalizing our proposal to use the
charge inflation and CCR adjustment factors
determined in the FY 2022 IPPS/LTCH PPS
final rule when calculating the FY 2023
outlier fixed-loss amount.
For this final rule, for FY 2023, using the
best available data, we calculated a fixed-loss
amount that would maintain estimated HCO
payments at the projected 7.975 percent of
total estimated LTCH PPS payments for
LTCH PPS standard Federal payment rate
cases (based on the payment rates and
policies for these cases presented in this final
rule). Based on the full set of LTCH claims
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
data (including COVID–19 cases) from the
March 2022 update of the FY 2021 MedPAR
file adjusted for charge inflation and using
adjusted CCRs from the March 2022 update
of the PSF, we calculated a fixed-loss amount
of $37,900. Based on the set of LTCH claims
data that excludes COVID–19 cases from the
March 2022 update of the FY 2021 MedPAR
file adjusted for charge inflation and using
adjusted CCRs from the March 2022 update
of the PSF, we calculated a fixed-loss amount
of $39,135. We identified COVID–19 cases as
any claim in the FY 2021 MedPAR file with
a principal or secondary diagnosis of COVID–
19 (ICD–10–CM diagnosis code U07.1), just
as we did for the calculation of the FY 2023
MS–LTC–DRG relative weights. Accordingly,
under the broad authority of section 123(a)(1)
of the BBRA and section 307(b)(1) of the
BIPA, we are establishing a fixed-loss amount
for LTCH PPS standard Federal payment rate
cases for FY 2023 of $38,518, which is the
average of the fixed-loss amounts calculated
from FY 2021 claims data including and
excluding COVID–19 cases. We project that
this fixed-loss amount will result in
estimated outlier payments projected to be
equal to 7.975 percent of estimated FY 2023
payments for such cases. We are continuing,
as proposed, to make additional HCO
payment for the cost of an LTCH PPS
standard Federal payment rate case that
exceeds the HCO threshold amount that is
equal to 80 percent of the difference between
the estimated cost of the case and the outlier
threshold (the sum of the adjusted LTCH PPS
standard Federal payment rate payment and
the fixed-loss amount for LTCH PPS standard
Federal payment rate cases of $38,518). We
note that this revised amount is considerably
lower than our proposed fixed-loss amount of
$44,182. We also note that if we had not
excluded CCN 312024 from our calculations,
the averaged fixed-loss amount would have
been $39,556.
4. High-Cost Outlier Payments for Site
Neutral Payment Rate Cases
When we implemented the application of
the site neutral payment rate in FY 2016, in
examining the appropriate fixed-loss amount
for site neutral payment rate cases issue, we
considered how LTCH discharges based on
historical claims data would have been
classified under the dual rate LTCH PPS
payment structure and the CMS’ Office of the
Actuary projections regarding how LTCHs
will likely respond to our implementation of
policies resulting from the statutory payment
changes. We again relied on these
considerations and actuarial projections in
FY 2017 and FY 2018 because the historical
claims data available in each of these years
were not all subject to the LTCH PPS dual
rate payment system. Similarly, for FYs 2019
through 2022, we continued to rely on these
considerations and actuarial projections
because, due to the transitional blended
payment policy for site neutral payment rate
cases, FY 2018 and FY 2019 claims for these
cases were not subject to the full effect of the
site neutral payment rate.
For FYs 2016 through 2022, our actuaries
projected that the proportion of cases that
would qualify as LTCH PPS standard Federal
payment rate cases versus site neutral
payment rate cases under the statutory
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
provisions would remain consistent with
what is reflected in the historical LTCH PPS
claims data. Although our actuaries did not
project an immediate change in the
proportions found in the historical data, they
did project cost and resource changes to
account for the lower payment rates. Our
actuaries also projected that the costs and
resource use for cases paid at the site neutral
payment rate would likely be lower, on
average, than the costs and resource use for
cases paid at the LTCH PPS standard Federal
payment rate and would likely mirror the
costs and resource use for IPPS cases
assigned to the same MS–DRG, regardless of
whether the proportion of site neutral
payment rate cases in the future remains
similar to what is found based on the
historical data. As discussed in the FY 2016
IPPS/LTCH PPS final rule (80 FR 49619), this
actuarial assumption is based on our
expectation that site neutral payment rate
cases would generally be paid based on an
IPPS comparable per diem amount under the
statutory LTCH PPS payment changes that
began in FY 2016, which, in the majority of
cases, is much lower than the payment that
would have been paid if these statutory
changes were not enacted. In light of these
projections and expectations, we discussed
that we believed that the use of a single
fixed-loss amount and HCO target for all
LTCH PPS cases would be problematic.
In addition, we discussed that we did not
believe that it would be appropriate for
comparable LTCH PPS site neutral payment
rate cases to receive dramatically different
HCO payments from those cases that would
be paid under the IPPS (80 FR 49617 through
49619 and 81 FR 57305 through 57307). For
those reasons, we stated that we believed that
the most appropriate fixed-loss amount for
site neutral payment rate cases for FYs 2016
through 2022 would be equal to the IPPS
fixed-loss amount for that particular fiscal
year. Therefore, we established the fixed-loss
amount for site neutral payment rate cases as
the corresponding IPPS fixed-loss amounts
for FYs 2016 through 2022. In particular, in
FY 2022, we established the fixed-loss
amount for site neutral payment rate cases as
the FY 2021 IPPS fixed-loss amount of
$30,988 (86 FR 45567).
As discussed in section I.F. of the preamble
of this final rule, we are finalizing our
proposal to use FY 2021 data in the FY 2023
LTCH PPS ratesetting. Section 3711(b)(2) of
the CARES Act, which provided a waiver of
the application of the site neutral payment
rate for LTCH cases admitted during the
COVID–19 PHE period, was in effect for the
entirety of FY 2021. Therefore, all LTCH PPS
cases in FY 2021 were paid the LTCH PPS
standard Federal rate regardless of whether
the discharge met the statutory patient
criteria. Because not all FY 2021 claims in
the data used for this final rule were subject
to the site neutral payment rate, we continue
to rely on the same considerations and
actuarial projections used in FYs 2016
through 2022 when developing a fixed-loss
amount for site neutral payment rate cases for
FY 2023. Our actuaries continue to project
that the costs and resource use for FY 2023
cases paid at the site neutral payment rate
would likely be lower, on average, than the
PO 00000
Frm 00671
Fmt 4701
Sfmt 4700
49449
costs and resource use for cases paid at the
LTCH PPS standard Federal payment rate
and will likely mirror the costs and resource
use for IPPS cases assigned to the same MS–
DRG, regardless of whether the proportion of
site neutral payment rate cases in the future
remains similar to what was found based on
the historical data. (Based on the FY 2021
LTCH claims data used in the development
of this final rule, if the provisions of the
CARES Act had not been in effect,
approximately 72 percent of LTCH cases
would have been paid the LTCH PPS
standard Federal payment rate and
approximately 28 percent of LTCH cases
would have been paid the site neutral
payment rate for discharges occurring in FY
2021.)
For these reasons, we proposed that the
most appropriate fixed-loss amount for site
neutral payment rate cases for FY 2023 is the
IPPS fixed-loss amount for FY 2023.
Therefore, consistent with past practice, we
proposed that the applicable HCO threshold
for site neutral payment rate cases is the sum
of the site neutral payment rate for the case
and the IPPS fixed-loss amount. That is, we
proposed a fixed-loss amount for site neutral
payment rate cases of $43,214, which is the
same proposed FY 2023 IPPS fixed-loss
amount discussed in section II.A.4.j.(1). of
the Addendum to the proposed rule.
Accordingly, for FY 2023, we proposed to
calculate a HCO payment for site neutral
payment rate cases with costs that exceed the
HCO threshold amount that is equal to 80
percent of the difference between the
estimated cost of the case and the outlier
threshold (the sum of the site neutral
payment rate payment and the fixed-loss
amount for site neutral payment rate cases of
$43,214).
Comment: Some commenters opposed the
proposed fixed-loss amount for site neutral
payment rate cases. A commenter stated that
increases in the fixed-loss amount for site
neutral payment rate cases should be limited
to no more than the market basket percent
increase. Other commenters stated that CMS
should calculate the fixed-loss amount for
site neutral payment rate cases using a
combination of FY 2019 and FY 2021 data.
Response: As stated earlier, our actuaries
continue to project that site neutral payment
rate cases in FY 2023 will mirror an IPPS
case paid under the same MS–DRG. That is,
our actuaries continue to project that the
costs and resource use for FY 2023 cases paid
at the site neutral payment rate would likely
be lower, on average, than the costs and
resource use for cases paid at the LTCH PPS
standard Federal payment rate and will likely
mirror the costs and resource use for IPPS
cases assigned to the same MS DRG, on
average, regardless of whether the proportion
of site neutral payment rate cases in the
future remains similar to what was found
based on the historical data. For these
reasons, we continue to believe that the most
appropriate fixed-loss amount for site neutral
payment rate cases for FY 2023 is the IPPS
fixed-loss amount for FY 2023. With respect
to comments on the data used in determining
the site neutral fixed-loss amount, we refer
the reader to section II.A.4. of the addendum
to this final rule for a complete summary and
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49450
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
response to comments received on our
proposed use of FY 2021 data and our
proposed modifications to our usual
methodology when determining the FY 2023
outlier fixed-loss amounts for IPPS cases,
which as described later in this section, is the
same as the site neutral fixed-loss amount.
In this final rule, after considering public
comments on our proposals, we are finalizing
our proposals as described previously,
without modification. Therefore, for FY 2023,
as we proposed, we are establishing that the
applicable HCO threshold for site neutral
payment rate cases is the sum of the site
neutral payment rate for the case and the
IPPS fixed loss amount. That is, we are
establishing a fixed-loss amount for site
neutral payment rate cases of $38,859, which
is the same FY 2023 IPPS fixed loss amount
discussed in section II.A.4.j.(1). of the
Addendum to this final rule. Accordingly,
under this policy, for FY 2023, we will
calculate a HCO payment for site neutral
payment rate cases with costs that exceed the
HCO threshold amount, which is equal to 80
percent of the difference between the
estimated cost of the case and the outlier
threshold (the sum of site neutral payment
rate payment and the fixed loss amount) for
site neutral payment rate cases of $38,859.
In establishing a HCO policy for site
neutral payment rate cases, we proposed a
budget neutrality adjustment under
§ 412.522(c)(2)(i). We proposed this
requirement because we believed, and
continue to believe, that the HCO policy for
site neutral payment rate cases should be
budget neutral, just as the HCO policy for
LTCH PPS standard Federal payment rate
cases is budget neutral, meaning that
estimated site neutral payment rate HCO
payments should not result in any change in
estimated aggregate LTCH PPS payments.
To ensure that estimated HCO payments
payable to site neutral payment rate cases in
FY 2023 would not result in any increase in
estimated aggregate FY 2023 LTCH PPS
payments, under the budget neutrality
requirement at § 412.522(c)(2)(i), it is
necessary to reduce site neutral payment rate
payments by 5.1 percent to account for the
estimated additional HCO payments payable
to those cases in FY 2023. Consistent with
our historical practice, we proposed
continuing this policy.
As discussed earlier, consistent with the
IPPS HCO payment threshold, we estimate
the proposed fixed-loss threshold would
result in FY 2023 HCO payments for site
neutral payment rate cases to equal 5.1
percent of the site neutral payment rate
payments that are based on the IPPS
comparable per diem amount. As such, to
ensure estimated HCO payments payable for
site neutral payment rate cases in FY 2023
would not result in any increase in estimated
aggregate FY 2023 LTCH PPS payments,
under the budget neutrality requirement at
§ 412.522(c)(2)(i), it is necessary to reduce the
site neutral payment rate amount paid under
§ 412.522(c)(1)(i) by 5.1 percent to account
for the estimated additional HCO payments
payable for site neutral payment rate cases in
FY 2023. To achieve this, for FY 2023, we
proposed applying a budget neutrality factor
of 0.949 (that is, the decimal equivalent of a
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
5.1 percent reduction, determined as
1.0¥5.1/100 = 0.949) to the site neutral
payment rate for those site neutral payment
rate cases paid under § 412.522(c)(1)(i). We
proposed that, consistent with our current
policy, this HCO budget neutrality
adjustment would not be applied to the HCO
portion of the site neutral payment rate
amount (81 FR 57309).
Comment: A commenter, in keeping with
comments we have received since the
inception of the dual rate payment system
that created the site neutral payment rate,
objected to the proposed site neutral payment
rate HCO budget neutrality adjustment. The
commenter’s objection continues to be based
on the belief that, because the IPPS base rates
used in the IPPS comparable per diem
amount calculation of the site neutral
payment rate include a budget neutrality
adjustment for IPPS HCO payments (for
example, a 5.1 percent adjustment on the
operating IPPS standardized amount), a
‘‘second’’ budget neutrality factor is
unnecessary and duplicative.
Response: We continue to disagree with
the commenters that a budget neutrality
adjustment for site neutral payment rate HCO
payments is unnecessary or duplicative. We
have stated such disagreement during each
previous rulemaking cycle. We refer readers
to 84 FR 42648 through 42649, 83 FR 41737
through 41738, 82 FR 38545 through 38546,
81 FR 57308 through 57309, and 80 FR 49621
through 49622 for a more detailed discussion
in response to such comments.
After consideration of public comments,
for the reasons discussed previously, we are
adopting our proposed site neutral payment
rate HCO budget neutrality adjustment as
final without modification. Specifically, for
FY 2023, as we proposed, we are applying a
budget neutrality factor of 0.949 (that is, the
decimal equivalent of a 5.1 percent
reduction, determined as 1.0¥ 5.1/100 =
0.949) to the site neutral payment rate for
those site neutral payment rate cases paid
under § 412.522(c)(1)(i). We note that,
consistent with our current policy, this HCO
budget neutrality adjustment will not apply
to the HCO portion of the site neutral
payment rate amount.
E. Update to the IPPS Comparable Amount
To Reflect the Statutory Changes to the IPPS
DSH Payment Adjustment Methodology
In the FY 2014 IPPS/LTCH PPS final rule
(78 FR 50766), we established a policy to
reflect the changes to the Medicare IPPS DSH
payment adjustment methodology made by
section 3133 of the Affordable Care Act in the
calculation of the ‘‘IPPS comparable amount’’
under the SSO policy at § 412.529 and the
‘‘IPPS equivalent amount’’ under the site
neutral payment rate at § 412.522.
Historically, the determination of both the
‘‘IPPS comparable amount’’ and the ‘‘IPPS
equivalent amount’’ includes an amount for
inpatient operating costs ‘‘for the costs of
serving a disproportionate share of lowincome patients.’’ Under the statutory
changes to the Medicare DSH payment
adjustment methodology that began in FY
2014, in general, eligible IPPS hospitals
receive an empirically justified Medicare
DSH payment equal to 25 percent of the
PO 00000
Frm 00672
Fmt 4701
Sfmt 4700
amount they otherwise would have received
under the statutory formula for Medicare
DSH payments prior to the amendments
made by the Affordable Care Act. The
remaining amount, equal to an estimate of 75
percent of the amount that otherwise would
have been paid as Medicare DSH payments,
reduced to reflect changes in the percentage
of individuals who are uninsured and any
additional statutory adjustment, is made
available to make additional payments to
each hospital that qualifies for Medicare DSH
payments and that has uncompensated care.
The additional uncompensated care
payments are based on the hospital’s amount
of uncompensated care for a given time
period relative to the total amount of
uncompensated care for that same time
period reported by all IPPS hospitals that
receive Medicare DSH payments.
To reflect the statutory changes to the
Medicare DSH payment adjustment
methodology in the calculation of the ‘‘IPPS
comparable amount’’ and the ‘‘IPPS
equivalent amount’’ under the LTCH PPS, we
stated that we will include a reduced
Medicare DSH payment amount that reflects
the projected percentage of the payment
amount calculated based on the statutory
Medicare DSH payment formula prior to the
amendments made by the Affordable Care
Act that will be paid to eligible IPPS
hospitals as empirically justified Medicare
DSH payments and uncompensated care
payments in that year (that is, a percentage
of the operating Medicare DSH payment
amount that has historically been reflected in
the LTCH PPS payments that are based on
IPPS rates). We also stated that the projected
percentage will be updated annually,
consistent with the annual determination of
the amount of uncompensated care payments
that will be made to eligible IPPS hospitals.
We believe that this approach results in
appropriate payments under the LTCH PPS
and is consistent with our intention that the
‘‘IPPS comparable amount’’ and the ‘‘IPPS
equivalent amount’’ under the LTCH PPS
closely resemble what an IPPS payment
would have been for the same episode of
care, while recognizing that some features of
the IPPS cannot be translated directly into
the LTCH PPS (79 FR 50766 through 50767).
For FY 2023, as discussed in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR 28694)
and in greater detail in section V.E.4.b. of the
preamble of this final rule, based on the most
recent data available, our estimate of 75
percent of the amount that would otherwise
have been paid as Medicare DSH payments
(under the methodology outlined in section
1886(r)(2) of the Act) is adjusted to 65.71
percent of that amount to reflect the change
in the percentage of individuals who are
uninsured. The resulting amount is then used
to determine the amount available to make
uncompensated care payments to eligible
IPPS hospitals in FY 2023. In other words,
the amount of the Medicare DSH payments
that would have been made prior to the
amendments made by the Affordable Care
Act is adjusted to 49.28 percent (the product
of 75 percent and 65.71 percent) and the
resulting amount is used to calculate the
uncompensated care payments to eligible
hospitals. As a result, for FY 2023, we
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
amendments made by the Affordable Care
Act.
F. Computing the Adjusted LTCH PPS
Federal Prospective Payments for FY 2023
Section 412.525 sets forth the adjustments
to the LTCH PPS standard Federal payment
rate. Under the dual rate LTCH PPS payment
structure, only LTCH PPS cases that meet the
statutory criteria to be excluded from the site
neutral payment rate are paid based on the
LTCH PPS standard Federal payment rate.
Under § 412.525(c), the LTCH PPS standard
Federal payment rate is adjusted to account
for differences in area wages by multiplying
the labor-related share of the LTCH PPS
standard Federal payment rate for a case by
the applicable LTCH PPS wage index (the
proposed FY 2023 values are shown in
Tables 12A through 12B listed in section VI.
of the Addendum to this final rule and are
available via the internet on the CMS
website). The LTCH PPS standard Federal
payment rate is also adjusted to account for
the higher costs of LTCHs located in Alaska
and Hawaii by the applicable COLA factors
(the final FY 2023 factors are shown in the
chart in section V.C. of this Addendum) in
accordance with § 412.525(b). In this final
rule, we are establishing an LTCH PPS
standard Federal payment rate for FY 2023 of
$46,432.77 as discussed in section V.A. of the
Addendum to this final rule. We illustrate
the methodology to adjust the LTCH PPS
standard Federal payment rate for FY 2023,
applying our finalized LTCH PPS amounts
for the standard Federal payment rate, MS–
LTC–DRG relative weights, and wage index
in the following example:
Example:
During FY 2023, a Medicare discharge that
meets the criteria to be excluded from the site
neutral payment rate, that is, an LTCH PPS
standard Federal payment rate case, is from
an LTCH that is located in CBSA 16984,
which has a FY 2023 LTCH PPS wage index
value of 1.0437 (as shown in Table 12A listed
in section VI. of the Addendum to this final
rule). The Medicare patient case is classified
into proposed MS–LTC–DRG 189 (Pulmonary
Edema & Respiratory Failure), which has a
relative weight for FY 2023 of 0.9606 (as
shown in Table 11 listed in section VI. of the
Addendum to this final rule). The LTCH
submitted quality reporting data for FY 2023
in accordance with the LTCH QRP under
section 1886(m)(5) of the Act.
To calculate the LTCH’s total adjusted
Federal prospective payment for this
Medicare patient case in FY 2023, we
computed the wage-adjusted Federal
prospective payment amount by multiplying
the unadjusted FY 2023 LTCH PPS standard
Federal payment rate ($46,432.77) by the
labor-related share (0.680 percent) and the
wage index value (1.0437). This wageadjusted amount was then added to the
proposed nonlabor-related portion of the
unadjusted proposed LTCH PPS standard
Federal payment rate (0.320 percent; adjusted
for cost of living, if applicable) to determine
the adjusted LTCH PPS standard Federal
payment rate, which is then multiplied by
the MS–LTC–DRG relative weight (0.9606) to
calculate the total adjusted LTCH PPS
standard Federal prospective payment for FY
2023 ($45,928.75). The table illustrates the
components of the calculations in this
example.
Unadjusted LTCH PPS Standard Federal Prospective Payment Rate
Labor-Related Share
Labor-Related Portion of the LTCH PPS Standard Federal Pavment Rate
Wage Index (CBSA 16984)
Wage-Adjusted Labor Share of the LTCH PPS Standard Federal Payment Rate
Nonlabor-Related Portion of the LTCH PPS Standard Federal Pavment Rate ($46,432.77 x 0.32)
Adjusted LTCH PPS Standard Federal Payment Amount
MS-LTC-DRG 189 Relative Weight
Total Adjusted LTCH PPS Standard Federal Prospective Payment
khammond on DSKJM1Z7X2PROD with RULES2
VI. Tables Referenced in This Final Rule
Generally Available Through the Internet on
the CMS Website
This section lists the tables referred to
throughout the preamble of this final rule
and in the Addendum. In the past, a majority
of these tables were published in the Federal
Register as part of the annual proposed and
final rules. However, similar to FYs 2012
through 2022, for the FY 2023 rulemaking
cycle, the IPPS and LTCH PPS tables will not
be published in the Federal Register in the
annual IPPS/LTCH PPS proposed and final
rules and will be available through the
internet. Specifically, all IPPS tables listed in
the final rule, with the exception of IPPS
Tables 1A, 1B, 1C, and 1D, and LTCH PPS
Table 1E, will generally be available through
the internet. IPPS Tables 1A, 1B, 1C, and 1D,
and LTCH PPS Table 1E are displayed at the
end of this section and will continue to be
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
published in the Federal Register as part of
the annual proposed and final rules. For
additional discussion of the information
included in the IPPS and LTCH PPS tables
associated with the IPPS/LTCH PPS
proposed and final rules, as well as prior
changes to the information included in these
tables, we refer readers to the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45569 through
45571).
In addition, under the HAC Reduction
Program, established by section 3008 of the
Affordable Care Act, a hospital’s total
payment may be reduced by 1 percent if it
is in the lowest HAC performance quartile.
The hospital-level data for the FY 2023 HAC
Reduction Program will be made publicly
available once it has undergone the review
and corrections process.
In the FY 2023 IPPS/LTCH proposed rule
(87 FR 28695), we noted that Tables 7A and
7B historically contained the Medicare
PO 00000
Frm 00673
Fmt 4701
Sfmt 4700
$46,432.77
X 0.68
= $31,574.28
X 1.0437
= $32,954.08
+ $14,858.49
= $47,812.57
X 0.9606
= $45,928.75
prospective payment system selected
percentile lengths of stay for the MS–DRGs
for the prior year and upcoming fiscal year.
As discussed in section II.E of the FY 2023
IPPS/LTCH proposed rule (87 FR 28197—
28204), we proposed to determine the MS–
DRG relative weights for FY 2023 by
averaging the relative weights as calculated
with and without COVID–19 cases in the FY
2021 data. Because we proposed to use MS–
DRG weights based on an average of the
relative weights, we stated that the percentile
lengths of stay, which are based on separate
sets of MS–DRG relative weights prior to
averaging are not applicable to the proposed
averaged MS–DRG relative weights for FY
2023. The separate percentile lengths of stay
statistics are only applicable to the relative
weights as calculated with and without
COVID–19 cases. Additionally, we also stated
that unlike the other files listed as tables in
this section of the final rule that typically
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.222
projected that the reduction in the amount of
Medicare DSH payments pursuant to section
1886(r)(1) of the Act, along with the
payments for uncompensated care under
section 1886(r)(2) of the Act, will result in
overall Medicare DSH payments of 74.28
percent of the amount of Medicare DSH
payments that would otherwise have been
made in the absence of the amendments
made by the Affordable Care Act (that is, 25
percent + 49.28 percent = 74.28 percent).
Therefore, for FY 2023, in the FY 2023
IPPS/LTCH PPS proposed rule, we proposed
to establish that the calculation of the ‘‘IPPS
comparable amount’’ under § 412.529 would
include an applicable operating Medicare
DSH payment amount that is equal to 74.28
percent of the operating Medicare DSH
payment amount that would have been paid
based on the statutory Medicare DSH
payment formula absent the amendments
made by the Affordable Care Act.
Furthermore, consistent with our historical
practice, we proposed that if more recent
data became available, we would use that
data to determine this factor in the final rule.
We did not receive any public comments
in response to our proposal. In addition,
there are no more recent data available to use
that would affect the calculations determined
in the proposed rule. Therefore, we are
finalizing our proposal that, for FY 2023, the
calculation of the ‘‘IPPS comparable amount’’
under § 412.529 would include an applicable
operating Medicare DSH payment amount
that is equal to 74.28 percent of the operating
Medicare DSH payment amount that would
have been paid based on the statutory
Medicare DSH payment formula absent the
49451
khammond on DSKJM1Z7X2PROD with RULES2
49452
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
contain information/variables relating to a
hospital’s IPPS claim for payment, Tables 7A
and 7B are informational files containing
percentile lengths of stay that are not used for
claim payment. Therefore, in the FY 2023
IPPS/LTCH proposed rule (87 FR 28695),
beginning with the FY 2023 IPPS/LTCH PPS
proposed rule, we proposed to instead
provide the percentile length of stay
information previously included in Tables
7A and 7B in the supplemental AOR/BOR
data file, as described in section XII.A. of this
final rule, which contains additional data
relevant to the MS–DRG relative weights. For
FY 2023, because we proposed to average the
relative weights, in the proposed rule we
provided an AOR/BOR file for the relative
weights calculated with COVID–19 cases in
the December 2021 update of the FY 2021
MedPAR file and an AOR/BOR file for the
relative weights calculated without COVID–
19 cases in the December 2021 update of the
FY 2021 MedPAR file (we note, for this final
rule we used the March 2022 update of the
FY 2021 MedPAR file). Therefore, instead of
including the percentile lengths of stay that
are typically in Tables 7A and 7B (that is, for
the proposed rule, the selected percentile
lengths of stay based on the MedPAR data
and MS–DRGs for the prior year and
upcoming fiscal year (for FY 2023, this
would be the version 40 GROUPER and
version 39 GROUPER)) we proposed to
include this statistical information in the
AOR/BOR File for the relative weights as
calculated with and without COVID–19
cases. The AOR/BOR files can be found on
the FY 2023 IPPS final rule home page on the
CMS website at https://www.cms.gov/
Medicare/Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/. We note, as
discussed in section II.E of this final rule,
after consideration of the public comments,
we are finalizing our proposal to determine
the MS–DRG relative weights for FY 2023 by
averaging the relative weights as calculated
with and without COVID–19 cases in the FY
2021 data.
We did not receive any comments on our
proposal previously noted. Therefore, we are
finalizing as proposed without modification
that beginning with the FY 2023 IPPS/LTCH
PPS proposed and final rules, to provide the
percentile length of stay information
previously included in Tables 7A and 7B in
the supplemental AOR/BOR data file.
For this FY 2023 IPPS/LTCH final rule,
because we are finalizing to average the
relative weights, similar to the proposed rule,
we are providing an AOR/BOR file for the
relative weights calculated with COVID–19
cases in the March 2022 update of the FY
2021 MedPAR file and an AOR/BOR file for
the relative weights calculated without
COVID–19 cases in the March 2022 update of
the FY 2021 MedPAR file. Both of these files
will include the percentile lengths of stay
that were typically in Tables 7A and 7B.
As was the case for the FY 2022 IPPS/
LTCH PPS proposed and final rules, we are
no longer including Table 15, which had
typically included the fiscal year
readmissions payment adjustment factors
because hospitals have not yet had the
opportunity to review and correct the data
before the data are made public under our
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
policy regarding the reporting of hospitalspecific data. After hospitals have been given
an opportunity to review and correct their
calculations for FY 2023, we will post Table
15 (which will be available via the internet
on the CMS website) to display the final FY
2023 readmissions payment adjustment
factors that will be applicable to discharges
occurring on or after October 1, 2022. We
expect Table 15 will be posted on the CMS
website in the fall of 2022.
Readers who experience any problems
accessing any of the tables that are posted on
the CMS websites identified in this final rule
should contact Michael Treitel at (410) 786–
4552.
The following IPPS tables for this final rule
are generally available through the internet
on the CMS website at https://www.cms.gov/
Medicare/Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/. Click on the
link on the left side of the screen titled ‘‘FY
2023 IPPS Final Rule Home Page’’ or ‘‘Acute
Inpatient-Files-for Download.’’ We refer
readers to section I.O. of the Appendix A of
this final rule for a discussion of the
supplemental data files we are making
available based on the use of the FY 2021
data without the modifications to our usual
methodologies for the calculation of the FY
2023 MS–DRG and MS–LTC–DRG relative
weights or our usual methodologies for the
determination of the FY 2023 outlier fixedloss amount for IPPS cases and LTCH PPS
standard Federal payment rate cases for this
FY 2023 ratesetting, which we are also
making available on the CMS website.
PO 00000
Table 2—Case-Mix Index and Wage Index
Table by CCN—FY 2023 Final Rule
Table 3—Wage Index Table by CBSA—FY
2023 Final Rule
Table 4A—List of Counties Eligible for the
Out-Migration Adjustment Under Section
1886(d)(13) of the Act—FY 2023 Final Rule
Table 4B—Counties Redesignated Under
Section 1886(d)(8)(B) of the Act (LUGAR
Counties)—FY 2023 Final Rule
Table 5—List of Medicare Severity
Diagnosis-Related Groups (MS–DRGs),
Relative Weighting Factors, and Geometric
and Arithmetic Mean Length of Stay—FY
2023
Table 6A—New Diagnosis Codes—FY 2023
Table 6B—New Procedure Codes—FY 2023
Table 6C—Invalid Diagnosis Codes—FY
2023
Table 6D—Invalid Procedure Codes—FY
2023
Table 6E.—Revised Diagnosis Code Titles—
FY 2023
Table 6G.1.—Secondary Diagnosis Order
Additions to the CC Exclusions List—FY
2023
Table 6G.2.—Principal Diagnosis Order
Additions to the CC Exclusions List—FY
2023
Table 6H.1.—Secondary Diagnosis Order
Deletions to the CC Exclusions List—FY 2023
Table 6H.2.—Principal Diagnosis Order
Deletions to the CC Exclusions List—FY 2023
Table 6I.—Complete MCC List—FY 2023
Table 6I.1.—Additions to the MCC List—FY
2023
Table 6I.2.—Deletions to the MCC List—FY
2023
Table 6J.—Complete CC List—FY 2023
Table 6J.1.—Additions to the CC List—FY
2023
Table 6J.2.—Deletions to the CC List—FY
2023
Table 6K.—Complete List of CC Exclusions—
FY 2023
Table 6P.—ICD–10–CM and ICD–10–PCS
Codes for MS–DRG Changes—FY 2023
(Table 6P contains multiple tables, 6P.1a.
through 6P.1f that include the ICD–10–CM
and ICD–10–PCS code lists relating to
specific MS–DRG changes. These tables are
referred to throughout section II.D. of the
preamble of this final rule.)
Frm 00674
Fmt 4701
Sfmt 4700
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Table 8A.—FY 2023 Statewide Average
Operating Cost-to-Charge Ratios (CCRs) for
Acute Care Hospitals (Urban and Rural)
index.html under the list item for Regulation
Number CMS–1771–F:
49453
Table 8C.—FY 2023 Statewide Average Total
Cost-to-Charge Ratios (CCRs) for LTCHs
(Urban and Rural)
Table 11.—MS–LTC–DRGs, Relative
Weights, Geometric Average Length of Stay,
and Short-Stay Outlier (SSO) Threshold for
LTCH PPS Discharges Occurring from
October 1, 2022, through September 30, 2023
Table 8B.—FY 2023 Statewide Average
Capital Cost-to-Charge Ratios (CCRs) for
Acute Care Hospitals
Table 18.—FY 2023 Medicare DSH
Uncompensated Care Payment Factor 3
Table 12A.—LTCH PPS Wage Index for
Urban Areas for Discharges Occurring from
October 1, 2022, through September 30, 2023
The following LTCH PPS tables for this FY
2023 final rule are available through the
internet on the CMS website at https://
www.cms.gov/Medicare/Medicare-Fee-forService-Payment/LongTermCareHospitalPPS/
Table 12B.—LTCH PPS Wage Index for
Rural Areas for Discharges Occurring from
October 1, 2022, through September 30, 2023
TABLE lA.-NATIONAL ADJUSTED OPERATING STANDARDIZED
AMOUNTS, LABOR/NONLABOR (67.6 PERCENT LABOR
SHARE/32.4 PERCENT NONLABOR SHARE IF WAGE INDEX
IS GREATER THAN 1)--FY 2023
Hospital Submitted
Quality Data and is a
Meaningful EHR User
mndate = 3.8 Percent)
Labor
I Nonlabor
$4,310.00 I
$2,065.74
Hospital Submitted Quality
Data and is NOT a
Meaningful EHR User
(Update= 0.725 Percent)
Labor
I Nonlabor
$4,182.32 I
$2,004.54
Hospital Did NOT Submit
Quality Data and is a
Meaningful EHR User
/TTndate = 2. 775 Percent)
Labor
I Nonlabor
$4,267.44 I
$2,045.34
Hospital Did NOT Submit
Quality Data and is NOT a
Meaningful EHR User
(Update= -0.3 Percent)
Labor
I Nonlabor
$4,139.76 I $1,984.15
TABLE 1B.-NATIONAL ADJUSTED OPERATING STANDARDIZED
AMOUNTS, LABOR/NONLABOR (62 PERCENT LABOR SHARE/38 PERCENT
NONLABOR SHARE IF WAGE INDEX IS LESS THAN OR EQUAL TO 1)-FY
2023
Hospital Submitted
Quality Data and is a
Meaningful EHR User
(Update= 3.8 Percent)
Labor
I Nonlabor
$2,422.78
$3,952.96 I
Hospital Submitted Quality
Data and is NOT a
Meaningful EHR User
(Update= 0.725 Percent)
Labor
I Nonlabor
$2,351.01
$3,835.85 I
Hospital Did NOT Submit
Quality Data and is a
Meaningful EHR User
(Update= 2.775 Percent)
Labor
I Nonlabor
$2,398.86
$3,913.92 I
Hospital Did NOT Submit
Quality Data and is NOT a
Meaningful EHR User
(Update= -0.3 Percent)
Labor
I Nonlabor
$3,796.82 I $2,327.09
I Not Applicable
$3,952.96
I
$2,422.78
$3,874.89
I
$2,374.93
FY 2023, there are no CBSAs in Puerto Rico with a national wage index greater than 1.
khammond on DSKJM1Z7X2PROD with RULES2
TABLE lD.-CAPITAL STANDARD FEDERAL PAYMENT RATE-FY 2023
Rate
$483.76
I National
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00675
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.225
Not Applicable
1 For
ER10AU22.224
National1
ER10AU22.223
Hospital is a Meaningful EHR User Hospital is NOT a Meaningful EHR
and Wage Index Less Than or Equal User and Wage Index Less Than or
Equal to 1 (Update= 1.75)
Rates if Wage Index Greater Than 1
to 1 (Update= 3.8)
Labor
Labor
Labor
I Nonlabor
I Nonlabor
I Nonlabor
ER10AU22.226
TABLE lC.-ADJUSTED OPERATING STANDARDIZED AMOUNTS FOR
HOSPITALS IN PUERTO RICO, LABOR/NONLABOR (NATIONAL:
62 PERCENT LABOR SHARE/38 PERCENT NONLABOR SHARE BECAUSE
WAGE INDEX IS LESS THAN OR EQUAL TO 1);-FY 2023
49454
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE lE.-LTCH PPS STANDARD FEDERAL
PAYMENT RA TE--FY 2023
Appendix A: Economic Analyses
I. Regulatory Impact Analysis
khammond on DSKJM1Z7X2PROD with RULES2
A. Statement of Need
This final rule is necessary in order to
make payment and policy changes under the
IPPS for Medicare acute care hospital
inpatient services for operating and capitalrelated costs as well as for certain hospitals
and hospital units excluded from the IPPS.
This final rule also is necessary to make
payment and policy changes for Medicare
hospitals under the LTCH PPS. Also, as we
note later in this Appendix, the primary
objective of the IPPS and the LTCH PPS is
to create incentives for hospitals to operate
efficiently and minimize unnecessary costs,
while at the same time ensuring that
payments are sufficient to adequately
compensate hospitals for their legitimate
costs in delivering necessary care to
Medicare beneficiaries. In addition, we share
national goals of preserving the Medicare
Hospital Insurance Trust Fund.
We believe that the changes in this final
rule, such as the updates to the IPPS and
LTCH PPS rates, and the final policies and
discussions relating to applications for new
technology add-on payments, are needed to
further each of these goals while maintaining
the financial viability of the hospital industry
and ensuring access to high quality health
care for Medicare beneficiaries.
We expect that these changes will ensure
that the outcomes of the prospective payment
systems are reasonable and provide equitable
payments, while avoiding or minimizing
unintended adverse consequences.
1. Acute Care Hospital Inpatient Prospective
Payment System (IPPS)
a. Update to the IPPS Payment Rates
In accordance with section 1886(b)(3)(B) of
the Act and as described in section V.A. of
the preamble to this final rule, we updated
the national standardized amount for
inpatient hospital operating costs by the
applicable percentage increase of 3.8 percent
(that is, a 4.1 percent market basket update
with a reduction of 0.3 percentage point for
the productivity adjustment) and by a 0.5
percentage point adjustment required under
section 414 of the MACRA. We are also
applying the applicable percentage increase
(including the market basket update and the
productivity adjustment) to the hospitalspecific rates.
Hospitals that do not submit quality
information under rules established by the
Secretary and that are meaningful EHR users
under section 1886(b)(3)(B)(ix) of the Act
would receive an applicable percentage
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
increase of 2.775 percent. Hospitals that are
identified as not meaningful EHR users and
do submit quality information under section
1886(b)(3)(B)(viii) of the Act would receive
an applicable percentage increase of 0.725
percent.
Hospitals that are identified as not
meaningful EHR users under section
1886(b)(3)(B)(ix) of the Act and also do not
submit quality data under section
1886(b)(3)(B)(viii) of the Act will receive an
applicable percentage increase of ¥0.3
percent, which reflects a one-quarter percent
reduction of the market basket update for
failure to submit quality data and a threequarter percent reduction of the market
basket update for being identified as not a
meaningful EHR user.
b. Use of FY 2021 Data in the FY 2023 IPPS
and LTCH PPS Ratesetting
As discussed in section I.A. of the
preamble of this final rule, we believe that it
is reasonable to assume that some Medicare
beneficiaries will continue to be hospitalized
with COVID–19 at IPPS hospitals and LTCHs
in FY 2023. Accordingly, we believe it is
appropriate to use FY 2021 data, specifically
the FY 2021 MedPAR claims file and the FY
2020 HCRIS dataset (which contains data
from many cost reports ending in FY 2021
based on each hospital’s cost reporting
period) as the most recent available data
during the period of the COVID–19 PHE, for
purposes of the FY 2023 IPPS and LTCH PPS
ratesetting. However, we also believe it is
reasonable to assume based on the
information available at this time that there
will be fewer COVID 19 hospitalizations in
FY 2023 than in FY 2021 given the more
recent trends in the CDC hospitalization data
since the Omicron variant peak in January,
2022. Accordingly, because we anticipate
Medicare inpatient hospitalizations for
COVID–19 will continue in FY 2023 but at
a lower level, we are using FY 2021 data for
purposes of the FY 2023 IPPS and LTCH PPS
ratesetting but with modifications to our
usual ratesetting methodologies to account
for the anticipated decline in COVID–19
hospitalizations of Medicare beneficiaries at
IPPS hospitals and LTCHs as compared to FY
2021.
First, we are modifying the calculation of
the FY 2023 MS–DRG and MS LTC DRG
relative weights. The final policy to modify
the methodology for determining the FY 2023
IPPS MS–DRG relative weights is discussed
in section II.E. of the preamble of this final
rule. The final policy to modify the
methodology for determining the FY 2023
LTCH PPS MS–LTC–DRG relative weights is
discussed in greater detail in section VIII.B.
PO 00000
Frm 00676
Fmt 4701
Sfmt 4700
of the preamble of this final rule. This
modification primarily impacts MS–DRGs
and MS–LTC DRGs with larger numbers of
COVID–19 cases, for example MS–DRG 870
(Septicemia or Severe Sepsis with MV >96
hours). IPPS hospitals that disproportionately
treat high numbers of COVID–19 cases will
generally see increased non-outlier payments
compared to what those payments would
have been had we excluded the COVID–19
cases entirely, and lower payments compared
to if we had not made any modifications to
our usual methodology for calculating the
relative weights. This final policy reflects our
belief that there will be fewer COVID–19
cases in FY 2023 than in FY 2021, but there
will still be COVID–19 cases in FY 2023.
Second, we also are modifying our
methodologies for determining the FY 2023
outlier fixed-loss amount for IPPS cases and
LTCH PPS standard Federal payment rate
cases. The final policy to modify the
methodology for determining the FY 2023
outlier fixed-loss amounts for IPPS cases is
discussed in section II.A.4. of the Addendum
to this final rule. The final policy to modify
the methodology for determining the FY 2023
outlier fixed loss amounts for LTCH PPS
standard Federal payment rate cases is
discussed in section V.D.3. of the Addendum
to this final rule. This modification has a
greater impact on hospitals with larger
numbers of outlier cases. IPPS hospitals that
receive outlier payments will see lower
outlier payments compared to what those
payments would have been had we excluded
the COVID–19 cases entirely, and higher
outlier payments compared to if we had not
made any modifications to our usual
methodology for calculating the outlier fixed
loss amount. Again, this final policy reflects
our belief that there will be fewer COVID–19
cases in FY 2023 than in FY 2021, but there
will still be COVID–19 cases in FY 2023.
c. Cap on Reductions in Medicare Severity
Diagnosis-Related Group (MS–DRG) Relative
Weights
As described in section II.E.2. of the
preamble of this final rule, we have further
considered requests made by commenters
that we address year-to-year fluctuations in
relative weights, particularly for low volume
MS–DRGs, and to mitigate the financial
impacts of significant fluctuations. As
described in section II.E.2. of this final rule,
for these low volume MS–DRGs, fluctuations
in the volume or mix of cases and/or the
presence of a few high cost or low cost cases
can have a disproportionate impact on the
calculated relative weight, thus resulting in
greater year-to-year variation in the relative
weights for these MS–DRGs. Consistent with
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.227
Full Update
Reduced Update*
(3.8 Percent)
(1.8 Percent)
Standard Federal Rate
$46,432.77
$45,538.11
* For L TCHs that fail to submit quality reporting data for FY 2023 in accordance with the L TCH Quality Reporting
Program (LTCH QRP), the annual update is reduced by 2.0 percentage points as required by section 1886(m)(5) of the
Act.
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
our statutory authority under section
1886(d)(4)(B) and (C) of the Act to assign and
update appropriate weighting factors,
beginning in FY 2023, we are finalizing a
permanent 10-percent cap on the reduction
in a MS–DRG’s relative weight in a given
fiscal year. This final policy is consistent
with our general authority to assign and
update appropriate weighting factors as part
of our annual reclassifications of the MS–
DRGs and recalibration of the relative
weights under sections 1886(d)(4)(B) and
(C)(i) of the Act, as well as the requirements
of section 1886(d)(4)(C)(iii) of the Act, which
specifies that the annual DRG reclassification
and recalibration of the relative weights be
made in a manner that ensures that aggregate
payments to hospitals are not affected. In
addition, we have authority to implement
this cap and the associated budget neutrality
adjustment under our special exceptions and
adjustments authority at section
1886(d)(5)(I)(i) of the Act, which similarly
gives the Secretary broad authority to provide
by regulation for such other exceptions and
adjustments to the payment amounts under
section 1886(d) of the Act as the Secretary
deems appropriate. For the vast majority of
hospitals, the impact of the 10-percent cap,
inclusive of the budget neutrality factor, is
less than 0.1 percent. We note that the impact
of not finalizing a 10-percent cap for FY
2023, or finalizing a higher cap, such as 15
or 20 percent, would be most marked for
hospitals whose case mix includes more MS–
DRGs experiencing reductions of greater than
10-percent for FY 2023. The impact of
finalizing a lower cap, such as 5 percent,
would be increases to hospitals whose case
mix includes more MS–DRGs experiencing
reductions of between 5 and 10 percent, with
a corresponding increase in the budget
neutrality adjustment for all hospitals.
d. Add-On Payments for New Services and
Technologies
Consistent with sections 1886(d)(5)(K) and
(L) of the Act, CMS reviews applications for
new technology add-on payments based on
the eligibility criteria at 42 CFR 412.87. As
set forth in 42 CFR 412.87(e)(1), CMS
considers whether a technology meets the
criteria for the new technology add-on
payment and announces the results as part of
its annual updates and changes to the IPPS.
(1) Proposal To Use National Drug Codes
(NDCs) for Identification of Certain
Therapeutic Agents Approved for New
Technology Add-On Payment
In section II.F.8. of the preamble of this
final rule, we detail our proposal to use
National Drug Codes (NDCs) to identify cases
involving use of therapeutic agents approved
for new technology add-on payments, and
discuss comments received. After
consideration of the comments received,
including concerns that our proposed use of
NDCs for this purpose may impose new
administrative burdens to hospitals, we are
not finalizing this proposal, and will instead
reassess this policy proposal in future
rulemaking.
(2) Publicly Post Applications for New
Technology Add-On Payments
As discussed in section II.F.9. of the
preamble of this final rule, beginning with
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
the FY 2024 application cycle for new
technology add-on payments, we are
finalizing our proposal to publicly post
online the completed application forms and
certain related materials, including updated
application information submitted
subsequent to the initial application
submission, with the exception of cost and
volume information and certain additional
information and materials, as discussed more
fully in section II.F.9. of the preamble of this
final rule. We have received requests from
the public to access and review the new
technology add-on payment applications to
further facilitate comment on whether a
technology meets the new technology add-on
payment criteria. Making this information
publicly available may also foster greater
input from interested parties based on their
review of the completed application forms
and related materials.
Additionally, we believe that posting the
applications online will reduce the risk that
we may inadvertently omit or misrepresent
relevant information submitted by
applicants, or are perceived as
misrepresenting such information, in our
summaries in the rules. It also will
streamline our evaluation process, including
the identification of critical questions in the
proposed rule, particularly as the number
and complexity of the applications have been
increasing over time. That is, by making the
applications available to the public online,
we will afford more time for CMS to process
and analyze the supporting data and
evidence rather than reiterate parts of the
application in the rule.
e. Permanent Cap on Wage Index Decreases
Consistent with section 1886(d)(3)(E) of the
Act, we adjust the IPPS standardized
amounts for area differences in hospital wage
levels by a factor (established by the
Secretary) reflecting the relative hospital
wage level in the geographic area of the
hospital compared to the national average
hospital wage level and update the wage
index annually based on a survey of wages
and wage-related costs of short-term, acute
care hospitals. As described in section III.N.
of the preamble of this final rule, we have
further considered the comments we received
during the FY 2022 rulemaking
recommending a permanent 5-percent cap
policy to prevent large year-to-year variations
in wage index values as a means to reduce
overall volatility for hospitals. Under the
authority at sections 1886(d)(3)(E) and
1886(d)(5)(I)(i) of the Act, for FY 2023 and
subsequent years, we proposed to apply a 5percent cap on any decrease to a hospital’s
wage index from its wage index in the prior
FY, regardless of the circumstances causing
the decline. That is, we proposed that a
hospital’s wage index for FY 2023 would not
be less than 95 percent of its final wage index
for FY 2022, and that for subsequent years,
a hospital’s wage index would not be less
than 95 percent of its final wage index for the
prior FY. We also proposed to apply the
proposed wage index cap policy in a budget
neutral manner through a national
adjustment to the standardized amount under
our authority in sections 1886(d)(3)(E) and
1886(d)(5)(I)(i) of the Act. As described in
section III.N. of the preamble of this final
PO 00000
Frm 00677
Fmt 4701
Sfmt 4700
49455
rule, after consideration of the public
comments received, we are finalizing these
proposals without modification.
We note that the impact of not finalizing
a 5 percent cap, or finalizing a higher cap,
such as 10 percent, would be most marked
for hospitals who have wage index changes
of greater than 5 percent but less than the
selected cap level, if any, in a given fiscal
year. For example, in FY 2023 if the cap were
10 percent instead of 5 percent,
approximately 12 hospitals would qualify vs
approximately 125 hospitals under our
adopted policy. The impact of finalizing a
lower cap would be increases in payment to
hospitals with wage index changes between
a lower level and 5 percent, with a
corresponding increase in the size of the
budget neutrality adjustment for all hospitals.
f. Continuation of the Low Wage Index
Hospital Policy
To help mitigate wage index disparities
between high wage and low wage hospitals,
in the FY 2020 IPPS/LTCH PPS rule (84 FR
42326 through 42332), we adopted a policy
to increase the wage index values for certain
hospitals with low wage index values (the
low wage index hospital policy). This policy
was adopted in a budget neutral manner
through an adjustment applied to the
standardized amounts for all hospitals. We
also indicated our intention that this policy
would be effective for at least 4 years,
beginning in FY 2020, in order to allow
employee compensation increases
implemented by these hospitals sufficient
time to be reflected in the wage index
calculation. As discussed in section III.G.4. of
the preamble of this final rule, for FY 2023,
we are continuing the low wage index
hospital policy, and are also applying this
policy in a budget neutral manner by
applying an adjustment to the standardized
amounts.
g. Application of the Rural Floor
As discussed in section III.G.1. of the
preamble of this final rule, based on the
district court’s decision in Citrus HMA, LLC,
d/b/a Seven Rivers Regional Medical Center
v. Becerra, No. 1:20–cv–00707 (D.D.C.) and
the comments we received, we are not
finalizing our rural floor wage index policy
as proposed, which would have excluded
§ 412.103 hospitals from the calculation of
the rural floor and from the calculation of
‘‘the wage index for rural areas in the State
in which the county is located’’ as referred
to in section 1886(d)(8)(C)(iii) of the Act.
Rather, we are finalizing a policy that
calculates the rural floor as it was calculated
before FY 2020. For FY 2023 and subsequent
years, we are finalizing a policy to include
the wage data of hospitals that have
reclassified from urban to rural under section
1886(d)(8)(E) of the Act (as implemented in
the regulations at § 412.103) and have no
additional form of reclassification (MGCRB
or Lugar) in the calculation of the rural floor,
and to include the wage data of such
hospitals in the calculation of ‘‘the wage
index for rural areas in the State in which the
county is located’’ as referred to in section
1886(d)(8)(C)(iii) of the Act.
The rural floor, which is budget neutral
overall, increases payments to urban
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49456
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
hospitals whose wage index would otherwise
be below the rural floor for their state. The
policy we are adopting in section III.G.1. of
the preamble of this final rule increases the
rural floor in some states (for example,
Arizona, Utah). This will generally increase
payments to some urban hospitals in those
states because their wage index will be
higher than it otherwise would have been in
the absence of this change. After application
of the rural floor, we reduce the wage index
of all hospitals by applying a budget
neutrality factor to offset the increased
payments. We note that there is either no
increase in the rural floor or the increase in
the rural floor is nominal in the majority of
states, and the majority of hospitals will only
experience payment decreases due to the
effect of the increase in the budget neutrality
adjustment.
h. Payment Adjustment for Medicare
Disproportionate Share Hospitals (DSHs)
In this final rule, as required by section
1886(r)(2) of the Act, we are updating our
estimates of the three factors used to
determine uncompensated care payments for
FY 2023. We are finalizing our proposal to
adopt a multiyear averaging methodology to
determine Factor 3 of the uncompensated
care payment methodology, which will help
to mitigate against large fluctuations in
uncompensated care payments from year to
year. Specifically, we are using a 2-year
average of audited data on uncompensated
care costs from Worksheet S–10 from the FY
2018 and FY 2019 cost reports to calculate
Factor 3 for FY 2023 for all eligible hospitals,
including Indian Health Service (IHS) and
Tribal hospitals and hospitals located in
Puerto Rico. In addition, for FY 2024 and
subsequent fiscal years, we will determine
Factor 3 for all eligible hospitals using a 3year average of the data on uncompensated
care costs from Worksheet S–10 for the 3
most recent fiscal years for which audited
data are available.
We recognize that discontinuing the use of
the low-income insured days proxy to
calculate Factor 3 in the uncompensated care
payment methodology for IHS and Tribal
hospitals and Puerto Rico hospitals could
result in a significant financial disruption for
these hospitals. Accordingly, we are also
finalizing our proposal to use our authority
under section 1886(d)(5)(I) of the Act to
establish a new supplemental payment for
these hospitals for FY 2023 and subsequent
fiscal years. Refer to section I.H.2. of this
Appendix for additional analysis on this new
supplemental payment for FY 2023.
In the FY 2023 IPPS/LTCH PPS proposed
rule, we proposed to revise our regulation
governing the calculation of the Medicaid
fraction of the DSH calculation with respect
to the treatment of section 1115
demonstration days. As discussed in section
IV.F. of the preamble of this final rule, we are
not moving forward with the proposed
revisions to the regulations relating to the
treatment of section 1115 demonstration days
for purposes of the DSH adjustment in this
final rule. We expect to revisit the issue of
section 1115 demonstration days in future
rulemaking, and we encourage interested
parties to review any future proposal on this
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
issue and to submit their comments at that
time.
i. Effects of Implementation of the Rural
Community Hospital Demonstration Program
in FY 2023
The Rural Community Hospital
Demonstration (RCHD) was authorized
originally for a 5-year period by section 410A
of the Medicare Prescription Drug,
Improvement, and Modernization Act of
2003 (MMA) (Pub. L. 108–173), and it was
extended for another 5-year period by section
3123 and 10313 of the Affordable Care Act
(Pub. L. 111–148). Section 15003 of the 21st
Century Cures Act (Cures Act) (Pub. L. 114–
255) extended the demonstration for an
additional 5-year period, and section 128 of
the Consolidated Appropriations Act of
2021(Pub. L. 116–159) included an
additional 5-year re-authorization through
2028. CMS has conducted the demonstration
since 2004, which allows enhanced, costbased payment for Medicare inpatient
services for up to 30 small rural hospitals.
The authorizing legislation imposes a strict
budget neutrality requirement. In this final
rule, we summarized the status of the
demonstration program, and the ongoing
methodologies for implementation and
budget neutrality.
2. Payments for Graduate Medical Education
(GME)
On May 17, 2021, the U.S. District Court
for the District of Columbia ruled against
CMS’s method of calculating direct GME
payments to teaching hospitals when those
hospitals’ weighted full-time equivalent
(FTE) counts exceed their direct GME FTE
cap. In Milton S. Hershey Medical Center, et
al. v. Becerra, the court ordered CMS to
recalculate reimbursement owed, holding
that CMS’s regulation impermissibly
modified the statutory weighting factors.
After reviewing the statutory language
regarding the direct GME FTE cap and the
court’s opinion in Milton S. Hershey Medical
Center, et al. v. Becerra, we are finalizing, as
described in greater detail in section V.F.2.
of the preamble of this final rule, a modified
policy to be applied retroactively and
prospectively for all teaching hospitals.
Specifically, effective for cost reporting
periods beginning on or after October 1, 2001
that are open or reopenable, we specified that
if the hospital’s unweighted number of FTE
residents exceeds the FTE cap, and the
number of weighted FTE residents also
exceeds that FTE cap, the respective primary
care and obstetrics and gynecology weighted
FTE counts and other weighted FTE counts
are adjusted to make the total weighted FTE
count equal the FTE cap. If the number of
weighted FTE residents does not exceed that
FTE cap, then the allowable weighted FTE
count for direct GME payment is the actual
weighted FTE count. We estimate the impact
of this modified policy to be $170 million for
FY 2023.
3. Frontier Community Health Integration
Project (FCHIP) Demonstration
The Frontier Community Health
Integration Project (FCHIP) demonstration
was authorized under section 123 of the
Medicare Improvements for Patients and
PO 00000
Frm 00678
Fmt 4701
Sfmt 4700
Providers Act of 2008 (Pub. L. 110–275), as
amended by section 3126 of the Affordable
Care Act (ACA) of 2010 (Pub. L. 114–158),
and most recently re-authorized and
extended by the Consolidated Appropriations
Act of 2021 (Pub. L. 116–159). The legislation
authorized a demonstration project to allow
eligible entities to develop and test new
models for the delivery of health care in
order to improve access to and better
integrate the delivery of acute care, extended
care and other health care services to
Medicare beneficiaries in certain rural areas.
The FCHIP demonstration initial period was
conducted in 10 critical access hospitals
(CAHs) from August 1, 2016, to July 31, 2019,
and the demonstration ‘‘extension period’’
began on January 1, 2022, and run through
June 30, 2027.
The authorizing legislation requires the
FCHIP demonstration to be budget neutral. In
this final rule, we will continue with the
budget neutrality approach used in the
demonstration initial period for the
demonstration extension period—to offset
payments across CAHs nationally—should
the demonstration incur costs to Medicare.
4. Update to the LTCH PPS Payment Rates
As described in section VIII.C.2. of the
preamble of this final rule, in order to update
payments to LTCHs using the best available
data, we updated the LTCH PPS standard
Federal payment rate by 3.8 percent (that is,
a 4.1 percent market basket update with a
reduction of 0.3 percentage point for the
productivity adjustment, as required by
section 1886(m)(3)(A)(i) of the Act). LTCHs
that failed to submit quality data, as required
by 1886(m)(5)(A)(i) of the Act and described
in section VIII.C.2. of the preamble of this
final rule, will receive an update of 1.8
percent, which reflects a 2.0 percentage
points reduction for failure to submit quality
data.
5. Hospital Quality Programs
Section 1886(b)(3)(B)(viii) of the Act
requires subsection (d) hospitals to report
data in accordance with the requirements of
the Hospital IQR Program for purposes of
measuring and making publicly available
information on health care quality, and links
the quality data submission to the annual
applicable percentage increase. Sections
1886(b)(3)(B)(ix), 1886(n), and 1814(l) of the
Act require eligible hospitals and CAHs to
demonstrate they are meaningful users of
certified EHR technology for purposes of
electronic exchange of health information to
improve the quality of health care, and links
the submission of information demonstrating
meaningful use to the annual applicable
percentage increase for eligible hospitals and
the applicable percent for CAHs. Section
1886(m)(5) of the Act requires each LTCH to
submit quality measure data in accordance
with the requirements of the LTCH QRP for
purposes of measuring and making publicly
available information on health care quality,
and in order to avoid a 2-percentage point
reduction. Section 1886(o) of the Act requires
the Secretary to establish a value-based
purchasing program under which valuebased incentive payments are made in a
fiscal year to hospitals that meet the
performance standards established on an
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
announced set of quality and efficiency
measures for the fiscal year. The purposes of
the Hospital VBP Program include measuring
the quality of hospital inpatient care, linking
hospital measure performance to payment,
and making publicly available information
on hospital quality of care. Section 1886(p)
of the Act requires a reduction in payment
for subsection (d) hospitals that rank in the
worst-performing 25 percent with respect to
measures of hospital-acquired conditions
under the HAC Reduction Program for the
purpose of measuring, linking measure
performance to payment, and making
publicly available information on health care
quality. Section 1886(q) of the Act requires
a reduction in payment for subsection (d)
hospitals for excess readmissions based on
measures for applicable conditions under the
Hospital Readmissions Reduction Program
for the purpose of measuring, linking
measure performance to payment, and
making publicly available information on
health care quality. Section 1866(k) of the
Act applies to hospitals described in section
1886(d)(1)(B)(v) of the Act (referred to as
‘‘PPS-Exempt Cancer Hospitals’’ or ‘‘PCHs’’)
and requires PCHs to report data in
accordance with the requirements of the
PCHQR Program for purposes of measuring
and making publicly available information
on the quality of care furnished by PCHs,
however, there is no reduction in payment to
a PCH that does not report data.
6. Other Provisions
a. Codification of the Costs Incurred for
Qualified and Non-Qualified Deferred
Compensation Plans
As discussed in section X.A. of the
preamble of this final rule, we codify in
regulation certain general requirements;
definitions; requirements for costs of the
plans to be allowable under the program;
additional requirements for payments to
funded defined benefit plans; data and
documentation requirements to support
payments/contributions to the plans; and
allowable administrative and other costs
associated with the plans, including costs
related to the Pension Benefit Guarantee
Corporation.
b. Condition of Participation (CoP)
Requirements for Hospitals and CAHs To
Continue Reporting Data for COVID–19 and
Influenza After the PHE Ends as Determined
by the Secretary
Section X.B. of the preamble of this final
rule revises the hospital and CAH infection
prevention and control CoP requirements to
require hospitals and CAHs, after the
conclusion of the current COVID–19 PHE, to
continue COVID–19 and seasonal influenza
related reporting. The revisions will continue
to apply upon conclusion of the COVID–19
PHE and will continue until April 30, 2024,
unless the Secretary establishes an earlier
ending date. In addition, as noted previously,
we have withdrawn our proposal to establish
additional data reporting requirements to
address future PHEs related to epidemics and
infectious diseases.
We believe these data will offer the most
valuable information during a post-PHE state
by continuing to capture critical data on
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
COVID–19 for ongoing surveillance and to
inform any potential action to protect patient
health and safety. As previously discussed,
these data will enable the federal government
to monitor the ability of facilities to provide
safe care for patients by determining the
number of COVID–19 and influenza
infections being treated by facilities; the
quantity of resources available to facilities
and the volume of resources they are using;
and facilities’ continued capacity to provide
safe patient care. In addition, as done
throughout the COVID–19 pandemic, local,
state, and federal authorities will continue to
use these data to identify possible resurgence
in cases and outbreaks, for resource
allocation purposes, and to update guidance
pertaining to the safe provision of patient
care.
As discussed in section X.B. of this rule,
due to the unpredictable nature of the novel
SARS–CoV–2 virus that causes COVID–19, in
the event that the PHE declaration ends, we
believe that continuing COVID–19-related
data reporting through April 2024 is
necessary to protect the health and safety of
hospital and CAH patients as well as the
communities in which the hospitals and
CAHs are located. The COVID–19-related
data reported by all hospitals and CAHs,
have been, and continue to be, important in
supporting surveillance of, and response to,
COVID–19 and other respiratory illnesses.
These data play an important role in
evaluating spread of respiratory viruses and
infections, including but not limited to
COVID–19 and influenza. Retaining the data
reporting requirements after the end of the
current COVID–19 PHE is an important
element of maintaining effective surveillance
of this novel virus. Timely and actionable
surveillance will enable CMS to continue to
respond to facilities in need of additional
technical support and oversight, should they
experience increased cases or outbreaks of
COVID–19 and/or influenza.
As noted, we do not expect continued
daily reporting for COVID–19 or influenza
outside of a declared PHE. Moreover, the rule
allows for the scope of data categories and
frequency of data collection and reporting to
be reduced and limited, as determined by the
Secretary, responsive to evolving clinical and
epidemiology circumstances. These
requirements will not be implemented and
enforced until the current COVID–19 PHE
declaration concludes, and CMS will issue
guidance indicating such a transition.
Reporting frequency and requirements will
be communicated to hospitals, stakeholders,
and the public following a model similar to
that which we used to inform regulated
entities at the beginning of the COVID–19
PHE (see QSO–21–03–Hospitals/CAHs at
https://www.cms.gov/files/document/qso-2103-hospitalscahs.pdf-0). As discussed in
section XII.B. of the preamble of this final
rule, Collection of Information Requirements,
we expect a burden increase of $38,204,400
or approximately $6,162 per facility annually
for weekly reporting (an average response
time of 1.5 hours per week for a registered
nurse with an average hourly salary of $79).
We note that efforts are underway to
automate hospital and CAH reporting that
have the potential to significantly decrease
reporting burden and improve reliability.
PO 00000
Frm 00679
Fmt 4701
Sfmt 4700
49457
B. Overall Impact
We have examined the impacts of this final
rule as required by Executive Order 12866 on
Regulatory Planning and Review (September
30, 1993), Executive Order 13563 on
Improving Regulation and Regulatory Review
(January 18, 2011), the Regulatory Flexibility
Act (RFA) (September 19, 1980, Pub. L. 96–
354), section 1102(b) of the Social Security
Act, section 202 of the Unfunded Mandates
Reform Act of 1995 (March 22, 1995; Pub. L.
104–4), Executive Order 13132 on Federalism
(August 4, 1999), and the Congressional
Review Act (5 U.S.C. 804(2)).
Executive Orders 12866 and 13563 direct
agencies to assess all costs and benefits of
available regulatory alternatives and, if
regulation is necessary, to select regulatory
approaches that maximize net benefits
(including potential economic,
environmental, public health and safety
effects, distributive impacts, and equity).
Section 3(f) of Executive Order 12866 defines
a ‘‘significant regulatory action’’ as an action
that is likely to result in a rule: (1) having an
annual effect on the economy of $100 million
or more in any 1 year, or adversely and
materially affecting a sector of the economy,
productivity, competition, jobs, the
environment, public health or safety, or state,
local or tribal governments or communities
(also referred to as ‘‘economically
significant’’); (2) creating a serious
inconsistency or otherwise interfering with
an action taken or planned by another
agency; (3) materially altering the budgetary
impacts of entitlement grants, user fees, or
loan programs or the rights and obligations
of recipients thereof; or (4) raising novel legal
or policy issues arising out of legal mandates,
the President’s priorities, or the principles set
forth in the Executive order.
A regulatory impact analysis (RIA) must be
prepared for major rules with significant
regulatory action/s and/or with economically
significant effects ($100 million or more in
any 1 year). Based on our estimates, OMB’s
Office of Information and Regulatory Affairs
has determined this rulemaking is
‘‘economically significant’’ as measured by
the $100 million threshold, and hence also a
major rule under Subtitle E of the Small
Business Regulatory Enforcement Fairness
Act of 1996 (also known as the Congressional
Review Act). Accordingly, we have prepared
a Regulatory Impact Analysis that to the best
of our ability presents the costs and benefits
of the rulemaking. OMB has reviewed these
finalized regulations, and the Departments
have provided the following assessment of
their impact.
We estimate that the changes for FY 2023
acute care hospital operating and capital
payments will redistribute amounts in excess
of $100 million to acute care hospitals. The
applicable percentage increase to the IPPS
rates required by the statute, in conjunction
with other payment changes in this final rule,
will result in an estimated $1.4 billion
increase in FY 2023 payments, primarily
driven by: (a) a combined $2.4 billion
increase in FY 2023 operating payments,
including uncompensated care payments and
supplemental payments; and (b) a combined
decrease of $ 1.0 billion resulting from
estimated changes in new technology add-on
E:\FR\FM\10AUR2.SGM
10AUR2
49458
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
payments, the change to the GME weighting
methodology, the expiration of the lowvolume payment adjustment, and FY 2023
capital payments. These changes are relative
to payments made in FY 2022. The impact
analysis of the capital payments can be found
in section I.I. of this Appendix. In addition,
as described in section I.J. of this Appendix,
LTCHs are expected to experience an
increase in payments by approximately $71
million in FY 2023 relative to FY 2022.
Our operating impact estimate includes the
0.5 percentage point adjustment required
under section 414 of the MACRA applied to
the IPPS standardized amount, as discussed
in section II.D. of the preamble of this final
rule. In addition, our operating payment
impact estimate includes the 3.8 percent
hospital update to the standardized amount
(which includes the estimated 4.1 percent
market basket update reduced by the 0.3
percentage point for the productivity
adjustment). The estimates of IPPS operating
payments to acute care hospitals do not
reflect any changes in hospital admissions or
real case-mix intensity, which will also affect
overall payment changes.
The analysis in this Appendix, in
conjunction with the remainder of this
document, demonstrates that this final rule is
consistent with the regulatory philosophy
and principles identified in Executive Orders
12866 and 13563, the RFA, and section
1102(b) of the Act. This final rule will affect
payments to a substantial number of small
rural hospitals, as well as other classes of
hospitals, and the effects on some hospitals
may be significant. Finally, in accordance
with the provisions of Executive Order
12866, the Office of Management and Budget
has reviewed this final rule.
C. Objectives of the IPPS and the LTCH PPS
The primary objective of the IPPS and the
LTCH PPS is to create incentives for
hospitals to operate efficiently and minimize
unnecessary costs, while at the same time
ensuring that payments are sufficient to
adequately compensate hospitals for their
costs in delivering necessary care to
Medicare beneficiaries. In addition, we share
national goals of preserving the Medicare
Hospital Insurance Trust Fund.
We believe that the changes in this final
rule would further each of these goals while
maintaining the financial viability of the
hospital industry and ensuring access to high
quality health care for Medicare
beneficiaries. We expect that these changes
will ensure that the outcomes of the
prospective payment systems are reasonable
and equitable, while avoiding or minimizing
unintended adverse consequences.
Because this final rule contains a range of
policies, we refer readers to the section of the
final rule where each policy is discussed.
These sections include the rationale for our
decisions, including the need for the policy.
D. Limitations of Our Analysis
The following quantitative analysis
presents the projected effects of our policy
changes, as well as statutory changes
effective for FY 2023, on various hospital
groups. We estimate the effects of individual
policy changes by estimating payments per
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
case, while holding all other payment
policies constant. We use the best data
available, but, generally unless specifically
indicated, we do not attempt to make
adjustments for future changes in such
variables as admissions, lengths of stay, case
mix, changes to the Medicare population, or
incentives. In addition, we discuss
limitations of our analysis for specific
policies in the discussion of those policies as
needed.
E. Hospitals Included In and Excluded From
the IPPS
The prospective payment systems for
hospital inpatient operating and capitalrelated costs of acute care hospitals
encompass most general short-term, acute
care hospitals that participate in the
Medicare program. There were 25 Indian
Health Service hospitals in our database,
which we excluded from the analysis due to
the special characteristics of the prospective
payment methodology for these hospitals.
Among other short term, acute care hospitals,
hospitals in Maryland are paid in accordance
with the Maryland Total Cost of Care Model,
and hospitals located outside the 50 States,
the District of Columbia, and Puerto Rico
(that is, 6 short-term acute care hospitals
located in the U.S. Virgin Islands, Guam, the
Northern Mariana Islands, and American
Samoa) receive payment for inpatient
hospital services they furnish on the basis of
reasonable costs, subject to a rate-of-increase
ceiling.
As of March 2022, there were 3,142 IPPS
acute care hospitals included in our analysis.
This represents approximately 53 percent of
all Medicare-participating hospitals. The
majority of this impact analysis focuses on
this set of hospitals. There also are
approximately 1,425 CAHs. These small,
limited service hospitals are paid on the basis
of reasonable costs, rather than under the
IPPS. IPPS-excluded hospitals and units,
which are paid under separate payment
systems, include IPFs, IRFs, LTCHs, RNHCIs,
children’s hospitals, cancer hospitals,
extended neoplastic disease care hospital,
and short-term acute care hospitals located in
the Virgin Islands, Guam, the Northern
Mariana Islands, and American Samoa.
Changes in the prospective payment systems
for IPFs and IRFs are made through separate
rulemaking. Payment impacts of changes to
the prospective payment systems for these
IPPS-excluded hospitals and units are not
included in this final rule. The impact of the
final update and policy changes to the LTCH
PPS for FY 2023 is discussed in section I.J.
of this Appendix.
F. Effects on Hospitals and Hospital Units
Excluded From the IPPS
As of July 2022, there were 92 children’s
hospitals, 11 cancer hospitals, 6 short termacute care hospitals located in the Virgin
Islands, Guam, the Northern Mariana Islands
and American Samoa, 1 extended neoplastic
disease care hospital, and 14 RNHCIs being
paid on a reasonable cost basis subject to the
rate-of-increase ceiling under § 413.40. (In
accordance with § 403.752(a) of the
regulation, RNHCIs are paid under § 413.40.)
Among the remaining providers, the
PO 00000
Frm 00680
Fmt 4701
Sfmt 4700
rehabilitation hospitals and units, and the
LTCHs, are paid the Federal prospective per
discharge rate under the IRF PPS and the
LTCH PPS, respectively, and the psychiatric
hospitals and units are paid the Federal per
diem amount under the IPF PPS. As stated
previously, IRFs and IPFs are not affected by
the rate updates discussed in this final rule.
The impacts of the changes on LTCHs are
discussed in section I.J. of this Appendix.
For the children’s hospitals, cancer
hospitals, short-term acute care hospitals
located in the Virgin Islands, Guam, the
Northern Mariana Islands, and American
Samoa, the extended neoplastic disease care
hospital, and RNHCIs, the update of the rateof-increase limit (or target amount) is the
estimated FY 2023 percentage increase in the
2018-based IPPS operating market basket,
consistent with section 1886(b)(3)(B)(ii) of
the Act, and §§ 403.752(a) and 413.40 of the
regulations. Consistent with current law,
based on IGI’s second quarter 2022 forecast
of the 2018-based IPPS market basket
increase, we are estimating the FY 2023
update to be 4.1 percent (that is, the estimate
of the market basket rate-of-increase), as
discussed in section V.A. of the preamble of
this final rule. However, the Affordable Care
Act requires a productivity adjustment (0.3
percentage point reduction for FY 2023),
resulting in a 3.8 percent applicable
percentage increase for IPPS hospitals that
submit quality data and are meaningful EHR
users, as discussed in section V.A. of the
preamble of this rule. Children’s hospitals,
cancer hospitals, short term acute care
hospitals located in the Virgin Islands, Guam,
the Northern Mariana Islands, and American
Samoa, the extended neoplastic disease care
hospital, and RNHCIs that continue to be
paid based on reasonable costs subject to
rate-of-increase limits under § 413.40 of the
regulations are not subject to the reductions
in the applicable percentage increase
required under the Affordable Care Act.
Therefore, for those hospitals paid under
§ 413.40 of the regulations, the update is the
percentage increase in the 2018-based IPPS
operating market basket for FY 2023,
estimated at 4.1 percent.
The impact of the update in the rate-ofincrease limit on those excluded hospitals
depends on the cumulative cost increases
experienced by each excluded hospital since
its applicable base period. For excluded
hospitals that have maintained their cost
increases at a level below the rate-of-increase
limits since their base period, the major effect
is on the level of incentive payments these
excluded hospitals receive. Conversely, for
excluded hospitals with cost increases above
the cumulative update in their rate-ofincrease limits, the major effect is the amount
of excess costs that would not be paid.
We note that, under § 413.40(d)(3), an
excluded hospital that continues to be paid
under the TEFRA system and whose costs
exceed 110 percent of its rate-of-increase
limit receives its rate-of-increase limit plus
the lesser of: (1) 50 percent of its reasonable
costs in excess of 110 percent of the limit; or
(2) 10 percent of its limit. In addition, under
the various provisions set forth in § 413.40,
hospitals can obtain payment adjustments for
justifiable increases in operating costs that
exceed the limit.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
G. Quantitative Effects of the Policy Changes
Under the IPPS for Operating Costs
1. Basis and Methodology of Estimates
In this final rule, we are announcing policy
changes and payment rate updates for the
IPPS for FY 2023 for operating costs of acute
care hospitals. The FY 2023 updates to the
capital payments to acute care hospitals are
discussed in section I.I. of this Appendix.
Based on the overall percentage change in
payments per case estimated using our
payment simulation model, we estimate that
total FY 2023 operating payments will
increase by 2.6 percent, compared to FY
2022. In addition to the applicable
percentage increase, this amount reflects the
+0.5 percentage point permanent adjustment
to the standardized amount required under
section 414 of MACRA. The impacts do not
reflect changes in the number of hospital
admissions or real case-mix intensity, which
would also affect overall payment changes.
We have prepared separate impact analyses
of the changes to each system. This section
deals with the changes to the operating
inpatient prospective payment system for
acute care hospitals. Our payment simulation
model relies on the best available claims data
to enable us to estimate the impacts on
payments per case of certain changes in this
final rule. As discussed in section I.F of this
final rule, we believe that the FY 2021 claims
data is the best available data for purposes of
the FY 2023 ratesetting and this impact
analysis reflects the use of that data.
However, there are other changes for which
we do not have data available that would
allow us to estimate the payment impacts
using this model. For those changes, we have
attempted to predict the payment impacts
based upon our experience and other more
limited data.
The data used in developing the
quantitative analyses of changes in payments
per case presented in this section are taken
from the FY 2021 MedPAR file, as discussed
previously in this final rule, and the most
current Provider-Specific File (PSF) that is
used for payment purposes. Although the
analyses of the changes to the operating PPS
do not incorporate cost data, data from the
best available hospital cost reports were used
to categorize hospitals, as also discussed
previously in this final rule. Our analysis has
several qualifications. First, in this analysis,
we do not adjust for future changes in such
variables as admissions, lengths of stay, or
underlying growth in real case-mix. Second,
due to the interdependent nature of the IPPS
payment components, it is very difficult to
precisely quantify the impact associated with
each change. Third, we use various data
sources to categorize hospitals in the tables.
In some cases, particularly the number of
beds, there is a fair degree of variation in the
data from the different sources. We have
attempted to construct these variables with
the best available source overall. However,
for individual hospitals, some
miscategorizations are possible.
Using cases from the FY 2021 MedPAR
file, we simulate payments under the
operating IPPS given various combinations of
payment parameters. As described
previously, Indian Health Service hospitals
and hospitals in Maryland were excluded
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
from the simulations. The impact of
payments under the capital IPPS, and the
impact of payments for costs other than
inpatient operating costs, are not analyzed in
this section. Estimated payment impacts of
the capital IPPS for FY 2023 are discussed in
section I.I. of this Appendix.
We discuss the following changes:
• The effects of the application of the
applicable percentage increase of 3.8 percent
(that is, a 4.1 percent market basket update
with a reduction of 0.3 percentage point for
the productivity adjustment), and a 0.5
percentage point adjustment required under
section 414 of the MACRA to the IPPS
standardized amount, and the applicable
percentage increase (including the market
basket update and the productivity
adjustment) to the hospital-specific rates.
• The effects of the changes to the relative
weights and MS–DRG GROUPER.
• The effects of the changes in hospitals’
wage index values reflecting updated wage
data from hospitals’ cost reporting periods
beginning during FY 2019, compared to the
FY 2018 wage data, to calculate the FY 2023
wage index.
• The effects of the geographic
reclassifications by the MGCRB (as of
publication of this final rule) that will be
effective for FY 2023.
• The effects of the rural floor with the
application of the national budget neutrality
factor to the wage index.
• The effects of the imputed floor wage
index adjustment. This provision is not
budget neutral.
• The effects of the frontier State wage
index adjustment under the statutory
provision that requires hospitals located in
States that qualify as frontier States to not
have a wage index less than 1.0. This
provision is not budget neutral.
• The effects of the implementation of
section 1886(d)(13) of the Act, as added by
section 505 of Public Law 108–173, which
provides for an increase in a hospital’s wage
index if a threshold percentage of residents
of the county where the hospital is located
commute to work at hospitals in counties
with higher wage indexes for FY 2023. This
provision is not budget neutral.
• The effects of the expiration of the
special payment status for MDHs at the end
of FY 2022 under current law as a result of
which MDHs that currently receive the
higher of payments made based on the
Federal rate or the payments made based on
the Federal rate plus 75 percent of the
difference between payments based on the
Federal rate and the hospital-specific rate
will be paid based on the Federal rate starting
in FY 2023.
• The total estimated change in payments
based on the FY 2023 policies relative to
payments based on FY 2022 policies.
To illustrate the impact of the FY 2023
changes, our analysis begins with a FY 2022
baseline simulation model using: the FY
2022 applicable percentage increase of 2.0
percent; the 0.5 percentage point adjustment
required under section 414 of the MACRA
applied to the IPPS standardized amount; the
FY 2022 MS–DRG GROUPER (Version 39);
the FY 2022 CBSA designations for hospitals
based on the OMB definitions from the 2010
PO 00000
Frm 00681
Fmt 4701
Sfmt 4700
49459
Census; the FY 2022 wage index; and no
MGCRB reclassifications. Outlier payments
are set at 5.1 percent of total operating MS–
DRG and outlier payments for modeling
purposes.
Section 1886(b)(3)(B)(viii) of the Act, as
added by section 5001(a) of Public Law 109–
171, as amended by section 4102(b)(1)(A) of
the ARRA (Pub. L. 111–5) and by section
3401(a)(2) of the Affordable Care Act (Pub. L.
111–148), provides that, for FY 2007 and
each subsequent year through FY 2014, the
update factor will include a reduction of 2.0
percentage points for any subsection (d)
hospital that does not submit data on
measures in a form and manner, and at a time
specified by the Secretary. Beginning in FY
2015, the reduction is one-quarter of such
applicable percentage increase determined
without regard to section 1886(b)(3)(B)(ix),
(xi), or (xii) of the Act, or one-quarter of the
market basket update. Therefore, hospitals
that do not submit quality information under
rules established by the Secretary and that
are meaningful EHR users under section
1886(b)(3)(B)(ix) of the Act would receive an
applicable percentage increase of 2.775
percent. At the time this impact was
prepared, 24 hospitals are estimated to not
receive the full market basket rate-of-increase
for FY 2023 because they failed the quality
data submission process or did not choose to
participate, but are meaningful EHR users.
For purposes of the simulations shown later
in this section, we modeled the payment
changes for FY 2023 using a reduced update
for these hospitals.
For FY 2023, in accordance with section
1886(b)(3)(B)(ix) of the Act, a hospital that
has been identified as not a meaningful EHR
user will be subject to a reduction of threequarters of such applicable percentage
increase determined without regard to
section 1886(b)(3)(B)(ix), (xi), or (xii) of the
Act. Therefore, hospitals that are identified
as not meaningful EHR users and do submit
quality information under section
1886(b)(3)(B)(viii) of the Act would receive
an applicable percentage increase of 0.725
percent. At the time this impact analysis was
prepared, 158 hospitals are estimated to not
receive the full market basket rate-of-increase
for FY 2023 because they are identified as not
meaningful EHR users that do submit quality
information under section 1886(b)(3)(B)(viii)
of the Act. For purposes of the simulations
shown in this section, we modeled the
payment changes for FY 2023 using a
reduced update for these hospitals.
Hospitals that are identified as not
meaningful EHR users under section
1886(b)(3)(B)(ix) of the Act and also do not
submit quality data under section
1886(b)(3)(B)(viii) of the Act would receive
an applicable percentage increase of -0.3
percent, which reflects a one-quarter
reduction of the market basket update for
failure to submit quality data and a threequarter reduction of the market basket update
for being identified as not a meaningful EHR
user. At the time this impact was prepared,
20 hospitals are estimated to not receive the
full market basket rate-of-increase for FY
2023 because they are identified as not
meaningful EHR users that do not submit
quality data under section 1886(b)(3)(B)(viii)
of the Act.
E:\FR\FM\10AUR2.SGM
10AUR2
49460
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
Each policy change, statutory or otherwise,
is then added incrementally to this baseline,
finally arriving at an FY 2023 model
incorporating all of the changes. This
simulation allows us to isolate the effects of
each change.
Our comparison illustrates the percent
change in payments per case from FY 2022
to FY 2023. Two factors not discussed
separately have significant impacts here. The
first factor is the update to the standardized
amount. In accordance with section
1886(b)(3)(B)(i) of the Act, we are updating
the standardized amounts for FY 2023 using
an applicable percentage increase of 3.8
percent. This includes the FY 2023
forecasted IPPS operating hospital market
basket increase of 4.1 percent with a 0.3
percentage point reduction for the
productivity adjustment. Hospitals that fail to
comply with the quality data submission
requirements and are meaningful EHR users
will receive a update of 2.775 percent. This
update includes a reduction of one-quarter of
the market basket update for failure to submit
these data. Hospitals that do comply with the
quality data submission requirements but are
not meaningful EHR users will receive an
update of 0.725 percent, which includes a
reduction of three-quarters of the market
basket update. Furthermore, hospitals that do
not comply with the quality data submission
requirements and also are not meaningful
EHR users would receive an update of ¥0.3
percent. Under section 1886(b)(3)(B)(iv) of
the Act, the update to the hospital-specific
amounts for SCHs is also equal to the
applicable percentage increase, or 3.8
percent, if the hospital submits quality data
and is a meaningful EHR user.
A second significant factor that affects the
changes in hospitals’ payments per case from
FY 2022 to FY 2023 is the change in
hospitals’ geographic reclassification status
from one year to the next. That is, payments
may be reduced for hospitals reclassified in
FY 2022 that are no longer reclassified in FY
2023. Conversely, payments may increase for
hospitals not reclassified in FY 2022 that are
reclassified in FY 2023.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
2. Analysis of Table I
Table I displays the results of our analysis
of the changes for FY 2023. The table
categorizes hospitals by various geographic
and special payment consideration groups to
illustrate the varying impacts on different
types of hospitals. The top row of the table
shows the overall impact on the 3,142 acute
care hospitals included in the analysis.
The next two rows of Table I contain
hospitals categorized according to their
geographic location: urban and rural. There
are 2,420 hospitals located in urban areas and
722 hospitals in rural areas included in our
analysis. The next two groupings are by bedsize categories, shown separately for urban
and rural hospitals. The last groupings by
geographic location are by census divisions,
also shown separately for urban and rural
hospitals.
The second part of Table I shows hospital
groups based on hospitals’ FY 2023 payment
classifications, including any
reclassifications under section 1886(d)(10) of
the Act. For example, the rows labeled urban
and rural show that the numbers of hospitals
paid based on these categorizations after
consideration of geographic reclassifications
(including reclassifications under sections
1886(d)(8)(B) and 1886(d)(8)(E) of the Act
that have implications for capital payments)
are 1,861, and 1,281, respectively.
The next three groupings examine the
impacts of the changes on hospitals grouped
by whether or not they have GME residency
programs (teaching hospitals that receive an
IME adjustment) or receive Medicare DSH
payments, or some combination of these two
adjustments. There are 1,939 nonteaching
hospitals in our analysis, 929 teaching
hospitals with fewer than 100 residents, and
274 teaching hospitals with 100 or more
residents.
In the DSH categories, hospitals are
grouped according to their DSH payment
status, and whether they are considered
urban or rural for DSH purposes. The next
category groups together hospitals considered
urban or rural, in terms of whether they
receive the IME adjustment, the DSH
adjustment, both, or neither.
The next six rows examine the impacts of
the changes on rural hospitals by special
PO 00000
Frm 00682
Fmt 4701
Sfmt 4700
payment groups (SCHs and RRCs) and
reclassification status from urban to rural in
accordance with section 1886(d)(8)(E) of the
Act. Of the hospitals that are not reclassified
from urban to rural, there are 148 RRCs, 256
SCHs, and 122 hospitals that are both SCHs
and RRCs. Of the hospitals that are
reclassified from urban to rural, there are 470
RRCs, 47 SCHs, and 39 hospitals that are
both SCHs and RRCs.
The next series of groupings are based on
the type of ownership and the hospital’s
Medicare and Medicaid utilization expressed
as a percent of total inpatient days. These
data were taken from the most recent
available Medicare cost reports.
The next grouping is based on hospitals’
reporting of diagnosis codes describing
patients experiencing homelessness. This
row reflects hospitals whose claims indicate
that at least 5 percent of their IPPS cases
involve these patients based on the reporting
of ICD–10–CM diagnosis code Z59.0
(Homelessness). We note that hospitals are
not required to identify these patients on
their claims, and reporting this information
on the claim does not currently impact
Medicare payment. There may be other
hospitals with at least 5 percent of their IPPS
cases involving these patients, however we
are unable to identify these hospitals. We
refer the reader to Section II.D.13.d. of this
FY 2023 IPPS/LTCH PPS final rule for
discussion of the comments we received in
response to our request for information on
the reporting of social determinants of health
diagnosis codes, such as diagnosis code
Z59.0 (Homelessness), in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28177).
The next grouping concerns the geographic
reclassification status of hospitals. The first
subgrouping is based on whether a hospital
is reclassified or not. The second and third
subgroupings are based on whether urban
and rural hospitals were reclassified by the
MGCRB for FY 2023 or not, respectively. The
fourth subgrouping displays hospitals that
reclassified from urban to rural in accordance
with section 1886(d)(8)(E) of the Act. The
fifth subgrouping displays hospitals deemed
urban in accordance with section
1886(d)(8)(B) of the Act.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
VerDate Sep<11>2014
TABLE 1.-IMPACT ANALYSIS OF CHANGES TO THE IPPS
FOR OPERATING COSTS FOR FY 2023
Jkt 256001
Expiration of
MDHStatus
AUFY2023
Changes
(6) 7
(7)"
(8).
PO 00000
Frm 00683
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
(4)5
(5)6
0.0
0.0
0.3
-0.2
2.6
2,420
722
4.3
4.0
0.0
0.1
0.0
0.0
-0.1
1.0
0.0
-0.2
0.3
0.1
-0.1
-0.7
2.6
2.4
653
700
411
409
245
4.2
4.3
4.3
4.3
4.2
0.0
0.2
0.1
0.0
-0.1
0.0
0.0
0.0
0.0
0.0
-0.8
-0.1
0.1
0.1
-0.2
0.2
0.2
0.0
0.0
0.0
0.6
0.3
0.3
0.3
0.2
-1.6
-0.3
0.0
0.0
0.0
1.1
2.9
3.0
2.7
2.4
358
201
84
46
33
3.8
3.9
4.0
4.1
4.0
0.0
0.2
0.3
0.1
0.1
-0.1
0.0
0.0
-0.1
0.2
0.5
0.6
1.3
1.0
1.6
-0.3
-0.2
-0.2
-0.2
-0.3
0.2
0.3
0.0
0.1
0.0
-1.6
-1.7
-0.1
0.0
0.0
0.9
1.3
3.5
3.1
3.4
107
295
373
156
402
140
362
176
359
50
4.2
4.3
4.3
4.2
4.3
4.3
4.3
4.2
4.2
4.3
-0.1
0.1
-0.1
-0.2
0.0
0.1
0.1
-0.1
0.1
0.6
-0.4
0.1
-0.2
-0.3
-0.2
-0.2
0.4
-0.1
0.5
-0.5
1.8
0.5
-0.3
-0.7
-0.7
-0.7
-0.7
0.2
0.3
-1.3
3.8
-0.4
-0.4
-0.4
-0.4
-0.4
-0.4
1.1
0.0
0.4
0.7
0.4
0.1
0.8
0.3
0.0
0.0
0.3
0.1
0.1
-0.2
-0.1
-0.3
0.0
-0.1
0.0
-0.1
0.0
0.0
0.0
3.2
2.5
2.3
2.2
2.4
2.5
3.0
4.1
2.4
3.8
19
49
113
86
109
141
134
47
24
4.1
4.1
4.0
3.7
4.0
4.1
4.0
3.2
3.9
-0.2
0.0
-0.1
0.0
0.4
0.4
0.3
0.0
0.2
0.6
-0.2
-0.2
0.2
0.0
-0.1
0.4
-0.7
-0.1
-0.1
1.3
1.2
-0.1
1.5
1.4
1.5
0.1
0.9
-0.3
-0.2
-0.2
-0.1
-0.2
-0.3
-0.3
-0.2
-0.1
0.2
0.0
0.0
0.2
0.1
0.1
0.0
1.2
0.0
-1.7
-0.6
-2.5
-0.3
-0.1
-0.2
-0.4
0.0
0.0
0.1
2.5
0.1
2.9
3.6
3.2
2.8
2.8
3.4
1,861
1,281
4.3
4.2
0.0
0.0
0.0
0.0
-0.8
0.9
-0.1
0.1
0.3
0.2
0.0
-0.3
2.5
2.7
1,939
929
4.2
4.3
0.1
0.0
0.1
0.0
0.0
0.0
0.1
-0.1
0.2
0.3
-0.4
-0.1
2.6
2.6
Number
of
Hosuita1s 1
3,142
(1)2
49461
FY2023 Wage
Data with
Application of
Wage Budget
Neutrality
(3)4
0.0
FY2023
MGCRB
Reclassifications
4.2
FY2023
Weights and
DRG
Changes with
Application
of Budget
Neutrality
(2)3
0.0
Hospital
Rate
Update and
Adjustment
under
MACRA
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
ER10AU22.228
All Hospitals
Bv Geoe;rauhic Location:
Urban hosoitals
Rural hospitals
Bed Size (Urban):
0-99 beds
100-199 beds
200-299 beds
300-499 beds
500 or more beds
Bed Size (Rural):
0-49 beds
50-99 beds
100-149 beds
150-199 beds
200 or more beds
Urban bv Ree;ion:
New England
Middle Atlantic
East North Central
West North Central
South Atlantic
East South Central
West South Central
Mountain
Pacific
Puerto Rico
Rural bv Ree;ion:
New England
Middle Atlantic
East North Central
West North Central
South Atlantic
East South Central
West South Central
Mountain
Pacific
Bv Payment Classification:
Urban hosoitals
Rural areas
Teachine; Status:
Nonteaching
Fewer than 100 residents
Application
of the
Imputed
Floor,
Frontier
State Wage
Index and
Outmigration
Adjustment
Rural
Floor with
Application
of National
Rural
Floor
Budget
Neutrality
khammond on DSKJM1Z7X2PROD with RULES2
Jkt 256001
PO 00000
Frm 00684
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
0.0
369
1,129
363
4.3
4.3
4.3
-0.3
0.1
0.3
0.1
0.0
0.1
-0.3
-0.8
-0.7
105
264
674
22
216
4.2
3.8
4.2
4.4
4.2
-0.2
0.1
0.0
0.0
0.1
-0.3
0.0
0.0
0.1
0.0
1.2
0.1
0.9
-0.1
0.0
0.1
1.1
663
60
829
309
4.3
4.3
4.3
4.3
0.0
-0.4
0.2
-0.3
0.0
0.2
0.0
0.1
148
470
256
47
122
39
4.4
4.2
3.7
3.7
3.8
3.9
0.1
-0.1
0.1
0.0
0.1
-0.3
1,915
789
438
4.3
4.2
4.1
790
2,072
225
30
4.2
4.2
4.2
3.1
2,082
942
94
24
45
1,004
2,138
840
1,594
282
Number
of
Hosuitals 1
274
0.2
Expiration of
MDHStatns
(7)"
0.0
-0.2
-0.1
0.3
0.5
0.3
0.5
-0.2
0.0
-0.4
2.3
2.5
2.7
1.1
-0.5
0.2
0.1
0.2
0.0
0.2
-1.7
0.0
-0.1
-3.4
-4.8
1.7
3.8
2.8
0.1
-4.0
-0.8
0.2
-0.7
-0.6
-0.2
-0.1
0.1
-0.2
0.4
0.5
0.2
0.6
0.0
-0.3
0.0
-0.1
2.5
2.0
2.7
2.5
-0.1
0.0
0.0
0.0
0.0
0.0
1.5
1.0
0.0
0.0
0.3
0.1
-0.2
0.2
0.0
0.1
-0.1
-0.1
0.3
0.2
0.1
0.0
0.0
0.0
-0.7
-0.1
0.0
0.0
0.0
0.0
2.0
2.8
3.6
3.8
3.5
3.3
0.0
0.2
0.1
0.0
0.0
0.1
0.1
-0.1
-0.4
0.0
0.1
-0.2
0.3
0.2
0.1
-0.2
-0.1
-0.1
2.5
3.3
2.4
0.1
0.0
0.1
-0.4
0.1
-0.1
-0.7
-0.2
0.0
0.6
-0.4
0.1
0.3
0.4
0.0
0.0
-0.2
-0.3
-1.1
0.1
0.0
0.1
-0.5
-1.1
2.9
2.5
2.8
0.3
4.2
4.2
4.1
4.1
4.2
-0.1
0.1
0.9
1.0
1.0
0.0
0.0
0.4
1.2
0.5
0.1
-0.1
-0.7
-0.9
-0.7
-0.1
0.1
0.5
-0.3
-0.2
0.3
0.3
0.2
0.1
0.2
-0.3
0.0
0.0
0.0
0.0
2.4
2.8
3.5
4.4
3.9
4.2
4.3
4.2
4.3
4.1
0.0
0.0
-0.1
0.0
0.2
0.0
0.0
0.0
0.0
-0.1
1.2
0.1
-0.1
0.1
-0.1
-0.2
0.1
0.4
0.2
0.4
0.1
-0.1
-0.2
-0.2
0.0
-0.5
2.8
2.4
2.7
2.5
2.8
(1)2
(4)5
-1.1
1.1
-1.3
1.9
1.1
(6) 7
All FY2023
Changes
(8)9
2.5
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
FY2023
MGCRB
Reclassifications
4.2
FY2023Wage
Data with
Application of
Wage Budget
Neutrality
(3)4
0.0
Hospital
Rate
Update and
Adjustment
under
MACRA
Application
of the
Imputed
Floor,
Frontier
State Wage
Index and
Outmigration
Adjnstment
49462
VerDate Sep<11>2014
ER10AU22.229
100 or more residents
UrbanDSH:
Non-DSH
100 or more beds
Less than 100 beds
RuralDSH:
Non-DSH
SCH
RRC
100 or more beds
Less than 100 beds
Urban teachine and DSH:
Both teaching and DSH
Teaching and no DSH
No teaching and DSH
No teaching and no DSH
Suecial Hosuital Tynes:
RRC
RRC with Section 401 Rural Reclassification
SCH
SCH with Section 401 Rural Reclassification
SCHandRRC
SCH and RRC with Section 401 Rural
Reclassification
Tvue of Ownershiu:
Voluntary
Proprietarv
Government
Medicare Utilization as a Percent oflnpatient
Days:
0-25
25-50
50-65
Over 65
Medicaid Utilization as a Percent of Inpatient
Days:
0-25
25-50
50-65
Over 65
Hospitals with 5% or more of cases that
reuorted exueriencim! homelessness
FY 2023 Reclassifications:
All Reclassified Hospitals
Non-Reclassified Hosoitals
Urban Hospitals Reclassified
Urban Non-Reclassified Hospitals
Rural Hospitals Reclassified Full Year
FY2023
Weights and
DRG
Changes with
Application
of Budget
Neutrality
(2)3
0.0
Rural
Floor with
Application
of National
Rural
Floor
Budget
Nentrality
(5)"
0.0
khammond on DSKJM1Z7X2PROD with RULES2
VerDate Sep<11>2014
Jkt 256001
PO 00000
Frm 00685
Rural Non-Reclassified Hospitals Full Year
All Section 401 Rural Reclassified Hospitals
Other Reclassified Hospitals (Section
1886( d)(8)(B))
426
615
56
(1)2
3.8
4.2
4.2
FY2023
Weights and
DRG
Changes with
Application
of Budget
Neutrality
(2)3
FY2023 Wage
Data with
Application of
Wage Budget
Neutrality
(3)4
0.1
-0.1
0.2
0.1
0.0
0.0
FY2023
MGCRB
Reclassifications
Application
of the
Imputed
Floor,
Frontier
State Wage
Index and
Outmigration
Adjustment
Expiration of
MOH Status
AUFY2023
Changes
(4)5
(5)•
(6) 7
(7)"
(8)'
-0.5
0.9
3.0
-0.2
0.2
-0.4
0.2
0.2
0.2
-0.9
-0.2
-2.0
1.9
2.7
0.6
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
1 Because data necessary to classify some hospitals by category were missing, the total number of hospitals in each category may not equal the national total. Discharge data are from FY 2021, and
hospital cost report data are from the latest available reporting periods.
2 This column displays the payment impact of the hospital rate update and other adjustments, including the 3.8 percent update to the national standardized amount and the hospital-specific rate (the 4.1
percent market basket update reduced by 0.3 percentage point for the productivity adjustment), and the 0.5 percentage point adjustment to the national standardized amount required under section 414 of
theMACRA.
3 This column displays the payment impact of the changes to the Version 40 GROUPER, the changes to the relative weights and the recalibration of the MS-DRG weights based on FY 2021 MedP AR
data as the best available data, and the permanent IO-percent cap where the relative weight for a MS-DRG would decrease by more than 10 percent in a given fiscal year. This column displays the
application of the recalibration budget neutrality factors of 1.000509and 0.999764.
4 This column displays the payment impact of the update to wage index data using FY 2019 cost report data and the 0MB labor market area delineations based on 2010 Decennial Census data. This
column displays the payment impact of the application of the wage budget neutrality factor, which is calculated separately from the recalibration budget neutrality factor. The wage budget neutrality
factor is 1.000968.
5 Shown here are the effects of geographic reclassifications by the Medicare Geographic Classification Review Board (MGCRB). The effects demonstrate the FY 2023 payment impact of going from no
reclassifications to the reclassifications scheduled to be in effect for FY 2023. Reclassification for prior years has no bearing on the payment impacts shown here. This column reflects the geographic
budget neutrality factor of0.984399.
6 This column displays the effects of the rural floor. The Affordable Care Act requires the rural floor budget neutrality adjustment to be a I 00 percent national level adjustment. The rural floor budget
neutrality factor applied to the wage index is 0.991909.
7 This column shows the combined impact of(!) the imputed floor for all-urban states (2) the policy that requires hospitals located in frontier States have a wage index no less than 1.0; and (3) the policy
which provides for an increase in a hospital's wage index if a threshold percentage of residents of the county where the hospital is located commute to work at hospitals in counties with higher wage
indexes. These are not budget neutral policies.
8 This column displays the impact of the expiration ofMDH status for FY 2023, a non-budget neutral payment provision.
9 This column shows the estimated change in payments from FY 2022 to FY 2023.
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
Number
of
Hosoitals 1
Hospital
Rate
Update and
Adjustment
under
MACRA
Rural
Floor with
Application
of National
Rural
Floor
Budget
Neutrality
49463
ER10AU22.230
khammond on DSKJM1Z7X2PROD with RULES2
49464
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
a. Effects of the Hospital Update and Other
Adjustments (Column 1)
As discussed in section V.A. of the
preamble of this final rule, this column
includes the hospital update, including the
4.1 percent market basket update reduced by
the 0.3 percentage point for the productivity
adjustment. In addition, as discussed in
section II.D. of the preamble of this final rule,
this column includes the FY 2023 +0.5
percentage point adjustment required under
section 414 of the MACRA. As a result, we
are making a 4.3 percent update to the
national standardized amount. This column
also includes the update to the hospitalspecific rates which includes the 4.1 percent
market basket update reduced by the 0.3
percentage point for the productivity
adjustment. As a result, we are making a 3.8
percent update to the hospital-specific rates.
Overall, hospitals will experience a 4.2
percent increase in payments primarily due
to the combined effects of the hospital update
to the national standardized amount and the
hospital update to the hospital-specific rate.
Hospitals that are paid under the hospitalspecific rate will experience a 3.8 percent
increase in payments; therefore, hospital
categories containing hospitals paid under
the hospital-specific rate will experience a
lower than average increase in payments.
b. Effects of the Changes to the MS–DRG
Reclassifications and Relative Cost-Based
Weights With Recalibration Budget
Neutrality (Column 2)
Column 2 shows the effects of the changes
to the MS–DRGs and relative weights with
the application of the recalibration budget
neutrality factor to the standardized amounts.
Section 1886(d)(4)(C)(i) of the Act requires us
annually to make appropriate classification
changes in order to reflect changes in
treatment patterns, technology, and any other
factors that may change the relative use of
hospital resources. Consistent with section
1886(d)(4)(C)(iii) of the Act, we calculated a
recalibration budget neutrality factor to
account for the changes in MS–DRGs and
relative weights to ensure that the overall
payment impact is budget neutral. As
discussed in section VIII.B.3.b. of the
preamble of this final rule, we are also
establishing a permanent 10-percent cap on
the reduction in a MS–DRG’s relative weight
in a given year and an associated
recalibration cap budget neutrality factor to
account for the 10-percent cap on relative
weight reductions to ensure that the overall
payment impact is budget neutral.
As discussed in section II.E. of the
preamble of this final rule, the FY 2023 MS–
DRG relative weights will be 100 percent
cost-based and 100 percent MS–DRGs. For
FY 2023, we are calculating the MS–DRGs
using the FY 2021 MedPAR data grouped to
the Version 40 (FY 2023) MS–DRGs. The
reclassification changes to the GROUPER are
described in more detail in section II.D. of
the preamble of this final rule.
The ‘‘All Hospitals’’ line in Column 2
indicates that changes due to the MS–DRGs
and relative weights will result in a 0.0
percent change in payments with the
application of the recalibration budget
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
neutrality factor of 1.000509 and the
recalibration cap budget neutrality factor of
0.999764 to the standardized amount.
c. Effects of the Wage Index Changes
(Column 3)
Column 3 shows the impact of the updated
wage data, with the application of the wage
budget neutrality factor. The wage index is
calculated and assigned to hospitals on the
basis of the labor market area in which the
hospital is located. Under section
1886(d)(3)(E) of the Act, beginning with FY
2005, we delineate hospital labor market
areas based on the Core Based Statistical
Areas (CBSAs) established by OMB. The
current statistical standards used in FY 2023
are based on OMB standards published on
February 28, 2013 (75 FR 37246 and 37252),
and 2010 Decennial Census data (OMB
Bulletin No. 13–01), as updated in OMB
Bulletin Nos. 15–01, 17–01, 18–04, and 20–
01. (We refer readers to the FY 2015 IPPS/
LTCH PPS final rule (79 FR 49951 through
49963) for a full discussion on our adoption
of the OMB labor market area delineations,
based on the 2010 Decennial Census data,
effective beginning with the FY 2015 IPPS
wage index; to the FY 2017 IPPS/LTCH PPS
final rule (81 FR 56913) for a discussion of
our adoption of the CBSA updates in OMB
Bulletin No. 15–01, which were effective
beginning with the FY 2017 wage index; to
the FY 2020 IPPS/LTCH PPS final rule (83 FR
41362) for a discussion of our adoption of the
CBSA update in OMB Bulletin No. 17–01 for
the FY 2020 wage index; to the FY 2021
IPPS/LTCH PPS final rule (85 FR 58743
through 58755) for a discussion of our
adoption of the CBSA update in OMB
Bulletin No. 18–04 for the FY 2021 wage
index; and to the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45163) for a discussion of
our adoption of the CBSA update in OMB
Bulletin No. 20–01 for the FY 2022 wage
index.)
Section 1886(d)(3)(E) of the Act requires
that, beginning October 1, 1993, we annually
update the wage data used to calculate the
wage index. In accordance with this
requirement, the wage index for acute care
hospitals for FY 2023 is based on data
submitted for hospital cost reporting periods,
beginning on or after October 1, 2018 and
before October 1, 2019. The estimated impact
of the updated wage data and the OMB labor
market area delineations on hospital
payments is isolated in Column 3 by holding
the other payment parameters constant in
this simulation. That is, Column 3 shows the
percentage change in payments when going
from a model using the FY 2022 wage index,
the labor-related share of 67.6 percent, under
the OMB delineations and having a 100percent occupational mix adjustment
applied, to a model using the FY 2023 prereclassification wage index with the laborrelated share of 67.6 percent, under the OMB
delineations, also having a 100-percent
occupational mix adjustment applied, while
holding other payment parameters, such as
use of the Version 40 MS–DRG GROUPER
constant. The FY 2023 occupational mix
adjustment is based on the CY 2019
occupational mix survey.
PO 00000
Frm 00686
Fmt 4701
Sfmt 4700
In addition, the column shows the impact
of the application of the wage budget
neutrality to the national standardized
amount. In FY 2010, we began calculating
separate wage budget neutrality and
recalibration budget neutrality factors, in
accordance with section 1886(d)(3)(E) of the
Act, which specifies that budget neutrality to
account for wage index changes or updates
made under that subparagraph must be made
without regard to the 62 percent labor-related
share guaranteed under section
1886(d)(3)(E)(ii) of the Act. Therefore, for FY
2023, as proposed, we are calculating the
wage budget neutrality factor to ensure that
payments under updated wage data and the
labor-related share of 67.6 percent are budget
neutral, without regard to the lower laborrelated share of 62 percent applied to
hospitals with a wage index less than or
equal to 1.0. In other words, the wage budget
neutrality is calculated under the assumption
that all hospitals receive the higher laborrelated share of the standardized amount.
The FY 2023 wage budget neutrality factor is
1.000968 and the overall payment change is
0 percent.
Column 3 shows the impacts of updating
the wage data. Overall, the new wage data
and the labor-related share, combined with
the wage budget neutrality adjustment, will
lead to no change for all hospitals, as shown
in Column 3.
In looking at the wage data itself, the
national average hourly wage will increase
2.7 percent compared to FY 2022. Therefore,
the only manner in which to maintain or
exceed the previous year’s wage index was to
match or exceed the 2.7 percent increase in
the national average hourly wage. Of the
3,117 hospitals with wage data for both FYs
2022 and 2023, 1,427 or 45.8 percent will
experience an average hourly wage increase
of 2.7 percent or more.
The following table compares the shifts in
wage index values for hospitals due to
changes in the average hourly wage data for
FY 2023 relative to FY 2022. These figures
reflect changes in the ‘‘pre-reclassified,
occupational mix-adjusted wage index,’’ that
is, the wage index before the application of
geographic reclassification, the rural floor,
the out-migration adjustment, and other wage
index exceptions and adjustments. We note
that the ‘‘post-reclassified wage index’’ or
‘‘payment wage index,’’ which is the wage
index that includes all such exceptions and
adjustments (as reflected in Tables 2 and 3
associated with this final rule) is used to
adjust the labor-related share of a hospital’s
standardized amount, either 67.6 percent or
62 percent, depending upon whether a
hospital’s wage index is greater than 1.0 or
less than or equal to 1.0. Therefore, the prereclassified wage index figures in the
following table may illustrate a somewhat
larger or smaller change than will occur in
a hospital’s payment wage index and total
payment.
The following table shows the projected
impact of changes in the area wage index
values for urban and rural hospitals.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
33 established the rural floor by requiring
that the wage index for a hospital in any
urban area cannot be less than the wage
index applicable to hospitals located in rural
areas in the same state. We apply a uniform
budget neutrality adjustment to the wage
index. Column 5 shows the effects of the
rural floor.
The Affordable Care Act requires that we
apply one rural floor budget neutrality factor
to the wage index nationally. We have
calculated an FY 2023 rural floor budget
neutrality factor to be applied to the wage
index of 0.991909, which would reduce wage
indexes by 0.8 percent.
Column 5 shows the projected impact of
the rural floor with the national rural floor
budget neutrality factor applied to the wage
index based on the OMB labor market area
delineations. The column compares the postreclassification FY 2023 wage index of
providers before the rural floor adjustment
and the post-reclassification FY 2023 wage
index of providers with the rural floor
adjustment based on the OMB labor market
area delineations. Only urban hospitals can
benefit from the rural floor. Because the
provision is budget neutral, all other
hospitals that do not receive an increase to
their wage index from the rural floor
adjustment (that is, all rural hospitals and
those urban hospitals to which the
adjustment is not made) would experience a
decrease in payments due to the budget
neutrality adjustment that is applied to the
wage index nationally. (As discussed in
section III.G.1. of the preamble of this final
rule, based on the district court’s decision in
Citrus, we calculated the rural floor for FY
2023 including the wage data of hospitals
that have reclassified as rural under
§ 412.103.)
We estimate that 275 hospitals will receive
the rural floor in FY 2023. All IPPS hospitals
in our model will have their wage indexes
reduced by the rural floor budget neutrality
adjustment of 0.991909. We project that, in
aggregate, rural hospitals will experience a
0.2 percent decrease in payments as a result
of the application of the rural floor budget
neutrality because the rural hospitals do not
benefit from the rural floor, but have their
wage indexes downwardly adjusted to ensure
that the application of the rural floor is
budget neutral overall. We project that, in the
aggregate, hospitals located in urban areas
will experience no change in payments
because increases in payments to hospitals
benefitting from the rural floor offset
decreases in payments to nonrural floor
urban hospitals whose wage index is
PO 00000
Frm 00687
Fmt 4701
Sfmt 4700
downwardly adjusted by the rural floor
budget neutrality factor. Urban hospitals in
the New England region would experience a
3.8 percent increase in payments primarily
due to the application of the rural floor in
Massachusetts.
f. Effects of the Application of the Imputed
Floor, Frontier State Wage Index and OutMigration Adjustment (Column 6)
This column shows the combined effects of
the application of the following: (1) the
imputed floor under section
1886(d)(3)(E)(iv)(I) and (II) of the Act, which
provides that for discharges occurring on or
after October 1, 2021, the area wage index
applicable to any hospital in an all-urban
State may not be less than the minimum area
wage index for the fiscal year for hospitals in
that State established using the methodology
described in § 412.64(h)(4)(vi) as in effect for
FY 2018; (2) section 10324(a) of the
Affordable Care Act, which requires that we
establish a minimum post-reclassified wage
index of 1.00 for all hospitals located in
‘‘frontier States;’’ and (3) the effects of section
1886(d)(13) of the Act, as added by section
505 of Public Law 108–173, which provides
for an increase in the wage index for
hospitals located in certain counties that
have a relatively high percentage of hospital
employees who reside in the county, but
work in a different area with a higher wage
index.
These three wage index provisions are not
budget neutral and will increase payments
overall by 0.3 percent compared to the
provisions not being in effect.
Section 1886(d)(3)(E)(iv)(III) of the Act
provides that the imputed floor wage index
for all-urban States shall not be applied in a
budget neutral manner. Therefore, the
imputed floor adjustment is estimated to
increase IPPS operating payments by
approximately $124 million. There are an
estimated 66 providers in Connecticut,
Delaware, Washington DC, New Jersey, and
Rhode Island that will receive the imputed
floor wage index.
The term ‘‘frontier States’’ is defined in the
statute as States in which at least 50 percent
of counties have a population density less
than 6 persons per square mile. Based on
these criteria, 5 States (Montana, Nevada,
North Dakota, South Dakota, and Wyoming)
are considered frontier States and an
estimated 44 hospitals located in Montana,
North Dakota, South Dakota, and Wyoming
would receive a frontier wage index of
1.0000. We note, the rural floor for Nevada
exceeds the frontier state wage index of 1.000
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.231
Number of Hospitals
Urban
Rural
2
0
24
0
2,330
706
48
7
0
0
1
0
FY 2023 Percenta2e Chan2e in Area Wa2e Index Values
Increase 10 percent or more
Increase greater than or equal to 5 percent and less than 10 percent
Increase or decrease less than 5 percent
Decrease greater than or equal to 5 percent and less than 10 percent
Decrease 10 percent or more
Unchanged
d. Effects of MGCRB Reclassifications
(Column 4)
Our impact analysis to this point has
assumed acute care hospitals are paid on the
basis of their actual geographic location (with
the exception of ongoing policies that
provide that certain hospitals receive
payments on bases other than where they are
geographically located). The changes in
Column 4 reflect the per case payment
impact of moving from this baseline to a
simulation incorporating the MGCRB
decisions for FY 2023.
By spring of each year, the MGCRB makes
reclassification determinations that will be
effective for the next fiscal year, which
begins on October 1. The MGCRB may
approve a hospital’s reclassification request
for the purpose of using another area’s wage
index value. Hospitals may appeal denials by
the MGCRB of reclassification requests to the
CMS Administrator. Further, hospitals have
45 days from the date the IPPS proposed rule
is issued in the Federal Register to decide
whether to withdraw or terminate an
approved geographic reclassification for the
following year (we refer readers to the
discussion of our clarification of this policy
in section III.I.2. of the preamble of this final
rule.)
The overall effect of geographic
reclassification is required by section
1886(d)(8)(D) of the Act to be budget neutral.
Therefore, for purposes of this impact
analysis, as proposed, we are applying an
adjustment of 0.984399 to ensure that the
effects of the reclassifications under sections
1886(d)(8)(B) and (C) and 1886(d)(10) of the
Act are budget neutral (section II.A. of the
Addendum to this final rule).
Geographic reclassification generally
benefits hospitals in rural areas. We estimate
that the geographic reclassification will
increase payments to rural hospitals by an
average of 1.0 percent. By region, most rural
hospital categories will experience increases
in payments due to MGCRB reclassifications.
Table 2 listed in section VI. of the
Addendum to this final rule and available via
the internet on the CMS website reflects the
reclassifications for FY 2023.
e. Effects of the Rural Floor, Including
Application of National Budget Neutrality
(Column 5)
As discussed in section III.B. of the
preamble of the FY 2009 IPPS final rule, the
FY 2010 IPPS/RY 2010 LTCH PPS final rule,
the FYs 2011 through 2022 IPPS/LTCH PPS
final rules, and this FY 2023 IPPS/LTCH PPS
final rule, section 4410 of Public Law 105–
49465
49466
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
and therefore no hospitals in Nevada receive
the frontier state wage index. Overall, this
provision is not budget neutral and is
estimated to increase IPPS operating
payments by approximately $71 million.
In addition, section 1886(d)(13) of the Act
provides for an increase in the wage index for
hospitals located in certain counties that
have a relatively high percentage of hospital
employees who reside in the county, but
work in a different area with a higher wage
index. Hospitals located in counties that
qualify for the payment adjustment will
receive an increase in the wage index that is
equal to a weighted average of the difference
between the wage index of the resident
county, post-reclassification and the higher
wage index work area(s), weighted by the
overall percentage of workers who are
employed in an area with a higher wage
index. There are an estimated 210 providers
that will receive the out-migration wage
adjustment in FY 2023. This out-migration
wage adjustment is not budget neutral, and
we estimate the impact of these providers
receiving the out-migration increase will be
approximately $53 million.
g. Effects of the Expiration of MDH Special
Payment Status (Column 7)
Column 7 shows our estimate of the
changes in payments due to the expiration of
MDH status, a nonbudget neutral payment
provision. Section 50205 of the Bipartisan
Budget Act of 2018 (Pub. L. 115–123, enacted
on February 9, 2018) extended the MDH
program (which, under previous law, was to
be in effect for discharges before October 1,
2017 only) for discharges occurring on or
after October 1, 2017, through FY 2022 (that
is, for discharges occurring on or before
September 30, 2022). Therefore, under
current law, the MDH program will expire at
the end of FY 2022. Hospitals that qualified
to be MDHs receive the higher of payments
made based on the Federal rate or the
payments made based on the Federal rate
amount plus 75 percent of the difference
between payments based on the Federal rate
and payments based on the hospital-specific
rate (a hospital-specific cost-based rate).
Because this provision was not budget
neutral, the expiration of this payment
provision results in a 0.2 percent decrease in
payments overall. There are currently 173
MDHs, of which we estimate 91 would have
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
been paid under the blended payment of the
Federal rate and hospital-specific rate if the
MDH program had not expired. Because
those 91 MDHs will no longer receive the
blended payment and will be paid only
under the Federal rate in FY 2023, it is
estimated that those hospitals would
experience an overall decrease in payments
of approximately $180 million.
h. Effects of All FY 2022 Changes (Column
8)
Column 8 shows our estimate of the
changes in payments per discharge from FY
2022 and FY 2023, resulting from all changes
reflected in this rule for FY 2023. It includes
combined effects of the year-to-year change
of the previous columns in the table.
The average increase in payments under
the IPPS for all hospitals is approximately 2.6
percent for FY 2023 relative to FY 2022 and
for this row is primarily driven by the
changes reflected in Column 1. Column 8
includes the annual hospital update of 3.8
percent to the national standardized amount.
This annual hospital update includes the 4.1
percent market basket update reduced by the
0.3 percentage point productivity adjustment.
As discussed in section II.D. of the preamble
of this final rule, this column also includes
the +0.5 percentage point adjustment
required under section 414 of the MACRA.
Hospitals paid under the hospital-specific
rate would receive a 3.8 percent hospital
update. As described in Column 1, the
annual hospital update with the +0.5 percent
adjustment for hospitals paid under the
national standardized amount, combined
with the annual hospital update for hospitals
paid under the hospital-specific rates,
combined with the other adjustments
described previously and shown in Table I,
will result in a 2.6 percent increase in
payments in FY 2023 relative to FY 2022.
This column also reflects the estimated
effect of outlier payments returning to their
targeted levels in FY 2023 as compared to the
estimated outlier payments for FY 2022
produced from our payment simulation
model. As discussed in section II.A.4.j. of the
Addendum to this final rule, the statute
requires that outlier payments for any year
are projected to be not less than 5 percent nor
more than 6 percent of total operating DRG
payments plus outlier payments, and also
requires that the average standardized
PO 00000
Frm 00688
Fmt 4701
Sfmt 4700
amount be reduced by a factor to account for
the estimated proportion of total DRG
payments made to outlier cases. As proposed,
we are continuing to use a 5.1 percent target
(or an outlier offset factor of 0.949) in
calculating the outlier offset to the
standardized amount, just as we did for FY
2022. Therefore, our estimate of payments
per discharge for FY 2023 from our payment
simulation model reflects this 5.1 percent
outlier payment target. Our payment
simulation model shows that estimated
outlier payments for FY 2022 exceed that
target by approximately 1.7 percent.
Therefore, our estimate of the changes in
payments per discharge from FY 2022 and
FY 2023 in Column 8 reflects the estimated
-1.7 percent change in outlier payments
produced by our payment simulation model
when returning to the 5.1 percent outlier
target for FY 2023. There are also interactive
effects among the various factors comprising
the payment system that we are not able to
isolate, which may contribute to our estimate
of the changes in payments per discharge
from FY 2022 and FY 2023 in Column 8.
Overall payments to hospitals paid under
the IPPS due to the applicable percentage
increase and proposed changes to policies
related to MS–DRGs, geographic adjustments,
and outliers are estimated to increase by 2.6
percent for FY 2023. Hospitals in urban areas
will experience a 2.6 percent increase in
payments per discharge in FY 2023
compared to FY 2022. Hospital payments per
discharge in rural areas are estimated to
increase by 2.4 percent in FY 2023.
3. Impact Analysis of Table II
Table II presents the projected impact of
the changes for FY 2023 for urban and rural
hospitals and for the different categories of
hospitals shown in Table I. It compares the
estimated average payments per discharge for
FY 2022 with the estimated average
payments per discharge for FY 2023, as
calculated under our models. Therefore, this
table presents, in terms of the average dollar
amounts paid per discharge, the combined
effects of the changes presented in Table I.
The estimated percentage changes shown in
the last column of Table II equal the
estimated percentage changes in average
payments per discharge from Column 8 of
Table I.
E:\FR\FM\10AUR2.SGM
10AUR2
49467
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE 11.--IMPACT ANALYSIS OF CHANGES FOR FY 2023 ACUTE CARE
HOSPITAL OPERATING PROSPECTIVE PAYMENT SYSTEM
(PAYMENTS PER DISCHARGE)
FY2022
FY2023
Number of
Hospitals
Payment Per
Discharge
Payment Per
Discharge
Changes
(I)
(2)
(3)
(4)
All Hospitals
Bv Geo!!raphic Location:
Urban hospitals
Rural hospitals
Bed Size (Urban):
0-99 beds
100-199 beds
200-299 beds
300-499 beds
500 or more beds
Bed Size (Rural):
0-49 beds
50-99 beds
100-149 beds
150-199 beds
200 or more beds
Urban bv Re!!ion:
New England
Middle Atlantic
East North Central
West North Central
South Atlantic
East South Central
West South Central
Mountain
Pacific
Puerto Rico
Rural bv Re!!ion:
New England
Middle Atlantic
East North Central
West North Central
South Atlantic
East South Central
West South Central
Mountain
Pacific
Bv Pavment Classification:
Urban hospitals
Rural areas
Teachin!! Status:
Nonteaching
Fewer than 100 residents
100 or more residents
UrbanDSH:
Non-DSH
100 or more beds
Less than 100 beds
RuralDSH:
Non-DSH
SCH
RRC
100 or more beds
Less than 100 beds
Urban teachin!! and DSH:
Both teaching and DSH
Teaching and no DSH
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00689
Estimated
Average
Fmt 4701
FY2023
3,142
15,064
15,453
2.6
2,420
722
15,450
11,264
15,852
11,530
2.6
2.4
653
700
411
409
245
11,638
12,336
13,921
15,259
19,035
11,761
12,693
14,345
15,677
19,492
1.1
2.9
3
2.7
2.4
358
201
84
46
33
9 656
10,973
10,930
12,354
12,935
9,743
11,118
11,312
12,740
13,372
0.9
1.3
3.5
3.1
3.4
107
295
373
156
402
140
362
176
359
50
16,943
18,132
14,666
14,816
13,341
12,824
13 506
15,343
19,835
9,110
17,480
18,590
15,001
15,140
13,659
13,147
13,915
15,965
20,305
9,461
3.2
2.5
2.3
2.2
2.4
2.5
3
4.1
2.4
3.8
19
49
113
86
109
141
134
47
24
16,103
11,001
11,471
11,804
10,381
10,144
9,730
13,126
15,534
16,125
11,281
11,487
12,144
10,759
10,464
10,002
13,500
16,066
0.1
2.5
0.1
2.9
3.6
3.2
2.8
2.8
3.4
1,861
1,281
14,338
15,990
14,700
16,414
2.5
2.7
1,939
929
274
11,851
13,898
21.998
12,156
14,266
22.553
2.6
2.6
2.5
369
1,129
363
12 491
14,828
10,749
12,782
15,205
11,039
2.3
2.5
2.7
105
264
674
22
216
14,163
12,442
16,726
13,264
9,297
14,405
12,911
17,198
13,279
8,921
1.7
3.8
2.8
0.1
-4
663
60
16,060
14 060
16,456
14,345
2.5
2
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.232
khammond on DSKJM1Z7X2PROD with RULES2
Estimated
Average
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Number of
Hospitals
Estimated
Average
FY2022
Payment Per
Discharge
Estimated
Average
FY 2023
Payment Per
Discharge
(1)
(2)
(3)
No teaching and DSH
No teaching and no DSH
Special Hospital Tvpes:
RRC
RRC with Section 401 Rural Reclassification
SCH
SCH with Section 401 Rural Reclassification
SCHandRRC
SCH and RRC with Section 401 Rural Reclassification
Tvpe of Ownership:
Voluntarv
Proprietarv
Government
Medicare Utilization as a Percent oflnpatient Davs:
0-25
25-50
50-65
Over65
Medicaid Utilization as a Percent oflnpatient Davs:
0-25
25-50
50-65
Over65
Hospitals with 5% or more of cases that reported
experiencine: homelessness
FY 2023 Reclassifications:
All Reclassified Hospitals
Non-Reclassified Hospitals
Urban Hospitals Reclassified
Urban Nonreclassified Hospitals
Rural Hospitals Reclassified Full Year
Rural Non-Reclassified Hospitals Full Year
All Section 401 Reclassified Hospitals:
Other Reclassified Hospitals (Section 1886(d)(8)(B))
khammond on DSKJM1Z7X2PROD with RULES2
H. Effects of Other Policy Changes
In addition to those policy changes
discussed previously that we are able to
model using our IPPS payment simulation
model, we are making various other changes
in this final rule. As noted in section I.D. of
this Appendix A, our payment simulation
model uses the most recent available claims
data to estimate the impacts on payments per
case of certain changes in this final rule.
Generally, we have limited or no specific
data available with which to estimate the
impacts of these changes using that payment
simulation model. For those changes, we
have attempted to predict the payment
impacts based upon our experience and other
more limited data. Our estimates of the likely
impacts associated with these other changes
are discussed in this section.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
829
309
12,077
11,689
12,409
11,983
2.7
2.5
148
470
256
47
122
39
11,620
17,565
11,626
14,462
13,174
15,623
11,848
18,057
12,045
15,009
13,637
16,137
2
2.8
3.6
3.8
3.5
3.3
1,915
789
438
15,141
13,173
17,122
15,515
13,613
17,540
2.5
3.3
2.4
790
2,072
225
30
17,643
14,501
12,154
9,588
18,155
14,858
12,496
9,614
2.9
2.5
2.8
0.3
2,082
942
94
24
13,649
17,466
20,166
21,038
13,980
17,949
20,872
21,971
2.4
2.8
3.5
4.4
45
19,202
19,952
3.9
1,004
2,138
840
1,594
282
426
615
56
15,971
14,291
16,472
14,488
11,381
11,120
17,132
10,488
16,418
14,631
16,913
14,851
11,697
11,328
17,590
10,554
2.8
2.4
2.7
2.5
2.8
1.9
2.7
0.6
1. Effects of Policy Changes Relating to New
Medical Service and Technology Add-On
Payments
a. FY 2023 Status of Technologies Approved
for FY 2022 New Technology Add-On
Payments
As discussed in section II.F.5.a. of the
preamble of this final rule, we are continuing
new technology add-on payments in FY 2023
for the 15 technologies that are still within
their newness period. Under § 412.88(a)(2),
the new technology add-on payment for each
case involving use of an approved technology
would be limited to the lesser of: (1) 65
percent of the costs of the new technology (or
75 percent of the costs for technologies
designated as Qualified Infectious Disease
Products (QIDPs) or approved under the
Limited Population Pathway for Antibacterial
and Antifungal Drugs (LPAD) pathway); or
(2) 65 percent of the amount by which the
PO 00000
Frm 00690
Fmt 4701
FY2023
Changes
(4)
Sfmt 4700
costs of the case exceed the standard MS–
DRG payment for the case (or 75 percent of
the amount for technologies designated as
QIDPs or approved under the LPAD
pathway). Because it is difficult to predict the
actual new technology add-on payment for
each case, the estimated total payments in
this final rule are based on the applicant’s
estimated cost and volume projections at the
time they submitted their original application
(unless the applicant provided updated
figures in a public comment) and the
assumption that every claim that would
qualify for a new technology add-on payment
would receive the maximum add-on
payment.
In the following table, we present
estimated total payments for the 15
technologies for which we are continuing to
make new technology add-on payments in
FY 2023:
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.233
49468
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49469
FY 2023 Estimates for Technologies Approved for New Technology Add-On Payments in FY 2022
FY2023NTAP
Amount (65 % or
Estimated Total FY
Estimated
Technology Name
75%)
2023 Impact
Cases
RvbrevantTM
349
$6,405.89
$2,235,655.61
Cosela™
435
$5,612.10
$2,441,263.50
ABECMA®
484
$289,532.75
$140,133,851.00
StrataGraft®
261
$44,200.00
$11,536,200.00
TECARTUS®
15
$259,350.00
$3,890,250.00
VEKLURY®
174,996
$2,028.00
$354,891,888.00
ZepzelcaTM
778
$9,145.50
$7,115,199.00
aprevo® lntervertebral Body Fusion Device
1,261
$40,950.00
$51,637,950.00
aScope® Duodeno
3,750
$1,296.75
$4,862,812.50
Caption Guidance™
2,592
$1,868.10
$4,842,115.20
HarmonyTM Transcatheter Pulmonary Valve
$26,975.00
(TPV) System
171
$4,612,725.00
Intercept®
2,296
$2,535.00
$5,820,360.00
ShockWave C2 Intravascular Lithotripsy (IVL)
$3,666.00
System
3,760
$13,784,160.00
Fetroia® rHABPN ABP)
379
$8,579.84
$3,251,759.36
Recarbrio™ (HABPNABP)
$9,576.51
$8,887,001.28
928
A11:11:regate Estimated Total FY 2023 Impact
$619,943,190.45
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
As discussed in section II.F.7. of the
preamble of this final rule, under the
alternative pathway for new technology addon payments, new technologies that are
medical products with a QIDP designation,
approved through the FDA LPAD pathway,
or are part of the Breakthrough Device
program will be considered not substantially
similar to an existing technology for purposes
of the new technology add-on payment under
the IPPS, and will not need to demonstrate
that the technology represents a substantial
clinical improvement. These technologies
must still be within the 2–3 year newness
period, as discussed in II.F.1.a.(1) of this final
rule, and must also still meet the cost
criterion.
As fully discussed in section II.F.7. of the
preamble of this final rule, we are approving
or conditionally approving 6 alternative
pathway applications for FY 2023 new
PO 00000
Frm 00691
Fmt 4701
Sfmt 4700
technology add-on payments, including 5
technologies that received a Breakthrough
Device designation from FDA and 1 that was
designated as a QIDP by FDA. Based on
information from the applicants at the time
of the final rule, we estimate that total
payments for the 6 technologies approved
under the alternative pathway will be
approximately $88.45 million for FY 2023.
Total estimated FY 2023 payments for new
technologies that are designated as a QIDP
are approximately $33.9 million, and total
estimated FY 2023 payments for new
technologies that are part of the Breakthrough
Device program are approximately $54.6
million.
In the following table, we present detailed
estimates for the six technologies for which
we are approving new technology add-on
payments under the alternative pathway in
FY 2023:
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.234
khammond on DSKJM1Z7X2PROD with RULES2
b. FY 2023 Applications for New Technology
Add-On Payments
In sections II.F.6. and 7. of the preamble to
this final rule, we discussed 11 technologies
for which we received applications for new
technology add-on payments for FY 2023. We
noted that of the 37 applications (19
alternative and 18 traditional) we received,
23 applicants withdrew their application (11
alternative and 12 traditional) prior to the
issuance of this final rule, and 3 technologies
(2 alternative and 1 traditional) did not meet
the July 1 deadline for FDA approval or
clearance of the technology and were
therefore ineligible for consideration for new
technology add-on payments for FY 2023. As
explained in the preamble to this final rule,
add-on payments for new medical services
and technologies under section 1886(d)(5)(K)
of the Act are not required to be budget
neutral.
49470
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
FY 2023 Estimates for New Technology Add-On Payments for Technologies under the Alternative Pathway
for FY 2023
FY2023NTAP
Pathway (QIDP,
Amount(65 %
Estimated Total FY
LPAD,or
Estimated
2023 Impact
Breakthrou2:h Device)
or 75 %)
Technolo2:v Name
Cases
Cerament® G
GORE TAG Thoracic
Branch Endoprosthesis
iFuse Bedrock Granite
Implant System
Thoraflex Hybrid
Device
ViviStim
DefenCath
Breakthrough Device
Breakthrough Device
1610
386
$4,918.55
$27,807.00
$7,918,865.50
$10,733,502.00
Breakthrough Device
1,480
$9,828.00
$14,545,440.00
Breakthrough Device
800
$22,750.00
$18,200,000.00
Breakthrough Device
QIDP
135
7726
$23,400.00
$4,387.50
$3,159,000.00
$33,897,825.00
Estimated Total FY 2023
Impact
$88,454,632.50
As fully discussed in section II.F.6. of the
preamble of this final rule, we are approving
three technologies that applied under the
traditional pathway for new technology addon payments for FY 2023, and providing new
technology add-on payments for one
application that is substantially similar to a
current NTAP-approved technology. Based
on information from the applicants at the
time of rulemaking, we estimate that total
payments for the four technologies for which
we are making new technology add-on
payments is approximately $75.16 million for
FY 2023.
In the following table, we present detailed
estimates for the four technologies for which
we are providing new technology add-on
payments under the traditional pathway in
FY 2023:
FY 2023 Estimates for New Technolo2:v Add-On Pavments for Technolo2:ies under the Traditional Pathway for FY 2023
Estimated
FY 2023 NTAP Amount
Estimated Total FY 2023
(65 % or 75 %)
Impact
Technolo2:v Name
Cases
Carvykti™
DARZALEX FASPRO®
Hemolung Respiratory Assist System (RAS)
LivtencityTM
241
25
161
129.5
$289,532.75
$5,159.41
$6,500.00
$32,500.00
$69,777,392.75
$128,985.19
$1,046,500.00
$4,208,750.00
A2:2:regate Estimated Total FY 2023 Impact
c. Total Estimated Costs for NTAP in FY 2023
In the following table, we present summary
estimates for all technologies approved for
$75,161,627.94
new technology add-on payments for FY
2023:
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
of 75 percent of what formerly would have
been paid as Medicare DSH payments (Factor
1), reduced to reflect changes in the
percentage of uninsured individuals and any
additional statutory adjustment (Factor 2), is
available to make additional payments to
each hospital that qualifies for Medicare DSH
payments and that has uncompensated care.
Each hospital eligible for Medicare DSH
PO 00000
Frm 00692
Fmt 4701
Sfmt 4700
payments will receive an additional payment
based on its estimated share of the total
amount of uncompensated care for all
hospitals eligible for Medicare DSH
payments. The uncompensated care payment
methodology has redistributive effects based
on the proportion of a hospital’s amount of
uncompensated care relative to the aggregate
amount of uncompensated care for all
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.236
As discussed in section IV.D. of the
preamble of this final rule, under section
3133 of the Affordable Care Act, hospitals
that are eligible to receive Medicare DSH
payments will receive 25 percent of the
amount they previously would have received
under the statutory formula for Medicare
DSH payments under section 1886(d)(5)(F) of
the Act. The remainder, equal to an estimate
$783,559,450.89
ER10AU22.235
khammond on DSKJM1Z7X2PROD with RULES2
Al!l!re2:ate Estimated Total FY 2023 Impact
ER10AU22.237
FY 2023 Estimates for New Technolo2:v Add-On Payments for FY 2023
Estimated Total FY 2023
Category
Impact
Technologies Continuing New Technology Add-on Payments in FY 2023
$619,943,190.45
Alternative Pathway Applications
$88,454,632.50
Traditional Pathway Applications
$75,161,627.94
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
hospitals eligible for Medicare DSH
payments (Factor 3). The change to Medicare
DSH payments under section 3133 of the
Affordable Care Act is not budget neutral.
In this final rule, we are establishing the
amount to be distributed as uncompensated
care payments to DSH eligible hospitals,
which for FY 2023 is $6,874,403,459.42. This
figure represents 75 percent of the amount
that otherwise would have been paid for
Medicare DSH payment adjustments adjusted
by a Factor 2 of 65.71 percent. For FY 2022,
the amount available to be distributed for
uncompensated care was $7,192,008,709.70
or 75 percent of the amount that otherwise
would have been paid for Medicare DSH
payment adjustments adjusted by a Factor 2
of 68.57 percent. In addition, under the new
supplemental payment for Indian Health
Service (IHS) and Tribal Hospitals and Puerto
Rico Hospitals, which we are establishing in
this final rule, these hospitals will receive
approximately $96.3 million in supplemental
payments, as determined based on the
difference between each hospital’s FY 2022
UCP (reduced by negative 4.4 percent, which
is the projected change between the FY 2023
total uncompensated care payment amount
and the total uncompensated care payment
amount for FY 2022) and its FY 2023 UCP
as calculated using the methodology adopted
in this final rule for FY 2023. For this final
rule, the total uncompensated care payments
and supplemental payments equal
approximately $6.971 billion. For FY 2023,
we are using 2 years of data on
uncompensated care costs from Worksheet
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
S–10 of the FY 2018 and 2019 cost reports
to calculate Factor 3 for all DSH-eligible
hospitals, including IHS/Tribal hospitals and
Puerto Rico hospitals. For a complete
discussion of the methodology for calculating
Factor 3 for FY 2023 and the methodology for
calculating the new supplemental payments,
we refer readers to sections IV.D. and IV.E.
of the preamble of this final rule.
To estimate the impact of the combined
effect of the changes in Factors 1 and 2, as
well as the changes to the data used in
determining Factor 3, on the calculation of
Medicare uncompensated care payments
along with the new supplemental payment
for Puerto Rico hospitals and IHS and Tribal
hospitals, which we are establishing using
our authority under section 1886(d)(5)(I) of
the Act, we compared total uncompensated
care payments estimated in the FY 2022
IPPS/LTCH PPS final rule to the combined
total of uncompensated care payments and
supplemental payments estimated in this FY
2023 IPPS/LTCH PPS final rule. For FY 2022,
we calculated 75 percent of the estimated
amount that would be paid as Medicare DSH
payments absent section 3133 of the
Affordable Care Act, adjusted by a Factor 2
of 68.57 percent and multiplied by a Factor
3 calculated using the methodology
described in the FY 2022 IPPS/LTCH PPS
final rule. For FY 2023, we calculated 75
percent of the estimated amount that would
be paid as Medicare DSH payments during
FY 2023 absent section 3133 of the
Affordable Care Act, adjusted by a Factor 2
of 65.71 percent and multiplied by a Factor
PO 00000
Frm 00693
Fmt 4701
Sfmt 4700
49471
3 calculated using the methodology
described previously. For the supplemental
payments for IHS/Tribal hospitals and Puerto
Rico hospitals, we calculated the difference
between the hospital’s adjusted base year
amount (as determined based on the
hospital’s FY 2022 uncompensated care
payment) and the hospital’s FY 2023
uncompensated care payment.
Our analysis included 2,368 hospitals that
are projected to be eligible for DSH in FY
2023. It did not include hospitals that had
terminated their participation in the
Medicare program as of June 3, 2022,
Maryland hospitals, new hospitals, and SCHs
that are expected to be paid based on their
hospital-specific rates. The 26 hospitals that
are anticipated to be participating in the
Rural Community Hospital Demonstration
Program were excluded from this analysis, as
participating hospitals are not eligible to
receive empirically justified Medicare DSH
payments and uncompensated care
payments. In addition, the data from merged
or acquired hospitals were combined under
the surviving hospital’s CMS certification
number (CCN), and the non-surviving CCN
was excluded from the analysis. The
estimated impact of the changes in Factors 1,
2, and 3 on uncompensated care payments
and of establishing the new supplemental
payment for IHS/Tribal hospitals and Puerto
Rico hospitals across all hospitals projected
to be eligible for DSH payments in FY 2023,
by hospital characteristic, is presented in the
following table:
E:\FR\FM\10AUR2.SGM
10AUR2
49472
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Modeled Uncompensated Care Payments* and Supplemental Payments for Estimated FY 2023 DSHs
by Hospital Type
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
FY 2023 Uncompensated
Care Payments and
Supplemental Payments**
($ in millions)
Dollar
Difference:
FY 2022FY 2023
($ in
millions)
(1)
(2)
(3)
(4)
Percent
Change**
*
(5)
2,368
$7,192
$6,971
-$221
-3.08%
1,920
1,004
916
448
6,789
4,146
2,643
403
6,592
4,073
2,519
379
-197
-73
-124
-24
-2.90
-1.77
-4.69
-6.00
363
780
777
284
1,532
4,974
265
1,492
4,835
-19
-39
-139
-6.55
-2.57
-2.80
346
90
12
219
136
47
206
127
45
-13
-9
-2
-5.81
-6.81
-4.52
87
236
315
104
322
126
236
135
316
43
186
819
800
354
1,759
439
1,434
299
607
93
175
765
762
357
1,713
428
1,401
292
611
87
-11
-54
-38
4
-45
-10
-32
-7
3
-6
-5.91
-6.58
-4.76
1.03
-2.58
-2.38
-2.26
-2.35
0.52
-6.24
7
21
66
15
12
43
11
12
43
-3
0
-1
-23.03
-3.76
-1.81
PO 00000
Frm 00694
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.238
khammond on DSKJM1Z7X2PROD with RULES2
Total
By Geographic Location
Urban Hospitals
Large Urban Areas
Other Urban Areas
Rural Hospitals
Bed Size (Urban)
0 to 99 Beds
100 to 249 Beds
250+ Beds
Bed Size (Rural)
0 to 99 Beds
I 00 to 249 Beds
250+ Beds
Urban by Region
New England
Middle Atlantic
South Atlantic
East North Central
East South Central
West North Central
West South Central
Mountain
Pacific
Puerto Rico
Rural bv Re2ion
New England
Middle Atlantic
South Atlantic
Number of
Estimated
DSHs
FY 2022 Final
Rule Estimated
Uncompensated
Care Payments
($ in millions)
49473
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Modeled Uncompensated Care Payments* and Supplemental Payments for Estimated FY 2023 DSHs
by Hospital Type
Number of
Estimated
DSHs
(1)
FY 2022 Final
Rule Estimated
Uncompensated
Care Payments
($ in millions)
(2)
23
117
5
88
14
5
FY 2023 Uncompensated
Care Payments and
Supplemental Payments**
($ in millions)
Dollar
Difference:
FY 2022FY2023
($ in
millions)
(3)
(4)
East North Central
27
East South Central
77
116
West North Central
West South Central
105
Mountain
23
Pacific
6
By Payment Classification
Urban Hospitals
1,457
4,482
831
2,950
Large Urban Areas
Other Urban Areas
626
1,532
Rural Hospitals
911
2,710
Teachin2 Status
Nonteaching
1,320
1,961
Fewer than 100 residents
779
2,486
100 or more residents
269
2,746
Type of Ownership
Voluntarv
1,478
4,102
Proprietarv
530
1 017
Government
360
2,073
Medicare Utilization
Percent****
0 to 25
694
3,434
25 to 50
1,553
3,685
111
50 to 65
70
Greater than 65
2
9
Medicaid Utilization
Percent****
0 to 25
1,378
$3,346
25 to 50
3,092
866
674
50 to 65
100
Greater than 65
24
81
Source: Dobson I Davanzo analysis of2018 and 2019 Hospital Cost Reports.
Percent
Change**
*
(5)
25
107
81
81
14
6
2
-10
-4
-7
-1
1
8.09
-8.74
-4.95
-8.51
-4.59
24.45
4,372
2,913
1,459
2,599
-110
-37
-73
-111
-2.46
-1.27
-4.76
-4.10
1,906
2,426
2,639
-55
-60
-106
-2.82
-2.40
-3.88
4,022
992
1,956
-80
-24
-117
-1.95
-2.37
-5.65
3,334
3,566
70
2
-101
-120
0
0
-2.94
-3.25
-0.38
-23.82
3,262
3,019
603
86
-84
-73
-71
5
-2.50
-2.35
-10.49
6.67
The changes in projected FY 2023
uncompensated care payments and
supplemental payments compared to the
total uncompensated care payments in FY
2022 are driven by a decrease in Factor 1 and
a decrease in Factor 2 and the establishment
of a new supplemental payment for DSHeligible IHS/Tribal hospitals and Puerto Rico
hospitals. Factor 1 has decreased from the FY
2022 final rule’s Factor 1 of $10.489 billion
to this final rule’s Factor 1 of $10.461 billion,
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
while the percent change in the percent of
individuals who are uninsured (Factor 2) has
decreased from 68.57 percent to 65.71
percent. In addition, we note that there is a
slight increase in the number of projected
DSHs to 2,368 at the time of the development
for this final rule compared to the projected
2,365 DSHs in the FY 2022 IPPS/LTCH PPS
correction notice (86 FR 58034). Based on the
changes, the impact analysis found that,
across all projected DSH eligible hospitals,
PO 00000
Frm 00695
Fmt 4701
Sfmt 4700
FY 2023 uncompensated care payments and
supplemental payments are estimated at
approximately $6.971 billion, or a decrease of
approximately 3.08 percent from FY 2022
uncompensated care payments
(approximately $7.192 billion). While these
changes will result in a net decrease in the
total amount available to be distributed in
uncompensated care payments and
supplemental payments, the projected
payment decreases vary by hospital type.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.239
khammond on DSKJM1Z7X2PROD with RULES2
*Dollar uncompensated care payments calculated by [0.75 * estimated section 1886(d)(5)(F) payments* Factor 2 * Factor 3].
When summed across all hospitals projected to receive DSH payments, uncompensated care payments are estimated to be $7,192
million in FY 2022 and uncompensated care payments and supplemental payments are estimated to be $6,971 million in FY
2023.
** For IRS/Tribal hospitals and Puerto Rico hospitals, this impact table reflects the supplemental payments.
*** Percentage change is determined as the difference between Medicare uncompensated care payments and supplemental
payments modeled for this FY 2023 IPPS/LTCH PPS final rule (column 3) and Medicare uncompensated care payments modeled
for the FY 2022 IPPS/L TCH PPS final rule correction notice (column 2) divided by Medicare uncompensated care payments
modeled for the FY 2022 IPPS/L TCH PPS final rule correction notice (column 2) times 100 percent.
****Hospitals with missing or unknown Medicare utilization or Medicaid utilization are not shown in the table.
khammond on DSKJM1Z7X2PROD with RULES2
49474
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
This redistribution of payments is caused by
changes in Factor 3 and the establishment the
new supplemental payment for DSH-eligible
IHS/Tribal hospitals and Puerto Rico
hospitals. As seen in the previous table, a
percent change of less than negative 3.08
percent indicates that hospitals within the
specified category are projected to experience
a larger decrease in payments, on average,
compared to the universe of projected FY
2023 DSH hospitals. Conversely, a percent
change greater than negative 3.08 percent
indicates that a hospital type is projected to
have a smaller decrease in payments or an
increase compared to the overall average. The
variation in the distribution of overall
payments by hospital characteristic is largely
dependent on a given hospital’s
uncompensated care costs as reported on the
Worksheet S–10 and used in the Factor 3
computation and whether the hospital is
eligible to receive the new supplemental
payment.
Rural hospitals, in general, are projected to
experience larger decreases in
uncompensated care payments and
supplemental payments compared to their
uncompensated care payments in FY 2022,
than their urban counterparts. Overall, rural
hospitals are projected to receive a 6.00
percent decrease in payments, which is a
greater decrease than the overall hospital
average, while urban hospitals are projected
to receive a 2.90 percent decrease in
payments, which is a slightly smaller
decrease than the overall hospital average.
By bed size, larger rural hospitals are
projected to receive the smallest decreases in
uncompensated care payments and
supplemental payments among rural
hospitals. Rural hospitals with 250+ beds are
projected to receive a 4.52 percent payment
decrease, and rural hospitals with 100–249
beds are projected to receive a 6.81 percent
decrease. Smaller rural hospitals with 0–99
beds are projected to receive a 5.81 percent
payment decrease. Among urban hospitals,
the smallest hospitals, those with 0–99 beds,
are projected to receive a 6.55 percent
decrease in payments, which is a greater
decrease than the overall hospital average. In
contrast, urban hospitals with 100–249 beds
and those with 250+ beds are projected to
receive decreases in payments of 2.57 and
2.80 percent, respectively, which are smaller
decreases than the overall hospital average.
By region, rural hospitals are generally
expected to receive larger than average
decreases in uncompensated care payments
and supplemental payments in most regions.
The exceptions are rural hospitals in the
South Atlantic Region, which are projected to
receive a smaller than average decrease of
1.81 percent in payments and rural hospitals
in the East North Central Region and the
Pacific Region, which are projected to receive
payment increases of 8.09 and 24.45 percent,
respectively. Regionally, urban hospitals are
projected to receive a more varied range of
payment changes. Urban hospitals in the
New England, Middle Atlantic, and South
Atlantic Regions, as well as hospitals in
Puerto Rico, are projected to receive larger
than average decreases in payments. Urban
hospitals in the East South Central, West
North Central, West South Central, and
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Mountain Regions are projected to receive
smaller than average decreases in payments.
Urban hospitals in the East North Central and
Pacific Regions are projected to receive
increases in average payments of 1.03 percent
and 0.52 percent, respectively.
By payment classification, although
hospitals in urban payment areas overall are
expected to receive a 2.46 percent decrease
in uncompensated care payments and
supplemental payments, hospitals in large
urban payment areas are expected to see a
decrease in payments of 1.27 percent, while
hospitals in other urban payment areas are
projected to receive the largest decrease of
4.76 percent. Hospitals in rural payment
areas are expected to receive a decrease in
payments of 4.10 percent.
Nonteaching hospitals are projected to
receive a payment decrease of 2.82 percent,
teaching hospitals with fewer than 100
residents are projected to receive a decrease
of 2.40 percent, and teaching hospitals with
100+ residents have a projected payment
decrease of 3.88 percent. Proprietary and
voluntary hospitals are projected to receive
smaller than average decreases of 2.37 and
1.95 percent respectively, while government
hospitals are expected to receive a larger than
average payment decrease of 5.65 percent.
Hospitals with less than 25 percent Medicare
utilization and hospitals with 50 to 65
percent Medicare utilization are projected to
receive smaller than average payment
decreases of 2.94 and 0.38 percent,
respectively, while hospitals with 25–50
percent and hospitals with greater than 65
percent Medicare utilization are projected to
receive larger than average payment
decreases of 3.25 and 23.82 percent,
respectively. All hospitals with less than 50
percent Medicaid utilization are projected to
receive smaller decreases in uncompensated
care payments and supplemental payments
than the overall hospital average percent
change, while hospitals with 50–65 percent
Medicaid utilization are projected to receive
larger than average decreases of 10.49
percent. Hospitals with greater than 65
percent Medicaid utilization are projected to
receive an increase of 6.67 percent.
The previous impact table reflects the total
combined uncompensated care payments and
supplemental payments modeled for FY 2023
for IHS/Tribal and Puerto Rico hospitals. In
FY 2023, IHS/Tribal hospitals’ and Puerto
Rico hospitals’ aggregate uncompensated care
payments are estimated to decrease by
approximately $103 million while the
aggregate supplemental payments to these
hospitals are estimated to be approximately
$96 million, a net decrease of approximately
$7 million. This difference is primarily
attributable to the change in the estimated
amount available for uncompensated care
payments in FY 2023 and estimated changes
in DSH status. We refer readers to the
discussion of the methodology for calculating
the new supplemental payments in sections
IV.E. of the preamble of this final rule. For
the estimated impacts on individual IHS/
Tribal hospitals and Puerto Rico hospitals,
we refer readers to the IPPS Payment Impact
File, which can be found on the FY 2023
IPPS final rule home page on the CMS
website at https://www.cms.gov/Medicare/
PO 00000
Frm 00696
Fmt 4701
Sfmt 4700
Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/. We note that
the amounts for this final rule differ from the
proposed rule amounts primarily due to
updated estimates of the amount available for
uncompensated care payments for FY 2023.
3. Effects of Changes to Low-Volume Hospital
Payment Adjustment Policy
In section V.C. of the preamble of this final
rule, we discuss the expiration of the
temporary changes to the low-volume
hospital payment policy originally provided
for by the Affordable Care Act and extended
through FY 2022 by subsequent legislation.
Effective for FY 2023 and subsequent years,
in order to qualify as a low-volume hospital,
a subsection (d) hospital must be more than
25 road miles from another subsection (d)
hospital and have less than 200 discharges
(that is, less than 200 discharges total,
including both Medicare and non-Medicare
discharges) during the fiscal year. Based
upon the best available data at this time, we
estimate the expiration of the temporary
changes to the low-volume hospital payment
policy will decrease aggregate low-volume
hospital payments by $437 million in FY
2023 as compared to FY 2022. These
payment estimates were determined based on
the estimated payments for the 632 providers
that are expected to no longer qualify under
the criteria that will apply in FY 2023, and
were calculated using the same methodology
used in developing the quantitative analyses
of changes in payments per case discussed
previously in section I.G. of this Appendix A.
4. Effects of Reductions Under the Hospital
Readmissions Reduction Program for FY
2023
In section V.H of the preamble of this final
rule, we discuss our policies for the FY 2023
Hospital Readmissions Reduction Program.
This program requires a reduction to a
hospital’s base operating MS–DRG payment
to account for excess readmissions of
selected applicable conditions and
procedures. The table and analysis in this
final rule illustrate the estimated financial
impact of the Hospital Readmissions
Reduction Program payment adjustment
methodology by hospital characteristics. In
the proposed rule, for the purpose of
modeling the estimated FY 2023 payment
adjustment factors that account for the
suppression of the pneumonia readmission
measure, we used the data from the FY 2022
Hospital Readmissions Reduction Program
for the five non-suppressed measures (acute
myocardial infarction—AMI, heart failure—
HF, chronic obstructive pulmonary disease—
COPD, coronary artery bypass graft—CABG,
and total hip arthroplasty/total knee
arthroplasty—THA/TKA) and the FY 2022
Hospital IPPS Proposed Rule Impact File to
analyze results by hospital characteristics. In
this final rule, we are updating the estimated
financial impact using the estimated payment
adjustment factors from the FY 2023 Hospital
Readmissions Reduction Program and the FY
2023 Hospital IPPS Proposed Rule Impact
File to analyze results by hospital
characteristics.
Hospitals are sorted into quintiles based on
the proportion of dual-eligible stays among
Medicare fee-for-service (FFS) and managed
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
care stays between July 1, 2018 and
December 1, 2019 and July 1, 2020 through
June 30, 2021 (that is, the data period used
for the FY 2023 Hospital Readmissions
Reduction Program). Hospitals’ excess
readmission ratios (ERRs) are assessed
relative to their peer group median and a
neutrality modifier is applied in the payment
adjustment factor calculation to maintain
budget neutrality. In this final rule, we are
providing an updated estimate of the
financial impact using the proportion of
dually-eligible beneficiaries, ERRs, and
aggregate payments for each condition/
procedure and all discharges for applicable
hospitals from the FY 2023 Hospital
Readmissions Reduction Program applicable
period. We note that for the FY 2023
applicable period, we will only be assessing
data from July 1, 2018 through December 1,
2019 and from July 1, 2020 through June 30,
2021 due to the COVID–19 public health
emergency (PHE) nationwide Extraordinary
Circumstance Exception (ECE) which
excluded data from January 1, 2020 through
June 30, 2020 from the Hospital
Readmissions Reduction Program
calculations.1169
khammond on DSKJM1Z7X2PROD with RULES2
1169 Although the FY 2023 performance period is
July 1, 2018 through June 30, 2021, first and second
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
The results in the table include 2,849 nonMaryland hospitals eligible to receive a
penalty during the performance period.
Hospitals are eligible to receive a penalty if
they have 25 or more eligible discharges for
at least one measure between July 1, 2018
through December 1, 2019 and July 1, 2020
through June 30, 2021. The second column
in the table indicates the total number of
non-Maryland hospitals with available data
for each characteristic that have an estimated
payment adjustment factor less than 1 (that
is, penalized hospitals).
The third column in the table indicates the
percentage of penalized hospitals among
those eligible to receive a penalty by hospital
characteristic. For example, 74.85 percent of
eligible hospitals characterized as nonteaching hospitals are expected to be
quarter data from CY 2020 is excluded from
program calculations due to the nationwide ECE
that was granted in response to the COVID–19 PHE.
Taking into consideration the 30-day window to
identify readmissions, the period for calculating
MS–DRG payments will be adjusted to July 1, 2018
through December 1, 2019 and then July 1, 2020
through June 30, 2021. Taking into consideration
the 30-day window to identify readmissions, the
period for identifying index stays will be adjusted
to July 1, 2018 through December 1, 2019 and July
1, 2020 through June 30, 2021.
PO 00000
Frm 00697
Fmt 4701
Sfmt 4700
49475
penalized. Among teaching hospitals, 86.77
percent of eligible hospitals with fewer than
100 residents and 88.06 percent of eligible
hospitals with 100 or more residents are
expected to be penalized.
The fourth column in the table estimates
the financial impact on hospitals by hospital
characteristic. The table shows the share of
penalties as a percentage of all base operating
DRG payments for hospitals with each
characteristic. This is calculated as the sum
of penalties for all hospitals with that
characteristic over the sum of all base
operating DRG payments for those hospitals
between October 1, 2020 through September
30, 2021 (FY 2021). For example, the penalty
as a share of payments for non-teaching
hospitals is 0.47 percent. This means that
total penalties for all non-teaching hospitals
are 0.47 percent of total payments for nonteaching hospitals. Measuring the financial
impact on hospitals as a percentage of total
base operating MS–DRG payments accounts
for differences in the amount of base
operating MS–DRG payments for hospitals
with the characteristic when comparing the
financial impact of the program on different
groups of hospitals.
E:\FR\FM\10AUR2.SGM
10AUR2
49476
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Source: The table results are based on the estimated FY 2023 payment adjustment factors of open, non-Maryland,
subsection (d) hospitals. The estimated FY 2023 payment adjustment factors are based on discharges between July 1,
2018 to December 1, 2019 and July 1, 2020 to June 30, 2021 (the FY 2023 Hospital Readmissions Reduction Program
performance period). Although data from all subsection (d) and Mary land hospitals are used in calculations of each
hospital's ERR, this table does not include results for Maryland hospitals and hospitals that are not open as of the
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00698
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.240
khammond on DSKJM1Z7X2PROD with RULES2
Estimated Percentage of Hospitals Penalized and Penalty as Share of Payments for FY
2023 Hospital Readmissions Reduction Proe:ram bv Hospital Characteristic
Percentage of Penalty as a
Number of Number of
Hospitals
Share of
Penalized Icl
Paymentsldl
Eligible
Penalized
Hospitalslal Hospitals lb I
(%)
Hospital Characteristic
(%)
All Hospitals
2,849
2,273
0.42
79.78
By Geoe:raphic Location (n=2,847)
2,175
1,789
82.25
0.42
Urban hospitals
1-99 beds
492
320
65.04
0.48
100-199 beds
643
547
85.07
0.48
200-299 beds
403
344
85.36
0.45
300-399 beds
279
255
91.40
0.46
400-499 beds
121
0.42
109
90.08
500 or more beds
237
214
90.30
0.34
Rural hospitals
482
0.44
672
71.73
1-49 beds
300
180
60.00
0.35
50-99 beds
210
155
73.81
0.48
100-149 beds
85
74
87.06
0.41
150-199 beds
41
92.68
38
0.48
200 or more beds
97.22
0.44
36
35
By Teachine: Statusl•l (n=2,847)
Non-teaching
1,702
1,274
74.85
0.47
Fewer than 100 residents
877
761
86.77
0.43
100 or more residents
268
236
88.06
0.35
By Ownership Type (n=2,846)
Government
293
390
75.13
0.35
Proorietarv
674
525
77.89
0.58
Voluntarv
1,782
1,453
81.54
0.40
By Safety-net Statuslfl (n=2,847)
Safety-net hospitals
551
442
80.22
0.31
Non-safety-net hospitals
2,296
1,829
79.66
0.45
By Disproportionate Share Hospital (DSH) Patient Percenta11:elgJ (n= 2,847)
0-24
1,136
869
76.50
0.50
25-49
1,410
1,165
82.62
0.39
50-64
181
149
82.32
0.31
65 and over
120
88
73.33
0.22
By Medicare Cost Report (MCR) Percentagelh,iJ (n= 2,842)
0-24
533
424
79.55
0.33
25-49
2,005
1,618
80.70
0.43
50-64
277
211
0.62
76.17
65 and over
27
15
55.56
0.48
By Ree:ion (n=2,849)
New England
124
110
88.71
0.62
Middle Atlantic
321
278
86.60
0.43
East North Central
462
368
79.65
0.46
West North Central
232
168
72.41
0.22
South Atlantic
481
417
86.69
0.49
East South Central
246
202
82.11
0.47
West South Central
430
337
78.37
0.39
Mountain
210
134
63.81
0.36
Pacific
343
259
75.51
0.29
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49477
October 2022 public reporting open hospital list because these hospitals are not eligible for a penalty under the
program. Hospitals are sorted into quintiles based on the proportion of Medicare FFS and managed care dual-eligible
stays for the multi-year performance period. Hospital characteristics are from the FY 2023 Hospital IPPS proposed
rule Impact File.
As discussed in the FY 2022 IPPS/L TCH PPS final rule, CMS will not use claims data representing quarter ( Q) 1 and Q2 2020 in
its calculations for the Hospital Readmissions Reduction Program (86 FR 45260 - 45261 ). The readmission measures
used in the Hospital Readmissions Reduction Program identify readmissions within 30 days of each index stay;
therefore, the performance period for the Hospital Readmissions Reduction Program will also not use claims data
representing the 30 days before January 1, 2020. The FY 2023 performance period for HRRP is July 1, 2018, to
December 1, 2019, and July 1, 2020, to June 30, 2021, so that no claims from Ql and Q2 2020 are used in the measure
or program calculations. As finalized in the FY 2022 IPPS/LTCH PPS final rule, the pneumonia readmission measure
is suppressed from FY 2023 Hospital Readmissions Reduction Program payment reduction calculations due to the
COVID-19 PHE's substantial impact on this measure (86 FR 45254-45256). The pneumonia measure results do not
contribute to FY 2023 Hospital Readmissions Reduction Program calculations.
• This column is the number of applicable hospitals within the characteristic that are eligible for a penalty (that is, they have 25
or more eligible discharges for at least one measure).
b This column is the number of applicable hospitals that are penalized (that is, they have 25 or more eligible discharges for at
least one measure and an estimated payment adjustment factor less than 1) within the characteristic.
c This column is the percentage of applicable hospitals that are penalized among hospitals that are eligible to receive a penalty by
characteristic.
d This column is calculated as the sum of all penalties for the group of hospitals with that characteristic divided by total base
operating MS-DRG payments for all those hospitals. MedPAR data from October 1, 2020 through September 31, 2021
(FY 2021) are used to calculate the total base operating MS-DRG payments.
• The total number of hospitals with hospital characteristics data may not add up to the total number of hospitals because not all
hospitals have data for all characteristics. Not all hospitals had data for geographic location, teaching status, safety-net
status, and DSH patient percentage (n=2,847; missing=2 for each), ownership type (n=2,846; missing=3), or MCR
percentage (n=2,842; missing=?).
r A hospital is considered a teaching hospital if it has an Indirect Medical Education adjustment factor for Operation PPS
(TCHOP) greater than zero.
g A hospital is considered a safety-net hospital if it is in the top DSH quintile.
h DSH patient percentage is the sum of the percentage of Medicare inpatient days attributable to patients eligible for both
Medicare Part A and Supplemental Security Income (SSI), and the percentage of total inpatient days attributable to
patients eligible for Medicaid but not Medicare Part A.
percent is the percentage of total inpatient stays from Medicare patients.
5. Effects of Changes Under the FY 2023
Hospital Value-Based Purchasing (VBP)
Program
In section V.I. of the preamble of this final
rule, we discuss the Hospital VBP Program
under which the Secretary makes valuebased incentive payments to hospitals based
on their performance on measures during the
performance period with respect to a fiscal
year. We are finalizing our proposals to
suppress the Hospital Consumer Assessment
of Healthcare Providers and Systems
(HCAHPS) survey and five HealthcareAssociated Infection (HAI) measures, as well
as to change the scoring and payment
methodologies for the FY 2023 program year,
such that hospitals would receive a valuebased incentive payment percentage that
results in a value-based incentive payment
amount that is equal to the applicable
percentage (2 percent). Specifically, we are
finalizing our proposal such that we would
calculate the measure rates for all of the
measures we have selected for the FY 2023
program year, but we would not generate
achievement or improvement points for any
of the measures we are finalizing for
suppression. Additionally, we are finalizing
our proposal to not award domain scores for
the Person and Community Engagement and
Safety domains. We are also not awarding
hospitals a Total Performance Score (TPS),
and will instead award hospitals a payment
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
incentive multiplier that results in a valuebased incentive payment amount that is
equal to the amount withheld for the fiscal
year (2 percent). That is, each hospital will
receive a 2-percent reduction to its base
operating DRG payment amount for each FY
2023 discharge and will then receive a valuebased incentive payment percentage that will
result in a value-based incentive payment
amount that is equal to the 2 percent
withheld. Because we are finalizing these
proposals, the impact for every hospital
under the Hospital VBP Program will be a net
percentage payment adjustment of zero.
In the FY 2023 IPPS/LTCH PPS proposed
rule, we provided the estimated impact of the
FY 2023 program because those impacts
would apply if the proposals discussed
previously were not finalized. However,
because we are finalizing the policies as
proposed, all adjustment factors for all
hospitals will reflect a net-neutral payment
adjustment for hospitals in accordance with
the finalized FY 2023 special scoring policy
at § 412.168.
6. Effects of Changes Under the HAC
Reduction Program for FY 2023
In the FY 2023 IPPS/LTCH PPS proposed
rule, we presented the estimated impact of
the FY 2023 Hospital-Acquired Condition
(HAC) Reduction Program on hospitals by
hospital characteristics in the following table.
The table in this section presents the
PO 00000
Frm 00699
Fmt 4701
Sfmt 4700
estimated proportion of hospitals in the
worst-performing quartile of Total HAC
Scores by hospital characteristic and
includes 3,119 non-Maryland hospitals that
participate in the HAC Reduction Program.
The first column presents a breakdown of
each characteristic and the second column
indicates the number of hospitals for the
respective characteristic. The third column in
the table indicates the number of hospitals
for each characteristic that would be in the
worst-performing quartile of Total HAC
Scores. The fourth column in the table
indicates the proportion of hospitals for each
characteristic that would be in the worst
performing quartile of Total HAC Scores.
In section V.J.2.b.(2). of this FY 2023 IPPS/
LTCH PPS final rule, we are finalizing our
proposal to suppress all six measures from
the HAC Reduction Program, calculate only
measure results for the HAI measures for the
FY 2023 program, and not calculate measure
scores or Total HAC Scores. Additionally, we
are not finalizing our proposal to not
calculate measure results for the CMS PSI 90
measure and thus will be calculating measure
results for purposes of public reporting for
the FY 2023 program.
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.241
khammond on DSKJM1Z7X2PROD with RULES2
i MCR
khammond on DSKJM1Z7X2PROD with RULES2
49478
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
Accordingly, since we are finalizing the
measure suppression proposal, no hospitals
will receive a payment reduction in the FY
2023 HAC Reduction Program.1170 In Table 1,
we present the estimated impact of the FY
2023 HAC Reduction Program on hospitals
by hospital characteristic for the finalized
proposal in section V.J.2.b.(2). whereby FY
2023 HAC Reduction Program measure
1170 Based on finalizing our suppression
proposals, we anticipate reduced savings to the
Medicare trust fund that is otherwise estimated at
approximately $350 million.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00700
Fmt 4701
Sfmt 4700
scores and Total HAC scores are not
calculated. Therefore, Table 1 illustrates the
number of hospitals participating in the FY
2023 HAC Reduction Program by hospital
characteristic; however, the remaining two
columns reflect values of zero because no
hospital would be in the worst-performing
quartile.
E:\FR\FM\10AUR2.SGM
10AUR2
49479
Table 1- Estimated Proportion of Hospitals in the Worst-Performing Quartile (>75th percentile) of the
Total HAC Scores for the FY 2023 HAC Reduction Program (by Hospital Characteristic)- Finalizing the
Proposal in Section V.J.2.b.(2).
Number of Hospitals in
the Worst-performing
Percent of Hospitals in the
Number of
Hospital Characteristic
Hospitals
Worst-performine: Quartileb
Quartile"
Totalc
3,119
0
0
By Geographic Location (n = 3,089)d
Urban hospitals
2,355
0
0
1-99 beds
622
0
0
100-199 beds
674
0
0
200-299 beds
416
0
0
300-399 beds
283
0
0
400-499 beds
122
0
0
500 or more beds
238
0
0
Rural hospitals
734
0
0
1-49 beds
358
0
0
50-99 beds
213
0
0
100-149 beds
86
0
0
150-199 beds
41
0
0
200 or more beds
36
0
0
By Safety-Net Status 0 (n = 3,089)
Non-safety net
2,464
0
0
Safety-net
625
0
0
By DSH Percentr (n = 3,089
0-24
1,266
0
0
25-49
1,464
0
0
50-64
201
0
0
65 and over
158
0
0
By Teaching Statusg (n =3,089)
Non-teaching
1,907
0
0
Fewer than 100 residents
912
0
0
100 or more residents
270
0
0
By Ownershiph (n = 3,088)
Voluntary
1,874
0
0
Proprietarv
754
0
0
Government
460
0
0
By MCR Percenti (n = 3,044)
0-24
643
0
0
25-49
2,070
0
0
50-64
294
0
0
65 and over
37
0
0
By Ree:ioni (n= 3,099)
New England
130
0
0
Mid-Atlantic
333
0
0
South Atlantic
507
0
0
East North Central
483
0
0
East South Central
282
0
0
West North Central
246
0
0
West South Central
500
0
0
Mountain
235
0
0
Pacific
383
0
0
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00701
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.242
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
49480
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
8. Effects of Implementation of the Rural
Community Hospital Demonstration Program
in FY 2022
7. Effects of the Changes to IME and Direct
GME Payments
a. Change to Direct GME Calculation in
Response to Decision in Milton S. Hershey
-------Medical Center et al v. Azar II
As discussed in section V.F.2. of the
preamble of this final rule, we are
implementing a modified direct GME
payment policy for all teaching hospitals.
Specifically, effective for cost reporting
periods beginning on or after October 1,
2001, for cost reports that are reopenable or
open, if the hospital’s unweighted number of
FTE residents exceeds the FTE cap, and the
number of weighted FTE residents also
exceeds that FTE cap, the respective primary
care and obstetrics and gynecology weighted
FTE counts and other weighted FTE counts
are adjusted to make the total weighted FTE
count equal the FTE cap. If the number of
weighted FTE residents does not exceed that
FTE cap, then the allowable weighted FTE
count for direct GME payment is the actual
weighted FTE count. We have estimated the
impact of this change for FY 2023 to be $170
million.
khammond on DSKJM1Z7X2PROD with RULES2
b. Effects of Allowing Medicare GME
Affiliation Agreements Within Certain Rural
Track FTE Limitations
In section V.F.4. of the preamble of this
final rule, we are finalizing a policy to allow
urban and rural hospitals that participate in
the same separately accredited 1–2 family
medicine rural track program and have rural
track FTE limitations to enter into ‘‘rural
track Medicare GME affiliation agreements’’
in order to share those cap slots, and
facilitate the cross-training of residents. In
addition, the final policy only allows urban
and rural hospitals to participate in rural
track Medicare GME affiliated groups if they
have rural track FTE limitations in place
prior to October 1, 2022. Under the final
policy, eligible urban and rural hospitals may
enter into rural track Medicare GME
affiliation agreements effective with the July
1, 2023, academic year. Because no newly
funded cap slots will be created, only
existing funded cap slots would be shared
between the participating affiliated hospitals,
there is no financial impact to this provision.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
In section V.K. of the preamble of this final
rule for FY 2023, we discussed our
implementation and budget neutrality
methodology for section 410A of Public Law
108–173, as amended by sections 3123 and
10313 of Public Law 111–148, by section
15003 of Public Law 114–255, and most
recently, by section 128 of Public Law 116–
260, which requires the Secretary to conduct
a demonstration that would modify payments
for inpatient services for up to 30 rural
hospitals.
Section 128 of Public Law 116–260
requires the Secretary to conduct the Rural
Community Hospital Demonstration for a 15year extension period (that is, for an
additional 5 years beyond the previous
extension period). In addition, the statute
provides for continued participation for all
hospitals participating in the demonstration
program as of December 30, 2019.
Section 410A(c)(2) of Public Law 108–173
requires that in conducting the
demonstration program under this section,
the Secretary shall ensure that the aggregate
payments made by the Secretary do not
exceed the amount which the Secretary
would have paid if the demonstration
program under this section was not
implemented (budget neutrality). We propose
to adopt the general methodology used in
previous years, whereby we estimated the
additional payments made by the program for
each of the participating hospitals as a result
of the demonstration, and then adjusted the
national IPPS rates by an amount sufficient
to account for the added costs of this
demonstration. In other words, we have
applied budget neutrality across the payment
system as a whole rather than across the
participants of this demonstration. The
language of the statutory budget neutrality
requirement permits the agency to implement
the budget neutrality provision in this
manner. The statutory language requires that
aggregate payments made by the Secretary do
not exceed the amount which the Secretary
would have paid if the demonstration was
not implemented, but does not identify the
PO 00000
Frm 00702
Fmt 4701
Sfmt 4700
range across which aggregate payments must
be held equal.
For this final rule, the resulting amount
applicable to FY 2023 is $72,449,896, which
we are including in the budget neutrality
offset adjustment for FY 2023. This estimated
amount is based on the specific assumptions
regarding the data sources used, that is,
recently available ‘‘as submitted’’ cost reports
and historical and currently finalized update
factors for cost and payment.
In previous years, we have incorporated a
second component into the budget neutrality
offset amounts identified in the final IPPS
rules. As finalized cost reports became
available, we determined the amount by
which the actual costs of the demonstration
for an earlier, given year differed from the
estimated costs for the demonstration set
forth in the final IPPS rule for the
corresponding fiscal year, and we
incorporated that amount into the budget
neutrality offset amount for the upcoming
fiscal year. We have calculated this
difference for FYs 2005 through 2016
between the actual costs of the demonstration
as determined from finalized cost reports
once available, and estimated costs of the
demonstration as identified in the applicable
IPPS final rules for these years.
With the extension of the demonstration
for another 5-year period, as authorized by
section 128 of Public Law 116–260, we will
continue this general procedure. At the time
of the FY 2023 proposed rule, all of the
finalized cost reports are available for the 17
hospitals that completed cost report periods
beginning in FY 2017 under the
demonstration payment methodology; these
cost reports show the actual costs of the
demonstration for this fiscal year to be
$35,989,928. We note that the FY 2017 IPPS
final rule included no budget neutrality offset
amount for that fiscal year. The final rule for
FY 2017 preceded the re-authorization of the
demonstration under the Cures Act.
Anticipating that the demonstration would
end in 2016, we projected no demonstration
cost estimate for the upcoming fiscal year, FY
2017, while we stated that we would
continue to reconcile actual costs when all
finalized cost reports for previous fiscal years
under the demonstration became available
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.243
Source: FY 2023 HAC Reduction Program final rule results are based on CDC NHSN HAI results from January I, 2021 through December 31,
2021. Hospital Characteristics are based on the FY 2023 Proposed Rule Impact File.
• This column is the number of non-Maryland hospitals with a Total HAC Score within the corresponding characteristic that are estimated to be in
the worst-performing quartile.
b This column is the percent of non-Maryland hospitals within each characteristic that are estimated to be in the worst-performing quartile. The
percentages are calculated by dividing the number of non-Maryland hospitals with a Total HAC Score in the worst-performing quartile by the
total number of non-Maryland hospitals with a Total HAC Score within that characteristic.
'The number ofnon-Maryland hospitals with a FY 2023 Total HAC Score (N = 3,119). Note that not all hospitals have data for all hospital
characteristics.
d The number of hospitals that had information for geographic location with bed size, Safety-net status, DSH percent, and teaching status (n =
3,089).
'A hospital is considered a Safety-net hospital if it is in the top quintile for DSH percent.
r The DSH patient percentage is equal to the sum of: ( 1) the percentage of Medicare inpatient days attributable to patients eligible for both
Medicare Part A and Supplemental Security Income; and (2) the percentage of total inpatient days attributable to patients eligible for Medicaid
but not Medicare Part A.
• A hospital is considered a teaching hospital if it has an IME adjustment factor for Operation PPS (TCHOP) greater than zero.
hNot all hospitals had data for Ownership (n = 3,088).
iNot all hospitals had data for MCR percent (n = 3,044).
iNot all hospitals had data for Region (n = 3,099).
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
(81 FR 57037). Thus, keeping with past
practice, for this final rule we are including
the actual costs of the demonstration as
determined from finalized cost reports for FY
2017 within the budget neutrality offset
amount for this upcoming fiscal year.
Therefore, for this FY 2023 IPPS/LTCH
PPS final rule, the budget neutrality offset
amount for FY 2023 is based on the sum of
two amounts:
• The amount representing the difference
applicable to FY 2023 between the sum of the
estimated reasonable cost amounts that
would be paid under the demonstration for
covered inpatient services to the 26 hospitals
participating in the fiscal year and the sum
of the estimated amounts that would
generally be paid if the demonstration had
not been implemented. This estimated
amount is $72,449,896.
• The amount by which the actual costs of
the demonstration in FY 2017 (as shown by
finalized cost reports from that fiscal year)
differ from the amount determined for FY
2017. Since no budget neutrality offset was
conducted in FY 2017, the amount of this
difference is the actual cost amount for FY
2017 $35,989,928.
We are thus subtracting the sum of these
amounts ($108,439,824) from the national
IPPS rates for FY 2023.
9. Effects of Continued Implementation of the
Frontier Community Health Integration
Project (FCHIP) Demonstration
In section VIIB.2. of the preamble of this
final rule we discuss the implementation of
the FCHIP Demonstration, which allows
eligible entities to develop and test new
models for the delivery of health care
services in eligible counties in order to
improve access to and better integrate the
delivery of acute care, extended care, and
other health care services to Medicare
beneficiaries in no more than four States.
Section 123 of Public Law 110–275 initially
required a 3-year period of performance. The
FCHIP Demonstration began on August 1,
2016, and concluded on July 31, 2019
(referred to in this section as the ‘‘initial
period’’). Section 129 of the Consolidated
Appropriations Act (Pub. L. 116–159)
extended the FCHIP Demonstration by 5
years (referred to in this section as the
‘‘extension period’’ of the demonstration).
The FCHIP Demonstration resumed on
January 1, 2022 and CAHs participating in
the demonstration project during the
extension period shall begin such
participation in the cost reporting year that
begins on or after January 1. Budget
neutrality estimates for the demonstration
described in the preamble of this final rule
are based on the demonstration extension
period.
As described in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45323 through 45328),
CMS waived certain Medicare rules for CAHs
participating in the demonstration initial
period to allow for alternative reasonable
cost-based payment methods in the three
distinct intervention service areas: telehealth
services, ambulance services, and skilled
nursing facility/nursing facility services.
These waivers were implemented with the
goal of increasing access to care with no net
increase in costs. As we explained in the FY
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
2022 IPPS/LTCH PPS final rule (86 FR 45323
through 45328), 10 CAHs were selected for
participation in the demonstration initial
period. Section 129 of Public Law 116–159,
stipulates that only the 10 CAHs that
participated in the initial period of the FCHIP
Demonstration are eligible to participate
during the extension period. Among the
eligible CAHs, six elected to participate in
the extension period. The selected CAHs are
located in two states—Montana and North
Dakota—and are implementing the three
intervention services. In the FY 2022 IPPS/
LTCH PPS final rule, CMS concluded that the
initial period of the FCHIP Demonstration
had satisfied the budget neutrality
requirement described in section 123(g)(1)(B)
of Public Law 110–275. Therefore, CMS did
not apply a budget neutrality payment offset
policy for the initial period of the
demonstration. In addition, in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45323
through 45328), we finalized a policy to
address the budget neutrality requirement for
the demonstration initial period. We also
discussed this policy in the FY 2017 IPPS/
LTCH PPS final rule (81 FR 57064 through
57065), the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38294 through 38296), the FY
2019 IPPS/LTCH PPS final rule (83 FR 41516
through 41517), the FY 2020 IPPS/LTCH PPS
final rule (84 FR 42427 through 42428) and
the FY 2021 IPPS/LTCH PPS final rule (85 FR
58894 through 58996).
As explained in the FY 2022 IPPS/LTCH
PPS final rule, we based our selection of
CAHs for participation in the demonstration
with the goal of maintaining the budget
neutrality of the demonstration on its own
terms meaning that the demonstration would
produce savings from reduced transfers and
admissions to other health care providers,
offsetting any increase in Medicare payments
as a result of the demonstration. However,
because of the small size of the
demonstration and uncertainty associated
with the projected Medicare utilization and
costs, the policy we finalized for the
demonstration initial period of performance
in the FY 2022 IPPS/LTCH PPS final rule
provides a contingency plan to ensure that
the budget neutrality requirement in section
123 of Public Law 110–275 is met.
For this final rule, we are adopting the
same budget neutrality policy contingency
plan used during the demonstration initial
period to ensure that the budget neutrality
requirement in section 123 of Public Law
110–275 is met during the demonstration
extension period. If analysis of claims data
for Medicare beneficiaries receiving services
at each of the participating CAHs, as well as
from other data sources, including cost
reports for the participating CAHs, shows
that increases in Medicare payments under
the demonstration during the 5-year
extension period is not sufficiently offset by
reductions elsewhere, we will recoup the
additional expenditures attributable to the
demonstration through a reduction in
payments to all CAHs nationwide.
Under the policy finalized in the FY 2022
IPPS/LTCH PPS final rule, we adopted the
policy finalized in the FY 2017 IPPS/LTCH
PPS final rule, in the event the demonstration
initial period was found not to have been
PO 00000
Frm 00703
Fmt 4701
Sfmt 4700
49481
budget neutral, any excess costs would be
recouped over a period of 3 cost reporting
years. In the FY 2023 IPPS/LTCH PPS
proposed rule, we sought public comment on
the proposal, as we proposed to revise an
aspect of the policy finalized in the FY 2022
IPPS/LTCH PPS final rule. Our new proposed
policy is in the event the demonstration
extension period is found not to have been
budget neutral, any excess costs would be
recouped within 1 fiscal year. We believe our
new proposed policy is a more efficient
timeframe for the government to conclude
the demonstration operational requirements
(such as analyzing claims data, cost report
data and/or other data sources) to adjudicate
the budget neutrality payment recoupment
process due to any excess cost that occurred
as result of the demonstration extension
period. As explained in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45323 through
45328), because of the small scale of the
demonstration, we indicated that we did not
believe it would be feasible to implement
budget neutrality for the demonstration
initial period by reducing payments to only
the participating CAHs. Therefore, in the
event that this demonstration extension
period is found to result in aggregate
payments in excess of the amount that would
have been paid if this demonstration
extension period were not implemented, our
policy is to comply with the budget
neutrality requirement finalized in the FY
2022 IPPS/LTCH PPS final rule, by reducing
payments to all CAHs, not just those
participating in the demonstration extension
period. We stated that we believe it is
appropriate to make any payment reductions
across all CAHs because the FCHIP
Demonstration was specifically designed to
test innovations that affect delivery of
services by the CAH provider category. As we
explained in the FY 2022 IPPS/LTCH PPS
final rule, we believe that the language of the
statutory budget neutrality requirement at
section 123(g)(1)(B) of Public Law 110–275
permits the agency to implement the budget
neutrality provision in this manner. The
statutory language merely refers to ensuring
that aggregate payments made by the
Secretary do not exceed the amount which
the Secretary estimates would have been paid
if the demonstration project was not
implemented, and does not identify the range
across which aggregate payments must be
held equal.
As explained in the FY 2022 IPPS/LTCH
PPS final rule, we finalized a policy to
address the demonstration budget neutrality
methodology and analytical approach for the
initial period of the demonstration.
Therefore, for the proposed rule, we
proposed to adopt the same budget neutrality
methodology and analytical approach used
during the demonstration initial period to
ensure budget neutrality for the extension
period. While we expect to use the same
methodology that was used to assess the
budget neutrality of the FCHIP
Demonstration during initial period of the
demonstration to assess the financial impact
of the demonstration during this extension
period, upon receiving data for the extension
period, we may update and/or modify the
FCHIP budget neutrality methodology and
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49482
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
analytical approach to ensure that the full
impact of the demonstration is appropriately
captured. Therefore, we did not propose to
apply a budget neutrality payment offset to
payments to CAHs in FY 2023. This policy
will have no impact for any national payment
system for FY 2023.
10. Effects of Codification of the Costs
Incurred for Qualified and Non-Qualified
Deferred Compensation Plans
In section X.A. of the preamble of this final
rule, we set forth our provisions to codify the
costs incurred for qualified and non-qualified
deferred compensation plans. We do not
believe that there are any costs associated
with the codification of this policy.
11. Effects of Condition of Participation (CoP)
Requirements for Hospitals and CAHs To
Continue Reporting Data for COVID–19 and
Influenza After the PHE Ends as Determined
by the Secretary
Section X.B. of the preamble of this final
rule revises the hospital and CAH infection
prevention and control CoP requirements to
require hospitals and CAHs, after the
conclusion of the current COVID–19 PHE, to
continue COVID–19 and seasonal influenza
related reporting. The revisions will continue
to apply upon conclusion of the COVID–19
PHE and will continue until April 30, 2024,
unless the Secretary establishes an earlier
ending date. Reporting frequency and
requirements will be communicated to
hospitals, stakeholders, and the public
following a model similar to that which we
used to inform regulated entities at the
beginning of the COVID–19 PHE (see QSO21-03-Hospitals/CAHs at https://
www.cms.gov/files/document/qso-21-03hospitalscahs.pdf-0). As discussed in section
XII.B. of the preamble of this final rule,
Collection of Information Requirements, we
expect a burden increase of $38,204,400 or
approximately $6,162 per facility annually
for weekly reporting. We note that efforts are
underway to automate hospital and CAH
reporting that have the potential to
significantly decrease reporting burden and
improve reliability.
Comment: Commenters noted that the data
being collected for automating this type of
reporting would not generally come from a
single system, noting that for example,
clinical data might come from the EHR, bed
capacity from a bed management system, PPE
from inventory systems, and medication and
vaccination inventory from pharmacy
information. These commenters noted that
resources will vary among facilities and that
some might use a combination of manual and
automated solutions because they may not
have (or need) all of these different systems.
Commenters also emphasized the importance
of IT staff in the deployment and
maintenance of such systems. A commenter
noted that estimates are available for the
initial costs for the development of various
interfaces, ranging from $3,000 to $25,000
depending on complexity and features,
however did not cite any specific resources.
In total, the commenter indicated that the
cost for the development of the initial
software to support long-term data collection
could be as much as $250,000 depending on
the specific needs of the facility and that
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
maintenance costs to support the
infrastructure could be between 10 and 25
percent of the initial software cost, totaling
around $300,000 for a 2-year period. The
commenter noted that some of these costs
may be offset by the ability of the IT staff to
repurpose existing automated solutions, but
noted this may only be feasible in larger
hospitals with more advanced IT staff and
capabilities. Lastly, the commenter indicated
that many CAHs have a much lower capacity
to support IT innovation and are unable to
fund extensive IT departments. Therefore,
the costs for this type of innovation are likely
to be much higher.
Response: We acknowledge that there are
uncertainties in planning for future
emergencies, and we understand that there
are lots of incentives and pathways to
consider with regard to preparedness. These
comments are helpful in understanding the
actions necessary and effort involved in
tracking and investing in infrastructure to be
prepared to timely and accurately report in
the event of a future PHE declaration. We
will consider this feedback as we continue to
assess the best way to align and incentivize
preparedness, while also reducing ongoing
burden and costs on regulated entities, and
ensuring flexibility to quickly respond to
emergencies.
I. Effects of Changes in the Capital IPPS
1. General Considerations
For the impact analysis presented in this
section of the final rule, we used data from
the March 2022 update of the FY 2021
MedPAR file and the March 2022 update of
the Provider-Specific File (PSF) that was
used for payment purposes. Although the
analyses of the changes to the capital
prospective payment system do not
incorporate cost data, we used the March
2022 update of the most recently available
hospital cost report data to categorize
hospitals. Our analysis has several
qualifications and uses the best data
available, as described later in this section of
the final rule.
Due to the interdependent nature of the
IPPS, it is very difficult to precisely quantify
the impact associated with each change. In
addition, we draw upon various sources for
the data used to categorize hospitals in the
tables. In some cases (for instance, the
number of beds), there is a fair degree of
variation in the data from different sources.
We have attempted to construct these
variables with the best available sources
overall. However, it is possible that some
individual hospitals are placed in the wrong
category.
Using cases from the March 2022 update of
the FY 2021 MedPAR file, we simulated
payments under the capital IPPS for FY 2022
and the payments for FY 2023 for a
comparison of total payments per case. Shortterm, acute care hospitals not paid under the
general IPPS (for example, hospitals in
Maryland) are excluded from the
simulations.
The methodology for determining a capital
IPPS payment is set forth at § 412.312. The
basic methodology for calculating the capital
IPPS payments in FY 2023 is as follows:
(Standard Federal rate) × (DRG weight) ×
(GAF) × (COLA for hospitals located in
PO 00000
Frm 00704
Fmt 4701
Sfmt 4700
Alaska and Hawaii) × (1 + DSH adjustment
factor + IME adjustment factor, if applicable).
In addition to the other adjustments,
hospitals may receive outlier payments for
those cases that qualify under the threshold
established for each fiscal year. We modeled
payments for each hospital by multiplying
the capital Federal rate by the geographic
adjustment factor (GAF) and the hospital’s
case-mix. Then we added estimated
payments for indirect medical education,
disproportionate share, and outliers, if
applicable. For purposes of this impact
analysis, the model includes the following
assumptions:
• The capital Federal rate was updated,
beginning in FY 1996, by an analytical
framework that considers changes in the
prices associated with capital-related costs
and adjustments to account for forecast error,
changes in the case-mix index, allowable
changes in intensity, and other factors. As
discussed in section III.A.1. of the
Addendum to this final rule, the update to
the capital Federal rate is 2.5 percent for FY
2023.
• In addition to the FY 2023 update factor,
the FY 2023 capital Federal rate was
calculated based on a GAF/DRG budget
neutrality adjustment factor of 1.0012, a
budget neutrality factor for the lowest
quartile hospital wage index adjustment and
the 5-percent cap on wage index decreases
policy of 0.9972, and a outlier adjustment
factor of 0.9448.
2. Results
We used the payment simulation model
previously described in section I.I. of
Appendix A of this final rule to estimate the
potential impact of the changes for FY 2023
on total capital payments per case, using a
universe of 3,142 hospitals. As previously
described, the individual hospital payment
parameters are taken from the best available
data, including the March 2022 update of the
FY 2021 MedPAR file, the March 2022
update to the PSF, and the most recent
available cost report data from the March
2022 update of HCRIS. In Table III, we
present a comparison of estimated total
payments per case for FY 2022 and estimated
total payments per case for FY 2023 based on
the FY 2023 payment policies. Column 2
shows estimates of payments per case under
our model for FY 2022. Column 3 shows
estimates of payments per case under our
model for FY 2023. Column 4 shows the total
percentage change in payments from FY 2022
to FY 2023. The change represented in
Column 4 includes the 2.50 percent update
to the capital Federal rate and other changes
in the adjustments to the capital Federal rate.
The comparisons are provided by: (1)
geographic location; (2) region; and (3)
payment classification.
The simulation results show that, on
average, capital payments per case in FY
2023 are expected to increase 0.6 percent
compared to capital payments per case in FY
2022. This expected increase is primarily due
to the 2.50 percent update to the capital
Federal rate for FY 2023 being partially offset
by an expected decrease in capital outlier
payments. As discussed in section III.A.2. of
the Addendum to this final rule, we estimate
for FY 2023 that outlier payments for capital-
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
related PPS payments would equal 5.52
percent of inpatient capital-related payments.
Although in the FY 2022 IPPS/LTCH PPS
final rule we estimated for FY 2022 that
outlier payments for capital-related PPS
payments would equal 5.29 percent of
inpatient capital related payments, our
payment simulation model for this final rule
shows that for FY 2022, estimated outlier
payments for capital-related PPS payments
are approximately 7.16 percent of inpatient
capital-related payments. This difference in
our estimate of FY 2022 outlier payments
compared to our estimate of FY 2023 outlier
payments is reflected in the average change
in capital payments per case in FY 2023 as
compared to FY 2022. Other factors that
contribute to the expected change in average
capital payments per case in FY 2023 as
compared to FY 2022 include changes in
capital DSH payments for hospitals that
reclassify from urban to rural under
§ 412.103. In general, regional variations in
estimated capital payments per case in FY
2023 as compared to capital payments per
case in FY 2022 are primarily due to the
changes in GAFs, and are generally
consistent with the projected changes in
payments due to changes in the wage index
(and policies affecting the wage index), as
shown in Table I in section I.G. of this
Appendix A.
The net impact of these changes is an
estimated 0.6 percent increase in capital
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
payments per case from FY 2022 to FY 2023
for all hospitals (as shown in Table III).
The geographic comparison shows that, on
average, hospitals in both urban and rural
classifications will experience an increase in
capital IPPS payments per case in FY 2023
as compared to FY 2022. Capital IPPS
payments per case will increase by an
estimated 0.5 percent for hospitals in urban
areas while payments to hospitals in rural
areas will increase by 0.4 percent in FY 2022
to FY 2023.
The comparisons by region show that the
change in capital payments per case from FY
2022 to FY 2023 for urban areas range from
a 0.1 percent increase for the New England
region to a 1.6 percent increase for the
Mountain region. Meanwhile, the change in
capital payments per case from FY 2022 to
FY 2023 for rural areas range from a 0.7
percent decrease for the Mountain rural
region to a 1.2 percent increase for the East
South Central rural region. These regional
differences are primarily due to the changes
in the GAFs and estimated changes in outlier
and DSH payments.
The comparison by hospital type of
ownership (Voluntary, Proprietary, and
Government) shows that proprietary
hospitals are expected to experience the
highest increase in capital payments per case
from FY 2022 to FY 2023 of 0.9 percent.
Meanwhile, government hospitals and
voluntary hospitals are expected to
PO 00000
Frm 00705
Fmt 4701
Sfmt 4700
49483
experience an increase in capital payments
per case from FY 2022 to FY 2023 of 0.6
percent and 0.5 percent, respectively.
Section 1886(d)(10) of the Act established
the MGCRB. Hospitals may apply for
reclassification for purposes of the wage
index for FY 2023. Reclassification for wage
index purposes also affects the GAFs because
that factor is constructed from the hospital
wage index. To present the effects of the
hospitals being reclassified as of the
publication of this final rule for FY 2023, we
show the average capital payments per case
for reclassified hospitals for FY 2023. Urban
reclassified hospitals are expected to
experience an increase in capital payments of
0.3 percent; urban nonreclassified hospitals
are expected to experience an increase in
capital payments of 0.7 percent. The lower
expected increase in payments for urban
reclassified hospitals compared to urban
nonreclassified hospitals is primarily due to
estimated decreases in capital DSH payments
to urban reclassified hospitals caused by the
number of hospitals that reclassify from
urban to rural under § 412.103. Rural
reclassified hospitals are expected to
experience an increase in capital payments of
0.9 percent; rural nonreclassified hospitals
are expected to experience a decrease in
capital payments of 0.3 percent.
E:\FR\FM\10AUR2.SGM
10AUR2
49484
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
TABLE III.-- COMPARISON OF TOTAL PAYMENTS PER CASE
[FY 2022 PAYMENTS COMPARED TO FY 2023 PAYMENTS]
Change
All Hospitals
By Geographic Location:
3,142
1,086
1,092
0.6
Urban hospitals
Rural hospitals
2,420
722
1,119
764
1,125
0.5
767
0.4
653
883
884
0.1
700
411
409
941
1,035
1,105
949
1,043
1,112
0.9
0.8
500 or more beds
Bed Size (Rural):
245
1,326
1,329
0.6
0.2
0-49 beds
50-99 beds
358
201
656
731
655
734
-0.2
0.4
84
46
742
858
750
857
1.1
-0.1
Bed Size (Urban):
0-99 beds
100-199 beds
200-299 beds
300-499 beds
100-149 beds
150-199 beds
200 or more beds
33
876
885
1.0
Urban by Region:
New England
Middle Atlantic
107
295
1,196
1,253
1,197
1,259
0.1
East North Central
West North Central
373
156
1,052
1,070
1,058
1,077
South Atlantic
East South Central
402
140
982
945
986
951
0.6
0.7
0.4
West South Central
Mountain
362
176
1,031
1,115
1,035
1,133
0.6
0.4
1.6
Pacific
Puerto Rico
Rural by Region:
New England
359
50
1,455
633
1,461
642
0.4
1.4
19
1,032
1,031
-0.1
Middle Atlantic
East North Central
49
113
725
753
783
715
733
755
782
722
1.1
0.3
-0.1
723
713
732
713
851
1.2
0.0
-0.7
977
0.0
West North Central
South Atlantic
86
109
141
134
East South Central
West South Central
Mountain
Pacific
By Payment Classification:
Urban hospitals
47
24
857
977
0.5
1.0
1,861
1,080
1,087
0.6
Rural areas
Teaching Status:
1,281
1,094
1,098
0.4
Nonteaching
Fewer than 100 residents
1,939
929
904
1,025
909
1,032
0.6
274
1,471
1,476
0.7
0.3
369
970
973
0.3
100 or more residents
UrbanDSH:
Non-DSH
khammond on DSKJM1Z7X2PROD with RULES2
Average
FY 2023 Payments/Case
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
PO 00000
Frm 00706
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.244
Average
FY 2022 Payments/Case
Number of Hospitals
Average
FY 2022 Payments/Case
Number of Hospitals
100 or more beds
Less than 100 beds
RuralDSH:
1,129
363
1,112
821
1,121
824
1,012
1,019
788
1,150
918
Change
0.8
0.4
Non-DSH
SCH
105
264
RRC
100 or more beds
674
22
793
1,147
918
Less than 100 beds
Urban teaching and DSH:
Both teaching and DSH
216
647
653
0.9
0.7
-0.6
663
60
829
1,175
1,184
1,044
1,050
0.8
0.6
958
932
965
934
0.7
0.2
0.8
0.2
-0.1
-1.2
0.3
0.0
Teaching and no DSH
No teaching and DSH
No teaching and no DSH
309
Special Hospital Types:
RRC
148
RRC with section 401 Rural Reclassification
SCH
470
256
878
1,215
745
885
1,218
744
SCH with section 401 Rural Reclassification
SCHandRRC
SCH and RRC with section 401 Rural
Reclassification
Type of Ownership:
Voluntary
47
122
906
844
895
848
39
1,005
1,017
1.2
1,915
1,090
1,095
789
438
1,000
1,177
1,009
1,184
0.5
0.9
790
2,072
225
1,220
1,061
1,228
1,065
30
883
690
893
690
0.4
1.1
0.0
2,082
1,006
1,010
0.4
942
94
24
1,220
1,447
1,523
1,228
1,457
1,564
0.7
0.7
2.7
45
1,379
1,404
1.8
Proprietary
Government
Medicare Utilization as a Percent oflnpatient
Days:
0-25
25-50
50-65
Over65
Medicaid Utilization as a Percent oflnpatient
Days:
0-25
25-50
50-65
Over 65
Hospitals with 5% or more of cases that
reported experiencinl! homelessness
FY 2023 Reclassifications:
All Reclassified Hospitals
Non-Reclassified Hospitals
0.5
0.6
0.7
1,004
1,113
1,118
0.4
1,064
1,149
1,070
1,153
0.6
Urban Hospitals Reclassified
2,138
840
Urban Non-Reclassified Hospitals
1,594
1,090
1,098
282
426
615
781
741
1,175
788
739
1,178
56
754
758
Rural Hospitals Reclassified Full Year
Rural Non-Reclassified Hospitals Full Year
All section 401 Rural Reclassified Hospitals
Other Reclassified Hospitals (section
1886(d)(8)(B))
khammond on DSKJM1Z7X2PROD with RULES2
Average
FY 2023 Payments/Case
49485
J. Effects of Payment Rate Changes and
Policy Changes Under the LTCH PPS
1. Introduction and General Considerations
In section VII. of the preamble of this final
rule and section V. of the Addendum to this
final rule, we set forth the annual update to
the payment rates for the LTCH PPS for FY
2023. In the preamble of this final rule, we
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
specify the statutory authority for the
provisions that are presented, identify the
policies for FY 2023, and present rationales
for our provisions as well as alternatives that
were considered. In this section of Appendix
A to this final rule, we discuss the impact of
the changes to the payment rate, factors, and
other payment rate policies related to the
PO 00000
Frm 00707
Fmt 4701
Sfmt 4700
0.3
0.7
0.9
-0.3
0.3
0.5
LTCH PPS that are presented in the preamble
of this final rule in terms of their estimated
fiscal impact on the Medicare budget and on
LTCHs.
There are 339 LTCHs included in this
impact analysis. We note that, although there
are currently approximately 346 LTCHs, for
purposes of this impact analysis, we
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.245
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
49486
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
excluded the data of all-inclusive rate
providers consistent with the development of
the FY 2023 MS–LTC–DRG relative weights
(discussed in section VII.B.3.c. of the
preamble of this final rule). Moreover, in the
claims data used for this final rule, two of
these 339 LTCHs only have claims for site
neutral payment rate cases and, therefore, do
not affect our impact analysis for LTCH PPS
standard Federal payment rate cases.
In the impact analysis, we used the
payment rate, factors, and policies presented
in this final rule, the 3.8 percent annual
update to the LTCH PPS standard Federal
payment rate, the update to the MS–LTC–
DRG classifications and relative weights, the
update to the wage index values and laborrelated share, and the best available claims
and CCR data to estimate the change in
payments for FY 2023.
Under the dual rate LTCH PPS payment
structure, payment for LTCH discharges that
meet the criteria for exclusion from the site
neutral payment rate (that is, LTCH PPS
standard Federal payment rate cases) is based
on the LTCH PPS standard Federal payment
rate. Consistent with the statute, the site
neutral payment rate is the lower of the IPPS
comparable per diem amount as determined
under § 412.529(d)(4), including any
applicable outlier payments as specified in
§ 412.525(a), reduced by 4.6 percent for FYs
2018 through 2026; or 100 percent of the
estimated cost of the case as determined
under § 412.529(d)(2). In addition, there are
two separate high cost outlier targets—one
for LTCH PPS standard Federal payment rate
cases and one for site neutral payment rate
cases. We note that section 3711(b)(2) of the
CARES Act has provided a waiver of the
application of the site neutral payment rate
for LTCH cases admitted during the COVID–
19 PHE period. At the time of development
of this final rule, the COVID–19 PHE is still
in effect. Therefore, all LTCH PPS cases up
to this point in FY 2022 have been paid the
LTCH PPS standard Federal rate regardless of
whether the discharge met the statutory
patient criteria. Since the expiration date of
the COVID–19 PHE is not yet known, for
purposes of this impact analysis, estimates of
total LTCH PPS payments for site neutral
payment rate cases in FYs 2022 and 2023
were calculated using the site neutral
payment rate determined under § 412.522(c)
and the provisions of the CARES Act were
not considered.
Based on the best available data for the 339
LTCHs in our database that were considered
in the analyses used for this final rule, we
estimate that overall LTCH PPS payments in
FY 2023 will increase by approximately 2.4
percent (or approximately $71 million) based
on the rates and factors presented in section
VII. of the preamble and section V. of the
Addendum to this final rule.
Based on the FY 2021 LTCH cases that
were used for the analysis in this final rule,
approximately 28 percent of those cases were
classified as site neutral payment rate cases
(that is, 28 percent of LTCH cases did not
meet the statutory patient-level criteria for
exclusion from the site neutral payment rate).
Our Office of the Actuary currently estimates
that the percent of LTCH PPS cases that will
be paid at the site neutral payment rate in FY
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
2023 will not change significantly from the
most recent historical data. We estimate IPPS
comparable per diem amounts using the prior
year’s IPPS rates and factors, updated to
reflect estimated changes to the IPPS rates
and payments finalized for FY 2023. Taking
this into account along with other changes
that will apply to the site neutral payment
rate cases in FY 2023, we estimate that
aggregate LTCH PPS payments for these site
neutral payment rate cases will increase by
approximately 2.8 percent (or approximately
$9 million). This projected increase in
payments to LTCH PPS site neutral payment
rate cases is primarily due to the finalized
updates to the IPPS rates and payments
reflected in our estimate of the IPPS
comparable per diem amount, as well as an
estimated increase in costs for these cases
determined using the charge and CCR
adjustment factors described in section
V.D.3.b. of the Addendum to this final rule.
We noted, we estimate payments to site
neutral payment rate cases in FY 2023 will
represent approximately 11 percent of
estimated aggregate FY 2023 LTCH PPS
payments.
Based on the FY 2021 LTCH cases that
were used for the analysis in this final rule,
approximately 72 percent of LTCH cases will
meet the patient-level criteria for exclusion
from the site neutral payment rate in FY
2023, and will be paid based on the LTCH
PPS standard Federal payment rate for the
full year. We estimate that total LTCH PPS
payments for these LTCH PPS standard
Federal payment rate cases in FY 2023 will
increase approximately 2.3 percent (or
approximately $61 million). This estimated
increase in LTCH PPS payments for LTCH
PPS standard Federal payment rate cases in
FY 2023 is primarily due to the 3.8 percent
annual update to the LTCH PPS standard
Federal payment rate for FY 2023 and the
projected 1.2 percent decrease in high cost
outlier payments as a percentage of total
LTCH PPS standard Federal payment rate
payments, which is discussed later in this
section of the final rule.
Based on the 339 LTCHs that were
represented in the FY 2021 LTCH cases that
were used for the analyses in this final rule
presented in this Appendix, we estimate that
aggregate FY 2022 LTCH PPS payments will
be approximately $2.985 billion, as compared
to estimated aggregate FY 2023 LTCH PPS
payments of approximately $3.056 billion,
resulting in an estimated overall increase in
LTCH PPS payments of approximately $71
million. We note that the estimated $71
million increase in LTCH PPS payments in
FY 2023 does not reflect changes in LTCH
admissions or case-mix intensity, which will
also affect the overall payment effects of the
policies in this final rule.
The LTCH PPS standard Federal payment
rate for FY 2022 is $44,713.67. For FY 2023,
we are establishing an LTCH PPS standard
Federal payment rate of $46,432.77 which
reflects the 3.8 percent annual update to the
LTCH PPS standard Federal payment rate
and the budget neutrality factor for updates
to the area wage level adjustment of
1.0004304 (discussed in section V.B.6. of the
Addendum to this final rule). For LTCHs that
fail to submit data for the LTCH QRP, in
PO 00000
Frm 00708
Fmt 4701
Sfmt 4700
accordance with section 1886(m)(5)(C) of the
Act, we are establishing an LTCH PPS
standard Federal payment rate of $45,538.11.
This LTCH PPS standard Federal payment
rate reflects the updates and factors
previously described, as well as the required
2.0 percentage point reduction to the annual
update for failure to submit data under the
LTCH QRP.
Table IV shows the estimated impact for
LTCH PPS standard Federal payment rate
cases. The estimated change attributable
solely to the annual update of 3.8 percent to
the LTCH PPS standard Federal payment rate
is projected to result in an increase of 3.6
percent in payments per discharge for LTCH
PPS standard Federal payment rate cases
from FY 2022 to FY 2023, on average, for all
LTCHs (Column 6). The estimated increase of
3.6 percent shown in Column 6 of Table IV
also includes estimated payments for shortstay outlier (SSO) cases, a portion of which
are not affected by the annual update to the
LTCH PPS standard Federal payment rate, as
well as the reduction that is applied to the
annual update for LTCHs that do not submit
the required LTCH QRP data. For most
hospital categories, the projected increase in
payments based on the LTCH PPS standard
Federal payment rate to LTCH PPS standard
Federal payment rate cases also rounds to
approximately 3.6 percent.
For FY 2023, we are updating the wage
index values based on the most recent
available data (data from cost reporting
periods beginning during FY 2019 which is
the same data used for the FY 2023 IPPS
wage index). In addition, we are establishing
a labor-related share of 68.0 percent for FY
2023, based on the most recent available data
(IGI’s second quarter 2022 forecast) on the
relative importance of the labor-related share
of operating and capital costs of the 2017based LTCH market basket. We also applying
an area wage level budget neutrality factor of
1.0004304 to ensure that the changes to the
area wage level adjustment will not result in
any change in estimated aggregate LTCH PPS
payments to LTCH PPS standard Federal
payment rate cases.
For LTCH PPS standard Federal payment
rate cases, we currently estimate high cost
outlier payments as a percentage of total
LTCH PPS standard Federal payment rate
payments will decrease from FY 2022 to FY
2023. Based on the FY 2021 LTCH cases that
were used for the analyses in this final rule,
we estimate that the FY 2022 high cost
outlier threshold of $33,015 (as established in
the FY 2022 IPPS/LTCH PPS final rule) will
result in estimated high cost outlier
payments for LTCH PPS standard Federal
payment rate cases in FY 2022 that are
projected to exceed the 7.975 percent target.
Specifically, we currently estimate that high
cost outlier payments for LTCH PPS standard
Federal payment rate cases will be
approximately 9.15 percent of the estimated
total LTCH PPS standard Federal payment
rate payments in FY 2022. Combined with
our estimate that FY 2023 high cost outlier
payments for LTCH PPS standard Federal
payment rate cases will be 7.975 percent of
estimated total LTCH PPS standard Federal
payment rate payments in FY 2023, this will
result in an estimated decrease in high cost
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
outlier payments as a percentage of total
LTCH PPS standard Federal payment rate
payments of approximately 1.2 percent
between FY 2022 and FY 2023. We note that,
in calculating these estimated high cost
outlier payments, we inflated charges
reported on the FY 2021 claims by the charge
inflation factor in section V.D.3.b. of the
Addendum to this final rule. We also note
that, in calculating these estimated high cost
outlier payments, we estimated the cost of
each case by multiplying the inflated charges
by the adjusted CCRs that we determined
using our finalized methodology described in
section V.D.3.b. of the Addendum to this
final rule.
Table IV shows the estimated impact of the
payment rate and policy changes on LTCH
PPS payments for LTCH PPS standard
Federal payment rate cases for FY 2023 by
comparing estimated FY 2022 LTCH PPS
payments to estimated FY 2023 LTCH PPS
payments. (As noted earlier, our analysis
does not reflect changes in LTCH admissions
or case-mix intensity.) We note that these
impacts do not include LTCH PPS site
neutral payment rate cases for the reasons
discussed in section I.J.3. of this Appendix.
Comment: We received comments
expressing concern about the 0.7 percent
increase in payments to LTCH PPS standard
Federal payment rate cases that we projected
in the proposed rule. Many commenters
stated that this projected increase was
insufficient and failed to recognize the
impact of increases in healthcare delivery
costs on LTCHs. A commenter stated that the
inadequacy of Medicare payments would
continue to challenge the financial viability
of LTCHs and their ability to provide care to
Medicare and other patients. Another
commenter stated that this projected increase
is insufficient and would not allow LTCHs to
compete for resources needed to care for
patients.
Response: We appreciate commenters’
concerns about the proposed 0.7 percent
increase in payments to LTCH PPS standard
Federal payment rate cases. Based on the
finalized payment rates and factors in this
final rule, we now project a 2.3 percent
increase in payments to LTCH PPS standard
Federal payment rate cases for FY 2023. This
change in projected payments is primarily
being driven by the annual update factor of
3.8 percent (that is, the most recent estimate
of the LTCH PPS market basket increase of
4.1 percent less the productivity adjustment
of 0.3 percentage point) which is 1.1 percent
higher than the proposed annual update
factor. As discussed in section VIII.C.2. of the
preamble to this final rule, we believe this
LTCH market basket increase appropriately
reflects the input price growth that LTCHs
will incur while providing medical services
in FY 2023. We note that the final FY 2023
LTCH market basket growth rate of 4.1
percent is the highest market basket update
implemented in an IPPS/LTCH final rule
since RY 2004.
Comment: Multiple commenters expressed
concern about the immediate, full
implementation of the site neutral payment
policy following the end of the PHE waiver.
Several of these commenters stated their
belief that cases paid at the site neutral
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
payment rate will continue to be underpaid
as those cases, according to commenters,
have on average higher levels of clinical
complexity and costs that significantly
exceed IPPS-level payment. Some
commenters requested that CMS implement
transition policies once the PHE ends that
would phase in the full implementation of
the site neutral payment policy, believing
such a transition period would help prevent
disruptions to LTCHs’ operations. A
commenter recommended that CMS pay site
neutral cases a blended site neutral and
standard Federal payment rate during this
transition period.
Response: We acknowledge commenters’
concerns about the costs of treating site
neutral cases, however, as noted by some
commenters and discussed previously, the
site neutral payment rate is a statutory
requirement and the statutory waiver of the
site neutral payment is only authorized for
the duration of the COVID–19 PHE. We did
not propose any transition policies that
would take effect following the end of the
PHE waiver. We note that on January 22,
2021, then-acting Secretary of HHS, Norris
Cochran, sent a letter to governors
announcing that when a decision is made to
terminate the public health emergency or let
it expire, HHS will provide states with 60
days’ notice prior to termination.1171
Therefore, LTCHs will have at least 60 days’
notice before the statutory waiver of the site
neutral payment rate expires.
As we discuss in detail throughout this
final rule, based on the best available data,
we believe that the provisions of this final
rule relating to the LTCH PPS, which are
projected to result in an overall increase in
estimated aggregate LTCH PPS payments,
and the resulting LTCH PPS payment
amounts, result in appropriate Medicare
payments that are consistent with the statute.
2. Impact on Rural Hospitals
For purposes of section 1102(b) of the Act,
we define a small rural hospital as a hospital
that is located outside of an urban area and
has fewer than 100 beds. As shown in Table
IV, we are projecting a 2.2 percent increase
in estimated payments for LTCH PPS
standard Federal payment rate cases for
LTCHs located in a rural area. This estimated
impact is based on the FY 2021 data for the
17 rural LTCHs (out of 337 LTCHs) that were
used for the impact analyses shown in Table
IV.
3. Anticipated Effects of LTCH PPS Payment
Rate Changes and Policy Changes
a. Budgetary Impact
Section 123(a)(1) of the BBRA requires that
the PPS developed for LTCHs ‘‘maintain
budget neutrality.’’ We believe that the
statute’s mandate for budget neutrality
applies only to the first year of the
implementation of the LTCH PPS (that is, FY
2003). Therefore, in calculating the FY 2003
standard Federal payment rate under
§ 412.523(d)(2), we set total estimated
payments for FY 2003 under the LTCH PPS
1171 https://ccf.georgetown.edu/wp-content/
uploads/2021/01/Public-Health-EmergencyMessage-to-Governors.pdf.
PO 00000
Frm 00709
Fmt 4701
Sfmt 4700
49487
so that estimated aggregate payments under
the LTCH PPS were estimated to equal the
amount that would have been paid if the
LTCH PPS had not been implemented.
Section 1886(m)(6)(A) of the Act
establishes a dual rate LTCH PPS payment
structure with two distinct payment rates for
LTCH discharges beginning in FY 2016.
Under this statutory change, LTCH
discharges that meet the patient-level criteria
for exclusion from the site neutral payment
rate (that is, LTCH PPS standard Federal
payment rate cases) are paid based on the
LTCH PPS standard Federal payment rate.
LTCH discharges paid at the site neutral
payment rate are generally paid the lower of
the IPPS comparable per diem amount,
reduced by 4.6 percent for FYs 2018 through
2026, including any applicable high cost
outlier (HCO) payments, or 100 percent of the
estimated cost of the case, reduced by 4.6
percent.
As discussed in section I.J.2. of this
Appendix, we project an increase in
aggregate LTCH PPS payments in FY 2023 of
approximately $71 million. This estimated
increase in payments reflects the projected
increase in payments to LTCH PPS standard
Federal payment rate cases of approximately
$61 million and the projected increase in
payments to site neutral payment rate cases
of approximately $9 million under the dual
rate LTCH PPS payment rate structure
required by the statute beginning in FY 2016.
As discussed in section V.D. of the
Addendum to this final rule, our actuaries
project cost and resource changes for site
neutral payment rate cases due to the site
neutral payment rates required under the
statute. Specifically, our actuaries project
that the costs and resource use for cases paid
at the site neutral payment rate will likely be
lower, on average, than the costs and
resource use for cases paid at the LTCH PPS
standard Federal payment rate, and will
likely mirror the costs and resource use for
IPPS cases assigned to the same MS–DRG.
While we are able to incorporate this
projection at an aggregate level into our
payment modeling, because the historical
claims data that we are using in this final
rule to project estimated FY 2023 LTCH PPS
payments (that is, FY 2021 LTCH claims
data) do not reflect this actuarial projection,
we are unable to model the impact of the
change in LTCH PPS payments for site
neutral payment rate cases at the same level
of detail with which we are able to model the
impacts of the changes to LTCH PPS
payments for LTCH PPS standard Federal
payment rate cases. Therefore, Table IV only
reflects changes in LTCH PPS payments for
LTCH PPS standard Federal payment rate
cases and, unless otherwise noted, the
remaining discussion in section I.J.3. of this
Appendix refers only to the impact on LTCH
PPS payments for LTCH PPS standard
Federal payment rate cases. In the following
section, we present our provider impact
analysis for the changes that affect LTCH PPS
payments for LTCH PPS standard Federal
payment rate cases.
b. Impact on Providers
The basic methodology for determining a
per discharge payment for LTCH PPS
standard Federal payment rate cases is
E:\FR\FM\10AUR2.SGM
10AUR2
49488
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
currently set forth under §§ 412.515 through
412.533 and 412.535. In addition to adjusting
the LTCH PPS standard Federal payment rate
by the MS–LTC–DRG relative weight, we
make adjustments to account for area wage
levels and SSOs. LTCHs located in Alaska
and Hawaii also have their payments
adjusted by a COLA. Under our application
of the dual rate LTCH PPS payment structure,
the LTCH PPS standard Federal payment rate
is generally only used to determine payments
for LTCH PPS standard Federal payment rate
cases (that is, those LTCH PPS cases that
meet the statutory criteria to be excluded
from the site neutral payment rate). LTCH
discharges that do not meet the patient-level
criteria for exclusion are paid the site neutral
payment rate, which we are calculating as the
lower of the IPPS comparable per diem
amount as determined under § 412.529(d)(4),
reduced by 4.6 percent for FYs 2018 through
2026, including any applicable outlier
payments, or 100 percent of the estimated
cost of the case as determined under existing
§ 412.529(d)(2). In addition, when certain
thresholds are met, LTCHs also receive HCO
payments for both LTCH PPS standard
Federal payment rate cases and site neutral
payment rate cases that are paid at the IPPS
comparable per diem amount.
To understand the impact of the changes
to the LTCH PPS payments for LTCH PPS
standard Federal payment rate cases
presented in this final rule on different
categories of LTCHs for FY 2023, it is
necessary to estimate payments per discharge
for FY 2022 using the rates, factors, and the
policies established in the FY 2022 IPPS/
LTCH PPS final rule and estimate payments
per discharge for FY 2023 using the rates,
factors, and the policies in this FY 2023
IPPS/LTCH PPS final rule (as discussed in
section VII. of the preamble of this final rule
and section V. of the Addendum to this final
rule). As discussed elsewhere in this final
rule, these estimates are based on the best
available LTCH claims data and other factors,
such as the application of inflation factors to
estimate costs for HCO cases in each year.
The resulting analyses can then be used to
compare how our policies applicable to
LTCH PPS standard Federal payment rate
cases affect different groups of LTCHs.
For the following analysis, we group
hospitals based on characteristics provided
in the OSCAR data, cost report data in
HCRIS, and PSF data. Hospital groups
included the following:
• Location: large urban/other urban/rural.
• Participation date.
• Ownership control.
• Census region.
• Bed size.
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
c. Calculation of LTCH PPS Payments for
LTCH PPS Standard Federal Payment Rate
Cases
For purposes of this impact analysis, to
estimate the per discharge payment effects of
our policies on payments for LTCH PPS
standard Federal payment rate cases, we
simulated FY 2022 and FY 2023 payments on
a case-by-case basis using historical LTCH
claims from the FY 2021 MedPAR files that
met or would have met the criteria to be paid
at the LTCH PPS standard Federal payment
rate if the statutory patient-level criteria had
been in effect at the time of discharge for all
cases in the FY 2021 MedPAR files. For
modeling FY 2022 LTCH PPS payments, we
used the FY 2022 standard Federal payment
rate of $44,713.67 (or $43,836.08 for LTCHs
that failed to submit quality data as required
under the requirements of the LTCH QRP).
Similarly, for modeling payments based on
the finalized FY 2023 LTCH PPS standard
Federal payment rate, we used the FY 2023
standard Federal payment rate of $46,432.77
(or $45,538.11 for LTCHs that failed to
submit quality data as required under the
requirements of the LTCH QRP). In each case,
we applied the applicable adjustments for
area wage levels and the COLA for LTCHs
located in Alaska and Hawaii. Specifically,
for modeling FY 2022 LTCH PPS payments,
we used the current FY 2022 labor-related
share (67.9 percent), the wage index values
established in the Tables 12A and 12B listed
in the Addendum to the FY 2022 IPPS/LTCH
PPS final rule (which are available via the
internet on the CMS website), the FY 2022
HCO fixed-loss amount for LTCH PPS
standard Federal payment rate cases of
$33,015 (as reflected in the FY 2022 IPPS/
LTCH PPS final rule), and the FY 2022 COLA
factors (shown in the table in section V.C. of
the Addendum to that final rule) to adjust the
FY 2022 nonlabor-related share (32.1
percent) for LTCHs located in Alaska and
Hawaii. Similarly, for modeling FY 2023
LTCH PPS payments, we used the FY 2023
LTCH PPS labor-related share (68.0 percent),
the FY 2023 wage index values from Tables
12A and 12B listed in section VI. of the
Addendum to this final rule (which are
available via the internet on the CMS
website), the FY 2023 HCO fixed-loss amount
for LTCH PPS standard Federal payment rate
cases of $38,518 (as discussed in section
V.D.3. of the Addendum to this final rule),
and the FY 2023 COLA factors (shown in the
table in section V.C. of the Addendum to this
final rule) to adjust the FY 2023 nonlaborrelated share (32.0 percent) for LTCHs
located in Alaska and Hawaii. We noted that
in modeling payments for HCO cases for
LTCH PPS standard Federal payment rate
cases, we inflated charges reported on the FY
2021 claims by the charge inflation factors in
PO 00000
Frm 00710
Fmt 4701
Sfmt 4700
section V.D.3.b. of the Addendum to this
final rule. We also noted that in modeling
payments for HCO cases for LTCH PPS
standard Federal payment rate cases, we
estimated the cost of each case by
multiplying the inflated charges by the
adjusted CCRs that we determined using our
finalized methodology described in section
V.D.3.b. of the Addendum to this final rule.
The impacts that follow reflect the
estimated ‘‘losses’’ or ‘‘gains’’ among the
various classifications of LTCHs from FY
2022 to FY 2023 based on the payment rates
and policy changes applicable to LTCH PPS
standard Federal payment rate cases
presented in this final rule. Table IV
illustrates the estimated aggregate impact of
the change in LTCH PPS payments for LTCH
PPS standard Federal payment rate cases
among various classifications of LTCHs. (As
discussed previously, these impacts do not
include LTCH PPS site neutral payment rate
cases.)
• The first column, LTCH Classification,
identifies the type of LTCH.
• The second column lists the number of
LTCHs of each classification type.
• The third column identifies the number
of LTCH cases expected to meet the LTCH
PPS standard Federal payment rate criteria.
• The fourth column shows the estimated
FY 2022 payment per discharge for LTCH
cases expected to meet the LTCH PPS
standard Federal payment rate criteria (as
described previously).
• The fifth column shows the estimated FY
2023 payment per discharge for LTCH cases
expected to meet the LTCH PPS standard
Federal payment rate criteria (as described
previously).
• The sixth column shows the percentage
change in estimated payments per discharge
for LTCH cases expected to meet the LTCH
PPS standard Federal payment rate criteria
from FY 2022 to FY 2023 due to the annual
update to the standard Federal rate (as
discussed in section V.A.2. of the Addendum
to this final rule).
• The seventh column shows the
percentage change in estimated payments per
discharge for LTCH PPS standard Federal
payment rate cases from FY 2022 to FY 2023
for changes to the area wage level adjustment
(that is, the updated hospital wage data and
labor-related share) and the application of the
corresponding budget neutrality factor (as
discussed in section V.B.6. of the Addendum
to this final rule).
• The eighth column shows the percentage
change in estimated payments per discharge
for LTCH PPS standard Federal payment rate
cases from FY 2022 (Column 4) to FY 2023
(Column 5) for all changes.
BILLING CODE 4120–01–P
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
VerDate Sep<11>2014
Jkt 256001
LTCH Classification
(1)
Average FY
2022LTCH
PPS Payment
Per Standard
Payment Rate
(4)
Average FY
2023LTCH
PPS Payment
Per Standard
Payment Rate 1
(5)
Change Due
to Change to
the Annual
Update to the
Standard
Federal Rate2
Percent Change
Due to Changes
to Area Wage
Adjustment with
Wage Budget
N eutrality3
(6)
(7)
Percent
Change Due to
All Standard
Payment Rate
Changes4
(8)
PO 00000
Frm 00711
Fmt 4701
Sfmt 4725
E:\FR\FM\10AUR2.SGM
10AUR2
337
50,755
52,314
53,521
3.6
0
2.3
BY LOCATION:
RURAL
URBAN
17
320
1,956
48,799
42,545
52,705
43,476
53,924
3.7
3.6
-0.4
0
2.2
2.3
BY PARTICIPATION DATE:
BEFORE OCT. 1983
OCT. 1983 - SEPT. 1993
OCT. 1993 - SEPT. 2002
AFTER OCTOBER 2002
10
38
135
154
1,244
6,344
20,756
22,411
50,595
59,585
51,641
50,974
51,187
61,141
52,929
52,042
3.7
3.5
3.6
3.6
-0.6
0.2
0.1
-0.2
1.2
2.6
2.5
2.1
BY OWNERSIDP TYPE:
VOLUNTARY
PROPRIETARY
GOVERNMENT
53
273
11
5,630
44,266
859
54,547
51,783
65,012
55,427
53,032
66,225
3.7
3.6
3.6
-0.2
0
-0.1
1.6
2.4
1.9
10
20
61
49
31
22
94
27
23
1,591
3,369
10,070
7,458
3,713
3,141
13,271
2,770
5,372
45,834
62,094
51,488
52,759
49,357
48,788
44,878
52,177
71,571
46,404
63,765
52,606
53,754
50,402
49,215
46,103
53,470
73,624
3.7
3.6
3.6
3.7
3.7
3.8
3.6
3.6
3.4
-0.6
0
-0.4
-0.3
-0.3
-0.5
0.3
-0.1
0.7
1.2
2.7
2.2
1.9
2.1
0.9
2.7
2.5
2.9
26
158
86
45
18
4
2,053
18,594
14,040
9,950
4,741
1,377
49,146
48,263
51,115
59,764
57,055
53,792
50,598
49,286
52,314
61,323
58,118
55,179
3.7
3.7
3.7
3.5
3.6
3.6
0.1
-0.2
-0.1
0.2
0
0.5
3.0
2.1
2.3
2.6
1.9
2.6
BYREGION:
NEW ENGLAND
MIDDLE ATLANTIC
SOUTH ATLANTIC
EAST NORTH CENTRAL
EAST SOUTH CENTRAL
WEST NORTH CENTRAL
WEST SOUTH CENTRAL
MOUNTAIN
PACIFIC
49489
ALL PROVIDERS
BYBEDSIZE:
BEDS: 0-24
BEDS: 25-49
BEDS: 50-74
BEDS: 75-124
BEDS: 125-199
BEDS: 200+
ER10AU22.246
No. ofLTCHS
(2)
Number ofLTCH
PPS Standard
Payment Rate
Cases
(3)
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
00:20 Aug 10, 2022
TABLE IV: IMPACT OF PAYMENT RATE AND POLICY CHANGES TO LTCH PPS PAYMENTS FOR
LTCHPPS STANDARD FEDERAL PAYMENT RATE CASES FOR
FY 2023 (ESTIMATED FY 2022 PAYMENTS COMPARED TO ESTIMATED FY 2023 PAYMENTS)
khammond on DSKJM1Z7X2PROD with RULES2
49490
Jkt 256001
Frm 00712
Fmt 4701
Sfmt 4700
10AUR2
for LTCH PPS standard Federal payment rate
cases are projected to increase 2.3 percent, on
average, for all LTCHs from FY 2022 to FY
2023 as a result of the payment rate and
policy changes applicable to LTCH PPS
standard Federal payment rate cases
E:\FR\FM\10AUR2.SGM
following summary of the impact (as shown
in Table IV) of the LTCH PPS payment rate
and policy changes for LTCH PPS standard
Federal payment rate cases presented in this
final rule. The impact analysis in Table IV
shows that estimated payments per discharge
PO 00000
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
BILLING CODE 4120–01–C
d. Results
00:20 Aug 10, 2022
Based on the FY 2021 LTCH cases (from
337 LTCHs) that were used for the analyses
in this final rule, we have prepared the
VerDate Sep<11>2014
ER10AU22.247
1 Estimated FY 2023 L TCH PPS payments for L TCH PPS standard Federal payment rate criteria based on the finalized payment rate and factor changes applicable to
such cases presented in the preamble of and the Addendum to this final rule.
2 Percent change in estimated payments per discharge for L TCH PPS standard Federal payment rate cases from FY 2022 to FY 2023 for the annual update to the L TCH
PPS standard Federal payment rate.
3 Percent change in estimated payments per discharge for L TCH PPS standard Federal payment rate cases from FY 2022 to FY 2023 for changes due to the changes to
the area wage level adjustment under§ 412.525(c) (that is., updated hospital wage data and the labor related share).
4 Percent change in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2022 (shown in Column 4) to FY 2023 (shown in
Column 5), including all of the changes to the rates and factors applicable to such cases presented in the preamble and the Addendum to this final rule. We note that this
column, which shows the percent change in estimated payments per discharge for all changes, does not equal the sum of the percent changes in estimated payments per
discharge for the annual update to the LTCH PPS standard Federal payment rate (Column 6) and the changes due to the changes to the area wage level adjustment with
budget neutrality (Column 7) due to the effect of estimated changes in estimated payments to aggregate HCO payments for LTCH PPS standard Federal payment rate
cases (as discussed in this impact analysis), as well as other interactive effects that cannot be isolated.
khammond on DSKJM1Z7X2PROD with RULES2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
presented in this final rule. This estimated
2.3 percent increase in LTCH PPS payments
per discharge was determined by comparing
estimated FY 2023 LTCH PPS payments
(using the finalized payment rates and factors
discussed in this final rule) to estimated FY
2022 LTCH PPS payments for LTCH
discharges which will be LTCH PPS standard
Federal payment rate cases if the dual rate
LTCH PPS payment structure was or had
been in effect at the time of the discharge (as
described in section I.J.3. of this Appendix).
As stated previously, we are finalizing the
update the LTCH PPS standard Federal
payment rate for FY 2023 by 3.8 percent. For
LTCHs that fail to submit quality data under
the requirements of the LTCH QRP, as
required by section 1886(m)(5)(C) of the Act,
a 2.0 percentage point reduction is applied to
the annual update to the LTCH PPS standard
Federal payment rate. Consistent with
§ 412.523(d)(4), we also are applying a budget
neutrality factor for changes to the area wage
level adjustment of 1.0004304 (discussed in
section V.B.6. of the Addendum to this final
rule), based on the best available data at this
time, to ensure that any changes to the area
wage level adjustment will not result in any
change (increase or decrease) in estimated
aggregate LTCH PPS standard Federal
payment rate payments. As we also
explained earlier in this section of the final
rule, for most categories of LTCHs (as shown
in Table IV, Column 6), the estimated
payment increase due to the 3.8 percent
annual update to the LTCH PPS standard
Federal payment rate is projected to result in
approximately a 3.6 percent increase in
estimated payments per discharge for LTCH
PPS standard Federal payment rate cases for
all LTCHs from FY 2022 to FY 2023. We note
our estimate of the changes in payments due
to the update to the LTCH PPS standard
Federal payment rate also includes estimated
payments for short-stay outlier (SSO) cases,
a portion of which are not affected by the
annual update to the LTCH PPS standard
Federal payment rate, as well as the
reduction that is applied to the annual
update for LTCHs that do not submit the
required LTCH QRP.
(1) Location
Based on the most recent available data,
the vast majority of LTCHs are located in
urban areas. Only approximately 5 percent of
the LTCHs are identified as being located in
a rural area, and approximately 4 percent of
all LTCH PPS standard Federal payment rate
cases are expected to be treated in these rural
hospitals. The impact analysis presented in
Table IV shows that the overall average
percent increase in estimated payments per
discharge for LTCH PPS standard Federal
payment rate cases from FY 2022 to FY 2023
for all hospitals is 2.3 percent. The projected
increase for urban and rural hospitals,
respectively, is 2.3 and 2.2.
(2) Participation Date
LTCHs are grouped by participation date
into four categories: (1) before October 1983;
(2) between October 1983 and September
1993; (3) between October 1993 and
September 2002; and (4) October 2002 and
after. Based on the best available data, the
categories of LTCHs with the largest expected
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
percentage of LTCH PPS standard Federal
payment rate cases (approximately 41
percent and 44 percent, respectively) are in
LTCHs that began participating in the
Medicare program between October 1993 and
September 2002 and after October 2002.
These LTCHs are expected to experience an
increase in estimated payments per discharge
for LTCH PPS standard Federal payment rate
cases from FY 2022 to FY 2023 of 2.5 percent
and 2.1 percent, respectively. LTCHs that
began participating in the Medicare program
between October 1983 and September 1993
are projected to experience an increase in
estimated payments per discharge for LTCH
PPS standard Federal payment rate cases
from FY 2022 to FY 2023 of 2.6 percent, as
shown in Table IV. Approximately 3 percent
of LTCHs began participating in the Medicare
program before October 1983, and these
LTCHs are projected to experience an
increase in estimated payments per discharge
for LTCH PPS standard Federal payment rate
cases from FY 2022 to FY 2023 of 1.2
percent.
(3) Ownership Control
LTCHs are grouped into three categories
based on ownership control type: voluntary,
proprietary, and government. Based on the
best available data, approximately 16 percent
of LTCHs are identified as voluntary (Table
IV). The majority (approximately 81 percent)
of LTCHs are identified as proprietary, while
government owned and operated LTCHs
represent approximately 3 percent of LTCHs.
Based on ownership type, proprietary LTCHs
are expected to experience an increase in
payments to LTCH PPS standard Federal
payment rate cases of 2.4 percent. Voluntary
LTCHs are expected to experience an
increase in payments to LTCH PPS standard
Federal payment rate cases from FY 2022 to
FY 2023 of 1.6 percent. Meanwhile,
government owned and operated LTCHs are
expected to experience an increase in
payments to LTCH PPS standard Federal
payment rate cases from FY 2022 to FY 2023
of 1.9 percent.
(4) Census Region
The comparisons by region show that the
changes in estimated payments per discharge
for LTCH PPS standard Federal payment rate
cases from FY 2022 to FY 2023 are projected
to range from an increase of 0.9 percent in
the West North Central region to a 2.9
percent increase in the Pacific region. These
regional variations are primarily due to the
changes to the area wage adjustment and
estimated changes in outlier payments.
(5) Bed Size
LTCHs are grouped into six categories
based on bed size: 0–24 beds; 25–49 beds;
50–74 beds; 75–124 beds; 125–199 beds; and
greater than 200 beds. We project that LTCHs
with 125–199 beds will experience the
lowest increase in payments for LTCH PPS
standard Federal payment rate cases, 1.9
percent. LTCHs with 0–24 beds are projected
to experience the largest increase in
payments of 3.0 percent. The remaining bed
size categories are projected to experience an
increase in payments in the range of 2.1 to
2.6 percent.
PO 00000
Frm 00713
Fmt 4701
Sfmt 4700
49491
4. Effect on the Medicare Program
As stated previously, we project that the
provisions of this final rule will result in an
increase in estimated aggregate LTCH PPS
payments to LTCH PPS standard Federal
payment rate cases in FY 2023 relative to FY
2022 of approximately $61 million (or
approximately 2.3 percent) for the 339
LTCHs in our database. Although, as stated
previously, the hospital-level impacts do not
include LTCH PPS site neutral payment rate
cases, we estimate that the provisions of this
final rule will result in an increase in
estimated aggregate LTCH PPS payments to
site neutral payment rate cases in FY 2023
relative to FY 2022 of approximately $9
million (or approximately 2.8 percent) for the
339 LTCHs in our database. (As noted
previously, we estimate payments to site
neutral payment rate cases in FY 2023
represent approximately 11 percent of total
estimated FY 2023 LTCH PPS payments.)
Therefore, we project that the provisions of
this final rule will result in an increase in
estimated aggregate LTCH PPS payments for
all LTCH cases in FY 2023 relative to FY
2022 of approximately 71 million (or
approximately 2.4 percent) for the 339
LTCHs in our database.
5. Effect on Medicare Beneficiaries
Under the LTCH PPS, hospitals receive
payment based on the average resources
consumed by patients for each diagnosis. We
do not expect any changes in the quality of
care or access to services for Medicare
beneficiaries as a result of this final rule, but
we continue to expect that paying
prospectively for LTCH services will enhance
the efficiency of the Medicare program. As
discussed previously, we do not expect the
continued implementation of the site neutral
payment system to have a negative impact on
access to or quality of care, as demonstrated
in areas where there is little or no LTCH
presence, general short-term acute care
hospitals are effectively providing treatment
for the same types of patients that are treated
in LTCHs.
K. Effects of Requirements for the Hospital
Inpatient Quality Reporting (IQR) Program
In section IX.E. of the preamble of this final
rule, we discuss our current requirements
and newly finalized requirements for
hospitals to report quality data under the
Hospital IQR Program to receive the full
annual percentage increase for the FY 2023
payment determination and subsequent
years.
In this final rule, we are adopting the
following measures: (1) Hospital
Commitment to Health Equity, beginning
with the CY 2023 reporting period/FY 2025
payment determination; (2) Screening for
Social Drivers of Health beginning with
voluntary reporting in the CY 2023 reporting
period and mandatory reporting beginning
with the CY 2024 reporting period/FY 2026
payment determination; (3) Screen Positive
Rate for Social Drivers of Health beginning
with voluntary reporting in the CY 2023
reporting period and mandatory reporting
beginning with the CY 2024 reporting period/
FY 2026 payment determination; (4)
Cesarean Birth electronic clinical quality
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49492
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
measure (eCQM) with inclusion in the eCQM
measure set beginning with the CY 2023
reporting period/FY 2025 payment
determination, and mandatory reporting
beginning with the CY 2024 reporting period/
FY 2026 payment determination; (5) Severe
Obstetric Complications eCQM with
inclusion in the eCQM measure set beginning
with the CY 2023 reporting period/FY 2025
payment determination, and mandatory
reporting beginning with the CY 2024
reporting period/FY 2026 payment
determination; (6) Hospital-Harm—OpioidRelated Adverse Events eCQM with inclusion
in the eCQM measure set beginning with the
CY 2024 reporting period/FY 2026 payment
determination; (7) Global Malnutrition
Composite Score eCQM with inclusion in the
eCQM measure set beginning with the CY
2024 reporting period/FY 2026 payment
determination; (8) Hospital-Level, Risk
Standardized Patient-Reported Outcomes
Performance Measure (PRO–PM) Following
Elective Primary Total Hip Arthroplasty
(THA) and/or Total Knee Arthroplasty (TKA),
beginning with two voluntary periods
followed by mandatory reporting beginning
with the reporting period which runs from
July 1, 2025 through June 30, 2026, impacting
the FY 2028 payment determination; (9)
Medicare Spending Per Beneficiary (MSPB)
Hospital beginning with the FY 2024
payment determination; and (10) HospitalLevel Risk-Standardized Complications Rate
(RSCR) Following Elective Primary THA/
TKA beginning with the FY 2024 payment
determination. We are refining two current
measures beginning with the FY 2024
payment determination: (1) Hospital-Level,
Risk-Standardized Payment Associated with
an Episode of Care for Primary Elective THA/
TKA; and (2) Excess Days in Acute Care
(EDAC) After Hospitalization for Acute
Myocardial Infarction (AMI). We are also: (1)
Establishing a hospital designation related to
maternal care to be publicly-reported on a
public-facing website beginning in Fall 2023,
and sought comments on other potential
associated activities regarding this
designation; (2) modifying our eCQM
reporting and submission requirements
whereby we are increasing the total number
of eCQMs to be reported from four to six
eCQMs beginning with the CY 2024 reporting
period/FY 2026 payment determination; (3)
modifying our case threshold exemptions
and zero denominator declaration policies for
hybrid measures as we believe they are not
applicable for those measure types beginning
with the FY 2026 payment determination; (4)
adopting reporting and submission
requirements for PRO–PMs; and (5)
modifying our eCQM validation policy to
increase the reporting of medical requests
from 75 percent of records to 100 percent of
records beginning with the FY 2025 payment
determination.
As shown in the summary table in section
XII.B.4. of the preamble of this final rule, we
estimate a total information collection
burden increase for 3,150 IPPS hospitals of
746,300 hours at a cost of $23,437,906
annually associated for our finalized policies
and updated burden estimates across a 4-year
period from the CY 2023 reporting period/FY
2025 payment determination through the CY
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
2026 reporting period/FY 2028 payment
determination, compared to our currently
approved information collection burden
estimates.
In section IX.E.5.a. of the preamble of this
final rule, we are adopting the Hospital
Commitment to Health Equity structural
measure. In order for hospitals to receive a
point for each of the five domains in the
measure, affirmative attestations are required
for each of the elements within a domain. For
hospitals that are unable to attest
affirmatively for an element, there are likely
to be additional costs associated with
activities such as updating hospital policies,
engaging senior leadership, participating in
new quality improvement activities,
performing additional data analysis, and
training staff. The extent of these costs will
vary from hospital to hospital depending on
what activities the hospital is already
performing, hospital size, and the individual
choices each hospital makes in order to meet
the criteria necessary to attest affirmatively.
In section IX.E.5.b.(1). of the preamble of
this final rule, we are adopting the Screening
for Social Drivers of Health measure. For
hospitals that are not currently administering
some screening mechanism and elect to begin
doing so as a result of this policy, there will
be some non-recurring costs associated with
changes in workflow and information
systems to collect the data. The extent of
these costs is difficult to quantify as different
hospitals may utilize different modes of data
collection (for example paper-based,
electronically patient-directed, clinicianfacilitated, etc.). In addition, depending on
the method of data collection utilized, the
time required to complete the survey may
add a negligible amount of time to patient
visits.
In section IX.E.5.g. of the preamble of this
final rule, we are adopting the THA/TKA
PRO–PM. For hospitals that are not currently
collecting this data and elect to begin doing
so as a result of this policy, there will be
some non-recurring costs associated with
changes in workflow and information
systems to collect the data. The extent of
these costs is difficult to quantify as different
hospitals may utilize different modes of data
collection (for example paper-based,
electronically patient-directed, clinicianfacilitated, etc.). While we assume the
majority of hospitals will report data for this
measure via the HQR System, we assume
some hospitals may elect to submit measure
data via a third-party CMS-approved survey
vendor, for which there are associated costs.
Under OMB control number 0938–0981 for
the HCAHPS Survey measure (expiration
date September 30, 2024), an estimate of
approximately $4,000 per hospital is used to
account for these costs. This estimate
originates from 2012, therefore, to account for
inflation (assuming end of CY 2012 to end of
CY 2021), we adjust the price using the
Bureau of Labor Statistics Consumer Price
Index and estimate an updated cost of
approximately $4,856 ($4,000 × 121.4
percent).1172
1172 U.S. Bureau of Labor Statistics. Historical
CPI–U data. Accessed on March 10, 2022. Available
at: https://www.bls.gov/cpi/tables/supplementalfiles/historical-cpi-u-202112.pdf.
PO 00000
Frm 00714
Fmt 4701
Sfmt 4700
We note that in sections IX.E.5.c., IX.E.5.d.,
IX.E.5.e, and IX.E.5.f. of the preamble of this
final rule, we are adopting four new eCQMs.
Similar to the FY 2019 IPPS/LTCH PPS final
rule regarding removal of eCQM measures,
while there is no change in information
collection burden related to those finalized
provisions, we believe that costs are
multifaceted and include not only the burden
associated with reporting, but also the costs
associated with implementing and
maintaining Hospital IQR Program measures
in hospitals’ EHR systems for all of the
eCQMs available for use in the Hospital IQR
Program (83 FR 41771). Additionally, two of
the four eCQMs are mandatory beginning
with the CY 2024 reporting period/FY 2026
payment determination and for subsequent
years; we account for the burden of collection
of information in section XII.B.4. (Collection
of Information) in our finalized policy to
increase our eCQM reporting and submission
requirements from four eCQMs to six eCQMs.
Because hospitals are already reporting
eCQMs, we do not believe there are any
additional costs associated with increasing
the number of eCQMs hospitals must report
beyond the burden discussed in the
collection of information section and the
costs previously discussed related to
adopting new eCQMs.
Historically, 100 hospitals, on average, that
participate in the Hospital IQR Program do
not receive the full annual percentage
increase in any fiscal year due to the failure
to meet all requirements of the Hospital IQR
Program. We anticipate that the number of
hospitals not receiving the full annual
percentage increase will be approximately
the same as in past years.
We received no comments on these effects.
L. Effects of Requirements for the PPSExempt Cancer Hospital Quality Reporting
(PCHQR) Program
In section IX.F. of the preamble of this final
rule, we discuss our policies for the quality
data reporting program for PPS-exempt
cancer hospitals (PCHs), which we refer to as
the PPS-Exempt Cancer Hospital Quality
Reporting (PCHQR) Program. The PCHQR
Program is authorized under section 1866(k)
of the Act, which was added by section 3005
of the Affordable Care Act. There is no
financial impact to PCH Medicare
reimbursement if a PCH does not submit
data.
In section IX.F.4. of the preamble of this
final rule, we are: (1) adopting and codifying
a patient safety exception for the measure
removal policy; (2) beginning public display
of the End-of-Life (EOL) measures with FY
2025 program year data; and (3) beginning
public display of the 30-Day Unplanned
Readmissions for Cancer Patients measures
with FY 2024 program year data. These
provisions do not result in additional
financial impact beyond the information
collection burden of 0 hours discussed in
section XII.B.XX of the preamble of this final
rule.
We received no comments on these effects.
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
M. Effects of Requirements for the Long-Term
Care Hospital Quality Reporting Program
(LTCH QRP)
In section IX.G. of the preamble of this
proposed rule, we are soliciting comment on
several issues but are not proposing any
policy changes. Given that there are no costs
for this provision.
N. Effects of Requirements Regarding the
Medicare Promoting Interoperability Program
In section IX.H. of this final rule, we are
finalizing the following changes for eligible
hospitals and critical access hospitals (CAHs)
that attest to CMS under the Medicare
Promoting Interoperability Program: (1) to
require and modify the Electronic Prescribing
Objective’s Query of PDMP measure while
maintaining the associated points at 10
points beginning with the electronic health
record (EHR) reporting period in CY 2023
with modification for an additional exclusion
based on public comment; (2) to expand the
Query of Prescription Drug Monitoring
Program (PDMP) measure to include not only
Schedule II opioids, but also Schedule III,
and IV drugs beginning with EHR reporting
periods in CY 2023; (3) to add a new Health
Information Exchange (HIE) Objective option,
the Enabling Exchange Under Trusted
Exchange Framework and Common
Agreement (TEFCA) measure (requiring a
yes/no response) beginning with EHR
reporting periods in CY 2023; (4) to modify
the Public Health and Clinical Data Exchange
Objective by adding an Antibiotic Use and
Resistance (AUR) measure in addition to the
current four required measures (Syndromic
Surveillance Reporting, Immunization
Registry Reporting, Electronic Case
Reporting, and Electronic Reportable
Laboratory Result Reporting) with
modification to begin with EHR reporting
periods in CY 2024; (5) to consolidate the
current options from three to two levels of
active engagement for the Public Health and
Clinical Data Exchange Objective and to
require the reporting of active engagement for
the measures under the objective beginning
with EHR reporting periods in CY 2023 with
modification to delay the requirement that
eligible hospital and CAHs may spend only
one EHR reporting period at the Preproduction and Validation level of active
engagement per measure until EHR reporting
period in CY 2024; (6) to institute public
reporting of certain Medicare Promoting
Interoperability Program data beginning from
the CY 2023 EHR reporting period; (7) to
modify the scoring methodology for the
Promoting Interoperability Program
beginning in the EHR reporting periods in CY
2023; and (8) to remove regulation text for
the objectives and measures in the Medicare
Promoting Interoperability Program from
paragraph (e) under 42 CFR 495.24 and add
new paragraph (f) beginning in CY 2023. We
are also finalizing adoption of four eCQMs:
(1) Severe Obstetric Complications eCQM
with inclusion in the eCQM measure set
beginning with the CY 2023 reporting period,
followed by mandatory reporting beginning
with the CY 2024 reporting period; (2)
Cesarean Birth (ePC–02) eCQM with
inclusion in the eCQM measure set beginning
with the CY 2023 reporting period followed
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
by mandatory reporting beginning with the
CY 2024 reporting period; (3) HospitalHarm—Opioid-Related Adverse Events
eCQM with inclusion in the eCQM measure
set beginning with the CY 2024 reporting
period; and (4) Global Malnutrition
Composite Score eCQM with inclusion in the
eCQM measure set beginning with the CY
2024 reporting period. Lastly, we are
finalizing a modification to our eCQM
reporting and submission requirements
whereby we are increasing the total number
of eCQMs to be reported from four to six
eCQMs beginning with the CY 2024 reporting
period.
As shown in summary table in section
XII.B.9.k. of the preamble of this final rule,
we estimate a total information collection
burden increase for 4,500 eligible hospitals
and CAHs of 5,513 hours at a cost of
$233,730 annually associated with our
finalized policies and updated burden
estimates across the CY 2023 and CY 2024
EHR reporting periods compared to our
currently approved information collection
burden estimates. We refer readers to section
XII.B.9. of the preamble of this final rule
(information collection requirements) for a
detailed discussion of the calculations
estimating the changes to the information
collection burden for submitting data to the
Medicare.
In section IX.H.4. of the preamble of this
final rule, we are finalizing to add the
Enabling Exchange Under TEFCA measure to
the Health Information Exchange Objective.
Eligible hospitals and CAHs currently may
choose to report the two Support Electronic
Referral Loop measures or may choose to
report the HIE Bi-Directional Exchange
measure. With the addition of this measure,
eligible hospitals and CAHs would be able to
choose to attest to Enabling Exchange Under
TEFCA as an alternative to reporting on other
measures in the objective and provide an
opportunity for eligible hospitals and CAHs
that are already voluntarily connecting to and
exchanging information under TEFCA to earn
credit for the Health Information Exchange
Objective. Because attesting to this measure
is voluntary and we assume eligible hospitals
and CAHs would already be engaging in the
activities necessary to attest ‘‘yes’’, we
assume no additional financial impact as a
result of this policy.
In section IX.H.5.b. of the preamble of this
final rule, we are finalizing the adoption of
a new Antimicrobial Use and Resistance
(AUR) Surveillance measure for eligible
hospitals and CAHs under the Promoting
Interoperability Program’s Public Health and
Clinical Data Exchange Objective with
associated exclusions with modification to
begin in the EHR reporting periods in CY
2024. To attest successfully, an eligible
hospital or CAH must be in active
engagement with CDC’s National Healthcare
Safety Network (NHSN) to submit AUR data
and receive a report from NHSN indicating
their successful submission of AUR data for
the EHR reporting period. Participation in
NHSN’s surveillance requires the purchase or
building of an AUR reporting solution. While
thousands of hospitals have voluntarily done
this to date, for hospitals who would be
required to, we estimate the cost to range
PO 00000
Frm 00715
Fmt 4701
Sfmt 4700
49493
between $17,000 and $388,500 annually,
with a median of $187,400.1173 We believe
these associated costs are outweighed by the
more than $4.6 billion in health care costs
spent annually treating antibiotic resistance
threats.1174
In section IX.H.5.c. of the preamble of this
final rule, we are finalizing to reduce the
number of active engagement options from
three to two and combine the ‘‘completed
registration to submit data’’ option with the
‘‘testing’’ and validation option. Because
these options were first available in 2016 and
the vast majority of eligible hospitals and
CAHs have completed the ‘‘completed
registration to submit data’’ option in the
years since, we believe any financial impact
associated with this finalized policy to be
negligible. Regarding the finalized policy to
allow eligible hospitals and CAHs to spend
only one EHR reporting period at the Preproduction and Validation phase, because
the goal for all eligible hospitals and CAHs
has historically been to eventually be at the
Validated Data Production option, we do not
believe there is any additional financial
impact associated with this policy.
In section IX.H.10.a.(2). of the preamble of
this final rule, we are finalizing to adopt four
new eCQMs. Similar to the FY 2019 IPPS/
LTCH PPS final rule regarding removal of
eCQM measures, while there is no change in
information collection burden related to
those finalized provisions, we believe that
costs are multifaceted and include not only
the burden associated with reporting but also
the costs associated with implementing and
maintaining program measures in hospitals’
EHR systems for all of the eCQMs available
for use in the Promoting Interoperability
Program (83 FR 41771). Additionally, for two
of the four eCQMs being finalized as
mandatory beginning with the CY 2024
reporting period and for subsequent years,
we account for the burden of collection of
information in section XII.B.9.e. (Collection
of Information) in our finalized policy to
increase our eCQM reporting and submission
requirements from four eCQMs to six eCQMs.
We received no comments on these effects.
O. Alternatives Considered
This final rule contains a range of policies.
It also provides descriptions of the statutory
provisions that are addressed, identifies the
finalized policies, and presents rationales for
our decisions and, where relevant,
alternatives that were considered.
1. Use of FY 2021 Data and Proposed
Methodology Modifications for the FY 2023
IPPS and LTCH PPS Ratesetting
In the FY 2022 IPPS/LTCH proposed rule
(87 FR 28740), we explained that for the IPPS
and LTCH PPS ratesetting, our longstanding
goal is to use the best available data. We
stated that given the persistence of the effects
of the virus that causes COVID–19 in the
Medicare FY 2020 data, the Medicare FY
2021 data, and the CDC hospitalization data,
coupled with the expectation for future
1173 https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC5051263/.
1174 https://www.cdc.gov/drugresistance/
solutions-initiative/stories/partnership-estimateshealthcare-cost.html.
E:\FR\FM\10AUR2.SGM
10AUR2
khammond on DSKJM1Z7X2PROD with RULES2
49494
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
variants, we believe that it is reasonable to
assume that some Medicare beneficiaries will
continue to be hospitalized with COVID–19
at IPPS hospitals and LTCHs in FY 2023.
Accordingly, we stated we believe it is
appropriate to use FY 2021 data, as the most
recent available data during the period of the
COVID–19 PHE, for purposes of the FY 2023
IPPS and LTCH PPS ratesetting.
We also stated in the FY 2022 IPPS/LTCH
proposed rule (87 FR 28740), we believe it is
reasonable to assume based on the
information available at this time that there
will be fewer COVID 19 hospitalizations in
FY 2023 than in FY 2021 given the more
recent trends in the CDC hospitalization data
since the Omicron variant peak in January,
2022. Accordingly, because we anticipate
Medicare inpatient hospitalizations for
COVID–19 will continue in FY 2023 but at
a lower level, we proposed to use FY 2021
data for purposes of the FY 2023 IPPS and
LTCH PPS ratesetting but with the following
modifications to our usual ratesetting
methodologies to account for the anticipated
decline in COVID–19 hospitalizations of
Medicare beneficiaries at IPPS hospitals and
LTCHs as compared to FY 2021.
• Calculate the relative weights for FY
2023 by first calculating two sets of weights,
one including and one excluding COVID–19
claims in the FY 2021 data, and then
averaging the two sets of relative weights to
determine the proposed FY 2023 relative
weight values.
• Modify our methodologies for
determining the FY 2023 outlier fixed-loss
amount for IPPS cases and LTCH PPS
standard Federal payment rate cases to use
charge inflation factors based on the increase
in charges that occurred from FY 2018 to FY
2019, which is the last 1-year period prior to
the COVID–19 PHE and to use CCR
adjustment factors based on the change in
CCRs that occurred between the March 2019
PSF and the March 2020 PSF, which is the
last 1-year period prior to the COVID–19
PHE.
We refer the reader to section II.E.2.c. of
the preamble and section II.A.4.j. of the
Addendum of this final rule for a complete
discussion regarding these proposed
modifications to our usual ratesetting
methodologies.
Alternatively, we considered not making
any of these modifications to our usual
methodologies for the calculation of the FY
2023 MS–DRG and MS–LTC–DRG relative
weights or the usual methodologies used to
determine the FY 2023 outlier fixed-loss
amount for IPPS cases and LTCH PPS
standard Federal payment rate cases.
Specifically, under this alternative approach,
we considered to—
• Calculate the relative weights using our
usual methodology for FY 2023 by including
all COVID–19 claims in the FY 2021 data
with no averaging of the relative weights as
calculated with and without the COVID–19
cases to determine the FY 2023 relative
weight values; and
• Use the same data we would ordinarily
use for purposes of this FY 2023 rulemaking
to compute the charge inflation factors and
CCR adjustment factors in determining the
FY 2023 outlier fixed-loss amount for IPPS
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
cases and LTCH PPS standard Federal
payment rate cases; specifically:
++ Charge inflation factors based on the
increase in charges that occurred from FY
2020 to FY 2021, which is the latest full
fiscal year period of MedPAR data available
to determine the increase in charges.
++ CCR adjustment factors based on the
change in CCRs that occurred between the
December 2020 PSF and the December 2021
PSF, which is the latest 1-year period of the
PSF to determine the adjustment factors to
the CCRs for the proposed rule (for the final
rule, we typically use updated PSF data to
determine the CCR adjustment factor which
for FY 2023 would be based on the change
in CCRs that occurred between the March
2021 PSF and the March 2022 PSF).
We note the FY 2023 outlier fixed-loss
amount would be significantly higher under
this alternative considered.
In order to facilitate comments on this
alternative approach as well as comments on
our proposed modifications to our usual
methodologies, we made available additional
files on the CMS website at https://
www.cms.gov/medicare/medicare-fee-forservice-payment/acuteinpatientpps, along
with the data files and information for our
proposed FY 2023 IPPS ratesetting. The
LTCH PPS specific files were posted the CMS
website at https://www.cms.gov/medicare/
medicare-fee-for-service-payment/
longtermcarehospitalpps, along with the data
files and information for our proposed FY
2023 LTCH PPS ratesetting.
Public comments were largely supportive
of CMS use of FY 2021 data including to
determine the FY 2023 MS–DRG relative
weights by averaging the relative weights as
calculated with and without COVID–19 cases
in the FY 2021 data. Some commenters
expressed concern about policies that may
limit the reimbursement for COVID–19 cases.
As discussed in section II.E. of the preamble
of this final rule, and following our review
of public comments, we are finalizing our
proposal to determine the FY 2023 MS–DRG
relative weights by averaging the relative
weights as calculated with and without
COVID–19 cases in the FY 2021 data. We
note, the finalization of our proposal to use
FY 2021 data and to modify our methodology
for determining the FY 2023 LTCH PPS MS–
LTC–DRG relative weights is discussed in
greater detail in section VIII.B. of the
preamble of this final rule.
As discussed in section II.A.4. and section
V.D.3. of the addendum to this final rule, we
received many comments supportive of our
proposed modifications to our usual
methodologies for determining the FY 2023
IPPS and LTCH PPS outlier fixed-loss
amounts.
As discussed in these sections, after
considering comments received, we are
finalizing our proposal to inflate the charges
on the FY 2021 MedPAR claims using charge
inflation factors computed by comparing the
average covered charge per case in the March
2019 MedPAR file of FY 2018 to the average
covered charge per case in the March 2020
MedPAR file of FY 2019, which is the last
1-year period prior to the COVID–19 PHE.
We also finalizing our proposal to adjust the
CCRs from the March 2021 update of the PSF
PO 00000
Frm 00716
Fmt 4701
Sfmt 4700
by comparing the percentage change in the
national average case-weighted CCR from the
March 2019 update of the PSF to the national
average case-weighted CCR from the March
2020 update of the PSF, which is the last 1year period prior to the COVID–19 PHE.
We also received many comments that
suggested other modifications CMS should
make to our usual methodologies for
determining the FY 2023 IPPS and LTCH PPS
outlier fixed-loss amounts. As also discussed
in section II.A.4. and section V.D.3. of the
addendum to this final rule, in response to
comments received, we are modifying our
proposed methodologies for establishing the
FY 2023 IPPS and LTCH PPS outlier fixedloss amounts. We specifically determined the
FY 2023 IPPS and LTCH PPS outlier fixedloss amounts as averages of these fixed-loss
amounts calculated including and excluding
COVID–19 claims. We believe this
adjustment to our proposed methodology
will better reflect a reasonable estimation of
the case mix for FY 2023 based on the
information available at this time and is also
consistent with the approach we are
finalizing for determining the FY 2023 IPPS
MS–DRG and LTCH PPS MS–LTC–DRG
relative weights.
In addition, as discussed in section II.A.4
of the addendum to this final rule, in
response to comments received, we are
further modifying our proposed methodology
for establishing the FY 2023 IPPS outlier
fixed-loss amount. Specifically, when
determining the FY 2023 IPPS outlier fixedloss amount, we included COVID–19 add-on
payments which were not accounted for in
our proposed methodology.
P. Overall Conclusion
1. Acute Care Hospitals
Acute care hospitals are estimated to
experience an increase of approximately $1.4
billion in FY 2023, including operating,
capital, and new technology changes, as well
as increased GME payments under our
changes in response to Milton S. Hershey
Medical Center, et al. v. Becerra and
payments under the new supplemental
payment for IHS/Tribal and Puerto Rico
hospitals. The estimated change in operating
payments is approximately $2.3 billion
(discussed in section I.G. and I.H. of this
Appendix). The estimated change in capital
payments is approximately $0.039 billion
(discussed in section I.I. of this Appendix).
The estimated change in new technology
add-on payments is approximately -$0.747
billion as discussed in section I.H. of this
Appendix. The change in new technology
add-on payments reflects the net impact of
new applications under the alternative
pathways and continuing new technology
add-on payments. Total may differ from the
sum of the components due to rounding.
Table I. of section I.G. of this Appendix
also demonstrates the estimated
redistributional impacts of the IPPS budget
neutrality requirements for the MS–DRG and
wage index changes, and for the wage index
reclassifications under the MGCRB.
We estimate that hospitals would
experience a 0.6 percent increase in capital
payments per case, as shown in Table III. of
section I.I. of this Appendix. We project that
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
there would be a $39 million increase in
capital payments in FY 2023 compared to FY
2022.
The discussions presented in the previous
pages, in combination with the remainder of
this final rule, constitute a regulatory impact
analysis.
2. LTCHs
Overall, LTCHs are projected to experience
an increase in estimated payments in FY
2023. In the impact analysis, we are using the
finalized rates, factors, and policies
presented in this final rule based on the best
available claims and CCR data to estimate the
change in payments under the LTCH PPS for
FY 2023. Accordingly, based on the best
available data for the 339 LTCHs included in
our analysis, we estimate that overall FY
2023 LTCH PPS payments will increase
approximately $71 million relative to FY
2022 primarily due to the annual update to
the LTCH PPS standard Federal rate.
Q. Regulatory Review Cost Estimation
If regulations impose administrative costs
on private entities, such as the time needed
to read and interpret a rule, we should
estimate the cost associated with regulatory
review. Due to the uncertainty involved with
accurately quantifying the number of entities
that would review the final rule, we assumed
that the total number of timely pieces of
correspondence on this year’s proposed rule
would be the number of reviewers of the final
rule. We acknowledge that this assumption
may understate or overstate the costs of
reviewing the rule. It is possible that not all
commenters reviewed this year’s rule in
detail, and it is also possible that some
reviewers chose not to comment on the
proposed rule. For these reasons, we believe
that the number of past commenters would
be a fair estimate of the number of reviewers
of the final rule. We recognize that different
types of entities are in many cases affected
by mutually exclusive sections of the rule.
Thus, for the purposes of our estimate we
assume that each reviewer read
approximately 50 percent of the proposed
rule. Finally, in our estimates, we have used
the 1,631 number of timely pieces of
correspondence on the FY 2023 IPPS/LTCH
PPS proposed rule as our estimate for the
number of reviewers of the final rule. We
continue to acknowledge the uncertainty
involved with using this number, but we
believe it is a fair estimate due to the variety
of entities affected and the likelihood that
some of them choose to rely (in full or in
part) on press releases, newsletters, fact
sheets, or other sources rather than the
comprehensive review of preamble and
regulatory text.
Using the wage information from the BLS
for medical and health service managers
(Code 11–9111), we estimate that the cost of
reviewing the final rule is $115.22 per hour,
49495
including overhead and fringe benefits
(https://www.bls.gov/oes/current/oes_
nat.htm). Assuming an average reading
speed, we estimate that it would take
approximately 30.06 hours for the staff to
review half of this final rule. For each IPPS
hospital or LTCH that reviews this final rule,
the estimated cost is $3,463.34 (30.06 hours
× $115.22). Therefore, we estimate that the
total cost of reviewing this final rule is
$5,648,700 ($3,463.34 × 1,631 reviewers).
II. Accounting Statements and Tables
A. Acute Care Hospitals
As required by OMB Circular A–4
(available at https://www.whitehouse.gov/wpcontent/uploads/legacy_drupal_files/omb/
circulars/A4/a-4.pdf), in Table V. of this
Appendix, we have prepared an accounting
statement showing the classification of the
expenditures associated with the provisions
of this final rule as they relate to acute care
hospitals. This table provides our best
estimate of the change in Medicare payments
to providers as a result of the changes to the
IPPS presented in this final rule. All
expenditures are classified as transfers to
Medicare providers.
As shown in Table V. of this Appendix, the
net costs to the Federal Government
associated with the policies in this final rule
are estimated at $1.4 billion.
TABLE V.-ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED
EXPENDITURES UNDER THE IPPS FROM FY 2022 TO FY 2023
Category
Annualized Monetized Transfers
From Whom to Whom
B. LTCHs
As discussed in section I.J. of this
Appendix, the impact analysis of the
payment rates and factors presented in this
final rule under the LTCH PPS is projected
to result in an increase in estimated aggregate
LTCH PPS payments in FY 2023 relative to
FY 2022 of approximately $71 million based
on the data for 339 LTCHs in our database
that are subject to payment under the LTCH
Transfers
$1.4 billion
Federal Government to IPPS Medicare Providers
PPS. Therefore, as required by OMB Circular
A–4 (available at https://
www.whitehouse.gov/wp-content/uploads/
legacy_drupal_files/omb/circulars/A4/a4.pdf), in Table VI. of this Appendix, we
have prepared an accounting statement
showing the classification of the
expenditures associated with the provisions
of this final rule as they relate to the changes
to the LTCH PPS. Table VI. of this Appendix
provides our best estimate of the estimated
change in Medicare payments under the
LTCH PPS as a result of the payment rates
and factors and other provisions presented in
this final rule based on the data for the 339
LTCHs in our database. All expenditures are
classified as transfers to Medicare providers
(that is, LTCHs).
As shown in Table VI. of this Appendix,
the net cost to the Federal Government
associated with the policies for LTCHs in this
final rule are estimated at $71 million.
III. Regulatory Flexibility Act (RFA)
Analysis
The RFA requires agencies to analyze
options for regulatory relief of small entities.
For purposes of the RFA, small entities
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Transfers
$71 million
Federal Government to L TCH Medicare Providers
include small businesses, nonprofit
organizations, and small government
jurisdictions. We estimate that most hospitals
and most other providers and suppliers are
small entities as that term is used in the RFA.
PO 00000
Frm 00717
Fmt 4701
Sfmt 4700
The great majority of hospitals and most
other health care providers and suppliers are
small entities, either by being nonprofit
organizations or by meeting the SBA
definition of a small business (having
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.249
Category
Annualized Monetized Transfers
From Whom to Whom
ER10AU22.248
khammond on DSKJM1Z7X2PROD with RULES2
TABLE VI.-ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED
EXPENDITURES FROM THE FY 2022 LTCH PPS TO THE FY 2023 LTCH PPS
khammond on DSKJM1Z7X2PROD with RULES2
49496
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
revenues of less than $8.0 million to $41.5
million in any 1 year). (For details on the
latest standards for health care providers, we
refer readers to page 38 of the Table of Small
Business Size Standards for NAIC 622 found
on the SBA website at https://www.sba.gov/
sites/default/files/files/Size_Standards_
Table.pdf.)
For purposes of the RFA, all hospitals and
other providers and suppliers are considered
to be small entities. Because all hospitals are
considered to be small entities for purposes
of the RFA, the hospital impacts described in
this final rule are impacts on small entities.
Individuals and States are not included in
the definition of a small entity. MACs are not
considered to be small entities because they
do not meet the SBA definition of a small
business.
HHS’s practice in interpreting the RFA is
to consider effects economically ‘‘significant’’
if greater than 5 percent of providers reach
a threshold of 3 to 5 percent or more of total
revenue or total costs. We believe that the
provisions of this final rule relating to IPPS
hospitals would have an economically
significant impact on small entities as
explained in this Appendix. Therefore, the
Secretary has certified that this final rule will
have a significant economic impact on a
substantial number of small entities. For
example, the majority of the 3,142 IPPS
hospitals included in the impact analysis
shown in ‘‘Table I.—Impact Analysis of
Proposed Changes to the IPPS for Operating
Costs for FY 2023,’’ on average are expected
to see increases in the range of 2.6 percent,
primarily due to the hospital rate update, as
discussed in section I.G. of this Appendix.
On average, the rate update for these
hospitals is estimated to be 4.2 percent.
The 339 LTCH PPS hospitals included in
the impact analysis shown in ‘‘Table IV.
Impact of Proposed Payment Rate and Policy
Changes to LTCH PPS Payments and Policy
Changes to LTCH PPS Payments for LTCH
PPS Standard Payment Rate Cases for FY
2023 (Estimated FY 2023 Payments
Compared to Estimated FY 2022 Payments)’’
on average are expected to see an increase of
approximately 2.3 percent, primarily due to
the 3.8 percent annual update to the LTCH
PPS standard Federal payment rate for FY
2023 and the 1.2 percent decrease in high
cost outlier payments as a percentage of total
LTCH PPS standard Federal payment rate
payments, as discussed in section I.J. of this
Appendix.
This final rule contains a range of policies.
It provides descriptions of the statutory
provisions that are addressed, identifies the
proposed policies, and presents rationales for
our decisions and, where relevant,
alternatives that were considered. The
analyses discussed in this Appendix and
throughout the preamble of this final rule
constitutes our regulatory flexibility analysis.
We solicited public comments on our
estimates and analysis of the impact of our
proposals on small entities.
IV. Impact on Small Rural Hospitals
Section 1102(b) of the Act requires us to
prepare a regulatory impact analysis for any
proposed or final rule that may have a
significant impact on the operations of a
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
substantial number of small rural hospitals.
This analysis must conform to the provisions
of section 604 of the RFA. With the exception
of hospitals located in certain New England
counties, for purposes of section 1102(b) of
the Act, we define a small rural hospital as
a hospital that is located outside of an urban
area and has fewer than 100 beds. Section
601(g) of the Social Security Amendments of
1983 (Pub. L. 98–21) designated hospitals in
certain New England counties as belonging to
the adjacent urban area. Thus, for purposes
of the IPPS and the LTCH PPS, we continue
to classify these hospitals as urban hospitals.
As shown in Table I. in section I.G. of this
Appendix, rural IPPS hospitals with 0–49
beds (358 hospitals) and 50–99 beds (201
hospitals) are expected to experience an
increase in payments from FY 2022 to FY
2023 of 0.9 percent and 1.3 percent,
respectively, primarily driven by the hospital
rate update and the expiration of the MDH
provision, as discussed in section I.G of this
Appendix. We refer readers to Table I. in
section I.G. of this Appendix for additional
information on the quantitative effects of the
policy changes under the IPPS for operating
costs.
All rural LTCHs (17 hospitals) shown in
Table IV. in section I.J. of this Appendix have
less than 100 beds. These hospitals are
expected to experience an increase in
payments from FY 2022 to FY 2023 of 2.2
percent, primarily due to the 3.8 percent
annual update to the LTCH PPS standard
Federal payment rate for FY 2023 and the
projected 1.2 percent decrease in high cost
outlier payments as a percentage of total
LTCH PPS standard Federal payment rate
payments, as discussed in section I.J. of this
Appendix.
V. Unfunded Mandates Reform Act Analysis
Section 202 of the Unfunded Mandates
Reform Act of 1995 (Pub. L. 104–4) also
requires that agencies assess anticipated costs
and benefits before issuing any rule whose
mandates require spending in any 1 year of
$100 million in 1995 dollars, updated
annually for inflation. In 2022, that threshold
level is approximately $165 million. This
final rule would not mandate any
requirements that meet the threshold for
State, local, or tribal governments, nor would
it affect private sector costs.
VI. Executive Order 13132
Executive Order 13132 establishes certain
requirements that an agency must meet when
it promulgates a proposed rule (and
subsequent final rule) that imposes
substantial direct requirement costs on state
and local governments, preempts state law,
or otherwise has federalism implications.
This final rule would not have a substantial
direct effect on state or local governments,
preempt states, or otherwise have a
federalism implication.
VII. Executive Order 13175
Executive Order 13175 directs agencies to
consult with Tribal officials prior to the
formal promulgation of regulations having
tribal implications. Section 1880(a) of the Act
states that a hospital of the Indian Health
Service, whether operated by such Service or
by an Indian tribe or tribal organization, is
PO 00000
Frm 00718
Fmt 4701
Sfmt 4700
eligible for Medicare payments so long as it
meets all of the conditions and requirements
for such payments which are applicable
generally to hospitals. Consistent with
section 1880(a) of the Act, this this final rule
contains general provisions also applicable to
hospitals and facilities operated by the
Indian Health Service or Tribes or Tribal
organizations under the Indian SelfDetermination and Education Assistance Act.
In the years prior to this rulemaking and
during this rulemaking, we have engaged in
consultation with Tribal officials on the
methodology for determining uncompensated
care payments to IHS and Tribal hospitals.
Tribal officials have expressed concern over
the long-term financial disruption to these
hospitals if the use of low-income insured
days as a proxy for the uncompensated care
costs of IHS and Tribal hospitals were to be
discontinued and data on uncompensated
care costs from Worksheet S–10 were to be
used to determine uncompensated care
payments to IHS and Tribal hospitals. As
discussed in section IV.D of the preamble of
this final rule, beginning in FY 2023, we are
discontinuing the use of low-income insured
days as a proxy for the uncompensated care
costs of IHS and Tribal hospitals and will
begin using data on uncompensated care
costs from Worksheet S–10 to determine
uncompensated care payments to IHS and
Tribal hospitals. However, as discussed in
section IV.E. of the preamble of this final
rule, after considering input received from
our consultations with Tribal officials, we are
also establishing a new supplemental
payment for IHS/Tribal hospitals beginning
in FY 2023 to avoid undue long-term
financial disruption to these hospitals as a
result of discontinuing the use of low-income
insured days as a proxy for uncompensated
care.
VIII. Executive Order 12866
In accordance with the provisions of
Executive Order 12866, the Office of
Management and Budget reviewed this final
rule.
Appendix B: Recommendation of
Update Factors for Operating Cost
Rates of Payment for Inpatient Hospital
Services
I. Background
Section 1886(e)(4)(A) of the Act requires
that the Secretary, taking into consideration
the recommendations of MedPAC,
recommend update factors for inpatient
hospital services for each fiscal year that take
into account the amounts necessary for the
efficient and effective delivery of medically
appropriate and necessary care of high
quality. Under section 1886(e)(5) of the Act,
we are required to publish update factors
recommended by the Secretary in the
proposed and final IPPS rules. Accordingly,
this Appendix provides the
recommendations for the update factors for
the IPPS national standardized amount, the
hospital-specific rate for SCHs and MDHs,
and the rate-of-increase limits for certain
hospitals excluded from the IPPS, as well as
LTCHs. In prior years, we made a
recommendation in the IPPS proposed rule
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
II. Inpatient Hospital Update for FY 2023
A. FY 2023 Inpatient Hospital Update
As discussed in section IV.A. of the
preamble to this final rule, for FY 2023,
consistent with section 1886(b)(3)(B) of the
Act, as amended by sections 3401(a) and
10319(a) of the Affordable Care Act, we are
setting the applicable percentage increase by
applying the following adjustments in the
following sequence. Specifically, the
applicable percentage increase under the
IPPS is equal to the rate-of-increase in the
hospital market basket for IPPS hospitals in
all areas, subject to a reduction of one-quarter
of the applicable percentage increase (prior to
the application of other statutory
adjustments; also referred to as the market
basket update or rate-of-increase (with no
adjustments)) for hospitals that fail to submit
quality information under rules established
by the Secretary in accordance with section
1886(b)(3)(B)(viii) of the Act and a reduction
of three-quarters of the applicable percentage
increase (prior to the application of other
statutory adjustments; also referred to as the
market basket update or rate-of-increase
(with no adjustments)) for hospitals not
considered to be meaningful electronic
health record (EHR) users in accordance with
section 1886(b)(3)(B)(ix) of the Act, and then
subject to an adjustment based on changes in
economy-wide productivity (the productivity
adjustment). Section 1886(b)(3)(B)(xi) of the
Act, as added by section 3401(a) of the
Affordable Care Act, states that application of
the productivity adjustment may result in the
applicable percentage increase being less
than zero. (We note that section
1886(b)(3)(B)(xii) of the Act required an
additional reduction each year only for FYs
2010 through 2019.)
We note that, in compliance with section
404 of the MMA, in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45194 through 45204),
we replaced the 2014-based IPPS operating
and capital market baskets with the rebased
and revised 2018-based IPPS operating and
capital market baskets beginning in FY 2022.
In the FY 2023 IPPS/LTCH PPS proposed
rule, in accordance with section 1886(b)(3)(B)
of the Act, we proposed to base the proposed
FY 2023 market basket update used to
determine the applicable percentage increase
for the IPPS on IGI’s fourth quarter 2021
forecast of the 2018-based IPPS market basket
rate-of-increase with historical data through
third quarter 2021, which was estimated to
be 3.1 percent. In accordance with section
1886(b)(3)(B) of the Act, as amended by
section 3401(a) of the Affordable Care Act, in
section IV.B. of the preamble of the FY 2023
IPPS/LTCH PPS proposed rule, based on
IGI’s fourth quarter 2021 forecast, we
proposed a productivity adjustment of 0.4
percentage point for FY 2023. We also
FY2023
Market Basket Rate-of-Increase
Adjustment for Failure to Submit Quality Data under Section 1886(6)(3)(B)(viii)
of the Act
Adjustment for Failure to be a Meaningful EHR User under Section
1886(6)(3)(B)(ix) of the Act
Productivitv Adiustment under Section 1886(6)(3)(B)(xi) of the Act
Applicable Percenta2e Increase Annlied to Standardized Amount
khammond on DSKJM1Z7X2PROD with RULES2
B. Update for SCHs for FY 2023
Section 1886(b)(3)(B)(iv) of the Act
provides that the FY 2023 applicable
percentage increase in the hospital-specific
rate for SCHs equals the applicable
percentage increase set forth in section
1886(b)(3)(B)(i) of the Act (that is, the same
update factor as for all other hospitals subject
to the IPPS).
Under current law, the MDH program is
effective for discharges through September
30, 2022, as discussed in the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41429 through
41430). Therefore, under current law, the
MDH program will expire at the end of FY
2022. We refer readers to section V.D. of the
preamble of this final rule for further
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
Hospital
Submitted
Quality Data
and is a
Meaningful
EHR User
4.1
Hospital
Submitted
Quality Data
and is NOT
a
Meaningful
EHR User
4.1
Hospital Did
NOT Submit
Quality Data
and is a
Meaningful
EHR User
4.1
Hospital Did
NOT Submit
Quality Data
and is NOT a
Meaningful
EHR User
4.1
0
0
-1.025
-1.025
0
-0.3
3.8
-3.075
-0.3
0.725
0
-0.3
2.775
-3.075
-0.3
-0.3
discussion of the expiration of the MDH
program.
As previously stated, the update to the
hospital specific rate for SCHs is subject to
section 1886(b)(3)(B)(i) of the Act, as
amended by sections 3401(a) and 10319(a) of
the Affordable Care Act. Accordingly,
depending on whether a hospital submits
quality data and is a meaningful EHR user,
we are establishing the same four applicable
percentage increases in the previous table for
the hospital-specific rate applicable to SCHs.
C. FY 2023 Puerto Rico Hospital Update
Because Puerto Rico hospitals are no
longer paid with a Puerto Rico-specific
standardized amount under the amendments
to section 1886(d)(9)(E) of the Act, there is no
longer a need for us to make an update to the
PO 00000
Frm 00719
Fmt 4701
proposed that if more recent data
subsequently became available, we would
use such data, if appropriate, to determine
the FY 2023 market basket update and
productivity adjustment for the FY 2023
IPPS/LTCH PPS final rule.
In the FY 2023 IPPS/LTCH PPS proposed
rule, based on IGI’s fourth quarter 2021
forecast of the 2018-based IPPS market basket
update and the productivity adjustment,
depending on whether a hospital submits
quality data under the rules established in
accordance with section 1886(b)(3)(B)(viii) of
the Act (hereafter referred to as a hospital
that submits quality data) and is a
meaningful EHR user under section
1886(b)(3)(B)(ix) of the Act (hereafter referred
to as a hospital that is a meaningful EHR
user), we presented four applicable
percentage increases that could be applied to
the standardized amount.
In accordance with section 1886(b)(3)(B) of
the Act, as amended by section 3401(a) of the
Affordable Care Act, we are establishing the
applicable percentages increase for the FY
2023 updates based on IGI’s second quarter
2022 forecast of the 2018-based IPPS market
basket of 4.1 percent and the productivity
adjustment of 0.3 percentage point, as
discussed in section V.A of the preamble of
this final rule, depending on whether a
hospital submits quality data under the rules
established in accordance with section
1886(b)(3)(B)(viii) of the Act and is a
meaningful EHR user under section
1886(b)(3)(B)(ix) of the Act, as shown in the
table in this section.
Sfmt 4700
Puerto Rico standardized amount. Hospitals
in Puerto Rico are now paid 100 percent of
the national standardized amount and,
therefore, are subject to the same update to
the national standardized amount discussed
under section IV.A.1. of the preamble of this
final rule.
In addition, as discussed in section IV.A.2.
of the preamble of this final rule, section 602
of Public Law 114–113 amended section
1886(n)(6)(B) of the Act to specify that
subsection (d) Puerto Rico hospitals are
eligible for incentive payments for the
meaningful use of certified EHR technology,
effective beginning FY 2016. In addition,
section 1886(n)(6)(B) of the Act was amended
to specify that the adjustments to the
applicable percentage increase under section
1886(b)(3)(B)(ix) of the Act apply to
E:\FR\FM\10AUR2.SGM
10AUR2
ER10AU22.250
and final rule for the update factors for the
payment rates for IRFs and IPFs. However,
for FY 2023, consistent with our approach for
FY 2022, we are including the Secretary’s
recommendation for the update factors for
IRFs and IPFs in separate Federal Register
documents at the time that we announce the
annual updates for IRFs and IPFs. We also
discuss our response to MedPAC’s
recommended update factors for inpatient
hospital services.
49497
khammond on DSKJM1Z7X2PROD with RULES2
49498
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
subsection (d) Puerto Rico hospitals that are
not meaningful EHR users, effective
beginning FY 2022.
Accordingly, for FY 2022, section
1886(b)(3)(B)(ix) of the Act in conjunction
with section 602(d) of Public Law 114–113
requires that any subsection (d) Puerto Rico
hospital that is not a meaningful EHR user as
defined in section 1886(n)(3) of the Act and
not subject to an exception under section
1886(b)(3)(B)(ix) of the Act will have ‘‘threequarters’’ of the applicable percentage
increase (prior to the application of other
statutory adjustments), or three-quarters of
the applicable market basket rate-of-increase,
reduced by 331⁄3 percent. The reduction to
three-quarters of the applicable percentage
increase for subsection (d) Puerto Rico
hospitals that are not meaningful EHR users
increases to 662⁄3 percent for FY 2023, and,
for FY 2024 and subsequent fiscal years, to
100 percent. In the FY 2019 IPPS/LTCH PPS
final rule, we finalized the payment
reductions (83 FR 41674).
Based on IGI’s fourth quarter 2021 forecast
of the 2018-based IPPS market basket update
with historical data through third quarter
2021, in the FY 2023 IPPS/LTCH PPS
proposed rule, in accordance with section
1886(b)(3)(B) of the Act, as previously
discussed, for Puerto Rico hospitals, we
proposed a market basket update of 3.1
percent and a productivity adjustment of 0.4
percentage point. Therefore, for FY 2023,
depending on whether a Puerto Rico hospital
is a meaningful EHR user, we stated that
there are two possible applicable percentage
increases that can be applied to the
standardized amount. Based on these data,
we determined the following proposed
applicable percentage increases to the
standardized amount for FY 2023 for Puerto
Rico hospitals:
• For a Puerto Rico hospital that is a
meaningful EHR user, we proposed an
applicable percentage increase to the FY
2023 operating standardized amount of 2.7
percent (that is, the FY 2023 estimate of the
proposed market basket rate-of-increase of
3.1 percent less an adjustment of 0.4
percentage point for the proposed
productivity adjustment).
• For a Puerto Rico hospital that is not a
meaningful EHR user, we proposed an
applicable percentage increase to the
operating standardized amount of 1.15
percent (that is, the FY 2023 estimate of the
proposed market basket rate-of-increase of
3.1 percent, less an adjustment of 1.55
percentage point (the proposed market basket
rate-of-increase of 3.1 percent × 0.75 × (2⁄3) for
failure to be a meaningful EHR user), and less
an adjustment of 0.4 percentage point for the
proposed productivity adjustment).
As noted previously, we proposed that if
more recent data subsequently became
available, we would use such data, if
appropriate, to determine the FY 2023 market
basket update and the productivity
adjustment for the FY 2023 IPPS/LTCH PPS
final rule.
As discussed in section V.A.1. of the
preamble of this final rule, based on more
recent data available for this FY 2023 IPPS/
LTCH PPS final rule (that is, IGI’s second
quarter 2022 forecast of the 2018-based IPPS
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
market basket rate-of-increase with historical
data through the first quarter of 2022), we
estimate that the FY 2023 market basket
update used to determine the applicable
percentage increase for the IPPS is 4.1
percent less a productivity adjustment of 0.3
percentage point. Therefore, in accordance
with section 1886(b)(3)(B) of the Act, for this
final rule, for Puerto Rico hospitals the more
recent update of the market basket update is
4.1 percent and a productivity adjustment of
0.3 percentage point. For FY 2023, depending
on whether a Puerto Rico hospital is a
meaningful EHR user, there are two possible
applicable percentage increases that can be
applied to the standardized amount. Based
on these data, we determined the following
applicable percentage increases to the
standardized amount for FY 2023 for Puerto
Rico hospitals:
• For a Puerto Rico hospital that is a
meaningful EHR user, an applicable
percentage increase to the FY 2023 operating
standardized amount of 3.8 percent (that is,
the FY 2023 estimate of the market basket
rate-of-increase of 4.1 percent less an
adjustment of 0.3 percentage point for the
productivity adjustment).
• For a Puerto Rico hospital that is not a
meaningful EHR user, an applicable
percentage increase to the operating
standardized amount of 1.75 percent (that is,
the FY 2023 estimate of the market basket
rate-of-increase of 4.1 percent, less an
adjustment of 2.05 percentage point (the
market basket rate of-increase of 4.1 percent
× 0.75 × (2⁄3) for failure to be a meaningful
EHR user), and less an adjustment of 0.3
percentage point for the productivity
adjustment).
D. Update for Hospitals Excluded From the
IPPS for FY 2023
Section 1886(b)(3)(B)(ii) of the Act is used
for purposes of determining the percentage
increase in the rate-of-increase limits for
children’s hospitals, cancer hospitals, and
hospitals located outside the 50 States, the
District of Columbia, and Puerto Rico (that is,
short-term acute care hospitals located in the
U.S. Virgin Islands, Guam, the Northern
Mariana Islands, and America Samoa).
Section 1886(b)(3)(B)(ii) of the Act sets the
percentage increase in the rate-of-increase
limits equal to the market basket percentage
increase. In accordance with § 403.752(a) of
the regulations, religious nonmedical health
care institutions (RNHCIs) are paid under the
provisions of § 413.40, which also use section
1886(b)(3)(B)(ii) of the Act to update the
percentage increase in the rate-of-increase
limits.
Currently, children’s hospitals, PPSexcluded cancer hospitals, RNHCIs, and
short-term acute care hospitals located in the
U.S. Virgin Islands, Guam, the Northern
Mariana Islands, and American Samoa are
among the remaining types of hospitals still
paid under the reasonable cost methodology,
subject to the rate-of-increase limits. In
addition, in accordance with § 412.526(c)(3)
of the regulations, extended neoplastic
disease care hospitals (described in
§ 412.22(i) of the regulations) also are subject
to the rate-of-increase limits. As discussed in
section VII. of the preamble of this final rule,
PO 00000
Frm 00720
Fmt 4701
Sfmt 4700
we are finalizing to use the percentage
increase in the 2018-based IPPS operating
market basket to update the target amounts
for children’s hospitals, PPS-excluded cancer
hospitals, RNHCIs, short-term acute care
hospitals located in the U.S. Virgin Islands,
Guam, the Northern Mariana Islands, and
American Samoa, and extended neoplastic
disease care hospitals for FY 2023 and
subsequent fiscal years. Accordingly, for FY
2023, the rate-of-increase percentage to be
applied to the target amount for these
children’s hospitals, cancer hospitals,
RNHCIs, extended neoplastic disease care
hospitals, and short-term acute care hospitals
located in the U.S. Virgin Islands, Guam, the
Northern Mariana Islands, and American
Samoa is the FY 2023 percentage increase in
the 2018-based IPPS operating market basket.
For this final rule, the current estimate of the
IPPS operating market basket percentage
increase for FY 2023 is 4.1 percent.
E. Update for LTCHs for FY 2023
Section 123 of Public Law 106–113, as
amended by section 307(b) of Public Law
106–554 (and codified at section 1886(m)(1)
of the Act), provides the statutory authority
for updating payment rates under the LTCH
PPS.
As discussed in section V.A. of the
Addendum to this final rule, we are
establishing an update to the LTCH PPS
standard Federal payment rate for FY 2023 of
3.8 percent, consistent with section
1886(m)(3) of the Act which provides that
any annual update be reduced by the
productivity adjustment described in section
1886(b)(3)(B)(xi)(II) of the Act (that is, the
productivity adjustment). Furthermore, in
accordance with the LTCHQR Program under
section 1886(m)(5) of the Act, we are
reducing the annual update to the LTCH PPS
standard Federal rate by 2.0 percentage
points for failure of a LTCH to submit the
required quality data. Accordingly, we are
establishing an update factor of 1.038 in
determining the LTCH PPS standard Federal
rate for FY 2023. For LTCHs that fail to
submit quality data for FY 2023, we are
establishing an annual update to the LTCH
PPS standard Federal rate of 1.8 percent (that
is, the annual update for FY 2023 of 3.8
percent less 2.0 percentage points for failure
to submit the required quality data in
accordance with section 1886(m)(5)(C) of the
Act and our rules) by applying a update
factor of 1.018 in determining the LTCH PPS
standard Federal rate for FY 2023. (We note
that, as discussed in section VII.D. of the
preamble of this final rule, the update to the
LTCH PPS standard Federal payment rate of
3.8 percent for FY 2023 does not reflect any
budget neutrality factors.)
III. Secretary’s Recommendations
MedPAC is recommending inpatient
hospital rates be updated by the amount
specified in current law. MedPAC’s rationale
for this update recommendation is described
in more detail in this section of the final rule.
As previously stated, section 1886(e)(4)(A) of
the Act requires that the Secretary, taking
into consideration the recommendations of
MedPAC, recommend update factors for
inpatient hospital services for each fiscal year
E:\FR\FM\10AUR2.SGM
10AUR2
Federal Register / Vol. 87, No. 153 / Wednesday, August 10, 2022 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES2
that take into account the amounts necessary
for the efficient and effective delivery of
medically appropriate and necessary care of
high quality. Consistent with current law,
depending on whether a hospital submits
quality data and is a meaningful EHR user,
we are recommending the four applicable
percentage increases to the standardized
amount listed in the table under section II.
of this Appendix B. We are recommending
that the same applicable percentage increases
apply to SCHs.
In addition to making a recommendation
for IPPS hospitals, in accordance with
section 1886(e)(4)(A) of the Act, we are
recommending update factors for certain
other types of hospitals excluded from the
IPPS. Consistent with our policies for these
facilities, we are recommending an update to
the target amounts for children’s hospitals,
cancer hospitals, RNHCIs, short-term acute
care hospitals located in the U.S. Virgin
Islands, Guam, the Northern Mariana Islands,
and American Samoa and extended
neoplastic disease care hospitals of 4.1
percent.
For FY 2023, consistent with policy set
forth in section VII. of the preamble of this
VerDate Sep<11>2014
00:20 Aug 10, 2022
Jkt 256001
final rule, for LTCHs that submit quality data,
we are recommending an update of 3.8
percent to the LTCH PPS standard Federal
rate. For LTCHs that fail to submit quality
data for FY 2023, we are recommending an
annual update to the LTCH PPS standard
Federal rate of 1.8 percent.
IV. MedPAC Recommendation for Assessing
Payment Adequacy and Updating Payments
in Traditional Medicare
In its March 2022 Report to Congress,
MedPAC assessed the adequacy of current
payments and costs, and the relationship
between payments and an appropriate cost
base. MedPAC recommended an update to
the hospital inpatient rates by the amount
specified in current law. MedPAC stated that
their payment adequacy indicators are mixed
but generally positive, and MedPAC
anticipates changes caused by the PHE to be
temporary. MedPAC anticipates that their
recommendation to update the IPPS payment
rate by the amount specified under current
law in 2023 will be enough to maintain
beneficiaries’ access to hospital inpatient and
outpatient care and keep IPPS payment rates
close to the cost of delivering high-quality
PO 00000
Frm 00721
Fmt 4701
Sfmt 9990
49499
care efficiently. We refer readers to the March
2022 MedPAC report, which is available for
download at www.medpac.gov, for a
complete discussion on these
recommendations.
Response: With regard to MedPAC’s
recommendation of an update to the hospital
inpatient rates equal to the amount specified
in current law, section 1886(b)(3)(B) of the
Act sets the requirements for the FY 2023
applicable percentage increase. Therefore,
consistent with the statute, we are
establishing an applicable percentage
increase for FY 2023 of 3.8 percent, provided
the hospital submits quality data and is a
meaningful EHR user consistent with these
statutory requirements.
We note that, because the operating and
capital payments in the IPPS remain
separate, we are continuing to use separate
updates for operating and capital payments
in the IPPS. The update to the capital rate is
discussed in section III. of the Addendum to
this final rule.
[FR Doc. 2022–16472 Filed 8–1–22; 4:15 pm]
BILLING CODE 4120–01–P
E:\FR\FM\10AUR2.SGM
10AUR2
Agencies
[Federal Register Volume 87, Number 153 (Wednesday, August 10, 2022)]
[Rules and Regulations]
[Pages 48780-49499]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-16472]
[[Page 48779]]
Vol. 87
Wednesday,
No. 153
August 10, 2022
Part II
Department of Health and Human Services
-----------------------------------------------------------------------
Centers for Medicare & Medicaid Services
-----------------------------------------------------------------------
42 CFR Parts 412, 413, et al.
Medicare Program; Hospital Inpatient Prospective Payment Systems for
Acute Care Hospitals and the Long Term Care Hospital Prospective
Payment System and Policy Changes and Fiscal Year 2023 Rates; Quality
Programs and Medicare Promoting Interoperability Program Requirements
for Eligible Hospitals and Critical Access Hospitals; Costs Incurred
for Qualified and Non-qualified Deferred Compensation Plans; and
Changes to Hospital and Critical Access Hospital Conditions of
Participation; Final Rule
Federal Register / Vol. 87 , No. 153 / Wednesday, August 10, 2022 /
Rules and Regulations
[[Page 48780]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
42 CFR Parts 412, 413, 482, 485, and 495
[CMS-1771-F]
RIN 0938-AU84
Medicare Program; Hospital Inpatient Prospective Payment Systems
for Acute Care Hospitals and the Long-Term Care Hospital Prospective
Payment System and Policy Changes and Fiscal Year 2023 Rates; Quality
Programs and Medicare Promoting Interoperability Program Requirements
for Eligible Hospitals and Critical Access Hospitals; Costs Incurred
for Qualified and Non-Qualified Deferred Compensation Plans; and
Changes to Hospital and Critical Access Hospital Conditions of
Participation
AGENCY: Centers for Medicare & Medicaid Services (CMS), Department of
Health and Human Services (HHS).
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: This final rule will: revise the Medicare hospital inpatient
prospective payment systems (IPPS) for operating and capital-related
costs of acute care hospitals; make changes relating to Medicare
graduate medical education (GME) for teaching hospitals; update the
payment policies and the annual payment rates for the Medicare
prospective payment system (PPS) for inpatient hospital services
provided by long-term care hospitals (LTCHs). In addition it will
establish new requirements and revise existing requirements for
eligible hospitals and critical access hospitals (CAHs) participating
in the Medicare Promoting Interoperability Program; and update policies
for the Hospital Readmissions Reduction Program, Hospital Inpatient
Quality Reporting (IQR) Program, Hospital VBP Program, Hospital-
Acquired Condition (HAC) Reduction Program, PPS-Exempt Cancer Hospital
Reporting (PCHQR) Program, and the Long-Term Care Hospital Quality
Reporting Program (LTCH QRP). It will also revise the hospital and
critical access hospital (CAH) conditions of participation (CoPs) for
infection prevention and control and antibiotic stewardship programs;
and codify and clarify policies related to the costs incurred for
qualified and non-qualified deferred compensation plans. Lastly, this
final rule will provide updates on the Rural Community Hospital
Demonstration Program and the Frontier Community Health Integration
Project.
DATES: This final rule is effective October 1, 2022.
FOR FURTHER INFORMATION CONTACT: Donald Thompson, and Michele Hudson,
(410) 786-4487 or [email protected], Operating Prospective Payment, MS-
DRG Relative Weights, Wage Index, Hospital Geographic
Reclassifications, Graduate Medical Education, Capital Prospective
Payment, Excluded Hospitals, Medicare Disproportionate Share Hospital
(DSH) Payment Adjustment, Sole Community Hospitals (SCHs), Medicare-
Dependent Small Rural Hospital (MDH) Program, Low-Volume Hospital
Payment Adjustment, and Critical Access Hospital (CAH) Issues.
Emily Lipkin, and Jim Mildenberger, [email protected], Long-Term Care
Hospital Prospective Payment System and MS-LTC-DRG Relative Weights
Issues.
Adina Hersko, [email protected], New Technology Add-On
Payments and New COVID-19 Treatments Add-on Payments Issues.
Mady Hue, [email protected], and Andrea Hazeley,
[email protected], MS-DRG Classifications Issues.
Siddhartha Mazumdar, siddhartha.mazumdar @cms.hhs,gov, Rural
Community Hospital Demonstration Program Issues.
Jeris Smith, [email protected], Frontier Community Health
Integration Project Demonstration Issues.
Sophia Chan, [email protected], Hospital Readmissions
Reduction Program--Administration Issues.
Tyson Nakashima, [email protected], Hospital Readmissions
Reduction Program--Measures Issues.
Jennifer Tate, [email protected], Hospital-Acquired
Condition Reduction Program--Administration Issues
Yuling Li, [email protected], Hospital-Acquired Condition
Reduction Program--Measures Issues.
Julia Venanzi, [email protected], Hospital Inpatient
Quality Reporting Program and Hospital Value-Based Purchasing Program--
Administration Issues
Melissa Hager, [email protected] and Ngozi Uzokwe,
[email protected]--Hospital Inpatient Quality Reporting Program
and Hospital Value-Based Purchasing Program--Measures Issues Except
Hospital Consumer Assessment of Healthcare Providers and Systems
Issues.
Elizabeth Goldstein, [email protected], Hospital
Inpatient Quality Reporting and Hospital Value-Based Purchasing--
Hospital Consumer Assessment of Healthcare Providers and Systems
Measures Issues.
Ora Dawedeit, [email protected], PPS-Exempt Cancer Hospital
Quality Reporting--Administration Issues.
Leah Domino, [email protected], PPS-Exempt Cancer Hospital
Quality Reporting Program-Measure Issues
Ariel Cress, [email protected], Long-Term Care Hospital
Quality Reporting Program--Data Reporting Issues.
Elizabeth Holland, [email protected], Medicare
Promoting Interoperability Program.
Dawn Linn, [email protected], Lela Strong,
[email protected], and Alpha Wilson, [email protected],
Conditions of Participation (CoP) Requirements for Hospitals and
Critical Access Hospitals (CAHs) to Continue Reporting Data for COVID-
19 and Influenza After the PHE ends as Determined by the Secretary.
SUPPLEMENTARY INFORMATION:
Tables Available Through the internet on the CMS website
The IPPS tables for this fiscal year (FY) 2023 final rule are
available through the internet on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. Click on the link on the left side of the
screen titled ``FY 2023 IPPS Final rule Home Page'' or ``Acute
Inpatient--Files for Download.'' The LTCH PPS tables for this FY 2023
final rule are available through the internet on the CMS website at
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/LongTermCareHospitalPPS/ under the list item for Regulation
Number CMS-1771-F. For further details on the contents of the tables
referenced in this final rule, we refer readers to section VI. of the
Addendum to this FY 2023 IPPS/LTCH PPS final rule.
Readers who experience any problems accessing any of the tables
that are posted on the CMS websites, as previously identified, should
contact Michael Treitel, [email protected].
Table of Contents
I. Executive Summary and Background
A. Executive Summary
B. Background Summary
C. Summary of Provisions of Recent Legislation Implemented in
This Final Rule
[[Page 48781]]
D. Issuance of Proposed Rulemaking
E. Advancing Health Information Exchange
F. Use of FY 2021 Data and Methodology Modifications for the FY
2023 IPPS and LTCH PPS Ratesetting
II. Changes to Medicare Severity Diagnosis-Related Group (MS-DRG)
Classifications and Relative Weights
A. Background
B. Adoption of the MS-DRGs and MS-DRG Reclassifications
C. FY 2023 MS-DRG Documentation and Coding Adjustment
D. Changes to Specific MS-DRG Classifications
E. Recalibration of the FY 2023 MS-DRG Relative Weights
F. Add-On Payments for New Services and Technologies for FY 2023
III. Changes to the Hospital Wage Index for Acute Care Hospitals
A. Background
B. Worksheet S-3 Wage Data for the FY 2022 Wage Index
C. Verification of Worksheet S-3 Wage Data
D. Method for Computing the FY 2022 Unadjusted Wage Index
E. Occupational Mix Adjustment to the FY 2023 Wage Index
F. Analysis and Implementation of the Occupational Mix
Adjustment and the FY 2023 Occupational Mix Adjusted Wage Index
G. Application of the Rural Floor, Application of the State
Frontier Floor, and Continuation of the Low Wage Index Hospital
Policy, and Budget Neutrality Adjustment
H. FY 2023 Wage Index Tables
I. Revisions to the Wage Index Based on Hospital Redesignations
and Reclassifications
J. Out-Migration Adjustment Based on Commuting Patterns of
Hospital Employees
K. Reclassification From Urban to Rural Under Section
1886(d)(8)(E) of the Act Implemented at 42 CFR 412.103
L. Process for Requests for Wage Index Data Corrections
M. Labor-Related Share for the FY 2023 Wage Index
IV. Payment Adjustment for Medicare Disproportionate Share Hospitals
(DSHs) for FY 2023 (Sec. 412.106)
A. General Discussion
B. Eligibility for Empirically Justified Medicare DSH Payments
and Uncompensated Care Payments
C. Empirically Justified Medicare DSH Payments
D. Uncompensated Care Payments
E. Supplemental Payment for Indian Health Service and Tribal
Hospitals and Puerto Rico Hospitals for FY 2023 and Subsequent
Fiscal Years
F. Counting Days Associated With Section 1115 Demonstrations in
the Medicaid Fraction
V. Other Decisions and Changes to the IPPS for Operating Costs
A. Changes in the Inpatient Hospital Updates for FY 2022 (Sec.
412.64(d))
B. Rural Referral Centers (RRCs)--Annual Updates to Case-Mix
Index (CMI) and Discharge Criteria (Sec. 412.96)
C. Payment Adjustment for Low-Volume Hospitals (Sec. 412.101)
D. Changes in the Medicare-Dependent, Small Rural Hospital (MDH)
Program (Sec. 412.108)
E. Indirect Medical Education (IME) Payment Adjustment Factor
(Sec. 412.105)
F. Payment for Indirect and Direct Graduate Medical Education
Costs (Sec. Sec. 412.105 and 413.75 Through 413.83)
G. Payment Adjustment for Certain Clinical Trial and Expanded
Access Use Immunotherapy Cases (Sec. Sec. 412.85 and 412.312)
H. Hospital Readmissions Reduction Program: Updates and Changes
(Sec. Sec. 412.150 Through 412.154)
I. Hospital Value-Based Purchasing (VBP) Program: Policy Changes
J. Hospital-Acquired Conditions (HAC) Reduction Program: Updates
and Changes (Sec. 412.170)
K. Rural Community Hospital Demonstration Program
VI. Changes to the IPPS for Capital-Related Costs
A. Overview
B. Additional Provisions
C. Annual Update for FY 2023
VII. Changes for Hospitals Excluded From the IPPS
A. Rate-of-Increase in Payments to Excluded Hospitals for FY
2023
B. Critical Access Hospitals (CAHs)
VIII. Changes to the Long-Term Care Hospital Prospective Payment
System (LTCH PPS) for FY 2023
A. Background of the LTCH PPS
B. Medicare Severity Long-Term Care Diagnosis-Related Group (MS-
LTC-DRG) Classifications and Relative Weights for FY 2023
C. Changes to the LTCH PPS Payment Rates and Other Changes to
the LTCH PPS for FY 2023
IX. Quality Data Reporting Requirements for Specific Providers and
Suppliers
A. Assessment of the Impact of Climate Change and Health Equity
B. Overarching Principles for Measuring Healthcare Quality
Disparities Across CMS Quality Programs--Request for Information
C. Continuing To Advance to Digital Quality Measurement and the
Use of Fast Healthcare Interoperability Resources (FHIR) in Hospital
Quality Programs--Request for Information
D. Advancing the Trusted Exchange Framework and Common
Agreement--Request for Information
E. Hospital Inpatient Quality Reporting (IQR) Program
F. PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program
G. Long-Term Care Hospital Quality Reporting Program (LTCH QRP)
H. Changes to the Medicare Promoting Interoperability Program
X. Changes for Hospitals and Other Providers and Suppliers
A. Codification of the Costs Incurred for Qualified and Non-
Qualified Deferred Compensation Plans
B. Condition of Participation (CoP) Requirements for Hospitals
and CAHs To Continue Reporting Data for COVID-19 and Influenza After
the PHE Ends as Determined by the Secretary
C. Request for Public Comments on IPPS Payment Adjustment for
N95 Respirators That Are Wholly Domestically Made
XI. MedPAC Recommendations
XII. Other Required Information
A. Publicly Available Files
B. Collection of Information Requirements
I. Executive Summary and Background
A. Executive Summary
1. Purpose and Legal Authority
This FY 2023 IPPS/LTCH PPS final rule makes payment and policy
changes under the Medicare inpatient prospective payment systems (IPPS)
for operating and capital-related costs of acute care hospitals as well
as for certain hospitals and hospital units excluded from the IPPS. In
addition, it makes payment and policy changes for inpatient hospital
services provided by long-term care hospitals (LTCHs) under the long-
term care hospital prospective payment system (LTCH PPS). This final
rule also makes policy changes to programs associated with Medicare
IPPS hospitals, IPPS-excluded hospitals, and LTCHs. In this FY 2023
final rule, we are implementing a permanent policy to cap wage index
decreases as well as continuing policies to address wage index
disparities impacting low wage index hospitals. We also are making
changes relating to Medicare graduate medical education (GME) for
teaching hospitals and new technology add-on payments.
We are establishing new requirements and revising existing
requirements for eligible hospitals and CAHs participating in the
Medicare Promoting Interoperability Program.
This final rule also acknowledges feedback we received on requests
for information on health impacts due to climate change, on overarching
principles in measuring healthcare quality disparities in hospital
quality programs and value-based purchasing programs, the LTCH QRP, and
on advancing the Trusted Exchange Framework and Common Agreement
(TEFCA). We thank commenters for their feedback.
Additionally, due to the impact of the COVID-19 PHE on measure data
used in the Hospital VBP Program and HAC Reduction Program, we are
finalizing our proposals to suppress several measures in both of those
programs for purposes of FY 2023 scoring and payment adjustments. For
transparency, we will continue to publicly report measure information
for all measures, including suppressed measures. In addition to these
measure suppressions
[[Page 48782]]
for the Hospital VBP Program, we are finalizing our proposal to
implement a special scoring methodology for FY 2023 that results in
each hospital receiving a value-based incentive payment amount that
matches their 2 percent reduction to the base operating MS-DRG payment
amount. Similarly, we are finalizing our proposal to suppress all six
measures in the HAC Reduction Program for the FY 2023 program year. We
are not finalizing our proposal to not calculate measure results or
scores for the CMS PSI 90 measure. Although we will not calculate or
report the CMS PSI 90 measure results for use in the HAC Reduction
Program scoring calculations for the program year, we will still
calculate and report CMS PSI 90 that is displayed on the main pages of
the Care Compare tool hosted by HHS after confidentially reporting
these results to hospitals via hospital-specific reports and a 30-day
preview period. Additionally, we will continue to calculate and report
measure results for the NHSN CDC HAI measures. For the FY 2023 program
year, hospitals participating in the HAC Reduction Program will not be
given a Total HAC score, nor will hospitals receive a payment penalty.
We are also providing estimated and newly established performance
standards for the Hospital VBP Program. For the Hospital Readmissions
Reduction Program, we are resuming the use of the one measure (which
was previously suppressed for the FY 2023 applicable period) for the FY
2024 applicable period, and incorporating measure updates to the six
condition/procedure measures addressed by the Hospital Readmission
Reduction Program to account for patient history of COVID-19.
Under various statutory authorities, we either discuss continued
program implementation or make changes to the Medicare IPPS, the LTCH
PPS, other related payment methodologies and programs for FY 2023 and
subsequent fiscal years, and other policies and provisions included in
this rule. These statutory authorities include, but are not limited to,
the following:
Section 1886(d) of the Social Security Act (the Act),
which sets forth a system of payment for the operating costs of acute
care hospital inpatient stays under Medicare Part A (Hospital
Insurance) based on prospectively set rates. Section 1886(g) of the Act
requires that, instead of paying for capital-related costs of inpatient
hospital services on a reasonable cost basis, the Secretary use a
prospective payment system (PPS).
Section 1886(d)(1)(B) of the Act, which specifies that
certain hospitals and hospital units are excluded from the IPPS. These
hospitals and units are: rehabilitation hospitals and units; LTCHs;
psychiatric hospitals and units; children's hospitals; cancer
hospitals; extended neoplastic disease care hospitals, and hospitals
located outside the 50 States, the District of Columbia, and Puerto
Rico (that is, hospitals located in the U.S. Virgin Islands, Guam, the
Northern Mariana Islands, and American Samoa). Religious nonmedical
health care institutions (RNHCIs) are also excluded from the IPPS.
Sections 123(a) and (c) of the BBRA (Public Law (Pub. L.)
106-113) and section 307(b)(1) of the BIPA (Pub. L. 106-554) (as
codified under section 1886(m)(1) of the Act), which provide for the
development and implementation of a prospective payment system for
payment for inpatient hospital services of LTCHs described in section
1886(d)(1)(B)(iv) of the Act.
Sections 1814(l), 1820, and 1834(g) of the Act, which
specify that payments are made to critical access hospitals (CAHs)
(that is, rural hospitals or facilities that meet certain statutory
requirements) for inpatient and outpatient services and that these
payments are generally based on 101 percent of reasonable cost.
Section 1886(a)(4) of the Act, which specifies that costs
of approved educational activities are excluded from the operating
costs of inpatient hospital services. Hospitals with approved graduate
medical education (GME) programs are paid for the direct costs of GME
in accordance with section 1886(h) of the Act.
Section 1886(b)(3)(B)(viii) of the Act, which requires the
Secretary to reduce the applicable percentage increase that would
otherwise apply to the standardized amount applicable to a subsection
(d) hospital for discharges occurring in a fiscal year if the hospital
does not submit data on measures in a form and manner, and at a time,
specified by the Secretary.
Section 1866(k) of the Act, which provides for the
establishment of a quality reporting program for hospitals described in
section 1886(d)(1)(B)(v) of the Act, referred to as ``PPS-exempt cancer
hospitals.''
Section 1886(o) of the Act, which requires the Secretary
to establish a Hospital Value-Based Purchasing (VBP) Program, under
which value-based incentive payments are made in a fiscal year to
hospitals meeting performance standards established for a performance
period for such fiscal year.
Section 1886(p) of the Act, which establishes a Hospital-
Acquired Condition (HAC) Reduction Program, under which payments to
applicable hospitals are adjusted to provide an incentive to reduce
hospital-acquired conditions.
Section 1886(q) of the Act, as amended by section 15002 of
the 21st Century Cures Act, which establishes the Hospital Readmissions
Reduction Program. Under the program, payments for discharges from an
applicable hospital as defined under section 1886(d) of the Act will be
reduced to account for certain excess readmissions. Section 15002 of
the 21st Century Cures Act directs the Secretary to compare hospitals
with respect to the number of their Medicare-Medicaid dual-eligible
beneficiaries (dual-eligibles) in determining the extent of excess
readmissions.
Section 1886(r) of the Act, as added by section 3133 of
the Affordable Care Act, which provides for a reduction to
disproportionate share hospital (DSH) payments under section
1886(d)(5)(F) of the Act and for a new uncompensated care payment to
eligible hospitals. Specifically, section 1886(r) of the Act requires
that, for fiscal year 2014 and each subsequent fiscal year, subsection
(d) hospitals that would otherwise receive a DSH payment made under
section 1886(d)(5)(F) of the Act will receive two separate payments:
(1) 25 percent of the amount they previously would have received under
section 1886(d)(5)(F) of the Act for DSH (``the empirically justified
amount''), and (2) an additional payment for the DSH hospital's
proportion of uncompensated care, determined as the product of three
factors. These three factors are: (1) 75 percent of the payments that
would otherwise be made under section 1886(d)(5)(F) of the Act; (2) 1
minus the percent change in the percent of individuals who are
uninsured; and (3) a hospital's uncompensated care amount relative to
the uncompensated care amount of all DSH hospitals expressed as a
percentage.
Section 1886(m)(5) of the Act, which requires the
Secretary to reduce by two percentage points the annual update to the
standard Federal rate for discharges for a long-term care hospital
(LTCH) during the rate year for LTCHs that do not submit data in the
form, manner, and at a time, specified by the Secretary.
Section 1886(m)(6) of the Act, as added by section
1206(a)(1) of the Pathway for Sustainable Growth Rate (SGR) Reform Act
of 2013 (Pub. L. 113-67) and amended by section 51005(a) of the
Bipartisan Budget Act of 2018 (Pub.
[[Page 48783]]
L. 115-123), which provided for the establishment of site neutral
payment rate criteria under the LTCH PPS, with implementation beginning
in FY 2016. Section 51005(b) of the Bipartisan Budget Act of 2018
amended section 1886(m)(6)(B) by adding new clause (iv), which
specifies that the IPPS comparable amount defined in clause (ii)(I)
shall be reduced by 4.6 percent for FYs 2018 through 2026.
Section 1899B of the Act, as added by section 2(a) of the
Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT
Act) (Pub. L. 113-185), which provides for the establishment of
standardized data reporting for certain post-acute care providers,
including LTCHs.
Section 1861(e) of the Act provides the specific statutory
authority for the hospital CoPs; section 1820(e) of the Act provides
similar authority for CAHs. The hospital provision at section
1861(e)(9) of the Act authorizes the Secretary to issue regulations the
Secretary deems necessary to protect the health and safety of patients
receiving services in those facilities; the CAH provision at section
1820(e)(3) of the Act authorizes the Secretary to issue such other
criteria as the Secretary may require.
2. Summary of the Major Provisions
The following is a summary of the major provisions in this final
rule. In general, these major provisions are being finalized as part of
the annual update to the payment policies and payment rates, consistent
with the applicable statutory provisions. A general summary of the
changes in this final rule is presented in section I.D. of the preamble
of this final rule.
a. MS-DRG Documentation and Coding Adjustment
Section 631 of the American Taxpayer Relief Act of 2012 (ATRA, Pub.
L. 112- 240) amended section 7(b)(1)(B) of Pub. L. 110-90 to require
the Secretary to make a recoupment adjustment to the standardized
amount of Medicare payments to acute care hospitals to account for
changes in MS-DRG documentation and coding that do not reflect real
changes in case-mix, totaling $11 billion over a 4-year period of FYs
2014, 2015, 2016, and 2017. The FY 2014 through FY 2017 adjustments
represented the amount of the increase in aggregate payments as a
result of not completing the prospective adjustment authorized under
section 7(b)(1)(A) of Public Law 110-90 until FY 2013. Prior to the
ATRA, this amount could not have been recovered under Public Law 110-
90. Section 414 of the Medicare Access and CHIP Reauthorization Act of
2015 (MACRA) (Pub. L. 114-10) replaced the single positive adjustment
we intended to make in FY 2018 with a 0.5 percent positive adjustment
to the standardized amount of Medicare payments to acute care hospitals
for FYs 2018 through 2023. (The FY 2018 adjustment was subsequently
adjusted to 0.4588 percent by section 15005 of the 21st Century Cures
Act.) Therefore, for FY 2023, we are making an adjustment of + 0.5
percent to the standardized amount.
b. Use of FY 2021 Data and Methodology Modifications for the FY 2023
IPPS and LTCH PPS Ratesetting
For the IPPS and LTCH PPS ratesetting, our longstanding goal is
always to use the best available data overall. In section I.F. of the
preamble of this final rule, we discuss our return to our historical
practice of using the most recent data available for purposes of FY
2023 ratesetting, including the FY 2021 MedPAR claims and FY 2020 cost
report data, with certain modifications to our usual ratesetting
methodologies to account for the anticipated decline in COVID-19
hospitalizations of Medicare beneficiaries at IPPS hospitals and LTCHs
as compared to FY 2021. As discussed in greater detail in section I.F.
of the preamble of this final rule, we believe that it is reasonable to
assume that some Medicare beneficiaries will continue to be
hospitalized with COVID-19 at IPPS hospitals and LTCHs in FY 2023.
Given this expectation, we believe it is appropriate to use FY 2021
data, as the most recent available data during the period of the COVID-
19 PHE, for purposes of the FY 2023 IPPS and LTCH PPS ratesetting.
However, as also discussed in greater detail in section I.F. of the
preamble of this final rule, we believe it is reasonable to assume
based on the information available at this time that there will be
fewer COVID-19 hospitalizations in FY 2023 than in FY 2021. Therefore,
we are finalizing our proposal to use the FY 2021 data for purposes of
the FY 2023 IPPS and LTCH PPS ratesetting but with modifications to our
usual ratesetting methodologies to account for the anticipated decline
in COVID-19 hospitalizations of Medicare beneficiaries at IPPS
hospitals and LTCHs as compared to FY 2021.
c. Continuation of the Low Wage Index Hospital Policy
To help mitigate wage index disparities between high wage and low
wage hospitals, in the FY 2020 IPPS/LTCH PPS rule (84 FR 42326 through
42332), we adopted a policy to increase the wage index values for
certain hospitals with low wage index values (the low wage index
hospital policy). This policy was adopted in a budget neutral manner
through an adjustment applied to the standardized amounts for all
hospitals. We also indicated our intention that this policy would be
effective for at least 4 years, beginning in FY 2020, in order to allow
employee compensation increases implemented by these hospitals
sufficient time to be reflected in the wage index calculation. We are
finalizing our proposals for the low wage index hospital policy to
continue for FY 2023, and to apply this policy in a budget neutral
manner by applying an adjustment to the standardized amounts.
d. Permanent Cap on Wage Index Decreases
Consistent with section 1886(d)(3)(E) of the Act, we adjust the
IPPS standardized amounts for area differences in hospital wage levels
by a factor (established by the Secretary) reflecting the relative
hospital wage level in the geographic area of the hospital compared to
the national average hospital wage level and update the wage index
annually based on a survey of wages and wage-related costs of short-
term, acute care hospitals. As described in section III.N. of the
preamble of this final rule, we have further considered the comments we
received during the FY 2022 rulemaking recommending a permanent 5-
percent cap policy to prevent large year-to-year variations in wage
index values as a means to reduce overall volatility for hospitals.
Under the authority at sections 1886(d)(3)(E) and 1886(d)(5)(I)(i) of
the Act, for FY 2023 and subsequent years, we proposed to apply a 5-
percent cap on any decrease to a hospital's wage index from its wage
index in the prior FY, regardless of the circumstances causing the
decline. That is, we proposed that a hospital's wage index for FY 2023
would not be less than 95 percent of its final wage index for FY 2022,
and that for subsequent years, a hospital's wage index would not be
less than 95 percent of its final wage index for the prior FY. We also
proposed to apply the proposed wage index cap policy in a budget
neutral manner through a national adjustment to the standardized amount
under our authority in sections 1886(d)(3)(E) and 1886(d)(5)(I)(i) of
the Act. After consideration of the public comments received, we are
finalizing these proposals without modification.
e. Application of the Rural Floor
As discussed in section III.G.1. of the preamble of this final
rule, based on the
[[Page 48784]]
district court's decision in Citrus HMA, LLC, d/b/a Seven Rivers
Regional Medical Center v. Becerra, No. 1:20-cv-00707 (D.D.C.)
(hereafter referred to as Citrus) and the comments we received, we are
not finalizing our rural floor wage index policy as proposed, which
would have excluded Sec. 412.103 hospitals from the calculation of the
rural floor and from the calculation of ``the wage index for rural
areas in the State in which the county is located'' as referred to in
section 1886(d)(8)(C)(iii) of the Act. Rather, we are finalizing a
policy that calculates the rural floor as it was calculated before FY
2020. For FY 2023 and subsequent years, we are finalizing a policy to
include the wage data of hospitals that have reclassified from urban to
rural under section 1886(d)(8)(E) of the Act (as implemented in the
regulations at Sec. 412.103) and have no additional form of
reclassification (MGCRB or Lugar) in the calculation of the rural
floor, and to include the wage data of such hospitals in the
calculation of ``the wage index for rural areas in the State in which
the county is located'' as referred to in section 1886(d)(8)(C)(iii) of
the Act.
f. DSH Payment Adjustment and Additional Payment for Uncompensated Care
Under section 1886(r) of the Act, which was added by section 3133
of the Affordable Care Act, starting in FY 2014, Medicare
disproportionate share hospitals (DSHs) receive 25 percent of the
amount they previously would have received under the statutory formula
for Medicare DSH payments in section 1886(d)(5)(F) of the Act. The
remaining amount, equal to 75 percent of the amount that otherwise
would have been paid as Medicare DSH payments, is paid as additional
payments after the amount is reduced for changes in the percentage of
individuals that are uninsured. Each Medicare DSH will receive an
additional payment based on its share of the total amount of
uncompensated care for all Medicare DSHs for a given time period.
In this final rule, we are updating our estimates of the three
factors used to determine uncompensated care payments for FY 2023. We
are also continuing to use uninsured estimates produced by CMS' Office
of the Actuary (OACT) as part of the development of the National Health
Expenditure Accounts (NHEA) in conjunction with more recently available
data in the calculation of Factor 2. For FY 2023, we are using the 2
most recent years of audited data on uncompensated care costs from
Worksheet S-10 of the FY 2018 cost reports and the FY 2019 cost reports
to calculate Factor 3 in the uncompensated care payment methodology for
all eligible hospitals. In addition, for FY 2024 and subsequent fiscal
years, we are using a 3-year average of the data on uncompensated care
costs from Worksheet S-10 for the 3 most recent fiscal years for which
audited data are available. Beginning in FY 2023, we are discontinuing
the use of low-income insured days as a proxy for uncompensated care to
determine Factor 3 for Indian Health Service (IHS) and Tribal hospitals
and hospitals located in Puerto Rico. In addition, we are implementing
certain methodological changes for calculating Factor 3 for FY 2023 and
subsequent fiscal years.
We recognize that discontinuing the use of the low-income insured
days proxy to calculate uncompensated care payments for Indian Health
Service (IHS) and Tribal hospitals and hospitals located in Puerto Rico
could result in a significant financial disruption for these hospitals.
Accordingly, we are using our exceptions and adjustments authority
under section 1886(d)(5)(I) of the Act to establish a new supplemental
payment for IHS and Tribal hospitals and hospitals located in Puerto
Rico, beginning in FY 2023.
As noted in section IV.F. of this final rule, we are not moving
forward with the proposed revisions to the regulations relating to the
treatment of section 1115 demonstration days for purposes of the DSH
adjustment in this final rule. We expect to revisit the issue of
section 1115 demonstration days in future rulemaking, and we encourage
interested parties to review any future proposal on this issue and to
submit their comments at that time.
g. Changes to GME Payments Based on Milton S. Hershey Medical Center,
et al. v. Becerra Litigation
On May 17, 2021, the U.S. District Court for the District of
Columbia ruled against CMS's method of calculating direct GME payments
to teaching hospitals when those hospitals' weighted full-time
equivalent (FTE) counts exceed their direct GME FTE cap. In Milton S.
Hershey Medical Center, et al. v. Becerra, the court ordered CMS to
recalculate reimbursement owed, holding that CMS's regulation
impermissibly modified the statutory weighting factors. The plaintiffs
in these consolidated cases alleged that as far back as 2005, the
proportional reduction that CMS applied to the weighted FTE count when
the weighted FTE count exceeded the FTE cap conflicted with the
Medicare statute, and it was an arbitrary and capricious exercise of
agency discretion under the Administrative Procedure Act. The court
held that the proportional reduction methodology impermissibly modified
the weighting factors statutorily assigned to residents and fellows.
The court granted the motion for summary judgment to plaintiffs'
motions, denied defendant's, and remanded to the Agency so that it
could recalculate plaintiffs' reimbursement payments consistent with
the court's opinion.
After reviewing the statutory language regarding the direct GME FTE
cap and the court's opinion, we have decided implement a modified
policy to be applied prospectively for all teaching hospitals, as well
as retroactively to the providers and cost years in Hershey and certain
other providers as described in greater detail in section V.F.2. of the
preamble of this final rule. The modified policy will address
situations for applying the FTE cap when a hospital's weighted FTE
count is greater than its FTE cap, but would not reduce the weighting
factor of residents that are beyond their initial residency period to
an amount less than 0.5. Specifically, effective for cost reporting
periods beginning on or after October 1, 2001, we are specifying that
if the hospital's unweighted number of FTE residents exceeds the FTE
cap, and the number of weighted FTE residents also exceeds that FTE
cap, the respective primary care and obstetrics and gynecology weighted
FTE counts and other weighted FTE counts are adjusted to make the total
weighted FTE count equal the FTE cap. If the number of weighted FTE
residents does not exceed that FTE cap, then the allowable weighted FTE
count for direct GME payment is the actual weighted FTE count.
h. Reduction of Hospital Payments for Excess Readmissions
We are making changes to policies for the Hospital Readmissions
Reduction Program, which was established under section 1886(q) of the
Act, as amended by section 15002 of the 21st Century Cures Act. The
Hospital Readmissions Reduction Program requires a reduction to a
hospital's base operating MS-DRG payment to account for excess
readmissions of selected applicable conditions. For FY 2023, the
reduction is based on a hospital's risk-adjusted readmission rate
during a multi-year period for acute myocardial infarction (AMI), heart
failure (HF), chronic obstructive pulmonary disease (COPD), elective
primary total hip arthroplasty/total knee arthroplasty (THA/TKA), and
coronary artery bypass graft (CABG)
[[Page 48785]]
surgery.\1\ In this FY 2023 IPPS/LTCH PPS final rule, we are discussing
the following policies: (1) resuming use of the Hospital 30-Day, All-
Cause, Risk-Standardized Readmission Rate (RSRR) following Pneumonia
Hospitalization measure (NQF #0506) for the FY 2024 program year; (2)
modification of the Hospital 30-Day, All-Cause, Risk-Standardized
Readmission Rate (RSRR) following Pneumonia Hospitalization measure
(NQF #0506) to exclude patients with COVID-19 diagnosis present on
admission from the measure numerator (outcome) and denominator
(cohort),\2\ beginning with the Hospital Specific Reports (HSRs) for
the FY 2023 program year; and (3) modification of all six condition/
procedure specific measures to include a covariate adjustment for
patient history of COVID-19 within 12 months prior to the index
admission beginning with the FY 2023 program year. In the FY 2023 IPPS/
LTCH PPS proposed rule we also sought comment on updating the Hospital
Readmissions Reduction Program to incorporate provider performance for
socially at-risk populations.
---------------------------------------------------------------------------
\1\ We note that in the FY 2023 IPPS/LTCH PPS proposed rule we
described the policy for FY 2017 and subsequent years, without
reference to flexibility due to the COVID-19 PHE. We have updated
this information to describe the policy for FY 2023.
\2\ We note that in the FY 2023 IPPS/LTCH PPS proposed rule (87
FR 28113) we inadvertently omitted reference to removing COVID-19
diagnosed patients from the numerator. We have corrected this
omission here.
---------------------------------------------------------------------------
i. Hospital Value-Based Purchasing (VBP) Program
Section 1886(o) of the Act requires the Secretary to establish a
Hospital VBP Program under which value-based incentive payments are
made in a fiscal year to hospitals based on their performance on
measures established for a performance period for such fiscal year. In
this final rule, we are finalizing our proposals to: (1) suppress the
Hospital Consumer Assessment of Healthcare Providers and Systems
(HCAHPS) and five Hospital-Acquired Infection (HAI) measures for the FY
2023 program year; and (2) update the baseline periods for certain
measures for the FY 2025 program year. We are also finalizing our
proposal to revise the scoring and payment methodology for the FY 2023
program year such that hospitals will not receive Total Performance
Scores (TPSs). Additionally, we are finalizing our proposal to award
each hospital a payment incentive multiplier that results in a value-
based incentive payment that is equal to the amount withheld for the
fiscal year (2 percent). We note that we are also announcing technical
updates to the measures in the Clinical Outcomes Domain.
j. Hospital-Acquired Condition (HAC) Reduction Program
In this FY 2023 IPPS/LTCH PPS final rule we are finalizing several
changes to the HAC Reduction Program, which was established under
section 1886(p) of the Act, to provide an incentive to hospitals to
reduce the incidence of hospital-acquired conditions. We refer readers
to the FY 2022 IPPS/LTCH PPS final rule for further details on our
measure suppression policy (86 FR 45301 through 45304). In this FY 2023
IPPS/LTCH PPS final rule, we are not finalizing our proposal to not
calculate or report measure results for the CMS PSI 90 measure for the
FY 2023 HAC Reduction Program. Although we will not calculate or report
CMS PSI 90 measure results for use in the HAC Reduction Program scoring
calculations for the program year, we will still calculate and report
CMS PSI 90 that is displayed on the main pages of the Compare tool
hosted by HHS after confidentially reporting these results to hospitals
via CMS PSI 90 specific HSRs and a 30-day preview period. We will
continue to calculate and report measure results for the NHSN CDC HAI
measures.
In this FY 2023 IPPS/LTCH PPS final rule, we are finalizing our
proposals to: (1) suppress the CMS PSI 90 measure and the five CDC NHSN
HAI measures from the calculation of measure scores and the Total HAC
Score, thereby not penalizing any hospital under the HAC Reduction
Program FY 2023 program year; (2) suppress CY 2021 CDC NHSN HAI
measures data from the FY 2024 HAC Reduction Program Year; (3) update
the measure specification to the minimum volume threshold for the CMS
PSI 90 measure beginning with the FY 2023 program year; (4) update the
measure specifications to risk-adjust for COVID-19 diagnosis in the CMS
PSI 90 measure beginning with the FY 2024 HAC Reduction Program Year;
and (5) update the NHSN CDC HAI data submission requirements for newly
opened hospitals beginning in the FY 2024 HAC Reduction Program.
In this FY 2023 IPPS/LTCH PPS final rule, we acknowledge feedback
we received on Requests for Information from stakeholders on two
topics: (1) the potential adoption of two digital National Healthcare
Safety Network (NHSN) measures: the NHSN Healthcare-associated
Clostridioides difficile Infection Outcome measure and NHSN Hospital-
Onset Bacteremia & Fungemia Outcome measure; and (2) on overarching
principles for measuring healthcare quality disparities across CMS
Quality Programs. In the FY 2023 IPPS/LTCH PPS proposed rule and this
final rule, we also clarified the removal of the no mapped location
policy beginning with the FY 2023 program year.
k. Hospital Inpatient Quality Reporting (IQR) Program
Under section 1886(b)(3)(B)(viii) of the Act, subsection (d)
hospitals are required to report data on measures selected by the
Secretary for a fiscal year in order to receive the full annual
percentage increase.
In this FY 2023 IPPS/LTCH PPS final rule, we are finalizing several
changes to the Hospital IQR Program. We are adopting 10 new measures:
(1) Hospital Commitment to Health Equity beginning with the CY 2023
reporting period/FY 2025 payment determination; (2) Screening for
Social Drivers of Health beginning with voluntary reporting for the CY
2023 reporting period and mandatory reporting beginning with the CY
2024 reporting period/FY 2026 payment determination; (3) Screen
Positive Rate for Social Drivers of Health beginning with voluntary
reporting for the CY 2023 reporting period and mandatory reporting
beginning with the CY 2024 reporting period/FY 2026 payment
determination; (4) Cesarean Birth electronic clinical quality measure
(eCQM) with inclusion in the eCQM measure set beginning with the CY
2023 reporting period/FY 2025 payment determination, and mandatory
reporting beginning with the CY 2024 reporting period/FY 2026 payment
determination; (5) Severe Obstetric Complications eCQM with inclusion
in the eCQM measure set beginning with the CY 2023 reporting period/FY
2025 payment determination, and mandatory reporting beginning with the
CY 2024 reporting period/FY 2026 payment determination; (6) Hospital-
Harm--Opioid-Related Adverse Events eCQM (NQF #3501e) inclusion in the
eCQM measure set beginning with the CY 2024 reporting period/FY 2026
payment determination; (7) Global Malnutrition Composite Score eCQM
(NQF #3592e) inclusion in the eCQM measure set beginning with the CY
2024 reporting period/FY 2026 payment determination; (8) Hospital-
Level, Risk Standardized Patient-Reported Outcomes Performance Measure
Following Elective Primary Total Hip Arthroplasty (THA) and/or Total
Knee Arthroplasty (TKA) (NQF #3559) beginning with two voluntary
periods, followed by mandatory reporting for the
[[Page 48786]]
reporting period which runs from July 1, 2025 through June 30, 2026,
impacting the FY 2028 payment determination; (9) Medicare Spending Per
Beneficiary (MSPB) Hospital measure (NQF #2158) beginning with the FY
2024 payment determination; and (10) Hospital-Level Risk-Standardized
Complication Rate (RSCR) Following Elective Primary THA/TKA (NQF #1550)
beginning with the FY 2024 payment determination. We are refining two
current measures beginning with the FY 2024 payment determination: (1)
Hospital[hyphen]Level, Risk[hyphen]Standardized Payment Associated with
an Episode-of-Care for Primary Elective THA/TKA measure; and (2) Excess
Days in Acute Care (EDAC) After Hospitalization for Acute Myocardial
Infarction (AMI) measure (NQF #2881). In this FY 2023 IPPS/LTCH PPS
final rule, we acknowledge feedback we received on the potential future
development and inclusion of two National Healthcare Safety Network
(NHSN) measures: (1) Healthcare-Associated Clostridioides difficile
Infection Outcome; and (2) Hospital-Onset Bacteremia & Fungemia
Outcome. We thank commenters for their feedback.
We are finalizing changes to current policies related to eCQMs and
hybrid measures: (1) Modification of the eCQM reporting and submission
requirements to increase the number of eCQMs to be reported beginning
with the CY 2024 reporting period/FY 2026 payment determination; (2)
removal of the zero denominator declarations and case threshold
exemption policies for hybrid measures beginning with the FY 2026
payment determination; (3) adoption of data submission and reporting
requirements for patient-reported outcome-based performance measures
(PRO-PMs) beginning with the FY 2026 payment determination; and (4)
modification of the eCQM validation policy to increase the requirement
from 75 percent to 100 percent of requested medical records, beginning
with the FY 2025 payment determination.
With respect to public reporting, we are establishing a hospital
designation related to maternity care to be publicly-reported on a
public-facing website beginning in Fall 2023. In the FY 2023 IPPS/PPS
LTCH PPS proposed rule, we sought comments on other potential
associated activities regarding this designation (87 FR 28549 through
28550). Additionally, we sought comments on ongoing ways we can advance
digital quality measurement and use of Fast Healthcare Interoperability
Resources (FHIR) (87 FR 28486 through 28489). We thank commenters for
their feedback.
l. PPS-Exempt Cancer Hospital Quality Reporting Program
Section 1866(k)(1) of the Act requires, for purposes of FY 2014 and
each subsequent fiscal year, that a hospital described in section
1886(d)(1)(B)(v) of the Act (a PPS-exempt cancer hospital, or a PCH)
submit data in accordance with section 1866(k)(2) of the Act with
respect to such fiscal year. There is no financial impact to PCH
Medicare payment if a PCH does not participate.
In this FY 2023 IPPS/LTCH PPS final rule, we are finalizing our
proposal to adopt a patient safety exception into the measure removal
policy. We are also finalizing our proposal to begin public display of
the 30-Day Unplanned Readmissions for Cancer Patients measure (NQF
#3188) (PCH-36). We are finalizing with modification our proposal to
begin public display of the Proportion of Patients Who Died from Cancer
Receiving Chemotherapy in the Last 14 Days of Life measure (NQF #0210)
(PCH-32), the Proportion of Patients Who Died from Cancer Not Admitted
to Hospice measure (NQF #0215) (PCH-34), the Proportion of Patients Who
Died from Cancer Admitted to the ICU in the Last 30 Days of Life
measure (NQF #0213) (PCH-33), and the Proportion of Patients Who Died
from Cancer Admitted to Hospice for Less Than Three Days measure (NQF
#0216) (PCH-35). In addition, along with the Hospital IQR and HAC
Reduction Programs, we respond to comments received on our request for
comment on the potential adoption of two digital National Healthcare
Safety Network (NHSN) measures: the NHSN Healthcare-associated
Clostridioides difficile Infection Outcome measure and NHSN Hospital-
Onset Bacteremia and Fungemia Outcome measure.
m. Medicare Promoting Interoperability Program
For CY 2023, we are finalizing several proposed changes to the
Medicare Promoting Interoperability Program. Specifically, we are: (1)
requiring the Electronic Prescribing Objective's Query of Prescription
Drug Monitoring Program (PDMP) measure while maintaining the associated
points at 10 points beginning with the EHR reporting period in CY 2023;
(2) expanding the Query of PDMP measure to not only include Schedule II
opioids but also Schedule III and IV drugs beginning with the CY 2023
EHR reporting period and are adding exclusions; (3) adding a new Health
Information Exchange (HIE) Objective option, the Enabling Exchange
under the Trusted Exchange Framework and Common Agreement (TEFCA)
measure (requiring a yes/no response), as an optional alternative to
fulfill the objective, beginning with the CY 2023 EHR reporting period;
(4) modifying the Public Health and Clinical Data Exchange Objective by
adding an Antibiotic Use and Antibiotic Resistance (AUR) measure in
addition to the current four required measures (Syndromic Surveillance
Reporting, Immunization Registry Reporting, Electronic Case Reporting,
and Electronic Reportable Laboratory Result Reporting) beginning with
the CY 2024 EHR reporting period; (5) consolidating the current options
from three to two levels of active engagement for the Public Health and
Clinical Data Exchange Objective, requiring the reporting of the active
engagement option selected for the measures under the objective
beginning with the CY 2023 EHR reporting period, and modifying the
amount of time spent at the option 1 level of active engagement (pre-
production and validation) to one EHR reporting period beginning with
the CY 2024 EHR reporting period; (6) modifying the scoring methodology
for the Medicare Promoting Interoperability Program beginning in CY
2023; (7) instituting public reporting of certain Medicare Promoting
Interoperability Program data beginning with the CY 2023 EHR reporting
period; (8) removing regulation text for the objectives and measures in
the Medicare Promoting Interoperability Program from paragraph (e)
under 42 CFR 495.24 and adding new paragraph (f) beginning in CY 2023;
and (9) adopting two new eCQMs in the Medicare Promoting
Interoperability Program's eCQM measure set beginning with the CY 2023
reporting period, two new eCQMs in the Medicare Promoting
Interoperability Program's eCQM measure set beginning with the CY 2024
reporting period, and modifying the eCQM data reporting and submission
requirements to increase the number of eCQMs required to be reported
and the total number of eCQMs to be reported beginning with the CY 2024
reporting period, which is in alignment with the eCQM updates finalized
for the Hospital IQR Program.
n. Condition of Participation (CoP) Requirements for Hospitals and CAHs
to Continue Reporting Data for COVID-19 and Influenza After the PHE
ends as Determined by the Secretary
In this final rule, we are revising the hospital and CAH infection
prevention and control CoP requirements to continue COVID-19-related
reporting requirements commencing either upon the conclusion of the
current COVID-19 PHE declaration or the effective date of
[[Page 48787]]
this proposed rule, whichever is later, and lasting until April 30,
2024 (unless the Secretary determines an earlier end date). We have
withdrawn our proposal to establish additional data reporting
requirements to address future PHEs related to epidemics and infectious
diseases.
3. Summary of Costs and Benefits
The following table provides a summary of the costs, savings, and
benefits associated with the major provisions described in section
I.A.3. of the preamble of this final rule.
[[Page 48788]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.000
[[Page 48789]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.001
[[Page 48790]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.002
[[Page 48791]]
B. Background Summary
1. Acute Care Hospital Inpatient Prospective Payment System (IPPS)
Section 1886(d) of the Act sets forth a system of payment for the
operating costs of acute care hospital inpatient stays under Medicare
Part A (Hospital Insurance) based on prospectively set rates. Section
1886(g) of the Act requires the Secretary to use a prospective payment
system (PPS) to pay for the capital-related costs of inpatient hospital
services for these ``subsection (d) hospitals.'' Under these PPSs,
Medicare payment for hospital inpatient operating and capital-related
costs is made at predetermined, specific rates for each hospital
discharge. Discharges are classified according to a list of diagnosis-
related groups (DRGs).
The base payment rate is comprised of a standardized amount that is
divided into a labor-related share and a nonlabor-related share. The
labor-related share is adjusted by the wage index applicable to the
area where the hospital is located. If the hospital is located in
Alaska or Hawaii, the nonlabor-related share is adjusted by a cost-of-
living adjustment factor. This base payment rate is multiplied by the
DRG relative weight.
If the hospital treats a high percentage of certain low-income
patients, it receives a percentage add-on payment applied to the DRG-
adjusted base payment rate. This add-on payment, known as the
disproportionate share hospital (DSH) adjustment, provides for a
percentage increase in Medicare payments to hospitals that qualify
under either of two statutory formulas designed to identify hospitals
that serve a disproportionate share of low-income patients. For
qualifying hospitals, the amount of this adjustment varies based on the
outcome of the statutory calculations. The Affordable Care Act revised
the Medicare DSH payment methodology and provides for a new additional
Medicare payment beginning on October 1, 2013, that considers the
amount of uncompensated care furnished by the hospital relative to all
other qualifying hospitals.
If the hospital is training residents in an approved residency
program(s), it receives a percentage add-on payment for each case paid
under the IPPS, known as the indirect medical education (IME)
adjustment. This percentage varies, depending on the ratio of residents
to beds.
Additional payments may be made for cases that involve new
technologies or medical services that have been approved for special
add-on payments. In general, to qualify, a new technology or medical
service must demonstrate that it is a substantial clinical improvement
over technologies or services otherwise available, and that, absent an
add-on payment, it would be inadequately paid under the regular DRG
payment. In addition, certain transformative new devices and certain
antimicrobial products may qualify under an alternative inpatient new
technology add-on payment pathway by demonstrating that, absent an add-
on payment, they would be inadequately paid under the regular DRG
payment.
The costs incurred by the hospital for a case are evaluated to
determine whether the hospital is eligible for an additional payment as
an outlier case. This additional payment is designed to protect the
hospital from large financial losses due to unusually expensive cases.
Any eligible outlier payment is added to the DRG-adjusted base payment
rate, plus any DSH, IME, and new technology or medical service add-on
adjustments and, beginning in FY 2023 for IHS and Tribal hospitals and
hospitals located in Puerto Rico, the new supplemental payment.
Although payments to most hospitals under the IPPS are made on the
basis of the standardized amounts, some categories of hospitals are
paid in whole or in part based on their hospital-specific rate, which
is determined from their costs in a base year. For example, sole
community hospitals (SCHs) receive the higher of a hospital-specific
rate based on their costs in a base year (the highest of FY 1982, FY
1987, FY 1996, or FY 2006) or the IPPS Federal rate based on the
standardized amount. SCHs are the sole source of care in their areas.
Specifically, section 1886(d)(5)(D)(iii) of the Act defines an SCH as a
hospital that is located more than 35 road miles from another hospital
or that, by reason of factors such as an isolated location, weather
conditions, travel conditions, or absence of other like hospitals (as
determined by the Secretary), is the sole source of hospital inpatient
services reasonably available to Medicare beneficiaries. In addition,
certain rural hospitals previously designated by the Secretary as
essential access community hospitals are considered SCHs.
Under current law, the Medicare-dependent, small rural hospital
(MDH) program is effective through FY 2022. For discharges occurring on
or after October 1, 2007, but before October 1, 2022, an MDH receives
the higher of the Federal rate or the Federal rate plus 75 percent of
the amount by which the Federal rate is exceeded by the highest of its
FY 1982, FY 1987, or FY 2002 hospital-specific rate. MDHs are a major
source of care for Medicare beneficiaries in their areas. Section
1886(d)(5)(G)(iv) of the Act defines an MDH as a hospital that is
located in a rural area (or, as amended by the Bipartisan Budget Act of
2018, a hospital located in a State with no rural area that meets
certain statutory criteria), has not more than 100 beds, is not an SCH,
and has a high percentage of Medicare discharges (not less than 60
percent of its inpatient days or discharges in its cost reporting year
beginning in FY 1987 or in two of its three most recently settled
Medicare cost reporting years). As section 50205 of the Bipartisan
Budget Act extended the MDH program through FY 2022 only, for FY 2023,
beginning on October 1, 2022, the MDH program will no longer be in
effect absent a change in law. Because the MDH program is not
authorized by statute beyond September 30, 2022, beginning October 1,
2022, all hospitals that previously qualified for MDH status under
section 1886(d)(5)(G) of the Act will no longer have MDH status and
will be paid based on the IPPS Federal rate.
Section 1886(g) of the Act requires the Secretary to pay for the
capital-related costs of inpatient hospital services in accordance with
a prospective payment system established by the Secretary. The basic
methodology for determining capital prospective payments is set forth
in our regulations at 42 CFR 412.308 and 412.312. Under the capital
IPPS, payments are adjusted by the same DRG for the case as they are
under the operating IPPS. Capital IPPS payments are also adjusted for
IME and DSH, similar to the adjustments made under the operating IPPS.
In addition, hospitals may receive outlier payments for those cases
that have unusually high costs.
The existing regulations governing payments to hospitals under the
IPPS are located in 42 CFR part 412, subparts A through M.
2. Hospitals and Hospital Units Excluded From the IPPS
Under section 1886(d)(1)(B) of the Act, as amended, certain
hospitals and hospital units are excluded from the IPPS. These
hospitals and units are: Inpatient rehabilitation facility (IRF)
hospitals and units; long-term care hospitals (LTCHs); psychiatric
hospitals and units; children's hospitals; cancer hospitals; extended
neoplastic disease care hospitals, and hospitals located outside the 50
States, the District of Columbia, and Puerto Rico (that is, hospitals
located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands,
and American Samoa). Religious nonmedical health care
[[Page 48792]]
institutions (RNHCIs) are also excluded from the IPPS. Various sections
of the Balanced Budget Act of 1997 (BBA) (Pub. L. 105-33), the
Medicare, Medicaid and SCHIP [State Children's Health Insurance
Program] Balanced Budget Refinement Act of 1999 (BBRA, Pub. L. 106-
113), and the Medicare, Medicaid, and SCHIP Benefits Improvement and
Protection Act of 2000 (BIPA, Pub. L. 106-554) provide for the
implementation of PPSs for IRF hospitals and units, LTCHs, and
psychiatric hospitals and units (referred to as inpatient psychiatric
facilities (IPFs)). (We note that the annual updates to the LTCH PPS
are included along with the IPPS annual update in this document.
Updates to the IRF PPS and IPF PPS are issued as separate documents.)
Children's hospitals, cancer hospitals, hospitals located outside the
50 States, the District of Columbia, and Puerto Rico (that is,
hospitals located in the U.S. Virgin Islands, Guam, the Northern
Mariana Islands, and American Samoa), and RNHCIs continue to be paid
solely under a reasonable cost-based system, subject to a rate-of-
increase ceiling on inpatient operating costs. Similarly, extended
neoplastic disease care hospitals are paid on a reasonable cost basis,
subject to a rate-of-increase ceiling on inpatient operating costs.
The existing regulations governing payments to excluded hospitals
and hospital units are located in 42 CFR parts 412 and 413.
3. Long-Term Care Hospital Prospective Payment System (LTCH PPS)
The Medicare prospective payment system (PPS) for LTCHs applies to
hospitals described in section 1886(d)(1)(B)(iv) of the Act, effective
for cost reporting periods beginning on or after October 1, 2002. The
LTCH PPS was established under the authority of sections 123 of the
BBRA and section 307(b) of the BIPA (as codified under section
1886(m)(1) of the Act). Section 1206(a) of the Pathway for SGR Reform
Act of 2013 (Pub. L. 113-67) established the site neutral payment rate
under the LTCH PPS, which made the LTCH PPS a dual rate payment system
beginning in FY 2016. Under this statute, effective for LTCH's cost
reporting periods beginning in FY 2016 cost reporting period, LTCHs are
generally paid for discharges at the site neutral payment rate unless
the discharge meets the patient criteria for payment at the LTCH PPS
standard Federal payment rate. The existing regulations governing
payment under the LTCH PPS are located in 42 CFR part 412, subpart O.
Beginning October 1, 2009, we issue the annual updates to the LTCH PPS
in the same documents that update the IPPS.
4. Critical Access Hospitals (CAHs)
Under sections 1814(l), 1820, and 1834(g) of the Act, payments made
to critical access hospitals (CAHs) (that is, rural hospitals or
facilities that meet certain statutory requirements) for inpatient and
outpatient services are generally based on 101 percent of reasonable
cost. Reasonable cost is determined under the provisions of section
1861(v) of the Act and existing regulations under 42 CFR part 413.
5. Payments for Graduate Medical Education (GME)
Under section 1886(a)(4) of the Act, costs of approved educational
activities are excluded from the operating costs of inpatient hospital
services. Hospitals with approved graduate medical education (GME)
programs are paid for the direct costs of GME in accordance with
section 1886(h) of the Act. The amount of payment for direct GME costs
for a cost reporting period is based on the hospital's number of
residents in that period and the hospital's costs per resident in a
base year. The existing regulations governing payments to the various
types of hospitals are located in 42 CFR part 413.
C. Summary of Provisions of Recent Legislation Implemented in This
Final Rule
1. The Medicare Access and CHIP Reauthorization Act of 2015 (Pub. L.
114-10)
Section 414 of the Medicare Access and CHIP Reauthorization Act of
2015 (MACRA, Pub. L. 114-10) specifies a 0.5 percent positive
adjustment to the standardized amount of Medicare payments to acute
care hospitals for FYs 2018 through 2023. These adjustments follow the
recoupment adjustment to the standardized amounts under section 1886(d)
of the Act based upon the Secretary's estimates for discharges
occurring from FYs 2014 through 2017 to fully offset $11 billion, in
accordance with section 631 of the ATRA. The FY 2018 adjustment was
subsequently adjusted to 0.4588 percent by section 15005 of the 21st
Century Cures Act.
D. Issuance of Proposed Rulemaking
In the FY 2023 IPPS/LTCH PPS proposed rule appearing in the May 10,
2022 Federal Register (87 FR 28108), we set forth proposed payment and
policy changes to the Medicare IPPS for FY 2023 operating costs and
capital-related costs of acute care hospitals and certain hospitals and
hospital units that are excluded from IPPS. In addition, we set forth
proposed changes to the payment rates, factors, and other payment and
policy-related changes to programs associated with payment rate
policies under the LTCH PPS for FY 2023.
The following is a general summary of the changes that we proposed
to make.
1. Proposed Changes to MS-DRG Classifications and Recalibrations of
Relative Weights
In section II. of the preamble of the proposed rule, we include the
following:
Proposed changes to MS-DRG classifications based on our
yearly review for FY 2023.
Proposed adjustment to the standardized amounts under
section 1886(d) of the Act for FY 2023 in accordance with the
amendments made to section 7(b)(1)(B) of Public Law 110-90 by section
414 of the MACRA.
Proposed recalibration of the MS-DRG relative weights,
including a proposed 10-percent cap on decreases in an MS-DRG relative
weight from one fiscal year to the next.
A discussion of the proposed FY 2023 status of new
technologies approved for add-on payments for FY 2022, a presentation
of our evaluation and analysis of the FY 2023 applicants for add-on
payments for high-cost new medical services and technologies (including
public input, as directed by Pub. L. 108-173, obtained in a town hall
meeting) for applications not submitted under an alternative pathway,
and a discussion of the proposed status of FY 2023 new technology
applicants under the alternative pathways for certain medical devices
and certain antimicrobial products.
A proposal to use National Drug Codes (NDCs) to identify
cases involving use of therapeutic agents approved for new technology
add-on payments.
A proposal to publicly post online future applications for
new technology add-on payments. Specifically, beginning with the FY
2024 application cycle, we proposed to post online the completed
application forms and certain related materials and updated application
information submitted subsequent to the initial application submission
for new technology add-on payments, with the exception of certain cost
and volume information and certain additional materials (as discussed
more fully in section II.F.9. of the proposed rule), no later than the
issuance of the proposed rule.
[[Page 48793]]
2. Proposed Changes to the Hospital Wage Index for Acute Care Hospitals
In section III. of the preamble of the proposed rule, we proposed
to make revisions to the wage index for acute care hospitals and the
annual update of the wage data. Specific issues addressed include, but
were not limited to, the following:
The proposed FY 2023 wage index update using wage data
from cost reporting periods beginning in FY 2019.
Calculation, analysis, and implementation of the proposed
occupational mix adjustment to the wage index for acute care hospitals
for FY 2023 based on the 2019 Occupational Mix Survey.
Proposed application of the rural, imputed and frontier
State floors, and continuation of the low wage index hospital policy.
Proposed revisions to the wage index for acute care
hospitals, based on hospital redesignations and reclassifications under
sections 1886(d)(8)(B), (d)(8)(E), and (d)(10) of the Act.
Proposed adjustment to the wage index for acute care
hospitals for FY 2023 based on commuting patterns of hospital employees
who reside in a county and work in a different area with a higher wage
index.
Proposed permanent cap on annual wage index decreases.
Proposed labor-related share for the proposed FY 2023 wage
index.
3. Other Decisions and Proposed Changes to the IPPS for Operating Costs
In section V. of the preamble of the proposed rule, we discuss
proposed changes or clarifications of a number of the provisions of the
regulations in 42 CFR parts 412 and 413, including the following:
Proposed inpatient hospital update for FY 2023.
Proposed updated national and regional case-mix values and
discharges for purposes of determining RRC status.
Proposed payment adjustment for low-volume hospitals for
FY 2023 and subsequent years.
The statutorily required IME adjustment factor for FY
2023.
Proposed changes to the methodologies for determining
Medicare DSH payments and the additional payments for uncompensated
care.
Proposed new supplemental payment for IHS/Tribal and
Puerto Rico hospitals.
Proposed revisions to the regulations regarding the
counting of days associated with section 1115 demonstrations in the
Medicaid fraction.
Discussion of statutory expiration of the MDH program at
the end of FY 2022.
Proposed requirements for payment adjustments under the
Hospital Readmissions Reduction Program for FY 2023.
The provision of estimated and newly established
performance standards for the calculation of value-based incentive
payments, as well as a proposal to suppress multiple measures and
provide net-neutral payment adjustments under the Hospital Value-Based
Purchasing Program.
Proposed requirements for payment adjustments to hospitals
under the HAC Reduction Program for FY 2023.
Discussion of and proposed changes relating to the
implementation of the Rural Community Hospital Demonstration Program in
FY 2023.
Proposed GME payment change in response to Milton S.
Hershey Medical Center et al v. Becerra litigation.
Proposed nursing and allied health education program
Medicare Advantage (MA) add-on rates and direct GME MA percent
reductions for CYs 2020 and 2021.
Proposal to allow Medicare GME affiliation agreements
within certain rural track full-time equivalent limitations.
Proposed payment adjustment for certain clinical trial and
expanded access use immunotherapy cases.
4. Proposed FY 2023 Policy Governing the IPPS for Capital-Related Costs
In section VI. of the preamble to the proposed rule, we discussed
the proposed payment policy requirements for capital-related costs and
capital payments to hospitals for FY 2023.
5. Proposed Changes to the Payment Rates for Certain Excluded
Hospitals: Rate-of-Increase Percentages
In section VII. of the preamble of the proposed rule, we discussed
the following:
Proposed changes to payments to certain excluded hospitals
for FY 2023.
Proposed continued implementation of the Frontier
Community Health Integration Project (FCHIP) Demonstration.
6. Proposed Changes to the LTCH PPS
In section VIII. of the preamble of the proposed rule, we set forth
proposed changes to the LTCH PPS Federal payment rates, factors, and
other payment rate policies under the LTCH PPS for FY 2023.
7. Proposed Changes Relating to Quality Data Reporting for Specific
Providers and Suppliers
In section IX. of the preamble of the proposed rule, we addressed
the following:
Proposed requirements for the Hospital Inpatient Quality
Reporting (IQR) Program.
Proposed changes to the requirements for the quality
reporting program for PPS-exempt cancer hospitals (PCHQR Program).
For the Long Term Care Hospital Quality Reporting Program
(LTCH QRP), we requested information on CMS' overarching principles for
measuring healthcare disparities across CMS Quality Programs, including
the LTCH QRP. We also requested information on the potential adoption
of one future National Healthcare Safety Network (NHSN) digital quality
measure (dQM) for the LTCH QRP, as well as quality measure concepts
under consideration for future years.
Proposed changes to requirements pertaining to eligible
hospitals and CAHs participating in the Medicare Promoting
Interoperability Program.
8. Other Proposals and Comment Solicitations Included in the Proposed
Rule
Section X. of the preamble to the proposed rule includes the
following:
Proposed codification of policies related to the costs
incurred for qualified and non-qualified deferred compensation plans.
Proposed changes pertaining to the CoPs at 42 CFR part 482
for hospitals, and at 42 CFR part 485, subpart F, for CAHs.
Solicitation of comments on the appropriateness of payment
adjustments that would account for the additional resource costs for
hospitals for the procurement of wholly domestically made NIOSH-
approved surgical N95 respirators.
9. Other Provisions of the Proposed Rule
Section XI. of the preamble to the proposed rule includes our
discussion of the MedPAC Recommendations.
Section XII. of the preamble to the proposed rule included the
following:
A descriptive listing of the public use files associated
with the proposed rule.
The collection of information requirements for entities
based on our proposals.
Information regarding our responses to public comments.
[[Page 48794]]
10. Determining Prospective Payment Operating and Capital Rates and
Rate-of-Increase Limits for Acute Care Hospitals
In sections II. and III. of the Addendum to the proposed rule, we
set forth proposed changes to the amounts and factors for determining
the proposed FY 2023 prospective payment rates for operating costs and
capital-related costs for acute care hospitals. We proposed to
establish the threshold amounts for outlier cases. In addition, in
section IV. of the Addendum to the proposed rule, we addressed the
proposed update factors for determining the rate-of-increase limits for
cost reporting periods beginning in FY 2023 for certain hospitals
excluded from the IPPS.
11. Determining Prospective Payment Rates for LTCHs
In section V. of the Addendum to the proposed rule, we set forth
proposed changes to the amounts and factors for determining the
proposed FY 2023 LTCH PPS standard Federal payment rate and other
factors used to determine LTCH PPS payments under both the LTCH PPS
standard Federal payment rate and the site neutral payment rate in FY
2023. We are proposed to establish the adjustments for the wage index,
labor-related share, the cost-of-living adjustment, and high-cost
outliers, including the applicable fixed-loss amounts and the LTCH
cost-to-charge ratios (CCRs) for both payment rates.
12. Impact Analysis
In Appendix A of the proposed rule, we set forth an analysis of the
impact the proposed changes would have on affected acute care
hospitals, CAHs, LTCHs and other entities.
13. Recommendation of Update Factors for Operating Cost Rates of
Payment for Hospital Inpatient Services
In Appendix B of the proposed rule, as required by sections
1886(e)(4) and (e)(5) of the Act, we provided our recommendations of
the appropriate percentage changes for FY 2023 for the following:
A single average standardized amount for all areas for
hospital inpatient services paid under the IPPS for operating costs of
acute care hospitals (and hospital-specific rates applicable to SCHs
and MDHs).
Target rate-of-increase limits to the allowable operating
costs of hospital inpatient services furnished by certain hospitals
excluded from the IPPS.
The LTCH PPS standard Federal payment rate and the site
neutral payment rate for hospital inpatient services provided for LTCH
PPS discharges.
14. Discussion of Medicare Payment Advisory Commission Recommendations
Under section 1805(b) of the Act, MedPAC is required to submit a
report to Congress, no later than March 15 of each year, in which
MedPAC reviews and makes recommendations on Medicare payment policies.
MedPAC's March 2022 recommendations concerning hospital inpatient
payment policies address the update factor for hospital inpatient
operating costs and capital-related costs for hospitals under the IPPS.
We addressed these recommendations in Appendix B of the proposed rule.
For further information relating specifically to the MedPAC March 2022
report or to obtain a copy of the report, contact MedPAC at (202) 220-
3700 or visit MedPAC's website at https://www.medpac.gov.
E. Advancing Health Information Exchange
The Department of Health and Human Services (HHS) has a number of
initiatives designed to encourage and support the adoption of
interoperable health information technology and to promote nationwide
health information exchange to improve health care and patient access
to their digital health information.
To further interoperability in post-acute care settings, CMS and
the Office of the National Coordinator for Health Information
Technology (ONC) participate in the Post-Acute Care Interoperability
Workgroup (PACIO) to facilitate collaboration with industry
stakeholders to develop Health Level Seven International[supreg] (HL7)
Fast Healthcare Interoperability Resources[supreg] (FHIR) standards.
These standards could support the exchange and reuse of patient
assessment data derived from the post-acute care (PAC) setting
assessment tools, such as Minimum Data Set (MDS), Inpatient
Rehabilitation Facility-Patient Assessment Instrument (IRF-PAI), Long
Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation
(CARE) Data Set (LCDS), Outcome and Assessment Information Set (OASIS),
and other sources.3 4 The PACIO Project has focused on HL7
FHIR implementation guides for functional status, cognitive status and
new use cases on advance directives, re-assessment timepoints, and
Speech, Language, Swallowing Cognitive communications and Hearing
(SPLASCH).\5\ We encourage PAC provider and health information
technology (IT) vendor participation as the efforts advance. The CMS
Data Element Library (DEL) continues to be updated and serves as a
resource for PAC assessment data elements and their associated mappings
to health IT standards, such as Logical Observation Identifiers Names
and Codes (LOINC) and Systematized Nomenclature of Medicine Clinical
Terms (SNOMED).\6\ The DEL furthers CMS' goal of data standardization
and interoperability. Standards in the DEL can be referenced on the CMS
website (https://del.cms.gov/DELWeb/pubHome) and in the ONC
Interoperability Standards Advisory (ISA). The 2022 ISA is available at
https://www.healthit.gov/isa/sites/isa/files/inline-files/2022-ISA-Reference-Edition.pdf.
---------------------------------------------------------------------------
\3\ HL7 FHIR Release 4. Available at: https://www.hl7.org/fhir/.
\4\ HL7 FHIR. PACIO Functional Status Implementation Guide.
Available at: https://paciowg.github.io/functional-status-ig/.
\5\ PACIO Project. Available at: https://pacioproject.org/about/.
\6\ CMS Data Element Library Fact Sheet. Available at: https://www.cms.gov/newsroom/fact-sheets/cms-data-element-library-fact-sheet.
---------------------------------------------------------------------------
The 21st Century Cures Act (Cures Act) (Pub. L. 114-255, enacted
December 13, 2016) required HHS and ONC to take steps further
interoperability for providers in settings across the care
continuum.\7\ Specifically, section 4003(b) of the Cures Act required
ONC to take steps to advance interoperability through the development
of a a Trusted Exchange Framework and Common Agreement aimed at
establishing full network-to-network exchange of health information
nationally. On January 18, 2022, ONC announced a significant milestone
by releasing the Trusted Exchange Framework \8\ and Common Agreement
Version 1.\9\ The Trusted Exchange Framework is a set of non-binding
principles for health information exchange, and the Common Agreement is
a contract that advances those principles. The Common Agreement and the
incorporated by reference Qualified Health Information Network
Technical Framework Version 1 establish the technical infrastructure
[[Page 48795]]
model and governing approach for different health information networks
and their users to securely share clinical information with each other,
all under commonly agreed to terms. The technical and policy
architecture of how exchange occurs under the Common Agreement follows
a network-of-networks structure, which allows for connections at
different levels and is inclusive of many different types of entities
at those different levels, such as health information networks,
healthcare practices, hospitals, public health agencies, and Individual
Access Services (IAS) Providers.\10\ For more information, we refer
readers to https://www.healthit.gov/topic/interoperability/trusted-exchange-framework-and-common-agreement.
---------------------------------------------------------------------------
\7\ Public Law 114-255, sections 4001 through 4008. Available
at: https://www.govinfo.gov/content/pkg/PLAW-114publ255/html/PLAW-114publ255.htm.
\8\ The Trusted Exchange Framework (TEF): Principles for Trusted
Exchange (Jan. 2022). Available at: https://www.healthit.gov/sites/default/files/page/2022-01/Trusted_Exchange_Framework_0122.pdf.
\9\ Common Agreement for Nationwide Health Information
Interoperability Version 1 (Jan. 2022). Available at: https://www.healthit.gov/sites/default/files/page/2022-01/Common_Agreement_for_Nationwide_Health_Information_Interoperability_Version_1.pdf.
\10\ The Common Agreement defines Individual Access Services
(IAS) as ``with respect to the Exchange Purposes definition, the
services provided utilizing the Connectivity Services, to the extent
consistent with Applicable Law, to an Individual with whom the QHIN,
Participant, or Subparticipant has a Direct Relationship to satisfy
that Individual's ability to access, inspect, or obtain a copy of
that Individual's Required Information that is then maintained by or
for any QHIN, Participant, or Subparticipant.'' The Common Agreement
defines ``IAS Provider'' as: ``Each QHIN, Participant, and
Subparticipant that offers Individual Access Services.'' See Common
Agreement for Nationwide Health Information Interoperability Version
1, at 7 (Jan. 2022), https://www.healthit.gov/sites/default/files/page/2022-01/Common_Agreement_for_Nationwide_Health_Information_Interoperability_Version_1.pdf.
---------------------------------------------------------------------------
We invite providers to learn more about these important
developments and how they are likely to affect LTCHs.
Comment: A commenter expressed support for efforts across HHS to
advance health information technology exchange and encouraged use of a
standard set of data by providers and health IT vendors, including
efforts through the PACIO project. The commenter also noted a recent
National Academies report describing technology barriers for PAC
settings due to not being eligible for previous incentives to purchase
technology certified under the ONC Health IT Certification Program. The
commenter supported recommendations in the report for HHS to pursue
financial incentives for post-acute care settings to adopt certified
health information technology in order to enable health information
exchange.
Response: We will take this comment into consideration as we
coordinate with Federal partners, including ONC, on interoperability
initiatives, and to inform future rulemaking.
F. Use of FY 2021 Data and Methodology Modifications for the FY 2023
IPPS and LTCH PPS Ratesetting
We primarily use two data sources in the IPPS and LTCH PPS
ratesetting: claims data and cost report data. The claims data source
is the MedPAR file, which includes fully coded diagnostic and procedure
data for all Medicare inpatient hospital bills for discharges in a
fiscal year. The cost report data source is the Medicare hospital cost
report data files from the most recent quarterly Healthcare Cost Report
Information System (HCRIS) release. Our goal is always to use the best
available data overall for ratesetting. Ordinarily, the best available
MedPAR data is the most recent MedPAR file that contains claims from
discharges for the fiscal year that is 2 years prior to the fiscal year
that is the subject of the rulemaking. Ordinarily, the best available
cost report data is based on the cost reports beginning 3 fiscal years
prior to the fiscal year that is the subject of the rulemaking.
However, in the FY 2022 IPPS/LTCH PPS final rule (86 FR 44789 through
44793), as discussed in more detail below, we finalized our proposal to
use FY 2019 data for the FY 2022 ratesetting for circumstances where
the FY 2020 data (the most recently available data at the time of
rulemaking) was significantly impacted by the COVID-19 PHE.
As we discussed in the FY 2022 IPPS/LTCH PPS final rule, the FY
2020 MedPAR claims file and the FY 2019 HCRIS dataset both contained
data that was significantly impacted by the COVID-19 PHE, primarily in
that the utilization of services at IPPS hospitals and LTCHs was
generally markedly different for certain types of services in FY 2020
than would have been expected in the absence of the PHE. However, the
most recent vaccination and hospitalization data from the CDC at the
time of development of that rule supported our belief at the time that
the risk of COVID-19 in FY 2022 would be significantly lower than the
risk of COVID-19 in FY 2020 and there would be fewer COVID-19
hospitalizations for Medicare beneficiaries in FY 2022 than there were
in FY 2020. Therefore, we finalized our proposal to use FY 2019 data
for the FY 2022 ratesetting for circumstances where the FY 2020 data
was significantly impacted by the COVID-19 PHE, based on the belief
that FY 2019 data from before the COVID-19 PHE would be a better
overall approximation of the FY 2022 inpatient experience at both IPPS
hospitals and LTCHs. For example, we used the FY 2019 MedPAR claims
data for purposes where we ordinarily would have used the FY 2020
MedPAR claims data. We also used cost report data from the FY 2018
HCRIS file for purposes where we ordinarily would have used the FY 2019
HCRIS file (since the FY 2019 cost report data from HCRIS contained
many cost reports ending in FY 2020 based on each hospital's cost
reporting period).
Similar to our analysis of the FY 2020 MedPAR claims file and the
FY 2019 HCRIS dataset for the FY 2022 IPPS/LTCH PPS rulemaking, in the
FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28123 through 28125) we
discussed that the FY 2021 MedPAR claims file and the FY 2020 HCRIS
dataset also both contain data that was significantly impacted by the
virus that causes COVID-19, primarily in that the utilization of
services at IPPS hospitals and LTCHs was again generally markedly
different for certain types of services in FY 2021 than would have been
expected in the absence of the virus that causes COVID-19.
Specifically, the share of admissions at IPPS hospitals and LTCHs for
MS-DRGs and MS-LTC-DRGs associated with the treatment of COVID-19
continued to remain significantly higher than levels prior to the
COVID-19 PHE. For example, in FY 2019, the share of IPPS cases and LTCH
PPS standard Federal payment rate cases grouped to MS-DRG and MS-LTC-
DRG 177 (Respiratory infections and inflammations with MCC) was
approximately 1 percent and 2 percent, respectively. In comparison, in
FY 2021, the share of IPPS cases and LTCH PPS standard Federal payment
rate cases grouped to MS-DRG 177 was approximately 6 percent and 8
percent, respectively.
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28123 through
28124), we reviewed the most recent data from the CDC on new inpatient
hospital admissions of patients with confirmed COVID-19. We presented
this CDC graph which illustrates new inpatient hospital admissions of
patients with confirmed COVID-19 from August 1, 2020 through February
15, 2022 (https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/02182022/images/hospitalizations_02182022.jpg?_=35767,
accessed February 22, 2022).
[[Page 48796]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.003
We stated that the low point of the graph (late June 2021)
approximately coincides with the time of the development of the FY 2022
IPPS/LTCH PPS final rule and generally supports, in conjunction with
the other factors discussed in that rulemaking (including the most
recent vaccination data from the CDC), our assumption in the final rule
that the FY 2022 time period would be more similar to the time period
prior to the PHE. We stated that the graph also shows that the virus
that causes COVID-19 has continued to significantly impact
hospitalizations for the time period subsequent to the development of
the FY 2022 IPPS/LTCH PPS final rule.
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28124), we also
presented information from the CDC on the likelihood of future COVID-19
variants. We noted that the most recent increase in hospitalizations
was primarily associated with the Omicron variant of the virus \11\ and
that the CDC has stated that new variants will continue to emerge.
Viruses constantly change through mutation and sometimes these
mutations result in a new variant of the virus. The CDC and other
public health organizations monitor all variants of the virus that
causes COVID-19 in the United States and globally. Scientists monitor
all variants but may classify certain ones as variants being monitored,
variants of interest, variants of concern and variants of high
consequence. Some variants spread more easily and quickly than other
variants, which may lead to more cases of COVID-19. Even if a variant
causes less severe disease in general, an increase in the overall
number of cases could cause an increase in hospitalizations (see
https://www.cdc.gov/coronavirus/2019-ncov/variants/about-variants.html,
accessed February 25, 2022).
---------------------------------------------------------------------------
\11\ https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html.
---------------------------------------------------------------------------
Given the effects of the virus that causes COVID-19 in the Medicare
FY 2020 data, the Medicare FY 2021 data, and the CDC hospitalization
data, coupled with the expectation for future variants, in the proposed
rule we stated our belief that it is reasonable to assume that some
Medicare beneficiaries will continue to be hospitalized with COVID-19
at IPPS hospitals and LTCHs in FY 2023. Accordingly, we stated that we
believe it would be appropriate to use FY 2021 data, specifically the
FY 2021 MedPAR claims file and the FY 2020 HCRIS dataset (which
contains data from many cost reports ending in FY 2021 based on each
hospital's cost reporting period) as the most recent available data
during the period of the COVID-19 PHE, for purposes of the FY 2023 IPPS
and LTCH PPS ratesetting. However, we also stated our belief that it
would be reasonable to assume based on the information available at the
time that there will be fewer COVID-19 hospitalizations in FY 2023 than
in FY 2021 given the more recent trends in the CDC hospitalization data
since the Omicron variant peak in January, 2022. Accordingly, because
we anticipated Medicare inpatient hospitalizations for COVID-19 would
continue in FY 2023 but at a lower level, we proposed to use FY 2021
data for purposes of the FY 2023 IPPS and LTCH PPS ratesetting but with
modifications to our usual ratesetting methodologies to account for the
anticipated decline in COVID-19 hospitalizations of Medicare
beneficiaries at IPPS hospitals and LTCHs as compared to FY 2021.
First, we proposed to modify the calculation of the FY 2023 MS-DRG
and MS-LTC-DRG relative weights. We observed that COVID-19 cases were
impacting the relative weights as calculated using the FY 2021 MedPAR
data for a few COVID-19-related MS-DRGs and MS-LTC-DRGs. As an example,
for MS-DRG and MS-LTC-DRG 870 (Septicemia or Severe Sepsis with MV >96
hours), the MS-DRG and MS-LTC-DRG relative weights calculated using the
FY 2021 MedPAR data are approximately 9 and 3 percent higher,
respectively, compared to their relative weights if calculated
excluding COVID-19 cases. Because this MS-DRG contains a mix of COVID-
19 cases and non-COVID-19 cases with different average costs, the
relative weight for this MS-DRG is dependent on that mix of cases. As
stated in the proposed rule, we believed it is reasonable to assume
that there would be fewer COVID-19 hospitalizations among Medicare
beneficiaries in FY 2023 than there were in FY 2021; however, we also
stated that it is not possible to know precisely how COVID-19
hospitalizations in FY 2023 will compare to FY 2021. We stated our
belief that averaging the relative weights as calculated with and
without the COVID-19 cases reflected in the FY 2021 MedPAR data would
reflect a reasonable estimation of the case mix for FY 2023 based on
the information available at the time, and more accurately estimate the
relative resource use for the cases treated in FY 2023. Therefore, we
proposed to calculate the relative weights for FY 2023 by first
calculating two sets of weights, one including and one excluding COVID-
19 claims, and then averaging the two sets of relative weights to
determine the proposed FY 2023 relative weight values. We believed this
proposed modification to our relative weight setting methodology would
appropriately reduce, but not remove entirely, the effect of COVID-19
cases
[[Page 48797]]
on the relative weight calculations, consistent with our expectation
that Medicare inpatient hospitalizations for COVID-19 will continue in
FY 2023 at a lower level as compared to FY 2021, and provide a more
accurate estimate of relative resource use for FY 2023 than if we were
to calculate the proposed relative weights using all applicable cases
in the FY 2021 data.
We also proposed to modify our methodologies for determining the FY
2023 outlier fixed-loss amount for IPPS cases and LTCH PPS standard
Federal payment rate cases. The methodologies for determining both of
these outlier fixed-loss amounts include calculating and applying a
charge inflation factor to increase charges from the claim year to the
rulemaking year, as well as calculating and applying cost-to-charge
ratio (CCR) adjustment factors to adjust CCRs used to make payments in
the current year to the rulemaking year. The charge inflation factors
calculated using the 2 most recently available years of MedPAR claims
data (FY 2020 and FY 2021) that would ordinarily be used for the FY
2023 proposed rule to inflate the charges on the FY 2021 MedPAR claims
were abnormally high as compared to recent historical levels prior to
the PHE (for example, for the IPPS, approximately 10 percent based on
the FY 2020 and FY 2021 MedPAR claims data as compared to approximately
6 percent based on the FY 2018 and FY 2019 MedPAR claims data).
Furthermore, the IPPS operating and capital CCR adjustment factors
calculated based on the percentage changes in the CCRs from the
December 2020 update of the Provider Specific File (PSF) to the
December 2021 update of the PSF that would ordinarily be used for the
FY 2023 proposed rule to adjust the CCRs from the December 2021 update
of the PSF were also abnormally high as compared to recent historical
levels prior to the PHE (for example, for the IPPS operating CCR
adjustment factor, a factor of approximately 1.03 based on the December
2020 and December 2021 updates to the PSF as compared to a factor of
approximately 0.97 based on the March 2019 and March 2020 updates to
the PSF). In the proposed rule, we stated our belief that these
abnormally high charge inflation and CCR adjustment factors as compared
to historical levels were partially due to the high number of COVID-19
cases with higher charges that were treated in IPPS hospitals and LTCHs
in FY 2021. We also stated our belief that there will be fewer COVID-19
cases in FY 2023 than in FY 2021 and that therefore, we do not believe
it is reasonable to assume charges and CCRs will continue to increase
at these abnormally high rates. Consequently, when determining the FY
2023 outlier fixed-loss amounts for IPPS cases and LTCH PPS standard
Federal payment rate cases, we proposed to inflate the charges on the
FY 2021 MedPAR claims using charge inflation factors computed by
comparing the average covered charge per case in the March 2019 MedPAR
file of FY 2018 to the average covered charge per case in the March
2020 MedPAR file of FY 2019, which is the last 1-year period prior to
the COVID-19 PHE. We also proposed to adjust the CCRs from the December
2021 update of the PSF by comparing the percentage change in the
national average case-weighted CCR from the March 2019 update of the
PSF to the national average case-weighted CCR from the March 2020
update of the PSF, which is the last 1-year period prior to the COVID-
19 PHE. We stated our belief that using the charge inflation factors
and CCR adjustment factors derived from data prior to the COVID-19 PHE
would provide a more reasonable approximation of the increase in costs
that will occur from FY 2021 to FY 2023 because we do not believe the
charge inflation that has occurred during the PHE will continue as the
number of higher cost COVID-19 cases declines.
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28740 through
28741) we also requested comments on, as an alternative to our proposed
approach, the use of the FY 2021 data for purposes of FY 2023
ratesetting without these proposed modifications to our usual
methodologies for the calculation of the FY 2023 MS-DRG and MS-LTC-DRG
relative weights or the usual methodologies used to determine the FY
2023 outlier fixed-loss amount for IPPS cases and LTCH PPS standard
Federal payment rate cases. We noted that the FY 2023 outlier fixed-
loss amount would be significantly higher under this alternative
approach. In order to illustrate the effect of our proposed
modifications on the relative weights and fixed loss amount, we made
available supplemental information, including the relative weights and
fixed-loss amount calculated without the proposed modifications to our
usual methodologies.
The comments we received on our proposal to use FY 2021 data for
purposes of the FY 2023 IPPS and LTCH PPS ratesetting were focused on
the specific use of FY 2021 data when determining the FY 2023 relative
weights or outlier fixed-loss amounts. Therefore, we refer the reader
to section II.E. of the preamble of this final rule for our summary and
response to comments received on our proposed use of FY 2021 data and
our proposed modifications to our usual methodology when determining
the FY 2023 IPPS MS-DRG relative weights. We refer the reader to
section VIII.B. of the preamble of this final rule for our summary and
response to comments received on our proposed use of FY 2021 data and
our proposed modifications to our usual methodology when determining
the FY 2023 LTCH PPS MS-LTC-DRG relative weights. We refer the reader
to section II.A.4. of the addendum to this final rule for our summary
and response to comments received on our proposed use of FY 2021 data
and our proposed modifications to our usual methodology when
determining the FY 2023 outlier fixed-loss amounts for IPPS cases. We
refer the reader to section V.D.3. of the Addendum to this final rule
for our summary and response to comments received on our proposed use
of FY 2021 data and our proposed modifications to our usual methodology
when determining the FY 2023 outlier fixed-loss amounts for LTCH PPS
standard Federal payment rate cases.
Since the publication of the proposed rule, we have continued to
monitor hospitalization data reported by the CDC. This CDC graph
illustrates new inpatient hospital admissions of patients with
confirmed COVID-19 from August 1, 2020 through July 6, 2022 (https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/07082022/images/Hospitalizations.png?_=90548, accessed July 08, 2022).
[[Page 48798]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.004
The graph shows that new COVID-19 hospital admissions reached a low
point in early April 2022, however have steadily increased since.
After reviewing the latest CDC hospitalization data, coupled with
the expectation for future variants,\12\ we continue to believe that it
is reasonable to assume that some Medicare beneficiaries will continue
to be hospitalized with COVID-19 at IPPS hospitals and LTCHs in FY
2023. We also continue to believe that it would be reasonable to assume
based on the information available at this time that there will be
fewer COVID-19 hospitalizations in FY 2023 than in FY 2021 given that
the current levels of hospitalizations are much lower than the Omicron
variant peak in January 2022.
---------------------------------------------------------------------------
\12\ https://www.cdc.gov/coronavirus/2019-ncov/variants/about-variants.html.
---------------------------------------------------------------------------
Therefore, after considering the comments received and based on our
evaluation of the information available at this time, we are finalizing
our proposal to use FY 2021 data for purposes of the FY 2023 IPPS and
LTCH PPS ratesetting. (That is, the FY 2021 MedPAR claims file and the
FY 2020 HCRIS dataset (which contains data from many cost reports
ending in FY 2021 based on each hospital's cost reporting period).) We
are also finalizing, as proposed, modifications to our usual
methodology for determining the FY 2023 IPPS MS-DRG relative weights
and FY 2023 LTCH PPS MS-LTC-DRG relative weights. Specifically, for FY
2023, we calculated the relative weights by first calculating two sets
of weights, one including and one excluding COVID-19 claims, and then
averaging the two sets of relative weights to determine the final
relative weight values. The finalization of our proposal to use FY 2021
data and to modify our methodology for determining the FY 2023 IPPS MS-
DRG relative weights is discussed in greater detail in section II.E. of
the preamble of this final rule. The finalization of our proposal to
use FY 2021 data and to modify our methodology for determining the FY
2023 LTCH PPS MS-LTC-DRG relative weights is discussed in greater
detail in section VIII.B. of the preamble of this final rule.
As discussed in section II.A.4. and section V.D.3. of the addendum
to this final rule, we received many comments supportive of our
proposed modifications to our usual methodologies for determining the
FY 2023 IPPS and LTCH PPS outlier fixed-loss amounts. As discussed in
these sections, after considering comments received, we are finalizing
our proposal to inflate the charges on the FY 2021 MedPAR claims using
charge inflation factors computed by comparing the average covered
charge per case in the March 2019 MedPAR file of FY 2018 to the average
covered charge per case in the March 2020 MedPAR file of FY 2019, which
is the last 1-year period prior to the COVID-19 PHE. We are also
finalizing our proposal to adjust the CCRs from the March 2021 update
of the PSF by comparing the percentage change in the national average
case-weighted CCR from the March 2019 update of the PSF to the national
average case-weighted CCR from the March 2020 update of the PSF, which
is the last 1-year period prior to the COVID-19 PHE.
We also received many comments that suggested other modifications
CMS should make to our usual methodologies for determining the FY 2023
IPPS and LTCH PPS outlier fixed-loss amounts. As also discussed in
section II.A.4. and section V.D.3. of the addendum to this final rule,
after consideration of the comments received, we are modifying our
proposed methodologies for establishing the FY 2023 IPPS and LTCH PPS
outlier fixed-loss amounts by calculating the FY 2023 IPPS and LTCH PPS
outlier fixed-loss amounts as averages of the fixed-loss amounts as
calculated including and excluding COVID-19 claims. We believe this
adjustment to our proposed methodology will better reflect a reasonable
estimation of the case mix for FY 2023 based on the information
available at this time and is also consistent with the approach we are
finalizing for determining the FY 2023 IPPS MS-DRG and LTCH PPS MS-LTC-
DRG relative weights.
In addition, as discussed in section II.A.4. of the Addendum to
this final rule, after consideration of comments received, we are also
further modifying our proposed methodology for establishing the FY 2023
IPPS outlier fixed-loss amount by including the increases in payments
for COVID-19 cases provided by the CARES Act in the calculation of the
outlier fixed-loss amount.
II. Changes to Medicare Severity Diagnosis-Related Group (MS-DRG)
Classifications and Relative Weights
A. Background
Section 1886(d) of the Act specifies that the Secretary shall
establish a classification system (referred to as diagnosis-related
groups (DRGs)) for inpatient discharges and adjust payments under the
IPPS based on appropriate weighting factors assigned to each DRG.
Therefore, under the IPPS, Medicare pays for inpatient hospital
services on a rate per discharge basis that varies according to the DRG
to which a beneficiary's stay is assigned. The formula used to
calculate payment
[[Page 48799]]
for a specific case multiplies an individual hospital's payment rate
per case by the weight of the DRG to which the case is assigned. Each
DRG weight represents the average resources required to care for cases
in that particular DRG, relative to the average resources used to treat
cases in all DRGs.
Section 1886(d)(4)(C) of the Act requires that the Secretary adjust
the DRG classifications and relative weights at least annually to
account for changes in resource consumption. These adjustments are made
to reflect changes in treatment patterns, technology, and any other
factors that may change the relative use of hospital resources.
B. Adoption of the MS-DRGs and MS-DRG Reclassifications
For information on the adoption of the MS-DRGs in FY 2008, we refer
readers to the FY 2008 IPPS final rule with comment period (72 FR 47140
through 47189).
For general information about the MS-DRG system, including yearly
reviews and changes to the MS-DRGs, we refer readers to the previous
discussions in the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR
43764 through 43766) and the FYs 2011 through 2022 IPPS/LTCH PPS final
rules (75 FR 50053 through 50055; 76 FR 51485 through 51487; 77 FR
53273; 78 FR 50512; 79 FR 49871; 80 FR 49342; 81 FR 56787 through
56872; 82 FR 38010 through 38085, 83 FR 41158 through 41258, 84 FR
42058 through 42165, 85 FR 58445 through 58596, 86 FR 44795 through
44961, respectively).
C. FY 2023 MS-DRG Documentation and Coding Adjustment
1. Background on the Prospective MS-DRG Documentation and Coding
Adjustments for FY 2008 and FY 2009 Authorized by Pub. L. 110-90 and
the Recoupment or Repayment Adjustment Authorized by Section 631 of the
American Taxpayer Relief Act of 2012 (ATRA).
In the FY 2008 IPPS final rule with comment period (72 FR 47140
through 47189), we adopted the MS-DRG patient classification system for
the IPPS, effective October 1, 2007, to better recognize severity of
illness in Medicare payment rates for acute care hospitals. The
adoption of the MS-DRG system resulted in the expansion of the number
of DRGs from 538 in FY 2007 to 745 in FY 2008. By increasing the number
of MS-DRGs and more fully taking into account patient severity of
illness in Medicare payment rates for acute care hospitals, MS-DRGs
encourage hospitals to improve their documentation and coding of
patient diagnoses.
In the FY 2008 IPPS final rule with comment period (72 FR 47175
through 47186), we indicated that the adoption of the MS-DRGs had the
potential to lead to increases in aggregate payments without a
corresponding increase in actual patient severity of illness due to the
incentives for additional documentation and coding. In that final rule
with comment period, we exercised our authority under section
1886(d)(3)(A)(vi) of the Act, which authorizes us to maintain budget
neutrality by adjusting the national standardized amount, to eliminate
the estimated effect of changes in coding or classification that do not
reflect real changes in case-mix. Our actuaries estimated that
maintaining budget neutrality required an adjustment of -4.8 percentage
points to the national standardized amount. We provided for phasing in
this -4.8 percentage point adjustment over 3 years. Specifically, we
established prospective documentation and coding adjustments of -1.2
percentage points for FY 2008, -1.8 percentage points for FY 2009, and
-1.8 percentage points for FY 2010.
On September 29, 2007, Congress enacted the TMA [Transitional
Medical Assistance], Abstinence Education, and QI [Qualifying
Individuals] Programs Extension Act of 2007 (Pub. L. 110-90). Section
7(a) of Public Law 110-90 reduced the documentation and coding
adjustment made as a result of the MS-DRG system that we adopted in the
FY 2008 IPPS final rule with comment period to -0.6 percentage point
for FY 2008 and -0.9 percentage point for FY 2009.
As discussed in prior year rulemakings, and most recently in the FY
2017 IPPS/LTCH PPS final rule (81 FR 56780 through 56782), we
implemented a series of adjustments required under sections 7(b)(1)(A)
and 7(b)(1)(B) of Public Law 110-90, based on a retrospective review of
FY 2008 and FY 2009 claims data. We completed these adjustments in FY
2013 but indicated in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53274
through 53275) that delaying full implementation of the adjustment
required under section 7(b)(1)(A) of Public Law 110-90 until FY 2013
resulted in payments in FY 2010 through FY 2012 being overstated, and
that these overpayments could not be recovered under Public Law 110-90.
In addition, as discussed in prior rulemakings and most recently in
the FY 2018 IPPS/LTCH PPS final rule (82 FR 38008 through 38009),
section 631 of the American Taxpayer Relief Act of 2012 (ATRA) amended
section 7(b)(1)(B) of Public Law 110-90 to require the Secretary to
make a recoupment adjustment or adjustments totaling $11 billion by FY
2017. This adjustment represented the amount of the increase in
aggregate payments as a result of not completing the prospective
adjustment authorized under section 7(b)(1)(A) of Public Law 110-90
until FY 2013.
2. Adjustments Made for FYs 2018, 2019, 2020, 2021, and 2022 as
Required Under Section 414 of Public Law 114-10 (MACRA) and Section
15005 of Public Law 114-255
As stated in the FY 2017 IPPS/LTCH PPS final rule (81 FR 56785),
once the recoupment required under section 631 of the ATRA was
complete, we had anticipated making a single positive adjustment in FY
2018 to offset the reductions required to recoup the $11 billion under
section 631 of the ATRA. However, section 414 of the MACRA (which was
enacted on April 16, 2015) replaced the single positive adjustment we
intended to make in FY 2018 with a 0.5 percentage point positive
adjustment for each of FYs 2018 through 2023. In the FY 2017
rulemaking, we indicated that we would address the adjustments for FY
2018 and later fiscal years in future rulemaking. Section 15005 of the
21st Century Cures Act (Pub. L. 114-255), which was enacted on December
13, 2016, amended section 7(b)(1)(B) of the TMA, as amended by section
631 of the ATRA and section 414 of the MACRA, to reduce the adjustment
for FY 2018 from a 0.5 percentage point positive adjustment to a 0.4588
percentage point positive adjustment. As we discussed in the FY 2018
rulemaking, we believe the directive under section 15005 of Public Law
114-255 is clear. Therefore, in the FY 2018 IPPS/LTCH PPS final rule
(82 FR 38009) for FY 2018, we implemented the required +0.4588
percentage point adjustment to the standardized amount. In the FY 2019
IPPS/LTCH PPS final rule (83 FR 41157), the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42057), the FY 2021 IPPS/LTCH PPS final rule (85 FR 58444
and 58445), and the FY 2022 IPPS/LTCH PPS final rule (86 FR 44794 and
44795), consistent with the requirements of section 414 of the MACRA,
we implemented 0.5 percentage point positive adjustments to the
standardized amount for FY 2019, FY 2020, FY 2021, and FY 2022,
respectively. We indicated the FY 2018, FY 2019, FY 2020, FY 2021, and
FY 2022 adjustments were permanent adjustments to payment rates. We
also
[[Page 48800]]
stated that we plan to propose a future adjustment required under
section 414 of the MACRA for FY 2023 in future rulemaking.
3. Adjustment for FY 2023
Consistent with the requirements of section 414 of the MACRA, we
proposed to implement a 0.5 percentage point positive adjustment to the
standardized amount for FY 2023. We stated that this would constitute a
permanent adjustment to payment rates. We also stated that this
proposed 0.5 percentage point positive adjustment is the final
adjustment prescribed by section 414 of the MACRA. Along with the
0.4588 percentage point positive adjustment for FY 2018, and the 0.5
percentage point positive adjustments for FY 2019, FY 2020, FY 2021,
and FY 2022, this final adjustment will result in combined positive
adjustment of 2.9588 percentage points (or the sum of the adjustments
for FYs 2018 through 2023) to the standardized amount.
We received no public comments on the proposed adjustment for FY
2023 and are finalizing our proposal to implement a 0.5 percentage
point positive adjustment to the standardized amount for FY 2023. As
indicated, this finalized 0.5 percentage point positive adjustment for
FY 2023 is the final adjustment prescribed by section 414 of the MACRA.
D. Changes to Specific MS-DRG Classifications
1. Discussion of Changes to Coding System and Basis for FY 2023 MS-DRG
Updates
a. Conversion of MS-DRGs to the International Classification of
Diseases, 10th Revision (ICD-10)
As of October 1, 2015, providers use the International
Classification of Diseases, 10th Revision (ICD-10) coding system to
report diagnoses and procedures for Medicare hospital inpatient
services under the MS-DRG system instead of the ICD-9-CM coding system,
which was used through September 30, 2015. The ICD-10 coding system
includes the International Classification of Diseases, 10th Revision,
Clinical Modification (ICD-10-CM) for diagnosis coding and the
International Classification of Diseases, 10th Revision, Procedure
Coding System (ICD-10-PCS) for inpatient hospital procedure coding, as
well as the ICD-10-CM and ICD-10-PCS Official Guidelines for Coding and
Reporting. For a detailed discussion of the conversion of the MS-DRGs
to ICD-10, we refer readers to the FY 2017 IPPS/LTCH PPS final rule (81
FR 56787 through 56789).
b. Basis for FY 2023 MS-DRG Updates
Given the need for more time to carefully evaluate requests and
propose updates, as discussed in the FY 2018 IPPS/LTCH PPS final rule
(82 FR 38010), we changed the deadline to request updates to the MS-
DRGs to November 1 of each year, which provided an additional five
weeks for the data analysis and review process. In the FY 2021 IPPS/
LTCH PPS proposed rule (85 FR 32472), we stated that with the continued
increase in the number and complexity of the requested changes to the
MS-DRG classifications since the adoption of ICD-10 MS-DRGs, and to
consider as many requests as possible, more time is needed to carefully
evaluate the requested changes, analyze claims data, and consider any
proposed updates. We further stated we were changing the deadline to
request changes to the MS-DRGs to October 20 of each year to allow for
additional time for the review and consideration of any proposed
updates. However, in the FY 2021 IPPS/LTCH PPS final rule (85 FR
58445), due to the unique circumstances for the FY 2021 IPPS/LTCH PPS
final rule for which we waived the delayed effective date, we
maintained the deadline of November 1, 2020 for FY 2022 MS-DRG
classification change requests. We also noted that we expected to
reconsider a change in the deadline beginning with comments and
suggestions submitted for FY 2023. In the FY 2022 IPPS/LTCH PPS
proposed rule, we stated that while we continue to believe that a
change in the deadline from November 1 to October 20 would provide
hospitals sufficient time to assess potential impacts and inform future
MS-DRG recommendations, we were maintaining the deadline of November 1
for FY 2023 MS-DRG classification change requests. As discussed in the
FY 2022 IPPS/LTCH PPS final rule (86 FR 44795), we received public
comments expressing support for a future change to the deadline for
requesting updates to the MS-DRG classifications from November 1 to
October 20, and we noted in response that we may consider any changes
to the deadline or frequency for submissions of requests for MS-DRG
classification changes for future fiscal years. Beginning with FY 2024
MS-DRG classification change requests, we are changing the deadline to
request changes to the MS-DRGs to October 20 of each year to allow for
additional time for the review and consideration of any proposed
updates. As previously discussed, we continue to believe such a change
would allow hospitals sufficient time to assess potential impacts and
inform future MS-DRG recommendations, while also providing CMS the
additional time needed for evaluation of the requested changes,
analysis of claims data, and consideration of any proposed updates.
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule, we are
also changing the process for submitting requested updates to the MS-
DRG classifications, beginning with the FY 2024 MS-DRG classification
change requests. CMS is in the process of implementing a new electronic
application intake system, Medicare Electronic Application Request
Information SystemTM (MEARIS\TM\), for users to submit new
technology add-on payment applications, requests for ICD-10-PCS
procedure codes, and other requests. To simplify and streamline the
process for submission of standardized applications and requests that
inform payment policy under the IPPS, we will also be using this new
system for submission of MS-DRG classification change requests. We
believe that submission of MS-DRG reclassification requests through
MEARIS\TM\ will not only help CMS to track such requests, but it will
also create efficiencies for requestors when compared to the previous
submission process.
Accordingly, beginning with the FY 2024 MS-DRG classification
change requests, CMS will only accept such requests submitted via
MEARIS,\TM\ and will no longer consider any such requests that are sent
via email. We note that, beginning April 5, 2022, MEARIS\TM\ became
available for users to begin gaining familiarity with this new approach
for submitting MS-DRG classification change requests. MEARIS,\TM\
including the mechanism for submitting MS-DRG classification change
requests, can be accessed at: https://mearis.cms.gov. As stated in the
proposed rule, within MEARIS\TM\ we have built in several resources to
support users, including a ``Resources'' section (available at https://mearis.cms.gov/public/resources) and technical support available under
``Useful Links'' at the bottom of the MEARIS\TM\ site. Questions
regarding the MEARIS\TM\ system can be submitted to CMS using the form
available under ``Contact'' at: https://mearis.cms.gov/public/resources?app=msdrg.
We also note that, as discussed in section II.D.17. of the preamble
of the proposed rule and this final rule, effective January 5, 2022,
MEARIS\TM\ was made available for users to begin gaining familiarity
with a new approach
[[Page 48801]]
and process to submit ICD-10-PCS procedure code requests.
As noted previously, interested parties had to submit MS-DRG
classification change requests for FY 2023 by November 1, 2021. As we
have discussed in prior rulemaking, we may not be able to fully
consider all of the requests that we receive for the upcoming fiscal
year. We have found that, with the implementation of ICD-10, some types
of requested changes to the MS-DRG classifications require more
extensive research to identify and analyze all of the data that are
relevant to evaluating the potential change. We note in the discussion
that follows those topics for which further research and analysis are
required, and which we will continue to consider in connection with
future rulemaking. Interested parties should submit any comments and
suggestions for FY 2024 by October 20, 2022 via the new electronic
intake system, Medicare Electronic Application Request Information
SystemTM (MEARISTM) at: https://mearis.cms.gov/public/home.
We provided a test version of the ICD-10 MS-DRG GROUPER Software,
Version 40, in connection with the FY 2023 IPPS/LTCH PPS proposed rule
so that the public can better analyze and understand the impact of the
proposals included in the proposed rule. We noted that this test
software reflected the proposed GROUPER logic for FY 2023. Therefore,
it included the new diagnosis and procedure codes that are effective
for FY 2023 as reflected in Table 6A.--New Diagnosis Codes--FY 2023 and
Table 6B.--New Procedure Codes--FY 2023 that were associated with the
proposed rule and did not include the diagnosis codes that are invalid
beginning in FY 2023 as reflected in Table 6C.--Invalid Diagnosis
Codes--FY 2023 associated with the proposed rule. We noted that at the
time of the development of the proposed rule there were no procedure
codes designated as invalid for FY 2023, and therefore, there was no
Table 6D--Invalid Procedure Codes--FY 2023 associated with the proposed
rule. Those tables were not published in the Addendum to the proposed
rule, but are available via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html as described in section VI. of the
Addendum to the proposed rule. Because the diagnosis codes no longer
valid for FY 2023 are not reflected in the test software, we made
available a supplemental file in Table 6P.1a that includes the mapped
Version 40 FY 2023 ICD-10-CM codes and the deleted Version 39.1 FY 2022
ICD-10-CM codes that should be used for testing purposes with users'
available claims data. Therefore, users had access to the test software
allowing them to build case examples that reflect the proposals that
were included in the proposed rule. In addition, users were able to
view the draft version of the ICD-10 MS-DRG Definitions Manual, Version
40.
The test version of the ICD-10 MS-DRG GROUPER Software, Version 40,
the draft version of the ICD-10 MS-DRG Definitions Manual, Version 40,
and the supplemental mapping files in Table 6P.1a of the FY 2022 and FY
2023 ICD-10-CM diagnosis codes are available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.
Following are the changes that we proposed to the MS-DRGs for FY
2023. We invited public comments on each of the MS-DRG classification
proposed changes, as well as our proposals to maintain certain existing
MS-DRG classifications discussed in the proposed rule. In some cases,
we proposed changes to the MS-DRG classifications based on our analysis
of claims data and consultation with our clinical advisors. In other
cases, we proposed to maintain the existing MS-DRG classifications
based on our analysis of claims data and consultation with our clinical
advisors. As discussed in section I.F of the preamble of the proposed
rule, we proposed to use the FY 2021 MedPAR data for purposes of this
FY 2023 IPPS rulemaking, with certain proposed modifications to the
relative weight and outlier methodologies. For the FY 2023 IPPS/LTCH
PPS proposed rule, our MS-DRG analysis was based on ICD-10 claims data
from the September 2021 update of the FY 2021 MedPAR file, which
contains hospital bills received from October 1, 2020 through September
30, 2021, for discharges occurring through September 30, 2021. In our
discussion of the proposed MS-DRG reclassification changes, we referred
to these claims data as the ``September 2021 update of the FY 2021
MedPAR file.''
In this FY 2023 IPPS/LTCH PPS final rule, we summarize the public
comments we received on our proposals, present our responses, and state
our final policies. For this FY 2023 final rule, we generally did not
perform any further MS-DRG analysis of claims data. Therefore, the MS-
DRG analysis is based on ICD-10 claims data from the September 2021
update of the FY 2021 MedPAR file, as set forth in the proposed rule,
except as otherwise noted.
As explained in previous rulemaking (76 FR 51487), in deciding
whether to propose to make further modifications to the MS-DRGs for
particular circumstances brought to our attention, we consider whether
the resource consumption and clinical characteristics of the patients
with a given set of conditions are significantly different than the
remaining patients represented in the MS-DRG. We evaluate patient care
costs using average costs and lengths of stay and rely on the judgment
of our clinical advisors to determine whether patients are clinically
distinct or similar to other patients represented in the MS-DRG. In
evaluating resource costs, we consider both the absolute and percentage
differences in average costs between the cases we select for review and
the remainder of cases in the MS-DRG. We also consider variation in
costs within these groups; that is, whether observed average
differences are consistent across patients or attributable to cases
that are extreme in terms of costs or length of stay, or both. Further,
we consider the number of patients who will have a given set of
characteristics and generally prefer not to create a new MS-DRG unless
it would include a substantial number of cases.
In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58448), we finalized
our proposal to expand our existing criteria to create a new
complication or comorbidity (CC) or major complication or comorbidity
(MCC) subgroup within a base MS-DRG. Specifically, we finalized the
expansion of the criteria to include the NonCC subgroup for a three-way
severity level split. We stated our belief that applying these criteria
to the NonCC subgroup would better reflect resource stratification as
well as promote stability in the relative weights by avoiding low
volume counts for the NonCC level MS-DRGs. We noted that in our
analysis of MS-DRG classification requests for FY 2021 that were
received by November 1, 2019, as well as any additional analyses that
were conducted in connection with those requests, we applied these
criteria to each of the MCC, CC, and NonCC subgroups. We also noted
that the application of the NonCC subgroup criteria going forward may
result in modifications to certain MS-DRGs that are currently split
into three severity levels and result in MS-DRGs that are split into
two severity levels. We stated that any proposed modifications to the
MS-DRGs would be addressed in future rulemaking consistent with our
annual process and reflected in Table 5--Proposed List of Medicare
Severity Diagnosis Related Groups (MS-DRGs),
[[Page 48802]]
Relative Weighting Factors, and Geometric and Arithmetic Mean Length of
Stay for the applicable fiscal year.
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44798), we finalized
a delay in applying this technical criterion to existing MS-DRGs until
FY 2023 or future rulemaking, in light of the PHE. Commenters
recommended that a complete analysis of the MS-DRG changes to be
proposed for future rulemaking in connection with the expanded three-
way severity split criteria be conducted and made available to enable
the public an opportunity to review and consider the redistribution of
cases, the impact to the relative weights, payment rates, and hospital
case mix to allow meaningful comment prior to implementation.
In our analysis of the MS-DRG classification requests for FY 2023
that we received by November 1, 2021, as well as any additional
analyses that were conducted in connection with those requests, we
applied these criteria to each of the MCC, CC, and NonCC subgroups, as
described in the following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.005
In general, once the decision has been made to propose to make
further modifications to the MS-DRGs as described previously, such as
creating a new base MS-DRG, or in our evaluation of a specific MS-DRG
classification request to split (or subdivide) an existing base MS-DRG
into severity levels, all five criteria must be met for the base MS-DRG
to be split (or subdivided) by a CC subgroup. We note that in our
analysis of requests to create a new MS-DRG, we typically evaluate the
most recent year of MedPAR claims data available. For example, in the
FY 2023 IPPS/LTCH PPS proposed rule we stated our MS-DRG analysis was
based on ICD-10 claims data from the September 2021 update of the FY
2021 MedPAR file. However, in our evaluation of requests to split an
existing base MS-DRG into severity levels, as noted in prior rulemaking
(80 FR 49368), we typically analyze the most recent 2 years of data.
This analysis includes 2 years of MedPAR claims data to compare the
data results from 1 year to the next to avoid making determinations
about whether additional severity levels are warranted based on an
isolated year's data fluctuation and also, to validate that the
established severity levels within a base MS-DRG are supported. The
first step in our process of evaluating if the creation of a new CC
subgroup within a base MS-DRG is warranted is to determine if all the
criteria are satisfied for a three-way split. If the criteria fail, the
next step is to determine if the criteria are satisfied for a two-way
split. If the criteria for both of the two-way splits fail, then a
split (or CC subgroup) would generally not be warranted for that base
MS-DRG. If the three-way split fails on any one of the five criteria
and all five criteria for both two-way splits (1_23 and 12_3) are met,
we would apply the two-way split with the highest R2 value. We note
that if the request to split (or subdivide) an existing base MS-DRG
into severity levels specifies the request is for either one of the
two-way splits (1_23 or 12_3), in response to the specific request, we
will evaluate the criteria for both of the two-way splits,
[[Page 48803]]
however we do not also evaluate the criteria for a three-way split.
In the FY 2023 IPPS/LTCH PPS proposed rule, we stated that using
the September 2021 update of the FY 2021 MedPAR file, we analyzed how
applying the NonCC subgroup criteria to all MS-DRGs currently split
into three severity levels would affect the MS-DRG structure beginning
in FY 2023. We noted that findings from our analysis indicated that
approximately 41 MS-DRGs would be subject to change based on the three-
way severity level split criterion finalized in FY 2021. Specifically,
we found that applying the NonCC subgroup criteria to all MS-DRGs
currently split into three severity levels would result in the deletion
of 123 MS-DRGs (41 MS-DRGs x 3 severity levels = 123) and the creation
of 75 new MS-DRGs. We further noted that these updates would also
involve a redistribution of cases, which would impact the relative
weights, and, thus, the payment rates proposed for particular types of
cases. We referred the reader to Table 6P.1b associated with the
proposed rule for the list of the 123 MS-DRGs that would be subject to
deletion and the list of the 75 new MS-DRGs that would be proposed for
creation for FY 2023 under this policy if the NonCC subgroup criteria
were applied.
We stated in the proposed rule that in light of the ongoing public
health emergency (PHE), we continue to have concerns about the impact
of implementing this volume of MS-DRG changes at this time, and believe
it may be appropriate to continue to delay application of the NonCC
subgroup criteria to existing MS-DRGs to maintain more stability in the
current MS-DRG structure and until such time additional analyses can be
performed to assess impacts, as discussed in response to comments in
the FY 2022 IPPS/LTCH PPS final rule. Therefore, we proposed to delay
application of the NonCC subgroup criteria to existing MS-DRGs with a
three-way severity level split for FY 2023, and to instead maintain the
current structure of the 41 MS-DRGs that currently have a three-way
severity level split (total of 123 MS-DRGs) that would otherwise be
subject to these criteria. We stated that we intend to address the
application of the NonCC subgroup criteria to existing MS-DRGs with a
three-way severity level split in future rulemaking.
Comment: Commenters expressed overwhelming support for our proposal
to delay application of the NonCC subgroup criteria to existing MS-DRGs
with a three-way severity level split for FY 2023 and to maintain the
current structure of the MS-DRGs. A few commenters who agreed with the
proposal to delay the application of the NonCC subgroup criteria also
requested that CMS provide interested parties with an opportunity to
review and comment on impacts to the relative weights before a proposal
is finalized. The commenters stated it would be helpful if CMS made
claims data available, including volumes by MS-DRG, that support the
proposal to reduce the 123 MS-DRGs.
Response: We thank the commenters for their support. In response to
the commenters who requested the opportunity to review and comment on
impacts to the relative weights before a proposal is finalized, we
intend to provide a comprehensive analysis in future rulemaking based
on the comments and feedback we have received. We are providing the
claims data from the September 2021 update of the FY 2021 MedPAR file
that was reviewed for FY 2023 in our analyses of how applying the NonCC
subgroup criteria to all MS-DRGs currently split into three severity
levels would have potentially affected the MS-DRG structure beginning
in FY 2023. We refer the reader to Table 6P.1b associated with this
final rule and available via the internet on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS.
Comment: A commenter who strongly agreed with the proposal to delay
the application of the NonCC subgroup criteria stated that in addition
to providing a detailed explanation and impact files in the future,
that CMS should consider clarifying and addressing the following
issues: why the list of MS-DRGs that were proposed to be removed in FY
2022 is not the same list of MS-DRGs proposed to be removed for FY
2023, why the list of MS-DRGs that were proposed to become a single,
base MS-DRG for FY 2022 now appear to meet the criteria for a three-way
severity level split for FY 2023, and why MS-DRGs proposed to maintain
a three-way severity level split for FY 2022 now appear to meet the
criteria for a two-way or three-way severity level split for FY 2023.
This commenter also stated that the MS-DRGs displayed in Table 6P.1b
associated with the proposed rule include a list of MS-DRGs that would
be subject to deletion and a list of MS-DRGs that would be proposed for
creation with XXX for the numbers. According to the commenter, many of
the listed MS-DRGs have the same narrative description, however, it
appears they would obtain a new MS-DRG number. The commenter questioned
why MS-DRGs with the same description would have new MS-DRG numbers
assigned. This commenter also suggested that CMS consider patient case-
mix with regard to volumes, and stated Medicare would not have the
volume for the obstetric related MS-DRGs. The commenter requested that
CMS also examine the impact of maternal health quality initiatives and
maternity hospital designation in connection with the solicitation for
comments on low volume MS-DRGs. Lastly, the commenter recommended that
CMS utilize two years of good data to examine the impact of the
proposed redistribution in future analyses and determine if the
proposed MS-DRG changes and associated relative weights appropriately
reflect resource consumption.
Response: We appreciate the commenter's feedback. We acknowledge
that the list of MS-DRGs identified as potentially subject to removal
for FY 2022 differs from the list of MS-DRGs identified as potentially
subject to removal and provided for FY 2023 in connection with the
NonCC subgroup criteria discussion. We also acknowledge that the list
of MS-DRGs identified as potentially subject to creation for FY 2022
differs from the list of MS-DRGs identified as potentially subject to
removal and provided for FY 2023 in connection with the NonCC subgroup
criteria discussion. The lists differ as a result of the claims data
that was analyzed for our MS-DRG analysis and rulemaking each fiscal
year. We provided the results of both the FY 2019 and FY 2020 MedPAR
claims data as displayed in Table 6P.11 in association with the FY 2022
IPPS/LTCH PPS final rule (available via the internet on the CMS website
at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS).
By comparison, for FY 2023, consistent with our finalized policy to
use the FY 2021 MedPAR data for purposes of this FY 2023 rulemaking, we
have provided the FY 2021 MedPAR claims data for the listed MS-DRGs in
Table 6P.1b in association with this final rule, as noted earlier in
this section. Because there is variation in the claims data reported
from year to year, it is expected that there may be fluctuations in the
data that could affect the list of MS-DRGs potentially subject to
change in connection with the application of the NonCC subgroup
criteria for a particular fiscal year. However, we believe that
reliability and stability of the data is an important consideration
with respect to the
[[Page 48804]]
application of the NonCC subgroup criteria and will give careful
consideration to the number of years of data to analyze in connection
with any future proposed policy changes as well as the impacts on
relative weights, as we continue to assess all the comments and
feedback we have received, particularly in light of the ongoing public
health emergency. We also take this opportunity to note that the listed
MS-DRGs as displayed in the tables (for both FY 2022 and FY 2023) are
for illustrative purposes as the intent was to show the MS-DRGs that
would potentially be subject to deletion and the MS-DRGs that would
potentially be subject to creation if the NonCC subgroup criteria were
to be applied for the applicable fiscal year. Because we did not
propose the application of these criteria to existing MS-DRGs with a
three-way severity level split for either FY 2022 or FY 2023, and we
have not yet completed the comprehensive impact analysis of any such
future proposed changes, as previously discussed, we are clarifying
that both the MS-DRG numbers and MS-DRG titles that may eventually be
subject to change in connection with a future proposal to apply the
NonCC subgroup criteria may, in the interim, be subject to further
modifications as a result of our annual review of the MS-DRG
classifications. As such, any future proposed MS-DRG changes will be
considered in connection with the analysis that is performed for
application of the MCC, CC and NonCC subgroup criteria to the MS-DRGs
that are in effect at that time.
In response to the commenter's question regarding why new MS-DRG
numbers would be considered, we note that new MS-DRG numbers are
preferred because we anticipate that individuals, payers, and
organizations conducting analysis would need to be aware if proposed
changes to base DRG concepts are made to allow them time to adjust
their programs, analyses, or queries that may have hard coded the DRG
numbers. Other agencies that utilize MS-DRGs may perform minimal
updates to their relative weights, quality risk adjustment or exclusion
criteria and only focus on new MS-DRGs, thereby potentially creating
additional operational or system challenges if an existing MS-DRG
number were to be reused. To minimize confusion for those who rely on
MS-DRG concepts year to year, and avoid unintended consequences from
the reuse of an existing DRG number for a different concept, we believe
it is appropriate to consider revisions to both the MS-DRG number and
corresponding description.
Comment: Other commenters requested CMS consider continuing the
delay beyond the period of the public health emergency (PHE). The
commenters indicated that hospital claims and cost report data impacted
by the COVID-19 pandemic should not be used as the basis of MS-DRG
consolidation since utilization may be artificially low during the PHE.
Response: We thank the commenters for their feedback. As stated
earlier in this section, we are giving careful consideration to all the
recommendations and suggestions we have received in connection with the
NonCC subgroup criteria discussion.
Comment: Another commenter expressed concern with regard to how the
NonCC subgroup criteria are to be applied. The commenter stated they
understood the policy to mean that the NonCC subgroup criteria would
only be applied to new requests for MS-DRG splits, not to existing MS-
DRGs. The commenter also stated they were unclear when the proposal was
finalized since, according to the commenter, CMS would have needed to
specify the intent to apply the NonCC subgroup criteria to all existing
MS-DRGs versus only for the creation of new MS-DRGs. Additionally, this
commenter urged CMS to conduct a full analysis that demonstrates the
explanatory power of the proposed new MS-DRGs is an improvement over
the current MS-DRGs, similar to the analysis that was performed for the
transition from CMS DRGs to MS-DRGs in FY 2008. The commenter indicated
that a comprehensive analysis is critical for interested parties to
provide meaningful comments.
Response: In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44796), we
summarized the discussion pertaining to the NonCC subgroup criteria
policy finalized for FY 2021. In that discussion we noted that the
application of the NonCC subgroup criteria going forward may result in
modifications to certain MS-DRGs that are currently split into three
severity levels and result in MS-DRGs that are split into two severity
levels. We stated that any proposed modifications to the MS-DRGs would
be addressed in future rulemaking consistent with our annual process
and reflected in Table 5--Proposed List of Medicare Severity Diagnosis
Related Groups (MS-DRGs), Relative Weighting Factors, and Geometric and
Arithmetic Mean Length of Stay for the applicable fiscal year. As
discussed in the proposed rule, we applied the nonCC subgroup criteria
to each of the MCC, CC, and NonCC subgroups, in our analysis of the MS-
DRG classification requests for FY 2023 that we received by November 1,
2021, as well as any additional analyses that were conducted in
connection with those requests. We also note that new requests to
subdivide a MS-DRG frequently pertain to existing MS-DRGs which differs
from requests to create a new base MS-DRG for which the criteria to
create subgroups is subsequently applied. In response to the
commenter's recommendation that CMS conduct a full analysis similar to
the analysis that was performed for the transition from CMS DRGs to MS-
DRGs in FY 2008, we appreciate the commenter's suggestion and will take
it under advisement.
Comment: Another commenter who recognized differences between the
list of MS-DRGs shown for FY 2022 and FY 2023 requested additional
transparency for the data being presented for review and for CMS to
consider analyzing data from other databases, such as Medicaid or
States, to supplement the MS-DRGs known to have lower volumes among the
Medicare population (for example, Obstetric MS-DRGs). This commenter
also expressed concern about the potential impact to community
hospitals if proposed MS-DRG changes in connection with the NonCC
subgroup criteria result in significant MS-DRG redistribution.
Response: We thank the commenter for their feedback. As discussed
previously, we intend to conduct a comprehensive analysis of the
application of the NonCC subgroup criteria that would be made publicly
available for review and comment in connection with any proposed MS-DRG
changes for future rulemaking.
After consideration of the public comments we received, we are
finalizing our proposal to delay the application of the NonCC subgroup
criteria to existing MS-DRGs with a three-way severity level split
until FY 2024 or later, and are finalizing for FY 2023 to maintain the
current structure of the 41 MS-DRGs that currently have a three-way
severity level split.
We are making the FY 2023 ICD-10 MS-DRG GROUPER and Medicare Code
Editor (MCE) Software Version 40, the ICD-10 MS-DRG Definitions Manual
files Version 40 and the Definitions of Medicare Code Edits Manual
Version 40 available to the public on our CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.
[[Page 48805]]
2. Pre-MDC: MS-DRG 018 Chimeric Antigen Receptor (CAR) T-cell and Other
Immunotherapies
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44798 through
44806), we finalized our proposal to assign procedure codes describing
CAR T-cell, non-CAR T-cell, and other immunotherapies to Pre-MDC MS-DRG
018 and to revise the title for Pre-MDC MS-DRG 018 to ``Chimeric
Antigen Receptor (CAR) T-cell and Other Immunotherapies'' to reflect
this assignment. In that discussion, we noted that a few commenters
recommended we continue to work with interested parties on ways to
improve the predictability and stability of hospital payments for these
complex, novel cell therapies and that we should continue to monitor
and assess the appropriateness of therapies assigned to MS-DRG 018, if
they continue to be aligned on resource use, and whether additional
refinements or MS-DRGs may be warranted in the future.
We also noted that the process of code creation and proposed
assignment to the most appropriate MS-DRG exists independently,
regardless of whether there is an associated application for a new
technology add-on payment for a product or technology submitted for
consideration in a given fiscal year. Specifically, requests for a new
code(s) or updates to existing codes are addressed through the ICD-10
Coordination and Maintenance Committee meetings, held annually in the
spring and fall, where code proposals are presented and the public is
provided the opportunity to comment. All codes finalized from the fall
meeting are subsequently proposed for assignment under the ICD-10 MS-
DRGs through rulemaking. We refer the reader to section II.D.17 of the
preamble of this final rule for additional information regarding the
ICD-10 Coordination and Maintenance Committee meeting process.
As stated in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28130),
there were no requests or proposals for new procedure codes to describe
the administration of a CAR T-cell or another type of gene or cellular
therapy discussed at the September 14-15, 2021 ICD-10 Coordination and
Maintenance Committee meeting. For the March 8-9, 2022 ICD-10
Coordination and Maintenance Committee meeting, there were topics
included on the agenda and in the related meeting materials that
included proposals for new procedure codes to describe the
administration of a CAR T-cell or another type of gene or cellular
therapy product. The agenda and related meeting materials for these
specific topics are available via the internet on the CMS website at:
https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials.
As stated in the FY 2022 IPPS/LTCH PPS final rule (86 FR 44805) and
noted previously, the process of code creation and proposed assignment
to the most appropriate MS-DRG exists independently, regardless of
whether there is an associated application for a new technology add-on
payment for a product or technology submitted for consideration in a
given fiscal year. We also clarified that the assignment of a procedure
code to a MS-DRG is not dependent upon a product's FDA approval.
Similarly, the creation of a code to describe a technology that is
utilized in the performance of a procedure or service does not require
FDA approval of the technology.
Because the diagnosis and procedure code proposals that are
presented at the March meeting for an October 1 implementation
(upcoming FY) are not finalized in time to include in Table 6A.--New
Diagnosis Codes and Table 6B.--New Procedure Codes in association with
the proposed rule, as noted in prior rulemaking, we use our established
process to examine the MS-DRG assignment for the predecessor codes to
determine the most appropriate MS-DRG assignment. Specifically, we
review the predecessor code and MS-DRG assignment most closely
associated with the new procedure code, and in the absence of claims
data, we consider other factors that may be relevant to the MS-DRG
assignment, including the severity of illness, treatment difficulty,
complexity of service and the resources utilized in the diagnosis or
treatment of the condition. We have noted in prior rulemaking that this
process does not automatically result in the new procedure code being
assigned to the same MS-DRG or to have the same designation (O.R.
versus Non-O.R.) as the predecessor code.
As stated in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28130),
in response to commenters' recommendation that we continue to assess
the appropriateness of the therapies assigned to Pre-MDC MS-DRG 018, we
provided the results of our data analysis using the September 2021
update of the FY 2021 MedPAR file for cases reporting the
administration of a CAR T-cell or other immunotherapy in Pre-MDC MS-DRG
018 and the number of cases reporting a secondary diagnosis of Z00.6
(Encounter for examination for normal comparison and control in
clinical research program). We noted that if a procedure code that is
assigned to the logic for Pre-MDC MS-DRG 018 is not listed it is
because there were no cases found. We also noted there were no cases
reporting diagnosis code Z00.6 as a principal diagnosis. Our findings
are shown in the following table.
[[Page 48806]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.006
The data show that there is a wide range in the volume of cases (4
cases versus 435 cases), average length of stay (11.3 days versus 20.3
days), and average costs ($157,950 versus $310,561) reporting the
administration of CAR T-cell therapies in MS-DRG 018. This is to be
expected since these therapies continue to evolve and the ICD-10-PCS
coding to identify and describe these therapies also continues to be
refined through the ICD-10 Coordination and Maintenance Committee
meeting process. As additional claims data becomes available for these
therapies, we will continue to evaluate to determine if further
modifications to Pre-MDC MS-DRG 018 are warranted.
We noted in the proposed rule that in response to our statement in
the FY 2022 IPPS/LTCH PPS final rule that we plan to continue engaging
with interested parties on additional options for consideration in this
field of cellular and gene therapies, we received additional feedback
and suggestions, including recommendations for Town Hall meetings/
listening sessions to discuss the interconnectedness of these issues;
exploration of what was described as a different set and kind of MS-
DRGs that would reward providers for controlling patient care costs,
without consideration of product costs outside of their control; and
evaluation of the creation and assignment of multiple MS-DRGs for cell
and gene therapy cases: one to cover patient care costs, the other to
cover product costs across therapeutic product categories.
We stated we appreciated this additional feedback and will continue
to consider these issues and suggestions in connection with future
rulemaking. We also stated we intend to continue engaging with
interested parties by sharing updates from our analysis of claims data
as we examine and explore potential refinements for these therapies
under the IPPS.
Comment: Several commenters expressed support and appreciation that
for FY 2023, CMS proposed to maintain the current structure of Pre-MDC
MS-DRG 018 that includes ``Other Immunotherapies'', and to maintain its
current methodology used to determine the relative weight. Some
commenters acknowledged that it is difficult to predict what the
associated costs will be in the future for CAR T-cell and other
immunotherapies that remain under development. These commenters urged
CMS to consider factors such as new or different side effects and how
other therapeutic agents that could be administered simultaneously in
connection with these therapies may potentially lead to toxicity, as
continued monitoring of resource utilization and data analysis for Pre-
MDC MS-DRG 018 occurs. Other commenters commended CMS for its
commitment to engage with interested parties as the agency continues to
analyze claims data and consider the feedback that has been received to
date for these therapies.
Response: We thank the commenters for their support and appreciate
the additional feedback on other factors to consider as we continue to
monitor and analyze the data for Pre-MDC MS-DRG 018. As noted in prior
rulemaking, we have received several suggestions, recommendations, and
options pertaining to how CAR T-cell and other immunotherapies may be
classified under the IPPS in the future. We intend to further examine
the feedback received and maintain transparency in our approach moving
forward, with the shared goal of enabling continued access to these and
other vital treatments for Medicare beneficiaries.
Comment: Similar to the public comments received in response to the
FY 2022 IPPS/LTCH PPS proposed rule, for FY 2023, some commenters again
expressed concerns with the non-CAR T-cell therapies and other
immunotherapies that may be assigned to Pre-MDC MS-DRG 018 and stated
that these potential assignments could lead to fluctuations in the
relative weight. A few commenters requested that Pre-MDC MS-DRG 018 be
limited to CAR T-cell therapies. Other commenters encouraged CMS to
clarify its methodology and criteria for assigning new procedure codes
to Pre-MDC MS-DRG 018. Some commenters expressed continued concern with
the revision to the title for Pre-MDC MS-DRG 018 that was finalized
effective FY
[[Page 48807]]
2022 to include ``Other Immunotherapies''.
Response: In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44798
through 44806), we provided detailed summaries and responses to these
same or similar concerns and comments. In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28129 through 28131), we provided an overview of
the assignment of new procedure codes to Pre-MDC MS-DRG 018 and
reiterated much of the discussion from FY 2022 rulemaking. As stated in
prior rulemaking, the MS-DRG system is a system of averages and it is
expected that within the diagnostic related groups, some cases may
demonstrate higher than average costs, while other cases may
demonstrate lower than average costs. We have not made any changes to
our established processes or methodologies for MS-DRG assignment of new
procedure codes, including with regard to case assignment to Pre-MDC
MS-DRG 018, and we refer the reader to the detailed discussion related
to Pre-MDC MS-DRG 018 in the FY 2022 IPPS/LTCH PPS final rule. We note
that additional claims data is needed to fully analyze and consider all
the recommendations we have received, and to potentially develop
alternative proposals with respect to payment for these therapies under
the IPPS. There is also uncertainty with regard to the number and types
of therapies currently under development or undergoing studies and how
soon they will be available. We recognize the concerns that have been
expressed by commenters and we are also continuing to assess the
reliability and stability of the data in light of the ongoing public
health emergency.
Comment: Many commenters expressed appreciation to CMS for
providing transparency with the cases reporting the administration of a
CAR T-cell or other immunotherapy in the FY 2021 MedPAR claims data for
Pre-MDC MS-DRG 018. However, a commenter indicated there was confusion
about the coded claims data as presented in the proposed rule since the
procedure codes described as new technology group 7 became effective
October 1, 2021 (FY 2022), which is one year later than the FY 2021
data that was shown in the table in the preamble of the proposed rule.
The commenter requested that CMS provide clarification to help
eliminate any additional confusion for readers and interested parties
who also analyze the data for these therapies.
Response: We thank the commenters for their support. The FY 2021
MedPAR claims data were regrouped using the proposed FY 2023 MS-DRG
classifications, therefore, coded claims data for the procedure codes
describing the administration of CAR T-cell and other immunotherapy
agents reported in FY 2021 was mapped from the FY 2021 MedPAR coded
claims data to the procedure codes that are effective for FY 2023.
Specifically, the codes that were effective for FY 2021 and are no
longer valid were mapped to the new procedure codes that are valid for
FY 2023. We also note, as generally stated in the preamble of the
proposed rule each year, the diagnosis and procedure codes from the
specified FY MedPAR claims data are grouped through the applicable
version of the proposed FY GROUPER. For example, as discussed in
section II.E.1. of the preamble of the proposed rule (87 FR 28197), the
proposed FY 2023 relative weights are based on the ICD-10-CM diagnosis
codes and ICD-10-PCS procedure codes from the FY 2021 MedPAR claims
data, grouped through the ICD-10 version of the proposed FY 2023
GROUPER (Version 40).
Comment: A commenter suggested that CMS consider establishing a
timeframe that would enable the public to comment on procedure codes
that may be assigned to Pre-MDC MS-DRG 018 upon being approved and
finalized after the spring ICD-10 Coordination and Maintenance
Committee meeting. The commenter stated that currently, because
procedure codes that are discussed at the spring ICD-10 Coordination &
Maintenance (C&M) Committee meeting do not receive proposed assignments
and are not published with the IPPS proposed rule given the timing,
there is no opportunity for interested parties to provide feedback to
CMS about MS-DRG assignments for new codes, including assignment to MS-
DRG-018. The commenter acknowledged the C&M meeting is not the
appropriate forum for the public to provide input on MS-DRG assignment,
however, because Pre-MDC MS-DRG 018 currently has a limited number of
procedure codes assigned to it, the commenter stated that interested
parties should have the opportunity to review and comment on potential
assignment to Pre-MDC MS-DRG 018. This commenter also maintained that
it has a unique relationship with the therapies currently assigned to
Pre-MDC MS-DRG 018 as its membership is the predominant specialty
society associated with these therapies and has the experience and
clinical understanding related to resource utilization associated with
the administration of these therapies.
Response: We appreciate the commenter's feedback. As discussed
elsewhere in this rule as well as in prior rulemaking, because the
procedure code proposals discussed at the Spring ICD-10 Coordination
and Maintenance Committee meeting are not finalized in time to include
in Table 6B.--New Procedure codes associated with the proposed rule,
CMS uses an established process to determine the most appropriate MS-
DRG assignment for these new procedure codes for the upcoming fiscal
year. While we understand and acknowledge the uniqueness of CAR T-cell,
gene, and cellular therapies, we believe it is necessary to further
examine how and when we could alter our current methodology and
timelines to provide the opportunity for interested parties to submit
comments and feedback in the assignment of new procedure codes that are
finalized after the spring meeting. We also note, as discussed in the
proposed rule (87 FR 28130), all codes finalized from the fall meeting
are subsequently proposed for assignment under the ICD-10 MS-DRGs
through rulemaking, therefore, interested parties seeking the
opportunity to more fully comment on potential MS-DRG assignment(s)
have the opportunity to submit requests for consideration of proposed
new procedure codes in association with these therapies to be discussed
at the fall meeting versus the spring meeting. Alternatively,
interested parties may use current coding information as shown in the
ICD-10 Coordination and Maintenance Committee meeting materials to
consider the potential MS-DRG assignments for any procedure codes that
may be finalized after the March meeting and submit public comments for
consideration.
As noted in the proposed rule, for the March 8-9, 2022 ICD-10
Coordination and Maintenance Committee meeting there were two topics
included on the agenda and in the related meeting materials that
included proposals for new procedure codes to describe the
administration of a CAR T-cell or another type of gene or cellular
therapy product. The two topics are Administration of afamitresgene
autoleucel (afami-cel), a specific peptide enhanced affinity receptor
(SPEAR) T-cell therapy and Administration of Tabelecleucel (tab-
cel[supreg]), an allogeneic Epstein-Barr virus (EBV)-specific T-cell
immunotherapy, both of which were approved for new procedure codes
following the March meeting. We refer the reader to the CMS website at
https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials for
additional detailed information regarding these code requests.
[[Page 48808]]
Because the diagnosis and procedure code proposals that are
presented at the March ICD-10-CM Coordination and Maintenance Committee
meeting for an October 1 implementation (upcoming FY) are not finalized
in time to include in Table 6A.--New Diagnosis Codes and Table 6B.--New
Procedure Codes in association with the proposed rule, as we have noted
in prior rulemaking, we use our established process to examine the MS-
DRG assignment for the predecessor codes to determine the most
appropriate MS-DRG assignment. Specifically, we review the predecessor
code and MS-DRG assignment most closely associated with the new
procedure code, and in the absence of claims data, we consider other
factors that may be relevant to the MS-DRG assignment, including the
severity of illness, treatment difficulty, complexity of service and
the resources utilized in the diagnosis and/or treatment of the
condition. We have noted in prior rulemaking that this process does not
automatically result in the new procedure code being assigned to the
same MS-DRG or to have the same designation (O.R. versus Non-O.R.) as
the predecessor code. As shown in Table 6B.--New Procedure Codes
associated with this final rule and available via the internet on the
CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS, new procedure codes for these two therapies
have been finalized for assignment to Pre-MDC MS-DRG 018 effective with
discharges on and after October 1, 2022 (FY 2023).
We appreciate the public comments we received, and, as noted, will
continue to evaluate the recommendations and options provided by
commenters related to these therapies as well as to monitor the
available claims data.
3. MDC 01 (Diseases and Disorders of the Nervous System)
a. Laser Interstitial Thermal Therapy (LITT)
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44812 through
44814), we finalized the reassignment of 31 ICD-10-PCS procedure codes
describing laser interstitial thermal therapy (LITT) of various body
parts to more clinically appropriate MS-DRGs, as shown in Table 6P.2b
associated with the FY 2022 IPPS/LTCH PPS final rule and available via
the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS, including the
reassignment of procedure codes D0Y0KZZ (Laser interstitial thermal
therapy of brain) and D0Y1KZZ (Laser interstitial thermal therapy of
brain stem), which were reassigned from MS-DRG 023 (Craniotomy with
Major Device Implant or Acute Complex CNS Principal Diagnosis with MCC
or Chemotherapy Implant or Epilepsy with Neurostimulator), MS-DRG 024
(Craniotomy with Major Device Implant or Acute Complex CNS Principal
Diagnosis without MCC), and MS-DRGs 025, 026, and 027 (Craniotomy and
Endovascular Intracranial Procedures with MCC, with CC, and without CC/
MCC, respectively) to MS-DRGs 040, 041, and 042 (Peripheral, Cranial
Nerve and Other Nervous System Procedures with MCC, with CC and without
CC/MCC, respectively).
We also finalized the redesignation of these two LITT procedures
(codes D0Y0KZZ and D0Y1KZZ) and the reassignment from extensive O.R.
procedures in MS-DRGs 981, 982 and 983 (Extensive O.R. Procedure
Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC,
respectively) to non-extensive O.R. procedures in MS-DRGs 987, 989, and
989 (Non-Extensive O.R. Procedure Unrelated to Principal Diagnosis with
MCC, with CC, and without CC/MCC, respectively) (86 FR 44889).
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28131), for FY 2023, we received two requests from the manufacturers of
the LITT technology (Medtronic and Monteris[supreg] Medical) to reverse
the MS-DRG reassignment for the ICD-10 procedure codes that identify
LITT of the brain and brain stem (codes D0Y0KZZ and D0Y1KZZ) from the
MS-DRGs for peripheral, cranial nerve and other nervous system
procedures (MS-DRGs 040, 041, and 042) back to the MS-DRGs for
craniotomy and endovascular procedures (MS-DRGs 023, 024, 025, 026, and
027). The first requestor acknowledged that the technique utilized in
the performance of LITT procedures for the brain and brain stem are
minimally invasive and do not involve a craniotomy however, the
requestor also stated the procedures assigned to MS-DRGs 025, 026, and
027 are not exclusive to craniotomies. The requestor further stated
that these LITT procedures involve a twist drill or burr hole and are
similar to other non-craniotomy procedures in MS-DRGs 025, 026, and 027
including radioactive elements and neurostimulator leads that involve
inserting these devices into the brain.
In its review of the other procedures assigned to MS-DRGs 040, 041,
and 042, the requestor stated that there are distinct clinical
differences between the invasiveness of LITT that involves
instrumentation being placed deeply within the brain tissue and the
non-invasiveness of stereotactic radiosurgery that does not involve
entering the brain with instrumentation. The requestor also indicated
LITT utilizes a different modality via direct thermal ablation compared
to stereotactic radiosurgery that utilizes externally-generated
ionizing radiation.
The requestor performed its own data analysis for LITT procedures
of the brain and brain stem using MedPAR data from FY 2019 through FY
2022 impact files. According to the requestor, its findings demonstrate
that the costs of the cases reporting LITT of the brain or brain stem
are better aligned with MS-DRGs 025, 026, and 027 compared to MS-DRGs
040, 041, and 042.
The second requestor similarly discussed the steps and resources
involved in the performance of LITT procedures for the brain and brain
stem, provided its detailed analysis on the indications for LITT (brain
tumors and epileptic foci), compared LITT to other procedures in MS-
DRGs 025, 026, and 027 and stated that the majority of the procedures
currently assigned to MS-DRGs 040, 041, 042 are not performed for the
treatment of brain cancer or epilepsy. The requestor stated that the
LITT procedure is on the inpatient only list and is only performed on
Medicare beneficiaries in the inpatient hospital setting. The requestor
provided the top 10 principal diagnoses associated with LITT of brain
cases it found based on its analysis, and identified the diagnoses for
which there were less than 10 cases with an asterisk, as reflected in
the following table.
[[Page 48809]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.007
The requestor asserted that the statement in the FY 2022 IPPS/LTCH
PPS final rule that the technique to perform the LITT procedure on
brain and brain stem structures is considered minimally invasive and
does not involve a craniotomy, and that therefore, continued assignment
to the craniotomy MS-DRGs is not clinically appropriate,
mischaracterizes both the LITT procedures and universe of services
assigned to MS-DRGs 023 through 027. The requestor acknowledged that
the craniotomy procedures listed in the logic for MS-DRGs 023 through
027 include open procedures but stated the logic also lists less
invasive procedures including percutaneous and percutaneous endoscopic
procedures. The requestor asserted that open procedures are a minority
of the ICD-10-PCS codes assigned to these MS-DRGs.
In addition, the requestor stated that LITT and craniotomy are in
fact very clinically similar; in that both procedures are intended to
remove and destroy the targeted tumor and lesion with a different
surgical tool used (scalpel versus heated ablation probe). According to
the requestor, brain LITT procedures involve insertion of laser probes
into the brain which requires opening both the skull and dura, similar
to a craniotomy. The requestor also stated that craniotomy and LITT
share several procedural characteristics and provided the following
list.
Require an operating room;
Performed under general anesthesia;
Require creation of burr holes and invasive skull
fixation;
Require a sterile field, incision, opening of the skull
and dura;
Cause tissue to be immediately destroyed or excised;
Carry a risk of immediate intracranial bleeding;
Require closure of the scalp wound;
Risk intracranial infection; and
Require a hospital stay of one or more nights.
In contrast, the requestor stated that procedures assigned to MS-
DRGs 040, 041, and 042 are primarily nerve procedures or excision or
detachment procedures performed on parts of the body other than the
head, including the upper and lower extremities. According to the
requestor, none of the procedures in MS-DRGs 040, 041, and 042 require
drilling into the patient's skull, a step which is integral to LITT.
The requestor provided the following top 10 principal diagnoses
associated with cases it found in MS-DRGs 040, 041, and 042 during its
analysis and stated that most of the procedures assigned to MS-DRGs
040, 041, and 042 are not typically performed in the treatment of brain
cancer or epilepsy.
[GRAPHIC] [TIFF OMITTED] TR10AU22.008
[[Page 48810]]
However, the requestor stated an exception is stereotactic
radiosurgery (SRS) procedures performed on the brain and brain stem
that are assigned to MS-DRGs 040, 041, and 042 and are used to treat
brain cancer. According to the requestor, craniotomy, LITT and SRS are
all image-guided procedures used to treat a variety of brain disorders
including tumors and epilepsy, although it stated that is where any
similarity between LITT and SRS ends and where the procedural
similarities between craniotomy and LITT begin.
The requestor stated SRS is a non-invasive procedure that gradually
destroys or inactivates tissues in or around the brain and is typically
performed on an outpatient basis while inpatient SRS treatment is rare.
According to the requestor, SRS does not require an operating room, is
rarely done under general anesthesia (children and highly
claustrophobic individuals being an exception), and does not require
(but can use) rigid skull fixation. In addition, the requestor stated
that because it is non-invasive, there is no need for a sterile field,
incision, opening/closing of the skull, opening/closing of the dura,
suturing/stapling the wound, and produces essentially no risk of
immediate intracranial bleeding or delayed infection. According to the
requestor, LITT is much more invasive than SRS using a head frame and
involves and requires the same surgical skill and hospital resources as
craniotomies.
In the proposed rule we noted that following the submission of the
two FY 2023 MS-DRG classification change requests for LITT, these same
two requestors (the manufacturers of the LITT technology) submitted a
joint code proposal requesting an overall change to how LITT is
classified within the ICD-10-PCS classification and for consideration
as an agenda topic to be discussed at the March 8-9, 2022 ICD-10
Coordination and Maintenance Committee meeting. The proposal was
presented and discussed at the March 8-9, 2022 ICD-10 Coordination and
Maintenance Committee meeting. We referred the reader to the CMS
website at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials for additional detailed information regarding the request,
including a recording of the discussion and the related meeting
materials. Public comments in response to the code proposal were due by
April 8, 2022.
Because the diagnosis and procedure code proposals that are
presented at the March ICD-10-CM Coordination and Maintenance Committee
meeting for an October 1 implementation (upcoming FY) are not finalized
in time to include in Table 6A. --New Diagnosis Codes and Table 6B.--
New Procedure Codes in association with the proposed rule, as we have
noted in prior rulemaking and discuss further in this section, we use
our established process to examine the MS-DRG assignment for the
predecessor codes to determine the most appropriate MS-DRG assignment.
Specifically, we review the predecessor code and MS-DRG assignment most
closely associated with the new procedure code, and in the absence of
claims data, we consider other factors that may be relevant to the MS-
DRG assignment, including the severity of illness, treatment
difficulty, complexity of service and the resources utilized in the
diagnosis and/or treatment of the condition. We have noted in prior
rulemaking that this process does not automatically result in the new
procedure code being assigned to the same MS-DRG or to have the same
designation (O.R. versus Non-O.R.) as the predecessor code. Under this
established process, the MS-DRG assignment for the upcoming fiscal year
for any new diagnosis or procedure codes finalized after the March
meeting would be reflected in Table 6A.--New Diagnosis Codes and Table
6B.--New Procedure Codes associated with the final rule for that fiscal
year. However, as stated in the proposed rule, in light of the unique
circumstances relating to these procedures, for which there was a
pending proposal to reclassify LITT within ICD-10-PCS and for new
procedure codes discussed at the March meeting, as well as an MS-DRG
reclassification request to reassign the existing codes describing
these procedures, we addressed in this section first, the code proposal
discussed at the March meeting and the possible MS-DRG assignments for
any new codes that may be approved, and then secondly, the requested
reassignment of the existing codes, in the event the new codes are not
approved.
To summarize, as discussed at the March meeting, the code proposal
was to reclassify LITT procedures from the Radiation Therapy section of
ICD-10-PCS (Section D) to the Medical and Surgical section of ICD-10-
PCS. Specifically, the proposal was to reclassify LITT procedures to
the root operation Destruction. In ICD-10-PCS, the root operation
Destruction is defined as physical eradication of all or a portion of a
body part by the direct use of energy, force, or a destructive agent.
According to the requestors, LITT is misclassified to section D-
Radiation Therapy in ICD-10-PCS possibly because of terminology that
was used for predicate devices, whose indications included the phrase
``interstitial irradiation or thermal therapy'' in describing LITT's
method of action. The requestors stated LITT is thermal therapy,
destroying soft tissue using heat generated by a laser probe at the
target site and that the LITT procedure does not use ionizing
radiation, which is what the term ``radiation'' commonly refers to in
the general medical sense. The requestors also stated that by itself,
radiation is a broad term and provided an example that the spectrum of
electromagnetic radiation technically encompasses low energy non-
ionizing radio waves, microwaves, and infrared to high energy ionizing
X-rays and gamma rays while ionizing radiation creates ions in the
cells it passes through by removing electrons, a process which kills or
alters the cells over time.
The requestors further stated that only certain medical uses of
radiation are classified to section D-Radiation Therapy. For instance,
section D-Radiation Therapy categorizes treatments using ionizing
radiation, including beam radiation, brachytherapy, and stereotactic
radiosurgery. All of these deliver concentrated ionizing radiation to
eradicate abnormal cells, most commonly neoplasms. Other treatments
classified to section D-Radiation Therapy, such as hyperthermia, are
used as adjuncts to ionizing radiation. The requestors asserted that
while LITT eradicates abnormal cells, it does so with heat, not
ionizing radiation and rather than a radiation therapy procedure, LITT
is a surgical procedure. According to the requestors, LITT would be
more appropriately classified as an ablation procedure with the root
operation Destruction.
As stated in the proposed rule, the original request for a new
code(s) to describe the LITT technology was initially discussed at the
September 24-25, 2008 ICD-9-CM Coordination and Maintenance Committee
meeting. At that time, the requestor sought an April 1, 2009
implementation date. Public comments opposed an April 1, 2009
implementation date, therefore, effective October 1, 2009 (FY 2010),
ICD-9-CM procedure codes were created to identify procedures performed
utilizing the LITT technology. The following table lists the ICD-9-CM
procedure codes describing LITT and their respective MDC and MS-DRG
assignments under the ICD-9 based MS-DRGs. We refer the reader to the
ICD-9 and ICD-10 MS-DRG Definitions Manual Files V33 (available via the
[[Page 48811]]
internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Acute-Inpatient-Files-for-Download-Items/FY2016-Final-Rule-Correction-Notice-Files in the
Downloads section) for complete documentation of the GROUPER logic for
ICD-9.
[GRAPHIC] [TIFF OMITTED] TR10AU22.009
The requestors maintain that although LITT was used to treat a
variety of anatomic sites when it was first introduced, its current
primary use is intracranial, specifically to treat brain tumors and
epileptic foci. However, the requestors stated it is also used to treat
radiation necrosis, an inflammatory response from prior treatment with
ionizing radiation.
We noted in the proposed rule that currently, in the U.S., there
are only two LITT systems in use, VisualaseTM MRI-Guided
Laser Ablation (Medtronic) and the Neuroblate[supreg] System
(Monteris[supreg] Medical). The requestors also stated that over the
last six years, the Indications for Use (IFU) for one of the two U.S.
approved LITT technologies (Neuroblate[supreg]) has been updated to
reflect the system's current use in the brain and to align with the
intended neurosurgical patient population. The requestor indicated
applications in the spine are also anticipated in the future within the
central nervous system.
As previously noted, the deadline for receipt of public comments
for the proposed reclassification of LITT procedures that was presented
at the March 8-9, 2022 ICD-10 Coordination and Maintenance Committee
meeting along with the corresponding proposal for new procedure codes
was April 8, 2022, and the final code decisions on these proposals were
not yet available for inclusion in Table 6B.--New Procedure Codes
associated with the FY 2023 IPPS/LTCH PPS proposed rule. However, as
discussed in prior rulemaking (86 FR 44805), codes that are finalized
after the March meeting are reviewed and subject to our established
process of initially reviewing the predecessor codes MS-DRG assignment
and designation, while considering other relevant factors (for example,
severity of illness, treatment difficulty, complexity of service and
the resources utilized in the diagnosis and/or treatment of the
condition) as previously described. The codes that are finalized after
the March meeting are specifically identified with a footnote in Tables
6A.--New Diagnosis Codes and Table 6B.--New Procedure Codes that are
made publicly available in association with the final rule via the
internet on the CMS website at https://www.cms.gov/medicare/medicare-
fee-for-service-payment/acuteinpatientpps. The public may provide
feedback on these finalized assignments, which is then taken into
consideration for the following fiscal year.
We stated in the proposed rule that the MS-DRG assignment for any
new procedure codes describing LITT, if finalized following the March
meeting, would be reflected in Table 6B.--New Procedure Codes
associated with the final rule for FY 2023. However, in light of the
unique circumstances with respect to these procedures, for which there
was both a proposal for reclassifying LITT from the Radiation Therapy
section of the procedure code classification to the Medical/Surgical
section with new ICD-10-PCS procedure code(s) and a separate MS-DRG
reclassification request on the existing procedure codes, we provided
the opportunity for public comment on possible MS-DRG assignments for
the requested new procedure codes describing LITT that may apply based
on the application of our established process and analysis, in the
event the new codes were finalized for FY 2023. We also noted that
while we discussed the potential MS-DRG assignments for new procedure
codes describing LITT, interested parties may use current coding
information to consider the potential MS-DRG assignments for any other
procedure codes that may be finalized after the March meeting and
submit public comments for consideration. Specifically, in the ICD-10
Coordination and Maintenance Committee meeting materials (available via
the internet on the CMS website at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials), for each procedure code
proposal we provide the current coding that is applicable within the
classification and that should be reported in the absence of a more
unique code, or until such time a new code is created and becomes
effective. The procedure code(s) listed in current coding are
generally, but not always, the same code(s) that are considered as the
predecessor code(s) for purposes of MS-DRG assignment. As previously
noted, our process for determining the MS-DRG assignment for a new
procedure code does not automatically result in the new procedure code
being assigned to the
[[Page 48812]]
same MS-DRG or having the same designation (O.R. versus Non-O.R.) as
the predecessor code. However, this current coding information can be
used in conjunction with the GROUPER logic, as set forth in the ICD-10
MS-DRG Definitions Manual and publicly available via the internet on
our CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software
to review the MS-DRG assignment of the current code(s) and examine the
potential MS-DRG assignment of the proposed code(s), to assist in
formulating any public comments for submission to CMS for
consideration.
We noted in the proposed rule that, unlike the typical code request
for a new or revised procedure code that involves a new technology or a
new approach to performing an existing procedure, the circumstances for
this particular request are distinct in that the code request would
reclassify LITT within the ICD-10-PCS classification from section D--
Radiation Therapy to the root operation Destruction in the Medical and
Surgical section of ICD-10-PCS. Therefore, in light of the unique
considerations with respect to the requested reclassification of the
LITT procedures in connection with the pending code proposal, we stated
we believe it was appropriate to utilize the assignments and
designations of the procedure codes describing Destruction of the
respective anatomic body site as predecessor codes rather than the
current codes describing LITT from the Radiation Therapy section of
ICD-10-PCS in considering potential MS-DRG assignment for the requested
new LITT procedure codes.
As previously discussed, under our established process for
determining the MS-DRG assignment for newly approved procedure codes,
we examine the MS-DRG assignment for the predecessor codes to determine
the most appropriate MS-DRG assignment for the new codes. Specifically,
we review the predecessor code and MS-DRG assignment most closely
associated with the new procedure code, and in the absence of claims
data, we consider other factors that may be relevant to the MS-DRG
assignment, including the severity of illness, treatment difficulty,
complexity of service and the resources utilized in the diagnosis and/
or treatment of the condition. As we have noted in prior rulemaking,
this process does not automatically result in the new procedure code
being assigned to the same MS-DRG or to have the same designation (O.R.
versus Non-O.R.) as the predecessor code.
Applying this established review process to the proposed codes for
the LITT procedures, we stated we believe that, based on the
predecessor codes, and as previously noted, the potential assignments
and designations would align with the assignments and designations of
the procedure codes describing Destruction of the respective anatomic
body site. For example, as discussed in the preamble of the proposed
rule and earlier in this section of this final rule, the code request
involved reclassifying LITT procedures from section D--Radiation
Therapy to the root operation Destruction in the Medical and Surgical
section of ICD-10-PCS. The root operation Destruction is appropriate to
identify and report procedures, such as ablation, that are performed on
various body parts. The code request also involved creating what is
referred to as a qualifier value, to uniquely describe LITT as the
modality. The qualifier value is the seventh character or digit, in a
valid ICD-10-PCS procedure code.
We presented the following ICD-10-PCS table in the proposed rule,
which illustrates an example of the proposed procedure codes for LITT
of the brain and brain stem, and cervical, thoracic, and lumbar spinal
cord body parts, including the qualifier value that was presented and
discussed at the March 8-9, 2022 ICD-10 Coordination and Maintenance
Committee meeting.
[GRAPHIC] [TIFF OMITTED] TR10AU22.010
We noted in the proposed rule that the code proposal presented only
provided the body part value 0 Brain, for reporting any LITT procedures
performed on the brain, as well as, the brain stem, consistent with the
current available body part option in Table 005, Destruction of Central
Nervous System and Cranial Nerves, where the predecessor code is
located. We also noted that the predecessor code(s) and associated MS-
DRG assignments for the proposed new procedure code(s) describing LITT
of the brain and spinal cord under MDC 01 are identified as follows.
[[Page 48813]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.011
As shown in the table, the procedure codes describing destruction
of brain with an open, percutaneous or percutaneous endoscopic approach
are assigned to MS-DRGs 023 through 027 (craniotomy and endovascular
procedures) and the procedure codes describing destruction of cervical,
thoracic or lumbar spinal cord with an open, percutaneous or
percutaneous endoscopic approach are assigned to MS-DRG 028 (Spinal
Procedures with MCC), MS-DRG 029 (Spinal Procedures with CC or Spinal
Neurostimulators), and MS-DRG 030 (Spinal Procedures without CC/MCC).
We referred the reader to Table 6P.2a associated with the proposed
rule (and available via the internet at: https://www.cms.gov/medicare/
medicare-fee-for-service-payment/acuteinpatientpps) to review the
potential MDCs, MS-DRGs, and O.R. versus Non-O.R. designations
identified based on this analysis of the proposed new procedure codes
describing LITT as presented and discussed at the meeting. We noted
that Table 6P.2a also includes the predecessor codes that we utilized
to inform this analysis. We stated that if finalized, the new procedure
codes would be included in the FY 2023 code update files that are made
available in late May/early June via the internet on the CMS website
at: https://www.cms.gov/medicare/coding/icd10. Additionally, we noted
that if finalized, the new procedure codes describing LITT would be
displayed in Table 6B.--New Procedure Codes, and the existing codes
describing LITT would be deleted and reflected in Table 6D.--Invalid
Procedure Codes, in association with the FY 2023 IPPS/LTCH PPS final
rule. We referred the reader to section II.D.14. of the preamble of the
proposed rule for further information regarding the files.
We note that the proposal to reclassify LITT procedures of the
brain, brain stem and other anatomic sites in ICD-10-PCS that was
discussed at the March 8-9, 2022 ICD-10 Coordination and Maintenance
Committee meeting was approved and new procedure codes describing LITT
of the brain and other anatomic sites were finalized as reflected in
the FY 2023 ICD-10-PCS Code Update files that were made publicly
available via the internet on the CMS website at https://www.cms.gov/
Medicare/Coding/ICD10 on May 26, 2022. We also note that the new
procedure codes effective October 1, 2022 describing LITT of the brain
and other anatomic sites are displayed in Table 6B.--New Procedure
Codes, and the existing codes describing LITT of the brain, brain stem,
and other anatomic sites that are being deleted effective October 1,
2022 are reflected in Table 6D.--Invalid Procedure Codes, in
association with this FY 2023 IPPS/LTCH PPS final rule and available
via the internet on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. Below we summarize
the public comments we received and present our responses.
Comment: Commenters expressed appreciation that the proposal to
reclassify LITT procedures in ICD-10-PCS that was discussed at the
March 8-9, 2022 ICD-10 Coordination and Maintenance Committee meeting
was approved and new procedure codes have been finalized as reflected
in the FY 2023 ICD-10-PCS Code Update files that were made publicly
available via the internet on the CMS website at https://www.cms.gov/
Medicare/Coding/ICD10 on May 26, 2022. Commenters also indicated it is
appropriate to utilize procedure codes with the root operation
Destruction as the predecessor codes for MS-DRG assignment of the new
LITT procedure codes for all the anatomic body sites. Several
commenters expressed support for the assignment of cases reporting new
procedure codes for LITT of brain (includes brain stem) from MS-DRGs
040, 041, and 042 to MS-DRGs 025, 026 and 027 and urged CMS to finalize
this assignment. The commenters commended CMS for recognizing the
unique clinical circumstances related to LITT procedures of the brain
as being more appropriately aligned with MS-DRGs 025, 026 and 027. A
commenter acknowledged that the new procedure codes for LITT of brain
had not yet been finalized at the time of the development of the
proposed rule and therefore, were not reflected in the V40 Test GROUPER
software, however, the commenter encouraged CMS to ensure the final V40
GROUPER logic reflects the new procedure codes for LITT of brain and
assignment to MS-DRGs 025, 026 and 027.
Response: We thank the commenters for their support. In addition to
the new procedure codes describing LITT being made publicly available
in the FY 2023 ICD-10-PCS Code Update files via the internet on the CMS
website at https://www.cms.gov/Medicare/Coding/ICD10, we note that, as
previously stated, the new procedure codes are also reflected in Table
6B.--New Procedure Codes, in association with this final rule and
available via the internet on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS with their
finalized MS-DRG assignments. As shown in the table, procedure codes
describing LITT of brain (root operation Destruction), are assigned to
MS-DRGs 025, 026 and 027 for FY 2023. This assignment is also reflected
in the final V40 GROUPER logic. Existing procedure
[[Page 48814]]
codes D0Y0KZZ (Laser interstitial thermal therapy of brain) and D0Y1KZZ
(Laser interstitial thermal therapy of brain stem) will be deleted
effective October 1, 2022, as reflected in Table 6D.--Invalid Procedure
Codes, in association with this final rule and available via the
internet on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS.
As discussed in the proposed rule and previously discussed in this
final rule, we also received requests to reassign the existing ICD-10
procedure codes that identify LITT of the brain and brain stem (codes
D0Y0KZZ and D0Y1KZZ). We stated in the proposed rule that in the event
there is not support for the proposed reclassification of LITT
procedures and the corresponding new procedure codes as presented at
the March 8-9, 2022 ICD-10 Coordination and Maintenance Committee
meeting, we were also providing the results of our analysis of these
existing codes and our proposed MS-DRG assignments for FY 2023, if
those existing codes are retained.
In the proposed rule we stated that we examined claims data from
the September 2021 update of the FY 2021 MedPAR file for MS-DRGs 023,
024, 025, 026, and 027, in addition to MS-DRGs 040, 041, and 042 for
cases reporting LITT of the brain (code D0Y0KZZ) or brain stem (code
D0Y1KZZ). We noted that if a procedure code is not listed it is because
there were no cases found reporting that procedure code. Our findings
are shown in the following tables.
[GRAPHIC] [TIFF OMITTED] TR10AU22.012
[GRAPHIC] [TIFF OMITTED] TR10AU22.013
As shown, we found a total of 123 cases reporting LITT of the brain
across MS-DRGs 023, 025, 026, and 027. There were no cases found in MS-
DRG 024. The cases reporting LITT of the brain grouped to these MS-DRGs
because another O.R. procedure that is assigned to the respective MS-
DRG was also reported. We referred the reader to Table 6P.2b in
association with the proposed rule for the list of the other
[[Page 48815]]
O.R. procedures we identified that were also reported with LITT of the
brain.
For MS-DRGs 040, 041, and 042, we found a total of 54 cases
reporting LITT of the brain and 2 cases reporting LITT of the brain
stem. While the average costs of the cases reporting LITT of the brain
were higher compared to all the cases in their respective MS-DRGs, the
average length of stay was shorter. For example, the data demonstrates
a shorter average length of stay (8.1 days versus 9.9 days) and higher
average costs ($40,458 versus $30,212) for the 14 cases reporting LITT
of brain in MS-DRG 040 compared to all the cases in MS-DRG 040. There
were no cases found to report LITT of brain stem in MS-DRG 040. For MS-
DRG 041, we found 16 cases reporting LITT of brain with an average
length of stay of 3.4 days and average costs of $23,278 and 1 case
reporting LITT of brain stem with an average length of stay of 1 day
and average costs of $10,222. The average length of stay for all the
cases in MS-DRG 041 is 5 days with average costs of $19,090. The data
demonstrates a shorter average length of stay (3.4 days and 1 day,
respectively, versus 5 days) for the 16 cases reporting LITT of brain
and the 1 case reporting LITT of brain stem. The data also demonstrates
higher average costs ($23,278 versus $19,090) for the 16 cases
reporting LITT of brain, and lower average costs for the 1 case
reporting LITT of brain stem ($10,222 versus $19,090), as compared to
the average costs of all cases in MS-DRG 041. For MS-DRG 042, we found
24 cases reporting LITT of brain with an average length of stay of 1.7
days and average costs of $22,426 and 1 case reporting LITT of brain
stem with an average length of stay of 2 days and average costs of
$32,668. The average length of stay for all the cases in MS-DRG 042 is
2.9 days with average costs of $15,451. The data demonstrates a shorter
average length of stay (1.7 days and 2 days, respectively, versus 2.9
days) for the 24 cases reporting LITT of brain and the 1 case reporting
LITT of brain stem. The data also demonstrate higher average costs
($22,426 and $32,668, respectively versus $15,451) for the 24 cases
reporting LITT of brain and the 1 case reporting LITT of brain stem,
compared to all the cases in MS-DRG 042.
We noted in the proposed rule that, based on the findings from our
analysis, we considered whether other factors, such as the reporting of
secondary MCC and CC diagnoses, may have contributed to the higher
average costs for these cases. Specifically, we conducted additional
analyses of the claims data from the September 2021 update of the FY
2021 MedPAR file to determine what secondary MCC diagnoses were also
reported for the 14 cases reporting LITT of brain in MS-DRG 040 and
what secondary CC diagnoses were reported for the 17 cases (16 for LITT
of brain and 1 for LITT of brain stem) in MS-DRG 041. Our findings are
shown in the following tables.
[GRAPHIC] [TIFF OMITTED] TR10AU22.014
[[Page 48816]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.015
We noted that we did not find any other O.R. procedures reported on
the claims in addition to the procedures for LITT of brain or brain
stem for MS-DRGs 040, 041 and 042.
The data shows that at least one of the listed secondary MCC
diagnoses was reported with each claim for LITT of brain identified in
MS-DRG 040 and the average length of stay for these cases ranged from 9
days to 48 days and the average costs of these cases ranged from
$41,486 to $80,745. We note that this data reflects the frequency with
which each of the listed diagnoses was reported on a claim with LITT of
brain. Therefore, multiple MCCs from this list of diagnoses may have
been reported on a single claim. In addition, while the logic for case
assignment to MS-DRG 040 requires at least one secondary MCC diagnosis,
we conducted additional detailed analyses for MS-DRG 040, as shown in
Table 6P.2f, to determine whether there were also secondary CC
diagnoses reported in conjunction with one or more of the listed MCC
diagnoses that may be contributing to the higher average costs for
cases reporting LITT of brain in MS-DRG 040 in comparison to all the
cases in MS-DRG 040. We found that 6 of the 14 cases reporting at least
one or more secondary MCC diagnosis also reported one or more secondary
CC diagnosis, which would appear to support that the severity of
illness for these patients, as identified by the secondary MCC and CC
diagnoses, may be more directly related to the higher average costs for
these patients than the LITT procedure itself.
Similarly, the data for MS-DRG 041 show the frequency with which
each of the listed secondary CC diagnoses was reported with LITT of
brain or brain stem. Results from the analysis for the 17 cases (16 for
LITT of brain and 1 for LITT of brain stem) show the average length of
stay for these cases ranged from 1 day to 29 days and the average costs
ranged from $9,101 to $57,999. These data analysis findings for MS-DRG
041 also appear to support our belief that the severity of illness for
[[Page 48817]]
these patients, as identified by the listed secondary CC diagnoses, may
be more directly related to the higher average costs for these patients
than the LITT procedure itself.
As stated in the proposed rule and previously in this final rule,
we did not find any other O.R. procedures reported on the claims in
addition to the procedures for LITT of brain or brain stem for MS-DRGs
040, 041 and 042. Since the logic for case assignment to MS-DRG 042 is
not based on the reporting requirement of any CC or MCC diagnoses, we
conducted a detailed analysis of the claims data to determine what
other factors may be contributing to the higher average costs and
shorter average length of stay for these cases in comparison to all the
cases in MS-DRG 042. We refer the reader to Table 6P.2g associated with
the proposed rule for the findings from our analysis. As shown in the
data, the majority of the cases (15 of 25) had a principal diagnosis of
epilepsy, 8 cases had a principal diagnosis related to malignant
neoplasm of the brain or brain structures, 1 case had a principal
diagnosis of hemangioma of intracranial structures and 1 case had a
principal diagnosis of unspecified convulsions. The data also
demonstrate that 16 of the 25 cases reported in MS-DRG 042 include
patients who were under the age of 65, with ages ranging from 32 years
old to 64 years old. We note that patients diagnosed with epilepsy are
eligible for coverage since it is a condition that qualifies under
certain criteria. It is not entirely clear if the age of these patients
had any impact on the average length of stay since the average length
of stay of the 24 cases reporting LITT of brain was 1.7 days and the 1
case reporting LITT of brain stem was 2 days.
As stated previously, the logic for case assignment to MS-DRG 042
is not dependent on the reporting of any CC or MCC diagnoses, however,
based on the diagnoses reflected in the claims data for MS-DRG 042, it
is possible that conditions such as obesity and chronic conditions
requiring the long-term use of certain therapeutic agents may be
contributing factors to the consumption of resources, separately from
the LITT procedure. We found 17 of the 25 cases reporting LITT of brain
or brain stem to also report one or both of these conditions.
We also reviewed the number of cases of LITT of the brain or brain
stem procedures reported in the data since the transition to ICD-10.
Specifically, we examined the claims data for cases reporting LITT of
brain or brain stem as a standalone procedure or with another procedure
in the FY 2016 through FY 2021 MedPAR data files across all MS-DRGs.
The findings from our analysis are shown in table 6P.2e associated with
the proposed rule.
The data demonstrates that since the implementation of ICD-10, a
shift in the reporting of LITT of brain and brain stem procedures has
occurred. For example, the FY 2016, FY 2017 and FY 2018 MedPAR data
reflect that the number of cases for which LITT of brain or brain stem
procedures were reported as a standalone procedure is higher in
comparison to the number of cases reported with another procedure.
Conversely, the FY 2019, FY 2020, and FY 2021 MedPAR data reflect that
the number of cases for which LITT of brain or brain stem procedures
were reported as a standalone procedure is lower in comparison to the
number of cases reported with another procedure. The data also reflect
that the average length of stay is shorter and the average costs are
lower for cases reporting LITT of brain or brain stem as a standalone
procedure in comparison to the average length of stay and average costs
for cases reported with another procedure across the FY 2016 through FY
2021 MedPAR data files. Lastly, the data demonstrate that overall, the
number of cases for which LITT of brain or brain stem procedures was
performed had remained fairly stable at over 100 cases with increases
in the FY 2017, FY 2020 and FY 2021 MedPAR data files of 156, 154 and
185 cases, respectively.
As discussed in the proposed rule, we also analyzed claims data
from the September 2021 update of the FY 2021 MedPAR file for cases
reporting LITT of other anatomic sites across all MS-DRGs. Although the
requestors indicated that LITT is primarily performed on intracranial
lesions, as shown in Table 6P.2c associated with the proposed rule, we
identified a small number of cases reporting LITT of the lung, rectum,
liver, breast, and prostate, for a total of 29 cases where LITT was
performed on other body parts/anatomic sites.
For example, we found a total of 5 cases reporting LITT of lung
across 5 different MS-DRGs. Of these 5 cases, 2 cases had a longer
average length of stay and higher average costs in comparison to all
the cases in their respective MS-DRG. Specifically, for MS-DRG 163
(Major Chest Procedures with MCC), we found 1 case reporting LITT of
lung with an average length of stay of 17 days and average costs of
$41,467. The average length of stay for all cases in MS-DRG 163 is 10.7
days with average costs of $38,367. The data demonstrates a difference
of 6.3 days (17-10.7 = 6.3) for the average length of stay and a
difference of $3,100 in average costs ($41,467-$38,367 = $3,100) for
the 1 case reporting LITT of lung in MS-DRG 163 compared to all the
cases in MS-DRG 163. For MS-DRG 167 (Other Respiratory System O.R.
Procedures with CC), we found 1 case reporting LITT of lung with an
average length of stay of 7 days and average costs of $22,975. The
average length of stay for all cases in MS-DRG 167 is 4.6 days with
average costs of $15,397. The data demonstrates a difference of 2.4
days (7-4.6 = 2.4) for the average length of stay and a difference of
$7,578 in average costs ($22,975-$15,397 = $7,578) for the 1 case
reporting LITT of lung in MS-DRG 167 compared to all the cases in MS-
DRG 167. The data for the remaining 3 cases reporting LITT of lung
demonstrated a shorter average length of stay and lower average costs
in comparison to all the cases in their respective MS-DRGs.
We found 1 case reporting LITT of rectum in MS-DRG 357 (Other
Digestive System O.R. Procedures with CC) with a shorter average length
of stay (4 days versus 5.6 days) and lower average costs ($3,069 versus
$18,065) as compared to all the cases in MS-DRG 357. We also found 1
case reporting LITT of liver in MS-DRG 405 (Pancreas Liver and Shunt
Procedures with MCC) with a longer average length of stay (20 days
versus 12.3 days) and higher average costs ($49,0695 versus $43,771) as
compared to all the cases in MS-DRG 405.We also found 1 case reporting
LITT of right breast in MS-DRG 580 (Other Skin Subcutaneous Tissue and
Breast Procedures with CC) with a longer average length of stay (19
days versus 5.4 days) and higher average costs ($32,064 versus $13,767)
as compared to all the cases in MS-DRG 580.
Lastly, we found 21 cases reporting LITT of prostate across 14 MS-
DRGs. Of those 21 cases, 6 cases had a longer average length of stay or
higher average costs, or both, in comparison to the average length of
stay and average costs of all the cases in their respective MS-DRG. For
example, in MS-DRG 650 (Kidney Transplant with Hemodialysis with MCC)
we found 1 case reporting LITT of prostate with an average length of
stay of 36 days and average costs of $67,238. The average length of
stay for all cases in MS-DRG 650 is 8.1 days with average costs of
$38,139. The data demonstrates a difference of 27.9 days (36-8.1 =
27.9) for the average length of stay and a difference of $29,099 in
average costs ($67,238-$38,139 = $29,099) for the 1 case reporting LITT
of prostate in MS-
[[Page 48818]]
DRG 650 compared to all the cases in MS-DRG 650. We also found 1 case
reporting LITT of prostate in MS-DRG 659 (Kidney and Ureter Procedures
for Non-Neoplasm with MCC) with an average length of stay of 26 days.
The average length of stay for all cases in MS-DRG 659 is 7.8 days,
demonstrating a difference of 18.2 days (26-7.8 = 18.2). We found 1
case reporting LITT of prostate in MS-DRG 712 (Testes Procedures
without CC/MCC) with average costs of $15,669. The average costs for
all cases in MS-DRG 712 is $10,482, demonstrating a difference of
$5,187 ($15,669-$10,482 = $5,187). We found 1 case reporting LITT of
prostate in MS-DRG 987 with an average length of stay of 23 days and
average costs of $35,465. The average length of stay for all cases in
MS-DRG 987 is 10.9 days with average costs of $26,657. The data
demonstrates a difference of 12.1 days (23-10.9 = 12.1) for the average
length of stay and a difference of $8,808 in average costs ($35,465-
$26,657 = $8,808) for the 1 case reporting LITT of prostate in MS-DRG
987 compared to all the cases in MS-DRG 987. Lastly, we found 2 cases
reporting LITT of prostate in MS-DRG 988 (Non-Extensive O.R. Procedures
Unrelated to Principal Diagnosis with CC) with average costs of
$17,126. The average costs for all cases in MS-DRG 988 is $13,670,
demonstrating a difference of $3,456 ($17,126-$13,670 = $3,456) for the
2 cases reporting LITT of prostate in MS-DRG 988.
We refer the reader to Table 6P.2c associated with the proposed
rule for the detailed findings from our analysis. We note that if the
procedure code describing LITT of a specific anatomic site is not
listed it is because there were no cases found.
We noted in the proposed rule that for the 10 cases previously
described, for which LITT of a different anatomic site from the brain
or brain stem was reported and had a longer average length of stay or
higher average costs, or both, in comparison to the average length of
stay and average costs of all the cases in their respective MS-DRG,
that with the exception of MS-DRG 712, all the other MS-DRGs include a
``with MCC'' or ``with CC'' designation, or were reported in a surgical
MS-DRG. We stated we believe that these other factors may have
contributed to the longer average length of stay and higher average
costs for these cases, therefore we conducted additional analyses of
the claims data to determine what diagnoses or procedures were also
reported. We refer the reader to Table 6P.2d associated with the
proposed rule for the findings from our detailed analysis of these 10
cases.
As shown in Table 6P.2d associated with the proposed rule, the data
demonstrate that a number of MCC and/or CC secondary diagnoses were
reported for each of the 10 cases and that the surgical procedures that
were reported in addition to the LITT procedure seem to have
contributed to the longer average length of stay and higher average
costs for those cases when compared to the average length of stay and
average costs for all the cases in their respective MS-DRG. For
example, in case number 1 there are 2 diagnoses that are designated as
MCC conditions and 5 diagnoses that that are designated as CC
conditions with procedure codes describing a kidney transplant,
hemodialysis, and insertion of a ureteral stent that were reported
along with LITT of prostate. For case number 3 there are 4 diagnoses
that are designated as MCC conditions and 6 diagnoses that are
designated as CC conditions with procedure codes describing
bronchoscopic treatment of a bronchial tumor with and without stents,
as well as the use of mechanical ventilation. Overall, the data appear
to indicate that the performance of the LITT procedure was not the
underlying reason for, or main driver of, the increase in resource
utilization for those cases.
As noted in the proposed rule, the requestors indicated that LITT
is primarily being performed on intracranial lesions. However, as
previously summarized, we identified a limited number of cases
reporting LITT procedures for other anatomic sites. We stated in the
proposed rule that we are interested in comments regarding the use of
and experience with LITT for these other anatomic sites.
As discussed in the proposed rule, based on our analysis of the FY
2021 MedPAR claims data for cases reporting LITT of brain or brain stem
(codes D0Y0KZZ and D0Y1KZZ) in MS-DRGs 040, 041, and 042, we agree with
the requestors that the average costs of these cases are higher as
compared to the average costs of all cases assigned to MS-DRGs 040,
041, and 042. For the reasons summarized, in the proposed rule we also
stated we believe that other factors, including the reporting of
secondary MCC and CC diagnoses, may be contributing to the higher
average costs for these cases. As discussed in the FY 2022 IPPS/LTCH
PPS final rule (86 FR 44813), we examined procedure codes D0Y0KZZ and
D0Y1KZZ describing LITT of brain and brain stem, respectively, and
stated that the technique to perform the LITT procedure on these
structures is considered minimally invasive and does not involve a
craniotomy, therefore, continued assignment to the craniotomy MS-DRGs
is not clinically appropriate. As noted in the proposed rule, our
clinical advisors continue to maintain that LITT is a minimally
invasive procedure, requiring only a tiny incision for purposes of a
burr hole and that patients are often only kept overnight (as reflected
in the detailed claims data). However, we stated that we also recognize
that craniotomy and LITT share common procedural characteristics
including use of an operating room, carry risk of immediate
intracranial bleeding or infection, and cause tissue to be immediately
destroyed or excised. We noted that while the data do not demonstrate
that the LITT procedure is the underlying reason for the higher average
costs and consumption of resources for the small number of cases
reporting LITT of brain (54 cases) or brain stem (2 cases) that we
found in MS-DRGs 040, 041, and 042, the data do demonstrate that the
patients receiving this treatment therapy have brain tumors or epilepsy
combined with multiple comorbidities or chronic conditions
necessitating long-term use of medications, or both, and we noted the
indications for LITT (brain tumors and epileptic foci) are better
aligned with MS-DRGs 025, 026, and 027 as compared to MS-DRGs 040, 041,
and 042.
As discussed in the proposed rule, we intend to more fully evaluate
the logic for the procedures specifically involving a craniotomy, as
well as the overall structure of MS-DRGs 023 through 027, and we
believe that reassignment of cases reporting LITT of brain or brain
stem to MS-DRGs 025, 026, and 027 would be an appropriate first step in
connection with these efforts. For example, while we recognize the
distinctions between open craniotomy procedures and minimally invasive
percutaneous intracranial procedures, we also recognize that the
current logic for MS-DRGs 025 through 027 also includes other
endovascular intracranial procedures performed using percutaneous or
percutaneous endoscopic approaches, and we believe that further review
of the clinical coherence of the procedures assigned to these MS-DRGs
may be warranted. Our clinical advisors noted that while the typical
patient treated with LITT usually has a single small scalp incision
through which a hole approximately the diameter of a straw is drilled,
with no extensive surgical exposure, that LITT
[[Page 48819]]
can still be employed for another subset of more complex patients,
including patients with primary brain malignancies and those with
larger metastatic lesions or multiple lesions. For this subset of more
complex patients, a longer post-operative stay with direct medical
supervision may be necessary. As such, we stated in the proposed rule
that we believe reassigning these procedures to MS-DRGs 025 through 027
for FY 2023 would be appropriate as we consider restructuring MS-DRGs
023 through 027, including how to better align the clinical indications
with the performance of specific intracranial procedures. Accordingly,
for these reasons, we stated in the proposed rule that in the event
there is not support for the proposed reclassification of LITT
procedures and the corresponding new procedure codes as presented at
the March 8-9, 2022 ICD-10 Coordination and Maintenance Committee
meeting, we were proposing to reassign the existing procedure codes
describing LITT of the brain or brain stem from MS-DRGs 040, 041, and
042 to MS-DRGs 025, 026, and 027 for FY 2023. We also proposed to
maintain the MS-DRG assignments for the existing procedure codes
describing LITT of other anatomic sites as finalized and displayed in
Table 6P.2b in association with the FY 2022 IPPS/LTCH PPS final rule,
for FY 2023. Lastly, we noted in the proposed rule that we did not
receive any comments or requests to reconsider those finalized MS-DRG
assignments for FY 2023.
As noted, we stated in the proposed rule that we were proposing to
reassign the existing procedure codes describing LITT of the brain or
brain stem from MS-DRGs 040, 041, and 042 to MS-DRGs 025, 026, and 027
for FY 2023, in the event there was not support for the proposed
reclassification of LITT procedures and the corresponding new procedure
codes as presented at the March 8-9, 2022 ICD-10 Coordination and
Maintenance Committee meeting. As the proposed reclassification of the
LITT procedures and the corresponding new procedure codes were approved
following the March meeting, and the existing procedure codes D0Y0KZZ
(Laser interstitial thermal therapy of brain) and D0Y1KZZ (Laser
interstitial thermal therapy of brain stem) will be deleted effective
October 1, 2022, we are not finalizing the proposed reassignment of
these existing codes for FY 2023. As previously noted, and as reflected
in Table 6B.--New Procedure Codes associated with this final rule, the
new procedure codes describing LITT of brain (root operation
Destruction) are assigned to MS-DRGs 025, 026 and 027 for FY 2023. We
did not receive any public comments on our proposal to maintain the MS-
DRG assignments for the existing procedure codes describing LITT of
other anatomic sites as finalized and displayed in Table 6P.2b in
association with the FY 2022 IPPS/LTCH PPS final rule, for FY 2023. As
previously noted, the existing procedure codes describing LITT of other
anatomic sites will also be deleted effective October 1, 2023;
therefore, we are not finalizing the proposed reassignment of these
existing codes for FY 2023. The MS-DRG assignments for the newly
approved procedure codes describing LITT of other anatomic sites for FY
2023 are displayed in Table 6B in association with this final rule.
As noted in the proposed rule, in connection with our analysis of
cases reporting LITT procedures performed on the brain or brain stem in
MDC 01, we have started to examine the logic for case assignment to MS-
DRGs 023 through 027 to determine where further refinements could
potentially be made to better account for differences in the technical
complexity and resource utilization among the procedures that are
currently assigned to those MS-DRGs. Specifically, we are in the
process of evaluating procedures that are performed using an open
craniotomy (where it is necessary to surgically remove a portion of the
skull) versus a percutaneous burr hole (where a hole approximately the
size of a pencil is drilled) to obtain access to the brain in the
performance of a procedure. We are also reviewing the indications for
these procedures, for example, malignant neoplasms versus epilepsy to
consider if there may be merit in considering restructuring the current
MS-DRGs to better recognize the clinical distinctions of these patient
populations in the MS-DRGs. We believe it is worthwhile to also compare
the claims data for epilepsy patients who are treated with a
neurostimulator implant versus a LITT procedure, as well as the claims
data for patients with a diagnosis of epilepsy or malignant neoplasms
who undergo a LITT procedure. Our analysis also includes reviewing the
claims data with regard to the cases that reflect a procedure that is
generally performed with another O.R. procedure versus a standalone
procedure.
As we continue this analysis of the claims data with respect to MS-
DRGs 023 through 027, we stated that we are also seeking public
comments and feedback on other factors that should be considered in the
potential restructuring of these MS-DRGs.
Comment: In response to CMS's request for public comment and
feedback on the potential restructuring of the craniotomy MS-DRGs for
future consideration, some commenters disagreed and stated that such a
restructuring is not necessary. These commenters stated that should CMS
consider future modifications to the logic for case assignment to MS-
DRGs 023 through 027, the agency provide adequate notice for interested
parties to assess the impact of any proposed changes.
Another commenter expressed appreciation that CMS indicated it is
continuing to analyze if additional restructuring for MS-DRGs 023
through 027 may be warranted and agreed that the logic for these MS-
DRGs has become more complex. The commenter stated they will be
performing analyses and plan to submit their findings by the October
20, 2022 deadline. Another commenter urged CMS to also consider the
costs of procedures with respect to whether a device is inserted or
implanted in combination with the approach and clinical indications
because of the various diagnoses and procedures that may group to MS-
DRGs 023 through 027. This commenter expressed support for further
collaboration to better align resources and clinical characteristics
among within these MS-DRGs.
Another commenter who also expressed appreciation that CMS has
signaled its intent on analyzing MS-DRGs 023 through 027 recommended
that CMS also expand its analysis to include MS-DRGs 020 through 022
(Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage
with MCC, with CC, and without CC/MCC, respectively). According to the
commenter, the payment rates for a subset of the procedures that group
to these MS-DRGs appear to no longer adequately reflect the utilization
of resources. The commenter encouraged CMS to analyze these MS-DRGs and
determine if additional modifications may be warranted.
Response: We thank the commenters for their feedback and will take
these recommendations into consideration as we further examine the
logic for case assignment. We note that we would address any proposed
modifications to the existing logic in future rulemaking.
As previously described in the proposed rule and this final rule,
we are examining procedures by their approach (open versus
percutaneous), clinical indications, and procedures that involve the
insertion or implantation of a device. We recognize the logic for MS-
DRGs 023 through 027 has grown more
[[Page 48820]]
complex over the years and believe there is opportunity for further
refinement. We refer the reader to the ICD-10 MS-DRG Definitions
Manual, version 40, which is available via the internet on the CMS
website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software for
complete documentation of the GROUPER logic for MS-DRGs 023 through
027. Feedback and other suggestions may be submitted by October 20,
2022 and directed to the new electronic intake system, Medicare
Electronic Application Request Information SystemTM
(MEARISTM), discussed in section II.D.1.b of the preamble of
this final rule at: https://mearis.cms.gov/public/home.
b. Vagus Nerve Stimulation
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28141 through
28151), we discussed a request we received to review the MS-DRG
assignment for cases that identify patients who receive an implantable
vagus nerve stimulation system for heart failure. The vagus nerve, also
called the X cranial nerve or the 10th cranial nerve, is the longest
and most complex of the cranial nerves. There is one vagus nerve on
each side of the body that runs from the brain through the face and
thorax to the abdomen. According to the requestor, cranial nerve
stimulation (CNS), which includes vagus nerve stimulation, is a well-
established therapy for various indications including epilepsy,
treatment resistant depression (TRD) and obstructive sleep apnea (OSA),
and is now being investigated and studied for use in patients with
heart failure.
According to the requestor, heart failure, or the heart's inability
to pump an adequate supply of blood and oxygen to support the other
organs of the body, is an autonomic nervous system dysfunction. The
brain controls the function of the heart through the sympathetic branch
and the parasympathetic branches of the autonomic nervous system. In
heart failure, there is an imbalance in the autonomic nervous system.
The vagus nerve stimulation system for heart failure is comprised of an
implantable pulse generator, an electrical lead, and a programming
computer system. The pulse generator, which is usually implanted just
under the skin of the pectoral region, sends the energy to the vagus
nerve through the lead. The lead is a flexible insulated wire that is
guided under the skin from the chest up to the neck and is implanted
onto the vagus nerve and transmits tiny electrical impulses from the
generator to the nerve. These electrical impulses to the vagus nerve
are intended to activate the parasympathetic branch of the autonomic
nervous system to restore balance.
The requestor stated that cases reporting a procedure code
describing the insertion of a neurostimulator lead onto the vagus nerve
and a procedure code describing the insertion of a stimulator generator
with a principal diagnosis code describing epilepsy, TRD or OSA are
assigned to surgical MS-DRGs 040, 041 and 042 (Peripheral Cranial Nerve
and Other Nervous System Procedures with MCC, with CC or Peripheral
Neurostimulator, and without CC/MCC, respectively) in MDC 01 (Diseases
and Disorders of the Nervous System). However, when the same codes
describing the insertion of a neurostimulator lead onto the vagus nerve
and the insertion of a stimulator generator are reported with a
principal diagnosis of heart failure, the cases instead are assigned to
surgical MS-DRGs 252, 253 and 254 (Other Vascular Procedures with MCC,
with CC, without MCC respectively) in MDC 05 (Diseases and Disorders of
the Circulatory System).
The requestor stated that the treatment of autonomic nervous system
dysfunction is the underlying therapeutic objective of cranial nerve
stimulation for heart failure, and therefore the diagnosis of heart
failure is more clinically coherent with other diagnoses in MDC 01. As
a result, the requestor, who is developing the VITARIA[supreg] System,
an active implantable neuromodulation system that uses vagus nerve
stimulation to deliver autonomic regulation therapy (ART) for an
indicated use that includes patients who have moderate to severe heart
failure, submitted a request to reassign cases reporting a procedure
code describing the insertion of a neurostimulator lead onto the vagus
nerve and a procedure code describing the insertion of a stimulator
generator with a principal diagnosis code describing heart failure,
from MS-DRGs 252, 253 and 254 in MDC 05 to MS-DRGs 040, 041 and 042 in
MDC 01. This requestor also submitted an application for new technology
add-on payment for FY 2023. As discussed in section II.F.7. of the
preamble of this final rule, the new technology add-on payment
application for the VITARIA[supreg] System for FY 2023 was withdrawn
prior to the issuance of this final rule.
According to the requestor, the following ICD-10-PCS procedure code
pair identifies the insertion of a vagus nerve stimulation system for
heart failure:
[GRAPHIC] [TIFF OMITTED] TR10AU22.016
We stated in the FY 2023 IPPS/LTCH PPS proposed rule that the
requestor performed its own analysis of Medicare claims from 2020 and
stated that it found that patients enrolled in their pivotal clinical
trials had an average length of stay of 6.38 days. According to the
requestor this finding indicated a resource coherence more similar to
cases assigned to MS-DRGs 040, 041 and 042, whose average lengths of
stay ranges from 2 to 8 days, when compared to the average lengths of
stay of 1 to 3 days for cases assigned to MS-DRGs 252 and 253. The
requestor stated their own analysis of 2019 and 2020 Medicare claims
data also showed that fewer than 11 cases with procedure codes
describing the implantation of a vagus nerve stimulation system map to
MS-DRGs 252, 253 and 254 annually but it is expected that Medicare
patients will receive vagus nerve stimulation system for heart failure
on an inpatient basis. Because of the shared clinical and resource
similarity of the procedure to implant the VITARIA[supreg] system to
other CNS procedures, regardless of indication, the requestor stated
that CNS procedures for the treatment of heart failure should also be
assigned to MS-DRGs 040, 041 and 042. The requestor also noted that the
title of MS-DRGs
[[Page 48821]]
252, 253 and 254 is ``Other Vascular Procedures with MCC, with CC,
without MCC respectively''. Since no vascular access is involved in the
procedure to implant vagus nerve stimulation systems, the requestor
stated MS-DRGs 252, 253 and 254 were not appropriate mappings for these
procedures.
We stated in the proposed rule that the ICD-10-CM diagnosis codes
that describe heart failure are found in the following table. These
diagnosis codes are all currently assigned to MDC 05.
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR10AU22.017
The ICD-10-PCS codes that identify the insertion of a
neurostimulator lead onto the vagus nerve are listed in the following
table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.018
[[Page 48822]]
The ICD-10-PCS codes that identify the insertion of a stimulator
generator are listed in the following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.019
[[Page 48823]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.020
[[Page 48824]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.021
We stated our analysis of this grouping issue confirmed that, when
a procedure code describing the insertion of a neurostimulator lead
onto the vagus nerve and a procedure code describing the insertion of a
stimulator generator are reported with a principal diagnosis code
describing heart failure, these cases group to surgical MS-DRGs 252,
253 and 254 (Other Vascular Procedures with MCC, with CC, without MCC
respectively).
We noted that cases involving the use of a peripheral
neurostimulator and a diagnosis from MDC 01 are assigned to MS-DRG 041
only. The GROUPER logic for MS-DRGs 040, 041, and 042 is reflected in
the logic table:
[[Page 48825]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.022
We refer the reader to the ICD-10 MS-DRG Version 39.1 Definitions
Manual (which is available via the internet on the CMS website at:
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software) for complete
documentation of the GROUPER logic for the listed MS-DRGs.
In the proposed rule, we stated that we examined claims data from
the September 2021 update of the FY 2021 MedPAR file for MS-DRGs 252,
253 and 254 to identify the subset of cases within MS-DRGs 252, 253 and
254 reporting a procedure code describing the insertion of a
neurostimulator lead onto the vagus nerve and a procedure code
describing the insertion of a stimulator generator with a principal
diagnosis of heart failure. We stated we found zero cases in MS-DRGs
252, 253 and 254 reporting a procedure code describing the insertion of
a neurostimulator lead onto the vagus nerve and a procedure code
describing the insertion of a stimulator generator with a principal
diagnosis of heart failure. In an attempt to further examine this
issue, we then examined claims data from the September 2021 update of
the FY 2021 MedPAR file for MS-DRGs 252, 253 and 254 to identify the
subset of cases within MS-DRGs 252, 253 and 254 reporting a procedure
code describing the insertion of a neurostimulator lead onto the vagus
nerve and a procedure code describing the insertion of a stimulator
generator with a secondary diagnosis of heart failure and similarly
found zero cases.
We indicated in the proposed rule that the results of the claims
analysis demonstrated that there was not sufficient claims data in the
MedPAR file on which to assess the resource use of cases reporting a
procedure code describing the insertion of a neurostimulator lead onto
the vagus nerve and a procedure code describing the insertion of a
stimulator generator with a principal or secondary diagnosis of heart
failure as compared to other cases assigned to MS-DRGs 252, 253, and
254.
As discussed in the proposed rule, in reviewing the requestor's
concerns regarding clinical coherence, our clinical advisors
acknowledged that heart failure is a complex syndrome involving
autonomic nervous system dysfunction, however our clinical advisors
disagreed with assigning the diagnosis codes describing heart failure
to MDC 01 (Diseases and Disorders of the Nervous System). Our clinical
advisors noted the concept of clinical coherence requires that the
patient characteristics included in the definition of each MS-DRG
relate to a common organ system or etiology. As the listed diagnosis
codes describe heart failure, we stated these diagnosis codes are
appropriately assigned to MDC 05 (Diseases and Disorders of the
Circulatory System). Our clinical advisors also stated it would not be
appropriate to move these diagnoses into MDC 01 because it could
inadvertently cause cases reporting these same MDC 05 diagnoses with a
circulatory system procedure to be assigned to an unrelated MS-DRG
because whenever there is a surgical procedure reported on the claim
that is unrelated to the MDC to which the case was assigned based on
the principal diagnosis, it results in a MS-DRG assignment to a
surgical class referred to as ``unrelated operating room procedures''.
To further examine the impact of moving the diagnoses describing
heart failure into MDC 01, we stated we analyzed claims data for cases
reporting a circulatory system O.R. procedure and a principal diagnosis
of heart failure. Our findings are reflected in the following table.
[[Page 48826]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.023
[[Page 48827]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.024
[[Page 48828]]
As shown in the table, if we were to move diagnosis codes
describing heart failure to MDC 01, 20,199 cases would be assigned to
the surgical class referred to as ``unrelated operating room
procedures'' as an unintended consequence because the surgical
procedure reported on the claim would be considered unrelated to the
MDC to which the case was assigned based on the principal diagnosis.
In response to the requestor's concerns regarding the title of MS-
DRGs 252, 253 and 254, we noted that, as stated in the ICD-10 MS-DRG
Definitions Manual, ``In each MDC there is usually a medical and a
surgical class referred to as ``other medical diseases'' and ``other
surgical procedures,'' respectively. The ``other'' medical and surgical
classes are not as precisely defined from a clinical perspective. The
other classes would include diagnoses or procedures which were
infrequently encountered or not well defined clinically. For example,
the ``other'' medical class for the Respiratory System MDC would
contain the diagnoses ``other somatoform disorders'' and ``congenital
malformation of the respiratory system,'' while the ``other'' surgical
class for the female reproductive MDC would contain the surgical
procedures ``excision of liver'' (liver biopsy in ICD-9-CM) and
``inspection of peritoneal cavity'' (exploratory laparotomy in ICD-9-
CM). The ``other'' surgical category contains surgical procedures
which, while infrequent, could still reasonably be expected to be
performed for a patient in the particular MDC. There are, however, also
patients who receive surgical procedures which are completely unrelated
to the MDC to which the patient was assigned. An example of such a
patient would be a patient with a principal diagnosis of pneumonia
whose only surgical procedure is a destruction of prostate
(transurethral prostatectomy in ICD-9-CM). Such patients are assigned
to a surgical class referred to as ``unrelated operating room
procedures.'' '' We further noted that MS-DRGs 252, 253, and 254 (Other
Vascular Procedures with MCC, with CC, and without CC/MCC,
respectively) are examples of the ``other'' surgical class, therefore
it is expected that there will be procedures not as precisely
clinically aligned within the definition (logic) of these MS-DRGs.
We stated in the proposed rule that considering that there was no
data in the FY 2021 MedPAR file to support a reassignment of these
cases based on resource consumption, the analysis of clinical coherence
as discussed previously, and the impact that moving the diagnoses
describing heart failure into MDC 01 from MDC 05 would have on heart
failure cases, we did not believe a reassignment of these cases was
appropriate at this time. We stated we could continue to evaluate the
clinical coherence and resource consumption costs that impact this
subset of cases and their current MS-DRG assignment as data become
available for future rulemaking.
In summary for the reasons stated previously, we did not propose to
reassign cases reporting a procedure code describing the insertion of a
neurostimulator lead onto the vagus nerve and a procedure code
describing the insertion of a stimulator generator with a principal
diagnosis of heart failure from MS-DRGs 252, 253 and 254 to MS-DRGs
040, 041 and 042.
Comment: Commenters expressed support for CMS' decision to not
propose to reassign cases reporting a procedure code describing the
insertion of a neurostimulator lead onto the vagus nerve and a
procedure code describing the insertion of a stimulator generator with
a principal diagnosis of heart failure from MS-DRGs 252, 253 and 254 to
MS-DRGs 040, 041 and 042.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to maintain the current assignment of cases
reporting a procedure code describing the insertion of a
neurostimulator lead onto the vagus nerve and a procedure code
describing the insertion of a stimulator generator with a principal
diagnosis of heart failure to MS-DRGs 252, 253 and 254, without
modification, for FY 2023.
We further stated in the proposed rule that as we examined the
GROUPER logic that would determine an assignment of a case to MS-DRGs
252, 253 and 254, we noted the logic for MS-DRGs 252, 253 and 254
includes ICD-10-PCS procedure codes that describe the insertion of the
stimulator generator. We refer the reader to the ICD-10 MS-DRG Version
39.1 Definitions Manual (which is available via the internet on the CMS
website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software) for
complete documentation of the GROUPER logic for the listed MS-DRGs. We
stated that during our review of the stimulator generator insertion
procedures assigned to these MS-DRGs, we identified the following 24
procedure codes that describe the insertion of a stimulator generator,
differentiated by device type (for example single array or multiple
array), that did not exist in the logic for MS-DRGs 252, 253 and 254.
[[Page 48829]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.025
For clinical consistency with the other procedure codes describing
the insertion of the stimulator generator currently assigned to these
MS-DRGs, we proposed to add the 24 ICD-10-PCS codes listed previously
to MS-DRGs 252, 253 and 254, (Other Vascular Procedures with MCC, with
CC, and without CC/MCC, respectively) in MDC 05 (Diseases and Disorders
of the Circulatory System) effective October 1, 2022 for FY 2023.
Comment: Commenters supported the proposal to add the 24 ICD-10-PCS
codes to MS-DRGs 252, 253 and 254, (Other Vascular Procedures with MCC,
with CC, and without CC/MCC, respectively) in MDC 05 (Diseases and
Disorders of the Circulatory System).
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to add the 24 ICD-10-PCS codes listed
previously to MS-DRGs 252, 253 and 254, (Other Vascular Procedures with
MCC, with CC, and without CC/MCC, respectively) in MDC 05 (Diseases and
Disorders of the Circulatory System) without modification, effective
October 1, 2022 for FY 2023.
Also, in the proposed rule we stated that as we examined the
GROUPER logic that would determine an assignment of a case to MS-DRG
041,
[[Page 48830]]
we noted that the logic for case assignment to MS-DRG 041 as displayed
in the ICD-10 MS-DRG Version 39.1 Definitions Manual, available via the
internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.html contains code combinations or ``clusters'' representing
the insertion of a neurostimulator lead and the insertion of a
stimulator generator that are captured under a list referred to as
``Peripheral Neurostimulators.'' During our review of the procedure
code clusters in this list, we noted that ICD-10-PCS procedure code
clusters describing the insertion of a neurostimulator lead and the
insertion of the stimulator generator differentiated by device type
(for example single array or multiple array), approach and anatomical
site placement are captured. However, procedure code clusters
describing the insertion of stimulator generator, that is not
differentiated by device type, and a neurostimulator lead were
inadvertently excluded. We refer the reader to Table 6P.3a associated
with the proposed rule (which is available via the internet on the CMS
website at: https://www.cms.hhs.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/) for the list of the 108 ICD-10-
PCS code clusters that were inadvertently excluded and do not exist in
the logic for MS-DRG 041.
For clinical consistency, our clinical advisors supported the
addition of the 108 procedure code clusters to the GROUPER logic list
referred to as ``Peripheral Neurostimulators'' for MS-DRG 041 that
describe the insertion of stimulator generator, not differentiated by
device type, and a neurostimulator lead. Therefore, we proposed to add
the 108 ICD-10-PCS code clusters listed in Table 6P.3a in association
with the proposed rule that describe the insertion of a stimulator
generator, that is not differentiated by device type, and a
neurostimulator lead to MS-DRG 041, effective October 1, 2022 for FY
2023.
Comment: Commenters expressed support for CMS' proposal to add the
108 ICD-10-PCS code clusters listed in Table 6P.3a in association with
the proposed rule that describe the insertion of a stimulator
generator, that is not differentiated by device type, and a
neurostimulator lead to MS-DRG 041. A commenter stated that this
proposal will clinically align these procedures with other procedures
in their respective MS-DRGs.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to add the 108 procedure code clusters listed
in Table 6P.3a in association with the proposed rule that describe the
insertion of stimulator generator, not differentiated by device type,
and a neurostimulator lead to the GROUPER logic list referred to as
``Peripheral Neurostimulators'' for MS-DRG 041 (Peripheral, Cranial
Nerve and Other Nervous System Procedures with CC or Peripheral
Neurostimulator) without modification, effective October 1, 2022 for FY
2023.
4. MDC 02 (Diseases and Disorders of the Eye): Retinal Artery Occlusion
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28151 through
28155), we discussed a request we received to reassign cases reporting
diagnosis codes describing central retinal artery occlusion, and the
closely allied condition branch retinal artery occlusion, from MS-DRG
123 (Neurological Eye Disorders) in MDC 02 (Diseases and Disorders of
the Eye) to MS-DRGs 061, 062, and 063 (Ischemic Stroke Precerebral
Occlusion or Transient Ischemia with Thrombolytic Agent with MCC, with
CC, and without CC/MCC, respectively) in MDC 01 (Diseases and Disorders
of the Nervous System).
Retinal artery occlusion refers to blockage of the retinal artery
that carries oxygen to the nerve cells in the retina at the back of the
eye, often by an embolus or thrombus. A blockage in the main artery in
the retina is called central retinal artery occlusion (CRAO). A
blockage in a smaller artery is called branch retinal artery occlusion
(BRAO). According to the requestor, in the current mapping to MS-DRG
123, diagnoses of CRAO and BRAO are being captured inappropriately as
eye disorders in MDC 02. Instead, the requestor stated that CRAO and
BRAO are forms of acute ischemic stroke which occur when a vessel
supplying blood to the brain is obstructed.
The requestor stated the retina is a core component of the central
nervous system and there is growing recognition that damage to it is a
vascular neurological problem and not an ophthalmological one. Patients
with CRAO or BRAO are typically very sick, have an underlying
condition, and are at imminent risk for further events including heart
attack or brain stroke. A diagnosis of CRAO or BRAO requires an urgent,
structured and multidisciplinary team-based examination to evaluate and
treat other diagnoses that may be present such as high blood pressure,
dyslipidemia, diabetes mellitus, obesity, obstructive sleep apnea and
smoking to ameliorate the risks of a subsequent, potentially lethal,
cardiovascular event.
The requestor further stated new evidence outlines treatment of
patients with CRAO with acute stroke protocols, specifically with
intravenous thrombolysis (IV tPA) or hyperbaric oxygen therapy (HBOT),
to improve outcomes. According to the requestor, BRAO is less commonly
treated with IV tPA than CRAO but also requires an urgent and thorough
diagnostic workup as with any other form of stroke. The requestor
stated the current assignment of these conditions to MS-DRG 123 does
not properly recognize disease complexity and allocation of resources
for care for these cases. The requestor stated that patients with CRAO
or BRAO more closely resemble patients currently mapped to MS-DRGs 061,
062, and 063 in terms of in resource intensity and criticality and that
in instances where HBOT is the chosen treatment modality, any revised
MS-DRG mapping should include the ICD-10-PCS codes for HBOT.
As noted in the proposed rule, the ICD-10-CM codes that describe
CRAO and BRAO are found in the following table.
[[Page 48831]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.026
Thrombolytic therapy is identified with the following ICD-10-PCS
procedure codes.
[GRAPHIC] [TIFF OMITTED] TR10AU22.027
The requestor identified three ICD-10-PCS codes that they stated
describe HBOT.
[GRAPHIC] [TIFF OMITTED] TR10AU22.028
We stated in the proposed rule that during our review of this
issue, we included the three procedure codes as identified by the
requestor as describing HBOT, as well as the similar procedure code
5A05221 (Extracorporeal hyperbaric oxygenation, continuous) that also
describes HBOT, differing only in duration.
We stated that our analysis of this grouping issue confirmed that,
when a procedure code describing the administration of a thrombolytic
agent or a procedure code describing HBOT is reported with principal
diagnosis code describing CRAO or BRAO, these cases group to medical
MS-DRG 123. We began our analysis by examining claims data from the
September 2021 update of the FY 2021 MedPAR file for MS-DRG 123 to (1)
identify cases reporting a principal diagnosis code describing CRAO or
BRAO without a procedure code describing the administration of a
thrombolytic agent or a procedure code describing HBOT; (2) identify
cases reporting diagnosis codes describing CRAO or BRAO with a
procedure code describing HBOT; and (3) identify cases reporting
diagnosis codes describing CRAO or BRAO with a procedure code
describing the administration of a thrombolytic agent. Our findings are
shown in the following table:
[[Page 48832]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.029
As shown in the table, we identified a total of 2,642 cases within
MS-DRG 123 with an average length of stay of 2.5 days and average costs
of $6,457. Of these 2,642 cases, there are 774 cases that reported a
principal diagnosis code describing CRAO or BRAO without a procedure
code describing the administration of a thrombolytic agent or a
procedure code describing HBOT with an average length of stay of 2.2
days and average costs of $5,482. There are nine cases that reported a
principal diagnosis code describing CRAO or BRAO with a procedure code
describing HBOT with an average length of stay of 2 days and average
costs of $6,491. There are 47 cases that reported a principal diagnosis
code describing CRAO or BRAO with a procedure code describing the
administration of a thrombolytic agent with an average length of stay
of 2.3 days and average costs of $14,335.
The data analysis shows that the 774 cases in MS-DRG 123 reporting
a principal diagnosis code describing CRAO or BRAO without a procedure
code describing the administration of a thrombolytic agent or a
procedure code describing HBOT have average costs lower than the
average costs in the FY 2021 MedPAR file for MS-DRG 123 ($5,482
compared to $6,457), and the average length of stay is shorter (2.2
days compared to 2.5 days). For the nine cases in MS-DRG 123 reporting
a principal diagnosis code describing CRAO or BRAO with a procedure
code describing HBOT, the average length of stay is shorter (2 days
compared to 2.5 days) and the average costs ($6,491 compared to $6,457)
are slightly higher than the average length of stay and average costs
compared to all cases in that MS-DRG. For the 47 cases in MS-DRG 123
reporting a principal diagnosis code describing CRAO or BRAO with a
procedure code describing the administration of a thrombolytic agent,
the average length of stay is slightly shorter (2.3 days compared to
2.5 days) and the average costs are higher ($14,335 compared to $6,457)
than the average length of stay and average costs compared to all cases
in that MS-DRG.
We also examined claims data from the September 2021 update of the
FY 2021 MedPAR file for MS-DRGs 061, 062, and 063. Our findings are
shown in the following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.030
BILLING CODE 4120-01-C
We stated in the proposed rule that because MS-DRG 123 is a base
DRG and there is a three-way split within MS-DRGs 061, 062, and 063, we
also analyzed the 47 cases reporting a principal diagnosis code
describing CRAO or BRAO with a procedure code describing the
administration of a thrombolytic agent and the nine cases reporting a
principal diagnosis code describing CRAO or BRAO with a procedure code
describing HBOT for the presence or absence of a secondary diagnosis
designated as a complication or comorbidity (CC) or a major
complication or comorbidity (MCC).
[[Page 48833]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.031
We stated that this data analysis showed that the cases in MS-DRG
123 reporting a principal diagnosis code describing CRAO or BRAO with a
procedure code describing the administration of a thrombolytic agent or
with a procedure code describing HBOT when distributed based on the
presence or absence of a secondary diagnosis designated as a CC or an
MCC have average costs lower than the average costs in the FY 2021
MedPAR file for MS-DRGs 061, 062, and 063 respectively, and the average
lengths of stay are shorter. Accordingly, we stated that we did not
believe the data adequately supported a potential reassignment of these
cases to MS-DRGs 061, 062, and 063 respectively.
Our clinical advisors reviewed this issue and the related data
analysis and did not believe that the small subset of patients with a
diagnosis of CRAO or BRAO receiving a thrombolytic agent or hyperbaric
oxygen therapy warranted a separate MS-DRG or reassignment at this
time. We stated our clinical advisors noted the average costs for cases
of patients with a diagnosis of CRAO or BRAO receiving HBOT are only
slightly higher than the average costs for all cases in MS-DRG 123
($6,491 compared to $6,457). The average costs for cases of patients
with a diagnosis of CRAO or BRAO receiving a thrombolytic agent are
higher than the average costs for all cases in MS-DRG 123 however when
distributed based on the presence or absence of a secondary diagnosis
designated as a complication or comorbidity (CC) or a major
complication or comorbidity (MCC), we stated that it was unclear to
what degree the higher average costs for these cases are attributable
to the severity of illness of the patient and other circumstances of
the admission as opposed to the administration of a thrombolytic agent,
as the claims data reflects a wide variance with regard to average
costs for these cases.
Our clinical advisors further noted that ischemia is defined as a
condition in which the blood vessels become blocked, and blood flow is
stopped or reduced. The condition has many potential causes, including
a blockage caused by a blood clot, or due to buildup of deposits, such
as cholesterol. Ischemia can occur anywhere in the body, and the
different names for the condition depend on the organ or body part
affected such as the brain (cerebral ischemia), heart (ischemic heart
disease, myocardial ischemia, or cardiac ischemia), and intestines
(mesenteric ischemia or bowel ischemia), legs (critical limb ischemia--
a form of peripheral artery disease), and skin (cutaneous ischemia),
while they are similar in that they all involve a blocked blood vessel.
In ICD-10 the body or organ system is the axis of the
classification and diagnosis codes describing ischemia affecting other
body parts are classified by the body or organ system affected. For
example, codes describing myocardial ischemia are assigned to MDC 05
(Diseases and Disorders of the Circulatory System) and codes describing
mesenteric ischemia are assigned to MDC 06 (Diseases and Disorders of
the Digestive System). Our clinical advisors disagreed with assigning
the diagnosis codes describing CRAO and BRAO to MDC 01. Our clinical
advisors noted the concept of clinical coherence generally requires
that the patient characteristics included in the definition of each MS-
DRG relate to a common organ system or etiology and that a specific
medical specialty should typically provide care to the patients in the
DRG. While closely related, the eyes and the brain are different
organs. Our clinical advisors stated that because the diagnosis codes
used to report CRAO and BRAO describe ischemia affecting the retina,
these diagnosis codes are appropriately assigned to MDC 02 (Diseases
and Disorders of the Eye). The retina is a collection of cells at the
back of the eye where the processing of visual information begins. Due
to the retina's vital role in vision, damage to it can cause permanent
blindness. The presence of CRAO or BRAO requires input from an
ophthalmologist and treatment for these diagnoses would be expected to
utilize different resources than a diagnosis of cerebral ischemia which
may or may not involve visual impairment. Other possible interventions
for CRAO or BRAO include attempting to lower the intraocular pressure
with medication or by using a small-gauge needle to remove fluid to try
to dislodge the embolus or ocular massage to dislodge the clot, which
are not interventions generally performed for a diagnosis of acute
ischemic stroke.
We stated in the FY 2023 IPPS/LTCH PPS proposed rule that to
explore other mechanisms to address this request, we also reviewed
claims data to consider the option of adding another severity level to
the current structure of MS-DRG 123 (Neurological Eye Disorders) and
assigning the cases with a principal diagnosis of CRAO or BRAO with a
procedure code describing the administration of a thrombolytic agent to
the highest level. This option would have involved modifying the
current base MS-DRG to a two-way severity level split or to a three-way
severity level split of ``with MCC or thrombolytic agent, with CC, and
without CC/MCC.'' Therefore, it would have included proposing new MS-
DRGs if the data and our clinical advisors supported creation of new
MS-DRGs. However, as displayed in the data findings in the table that
follows, we found that the
[[Page 48834]]
data did not support this option. We applied the five criteria as
described in section II.D.1.b. of the preamble of the proposed rule and
this final rule to determine if it would be appropriate to subdivide
cases currently assigned to MS-DRG 123 into severity levels. This
analysis generally includes two years of MedPAR claims data to compare
the data results from one year to the next to avoid making
determinations about whether additional severity levels are warranted
based on an isolated year's data fluctuation and also, to validate that
the established severity levels within a base MS-DRG are supported.
However, as discussed in the FY 2022 IPPS/LTCH PPS proposed rule (86 FR
25092), our MS-DRG analysis last year was based on ICD-10 claims data
from the March 2020 update of the FY 2019 MedPAR file, which contains
hospital claims received from October 1, 2018 through March 31, 2020,
for discharges occurring through September 30, 2019 and the ICD-10
claims data from the September 2020 update of the FY 2020 MedPAR file,
which contains hospital claims received from October 1, 2019 through
September 30, 2020, for discharges occurring through September 30, 2020
given the potential impact of the PHE for COVID-19. Therefore, for the
FY 2023 IPPS/LTCH PPS proposed rule, we reviewed the claims data for
base MS-DRG 123 using the March 2020 update of the FY 2019 MedPAR file
and the September 2020 update of the FY 2020 MedPAR file, which were
used in our analysis of claims data for MS-DRG reclassification
requests for FY 2022. We also reviewed the claims data for base MS-DRG
123 using the September 2021 update of the FY 2021 MedPAR file, which
were used in our analysis of claims data for MS-DRG reclassification
requests for FY 2023. Our findings are shown in the table:
[GRAPHIC] [TIFF OMITTED] TR10AU22.032
We stated that we applied the criteria to create subgroups for the
three-way severity level split. We referred the reader to section
II.D.1.b. of the preamble of the FY 2023 IPPS/LTCH PPS proposed rule,
for related discussion regarding our finalization of the expansion of
the criteria to include the NonCC subgroup and our proposal to continue
to delay application of the NonCC subgroup criteria to existing MS-DRGs
with a three-way severity level split to maintain more stability in the
current MS-DRG structure. We found that the criterion that there be at
least 500 cases for each subgroup was not met, as shown in the table
based on the data in the FY 2019, FY 2020, and FY 2021 MedPAR files.
Specifically, for the ``with MCC'', ``with CC'', and ``without CC/MCC''
split, there were only 376 cases in the ``with MCC'' subgroup based on
the data in the FY 2019 MedPAR file, only 345 cases in the ``with MCC''
subgroup based on the data in the FY 2020 MedPAR file and only 374
cases in the ``with MCC'' subgroup based on the data in the FY 2021
MedPAR file.
We then applied the criteria to create subgroups for the two-way
severity level splits. For the ``with MCC'' and ``without MCC''
(CC+NonCC) split, the criterion that there be at least 500 cases for
each subgroup failed due to low volume each year, specifically, for the
``with MCC'' subgroup as previously described. For the ``with CC/MCC''
and ``without CC/MCC'' (NonCC) split, we found that the criterion that
there be at least a $2,000 difference in average costs between the
``with CC/MCC'' and ``without CC/MCC'' subgroups also failed. In the FY
2019 MedPAR file, our data analysis shows average costs in the
hypothetical ``with CC/MCC'' subgroup of $6,282 and average costs in
the hypothetical ``without CC/MCC'' subgroup of $4,832, for a
difference of only $1,450 ($6,282 minus $4,832 = $1,450). In the FY
2020 MedPAR file, our data analysis shows average costs in the
hypothetical ``with CC/MCC'' subgroup of $6,573 and average costs in
the hypothetical ``without CC/MCC'' subgroup of $5,122, for a
difference of only $1,451 ($6,573 minus $5,122 = $1,451). In the FY
2021 MedPAR file, our data analysis shows average costs in the
hypothetical ``with CC/MCC'' subgroup of $7,176 and average costs in
the hypothetical ``without CC/MCC'' subgroup of $5,364, for a
difference of only $1,812 ($7,176 minus $5,364 = $1,812). We stated
that our data analysis indicated that the current base MS-DRG 123
maintains the overall accuracy of the IPPS, and that the claims data
did not support a three-way or a two-way severity level split for MS-
DRG 123.
Lastly, we stated we explored reassigning cases with a principal
diagnosis of CRAO or BRAO that receive the administration of a
thrombolytic agent to other MS-DRGs within MDC 02. However, our review
did not support reassignment of these cases to any other medical MS-
DRGs as these cases would not be clinically coherent with the cases
assigned to those other MS-DRGs.
Therefore, based on the various data analyses we performed to
explore the possible reassignment of cases with a principal diagnosis
of CRAO or BRAO with a procedure code describing the administration of
a thrombolytic agent or a procedure code describing hyperbaric oxygen
therapy, and the clinical analysis as previously discussed, for FY 2023
we did not propose any MS-DRG changes for cases with a principal
diagnosis of CRAO or BRAO with a procedure code describing the
administration of a thrombolytic agent or a procedure code describing
hyperbaric oxygen therapy.
Comment: Some commenters expressed support for CMS' decision to not
propose any MS-DRG changes for cases with a principal diagnosis of CRAO
or BRAO with a procedure code describing the administration of a
thrombolytic agent or a procedure code describing hyperbaric oxygen
therapy.
Response: We appreciate the commenters' support.
Comment: Other commenters opposed or expressed concerns with CMS'
decision to not propose any MS-DRG changes for cases with a principal
diagnosis of CRAO or BRAO with a procedure code describing the
administration of a thrombolytic agent or a procedure code describing
hyperbaric oxygen therapy. These commenters stated from a
pathophysiologic perspective, CRAO is the same process as a stroke of
the brain and that the retina, although located within the eye, is a
core component of the central nervous system and consists of brain
cells (neurons) that also extend
[[Page 48835]]
through the entire course of the brain. These commenters also stated
that the relationship of any particular tissue to its organ is related
to its structure and function, and not its location. According to the
commenters, acute CRAO is a medical emergency, equivalent to acute
cerebral ischemic stroke, that needs to be treated in the same way with
urgent inpatient evaluation, cerebrovascular and cardiac workup, and
intervention. The commenters urged CMS to assign cases reporting
diagnosis codes describing central retinal artery occlusion with a
procedure code describing the administration of a thrombolytic agent or
a procedure code describing hyperbaric oxygen therapy to MS-DRGs 061,
062, and 063 to ensure appropriate payment for these cases.
Response: We thank the commenters for their feedback. Our clinical
advisors reviewed the commenters' concerns and note that although
commenters' state the relationship of any particular tissue to its
organ is related to its structure and function, and not its location,
in ICD-10, however, the body or organ system is the axis of the
classification. By design, the patient characteristics included in the
definition of each MS-DRG relate to a common organ system or etiology.
Our clinical advisors agree with commenters that the retina is similar
to the brain in terms of cellular and functional elements, but they
note the retina is a part of the eye. Our clinical advisors state that
the presence of CRAO or BRAO, which typically presents sudden, painless
monocular loss of visual acuity and peripheral vision, requires input
from an ophthalmologist which would not always be expected in a
diagnosis of cerebral ischemia, which may or may not involve visual
impairment. Our clinical advisors continue to believe CRAO and BRAO are
appropriately classified with other eye conditions currently assigned
to MDC 02.
Therefore, after consideration of the public comments we received,
and for the reasons discussed, we are finalizing our proposal, without
modification, to maintain the current assignment of cases with a
principal diagnosis of CRAO or BRAO with a procedure code describing
the administration of a thrombolytic agent or a procedure code
describing hyperbaric oxygen therapy.
5. MDC 04 (Diseases and Disorders of the Respiratory System): Acute
Respiratory Distress Syndrome (ARDS)
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28155 through
28156), we discussed a request we received to reassign cases reporting
diagnosis code J80 (Acute respiratory distress syndrome) as the
principal diagnosis from MS-DRG 204 (Respiratory Signs and Symptoms) to
MS-DRG 189 (Pulmonary Edema and Respiratory Failure).
According to the requestor, when a patient presents with the
condition of acute respiratory failure that progresses to acute
respiratory distress syndrome (ARDS) during the hospital stay, official
coding guidance instructs to only report the diagnosis code for ARDS
(code J80). The requestor stated that in the American Hospital
Association's (AHA) Coding Clinic for ICD-10-CM and ICD-10-PCS, Fourth
Quarter 2020 publication, for a patient who is admitted in acute
hypoxic respiratory failure that progresses to ARDS, the advice is to
assign code J80, Acute respiratory distress syndrome. Additionally, in
the ICD-10-CM Tabular List of Diseases, per the Excludes 1 note under
category J96 (Respiratory failure, not elsewhere classified) only code
J80 should be assigned when respiratory failure and ARDS are both
documented. The same publication also maintained that ARDS is a life-
threatening form of respiratory failure and is not an unrelated
condition. Therefore, when acute respiratory failure is documented
along with ARDS, only one code is reported to capture the highest level
of severity.
The requestor also conveyed the Fourth Quarter 2020 publication's
reference to previously published advice from the Fourth Quarter 2017
publication that stated, ``Acute respiratory distress syndrome (ARDS)
is a life-threatening condition. ARDS is a rapidly progressive disorder
that has symptoms of dyspnea, tachypnea, and hypoxemia. Fluid builds up
in the alveoli and lowers the amount of oxygen that is circulated
through the bloodstream. Low levels of oxygen in the blood threatens
organ function. ARDS is often associated with sepsis, pneumonia, trauma
and aspiration. The majority of people who develop ARDS are already in
the hospital in critical condition from some other health complication.
The focus of treatment is getting oxygen to the organs.''
We examined claims data from the September 2021 update of the FY
2021 MedPAR file for all cases in MS-DRG 204 and the cases reporting
ARDS (code J80) as a principal diagnosis. Our findings are shown in the
following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.033
As shown in the table, the data demonstrate a longer average length
of stay (7.6 days versus 2.8 days) and higher average costs ($15,077
versus $6,780) for the 96 cases reporting ARDS (code J80) as a
principal diagnosis when compared to all 5,241 cases in MS-DRG 204.
We also examined claims data from the September 2021 update of the
FY 2021 MedPAR file for all cases in MS-DRG 189. Our findings are shown
in the following table.
[[Page 48836]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.034
We stated in the proposed rule that the data analysis supports that
cases reporting ARDS (code J80) are more appropriately aligned with the
average length of stay and average costs of the cases in MS-DRG 189 in
comparison to MS-DRG 204 when ARDS is reported as a principal
diagnosis. We also stated in the proposed rule that we agree,
consistent with the coding clinic advice, ARDS is a life-threatening
form of respiratory failure and the conventions of the ICD-10-CM
classification as displayed in the Tabular List of Diseases Excludes
note, support the concept that cases reporting ARDS as a principal
diagnosis are more clinically coherent with the other conditions
currently assigned to MS-DRG 189.
For these reasons, we proposed to reassign cases reporting ARDS
(code J80) as a principal diagnosis from MS-DRG 204 to MS-DRG 189
effective FY 2023.
Comment: Commenters supported the proposal to reassign cases
reporting diagnosis code J80 as a principal diagnosis from MS-DRG 204
to MS-DRG 189.
Response: We thank the commenters for their support.
After consideration of the public comments we received, we are
finalizing our proposal to reassign cases reporting ARDS (code J80) as
a principal diagnosis from MS-DRG 204 to MS-DRG 189 effective FY 2023.
6. MDC 05 (Diseases and Disorders of the Circulatory System)
a. Percutaneous Transluminal Coronary Angioplasty (PTCA) Logic
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28156 through
28157), we stated that we identified a replication issue from the ICD-9
based MS-DRGs to the ICD-10 based MS-DRGs for procedure code 02UG3JE
(Supplement mitral valve created from left atrioventricular valve with
synthetic substitute, percutaneous approach) that was created effective
October 1, 2016 (FY 2017), to identify and describe further
interventions that may occur for a patient who had previously undergone
cardiac valve surgery to correct a congenital anomaly, such as repair
of a complete common atrioventricular canal defect.
As stated in the proposed rule, we used our established process in
the assignment of new procedure code 02UG3JE to the most appropriate
MS-DRG(s) for FY 2017. Procedure code 02UG3JE was proposed for
assignment to the same MS-DRGs as its predecessor code. The predecessor
code for procedure code 02UG3JE as shown in the 2017 ICD-10-PCS
conversion table (available via the internet on the CMS web page at:
https://www.cms.gov/Medicare/Coding/ICD10/2017-ICD-10-PCS-and-GEMs) is
02UG3JZ (Supplement mitral valve with synthetic substitute,
percutaneous approach). The ICD-9-CM comparable translation for this
code (02UG3JZ) is procedure code 35.97 (Percutaneous mitral valve
repair with implant), which identifies the use of the MitraClip[supreg]
technology that has been discussed extensively in prior rulemaking.
In the FY 2017 rulemaking, using our established process, new
procedure code 02UG3JE was proposed and finalized for assignment to the
following MS-DRGs for FY 2017, as also shown in Table 6B.--New
Procedure Codes in association with the FY 2017 IPPS/LTCH PPS proposed
and final rules (available via the internet on the CMS web page at:
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Acute-Inpatient-Files-for-Download). We noted that
the listed MS-DRGs also reflect the MS-DRGs that the predecessor code
(02UG3JZ) was assigned to at the time of the proposed rule.
[GRAPHIC] [TIFF OMITTED] TR10AU22.035
However, as also discussed in the FY 2017 IPPS/LTCH PPS final rule
(81 FR 56809 through 56813), in connection with replication efforts
between the ICD-9 and ICD-10 based MS-DRGs and the surgical hierarchy,
the predecessor procedure code (02UG3JZ) was reassigned from MS-DRGs
273 and 274 to MS-DRG 228 (Other Cardiothoracic Procedures with MCC)
and revised MS-DRG 229 (Other Cardiothoracic Procedures without MCC),
and was removed from the PTCA logic for MS-DRGs 231 and 232. However,
these proposed and finalized MS-DRG changes for procedure code 02UG3JZ
were not considered for purposes of the MS-DRG assignments for new
procedure code 02UG3JE, which were instead finalized as proposed based
on the existing MS-DRG assignments for the predecessor code, and code
02UG3JE continued to remain on the
[[Page 48837]]
PTCA list in the GROUPER logic for MS-DRGs 231 and 232.
As noted in the proposed rule, our clinical advisors stated that
procedure code 02UG3JE does not describe a PTCA procedure. As also
noted in the proposed rule, we analyzed claims data from the September
2021 update of the FY 2021 MedPAR file for cases in MS-DRGs 231 and 232
to determine if there were any cases reported with procedure code
02UG3JE, and there were no such cases found.
Accordingly, because the procedure described by procedure code
02UG3JE is not clinically consistent with a PTCA procedure and it was
initially assigned to the list for PTCA procedures in the GROUPER logic
as a result of replication in the transition from ICD-9 to ICD-10 based
MS-DRGs, we proposed to remove procedure code 02UG3JE from the list for
PTCA procedures in the GROUPER logic for MS-DRGs 231 and 232 effective
FY 2023. We also proposed to maintain the MS-DRG assignment for
procedure code 02UG3JE in MS-DRGs 266 and 267 (Endovascular Cardiac
Valve Replacement and Supplement Procedures with and without MCC,
respectively) for FY 2023.
Comment: Commenters agreed with the proposal to remove procedure
code 02UG3JE from the GROUPER logic for MS-DRGs 231 and 232 and to
maintain the assignment in MS-DRGs 266 and 267.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to remove procedure code 02UG3JE from the list
for PTCA procedures in MS-DRGs 231 and 232 and to maintain the
assignment for code 02UG3JE in MS-DRGs 266 and 267 in the GROUPER logic
for FY 2023.
b. Neuromodulation Device Implant for Heart Failure
(BarostimTM Baroreflex Activation Therapy)
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28157 through 28162), the BAROSTIM NEOTM System is the first
neuromodulation device system designed to trigger the body's main
cardiovascular reflex to target symptoms of heart failure. The system
consists of an implantable pulse generator (IPG) that is implanted
subcutaneously in the upper chest below the clavicle, a stimulation
lead that is sutured to either the right or left carotid sinus to
activate the baroreceptors in the wall of the carotid artery and a
wireless programmer system that is used to non-invasively program and
adjust BAROSTIM NEOTM therapy via telemetry. The BAROSTIM
NEOTM System is indicated for the improvement of symptoms of
heart failure in a subset of patients with symptomatic New York Heart
Association (NYHA) class II and III heart failure with low cardiac
ejection fractions who do not benefit from guideline directed
pharmacologic therapy or qualify for Cardiac Resynchronization Therapy
(CRT).
The BAROSTIM NEOTM System was approved for new
technology add-on payments for FY 2021 (85 FR 58716 through 58717) and
FY 2022 (86 FR 44974). We refer readers to section II.F.5.a of the
preamble of the proposed rule and this final rule for a discussion
regarding the FY 2023 status of technologies approved for FY 2022 new
technology add-on payments, including the BAROSTIM NEOTM
System.
For the FY 2023 IPPS/LTCH PPS proposed rule, we received a request
to (1) reassign the ICD-10-PCS procedure codes that describe the
implantation of the BAROSTIM NEOTM System from MS-DRGs 252,
253 and 254 (Other Vascular Procedures with MCC, with CC, without MCC
respectively) to MS-DRGs 222, 223, 224, 225, 226, and 227 (Cardiac
Defibrillator Implant with and without Cardiac Catheterization with and
without AMI/HF/Shock with and without MCC, respectively) and (2)
reassign the procedure code that describes the placement of a BAROSTIM
NEOTM IPG alone from MS-DRGs 252, 253 and 254 to MS-DRG 245
(AICD Generator Procedures).
We stated in the FY 2023 IPPS/LTCH PPS proposed rule that the
following ICD-10-PCS procedure codes uniquely identify the implantation
of the BAROSTIM NEOTM System: 0JH60MZ (Insertion of
stimulator generator into chest subcutaneous tissue and fascia, open
approach) in combination with 03HK3MZ (Insertion of stimulator lead
into right internal carotid artery, percutaneous approach) or 03HL3MZ
(Insertion of stimulator lead into left internal carotid artery,
percutaneous approach). The requestor noted that ICD-10-PCS codes
0JH60MZ, 03HK3MZ and 03HL3MZ are individually assigned to MDC 05 in MS-
DRGs 252, 253, and 254 but not mapped to the logic of these MS-DRGs in
a code combination or code cluster. According to the requestor this
means that cases with a principal diagnosis from MDC 05 with procedure
codes describing the implantation of a BAROSTIM NEOTM system
(0JH60MZ with 03HL3MZ or 03HK3MZ); with procedure codes describing
placement of the stimulator generator alone (0JH60MZ); or with
procedure codes describing the placement of a carotid sinus lead only
(03HL3MZ or 03HK3MZ) are all assigned to MS-DRGs 252, 253, and 254,
despite the significant differences in the clinical coherence and
resources required to perform these distinct procedures.
The requestor stated that cases reporting procedure codes
describing the implantation of a BAROSTIM NEOTM system are
more clinically similar to, and have costs that are more closely
aligned to, cases within MS-DRGs 222, 223, 224, 225, 226, and 227. The
requestor stated that according to its own analysis, the population of
Medicare patients surgically treated with procedures assigned to MS-
DRGs 222, 223, 224, 225, 226, and 227 is essentially identical to the
population treated with the BAROSTIM NEOTM System. According
to the requestor, this congruent patient population accounts for
essentially all cases assigned to MS-DRGs 222, 223, 224, 225, 226, and
227. The requestor stated their analysis demonstrated that over 80% of
the cases in MS-DRGs 222, 223, 224, 225, 226, and 227 had a diagnosis
of heart failure, compared to only 30% of cases with a diagnosis of
heart failure assigned to MS-DRGs 252, 253, and 254. The requestor
stated that the subset of patients that have an indication for the
implantation of a BAROSTIM NEOTM system also have
indications for the implantation of Implantable Cardioverter
Defibrillators (ICD), Cardiac Resynchronization Therapy Defibrillators
(CRT-D) and/or Cardiac Contractility Modulation (CCM) devices, all of
which also require the permanent implantation of a programmable,
electrical pulse generator and at least one electrical lead. The
requestor specifically highlighted that the procedure code combinations
describing the implantation of a cardiac contractility modulation (CCM)
device system, which consists of a programmable implantable pulse
generator (IPG) and three leads, one of which is implanted into the
right atrium and the other two leads which are inserted into the right
ventricle is assigned to MS-DRGs 222, 223, 224, 225, 226, and 227, and
the codes describing the insertion of contractility modulation device
generator alone are assigned to MS-DRG 245. The requestor stated that
the average resource utilization required to implant the BAROSTIM
NEOTM System demonstrates a significant disparity compared
to all procedures within MS-DRGs 252, 253, and 254 and noted that the
cost of the BAROSTIM NEOTM implantable device is $35,000,
which is in range with the cost of the other
[[Page 48838]]
cardiac implantable devices (for example ICD, CRT-D, and CCM) assigned
to MS-DRGs 222, 223, 224, 225, 226, and 227.
The requestor stated that the majority of the procedures assigned
to MS-DRGs 252, 253, and 254 are primarily designed to identify,
diagnose, clear and restructure veins and arteries, excluding those
that require implantable devices. Furthermore, the requestor stated the
surgical procedures within MS-DRGs 252, 253, and 254 are not intended
to treat or improve the function of the heart, nor treat the symptoms
of heart failure.
The requestor acknowledged that there are very few cases within the
publicly available Medicare inpatient claims data that potentially
includes procedure codes describing the implantation of a BAROSTIM
NEOTM system. The requestors' own analysis revealed fewer
than 11 cases with procedure codes describing the implantation of a
BAROSTIM NEOTM system in the combined FY 2019 and FY 2020
MedPAR data and noted that during much of this time period, the
BAROSTIM NEOTM System was only implanted as part of a
controlled clinical trial. The requestor stated that this incomplete
data should not be used to determine initial MS-DRG assignments,
especially for new FDA designated `breakthrough' medical technologies
like the BAROSTIM NEOTM system. Rather, the requestor stated
that CMS should use available information and expert knowledge to make
initial MS-DRG assignments, while waiting for a substantial number of
Medicare covered, post-approved claims from a disperse set of hospitals
to reconsider MS-DRG assignments as necessary. The requestor cautioned
that upon new technology add-on payments expiration, and if the
inadequate MS-DRG assignment for these procedures continues, inpatient
admissions to implant the BAROSTIM NEOTM system will be paid
less than outpatient admissions to perform the same procedures.
The ICD-10-CM diagnosis codes that describe heart failure are found
in the following table. These diagnosis codes are all currently
assigned to MDC 05.
[[Page 48839]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.036
We stated in the proposed rule that first, we examined claims data
from the September 2021 update of the FY 2021 MedPAR file for MS-DRGs
252, 253 and 254 to identify cases reporting a diagnosis of heart
failure and procedure codes describing the implantation of the BAROSTIM
NEOTM system with or without a procedure code describing the
performance of a cardiac catheterization as MS-DRGs 222, 223, 224, 225,
226, and 227 are defined by the performance of cardiac catheterization.
Our findings are shown in the following table.
[[Page 48840]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.037
As shown in the table, the data analysis performed indicates that
the two cases in MS-DRG 252 reporting procedure codes describing the
implantation of a BAROSTIM NEOTM system have an average
length of stay that is shorter than the average length of stay for all
the cases in MS-DRG 252 (4.5 days versus 7.6 days) and higher average
costs when compared to all the cases in MS-DRG 252 ($67,588 versus
$27,488). These two cases did not also report a procedure code
describing the performance of a cardiac catherization. The one case in
MS-DRG 253 reporting procedure codes describing the implantation of a
BAROSTIM NEOTM system had a length of stay that is shorter
than the average length of stay for all the cases in MS-DRG 253 (1 day
versus 5.2 days) and lower costs when compared to all the cases in MS-
DRG 253 ($19,237 versus $21,978). This case did not also report a
procedure code describing the performance of a cardiac catherization.
We found zero cases in MS-DRG 254 reporting procedure codes describing
the implantation of a BAROSTIM NEOTM system.
We stated that our clinical advisors reviewed this data and noted
that was it is difficult to detect patterns of complexity and resource
intensity based on the three cases that reported procedure codes
describing the implantation of a BAROSTIM NEOTM system. The
claims data also reflect a wide variance with regard to the length of
stay and average costs for the three cases that did report the
implantation of a BAROSTIM NEOTM system. We stated that the
results of the claims analysis demonstrated we did not have sufficient
claims data on which to base and evaluate any proposed changes to the
current MS-DRG assignment. We also stated that our clinical advisors
also expressed concern in equating the implantation of a BAROSTIM
NEOTM system to the placement of ICD, CRT-D, and CCM devices
as these devices all differ in terms of technical complexity and
anatomical placement of the electrical lead(s). Our clinical advisors
noted there is no intravascular component or vascular puncture involved
when implanting a BAROSTIM NEOTM system. Our clinical
advisors also noted the placement of ICD, CRT-D, and CCM devices
generally involve a lead being affixed to the myocardium, being
threaded through the coronary sinus or crossing a heart valve and are
procedures that involve a greater level of complexity than affixing the
stimulator lead to either the right or left carotid sinus when
implanting a BAROSTIM NEOTM system.
Next, to evaluate the request to reassign the procedure code that
describes the placement of a BAROSTIM NEOTM IPG alone from
MS-DRGs 252, 253 and 254 to MS-DRG 245 (AICD Generator Procedures), we
stated in the proposed rule that we examined claims data from the
September 2021 update of the FY 2021 MedPAR file for all cases in MS-
DRGs 252, 253 and 254 and compared the results to cases with a
procedure code describing placement of the stimulator generator alone.
Our findings are shown in the following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.038
[[Page 48841]]
As shown in the table, the data analysis performed indicates that
the 12 cases in MS-DRG 252 reporting a procedure code describing
placement of the stimulator generator alone have an average length of
stay that is longer than the average length of stay for all the cases
in MS-DRG 252 (8.8 days versus 7.6 days) and higher average costs when
compared to all the cases in MS-DRG 252 ($56,622 versus $27,488). The
four cases in MS-DRG 253 reporting a procedure code describing
placement of the stimulator generator alone have an average length of
stay that is shorter than the average length of stay for all the cases
in MS-DRG 253 (2.5 days versus 5.2 days) and higher average costs when
compared to all the cases in MS-DRG 253 ($30,451 versus $21,978). We
found zero cases in MS-DRG 254 reporting a procedure code describing
placement of the stimulator generator alone.
We stated that our clinical advisors reviewed this data, and found,
similar to the analysis of the data from the three cases that reported
procedure codes describing the implantation of a BAROSTIM
NEOTM system, that it was difficult to detect patterns of
complexity and resource intensity based on the few cases that reported
procedure codes describing placement of the stimulator generator alone.
The claims data similarly reflects a wide variance with regard to the
length of stay and average costs for these cases that did report the
placement of the stimulator generator alone, indicating there may have
been other factors contributing to the higher costs. When reviewing the
consumption of hospital resources for this small subset of cases, the
claims data also suggest that the increased costs may be attributable
to the severity of illness of the patient and other circumstances of
the admission as the patients tended to have a major complication or
co-morbid (MCC) condition reported based on the MS-DRG assigned.
We stated in the proposed rule that we recognized the average costs
of the small numbers of cases reporting a procedure code describing
placement of the stimulator generator alone are greater when compared
to the average costs of all cases in their respective MS-DRG. We noted
that the MS-DRG system is a system of averages and it is expected that
within the diagnostic related groups, some cases may demonstrate higher
than average costs, while other cases may demonstrate lower than
average costs. We further noted that section 1886(d)(5)(A) of the Act
provides for Medicare payments to Medicare-participating hospitals in
addition to the basic prospective payments for cases incurring
extraordinarily high costs.
In response to the requestor's concerns regarding procedures
currently assigned to MS-DRGs 252, 253 and 254, as discussed in section
II.D.3.b. of the preamble of the proposed rule and this final rule, we
note that MS-DRGs 252, 253, and 254 (Other Vascular Procedures with
MCC, with CC, and without CC/MCC, respectively) are examples of the
``other'' surgical class, and therefore it is expected that there will
be procedures not as precisely clinically aligned within the definition
(logic) of these MS-DRGs. In regard to the concern about the
implications for reimbursement when these procedures are performed in
the outpatient setting as opposed to the inpatient setting, we noted
that the goals of reviewing the MS-DRG assignments of particular
procedures are to better clinically represent the resources involved in
caring for these patients and to enhance the overall accuracy of the
system.
In the proposed rule, in response to the requestor's statement that
CMS should use available information and expert knowledge to make
initial MS-DRG assignments, while waiting for a substantial number of
Medicare covered, post-approved claims from a disperse set of hospitals
to reconsider MS-DRG assignments as necessary, we noted that we use our
established process for GROUPER assignments for new diagnosis and
procedure codes. Specifically, consistent with our established process
for assigning new diagnosis and procedure codes, we stated that we
review the predecessor code and MS-DRG assignment most closely
associated with the new diagnosis or procedure code, and in the absence
of claims data, we consider other factors that may be relevant to the
MS-DRG assignment, including the severity of illness, treatment
difficulty, complexity of service and the resources utilized in the
diagnosis or treatment of the condition. We noted that this process
will not automatically result in the new diagnosis or procedure code
being assigned to the same MS-DRG or having the same designation as the
predecessor code. Members of the public have the opportunity to provide
feedback on the assignment and designation of the codes if they
disagree. We referred the reader to section II.D.17 of the proposed
rule for a more detailed discussion of this process. We noted that when
BAROSTIM NEOTM applied for new technology add-on payment, it
was noted that the technology could be uniquely identified using a
combination of existing ICD-10-PCS codes that were already assigned to
MS-DRGs, and this circumstance generally would not provide a basis for
MS-DRG reassignment.
Lastly, as discussed in the proposed rule, our clinical advisors
expressed concern regarding making proposed MS-DRG changes based on a
specific, single technology (BAROSTIM NEOTM system),
identified by only one unique procedure code combination versus
considering proposed changes based on a group of related procedure
codes that can be reported to describe that same type or class of
technology, which is more consistent with the intent of the MS-DRGs.
We stated that we believed that as the number of cases reporting
procedure codes describing the implantation of neuromodulation devices
for heart failure increases, a better view of the associated costs and
lengths of stay on average will be reflected in the data for purposes
of assessing any reassignment of these cases. We indicated that our
clinical advisors stated that it would not be appropriate to reassign
cases for patients from MS-DRGs 252, 253 and 254 to MS-DRGs 222, 223,
224, 225, 226, and 227 in the absence of additional data to better
determine the resource utilization for this subset of patients to help
inform whether a reassignment would be clinically warranted. Therefore,
for the reasons stated previously, we proposed to maintain the
assignment of cases reporting procedure codes that describe the
implantation of a neuromodulation device in MS-DRGs 252, 253 and 254
for FY 2023. We also proposed to maintain the assignment of cases
reporting a procedure code describing placement of a stimulator
generator alone in MS-DRGs 252, 253 and 254 for FY 2023.
Comment: Commenters expressed support for CMS' proposal to maintain
the assignment of cases reporting procedure codes that describe the
implantation of a neuromodulation device for heart failure in MS-DRGs
252, 253 and 254 and to maintain the assignment of cases reporting a
procedure code describing placement of a stimulator generator alone in
MS-DRGs 252, 253 and 254 for FY 2023.
Response: We appreciate the commenters' support.
Comment: A commenter opposed CMS' proposal. The commenter stated
that in their own analysis of the MedPAR data, and from their real-
world experience, patients with an indication for implantation of a
neuromodulation device were not always admitted with a heart failure
diagnosis. Many patients presented with multiple comorbidities, and
various cardiovascular diagnosis
[[Page 48842]]
(for example, syncope, tachycardia, atrial fibrillation etc.) which
lead to heart failure or are concomitant with heart failure.
This commenter further stated that in their review of the data that
CMS presented, the cost of cases with a diagnosis of heart failure with
procedure codes describing the implantation of a neuromodulation device
without cardiac catheterization and the cost of cases with a procedure
code describing placement of the stimulator generator alone are both
more than twice that of all cases in MS-DRG 252. The commenter stated
even given these disparities, they did not believe that the full costs
of the implantation of a neuromodulation device system have been
appreciated in the MedPAR data files. According to the commenter, the
manufacturer did not charge a cost for the device during clinical
trials for the BAROSTIM NEOTM so such claims do not reflect
the full device cost. The commenter also stated that the COVID-19
pandemic has had a negative impact on inpatient hospital uptake of this
new technology, which in turn has also limited the data available to
support an accurate and appropriate MS-DRG assignment. The commenter
stated they believe the fact that there are few cases in the MedPAR
data files to date is not a reason to allow an overly mispriced MS-DRG
assignment. The commenter stated that while BAROSTIM NEOTM
procedures are typically performed in the outpatient setting, it is
important to preserve inpatient access for those patients with
comorbidities or other risk factors that necessitate an inpatient level
of care. According to this commenter, the current MS-DRG assignments
for procedure codes that describe the implantation of a neuromodulation
device for heart failure would result in a lower payment than
procedures performed in the outpatient setting and could result in
barriers to treatment for patients who are not suitable candidates for
the outpatient setting.
This commenter urged CMS to reassign the ICD-10-PCS procedure codes
that describe the implantation of a neuromodulation device for heart
failure from MS-DRGs 252, 253 and 254 to MS-DRGs 222, 223, 224, 225,
226 and 227 as requested. As alternatives, the commenter recommended to
CMS, to instead, consider reassigning the ICD-10-PCS procedure codes
that describe the implantation of the BAROSTIM NEOTM System
from MS-DRGs 252, 253 and 254 to MS-DRGs 270, 271 and 272 (Other Major
Cardiovascular Procedures with MCC, with CC, and without CC/MCC,
respectively) or even create a new MS-DRG that appropriately describes
these procedures.
Response: We appreciate the commenter's feedback and concern. With
regard to the commenter's concern that patients with an indication for
the implantation of neuromodulation devices are not always admitted
with heart failure diagnoses, we wish to confirm that the examination
of claims data from the September 2021 update of the FY 2021 MedPAR
file for MS-DRGs 252, 253 and 254 to identify cases reporting a
diagnosis of heart failure and procedure codes describing the
implantation of neuromodulation devices for heart failure with or
without a procedure code describing the performance of a cardiac
catheterization, as discussed in the proposed rule, included cases
reporting a diagnosis of heart failure as either a principal or
secondary diagnosis.
Our clinical advisors reviewed commenter's concerns and continue to
note we do not have sufficient claims data on which to base and
evaluate any proposed changes to the current MS-DRG assignment, given
the difficulties of assessing patterns of complexity and resource
intensity based on the limited number of cases identified. Our clinical
advisors also continue to express concern in equating the implantation
of neuromodulation devices for heart failure to the placement of ICD,
CRT-D, and CCM devices as these devices all differ in terms of
technical complexity and anatomical placement of the electrical
lead(s), as discussed in the proposed rule. In regard to the concern
about the implications for payment when these procedures are performed
in the outpatient setting as opposed to the inpatient setting, as noted
in the proposed rule, and in prior rulemaking, the goals of reviewing
the MS-DRG assignments of particular procedures are to better
clinically represent the resources involved in caring for these
patients and to enhance the overall accuracy of the system.
With regard to the commenter's concern that there may have been
other contributing factors that limited the data available to support
an accurate and appropriate MS-DRG assignment of these cases, our
clinical advisors believe that as the number of cases reporting
procedure codes describing the implantation of neuromodulation devices
for heart failure increases, the associated resource utilization can be
better assessed for purposes of evaluating any reassignment of these
cases. As additional claims data becomes available, we will continue to
analyze the clinical nature of procedure codes describing the
implantation of neuromodulation devices for heart failure and their MS-
DRG assignments, including potential alternative MS-DRG assignments, to
further improve the overall accuracy of the IPPS payments in future
rulemaking.
Therefore, after consideration of the public comments we received,
and for the reasons stated earlier, we are finalizing our proposal to
maintain the assignment of cases reporting procedure codes that
describe the implantation of a neuromodulation device in MS-DRGs 252,
253 and 254, without modification, for FY 2023. We are also finalizing
our proposal to maintain the assignment of cases reporting a procedure
code describing placement of a stimulator generator alone in MS-DRGs
252, 253 and 254, without modification, effective October 1, 2022 for
FY 2023.
In the proposed rule, we also noted that during our review of this
issue, as we examined the GROUPER logic that would determine an
assignment of a case to MS-DRGs 222, 223, 224, 225, 226, and 227, we
found two diagnosis codes describing heart failure that are not
currently in the listed principal diagnoses in the GROUPER logic for
MS-DRGs 222 and 223 (Cardiac Defibrillator Implant with Cardiac
Catheterization with AMI, HF or Shock with and without MCC,
respectively). These diagnosis codes are listed in the following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.039
[[Page 48843]]
We stated that as a result, when either of these codes are coded as
a principal diagnosis, MS-DRGs 224 and 225 (Cardiac Defibrillator
Implant with Cardiac Catheterization without AMI, HF, or Shock with and
without MCC, respectively) are instead assigned when reported with a
procedure code combination describing the implantation of a cardiac
defibrillator and a procedure describing the performance of a cardiac
catherization procedure. We referred the reader to the ICD-10 MS-DRG
Definitions Manual Version 39.1, which is available via the internet on
the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software
for complete documentation of the GROUPER logic for MS-DRGs 222, 223,
224, and 225.
In the proposed rule, we stated that our clinical advisors reviewed
this issue and believed that cases reporting diagnosis code I97.130 or
I97.131 as a principal diagnosis are associated with a severity of
illness on par with cases reporting a principal diagnosis of a type of
heart failure. We noted that in order to code postprocedural heart
failure in ICD-10-CM, instructional notes at category I50 direct to
``code first heart failure following surgery'' (that is, I97.130 and
I97.131) with a second code from subcategory of I50 listed after the
postprocedural heart failure code to specify the type of heart failure.
We stated that our clinical advisors recommended adding diagnosis codes
I97.130 and I97.131 to the logic list of principal diagnoses that
describe heart failure for clinical consistency, recognizing that
coding guidelines instruct to code I97.130 and I97.131 before the codes
from subcategory of I50 that specify the type of heart failure, as the
codes from subcategory of I50 are currently in the listed principal
diagnoses in the GROUPER logic for MS-DRGs 222 and 223. Therefore, we
proposed to modify the GROUPER logic to allow cases reporting diagnosis
code I97.130 or I97.131 as a principal diagnosis to group to MS-DRGs
222 and 223 when reported with qualifying procedures.
Comment: Commenters expressed support for CMS' proposal to modify
the GROUPER logic to allow cases reporting diagnosis code I97.130 or
I97.131 as a principal diagnosis to group to MS-DRGs 222 and 223 when
reported with qualifying procedures.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to modify the GROUPER logic to allow cases
reporting diagnosis code I97.130 or I97.131 as a principal diagnosis to
group to MS-DRGs 222 and 223 when reported with qualifying procedures,
without modification, effective October 1, 2022 for FY 2023.
c. Cardiac Mapping
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28162 through 28163), we identified a replication issue from the ICD-9
based MS-DRGs to the ICD-10 based MS-DRGs for procedure code 02K80ZZ
(Map conduction mechanism, open approach). Cardiac mapping describes
the creation of detailed maps to detect how the electrical signals that
control the timing of the heart rhythm move between each heartbeat to
identify the location of rhythm disorders. Cardiac mapping is generally
performed during open-heart surgery or performed via cardiac
catherization.
In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49363 through
49369), we discussed a request to remove the cardiac ablation and other
specified cardiovascular procedures from the following MS-DRGs, and to
create new MS-DRGs to classify these procedures:
MS-DRG 246 (Percutaneous Cardiovascular Procedure with
Drug- Eluting Stent with MCC or 4+ Vessels/Stents);
MS-DRG 247 (Percutaneous Cardiovascular Procedure with
Drug-Eluting Stent without MCC);
MS-DRG 248 (Percutaneous Cardiovascular Procedure with
Non-Drug-Eluting Stent with MCC or 4+ Vessels/Stents);
MS-DRG 249 (Percutaneous Cardiovascular Procedure with
Non- Drug-Eluting Stent without MCC);
MS-DRG 250 (Percutaneous Cardiovascular Procedure without
Coronary Artery Stent with MCC); and
MS-DRG 251 (Percutaneous Cardiovascular Procedure without
Coronary Artery Stent without MCC).
The requestor recommended that CMS assign the following ICD-9-CM
procedure codes that identify and describe cardiac ablation procedures
and the other percutaneous intracardiac procedures to the newly created
MS-DRGs:
35.52 (Repair of atrial septal defect with prosthesis,
closed technique);
35.96 (Percutaneous balloon valvuloplasty);
35.97 (Percutaneous mitral valve repair with implant);
37.26 (Catheter based invasive electrophysiologic
testing);
37.27 (Cardiac mapping);
37.34 (Excision or destruction of other lesion or tissue
of heart, endovascular approach);
37.36 (Excision, destruction, or exclusion of left atrial
appendage (LAA)); and
37.90 (Insertion of left atrial appendage device).
We stated we agreed that creating these new MS-DRGs would better
reflect utilization of resources and clinical cohesiveness for
intracardiac procedures in comparison to intracoronary procedures.
Therefore, after consideration of the public comments we received, we
finalized our proposal to create MS-DRGs 273 (Percutaneous Intracardiac
Procedures with MCC) and MS-DRG 274 (Percutaneous Intracardiac
Procedures without MCC) for the FY 2016 ICD-10 MS-DRGs Version 33 and
finalized the assignment of the procedures performed within the heart
chambers using intracardiac techniques to the two new MS-DRGs.
In the FY 2016 rulemaking, we stated that the comparable ICD-10-PCS
code translations for ICD-9-CM procedure code 37.27 (Cardiac mapping)
were ICD-10-PCS codes 02K83ZZ (Map conduction mechanism, percutaneous
approach) and 02K84ZZ (Map conduction mechanism, percutaneous
endoscopic approach). However, code 02K80ZZ (Map Conduction Mechanism,
Open Approach), which is also a comparable ICD-10-PCS code translation
for ICD-9-CM procedure code 37.27, was inadvertently excluded.
Consequently, procedure code 02K80ZZ continued to remain in the GROUPER
logic for MS-DRGs 246, 247, 248, 249, 250 and 251.
In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58477), we finalized
a revision to the titles for MS-DRGs 273 and 274 to ``Percutaneous and
Other Intracardiac Procedures with and without MCC, respectively'' to
better reflect the procedures assigned to them.
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule, in the
ICD-10 MS-DRGs Definitions Manual Version 39.1, procedure code 02K80ZZ
is currently recognized as a non-O.R. procedure that affects the MS-DRG
to which it is assigned. We stated that our clinical advisors reviewed
this grouping issue and stated that procedure code 02K80ZZ does not
describe a percutaneous cardiovascular procedure. We stated that our
clinical advisors supported the reassignment of code 02K80ZZ for
clinical coherence, noting the procedure should be appropriately
grouped along with other procedure codes that describe cardiac mapping
currently assigned to MS-DRGs 273 and
[[Page 48844]]
274. Accordingly, because the procedure described by procedure code
02K80ZZ is not clinically consistent with percutaneous cardiovascular
procedures and it was initially assigned MS-DRGs 246, 247, 248, 249,
250 and 251 as a result of replication in the transition from ICD-9 to
ICD-10 based MS-DRGs, we proposed the reassignment of procedure code
02K80ZZ from MS-DRGs 246, 247, 248, 249, 250 and 251 to MS-DRGs 273 and
274 (Percutaneous and Other Intracardiac Procedures with and without
MCC, respectively) in MDC 05 effective FY 2023.
As discussed in section II.D.1.b of the preamble of the proposed
rule, we noted that we were providing a test version of the ICD-10 MS-
DRG GROUPER Software, Version 40, so that the public could better
analyze and understand the impact of the proposals included in the
proposed rule. We noted that at the time of the development of the test
software this issue was unable to be addressed and therefore, it did
not reflect the proposed reassignment of procedure code 02K80ZZ from
MS-DRGs 246, 247, 248, 249, 250 and 251 to MS-DRGs 273 and 274
(Percutaneous and Other Intracardiac Procedures with and without MCC,
respectively) in MDC 05 for Version 40.
Comment: Commenters agreed with our proposal to reassign procedure
code 02K80ZZ from MS-DRGs 246, 247, 248, 249, 250 and 251 to MS-DRGs
273 and 274 (Percutaneous and Other Intracardiac Procedures with and
without MCC, respectively). A few commenters stated that they
appreciate CMS identifying a replication issue from the ICD-9 based MS-
DRGs to the ICD-10 based MS-DRGs and supported the reassignment of
procedure code 02K80ZZ. A commenter agreed that cardiac mapping is
generally performed during open-heart surgery or performed via cardiac
catheterization to create detailed maps of electrical signals to
identify the location of rhythm disorders.
Response: We thank the commenters for their support.
Comment: Other commenters opposed the proposal. Several commenters
noted that CMS stated that code 02K80ZZ affects the MS-DRG to which it
is assigned, however, based on their review of the MS-DRG logic, code
02K80ZZ is designated as a non-O.R procedure and does not affect MS-DRG
assignment. Other commenters expressed concern that data was not
analyzed to see if code 02K80ZZ had been found in MS-DRGs 246, 247,
248, 249, 250 and 251. A commenter stated that should it be determined
that code 02K80ZZ had not been found in MS-DRGs 246, 247, 248, 249, 250
and 251, then they agreed with removal of code 02K80ZZ from these MS-
DRGs and reassignment to MS-DRGs 273-274. However, should the analysis
show code 02K80ZZ assigned to MS-DRGs 246, 247, 248, 249, 250 and 251,
this commenter suggested CMS consider if the assignment of code 02K80ZZ
to these MS-DRGs should be maintained, and if not, what ramifications
the reassignment would have.
A few commenters recommended that CMS consider assigning code
02K80ZZ to MS-DRGs 228 and 229 (Other Cardiothoracic Procedures with
and without MCC, respectively) instead. Some commenters stated that
they believe that procedures to map conduction mechanism share similar
clinical and resource consumption as the surgical ablation procedures
performed via an open approach that are currently assigned to MS-DRGs
228 and 229. These commenters further stated that given that 02K80ZZ
(Map conduction mechanism, open approach) does not describe a
percutaneous cardiovascular procedure, they did not recommend the
assignment of the code to MS-DRGs 273 and 274. A commenter stated that
based on their own analysis, 02K80ZZ is more often assigned to MS-DRGs
228 and 229 than to MS-DRGs 273 and 274, and furthermore, the ICD-10-
PCS codes included in MS-DRGs 273 and 274 are ablation procedures via
percutaneous approach. Another commenter asserted that the procedures
in MS-DRGs 273 and 274 are all percutaneous approach procedures.
Response: We thank the commenters for their feedback.
We note that in the ICD-10 MS-DRGs Definitions Manual Version 39.1,
procedure code 02K80ZZ is in fact recognized as a non-O.R. procedure
affecting MS-DRGs 246, 247, 248, 249, 250 and 251, specifically. Under
the IPPS MS-DRGs, each ICD-10-PCS procedure code has designations that
determine whether and in what way the presence of that procedure on a
claim impacts the MS-DRG assignment. First, each ICD-10-PCS procedure
code is either designated as an O.R. procedure for purposes of MS-DRG
assignment (``O.R. procedures'') or is not designated as an O.R.
procedure for purposes of MS-DRG assignment (``non-O.R. procedures'').
For each procedure that is designated as a non-O.R. procedure, that
non-O.R. procedure is further classified as either affecting the MS-DRG
assignment or not affecting the MS-DRG assignment. We refer to these
designations that do affect MS-DRG assignment as ``non O.R. affecting
the MS-DRG'' because these procedure codes describe procedures that
would generally require a greater intensity of resources for facilities
to manage the cases included in the definition (logic) of these MS-
DRGs. We refer readers to the ICD-10 MS-DRG Version 39.1 Definitions
Manual at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.html for
detailed information regarding the designation of procedures as O.R. or
non-O.R. (affecting the MS-DRG) in Appendix E--Operating Room
Procedures and Procedure Code/MS-DRG Index. Procedures designated as
``non O.R. affecting the MS-DRG'' are listed in Appendix E with an
asterisk.
In response to the comments expressing concern that data was not
analyzed to determine if there were any cases reported with procedure
code 02K80ZZ in MS-DRGs 246, 247, 248, 249, 250 and 251, we refer the
reader to Table 6P.1e associated with this final rule and available via
the internet at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. This table displays the findings from our
analysis of the claims data from the September 2021 update of the FY
2021 MedPAR file to determine if there were any cases reported with
procedure code 02K80ZZ assigned to MS-DRGs 246, 247, 248, 249, 250 and
251 and reflects that there were no such cases found.
With regard to the commenters' concerns that procedures to map
conduction mechanism share similar clinical and resource consumption as
surgical ablation procedures performed via an open approach, our
clinical advisors note that while cardiac mapping can be used to
identify and localize areas responsible for rhythm disturbances to
serve as a target for surgical ablation, each of these procedures are
defined by clinically distinct definitions and objectives, which is why
there are separate and unique ICD-10-PCS procedure codes within the
classification for reporting purposes. Our clinical advisors note that
cardiac mapping describes the creation of detailed maps, generally
involving the use of electrodes and a mapping system (consisting of
amplifiers and a recording and analysis system), to detect how the
electrical signals that control the timing of the heart rhythm move
between each heartbeat to identify the location of rhythm disorders.
Surgical ablation, however, describes the burning or freezing of tissue
on the inside of the heart to disrupt faulty electrical signals causing
the arrhythmia.
[[Page 48845]]
We also note in response to the comments received that percutaneous
ablation procedures are not the only procedures assigned to MS-DRGs 273
and 274. Of note, left atrial appendage closure (LAAC) procedures, with
and without an implant, are also assigned to MS-DRGs 273 and 274. In
response to the commenters who did not agree with the proposal to
reassign procedure code 02K80ZZ from MS-DRGs 246, 247, 248, 249, 250
and 251 to MS-DRGs 273 and 274 based on the open approach of the
procedure, as noted in the proposed rule, in the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58477), we finalized a revision to the titles for MS-
DRGs 273 and 274 to ``Percutaneous and Other Intracardiac Procedures
with and without MCC, respectively'' to better reflect the procedures
assigned, as not only percutaneous procedures are assigned to these MS-
DRGs. We refer the reader to the ICD-10 MS-DRG Definitions Manual,
version 39.1, which is available via the internet on the CMS website
at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software for complete
documentation of the GROUPER logic for MS-DRGs 273 and 274.
Our clinical advisors continue to note that code 02K80ZZ (Map
Conduction Mechanism, Open Approach), which is a comparable ICD-10-PCS
code translation for ICD-9-CM procedure code 37.27 (Cardiac mapping),
was inadvertently excluded in FY 2016 rulemaking when we finalized our
proposal to create MS-DRGs 273 and MS-DRG 274 to better reflect
utilization of resources and clinical cohesiveness for intracardiac
procedures in comparison to intracoronary procedures. Our clinical
advisors continue to support the reassignment of code 02K80ZZ for
clinical coherence, noting the procedure should be appropriately
grouped along with other procedure codes that describe cardiac mapping
that are currently assigned to MS-DRGs 273 and 274.
Therefore, after consideration of the public comments we received,
and for the reasons discussed, we are finalizing our proposal to
reassign procedure code 02K80ZZ from MS-DRGs 246, 247, 248, 249, 250
and 251 to MS-DRGs 273 and 274 (Percutaneous and Other Intracardiac
Procedures with and without MCC, respectively) in MDC 05 for Version
40, without modification.
d. Surgical Ablation
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44836 through
44848), we discussed a two-part request we received to review the MS-
DRG assignments for cases involving the surgical ablation procedure for
atrial fibrillation. The first part of the request was to create a new
classification of surgical ablation MS-DRGs to better accommodate the
costs of open concomitant surgical ablations. The requestor identified
the following potential procedure combinations that would comprise an
``open concomitant surgical ablation'' procedure.
Open CABG + open surgical ablation
Open MVR + open surgical ablation
Open AVR + open surgical ablation
Open MVR + open AVR + open surgical ablation
Open MVR + open CABG + open surgical ablation
Open MVR + open AVR + open CABG + open surgical ablation
Open AVR + open CABG + open surgical ablation
As discussed in the FY 2022 IPPS/LTCH PPS final rule, we examined
claims data from the March 2020 update of the FY 2019 MedPAR file and
the September 2020 update of the FY 2020 MedPAR file for cases
reporting procedure code combinations describing open concomitant
surgical ablations. We refer the reader to Table 6P.1o associated with
the FY 2022 final rule (which is available via the internet on the CMS
website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS) for data analysis findings of cases
reporting procedure code combinations describing open concomitant
surgical ablations. We stated our analysis showed while the average
lengths of stay and average costs of cases reporting procedure code
combinations describing open concomitant surgical ablations are higher
than all cases in their respective MS-DRG, we found variation in the
volume, length of stay, and average costs of the cases. We also stated
findings from our analysis indicated that MS-DRGs 216, 217, and 218
(Cardiac Valve and Other Major Cardiothoracic Procedures with Cardiac
Catheterization with MCC, with CC, and without CC/MCC, respectively) as
well as approximately 31 other MS-DRGs would be subject to change based
on the three-way severity level split criterion finalized in FY 2021.
We refer the reader to section II.D.1.b. of the FY 2022 IPPS/LTCH PPS
final rule (86 FR 44796 through 44798), for related discussion
regarding our finalization of the proposal to delay application of the
NonCC subgroup criteria to existing MS-DRGs with three-way severity
level split to maintain more stability in the current MS-DRG structure.
In the FY 2022 final rule, we finalized our proposal to revise the
surgical hierarchy for the MS-DRGs in MDC 05 (Diseases and Disorders of
the Circulatory System) to sequence MS-DRGs 231-236 (Coronary Bypass)
above MS-DRGs 228 and 229 (Other Cardiothoracic Procedures with and
without MCC, respectively), effective October 1, 2021. In addition, we
also finalized the assignment of cases with a procedure code describing
coronary bypass and a procedure code describing open ablation to MS-
DRGs 233 and 234 and changed the titles of these MS-DRGs to ``Coronary
Bypass with Cardiac Catheterization or Open Ablation with and without
MCC, respectively'' to reflect this reassignment for FY 2022.
In response to this final policy, as discussed in the FY 2023 IPPS/
LTCH PPS proposed rule (87 FR 28163), we received a request to again
review the MS-DRG assignment of cases involving open concomitant
surgical ablation procedures. The requestor stated they continue to
believe that the average hospital costs for surgical ablation for
atrial fibrillation demonstrates a cost disparity compared to all
procedures within their respective MS-DRGs. The requestor suggested
that when open surgical ablation is performed with MVR, or AVR or MVR/
AVR + CABG that these procedures are either (1) assigned to a different
family of MS-DRGs or (2) assigned to MS-DRGs 216 and 217 (Cardiac Valve
and Other Major Cardiothoracic Procedures with Cardiac Catheterization
with MCC and with CC, respectively) similar to what CMS did with CABG
and open ablation procedures in the FY 2022 rulemaking to better
accommodate the added cost of open concomitant surgical ablation.
In the proposed rule we stated the change to the surgical hierarchy
in MDC 05 and the assignment of cases with a procedure code describing
coronary bypass and a procedure code describing open ablation to MS-
DRGs 233 and 234 is recent, only becoming effective October 1, 2021. We
stated that we believed more time was needed before considering to
again review the MS-DRG assignment of cases reporting procedure code
combinations describing open concomitant surgical ablations as the data
from the September 2021 update of the FY 2021 MedPAR file does not
reflect our FY 2022 finalization. In addition, our clinical advisors
continued to state that in open concomitant surgical ablation
procedures, the CABG, MVR, and AVR components of the procedure are more
technically complex than the open surgical ablation procedure. They
also stated that the finalized revision to the
[[Page 48846]]
surgical hierarchy leads to a grouping that is more coherent and better
accounts for the resources expended to address the more complex
procedures from other cases redistributed during the hierarchy change.
As noted, we stated that we believed that additional time was needed to
allow for further analysis of the claims data to reflect our FY 2022
finalization, and also to determine to what extent the patient's co-
morbid conditions are also contributing to costs and to identify other
contributing factors that might exist with respect to the increased
length of stay and costs of this subset of cases in these MS-DRGs, as
discussed in the FY 2022 IPPS/LTCH PPS final rule.
Comment: Commenters expressed support of CMS' decision to allow
additional time for the claims data to reflect our FY 2022 finalization
before further analysis. Commenters stated that the finalized changes
to surgical hierarchy for cardiac procedures were positive and will
improve patient access. Other commenters stated that the finalized
changes to the MS-DRG assignment of cases with a procedure code
describing coronary bypass and a procedure code describing open
ablation were timely.
Response: We thank the commenters for their support.
Comment: Some commenters opposed CMS' decision and suggested that
Medicare cover both aortic valve replacement surgery and surgical
treatment for atrial fibrillation.
Response: We note that the Definitions Manual display of the
GROUPER logic assignment for each procedure code is not an indication
of whether or not a particular procedure is covered for payment
purposes. The MS-DRG logic must specifically require a condition to
group based on whether it is reported as a principal diagnosis or a
secondary diagnosis, and consider any procedures that are reported, in
addition to consideration of the patient's age, sex and discharge
status in order to affect the MS-DRG assignment. In other words, cases
will group according to the GROUPER logic, regardless of any coding
guidelines or coverage policies. It is the Medicare Code Editor (MCE)
and other payer-specific edits that identify inconsistencies in the
coding guidelines or coverage policies. These data integrity edits
address issues such as data validity, coding rules, and coverage
policies. Since the inception of the IPPS, the data editing function
has been a separate and independent step in the process of determining
a DRG assignment. The separation of the MS-DRG grouping and data
editing functions allows the MS-DRG GROUPER to remain stable even
though coding rules and coverage policies may change during the fiscal
year.
Comment: Other commenters opposed CMS' decision and stated CMS
needs to finish the work that was started and improve hospital payment
for valvular procedures with surgical ablation for atrial fibrillation.
These commenters stated that the finalization of the revision to the
surgical hierarchy for the MS-DRGs in MDC 05 and the finalization of
the assignment of cases with a procedure code describing coronary
bypass and a procedure code describing open ablation to MS-DRGs 233 and
234 in FY 2022 rulemaking does not address the increased costs of cases
describing open concomitant surgical ablation performed with open valve
procedures that are assigned to MS-DRGs 216 through 221. A few
commenters asserted that hospitals are forced to lose money on these
lifesaving treatments because CMS has not addressed this underpayment.
Other commenters stated that CMS did not provide transparent data
analysis of cases describing open surgical ablation for atrial
fibrillation performed during open valve procedures so the provider
community could appropriately evaluate.
Commenters stated that treating atrial fibrillation during the same
surgical session as an open valve procedure requires significant device
costs, additional operating room time, and specialized staff. A
commenter stated that even if the surgical ablation procedure is less
technically complex than CABG, MVR, and/or AVR, hospitals still bear
significant costs for furnishing the ablation procedure when the
additional costs of the innovative device technologies (such as
radiofrequency ablation clamps, cryoablation probes, and left atrial
appendage management devices) that are used during the procedure are
considered. Commenters expressed concern that given the added costs of
performing as many as three procedures at the same time, hospitals may
more likely schedule the patient for separate procedures even though
guidelines of the Society for Thoracic Surgeons and the Heart Rhythm
Society recommend performing surgical ablation for atrial fibrillation
at the time of open-heart procedures when indicated. These commenters
further stated they believed it did not seem financially prudent to
compel patients to undergo multiple procedures, potentially costing
more in the long run, when their atrial fibrillation could be treated
during the same open-heart operation. Many commenters urged CMS to
either (1) assign the cases to a different family of MS-DRGs or (2)
assign these cases to MS-DRGs 216 and 217 (Cardiac Valve and Other
Major Cardiothoracic Procedures with Cardiac Catheterization with MCC
and with CC, respectively) as originally requested.
Another commenter stated they respected the position of CMS'
clinical advisors given the complexity of the involved procedures and
noted that the issue of multiple procedures or interventions performed
during a single hospital stay is also a problem in other areas of
cardiology and warrants a meaningful solution. This commenter stated
they believed that since performing procedures concomitantly is more
efficient, more convenient, provides a better prognosis for the patient
and could be more cost effective than the procedures being performed in
different hospital stays, there should be a mechanism for
differentiated payment when procedures are performed concomitantly,
when it is best for the patient. This commenter recommended that CMS
create a supplemental payment mechanism that could be modeled based on
the respective costs of the individual procedures determined by claims
data and then adjusted for efficiencies of a single operative session
to facilitate incremental payment when two major procedures are
performed during the same hospital admission and urged CMS to solicit
further comment on possible methodological solutions to accommodate
costs when two procedures are performed concomitantly.
Response: We appreciate the commenters' feedback.
We refer readers to Tables 6P.1c and 6P1.d associated with this
final rule (which are available via the internet on the CMS website at:
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS) for the data analysis of cases reporting procedure
code combinations describing open concomitant surgical ablations in the
September 2021 update of the FY 2021 MedPAR file. Table 6P.1c
associated with this final rule sets forth the list of ICD-10-PCS
procedure codes reflecting mitral valve repair or replacement (MVR),
aortic valve repair or replacement (AVR), and coronary artery bypass
grafting (CABG) procedures that we examined in this analysis. Table
6P.1d associated with this final rule shows the data analysis findings
of cases reporting procedure code combinations describing open
concomitant surgical ablations assigned to MS-DRGs 216, 217, 218, 219,
220 and
[[Page 48847]]
221 from the September 2021 update of the FY 2021 MedPAR file.
As shown in Table 6P.1d associated with this final rule, while the
average lengths of stay and average costs of cases reporting procedure
code combinations describing open concomitant surgical ablations are
higher than all cases in their respective MS-DRG, we found there is
variation in the volume, length of stay, and average costs of the
cases. For MS-DRG 216, we found 870 cases reporting procedure code
combinations describing open concomitant surgical ablations with the
average length of stay ranging from 16.8 days to 20.5 days and average
costs ranging from $90,122 to $156,617 for these cases. For MS-DRG 217,
we found 168 cases reporting procedure code combinations describing
open concomitant surgical ablations with the average length of stay
ranging from 7.5 days to 12 days and average costs ranging from $48,644
to $74,594 for these cases. For MS-DRG 218, we found zero cases
reporting procedure code combinations describing open concomitant
surgical ablations. For MS-DRG 219, we found 1,940 cases reporting
procedure code combinations describing open concomitant surgical
ablations with the average length of stay ranging from 11.2 days to
13.4 days and average costs ranging from $70,816 to $86,805 for these
cases. For MS-DRG 220, we found 1,338 cases reporting procedure code
combinations describing open concomitant surgical ablations with the
average length of stay ranging from 7.1 days to 8.8 days and average
costs ranging from $49,326 to $65,611 for these cases. For MS-DRG 221,
we found 60 cases reporting procedure code combinations describing open
concomitant surgical ablations with the average length of stay ranging
from 5.6 days to 6.3 days and average costs ranging from $44,247 to
$47,418 for these cases.
As noted, and similar to our analysis of the data for the FY 2022
IPPS/LTCH PPS rulemaking, the data analysis shows that while the
average lengths of stay and average costs of cases reporting procedure
code combinations describing open concomitant surgical ablations are
higher than all cases in their respective MS-DRG, there is variation in
the volume, length of stay, and average costs of the cases. As we
discuss later in this section, the analysis also shows that the cases
reporting an open concomitant surgical ablation code combination are
predominately found in the higher (CC or MCC) severity level MS-DRGs of
their current base MS-DRG assignment. Moreover, as also previously
noted, the data from the September 2021 update of the FY 2021 MedPAR
file does not reflect our FY 2022 finalization. We continue to believe
that additional time is needed to allow for further analysis of the
claims data to reflect our FY 2022 finalization, and also to determine
to what extent the patient's co-morbid conditions or other factors may
be contributing to the increased length of stay and costs of this
subset of cases, as discussed previously.
In response to comments that urged CMS to assign cases reporting
procedure code combinations describing open concomitant surgical
ablations currently assigned to MS-DRGs 216, 217, 218, 219, 220 and 221
to MS-DRGs 216 and 217 only, MS-DRGs 216, 217 and 218 are defined by
the performance of cardiac catheterization. The performance of a
cardiac catherization procedure could be also contributing to the
increased average costs of cases reporting procedure code combinations
describing open concomitant surgical ablations currently assigned to
MS-DRGs 216, 217 and 218. Our clinical advisors have expressed concern
about the effect on clinical coherence of assigning cases reporting
procedure code combinations describing open concomitant surgical
ablations that do not also have a cardiac catherization procedure
reported to MS-DRGs that are defined by the performance of that
procedure.
We also note, as discussed in Section D.1.b of the proposed rule
and this final rule, using the September 2021 update of the FY 2021
MedPAR file, we analyzed how applying the NonCC subgroup criteria to
all MS-DRGs currently split into three severity levels would affect the
MS-DRG structure beginning in FY 2022. Similar to our findings
discussed in the FY 2022 IPPS/LTCH final rule, findings from our
analysis using the September 2021 update of the FY 2021 MedPAR file
indicated that MS-DRGs 216, 217, 218 as well as approximately 40 other
MS-DRGs would be subject to change based on the three-way severity
level split criterion finalized in FY 2021. While we are finalizing the
delay of the application of the NonCC subgroup criteria to existing MS-
DRGs with a three-way severity level split until FY 2024 or later, and
to maintain the current structure of the 41 MS-DRGs that currently have
a three-way severity level split (total of 123 MS-DRGs) that would
otherwise be subject to these criteria, we note that the total number
of cases in MS-DRG 218 is again below 500, and that we may consider
consolidating these MS-DRGs into two severity levels based on the
application of the NonCC subgroup criteria in future rule-making. We
refer the reader to Table 6P.1b associated with the proposed rule and
this final rule (which is available via the internet on the CMS website
at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS) for the list of the 123 MS-DRGs that would be
subject to deletion and the list of the 75 new MS-DRGs that would have
been proposed for creation under this policy if the NonCC subgroup
criteria were applied.
In response to comments that the finalized revision to the surgical
hierarchy did not adequately address the increased costs of cases
associated with open concomitant surgical ablation and that urged CMS
to create new MS-DRGs for these open concomitant procedures as
originally requested, our clinical advisors continue to believe
additional time is needed to review the clinical nature of cases
reporting an open concomitant surgical ablation code combination before
exploring a proposal to create new MS-DRGs for this subset of cases
currently assigned to MS-DRGs 216 through 221 given the complexity of
these code combinations and the corresponding data. Our analysis using
the September 2021 update of the FY 2021 MedPAR file reflects that the
cases reporting an open concomitant surgical ablation code combination
are predominately found in the higher (CC or MCC) severity level MS-
DRGs of their current base MS-DRG assignment, suggesting that the
patient's co-morbid conditions may also be contributing to higher costs
of these cases. Secondly, for the numerous procedure combinations that
would comprise an ``open concomitant surgical ablation'' procedure, the
increase in average costs appears to directly correlate with the number
of procedures performed. For example, cases that describe ``Open MVR +
open surgical ablation'' generally demonstrate costs that are lower
than cases that describe ``Open MVR + open AVR + open CABG + open
surgical ablation.'' Therefore, our clinical advisors continue to
believe that additional time is needed to allow for further analysis of
the claims data to determine to what extent the patient's co-morbid
conditions are also contributing to higher costs and to identify other
contributing factors that might exist with respect to the increased
length of stay and costs of these cases in these MS-DRGs. Our clinical
advisors continue to believe that future data findings may demonstrate
additional variance in resource utilization for this patient
population.
With respect to commenters' concerns regarding a mechanism for
[[Page 48848]]
differentiated payment when procedures are performed concomitantly, we
agree that the performance of concomitant procedures is an area that
warrants more analysis across the MS-DRG classification, as the
performance of ``concomitant procedures'' may affect the consumption of
resources in other clinical scenarios as well, especially when the use
of devices is involved. As discussed in prior rulemaking, the MS-DRGs
are a classification system intended to group together diagnoses and
procedures with similar clinical characteristics and utilization of
resources. It has been difficult to identify other MS-DRGs that would
be more appropriate MS-DRG assignments for these concomitant procedures
based on the variance in the clinical characteristics and utilization
of resources for concomitant procedures, which can depend on the number
of procedures being performed concomitantly and the nature of these
procedures. We are interested in receiving feedback on possible
mechanisms through which we can address concomitant procedures. We are
also interested in receiving feedback on how CMS can mitigate any
unintended negative payment impacts to providers providing concomitant
procedures. Commenters can continue to submit their recommendations via
the new electronic intake system, Medicare Electronic Application
Request Information SystemTM (MEARISTM) at:
https://mearis.cms.gov/public/home. We will consider these public
comments for possible proposals in future rulemaking as part of our
annual review process.
Comment: Some commenters noted that cases describing standalone
hybrid percutaneous endoscopic surgical ablation are assigned MS-DRGs
228 and 229 (Other Cardiothoracic Procedures with and without MCC,
respectively) and noted that payment for MS-DRGs 228 and 229 has been
trending downward over the last six years. These commenters stated that
the downward payment trend for MS-DRGs 228 and 229 has resulted in
hospitals being undercompensated for the costs of furnishing standalone
hybrid percutaneous endoscopic surgical ablation procedures for atrial
fibrillation. Other commenters stated that CMS did not provide
transparency to the details of its analysis to support why standalone
hybrid surgical ablation procedures should not be moved from MS-DRGs
228 and 229.
Some commenters stated that the decline in payment for standalone
hybrid percutaneous endoscopic surgical ablation procedures makes it
impossible for their facilities to continue to provide these needed
procedures to patients suffering from atrial fibrillation. A commenter
stated the proposed relative weight does not accurately reflect the
costs of these device intensive procedures and that there has been no
transparency into the cause for these significant declines. Another
commenter stated that their facility has been especially impacted by
COVID-19 and stated that for CMS to expect facilities to be able to
continue to provide patients with needed medical services such as
hybrid percutaneous endoscopic surgical ablation at such a steep
decrease in payment is intolerable for hospitals. Other commenters
asserted that hospitals will be forced to postpone or ``trim back'' on
providing patients access to more complex, resource intensive
procedures such as these, to better align their costs with what they
asserted were Medicare's inadequate payment levels. These commenters
proposed two possible remedies to this underpayment, that CMS either
(1) use its statutory authority to not reduce the relative weight and
payment for MS-DRGs 228 and 229, or (2) assign cases reporting
procedure codes describing standalone percutaneous endoscopic surgical
ablation from MS-DRGs 228 and 229 to the higher (MCC) severity level
MS-DRG of its current base MS-DRG assignment, which is MS-DRG 228
(Other Cardiothoracic Procedures with MCC), to prevent underpayment for
these procedures and avoid disruptions in beneficiary access.
Response: We appreciate the commenters' feedback. We note that we
did not receive a specific request to change the MS-DRG assignment for
standalone percutaneous endoscopic surgical ablation procedures for
consideration for the FY 2023 IPPS/LTCH PPS proposed rule. We note a
request to reassign cases describing standalone percutaneous endoscopic
surgical ablation from MS-DRGs 228 and 229 (Other Cardiothoracic
Procedures with and without MCC, respectively) to higher weighted MS-
DRGs 219 and 220 (Cardiac Valve and Other Major Cardiothoracic
Procedures without Cardiac Catheterization with MCC and with CC,
respectively) was discussed in the FY 2022 IPPS/LTCH PPS proposed rule.
In the FY 2022 IPPS/LTCH final rule, in response to comments received
on the proposed rule, we also discussed the assignment of cases
reporting procedure codes describing standalone percutaneous endoscopic
surgical ablation from MS-DRGs 228 and 229 to the higher (MCC) severity
level MS-DRG of its current base MS-DRG assignment in the FY 2022 IPPS/
LTCH PPS final rule. We refer readers to the FY 2022 IPPS/LTCH PPS
final rule (86 FR 44844 through 44848) for a complete discussion.
In the request to again review the MS-DRG assignment of surgical
ablation procedures in FY 2023 rulemaking, however, the requestor
stated in their submission that while surgical ablation represents
losses across all procedure types, they recommended focusing on
addressing open concomitant surgical ablation in FY 2023 rulemaking and
did not request a change to the MS-DRG assignment for standalone
percutaneous endoscopic surgical ablation. Therefore, cases describing
standalone percutaneous endoscopic surgical ablation were not
considered in the FY 2023 IPPS/LTCH PPS proposed rule.
In response to the comment that hospitals may postpone or ``trim
back'' on providing patients access to these procedures in order to
better align their costs with Medicare payment levels, as we have
stated in prior rulemaking, it is not appropriate for facilities to
deny treatment to beneficiaries needing a specific type of therapy or
treatment that potentially involves increased costs.
We acknowledge the reduction in the proposed FY 2023 relative
weights for MS-DRGs 228 and 229 (approximately 7% and 4%, respectively
from the FY 2022 relative weight), however, we note we did not propose
a change to the GROUPER logic of MS-DRGs 228 and 229 for FY 2023.
However, there have been previous changes to the structure of MS-DRGs
228 and 229 over the past six years. It is to be expected that when MS-
DRGs are restructured, such as when procedure codes are reassigned or
the hierarchy within an MDC is revised, resulting in a different case-
mix within the MS-DRGs, the relative weights of the MS-DRGs will change
as a result. We believe the trending reduction in relative weights for
MS-DRGs 228 and 229 over time to be appropriately driven by the
underlying data in the six years since CMS began using the ICD-10 data
in calculating the relative weights and is reflective of the change in
case-mix within these MS-DRGs. Specifically, in the FY 2017 IPPS/LTCH
PPS final rule (81 FR 56809 through 56813), we finalized our proposal
to collapse MS-DRGs 228, 229, and 230 from three severity levels to two
severity levels by deleting MS-DRG 230 and revised the structure of MS-
DRG 229. We also finalized our proposal to reassign ICD-9-CM procedure
code 35.97 and the cases reporting ICD-10-PCS procedure
[[Page 48849]]
code 02UG3JZ (Supplement mitral valve with synthetic substitute,
percutaneous approach) from MS-DRGs 273 and 274 to MS-DRG 228 and
revised the titles of MS-DRG 228 and 229. In the FY 2020 IPPS/LTCH PPS
final rule (84 FR 42080 through 56813) we finalized our proposal to
modify the structure of MS-DRGs 266 and 267 by reassigning ICD-10-PCS
procedure code 02UG3JZ describing a transcatheter mitral valve repair
with implant procedure from MS-DRGs 228 and 229 to MS-DRGs 266 and 267
and revised the titles of MS-DRGs 266 and 267. Finally, as discussed in
the FY 2022 IPPS/LTCH PPS final rule, and earlier in this section, we
finalized a revision to the surgical hierarchy for the MS-DRGs in MDC
05 to sequence MS-DRGs 231-236 (Coronary Bypass) above MS-DRGs 228 and
229 for FY 2022. Therefore, the data appear to reflect that the
difference in the relative weights shown in Table 5-List of Medicare
Severity Diagnosis Related Groups (MS-DRGs), Relative Weighting
Factors, and Geometric and Arithmetic Mean Length of Stay associated
with final rule for the applicable fiscal year can be attributed to the
fact that these previously finalized policies resulted in a different
case-mix within the MS-DRGs, which is then being reflected in the
relative weights. We refer the reader to section II.E. of the preamble
of this FY 2023 IPPS/LTCH PPS final rule for a complete discussion of
the relative weight calculations for FY 2023, including our finalized
policies to use 50 percent of the relative weights calculated using all
cases in the FY 2021 MedPAR data and 50 percent of the relative weights
calculated without COVID-19 cases in the FY 2021 MedPAR data to
calculate the relative weights for FY 2023, and to apply a permanent
10-percent cap on the reduction in a MS-DRG's relative weight in a
given fiscal year, beginning in FY 2023.
We appreciate the commenters' support and feedback, and intend to
continue to consider these issues. For the reasons summarized earlier,
and after consideration of the public comments we received, we are not
making any MS-DRG changes for cases involving the open concomitant
surgical ablation procedures or for cases describing standalone
percutaneous endoscopic surgical ablation for FY 2023.
7. MDC 06 (Diseases and Disorders of the Digestive System):
Appendicitis
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28163 through
28165), we discussed a request we received to reconsider the MS-DRG
assignment for diagnosis code K35.20 (Acute appendicitis with
generalized peritonitis, without abscess). According to the requestor,
when this code is reported in combination with any one of the
corresponding procedure codes that describe an appendectomy, the case
is grouping to MS-DRGs 341, 342, and 343 (Appendectomy without
Complicated Principal Diagnosis with MCC, with CC, and without CC/MCC,
respectively). Alternatively, the requestor stated that when diagnosis
code K35.32 (Acute appendicitis with perforation and localized
peritonitis, without abscess) is reported in combination with any one
of the corresponding procedure codes that describe an appendectomy, the
case is grouping to MS-DRGs 338, 339, and 340 (Appendectomy with
Complicated Principal Diagnosis with MCC, with CC, and without CC/MCC,
respectively).
The requestor asserted that the difference in MS-DRG assignment
suggests that localized peritonitis is more severe or requires an
additional level of care over and above that for generalized
peritonitis. The requestor stated that clinically, both localized and
generalized peritonitis, when treated with an appendectomy require the
same level of patient care, including extensive intraoperative
irrigation at the surgical site, direct inspection or imaging of the
abdomen to look for possible abscess, use of intravenous antibiotics,
and prolonged inpatient monitoring. The requestor added that
generalized peritonitis can be thought of as a progression of the
localized peritonitis condition and that patients progress from
localized to generalized peritonitis and not vice versa.
In the proposed rule we noted that this topic has been discussed
previously in our FY 2019 (83 FR 41230) and FY 2021 rulemakings (85 FR
32500 through 32503) and (85 FR 58484 through 58488). Effective FY 2019
(October 1, 2018) diagnosis code K35.2 (Acute appendicitis with
generalized peritonitis) was expanded to K35.20 (Acute appendicitis
with generalized peritonitis, without abscess); and K35.21 (Acute
appendicitis with generalized peritonitis, with abscess). In addition,
code K35.3 (Acute appendicitis with localized peritonitis) was expanded
to K35.30 (Acute appendicitis with localized peritonitis, without
perforation or gangrene); K35.31 (Acute appendicitis with localized
peritonitis and gangrene, without perforation); K35.32 (Acute
appendicitis with perforation and localized peritonitis, without
abscess); and K35.33 (Acute appendicitis with perforation and localized
peritonitis, with abscess).
We finalized the severity level designations for these new
diagnosis codes in the FY 2019 IPPS/LTCH PPS final rule and stated our
clinical advisors believed that the new diagnosis codes for acute
appendicitis described as ``with abscess'' or ``with perforation'' were
clinically qualified for the MCC severity level designation, while
acute appendicitis ``without abscess'' or ``without perforation'' were
clinically qualified for the CC severity level designation because
cases with abscess or perforation would be expected to require more
clinical resources and time to treat while those cases ``without
abscess'' or ``without perforation'' are not as severe clinical
conditions.
As discussed in our FY 2021 rulemaking, we received the request to
add K35.20 (Acute appendicitis with generalized peritonitis, without
abscess) to the list of complicated principal diagnoses so that all
ruptured/perforated appendicitis codes in MDC 06 group to MS-DRGs 338,
339, and 340 (Appendectomy with Complicated Principal Diagnosis with
MCC, with CC, and without CC/MCC, respectively) as K35.20 is the only
ruptured appendicitis code not included in the list of complicated
principal diagnosis codes. At that time, we noted that the inclusion
term at subcategory K35.2 (Acute appendicitis with generalized
peritonitis) is: ``Appendicitis (acute) with generalized (diffuse)
peritonitis following rupture or perforation of the appendix''. The
requestor stated that code K35.20 (Acute appendicitis with generalized
peritonitis, without abscess) describes a generalized, more extensive
form of peritonitis than code K35.32 (Acute appendicitis with
perforation and localized peritonitis, without abscess). We noted that
our clinical advisors agreed that the presence of an abscess would
clinically determine whether a diagnosis of acute appendicitis would be
considered a complicated principal diagnosis. As diagnosis code K35.20
is described as ``without'' an abscess, our clinical advisors
recommended that K35.20 not be added to the list of complicated
principal diagnoses for MS-DRGS 338, 339, and 340. We also proposed to
remove diagnosis code K35.32 (Acute appendicitis with perforation and
localized peritonitis, without abscess) from the complicated principal
diagnosis list.
In response to that proposal, some commenters disagreed. A
commenter stated that when ruptured appendicitis results in generalized
peritonitis, resources are greater because the
[[Page 48850]]
infection is not walled off, not localized, and has spread to two or
more compartments within the abdominal cavity. According to the
commenter, clinical literature supports the statement that generalized
peritonitis is a more morbid (severe) presentation than just
perforation or localized abscess. After consideration of the comments
received and for the reasons discussed in the FY 2021 final rule, we
did not finalize our proposals in that final rule. We concurred that
the expansion of diagnosis codes K35.2 and K35.3 to introduce
additional clinical concepts effective October 1, 2018 significantly
changed the scope and complexity of the diagnosis codes for this subset
of patients. We also stated NCHS' staff acknowledged the clinical
concerns based on the manner in which diagnosis codes K35.2 and K35.3
were expanded and confirmed that they would consider further review of
these newly expanded codes with respect to the clinical concepts.
We communicated with the CDC/NCHS staff regarding this repeat
request submitted for FY 2023 consideration. The CDC/NCHS staff
included these codes describing appendicitis on the agenda and a
proposal for further revisions was presented for discussion at the
March 8-9, 2022 ICD-10 Coordination and Maintenance Committee meeting.
Specifically, the CDC/NCHS staff proposed to expand current diagnosis
codes K35.20 and K35.21, making them sub-subcategories and creating new
diagnosis codes to identify and describe acute appendicitis with
generalized peritonitis, with perforation and without perforation, and
unspecified as to perforation, as shown in the following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.040
We refer the reader to the CDC website at: https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm for additional detailed information
regarding the proposal, including a recording of the discussion and the
related meeting materials.
We noted in the proposed rule that the deadline for submitting
public comments on the diagnosis code proposals discussed at the March
8-9, 2022 ICD-10 Coordination and Maintenance Committee meeting was May
9, 2022 and according to the CDC/NCHS staff, the diagnosis code
proposals are being considered for an October 1, 2023 implementation
(FY 2024). We stated that any future proposed changes to the MS-DRGs
for Appendectomy would be dependent on the diagnosis code revisions
that are finalized by the CDC/NCHS. Since it is not clear what code
changes may be finalized, including whether public comments expressed
support for the proposed changes or provided alternative options for
consideration, we stated in the proposed rule that we believe it is
appropriate to delay any possible MS-DRG modifications for future
rulemaking. Therefore, we did not propose a change to the MS-DRG
assignment or the current structure for MS-DRGs 338, 339, 340, 341,
342, and 343. Although we did not propose a change to the MS-DRG
assignments for FY 2023, we made the findings from our data analysis
available for the listed MS-DRGs and the associated diagnosis codes to
help inform future comments. We referred the reader to Table 6P.4a
associated with the proposed rule (which is available via the internet
on the CMS website at: https://www.cms.gov/medicare/medicare-fee-for-
service-payment/acuteinpatientpps).
Comment: Commenters agreed with our proposal to maintain the
structure of MS-DRGs 338, 339, 340, 341, 342, and 343 including the MS-
DRG assignment for diagnosis code K35.20 to MS-DRGs 341, 342, and 343.
However, a commenter opposed CMS's proposal and stated they agreed with
the requestor that all diagnosis codes describing a ruptured or
perforated appendix should group to MS-DRGs 338, 339, and 340. The
commenter stated that the condition described by code K35.20 can be
associated with the risk of postoperative abscess formation and
extended length of hospital stay, thereby warranting classification as
a complicated diagnosis. This commenter urged CMS to reassign code
K35.20 from MS-DRGs 341, 342, and 343 to MS-DRGs 338, 339, and 340 for
FY 2023.
Response: We thank the commenters for their support and feedback.
In response to the commenter who urged CMS to reassign diagnosis code
K35.20 from MS-DRGs 341, 342, and 343 to MS-DRGs 338, 339, and 340 for
FY 2023, we note that the CDC/NCHS staff are in the process of
reviewing public comments related to the proposed revision to certain
diagnosis codes describing acute appendicitis that was presented at the
March 8-9, 2022 ICD-10 Coordination and Maintenance Committee meeting,
as discussed in the proposed rule. Accordingly, we continue to believe
it is appropriate to delay any potential MS-DRG modifications as we do
not yet know what the finalized code updates, including any
corresponding changes to the Index to Diseases and Injuries and Tabular
List of Diseases, might be. We will continue to collaborate with the
CDC/NCHS regarding this issue.
After consideration of the public comments we received, we are
maintaining the current structure of MS-DRGs 338, 339, 340, 341, 342,
and 343 and the MS-DRG assignment of diagnosis code K35.20 for FY 2023.
8. MDC 07 (Diseases and Disorders of the Hepatobiliary System and
Pancreas): Laparoscopic Cholecystectomy With Common Bile Duct
Exploration
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28165), we stated
that we received a request to review the MS-DRG assignment when
procedure code 0FC94ZZ (Extirpation of matter from common bile duct,
percutaneous endoscopic approach) that describes a common bile duct
exploration with gallstone removal procedure using a laparoscopic
approach, is reported with a laparoscopic cholecystectomy. The
procedure codes describing a laparoscopic cholecystectomy are
[[Page 48851]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.041
According to the requestor, when a laparoscopic cholecystectomy is
reported with any one of the listed procedure codes with a common bile
duct exploration and gallstone removal procedure that is performed
laparoscopically and reported with procedure code 0FC94ZZ, the
resulting assignment is MS-DRGs 417, 418 and 419 (Laparoscopic
Cholecystectomy without C.D.E. with MCC, with CC, and without CC/MCC,
respectively). This MS-DRG assignment does not recognize that a common
bile duct exploration (C.D.E.) was performed. However, the requestor
stated that when procedure code 0FC90ZZ (Extirpation of matter from
common bile duct, open approach) that describes a common bile duct
exploration with gallstone removal procedure using an open approach is
reported with any one of the listed procedure codes describing a
laparoscopic cholecystectomy, the resulting assignment is MS-DRGs 411,
412, and 413 (Cholecystectomy with C.D.E. with MCC, with CC, and
without CC/MCC, respectively). The requestor stated that this MS-DRG
assignment appropriately recognizes that a common bile duct exploration
was performed. The requestor questioned why only the common bile duct
exploration with gallstone removal procedure performed using an open
approach (code 0FC90ZZ) grouped appropriately when reported with the
laparoscopic cholecystectomy.
We stated in the proposed rule that we reviewed procedure code
0FC94ZZ and found that it is currently designated as a non-O.R.
procedure, therefore, the GROUPER logic does not recognize this
procedure for purposes of MS-DRG assignment. We also noted that MS-DRGs
411, 412, and 413 include cholecystectomy procedures performed by
either an open or a percutaneous endoscopic (laparoscopic) approach. We
referred the reader to the V39.1 ICD-10 MS-DRG Definitions Manual,
which is available via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software for complete
documentation of the GROUPER logic for MS-DRGs 411, 412, 413, 417, 418
and 419.
As stated in the proposed rule, we analyzed claims data from the
September 2021 update of the FY 2021 MedPAR file for all cases in MS-
DRGs 411, 412, 413, 417, 418, and 419. Because the logic for MS-DRGs
411, 412, and 413 includes cholecystectomy procedures performed by
either an open or percutaneous endoscopic (laparoscopic) approach, we
also analyzed the cases reported with each approach separately. The
findings from our analysis are shown in the following tables.
[GRAPHIC] [TIFF OMITTED] TR10AU22.042
[GRAPHIC] [TIFF OMITTED] TR10AU22.043
[[Page 48852]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.044
In MS-DRG 411, we found a total of 116 cases with an average length
of stay of 8.5 days and average costs of $29,332. Of those 116 cases,
there were 56 cases reporting an open cholecystectomy, with an average
length of stay of 10.7 days and average costs of $36,135 and 60 cases
reporting a laparoscopic cholecystectomy, with an average length of
stay of 6.5 days and average costs of $22,982. The data show that the
cases reporting an open cholecystectomy have a longer average length of
stay (10.7 days versus 6.5 days) and higher average costs ($36,135
versus $22,982) compared to the cases reporting a laparoscopic
cholecystectomy. The data also show that the cases reporting an open
cholecystectomy have a longer average length of stay (10.7 days versus
8.5 days) and higher average costs ($36,135 versus $29,332) compared to
all the cases in MS-DRG 411. Similar findings are demonstrated for MS-
DRGs 412 and 413, where the data show that the cases reporting an open
cholecystectomy have a longer average length of stay and higher average
costs compared to the cases reporting a laparoscopic cholecystectomy,
and also, when compared to all the cases in their respective MS-DRGs.
We then analyzed claims data from the September 2021 update of the
FY 2021 MedPAR file for cases reporting procedure code 0FC94ZZ in MS-
DRGs 417, 418, and 419 to assess how often it was reported. The
findings from our analysis are shown in the following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.045
We found a total of 231 cases across MS-DRGs 417, 418, and 419 with
an average length of stay of 4.6 days and average costs of $15,348
reporting procedure code 0FC94ZZ. In our review of the cases reporting
a laparoscopic cholecystectomy across MS-DRGs 411, 412, and 413, we
found a total of 178 cases with an average length of stay of 5.3 days
and average costs of $18,206.
We also examined claims data from the September 2021 update of the
FY 2021 MedPAR file for cases reporting procedure code 0FC94ZZ across
all the MS-DRGs without another O.R. procedure reported, to assess the
number of cases and in which MS-DRGs procedure code 0FC94ZZ was found.
The findings from our analysis are shown in the following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.046
[[Page 48853]]
The data analysis shows procedure code 0FC94ZZ was reported in a
total of 32 cases across 7 MS-DRGs with an average length of stay of
5.9 days and average costs of $16,087. While procedure code 0FC94ZZ is
designated as non-O.R., we also analyzed the average length of stay and
average costs of the cases found within each of the 7 MS-DRGs reporting
procedure code 0FC94ZZ against all the cases in their respective MS-
DRGs, to determine if there was any indication that the performance of
the procedure described by procedure code 0FC94ZZ may have had any
impact. For instance, as shown in the table, for MS-DRG 438 we found 2
cases reporting procedure code 0FC94ZZ with an average length of stay
of 14 days and average costs of $26,092. In the September 2021 update
of the FY 2021 MedPAR file, the total number of cases for MS-DRG 438 is
10,240 with an average length of stay of 6.4 days and average costs of
$13,341. The 2 cases reporting procedure code 0FC94ZZ have
approximately twice the average length of stay (14 days versus 6.4
days) and approximately twice the average costs ($26,092 versus
$13,341) compared to all the cases for MS-DRG 438. In the absence of
additional analysis, it is unknown if these differences can be
attributed to other factors, such as the MCCs that were reported in
these cases. Similar findings were found for MS-DRGs 441, 445, 446, and
871. We noted in the proposed rule that we will consider if further
detailed analysis may be warranted for these cases.
As stated in the proposed rule, our clinical advisors agreed that
procedure code 0FC94ZZ describes a common bile duct exploration
procedure with removal of a gallstone and should be added to the logic
for case assignment to MS-DRGs 411, 412, and 413 for clinical coherence
with the other procedures that describe a common bile duct exploration.
Therefore, for FY 2023, we proposed to redesignate procedure code
0FC94ZZ from a non-O.R. procedure to an O.R. procedure and add it to
the logic list for common bile duct exploration (CDE) in MS-DRGs 411,
412, and 413 (Cholecystectomy with C.D.E. with MCC, with CC, and
without CC/MCC, respectively) in MDC 07 to appropriately reflect when
this procedure is performed and improve the clinical coherence of the
patients assigned to these MS-DRGs.
Comment: Commenters agreed with our proposal to redesignate
procedure code 0FC94ZZ from a non-O.R. procedure to an O.R. procedure
and to add it to the logic list for common bile duct exploration (CDE)
procedures in MS-DRGs 411, 412, and 413.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to redesignate procedure code 0FC94ZZ from a
non-O.R. procedure to an O.R. procedure and to add it to the logic list
for common bile duct exploration (CDE) procedures in MS-DRGs 411, 412,
and 413 for FY 2023.
In addition, we noted in the proposed rule that MS-DRGs 414, 415,
and 416 (Cholecystectomy Except by Laparoscope without C.D.E. with MCC,
with CC and without CC/MCC, respectively) also reflect cholecystectomy
procedures, however, the logic is specifically defined for open
cholecystectomy procedures without a common bile duct exploration
procedure performed. Since MS-DRGs 411, 412, and 413 reflect cases
where an open or laparoscopic cholecystectomy is performed with a
common bile duct exploration procedure, MS-DRGs 414, 415, and 416
reflect cases where only an open cholecystectomy is performed without a
common bile duct exploration procedure, and MS-DRGs 417, 418, and 419
reflect cases where only a laparoscopic cholecystectomy is performed
without a common bile duct exploration procedure, we stated we believe
there may be an opportunity to further refine these MS-DRGs once
additional analysis is performed for consideration in future
rulemaking. For example, we indicated we could consider proposing to
restructure these cholecystectomy MS-DRGs to reflect the following two
concepts, if supported by the data, and relatedly, to determine if
severity levels are also supported according to the existing criteria.
Open Cholecystectomy with or without C.D.E.; and
Laparoscopic Cholecystectomy with or without C.D.E.
Comment: Commenters agreed that there may be an opportunity to
further refine the MS-DRGs for cholecystectomy procedures and
encouraged CMS to conduct further review and analysis of the procedure
codes describing cholecystectomy with common bile duct exploration for
consideration in future rulemaking.
Response: We thank the commenters for their support and continue to
solicit any additional feedback from the public on this and any
alternative recommendations or options to further refine these MS-DRGs
for future consideration. As discussed in section II.D.1.b. of the
preamble of the proposed rule and this final rule, feedback and other
suggestions should be directed to the new electronic intake system,
Medicare Electronic Application Request Information SystemTM
(MEARISTM) at: https://mearis.cms.gov/public/home, with any
comments and suggestions for consideration for FY 2024 to be submitted
by October 20, 2022.
9. MDC 10 (Diseases and Disorders of the Endocrine System): Eladocagene
Exuparvovec Gene Therapy
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44895), we finalized
the redesignation of code XW0Q316 (Introduction of eladocagene
exuparvovec into cranial cavity and brain, percutaneous approach, new
technology group 6) from a Non-O.R. procedure to an O.R. procedure,
assigned to MS-DRGs 628, 629, and 630 (Other Endocrine, Nutritional and
Metabolic O.R. Procedures with MCC, with CC, and without CC/MCC,
respectively) in MDC 10 (Endocrine, Nutritional and Metabolic Diseases
and Disorders) and to MS-DRGs 987, 988, and 989 (Non-Extensive O.R.
Procedure Unrelated to Principal Diagnosis with MCC, with CC and
without MCC/CC, respectively). In the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28167 through 28168) we discussed a request we received to
reconsider this assignment for FY 2023. According to the requestor, the
clinical characteristics and costs of cases assigned to MS-DRGs 628
through 630 are significantly different from those associated with the
administration of eladocagene exuparvovec. The requestor performed its
own analysis, using deep brain stimulation for epilepsy and selective
dorsal rhizotomy for cerebral palsy as proxies, and stated that based
on its findings for the initial cost analysis and clinical comparison,
that MS-DRG 23 (Craniotomy with Major Device Implant or Acute Complex
CNS Principal Diagnosis with MCC or Chemotherapy Implant or Epilepsy
with Neurostimulator), MS-DRG 24 (Craniotomy with Major Device Implant
or Acute Complex CNS Principal Diagnosis without MCC) and MS-DRGs 25,
26, and 27 (Craniotomy and Endovascular Intracranial Procedures with
MCC, with CC, and without CC/MCC, respectively) may be more
appropriate. However, the requestor also stated that while the clinical
aspects of eladocagene exuparvovec cases are similar to those of MS-
DRGs 23 through 27, the costs are much higher and neither MS-DRGs 628,
629, 630 or MS-DRGs 23 through 27 are appropriate. Therefore, the
requestor stated its belief
[[Page 48854]]
that assigning eladocagene exuparvovec cases to new MS-DRGs is
warranted.
Eladocagene exuparvovec is a gene therapy for the treatment of
patients with aromatic L-amino acid decarboxylase (AADC) deficiency, a
rare genetic and fatal condition identified with ICD-10-CM diagnosis
code E70.81. Patients with AADC deficiency are generally observed to
have onset of symptoms in the first year of life, most notably
hypotonia (muscle weakness), followed by movement disorders,
developmental delay and autonomic signs, such as hyperhidrosis (profuse
sweating unrelated to heat or exercise). It is understood that the
long-term implications of this disease are severe, resulting in severe
deficits and limitations in life expectancy. Because the condition is
primarily diagnosed in the pediatric population, we would not expect to
find any meaningful volume of cases in the MedPAR data.
As discussed in the proposed rule, we analyzed claims data from the
September 2021 update of the FY 2021 MedPAR file for MS-DRGs 628, 629,
and 630 for cases reporting procedure code XW0Q316 and did not find any
cases. We then extended our analysis to all MS-DRGs and found 1 case
reporting the administration of this therapy in MS-DRG 829
(Myeloproliferative Disorders or Poorly Differentiated Neoplasms with
Other Procedures with CC/MCC) with an average length of stay of 2 days
and average costs of $1,544. As we have discussed elsewhere we
generally prefer not to create a new MS-DRG unless it would include a
substantial number of cases. However, as discussed in section
II.D.19.b. of the preamble of the proposed rule and this final rule, we
are seeking public comment on possible mechanisms through which we can
address rare diseases and conditions that are represented by low
volumes in our claims data. We believe this topic, relating to the
administration of treatment to address the rare genetic and fatal
condition of AADC deficiency, is appropriately aligned with and should
be considered as part of that effort. Therefore, we stated in the
proposed rule that we are maintaining the current structure for MS-DRGs
628, 629, and 630 for FY 2023, but would continue to consider this
request in connection with our evaluation of possible mechanisms to
address rare diseases and conditions in the MS-DRG structure, as
discussed later in this rule.
Comment: Commenters agreed with our decision to maintain the
current MS-DRG assignment for cases reporting the administration of
eladocagene exuparvovec. Other commenters urged CMS to consider
appropriate MS-DRG assignment and payment for gene therapy
intracerebral infusion therapies. The commenters stated there is
anticipated rapid development and potential for these therapies to help
patients. The commenters also expressed appreciation for CMS' request
for feedback on MS-DRG assignment for rare diseases and stated that
gene therapy represents an area of significant innovation in treating
these conditions. The commenters suggested that CMS carefully consider
the MS-DRG assignment for procedures that involve an intracerebral
infusion of gene therapy or stem cell products that are currently under
development for several neurologic disorders including Parkinson's,
which is very common, and aromatic L-amino acid decarboxylase
deficiency, which is very rare. The commenters stated that
intracerebral infusion therapies are unique procedures requiring vastly
different hospital resources compared to more traditional neurosurgical
procedures. According to the commenters, appropriate MS-DRG assignment
or consideration for creating new MS-DRG categories will be essential
to assuring access to these therapies.
Response: We appreciate the commenters' support and feedback.
Comment: A couple commenters disagreed with CMS's decision to
maintain the current MS-DRG assignment for cases reporting the
administration of eladocagene exuparvovec. The commenters requested
that CMS consider creating a new MS-DRG for neurosurgical gene therapy.
A commenter indicated that because eladocagene exuparvovec has not yet
been approved by the FDA they are unable to appropriately identify
cases in the claims data. This commenter stated that there are
currently approximately 68 gene therapy trials for central nervous
system disorders, therefore, the decision to create or not create a new
MS-DRG may have broader implications.
Response: We appreciate the commenters' feedback. As discussed in
the proposed rule, our analysis of claims data, which identified only
one case reporting the administration of this therapy, did not support
a proposal to create a new MS-DRG. The MS-DRGs are a classification
system intended to group together those diagnoses and procedures with
similar clinical characteristics and utilization of resources. As
discussed previously and in prior rulemaking, we generally prefer not
to create a new MS-DRG unless it would include a substantial number of
cases, as having large clinical cohesive groups within an MS-DRG
provides greater stability for annual updates to the relative payment
weights. We acknowledge the complexities related to classifying cases
that are represented by low volumes in our claims data and believe that
further review of this issue also aligns with our intent to consider
how rare diseases or conditions may be classified under the IPPS.
After consideration of the public comments we received, we are
maintaining the current MS-DRG assignment for cases reporting the
administration of eladocagene exuparvovec for FY 2023. We will continue
to explore appropriate mechanisms to address therapies indicated for
rare diseases. We also refer the reader to section II.D.19.a of the
preamble of this final rule for a discussion of the feedback received
in response to the comment solicitation on possible mechanisms to
address rare diseases and conditions in the MS-DRG structure.
10. MDC 15 Newborns and Other Neonates With Conditions Originating in
Perinatal Period: MS-DRG 795 Normal Newborn
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28168 through
28170), we discussed a request we received to review the MS-DRG
assignment of newborn encounters with diagnosis codes describing
contact with and (suspected) exposure to COVID-19 when the condition is
ruled out after clinical evaluation and negative workup. The requestor
expressed concern that a newborn encounter coded with a principal
diagnosis code from category Z38 (Liveborn infants according to place
of birth and type of delivery), followed by codes Z05.1 (Observation
and evaluation of newborn for suspected infectious condition ruled out)
and Z20.822 (Contact with and (suspected) exposure to COVID-19) is
assigned to MS-DRG 794 (Neonate with Other Significant Problems). The
requestor stated that this assignment appears to be in error and that
the assignment should instead be to MS-DRG 795 (Normal Newborn).
In the proposed rule we stated that our analysis of this grouping
issue confirmed that, when a principal diagnosis code from category Z38
(Liveborn infants according to place of birth and type of delivery),
followed by codes Z05.1 (Observation and evaluation of newborn for
suspected infectious condition ruled out) and Z20.822 (Contact with and
(suspected) exposure to COVID-19), the case is assigned to MS-DRG 794.
[[Page 48855]]
We stated that as we examined the GROUPER logic that would
determine an assignment of cases to MS-DRG 795, we noted the ``only
secondary diagnosis'' list under MS-DRG 795 includes the following five
ICD-10-CM diagnosis codes from ICD-10-CM category Z20. We refer the
reader to the ICD-10 MS-DRG Version 39.1 Definitions Manual (which is
available via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software for complete documentation of the GROUPER
logic for the MS-DRG 795.
[GRAPHIC] [TIFF OMITTED] TR10AU22.047
As discussed in the proposed rule, in reviewing the ICD-10-CM
diagnosis code classification and the GROUPER logic list, we noted that
the 13 ICD-10-CM diagnosis codes, also from category Z20, listed in the
following table were inadvertently omitted from the ``only secondary
diagnosis'' list under MS-DRG 795.
[GRAPHIC] [TIFF OMITTED] TR10AU22.048
We reviewed section I.C.21.c.1 of the 2022 ICD-10-CM Official
Guidelines for Coding and Reporting which state ``category Z20
indicates contact with, and suspected exposure to, communicable
diseases. These codes are for patients who are suspected to have been
exposed to a disease by close personal contact with an infected
individual or are in an area where a disease is epidemic . . . Contact/
exposure codes may be used as a first-listed code to explain an
encounter for testing, or, more commonly, as a secondary code to
identify a potential risk.'' Per the Excludes1 note at category Z20,
when applicable, diagnoses of current infectious or parasitic disease
are coded instead of codes from category Z20.
We stated in the proposed rule that our clinical advisors reviewed
this issue and agreed that patients exposed to communicable diseases
that are worked up or treated prophylactically or both, and for whom
those conditions are later determined after study to not be present,
are distinct from patients with identified signs or symptoms of a
suspected problem or diagnosed with having that communicable disease.
Our clinical advisors supported adding the 13 diagnosis codes listed
previously to the logic of MS-DRG 795 for clinical consistency with the
five other diagnosis codes describing contact with, and suspected
exposure to, communicable diseases currently assigned to the ``only
secondary diagnosis'' list under MS-DRG 795.
After review of the coding guidelines and conventions, and
discussion with our clinical advisors, we stated that we agreed with
the requestor that in these circumstances, these encounters should not
map to MS-DRG 794 (Neonate with Other Significant Problems) and should
instead be assigned to MS-DRG 795 (Normal Newborn). Therefore, we
proposed to add the 13 diagnosis codes listed previously that describe
contact with and (suspected) exposure to communicable diseases to the
``only secondary diagnosis'' list under MS-DRG 795 (Normal Newborn).
Under this proposal, cases with a principal diagnosis described by an
ICD-10-CM code from category Z38 (Liveborn infants according to place
of birth and type of delivery), following by codes Z05.1 (Observation
and evaluation of newborn for suspected infectious condition ruled out)
and Z20.822 (Contact with and (suspected) exposure to COVID-19) will be
assigned to MS-DRG 795.
Comment: Commenters expressed support for CMS' proposal to add the
13 diagnosis codes listed previously that describe contact with and
(suspected) exposure to communicable diseases to the ``only secondary
diagnosis'' list under MS-DRG 795 (Normal Newborn).
Response: We appreciate the commenters' support.
[[Page 48856]]
Comment: A few commenters opposed CMS's proposal and stated that
newborns exposed to communicable diseases often require care and
treatment well above that of a normal newborn in terms of requiring
increased evaluation, monitoring, testing, and prophylactic treatment.
Some commenters stated that these newborns are not ``normal newborns''
due to the specific exposures they have had. These commenters listed a
number of communicable diseases as examples and indicated the specific
interventions such as evaluations, screenings, assessments, extra
monitoring, laboratory studies, prophylactic treatments and sometimes
isolation that can be required to prevent disease or complications when
contact or (suspected) exposure occurs. Another commenter noted that
there is a substantial difference in the FY 2023 proposed relative
weights between MS-DRG 795 and MSDRG 794 and stated that ``exposure
only'' cases fall in between the two MS-DRGs in terms of resource
utilization. This commenter stated that a review of the cases at their
facility shows that cases assigned to MS-DRG 794 with only a diagnosis
code describing contact with and (suspected) exposure to communicable
diseases driving the MS-DRG assignment had longer lengths of stay and
higher charges than cases assigned to MS-DRG 795, while having shorter
lengths of stay and lower charges than other cases assigned to MS-DRG
794 with diagnoses describing conditions other than contact with and
(suspected) exposure driving the MS-DRG assignment. This commenter also
stated that they believed that the five ICD-10-CM diagnosis codes from
ICD-10-CM category Z20 currently listed in the ``only secondary
diagnosis'' list under MS-DRG 795 are currently inappropriately
included and requested that either the 13 codes for contact with and
(suspected) exposure remain assigned to MS-DRG 794 and the five codes
currently in MS-DRG 795 be reassigned to MS-DRG 794 or a new MS-DRG be
created that would include newborns that fall into the ``exposure
only'' category, with a relative weight that falls somewhere between
the relative weights of MS-DRG 794 and 795 to accurately capture
resource utilization.
Response: We thank the commenters for their feedback. Our clinical
advisors reviewed the commenters' concerns. While our clinical advisors
agree that patients exposed to communicable diseases can require workup
or prophylactic treatment, they continue to state these patients are
distinct from patients with identified signs or symptoms of a suspected
problem or diagnosed with having that communicable disease. Our
clinical advisors noted that the subset of newborns with a principal or
secondary diagnosis listed in the logic list for MS-DRG 794 (Neonate
with Other Significant Problems) are clinically distinct and often
represent a more severe set of patients. Accordingly, our clinical
advisors continue to believe that the five other diagnosis codes
describing contact with, and suspected exposure to, communicable
diseases are appropriately assigned to the ``only secondary diagnosis''
list under MS-DRG 795, and also continue to support adding the 13
diagnosis codes listed previously to the logic of MS-DRG 795 for
clinical consistency. We appreciate the commenters' feedback suggesting
further review of the newborn MS-DRGs and agree that these groupings
warrant special consideration. As discussed in prior rulemaking, we
generally do not adopt the same approach to refine the maternity and
newborn MS-DRGs because of the extremely low volume of Medicare
patients there are in these DRGs.
After consideration of the public comments we received, and for the
reasons discussed, we are finalizing our proposal to add the 13
diagnosis codes listed previously that describe contact with and
(suspected) exposure to communicable diseases to the ``only secondary
diagnosis'' list under MS-DRG 795 (Normal Newborn), without
modification, for FY 2023.
In addition, as discussed in the proposed rule, as we examined the
GROUPER logic that would determine an assignment of cases to MS-DRGs in
MDC 15, we noted the logic for MS-DRG 790 (Extreme Immaturity or
Respiratory Distress Syndrome Neonate) includes ICD-10-CM diagnosis
codes that describe extremely low birth weight newborn, extreme
immaturity of newborn and respiratory distress syndrome of newborn. We
referred the reader to the ICD-10 MS-DRG Version 39.1 Definitions
Manual (which is available via the internet on the CMS website at:
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software) for complete
documentation of the GROUPER logic for MS-DRG 790. We stated that
during our review of the diagnosis codes assigned to these MS-DRGs, we
identified three diagnosis codes that do not exist in the logic for MS-
DRG 790. The three diagnosis codes and their current MS-DRG assignments
are listed in the following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.049
We stated our clinical advisors reviewed this grouping issue and
noted that while virtually every neonate under 1000 grams, which is the
definition of extremely low birth weight (ELBW), will have a weight
documented somewhere in the medical record, in the rare instance that
it is not, if the diagnosis documented by the provider is ``ELBW'' the
neonate would be in a higher risk category. Our clinical advisors also
noted that whereas weight is measured with high precision, gestational
age is more complicated. With the exception of in vitro fertilization,
gestational age is an estimate. Our clinical advisors stated similar to
documentation of ``ELBW'', if the diagnosis documented by the provider
is ``extreme immaturity of newborn'' the neonate would be in a higher
risk category. These diagnoses
[[Page 48857]]
describe conditions that require advanced care and resources similar to
other conditions already assigned to the logic of MS-DRG 790 even in
cases where the birth weight, or weeks of gestation, are unspecified.
For clinical consistency, our clinical advisors supported the
addition of these three diagnosis codes to the GROUPER logic list for
MS-DRG 790. Therefore, we proposed to reassign ICD-10-CM diagnosis
codes P07.00, P07.20 and P07.26 to MS-DRG 790, effective October 1,
2022 for FY 2023.
Comment: Commenters expressed support for CMS' proposal to reassign
ICD-10-CM diagnosis codes P07.00, P07.20 and P07.26 to MS-DRG 790.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to reassign ICD-10-CM diagnosis codes P07.00,
P07.20 and P07.26 to MS-DRG 790, without modification, effective
October 1, 2022 for FY 2023.
11. Review of Procedure Codes in MS-DRGs 981 Through 983 and 987
Through 989
We annually conduct a review of procedures producing assignment to
MS-DRGs 981 through 983 (Extensive O.R. Procedure Unrelated to
Principal Diagnosis with MCC, with CC, and without CC/MCC,
respectively) or MS-DRGs 987 through 989 (Non-Extensive O.R. Procedure
Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC,
respectively) on the basis of volume, by procedure, to see if it would
be appropriate to move cases reporting these procedure codes out of
these MS-DRGs into one of the surgical MS-DRGs for the MDC into which
the principal diagnosis falls. The data are arrayed in two ways for
comparison purposes. We look at a frequency count of each major
operative procedure code. We also compare procedures across MDCs by
volume of procedure codes within each MDC. We use this information to
determine which procedure codes and diagnosis codes to examine. We
identify those procedures occurring in conjunction with certain
principal diagnoses with sufficient frequency to justify adding them to
one of the surgical MS-DRGs for the MDC in which the diagnosis falls.
We also consider whether it would be more appropriate to move the
principal diagnosis codes into the MDC to which the procedure is
currently assigned.
In addition to this internal review, we also consider requests that
we receive to examine cases found to group to MS-DRGs 981 through 983
or MS-DRGs 987 through 989 to determine if it would be appropriate to
add procedure codes to one of the surgical MS-DRGs for the MDC into
which the principal diagnosis falls or to move the principal diagnosis
to the surgical MS-DRGs to which the procedure codes are assigned.
Based on the results of our review of the claims data from the
September 2021 update of the FY 2021 MedPAR file, as well as our review
of the requests that we received to examine cases found to group to MS-
DRGs 981 through 983 or MS-DRGs 987 through 989, we proposed to move
the cases reporting the procedures and/or principal diagnosis codes
described in this section of this rule from MS-DRGs 981 through 983 or
MS-DRGs 987 through 989 into one of the surgical MS-DRGs for the MDC
into which the principal diagnosis or procedure is assigned.
a. Embolization of Portal and Hepatic Veins
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28170), we received a request to reassign cases with a principal
diagnosis from MDC 07 (Diseases and Disorders of the Hepatobiliary
System and Pancreas) when reported with procedures involving the
embolization of a hepatic or portal vein from MS-DRGs 981, 982 and 983
(Extensive O.R. Procedures Unrelated to Principal Diagnosis with MCC,
with CC, and without CC/MCC, respectively) to MS-DRGs 423, 424, and 425
(Other Hepatobiliary or Pancreas Procedures with MCC, with CC, and
without CC/MCC, respectively) in MDC 07.
We noted that in ICD-10-PCS, the root operation selected to code
embolization procedures is dependent on the objective of the procedure.
If the objective of an embolization procedure is to completely close a
vessel, the root operation Occlusion is coded. ICD-10-PCS procedure
codes 06L43DZ (Occlusion of hepatic vein with intraluminal device,
percutaneous approach) or 06L83DZ (Occlusion of portal vein with
intraluminal device, percutaneous approach) may be reported to describe
embolization procedures to completely close off a hepatic or portal
vein with an intraluminal device. If the objective of an embolization
procedure is to narrow the lumen of a vessel, the root operation
Restriction is coded. ICD-10-PCS procedure codes 06V43DZ (Restriction
of hepatic vein with intraluminal device, percutaneous approach) or
06V83DZ (Restriction of portal vein with intraluminal device,
percutaneous approach) may be reported to describe embolization
procedures to narrow or partially occlude a hepatic or portal vein with
an intraluminal device.
These four ICD-10-PCS procedure codes, as well as their MDC
assignments, are listed in the table:
[GRAPHIC] [TIFF OMITTED] TR10AU22.050
We stated in the proposed rule that our analysis of this grouping
issue confirmed that when a procedure code describing the percutaneous
occlusion or restriction of the hepatic or portal vein with
intraluminal device is reported with a principal diagnosis from MDC 07,
these cases group to MS-DRGs 981, 982, and 983 (Extensive O.R.
Procedure Unrelated to Principal Diagnosis with MCC, with CC, and
without CC/MCC, respectively). Whenever there is a surgical procedure
reported on the claim that is unrelated to the MDC to which the case
was assigned based on the principal diagnosis, it results in an MS-DRG
assignment to a surgical class referred to as ``unrelated operating
room procedures''.
As noted in the proposed rule, to understand the resource use for
the subset of cases reporting procedure codes 06L43DZ, 06L83DZ, 06V43DZ
or 06V83DZ with a principal diagnosis from MDC 07 that are currently
grouping to MS-DRGs 981, 982, and
[[Page 48858]]
983, we examined claims data from the September 2021 update of the FY
2021 MedPAR file for the average length of stay and average costs for
these cases. Our findings are shown in the following table:
[GRAPHIC] [TIFF OMITTED] TR10AU22.051
We also examined the data for cases in MS-DRGs 423, 424, and 425,
and our findings are shown in the following table:
[GRAPHIC] [TIFF OMITTED] TR10AU22.052
As noted in the proposed rule, while the claims analysis based on
the September 2021 update of the FY 2021 MedPAR file identified only 34
cases for which these procedures were reported with a principal
diagnosis from MDC 07 resulting in assignment to MS-DRGs 981 through
983, and the average length of stay and average costs for these cases
vary in comparison to the average length of stay and average costs of
all cases in MS-DRGs 423, 424, and 425, given the clinical indications
for hepatic or portal vein embolization procedures, such as to induce
regrowth on one side of the liver in advance of a planned hepatic
resection on the other side, we stated we believed it was clinically
appropriate to add these procedure codes describing the percutaneous
occlusion or restriction of the hepatic or portal vein with
intraluminal device to MS-DRGs 423, 424, and 425 in MDC 07. Our
clinical advisors stated that these procedures are clearly related to
the principal diagnoses as they are procedures performed for
hepatobiliary diagnoses, namely hepatocellular carcinoma and liver
metastases, so it is clinically appropriate for the procedures to group
to the same MDC as the principal diagnoses. Our clinical advisors also
stated the procedures describing the percutaneous occlusion or
restriction of the hepatic or portal vein with intraluminal device are
consistent with the existing procedure codes included in the logic for
case assignment to MS-DRGs 423, 424, and 425.
Therefore, we proposed to add ICD-10-PCS procedure codes 06L43DZ,
06L83DZ, 06V43DZ and 06V83DZ to MDC 07 in MS-DRGs 423, 424 and 425.
Under this proposal, cases reporting procedure codes 06L43DZ, 06L83DZ,
06V43DZ or 06V83DZ in conjunction with a principal diagnosis code from
MDC 07 would group to MS-DRGs 423, 424 and 425.
Comment: Commenters expressed support for CMS' proposal to add ICD-
10-PCS procedure codes 06L43DZ, 06L83DZ, 06V43DZ and 06V83DZ to MDC 07
in MS-DRGs 423, 424 and 425. A commenter stated that this proposal is
in line with resources utilized in performing the procedures and also
helps organizations better manage their Program for Evaluating Payment
Patterns Electronic Report (PEPPER) data related to DRG 981 and 982.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to add ICD-10-PCS procedure codes 06L43DZ,
06L83DZ, 06V43DZ and 06V83DZ to MDC 07 in MS-DRGs 423, 424 and 425,
without modification, effective October 1, 2022 for FY 2023.
b. Percutaneous Excision of Hip Muscle
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28171), we received a request to examine cases reporting a procedure
describing
[[Page 48859]]
percutaneous biopsies of muscle. The requestor stated that when
procedures describing the percutaneous excision of the left hip muscle
for diagnostic purposes are reported with a principal diagnosis from
MDC 06 (Diseases and Disorders of the Digestive System) such as K68.12
(Psoas muscle abscess), the cases are assigned to MS-DRGs 981, 982, and
983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with
MCC, with CC, and without CC/MCC, respectively). However, when
procedures describing the percutaneous excision of the retroperitoneum
for diagnostic purposes are reported with the same principal diagnosis
of psoas muscle abscess, the cases are assigned to medical MS-DRGs 371,
372, and 373 (Major Gastrointestinal Disorders and Peritoneal
Infections with MCC, with CC, and without CC/MCC, respectively). The
requestor stated the cases at their facility with a principal diagnosis
of psoas muscle abscess when reported with a procedure describing a
biopsy of the left muscle had an average length of stay comparable to
other cases assigned to MS-DRGs 371, 372, and 373. The requestor
provided ICD-10-PCS procedure code 0KBP3ZX (Excision of left hip
muscle, percutaneous approach, diagnostic) in its request and
recommended that CMS evaluate the assignment of procedure code 0KBP3ZX
because procedures describing the percutaneous excision of the left hip
muscle for diagnostic purposes appear to be related to a diagnosis of
psoas muscle abscess.
We stated in the proposed rule that in order to analyze this
request, we first identified the similar ICD-10-PCS procedure codes
that also describe the excision of hip muscle. We noted that under the
ICD-10-PCS procedure classification, biopsy procedures are identified
by the 7th digit qualifier value ``diagnostic'' in the code
description. The four ICD-10-PCS procedure codes that describe the
excision of hip muscle, as well as their MDC assignments, are listed in
the table:
[GRAPHIC] [TIFF OMITTED] TR10AU22.053
We stated in the proposed rule that our analysis of this grouping
issue confirmed that when procedure codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX or
0KBP3ZZ are reported with a principal diagnosis from MDC 06, such as
K68.12, these cases group to MS-DRGs 981, 982, and 983. As noted in the
previous discussion, whenever there is a surgical procedure reported on
the claim that is unrelated to the MDC to which the case was assigned
based on the principal diagnosis, it results in a MS-DRG assignment to
a surgical class referred to as ``unrelated operating room
procedures''.
As noted in the proposed rule, we examined the claims data from the
September 2021 update of the FY 2021 MedPAR file to identify cases
reporting procedure codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX, or 0KBP3ZZ with a
principal diagnosis of K68.12 (Psoas muscle abscess) that are currently
grouping to MS-DRGs 981, 982, and 983. Our findings are shown in this
table:
[GRAPHIC] [TIFF OMITTED] TR10AU22.054
As shown, in our analyses of the claims data for MS-DRGs 981
through 983, we found a total of seven cases reporting procedures
describing excision of hip muscle with a principal diagnosis of K68.12
in the September 2021 update of the FY 2021 MedPAR file.
We stated in the proposed rule that to further evaluate this issue,
we examined claims data from the September 2021 update of the FY 2021
MedPAR file for cases reporting any one of the four procedure codes
(0KBN3ZX, 0KBN3ZZ, 0KBP3ZX, or 0KBP3ZZ) in MS-DRGs
[[Page 48860]]
981 through 983 with a principal diagnosis from MDC 06. Our findings
are shown in the following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.055
As shown, in our analyses of the claims data for MS-DRGs 981
through 983, we found a total of 14 cases reporting procedures
describing excision of hip muscle with a principal diagnosis from MDC
06 in the September 2021 update of the FY 2021 MedPAR file.
We also stated in the proposed rule that we examined the data for
cases in MS-DRGs 371, 372, and 373, and our findings are shown in the
following table:
[GRAPHIC] [TIFF OMITTED] TR10AU22.056
As discussed in the proposed rule, we reviewed these procedures and
our clinical advisors stated that procedures that describe the
percutaneous excision of hip muscle are not surgical in nature and
would not be the main reason for inpatient hospitalization or be
considered the principal driver of resource expenditure. Our clinical
advisors stated although a correlation cannot usually be made between
procedures performed in general anatomic regions, such as the
retroperitoneum, and procedures performed in specific body parts, such
as muscle, because procedures coded with general anatomic region body
parts represent a broader range of procedures that cannot be coded to a
specific body part, they agreed that in this instance procedures that
describe the percutaneous excision of hip muscle should have the same
designation as the ICD-10-PCS procedure codes that describe the
percutaneous excision of the retroperitoneum that are currently
designated as non-O.R. procedures.
We stated that our clinical advisors reviewed this analysis and
believed that, for clinical coherence and consistency, it would be
appropriate to designate ICD-10-PCS codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX,
and 0KBP3ZZ as non-O.R. procedures.
Therefore, we proposed to remove codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX,
and 0KBP3ZZ from the FY 2023 ICD-10 MS-DRGs Version 40 Definitions
Manual in Appendix E--Operating Room Procedures and Procedure Code/MS-
DRG Index as O.R. procedures. Under this proposal, these procedures
would no longer impact MS-DRG assignment. Cases reporting procedure
codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX, and 0KBP3ZZ in conjunction with a
principal diagnosis code from MDC 06 would group to MS-DRGs 371, 372,
and 373.
Comment: Some commenters expressed support for CMS' proposal to
remove codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX, and 0KBP3ZZ from the FY 2023
ICD-10 MS-DRGs Version 40 Definitions Manual in Appendix E--Operating
Room Procedures and Procedure Code/MS-DRG Index as O.R. procedures.
Response: We appreciate the commenters' support.
Comment: A commenter opposed CMS' proposal to designate ICD-10-PCS
codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX, and 0KBP3ZZ as non-O.R. procedures and
stated that they did not believe this proposal was warranted based on
the work involved in performing the procedures.
Response: We thank the commenter for their feedback. Our clinical
advisors reviewed the commenter's concerns and continue to support a
non-O.R. designation for procedure codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX, and
[[Page 48861]]
0KBP3ZZ that describe the percutaneous excision of hip muscle. Our
clinical advisors continue to state that procedure codes that describe
the percutaneous excision of hip muscle are not surgical in nature and
these procedures should have the same designation as the ICD-10-PCS
procedure codes that describe the percutaneous excision of the
retroperitoneum that are currently designated as non-O.R. procedures.
After consideration of the public comments we received, for the
reasons stated, we are finalizing our proposal to remove codes 0KBN3ZX,
0KBN3ZZ, 0KBP3ZX, and 0KBP3ZZ from the FY 2023 ICD-10 MS-DRGs Version
40 Definitions Manual in Appendix E--Operating Room Procedures and
Procedure Code/MS-DRG Index as O.R. procedures, without modification,
effective October 1, 2022 for FY 2023. Under this final policy, these
procedures will no longer impact MS-DRG assignment.
In addition, as discussed in the proposed rule, we also conduct an
internal review and consider requests that we receive to examine cases
found to group to MS-DRGs 981 through 983 or MS-DRGs 987 through 989 to
determine if it would be appropriate for the cases to be reassigned
from one of the MS-DRG groups to the other. In the proposed rule, we
stated that based on the results of our review of the claims data from
the September 2021 update of the FY 2021 MedPAR file we did not
identify any cases for reassignment. We also stated we did not receive
any requests suggesting reassignment. Therefore, for FY 2023 we did not
propose to move any cases reporting procedure codes from MS-DRGs 981
through 983 to MS-DRGs 987 through 989 or vice versa.
Comment: Commenters expressed support for CMS' decision to not
propose to move any cases reporting procedure codes from MS-DRGs 981
through 983 to MS-DRGs 987 through 989 or vice versa.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing the structure of MS-DRGs 981 through 983 and MS-DRGs 987
through 989 for FY 2023 without modification.
12. Operating Room (O.R.) and Non-O.R. Issues
a. Background
Under the IPPS MS-DRGs (and former CMS MS-DRGs), we have a list of
procedure codes that are considered operating room (O.R.) procedures.
Historically, we developed this list using physician panels that
classified each procedure code based on the procedure and its effect on
consumption of hospital resources. For example, generally the presence
of a surgical procedure which required the use of the operating room
would be expected to have a significant effect on the type of hospital
resources (for example, operating room, recovery room, and anesthesia)
used by a patient, and therefore, these patients were considered
surgical. Because the claims data generally available do not precisely
indicate whether a patient was taken to the operating room, surgical
patients were identified based on the procedures that were performed.
Generally, if the procedure was not expected to require the use of the
operating room, the patient would be considered medical (non-O.R.).
Currently, each ICD-10-PCS procedure code has designations that
determine whether and in what way the presence of that procedure on a
claim impacts the MS-DRG assignment. First, each ICD-10-PCS procedure
code is either designated as an O.R. procedure for purposes of MS- DRG
assignment (``O.R. procedures'') or is not designated as an O.R.
procedure for purposes of MS-DRG assignment (``non-O.R. procedures'').
Second, for each procedure that is designated as an O.R. procedure,
that O.R. procedure is further classified as either extensive or non-
extensive. Third, for each procedure that is designated as a non-O.R.
procedure, that non-O.R. procedure is further classified as either
affecting the MS-DRG assignment or not affecting the MS-DRG assignment.
We refer to these designations that do affect MS-DRG assignment as
``non O.R. affecting the MS-DRG.'' For new procedure codes that have
been finalized through the ICD-10 Coordination and Maintenance
Committee meeting process and are proposed to be classified as O.R.
procedures or non-O.R. procedures affecting the MS-DRG, our clinical
advisors recommend the MS-DRG assignment which is then made available
in association with the proposed rule (Table 6B.--New Procedure Codes)
and subject to public comment. These proposed assignments are generally
based on the assignment of predecessor codes or the assignment of
similar codes. For example, we generally examine the MS-DRG assignment
for similar procedures, such as the other approaches for that
procedure, to determine the most appropriate MS-DRG assignment for
procedures proposed to be newly designated as O.R. procedures. As
discussed in section II.D.14 of the preamble of this final rule, we are
making Table 6B.--New Procedure Codes--FY 2023 available on the CMS
website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. We also refer readers to the ICD-
10 MS-DRG Version 39.1 Definitions Manual at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.html for detailed information regarding
the designation of procedures as O.R. or non-O.R. (affecting the MS-
DRG) in Appendix E--Operating Room Procedures and Procedure Code/MS-DRG
Index.
In the FY 2020 IPPS/LTCH PPS proposed rule, we stated that, given
the long period of time that has elapsed since the original O.R.
(extensive and non-extensive) and non-O.R. designations were
established, the incremental changes that have occurred to these O.R.
and non-O.R. procedure code lists, and changes in the way inpatient
care is delivered, we plan to conduct a comprehensive, systematic
review of the ICD-10-PCS procedure codes. This will be a multi year
project during which we will also review the process for determining
when a procedure is considered an operating room procedure. For
example, we may restructure the current O.R. and non O.R.-designations
for procedures by leveraging the detail that is now available in the
ICD-10 claims data. We refer readers to the discussion regarding the
designation of procedure codes in the FY 2018 IPPS/LTCH PPS final rule
(82 FR 38066) where we stated that the determination of when a
procedure code should be designated as an O.R. procedure has become a
much more complex task. This is, in part, due to the number of various
approaches available in the ICD-10-PCS classification, as well as
changes in medical practice. While we have typically evaluated
procedures on the basis of whether or not they would be performed in an
operating room, we believe that there may be other factors to consider
with regard to resource utilization, particularly with the
implementation of ICD-10.
We discussed in the FY 2020 IPPS/LTCH PPS proposed rule that as a
result of this planned review and potential restructuring, procedures
that are currently designated as O.R. procedures may no longer warrant
that designation, and conversely, procedures that are currently
designated as non-O.R.
[[Page 48862]]
procedures may warrant an O.R. type of designation. We intend to
consider the resources used and how a procedure should affect the MS-
DRG assignment. We may also consider the effect of specific surgical
approaches to evaluate whether to subdivide specific MS DRGs based on a
specific surgical approach. We plan to utilize our available MedPAR
claims data as a basis for this review and the input of our clinical
advisors. As part of this comprehensive review of the procedure codes,
we also intend to evaluate the MS-DRG assignment of the procedures and
the current surgical hierarchy because both of these factor into the
process of refining the ICD-10 MS-DRGs to better recognize complexity
of service and resource utilization.
In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58540 through
58541), we provided a summary of the comments we had received in
response to our request for feedback on what factors or criteria to
consider in determining whether a procedure is designated as an O.R.
procedure in the ICD-10-PCS classification system for future
consideration.
We stated in the proposed rule that in consideration of the ongoing
PHE, we continue to believe it may be appropriate to allow additional
time for the claims data to stabilize prior to selecting the timeframe
to analyze for this review. Additional time is also necessary as we
continue to develop our process and methodology. Therefore, we stated
that we will provide more detail on this analysis and the methodology
for conducting this review in future rulemaking.
Comment: Commenters supported CMS' plan to continue to conduct the
comprehensive, systematic review of the ICD-10-PCS codes that includes
a process for determining when a procedure is designated as O.R. or
non-O.R. These commenters expressed support of CMS' decision to allow
additional time for the claims data to stabilize prior to selecting the
timeframe to analyze for this review in consideration of the ongoing
PHE. A commenter stated they appreciate that CMS is taking the
appropriate time before deciding whether and how to restructure the
current O.R. and non-O.R. designations. Another commenter acknowledged
that O.R. and non-O.R. designation determinations are a substantial
undertaking that may significantly restructure many MS-DRGs.
Response: We thank the commenters for their support and appreciate
their acknowledgement of the magnitude of this effort.
Comment: Other commenters stated that designation of O.R. versus
non-O.R. may no longer be the most critical differentiator between
resource-intensive procedures for MS-DRG purposes. These commenters
noted that medical practice is changing and presently, there are
increasingly complex and resource-intensive procedures performed by
hospitals that do not involve the use of an operating room. A commenter
stated that because of technological advances, sophisticated resource-
intensive procedures are no longer confined to the operating room
setting.
Other commenters highlighted stem cell transplants (SCT), Chimeric
Antigen Receptor (CAR) T-cell therapy, and other novel cell and gene
therapies as examples of therapeutic interventions that have similar or
greater resource utilization and complexity than some O.R. designated
procedures, while not being currently designated as O.R. procedures
themselves. Another commenter noted that some procedures performed in
interventional radiology suites and cardiac catheterization labs can
utilize more advanced equipment and supplies than procedures performed
in a traditional operating room with minimally installed equipment. As
part of the broader and continuing conversation about future MS-DRG
assignments and designations for these procedures and therapies, these
commenters encouraged CMS to consider how other factors influence
resource utilization, and recommended CMS consider questions such as
whether:
certain types of interventions, such as the administration
of certain complex drugs/biologics or therapies (for example, radiation
therapy), that demonstrate higher costs and resource utilization,
warrant consideration of a designation as an O.R. procedure or another
equivalent designation?
certain types of procedures and therapies make up a
substantial percentage of the costs within a particular MS-DRG?
there is an average amount of cost within the relative
weight of a MS-DRG that represents significant resource utilization and
complexity?
complex infusion-type administration of novel and
potentially curative cell and gene therapies should be considered for
new category of MS-DRGs, to be added to the current categories of Pre-
MDC MS-DRGs, Surgical MS-DRGs and Medical MS-DRGs?
Response: CMS appreciates the commenters' feedback and
recommendations as to factors to consider in evaluating O.R.
designations. As stated previously, we have typically evaluated
procedures on the basis of whether or not they would be performed in an
operating room. We agree with commenters and believe that there may be
other factors to consider with regard to resource utilization,
particularly with the implementation of ICD-10. As discussed in the
proposed rule, we are exploring alternatives on how we may restructure
the current O.R. and non-O.R. designations for procedures by leveraging
the detail that is available in the ICD-10 claims data. We continue to
develop our process and methodology, and will provide more detail in
future rulemaking.
Comment: Several commenters suggested that CMS work closely with
physician specialty societies and interested parties to identify the
most important drivers of complexity and resource use in the hospital
setting. Other commenters suggested CMS engage the broader community by
convening town halls or listening sessions. A few commenters suggested
that CMS allow sufficient time for provider review and stated that
thorough data analysis with provider input is critical to allow for
appropriate insight in provider comments. A commenter recommended that
CMS be transparent in its methodology, identify criteria or metrics
used to determine what does and does not constitute significant
resource utilization and complexity across MS-DRGs, and be receptive to
public opinion. Another commenter stated that they look forward to CMS
providing more detail on this analysis and expressed that they would
appreciate advanced notice for comment in future rulemaking regarding
the proposed methodology for conducting this review.
Response: CMS appreciates this feedback. We note that CMS has
already convened an internal workgroup comprised of clinicians, coding
specialists and other policy analysts, and we look forward to further
feedback from the public. Recognizing sufficient time is needed to
provide feedback on what factors or criteria to consider in determining
whether a procedure should be designated as an O.R. procedure in the
ICD-10-PCS classification system, we have provided opportunity for the
public to provide feedback beginning with the FY 2018 final rule and we
continue to solicit input. We encourage the public to submit comments
on other factors to consider in our refinement efforts to recognize and
differentiate consumption of resources for the ICD-10 MS-DRGs timely
for consideration. We will also
[[Page 48863]]
explore additional means of eliciting feedback, and will notify the
public of any such other opportunities for communication and comment in
the future. Once we are in a position to provide more detail on this
analysis and the methodology for conducting this comprehensive review,
we will do so in future rulemaking.
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28174 through 28175), we received the following requests regarding
changing the designation of specific ICD-10-PCS procedure codes from
non-O.R. to O.R. procedures. In this section of this rule, as we did in
the proposed rule, we summarize these requests and address why we are
not considering a change to the designation of these codes at this time
and, further, respond to the public comments we received regarding
these requests.
We received a request to change the designation of all ICD-10-PCS
procedure codes that describe diagnostic and therapeutic percutaneous
endoscopic procedures performed on thoracic and abdominal organs, from
non-O.R. to O.R. According to the requestor, thoracoscopic and
laparoscopic procedures are always performed in the operating room
under general anesthesia. In the proposed rule, we stated we believed
additional time was needed to fully examine the numerous ICD-10-PCS
codes in the classification that describe diagnostic and therapeutic
percutaneous endoscopic procedures performed on thoracic and abdominal
organs as there are over 19,000 ICD-10-PCS codes in the classification
that describe procedures performed using a percutaneous endoscopic
approach. As we have signaled in prior rulemaking, the designation of
an O.R. procedure encompasses more than the physical location of the
hospital in which the procedure may be performed. We also examine if,
and in what way, the performance of the procedure affects the resource
expenditure in those admissions in the inpatient setting, in addition
to examining other clinical factors such as procedure complexity, and
need for anesthesia administration as well as other types of sedation.
We stated we will continue to evaluate the ICD-10-PCS procedure codes
that describe diagnostic and therapeutic percutaneous endoscopic
procedures performed on thoracic and abdominal organs as we conduct a
comprehensive, systematic review of the ICD-10-PCS procedure codes.
Comment: A commenter stated that they agreed with the request to
change the designation of all lCD-10-PCS procedure codes that describe
diagnostic and therapeutic percutaneous endoscopic procedures performed
on thoracic and abdominal organs from non-O.R. to O.R. and stated that
these procedures would likely occur in an operating room under general
anesthesia. Another commenter stated that while they did not dispute
that there may be over 19,000 ICD-10-PCS codes that describe procedures
performed using a percutaneous endoscopic approach, they believed that
this list could be whittled down substantially by considering only
codes describing procedures performed on thoracic and abdominal organs.
This commenter stated that even with a smaller list utilizing the
criteria they suggested, they could not think of a thoracoscopic or
laparoscopic procedure that would not require general anesthesia and be
performed in an operating room and urged CMS to designate all ICD-10-
PCS procedure codes that describe diagnostic and therapeutic
percutaneous endoscopic procedures performed on thoracic and abdominal
organs as operating room procedures.
Response: We appreciate the commenters' feedback. We also
appreciate the commenter's suggestion, however, as stated in the
proposed rule, and in prior rulemaking, we plan to conduct a
comprehensive, systematic review of the ICD-10-PCS procedure codes. Our
clinical advisors recommended that rather than evaluating the procedure
codes describing diagnostic and therapeutic percutaneous endoscopic
procedures performed on thoracic and abdominal organs in isolation,
analysis should be performed for this subset of procedure codes across
the MS-DRGs, as part of the comprehensive procedure code review. As a
component of our broader comprehensive procedure code review, we are
also reviewing the process for determining when a procedure is
considered an operating room procedure. For example, we may restructure
the current O.R. and non-O.R. designations for procedures by leveraging
the detail that is available in the ICD-10 claims data. Therefore,
after consideration of the public comments we received, and for the
reasons discussed, we are not making changes in this final rule to the
designation of all ICD-10-PCS procedure codes that describe diagnostic
and therapeutic percutaneous endoscopic procedures performed on
thoracic and abdominal organs, from non-O.R. to O.R. We will provide
more detail on the comprehensive procedure code review and the
methodology for conducting this review in future rulemaking.
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44892 through 44895)
CMS finalized the proposal to remove the 22 codes that describe the
open drainage of subcutaneous tissue and fascia listed in the following
table from the ICD-10 MS-DRGs Version 39.1 Definitions Manual in
Appendix E--Operating Room Procedures and Procedure Code/MS-DRG Index
as O.R. procedures. Under this finalization, these procedures no longer
impact MS-DRG assignment.
[[Page 48864]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.057
In the FY 2022 final rule we noted that the designation of the 22
procedure codes that describe the open drainage of subcutaneous tissue
and fascia as O.R. procedures was a result of a replication error in
transitioning to ICD-10. This replication error led to ICD-10-PCS
procedure codes that describe the open drainage of subcutaneous tissue
and fascia being listed as comparable translations for ICD-9-CM code
83.09 (Other incision of soft tissue), which was designated as a non-
extensive O.R. procedure under the ICD-9-CM MS-DRGs Version 32, as
opposed to being listed as comparable translations for ICD-9-CM code
86.04 (Other incision with drainage of skin and subcutaneous tissue)
which was designated as a non-O.R. procedure under the ICD-9-CM MS-DRGs
Version 32. We stated in the FY 2022 final rule that designating the 22
procedure codes that describe the open drainage of subcutaneous tissue
and fascia as non-O.R. procedures would result in a more accurate
replication of the comparable procedure, under the ICD-9-CM MS-DRGs
Version 32 which was 86.04, not 83.09 and is more aligned with current
shifts in treatment practices.
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule, we
received a request to re-examine this change in designation. According
to the requestor, open procedures for the drainage of subcutaneous
tissue and fascia are indeed typically performed in the operating room
under general anesthesia and involve making incisions through the
subcutaneous tissue into fascia for therapeutic drainage, breaking up
of loculations, and irrigation. We stated that while our clinical
advisors did not disagree with the requestor that these procedures can
involve making incisions through the subcutaneous tissue into fascia,
they continued to state procedures describing the open drainage of
subcutaneous tissue and fascia can now be safely performed in the
outpatient setting and when performed during a hospitalization, they
are typically performed in conjunction with another O.R. procedure. For
the reasons discussed in the FY 2022 final rule, our clinical advisors
stated that the non-O.R. designation of the 22 procedure codes that
describe the open drainage of subcutaneous tissue and fascia as
finalized in the FY 2022 final rule better reflects the associated
technical complexity and hospital resource use of these procedures.
Comment: Some commenters opposed the non-O.R. designation of the 22
procedure codes that describe the open drainage of subcutaneous tissue
and fascia as finalized in the FY 2022 final rule and urged that these
codes be designated as O.R. procedures for FY 2023. These commenters
stated that procedure codes that describe the open drainage of
subcutaneous tissue and fascia are indeed performed in the operating
room under general anesthesia, are surgical in nature, and an O.R.
designation would more accurately capture the utilization of resources.
A commenter stated that a review of the cases at their facility shows
that approximately 80% of the procedures describing open drainage of
subcutaneous tissue and fascia are performed in an O.R. setting
requiring anesthesia, with a much lesser percentage performed at the
bedside. Another commenter noted in the FY 2018 IPPS proposed rule,
these same 22 ICD-10-PCS codes were identified and a commenter opposed
the proposal to re-designate these codes at that time. In response to
the issues raised by this commenter, CMS agreed in the FY 2018
[[Page 48865]]
IPPS final rule to maintain the designation of the 22 procedure codes.
This commenter stated the rationale to maintain these 22 codes as O.R.
procedures has not changed and that there is no safe way to effectively
drain an infection involving the subfascial plane without the resources
of an operating room.
Response: Our clinical advisors reviewed the commenters' concerns
and continue to state that treatment practices have continued to shift
since FY 2018 rulemaking. As stated in the FY 2022 final rule in
response to similar comments, procedures describing the open drainage
of subcutaneous tissue and fascia can now be safely performed in the
outpatient setting and when performed during a hospitalization, it is
typically in conjunction with another O.R. procedure. In cases where
procedures describing open drainage of subcutaneous tissue and fascia
are the only procedures performed in an admission, the admission is
quite likely due to need for IV antibiotics as opposed to the need for
operating room resources in an inpatient setting.
We refer the reader to Table 6P.1f associated with this final rule
(which is available via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS) for the data analysis of cases reporting the 22
procedure codes that describe the open drainage of subcutaneous tissue
and fascia in the September 2021 update of the FY 2021 MedPAR file. We
note that within each MDC, the MS-DRGs are divided into medical and
surgical categories. In general, surgical MS-DRGs are further defined
based on the precise surgical procedure performed while the medical MS-
DRGs are further defined based on the precise principal diagnosis for
which a patient was admitted to the hospital. In Table 6P.1f associated
with this final rule, column B displays the category of each MS-DRG in
MS-DRG GROUPER Version 39.1. The letter M is used to designate a
medical MS-DRG and the letter P is used to designate a surgical MS-DRG.
As shown in the table, when the procedure codes that describe the open
drainage of the subcutaneous tissue and fascia are reported,
approximately 70% of the MS-DRGs assigned are classified as surgical
MS-DRGs which indicates at least one procedure code designated as an
O.R. procedure was also reported in these cases. We refer the reader to
the ICD-10 MS-DRG Version 39.1 Definitions Manual (which is available
via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatientPPS/MS-DRGClassifications-and-Software) for complete documentation of the
GROUPER logic for the listed MS-DRGs.
Our clinical advisors continue to state that procedure codes that
describe the open drainage of subcutaneous tissue and fascia do not
reflect the technical complexity or resource intensity in comparison to
other procedures that are designated as O.R. procedures. They also
continue to state that the non-O.R. designation of the 22 procedure
codes that describe the open drainage of subcutaneous tissue and fascia
as finalized in the FY 2022 final rule better reflects the associated
technical complexity and hospital resource use of these procedures.
Therefore, after consideration of the public comments we received,
and for the reasons discussed, we are not making changes in this final
rule to the designation of the 22 codes that describe the open drainage
of subcutaneous tissue and fascia listed in the previous table.
13. Changes to the MS-DRG Diagnosis Codes for FY 2023
a. Background of the CC List and the CC Exclusions List
Under the IPPS MS-DRG classification system, we have developed a
standard list of diagnoses that are considered CCs. Historically, we
developed this list using physician panels that classified each
diagnosis code based on whether the diagnosis, when present as a
secondary condition, would be considered a substantial complication or
comorbidity. A substantial complication or comorbidity was defined as a
condition that, because of its presence with a specific principal
diagnosis, would cause an increase in the length-of-stay by at least 1
day in at least 75 percent of the patients. However, depending on the
principal diagnosis of the patient, some diagnoses on the basic list of
complications and comorbidities may be excluded if they are closely
related to the principal diagnosis. In FY 2008, we evaluated each
diagnosis code to determine its impact on resource use and to determine
the most appropriate CC subclassification (NonCC, CC, or MCC)
assignment. We refer readers to sections II.D.2. and 3. of the preamble
of the FY 2008 IPPS final rule with comment period for a discussion of
the refinement of CCs in relation to the MS-DRGs we adopted for FY 2008
(72 FR 47152 through 47171).
b. Overview of Comprehensive CC/MCC Analysis
In the FY 2008 IPPS/LTCH PPS final rule (72 FR 47159), we described
our process for establishing three different levels of CC severity into
which we would subdivide the diagnosis codes. The categorization of
diagnoses as a MCC, a CC, or a NonCC was accomplished using an
iterative approach in which each diagnosis was evaluated to determine
the extent to which its presence as a secondary diagnosis resulted in
increased hospital resource use. We refer readers to the FY 2008 IPPS/
LTCH PPS final rule (72 FR 47159) for a complete discussion of our
approach. Since the comprehensive analysis was completed for FY 2008,
we have evaluated diagnosis codes individually when assigning severity
levels to new codes and when receiving requests to change the severity
level of specific diagnosis codes.
We noted in the FY 2020 IPPS/LTCH PPS proposed rule (84 FR 19235
through 19246) that with the transition to ICD-10-CM and the
significant changes that have occurred to diagnosis codes since the FY
2008 review, we believed it was necessary to conduct a comprehensive
analysis once again. Based on this analysis, we proposed changes to the
severity level designations for 1,492 ICD-10-CM diagnosis codes and
invited public comments on those proposals. As summarized in the FY
2020 IPPS/LTCH PPS final rule, many commenters expressed concern with
the proposed severity level designation changes overall and recommended
that CMS conduct further analysis prior to finalizing any proposals.
After careful consideration of the public comments we received, as
discussed further in the FY 2020 final rule, we generally did not
finalize our proposed changes to the severity designations for the ICD-
10-CM diagnosis codes, other than the changes to the severity level
designations for the diagnosis codes in category Z16- (Resistance to
antimicrobial drugs) from a NonCC to a CC. We stated that postponing
adoption of the proposed comprehensive changes in the severity level
designations would allow further opportunity to provide additional
background to the public on the methodology utilized and clinical
rationale applied across diagnostic categories to assist the public in
its review. We refer readers to the FY 2020 IPPS/LTCH PPS final rule
(84 FR 42150 through 42152) for a complete discussion of our response
to public comments regarding the proposed
[[Page 48866]]
severity level designation changes for FY 2020.
As discussed in the FY 2021 IPPS/LTCH PPS proposed rule (85 FR
32550), to provide the public with more information on the CC/MCC
comprehensive analysis discussed in the FY 2020 IPPS/LTCH PPS proposed
and final rules, CMS hosted a listening session on October 8, 2019. The
listening session included a review of this methodology utilized to
mathematically measure the impact on resource use. We refer readers to
https://www.cms.gov/Outreach-and-Education/Outreach/OpenDoorForums/Downloads/10082019ListingSessionTrasncriptandQandAsandAudioFile.zip for
the transcript and audio file of the listening session. We also refer
readers to https://www.cms.gov/Medicare/MedicareFee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.html for
the supplementary file containing the mathematical data generated using
claims from the FY 2018 MedPAR file describing the impact on resource
use of specific ICD-10-CM diagnosis codes when reported as a secondary
diagnosis that was made available for the listening session.
In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58550 through
58554), we discussed our plan to continue a comprehensive CC/MCC
analysis, using a combination of mathematical analysis of claims data
as discussed in the FY 2020 IPPS/LTCH PPS proposed rule (84 FR 19235)
and the application of nine guiding principles and plan to present the
findings and proposals in future rulemaking. The nine guiding
principles are as follows:
Represents end of life/near death or has reached an
advanced stage associated with systemic physiologic decompensation and
debility.
Denotes organ system instability or failure.
Involves a chronic illness with susceptibility to
exacerbations or abrupt decline.
Serves as a marker for advanced disease states across
multiple different comorbid conditions.
Reflects systemic impact.
Post-operative/post-procedure condition/complication
impacting recovery.
Typically requires higher level of care (that is,
intensive monitoring, greater number of caregivers, additional testing,
intensive care unit care, extended length of stay).
Impedes patient cooperation or management of care or both.
Recent (last 10 years) change in best practice, or in
practice guidelines and review of the extent to which these changes
have led to concomitant changes in expected resource use.
We refer readers to the FY 2021 IPPS/LTCH PPS final rule for a
complete discussion of our response to public comments regarding the
nine guiding principles.
In the FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25175 through
25180), as another interval step in our comprehensive review of the
severity designations of ICD-10-CM diagnosis codes, we requested public
comments on a potential change to the severity level designations for
``unspecified'' ICD-10-CM diagnosis codes that we were considering
adopting for FY 2022. Specifically, we noted we were considering
changing the severity level designation of ``unspecified'' diagnosis
codes to a NonCC where there are other codes available in that code
subcategory that further specify the anatomic site. As summarized in
the FY 2022 IPPS/LTCH PPS final rule, many commenters expressed concern
with the potential severity level designation changes overall and
recommended that CMS delay any possible change to the designation of
these codes to give hospitals and their physicians time to prepare.
After careful consideration of the public comments we received, we
maintained the severity level designation of the ``unspecified''
diagnosis codes currently designated as a CC or MCC where there are
other codes available in that code subcategory that further specify the
anatomic site for FY 2022. We refer readers to the FY 2022 IPPS/LTCH
PPS final rule (86 FR 44916 through 44926) for a complete discussion of
our response to public comments regarding the potential severity level
designation changes. Instead, for FY 2022, we finalized a new Medicare
Code Editor (MCE) code edit for ``unspecified'' codes, effective with
discharges on and after April 1, 2022. We stated we believe finalizing
this new edit would provide additional time for providers to be
educated while not affecting the payment the provider is eligible to
receive. We refer the reader to section II.D.14.e. of the FY 2022 IPPS/
LTCH PPS final rule (86 FR 44940 through 44943) for the complete
discussion.
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule, as this
new edit became effective beginning with discharges on and after April
1, 2022, we stated our clinical advisors believed it was appropriate to
not propose to change the designation of any ICD-10-CM diagnosis codes,
including the unspecified codes that are subject to the ``Unspecified
Code'' edit, as we continue our comprehensive CC/MCC analysis to allow
interested parties the time needed to become acclimated to the new
edit.
Comment: Commenters stated that they appreciate and agree with CMS'
decision not to propose any further changes to the designation of any
ICD-10-CM diagnosis codes, including the unspecified codes, at this
time. These commenters recommended that CMS allow one to two full years
of data availability before proposing any additional changes to the
designation of any ICD-10-CM diagnosis code, given that the new MCE
edit was recently implemented on April 1, 2022 and stated that having
one to two full years of data will afford more meaningful analysis in
future rulemaking considerations as part of the comprehensive CC/MCC
analysis.
Response: We appreciate the commenters' support. With respect to
the commenters who suggested allowing one to two full years of data
availability before proposing any additional changes, we appreciate the
feedback and will take these suggestions under consideration.
We continue to solicit feedback regarding the guiding principles,
as well as other possible ways we can incorporate meaningful indicators
of clinical severity. We have made available on the CMS website updated
impact on resource use files so that the public can review the
mathematical data for the impact on resource use generated using claims
from the FY 2019 MedPAR file, the FY 2020 MedPAR file and the FY 2021
MedPAR files. The link to these files is posted on the CMS website at
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software. When providing
additional feedback or comments, we encourage the public to provide a
detailed explanation of how applying a suggested concept or principle
would ensure that the severity designation appropriately reflects
resource use for any diagnosis code. We also continue to be interested
in receiving feedback on how we might otherwise foster the
documentation and reporting of the most specific diagnosis codes
supported by the available medical record documentation and clinical
knowledge of the patient's health condition to more accurately reflect
each health care encounter and improve the reliability and validity of
the coded data. Interested parties can submit any comments and
recommendations for FY 2024 by
[[Page 48867]]
October 20, 2022 via the new electronic intake system, Medicare
Electronic Application Request Information SystemTM
(MEARISTM) at: https://mearis.cms.gov/public/home.
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28177), for new diagnosis codes approved for FY 2023, consistent with
our annual process for designating a severity level (MCC, CC or NonCC)
for new diagnosis codes, we first review the predecessor code
designation, followed by review and consideration of other factors that
may be relevant to the severity level designation, including the
severity of illness, treatment difficulty, complexity of service and
the resources utilized in the diagnosis or treatment of the condition.
We noted that this process does not automatically result in the new
diagnosis code having the same designation as the predecessor code. We
refer the reader to section II.D.14 of this final rule for the
discussion of the proposed changes to the ICD-10-CM and ICD-10-PCS
coding systems for FY 2023.
c. Requested Changes to Severity Levels
In the FY 2023 IPPS/LTCH PPS proposed rule, we noted that we
received several requests to change the severity level designations of
specific ICD-10-CM diagnosis codes, including a request to analyze a
subset of the social determinants of health (SDOH) diagnosis codes. We
stated our clinical advisors believed it was appropriate to consider
these requests in connection with our continued comprehensive CC/MCC
analysis in future rulemaking, rather than proposing to change the
designation of individual ICD-10-CM diagnosis codes at this time.
However, we refer the reader to section II.D.13.d for further
discussion related to the diagnosis codes describing social
determinants of health. As discussed in the proposed rule and noted
earlier in this section, we plan to continue a comprehensive CC/MCC
analysis, using a combination of mathematical analysis of claims data
and the application of nine guiding principles. We will consider these
individual requests received for changes to severity level designations
as we continue our comprehensive CC/MCC analysis and will provide more
detail in future rulemaking.
d. Request for Information on Social Determinants of Health Diagnosis
Codes
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28177 through 28181), we solicited public comments on how the reporting
of diagnosis codes in categories Z55-Z65 may improve our ability to
recognize severity of illness, complexity of service, and/or
utilization of resources under the MS-DRGs as described further in this
section. Consistent with the Administration's goal of advancing health
equity for all, including members of historically underserved and
under-resourced communities, as described in the President's January
20, 2021 Executive Order 13985 on ``Advancing Racial Equity and Support
for Underserved Communities Through the Federal Government,'' \13\ we
stated we were also interested in receiving feedback on how we might
otherwise foster the documentation and reporting of the diagnosis codes
describing social and economic circumstances to more accurately reflect
each health care encounter and improve the reliability and validity of
the coded data including in support of efforts to advance health
equity.
---------------------------------------------------------------------------
\13\ Available at: https://www.federalregister.gov/documents/2021/01/25/2021-01753/advancing-racial-equity-and-support-for-underserved-communities-through-the-federal-government.
---------------------------------------------------------------------------
Social determinants of health (SDOH) are the conditions in the
environments where people are born, live, learn, work, play, worship,
and age that affect a wide range of health, functioning, and quality-
of-life outcomes and risks.\14\ These circumstances or determinants
influence an individual's health status and can contribute to wide
health disparities and inequities. While SDOH do not describe current
illnesses or injuries at the individual level, they are widely
recognized as important potential predictors of risk for developing
medical conditions like heart disease, diabetes, and obesity. In ICD-
10-CM, the Z codes found in Chapter 21 represent reasons for
encounters, and are provided for occasions when circumstances other
than a disease, injury or external cause classifiable to categories
A00-Y89 are recorded as `diagnoses' or `problems'. The subset of Z
codes that describe the social determinants of health are found in
categories Z55-Z65 (Persons with potential health hazards related to
socioeconomic and psychosocial circumstances). These codes describe a
range of issues related--but not limited--to education and literacy,
employment, housing, ability to obtain adequate amounts of food or safe
drinking water, and occupational exposure to toxic agents, dust, or
radiation. We noted that effective October 1, 2021, the Centers for
Disease Control and Prevention (CDC) National Center for Health
Statistics (NCHS) added 11 new diagnosis codes describing SDOH to
provide additional information regarding determinants such as housing,
food insecurity, and transportation. In addition, section I.B.14 of the
FY 2022 ICD-10-CM Official Guidelines for Coding and Reporting was
updated to provide clarification of the term ``clinician'' in reporting
codes related to social determinants of health and clarified the
documentation that can be utilized to assign SDOH codes when included
in the official medical record. In this context, ``clinicians'' other
than the patient's provider refer to ``healthcare professionals
permitted, based on regulatory or accreditation requirements or
internal hospital policies, to document in a patient's official medical
record.'' \15\
---------------------------------------------------------------------------
\14\ Available at: https://health.gov/healthypeople/objectives-and-data/social-determinants-health.
\15\ Available at: https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2022/10cmguidelines-FY2022-April%201%20update%202-3-22.pdf.
---------------------------------------------------------------------------
As stated in the proposed rule, reporting SDOH Z codes in inpatient
claims data could enhance quality improvement activities, track factors
that influence people's health, and provide further insight into
existing health inequities.16 17 18 More routine collection
of SDOH Z codes could also likely improve coordination within hospitals
to utilize the data across their clinical care and discharge planning
teams, including with post-acute partners. CMS has heard from
interested parties about a number of reasons for why there may be less
routine documentation and reporting of SDOH in the inpatient setting.
First, Z codes are not required to be reported by inpatient hospitals
and generally do not affect MS-DRG assignment. Rather, these codes are
currently reported voluntarily by providers when and if supported in
the medical record
---------------------------------------------------------------------------
\16\ Maksut JL, Hodge C, Van CD, Razmi, A, & Khau MT.
Utilization of Z Codes for Social Determinants of Health among
Medicare Fee-For-Service Beneficiaries, 2019. Office of Minority
Health (OMH) Data Highlight No. 24. Centers for Medicare & Medicaid
Services (CMS), Baltimore, MD, 2021.
\17\ Truong HP, Luke AA, Hammond G, Wadhera RK, Reidhead M,
Joynt Maddox KE. Utilization of Social Determinants of Health ICD-10
Z-Codes Among Hospitalized Patients in the United States, 2016-2017.
Med Care. 2020;58(12):1037-1043. doi:10.1097/MLR.0000000000001418.
\18\ Wark K, Cheung K, Wolter E, Avey JP. Engaging stakeholders
in integrating social determinants of health into electronic health
records: A scoping review. International Journal of Circumpolar
Health. 2021 Jan 1;80(1):1943983.
---------------------------------------------------------------------------
[[Page 48868]]
documentation. As such, consistent protocols may not be in place for
documenting and reporting. Second, many of the circumstances captured
through SDOH Z codes are dependent on the willingness of patients to
discuss personal social, economic, or environmental conditions.
Providers may or may not be able to reliably document certain
circumstances,\19\ as a result, in the medical records. There are also
questions of how bias can play into screening for SDOH and how systemic
bias within the health care system can play a role in this process.\20\
CMS has also heard of the significant pressures on provider time, and
whether providers have access to comprehensive care and coordination
teams, including social workers, who may be more appropriately skilled
to assess certain SDOH.
---------------------------------------------------------------------------
\19\ Garg A, Boynton-Jarrett R, Dworkin PH. Avoiding the
Unintended Consequences of Screening for Social Determinants of
Health. JAMA. 2016;316(8):813-814. doi:10.1001/jama.2016.9282.
\20\ Egede LE, Walker RJ, Williams JS. Intersection of
Structural Racism, Social Determinants of Health, and Implicit Bias
With Emergency Physician Admission Tendencies. JAMA Netw Open.
2021;4(9):e2126375. doi:10.1001/jamanetworkopen.2021.26375.
---------------------------------------------------------------------------
Given that SDOH diagnosis codes describe economic and environmental
circumstances faced by patients and often correlate with substantial
variance in health outcomes,\21\ more widely adopted consistent
documentation and reporting in the inpatient setting could better
identify non-medical factors affecting health and track progress toward
addressing them. Doing so could also aid in work toward formulating
more comprehensive and actionable policies to address health equity and
promote the highest quality, best-value care for all beneficiaries.
---------------------------------------------------------------------------
\21\ Commission on Social Determinants of Health. Closing the
gap in a generation: health equity through action on the social
determinants of health: final report of the commission on social
determinants of health. World Health Organization, 2008.
---------------------------------------------------------------------------
As we discuss more fully later in this section of this final rule,
as we did in the proposed rule, we believe reporting of SDOH Z codes
may also better determine the resource utilization for treating
patients experiencing these circumstances to help inform whether a
change to the severity designation of these codes would be clinically
warranted as we continue a comprehensive CC/MCC analysis, using a
combination of mathematical analysis of claims data as discussed in the
FY 2020 IPPS/LTCH PPS proposed rule (84 FR 19235) and the application
of nine guiding principles.
There are 96 diagnosis codes that describe the social determinants
of health found in categories Z55-Z65. These 96 diagnosis codes for
which we solicited comments as described in the proposed rule are shown
in Table 6P.5a associated with the proposed rule (which is available
via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS). We note we also
made available the data describing the impact on resource use when
reported as a secondary diagnosis for all 96 ICD-10-CM Z codes that
describe the social determinants of health from categories Z55-Z65.
These data are consistent with data historically used to mathematically
measure impact on resource use for secondary diagnoses, and the data
which we plan to use in combination with application of the nine
guiding principles as we continue the comprehensive CC/MCC analysis.
In Table 6P.5a associated with the proposed rule, column C displays
the FY 2021 severity level designation for these diagnosis codes in MS-
DRG GROUPER Version 38.1. Column D displays CMS's current FY 2022
severity level designation in MS-DRG GROUPER Version 39.1. Columns E-N
show data on the impact on resource use generated using discharge
claims from the September 2021 update of the FY 2021 MedPAR file and
MS-DRG GROUPER Version 39.1. For further information on the data on the
impact on resource use as displayed in Columns E-N, we refer readers to
the FY 2008 IPPS/LTCH PPS final rule (72 FR 47159) for a complete
discussion of the methodology utilized to mathematically measure the
impact on resource use. Also, as discussed in the FY 2021 IPPS/LTCH PPS
proposed rule (85 FR 32550), to provide the public with more
information on the CC/MCC comprehensive analysis discussed in the FY
2020 IPPS/LTCH PPS proposed and final rules, CMS hosted a listening
session on October 8, 2019. The listening session included a review of
this methodology utilized to mathematically measure the impact on
resource use. We refer readers to https://www.cms.gov/Outreach-and-Education/Outreach/OpenDoorForums/Downloads/10082019ListingSessionTrasncriptandQandAsandAudioFile.zip for the
transcript and audio file of the listening session. We also refer
readers to https://www.cms.gov/Medicare/MedicareFee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.html for
the supplementary file containing the data describing the impact on
resource use of specific ICD-10-CM diagnosis codes when reported as a
secondary diagnosis that was made available for the listening session.
We note that the supplementary file that was made available for the
listening session contains the mathematical data for the impact on
resource use generated using claims from the FY 2018 MedPAR file. We
have also made available on the CMS website updated impact on resource
use files so that the public can review the mathematical data for the
impact on resource use generated using claims from the FY 2019 MedPAR
file, FY 2020 MedPAR file and the FY 2021 MedPAR files.
In the FY 2008 IPPS/LTCH PPS final rule (72 FR 47159), we described
the categorization of diagnoses as an MCC, a CC, or a NonCC,
accomplished using an iterative approach in which each diagnosis was
evaluated to determine the extent to which its presence as a secondary
diagnosis resulted in increased hospital resource use. As such, the
designation of CC or MCC is intended to account for the increased
resources required to address a condition as a secondary diagnosis. In
Version 39.1, the 96 diagnosis codes that describe the social
determinants of health from categories Z55-Z65 have a severity
designation of NonCC.
In the proposed rule, we noted that if SDOH Z codes are not
consistently reported in inpatient claims data, our methodology
utilized to mathematically measure the impact on resource use, as
described previously, may not adequately reflect what additional
resources were expended by the hospital to address these SDOH
circumstances in terms of requiring clinical evaluation, extended
length of hospital stay, increased nursing care or monitoring or both,
and comprehensive discharge planning. In the proposed rule, we sought
public comment on whether CMS should consider requiring more robust
documentation and claims data reporting to inform the impact on
resource use these determinants have on caring for patients affected by
these circumstances in an inpatient setting and inform our decision-
making in a future year in determining the most appropriate CC subclass
(NonCC, CC, or MCC) assignment for each SDOH Z code as a secondary
diagnosis. We also sought public comment on developing protocols to
standardize the screening for SDOH for all patients, and then
consistently document and report such codes and on whether such
protocols should vary based on certain factors, such as hospital size
and type. For instance, we noted in the proposed rule that we
recognized that hospitals have different mixes of patients and volume
of patients, and as such, may have
[[Page 48869]]
different staffing resources to devote to proper documentation and
coding of SDOH. In particular, we stated we were interested in hearing
the perspectives of different sized hospitals in both urban and rural
settings, and hospitals disproportionately serving members of
historically underserved and under-resourced communities in regard to
their experience with reporting of SDOH. We also stated we were
additionally interested in learning how reporting SDOH Z codes may be
used to inform community health need assessment activities required by
non-profit hospitals.
In the proposed rule, we also recognized that there is a potential
for different uses and complexity in appropriately determining and
reporting the full range of Z codes. For instance, certain code
categories like Z62 (Problems related to upbringing) and Z63 (Other
problems related to principal support group, including family
circumstances) may require specialized clinical training to diagnose
and document, which may not be the primary purpose of the inpatient
admission. Category Z57 describes occupational exposure to risk
factors, which also may not be apparent in most inpatient admissions
and would rely upon the patient providing this information voluntarily.
Category Z60 (Problems related to social environment) also describes
problems of adjustment to life-cycle transitions, which also may or may
not be readily apparent or discussed by the patient in relation to the
inpatient admission.
Thus, we sought comment on which specific SDOH Z codes were most
likely to influence (that is, increase) hospital resource utilization
related to inpatient care, including any supporting information that
correlates inpatient hospital resource use to specific SDOH Z codes. In
the proposed rule, we stated CMS believed a potential starting point
for discussion was consideration of the SDOH Z diagnosis codes
describing homelessness. Homelessness can be reasonably expected to
have an impact on hospital utilization.\22\ Healthcare needs for
patients experiencing homelessness may be associated with increased
resource utilization compared to other patients due to difficulty
finding discharge destinations to meet the patient's multifaceted needs
which can result in longer inpatient stays and can have financial
impacts for hospitals.\23\ Longer hospital stays for these patients
\24\ can also be associated with increased costs because patients
experiencing homelessness are less able to access care at early stages
of illness, and also may be exposed to communicable disease and harsh
climate conditions, resulting in more severe and complex symptoms by
the time they are admitted to hospitals, potentially leading to worse
health outcomes. We stated in the proposed rule that patients
experiencing homelessness can also be disproportionately affected by
mental health diagnoses and issues with substance use disorders. In
addition, patients experiencing homelessness may have limited or no
access to prescription medicines or over-the-counter medicines,
including adequate locations to store medications away from the heat or
cold,\25\ and studies have shown difficulties adhering to medication
regimens among persons experiencing homeless.\26\ Patients experiencing
homelessness may also face challenges in accessing transplants and
clinicians may defer care because of the uncertain post-acute
discharge.
---------------------------------------------------------------------------
\22\ Koh HK, O'Connell JJ. Improving Health Care for Homeless
People. JAMA. 2016;316(24):2586-2587. doi:10.1001/jama.2016.18760.
\23\ Canham SL, Custodio K, Mauboules C, Good C, Bosma H. Health
and Psychosocial Needs of Older Adults Who Are Experiencing
Homelessness Following Hospital Discharge. Gerontologist. 2020 May
15;60(4):715-724. doi: 10.1093/geront/gnz078. PMID: 31228238.
https://pubmed.ncbi.nlm.nih.gov/31228238/.
\24\ Hwang SW, Weaver J, Aubry T. Hospital costs and length of
stay among homeless patients admitted to medical, surgical, and
psychiatric services. Med Care. 2011;49:350-354. https://journals.lww.com/lww-medicalcare/Fulltext/2019/01000/Trends,_Causes,_and_Outcomes_of_Hospitalizations.4.aspx.
\25\ Sun R (AHRQ), Karaca Z (AHRQ), Wong HS (AHRQ).
Characteristics of Homeless Individuals Using Emergency Department
Services in 2014. HCUP Statistical Brief #229. October 2017. Agency
for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/reports/statbriefs/sb229-Homeless-ED-Visits-2014.pdf.
\26\ Coe, Antoinette B. Coe et al. ``Medication Adherence
Challenges Among Patients Experiencing Homelessness in a Behavioral
Health Clinic. https://journals.lww.com/lww-medicalcare/Fulltext/2019/01000/Trends,_Causes,_and_Outcomes_of_Hospitalizations.4.aspx.
---------------------------------------------------------------------------
To further examine the diagnosis codes that describe SDOH, in the
proposed rule we reviewed the data on the impact on resource use for
diagnosis code Z59.0 (Homelessness) when reported as a secondary
diagnosis to facilitate discussion for the purposes of the comment
solicitation. We noted that prior to FY 2022, homelessness was one of
the more frequently reported codes that describe social determinants of
health. We also noted that effective FY 2022, the subcategory was
expanded and now includes codes Z59.00 (Homelessness, unspecified),
Z59.01 (Sheltered homelessness), and code Z59.02 (Unsheltered
homelessness).
In the FY 2020 IPPS/LTCH PPS proposed rule (84 FR 19243 through
19244), as part of our proposal to change the severity level
designations for 1,492 ICD-10-CM diagnosis codes, we proposed to change
the severity level designation of code Z59.0 (Homelessness) from NonCC
to CC. We stated that because the C1 value (C1 = 1.5964) in the table
was generally close to 2, the data suggested that when reported as a
secondary diagnosis, the resources involved in caring for a patient
experiencing homelessness supported increasing the severity level from
a NonCC to a CC. In the FY 2020 IPPS/LTCH PPS proposed rule, we also
stated our clinical advisors reviewed these data and believed the
resources involved in caring for these patients are more aligned with a
CC. As noted in section II.D.13.b of the proposed rule and this final
rule, many commenters expressed concern with the proposed severity
level designation changes overall and consequently we generally did not
finalize our proposed changes to the severity designations for the
1,492 ICD-10-CM diagnosis codes, at that time. However, the proposal to
change the severity designation of code Z59.0 specifically did receive
mostly supportive comments. We stated in the proposed rule that many
commenters stated that a patient experiencing homelessness requires
significant coordination of social services along with their health
care. Another commenter also recommended that CMS expand the change in
designation to all the codes in category Z59, not just code Z59.0.
Another commenter, while indicating their support of the proposal,
noted that it is unclear that the status/condition would result in
increased hospital resource use.
As discussed in the proposed rule, our proposal in FY 2020 was
based on the data for the impact on resource use generated using claims
from the FY 2018 MedPAR file. The following table reflects the impact
on resource use data generated using claims from the FY 2019 MedPAR
file, FY 2020 MedPAR file and the FY 2021 MedPAR file, respectively,
for the diagnosis code that describes homelessness as a NonCC. We noted
there is currently no data for codes Z59.01 (Sheltered homelessness)
and code Z59.02 (Unsheltered homelessness) as these codes became
effective on October 1, 2021. Again, we refer readers to the FY 2008
IPPS/LTCH PPS final rule (72 FR 47159) for a complete discussion of our
historical approach to mathematically evaluate the extent to which the
presence of an ICD-
[[Page 48870]]
10-CM code as a secondary diagnosis resulted in increased hospital
resource use, and the explanation of the columns in the table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.058
As shown in the table, we examined data for the diagnosis code(s)
that describe homelessness as a NonCC in FY 2019 through FY 2021. When
examining diagnosis code Z59.0 (Homelessness), the value in column C1
is closer to 2.0 than to 1.0 in FY 2019 and FY 2020, though we noted
that we did not use FY 2020 data for rate setting purposes in light of
impacts related to the PHE for COVID-19 as described in the FY 2022
IPPS/LTCH PPS final rule (86 FR 44778). The data suggests that when
homelessness is reported as a secondary diagnosis, the resources
involved in caring for these patients are more aligned with a CC than a
NonCC or an MCC, as explained in the FY 2008 IPPS/LTCH PPS final rule
(72 FR 47159). However, in FY 2021, the C1 value is generally closer to
1, which suggest the resources involved in caring for patients
experiencing homelessness are more aligned with a NonCC severity level
than a CC or an MCC severity level. We also noted fluctuations in the
C1 values year to year. We stated we were uncertain if the data from FY
2021, in particular, reflect fluctuations that may be a result of the
public health emergency or even reduced hospitalizations of certain
conditions. We also stated we were uncertain if homelessness may be
underreported when there is not an available field on the claim when
other diagnoses are reported instead. We sought public comment on these
possibilities, particularly to inform our understanding of the trend of
the C1 value.
As we have stated in prior rulemaking, these mathematical
constructs are used in conjunction with the judgment of our clinical
advisors to classify each secondary diagnosis reviewed. We presented
these data to highlight that the resources expended in caring for
patients reported to be affected by a SDOH such as homelessness during
an inpatient hospitalization may not be consistently expressed in the
inpatient claims data and to demonstrate how reporting the SDOH Z codes
could more accurately reflect the health care encounter and improve the
reliability and validity of the coded data.
In summary, we stated we would appreciate public comment on these
issues, including on the following questions:
How the reporting of certain Z codes--and if so, which Z
codes \27\--may improve our ability to recognize severity of illness,
complexity of service, and utilization of resources under the MS-DRGs?
---------------------------------------------------------------------------
\27\ https://www.cms.gov/files/document/zcodes-infographic.pdf.
---------------------------------------------------------------------------
Whether CMS should require the reporting of certain Z
codes--and if so, which ones--to be reported on hospital inpatient
claims to strengthen data analysis?
The additional provider burden and potential benefits of
documenting and reporting of certain Z codes, including potential
benefits to beneficiaries.
Whether codes in category Z59 (Homelessness) have been
underreported and if so, why? In particular, we stated we were
interested in hearing the perspectives of large urban hospitals, rural
hospitals, and other hospital types in regard to their experience. We
also sought comments on how factors such as hospital size and type
might impact a hospital's ability to develop standardized consistent
protocols to better screen, document and report homelessness.
As discussed in the proposed rule, we stated that the comments we
receive on these issues may also be informative as we evaluate whether
to develop a proposal in future rulemaking to change the severity level
designation of the diagnosis codes describing homelessness from NonCC
to CC and whether other SDOH, as described by Z codes, are also
appropriate candidates to be proposed for designation as CCs.
We noted that examining the severity level designation of diagnosis
codes is just one area to possibly support documentation and reporting
of SDOH in the inpatient setting. We stated we were also interested in
ideas from the public on how the MS-DRG classification can be utilized
in agency wide efforts to advance health equity, expand access, drive
high-quality, person-centered care, and promote affordability and
sustainability in the Medicare program. Specifically, we invited public
comment on ways the MS-DRG classification can be useful in addressing
the challenges of defining and collecting accurate and standardized
self-identified socioeconomic information for the purposes of
reporting, measure stratification, and other data collection efforts.
We stated we were interested in learning more about the potential
benefits and challenges associated with the collection of SDOH data in
the inpatient setting. Feedback on the limitations and barriers
providers could experience as they consider more robust documentation
and reporting would also help inform our development of appropriately
tailored efforts that address and mitigate barriers for all hospital
types across communities and patient mixes. We stated we would take
commenters' feedback into consideration in future policy development.
In this FY 2023 IPPS/LTCH PPS final rule, we present a summation of
the comments we received in response to our request for information on
SDOH diagnosis codes, including how the reporting of SDOH diagnosis
codes may improve our ability to recognize severity of illness,
complexity of service, and/or utilization of resources under the MS-
DRGs, as well as how we might otherwise foster the documentation and
reporting of the diagnosis codes describing social and economic
circumstances to more accurately reflect each health care encounter and
improve the reliability and validity of the coded data, including in
support of efforts to advance health equity. We thank commenters for
sharing their views and their willingness to support CMS in these
efforts.
Comment: Many commenters applauded CMS' efforts to encourage
documentation and reporting of SDOH diagnosis codes given the impact
that social risks can have on health outcomes. These commenters stated
that it is critical that physicians, other health care professionals,
and facilities
[[Page 48871]]
recognize the impact SDOH have on the health of their patients.
Commenters stated that they agree that better reporting of these SDOH Z
codes through inpatient claims could enhance coordination within
hospitals across clinical care teams and discharge planning, and with
post-acute care providers. A commenter stated that SDOH data can be
extremely valuable and powerful tools to improve healthcare, and stated
that they were confident that CMS' encouragement of the use of this
data would lead to better healthcare for our country.
Some commenters stated that while the documentation and reporting
of SDOH diagnosis codes is important to address healthcare inequities,
the collection of this data may place significant burden on facilities
and providers and have tremendous operational and technology impacts.
Commenters stated that hospitals have demonstrated significant
variability in screening capabilities and referral practices, and
inpatient settings require additional time to develop screening
protocols and ensure that screening results are documented in a place
where they can be captured for claims. Other commenters stated
assigning codes for SDOH can be a time-consuming and labor-intensive
process, as many electronic health records (EHRs) do not have easy
pathways to add a Z code to the problem or diagnosis list. Other
commenters stated that one of the major challenges to providers is
ensuring that SDOH information documented in the EHR and reported on
the claim is accurate as patients' circumstances are ever changing. A
commenter stated that it is not feasible for hospitals to screen for
every SDOH due to the time and resources involved for both patients and
providers and suggested that rather than require this process be
repeated with each encounter, CMS should permit SDOH information to
carry forward across encounters until new documentation supports
removal or revision to the initial SDOH diagnosis codes to minimize the
administrative burden. Commenters also stated that the challenge of
increased documentation reviews by coding staff would be further
exacerbated by staffing shortages within the industry, as well as
coding productivity standards. A few commenters stated for rural
hospitals, bandwidth is already low due to workforce shortages and
heavy caseloads. These commenters stated that adding any screening and
documentation processes for SDOH, on top of existing workloads, may
require more than a physician or nurse and instead may require engaging
a staff such as social workers or psychologists who may not be standard
members of care teams at all rural hospitals.
Many commenters stated there was a lack of standard, nationally
accepted definitions of the SDOH Z codes and that there are potential
gaps that may come with the use of, and reporting related to SDOH Z
codes. Other commenters stated that SDOH Z codes are informative but
some descriptions lack specificity and may be too broad to distinctly
capture enough detail around the type of care that the patient needs
relative to their diagnosis and their SDOH challenges. Commenters also
identified the lack of national data and exchange standards for capture
of the SDOH Z codes as an additional barrier. Commenters stated that
while fully supporting efforts to improve and increase the collection
of SDOH data, they believed that other options exist that would make it
feasible for hospitals of all sizes and types to consistently collect
data in a standardized manner without creating undue burden and
suggested that CMS consider developing a broader strategy for
collecting SDOH data. A commenter specifically suggested that CMS
coordinate with states, which are often requiring their own assessments
to identify social risk and needs, to reduce burden. Another commenter
stated that they believed that the creation of a new Hierarchical
Condition Category for SDOH Z codes could help improve documentation
efforts since, according to this commenter, organizations that treat
these high-risk patients are reimbursed at higher rates than those
patients who are not grouped into these HCCs.
Commenters recommended that CMS consider reimbursement incentives
for documenting and reporting of SDOH Z codes to help health care
providers build and sustain systemic screening and documentation, which
will ultimately lead to better health for patients. Many commenters
stated that they agree that codes in category Z59 (Homelessness) have
been underreported and that increasing the severity level of the codes
that describe homelessness from a NonCC to a CC could prompt more
rigorous documentation and reporting. Commenters stated that they
believe that homelessness involves a level of care in line with
diagnoses currently designated as CCs. Some commenters stated that
patients experiencing homelessness can often increase inpatient costs
by creating discharge disposition challenges that lead to an extended
length of stay. A few commenters noted that in their experience,
extended lengths of stay were particularly high for patients
experiencing homelessness who underwent surgery. Another commenter
stated that based on their own analysis, homelessness has an effect on
resource utilization on par with other diagnoses currently designated
as MCCs but stated elevation to a CC is the most reasonable first step
to help drive the reporting of these SDOH Z codes, and help drive
subsequent, meaningful evaluation of outcomes.
Commenters encouraged CMS to examine other SDOH Z codes that
describe circumstances such as food insecurity, lack of adequate food
and drinking water, extreme poverty, lack of transportation and
unemployment, to determine the hospital resource utilization related to
addressing these factors and to analyze whether these SDOH Z codes
should be considered for designation as CCs as well. Some commenters
also pointed to conditions outside of the SDOH Z codes such as: medical
debt, malnutrition, elder abuse and neglect, underdosing of medication,
personal history of falling and awaiting organ transplant status as
examples of other areas where fostering better documentation and
reporting could improve health outcomes.
Other commenters expressed concern and stated that they believed
that while some SDOH diagnoses could have some impact for MS-DRG
assignment due to additional efforts needed around discharge planning,
generally SDOH diagnoses should have limited impact on severity of
illness. Rather, according to these commenters, the impact is more
important for risk adjustment for population-based initiatives, such as
a readmissions program. A commenter stated that simply elevating SDOH
Z-codes to CCs and marginally increasing reimbursement will be
inadequate to meaningfully drive CMS' stated equity mission. Another
commenter noted that in some cases, patients experiencing circumstances
described by SDOH Z codes may require social services support to
address a need post-discharge, but the complexity of the inpatient
clinical services is not affected. A commenter, while supportive of the
consideration of the change in designation, expressed concern that
increasing the severity level of the codes that describe homelessness
from a NonCC to a CC could potentially lead to fraudulent or abusive
coding practices in order to raise the payment rate for an encounter.
Another commenter recommended that safeguards be put in place to
disallow oversight agencies (such as Recovery Audit Contractors (RAC)
and third-party
[[Page 48872]]
payer validations) from challenging MS-DRG assignment, and instead
honor the reporting of the code when supported by documentation,
especially in instances where homelessness might be the only
complication or comorbidity coded.
While commending CMS' efforts, many commenters cautioned that
mandating the reporting of SDOH Z codes could necessitate making
changes to the institutional claim form. Currently, only 25 diagnoses
are captured on the electronic claim form. Commenters noted that
documenting and reporting the social and economic circumstances
patients may be experiencing may require a substantial number of SDOH Z
codes, and stated that this could lead to the crowding out of other
diagnosis codes that also need to be captured on the claim form such as
codes for medical diagnoses, comorbidities, Hierarchical Condition
Category (HCC) coding, Hospital Acquired Conditions (HAC), and patient
safety indicators (PSI) due to limited space.
Several commenters expressed concern and stated that they did not
believe that CMS proposed a clear, compelling, or significant benefit
to patients as a result of collecting this data. These commenters
cautioned against requiring hospitals to implement the collection of
sensitive information for the purposes of analysis, and asserted that
CMS will be placing hospitals in the precarious position of asking
sensitive and intimate social questions, while often not having
solutions to mitigate or eliminate these risks, as they stated the
documentation of social risks does not in and of itself improve health
outcomes. A commenter stated that studies have shown that many
providers are wary of screening for social needs, if they believe they
do not also have the ability to make referrals or to connect patients
to resources to address their needs. Other commenters expressed concern
and stated it is counterproductive for hospitals to collect SDOH data
without having resources and pathways in place to offer help. A few
commenters stated that by requiring medical facilities to report this
data, CMS is diverting resources and time from patient care and stated
that CMS should not be pursing an initiative that is meant to collect
data on non-medical information. A commenter stated that although the
collection of SDOH information can occur during inpatient visits,
documentation and reporting of this data may be actually best suited to
outpatient office visits, where providers may have a greater
opportunity to interact with their patients and the ability to consider
more proactive approaches to help address their social needs.
Many other commenters also expressed concern and stated that while
SDOH information can be useful for administrative use and payment
adjustment, information about an individual's social risk and needs has
been shown to be sensitive, and individuals are often hesitant to
disclose this information for fear of bias, misuse, or discrimination.
Commenters stated patients may not see the relevance of providing
information to their providers related to SDOH that may not be directly
applicable to why they are seeking care. These commenters stated that
there are significant concerns from physicians, other providers, and
patients about ``medicalizing'' SDOH in the electronic health record
and stated mechanisms must be established to shield this sensitive
information on certain forms, charts, health records, and discharge
papers. Commenters noted that when SDOH Z codes are entered via an EHR
or other form of collection, those results show up on the patient's
after-visit summary, which may be concerning for patients. Commenters
also expressed concern that SDOH Z codes may ``follow'' a patient for
too many years and cause potential discrimination, bias, or other
misunderstandings in the future. Commenters stated that hospitals must
be equipped with tools to communicate the context of SDOH Z codes with
patients at the point of screening or self-reporting so that patients
understand the rationale for data collection and how it can help
address their needs. Several commenters stated that CMS should also put
in place Conditions of Participation requiring hospitals to train their
staff on how this information can and cannot be used to prevent
information being used in discriminatory pricing, care, or other
purposes.
Many commenters stated that the most immediate and important action
CMS could take to increase the use of SDOH Z codes is to finalize the
evidence-based ``Screening for Social Drivers of Health'' and ``Screen
Positive Rate for Social Drivers of Health'' measures proposed to be
adopted in the Hospital Inpatient Quality Reporting (IQR) Program.
These commenters stated that these measures create an opportunity to
collect inpatient SDOH data at a scale that could significantly improve
MS-DRGs' precision and ability to recognize severity and complexity of
service and utilization of resources. Many commenters stated that
absent these measures and associated data, SDOH Z codes will continue
to be underreported and unreliable. We refer the reader to section
IX.E.5.b of the preamble of the proposed rule and this final rule for
further discussion regarding new measures for the Hospital IQR Program
measure set. These commenters urged CMS to start with an incremental
approach in requiring the reporting of SDOH Z codes and suggested that
reporting should be optional or voluntary for at least two-three years
to allow providers and CMS to gain experience in reporting and
collecting this data. If the reporting of the SDOH Z codes becomes
mandatory, these commenters recommended that the requirement start with
the subset of SDOH Z codes that directly align with the social needs
identified in the five core domains of the proposed measures.
Response: We again thank commenters for sharing their views and
their willingness to support CMS in these efforts. We will take the
commenters' feedback into consideration in future policy development.
e. Additions and Deletions to the Diagnosis Code Severity Levels for FY
2023
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28181) we noted
the following tables identify the proposed additions and deletions to
the diagnosis code MCC severity levels list and the proposed additions
and deletions to the diagnosis code CC severity levels list for FY 2023
and are available via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html
Table 6I.1--Proposed Additions to the MCC List--FY 2023;
Table 6I.2--Proposed Deletions to the MCC List--FY 2023;
Table 6J.1--Proposed Additions to the CC List--FY 2023; and
Table 6J.2--Proposed Deletions to the CC List--FY 2023.
Comment: Commenters agreed with the proposed additions and
deletions to the MCC and CC lists as shown in tables 6I.1, 6I.2, 6J.1,
and 6J.2 associated with the proposed rule.
Response: We appreciate the commenters' support.
The following tables associated with this final rule reflect the
finalized severity levels under Version 40 of the ICD-10 MS-DRGs for FY
2023 and are available via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS; Table 6I. --Complete MCC List--FY 2023; Table
[[Page 48873]]
6I.1--Additions to the MCC List--FY 2023; Table 6I.2--Deletions to the
MCC List--FY 2022; Table 6J.--Complete CC List--FY 2023; Table 6J.1--
Additions to the CC List--FY 2023; and Table 6J.2--Deletions to the CC
List--FY 2023.
f. CC Exclusions List for FY 2023
In the September 1, 1987 final notice (52 FR 33143) concerning
changes to the DRG classification system, we modified the GROUPER logic
so that certain diagnoses included on the standard list of CCs would
not be considered valid CCs in combination with a particular principal
diagnosis. We created the CC Exclusions List for the following reasons:
(1) to preclude coding of CCs for closely related conditions; (2) to
preclude duplicative or inconsistent coding from being treated as CCs;
and (3) to ensure that cases are appropriately classified between the
complicated and uncomplicated DRGs in a pair.
In the May 19, 1987 proposed notice (52 FR 18877) and the September
1, 1987 final notice (52 FR 33154), we explained that the excluded
secondary diagnoses were established using the following five
principles:
Chronic and acute manifestations of the same condition
should not be considered CCs for one another.
Specific and nonspecific (that is, not otherwise specified
(NOS)) diagnosis codes for the same condition should not be considered
CCs for one another.
Codes for the same condition that cannot coexist, such as
partial/total, unilateral/bilateral, obstructed/unobstructed, and
benign/malignant, should not be considered CCs for one another.
Codes for the same condition in anatomically proximal
sites should not be considered CCs for one another.
Closely related conditions should not be considered CCs
for one another.
The creation of the CC Exclusions List was a major project
involving hundreds of codes. We have continued to review the remaining
CCs to identify additional exclusions and to remove diagnoses from the
master list that have been shown not to meet the definition of a CC. We
refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50541
through 50544) for detailed information regarding revisions that were
made to the CC and CC Exclusion Lists under the ICD-9-CM MS-DRGs.
The ICD-10 MS-DRGs Version 39.1 CC Exclusion List is included as
Appendix C in the ICD-10 MS-DRG Definitions Manual, which is available
via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html, and
includes two lists identified as Part 1 and Part 2. Part 1 is the list
of all diagnosis codes that are defined as a CC or MCC when reported as
a secondary diagnosis. For all diagnosis codes on the list, a link is
provided to a collection of diagnosis codes which, when reported as the
principal diagnosis, would cause the CC or MCC diagnosis to be
considered as a NonCC. Part 2 is the list of diagnosis codes designated
as a MCC only for patients discharged alive; otherwise, they are
assigned as a NonCC.
In the FY 2023 IPPS/LTCH PPS proposed rule, we proposed additional
changes to the ICD-10 MS-DRGs Version 40 CC Exclusion List based on the
diagnosis and procedure code updates as discussed in section II.D.14.
of the proposed rule and set forth in Tables 6G.1, 6G.2, 6H.1, and 6H.2
associated with the proposed rule and available via the internet on the
CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS.
As discussed in section II.D.14 of the preamble of this final rule,
we are finalizing, without modification, the proposed assignments and
designations for the diagnosis codes after consideration of the public
comments received. Therefore, the finalized CC Exclusions List as
displayed in Tables 6G.1, 6G.2, 6H.1, 6H.2, and 6K, associated with
this final rule reflect the severity levels under V40 of the ICD-10 MS-
DRGs. We have developed Table 6G.1.--Secondary Diagnosis Order
Additions to the CC Exclusions List--FY 2023; Table 6G.2.--Principal
Diagnosis Order Additions to the CC Exclusions List--FY 2023; Table
6H.1.--Secondary Diagnosis Order Deletions to the CC Exclusions List--
FY 2023; and Table 6H.2.--Principal Diagnosis Order Deletions to the CC
Exclusions List--FY 2023; and Table 6K. Complete List of CC
Exclusions--FY 2023.
For Table 6G.1, each secondary diagnosis code finalized for
addition to the CC Exclusion List is shown with an asterisk and the
principal diagnoses finalized to exclude the secondary diagnosis code
are provided in the indented column immediately following it. For Table
6G.2, each of the principal diagnosis codes for which there is a CC
exclusion is shown with an asterisk and the conditions finalized for
addition to the CC Exclusion List that will not count as a CC are
provided in an indented column immediately following the affected
principal diagnosis. For Table 6H.1, each secondary diagnosis code
finalized for deletion from the CC Exclusion List is shown with an
asterisk followed by the principal diagnosis codes that currently
exclude it. For Table 6H.2, each of the principal diagnosis codes is
shown with an asterisk and the finalized deletions to the CC Exclusions
List are provided in an indented column immediately following the
affected principal diagnosis. Tables 6G.1, 6G.2, 6H.1, and 6H.2
associated with this final rule are available via the internet on the
CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.
The ICD-10 MS-DRGs Version 40 CC Exclusion List is included as
Appendix C of the Definitions Manual (available in two formats; text
and HTML). The manuals are available via the internet on the CMS
website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software and each
format includes two lists identified as Part 1 and Part 2. Part 1 is
the list of all diagnosis codes that are defined as a CC or MCC when
reported as a secondary diagnosis. For all diagnosis codes on the list,
a link (HTML version) is provided to a collection of diagnosis codes
which, when used as the principal diagnosis, would cause the CC or MCC
diagnosis to be considered as a NonCC. Part 2 is the list of diagnosis
codes designated as a MCC only for patients discharged alive;
otherwise, they are assigned as a NonCC.
14. Changes to the ICD-10-CM and ICD-10-PCS Coding Systems
To identify new, revised and deleted diagnosis and procedure codes,
for FY 2023, we have developed Table 6A.--New Diagnosis Codes, Table
6B.--New Procedure Codes, Table 6C.--Invalid Diagnosis Codes, Table
6D.--Invalid Procedure Codes, and Table 6E.--Revised Diagnosis Code
Titles for this final rule.
These tables are not published in the Addendum to the proposed rule
or final rule, but are available via the internet on the CMS website
at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html as described in section VI. of the
Addendum to this final rule. As discussed in section II.D.17. of the
preamble of the proposed rule and this final rule, the code titles are
adopted as part of the ICD-10 Coordination and Maintenance Committee
meeting process. Therefore, although we publish the code titles in the
IPPS proposed and final rules, they are not subject to comment in the
proposed or final rules.
[[Page 48874]]
We are finalizing the MDC and MS-DRG assignments for the new
diagnosis codes and procedure codes as set forth in Table 6A.--New
Diagnosis Codes and Table 6B.--New Procedure Codes. In addition, the
finalized severity level designations for the new diagnosis codes are
set forth in Table 6A. and the finalized O.R. status for the new
procedure codes are set forth in Table 6B. Consistent with our
established process, we examined the MS-DRG assignment and the
attributes (severity level and O.R. status) of the predecessor
diagnosis or procedure code, as applicable, to inform our finalized
assignments and designations.
Specifically, we review the predecessor code and MS-DRG assignment
most closely associated with the new diagnosis or procedure code, and
in the absence of claims data, we consider other factors that may be
relevant to the MS-DRG assignment, including the severity of illness,
treatment difficulty, complexity of service and the resources utilized
in the diagnosis or treatment of the condition. We note that this
process does not automatically result in the new diagnosis or procedure
code being proposed for assignment to the same MS-DRG or to have the
same designation as the predecessor code.
We are making available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html
the following tables associated with this final rule:
Table 6A.--New Diagnosis Codes--FY 2023
Table 6B.--New Procedure Codes--FY 2023
Table 6C.--Invalid Diagnosis Codes--FY 2023
Table 6D.--Invalid Procedure Codes--FY 2023
Table 6E.--Revised Diagnosis Code Titles--FY 2023
Table 6G.1.--Secondary Diagnosis Order Additions to the CC
Exclusions List--FY 2023
Table 6G.2.--Principal Diagnosis Order Additions to the CC
Exclusions List--FY 2023
Table 6H.1.--Secondary Diagnosis Order Deletions to the CC
Exclusions List--FY 2023
Table 6H.2.--Principal Diagnosis Order Deletions to the CC
Exclusions List--FY 2023
Table 6I.--Complete MCC List--FY 2023
Table 6I.1.--Additions to the MCC List--FY 2023
Table 6I.2.--Deletions to the MCC List--FY 2023
Table 6J.--Complete CC List--FY 2023
Table 6J.1.--Additions to the CC List--FY 2023
Table 6J.2.--Deletions to the CC List--FY 2023
Table 6K.--Complete List of CC Exclusions--FY 2023.
15. Changes to the Medicare Code Editor (MCE)
The Medicare Code Editor (MCE) is a software program that detects
and reports errors in the coding of Medicare claims data. Patient
diagnoses, procedure(s), and demographic information are entered into
the Medicare claims processing systems and are subjected to a series of
automated screens. The MCE screens are designed to identify cases that
require further review before classification into an MS-DRG.
As discussed in the FY 2022 IPPS/LTCH PPS final rule (86 FR 44936),
we made available the FY 2022 ICD-10 MCE Version 39 manual file. The
manual contains the definitions of the Medicare code edits, including a
description of each coding edit with the corresponding diagnosis and
procedure code edit lists. The link to this MCE manual file, along with
the link to the mainframe and computer software for the MCE Version 39
(and ICD-10 MS-DRGs) are posted on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.
In the FY 2023 IPPS/LTCH PPS proposed rule, we discussed the
proposals we were making based on our internal review and analysis. We
noted that we did not receive any specific MCE requests by the November
1, 2021 deadline. In this FY 2023 IPPS/LTCH PPS final rule, we present
a summation of the comments we received in response to the MCE
proposals presented based on internal review and analyses in the
proposed rule, our responses to those comments, and our finalized
policies.
In addition, as a result of new and modified code updates approved
after the annual spring ICD-10 Coordination and Maintenance Committee
meeting, we routinely make changes to the MCE. In the past, in both the
IPPS proposed and final rules, we have only provided the list of
changes to the MCE that were brought to our attention after the prior
year's final rule. We historically have not listed the changes we have
made to the MCE as a result of the new and modified codes approved
after the annual spring ICD-10 Coordination and Maintenance Committee
meeting. These changes are approved too late in the rulemaking schedule
for inclusion in the proposed rule. Furthermore, although our MCE
policies have been described in our proposed and final rules, we have
not provided the detail of each new or modified diagnosis and procedure
code edit in the final rule. However, we make available the finalized
Definitions of Medicare Code Edits (MCE) file. Therefore, we are making
available the FY 2023 ICD-10 MCE Version 40 Manual file, along with the
link to the mainframe and computer software for the MCE Version 40 (and
ICD-10 MS-DRGs), on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.
a. External Causes of Morbidity Codes as Principal Diagnosis
In the MCE, the external cause codes (V, W, X, or Y codes) describe
the circumstance causing an injury, not the nature of the injury, and
therefore should not be used as a principal diagnosis.
As discussed in section II.D.14. of the preamble of the proposed
rule and this final rule, Table 6C.--Invalid Diagnosis Codes, lists the
diagnosis codes that are no longer effective as of October 1, 2022.
Included in this table are codes currently subject to the External
causes of morbidity codes as principal diagnosis edit. We proposed to
delete the ICD-10-CM diagnosis codes shown in Table 6P.6a associated
with the proposed rule and available via the internet on the CMS
website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS that are currently subject to the External
causes of morbidity codes as principal diagnosis edit since they will
no longer be valid for reporting purposes.
Comment: Commenters agreed with CMS's proposal to remove the
diagnosis codes listed in Table 6P.6a from the External Causes of
Morbidity edit code list since they are no longer valid.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to delete the diagnosis codes listed in Table
6P.6a associated with the proposed rule from the External Causes of
Morbidity edit code list under the ICD-10 MCE Version 40, effective
October 1, 2022.
b. Age Conflict Edit
In the MCE, the Age conflict edit exists to detect inconsistencies
between a patient's age and any diagnosis on the patient's record; for
example, a 5-year-
[[Page 48875]]
old patient with benign prostatic hypertrophy or a 78-year-old patient
coded with a delivery. In these cases, the diagnosis is clinically and
virtually impossible for a patient of the stated age. Therefore, either
the diagnosis or the age is presumed to be incorrect. Currently, in the
MCE, the following four age diagnosis categories appear under the Age
conflict edit and are listed in the manual and written in the software
program:
Perinatal/Newborn--Age 0 years only; a subset of diagnoses
which will only occur during the perinatal or newborn period of age 0
(for example, tetanus neonatorum, health examination for newborn under
8 days old).
Pediatric--Age is 0-17 years inclusive (for example,
Reye's syndrome, routine child health exam).
Maternity--Age range is 9-64 years inclusive (for example,
diabetes in pregnancy, antepartum pulmonary complication).
Adult--Age range is 15-124 years inclusive (for example,
senile delirium, mature cataract).
(1) Maternity Diagnoses
Under the ICD-10 MCE, the Maternity diagnoses category for the Age
conflict edit considers the age range of 9 to 64 years inclusive. For
that reason, the diagnosis codes on this Age conflict edit list would
be expected to apply to conditions or disorders specific to that age
group only.
As discussed in section II.D.14. of the preamble of the proposed
rule and this final rule, Table 6A.--New Diagnosis Codes, lists the
diagnosis codes that have been approved to date which will be effective
with discharges on and after October 1, 2022. We proposed to add new
ICD-10-CM diagnosis codes to the edit code list for the Maternity
diagnoses category as shown in Table 6P.6b associated with the proposed
rule and available via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS
under the Age conflict edit.
Comment: Commenters agreed with CMS's proposal to add the diagnosis
codes listed in Table 6P.6b to the Maternity diagnoses edit code list.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to add the diagnosis codes as shown in Table
6P.6b associated with the proposed rule to the Maternity diagnoses edit
code list.
In addition, as discussed in section II.D.14. of the preamble of
the proposed rule and this final rule, Table 6C.--Invalid Diagnosis
Codes, lists the diagnosis codes that are no longer effective as of
October 1, 2022. We proposed to delete the following diagnosis codes
from the Maternity diagnoses edit code list.
[GRAPHIC] [TIFF OMITTED] TR10AU22.059
Comment: Commenters agreed with CMS's proposal to remove the
diagnosis codes listed in the previous table from the Maternity
diagnoses edit code list since they are no longer valid.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to remove the diagnosis codes listed in the
previous table from the Maternity diagnoses edit code list under the
ICD-10 MCE Version 40, effective October 1, 2022.
(2) Adult Diagnoses
Under the ICD-10 MCE, the Adult diagnoses category for the Age
conflict edit considers the age range of 15 to 124 years inclusive. For
that reason, the diagnosis codes on this Age conflict edit list would
be expected to apply to conditions or disorders specific to that age
group only.
As discussed in section II.D.14. of the preamble of the proposed
rule and this final rule, Table 6A.--New Diagnosis Codes, lists the
diagnosis codes that have been approved which will be effective with
discharges on and after October 1, 2022. We proposed to add the
following new ICD-10-CM diagnosis codes to the edit code list for the
Adult diagnoses category under the Age conflict edit.
[[Page 48876]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.060
Comment: Commenters agreed with CMS's proposal to add the diagnosis
codes listed in the previous table to the Adult diagnoses edit code
list.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to add the diagnosis codes listed in the
previous table to the Adult diagnoses edit code list under the ICD-10
MCE Version 40, effective October 1, 2022.
In addition, as discussed in section II.D.14. of the preamble of
the proposed rule and this final rule, Table 6C.--Invalid Diagnosis
Codes, lists the diagnosis codes that are no longer effective as of
October 1, 2022. We proposed to delete the following codes from the
Adult diagnoses edit code list.
[[Page 48877]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.061
Comment: Commenters agreed with CMS's proposal to remove the
diagnosis codes listed in the previous table from the Adult diagnoses
edit code list since they are no longer valid.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to remove the diagnosis codes listed in the
previous table from the Adult diagnoses edit code list under the ICD-10
MCE Version 40, effective October 1, 2022.
c. Sex Conflict Edit
In the MCE, the Sex conflict edit detects inconsistencies between a
patient's sex and any diagnosis or procedure on the patient's record;
for example, a male patient with cervical cancer (diagnosis) or a
female patient with a prostatectomy (procedure). In both instances, the
indicated diagnosis or the procedure conflicts with the stated sex of
the patient. Therefore, the patient's diagnosis, procedure, or sex is
presumed to be incorrect.
Comment: A commenter requested clarification on how the sex
conflict edits consider patients who identify as transgender.
Response: The sex conflict edit under the MCE is consistent with 45
CFR 170.207(n) which states that birth sex must be coded as Male,
Female or Unknown. Gender identity is a separate data element under 45
CFR 170.207(o). We note that any proposed changes to account for gender
identity on the CMS-1450 form would need to be submitted to the
National Uniform Billing Committee (NUBC) for consideration.
Comment: Another commenter expressed concerns about the existing
ICD-10 codes and edits that appear to be sex specific (that is, male
only or female only). According to the commenter, reporting of these
codes for patients who identify as transgender may result in treatment
being delayed or denied. The commenter acknowledged the necessity in
aligning a patient's historical health data with that of their gender
identity and personal anatomy, however, according to the commenter,
removal of sex specific codes from the MCE would be beneficial for
nonbinary people as well.
Another commenter stated that transgender individuals may be
alienated and deterred from seeking medical care in the future as a
result of inappropriate claims denial due to the Sex conflict edit. The
commenter stated that obstetricians-gynecologists specifically have
conveyed the need to document and report a patient's gender identity in
combination with their sex to provide quality, patient-centered care.
The commenter also stated they have made recommendations to the Office
of the National Coordinator for Health Information Technology (ONC) to
include the data element ``gender'' in its minimum certification
criteria for electronic health records. The commenter recommended that
CMS work with ONC to ensure that automated claim editors, like the MCE,
do not require obstetrician-gynecologists and other health care
professionals to misrepresent their patients' genders to provide the
appropriate clinical care. Lastly, the commenter encouraged CMS to
continue its efforts to reduce the administrative burden by adapting
the MCE and other systems to fit the needs of all physicians and their
patients.
Response: We appreciate the commenters' feedback. We intend to
explore alternative options that may help to address the challenges
described by the commenters with claims processing for individuals who
identify as transgender or nonbinary.. We are interested in feedback
and comments on other ways for which these issues could be considered
from a process, systems and operational perspective. Comments should be
directed to the new electronic intake system, Medicare Electronic
Application Request Information SystemTM
(MEARISTM), discussed in section II.D.1.b of the preamble of
the proposed rule and this final rule at: https://mearis.cms.gov/public/home by October 20, 2022
(1) Diagnoses for Females Only Edit
As discussed in section II.D.14. of the preamble of the proposed
rule and this final rule, Table 6A.--New Diagnosis Codes, lists the new
diagnosis codes that have been approved to date which will be effective
with discharges on and after October 1, 2022. We proposed to add new
ICD-10-CM diagnosis codes to the edit code list for the Diagnoses for
females only category as shown in Table 6P.6c associated with the
proposed rule and available via the internet on the CMS website at:
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS under the Sex conflict edit.
Comment: Commenters agreed with CMS's proposal to add the diagnosis
codes listed in Table 6P.6c to the Diagnoses for females only edit code
list.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to add the diagnosis codes as shown in Table
6P.6c associated with the proposed rule to the Diagnoses for females
only edit code list.
In addition, as discussed in section II.D.14. of the preamble of
the proposed rule and this final rule, Table 6C.--Invalid Diagnosis
Codes, lists the diagnosis codes that are no longer effective as of
October 1, 2022. We proposed to delete the following codes from the
Diagnoses for females only edit code list.
[[Page 48878]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.062
Comment: Commenters agreed with CMS's proposal to remove the
diagnosis codes listed in the previous table from the Diagnoses for
females only edit code list since they are no longer valid.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to remove the diagnosis codes listed in the
previous table from the Diagnoses for female only edit code list under
the ICD-10 MCE Version 40, effective October 1, 2022.
(2) Procedures for Males Only
As discussed in section II.D.14. of the preamble of the proposed
rule and this final rule, Table 6B.--New Procedure Codes, lists the new
procedure codes that have been approved to date which will be effective
with discharges on and after October 1, 2022. Included in this table
are the following procedure codes we proposed to add to the edit code
list for the Procedures for males only category under the Sex conflict
edit.
[GRAPHIC] [TIFF OMITTED] TR10AU22.063
Comment: Commenters agreed with CMS's proposal to add the diagnosis
codes listed in the previous table to the Procedures for males only
edit code list.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to add the diagnosis codes listed in the
previous table to the Procedures for males only
[[Page 48879]]
edit code list under the ICD-10 MCE Version 40, effective October 1,
2022.
d. Manifestation Code as Principal Diagnosis Edit
In the ICD-10-CM classification system, manifestation codes
describe the manifestation of an underlying disease, not the disease
itself, and therefore should not be used as a principal diagnosis.
As discussed in section II.D.14. of the preamble of the proposed
rule and this final rule, Table 6A.--New Diagnosis Codes, lists the new
diagnosis codes that have been approved which will be effective with
discharges on and after October 1, 2022. Included in this table are the
following new ICD-10-CM diagnosis codes that we proposed to add to the
edit code list for the Manifestation code as principal diagnosis edit,
because the disease itself would be required to be reported first.
[GRAPHIC] [TIFF OMITTED] TR10AU22.064
Comment: Commenters agreed with CMS's proposal to add the diagnosis
codes listed in the previous table to the Manifestation code as
principal diagnosis edit code list.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to add the diagnosis codes listed in the
previous table to the Manifestation code as principal diagnosis edit
code list under the ICD-10 MCE Version 40, effective October 1, 2022.
In addition, as discussed in section II.D.14. of the preamble of
the proposed rule and this final rule, Table 6C.--Invalid Diagnosis
Codes, lists the diagnosis codes that are no longer effective as of
October 1, 2022. Included in this table is ICD-10-CM diagnosis code
F02.81 (Dementia in other diseases classified elsewhere with behavioral
disturbance), that is currently listed on the edit code list for the
Manifestation code as principal diagnosis edit. We proposed to delete
this code from the Manifestation code as principal diagnosis edit code
list.
Comment: Commenters agreed with CMS's proposal to remove diagnosis
code F02.81 from the Manifestation code as principal diagnosis edit
code list since it is no longer valid.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to remove diagnosis code F02.81 from the
Manifestation code as principal diagnosis edit code list under the ICD-
10 MCE Version 40, effective October 1, 2022.
e. Unacceptable Principal Diagnosis Edit
In the MCE, there are select codes that describe a circumstance
which influences an individual's health status but does not actually
describe a current illness or injury. There also are codes that are not
specific manifestations but may be due to an underlying cause. These
codes are considered unacceptable as a principal diagnosis. In limited
situations, there are a few codes on the MCE Unacceptable Principal
Diagnosis edit code list that are considered ``acceptable'' when a
specified secondary diagnosis is also coded and reported on the claim.
As discussed in section II.D.14. of the preamble of the proposed
rule and this final rule, Table 6A.--New Diagnosis Codes, lists the new
diagnosis codes that have been approved which will be effective with
discharges on and after October 1, 2022. Additionally, as discussed in
section II.D.1.b of the preamble of the proposed rule and this final
rule, we provided a test version of the ICD-10 MS-DRG GROUPER Software,
Version 40, so that the public could better analyze and understand the
[[Page 48880]]
impact of the proposals included in the proposed rule. We noted that at
the time of the development of the test software, a subset of the
listed codes (F01.511 through F01.C4) that were proposed for this edit
were unable to be included and therefore, the test software does not
reflect these codes. We proposed to add the following new ICD-10-CM
diagnosis codes to the Unacceptable Principal Diagnosis edit code list.
[GRAPHIC] [TIFF OMITTED] TR10AU22.065
[[Page 48881]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.066
Comment: Commenters agreed with our proposal to add the diagnosis
codes listed in the previous table to the Unacceptable Principal
Diagnosis edit code list.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to add the diagnosis codes listed in the
previous table to the Unacceptable Principal Diagnosis edit code list
under the ICD-10 MCE Version 40, effective October 1, 2022.
In addition, as discussed in section II.D.14. of the preamble of
the proposed rule and this final rule, Table 6C.--Invalid Diagnosis
Codes, lists the diagnosis codes that are no longer effective as of
October 1, 2022. We proposed to delete the following codes from the
Unacceptable Principal Diagnosis edit code list.
[GRAPHIC] [TIFF OMITTED] TR10AU22.067
Comment: Commenters agreed with CMS's proposal to remove diagnosis
codes Z87.76, Z91.11, and Z91.19 from the Unacceptable principal
diagnosis edit code list since they are no longer valid.
Response: We appreciate the commenters' support. After
consideration of the public comments we received, we are finalizing our
proposal to remove the diagnosis codes listed in the previous table
from the Unacceptable Principal Diagnosis edit code list under the ICD-
10 MCE Version 40, effective October 1, 2022.
[[Page 48882]]
f. Unspecified Code
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44940 through
44943), we finalized the implementation of a new Unspecified code edit,
effective with discharges on and after April 1, 2022. Unspecified codes
exist in the ICD-10-CM classification for circumstances when
documentation in the medical record does not provide the level of
detail needed to support reporting a more specific code. However, in
the inpatient setting, there should generally be very limited and rare
circumstances for which the laterality (right, left, bilateral) of a
condition is unable to be documented and reported.
As discussed in section II.D.14. of the preamble of the proposed
rule and this final rule, Table 6A.--New Diagnosis Codes, lists the new
diagnosis codes that have been approved to date which will be effective
with discharges on and after October 1, 2022. We proposed to add the
following new ICD-10-CM diagnosis codes to the Unspecified code edit
code list.
[GRAPHIC] [TIFF OMITTED] TR10AU22.068
Comment: Commenters agreed with our proposal to add the diagnosis
codes listed in the previous table to the Unspecified code edit code
list.
Response: We appreciate the commenters' support.
After consideration of the public comments we received, we are
finalizing our proposal to add the diagnosis codes listed in the
previous table to the Unspecified code edit code list under the ICD-10
MCE Version 40, effective October 1, 2022.
g. Future Enhancement
In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38053 through 38054)
we noted the importance of ensuring accuracy of the coded data from the
reporting, collection, processing, coverage, payment and analysis
aspects. Subsequently, in the FY 2019 IPPS/LTCH PPS proposed rule (83
FR 20235) we stated that we engaged a contractor to assist in the
review of the limited coverage and non-covered procedure edits in the
MCE that may also be present in other claims processing systems that
are utilized by our MACs. The MACs must adhere to criteria specified
within the National Coverage Determinations (NCDs) and may implement
their own edits in addition to what is already incorporated into the
MCE, resulting in duplicate edits. The objective of this review is to
identify where duplicate edits may exist and to determine what the
impact might be if these edits were to be removed from the MCE.
We have also noted that the purpose of the MCE is to ensure that
errors and inconsistencies in the coded data are recognized during
Medicare claims processing. As we indicated in the FY 2019 IPPS/LTCH
PPS final rule (83 FR 41228), we are considering whether the inclusion
of coverage edits in the MCE necessarily aligns with that specific goal
because the focus of coverage edits is on whether or not a particular
service is covered for payment purposes and not whether it was coded
correctly.
Comment: A few commenters requested that CMS continue to include
the existing coverage edits in the MCE. According to the commenters,
the MACs software and systems may not be consistently updated and
current, therefore, coding edits may trigger erroneously only to be
dismissed on appeal when it is discovered that the code in question is
covered under an NCD. The commenters stated their belief that the
national MCE provides important safeguards for claims processing and
coverage.
Response: We appreciate the commenters' feedback.
As we continue to evaluate the purpose and function of the MCE with
respect to ICD-10, we encourage public input for future discussion. As
we have discussed in prior rulemaking, we recognize a need to further
examine the current list of edits and the definitions of those edits.
We continue to encourage public comments on whether there are
additional concerns with the current edits, including specific edits or
language that should be removed or revised, edits that should be
combined, or new edits that should be added to assist in detecting
errors or inaccuracies in the coded data. Comments should be directed
to the new electronic intake system, Medicare Electronic Application
Request Information SystemTM (MEARISTM),
discussed in section II.D.1.b of the preamble of the proposed rule and
this final rule at: https://mearis.cms.gov/public/home by October 20,
2022.
16. Changes to Surgical Hierarchies
Some inpatient stays entail multiple surgical procedures, each one
of which, occurring by itself, could result in assignment of the case
to a different MS-DRG within the MDC to which the principal diagnosis
is assigned. Therefore, it is necessary to have a decision rule within
the GROUPER by which these cases are assigned to a single MS-DRG. The
surgical hierarchy, an ordering of surgical classes from most resource-
intensive to least resource-intensive, performs that function.
Application of this hierarchy ensures that cases involving multiple
surgical procedures are assigned to the MS-DRG associated with the most
resource-intensive surgical class.
A surgical class can be composed of one or more MS-DRGs. For
example, in MDC 11, the surgical class ``kidney transplant'' consists
of a single MS-DRG (MS-DRG 652) and the class ``major bladder
procedures'' consists of three MS-DRGs (MS-DRGs 653, 654, and 655).
Consequently, in many cases, the surgical hierarchy has an impact on
more than one MS-DRG. The methodology for determining the most
resource-intensive surgical class involves weighting the average
resources for each MS-DRG by frequency to determine the weighted
average resources for each surgical class. For example, assume surgical
class A includes MS-DRGs 001 and 002 and surgical class B includes MS-
DRGs 003, 004, and 005. Assume also that the average costs of MS-DRG
001 are higher than that of MS-DRG 003, but the average costs of MS-
DRGs 004 and 005 are higher than the average costs of MS-DRG 002. To
determine whether surgical class A should be higher or lower than
surgical class B in the surgical hierarchy, we would weigh the
[[Page 48883]]
average costs of each MS-DRG in the class by frequency (that is, by the
number of cases in the MS-DRG) to determine average resource
consumption for the surgical class. The surgical classes would then be
ordered from the class with the highest average resource utilization to
that with the lowest, with the exception of ``other O.R. procedures''
as discussed in this final rule.
This methodology may occasionally result in assignment of a case
involving multiple procedures to the lower-weighted MS-DRG (in the
highest, most resource-intensive surgical class) of the available
alternatives. However, given that the logic underlying the surgical
hierarchy provides that the GROUPER search for the procedure in the
most resource-intensive surgical class, in cases involving multiple
procedures, this result is sometimes unavoidable.
We note that, notwithstanding the foregoing discussion, there are a
few instances when a surgical class with a lower average cost is
ordered above a surgical class with a higher average cost. For example,
the ``other O.R. procedures'' surgical class is uniformly ordered last
in the surgical hierarchy of each MDC in which it occurs, regardless of
the fact that the average costs for the MS-DRG or MS-DRGs in that
surgical class may be higher than those for other surgical classes in
the MDC. The ``other O.R. procedures'' class is a group of procedures
that are only infrequently related to the diagnoses in the MDC, but are
still occasionally performed on patients with cases assigned to the MDC
with these diagnoses. Therefore, assignment to these surgical classes
should only occur if no other surgical class more closely related to
the diagnoses in the MDC is appropriate.
A second example occurs when the difference between the average
costs for two surgical classes is very small. We have found that small
differences generally do not warrant reordering of the hierarchy
because, as a result of reassigning cases on the basis of the hierarchy
change, the average costs are likely to shift such that the higher-
ordered surgical class has lower average costs than the class ordered
below it.
Based on the changes that we proposed to make for FY 2023, as
discussed in section II.D. of the preamble of the proposed rule and
this final rule, we are maintaining the existing surgical hierarchy for
FY 2023.
17. Maintenance of the ICD-10-CM and ICD-10-PCS Coding Systems
In September 1985, the ICD-9-CM Coordination and Maintenance
Committee was formed. This is a Federal interdepartmental committee,
co-chaired by the Centers for Disease Control and Prevention's (CDC)
National Center for Health Statistics (NCHS) and CMS, charged with
maintaining and updating the ICD-9-CM system. The final update to ICD-
9-CM codes was made on October 1, 2013. Thereafter, the name of the
Committee was changed to the ICD-10 Coordination and Maintenance
Committee, effective with the March 19-20, 2014 meeting. The ICD-10
Coordination and Maintenance Committee addresses updates to the ICD-10-
CM and ICD-10-PCS coding systems. The Committee is jointly responsible
for approving coding changes, and developing errata, addenda, and other
modifications to the coding systems to reflect newly developed
procedures and technologies and newly identified diseases. The
Committee is also responsible for promoting the use of Federal and non-
Federal educational programs and other communication techniques with a
view toward standardizing coding applications and upgrading the quality
of the classification system.
The official list of ICD-9-CM diagnosis and procedure codes by
fiscal year can be found on the CMS website at: https://cms.hhs.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/codes.html. The official
list of ICD-10-CM and ICD-10-PCS codes can be found on the CMS website
at: https://www.cms.gov/Medicare/Coding/ICD10/.
The NCHS has lead responsibility for the ICD-10-CM and ICD-9-CM
diagnosis codes included in the Tabular List and Alphabetic Index for
Diseases, while CMS has lead responsibility for the ICD-10-PCS and ICD-
9-CM procedure codes included in the Tabular List and Alphabetic Index
for Procedures.
The ICD-10 Coordination and Maintenance Committee holds its
meetings in the spring and fall to update the codes and the applicable
payment and reporting systems by October 1 or April 1 of each year.
Items are placed on the agenda for the Committee meeting if the request
is received at least 3 months prior to the meeting. This requirement
allows time for staff to review and research the coding issues and
prepare material for discussion at the meeting. It also allows time for
the topic to be publicized in meeting announcements in the Federal
Register as well as on the CMS website.
The Committee encourages participation in the previously mentioned
process by health- related organizations and other interested parties.
In this regard, the Committee holds public meetings for discussion of
educational issues and proposed coding changes. These meetings provide
an opportunity for representatives of recognized organizations in the
coding field, such as the American Health Information Management
Association (AHIMA), the American Hospital Association (AHA), and
various physician specialty groups, as well as individual physicians,
health information management professionals, and other members of the
public, to contribute ideas on coding matters. After considering the
opinions expressed during the public meetings and in writing, the
Committee formulates recommendations, which then must be approved by
the agencies. A complete addendum describing details of all diagnosis
and procedure coding changes, both tabular and index, is published on
the CMS and NCHS websites in June of each year. Publishers of coding
books and software use this information to modify their products that
are used by health care providers.
The Committee presented proposals for coding changes for
implementation in FY 2023 at a public meeting held on September 14-15,
2021 and finalized the coding changes after consideration of comments
received at the meetings and in writing by November 15, 2021.
The Committee held its 2022 meeting on March 8-9, 2022. The
deadline for submitting comments on the procedure code proposals that
are being considered for an October 1, 2022 implementation was April 8,
2022. The deadline for submitting comments on the diagnosis code
proposals that are being considered for an October 1, 2023
implementation was May 9, 2022. It was announced at this meeting that
any new diagnosis and procedure codes for which there was consensus of
public support and for which complete tabular and indexing changes
would be made by June 2022 would be included in the October 1, 2022
update to the ICD-10-CM diagnosis and ICD-10-PCS procedure code sets.
It was also announced at this meeting that we are changing the process
for submitting requested updates to the ICD-10-PCS classification,
beginning with the procedure code requests submitted for consideration
for the September 13-14, 2022 ICD-10 Coordination and Maintenance
Committee Meeting. As stated in section II.D.1.b. of the preamble of
the proposed rule and this final rule, CMS is in the process of
implementing a new electronic application intake system, MEARIS\TM\.
Effective January 5, 2022, MEARIS\TM\ became available as an initial
release for users to begin gaining familiarity with a
[[Page 48884]]
new approach and process to submit ICD-10-PCS procedure code requests.
Information on this new approach for submitting an ICD-10-PCS code
request can be accessed at: https://mearis.cms.gov. Effective March 1,
2022, the full release of MEARIS\TM\ became active for ICD-10-PCS code
request submissions. ICD-10-PCS code request submissions were due no
later than June 10, 2022 to be considered for the September 13-14, 2022
ICD-10 Coordination and Maintenance Committee Meeting. Moving forward,
CMS will only accept ICD-10-PCS code requests submitted via MEARIS\TM\.
Requests submitted through the ICDProcedureCodeRequest mailbox will no
longer be considered. Within MEARIS\TM\, we have built in several
resources to support users, including a ``Resources'' section
(available at https://mearis.cms.gov/public/resources) and technical
support available under ``Useful Links'' at the bottom of the
MEARIS\TM\ site. Questions regarding MEARIS\TM\ can be submitted to CMS
using the form available under ``Contact'' at: https://mearis.cms.gov/public/resources.
As discussed in earlier sections of the preamble of this final
rule, there are new, revised, and deleted ICD-10-CM diagnosis codes and
ICD-10-PCS procedure codes that are captured in Table 6A.--New
Diagnosis Codes, Table 6B.--New Procedure Codes, Table 6C.--Invalid
Diagnosis Codes, Table 6D.--Invalid Procedure Codes, and Table 6E.--
Revised Diagnosis Code Titles for this final rule, which are available
via the internet on the CMS website at: https://www.cms.gov/medicare/
medicare-fee-for-service-payment/acuteinpatientpps. The code titles are
adopted as part of the ICD-10 Coordination and Maintenance Committee
process. Therefore, although we make the code titles available through
tables in association with the IPPS proposed and final rules, they are
not subject to comment in the proposed or final rule. Because of the
length of these tables, they are not published in the Addendum to the
proposed or final rule. Rather, they are available via the internet as
discussed in section VI. of the Addendum to the proposed rule and this
final rule.
Recordings for the virtual meeting discussions of the procedure
codes at the Committee's September 14-15, 2021 meeting and the March 8-
9, 2022 meeting can be obtained from the CMS website at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials. The
materials for the discussions relating to diagnosis codes at the
September 14-15, 2021 meeting and March 8-9, 2022 meeting can be found
through the CDC website at: https://www.cdc.gov/nchs/icd/icd10cm_maintenance.html. These websites also provide detailed
information about the Committee, including information on requesting a
new code, participating in a Committee meeting, timeline requirements
and meeting dates.
We encourage commenters to submit questions and comments on coding
issues involving diagnosis codes via Email to: [email protected].
Questions and comments concerning the procedure codes should be
submitted via Email to: [email protected].
We stated in the proposed rule that as a result of the ongoing
COVID-19 public health emergency, the CDC implemented three new
diagnosis codes describing immunization status related to COVID-19 into
the ICD-10-CM effective with discharges on and after April 1, 2022.
The diagnosis codes are as follows:
[GRAPHIC] [TIFF OMITTED] TR10AU22.069
We refer the reader to the CDC web page at https://www.cdc.gov/nchs/icd/icd10cm.htm for additional details regarding the
implementation of these new diagnosis codes.
As discussed in the proposed rule, we provided the MS-DRG
assignments for the three diagnosis codes effective with discharges on
and after April 1, 2022, consistent with our established process for
assigning new diagnosis codes. Specifically, we review the predecessor
diagnosis code and MS-DRG assignment most closely associated with the
new diagnosis code, and consider other factors that may be relevant to
the MS-DRG assignment, including the severity of illness, treatment
difficulty, and the resources utilized for the specific condition/
diagnosis. We note that this process does not automatically result in
the new diagnosis code being assigned to the same MS-DRG as the
predecessor code. The assignments for the previously listed diagnosis
codes are reflected in Table 6A.--New Diagnosis Codes associated with
the proposed rule and available via the internet on the CMS website at
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. As with the other new diagnosis codes and MS-DRG
assignments included in Table 6A in association with the proposed rule,
we solicited public comments on the most appropriate MDC, MS-DRG, and
severity level assignments for these codes for FY 2023, as well as any
other options for the GROUPER logic.
We did not receive any comments opposing the MDC, MS-DRG, and
severity level assignments for the listed codes and are therefore,
finalizing the assignments as reflected in Table 6A.--New Diagnosis
Codes in association with this final rule.
In addition, we noted in the proposed rule that CMS implemented
nine new procedure codes describing the introduction or infusion of
therapeutics, including vaccines for COVID-19prevention, into the ICD-
10-PCS effective with discharges on and after April 1, 2022. The nine
procedure codes listed in this section of this rule are designated as
non-O.R. and do not affect any MDC or MS-DRG assignment as shown in the
following table.
[[Page 48885]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.070
The ICD-10 MS-DRG assignment for cases reporting any one of the
nine procedure codes is dependent on the reported principal diagnosis,
any secondary diagnoses defined as a CC or MCC, procedures or services
performed, age, sex, and discharge status. The nine procedure codes are
reflected in Table 6B.--New Procedure Codes in association with the
proposed rule and available via the internet on the CMS website at:
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. As with the other new procedure codes and MS-DRG
assignments included in Table 6B in association with the proposed rule,
we solicited public comments on the most appropriate MDC, MS-DRG, and
operating room status assignments for these codes for FY 2023, as well
as any other options for the GROUPER logic.
We did not receive any comments opposing the MDC, MS-DRG, and
operating room status assignments for the listed codes and are
therefore, finalizing the assignments as reflected in Table 6B.--New
Procedure Codes in association with this final rule.
In the proposed rule we also noted that Change Request (CR) 12578,
Transmittal 11174, titled ``April 2022 Update to the Medicare
Severity--Diagnosis Related Group (MS-DRG) Grouper and Medicare Code
Editor (MCE) Version 39.1 for the International Classification of
Diseases, Tenth Revision (ICD-10) Diagnosis Codes for 2019 Novel
Coronavirus (COVID-19) Vaccination Status and ICD-10 Procedure Coding
System (PCS) Codes for Introduction or Infusion of Therapeutics and
Vaccines for COVID-19 Treatment'', was issued on January 14, 2022
(available via the internet on the CMS website at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Transmittals/r11174cp)
regarding the release of an updated version of the ICD-10 MS-DRG
GROUPER and Medicare Code Editor software, Version 39.1, effective with
discharges on and after April 1, 2022, reflecting the new diagnosis and
procedure codes. The updated software, along with the updated ICD-10
MS-DRG V39.1 Definitions Manual and the Definitions of Medicare Code
Edits V39.1 manual is available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.
In the September 7, 2001 final rule implementing the IPPS new
technology add-on payments (66 FR 46906), we indicated we would attempt
to include proposals for procedure codes that would describe new
technology discussed and approved at the Spring meeting as part of the
code revisions effective the following October.
Section 503(a) of Public Law 108-173 included a requirement for
updating diagnosis and procedure codes twice a year instead of a single
update on October 1 of each year. This requirement was included as part
of the amendments to the Act relating to recognition of new technology
under the IPPS. Section 503(a) of Public Law 108-173 amended section
1886(d)(5)(K) of the Act by adding a clause (vii) which states that the
Secretary shall provide for the addition of new diagnosis and procedure
codes on April 1 of each year, but the addition of such codes shall not
require the Secretary to adjust the payment (or diagnosis-related group
[[Page 48886]]
classification) until the fiscal year that begins after such date. This
requirement improves the recognition of new technologies under the IPPS
by providing information on these new technologies at an earlier date.
Data will be available 6 months earlier than would be possible with
updates occurring only once a year on October 1.
In the FY 2005 IPPS final rule, we implemented section
1886(d)(5)(K)(vii) of the Act, as added by section 503(a) of Public Law
108-173, by developing a mechanism for approving, in time for the April
update, diagnosis and procedure code revisions needed to describe new
technologies and medical services for purposes of the new technology
add-on payment process. We also established the following process for
making those determinations. Topics considered during the Fall ICD-10
(previously ICD-9-CM) Coordination and Maintenance Committee meeting
were considered for an April 1 update if a strong and convincing case
was made by the requestor during the Committee's public meeting. The
request needed to identify the reason why a new code was needed in
April for purposes of the new technology process. Meeting participants
and those reviewing the Committee meeting materials were provided the
opportunity to comment on the expedited request. We refer the reader to
the FY 2022 IPPS/LTCH PPS final rule (86 FR 44950) for further
discussion of the implementation of this prior April 1 update for
purposes of the new technology add-on payment process.
However, as discussed in the FY 2022 IPPS/LTCH PPS final rule (86
FR 44950 through 44956), we adopted an April 1 implementation date, in
addition to the annual October 1 update, beginning with April 1, 2022.
We noted that the intent of this April 1 implementation date is to
allow flexibility in the ICD-10 code update process. With this new
April 1 update, CMS now uses the same process for consideration of all
requests for an April 1 implementation date, including for purposes of
the new technology add-on payment process (that is, the prior process
for consideration of an April 1 implementation date only if a strong
and convincing case was made by the requestor during the meeting no
longer applies). We are continuing to use several aspects of our
existing established process to implement new codes through the April 1
code update, which includes presenting proposals for April 1
consideration at the September ICD-10 Coordination and Maintenance
Committee meeting, requesting public comments, reviewing the public
comments, finalizing codes, and announcing the new codes with their
assignments consistent with the new GROUPER release information. We
note that under our established process, requestors indicate whether
they are submitting their code request for consideration for an April 1
implementation date or an October 1 implementation date. The ICD-10
Coordination and Maintenance Committee makes efforts to accommodate the
requested implementation date for each request submitted. However, the
Committee determines which requests are to be presented for
consideration for an April 1 implementation date or an October 1
implementation date. As discussed earlier in this section of the
preamble of this final rule, there were code proposals presented for an
expedited April 1, 2022 implementation at the September 14-15, 2021
Committee meetings that involved treatments related to the COVID-19
PHE. One of these code proposals was also in connection with a request
for a new technology add-on payment application. Following the receipt
of public comments, the code proposals were approved and finalized,
therefore, there were new codes implemented April 1, 2022.
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule, consistent
with the process we outlined for the April 1 implementation date, we
announced the new codes in November 2021 and provided the updated code
files and ICD-10-CM Official Guidelines for Coding and Reporting in
December 2021. On January 24, 2022 the Federal Register notice for the
March 8-9, 2022 ICD-10 Coordination and Maintenance Committee Meeting
was published that includes the tentative agenda and identifies which
topics are related to a new technology add-on payment application. By
February 1, 2022 we made available the updated V39.1 ICD-10 MS-DRG
Grouper software and related materials via the internet on CMS web page
at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.
Comment: A few commenters expressed concerns with the meeting
process and timing for the implementation of new ICD-10-CM diagnosis
codes by the CDC/NCHS. The commenters urged CMS to work with the CDC/
NCHS on expediting the finalization of proposed new diagnosis codes in
light of the option to implement codes on April 1. Another commenter
expressed support for the ability of an April implementation and
expedited diagnosis codes to improve reporting and health equity. The
commenter requested that CMS consider utilizing this April 1 pathway to
advance the Agency's and the health care system's equity goals,
specifically for diagnosis codes that describe social and economic
circumstances to more accurately reflect health care encounters and
episodes of care while also contributing to reliability and validity of
coded claims data.
Response: We thank the commenters for the feedback. As we have
noted in prior rulemaking (85 FR 58556) the CDC/NCHS has lead
responsibility for the ICD-10-CM diagnosis classification while CMS has
lead responsibility for the ICD-10-PCS procedure classification. Each
organization has their own established process in responding to
requests for code updates, including when specific topics may appear on
the agenda of an ICD-10 Coordination and Maintenance Committee meeting
and the fiscal year in which code proposals are considered for
implementation.
ICD-9-CM addendum and code title information is published on the
CMS website at: https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/addendum. ICD-10-CM and ICD-10-PCS addendum
and code title information is published on the CMS website at: https://www.cms.gov/medicare/coding/icd10. CMS also sends electronic files
containing all ICD-10-CM and ICD-10-PCS coding changes to its Medicare
contractors for use in updating their systems and providing education
to providers. Information on ICD-10-CM diagnosis codes, along with the
Official ICD-10-CM Coding Guidelines, can be found on the CDC website
at: https://www.cdc.gov/nchs/icd/icd10cm.htm. Additionally, information
on new, revised, and deleted ICD-10-CM diagnosis and ICD-10-PCS
procedure codes is provided to the AHA for publication in the Coding
Clinic for ICD-10. The AHA also distributes coding update information
to publishers and software vendors.
In the proposed rule we noted that for FY 2022, there are currently
72,750 diagnosis codes and 78,229 procedure codes. We also noted that
as displayed in Table 6A.--New Diagnosis Codes and in Table 6B.--New
Procedure Codes associated with the proposed rule (and available via
the internet on the CMS website at https://www.cms.gov/medicare/
medicare-fee-for-service-payment/acuteinpatientpps), there were 1,176
new diagnosis codes and 45 new
[[Page 48887]]
procedure codes that had been finalized for FY 2023 at the time of the
development of the proposed rule. As discussed in section II.D.14 of
the preamble of this final rule, we are making available Table 6A.--New
Diagnosis Codes, Table 6B.--New Procedure Codes, Table 6C.--Invalid
Diagnosis Codes, Table 6D.--Invalid Procedure Codes and Table 6E.--
Revised Diagnosis Code Titles via the internet on the CMS website at:
https://www.cms.gov/medicare/medicare-fee-for-service-payment/
acuteinpatientpps in association with this final rule. As shown in
Table 6B.--New Procedure Codes, there were procedure codes discussed at
the March 8-9, 2022 ICD-10 Coordination and Maintenance Committee
meeting that were not finalized in time to include in the proposed rule
and are identified with an asterisk. We refer the reader to Table 6B.--
New Procedure Codes associated with this final rule and available via
the internet on the CMS website at: https://www.cms.gov/medicare/
medicare-fee-for-service-payment/acuteinpatientpps for the detailed
list of these additional 286 new procedure codes. The addition of these
286 new procedure codes to the 45 procedure codes that had been
finalized at the time of the development of the proposed rule results
in a total of 331 (45 + 286 = 331) new procedure codes for FY 2023.
We also note, as reflected in Table 6C.--Invalid Diagnosis Codes
and in Table 6D.--Invalid Procedure Codes, there are a total of 287
diagnosis codes and 64 procedure codes that will become invalid
effective October 1, 2022. Based on these code updates, effective
October 1, 2022, there are a total of 73,639 ICD-10-CM diagnosis codes
and 78,496 ICD-10-PCS procedure codes for FY 2023 as shown in the
following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.071
As stated previously, the public is provided the opportunity to
comment on any requests for new diagnosis or procedure codes discussed
at the ICD-10 Coordination and Maintenance Committee meeting. The code
titles are adopted as part of the ICD-10 Coordination and Maintenance
Committee process. Thus, although we publish the code titles in the
IPPS proposed and final rules, they are not subject to comment in the
proposed or final rules.
18. Replaced Devices Offered Without Cost or With a Credit
a. Background
In the FY 2008 IPPS final rule with comment period (72 FR 47246
through 47251), we discussed the topic of Medicare payment for devices
that are replaced without cost or where credit for a replaced device is
furnished to the hospital. We implemented a policy to reduce a
hospital's IPPS payment for certain MS-DRGs where the implantation of a
device that subsequently failed or was recalled determined the base MS-
DRG assignment. At that time, we specified that we will reduce a
hospital's IPPS payment for those MS-DRGs where the hospital received a
credit for a replaced device equal to 50 percent or more of the cost of
the device.
In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51556 through
51557), we clarified this policy to state that the policy applies if
the hospital received a credit equal to 50 percent or more of the cost
of the replacement device and issued instructions to hospitals
accordingly.
b. Changes for FY 2023
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule, for FY
2023 we proposed not to add any MS-DRGs to the policy for replaced
devices offered without cost or with a credit. We proposed to continue
to include the existing MS-DRGs currently subject to the policy as
displayed in the following table.
[[Page 48888]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.072
[GRAPHIC] [TIFF OMITTED] TR10AU22.073
We did not receive any public comments opposing our proposal to
continue to include the existing MS-DRGs currently subject to the
policy. Therefore, we are finalizing the list of MS-DRGs in the table
included in the proposed rule and in this final rule that will be
subject to the replaced devices offered without cost or with a credit
policy effective October 1, 2022. The final list of MS-DRGs subject to
the IPPS policy for replaced devices offered without cost or with a
credit will be issued to providers in the form of a Change Request
(CR).
19. Other Policy Issues
a. Comment Solicitation on Possible Mechanisms To Address Rare Diseases
and Conditions Represented by Low Volumes Within the MS-DRG Structure
As discussed in section II.D.13.d of the preamble of the proposed
rule and this final rule, we solicited public
[[Page 48889]]
comments involving how the reporting of certain diagnosis codes may
improve our ability to recognize severity of illness, complexity of
service, and utilization of resources under the MS-DRGs, as well as
feedback on mechanisms to improve the reliability and validity of the
coded data as part of an ongoing effort across CMS to evaluate and
develop policies to reduce health disparities. In concert with that
effort, as discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28195 through 28197) we also solicited comments to explore possible
mechanisms through which we could address rare diseases and conditions
that are represented by low volumes in our claims data.
We stated in the FY 2023 proposed rule that one subset of our
beneficiary population for which we sought comment on potential issues
related to patient access in the inpatient setting were patients
diagnosed with rare diseases and conditions that are represented by low
volumes in our claims data. We noted that the Orphan Drug Act (ODA)
added section 526(a)(2)(B) to the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 360bb(a)(2)(B)), defining a rare disease or condition as
``any disease or condition which (A) affects less than 200,000 persons
in the United States, or (B) affects more than 200,000 in the United
States and for which there is no reasonable expectation that the cost
of developing and making available in the United States a drug for such
disease or condition will be recovered from sales in the United States
of such drug.'' Most rare diseases, however, affect far fewer people.
The Genetic and Rare Diseases Information Center (GARD), which was
created in 2002 by the National Institutes of Health (NIH) Office of
Rare Diseases Research, estimates that there are as many as 7,000
distinct rare diseases. Rare diseases, which can include genetic
diseases, autoimmune conditions, some cancers, and uncommon infections,
are highly diverse, may affect many organ systems and have wide
variations in the rates and patterns of manifestations and progression.
The ODA created a process for the U.S. Food and Drug Administration
(FDA) to identify a drug as a drug developed for the treatment of a
rare disease or condition called ``orphan-drug designation''. The
sponsor of a drug that has orphan drug designation may be eligible for
certain financial incentives, such as tax credits and potentially seven
years of market exclusivity after approval, all of which are intended
to incentivize developing drugs for small numbers of patients. We
stated that we heard from some interested parties, however, that there
may be a number of barriers to providers in treating these patients
with these orphan designated drugs in the Medicare hospital inpatient
setting.
According to these interested parties, one significant barrier that
continues to present challenges to manufacturers is accessing formulary
coverage for potentially high cost therapeutics for rare diseases.
These interested parties stated that hospitals utilize formularies for
inpatient drugs as a cost-management tool that strongly incentivizes
physicians to use on-formulary drugs over off-formulary drugs, whenever
clinically appropriate to do so. A drug formulary is defined as a list
of medications and continually updated related information, that
represents the clinical judgment of pharmacists, physicians, and other
experts in the diagnosis and treatment of disease or promotion of
health. It is often described as a list of medications routinely
stocked by the health care system. These interested parties stated that
although certain therapeutics can be associated with better outcomes
for patients with rare diseases, the lack of access to hospital
formularies represents a hurdle under the IPPS MS-DRGs. According to
these interested parties, when Medicare reimbursement is insufficient
to cover the costs of certain therapeutics that treat patients with
rare diseases, a disincentive can be created in addressing these
conditions.
For the purposes of the comment solicitation in the proposed rule,
we described three selected requests we had received relating to the
MS-DRG classification of rare diseases and conditions that are
represented by low volumes in our claims data.
In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53311), the FY 2015
IPPS/LTCH PPS final rule (79 FR 49901) and the FY 2019 IPPS/LTCH PPS
final rule (83 FR 41200), we discussed requests we received to revise
the MS-DRG classification for cases of patients diagnosed with
porphyria to recognize the resource requirements in caring for these
patients, to ensure appropriate payment for these cases, and to
preserve patient access to necessary treatments. Porphyria is defined
as a group of rare disorders (``porphyrias'') that interfere with the
production of hemoglobin that is needed for red blood cells. While some
of these disorders are genetic (inborn) and others are acquired, they
all result in the abnormal accumulation of hemoglobin building blocks,
called porphyrins, which can be deposited in the tissues where they
particularly interfere with the functioning of the nervous system and
the skin. Treatment for patients suffering from disorders of porphyrin
metabolism consists of an intravenous injection of Panhematin[supreg]
(hemin for injection).
In the FY 2019 proposed rule, we stated our data analysis showed
that cases reporting diagnosis code E80.21 (Acute intermittent
(hepatic) porphyria) as the principal diagnosis in MS-DRG 642 (Inborn
and Other Disorders of Metabolism) had higher average costs and longer
average lengths of stay compared to the average costs and length of
stay for all other cases in MS-DRG 642. However, after considering
these findings in the context of the current MS-DRG structure, we
stated that we were unable to identify an MS-DRG that would more
closely parallel these cases with respect to average costs and length
of stay that would also be clinically aligned. We further stated that
our clinical advisors believed that, in the current MS-DRG structure,
the clinical characteristics of patients in these cases are most
closely aligned with the clinical characteristics of patients in all
cases in MS-DRG 642. Moreover, given the small number of porphyria
cases, we stated we did not believe there was justification for
creating a new MS-DRG and did not propose to revise the MS-DRG
classification for porphyria cases.
In response, some commenters described significant difficulties
encountered by patients with acute porphyria attacks in obtaining
Panhematin[supreg] when presenting to an inpatient hospital, which they
attributed to the strong financial disincentives faced by facilities to
treat these cases on an inpatient basis. The commenters stated that,
based on the lower than expected average cost per case and longer than
expected length of stay for acute porphyria attacks, it appeared that
facilities were frequently not providing Panhematin[supreg] to patients
in this condition, and instead attempting to provide symptom relief and
transferring patients to an outpatient setting to receive the drug
where they can be adequately paid. The commenters stated that this is
in contrast to the standard of care for acute porphyria attacks and
could result in devastating long-term health consequences.
In the FY 2019 final rule (83 FR 41200), as we have stated in prior
rulemaking, we noted it is not appropriate for facilities to deny
treatment to beneficiaries needing a specific type of therapy or
treatment that involves increased costs. We further noted the MS-DRG
system is a system of averages and it is expected that across
[[Page 48890]]
the diagnostic related groups that within certain groups, some cases
may demonstrate higher than average costs, while other cases may
demonstrate lower than average costs. While we recognized the average
costs of the small number of porphyria cases were greater than the
average costs of the cases in MS-DRG 642 overall, we also noted that an
averaged payment system depends on aggregation of similar cases with a
range of costs, and that we seek to identify sufficiently large sets of
claims data with a resource/cost similarity and clinical similarity in
developing diagnostic-related groups rather than smaller subsets of
diagnoses. We further stated that we were sensitive to the commenters'
concerns about access to treatment for beneficiaries who have been
diagnosed with this condition and we would continue to explore
mechanisms through which to address rare diseases and low volume DRGs.
Similarly, in the FY 2022 IPPS/LTCH PPS final rule (86 FR 44869),
we discussed a request we received to review potential access issues in
the inpatient setting for the administration of ANDEXXA[supreg].
ANDEXXA[supreg] (coagulation factor Xa (recombinant), inactivated-zhzo)
is a recombinant decoy protein that rapidly reverses the anticoagulant
effects of two direct oral anticoagulants, apixaban and rivaroxaban,
when reversal of anticoagulation is needed due to life-threatening or
uncontrolled bleeding in indications such as intracranial hemorrhages
(ICHs) and gastrointestinal bleeds (GIBs). We noted that while our data
findings demonstrated the average costs for the cases reporting the
intravenous administration of ANDEXXA[supreg] were higher when compared
to all cases in their respective MS-DRG, these cases represented a very
small percentage of the total number of cases reported in those MS-
DRGs. We stated we were unable to identify another MS-DRG that would be
a more appropriate MS-DRG assignment for these cases based on the
indication for this therapeutic drug. We also stated that while we were
sensitive to the requestors' concerns about continued access to
treatment for beneficiaries who require the reversal of anticoagulation
due to life-threatening or uncontrolled bleeding, we indicated
additional time was needed to explore options and other mechanisms
through which to address low volume, high-cost drugs outside of the MS-
DRGs.
Lastly, in the proposed rule, we discussed a request we received to
reconsider how cases reporting the administration of Zulresso[supreg]
(brexanolone) are recognized for payment under the ICD-10 MS-DRGs in an
effort to improve access to treatment for maternal mental health. On
March 19, 2019 Zulresso[supreg] (brexanolone) became the first Food and
Drug Administration (FDA) approved drug, specifically for postpartum
depression (PPD) in adults. According to the requestor, PPD is one of
the most common complications during and after pregnancy. The requestor
stated PPD is a serious but manageable disorder and that with early
treatment, the life of the mother, baby, and the entire family could be
positively impacted. The requestor indicated it shares CMS's goals of
addressing disparities in access to care, and urged CMS to take
additional steps to address inequities in women's health by permitting
separate payment for Zulresso[supreg] (brexanolone), in addition to the
MS-DRG payment.
As discussed in the proposed rule, effective with discharges on and
after October 1, 2020, cases reporting the administration of
Zulresso[supreg] in the inpatient setting are identified by ICD-10-PCS
procedure codes XW03306 (Introduction of brexanolone into peripheral
vein, percutaneous approach, new technology group 6) or XW04306
(Introduction of brexanolone into central vein, percutaneous approach,
new technology group 6). These procedure codes are designated as non-O.
R. procedures and do not affect the MS-DRG assignment when reported on
an inpatient claim. We noted that an application for new technology
add-on payment for Zulresso[supreg] (brexanolone) was discussed in the
FY 2021 IPPS/LTCH PPS proposed rule (85 FR 32672 through 32676) and was
not approved, as discussed in the final rule (85 FR 58709 through
58715).
We stated we analyzed claims from the September 2021 update of the
FY 2021 MedPAR file for cases reporting the administration of
Zulresso[supreg] (brexanolone). Our analysis of the claims data
identified only one case reporting the administration of
Zulresso[supreg] (brexanolone) in MS-DRG 870 (Septicemia or Severe
Sepsis with MV >96 Hours) with an average length of stay of 22 days and
average costs of $67,812. For all cases in MS-DRG 870, the average
costs are $55,459 and the average length of stay is 15.9 days. We
stated that while the average length of stay for the case reporting the
administration of Zulresso[supreg] (brexanolone) was greater (22 days
versus 15.9 days) and the average costs were higher ($67,812 versus
$55,459), than all cases in MS-DRG 870 it was unclear if treatment with
Zulresso[supreg] (brexanolone) was the underlying reason for these
factors, given that the MS-DRG assigned is for sepsis and it is not
uncommon for sepsis patients to have multiple co-morbidities and
intensive treatment strategies to address this severe, often life
threatening condition.
We stated we appreciated the requestor's interest in sharing CMS's
goal of advancing women's health, however, we noted that the population
in which Zulresso[supreg] (brexanolone) is indicated generally does not
include our inpatient Medicare population. As we have stated in prior
rulemaking, (83 FR 41210), we have not adopted the same approach to
refine the maternity and newborn MS-DRGs because of the extremely low
volume of Medicare patients there are in these MS-DRGs. When there is
not a high volume of these cases (for example, maternity and newborn)
represented in the Medicare data, we generally advise that other payers
should develop DRGs to address the needs of their patients. We stated
we believed the same would apply with respect to administration of
Zulresso[supreg] (brexanolone) for which, as noted, we identified only
one case in the FY 2021 MedPAR file.
As discussed in prior rulemaking, the MS-DRGs are a classification
system intended to group together diagnoses and procedures with similar
clinical characteristics and utilization of resources. Rare diseases
and conditions that are represented by low volumes in our claims data
however, pose a unique challenge to this methodology as these
conditions by definition affect small subsets of the population. In the
proposed rule, we stated that it has been difficult to identify other
MS-DRGs that would be more appropriate MS-DRG assignments for these
rare conditions based on the wide variance in the clinical
characteristics and utilization of resources for each condition,
depending on the diagnosis. Creating a new MS-DRG for these conditions
as a distinct ``related'' group is also challenging for the same
reasons.
As previously noted, we generally seek to identify sufficiently
large sets of claims data with a resource/cost similarity and clinical
similarity in developing diagnostic-related groups rather than smaller
subsets. In the proposed rule, we stated that we have been concerned
that basing MS-DRG reclassification decisions on small numbers of cases
could lead to complexities in establishing the relative payment weights
for the MS-DRGs because several expensive cases could impact the
overall relative payment weight. Having larger clinical cohesive groups
within an MS-DRG provides greater stability and thus predictability
[[Page 48891]]
for hospitals for annual updates to the relative payment weights.
As also previously noted, the MS-DRG system is a system of averages
and it is expected that within the diagnostic related groups, some
cases may demonstrate higher than average costs, while other cases may
demonstrate lower than average costs. However, as noted, cases
involving treatment of rare diseases may involve more resource use than
other cases in their respective MS-DRG. Section 1886(d)(5)(A) of the
Act provides for Medicare payments to Medicare-participating hospitals
in addition to the basic prospective payments for cases incurring
extraordinarily high costs, however we solicited feedback on other
mechanisms we could explore through which we can address concerns
relating to payment for patients with rare diseases and conditions that
are represented by low volumes in our claims data. We stated we were
also interested in receiving comments on other meaningful ways in which
we might potentially improve access to treatment for postpartum
depression in certain populations, including through activities
pursuant to Vice President Harris's Call to Action to Reduce Maternal
Mortality and Morbidity.\28\
---------------------------------------------------------------------------
\28\ Available at: https://www.whitehouse.gov/briefing-room/statements-releases/2021/12/07/fact-sheet-vice-president-kamala-harris-announces-call-to-action-to-reduce-maternal-mortality-and-morbidity/.
---------------------------------------------------------------------------
To inform decision making, we stated we were also looking for
feedback on how to mitigate any unintended negative payment impacts to
providers serving patients with rare diseases or conditions that are
represented by low volumes in our claims data. In particular, we stated
we were interested in hearing the perspectives of large urban
hospitals, rural hospitals, and other hospital types in regard to their
experience. We also sought comments on how factors such as hospital
size and type might impact a hospital's ability to develop protocols to
better address these conditions. We stated we would take commenters'
feedback into consideration in future policy development.
Comment: Many commenters stated they appreciated CMS' attention and
the acknowledgment of the challenging nature of rare diseases as part
of a reporting and payment structure. Commenters also expressed that
they fully support the Administration's initiatives that champion
policies to improve maternal health and equity, especially as it
relates to PPD. Most commenters provided recommendations and suggested
CMS explore mechanisms such as--
Creating a ``permanent'' payment methodology approach
which combines the MS-DRG ``fixed price'' with continued partial
payment for the actual cost of treatment per stay;
Creating new MS-DRGs for certain low-volume therapies or
for orphan conditions with more flexible cost outlier funding;
Creating new MS-DRG categories to ensure access to rapidly
expanding transformative therapies like cell and gene therapies;
Creating a new enhanced new technology add-on payment-like
pathway that establishes separate payment for low volume high-cost
drugs;
Reimbursing hospitals for orphan drugs based on the
Average Sales Price (ASP) as published in the HOPD Addendum B file
using the same authority that the Agency relied on to make the recent
COVID-19 payment adjustments;
Carving-out ``clinical trial'' inpatient stays to ensure
that the MS-DRG payment rate is not adversely impacted by facility-
reported costs that do not include acquisition costs;
Exploring databases outside of the MedPAR to obtain claims
data for inclusion analysis;
Creating a rare disease diagnosis code designation,
similar to the complication or comorbidity (CC) and major complication
or comorbidity (MCC) severity designations;
Establishing a central formulary to provide high cost
drugs for rare conditions instead of utilizing individual hospital
pharmacy formularies to ease burdens of carrying high cost drugs on
rural and smaller hospitals, as drug transport can potentially be
cheaper then patient transport;
Waiving the 500 case threshold when deciding whether an
MS-DRG change should be proposed.
Specifically, in discussing how cases reporting the administration
of Zulresso[supreg] (brexanolone) are recognized for payment,
commenters stated that if Medicare commits to creating MS-DRGs around
the Medicare population giving birth, the impacts of this progress
would have far-reaching effects beyond Medicare beneficiaries as it
will serve as the foundation for commercial and Medicaid payments.
Response: We appreciate the input provided by commenters in
response to this request for information and we thank commenters for
the acknowledgment of the challenges rare diseases or conditions that
are represented by low volumes present as part of a reporting and
reimbursement structure. We thank the commenters for their support and
consideration of these issues. We will take the comments received in
response to the solicitation into consideration as we continue to
explore mechanisms to address concerns relating to payment for patients
with rare diseases and conditions that are represented by low volumes
in our claims data.
20. Out of Scope Public Comments Received
We received public comments on MS-DRG related issues that were
outside the scope of the proposals included in the FY 2023 IPPS/LTCH
PPS proposed rule. Because we consider these public comments to be
outside the scope of the proposed rule, we are not addressing them in
this final rule. As stated in section II.D.1.b. of the preamble of this
final rule, we encourage individuals with comments about MS-DRG
classifications to submit these comments no later than October 20, 2022
via the new electronic intake system, Medicare Electronic Application
Request Information SystemTM (MEARISTM) at:
https://mearis.cms.gov/public/home so that they can be considered for
possible inclusion in the annual proposed rule. We will consider these
public comments for possible proposals in future rulemaking as part of
our annual review process.
II. Changes to Medicare Severity Diagnosis-Related Group (MS-DRG)
Classifications and Relative Weights
E. Recalibration of the FY 2023 MS-DRG Relative Weights
1. Data Sources for Developing the Relative Weights
Consistent with our established policy, in developing the MS-DRG
relative weights for FY 2023, we proposed to use two data sources:
claims data and cost report data. The claims data source is the MedPAR
file, which includes fully coded diagnostic and procedure data for all
Medicare inpatient hospital bills. The FY 2021 MedPAR data used in this
final rule include discharges occurring on October 1, 2020, through
September 30, 2021, based on bills received by CMS through March 31,
2022, from all hospitals subject to the IPPS and short-term, acute care
hospitals in Maryland (which at that time were under a waiver from the
IPPS).
The FY 2021 MedPAR file used in calculating the relative weights
includes data for approximately 7,444,003
[[Page 48892]]
Medicare discharges from IPPS providers. Discharges for Medicare
beneficiaries enrolled in a Medicare Advantage managed care plan are
excluded from this analysis. These discharges are excluded when the
MedPAR ``GHO Paid'' indicator field on the claim record is equal to
``1'' or when the MedPAR DRG payment field, which represents the total
payment for the claim, is equal to the MedPAR ``Indirect Medical
Education (IME)'' payment field, indicating that the claim was an ``IME
only'' claim submitted by a teaching hospital on behalf of a
beneficiary enrolled in a Medicare Advantage managed care plan. In
addition, the March 2022 update of the FY 2021 MedPAR file complies
with version 5010 of the X12 HIPAA Transaction and Code Set Standards,
and includes a variable called ``claim type.'' Claim type ``60''
indicates that the claim was an inpatient claim paid as fee-for-
service. Claim types ``61,'' ``62,'' ``63,'' and ``64'' relate to
encounter claims, Medicare Advantage IME claims, and HMO no-pay claims.
Therefore, the calculation of the relative weights for FY 2023 also
excludes claims with claim type values not equal to ``60.'' The data
exclude CAHs, including hospitals that subsequently became CAHs after
the period from which the data were taken. We note that the FY 2023
relative weights are based on the ICD-10-CM diagnosis codes and ICD-10-
PCS procedure codes from the FY 2021 MedPAR claims data, grouped
through the ICD-10 version of the FY 2023 GROUPER (Version 40).
The second data source used in the cost-based relative weighting
methodology is the Medicare cost report data files from the HCRIS. In
general, we use the HCRIS dataset that is 3 years prior to the IPPS
fiscal year. Specifically, for this final rule, we used the March 2022
update of the FY 2020 HCRIS for calculating the FY 2023 cost-based
relative weights. Consistent with our historical practice, for this FY
2023 final rule, we are providing the version of the HCRIS from which
we calculated these 19 CCRs on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. Click on
the link on the left side of the screen titled ``FY 2023 IPPS Final
Rule Home Page'' or ``Acute Inpatient Files for Download.''
2. Methodology for Calculation of the Relative Weights
a. General
We calculated the FY 2023 relative weights based on 19 CCRs. The
methodology we proposed to use to calculate the FY 2023 MS-DRG cost-
based relative weights based on claims data in the FY 2021 MedPAR file
and data from the FY 2020 Medicare cost reports is as follows:
To the extent possible, all the claims were regrouped
using the FY 2023 MS-DRG classifications discussed in sections II.B.
and II.D. of the preamble of this final rule.
The transplant cases that were used to establish the
relative weights for heart and heart-lung, liver and/or intestinal, and
lung transplants (MS-DRGs 001, 002, 005, 006, and 007, respectively)
were limited to those Medicare-approved transplant centers that have
cases in the FY 2021 MedPAR file. (Medicare coverage for heart, heart-
lung, liver and/or intestinal, and lung transplants is limited to those
facilities that have received approval from CMS as transplant centers.)
Organ acquisition costs for kidney, heart, heart-lung,
liver, lung, pancreas, and intestinal (or multivisceral organs)
transplants continue to be paid on a reasonable cost basis.
Because these acquisition costs are paid separately from the
prospective payment rate, it is necessary to subtract the acquisition
charges from the total charges on each transplant bill that showed
acquisition charges before computing the average cost for each MS-DRG
and before eliminating statistical outliers.
Section 108 of the Further Consolidated Appropriations Act, 2020
provides that, for cost reporting periods beginning on or after October
1, 2020, costs related to hematopoietic stem cell acquisition for the
purpose of an allogeneic hematopoietic stem cell transplant shall be
paid on a reasonable cost basis. We refer the reader to the FY 2021
IPPS/LTCH PPS final rule for further discussion of the reasonable cost
basis payment for cost reporting periods beginning on or after October
1, 2020 (85 FR 58835 through 58842). For FY 2022 and subsequent years,
we subtract the hematopoietic stem cell acquisition charges from the
total charges on each transplant bill that showed hematopoietic stem
cell acquisition charges before computing the average cost for each MS-
DRG and before eliminating statistical outliers.
Claims with total charges or total lengths of stay less
than or equal to zero were deleted. Claims that had an amount in the
total charge field that differed by more than $30.00 from the sum of
the routine day charges, intensive care charges, pharmacy charges,
implantable devices charges, supplies and equipment charges, therapy
services charges, operating room charges, cardiology charges,
laboratory charges, radiology charges, other service charges, labor and
delivery charges, inhalation therapy charges, emergency room charges,
blood and blood products charges, anesthesia charges, cardiac
catheterization charges, CT scan charges, and MRI charges were also
deleted.
At least 93.0 percent of the providers in the MedPAR file
had charges for 14 of the 19 cost centers. All claims of providers that
did not have charges greater than zero for at least 14 of the 19 cost
centers were deleted. In other words, a provider must have no more than
five blank cost centers. If a provider did not have charges greater
than zero in more than five cost centers, the claims for the provider
were deleted.
Statistical outliers were eliminated by removing all cases
that were beyond 3.0 standard deviations from the geometric mean of the
log distribution of both the total charges per case and the total
charges per day for each MS-DRG.
Effective October 1, 2008, because hospital inpatient
claims include a POA indicator field for each diagnosis present on the
claim, only for purposes of relative weight-setting, the POA indicator
field was reset to ``Y'' for ``Yes'' for all claims that otherwise have
an ``N'' (No) or a ``U'' (documentation insufficient to determine if
the condition was present at the time of inpatient admission) in the
POA field.
Under current payment policy, the presence of specific HAC codes,
as indicated by the POA field values, can generate a lower payment for
the claim. Specifically, if the particular condition is present on
admission (that is, a ``Y'' indicator is associated with the diagnosis
on the claim), it is not a HAC, and the hospital is paid for the higher
severity (and, therefore, the higher weighted MS-DRG). If the
particular condition is not present on admission (that is, an ``N''
indicator is associated with the diagnosis on the claim) and there are
no other complicating conditions, the DRG GROUPER assigns the claim to
a lower severity (and, therefore, the lower weighted MS-DRG) as a
penalty for allowing a Medicare inpatient to contract a HAC. While the
POA reporting meets policy goals of encouraging quality care and
generates program savings, it presents an issue for the relative
weight-setting process. Because cases identified as HACs are likely to
be more complex than similar cases that are not identified as HACs, the
charges associated with HAC cases are likely to be higher as well.
Therefore, if the higher charges of these HAC claims are grouped into
lower
[[Page 48893]]
severity MS-DRGs prior to the relative weight-setting process, the
relative weights of these particular MS-DRGs would become artificially
inflated, potentially skewing the relative weights. In addition, we
want to protect the integrity of the budget neutrality process by
ensuring that, in estimating payments, no increase to the standardized
amount occurs as a result of lower overall payments in a previous year
that stem from using weights and case-mix that are based on lower
severity MS-DRG assignments. If this would occur, the anticipated cost
savings from the HAC policy would be lost.
To avoid these problems, we reset the POA indicator field to ``Y''
only for relative weight-setting purposes for all claims that otherwise
have an ``N'' or a ``U'' in the POA field. This resetting ``forced''
the more costly HAC claims into the higher severity MS-DRGs as
appropriate, and the relative weights calculated for each MS-DRG more
closely reflect the true costs of those cases.
In addition, in the FY 2013 IPPS/LTCH PPS final rule, for FY 2013
and subsequent fiscal years, we finalized a policy to treat hospitals
that participate in the Bundled Payments for Care Improvement (BPCI)
initiative the same as prior fiscal years for the IPPS payment modeling
and ratesetting process without regard to hospitals' participation
within these bundled payment models (77 FR 53341 through 53343).
Specifically, because acute care hospitals participating in the BPCI
Initiative still receive IPPS payments under section 1886(d) of the
Act, we include all applicable data from these subsection (d) hospitals
in our IPPS payment modeling and ratesetting calculations as if the
hospitals were not participating in those models under the BPCI
initiative. We refer readers to the FY 2013 IPPS/LTCH PPS final rule
for a complete discussion on our final policy for the treatment of
hospitals participating in the BPCI initiative in our ratesetting
process. For additional information on the BPCI initiative, we refer
readers to the CMS' Center for Medicare and Medicaid Innovation's
website at https://innovation.cms.gov/initiatives/Bundled-Payments/ and to section IV.H.4. of the preamble of the FY 2013 IPPS/
LTCH PPS final rule (77 FR 53341 through 53343).
The participation of hospitals in the BPCI initiative concluded on
September 30, 2018. The participation of hospitals in the BPCI Advanced
model started on October 1, 2018. The BPCI Advanced model, tested under
the authority of section 1115A of the Act, is comprised of a single
payment and risk track, which bundles payments for multiple services
beneficiaries receive during a Clinical Episode. Acute care hospitals
may participate in BPCI Advanced in one of two capacities: as a model
Participant or as a downstream Episode Initiator. Regardless of the
capacity in which they participate in the BPCI Advanced model,
participating acute care hospitals will continue to receive IPPS
payments under section 1886(d) of the Act. Acute care hospitals that
are Participants also assume financial and quality performance
accountability for Clinical Episodes in the form of a reconciliation
payment. For additional information on the BPCI Advanced model, we
refer readers to the BPCI Advanced web page on the CMS Center for
Medicare and Medicaid Innovation's website at https://innovation.cms.gov/initiatives/bpci-advanced/. Consistent with our
policy for FY 2022, and consistent with how we have treated hospitals
that participated in the BPCI Initiative, for FY 2023, we continue to
believe it is appropriate to include all applicable data from the
subsection (d) hospitals participating in the BPCI Advanced model in
our IPPS payment modeling and ratesetting calculations because, as
noted previously, these hospitals are still receiving IPPS payments
under section 1886(d) of the Act. Consistent with the FY 2022 IPPS/LTCH
PPS final rule, we also proposed to include all applicable data from
subsection (d) hospitals participating in the Comprehensive Care for
Joint Replacement (CJR) Model in our IPPS payment modeling and
ratesetting calculations.
The charges for each of the 19 cost groups for each claim were
standardized to remove the effects of differences in area wage levels,
IME and DSH payments, and for hospitals located in Alaska and Hawaii,
the applicable cost-of-living adjustment. Because hospital charges
include charges for both operating and capital costs, we standardized
total charges to remove the effects of differences in geographic
adjustment factors, cost-of-living adjustments, and DSH payments under
the capital IPPS as well. Charges were then summed by MS-DRG for each
of the 19 cost groups so that each MS-DRG had 19 standardized charge
totals. Statistical outliers were then removed. These charges were then
adjusted to cost by applying the national average CCRs developed from
the FY 2020 cost report data.
The 19 cost centers that we used in the relative weight calculation
are shown in a supplemental data file, Cost Center HCRIS Lines
Supplemental Data File, posted via the internet on the CMS website for
this final rule and available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. The supplemental data file
shows the lines on the cost report and the corresponding revenue codes
that we used to create the 19 national cost center CCRs. In the FY 2023
IPPS/LTCH PPS proposed rule, we stated that if we receive comments
about the groupings in this supplemental data file, we may consider
these comments as we finalize our policy.
Comment: A commenter requested that CMS create a dedicated cost
center line for cell and gene therapy product cost information, which
would enable the agency to create a 20th cost center that is separate
from the drugs/pharmacy cost center.
Response: We appreciate the commenter's request regarding the
creation of new cost centers for cell and gene therapy product cost
information and may consider this request in connection with future
rulemaking.
After consideration of the comment received, we are finalizing our
proposal to use the 19 national cost center CCRs to calculate the
relative weights for FY 2023.
Consistent with historical practice, we account for rare situations
of non-monotonicity in a base MS-DRG and its severity levels, where the
mean cost in the higher severity level is less than the mean cost in
the lower severity level, in determining the relative weights for the
different severity levels. If there are initially non-monotonic
relative weights in the same base DRG and its severity levels, then we
combine the cases that group to the specific non-monotonic MS-DRGs for
purposes of relative weight calculations. For example, if there are two
non-monotonic MS-DRGs, combining the cases across those two MS-DRGs
results in the same relative weight for both MS-DRGs. The relative
weight calculated using the combined cases for those severity levels is
monotonic, effectively removing any non-monotonicity with the base DRG
and its severity levels. For this FY 2023 final rule, this calculation
was applied to address non-monotonicity for cases that grouped to MS-
DRG 793 and MS-DRG 794. In the supplemental file titled AOR/BOR File,
we include statistics for the affected MS-DRGs both separately and with
cases combined.
We invited public comments on our proposals related to
recalibration of the proposed FY 2023 relative weights and the changes
in the relative weights from FY 2022.
[[Page 48894]]
Comment: A commenter requested that CMS study whether it might be
appropriate to define the labor portion individually for each of the 19
cost centers and only standardize that portion, particularly if doing
so improves the explanatory power of all MS-DRGs. This commenter
requested that CMS conduct this study in collaboration with
stakeholders and release this analysis in future rulemaking.
Response: We appreciate the commenter's request that CMS study the
appropriateness of defining the labor portion individually for each of
the 19 cost centers and standardizing only that portion, and we may
consider this request in connection with future rulemaking.
After consideration of the comment received, we are finalizing our
proposals related to the recalibration of the FY 2023 relative weights.
We summarize and respond to comments relating to the methodology for
calculating the relative weight for MS-DRG 018 in the next section of
this final rule.
b. Relative Weight Calculation for MS-DRG 018
As discussed in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58599
through 58600), we created MS-DRG 018 for cases that include procedures
describing CAR T-cell therapies, which were reported using ICD-10-PCS
procedure codes XW033C3 or XW043C3. Effective for FY 2022, we revised
MS-DRG 018 to include cases that report the procedure codes for CAR T-
cell and non-CAR T-cell therapies and other immunotherapies (86 FR
44798 through 448106). We refer the reader to section II.D.2. of this
final rule for discussion of the agenda items for the March 8-9, 2022
ICD-10 Coordination and Maintenance Committee meeting relating to new
procedure codes to describe the administration of a CAR T-cell or
another type of gene or cellular therapy product, as well as our
established process for determining the MS-DRG assignment for codes
approved at the March meeting.
For MS-DRG 018, we include a modification to our existing relative
weight methodology to ensure that the relative weight for MS-DRG 018
appropriately reflects the relative resources required for providing
CAR T-cell and non-CAR T-cell therapies and other immunotherapies
outside of a clinical trial, while still accounting for the clinical
trial cases in the overall average cost for all MS-DRGs. For cases that
group to MS-DRG 018, we do not include claims determined to be clinical
trial claims that group to MS-DRG 018 when calculating the average cost
for MS-DRG 018 that is used to calculate the relative weight for this
MS-DRG, with the additional refinements that: (a) when the CAR T-cell,
non-CAR T-cell or other immunotherapy product is purchased in the usual
manner, but the case involves a clinical trial of a different product,
we include the claim when calculating the average cost for MS-DRG 018
to the extent such claims can be identified in the historical data; and
(b) when there is expanded access use of the CAR T-cell, non-CAR T-cell
or other immunotherapy product, these cases will not be included when
calculating the average cost for new MS DRG 018 to the extent such
claims can be identified in the historical data (85 FR 58600). We also
calculate an adjustment to account for the CAR T-cell, non-CAR T-cell
and other immunotherapy cases determined to be clinical trial cases, as
described later in this final rule and include revenue center 891 in
our calculation of standardized drug charges for MS-DRG 018. We refer
the reader to the FY 2021 IPPS/LTCH PPS final rule for further
discussion of our modifications to the relative weight calculation for
MS-DRG 018.
We proposed to continue to use the same process to identify
clinical trial claims in the FY 2021 MedPAR for purposes of calculating
the FY 2023 relative weights. We continue to use the proxy of
standardized drug charges of less than $373,000, which was the average
sales price of KYMRIAH and YESCARTA, which are the two CAR T-cell
biological products in the FY 2021 MedPAR data used for this final
rule. (As previously noted, effective beginning FY 2022, we revised MS-
DRG 018 to include cases that report the procedure codes for CAR T-cell
and non-CAR T-cell therapies and other immunotherapies (86 FR 44798
through 448106).) Using the same methodology from the FY 2021 IPPS/LTCH
PPS final rule, we proposed to apply an adjustment to account for the
CAR T cell therapy cases identified as clinical trial cases in
calculating the national average standardized cost per case that is
used to calculate the relative weights for all MS-DRGs:
Calculate the average cost for cases to be assigned to MS-
DRG 018 that contain ICD-10-CM diagnosis code Z00.6 or contain
standardized drug charges of less than $373,000.
Calculate the average cost for all other cases to be
assigned to MS-DRG 018.
Calculate an adjustor by dividing the average cost
calculated in step 1 by the average cost calculated in step 2.
Apply the adjustor calculated in step 3 to the cases
identified in step 1 as clinical trial cases, then add this adjusted
case count to the non-clinical trial case count prior to calculating
the average cost across all MS-DRGs.
Additionally, we are continuing our finalized methodology for
calculating this payment adjustment, such that: (a) when the CAR T-
cell, non-CAR T-cell or other immunotherapy product is purchased in the
usual manner, but the case involves a clinical trial of a different
product, the claim will be included when calculating the average cost
for cases not determined to be clinical trial cases; and (b) when there
is expanded access use of immunotherapy, these cases will be included
when calculating the average cost for cases determined to be clinical
trial cases. However, we continue to believe to the best of our
knowledge there are no claims in the historical data (FY 2021 MedPAR)
used in the calculation of the adjustment for cases involving a
clinical trial of a different product, and to the extent the historical
data contain claims for cases involving expanded access use of
immunotherapy we believe those claims would have drug charges less than
$373,000.
Applying this previously finalized methodology, based on the
December 2021 update of the FY 2021 MedPAR file used for the proposed
rule, we estimated that the average costs of cases assigned to MS-DRG
018 that are identified as clinical trial cases ($61,356) were 20
percent of the average costs of the cases assigned to MS-DRG 018 that
are identified as non-clinical trial cases ($299,460). Accordingly, as
we did for FY 2022, we proposed to adjust the transfer-adjusted case
count for MS-DRG 018 by applying the proposed adjustor of 0.20 to the
applicable clinical trial and expanded access use immunotherapy cases,
and to use this adjusted case count for MS-DRG 018 in calculating the
national average cost per case, which is used in the calculation of the
relative weights. Therefore, in calculating the national average cost
per case for purposes of the proposed rule, each case identified as an
applicable clinical trial or expanded access use immunotherapy case was
adjusted by 0.20. As we did for FY 2022, we applied this same adjustor
for the applicable cases that group to MS-DRG 018 for purposes of
budget neutrality and outlier simulations. We also proposed to update
the value of the adjustor based on more recent data for the final rule.
Comment: Several commenters were supportive of CMS' continued use
of MS-DRG 018 as it is currently
[[Page 48895]]
structured, including the identification and exclusion of CAR T-cell
clinical trial and expanded access use cases assigned to MS-DRG 018.
Commenters stated that the stability of MS-DRG 018 will help ensure
beneficiary access to CAR T-cell therapy services. One commenter stated
that analysis of CAR T-cell claims data from FY 2021 through the first
quarter of FY 2022 shows significant improvement in patient access to
CAR T. Another commenter requested that CMS reevaluate the clinical
trial threshold annually as acquisition costs increase and additional
therapies are introduced to MS-DRG 018.
Other commenters stated that they were concerned with what they
stated were Medicare under-reimbursements for CAR T-cell technology,
especially given the array of resources used to treat patients
undergoing these complex, novel cell therapies and the adverse impact
inadequate reimbursement has on beneficiary access. A commenter stated
that payment for MS-DRG 018 is almost 30 percent below the cost of CAR
T-cell cases and does not cover the cost of the therapy itself. A
commenter recommended that CMS cover the full cost of the CAR T-cell
therapy, while another commenter requested that CMS implement a policy
solution that will ensure providers recoup at least the invoice cost of
the CAR T-cell product. The commenter referenced prior comments about
options for such policy solutions. Some commenters stated that the
increase in the fixed-loss threshold makes it even more difficult to
obtain adequate reimbursement. A commenter requested that CMS closely
monitor reimbursement rates for CAR T-cell therapies to ensure that
hospital facilities can continue to provide access to these treatments.
Response: We appreciate the support and feedback on our proposal to
use the same ratesetting methodology for MS-DRG 018 in FY 2023 as we
have in prior years. With regard to the commenter who requested that
CMS reevaluate the clinical trial threshold annually, we note that we
continue to monitor the data and may engage further with the public and
consider this comment in connection with future rulemaking. With regard
to the comments that the MS-DRG relative weight for MS-DRG 018 is
inadequate and does not result in payment that fully covers the
hospital resource costs, we refer readers to the FY 2022 IPPS/LTCH
final rule (86 FR 44965) where we responded to similar comments.
Comment: A commenter stated that they understand that outliers are
removed in the development of MS-DRGs so that they do not skew the
results. The commenter found that in the calculation of the relative
weights, MS-DRG 018 has the highest percent of cases removed as
statistical outliers. The commenter stated the removal of these cases
resulted in a lower standardized cost per inpatient stay. Another
commenter requested that CMS monitor the impact that the removal of
these statistical outliers has on MS-DRG 018 and other low volume
services.
Response: We examined the cases referenced by the commenter that
were removed as statistical outliers in the FY 2021 MedPAR claims data.
We found that these cases had very high charges and very short lengths
of stay, with daily charges in excess of $1.2 million relative to the
average daily charge of $114,000 for MS-DRG 018. As described earlier
in this section, our standard method to identify and remove statistical
outliers excludes cases with total charges and total daily charges that
are beyond 3 standard deviations from the geometric mean of the log
distribution of both average total charges and average total daily
charges of the respective MS-DRG. As described in section III.B.4.b. of
the preamble of this final rule with respect to the MS-LTC-DRGs,
statistical outliers are removed because we believe that they may
represent aberrations in the data that distort the measure of average
resource use. For this reason, we believe that the cases identified by
the commenters are appropriately excluded as outliers, as their
inclusion could distort the measure of average resource use for MS-DRG
018. We will continue to monitor the removal of statistical outliers in
calculating the relative weights for MS-DRG 018.
Comment: A commenter recommended that CMS establish a new,
alternative payment model under CMMI for gene and cell therapies,
outside of the constraints of the IPPS. The commenter stated that this
would provide a clearer path to coverage and payment policy that can
improve patient access. Another commenter stated that some exceptions
to the standard IPPS process are and will continue to be needed to
allow hospitals to make lifesaving therapies available at launch to
Medicare beneficiaries as soon as possible.
Response: We believe that is premature to make structural changes
to the IPPS at this time to pay for gene and cell therapies. We may
consider these comments for future rulemaking as we gain more
experience in paying for these therapies under the IPPS.
Comment: Some commenters expressed concern that CMS mapped revenue
codes 087X for cell and gene therapy services furnished by hospital
staff to the drug cost group. One commenter stated that the NUBC
definition states this revenue code series is for ``[c]harges for
procedures performed by staff for the acquisition and infusion/
injection of genetically modified cells''. The commenter stated that
there is no standard cost center to report staff expense associated
with the 087X series, but that it is inappropriate to assign the
revenue for cell collection and processing services employed by
hospital nursing and laboratory staff to the drug/pharmacy cost center.
The commenter stated that if CMS finalizes this proposed mapping, it
will be inconsistent with the mapping of revenues and expenses that
hospitals are required to adhere to in their cost reports. A commenter
suggested that CMS should revise the mapping of the 087X revenue codes
to more closely reflect the departments where the staff expenses are
recorded on the cost report. Commenters suggested that CMS map revenue
codes 0871 and 0874 to the ``other'' cost center and 0872 and 0873 to
the laboratory cost center. A commenter requested that CMS allow
providers to bill for cell collection and cell processing services on
the day that the services are rendered rather than adding them to the
inpatient claim. The commenter stated that these are separate from the
manufacturing process and are not included in the acquisition cost of
the product.
Response: We disagree with the commenters that revenue center codes
087X are inappropriately mapped to the drug cost center. Cell
collection and processing activities are part of the steps required to
manufacture the drug, and thus assignment to the drug cost center
accurately allocates these costs. Given this, we believe it is
appropriate to apply the drug CCR to these charges for purposes of
calculating the relative weights. With respect to the commenter who
indicated that finalizing the proposed assignment of the 087X codes
would be inconsistent with the mapping of revenues and expenses
hospitals are required to adhere to in their cost reports, it is
unclear to us what requirements are being referred to. With respect to
the commenter who requested that CMS allow separate billing for the
cell collection and processing services, as we discussed in the CY 2022
OPPS final rule (86 FR 63550), CMS does not believe that separate
payment is necessary for the various steps required to collect and
prepare the genetically modified T-cells, and Medicare does not
generally pay separately for each step
[[Page 48896]]
used to manufacture a drug or biological product.
Comment: A commenter requested that CMS consider allowing hospitals
to use expanded access condition code 90 instead of the remarks field,
which would remove a layer of manual work required by the MACs, which
would decrease the opportunity for errors.
Response: We agree with the commenter that the availability of
condition code 90 obviates the need for the use of the remarks field to
identify expanded access claims that group to MS-DRG 018 for the
purposes of applying the clinical trial adjustment. Effective October
1, 2022, providers should submit condition code 90 to identify expanded
access claims that group to MS-DRG 018, rather than the remarks field.
The MACs will no longer flag cases as expanded access claims based on
information submitted in the remarks field for claims submitted on or
after October 1, 2022.
Comment: A commenter requested that CMS provide additional
clarification on the agency's methodology to develop the relative
weight for both MS-DRG 018 and its overall ratesetting methodology.
This commenter requested that CMS describe the order of operations,
including step-by-step instructions of when to exclude certain types of
claims. This commenter also requested that CMS clarify whether the
agency trims claims first, and then sets aside clinical trial cases, or
sets aside clinical trial claims and claims with less than $373,000 and
then performs trimming.
Response: In response to the commenter's specific question
regarding when CMS removes clinical trial cases from MS-DRG 018, the
trims to remove clinical trial cases from MS-DRG 018 are done prior to
the elimination of statistical outliers. In response to the commenter's
request that we clarify our relative weight methodology more generally,
we note that in each year's IPPS/LTCH PPS proposed and final rules, we
include a section describing the recalibration of the MS-DRG relative
weights and methodology for calculating the relative weights. We refer
readers to sections II.E.1. and E.2.a. of the preamble of this final
rule, in which we describe the trims we apply to the MedPAR claims to
exclude non-IPPS claims, and provide a detailed description of the
methodology we use to calculate the relative weights. The order that
the trims are applied is consistent with the narrative description of
our methodology. In addition, since the creation of MS-DRG 018, we have
provided a description of the calculation of the relative weight for
MS-DRG 018, including a step-by-step calculation of the CAR T-cell
clinical trial adjustment factor, as set forth earlier in this section.
We also note that some commenters requested additional
clarifications regarding billing instructions for CAR T-cell therapies,
such as appropriate CAR T-cell billing and charges. We do not believe
changes to billing guidance are needed at this time but will take these
comments into consideration when developing policies and program
requirements for future years for CAR T-cell therapy policy.
After consideration of the public comments we received, we are
finalizing our proposals regarding the calculation of the relative
weight for MS-DRG 018. Applying this finalized methodology, based on
the March 2022 update of the FY 2021 MedPAR file used for this final
rule, we estimated that the average costs of cases assigned to MS-DRG
018 that are identified as clinical trial cases ($61,540) were 21
percent of the average costs of the cases assigned to MS-DRG 018 that
are identified as non-clinical trial cases ($293,546). Accordingly, as
we did for FY 2022, we are finalizing our proposal to adjust the
transfer-adjusted case count for MS-DRG 018 by applying the adjustor of
0.21 to the applicable clinical trial and expanded access use
immunotherapy cases, and to use this adjusted case count for MS-DRG 018
in calculating the national average cost per case, which is used in the
calculation of the relative weights. Therefore, in calculating the
national average cost per case for purposes of this final rule, each
case identified as an applicable clinical trial or expanded access use
immunotherapy case was adjusted by 0.21. As we did for FY 2022, we are
applying this same adjustor for the applicable cases that group to MS
DRG 018 for purposes of budget neutrality and outlier simulations.
c. Averaging of Relative Weights for FY 2023
In section I.F. of the proposed rule and this final rule, we
discuss our proposal to use the FY 2021 MedPAR data for purposes of FY
2023 IPPS ratesetting, with certain proposed modifications to our usual
methodologies, including an averaging approach for calculating the FY
2023 relative weights. As discussed in the proposed rule, we observed
that COVID-19 cases were impacting the relative weights as calculated
using the FY 2021 claims data for a few COVID-19-related MS-DRGs. For
example, for MS-DRG 870 (Septicemia or Severe Sepsis with MV >96
hours), the relative weight calculated using the FY 2021 MedPAR data
was approximately 9 percent higher than the relative weight calculated
excluding the COVID-19 cases in the FY 2021 data. As also discussed in
that section, we believe it is reasonable to assume that there will be
fewer COVID-19 hospitalizations among Medicare beneficiaries in FY 2023
than there were in FY 2021. However, we cannot know the precise number
of COVID-19 hospitalizations among Medicare beneficiaries in FY 2023.
To account for the anticipated decline in COVID-19 hospitalizations of
Medicare beneficiaries as compared to FY 2021, we proposed to determine
the MS-DRG relative weights for FY 2023 by averaging the relative
weights as calculated with and without COVID-19 cases in the FY 2021
data, as described in greater detail in this section. Given the
uncertainty in the number of COVID-19 hospitalizations in FY 2023, we
proposed to use 50 percent of the relative weights calculated using all
applicable cases in the FY 2021 claims data and 50 percent of the
relative weights calculated without the COVID-19 cases in the FY 2021
claims data. We stated that we believe this proposed approach would
appropriately reduce, but not remove entirely, the effect of COVID-19
cases on the relative weight calculations, consistent with our
expectation that Medicare inpatient hospitalizations for COVID-19 will
continue in FY 2023 at a lower level as compared to FY 2021. By
averaging the relative weights in this manner, we stated that we
believe the result would reflect a reasonable estimation of the case
mix for FY 2023 based on the information available at the time, as
discussed in section I.F. of the preamble to the proposed rule and this
final rule, and more accurately estimate the relative resource use for
the cases treated in FY 2023 than if we were to calculate the proposed
relative weights based on 100 percent of the relative weights as
calculated for all applicable cases in the FY 2021 data. For the
proposed rule, our proposed calculation was as follows:
Step 1: Calculate a set of relative weights using all
applicable cases in the December 2021 update of the FY 2021 MedPAR
data, using the methodology as described earlier in this section, and
then applying a normalization adjustment factor as described later in
this section.
Step 2: Calculate a set of relative weights using the
December 2021 update of the FY 2021 MedPAR data excluding cases with a
principal or secondary diagnosis of COVID-19 (ICD-10-CM diagnosis code
U07.1), and
[[Page 48897]]
otherwise using the methodology as described earlier in this section,
and then applying a normalization adjustment factor as described later
in this section.
Step 3: Average the results of step 1 and step 2 to
calculate a set of averaged relative weights, geometric mean length of
stays, and arithmetic mean length of stays.
Step 4: Calculate the proposed FY 2023 relative weights by
applying an additional normalization factor to these averaged relative
weights. This additional normalization factor is necessary to ensure
that the average case weight as calculated in step 3 of this proposed
averaging methodology for recalibration of the FY 2023 relative weights
is equal to the average case weight before recalibration. We note that
this factor is very close to 1 and is described later in this section.
We noted that in Step 5 of this proposed calculation, we applied
the proposed 10 percent cap to the relative weights for those MS-DRGs
for which the relative weight as calculated in Step 4 would otherwise
have declined by more than 10 percent from the FY 2022 relative weight,
as discussed more fully later in this section. We also noted that we
intended to update this calculation for the final rule using the March
2022 update of the FY 2021 MedPAR file.
We set forth the proposed relative weights, geometric mean length
of stay, and average length of stay as calculated using this proposed
methodology in Table 5 associated with the proposed rule, which is
available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. We also made available the
relative weights, geometric mean length of stay, and average length of
stay as calculated in steps 1 and 2 of this proposed methodology on our
website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS.
Comment: Several commenters supported our proposal to average the
relative weights calculated with and without COVID-19 cases, stating
that this would more accurately account for the anticipated change in
case mix as COVID-19 cases decline.
Another commenter supported an alternative MS-DRG relative weight
methodology, but stated that the proposed methodology does not do
enough to control for variability. This commenter requested that CMS
use FY 2019 claims or some other alternate blend using the FY 2021
claims to establish the FY 2023 relative weights.
Some commenters expressed concern about policies that may limit the
reimbursement for COVID-19 cases. A commenter suggested increasing the
relative weights for the MS-DRGs that have documented COVID-19 cases,
but recommended that CMS consider a process to differentiate patients
who test asymptomatically for COVID-19 from those whose COVID-19
infection is causing clinical symptoms to worsen. The commenter stated
that this approach would better target the more resource intensive
beneficiaries without artificially constraining reimbursement for their
care.
Response: We appreciate commenters' support for and feedback on our
proposal. However, we disagree that we should blend other data sources
or take additional steps to control for variability in the FY 2023
relative weights. As we stated in the FY 2023 IPPS/LTCH PPS proposed
rule, we cannot know the precise number of COVID-19 hospitalizations
among Medicare beneficiaries as compared to FY 2021. Our proposal to
average the relative weights is intended to reflect a reasonable
estimation of the case mix for FY 2023 based on the information
available at this time, not to completely remove all variability in the
FY 2023 relative weights. Our proposed methodology uses the FY 2021
MedPAR claims file to determine the FY 2023 relative weights, as the
most recent available data during the period of the COVID-19 PHE, with
modifications to account for the anticipated decline in COVID-19
hospitalizations of Medicare beneficiaries at IPPS hospitals as
compared to FY 2021. As discussed in section I.F. of this final rule,
after reviewing the latest CDC hospitalization data available at this
time, we continue to believe that it is reasonable to assume that some
Medicare beneficiaries will be hospitalized with COVID-19 at IPPS
hospitals in FY 2023, but that there will be fewer COVID 19
hospitalizations as compared to FY 2021. With respect to the
commenters' concerns about policies that may limit reimbursement for
COVID-19 cases, we note that the majority of cases that include a
diagnosis of COVID-19 (ICD-10-CM diagnosis code U07.1) group to MS-DRGs
177 and 871, and that the relative weights calculated using the
proposed averaging methodology for FY 2023 are higher than the FY 2022
relative weights for these MS-DRGs. For MS-DRG 177, the relative weight
calculated using the proposed averaging approach is also higher than
the relative weight calculated using all applicable cases in the FY
2021 MedPAR file. For MS-DRG 871, while the relative weight calculated
using the proposed averaging approach is lower than the relative weight
calculated using all applicable cases in the FY 2021 MedPAR file, it is
still an increase as compared to the relative weight for FY 2022.
Moreover, as previously discussed, we believe that use of the proposed
averaging methodology would provide a more accurate estimate of
relative resource use for FY 2023 than if we were to calculate the
proposed relative weights using all applicable cases in the FY 2021
data, and is consistent with our expectation, based on the information
available at this time, that Medicare inpatient hospitalizations for
COVID-19 will continue in FY 2023 at a lower level as compared to FY
2021. With regard to the suggestion about differentiating between
symptomatic and asymptomatic COVID-19 cases, at this time we do not
believe it is operationally feasible to make such a distinction given
that separate coding does not exist to differentiate these cases. We
may consider this suggestion in connection with future rulemaking.
After consideration of comments received, we are finalizing our
proposal to determine the FY 2023 MS-DRG relative weights by averaging
the relative weights as calculated with and without COVID-19 cases in
the FY 2021 data, as previously described. As previously discussed, for
this final rule, we are using the March 2022 update of the FY 2021
MedPAR file to determine the final relative weights for FY 2023. The
relative weights, geometric mean length of stay, and average length of
stay as calculated using this methodology are set forth in Table 5
associated with this final rule, which is available on the CMS website
at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. We are also making available the relative weights,
geometric mean length of stay, and average length of stay as calculated
in steps 1 and 2 of this methodology on our website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS.
d. Cap for Relative Weight Reductions
In the FY 2018 IPPS/LTCH PPS final rule, we summarized comments we
had received requesting a transition period for substantial reductions
in relative weights in order to facilitate payment stability.
Specifically, some commenters requested that CMS establish a cap on the
decline in a relative weight from FY 2017 to FY 2018, or a phase-in or
multi-year transition period in cases of substantial fluctuation of
payment rates (82 FR 38103).
[[Page 48898]]
After consideration of these comments, and for the reasons
discussed in the FY 2018 final rule, we adopted a temporary one-time
measure for FY 2018 for MS-DRGs where the relative weight would have
declined by more than 20 percent from the FY 2017 relative weight,
consistent with our general authority to assign and update appropriate
weighting factors under sections 1886(d)(4)(B) and (C) of the Act (82
FR 38103). Specifically, for these MS-DRGs, the relative weight for FY
2018 was set at 80 percent of the FY 2017 relative weight. In the FY
2019 IPPS/LTCH PPS final rule, in response to similar comments, we
adopted a temporary one-time measure for FY 2019 for an MS-DRG where
the FY 2018 relative weight declined by 20 percent from the FY 2017
relative weight and the FY 2019 relative weight would have declined by
20 percent or more from the FY 2018 relative weight (83 FR 41273).
Specifically, for an MS-DRG meeting this criterion, we set the FY 2019
relative weight equal to the FY 2018 relative weight. In the FY 2020
IPPS/LTCH PPS final rule, in response to similar comments, we adopted a
temporary one-time measure for FY 2020 for an MS-DRG where the FY 2018
relative weight declined by 20 percent from the FY 2017 relative weight
and the FY 2020 relative weight would have declined by 20 percent or
more from the FY 2019 relative weight, which was maintained at the FY
2018 relative weight (84 FR 42167). Specifically, for an MS-DRG meeting
this criterion, we set the FY 2020 relative weight equal to the FY 2019
relative weight, which was in turn set equal to the FY 2018 relative
weight.
In the FY 2021 IPPS/LTCH PPS proposed rule, we noted the one-time
measure adopted for FY 2020 and sought comment on whether we should
consider a similar policy for FY 2021, or an alternative approach such
as averaging the FY 2020 relative weight and the otherwise applicable
FY 2021 relative weight for MS-DRG 215, which was the only MS-DRG
impacted by the FY 2020 policy setting the FY 2020 relative weight
equal to the FY 2019 relative weight. Commenters generally supported
either setting the FY 2021 weight for MS-DRG 215 equal to the FY 2020
relative weight or an averaging approach. Some commenters requested
that CMS consider such an approach when the relative weight for an MS-
DRG is drastically reduced in a given year, particularly when it
follows a significant decline in prior years. After consideration of
comments received, and for the reasons discussed in the FY 2021 final
rule, we set the FY 2021 relative weight for MS-DRG 215 equal to the
average of the FY 2020 relative weight and the otherwise applicable FY
2021 weight. With regard to the concerns raised about other MS-DRGs
with significant reductions relative to FY 2020, we noted that these
other MS-DRGs were low volume in our claims data, and therefore
typically experience a greater degree of year-to-year variation. We
acknowledged the longstanding concerns related to low volume MS-DRGs
and stated that we would take into consideration the unique issues
relating to such MS-DRGs and the stability of their weights for future
rulemaking.
As we stated in the FY 2023 IPPS/LTCH PPS proposed rule, we have
continued to consider the comments we received in response to prior
rulemaking recommending that CMS limit significant declines in the
relative weights for the MS-DRGs more broadly, including by
establishing a cap on the degree to which the relative weight for an
MS-DRG may decline from one fiscal year to the next. For prior fiscal
years, as previously discussed, we have adopted limited, temporary
measures to address potentially substantial declines in the relative
weights in certain outlier circumstances to mitigate the impacts of
such declines. However, we have also acknowledged commenters' concerns
related to significant reductions in the weights for other MS-DRGs, in
particular low volume MS-DRGs. For these low volume MS-DRGs,
fluctuations in the volume or mix of cases and/or the presence of a few
high cost or low cost cases can have a disproportionate impact on the
calculated relative weight, thus resulting in greater year-to-year
variation in the relative weights for these MS-DRGs. This variation may
reduce the predictability and stability of an individual hospital's
Medicare payments from year-to-year. We also recognize that significant
declines in the relative weights may occur for higher-volume MS-DRGs,
with such fluctuations likewise affecting the predictability and
stability of hospital payments.
In light of these concerns, we have further considered requests
made by commenters that we address year-to-year fluctuations in
relative weights, particularly for low volume MS-DRGs, and to mitigate
the financial impacts of significant fluctuations. In consideration of
the concerns that commenters have raised about year-to-year
fluctuations in relative weights and the financial impacts of
significant fluctuations, we stated in the proposed rule that we
believe it would be appropriate to limit such fluctuations by applying
a cap on reductions in the relative weight for an MS-DRG for a given
fiscal year. Therefore, consistent with our statutory authority under
section 1886(d)(4)(B) and (C) of the Act to assign and update
appropriate weighting factors, we proposed a permanent 10-percent cap
on the reduction in an MS-DRG's relative weight in a given fiscal year,
beginning in FY 2023. This proposal is consistent with our general
authority to assign and update appropriate weighting factors as part of
our annual reclassification of the MS-DRGs and recalibration of the
relative weights under sections 1886(d)(4)(B) and (C)(i) of the Act, as
well as the requirements of section 1886(d)(4)(C)(iii) of the Act,
which specifies that the annual DRG reclassification and recalibration
of the relative weights be made in a manner that ensures that aggregate
payments to hospitals are not affected. In addition, we have authority
to implement this proposed cap and the associated budget neutrality
adjustment under our special exceptions and adjustments authority at
section 1886(d)(5)(I)(i) of the Act, which similarly gives the
Secretary broad authority to provide by regulation for such other
exceptions and adjustments to the payment amounts under section 1886(d)
of the Act as the Secretary deems appropriate. As discussed, we believe
this cap on declines in the relative weights would be appropriate in
order to promote predictability and stability in hospital payments and
to mitigate the financial impacts of significant fluctuations in the
weights. That is, by smoothing year-to-year changes in the MS-DRG
relative weights, we stated that this proposal would provide greater
predictability to hospitals, allowing time to adjust to significant
changes to relative weights. Moreover, consistent with the budget
neutrality requirement for annual updates to the relative weights,
including our implementation of similar caps on significant declines in
the relative weight for prior fiscal years, we believe that application
of this proposed 10-percent cap on relative weight reductions should
not increase estimated aggregate Medicare payments beyond the payments
that would be made had we never applied this cap. Accordingly, we
proposed to apply a budget neutrality adjustment to the standardized
amount for all hospitals to ensure that application of the proposed 10-
percent cap does not result in an increase or decrease of estimated
aggregate payments. For a further discussion of the budget neutrality
[[Page 48899]]
adjustment, we refer readers to the Addendum of the proposed rule and
this final rule.
Under this proposal, in cases where the relative weight for a MS-
DRG would decrease by more than 10 percent in a given fiscal year, we
proposed to limit the reduction to 10 percent for that fiscal year. For
example, if the relative weight for an MS-DRG in FY 2022 is 1.100 and
the relative weight for FY 2023 would otherwise be 0.9350, which would
represent a decrease of 15 percent from FY 2022, the reduction would be
limited to 10 percent, such that the proposed relative weight for FY
2023 for MS-DRG XYZ would be 0.9900 (that is, 0.90 x FY 2022 weight of
1.100). The proposed relative weights for FY 2023 as set forth in Table
5 associated with the proposed rule and available on the CMS website at
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS reflect the application of this proposed cap.
As previously summarized, in the past, we have adopted a temporary
cap of 20 percent on the decline in an MS-DRG's relative weight to
address certain outlier circumstances. However, as also previously
discussed, we recognize that hospitals may benefit from the phase-in of
smaller declines in the relative weight that may nonetheless contribute
to less stability and predictability in hospital payment rates.
Accordingly, for purposes of this proposed permanent cap, we considered
that a higher cap, such as the 20-percent cap that we have applied
previously (see, for example, 82 FR 38103), would limit declines in the
relative weights for fewer MS-DRGs (5 MS-DRGs in our analysis of the
March 2022 update of the FY 2021 MedPAR claims), while a lower cap,
such as a 5-percent cap, would limit declines in the relative weights
for more MS-DRGs (92 MS-DRGs in our analysis of the March 2022 update
of the FY 2021 MedPAR claims), but with a larger associated budget
neutrality adjustment to the standardized amount. On balance, we stated
that we believe that a 10-percent cap would mitigate financial impacts
resulting from significant fluctuations in the relative weights,
particularly for low volume MS-DRGs, without the larger budget
neutrality adjustment associated with a smaller cap. We noted that this
proposed policy would limit declines in the relative weight for 27 MS-
DRGs, based on the FY 2021 claims data used for the proposed rule;
based on the March 2022 update of the FY 2021 claims data used for this
final rule, we note that it would limit declines in the relative
weights for 31 MS-DRGs.
We noted that this proposed 10-percent cap on reductions to an MS-
DRG's relative weight would apply only to a given MS-DRG with its
current MS-DRG number. In cases where CMS creates new MS-DRGs or
modifies the MS-DRGs as part of its annual reclassifications resulting
in renumbering of one or more MS-DRGs, we proposed that this limit on
the reduction in the relative weight would not apply to any MS-DRGs
affected by the renumbering (that is, the proposed 10-percent cap would
not apply to the relative weight for any new or renumbered MS-DRGs for
the fiscal year). We proposed to modify the regulations at Sec.
412.60(b) to reflect this proposed permanent cap on relative weight
reductions. We sought comments on our proposal to apply a 10-percent
cap on decreases in an MS-DRG relative weight from one fiscal year to
the next.
Comment: Many commenters supported our proposal to cap yearly
reductions in an MS-DRG's relative weight to 10%. Commenters stated
that significant year-over-year reductions can disrupt patient access
to medically necessary treatment, that large swings are inconsistent
with the principle of payment stability, and that a permanent 10
percent cap would provide more time for providers to adjust to
significant changes in relative weights. A commenter stated that a cap
on relative weight decreases could incentivize greater innovation, as
hospitals may avoid MS-DRGs with significant declines, even if they
offer more innovative, cost-saving treatment approaches. This commenter
stated that mitigating large year-to-year payment changes would
encourage providers to use the most clinically appropriate care.
Commenters also stated that the cap is particularly helpful for low
volume services, as they stated that shifts in these MS-DRGs are not
reflective of true changes in the cost of care.
Some commenters requested that CMS apply the cap in a non-budget
neutral manner. A commenter requested that CMS monitor for any
unintended consequences of the cap, given that it is budget neutral.
Many commenters requested that CMS finalize a permanent lower cap,
with some commenters expressing concern that with a 10% cap, there are
still sizable reductions for high-cost MS-DRGs. Other commenters
requested that CMS finalize a one-year cap of 5%, followed by a
permanent cap of 10%. Several commenters recommended a permanent 5%
cap, while others requested CMS set the floor as low as possible. Some
commenters noted that a broad range of MS-DRGs have weight fluctuations
in FY 2023 due to unique circumstances, such as the first use of
hospital data impacted by the COVID-19 PHE for IPPS ratesetting. A
commenter stated that the 10% cap benefits mostly medical MS-DRGs,
while many surgical MS-DRGs would experience reductions greater than 5
percent but less than 10 percent. This commenter stated that capping
reductions at 5% is consistent with the rationale to blend hospital
claims with and without COVID-19, due to the uncertainty around the
degree to which FY 2021 will reflect hospitals' costs and case mix in
FY 2023. One commenter noted that their analysis of the MS-DRG relative
weights showed that the average yearly variation in relative weights
was 5%, so a permanent 5% cap is more in line with historical MS-DRG
variation. A commenter stated that there is precedent of a 5% cap in
other parts of the IPPS, such as the wage index.
One commenter requested that if CMS finalizes a 10% cap, that the
agency continue to monitor whether a 10% cap is appropriate. A
commenter requested that CMS update this policy clearly and
transparently, and with additional stakeholder input, on an annual
basis to maintain stability and predictability.
Some commenters acknowledged that setting a lower threshold for the
cap would necessitate a larger budget neutrality adjustment, but that
the redistributive impact would be minimal overall. These commenters
stated that on balance it is still preferable to smooth the impact of
steep payment declines for a larger number of services.
One commenter stated that it is premature for CMS to adopt a
permanent cap, and recommended that CMS implement the 10% cap for FY
2023 only without a budget neutrality offset. This commenter stated
that as COVID-19 becomes more endemic in the population, and less
severe and costly in hospitals, Medicare utilization would be expected
to return to its former level of annual stability, negating the need
for a permanent cap on reductions to relative weights.
A commenter requested that any caps on the maximum annual change to
the MS-DRG relative weights should not apply to just decreases but to
increases as well.
A commenter stated that any new MS-DRG or modified version of an
existing MS-DRG would benefit from the 10% cap in subsequent years
following its introduction or modification. This commenter requested
that CMS apply the 10% cap to all MS-DRGs once the MS-DRG has been
established and gone through at least one year of the relative weight
setting
[[Page 48900]]
process. This commenter also requested that CMS consider how this type
of policy could support long term payment stability for relative
weights and hospital payments.
One commenter suggested that similar caps on payment reductions
would be beneficial under the OPPS and PFS for revised or bundled
coding updates.
Response: We appreciate commenters' support for and feedback on our
proposal. However, we disagree with the suggestion that the proposed
cap be applied in a non-budget neutral manner. As we stated in the
IPPS/LTCH PPS proposed rule, our proposal is consistent with the
requirements of section 1886(d)(4)(C)(iii) of the Act, which specifies
that the annual DRG reclassification and recalibration of the relative
weights be made in a manner that ensures that aggregate payments to
hospitals are not affected. Consistent with this budget neutrality
requirement for annual updates to the relative weights, we believe that
application of this proposed 10-percent cap on relative weight
reductions should not increase estimated aggregate Medicare payments
beyond the payments that would be made had we never applied this cap.
This is also consistent with our implementation of similar caps on
significant declines in the relative weight for prior fiscal years, as
previously summarized.
We appreciate commenters' feedback on the size of the cap on year-
to-year declines in an MS-DRG's relative weight, however we disagree
that we should finalize a lower cap, whether for one year or on a
permanent basis. As discussed in the proposed rule, after considering
larger and smaller caps, we determined that on balance, a 10-percent
cap would promote predictability and mitigate financial impacts
resulting from significant fluctuations in the relative weights,
particularly for low volume MS-DRGs, without the larger budget
neutrality adjustment associated with a smaller cap. With respect to
commenters who stated that we should finalize a five percent cap
because there were greater fluctuations due to the first use of the PHE
data for ratesetting and that many surgical MS-DRGs would experience
declines of between 5 and 10 percent, we note that declines in relative
weights between 5 and 10 percent are not uncommon. For example, we note
that prior to the PHE, and relative to the 25 medical MS-DRGs and 36
surgical MS-DRGs for which the FY 2023 relative weight is declining
between 5 and 10 percent as compared to FY 2022 (based on the March
2022 update of the FY 2021 claims data used for this final rule), for
the FY 2020 IPPS/LTCH PPS final rule, 27 surgical MS-DRGs and 21
medical MS-DRGs declined between 5 and 10 percent, and for the FY 2019
IPPS/LTCH PPS final rule, 32 surgical MS-DRGs and 25 medical MS-DRGs
declined between 5 and 10 percent. Therefore, we do not believe that
the number of MS-DRGs for which the FY 2023 relative weight is
declining between 5 and 10 percent is unusual or necessarily related to
the first use of the PHE data. We therefore continue to believe that a
10-percent cap strikes the appropriate balance between considerations
of promoting predictability and mitigating financial impacts resulting
from significant fluctuations in the relative weights, without the
larger budget neutrality adjustment associated with a smaller cap. We
acknowledge commenters' observation that most MS-DRGs impacted by the
cap for FY 2023 are medical MS-DRGs; we note that the particular MS-
DRGs impacted in a given year would be expected to fluctuate based on
changes in the underlying data or as result of reclassifications.
With respect to the commenters who requested that CMS implement a
10-percent cap for one year only or update the policy on an annual
basis, we believe that in order to better promote predictability and
stability in hospital payments, it is appropriate to finalize a
permanent 10-percent cap on year-to-year declines in the relative
weight, beginning with the FY 2023 relative weights. We expect to
continue to monitor the effects of this cap, including the number of
MS-DRGs subject to the cap for any given fiscal year, and to present in
the Addendum to the annual proposed and final rules the budget
neutrality adjustment for reclassification and recalibration of the MS-
DRG relative weights with application of this cap. We also anticipate
continuing to make available on the CMS website a supplemental file
demonstrating the application of the permanent 10 percent cap for
future years.
With regard to the comment requesting that caps on maximum changes
to an MS-DRG's relative weight apply to increases as well, as discussed
in the IPPS/LTCH PPS proposed rule, our goal in smoothing year-to-year
changes in the relative weights is to mitigate financial impacts
associated with significant declines in an MS-DRG's relative weight and
allow hospitals more time to adjust to such changes by phasing-in these
declines. In cases where the underlying data or MS-DRG
reclassifications result in an increase to an MS-DRG's relative weight,
we do not believe a such a phase-in is appropriate.
With regard to new or modified MS-DRGs, we are clarifying that
after the first fiscal year that these new or modified MS-DRGs take
effect, any changes to the relative weights for those MS-DRGs would
also be subject to the 10-percent cap.
With regard to the commenter's suggestion about long-term payment
stability, we note that the goal of this policy is to smooth year-to-
year changes.
With regard to similar caps on payment under other payment systems,
we note that this comment is outside the scope of the proposals
included in the FY 2023 IPPS/LTCH PPS proposed rule, and we are
therefore not addressing this comment in this final rule. We may
consider this comment in connection with future rulemaking.
After consideration of comments received, we are finalizing the
proposed permanent 10-percent cap on the reduction in an MS-DRG's
relative weight in a given fiscal year and the associated budget
neutrality adjustment to the standardized amount, as previously
described in this section, beginning in FY 2023. We are also finalizing
our proposed modifications to the regulations at Sec. 412.60(b) to
reflect this permanent cap on relative weight reductions. The final
relative weights for FY 2023 as set forth in Table 5 associated with
this final rule and available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS
reflect the application of this finalized cap. For a further discussion
of the budget neutrality adjustment for FY 2023, we refer readers to
the Addendum of this final rule.
3. Development of National Average CCRs
We developed the national average CCRs as follows:
Using the FY 2020 cost report data, we removed CAHs, Indian Health
Service hospitals, all-inclusive rate hospitals, and cost reports that
represented time periods of less than 1 year (365 days). We included
hospitals located in Maryland because we include their charges in our
claims database. Then we created CCRs for each provider for each cost
center (see the supplemental data file for line items used in the
calculations) and removed any CCRs that were greater than 10 or less
than 0.01. We normalized the departmental CCRs by dividing the CCR for
each department by the total CCR for the hospital for the purpose of
trimming the data. Then we took the logs of the
[[Page 48901]]
normalized cost center CCRs and removed any cost center CCRs where the
log of the cost center CCR was greater or less than the mean log plus/
minus 3 times the standard deviation for the log of that cost center
CCR. Once the cost report data were trimmed, we calculated a Medicare-
specific CCR. The Medicare-specific CCR was determined by taking the
Medicare charges for each line item from Worksheet D-3 and deriving the
Medicare-specific costs by applying the hospital-specific departmental
CCRs to the Medicare-specific charges for each line item from Worksheet
D-3. Once each hospital's Medicare-specific costs were established, we
summed the total Medicare-specific costs and divided by the sum of the
total Medicare-specific charges to produce national average, charge-
weighted CCRs.
After we multiplied the total charges for each MS-DRG in each of
the 19 cost centers by the corresponding national average CCR, we
summed the 19 ``costs'' across each MS-DRG to produce a total
standardized cost for the MS-DRG. The average standardized cost for
each MS-DRG was then computed as the total standardized cost for the
MS-DRG divided by the transfer-adjusted case count for the MS-DRG. The
average cost for each MS-DRG was then divided by the national average
standardized cost per case to determine the proposed relative weight.
As discussed earlier in this section, we are finalizing our
proposal to (a) use 50 percent of the relative weights calculated using
all cases in the FY 2021 MedPAR data and 50 percent of the relative
weights calculated without COVID-19 cases in the FY 2021 MedPAR data to
calculate the relative weights for FY 2023; and (b) apply a permanent
10-percent cap on the reduction in a MS-DRG's relative weight in a
given fiscal year, beginning in FY 2023.
In developing the relative weights consistent with these finalized
policies, we first created a set of relative weights using all
applicable cases in the March 2022 update of the FY 2021 MedPAR data,
using the methodology as described earlier in this section (Step 1).
These relative weights were then normalized by an adjustment factor of
1.948410 so that the average case weight after recalibration was equal
to the average case weight before recalibration. The normalization
adjustment is intended to ensure that recalibration by itself neither
increases nor decreases total payments under the IPPS, as required by
section 1886(d)(4)(C)(iii) of the Act.
Next, we created a set of relative weights using the March 2022
update of the FY 2021 MedPAR data excluding cases with a principal or
secondary diagnosis of COVID-19 (ICD-10-CM diagnosis code U07.1), and
otherwise using the methodology as described earlier in this section
(Step 2). These relative weights were then normalized by an adjustment
factor of 1.916445.
We then averaged the results of Step 1 and Step 2 (Step 3), and
normalized these relative weights by applying an adjustment factor of
1.000212 (Step 4). This normalization adjustment is intended to ensure
that this averaging methodology for recalibration of the FY 2023
relative weights neither increases nor decreases total payments under
the IPPS, as required by section 1886(d)(4)(C)(iii) of the Act.
Finally, we applied the 10 percent cap to the relative weights for
those MS-DRGs for which the relative weight as calculated in Step 4
would otherwise have declined by more than 10 percent from the FY 2022
relative weight (Step 5). Specifically, for those MS-DRGs for which the
relative weight as calculated in Step 4 declined by more than 10
percent from the FY 2022 relative weight, we set the FY 2023 relative
weight equal to 90 percent of the FY 2022 relative weight. The relative
weights for FY 2023 as set forth in Table 5 associated with this final
rule and available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS reflect the
application of this cap. We are also making available a supplemental
file setting forth the relative weights as calculated with all cases
(Step 1), excluding cases with a principal or secondary diagnosis of
COVID-19 (Step 2), following application of the normalization factor
and prior to the application of this cap (Step 4), and with the
application of this cap (Step 5) along with the other supplemental
files for this final rule, on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS.
The 19 national average CCRs for FY 2023 are as follows:
BILLING CODE 4120-01-P
[[Page 48902]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.074
Since FY 2009, the relative weights have been based on 100 percent
cost weights based on our MS-DRG grouping system.
When we recalibrated the DRG weights for previous years, we set a
threshold of 10 cases as the minimum number of cases required to
compute a reasonable weight. We are proposed to use that same case
threshold in recalibrating the proposed MS-DRG relative weights for FY
2023. Using data from the FY 2021 MedPAR file, there were 7 MS-DRGs
that contain fewer than 10 cases. For FY 2023, because we do not have
sufficient MedPAR data to set accurate and stable cost relative weights
for these low-volume MS-DRGs, we proposed to compute relative weights
for the low-volume MS-DRGs by adjusting their final FY 2022 relative
weights by the percentage change in the average weight of the cases in
other MS-DRGs from FY 2022 to FY 2023. The crosswalk table is as
follows.
[[Page 48903]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.075
BILLING CODE 4120-01-C
We did not receive any public comments on our proposals and we are
finalizing our proposals without modification.
F. Add-On Payments for New Services and Technologies for FY 2023
1. Background
Sections 1886(d)(5)(K) and (L) of the Act establish a process of
identifying and ensuring adequate payment for new medical services and
technologies (sometimes collectively referred to in this section as
``new technologies'') under the IPPS. Section 1886(d)(5)(K)(vi) of the
Act specifies that a medical service or technology will be considered
new if it meets criteria established by the Secretary after notice and
opportunity for public comment. Section 1886(d)(5)(K)(ii)(I) of the Act
specifies that a new medical service or technology may be considered
for new technology add-on payment if, based on the estimated costs
incurred with respect to discharges involving such service or
technology, the DRG prospective payment rate otherwise applicable to
such discharges under this subsection is inadequate. The regulations at
42 CFR 412.87 implement these provisions and Sec. 412.87(b) specifies
three criteria for a new medical service or technology to receive the
additional payment: (1) the medical service or technology must be new;
(2) the medical service or technology must be costly such that the DRG
rate otherwise applicable to discharges involving the medical service
or technology is determined to be inadequate; and (3) the service or
technology must demonstrate a substantial clinical improvement over
existing services or technologies. In addition, certain transformative
new devices and antimicrobial products may qualify under an alternative
inpatient new technology add-on payment pathway, as set forth in the
regulations at Sec. 412.87(c) and (d). We note that section
1886(d)(5)(K)(i) of the Act requires that the Secretary establish a
mechanism to recognize the costs of new medical services and
technologies under the payment system established under that
subsection, which establishes the system for paying for the operating
costs of inpatient hospital services. The system of payment for capital
costs is established under section 1886(g) of the Act. Therefore, as
discussed in prior rulemaking (72 FR 47307 through 47308), we do not
include capital costs in the add-on payments for a new medical service
or technology or make new technology add-on payments under the IPPS for
capital-related costs.
In this rule, we highlight some of the major statutory and
regulatory provisions relevant to the new technology add-on payment
criteria, as well as other information. For further discussion on the
new technology add-on payment criteria, we refer readers to the FY 2012
IPPS/LTCH PPS final rule (76 FR 51572 through 51574), the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42288 through 42300), and the FY 2021 IPPS/
LTCH PPS final rule (85 FR 58736 through 58742).
a. New Technology Add-On Payment Criteria
(1) Newness Criterion
Under the first criterion, as reflected in Sec. 412.87(b)(2), a
specific medical service or technology will no longer be considered
``new'' for purposes of new medical service or technology add-on
payments after CMS has recalibrated the MS-DRGs, based on available
data, to reflect the cost of the technology. We note that we do not
consider a service or technology to be new if it is substantially
similar to one or more existing technologies. That is, even if a
medical product receives a new FDA approval or clearance, it may not
necessarily be considered ``new'' for purposes of new technology add-on
payments if it is ``substantially similar'' to another medical product
that was approved or cleared by FDA and has been on the market for more
than 2 to 3 years. In the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74
FR 43813 through 43814), we established criteria for evaluating whether
a new technology is substantially similar to an existing technology,
specifically whether: (1) a product uses the same or a similar
mechanism of action to achieve a therapeutic outcome; (2) a product is
assigned to the same or a different MS-DRG; and (3) the new use
[[Page 48904]]
of the technology involves the treatment of the same or similar type of
disease and the same or similar patient population. If a technology
meets all three of these criteria, it would be considered substantially
similar to an existing technology and would not be considered ``new''
for purposes of new technology add-on payments. For a detailed
discussion of the criteria for substantial similarity, we refer readers
to the FY 2006 IPPS final rule (70 FR 47351 through 47352) and the FY
2010 IPPS/LTCH PPS final rule (74 FR 43813 through 43814).
(2) Cost Criterion
Under the second criterion, Sec. 412.87(b)(3) further provides
that, to be eligible for the add-on payment for new medical services or
technologies, the MS-DRG prospective payment rate otherwise applicable
to discharges involving the new medical service or technology must be
assessed for adequacy. Under the cost criterion, consistent with the
formula specified in section 1886(d)(5)(K)(ii)(I) of the Act, to assess
the adequacy of payment for a new technology paid under the applicable
MS-DRG prospective payment rate, we evaluate whether the charges of the
cases involving a new medical service or technology will exceed a
threshold amount that is the lesser of 75% of the standardized amount
(increased to reflect the difference between cost and charges) or 75%
of one standard deviation beyond the geometric mean standardized charge
for all cases in the MS-DRG to which the new medical service or
technology is assigned (or the case-weighted average of all relevant
MS-DRGs if the new medical service or technology occurs in many
different MS-DRGs). The MS-DRG threshold amounts generally used in
evaluating new technology add-on payment applications for FY 2023 are
presented in a data file that is available, along with the other data
files associated with the FY 2022 IPPS/LTCH PPS final rule and
correction notice, on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.
We note that, under the policy finalized in the FY 2021 IPPS/LTCH
PPS final rule (85 FR 58603 through 58605), beginning with FY 2022, we
use the proposed threshold values associated with the proposed rule for
that fiscal year to evaluate the cost criterion for all applications
for new technology add-on payments and previously approved technologies
that may continue to receive new technology add-on payments, if those
technologies would be assigned to a proposed new MS-DRG for that same
fiscal year.
As finalized in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41275),
beginning with FY 2020, we include the thresholds applicable to the
next fiscal year (previously included in Table 10 of the annual IPPS/
LTCH PPS proposed and final rules) in the data files associated with
the prior fiscal year. Accordingly, the proposed thresholds for
applications for new technology add-on payments for FY 2024 were
presented in a data file that is available on the CMS website, along
with the other data files associated with the FY 2023 final rule, by
clicking on the FY 2023 IPPS final rule home page at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule, in the FY
2022 IPPS/LTCH PPS final rule, we finalized our proposal to use the FY
2019 MedPAR claims data where we ordinarily would have used the FY 2020
MedPAR claims data for purposes of FY 2022 ratesetting. Consistent with
that final policy, we finalized our proposal to use the FY 2019 claims
data to set the thresholds for applications for new technology add-on
payments for FY 2023. We note that, for the reasons discussed in
section I.F. of the preamble of the proposed rule and this final rule,
we proposed to use the FY 2021 MedPAR claims data for FY 2023
ratesetting, with certain proposed modifications to our relative weight
setting and outlier methodologies. Consistent with this proposal, for
the FY 2024 proposed threshold values, we proposed to use the FY 2021
claims data to set the proposed thresholds for applications for new
technology add-on payments for FY 2024. In addition, as discussed in
section III.E.1.c. of the proposed rule and this final rule, we
proposed to use an averaging approach for calculating the FY 2023
relative weights, to account for the anticipated decline in COVID-19
hospitalizations of Medicare beneficiaries as compared to FY 2021.
Specifically, we proposed to average the relative weights as calculated
with and without COVID-19 cases in the FY 2021 data to determine the
MS-DRG relative weights for FY 2023. Certain steps of calculating the
thresholds for applications for new technology add-on payments use the
same charge data that is used to calculate the MS-DRG weights. As a
result, different average charges per MS-DRG are calculated using the
charge data for the relative weights as calculated with and without
COVID-19 cases. Therefore, for purposes of calculating the FY 2024
thresholds, we also proposed to average the data in the steps of the
calculation that use charge data from the calculation of the MS-DRG
weights. In addition, as discussed in section I.O. of the appendix of
the FY 2023 IPPS/LTCH proposed rule (87 FR 28740 through 28741), we
also considered, as an alternative to our proposal, calculating the FY
2023 MS-DRG relative weights without the proposed averaging approach to
account for COVID-19 cases. In connection with this alternative
approach, we made available the threshold values as calculated without
this averaged data on the ``FY 2023 Final Rule Homepage'' at https://
www.cms.gov/medicare/medicare-fee-for-service-payment/
acuteinpatientpps, as well as other supplemental files as discussed
further in section I.O. of Appendix A of this final rule.
As discussed in section I.F. of the preamble of this final rule, we
are finalizing our proposal to use the FY 2021 MedPAR claims data for
FY 2023 ratesetting. Also, as discussed in section II.E of this final
rule we are finalizing our proposal to average the relative weights as
calculated with and without COVID-19 cases in the FY 2021 data to
determine the MS-DRG relative weights for FY 2023. We did not receive
any public comments on our proposal to average the data in the steps of
the calculation of the FY 2024 thresholds that use charge data from the
calculation of the MS-DRG weights, as discussed in the proposed rule.
Accordingly, in this final rule, we are finalizing to use FY 2021
claims data to set the thresholds for applications for new technology
add-on payments for FY 2024, and we are also finalizing to average the
data in the steps of the calculation of the FY 2024 thresholds that use
charge data from the calculation of the MS-DRG weights, as described
previously. The finalized thresholds for applications for new
technology add-on payments for FY 2024 are presented in a data file
that is available on the CMS website, along with the other data files
associated with this FY 2023 final rule, by clicking on the FY 2023
IPPS Final Rule Home Page at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.
In the September 7, 2001, final rule that established the new
technology add-on payment regulations (66 FR 46917), we discussed that
applicants should submit a significant sample of data to demonstrate
that the medical service or technology meets the high-cost threshold.
Specifically, applicants should submit a sample of sufficient size to
enable us to undertake an initial
[[Page 48905]]
validation and analysis of the data. We also discussed in the September
7, 2001, final rule (66 FR 46917) the issue of whether the Health
Insurance Portability and Accountability Act (HIPAA) Privacy Rule at 45
CFR parts 160 and 164 applies to claims information that providers
submit with applications for new medical service or technology add-on
payments. We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76
FR 51573) for further information on this issue.
(3) Substantial Clinical Improvement Criterion
Under the third criterion at Sec. 412.87(b)(1), a medical service
or technology must represent an advance that substantially improves,
relative to technologies previously available, the diagnosis or
treatment of Medicare beneficiaries. In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42288 through 42292), we prospectively codified in our
regulations at Sec. 412.87(b) the following aspects of how we evaluate
substantial clinical improvement for purposes of new technology add-on
payments under the IPPS:
The totality of the circumstances is considered when
making a determination that a new medical service or technology
represents an advance that substantially improves, relative to services
or technologies previously available, the diagnosis or treatment of
Medicare beneficiaries.
A determination that a new medical service or technology
represents an advance that substantially improves, relative to services
or technologies previously available, the diagnosis or treatment of
Medicare beneficiaries means--
++ The new medical service or technology offers a treatment option
for a patient population unresponsive to, or ineligible for, currently
available treatments;
++ The new medical service or technology offers the ability to
diagnose a medical condition in a patient population where that medical
condition is currently undetectable, or offers the ability to diagnose
a medical condition earlier in a patient population than allowed by
currently available methods, and there must also be evidence that use
of the new medical service or technology to make a diagnosis affects
the management of the patient;
++ The use of the new medical service or technology significantly
improves clinical outcomes relative to services or technologies
previously available as demonstrated by one or more of the following: a
reduction in at least one clinically significant adverse event,
including a reduction in mortality or a clinically significant
complication; a decreased rate of at least one subsequent diagnostic or
therapeutic intervention; a decreased number of future hospitalizations
or physician visits; a more rapid beneficial resolution of the disease
process treatment including, but not limited to, a reduced length of
stay or recovery time; an improvement in one or more activities of
daily living; an improved quality of life; or, a demonstrated greater
medication adherence or compliance; or
++ The totality of the circumstances otherwise demonstrates that
the new medical service or technology substantially improves, relative
to technologies previously available, the diagnosis or treatment of
Medicare beneficiaries.
Evidence from the following published or unpublished
information sources from within the United States or elsewhere may be
sufficient to establish that a new medical service or technology
represents an advance that substantially improves, relative to services
or technologies previously available, the diagnosis or treatment of
Medicare beneficiaries: clinical trials, peer reviewed journal
articles; study results; meta-analyses; consensus statements; white
papers; patient surveys; case studies; reports; systematic literature
reviews; letters from major healthcare associations; editorials and
letters to the editor; and public comments. Other appropriate
information sources may be considered.
The medical condition diagnosed or treated by the new
medical service or technology may have a low prevalence among Medicare
beneficiaries.
The new medical service or technology may represent an
advance that substantially improves, relative to services or
technologies previously available, the diagnosis or treatment of a
subpopulation of patients with the medical condition diagnosed or
treated by the new medical service or technology.
We refer the reader to the FY 2020 IPPS/LTCH PPS final rule for
additional discussion of the evaluation of substantial clinical
improvement for purposes of new technology add-on payments under the
IPPS.
We note, consistent with the discussion in the FY 2003 IPPS final
rule (67 FR 50015), that while FDA has regulatory responsibility for
decisions related to marketing authorization (for example, approval,
clearance, etc.), we do not rely upon FDA criteria in our evaluation of
substantial clinical improvement for purposes of determining what
drugs, devices, or technologies qualify for new technology add-on
payments under Medicare. This criterion does not depend on the standard
of safety and effectiveness on which FDA relies but on a demonstration
of substantial clinical improvement in the Medicare population.
b. Alternative Inpatient New Technology Add-On Payment Pathway
Beginning with applications for FY 2021 new technology add-on
payments, under the regulations at Sec. 412.87(c), a medical device
that is part of FDA's Breakthrough Devices Program may qualify for the
new technology add-on payment under an alternative pathway.
Additionally, under the regulations at Sec. 412.87(d) for certain
antimicrobial products, beginning with FY 2021, a drug that is
designated by FDA as a Qualified Infectious Disease Product (QIDP),
and, beginning with FY 2022, a drug that is approved by FDA under the
Limited Population Pathway for Antibacterial and Antifungal Drugs
(LPAD), may also qualify for the new technology add-on payment under an
alternative pathway. We refer the reader to the FY 2020 IPPS/LTCH PPS
final rule (84 FR 42292 through 42297) and the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58737 through 58739) for further discussion on this
policy. We note that a technology is not required to have the specified
FDA designation at the time the new technology add-on payment
application is submitted. CMS reviews the application based on the
information provided by the applicant only under the alternative
pathway specified by the applicant at the time of new technology add-on
payment application submission. However, to receive approval for the
new technology add-on payment under that alternative pathway, the
technology must have the applicable FDA designation and meet all other
requirements in the regulations in Sec. 412.87(c) and (d), as
applicable.
(1) Alternative Pathway for Certain Transformative New Devices
For applications received for new technology add-on payments for FY
2021 and subsequent fiscal years, if a medical device is part of FDA's
Breakthrough Devices Program and received FDA marketing authorization,
it will be considered not substantially similar to an existing
technology for purposes of the new technology add-on payment under the
IPPS, and will not need to meet the requirement under Sec.
412.87(b)(1) that it represent an advance that substantially improves,
[[Page 48906]]
relative to technologies previously available, the diagnosis or
treatment of Medicare beneficiaries. Under this alternative pathway, a
medical device that has received FDA marketing authorization (that is,
has been approved or cleared by, or had a De Novo classification
request granted by, FDA) and that is part of FDA's Breakthrough Devices
Program will need to meet the requirements of Sec. 412.87(c). We note
that in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58734 through
58736), we clarified our policy that a new medical device under this
alternative pathway must receive marketing authorization for the
indication covered by the Breakthrough Devices Program designation. We
refer the reader to the FY 2021 IPPS/LTCH PPS final rule (85 FR 58734
through 58736) for further discussion regarding this clarification.
(2) Alternative Pathway for Certain Antimicrobial Products
For applications received for new technology add-on payments for
certain antimicrobial products, beginning with FY 2021, if a technology
is designated by FDA as a QIDP and received FDA marketing
authorization, and, beginning with FY 2022, if a drug is approved under
FDA's LPAD pathway and used for the indication approved under the LPAD
pathway, it will be considered not substantially similar to an existing
technology for purposes of new technology add-on payments and will not
need to meet the requirement that it represent an advance that
substantially improves, relative to technologies previously available,
the diagnosis or treatment of Medicare beneficiaries. Under this
alternative pathway for QIDPs and LPADs, a medical product that has
received FDA marketing authorization and is designated by FDA as a QIDP
or approved under the LPAD pathway will need to meet the requirements
of Sec. 412.87(d).
We refer the reader to the FY 2020 IPPS/LTCH PPS final rule (84 FR
42292 through 42297) and FY 2021 IPPS/LTCH PPS final rule (85 FR 58737
through 58739) for further discussion on this policy. We note, in the
FY 2021 IPPS/LTCH PPS final rule (85 FR 58737 through 58739), we
clarified that a new medical product seeking approval for the new
technology add-on payment under the alternative pathway for QIDPs must
receive marketing authorization for the indication covered by the QIDP
designation. We also finalized our policy to expand our alternative new
technology add-on payment pathway for certain antimicrobial products to
include products approved under the LPAD pathway and used for the
indication approved under the LPAD pathway.
c. Additional Payment for New Medical Service or Technology
The new medical service or technology add-on payment policy under
the IPPS provides additional payments for cases with relatively high
costs involving eligible new medical services or technologies, while
preserving some of the incentives inherent under an average-based
prospective payment system. The payment mechanism is based on the cost
to hospitals for the new medical service or technology. As noted
previously, we do not include capital costs in the add-on payments for
a new medical service or technology or make new technology add-on
payments under the IPPS for capital-related costs (72 FR 47307 through
47308).
For discharges occurring before October 1, 2019, under Sec.
412.88, if the costs of the discharge (determined by applying operating
cost-to-charge ratios (CCRs) as described in Sec. 412.84(h)) exceed
the full DRG payment (including payments for IME and DSH, but excluding
outlier payments), CMS made an add-on payment equal to the lesser of:
(1) 50% of the costs of the new medical service or technology; or (2)
50% of the amount by which the costs of the case exceed the standard
DRG payment.
Beginning with discharges on or after October 1, 2019, for the
reasons discussed in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42297
through 42300), we finalized an increase in the new technology add-on
payment percentage, as reflected at Sec. 412.88(a)(2)(ii).
Specifically, for a new technology other than a medical product
designated by FDA as a QIDP, beginning with discharges on or after
October 1, 2019, if the costs of a discharge involving a new technology
(determined by applying CCRs as described in Sec. 412.84(h)) exceed
the full DRG payment (including payments for IME and DSH, but excluding
outlier payments), Medicare will make an add-on payment equal to the
lesser of: (1) 65% of the costs of the new medical service or
technology; or (2) 65% of the amount by which the costs of the case
exceed the standard DRG payment. For a new technology that is a medical
product designated by FDA as a QIDP, beginning with discharges on or
after October 1, 2019, if the costs of a discharge involving a new
technology (determined by applying CCRs as described in Sec.
412.84(h)) exceed the full DRG payment (including payments for IME and
DSH, but excluding outlier payments), Medicare will make an add-on
payment equal to the lesser of: (1) 75% of the costs of the new medical
service or technology; or (2) 75% of the amount by which the costs of
the case exceed the standard DRG payment. For a new technology that is
a medical product approved under FDA's LPAD pathway, beginning with
discharges on or after October 1, 2020, if the costs of a discharge
involving a new technology (determined by applying CCRs as described in
Sec. 412.84(h)) exceed the full DRG payment (including payments for
IME and DSH, but excluding outlier payments), Medicare will make an
add-on payment equal to the lesser of: (1) 75% of the costs of the new
medical service or technology; or (2) 75% of the amount by which the
costs of the case exceed the standard DRG payment. As set forth in
Sec. 412.88(b)(2), unless the discharge qualifies for an outlier
payment, the additional Medicare payment will be limited to the full
MS-DRG payment plus 65% (or 75% for certain antimicrobial products
(QIDPs and LPADs)) of the estimated costs of the new technology or
medical service. We refer the reader to the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42297 through 42300) for further discussion on the increase
in the new technology add-on payment beginning with discharges on or
after October 1, 2019.
Section 503(d)(2) of Public Law 108-173 provides that there shall
be no reduction or adjustment in aggregate payments under the IPPS due
to add-on payments for new medical services and technologies.
Therefore, in accordance with section 503(d)(2) of Public Law 108-173,
add-on payments for new medical services or technologies for FY 2005
and subsequent years have not been subjected to budget neutrality.
d. Evaluation of Eligibility Criteria for New Medical Service or
Technology Applications
In the FY 2009 IPPS final rule (73 FR 48561 through 48563), we
modified our regulation at Sec. 412.87 to codify our longstanding
practice of how CMS evaluates the eligibility criteria for new medical
service or technology add-on payment applications. That is, we first
determine whether a medical service or technology meets the newness
criterion, and only if so, do we then make a determination as to
whether the technology meets the cost threshold and represents a
substantial clinical improvement over existing medical services or
technologies. We specified that all applicants for new technology add-
on payments must have FDA approval or clearance by July 1 of the
[[Page 48907]]
year prior to the beginning of the fiscal year for which the
application is being considered. In the FY 2021 IPPS/LTCH PPS final
rule, to more precisely describe the various types of FDA approvals,
clearances and classifications that we consider under our new
technology add-on payment policy, we finalized a technical
clarification to the regulation to indicate that new technologies must
receive FDA marketing authorization (such as pre-market approval (PMA);
510(k) clearance; the granting of a De Novo classification request, or
approval of a New Drug Application (NDA)) by July 1 of the year prior
to the beginning of the fiscal year for which the application is being
considered. Consistent with our longstanding policy, we consider FDA
marketing authorization as representing that a product has received FDA
approval or clearance when considering eligibility for the new
technology add-on payment under Sec. 412.87(e)(2) (85 FR 58742).
Additionally, in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58739
through 58742), we finalized our proposal to provide conditional
approval for new technology add-on payment for a technology for which
an application is submitted under the alternative pathway for certain
antimicrobial products at Sec. 412.87(d) that does not receive FDA
marketing authorization by the July 1 deadline specified in Sec.
412.87(e)(2), provided that the technology otherwise meets the
applicable add-on payment criteria. Under this policy, cases involving
eligible antimicrobial products would begin receiving the new
technology add-on payment sooner, effective for discharges the quarter
after the date of FDA marketing authorization provided that the
technology receives FDA marketing authorization by July 1 of the
particular fiscal year for which the applicant applied for new
technology add-on payments.
e. New Technology Liaisons
Many interested parties (including device/biologic/drug developers
or manufacturers, industry consultants, others) engage CMS for
coverage, coding, and payment questions or concerns. In order to
streamline engagement by centralizing the different innovation pathways
within CMS including new technology add-on payments, CMS has
established a team of new technology liaisons that can serve as an
initial resource for interested parties. This team is available to
assist with all of the following:
Help to point interested parties to or provide information
and resources where possible regarding process, requirements, and
timelines.
Coordinate and facilitate opportunities for interested
parties to engage with various CMS components.
Serve as a primary point of contact for interested parties
and provide updates on developments where possible or appropriate.
We received many questions from interested parties with respect to
pursuing new technology add-on payments who may not be entirely
familiar with working with CMS. While we encourage interested parties
to first review our resources available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech, we
know that there may be additional questions about the application
process. Interested parties with further questions about Medicare's
coverage, coding, and payment processes, and about how they can
navigate these processes, whether for new technology add-on payments or
otherwise, can contact the new technology liaison team at
[email protected].
f. Application Information for New Medical Services or Technologies
Applicants for add-on payments for new medical services or
technologies for FY 2024 must submit a formal request, including a full
description of the clinical applications of the medical service or
technology and the results of any clinical evaluations demonstrating
that the new medical service or technology represents a substantial
clinical improvement (unless the application is under one of the
alternative pathways as previously described), along with a significant
sample of data to demonstrate that the medical service or technology
meets the high-cost threshold. CMS will review the application based on
the information provided by the applicant under the pathway specified
by the applicant at the time of application submission. Complete
application information, along with final deadlines for submitting a
full application, will be posted as it becomes available on the CMS
website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html. To allow interested parties to
identify the new medical services or technologies under review before
the publication of the final rule for FY 2024, the CMS website also
will post the tracking forms completed by each applicant. We note that
the burden associated with this information collection requirement is
the time and effort required to collect and submit the data in the
formal request for add-on payments for new medical services and
technologies to CMS. The aforementioned burden is subject to the Paper
Reduction Act (PRA) and approved under OMB control number 0938-1347,
and has an expiration date of 11/30/2023.
As discussed previously, in the FY 2020 IPPS/LTCH PPS final rule,
we adopted an alternative inpatient new technology add-on payment
pathway for certain transformative new devices and for Qualified
Infectious Disease Products, as set forth in the regulations at Sec.
412.87(c) and (d). The change in burden associated with these changes
to the new technology add-on payment application process were discussed
in a revision of the information collection requirement (ICR) request
currently approved under OMB control number 0938-1347, with an
expiration date of November 30, 2023. In accordance with the
implementing regulations of the PRA, we detailed the revisions of the
ICR and published the required 60-day notice on August 15, 2019 (84 FR
41723), and 30-day notice on December 17, 2019 (84 FR 68936), to
solicit public comments.
2. Public Input Before Publication of a Notice of Proposed Rulemaking
on Add-On Payments
Section 1886(d)(5)(K)(viii) of the Act, as amended by section
503(b)(2) of Public Law 108-173, provides for a mechanism for public
input before publication of a notice of proposed rulemaking regarding
whether a medical service or technology represents a substantial
clinical improvement. The process for evaluating new medical service
and technology applications requires the Secretary to do all of the
following:
Provide, before publication of a proposed rule, for public
input regarding whether a new service or technology represents an
advance in medical technology that substantially improves the diagnosis
or treatment of Medicare beneficiaries.
Make public and periodically update a list of the services
and technologies for which applications for add-on payments are
pending.
Accept comments, recommendations, and data from the public
regarding whether a service or technology represents a substantial
clinical improvement.
Provide, before publication of a proposed rule, for a
meeting at which organizations representing hospitals, physicians,
manufacturers, and any other interested party may present comments,
recommendations, and data
[[Page 48908]]
regarding whether a new medical service or technology represents a
substantial clinical improvement to the clinical staff of CMS.
In order to provide an opportunity for public input regarding add-
on payments for new medical services and technologies for FY 2023 prior
to publication of the FY 2023 IPPS/LTCH PPS proposed rule, we published
a notice in the Federal Register on September 24, 2021 (86 FR 53056),
and held a virtual town hall meeting on December 14, 2021. In the
announcement notice for the meeting, we stated that the opinions and
presentations provided during the meeting would assist us in our
evaluations of applications by allowing public discussion of the
substantial clinical improvement criterion for the FY 2023 new medical
service and technology add-on payment applications before the
publication of the FY 2023 IPPS/LTCH IPPS proposed rule.
Approximately 378 individuals registered to attend the virtual town
hall meeting. We posted the recordings of the virtual town hall on the
CMS web page at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.
We considered each applicant's presentation made at the town hall
meeting, as well as written comments received by the December 27, 2021,
deadline, in our evaluation of the new technology add-on payment
applications for FY 2023 in the development of the FY 2023 IPPS/LTCH
PPS proposed rule. In response to the published notice and the December
14, 2021, New Technology Town Hall meeting, we received written
comments regarding the applications for FY 2023 new technology add on
payments. As explained earlier and in the Federal Register notice
announcing the New Technology Town Hall meeting (86 FR 53056 through
53059), the purpose of the meeting was specifically to discuss the
substantial clinical improvement criterion with regard to pending new
technology add-on payment applications for FY 2023. Therefore, we did
not summarize the written comments in the proposed rule that are
unrelated to the substantial clinical improvement criterion. In section
II.F.6. of the preamble of the proposed rule, we summarized comments
regarding individual applications, or, if applicable, indicated that
there were no comments received in response to the New Technology Town
Hall meeting notice or New Technology Town Hall meeting, at the end of
each discussion of the individual applications.
3. ICD-10-PCS Section ``X'' Codes for Certain New Medical Services and
Technologies
As discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49434),
the ICD-10-PCS includes a new section containing the new Section ``X''
codes, which began being used with discharges occurring on or after
October 1, 2015. Decisions regarding changes to ICD-10-PCS Section
``X'' codes will be handled in the same manner as the decisions for all
of the other ICD-10-PCS code changes. That is, proposals to create,
delete, or revise Section ``X'' codes under the ICD-10-PCS structure
will be referred to the ICD-10 Coordination and Maintenance Committee.
In addition, several of the new medical services and technologies that
have been, or may be, approved for new technology add-on payments may
now, and in the future, be assigned a Section ``X'' code within the
structure of the ICD-10-PCS. We posted ICD-10-PCS Guidelines on the CMS
website at https://www.cms.gov/medicare/icd-10/2021-icd-10-pcs,
including guidelines for ICD-10-PCS Section ``X'' codes. We encourage
providers to view the material provided on ICD-10-PCS Section ``X''
codes.
As discussed in more detail in section II.F.8. of the preamble of
this final rule, in the FY 2023 IPPS/LTCH PPS proposed rule, we
proposed to use NDCs instead of ICD-10-PCS Section ``X'' codes to
identify cases involving the use of therapeutic agents approved for new
technology add-on payments beginning with a transitional period in FY
2023. We refer the reader to section II.F.8. of the preamble of this
final rule for a full discussion of this proposal and the comments
received.
4. New COVID-19 Treatments Add-On Payment (NCTAP)
In response to the COVID-19 public health emergency (PHE), we
established the New COVID-19 Treatments Add-on Payment (NCTAP) under
the IPPS for COVID-19 cases that meet certain criteria (85 FR 71157
through 71158). We believe that as drugs and biological products become
available and are authorized for emergency use or approved by FDA for
the treatment of COVID-19 in the inpatient setting, it is appropriate
to increase the current IPPS payment amounts to mitigate any potential
financial disincentives for hospitals to provide new COVID-19
treatments during the PHE. Therefore, effective for discharges
occurring on or after November 2, 2020 and until the end of the PHE for
COVID-19, we established the NCTAP to pay hospitals the lesser of (1)
65% of the operating outlier threshold for the claim or (2) 65% of the
amount by which the costs of the case exceed the standard DRG payment,
including the adjustment to the relative weight under section 3710 of
the Coronavirus Aid, Relief, and Economic Security (CARES) Act, for
certain cases that include the use of a drug or biological product
currently authorized for emergency use or approved for treating COVID-
19.
In the FY 2022 IPPS/LTCH PPS final rule, we finalized a change to
our policy to extend NCTAP through the end of the FY in which the PHE
ends for all eligible products in order to continue to mitigate
potential financial disincentives for hospitals to provide these new
treatments, and to minimize any potential payment disruption
immediately following the end of the PHE. We also finalized that, for a
drug or biological product eligible for NCTAP that is also approved for
new technology add-on payments, we will reduce the NCTAP for an
eligible case by the amount of any new technology add-on payments so
that we do not create a financial disincentive between technologies
eligible for both the new technology add-on payment and NCTAP compared
to technologies eligible for NCTAP only (85 FR 45162).
Further information about NCTAP, including updates and a list of
currently eligible drugs and biologicals, is available on the CMS
website at https://www.cms.gov/medicare/covid-19/new-covid-19-treatments-add-payment-nctap.
5. FY 2023 Status of Technologies Receiving New Technology Add-On
Payments for FY 2022
In this section of the final rule, we discuss the proposed FY 2023
status of 37 technologies approved for FY 2022 new technology add-on
payments, including 2 technologies approved for 2 separate add-on
payments for different indications (RECARBRIOTM and
FETROJA[supreg]), and our finalized policies, as set forth in the
tables that follow. In general, we extend new technology add-on
payments for an additional year only if the 3-year anniversary date of
the product's entry onto the U.S. market occurs in the latter half of
the upcoming fiscal year. We note that, as discussed later in this
section, we provided a 1-year extension of new technology add-on
payments for FY 2022 for 13 technologies for which the new technology
add-on payment would otherwise have been discontinued beginning in FY
2022 using our authority under section 1886(d)(5)(I) of the Act.
[[Page 48909]]
Additionally, we note that we conditionally approved CONTEPO for FY
2022 new technology add-on payments under the alternative pathway for
certain antimicrobial products (86 FR 45155), subject to the technology
receiving FDA marketing authorization by July 1, 2022. In the FY 2023
IPPS LTCH/PPS proposed rule, we stated that if CONTEPO receives FDA
marketing authorization prior to July 1, 2022, we were proposing to
continue making new technology add-on payments for CONTEPO for FY 2023.
We stated that if CONTEPO does not receive FDA marketing authorization
by July 1, 2022, then it would not be eligible for new technology add-
on payments for FY 2022, and therefore would not be eligible for the
continuation of new technology add-on payments for FY 2023. Because
CONTEPO did not receive FDA approval by July 1, 2022, no new technology
add-on payments will be made for cases involving the use of CONTEPO for
FY 2022, and CONTEPO is therefore not eligible for the continuation of
new technology add-on payments for FY 2023.
a. FY 2023 Status of Technologies Approved for FY 2022 New Technology
Add-On Payments
As noted previously, we used our authority under section
1886(d)(5)(I) of the Act to allow a 1-year extension of new technology
add-on payments for FY 2022 for 13 technologies for which the add-on
payments would otherwise be discontinued beginning in FY 2022 because
the technologies would no longer be considered ``new'' for FY 2022. In
this section, we discuss the proposed FY 2023 status for the remaining
24 technologies approved for FY 2022 new technology add-on payments and
our finalized policies. Specifically, in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28210-28212), we presented our proposals to
continue the new technology add-on payment for FY 2023 for those
technologies that were approved for the new technology add-on payment
for FY 2022 and which would still be considered ``new'' for purposes of
new technology add-on payments for FY 2023. We also presented our
proposals to discontinue new technology add-on payment for FY 2023 for
those technologies that were approved for the new technology add-on
payment for FY 2022 and which would no longer be considered ``new'' for
purposes of new technology add-on payments for FY 2023.
Our policy is that a medical service or technology may continue to
be considered ``new'' for purposes of new technology add-on payments
within 2 or 3 years after the point at which data begin to become
available reflecting the inpatient hospital code assigned to the new
service or technology. Our practice has been to begin and end new
technology add-on payments on the basis of a fiscal year, and we have
generally followed a guideline that uses a 6-month window before and
after the start of the fiscal year to determine whether to extend the
new technology add-on payment for an additional fiscal year. In
general, we extend new technology add-on payments for an additional
year only if the 3-year anniversary date of the product's entry onto
the U.S. market occurs in the latter half of the fiscal year (70 FR
47362).
In the proposed rule, we provided a table listing the technologies
for which we proposed to continue making new technology add-on payments
for FY 2023 because they would still be considered ``new'' for purposes
of new technology add-on payments (87 FR 28213 through 28214). This
table also presented the newness start date, new technology add-on
payment start date, 3-year anniversary date of the product's entry onto
the U.S. market, relevant final rule citations from prior fiscal years,
proposed maximum add-on payment amount, and coding assignments for each
technology. We referred readers to the final rules cited in the table
for a complete discussion of the new technology add-on payment
application, coding and payment amount for each of these technologies,
including the applicable indications and discussion of the newness
start date.
We invited public comments on our proposals to continue new
technology add-on payments for FY 2023 for the technologies listed in
the table in the proposed rule.
Comment: Commenters overwhelmingly supported our proposed
continuation of new technology add-on payments for FY 2023 for those
technologies that were approved for the new technology add-on payment
for FY 2022 and which would still be considered ``new'' for purposes of
new technology add-on payments for FY 2023.
Response: We appreciate the commenters' support.
In the proposed rule, we noted, as discussed in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45104 through 45107), on May 1, 2020,
VEKLURY[supreg] (remdesivir) received an Emergency Use Authorization
(EUA) from FDA for the treatment of suspected or laboratory confirmed
COVID-19 in adults and children hospitalized with severe disease. The
applicant asserted that between July 1, 2020 and September 30, 2020, it
entered into an agreement with the U.S. Government to allocate and
distribute commercially-available VEKLURY[supreg] across the country.
The applicant stated that under this agreement, the first sale of
VEKLURY[supreg] was completed on July 10, 2020. The applicant stated
that they transitioned to a more traditional, unallocated model of
distribution as of October 1, 2020. In the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45107), we determined that VEKLURY[supreg] meets the
newness criterion with an indication for use in adults and pediatric
patients (12 years of age and older and weighing at least 40 kg) for
the treatment of COVID-19 requiring hospitalization. We stated that
consistent with our longstanding policy, we considered the newness
period for VEKLURY[supreg] to begin on October 22, 2020, when the NDA
for VEKLURY[supreg] was approved by FDA for adults and pediatric
patients (12 years of age and older and weighing at least 40 kg) for
the treatment of COVID-19 requiring hospitalization. We also discussed
comments solicited regarding the newness period for products available
through an EUA for COVID-19 in section II.F.7. of the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45159 through 45160), including comments we
received regarding the potential variability in cost estimates for
technologies available under an EUA due to government price subsidies
or variable treatment practices in the context of the global pandemic
and comments suggesting that CMS monitor pricing changes for products
available under an EUA once a product receives full marketing
authorization, instead of basing the newness period on data that may
have become available under an EUA, and indicated that we would
consider these comments for future rulemaking.
We stated in the proposed rule (87 FR 28212) that after further
review of the information provided by the applicant, we believed that
additional information related to VEKLURY[supreg]'s commercial
availability is relevant to assessing the start of the newness period
for VEKLURY[supreg]. We noted that the applicant stated that once
VEKLURY[supreg] was issued an EUA, from May through June 2020, the
entire existing supply of VEKLURY[supreg] was donated worldwide and
distributed to hospitals free of charge.\29\ The applicant further
stated that the commercial list price of the technology was announced
when it entered into the agreement with the U.S.
[[Page 48910]]
Government previously described, in anticipation of the post-donation
phase. Under this agreement, the U.S. Government allocated
VEKLURY[supreg] to each hospital, and the hospitals would then choose
to purchase quantities of VEKLURY[supreg] directly from the applicant's
subsidiary who was the sole distributor.30 31
---------------------------------------------------------------------------
\29\ https://stories.gilead.com/articles/an-update-on-covid-19-from-our-chairman-and-ceo.
\30\ Remdesivir for the Commercial Marketplace. https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Pages/factsheet.aspx.
\31\ Department of Health and Human Services, Office of the
Assistant Secretary for Preparedness and Response (ASPR). ASPR's
Portfolio of COVID-19 Medical Countermeasures Made Available as a
Licensed Product. https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Pages/Veklury.aspx.
---------------------------------------------------------------------------
We stated in the proposed rule that we continue to believe this
issue is complex, particularly as it relates to VEKLURY[supreg] as a
technology that has been available under both an EUA and an NDA. As
discussed in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45159 through
45160), while an EUA is not marketing authorization within the meaning
of Sec. 412.87(e)(2) for purposes of eligibility for new technology
add-on payments, data reflecting the costs of products that have
received an EUA could become available as soon as the date of the EUA
issuance and prior to receiving FDA approval or clearance. In the case
of VEKLURY[supreg], we stated that we believe that there may be unique
considerations in determining the start of the newness period in light
of the donation period, during which the technology was distributed at
no cost. Accordingly, while we noted that we continue to believe that
data reflecting the costs of a product that has received an EUA could
become available as soon as the date of EUA issuance for that product,
we believed that with respect to VEKLURY[supreg], such data may not
have become available until after the end of the donation period, when
the technology became commercially available, on July 1, 2020. For
these reasons, after further consideration, we stated that we believe
the newness period for VEKLURY[supreg] may more appropriately begin on
July 1, 2020, the date on which the technology became available for
sale under the allocation agreement. We noted that VEKLURY[supreg]
would still be considered new for FY 2023 regardless of whether the
newness period began on May 1 (the date of the EUA), July 1 (the date
the donation phase ended), October 22 (the date of the NDA), or some
other date in between, as in all cases the three-year anniversary date
would occur after April 1, 2023, and therefore the product would remain
eligible for FY 2023 new technology add-on payments.
Therefore, we proposed to continue new technology add-on payments
for VEKLURY[supreg] for FY 2023. We invited public comments on this
proposal, including the newness start date for VEKLURY[supreg]. As
discussed, while we continue to believe that data reflecting the costs
of a product that has received an EUA could become available as soon as
the date of EUA issuance for that product, we also recognize that there
may be unique considerations in determining the start of the newness
period for a product available under an EUA. We are continuing to
consider the comments as discussed in the FY 2022 IPPS/LTCH PPS final
rule (86 FR 45159) regarding the newness period for products available
through an EUA for COVID-19, and we welcomed additional comments in the
proposed rule.
Comment: The applicant submitted a comment with respect to the
start of the newness period for VEKLURY[supreg]. The applicant noted
that there is no material impact on eligibility for new technology add-
on payments for VEKLURY[supreg], regardless of whether CMS uses July 1
2020, the date VEKLURY[supreg] became available for sale under the
allocation agreement, or October 22, 2020, the date of FDA approval as
the start of the newness period for VEKLURY[supreg]. The applicant
maintained that using either date and applying CMS' standard
methodology of calculating the period of eligibility for new technology
add-on payments would result in VEKLURY[supreg] staying within its
newness period through FY 2023 (October 1, 2022-September 30, 2023),
and that VEKLURY[supreg] would not be eligible for new technology add-
on payments in FY 2024 in either circumstance.
The applicant stated that the primary effect of CMS' revisiting of
the VEKLURY[supreg] newness determination would be to set a precedent
that would affect the future eligibility for new technology add-on
payments of other EUA products. To this point, the applicant referred
to the FY 2022 IPPS final rule where CMS originally finalized the
newness date for VEKLURY[supreg] and stated that products that do not
have FDA approval or clearance, including products available in the
U.S. under an EUA, are not eligible for new technology add-on payments
(86 FR 45106-07). The applicant also pointed to 42 CFR 412.87(b) which
outlines additional eligibility criteria for substantial clinical
improvement, cost, and newness that must all be met in order for a
product to be eligible for new technology add-on payments. The
applicant stated it is reasonable to assume these requirements should
not be in conflict with respect to how they are evaluated and
implemented, including with respect to the timelines applied to the
determination of eligibility for new technology add-on payments.
Furthermore, the applicant stated that CMS confirmed that using the
date of FDA approval as the beginning of the newness period for
VEKLURY[supreg] was consistent with its longstanding policy, with the
commenter referencing CMS's statement that generally, its policy is
``to begin the newness period on the date of FDA approval or clearance
or, if later, the date of availability of the product on the U.S.
market, when [data] reflecting the costs of the technology begin to
become available for the recalibration of the MS-DRGs'' (86 FR 45159)
(emphasis added). The applicant asserted that using a date prior to FDA
approval as the beginning of the newness period would therefore serve
as a departure from how CMS has traditionally determined newness for
the purposes of new technology add-on payments, as there is no
precedent to use a date earlier than FDA approval as the date of market
availability.
The applicant stated that VEKLURY[supreg]'s distribution and
commercialization framework over the course of the COVID-19 pandemic,
through which VEKLURY[supreg] was available through emergency and
compassionate use programs, donations, and a post-donation model in
collaboration with the federal government, were all implemented prior
to VEKLURY[supreg] receiving FDA approval and does not in any way
resemble the current distribution and reimbursement paradigm. The
applicant further stated that its experience during the EUA period does
not reflect the type of distribution and reimbursement environment that
would support a newness period that begins prior to the FDA approval
date for VEKLURY[supreg]. The applicant stated that the data collected
on utilization and resource use during the EUA period likely would not
be representative of utilization or resource use following FDA
approval, given that the EUA period occurred within the context of a
global pandemic and a time of extreme uncertainty for the health care
system. The applicant pointed to CMS's use of FY 2019 data for FY 2022
ratesetting for circumstances where the FY 2020 data was significantly
impacted by the COVID-19 PHE, and reasoned that VEKLURY[supreg]'s
utilization would be similarly impacted by the PHE as its EUA period
occurred almost entirely in FY 2020.
[[Page 48911]]
The applicant urged that CMS continue to determine the start of the
newness period for VEKLURY[supreg] and other products originally
available in the U.S. under an EUA using what it stated was the same
policy CMS has applied for all other products approved for new
technology add-on payment, which is to use the date of FDA approval or,
if later, the date of market availability in the U.S. For
VEKLURY[supreg], the applicant stated that this date is October 22,
2020, the date of FDA approval. The applicant stated that maintaining
this policy aligns to existing precedent, simplifies the newness
determination process, and applies a consistent policy across products.
Response: We thank the applicant for its input. As discussed in the
FY 2018 IPPS final rule (82 FR 38115), the period of newness does not
necessarily start with the approval date for the medical service or
technology and instead begins with availability of the product on the
U.S. market, which is when data become available. We have consistently
applied this standard and believe that it is consistent with the
purpose of new technology add-on payments. Therefore, while generally
our policy is to begin the newness period on the date of FDA approval
or clearance, we may also consider a documented delay in the
technology's market availability in our determination of newness (77 FR
53348 and 70 FR 47341). Accordingly, we agree that in general, we have
begun the newness period on the date of FDA approval or clearance or,
if later, the date of availability of the product onto the US market,
based on such a documented delay, as that is when data reflecting the
costs of the technology begin to become available. However, as we
discussed in the FY 2022 final rule, for a product with an EUA, the
data reflecting the costs of that product could become available as
soon as the date of EUA issuance, and prior to FDA approval or
clearance. Therefore, while a product approved under an EUA and for
which there is data reflecting the costs of the technology prior to FDA
approval may be factually distinct from a product for which there is a
documented delay in marketing availability following FDA approval, we
disagree that beginning the newness period on the date of EUA issuance
and prior to FDA approval would be inconsistent with our longstanding
policy of beginning the newness period with the availability of the
product on the U.S. market. With regard to the additional criteria for
eligibility for the new technology add-on payment, we refer readers to
the FY 2022 final rule for our discussion of the eligibility of a
product available only through an EUA for the new technology add-on
payment under section 412.87(e)(2) (86 FR 45048 through 45049), as well
as the comment solicitation on the new technology add-on payment
newness period for products available through an EUA (86 FR 45159
through 45160). With respect to the applicant's comment that
VEKLURY[supreg]'s utilization may have been impacted by the COVID-19
PHE during the EUA period, we note that the EUA for VEKLURY[supreg] was
directly related to COVID-19.
We agree with the applicant that regardless of whether
VEKLURY's[supreg] newness period begins on July 1, 2020, the date
VEKLURY[supreg] became available for sale under the allocation
agreement, or October 22, 2020, the date of FDA approval, the
application of CMS' standard methodology for determining the period of
eligibility for new technology add-on payments results in
VEKLURY[supreg] remaining within its newness period through FY 2023
(October 1, 2022-September 30, 2023), and that VEKLURY[supreg] would
not be eligible for new technology add-on payments in FY 2024 in either
circumstance. Accordingly, we are finalizing our proposal to continue
new technology add-on payments for VEKLURY[supreg] for FY 2023, as
reflected in Table II.F.-01 of this final rule. As stated previously,
we also recognize that there may be unique considerations associated
with determining the start of the newness period for a product
available under an EUA prior to receiving FDA approval, including as
discussed in the applicant's comments. Accordingly, we will continue to
consider the comments received regarding the newness period for
products available through an EUA for COVID-19 for future rulemaking.
In the FY 2023 IPPS/LTCH PPS proposed rule, we noted that we also
proposed to continue new technology add-on payments for Caption
Guidance for FY 2023, a technology sold on a subscription basis. We
stated we continued to welcome comments from the public as to the
appropriate method to determine a cost per case for technologies sold
on a subscription basis, including comments on whether the cost per
case should be estimated based on subscriber hospital data as described
previously, and if so, whether the cost analysis should be updated
based on the most recent subscriber data for each year for which the
technology may be eligible for the new technology add-on payment.
We did not receive any comments regarding the appropriate method to
determine a cost per case for technologies sold on a subscription
basis, and we will continue to consider these issues.
Comment: The applicant for Abecma[supreg] submitted a comment
stating its strong support for the continuation of new technology add-
on payments for Abecma[supreg] for FY 2023. The applicant stated that
although Abecma[supreg] received FDA approval on March 26, 2021, it did
not enter the U.S. market until May 10, 2021, when the date of first
sale occurred and the new technology was first reflected in claims
data. The applicant stated that the newness period for Abecma[supreg]
should therefore begin on May 10, 2021 as CMS' policy is to begin the
newness period on the date of a product's entry onto the U.S. market.
The applicant further stated that Abecma[supreg]'s new technology add-
on payment status should be extended beyond FY 2023, as CMS policy is
to extend new technology add-on payments for an additional year when
the 3-year anniversary of market entry occurs in the latter half of the
fiscal year.
Response: We thank the applicant for its comment. As stated
previously, while CMS may consider a documented delay in the
technology's market availability in our determination of newness, our
policy for determining whether to extend new technology add-on payments
for an additional year generally applies regardless of the volume of
claims for the technology after the beginning of the newness period (83
FR 41280). We do not consider the date of first sale of a product as an
indicator of the entry of a product onto the U.S. market. The applicant
states that the date of first sale of Abecma[supreg] was May 10, 2021,
but it is unclear from the information provided when the technology
first became available for sale and, absent additional information from
the applicant, we cannot determine a newness date based on a documented
delay in the technology's availability on the U.S. market.
We further note that, as discussed in section II.F.6.a. of the
preamble of this final rule, because CARVYKTITM is
substantially similar to ABECMA[supreg], we are using a single cost for
purposes of determining the new technology add-on payment amount for
CARVYKTITM and ABECMA[supreg] for FY 2023. As discussed in
section II.F.6.a., we determined a weighted average of the cost of
CARVYKTITM and ABECMA[supreg] based upon the projected
numbers of cases involving each technology to determine
[[Page 48912]]
the maximum new technology add-on payment. To compute the weighted cost
average, we summed the total number of projected cases for each of the
applicants, which equaled 420 cases (241 plus 179). We then divided the
number of projected cases for each of the applicants by the total
number of cases, which resulted in the following case weighted
percentages: 57% for CARVYKTITM and 43% for ABECMA[supreg].
We then multiplied the cost per case for the manufacturer specific drug
by the case-weighted percentage (0.57 * $465,000 = $265,050 for
CARVYKTITM and 0.43 * $419,500 = $180,385 for
ABECMA[supreg]). This resulted in a case-weighted average cost of
$445,435 for the technology.
Under Sec. 412.88(a)(2), we limit new technology add-on payments
to the lesser of 65% of the average cost of the technology, or 65% of
the costs in excess of the MS-DRG payment for the case. As a result,
the maximum new technology add-on payment for a case involving the use
of CARVYKTITM and ABECMA[supreg] is $289,532.75 for FY 2023,
as is reflected in Table II.F.-01 of this final rule.
Comment: Several commenters requested that CMS update the maximum
new technology add-on payment amount to reflect the current Wholesale
Acquisition Cost (WAC) per vial of their respective technologies. The
applicant for ZepzelcaTM requested the maximum new
technology add-on payment amount for ZepzelcaTM be updated
from $8,622.90 to $9,145.50 to reflect the updated WAC of $7,035 per
vial of ZepzelcaTM. The applicant for CoselaTM
requested the maximum new technology add-on payment amount for
CoselaTM be updated to reflect the updated WAC of $1,439 per
vial of CoselaTM.
Response: We appreciate the updated cost information.
ZepzelcaTM's current new technology add-on payment amount is
$8,622.90 for 2 single-dose vials and reflects the WAC at the time of
ZepzelcaTM's entry onto the U.S. market (2 single-dose vials
per dose x $6,633 per vial multiplied by 0.65). For FY 2023, the
maximum new technology add-on payment amount using the updated WAC is
$9,145.50 (2 single-dose vials per dose x $7,035 per vial multiplied by
0.65), as reflected in Table II.F.-01 in this final rule.
Similarly, CoselaTM's current new technology add-on
payment amount is $5,526.30 (3 doses of CoselaTM x 2 single-
dose vials per dose x $1,417 per vial multiplied by 0.65). For FY 2023,
the maximum new technology add-on payment amount using the updated WAC
is $5,612.10 (3 doses of CoselaTM x 2 single-dose vials x
$1,439 per vial multiplied by 0.65) as reflected in Table II.F.-01 in
this final rule.
After consideration of the public comments we received, we are
finalizing our proposal to continue new technology add-on payments for
FY 2023 for the technologies that were approved for new technology add-
on payment for FY 2022 and would still be considered ``new'' for
purposes of new technology add-on payments for FY 2023, as listed in
the proposed rule and in the following Table II.F.-01 in this section
of this final rule.
We note that Table II.F.-01 below is the same as Table II.F.-02
that was presented in the proposed rule, but Table II.F.-01 in this
final rule includes the updated cost information for
ZepzelcaTM, CoselaTM, and Abecma[supreg], as
discussed previously. Table II.F.-01 also includes updated cost
information for aScope Duodeno[supreg] to reflect the cost of the
technology alone, rather than a case-weighted average with EXALT Model
DTM, as discussed later in this section. The following table
also presents the newness start date, new technology add-on payment
start date, 3-year anniversary date of the product's entry onto the
U.S. market, relevant final rule citations from prior fiscal years,
maximum add-on payment amount, and coding assignments. We refer readers
to the final rules cited in the following table for a complete
discussion of the new technology add-on payment application, coding and
payment amount for these technologies, including the applicable
indications and discussion of the newness start date.
BILLING CODE 4120-01-P
[[Page 48913]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.076
[[Page 48914]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.077
BILLING CODE 4120-01-C
[[Page 48915]]
In the proposed rule, we provided a table listing the technologies
for which we proposed to discontinue making new technology add-on
payments for FY 2023 because they are no longer ``new'' for purposes of
new technology add-on payments (87 FR 28211). This table also presented
the newness start date, new technology add-on payment start date, the
3-year anniversary date of the product's entry onto the U.S. market,
relevant final rule citations from prior fiscal years, and coding
assignments for each technology. We referred readers to the final rules
cited in the table for a complete discussion of the new technology add-
on payment application, coding and payment amount for these
technologies, including the applicable indications and discussion of
the newness start date.
We invited public comments on our proposals to discontinue new
technology add-on payments for FY 2023 for the technologies listed in
the table in the proposed rule.
Comment: A commenter supported our proposal to discontinue new
technology add-on payments for AZEDRA[supreg], which will no longer be
considered new as its 3-year anniversary date of entry onto the U.S.
market will occur prior to FY 2023.
Response: We appreciate the commenter's support and are finalizing
our proposal to discontinue new technology add-on payments for
AZEDRA[supreg] for FY 2023.
Comment: Many commenters stated their opposition to discontinuing
new technology add-on payments for technologies whose 3-year
anniversary of entry onto the U.S. market will occur prior to FY 2023
or in the first half of FY 2023. These commenters encouraged CMS to use
its legal authority under section 1886(d)(5)(I) of the Act to extend
new technology add-on payments through FY 2023 due to a historic
decline in utilization during the COVID-19 pandemic.
Response: We thank the commenters for their input. Consistent with
the statute and our implementing regulations, a technology is no longer
considered as ``new'' once it is more than 2 to 3 years old,
irrespective of how frequently the medical service or technology has
been used in the Medicare population (70 FR 47349). As such, once a
technology has been available on the U.S. market for more than 2 to 3
years, we consider the costs to be included in the MS-DRG relative
weights regardless of whether the technology's use in the Medicare
population has been frequent or infrequent. Therefore, we do not
believe that case volume is a relevant consideration for making the
determination as to whether a product is ``new,'' and we are not
extending new technology add-on payments for technologies whose 3-year
anniversary of entry onto the U.S. market will occur prior to FY 2023
or in the first half of FY 2023. We refer readers to the FY 2022 IPPS/
LTCH PPS final rule (86 FR 44975 through 44979) and section II.F.5.b of
this FY 2023 final rule for discussion of our policy to allow for a 1-
year extension of new technology add-on payments for FY 2022 because of
the unique circumstances associated with ratesetting for FY 2022, for
which CMS used FY 2019 data instead of FY 2020 data to develop the FY
2022 relative weights.
Comment: Several commenters disagreed with CMS's proposal to
discontinue new technology add-on payments for EXALT Model
DTM Single-Use Duodenoscope while continuing payments for
aScope[supreg] Duodeno through FY 2023 based on the different FDA
clearance dates for the two technologies. These commenters recommended
that CMS create a single newness date and extend new technology add-on
payments for both products through the end of FY 2023. The commenters
noted that there is no mechanism for hospitals to distinguish between
the two devices when reporting claims to CMS, as the duodenoscopes
share one add-on payment amount and are identified using the same ICD-
10-PCS codes.
Another commenter, the applicant for EXALT Model DTM,
stated that creating a single newness date and discontinuation date for
a combined new technology add-on payment is consistent with prior CMS
decision-making regarding substantially similar technologies such as
IMFINZI[supreg] and TECENTRIQ[supreg] from the FY 2021 IPPS final rule,
and the LUTONIX[supreg] and IN.PACTTM AdmiralTM
drug-coated balloons in the FY 2016 IPPS final rule. The commenter
noted that, in these instances, CMS finalized the proposal to
discontinue the new technology add-on payment for both technologies on
the same date and calculated a case-weighted average cost resulting in
the same maximum add-on payment for both technologies. The commenter
further noted that CMS determined the drug-coated balloons were
identifiable using the same ICD-10-PCS procedure codes, and that
IMFINZI[supreg] and TECENTRIQ[supreg] received a one-year extension
through FY 2022 based on CMS' decision to use FY 2019 data (instead of
FY 2020 data) for the FY 2022 IPPS rate setting. The commenter
requested that CMS discontinue the new technology add-on payments for
both EXALT Model DTM and aScopeTM Duodeno at the
same time, preferably at the end of FY 2023. As an alternative, the
applicant recommended that CMS recalculate the maximum payment amount
from the current case-weighted average of $1,715 per case to reflect
65% of the cost of aScopeTM Duodeno only.
Response: We thank the commenters for their input. As stated
previously, a technology is no longer considered ``new'' once it is
more than 2 to 3 years old, irrespective of how frequently the medical
service or technology has been used in the Medicare population (70 FR
47349). As such, once a technology has been available on the U.S.
market for more than 2 to 3 years, we consider the costs to be included
in the MS-DRG relative weights regardless of whether the technology's
use in the Medicare population has been frequent or infrequent.
Additionally, we note that under Sec. 412.87(c), applications received
for new technology add-on payments for FY 2021 and subsequent fiscal
years for medical devices that are part of FDA's Breakthrough Devices
Program and received FDA marketing authorization will be considered not
substantially similar to an existing technology for purposes of the new
technology add-on payment under the IPPS. Because EXALT Model
DTM and aScopeTM Duodeno both applied under the
alternative pathway for transformative new technologies, the
applicant's comparison to IMFINZI[supreg] and TECENTRIQ[supreg] from
the FY 2021 IPPS final rule (85 FR 58672 through 58684), and the
LUTONIX[supreg] and IN.PACTTM AdmiralTM drug-
coated balloons in the FY 2016 IPPS final rule (80 FR 49461 through
49470), where the technologies were determined to be substantially
similar and therefore had the same newness period, is not relevant.
Thus, we are finalizing our proposal to discontinue new technology add-
on payment for EXALTTM Model DTM for FY 2023.
We agree with the applicant's alternative recommendation that the
maximum new technology add-on payment amount should reflect the cost of
aScopeTM Duodeno only. Based on information provided in its
application for FY 2022 new technology add-on payment, the cost of the
aScopeTM Duodeno is $1,995. Under Sec. 412.88(a)(2), we
limit new technology add-on payments to the lesser of 65% of the
average cost of the technology, or 65% of the costs in excess of the
MS-DRG payment for the case. As a result, we are finalizing that the
maximum new technology add-on payment for a case involving the use of
the aScopeTM Duodeno would be $1,296.75 for FY
[[Page 48916]]
2022 (that is, 65% of the average cost of the technology). Cases
involving the use of aScopeTM Duodeno will continue to be
identified by the following ICD-10-PCS procedure codes: XFJB8A7
(Inspection of hepatobiliary duct using single-use duodenoscope, new
technology group 7) or XFJD8A7 (Inspection of pancreatic duct using
single-use duodenoscope, new technology group).
After consideration of the public comments we received, we are
finalizing our proposal to discontinue new technology add-on payments
for the technologies as listed in the proposed rule and in the
following Table II.F.-02 of this final rule for FY 2023 because they
are no longer ``new'' for purposes of new technology add-on payments.
This table also presents the newness start date, new technology add-on
payment start date, the 3-year anniversary date of the product's entry
onto the U.S. market, and relevant final rule citations from prior
fiscal years. We also refer readers to the final rules cited in the
following table for a complete discussion of the new technology add-on
payment application, coding and payment amount for these technologies,
including the applicable indications and discussion of the newness
start date.
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR10AU22.078
[[Page 48917]]
BILLING CODE 4120-01-C
b. Status of Technologies Provided a One-Year Extension of New
Technology Add-On Payments in FY 2022
As stated in the FY 2022 IPPS/LTCH PPS final rule (86 FR 44789),
our goal is always to use the best available data overall for
ratesetting. The best available MedPAR data will typically be the most
recent MedPAR file that contains claims from discharges for the fiscal
year that is 2 years prior to the fiscal year that is the subject of
the rulemaking.
In the FY 2022 IPPS/LTCH PPS final rule, for the reasons discussed,
we finalized that we would use FY 2019 MedPAR data instead of FY 2020
MedPAR data to develop the FY 2022 MS-DRG relative weights (86 FR 44789
through 44793). Because we finalized that we would use FY 2019 MedPAR
data instead of FY 2020 MedPAR data for the development of the FY 2022
MS-DRG relative weights, we stated that the costs for a new technology
for which the 3-year anniversary date of the product's entry onto the
U.S. market occurs prior to the latter half of FY 2022 may not be fully
reflected in the MedPAR data used to recalibrate the MS-DRG relative
weights for FY 2022. Therefore, in light of this final policy, we
finalized our proposal to use our authority under section 1886(d)(5)(I)
of the Act to allow for a 1-year extension of new technology add-on
payments for FY 2022 for 13 technologies (as listed in the proposed
rule and in Table II.F.-03 of this final rule) for which the new
technology add-on payment would have otherwise been discontinued
beginning with FY 2022. We refer the reader to the FY 2022 IPPS/LTCH
PPS final rule (86 FR 44975 through 44979) for a complete discussion
regarding this 1-year extension for FY 2022.
For FY 2023 ratesetting, as discussed in section I.F. of this final
rule, we believe the best available data is the FY 2021 MedPAR file. As
discussed in section I.F. of this final rule, for FY 2023, we are
finalizing our proposal to use the FY 2021 MedPAR (the best available
data at the time of this final rule) for FY 2023 ratesetting, including
for purposes of developing the FY 2023 relative weights. We refer the
reader to section I.F. of this final rule for a complete discussion
regarding our final policy to use the FY 2021 MedPAR for the FY 2023
ratesetting and recalibration of the FY 2023 MS-DRG relative weights.
As noted previously, our policy is that a medical service or
technology may continue to be considered ``new'' for purposes of new
technology add-on payments within 2 or 3 years after the point at which
data begin to become available reflecting the inpatient hospital code
assigned to the new service or technology. For FY 2023, because we
proposed to use FY 2021 MedPAR data to recalibrate the FY 2023 MS-DRG
relative weights, we stated in the proposed rule that we believe the
costs of the 13 technologies as listed in the proposed rule (87 FR
28216 through 28217) and in Table II.F.-03 of this final rule, for
which the 3-year anniversary date of the product's entry onto the U.S.
market occurs prior to FY 2023 (and therefore are no longer ``new''),
may now be fully reflected in the MedPAR data used to recalibrate the
MS-DRG relative weights for FY 2023. As a result, we proposed to
discontinue new technology add-on payments for these 13 technologies in
FY 2023. We also refer readers to the final rules cited in Table II.F.-
03 for a complete discussion of the new technology add-on payment
application, coding and payment amount for these technologies,
including the applicable indications and discussion of the newness
start date.
We invited public comments on our proposals to discontinue new
technology add-on payments for FY 2023 for these 13 technologies listed
in the proposed rule and Table II.F.-03.
Comment: Many commenters, including several applicants for
technologies currently receiving new technology add-on payments, stated
their opposition to discontinuing new technology add-on payments for
technologies that received a one-year extension in FY 2022. These
commenters stated that the FY 2021 MedPAR claims data are distorted due
to effects of the COVID-19 pandemic and should not be used to
recalibrate the MS-DRG relative weights. The commenters encouraged CMS
to use its legal authority under section 1886(d)(5)(I) of the Act to
extend new technology add-on payments through FY 2023.
Another commenter stated that while it is accurate that the costs
of the technologies are reflected in the FY 2021 MedPAR data used for
ratesetting purposes, the existence of such claims data does not mean
that the costs of the technology are truly captured, nor does it mean
that the pandemic has not impacted adoption of the new technologies and
services. This commenter referenced several studies to demonstrate the
impact of the PHE on hospitals, including critical staff shortages and
financial instability due to lower revenues and inflation. The
commenter also provided an analysis of FY 2021 claims data that found
that the average standardized costs when accounting for cases using its
technology or comparable technology reported under the same ICD-10-PCS
codes increased by less than 0.5% compared to average standardized
costs that do not account for cases reported under these codes.
Response: We thank the commenters for their input. Consistent with
the statute and our implementing regulations, a technology is no longer
considered as ``new'' once it is more than 2 to 3 years old,
irrespective of how frequently the medical service or technology has
been used in the Medicare population (70 FR 47349). As such, once a
technology has been available on the U.S. market for more than 2 to 3
years, we consider the costs to be included in the MS-DRG relative
weights regardless of whether the technology's use in the Medicare
population has been frequent or infrequent. Therefore, we do not
believe that case volume is a relevant consideration for making the
determination as to whether a product is ``new''. Additionally, as
previously discussed, in the FY 2022 IPPS/LTCH PPS final rule (86 FR
44975 through 44979), we finalized a 1-year extension of new technology
add-on payments for FY 2022 in light of the unique circumstances
associated with ratesetting for FY 2022, for which CMS finalized the
use of the FY 2019 MedPAR data instead of the FY 2020 MedPAR data to
develop the FY 2022 relative weights. For FY 2023, because we are
finalizing the use of the FY 2021 MedPAR data for FY 2023 ratesetting,
including for purposes of developing the FY 2023 relative weights, we
believe the costs of these technologies are now reflected in the MedPAR
data used to recalibrate the MS-DRG relative weights for FY 2023.
Therefore, we are not extending new technology add-on payments for
technologies that received a one-year extension in FY 2022. We refer
readers to sections section I.F. and II.E. of this final rule for
discussion of CMS's finalized policy to use the FY 2021 MedPAR claims
data to recalibrate the FY 2023 MS-DRG relative weights, including the
finalized modifications to the relative weight setting methodology to
account for the anticipated decline in COVID-19 hospitalizations of
Medicare beneficiaries at IPPS hospitals as compared to FY 2021.
After consideration of the public comments we received, we are
finalizing our proposal to discontinue new technology add-on payments
for the technologies as listed in the proposed rule and in the
following Table II.F.-03 of this final rule for FY 2023. This table
also presents the
[[Page 48918]]
newness start date, new technology add-on payment start date, the 3-
year anniversary date of the product's entry onto the U.S. market, and
relevant final rule citations from prior fiscal years. We also refer
readers to the final rules cited in the following table for a complete
discussion of the new technology add-on payment application, coding and
payment amount for these technologies, including the applicable
indications and discussion of the newness start date.
BILLING CODE 4120-01-P
[[Page 48919]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.079
[[Page 48920]]
BILLING CODE 4120-01-C
6. FY 2023 Applications for New Technology Add-On Payments (Traditional
Pathway)
We received 18 applications for new technology add-on payments for
FY 2023 under the traditional new technology add-on payment pathway. In
accordance with the regulations under Sec. 412.87(e), applicants for
new technology add-on payments must have received FDA approval or
clearance by July 1 of the year prior to the beginning of the fiscal
year for which the application is being considered. Five applicants
withdrew their applications prior to the issuance of the proposed rule.
Subsequently, seven applicants withdrew their respective applications
for lifileucel, narsoplimab, TERLIVAZ (terlipressin), teclistamab,
mosunetuzumab, XENOVIEW, and treosulfan prior to the issuance of this
FY 2023 IPPS/LTCH PPS final rule. In addition, in accordance with Sec.
412.87(c), applicants for new technology add-on payments must have FDA
approval or clearance by July 1 of each year prior to the beginning of
the fiscal year for which the application is being considered. One
applicant, Boehringer Ingelheim Pharmaceuticals, Inc., for spesolimab,
did not receive FDA approval for its technology by July 1, 2022.
Therefore, spesolimab is not eligible for consideration for new
technology add-on payments for FY 2023. Consistent with our standard
approach, we are not including in this final rule the description and
discussion of applications that were withdrawn or that are ineligible
for consideration for FY 2023 due to not meeting the July 1 deadline,
described previously, which were included in the FY 2023 IPPS/LTCH PPS
proposed rule. We are also not summarizing nor responding to public
comments received regarding these withdrawn or ineligible applications
in this final rule. A discussion of the five remaining applications is
presented below.
a. CARVYKTITM (Ciltacabtagene Autoleucel)
Janssen Biotech, Inc., submitted an application for new technology
add-on payments for CARVYKTITM (ciltacabtagene autoleucel)
for FY 2023. CARVYKTITM is an autologous chimeric-antigen
receptor (CAR) T-cell therapy directed against B cell maturation
antigen (BCMA) for the treatment of patients with multiple myeloma. We
note that Janssen Biotech, Inc. previously submitted an application for
new technology add-on payments for CARVYKTITM for FY 2022
under the name ciltacabtagene autoleucel, as summarized in the FY 2022
IPPS/LTCH PPS final rule (86 FR 25233 through 25239), but withdrew that
application prior to the issuance of the FY 2022 IPPS/LTCH PPS final
rule (86 FR 44979).
The applicant stated that ciltacabtagene autoleucel refers to both
JNJ-4528, an investigational BCMA-directed CAR T-cell therapy for
previously treated patients with multiple myeloma, and LCAR-B38M, the
investigational product (ciltacabtagene autoleucel) being studied in
China. Both JNJ-4528 and LCAR-B38M are representative of the same CAR
T-cell therapy, ciltacabtagene autoleucel.
Multiple myeloma is an incurable blood cancer that affects a type
of white blood cell called plasma cells.\32\ Plasma cells, found in
bone marrow, make the antibodies that help the body attack and kill
various pathogens. According to the applicant, when damaged, malignant
plasma cells rapidly spread and replace the normal cells in the bone
marrow.\33\ The applicant asserted the median age of onset is 69 years
old and only 3% of patients are less than 45 at the age of diagnosis;
it was estimated that in 2021 nearly 35,000 people would be diagnosed
and more than 12,000 will die from multiple myeloma in the US.\34\
According to the applicant, multiple myeloma is associated with
substantial morbidity and mortality\35\ and median 5 year survival is
56%.\36\
---------------------------------------------------------------------------
\32\ Ho, M., Chen, T., Liu, J. et al. Targeting histone
deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits
multiple myeloma proliferation by modulating exosomes and IL-6
trans-signaling. Leukemia 34, 196-209 (2020). https://doi.org/10.1038/s41375-019-0493-x.
\33\ Utley A, Lipchick B, Lee KP, Nikiforov MA. Targeting
Multiple Myeloma through the Biology of Long-Lived Plasma Cells.
Cancers (Basel). 2020 Jul 30;12(8):2117.
\34\ Surveillance, Epidemiology, and End Results (SEER) Program.
SEER database 2020; https://seer.cancer.gov/statfacts/html/mulmy.html.
\35\ Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado
MP, Foreman K, Gupta R, Harvey J, Hosgood HD, Jakovljevic M, Khader
Y, Linn S, Lad D, Mantovani L, Nong VM, Mokdad A, Naghavi M, Postma
M, Roshandel G, Shackelford K, Sisay M, Nguyen CT, Tran TT, Xuan BT,
Ukwaja KN, Vollset SE, Weiderpass E, Libby EN, Fitzmaurice C. Global
Burden of Multiple Myeloma: A Systematic Analysis for the Global
Burden of Disease Study 2016. JAMA Oncol. 2018 Sep 1;4(9):1221-1227.
\36\ SEER database 2020; https://seer.cancer.gov/statfacts/html/mulmy.html.
---------------------------------------------------------------------------
According to the applicant, introduction of new treatment options
in the last 2 decades has extended the median survival of multiple
myeloma patients. The applicant asserted that the introduction of
proteasome inhibitors (PI) (for example, bortezomib, carfilzomib, and
ixazomib), histone deacetylase inhibitors (for example, panobinostat,
vorinostat), immunomodulatory agents (IMiD) (for example, thalidomide,
lenalidomide, and pomalidomide), monoclonal antibodies (daratumumab and
elotuzumab), and stem cell transplantation, have allowed numerous
therapeutic options for patients with multiple myeloma (Rajkumar 2020).
According to the applicant, the National Comprehensive Cancer Network
(NCCN) recommended treatment regimen for first-line therapy of multiple
myeloma is bortezomib (a PI), lenalidomide (an IMiD) and
dexamethasone.\37\ According to the applicant, the strategy of triplet
therapies for patients with newly diagnosed multiple myeloma, followed
by high-dose chemotherapy and autologous stem-cell transplantation for
eligible patients, and subsequently consolidation and maintenance
therapy, is the current treatment roadmap for patients.\38\ However,
despite these treatments, according to the applicant, most patients
will relapse after first-line treatment and require further
treatment\39\ with only 50% survival of relapsed patients after 5
years.40 41 The applicant stated that as multiple myeloma
progresses, each subsequent line of treatment is associated with
shorter progression free survival (PFS) and decreased rate, depth, and
durability of response and worsening of quality of life.\42\ In
addition, cumulative and long-term toxicities are often associated with
long-term therapy (Ludwig, 2018). Thus, according to the applicant,
there remains an ongoing need for additional therapeutic approaches
when the disease is resistant to available therapy.
---------------------------------------------------------------------------
\37\ National Comprehensive Cancer Network (NCCN) NCCN clinical
practice guidelines in oncology. Multiple Myeloma. Version 2. 2021--
September 9, 2020.
\38\ Branagan A, Lei M, Lou U, Raje N. Current Treatment
Strategies for Multiple Myeloma. JCO Oncol Pract. 2020 Jan;16(1):5-
14.
\39\ Sonneveld P, Broij lA. Treatment of relapsed and refractory
multiple myeloma. Haematologica. 2016;101(4):396-406.
\40\ SEER database 2020; https://seer.cancer.gov/statfacts/html/mulmy.html.
\41\ Global Cancer Observatory. GLOBOCAN database 2018; https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.
\42\ Yong K, Delforge M, Driessen C, Fink L, Flinois A,
Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen
P, Cavo M. Multiple myeloma: patient outcomes in real-world
practice. Br J Haematol. 2016 Oct;175(2):252-264.
---------------------------------------------------------------------------
The applicant asserted that relapsed and refractory (r/r) multiple
myeloma (RRMM) constitutes a specific unmet medical need. According to
the applicant, patients with r/r disease are defined as those who,
having achieved
[[Page 48921]]
a minor response or better, relapse and then progress while on therapy,
or experience progression within 60 days of their last
therapy.43 44 The applicant stated the introduction of a new
class of agents, CD38-targeting monoclonal antibodies (CD38 MoAbs),
daratumumab and isatuximab, have improved options in r/r patients.\45\
The applicant asserted that given these advances, guideline
recommendations following first-line therapy are varied, with treatment
options including combinations of novel agents with existing standard
of care regimens, and include triplet and quadruplet regimens, creating
a complex treatment landscape.\46\ According to the applicant, while
triplet regimens should be used as the standard therapy for patients
with multiple myeloma, elderly or frail patients may be treated with
double regimens.\47\ The applicant further stated that for patients
with RRMM who have received at least three prior lines of therapy,
including a PI, an IMiD and an anti-CD38, there does not exist a
standard or consensus for treatment at this time, and often, supportive
care/palliative care is the only option.\48\
---------------------------------------------------------------------------
\43\ Castelli R, Orofino N, Losurdo A, Gualtierotti R, Cugno M.
Choosing treatment options for patients with relapsed/refractory
multiple myeloma. Expert Rev Anticancer Ther. 2014 Feb;14(2):199-
215.
\44\ Nooka AK, Kastritis E, Dimopoulos MA, Lonial S. Treatment
options for relapsed and refractory multiple myeloma. Blood. 2015
May 14;125(20):3085-99.
\45\ Van de Donk NWCJ, Richardson PG, Malavasi F. CD38
antibodies in multiple myeloma: back to the future. Blood. 2018 Jan
4;131(1):13-29.
\46\ National Comprehensive Cancer Network (NCCN) NCCN clinical
practice guidelines in oncology. Multiple Myeloma. Version 2. 2021--
September 9, 2020.
\47\ Ibid.
\48\ Maples KT, Joseph NS, Harvey RD. Current developments in
the combination therapy of relapsed/refractory multiple myeloma.
Expert Rev Anticancer Ther. 2020 Sep 24.
---------------------------------------------------------------------------
According to the applicant, multiple myeloma remains incurable and
most patients eventually relapse, even with the advent of new
treatments.\49\ The applicant further stated that novel, innovative
therapies are needed to improve long-term survival and outcomes. The
applicant asserted that CAR T-cell-based therapies offer potential
advantages over current therapeutic strategies. According to the
applicant, while other therapies require long-term repetitive
administration generally until progression of disease, CAR T-cell
therapy is a single infusion treatment due to live T-cell expansion in
the patient and long-term disease response. The applicant asserted that
CARVYKTITM is an autologous CAR T-cell therapy directed
against B cell maturation antigen (BCMA) for the treatment of patients
with multiple myeloma. The applicant stated that BCMA, a protein that
is highly expressed on myeloma cells\50\ and is a member of the tumor
necrosis factor (TNF) receptor family, plays a central role in
regulating B-cell maturation and differentiation into plasma cells.\51\
\52\ The applicant stated BCMA is selectively expressed on a subset of
B cells (plasma cell neoplasms including myeloma cells) and is more
stably expressed specifically on the B cell lineage, compared with key
plasma cell marker CD138, which is also expressed on normal fibroblasts
and epithelial cells.53 54 55 According to the applicant,
these expression characteristics make BCMA an ideal therapeutic target
for the treatment of multiple myeloma.56 57
CARVYKTITM, according to the applicant, is a unique,
structurally differentiated BCMA-targeting chimeric antigen receptor
with two distinct BCMA-binding domains that can identify and eliminate
myeloma cells.
---------------------------------------------------------------------------
\49\ Rajkumar SV, Kumar S. Multiple myeloma current treatment
algorithms. Blood Cancer J. 2020 Sep 28;10(9):94.
\50\ Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation
Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based
Immunotherapy. Front Immunol. 2018 Aug 10;9:1821.
\51\ Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation
Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based
Immunotherapy. Front Immunol. 2018 Aug 10;9:1821.
\52\ Tai YT, Anderson KC. Targeting B-cell maturation antigen in
multiple myeloma. Immunotherapy. 2015;7(11):1187-99.
\53\ Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation
Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based
Immunotherapy. Front Immunol. 2018 Aug 10;9:1821.
\54\ Tai YT, Anderson KC. Targeting B-cell maturation antigen in
multiple myeloma. Immunotherapy. 2015;7(11):1187-99.
\55\ Palaiologou M, Delladetsima I, Tiniakos D. CD138 (syndecan-
1) expression in health and disease. Histol Histopathol. 2014
Feb;29(2):177-89.
\56\ Ibid.
\57\ Frigyesi I, Adolfsson J, Ali M, Christophersen MK, Johnsson
E, Turesson I, Gullberg U, Hansson M, Nilsson B. Robust isolation of
malignant plasma cells in multiple myeloma. Blood. 2014 Feb
27;123(9):1336-40.
---------------------------------------------------------------------------
The applicant asserted that CAR T-cell technology is a form of
immunotherapy and is a ``living drug'' that utilizes specially altered
T cells, part of the immune system, to fight cancer. According to the
applicant, a sample of the patient's T cells are collected from the
blood, then modified in a laboratory setting to express a CAR.\58\ The
applicant stated chimeric antigen receptors are specifically designed
receptor proteins that are made up of three distinct features: (1) a
target recognition domain (typically derived from a single domain of an
antibody) that sits on the cell's exterior; (2) a co-stimulatory domain
on the cell's interior that boosts activation, enhances survival and
expansion of the modified cells; and (3) an interior stimulatory domain
that supports activation and target killing.\59\ According to the
applicant, the binding domain expressed on the surface of T cells gives
them the new ability to target a specific protein. The applicant
stated, when the target is recognized, the intracellular portions of
the receptor send signals within the T cells to destroy the target
cells. The applicant asserted these engineered CAR T-cells are
reinfused back into the same patient, which enables these specialized T
cells to latch onto the target antigen and abolish the tumor cells.
---------------------------------------------------------------------------
\58\ June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N
Engl J Med. 2018 Jul 5;379(1):64-73.
\59\ Sadelain M. Chimeric antigen receptors: driving immunology
towards synthetic biology. Curr Opin Immunol. 2016 Aug;41:68-76.
---------------------------------------------------------------------------
According to the applicant, CARVYKTITM is a CAR T-cell
immunotherapy designed to recognize myeloma cells and target their
destruction. According to the applicant, CARVYKTITM's CAR T-
cell technology consists of harvesting the patient's own T cells,
programming them to express a chimeric antigen receptor that identifies
BCMA, a protein highly expressed on the surface of malignant multiple
myeloma B-lineage cells, and reinfusing these modified cells back into
the patient where they bind to and eliminate myeloma tumor cells. The
applicant asserted that, unlike the chimeric antigen receptor design of
currently approved CAR T-cell immunotherapies, which are composed of a
single-domain antibody (sdAbs), CARVYKTITM is composed of
two antibody binding domains that allow for high recognition of human
BCMA (CD269) and elimination of BCMA expressing myeloma cells.
According to the applicant, the two distinct BCMA-binding domains
confer avidity and distinguish CARVYKTITM from other BCMA-
targeting products. The applicant stated the BCMA binding domains are
linked to the receptor's interior costimulatory (4-1BB) and signaling
(CD3[zeta]) domains through a transmembrane linker (CD8a). The
applicant asserted these intracellular domains are critical components
for T cell growth and anti-tumor activity \60\ in the body once CAR T-
cells are bound to a BCMA target on multiple myeloma cells.
---------------------------------------------------------------------------
\60\ Maher J, Brentjens RJ, Gunset G, Rivi[egrave]re I, Sadelain
M. Human T-lymphocyte cytotoxicity and proliferation directed by a
single chimeric TCRzeta/CD28 receptor.
---------------------------------------------------------------------------
[[Page 48922]]
With respect to the newness criterion, according to the applicant,
CARVYKTITM was granted Breakthrough Therapy designation in
December 2019 for the treatment of adult patients with relapsed or
refractory multiple myeloma, who previously received a proteasome
inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Per
the applicant, FDA approved the Biologics License Application (BLA) for
CARVYKTITM on February 28, 2022 for the treatment of adult
patients with relapsed or refractory multiple myeloma after four or
more prior lines of therapy, including a proteasome inhibitor, an
immunomodulatory agent, and an anti-CD38 monoclonal antibody. The
applicant stated that procedures involving the administration of
CARVYKTITM can be uniquely identified using the following
ICD-10-PCS procedure codes: XW033A7 (Introduction of ciltacabtagene
autoleucel into peripheral vein, percutaneous approach, new technology
group 7) or XW043A7 (Introduction of ciltacabtagene autoleucel into
central vein, percutaneous approach, new technology group 7). The
applicant also noted that they will submit a request for a Healthcare
Common Procedure Coding System (HCPCS) code specific to the
administration of CARVYKTITM once the product is eligible
for such a code.
As previously stated, if a technology meets all three of the
substantial similarity criteria as previously described, it would be
considered substantially similar to an existing technology and
therefore would not be considered ``new'' for purposes of new
technology add-on payments.
With respect to whether a product uses the same or a similar
mechanism of action when compared to an existing technology to achieve
a therapeutic outcome, the applicant asserted that
CARVYKTITM has a unique mechanism of action because it has
two distinct binding domains that confer avidity to the BCMA antigen, a
4-1BB costimulatory domain and a CD3z signaling domain, whereas other
CAR T-cell products have only one target binding domain. The applicant
asserted that ABECMA[supreg] also targets BCMA, but does so by binding
to a single BCMA domain. In addition to detail provided in the
applicant's FY 2022 application (as discussed in 86 FR 25235 through
25236), the applicant asserted that CARVYKTITM differs
significantly from ABECMA[supreg] and other BCMA-targeting agents,
including Blenrep, because it targets BCMA with two distinct binding
domains. According to the applicant, the distinct BCMA-binding moieties
confer avidity and distinguish CARVYKTITM from other BCMA
CAR T-cell constructs providing a novel mechanism of action.\61\ The
applicant added, the 4-1BB and CD3z domains on the CAR optimize T cell
activation and proliferation.\62\ According to the applicant, non-
clinical pharmacology and toxicology have been used to characterize the
biological activity and mechanism of action of CARVYKTITM
and confirm the on-target specificity to BCMA through (1) in vitro
binding characterization; (2) in vitro co-culture assays to assess CAR
T-cell cytotoxicity and cytokine release; (3) in vivo efficacy studies
in mice with human CAR T- cells; and (4) an in vivo safety study.
According to the applicant, because CARVYKTITM has a novel
mechanism of action with two distinct BCMA-binding domains that confer
binding avidity and unprecedented clinical activity compared with other
novel anti-myeloma treatments in comparable study populations, it is
unlike any existing technology utilized to treat relapsed/refractory
multiple myeloma.
---------------------------------------------------------------------------
\61\ Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, Xu J, Zhuang
Y, Zhang W, Weng XQ, Wu J, Wang Y, Wang J, Yan H, Xu WB, Jiang H, Du
J, Ding XY, Li B, Li JM, Fu WJ, Zhu J, Zhu L, Chen Z, Fan XF, Hou J,
Li JY, Mi JQ, Chen SJ. Exploratory trial of a biepitopic CAR T-
targeting B cell maturation antigen in relapsed/refractory multiple
myeloma. Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551.
\62\ Weinkove R, George P, Dasyam N, McLellan AD. Selecting
costimulatory domains for chimeric antigen receptors: functional and
clinical considerations. Clin Transl Immunology. 2019 May
11;8(5):e1049.
---------------------------------------------------------------------------
With regard to whether a product is assigned to the same DRG when
compared to an existing technology, the applicant asserted that because
CMS has suggested that all inpatient hospitalizations involving a CAR
T-cell treatment will be assigned to DRG 018 (Chimeric Antigen Receptor
(CAR) T-Cell and Other Immunotherapies), CARVYKTITM is
expected to be assigned to the same DRG as other multiple myeloma cases
treated with a CAR T-cell therapy. We note that the DRG assignment was
finalized to Pre-MDC MS-DRG 018, effective October 1, 2022 and is
reflected in the V39.1 ICD-10 MS-DRG Grouper effective April 1, 2022
(86 FR 58021).\63\
---------------------------------------------------------------------------
\63\ CMS Manual System, Pub. 100-04 Medicare Claims Processing,
Transmittal 11255. February 4, 2022; https://www.cms.gov/files/document/r11255cp.pdf.
---------------------------------------------------------------------------
With regard to whether the new use of the technology involves the
treatment of the same or similar type of disease and the same or
similar patient population when compared to an existing technology, the
applicant asserted in its application that CARVYKTITM is
indicated for a broader population than other available therapies,
specifically multiple myeloma patients having received three prior
therapies. The applicant asserted in its application that Blenrep and
ABECMA[supreg] are indicated only for those with at least 4 prior
therapies whereas CARVYKTITM had a proposed indication for
the treatment of patients with 3 or more prior therapies. According to
the applicant, CARVYKTITM could potentially be used in a
broader multiple myeloma population, that includes patients after 3
prior therapies as opposed to 4 for Blenrep and ABECMA[supreg].
According to the applicant, in the registrational trial CARTITUDE
1, 17% (a total of 17 patients) of patients had only three prior lines
of therapy; results were presented at the American Society of
Hematology (ASH) 2021 meeting on fourth line patients. The applicant
stated that among those with three prior lines of therapy, the response
rate was 100%, the median duration of response (DoR) was 21.8 months,
minimal residual disease (MRD) negativity was found in 80%, the 18-
month progression free survival (PFS) was 75.6%, and the 18-month
overall survival (OS) was 88.2 months. According to the applicant,
because the sample size was small (17), median endpoints may not be as
rigorous as in the larger population.
According to the applicant, the distinction between three and four
previous lines of therapy is important. The applicant asserted with
each subsequent therapy patients generally become frailer and their
prognosis worsens. The applicant stated that studies comparing fourth
line to fifth line are not as common as trials studying earlier lines,
but in a real-world study by Yong et al. the percent of myeloma
patients who were able to move from third line therapy to fourth line
was 15% of all diagnosed myeloma patients, and only 1% of patients
moved to a fifth line.\64\ The applicant added that in the same study
of those patients in first line therapy, approximately 90% of patients
were able to discontinue treatment due to remission and/or planned end
of treatment while only 13% of those in fifth line ended treatment due
to stable disease/remission.
---------------------------------------------------------------------------
\64\ Yong et al. 2016. Multiple Myeloma: Patient outcomes in
real-world practice. British Journal of Haematology, 175; 252-264.
doi: 10.1111/bjh.14213.
---------------------------------------------------------------------------
The applicant asserted that for these reasons,
CARVYKTITM does not meet the third criterion and is
therefore a new technology with regards to the
[[Page 48923]]
population having been studied and being targeted for use.
In summary, the applicant asserted that CARVYKTITM meets
the newness criterion because it is not substantially similar to other
available therapies due to its unique mechanism of action, with two
distinct binding domains that confer avidity to the BCMA antigen, and
because it treats a different patient population, RRMM patients who
received three prior therapies.
In the FY 2023 IPPS/LTCH PPS proposed rule, as stated in the FY
2022 proposed rule (86 FR 25236), we noted that CARVYKTITM
may have a similar mechanism of action to that of ABECMA[supreg]. We
also noted that ABECMA[supreg] received approval for new technology
add-on payments for FY 2022 for the treatment of adult patients with
RRMM after four or more prior lines of therapy, including an
immunomodulatory agent, a proteasome inhibitor, and an anti-CD38
monoclonal antibody (86 FR 45028 through 45035). We stated that
although the number of BCMA binding domains of CARVYKTITM
and ABECMA[supreg] differ, it appeared that the mechanism of action for
both therapies is the binding to BCMA by a CAR construct, which results
in T-cell activation and killing of malignant myeloma cells. We noted
that the applicant asserted that CARVYKTITM's mechanism of
action is unique due to its dual binding domain which affects the
therapy's clinical activity, as compared to existing technologies with
a single binding domain. However, we were unclear as to how the
additional BCMA binding domain represents a change in the mechanism of
action of this therapy, or if it may instead relate to an assessment of
whether the technology meets the substantial clinical improvement
criterion. Because of the potential similarity with the BCMA antigen
and other actions, we stated our belief that the mechanism of action
for CARVYKTITM may be the same or similar to that of
ABECMA[supreg].
We also noted that the applicant stated that CARVYKTITM
may serve a new patient population if approved as a fourth line
treatment, as existing treatments are approved for fifth line
treatment. However, because CARVYKTITM's recent approval
stated that it is indicated for fifth line treatment, we questioned
whether CARVYKTITM treats a new patient population.\65\
---------------------------------------------------------------------------
\65\ https://www.fda.gov/media/156572/download.
---------------------------------------------------------------------------
Accordingly, as it appeared that CARVYKTITM and
ABECMA[supreg] are purposed to achieve the same therapeutic outcome
using the same or similar mechanism of action, are assigned to the same
MS-DRG, and treat the same or similar patient population and disease,
we stated our belief that these technologies may be substantially
similar to each other. We noted that if this technology is
substantially similar to ABECMA[supreg], we believe the newness period
for this technology would begin on March 26, 2021, the date
ABECMA[supreg] received FDA approval. We expressed our interest in
information on how these two technologies may differ from each other
with respect to the substantial similarity criteria and newness
criterion. We invited public comment on whether CARVYKTITM
meets the newness criterion, including whether CARVYKTITM is
substantially similar to ABECMA[supreg] for purposes of new technology
add-on payments.
Comment: Several commenters voiced their support for
CARVYKTITM in their general comments supporting all CAR T-
cell therapies. The commenters encouraged CMS to consider approving the
new technology add-on payment for new CAR T-cell therapies, including
CARVYKTI, as they stated this encourages hospitals to adopt
breakthrough technologies by helping them recover some of the increased
costs associated with offering innovative treatments to patients.
Response: We thank the commenters for their support.
Comment: The applicant submitted a comment in response to concerns
raised by CMS in the proposed rule, reiterating that
CARVYKTITM meets the newness criterion and is not
substantially similar to ABECMA[supreg] and other multiple myeloma
treatments. The applicant stated that, while both CARVYKTITM
and ABECMA[supreg] are CAR T-cell therapies directed against BCMA for
the treatment of patients with multiple myeloma, there are mechanistic
differences that contribute to a different CAR T-cell dose,
pharmacokinetic/pharmacodynamic profile, and a different time frame for
the development of cytokine release syndrome (CRS) as compared to
ABECMA[supreg]'s single binding domain. The applicant presented the
following table outlining the key scientific differences between
CARVYKTITM and ABECMA[supreg].
[[Page 48924]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.080
In terms of differences in dosage, the applicant stated the
clinical target dose of CARVYKTITM is 0.75 x10\6\ CAR-
positive viable T-cells/kg whereas ABECMA[supreg] is 300-400 x 10\6\
cells/kg. In terms of differences in expansion of T-cell populations,
the applicant stated that CARVYKTITM has preferential
expansion of CD8 T-cells as opposed to CD4 T-cells for ABECMA[supreg].
In terms of the differences in pharmacokinetic and pharmacodynamic
properties, the applicant stated that the median time to reach maximum
expansion for CARVYKTITM was approximately 13 days after
infusion, whereas for ABECMA[supreg] it was much sooner. According to
the applicant, because of this longer lag time for maximal expansion,
the highest peak IL-6 levels is around 10 days for
CARVYKTITM as opposed to 5 days with ABECMA[supreg], which
resulted in differences in the side effect profile, as the median time
to onset of CRS is 7 days for CARVYKTITM as opposed to 1 day
for ABECMA[supreg]. The applicant stated that patients with CRS of
Grade 3 severity had IL-6 peak levels of ~1,000 pg/ml with
CARVYKTITM as opposed to over 10,000 pg/ml with
ABECMA[supreg]. The applicant also stated that the return to baseline
levels of IL-6 occurred in 2-3 months for patients treated with
CARVYKTITM as opposed to 1 month with ABECMA[supreg].
Lastly, the applicant stated that another important distinction between
CARVYKTITM and ABECMA[supreg] was that CARVYKTITM
is derived from llama antibodies directed against BCMA whereas
ABECMA[supreg] is derived from mouse antibodies. We note that the
applicant agreed with our assessment that CARVYKTITM does
not treat a new population.
Another commenter requested that CARVYKTITM be
considered for a separate new technology add-on payment and should not
be combined with other new technologies as the commenter considers the
newness, cost, and substantial clinical improvement requirements met
for CARVYKTITM. Per the commenter, this would ensure the
maximum impact for each product for CAR T-cell therapy, which the
commenter stated is significantly underpaid.
Response: We appreciate the information submitted by commenters
regarding the newness criterion for CARVYKTITM. However, we
disagree that CARVYKTITM has a unique mechanism of action.
While the applicant highlighted differences between
CARVYKTITM and ABECMA[supreg], such as number of domains,
dosage, time to CRS onset, pharmacokinetic/pharmacodynamic profile,
side effects, source of antibodies, and CD4/CD8 ratios, we do not
believe these meaningfully differentiate the mechanism of action of
CARVYKTITM from other BCMA-directed CAR T-cell therapies
such as ABECMA[supreg], as they are both considered genetically
modified autologous T-cell immunotherapies that bind to BCMA-expressing
cancer cells.
While CARVYKTITM has two BCMA binding domains as opposed
to one binding domain for ABECMA[supreg], the resulting mechanism of
action produces the same therapeutic outcome of CAR expressing CD4 and
CD8 T-cells directed against BCMA for the treatment of multiple
myeloma. We also disagree with applicant's assertion that
CARVYKTITM's preferential expansion of CD8 T-cells leads to
a different mechanism of action, as both CARVYKTITM and
ABECMA[supreg] produce a combination of CD4 and CD8 T-cells. While the
ratio of these T-cells may vary, it does not substantiate a difference
in mechanism of action which, as noted previously, is the targeting of
and binding to the BCMA-expressing cancer cells. Lastly, we disagree
that a difference in dosage and production represents a different
mechanism of action. We refer the reader to the FY 2022 IPPS/LTCH PPS
final rule (86 FR 44996 through 45000) for a further discussion of this
issue, where we determined that BREYANZI[supreg] had a similar
mechanism of action to KYMRIAH[supreg] and YESCARTA[supreg].
After consideration of the comments received, and for the reasons
discussed, we believe that CARVYKTITM and ABECMA[supreg] use
the same or a similar mechanism of action to achieve a therapeutic
outcome, as both products are BCMA-targeting CAR T-cell immunotherapies
that result in similar T-cell activation and killing of malignant
myeloma cells. Furthermore, as discussed previously,
CARVYKTITM maps to the same MS-DRG and treats the same
patient population (those with multiple myeloma after 4 or more prior
lines of therapy) as ABECMA[supreg] and other CAR T-cell therapies.
Accordingly, because CARVYKTITM meets all three of the
substantial similarity criteria, we believe that it is substantially
similar to ABECMA[supreg]. In
[[Page 48925]]
accordance with our policy, because these technologies are
substantially similar to each other, we use the earliest market
availability date submitted as the beginning of the newness period for
both technologies. Therefore, we consider the beginning of the newness
period for CARVYKTI[supreg] to be March 26, 2021, which is the date
that ABECMA[supreg] received FDA marketing authorization.
Consistent with our policy statements in the past regarding
substantial similarity, we will not be making a determination on cost
and substantial clinical improvement for CARVYKTITM.
Specifically, we have noted that approval of new technology add-on
payments would extend to all technologies that are substantially
similar, and if substantially similar technologies are submitted for
review in different (and subsequent) years, we evaluate and make a
determination on the first application and apply that same
determination to the second application (85 FR 58679). Since
ABECMA[supreg] was approved for new technology add-on payments for FY
2022 and is still within its newness period for FY 2023, and we have
determined that CARVYKTITM is substantially similar to
ABECMA[supreg], we apply that same approval for new technology add-on
payments to CARVYKTITM. We note that we received public
comments with regard to the cost and substantial clinical improvement
criteria for this technology, but because the determination made in the
FY 2022 IPPS/LTCH PPS final rule for ABECMA[supreg] is applied to
CARVYKTITM due to their substantial similarity, we are not
summarizing comments received or making a determination on those
criteria in this final rule.
Cases involving the use of CARVYKTITM that are eligible
for new technology add-on payments will be identified by procedure
codes XW033A7 (Introduction of ciltacabtagene autoleucel into
peripheral vein, percutaneous approach, new technology group 7) or
XW043A7 (Introduction of ciltacabtagene autoleucel into central vein,
percutaneous approach, new technology group 7). In its application, the
applicant estimated that the cost of CARVYKTITM is
$465,000.00 per patient. Because CARVYKTITM is substantially
similar to ABECMA[supreg], we believe using a single cost for purposes
of determining the new technology add-on payment amount is appropriate
for CARVYKTITM and ABECMA[supreg] even though each applicant
has its own set of codes. We also believe using a single cost provides
predictability regarding the add-on payment when using
CARVYKTITM and ABECMA[supreg] for the treatment of patients
with RRMM. As such, we believe that the use of a weighted average of
the cost of CARVYKTITM and ABECMA[supreg] based upon the
projected numbers of cases involving each technology to determine the
maximum new technology add-on payment would be most appropriate. To
compute the weighted cost average, we summed the total number of
projected cases for each of the applicants, which equaled 420 cases
(241 plus 179). We then divided the number of projected cases for each
of the applicants by the total number of cases, which resulted in the
following case weighted percentages: 57% for CARVYKTITM and
43% for ABECMA[supreg]. We then multiplied the cost per case for the
manufacturer specific drug by the case-weighted percentage (0.57 *
$465,000 = $265,050 for CARVYKTITM and 0.43 * $419,500 =
$180,385 for ABECMA[supreg]). This resulted in a case-weighted average
cost of $445,435 for the technology.
Under Sec. 412.88(a)(2), we limit new technology add-on payments
to the lesser of 65% of the average cost of the technology, or 65% of
the costs in excess of the MS-DRG payment for the case. As a result,
the maximum new technology add-on payment for a case involving the use
of CARVYKTITM or ABECMA[supreg] is $289,532.75 for FY 2023.
b. DARZALEX FASPRO[supreg] (daratumumab and hyaluronidase-fihj)
Janssen Biotech, Inc., submitted an application for new technology
add-on payments for DARZALEX FASPRO[supreg] for FY 2023. DARZALEX
FASPRO[supreg] is a combination of daratumumab (a monoclonal CD38-
directed cytolytic antibody), and hyaluronidase (an endoglycosidase)
indicated for the treatment of light chain (AL) amyloidosis in
combination with bortezomib, cyclophosphamide and dexamethasone
(CyBorD) in newly diagnosed patients and is administered through a
subcutaneous injection.
According to the applicant, AL amyloidosis is a life-threatening
blood disorder caused by increased production of misfolded
immunoglobulin light chains by an abnormal proliferation of malignant
CD38+ plasma cells. Per the applicant, these deficient immunoglobulin
light chains aggregate into highly ordered amyloid fibrils that deposit
in tissues, eventually resulting in progressive organ dysfunction and
damage due to the toxic effect of the misfolded proteins
(proteotoxicity) and the distortion of the normal tissue architecture
by the amyloid deposits.\66\ The applicant stated that the most
frequently affected organs are the heart, kidney, liver, spleen,
gastrointestinal tract and nervous system. Per the applicant, patients
often have a poor prognosis, and as many as 30% of patients with AL
amyloidosis die within the first year after diagnosis. The applicant
stated that approximately 4,500 people in the US develop AL amyloidosis
each year.\67\ The applicant stated that while there were no FDA
approved therapies prior to daratumumab, a number of therapies were
used clinically to treat AL amyloidosis including combination therapies
like cyclophosphamide-bortezomib-dexamethasone (CyBorD), bortezomib-
lenalidomide-dexamethasone (VRd), bortezomib-melphalan-dexamethasone
(VMd), melphalan-dexamethasone (Md), and bortezomib-dexamethasone (Vd).
The applicant further noted that none of these combination regimens are
approved for use by FDA in this specific indication.
---------------------------------------------------------------------------
\66\ Merlini et al. Systemic immunoglobin light chain
amyloidosis. Nat Rev Dis Primers. 2018; 4:38-19.
\67\ Amyloidosis Foundation. AL amyloidosis facts. https://www.amyloidosis.org/facts/al/. Accessed September 2021.
---------------------------------------------------------------------------
According to the applicant, DARZALEX FASPRO[supreg] is the first
and only FDA-approved treatment for patients with AL amyloidosis and is
also approved for multiple indications for treatment of patients with
multiple myeloma. The applicant stated that the indication for the
technology for which it is submitting a new technology add-on payment
application is for the treatment of adult patients with AL amyloidosis
in combination with bortezomib, cyclophosphamide and dexamethasone in
newly diagnosed patients. The applicant noted that DARZALEX
FASPRO[supreg] is not indicated nor recommended to be used in patients
with AL amyloidosis who have NYHA Class IIIB or Class IV cardiac
disease or Mayo Stage IIIB, except in the context of controlled
clinical trials.
According to the applicant, DARZALEX FASPRO[supreg] is the
subcutaneous formulation of daratumumab, which is a human IgG-kappa
monoclonal antibody that targets CD38, an enzymatic protein that is
uniformly expressed on human plasma cells. Per the applicant, in
DARZALEX FASPRO[supreg], daratumumab is co-formulated with recombinant
human hyaluronidase (rHuP20), which critically allows daratumumab to be
administered in a volume of 15 mL by a 3-5 minute injection under the
skin, compared to the 500-1000 mL volume
[[Page 48926]]
and 3-7 hour administration time required for IV daratumumab. The
applicant further noted that given the cardiac and renal dysfunction
which afflicts many AL amyloidosis patients and makes them poor
candidates for large volume IV administration, rHuP20 is a critical
component of DARZALEX FASPRO[supreg]. Per the applicant, daratumamab
binds to the CD38 protein on the surface of the malignant plasma cells
which are responsible for abnormal amyloid protein production in AL
amyloidosis, directly killing the malignant CD38+ plasma cells and/or
directing the immune system to destroy them. The immunomodulatory
response consists of CD8+ clonal expansion, CD38 enzymatic inhibition,
complement activation and cell recruitment to enable antibody dependent
cellular phagocytosis (ADPC) and antibody dependent cellular
cytotoxicity (ADCC). Per the applicant, the mechanism of actions of
daratumumab in AL amyloidosis are the same as the mechanisms of action
of daratumumab in multiple myeloma, since both disease entities are
disorders of malignant CD38+ plasma cells.68 69 70
---------------------------------------------------------------------------
\68\ de Weers et al. Daratumumab, a Novel Therapeutic Human CD38
Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other
Hematogical Tumors. J Immunol 2011;186:1840-1848).
\69\ Overdijk et al. Antibody-mediated phagocytosis contributes
to the anti-tumor activity of the therapeutic antibody daratumumab
in lymphoma and multiple myeloma. MAbs.2015;7:311-321).
\70\ Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab
depletes CD38+ immune regulatory cells, promotes T-cell expansion,
and skews T-cell repertoire in multiple myeloma. Blood 2016; 128:
384-94.
---------------------------------------------------------------------------
The applicant stated that without hyaluronidase, it is not possible
to inject more than 2-3 mL of drug directly into the subcutaneous
tissue under the skin. Per the applicant rHuPH20 naturally mimics
natural hyaluronidase and increases the permeability of subcutaneous
tissue by degrading hyaluronan. By co-formulating daratumumab with
rHuPH20, it becomes possible for 15 mL containing 1,800 mg of
daratumamab to be administered subcutaneously in approximately 3 to 5
minutes. The applicant stated that the ability to administer
daratumumab subcutaneously reduces the reaction rate to daratumumab,
may improve convenience and patient satisfaction, and greatly reduces
the volume of administration, which is critical in light of the cardiac
dysfunction and kidney dysfunction which afflict many patients with AL
amyloidosis.
With respect to the newness criterion, the applicant stated that
DARZALEX FASPRO[supreg] was granted accelerated approval from FDA on
January 15, 2021, indicated for the treatment of adult patients with
light chain (AL) amyloidosis in combination with bortezomib,
cyclophosphamide and dexamethasone in newly diagnosed patients. Per the
applicant, DARZALEX FASPRO[supreg] is not indicated and recommended for
the treatment of patients with AL amyloidosis who have NYHA Class IIIB
or Class IV cardiac disease or Mayo Stage IIIB outside of controlled
clinical trials.\71\ The applicant also stated that DARZALEX
FASPRO[supreg] received FDA approval on September 26, 2019, for the
treatment of adult patients with multiple myeloma as part of a
combination therapy in newly diagnosed patients eligible for autologous
stem cell transplant, and on May 1, 2020, for the treatment of patients
with multiple myeloma. As stated previously, the indication for which
the applicant submitted an application for new technology add-on
payments is for the treatment of adult patients with AL amyloidosis in
combination with bortezomib, cyclophosphamide and dexamethasone in
newly diagnosed patients. The applicant stated that DARZALEX
FASPRO[supreg] for newly diagnosed AL amyloidosis was commercially
available immediately following the accelerated approval granted by
FDA. The recommended dosage for DARZALEX FASPRO[supreg] for newly
diagnosed AL amyloidosis is 1,800 mg of daratumumab and 30,000 units of
hyaluronidase administered subcutaneously over approximately 3 to 5
minutes in combination with bortezomib, cyclophosphamide and
dexamethasone. According to the applicant, patients receiving DARZALEX
FASPRO[supreg] for this indication receive a weekly dose for the first
8 weeks (week 1 to week 8), one dose every 2 weeks from week 9 to week
24, followed by one dose monthly from week 25 onward until disease
progression for a maximum of 2 years.
---------------------------------------------------------------------------
\71\ According to the applicant, continued approval for this
indication may be contingent upon verification and description of
clinical benefit in confirmatory trials.
---------------------------------------------------------------------------
The applicant submitted a request for a unique ICD-10-PCS code to
identify procedures involving the administration of DARZALEX
FASPRO[supreg], and was granted approval to identify DARZALEX
FASPRO[supreg] administration with ICD-10-PCS code XW01318
(Introduction of daratumumab and hyaluronidase-fihj into subcutaneous
tissue, percutaneous approach, new technology group 8), effective
October 1, 2022. We note that DARZALEX FASPRO[supreg] is also approved
for multiple indications for the treatment of patients with multiple
myeloma, and this PCS code would not uniquely identify use of the
technology for the indication for which the applicant has applied for a
new technology add-on payment. The applicant stated that E85.81 (Light
chain (AL) amyloidosis) may be used to currently identify the
indication for DARZALEX FASPRO[supreg] under the ICD-10-CM coding
system. Therefore, the administration of DARZALEX FASPRO[supreg] for
the AL amyloidosis indication could be uniquely identified with
XW01318, in combination with E85.81.
As previously discussed, if a technology meets all three of the
substantial similarity criteria under the newness criterion, it would
be considered substantially similar to an existing technology and would
not be considered ``new'' for the purposes of new technology add-on
payments.
---------------------------------------------------------------------------
\72\ Adams et al. Proteasome Inhibitors: A Novel Class of Potent
and Effective Antitumor Agents. Cancer Res 1999;55; 2615-2622.
\73\ Adams et al. The proteasome: a suitable antineoplastic
target. Nat Rev Cancer 2004; 4:349-360.
---------------------------------------------------------------------------
With respect to the first criterion, whether a technology uses the
same or similar mechanism of action to achieve a therapeutic outcome,
the applicant stated that it does not use the same or similar mechanism
of action as existing technologies. The applicant stated that DARZALEX
FASPRO[supreg] was the first drug approved by FDA for treatment of AL
amyloidosis and its mechanism of action is different from that of any
other drug previously used to treat AL amyloidosis. According to the
applicant, the other therapies currently used to treat amyloidosis off-
label (for example, bortezomib, cyclophosphamide, melphalan,
lenlidomide) all have different mechanisms of action; none of them are
monoclonal antibodies that specifically bind to CD38 on malignant
plasma cells. The applicant stated that bortezomib induces cell death
of the malignant plasma cell by inhibition of the 26S proteasome which
plays a key role in cell survival by regulating protein breakdown in a
controlled fashion. The applicant further stated that when bortezomib
inhibits proteasome function, the normal balance within a cell is
disrupted, resulting in a buildup of cell cycle and regulatory proteins
which eventually leads to cell death.72 73 Per the
applicant, lenalidomide is an immunomodulator which modulates the E3
ubiquitin ligase complex. Modulation of this E3 ubiquitin ligase
[[Page 48927]]
complex by lenalidomide eventually leads to enhanced function of
specific immune cells and induction of cell death and the exact
mechanism of action of lenalidomide is still not fully
understood.74 75 The applicant stated that both melphalan
and cyclophosphamide are alkylating chemotherapy drugs that add an
alkyl group to the guanine base of the DNA molecule, preventing the
strands of the double helix from linking, which causes breakage of the
DNA strands, affecting the ability of the cancer cell to multiply. Per
the applicant, like bortezomib and lenalidomide, melphalan and
cyclophosphamide are not approved by FDA for the use in patients with
AL amyloidosis. The applicant also noted that while the National
Comprehensive Cancer Network[supreg] (NCCN[supreg]) Guidelines for
Systemic Light Chain Amyloidosis state that both IV and SQ daratumumab
can be used to treat previously treated amyloidosis,\76\ IV daratumumab
is not approved by FDA for the treatment of patients with amyloidosis
(newly diagnosed and previously treated). The applicant also stated
that DARZALEX FASPRO[supreg] is the more appropriate option in the AL
amyloidosis patient population due to the fact that subcutaneous dosing
has a negligible volume administration (15 ml for SC vs up to 1,000 ml
for IV), which is particularly important in patients with AL
amyloidosis who often have compromised cardiac and renal function due
to the amyloid deposition in cardiac and kidney tissue.
---------------------------------------------------------------------------
\74\ Kastritis et al. Primary treatment of light chain
amyloidosis with Bortezomib, lenalidomide and dexamethasone. Blood
Adv 2019;3:3002-3009.
\75\ Revlimid Prescribing Info.
\76\ NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines[supreg]): Systemic Light Chain amyloidosis (Version
1.2022). National Comprehensive Cancer Network. www.nccn.org.
Published August 29 June 2021. Accessed July 21, 2021.
---------------------------------------------------------------------------
With respect to the second criterion, whether a product is assigned
to the same or a different MS-DRG, the applicant stated that this
product is not expected to change the DRG assignment of a case when
used for the treatment of AL amyloidosis.
With respect to the third criterion, whether the new use of
technology involves the treatment of the same or similar type of
disease and the same or similar patient population when compared to an
existing technology, the applicant stated that DARZALEX FASPRO[supreg]
does not meet this criterion because it was the first approved drug to
treat patients with AL amyloidosis. The applicant also stated that the
NCCN[supreg] Guidelines for Systemic Light Chain Amyloidosis reflect
the limited treatment options for this specific disease. The applicant
further stated that DARZALEX FASPRO[supreg] in combination with CyBorD
is the only treatment with a Category 1 recommendation \77\ in the
NCCN[supreg] Guidelines for patients with newly diagnosed AL
amyloidosis.\78\
---------------------------------------------------------------------------
\77\ Per the NCCN[supreg], a Category 1 recommendation is
``Based upon high-level evidence, there is uniform NCCN[supreg]
consensus that the intervention is appropriate.''
\78\ NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines[supreg]): Systemic Light Chain amyloidosis (Version
1.2022). National Comprehensive Cancer Network. www.nccn.org.
Published August 29 June 2021. Accessed July 21, 2021.
---------------------------------------------------------------------------
In summary, the applicant believes that DARZALEX FASPRO[supreg] is
not substantially similar to other currently available therapies and/or
technologies because it has a unique mechanism of action and because it
is the first FDA approved treatment for AL amyloidosis.
We invited public comments on whether DARZALEX FASPRO[supreg] is
substantially similar to existing technologies and whether DARZALEX
FASPRO[supreg] meets the newness criterion.
Comment: The applicant submitted a comment reiterating its belief
that DARZALEX FASPRO[supreg] meets the newness criterion because it was
the first drug approved by FDA for patients with newly diagnosed light
chain amyloidosis and that the mechanism of action is different from
that of any other drug previously used to treat AL amyloidosis in that
it is a monoclonal antibody that specifically binds to CD38 on
malignant cancer cells. The applicant stated that because of this
unique mechanism of action, DARZALEX FASPRO[supreg] for AL is not
substantially similar to current treatments for AL and therefore meets
the newness criterion.
Response: We thank the applicant for its comment. Based on our
review of comments received and information submitted by the applicant
as part of its FY 2023 new technology add-on payment application for
DARZALEX FASPRO[supreg], we agree with the applicant that DARZALEX
FASPRO[supreg] has a unique mechanism of action as the first FDA
approved treatment for AL amyloidosis. Therefore, we believe that
DARZALEX FASPRO[supreg] is not substantially similar to existing
treatment options and meets the newness criterion. We consider the
beginning of the newness period to commence when DARZALEX
FASPRO[supreg] was approved by FDA for the treatment of adult patients
with light chain (AL) amyloidosis in combination with bortezomib,
cyclophosphamide and dexamethasone in newly diagnosed patients, on
January 15, 2021.
With respect to the cost criterion, the applicant presented the
following analysis to demonstrate that DARZALEX FASPRO[supreg] meets
the cost criterion. To identify cases representing patients who may be
eligible for treatment with DARZALEX FASPRO[supreg], the applicant
searched the FY 2019 MedPAR database released with the FY 2022 IPPS
final rule and stated that it used fee-for-service IPPS discharges,
plus Maryland hospital discharges. The applicant searched for claims
reporting ICD-10-CM diagnosis code E85.81 (Light chain amyloidosis) in
conjunction with at least one of the following additional ICD-10-CM
diagnosis codes:
BILLING CODE 4120-01-P
[[Page 48928]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.081
The applicant excluded cases with a length of stay greater than 7
days from the analysis. According to the applicant, administration of
DARZALEX FASPRO[supreg] would likely be delayed if a patient becomes
seriously ill during the course of treatment, so it is unlikely a
patient would receive DARZALEX FASPRO[supreg] during an inpatient stay
lasting longer than 7 days. The applicant indicated that based on the
advice of clinical experts, it also excluded cases mapped to the
following MS-DRGs, as DARZALEX FASPRO[supreg] would not be an
appropriate treatment for patients receiving treatment for such
conditions:
[[Page 48929]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.082
[[Page 48930]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.083
After applying the case selection and exclusion criteria, the
applicant's search resulted in the identification of 114 MS-DRGs using
the FY 2019 MedPAR file dataset. The applicant imputed a case count of
11 for 104 MS-DRGs with
[[Page 48931]]
fewer than 11 cases, resulting in a total of 1,494 cases mapping to the
114 MS-DRGs.
[GRAPHIC] [TIFF OMITTED] TR10AU22.084
[[Page 48932]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.085
[[Page 48933]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.086
BILLING CODE 4120-01-C
The applicant determined an average unstandardized case weighted
charge per case of $47,599.
The applicant did not remove charges for related or prior
technologies because, per the applicant, DARZALEX FASPRO[supreg] would
not replace other therapies a patient may receive during an inpatient
stay. Next, the applicant standardized the charges using the FY 2022
IPPS/LTCH PPS final rule impact file and applied a 4-year inflation
factor of 1.281834 or 28.1834% based on the inflation factor used in
the FY 2022 IPPS/LTCH PPS final rule to update the outlier threshold
(86 FR 45542). The applicant then added charges for the new technology
by multiplying the per treatment cost of DARZALEX FASPRO[supreg] by the
inverse of the national average drug CCR of 0.187 from the FY 2022
IPPS/LTCH PPS final rule (86 FR 44966).
The applicant calculated a final inflated average case-weighted
standardized charge per case of $92,916, which exceeded the average
case-weighted threshold amount of $61,426. Because the final inflated
average case-weighted standardized charge per case exceeded the average
case-weighted threshold amount, the applicant maintained that DARZALEX
FASPRO[supreg] meets the cost criterion.
We invited public comment on whether DARZALEX FASPRO[supreg] meets
the cost criterion.
Comment: The applicant submitted a comment reiterating its belief
that because the final inflated average case-weighted standardized
charge per case exceeded the average case-weighted threshold amount,
DARZALEX FASPRO[supreg] meets the cost criterion.
Response: We thank the commenter for its comment. We agree the
final inflated average case-weighted standardized charge per case
exceeded the average case-weighted threshold amount. Therefore,
DARZALEX FASPRO[supreg] meets the cost criterion.
With regard to the substantial clinical improvement criterion, the
applicant asserted that DARZALEX FASPRO[supreg] represents a
substantial clinical improvement over existing technologies because it
offers a treatment option for a patient population unresponsive to, or
ineligible for, currently available treatments. The applicant also
asserted that DARZALEX FASPRO[supreg] demonstrates significant
improvement in a number of clinical outcomes including hematologic
complete response (hemCR), prolonged survival free from major organ
deterioration, increased cardiac and renal response rates, with a
demonstrated safety and tolerability profile and no negative impact to
health-related quality of life based on patient-reported outcomes.
With regard to the claim that DARZALEX FASPRO[supreg] offers a
treatment option for a patient population unresponsive to, or
ineligible for, currently available treatments, the applicant stated
that the initial standard of therapy (CyBorD) is considered inadequate,
as most patients do not respond adequately to the CyBorD regimen alone.
Furthermore, according to the applicant, the ANDROMEDA data shows that
>80% of patients do not achieve a hemCR, >75% of patients with cardiac
disease do not have an organ response, and >75% of patients with renal
disease do not have an organ response when treated with the initial
standard of therapy CyBorD. Per the applicant, there is a high unmet
need to improve treatment for AL amyloidosis patients. The applicant
stated that rapid and deep response like hemCR are critical and are
strongly associated with organ response and improved survival in AL
amyloidosis.\79\ Per the applicant, adding DARZALEX FASPRO[supreg] to
CyBorD increases the hemCR rate by three-fold and doubles the cardiac
and renal response rates, thereby addressing this high unmet medical
need.
---------------------------------------------------------------------------
\79\ Comenzo RL, Reece D, Palladini G, et al. Consensus
guidelines for the conduct and reporting of clinical trials in
systemic light chain amyloidosis. Leukemia. 2012;26: 2317-2325.
---------------------------------------------------------------------------
With regard to the claim that the use of DARZALEX FASPRO[supreg]
significantly improves clinical outcomes for a patient population as
compared to currently available treatments, as stated previously, the
applicant asserted that DARZALEX FASPRO[supreg] represents a
substantial clinical improvement over existing technologies because it:
(1) demonstrates a consistent safety profile; (2) significantly
improves hematologic complete response (hemCR rates); (3) maintains the
increased hemCR rates for pre-specified subgroups; (4) shortens the
time to hemCR; (5) improves very good partial response (VGPR) or better
rates; (6) substantially improves cardiac response at 6 and at 12
months; (7) improves renal response at 6 and at 12 months; (8) improves
major-organ deterioration or progression-free survival (MOD-PFS); (9)
improves Global Health status and fatigue as of cycle 6 of treatment,
and maintains health-related quality of life (HRQoL); and (10) provides
important advantages for the population with AL.
In support of these claims, the applicant submitted the ANDROMEDA
phase 3 trial as well as presentations related to these trials. The
applicant stated that data in the ANDROMEDA study demonstrated that
DARZALEX FASPRO[supreg] led to significantly better outcomes both at
the time of the
[[Page 48934]]
primary analysis \80\ as well as at the time of updated analyses which
were presented at the 2021 ASCO annual meeting and 2021 EHA annual
meeting.\81\
---------------------------------------------------------------------------
\80\ Kastritis et al. Daratumumab-Based Treatment for
Immunoglobulin Light-Chain Amyloidosis. New England Journal of
Medicine (NEJM). 2021; 385:46-58.
\81\ Kastritis E, et al., Subcutaneous Daratumumab +
Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients
with Newly Diagnosed Light Chain (AL) Amyloidosis: Updated Results
from the Phase 3 ANDROMEDA Study, Oral presentation at: American
Society for Oncology (ASCO) Annual Virtual Meeting; June 4-8, 2021 &
Oral presentation at: European Hematology Association (EHA) Annual
Virtual Meeting; June 9-17, 2021.
---------------------------------------------------------------------------
ANDROMEDA was a randomized, open-label, phase 3 study of 388
patients with newly diagnosed AL amyloidosis randomized 1:1 to receive
6 cycles of CyBorD, either alone (control group, n=193) or in
combination with daratumumab SC (that is, DARZALEX FASPRO[supreg]),
followed by DARZALEX FASPRO[supreg] monotherapy every 4 weeks for up to
24 additional cycles (daratumumab group, n=195). The study enrolled
patients between May 3, 2018 and August 15, 2019. Median age was 64
(range 34-87). The study reported a median 11.4 month follow-up for the
published trial, and 20.3 months for the follow-up data. The primary
endpoint was hemCR, defined as having negative serum and urine
immunofixation and a free light chain ratio (FLCr) within the reference
range or abnormal free light-chain ratio if the uninvolved free light
chain (uFLC) is higher than the involved free light chain (iFLC).
According to the applicant, this definition of hemCR is in line with a
recent clarification of the Internal Society of Amyloidosis
guidelines.\82\ Secondary endpoints were survival free from major organ
deterioration or hematologic progression (composite end point that
included end-stage cardiac or renal failure, hematologic progression),
or death, organ response, overall survival, hematologic complete
response at 6 months, VGPR or better, time to and duration of
hematologic complete response, time to next treatment, and reduction in
fatigue. The applicant noted that the safety population in the
ANDROMEDA study consisted of 193 patients in the daratumumab arm and
188 patients in the control arm.
---------------------------------------------------------------------------
\82\ Palladini et al. Daratumumab plus CyBord for patients with
newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Blood.2020;136:71-80.
---------------------------------------------------------------------------
The applicant also cited an oral presentation, presented at the
American Society of Clinical Oncology (ASCO) 2021 and European
Hematology Association (EHA) 2021 annual meetings, with updated data
from the ANDROMEDA study after 20.3 months of follow-up, which
described sustained primary outcome of higher rates of hemCR across
subgroups as well as improved secondary endpoints of cardiac and renal
response rate at 12 months. In the intent to treat population, there
were 11 deaths in the CyBorD group compared to 7 deaths in the control
group.\83\
---------------------------------------------------------------------------
\83\ Kastritis E, et al., Subcutaneous Daratumumab +
Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients
with Newly Diagnosed Light Chain (AL) Amyloidosis: Updated Results
from the Phase 3 ANDROMEDA Study, Oral presentation at: American
Society for Oncology (ASCO) Annual Virtual Meeting; June 4-8, 2021 &
Oral presentation at: European Hematology Association (EHA) Annual
Virtual Meeting; June 9-17, 2021.
---------------------------------------------------------------------------
In support of its assertion that DARZALEX FASPRO[supreg]
demonstrates a consistent safety profile, the applicant cited Kastritis
et al., discussed previously, stating that the safety profiles of
daratumumab and bortezomib, cyclophosphamide, and dexamethasone in the
ANDROMEDA trial were consistent with their known profiles and the
underlying disease from previous trials.\84\ To support its assertion
that DARZALEX FASPRO[supreg] significantly improves hemCR rate, the
applicant stated that the trial results showed that patients treated
with DARZALEX FASPRO[supreg] demonstrated a statistically significant
increase in hemCR compared to control (53.3% versus 18.1%; relative
risk ratio, 2.9; 95% CI, 2.1 to 4.1; odds ratio, 5.1; 95% CI, 3.2 to
8.2; p <0.001 for both comparisons) at the 11.4 month median follow-up.
To support its assertion that DARZALEX FASPRO[supreg] results in a
shorter time to hemCR, the applicant noted that in the trial, median
time to hemCR was 60 days in the daratumumab group and 85 days in the
control group. In support of its assertion that the increased hemCR
rate was maintained for pre-specified subgroups, the applicant also
stated that hemCR remained consistent in most prespecified subgroups
(for example, sex, age, weight, race, cardiac stage, etc.) receiving
daratumumab.\85\ The applicant also cited results from the oral
presentation, discussed previously, stating that after a median follow
up of 20.3 months, the percentage of patients who achieved hemCR
increased to 59% in the daratumumab group vs 19% in the control group
(odds ratio: 5.9; 95% CI, 3.7 to 9.4; P <0.001), and that this
advantage was seen consistently across all prespecified subgroups.\86\
The applicant stated that rapid and deep hematologic responses are
critical and are strongly associated with organ response and improved
survival in AL amyloidosis.\87\
---------------------------------------------------------------------------
\84\ Kastritis E, et al., Daratumumab-Based Treatment for
Immunoglobulin Light-Chain Amyloidosis, N Eng J Med. 2021; 385:46-
58.
\85\ Kastritis E, et al., Daratumumab-Based Treatment for
Immunoglobulin Light-Chain Amyloidosis, N Eng J Med. 2021; 385:46-
58.
\86\ Kastritis E, et al., Subcutaneous Daratumumab +
Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients
with Newly Diagnosed Light Chain (AL) Amyloidosis: Updated Results
from the Phase 3 ANDROMEDA Study, Oral presentation at: American
Society for Oncology (ASCO) Annual Virtual Meeting; June 4-8, 2021 &
Oral presentation at: European Hematology Association (EHA) Annual
Virtual Meeting; June 9-17, 2021.
\87\ Comenzo RL, Reece D, Palladini G, et al. Consensus
guidelines for the conduct and reporting of clinical trials in
systemic light chain amyloidosis. Leukemia. 2012;26: 2317-2325.
---------------------------------------------------------------------------
In support of its assertion that DARZALEX FASPRO[supreg] improved
VGPR or better rates, the applicant also stated that the trial
demonstrated that the secondary endpoint of VGPR or better was 78.5% in
the daratumumab group and 49.2% in the control group (relative risk
ratio, 1.6; 95% CI, 1.4 to 1.9; odds ratio, 3.8; 95% CI, 2.4 to
5.9).\88\ Per the applicant, the substantial improvements in
hematologic response rates and other endpoints like cardiac and renal
response and MOD-PFS indicate the clinical meaningfulness of these
efficacy results.
---------------------------------------------------------------------------
\88\ Kastritis et al., Daratumumab for immunoglobulin light-
chain amyloidosis. N Eng J Med 2021; 385:48-58.
---------------------------------------------------------------------------
In support of its assertion that DARZALEX FASPRO[supreg]
substantially improves cardiac response at 6 and at 12 months,
according to the applicant, of the subgroup that was evaluated for
cardiac response (118 in the daratumumab group and 117 in the control
group), 41.5% in the daratumumab group and 22.2% in the control group
(odds ratio, 2.44; 95% CI: 1.35 to 4.42) demonstrated a cardiac
response at 6 months.\89\ The applicant noted that at a median follow
up of 20.3 months, cardiac response rates were higher with in the
daratumumab group compared to CyBorD alone at 6 months (42% versus 22%,
odds ratio 2.4, 95% CI 1.4 to 4.4; P = .0029) and at 12 months (57%
versus 28%, odds ratio 3.5 95% CI 2.0 to 6.2; P <0.0001).\90\ In
addition, in support of its assertion that
[[Page 48935]]
DARZALEX FASPRO[supreg] improves renal response at 6 and at 12 months,
the applicant noted that in the subgroup evaluated for renal response
(117 in the daratumumab group and 113 in the control group), 53.0% of
patients in the daratumumab group and 23.9% in the control group (odds
ratio, 3.34; 95% CI: 1.88 to 5.94) demonstrated a renal response at 6
months.\91\ The applicant noted that at a median follow up of 20.3
months, renal response rates were higher with in the daratumumab group
compared to CyBorD alone at 6 months (54% vs 27%; odds ratio 3.3 95% CI
1.9 to 5.9; P <0.0001) and at 12 months (57% vs 27%; odds ratio 4.1 95%
CI 2.3 to 7.3; P <0.0001).\92\ The applicant noted that the percentages
of patients who had a cardiac or renal response were substantially
higher in the daratumumab group than in the control group, which it
stated was an important finding given that organ responses are also a
predictor of improved survival.
---------------------------------------------------------------------------
\89\ Kastritis E, et al., Daratumumab-Based Treatment for
Immunoglobulin Light-Chain Amyloidosis, N Eng J Med. 2021; 385:46-
58.
\90\ Kastritis E, et al., Subcutaneous Daratumumab +
Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients
with Newly Diagnosed Light Chain (AL) Amyloidosis: Updated Results
from the Phase 3 ANDROMEDA Study, Oral presentation at: American
Society for Oncology (ASCO) Annual Virtual Meeting; June 4-8, 2021 &
Oral presentation at: European Hematology Association (EHA) Annual
Virtual Meeting; June 9-17, 2021.
\91\ Kastritis E, et al., Daratumumab-Based Treatment for
Immunoglobulin Light-Chain Amyloidosis, N Eng J Med. 2021; 385:46-
58.
\92\ Kastritis E, et al., Subcutaneous Daratumumab +
Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients
with Newly Diagnosed Light Chain (AL) Amyloidosis: Updated Results
from the Phase 3 ANDROMEDA Study, Oral presentation at: American
Society for Oncology (ASCO) Annual Virtual Meeting; June 4-8, 2021 &
Oral presentation at: European Hematology Association (EHA) Annual
Virtual Meeting; June 9-17, 2021.
---------------------------------------------------------------------------
In support of its assertion that DARZALEX FASPRO[supreg] improves
MOD-PFS, the applicant noted significant findings of secondary endpoint
survival free from major organ deterioration or hematologic progression
in the daratumumab group compared to control (hazard ratio for major
organ deterioration, hematologic progression, or death, 0.58; 95% CI,
0.36 to 0.93; P = 0.02).\93\
---------------------------------------------------------------------------
\93\ Kastritis et al. Daratumumab-Based Treatment for
Immunoglobulin Light-Chain Amyloidosis. NEJM. 2021;385:46-58.
---------------------------------------------------------------------------
With regard to the claim that DARZALEX FASPRO[supreg] improves
Global Health status (GHS) and fatigue as of cycle 6 of treatment, as
well as maintains HRQoL, the applicant cited a poster presentation of a
subgroup analysis on patient reported outcomes (PRO) for patients
participating in the ANDROMEDA study.\94\ The applicant noted that the
patients were provided with PRO questionnaires and assessed on day 1 of
cycles -1-6 as well as every 8 weeks thereafter in the daratumumab
group. The applicant stated that of the 388 patients randomized in the
study, compliance rates for all PRO questionnaires were >90% at
baseline and >83% through Cycle 6. The questionnaires included the
European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire Core 30-item (EORTC QLQ-C30), the EuroQol 5-
dimensional descriptive system (EQ-5D-5L), and Short Form-36 (SF-36).
Secondary endpoints centered around improvements in EORTC QLQ-C30
global health status (GHS), fatigue scale scores, and SF-36 mental
component summary (MCS) score. Exploratory outcomes included physical
function assessment, symptom improvement, functional improvement, and
health utility as measured by the SF-36, EORTC QLQC30 with supplemental
symptom items, and the EQ-5D-5L.
---------------------------------------------------------------------------
\94\ Sanchorawala et al., Health-Related Quality of Life in
Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib,
Cyclophosphamide, and Dexamethasone: Results from the Phase 3
ANDROMEDA Study, Poster presentation at: American Society of
Hematology (ASH) Annual Virtual Meeting; December 5-8, 2020.
---------------------------------------------------------------------------
The applicant stated that the results from this presentation show
that following Cycle 6, improvements in GHS and fatigue were reported
in patients in the treatment group, and that these findings further
support the value of daratumumab SQ plus CyBorD (Dara-CyBorD) in
patients with AL amyloidosis. The applicant also stated that patients
with AL amyloidosis treated with Dara-CyBorD experienced clinical
improvements without any decrement in HRQoL over 6 cycles. The
applicant noted that the findings demonstrated that the median time to
improvement was shorter in the treatment group than in the control
group for EORTC QLQ-C30 GHS (CyBorD: 16.79 months, 95% CI:11.79 to NE,
Dara-CyBorD: 7.82 months, 95% CI: 3.94 to 17.58, HR 1.53; 95% CI: 1.10
to 2.13), fatigue scales (CyBorD: NE, 95% CI:8.44 to NE, Dara-CyBorD:
9.30 months, 95% CI: 5.55 to 13.01, HR 1.39; 95% CI: 1.00 to 1.93) and
EQ-5D-5L visual analog scale (CyBorD: NE, 95% CI:16.79 to NE, Dara-
CyBorD: 10.05 months, 95% CI: 8.41 to NE, HR 1.21; 95% CI: 0.86 to
1.71). The applicant also noted that the findings demonstrated that
median time to worsening was longer in the treatment group than in the
control group for EORTC QLQ-C30 GHS (CyBorD: 2.89 months, 95% CI:2.23
to 3.78, Dara-CyBorD: 4.70 months, 95% CI: 2.83 to 7.36, HR 0.87; 95%
CI: 0.66 to 1.13) and fatigue scales (CyBorD: 3.75 months, 95% CI: 2.86
to 4.76 Dara-CyBorD: 8.84 months, 95% CI: 3.75 to NE, HR 0.78; 95% CI:
0.58 to 1.04) and EQ-5D-5L visual analog scale (CyBorD: 3.38 months,
95% CI:2.79 to 4.67, Dara-CyBorD: 4.14 months, 95% CI: 2.86 to 7.66, HR
0.89; 95% CI: 0.67 to 1.19).\95\
---------------------------------------------------------------------------
\95\ Sanchorawala et al., Health-Related Quality of Life in
Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib,
Cyclophosphamide, and Dexamethasone: Results from the Phase 3
ANDROMEDA Study, Poster presentation at: American Society of
Hematology (ASH) Annual Virtual Meeting; December 5-8, 2020.
---------------------------------------------------------------------------
Finally, the applicant stated that DARZALEX FASPRO[supreg] provides
important advantages to the population with AL amyloidosis because the
subcutaneous administration allows for a negligible volume of
administration and a reduced rate of systemic administration-related
reactions.\96\
---------------------------------------------------------------------------
\96\ Kastritis et al. Daratumumab-Based Treatment for
Immunoglobulin Light-Chain Amyloidosis. NEJM. 2021;385:46-58.
---------------------------------------------------------------------------
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28234 through
28235), after review of the information provided by the applicant, we
stated we had the following concerns regarding whether DARZALEX
FASPRO[supreg] meets the substantial clinical improvement criterion.
First, with respect to the ANDROMEDA trial, we noted that the study's
open label and unblinded design adds a potential risk of bias which may
affect the treatment effect reported by the applicant. Additionally, we
noted that the ANDROMEDA trial used stratified randomization which
resulted in potentially substantive differences between the treatment
and control group at baseline; for example, the control group was
slightly older, with more males, and more people at higher cardiac
stage (based on N-terminal pro-B-type natriuretic peptide and high-
sensitivity cardiac troponin T). The groups also differed by Eastern
Cooperative Oncology Group (ECOG) performance-status scores and
uninvolved free light chain (dFLC) levels, and renal function.
Additionally, compared to control, the daratumumab group appeared to
have higher rates of peripheral sensory neuropathy, upper respiratory
infection, and neutropenia in the longer term data.\97\ We questioned
whether these differences noted at baseline are in fact significant and
would have the potential to impact the treatment effect seen in this
study. In terms of study outcomes, the ANDROMEDA study relied on
hematologic and organ-based laboratory-based outcomes, but we
questioned
[[Page 48936]]
whether a primary endpoint of overall survival would have provided
stronger evidence.
---------------------------------------------------------------------------
\97\ Kastritis E, et al., Subcutaneous Daratumumab +
Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients
with Newly Diagnosed Light Chain (AL) Amyloidosis: Updated Results
from the Phase 3 ANDROMEDA Study, Oral presentation at: American
Society for Oncology (ASCO) Annual Virtual Meeting; June 4-8, 2021 &
Oral presentation at: European Hematology Association (EHA) Annual
Virtual Meeting; June 9-17, 2021.
---------------------------------------------------------------------------
Second, we had concerns about the generalizability of the ANDROMEDA
population and subgroups. As clarified by the applicant during the New
Technology Town Hall meeting, all subjects in the ANDROMEDA trial
received DARZALEX FASPRO[supreg] in the outpatient setting. As such, we
questioned whether the outcomes for this outpatient population are
generalizable to patients who are sufficiently ill to require
hospitalization. In regard to subpopulations, we noted that the
prespecified groups and the studies of cardiac stage and Asian cohorts
exhibit the same potential limitations of the main trial with small
sample size, open-label, and limited follow-up. We noted that small
sample size resulted in wider confidence intervals in some subgroups,
which may limit the generalizability of the treatment results. For
example, in the ANDROMEDA prespecified groups, the subgroups `other'
race, cardiac stage I at baseline, and renal stage III had wider
confidence intervals than other subgroups. Finally, while the applicant
provided a phase 2 poster presentation in support of DARZALEX
FASPRO[supreg] we questioned the extent to which these results are
generalizable to the indication for which the applicant has applied for
the new technology add-on payment (that is, the treatment of adult
patients with light chain (AL) amyloidosis in combination with
bortezomib, cyclophosphamide and dexamethasone in newly diagnosed
patients) given that the indication within this source (that is
monotherapy in patients with Stage 3B AL amyloidosis), does not
match.\98\
---------------------------------------------------------------------------
\98\ Kastritis E, et al., Subcutaneous Daratumumab +
Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients
with Newly Diagnosed Light Chain (AL) Amyloidosis: Updated Results
from the Phase 3 ANDROMEDA Study, Oral presentation at: American
Society for Oncology (ASCO) Annual Virtual Meeting; June 4-8, 2021 &
Oral presentation at: European Hematology Association (EHA) Annual
Virtual Meeting; June 9-17, 2021.
---------------------------------------------------------------------------
We noted that the applicant provided the outcomes of secondary
endpoints which appear to be exploratory or novel for some of the data
presented in posters in support of its claims, such as the quality of
life assessments \99\ and hematologic response as measured by involved
and uninvolved free light chain,\100\ and we noted that some of the
endpoints are still being studied and validated. Specifically, we
questioned whether these surrogate endpoints may be used to
appropriately evaluate the measure for which they are intended to
assess. We requested further information on whether these secondary
endpoints have been appropriately validated in relevant clinical
settings.
---------------------------------------------------------------------------
\99\ Sanchorawala et al., Health-Related Quality of Life in
Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib,
Cyclophosphamide, and Dexamethasone: Results from the Phase 3
ANDROMEDA Study, Poster presentation at: American Society of
Hematology (ASH) Annual Virtual Meeting; December 5-8, 2020.
\100\ Comenzo et al., Reduction in Absolute Involved Free Light
Chain and Difference Between Involved and Uninvolved Free Light
Chain is Associated with Prolonged Major Organ Deterioration
Progression Free survival in Patient with Newly Diagnosed AL
Amyloidosis Receiving Bortezomib, Cyclophosphamide and Dexamethasone
with or without Daratumumab: Results from ANDROMEDA, Oral
presentation at: American Society of Hematology (ASH) Annual Virtual
Meeting; December 5-8, 2020.
---------------------------------------------------------------------------
We invited public comments on whether DARZALEX FASPRO[supreg] meets
the substantial clinical improvement criterion.
Comment: The applicant submitted a comment in response to CMS'
concerns pertaining to substantial clinical improvement. With respect
to our concern that the open label and unblinded study design of the
ANDROMEDA trial may result in a biased treatment effect, the applicant
stated that clinical trials designed to evaluate treatment effects in
patients with AL amyloidosis need to account for the heterogeneity of
the disease, the number of affected organs, including the heart,
kidney, and liver, and the severity of organ involvement. Per the
applicant, in addition to randomization by chance to the experimental
Dara-CyBorD arm or the control CyBorD arm, subjects in the ANDROMEDA
trial were randomized by cardiac stage, by whether transplant was
typically offered, and by renal function. The applicant stated that
efficacy data were adjudicated by an independent review committee whose
members were unaware of the trial-group assignments. The applicant
stated that patients in the control arm were marginally older and that
there were slightly more males than females but that these small
differences are not expected to cause a major difference in outcomes.
The applicant also stated that the slight increase in males in this
study is similar to an analysis of U.S. commercial and Medicare
Supplemental claims data that found the prevalence of AL amyloidosis is
higher in males (approximately 55% male).\101\
---------------------------------------------------------------------------
\101\ Quock et al. Epidemiology of AL amyloidosis: a real-world
study using US claims data. Blood Adv 2018: 2: 1046-1053.
---------------------------------------------------------------------------
The applicant stated that the percentage of subjects in cardiac
stage IIIA was similar in the two treatment arms.\102\ Per the
applicant, neither the slightly higher percentage of subjects with
cardiac stage IIIB (3.1% vs. 1.0%) in the CyBorD arm nor the observed
small differences in the ECOG status and renal status between the two
arms are expected to have a major difference on the final outcomes.
---------------------------------------------------------------------------
\102\ Kastritis et al., NEJM, 2021.
---------------------------------------------------------------------------
With regard to the concern regarding higher peripheral sensory
neuropathy, upper respiratory infection, and neutropenia in longer term
data for the daratumumab group compared to the control group, the
applicant stated that the relative incidence of infections like
pneumonia as well as peripheral sensory neuropathy and neutropenia
should be interpreted in the context of longer treatment exposure for
patients receiving Dara-CyBorD vs. CyBorD. The applicant stated that
when adjusted for exposure to trial treatment, the incidence of overall
and grade 3 or 4 adverse events was lower in the daratumumab group than
in the control group.\103\
---------------------------------------------------------------------------
\103\ Kastritis et al., NEJM, 2021.
---------------------------------------------------------------------------
With regard to the concern regarding hematologic and organ-based
laboratory-based outcomes instead of overall survival, the applicant
stated that primary treatment is targeted toward suppression of amyloid
light chain synthesis in order to improve organ function. The applicant
stated that treatment efficacy is typically determined by hematologic
response and that the current staging systems for AL amyloidosis are
based on circulating markers of cardiac, renal, and B cell clonal
disease and are used for clinical trial design and to determine patient
management. The applicant stated that because clinical presentation and
long-term outcomes depend on adequate organ function, complete response
(CR) does not completely describe the clinical efficacy of treatment in
patients with AL amyloidosis. The applicant stated that organ response
rates can be used but there are limitations with only using these
biomarkers to monitor organ response. The applicant stated that, in
consultation with and with the approval of the FDA, major organ
deterioration-progression free survival (MOD-PFS) and major organ
deterioration-event free survival (MOD-EFS) were chosen as secondary
endpoints and were calculated as a composite endpoint of clinically
observable endpoints. The applicant stated that several clinical
studies have demonstrated that hematologic and organ responses were
[[Page 48937]]
very strong predictors of overall survival.\104\ \105\ \106\
---------------------------------------------------------------------------
\104\ Palladini G et al. Management of AL amyloidosis in 2020.
Blood 2020; 136:2620-2627.
\105\ Palladini et al., J Clin Oncology 2012.
\106\ Comenzo et al. Leukemia 2012.
---------------------------------------------------------------------------
With regard to the concern for generalizability of the study
population in an outpatient setting, the applicant stated that many
factors contribute to whether a patient is treated as an outpatient or
as an inpatient. Per the applicant, patients with similar clinical
status might be treated in the inpatient setting because of the
availability of health care personnel, insurance status, and available
outpatient resources for patient follow-up. The applicant stated that
the ANDROMEDA study was performed in an outpatient setting but there
were patients with cardiac organ involvement that might have been
hospitalized for treatment of cardiac disease and may have also be
receiving treatment for AL amyloidosis, either as initiation of
treatment or a part of a subsequent treatment cycle. The applicant
stated that although the number of inpatient hospitalized individuals
receiving a treatment cycle with Dara-CyBorD is expected to be low, it
is important to ensure health care equity and access to the only FDA
approved drug for treatment of newly diagnosed AL amyloidosis,
regardless of treatment setting.
With regard to the small sample size and large confidence intervals
in subgroup studies, the applicant stated that the variability in
subgroup sizes could lead to wide confidence intervals, especially in
the smaller subgroup sizes. The applicant also stated that there is
strong numerical trend for improved outcomes with similar odds ratios
in the Dara-CyborD arm across all subgroups.
With regard to the concern that the poster presentation did not
match the indication for which the applicant has applied for the new
technology add-on payment, the applicant stated that the use of
daratumumab monotherapy in cardiac stage IIIB is still under
investigation and although related data might be included in supporting
documents, this information should be considered investigational. The
applicant stated that its request for the new technology add-on payment
is limited to the FDA approved indication: treatment of adult patients
with newly diagnosed AL amyloidosis with NYHA or Mayo cardiac stage
IIIA or less in combination with CyBorD.
With regard to our inquiry about the use of exploratory secondary
endpoints in relevant clinical settings, the applicant stated that
information about patient reported outcomes assessing the impact of
treatment on quality of life provides early positive findings
associated with the addition of DARZALEX FASPRO[supreg] to the CyBorD
treatment combination but agreed that the information is preliminary
and additional patient reported outcomes need to be obtained for AL
amyloidosis patients at the time of diagnosis, during follow-up, and as
the disease progresses. The applicant stated that the exploratory
endpoints of iFLC <=20mg/L and dFLC <=10 mg/L also confirm the
consistency of improved results of adding daratumumab to CyBorD.
Finally, the applicant stated that besides the exploratory endpoints,
the ANDROMEDA trial used the established primary endpoint of
hematologic CR and the secondary endpoint of organ response which are
defined in the International Society of Amyloidosis (ISA) guidelines
and have been shown to be very good predictors for overall survival.
We also received an additional comment stating that DARZALEX
FASPRO[supreg] improves progression free survival and organ survival
across staging and that its combination with CyBorD has become standard
of care and frontline treatment for patients with AL amyloidosis. The
commenter further stated that rapidly achieving normalization of
circulating immunogloblin free light chain is critical to offer the
best chances of organ response and survival as time is of the essence
in this disease, and organ response cannot occur in the absence of a
hematologic remission. The commenter stated that adequate reimbursement
will allow healthcare providers to adequately serve this critically ill
patient population in both inpatient and outpatient settings, and will
prevent having to withhold or delay the best possible regimen in the
face of a requirement for an inpatient stay.
Response: We thank the commenters for their comments regarding the
substantial clinical improvement criterion. Based on the additional
information received, we agree that DARZALEX FASPRO[supreg] represents
a substantial clinical improvement over existing technologies for the
treatment of AL amyloidosis patients because it demonstrates improved
clinical outcomes as compared to the standard of care CyBorD, including
a higher rate of hemCR and longer major MOD-PFS.
After consideration of the public comments we received and the
information included in the applicant's new technology add-on payment
application, we have determined that DARZALEX FASPRO[supreg] meets the
criteria for approval for new technology add-on payment. Therefore, we
are approving new technology add-on payments for this technology for FY
2023. Cases involving the use of DARZALEX FASPRO[supreg] that are
eligible for new technology add-on payments will be identified by ICD-
10-PCS code XW01318 (Introduction of daratumumab and hyaluronidase-fihj
into subcutaneous tissue, percutaneous approach, new technology group
8) in combination with ICD-10-CM code E85.81 (Light chain (AL)
amyloidosis).
In its application, the applicant estimated that the cost of
DARZALEX FASPRO[supreg] is $7,937.55 per patient. Under Sec.
412.88(a)(2), we limit new technology add-on payments to the lesser of
65% of the average cost of the technology, or 65% of the costs in
excess of the MS-DRG payment for the case. As a result, the maximum new
technology add-on payment for a case involving the use of DARZALEX
FASPRO[supreg] is $5,159.41 for FY 2023.
c. Hemolung Respiratory Assist System (Hemolung RAS)
ALung Technologies, Inc. submitted an application for new
technology add-on payments for the Hemolung Respiratory Assist System
(Hemolung RAS) for FY 2023. The applicant stated that the Hemolung RAS
is the first and only FDA authorized technology for the treatment of
acute, hypercapnic respiratory failure using an extracorporeal circuit
to remove CO2 directly from the blood. Per the applicant,
patients experiencing acute, hypercapnic respiratory failure are unable
to remove excess CO2 waste molecules from their blood via
their lungs, resulting in accumulation of CO2 in their blood
(hypercapnia), acid/base derangement (respiratory acidosis), and life-
threatening clinical sequelae.\107\ The applicant stated that the
Hemolung RAS does not treat a specific disease but removes
CO2 directly from the blood to treat a variety of underlying
respiratory disease states, including, but not limited to, cystic
fibrosis (CF), chronic obstructive pulmonary disease (COPD), and
asthma, where CO2 retention (hypercapnia) is the primary
cause of continued clinical deterioration.
---------------------------------------------------------------------------
\107\ Nin, N. et al. Severe hypercapnia and outcome of
mechanically ventilated patients with moderate or severe acute
respiratory distress syndrome. Intensive Care Med 43, 200-208
(2017).
---------------------------------------------------------------------------
Per the applicant, the Hemolung RAS provides low-flow, veno-venous
extracorporeal carbon dioxide removal (ECCO2R) using a 15.5
French dual lumen catheter inserted percutaneously in the femoral or
jugular vein, providing
[[Page 48938]]
partial ventilatory lung support independent of the lungs as an
alternative or supplement to invasive mechanical ventilation. The
applicant stated that the Hemolung RAS removes up to 50% of basal
metabolic carbon dioxide (CO2) production at circuit blood
flows of 350-550 mL/min. According to the applicant, the Hemolung RAS
is not intended to provide therapeutic levels of oxygenation. The
applicant stated that during the Hemolung RAS therapy, blood passing
through the circuit is oxygenated; however, at low extracorporeal blood
flows, the limited oxygen-carrying capacity of blood precludes
meaningful oxygenation of mixed venous blood. The applicant explained
that extracorporeal therapy with the Hemolung RAS requires continuous
systemic anticoagulation with unfractionated heparin or a standard of
care alternative to prevent clotting of blood in the circuit.
With respect to the newness criterion, the applicant stated that
the Hemolung RAS received Breakthrough Device Designation from FDA in
2015 specific to COPD patients experiencing acute, refractory,
hypercapnic respiratory failure. The applicant stated it is not
applying under the Breakthrough Device Alternative Pathway in the
current application for new technology add-on payments, as the
Breakthrough Device indication is different from its FDA De Novo
indication. The applicant explained that the Hemolung RAS was
classified as a Class III device and received a Breakthrough Device
designation for COPD only. According to the applicant, on April 22,
2020, the Hemolung RAS received an Emergency Use Authorization (EUA) to
treat lung failure due to COVID-19 when used as an adjunct to
noninvasive or invasive mechanical ventilation in reducing hypercapnia
and hypercapnic acidosis due to COVID-19 and/or maintaining normalized
levels of partial pressure of carbon dioxide (PCO2) and pH
in patients suffering from acute, reversible respiratory failure due to
COVID-19 for whom ventilation of CO2 cannot be adequately,
safely, or tolerably achieved. The applicant further explained Hemolung
RAS was later classified as a Class II device under the De Novo
pathway. The applicant indicated its De Novo classification request
(DEN210006) was granted on November 13, 2021, for the indication of
respiratory support providing extracorporeal carbon dioxide
(CO2) removal from the patient's blood for up to five days
in adults with acute, reversible respiratory failure for whom
ventilation of CO2 cannot be adequately or safely achieved
using other available treatment options and continued clinical
deterioration is expected. According to the applicant, the De Novo
classified Hemolung RAS became available on the market on November 15,
2021, the first business day following the FDA authorization. The
applicant indicated that it is seeking new technology add-on payments
for FY 2023 for the FDA De Novo indication for the treatment of
hypercapnic respiratory failure due to all causes in adults, which
would include the EUA indication for the use of the Hemolung RAS in
patients with respiratory failure caused by COVID-19. The applicant
stated that the following ICD-10-PCS code may be used to uniquely
describe procedures involving the use of the Hemolung RAS: 5A0920Z
(Assistance with respiratory filtration, continuous,
ECCO2R).
As previously discussed, if a technology meets all three of the
substantial similarity criteria under the newness criterion, it would
be considered substantially similar to an existing technology and would
not be considered ``new'' for the purposes of new technology add-on
payments. According to the applicant, patients experiencing acute,
hypercapnic respiratory failure are treated pharmacologically and with
non-invasive ventilatory support as a first line treatment. The
applicant stated that if these treatments are insufficient to support
the failing lungs, escalation of ventilatory support via intubation and
invasive mechanical ventilation (IMV) are the only available treatment
options. According to the applicant, patients who are intubated and
invasively mechanically ventilated are at significant risk for
increased morbidity and mortality. The applicant stated that no
additional treatments are available if IMV is insufficient to correct
refractory hypercapnia and respiratory acidosis, which ultimately lead
to cardiopulmonary collapse and death. Furthermore, the applicant
stated that no treatment options are available for patients who have a
Do Not Intubate (DNI) order.
With respect to the first criterion, whether a product uses the
same or similar mechanism of action to achieve a therapeutic outcome,
the applicant stated that the Hemolung RAS has a different mechanism of
action compared to existing technologies. According to the applicant,
IMV, the only existing technology used to treat acute, refractory,
hypercapnic respiratory failure, utilizes positive airway pressure to
deliver oxygen and remove CO2 from the lungs, whereas the
Hemolung RAS removes CO2 directly from the blood,
independent of the lungs and allowing the lungs to rest and recover.
Thus, the applicant asserted that the Hemolung RAS uses a different
mechanism of action when compared to the existing therapeutic option
(that is, IMV). The applicant also stated that extracorporeal membrane
oxygenation (ECMO) is a rescue therapy for patients experiencing
refractory hypoxemic respiratory failure, where insufficient
oxygenation is the source of the respiratory failure. However, the
applicant stated that ECMO is not suitable, nor FDA-approved, as a
treatment for acute, hypercapnic respiratory failure. Therefore, the
applicant asserted that ECMO and the Hemolung RAS are fundamentally
different technologies used to treat different patient populations.
With respect to the second criterion, whether a product is assigned
to the same or a different MS-DRG when compared to an existing
technology, the applicant stated that the Hemolung RAS is assigned to
the same MS-DRGs when compared to an existing technology. Per the
applicant, the Hemolung RAS is an escalation therapy to be used when
current therapies are unable to support a patient's failing lungs and
continued clinical deterioration is expected. The applicant noted that
MS-DRGs 207 and 208 (Respiratory System Diagnosis with Ventilator
Support >96 Hours and Respiratory System Diagnosis with Ventilator
Support <=96 Hours, respectively) relate to the treatment of
respiratory failure using mechanical ventilation, so the Hemolung RAS
may be assigned to the same MS-DRGs if mechanical ventilation is unable
to safely or adequately remove CO2 from the blood.
With respect to the third criterion, whether the new use of
technology involves the treatment of the same or similar type of
disease and the same or similar patient population when compared to an
existing technology, the applicant stated that the Hemolung RAS and IMV
are both used to treat patients experiencing acute, refractory,
hypercapnic respiratory failure due to numerous disease etiologies and
pathophysiologies. However, the applicant noted that the Hemolung RAS
is indicated for use as an escalation therapy when IMV is unable to
safely or adequately remove CO2 from the blood and continued
clinical deterioration is expected.
In summary, the applicant maintained that the Hemolung RAS is not
substantially similar to currently available therapies and/or
technologies because it uses a new mechanism of
[[Page 48939]]
action and therefore the technology meets the ``newness'' criterion.
We stated in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28236
through 28237) that, as noted previously, the applicant received an FDA
De Novo classification for the device on November 13, 2021 (with the
product becoming commercially available on November 15, 2021), for the
FDA De Novo indication that is the subject of this application, for the
treatment of hypercapnic respiratory failure due to all causes in
adults. This De Novo indication would include use of the product for
the indication for which the applicant initially received an EUA from
FDA, for the use of the Hemolung RAS in patients with respiratory
failure caused by COVID-19. In the FY 2005 IPPS/LTCH PPS final rule, we
stated that the intent of section 1886(d)(5)(K) of the Act and
regulations under Sec. 412.87(b)(2) is to pay for new medical services
and technologies for the first 2 to 3 years that a product comes on the
market, during the period when the costs of the new technology are not
yet fully reflected in the MS-DRG weights (69 FR 49002). While our
policy is, generally, to begin the newness period on the date of FDA
approval or clearance or, if later, the date of availability of the
product on the U.S. market as discussed in prior rulemaking (77 FR
53348), we have noted that data reflecting the costs of products that
have received an EUA could become available as soon as the date of the
EUA issuance and prior to receiving FDA approval or clearance (86 FR
45159). We refer readers to section II.F.7. of the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45159 through 45160), for discussion of our
solicitation of comments regarding the newness period for products
available through an EUA for COVID-19. As discussed in section II.F.4.
of the preamble of this final rule, we are continuing to consider the
comments we received regarding the newness period for products
available through an EUA for COVID-19 as discussed in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45159), and we welcomed additional comments
in the proposed rule.
Therefore, we stated that because data reflecting the costs of the
Hemolung RAS used for the indication of COVID-19 could be available
beginning with the EUA on April 22, 2020, we questioned whether the
newness period for the use of the Hemolung RAS for patients with COVID-
19 should begin with the date of EUA issuance, April 22, 2020, while
the newness period for the use of Hemolung RAS for patients with other
causes of hypercapnic respiratory failure unrelated to COVID-19 should
begin on the date of commercial availability of the De Novo classified
device, November 15, 2021. As discussed in the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45159 through 45160), under the current regulations
at 42 CFR 412.87(e)(2) and consistent with our longstanding policy of
not considering eligibility for new technology add-on payments prior to
a product receiving FDA approval or clearance, a product available only
through an EUA would not be eligible for new technology add-on
payments. Therefore, cases involving pediatric patients, or cases
involving the use of the Hemolung RAS for greater than 5 days, would
not be eligible for new technology add-on payment if the Hemolung RAS
is approved for new technology add-on payment for the patient
population indicated in its FDA De Novo marketing authorization.
We invited public comments on whether the newness period for the
Hemolung RAS when used for patients with COVID-19 should begin on April
22, 2020 (the date of its EUA), when the product became available on
the market for this indication. We also invited public comments on
whether the Hemolung RAS is substantially similar to existing
technologies and whether the Hemolung RAS meets the newness criterion.
Comment: The applicant submitted a public comment regarding the
newness date for the Hemolung RAS. The applicant stated that the
newness period for COVID-19 Hemolung RAS cases should begin on November
15, 2021 (the date of commercial availability of the De Novo classified
device), instead of April 22, 2020 (the date of the Hemolung RAS EUA).
The applicant indicated that it provided the Hemolung RAS to hospitals
free or at cost to swiftly respond to the global pandemic, and that it
did not profit from EUA therapies. The applicant stated that
additionally, during the EUA period, hospitals were not seeking payment
for Hemolung RAS therapy. The applicant stated that, therefore, cost
data collected during the EUA period and prior to FDA clearance do not
accurately reflect the added cost of Hemolung RAS therapy.
Response: We thank the applicant for its comment. We note that, as
discussed in previous rulemaking, the intent of section 1886(d)(5)(K)
of the Act and regulations under Sec. 412.87(b)(2) is to pay for new
medical services and technologies for the first 2 to 3 years that a
product comes on the market, during the period when the costs of the
new technology are not yet fully reflected in the DRG weights. While
the commenter stated that it provided the Hemolung RAS to hospitals
free or at cost, and that hospitals were not seeking payment for the
Hemolung RAS therapy during the EUA period, additional information
regarding whether hospitals charged for use of the Hemolung RAS therapy
between the date of its EUA and the date of commercial availability of
the De Novo classified device, and how it impacts whether use of the
technology may be reflected in the data, would be helpful in
determining that data reflecting the cost of the product did not become
available until the date of commercial availability of the De Novo
classified device. However, we note that regardless of whether we
consider the beginning of the newness period to commence for the use of
the Hemolung RAS for patients with COVID-19 on April 22, 2020 (the date
of its EUA) or November 15, 2021 (the date of commercial availability
of the De Novo classified device), in both cases, the three-year
anniversary date would occur after April 1, 2023, and, therefore, the
technology would be considered new for this indication for FY 2023. As
we discuss elsewhere in this rule, we also recognize that there may be
unique considerations associated with determining the start of the
newness period for a product available under an EUA prior to receiving
FDA approval, and will continue to consider the comments received
regarding the newness period for products available through an EUA for
COVID-19 for future rulemaking. We consider the beginning of the
newness period to commence for the use of the Hemolung RAS for patients
with other causes of hypercapnic respiratory failure unrelated to
COVID-19 on the date of commercial availability of the De Novo
classified device, November 15, 2021. Accordingly, we consider the
Hemolung RAS to be new for FY 2023 for use in patients with both COVID-
19 and hypercapnic respiratory failure unrelated to COVID-19, and
therefore the product meets the newness criterion for all patient
populations indicated in its FDA De Novo marketing authorization.
Based on the information provided in the application for new
technology add-on payments, and after consideration of the public
comments we received, we believe the Hemolung RAS is not substantially
similar to existing treatment options and meets the newness criterion.
With respect to the cost criterion, the applicant presented the
following analysis. The applicant searched the FY 2019 MedPAR Limited
Data Set (LDS) for cases that received ventilator support to identify
patients who may
[[Page 48940]]
have been eligible for the Hemolung RAS. The applicant reviewed
multiple ICD-10-CM and ICD-10-PCS codes related to respiratory failure
and hypercapnic disease and determined that two ICD-10-PCS codes were
most applicable: 5A1955Z (Respiratory ventilation, greater than 96
consecutive hours) and 5A1945Z (Respiratory ventilation, 24-96
consecutive hours). We noted that, in the applicant's analysis, it
listed ICD-10-PCS code 5A1955Z as 5A1935Z (Respiratory ventilation,
greater than 96 consecutive hours), but we believed the applicant
intended to reference the correct ICD-10-PCS code 5A1955Z (Respiratory
ventilation, greater than 96 consecutive hours) to correctly map to MS-
DRG 207 (Respiratory System Diagnosis with Ventilator Support >96
Hours).
The applicant identified 68,317 cases mapping to MS-DRGs 207
(Respiratory System Diagnosis with Ventilator Support >96 Hours) and
208 (Respiratory System Diagnosis with Ventilator Support <= 96 Hours).
MS-DRG 207 contained 24.6% of the cases and MS-DRG 208 contained the
remaining 75.4% of cases.
Next, the applicant removed 100% of the inhalation charges and
charges associated with a 1-day length of stay (LOS) in the ICU. The
applicant explained that it removed the 1 day of routine care plus ICU
day charges based on an assumed LOS reduction associated with the use
of the Hemolung RAS from relevant cases (as compared to cases without
the Hemolung RAS) to estimate the potential decrease in costs as a
result of the use of the Hemolung RAS.\108\ The applicant then
standardized the charges and applied a 4-year inflation factor of
1.281834 or 28.1834%, based on the inflation factor used in the FY 2022
IPPS/LTCH PPS final rule and correction notice to calculate outlier
threshold charges (86 FR 45542). The applicant then added charges for
the new technology, which it calculated by dividing the cost of the
Hemolung RAS by the national average CCR for inhalation therapy, which
is 0.147 (86 FR 44966).
---------------------------------------------------------------------------
\108\ Tiruvoipati, et al., ``Effects of Hypercapnia and
Hypercapnic Acidosis on Hospital Mortality in Mechanically
Ventilated Patients:'' Crit Care Med. Vol 456(7). e649-e656
---------------------------------------------------------------------------
The applicant calculated a final inflated average case-weighted
standardized charge per case of $178,436, which exceeded the average
case-weighted threshold amount of $102,867. Because the final inflated
average case-weighted standardized charge per case exceeded the average
case-weighted threshold amount, the applicant maintained that the
Hemolung RAS meets the cost criterion.
After review of the cost analysis provided by the applicant, we
questioned whether the analysis should have included patients who would
also require a tracheostomy, which could result in cases mapping to the
Pre-Major Diagnostic Category (Pre-MDC) MS-DRGs 003 or 004 if used with
mechanical ventilation, and whether the inclusion of those additional
MS-DRGs would impact the cost analysis. We sought comments on whether
the Hemolung RAS meets the cost criterion.
Comment: The applicant submitted a public comment and updated cost
criterion analysis, which included a subset of cases in MS-DRG 003 and
MS-DRG 004 in response to our concerns. The applicant stated that cases
mapping to these MS-DRGs included non-extracorporeal membrane
oxygenation (ECMO) cases with a tracheostomy, receiving mechanical
ventilation, and with a primary diagnosis code for hypercapnia or
chronic obstructive pulmonary disease (COPD). The applicant followed
the same methodology as its original analysis and stated that even when
including the subset of cases in MS-DRGs 003 and 004, the case-weighted
standardized charges exceed the threshold amount, and the Hemolung RAS
meets the cost criterion.
Response: We appreciate the applicant providing an updated cost
criterion analysis that includes a subset of patients who would also
require a tracheostomy, which resulted in cases mapping to the Pre-
Major Diagnostic Category (Pre-MDC) MS-DRGs 003 or 004 if used with
mechanical ventilation. Based on the information provided by the
applicant, because the final inflated average case-weighted
standardized charge per case exceeded the case-weighted threshold
amount in all scenarios presented by the applicant, we agree with the
applicant that the Hemolung RAS meets the cost criterion.
With regard to the substantial clinical improvement criterion, the
applicant asserted that the Hemolung RAS offers a treatment option for
patients unresponsive to non-invasive mechanical ventilation (NIV),
patients unresponsive to invasive mechanical ventilation (IMV), and
patients ineligible for currently available treatments (that is,
failure of NIV with DNI order). Further, the applicant asserted that
the Hemolung RAS significantly improves clinical outcomes relative to
available services or technologies.
With regard to the claim that the Hemolung RAS offers a treatment
option for patients unresponsive to NIV, the applicant noted that while
acute respiratory failure can often be treated with NIV, which does not
require intubation and is typically safe and well tolerated, 12-50% of
patients are unresponsive to NIV as a result of several factors,
including elevated respiratory rates, uncorrected respiratory acidosis,
and reduced level of consciousness.109 110 111 Further, the
applicant stated that if a patient fails NIV, the only currently
indicated treatment is escalation to IMV; however, per the applicant,
intubation and IMV following NIV failure is associated with a 200%
increase in mortality compared to patients successfully treated with
NIV; 27% vs 9% mortality rate, respectively.\112\
---------------------------------------------------------------------------
\109\ Conti, V. et al. Predictors of outcome for patients with
severe respiratory failure requiring noninvasive mechanical
ventilation. Eur Rev Med Pharmacol Sci 19, 3855-3860 (2015).
\110\ Bott, J. et al. Randomised controlled trial of nasal
ventilation in acute ventilatory failure due to chronic obstructive
airways disease. Lancet 341, 1555-1557 (1993).
\111\ Phua, J., Kong, K., Lee, K.H., Shen, L. & Lim, T.K.
Noninvasive ventilation in hypercapnic acute respiratory failure due
to chronic obstructive pulmonary disease vs. other conditions:
effectiveness and predictors of failure. Intensive Care Med 31, 533-
539 (2005).
\112\ Chandra, D. et al. Outcomes of noninvasive ventilation for
acute exacerbations of chronic obstructive pulmonary disease in the
United States, 1998-2008. Am. J. Respir. Crit. Care Med. 185, 152-
159 (2012).
---------------------------------------------------------------------------
The applicant asserted that the Hemolung RAS can be an effective
tool for patients unresponsive to NIV by rapidly correcting respiratory
acidosis (pH and arterial partial pressure of carbon dioxide
(PaCO2)), thereby reducing respiratory drive and improving
NIV efficacy. In support of this claim, the applicant submitted a
consensus paper by Combes et al.\113\ In this consensus paper, 14
clinical experts in critical care and respiratory support using
ECCO2R convened to determine how ECCO2R therapy
is applied, identify how patients are selected, and discuss how
treatment decisions are made. Per the applicant, the results of the
paper showed that there were two groups of patients where
ECCO2R therapy was indicated--patients with acute
respiratory distress syndrome (ARDS) or patients with COPD. The
treatment goal for ECCO2R therapy in patients with ARDS is
to provide ultra-protective lung ventilation via managing
CO2 levels. The criteria for initiating ECCO2R
therapy in patients with ARDS and on NIV is when there was no decrease
in PaCO2 and no decrease in respiratory rate. In patients
with acute
[[Page 48941]]
COPD exacerbation, treatment targets were patient comfort, pH between
7.30-7.35, respiratory rate less than 20-25 breaths per minute,
decrease of PaCO2 by 10-20%, weaning from NIV, decrease in
bicarbonate levels (HCO3\-\), and maintaining hemodynamic
stability. The clinical experts came to the consensus that
ECCO2R therapy may be an effective support treatment for
adults with ARDS or COPD exacerbation, but noted the need for further
evidence from randomized clinical trials and/or high quality
prospective studies to better guide decision-making.
---------------------------------------------------------------------------
\113\ Combes, A. et al. ECCO2R therapy in the ICU:
consensus of a European round table meeting. Critical Care 24,
(2020).
---------------------------------------------------------------------------
The applicant also submitted three peer-reviewed publications in
support of this claim. First the applicant cited Bonin et al.,\114\ a
case study of a 50-year-old male awaiting a bilateral lung transplant,
admitted for COPD exacerbation caused by infection. The patient was
initially treated with antibiotics and continuous NIV, which he
tolerated for three days. After three days, the patient decompensated
due to a spontaneous pneumothorax. The lung was emergently reinflated,
but the patient's respiratory status continued to decline with a
PaCO2 between 72-85 mmHg, pH of less than 7.3, and a
respiratory rate of 30-40. The patient showed signs of exhaustion but
did not qualify for intubation due to the recent pneumothorax. The
patient consented to the Hemolung RAS therapy and within the first hour
of treatment, the patient's respiratory rate improved to around 10
breaths/minute. However, the patient was no longer able to tolerate the
NIV minimum set breathing rate, so the minimum set breathing rate was
turned off. The PaCO2 decreased to 55-60 mmHg for the
duration of therapy (6 days). The patient was able to be successfully
weaned from continuous NIV. The patient was also able to take oral
nutrition and participate in interventions against pressure sores.
After day 6, the patient was able to wean from the Hemolung RAS support
and continue with intermittent NIV support.
---------------------------------------------------------------------------
\114\ Bonin, F., Sommerwerck, U., Lund, L. & Teschler, H.
Avoidance of intubation during acute exacerbation of chronic
obstructive pulmonary disease for a lung transplant candidate using
extracorporeal carbon dioxide removal with the Hemolung. The Journal
of Thoracic and Cardiovascular Surgery 145, e43-e44 (2013).
---------------------------------------------------------------------------
Second, the applicant cited a multi-national pilot study done by
Burki et al.\115\ in India and Germany. There were 20 COPD patients
with hypercapnic respiratory failure treated with ECCO2R therapy and
placed into 1 of 3 groups. Group 1 had seven patients on NIV with a
high likelihood of requiring IMV; Group 2 had two patients who could
not be weaned from NIV; and Group 3 had 11 patients on IMV who failed
weaning attempts. The authors found that the device was well-tolerated
with complications and rates similar to those seen with central venous
catheterization. The patients in Group 1 successfully avoided IMV as a
result of ECCO2R therapy, although three patients died
within 30 days of ECCO2R therapy due to underlying disease
states. The patients in Group 2 were successfully weaned from
continuous NIV after receiving ECCO2R therapy and were alive
30 days after ECCO2R therapy, but remained on intermittent
non-invasive, positive-pressure ventilation (NIPPV) support. Of the
patients in Group 3, nine of the 11 patients had been on IMV for
greater than 15 days prior to ECCO2R therapy. In Group 3,
three patients were weaned from IMV, three patients had decreased IMV
support, one patient expired from retroperitoneal bleed following
catheterization, and one patient remained on the same level of
ventilatory support despite receiving ECCO2R therapy. The
authors concluded that the single catheter, low-flow ECCO2R
system, provided clinically useful levels of CO2 removal in
patients with COPD and could be a potentially valuable addition to the
treatment of hypercapnic respiratory failure.
---------------------------------------------------------------------------
\115\ Burki, N. et al. A novel extracorporeal CO2
removal system: Results of a pilot study of hypercapnic respiratory
failure in patients with COPD. Chest 143, 678-686 (2013).
---------------------------------------------------------------------------
Third, the applicant cited a case series by Tiruvoipati et al.
(2016),\116\ which retrospectively reviewed 15 patients among three
Australian ICUs treated with the Hemolung RAS who had severe
hypercapnic respiratory failure due to COPD, ARDS, asthma, or
bronchiolitis obliterans syndrome (BOS), to show that ECCO2R
was safe and effective in the removal of CO2. For five
patients (four with COPD and one with BOS), the indication for the
Hemolung RAS was to avoid intubation, whereas for the other 10 patients
(five with acute lung injury/ARDS, three with asthma, and two with
COPD), the indication was to institute lung-protective ventilation. The
median age of the patients was 61.5 years; 12 patients were men, the
median Acute Physiology and Chronic Health Evaluation III (APACHE III)
score was 85, and the median duration of ECCO2R was 5 days.
The primary outcome measures of the study were clearance of
CO2 and change in pH with the use of ECCO2R.
Secondary outcome measures included complications associated with
Hemolung RAS use, survival to weaning from the Hemolung RAS, and
survival to ICU and hospital discharge. There was no specified protocol
for managing mechanical ventilation across the three centers; however,
all centers used low-pressure ventilation for ARDS. For asthma, the
mechanical ventilation was characterized by low tidal volume, low
respiratory rate, and short inspiratory time associated with prolonged
expiratory time to avoid dynamic hyperinflation. Four of the five
patients treated for this indication, as well as all 10 patients who
were treated to institute lung-protective ventilation, avoided
intubation; successful lung-protective ventilation was achieved by a
reduction in peak inspiratory pressure, tidal volume, and minute
ventilation. The clearance of CO2 and return of
PaCO2 to near-normal levels was achieved within 6 hours, and
there was significant reduction in minute ventilation and peak airway
pressures. Complications reported during the study included hemorrhage,
thrombocytopenia, and compartment syndrome, none of which required
cessation of the Hemolung RAS therapy. Overall, 93.3% of the patients
survived to discontinuation of ECCO2R, 73.3% of patients
survived to ICU discharge, and 66.66% of patients survived to hospital
discharge. In conclusion, the study authors stated that the Hemolung
RAS appears to be safe and effective for managing hypercapnic
respiratory failure of various etiologies, but noted that more research
is needed to clarify which patients may benefit most from this therapy.
---------------------------------------------------------------------------
\116\ Tiruvoipati, R. et al. Early experience of a new
extracorporeal carbon dioxide removal device for acute hypercapnic
respiratory failure. Crit Care Resusc 18, 261-269 (2016).
---------------------------------------------------------------------------
In addition to the previous peer-reviewed studies, the applicant
also cited the Hemolung RAS Registry Program Analysis in support of its
claim.\117\ Per the applicant, the voluntary Hemolung RAS Registry
Program collected data from commercial use of the Hemolung RAS outside
of the US as well as US EUA therapies. 176 patients from the Hemolung
RAS Registry were analyzed to evaluate the benefits and safety of the
Hemolung RAS therapy. The applicant stated that the Hemolung RAS
Registry Program Analysis demonstrated that 86% (19/22) of patients
failing NIV avoided
[[Page 48942]]
intubation due to the Hemolung RAS therapy.
---------------------------------------------------------------------------
\117\ Alung, Inc., HL-CA-1600, Hemolung RAS Registry. A
Retrospective Registry Involving Voluntary Reporting of De-
identified, Standard of Care Data Following the Commercial Use of
the Hemolung Respiratory Assist System (RAS). ClinicalTrials.gov.
Retrieved December 21, 2021, from Hemolung RAS Registry Program--
Full Text View--ClinicalTrials.gov.
---------------------------------------------------------------------------
With respect to the applicant's assertion that the Hemolung RAS
offers a treatment option for patients unresponsive to IMV and are
retaining CO2, the applicant stated that the Hemolung RAS
de-couples CO2 removal from the mechanical ventilator
thereby allowing correction of hypercapnia and hypercapnic acidosis
without a dangerous escalation of ventilator settings. The applicant
provided 10 publications that document the use of the Hemolung RAS in
patients unresponsive to IMV to significantly reduce ventilator
settings to lung safe levels or to significantly correct and control
hypercapnic acidosis, including Tiruvoipati et al. (2016) \118\ and
Combes et al.,\119\ discussed previously.
---------------------------------------------------------------------------
\118\ Tiruvoipati, R. et al. Early experience of a new
extracorporeal carbon dioxide removal device for acute hypercapnic
respiratory failure. Crit Care Resusc 18, 261-269 (2016).
\119\ Combes, A. et al. ECCO2R therapy in the ICU:
consensus of a European round table meeting. Critical Care 24,
(2020).
---------------------------------------------------------------------------
In the first case study, a 44-year-old male with acute asthma
exacerbation went into respiratory arrest and was intubated in the
emergency department (ED).\120\ The patient was found to have a left
tension pneumothorax, which was decompressed, and then developed a
second tension pneumothorax on the right side, which was also
decompressed. The patient was transferred to the ICU for further
management. The patient continued to deteriorate over the subsequent 48
hours due to subcutaneous emphysema and ongoing air leaks, and after 72
hours had uncontrollable hypercapnia (PaCO2 73, pH 7.22)
despite optimal medical management with corticosteroids, nebulized and
intravenous bronchodilators, magnesium, ketamine, and muscle relaxants.
ECCO2R was indicated for hypercapnia and to facilitate de-
escalation of IMV. After initiating ECCO2R, it was possible
to decrease the support on the IMV while maintaining satisfactory gas
exchange and allowing the withdrawal of muscle relaxants. Within 1 hour
of initiation of ECCO2R, the pH improved from 7.22 to 7.28,
and the PaCO2 went from 68.1 to 60.6. The patient remained
on ECCO2R for a total of 7 days mainly due to ongoing air
leaks from three chest drains and a bleeding complication that was
managed with transfusion. After discontinuing ECCO2R
therapy, the patient received a tracheostomy to assist in weaning from
IMV. The patient was successfully weaned from IMV after 23 days in the
ICU and was ultimately discharged home. The authors discussed that
while this patient could have been treated with ECMO, the use of ECMO
is limited to specialized centers and requires a multidisciplinary
approach for a successful outcome.
---------------------------------------------------------------------------
\120\ Tiruvoipati R., et al. Low-flow veno-venous extracorporeal
carbon dioxide removal in the management of severe status
asthmatics: a case report. Clin Respir J. 2014;10(5):653-656.
---------------------------------------------------------------------------
In the second case study, the Hemolung RAS system was used to treat
hypercapnia in a 58-year-old male patient with an out-of-hospital
cardiac arrest where mechanical ventilation failed to achieve
normocapnia.\121\ The patient was intubated in the ED and treated with
nebulized bronchodilators, corticosteroids, and therapeutic
hypothermia. Initially, the PaCO2 was 82 mmHg (baseline 50
mmHg) with a pH of 7.20, but as the next few hours progressed, the
patient became more difficult to ventilate and the PaCO2
increased to 94 mmHg. ECCO2R therapy was indicated to
prevent lung injury and secondary brain injury. After initiating the
Hemolung RAS, the minute ventilation and the respiratory rate could be
decreased and the team was able to optimize the inspiratory and
expiratory time ration to minimize the risk of barotrauma. The patient
was on the Hemolung RAS therapy for 3 days and was able to de-escalate
the ventilator settings, but still required mechanical ventilation.
After cessation of the Hemolung RAS therapy, the patient started to
show signs of significant hypoxic brain injury. Despite maximal medical
treatment, the neurological prognosis was considered to be very poor,
and all life-sustaining therapies were withdrawn. The authors stated
that ECCO2R therapy is safe to use in a metropolitan
hospital where the staff have a limited period of education, and that
the extracorporeal therapy was delivered without complications. The
authors also stated that ECMO is not an option in every health care
center since it requires a specialized team including cardiac surgeons
and perfusionists and is costly. The authors stated that
ECCO2R is less invasive and able to provide partial
respiratory support. Thus, the authors concluded that ECCO2R
may have a role in patients with severe respiratory failure when IMV
alone is inadequate and in centers that are not capable of initiating
ECMO in the management of severe hypercapnic respiratory failure.
---------------------------------------------------------------------------
\121\ Tiruvoipati R., et al. Management of severe hypercapnia
post cardiac arrest with extracorporeal carbon dioxide removal.
Anaesth Intensive Care. 2014;42(2):248-252.
---------------------------------------------------------------------------
Next, the applicant cited a United Kingdom case study about a 48-
year-old male presenting to the ED with 7 days of cough, fever, and
shortness of breath.\122\ He tested positive for COVID-19 via
respiratory viral swab and had a chest x-ray demonstrating bilateral
infiltrates. He initially required supplemental oxygen via facemask and
oral doxycycline to treat possible bacterial co-infection. He continued
to deteriorate, was trialed on NIV and failed, and was then
transitioned to IMV on day four of the hospitalization and transferred
to the ICU for further management. The patient continued to deteriorate
and within a week and was found to be in ARDS due to COVID-19
pneumonitis. The patient was treated with several strategies for lung
recruitment, and was referred to ECMO but was declined on the basis of
futility. The treatment team believed that continuing to treat the
patient with high airway pressure was contributing to the progression
of the ARDS, so the Hemolung RAS was initiated as a rescue therapy.
After initiation, the PaCO2 and pH improved, which allowed
the treatment team to reduce the tidal volume and respiratory rate. The
patient spent 6 days on the Hemolung RAS without bleeding events or
vasopressors and could continue to receive prone position ventilation
without complication. The patient was successfully weaned from the
Hemolung RAS and then completed a slow respiratory wean followed by a
percutaneous tracheostomy. The patient was ultimately discharged from
the ICU to home with mobility and cognition intact. The authors
concluded that ECCO2R can be used as a rescue therapy for
patients with hypercapnic respiratory failure resulting from ARDS in
COVID-19 pneumonitis and to facilitate lung protective ventilation in
patients on IMV. According to the authors, refractory hypercapnia is an
acceptable indication for ECMO in ARDS and that ECCO2R can
be considered as rescue therapy if ECMO is deemed inappropriate or
cannot be delivered due to resource constraints. Per the authors,
potential advantages of using ECCO2R over ECMO include lack
of requirement for transfer to an ECMO center, smaller catheter size,
and lower blood flow rate which may reduce the likelihood of
complications.
---------------------------------------------------------------------------
\122\ Tully R.P., et al. The successful use of extracorporeal
carbon dioxide removal as a rescue therapy in a patient with severe
COVID-19 pneumonitis. Anaesthesia Reports 2020; 8:113-115.
---------------------------------------------------------------------------
The applicant also cited a case study of an 18-year-old male with
solitary mediastinal metastasis and ARDS, in which the Hemolung RAS was
used to facilitate de-escalation of mechanical
[[Page 48943]]
ventilation.\123\ Post-treatment with chemotherapy, a residual
mediastinal mass was found with extension to the left lung hilum. The
patient underwent lung resection and was extubated postoperatively
without issue. The patient became febrile and developed a progressively
extensive right lung infiltrate. On postoperative day five, the patient
developed severe hypercapnia, hypoxemia, and hypotension, necessitating
re-intubation and invasive mechanical ventilation. The Hemolung RAS was
initiated to provide ECCO2R. Arterial PCO2
decreased from 73 to 53 mmHg within 4 hours (with a concomitant pH
increase from 7.28 to 7.44), permitting tidal volume reduction to 3.5
mL/kg, and plateau airway pressure to 25 cm H2O, with simultaneous
hemodynamic improvement. ECCO2R was titrated to maintain an
arterial PCO2 between 45 and 50 mmHg, and the patient was
weaned and decannulated after 71 hours of support. The patient was
removed from mechanical ventilation within 24 hours and then
transferred to an intermediate care unit. No ECCO2R-related
complications were observed. The authors stated the Hemolung RAS has a
conceptual advantage over ECMO as the Hemolung RAS uses one small dual-
lumen venous catheter, without additional arterial access and its
attendant risks. The authors concluded that in appropriately selected
patients, a minimally invasive ECCO2R approach may be
useful.
---------------------------------------------------------------------------
\123\ Akkanti B., et al. Low-flow extracorporeal carbon dioxide
removal using the Hemolung Respiratory Dialysis System[supreg] to
facilitate lung-protective mechanical ventilation in acute
respiratory distress syndrome. J Extra Corpor Technol.
2017;49(2):112-114.
---------------------------------------------------------------------------
Next, the applicant cited a case study by Saavedra-Romero et
al.,\124\ which describes the use of ECCO2R immediately
administered with lung-protective mechanical ventilation on a patient
with COVID-19 ARDS in her mid-60s. The authors stated that, upon
arrival to the ICU, on inpatient day 5, the patient's oxygen saturation
by pulse oximeter (SpO2) was 77%, blood pressure (BP) 90/40
on norepinephrine at 10[thinsp]mcg/min, and the patient's initial
arterial blood gas (ABG) results were pH = 7.14, PaCO2 = 90
mmHg, PaO2 = 52 mmHg, and HCO3 = 30 mEq/L. The
patient had significant whole-body subcutaneous crepitus, and the chest
x-ray (CXR) showed an inflated right lung, subcutaneous emphysema, and
an appropriately positioned endotracheal tube (ETT). The patient became
increasingly tachycardic and tachypneic due to further worsening of
hypercapnia and respiratory acidosis. ECCO2R was initiated
using the Hemolung RAS and was administered for 17 days without
complications. Ventilator settings were maintained at PEEP of 14, rate
of 26, and minute ventilation at 7.8 liters during the first 24 hours.
Respiratory rate and tidal volumes were subsequently titrated downward,
maintaining adequate oxygen levels and permissive hypercapnia. The
patient's chest tubes were removed 4 days after the Hemolung RAS
decannulation, and the patient was weaned from mechanical ventilation
28 days from ICU admission, and discharged 47 days after admission. The
authors stated that this case report highlights the use of
ECCO2R to facilitate effective treatment of a patient with
severe hypercapnic respiratory failure secondary to COVID-19 ARDS and
multiple risk factors for death. The authors stated that treatment with
ECCO2R allowed a lung-protective ventilator management
strategy with ultralow tidal volumes, minimizing the risk of
ventilator-induced lung injury, attenuating severe hypercapnia and
acidosis, and limiting the expansion of an existing pneumothorax. The
authors concluded that ECCO2R facilitates early lung-
protective ventilation and control of refractory hypercapnia and can be
safely utilized to increase the likelihood of survival among patients
with severe COVID-19 ARDS.
---------------------------------------------------------------------------
\124\ Saavedra-Romero R., et al. Treatment of Severe Hypercapnic
Respiratory Failure Caused by SARS-CoV-2 Lung Injury with
ECCO2R Using the Hemolung Respiratory Assist System. Case
Reports in Critical Care 2021; 1-5.
---------------------------------------------------------------------------
Finally, the applicant cited a case study by Bermudez et al.,\125\
in which a 33-year-old male with cystic fibrosis (CF), post double lung
transplantation who developed severe hypercarbic respiratory failure
due to adenovirus pneumonia requiring hospitalization, tracheostomy,
and prolonged IMV for greater than 30 days. The patient was transferred
to a tertiary care center and was treated with the Hemolung RAS because
of persistent hypoxemia and hypercarbia. The patient was not a
candidate for ECMO because of frail clinical condition, volume
overload, and need for a redo lung transplantation. After 4 days of the
Hemolung RAS support, the patient was weaned from vasopressors, and
after 9 days, the patient was accepted as a candidate for redo lung
transplantation because of considerable clinical improvement.
---------------------------------------------------------------------------
\125\ Bermudez, et al. ``Prolonged Use of the Hemolung
Respiratory Assist System as a Bridge to Redo Lung Transplantation''
Annals of Thorac Surg. 2015 Vol 100 (6). P. 2330-2333.
---------------------------------------------------------------------------
Lastly, the applicant provided a retrospective, multicenter study
of 31 patients placed on the Hemolung RAS at 8 sites across the
U.S.\126\ The cohort was comprised of patients with COVID-19 who were
mechanically ventilated with severe hypercapnia and respiratory
acidosis and treated with low-flow extracorporeal CO2
removal treated between March 4 and September 30, 2020. Two patients
underwent cannulation but were never started on therapy due to a
vascular access failure in one patient and immediate circuit clotting
in the other. For the 29 patients who received the Hemolung RAS
treatment, analysis of covariance revealed a significant improvement
trend in both pH and PaCO2 (p < 0.0001). Comparison of time
intervals yielded a statistically significant improvement in pH (7.24
0.12 to 7.35 0.07; p < 0.0001) and decrease
in PCO2 (79 23 to 58 14; p <
0.0001) from baseline to 24 hours after start of therapy. There were
numerical, but not significant, decreases from baseline to 24 hours in
respiratory rate (26.6 5.4 to 23.4 4.9),
tidal volume (407 100 to 386 75[thinsp]mL),
and minute ventilation (10.2 3.2 to 8.7
2.2[thinsp]L/min). The authors indicated that this is the first
reported use of ECCO2R in the U.S. for this patient
population. The authors reported that limitations of the study are its
small size and single-cohort retrospective nature. The applicant stated
that the study results demonstrated the efficacy of ECCO2R
using the Hemolung RAS to improve respiratory acidosis in patients with
severe hypercapnic respiratory failure due to COVID-19.
---------------------------------------------------------------------------
\126\ Akkanti B., et al. Physiologic Improvement in Respiratory
Acidosis Using Extracorporeal CO2 Removal With Hemolung
Respiratory Assist System in the Management of Severe Respiratory
Failure From Coronavirus Disease 2019. Critical Care Explorations.
2021;3:e0372.
---------------------------------------------------------------------------
In addition to the case reports and retrospective study, the
applicant also cited to the Hemolung RAS Registry Program Analysis,
discussed previously, in support of its claim.\127\ The applicant
stated that the Hemolung RAS Registry Program Analysis demonstrated
clinically and statistically significant correction of pH and
PaCO2 within the first day of the Hemolung RAS therapy
(p<0.05).\128\ Additionally, the applicant noted that the statistical
analysis showed this correction in pH and PaCO2
[[Page 48944]]
was independent of the patient's primary diagnosis.
---------------------------------------------------------------------------
\127\ Alung, Inc., HL-CA-1600, Hemolung RAS Registry. A
Retrospective Registry Involving Voluntary Reporting of De-
identified, Standard of Care Data Following the Commercial Use of
the Hemolung Respiratory Assist System (RAS). ClinicalTrials.gov.
Retrieved December 21, 2021, from Hemolung RAS Registry Program--
Full Text View--ClinicalTrials.gov.
\128\ Ibid. ClinicalTrials.gov. Retrieved December 21, 2021,
from Hemolung RAS Registry Program--Full Text View--
ClinicalTrials.gov.
---------------------------------------------------------------------------
With respect to the applicant's assertion that the Hemolung RAS
offers a treatment option for patients ineligible for currently
available treatments (for example, patients with a DNI order), the
applicant reiterated that intubation with IMV is the only currently
available treatment option for patients failing NIV; however, the
applicant indicated that these patients have no other therapeutic
options if they were to fail NIV because of their preference to not be
intubated. According to the applicant, the CO2 removal by
the Hemolung RAS would rapidly correct the pH and PaCO2
which would reduce the respiratory drive and improve NIV efficacy and
prevent continued clinical deterioration.129 130
---------------------------------------------------------------------------
\129\ Burki, N. et al. A novel extracorporeal CO2
removal system: Results of a pilot study of hypercapnic respiratory
failure in patients with COPD. Chest 143, 678-686 (2013).
\130\ Tiruvoipati, R. et al. Early experience of a new
extracorporeal carbon dioxide removal device for acute hypercapnic
respiratory failure. Crit Care Resusc 18, 261-269 (2016).
---------------------------------------------------------------------------
The applicant submitted three peer-reviewed case reports that have
documented the use of the Hemolung RAS in patients failing NIV with a
DNI order. In the first case study done in Germany,\131\ a 72-year-old
female with a past medical history of severe COPD (GOLD 4, nocturnal
home ventilation therapy) with a DNI order presented to an ED in a
hypercapnic coma. The patient had a Glasgow Coma Score of 3, pH of
6.97, and PaCO2 greater than 150 mmHg. The patient was
hemodynamically stable on NIV with a respiratory rate of 28, oxygen
saturation of 88% on supplemental oxygen with an inspired fraction
(FiO2) of 30%. After 30 minutes of NIV treatment, the
patient's PaCO2 improved, but the patient was nearly
unconscious and was transferred to the ICU. Because of the high
predictive mortality for patients with severe COPD who fail NIV and
require intubation and invasive mechanical ventilation, combined with
the patient's DNI order, the Hemolung RAS was initiated to supplement
treatment. Within the first hour of treatment with both NIV and
Hemolung RAS, the PaCO2 levels continued to decrease from
109 mmHg to 89 mmHg and the patient's level of consciousness improved
after about 25 minutes. Ultimately, the patient was able to start oral
nutrition, communicate, and start mobilizing early because of her
improved mental state within four hours of starting the Hemolung RAS
and was discharged to rehabilitation.
---------------------------------------------------------------------------
\131\ Engel, M., Albrecht, H. & Volz, S. Use of Extracorporeal
CO2 Removal to Avoid Invasive Mechanical Ventilation in
Hypercapnic Coma and Failure of Noninvasive Ventilation. J Pulm
Respir Med 6, 1-3 (2016).
---------------------------------------------------------------------------
The second case study by Mani et al. described two patients with
severe COPD admitted to the ICU with an acute COPD exacerbation
requiring NIV, but failed NIV treatments.\132\ A 69-year-old female in
India was admitted with acute COPD exacerbation, waning consciousness
and a pH of 7.20 and PaCO2 of 101 mmHg. After starting NIV
for 2 hours, the PaCO2 had risen to 105 mmHg and pH had
dropped to 7.193. After 1 hour of the Hemolung RAS treatment and NIV,
the PaCO2 declined to 93 mmHg with a pH 7.25. After 6 hours
of treatment with the Hemolung RAS and NIV, the patient was awake with
a PaCO2 of 68 mmHg and a pH of 7.35. Ultimately, she was
discharged to home on home oxygen and nocturnal NIV. There was also a
report of a 78-year-old male with COPD and other comorbidities who had
a DNI order in Germany. He was admitted with an acute COPD exacerbation
and treated with NIV after his initial arterial blood gas (ABG) showed
PaCO2 92 mmHg and pH of 7.24. After treatment with both the
Hemolung RAS and NIV for 1 hour, the patient's PaCO2 dropped
to 68 mmHg and pH 7.33. Ultimately, the patient was discharged to home
on nocturnal NIV. Both patients were both diagnosed with
thrombocytopenia as a known complication of extracorporeal therapy, but
neither required transfusion.
---------------------------------------------------------------------------
\132\ Mani, R.K., Schmidt, W., Lund, L.W. & Herth, F.J.F.
Respiratory dialysis for avoidance of intubation in acute
exacerbation of COPD. ASAIO J 59, 675-678 (2013).
---------------------------------------------------------------------------
The applicant submitted a third case study in which Cole et al.
describe a 62-year-old female with past medical history of COPD (GOLD
class 3) and 2 recent hospitalizations for COPD exacerbations in the
past 60 days.\133\ The patient had hypercapnic respiratory failure for
which she did not want to be intubated, so she was started on NIV. She
initially improved, but by day four of NIV treatment, she deteriorated,
as evidenced by tachypnea and fatigue due to increased work of
breathing. She was started on the Hemolung RAS and within two hours
therapy with the Hemolung RAS alone (patient requested to stop NIV with
the initiation of the Hemolung RAS), the patient's respiratory rate
improved. Within 6 hours, the patient was able to converse and fully
engage with her treatment. Ultimately the patient was discharged to
home at her baseline activity level and did not require home oxygen
therapy, and was not readmitted to hospital within 30 days of
discharge.
---------------------------------------------------------------------------
\133\ Cole, S. et al. Extracorporeal carbon dioxide removal as
an alternative to endotracheal intubation for noninvasive
ventilation failure in acute exacerbation of COPD. J Int Care Soc
15, 344-346 (2014).
---------------------------------------------------------------------------
Furthermore, the applicant claimed that the Hemolung RAS
significantly improves clinical outcomes relative to services or
technologies previously available by mitigating the harmful clinical
sequelae from hypercapnic acidosis and facilitates de-escalation of
high pressure and high volume ventilatory support or prevent
intubation, both of which are known predictors for poor clinical
outcomes. Thus, per the applicant, the correction of hypercapnia and
hypercapnic acidosis (that is, pH and PaCO2) are appropriate
surrogate markers for improved clinical outcomes in critically ill,
mechanically ventilated patients. Per the applicant, the use of
correction of hypercapnia and hypercapnic acidosis as surrogate markers
for improved clinical outcomes was accepted by FDA as evidence of the
clinical benefit of the Hemolung RAS as part of FDA's clearance of its
De Novo request.
The applicant asserted that the pH and PaCO2 correction
due to the Hemolung RAS therapy provide the following six improved
outcomes: (1) reduced mortality in intubated and IMV patients; (2)
reduced length of stay in IMV patients; (3) de-escalation of mechanical
ventilation settings (decreased rate of subsequent diagnostic or
therapeutic interventions); (4) avoidance of intubation following NIV
failure; (5) reduced mortality in NIV patients; and (6) improvement in
activities of daily living/quality of life.
In support of its assertion that the Hemolung RAS reduces mortality
in intubated and IMV patients, the applicant cited two background
studies.134 135 In the study by Nin et al., the authors
completed a secondary analysis of 3 prospective, non-interventional
cohort studies in 1,899 patients with ARDS among 40 ICUs. The goal of
the study was to determine the relationship between severe hypercapnia
(PaO2 >=50 mmHg) in the first 48 hours following onset of
ARDS and mortality. The applicant stated that the study results
demonstrate that severe hypercapnia in IMV patients was independently
associated with increased risk of ICU mortality (odds
[[Page 48945]]
ratio: 1.93, 95% CI: 1.32-2.81, p = 0.001). The second study by
Tiruvoipati et al. (2017), was a multicenter, binational, retrospective
study that included 252,812 patients of 3 cohorts: normocapnia and
normal pH (n = 110,104), compensated hypercapnia (n = 20,463), and
hypercapnic acidosis (n = 122,245), that aimed to determine the
relationship between these states and Acute Physiology and Chronic
Health Evaluation (APACHE) III score and mortality. The study found
that those with compensated hypercapnia and hypercapnic acidosis had
higher APACHE III scores (49.2 vs. 53.2 vs. 68.6, p<0.01); mortality
was highest in the hypercapnic acidosis patients (OR: 1.18, 95% CI:
1.1-1.25) and lowest in the normocapnia and normal pH, p < 0.001. The
applicant stated that the adjusted odds ratio for hospital mortality
remained significantly higher in compensated hypercapnia and
hypercapnic acidosis when compared with patients with normocapnia and
normal pH irrespective of their P/F ratios.
---------------------------------------------------------------------------
\134\ Nin, et al., ``Severe hypercapnia and outcome of
mechanically ventilated patients with moderate or severe acute
respiratory distress syndrome'' Intensive Care Med. 2017. p. 200--
208.
\135\ Tiruvoipati, et al., ``Effects of Hypercapnia and
Hypercapnic Acidosis on Hospital Mortality in Mechanically
Ventilated Patients'' Crit Care Med. 2017. Vol 456(7). e649-e656.
---------------------------------------------------------------------------
In support of the applicant's second assertion that use of the
Hemolung RAS contributes to reduced LOS in IMV patients, the applicant
cited Tiruvoipati et al. (2017), previously discussed.\136\ The median
hospital LOS was 10.5 days in the normocapnia and normal pH group, 12
days in the compensated hypercapnia group and 11 days in the
hypercapnic acidosis group (p<0.001). The median ICU LOS was 1.9 days
vs 2.2 days vs. 2.9 days in the normocapnia/normal pH group vs.
compensated hypercapnia group vs. the hypercapnic acidosis group,
respectively (p<0.001). The authors noted that that there was increased
mortality in patients with hypercapnic acidosis and compensated
hypercapnia with unclear cause.
---------------------------------------------------------------------------
\136\ Ibid.
---------------------------------------------------------------------------
In support of the applicant's assertion that use of the Hemolung
RAS results in de-escalation of mechanical ventilation settings and
decreased rate of subsequent diagnostic or therapeutic interventions,
the applicant cited the Tully et al. case report,\137\ discussed
previously, in which intubated patients had a 20% decrease in peak
airways pressure and 30% decrease in driving pressure during the
Hemolung RAS therapy. The applicant also cited the Tiruvoipati et al.
(2016) study, discussed previously, in which 10 patients showed a 19%
decrease in peak respiratory pressure and a 26% decrease in minute
ventilation within 1 day of the Hemolung RAS therapy.\138\ The
applicant also cited the Hemolung RAS Registry Program Analysis,\139\
which demonstrated statistically significant correction of pH and
PaCO2 within the first day of the Hemolung RAS therapy
(p<0.05).
---------------------------------------------------------------------------
\137\ Tully R.P., et al. The successful use of extracorporeal
carbon dioxide removal as a rescue therapy in a patient with severe
COVID-19 pneumonitis. Anaesthesia Reports 2020; 8:113-115.
\138\ Tiruvoipati, R., et al. Effects of Hypercapnia and
Hypercapnic Acidosis on Hospital Mortality in Mechanically
Ventilated Patients*: Critical Care Medicine. 2017;45(7):e649-e656.
\139\ Alung, Inc., HL-CA-1600, Hemolung RAS Registry. A
Retrospective Registry Involving Voluntary Reporting of De-
identified, Standard of Care Data Following the Commercial Use of
the Hemolung Respiratory Assist System (RAS). ClinicalTrials.gov.
Retrieved December 21, 2021, from Hemolung RAS Registry Program--
Full Text View--ClinicalTrials.gov.
---------------------------------------------------------------------------
In support of its assertion that use of the Hemolung RAS
contributes to avoidance of intubation following NIV failure, the
applicant noted that respiratory acidosis is the primary determinant of
NIV failure citing risk charts using a background study from
Confalonieri et al.,\140\ in which data from 1,033 patients admitted to
experienced hospital units was used to predict the likelihood of
failure of noninvasive positive pressure ventilation (NPPV). The
prediction charts were calculated using the APACHE II, GCS, pH, and
respiratory rate data of 1,033 patients admitted with acute respiratory
failure due to exacerbation of COPD treated with NIV. The applicant
stated that the study results show that pH <7.25 (acidosis) after 2
hours of NIV is the primary determinant of NIV failure [odds ratio:
21.02; 95% CI: 10.07-43.87], and that additionally, a pH between 7.25
and 7.29 (acidosis) after 2 hours of NIV is also significant predictor
of NIV failure [odds ratio:2.92; 95% CI: 1.62-5.28]. The applicant
stated that accuracy and generalizability of the model's ability to
predict NIV failure was validated on an independent group of 145 COPD
patients treated with NIV.
---------------------------------------------------------------------------
\140\ Confalonieri M., et al. A chart of failure risk for
noninvasive ventilation in patients with COPD exacerbation. European
Respiratory Journal. 2005;25(2):348-355.
---------------------------------------------------------------------------
In a prospective, single-arm feasibility study, Burki et al.,
previously discussed, stated that 100% (7/7) patients failing NIV and
treated with the Hemolung RAS therapy avoided intubation and 100% (2/2)
patients failing NIV with a DNI and treated with the Hemolung RAS
therapy were successfully weaned from NIV.\141\ The applicant cited a
retrospective review by Tiruvoipati et al. (2016), also previously
discussed, in which 80% (4/5) of patients failing NIV and treated with
Hemolung RAS therapy avoided intubation.\142\ Furthermore, the
applicant cited an unpublished study of the Hemolung RAS Registry
Program Analysis,\143\ in which 86% of patients (19 of the 22 patients
in the analysis) who failed NIV and were treated with the Hemolung RAS
therapy avoided intubation.
---------------------------------------------------------------------------
\141\ Burki N., et al. A novel extracorporeal CO2
removal system: Results of a pilot study of hypercapnic respiratory
failure in patients with COPD. Chest. 2013;143(3):678-686.
\142\ Tiruvoipati R., et al. Early experience of a new
extracorporeal carbon dioxide removal device for acute hypercapnic
respiratory failure. Crit Care Resusc. 2016;18(4):261-269.
\143\ The applicant cited an unpublished study using data
collected from physicians as part of the Hemolung Registry Program.
We believe information regarding the Hemolung Registry Program is
available here: Alung, Inc., HL-CA-1600, Hemolung RAS Registry. A
Retrospective Registry Involving Voluntary Reporting of De-
identified, Standard of Care Data Following the Commercial Use of
the Hemolung Respiratory Assist System (RAS). ClinicalTrials.gov.
Retrieved December 21, 2021, from Hemolung RAS Registry Program--
Full Text View--ClinicalTrials.gov.
---------------------------------------------------------------------------
In support of the assertion that the Hemolung RAS reduced mortality
in NIV patients, the applicant submitted two retrospective studies as
background studies, in addition to two case studies that utilized the
technology. The first background study \144\ was a retrospective
analysis of data from the Healthcare Cost and Utilization Project's
Nationwide Inpatient Sample between 1998 and 2008 to assess the pattern
and NIPPV use for acute exacerbations of COPD. The patient cohort was
defined as people greater than 35-years-old admitted with a primary
diagnosis of COPD or a primary diagnosis of respiratory failure with a
secondary diagnosis of COPD. The study demonstrated a decline over time
in overall in-hospital mortality for those patients treated with NIPPV
without a subsequent need for IMV. Mortality was high and increased
over time in patients who transitioned from NIPPV to IMV (27%) compared
to those patients who did not transition (9%). Charges for
hospitalization increased from 1998 to 2008, especially for patients
who transitioned from NIPPV to IMV. LOS decreased in all patients
except those who transitioned from NIPPV to IMV. The authors noted a
few limitations that would have allowed for a more detailed examination
of predictors of NIPPV failure and death, including the lack of
information on the severity of the exacerbation, response to NIPPV
treatment, end-of-life decision-making,
[[Page 48946]]
or location of the patient in the hospital (ICU vs. medical ward vs.
ED, etc.).
---------------------------------------------------------------------------
\144\ Chandra, et al, ``Outcomes of noninvasive ventilation for
acute exacerbations of chronic obstructive pulmonary disease in the
United States, 1998-2008'' Am J. Respir Crit Care Med. 2012. Vol 185
(2). p. 152-159
---------------------------------------------------------------------------
The applicant also cited a retrospective study by Sprooten et
al.\145\ as background, that looked at patients admitted to the
Respicare Unit located in Maastricht University Medical Center (MUMC)
in the Netherlands between 2009 and 2011 who met the criteria of
admitted for exacerbation of COPD requiring NIV therapy and a
definitive COPD diagnosis. In-hospital mortality was 14% with a median
LOS of 16.5 days. Overall, this single-center study showed that
patients who are admitted to the hospital for a first hospitalization
requiring NIV for acute respiratory due to COPD exacerbation have a
high short- and long-term mortality rate. According to the article,
older age, NIV use greater than eight days and lack of successful NIV
response were independent prognostic factors to two-year mortality
rather than response of levels of PaCO2 or pH.
---------------------------------------------------------------------------
\145\ Sprooten, et al. ``Predictors for long-term mortality in
COPD patients requiring non-invasive positive pressure ventilation
for the treatment of acute respiratory failure'' Clinical Resp J.
2020. Vol 14 (12). p. 1144-1152
---------------------------------------------------------------------------
The applicant also cited two case studies where the Hemolung RAS
was used to successfully treat patients in hypercapnic respiratory
failure caused by COPD. The applicant stated that in these case
reports, the Hemolung RAS therapy prevented imminent death in COPD
patients with a DNI order who were failing NIV. In a case study by
Engel et al., previously described,\146\ a 72-year-old female with
hypercapnic coma due to COPD exacerbation was administered the Hemolung
RAS; after 4 hours, PaCO2, pH, and clinical parameters
improved, and the patient was weaned off therapy after 7 days.
---------------------------------------------------------------------------
\146\ Engel, et al. ``Use of Extracorporeal CO2
Removal to Avoid Invasive Mechanical Ventilation in Hypercapnic Coma
and Failure of Noninvasive Ventilation'' J. Pulm & Resp Med. 2016
Vol 6 (3) p.1-3.
---------------------------------------------------------------------------
In a second study by Mani et al., previously described,\147\ the
Hemolung RAS was used to treat two patients. The first patient, a 69-
year-old female with COPD, was placed on the Hemolung RAS after failing
NIV treatment. After 66 hours of treatment, the patient was weaned off
the Hemolung RAS, and was discharged home 4 days later. The second
patient, a 78-year-old male with COPD, was placed on the Hemolung RAS
after failing NIV treatment. After 48 hours of treatment, the patient
was weaned off the Hemolung RAS, and was discharged home 10 days later.
---------------------------------------------------------------------------
\147\ Mani, R.K., Schmidt, W., Lund, L.W. & Herth, F.J.F.
Respiratory dialysis for avoidance of intubation in acute
exacerbation of COPD. ASAIO J. 59, 675-678 (2013).
---------------------------------------------------------------------------
In support of the assertion that the Hemolung RAS improves
activities of daily living/quality of life, the applicant submitted one
randomized controlled trial (RCT) abstract and three case studies. In
the RCT abstract by Barrett at al.,\148\ 18 patients (median age: 67.5
years) with acute hypercapnic respiratory failure due to exacerbations
of COPD were randomized to receive NIV alone or ECCO2R and
NIV. The applicant stated that the study included patients who were at
high risk of failing NIV (pH<7.30 after >=1 hour of NIV). The applicant
stated that the control arm continued to be treated with NIV only (n=9)
and the test arm was treated with ECCO2R (n=9). The primary
endpoint was the time to cessation of NIV. Secondary outcomes included
device tolerance and complications, changes in arterial blood gases
(ABGs) and hospital survival. The time to NIV discontinuation was
shorter in the ECCO2R arm (7 hours) vs in the NIV alone arm
(24.5 hours), p = 0.004. The study claimed that dyspnea rapidly
improved with ECCO2R, but that ICU and hospital LOS were
longer with the ECCO2R group and there was no difference in
mortality or functional outcomes at follow-up. The authors concluded
that ECCO2R can be an alternative to NIV for patients who
are at risk of failing or cannot tolerate NIV, or for patients in whom
a more rapid correction of hypercapnia is desirable.
---------------------------------------------------------------------------
\148\ Barrett, N., et al. A randomized controlled trial of Non-
Invasive Ventilation compared with ECCO2R for Acute
Hypercapnic Exacerbations of COPD. ASAIO J. 2021; 67 (Supp 3)
Presented at the 32nd Annual ELSO Conference.
---------------------------------------------------------------------------
The applicant referred to three case studies using the Hemolung RAS
to treat hypercapnic respiratory failure, to demonstrate improvement in
activities of daily living/quality of life. In the case study by Engel
et al., previously described,\149\ the applicant stated that early
mobilization, communication, and nutrition were facilitated with
Hemolung therapy. In the Bermudez et al. case study, previously
discussed,\150\ the Hemolung RAS was successfully used to bridge a
patient with COPD to a lung transplantation. The applicant stated that
considerable clinical improvement attributed to Hemolung therapy
permitted the patient to be awake and mobilized to sit on the edge of
the bed. In the Bonin et al. case study, previously discussed,\151\ the
applicant stated that drinking and recovery from pressure sores were
possible by day three of the Hemolung RAS.
---------------------------------------------------------------------------
\149\ Engel, et al. ``Use of Extracorporeal CO2
Removal to Avoid Invasive Mechanical Ventilation in Hypercapnic Coma
and Failure of Noninvasive Ventilation'' J. Pulm & Resp Med. 2016
Vol 6 (3) p.1-3.
\150\ Bermudez, et al. ``Prolonged Use of the Hemolung
Respiratory Assist System as a Bridge to Redo Lung Transplantation''
Annals of Thorac Surg. 2015 Vol 100 (6). p. 2330-2333.
\151\ Bonin, et al. ``Avoidance of intubation during acute
exacerbation of chronic obstructive pulmonary disease for a lung
transplant candidate using extracorporeal carbon dioxide removal
with the Hemolung''. J. Thorac Cardiovac Surg. 2013. Vol 145 (5).
e43-e44.
---------------------------------------------------------------------------
After review of the information provided by the applicant, we
stated that we had the following concerns regarding whether the
Hemolung RAS meets the substantial clinical improvement criterion. We
noted that the evidence provided for several of the claims of
substantial clinical improvement include small, non-randomized studies
without the use of comparators or controls, including case studies,
which may affect the ability to draw meaningful conclusions about
treatment outcomes from the results of the studies. We stated that the
benefits of avoiding intubation or de-escalating IMV settings are
described in case studies, but the absence of comparative data may make
it more difficult to determine whether there are clinically meaningful
changes in these outcomes. We also noted that in the one abstract of an
RCT using the Hemolung RAS,\152\ although the time to NIV
discontinuation was shorter in the ECCO2R arm than in the
NIV alone arm, the ICU and hospital length of stay were longer with the
ECCO2R group and there were no differences in mortality or
functional outcomes at follow-up. Additionally, while the applicant
stated that the Hemolung RAS results in improved clinical outcomes,
such as reducing mortality in NIV patients compared to continuing the
patient's previous treatment, given that many of the case studies
provided as evidence to support improved clinical outcomes included
only one or two patients, it was not clear whether or not the results
of these studies are generalizable to the Medicare population. We also
noted that several of the case studies, for example, Bonin et al., Mani
et al., Tully et al., etc., mentioned by the applicant included
patients and cases from outside the U.S., and we questioned if there
may be differences in treatment guidelines between these countries that
may have affected clinical outcomes. Lastly, we noted that for several
of the claims of substantial clinical improvement, the applicant
provided
[[Page 48947]]
evidence from background studies that did not utilize the Hemolung RAS
to support the use of the technology to improve clinical outcomes. For
example, in support of its assertion that the Hemolung RAS reduces
mortality in NIPPV patients, the study cited by the applicant only
addressed NIPPV as a treatment option to treat exacerbations in
patients with COPD, but did not directly address the use of the
Hemolung RAS as an intervention.
---------------------------------------------------------------------------
\152\ Barrett, N., et al. A randomized controlled trial of Non-
Invasive Ventilation compared with ECCO2R for Acute
Hypercapnic Exacerbations of COPD. ASAIO J. 2021; 67 (Supp 3)
Presented at the 32nd Annual ELSO Conference.
---------------------------------------------------------------------------
We invited public comments on whether the Hemolung RAS meets the
substantial clinical improvement criterion.
Comment: The applicant submitted comments in response to CMS'
concerns in the FY2023 IPPS/LTCH PPS proposed rule (87 FR 28243)
regarding whether the Hemolung RAS meets the substantial clinical
improvement criterion. In response to our concerns as to whether the
results of non-controlled data may affect the ability to draw
meaningful conclusions regarding treatment outcomes and the use of
background studies to support claims of substantial clinical
improvement, the applicant stated that it acknowledges randomized
controlled trial (RCT) data is the gold standard and the limitations of
non-controlled data, but that large RCTs investigating medical devices
in the critical care setting present unique enrollment challenges. The
applicant stated that it is currently conducting the VENT-AVOID RCT in
the US (``the Trial''--NCT03255057) investigating the use of the
Hemolung RAS in COPD patients, which has faced slow enrollment since it
began in 2018, with the COVID-19 pandemic further slowing enrollment.
The applicant explained that one reason for the slow enrollment is the
highly specific inclusion and exclusion criteria required by RCTs,
which is typical of COPD trials. The applicant cited a study that
evaluated the number of patients who would meet the inclusion criteria
commonly used in COPD clinical trials, where the results demonstrated
only 17% of the COPD population would meet the inclusion criteria.\153\
---------------------------------------------------------------------------
\153\ Herland K, Akselsen JP, Skj[oslash]nsberg OH, Bjermer L.
How representative are clinical study patients with asthma or COPD
for a larger ``real life'' population of patients with obstructive
lung disease? Respiratory Medicine. 2005;99(1):11-19. doi:10.1016/
j.rmed.2004.03.026.
---------------------------------------------------------------------------
The applicant stated that it believes a substantial amount of real-
world evidence supports the technology's use, and as such, the
background studies (with a combined >200,000 mechanically ventilated
patients) are included to provide evidence demonstrating the life-
threatening clinical sequelae that result from hypercapnia and
respiratory acidosis in critically ill patients, including increased
risk of ICU and hospital mortality, and longer ICU and hospital lengths
of stay.154 155 The applicant stated that it believes the
Hemolung evidence submitted to demonstrate substantial clinical
improvement reflects the real-world use and the true impact the
Hemolung RAS will have on the Medicare population, and that it is clear
that providing clinicians with a tool to effectively correct pH and
PaCO2 independently of the lungs will have a significant
positive impact on the outcomes of acute respiratory failure patients.
---------------------------------------------------------------------------
\154\ Nin N., Muriel A., Pe[ntilde]uelas O., et al. Severe
hypercapnia and outcome of mechanically ventilated patients with
moderate or severe acute respiratory distress syndrome. Intensive
Care Med. 2017;43(2):200-208. doi:10.1007/s00134-016-4611-1.
\155\ Tiruvoipati R., Pilcher D., Buscher H., Botha J., Bailey
M. Effects of Hypercapnia and Hypercapnic Acidosis on Hospital
Mortality in Mechanically Ventilated Patients*: Critical Care
Medicine. 2017;45(7):e649-e656. doi:10.1097/CCM.0000000000002332.
---------------------------------------------------------------------------
In response to our concerns as to whether the results of the
Hemolung RAS case studies that included only one or two patients were
generalizable to the Medicare population, the applicant stated that the
epidemiology of acute respiratory distress and need for mechanical
ventilation in older adults is well established. The applicant noted
that there is a natural physiologic decline in lung function with age,
which makes safely and adequately ventilating older patients,
especially those with respiratory disease, challenging. The applicant
noted that at generally accepted lung protective ventilation settings,
older patients are more susceptible to an accumulation CO2
due to poor baseline lung function. The applicant also stated that use
of the Hemolung RAS in COPD patients is highly generalizable to the
Medicare population given that the prevalence of COPD increases with
age, and that in COPD patients failing non-invasive ventilation (NIV),
avoiding intubation has a substantial mortality benefit (9% vs
27%).\156\
---------------------------------------------------------------------------
\156\ Chandra D., Stamm J.A., Taylor B., et al. Outcomes of
noninvasive ventilation for acute exacerbations of chronic
obstructive pulmonary disease in the United States, 1998-2008. Am J.
Respir Crit Care Med. 2012;185(2):152-159. doi:10.1164/rccm.201106-
1094OC.
---------------------------------------------------------------------------
In response to our concern as to whether the potential differences
in treatment guidelines between countries of case studies may have
affected clinical outcomes, the applicant referenced the consensus
guideline in the US and Europe that generally the goal when ventilating
patients is to utilize low volumes and pressures, which can result in
CO2 accumulation in the blood. The applicant explained that
as CO2 accumulation is a basic physiologic response to these
ventilator settings, patient location does not affect clinical
improvements resulting from the Hemolung RAS therapy.
In response to our concern that the ICU and hospital stays were
longer with the ECCO2R group and there were no differences
in mortality or functional outcomes at follow-up, the applicant
submitted a recently published RCT \157\ with additional data and
analysis of its study results on LOS. The applicant cited that the ICU
and hospital LOS were both 4-5 days longer with ECCO2R than
with NIV, which was due to a longer ICU LOS. The applicant noted that
time from ICU discharge to home discharge was equal in both groups. The
applicant noted that with NIV, nurse-led weaning occurred 24/7, based
around arterial blood gases, respiratory rate and patient preference,
and that patients were discharged to the ward during the daytime if
they had been off NIV overnight. In addition, the applicant stated that
patients who consistently declined NIV were discharged to a ward bed
regardless of pH and this will have contributed to the lower ICU length
of stay in the NIV arm. The applicant noted that the protocol for
patients receiving ECCO2R did not allow weaning overnight,
and there was a median of eight hours from cessation of
ECCO2R to decannulation and unit protocols required a
further overnight stay for observation.
---------------------------------------------------------------------------
\157\ Barrett N.A., Hart N., Daly K.J.R., et al. A randomised
controlled trial of non-invasive ventilation compared with
extracorporeal carbon dioxide removal for acute hypercapnic
exacerbations of chronic obstructive pulmonary disease. Ann
Intensive Care. 2022;12(1):36. doi:10.1186/s13613-022-01006-8.
---------------------------------------------------------------------------
The applicant also explained that the study results showed that
time to NIV cessation was significantly shorter in the
ECCO2R arm than in the NIV arm (7 hrs. vs 24:30 hrs., p =
0.004). The applicant noted that at one-hour post-randomization the pH
was significantly higher in the ECCO2R arm (p<0.001), and at
4 hours post randomization the PaCO2 was significantly lower
(p<0.001) in the ECCO2R arm, compared to the NIV only arm.
The applicant stated that ECCO2R also resulted in a
significant and rapid reduction in subjective discomfort and dyspnea
measured using a visual analogue scale (VAS), where a higher score
indicates higher subjective discomfort and dyspnea.
Several other commenters also indicated their support for the
[[Page 48948]]
Hemolung RAS. A commenter stated that the Hemolung RAS was used in
their center and proved to be reliable (removing approximately 80 ccs
of CO2/min) and was well-accepted by staff. The commenter
noted that the staff considered it easy to use compared to ECMO, and
were generally able to manage it while also managing other ECMO
patients. The commenter stated that the Hemolung RAS will occupy an
important niche in treating patients with acute hypercapnic respiratory
failure, avoiding intubation up front in some patients as well as
facilitating weaning off the ventilator in other cases where intubation
was necessary initially.
A group of commenters submitted a comment stating that their
experience with the Hemolung RAS underscored the importance of this
technology in the Medicare population requiring inpatient management of
hypercapnic respiratory failure. The commenters stated that IMV not
only does not address the underlying clinical condition leading to
hypercapnia, but it also compounds it by elevating pressures applied to
the lung in an attempt to increase tidal ventilation, which contributes
to morbidity and mortality, and that prior to the introduction of the
Hemolung, it was the only option available. The commenters stated that
they considered the Hemolung RAS a new technology that allows the
patient on IMV to be managed with lower pressures instead of higher,
earlier removal from mechanical ventilation, or even avoid mechanical
ventilation, which the commenter noted is particularly important for
patients with a do not intubate order for whom there are no other
treatment alternatives. The commenters considered the Hemolung RAS as
representing a significant clinical improvement for patients with
hypercapnic respiratory failure in the inpatient setting, particularly
for Medicare patients due to their age and risk of complications of the
current standard of care.
Response: We thank the applicant and other commenters for their
comments. Based on the additional information received, we agree with
the applicant that the Hemolung RAS represents a substantial clinical
improvement over existing technologies because the technology offers a
treatment option for hypercapnic respiratory failure due to all causes
in adults while avoiding intubation or facilitating extubation. We also
agree with the applicant that the Hemolung RAS fills an unmet need for
patients ineligible for currently available treatments, such as
mechanical ventilation (for example, in patients with a DNI order). The
Hemolung RAS provides extracorporeal CO2 removal from the
patient's blood for up to 5 days in adults with acute, reversible
respiratory failure for whom ventilation of CO2 cannot be
adequately or safely achieved using other available treatment options
and continued clinical deterioration is expected. For this reason, we
agree that the Hemolung RAS offers a valuable treatment option for
patients at risk for complications from, unresponsive to, and/or
ineligible for, mechanical ventilation.
After consideration of the public comments we received, we have
determined that the Hemolung RAS meets the criteria for approval for
new technology add-on payments. Therefore, we are approving new
technology add-on payments for use of the Hemolung RAS for the
indications approved under its FDA De Novo marketing authorization for
FY 2023. As discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28236) consistent with our longstanding policy of not considering
eligibility for new technology add-on payments prior to a product
receiving FDA approval or clearance, a product available only through
an EUA would not be eligible for new technology add-on payments.
Therefore, cases involving pediatric patients, or cases involving the
use of the Hemolung RAS for greater than 5 days, would not be eligible
for new technology add-on payments, as they do not fall under the
patient population indicated in its FDA De Novo marketing
authorization. Cases involving the use of the Hemolung RAS that are
eligible for new technology add-on payments will be identified by ICD-
10-PCS procedure code 5A0920Z (Assistance with respiratory filtration,
continuous).
In its application, the applicant estimated that the cost of
Hemolung RAS is $10,000, which includes the $7,500 cost of the
cartridge and the $2,500 cost of the catheter. Under Sec.
412.88(a)(2), we limit new technology add-on payments to the lesser of
65% of the average cost of the technology, or 65% of the costs in
excess of the MS-DRG payment for the case. As a result, the maximum new
technology add-on payment for a case involving the use of Hemolung RAS
is $6,500 for FY 2023.
d. LIVTENCITYTM (Maribavir)
Takeda Pharmaceuticals U.S.A., Inc. submitted an application for
new technology add-on payments for LIVTENCITYTM (maribavir)
for FY 2023. LIVTENCITYTM is a cytomegalovirus (CMV) pUL97
kinase inhibitor indicated for the treatment of adults and pediatrics
(12 years of age and older and weighing at least 35 kg) with post-
transplant CMV infection/disease that is refractory to treatment (with
or without genotypic resistance) to ganciclovir, valganciclovir,
cidofovir, or foscarnet.
According to the applicant, LIVTENCITYTM is the only
antiviral therapy indicated to treat post-transplant patients with CMV
in solid organ transplant (SOT) and hematopoietic stem cell transplant
(HCT). Per the applicant, LIVTENCITYTM provides multi-
targeted anti-CMV activity by inhibiting protein kinase UL97 and its
natural substrates, which subsequently inhibits CMV DNA replication,
encapsidation, and nuclear egress of viral capsids.
The applicant stated that CMV is one of the most common viral
infections experienced by transplant recipients, with an estimated
incidence rate between 16%-56% in SOT recipients and 30%-70% in HCT
recipients.\158\ CMV is a beta herpesvirus that commonly infects
humans; serologic evidence of prior infection can be found in 40%-100%
of various populations.\159\ CMV typically resides latent and
asymptomatic in the body but may reactivate during periods of
immunosuppression. The applicant estimated that there are approximately
200,000 adult transplants per year globally and an estimated 1,435
cases of CMV post-transplant in the Medicare population per year. The
applicant stated that in transplant patients, reactivation of CMV can
potentially lead to serious consequences including loss of the
transplanted organ and, in extreme cases, death.
---------------------------------------------------------------------------
\158\ Azevedo L, Pierrotti L, Abdala E, et al. Cytomegalovirus
infection in transplant recipients. Clinics.2015;70(7):515-523.
doi:10.6061/clinics/2015(07)09; World Health Organization (WHO).
International Report on Organ Donation and Transplantation
Activities--Executive Summary 2018.
\159\ Krech U. Complement-fixing antibodies against
cytomegalovirus in different parts of the world. Bull WHO.
1973(49):103-106.
---------------------------------------------------------------------------
Per the applicant, there are four FDA-approved therapies for the
treatment and/or prevention (that is, prophylaxis) of CMV disease:
valganciclovir, ganciclovir, foscarnet, and cidofovir. The applicant
stated that ganciclovir and valganciclovir are approved for prevention
of CMV disease in transplant recipients and for treatment of CMV
retinitis in immunocompromised hosts, including those with Acquired
Immune Deficiency Syndrome (AIDS); and foscarnet and cidofovir are
approved for treatment of CMV retinitis in AIDS patients. Per the
applicant, none of these four therapies are FDA-approved for the
treatment of resistant or
[[Page 48949]]
refractory CMV infection and disease. The applicant provided a table
that included the therapy, transplant type, mechanism of action,
approved indications that were CMV-related, and the formulation(s).
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR10AU22.087
BILLING CODE 4120-01-C
With respect to the newness criterion, the applicant stated that
LIVTENCITYTM was granted Breakthrough Therapy, Priority
Review, and Orphan Drug designations from FDA, and subsequently
received FDA approval for its New Drug Application on November 23,
2021. LIVTENCITYTM is indicated for the treatment of adults
and pediatric patients (12 years of age or older and weighing at least
35 kg) with post-transplant CMV infection/disease that is refractory to
treatment (with or without genotypic resistance) with ganciclovir,
valganciclovir, cidofovir, or foscarnet. Per the applicant,
LIVTENCITYTM became commercially available on December 2,
2021. The applicant did not explain the reason for the delay between
market authorization and commercial availability. The recommended
dosing is 400 mg (two 200 mg tablets) orally twice daily with or
without food. The applicant stated that if LIVTENCITYTM is
co-administered with carbamazepine, then the dosage is increased to 800
mg twice daily; if co-administered with phenytoin or phenobarbital, the
dosage is increased to 1,200 mg twice daily.
---------------------------------------------------------------------------
\160\ VALCTE[supreg] (valganciclovir) United States Prescibing
Information (2018).
\161\ CYTOVENE-IV[supreg] (ganciclovir) United States Prescibing
Information (2018).
\162\ FOSCAVIR[supreg] (foscarnet) United States Prescibing
Information (2017).
\163\ VISTIDE[supreg] (cidofovir) United States Prescibing
Information (2010).
---------------------------------------------------------------------------
According to the applicant, ICD-10-PCS code 3E0DX29 (Introduction
of other anti-infective into mouth and pharynx, external approach) may
be used to identify administration of LIVTENCITYTM but does
not uniquely identify it. The following ICD-10-PCS procedure codes were
created to uniquely describe the use of LIVTENCITYTM,
effective October 1, 2022: XW0DX38 (Introduction of
[[Page 48950]]
maribavir anti-infective into mouth and pharynx, external approach, new
technology group 8), XW0G738 (Introduction of maribavir anti-infective
into upper gi, via natural or artificial opening, new technology group
8), and XW0H738 (Introduction of maribavir anti-infective into lower
gi, via natural or artificial opening, new technology group 8).
As previously discussed, if a technology meets all three of the
substantial similarity criteria under the newness criterion, it would
be considered substantially similar to an existing technology and would
not be considered ``new'' for the purposes of new technology add-on
payments.
With respect to the first criterion, whether a technology uses the
same or similar mechanism of action to achieve a therapeutic outcome,
the applicant stated that LIVTENCITYTM targets a different
gene locus (pUL97 vs. pUL54) than the existing therapies to treat CMV
infection, including those resistant or refractory to conventional
therapy. Specifically, LIVTENCITYTM inhibits CMV DNA
replication, encapsidation, and nuclear egress of viral capsids through
inhibition of pUL97 and its natural substrates. The applicant provided
the mechanisms of action for the other existing anti-CMV drugs, namely
valganciclovir ganciclovir, foscarnet, and cidofovir in the table
previously listed and concluded that LIVTENCITYTM uses a
different mechanism of action compared to existing anti-CMV drugs.
With respect to the second criterion, whether a technology is
assigned to the same or a different MS-DRG when compared to an existing
technology, the applicant stated that LIVTENCITYTM is
expected to be assigned to the same MS-DRGs as therapies that are
currently used off-label for the treatment of CMV infection or disease.
With respect to the third criterion, whether the new use of
technology involves the treatment of the same or similar type of
disease and the same or similar patient population when compared to an
existing technology, the applicant noted that there are no other
existing therapies indicated to treat the same or similar type of
disease or patient population as LIVTENCITYTM. The applicant
noted that currently available therapies are used off-label to treat
patients with refractory or resistant CMV infection or disease. Thus,
the applicant maintained that LIVTENCITYTM is indicated to
treat a different patient population compared to existing technologies.
In summary, the applicant asserted that LIVTENCITYTM is
not substantially similar to other currently available therapies
because it uses a new mechanism of action and is indicated to treat a
unique patient population and/or disease and, therefore, the technology
meets the newness criterion. We invited public comments on whether
LIVTENCITYTM is substantially similar to existing
technologies and whether LIVTENCITYTM meets the newness
criterion. As noted in the proposed rule, the applicant did not explain
the reason for the delay between market authorization and commercial
availability, and we requested additional information regarding this
point.
Comment: The applicant submitted comments in response to CMS'
request for additional information on the delay between market
authorization and commercial availability of LIVTENCITYTM.
Per the applicant, between FDA marketing authorization on November 23,
2021 and commercial availability on December 2, 2021, the applicant
applied final packaging and labeling and worked to ship the product to
specialty pharmacies and distributors as soon as finished goods were
available.
Response: We thank the applicant for the additional information
regarding the delay between market authorization and commercial
availability. We agree with the applicant that the beginning of the
newness period for LIVTENCITYTM is December 2, 2021, the
date the product became commercially available.
Comment: A commenter agreed that LIVTENCITYTM does not
meet the first and third substantial similarity criteria as it stated
that there are no other antivirals with a similar mechanism of action
and LIVTENCITYTM offers a novel treatment option for
patients with no other antivirals currently approved for the treatment
of post-transplant CMV refractory to traditional treatments. They
agreed with the applicant that LIVTENCITYTM is likely to
share the same MS-DRGs as off-label agents currently used for CMV
infection or disease.
Response: We thank the commenter for their input. We agree with the
commenter that LIVTENCITYTM has a unique mechanism of action
and offers a novel treatment option for patients with post-transplant
CMV refractory to traditional treatments.
Based on information submitted by the applicant in its comment and
as part of its FY 2023 new technology add-on payment application for
LIVTENCITYTM, as discussed in the proposed rule (87 FR 28258
through 28259) and previously summarized, we believe that
LIVTENCITYTM has a unique mechanism of action because it
inhibits pUL97, which is involved in terminal DNA processing, including
DNA elongation, encapsidation, and nuclear egress of viral capsids,
whereas existing therapies inhibit CMV DNA polymerase (pUL54) or the
CMV DNA terminase complex (pUL51, pUL56, and pUL89) that is required
for viral DNA processing and packaging. We also believe that
LIVTENCITYTM is indicated to treat a unique patient
population and/or disease, as it is the only FDA-approved antiviral
therapy indicated to treat post-transplant patients with CMV disease in
solid organ transplant (SOT) and hematopoietic stem cell transplant
(HCT). Therefore, LIVTENCITYTM is not substantially similar
to existing treatment options and meets the newness criterion. As
stated previously, we consider the beginning of the newness period to
commence on December 2, 2021 based on information provided by the
applicant that the product first became available for sale on that
date.
With respect to the cost criterion, the applicant presented the
following analysis. To identify patients who may be eligible to receive
LIVTENCITYTM as a treatment, the applicant searched the 2019
MedPAR dataset for cases with the following ICD-10-CM codes for CMV and
post-transplant SOT and HCT infection. The applicant included inpatient
discharges under Medicare fee-for-service (FFS) and excluded Medicare
Advantage discharges.
BILLING CODE 4120-01-P
[[Page 48951]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.088
The applicant identified 1,435 claims mapping to 108 MS-DRGs. For
MS-DRGs where the case volume was below 11, the applicant imputed a
count of 11 cases. The table lists the nine MS-DRGs with the highest
volume of cases.
[GRAPHIC] [TIFF OMITTED] TR10AU22.089
BILLING CODE 4120-01-C
The applicant did not remove charges for a prior technology, as the
applicant claimed that any current treatment that is used off-label to
treat CMV patients post-transplant SOT and HCT may not be reflected in
claims data. The applicant further explained that in cases where an
off-label treatment is reflected on the claim, LIVTENCITYTM
might be used as a second-line treatment rather than to replace the
off-label treatment. The applicant then standardized the charges and
applied a 4-year inflation factor of 1.281834 or 28.1834%, based on the
inflation factor used in the FY 2022 IPPS/LTCH PPS final rule and
correction notice to update the outlier threshold (86 FR 45542). The
applicant added charges for the new technology by dividing the cost of
LIVTENCITYTM by the national average CCR for drugs which is
0.187 (86 FR 44966). The applicant estimated the costs of
LIVTENCITYTM based on 8-week dosing regimens to complete the
full treatment.
The applicant calculated a final inflated average case-weighted
standardized charge per case of $508,855 which exceeded the average
case-weighted threshold amount of $76,739.
We invited public comments on whether LIVTENCITYTM meets
the cost criterion.
We did not receive any comments on whether LIVTENCITY\TM\ meets the
cost criterion. Based on the information submitted by the applicant as
part of its FY 2023 new technology add-on payment application for
LIVTENCITYTM, as discussed in the proposed rule (87 FR 28259
through 28260) and previously summarized, the final inflated average
case-weighted
[[Page 48952]]
standardized charge per case exceeds the average case-weighted
threshold amount. Therefore, LIVTENCITYTM meets the cost
criterion.
With regard to the substantial clinical improvement criterion, the
applicant asserted that LIVTENCITYTM represents a new
treatment option for a patient population unresponsive to, or
ineligible for, currently available treatments. To support this claim,
the applicant reiterated that there are no existing therapies that are
approved by FDA to treat post-transplant patients with refractory or
resistant CMV infection or disease. The applicant also asserted that
the use of LIVTENCITYTM may significantly improve clinical
outcomes by improving efficacy and reducing adverse effects compared to
available therapies.
To support the claim of improved efficacy, the applicant cited
results from SOLSTICE, a phase III, open-label, randomized controlled
trial in which 352 transplant recipients [HCT (n=211) and SOT (n=141)]
with refractory \164\ or resistant \165\ CMV were assigned 2:1 to
receive 400 mg of LIVTENCITYTM twice daily (n=235) or
investigator-assigned therapy (IAT) with drug-specific dosing (n=117)
for 8 weeks, with 12 weeks of follow-up.\166\ The choice of specific
IAT was at the investigators' discretion and included mono- or
combination therapy (<=2 drugs) with intravenous (IV) ganciclovir, oral
valganciclovir, IV foscarnet or IV cidofovir, where switching between
ganciclovir and valganciclovir was permitted. The median (range)
duration of exposure was 57 (2-64) days in the LIVTENCITYTM
arm and 34 (4-64) days with IAT. The primary endpoint was the
proportion of patients achieving CMV clearance at 8 weeks, and the key
secondary endpoint was achievement of CMV clearance \167\ and symptom
control \168\ at the end of week 8, maintained through week 16. With
respect to the primary endpoint, the applicant indicated that CMV
clearance at 8 weeks was achieved in 55.7% (n=131/235) of the
LIVTENCITYTM group and 23.9% (n=28/117) of the IAT group
with an adjusted difference of 32.8%, where the results achieved
statistical significance [95% CI, 22.8-42.7%, p<0.001]. With respect to
the secondary endpoint, the applicant indicated that 18.7% (n=44/235)
of the LIVTENCITYTM-treated group and 10.3% (n=12/117) of
IAT-treated group maintained CMV viremia clearance and symptom control
through week 16 (p=0.013).\169\ The applicant stated that, based on
these results, LIVTENCITYTM is superior to conventional
antiviral therapies in achieving and maintaining CMV viremia clearance
and symptom control.
---------------------------------------------------------------------------
\164\ Failure to achieve >1 log10 decrease in CMV DNA
after at least 14 days of anti-CMV treatment.
\165\ At least 1 genetic mutation associated with resistance to
ganciclovir/valganciclovir, foscarnet, and/or cidofovir.
\166\ Avery RK, Alain S, Alexander B, et al. Maribavir for
refractory cytomegalovirus infections with or without resistance
post-transplant: results from a phase 3 randomized clinical trial
(accepted manuscript). Clin Infect Dis. 2021; ciab988, https://doi.org/10.1093/cid/ciab988.
\167\ Measured as CMV DNA level less than lower limit of
quantification.
\168\ Resolution or improvement in tissue-invasive CMV disease
or syndrome for participants symptomatic at baseline or no new
symptoms of tissue-invasive CMV disease or syndrome for participants
asymptomatic at baseline.
\169\ Avery RK, Alain S, Alexander B, et al. Maribavir for
refractory cytomegalovirus infections with or without resistance
post-transplant: results from a phase 3 randomized clinical trial
(accepted manuscript). Clin Infect Dis. 2021; ciab988, https://doi.org/10.1093/cid/ciab988.
---------------------------------------------------------------------------
The applicant also claimed that the efficacy of
LIVTENCITYTM is consistent across SOT types, as evidenced by
an unpublished subgroup analysis by Avery et al.\170\ which evaluated
211 SOT patients from the SOLSTICE trial for CMV clearance
(LIVTENCITYTM vs. conventional) by transplant type, with the
following results: heart: 42.9% (n=6/14) vs. 11.1% (n=1/9) (adjusted
difference: 30.7% [95% CI, -1.72-63.15%]); lung: 47.5% (n=19/40) vs.
13.6% (n=3/22), adjusted difference: 38.2% [95% CI, 16.89-59.53%];
kidney: 59.5% (n=44/74) vs. 34.4% (n=11/32); adjusted difference: 26.7%
[95% CI, 7.48-45.85%].
---------------------------------------------------------------------------
\170\ Avery RK, Blumberg EA, Florescu D, et al. A randomized
phase 3 open-label study of maribavir vs. investigator-assigned
therapy for refractory/resistant cytomegalovirus infection in
transplant recipients: subgroup analyses of efficacy by organ. in:
The 2021 American Transplant Congress; 2021. Abstract LB 9.
---------------------------------------------------------------------------
Finally, with regard to efficacy, the applicant stated that
LIVTENCITYTM is active against refractory or resistant CMV
infections and tolerable across doses. To support this claim, the
applicant pointed to a randomized, dose-ranging, open-label, phase II
study by Papanicolaou et al.,\171\ in which HCT and SOT recipients with
refractory or resistant CMV infections (n=120) were randomized 1:1:1 to
twice-daily LIVTENCITYTM doses of 400 mg (n=40), 800 mg
(n=40), or 1,200 mg (n=40) for up to 24 weeks. The primary efficacy
endpoint was the proportion of patients with confirmed undetectable
plasma CMV DNA within 6 weeks of treatment. About two-thirds (n=80/120)
of the patients achieved undetectable plasma CMV DNA within 6 weeks of
treatment among all doses [95% CI, 57-75%], and 70% of patients
receiving 400 mg of LIVTENCITYTM twice daily [95% CI, 53-
83]; 62% of patients receiving 800 mg twice daily [95% CI, 46-77%], and
68% of patients receiving 1,200 mg twice daily [95% CI, 51-81%]
achieved the primary endpoint. About a third of patients experienced
recurrent CMV infection while on LIVTENCITYTM (n=25) and 13
patients developed mutations conferring LIVTENCITYTM
resistance.
---------------------------------------------------------------------------
\171\ Papanicolaou GA, Silveira FP, Langston AA, et al. MBV for
r/r CMV infections in HCT or SOT recipients: A randomized, dose-
ranging, double-blind, phase 2 study. Clin Infect Dis.
2019;68(8):1255-1264. doi:10.1093/cid/ciy706.
---------------------------------------------------------------------------
To support the claim of decreased adverse effects, the applicant
cited the results of two secondary endpoints from the SOLSTICE trial.
Per the applicant, neutropenia and acute kidney injury are known,
common adverse effects associated with valganciclovir/ganciclovir and
foscarnet, respectively. The applicant noted that the rates of
treatment-related neutropenia and acute kidney injury were both 1.7%
(n=4/234), separately, in the LIVTENCITYTM treatment group.
The applicant also noted that the rate of neutropenia was 25% (n=14/56)
in the valganciclovir/ganciclovir group, and the rate of acute kidney
injury was 19.1% (n=9/47) in the foscarnet group.\172\ The applicant
maintained that the rate of treatment-related neutropenia and acute
kidney injury was lower in the LIVTENCITYTM group vs.
conventional therapy group. The applicant asserted that, based on these
results, LIVTENCITYTM has a lower incidence of treatment-
related toxicities than existing therapies.
---------------------------------------------------------------------------
\172\ Avery R.K., Alain S., Alexander B., et al. Maribavir for
refractory cytomegalovirus infections with or without resistance
post-transplant: results from a phase 3 randomized clinical trial
(accepted manuscript). Clin Infect Dis. 2021; ciab988, https://doi.org/10.1093/cid/ciab988.
---------------------------------------------------------------------------
The applicant more specifically claimed that transplant patients
treated with LIVTENCITYTM for CMV infection experienced a
lower incidence of treatment-related neutropenia compared with
valganciclovir. To support this claim, the applicant cited the primary
safety endpoint from Maertens et al.,\173\ a parallel-group, phase II
study. In this open-label, LIVTENCITYTM-blinded trial, 120
HCT or SOT recipients with CMV reactivation were randomly assigned to
receive LIVTENCITYTM at a dose of 400 mg (n=40), 800 mg
(n=40), or 1,200 mg (n=40) twice daily or the standard dose of
valganciclovir for 12 weeks for preemptive treatment. The primary
efficacy endpoint was the
[[Page 48953]]
percentage of patients with a response to treatment, defined as
confirmed undetectable CMV DNA in plasma, within 3 weeks and 6 weeks
after the start of treatment. The primary safety endpoint was the
incidence of adverse events that occurred or worsened during treatment.
Specifically, the applicant cited the rate of treatment-emergent
neutropenia in this study which was identified in 4% (n=5/118) of
patients administered LIVTENCITYTM versus 15% (n=6/39) of
patients administered valganciclovir through week 6. Similar results
were found through week 12: 5% (n=6/118) vs. 18% (n=7/39). The
statistical significance of the difference in treatment-emergent
neutropenia between the two groups was not reported in the study.
---------------------------------------------------------------------------
\173\ Maertens J., Cordonnier C., Jaksch P., et al. Maribavir
for preemptive treatment of cytomegalovirus reactivation. N. Engl J.
Med. 2019;381(12):1136-1147. doi:10.1056/NEJMoa1714656.
---------------------------------------------------------------------------
Finally, the applicant stated that LIVTENCITYTM had a
lower incidence of adverse events leading to discontinuation. To
support this assertion, the applicant cited the rate of treatment-
emergent adverse effects (TEAEs) leading to discontinuation from
SOLSTICE, which was lower in the LIVTENCITYTM group (13.2%
(n=31/324)) vs. the conventional group (31.9% (n=37/116)).\174\
---------------------------------------------------------------------------
\174\ Avery R.K., Alain S., Alexander B., et al. Maribavir for
refractory cytomegalovirus infections with or without resistance
post-transplant: results from a phase 3 randomized clinical trial
(accepted manuscript). Clin Infect Dis. 2021; ciab988, https://doi.org/10.1093/cid/ciab988.
---------------------------------------------------------------------------
In the proposed rule, we stated we had the following concerns
regarding whether LIVTENCITYTM meets the substantial
clinical improvement criterion. First, while the applicant provided
data to demonstrate that the proportion of patients achieving CMV
clearance at 8 weeks was higher among patients using
LIVTENCITYTM, there were similar rates of mortality and new-
onset CMV between the 2 treatment groups in this trial:
LIVTENCITYTM vs. comparator: 11% (n=27/235) vs. 6% (n=13/
117) and 6% (n=14/235) vs. 6% (n=7/113), respectively.\175\ We also
noted that it is unclear whether the SOLSTICE study was sufficiently
powered to detect a difference in CMV viremia clearance at week 16, one
of the study's secondary endpoints.\176\ We further noted that while
the rate of TEAEs leading to discontinuation was lower in the
LIVTENCITYTM group, the rate of overall TEAEs and serious
TEAEs in the SOLSTICE trial was similar between the two treatment
groups [LIVTENCITYTM vs. comparator: any TEAE: 97.4% (n=229/
234) vs. 91.4% (n=106/116), serious TEAE: 38.5% vs. 37.1%].\177\
Furthermore, we stated that we would appreciate additional information
from the applicant regarding safeguards taken to minimize or prevent
bias from the treating physician in choosing the conventional therapy
for patients in the investigator-assigned therapy group of the phase
III trial.
---------------------------------------------------------------------------
\175\ Ibid.
\176\ Ibid.
\177\ Ibid.
---------------------------------------------------------------------------
We invited public comments on whether LIVTENCITYTM meets
the substantial clinical improvement criterion.
Comment: We received several comments in support of approving new
technology add-on payments for LIVTENCITYTM. The applicant
reiterated four reasons LIVTENCITYTM meets the substantial
clinical improvement criterion, including: (1) being a new treatment
option for a patient population unresponsive to, or ineligible for,
currently available treatments; (2) more rapid resolution of infection/
disease; (3) reduction in at least one clinically significant adverse
event, and (4) decreased number of hospitalizations. The applicant also
submitted comments in response to CMS' concerns regarding the
substantial clinical improvement criterion.
With respect to the concern that there were similar rates of
mortality and new-onset CMV between the two treatment groups in the
SOLSTICE study, the applicant stated that the study was not
sufficiently powered nor was it long enough in duration to detect a
difference in these two endpoints. With respect to all-cause mortality,
the applicant stated that 8 weeks is often the longest duration
permissible due to toxicities associated with the IAT treatment group,
and that the underlying medical history of the patients and the short
study duration contributed to the similar rate of mortality. The
applicant further explained that all-cause mortality rates were
assessed based on the randomized treatment group, regardless of
LIVTENCITYTM rescue treatment in the IAT group. With respect
to new-onset CMV, the applicant stated that CMV treatment, either via
secondary prophylaxis or treatment with LIVTENCITYTM, was
not allowed after 8 weeks which could explain the similar rates between
the two groups. They also noted that a higher proportion of
LIVTENCITYTM patients with new onset symptomatic CMV were
primary responders to LIVTENCITYTM treatment versus the IAT
patients. Furthermore, the study participants had a history of multiple
past recurrences, increasing the likelihood of CMV recurrence. Finally,
the applicant emphasized that clinically relevant recurrence is more
clinically meaningful than overall recurrence.
Another commenter concurred with the applicant, stating that the
SOLSTICE study design and imbalances in certain, therapy-independent
baseline characteristics for the LIVTENCITYTM group (for
example, presence of CMV disease) could make it difficult to identify
true differences in all-cause mortality and new-onset CMV amongst
LIVTENCITYTM and comparators.
The applicant also responded to CMS' concern that the SOLSTICE
study was not sufficiently powered to detect difference in CMV viremia
clearance at week 16, one of the study's secondary endpoints. The
applicant noted that the study was powered to detect difference in CMV
viremia at week 8, which was the primary endpoint of the study.
In response to CMS' concern that overall rate of TEAEs and serious
TEAEs in the SOLSTICE trial was similar between the two treatment
groups, the applicant stated that the similar rate of TEAEs was due to
complexity of the patient population. They noted that the rate of TEAEs
in the LIVTENCITYTM group was driven by mild dysgeusia.
Similarly, a commenter stated that while the rate of any TEAEs was
similar for LIVTENCITYTM versus IAT, patients in the
LIVTENCITYTM group primarily experienced dysgeusia which did
not result in treatment discontinuation, while patients in the IAT
group experienced cytopenias and renal disorders that did lead to
treatment discontinuation. The applicant also stated that the rate of
TEAEs was not adjusted for drug exposure; drug exposure was longer in
the LIVTENCITYTM group versus the IAT group due to
toxicities in the IAT group. Finally, they noted that TEAEs leading to
discontinuation was higher in the IAT group versus the
LIVTENCITYTM group.
Another commenter stated, with respect to the same concern, that
while the rates of any serious TEAEs were similar between the groups,
the rate of treatment-related serious TEAEs was lower in the
LIVTENCITYTM group versus IAT (5.1% vs. 14.7%,
respectively), with the benefit persisting when taking into account
discontinuation rates. The commenter cited this result in support of a
finding that LIVTENCITYTM is a unique oral therapeutic
option for CMV that does not share the same problematic adverse events
of currently used off-label agents which the commenter stated often
lead to treatment discontinuation and thus,
[[Page 48954]]
suboptimal treatment of CMV infection and disease.
The applicant also responded to CMS' request for additional
information on safeguards taken to minimize or prevent bias from the
treating physician in choosing the conventional therapy for patients in
the IAT group of the SOLSTICE study. The applicant noted that SOLSTICE
was designed as an open-label study because the investigators had to
individualize the selection of the effective comparator in medically
complex patients with concomitant medications and adjust dosing of the
IAT agents based on renal function. Thus, the applicant asserted that
an open-label design was a safe and practical way to conduct the study.
The applicant also noted that the primary endpoint of the study was
assessed based on an objective laboratory endpoint at a fixed
timepoint. They stated that multiple sensitivity analyses were
conducted to address potential bias due to different rates of early
treatment discontinuation and that the primary endpoint was evaluated
in subgroups to establish treatment consistency and study
generalizability. The results of these sensitivity analyses of the
primary efficacy endpoint were consistent with the results of the
primary efficacy analysis and the benefit of the technology was also
consistent across key subpopulations.
Response: We thank the commenters for their input and appreciate
the clarifications in response to our concerns regarding the similar
rates of mortality and new-onset CMV between the two treatment groups,
the insufficient power to detect a difference in CMV viremia clearance
at week 16, and the similar rates of overall TEAEs and serious TEAEs in
the SOLSTICE study. Based on the additional information received, we
agree that LIVTENCITYTM represents a substantial clinical
improvement over existing technologies because it provides a new
treatment option for a patient population unresponsive to, or
ineligible for, currently available treatments, and significantly
improves the proportion of patients achieving CMV viremia at 8 weeks
and maintaining CMV clearance and symptom control at week 8 through
week 16, as well as reduces adverse effects such as neutropenia and
nephrotoxicity compared to available therapies.
After consideration of the public comments we received, we have
determined that LIVTENCITYTM meets the criteria for approval
for new technology add-on payment. Therefore, we are approving new
technology add-on payments for LIVTENCITYTM for FY 2023.
Cases involving the use of LIVTENCITYTM that are eligible
for new technology add-on payments will be identified by ICD-10-PCS
procedure codes XW0DX38 (Introduction of maribavir anti-infective into
mouth and pharynx, external approach, new technology group 8), XW0G738
(Introduction of maribavir anti-infective into upper GI, via natural or
artificial opening, new technology group 8), or XW0H738 (Introduction
of maribavir anti-infective into lower GI, via natural or artificial
opening, new technology group 8).
In its application, the applicant estimated that the cost of
LIVTENCITYTM is $50,000 for an 8-week course of therapy.
Under Sec. 412.88(a)(2), we limit new technology add-on payments to
the lesser of 65% of the average cost of the technology, or 65% of the
costs in excess of the MS-DRG payment for the case. As a result, the
maximum new technology add-on payment for a case involving the use of
LIVTENCITYTM is $32,500 for FY 2023.
e. UPLIZNA[supreg] (Inebilizumab-Cdon)
HTI-DAC, the manufacturer under the distributor Horizon
Therapeutics USA, Inc., submitted an application for new technology
add-on payment for UPLIZNA[supreg] (inebilizumab-cdon) for FY 2023. Per
the applicant, UPLIZNA[supreg] is the first FDA-approved anti-cluster
of differentiation 19 (CD19) B-cell depleter for the treatment of
neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-
aquaporin-4 (AQP4) antibody positive, for which 80% of all patients
with NMOSD test positive.\178\ According to the applicant, the goal of
UPLIZNA[supreg] is to reduce the risk of relapse and disability
progression. The applicant explained UPLIZNA[supreg] is a CD19+ B cell-
directed humanized afucosylated immunoglobulin F1 (IgG1) monoclonal
antibody. The applicant further explained that CD19 is a cell surface
antigen expressed on a broad range of B lymphocytes. Per the applicant,
UPLIZNA[supreg] is a B-cell depleter that binds specifically to CD19,
allowing it to target an extended range of B-cells that play a role in
NMOSD. The applicant stated that following cell surface binding to
CD19+ B lymphocytes, UPLIZNA[supreg] causes antibody-dependent cellular
cytolysis (ADCC), resulting in significant and robust B-cell depletion.
---------------------------------------------------------------------------
\178\ Wingerchuck, D. (2009, November 15). Neuromyelitis optica:
Effect of gender. Journal of the Neurological Sciences. Retrieved
October 6, 2021, from https://pubmed.ncbi.nlm.nih.gov/19740485/.
---------------------------------------------------------------------------
NMOSD is a rare, severe autoimmune disease of the central nervous
system that causes damage to the optic nerve, spinal cord, and brain
stem. NMOSD affects approximately 10,000-15,000 people in the United
States, and the incidence rate may be up to 9 times higher for women
than for men, with prevalence approximately 2- to 3-fold higher among
Black and Asian populations.\179\ According to the applicant, NMOSD is
characterized by unpredictable, recurrent attacks of inflammation of
the optic nerve (optic neuritis) and/or of the spinal cord (transverse
myelitis), and may also affect regions of the brain. The applicant
stated that attacks can be severe and result in life-altering permanent
disability, such as blindness and paralysis, and that recurring attacks
can have cumulative effects resulting in significant morbidity.
According to the applicant, aquaporin-4 antibodies are highly specific
to NMOSD and AQP4 is expressed on astrocytes throughout the central
nervous system. Per the applicant, in NMOSD, AQP4 antibodies bind to
AQP4, resulting in astrocyte cell death and inflammation. The applicant
stated that a sub-population of B-lineage cells, CD19+ plasmablasts,
produce AQP4 antibodies and that certain CD19+ B-cells are increased in
the blood of AQP4-seropositive individuals with NMOSD, with the highest
levels observed during an attack. According to the applicant, by
depleting a wide range of B-cells that express CD19 (including
plasmablasts and some plasma cells), UPLIZNA[supreg] reduces the risk
of relapses or attacks that may lead to permanent disability in NMOSD
patients.
---------------------------------------------------------------------------
\179\ Flanagan, E.P. et al. (2016, April 4). Epidemiology of
aquaporin[hyphen]4 autoimmunity and Neuromyelitis Optica Spectrum.
Wiley Online Library. Retrieved October 6, 2021, from https://onlinelibrary.wiley.com/doi/10.1002/ana.24617.
---------------------------------------------------------------------------
With respect to the newness criterion, the applicant stated that
UPLIZNA[supreg] was designated as a Breakthrough Therapy and received
Orphan Drug designation on February 10, 2016 for the treatment of
NMOSD.\180\ Per the applicant, UPLIZNA[supreg] received FDA approval on
June 11, 2020, for the treatment of NMOSD in adult patients who are
AQP4 antibody positive (BLA #761142). The applicant stated that
UPLIZNA[supreg] became commercially available on July 9, 2020,
following FDA approval. According to the applicant, UPLIZNA[supreg] is
administered as an intravenous infusion, and titrated to completion,
over approximately 90 minutes under the close supervision of an
experienced
[[Page 48955]]
healthcare professional. The applicant stated that the recommended
initial dose is a 300 mg intravenous infusion followed 2 weeks later by
a second 300 mg intravenous infusion. The applicant also stated that
subsequent doses, starting 6 months from the first infusion, consist of
a single 300 mg intravenous infusion every 6 months.
---------------------------------------------------------------------------
\180\ U.S. Food and Drug Administration website: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm.
---------------------------------------------------------------------------
According to the applicant, the following ICD-10-PCS procedure
codes may be used to identify administration of UPLIZNA[supreg] in the
inpatient setting, though they are not specific to UPLIZNA[supreg]:
3E033GC (Introduction of other therapeutic substance into the
peripheral vein, percutaneous approach) or 3E043GC (Introduction of
other therapeutic substance into central vein, percutaneous approach).
Effective October 1, 2022, the following ICD-10-PCS procedure codes
were created to uniquely describe the use of UPLIZNA[supreg]: XW03398
(Introduction of inebilizumab-cdon into peripheral vein, percutaneous
approach, new technology group 8) and XW04398 (Introduction of
inebilizumab-cdon into central vein, percutaneous approach, new
technology group 8).
As previously discussed, if a technology meets all three of the
substantial similarity criteria under the newness criterion, it would
be considered substantially similar to an existing technology and would
not be considered ``new'' for the purposes of new technology add-on
payments. According to the applicant, the only approved treatments for
NMOSD are UPLIZNA[supreg], Soliris[supreg] (eculizumab), and
ENSPRYNGTM (satralizumab). We note that
ENSPRYNGTM and Soliris[supreg] previously submitted
applications for new technology add-on payments. Please see discussion
of ENSPRYNGTM in the FY 2022 IPPS/LTCH PPS final rule (86 FR
45019 through 45028) and Soliris[supreg] in the FY 2021 IPPS/LTCH PPS
final rule (85 FR 58684 through 58689).
With respect to the first criterion, whether a product uses the
same or similar mechanism of action to achieve a therapeutic outcome,
the applicant stated that UPLIZNA[supreg] is the only treatment for
NMOSD that targets B-cells and causes B-cell depletion. The applicant
contrasted the mechanism of action of UPLIZNA[supreg] with those of
Soliris[supreg] and ENSPRYNGTM. Per the applicant, the
mechanism of action of Soliris[supreg] is the inhibition of aquaporin-
4-antibody induced terminal complement C5b-9 deposition.\181\ The
applicant explained that Soliris[supreg] specifically binds to
complement protein C5, inhibiting its cleavage to C5a and C5b and
preventing the generation of C5b-9. The applicant also stated that
ENSPRYNGTM is a recombinant humanized anti-human
interleukin-6 (IL-6) receptor monoclonal antibody. Per the applicant,
the mechanism of action of ENSPRYNGTM involves the
inhibition of IL-6-mediated signaling through binding to soluble and
membrane-bound IL-6 receptors.\182\ Thus, the applicant asserted that
each of the three FDA approved treatments for NMOSD--UPLIZNA[supreg],
Soliris[supreg], and ENSPRYNGTM--bind to a different
molecular target and have different mechanisms of action.
---------------------------------------------------------------------------
\181\ U.S. Food and Drug Administration. (2019, June). Soliris
Prescribing Information. Retrieved October 6, 2021, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125166s431lbl.pdf.
\182\ Genentech. (2020, August). ENSPRYNG Factsheet. Retrieved
October 6, 2021, from https://www.gene.com/download/pdf/genentech_enspryng_factsheet.pdf.
---------------------------------------------------------------------------
With respect to the second criterion, whether a product is assigned
to the same or a different MS-DRG when compared to an existing
technology, the applicant stated that cases representing patients who
may be eligible for treatment with UPLIZNA[supreg] map to MS-DRGs 058,
059, or 060 (Multiple Sclerosis and Cerebellar Ataxia with MCC, with
CC, or without CC/MCC, respectively), which are the same MS-DRGs to
which existing technologies may also be assigned.
With respect to the third criterion, whether the new use of
technology involves the treatment of the same or similar type of
disease and the same or similar patient population when compared to an
existing technology, the applicant asserted that, while UPLIZNA[supreg]
treats a patient population with the same type of disease (NMOSD) as
Soliris[supreg] or ENSPRYNGTM, it offers a treatment option
for a subset of this patient population, which differentiates it from
existing technologies. Per the applicant, UPLIZNA[supreg] has not been
shown to carry an increased risk of meningitis and may be used in
patient populations who are unvaccinated with the meningococcal vaccine
and/or are not able to use prophylactic antibiotics. The applicant
noted that while patients with NMOSD who are unvaccinated with the
meningococcal vaccine can still receive other approved treatments for
NMOSD, such as Soliris[supreg] or ENSPRYNGTM, they need to
have a risk reduction protocol instituted at the time of treatment and,
in some cases, may require two weeks of prophylactic antibacterial
treatment first.183 184
---------------------------------------------------------------------------
\183\ Soliris[supreg] prescribing details: https://solirispro.com/pdf/Soliris_USPI.pdf.
\184\ ENSPRYNGTM prescribing information: https://www.gene.com/download/pdf/enspryng_prescribing.pdf.
---------------------------------------------------------------------------
In summary, the applicant maintained that UPLIZNA[supreg] is not
substantially similar to other currently available therapies and/or
technologies because it uses a new mechanism of action and treats a
different subset of the patient population with NMOSD compared to an
existing technology.
In the proposed rule, we questioned whether the subset of the
patient population with NMOSD--specifically, patients who are
unvaccinated with the meningococcal vaccine--is considered a new
patient population since, as previously discussed in the FY 2022 IPPS/
LTCH PPS final rule (86 FR 45021), ENSPRYNGTM is also not
contraindicated in patients with unresolved serious Neisseria
meningitidis infections, and therefore, may be a treatment option for
patients with meningococcal disease as well as UPLIZNA[supreg].
Furthermore, as we previously stated in the FY 2022 IPPS/LTCH PPS final
rule, individuals that are not vaccinated against Neisseria
meningitidis are not considered a separate patient population because
eligibility can be easily attained via a widely available vaccine (86
FR 45027). Additionally, we questioned whether the additional
requirements for patients taking Soliris[supreg]--namely participation
in a risk reduction protocol related to the associated risk of
meningococcal infections, and prophylactic antibiotic treatment that
may result in a 2-week delay for treatment--constitute a new patient
population for technologies without those requirements.
We invited public comments on whether UPLIZNA[supreg] is
substantially similar to existing technologies and whether
UPLIZNA[supreg] meets the newness criterion.
Comment: The applicant submitted a public comment regarding the
newness criterion. With respect to the first criterion to determine
newness, whether a product uses the same or similar mechanism of
action, the applicant reiterated its assertion that UPLIZNA[supreg] has
a novel mechanism of action which satisfies the newness criterion. The
applicant stated that UPLIZNA[supreg] is the first and only B-cell
depleting monotherapy approved for neuromyelitis optica spectrum
disorder (NMOSD) in adult patients who are anti-aquaporin-4 antibody
positive. The applicant explained that the mechanism of action of
UPLIZNA[supreg] involves binding to CD19+ B-cells leading to antibody-
dependent, cell-mediated B-cell depletion. As a result, the applicant
[[Page 48956]]
stated UPLIZNA[supreg] reduces the damage caused to the optic nerve,
spinal cord, and brain by NMOSD attacks, thus reducing cumulative
damage and rates of disability.
With respect to the third criterion to determine newness and our
concern that patients who are unvaccinated with the meningococcal
vaccine may not represent a new patient population for NMOSD, the
applicant stated that in small populations such as those with rare
diseases, special considerations such as vaccination status, prior
therapies, drug interactions, or contraindications are important as
certain nuances related to a particular treatment within these small
populations can be uncovered, and providers must often choose one
therapy over another due to specific patient attributes and health
histories.
Response: We appreciate the applicant's input and agree that
UPLIZNA[supreg] has a unique mechanism of action when compared to
existing technologies for treating NMOSD, as UPLIZNA[supreg] is the
only CD19+ B-cell depleting monotherapy approved for NMOSD in adult
patients who are anti-aquaporin-4 antibody positive, compared to
Soliris[supreg] which specifically binds to complement protein C5, and
ENSPRYNGTM which binds to soluble and membrane-bound IL-6
receptors. However, we continue to believe that UPLIZNA[supreg] does
not represent a treatment option for a new patient population. We
stated in the FY 2022 IPPS/LTCH PPS final rule that individuals who are
not vaccinated against Neisseria meningitidis are not considered a
separate patient population because eligibility can easily be attained
via a widely available vaccine (86 FR 45027). In addition,
ENSPRYNGTM, another approved medication for the treatment of
NMOSD, is also not contraindicated in patients with unresolved serious
Neisseria meningitidis infections and therefore, may be a treatment
option for patients with meningococcal disease along with
UPLIZNA[supreg].
Based on the comments received and the information submitted as
part of the FY 2023 new technology add-on payment application for
UPLIZNA[supreg], as discussed in the proposed rule (87 FR 28303 through
28304) and in this final rule, we believe that UPLIZNA[supreg] has a
unique mechanism of action and is not substantially similar to existing
treatment options for NMOSD. While the applicant stated that it became
commercially available on July 9, 2020, we believe that the beginning
of the newness period for UPLIZNA[supreg] would be June 11, 2020, which
is the date that UPLIZNA[supreg] received FDA marketing authorization,
as the applicant did not provide documentation of a delay in commercial
availability.
With respect to the cost criterion, the applicant presented the
following analysis. The applicant searched the FY 2019 Medicare
Provider Analysis and Review (MedPAR) Hospital Limited Data Set (LDS)
for cases with ICD-10-CM diagnosis code G36.0 for Neuromyelitis optica
[Devic] (NMOSD) coded in the first diagnosis position. The applicant
determined that cases representing patients who may be eligible for
treatment with UPLIZNA[supreg] would map to MS-DRGs 058, 059, or 060
(Multiple Sclerosis and Cerebellar Ataxia with MCC, with CC, or without
CC/MCC, respectively).
The applicant determined a case count of 257 after imputing a value
of 11 for MS-DRGs with a case volume under 11. The applicant then
removed 100% of the drug charges to estimate the potential decrease in
costs due to the use of UPLIZNA[supreg]. The applicant noted that,
although use of UPLIZNA[supreg] would replace current drug charges for
therapies such as azathioprine, methotrexate, and rituximab, it is not
possible to differentiate between drug costs on MedPAR claims, and so
it removed all drug charges to be conservative. The applicant then
standardized the charges and applied a 4-year inflation factor of
1.281834, or 28.1834%, based on the inflation factor used to update the
outlier threshold in the FY 2022 IPPS/LTCH PPS final rule (86 FR
45542). The applicant added charges for the new technology by dividing
the estimated cost of UPLIZNA[supreg] by the national average CCR for
drugs which is 0.187, from the FY 2022 IPPS/LTCH PPS final rule (86 FR
44966).
The applicant calculated a final inflated average case-weighted
standardized charge per case of $764,547, which exceeded the average
case-weighted threshold amount of $48,165. Because the final inflated
average case-weighted standardized charge per case exceeded the average
case-weighted threshold amount, the applicant asserted that
UPLIZNA[supreg] meets the cost criterion.
We invited public comments on whether UPLIZNA[supreg] meets the
cost criterion.
We did not receive any comments on whether UPLIZNA[supreg] meets
the cost criterion. Based on the information submitted by the applicant
as part of its FY 2023 new technology add-on payment application for
UPLIZNA[supreg], as discussed in the proposed rule (87 FR 28304) and
previously summarized, the final inflated average case-weighted
standardized charge per case exceeded the average case-weighted
threshold amount. Therefore, UPLIZNA[supreg] meets the cost criterion.
With regard to the substantial clinical improvement criterion, the
applicant made two assertions. First, the applicant asserted that
UPLIZNA[supreg] offers a treatment option for a patient population that
is ineligible for currently available treatments. Specifically, the
applicant asserted that UPLIZNA[supreg] is a new treatment option for
patients who carry an increased risk of meningitis, patients following
treatments with more frequent and burdensome dosing schedules, and
patient populations more likely to be impacted by health disparities.
Finally, the applicant asserted that UPLIZNA[supreg] significantly
improves clinical outcomes relative to currently available technologies
because it reduced the risk of NMOSD attacks and disability progression
among patients with NMOSD when compared to placebo in the N-MOmentum
trial, which the applicant asserted is the largest NMOSD study
conducted.\185\
---------------------------------------------------------------------------
\185\ Marignier, R. et al., (2021, March 26). Disability
Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis
Optica Spectrum Disorder. Neurology[supreg] neuroimmunology &
neuroinflammation. Retrieved October 6, 2021, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054974/.
---------------------------------------------------------------------------
With respect to the applicant's assertion that UPLIZNA[supreg] is a
substantial clinical improvement over existing technologies because it
represents a new treatment option for a patient population ineligible
for currently available treatments, the applicant stated that
UPLIZNA[supreg] may be used in patient populations who are unvaccinated
with the meningococcal vaccine and/or are not able to use prophylactic
antibiotics because UPLIZNA[supreg] has not been shown to carry an
increased risk of meningitis, as compared with Soliris[supreg].
To support this claim, the applicant cited an article from the CDC
explaining that patients taking complement inhibitors, such as
Soliris[supreg], are at an increased risk for meningococcal disease
\186\ and referenced the CDC's recommendation that patients receive the
meningococcal vaccination prior to initiating treatment with a
complement inhibitor. The applicant also cited a
[[Page 48957]]
study by McNamara et al.\187\ that identified 16 cases in the U.S.
between 2008 and 2016 of patients who were taking Soliris[supreg] who
had meningococcal disease despite having received at least 1 dose of
meningococcal vaccine before disease onset. Referring to the same
article by McNamara et al., the applicant stated that some healthcare
providers recommend prophylactic antibiotics even for vaccinated
patients during treatment with Soliris[supreg], exposing them to long-
term antibiotic use, which carries the risk of developing antimicrobial
resistance.
---------------------------------------------------------------------------
\186\ Centers for Disease Control and Prevention. (2019, May
31). Taking complement inhibitors increases risk for meningococcal
disease/CDC. Centers for Disease Control and Prevention. Retrieved
October 1, 2021, from https://www.cdc.gov/meningococcal/about/soliris-patients.html.
\187\ McNamara, L. et al. (2017, July 7). High Risk for Invasive
Meningococcal Disease Among Patients Receiving Eculizumab (Soliris)
Despite Receipt of Meningococcal Vaccine. Retrieved October 6, 2021,
from https://www.cdc.gov/mmwr/volumes/66/wr/pdfs/mm6627e1.pdf.
---------------------------------------------------------------------------
Furthermore, the applicant claimed that UPLIZNA[supreg] represents
a new treatment option for patients following treatments with more
frequent and burdensome dosing schedules than UPLIZNA[supreg]. Per the
applicant, the dosing schedule for UPLIZNA[supreg] consists of 2
initial doses delivered 2 weeks apart, followed by 1 dose every 6
months after that.\188\ In comparison, based on the FDA prescribing
information for Soliris[supreg], the applicant asserted that
UPLIZNA[supreg]'s 6-month dosing regimen is less frequent than that of
Soliris[supreg], and, therefore, is less burdensome to follow.\189\ The
applicant asserted the dosing schedule for UPLIZNA[supreg] is more
amenable to NMOSD patients for whom more frequent intravenous infusions
may be burdensome and stated that its characteristics as a treatment
regimen, compared to SolirisTM, may help to improve
medication adherence and decrease likelihood of relapse and
hospitalization relative to placebo. To further demonstrate that
UPLIZNA[supreg] may help to improve long-term patient adherence,
compared to SolirisTM, the applicant provided a review by
Vlasnik et al.\190\ noting that medication regimen complexity is one
factor that can negatively affect adherence. The applicant emphasized
that, for NMOSD, medication adherence to maintain immune suppression is
essential for reducing the risk of attacks, which can lead to
hospitalization, vision loss and paralysis. Finally, the applicant
stated that UPLIZNA[supreg] poses less of a barrier for patient access,
as it does not require patients or providers to participate in FDA's
Risk Evaluation and Mitigation Strategy (REMS) program, or receive
additional counselling regarding the program, as required by
Soliris[supreg].\191\
---------------------------------------------------------------------------
\188\ U.S. Food and Drug Administration. (2007, March).
Highlights of prescribing information administration. Retrieved
October 6, 2021, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125166lbl.pdf.
\189\ U.S. Food and Drug Administration. Alexion briefing
information for the November 18, 2014, meeting of the Drug Safety
and Risk Management Advisory Committee. https://www.fda.gov/advisory-committees/human-drug-advisory-committees/drug-safety-and-risk-management-advisory-committee.
\190\ Vlasnik, J. J., Aliotta, S. L., & DeLor, B. (2005, April
7). Medication adherence: Factors influencing compliance with
prescribed medication plans. The Case Manager. Retrieved October 6,
2021, from https://www.sciencedirect.com/science/article/abs/pii/S1061925905000263?via%3Dihub.
\191\ Alexion Pharmaceutical, Inc. (2020). Soliris REMS.
Retrieved October 6, 2021, from https://solirisrems.com/.
---------------------------------------------------------------------------
To support its claim that UPLIZNA[supreg] is a new treatment option
for populations that are more likely to be impacted by health
disparities, the applicant noted UPLIZNA[supreg]'s durable efficacy and
favorable safety profile among African Americans with NMOSD. To support
this claim, the applicant cited the safety results published by Cree et
al.\192\ from both a randomized control period (RCP) and an open label
period (OLP) of the N-MOmentum trial. The RCP phase of N-Momentum was a
multicenter, double-blind, 2/3 study conducted at 99 outpatient
specialty clinics or hospitals in 25 countries that lasted up to 197
days. The primary endpoint was time to onset of an NMOSD attack, as
determined by the investigator and adjudication committee. Eligible
participants were randomized in a 3:1 ratio to receive either 300 mg
intravenous UPLIZNA[supreg] (n=174) or a saline placebo (n=56) on days
1 and 15. Participants continued through the RCP for up to 28 weeks
unless they had a confirmed NMOSD attack, at which point they could
choose to continue in the OLP phase of the trial. The OLP included
eligible adult participants (n=230) who had had at least 1 NMOSD attack
in the year before screening or at least 2 attacks requiring rescue
therapy in the 2 years before screening. During the OLP, all patients
received UPLIZNA[supreg] for at least 2 years. As recommended by an
independent committee, enrollment in the RCP phase stopped prior to
study completion due to the early findings where 21 of 174 participants
(12%) receiving UPLIZNA[supreg] had an attack as compared with 22 of
the 56 placebo recipients (39%). Marignier et al. (2021) assessed
treatment effects in N-MOmentum by measuring score worsening of the
Expanded Disability Status Scale (EDSS) and modified Rankin Scale (mRS)
scores.\193\ EDSS scores were measured at baseline, then at RCP study
weeks 12 and 28, and every 3 months during the OLP, and within 5 days
of a potential attack. mRS scores were measured at baseline, and at
weeks 4, 8, 12, 16, 22, and 28 of the RCP. The Marignier results from
the N-MOmentum study found the annualized attack rate for African
Americans was lower at 0.06 compared to an annualized attack rate of
0.09 in the overall group exposed to UPLIZNA[supreg]. The applicant
stated that among the 19 African American participants who received
UPLIZNA[supreg] or placebo during the RCP and/or OLP of the N-MOmentum
trial, three had attacks 18, 29, and 104 days after their first
UPLIZNA[supreg] dose. The summary of baseline demographics and
characteristics of the intent-to-treat population notes that there were
14 African American participants who received UPLIZNA[supreg] and 5 who
received the placebo.\194\
---------------------------------------------------------------------------
\192\ Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ,
Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ,
Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S,
Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study
investigators. Inebilizumab for the treatment of neuromyelitis
optica spectrum disorder (N-MOmentum): a double-blind, randomised
placebo-controlled phase 2/3 trial. Lancet. 2019 Oct
12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub
2019 Sep 5. PMID: 31495497.
\193\ Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock
SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O,
Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees
W, Smith M, Ratchford JN, Katz E, Cree BAC; N-MOmentum Study
Investigators. Disability Outcomes in the N-MOmentum Trial of
Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurol
Neuroimmunol Neuroinflamm. 2021 Mar 26;8(3):e978. doi: 10.1212/
NXI.0000000000000978. PMID: 33771837; PMCID: PMC8054974.
\194\ Ibid.
---------------------------------------------------------------------------
With respect to its claim that UPLIZNA[supreg] significantly
improves clinical outcomes relative to previously available treatment
options, the applicant stated that patients taking UPLIZNA[supreg] had
a reduced risk of NMOSD attacks and disability progression when
compared to placebo in the N-MOmentum trial. The applicant again
referenced the results of the N-MOmentum trial reported by Cree et al.,
where 21 (12%) of the 174 participants receiving UPLIZNA[supreg] had an
attack by the time enrollment ended versus 22 (39%) of the 56
participants receiving placebo (hazard ratio (HR) 0[middot]272 [95% CI
0[middot]150-0[middot]496]; p<0[middot]0001). The applicant also
referred to the N-MOmentum results from the OLP and asserted that they
show long-term treatment with UPLIZNA[supreg] provided a sustained
reduction in NMOSD attack risk, MRI lesions, and NMOSD-related
hospitalizations regardless of treatment provided during the RCP. The
applicant
[[Page 48958]]
referenced the disability data published by Marignier et al.\195\ from
the results of the N-MOmentum trial on the use of UPLIZNA[supreg] and
asserted that they showed favorable results among patients with NMOSD
when compared to placebo. Specifically, Marignier et al. assessed the
treatment effects of UPLIZNA[supreg] in comparison with placebo by
using a worsening score of the Expanded Disability Status Scale (EDSS)
to measure confirmed disability progression (CDP). The applicant
asserted that the results show UPLIZNA[supreg] reduced the risk of 3-
month CDP compared with placebo (HR: 0.375; 95% CI: 0.148-0.952;
p=0.0390). The applicant also stated that UPLIZNA[supreg] showed a
significantly lower risk of relapse among patients with NMOSD when
compared to placebo. The applicant cited results from Pittock et
al.,\196\ a randomized, double-blind, time-to-event trial in which 143
adult subjects were randomly assigned to receive either UPLIZNA[supreg]
or placebo weekly and continued use of an immunosuppressive therapy, as
needed. The primary endpoint was the first adjudicated relapse, while
secondary endpoints included the adjudicated annualized relapse rate.
Pittock et al. reported that adjudicated relapses occurred in 3 of 96
patients (3%) in the UPLIZNA[supreg] group and 20 of 47 (43%) in the
placebo group (hazard ratio 0.06; 95% confidence interval [CI], 0.02 to
0.20; P<0.001). The adjudicated annualized relapse rate was 0.02 in the
eculizumab group and 0.35 in the placebo group (rate ratio, 0.04; 95%
CI, 0.01 to 0.15; P<0.001). Referring to the results from the Pittock
et al. study, the applicant asserted that UPLIZNA[supreg] showed a
consistent effect in reducing the risk of attack compared to placebo,
regardless of baseline disability status, attack history, or disease
duration.\197\
---------------------------------------------------------------------------
\195\ Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock
SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O,
Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees
W, Smith M, Ratchford JN, Katz E, Cree BAC; N-MOmentum Study
Investigators. Disability Outcomes in the N-MOmentum Trial of
Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurol
Neuroimmunol Neuroinflamm. 2021 Mar 26;8(3): e978. doi: 10.1212/
NXI.0000000000000978. PMID: 33771837; PMCID: PMC8054974.
\196\ Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace
J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A,
Fujita KP, Armstrong R, Wingerchuk DM. Eculizumab in Aquaporin-4-
Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019
Aug 15;381(7):614-625. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.
PMID: 31050279.
\197\ Ibid.
---------------------------------------------------------------------------
In the proposed rule, we stated we had the following concerns
regarding whether UPLIZNA[supreg] meets the substantial clinical
improvement criterion. First, we noted that while the applicant
provided data comparing UPLIZNA[supreg] to placebo, we did not receive
any data to demonstrate improved outcomes over existing FDA approved
treatments. We stated that additional information comparing outcomes
such as relapse rate, risk of relapse, and disability progression for
patients receiving UPLIZNA[supreg] versus other currently available
treatments would help inform our assessment of whether UPLIZNA[supreg]
demonstrates a substantial clinical improvement over existing
technologies. Second, while the applicant asserted that UPLIZNA[supreg]
represents a new treatment option for patients who are unvaccinated
with the meningococcal vaccine, similar to the discussion in the FY
2022 IPPS/LTCH PPS final rule (86 FR 45021) in response to a similar
assertion with respect to ENSPRYNGTM, we noted that
ENSPRYNG[supreg] is also not contraindicated in patients with
unresolved serious Neisseria meningitidis infection and therefore may
also be a treatment option for patients with meningococcal disease. We
further noted that the use of ENSPRYNGTM to treat patients
with NMOSD does not require a meningococcal vaccination. We noted that
the applicant sought to support its claim that UPLIZNA[supreg]
represents a new treatment option for patients who are unvaccinated
against Neisseria meningitidis through the inference that
Soliris[supreg] has a high risk of causing meningitis; however, as
stated in the proposed rule, we had concerns about the applicant's
claim because Neisseria meningitidis may easily be mitigated through
the use of a common vaccine or antimicrobials. As discussed in the FY
2022 IPPS/LTCH PPS final rule in response to similar claims with
respect to ENSPRYNG[supreg], and as noted previously, individuals that
are not vaccinated against Neisseria mengitidis are not considered a
separate patient population because eligibility can be easily attained
via a widely available vaccine and are also able to receive treatment
with UPLIZNA[supreg] which does not require a vaccine (86 FR 45027).
With regard to the applicant's claim that UPLIZNA[supreg] is a new
treatment option for patients following treatments with more frequent
dosing schedules, we stated in the proposed rule that we are unsure
whether these patients may be considered as a separate patient
population ineligible for currently available treatments. For example,
although the applicant compared the UPLIZNA[supreg] dosing regimen
against Soliris[supreg], it did not provide a similar comparison
against ENSPRYNGTM, which--similar to UPLIZNA[supreg]--does
not require frequent intravenous infusions or participation in the FDA
REMS program (see 86 FR 45020). Therefore, we stated that it is unclear
whether UPLIZNA[supreg] provides a treatment option for a separate
patient population that is ineligible for currently available
treatments, when there are other available treatments, like
ENSPRYNGTM, without the limitations that the applicant
described with respect to Soliris[supreg]. In addition, while the
applicant stated that UPLIZNA's[supreg] dosing regimen may help to
improve long-term patient medication adherence and decrease the
likelihood of relapse and hospitalization, we questioned the strength
of the correlation between UPLIZNA's[supreg] dosing regimen and these
outcomes. We stated our interest in additional information on the
efficacy results of UPLIZNA[supreg] among African Americans with NMOSD,
as cited by the applicant, as we understand that NMOSD
disproportionately affects African American and Asian populations at
rates approximately 2- to 3-fold higher than their Caucasian
counterparts.\198\ Specifically, we questioned whether the
retrospective analysis of the results from the N-MOmentum trial on the
annualized attack rate for African Americans (0.06 compared with 0.09
in the overall group) is generalizable to larger populations because
the study included low numbers of participants. Of the 20 African
American participants randomized in N-Momentum, 19 were AQP4 antibody
positive and 1 was AQP4 antibody negative. As a result, of the 19
participants, 14 received UPLIZNA[supreg], and only 5 received
placebo.199 200 We further noted that the applicant did not
provide comparative data on the efficacy of UPLIZNA[supreg],
[[Page 48959]]
Soliris[supreg], and ENSPRYNGTM in these populations.
---------------------------------------------------------------------------
\198\ Flanagan, E.P. et al. (2016, April 4). Epidemiology of
aquaporin[hyphen]4 autoimmunity and Neuromyelitis Optica Spectrum.
Wiley Online Library. Retrieved October 6, 2021, from https://onlinelibrary.wiley.com/doi/10.1002/ana.24617.
\199\ Bernitsas, E., Cimbora, D., Dinh, Q., She, D., Katz, E.
Safety and Efficacy of Inebilizumab in African Americans with
Neuromyelitis Optica Spectrum Disorder. Poster presentation at the
15th World Congress on Controversies in Neurology (CONy Virtual).
September 23-26, 2021.
\200\ Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ,
Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ,
Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S,
Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study
investigators. Inebilizumab for the treatment of neuromyelitis
optica spectrum disorder (N-MOmentum): a double-blind, randomised
placebo-controlled phase 2/3 trial. Lancet. 2019 Oct
12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub
2019 Sep 5. PMID: 31495497.
---------------------------------------------------------------------------
We invited public comments on whether UPLIZNA[supreg] meets the
substantial clinical improvement criterion.
Comment: We received several comments in support of new technology
add-on payments for UPLIZNA[supreg], including one from the applicant,
in response to CMS' concerns in the proposed rule. With respect to the
concern regarding the lack of data comparing UPLIZNA[supreg] to
existing FDA-approved treatments, the applicant stated that conducting
head-to-head trials is often not possible when studying rare diseases
due to the small patient populations and potential delays if trials for
the same indication are running simultaneously. The applicant noted
that the timing and availability of Soliris[supreg] and
ENSPRYNGTM (approved by FDA on June 27, 2019 and August 17,
2020, respectively) did not allow for comparative trials, as there were
no approved medications for the treatment of NMOSD for the entirety of
the N-MOmentum study. The applicant stated that CMS has granted new
technology add-on payments in situations where comparative head-to-head
trials were not available, referencing two technologies without
comparative clinical data that were granted new technology add-on
payments in FY 2019 and FY 2022, as well as two additional examples
from FY 2022 that were both FDA-approved based on the results of
single-arm clinical trials. We note that the applicant did not identify
the specific technologies. The applicant stated that, because these
products were granted new technology add-on payments without direct
comparative data with their respective clinical competitors, that
substantial clinical improvement can be ascertained through product
attributes and randomized clinical trial outcomes in the absence of
direct, comparative head-to-head trials.
With respect to the concern regarding the lack of data
demonstrating improved outcomes over existing FDA approved treatments,
the applicant noted that N-MOmentum is the largest-ever clinical trial
conducted in patients with NMOSD, the results of which showed that
patients taking UPLIZNA[supreg] experienced fewer relapses and fewer
hospitalizations than patients on placebo. The applicant stated that
compared with placebo, patients treated with UPLIZNA[supreg] had a
reduced risk of 3-month EDSS-confirmed disability progression (CDP).
The applicant also noted that although disability outcomes data cannot
be compared across therapies, other therapies' disability data were
studied using different endpoints as secondary measures and/or were not
reported because of lack of statistical significance. The applicant
referred to the PREVENT trial for Soliris[supreg], which studied EDSS
and mRS as secondary outcome measures up to 211 weeks and noted that
there was no significant difference in disability progression between
the Soliris[supreg] groups and placebo. The applicant also referred to
the SakuraStar and SakuraSky trials for ENSPRYNG and noted that no
significant effect on disability was observed. In contrast, the
applicant stated that UPLIZNA[supreg] showed a consistent effect in
reducing the risk of disability worsening compared to placebo,
regardless of baseline disability status, attack history, or disease
duration. The applicant asserted that despite head-to-head studies not
being possible at the time registrational trials were conducted, the
data and efficacy and clinical efficiency attributes of UPLIZNA[supreg]
present an improvement for patients over other therapies.
In response to CMS' feedback regarding the comparison of dosing and
long-term adherence to other available treatments for NMOSD, the
applicant confirmed it had provided details of dosing for
Soliris[supreg] in its application and included dosing details for
ENSPRYNGTM in its comments, noting that
ENSPRYNGTM requires more frequent administration than
UPLIZNA[supreg]. The applicant referenced long-term adherence data
showing that UPLIZNA[supreg] adherence was approximately 85% after two
years. The applicant stated that the improved medication adherence data
from analogue disease states suggest that twice yearly dosing, as with
UPLIZNA[supreg], is associated with improved adherence over other
regimens. The applicant also stated that the data suggest that
adherence and persistence to therapy may lead to improved clinical
outcomes.
In addition, the applicant extrapolated results from a
retrospective claims analysis looking at the use of MS disease-
modifying therapies (DMTs) that concluded that a twice-yearly dosing
schedule achieved superior adherence and persistence at 12, 18, and 24
months versus other dosing regimens or routes of administration. Other
commenters also mentioned the convenient dosing schedule of
UPLIZNA[supreg], which potentially simplifies the lives of NMOSD
patients and thereby improves compliance, which they noted is critical
for the prevention of disease relapse and for ensuring good patient
outcomes.
The applicant noted that persistence and adherence to a therapy
such as UPLIZNA[supreg] are important to achieving positive clinical
outcomes, and reiterated that studies have shown that relapses can lead
to hospitalizations, long-term disability, and permanent harm to the
patient. According to a commenter, administration of UPLIZNA[supreg] in
the hospital setting, immediately after diagnosis and acute treatment
of the relapse can be life saving for the patient, as early treatment
leads to better outcomes and reduces relapse rate and subsequent
disability. Commenters emphasized the potential for permanent damage
related to relapses of NMOSD and therefore the importance of timely
treatment to prevent relapse.
The applicant also responded to CMS' question regarding the
generalizability of the retrospective analysis of the efficacy results
of UPLIZNA[supreg] among Black/African American patients with NMOSD,
which the applicant provided to support its claim that UPLIZNA[supreg]
is a new treatment option for populations that are more likely to be
impacted by health disparities. NMOSD disproportionately affects Black/
African American and Asian populations at rates approximately 2-to 3-
fold higher than Caucasians. As noted in its application, the applicant
stated that the annualized attack rates for Black/African American
participants observed in the N-MOmentum study were promising, despite
the relatively low number of participants in the study. The applicant
noted that the FDA Statistical Review of UPLIZNA[supreg] confirmed that
the applicant could report subgroup analyses based on sex, race, age,
and region and these data suggest that UPLIZNA[supreg] is at least as
effective in the Black/African American subpopulation as it is in the
general patient population. The applicant noted the difficulty of
enrolling large numbers of patients in studies for rare conditions, and
stated that subgroup data provided can still represent important
considerations in identifying a benefit in populations that face
disproportionately higher rates of NMOSD. As is often the case with
rare diseases such as NMOSD, relatively small numbers of participants
result in small subpopulations; however, the applicant noted,
interpreting results in small subgroups must be done cautiously.
Response: We thank the commenters for their input. After further
review, we continue to have concerns as to whether UPLIZNA[supreg]
meets the substantial clinical improvement criterion to be approved for
new technology add-on payments. We agree with the
[[Page 48960]]
commenters that timely treatment for relapse prevention in NMOSD is
important. However, it is unclear whether UPLIZNA[supreg] leads to
improved relapse prevention, or other improved outcomes, as compared to
other available treatments for NMOSD. We note that the applicant did
not provide data comparing outcomes such as time to first relapse and
number of relapses with Soliris[supreg] or UPLIZNA[supreg]. We further
note that the applicant stated that, of the available therapies, only
UPLIZNA[supreg] demonstrated a statistically significant effect on
disability progression compared to placebo in its clinical trial.
However, as the applicant noted, there were differences between the
trials, including size of the trials and disability endpoints assessed.
We believe this makes it difficult to demonstrate superior effect on
disability progression, especially without a comparison of relapse
rates, with which disability is associated. We also note that time-to-
first-relapse is one endpoint that was consistent across all three
trials, and that the results of a meta analysis comparing published
efficacy outcomes for Soliris[supreg], UPLIZNA[supreg], and
ENSPRYNGTM showed that Soliris[supreg] demonstrated greater
efficacy in prolonging time-to-relapse compared to UPLIZNA[supreg] and
ENSPRYNGTM.\201\ While we agree with the applicant that substantial
clinical improvement can be determined without head-to-head trials, we
note that we evaluate every application on its own data and merits to
determine whether it meets the new technology add-on payment criterion
for substantial clinical improvement, and we consider variations in the
currently available technologies that an applicant technology is
compared against for the purposes of determining whether the technology
represents a substantial clinical improvement over existing
technologies. We further note that it is unclear which technologies the
applicant is referring to in stating that CMS has previously approved
new technology add-on payments for technologies without a demonstration
of comparative outcomes.
---------------------------------------------------------------------------
\201\ Wingerchuck, et al. Indirect comparison analysis of FDA-
approved treatment options for adults with aquaporin-4
immunoglobulin G-positive neuromyelitis optica spectrum disorder.
---------------------------------------------------------------------------
Furthermore, with regard to improved adherence, while the applicant
provided information regarding UPLIZNA[supreg] adherence, it did not
compare these values to adherence for other therapies and therefore
this information does not support a finding of substantial clinical
improvement. Lastly, the retrospective claims analysis the applicant
provided to support a correlation between long-term medication
adherence and decreased relapse and hospitalization assessed the
adherence and persistence of multiple sclerosis patients treated with a
drug that had the same dosing regimen as UPLIZNA[supreg]--but not NMOSD
patients treated with UPLIZNA[supreg].
After review of the information submitted by the applicant as part
of its FY 2023 new technology add-on payment application for
UPLIZNA[supreg] and consideration of the comments received, we are
unable to determine that UPLIZNA[supreg] meets the substantial clinical
improvement criterion for the reasons discussed in the proposed rule
and in this final rule, and therefore we are not approving new
technology add-on payments for UPLIZNA[supreg] for FY 2023.
7. FY 2023 Applications for New Technology Add-On Payments (Alternative
Pathways)
As discussed previously, beginning with applications for FY 2021,
under the regulations at Sec. 412.87(c), a medical device that is part
of FDA's Breakthrough Devices Program and has received marketing
authorization for the indication covered by the Breakthrough Device
designation may qualify for the new technology add-on payment under an
alternative pathway. Additionally, beginning with FY 2021, under the
regulations at Sec. 412.87(d), a medical product that is designated by
FDA as a QIDP and has received marketing authorization for the
indication covered by the QIDP designation, and, beginning with FY
2022, a medical product that is a new medical product approved under
FDA's LPAD and used for the indication approved under the LPAD pathway,
may also qualify for the new technology add-on payment under an
alternative pathway. Under an alternative pathway, a technology will be
considered not substantially similar to an existing technology for
purposes of the new technology add-on payment under the IPPS and will
not need to meet the requirement that it represents an advance that
substantially improves, relative to technologies previously available,
the diagnosis or treatment of Medicare beneficiaries. These
technologies must still be within the 2-3 year newness period to be
considered ``new,'' and must also still meet the cost criterion. We
refer readers to section II.H.8. of the preamble of the FY 2020 IPPS/
LTCH PPS final rule (84 FR 42292 through 42297) and section II.F.6 of
preamble of the FY 2021 IPPS/LTCH PPS final rule (85 FR 58715 through
58733) for further discussion of the alternative new technology add-on
payment pathways for these technologies.
We note, section 1886(d)(5)(K)(ii)(II) of the Act provides for the
collection of data with respect to the costs of a new medical service
or technology described in subclause (I) for a period of not less than
2 years and not more than 3 years beginning on the date on which an
inpatient hospital code is issued with respect to the service or
technology. Our regulations in Sec. 412.87(c)(2) for breakthrough
devices and Sec. 412.87(d)(2) for certain antimicrobial products state
that a medical device/product that meets the condition in paragraph
(c)(1) or (d)(1) of Sec. 412.87 will be considered new for not less
than 2 years and not more than 3 years after the point at which data
begin to become available reflecting the inpatient hospital code (as
defined in section 1886(d)(5)(K)(iii) of the Act) assigned to the new
technology (depending on when a new code is assigned and data on the
new technology become available for DRG recalibration). After CMS has
recalibrated the DRGs, based on available data, to reflect the costs of
an otherwise new medical technology, the medical technology will no
longer be considered ``new'' under the criterion of this section.
We received 19 applications for new technology add-on payments for
FY 2023 under the new technology add-on payment alternative pathways.
Six applicants withdrew applications prior to the issuance of the
proposed rule. Subsequently, five applicants withdrew their respective
applications for LigaPASS 2.0 PJK Prevention System, Magnus
Neuromodulation System with SAINT Technology, the Precision
TAVITM Coronary Module, the TOPSTM System, and
the VITARIA[supreg] System prior to the issuance of this final rule.
Two applicants, Phagenesis Ltd. (the applicant for Phagenyx[supreg]
System) and Neuro Event Labs, Inc. (the applicant for the Nelli[supreg]
Seizure Monitoring System), did not meet the July 1 deadline for FDA
approval or clearance of the technology and, therefore, the
technologies are not eligible for consideration for new technology add-
on payments for FY 2023. A discussion of the remaining 6 applications
is presented in this final rule, including 5 technologies that have
received a Breakthrough Device designation from FDA and 1 that was
designated as a QIDP by FDA.
In accordance with the regulations under Sec. 412.87(e)(2),
applicants for new technology add-on payments, including Breakthrough
Devices, must have FDA marketing authorization by July 1 of the
[[Page 48961]]
year prior to the beginning of the fiscal year for which the
application is being considered. Under the policy finalized in the FY
2021 IPPS/LTCH PPS final rule (85 FR 58742), we revised the regulations
at Sec. 412.87(e) by adding a new paragraph (e)(3) which provides for
conditional approval for a technology for which an application is
submitted under the alternative pathway for certain antimicrobial
products (QIDPs and LPADs) at Sec. 412.87(d) that does not receive FDA
marketing authorization by the July 1 deadline specified in Sec.
412.87(e)(2), provided that the technology receives FDA marketing
authorization by July 1 of the particular fiscal year for which the
applicant applied for new technology add-on payments. We refer the
reader to the FY 2021 IPPS/LTCH PPS final rule for a complete
discussion of this policy (85 FR 58737 through 58742).
As we did in the FY 2022 IPPS/LTCH PPS proposed rule, for
applications under the alternative new technology add-on payment
pathway, in the FY 2023 IPPS/LTCH PPS proposed rule, we proposed to
approve or disapprove each of these six applications for FY 2023 new
technology add-on payments. Therefore, in this section of the preamble
of this final rule, we provide background information on each of the
remaining six alternative pathway applications and our determinations
as to whether or not each technology is eligible for new technology
add-on payments for FY 2023. Consistent with our standard approach, we
are not including in this final rule the description and discussion of
applications that were withdrawn or that are ineligible for
consideration for FY 2023 due to not meeting the July 1 deadline,
described previously, which were included in the FY 2023 IPPS/LTCH PPS
proposed rule. We are also not summarizing nor responding to public
comments received regarding these withdrawn or ineligible applications
in this final rule.
a. Alternative Pathway for Breakthrough Devices
(1) CERAMENT[supreg] G
BONESUPPORT AB submitted an application for new technology-add on
payments for CERAMENT[supreg] G for FY 2023. Per the applicant,
CERAMENT[supreg] G is an injectable bone-void filler made of calcium
sulfate, hydroxyapatite, and gentamicin sulfate indicated for the
surgical treatment of osteomyelitis. Per the applicant, this bone graft
substitute fills gaps resulting from debridement of infected bone and
prevents colonization of sensitive bacteria, promoting bone healing in
two ways. The applicant stated that the primary mode of action is for
CERAMENT[supreg] G to act as a resorbable ceramic bone-void filler
intended to fill gaps and voids in the skeleton system created when
infected bone is debrided. The applicant also stated that the secondary
mode of action is to prevent the colonization of gentamicin-sensitive
microorganisms in order to protect bone healing. Per the applicant,
CERAMENT[supreg] G may eliminate the need to harvest autologous bone,
avoiding pain and infection at the donor site. We note that BONESUPPORT
Inc. previously submitted an application for new technology add-on
payments for CERAMENT[supreg] G for FY 2022, as summarized in the FY
2022 IPPS/LTCH PPS proposed rule (86 FR 25368 through 25373) but the
technology did not meet the deadline of July 1, 2021, for FDA approval
or clearance of the technology and, therefore, was not eligible for
consideration for new technology add-on payments for FY 2022 (86 FR
45126 through 45127).
According to the applicant, CERAMENT[supreg] G is designated as a
Breakthrough Device for use as a bone-void filler as an adjunct to
systemic antibiotic therapy and surgical debridement as part of the
surgical treatment of osteomyelitis. The technology received FDA De
Novo marketing authorization on May 17, 2022 with an indication for use
as a bone void filler in skeletally mature patients as an adjunct to
systemic antibiotic therapy and surgical debridement (standard
treatment approach to a bone infection) as part of the surgical
treatment of osteomyelitis in defects in the extremities. The applicant
applied for and received a unique ICD-10-PCS procedure code to identify
cases involving the administration of CERAMENT[supreg] G in 2021.
Effective October 1, 2021, CERAMENT[supreg] G administration can be
identified by ICD-10-PCS procedure code XW0V0P7 (Introduction of
antibiotic eluting bone void filler into bones, open approach, new
technology group 7), which is unique to CERAMENT[supreg] G
administration. The applicant stated that the following existing ICD-
10-CM codes for osteomyelitis appropriately describe the proposed
indication for which the device received Breakthrough Device
designation (``Breakthrough Device Indication''):
[GRAPHIC] [TIFF OMITTED] TR10AU22.090
With respect to the cost criterion, the applicant identified
candidate cases using ICD-10-PCS procedure and ICD-10-CM diagnosis
codes, which are detailed in the tables in this section. With these
codes identified, the applicant then went through the Grouper logic in
the MS-DRG v39.0 Definitions Manual and located where cases with these
codes would be assigned in the MS-DRG system. This process yielded 13
MS-DRGs which the applicant used for their analysis. The applicant also
submitted an additional subanalysis using only cases from the
applicant's top three identified MS-DRGs (464, 493, and 504), to
demonstrate that the technology meets the cost criterion.
Under the first analysis, the applicant searched claims in the FY
2019
[[Page 48962]]
MedPAR final rule dataset within the 13 identified MS-DRGs that
reported one of the M86 ICD-10-CM diagnosis codes listed previously in
combination with the ICD-10-PCS procedure codes listed in the following
table, which identify procedures that could involve the use of
CERAMENT[supreg] G as an adjunct to systemic antibiotic therapy and
surgical debridement where there is a need for supplemental bone void
filler material.
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR10AU22.091
[[Page 48963]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.092
[[Page 48964]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.093
[[Page 48965]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.094
The applicant identified 11,620 cases across 13 MS-DRGs as
identified in the table that follows:
[GRAPHIC] [TIFF OMITTED] TR10AU22.095
BILLING CODE 4120-01-C
The applicant noted that candidate cases for CERAMENT[supreg] G
with osteomyelitis would qualify for the CC/MCC MS-DRGs because
osteomyelitis is listed in the Grouper as a CC condition. Therefore,
the applicant concluded that cases with osteomyelitis would not be
grouped in the uncomplicated MS-DRGs (for example, 465, 494, etc.). The
applicant stated that because osteomyelitis is never assigned to
uncomplicated surgical MS-DRGs, it excluded uncomplicated MS-DRGs from
its analysis.
The applicant then removed charges for the prior technology that
may be replaced by CERAMENT[supreg] G. The applicant conducted a market
analysis that identified 3 types of prior technology devices:
Poly(methyl methacrylate) (PMMA) manually mixed with antibiotics, PMMA
pre-loaded with antibiotics, and calcium sulfate (CaS) mixed with
antibiotics. The applicant researched the average sales price (ASP) for
major competitors for 5cc and 10cc of each device type and calculated a
weighted average cost of $444 per 5cc and $727 per 10cc.\202\ Then the
applicant converted costs to charges by dividing costs by the Supplies
&
[[Page 48966]]
Equipment CCR of 0.297 (86 FR 44966). Using this CCR, $444 per 5cc and
$727 per 10cc yielded an estimated hospital charge of prior
technologies of $1,495 per 5cc and $2,449 per 10cc. The applicant
explained that the total amount of antibiotics depends on the amount of
product required for different sized bones. The applicant then
standardized the charges and applied a 4-year inflation factor of
1.281834 based on the inflation factor used to update the outlier
threshold in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45542).
---------------------------------------------------------------------------
\202\ The applicant's analysis was informed by 2019 and 2020
data for Osteoset, Stimulan, and Calcigen S (calcium sulfates mixed
with antibiotics), Palacos, Cobalt (PMMA manually mixed with
antibiotics), Cobalt G, Biomet Bone Cement R, and Refobacin Bone
Cement R (PMMA pre-loaded with antibiotics) from three sources: an
iData Market Research 2019 Sku Data Report, Global Data US Hospital
Bone Grafts and Substitutes Q3 2019 Report, and feedback from sales
representatives in the field.
---------------------------------------------------------------------------
The applicant added estimated charges for the new technology by
dividing the estimated, expected hospital list price for the device
(based on expected 5/10/15 cc costs for CERAMENT[supreg] G, by MS-DRG),
by the aforementioned Supplies & Equipment CCR of 0.297.
The applicant calculated a final inflated case-weighted average
standardized charge per case of $135,258 and an average case-weighted
threshold of $86,603. Because the final inflated average case-weighted
standardized charge per case exceeded the average case-weighted
threshold amount, the applicant asserted that the technology meets the
cost criterion.
The applicant also provided an alternate cost analysis using the
applicant's top three identified MS-DRGs (464, 493, and 504), which
together constituted more than half of the applicant's identified
cases. Using the same methodology and data sources noted previously,
the applicant calculated a final inflated case-weighted average
standardized charge per case of $112,316 and an average case-weighted
threshold of $77,375. The applicant maintained that CERAMENT[supreg] G
meets the cost criterion under this alternate analysis.
We stated in the proposed rule that we agree with the applicant
that CERAMENT[supreg] G meets the cost criterion and therefore, subject
to the technology receiving FDA marketing authorization for use as a
bone-void filler as an adjunct to systemic antibiotic therapy and
surgical debridement as part of the surgical treatment of osteomyelitis
by July 1, 2022, we proposed to approve CERAMENT[supreg] G for new
technology add-on payments for FY 2023.
Based on preliminary information from the applicant at the time of
the proposed rule, the total cost of CERAMENT[supreg] G for a typical
patient was determined to be $7,567 per procedure. Per the applicant,
the amount of CERAMENT[supreg] G used per patient depends on the
complexity of the patient's injury, subsequent comorbidities, as well
as the location and size of the bone void. The applicant expects that
an average patient will require ~10cc per procedure, based on the case
weighted volume of expected utilization across the MS-DRGs. From this
weighted average, the applicant derived the average, weighted cost of
$7,567 per patient. We noted that the cost information for this
technology may be updated in the final rule based on revised or
additional information CMS receives prior to the final rule. Under
Sec. 412.88(a)(2), we limit new technology add-on payments to the
lesser of 65% of the average cost of the technology, or 65% of the
costs in excess of the MS-DRG payment for the case. As a result, we
proposed that the maximum new technology add-on payment for a case
involving the use of the product CERAMENT[supreg] G would be $4,918.55
for FY 2022 (that is, 65% of the average cost of the technology).
We invited public comments on whether CERAMENT[supreg] G meets the
cost criterion and our proposal to approve new technology add-on
payments for CERAMENT[supreg] G for FY 2023, subject to
CERAMENT[supreg] G receiving FDA marketing authorization for use as a
bone-void filler as an adjunct to systemic antibiotic therapy and
surgical debridement as part of the surgical treatment of osteomyelitis
by July 1, 2022.
Comment: We received a public comment urging CMS to finalize its
proposals to approve new technology add-on payments for multiple
technologies for FY 2023, including CERAMENT G[supreg], in order to
foster innovation and make life and ability-saving devices more readily
available to patients.
Response: We appreciate the comment.
Based on the information provided in the application for new
technology add-on payments, we believe CERAMENT[supreg] G meets the
cost criterion. The technology received FDA De Novo marketing
authorization on May 17, 2022 with an indication for use as a bone void
filler in skeletally mature patients as an adjunct to systemic
antibiotic therapy and surgical debridement (standard treatment
approach to a bone infection) as part of the surgical treatment of
osteomyelitis in defects in the extremities, that is covered by its
Breakthrough Device designation. Therefore, we are finalizing our
proposal to approve new technology add-on payments for CERAMENT[supreg]
G for FY 2023. We consider the beginning of the newness period to
commence on May 17, 2022, the date on which the technology received its
FDA De Novo marketing authorization for the indication covered by its
Breakthrough Device designation.
Based on the information available at the time of this final rule,
the cost per case of CERAMENT[supreg] G is $7,567.00. Under Sec.
412.88(a)(2), we limit new technology add-on payments to the lesser of
65% of the average cost of the technology, or 65% of the costs in
excess of the MS-DRG payment for the case. As a result, we are
finalizing that the maximum new technology add-on payment for a case
involving the use of CERAMENT[supreg] G is $4,918.55 for FY 2023 (that
is, 65% of the average cost of the technology). Cases involving the use
of CERAMENT[supreg] G that are eligible for new technology add-on
payments will be identified by ICD-10-PCS procedure code XW0V0P7
(Introduction of antibiotic-eluting bone void filler into bones, open
approach, new technology group 7).
(2) GORE[supreg] TAG[supreg] Thoracic Branch Endoprosthesis (TBE
Device)
W.L. Gore and Associates, Inc., submitted an application for new
technology add-on payments for the GORE[supreg] TAG[supreg] Thoracic
Branch Endoprosthesis (TBE) device for FY 2023. According to the
applicant, the GORE[supreg] TAG[supreg] TBE device is a modular device
consisting of three components, an Aortic Component, a Side Branch
Component, and an optional Aortic Extender Component, each of which is
pre-mounted on a catheter delivery system for treatment of thoracic
aortic aneurysms, traumatic aortic transection, and aortic dissection.
According to the applicant, the GORE[supreg] TAG[supreg] TBE device
was granted designation under the Expedited Access Pathway (EAP) by FDA
(and is therefore considered part of the Breakthrough Devices Program
by FDA) on July 17, 2015, for endovascular repair of descending
thoracic aortic and aortic arch for patients who have appropriate
anatomy. The applicant indicated that it anticipated receiving
premarket approval of the GORE[supreg] TAG[supreg] TBE device as a
Class III device from FDA in Spring 2022 with a proposed indication for
endovascular repair of lesions of the descending thoracic aorta, while
maintaining flow into the left subclavian artery, in patients who have
adequate iliac/femoral access, and eligible proximal aorta, left
subclavian, or distal landing zones (isolated lesion patients only). We
noted in the proposed rule that since the indication for which the
applicant anticipated receiving premarket approval was included within
the scope of the EAP designation, it appeared that the
[[Page 48967]]
proposed PMA indication was appropriate for new technology add-on
payment under the alternative pathway criteria. Subsequently, the
applicant received premarket approval on May 13, 2022 with an
indication for endovascular repair of lesions of the descending
thoracic aorta, while maintaining flow into the left subclavian artery,
in patients who are at high risk for debranching subclavian procedures
and who have appropriate anatomy, which is within the scope of the EAP
designation.
The applicant noted that a combination of two existing ICD-10-PCS
procedure codes can be used to uniquely identify the GORE[supreg]
TAG[supreg] TBE: 02VW4EZ (Restriction of thoracic aorta, descending
with branched or fenestrated intraluminal device, one or two arteries,
percutaneous endoscopic approach), in combination with 02VX4EZ
(Restriction of thoracic aorta, ascending/arch with branched or
fenestrated intraluminal device, one or two arteries, percutaneous
endoscopic approach). Per the applicant, the GORE[supreg] TAG[supreg]
TBE device is placed such that it straddles two anatomic regions, the
descending thoracic aorta and thoracic aortic arch, thereby
necessitating the use of both ICD-10-PCS procedure codes to accurately
describe the use of the device.
With regard to the cost criterion, the applicant searched the FY
2019 MedPAR dataset from the FY 2022 IPPS proposed rule for cases
reporting a combination of a thoracic endovascular repair (TEVAR)
procedure and a bypass procedure. The applicant listed the following
ICD-10-PCS codes for TEVAR procedures and bypass procedures, which the
applicant used to identify potential cases that may be eligible for
treatment with the GORE[supreg] TAG[supreg] TBE device. Per the
applicant, cases with at least one ICD-10-PCS procedure code from each
category were included in the analysis.
[GRAPHIC] [TIFF OMITTED] TR10AU22.096
[GRAPHIC] [TIFF OMITTED] TR10AU22.097
The applicant identified 210 cases mapping to five MS-DRGs. The
applicant then removed charges for the technology being replaced. The
applicant stated that the use of TAG[supreg] Conformable devices in
cases that also use the GORE[supreg] TAG[supreg] TBE device is entirely
dependent on the patient's anatomy. The applicant explained that the
average case utilizing the GORE[supreg] TAG[supreg] TBE device uses 0.6
TAG[supreg] Conformable devices, compared to an average of 1.4
TAG[supreg] Conformable devices per procedure for current TEVAR cases,
resulting in a difference of 0.8 TAG[supreg] Conformable devices which
will no longer be used in cases utilizing the GORE[supreg] TAG[supreg]
TBE device. Accordingly, 80% of all device implant charges were removed
from the claims to be conservative, per the applicant. The applicant
then removed other charges related to the prior technology. According
to the applicant, a research study \203\ that compared 24 patients
treated with TBE to 31 patients treated with the traditional method at
one facility found that TBE device cases have a 19% reduction in
operating room (OR) time compared to the OR time for the combined
procedures (TEVAR with a bypass procedure), and a 48% reduction in
length of stay. Accordingly, the applicant removed 19% of OR charges
(revenue code 0360), removed 48% of routine charges (revenue code 01XX)
when a claim showed routine charges, and removed 48% of intensive care
unit (ICU) charges if a claim included no routine charges. The
applicant then standardized the charges and applied a 4-year inflation
factor of 1.2818 based on the inflation factor used in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45538), to update the charges from FY
2019 to FY 2023. The applicant then added charges for the new
technology by dividing the average per patient cost of the GORE[supreg]
TAG[supreg] TBE device by the national CCR for implantable devices
(0.293) from the FY
[[Page 48968]]
2022 IPPS/LTCH PPS final rule (86 FR 44966). The applicant calculated a
final inflated case-weighted average standardized charge per case of
$400,515 and an average case-weighted threshold of $217,182. Because
the final inflated average case-weighted standardized charge per case
exceeded the average case-weighted threshold amount, the applicant
asserted that the technology meets the cost criterion.
---------------------------------------------------------------------------
\203\ Shultze W, Baxter R, Gable C, et al. Comparison Of
Surgical Debranching Versus Branched Endografts In Zone 2 TEVAR.
Oral presentation at the Society for Vascular Surgery Meeting; March
2021, Miami FL. https://symposium.scvs.org/abstracts/2021/M76.cgi.
---------------------------------------------------------------------------
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28324), we noted
that the charges removed for prior technology are based on length of
stay in a small study conducted at a single institution. Specifically,
the study involved 24 patients who received the TBE device during
elective procedures and 31 who had the procedures with bypass. Three of
these procedures were emergent and only 14 and 17, respectively, were
procedures in Zone 2 where the GORE[supreg] TAG[supreg] TBE would be
indicated. Given the small percentage of procedures that directly
relate to the proposed GORE[supreg] TAG[supreg] TBE indication, we
questioned the extent to which these results are generalizable to the
cost analysis performed above and the greater Medicare population.
Additionally, the applicant did not specify the revenue codes used to
identify and remove intensive care unit charges. We noted the applicant
listed two ICD-10-PCS codes (03S43ZZ and 03SQ3ZZ) in their analysis
which are percutaneous procedures and questioned whether the inclusion
of these codes was appropriate as the devices currently used to repair
the aortic arch require the creation of a bypass performed in an open
surgery. We also questioned whether the cases that the applicant
identified were appropriately representative of cases eligible for
treatment with GORE[supreg] TAG[supreg] TBE and requested additional
information to clarify this issue.
Subject to the applicant adequately addressing these concerns, we
stated in the proposed rule that we agreed that the technology meets
the cost criterion and therefore proposed to approve the GORE[supreg]
TAG[supreg] TBE device for new technology add-on payments for FY 2023,
subject to the technology receiving FDA marketing authorization for the
proposed indication by July 1, 2022.
Based on preliminary information from the applicant at the time of
the proposed rule, the per-patient anticipated hospital cost of the
GORE[supreg] TAG[supreg] TBE device was $42,780. We noted that the cost
information for this technology may be updated in the final rule based
on revised or additional information CMS receives prior to the final
rule. Under Sec. 412.88(a)(2), we limit new technology add-on payments
to the lesser of 65% of the average cost of the technology, or 65% of
the costs in excess of the MS-DRG payment for the case. In the proposed
rule, we stated that in the event we were to receive supplemental
information from the applicant to adequately address our concerns
regarding the cost criterion, and we were to approve new technology
add-on payments for the GORE[supreg] TAG[supreg] TBE device in the
final rule, the maximum new technology add-on payment for a case
involving the use of the GORE[supreg] TAG[supreg] TBE device would be
$27,807 for FY 2023 (that is, 65% of the average cost of the
technology).
We invited public comments on whether the GORE[supreg] TAG[supreg]
TBE device meets the cost criterion and our proposal to approve new
technology add-on payments for the GORE[supreg] TAG[supreg] TBE device
for FY 2023, subject to the technology receiving FDA marketing
authorization for the proposed indication that corresponds to the EAP
designation by July 1, 2022.
Comment: The applicant provided comments and a revised cost
analysis in response to CMS' concerns identified in the proposed rule.
With respect to the concern that the charges removed for prior
technology were based on length of stay in a small study conducted at a
single institution, the applicant stated that the pivotal trial for the
GORE[supreg] TAG[supreg] TBE device was conducted at 40 U.S. sites and
the separate outcome sub-study was based at a site that had the highest
numbers of enrolled participants. In addition, the applicant stated
that the length of stay and length of time in the ICU was similar for
all sites in the clinical trial and therefore the cost estimates from a
single institution are reflective of the cost of care provided at other
sites.
With respect to the concern about results being generalizable to
the greater Medicare population, the applicant stated that the median
age of outcome sub-study participants was 65 years, and that half of
all participants were of Medicare-eligible age. The applicant also
noted that the outcome sub-study population (24 GORE[supreg]
TAG[supreg] TBE patients and 31 SR-TEVAR patients) represented more
than a quarter of a total of 202 GORE[supreg] TAG[supreg] TBE-eligible
cases in the FY 2019 Medicare claims. Per the applicant, this sample of
the 202 eligible cases in the FY 2019 Medicare claims is large enough
to appropriately estimate the costs associated with the GORE[supreg]
TAG[supreg] TBE procedure and that, based on the median age, the
estimate is generalizable to the Medicare population.
With respect to the concern as to whether the cases identified by
the applicant were appropriately representative of cases eligible for
treatment with GORE[supreg] TAG[supreg] TBE, the applicant stated that
the GORE[supreg] TAG[supreg] TBE device replaces two separate operating
room procedures: a left subclavian artery (SA) bypass procedure,
usually an open surgery, and a percutaneous thoracic endograft implant
procedure, commonly referred to as SR-TEVAR, because it contains a
branched element that is inserted into the left subclavian artery
thereby maintaining blood flow and eliminating the need for a SA bypass
procedure. The applicant stated that the outcome sub-study provides
information on resource use differences between patients undergoing TBE
procedures compared to a combination of surgical revascularization and
thoracic endograft implant. The applicant stated that including cases
that involved both procedures (that is, the SA bypass procedure and the
TEVAR procedure) in the cost criterion analysis and removing 100% of
device charges as well as other related service charges (19% of OR
charges and 48% of routine care charges) better reflects the estimate
of the GORE[supreg] TAG[supreg] TBE standardized charges. In the
updated analysis, the applicant removed 100% of all device charges from
the MedPAR cases compared to removing 80%, which it did in its original
application.
The applicant further indicated that while every patient
presentation of aortic disease is unique in length, type, and severity
of disease, all patients in the outcome sub-study had serious aortic
disease that needed repair in the left subclavian artery, even if cases
were characterized as an elective surgery for purposes of the study
reporting. The applicant also stated that the ends of the device must
exceed the length of the diseased aorta on both ends, the proximal and
distal locations of the implanted device varied, depending on the
length of the aortic disease, and as such, the devices can span several
zones. The applicant further noted that all cases, emergent or
elective, had similar resource use.
With respect to the concern that the revenue codes used to identify
and remove intensive care unit charges were not specified, the
applicant stated that it used CMS revenue codes 020x and 021x to
identify intensive care unit charges in the rate-setting methodology.
We note that revenue code descriptions for 021x and 021x are Intensive
Care Unit and Coronary Care Unit, respectively.
[[Page 48969]]
With respect to our inquiry about the inclusion of two codes for
percutaneous procedures, the applicant explained that it included the
two percutaneous approach codes in its original cost analysis in order
to pick up all bypass surgery codes. The applicant then explained that
eliminating these two codes from the inclusion criteria for the revised
analysis excluded only one case. The applicant noted that removing the
one percutaneous SA bypass case limited the revised cost criterion
analysis to only those cases where the subclavian artery bypass surgery
was coded as an open approach.
The applicant reported that the updated cost criterion analysis
resulted in a threshold amount of $217,080 and a new standardized
charge estimate of $377,857. The applicant stated that the new
standardized charge estimate still greatly exceeds the new technology
add-on payment threshold and the GORE[supreg] TAG[supreg] TBE device
meets the cost criterion requirement.
The applicant also stated that upon further consultation with
clinical experts, the better combination of ICD-10-PCS codes to
identify cases utilizing the technology would be 02VW3DZ (Restriction
of thoracic aorta, descending with intraluminal device, percutaneous
approach), in combination with 02VX3EZ (restriction of thoracic aorta,
ascending/arch with branched or fenestrated intraluminal device, one or
two arteries, percutaneous approach) and requested that these codes be
used to identify the GORE[supreg] TAG[supreg] TBE for purposes of new
technology add-on payment instead of the codes included in the proposed
rule.
Another commenter familiar with the applicant's cost study
submitted a public comment reiterating the applicant's statements
regarding the characteristics of the single institution upon which the
applicant's cost analysis was based, disease severity in the patient
population, the uniform requirement of Zone 2 repair despite variation
of distal zones treated, and generalizability of the study population
to the Medicare population. Based on the results achieved for patients
receiving the TBE graft as compared to the TEVAR and subclavian artery
bypass, this commenter recommended that CMS approve the GORE[supreg]
TAG[supreg] TBE for new technology add on payments.
Response: We thank the commenters for their comments and appreciate
the additional clarification regarding the cost criterion. Based on the
information provided in the application for new technology add-on
payments, and after consideration of the public comments we received,
we believe the GORE[supreg] TAG[supreg] Thoracic Branch Endoprosthesis
(TBE) meets the cost criterion. GORE[supreg] TAG[supreg] TBE received
marketing authorization from FDA on May 13, 2022 for the indication
covered by its Breakthrough Device designation for endovascular repair
of lesions of the descending thoracic aorta, while maintaining flow
into the left subclavian artery, in patients who are at high risk for
debranching subclavian procedures and who have appropriate anatomy.
Therefore, we are finalizing our proposal to approve new technology
add-on payments for the GORE[supreg] TAG[supreg] TBE for FY 2023 and we
consider the beginning of the newness period to commence on May 13,
2022, which is the date on which the technology received FDA marketing
authorization for the indication covered by its Breakthrough Device
designation.
Based on the information at the time of this final rule, the cost
per case of the GORE[supreg] TAG[supreg] TBE is $42,780. Under Sec.
412.88(a)(2), we limit new technology add-on payments to the lesser of
65% of the average cost of the technology, or 65% of the costs in
excess of the MS DRG payment for the case. As a result, we are
finalizing that the maximum new technology add-on payment for a case
involving the use of the GORE[supreg] TAG[supreg] TBE is $27,807 for FY
2023 (that is, 65% of the average cost of the technology). Cases
involving the use of GORE[supreg] TAG[supreg] TBE that are eligible for
new technology add-on payments will be identified by ICD-10-PCS codes:
02VW3DZ (Restriction of thoracic aorta, descending with intraluminal
device, percutaneous approach) in combination with 02VX3EZ (Restriction
of thoracic aorta, ascending/arch with branched or fenestrated
intraluminal device, one or two arteries, percutaneous approach).
(3) iFuse Bedrock Granite Implant System
SI-BONE, Inc., submitted an application for new technology add-on
payments for the iFuse Bedrock Granite Implant System for FY 2023.
According to the applicant, the iFuse Bedrock Granite Implant System is
a sterile, single-use permanent implant intended to provide sacropelvic
fusion of the sacroiliac joint and fixation to the pelvis when used in
conjunction with commercially available pedicle screw fixation systems
as a foundational element for segmental spinal fusion. The applicant
stated that the joint fusion occurs as a result of the device's porous
surface and interstices, and fixation occurs through the device's
helical threaded design and traditional posterior fixation rod
connection. Per the applicant, the iFuse Bedrock Granite Implant System
can be placed into the pelvis in two trajectories: sacroalar-iliac
(SAI) trajectory (that is, into the sacrum, across the SI joint and
into the ilium) or directly into the ilium, and joint fusion occurs
only when the SAI trajectory is used.
According to the applicant, the iFuse Bedrock Granite Implant
System received FDA Breakthrough Device designation on November 23,
2021 for sacropelvic fixation and as an adjunct for sacroiliac joint
fusion (when used with commercially available sacroiliac joint fusion
promoting devices) in conjunction with commercially available posterior
pedicle screw systems for the treatment of the acute and chronic
instabilities or deformities of the thoracic, lumbar, and sacral spine;
degenerative disc disease (DDD) as defined by back pain of discogenic
origin with degeneration of the disc confirmed by patient history and
radiographic studies; severe spondylolisthesis (Grades 3 and 4) of the
L5-S1 vertebra in skeletally mature patients receiving fusions by
autogenous bone graft having implants attached to the lumbar and sacral
spine (L3 to sacrum) with removal of the implants after the attainment
of a solid fusion; spondylolisthesis; trauma (that is, fracture or
dislocation); spinal stenosis; deformities or curvatures (that is,
scoliosis, kyphosis, and/or lordosis); spinal tumor; pseudarthrosis;
and/or failed previous fusion. Subsequently, the iFuse Bedrock Granite
Implant System received 510(k) clearance from FDA on May 26, 2022
(K220195) for the same indication.
The applicant stated that ICD-10-PCS codes that may be utilized to
describe the placement of an internal fixation device into the pelvic
bone or acetabulum, listed in the following table, do not distinctly
identify the iFuse Bedrock Granite Implant System.
[[Page 48970]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.098
The applicant submitted a request to the ICD-10 Coordination and
Maintenance Committee for approval of a unique code for FY 2023 and was
granted approval to identify the iFuse Bedrock Granite Implant System
using the following procedure codes effective October 1, 2022:
[GRAPHIC] [TIFF OMITTED] TR10AU22.099
With regard to the cost criterion, the applicant conducted two
analyses based on 100% of identified claims and 78% of identified
claims. To identify potential cases where the iFuse Bedrock Granite
Implant System could be utilized, the applicant searched the FY 2019
MedPAR final rule file for claims reporting a combination of at least
one of the ICD-10-PCS procedure codes for the placement of an internal
fixation device into the pelvic bone or acetabulum, noted previously,
and at least one of the following ICD-10-CM diagnosis codes used to
describe the indication under the Breakthrough Device designation.
BILLING CODE 4120-01-P
[[Page 48971]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.100
[[Page 48972]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.101
For the analysis using 100% of cases, the applicant identified
2,165 cases mapping to the following 26 MS-DRGs:
[[Page 48973]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.102
BILLING CODE 4120-01-C
The applicant then removed 50% of the charges associated with
medical supplies and implantable devices (revenue centers 027x and
0624). The applicant stated that the removal of 50% of the charges
associated with medical supplies and implantable devices reflects a
conservative estimate as the iFuse Bedrock Granite Implant System is
used in conjunction with commercially available pedicle screw fixation
systems as a foundational element for segmental spinal fusion. The
applicant then standardized the charges and applied the three-year
inflation factor of 20.4% used to update the outlier threshold in the
FY 2022 IPPS/LTCH PPS final rule (86 FR 45542) to update the charges
from FY 2019 to FY 2022. The applicant then added charges for the new
technology by dividing the per-patient anticipated hospital cost of the
iFuse Bedrock Granite Implant System by the national average cost-to-
charge ratio for implantable devices (0.239) from the FY 2022 IPPS/LTCH
PPS final rule. Under the analysis based on 100% of identified claims,
the applicant calculated a final inflated case-weighted average
standardized charge per case of $254,264 and an average case-weighted
threshold of $159,841.
For the analysis using 78% of cases, the applicant identified 1,682
cases mapping to 4 MS-DRGs. The applicant conducted the same analysis
noted previously and determined a final inflated case-weighted average
standardized charge per case of $253,333 and an average case-weighted
threshold of $164,561. Because the final inflated case-weighted average
standardized charge per case exceeded the average case-weighted
threshold amount under both analyses, the applicant asserted that the
technology meets the cost criterion.
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28327), we agreed
with the applicant that iFuse Bedrock Granite Implant System meets the
cost criterion and therefore we proposed to approve the iFuse Bedrock
Granite Implant System for new technology add-on payments for FY 2023,
subject to the technology receiving FDA marketing authorization for the
indication corresponding to the Breakthrough Device designation by July
1, 2022.
Based on preliminary information from the applicant at the time of
the proposed rule, the per-patient anticipated hospital cost of the
iFuse Bedrock Granite Implant System was $15,120. We noted that the
cost information for this technology may be updated in the final rule
based on revised or additional information CMS receives prior to the
final rule. Under Sec. 412.88(a)(2), we limit new technology add-on
payments to the lesser of 65% of the average cost of the technology, or
65% of the costs in excess of the MS-DRG payment for the case. As a
result, we proposed that the maximum new technology add-on payment for
a case involving the use of the iFuse Bedrock Granite Implant System
would be $9,828 for FY 2023 (that is, 65% of the average cost of the
technology).
We invited public comments on whether the iFuse Bedrock Granite
Implant System meets the cost criterion and our proposal to approve new
technology add-on payments for the iFuse Bedrock Granite Implant System
for FY 2023, subject to the technology receiving FDA marketing
authorization for the indication corresponding to the Breakthrough
Device designation by July 1, 2022.
Comment: We received a few comments supporting CMS' proposal to
approve the iFuse Bedrock Granite Implant System for new technology
add-on payments. One of the commenters also agreed with CMS that the
technology meets the cost criterion.
Response: We appreciate the input from the commenters.
[[Page 48974]]
Based on the information provided in the application for new
technology add-on payments, and after consideration of the public
comments we received, we believe the iFuse Bedrock Granite Implant
System meets the cost criterion. The iFuse Bedrock Granite Implant
System received marketing authorization from FDA on May 26, 2022 for
the indication covered by the Breakthrough Device designation, for
sacropelvic fixation and as an adjunct for sacroiliac joint fusion
(when used with commercially available sacroiliac joint fusion
promoting devices) in conjunction with commercially available posterior
pedicle screw systems for the treatment of the acute and chronic
instabilities or deformities of the thoracic, lumbar, and sacral spine;
degenerative disc disease (DDD) as defined by back pain of discogenic
origin with degeneration of the disc confirmed by patient history and
radiographic studies; severe spondylolisthesis (Grades 3 and 4) of the
L5-S1 vertebra in skeletally mature patients receiving fusions by
autogenous bone graft having implants attached to the lumbar and sacral
spine (L3 to sacrum) with removal of the implants after the attainment
of a solid fusion; spondylolisthesis; trauma (that is, fracture or
dislocation); spinal stenosis; deformities or curvatures (that is,
scoliosis, kyphosis, and/or lordosis); spinal tumor; pseudarthrosis;
and/or failed previous fusion. Therefore, we are finalizing our
proposal to approve new technology add-on payments for the iFuse
Bedrock Granite Implant System for FY 2023, and we consider the
beginning of the newness period to commence on May 26, 2022, which is
the date on which the technology received FDA marketing authorization
for the indication covered by its Breakthrough Device designation.
Based on the information at the time of this final rule, the cost
per case of the iFuse Bedrock Granite Implant System is $15,120. Under
Sec. 412.88(a)(2), we limit new technology add-on payments to the
lesser of 65% of the average cost of the technology, or 65% of the
costs in excess of the MS-DRG payment for the case. As a result, we are
finalizing that the maximum new technology add-on payment for a case
involving the use of the iFuse Bedrock Granite Implant System is $9,828
for FY 2023 (that is, 65% of the average cost of the technology). Cases
involving the use of the iFuse Bedrock Granite Implant System that are
eligible for new technology add-on payments will be identified by one
of the following ICD-10- PCS codes:
[GRAPHIC] [TIFF OMITTED] TR10AU22.103
(4) ThoraflexTM Hybrid Device
Terumo Aortic submitted an application for new technology-add on
payments for the ThoraflexTM Hybrid Device for FY 2023. Per
the applicant, the device is a sterile single-use, gelatin sealed
Frozen Elephant Trunk (FET) surgical medical device. The applicant
explained that the device is deployed through an opened aortic arch and
then positioned into the descending thoracic aorta. The applicant
further explained that, once it is completely deployed, the collar is
sutured to the aorta, and graft anastomoses are then performed in a
manner depending upon the chosen product design (which the applicant
specified as either the Plexus or the Ante-Flo). The device includes a
proximal crimped polyester surgical graft, central polyester collar,
and distal nitinol ring stents supported by thin wall polyester fabric.
The applicant also noted that the device has a unique gelatin sealant
that acts as a seal, preventing blood loss through the polyester fabric
product wall. We note that Terumo Aortic previously submitted an
application for new technology add-on payments for the
ThoraflexTM Hybrid Device for FY 2022, as summarized in the
FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25390) which was withdrawn
prior to the issuance of the FY 2022 IPPS/LTCH PPS final rule (86 FR
45127).
According to the applicant, the ThoraflexTM Hybrid
Device received Breakthrough Device designation on March 20, 2020 for
the open surgical repair or replacement of damaged or diseased vessels
of the aortic arch and descending aorta, with or without involvement of
the ascending aorta, in cases of aneurysm and/or dissection. The
applicant received FDA marketing authorization on April 19, 2022 for
the same indication as the Breakthrough Device designation. According
to the applicant, the ICD-10 Coordination and Maintenance Committee
approved the following ICD-10-PCS codes to specifically describe the
use of the ThoraflexTM Hybrid Device, effective October 1,
2021: X2RX0N7 (Replacement of thoracic aorta arch with branched
synthetic substitute with intraluminal device, new technology
[[Page 48975]]
group 7) and X2VW0N7 (Restriction of thoracic descending aorta with
branched synthetic substitute with intraluminal device, new technology
group 7).
With respect to the cost criterion, the applicant conducted two
analyses based on 100% of identified claims and 74% of identified
claims. To identify potential cases where the ThoraflexTM
Hybrid Device could be utilized, the applicant searched the FY 2019
MedPAR file for claims reporting the following ICD-10-PCS codes for
thoracic aortic replacement procedures: 02RX08Z (Replacement of
thoracic aorta, ascending/arch with zooplastic tissue, open approach),
02RX0JZ (Replacement of thoracic aorta, ascending/arch with synthetic
tissue, open approach), and 02RX0KZ (Replacement of thoracic aorta,
ascending/arch with nonautologous tissue substitute, open approach).
For the analysis using 100% of cases, the applicant identified
5,374 cases mapping to 21 MS-DRGs. The applicant then removed charges
for the technology being replaced. Per the applicant, the use of the
ThoraflexTM Hybrid device is expected to replace a portion
of prior technologies. The applicant explained that because an estimate
of the percentage of these total charges that would be replaced could
not be determined, it removed 100% of charges associated with medical/
surgical supplies and devices (revenue centers 027x and 0624). The
applicant then standardized the charges and applied the 3-year outlier
inflation factor of 1.204686 used to update the outlier threshold in
the FY 2022 IPPS/LTCH PPS final rule (86 FR 45542) to update the
charges from FY 2019 to FY 2022. The applicant then added charges for
the new technology. The applicant multiplied the cost of the technology
by the national cost-to-charge ratio for implantable devices from the
FY 2022 IPPS/LTCH PPS final rule (0.293) to calculate estimated average
hospital charges associated with the device. Under this analysis, based
on 100% of identified claims, the applicant calculated a final inflated
case-weighted average standardized charge per case of $420,924 and an
average case-weighted threshold of $230,659.
Under the analysis based on 74% of cases, the applicant used the
same methodology, which identified 3,980 cases across MS-DRGs 219 and
220. The applicant determined the average case-weighted threshold of
$211,423 and a final inflated average standardized charge per case of
$373,273. Because the final inflated case-weighted average standardized
charge per case exceeded the average case-weighted threshold amount
under both analyses, the applicant asserted that the technology meets
the cost criterion.
In the proposed rule, we stated that we agree with the applicant
that the ThoraflexTM Hybrid Device meets the cost criterion
and therefore proposed to approve the ThoraflexTM Hybrid
Device for new technology add-on payments for FY 2023, subject to the
technology receiving FDA marketing authorization for the open surgical
repair or replacement of damaged or diseased vessels of the aortic arch
and descending aorta, with or without involvement of the ascending
aorta, in cases of aneurysm and/or dissection by July 1, 2022.
Based on preliminary information from the applicant at the time of
the proposed rule, the cost of the ThoraflexTM Hybrid Device
was $35,000 per patient. We noted that the cost information for this
technology may be updated in the final rule based on revised or
additional information CMS receives prior to the final rule. Under
Sec. 412.88(a)(2), we limit new technology add-on payments to the
lesser of 65% of the average cost of the technology, or 65% of the
costs in excess of the MS-DRG payment for the case. As a result, we
proposed that the maximum new technology add-on payment for a case
involving the use of ThoraflexTM Hybrid Device would be
$22,750 per patient for FY 2023 (that is, 65% of the average cost of
the technology).
We invited public comments on whether the ThoraflexTM
Hybrid Device meets the cost criterion and our proposal to approve new
technology add-on payments for the ThoraflexTM Hybrid Device
for FY 2023, subject to the ThoraflexTM Hybrid Device
receiving FDA marketing authorization by July 1, 2022 for the open
surgical repair or replacement of damaged or diseased vessels of the
aortic arch and descending aorta, with or without involvement of the
ascending aorta, in cases of aneurysm and/or dissection.
Comment: The applicant submitted a public comment expressing
support for the approval of the ThoraflexTM Hybrid Device
for the new technology add-on payment for FY 2023. The applicant
emphasized that both X2RX0N7 (Replacement of thoracic aorta arch with
branched synthetic substitute with intraluminal device, new technology
group 7) and X2VW0N7 (Restriction of thoracic descending aorta with
branched synthetic substitute with intraluminal device, new technology
group 7) need to be reported concurrently to appropriately describe the
implant procedure for the ThoraflexTM Hybrid Device.
Response: We appreciate the applicant's support.
Based on the information provided in the application for new
technology add-on payments, and after consideration of the public
comments we received, we believe the ThoraflexTM Hybrid
Device meets the cost criterion. The ThoraflexTM Hybrid
Device received marketing authorization from FDA on April 19, 2022 for
the indications covered by its Breakthrough Device designation for the
open surgical repair or replacement of damaged or diseased vessels of
the aortic arch and descending aorta, with or without involvement of
the ascending aorta, in cases of aneurysm and/or dissection. Therefore,
we are finalizing our proposal to approve new technology add-on
payments for the ThoraflexTM Hybrid Device for FY 2023, and
we consider the beginning of the newness period to commence on April
19, 2022, which is the date on which the technology received FDA
marketing authorization for the indication covered by its Breakthrough
Device designation.
Based on the information at the time of this final rule, the cost
per case of the ThoraflexTM Hybrid Device is $35,000 per
patient. Under Sec. 412.88(a)(2), we limit new technology add-on
payments to the lesser of 65% of the average cost of the technology, or
65% of the costs in excess of the MS DRG payment for the case. As a
result, we are finalizing that the maximum new technology add-on
payment for a case involving the use of the ThoraflexTM
Hybrid Device is $22,750 for FY 2023 (that is, 65% of the average cost
of the technology). Cases involving the use of the
ThoraflexTM Hybrid Device that are eligible for new
technology add-on payments will be identified by the ICD-10-PCS code
X2RX0N7 (Replacement of thoracic aorta arch with branched synthetic
substitute with intraluminal device, new technology group 7) in
combination with the ICD-10-PCS code X2VW0N7 (Restriction of thoracic
descending aorta with branched synthetic substitute with intraluminal
device, new technology group 7).
(5) ViviStim[supreg] Paired VNS System
MicroTransponder, Inc. submitted an application for new technology
add-on payments for the ViviStim[supreg] Paired VNS System for FY 2023.
According to the applicant, the ViviStim[supreg] Paired VNS System is a
paired vagus nerve stimulation therapy intended to stimulate the vagus
nerve during rehabilitation therapy to reduce upper extremity motor
deficits and improve
[[Page 48976]]
motor function in chronic ischemic stroke patients with moderate to
severe arm impairment. The applicant stated that the Vivistim[supreg]
Paired VNS System is comprised of an Implantable Pulse Generator (IPG),
an implantable stimulation Lead, and an external paired stimulation
controller which is composed of the external Wireless Transmitter (WT)
and the external Stroke Application and Programming Software (SAPS).
According to the applicant, the external paired stimulation controller
(SAPS and WT) enables the implanted components (the IPG and Lead) to
stimulate the vagus nerve during rehabilitation. The applicant stated
that patients undergo 25-30 hours of in-clinic rehabilitation over 6
weeks, where the ViviStim[supreg] Paired VNS System is actively paired
with rehabilitation by a therapist. The applicant further stated that
following this in-clinic rehabilitation period, when directed by a
physician and with appropriate programming to the IPG, the patient can
initiate at-home use by swiping a magnet over the IPG implant site
which activates the IPG to deliver stimulation while rehabilitation
movements are performed.
The applicant stated that the ViviStim[supreg] Paired VNS System
was designated as a Breakthrough Device on February 10, 2021 for use in
stimulating the vagus nerve during rehabilitation therapy in order to
reduce upper extremity motor deficits and improve motor function in
chronic ischemic stroke patients with moderate to severe arm
impairment. According to the applicant, the ViviStim[supreg] Paired VNS
System received FDA premarket approval on August 27, 2021 as a Class
III implantable device for the same indication. The applicant stated
that the technology became commercially available on April 29, 2022 due
to manufacturing delays.
According to the applicant, there are no unique ICD-10-PCS
procedure codes to report the implantation of the device. The applicant
noted that together the following two ICD-10-PCS codes describe the
insertion of the ViviStim[supreg] Paired VNS System: 0JH60BZ (Insertion
of single array stimulator generator into chest subcutaneous tissue and
fascia, open approach) and 00HE0MZ (Insertion of neurostimulator lead
into cranial nerve, open approach). The applicant noted that these
codes may be used for any cranial nerve stimulator insertion procedure,
including VNS therapy for treatment resistant depression, VNS therapy
for refractory epilepsy, and upper airway stimulation to treat
obstructive sleep apnea. The applicant submitted a request to the ICD-
10 Coordination and Maintenance Committee for approval of a unique code
for FY 2022 to identify insertion of the ViviStim[supreg] Paired VNS
System and was granted approval for the following procedure code
effective October 1, 2022: X0HQ3R8 (Insertion of neurostimulator lead
with paired stimulation system into vagus nerve, percutaneous approach,
new technology group 8).
The applicant also provided the ICD-10-CM diagnosis codes in the
table that follows. The applicant stated that moderate to severe upper
limb impairment is described in the ICD-10-CM as monoplegia (single
limb) or hemiplegia (single laterality, including upper limb). The
applicant stated that the FY 2021 ICD-10-CM code set \204\ includes
monoplegia and hemiplegia as a sequela of infarction (stroke), and
delineates codes based upon stroke type (hemorrhagic versus ischemic).
Therefore, the applicant stated that the ICD-10-CM diagnosis codes in
the following table describe chronic moderate to severe upper arm
impairment as a sequela of ischemic stroke, and are related to the use
of the ViviStim[supreg] Paired VNS System.
[GRAPHIC] [TIFF OMITTED] TR10AU22.104
With respect to the cost criterion, the applicant presented the
following analysis. The applicant searched the FY 2019 MedPAR claims
data set released with the FY 2022 IPPS/LTCH PPS final rule for cases
representing patients who may be eligible for the ViviStim[supreg]
Paired VNS System. The applicant identified cases reporting the ICD-10-
PCS codes 0JH60BZ and 00HE0MZ in combination with one of the ICD-10-CM
diagnosis codes, noted previously, describing moderate to severe upper
limb impairment. The applicant then mapped the cases to the appropriate
MS-DRGs using MS-DRG Grouper Version 39.0. After imputing a case count
of 11 for those MS-DRGs with fewer than 11 cases, the applicant
identified 285 claims mapping to 12 MS-DRGs, with 65% of cases mapping
to MS-DRGs 024 (Craniotomy with Major Device Implant or Acute Complex
CNS Principal Diagnosis without MCC), 041 (Peripheral Cranial Nerve and
Other Nervous System Procedures with CC or Peripheral Neurostimulator)
and 042 (Peripheral Cranial Nerve and Other Nervous System Procedures
without CC/MCC).
---------------------------------------------------------------------------
\204\ https://www.cms.gov/medicare/icd-10/2021-icd-10-cm,
effective October 1, 2020 through September 30, 2021.
---------------------------------------------------------------------------
The applicant then removed 100% of charges associated with Medical/
Surgical Supplies and Devices (prior technology, revenue centers 027X,
and 0624). The applicant asserted that the use of the Vivistim[supreg]
Paired VNS System is expected to replace the majority of existing
technologies, although some devices would still be required to perform
the procedure. The applicant stated that because it could not determine
the estimated percentage of the total charges that would be replaced,
it removed 100% of these total charges to be as conservative as
possible. The applicant did not remove charges related to the
technology being replaced,
[[Page 48977]]
stating that the financial impact of utilizing the Vivistim[supreg]
Paired VNS System on hospital resources compared to prior technologies
other than on Medical Supplies is minimal, and that 100% of charges for
Medical/Surgical Supplies had been removed in the previous step.
The applicant standardized the charges by applying the three-year
inflation factor of 1.20469 used in the FY 2022 IPPS/LTCH PPS final
rule and correction notice to calculate outlier threshold charges (86
FR 45542). The applicant then added charges for the new technology by
dividing the cost of the ViviStim[supreg] Paired VNS System by the
national average CCR for implantable devices which is 0.293 as
published in the FY 2022 IPPS/LTCH IPPS final rule (86 FR 44966). The
applicant calculated a final inflated average case-weighted
standardized charge per case of $200,398 which exceeded the average
case-weighted threshold amount of $107,963. Because the final inflated
average case-weighted standardized charge per case exceeded the average
case-weighted threshold amount, the applicant maintained that the
ViviStim[supreg] Paired VNS System meets the cost criterion.
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28350), we agreed
with the applicant that the ViviStim[supreg] Paired VNS System meets
the cost criterion and therefore proposed to approve the
ViviStim[supreg] Paired VNS System for new technology add-on payments
for FY 2023.
Based on preliminary information from the applicant at the time of
the proposed rule, the total cost of the ViviStim[supreg] Paired VNS
System to the hospital was $36,000 per patient. According to the
applicant, this cost represents the entire per-patient cost of the
system to hospital providers--specifically for the cost of the
Implantable Pulse Generator and stimulation lead. Per the applicant,
there is no charge associated with the external paired stimulation
controller and the magnet/take-home patient programmer. The applicant
stated that the external paired stimulation controller may be used on
multiple patients and that it retains a service agreement with each
provider to own, maintain, and update the hardware and software that
resides on that device component. The applicant has also stated that
they have this service agreement with providers for the magnet/take-
home patient programmer. Therefore, as the applicant has stated they
retain and maintain the reusable hardware components at no charge to
the providers, we stated that it appeared that capital components were
not included in the cost of the technology. We welcomed public comment
on the cost information provided by the applicant for the purpose of
calculating the new technology add-on payment amount.
We noted that the cost information for this technology may be
updated in the final rule based on revised or additional information
CMS receives prior to the final rule. Under Sec. 412.88(a)(2), we
limit new technology add-on payments to the lesser of 65% of the
average cost of the technology, or 65% of the costs in excess of the
MS-DRG payment for the case. As a result, we proposed that the maximum
new technology add-on payment for a case involving the use of the
ViviStim[supreg] Paired VNS System would be $23,400 for FY 2023 (that
is, 65% of the average cost of the technology).
We invited public comments on whether the ViviStim[supreg] Paired
VNS System meets the cost criterion and our proposal to approve new
technology add-on payments for the ViviStim[supreg] Paired VNS System
for FY 2023 for use in stimulating the vagus nerve during
rehabilitation therapy in order to reduce upper extremity motor
deficits and improve motor function in chronic ischemic stroke patients
with moderate to severe arm impairment.
Comment: We received a few comments supporting our proposal to
approve new technology add-on payments for FY 2023. The applicant also
noted that the ViviStim[supreg] Paired VNS System received FDA
premarket approval on August 27, 2021; however, a manufacturing delay
prevented market availability of the device until April 29, 2022. The
applicant requested that CMS begin the newness period for the
Vivistim[supreg] Paired VNS System using the latter market availability
date of April 29, 2022. The applicant also supported our proposed
maximum new technology add-on payment amount.
Response: We thank the commenters for their support and feedback.
We agree that the newness date for this technology is the date on which
ViviStim[supreg] Paired VNS System became available on the market,
April 29, 2022. We note that though, generally, our policy is to begin
the newness period on the date of FDA approval or clearance, we may
consider a documented delay in the technology's market availability in
our determination of newness (77 FR 53348 and 70 FR 47341).
Based on the information provided in the application for new
technology add-on payments, and after consideration of the public
comments we received, we believe the ViviStim[supreg] Paired VNS System
meets the cost criterion. Therefore, we are finalizing our proposal to
approve new technology add-on payments for the ViviStim[supreg] Paired
VNS System for FY 2023, and we consider the beginning of the newness
period to commence on April 29, 2022, which is when the technology
became commercially available for the indication covered by its
Breakthrough Device designation, for use in stimulating the vagus nerve
during rehabilitation therapy in order to reduce upper extremity motor
deficits and improve motor function in chronic ischemic stroke patients
with moderate to severe arm impairment.
Based on the information at the time of this final rule, the cost
per case of the ViviStim[supreg] Paired VNS System is $36,000.
According to the applicant, this cost represents the entire per-patient
cost of the system to hospital providers, specifically for the
implantable pulse generator and stimulation lead. Under Sec.
412.88(a)(2), we limit new technology add-on payments to the lesser of
65% of the average cost of the technology, or 65% of the costs in
excess of the MS DRG payment for the case. As a result, we are
finalizing that the maximum new technology add-on payment for a case
involving the use of the ViviStim[supreg] Paired VNS System would be
$23,400 for FY 2023 (that is, 65% of the average cost of the
technology). Cases involving the use of the ViviStim[supreg] Paired VNS
System that are eligible for new technology add-on payments will be
identified by the ICD-10-PCS procedure code X0HQ3R8 (Insertion of
neurostimulator lead with paired stimulation system into vagus nerve,
percutaneous approach, new technology group 8).
[[Page 48978]]
b. Alternative Pathways for Qualified Infectious Disease Products
(QIDPs)
(1) DefenCathTM (Solution of Taurolidine (13.5 mg/mL) and
Heparin (1000 USP Units/mL))
CorMedix Inc. submitted an application for new technology add-on
payments for DefenCathTM (solution of taurolidine (13.5 mg/
mL) and heparin (1000 USP Units/mL)) for FY 2023. The applicant stated
that DefenCathTM is a proprietary formulation of
taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-
coagulant, that is under development for use as catheter lock solution,
with the aim of reducing the risk of catheter-related bloodstream
infections (CRBI) from in-dwelling catheters in patients undergoing
hemodialysis (HD) through a central venous catheter (CVC). According to
the applicant, in vitro studies of DefenCathTM indicate
broad antimicrobial activity against gram-positive and gram-negative
bacteria, including antibiotic resistant strains as well as
mycobacteria and clinically relevant fungi. The applicant stated that
DefenCathTM is available in a single-dose vial, which is
sufficient to fill both lumens of the HD catheter, and is instilled
into the catheter lumen as a lock solution at the conclusion of each
dialysis session and aspirated at the beginning of the next dialysis
session. The applicant noted that DefenCathTM cannot be
flushed or injected into the patient and that dosing is calibrated to
the volume of the catheter lumens.
Per the applicant, DefenCathTM was designated by FDA as
a QIDP in 2015 for the prevention of CRBSI in patients with end-stage
renal disease (ESRD) receiving HD through a central venous catheter,
and has been granted FDA Fast Track status. The applicant indicated
that it is pursuing an NDA under FDA's LPAD for the same indication,
which the applicant also stated received Priority Review. The applicant
noted that FDA issued a Complete Response Letter in 2021 denying the
NDA due to concerns with the third-party manufacturing facility. The
applicant stated that the NDA has been resubmitted and anticipates
approval in the third quarter of CY 2022.\205\ We note that, as an
application submitted under the alternative pathway for certain
antimicrobial products at Sec. 412.87(d), DefenCathTM is
eligible for conditional approval for new technology add-on payments if
it does not receive FDA marketing authorization by the July 1 deadline
specified in Sec. 412.87(e)(2), provided that the technology receives
FDA marketing authorization by July 1 of the particular fiscal year for
which the applicant applied for new technology add-on payments (that
is, July 1, 2023).
---------------------------------------------------------------------------
\205\ The statement in the proposed rule (87 FR 28350) that the
applicant anticipated approval before July 1, 2022 was in error and
has been corrected here.
---------------------------------------------------------------------------
The applicant applied for and received a unique ICD-10-PCS
procedure code to identify cases involving the administration of
DefenCathTM in 2022. Effective October 1, 2022,
DefenCathTM administration can be identified by ICD-10-PCS
procedure XY0YX28 (Extracorporeal introduction of taurolidine anti-
infective and heparin anticoagulant, new technology group 8).
With regard to the cost criterion, the applicant provided two
analyses to demonstrate that DefenCathTM meets the cost
criterion. The applicant first searched the FY 2019 MedPAR file
released with the FY 2022 IPPS/LTCH PPS final rule for claims based on
the presence of one of the following ICD-10-CM diagnosis codes used to
identify ESRD, chronic kidney disease (CKD), acute kidney injury (AKI)
or acute tubular necrosis (ATN).
[GRAPHIC] [TIFF OMITTED] TR10AU22.105
Per the applicant, DefenCathTM will be used for patients
receiving HD through a CVC. The applicant stated that coding to
identify this population is difficult because the available CVC codes
only describe the insertion of a CVC. The applicant asserted that it is
not possible to identify in the MedPAR file those patients who had
previously received a CVC and are now hospitalized and receiving HD.
Therefore, the applicant developed two sets of selection criteria:
claims with codes for HD (Analysis A) and claims with codes for both HD
and CVC (Analysis B). The applicant asserted that Analysis A overstates
the population of patients eligible for DefenCathTM because
it includes any patient receiving HD, regardless of whether a central
venous catheter is used. The applicant also asserted that Analysis B
undercounts the potential cases because CVC codes are not always
available on inpatient claims.
In the first analysis (Analysis A), which included only claims with
codes for chronic HD, the applicant searched for claims based on the
presence of one of the ICD-10-CM diagnosis codes previously listed and
then limited the selection criteria to claims including ICD-10-CM
diagnosis code Z49.31 (encounter for adequacy testing for HD)
[[Page 48979]]
or one of the following ICD-10-PCS procedure codes for HD:
[GRAPHIC] [TIFF OMITTED] TR10AU22.106
After imputing a case count of 11 to any MS-DRG with fewer than 11
cases in the FY 2019 MedPAR file released with the FY 2022 IPPS final
rule, the applicant identified a total of 490,790 cases mapping to 512
MS-DRGs. The following table shows the top 20 MS-DRGs, which account
for 57% of all cases included in Analysis A.
[GRAPHIC] [TIFF OMITTED] TR10AU22.107
For Analysis B, the applicant used the same case selection criteria
as Analysis A (the presence of an ICD-10-procedure or diagnosis code
for HD only) but further limited cases to those that include one of the
following ICD-10 procedure codes for the insertion of a CVC.
[[Page 48980]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.108
The applicant asserted that the patient population in Analysis B
(HD and central venous catheter) is more likely to receive
DefenCathTM during an inpatient stay. After imputing a case
count of 11 to any MS-DRG with fewer than 11 cases, the applicant
identified a total of 60,679 cases mapping to 408 MS-DRGs. The
following table shows the top 20 MS-DRGs by case count, which account
for 72% of all cases included in Analysis B.
[GRAPHIC] [TIFF OMITTED] TR10AU22.109
In both analyses, the applicant did not remove charges for prior
technology because DefenCathTM would not replace other
therapies a patient may receive during an inpatient stay. The applicant
standardized the charges using the FY 2022 IPPS final rule impact file
and applied a 4-year inflation factor of 1.281834 to update the charges
from FY 2019 to FY 2023 based on the inflation factor used to update
the outlier threshold in the FY 2022 IPPS/LTCH PPS final rule (86 FR
45542). The applicant did not add charges for new technology as the
cost of DefenCathTM has not yet been determined but believes
that the technology meets the
[[Page 48981]]
cost criterion without the additional charges.
The applicant calculated a final inflated case-weighted average
standardized charge per case of $116,221 for Analysis A and a final
inflated case-weighted average standardized charge per case of $203,746
for Analysis B. The applicant also determined an average case weighted
threshold amount of $77,290 in Scenario A and $96,645 in Scenario B.
Because the final inflated case-weighted average standardized charge
per case for each scenario exceeded the average case-weighted threshold
amount for both scenarios, the applicant asserted that
DefenCathTM meets the cost criterion.
In the proposed rule, we agreed that the technology meets the cost
criterion and therefore proposed to approve DefenCath\TM\ for new
technology add on payments for FY 2023. We stated in the proposed rule
that we expected the applicant to submit its cost per case information
prior to the final rule, and that we would provide an update regarding
the new technology add-on payment amount for the technology in this
final rule. We stated that any new technology add-on payment for
DefenCathTM would be subject to our policy under Sec.
412.88(a)(2) where we limit new technology add-on payments for QIDPs to
the lesser of 75% of the average cost of the technology, or 75% of the
costs in excess of the MS-DRG payment for the case.
We invited comments on whether DefenCathTM meets the
cost criterion and our proposal to approve DefenCathTM for
new technology add-on payments for FY 2023.
Comment: The applicant submitted a public comment in support of
CMS' proposal to approve new technology add-on payments for FY 2023 for
DefenCathTM. The applicant requested that CMS correct
erroneous information from the proposed rule, stating that the FDA new
device approval date is expected later in the third quarter of 2022,
rather than by July 1, 2022, as stated in the proposed rule. The
applicant also provided the anticipated cost of DefenCathTM,
which the applicant states is $5,850 to the hospital, per patient.
Response: We appreciate the applicant's support and provision of
the cost information. We appreciate the applicant's clarification that
the FDA new device approval date is anticipated late in the third
quarter of CY 2022 rather than by July 1, 2022 as stated in the
proposed rule. This discussion now accurately reflects the anticipated
timeline for FDA approval.
Comment: A commenter expressed concern that without information on
the cost of DefenCathTM at the time of the publication of
the proposed rule, it is difficult to comment positively or negatively
on the cost of the technology. This commenter also expressed concern
that, without FDA approval at the time of the publication of the
proposed rule, it is likewise difficult to comment on the potential
impact of the technology. The commenter raised concerns that applicants
under the Alternative Pathway for Transformative New Devices and
Alternative Pathway for Certain Antimicrobial Products do not have to
meet the substantial clinical improvement criterion under 412.87(d) and
recommend that CMS incorporate substantial clinical improvement in its
evaluation of applicants under the alternative pathways.
Response: We thank the commenter for its input. As discussed in FY
2020 IPPS/LTCH PPS final rule (84 FR 42294 through 42295), we believe
that although there may be less certainty of clinical benefit or data
representing the Medicare beneficiary population as compared to the
evidence standard for substantial clinical improvement under the
current new technology add-on payment policy pathway, the benefits of
providing early access to critical and life-saving new cures and
technologies that improve beneficiary health outcomes support the
alternative pathway. We also stated our belief that the evidence base
to demonstrate substantial clinical improvement may not be fully
developed at the time of FDA marketing authorization. We refer the
reader to the FY 2020 IPPS/LTCH PPS final rule for a further discussion
of the development of these alternative pathways.
With respect to cost information, consistent with the formula
specified in section 1886(d)(5)(K)(ii)(I) of the Act, we assess the
adequacy of the MS-DRG prospective payment rate otherwise applicable to
discharges involving the new medical service or technology by
evaluating whether the charges for cases involving the new technology
exceed certain threshold amounts. The MS-DRG threshold amounts used in
evaluating new technology add-on payment applications for FY 2023 are
presented in a data file that is available, along with the other data
files associated with the FY 2022 IPPS final rule on the CMS website
at: https://www.cms.gov/medicare/acute-inpatient-pps/fy-2022-ipps-final-rule-home-page. As discussed in the proposed rule, we agreed that
based on the applicant's cost analysis, the final inflated case-
weighted average standardized charge per case for the technology
exceeded the applicable average case-weighted threshold amount. We also
note that applicants for new technology add-on payment are not required
to have FDA approval by the time of the publication of the proposed
rule. In addition, and as discussed in the proposed rule and later in
this final rule, where cost information is not yet available at the
time of the proposed rule, we note our expectation is that the
applicant will submit cost information prior to the final rule, and
indicate that we will provide an update regarding the new technology
add-on payment amount for the technology, if approved, in the final
rule.
Based on the information provided in the application for new
technology add-on payments, and after consideration of the public
comments we received, we believe DefenCathTM (a single dose
vial, solution of Taurolidine (13.5 mg/mL) and Heparin (1000 USP Units/
mL)) meets the cost criterion. Therefore, we are granting a conditional
approval for DefenCathTM for new technology add-on payments
for FY 2023, subject to the technology receiving FDA marketing
authorization by July 1, 2023 (that is, by July 1 of the fiscal year
for which the applicant applied for new technology add-on payments
(2023)). In the proposed rule we stated that as an application
submitted under the alternative pathway for certain antimicrobial
products at Sec. [thinsp]412.87(d), DefenCathTM is eligible
for conditional approval for new technology add-on payments if it does
not receive FDA marketing authorization by the July 1 deadline
specified in Sec. [thinsp]412.87(e)(2), provided that the technology
receives FDA marketing authorization by July 1 of the particular fiscal
year for which the applicant applied for new technology add-on payments
(that is, July 1, 2023) (87 FR 28350). If DefenCathTM
receives FDA marketing authorization before July 1, 2023, the new
technology add-on payment for cases involving the use of this
technology would be made effective for discharges beginning in the
first quarter after FDA marketing authorization is granted. If FDA
marketing authorization is received on or after July 1, 2023, no new
technology add-on payments will be made for cases involving the use of
DefenCathTM for FY 2023.
Based on the information at the time of this final rule, the cost
per case of the DefenCathTM is $5,850. Under Sec.
412.88(a)(2) we limit new technology add-on payments for QIDPs to the
lesser of 75% of the average cost of the technology, or 75% of the
costs in excess of the MS-DRG payment for the case. As a result, we are
finalizing that,
[[Page 48982]]
subject to DefenCathTM receiving marketing authorization by
July 1, 2023, the maximum new technology add-on payment for a case
involving the use of DefenCathTM will be for $4,387.50 for
FY 2023 (that is, 75% of the average cost of the technology). Cases
involving the use of DefenCathTM that are eligible for new
technology add-on payments will be identified by ICD-10-PCS procedure
code XY0YX28 (Extracorporeal introduction of taurolidine anti-infective
and heparin anticoagulant, new technology group 8).
c. Other Comments
We received several public comments on new technology add-on
payment alternative pathway recommendations that were outside the scope
of the proposals included in the FY 2023 IPPS/LTCH PPS proposed rule
and we are therefore not addressing them in this final rule. We
appreciate these comments and may consider them for possible proposals
in future rulemaking.
8. Use of National Drug Codes (NDCs) To Identify Cases Involving Use of
Therapeutic Agents Approved for New Technology Add-On Payment
As discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49434
through 49435), as a part of the transition to the ICD-10-CM diagnosis
and ICD-10-PCS procedure coding system from the ICD-9-CM coding system,
CMS established the use of Section ``X'' New Technology codes within
the ICD-10-PCS classification to more specifically identify new
technologies or procedures that have historically not been captured
through ICD-9-CM codes, or to more precisely describe information on a
specific procedure or technology than is found with the other sections
of ICD-10-PCS. However, as noted in the FY 2023 IPPS/LTCH PPS proposed
rule (87 FR 28353 through 28355), CMS continued to receive comments
from interested parties, including representatives from hospital
associations, software vendors, professional societies, and coding
professionals, opposing the continued creation of new ICD-10-PCS (for
example, Section X) procedure codes for the purpose of administering
the new technology add-on payment for drugs and biologics.
Specifically, public comments from the ICD-10 Coordination and
Maintenance Committee Meetings have stated that the ICD-10-PCS
classification system was not intended to represent unique drugs/
therapeutic agents and is not an appropriate code set for this purpose.
Commenters explained that, since the implementation of ICD-10, Section
X codes have been established for procedures describing the
administration of a drug/therapeutic agent, which historically were not
typically coded in the inpatient hospital setting. Commenters stated
their belief that it was not logical nor should it be expected for
hospital coding professionals to seek codes for the administration of
drugs within the ICD-10-PCS classification system. In addition, we
noted that over the past 3 years, the number of applications for new
technology add-on payments has continued to increase, which has
subsequently resulted in an increasing number of requests for unique
ICD-10-PCS (for example, Section X) procedure codes specifically for
the purposes of administering the new technology add-on payments.
As discussed in the proposed rule, the current process of
requesting, proposing, finalizing and assigning new ICD-10-PCS
procedure codes to identify and describe the administration of drugs
involves several steps, as described further in this section, and
frequently results in a number of procedure codes that are created
unnecessarily when the drug/therapeutic agents do not receive approval
for the new technology add-on payments, as the administration of drugs/
therapeutic agents is not typically coded in the inpatient hospital
setting. Applicants seeking a unique ICD-10-PCS (for example, Section
X) procedure code to identify the use of their technology for purposes
of new technology add-on payments must complete the code request
process prior to learning the outcome of their new technology add-on
payment application. This process involves a number of steps,
including: gathering relevant information and submitting the ICD-10-PCS
code request; developing a slide deck for the ICD-10 Coordination and
Maintenance Committee Meeting; and reviewing the background paper draft
for the ICD-10 Coordination and Maintenance Committee Meeting agenda
and meeting materials. CMS also expends significant time, effort, and
resources to administer this process, which is compounded by the
increasing number of requests for unique ICD-10-PCS (for example,
Section X) procedure codes. CMS must work with applicants to review,
prepare, and present the code proposals at ICD-10 Coordination and
Maintenance Committee Meetings, then review and summarize public
comments received in response to the meetings, and ultimately make a
decision on the codes requested for new technology add-on payment
policy purposes before the outcome of the new technology add-on payment
application (approval or denial) is known. Following the end of the
three-year timeframe for which a code was created in connection with a
new technology add-on payment application, the disposition of the
Section X code is addressed at a later ICD-10 Coordination and
Maintenance Committee meeting and CMS subsequently receives public
comments that must be reviewed regarding this disposition.
We stated that interested parties had submitted comments that
suggested alternative options to the use of Section X procedure codes
to identify therapeutic agents for the administration of the new
technology add-on payment policy. The majority of commenters supported
using National Drug Codes (NDCs), because it would avoid creating
duplicate codes within the ICD-10-PCS and NDC code sets to identify the
same technology/product, which would allow for predictive and efficient
coding. Commenters also stated that using NDCs would generate product
data on inpatient claims that would allow for outcomes analyses, thus
providing the same benefit as a unique ICD-10-PCS code. Some commenters
suggested using the 3E0 Administration Table within the ICD-10-PCS code
set, as opposed to Section X, as they stated this would be a more
intuitive location for coders to look for ICD-10-PCS procedure codes
describing the administration of therapeutic agents. However, a
commenter noted that this would be unsustainable due to the potentially
large number of new products coming to market. A few commenters also
suggested using different drug terminologies, such as RxNorm, in lieu
of using Section X codes for the time period needed to administer the
new technology add-on payment. We also noted that we have previously
established the use of NDCs as an alternative code set for the purposes
of administering the new technology add-on payment in circumstances
where an ICD-10-PCS code was not available to uniquely identify the use
of the technology. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53351
through 53354), we established the use of the NDC code set to identify
oral medications where no inpatient procedure was associated, to report
the oral administration of the drug DIFICIDTM. We finalized
that the NDC for DIFICIDTM would be used in conjunction with
an ICD-9-CM diagnosis code to uniquely identify the indication for
which administration of the drug (technology) was performed for
[[Page 48983]]
new technology add-on payment purposes. In the FY 2019 IPPS/LTCH PPS
final rule (83 FR 41311), we stated that we believed that the
circumstances with respect to the identification of eligible cases
reporting the use of VABOMERETM, which was administered by
IV infusion, were similar to those addressed in the FY 2013 IPPS/LTCH
PPS final rule with regard to DIFICIDTM because we also did
not have current ICD-10-PCS code(s) to uniquely identify the use of
VABOMERETM to make the new technology add-on payments.
Therefore, consistent with our approach in FY 2013, we stated that we
would identify cases involving the use of VABOMERETM that
were eligible for FY 2019 new technology add-on payments using its NDCs
65293-0009-01 or 70842-0120-01\206\ (VABOMERETM Meropenem-
Vaborbactam Vial). At the time of its new technology add-on payment
application approval, VABOMERETM was not assigned a
corresponding ICD-10-PCS procedure or ICD-10-CM diagnosis code along
with its NDCs. In addition, cases involving the use of two therapeutic
agents that qualify for NCTAP, which is administered similarly to the
new technology add-on payment, are identified using the NDCs for these
products for the purposes of the NCTAP, because there are not currently
ICD-10-PCS procedure codes that uniquely describe the administration of
these therapies.\207\
---------------------------------------------------------------------------
\206\ We note that these are not the FDA assigned NDCs, but
rather have been converted from 10-digit NDCs assigned by FDA to the
HIPAA compliant 11-digit format.
\207\ New COVID-19 Treatments Add-On Payment (NCTAP) https://www.cms.gov/medicare/covid-19/new-covid-19-treatments-add-payment-nctap.
---------------------------------------------------------------------------
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28353 through
28355), we stated that we believed that our previous policies regarding
the use of NDCs to identify the administration of certain therapeutic
agents could be consistently applied toward broader future usage of the
NDCs to identify therapeutic agents eligible for the new technology
add-on payment. Additionally, we stated that we believed that the use
of an existing code set to identify therapeutic agents eligible for the
new technology add-on payment would address concerns raised by
commenters regarding the use of the ICD-10-PCS classification system to
identify these agents, and reduce the need for applicants to seek a
unique ICD-10-PCS code through the ICD-10-PCS Section X code request
process in advance of a determination on their new technology add-on
payment applications.
Therefore, as we discussed further in this section of the proposed
rule and this final rule, we proposed for FY 2024 to instead use NDCs
to identify cases involving the use of therapeutic agents approved for
the new technology add-on payment. We stated that we anticipated that
this proposal would reduce work for hospital coding professionals in
becoming familiar with newly created ICD-10-PCS Section X codes to
describe the administration of therapeutic agents and in searching for
these codes within the documentation and within the classification in
what may be non-intuitive locations. We stated that we also expected
that the proposed change would address concerns regarding the creation
of duplicative codes within the ICD-10-PCS procedure coding system to
describe the administration of therapeutic agents, which would also
reduce the need for vendors to incorporate additional procedure codes
into their coding products; for educators to provide training on these
codes; and for programmers to maintain codes that may be seldom
reported on inpatient claims but for the purposes of the new technology
add-on payment, in their databases. We stated it would also reduce
efforts associated with determining the disposition of procedure codes
describing therapeutic agents that have reached the end of their 3-year
new technology add-on payment timeframe.
Furthermore, we stated that we believed that NDCs are a viable
alternative to Section X codes for the administration of the new
technology add-on payment for therapeutic agents. We stated that we
believed inpatient hospital staff are familiar with using NDCs, and as
stated earlier, we have previously utilized NDCs to administer the new
technology add-on payment. However, to allow for adequate time to
implement this regular usage of NDCs with the new technology add-on
payment for health care providers and hospital coding professionals, we
proposed a transitional period for FY 2023. During this transitional
period, we proposed to utilize NDCs to identify the administration of
therapeutic agents for new technology add-on payment purposes. However,
we also proposed to utilize ICD-10-PCS Section X codes, including codes
newly created for FY 2023, for therapeutic agents during the FY 2023
new technology add-on payment application cycle. Beginning with the FY
2024 new technology add-on payment application cycle, we proposed to
utilize only NDCs to identify claims involving the administration of
therapeutic agents approved for the new technology add-on payment, with
the exception of claims involving therapeutic agents that are not
assigned an NDC by FDA (for example, blood, blood products, etc.) and
are approved for the new technology add-on payment. Cases involving the
use of these technologies approved for the new technology add-on
payment would continue to be identified based on the assigned ICD-10-
PCS procedure code. A unique ICD-10-PCS procedure code would also still
be needed to identify cases involving the use of CAR T-cell and other
immunotherapies that may be assigned to Pre-MDC MS-DRG 018, because the
ICD-10 MS-DRG GROUPER logic for assignment to Pre-MDC MS-DRG 018 is
comprised of the procedure codes describing these CAR T-cell and other
immunotherapy products. Therefore, under the proposal, beginning with
FY 2024 new technology add-on payment applications submitted for a
therapeutic agent, CMS would review the information and inform the
applicant, in advance of the deadline for submitting an ICD-10-PCS
procedure code request to the ICD-10 Coordination and Maintenance
Committee for consideration at the March meeting, if it would be
necessary to submit such a code request for purposes of identifying
cases involving the use of the therapeutic agent for the new technology
add-on payment, if approved, or if, based on the information made
available with the application, the NDC could be used to identify such
cases, and therefore, the applicant would not need to submit an ICD-10-
PCS procedure code request. For each applicable technology that may be
approved for new technology add-on payment, we proposed to indicate the
NDC(s) to use to identify cases involving the administration of the
therapeutic agent for purposes of the new technology add-on payment.
Specifically, we proposed that, during the transitional period
beginning with discharges on or after October 1, 2022 (FY 2023), the
administration of therapeutic agents newly approved for new technology
add-on payments would be uniquely identified using either their
respective NDC(s) or ICD-10-PCS procedure code(s), in combination with
ICD-10-CM codes when appropriate. As stated in our FY 2013 IPPS/LTCH
PPS final rule, the use of the NDCs ``does not preclude CMS from using
additional ICD-9-CM procedure or diagnosis codes to identify cases for
this new technology in conjunction with this alternative code
[[Page 48984]]
set'' (77 FR 53352). Therefore, we stated when necessary, we may
require the use of additional ICD-10-PCS procedure and/or ICD-10-CM
diagnosis codes to uniquely identify cases using these technologies. We
stated that we would continue the use of the existing ICD-10-PCS
procedure codes to identify the administration of therapeutic agents
previously approved for the new technology add-on payment and that
remain eligible for the new technology add-on payment for FY 2023.
We further proposed that, beginning with discharges on or after
October 1, 2023 (FY 2024), the administration of therapeutic agents
newly approved for the new technology add-on payments beginning FY 2024
or a subsequent fiscal year would be uniquely identified only by their
respective NDC(s), along with the corresponding existing ICD-10 code(s)
required to uniquely identify the therapeutic agents, when necessary,
to make the new technology add-on payments. For technologies that were
newly approved for new technology add-on payments for FY 2023
(beginning with discharges on or after October 1, 2022) and remain
eligible for the new technology add-on payment for FY 2024 or a
subsequent fiscal year, we proposed to continue to allow the use of
either the existing ICD-10-PCS procedure codes or NDCs to identify the
administration of those therapeutic agents. For technologies that were
newly approved for new technology add-on payments prior to FY 2023 and
remain eligible for the new technology add-on payment for FY 2024 or a
subsequent fiscal year, we stated we would continue to use the existing
ICD-10-PCS procedure codes to identify the administration of those
therapeutic agents. We invited public comments on our proposal to
utilize NDCs to identify claims involving the use of therapeutic agents
approved for new technology add-on payments, including any potential
concerns regarding adoption of this code set for the identification of
therapeutic agents for purposes of new technology add-on payments.
Comment: We received multiple comments related to the proposed
policy. A commenter stated that the ICD-10-PCS coding system is not
intended to represent unique therapeutic agents and is not an
appropriate code set for this purpose. The commenter also stated that
ICD-10-PCS codes have often been created unnecessarily because the
therapeutic agent was not approved for a new technology add-on payment,
and that in the absence of a new technology add-on payment,
administration of therapeutic agents is not typically coded in the
hospital inpatient setting. The commenter stated that assignment of
ICD-10-PCS codes by coding professionals solely for new technology add-
on payment purposes, for services that would not otherwise be coded in
the inpatient setting, is administratively burdensome. Another
commenter mentioned that using FDA's NDCs would allow for superior data
capture methods and eliminate manual intervention to complete coding.
Another commenter stated that given the likelihood of continued
therapeutic innovation, it viewed this proposed policy as a path toward
earlier access to these therapies by Medicare beneficiaries. A
commenter stated that as hospitals typically capture all NDCs related
to a patient stay within their electronic medical record systems, these
codes could easily be included with claims. The commenter requested
that CMS configure its system to accept all NDC codes, not just those
related to products eligible to receive new technology add-on payments,
to significantly reduce administrative burden for hospitals.
Several commenters also suggested that if CMS finalizes this
policy, we should establish a process to promote and educate hospitals
on this policy change to ensure that they are prepared for billing
under the new process, including clearly indicating which NDC(s) should
be used to identify a particular therapeutic agent for new technology
add-on payment purposes, as some therapeutic agents may have more than
one applicable NDC. Multiple commenters also urged CMS to extend the
proposed transitional process from one year to two years, that is,
through FY 2024, with NDC utilization beginning in FY 2025. Some
commenters also suggested that during this two-year transition period,
CMS should analyze claims data and obtain feedback from interested
parties to understand hospitals' usage of NDCs, prior to eliminating
the process for using ICD-10-PCS codes.
A commenter expressed support for our proposal to continue use of
ICD-10-PCS codes for cases assigned to Pre-MDC MS-DRG 018 (Chimeric
Antigen Receptor (CAR) T-cell and Other Immunotherapies) because
hospitals may not have had experience with submitting NDCs as part of
hospital inpatient claim forms for such cases. Another commenter stated
that it was concerned with our proposal to use NDCs in lieu of ICD-10-
PCS codes for allogeneic HSCT donor sources because providers, such as
hospitals, primarily report ICD-10-PCS codes and are unfamiliar with
NDCs for these donor sources. The commenter requested that CMS expand
our proposed exceptions to the use of NDCs for therapeutic agents to
also include the unique ICD-10-PCS codes describing the infusion of
therapeutics that begin with the characters XW1, as well as any future
advanced cell therapy donor sources.
A commenter explained that it disagreed with creating individual
ICD-10-PCS codes for specific drugs because it believed that ICD-10-PCS
nomenclature is for surgical procedures and not specific drugs. The
commenter expressed that coders do not routinely assign ICD-10-PCS
codes for example, for drugs, radiology procedures, and lab tests, and
that this would be an administrative burden on coders, as well as
billers, to ensure these drugs are identified through ICD-10-PCS
coding. The commenter stated that it would be more cost effective to
identify these specific drugs by their NDC number and not an ICD-10-PCS
code to ensure adequate reimbursement. Another commenter recommended
that CMS reevaluate our proposal to transition to the use of NDCs to
identify the administration of a therapeutic agent for purposes of new
technology add-on payment because the commenter stated that it would
add undue burden on coders who typically do not assign ICD-10-PCS codes
for drug administration for inpatient cases. The commenter also
requested that CMS pursue broader inpatient claims reporting
improvements.
Response: We appreciate the input from the commenters on our
proposed use of NDCs to identify cases involving use of therapeutic
agents approved for new technology add-on payment and have taken these
comments into consideration, as discussed later in this section.
Comment: A couple of commenters were grateful to CMS for listening
to feedback from interested parties and putting this proposal forward,
but had significant questions about implementation and existing
hospital resources for CMS to address prior to finalizing the use of
NDCs, and recommended that CMS retain the ICD-10-PCS coding for new
technology add-on payments. Other commenters stated that CMS does not
currently require NDC reporting on Medicare inpatient claims, except in
rare cases of previous new technology add-on payments, and that
reporting NDCs for only the occasional drug, and on an inpatient claim,
would create new operational burdens for hospitals, especially smaller
and rural hospitals, that do not currently have a system for concurrent
scanning of NDCs upon administration
[[Page 48985]]
of therapeutic agents. Another commenter stated that some hospitals
already have systems that would provide an automated method of
capturing NDC codes on inpatient claims, but that other facilities,
will face new and laborious manual processes despite reporting NDCs on
certain outpatient claims. A commenter noted that a recent analysis of
hospitals by Deloitte found that incorrect or missing NDC data had
caused inaccurate billing.\208\ The commenter further stated that it
believed the process to educate hospitals and subsequently require the
use of NDCs could possibly create a greater administrative burden than
it would save. Some commenters also noted that these burdens would come
at a time when hospitals continue to address resource and staffing
constraints resulting from the COVID-19 PHE. A commenter explained that
the transition to NDCs may create complexity in tracking patient cases,
which may make it difficult to perform further valuable research on
quality of care issues and health outcomes. Another commenter stated
that it believed any changes to the current process should be done in a
careful manner to ensure that CMS' efforts to move to a more
streamlined system do not have any inadvertent implications on claims
data.
---------------------------------------------------------------------------
\208\ Evaluating Hospital Pharmacy Inventory Management and
Revenue Cycle Processes, White Paper Guidance for Healthcare
Internal Auditors https://ahia.org/assets/Uploads/pdfUpload/WhitePapers/EvaluatingHospitalPharmacyInventoryManagementandRevenueCycleProcesses.pdf.
---------------------------------------------------------------------------
A commenter stated that because there are multiple proposed
exceptions to the use of NDCs, the streamlining and burden reduction of
this policy may be limited. Another commenter stated that this proposal
would unnecessarily require two separate standards for devices and
drugs.
A commenter stated that hospitals are faced with increasingly
complex requirements to report drugs to secure reimbursement with
variations based upon code sets and patient status. The commenter
stated that for inpatient claims there are two ways of reporting drugs
for additional payment: hemophilia products reported with HCPCS codes
and billed units per date of service (DOS), and new technology add-on
payment-eligible drugs reported with a single ICD-10-PCS code
independent of number of doses or days administered. The commenter
further stated that outpatient claims are reported with HCPCS code and
billed units per DOS, with the exception of self-administered oral
drugs that were not assigned HCPCS codes, as well as specific new drugs
and biologicals billed under the HCPCS Code C9399 (Unclassified drug or
biological) and for which the commenter stated that CMS requires that
the drug name, dose, amount of waste and NDC number be manually added
to the remarks section of the claim. The commenter stated that hospital
pharmacy and billing IT systems need remediation with complex
maintenance in order to accurately bill drugs based upon the type of
drug, whether it is eligible for new technology add-on payment and the
status of the patient, and that many hospitals currently do not bill
some new technology add-on payment-eligible drugs due to the cumbersome
process and amount of the anticipated reimbursement, which the
commenter stated could lead to inadvertent billing errors or omissions
when a business decision is made that the anticipated payment will be
less than the cost to remediate IT systems and maintain these complex
billing rules. The commenter further stated that inaccurate data could
lead to erroneous future rate-setting by CMS when data is missing from
claims. The commenter recommended that CMS instead consider that new
technology add-on payment-eligible drugs be billed on inpatient claims
with the same instructions as currently used to report hemophilia
products, with HCPCS codes and billing units by DOS. The commenter
explained that having one way to bill drugs on inpatient and outpatient
claims would reduce IT programming expense and reduce errors with
increased standardization. The commenter requested that the CMS HCPCS
Working Group assign HCPCS codes to items eligible for new technology
add-on payment, even if they normally would not be assigned a HCPCS
code. The commenter stated that as HCPCS codes are assigned quarterly,
this would eliminate the need for special notification if new NDCs are
marketed after the implementation of the new technology add-on payment
status and before the next rule-making cycle. The commenter further
recommended that if CMS were to finalize its proposal to use NDCs, CMS
should work with the National Uniform Billing Committee (NUBC) to
clarify how 5010 HIPAA transaction standard units of measure and
billing quantities should be calculated and reported. The commenter
also recommended that CMS work with NUBC to require all payers to
accept NDCs on inpatient claims to avoid payer-specific instructions,
which require complex and expensive IT programming.
This commenter and several other commenters also requested CMS
provide additional information in rulemaking on how NDCs would be
utilized: if a NDC may be reported on multiple DOS, or if multi-day
therapies must be combined into a single line; whether units of
measures and quantities would be required to be reported; if this
policy would apply specifically for therapeutic agents eligible for new
technology add-on payment or for all therapeutic agents used in
Medicare; how a drug product with multiple NDCs would be handled; and
how CMS would publish available NDCs for analysis by interested parties
and update NDCs if the codes were changed by FDA post-rulemaking.
Several commenters also emphasized the complexity of information
transfer from the 10-digit FDA-assigned NDC number format to the 5010
HIPAA transaction standard required 11-digit NDC number format used for
billing on claims, especially when trying to reconstitute the NDC back
to its FDA standard. Other commenters noted future concerns with
potential changes in FDA assignment of NDC numbers from 10-digits to a
new 16-digit format, as well as the modifications needed to the 837I/
UB-04 forms to accommodate this change.
In addition, commenters highlighted issues regarding a lack of
national standards for correctly coding drugs using NDCs, as well as a
lack of acceptance of NDCs by all payers, on inpatient claims. A
commenter further stated that without specific guidance, current NDC
reporting is often inaccurate, resulting in increasing claim rejections
for an invalid NDC number. A couple of commenters explained that
currently, Form Locator 43 (FL43) on the UB-04 form is not unique to
only the NDC number. A commenter stated that they believed that the
proposed usage of this field may not be allowed because FL43 is
intended for the reporting of NDCs for Medicaid drug rebates, but not
for the new technology add-on payment. Some commenters also stated that
there was a potential for claim line limits to be reached if multiple
NDCs were reported on one claim. These commenters believed that this
policy change should be considered as part of broader inpatient claims
reporting improvements, with another commenter further stating that
grouping together necessary changes to 837I/UB-04 claim forms,
alongside updated instructions on NDC reporting for inpatients, would
minimize short-term burden as well as data inaccuracies.
Due to these concerns, a few commenters suggested that CMS further
[[Page 48986]]
study the feasibility of this proposed policy change though a Technical
Advisory Group (TAG), consisting of industry experts, before finalizing
and implementing this policy. A commenter further recommended that
other suggestions noted by CMS, such as the 3E0 Administration Table
within ICD-10-PCS code set and RxNorm, along with other options, such
as the HCPCS code set or a revision to the process that allows the ICD-
10-PCS code to be pending assignment until the finalization of the new
technology add-on payment determination, should be explored by the TAG
and presented in an upcoming proposed rule. Another commenter
recommended that CMS address alignment with timing for U.S.
implementation of ICD-11 codes.
Response: We appreciate the input from commenters on our proposed
use of NDCs to identify cases involving use of therapeutic agents
approved for new technology add-on payments. We acknowledge that
interested parties have continued to share concerns regarding our
current use of the ICD-10-PCS classification system to identify
therapeutic agents eligible for new technology add-on payments. As
discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28353
through 28355), we had anticipated that our proposal to use the NDC,
with its previously established use as an alternative code set for the
purposes of administering the new technology add-on payment, would
reduce work for hospital coding professionals in becoming familiar with
newly created ICD-10-PCS Section X codes to describe the administration
of therapeutic agents. We had also expected that this proposed change
would address concerns regarding the creation of duplicative codes
within the ICD-10-PCS procedure coding system, which would also reduce
the need for vendors to incorporate additional procedure codes into
their coding products; for educators to provide training on these
codes; and for programmers to maintain codes that may be seldom
reported on inpatient claims but for the purposes of the new technology
add-on payment in their databases.
However, as previously summarized, commenters have shared concerns
that our proposed use of NDCs for this purpose may impose new
administrative burdens to hospitals. For example, commenters indicated
that hospital pharmacy and billing IT systems that are not currently
required to use NDCs for billing on inpatient Medicare claims may need
to use manual processes to report NDCs for the purposes of new
technology add-on payments, because they may not have existing
automated systems in place.
Furthermore, based on review of comments, it is unclear to us the
extent to which hospitals and health care providers would utilize NDCs
during a transition period in FY 2023, especially if they believe
adding these manual processes may result in inadvertent billing errors
for therapeutic agents eligible for new technology add-on payments,
which commenters state may be further compounded by staffing shortages
due to the COVID-19 pandemic. This may limit our ability to obtain
comprehensive feedback from interested parties during the transition
period, as suggested by commenters, or perform an analysis of claims
data to assess if NDCs are being used, prior to fully transitioning to
using NDCs for this purpose.
Therefore, after careful consideration of the concerns raised by
commenters, we are not finalizing this proposed policy, and will
instead reassess this policy proposal in future rulemaking. We believe
that this will allow for adequate time to evaluate and consider the
issues raised by commenters. We understand that commenters would be
interested in further details on how NDCs would be operationalized for
the purposes of any such policy change, along with a process to educate
hospitals on these changes to ensure accurate billing throughout a
transition period. We appreciate that commenters have raised a number
of important questions on our proposal, and we will continue to engage
the public in these conversations.
9. Proposal to Publicly Post New Technology Add-On Payment Applications
As noted in section II.F.1.f. of the preamble of this final rule,
applicants for new technology add-on payments for new medical services
or technologies must submit a formal request, including a full
description of the clinical applications of the medical service or
technology and the results of any clinical evaluations demonstrating
that the new medical service or technology represents a substantial
clinical improvement (unless the application is under one of the
alternative pathways), along with a significant sample of data to
demonstrate the new medical service or technology meets the high-cost
threshold (OMB-0938-1347). See section II.F.1.f. of the preamble of
this final rule for further details on the data and evidence that can
be submitted. We post complete application information and final
deadlines for submitting a full application on the CMS website at
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech. We also post on the same website tracking
forms completed by each applicant, which include the name of each
applicant, name of the technology, and a brief description so that
interested parties can identify the new medical services or
technologies under review before the annual proposed rule.
Additionally, section 1886(d)(5)(K)(viii) of the Act provides for a
mechanism for public input before the publication of a proposed rule
regarding whether a medical service or technology represents a
substantial clinical improvement. Consistent with the Act, we hold an
annual Town Hall meeting, typically in December following notice of the
meeting in the Federal Register.
As set forth in 42 CFR 412.87(e)(1), CMS considers whether a
technology meets the criteria for the new technology add-on payment and
announces the results as part of its annual updates and changes to the
IPPS. Accordingly, in drafting the proposed rule, CMS reviews each new
technology add-on payment application it receives under the pathway
specified by the applicant at the time of application submission, along
with supplemental information\209\ obtained from the applicant,
information provided at the Town Hall meeting, and comments received in
response to the Town Hall meeting. In the proposed rule, CMS summarizes
the information contained in the application, including the applicant's
explanation of what the technology does, background on the disease
process, information about the FDA approval/clearance, and the
applicant's assertions and supporting data on how the technology meets
the new technology add-on payment criteria under Sec. 412.87. In
summarizing this information for inclusion in the proposed rule, CMS
restates or paraphrases information contained in the application and
attempts to avoid misrepresenting or omitting any of an applicant's
claims. CMS also tries to ensure that sufficient information is
provided in the proposed rule to facilitate public comments on whether
the medical service or technology meets the new technology add-on
payment criteria. Currently, however, CMS does not make the
applications themselves, as completed by the applicants, publicly
available. In addition, CMS generally
[[Page 48987]]
does not take into consideration information that is marked as
confidential when determining whether a technology meets the criteria
for new technology add-on payments.
---------------------------------------------------------------------------
\209\ For the FY 2023 new technology add-on payment
applications, the supplemental information deadline to guarantee
inclusion in the IPPS proposed rule was December 17, 2021.
---------------------------------------------------------------------------
We note that in the past, CMS has received requests from the public
to access and review the new technology add-on payment applications to
further facilitate comment on whether a technology meets the new
technology add-on payment criteria. In consideration of this issue, we
stated in the proposed rule that we agree that review of the original
source information from the applications for new technology add-on
payments may help to inform public comment. Further, making this
information publicly available may foster greater input from experts in
the stakeholder community based on their review of the completed
application forms and related materials. Accordingly, as we discuss
further in this section of the proposed rule and this final rule, we
stated that we believe that providing additional information to the
public by publicly posting the applications and certain related
materials online may help to further engage the public and foster
greater input and insights on the various new medical services and
technologies presented annually for consideration for new technology
add-on payments.
We stated that we also believe that posting the applications online
would reduce the risk that we may inadvertently omit or misrepresent
relevant information submitted by applicants, or are perceived as
misrepresenting such information, in our summaries in the rules. It
also would streamline our evaluation process, including the
identification of critical questions in the proposed rule, particularly
as the number and complexity of the applications have been increasing
over time. That is, by making the applications available to the public
online, we would afford more time for CMS to process and analyze the
supporting data and evidence rather than reiterate parts of the
application in the rule.
Therefore, to increase transparency, enable increased stakeholder
engagement, and further improve and streamline our evaluation process,
we proposed in the FY 2023 IPPS/LTCH PPS proposed rule to publicly post
online future applications for new technology add-on payments.
Specifically, beginning with the FY 2024 application cycle, we proposed
to post online the completed application forms and certain related
materials (for example, attachments, uploaded supportive materials)
that we receive from applicants. Additionally, we proposed to post
information acquired subsequent to the application submission (for
example, comments received after the New Technology Town Hall, updated
application information, additional clinical studies, etc.). We
proposed that we would not post the cost and volume information the
applicant provides in the application form itself or as attached
materials, or any material included with the application that the
applicant indicates is not releasable to the public because the
applicant does not own the copyright or the applicant does not have the
appropriate license to make the material available to the public, as
further described in the next paragraph. We proposed that we would
publicly post the completed application forms and related materials no
later than the issuance of the proposed rule, which would afford the
public the full public comment period to review the information
provided by the applicant in its application.
With respect to copyrighted materials, we proposed that on the
application form itself, the applicant would be asked to provide a
representation that the applicant owns the copyright or otherwise has
the appropriate license to make all the copyrighted material included
with its application public with the exception of those materials
identified by the applicant as not releasable to the public, as
applicable. For any material included with the application that the
applicant indicates as copyrighted and/or not otherwise releasable to
the public, we proposed that the applicant must either provide a link
to where the material can be accessed or provide an abstract or summary
of the material that CMS can make public, and CMS will then post that
link or abstract or summary online, along with the other posted
application materials. We invited comments on this proposal.
Under our current practice, we include in the final rule
information on the cost of each technology that is approved for the new
technology add-on payment for the purposes of calculating the maximum
add-on payment, and information on the anticipated volume of the
technology for purposes of the impact analysis. For the proposed rule,
specifically for applications submitted under the alternative pathway,
our current practice is to propose whether or not to approve the
application based on the eligibility criteria for the alternative
pathway under 42 CFR 412.87(c) or (d) and, where cost information is
available from the applicant, to use this information in proposing a
maximum add-on payment amount. Where cost information is not yet
available, we note our expectation is that the applicant will submit
cost information prior to the final rule, and indicate that we will
provide an update regarding the new technology add-on payment amount
for the technology, if approved, in the final rule. We noted that we
would continue this same approach with respect to including cost and
volume information in the proposed and final rules. However, as noted,
under our proposal to post online the new technology add-on payment
applications, we would not include cost and volume information for
either traditional or alternative pathway applications as part of the
application materials that would be posted online.
We noted that at times an applicant may furnish information marked
as proprietary or trade secret information along with its application
for new technology add-on payments. Currently, the application
specifies that data provided in the application or tracking form may be
subject to disclosure and instructs the applicant to mark any
proprietary or trade secret information so that CMS can attempt, to the
extent allowed under Federal law, to keep the information protected
from public view.\210\ We further stated that this instruction would
change under our proposal such that information included in the
application, other than cost and volume information, would be made
publicly available online through posting of the application. We
emphasized that the applicant should not submit as part of its
application any such proprietary or trade secret information that it
does not want to be made publicly available online. As noted, under our
existing practice we stated that we generally do not consider
information that is marked as confidential, proprietary, or trade
secret when determining whether a technology meets the criteria for new
technology add-on payments.
---------------------------------------------------------------------------
\210\ See new technology add-on payment application included in
the FY 2023 New Technology Application Packet, available at: https://www.cms.gov/files/zip/fy-2023-new-technology-application-packet.zip; and FY 2023 Tracking Forms, available at: https://www.cms.gov/files/document/fy-2023-tracking-forms-applicants.pdf.
---------------------------------------------------------------------------
We also stated that this proposal would not change the current
timeline or evaluation process for new technology add-on payments, the
criteria used to assess applications, or the deadlines for various data
submissions. Additionally, we stated that we do not expect added
burdens on prospective applicants as a result of this
[[Page 48988]]
proposal since we did not propose to fundamentally change the
information collected in the application itself or the supplemental
information that would be furnished to support the application. As
noted, the aim of the proposed policy change is to increase accuracy,
transparency, and efficiency for both CMS and stakeholders.
In connection with the proposal to post the new technology
applications online, we stated that we expect we would also make
changes to the summaries that appear in the annual proposed and final
rules, given that the public would have access to the submitted
applications themselves (excluding certain information and materials as
described previously), while also continuing to provide sufficient
information in the rules to facilitate public comments on whether a
medical service or technology meets the new technology add-on payment
criteria. Specifically, we stated that we do not anticipate summarizing
each entire application in the Federal Register as we have in the past,
given the expanded and public access to the applications under the
proposal. In some instances, such as the discussion of the substantial
clinical improvement criterion, we stated that we expect to provide a
more concise summary of the evidence or a more targeted discussion of
the applicant's claims about how that criterion is met based on the
evidence and supporting data (although this may vary depending on the
application, new medical service or technology, and the nature of
supporting materials provided). We expect that we would continue to
generally include, at a high-level, the following information in the
proposed and final rules: the technology and applicant name; a
description of what the technology does; background on the disease
process; the FDA approval/clearance status; and a summary of the
applicant's assertions. We also noted we expect to provide more
succinct information as part of the summaries in the proposed and final
rules regarding the applicant's assertions as to how the medical
service or technology meets the newness, cost, and substantial clinical
improvement criteria. For example, we would provide a list of the
applicant's assertions for whether the technology meets the three sub-
criteria under the substantial clinical improvement criterion \211\ and
a list of the sources of data submitted in support of the assertions,
along with references to the application in support of these lists. In
the proposed rule, we stated we would also continue to provide
discussion of the concerns or issues we identified with respect to
applications submitted under the traditional pathway, and for an
alternative pathway application, we intend to continue to propose
whether to approve or disapprove the application, including noting any
concerns we have identified, and, as applicable, the maximum add-on
payment amount, where cost information is available. In the final rule,
we would continue to provide an explanation of our determination of
whether a medical service or technology meets the applicable new
technology add-on payment criteria and, for approved technologies, the
final add-on payment amounts. We stated that as noted, we believe the
proposal to post online the completed application forms and other
information described previously would afford greater transparency
during the annual rulemaking, for purposes of determining whether a
medical service or technology is eligible for new technology add-on
payments.
---------------------------------------------------------------------------
\211\ Sub-criteria referenced are those listed in Question 36 of
the new technology add-on payment application, specifically
Questions 36a-36c.
---------------------------------------------------------------------------
We sought public comment on our proposal to publicly post online
the completed application forms and certain related materials and
updated application information submitted subsequent to the initial
application submission for new technology add-on payments, beginning
with applications for FY 2024.
Comment: We received many public comments regarding this policy
proposal. Overall, commenters appreciated the agency's aims in making
the proposal of fostering greater transparency and public input, while
mitigating increased burdens and workloads associated with the rising
complexity and number of new technology add-on payment applications
submitted annually. A few commenters were fully supportive of our
proposal, while a majority of the remaining commenters supported the
proposal, while suggesting modifications to address concerns about the
disclosure of certain information. In particular, these commenters were
encouraged by CMS' proposal not to include cost and volume information
as part of the application materials that would be posted online, but
stated that the proposal did not go far enough to protect potentially
confidential, commercially sensitive information (for example,
biologics license applications (BLA) or nonpublic studies), and
recommended that CMS modify the proposal, offering suggestions for
ensuring that such information not be posted online.
Some commenters requested that CMS bifurcate the application to
allow a section for information that would not be posted online, afford
applicants the opportunity to submit a separate file of confidential
information, or allow information in the application to be redacted.
Other commenters requested that CMS continue the practice of allowing
the applicant to mark sensitive proprietary or trade secret information
as confidential and not for posting online. Commenters stated that if
the full application were posted online, applicants may refrain from
submitting certain information necessary to support the application and
meet the new technology add-on payment criteria (for example, clinical
information cited but not yet in the public domain and prior to FDA
approval and information concerning newness, such as engineering
specifics), resulting in applications that are less complete or robust,
and therefore, would compromise the goals of the new technology add-on
payment process. Absent protection of this information, commenters
stated that applicants could apply only after FDA approval, creating
significant delays in new technology add-on payment approvals and
subsequent beneficiary access.
Commenters also acknowledged that CMS generally does not consider
confidential or proprietary information in making a determination
whether a new technology meets the new technology add-on payment
criteria, but believed there could be circumstances where such
information could contribute to the agency's overall understanding of a
technology, therapeutic area, or other relevant question that arises
during its review (for example, pre-publication study results, which
are kept from public release pending their publication in peer-reviewed
scientific publications). Another commenter asserted that such data can
help CMS better understand the technology and make a more informed
decision about the application. The commenters also stated that,
without protection of such information, companies would no longer be
able to submit such studies until after publication. Commenters also
stated that the proposed policy puts the onus on the applicant to not
submit this type of information without recognizing that a
comprehensive application might require such information.
Additionally, commenters were generally supportive of our proposal
regarding copyrighted material.
[[Page 48989]]
Response: We appreciate the support for our proposal and our
efforts toward greater transparency, public input, and streamlining of
the new technology add-on application process. In making our proposal,
we indicated that applicants should not submit proprietary or trade
secret information with the application, to avoid such information
being posted online as part of the application. Moreover, we proposed
not to continue our practice of allowing applicants to mark such
information to be withheld from disclosure given that our general
policy is not to consider information that is marked confidential,
proprietary, or trade secret when determining whether a technology
meets the criteria for new technology add-on payments and given the
need for the public to understand the information we are relying on in
making such decisions. However, in consideration of public comments, we
will provide a mechanism for applicants to submit confidential
information, including proprietary or trade secret information, that
will not be posted online. We anticipate providing a section on the
application where applicants can submit confidential information
separately from non-confidential information, or otherwise marking
sections or questions in the application for which we will not post the
information online. Applicants would still be required to submit cost
and volume information in the application since this information is
necessary; however, we will indicate in the application that cost and
volume information will not be publicly posted but certain cost and
volume information may still be summarized and discussed in the
proposed rule, as is consistent with our current practice. Applicants
should expect that, unless otherwise noted in the application that
certain information will not be posted publicly (for example, contact
information), everything else may be posted publicly. We emphasize that
it is the applicant's responsibility to put confidential information
only in the areas of the application designated for confidential
information and not elsewhere in the application. However, as
previously noted, applicants should consider what they include in a
confidential section of the application given that we generally do not
consider any information that cannot be made public when determining
whether a technology meets the new technology add-on payment criteria.
With respect to copyrighted information, we are finalizing our proposal
without modification.
Additionally, we note that in the past we have received
applications in which all the data and information in an application
are marked as proprietary or confidential, or where certain information
provided in support of the applicant's assertions regarding eligibility
for the new technology add-on payment, for example a claim of
substantial clinical improvement, is marked as such. In such cases, we
reiterate that we generally will not be able to consider that data and
information when determining whether a technology meets the criteria
for new technology add-on payments. Our process provides for public
input, so it is important that we provide the information needed for
the public to meaningfully comment on the new technology add-on payment
applications, including the applicants' assertions as to why a
technology meets the new technology add-on payment criteria.
Comment: A commenter suggested that CMS further study ways to
improve and streamline the annual review process. Another commenter
requested that CMS defer a decision until the FY 2025 application
cycle, allowing more time for interested parties and the agency to more
thoroughly consider the implications and potential options to improve
the efficiency and capacity of the review process.
Response: As we stated in the proposed rule, we proposed to
publicly post online applications for new technology add-on payments to
increase transparency, enable increased engagement with interested
parties, and improve and streamline our evaluation process. Through
this policy, we also are attempting to address some of the downsides
and challenges of our current practice of summarizing the contents of
the applications by restating or paraphrasing information, ensuring
that sufficient information is provided in the proposed rule, and
avoiding misrepresenting or omitting any of the applicants' claims.
Posting the application and certain related materials online, subject
to certain exceptions as discussed in this section, is a
straightforward solution and strikes a balance between affording
greater transparency and streamlining the application process. Given
the reasons we have noted previously, the overall support for the
proposal, and after considering the other feedback and suggestions by
commenters, we are finalizing our proposal to post applications online,
but as previously discussed, we will provide a mechanism for applicants
to submit confidential information that would not be included as part
of the application materials posted online. We also continue to welcome
feedback on the application and review process, including potential
options for improving the efficiency and capacity of this process, and
we will continue to consider this issue.
Comment: A few commenters raised concerns about the timing of when
applications would be posted online. A commenter questioned whether the
agency planned to post all applications and related materials online at
the same time, or on a rolling basis as they are received and deemed
complete, noting that the specific timing of online posting would be
highly relevant to applicants given that under the current process,
applicants have the opportunity to amend or withdraw an application
prior to presentation at the New Technology Town Hall or issuance of
the proposed rule. The commenter believed that any new online posting
process should preserve an applicant's ability to withdraw an
application prior to posting, noting that many applicants submit
materials before certainty that the technology meets the criteria for a
new technology add-on payment, and with an intent to either supplement
or withdraw the application during the cycle, because the annual
application cycle often requires a submission well in advance of market
introduction. Another commenter noted the fluidity and frequent updates
of the data collection process in these applications, which may occur
more quickly than the public notice and comment period and therefore,
the information made available by CMS may not be current when it is
released.
Response: We agree with the commenter that additional information
related to the application may be submitted up until the release of the
proposed rule and understand that posting the complete application and
supplemental information all at once is preferable to continually
updating the application information online. Accordingly, we are
clarifying that under the final policy we are adopting, we will
publicly post the application and any additional information received
(with the exception of certain confidential, cost and volume, or
copyrighted information as explained previously) at the time the
proposed rule is published and no sooner. With regard to the
commenter's concern about an applicant's ability to withdraw
applications during the application process, we clarify that the policy
we are finalizing would not change an applicant's ability to withdraw
its application prior to the proposed rule being published and, in such
cases, we
[[Page 48990]]
would not post those applications online or address them in the
proposed rule. In instances, however, where the applicant withdraws its
application from consideration after the proposed rule is issued, the
application would remain posted online (that is, corresponding to the
published discussion of the application in the proposed rule).
After considering the comments, and for the reasons discussed, we
are finalizing our proposal to publicly post online new technology add-
on payment applications, including the completed application forms,
certain related materials (as described previously), and any additional
updated application information submitted subsequent to the initial
application submission (except certain volume, cost and other
information identified by the applicant as confidential), beginning
with the application cycle for FY 2024, at the time the proposed rule
is published. We are finalizing as proposed our proposal with respect
to the treatment of copyrighted information. We are finalizing a
modification to our proposal to provide a mechanism for applicants to
submit confidential information that would not be posted online, such
as in a separate section of the application, or by identifying
particular questions for which the information submitted would not be
publicly posted. We will not publicly post cost and volume information;
however, consistent with our current practice, we will continue to
summarize and discuss certain cost and volume information for the
proposed rule and will indicate as such in the application. With the
exception of information included in a confidential information section
of the application, cost and volume information, and materials
identified by the applicant as copyrighted and/or not otherwise
releasable to the public, the contents of the application and related
materials may be posted publicly. We further clarify that we will post
these application materials at the time of the proposed rule and no
sooner, and that we will not post applications that are withdrawn prior
to publication of the proposed rule.
III. Changes to the Hospital Wage Index for Acute Care Hospitals
A. Background
1. Legislative Authority
Section 1886(d)(3)(E) of the Act requires that, as part of the
methodology for determining prospective payments to hospitals, the
Secretary adjust the standardized amounts for area differences in
hospital wage levels by a factor (established by the Secretary)
reflecting the relative hospital wage level in the geographic area of
the hospital compared to the national average hospital wage level. We
currently define hospital labor market areas based on the delineations
of statistical areas established by the Office of Management and Budget
(OMB). A discussion of the FY 2023 hospital wage index based on the
statistical areas appears under section III.A.2. of the preamble of
this final rule.
Section 1886(d)(3)(E) of the Act requires the Secretary to update
the wage index annually and to base the update on a survey of wages and
wage-related costs of short-term, acute care hospitals. CMS collects
these data on the Medicare cost report, CMS Form 2552-10, Worksheet S-
3, Parts II, III, IV. The OMB control number for this information
collection request is 0938-0050, which expired on March 31, 2022. A 30-
day Federal Register notice published on June 22, 2022 (87 FR 37338)
for the reinstatement of the information collection request. The
comment period closed July 22, 2022. Section 1886(d)(3)(E) of the Act
also requires that any updates or adjustments to the wage index be made
in a manner that ensures that aggregate payments to hospitals are not
affected by the change in the wage index. The adjustment for FY 2023 is
discussed in section II.B. of the Addendum to this final rule.
As discussed in section III.I. of the preamble of this final rule,
we also take into account the geographic reclassification of hospitals
in accordance with sections 1886(d)(8)(B) and 1886(d)(10) of the Act
when calculating IPPS payment amounts. Under section 1886(d)(8)(D) of
the Act, the Secretary is required to adjust the standardized amounts
so as to ensure that aggregate payments under the IPPS after
implementation of the provisions of sections 1886(d)(8)(B),
1886(d)(8)(C), and 1886(d)(10) of the Act are equal to the aggregate
prospective payments that would have been made absent these provisions.
The budget neutrality adjustment for FY 2023 is discussed in section
II.A.4.b. of the Addendum to this final rule.
Section 1886(d)(3)(E) of the Act also provides for the collection
of data every 3 years on the occupational mix of employees for short-
term, acute care hospitals participating in the Medicare program, in
order to construct an occupational mix adjustment to the wage index.
(The OMB control number for approved collection of this information is
0938-0907, which expires on October 31, 2022. An extension of the
information collection request is currently being developed. The public
will have an opportunity to review and submit comments regarding the
extension of this PRA package through a public notice and comment
period separate from this rulemaking.) A discussion of the occupational
mix adjustment that we are applying to the FY 2023 wage index appears
under sections III.E. and F. of the preamble of this final rule.
2. Core-Based Statistical Areas (CBSAs) for the FY 2023 Hospital Wage
Index
The wage index is calculated and assigned to hospitals on the basis
of the labor market area in which the hospital is located. Under
section 1886(d)(3)(E) of the Act, beginning with FY 2005, we delineate
hospital labor market areas based on OMB-established Core-Based
Statistical Areas (CBSAs). The current statistical areas (which were
implemented beginning with FY 2015) are based on revised OMB
delineations issued on February 28, 2013, in OMB Bulletin No. 13-01.
OMB Bulletin No. 13-01 established revised delineations for
Metropolitan Statistical Areas, Micropolitan Statistical Areas, and
Combined Statistical Areas in the United States and Puerto Rico based
on the 2010 Census, and provided guidance on the use of the
delineations of these statistical areas using standards published in
the June 28, 2010, Federal Register (75 FR 37246 through 37252). We
refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 49951
through 49963 and 49973 through 49982)) for a full discussion of our
implementation of the OMB statistical area delineations beginning with
the FY 2015 wage index.
Generally, OMB issues major revisions to statistical areas every 10
years, based on the results of the decennial census. However, OMB
occasionally issues minor updates and revisions to statistical areas in
the years between the decennial censuses through OMB Bulletins. On July
15, 2015, OMB issued OMB Bulletin No. 15-01, which provided updates to
and superseded OMB Bulletin No. 13-01 that was issued on February 28,
2013. The attachment to OMB Bulletin No. 15-01 provided detailed
information on the update to statistical areas since February 28, 2013.
The updates provided in OMB Bulletin No. 15-01 were based on the
application of the 2010 Standards for Delineating Metropolitan and
Micropolitan Statistical Areas to Census Bureau population estimates
for July 1, 2012, and July 1, 2013. In the FY 2017 IPPS/LTCH PPS final
rule (81 FR 56913), we adopted the updates set forth in OMB Bulletin
No. 15-01 effective
[[Page 48991]]
October 1, 2016, beginning with the FY 2017 wage index. For a complete
discussion of the adoption of the updates set forth in OMB Bulletin No.
15-01, we refer readers to the FY 2017 IPPS/LTCH PPS final rule. In the
FY 2018 IPPS/LTCH PPS final rule (82 FR 38130), we continued to use the
OMB delineations that were adopted beginning with FY 2015 to calculate
the area wage indexes, with updates as reflected in OMB Bulletin No.
15-01 specified in the FY 2017 IPPS/LTCH PPS final rule.
On August 15, 2017, OMB issued OMB Bulletin No. 17-01, which
provided updates to and superseded OMB Bulletin No. 15-01 that was
issued on July 15, 2015. The attachments to OMB Bulletin No. 17-01
provided detailed information on the update to statistical areas since
July 15, 2015, and were based on the application of the 2010 Standards
for Delineating Metropolitan and Micropolitan Statistical Areas to
Census Bureau population estimates for July 1, 2014 and July 1, 2015.
In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41362 through 41363), we
adopted the updates set forth in OMB Bulletin No. 17-01 effective
October 1, 2018, beginning with the FY 2019 wage index. For a complete
discussion of the adoption of the updates set forth in OMB Bulletin No.
17-01, we refer readers to the FY 2019 IPPS/LTCH PPS final rule. In the
FY 2020 IPPS/LTCH PPS final rule (84 FR 42300 through 42301), we
continued to use the OMB delineations that were adopted beginning with
FY 2015 (based on the revised delineations issued in OMB Bulletin No.
13-01) to calculate the area wage indexes, with updates as reflected in
OMB Bulletin Nos. 15-01 and 17-01.
On April 10, 2018 OMB issued OMB Bulletin No. 18-03 which
superseded the August 15, 2017, OMB Bulletin No. 17-01. On September
14, 2018, OMB issued OMB Bulletin No. 18-04 which superseded the April
10, 2018 OMB Bulletin No. 18-03. Historically OMB bulletins issued
between decennial censuses have only contained minor modifications to
CBSA delineations based on changes in population counts. However, OMB's
2010 Standards for Delineating Metropolitan and Micropolitan
Statistical Areas to Census Bureau population estimates created a
larger mid-decade redelineation that takes into account commuting data
from the American Commuting Survey. As a result, the September 14,
2018, OMB Bulletin No. 18-04 included more modifications to the CBSAs
than are typical for OMB bulletins issued between decennial censuses.
In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58743 through 58755)
we adopted the updates set forth in OMB Bulletin No. 18-04 effective
October 1, 2020, beginning with the FY 2021 wage index. For a complete
discussion of the adoption of the updates set forth in OMB Bulletin No.
18-04, we refer readers to the FY 2021 IPPS/LTCH PPS final rule.
On March 6, 2020, OMB issued Bulletin No. 20-01, which provided
updates to and superseded OMB Bulletin No. 18-04 that was issued on
September 14, 2018. The attachments to OMB Bulletin No. 20-01 provided
detailed information on the update to statistical areas since September
14, 2018, and were based on the application of the 2010 Standards for
Delineating Metropolitan and Micropolitan Statistical Areas to Census
Bureau population estimates for July 1, 2017, and July 1, 2018. After
reviewing OMB Bulletin No. 20-01, we determined that the changes in
Bulletin 20-01 encompassed delineation changes that would not affect
the Medicare wage index for FY 2022. While we adopted the updates set
forth in OMB Bulletin No. 20-01 in the FY 2022 IPPS/LTCH PPS final rule
(86 FR 45163 through 45164) consistent with our general policy of
adopting OMB delineation updates, we also noted that specific wage
index updates would not be necessary for FY 2022 as a result of
adopting these updates. In other words, the updates set forth in OMB
Bulletin No. 20-01 would not affect any hospital's geographic area for
purposes of the wage index calculation for FY 2022. For a complete
discussion of the adoption of the updates set forth in OMB Bulletin No.
20-01, we refer readers to the FY 2022 IPPS/LTCH PPS final rule (86 FR
45163 through 45164).
For FY 2023, we are continuing to use the OMB delineations that
were adopted beginning with FY 2015 (based on the revised delineations
issued in OMB Bulletin No. 13-01) to calculate the area wage indexes,
with updates as reflected in OMB Bulletin Nos. 15-01, 17-01, 18-04 and
20-01.
In connection with our adoption in FY 2021 of the updates in OMB
Bulletin 18-04, we adopted a policy to place a 5-percent cap, for FY
2021, on any decrease in a hospital's wage index from the hospital's
final wage index in FY 2020 so that a hospital's final wage index for
FY 2021 would not be less than 95 percent of its final wage index for
FY 2020. We refer the reader to the FY 2021 IPPS/LTCH PPS final rule
(85 FR 58753 through 58755) for a complete discussion of this
transition. As finalized in the FY 2021 IPPS/LTCH PPS final rule, this
transition was set to expire at the end of FY 2021. However, given the
unprecedented nature of the ongoing COVID-19 public health emergency
(PHE), we adopted a policy in the FY 2022 IPPS/LTCH PPS final rule to
apply an extended transition to the FY 2022 wage index for hospitals
that received the transition in FY 2021. Specifically, we continued a
wage index transition for FY 2022 (for hospitals that received the
transition in FY 2021) under which we applied a 5 percent cap on any
decrease in the hospital's wage index compared to its wage index for FY
2021 to mitigate significant negative impacts of, and provide
additional time for hospitals to adapt to, the CMS decision to adopt
the revised OMB delineations. We also applied a budget neutrality
adjustment to the standardized amount so that our transition in FY 2022
was implemented in a budget neutral manner under our authority in
section 1886(d)(5)(I) of the Act. We refer the reader to the FY 2022
IPPS/LTCH PPS final rule (85 FR 45164 through 45165) for a complete
discussion of this transition. We also refer readers to section III.N.
of the preamble of this final rule which discusses our permanent policy
to apply a 5-percent cap on any decrease in a hospital's wage index
compared to its wage index from the prior fiscal year.
3. Codes for Constituent Counties in CBSAs
CBSAs are made up of one or more constituent counties. Each CBSA
and constituent county has its own unique identifying codes. There are
two different lists of codes associated with counties: Social Security
Administration (SSA) codes and Federal Information Processing Standard
(FIPS) codes. Historically, CMS has listed and used SSA and FIPS county
codes to identify and crosswalk counties to CBSA codes for purposes of
the hospital wage index. As we discussed in the FY 2018 IPPS/LTCH PPS
final rule (82 FR 38129 through 38130), we have learned that SSA county
codes are no longer being maintained and updated. However, the FIPS
codes continue to be maintained by the U.S. Census Bureau. We believe
that using the latest FIPS codes will allow us to maintain a more
accurate and up-to-date payment system that reflects the reality of
population shifts and labor market conditions.
The Census Bureau's most current statistical area information is
derived from ongoing census data received since 2010; the most recent
data are from 2020. The Census Bureau maintains a complete list of
changes to counties or county equivalent entities on the
[[Page 48992]]
website at https://www.census.gov/programs-surveys/geography/technical-documentation/county-changes.html. We believe that it is important to
use the latest counties or county equivalent entities in order to
properly crosswalk hospitals from a county to a CBSA for purposes of
the hospital wage index used under the IPPS.
In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38129 through
38130), we adopted a policy to discontinue the use of the SSA county
codes and began using only the FIPS county codes for purposes of cross
walking counties to CBSAs. In addition, in the same rule, we
implemented the latest FIPS code updates, which were effective October
1, 2017, beginning with the FY 2018 wage indexes. These updates have
been used to calculate the wage indexes in a manner generally
consistent with the CBSA-based methodologies finalized in the FY 2005
IPPS final rule and the FY 2015 IPPS/LTCH PPS final rule. We refer the
reader to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38129 through
38130) for a complete discussion of our adoption of FIPS county codes.
Based on the latest information included in the Census Bureau's
website at https://www.census.gov/programs-surveys/geography/technical-documentation/county-changes.2010.html, the Census Bureau has made the
following updates to the FIPS codes for counties or county equivalent
entities:
Chugach Census Area, AK (FIPS State County Code 02-063)
and Copper River Census Area, AK (FIPS State County Code 02-066), were
created from former Valdez-Cordova Census Area (02-261) which was
located in CBSA 02. The CBSA code for these two new county equivalents
remains 02.
We believe that it is important to use the latest counties or
county equivalent entities in order to properly crosswalk hospitals
from a county to a CBSA for purposes of the hospital wage index used
under the IPPS. In addition, we believe that using the latest FIPS
codes allows us to maintain a more accurate and up-to-date payment
system that reflects the reality of population shifts and labor market
conditions. Therefore, in the FY 2023 IPPS/LTCH PPS proposed rule (87
FR 28359), we proposed to implement these FIPS code updates listed
previously, effective October 1, 2022, beginning with the FY 2023 wage
indexes. We proposed to use these update changes to calculate area wage
indexes in a manner that is generally consistent with the CBSA-based
methodologies finalized in the FY 2005 IPPS final rule (69 FR 49026
through 49034) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 49951
through 49963). We note that while the county update changes listed
previously changed the county names, the CBSAs to which these counties
map did not change from the prior counties. Therefore, we stated that
there would be no impact or change to hospitals in these counties for
purposes of the hospital wage index as a result of our implementation
of these FIPS code updates. We invited public comments on our
proposals.
We did not receive any public comments on our proposals. Therefore,
for the reasons discussed earlier, we are finalizing our proposal,
without modification, to implement the FIPS code updates listed
previously, effective October 1, 2022, beginning with the FY 2023 wage
indexes. As we proposed, we will use these update changes to calculate
the area wage indexes in a manner that is generally consistent with the
CBSA-based methodologies finalized in the FY 2005 IPPS final rule and
the FY 2015 IPPS/LTCH PPS final rule. For FY 2023, Tables 2 and 3
associated with this final rule and the County to CBSA Crosswalk File
and Urban CBSAs and Constituent Counties for Acute Care Hospitals File
posted on the CMS website reflect these FIPS code updates.
B. Worksheet S-3 Wage Data for the FY 2023 Wage Index
The FY 2023 wage index values are based on the data collected from
the Medicare cost reports submitted by hospitals for cost reporting
periods beginning in FY 2019 (the FY 2022 wage indexes were based on
data from cost reporting periods beginning during FY 2018).
1. Included Categories of Costs
The FY 2023 wage index includes all of the following categories of
data associated with costs paid under the IPPS (as well as outpatient
costs):
Salaries and hours from short-term, acute care hospitals
(including paid lunch hours and hours associated with military leave
and jury duty).
Home office costs and hours.
Certain contract labor costs and hours, which include
direct patient care, certain top management, pharmacy, laboratory, and
nonteaching physician Part A services, and certain contract indirect
patient care services (as discussed in the FY 2008 final rule with
comment period (72 FR 47315 through 47317)).
Wage-related costs, including pension costs (based on
policies adopted in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51586
through 51590) and modified in the FY 2016 IPPS/LTCH PPS final rule (80
FR 49505 through 49508)) and other deferred compensation costs.
2. Excluded Categories of Costs
Consistent with the wage index methodology for FY 2022, the wage
index for FY 2023 also excludes the direct and overhead salaries and
hours for services not subject to IPPS payment, such as skilled nursing
facility (SNF) services, home health services, costs related to GME
(teaching physicians and residents) and certified registered nurse
anesthetists (CRNAs), and other subprovider components that are not
paid under the IPPS. The FY 2023 wage index also excludes the salaries,
hours, and wage-related costs of hospital-based rural health clinics
(RHCs), and Federally Qualified Health Centers (FQHCs) because Medicare
pays for these costs outside of the IPPS (68 FR 45395). In addition,
salaries, hours, and wage-related costs of CAHs are excluded from the
wage index for the reasons explained in the FY 2004 IPPS final rule (68
FR 45397 through 45398). For FY 2020 and subsequent years, other wage-
related costs are also excluded from the calculation of the wage index.
As discussed in the FY 2019 IPPS/LTCH final rule (83 FR 41365 through
41369), other wage-related costs reported on Worksheet S-3, Part II,
Line 18 and Worksheet S-3, Part IV, Line 25 and subscripts, as well as
all other wage-related costs, such as contract labor costs, are
excluded from the calculation of the wage index.
3. Use of Wage Index Data by Suppliers and Providers Other Than Acute
Care Hospitals Under the IPPS
Data collected for the IPPS wage index also are currently used to
calculate wage indexes applicable to suppliers and other providers,
such as SNFs, home health agencies (HHAs), ambulatory surgical centers
(ASCs), and hospices. In addition, they are used for prospective
payments to IRFs, IPFs, and LTCHs, and for hospital outpatient
services. We note that, in the IPPS rules, we do not address comments
pertaining to the wage indexes of any supplier or provider except IPPS
providers and LTCHs. Such comments should be made in response to
separate proposed rules for those suppliers and providers. We did not
receive any comments on the discussion in this section.
C. Verification of Worksheet S-3 Wage Data
The wage data for the FY 2023 wage index were obtained from
Worksheet S-
[[Page 48993]]
3, Parts II, III and IV of the Medicare cost report, CMS Form 2552-10
for cost reporting periods beginning on or after October 1, 2018, and
before October 1, 2019. (As noted in section III.A.1 of the preamble of
this final rule, the OMB control number for this information collection
request is 0938-0050, which expired on March 31, 2022. A 30-day Federal
Register notice published on June 22, 2022 (87 FR 37338) for the
reinstatement of the information collection request. The comment period
closed July 22, 2022). For wage index purposes, we refer to cost
reports beginning on or after October 1, 2018, and before October 1,
2019 as the ``FY 2019 cost report,'' the ``FY 2019 wage data,'' or the
``FY 2019 data.'' Instructions for completing the wage index sections
of Worksheet S-3 are included in the Provider Reimbursement Manual
(PRM), Part 2 (Pub. 15-2), Chapter 40, Sections 4005.2 through 4005.4.
The data file used to construct the FY 2023 wage index includes FY 2019
data submitted to us as of the end of June 2022. As in past years, we
performed an extensive review of the wage data, mostly through the use
of edits designed to identify aberrant data.
Consistent with the IPPS and LTCH PPS ratesettings, our policy
principles with regard to the wage index include generally using the
most current data and information available which is usually data on a
4-year lag (for example, for the FY 2022 wage index we used cost report
data from FY 2018) . In section I.F. of the preamble of this final
rule, we discuss our analysis of the best available data for use in the
development of this FY 2023 IPPS/LTCH PPS final rule given the
potential impact of the public health emergency (PHE) for the
Coronavirus Disease (COVID-19). For the FY 2023 wage index, the best
available data typically would be from the FY 2019 wage data. Our
review and analysis of the FY 2019 wage data shows that the data is not
significantly impacted by COVID-19 PHE. A comparison of providers shows
similar trends in those with cost reports ending during the PHE as
compared to providers without cost reports ending during the PHE. The
data also shows that changes in the average hourly wage (AHW) for
providers were consistent between providers with cost reports ending
during the PHE as compared to providers without cost reports ending
during the PHE. It appears that the overall impact of the COVID-19 PHE
on the FY 2019 wage data has been minimal. Additionally, the changes in
the wage data from FY 2018 to FY 2019 show similar trends in the change
of the data from FY 2017 to FY 2018. Therefore, we proposed to use the
FY 2019 wage data for the FY 2023 wage index.
Comment: A commenter expressed concern that the review and analysis
of the FY 2019 wage data with regard to the impact by COVID-19 PHE was
unclear. The commenter noted that the proposed rule did not reference
tables or files for the public to review to confirm the agency's
conclusion. The commenter also stated that it is confusing why CMS
stated that the FY 2019 wage data was not impacted by the PHE given
that the PHE did not begin until March 2020. The commenter encouraged
CMS to share source information so stakeholders can better understand
the agency's position, particularly given the review of data suggests
that the cost of staffing has increased substantially.
Response: With regard to the commenter that stated that the PHE did
not begin until March 2020, we note that the PHE was declared on
January 31, 2020 in response to COVID-19. We also note that in March
2020, the World Health Organization declared the COVID-19 outbreak a
pandemic.
As previously stated, our review and analysis of the FY 2019 wage
data shows that the data is not significantly impacted by COVID-19 PHE.
We use the latest audited data to calculate the wage index. The latest
audited data as of the FY 2023 rulemaking cycle is cost reports with a
begin date during FY 2019. Because we use audited cost report data with
a begin date in FY 2019 (on or after Oct 1, 2018 through on or before
September 30, 2019), the latest cost report with a begin date in FY
2019 would be September 30, 2019 which would end typically 12 months
later on September 30, 2020 (which would include some months in the
PHE). The earlier the cost report begin date the less months of data
are included in the period of the PHE. As noted in this section of this
rule, there are 3,136 providers included in the wage index for FY 2023.
Approximately 1,300 hospitals have cost report data from FY 2019
that has some months of data touching the PHE in the period of January
31, 2020 through September 30, 2020. We note, while the PHE was
declared January 31, 2020, the impact of the PHE began to be felt by
hospitals beginning in March 2020 (which is re-enforced by the
commenter that stated its belief that the PHE began in March 2020). Of
these 1,300 hospitals:
Approximately 80 hospitals have a cost reporting period of
04/01/2019 through 03/30/2020 (one month of data in the period between
March 2020 through September 2020).
Approximately 1,000 hospitals have a cost reporting period
of 07/01/2019 through 06/30/2020 (four months of data in the period
between March 2020 through September 2020).
Approximately 85 hospitals have a cost reporting period of
09/01/2019 through 08/30/2020 (six months of data in the period between
April 2020 through September 2020).
Based on the previous, approximately 37 percent of hospitals
include data from the period of March 2020 through September 2020. The
majority of these hospitals (1,000) have a cost report begin date of
July 1, 2019 which accounts for approximately 32 percent of all
hospitals cost report data; also, the majority of the cost report data
for these hospitals (8 months) is not impacted by the PHE. Therefore,
the overwhelming majority of hospitals data has no data from the period
of March 2020 through September 2020. While some cost reports included
some months of data from the period of March 2020 through September
2020, as previously stated, the data shows that changes in the average
hourly wage (AHW) for providers were consistent between providers with
cost reports ending during the PHE as compared to providers without
cost reports ending during the PHE. Additionally, the changes in the
wage data from FY 2018 to FY 2019 show similar trends in the change of
the data from FY 2017 to FY 2018. We also note, AHW data by provider
and CBSA is readily available in our Public Use Files released with
each proposed and final rule each fiscal year. Therefore, any
comparisons that CMS made within the current year data and prior year
data can easily be replicated by the public. We did not receive any
comments questioning whether certain providers or CBSAs AHW were
grossly affected by the PHE. Therefore, we continue to believe that the
data shows that changes in the average hourly wage (AHW) for providers
were consistent between providers with cost reports ending during the
PHE as compared to providers without cost reports ending during the
PHE.
We also note, in section G.2.c. of Appendix A of the FY 2023 IPPS/
LTCH proposed rule (87 FR 28709), we provided a table showing the
projected impact of proposed changes in the area wage index values for
urban and rural hospitals. Specifically, the table compares the shifts
in wage index values for hospitals due to proposed changes in the
average hourly wage data
[[Page 48994]]
for FY 2023 relative to FY 2022. We refer the commenter to this table
as well as a similar table that is published in section G.2.c. of
Appendix A in this final rule.
Finally, CMS will be looking at the differential effects of the
COVID-19 PHE on the audited wage data in future fiscal years. We plan
to review the audited wage data, and the impacts of the COVID-19 PHE on
such data and evaluate these data for future rulemaking.
We requested that our MACs revise or verify data elements that
result in specific edit failures. For the proposed FY 2023 wage index,
we identified and excluded 86 providers with aberrant data that should
not be included in the wage index. However, we stated that if data
elements for some of these providers are corrected, we intended to
include data from those providers in the final FY 2023 wage index. We
also adjusted certain aberrant data and included these data in the wage
index. For example, in situations where a hospital did not have
documentable salaries, wages, and hours for housekeeping and dietary
services, we imputed estimates, in accordance with policies established
in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49965 through 49967). We
instructed MACs to complete their data verification of questionable
data elements and to transmit any changes to the wage data no later
than March 19, 2022. For the final FY 2023 wage index, we restored the
data of 23 hospitals to the wage index because their data was either
verified or improved, and removed the data of 0 hospitals for the first
time after the proposed rule due to its data being aberrant. We also
restored the data of one provider that we inadvertently excluded from
the proposed rule that was not on the delete list in the proposed rule
public use file. Thus, 63 hospitals with aberrant data remain excluded
from the FY 2023 wage index (86-23 = 63).
In constructing the proposed FY 2023 wage index, we included the
wage data for facilities that were IPPS hospitals in FY 2019, inclusive
of those facilities that have since terminated their participation in
the program as hospitals, as long as those data did not fail any of our
edits for reasonableness. We stated in the proposed rule (87 FR 28630
through 28632) that we believe that including the wage data for these
hospitals is, in general, appropriate to reflect the economic
conditions in the various labor market areas during the relevant past
period and to ensure that the current wage index represents the labor
market area's current wages as compared to the national average of
wages. However, we excluded the wage data for CAHs as discussed in the
FY 2004 IPPS final rule (68 FR 45397 through 45398); that is, any
hospital that is designated as a CAH by 7 days prior to the publication
of the preliminary wage index public use file (PUF) is excluded from
the calculation of the wage index. For the proposed FY 2023 wage index,
we removed 3 hospitals that converted to CAH status on or after January
24, 2021, the cut-off date for CAH exclusion from the FY 2022 wage
index, and through and including January 21, 2022, the cut-off date for
CAH exclusion from the FY 2023 wage index. Since the proposed rule, we
learned of 0 more hospitals that converted to CAH status on or after
January 24, 2021, and through and including January 21, 2022, the cut-
off date for CAH exclusion from the FY 2023 wage index, for a total of
3 hospitals that were removed from the FY 2023 wage index due to
conversion to CAH status. In summary, we calculated the FY 2023 wage
index using the Worksheet S-3, Parts II and III wage data of 3,136
hospitals.
For the FY 2023 wage index, we allotted the wages and hours data
for a multicampus hospital among the different labor market areas where
its campuses are located using campus full-time equivalent (FTE)
percentages as originally finalized in the FY 2012 IPPS/LTCH PPS final
rule (76 FR 51591). Table 2, which contains the FY 2023 wage index
associated with this final rule (available via the internet on the CMS
website), includes separate wage data for the campuses of 26
multicampus hospitals. The following chart lists the multicampus
hospitals by CSA certification number (CCN) and the FTE percentages on
which the wages and hours of each campus were allotted to their
respective labor market areas:
BILLING CODE 4120-01-P
[[Page 48995]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.110
[[Page 48996]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.111
BILLING CODE 4120-01-C
We noted that, in past years, in Table 2, we have placed a ``B'' to
designate the subordinate campus in the fourth position of the hospital
CCN. However, for the FY 2019 IPPS/LTCH PPS proposed and final rules
and subsequent rules, we have moved the ``B'' to the third position of
the CCN. Because all IPPS hospitals have a ``0'' in the third position
of the CCN, we believe that placement of the ``B'' in this third
position, instead of the ``0'' for the subordinate campus, is the most
efficient method of identification and interferes the least with the
other, variable, digits in the CCN.
Comment: Commenters opposed the exclusion of hospitals' wage data.
These commenters stated that excluding accurate and verified data is
inconsistent with the extensive process established by CMS to ensure
the accuracy and reliability of hospital wage index data. Commenters
also raised concerns about the lawfulness of excluding wage data for
these hospitals, stating that section 1886(d)(3)(E) of the Act does not
provide the authority for CMS to delete accurately-reported wage data,
and doing so is arbitrary and capricious.
Specifically, a commenter opposed the exclusion of hospitals' wage
data where hospitals timely submitted corrections or appeals. The
commenter stated that where hospitals have available timely-submitted,
corrected and verifiable data CMS is obligated to use such data in the
wage index calculation. The commenter also stated that there is no
statute or regulation authorizing CMS to exclude hospital data based on
a unilateral determination that the data is aberrant.
Response: We responded to similar comments in the FY 2016 IPPS/LTCH
PPS final rule (80 FR 49490 through 49491) and the FY 2022 IPPS/LTCH
PPS final rule (86 FR 45168 through 45169). Section 1886(d)(3)(E) of
the Act requires the Secretary to adjust the proportion of hospitals'
costs attributable to wages and wage-related costs for area differences
reflecting the relative hospital wage level in the geographic area of
the hospital compared to the national average hospital wage level. As
previously stated in those final rules in response to similar comments,
we believe that, under this section of the
[[Page 48997]]
Act, we have discretion to exclude aberrant hospital data from the wage
index PUFs to help ensure that the costs attributable to wages and
wage-related costs in fact reflect the relative hospital wage level in
the hospitals' geographic area. We refer commenters to our previous
responses to comments at the Federal Register pages cited earlier in
this response with regard to the exclusion of hospitals' wage data from
the wage index.
Comment: Some commenters urged CMS to lessen the lag of four years
in hospitals' cost report data used for the wage index (for example, FY
2019 cost report data used for the FY 2023 wage index) and to consider
alternate methods to collect more accurate data.
Another commenter stated that CMS should offer short[hyphen]term
assistance to the hospital community, considering inflationary updates
to the wage index as necessary to preserve current service levels,
which the commenter believes is a particular risk point for underserved
populations. The commenter recommended a more time[hyphen]sensitive and
layered approach to wage index updates to account for excess labor
costs driven by increased contract labor and reimbursement rates to
preserve our critical national hospital system infrastructure. The
commenter stated that CMS could accomplish this by leveraging current
Medicare cost report surveys to develop a wage adjustment until the
labor market stabilizes. This approach would account for regional
disparities and impact, use known and accepted survey data, create a
standardized and auditable system, and support hospitals without
disrupting the baseline Medicare wage index.
Response: CMS used the most recent audited surveys and data to
develop the FY 2023 wage index. We are unclear what alternative data or
which current surveys and reporting the commenters are referring to. We
note, audited cost report data from FY 2020 will be used for FY 2024
and is not available at the time of this final rule. Therefore, we are
unable to account for regional differences without audited data. Also,
as previously noted, section 1886(d)(3)(E) of the Act requires that, as
part of the methodology for determining prospective payments to
hospitals, the Secretary adjust the standardized amounts for area
differences in hospital wage levels by a factor (established by the
Secretary) reflecting the relative hospital wage level in the
geographic area of the hospital compared to the national average
hospital wage level. Uniformly adjusting the salaries and hours for all
areas (which is used to calculate an areas AHW) would lead to a
commensurate change to the national AHW and not the wage index itself.
This is because the wage index is required to be a relative measure.
Further, we refer the commenter to the discussion on the market basket
in section V. A. 1. of the preamble of this final rule for which we now
have an updated forecast of the price proxies underlying the market
basket that incorporates more recent historical data and reflects a
revised outlook regarding the U.S. economy (including the more recent
historical CPI growth, impacts of the Russia/Ukraine war, current
expectations regarding changes to Federal Reserve interest rates, and
tight labor markets). Additionally, we note that section
1886(d)(3)(E)(i) of the Act requires us to make any updates or
adjustments to the wage index in a manner that ensures that aggregate
payments under section 1886(d) are not affected by the change in the
wage index. Section 1886(d)(3)(E)(i) of the Act requires that we
implement the wage index adjustment in a budget neutral manner.
Therefore, since the wage index is subject to budget neutrality, any
increases or decreases as a result of the data from one FY to the next
FY would be implemented in a budget neutral manner.
D. Method for Computing the FY 2023 Unadjusted Wage Index
As stated in the proposed rule (87 FR 28362 through 28365), the
method used to compute the FY 2023 wage index without an occupational
mix adjustment follows the same methodology that we used to compute the
wage indexes without an occupational mix adjustment in the FY 2021
IPPS/LTCH PPS final rule (see 85 FR 58758 through 58761, September 18,
2020), and we did not propose any changes to this methodology. We have
restated our methodology in this section of this final rule.
Step 1.--We gathered data from each of the non-Federal, short-term,
acute care hospitals for which data were reported on the Worksheet S-3,
Parts II and III of the Medicare cost report for the hospital's cost
reporting period relevant to the wage index (in this case, for FY 2023,
these were data from cost reports for cost reporting periods beginning
on or after October 1, 2018, and before October 1, 2019). In addition,
we included data from some hospitals that had cost reporting periods
beginning before October 2018 and reported a cost reporting period
covering all of FY 2019. These data were included because no other data
from these hospitals would be available for the cost reporting period
as previously described, and because particular labor market areas
might be affected due to the omission of these hospitals. However, we
generally describe these wage data as FY 2019 data. We note that, if a
hospital had more than one cost reporting period beginning during FY
2019 (for example, a hospital had two short cost reporting periods
beginning on or after October 1, 2018, and before October 1, 2019), we
include wage data from only one of the cost reporting periods, the
longer, in the wage index calculation. If there was more than one cost
reporting period and the periods were equal in length, we included the
wage data from the later period in the wage index calculation.
Step 2.--Salaries.--The method used to compute a hospital's average
hourly wage excludes certain costs that are not paid under the IPPS.
(We note that, beginning with FY 2008 (72 FR 47315), we included what
were then Lines 22.01, 26.01, and 27.01 of Worksheet S-3, Part II of
CMS Form 2552-96 for overhead services in the wage index. Currently,
these lines are lines 28, 33, and 35 on CMS Form 2552-10. However, we
note that the wages and hours on these lines are not incorporated into
Line 101, Column 1 of Worksheet A, which, through the electronic cost
reporting software, flows directly to Line 1 of Worksheet S-3, Part II.
Therefore, the first step in the wage index calculation is to compute a
``revised'' Line 1, by adding to the Line 1 on Worksheet S-3, Part II
(for wages and hours respectively) the amounts on Lines 28, 33, and
35.) In calculating a hospital's Net Salaries (we note that we
previously used the term ``average'' salaries in the FY 2012 IPPS/LTCH
PPS final rule (76 FR 51592), but we now use the term ``net'' salaries)
plus wage-related costs, we first compute the following: Subtract from
Line 1 (total salaries) the GME and CRNA costs reported on CMS Form
2552-10, Lines 2, 4.01, 7, and 7.01, the Part B salaries reported on
Lines 3, 5 and 6, home office salaries reported on Line 8, and exclude
salaries reported on Lines 9 and 10 (that is, direct salaries
attributable to SNF services, home health services, and other
subprovider components not subject to the IPPS). We also subtract from
Line 1 the salaries for which no hours were reported. Therefore, the
formula for Net Salaries (from Worksheet S-3, Part II) is the
following:
((Line 1 + Line 28 + Line 33 + Line 35)-(Line 2 + Line 3 + Line
4.01 + Line 5 + Line 6 + Line 7 + Line 7.01 + Line 8 + Line 9 + Line
10)).
[[Page 48998]]
To determine Total Salaries plus Wage-Related Costs, we add to the
Net Salaries the costs of contract labor for direct patient care,
certain top management, pharmacy, laboratory, and nonteaching physician
Part A services (Lines 11, 12 and 13), home office salaries and wage-
related costs reported by the hospital on Lines 14.01, 14.02, and 15,
and nonexcluded area wage-related costs (Lines 17, 22, 25.50, 25.51,
and 25.52). We note that contract labor and home office salaries for
which no corresponding hours are reported are not included. In
addition, wage-related costs for nonteaching physician Part A employees
(Line 22) are excluded if no corresponding salaries are reported for
those employees on Line 4. The formula for Total Salaries plus Wage-
Related Costs (from Worksheet S-3, Part II) is the following: ((Line 1
+ Line 28 + Line 33 + Line 35)-(Line 2 + Line 3 + Line 4.01 + Line 5 +
Line 6 + Line 7 + Line 7.01 + Line 8 + Line 9 + Line 10)) + (Line 11 +
Line 12 + Line 13 + Line 14.01 + 14.02 + Line 15) + (Line 17 + Line 22
+ 25.50 + 25.51 + 25.52).
Step 3.--Hours.--With the exception of wage-related costs, for
which there are no associated hours, we compute total hours using the
same methods as described for salaries in Step 2. The formula for Total
Hours (from Worksheet S-3, Part II) is the following:
((Line 1 + Line 28 + Line 33 + Line 35)-(Line 2 + Line 3 + Line
4.01 + Line 5 + Line 6 + Line 7 + Line 7.01 + Line 8 + Line 9 + Line
10)) + (Line 11 + Line 12 + Line 13 + Line 14.01 + 14.02 + Line 15).
Step 4.--For each hospital reporting both total overhead salaries
and total overhead hours greater than zero, we then allocate overhead
costs to areas of the hospital excluded from the wage index
calculation. First, we determine the ``excluded rate'', which is the
ratio of excluded area hours to Revised Total Hours (from Worksheet S-
3, Part II) with the following formula: (Line 9 + Line 10)/(Line 1 +
Line 28 + Line 33 + Line 35)--(Lines 2, 3, 4.01, 5, 6, 7, 7.01, and 8
and Lines 26 through 43). We then compute the amounts of overhead
salaries and hours to be allocated to the excluded areas by multiplying
the previously discussed ratio by the total overhead salaries and hours
reported on Lines 26 through 43 of Worksheet S-3, Part II. Next, we
compute the amounts of overhead wage-related costs to be allocated to
the excluded areas using three steps:
We determine the ``overhead rate'' (from Worksheet S-3,
Part II), which is the ratio of overhead hours (Lines 26 through 43
minus the sum of Lines 28, 33, and 35) to revised hours excluding the
sum of lines 28, 33, and 35 (Line 1 minus the sum of Lines 2, 3, 4.01,
5, 6, 7, 7.01, 8, 9, 10, 28, 33, and 35). We note that, for the FY 2008
and subsequent wage index calculations, we have been excluding the
overhead contract labor (Lines 28, 33, and 35) from the determination
of the ratio of overhead hours to revised hours because hospitals
typically do not provide fringe benefits (wage-related costs) to
contract personnel. Therefore, it is not necessary for the wage index
calculation to exclude overhead wage-related costs for contract
personnel. Further, if a hospital does contribute to wage-related costs
for contracted personnel, the instructions for Lines 28, 33, and 35
require that associated wage-related costs be combined with wages on
the respective contract labor lines. The formula for the Overhead Rate
(from Worksheet S-3, Part II) is the following: (Lines 26 through 43--
Lines 28, 33 and 35)/((((Line 1 + Lines 28, 33, 35)-(Lines 2, 3, 4.01,
5, 6, 7, 7.01, 8, and 26 through 43))-(Lines 9 and 10)) + (Lines 26
through 43-Lines 28, 33, and 35)).
We compute overhead wage-related costs by multiplying the
overhead hours ratio by wage-related costs reported on Part II, Lines
17, 22, 25.50, 25.51, and 25.52.
We multiply the computed overhead wage-related costs by
the previously described excluded area hours ratio.
Finally, we subtract the computed overhead salaries, wage-related
costs, and hours associated with excluded areas from the total salaries
(plus wage-related costs) and hours derived in Steps 2 and 3.
Step 5.--For each hospital, we adjust the total salaries plus wage-
related costs to a common period to determine total adjusted salaries
plus wage-related costs. To make the wage adjustment, we estimate the
percentage change in the employment cost index (ECI) for compensation
for each 30-day increment from October 14, 2018, through April 15,
2020, for private industry hospital workers from the Bureau of Labor
Statistics' (BLS') Compensation and Working Conditions. We use the ECI
because it reflects the price increase associated with total
compensation (salaries plus fringes) rather than just the increase in
salaries. In addition, the ECI includes managers as well as other
hospital workers. This methodology to compute the monthly update
factors uses actual quarterly ECI data and assures that the update
factors match the actual quarterly and annual percent changes. We also
note that, since April 2006 with the publication of March 2006 data,
the BLS' ECI uses a different classification system, the North American
Industrial Classification System (NAICS), instead of the Standard
Industrial Codes (SICs), which no longer exist. We have consistently
used the ECI as the data source for our wages and salaries and other
price proxies in the IPPS market basket, and we did not propose to make
any changes to the usage of the ECI for FY 2023. The factors used to
adjust the hospital's data are based on the midpoint of the cost
reporting period, as indicated in this rule.
Step 6.--Each hospital is assigned to its appropriate urban or
rural labor market area before any reclassifications under section
1886(d)(8)(B), 1886(d)(8)(E), or 1886(d)(10) of the Act. Within each
urban or rural labor market area, we add the total adjusted salaries
plus wage-related costs obtained in Step 5 for all hospitals in that
area to determine the total adjusted salaries plus wage-related costs
for the labor market area.
Step 7.--We divide the total adjusted salaries plus wage-related
costs obtained under Step 6 by the sum of the corresponding total hours
(from Step 4) for all hospitals in each labor market area to determine
an average hourly wage for the area.
Step 8.--We add the total adjusted salaries plus wage-related costs
obtained in Step 5 for all hospitals in the Nation and then divide the
sum by the national sum of total hours from Step 4 to arrive at a
national average hourly wage.
Step 9.--For each urban or rural labor market area, we calculate
the hospital wage index value, unadjusted for occupational mix, by
dividing the area average hourly wage obtained in Step 7 by the
national average hourly wage computed in Step 8.
Step 10.--For each urban labor market area for which we do not have
any hospital wage data (either because there are no IPPS hospitals in
that labor market area, or there are IPPS hospitals in that area but
their data are either too new to be reflected in the current year's
wage index calculation, or their data are aberrant and are deleted from
the wage index), we finalized in the FY 2020 IPPS/LTCH PPS final rule
(84 FR 42305) that, for FY 2020 and subsequent years' wage index
calculations, such CBSA's wage index would be equal to total urban
salaries plus wage-related costs (from Step 5) in the State, divided by
the total urban hours (from Step 4) in the State, divided by the
national average hourly wage from Step 8 (see 84 FR 42305 and 42306,
August 16, 2019). We stated that we believe that, in the absence of
wage data for an urban labor market area, it is reasonable to use a
[[Page 48999]]
statewide urban average, which is based on actual, acceptable wage data
of hospitals in that State, rather than impute some other type of value
using a different methodology. For calculation of the FY 2023 wage
index, we note there is one urban CBSA for which we do not have IPPS
hospital wage data. In Table 3 (which is available via the internet on
the CMS website) which contains the area wage indexes, we include a
footnote to indicate to which CBSAs this policy applies. These CBSAs'
wage indexes would be equal to total urban salaries plus wage-related
costs (from Step 5) in the respective State, divided by the total urban
hours (from Step 4) in the respective State, divided by the national
average hourly wage (from Step 8) (see 84 FR 42305 and 42306, August
16, 2019). Under this step, we also apply our policy with regard to how
dollar amounts, hours, and other numerical values in the wage index
calculations are rounded, as discussed in this section of this rule.
We refer readers to section II. of the Appendix of the final rule
for the policy regarding rural areas that do not have IPPS hospitals.
Step 11.--Section 4410 of Public Law 105-33 provides that, for
discharges on or after October 1, 1997, the area wage index applicable
to any hospital that is located in an urban area of a State may not be
less than the area wage index applicable to hospitals located in rural
areas in that State. The areas affected by this provision are
identified in Table 2 listed in section VI. of the Addendum to the
final rule and available via the internet on the CMS website.
Following is our policy with regard to rounding of the wage data
(dollar amounts, hours, and other numerical values) in the calculation
of the unadjusted and adjusted wage index, as finalized in the FY 2020
IPPS/LTCH final rule (84 FR 42306, August 16, 2019). For data that we
consider to be ``raw data,'' such as the cost report data on Worksheets
S-3, Parts II and III, and the occupational mix survey data, we use
such data ``as is,'' and do not round any of the individual line items
or fields. However, for any dollar amounts within the wage index
calculations, including any type of summed wage amount, average hourly
wages, and the national average hourly wage (both the unadjusted and
adjusted for occupational mix), we round the dollar amounts to 2
decimals. For any hour amounts within the wage index calculations, we
round such hour amounts to the nearest whole number. For any numbers
not expressed as dollars or hours within the wage index calculations,
which could include ratios, percentages, or inflation factors, we round
such numbers to 5 decimals. However, we continue rounding the actual
unadjusted and adjusted wage indexes to 4 decimals, as we have done
historically.
As discussed in the FY 2012 IPPS/LTCH PPS final rule, in ``Step
5,'' for each hospital, we adjust the total salaries plus wage-related
costs to a common period to determine total adjusted salaries plus
wage-related costs. To make the wage adjustment, we estimate the
percentage change in the employment cost index (ECI) for compensation
for each 30-day increment from October 14, 2018, through April 15,
2020, for private industry hospital workers from the BLS' Compensation
and Working Conditions. We have consistently used the ECI as the data
source for our wages and salaries and other price proxies in the IPPS
market basket, and we did not propose any changes to the usage of the
ECI for FY 2023. The factors used to adjust the hospital's data were
based on the midpoint of the cost reporting period, as indicated in the
following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.112
[[Page 49000]]
For example, the midpoint of a cost reporting period beginning
January 1, 2019, and ending December 31, 2019, is June 30, 2019. An
adjustment factor of 1.01630 was applied to the wages of a hospital
with such a cost reporting period.
Previously, we also would provide a Puerto Rico overall average
hourly wage. As discussed in the FY 2017 IPPS/LTCH PPS final rule (81
FR 56915), prior to January 1, 2016, Puerto Rico hospitals were paid
based on 75 percent of the national standardized amount and 25 percent
of the Puerto Rico-specific standardized amount. As a result, we
calculated a Puerto Rico specific wage index that was applied to the
labor-related share of the Puerto Rico-specific standardized amount.
Section 601 of the Consolidated Appropriations Act, 2016 (Pub. L. 114-
113) amended section 1886(d)(9)(E) of the Act to specify that the
payment calculation with respect to operating costs of inpatient
hospital services of a subsection (d) Puerto Rico hospital for
inpatient hospital discharges on or after January 1, 2016, shall use
100 percent of the national standardized amount. As we stated in the FY
2017 IPPS/LTCH PPS final rule (81 FR 56915 through 56916), because
Puerto Rico hospitals are no longer paid with a Puerto Rico specific
standardized amount as of January 1, 2016, under section 1886(d)(9)(E)
of the Act, as amended by section 601 of the Consolidated
Appropriations Act, 2016, there is no longer a need to calculate a
Puerto Rico specific average hourly wage and wage index. Hospitals in
Puerto Rico are now paid 100 percent of the national standardized
amount and, therefore, are subject to the national average hourly wage
(unadjusted for occupational mix) and the national wage index, which is
applied to the national labor-related share of the national
standardized amount. Therefore, for FY 2023, there is no Puerto Rico-
specific overall average hourly wage or wage index.
Based on the methodology, as previously discussed, we stated in the
proposed rule (87 FR 28365) that the proposed FY 2023 unadjusted
national average hourly wage was $47.77.
We did not receive any comments regarding the discussion of our
method for computing the FY 2023 unadjusted wage index. Based on the
previously described methodology, the final FY 2023 unadjusted national
average hourly wage is the following:
[GRAPHIC] [TIFF OMITTED] TR10AU22.113
E. Occupational Mix Adjustment to the FY 2023 Wage Index
As stated earlier, section 1886(d)(3)(E) of the Act provides for
the collection of data every 3 years on the occupational mix of
employees for each short-term, acute care hospital participating in the
Medicare program, in order to construct an occupational mix adjustment
to the wage index, for application beginning October 1, 2004 (the FY
2005 wage index). The purpose of the occupational mix adjustment is to
control for the effect of hospitals' employment choices on the wage
index. For example, hospitals may choose to employ different
combinations of registered nurses, licensed practical nurses, nursing
aides, and medical assistants for the purpose of providing nursing care
to their patients. The varying labor costs associated with these
choices reflect hospital management decisions rather than geographic
differences in the costs of labor.
1. Use of 2019 Medicare Wage Index Occupational Mix Survey for the FY
2023 Wage Index
Section 304(c) of the Consolidated Appropriations Act, 2001 (Pub.
L. 106- 554) amended section 1886(d)(3)(E) of the Act to require CMS to
collect data every 3 years on the occupational mix of employees for
each short-term, acute care hospital participating in the Medicare
program. As discussed in the FY 2022 IPPS/LTCH PPS proposed rule (86 FR
25402 through 25403) and final rule (86 FR 45173), we collected data in
2019 to compute the occupational mix adjustment for the FY 2022, FY
2023, and FY 2024 wage indexes. The FY 2023 occupational mix adjustment
is based on the calendar year (CY) 2019 survey. Hospitals were required
to submit their completed 2019 surveys (Form CMS-10079, OMB Number
0938-0907, expiration date October 31, 2022) to their MACs by September
3, 2020. It should be noted that this collection of information was
approved under OMB control number 0938-0907 with an expiration date of
October 31, 2022. An extension of the information collection request is
currently being developed. The public will have an opportunity to
review and submit comments regarding the extension of this PRA package
through a public notice and comment period separate from this
rulemaking. The preliminary, unaudited CY 2019 survey data were posted
on the CMS website on September 8, 2020. As with the Worksheet S-3,
Parts II and III cost report wage data, as part of the FY 2023 desk
review process, the MACs revised or verified data elements in
hospitals' occupational mix surveys that resulted in certain edit
failures.
2. Calculation of the Occupational Mix Adjustment for FY 2023
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28366), for FY
2023, we proposed to calculate the occupational mix adjustment factor
using the same methodology that we have used since the FY 2012 wage
index (76 FR 51582 through 51586) and to apply the occupational mix
adjustment to 100 percent of the FY 2023 wage index. In the FY 2020
IPPS/LTCH PPS final rule (84 FR 42308), we modified our methodology
with regard to how dollar amounts, hours, and other numerical values in
the unadjusted and adjusted wage index calculation are rounded, in
order to ensure consistency in the calculation. According to the policy
finalized in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42308 and
42309), for data that we consider to be ``raw data,'' such as the cost
report data on Worksheets S-3, Parts II and III, and the occupational
mix survey data, we continue to use these data ``as is'', and not round
any of the individual line items or fields. However, for any dollar
amounts within the wage index calculations, including any type of
summed wage amount, average hourly wages, and the national average
hourly wage (both the unadjusted and adjusted for occupational mix), we
round such dollar amounts to 2 decimals. We round any hour amounts
within the wage index calculations to the nearest whole number. We
round any numbers not expressed as dollars or hours in the wage index
calculations, which could include ratios, percentages, or inflation
factors, to 5 decimals. However, we continue rounding the actual
unadjusted and adjusted wage indexes to 4 decimals, as we have done
historically.
Similar to the method we use for the calculation of the wage index
without occupational mix, salaries and hours for a multicampus hospital
are allotted among the different labor market areas where its campuses
are located. Table 2
[[Page 49001]]
associated with this final rule (which is available via the internet on
the CMS website), which contains the final FY 2023 occupational mix
adjusted wage index, includes separate wage data for the campuses of
multicampus hospitals. We refer readers to section III.C. of the
preamble of this final rule for a chart listing the multicampus
hospitals and the FTE percentages used to allot their occupational mix
data.
Because the statute requires that the Secretary measure the
earnings and paid hours of employment by occupational category not less
than once every 3 years, all hospitals that are subject to payments
under the IPPS, or any hospital that would be subject to the IPPS if
not granted a waiver, must complete the occupational mix survey, unless
the hospital has no associated cost report wage data that are included
in the FY 2023 wage index. For the proposed FY 2023 wage index, we used
the Worksheet S-3, Parts II and III wage data of 3,112 hospitals, and
we used the occupational mix surveys of 3,010 hospitals for which we
also had Worksheet S-3 wage data, which represented a ``response'' rate
of 97 percent (3,010/3,112). For the proposed FY 2023 wage index, we
applied proxy data for noncompliant hospitals, new hospitals, or
hospitals that submitted erroneous or aberrant data in the same manner
that we applied proxy data for such hospitals in the FY 2012 wage index
occupational mix adjustment (76 FR 51586). As a result of applying this
methodology, the proposed FY 2023 occupational mix adjusted national
average hourly wage was $47.71.
We did not receive any comments on our proposed calculation of the
occupational mix adjustment to the FY 2023 wage index. Thus, for the
reasons discussed in this final rule and in the FY 2023 IPPS/LTCH PPS
proposed rule, we are finalizing our proposal, without modification to
calculate the occupational mix adjustment factor using the same
methodology that we have used since the FY 2012 wage index and to apply
the occupational mix adjustment to 100 percent of the FY 2023 wage
index.
For the final FY 2023 wage index, we are using the Worksheet S3,
Parts II and III wage data of 3,136 hospitals, and we are using the
occupational mix surveys of 3,035 hospitals for which we also have
Worksheet S-3 wage data, which is a ``response'' rate of 97 percent
(3,035/3,136). For the final FY 2023 wage index, we are applying proxy
data for noncompliant hospitals, new hospitals, or hospitals that
submitted erroneous or aberrant data in the same manner that we applied
proxy data for such hospitals in the FY 2012 wage index occupational
mix adjustment (76 FR 51586). As a result of applying this methodology,
the final FY-2023 occupational mix adjusted national average hourly
wage is the following:
[GRAPHIC] [TIFF OMITTED] TR10AU22.114
F. Analysis and Implementation of the Proposed Occupational Mix
Adjustment and the FY 2023 Occupational Mix Adjusted Wage Index
As discussed in section III.E. of the preamble of this final rule,
for FY 2023, we are applying the occupational mix adjustment to 100
percent of the FY 2023 wage index. We calculated the occupational mix
adjustment using data from the 2019 occupational mix survey data, using
the methodology described in the FY 2012 IPPS/LTCH PPS final rule (76
FR 51582 through 51586).
The FY 2023 national average hourly wages for each occupational mix
nursing subcategory as calculated in Step 2 of the occupational mix
calculation are as follows:
[GRAPHIC] [TIFF OMITTED] TR10AU22.115
The national average hourly wage for the entire nurse category is
computed in Step 5 of the occupational mix calculation. Hospitals with
a nurse category average hourly wage (as calculated in Step 4) of
greater than the national nurse category average hourly wage receive an
occupational mix adjustment factor (as calculated in Step 6) of less
than 1.0. Hospitals with a nurse category average hourly wage (as
calculated in Step 4) of less than the national nurse category average
hourly wage receive an occupational mix adjustment factor (as
calculated in Step 6) of greater than 1.0.
Based on the 2019 occupational mix survey data, we determined (in
Step 7 of the occupational mix calculation) the following:
[GRAPHIC] [TIFF OMITTED] TR10AU22.116
[[Page 49002]]
We compared the FY 2023 occupational mix adjusted wage indexes for
each CBSA to the unadjusted wage indexes for each CBSA. Applying the
occupational mix adjustment to the wage data resulted in the following:
[GRAPHIC] [TIFF OMITTED] TR10AU22.117
These results indicate that a smaller percentage of urban areas
(53.6 percent) would benefit from the occupational mix adjustment than
would rural areas (57.4 percent).
G. Application of the Rural Floor, Application of the Imputed Floor,
Application of the State Frontier Floor, Continuation of the Low Wage
Index Hospital Policy, and Budget Neutrality Adjustment
1. Rural Floor
Section 4410(a) of the Balanced Budget Act of 1997 (Pub. L. 105-33)
provides that, for discharges on or after October 1, 1997, the area
wage index applicable to any hospital that is located in an urban area
of a State may not be less than the area wage index applicable to
hospitals located in rural areas in that State. This provision is
referred to as the rural floor. Section 3141 of the Patient Protection
and Affordable Care Act (Pub. L. 111-148) also requires that a national
budget neutrality adjustment be applied in implementing the rural
floor.
In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42332 through
42336), we removed urban to rural reclassifications from the
calculation of the rural floor to prevent inappropriate payment
increases under the rural floor due to rural reclassifications, such
that, beginning in FY 2020, the rural floor was calculated without
including the wage data of hospitals that have reclassified as rural
under section 1886(d)(8)(E) of the Act (as implemented in the
regulations at Sec. 412.103). For FY 2023, we proposed to continue to
calculate the rural floor without the wage data of hospitals that have
reclassified as rural under Sec. 412.103 (87 FR 28367-28368). Also,
for the purposes of applying the provisions of section
1886(d)(8)(C)(iii) of the Act, effective beginning in FY 2020, we
removed the data of hospitals reclassified from urban to rural under
section 1886(d)(8)(E) of the Act (as implemented in the regulations at
Sec. 412.103) from the calculation of ``the wage index for rural areas
in the State in which the county is located'' as referred to in section
1886(d)(8)(C)(iii) of the Act (84 FR 42333). In the IPPS/LTCH PPS
proposed rule (87 FR 28367 and 28368), we proposed to continue to apply
this policy for FY 2023.
We noted in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28368)
that the FY 2020 rural floor policy and the related budget neutrality
adjustment were the subject of pending litigation, including in Citrus
HMA, LLC, d/b/a Seven Rivers Regional Medical Center v. Becerra, No.
1:20-cv-00707 (D.D.C.) (hereafter referred to as Citrus). On April 8,
2022, the district court in Citrus granted in part the plaintiff
hospitals' motion for summary judgment and denied the Secretary's
cross-motion for summary judgment. The court found that the Secretary
did not have authority under section 4410(a) of the Balanced Budget Act
of 1997 to establish a rural floor lower than the rural wage index for
a state. We stated that while Citrus involves only FY 2020, the court's
decision--which is subject to potential appeal--may have implications
for FY 2023 payment rates. We stated that we were continuing to
evaluate the court's decision, and although we proposed for the rural
floor wage index policy (and the related budget neutrality adjustment)
to continue for FY 2023, we stated we may decide to take a different
approach in the final rule, depending on public comments or
developments in the court proceedings.
Comments: Several commenters supported CMS's policy established
beginning in FY 2020 to exclude the wage data of Sec. 412.103
hospitals from the rural floor calculation. Some commenters
specifically stated that this policy restores fairness in the wage
index by preventing certain states from manipulating the wage index
system to artificially inflate the wage indexes of hospitals in the
state at the expense of all other states, due to the rural floor
national budget neutrality adjustment required by section 3141 of
Public Law 111-148.
Many commenters urged CMS to acquiesce to the district court's
decision in Citrus, discontinue the policy of excluding the wage data
of Sec. 412.103 hospitals from the rural floor calculation, and revert
to the policy that existed prior to FY 2020. The commenters stated
their belief that the court's analysis was thorough and that continuing
the rural floor policy would
[[Page 49003]]
only increase the agency's exposure to future lawsuits. Commenters
asserted that the plain language of the statute does not provide for a
free-floating rural floor that is not linked to the rural wage index.
One of the commenters advocating for CMS to revert to the policy that
applied prior to FY 2020 requested that if CMS does choose to continue
its current rural floor policy in FY 2023, it should do so in a non-
budget neutral manner.
Other commenters also suggested that along with including the wage
data of Sec. 412.103 hospitals in the rural floor calculation, CMS
should include the wage data of Sec. 412.103 hospitals for purposes of
the calculation required by Sec. 1886(d)(8)(C)(ii) of the Act. Two
commenters specifically asserted that CMS should include the wage data
of Sec. 412.103 hospitals that also have an Medicare Geographic
Classification Review Board (MGCRB) reclassification for purposes of
the calculation required by Sec. 1886(d)(8)(C)(ii) of the Act.
Specifically, these commenters stated that when a geographically rural
hospital has an active MGCRB reclassification to another area, CMS
includes the wage data of the hospital in calculating the rural wage
index of the state in which that hospital is located, if not doing so
would reduce the wage index for that rural area, as described in Sec.
1886(d)(8)(C)(ii) of the Act. However, the commenters stated that CMS
does not treat the wage data of hospitals with a Sec. 412.103
reclassification in addition to an MGCRB reclassification in the same
manner as geographically rural hospitals with an MGCRB
reclassification. A commenter stated that treating hospitals with dual
Sec. 412.103 and MGCRB reclassifications in the same manner as other
rural hospitals for the calculation required by Sec. 1886(d)(8)(C)(ii)
would help address rural floor manipulation by mitigating the impact
that one or two Sec. 412.103 hospitals remaining rural for wage index
purposes would have on the rural wage index and rural floor.
Response: We appreciate the commenters' input. In response to the
comments supporting our proposal to continue our policy of excluding
the wage data of Sec. 412.103 hospitals from the rural floor
calculation for FY 2023, we appreciate the concern regarding wage index
manipulation, particularly arising from high wage hospitals in certain
states reclassifying as rural under Sec. 412.103 to inflate the rural
wage index. However, as noted by a commenter, a national budget
neutrality adjustment is required by section 3141 of Public Law 111-
148. As stated in response to comments in the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45175 through 45176) and in the FY 2017 IPPS/LTCH PPS
final rule (81 FR 56920), section 3141 requires that budget neutrality
for the rural floor be applied ``through a uniform, national adjustment
to the area wage index'' instead of within each State beginning in FY
2011 (75 FR 50160). Accordingly, we do not have the authority to
calculate rural floor budget neutrality in a State-specific manner.
With regard to the comments concerning the district court's
decision in Citrus, prior to FY 2020, it was our policy to have the
rural wage index set the rural floor, resulting in identical wage index
values for a state's rural area and rural floor. We changed that policy
in the FY 2020 IPPS/LTCH PPS final rule to prevent inappropriate
payment increases under the rural floor due to rural reclassifications
under Sec. 412.103 (84 FR 42332 through 42336). We explained that
rather than raising the payment of some urban hospitals to the level of
the average rural hospital in their State, as we believed was the
intent of the rural floor policy, the rural floor calculation prior to
FY 2020 enabled urban hospitals to have their payments raised to the
relatively high level of one or more geographically urban hospitals
reclassified as rural (84 FR 42334). This policy change beginning in FY
2020 to exclude Sec. 412.103 hospitals from the rural floor
calculation created a rural area wage index separate from the rural
floor, with the rural floor for the state typically lower than the
rural wage index.
We understand that our policy of setting a rural floor lower than
the rural wage index for a state is inconsistent with the district
court's decision in Citrus. Following our review of that decision and
the comments we received on the proposed rule, we are finalizing a
policy that calculates the rural floor as it was calculated before FY
2020. Specifically, for FY 2023 and subsequent years, we are finalizing
a policy to include the wage data of hospitals that have reclassified
from urban to rural under section 1886(d)(8)(E) of the Act (as
implemented in the regulations at Sec. 412.103) and have no additional
form of reclassification (MGCRB or Lugar) in the calculation of the
rural floor, and to include the wage data of such hospitals in the
calculation of ``the wage index for rural areas in the State in which
the county is located'' as referred to in section 1886(d)(8)(C)(iii) of
the Act.
With regard to the application of the hold harmless policy that the
commenters referenced at Sec. 1886(d)(8)(C)(ii), the statute requires
that a rural area be held harmless from the effects of hospitals
reclassifying under Lugar or the MGCRB. Specifically, Sec.
1886(d)(8)(C)(ii) states: ``If the application of subparagraph (B) or a
decision of the Medicare Geographic Classification Review Board or the
Secretary under paragraph (10), by treating hospitals located in a
rural county or counties as not being located in the rural area in a
State, reduces the wage index for that rural area (as applied under
this subsection), the Secretary shall calculate and apply such wage
index under this subsection as if the hospitals so treated had not been
excluded from calculation of the wage index for that rural area.''
The commenters suggest that CMS should include the wage data of
Sec. 412.103 hospitals that also have a MGCRB reclassification for
purposes of the calculation required by Sec. 1886(d)(8)(C)(ii),
thereby treating hospitals with dual Sec. 412.103 and MGCRB
reclassifications no differently than geographically rural hospitals
with MGCRB reclassifications for the hold-harmless comparison at Sec.
1886(d)(8)(C)(ii). Specifically, this would involve calculating the
rural area wage index including the data of all Sec. 412.103
hospitals, and then comparing it to a wage index with the effect of
MGCRB reclassifications and Lugar hospital statuses applied, in order
to possibly hold the rural area harmless from the effect of MGCRB
reclassifications and Lugar hospital statuses.
As we explained in response to a similar comment in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45181), CMS continues to treat Sec.
412.103 hospitals as rural as required by the statute even if such
hospitals have an additional MGCRB reclassification by affording the
hospital the benefits of rural status, such as 340B program and RRC
eligibility. However, in developing our policies for how hospitals with
dual reclassifications would be treated in wage index calculations
following our April 21, 2016 IFC (81 FR 23428 through 23438), CMS
discussed the effect of simultaneous Sec. 412.103 and MGCRB
reclassifications. We stated that when there is both a Sec. 412.103
reclassification and an MGCRB reclassification, the MGCRB
reclassification would control for wage index calculation and payment
purposes. We explained that ``In these circumstances, we believe it is
appropriate to rely on the urban MGCRB reclassification to include the
hospital's wage data in the calculation of the urban CBSA wage index.
Further, we believe it is appropriate to rely on the
[[Page 49004]]
urban MGCRB reclassification to ensure that the hospital be paid based
on its urban MGCRB wage index. While rural reclassification confers
other rural benefits besides the wage index under section 1886(d) of
the Act, a hospital that chooses to pursue reclassification under the
MGCRB (while also maintaining a rural reclassification under Sec.
412.103) would do so solely for wage index payment purposes.'' (81 FR
23434). We continue to believe that policy, developed through
rulemaking, is appropriate, since MGCRB reclassifications are solely
for wage index payment purposes. Furthermore, the approach the
commenters suggest would constitute a significant change to our current
policy for Sec. 412.103 hospitals that also have a MGCRB
reclassification, and would create numerous downstream effects across
IPPS ratesetting that might not be favorable to hospitals, contrary to
the commenters' intent. For example, some states would experience a
decline in their rural wage index if we were to treat hospitals with
dual Sec. 412.103 and MGCRB reclassifications no differently than
geographically rural hospitals with MGCRB reclassifications. In
response to the commenters' assertion that such treatment would address
rural floor manipulation, we note that the commenters' suggested
treatment of hospitals with dual Sec. 412.103 and MGCRB
reclassifications would potentially allow for other forms of wage index
manipulation. For example, high-wage hospitals could obtain Sec.
412.103 status, reclassify back to their home area under the MGCRB, in
order to have their Sec. 412.103 rural reclassifications raise the
rural wage index via the hold harmless provision at Sec.
1886(d)(8)(C)(ii), without lowering the hospitals' own wage index. We
did not propose the policy the commenters suggest, and it would
constitute a significant change with numerous effects on the IPPS wage
index. We do not think it would be appropriate to adopt such a policy
without describing it in a proposed rule and obtaining public comments
from all interested parties. Therefore, in this final rule we are not
adopting the policy the commenters suggest.
Based on the district court's decision in Citrus and the comments
we received, we are not finalizing our rural floor wage index policy as
proposed, which would have excluded Sec. 412.103 hospitals from the
calculation of the rural floor and from the calculation of ``the wage
index for rural areas in the State in which the county is located'' as
referred to in section 1886(d)(8)(C)(iii) of the Act. Rather, we are
finalizing a policy that calculates the rural floor as it was
calculated before FY 2020. This decision follows our review of the
decision in Citrus and the comments received, including comments urging
us to revert to our pre-2020 policy. For FY 2023 and subsequent years,
we are finalizing a policy to include the wage data of hospitals that
have reclassified from urban to rural under section 1886(d)(8)(E) of
the Act (as implemented in the regulations at Sec. 412.103) and have
no additional form of reclassification (MGCRB or Lugar) in the
calculation of the rural floor, and to include the wage data of such
hospitals in the calculation of ``the wage index for rural areas in the
State in which the county is located'' as referred to in section
1886(d)(8)(C)(iii) of the Act. We will apply the same policy as prior
to the FY 2020 final rule for calculating the rural floor, in which the
rural wage index sets the rural floor. Based on the FY 2023 wage index
associated with this final rule (which is available via the internet on
the CMS website) and based on the calculation of the rural floor
including the wage data of hospitals that have reclassified as rural
under Sec. 412.103, we estimate that 275 hospitals would receive an
increase in their FY 2023 wage index due to the application of the
rural floor.
2. Imputed Floor
In the FY 2005 IPPS final rule (69 FR 49109 through 49111), we
adopted the imputed floor policy as a temporary 3-year regulatory
measure to address concerns from hospitals in all urban States that
have stated that they are disadvantaged by the absence of rural
hospitals to set a wage index floor for those States. We extended the
imputed floor policy eight times since its initial implementation, the
last of which was adopted in the FY 2018 IPPS/LTCH PPS final rule and
expired on September 30, 2018. (We refer readers to further discussions
of the imputed floor in the IPPS/LTCH PPS final rules from FYs 2014
through 2019 (78 FR 50589 through 50590, 79 FR 49969 through 49971, 80
FR 49497 through 49498, 81 FR 56921 through 56922, 82 FR 38138 through
38142, and 83 FR 41376 through 41380, respectively) and to the
regulations at 42 CFR 412.64(h)(4).) For FYs 2019, 2020, and 2021,
hospitals in all-urban states received a wage index that was calculated
without applying an imputed floor, and we no longer included the
imputed floor as a factor in the national budget neutrality adjustment.
In computing the imputed floor for an all-urban State under the
original methodology established beginning in FY 2005, we calculated
the ratio of the lowest-to-highest CBSA wage index for each all-urban
State as well as the average of the ratios of lowest-to-highest CBSA
wage indexes of those all-urban States. We then compared the State's
own ratio to the average ratio for all-urban States and whichever was
higher was multiplied by the highest CBSA wage index value in the
State--the product of which established the imputed floor for the
State. We adopted a second, alternative methodology beginning in FY
2013 (77 FR 53368 through 53369) to address the concern that the
original imputed floor methodology guaranteed a benefit for one all-
urban State with multiple wage indexes (New Jersey) but could not
benefit another all-urban State, Rhode Island, which had only one CBSA.
Under the alternative methodology, we first determined the average
percentage difference between the post reclassified, pre-floor area
wage index and the post-reclassified, rural floor wage index (without
rural floor budget neutrality applied) for all CBSAs receiving the
rural floor. The lowest post reclassified wage index assigned to a
hospital in an all-urban State having a range of such values then was
increased by this factor, the result of which established the State's
alternative imputed floor. Under the updated OMB labor market area
delineations adopted by CMS beginning in FY 2015, Delaware became an
all-urban State, along with New Jersey and Rhode Island, and was
subject to an imputed floor as well. In addition, we adopted a policy,
as reflected at Sec. 412.64(h)(4)(vi), that, for discharges on or
after October 1, 2012, and before October 1, 2018, the minimum wage
index value for a State is the higher of the value determined under the
original methodology or the value determined under the alternative
methodology. The regulations implementing the imputed floor wage index,
both the original methodology and the alternative methodology, were set
forth at Sec. 412.64(h)(4).
Section 9831 of the American Rescue Plan Act of 2021 (Pub. L. 117-
2) enacted on March 11, 2021, amended section 1886(d)(3)(E)(i) of the
Act (42 U.S.C. 1395ww(d)(3)(E)(i)) and added section 1886(d)(3)(E)(iv)
of the Act to establish a minimum area wage index for hospitals in all-
urban States for discharges occurring on or after October 1, 2021.
Specifically, section 1886(d)(3)(E)(iv)(I) and (II) of the Act provides
that for discharges occurring on or after October 1, 2021, the area
wage index applicable to any hospital in
[[Page 49005]]
an all-urban State may not be less than the minimum area wage index for
the fiscal year for hospitals in that State established using the
methodology described in Sec. 412.64(h)(4)(vi) as in effect for FY
2018. Thus, effective beginning October 1, 2021 (FY 2022), section
1886(d)(3)(E)(iv) of the Act reinstates the imputed floor wage index
policy for all-urban States, with no expiration date, using the
methodology described in 42 CFR 412.64(h)(4)(vi) as in effect for FY
2018. As discussed previously, under Sec. 412.64(h)(4)(vi), the
minimum wage index value for hospitals in an all-urban State is the
higher of the value determined using the original methodology (as set
forth at Sec. 412.64(h)(4)(i) through (v)) or the value determined
using alternative methodology (as set forth at Sec.
412.64(h)(4)(vi)(A) and (B)) for calculating an imputed floor.
Therefore, as provided in Sec. 412.64(h)(4)(vi), we apply the higher
of the value determined under the original or alternative methodology
for calculating a minimum wage index, or imputed floor, for all-urban
States effective beginning with FY 2022. We note that the rural floor
values used in the alternative methodology at Sec. 412.64(h)(4)(vi)(A)
and (B) would now include the wage data of hospitals reclassified under
Sec. 412.103 that have no additional form of reclassification (MGCRB
or Lugar), according to the rural floor wage index policy finalized in
this final rule in which we calculate the rural floor for FY 2023
including the wage data of such hospitals.
Unlike the imputed floor that was in effect from FYs 2005 through
2018, section 1886(d)(3)(E)(iv)(III) of the Act provides that the
imputed floor wage index shall not be applied in a budget neutral
manner. Specifically, section 9831(b) of Public Law 117-2 amends
section 1886(d)(3)(E)(i) of the Act to exclude the imputed floor from
the budget neutrality requirement under section 1886(d)(3)(E)(i) of the
Act. In other words, the budget neutrality requirement under section
1886(d)(3)(E)(i) of the Act, as amended, must be applied without taking
into account the imputed floor adjustment under section
1886(d)(3)(E)(iv) of the Act. When the imputed floor was in effect from
FY 2005 through FY 2018, to budget neutralize the increase in payments
resulting from application of the imputed floor, we calculated the
increase in payments resulting from the imputed floor together with the
increase in payments resulting from the rural floor and applied an
adjustment to reduce the wage index. By contrast, for FY 2022 and
subsequent years, we apply the imputed floor after the application of
the rural floor and apply no reductions to the standardized amount or
to the wage index to fund the increase in payments to hospitals in all-
urban States resulting from the application of the imputed floor
required under section 1886(d)(3)(E)(iv) of the Act.
The imputed floor under section 1886(d)(3)(E)(iv) of the Act
applies to all-urban States, as defined in new subclause (IV). Section
1886(d)(3)(E)(iv)(IV) provides that, for purposes of the imputed floor
wage index under clause (iv), the term all-urban State means a State in
which there are no rural areas (as defined in section 1886(d)(2)(D) of
the Act) or a State in which there are no hospitals classified as rural
under section 1886 of the Act. Under this definition, given that it
applies for purposes of the imputed floor wage index, we consider a
hospital to be classified as rural under section 1886 of the Act if it
is assigned the State's rural area wage index value. Therefore, under
the definition at section 1886(d)(3)(E)(iv)(IV) of the Act, ``a State
in which there are no hospitals classified as rural under this
section'' includes a State that has a rural area but no hospitals that
receive the rural area wage index under section 1886(d) of the Act. For
purposes of this definition, hospitals redesignated as rural under
section 1886(d)(8)(E) of the Act (412.103 rural reclassifications) are
considered classified as rural if they receive the rural wage index;
however, hospitals that are deemed urban under section 1886(d)(8)(B) of
the Act (in Lugar counties), or are reclassified to an urban area under
section 1886(d)(10) of the Act (MGCRB reclassifications) are not
considered classified as rural because they do not receive the rural
wage index. In contrast, we note that in the imputed floor policy in
effect from FY 2005 through FY 2018, we did not consider a State to
qualify for ``all urban status'' if there were one or more hospitals
geographically located in the rural area of the State, even if all such
hospitals subsequently reclassified to receive an urban area wage
index. There is one State, Connecticut, that would be eligible for the
imputed floor because there are currently no hospitals in Connecticut
that are classified as rural under section 1886(d) for purposes of the
wage index--in other words, there are no hospitals that receive the
rural wage index. There is currently one rural county in Connecticut.
All hospitals in this county are either deemed urban under section
1886(d)(8)(B) of the Act or receive an MGCRB reclassification under
section 1886(d)(10) of the Act. While several Connecticut hospitals
were approved for rural reclassification under section 1886(d)(8)(E) of
the Act, at this point all have received a subsequent urban
reclassification under section 1886(d)(10) of the Act.
Additionally, under section 1861(x) of the Act, the term State has
the meaning given to it in section 210(h) of the Act. Because section
210(h) of the Act defines the word State to also include the District
of Columbia and the Commonwealth of Puerto Rico, Washington, DC and
Puerto Rico may also qualify as all-urban States for purposes of the
imputed floor if the requirements of section 1886(d)(3)(E)(iv)(IV) of
the Act are met. Based on data available for this final rule, the
following States would be all-urban States as defined in section
1886(d)(3)(E)(iv)(IV) of the Act, and thus hospitals in such States
would be eligible to receive an increase in their wage index due to
application of the imputed floor for FY 2023: New Jersey, Rhode Island,
Delaware, Connecticut, and Washington, DC.
In the FY 2022 IPPS/LTCH PPS final rule, we revised the regulations
at Sec. 412.64(e)(1) and (4) and (h)(4) and (5) to implement the
imputed floor required by section 1886(d)(3)(E)(iv) of the Act for
discharges occurring on or after October 1, 2021. The imputed floor
will be applied for FY 2023 in accordance with the policies adopted in
the FY 2022 IPPS/LTCH PPS final rule. For more information regarding
our implementation of the imputed floor required by section
1886(d)(3)(E)(iv) of the Act, we refer readers to the discussion in the
FY 2022 IPPS/LTCH PPS final rule (86 FR 45176 through 45178).
Comment: Several commenters supported the application of the
imputed floor wage index policy, including the policy's definition of
all-urban states as well as its non-budget neutral application as
required by section 9831 of the American Rescue Plan Act of 2021. A
commenter opposed the imputed floor policy, stating that it unfairly
manipulates the wage index to benefit a handful of only-urban states
and territories, but acknowledged that the imputed floor policy is
derived from legislation enacted by Congress.
Response: We appreciate the commenters' support of our application
of the statutory imputed floor policy. Responding to the commenter
opposed to this policy, we underscore that, as the commenter pointed
out, the imputed floor was established by section 9831 of the American
Rescue Plan Act of 2021.
[[Page 49006]]
Accordingly, CMS does not have discretion to not apply the imputed
floor.
After consideration of the public comments, we will apply the
imputed floor required by section 1886(d)(3)(E)(iv) of the Act for
discharges occurring on or after October 1, 2022 in accordance with our
existing policies.
3. State Frontier Floor for FY 2023
Section 10324 of Public Law 111-148 requires that hospitals in
frontier States cannot be assigned a wage index of less than 1.0000.
(We refer readers to the regulations at 42 CFR 412.64(m) and to a
discussion of the implementation of this provision in the FY 2011 IPPS/
LTCH PPS final rule (75 FR 50160 through 50161).) In the FY 2023 IPPS/
LTCH PPS proposed rule, we did not propose any changes to the frontier
floor policy for FY 2023. In the proposed rule we stated that 44
hospitals would receive the frontier floor value of 1.0000 for their FY
2023 proposed wage index. These hospitals are located in Montana, North
Dakota, South Dakota, and Wyoming.
We did not receive any public comments on the application of the
State frontier floor for FY 2023. In this final rule, 44 hospitals will
receive the frontier floor value of 1.0000 for their FY 2023 wage
index. These hospitals are located in Montana, North Dakota, South
Dakota, and Wyoming. We note that while Nevada meets the criteria of a
frontier State, all hospitals within the State currently receive a wage
index value greater than 1.0000. The areas affected by the rural and
frontier floor policies for the final FY 2023 wage index are identified
in Table 2 associated with this final rule, which is available via the
internet on the CMS website.
4. Continuation of the Low Wage Index Hospital Policy; Budget
Neutrality Adjustment
To help mitigate wage index disparities, including those resulting
from the inclusion of hospitals with rural reclassifications under 42
CFR 412.103 in the rural floor, in the FY 2020 IPPS/LTCH PPS final rule
(84 FR 42325 through 42339), we finalized policies to reduce the
disparity between high and low wage index hospitals by increasing the
wage index values for certain hospitals with low wage index values and
doing so in a budget neutral manner through an adjustment applied to
the standardized amounts for all hospitals, as well as by changing the
calculation of the rural floor. We also provided for a transition in FY
2020 for hospitals experiencing significant decreases in their wage
index values as compared to their final FY 2019 wage index, and made
these changes in a budget neutral manner.
We increase the wage index for hospitals with a wage index value
below the 25th percentile wage index value for a fiscal year by half
the difference between the otherwise applicable final wage index value
for a year for that hospital and the 25th percentile wage index value
for that year across all hospitals (the low wage index hospital
policy). We stated in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42326
through 42328) our intention that this policy will be effective for at
least 4 years, beginning in FY 2020, in order to allow employee
compensation increases implemented by these hospitals sufficient time
to be reflected in the wage index calculation. We noted in the FY 2023
IPPS/LTCH PPS proposed rule (87 FR 28369) that the FY 2020 low wage
index hospital policy and the related budget neutrality adjustment are
the subject of pending litigation, including in Bridgeport Hospital, et
al., v. Becerra, No. 1:20-cv-01574 (D.D.C.) (hereafter referred to as
Bridgeport). On March 2, 2022, the district court in Bridgeport granted
in part the plaintiff hospitals' motion for summary judgment and denied
the Secretary's cross-motion for summary judgment. The court found that
the Secretary did not have authority under section 1886(d)(3)(E) or
1886(d)(5)(I)(i) of the Act to adopt the low wage index hospital policy
and ordered additional briefing on the appropriate remedy. We stated
that while Bridgeport involves only FY 2020, the court's decision--
which is not final at this time and is also subject to potential
appeal--may have implications for FY 2023 payment rates. We stated that
we were continuing to evaluate the court's decision, and although we
proposed the low wage index hospital policy (and the related budget
neutrality adjustment, discussed in this section of this rule) to
continue for FY 2023, we stated that we may decide to take a different
approach in the final rule, depending on public comments or
developments in the court proceedings. In order to offset the estimated
increase in IPPS payments to hospitals with wage index values below the
25th percentile wage index value, for FY 2023 and for subsequent fiscal
years during which the low wage index hospital policy is in effect, we
proposed to apply a budget neutrality adjustment in the same manner as
we applied it in FYs 2020, 2021, and 2022, as a uniform budget
neutrality factor applied to the standardized amount. We refer readers
to section II.A.4.f. of the addendum to this final rule for further
discussion of the budget neutrality adjustment for FY 2023. For
purposes of the low wage index hospital policy, based on the data for
this final rule, the table displays the 25th percentile wage index
value across all hospitals for FY 2023. FY 2023 25th Percentile Wage
Index Value 0.8427.
Comment: Many commenters supported the low wage index hospital
policy. Commenters praised the low wage index hospital policy for
already beginning to reduce wage index disparities and urged the agency
to continue with the policy for FY 2023 as proposed. Commenters
described dire consequences of the policy ending, with a commenter
specifically stating that Medicare payments to hospitals in Puerto Rico
could fall drastically. Numerous commenters representing hospitals in a
state with relatively low wages indicated that they have used the
increased payments resulting from the low wage index hospital policy as
CMS intended, by raising compensation for their workers. However, these
commenters stated that the national average hourly wage increased at an
even higher rate due to COVID-19, indicating that additional time for
the policy and continued efforts on behalf of low wage hospitals are
required. A commenter requested that CMS consider the effects of COVID-
19 as CMS decides how it will appropriately evaluate the effectiveness
of its policy to raise low wage hospitals' wage indexes in the near
future, and another commenter specifically requested that CMS extend
the policy for at least four additional years due to COVID-19. A
commenter stated that CMS should maintain the policy until CMS can
verify that increased hospital compensation under the policy has led to
increased wage indexes, consistent with original intent of the policy.
Response: We appreciate the many comments received in support of
our low wage index hospital policy and the feedback regarding
achievement of the intended policy goal. We appreciate the commenters'
requests to consider the impacts of COVID-19, to extend this policy
beyond four years due to COVID-19, and to extend the policy until the
intended goals of the policy are reached. We appreciate commenters'
suggestions on how we might evaluate the effectiveness of the policy
and may consider those suggestions in future rulemaking.
Comment: Many commenters supported increasing the wage index values
of low-wage hospitals, but urged CMS to do so in a non-budget-neutral
[[Page 49007]]
manner. Commenters stated that implementing the policy with a budget
neutrality adjustment merely shifts funds from one group to another.
Commenters urged CMS to consider wage index reforms that lift low wage
hospitals' wage indexes without reducing the standardized operating
rate for all hospitals, which commenters indicated already receive
Medicare reimbursement at rates that are less than the actual cost of
care. A commenter stated that for hospitals between the 22nd and 25th
percentile, the reduction due to the budget neutrality adjustment is
greater than the benefit received from the quartile adjustment. This
commenter suggested holding hospitals under the 25th percentile
harmless by slightly reducing the labor-related share for those
hospitals that have a wage index greater than 1, or via a graduated
reduction to the standardized rate based on wage index percentile.
Other alternative methodologies and data suggested by commenters
included: reducing the wage indexes of hospitals with wage index values
above the 75th percentile through a budget neutrality adjustment;
verifying local labor prices with wage data audits; working with
Congress to create a new designated pool of funding; working with
Congress to minimize wage index cliffs; shortening the lag in hospital
wage data used to construct the wage index; and setting a national wage
index floor of 1.000.
Response: We disagree with the commenters that the low wage index
hospital policy should be implemented in a non-budget neutral manner.
As we stated in response to similar comments in the FY 2020 IPPS/LTCH
PPS final rule (84 FR 42331 and 42332) and the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45180), under section 1886(d)(3)(E) of the Act, the
wage index adjustment is required to be implemented in a budget neutral
manner. However, even if the wage index were not required to be budget
neutral under section 1886(d)(3)(E) of the Act, we would consider it
inappropriate to use the wage index to increase or decrease overall
IPPS spending. As we stated in the FY 2020 IPPS/LTCH PPS final rule (84
FR 42331), the wage index is not a policy tool but rather a technical
adjustment designed to be a relative measure of the wages and wage-
related costs of subsection (d) hospitals. As a result, as we explained
in the FY 2020 IPPS/LTCH PPS final rule, if it were determined that
section 1886(d)(3)(E) of the Act does not require the wage index to be
budget neutral, we invoke our authority at section 1886(d)(5)(I) of the
Act in support of such a budget neutrality adjustment.
With regard to the commenter's assertion about a possible reduction
to overall payment if the amount of benefit received from the wage
index boost is less than the reduction to the standardized amount, we
believe we have applied both the quartile policy and the budget
neutrality policy appropriately, as we explained in response to
comments in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45180). The
quartile adjustment is applied to the wage index, which resulted in an
increase to the wage index for hospitals below the 25th percentile. The
budget neutrality adjustment is applied to the standardized amount in
order to ensure that the low wage index hospital policy is implemented
in a budget neutral manner. Thus, consistent with our current
methodology for implementing wage index budget neutrality under section
1886(d)(3)(E) of the Act and with how we implemented budget neutrality
for the low wage index hospital policy in FY 2020, we believe it is
appropriate to continue to apply a budget neutrality adjustment to the
national standardized amount for all hospitals so that the low wage
index hospital policy is implemented in a budget neutral manner for FY
2023.
We appreciate the commenters' range of suggested alternatives.
Because we did not propose alternatives with regard to the low wage
index hospital policy, we consider these comments to be outside the
scope of the FY 2023 IPPS/LTCH PPS proposed rule. We are not addressing
them in this final rule but may consider them in future rulemaking.
Comment: Several commenters opposed the low wage index hospital
policy, stating that it is inappropriately redistributive, ineffective,
and outside the agency's statutory authority under section
1886(d)(3)(E) of the Act. Specifically, a commenter stated that
although the policy is intended to help rural hospitals, rural
hospitals in certain states do not benefit from this policy.
Furthermore, the commenter stated that the policy undermines the intent
of the wage index by not recognizing real differences in labor costs.
Response: In response to comments opposing the low wage index
hospital policy, we believe we addressed the stated concerns in our
responses to comments when we first finalized the policy and the
related budget neutrality adjustment in the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42325 through 42332). Concerning the policy's
redistributive effect, we refer readers to our response to the comments
above about budget neutrality. With regard to the policy's
effectiveness, we believe the comments in support of the policy,
specifically comments from relatively low-wage hospitals stating that
the increased payments under the policy have allowed them to raise
compensation for their workers, indicate that many low wage hospitals
are benefiting from this policy. Furthermore, we stated in the FY 2020
IPPS/LTCH PPS final rule (84 FR 42326 through 42328) our intention that
this policy will be effective for at least 4 years, until the policy's
effects could be reflected in the wage index data. In response to the
comment stating that although the policy is intended to help rural
hospitals, rural hospitals in certain states do not benefit from this
policy, we refer readers to our response to a similar comment in the FY
2020 IPPS/LTCH PPS final rule (84 FR 42328) regarding the policy's
effect on rural hospitals.
In response to comments stating the policy exceeds CMS's statutory
authority, we refer the commenters to our prior discussion of the
authority for the policy in the FY 2020 IPPS/LTCH PPS final rule (84 FR
42326 through 42332).
In response to the commenter who asserted that the low wage index
hospital policy does not recognize real differences in labor costs, we
continue to believe, for the reasons stated in the FY 2020 IPPS/LTCH
PPS final rule (84 FR 42327-42328), that by preserving the rank order
in wage index values, our policy continues to reflect meaningful
distinctions between the employee compensation costs faced by hospitals
in different geographic areas. Thus, under the low wage index hospital
policy, we believe the wage index for low wage index hospitals
appropriately reflects the relative hospital wage level in those areas
compared to the national average hospital wage level.
Comment: Many commenters noted that the low wage index hospital
policy is currently the subject of pending litigation in Bridgeport. A
few commenters urged CMS not to finalize the policy for FY 2023, or to
wait until a final court decision is reached. One such commenter
suggested CMS should eliminate the budget neutrality adjustments for
FYs 2020, 2021, and 2022 in light of Bridgeport. Many commenters urged
CMS to appeal the district court's decision in Bridgeport. These
commenters stated that the consequences of halting the policy would be
dire, and that CMS has broad authority under section 1886(d)(3)(E) to
make policy adjustments, such as the
[[Page 49008]]
imputed floor policy implemented in 2005 that was implemented by CMS as
a policy measure to address concerns from hospitals in all-urban
states. These commenters further stated that this step towards
achieving health equity is justified, and that CMS implemented the low
wage index hospital policy via notice-and-comment rulemaking.
Response: We appreciate the commenters' input. As we stated in the
proposed rule, the FY 2020 low wage index hospital policy and the
related budget neutrality adjustment are the subject of pending
litigation, including in Bridgeport. As Bridgeport is pending
litigation, we are unable to provide further information at this time.
We disagree with the district court's conclusion that the Social
Security Act does not authorize the Secretary to adopt the low wage
index hospital policy, and we note that its decision remains subject to
potential appeal. We also note that plaintiffs in Bridgeport only
challenged the low wage index hospital and associated budget neutrality
adjustment policies for FY 2020.
After consideration of the comments we received, and for the
reasons stated above and in the proposed rule, we are finalizing as
proposed to continue the low wage index hospital policy and the related
budget neutrality adjustment for FY 2023.
H. FY 2023 Wage Index Tables
In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49498 and 49807
through 49808), we finalized a proposal to streamline and consolidate
the wage index tables associated with the IPPS proposed and final rules
for FY 2016 and subsequent fiscal years. Effective beginning FY 2016,
with the exception of Table 4E, we streamlined and consolidated 11
tables (Tables 2, 3A, 3B, 4A, 4B, 4C, 4D, 4F, 4J, 9A, and 9C) into 2
tables (Tables 2 and 3). In this FY 2023 IPPS/LTCH PPS final rule, as
provided beginning with the FY 2021 IPPS/LTCH PPS final rule, we have
included Table 4A which is titled ``List of Counties Eligible for the
Out-Migration Adjustment under Section 1886(d)(13) of the Act'' and
Table 4B titled ``Counties redesignated under section 1886(d)(8)(B) of
the Act (Lugar Counties).'' We refer readers to section VI. of the
Addendum to this final rule for a discussion of the wage index tables
for FY 2023.
I. Revisions to the Wage Index Based on Hospital Redesignations and
Reclassifications
1. General Policies and Effects of Reclassification and Redesignation
Under section 1886(d)(10) of the Act, the Medicare Geographic
Classification Review Board (MGCRB) considers applications by hospitals
for geographic reclassification for purposes of payment under the IPPS.
Hospitals must apply to the MGCRB to reclassify not later than 13
months prior to the start of the fiscal year for which reclassification
is sought (usually by September 1). Generally, hospitals must be
proximate to the labor market area to which they are seeking
reclassification and must demonstrate characteristics similar to
hospitals located in that area. The MGCRB issues its decisions by the
end of February for reclassifications that become effective for the
following fiscal year (beginning October 1). The regulations applicable
to reclassifications by the MGCRB are located in 42 CFR 412.230 through
412.280. (We refer readers to a discussion in the FY 2002 IPPS final
rule (66 FR 39874 and 39875) regarding how the MGCRB defines mileage
for purposes of the proximity requirements.) The general policies for
reclassifications and redesignations and the policies for the effects
of hospitals' reclassifications and redesignations on the wage index
are discussed in the FY 2012 IPPS/LTCH PPS final rule for the FY 2012
final wage index (76 FR 51595 and 51596). We note that rural hospitals
reclassifying under the MGCRB to another State's rural area are not
eligible for the rural floor, because the rural floor may apply only to
urban, not rural, hospitals.
In addition, in the FY 2012 IPPS/LTCH PPS final rule, we discussed
the effects on the wage index of urban hospitals reclassifying to rural
areas under 42 CFR 412.103. In the FY 2020 IPPS/LTCH PPS final rule (84
FR 42332 through 42336), we finalized a policy to exclude the wage data
of urban hospitals reclassifying to rural areas under 42 CFR 412.103
from the calculation of the rural floor. In section III.G.1 of this
final rule, for FY 2023 and subsequent years, we are finalizing a
policy that calculates the rural floor as it was calculated before FY
2020. Hospitals that are geographically located in States without any
rural areas are ineligible to apply for rural reclassification in
accordance with the provisions of 42 CFR 412.103.
On April 21, 2016, we published an interim final rule with comment
period (IFC) in the Federal Register (81 FR 23428 through 23438) that
included provisions amending our regulations to allow hospitals
nationwide to have simultaneous Sec. 412.103 and MGCRB
reclassifications. For reclassifications effective beginning FY 2018, a
hospital may acquire rural status under Sec. 412.103 and subsequently
apply for a reclassification under the MGCRB using distance and average
hourly wage criteria designated for rural hospitals. In addition, we
provided that a hospital that has an active MGCRB reclassification and
is then approved for redesignation under Sec. 412.103 will not lose
its MGCRB reclassification; such a hospital receives a reclassified
urban wage index during the years of its active MGCRB reclassification
and is still considered rural under section 1886(d) of the Act and for
other purposes.
We discussed that when there is both a Sec. 412.103 redesignation
and an MGCRB reclassification, the MGCRB reclassification controls for
wage index calculation and payment purposes. We exclude hospitals with
Sec. 412.103 redesignations from the calculation of the reclassified
rural wage index if they also have an active MGCRB reclassification to
another area. That is, if an application for urban reclassification
through the MGCRB is approved, and is not withdrawn or terminated by
the hospital within the established timelines, we consider the
hospital's geographic CBSA and the urban CBSA to which the hospital is
reclassified under the MGCRB for the wage index calculation. We refer
readers to the April 21, 2016 IFC (81 FR 23428 through 23438) and the
FY 2017 IPPS/LTCH PPS final rule (81 FR 56922 through 56930), in which
we finalized the April 21, 2016 IFC, for a full discussion of the
effect of simultaneous reclassifications under both the Sec. 412.103
and the MGCRB processes on wage index calculations. For a discussion on
the effects of reclassifications under Sec. 412.103 on the rural area
wage index and the calculation of the rural floor for FY 2020 through
FY 2022, we refer readers to the FY 2020 IPPS/LTCH PPS final rule (84
FR 42332 through 42336). For a discussion of the effects of
reclassifications under Sec. 412.103 on the rural area wage index and
the calculation of the rural floor for FY 2023 and subsequent years, we
refer readers to section III.G.1 of this final rule.
On May 10, 2021, we published an IFC in the Federal Register (86 FR
24735 through 24739) that included provisions amending our regulations
to allow hospitals with a rural redesignation to reclassify through the
MGCRB using the rural reclassified area as the geographic area in which
the
[[Page 49009]]
hospital is located. We revised our regulation so that the redesignated
rural area, and not the hospital's geographic urban area, is considered
the area a Sec. 412.103 hospital is located in for purposes of meeting
MGCRB reclassification criteria, including the average hourly wage
comparisons required by Sec. 412.230(a)(5)(i) and (d)(1)(iii)(C).
Similarly, we revised the regulations to consider the redesignated
rural area, and not the geographic urban area, as the area a Sec.
412.103 hospital is located in for the prohibition at Sec.
412.230(a)(5)(i) on reclassifying to an area with a pre-reclassified
average hourly wage lower than the prereclassified average hourly wage
for the area in which the hospital is located. Effective for
reclassification applications due to the MGCRB for reclassification
beginning in FY 2023, a Sec. 412.103 hospital could apply for a
reclassification under the MGCRB using the State's rural area as the
area in which the hospital is located. We refer readers to the May 10,
2021 IFC (86 FR 24735 through 24739) and the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45187 through 45190), in which we finalized the May
10, 2021 IFC, for a full discussion of these policies.
2. MGCRB Reclassification and Redesignation Issues for FY 2023
a. FY 2023 Reclassification Application Requirements and Approvals
As previously stated, under section 1886(d)(10) of the Act, the
MGCRB considers applications by hospitals for geographic
reclassification for purposes of payment under the IPPS. The specific
procedures and rules that apply to the geographic reclassification
process are outlined in regulations under 42 CFR 412.230 through
412.280. At the time this final rule was drafted, the MGCRB had
completed its review of FY 2023 reclassification requests. Based on
such reviews, there are 383 hospitals approved for wage index
reclassifications by the MGCRB starting in FY 2023. Because MGCRB wage
index reclassifications are effective for 3 years, for FY 2023,
hospitals reclassified beginning in FY 2021 or FY 2022 are eligible to
continue to be reclassified to a particular labor market area based on
such prior reclassifications for the remainder of their 3-year period.
There were 311 hospitals approved for wage index reclassifications in
FY 2021 that will continue for FY 2023, and 315 hospitals approved for
wage index reclassifications in FY 2022 that will continue for FY 2023.
Of all the hospitals approved for reclassification for FY 2021, FY 2022
and FY 2023, based upon the review at the time of the final rule, 1,009
hospitals are in a MGCRB reclassification status for FY 2023 (with 166
of these hospitals reclassified back to their geographic location).
Under the regulations at 42 CFR 412.273, hospitals that have been
reclassified by the MGCRB are permitted to withdraw their applications
if the request for withdrawal is received by the MGCRB any time before
the MGCRB issues a decision on the application, or after the MGCRB
issues a decision, provided the request for withdrawal is received by
the MGCRB within 45 days of the date that CMS' annual notice of
proposed rulemaking is issued in the Federal Register concerning
changes to the inpatient hospital prospective payment system and
proposed payment rates for the fiscal year for which the application
has been filed. For information about withdrawing, terminating, or
canceling a previous withdrawal or termination of a 3-year
reclassification for wage index purposes, we refer readers to Sec.
412.273, as well as the FY 2002 IPPS final rule (66 FR 39887 through
39888) and the FY 2003 IPPS final rule (67 FR 50065 through 50066).
Additional discussion on withdrawals and terminations, and
clarifications regarding reinstating reclassifications and ``fallback''
reclassifications were included in the FY 2008 IPPS final rule (72 FR
47333) and the FY 2018 IPPS/LTCH PPS final rule (82 FR 38148 through
38150).
We note that in the FY 2021 IPPS/LTCH final rule (85 FR 58771
through 58778), CMS finalized an assignment policy for hospitals
reclassified to CBSAs from which one or more counties moved to a new or
different urban CBSA under the revised OMB delineations based on OMB
Bulletin 18-04. We provided a table in that rule (85 FR 58777 and
58778) which described the assigned CBSA for all the MGCRB cases
subject to this policy. For such reclassifications that continue to be
active or are reinstated for FY 2023, the CBSAs assigned in the FY 2021
IPPS/LTCH final rule continue to be in effect.
Applications for FY 2024 reclassifications are due to the MGCRB by
September 1, 2022. We note that this is also the deadline for canceling
a previous wage index reclassification withdrawal or termination under
42 CFR 412.273(d). Applications and other information about MGCRB
reclassifications may be obtained beginning in mid-July 2022, via the
internet on the CMS website at https://www.cms.gov/Regulations-andGuidance/Review-Boards/MGCRB/, or by calling the MGCRB at
(410) 786-1174. This collection of information was previously approved
under OMB Control Number 0938-0573 which expired on January 31, 2021. A
reinstatement of this PRA package is currently being developed. The
public will have an opportunity to review and submit comments regarding
the reinstatement of this PRA package through a public notice and
comment period separate from this rulemaking.
Comment: A commenter requested that in light of potential actions
taken by CMS in response to the Bridgeport or Citrus decisions, CMS
should allow an additional 45-day withdrawal/termination period after
the publication of this final rule to allow hospitals to select the
wage index that would apply for FY 2023. As an alternative, citing a FY
2005 policy exception, the commenter suggested that CMS can assign
hospitals to the geographic area that is most advantageous to them.
Response: As previously discussed, in section III.G.4 of this final
rule, CMS is finalizing as proposed to continue the low wage index
hospital policy and the related budget neutrality adjustment for FY
2023 and is not implementing any changes at this time due to
Bridgeport. As previously discussed, in section III.G.1. of the
preamble of this final rule, we are modifying for FY 2023 and
subsequent years the calculation of the rural floor and ``the wage
index for rural areas in the State in which the county is located'' as
referred to in section 1886(d)(8)(C)(iii) of the Act, based on the
Citrus decision. Presumably, the commenter is requesting that we
provide an additional 45 days for hospitals with MGCRB
reclassifications to submit MGCRB withdrawal or termination requests,
or rescind such a request that was already approved. As previously
discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49973) and the
FY 2021 IPPS/LTCH PPS final rule (85 FR 58769--58770), we maintain that
information provided in the proposed rule constitutes the best
available data to assist hospitals in making reclassification
decisions. In the proposed rule, we acknowledged the district court
decisions in Bridgeport and Citrus, and we stated that we may decide to
take a different approach to our policies in the final rule, depending
on public comments or developments in the court proceedings. We believe
hospitals had the ability to make informed decisions weighing potential
outcomes based on the proposed rule.
In particular, we note that the state rural wage index published in
Table 3 of the FY 2023 IPPS/LTCH PPS proposed rule would be the rural
floor if we included 412.103 hospitals in the
[[Page 49010]]
calculation of the rural floor. Therefore, information with regard to
what the rural floor would have been if we modified our policy was
available in the proposed rule. Further, looking at the states and
territories in Table 3 of the proposed rule, 40 states/territories in
the proposed rule had a rural floor that equals the rural wage index
(which includes Puerto Rico). Four states in the proposed rule are not
eligible for the rural floor since they are all urban states and
receive the imputed floor instead. Using data from Table 3 of the
proposed rule, this leaves the 8 states listed in the table that
follows with a difference between the state rural floor and state rural
wage index. As demonstrated in the table that follows, hospitals should
be able to make these MGCRB decisions based on the data in the proposed
rule as usual as an overwhelming majority of the states/territories
show no difference between the state rural wage index and state rural
floor, and those that do show a difference show a minimal variance.
Therefore, we do not believe the data justifies an additional 45 days
for hospitals with MGCRB reclassifications to submit MGCRB withdrawal
or termination requests or to rescind such a request that was already
approved.
[GRAPHIC] [TIFF OMITTED] TR10AU22.118
In addition, as we discussed in the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58769--58770), section 1886(d)(8)(D) of the Act requires
the Secretary to adjust the standardized amounts to ensure that the
application of certain provisions of the statute, including a decision
of the MGCRB or the Secretary under section 1886(d)(10), do not result
in aggregate payments under section 1886 that are greater or less than
those that would otherwise be made. If hospitals were to withdraw or
terminate reclassification statuses after the publication of the final
rule, as the commenter suggested CMS permit, any resulting changes in
the wage index would not have been taken into account when calculating
the IPPS standardized amounts in the final rule in accordance with the
statutory budget neutrality requirement. Therefore, it is necessary
that the values published in the final rule represent the final wage
index values reflective of reclassification decisions.
With regard to the FY 2005 exception referenced by the commenter,
CMS did provide an exception to the withdrawal and termination deadline
due to the implementation of special reclassifications under section
508 of Pub. L. 108-173 and general concerns regarding the
implementation of revised OMB labor market delineations based on the
2000 decennial census (69 FR 49060 and 49061). CMS inferred certain
wage index selections for section 508 hospitals where the preferred
option (depending on the finalization of proposed wage index policies)
was clear and obvious, and hospitals were granted a 30 day window after
the final rule to withdraw their reclassification request or to rescind
their previous withdrawal or termination request. With the relatively
few number of reclassified hospitals in FY 2005, it was plausible for
CMS to impute or infer the optimal reclassification status in certain
limited circumstances, and potentially allow for an additional window
of opportunity for hospitals to review their options to withdraw or
terminate MGCRB status. However, when factoring the large number of
currently reclassified hospitals and the iterative and compounding
impacts of various forms of wage index reclassification policy, various
wage index floor policies, and other adjustment policies; it does not
support the premise that additional opportunities to modify MGCRB
reclassification status would be feasible or would result in more
accurate or consistent results.
Comment: A commenter noted that the MGCRB issued determinations for
FY 2023 on January 24, 2022. The commenter stated that this was earlier
than in the past, when the MGCRB typically issued determinations mid-
February, to meet the statutory requirement for decisions to be issued
by the end of February. The commenter requested that CMS limit the
MGCRB from issuing decisions prior to the first week of February to
allow hospitals ample time to submit documentation of rural
reclassification, SCH and RRC status to the Board or to submit a
request to withdraw an application based on review of the January PUF.
The commenter stated that without a more definitive timeline, hospitals
face uncertainty if their documentation will be accepted by the MGCRB
and could be adversely affected by an early decision being issued by
the Board.
Response: We disagree with the commenter that hospitals are
disadvantaged by earlier issuance of MGCRB decisions. First, we believe
hospitals should submit applications complete with supporting
documentation at the time MGCRB applications are due. Hospitals taking
advantage of the MGCRB's practice of accepting supporting documentation
to supplement applications until the date of the MGCRB's review are
aware that the review is not held on the same date annually.
Furthermore, rural reclassification may be obtained at any time, and
hospitals seeking benefits of rural status for MGCRB reclassification
[[Page 49011]]
should plan accordingly. Finally, we note that hospitals dissatisfied
with the MGCRB's decision may request the Administrator's review under
Sec. 412.278. With regard to hospitals requesting to withdraw a
pending reclassification application following review of the January
PUF, hospitals may withdraw a reclassification after the MGCRB has
issued decisions, within 45 days of the date that CMS' annual notice of
proposed rulemaking is issued in the Federal Register, per the
regulations at Sec. 412.273. Therefore, we do not believe hospitals
are disadvantaged by the earlier timing of MGCRB decisions because they
can submit supporting documentation timely, obtain a rural
reclassification in advance, request the Administrator's review of an
MGCRB decision, and withdraw an unwanted reclassification.
Comment: A commenter requested that CMS change the special rule for
RRCs applying for reclassification at the MGCRB to afford hospitals the
same reclassification opportunities as similar hospitals competing in
the same labor market area. The commenter specifically suggested that
CMS revise its regulations to state that if a hospital is located
within five miles of another acute care hospital in the same CBSA with
a lower average hourly wage, the hospital may reclassify to the same
area as the lower wage hospital, if the applicable average hourly wage
requirements are met, rather than to the area that is closest to the
hospital.
Response: We appreciate the commenter's input. We did not propose
any changes to the regulation referenced by the commenter, Sec.
412.230(a)(3), the special rules for sole community hospitals and rural
referral centers. We are not finalizing any changes to the special rule
for RRCs applying for reclassification at the MGCRB in this final rule.
b. Clarification of Method for Submission Under Sec. 412.273
The regulations at 42 CFR 412.273 set forth the procedures for
withdrawing an MGCRB application, terminating an approved 3-year
reclassification, or canceling a previous withdrawal or termination
(also referred to as a reinstatement). The timing of such requests is
specified at Sec. 412.273(c) for terminations and withdrawals and at
paragraph (d)(2) for canceling a previous withdrawal or termination.
However, the method of submission is not clearly specified in the
regulations, other than the requirement that a request to cancel a
previous withdrawal or termination (a reinstatement), or to withdraw an
application or terminate an approved reclassification, be in writing
according to Sec. 412.273(d)(2) and (e). It has come to our attention
that this may be a source of confusion for hospital representatives
seeking to submit such requests. It is possible that hospital
representatives would attempt to send such requests to the MGCRB via
mail, email, or fax, rather than in the manner that the MGCRB can most
efficiently track and process.
Beginning with applications from hospitals to reclassify for FY
2020, the MGCRB requires applications, supporting documents, and
subsequent correspondence to be filed electronically through the MGCRB
module of the Office of Hearings Case and Document Management System
(``OH CDMS''). The MGCRB issues all of its notices and decisions via
email and these documents are accessible electronically through OH
CDMS. Registration instructions and the system user manual are
available at https://www.cms.gov/Regulations-and-Guidance/ReviewBoards/MGCRB/Electronic-Filing.html.
In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42313), we revised
the regulations at Sec. 412.256(a)(1) to require applications for
reclassification to be submitted to the MGCRB according to the method
prescribed by the MGCRB. However, the regulations at Sec. 412.273 for
withdrawals, terminations, or cancelations of a previous withdrawal or
termination (reinstatement) do not similarly specify a required manner
of submission. Therefore, to eliminate potential confusion about how to
submit withdrawal, termination, or cancelation (reinstatement)
requests, we proposed to align the regulations at Sec. 412.273 for
withdrawal, termination, or cancelation (reinstatement) requests with
the regulations at Sec. 412.256 for new applications by specifying
that withdrawal, termination, or cancelation (reinstatement) requests
also must be submitted to the MGCRB according to the method prescribed
by the MGCRB.
Specifically, we proposed to revise Sec. 412.273(d)(2) for timing
and process of cancellation requests and Sec. 412.273(e) for
withdrawal and termination requests. We proposed to revise Sec.
412.273(d)(2) to state that cancellation requests must be submitted in
writing to the MGCRB according to the method prescribed by the MGCRB no
later than the deadline for submitting reclassification applications
for the following fiscal year, as specified in Sec. 412.256(a)(2). We
also proposed to revise Sec. 412.273(e) by adding that requests to
withdraw an application or terminate an approved reclassification must
be submitted in writing to the MGCRB according to the method prescribed
by the MGCRB. We stated that we believe these proposed revisions to the
regulations would eliminate potential confusion; align our policy for
withdrawals, terminations, and cancelations (reinstatements) with our
policy for applications; and ensure requests are submitted to the MGCRB
through the method for submission that they can most efficiently
process.
Comment: A commenter supported the proposed changes to Sec.
412.273. The commenter stated that these changes will eliminate
potential confusion, align withdrawals, terminations, and cancellations
with the MGCRB application process, and ensure submissions can be
processed more efficiently by the MGCRB.
Response: We thank the commenter for supporting the proposed
changes. After consideration of the public comment we received, we are
finalizing as proposed without modification our changes to the
regulations at Sec. 412.273(d)(2) and (e).
3. Redesignations Under Section 1886(d)(8)(B) of the Act (Lugar Status
Determinations)
In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51599 through
51600), we adopted the policy that, beginning with FY 2012, an eligible
hospital that waives its Lugar status in order to receive the out-
migration adjustment has effectively waived its deemed urban status
and, thus, is rural for all purposes under the IPPS effective for the
fiscal year in which the hospital receives the outmigration adjustment.
In addition, in that rule, we adopted a minor procedural change that
would allow a Lugar hospital that qualifies for and accepts the out-
migration adjustment (through written notification to CMS within 45
days from the publication of the proposed rule) to waive its urban
status for the full 3-year period for which its out-migration
adjustment is effective. By doing so, such a Lugar hospital would no
longer be required during the second and third years of eligibility for
the out-migration adjustment to advise us annually that it prefers to
continue being treated as rural and receive the out-migration
adjustment. In the FY 2017 IPPS/LTCH PPS final rule (81 FR 56930), we
further clarified that if a hospital wishes to reinstate its urban
status for any fiscal year within this 3-year period, it must send a
request to CMS within 45 days of publication of the proposed rule for
that particular fiscal year. We indicated that such reinstatement
requests may be sent electronically to [email protected]. In the FY
2018 IPPS/LTCH
[[Page 49012]]
PPS final rule (82 FR 38147 through 38148), we finalized a policy
revision to require a Lugar hospital that qualifies for and accepts the
out-migration adjustment, or that no longer wishes to accept the out-
migration adjustment and instead elects to return to its deemed urban
status, to notify CMS within 45 days from the date of public display of
the proposed rule at the Office of the Federal Register. These revised
notification timeframes were effective beginning October 1, 2017. In
addition, in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38148), we
clarified that both requests to waive and to reinstate ``Lugar'' status
may be sent to [email protected]. To ensure proper accounting, we
requested that hospitals include their CCN, and either ``waive Lugar''
or ``reinstate Lugar'', in the subject line of these requests.
In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42314 and 42315), we
clarified that in circumstances where an eligible hospital elects to
receive the outmigration adjustment within 45 days of the public
display date of the proposed rule at the Office of the Federal Register
in lieu of its Lugar wage index reclassification, and the county in
which the hospital is located would no longer qualify for an out-
migration adjustment when the final rule (or a subsequent correction
notice) wage index calculations are completed, the hospital's request
to accept the outmigration adjustment would be denied, and the hospital
would be automatically assigned to its deemed urban status under
section 1886(d)(8)(B) of the Act. We stated that final rule wage index
values would be recalculated to reflect this reclassification, and in
some instances, after taking into account this reclassification, the
out-migration adjustment for the county in question could be restored
in the final rule. However, as the hospital is assigned a Lugar
reclassification under section 1886(d)(8)(B) of the Act, it would be
ineligible to receive the county outmigration adjustment under section
1886(d)(13)(G) of the Act.
We did not receive any requests to waive or reinstate an eligible
hospital's deemed urban status under section 1886(d)(8)(B) of the Act.
We did not receive any public comments on this policy for FY 2023.
J. Out-Migration Adjustment Based on Commuting Patterns of Hospital
Employees
In accordance with section 1886(d)(13) of the Act, as added by
section 505 of Public Law 108-173, beginning with FY 2005, we
established a process to make adjustments to the hospital wage index
based on commuting patterns of hospital employees (the ``out-
migration'' adjustment). The process, outlined in the FY 2005 IPPS
final rule (69 FR 49061), provides for an increase in the wage index
for hospitals located in certain counties that have a relatively high
percentage of hospital employees who reside in the county but work in a
different county (or counties) with a higher wage index.
Section 1886(d)(13)(B) of the Act requires the Secretary to use
data the Secretary determines to be appropriate to establish the
qualifying counties. When the provision of section 1886(d)(13) of the
Act was implemented for the FY 2005 wage index, we analyzed commuting
data compiled by the U.S. Census Bureau that were derived from a
special tabulation of the 2000 Census journey-to-work data for all
industries (CMS extracted data applicable to hospitals). These data
were compiled from responses to the ``long-form'' survey, which the
Census Bureau used at that time and which contained questions on where
residents in each county worked (69 FR 49062). However, the 2010 Census
was ``short form'' only; information on where residents in each county
worked was not collected as part of the 2010 Census. The Census Bureau
worked with CMS to provide an alternative dataset based on the latest
available data on where residents in each county worked in 2010, for
use in developing a new outmigration adjustment based on new commuting
patterns developed from the 2010 Census data beginning with FY 2016.
To determine the out-migration adjustments and applicable counties
for FY 2016, we analyzed commuting data compiled by the Census Bureau
that were derived from a custom tabulation of the American Community
Survey (ACS), an official Census Bureau survey, utilizing 2008 through
2012 (5-year) Microdata. The data were compiled from responses to the
ACS questions regarding the county where workers reside and the county
to which workers commute. As we discussed in prior IPPS/LTCH PPS final
rules, most recently in the FY 2022 IPPS/LTCH PPS final rule (86 FR
45184), we have applied the same policies, procedures, and computations
since FY 2012. We proposed to use them again for FY 2023, as we believe
they continue to be appropriate. We refer readers to the FY 2016 IPPS/
LTCH PPS final rule (80 FR 49500 through 49502) for a full explanation
of the revised data source.
For FY 2023, the out-migration adjustment will continue to be based
on the data derived from the custom tabulation of the ACS utilizing
2008 through 2012 (5-year) Microdata. For future fiscal years, we may
consider determining out-migration adjustments based on data from the
next Census or other available data, as appropriate. For FY 2023, we
did not propose any changes to the methodology or data source that we
used for FY 2016 (81 FR 25071). (We refer readers to a full discussion
of the out-migration adjustment, including rules on deeming hospitals
reclassified under section 1886(d)(8) or section 1886(d)(10) of the Act
to have waived the out-migration adjustment, in the FY 2012 IPPS/LTCH
PPS final rule (76 FR 51601 through 51602).)
We did not receive any public comments on this proposed policy for
FY 2023. Therefore, for the reasons set forth in this final rule and in
the FY 2023 IPPS/LTCH PPS proposed rule, for FY 2023, we are finalizing
our proposal, without modification, to continue using the same
policies, procedures, and computations that were used for the FY 2012
outmigration adjustment and that were applicable for FYs 2016 through
2022.
Table 2 associated with this final rule (which is available via the
internet on the CMS website) includes the out-migration adjustments for
the FY 2023 wage index. In addition, Table 4A associated with this
final rule, ``List of Counties Eligible for the Out-Migration
Adjustment under Section 1886(d)(13) of the Act'' (also available via
the internet on the CMS website) consists of the following: A list of
counties that are eligible for the out-migration adjustment for FY 2023
identified by FIPS county code, the final FY 2023 out-migration
adjustment, and the number of years the adjustment will be in effect.
K. Reclassification From Urban to Rural Under Section 1886(d)(8)(E) of
the Act Implemented at 42 CFR 412.103
Under section 1886(d)(8)(E) of the Act, a qualifying prospective
payment hospital located in an urban area may apply for rural status
for payment purposes separate from reclassification through the MGCRB.
Specifically, section 1886(d)(8)(E) of the Act provides that, not later
than 60 days after the receipt of an application (in a form and manner
determined by the Secretary) from a subsection (d) hospital that
satisfies certain criteria, the Secretary shall treat the hospital as
being located in the rural area (as defined in paragraph (2)(D)) of the
State in which the hospital is located. We refer readers
[[Page 49013]]
to the regulations at 42 CFR 412.103 for the general criteria and
application requirements for a subsection (d) hospital to reclassify
from urban to rural status in accordance with section 1886(d)(8)(E) of
the Act. The FY 2012 IPPS/LTCH PPS final rule (76 FR 51595 through
51596) includes our policies regarding the effect of wage data from
reclassified or redesignated hospitals. We refer readers to the FY 2020
IPPS/LTCH PPS final rule (84 FR 42332 through 42336) for a discussion
of our policy to calculate the rural floor without the wage data of
urban hospitals reclassifying to rural areas under 42 CFR 412.103, and
to section III.G.1 of this final rule for a discussion of our decision,
for FY 2023 and subsequent years, to calculate the rural floor as it
was calculated before FY 2020 by including the wage data of 412.103
hospitals.
In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41369 through
41374), we codified certain policies regarding multicampus hospitals in
the regulations at 42 CFR 412.92, 412.96, 412.103, and 412.108. We
stated that reclassifications from urban to rural under 42 CFR 412.103
apply to the entire hospital (that is, the main campus and its remote
location(s)). We also stated that a main campus of a hospital cannot
obtain an SCH, RRC, or MDH status, or rural reclassification under 42
CFR 412.103, independently or separately from its remote location(s),
and vice versa. However, we are aware that some urban hospitals operate
one or more remote location(s) in a State's rural area. In light of
this scenario, we wish to clarify that rural reclassification under 42
CFR 412.103 applies to the main campus and any remote location located
in an urban area. Under section 1886(d)(8)(E) of the Act, rural
reclassification is available only to a hospital that is located in an
urban area and satisfies the criteria specified in the statute. Thus, a
remote location that is located in a rural area would not qualify for
rural reclassification under section 1886(d)(8)(E) of the Act, as
implemented under 42 CFR 412.103. We proposed to add 42 CFR
412.103(a)(8) to clarify that for a multicampus hospital, approved
rural reclassification status applies to the main campus and any remote
location located in an urban area, including a main campus or any
remote location deemed urban under section 1886(d)(8)(B) of the Act.
We are also aware that CMS has not consistently reflected the
412.103 rural reclassification status in Table 2 of the annual IPPS/
LTCH PPS rulemaking for certain remote locations of hospitals that are
located in a different CBSA than the main campus. If a remote location
of a hospital is located in a different CBSA than the main campus of
the hospital, it is CMS's longstanding policy to assign that remote
location a wage index based on its own geographic area in order to
comply with the statutory requirement to adjust for geographic
differences in hospital wage levels (section 1886(d)(3)(E) of the Act).
Hospitals are required to identify and allocate wages and hours based
on FTEs for remote locations located in different CBSA on Worksheet S-
2, Part I, Lines 165 and 166 of form CMS-2552-10. In calculating wage
index values, CMS identifies the allocated wage data for these remote
locations in Table 2 with a ``B'' in the third position of the CCN.
As discussed previously, for a multicampus hospital, rural
reclassification under 42 CFR 412.103 applies to the main campus and
any remote location located in an urban area. The wage index
implications of this policy are that, barring another form of wage
index reclassification (for example, MGCRB reclassification), a main
campus or remote location with approved 412.103 rural reclassification
status would be assigned the rural wage index of its State. For FY
2023, we will list the 412.103 rural reclassification status for remote
locations (a remote location is listed with a ``B'' in the third digit
of the CCN) in Table 2 of the appendix to the final rule. We note that,
as of the date this final rule is issued, only one ``B'' location
(36B020) would be assigned its State's rural wage index in FY 2023 due
to the Sec. 412.103 rural reclassification status of the main provider
(360020). This location appears to have ceased inpatient activities, so
we do not expect a negative financial impact for FY 2023. However,
hospitals with Sec. 412.103 rural reclassification status and a remote
location in a different CBSA should evaluate potential wage index
outcomes for its remote location(s) when withdrawing or terminating
MGCRB reclassification, or canceling 412.103 rural reclassification
status. For example, if a hospital with 412.103 rural reclassification
status withdraws a separate active MGCRB reclassification for a remote
location, that remote location may be assigned the State's rural wage
index value, effective for FY 2023.
Comment: A commenter supported our proposal to clarify that
approved rural reclassification applies to a main campus and any remote
locations in an urban area. The commenter stated that this policy
allows for uniform treatment of all departments and campuses of the
same hospital.
Response: We appreciate the commenter's support. Consistent with
our clarification regarding multicampus hospitals, we are finalizing as
proposed without modification our addition to the regulations at 42 CFR
412.103(a)(8) to clarify that for a multicampus hospital, approved
rural reclassification status applies to the main campus and any remote
location located in an urban area, including a main campus or any
remote location deemed urban under section 1886(d)(8)(B) of the Act.
Table 2 associated with this FY 2023 IPPS/LTCH PPS final rule will
reflect the 412.103 rural reclassification status for remote locations
of hospitals that are located in a different CBSA than the main campus.
L. Process for Requests for Wage Index Data Corrections
1. Process for Hospitals To Request Wage Index Data Corrections
The preliminary, unaudited Worksheet S-3 wage data files and the CY
2019 occupational mix data files for the proposed FY 2023 wage index
were made available on May 24, 2021 through the internet on the CMS
website at https://www.cms.gov/medicaremedicare-fee-service-paymentacuteinpatientppswage-index-files/fy2023-wage-index-home-page.
On January 28, 2022, we posted a public use file (PUF) at https://www.cms.gov/medicaremedicare-fee-service-paymentacuteinpatientppswage-index-files/fy2023-wage-index-home-page containing FY 2023 wage index
data available as of January 28, 2022. This PUF contains a tab with the
Worksheet S-3 wage data (which includes Worksheet S-3, Parts II and III
wage data from cost reporting periods beginning on or after October 1,
2018 through September 30, 2019; that is, FY 2019 wage data), a tab
with the occupational mix data (which includes data from the CY 2019
occupational mix survey, Form CMS-10079), a tab containing the
Worksheet S-3 wage data of hospitals deleted from the January 28, 2022
wage data PUF, and a tab containing the CY 2019 occupational mix data
of the hospitals deleted from the January 28, 2022 occupational mix
PUF. In a memorandum dated January 20, 2022, we instructed all MACs to
inform the IPPS hospitals that they service of the availability of the
January 28, 2022 wage index data PUFs, and the process and timeframe
for requesting revisions in accordance with the FY 2023 Hospital Wage
Index Development Time Table available at https://www.cms.gov/files/document/fy2023-wi-time-table.pdf.
[[Page 49014]]
In the interest of meeting the data needs of the public, beginning
with the proposed FY 2009 wage index, we post an additional PUF on the
CMS website that reflects the actual data that are used in computing
the proposed wage index. The release of this file does not alter the
current wage index process or schedule. We notify the hospital
community of the availability of these data as we do with the current
public use wage data files through our Hospital Open Door Forum. We
encourage hospitals to sign up for automatic notifications of
information about hospital issues and about the dates of the Hospital
Open Door Forums at the CMS website at https://www.cms.gov/Outreach-and-Education/Outreach/OpenDoorForums.
In a memorandum dated May 11, 2021, we instructed all MACs to
inform the IPPS hospitals that they service of the availability of the
preliminary wage index data files and the CY 2019 occupational mix
survey data files posted on May 24, 2021, and the process and timeframe
for requesting revisions.
If a hospital wished to request a change to its data as shown in
the May 24, 2021, preliminary wage data files and occupational mix data
files, the hospital had to submit corrections along with complete,
detailed supporting documentation to its MAC so that the MAC received
them by September 2, 2021. Hospitals were notified of these deadlines
and of all other deadlines and requirements, including the requirement
to review and verify their data as posted in the preliminary wage index
data files on the internet, through the letters sent to them by their
MACs. We note, CMS issued a waiver due to Hurricane Ida and modified
the September 2, 2021, deadline specified in the FY 2023 Hospital Wage
Index Development Time Table for certain hospitals. Specifically, CMS
granted an extension until October 4, 2021, for hospitals in the States
of Louisiana and Mississippi to request revisions to and provide
documentation for their FY 2019 Worksheet S-3 wage data and CY 2019
occupational mix data as included in the May 24, 2021 preliminary
Public Use Files (PUFs), respectively. According to the waiver, MACs
must receive the revision requests and supporting documentation by
October 4, 2021. If hospitals encountered difficulty meeting the
extended deadline, hospitals were to communicate their concerns to CMS
via their MAC for CMS to consider an additional extension if CMS
determined it was warranted. Details regarding this waiver are
available on the CMS website at https://www.cms.gov/current-non-covid-emergencies, Additional IPPS Hospital Blanket Waivers (https://www.cms.gov/files/document/hurrican-ida-additional-ipps-hospital-blanket-waivers.pdf). November 15, 2021, was the deadline for MACs to
complete all desk reviews for hospital wage and occupational mix data
and transmit revised Worksheet S-3 wage data and occupational mix data
to CMS.
November 4, 2021, was the date by when MACs notified State hospital
associations regarding hospitals that failed to respond to issues
raised during the desk reviews. Additional revisions made by the MACs
were transmitted to CMS throughout January 2022. CMS published the wage
index PUFs that included hospitals' revised wage index data on January
28, 2022. Hospitals had until February 15, 2022, to submit requests to
the MACs to correct errors in the January 28, 2022 PUF due to CMS or
MAC mishandling of the wage index data, or to revise desk review
adjustments to their wage index data as included in the January 28,
2022, PUF. Hospitals also were required to submit sufficient
documentation to support their requests. Hospitals' requests and
supporting documentation must be received by the MAC by the February
deadline (that is, by February 15, 2022, for the FY 2023 wage index).
After reviewing requested changes submitted by hospitals, MACs were
required to transmit to CMS any additional revisions resulting from the
hospitals' reconsideration requests by March 18, 2022. Under our
current policy as adopted in the FY 2018 IPPS/LTCH PPS final rule (82
FR 38153), the deadline for a hospital to request CMS intervention in
cases where a hospital disagreed with a MAC's handling of wage data on
any basis (including a policy, factual, or other dispute) was April 1,
2022. Data that were incorrect in the preliminary or January 28, 2022
wage index data PUFs, but for which no correction request was received
by the February 15, 2022 deadline, are not considered for correction at
this stage. In addition, April 1, 2022, was the deadline for hospitals
to dispute data corrections made by CMS of which the hospital was
notified after the January 28, 2022, PUF and at least 14 calendar days
prior to April 1, 2022 (that is, March 18, 2022), that do not arise
from a hospital's request for revisions. The hospital's request and
supporting documentation must be received by CMS (and a copy received
by the MAC) by the April deadline (that is, by April 1, 2022, for the
FY 2023 wage index). We refer readers to the FY 2023 Hospital Wage
Index Development Time Table for complete details.
Hospitals were given the opportunity to examine Table 2 associated
with the proposed rule, which is listed in section VI. of the Addendum
to the proposed rule and available via the internet on the CMS website
at https://www.cms.gov/medicare/acute-inpatient-pps/fy-2023-ipps-proposed-rule-home-page. Table 2 associated with the proposed rule
contained each hospital's proposed adjusted average hourly wage used to
construct the wage index values for the past 3 years, including the
proposed FY 2023 wage index which was constructed from FY 2019 data. We
noted in the proposed rule that the proposed hospital average hourly
wages shown in Table 2 only reflected changes made to a hospital's data
that were transmitted to CMS by early February 2022.
We posted the final wage index data PUFs on April 29, 2022 on the
CMS website at https://www.cms.gov/medicaremedicare-fee-service-paymentacuteinpatientppswage-index-files/fy2023-wage-index-home-page.
The April 2022 PUFs are made available solely for the limited purpose
of identifying any potential errors made by CMS or the MAC in the entry
of the final wage index data that resulted from the correction process
previously described (the process for disputing revisions submitted to
CMS by the MACs by March 18, 2022, and the process for disputing data
corrections made by CMS that did not arise from a hospital's request
for wage data revisions as discussed earlier).
After the release of the April 2022 wage index data PUFs, changes
to the wage and occupational mix data can only be made in those very
limited situations involving an error by the MAC or CMS that the
hospital could not have known about before its review of the final wage
index data files. Specifically, neither the MAC nor CMS will approve
the following types of requests:
Requests for wage index data corrections that were
submitted too late to be included in the data transmitted to CMS by the
MACs on or before March 18, 2022.
Requests for correction of errors that were not, but could
have been, identified during the hospital's review of the January 28,
2022, wage index PUFs.
Requests to revisit factual determinations or policy
interpretations made by the MAC or CMS during the wage index data
correction process.
If, after reviewing the April 2022 final wage index data PUFs, a
hospital believes that its wage or occupational mix data are incorrect
due to a MAC or CMS error in the entry or tabulation of the final data,
the hospital was given the opportunity to notify both its MAC and
[[Page 49015]]
CMS regarding why the hospital believes an error exists and provide all
supporting information, including relevant dates (for example, when it
first became aware of the error). The hospital was required to send its
request to CMS and to the MAC so that it was received no later than May
27, 2022. May 27, 2022, was also the deadline for hospitals to dispute
data corrections made by CMS of which the hospital is notified on or
after 13 calendar days prior to April 1, 2022 (that is, March 19,
2022), and at least 14 calendar days prior to May 27, 2022 (that is,
May 13, 2022), that do not arise from a hospital's request for
revisions. (Data corrections made by CMS of which a hospital was
notified on or after 13 calendar days prior to May 27, 2022 (that is,
May 14, 2022), may be appealed to the Provider Reimbursement Review
Board (PRRB)). In accordance with the FY 2023 Hospital Wage Index
Development Time Table posted on the CMS website at https://www.cms.gov/files/document/fy2023-wi-time-table.pdf, the May appeals
were required to be sent via mail and email to CMS and the MACs. We
refer readers to the FY 2023 Hospital Wage Index Development Time Table
for complete details.
Verified corrections to the wage index data received timely (that
is, by May 27, 2022) by CMS and the MACs were incorporated into the
final FY 2023 wage index, which will be effective October 1, 2022.
We created the processes previously described to resolve all
substantive wage index data correction disputes before we finalize the
wage and occupational mix data for the FY 2023 payment rates.
Accordingly, hospitals that do not meet the procedural deadlines set
forth earlier will not be afforded a later opportunity to submit wage
index data corrections or to dispute the MAC's decision with respect to
requested changes. Specifically, our policy is that hospitals that do
not meet the procedural deadlines as previously set forth (requiring
requests to MACs by the specified date in February and, where such
requests are unsuccessful, requests for intervention by CMS by the
specified date in April) will not be permitted to challenge later,
before the PRRB, the failure of CMS to make a requested data revision.
We refer readers also to the FY 2000 IPPS final rule (64 FR 41513) for
a discussion of the parameters for appeals to the PRRB for wage index
data corrections. As finalized in the FY 2018 IPPS/LTCH PPS final rule
(82 FR 38154 through 38156), this policy also applies to a hospital
disputing corrections made by CMS that do not arise from a hospital's
request for a wage index data revision. That is, a hospital disputing
an adjustment made by CMS that did not arise from a hospital's request
for a wage index data revision is required to request a correction by
the first applicable deadline. Hospitals that do not meet the
procedural deadlines set forth earlier will not be afforded a later
opportunity to submit wage index data corrections or to dispute CMS'
decision with respect to changes.
Again, we believe the wage index data correction process described
earlier provides hospitals with sufficient opportunity to bring errors
in their wage and occupational mix data to the MAC's attention.
Moreover, because hospitals had access to the final wage index data
PUFs by late April 2022, they have an opportunity to detect any data
entry or tabulation errors made by the MAC or CMS before the
development and publication of the final FY 2023 wage index by August
2022, and the implementation of the FY 2023 wage index on October 1,
2022. Given these processes, the wage index implemented on October 1
should be accurate. Nevertheless, in the event that errors are
identified by hospitals and brought to our attention after May 27,
2022, we retain the right to make midyear changes to the wage index
under very limited circumstances.
Specifically, in accordance with 42 CFR 412.64(k)(1) of our
regulations, we make midyear corrections to the wage index for an area
only if a hospital can show that: (1) The MAC or CMS made an error in
tabulating its data; and (2) the requesting hospital could not have
known about the error or did not have an opportunity to correct the
error, before the beginning of the fiscal year. For purposes of this
provision, ``before the beginning of the fiscal year'' means by the May
deadline for making corrections to the wage data for the following
fiscal year's wage index (for example, May 27, 2022, for the FY 2023
wage index). This provision is not available to a hospital seeking to
revise another hospital's data that may be affecting the requesting
hospital's wage index for the labor market area. As indicated earlier,
because CMS makes the wage index data available to hospitals on the CMS
website prior to publishing both the proposed and final IPPS rules, and
the MACs notify hospitals directly of any wage index data changes after
completing their desk reviews, we do not expect that midyear
corrections will be necessary. However, under our current policy, if
the correction of a data error changes the wage index value for an
area, the revised wage index value will be effective prospectively from
the date the correction is made.
In the FY 2006 IPPS final rule (70 FR 47385 through 47387 and
47485), we revised 42 CFR 412.64(k)(2) to specify that, effective on
October 1, 2005, that is, beginning with the FY 2006 wage index, a
change to the wage index can be made retroactive to the beginning of
the Federal fiscal year only when CMS determines all of the following:
(1) The MAC or CMS made an error in tabulating data used for the wage
index calculation; (2) the hospital knew about the error and requested
that the MAC and CMS correct the error using the established process
and within the established schedule for requesting corrections to the
wage index data, before the beginning of the fiscal year for the
applicable IPPS update (that is, by the May 27, 2022, deadline for the
FY 2023 wage index); and (3) CMS agreed before October 1 that the MAC
or CMS made an error in tabulating the hospital's wage index data and
the wage index should be corrected.
In those circumstances where a hospital requested a correction to
its wage index data before CMS calculated the final wage index (that
is, by the May 27, 2022 deadline for the FY 2023 wage index), and CMS
acknowledges that the error in the hospital's wage index data was
caused by CMS' or the MAC's mishandling of the data, we believe that
the hospital should not be penalized by our delay in publishing or
implementing the correction. As with our current policy, we indicated
that the provision is not available to a hospital seeking to revise
another hospital's data. In addition, the provision cannot be used to
correct prior years' wage index data; it can only be used for the
current Federal fiscal year. In situations where our policies would
allow midyear corrections other than those specified in 42 CFR
412.64(k)(2)(ii), we continue to believe that it is appropriate to make
prospective-only corrections to the wage index.
We note that, as with prospective changes to the wage index, the
final retroactive correction will be made irrespective of whether the
change increases or decreases a hospital's payment rate. In addition,
we note that the policy of retroactive adjustment will still apply in
those instances where a final judicial decision reverses a CMS denial
of a hospital's wage index data revision request.
2. Process for Data Corrections by CMS After the January 28 Public Use
File (PUF)
The process set forth with the wage index time table discussed in
section
[[Page 49016]]
III.L.1. of the preamble of this final rule allows hospitals to request
corrections to their wage index data within prescribed timeframes. In
addition to hospitals' opportunity to request corrections of wage index
data errors or MACs' mishandling of data, CMS has the authority under
section 1886(d)(3)(E) of the Act to make corrections to hospital wage
index and occupational mix data in order to ensure the accuracy of the
wage index. As we explained in the FY 2016 IPPS/LTCH PPS final rule (80
FR 49490 through 49491) and the FY 2017 IPPS/LTCH PPS final rule (81 FR
56914), section 1886(d)(3)(E) of the Act requires the Secretary to
adjust the proportion of hospitals' costs attributable to wages and
wage-related costs for area differences reflecting the relative
hospital wage level in the geographic areas of the hospital compared to
the national average hospital wage level. We believe that, under
section 1886(d)(3)(E) of the Act, we have discretion to make
corrections to hospitals' data to help ensure that the costs
attributable to wages and wage-related costs in fact accurately reflect
the relative hospital wage level in the hospitals' geographic areas.
We have an established multistep, 15-month process for the review
and correction of the hospital wage data that is used to create the
IPPS wage index for the upcoming fiscal year. Since the origin of the
IPPS, the wage index has been subject to its own annual review process,
first by the MACs, and then by CMS. As a standard practice, after each
annual desk review, CMS reviews the results of the MACs' desk reviews
and focuses on items flagged during the desk review, requiring that, if
necessary, hospitals provide additional documentation, adjustments, or
corrections to the data. This ongoing communication with hospitals
about their wage data may result in the discovery by CMS of additional
items that were reported incorrectly or other data errors, even after
the posting of the January 28 PUF, and throughout the remainder of the
wage index development process. In addition, the fact that CMS analyzes
the data from a regional and even national level, unlike the review
performed by the MACs that review a limited subset of hospitals, can
facilitate additional editing of the data that may not be readily
apparent to the MACs. In these occasional instances, an error may be of
sufficient magnitude that the wage index of an entire CBSA is affected.
Accordingly, CMS uses its authority to ensure that the wage index
accurately reflects the relative hospital wage level in the geographic
area of the hospital compared to the national average hospital wage
level, by continuing to make corrections to hospital wage data upon
discovering incorrect wage data, distinct from instances in which
hospitals request data revisions.
We note that CMS corrects errors to hospital wage data as
appropriate, regardless of whether that correction will raise or lower
a hospital's average hourly wage. For example, as discussed in section
III.C. of the preamble of the FY 2019 IPPS/LTCH PPS final rule (83 FR
41364), in situations where a hospital did not have documentable
salaries, wages, and hours for housekeeping and dietary services, we
imputed estimates, in accordance with policies established in the FY
2015 IPPS/LTCH PPS final rule (79 FR 49965 through 49967). Furthermore,
if CMS discovers after conclusion of the desk review, for example, that
a MAC inadvertently failed to incorporate positive adjustments
resulting from a prior year's wage index appeal of a hospital's wage-
related costs such as pension, CMS would correct that data error and
the hospital's average hourly wage would likely increase as a result.
While we maintain CMS' authority to conduct additional review and
make resulting corrections at any time during the wage index
development process, in accordance with the policy finalized in the FY
2018 IPPS/LTCH PPS final rule (82 FR 38154 through 38156) and as first
implemented with the FY 2019 wage index (83 FR 41389), hospitals are
able to request further review of a correction made by CMS that did not
arise from a hospital's request for a wage index data correction.
Instances where CMS makes a correction to a hospital's data after the
January 28 PUF based on a different understanding than the hospital
about certain reported costs, for example, could potentially be
resolved using this process before the final wage index is calculated.
We believe this process and the timeline for requesting review of such
corrections (as described earlier and in the FY 2018 IPPS/LTCH PPS
final rule) promote additional transparency to instances where CMS
makes data corrections after the January 28 PUF, and provide
opportunities for hospitals to request further review of CMS changes in
time for the most accurate data to be reflected in the final wage index
calculations. These additional appeals opportunities are described
earlier and in the FY 2023 Hospital Wage Index Development Time Table,
as well as in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38154 through
38156).
M. Labor-Related Share for the FY 2023 Wage Index
Section 1886(d)(3)(E) of the Act directs the Secretary to adjust
the proportion of the national prospective payment system base payment
rates that are attributable to wages and wage related costs by a factor
that reflects the relative differences in labor costs among geographic
areas. It also directs the Secretary to estimate from time to time the
proportion of hospital costs that are labor-related and to adjust the
proportion (as estimated by the Secretary from time to time) of
hospitals' costs that are attributable to wages and wage-related costs
of the DRG prospective payment rates. We refer to the portion of
hospital costs attributable to wages and wage-related costs as the
labor-related share. The labor-related share of the prospective payment
rate is adjusted by an index of relative labor costs, which is referred
to as the wage index.
Section 403 of Public Law 108-173 amended section 1886(d)(3)(E) of
the Act to provide that the Secretary must employ 62 percent as the
labor-related share unless this would result in lower payments to a
hospital than would otherwise be made. However, this provision of
Public Law 108-173 did not change the legal requirement that the
Secretary estimate from time to time the proportion of hospitals' costs
that are attributable to wages and wage-related costs. Thus, hospitals
receive payment based on either a 62-percent labor-related share, or
the labor-related share estimated from time to time by the Secretary,
depending on which labor-related share resulted in a higher payment.
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45194 through
45208), we rebased and revised the hospital market basket. We
established a 2018-based IPPS hospital market basket to replace the
2014-based IPPS hospital market basket, effective October 1, 2021.
Using the 2018-based IPPS market basket, we finalized a labor-related
share of 67.6 percent for discharges occurring on or after October 1,
2021. In addition, in FY 2022, we implemented this revised and rebased
labor-related share in a budget neutral manner (86 FR 45529-45530).
However, consistent with section 1886(d)(3)(E) of the Act, we did not
take into account the additional payments that would be made as a
result of hospitals with a wage index less than or equal to 1.0000
being paid using a labor-related share lower than the labor-related
share of hospitals with a wage index greater than 1.0000.
[[Page 49017]]
The labor-related share is used to determine the proportion of the
national IPPS base payment rate to which the area wage index is
applied. We include a cost category in the labor related share if the
costs are labor intensive and vary with the local labor market. In the
FY 2022 IPPS/LTCH PPS final rule (86 FR 45204 through 45207), we
included in the labor-related share the national average proportion of
operating costs that are attributable to the following cost categories
in the 2018-based IPPS market basket: Wages and Salaries; Employee
Benefits; Professional Fees: Labor-Related; Administrative and
Facilities Support Services; Installation, Maintenance, and Repair
Services; and All Other: Labor-related Services. In the proposed rule,
for FY 2023, we did not propose to make any further changes to the
labor-related share. For FY 2023, we proposed to continue to use a
labor-related share of 67.6 percent for discharges occurring on or
after October 1, 2022.
As discussed in section V.A. of the preamble of this final rule,
prior to January 1, 2016, Puerto Rico hospitals were paid based on 75
percent of the national standardized amount and 25 percent of the
Puerto Rico-specific standardized amount. As a result, we applied the
Puerto Rico-specific labor-related share percentage and nonlabor-
related share percentage to the Puerto Rico-specific standardized
amount. Section 601 of the Consolidated Appropriations Act, 2016 (Pub.
L. 114-113) amended section 1886(d)(9)(E) of the Act to specify that
the payment calculation with respect to operating costs of inpatient
hospital services of a subsection (d) Puerto Rico hospital for
inpatient hospital discharges on or after January 1, 2016, shall use
100 percent of the national standardized amount. Because Puerto Rico
hospitals are no longer paid with a Puerto Rico-specific standardized
amount as of January 1, 2016, under section 1886(d)(9)(E) of the Act as
amended by section 601 of the Consolidated Appropriations Act, 2016,
there is no longer a need for us to calculate a Puerto Rico-specific
labor-related share percentage and nonlabor-related share percentage
for application to the Puerto Rico-specific standardized amount.
Hospitals in Puerto Rico are now paid 100 percent of the national
standardized amount and, therefore, are subject to the national labor-
related share and nonlabor related share percentages that are applied
to the national standardized amount. Accordingly, for FY 2023, we did
not propose a Puerto Rico-specific labor-related share percentage or a
nonlabor-related share percentage.
Comment: Some commenters stated that an analysis comparing
hospitals' average hourly wages calculated from data reported on
schedule S-3 of their FY 2019 to their 2020 cost reports shows that the
average hourly wage rose 4.14 percent among hospitals with a wage index
greater than 1.0. The commenters stated that this wage growth occurred
at the same time that hospital utilization was decreasing due to the
effects of the pandemic, resulting in a considerable increase in the
portion of overall hospital costs represented by labor.
In addition to requesting that CMS update the labor share, the
commenters requested that CMS modify its methodology to review only the
labor costs of hospitals in areas with a wage index greater than 1.0
because hospitals in areas with a wage index lower than 1.0 receive a
statutorily defined labor-related share of 62 percent. The commenters
stated that changes of the labor share are budget-neutral but updating
the share would ensure that a more appropriate amount of funds go to
hospitals in areas with a wage index greater than 1.0, where the
greatest increases in labor costs have been experienced. The commenters
explained that the same comparison of 2019 and 2020 average hourly
wages shows that hospitals with a wage index of 1.0 or less experienced
an increase of only 2.38 percent during that same period.
For the reasons above, the commenters requested that CMS consider
raising the labor-related share for hospitals with wage indexes greater
than 1.0 for FY 2023.
A commenter stated that it strongly supports continuing to utilize
a labor-related share of 67.6 percent for discharges. The commenter
also stated that given the extreme increases in labor costs industry-
wide due to the pandemic over the last three years, the commenter urged
CMS to re-base again for FY 2023 to reflect a more accurate labor-
related share.
A commenter stated that it experienced an exponential increase in
the cost of labor as a result of the COVID-19 pandemic and labor
shortages. The commenter requested that CMS evaluate the impact of
rising labor costs on wage indices.
Response: We appreciate the commenters' concerns regarding how
operating expenses for hospitals may have been impacted by the PHE.
However, we disagree with the commenters' suggestion to update the
labor related share for FY 2023. As published in the FY 2006 IPPS final
rule (70 FR 47403), in accordance with section 404 of Public Law 108-
173, CMS determined a new frequency for rebasing the hospital market
basket, including the labor-related share, of every four years.
Therefore, in the FY 2022 IPPS/LTCH final rule, we finalized to update
the labor related share to reflect the rebased and revised IPPS market
basket, which is based on 2018 data. The labor-related share is equal
to the national average proportion of operating costs that are
attributable to the following cost categories in the 2018-based IPPS
market basket: Wages and Salaries, Employee Benefits, Professional
Fees: Labor-Related, Administrative and Facilities Support Services,
Installation, Maintenance, and Repair Services, and All Other: Labor-
Related Services.
CMS did not propose to rebase and revise the IPPS market basket,
including the labor-related share, in the FY 2023 IPPS/LTCH proposed
rule. However, we did review the most recent Medicare cost report data
available for IPPS hospitals submitted as of March 2022, which includes
data for 2019-2020. The Medicare cost report data showed slight
decreases in the compensation cost weight (reflecting wages and
salaries, employee benefits, and direct patient care contract labor
costs as a percent of operating costs) in 2019 and 2020 resulting in a
compensation cost weight that is roughly 1 percentage point less than
the 2018-based IPPS market basket cost weight. The compensation cost
weight accounts for 53.0 percentage points of the 67.6 percentage point
labor-related share based on the 2018-based IPPS market basket.
We plan to review the 2021 Medicare cost report data as soon as
complete information is available and evaluate these data for future
rulemaking. We thank the commenters for their comments and will
consider the comments regarding the methodology for deriving the labor-
related share for future rulemaking. After consideration of the public
comments we received, for the reasons set forth above and in this final
rule and in the FY 2022 IPPS/LTCH PPS final rule, we are finalizing our
proposals, without modification, to continue to use a labor-related
share of 67.6 percent for discharges occurring on or after October 1,
2022 for all hospitals (including Puerto Rico hospitals) whose wage
indexes are greater than 1.0000.
Tables 1A and 1B, which are published in section VI. of the
Addendum to this FY 2023 IPPS/LTCH PPS final rule and available via the
internet on the CMS website, reflect the national labor-related share.
Table 1C, in section VI. of the Addendum to this
[[Page 49018]]
FY 2023 IPPS/LTCH PPS final rule and available via the internet on the
CMS website, reflects the national labor-related share for hospitals
located in Puerto Rico. For FY 2023, for all IPPS hospitals (including
Puerto Rico hospitals) whose wage indexes are less than or equal to
1.0000, we are applying the wage index to a labor-related share of 62
percent of the national standardized amount. For all IPPS hospitals
(including Puerto Rico hospitals) whose wage indexes are greater than
1.000, for FY 2023, we are applying the wage index to a labor-related
share of 67.6 percent of the national standardized amount.
N. Permanent Cap on Wage Index Decreases
1. Permanent Cap Policy for the Wage Index
In the FY 2020 IPPS/LTCH PPS final rule, CMS implemented a
transition policy for FY 2020 to place a 5 percent cap on any decrease
in a hospital's wage index from the hospital's final wage index in FY
2019 so that a hospital's final wage index for FY 2020 will not be less
than 95 percent of its final wage index for FY 2019 (84 FR 42336
through 42337). We implemented this transition due to the combined
effect of the policy changes for the FY 2020 wage index (including
policies to address wage index disparities between high and low wage
index hospitals), which we believed could lead to significant decreases
in the wage index values for some hospitals. We stated that this
transition would allow the effects of our policies to be phased in over
2 years with no estimated reduction in the wage index of more than 5
percent in FY 2020 (that is, no cap would be applied the second year).
We also stated that we believed 5 percent is a reasonable level for the
cap because it would effectively mitigate any significant decreases in
the wage index for FY 2020. We applied a budget neutrality adjustment
factor to the FY 2020 standardized amount for all hospitals to achieve
budget neutrality for the transition policy (84 FR 42337 through
42338).
In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58753 through
58755), to mitigate the effect of our adoption of the revised OMB
delineations in OMB Bulletin 18-04, we implemented for FY 2021 the same
5 percent cap transition policy that we had implemented for FY 2020.
Specifically, we placed a 5 percent cap on any decrease in a hospital's
wage index from the hospital's final wage index in FY 2020 so that a
hospital's final wage index for FY 2021 will not be less than 95
percent of its final wage index for FY 2020. We stated that for FY
2021, we did not believe it was necessary to implement the multifaceted
transitions (including a 1-year blended wage index) we established in
FY 2015 for the adoption of the new OMB delineations based on the new
decennial census data. The 5 percent cap transition policy resulted in
some hospitals receiving a transition adjustment that were not directly
affected by the adoption of the revised OMB delineations (85 FR 58754).
We applied a budget neutrality adjustment to the FY 2021 standardized
amount to achieve budget neutrality for the transition policy (85 FR
58755).
In the FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25397), given the
unprecedented nature of the ongoing COVID-19 PHE, we solicited comments
on whether it would be appropriate to continue to apply a transition to
the FY 2022 wage index for hospitals negatively impacted by our
adoption of the updates in OMB Bulletin 18-04. We received several
comments strongly recommending CMS extend a transition policy similar
to that implemented in FY 2020 and FY 2021. Commenters also recommended
CMS consider making a permanent 5 percent maximum reduction policy to
protect hospitals from large year-to-year variations in wage index
values as a means to reduce overall volatility. While we did not adopt
the commenters' suggestion for a permanent 5 percent cap policy, we did
finalize a transition policy for FY 2022 in the FY 2022 IPPS/LTCH PPS
final rule (86 FR 45164). Specifically, for hospitals that received the
transition in FY 2021, we continued a wage index transition for FY 2022
under which we apply a 5 percent cap on any decrease in the hospital's
wage index compared to its wage index for FY 2021 to mitigate
significant negative impacts of, and provide additional time for
hospitals to adapt to, the CMS decision to adopt the revised OMB
delineations. We applied a budget neutrality adjustment to the FY 2022
standardized amount so that the transition is implemented in a budget
neutral manner (86 FR 45165).
For FY 2023 and subsequent years, we further considered the
comments we received during the FY 2022 rulemaking recommending a
permanent 5 percent cap policy to prevent large year-to-year variations
in wage index values as a means to reduce overall volatility for
hospitals. In the past, we have established temporary transition
policies (as described above) when there have been significant changes
to wage index policy, and we have limited the duration of each
transition in order to phase in the effects of those policy changes. In
taking this temporary approach in the past, we have sought to mitigate
short-term instability and fluctuations that can negatively impact
hospitals. We also recognize that, absent any specific change in wage
index policy, significant year-to-year fluctuations in an area's wage
index can occur due to external factors beyond a hospital's control,
such as the COVID-19 PHE. For an individual hospital, these
fluctuations can be difficult to predict. We recognize that
predictability in Medicare payments is important to enable hospitals to
budget and plan their operations.
In light of these considerations, in the FY 2023 IPPS/LTCH PPS
proposed rule, we proposed a permanent approach to smooth year-to-year
decreases in hospitals' wage indexes (87 FR 28377 through 28380). We
proposed a policy that we believe increases the predictability of IPPS
payments for hospitals and mitigates instability and significant
negative impacts to hospitals resulting from changes to the wage index.
We stated that we also believe our proposed permanent policy would
eliminate the need for temporary and potentially uncertain transition
adjustments to the wage index in the future due to specific policy
changes or circumstances outside hospitals' control (for example, in
the event we adopt any future OMB revisions to the CBSA delineations).
As a result of this proposed policy, an otherwise rare but relatively
large year-to-year decrease in the wage index value for an individual
hospital would be phased in, providing the hospital with additional
time to plan appropriately and explore potential reclassification
options, if applicable. For example, if a change in OMB delineations
resulted in a hospital's wage index decreasing by more than 10 percent
in any given year, this proposed policy could provide at least one
additional year to phase in the decrease beyond a single ``transition''
year methodology, such as the transition policy finalized in the FY
2015 IPPS/LTCH PPS final rule (79 FR 49957 through 49962).
Typical year-to-year variation in the wage index has historically
been within 5 percent, and we stated in the proposed rule that we
expect this will continue to be the case in future years. Because
hospitals are usually experienced with this level of wage index
fluctuation, we stated that we believe applying a 5-percent cap on all
wage index decreases each year, regardless of the reason for the
decrease, would effectively mitigate instability in IPPS payments due
to any significant wage index decreases that may affect hospitals in a
year. In
[[Page 49019]]
addition, we stated that we believe that the predictability resulting
from a 5 percent cap on all wage index decreases would enable hospitals
to more effectively budget and plan their operations. Because applying
a 5-percent cap on all wage index decreases would represent a small
overall impact on the labor market area wage index system, we stated
that we believe it would ensure the wage index is a relative measure of
the value of labor in prescribed labor market areas. In the proposed
rule, we estimated that applying a 5-percent cap on all wage index
decreases would have a very small effect on the budget neutrality
factor associated with the cap applied to the standardized amount for
FY 2023 (discussed in section III.N.2 of the preamble of the proposed
rule). Because the wage index is a measure of the value of labor (wage
and wage-related costs) in a prescribed labor market area relative to
the national average, we stated that we anticipate that in the absence
of policy changes most hospitals will not experience year-to-year wage
index declines greater than 5 percent in any given year. Therefore, we
stated that we anticipate that the impact to the budget neutrality
factor associated with the cap in future years would continue to be
minimal. We stated that we also believe that when the 5-percent cap
would be applied under this proposal, in general it is likely that it
would be applied similarly to all hospitals in the same labor market
area, as the hospital average hourly wage data in the CBSA (and any
relative decreases compared to the national average hourly wage) would
be similar. While in certain circumstances this policy may result in
some hospitals in a CBSA receiving a higher wage index than others in
the same area, we stated that we believe the impact would be temporary.
For the reasons discussed in the proposed rule, we stated that we
believe a 5-percent cap on wage index decreases would be appropriate
for the IPPS. Therefore, for FY 2023 and subsequent years, we proposed
to apply a 5-percent cap on any decrease to a hospital's wage index
from its wage index in the prior FY, regardless of the circumstances
causing the decline. That is, we proposed that a hospital's wage index
for FY 2023 would not be less than 95 percent of its final wage index
for FY 2022, and that for subsequent years, a hospital's wage index
would not be less than 95 percent of its final wage index for the prior
FY. This also means that if a hospital's prior FY wage index is
calculated with the application of the 5-percent cap, the following
year's wage index would not be less than 95 percent of the hospital's
capped wage index in the prior FY. For example, if a hospital's wage
index for FY 2023 is calculated with the application of the 5-percent
cap, then its wage index for FY 2024 would not be less than 95 percent
of its capped wage index in FY 2023. We stated that we would reflect
the proposed wage index cap policy at 42 CFR 412.64(h). Specifically,
we proposed to add a new paragraph at 42 CFR 412.64(h)(7) to state that
beginning with fiscal year 2023, if CMS determines that a hospital's
wage index value for a fiscal year would decrease by more than 5
percent as compared to the hospital's wage index value for the prior
fiscal year, CMS limits the decrease to 5 percent for the fiscal year.
We stated that we have authority to implement the proposed wage
index cap policy and the associated proposed budget neutrality
adjustment (discussed in section III.N.2. of the preamble of the
proposed rule) under section 1886(d)(3)(E) of the Act, which gives the
Secretary broad authority to adjust for area differences in hospital
wage levels by a factor (established by the Secretary) reflecting the
relative hospital wage level in the geographic area of the hospital
compared to the national average hospital wage level, and requires
those adjustments to be budget neutral. We also stated that in
addition, we have authority to implement the proposed wage index cap
policy and the associated proposed budget neutrality adjustment
(discussed in section III.N.2. of the preamble of the proposed rule) as
an adjustment under section 1886(d)(5)(I)(i) of the Act, which
similarly gives the Secretary broad authority to provide by regulation
for such other exceptions and adjustments to such payment amounts under
subsection (d) as the Secretary deems appropriate.
We proposed to apply the wage index cap policy described above for
a FY using the final wage index applicable to the hospital on the last
day of the prior FY (except for newly opened hospitals, as discussed
below). In general, the final wage index applicable to the hospital on
the last day of the prior FY would be the wage index value listed for
the hospital in Table 2 of the IPPS/LTCH PPS final rule for that prior
FY (including any correction notices, if applicable). We stated that in
rulemaking for a FY, we intend to relist the wage index values from
Table 2 of the IPPS/LTCH PPS final rule for the prior FY, with updates
as described below. Under the proposed wage index cap policy described
above, we would use these values to determine a hospital's wage index
for a FY by capping it at 95 percent of the final wage index applicable
to the hospital on the last day of the prior FY (in general, the wage
index value listed for the hospital in Table 2 of the IPPS/LTCH PPS
final rule for the prior FY). We noted in the proposed rule that,
consistent with our past application of the 5 percent cap transition
policy (see the FY 2020 IPPS/LTCH PPS final rule (84 FR 42337)), the
proposed wage index cap policy described above would apply to hospitals
whose wage index is reduced by obtaining a urban to rural
reclassification under 42 CFR 412.103. Specifically, a hospital that
obtains a rural reclassification under 42 CFR 412.103 may be assigned
its State's rural wage index.\212\ While other forms of wage index
reclassification are effective with the start of a Federal fiscal year,
pursuant to 42 CFR 412.103(d)(1), the effective date of an approved
rural reclassification is the filing date of the application.
Therefore, the wage index values for hospitals that obtain rural
reclassification under 42 CFR 412.103 may change in the middle of a
Federal fiscal year and thus may not be reflected in Table 2 of the
IPPS/LTCH PPS final rule for that year. For example, if a hospital was
assigned its geographic wage index of 1.0001 in Table 2 of the FY 2022
IPPS/LTCH PPS final rule, but obtained a rural reclassification on
December 1, 2021 and was assigned its state's rural wage index of
0.9600 for the remainder of FY 2022; the FY 2023 cap would be based on
the 0.9600 value, not the 1.0001 value listed in Table 2 of the FY 2022
IPPS/LTCH PPS final rule. We stated that as in previous years, we would
instruct hospitals that obtain a rural reclassification under 42 CFR
412.103 to contact their MAC to ensure that their assigned wage index
does not result in a greater than 5 percent decrease from the
hospital's prior year wage index value (see the FY 2020 IPPS/LTCH PPS
final rule (84 FR 42337) and the FY 2021 IPPS/LTCH PPS final rule (85
FR 58754)).
---------------------------------------------------------------------------
\212\ As discussed in the FY 2016 IFC (81 FR 23428 through
23438), hospitals with simultaneous reclassifications under 412.103
and either Lugar or MGCRB reclassification process are not assigned
their State's rural wage index.
---------------------------------------------------------------------------
In Table 2 associated with this final rule, which is available via
the internet on the CMS website, we list the FY 2022 final wage index
value for all hospitals in column C. For additional clarity, we have
identified hospitals that have obtained rural reclassification after
the FY 2022 lock-in date, as described in 42 CFR 412.103(b)(6), and
that were assigned a different wage index than what was listed in Table
2 associated
[[Page 49020]]
with the FY 2022 IPPS/LTCH PPS correction notice (available on the
internet at https://www.cms.gov/files/zip/fy-2022-ipps-frtables-2-3-4a-4b.zip). In Table 2 associated with this final rule, the FY 2022 wage
index column for these hospitals will not use the values listed in
Table 2 associated with the FY 2022 IPPS/LTCH PPS correction notice
(available on the internet at https://www.cms.gov/files/zip/fy2022-ipps-fr-tables-2-3-4a-4b.zip), but will instead be updated with the
wage index value that is currently assigned to the hospitals. Under our
proposal described above, we would apply the wage index cap using the
actual final wage index value assigned to the hospital on the last day
of the prior Federal fiscal year rather than the value listed in Table
2 of the prior FY final rule. In the proposed rule, we identified in
Table 2 (posted on the FY 2023 proposed rule web page at https://
www.cms.gov/medicare/medicare-fee-for-service-payment/
acuteinpatientpps) all hospitals that obtained rural reclassification
under 42 CFR 412.103 after the FY 2022 lock-in date and that have no
other form of wage index reclassification applicable to them at this
time. This column in Table 2 has been revised for this final rule
(posted on the FY 2023 final rule web page at https://www.cms.gov/
medicare/medicare-fee-for-service-payment/acuteinpatientpps) to add
additional hospitals without another form of reclassification that
obtain rural reclassification under 42 CFR 412.103 before the FY 2023
lock-in date as described in 42 CFR 412.103(b)(6).
We stated in the proposed rule that hospitals that obtain rural
reclassification after the FY 2023 lock-in date will not be listed as
being reclassified as rural in the FY 2023 IPPS/LTCH PPS final rule. We
stated that if we finalize the proposed wage index cap policy described
above, these hospitals should contact their MAC to ensure that the
assigned rural wage index value is not less than 95 percent of their
final wage index value for FY 2022 (that is, the wage index assigned to
the hospital as of September 30, 2022).
For newly opened hospitals, we proposed to apply the proposed wage
index cap policy for a FY using the wage index value the hospital was
assigned for the prior FY. A new hospital would be paid the wage index
for the area in which it is geographically located for its first full
or partial fiscal year, and it would not receive a cap for that first
year because it would not have been assigned a wage index in the prior
year. Also, it is possible a new hospital may not be listed in Table 2
for several years since the hospitals listed in Table 2 are based on
historical data. We stated in the proposed rule that if we finalize the
proposed wage index cap policy described above, a new hospital may
contact their MAC to ensure that their assigned wage index value for
the upcoming FY is not less than 95 percent of the value assigned to
them for the prior Federal fiscal year. For example, if a hospital
begins operations on July 1, 2022, and is assigned its area wage index
of 0.9000 for the remainder of FY 2022, its FY 2023 wage index would be
capped at 95 percent of that value, and could not be lower than 0.8550
(0.95 x 0.9000) regardless of whether it was listed in Table 2 in the
FY 2022 IPPS/LTCH PPS final rule. A hospital that opens on December 1,
2022 would not be eligible for a capped wage index in FY 2023, as it
was not assigned a wage index during FY 2022.
In the proposed rule, we noted that if we adopt these proposals as
final policy, we would examine the effects of the policy on an ongoing
basis in the future in order to assess whether it effectively and
appropriately accomplishes the goal of increasing predictability and
stability in IPPS payments.
We received comments on our proposals and summarize and respond to
these comments in section III.N.2. below where we discuss the proposed
budget neutrality adjustment associated with the proposed wage index
cap policy. As we note below, we are finalizing our proposals regarding
the wage index cap policy without modification.
2. Permanent Cap Budget Neutrality
We proposed to implement the proposed wage index cap policy
(discussed above in section III.N.1 of the preamble of this final rule)
in a budget neutral manner through a national adjustment to the
standardized amount each fiscal year as we have implemented similar
past transition policies involving a cap on wage index decreases (for
example, see the FY 2021 IPPS/LTCH PPS final rule (85 FR 58755) and the
FY 2022 IPPS/LTCH PPS final rule (86 FR 45164 through 45165)). We
stated that we believe application of the proposed wage index cap
policy should not increase estimated aggregate Medicare payments beyond
the payments that would be made had we never applied the cap.
Specifically, we proposed to apply a budget neutrality adjustment
to ensure that estimated aggregate payments under our proposed wage
index cap policy for hospitals that would have a decrease in their wage
indexes for the upcoming fiscal year of more than 5 percent would equal
what estimated aggregate payments would have been without the proposed
wage index cap policy. To determine the proposed associated budget
neutrality factor, we stated that we would compare estimated aggregate
IPPS payments with and without the proposed wage index cap policy. As
discussed above in section III.N.1 of the preamble of this final rule,
in the propose rule, we stated that we have authority to implement this
budget neutrality adjustment under sections 1886(d)(3)(E) and
(d)(5)(I)(i) of the Act.
Comment: Commenters were generally supportive of CMS's proposal to
limit any decrease in a hospital's wage index value to be no greater
than 5 percent as compared to the hospital's wage index value for the
prior fiscal year. Commenters supported CMS's goal of increasing the
stability and predictability of payments under the IPPS. However,
several commenters contend that contrary to CMS's past statements, the
statute neither authorizes nor requires budget neutrality to offset
adjustments made under section 1886(d)(5)(I)(i). Some commenters
suggested that CMS should apply the cap in a manner that would not
reduce the wage indexes of other hospitals, contending this would lead
to less volatility in wage index values. Several commenters request CMS
review and seek alternatives to the proposed national budget neutrality
adjustment.
Response: We appreciate commenters' support of the proposed
permanent cap on wage index decreases. As discussed above in section
III.N.1 of the preamble of this final rule, we have authority to
implement the proposed budget neutrality adjustment associated with the
proposed cap under sections 1886(d)(3)(E) and (d)(5)(I)(i) of the Act.
Section 1886(d)(3)(E) gives the Secretary broad authority to adjust for
area differences in hospital wage levels by a factor (established by
the Secretary) reflecting the relative hospital wage level in the
geographic area of the hospital compared to the national average
hospital wage level, and requires those adjustments to be applied in a
budget neutral manner. However, even if the wage index were not
required to be budget neutral under section 1886(d)(3)(E) of the Act,
we would not consider it an appropriate alternative to use the wage
index and the proposed permanent cap on wage index decreases to
increase or decrease overall IPPS spending. The wage index is not a
policy tool but rather a technical adjustment designed to be a relative
measure of the wages and wage-related
[[Page 49021]]
costs of subsection (d) hospitals in the United States. Contrary to the
commenters' assertion, we also have authority to implement the proposed
budget neutrality adjustment associated with the proposed cap as an
adjustment under section 1886(d)(5)(I)(i) of the Act, which similarly
gives the Secretary broad authority to provide by regulation for such
other exceptions and adjustments to such payment amounts under
subsection (d) as the Secretary deems appropriate. Furthermore, our
past transition policies involving a 5 percent cap on wage index
decreases implemented in a budget neutral manner did not result in wage
index volatility, and we expect the same for the overall budget
neutrality adjustments associated with the permanent cap policy.
Comment: MedPAC supported the proposal to cap wage index decreases
at 5 percent, but suggested also applying a cap to increases of more
than 5 percent.
Response: We appreciate MedPAC's suggestion that the cap on wage
index changes of more than 5 percent should also be applied to
increases in the wage index. However, as we discussed in the proposed
rule, one purpose of the proposed policy is to help mitigate the
significant negative impacts of certain wage index changes. As we
discussed in the proposed rule, we believe applying a 5-percent cap on
all wage index decreases would support increased predictability about
IPPS payments for hospitals in the upcoming fiscal year, enabling them
to more effectively budget and plan their operations. That is, we
proposed to cap decreases because we believe that a hospital would be
able to more effectively budget and plan when there is predictability
about its expected minimum level of IPPS payments in the upcoming
fiscal year. We did not propose to limit wage index increases because
we do not believe such a policy is needed to enable hospitals to more
effectively budget and plan their operations. Therefore, we believe it
is appropriate for hospitals that experience an increase in their wage
index value to receive that wage index value.
Comment: A commenter suggested that if CMS discontinues the low
wage index hospital policy, hospitals that benefitted in the prior year
from that policy should not be subject to a 5 percent cap on any
decreases.
Response: We appreciate the commenter's suggestion. As discussed in
section III. G. 4 of this final rule, CMS is continuing the low wage
index hospital policy for FY 2023.
Comment: A commenter did not support CMS's proposed policy approach
to the wage index cap policy with regard to newly opened hospitals.
While the commenter stated they understand the rationale for CMS's
policy approach, they expressed concerns that it will create inequity
in Medicare payments for hospitals within the same market. The
commenter encouraged CMS to apply the same area wage index value for
new and existing hospitals under this policy.
Response: We understand the commenter's concern, but we do not
believe the scenario they are alluding to (that is, a labor market
where existing hospitals are receiving the cap, and new hospitals are
not) would neither be common nor require additional consideration. We
believe that on an ongoing basis, relatively few hospitals would
receive the cap, and even fewer would receive the cap in consecutive
years. As of this final rule, there will be 126 hospitals receiving the
cap in FY 2023, and only 12 that will receive a cap increase of greater
than 5 percent. Therefore, any potential difference in the wage index
value hospitals in the same labor market area receive would likely be
minimal and temporary. We proposed to examine the effects of this
policy on an ongoing basis to assess whether it effectively and
appropriately accomplishes the goal of increasing predictability and
stability in IPPS payments, and may reevaluate this issue in the
future. However, at this time, we do not believe that creating a policy
modification for hospitals that were not assigned a wage index in the
prior year is necessary.
After consideration of the public comments we received, for the
reasons discussed in this final rule and in the proposed rule, we are
finalizing as proposed, without modification, our wage index cap policy
and the associated budget neutrality adjustment. We will apply a 5-
percent cap on any decrease to a hospital's wage index from its wage
index in the prior FY, regardless of the circumstances causing the
decline. A hospital's wage index for FY 2023 will not be less than 95
percent of its final wage index for FY 2022, and for subsequent years,
a hospital's wage index will not be less than 95 percent of its final
wage index for the prior FY. For example, a hospital that received a
wage index of 1.0000 on September 30, 2022 could not receive a wage
index of less than 0.9500 for FY 2023. If a hospital's prior FY wage
index is calculated with the application of the 5-percent cap, the
following year's wage index will not be less than 95 percent of the
hospital's capped wage index in the prior FY. Except for newly opened
hospitals, we will apply the cap for a FY using the final wage index
applicable to the hospital on the last day of the prior FY. A newly
opened hospital would be paid the wage index for the area in which it
is geographically located for its first full or partial fiscal year,
and it would not receive a cap for that first year because it would not
have been assigned a wage index in the prior year.
We are adding a new paragraph at 42 CFR 412.64(h)(7) to state that
beginning with fiscal year 2023, if CMS determines that a hospital's
wage index value for a fiscal year would decrease by more than 5
percent as compared to the hospital's wage index value for the prior
fiscal year, CMS limits the decrease to 5 percent for the fiscal year.
We will apply the cap in a budget neutral manner through a national
adjustment to the standardized amount each fiscal year. Specifically,
we will apply a budget neutrality adjustment to ensure that estimated
aggregate payments under our wage index cap policy for hospitals that
would have a decrease in their wage indexes for the upcoming fiscal
year of more than 5 percent would equal what estimated aggregate
payments would have been without the wage index cap policy. We note
that the budget neutrality adjustment has been updated based on the
final rule data. We refer readers to the Addendum of this final rule
for further information regarding the budget neutrality calculations.
IV. Payment Adjustment for Medicare Disproportionate Share Hospitals
(DSHs) for FY 2023 (Sec. 412.106)
A. General Discussion
Section 1886(d)(5)(F) of the Act provides for additional Medicare
payments to subsection (d) hospitals that serve a significantly
disproportionate number of low-income patients. The Act specifies two
methods by which a hospital may qualify for the Medicare
disproportionate share hospital (DSH) adjustment. Under the first
method, hospitals that are located in an urban area and have 100 or
more beds may receive a Medicare DSH payment adjustment if the hospital
can demonstrate that, during its cost reporting period, more than 30
percent of its net inpatient care revenues are derived from State and
local government payments for care furnished to patients with low
incomes. This method is commonly referred to as the ``Pickle method.''
The second method for qualifying for the DSH payment adjustment, which
is the most common, is based on a complex statutory formula under which
the DSH payment adjustment is based on the hospital's
[[Page 49022]]
geographic designation, the number of beds in the hospital, and the
level of the hospital's disproportionate patient percentage (DPP). A
hospital's DPP is the sum of two fractions: the ``Medicare fraction''
and the ``Medicaid fraction.'' The Medicare fraction (also known as the
``SSI fraction'' or ``SSI ratio'') is computed by dividing the number
of the hospital's inpatient days that are furnished to patients who
were entitled to both Medicare Part A and Supplemental Security Income
(SSI) benefits by the hospital's total number of patient days furnished
to patients entitled to benefits under Medicare Part A. The Medicaid
fraction is computed by dividing the hospital's number of inpatient
days furnished to patients who, for such days, were eligible for
Medicaid, but were not entitled to benefits under Medicare Part A, by
the hospital's total number of inpatient days in the same period.
[GRAPHIC] [TIFF OMITTED] TR10AU22.119
Because the DSH payment adjustment is part of the IPPS, the
statutory references to ``days'' in section 1886(d)(5)(F) of the Act
have been interpreted to apply only to hospital acute care inpatient
days. Regulations located at 42 CFR 412.106 govern the Medicare DSH
payment adjustment and specify how the DPP is calculated as well as how
beds and patient days are counted in determining the Medicare DSH
payment adjustment. Under Sec. 412.106(a)(1)(i), the number of beds
for the Medicare DSH payment adjustment is determined in accordance
with bed counting rules for the IME adjustment under Sec. 412.105(b).
Section 3133 of the Patient Protection and Affordable Care Act, as
amended by section 10316 of the same Act and section 1104 of the Health
Care and Education Reconciliation Act (Pub. L. 111-152), added a
section 1886(r) to the Act that modifies the methodology for computing
the Medicare DSH payment adjustment. (For purposes of this final rule,
we refer to these provisions collectively as section 3133 of the
Affordable Care Act.) Beginning with discharges in FY 2014, hospitals
that qualify for Medicare DSH payments under section 1886(d)(5)(F) of
the Act receive 25 percent of the amount they previously would have
received under the statutory formula for Medicare DSH payments. This
provision applies equally to hospitals that qualify for DSH payments
under section 1886(d)(5)(F)(i)(I) of the Act and those hospitals that
qualify under the Pickle method under section 1886(d)(5)(F)(i)(II) of
the Act.
The remaining amount, equal to an estimate of 75 percent of what
otherwise would have been paid as Medicare DSH payments, reduced to
reflect changes in the percentage of individuals who are uninsured, is
available to make additional payments to each hospital that qualifies
for Medicare DSH payments and that has uncompensated care. The payments
to each hospital for a fiscal year are based on the hospital's amount
of uncompensated care for a given time period relative to the total
amount of uncompensated care for that same time period reported by all
hospitals that receive Medicare DSH payments for that fiscal year.
Since FY 2014, section 1886(r) of the Act has required that
hospitals that are eligible for DSH payments under section
1886(d)(5)(F) of the Act receive 2 separately calculated payments:
[GRAPHIC] [TIFF OMITTED] TR10AU22.120
[[Page 49023]]
Specifically, section 1886(r)(1) of the Act provides that the
Secretary shall pay to such subsection (d) hospital (including a Pickle
hospital) 25 percent of the amount the hospital would have received
under section 1886(d)(5)(F) of the Act for DSH payments, which
represents the empirically justified amount for such payment, as
determined by the MedPAC in its March 2007 Report to Congress. We refer
to this payment as the ``empirically justified Medicare DSH payment.''
In addition to this empirically justified Medicare DSH payment,
section 1886(r)(2) of the Act provides that, for FY 2014 and each
subsequent fiscal year, the Secretary shall pay to such subsection (d)
hospital an additional amount equal to the product of three factors.
The first factor is the difference between the aggregate amount of
payments that would be made to subsection (d) hospitals under section
1886(d)(5)(F) of the Act if subsection (r) did not apply and the
aggregate amount of payments that are made to subsection (d) hospitals
under section 1886(r)(1) of the Act for such fiscal year. Therefore,
this factor amounts to 75 percent of the payments that would otherwise
be made under section 1886(d)(5)(F) of the Act.
The second factor is, for FY 2018 and subsequent fiscal years, 1
minus the percent change in the percent of individuals who are
uninsured, as determined by comparing the percent of individuals who
were uninsured in 2013 (as estimated by the Secretary, based on data
from the Census Bureau or other sources the Secretary determines
appropriate, and certified by the Chief Actuary of CMS), and the
percent of individuals who were uninsured in the most recent period for
which data are available (as so estimated and certified), minus a
statutory adjustment of 0.2 percentage point for FYs 2018 and 2019.
The third factor is a percent that, for each subsection (d)
hospital, represents the quotient of the amount of uncompensated care
for such hospital for a period selected by the Secretary (as estimated
by the Secretary, based on appropriate data), including the use of
alternative data where the Secretary determines that alternative data
are available which are a better proxy for the costs of subsection (d)
hospitals for treating the uninsured, and the aggregate amount of
uncompensated care for all subsection (d) hospitals that receive a
payment under section 1886(r) of the Act. Therefore, this third factor
represents a hospital's uncompensated care amount for a given time
period relative to the uncompensated care amount for that same time
period for all hospitals that receive Medicare DSH payments in the
applicable fiscal year, expressed as a percent.
For each hospital, the product of these three factors represents
its additional payment for uncompensated care for the applicable fiscal
year. We refer to the additional payment determined by these factors as
the ``uncompensated care payment.'' In brief, the uncompensated care
payment for an individual hospital is determined as the product of the
following 3 factors:
[GRAPHIC] [TIFF OMITTED] TR10AU22.121
Section 1886(r) of the Act applies to FY 2014 and each subsequent
fiscal year. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50620
through 50647) and the FY 2014 IPPS interim final rule with comment
period (78 FR 61191 through 61197), we set forth our policies for
implementing the required changes to the Medicare DSH payment
methodology made by section 3133 of the Affordable Care Act for FY
2014. In those rules, we noted that, because section 1886(r) of the Act
modifies the payment required under section 1886(d)(5)(F) of the Act,
it affects only the DSH payment under the operating IPPS. It does not
revise or replace the capital IPPS DSH payment provided under the
regulations at 42 CFR part 412, subpart M, which was established
through the exercise of the Secretary's discretion in implementing the
capital IPPS under section 1886(g)(1)(A) of the Act.
Finally, section 1886(r)(3) of the Act provides that there shall be
no administrative or judicial review under section 1869, section 1878,
or otherwise of any estimate of the Secretary for purposes of
determining the factors described in section 1886(r)(2) of the Act or
of any period selected by the Secretary for the purpose of determining
those factors. Therefore, there is no administrative or judicial review
of the estimates developed for purposes of applying the three factors
used to determine uncompensated care payments, or the periods selected
in order to develop such estimates.
B. Eligibility for Empirically Justified Medicare DSH Payments and
Uncompensated Care Payments
As explained earlier, the payment methodology under section 3133 of
the Affordable Care Act applies to ``subsection (d) hospitals'' that
would otherwise receive a DSH payment made under section 1886(d)(5)(F)
of the Act. Therefore, hospitals must receive empirically justified
Medicare DSH payments in a fiscal year in order to receive an
additional Medicare uncompensated care payment for that year.
Specifically, section 1886(r)(2) of the Act states that, in addition to
the payment made to a subsection (d) hospital under section 1886(r)(1)
of the Act, the Secretary shall pay to such subsection (d) hospitals an
additional amount. Because section 1886(r)(1) of the Act refers to
empirically justified Medicare DSH payments, the additional payment
under section 1886(r)(2) of the Act is limited to hospitals that
receive empirically justified Medicare DSH payments in accordance with
section
[[Page 49024]]
1886(r)(1) of the Act for the applicable fiscal year.
In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50622) and the FY
2014 IPPS interim final rule with comment period (78 FR 61193), we
provided that hospitals that are not eligible to receive empirically
justified Medicare DSH payments in a fiscal year will not receive
uncompensated care payments for that year. We also specified that we
would make a determination concerning eligibility for interim
uncompensated care payments based on each hospital's estimated DSH
status for the applicable fiscal year (using the most recent data that
are available). For the proposed rule, we estimated DSH status for all
hospitals using the most recent available SSI ratios and information
from the most recent available Provider Specific File. We noted FY 2019
SSI ratios available on the CMS website were the most recent available
SSI ratios at the time of developing the proposed rule. If more recent
data on DSH eligibility become available before the final rule, we
stated that we would use such data in the final rule. For this FY 2023
IPPS/LTCH PPS final rule, the FY 2020 SSI ratios were available at the
time of developing this final rule. Our final determination of a
hospital's eligibility for uncompensated care payments will be based on
the hospital's actual DSH status at cost report settlement for FY 2023.
In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50622) and in the
rulemaking for subsequent fiscal years, we have specified our policies
for several specific classes of hospitals within the scope of section
1886(r) of the Act. In the FY 2023 IPPS/LTCH PPS proposed rule, we
discussed our specific policies regarding eligibility to receive
empirically justified Medicare DSH payments and uncompensated care
payments for FY 2023 with respect to the following hospitals.
Eligible hospitals include the following:
Subsection (d) Puerto Rico hospitals that are eligible for
DSH payments also are eligible to receive empirically justified
Medicare DSH payments and uncompensated care payments under section
1886(r) of the Act (78 FR 50623 and 79 FR 50006).
SCHs that are paid under the IPPS Federal rate receive
interim payments based on what we estimate and project their DSH status
to be prior to the beginning of the Federal fiscal year (based on the
best available data at that time) subject to settlement through the
cost report, and if they receive interim empirically justified Medicare
DSH payments in a fiscal year, they also will receive interim
uncompensated care payments for that fiscal year on a per discharge
basis, subject as well to settlement through the cost report. Final
eligibility determinations will be made at the end of the cost
reporting period at settlement, and both interim empirically justified
Medicare DSH payments and uncompensated care payments will be adjusted
accordingly (78 FR 50624 and 79 FR 50007).
Medicare-dependent, small rural hospitals (MDHs) are paid
based on the IPPS Federal rate or, if higher, the IPPS Federal rate
plus 75 percent of the amount by which the Federal rate is exceeded by
the updated hospital-specific rate from certain specified base years
(76 FR 51684). The IPPS Federal rate that is used in the MDH payment
methodology is the same IPPS Federal rate that is used in the SCH
payment methodology. Because MDHs are paid based on the IPPS Federal
rate, they continue to be eligible to receive empirically justified
Medicare DSH payments and uncompensated care payments if their DPP is
at least 15 percent, and we apply the same process to determine MDHs'
eligibility for interim empirically justified Medicare DSH and interim
uncompensated care payments as we do for all other IPPS hospitals.
Section 50205 of the Bipartisan Budget Act of 2018 (Pub. L. 115-
123), enacted on February 9, 2018, extended the MDH program for
discharges on or after October 1, 2017, through September 30, 2022. We
note that there has not been legislation at the time of development of
this final rule that would extend the MDH program beyond September 30,
2022. However, if the MDH program were to be extended beyond its
current expiration date, similar to how it was extended under the
Bipartisan Budget Act of 2018, we would continue to make a
determination concerning an MDH's eligibility for interim uncompensated
care payments based on the hospital's estimated DSH status for the
applicable fiscal year.
IPPS hospitals that elect to participate in the Bundled
Payments for Care Improvement Advanced (BPCI Advanced) model starting
October 1, 2018, will continue to be paid under the IPPS and,
therefore, are eligible to receive empirically justified Medicare DSH
payments and uncompensated care payments. The BPCI Advanced Model's
final performance year will end on December 31, 2023. For further
information regarding the BPCI Advanced model, we refer readers to the
CMS website at https://innovation.cms.gov/initiatives/bpci-advanced/.
IPPS hospitals that participate in the Comprehensive Care
for Joint Replacement Model (80 FR 73300) continue to be paid under the
IPPS and, therefore, are eligible to receive empirically justified
Medicare DSH payments and uncompensated care payments. We refer the
reader to the interim final rule with request for comments that
appeared in the November 6, 2020, Federal Register for a discussion of
the Model (85 FR 71167 through 71173). In that interim final rule, we
extended the Model's Performance Year 5 to September 30, 2021. In a
subsequent final rule that appeared in the May 3, 2021 Federal Register
(86 FR 23496), we further extended the Model for an additional three
performance years. The Model's Performance Year 8 will end on December
31, 2024.
Ineligible hospitals include the following:
Maryland hospitals are not eligible to receive empirically
justified Medicare DSH payments and uncompensated care payments under
the payment methodology of section 1886(r) of the Act because they are
not paid under the IPPS. As discussed in the FY 2019 IPPS/LTCH PPS
final rule (83 FR 41402 through 41403), CMS and the State have entered
into an agreement to govern payments to Maryland hospitals under a new
payment model, the Maryland Total Cost of Care (TCOC) Model, which
began on January 1, 2019. Under the Maryland TCOC Model, Maryland
hospitals will not be paid under the IPPS in FY 2023, and will be
ineligible to receive empirically justified Medicare DSH payments and
uncompensated care payments under section 1886(r) of the Act.
Sole community hospitals (SCHs) that are paid under their
hospital-specific rate are not eligible for Medicare DSH payments.
Hospitals participating in the Rural Community Hospital
Demonstration Program are not eligible to receive empirically justified
Medicare DSH payments and uncompensated care payments under section
1886(r) of the Act because they are not paid under the IPPS (78 FR
50625 and 79 FR 50008). The Rural Community Hospital Demonstration
Program was originally authorized for a 5-year period by section 410A
of the Medicare Prescription Drug, Improvement, and Modernization Act
of 2003 (MMA) (Pub. L. 108-173), and extended for another 5-year period
by sections 3123 and 10313 of the Affordable Care Act (Pub. L. 114-
255). The period of performance for this 5-
[[Page 49025]]
year extension period ended December 31, 2016. Section 15003 of the
21st Century Cures Act (Pub. L. 114-255), enacted December 13, 2016,
again amended section 410A of Public Law 108-173 to require a 10-year
extension period (in place of the 5-year extension required by the
Affordable Care Act), therefore requiring an additional 5-year
participation period for the demonstration program. Section 15003 of
Public Law 114-255 also required a solicitation for applications for
additional hospitals to participate in the demonstration program. The
period of performance for this 5-year extension period ended December
31, 2021. The Consolidated Appropriations Act, 2021 (Pub. L. 116-260)
amended section 410A of Public Law 108-173 to extend the Rural
Community Hospital Demonstration Program for an additional 5-year
period. The period of participation for the last hospital in the
demonstration under this most recent legislative authorization would
extend until June 30, 2028, as outlined in section V.K. of the preamble
of this final rule. Under the payment methodology that applies during
the third 5-year extension period for the demonstration program,
participating hospitals do not receive empirically justified Medicare
DSH payments, and they are also excluded from receiving interim and
final uncompensated care payments. At the time of development of this
final rule, we believe 26 hospitals may participate in the
demonstration program at the start of FY 2023.
We received no comments on our policy of using the best available
data regarding a hospital's estimated DSH status for purposes of
determining eligibility for interim uncompensated care payments for FY
2023. Our final determination of a hospital's eligibility for
uncompensated care payments for FY 2023 will continue to be based on
the hospital's actual DSH status at cost report settlement for the
payment year.
C. Empirically Justified Medicare DSH Payments
As we have discussed earlier, section 1886(r)(1) of the Act
requires the Secretary to pay 25 percent of the amount of the Medicare
DSH payment that would otherwise be made under section 1886(d)(5)(F) of
the Act to a subsection (d) hospital. Because section 1886(r)(1) of the
Act merely requires the program to pay a designated percentage of these
payments, without revising the criteria governing eligibility for DSH
payments or the underlying payment methodology, we stated in the FY
2014 IPPS/LTCH PPS final rule that we did not believe that it was
necessary to develop any new operational mechanisms for making such
payments. Therefore, in the FY 2014 IPPS/LTCH PPS final rule (78 FR
50626), we implemented this provision by advising Medicare
Administrative Contractors (MACs) to simply adjust the interim claim
payments to the requisite 25 percent of what would have otherwise been
paid. We also made corresponding changes to the hospital cost report so
that these empirically justified Medicare DSH payments can be settled
at the appropriate level at the time of cost report settlement. We
provided more detailed operational instructions and cost report
instructions following issuance of the FY 2014 IPPS/LTCH PPS final rule
that are available on the CMS website at https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2014-Transmittals-Items/R5P240.html.
We received public comments that were outside the scope of this
proposed rule. Many of these comments related to structural changes to
the DSH program. For example, a commenter recommended creating new
Conditions of Participation and Conditions of Coverage related to the
DSH program. Because we consider these public comments to be outside
the scope of the proposed rule, we are not addressing them in this
final rule.
D. Uncompensated Care Payments
As we discussed earlier, section 1886(r)(2) of the Act provides
that, for each eligible hospital in FY 2014 and subsequent years, the
uncompensated care payment is the product of three factors. These three
factors represent our estimate of 75 percent of the amount of Medicare
DSH payments that would otherwise have been paid, an adjustment to this
amount for the percent change in the national rate of uninsurance
compared to the rate of uninsurance in 2013, and each eligible
hospital's estimated uncompensated care amount relative to the
estimated uncompensated care amount for all eligible hospitals. In this
section of this final rule, we discuss the data sources and
methodologies for computing each of these factors, our final policies
for FYs 2014 through 2022, and our final policies for FY 2023.
1. Calculation of Factor 1 for FY 2023
Section 1886(r)(2)(A) of the Act establishes Factor 1 in the
calculation of the uncompensated care payment. Section 1886(r)(2)(A) of
the Act states that this factor is equal to the difference between: (1)
the aggregate amount of payments that would be made to subsection (d)
hospitals under section 1886(d)(5)(F) of the Act if section 1886(r) of
the Act did not apply for such fiscal year (as estimated by the
Secretary); and (2) the aggregate amount of payments that are made to
subsection (d) hospitals under section 1886(r)(1) of the Act for such
fiscal year (as so estimated).
Therefore, section 1886(r)(2)(A)(i) of the Act represents the
estimated Medicare DSH payments that would have been made under section
1886(d)(5)(F) of the Act if section 1886(r) of the Act did not apply
for such fiscal year. Under a prospective payment system, we would not
know the precise aggregate Medicare DSH payment amount that would be
paid for a Federal fiscal year until cost report settlement for all
IPPS hospitals is completed, which occurs several years after the end
of the Federal fiscal year. Therefore, section 1886(r)(2)(A)(i) of the
Act provides authority to estimate this amount, by specifying that, for
each fiscal year to which the provision applies, such amount is to be
estimated by the Secretary. Similarly, section 1886(r)(2)(A)(ii) of the
Act represents the estimated empirically justified Medicare DSH
payments to be made in a fiscal year, as prescribed under section
1886(r)(1) of the Act. Again, section 1886(r)(2)(A)(ii) of the Act
provides authority to estimate this amount. Therefore, Factor 1 is the
difference between our estimates of: (1) the amount that would have
been paid in Medicare DSH payments for the fiscal year, in the absence
of the new payment provision; and (2) the amount of empirically
justified Medicare DSH payments that are made for the fiscal year,
which takes into account the requirement to pay 25 percent of what
would have otherwise been paid under section 1886(d)(5)(F) of the Act.
In other words, this factor represents our estimate of 75 percent (100
percent minus 25 percent) of our estimate of Medicare DSH payments that
would otherwise be made, in the absence of section 1886(r) of the Act,
for the fiscal year.
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28383 through
28385), in order to determine Factor 1 in the uncompensated care
payment formula for FY 2023, we proposed to continue the policy
established in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50628
through 50630) and in the FY 2014 IPPS interim final rule with comment
period (78 FR 61194) of determining Factor 1 by developing estimates of
both the aggregate amount of Medicare DSH payments that would be made
in the absence of section 1886(r)(1) of the Act and the aggregate
amount of empirically justified
[[Page 49026]]
Medicare DSH payments to hospitals under section 1886(r)(1) of the Act.
Consistent with the policy that has applied in previous years, we
proposed that these estimates would not be revised or updated
subsequent to the publication of our final projections in this FY 2023
IPPS/LTCH PPS final rule.
Therefore, in order to determine the two elements of proposed
Factor 1 for FY 2023 (Medicare DSH payments prior to the application of
section 1886(r)(1) of the Act, and empirically justified Medicare DSH
payments after application of section 1886(r)(1) of the Act), for this
final rule, we used the most recently available projections of Medicare
DSH payments for the fiscal year, as calculated by CMS' Office of the
Actuary (OACT) using the most recently filed Medicare hospital cost
reports with Medicare DSH payment information and the most recent
Medicare DSH patient percentages and Medicare DSH payment adjustments
provided in the IPPS Impact File. The determination of the amount of
DSH payments is partially based on OACT's Part A benefits projection
model. One of the results of this model is inpatient hospital spending.
Projections of DSH payments require projections for expected increases
in utilization and case-mix. The assumptions that were used in making
these projections and the resulting estimates of DSH payments for FY
2020 through FY 2023 were discussed in the proposed rule in the table
titled ``Factors Applied for FY 2020 through FY 2023 to Estimate
Medicare DSH Expenditures Using FY 2019 Baseline'' (87 FR 28384).
For purposes of calculating the proposed Factor 1 and modeling the
impact of the FY 2023 IPPS/LTCH PPS proposed rule, we used the Office
of the Actuary's January 2022 Medicare DSH estimates, which were based
on data from the September 2021 update of the Medicare Hospital Cost
Report Information System (HCRIS) and the FY 2022 IPPS/LTCH PPS final
rule IPPS Impact File, published in conjunction with the publication of
the FY 2022 IPPS/LTCH PPS final rule. Because SCHs that are projected
to be paid under their hospital-specific rate are excluded from the
application of section 1886(r) of the Act, these hospitals also were
excluded from the January 2022 Medicare DSH estimates. Furthermore,
because section 1886(r) of the Act specifies that the uncompensated
care payment is in addition to the empirically justified Medicare DSH
payment (25 percent of DSH payments that would be made without regard
to section 1886(r) of the Act), Maryland hospitals, which are not
eligible to receive DSH payments, were also excluded from the Office of
the Actuary's January 2022 Medicare DSH estimates. The 26 hospitals
that are anticipated to participate in the Rural Community Hospital
Demonstration Program in FY 2023 were also excluded from these
estimates, because under the payment methodology that applies during
the third 5-year extension period, these hospitals are not eligible to
receive empirically justified Medicare DSH payments or uncompensated
care payments.
For the proposed rule, using the data sources as previously
discussed, the Office of the Actuary's January 2022 estimate of
Medicare DSH payments for FY 2023 without regard to the application of
section 1886(r)(1) of the Act, was approximately $13.266 billion.
Therefore, also based on the January 2022 estimate, the estimate of
empirically justified Medicare DSH payments for FY 2023, with the
application of section 1886(r)(1) of the Act, was approximately $3.316
billion (or 25 percent of the total amount of estimated Medicare DSH
payments for FY 2023). Under Sec. 412.106(g)(1)(i) of the regulations,
Factor 1 is the difference between these two OACT estimates. Therefore,
in the proposed rule, we proposed that Factor 1 for FY 2023 would be
$9,949,258,556.56, which was equal to 75 percent of the total amount of
estimated Medicare DSH payments for FY 2023 ($13,266 million minus
$3,316 million). In the FY 2023 IPPS/LTCH PPS proposed rule, we noted
that consistent with our approach in previous rulemakings, OACT
intended to use more recent data that may become available for purposes
of projecting the final Factor 1 estimates for this FY 2023 IPPS/LTCH
PPS final rule.
As we noted in the FY 2023 IPPS/LTCH PPS proposed rule, the Factor
1 estimates for proposed rules are generally consistent with the
economic assumptions and actuarial analysis used to develop the
President's Budget estimates under current law, and the Factor 1
estimates for the final rules are generally consistent with those used
for the Midsession Review of the President's Budget. As we have in the
past, for additional information on the development of the President's
Budget, we refer readers to the Office of Management and Budget website
at https://www.whitehouse.gov/omb/budget. Consistent with historical
practice, we indicated that we expected that the Midsession Review
would have updated economic assumptions and actuarial analysis, which
would be used for the development of Factor 1 estimates in the final
rule.
For a general overview of the principal steps involved in
projecting future inpatient costs and utilization, we refer readers to
the ``2021 Annual Report of the Boards of Trustees of the Federal
Hospital Insurance and Federal Supplementary Medical Insurance Trust
Funds'' available on the CMS website at https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/reportstrustfunds under ``Downloads.'' We note that the annual reports
of the Medicare Boards of Trustees to Congress represent the Federal
Government's official evaluation of the financial status of the
Medicare Program. The actuarial projections contained in these reports
are based on numerous assumptions regarding future trends in program
enrollment, utilization and costs of health care services covered by
Medicare, as well as other factors affecting program expenditures. In
addition, although the methods used to estimate future costs based on
these assumptions are complex, they are subject to periodic review by
independent experts to ensure their validity and reasonableness.
We also refer readers to the 2018 Actuarial Report on the Financial
Outlook for Medicaid for a discussion of general issues regarding
Medicaid projections (available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Research/ActuarialStudies/MedicaidReport).
Comment: As in previous years, a concern and/or request expressed
by some commenters was the need for greater transparency in the
methodology used by CMS and OACT to calculate Factor 1. Several
commenters specifically requested that a detailed description of the
methodology and the data behind the assumptions be made public.
Commenters requested that this information be provided in advance of
the publication of the final rule and in the IPPS proposed rule each
year going forward, so that the data is available to replicate CMS' DSH
calculation and comment sufficiently in future years.
In particular, commenters requested further explanation regarding
the estimate of the ``Other'' factor used to estimate Medicare DSH
payments. Commenters noted that the rule did not discuss why the
``Other'' factor varies so much over successive rule making cycles.
Additionally, a commenter asserted that the lack of opportunity
afforded to hospitals to review the data used in rulemaking is in
violation of the Administrative Procedure Act and
[[Page 49027]]
expressed concerns about the lack of transparency in how Factor 1 is
calculated, arguing that hospitals cannot meaningfully comment on the
methodology given the lack of details. In particular, this commenter
asserted that the proposed rule neither provided sufficient details nor
an explanation of the treatment of Medicaid expansions in the
calculation for Factor 1.
Response: We thank the commenters for their input. We disagree with
commenters' assertion regarding the lack of transparency with respect
to the methodology and assumptions used in the calculation of Factor 1.
As explained in the FY 2023 IPPS/LTCH PPS proposed rule and in this
section of this final rule, we have been and continue to be transparent
about the methodology and data used to estimate Factor 1. Regarding the
commenters who reference the Administrative Procedure Act, we note
that, under the Administrative Procedure Act, a proposed rule is
required to include either the terms or substance of the proposed rule
or a description of the subjects and issues involved. In this case, the
FY 2023 IPPS/LTCH PPS proposed rule did include a detailed discussion
of our proposed Factor 1 methodology and the data sources that would be
used in making our final estimate. Accordingly, we believe interested
parties were able to meaningfully comment on our proposed estimate of
Factor 1.
To provide context, we note that Factor 1 is not estimated in
isolation from other projections made by OACT. The Factor 1 estimates
for the proposed rules are generally consistent with the economic
assumptions and actuarial analyses used to develop the President's
Budget estimates under current law, and the Factor 1 estimates for the
final rule are generally consistent with those used for the Midsession
Review of the President's Budget. As we have in the past, for
additional information on the development of the President's Budget, we
refer readers to the Office of Management and Budget website at:
https://www.whitehouse.gov/omb/budget. For additional information on
the specific economic assumptions used in the Midsession Review of the
President's FY 2023 Budget, we refer readers to the ``Midsession Review
of the President's FY 2023 Budget'' also available on the Office of
Management and Budget website at: https://www.whitehouse.gov/omb/budget. We recognize that our reliance on the economic assumptions and
actuarial analyses used to develop the President's Budget and the
Midsession Review of the President's Budget in estimating Factor 1 has
an impact on hospitals, health systems, and other impacted parties who
wish to replicate the Factor 1 calculation, such as modeling the
relevant Medicare Part A portion of the budget. Yet, we believe
commenters are able to meaningfully comment on our proposed estimate of
Factor 1 without replicating the budget.
For a general overview of the principal steps involved in
projecting future inpatient costs and utilization, we refer readers to
the ``2022 Annual Report of the Boards of Trustees of the Federal
Hospital Insurance and Federal Supplementary Medical Insurance Trust
Funds'' available on the CMS website at: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ReportsTrustFunds/ under ``Downloads.'' We note that the
annual reports of the Medicare Boards of Trustees to Congress represent
the Federal Government's official evaluation of the financial status of
the Medicare Program. The actuarial projections contained in these
reports are based on numerous assumptions regarding future trends in
program enrollment, utilization and costs of health care services
covered by Medicare, as well as other factors affecting program
expenditures. In addition, although the methods used to estimate future
costs based on these assumptions are complex, they are subject to
periodic review by independent experts to ensure their validity and
reasonableness.
We also refer readers to the 2018 Actuarial Report on the Financial
Outlook for Medicaid which is available on the CMS website at: https://www.cms.gov/files/document/2018-report.pdf for a discussion of general
issues regarding Medicaid projections. Additionally, as described in
more detail later in this section, in the FY 2023 IPPS/LTCH PPS
proposed rule, we included information regarding the data sources,
methods, and assumptions employed by the actuaries in determining the
OACT's estimate of Factor 1. In summary, we indicated the historical
HCRIS data update OACT used to identify Medicare DSH payments. We
explained that the most recent Medicare DSH payment adjustments
provided in the IPPS Impact File were used, and we provided the
components of all update factors that were applied to the historical
data to estimate the Medicare DSH payments for the upcoming fiscal
year, along with the associated rationale and assumptions. This
discussion also included a description of the ``Other'' and
``Discharges'' assumptions, as well as additional information regarding
how we address Medicaid and CHIP expansion.
For further information on our assumptions regarding Medicaid
expansion in the Factor 1 calculation, we provide a discussion of more
recent estimates and assumptions regarding the Medicaid expansion as
part of the discussion of the final Factor 1 for FY 2023. This
discussion also incorporates the estimated impact of the COVID-19
public health emergency (PHE.)
Comment: Many commenters questioned the proposed rule's estimate of
the ``Discharge'' component of the Factor 1 calculation. Commenters
requested clarity on the Factor 1 calculations, which assume small
increases in discharge volume for FY 2022 and FY 2023.
Commenters noted that they are seeing trends that indicate that FY
2022 and FY 2023 discharge volumes, even though lower than pre-PHE
levels, will continue to increase substantially. Some commenters urged
CMS to reflect the same assumptions that the agency described in the
``April 2022 Announcement of CY 2023 Medicare Advantage Capitation
Rates and Part C and Part D Payment Policies,'' where the agency made
assumptions that Medicare ``utilization will begin to rebound.'' Other
commenters referenced a Kaufman Hall study, and stated that adjusted
national patient volume has increased by 18 percent from February 2022
to March 2022. A commenter referred to their own analysis of Medicare-
Fee-For-service (FFS) claims data from the Chronic Condition Warehouse
(CCW), which indicated that non-COVID-19 inpatient hospital discharge
volume increased 22 percent from February to March 2022. Other
commenters provided anecdotal data from their own hospitals and service
regions that show continued sustained volumes in 2022. These commenters
urged CMS to carefully monitor changes in discharge volume when
estimating Factor 1.
Commenters also urged CMS to use a later update to the claims data
to capture more of the increases in utilization that are anticipated
for FY 2022. Commenters noted that the ``Discharge'' factor used by the
OACT in estimating DSH expenditures was based on the December 2021
update of the MedPAR file, which includes data impacted by the PHE from
FY 2021 and the first three months of FY 2022. Some commenters
requested that CMS adjust the data used in the Factor 1 calculation for
COVID-19 PHE impacts while others suggested that CMS exclude data from
the latter parts of CY 2021 and early CY
[[Page 49028]]
2022. Other commenters urged CMS to consider excluding FY 2020 and FY
2021 discharges from the FY 2023 Factor 1 calculation, as data from
those years include atypical trends in Medicare discharges due to the
COVID-19 PHE.
Commenters pointed out that omitting FY 2020 and FY 2021 data would
be consistent with CMS' exclusion of FY 2020 data in setting FY 2022
payment rates and the agency's proposal to exclude FY 2020 data from
the per-discharge calculation in the FY 2023 IPPS/LTCH PPS proposed
rule. Further, some commenters noted that the completion factor CMS
used to estimate discharge volumes for FY 2021 and FY 2022 may not
fully account for discharges due to billing delays as a result of PHE-
related staffing shortages.
Finally, two commenters requested that for the FY 2024 IPPS/LTCH
PPS proposed rule, CMS consider using the latest available data for the
factors used to estimate Medicare DSH expenditures for purposes of
calculating Factor 1 to avoid as much change in the estimate of Factor
1 between the proposed and final rules for FY 2024.
Some commenters also raised concerns about the ``Case Mix'' update
factor used in the proposed FY 2023 Factor 1 calculation. Commenters
stated that the proposed ``Case Mix'' update factor underestimates the
complexity of patients returning to seek care following postponement or
deferral of care during the COVID-19 PHE. Commenters also stated that
CMS was using assumptions that are inconsistent with those that were
used to develop the 2023 Medicare Advantage capitation payments, where
the agency indicated an expectation that utilization will rebound in
2022 and finalized a risk score increase of 3.5 percentage points with
the underlying assumption that patients put off seeking medical care
throughout the PHE. Other commenters cited data from Kaufman Hall that
indicate that hospitals are beginning to see more complex patients as
shown by a nearly 5 percent increase in the average hospital length of
stay in 2022 as compared to 2021.
Response: We thank the commenters for their input on the impact of
the COVID-19 PHE on the factors used to estimate DSH payments for FY
2023. In updating our estimate of Factor 1 for this final rule, we
considered, as appropriate, the same set of factors that we used in the
proposed rule, which reflects the impact of the COVID-19 PHE. We then
updated estimates for the ``Discharges'' and ``Case Mix'' factors to
incorporate the latest available data. We provide further details on
the updated Factor 1 estimate and data sources as part of the
discussion of the final Factor 1 estimate for FY 2023 in this section
of the rule.
Regarding the comments requesting that we exclude and/or mitigate
the impacts of the COVID-19 PHE when estimating Factor 1 for FY 2023,
we note that the statute specifies that Factor 1 is based on the amount
of disproportionate share payments that would otherwise be made to
subsection (d) hospitals for the fiscal year. As discussed further in
this section, OACT's estimates of Medicare DSH payments used in the
development of Factor 1, reflect the estimated impact of the COVID-19
PHE on DSH payments during FY 2023.
We also note that, with regard to the commenters' questions and
concerns about the use of completion factors to adjust preliminary
data, OACT assumed a discharge completion factor of 0 percent for FY
2020 and 0 percent for FY 2021. We believe these assumptions are
consistent with historical patterns of completion factors that have
been determined for discharges and appropriately account for incomplete
claims data. We do not believe that excluding data from certain periods
is necessary to estimate DSH payments during FY 2023 for purposes of
the Factor 1 calculation, as required by the statute.
Regarding the comments requesting that CMS apply the same
assumptions the agency made when setting Medicare Advantage payment
rates, we note that Medicare Advantage and Medicare FFS are distinct
programs. Accordingly, the estimates for the ``Discharges'' and ``Case
Mix'' factors used to estimate Medicare DSH expenditures incorporate
OACT's analyses of ``Discharges'' and ``Case Mix'' using only claims
from the Medicare FFS program rather than claims from the Medicare
Advantage program.
In response to commenters' request that CMS use the latest
available estimates of historical data to avoid as much change in the
DSH Factor 1 estimate between the proposed and final rules for FY 2024,
we believe that the use of the most recent available data at the time
of the proposed and final rulemaking is appropriate to calculate Factor
1 and consistent with our approach in previous rulemakings. In this
final rule, OACT has updated the estimate of Factor 1 with more recent
economic assumptions and actuarial analyses.
Comment: Commenters expressed concern regarding the proposed $800
million reduction in the amount available to make uncompensated care
payments in FY 2023 compared to FY 2022. Commenters stated that this
reduction does not align with CMS' objective to reduce healthcare
inequities as the reduction disproportionately impacts safety-net
hospitals, which primarily serve low income and vulnerable populations.
Response: The statute specifies that Factor 1 is based on the
amount of disproportionate share payments that would otherwise be made
to subsection (d) hospitals for the fiscal year. Because our estimate
of Factor 1 is based on the best available data regarding the amount of
DSH payments that would otherwise be made during FY 2023, we believe it
is appropriate and consistent with the requirements of the statute.
After consideration of the public comments we received, we are
finalizing, as proposed, the methodology for calculating Factor 1 for
FY 2023. We discuss the resulting Factor 1 amount for FY 2023 in this
section. For this final rule, OACT used the most recently submitted
Medicare cost report data from the March 31, 2022, update of HCRIS to
identify Medicare DSH payments and the most recent Medicare DSH payment
adjustments provided in the Impact File published in conjunction with
the publication of the FY 2023 IPPS/LTCH PPS final rule and applied
update factors and assumptions for future changes in utilization and
case-mix to estimate Medicare DSH payments for the upcoming fiscal
year.
The June 2022 OACT estimate for Medicare DSH payments for FY 2023,
without regard to the application of section 1886(r)(1) of the Act, was
approximately $13.949 billion. This estimate excluded Maryland
hospitals participating in the Maryland All-Payer Model, hospitals
participating in the Rural Community Hospital Demonstration, and SCHs
paid under their hospital-specific payment rate. Therefore, based on
this June 2022 estimate, the estimate of empirically justified Medicare
DSH payments for FY 2023, with the application of section 1886(r)(1) of
the Act, was approximately $3.487 billion (or 25 percent of the total
amount of estimated Medicare DSH payments for FY 2023). Under Sec.
412.106(g)(1)(i) of the regulations, Factor 1 is the difference between
these two OACT estimates. Therefore, the final Factor 1 for FY 2023 is
$10,461,731,029.40, which is equal to 75 percent of the total amount of
estimated Medicare DSH payments for FY 2023 ($13,948,974,705.87 minus
$3,487,243,676.47).
The Office of the Actuary's estimates of DSH expenditures for FY
2023 for this final rule began with a baseline of $13.814 billion in
Medicare DSH
[[Page 49029]]
expenditures for FY 2019. The following table shows the factors applied
to update this baseline through the current estimate for FY 2023:
[GRAPHIC] [TIFF OMITTED] TR10AU22.122
In this table, the discharges column shows the changes in the
number of Medicare fee-for-service (FFS) inpatient hospital discharges.
The discharge figures for FY 2020 and FY 2021 are based on Medicare
claims data that have been adjusted by a completion factor to account
for incomplete claims data. We note that these claims data reflect the
impact of the pandemic. The discharge figure for FY 2022 is based on
preliminary data. The discharge figure for FY 2023 is an assumption
based on recent trends recovering back to the long-term trend and
assumptions related to how many beneficiaries will be enrolled in
Medicare Advantage (MA) plans. The discharge figures for FY 2020 to FY
2023 incorporate the actual impact and estimated future impact of the
COVID-19 pandemic. The case-mix column shows the estimated change in
case-mix for IPPS hospitals. The case-mix figures for FY 2020 and FY
2021 are based on actual claims data adjusted by a completion factor.
We note that these claims data reflect the impact of the pandemic. The
case-mix figure for FY 2022 is based on preliminary data and the case-
mix figure for FY 2023 is an assumption based on recent trends
recovering back to the long-term trend. The case-mix factor figures for
FY 2020 to FY 2023 incorporate the actual impact and estimated future
impact of the COVID-19 pandemic. The ``Other'' column shows the
increase in other factors that contribute to the Medicare DSH
estimates. These factors include the difference between the total
inpatient hospital discharges and the IPPS discharges, and various
adjustments to the payment rates that have been included over the years
but are not reflected in the other columns (such as the change in rates
for the 2-midnight stay policy and the 20 percent add-on for COVID-19
discharges). In addition, the ``Other'' column includes a factor for
the estimated changes in Medicaid enrollment. We note that this factor
also includes the estimated impacts on Medicaid enrollment from the
COVID-19 pandemic. We note that, based on the most recent available
data, Medicaid enrollment is estimated to change as follows: 2.0
percent in FY 2020, 9.5 percent in FY 2021, 4.2 percent in FY 2022, and
-5.7 percent in FY 2023. In the future, the assumptions regarding
Medicaid enrollment may change based on actual enrollment in the
States.
For a discussion of general issues regarding Medicaid projections,
we refer readers to the 2018 Actuarial Report on the Financial Outlook
for Medicaid, which is available on the CMS website at https://www.cms.gov/Research-Statistics-Data-and-Systems/Research/ActuarialStudies/MedicaidReport. We note that, in developing their
estimates of the effect of Medicaid enrollment increases on Medicare
DSH expenditures, our actuaries have assumed that the increases in the
number of Medicaid enrollees result in increases in Medicare DSH
expenditures at the same rate as historical relationships have shown.
In the future, the assumption about the average per-capita expenditures
of Medicaid beneficiaries who enrolled due to the COVID-19 pandemic may
change, given that the pandemic is still ongoing.
The following table shows the factors that are included in the
``Update'' column of the previous table:
[GRAPHIC] [TIFF OMITTED] TR10AU22.123
[[Page 49030]]
2. Calculation of Factor 2 for FY 2023
(a) Background
Section 1886(r)(2)(B) of the Act establishes Factor 2 in the
calculation of the uncompensated care payment. Section
1886(r)(2)(B)(ii) of the Act provides that, for FY 2018 and subsequent
fiscal years, the second factor is 1 minus the percent change in the
percent of individuals who are uninsured, as determined by comparing
the percent of individuals who were uninsured in 2013 (as estimated by
the Secretary, based on data from the Census Bureau or other sources
the Secretary determines appropriate, and certified by the Chief
Actuary of CMS) and the percent of individuals who were uninsured in
the most recent period for which data are available (as so estimated
and certified), minus 0.2 percentage point for FYs 2018 and 2019. In FY
2020 and subsequent fiscal years, there is no longer a reduction. We
note that, unlike section 1886(r)(2)(B)(i) of the Act, which governed
the calculation of Factor 2 for FYs 2014, 2015, 2016, and 2017, section
1886(r)(2)(B)(ii) of the Act permits the use of a data source other
than the CBO estimates to determine the percent change in the rate of
uninsurance beginning in FY 2018. In addition, for FY 2018 and
subsequent years, the statute does not require that the estimate of the
percent of individuals who are uninsured be limited to individuals who
are under 65 years of age. We proposed to use a methodology similar to
the one that was used in FY 2018 through FY 2022 to determine Factor 2
for FY 2023.
In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38197 and 38198), we
explained that we determined the data source for the rate of
uninsurance that, on balance, best meets all of our considerations and
is consistent with the statutory requirement that the estimate of the
rate of uninsurance be based on data from the Census Bureau or other
sources the Secretary determines appropriate, is the uninsured
estimates produced by OACT as part of the development of the National
Health Expenditure Accounts (NHEA). The NHEA represents the
government's official estimates of economic activity (spending) within
the health sector. The information contained in the NHEA has been used
to study numerous topics related to the health care sector, including,
but not limited to, changes in the amount and cost of health services
purchased and the payers or programs that provide or purchase these
services; the economic causal factors at work in the health sector; the
impact of policy changes, including major health reform; and
comparisons to other countries' health spending. Of relevance to the
determination of Factor 2 is that the comprehensive and integrated
structure of the NHEA creates an ideal tool for evaluating changes to
the health care system, such as the mix of the insured and uninsured,
because this information is integral to the well-established NHEA
methodology. A full description of the methodology used to develop the
NHEA is available on the CMS website at https://www.cms.gov/files/document/definitions-sources-and-methods.pdf. We note that the NHEA
estimates of uninsurance are for the total resident-based U.S.
population, including all people who usually reside in the 50 States or
the District of Columbia, but excluding individuals living in Puerto
Rico and areas under U.S. sovereignty, members of the U.S. Armed Forces
overseas, and U.S. citizens whose usual place of residence is outside
the U.S., plus a small (typically less that 0.2 percent of population)
adjustment to reflect Census undercounts. Thus, the NHEA estimates of
uninsurance are for U.S. residents of all ages and are not limited to a
specific age cohort, such as the population under the age of 65. As we
explained in the FY 2018 IPPS/LTCH PPS proposed and final rules, we
believe it is appropriate to use an estimate that reflects the rate of
uninsurance in the U.S. across all age groups. In addition, we continue
to believe that a resident-based population estimate more fully
reflects the levels of uninsurance in the U.S. that influence
uncompensated care for hospitals than an estimate that reflects only
legal residents.
The NHEA includes comprehensive enrollment estimates for total
private health insurance (PHI) (including direct and employer-sponsored
plans), Medicare, Medicaid, the Children's Health Insurance Program
(CHIP), and other public programs, and estimates of the number of
individuals who are uninsured. Estimates of total PHI enrollment are
available for 1960 through 2020, estimates of Medicaid, Medicare, and
CHIP enrollment are available for the length of the respective
programs, and all other estimates (including the more detailed
estimates of direct-purchased and employer-sponsored insurance) are
available for 1987 through 2020. The NHEA data are publicly available
on the CMS website at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/.
In order to compute Factor 2, the first metric that is needed is
the proportion of the total U.S. population that was uninsured in 2013.
In developing the estimates for the NHEA, OACT's methodology included
using the number of uninsured individuals for 1987 through 2009 based
on the enhanced Current Population Survey (CPS) from the State Health
Access Data Assistance Center (SHADAC). The CPS, sponsored jointly by
the U.S. Census Bureau and the U.S. Bureau of Labor Statistics (BLS),
is the primary source of labor force statistics for the population of
the United States. (We refer readers to the website at https://www.census.gov/programs-surveys/cps.html.) The enhanced CPS, available
from SHADAC (available at https://datacenter.shadac.org) accounts for
changes in the CPS methodology over time. OACT further adjusts the
enhanced CPS for an estimated undercount of Medicaid enrollees (a
population that is often not fully captured in surveys that include
Medicaid enrollees due to a perceived stigma associated with being
enrolled in the Medicaid program or confusion about the source of their
health insurance).
To estimate the number of uninsured individuals for 2010 through
2018, OACT extrapolates from the 2009 CPS data through 2018 using data
from the National Health Interview Survey (NHIS). The NHIS is one of
the major data collection programs of the National Center for Health
Statistics (NCHS), which is part of the Centers for Disease Control and
Prevention (CDC). The 2019 estimate was extrapolated using the 2019/
2018 trend from the American Community Survey (ACS). The 2020 estimate
was extrapolated using the 2020/2018 trend from the CPS as published by
the Census Bureau. The U.S. Census Bureau is the data collection agent
for the NHIS, the ACS, and the CPS. The results from these data sources
have been instrumental over the years in providing data to track health
status, health care access, and progress toward achieving national
health objectives. For further information regarding the NHIS, we refer
readers to the CDC website at https://www.cdc.gov/nchs/nhis/index.htm.
For further information regarding the ACS, we refer readers to the
Census Bureau's website at https://www.census.gov/programs-surveys/acs/
. For information regarding the data collection issues regarding the
2020 ACS, we refer readers to the Census Bureau's website at https://www.census.gov/newsroom/blogs/random-samplings/2021/10/pandemic-impact-on-2020-acs-1-year-data.html. Since the 2020 ACS data
[[Page 49031]]
were not available, the ACS data were not used for purposes of
estimating the number of uninsured individuals for 2020.
The next metrics needed to compute Factor 2 for FY 2023 are
projections of the rate of uninsurance in both CY 2022 and CY 2023. On
an annual basis, OACT projects enrollment and spending trends for the
coming 10-year period. The most recent projections are for 2021 through
2030. Those projections use the latest NHEA historical data, available
at the time of their construction. The NHEA projection methodology
accounts for expected changes in enrollment across all of the
categories of insurance coverage previously listed. The projected
growth rates in enrollment for Medicare, Medicaid, and CHIP are
developed to be consistent with the 2021 Medicare Trustees Report,
updated where possible with more recent data. Projected rates of growth
in enrollment for private health insurance and the uninsured are based
largely on OACT's econometric models, which rely on a set of
macroeconomic assumptions that are generally based on the 2021 Medicare
Trustees Report. Greater detail can be found in OACT's report titled
``Projections of National Health Expenditure: Methodology and Model
Specification,'' which is available on the CMS website at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/ProjectionsMethodology.pdf.
(b) Factor 2 for FY 2023
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule, using
these data sources and the previously described methodologies, OACT
estimated that the uninsured rate for the historical, baseline year of
2013 was 14 percent and for CYs 2022 and 2023 is 8.9 percent and 9.3
percent, respectively. As required by section 1886(r)(2)(B)(ii) of the
Act, the Chief Actuary of CMS has certified these estimates. We refer
readers to OACT's Memorandum on Certification of Rates of Uninsured
prepared for the FY 2023 IPPS/LTCH PPS proposed rule for further
details on the methodology and assumptions that were used in the
projection of these rates of uninsurance.\213\
---------------------------------------------------------------------------
\213\ OACT Memorandum on Certification of Rates of Uninsured.
March 28, 2022. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInPatientPPS/dsh.html.
---------------------------------------------------------------------------
As with the CBO estimates on which we based Factor 2 for fiscal
years before FY 2018, the NHEA estimates are for a calendar year. Under
the approach originally adopted in the FY 2014 IPPS/LTCH PPS final
rule, we have used a weighted average approach to project the rate of
uninsurance for each fiscal year. We continue to believe that, in order
to estimate the rate of uninsurance during a fiscal year accurately,
Factor 2 should reflect the estimated rate of uninsurance that
hospitals will experience during the fiscal year, rather than the rate
of uninsurance during only one of the calendar years that the fiscal
year spans. Accordingly, we proposed to continue to apply the weighted
average approach used in past fiscal years in order to estimate the
rate of uninsurance for FY 2023.
The OACT certified the estimate of the rate of uninsurance for FY
2023 determined using this weighted average approach to be reasonable
and appropriate for purposes of section 1886(r)(2)(B)(ii) of the Act.
In the FY 2023 IPPS/LTCH PPS proposed rule, we noted that we might also
consider the use of more recent data that might become available for
purposes of estimating the rates of uninsurance used in the calculation
of the final Factor 2 for FY 2023. In the proposed rule, we outlined
the calculation of the proposed Factor 2 for FY 2023 as follows:
Percent of individuals without insurance for CY 2013: 14 percent.
Percent of individuals without insurance for CY 2022: 8.9 percent.
Percent of individuals without insurance for CY 2023: 9.3 percent.
Percent of individuals without insurance for FY 2023 (0.25 times
0.089) + (0.75 times 0.093): 9.2 percent.
1- [verbar]((0.092-0.14)/0.14)[verbar] = 1-0.3429 = 0.6571 (65.71
percent).
For FY 2020 and subsequent fiscal years, section 1886(r)(2)(B)(ii)
of the Act no longer includes any reduction to the previous calculation
in order to determine Factor 2. Therefore, we proposed that Factor 2
for FY 2023 would be 65.71 percent.
The proposed FY 2023 uncompensated care amount was
$9,949,258,556.56 * 0.6571 = $6,537,657,797.52.
[GRAPHIC] [TIFF OMITTED] TR10AU22.124
In addition, we stated that it had recently come to our attention
that the provision of the regulations that addresses Factor 2
inadvertently omits any reference to the statutory methodology in
section 1886(r)(2)(B)(ii) of the Act for determining Factor 2 for FY
2018 and subsequent fiscal years. Accordingly, we proposed a technical
change to the regulation at Sec. 412.106 to update paragraph
(g)(1)(ii) to reflect the statutory requirements governing the
determination of Factor 2 for FY 2018 and subsequent fiscal years. We
explained that we have determined Factor 2 for FY 2018 through FY 2022
consistent with the plain language of section 1886(r)(2)(B)(ii) of the
Act; therefore, this proposed technical change is intended merely to
update our regulations to reflect the methodology for determining
Factor 2 that has applied since FY 2018 and will continue to apply for
FY 2023 and subsequent fiscal years.
We invited public comments on our proposed Factor 2 for FY 2023 and
on the proposed technical change to the regulation at Sec.
412.106(g)(1)(ii).
Comment: The majority of commenters discussed Factor 2 in the
context of the impact of the temporary COVID-19 PHE provisions, such as
the Families First Coronavirus Response Act's Medicaid continuous
coverage requirement and the American Rescue Plan's Marketplace
enhanced premium tax credits, on the uninsured rate for FY 2023.
Commenters questioned CMS' estimates for the FY 2023 uninsured rate and
urged the Office of the Actuary (OACT) to update its estimate of Factor
2 to account for the projected increases in the number of uninsured as
the COVID-19 PHE provisions expire. Many commenters questioned CMS'
estimated decrease in the uninsured rate from 9.6 percent in the FY
2022 IPPS/LTCH PPS final rule to 9.2 percent in FY 2023 IPPS/LTCH PPS
proposed rule and stated that they expect increases in the uninsured
rates in their communities. Further, many commenters noted that the
proposed decrease of $800 million in uncompensated care payments from
the level in FY 2022 was likely, in part, driven by the projected
uninsured rate. To that end, commenters cited CMS'
[[Page 49032]]
statement in the proposed rule that the agency might consider more
recent data that may have become available for the calculation of
Factor 2 in FY 2023 and urged CMS to use more recent data sources to
account for the anticipated increase in the uninsured rate. One
commenter requested that CMS consider temporarily changing its
methodology for calculating Factor 2 to better account for individuals
who may lose their healthcare coverage when various PHE provisions
expire and noted that CMS has taken similar approaches in other
Medicare payment areas affected by the COVID-19 PHE.
Many commenters referenced various data sources and analyses, such
as the Kaiser Family Foundation, the Urban Institute, and HHS'
Assistant Secretary for Planning and Evaluation (ASPE) which project 5
to 16 million individuals will lose their Medicaid coverage and another
3 million additional individuals will lose their marketplace insurance
in FY 2023. Accordingly, these commenters requested that CMS increase
Factor 2 to reflect the anticipated increase in the uninsured
population as suggested by these sources. In addition, one commenter
requested that CMS exclude FY 2020 and FY 2021 data when calculating
the uninsured rate to eliminate any irregularities due to the COVID-19
PHE.
Response: We thank the commenters for their input regarding the
estimate of Factor 2 for FY 2023 included in the proposed rule. In
response to commenters who requested that we update the estimate of the
FY 2023 uninsured rate to fully consider any changes due to the
anticipated expirations of the PHE and the Marketplace premium tax
credits, we note that the rate of uninsurance used for the calculation
of Factor 2 for the proposed rule, as well as for this final rule,
reflects CMS' latest analyses and projections. The projected enrollment
trends across all insurance types, as well as for the uninsured, take
into account the expected impacts of current law including the
termination of the Families First Coronavirus Response Act's continuous
coverage provision for Medicaid (assumed to expire when the PHE ends in
2022 and to be accompanied by a one-year transition of disenrollments
from the program for those no longer eligible) and the conclusion of
the enhanced Marketplace premium tax credits. We believe that this NHEA
projection, on balance, best meets all of our considerations for
ensuring that the data source that underlies the Factor 2 calculation
of the uninsured rate meets the statutory requirement that the estimate
be based on data sources that the Secretary determines to be
appropriate, is certified by CMS' Chief Actuary, and provides a
reasonable estimate for the rate of uninsurance that is available in
conjunction with the IPPS rulemaking cycle. We refer readers to OACT's
memorandum ``Certification of Rates of Uninsured'' and OACT's report
titled ``Projections of National Health Expenditure: Methodology and
Model Specification'' for further details on the methodology and
updated assumptions used in the calculation of the projected uninsured
rate.
We disagree with comments' suggestions that we exclude FY 2020 and
FY 2021 data, or any data from the COVID-19 PHE period, for purposes of
calculating the uninsured rate for FY 2023. The projections that
underlie the FY 2023 Factor 2 calculation should take into
consideration, and include, those elements that are expected to
influence health insurance enrollment trends during FY 2023, and the
resulting rate of uninsured, including the unique circumstance
associated with the COVID-19 pandemic.
Comment: Some commenters suggested that CMS use a different
estimate of the uninsured rate to calculate Factor 2 for FY 2023, while
acknowledging that OACT accounted for the expiration of the COVID-19
PHE provisions in its uninsurance estimates. These commenters indicated
that because the uninsured percent change serves as a proxy for the
change in the amount of uncompensated care that hospitals provide, it
would be appropriate for CMS to apply a case-mix adjuster to the
uninsured rate for FY 2023 to account for the rise in resources that
will be used by hospitals to provide care to uninsured individuals who
may have delayed their care during the COVID-19 PHE.
A few commenters requested that CMS maintain the same level of
uncompensated care funding as in FY 2022 ($7.2 billion) while another
commenter requested that CMS consider delaying any proposed changes to
the uncompensated care payment calculations until analyses can be
performed to determine the actual uninsured rate and related costs
following the end of the COVID-19 PHE. Other commenters urged CMS to be
transparent in its calculation of Factor 2 and how it accounts for
Medicaid expansion populations, while others urged CMS to be
transparent regarding the data sources used for calculating Factor 2
and the assumptions behind the uninsured rate.
Response: Regarding the commenters that requested modifications to
the uninsured rate, such as multiplying by a case-mix factor, we note
that these recommendations would not be consistent with the statutory
requirements in section 1886(r)(2)(B)(ii). The statute explicitly
specifies that Factor 2 be based on 1 minus the percent change in the
percent of individuals who are uninsured, as determined by comparing
the percent of individuals who were uninsured in 2013 and the percent
of individuals who were uninsured in the most recent period for which
data are available.
Regarding the comments recommending that CMS maintain total
uncompensated care payments at the FY 2022 level or delay any changes
to the amount available to make uncompensated care payments, we believe
estimating Factor 2 based on the best available data regarding the
expected rate of uninsurance in FY 2023 is appropriate and consistent
with the statute.
In response to the comments concerning transparency, we reiterate
that we have been and continue to be transparent with respect to the
methodology and data used to estimate Factor 2. The FY 2023 IPPS/LTCH
PPS proposed rule included a detailed discussion of our proposed Factor
2 methodology, as well as the data sources that would be used in making
our final estimate. For purposes of this final rule, we are using
projected rates of uninsurance for CY 2022 and CY 2023, which account
for the effects of the COVID-19 PHE and any legislative impacts arising
from the end of the COVID-19 PHE on insurance coverage. Section
1886(r)(2)(B)(ii) of the Act permits us to use a data source other than
CBO estimates to determine the percent change in the rate of
uninsurance beginning in FY 2018. We continue to believe that the NHEA
data and methodology used to estimate Factor 2 are transparent and best
meet all of our considerations for ensuring reasonable estimates for
the rate of uninsurance that are available in conjunction with the IPPS
rulemaking cycle. Accordingly, we continue to believe that it is
appropriate to calculate Factor 2 based on the NHEA-based projection of
the FY 2023 rate of uninsurance as we proposed.
After consideration of the public comments we received, we are
finalizing, as proposed, the Factor 2 calculation for FY 2023. The
estimates of the percent of uninsured individuals were produced and
certified by OACT for purposes of the FY 2023 IPPS proposed rule. Those
published CY and
[[Page 49033]]
estimated FY rates continue to be the latest available projections.
The calculation of the final Factor 2 for FY 2023 using a weighted
average of OACT's certified estimates is as follows:
Percent of individuals without insurance for CY 2013: 14 percent.
Percent of individuals without insurance for CY 2022: 8.9 percent.
Percent of individuals without insurance for CY 2023: 9.3 percent.
Percent of individuals without insurance for FY 2023 (0.25 times
0.089) + (0.75 times 0.093): 9.2 percent.
1- [verbar]((0.092-0.14)/0.14)[verbar] = 1-0.3429 = 0.6571 (65.71
percent).
Therefore, the final Factor 2 for FY 2023 is 65.71 percent. The
final FY 2023 uncompensated care amount is $10,461,731,029.40* 0.6571 =
$6,874,403,459.42.
[GRAPHIC] [TIFF OMITTED] TR10AU22.125
We did not receive any comments on our proposed technical change to
the regulation governing the calculation of Factor 2. We are finalizing
the update to Sec. 412.106(g)(1)(ii), as proposed.
3. Calculation of Proposed Factor 3 for FY 2023
(a) General Background
Section 1886(r)(2)(C) of the Act defines Factor 3 in the
calculation of the uncompensated care payment. As we have discussed
earlier, section 1886(r)(2)(C) of the Act states that Factor 3 is equal
to the percent, for each subsection (d) hospital, that represents the
quotient of: (1) the amount of uncompensated care for such hospital for
a period selected by the Secretary (as estimated by the Secretary,
based on appropriate data (including, in the case where the Secretary
determines alternative data are available that are a better proxy for
the costs of subsection (d) hospitals for treating the uninsured, the
use of such alternative data)); and (2) the aggregate amount of
uncompensated care for all subsection (d) hospitals that receive a
payment under section 1886(r) of the Act for such period (as so
estimated, based on such data).
Therefore, Factor 3 is a hospital-specific value that expresses the
proportion of the estimated uncompensated care amount for each
subsection (d) hospital and each subsection (d) Puerto Rico hospital
with the potential to receive Medicare DSH payments relative to the
estimated uncompensated care amount for all hospitals estimated to
receive Medicare DSH payments in the fiscal year for which the
uncompensated care payment is to be made. Factor 3 is applied to the
product of Factor 1 and Factor 2 to determine the amount of the
uncompensated care payment that each eligible hospital will receive for
FY 2014 and subsequent fiscal years. In order to implement the
statutory requirements for this factor of the uncompensated care
payment formula, it was necessary to determine: (1) the definition of
uncompensated care or, in other words, the specific items that are to
be included in the numerator (that is, the estimated uncompensated care
amount for an individual hospital) and the denominator (that is, the
estimated uncompensated care amount for all hospitals estimated to
receive Medicare DSH payments in the applicable fiscal year); (2) the
data source(s) for the estimated uncompensated care amount; and (3) the
timing and manner of computing the quotient for each hospital estimated
to receive Medicare DSH payments. The statute instructs the Secretary
to estimate the amounts of uncompensated care for a period based on
appropriate data. In addition, we note that the statute permits the
Secretary to use alternative data in the case where the Secretary
determines that such alternative data are available that are a better
proxy for the costs of subsection (d) hospitals for treating
individuals who are uninsured.
In the course of considering how to determine Factor 3 during the
rulemaking process for FY 2014, the first year for which section
1886(r) of the Act was in effect, we considered defining the amount of
uncompensated care for a hospital as the uncompensated care costs of
that hospital and determined that Worksheet S-10 of the Medicare cost
report would potentially provide the most complete data regarding
uncompensated care costs for Medicare hospitals. However, because of
concerns regarding variations in the data reported on Worksheet S-10
and the completeness of these data, we did not use Worksheet S-10 data
to determine Factor 3 for FY 2014, or for FYs 2015, 2016, or 2017.
Instead, we used alternative data on the utilization of insured low-
income patients, as measured by patient days, which we believed would
be a better proxy for the costs of hospitals in treating the uninsured
and therefore appropriate to use in calculating Factor 3 for these
years. Of particular importance in our decision to use proxy data was
the relative newness of Worksheet S-10, which went into effect on May
1, 2010. At the time of the rulemaking for FY 2014, the most recent
available cost reports would have been from FYs 2010 and 2011 and
submitted on or after May 1, 2010, when the new Worksheet S-10 went
into effect. However, we indicated our belief that Worksheet S-10 could
ultimately serve as an appropriate source of more direct data regarding
uncompensated care costs for purposes of determining Factor 3 once
hospitals were submitting more accurate and consistent data through
this reporting mechanism.
In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38202), we stated
that we could no longer conclude that alternative data to the Worksheet
S-10 are available for FY 2014 that are a better proxy for the costs of
subsection (d) hospitals for treating individuals who are uninsured.
Hospitals were on notice as of FY 2014 that Worksheet S-10 could
eventually become the data source for CMS to calculate uncompensated
care payments. Furthermore, hospitals' cost reports from FY 2014 had
been publicly available for some time, and CMS had analyses of
Worksheet S-10, conducted both internally and by stakeholders,
demonstrating that Worksheet S-10 accuracy had improved over time. We
refer readers to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38201
through 38203) for a complete discussion of these analyses.
In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38206), we
recognized commenters' concerns that, in continuing to use Medicaid
days as part of the proxy for uncompensated care, it would be possible
for hospitals in States that choose to expand Medicaid to receive
higher uncompensated care payments because they may have more Medicaid
patient days than hospitals in a State that does not choose to expand
Medicaid. In the FY 2018 IPPS/LTCH PPS final rule, we finalized a
methodology under which we calculated Factor 3 for all eligible
hospitals, with the exception of Puerto Rico hospitals and Indian
Health Service (IHS) and Tribal hospitals, using Worksheet S-10 data
from FY 2014 cost
[[Page 49034]]
reports in conjunction with low-income insured days proxy data based on
Medicaid days and SSI days. The time period for the Medicaid days data
was FY 2012 and FY 2013 cost reports, which reflected the most recent
available information regarding these hospitals' low-income insured
days before any expansion of Medicaid (82 FR 38208 through 38212).
In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41414), we stated
that with the additional steps we had taken to ensure the accuracy and
consistency of the data reported on Worksheet S-10 since the
publication of the FY 2018 IPPS/LTCH PPS final rule, we continued to
believe that we could no longer conclude that alternative data to the
Worksheet S-10 were currently available for FY 2014 or FY 2015 that
would be a better proxy for the costs of subsection (d) hospitals for
treating individuals who are uninsured. In the FY 2019 IPPS/LTCH PPS
final rule (83 FR 41428), we advanced the time period of the data used
in the calculation of Factor 3 forward by 1 year and used Worksheet S-
10 data from FY 2014 and FY 2015 cost reports in combination with the
low income insured days proxy for FY 2013 to determine Factor 3 for FY
2019. We note that, as discussed in the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42366), the use of 3 years of data to determine Factor 3
for FY 2018 and FY 2019 had the effect of smoothing the transition from
the use of low-income insured days to the use of Worksheet S-10 data.
As discussed in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41424),
we received overwhelming feedback from commenters emphasizing the
importance of audits in ensuring the accuracy and consistency of data
reported on the Worksheet S-10. We began auditing the Worksheet S-10
data for selected hospitals in the Fall of 2018 so that the audited
uncompensated care data from these hospitals would be available in time
for use in the FY 2020 IPPS/LTCH PPS proposed rule.
In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42368), we finalized
our proposal to use a single year of audited Worksheet S-10 cost report
data from FY 2015 in the methodology for determining Factor 3 for FY
2020. Although some commenters expressed support for the alternative
policy of using the more recent FY 2017 Worksheet S-10 data to
determine each hospital's share of uncompensated care costs in FY 2020,
given the feedback from commenters in response to both the FY 2019 and
FY 2020 IPPS/LTCH PPS proposed rules, emphasizing the importance of
audits in ensuring the accuracy and consistency of data reported on the
Worksheet S-10, we concluded that the FY 2015 Worksheet S-10 data were
the best available audited data to be used in determining Factor 3 for
FY 2020. We also noted that we had begun auditing the FY 2017 data in
July 2019, with the goal of having the FY 2017 audited data available
for future rulemaking.
In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58823 through
58825), we finalized our proposal to use the most recent available
single year of audited Worksheet S-10 data to determine Factor 3 for FY
2021 and subsequent fiscal years. We explained our belief that using
the most recent audited data available before the applicable Federal
fiscal year, will more accurately reflect a hospital's uncompensated
care costs, as opposed to averaging multiple years of data. We
explained that mixing audited and unaudited data for individual
hospitals by averaging multiple years of data could potentially lead to
a less smooth result. We also noted that if a hospital has relatively
different data between cost report years, we potentially would be
diluting the effect of our considerable auditing efforts and
introducing unnecessary variability into the calculation if we were to
use multiple years of data to calculate Factor 3. Therefore, we also
believed using a single year of audited cost report data would be an
appropriate methodology to determine Factor 3 for FY 2021 and
subsequent years, except for IHS and Tribal hospitals and hospitals
located in Puerto Rico. For IHS and Tribal hospitals and Puerto Rico
hospitals, we finalized the use of a low-income insured days proxy to
determine Factor 3 for FY 2021. We did not finalize a methodology to
determine Factor 3 for IHS and Tribal hospitals and Puerto Rico
hospitals for FY 2022 and subsequent years because we believed further
consideration and review of these hospitals' Worksheet S-10 data was
necessary (85 FR 58825).
In the FY 2021 IPPS/LTCH PPS final rule, we finalized the
definition of ``uncompensated care'' for FY 2021 and subsequent fiscal
years, for purposes of determining uncompensated care costs and
calculating Factor 3 (85 FR 58825 through 58828). Specifically,
``uncompensated care'' is defined as the amount on Line 30 of Worksheet
S-10, which is the cost of charity care (Line 23) and the cost of non-
Medicare bad debt and non-reimbursable Medicare bad debt (Line 29).
This is the same definition that we initially adopted in the FY 2018
IPPS/LTCH PPS final rule. We refer readers to the FY 2021 IPPS/LTCH PPS
rule (85 FR 58825 through 58828) for a discussion of additional topics
related to the definition of uncompensated care. We noted in the FY
2021 IPPS/LTCH PPS final rule that the Paper Reduction Act (PRA)
package for Form CMS-2552-10 would offer an additional opportunity to
comment on the cost reporting instructions. A PRA package with comment
period appeared in the November 10, 2020, Federal Register (85 FR
71653). We thank stakeholders for their comments on the PRA package.
For further information, we refer the readers to the following website.
https://www.reginfo.gov/public/do/PRAViewDocument?ref_nbr=202206-0938-017.
(b) Background on the Methodology Used To Calculate Factor 3 for FY
2022
Section 1886(r)(2)(C) of the Act governs both the selection of the
data to be used in calculating Factor 3, and also allows the Secretary
the discretion to determine the time periods from which we will derive
the data to estimate the numerator and the denominator of the Factor 3
quotient. Specifically, section 1886(r)(2)(C)(i) of the Act defines the
numerator of the quotient as the amount of uncompensated care for a
subsection (d) hospital for a period selected by the Secretary. Section
1886(r)(2)(C)(ii) of the Act defines the denominator as the aggregate
amount of uncompensated care for all subsection (d) hospitals that
receive a payment under section 1886(r) of the Act for such period. In
the FY 2014 IPPS/LTCH PPS final rule (78 FR 50638), we adopted a
process of making interim payments with final cost report settlement
for both the empirically justified Medicare DSH payments and the
uncompensated care payments required by section 3133 of the Affordable
Care Act. Consistent with that process, we also determined the time
period from which to calculate the numerator and denominator of the
Factor 3 quotient in a way that would be consistent with making interim
and final payments. Specifically, we must have Factor 3 values
available for hospitals that we estimate will qualify for Medicare DSH
payments and for those hospitals that we do not estimate will qualify
for Medicare DSH payments but that may ultimately qualify for Medicare
DSH payments at the time of cost report settlement.
In the FY 2022 IPPS/LTCH PPS final rule, we continued to apply the
following policies as part of the Factor 3 methodology: (1) the policy
regarding newly merged hospitals that was initially adopted in the FY
2015 IPPS/LTCH PPS final rule; (2) the policies regarding annualization
and long cost reports that were adopted in the FY
[[Page 49035]]
2018 and FY 2019 IPPS/LTCH PPS final rules, including a modified policy
for the rare cases where a provider has no cost report for the fiscal
year that is used in the Factor 3 methodology because the cost report
for the previous fiscal year spans both years; (3) the modified new
hospital policy that was finalized in the FY 2020 IPPS/LTCH PPS final
rule; (4) the new merger policy adopted in the FY 2021 IPPS/LTCH PPS
final rule that accounts for the merger effective date; and (5) the
policies regarding the application of statistical trim methodologies to
potentially aberrant CCRs and potentially aberrant uncompensated care
costs reported on the Worksheet S-10. We discuss these policies in
greater detail in this section.
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45244), we continued
to treat hospitals that merge after the development of the final rule
for the applicable fiscal year similar to new hospitals. As explained
in the FY 2015 IPPS/LTCH PPS final rule, for these newly merged
hospitals, we do not have data currently available to calculate a
Factor 3 amount that accounts for the merged hospital's uncompensated
care burden (79 FR 50021). In the FY 2015 IPPS/LTCH PPS final rule, we
finalized a policy under which Factor 3 for hospitals that we do not
identify as undergoing a merger until after the public comment period
and additional review period following the publication of the final
rule or that undergo a merger during the fiscal year would be
recalculated similar to new hospitals (79 FR 50021 and 50022).
Consistent with past policy, interim uncompensated care payments for
newly merged hospitals are based only on the data for the surviving
hospital's CCN available at the time of the development of the final
rule. However, at cost report settlement, we will determine the newly
merged hospital's final uncompensated care payment based on the
uncompensated care costs reported on its cost report for the applicable
fiscal year. That is, for FY 2022, we will revise the numerator of
Factor 3 for a newly merged hospital to reflect the uncompensated care
costs reported on the newly merged hospital's FY 2022 cost report.
In FY 2022 IPPS/LTCH PPS final rule, we continued the policy that
was finalized in the FY 2018 IPPS/LTCH PPS final rule of annualizing
uncompensated care cost data reported on the Worksheet S-10 if a
hospital's cost report does not equal 12 months of data, except in the
case of mergers, which would be subject to the modified merger policy
originally adopted in FY 2021. In addition, we continued the policies
that were finalized in the FY 2019 IPPS/LTCH PPS final rule (83 FR
41415) regarding the use of the longest cost report available within
the Federal fiscal year. We also applied the modified policy that was
adopted in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58829) for those
rare situations where a hospital has a cost report that starts in one
fiscal year but spans the entirety of the following fiscal year such
that the hospital has no cost report starting in that subsequent fiscal
year. Under this modified policy, we use the cost report that spans
both fiscal years for purposes of calculating Factor 3 when data from
the latter fiscal year are used in the Factor 3 methodology.
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 25454), we continued
the modified new hospital policy for new hospitals that do not have
data for the cost reporting period(s) used in the Factor 3 calculation
(that is, the most recent cost reporting year for which audits have
been conducted). Under the modified policy originally adopted for FY
2020, new hospitals that have a preliminary projection of being
eligible for Medicare DSH based on their most recent available
disproportionate patient percentages may receive interim empirically
justified DSH payments during the fiscal year. However, because these
hospitals do not have a cost report for the cost reporting period used
in the Factor 3 calculation and the projection of eligibility for DSH
payments is still preliminary, we are unable to calculate a prospective
Factor 3 for these hospitals and they do not receive interim
uncompensated care payments. The MAC will make a final determination
concerning whether the hospital is eligible to receive Medicare DSH
payments for the fiscal year at cost report settlement. Thus, for FY
2022, if a new hospital is ultimately determined to be eligible for
Medicare DSH payments for FY 2022, the hospital will receive an
uncompensated care payment calculated using a Factor 3, where the
numerator is the uncompensated care costs reported on Worksheet S-10 of
the hospital's FY 2022 cost report, and the denominator is the same
denominator that was used in the prospective Factor 3 calculation for
FY 2022 (that is, the sum of the uncompensated care costs reported on
Worksheet S-10 of the FY 2018 cost reports for all DSH-eligible
hospitals).
In the FY 2022 IPPS/LTCH PPS final rule, we continued the new
merger policy that accounts for the merger effective date, that was
originally adopted in FY 2021. To more accurately estimate
uncompensated care costs (UCC) for the hospitals involved in a merger
when the merger effective date occurs partway through the surviving
hospital's cost reporting period, we apply a policy of not annualizing
the acquired hospital's data. Under this policy, we use only the
portion of the acquired hospital's unannualized UCC data that reflects
the UCC incurred prior to the merger effective date, but after the
start of the surviving hospital's current cost reporting period. To do
this, we calculate a multiplier to be applied to the acquired
hospital's UCC. This multiplier represents the portion of the UCC data
from the acquired hospital that should be incorporated with the
surviving hospital's data to determine UCC for purposes of determining
Factor 3 for the surviving hospital. This multiplier is obtained by
calculating the number of days between the start of the applicable cost
reporting period for the surviving hospital and the merger effective
date, and then dividing this result by the total number of days in the
reporting period of the acquired hospital. Applying this multiplier to
the acquired hospital's unannualized UCC data will determine the final
portion of the acquired hospital's UCC that should be added to the UCC
of the surviving hospital for purposes of determining Factor 3 for the
merged hospital.
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 25454 and 25455), we
continued to apply a CCR trim methodology similar to the CCR trim
methodology policy that has been used for purposes of determining
uncompensated care payments since FY 2018. This CCR trim methodology is
consistent with the approach used in the outlier payment methodology
under Sec. 412.84(h)(3)(ii), which states that the Medicare contractor
may use a statewide average CCR for hospitals whose operating or
capital CCR is in excess of 3 standard deviations above the
corresponding national geometric mean. We refer readers to the
discussion in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58831) for a
detailed description of the steps used to determine the applicable CCR.
In addition, we continued the UCC data trim methodology for rare
situations where a hospital has potentially aberrant data that are
unrelated to its CCR (86 FR 45245). However, because we audit the
Worksheet S-10 data for a number of hospitals, we no longer believe it
is necessary to apply the trim methodology for hospitals whose cost
report has been audited. Accordingly, for FY 2022, we continued the
policy adopted in FY 2021 under which we exclude hospitals that were
part of the audits for the fiscal year used in the Factor 3 calculation
from the trim
[[Page 49036]]
methodology for potentially aberrant UCC. We also continued to apply a
modified trim methodology for all-inclusive rate providers (AIRPs) with
potentially aberrant UCC (86 FR 45235). Under this modified trim
methodology, when an AIRP's total UCC are greater than 50 percent of
its total operating costs when calculated using the CCR included on its
cost report for the most recent cost reporting year for which audits
have been conducted, we recalculate the AIRP's UCC using the CCR
reported on Worksheet S-10, line 1 of the hospital's most recent
available prior year cost report that does not result in UCC of over 50
percent of total operating costs.
In addition, in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45245
and 452456), we finalized an alternative trim specific to hospitals
that are not projected to be DSH-eligible and that do not have audited
FY 2018 Worksheet S-10 data for use in determining Factor 3. We
explained that we believe this new alternative trim more appropriately
addresses potentially aberrant insured patient charity care costs
compared to the existing trim, because the existing trim is based
solely on the ratio of total uncompensated care costs to total
operating costs and does not consider the level of insured patients'
charity care costs. Specifically, we finalized that, for the hospitals
that would be subject to the trim, if the hospital is ultimately
determined to be DSH-eligible at cost report settlement, then the MAC
would calculate a Factor 3 after reviewing the uncompensated care
information reported on Worksheet S-10 of the hospital's FY 2022 cost
report. We stated that we believe if a hospital subject to this trim is
ultimately determined to be DSH-eligible at cost report settlement, its
uncompensated care payment should be calculated only after the
hospital's reporting of insured charity care costs on its FY 2022
Worksheet S-10 has been reviewed. We noted that this approach is
comparable to the policy for new hospitals for which we cannot
calculate a prospective Factor 3 because they do not have Worksheet S-
10 data for the relevant fiscal year.
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45242 and 45243), we
continued the policy we first adopted for FY 2018 of substituting data
regarding FY 2013 low-income insured days for the Worksheet S-10 data
when determining Factor 3 for IHS and Tribal hospitals and subsection
(d) Puerto Rico hospitals that have a FY 2013 cost report. We stated
our belief that this approach was appropriate as the FY 2013 data
reflect the most recent available information regarding these
hospitals' low-income insured days before any expansion of Medicaid. In
addition, because we continued to use 1 year of insured low income
patient days as a proxy for uncompensated care for Puerto Rico
hospitals and residents of Puerto Rico are not eligible for SSI
benefits, we continued to use a proxy for SSI days for Puerto Rico
hospitals consisting of 14 percent of the hospital's Medicaid days, as
finalized in the FY 2017 IPPS/LTCH PPS final rule (81 FR 56953 through
56956).
We refer readers to the FY 2022 IPPS/LTCH PPS final rule (86 FR
45236) for a discussion of the approach that we continued to apply in
FY 2022 to determine Factor 3 for new Puerto Rico hospitals. In brief,
Puerto Rico hospitals that do not have a FY 2013 cost report were
considered new hospitals and subject to the new hospital policy, as
discussed previously. Specifically, the numerator of the Factor 3
calculation will be the uncompensated care costs reported on Worksheet
S-10 of the hospital's cost report for the applicable fiscal year and
the denominator is the same denominator that is determined
prospectively for purposes of determining Factor 3 for all DSH-eligible
hospitals.
Consistent with the policy adopted in the FY 2021 IPPS/LTCH PPS
final rule and codified in the regulations at Sec. 412.106(g)(8) for
subsequent fiscal years, in the FY 2022 IPPS/LTCH PPS final rule we
used a single year of Worksheet S-10 data from FY 2018 cost reports to
calculate Factor 3 for FY 2022 for all eligible hospitals with the
exception of IHS and Tribal hospitals and Puerto Rico hospitals that
have a cost report for 2013.
Therefore, for FY 2022, we applied the following methodology to
compute Factor 3 for each hospital:
Step 1: Select the provider's longest cost report from its Federal
fiscal year (FFY) 2018 cost reports. (Alternatively, in the rare case
when the provider has no FFY 2018 cost report because the cost report
for the previous Federal fiscal year spanned the FFY 2018 time period,
the previous Federal fiscal year cost report will be used in this
step.)
Step 2: Annualize the uncompensated care costs (UCC) from Worksheet
S-10 Line 30, if the cost report is more than or less than 12 months.
(If applicable, use the statewide average CCR (urban or rural) to
calculate uncompensated care costs.)
Step 3: Combine adjusted and/or annualized uncompensated care costs
for hospitals that merged using the merger policy.
Step 4: Calculate Factor 3 for IHS and Tribal hospitals and Puerto
Rico hospitals that have a cost report for 2013 using the low-income
insured days proxy based on FY 2013 cost report data and the most
recent available SSI ratio (or, for Puerto Rico hospitals, 14 percent
of the hospital's FY 2013 Medicaid days). The denominator is calculated
using the low-income insured days proxy data from all DSH eligible
hospitals.
Step 5: Calculate Factor 3 for the remaining DSH eligible hospitals
using annualized uncompensated care costs (Worksheet S-10 Line 30)
based on FY 2018 cost report data (from Step 1, 2 or 3). New hospitals
and the hospitals for which Factor 3 was calculated in Step 4 are
excluded from this calculation.
In the FY 2022 IPPS/LTCH PPS final rule, we amended the regulation
at Sec. 412.106 by adding a new paragraph (g)(1)(iii)(C)(9) to reflect
the methodology for computing Factor 3 for FY 2022 for IHS and Tribal
hospitals and for Puerto Rico hospitals that have a 2013 cost report.
We also finalized a conforming change to limit the reference to Puerto
Rico hospitals in Sec. 412.106(g)(1)(iii)(C)(8) to those Puerto Rico
hospitals that have a cost report for 2013.
(c) Changes to the Methodology for Calculating Factor 3 for FY 2023 and
Subsequent Fiscal Years
As described in the FY 2022 IPPS/LTCH PPS final rule, commenters
expressed concerns that the use of only 1 year of data to determine
Factor 3 would lead to significant variations in year-to-year
uncompensated care payments. Some stakeholders recommended the use of 2
years of historical Worksheet S-10 data (86 FR 45237). In the FY 2022
IPPS/LTCH PPS final rule, we stated that we would consider using
multiple years of data when the vast majority of providers have been
audited for more than 1 fiscal year under the revised reporting
instructions. The audits of FY 2019 cost reports began in 2021 and
those audited reports were available in time for the development of the
FY 2023 IPPS/LTCH PPS proposed rule. Feedback from previous audits and
lessons learned were incorporated into the audit process for the FY
2019 reports.
In consideration of the comments discussed in the FY 2022 IPPS/LTCH
PPS final rule, in the FY 2023 IPPS/LTCH PPS proposed rule, we proposed
to determine Factor 3 for FY 2023 using the average of the audited FY
2018 and audited FY 2019 reports. We stated our belief that this
proposal would address concerns from stakeholders regarding
[[Page 49037]]
year-to-year fluctuations in uncompensated care payments. In addition,
taking into consideration the comments recommending that CMS transition
to the use of 3 years of audited data, we indicated that we expect FY
2024 will be the first year that 3 years of audited data will be
available at the time of rulemaking. Accordingly, for FY 2024 and
subsequent fiscal years, we proposed to use a 3-year average of the
uncompensated care data from the 3 most recent fiscal years for which
audited data are available to determine Factor 3. Specifically, for FY
2024, we would expect to use data from FY 2018, FY 2019, and FY 2020
reports to calculate uncompensated care payments. In other words, for
each of the 3 most recent fiscal years for which audited data are
available at the time of rulemaking for the applicable fiscal year, we
would divide a hospital's uncompensated care costs for the fiscal year
by the estimated total uncompensated care costs of all DSH hospitals
for that fiscal year. Then, we would calculate an average of those
proportions to determine the hospital's Factor 3 for the applicable
Federal fiscal year. We explained that we believe the proposed approach
is generally consistent with our past practice of using the most recent
single year of audited data from the Worksheet S-10, while also
addressing commenters' concerns regarding year-to-year fluctuations in
uncompensated care payments. Consistent with the approach that we
followed when multiple years of data were previously used in the Factor
3 methodology, we proposed that if a hospital does not have data for
all 3 years used in the Factor 3 calculation, we would determine Factor
3 based on an average of the hospital's available data.
We invited public comments on our proposed methodology for
calculating Factor 3 for FY 2023 and subsequent fiscal years,
including, but not limited to, our proposal to use the most recent
audited Worksheet S-10 data from FY 2018 and FY 2019 cost reports to
determine Factor 3 for FY 2023, and our proposal to begin using the 3
most recent years of audited Worksheet S-10 data starting in FY 2024.
Comment: Commenters expressed continued support for the general use
of Worksheet S-10 data to calculate each hospital's share of
uncompensated care costs in FY 2023 and future years. Some commenters
also noted their long-standing support for using audited Worksheet S-10
data to promote an accurate and consistent calculation of uncompensated
care costs. One commenter, who supported using Worksheet S-10 data,
stressed the importance of ongoing refinements to the audit process to
ensure data accuracy, while another recommended that CMS regularly
assess and identify unusual or irregular trends in the data.
Response: We appreciate the support for our proposal to use
Worksheet S-10 data to calculate Factor 3 for FY 2023 and future years.
Regarding those comments that noted the importance of ongoing
refinements to the Worksheet S-10 audit process, we reiterate our
commitment to continue working with the MACs and providers on audit
improvements, including changes to increase the efficiency of the audit
process and build on the lessons learned in previous audit years. As
noted in the FY 2023 IPPS/LTCH PPS proposed rule, we believe that, on
balance, Worksheet S-10 data are the best available data to use for
calculating Factor 3 for FY 2023 and subsequent fiscal years.
Comment: An overwhelming majority of commenters expressed support
for CMS' proposal to calculate Factor 3 for FY 2023 based on a two-year
average of audited FY 2018 and FY 2019 Worksheet S-10 data. These
commenters also expressed support for the proposal to transition to use
of a three-year average of the most recent available audited Worksheet
S-10 data for FY 2024 and subsequent fiscal years. Some commenters
explicitly stated that they agreed with CMS that the use of only one
year of data could lead to undue fluctuations in year-to-year
uncompensated care payments. Supporters of these proposals also
specified several benefits from the use of a multi-year average of
Worksheet S-10 data, such as minimizing year-to-year volatility,
ensuring stability in future uncompensated care payments, and
mitigating the effect of irregular trends and data anomalies, like the
COVID-19 PHE. One commenter suggested that CMS consider working with
hospitals in future years to ensure that Worksheet S-10 data from the
COVID-19 PHE period is reported appropriately, given the PHE's
significant impact on the utilization of healthcare services. To this
end, one commenter recommended that CMS consider incorporating FY 2020
Worksheet S-10 data into the multi-year average for FY 2023 once the
data has been audited, as this approach would be more reflective of
current healthcare costs.
In contrast, only a handful of commenters expressed opposition to
using a two-year average of audited FY 2018 and FY 2019 Worksheet S-10
data for FY 2023 and a three-year average of Worksheet S-10 data to
calculate uncompensated care payments moving forward. One commenter
indicated that using a three-year average to calculate FY 2024
uncompensated care payments would dilute the impact of the COVID-19 PHE
on the FY 2020 Worksheet S-10 data. This commenter asserted that using
a multi-year average would benefit hospitals that received the highest
amount of Health Resources & Services Administration (HRSA) subsidies
and hospitals with lower uncompensated care costs, while harming
hospitals with higher uncompensated care cost data in FY 2020. The
commenter also requested that CMS provide expedited procedures for
reopening and correcting Worksheet S-10 data for the cost reporting
periods that will be used to calculate uncompensated care payments in
FY 2024 and future years.
Another commenter noted that the FY 2022 methodology based on one
year of audited Worksheet S-10 data was adequate and should not be
modified to a multi-year average, indicating that inconsistencies in
the methodology used to calculate Factor 3 from year to year add a
further burden to hospitals' ability to understand and predict their
uncompensated care payments. This commenter also urged CMS to reexamine
the continued use of FY 2018 Worksheet S-10 data to determine payments
for FY 2022, FY 2023, and FY 2024, as it may benefit hospitals that
provided elevated levels of uncompensated care in FY 2018, and
negatively impact those that provided less uncompensated care.
Finally, some commenters suggested alternative approaches to
calculating Factor 3 of the uncompensated care payment calculation that
went beyond the blending of historical Worksheet S-10 data for multiple
fiscal years.
Response: We thank commenters who expressed their support for our
proposal to use a two-year average of audited FY 2018 and FY 2019
Worksheet S-10 data to determine each hospital's share of uncompensated
care costs in FY 2023 and to use of a 3-year average of audited
Worksheet S-10 data starting in FY 2024. As explained in the FY 2023
IPPS/LTCH PPS proposed rule, we believe that using a multi-year average
of Worksheet S-10 data will provide assurance that hospitals'
uncompensated care payments remain stable and predictable and will not
be subject to unpredictable swings and anomalies in a hospital's
uncompensated care costs.
We also believe that our proposal to use multiple years of data is
responsive to past commenters' requests for the use of multiple years
of audited data. We disagree with the commenter who stated
[[Page 49038]]
that modifying the uncompensated care payment methodology to use
multiple years of data would put undue burden on a hospital's ability
to understand, budget, and forecast as we believe that our proposal to
use a multi-year average of Worksheet S-10 data to determine Factor 3
for FY 2023 and subsequent fiscal years is responsive to past
recommendations for smoothing fluctuations.
In relation to the commenter who noted that the multi-year average
will benefit hospitals that received the highest amount of HRSA
subsidies and hospitals with lower uncompensated care costs, we note
that cost reporting data from the COVID-19 PHE time period is not yet
available to be analyzed. We believe it would be premature to attempt,
in this rulemaking, to modify the methodology for determining
uncompensated care payments for a future year, specifically to address
the potential impact of the PHE-related subsidies.
In response to the request that we provide expedited procedures for
reopening and correcting Worksheet S-10 data that will be used in the
Factor 3 calculation, we note that we do not intend to establish fixed
timelines for reopenings across MACs, so we can retain the flexibility
to use our limited audit resources to address and prioritize audit
needs across all CMS programs each year. However, we note that MACs
work closely with hospitals regarding reopenings.
Regarding commenters' suggestions for alternative approaches to
calculating Factor 3 beyond the previously considered methodological
concepts for the blending of historical Worksheet S-10 data, we
appreciate commenters' input and note that we may consider these
suggestions in future rulemaking.
After consideration of the comments received, we are finalizing our
proposal to use a two-year average of audited FY 2018 and FY 2019
Worksheet S-10 data to calculate Factor 3 in FY 2023 and a three-year
average of audited data from the most recent fiscal years for which
audited data are available to determine Factor 3 in subsequent years.
We also note that the number of audited hospitals continues to increase
year to year and, as a result, we believe data from Worksheet S-10 will
improve in reliability over time. However, we will continue to audit
additional years of the Worksheet S-10 data and monitor the stability
of uncompensated care payments as we move forward with using a multi-
year average of audited Worksheet S-10 data for Factor 3 calculations.
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule, we have
determined Factor 3 for IHS and Tribal hospitals and Puerto Rico
hospitals, based on the low-income insured days proxy for uncompensated
care costs. In the FY 2022 IPPS/LTCH PPS final rule, we discussed
comments we had received from IHS/Tribal hospitals and Puerto Rico
hospitals about the significant challenges they face in relation to
uncompensated care reporting (86 FR 45242 and 45243). For example, a
commenter stated that the information technology systems used by IHS
and Tribal hospitals are not equipped to collect the necessary data for
the Worksheet S-10, noting that while IHS recently received funding to
upgrade its information technology system, it will take some time,
potentially years, before it is fully functional (86 FR 45242). Another
commenter expressed concerns that Puerto Rico hospitals were
understating the components of uncompensated care costs, and indicated
that technical education is needed to address the challenges Puerto
Rico hospitals have regarding charity care and bad debt reporting,
which the commenter stated would take years to address (86 FR 45243).
In the FY 2023 IPPS/LTCH PPS proposed rule, we acknowledged that to
the extent commenters have identified specific challenges for IHS/
Tribal hospitals and Puerto Rico hospitals in reporting uncompensated
care costs on Worksheet S-10, it is possible that after a sufficient
number of years these reporting challenges could be addressed. However,
despite the reporting challenges described by commenters, we expressed
our concern that the historical 2013-based data on low-income insured
days, which has been used as an alternative to data on uncompensated
care costs from the Worksheet S-10 to determine Factor 3 for IHS/Tribal
hospitals and Puerto Rico hospitals, is no longer a good proxy for the
costs of these hospitals in treating the uninsured, given the time that
has elapsed since 2013. In 2023, this data will be 10 years old and
there is no obvious way to update the information given our stated
concerns surrounding the differential impact of state Medicaid
expansions after 2013. In light of these concerns, we stated that we
could no longer conclude that alternative data to the data on
uncompensated care costs reported on Worksheet S-10 are currently
available for IHS/Tribal hospitals and Puerto Rico hospitals that are a
better proxy for the costs of these hospitals in treating the
uninsured. Accordingly, for FY 2023 and subsequent fiscal years, we
proposed to discontinue the use of low-income insured days as a proxy
for the uncompensated care costs of these hospitals and proposed to use
the same data to determine Factor 3 for IHS and Tribal hospitals and
Puerto Rico hospitals as for other hospitals. Specifically, for FY
2023, we would determine Factor 3 for IHS and Tribal hospitals and
Puerto Rico hospitals based on the average of the uncompensated care
data reported on Worksheet S-10 of their FY 2018 and FY 2019 cost
reports. However, we sought comments on alternatives both to our
proposal to use data on uncompensated care costs from the Worksheet S-
10 to determine Factor 3 for IHS/Tribal hospitals and Puerto Rico
hospitals and to the continued use of low-income insured days as a
proxy for the uncompensated care costs of these hospitals. We also
sought comments on how to best measure and define the uncompensated
care costs associated with these hospitals that might not otherwise be
captured in Factor 3 calculations based on Worksheet S-10 data. Because
we recognized that our proposal to discontinue the use of the low-
income insured days proxy and to rely solely on Worksheet S-10 data to
calculate Factor 3 of the uncompensated care payment methodology for
IHS/Tribal hospitals and Puerto Rico hospitals could result in a
significant financial disruption for these hospitals, we also proposed
to establish a new supplemental payment for IHS/Tribal hospitals and
Puerto Rico hospitals, beginning in FY 2023. We refer readers to
section IV.E. of the preamble of this final rule for a complete
discussion of this proposed new supplemental payment.
Prior to the proposed rulemaking for FY 2023, CMS consulted with
IHS and Tribes regarding our policies for determining uncompensated
care payments. They expressed that uncompensated care payments are
critical to the providers and should be maintained at their current
levels, at a minimum. As we explained in the FY 2023 IPPS/LTCH PPS
proposed rule, we considered this recent input along with previous
input from stakeholders in the development of our proposed policies. We
also welcomed additional input from stakeholders regarding the unique
circumstances of IHS/Tribal hospitals and Puerto Rico hospitals and/or
any mitigating factors, and noted that this input would inform our
considerations about our proposal to determine Factor 3 for these
hospitals using data from
[[Page 49039]]
Worksheet S-10 and the related proposal to establish a new supplemental
payment for IHS/Tribal hospitals and Puerto Rico hospitals.
We received comments on our proposal to discontinue the use of the
low-income insured days proxy and to rely solely on Worksheet S-10 data
to calculate Factor 3 of the uncompensated care payment methodology for
IHS/Tribal hospitals and Puerto Rico hospitals. Due to the close
interrelationship between this proposal and our proposal to establish a
new supplemental payment for IHS/Tribal hospitals and Puerto Rico
hospitals, we discuss those comments, along with the comments received
on the proposed new supplemental payment, and set forth our final
policies in Section IV.E of this final rule.
For purposes of the FY 2023 proposed rule, we used the December
2021 HCRIS extract to calculate Factor 3. We noted that we intended to
use the March 2022 update of HCRIS to calculate Factor 3 for the FY
2023 IPPS/LTCH PPS final rule. However, we stated that we may consider
the use of more recent data that may become available after March 2022,
but prior to the development of the final rule, if appropriate, for
purposes of calculating the final Factor 3 for this FY 2023 IPPS/LTCH
PPS final rule.
We received comments regarding the uncompensated care costs
definition and Worksheet S-10 cost report instructions.
Comment: With regard to the definition of uncompensated care,
several commenters urged CMS to include unreimbursed costs (shortfalls)
from Medicaid in the definition of uncompensated care. Specifically,
some commenters urged CMS to account for Medicaid shortfalls and
incorporate Line 31 of Worksheet S-10 along with already-utilized Line
30. In contrast, one commenter agreed with CMS that Medicaid
shortfalls, as currently reported on Worksheet S-10, should not be
included in the estimation of uncompensated care costs. Instead, the
commenter recommended that the agency revise Worksheet S-10 so data on
Medicaid shortfalls better resemble actual shortfalls incurred by
hospitals. The commenter further noted that such data will be
increasingly useful for informational purposes as previously uninsured
individuals gain access to Medicaid. Other commenters proposed
incorporating social determinants of health methodologies into
uncompensated care costs by including variables that describe
socioeconomic disadvantage such as accounting for costs incurred by
hospitals to improve access to healthy foods, transportation, health
screenings, technology assistance, and similar community needs.
Notably, another commenter suggested that CMS redefine uncompensated
care to align with the definitions used to determine community benefit
spending under the Internal Revenue Code.
Response: We appreciate commenters' suggestions for revisions and/
or modifications to Worksheet S-10. We will consider the concerns
raised by commenters as part of future cost report clarifications and
will make modifications as necessary to further improve and refine the
information that is reported on Worksheet S-10 to support collection of
the information necessary to implement section 1886(r)(2) of the Act.
With regard to the comments requesting that payment shortfalls from
Medicaid be included in uncompensated care cost calculations, we
continue to believe there are compelling arguments for excluding such
shortfalls from the definition of uncompensated care. First, we note
that we did not propose any changes to the definition of uncompensated
care costs, which was first adopted in the FY 2018 IPPS/LTCH PPS final
rule (82 FR 38215 through 38217) as the amount on Line 30 of Worksheet
S-10, which is the cost of charity care (Line 23) and the cost of non-
Medicare bad debt and non-reimbursable Medicare bad debt (Line 29).
Additionally, key interested parties (including MedPAC) do not consider
Medicaid shortfalls in their definition of uncompensated care.
Furthermore, we continue to believe that it is most consistent with
section 1886(r)(2) of the Act for Medicare uncompensated care payments
to target hospitals that incur a disproportionate share of
uncompensated care for patients with no insurance coverage. We also
note that even if we agreed that it would be appropriate to adjust the
definition of uncompensated care to include Medicaid shortfalls, this
would not be a feasible option at this time due to computational
limitations. Specifically, computing such shortfalls is operationally
problematic because Medicaid pays hospitals a single DSH payment that,
in part, covers the hospital's costs for providing care to the
uninsured and in part covers estimates of the Medicaid ``shortfalls.''
Therefore, it is not clear how CMS would determine how much of the
``shortfall'' is left after the Medicaid DSH payment is made. In
addition, in some States, hospitals return a portion of their Medicaid
revenues to the State via provider taxes and receive supplemental
payments in return (along with the federal match), making the
computation of ``shortfalls'' even more complex.
Regarding the request that we include costs incurred by hospitals
to address social determinants of health in the definition of
uncompensated care costs, we have consistently stated in past final
rules (85 FR 58826 and 86 FR 45239) in response to similar comments
that we believe the purpose of uncompensated care payments is to
provide additional payment to hospitals for treating the uninsured, not
for other costs incurred, including costs associated with addressing
social determinants of health, as commenters have suggested.
Accordingly, we do not believe changing the calculation of
uncompensated care costs is appropriate, at this time.
Comment: Commenters requested that CMS include all patient care
costs when calculating the cost-to-charge ratio (CCR) used in Worksheet
S-10 and urged CMS to include costs incurred for graduate medical
education (GME), costs of paying provider taxes associated with
Medicaid revenue, and costs of providing physician and other
professional services when calculating the CCR used to determine
uncompensated care costs on Worksheet S-10 in order to improve the
accuracy of that CCR.
Response: As we have stated in past rules (84 FR 42378, 85 FR
58826, and 86 FR 45239) in response to similar requests that we modify
the CCR used on Worksheet S-10, we continue to believe the CCR
calculation that is used in Worksheet S-10 is appropriate. Regarding
the request that we include GME costs, costs of paying provider taxes
associated with Medicaid revenue, and costs of providing physician and
other professional service when calculating CCR used in Worksheet S-10,
we note that because the CCR on Line 1 of Worksheet S-10 is obtained
from Worksheet C, Part I, and is also used in other IPPS rate setting
contexts (such as high-cost outliers and the calculation of the MS-DRG
relative weights) from which it is appropriate to exclude the costs
associated with supporting GME costs and the costs of physician and
professional services and costs of paying provider taxes, we remain
reluctant to adjust CCRs in the narrower context of calculating
uncompensated care costs. Therefore, as stated in past final rules, we
continue to believe that it is not appropriate, at this time, to modify
the calculation of the CCR on Line 1 of Worksheet S-10 to include any
additional costs in the numerator of the CCR calculation.
Comment: One commenter stated that large teaching hospitals (with
100+
[[Page 49040]]
residents) would experience an even larger uncompensated care payment
reduction, resulting in underserved and vulnerable populations having
less access to transplant programs (as these programs are often
operated by large teaching institutions). Another commenter expressed
concern that hospitals in Medicaid non-expansion states depend greatly
on uncompensated care payments for financial support, and this
commenter urged CMS to work with providers and patient advocates in
non-expansion states to screen patients for eligibility under either
financial assistance policies or premium support under the Affordable
Care Act before classifying the case as uncompensated care. The same
commenter noted that the equal weighting of bad debt and charity care
on the Worksheet S-10 disincentivizes hospitals from ensuring that
eligible patients receive charity care, as obtaining the qualification
for charity care entails long administrative processes.
Response: We thank commenters for their continued concern regarding
the distribution of uncompensated care payments and the impact of
reductions in uncompensated care payments on teaching hospitals.
However, as stated previously, the purpose of uncompensated care
payments is to provide additional payment to hospitals for treating the
uninsured. Uncompensated payments are not intended to provide support
for other activities that hospitals may undertake. We also note that
CMS does not set charity care criteria for hospitals, and within
reason, hospitals can establish their own criteria of what constitutes
charity care in their financial assistance policies.
Comment: With regard to Worksheet S-10 instructions and guidance, a
few commenters commended CMS for its efforts to provide clearer
instructions for Worksheet S-10. A few commenters requested that CMS
clarify inconsistent Worksheet S-10 instructions so that non-Medicare
bad debt is not multiplied by the CCR. These commenters noted that CMS'
revised instructions indicate that non-reimbursed Medicare bad debt is
not reduced by the CCR, but that CMS' September 2017 transmittal states
that non-Medicare bad debt should be multiplied by the CCR. One
commenter indicated that such practice is inconsistent with the way
non-reimbursable Medicare bad debt is treated.
Response: We appreciate commenters' concerns regarding the need for
clarification of the Worksheet S-10 instructions, as well as their
suggestions for revisions to improve reporting. We reiterate our
commitment to continuing to work with impacted parties to address their
concerns regarding Worksheet S-10 instructions and reporting through
provider education and further refinement of the instructions as
appropriate. We also encourage providers to share with their respective
MAC any questions regarding clarifications of instructions, reporting,
and submission deadlines.
We continue to believe that, as noted by a commenter, our efforts
to refine the instructions and guidance have improved provider
understanding of the Worksheet S-10 and added clarity to the
instructions. We also recognize that there are continuing opportunities
to further improve the accuracy and consistency of the information that
is reported on the Worksheet S-10, and to the extent that commenters
have raised new questions and concerns regarding the reporting
requirements, we will attempt to address them through future rulemaking
and/or sub-regulatory guidance and provider outreach. However, as
stated in previous rules, we continue to believe that the Worksheet S-
10 instructions are now sufficiently clear and allow hospitals to
accurately complete Worksheet S-10s.
Regarding the commenters' request that CMS clarify whether non-
Medicare bad debt is multiplied by CCR, we believe that the Worksheet
S-10 instructions are clear and indicate that the CCR is multiplied by
the non-Medicare bad debt amount on line 28.
Regarding the comments requesting specific structural changes to
Worksheet S-10 and/or further clarification of the reporting
instructions, we note that these comments fall outside the scope of
this final rule. We note that a recent PRA package for hospital cost
report is available at: https://www.cms.gov/regulations-and-guidancelegislationpaperworkreductionactof1995pra-listing/cms-2552-10.
We received comments regarding Worksheet S-10 data and audits.
Comment: In relation to the accuracy of the Worksheet S-10 data,
one commenter urged CMS to refine the instructions for reporting of
uncompensated care costs. The commenter's recommendations included that
CMS should mitigate the effect of anomalies in the cost data for the
COVID-19 PHE period and that CMS should consider the redistributive
effects of the COVID-19 PHE for purposes of determining uncompensated
care payments in future rulemaking. One commenter recommended that CMS
work with impacted providers in upcoming years to ensure that the data
from the COVID-19 PHE period is properly understood and correctly
reported. Another commenter urged CMS to account for the
unpredictability of the COVID-19 PHE, including the emergence of new
variants, in determining uncompensated care payments for future years.
Response: In regard to requests for CMS to mitigate the effect of
anomalies in FY 2020 through FY 2022 cost report data and account for
the unpredictability of the COVID-19 PHE in determining uncompensated
care payments for future years, we note that we are finalizing the
proposal to use a three-year average of the most recently audited cost
report data for FY 2024 and subsequent years. Using the three-year
average will smooth the variation in year-to-year uncompensated care
payments and lessen the impacts of COVID-19 PHE and future unforeseen
events. We also note that the calculations for Factor 1 and Factor 2
reflect the estimated impact of the COVID-19 PHE on DSH payments.
Further, we anticipate that there will be less fluctuation in cost
report data as the PHE disruptions on healthcare utilization fade. We
will continue to monitor the impacts of the PHE and will consider this
issue further in future rulemaking, as appropriate.
Comment: Some commenters commended CMS for the agency's efforts to
develop and improve the audit process for Worksheet S-10 data.
Specifically, one commenter commended CMS for its efforts to audit all
hospitals rather than only a portion, while another commenter
recommended that CMS expend all the necessary resources to continue to
audit Worksheet S-10 data for all DSH eligible hospitals.
Echoing concerns expressed in previous years, commenters encouraged
CMS to work with MACs to make the audit process clearer, more
consistent, and more complete. The same commenters provided several
recommendations, including that CMS establish a standardized process
across auditors, develop uniform standards regarding information
submission and acceptable documentation to meet audit requirements,
develop a transparent timeframe with sufficient lead time, target
specific data aspects for the audit, and develop a process for timely
appeals. Specifically, one commenter recommended that all hospitals be
audited using the same protocols and that having only some hospitals
subject to desk reviews is inequitable. A few commenters cited the
Medicare wage index audit as a model that CMS could use for Worksheet
S-10 audits. One commenter suggested that CMS ensure
[[Page 49041]]
that Worksheet S-10 audits impose minimal burden and are equitable and
uniform across hospitals. The same commenter also suggested that CMS
consider making the audit process more transparent by disclosing
criteria used to identify hospitals for audits and publishing audit
protocols in advance to allow hospitals time and opportunity to respond
to audits and address findings. Other recommendations from this
commenter included that CMS should conduct audits in advance of using
data for payment rate setting such that data are accurate and final,
select hospitals for audits in an equitable and systematic way, and
review audit findings to ensure that MACs and subcontractors are
consistently performing audits according to protocols.
Response: We thank commenters for their feedback on the audits of
the FY 2019 Worksheet S-10 data and their recommendations for future
audits. As we have stated previously in response to comments regarding
audit protocols, these are provided to the MACs in advance of the audit
so as to assure consistency and timeliness in the audit process. We
began auditing the FY 2019 Worksheet S-10 data for selected hospitals
last year so that the audited uncompensated care data for these
hospitals would be available in time for use in the FY 2023 IPPS/LTCH
PPS proposed rule. We chose to focus the audit on the FY 2019 cost
reports in order to maximize the available audit resources. Similarly,
as discussed in the FY 2022 IPPS/LTCH PPS final rule, we chose to focus
the audits on the FY 2018 cost reports in order to maximize the
available audit resources prior to the FY 2022 rulemaking. In response
to the consistent feedback from commenters emphasizing the importance
of audits in ensuring the accuracy and consistency of data reported on
the Worksheet S-10, we have also started the process of auditing FY
2020 Worksheet S-10 data.
We appreciate all commenters' input and recommendations on how to
improve our audit process and reiterate our commitment to continue
working with the MACs and providers on audit improvements, which
include making changes to increase the efficiency of the audit process,
building on the lessons learned in previous audit years. We will take
these recommendations into consideration for future rulemaking.
Regarding commenters' requests for a standard audit timeline, we do not
intend to establish a fixed timeline for audits across MACs at this
time such that we can retain the flexibility to use our limited audit
resources to address and prioritize audit needs across all CMS programs
each year. We note that MACs collaborate with providers regarding
scheduling dates during the Worksheet S-10 audit process. We also note
that MACs work closely with providers to balance the time needed to
complete the Worksheet S-10 audits and to minimize the burden on
providers and will continue to do so.
Regarding commenters' requests that we make public the audit
instructions and criteria, as we previously stated in the FY 2022 IPPS/
LTCH final rule and in prior rules, we do not make review protocols
public as CMS desk review and audit protocols are confidential and are
for CMS and MAC use only. We note that there is no requirement under
either the Administrative Procedure Act or the Medicare statute that
CMS establish audit protocols through notice and comment rulemaking.
Rather, it is sufficient that we provide impacted parties with notice
of our proposed methodology and the data sources that will be used, so
that they may have a meaningful opportunity to submit their views on
the proposed methodology and the adequacy of the data for the intended
purpose. Similarly, there is no requirement that we provide an
opportunity for comment on the actual findings or audit disallowances
determined for each hospital as these results are confidential to each
hospital.
Concerning commenters' recommendations that we establish a timely
review and appeals process for the Worksheet S-10 audits, we do not
plan to introduce such a process at this time in order to maximize
limited audit resources. However, we will continue to work with
impacted parties to address their concerns regarding the accuracy and
consistency of data reported on Worksheet S-10. We will also continue
to work to further improve reporting through revised instructions, and
will also work with MACs to ensure a more consistent audit process
across providers and MACs.
Regarding commenters' recommendations that we establish a similar
process to that of the wage index audits, at this point we do not plan
to introduce an audit process with such a structure in order to
maximize limited audit resources.
As discussed in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28392), for purposes of determining Factor 3 for FY 2023 and subsequent
fiscal years, we are continuing to apply the following policies: (1)
the merger policies that were initially adopted in the FY 2015 IPPS/
LTCH PPS final rule (79 FR 50021), as modified in the FY 2021 IPPS/LTCH
PPS final rule (85 FR 58828 and 58829) to incorporate the use of a
multiplier to account for merger effective date; (2) the policy for
hospitals with multiple cost reports, beginning in the same fiscal
year, of using the longest cost report and annualizing uncompensated
care data if a hospital's cost report does not equal 12 months of data;
(3) the policy, as modified in the FY 2021 IPPS/LTCH PPS final rule (85
FR 58829) and as further modified as proposed in the FY 2023 IPPS/LTCH
PPS proposed rule, for the rare case where a hospital has a cost report
that starts in one fiscal year and spans the entirety of the following
fiscal year, such that the hospital has no cost report for that
subsequent fiscal year, of using the cost report that spans both fiscal
years for the latter fiscal year; (4) the new hospital policy, as
modified in the FY 2020 IPPS/LTCH PPS final rule and as further
modified as proposed in this section; (5) the newly merged hospital
policy, with the modifications proposed in the FY 2023 IPPS/LTCH PPS
proposed rule; and (6) the policies regarding the application of
statistical trim methodologies to potentially aberrant CCRs and
potentially aberrant uncompensated care costs reported on the Worksheet
S-10, as modified as proposed in the FY 2023 IPPS/LTCH PPS proposed
rule.
Because we proposed to use multiple years of cost reports to
determine Factor 3 starting in FY 2023, we determined that it would
also be necessary to make a further modification to the policy
regarding cost reports that start in one fiscal year and span the
entirety of the following fiscal year. Specifically, in the rare cases
when we use a cost report that starts in one fiscal year and spans the
entirety of the subsequent Federal fiscal year to determine
uncompensated care costs for the subsequent Federal fiscal year, we
would not use the same cost report to determine the hospital's
uncompensated care costs for the earlier fiscal year. We explained that
using the same cost report to determine uncompensated care costs for
both fiscal years would not be consistent with our intent to smooth
year-to-year variation in uncompensated care costs. As an alternative,
we proposed to use the hospital's most recent prior cost report, if
that cost report spans the applicable period. In other words, in
determining Factor 3 for FY 2023, we would not use the same cost report
to determine the hospital's uncompensated care costs for both FY 2018
and FY 2019. Rather, we would use the cost report that spans the
entirety of FY 2019 to determine uncompensated care costs for FY 2019
and we would use the hospital's most recent prior cost report to
determine its uncompensated care costs for FY 2018,
[[Page 49042]]
provided that cost report spans some portion of Federal fiscal year
2018.
We did not receive comments on this proposed modification. We are
finalizing as proposed.
Scaling Factor
To address the effects of the calculating Factor 3 using data from
multiple fiscal years, in the FY 2023 IPPS/LTCH PPS proposed rule (87
FR 28392) we proposed to apply a scaling factor to the Factor 3 values
calculated for all DSH eligible hospitals so that total uncompensated
care payments to hospitals that are projected to be eligible for DSH
for a fiscal year will be consistent with the estimated amount
available to make uncompensated care payments for that fiscal year.
Specifically, we proposed to adopt a policy under which we divide 1
(the expected sum of all DSH-eligible hospitals' Factor 3 values) by
the actual sum of all DSH eligible hospitals' Factor 3 values and then
multiply the quotient by the uncompensated care payment determined for
each DSH eligible hospital to obtain a scaled uncompensated care
payment amount for each hospital. This process is designed to ensure
that the sum of the scaled uncompensated care payments for all
hospitals that are projected to be DSH eligible is consistent with the
estimate of the total amount available to make uncompensated care
payments for the applicable fiscal year. In the proposed rule, we noted
that a similar scaling factor methodology was previously used in both
FY 2018 (82 FR 38214 and 38215) and FY 2019 (83 FR 41414), when the
Factor 3 calculation also included multiple years of data.
We did not receive comments on this proposed scaling factor policy.
We are finalizing as proposed.
Modifications to New Hospital Policy for Purposes of Factor 3
We proposed to modify the new hospital policy that was initially
adopted in the FY 2020 IPPS/LTCH PPS final rule to determine Factor 3
for new hospitals. Consistent with our proposal to use multiple years
of cost reports to determine Factor 3, we proposed to define new
hospitals as hospitals that do not have cost report data for the most
recent year of data being used in the Factor 3 calculation. In other
words, the cut-off date for the new hospital policy would be the
beginning of the Federal fiscal year after the most recent year for
which audits of the Worksheet S-10 data have been conducted. For FY
2023, the FY 2019 cost reports are the most recent year of cost reports
for which audits of Worksheet S-10 data have been conducted. Thus,
hospitals with CCNs established on or after October 1, 2019, would be
subject to the new hospital policy in FY 2023.
Under the proposed modification to the new hospital policy, we
would continue the policy established in the FY 2020 IPPS/LTCH PPS
final rule (84 FR 42370) that if a new hospital has a preliminary
projection of being eligible for DSH payments based on its most recent
available disproportionate patient percentage, it may receive interim
empirically justified DSH payments. However, new hospitals would not
receive interim uncompensated care payments during FY 2023 because we
would have no FY 2018 or FY 2019 uncompensated care data on which to
determine what those interim payments should be. The MAC will make a
final determination concerning whether the hospital is eligible to
receive Medicare DSH payments at cost report settlement based on its FY
2023 cost report.
We also proposed to modify the methodology used to calculate Factor
3 for new hospitals. Specifically, we proposed to determine Factor 3
for new hospitals using a denominator based solely on uncompensated
care costs from cost reports for the most recent fiscal year for which
audits have been conducted. For example, if a new hospital is
ultimately determined to be eligible for Medicare DSH payments for FY
2023, the hospital will receive an uncompensated care payment
calculated using a Factor 3, where the numerator is the uncompensated
care costs reported on Worksheet S-10 of the hospital's FY 2023 cost
report, and the denominator is the sum of the uncompensated care costs
reported on Worksheet S-10 of the FY 2019 cost reports for all DSH-
eligible hospitals. In addition, we proposed to apply a scaling factor,
as discussed previously, to the Factor 3 calculation for a new
hospital. We explained that we believe applying the scaling factor is
appropriate for purposes of calculating Factor 3 for all hospitals,
including new hospitals and hospitals that are treated as new
hospitals, in order to improve consistency and predictability across
all hospitals.
Modifications to the Newly Merged Hospital Policy
In the FY 2023 IPPS/LTCH PPS rule, we stated that we will continue
to treat hospitals that merge after the development of the final rule
for the applicable fiscal year similar to new hospitals. As explained
in the FY 2015 IPPS/LTCH PPS final rule, for these newly merged
hospitals, we do not have data currently available to calculate a
Factor 3 amount that accounts for the merged hospital's uncompensated
care burden (79 FR 50021). In the FY 2015 IPPS/LTCH PPS final rule, we
finalized a policy under which Factor 3 for hospitals that we do not
identify as undergoing a merger until after the public comment period
and additional review period following the publication of the final
rule or that undergo a merger during the fiscal year will be
recalculated similar to new hospitals (79 FR 50021 and 50022).
Consistent with the policy adopted in the FY 2015 IPPS/LTCH PPS final
rule, we will continue to treat newly merged hospitals in a similar
manner to new hospitals, such that the newly merged hospital's final
uncompensated care payment will be determined at cost report settlement
where the numerator of the newly merged hospital's Factor 3 will be
based on the cost report of only the surviving hospital (that is, the
newly merged hospital's cost report) for the current fiscal year.
However, if the hospital's cost reporting period includes less than 12
months of data, the data from the newly merged hospital's cost report
will be annualized for purposes of the Factor 3 calculation. Consistent
with the proposed modification to the methodology used to determine
Factor 3 for new hospitals described previously, we proposed to
determine Factor 3 for newly merged hospitals using a denominator that
is the sum of the uncompensated care costs for all DSH-eligible
hospitals, as reported on Worksheet S-10 of their cost reports for the
most recent fiscal year for which audits have been conducted. In
addition, we would apply a scaling factor, as discussed previously, to
the Factor 3 calculation for a newly merged hospital. We stated our
belief that applying the scaling factor is appropriate for purposes of
calculating Factor 3 for all hospitals, including new hospitals and
hospitals that are treated as new hospitals, in order to improve
consistency and predictability across all hospitals.
We also explained that consistent with past policy, interim
uncompensated care payments for the newly merged hospital will be based
only on the data for the surviving hospital's CCN available at the time
of the development of the final rule. In other words, for FY 2023, the
eligibility of a newly merged hospital to receive interim uncompensated
care payments and the amount of any interim uncompensated care
payments, would be based on the uncompensated care costs from the FY
2018 and FY 2019 cost reports available for the surviving
[[Page 49043]]
CCN at the time the final rule is developed. However, at cost report
settlement, we would determine the newly merged hospital's final
uncompensated care payment based on the uncompensated care costs
reported on its FY 2023 cost report. That is, we would revise the
numerator of Factor 3 for the newly merged hospital to reflect the
uncompensated care costs reported on the newly merged hospital's FY
2023 cost report. The denominator would be the sum of the uncompensated
care costs reported on Worksheet S-10 of the FY 2019 cost reports for
all DSH-eligible hospitals, which is the most recent fiscal year for
which audits have been conducted.
Comment: A couple of commenters expressed support for the policy
currently in place for newly merged hospitals under which interim
uncompensated care payments are based on the data for the surviving
hospital's CCN available at the time of development of the final rule.
These commenters also indicated support for continuing the policy in
place for new hospitals, under which new hospitals with a CCN
established on or after October 2019 with a preliminary projection of
being eligible for DSH payments would receive interim empirically
justified DSH payments. MACs would then make the final determination
concerning whether a new hospital is eligible to receive DSH payments
at cost report settlement based on the new hospital's FY 2023 cost
report. One commenter requested that CMS provide clarification
regarding which cost report would be used in the numerator of the
Factor 3 calculation for a newly merged hospital or new hospital, and
whether the cost report beginning or ending in FY 2023 would be used.
Response: We appreciate the support for our current policies for
new and newly merged hospitals. In response to the comment asking for
clarification on whether a newly merged hospital or new hospital would
use its cost report beginning or ending in FY 2023, we note that the
new hospital policy and the newly merged hospital policy are based on
the start date of the hospital's cost reporting period. Specifically,
the Factor 3 calculation for a new hospital will be based on the
hospital's FY 2023 cost report (that is, a cost report with a start
date on or after October 1, 2022, and on or before September 30, 2023).
The numerator of the hospital's Factor 3 will be the hospital's total
uncompensated care costs from the Worksheet S-10 Line 30 of its FY 2023
cost report (annualized, if necessary). The denominator will be the
total national uncompensated care costs from the FY 2019 cost reports
as calculated in this FY 2023 IPPS/LTCH PPS final rule. In the case of
a new hospital or a newly merged hospital that has a cost report that
spans multiple Federal fiscal years, if the cost report is a FY 2023
cost report, there is only one denominator in the Factor 3 calculation.
In addition, the pro rata calculation (i.e., the hospital's cost
reporting period spans different Federal fiscal years) for a new
hospital or a newly merged hospital is calculated using only the FY2023
total uncompensated care amount (that is, the Factor 3 is multiplied by
the FY 2023 total uncompensated care amount, as finalized in this final
rule.).
After consideration of the comments received, we are finalizing the
proposed modifications to the new hospital and newly merged policies.
CCR Trim Methodology
The calculation of a hospital's total uncompensated care costs on
Worksheet S-10 requires the use of the hospital's cost to charge ratio
(CCR). Consistent with the process for trimming CCRs used in the FY
2021 IPPS/LTCH PPS final rule (85 FR 58831 and 58832), we explained in
the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28393) that we will
apply the following steps to determine the applicable CCR for FY 2018
reports and FY 2019 reports separately:
Step 1: Remove Maryland hospitals. In addition, we will remove all-
inclusive rate providers because their CCRs are not comparable to the
CCRs calculated for other IPPS hospitals.
Step 2: Calculate a CCR ``ceiling'' for the applicable fiscal year
with the following data: for each IPPS hospital that was not removed in
Step 1 (including non-DSH eligible hospitals), we use cost report data
to calculate a CCR by dividing the total costs on Worksheet C, Part I,
Line 202, Column 3 by the charges reported on Worksheet C, Part I, Line
202, Column 8. (Combining data from multiple cost reports from the same
fiscal year is not necessary, as the longer cost report will be
selected.) The ceiling is calculated as 3 standard deviations above the
national geometric mean CCR for the applicable fiscal year. This
approach is consistent with the methodology for calculating the CCR
ceiling used for high-cost outliers. Remove all hospitals that exceed
the ceiling so that these aberrant CCRs do not skew the calculation of
the statewide average CCR.
Step 3: Using the CCRs for the remaining hospitals in Step 2,
determine the urban and rural statewide average CCRs for the applicable
fiscal year for hospitals within each State (including non-DSH eligible
hospitals), weighted by the sum of total hospital discharges from
Worksheet S-3, Part I, Line 14, Column 15.
Step 4: Assign the appropriate statewide average CCR (urban or
rural) calculated in Step 3 to all hospitals, excluding all-inclusive
rate providers, with a CCR for the applicable fiscal year greater than
3 standard deviations above the national geometric mean for that fiscal
year (that is, the CCR ``ceiling''). For purposes of both the proposed
rule and this final rule, the statewide average CCR was applied to 8
hospitals' FY 2018 reports, of which 3 hospitals had FY 2018 Worksheet
S-10 data. The statewide average CCR was applied to 14 hospitals' FY
2019 reports, of which 6 hospitals had FY 2019 Worksheet S-10 data.
Step 5: For hospitals that did not report a CCR on Worksheet S-10,
Line 1, we assign them the statewide average CCR for the applicable
fiscal year as determined in step 3.
After completing the previously described steps, we re-calculate
the hospital's uncompensated care costs (Line 30) for the applicable
fiscal year using the trimmed CCR (the statewide average CCR (urban or
rural, as applicable)).
We did not receive any comments on the discussion of CCR trim
methodology. We are finalizing as proposed.
Modifications to the Uncompensated Care Data Trim Methodology
After applying the CCR trim methodology, there are rare situations
where a hospital has potentially aberrant uncompensated care data for a
fiscal year that are unrelated to its CCR. Therefore, in the FY 2023
IPPS LTCH/PPS proposed rule, we explained that under the trim
methodology for potentially aberrant UCC that was included as part of
the methodology for purposes of determining Factor 3 in the FY 2021
IPPS/LTCH PPS final rule (85 FR 58832), if the hospital's uncompensated
care costs for FY 2018 or FY 2019 are an extremely high ratio (greater
than 50 percent) of its total operating costs in the applicable fiscal
year, we will determine the ratio of uncompensated care costs to the
hospital's total operating costs from another available cost report,
and apply that ratio to the total operating expenses for the
potentially aberrant fiscal year to determine an adjusted amount of
uncompensated care costs for the applicable fiscal year. Specifically,
if a hospital's FY 2018 cost report is determined to include
potentially
[[Page 49044]]
aberrant data, data from its FY 2019 cost report will be used for the
ratio calculation. Thus, the hospital's uncompensated care costs for FY
2018 will be trimmed by multiplying its FY 2018 total operating costs
by the ratio of uncompensated care costs to total operating costs from
the hospital's FY 2019 cost report to calculate an estimate of the
hospital's uncompensated care costs for FY 2018 for purposes of
determining Factor 3 for FY 2023. Because we proposed to use multiple
years of cost reports in the Factor 3 calculation for FY 2023, we would
apply this same approach to address potentially aberrant data in the FY
2019 cost report, by trimming based on the hospital's FY 2020 cost
report.
In the FY 2023 IPPS/LTCH PPS proposed rule, we noted that we have
audited the FY 2018 and the FY 2019 Worksheet S-10 data for a number of
hospitals. Because the UCC data for these hospitals have been subject
to audit, we stated our belief that there is increased confidence that
if high uncompensated care costs are reported by these audited
hospitals, the information is accurate. Therefore, consistent with the
policy that was adopted in the FY 2021 IPPS/LTCH PPS final rule, we
stated that it would be unnecessary to apply the trim methodology for a
fiscal year for which a hospital's UCC data have been audited.
In addition to the UCC trim methodology, we stated that we would
continue to apply a trim specific to certain hospitals that do not have
audited FY 2018 Worksheet S-10 data and/or audited FY 2019 Worksheet S-
10 data. We noted that in rare cases, hospitals that are not currently
projected to be DSH eligible and that do not have audited Worksheet S-
10 data may have a potentially aberrant amount of insured patients'
charity care costs (line 23 column 2). Similar to the approach
initially adopted in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45245
and 45246), we proposed to continue to use a threshold of t3 standard
deviations from the mean ratio of insured patients' charity care costs
to total uncompensated care costs (line 23 column 2 divided by line 30)
and a dollar threshold that is the median total uncompensated care cost
reported on most recent audited cost reports for hospitals that were
projected to be DSH-eligible. We stated that we continue to believe
these thresholds are appropriate, in order to address potentially
aberrant data. However, we proposed to modify the calculation to
include Worksheet S-10 data from IHS/Tribal hospitals and Puerto Rico
hospitals consistent with our proposal to begin using Worksheet S-10
data to determine Factor 3 for these hospitals. We also proposed to
apply the same thresholds to identify potentially aberrant charity care
costs data for all cost reporting years that are used in determining
Factor 3. We noted that based on calculations from the FY 2019 reports,
the threshold amounts were similar to FY 2018 reports; therefore, we
explained that we believe it is reasonable to use the same thresholds
to identify aberrant data for both years. Thus, under the proposal, in
FY 2023 we would use the same thresholds to identify potentially
aberrant data for both FY 2018 and FY 2019 reports. In addition, we
proposed to apply the same threshold amounts originally calculated for
the FY 2018 reports to identify potentially aberrant data for
subsequent fiscal years in order to facilitate transparency and
predictability. Therefore, for FY 2023 and subsequent fiscal years, we
proposed that in the rare case that a hospital's insured patients'
charity care costs are greater than $7 million and the ratio of the
hospital's cost of insured patient charity care (line 23 column 2) to
total uncompensated care costs (line 30) is greater than 60 percent, we
would exclude the hospital from the prospective Factor 3 calculation.
We explained that this trim would only impact hospitals that are not
currently projected to be DSH-eligible; and therefore, are not part of
the calculation of the denominator of Factor 3, which includes only
uncompensated care costs for projected DSH-eligible hospitals.
Consistent with the approach adopted in the FY 2022 IPPS/LTCH PPS final
rule, if a hospital would be trimmed under both the UCC trim
methodology and this alternative trim, we would apply this trim in
place of the existing UCC trim methodology. We stated that we continue
to believe this alternative trim more appropriately addresses
potentially aberrant insured patient charity care costs compared to the
UCC trim methodology, because the UCC trim is based solely on the ratio
of total uncompensated care costs to total operating costs and does not
consider the level of insured patients' charity care costs.
In addition, we proposed to continue to apply the policy adopted in
the FY 2022 IPPS/LTCH PPS final rule, for the hospitals that would be
subject to this alternative trim and are ultimately determined to be
DSH-eligible at cost report settlement. We explained that if a hospital
subject to this trim is ultimately determined to be DSH-eligible at
cost report settlement, its uncompensated care payment should be
calculated only after the hospital's reporting of insured charity care
costs on its FY 2023 Worksheet S-10 has been reviewed. Accordingly, the
MAC would calculate a Factor 3 for the hospital only after reviewing
the uncompensated care information reported on Worksheet S-10 of the
hospital's FY 2023 cost report. Then we would calculate Factor 3 for a
hospital subject to this alternative trim using the same methodology
used to determine Factor 3 for new hospitals. Specifically, the
numerator would reflect the uncompensated care costs reported on the
hospital's FY 2023 cost report, while the denominator would reflect the
sum of the uncompensated care costs reported on Worksheet S-10 of the
FY 2019 cost reports of all DSH-eligible hospitals. In addition,
consistent with our proposed approach for new hospitals, we would apply
a scaling factor, as discussed previously, to the Factor 3 calculation
for these hospitals. We stated that we believe applying the scaling
factor is appropriate for purposes of calculating Factor 3 for all
hospitals, including new hospitals and hospitals that are treated as
new hospitals, in order to improve consistency and predictability
across all hospitals.
We did not receive any comments on the proposed modifications to
the uncompensated care data trim methodology. We are finalizing as
proposed.
Summary of Methodology
In summary, under the policies we are finalizing in this FY 2023
IPPS/LTCH PPS final rule, for FY 2023, we will compute Factor 3 for
each hospital using the following steps:
Step 1: Select the hospital's longest cost report from its Federal
fiscal year (FY) 2018 cost reports and the longest cost report from its
FY 2019 cost reports. (Alternatively, in the rare case when the
hospital has no cost report for a particular year because the cost
report for the previous Federal fiscal year spanned the more recent
Federal fiscal year, the previous Federal fiscal year cost report will
be used in this step. In the rare case, that using a previous Federal
fiscal year cost report results in a period without a report, we will
use the prior year report, if that cost report spanned the applicable
period. (For example, if a hospital does not have a FY 2019 cost report
because the hospital's FY 2018 cost report spanned the FY 2019 time
period, then we will use the FY 2018 cost report that spanned the FY
2019 time period for this step. Using the same example, where the
hospital's FY 2018 report is
[[Page 49045]]
used for the FY 2019 time period, then we will use the hospital's FY
2017 report if it spans some of the FY 2018 time period. In other
words, we will not use the same cost report for both the FY 2019 and
the FY 2018 time periods.) In general, we note that, for purposes of
the Factor 3 methodology, references to a fiscal year cost report are
to the cost report that spans the relevant Federal fiscal year period.
Step 2: Annualize the uncompensated care costs (UCC) from Worksheet
S-10 Line 30, if a cost report is more than or less than 12 months. (If
applicable, use the statewide average CCR (urban or rural) to calculate
uncompensated care costs.)
Step 3: Combine adjusted and/or annualized uncompensated care costs
for hospitals that merged using the merger policy.
Step 4: Calculate Factor 3 for all DSH eligible hospitals using
annualized uncompensated care costs (Worksheet S-10 Line 30) based on
FY 2018 cost report data and FY 2019 cost report data (from Step 1, 2
or 3). New hospitals and other hospitals that are treated as if they
are new hospitals for purposes of Factor 3 are excluded from this
calculation.
Step 5: Average the Factor 3 values from Step 4; that is, add the
Factor 3 values for FY 2018 and FY 2019 for each hospital, and divide
that amount by the number of cost reporting periods with data to
compute an average Factor 3 for the hospital. Multiply by a scaling
factor.
For FY 2024 and subsequent fiscal years, these steps will be
calculated using the most recent 3 years of audited cost reports. (For
example, in FY 2024, the FY 2018, FY 2019, and FY 2020 reports would be
used.)
In the FY 2023 IPPS/LTCH PPS proposed rule, we proposed to make a
conforming change to the existing regulation at Sec.
412.106(g)(1)(iii)(C)(8) and to add a new regulation at Sec.
412.106(g)(1)(iii)(C)(10) to reflect our proposal to calculate Factor 3
based on the most recent two years of audited data on uncompensated
care costs in FY 2023. We also proposed to add Sec.
412.106(g)(1)(iii)(C)(11) to reflect our proposal to calculate Factor 3
for FY 2024 and subsequent fiscal years based on a 3-year average of
the most recent available audited data on uncompensated care costs.
We did not receive any comments on these proposed changes to
regulations. We are finalizing the proposed changes with only minor
conforming changes for internal consistency.
(d) Per Discharge Amount of Interim Uncompensated Care Payments
Since FY 2014, we have made interim uncompensated care payments
during the fiscal year on a per discharge basis. We have used a 3-year
average of the number of discharges for a hospital to produce an
estimate of the amount of the hospital's uncompensated care payment per
discharge. Specifically, the hospital's total uncompensated care
payment amount for the applicable fiscal year, is divided by the
hospital's historical 3-year average of discharges computed using the
most recent available data to determine the uncompensated care payment
per discharge for that fiscal year.
In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45247 and 45248), we
modified this calculation for FY 2022 to be based on an average of FY
2018 and FY 2019 historical discharge data, rather than a 3-year
average that included data from FY 2018, FY 2019, and FY 2020. We
explained our belief that computing a 3-year average with the FY 2020
discharge data would underestimate discharges, due to the decrease in
discharges during the COVID-19 pandemic. For the same reason, we
proposed to modify this calculation for FY 2023 to be based on the
average of FY 2018, FY 2019, and FY 2021 historical discharge data,
rather than a 3-year average of the most recent 3 years of discharge
data from FY 2019, FY 2020, and FY 2021. We stated that computing a 3-
year average using the most recent 3 years would potentially
underestimate the number of discharges for FY 2023, due to the effects
of the COVID-19 pandemic in FY 2020, which was the first year of the
COVID-19 pandemic. Therefore, we explained our belief that the proposed
modification may result in a better estimate of the number of
discharges during FY 2023, for purposes of the interim uncompensated
care payment calculation. In addition, we noted that our proposal to
include discharge data from FY 2021 to compute this 3-year average was
consistent with the proposed use of FY 2021 Medicare claims in the IPPS
ratesetting, as discussed in section I.F. of the preamble of the FY
2023 IPPS/LTCH PPS proposed rule. Under this proposal, the resulting 3-
year average of the number of discharges would be used to calculate a
per discharge payment amount that will be used to make interim
uncompensated care payments to each projected DSH-eligible hospital
during FY 2023. We also explained that the interim uncompensated care
payments made to a hospital during the fiscal year will be reconciled
following the end of the year to ensure that the final payment amount
is consistent with the hospital's prospectively determined
uncompensated care payment for the FY 2023.
In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58833 and 58834), we
finalized a voluntary process through which a hospital may submit a
request to its MAC for a lower per discharge interim uncompensated care
payment amount, including a reduction to zero, once before the
beginning of the Federal fiscal year and/or once during the Federal
fiscal year. In conjunction with this request, the hospital must
provide supporting documentation demonstrating that there would likely
be a significant recoupment (for example, 10 percent or more of the
hospital's total uncompensated care payment or at least $100,000) at
cost report settlement if the per discharge amount is not lowered. For
example, a hospital might submit documentation showing a large
projected increase in discharges during the fiscal year to support
reduction of its per discharge uncompensated care payment amount. As
another example, a hospital might request that its per discharge
uncompensated care payment amount be reduced to zero midyear if the
hospital's interim uncompensated care payments during the year have
already surpassed the total uncompensated care payment calculated for
the hospital.
Under the policy we finalized in the FY 2021 IPPS/LTCH PPS final
rule, the hospital's MAC would evaluate these requests and the
supporting documentation before the beginning of the Federal fiscal
year and/or with midyear requests when the historical average number of
discharges is lower than the hospital's projected FY 2023 discharges.
If following review of the request and the supporting documentation,
the MAC agrees that there likely would be significant recoupment of the
hospital's interim Medicare uncompensated care payments at cost report
settlement, the only change that will be made is to lower the per
discharge amount either to the amount requested by the hospital or
another amount determined by the MAC to be appropriate to reduce the
likelihood of a substantial recoupment at cost report settlement. If
the MAC determines it would be appropriate to reduce the interim
Medicare uncompensated care payment per discharge amount, that updated
amount will be used for purposes of the outlier payment calculation for
the remainder of the Federal fiscal year. We refer readers to the
Addendum to this final
[[Page 49046]]
rule for a more detailed discussion of the steps for determining the
operating and capital Federal payment rate and the outlier payment
calculation. No change would be made to the total uncompensated care
payment amount determined for the hospital on the basis of its Factor
3. In other words, any change to the per discharge uncompensated care
payment amount will not change how the total uncompensated care payment
amount will be reconciled at cost report settlement.
Comment: A couple of commenters recommended that CMS use the
traditional payment reconciliation process to calculate final payments
for uncompensated care costs pursuant to section 1886(r)(2) of the Act.
These commenters did not object to CMS using prospective estimates,
derived from the best data available, to calculate interim payments for
uncompensated care costs. However, the commenters stated that interim
payments should be subject to later reconciliation based on estimates
derived from actual data from the federal fiscal year. These same
commenters also asserted that CMS has failed to provide a meaningful
opportunity to review and comment on the more recent data used in
developing the final rule before the agency publishes the final rule.
Response: Consistent with the position that we have taken in
rulemaking for previous years, we continue to believe that applying our
best estimates of the three factors used in the calculation of
uncompensated care payments to determine payments prospectively is most
conducive to administrative efficiency, finality, and predictability in
payments (78 FR 50628; 79 FR 50010; 80 FR 49518; 81 FR 56949; 82 FR
38195; 84 FR 42373; 85 FR 58833 and 86 FR 45246). We continue to
believe that, in affording the Secretary the discretion to estimate the
three factors used to determine uncompensated care payments and by
including a prohibition against administrative and judicial review of
those estimates in section 1886(r)(3) of the Act, Congress recognized
the importance of finality and predictability under a prospective
payment system. As a result, we do not agree with the commenters'
suggestion that we should establish a process for reconciling our
estimates of uncompensated care payments, which would be contrary to
the notion of a prospective payment system. Furthermore, we note that
this rulemaking has been conducted consistent with the requirements of
the Administrative Procedure Act and Title XVIII of the Act. Under the
Administrative Procedure Act, a proposed rule is required to include
either the terms or substance of the proposed rule or a description of
the subjects and issues involved. In this case, the FY 2023 IPPS/LTCH
PPS proposed rule included a detailed discussion of our proposed
methodology for calculating Factor 3 and the data that would be used.
We made public the best data available at the time of the proposed rule
in order to allow hospitals to understand the anticipated impact of the
proposed methodology and submit comments, and we have considered those
comments in determining our final policies for FY 2023.
(e) Process for Notifying CMS of Merger Updates and To Report Upload
Issues
As we have done for every proposed and final rule beginning in FY
2014, in conjunction with this final rule, we will publish on the CMS
website a table listing Factor 3 for all hospitals that we estimate
will receive empirically justified Medicare DSH payments in FY 2023
(that is, those hospitals that will receive interim uncompensated care
payments during the fiscal year), and for the remaining subsection (d)
hospitals and subsection (d) Puerto Rico hospitals that have the
potential of receiving an uncompensated care payment in the event that
they receive an empirically justified Medicare DSH payment for the
fiscal year as determined at cost report settlement. However, we note
that a Factor 3 will not be published for new hospitals and hospitals
that are subject to the alternative trim for hospitals with potentially
aberrant data that are not projected to be DSH-eligible.
We also will publish a supplemental data file containing a list of
the mergers that we are aware of and the computed uncompensated care
payment for each merged hospital. In the DSH uncompensated care
supplemental data file, we list new hospitals and the 10 hospitals that
would be subject to the alternative trim for hospitals with potentially
aberrant data that are not projected to be DSH-eligible, with a N/A in
the Factor 3 column.
Hospitals had 60 days from the date of public display of the FY
2023 IPPS/LTCH PPS proposed rule in the Federal Register to review the
table and supplemental data file published on the CMS website in
conjunction with the proposed rule and to notify CMS in writing of
issues related to mergers and/or to report potential upload
discrepancies due to MAC mishandling of Worksheet S-10 data during the
report submission process (for example, report not reflecting audit
results due to MAC mishandling or most recent report differs from
previously accepted amended report due to MAC mishandling). We stated
that comments raising issues or concerns that are specific to the
information included in the table and supplemental data file could be
submitted by email to the CMS inbox at [email protected]. We
indicated that we would address comments related to mergers and/or
reporting upload discrepancies submitted to the CMS DSH inbox as
appropriate in the table and the supplemental data file that we publish
on the CMS website in conjunction with the publication of this FY 2023
IPPS/LTCH PPS final rule. All other comments submitted in response to
our proposed policies for determining uncompensated care payments for
FY 2023 must have been submitted in one of the three ways found in the
ADDRESSES section of the proposed rule before the close of the comment
period in order to be assured consideration. In addition, we note that
the CMS DSH inbox is not intended for Worksheet S-10 audit process
related emails, which should be directed to the MACs.
For FY 2023, we again proposed that hospitals would have 15
business days from the date of public display of this FY 2023 IPPS/LTCH
PPS final rule in the Federal Register to review and submit comments on
the accuracy of the table and supplemental data file published in
conjunction with the final rule. Any changes to Factor 3 would be
posted on the CMS website and would be effective beginning October 1,
2022. We also explained that we continue to believe that hospitals have
sufficient opportunity during the comment period for the proposed rule
to provide information about recent and/or pending mergers and/or to
report upload discrepancies. Hospitals do not enter into mergers
without advanced planning. A hospital can inform CMS during the comment
period for the proposed rule regarding any merger activity not
reflected in supplemental file published in conjunction with the
proposed rule. As discussed in the proposed rule, we expected to use
data from the March 2022 HCRIS extract for the FY 2023 final rule,
which contributed to our increased confidence that hospitals would have
be able to comment on mergers and report any upload discrepancies
during the comment period for the FY 2023 IPPS/LTCH PPS proposed rule.
However, we noted that in the event that there were any remaining
merger updates and/or upload discrepancies after the final rule, the 15
business days from the date of
[[Page 49047]]
public display of the FY 2023 IPPS/LTCH PPS final rule deadline should
allow for the time necessary to prepare and make any corrections to
Factor 3 calculations before the beginning of the Federal fiscal year.
We did not receive comments on the notification process for mergers
or data upload issues. We are finalizing our proposal to afford
hospitals 15 business days from the public display of this FY 2023
IPPS/LTCH PPS final rule to submit via email any updated information on
mergers and/or to report upload discrepancies. We also note that the
historical FY 2018 and FY 2019 cost reports are publicly available on a
quarterly basis on the CMS website for analysis and additional review
of cost report data, separate from the supplemental data file published
with this final rule.
E. Supplemental Payment for Indian Health Service and Tribal Hospitals
and Puerto Rico Hospitals for FY 2023 and Subsequent Fiscal Years
In the IPPS/LTCH PPS rulemaking for several previous fiscal years,
Indian Health Service (IHS) and Tribal hospitals and hospitals located
in Puerto Rico have commented about the unique challenges they face
with respect to uncompensated care due to structural differences in
health care delivery and financing in these areas compared to the rest
of the country. In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR
28396), we referred readers to the FY 2022 IPPS/LTCH PPS final rule (86
FR 45242 and 45243) and the FY 2021 IPPS/LTCH PPS final rule (85 FR
58824 and 58825) for a discussion of these comments. We also explained
that we appreciated the concerns raised and the input offered by
commenters regarding the methodology for calculating uncompensated care
payments for IHS/Tribal hospitals and the Puerto Rico hospitals. After
taking into consideration stakeholders' longstanding concerns and their
input on potential approaches to address these concerns, we proposed to
establish a new permanent supplemental payment under the IPPS for IHS/
Tribal hospitals and hospitals located in Puerto Rico. As discussed in
greater detail in the proposed rule, we stated our belief that the
proposed new supplemental payment would mitigate the anticipated impact
on IHS/Tribal hospitals and hospitals located in Puerto Rico from our
proposal to discontinue the use of low-income insured days as a proxy
for their uncompensated care costs for purposes of determining Factor 3
of the uncompensated care payment methodology by providing for an
additional payment to these hospitals that would be determined based
upon the difference between the amount of the uncompensated care
payment determined for the hospital using Worksheet S-10 data and an
approximation of the amount the hospital would have received if we had
continued to use low-income insured days as a proxy for uncompensated
care.
As background, beginning in the FY 2018 IPPS/LTCH PPS final rule
when we first included Worksheet S-10 data in the calculation of Factor
3, and continuing through the FY 2022 IPPS/LTCH PPS final rule, we
relied on the authority under section 1886(r)(2)(C)(i) of the Act to
use alternative data that is a better proxy for the costs of hospitals
for treating the uninsured in order to determine Factor 3 for IHS/
Tribal and Puerto Rico hospitals using low-income insured days as a
proxy for uncompensated care costs. Since FY 2019, Factor 3 for these
hospitals has been determined using FY 2013 Medicaid days and the most
recent available data on SSI days. We believed this approach was
appropriate as the FY 2013 Medicaid days data reflect the most recent
available information regarding these hospitals' low-income insured
days before any expansion of Medicaid. In addition, because we
continued to use low-income insured patient days as a proxy for
uncompensated care for Puerto Rico hospitals and residents of Puerto
Rico are not eligible for SSI benefits, we continued to use a proxy for
SSI days for Puerto Rico hospitals consisting of 14 percent of the
hospital's Medicaid days, as initially adopted in the FY 2017 IPPS/LTCH
PPS final rule (81 FR 56953 through 56956). However, we recognized that
our proposal, which we are finalizing in this final rule, to
discontinue the use of low-income insured days as a proxy for
uncompensated care costs would result in a significant financial
disruption to the IHS/Tribal hospitals and hospitals located in Puerto
Rico. We explained that, for the vast majority of these hospitals, the
proposal to use uncompensated care data reported on Worksheet S-10 to
determine Factor 3 of the uncompensated care payment methodology would
be expected to result in an approximately 90 to 100 percent reduction
in uncompensated care payments for FY 2023 compared to FY 2022. We
referred readers to section I.H. of Appendix A of the proposed rule for
a discussion of the anticipated impact of the proposal to use
uncompensated care costs from Worksheet S-10 to determine uncompensated
care payments for IHS/Tribal hospitals and Puerto Rico hospitals and
the proposal to establish a new supplemental payment for these
hospitals.
In consideration of the unique circumstances faced by the hospitals
and the comments received from IHS/Tribal hospitals and Puerto Rico
hospitals in response to prior rulemaking, raising concerns regarding
financial stability in the event of a change in the data used to
determine Factor 3, we proposed to use our exceptions and adjustments
authority under section 1886(d)(5)(I) of the Act to establish a new
permanent supplemental payment under the IPPS for IHS/Tribal hospitals
and hospitals located in Puerto Rico, beginning in FY 2023. Section
1886(d)(5)(I) of the Act authorizes the Secretary to provide by
regulation for such other exceptions and adjustments to the payment
amounts under section 1886(d) of the Act as the Secretary deems
appropriate. We have determined, after taking into consideration
stakeholders' comments from prior rulemakings, that the supplemental
payment is necessary so as not to cause undue long-term financial
disruption to these hospitals as a result of our proposal to
discontinue the use of low-income insured days as a proxy for
uncompensated care in determining Factor 3 for IHS/Tribal hospitals and
Puerto Rico hospitals beginning in FY 2023. In the proposed rule, we
stated our belief that the proposed supplemental payment would help to
mitigate the anticipated impact of the proposed changes to the
uncompensated care payment methodology for these hospitals and
therefore prevent undue long-term financial disruption for these
providers.
We also stated that the proposed new supplemental payment would not
change in any way the DSH payment methodology under section
1886(d)(5)(F) of the Act or the uncompensated care payment methodology
under section 1886(r) of the Act. Therefore, the total uncompensated
care payment amount would not be affected by this proposal to establish
a supplemental payment for IHS/Tribal and hospitals located in Puerto
Rico nor would there be any impact on the amount of the uncompensated
care payment determined for each DSH-eligible hospital under Sec.
412.106(g)(1) of the regulations.
We proposed that for IHS and Tribal hospitals and hospitals located
in Puerto Rico for which Factor 3 of the uncompensated care payment
methodology was determined using the low-income insured days proxy in
FY
[[Page 49048]]
2022, we would calculate a supplemental payment as follows. We would
use the hospital's FY 2022 uncompensated care payment as the starting
point for this calculation. We explained that using the FY 2022
uncompensated care payment would be an appropriate starting point
because FY 2022 is the most recent year for which we used low-income
insured days data in the determination of uncompensated care payments
for IHS/Tribal hospitals and Puerto Rico hospitals and the purpose of
the proposed supplemental payment is to avoid undue long-term financial
disruption to these hospitals as a result of our proposal to
discontinue the use of low-income insured days as a proxy for
uncompensated care beginning in FY 2023. The base year amount would be
calculated as the hospital's FY 2022 uncompensated care payment
adjusted by one plus the percent change in the total uncompensated care
amount between the applicable year (for example, FY 2023 for purposes
of this rulemaking) and FY 2022, where the total uncompensated care
amount for a year is determined as the product of Factor 1 and Factor 2
for the applicable year. For example, if a hospital's FY 2022
uncompensated care payment was 1 million, and the percent change
between FY 2023 and FY 2022 total uncompensated care payments was
negative 9.1 percent, then the hospital's FY 2023 base year amount
would be 1 million * (1+(-0.091)), which is 909,000. For the hospitals
that were not projected to be DSH eligible in FY 2022, we proposed to
use the uncompensated care payment that the hospital would receive, if
the hospital were to be determined to be DSH eligible in FY 2022 at
cost report settlement. For purposes of the proposed rule, the percent
change between the proposed FY 2023 uncompensated care amount and final
FY 2022 uncompensated care amount was projected to be negative 9.1
percent. (This negative 9.1 percent change was calculated based on the
difference between the proposed FY 2023 uncompensated care amount of
approximately $6.537 billion and the final FY 2022 uncompensated care
amount of approximately $7.192 billion, divided by the final FY 2022
uncompensated care amount). Therefore, we proposed to calculate each
hospital's base year amount for FY 2023 by multiplying its FY 2022
uncompensated care amount by 0.909 (1-0.091). We note that in order to
determine the base year amount for a future fiscal year, the
calculation would be the hospital's FY2022 uncompensated care amount
multiplied by one plus the percent change in total uncompensated care
payments between FY 2022 and the applicable fiscal year. The hospital's
supplemental payment for a fiscal year would then be determined as the
difference between the hospital's base year amount and its
uncompensated care payment for the applicable fiscal year as determined
under Sec. 412.106(g). If the base year amount is equal to or lower
than the hospital's uncompensated care payment for the current fiscal
year, the hospital would not receive a supplemental payment because the
hospital would not be experiencing financial disruption in that year as
a result of the use of uncompensated care data from the Worksheet S-10
in determining Factor 3 of the uncompensated care payment methodology.
We proposed to align the eligibility and payment processes for the
new supplemental payment with the processes used to make uncompensated
care payments. Consistent with the process for determining eligibility
to receive interim uncompensated care payments adopted in the FY 2014
IPPS/LTCH final rule, for the supplemental payment, we proposed to base
eligibility to receive interim supplemental payments on a projection of
DSH eligibility for the applicable fiscal year. In addition, consistent
with the approach that is used to calculate interim uncompensated care
payments on a per discharge basis, for the supplemental payment, we
proposed to use an average of historical discharges to calculate a per
discharge amount for interim supplemental payments. We referred readers
to the FY 2014 IPPS/LTCH PPS final rule for additional background and
discussion of uncompensated care payment processes (78 FR 50643 through
50647). Consistent with our proposal to use 3 years of historical
discharges to determine interim uncompensated care payments for a
fiscal year, we proposed that the amount of a hospital's supplemental
payment calculated for a fiscal year would be divided by the hospital's
historical 3-year average of discharges computed using the most recent
available data to determine an estimated per discharge payment amount.
For FY 2023, we proposed to use FY 2018, FY 2019, and FY 2021
discharge data to determine a hospital's historical 3-year average of
discharges, because we continued to believe the FY 2020 discharge data
would underestimate discharges, due to the effects of the COVID-19
pandemic in FY 2020. In addition, consistent with the policy of
including per-discharge uncompensated care payment amounts in the
outlier calculation, which was initially adopted in the FY 2014 IPPS/
LTCH PPS final rule, we proposed to use our authority under section
1886(d)(5)(I) of the Act to include the per-discharge supplemental
payment in the outlier payment determination under section
1886(d)(5)(A) of the Act. We referred readers to the Addendum to the
proposed rule for further discussion of the outlier payment
calculation.
Consistent with the process used to reconcile interim uncompensated
care payments, we proposed that the MAC would reconcile the interim
supplemental payments at cost report settlement to ensure that the
hospital receives the full amount of the supplemental payment that was
determined prior to the start of the fiscal year. Consistent with the
process used for cost reporting periods that span multiple Federal
fiscal years, we proposed that a pro rata supplemental payment
calculation may be made if the hospital's cost reporting period differs
from the Federal fiscal year. Thus, the final supplemental payment
amounts that would be included on a cost report spanning two Federal
fiscal years would be the pro rata share of the supplemental payment
associated with each Federal fiscal year. This pro rata share would be
determined based on the proportion of the applicable Federal fiscal
year that is included in that cost reporting period. We referred
readers to the FY 2014 interim final rule for additional background and
discussion of the processes for determining pro rata uncompensated care
payments (78 FR 61191 through 61196).
We proposed that the MAC would make a final determination with
respect to a hospital's eligibility to receive the supplemental payment
for a fiscal year, in conjunction with its final determination of the
hospital's eligibility for DSH payments and uncompensated care payments
for that fiscal year. We noted that if a hospital is determined not to
be DSH eligible for a fiscal year then the hospital would not be
eligible to receive a supplemental payment for that fiscal year. In the
proposed rule, we stated our belief that linking eligibility for the
supplemental payment to eligibility for DSH payments and the
uncompensated care payment is appropriate because a hospital that is
not eligible to receive an uncompensated care payment for a fiscal year
would not experience any financial disruption due to the
discontinuation of the low-income insured days proxy and the use of
[[Page 49049]]
Worksheet S-10 data in determining Factor 3 for that fiscal year.
In addition, we proposed that IHS/Tribal hospitals and Puerto Rico
hospitals that do not have a FY 2022 Factor 3 amount determined under
Sec. 412.106(g)(1)(iii)(C)(9) using the low-income insured days proxy
or that are new hospitals that begin participating in the Medicare
program on or after October 1, 2022, would not be eligible to receive
the supplemental payment. We explained that these hospitals will not
experience any reduction to their uncompensated care payments due to
the proposed discontinuation of the low-income insured days proxy
because they are not currently receiving uncompensated care payments
determined using the proxy. We proposed to redesignate the existing
provision at Sec. 412.106(h) as Sec. 412.106(i) and to add a new
provision at Sec. 412.106(h) to reflect the methodology for
calculating the supplemental payment for FY 2023 and subsequent fiscal
years.
We sought comments on our proposal to establish this new
supplemental payment for IHS/Tribal hospitals and Puerto Rico
hospitals. As discussed in section IV.D.3. of this final rule, we also
solicited comments on alternatives both to our proposal to use data on
uncompensated care costs from the Worksheet S-10 to determine Factor 3
for IHS/Tribal hospitals and Puerto Rico hospitals and to the continued
use of low-income insured days as a proxy for the uncompensated care
costs of these hospitals. In addition, we sought comments on how to
best measure and define the uncompensated care costs associated with
these hospitals that might not otherwise be captured in Factor 3
calculations based on Worksheet S-10 data. Given the close
interrelationship between our proposed changes to the methodology for
determining Factor 3 of the uncompensated care payment methodology for
IHS/Tribal hospitals and Puerto Rico hospitals and the proposed new
supplemental payment for these hospitals, we discuss the comments
received on both proposals in this section of this final rule.
Comment: The majority of commenters expressed appreciation for CMS'
creativity in devising the proposed new supplemental payment to
mitigate the anticipated financial impact from the discontinuation of
low-income insured days as a proxy for uncompensated care costs for IHS
and Tribal hospitals and hospitals located in Puerto Rico. Some
commenters stated there are longstanding inequities in DSH and
uncompensated care calculations for Puerto Rico hospitals due to the
lack of an SSI benefit for residents of the U.S. territories. These
commenters also suggested an alternative methodology for calculating
the supplemental payment for hospitals in Puerto Rico.
Specifically, the commenters recommended that CMS calculate the
supplemental payment for Puerto Rico hospitals using a base year amount
determined from Medicaid days and an SSI days proxy of at least 40
percent but no less than 35 percent of Medicaid days, instead of the
current 14 percent. Commenters further suggested that CMS determine a
second empirical DSH eligibility threshold for hospitals in Puerto Rico
based on the suggested SSI days proxy of 40 percent of Medicaid days,
such that if the sum of the Medicaid fraction and the SSI days proxy
exceeds 15 percent, then the hospital would be eligible to receive
uncompensated care payments and the new supplemental payment. A
commenter, in support of this alternative methodology, noted that,
under the proposed supplemental payment methodology, Puerto Rico
hospitals would receive an 11.06 percent reduction in Medicare DSH
payments in FY 2023 as compared to FY 2022. The same commenter noted
that the reduction in DSH payments could also reduce Medicare Advantage
(MA) benchmarks for Puerto Rico in 2024 and, as a result, impact
approximately 630,000 Medicare beneficiaries enrolled in MA plans,
including 280,000 dual-eligible individuals.
Another commenter expressed support for the proposed
discontinuation of low-income insured days as a proxy for uncompensated
care costs for IHS and Tribal hospitals and hospitals located in Puerto
Rico. However, this commenter recommended that CMS reduce the size of
supplemental payments to hospitals in Puerto Rico to an empirically
justified level. This commenter noted that the continued use of
Medicaid days as a proxy for uncompensated care costs in Puerto Rico
has resulted in a substantial increase in uncompensated care payments.
Further, this commenter stated that maintaining the overall payments at
the proposed levels through the supplemental payment would create high
Medicare profit margins at Puerto Rico hospitals and distort the MA
benchmarks, as it would increase FFS spending by more than 25 percent
above what it would have been if Puerto Rico hospitals received
uncompensated care payments based only on their reported uncompensated
care costs. The commenter also opposed the disbursement of the
supplemental payments as an add-on payment to the IPPS payment rates
for hospitals in Puerto Rico and recommended that uncompensated care
payments not be factored into MA benchmarks.
A few commenters expressed support for the proposed supplemental
payment without suggesting enhancements to the policy. One of these
commenters emphasized the importance of implementing the supplemental
payment as a permanent policy.
A commenter opposed CMS' proposal to discontinue the calculation of
uncompensated care costs using low income insured days for hospitals in
Puerto Rico without a separate policy in place for receiving the
supplemental payment. Instead, the commenter suggested that CMS use a
phased approach such that the agency would continue to calculate
uncompensated care costs for hospitals in Puerto Rico using low income
insured days until a future rulemaking. The commenter further suggested
that CMS eventually phase in payments calculated using Worksheet S-10
along with the supplemental payment.
Another commenter specifically opposed the exclusion of new
hospitals in Puerto Rico from receiving the supplemental payment. The
same commenter noted that because hospitals newly established after
October 2013 did not have Medicaid days for the period before the
Affordable Care Act was implemented, the uncompensated care costs for
these hospitals are already calculated using Worksheet S-10 but with no
supplemental payments. The commenter also noted that because hospitals
established after October 2013 operate under the same conditions as
hospitals established before October 2013, these hospitals should
receive the proposed supplemental payments in a manner similar to those
hospitals for which we proposed to transition to the use of Worksheet
S-10 data to determine uncompensated care costs starting in FY 2023.
Finally, this commenter requested that CMS consider calculating
uncompensated care costs for an impacted Puerto Rico hospital
(established after 2013) for the period from FY 2020 through FY 2022
using Medicaid days and not Worksheet S-10 data.
Response: We appreciate this input from commenters regarding the
proposal to establish a new supplement payment for hospitals in Puerto
Rico and IHS and Tribal hospitals and the concerns raised regarding the
proposed changes to the data used to determine uncompensated care costs
for these hospitals. We continue to recognize the unique financial
circumstances and challenges
[[Page 49050]]
faced by Puerto Rico hospitals related to uncompensated care cost
reporting on Worksheet S-10. With regard to the recommendation to
calculate the supplemental payment using a base year amount determined
using Medicaid days and an SSI days proxy of at least 40 percent, we
note that since FY 2019, Factor 3 for hospitals in Puerto Rico has been
determined using FY 2013 Medicaid days and the most recent available
data on SSI days and because residents of Puerto Rico are not eligible
for SSI benefits, we continued to use a proxy for SSI days for Puerto
Rico hospitals consisting of 14 percent of the hospital's Medicaid
days, as initially adopted in the FY 2017 IPPS/LTCH PPS final rule (81
FR 56953 through 56956). We also note that we did not receive comments
expressing concerns regarding this policy when it was finalized for FY
2019. However, for the reasons explained in the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28391), we have determined that data on low income
insured days is no longer a good proxy for the costs of hospitals in
treating the uninsured and that we can no longer conclude that
alternative data to the data on uncompensated care costs reported on
the Worksheet S-10 are available for Puerto Rico hospitals that are a
better proxy for the costs of these hospitals in treating the
uninsured.
With respect to the comment recommending that we adopt a second
eligibility threshold for empirically justified DSH payments based on
the suggested SSI days proxy of 40 percent of Medicaid days, we note
that in the FY 2023 IPPS/LTCH PPS proposed rule, we did not propose to
adopt a proxy for Puerto Rico hospitals' SSI days for purposes of
determining eligibility to receive DSH payments and calculating the
empirically justified Medicare DSH payment. Therefore, we consider this
comment to be outside the scope of the proposed rule. We note, however,
that while section 1886(r)(2)(C)(i) of the Act allows for the use of
alternative data as a proxy to determine the costs of subsection (d)
hospitals for treating the uninsured for purposes of determining
uncompensated care payments, section 1886(r)(1) of the Act requires the
Secretary to pay an empirically justified DSH payment that is equal to
25 percent of the amount of the Medicare DSH payment that would
otherwise be made under section 1886(d)(5)(F) of the Act to a
subsection (d) hospital. Section 1886(d)(5)(F)(vi) of the Act, which
prescribes the disproportionate patient percentage used to determine
empirically justified Medicare DSH payments, specifically refers to the
SSI days in the Medicare fraction and does not allow the use of
alternative data. Accordingly, we disagree with the commenter's
assertion that there is legal support for CMS to use a proxy for Puerto
Rico hospitals' SSI days in the calculation of the empirically
justified Medicare DSH payment.
Regarding the comment that hospitals in Puerto Rico hospitals will
receive an 11.06 percent reduction in Medicare DSH payments in FY 2023
as compared to FY 2022, we note that, under the policies we are
finalizing in this final rule, the combined amount of uncompensated
care payments and supplemental payments for FY 2023 will be less than
11.06 percent below the amount of uncompensated care payments for FY
2022. We refer readers to the discussion of the impact of our final
policies regarding Medicare uncompensated care payments and the new
supplemental payment in Section I.H. of Appendix A of this final rule.
In addition, we note that the base year amount used in calculating the
supplemental payment will change over time relative to the total
uncompensated care amount. Accordingly, for years in which there is an
increase in the total uncompensated care total amount, the hospital's
supplemental payment calculation would reflect a higher base year
amount, and for the years in which there is a decrease in the total
uncompensated care total amount, the hospital's supplemental payment
calculation would reflect a lower base year amount.
With regard to the comment that the supplemental payment would
impact the Medicare Advantage benchmarks, we believe the combined
amount of empirically justified DSH payments, uncompensated care
payments, and supplemental payments to IHS/Tribal hospitals and Puerto
Rico hospitals will be comparable to the amount these hospitals would
have received if CMS had continued to use the low-income days proxy to
determine Factor 3 of the uncompensated care payment methodology. As a
result, the new supplemental payments are expected to have no impact on
MA benchmarks in Puerto Rico. Given that the MA capitation calculations
are on a different timeline than the annual rulemaking for the IPPS
(that is, calendar year rather than Federal fiscal year), the 2024 MA
benchmarks would be the first time any effects would be reflected.
We disagree with the commenter who noted that there is no mechanism
in place for receiving the supplemental payment. We refer readers to
the FY 2014 IPPS/LTCH PPS proposed rule for additional background and
discussion of uncompensated care payment processes (78 FR 50643 through
50647). As discussed in the FY 2023 IPPS/LTCH PPS proposed rule, we
proposed to determine an estimated per discharge add-on payment amount
based on the amount of a hospital's supplemental payment calculated for
a fiscal year divided by the hospital's historical three-year average
of discharges, computed using the most recently available data.
Regarding the concerns raised with respect to our proposal that
hospitals in Puerto Rico established after October 2013 would be
ineligible to receive the supplemental payment, we note that, as
explained in the FY 2023 IPPS/LTCH PPS proposed rule, we proposed to
establish the supplemental payment to mitigate any long-term financial
disruption as a result of our proposal to discontinue the use of low-
income insured days as a proxy for uncompensated care costs in
determining Factor 3. Uncompensated care costs for Puerto Rico
hospitals established after October 2013 are already determined using
Worksheet S-10 data. As a result, these hospitals will not experience
any reduction to their uncompensated care payments due to the proposed
discontinuation of the low-income insured days proxy because they are
not currently receiving uncompensated care payments determined using
the proxy. Thus, we do not believe it is appropriate to modify the
proposed eligibility criteria for the supplemental payment to include
these hospitals at this time. However, we intend to monitor
uncompensated care payments to these hospitals and may revisit this
issue in future rulemaking.
Regarding the commenter that requested that CMS consider
calculating the uncompensated care costs for FY 2020 through FY 2022
for a Puerto Rico hospital (established after 2013) using Medicaid days
and not Worksheet S-10 data, we believe this comment is out of scope of
this rulemaking. We note that the policy for new hospitals in Puerto
Rico was initially adopted in the FY 2019 IPPS/LTCH PPS final rule, and
we did not propose any modifications to this policy in the FY 2023
IPPS/LTCH PPS proposed rule.
Comment: Commenters expressed support for CMS' proposal to
establish a new supplemental payment for IHS and Tribal hospitals to
mitigate the anticipated impact of the agency's proposal to discontinue
the use of low-income insured days as a proxy to calculate
uncompensated care payments for these hospitals. Commenters requested
that CMS confirm that the
[[Page 49051]]
supplemental payments would result in an equal or higher uncompensated
care payment amount than in prior years. Commenters also opposed the
exclusion of new IHS and Tribal hospitals from receiving the
supplemental payment, with another commenter suggesting that CMS
finalize the supplemental payment for existing IHS/Tribal hospitals as
an interim measure while the agency devises an alternate approach that
would be applicable to all IHS/Tribal hospitals. These commenters also
urged CMS to provide an option for hospitals to opt out of the new
supplemental payment methodology in the future years if they preferred
payment in a manner similar to non-Tribal hospitals.
Response: We appreciate the input from commenters on our proposal
to establish a new supplemental payment for IHS and Tribal hospitals.
We continue to recognize the unique nature of these hospitals and the
special circumstances they face.
Regarding commenters' request that CMS confirm that the proposed
supplemental payment will result in an overall payment amount that is
equal to or higher than the uncompensated care payments for prior years
determined using the low-income days proxy, we note that the base year
amount used to calculate a hospital's supplemental payment will change
over time relative to changes in the total uncompensated care amount.
For years in which there is an increase in the total uncompensated care
total amount, the hospital's supplemental payment calculation would use
a higher base year amount, and for the years in which there is a
decrease in the total uncompensated care total amount, the hospital's
supplemental payment calculation would use a lower base year amount.
Regarding the concerns raised by commenters with respect to our
proposal to limit the new supplemental payment to existing IHS/Tribal
hospitals that have a Factor 3 amount for FY 2022 determined using the
low-income insured days proxy, we note that, as explained in the FY
2023 IPPS/LTCH PPS proposed rule, we proposed to establish the
supplemental payment to mitigate any long-term financial disruption as
a result of our proposal to discontinue the use of low-income insured
days as a proxy for uncompensated care costs in determining Factor 3.
However, new IHS/Tribal hospitals for which uncompensated care costs
have not previously been determined using the low-income insured days
proxy will not experience any reduction to their uncompensated care
payments due to the proposed discontinuation of the proxy. Thus, we do
not believe it is appropriate to extend the supplemental payment to
include new IHS/Tribal hospitals at this time. However, we will monitor
uncompensated care payments to these hospitals and may revisit this
issue in future rulemaking.
In regard to an option for hospitals to opt out of the new
supplemental payment methodology in the future years, we believe that
no modification to our proposed methodology is necessary, because,
under the proposed supplemental payment methodology, which we are
finalizing in this final rule, an IHS/Tribal hospital or Puerto Rico
hospital will receive the full uncompensated care payment determined
using its Worksheet S-10 data. A hospital will only receive the
supplemental payment if it increases the overall amount payable to the
hospital, so there does not appear to be a clear reason for a hospital
to opt out of the supplemental payment.
After consideration of the comments received, we are finalizing
both our proposal to discontinue the use of the low-income insured days
proxy and to rely solely on Worksheet S-10 data to calculate Factor 3
of the uncompensated care payment methodology for IHS/Tribal hospitals
and Puerto Rico hospitals and our proposal to establish a new
supplemental payment for Puerto Rico hospitals and IHS/Tribal
hospitals, without modification. We are also finalizing the proposed
provision at Sec. 412.106(h) governing the new supplemental payment
without modification.
The percent change between the final FY 2023 uncompensated care
amount and final FY 2022 uncompensated care amount is negative 4.4
percent. (This negative 4.4 percent change is calculated based on the
difference between the final FY 2023 uncompensated care amount of
approximately $6.874 billion and the final FY 2022 uncompensated care
amount of approximately $7.192 billion, divided by the final FY 2022
uncompensated care amount). Therefore, consistent with the methodology
in Sec. 412.106(h)(3)(i), we will calculate each hospital's base year
amount for FY 2023 by multiplying its FY 2022 uncompensated care amount
by 0.956 (1-0.044).
F. Medicare Disproportionate Share Hospital (DSH) Payments: Counting
Days Associated With Section 1115 Demonstrations in the Medicaid
Fraction (Sec. 412.106)
In the FY 2023 IPPS/LTCH PPS proposed rule, we proposed revisions
to the regulation relating to the treatment of section 1115
demonstration days for purposes of the DSH adjustment (87 FR 28398
through 28402). The agency received numerous, detailed comments on this
proposal. We thank the commenters for their input on the proposal. Due
to the number and nature of the comments that we received on our
proposal, and after further consideration of the issue, we have
determined not to move forward with the current proposal. We expect to
revisit the treatment of section 1115 demonstration days for purposes
of the DSH adjustment in future rulemaking, and we encourage interested
parties to review any future proposal on this issue and to submit their
comments at that time.
V. Other Decisions and Changes to the IPPS for Operating Costs
A. Changes in the Inpatient Hospital Update for FY 2023 (Sec.
412.64(d))
1. FY 2023 Inpatient Hospital Update
In accordance with section 1886(b)(3)(B)(i) of the Act, each year
we update the national standardized amount for inpatient hospital
operating costs by a factor called the ``applicable percentage
increase.'' For FY 2023, we stated in the proposed rule that we are
setting the applicable percentage increase by applying the adjustments
listed in this section in the same sequence as we did for FY 2022. (We
note that section 1886(b)(3)(B)(xii) of the Act required an additional
reduction each year only for FYs 2010 through 2019.) Specifically,
consistent with section 1886(b)(3)(B) of the Act, as amended by
sections 3401(a) and 10319(a) of the Affordable Care Act, we stated
that we are setting the applicable percentage increase by applying the
following adjustments in the following sequence. The applicable
percentage increase under the IPPS for FY 2023 is equal to the rate-of-
increase in the hospital market basket for IPPS hospitals in all areas,
subject to all of the following:
A reduction of one-quarter of the applicable percentage
increase (prior to the application of other statutory adjustments; also
referred to as the market basket update or rate-of-increase (with no
adjustments)) for hospitals that fail to submit quality information
under rules established by the Secretary in accordance with section
1886(b)(3)(B)(viii) of the Act.
A reduction of three-quarters of the applicable percentage
increase (prior to the application of other statutory adjustments; also
referred to as the market basket update or rate-of-increase
[[Page 49052]]
(with no adjustments)) for hospitals not considered to be meaningful
EHR users in accordance with section 1886(b)(3)(B)(ix) of the Act.
An adjustment based on changes in economy-wide multifactor
productivity (MFP) (the productivity adjustment).
Section 1886(b)(3)(B)(xi) of the Act, as added by section 3401(a)
of the Affordable Care Act, states that application of the productivity
adjustment may result in the applicable percentage increase being less
than zero.
We note, in compliance with section 404 of the MMA, in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45194 through 45204), we replaced the
2014-based IPPS operating and capital market baskets with the rebased
and revised 2018-based IPPS operating and capital market baskets
beginning in FY 2022.
We proposed to base the FY 2023 market basket update used to
determine the applicable percentage increase for the IPPS on IHS Global
Inc.'s (IGI's) fourth quarter 2021 forecast of the 2018-based IPPS
market basket rate-of-increase with historical data through third
quarter 2021, which was estimated to be 3.1 percent. We also proposed
that if more recent data subsequently became available (for example, a
more recent estimate of the market basket update), we would use such
data, if appropriate, to determine the FY 2023 market basket update in
the final rule.
Comment: Several commenters were concerned the proposed market
basket update was not accurately reflecting hospital input inflation
citing many examples including ongoing labor shortages, supply chain
disruptions, prices for medical equipment, and the impact of Ukraine/
Russia war. They urged CMS to adjust its market basket update
methodology for FY 2023 to adjust for more recent data and to further
adjust its estimate to appropriately capture significant inflationary
trends that will further fuel rising hospital operating costs but may
not yet be fully captured in IGI's updated market basket forecast in
the second quarter of 2022. Commenters requested CMS recognize that
hospital inflation will generally lag economy-wide inflation and that
the expectations for sustained inflation should be recognized in the
projection of the hospital market basket for FY 2023. Several
commenters stated the proposed market basket update is a time-lagged
estimate that uses historical data to forecast into the future. The
commenters stated that when historical data is no longer a good
predictor of future changes, the market basket becomes inadequate. A
commenter stated that the end of calendar year 2021 into calendar year
2022 should not be considered a steady-state economic environment that
is a continuance of past trends. A commenter encouraged CMS to err on
the side of steadily increasing inflation into 2023 rather than any
material deceleration assumption.
Other commenters urged CMS to rely on more recent forecasts to
determine the FY 2023 update. A commenter noted CBO May 2022 baseline
projections which had a market basket increase that is 1.1 percentage
points higher than the proposed FY 2023 IPPS market basket percentage
increase. Several commenters requested that CMS review other inflation
data sources such as the Consumer Price Index (CPI) and the core
Personal Consumption Expenditures deflator, and suggested that the
market basket increase at least match or exceed these rates of
increases.
Response: Section 1886(b)(3)(B)(iii) of the Act states the
Secretary shall update IPPS payments based on a market basket
percentage increase that reflects an index of appropriately weighted
indicators of changes in wages and prices that are representative of
the mix of goods and services included in such inpatient hospital
services. The 2018-based IPPS market basket is a fixed-weight,
Laspeyres-type price index that measures the change in price, over
time, of the same mix of goods and services purchased by hospitals in
the base period. The general inflation measures cited by the commenters
would not reflect this same mix of goods and services.
We agree with the commenters that recent higher inflationary trends
have impacted the outlook for price growth over the next several
quarters. At the time of the FY 2023 IPPS/LTCH PPS proposed rule, based
on IGI's fourth quarter 2021 forecast with historical data through
third quarter 2021, IGI forecasted the 2018-based IPPS market basket
update of 3.1 percent for FY 2023 reflecting forecasted compensation
prices of 3.8 percent (by comparison, compensation price growth in the
2018-based IPPS market basket averaged 2.2 percent from 2012-2021). As
stated previously, in the FY 2023 IPPS/LTCH PPS proposed rule, we
proposed that if more recent data became available, we would use such
data, if appropriate, to derive the final FY 2023 IPPS market basket
update for the final rule. For this final rule, we now have an updated
forecast of the price proxies underlying the market basket that
incorporates more recent historical data and reflects a revised outlook
regarding the U.S. economy (including the more recent historical CPI
growth, impacts of the Russia/Ukraine war, current expectations
regarding changes to Federal Reserve interest rates, and tight labor
markets). Based on IGI's second quarter 2022 forecast with historical
data through first quarter 2022, we are projecting a FY 2023 IPPS
market basket update of 4.1 percent (reflecting forecasted compensation
price growth of 4.8 percent) and productivity adjustment of 0.3
percentage point. Therefore, as discussed further in this section and
after consideration of the comments received, for FY 2023, the final
applicable percentage increase for a hospital that submitted quality
data and is a meaningful EHR user is 3.8 percent (4.1 percent less 0.3
percentage point), compared to the 2.7 percent that was proposed. We
note that the final FY 2023 IPPS market basket growth rate of 4.1
percent would be the highest market basket update implemented in an
IPPS final rule going back to FY 1998.
Comment: Several commenters suggested that CMS use alternative
sources of data that they stated better reflect input price inflation
to calculate the FY 2023 market basket update. A commenter stated that
in absence of such data, CMS is urged to consider an alternative
approach to better align the market basket updates with increases in
the costs needed to care for Medicare beneficiaries. Several commenters
encouraged CMS to implement a higher market basket update than
proposed, reflecting alternative sources of cost data such as the
Medicare cost reports. A commenter requested that CMS provide a market
basket update of at least 5 percent.
Several commenters proposed that CMS apply a market basket increase
of approximately 8 percent representing estimated trends in allowable
Medicare costs per risk-adjusted discharge from the Medicare cost
reports from FY 2019 to FY 2020. To support this method, commenters
provided the language in the IPPS statute and stated that they believe
that Medicare cost report data meets the statutory requirement as these
data capture all allowable costs, including personnel costs and
excluding non-operating costs that comprise routine, ancillary, and
special care unit inpatient hospital services. The commenter stated
that given that these data comprise all the costs--on a volume and
risk-adjusted basis--necessary to deliver hospital care it represents
``appropriately weighted indicators of changes in wages and prices
which are representative of the mix of good and services . . .''
necessary to provide inpatient hospital care to Medicare beneficiaries.
Commenters stated their belief that Medicare cost report data are a
more
[[Page 49053]]
accurate projection of the cost inflation anticipated by hospitals
during FY 2023 than the forecast IGI data used in the proposed rule.
The commenters further noted that changes in volume and intensity are
accounted for in the market basket update when CMS rebases or revises
it, which they stated is infrequent, typically occurring once every
four years. They believe their proposed methodology of using Medicare
cost report data would fully account for changes in volume and acuity
annually, thus resulting in a more accurate proxy.
Another commenter analyzed Medicare cost report data and found that
compensation costs increased by more than the IPPS market basket
updates of 3.0 percent and 2.4 percent for FYs 2020 and 2021,
respectively. The commenter recommended that CMS adjust the IGI
compensation price indices and the overall inpatient price indices
based on the percent change in compensation costs as derived from the
Medicare cost reports.
A commenter recommended that CMS use its exceptions and adjustments
authority to substitute Premier Inc. data for the IGI forecast to
provide hospitals with an increased payment update in FY 2023 to
accurately reflect labor costs. Additionally, the commenter recommended
that CMS' Office of the Actuary reevaluate the data sources that it
uses for calculating labor costs and consider adopting new or
supplemental data sources in future rulemaking that more accurately
reflect the cost of labor, such as more real time data from the
hospital community. While the commenter stated that they were unable to
forecast a market basket update for FY 2023, they noted the substantial
impact a 10 percent increase in the labor components would have on the
historical market basket for FY 2021, increasing the estimate by
several percentage points under this hypothetical scenario.
Response: We believe the 2018-based IPPS market basket increase
adequately reflects the average change in the price of goods and
services hospitals purchase in order to provide IPPS medical services,
and is technically appropriate to use as the market basket percentage
increase in accordance with section 1886(b)(3)(B)(iii). As described in
the FY 2022 IPPS/LTCH PPS final rule (86 FR 45194 through 45213), the
IPPS market basket is a fixed-weight, Laspeyres-type index that
measures price changes over time and would not reflect increases in
costs associated with changes in the volume or intensity of input goods
and services. As such, the IPPS market basket increase would reflect
the prospective price pressures described by the commenters as
increasing during a high inflation period (such as faster wage price
growth or higher energy prices), but would inherently not reflect other
factors that might increase the level of costs, such as the quantity of
labor used or any shifts between contract and staff nurses (which would
be reflected in the Medicare cost report data). We note that cost
changes (that is, the product of price and quantities) would only be
captured in the market basket weights when the index is rebased and the
base year is updated to a more recent time period.
We disagree with the commenters that costs as reported on the
Medicare cost report are suitable for determining the trend in
compensation prices for the market basket update. Section
1886(b)(3)(B)(iii) of the Act states the Secretary shall estimate a
market basket percentage increase based on an index of appropriately
weighted indicators of changes in wages and prices which are
representative of the mix of goods and services included in such
inpatient hospital services. While the current IPPS market basket
percentage increase captures price changes associated with the goods
and services hospitals purchase in providing care, the Medicare cost
report data also reflects factors that are beyond those that impact
wage or price growth. For instance, overall costs as reported by
hospitals would also reflect changes in the mix of inputs used to
provide services; since 2020, observed IPPS case-mix (and associated
higher payments to hospitals) has increased faster than in prior years
and would likely reflect the use of more skilled care needed to provide
these services.
Regarding commenters' request that CMS consider other methods and
data sources to calculate the final rule market basket update, we
believe the 2018-based IPPS market basket continues to appropriately
reflect IPPS cost structures and we believe the price proxies used
(such as those from BLS that reflect wage and benefit price growth) are
an appropriate representation of price changes for the inputs used by
hospitals in providing services. We further note that we did not
propose to use other methods or data sources to calculate the final
market basket update for FY 2023. Consistent with our proposal, we have
used more recent historical data and an updated forecast (that reflects
a revised inflationary outlook) to calculate a final IPPS market basket
percentage increase for FY 2023 of 4.1 percent, which is one percentage
point higher than the proposed market basket percentage increase of 3.1
percent set forth in the FY 2023 IPPS/LTCH PPS proposed rule.
Comment: Several commenters also expressed concerns regarding the
use of BLS' Employment Cost Index (ECI), which accounts for 53 percent
of the market basket, stating it did not accurately reflect hospitals'
compensation costs after the labor market changes triggered by the PHE.
A commenter stated that this claim can be evidenced by comparing growth
in labor costs from the Medicare cost report data to the ECI growth.
The commenters also state that hospitals have faced a shortage of local
labor as the PHE has progressed and have had to increasingly turn to
contract labor, particularly for the nursing professions, which in turn
has contributed to increased compensation costs. The commenters noted
that CMS's proposed market basket update reflected a 3.8 percent
increase in compensation, which they believe does not accurately
reflect changes in current labor costs that they believe are not
transitory.
Commenters noted that the ECI does not capture inflation in
contract labor compensation while the hospital market basket does
include contract labor costs when calculating the compensation cost
weights and stated that including the contract labor costs along with
other compensation costs assumes contract labor compensation growth
will grow at the same rate as non-contract labor compensation. The
commenters stated that this assumption is not supported by evidence
citing published studies. Commenters also noted analysis by Premier
Inc., which showed faster hourly labor rates than the ECI for FY 2021.
Response: As previously discussed, section 1886(b)(3)(B)(iii) of
the Act states the Secretary shall estimate a market basket percentage
increase based on an index of appropriately weighted indicators of
changes in wages and prices which are representative of the mix of
goods and services included in such inpatient hospital services. The
2018-based IPPS market basket is a fixed-weight, Laspeyres-type price
index that measures the change in price, over time, of the same mix of
goods and services purchased in the base period. Any changes in the
quantity or mix of goods and services (that is, intensity) purchased
over time relative to a base period are not measured. This type of IPPS
market basket has been in place since the implementation of the IPPS as
well as used for other CMS market baskets.
For the compensation cost weight in the 2018-based IPPS market
basket (which includes salaried and contract
[[Page 49054]]
labor employees), we use the ECI for wages and salaries and benefits
for all civilian hospital workers to proxy the price increases of labor
for IPPS hospitals. The ECI (published by the BLS) measures the change
in the hourly labor cost to employers, independent of the influence of
employment shifts among occupations and industry categories. We note
that the Medicare cost report data shows contract labor hours account
for about 3 percent of total compensation hours (reflecting employed
and contract labor staff) for IPPS hospitals in 2020. Data through 2021
are incomplete at this time. Therefore, while we acknowledge that the
ECI measures only reflect price changes for employed staff, we believe
that the ECI for hospital workers is accurately reflecting the price
change associated with the labor used to provide hospital care (as
employed workers' hours account for 97 percent of hospital compensation
hours) and appropriately does not reflect other factors that might
affect labor costs. Therefore, we believe it continues to be an
appropriate measure to use in the IPPS market basket. We also note that
based on IGI's second quarter 2022 forecast with historical data
through first quarter 2022, compensation price growth (using the ECIs)
for FY 2023 is now projected to be 4.8 percent, which is 1.0 percentage
point higher than projected price growth at the time of the FY 2023
IPPS/LTCH PPS proposed rule (3.8 percent).
Comment: A commenter encouraged CMS to consider whether additional
changes are needed regarding the rebasing and revising of the market
basket, given data from 2018 was relied upon in the FY 2022 IPPS/LTCH
PPS final rule to determine the appropriate mix of goods and services,
which may have been impacted by COVID-19. For example, they stated that
during the pandemic there has been increased use of personal protective
equipment, yet this utilization would not be captured in the market
basket, which was rebased and revised in the FY 2022 IPPS/LTCH PPS
final rule.
Response: As described previously, the IPPS market basket measures
price changes (including changes in the prices for wages and salaries)
over time and would not reflect increases in costs associated with
changes in the volume or intensity of input goods and services until
the market basket is rebased. The IPPS market basket was last rebased
in the FY 2022 IPPS/LTCH PPS final rule using 2018 Medicare cost
reports (86 FR 45194 through 45207), the most recent year of complete
data available at the time of the rebasing. We note that we did not
propose to rebase the IPPS market basket in the FY 2023 IPPS/LTCH PPS
proposed rule. However, we did review more recent Medicare cost report
data available for IPPS hospitals submitted as of March 2022, which
includes data for 2019-2020. The Medicare cost report data (which does
not allow us to separately identify costs for-PPE) showed slight
decreases in the compensation cost weight in 2019 and 2020 resulting in
a compensation cost weight that is roughly 1 percentage point less than
the 2018-based IPPS market basket cost weight. Data through 2021 are
incomplete at this time. The data also showed slight increases over the
2018 to 2020 time period in the pharmaceuticals cost weight and home
office cost weight of about 0.3 percentage point each. Based on this
preliminary analysis, the impact on the cost weights through 2020 are
minimal and it is unclear whether these trends (particularly the
compensation cost weight) through 2020 are reflective of sustained
shifts in the cost structure for hospitals or whether they were
temporary as a result of the PHE. Therefore, we continue to believe it
is premature at this time to use more recent Medicare cost report data
to derive a rebased and revised IPPS market basket. We will continue to
monitor these data and any changes to the IPPS market basket will be
proposed in future rulemaking.
Comment: Several commenters expressed concerns about the market
basket update calculations. Commenters stated that CMS calculates the
percent change by dividing the average input price indices in the most
recent four quarters by the average input price index in the previous
four quarters as derived from the most recently available IGI forecast.
However, the commenter stated that CMS does not consider the difference
between the base year estimates (from the time when prior year payment
rates are finalized) and updated estimates of the base year indices
since the prior year's market basket update calculation. Therefore,
they stated this current update method does not account for substantial
forecast errors driven by an unusually fast acceleration of the
inflation rate such as occurred in FY 2021. They urge CMS to leverage
its exceptions and adjustments authority under section 1886(d)(5)(I)(i)
of the Act to modify its methodology for FY 2023 to account for the
substantial forecast error in FYs 2021 and 2022. A commenter added that
it believes the understatement of the hospital market basket for FY
2021 and FY 2022 and potentially FY 2023 as well is such an occasion
for using the exceptions and adjustments authority. The commenter
stated that Premier data collected directly from hospitals is showing a
10 percent increase in 2022 to date for hospital compensation (67.6
percent of the market basket) compared to the 3.8 percent being
forecasted by IGI. The commenter recommended CMS make a one-time only
forecast error correction on the FY 2021 and FY 2022 market basket of a
combined 1.9 percentage points for FY 2023 using the exceptions and
adjustments authority. The commenter also recommended that CMS use its
exceptions and adjustments authority to substitute Premier data for the
IGI forecast to provide hospitals with an increased payment update in
FY 2023 to accurately reflect labor costs.
A commenter urged CMS to consider a one-time adjustment to ensure
that the FY 2023 rate increase is applied to a base rate that more
accurately incorporates actual inflation during the pandemic. The
commenter cited the unprecedented nature of the pandemic and its
extraordinary impact on hospital costs alongside record inflation for
the basis of this one-time adjustment.
Response: Section 1886(b)(3)(B) of the Act sets forth the update to
the standardized amounts based on the applicable percentage increase.
Although the statute does not include a forecast error adjustment,
commenters requested that CMS use its exceptions and adjustments
authority under section 1886(d)(5)(I)(i) of the Act to modify its
methodology to account for the forecast error in FYs 2021 and 2022. We
note that we did not propose to use our authority under section
1886(d)(5)(I)(i) of the Act to apply a forecast correction in updating
the IPPS rates for FY 2023. While there is no precedent to adjust for
market basket forecast error in the IPPS operating payment update, the
forecast error for a market basket update is equal to the actual market
basket increase for a given year less the forecasted market basket
increase. Due to the uncertainty regarding future price trends,
forecast errors can be both positive and negative. For example, the FY
2020 IPPS forecast error was -1.0 percentage point, and the FY 2021
IPPS forecast error was +0.7 percentage point; FY 2022 historical data
are not yet available to calculate a forecast error for FY 2022. As we
have discussed in past rulemaking, we believe that an important goal of
a PPS is predictability. For these reasons, we do not believe it is
appropriate to include adjustments to the market basket update for
future years based on the difference between the actual and forecasted
market basket increase in prior years. With regard to the comment
[[Page 49055]]
recommending the use of the Premier data, we refer to our response to
this comment as previously discussed earlier in this section, regarding
why we believe the 2018-based IPPS market basket increase adequately
reflects the average change in the price of goods and services
hospitals purchase in order to provide IPPS medical services, and is
technically appropriate to use as the market basket percentage increase
in accordance with section 1886(b)(3)(B)(iii).
We thank the commenters for their comments. After consideration of
the comments received and consistent with our proposal, we are
finalizing to use more recent data to determine the FY 2023 market
basket update for the final rule. Specifically, based on more recent
data available, we determined final applicable percentage increases to
the standardized amount for FY 2023, as specified in the table that
appears later in this section.
In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51689 through
51692), we finalized our methodology for calculating and applying the
productivity adjustment. As we explained in that rule, section
1886(b)(3)(B)(xi)(II) of the Act, as added by section 3401(a) of the
Affordable Care Act, defines this productivity adjustment as equal to
the 10-year moving average of changes in annual economy-wide, private
nonfarm business MFP (as projected by the Secretary for the 10-year
period ending with the applicable fiscal year, year, cost reporting
period, or other annual period). The U.S. Department of Labor's Bureau
of Labor Statistics (BLS) publishes the official measures of private
nonfarm business productivity for the U.S. economy. We note that
previously the productivity measure referenced in section
1886(b)(3)(B)(xi)(II) was published by BLS as private nonfarm business
multifactor productivity. Beginning with the November 18, 2021 release
of productivity data, BLS replaced the term multifactor productivity
(MFP) with total factor productivity (TFP). BLS noted that this is a
change in terminology only and will not affect the data or methodology.
As a result of the BLS name change, the productivity measure referenced
in section 1886(b)(3)(B)(xi)(II) is now published by BLS as private
nonfarm business total factor productivity. However, as mentioned, the
data and methods are unchanged. Please see www.bls.gov for the BLS
historical published TFP data. A complete description of IGI's TFP
projection methodology is available on the CMS website at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareProgramRatesStats/MarketBasketResearch. In addition, we
note that beginning with the FY 2022 IPPS/LTCH PPS final rule, we refer
to this adjustment as the productivity adjustment rather than the MFP
adjustment to more closely track the statutory language in section
1886(b)(3)(B)(xi)(II) of the Act. We note that the adjustment continues
to rely on the same underlying data and methodology.
For FY 2023, we proposed a productivity adjustment of 0.4 percent.
Similar to the proposed market basket update, for the proposed rule,
the estimate of the proposed FY 2023 productivity adjustment was based
on IGI's fourth quarter 2021 forecast. As noted previously, we proposed
that if more recent data subsequently became available, we would use
such data, if appropriate, to determine the FY 2023 productivity
adjustment for the final rule.
Comment: Several commenters requested that CMS use its ``special
exceptions and adjustments'' authority under section 1886(d)(5)(I)(i)
of the Act to eliminate the productivity adjustment for FY 2023. A
commenter requested that CMS work with Congress to permanently
eliminate the productivity adjustment to the annual hospital payment
updates. Another commenter stated that, if CMS does not use more recent
figures from BLS on economy-wide non-farm total factor productivity
when determining the adjustment to the IPPS market basket update for FY
2023, then the highly unusual circumstances of the COVID-19 pandemic
are sufficient reason for the Secretary to invoke section
1886(d)(5)(I)(i) ``exceptions and adjustments'' authority to provide a
one-time adjustment that offsets application of the otherwise
applicable productivity adjustment for FY 2023.
A commenter requested that CMS use its ``exceptions and
adjustments'' authority under section 1886(d)(5)(I)(i) of the Act to
remove the productivity adjustment for any fiscal year that was covered
under PHE determination (for example, 2020, 2021, and 2022) from the
calculation of market basket update for FY 2023 and any year
thereafter.
A commenter recommended that CMS withhold the proposed -0.4 percent
productivity adjustment until a federal fiscal year in which hospitals
are not operating under the public health emergency (PHE).
Response: While we appreciate the commenters' concerns, section
1886(b)(3)(B)(xi)(I) of the Act requires the application of the
productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of
the Act to the IPPS market basket update when determining the
applicable percentage increase. Section 1886(d)(5)(I)(i) of the Act
authorizes the Secretary to provide by regulation for such other
exceptions and adjustments to the payment amounts under section 1886(d)
of the Act as the Secretary deems appropriate.
We further note that we did not propose to use our authority under
section 1886(d)(5)(I)(i) of the Act in the FY 2023 IPPS/LTCH PPS
proposed rule to offset the productivity adjustment for FY 2023. Based
on the updated forecast for this final rule, and as discussed
elsewhere, we are projecting a FY 2023 IPPS market basket update of 4.1
percent and a productivity adjustment of 0.3 percentage point for this
final rule, as compared to the proposed market basket update of 3.1
percent and proposed productivity adjustment of 0.4 percentage point
set forth in the proposed rule. Additionally, we note Congress has
provided other funding to providers as a result of the COVID-19 PHE.
Specifically, the CARES Act provided additional payments for cases of
COVID-19 under the IPPS and also created the Provider Relief Fund to
reimburse providers, including IPPS providers, for increased expenses
or lost revenue attributable to COVID-19.
We thank the commenters for their comments. However, as previously
noted, section 1886(b)(3)(B)(xi)(II) of the Act, as added by section
3401(a) of the Affordable Care Act, requires a productivity adjustment
to the IPPS market basket update when determining the applicable
percentage increase. Consistent with our proposal, we are using more
recent data to determine the FY 2023 productivity adjustment for the
final rule. Specifically, based on IGI's second quarter 2022 forecast,
we are projecting a FY 2023 IPPS market basket update of 4.1 percent
and productivity adjustment of 0.3 percentage point. Therefore, as
discussed further in this section and after consideration of the
comments received, for FY 2023, the final IPPS applicable percentage
increase for a hospital that submitted quality data and is a meaningful
EHR user is 3.8 percent (4.1 percent less 0.3 percentage point).
Comment: Several commenters expressed concerns about the
productivity adjustment. A commenter stated that the measure of
productivity used by CMS is intended to ensure payments more accurately
reflect the true cost of providing patient care and effectively assumes
the hospital field can mirror productivity gains across the
[[Page 49056]]
private nonfarm business sector. Several commenters stated that this
has not been their experience during the pandemic. Commenters also
stated that even before the pandemic, CMS Office of the Actuary
questioned the wisdom of the underlying assumption in their analysis
that compares private non-farm total factor productivity growth measure
and a hospital-specific measure (https://www.cms.gov/files/document/productivity-memo.pdf). Commenters also stated that the latest data
indicates a decrease in productivity, not gains, citing the latest BLS
release of labor productivity data. Commenters had strong concerns
about the proposed productivity adjustment given the extreme and
uncertain circumstances in which their hospitals and health systems are
currently operating. Several commenters requested CMS use the latest
BLS data when determining the productivity adjustment for FY 2023.
Response: Section 1886(b)(3)(B)(xi)(II) of the Act requires the
productivity adjustment be equal to the 10-year moving average of
changes in annual economy-wide private nonfarm business total factor
productivity (as projected by the Secretary for the 10-year period
ending with the applicable fiscal year, year, cost reporting period, or
other annual period). For the FY 2023 IPPS/LTCH PPS proposed rule,
based on IGI's fourth quarter 2021 forecast, the productivity
adjustment was projected to be 0.4 percentage point for FY 2023. For
this final rule, based on IGI's second quarter 2022 forecast, we are
updating the productivity adjustment to reflect more recent historical
data as published by BLS as well as a revised economic outlook for FY
2022 and FY 2023. Using this more recent forecast, the FY 2023
productivity adjustment based on the 10-year moving average growth in
economy-wide total factor productivity for the period ending FY 2023 is
currently estimated to be 0.3 percent.
We thank the commenters for their comments. After consideration of
the comments received and consistent with our proposal, we are
finalizing as proposed to use more recent data to determine the FY 2023
productivity adjustment for the final rule.
Based on more recent data available for this FY 2023 IPPS/LTCH PPS
final rule (that is, IGI's second quarter 2022 forecast of the 2018-
based IPPS market basket rate-of-increase with historical data through
the first quarter of 2022), we estimate that the FY 2023 market basket
update used to determine the applicable percentage increase for the
IPPS is 4.1 percent. Based on more recent data available for this FY
2023 IPPS/LTCH PPS final rule (that is, IGI's second quarter 2022
forecast of the productivity adjustment), the current estimate of the
productivity adjustment for FY 2023 is 0.3 percentage point.
As previously discussed, based on the more recent data available,
for this final rule, we have determined four final applicable
percentage increases to the standardized amount for FY 2023. For FY
2023, depending on whether a hospital submits quality data under the
rules established in accordance with section 1886(b)(3)(B)(viii) of the
Act (hereafter referred to as a hospital that submits quality data) and
is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act
(hereafter referred to as a hospital that is a meaningful EHR user),
there are four possible applicable percentage increases that can be
applied to the standardized amount, as specified in this table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.126
In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42344), we revised
our regulations at 42 CFR 412.64(d) to reflect the current law for the
update for FY 2020 and subsequent fiscal years. Specifically, in
accordance with section 1886(b)(3)(B) of the Act, we added paragraph
(d)(1)(viii) to Sec. 412.64 to set forth the applicable percentage
increase to the operating standardized amount for FY 2020 and
subsequent fiscal years as the percentage increase in the market basket
index, subject to the reductions specified under Sec. 412.64(d)(2) for
a hospital that does not submit quality data and Sec. 412.64(d)(3) for
a hospital that is not a meaningful EHR user, less a productivity
adjustment. (As previously noted, section 1886(b)(3)(B)(xii) of the Act
required an additional reduction each year only for FYs 2010 through
2019.)
Section 1886(b)(3)(B)(iv) of the Act provides that the applicable
percentage increase to the hospital-specific rates for SCHs equals the
applicable percentage increase set forth in section 1886(b)(3)(B)(i) of
the Act (that is, the same update factor as for all other hospitals
subject to the IPPS). Therefore, the update to the hospital-specific
rates for SCHs also is subject to section 1886(b)(3)(B)(i) of the Act,
as amended by sections 3401(a) and 10319(a) of the Affordable Care Act.
Under current law, the MDH program is effective for discharges on
or before September 30, 2022, as discussed in the FY 2019 IPPS/LTCH PPS
final rule (83 FR 41429 through 41430). Therefore, under current law,
the MDH program will expire at the end of FY 2022. We
[[Page 49057]]
refer readers to section V.D. of the preamble of this final rule for
further discussion of the expiration of the MDH program.
For FY 2023, we proposed the following updates to the hospital-
specific rates applicable to SCHs: a proposed update of 2.7 percent for
a hospital that submits quality data and is a meaningful EHR user; a
proposed update of 0.375 percent for a hospital that submits quality
data and is not a meaningful EHR user; a proposed update of 1.925
percent for a hospital that fails to submit quality data and is a
meaningful EHR user; and a proposed update of -0.4 percent for a
hospital that fails to submit quality data and is not an meaningful EHR
user. We proposed that if more recent data subsequently became
available (for example, a more recent estimate of the market basket
update and the productivity adjustment), we would use such data, if
appropriate, to determine the update in the final rule.
We did not receive any public comments on our proposed updates to
hospital-specific rates applicable to SCHs. The general comments we
received on the proposed FY 2023 update (including the proposed market
basket update and productivity adjustment) are discussed earlier in
this section. For FY 2023, we are finalizing the proposal to determine
the update to the hospital specific rates for SCHs in this final rule
using the more recent available data, as previously discussed.
For this final rule, based on more recent available data, we are
finalizing the following updates to the hospital specific rates
applicable to SCHs: An update of 3.8 percent for a hospital that
submits quality data and is a meaningful EHR user; an update of 0.725
percent for a hospital that submits quality data and is not a
meaningful EHR user; an update of 2.775 percent for a hospital that
fails to submit quality data and is a meaningful EHR user; and an
update of -0.3 percent for a hospital that fails to submit quality data
and is not a meaningful EHR user.
2. FY 2023 Puerto Rico Hospital Update
Section 602 of Public Law 114-113 amended section 1886(n)(6)(B) of
the Act to specify that subsection (d) Puerto Rico hospitals are
eligible for incentive payments for the meaningful use of certified EHR
technology, effective beginning FY 2016. In addition, section
1886(n)(6)(B) of the Act was amended to specify that the adjustments to
the applicable percentage increase under section 1886(b)(3)(B)(ix) of
the Act apply to subsection (d) Puerto Rico hospitals that are not
meaningful EHR users, effective beginning FY 2022. Accordingly, for FY
2022, section 1886(b)(3)(B)(ix) of the Act in conjunction with section
602(d) of Public Law 114-113 requires that any subsection (d) Puerto
Rico hospital that is not a meaningful EHR user as defined in section
1886(n)(3) of the Act and not subject to an exception under section
1886(b)(3)(B)(ix) of the Act will have ``three-quarters'' of the
applicable percentage increase (prior to the application of other
statutory adjustments), or three-quarters of the applicable market
basket rate-of-increase, reduced by 33\1/3\ percent. The reduction to
three-quarters of the applicable percentage increase for subsection (d)
Puerto Rico hospitals that are not meaningful EHR users increases to
66\2/3\ percent for FY 2023, and, for FY 2024 and subsequent fiscal
years, to 100 percent. (We note that section 1886(b)(3)(B)(viii) of the
Act, which specifies the adjustment to the applicable percentage
increase for ``subsection (d)'' hospitals that do not submit quality
data under the rules established by the Secretary, is not applicable to
hospitals located in Puerto Rico.) The regulations at 42 CFR
412.64(d)(3)(ii) reflect the current law for the update for subsection
(d) Puerto Rico hospitals for FY 2022 and subsequent fiscal years. In
the FY 2019 IPPS/LTCH PPS final rule, we finalized the payment
reductions (83 FR 41674).
For FY 2023, consistent with section 1886(b)(3)(B) of the Act, as
amended by section 602 of Public Law 114-113, we are setting the
applicable percentage increase for Puerto Rico hospitals by applying
the following adjustments in the following sequence. Specifically, the
applicable percentage increase under the IPPS for Puerto Rico hospitals
will be equal to the rate of-increase in the hospital market basket for
IPPS hospitals in all areas, subject to a 66\2/3\ percent reduction to
three-fourths of the applicable percentage increase (prior to the
application of other statutory adjustments; also referred to as the
market basket update or rate-of-increase (with no adjustments)) for
Puerto Rico hospitals not considered to be meaningful EHR users in
accordance with section 1886(b)(3)(B)(ix) of the Act, and then subject
to the productivity adjustment at section 1886(b)(3)(B)(xi) of the Act.
As noted previously, section 1886(b)(3)(B)(xi) of the Act states that
application of the productivity adjustment may result in the applicable
percentage increase being less than zero.
Based on IGI's fourth quarter 2021 forecast of the 2018-based IPPS
market basket update with historical data through third quarter 2021,
in the FY 2023 IPPS/LTCH PPS proposed rule, in accordance with section
1886(b)(3)(B) of the Act, as discussed previously, for Puerto Rico
hospitals we proposed a market basket update of 3.1 percent and a
productivity adjustment of 0.4 percent. Therefore, for FY 2023,
depending on whether a Puerto Rico hospital is a meaningful EHR user,
we stated there would be two possible proposed applicable percentage
increases that could be applied to the standardized amount. Based on
these data, we determined the following proposed applicable percentage
increases to the standardized amount for FY 2023 for Puerto Rico
hospitals:
For a Puerto Rico hospital that is a meaningful EHR user,
we proposed an applicable percentage increase to the FY 2023 operating
standardized amount of 2.7 percent (that is, the FY 2023 estimate of
the proposed market basket rate-of-increase of 3.1 percent less an
adjustment of 0.4 percentage point for the proposed productivity
adjustment).
For a Puerto Rico hospital that is not a meaningful EHR
user, we proposed an applicable percentage increase to the operating
standardized amount of 1.15 percent (that is, the FY 2023 estimate of
the proposed market basket rate-of-increase of 3.1 percent, less an
adjustment of 1.55 percentage point (the proposed market basket rate-
of-increase of 3.1 percent x 0.75 x (\2/3\) for failure to be a
meaningful EHR user), and less an adjustment of 0.4 percentage point
for the proposed productivity adjustment).
We did not receive any public comments on our proposed updates to
the standardized amount for FY 2023 for Puerto Rico hospitals. The
general comments we received on the proposed FY 2023 update (including
the proposed market basket update and productivity adjustment) are
discussed in greater detail earlier in this section. For FY 2023, we
are finalizing the proposal to determine the update to the standardized
amount for FY 2023 for Puerto Rico hospitals in this final rule using
the more recent available data, as previously discussed.
As previously discussed in section V.A.1, based on more recent data
available for this final rule (that is, IGI's second quarter 2022
forecast of the 2018-based IPPS market basket rate-of-increase with
historical data through the first quarter of 2022), we estimate that
the FY 2023 market basket update used to determine the applicable
percentage increase for the IPPS is 4.1 percent and the productivity
adjustment is 0.3 percent. For FY 2023, depending on whether a Puerto
Rico hospital is a meaningful EHR user, there are two
[[Page 49058]]
possible applicable percentage increases that can be applied to the
standardized amount. Based on these data, accordance with section
1886(b)(3)(B) of the Act, we determined the following applicable
percentage increases to the standardized amount for FY 2023 for Puerto
Rico hospitals:
For a Puerto Rico hospital that is a meaningful EHR user,
an applicable percentage increase to the FY 2023 operating standardized
amount of 3.8 percent (that is, the FY 2023 estimate of the market
basket rate-of-increase of 4.1 percent less an adjustment of 0.3
percentage point for the productivity adjustment).
For a Puerto Rico hospital that is not a meaningful EHR
user, an applicable percentage increase to the operating standardized
amount of 1.75 percent (that is, the FY 2023 estimate of the market
basket rate-of-increase of 4.1 percent, less an adjustment of 2.05
percentage point (the market basket rate-of-increase of 4.1 percent x
0.75 x (\2/3\) for failure to be a meaningful EHR user), and less an
adjustment of 0.3 percentage point for the productivity adjustment).
[GRAPHIC] [TIFF OMITTED] TR10AU22.127
B. Rural Referral Centers (RRCs) Annual Updates to Case-Mix Index (CMI)
and Discharge Criteria (Sec. 412.96)
Under the authority of section 1886(d)(5)(C)(i) of the Act, the
regulations at Sec. 412.96 set forth the criteria that a hospital must
meet in order to qualify under the IPPS as a rural referral center
(RRC). RRCs receive special treatment under both the DSH payment
adjustment and the criteria for geographic reclassification.
Section 402 of Public Law 108-173 raised the DSH payment adjustment
for RRCs such that they are not subject to the 12-percent cap on DSH
payments that is applicable to other rural hospitals. RRCs also are not
subject to the proximity criteria when applying for geographic
reclassification. In addition, they do not have to meet the requirement
that a hospital's average hourly wage must exceed, by a certain
percentage, the average hourly wage of the labor market area in which
the hospital is located.
Section 4202(b) of Public Law 105-33 states, in part, that any
hospital classified as an RRC by the Secretary for FY 1991 shall be
classified as such an RRC for FY 1998 and each subsequent fiscal year.
In the August 29, 1997, IPPS final rule with comment period (62 FR
45999), we reinstated RRC status for all hospitals that lost that
status due to triennial review or MGCRB reclassification. However, we
did not reinstate the status of hospitals that lost RRC status because
they were now urban for all purposes because of the OMB designation of
their geographic area as urban. Subsequently, in the August 1, 2000
IPPS final rule (65 FR 47089), we indicated that we were revisiting
that decision. Specifically, we stated that we would permit hospitals
that previously qualified as an RRC and lost their status due to OMB
redesignation of the county in which they are located from rural to
urban, to be reinstated as an RRC. Otherwise, a hospital seeking RRC
status must satisfy all of the other applicable criteria. We use the
definitions of ``urban'' and ``rural'' specified in subpart D of 42 CFR
part 412. One of the criteria under which a hospital may qualify as an
RRC is to have 275 or more beds available for use (Sec.
412.96(b)(1)(ii)). A rural hospital that does not meet the bed size
requirement can qualify as an RRC if the hospital meets two mandatory
prerequisites (a minimum case-mix index (CMI) and a minimum number of
discharges), and at least one of three optional criteria (relating to
specialty composition of medical staff, source of inpatients, or
referral volume). (We refer readers to Sec. 412.96(c)(1) through (5)
and the September 30, 1988, Federal Register (53 FR 38513) for
additional discussion.) With respect to the two mandatory
prerequisites, a hospital may be classified as an RRC if--
The hospital's CMI is at least equal to the lower of the
median CMI for urban hospitals in its census region, excluding
hospitals with approved teaching programs, or the median CMI for all
urban hospitals nationally; and
The hospital's number of discharges is at least 5,000 per
year, or, if fewer, the median number of discharges for urban hospitals
in the census region in which the hospital is located. The number of
discharges criterion for an osteopathic hospital is at least 3,000
discharges per year, as specified in section 1886(d)(5)(C)(i) of the
Act.
In the FY 2022 final rule (86 FR 45217), in light of the COVID-19
PHE, we amended the regulations at Sec. 412.96(h)(1) to provide for
the use of the best available data rather than the latest available
data in calculating the national and regional CMI criteria. We also
amended the regulations at Sec. 412.96(c)(1) to indicate that the
individual hospital's CMI value for discharges during the same Federal
fiscal year used to compute the national and regional CMI values is
used for purposes of determining whether a hospital qualifies for RRC
classification. We also amended the regulations Sec. 412.96(i)(1) and
(2), which describe the methodology for calculating the number of
discharges criteria, to provide for the use of the best available data
rather than the latest available or most recent data when calculating
the regional discharges for RRC classification.
1. Case-Mix Index (CMI)
Section 412.96(c)(1) provides that CMS establish updated national
and
[[Page 49059]]
regional CMI values in each year's annual notice of prospective payment
rates for purposes of determining RRC status. The methodology we used
to determine the national and regional CMI values is set forth in the
regulations at Sec. 412.96(c)(1)(ii). The national median CMI value
for FY 2023 is based on the CMI values of all urban hospitals
nationwide, and the regional median CMI values for FY 2023 are based on
the CMI values of all urban hospitals within each census region,
excluding those hospitals with approved teaching programs (that is,
those hospitals that train residents in an approved GME program as
provided in Sec. 413.75). For the proposed rule, these values were
based on discharges occurring during FY 2021 (October 1, 2020 through
September 30, 2021), and include bills posted to CMS' records through
December 2021. We believe that this is the best available data for use
in calculating the national and regional median CMI values and is
consistent with our finalized proposal to use the FY 2021 MedPAR claims
data for FY 2023 ratesetting. We refer the reader to section I.F. of
the preamble of this final rule for a complete discussion regarding our
proposal and finalized policy to use the latest available data (that
is, the FY 2021 MedPAR data) as the best available data for purposes of
this FY 2023 rulemaking.
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28404), we
proposed that, in addition to meeting other criteria, if rural
hospitals with fewer than 275 beds are to qualify for initial RRC
status for cost reporting periods beginning on or after October 1,
2022, they must have a CMI value for FY 2021 that is at least--
1.8251 (national--all urban); or
The median CMI value (not transfer-adjusted) for urban
hospitals (excluding hospitals with approved teaching programs as
identified in Sec. 413.75) calculated by CMS for the census region in
which the hospital is located.
The proposed median CMI values by region were set forth in a table
in the proposed rule (87 FR 28405). We stated in the proposed rule that
we intended to update the proposed CMI values in the FY 2023 final rule
to reflect the updated FY 2021 MedPAR file, which will contain data
from additional bills received through March 2022.
Comment: Commenters supported our proposal to use FY 2021 data to
calculate the national and regional median CMI values for FY 2023.
Response: We appreciate the commenters' support.
Therefore, based on the best available data (FY 2021 bills received
through March 2022), in addition to meeting other criteria, if rural
hospitals with fewer than 275 beds are to qualify for initial RRC
status for cost reporting periods beginning on or after October 1,
2022, they must have a CMI value for FY 2021 that is at least:
1.8262 (national--all urban); or
The median CMI value (not transfer-adjusted) for urban
hospitals (excluding hospitals with approved teaching programs as
identified in Sec. 413.75) calculated by CMS for the census region in
which the hospital is located.
The final CMI values by region are set forth in the following
table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.128
A hospital seeking to qualify as an RRC should obtain its hospital-
specific CMI value (not transfer-adjusted) from its MAC. Data are
available on the Provider Statistical and Reimbursement (PS&R) System.
In keeping with our policy on discharges, the CMI values are computed
based on all Medicare patient discharges subject to the IPPS MS-DRG-
based payment.
3. Discharges
Section 412.96(c)(2)(i) provides that CMS set forth the national
and regional numbers of discharges criteria in each year's annual
notice of prospective payment rates for purposes of determining RRC
status. As specified in section 1886(d)(5)(C)(ii) of the Act, the
national standard is set at 5,000 discharges. In the FY 2023 IPPS/LTCH
PPS proposed rule (87 FR 28406), for FY 2023, we proposed to update the
regional standards based on discharges for urban hospitals' cost
reporting periods that began during FY 2020 (that is, October 1, 2019
through September 30, 2020). We believe that this is the best available
data for use in calculating the median number of discharges by region
and is consistent with our finalized data proposal to use cost report
data from cost reporting periods beginning during FY 2020 for FY 2023
ratesetting. We refer the reader to section I.F. of the preamble of
this final rule for a complete discussion regarding our proposal and
finalized policy to use the latest available data (that is, cost
reports beginning during FY 2020) as the best available data for
purposes of this FY 2023 rulemaking.
In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28405), we
proposed that, in addition to meeting other criteria, a hospital, if it
is to qualify for initial RRC status for cost reporting periods
beginning on or after October 1, 2022, must have, as the number of
discharges for its cost reporting period that began during FY 2020, at
least--
5,000 (3,000 for an osteopathic hospital); or
If less, the median number of discharges for urban
hospitals in the census region in which the hospital is located. (We
refer readers to the table set forth in the FY 2023 IPPS/LTCH PPS
proposed rule at 87 FR 28406). In the
[[Page 49060]]
proposed rule, we stated that we intended to update to update these
numbers in the FY 2023 final rule based on the latest available cost
report data.
Comment: Commenters supported our proposal to use FY 2020 data to
calculate median number of discharges by region for FY 2023.
Response: We appreciate the commenters' support.
Therefore, based on the best available discharge data at this time,
that is, for cost reporting periods that began during FY 2020, the
final median number of discharges for urban hospitals by census region
are set forth in the following table.
[GRAPHIC] [TIFF OMITTED] TR10AU22.129
We note that because the median number of discharges for hospitals
in each census region is greater than the national standard of 5,000
discharges, under this final rule, 5,000 discharges is the minimum
criterion for all hospitals, except for osteopathic hospitals for which
the minimum criterion is 3,000 discharges.
C. Payment Adjustment for Low-Volume Hospitals (Sec. 412.101)
1. Expiration of Temporary Changes to Low-Volume Hospital Payment
Policy
As discussed in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41398
through 41399), section 50204 of the Bipartisan Budget Act of 2018
(Pub. L. 115-123) modified the definition of a low-volume hospital and
the methodology for calculating the payment adjustment for low-volume
hospitals under section 1886(d)(12) of the Act for FYs 2019 through
2022. Beginning with FY 2023, the low-volume hospital qualifying
criteria and payment adjustment will revert to the statutory
requirements that were in effect prior to FY 2011, and the preexisting
low-volume hospital payment adjustment methodology and qualifying
criteria, as implemented in FY 2005 and discussed later in this section
of this final rule, will resume. (For additional information on the
temporary changes to the low-volume hospital payment policy, we refer
readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41398 through
41401). We also note, in that same final rule, we amended the
regulations at 42 CFR 412.101 to reflect the provisions of section
50204 of the Bipartisan Budget Act of 2018.) We discuss the payment
policies for FY 2023 in section V.C.3. of the preamble of this final
rule.
2. Background
Section 1886(d)(12) of the Act provides for an additional payment
to each qualifying low-volume hospital under the IPPS beginning in FY
2005. The additional payment adjustment to a low-volume hospital
provided for under section 1886(d)(12) of the Act is in addition to any
payment calculated under section 1886 of the Act. Therefore, the
additional payment adjustment is based on the per discharge amount paid
to the qualifying hospital under section 1886 of the Act. In other
words, the low-volume hospital payment adjustment is based on total per
discharge payments made under section 1886 of the Act, including
capital, DSH, IME, and outlier payments. For SCHs and MDHs, the low-
volume hospital payment adjustment is based in part on either the
Federal rate or the hospital-specific rate, whichever results in a
greater operating IPPS payment.
As discussed in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45219
through 45221), section 50204 of the Bipartisan Budget Act of 2018
(Pub. L. 115-123) modified the definition of a low-volume hospital and
the methodology for calculating the payment adjustment for low-volume
hospitals for FYs 2019 through 2022. Specifically, the qualifying
criteria for low-volume hospitals under section 1886(d)(12)(C)(i) of
the Act were amended to specify that, for FYs 2019 through 2022, a
subsection (d) hospital qualifies as a low-volume hospital if it is
more than 15 road miles from another subsection (d) hospital and has
less than 3,800 total discharges during the fiscal year. Section
1886(d)(12)(D) of the Act was also amended to provide that, for
discharges occurring in FYs 2019 through 2022, the Secretary determines
the applicable percentage increase using a continuous, linear sliding
scale ranging from an additional 25 percent payment adjustment for low-
volume hospitals with 500 or fewer discharges to a zero percent
additional payment for low-volume hospitals with more than 3,800
discharges in the fiscal year. Consistent with the requirements of
section 1886(d)(12)(C)(ii) of the Act, the term ``discharge'' for
purposes of these provisions refers to total discharges, regardless of
payer (that is, Medicare and non-Medicare discharges).
Beginning with FY 2023, the low-volume hospital qualifying criteria
and payment adjustment will revert to the statutory requirements that
were in effect prior to FY 2011. Section 1886(d)(12)(C)(i) of the Act
defines a low-volume hospital, for FYs 2005 through 2010 and FY 2023
and subsequent years, as a subsection (d) hospital that the Secretary
determines is located more than 25 road miles from another subsection
(d) hospital and that has less than 800 discharges during the fiscal
year. Section 1886(d)(12)(C)(ii) of the Act further stipulates that the
term ``discharge'' means an inpatient acute care discharge of an
individual, regardless of whether the individual is entitled to
benefits under Medicare Part A (except with respect to FYs 2011 through
2018). Therefore, for FYs 2005 through 2010 and FY 2019 and subsequent
years, the term ``discharge'' refers to total discharges, regardless of
payer (that is, Medicare and non-Medicare discharges), and as such the
[[Page 49061]]
term discharge continues to refer to total discharges for FY 2023 and
subsequent years. Furthermore, section 1886(d)(12)(B) of the Act
requires, for discharges occurring in FYs 2005 through 2010 and FY 2023
and subsequent years, that the Secretary determine an applicable
percentage increase for these low-volume hospitals based on the
``empirical relationship'' between the standardized cost-per-case for
such hospitals and the total number of discharges of such hospitals and
the amount of the additional incremental costs (if any) that are
associated with such number of discharges. The statute thus mandates
that the Secretary develop an empirically justifiable adjustment based
on the relationship between costs and discharges for these low-volume
hospitals. Section 1886(d)(12)(B)(iii) of the Act limits the applicable
percentage increase adjustment to no more than 25 percent.
Based on an analysis we conducted for the FY 2005 IPPS final rule
(69 FR 49099 through 49102), a 25-percent low-volume adjustment to all
qualifying hospitals with less than 200 discharges was found to be most
consistent with the statutory requirement to provide relief to low-
volume hospitals where there is empirical evidence that higher
incremental costs are associated with low numbers of total discharges.
In the FY 2006 IPPS final rule (70 FR 47432 through 47434), we stated
that multivariate analyses supported the existing low-volume adjustment
implemented in FY 2005. Accordingly, under the existing regulations, in
order for a hospital to continue to qualify as a low-volume hospital on
or after October 1, 2022, it must have fewer than 200 total discharges
during the fiscal year and be located more than 25 road miles from the
nearest ``subsection (d)'' hospital (see Sec. 412.101(b)(2)(i)). (For
additional information on the low-volume hospital payment adjustment
prior to FY 2018, we refer readers to the FY 2017 IPPS/LTCH PPS final
rule (81 FR 56941 through 56943). For additional information on the
low-volume hospital payment adjustment for FY 2018, we refer readers to
the FY 2018 IPPS notice (CMS-1677-N) that appeared in the April 26,
2018, Federal Register (83 FR 18301 through 18308). For additional
information on the low-volume hospital payment adjustment for FY 2019
through FY 2022, we refer readers to the FY 2019 IPPS/LTCH PPS final
rule (83 FR 41398 through 41399).)
3. Payment Adjustment for FY 2023 and Subsequent Fiscal Years
In accordance with section 1886(d)(12) of the Act, beginning with
FY 2023, the low-volume hospital definition and payment adjustment
methodology will revert back to the statutory requirements that were in
effect prior to the amendments made by the Affordable Care Act and
subsequent legislation. Therefore, effective for FY 2023 and subsequent
years, under current policy at Sec. 412.101(b), in order to qualify as
a low-volume hospital, a subsection (d) hospital must be more than 25
road miles from another subsection (d) hospital and have less than 200
discharges (that is, less than 200 discharges total, including both
Medicare and non-Medicare discharges) during the fiscal year. For FY
2023 and subsequent years, the statute specifies that a low-volume
hospital must have less than 800 discharges during the fiscal year.
However, as required by section 1886(d)(12)(B)(i) of the Act and as
discussed earlier, the Secretary has developed an empirically
justifiable payment adjustment based on the relationship, for IPPS
hospitals with less than 800 discharges, between the additional
incremental costs (if any) that are associated with a particular number
of discharges. Based on an analysis we conducted for the FY 2005 IPPS
final rule (69 FR 49099 through 49102), a 25-percent low-volume
adjustment to all qualifying hospitals with less than 200 discharges
was found to be most consistent with the statutory requirement to
provide relief for low-volume hospitals where there is empirical
evidence that higher incremental costs are associated with low numbers
of total discharges. (Under the policy we established in that same
final rule, hospitals with between 200 and 799 discharges do not
receive a low-volume hospital adjustment.)
For FYs 2005 through 2010 and FY 2018 and subsequent years, the
discharge determination is made based on the hospital's number of total
discharges, that is, Medicare and non-Medicare discharges. The
hospital's most recently submitted cost report is used to determine if
the hospital meets the discharge criterion to receive the low-volume
payment adjustment in the current year (Sec. 412.101(b)(2)(i)). We use
cost report data to determine if a hospital meets the discharge
criterion because this is the best available data source that includes
information on both Medicare and non-Medicare discharges. We note that,
for FYs 2011 through 2018, we used the most recently available MedPAR
data to determine the hospital's Medicare discharges because only
Medicare discharges were used to determine if a hospital met the
discharge criterion for those years.
In addition to the discharge criterion, a hospital must also meet
the mileage criterion to qualify for the low-volume payment adjustment.
As specified by section 1886(d)(12)(C)(i) of the Act, a low-volume
hospital must be more than 25 road miles (or 15 road miles for FYs 2011
through 2022) from another subsection (d) hospital. Accordingly, for FY
2023 and for subsequent fiscal years, in addition to the discharge
criterion, the eligibility for the low-volume payment adjustment is
also dependent upon the hospital meeting the mileage criterion at Sec.
412.101(b)(2)(i), which specifies that a hospital must be located more
than 25 road miles from the nearest subsection (d) hospital, consistent
with section 1886(d)(12)(C)(i) of the Act. We define, at Sec.
412.101(a), the term ``road miles'' to mean ``miles'' as defined at
Sec. 412.92(c)(1) (75 FR 50238 through 50275 and 50414).
Comment: Several commenters opposed the change to the low-volume
hospital policy in FY 2023. Many of those commenters stated that they
are concerned about the financial impact resulting from the decrease in
payments due to the expiration of the temporary changes to the low-
volume hospital payment policy. Some commenters requested that CMS use
its authority to extend the use of the modified definition of a low-
volume hospital and the methodology for calculating the payment
adjustment for low-volume hospitals. Some commenters stated their
belief that CMS has the authority to not allow the temporary changes to
expire. A commenter requested CMS use its discretion under the
Emergency Pandemic Declarations to extend the low-volume hospital
payment policy.
Response: We appreciate the commenters' sharing their concerns
regarding the financial impact resulting from the expiration of the
temporary changes to the low-volume hospital payment policy. As
previously discussed, section 1886(d)(12) of the Act sets forth the
applicable low-volume hospital policy beginning FY 2023. In response to
the comment that requested the temporary changes to the low-volume
hospital policy be extended using the discretion under the Emergency
Pandemic Declarations, we believe the commenter is referring to the use
of waivers under Section 1135 of the Act. While this provision
authorizes certain Medicare (and other) program requirements and
conditions of participation to be waived during certain emergencies,
this authority cannot be used to waive provisions of payment.
Comment: Several commenters support legislative action through the
[[Page 49062]]
Rural Hospital Support Act (H.R. 1887/S. 4009) to extend or make
permanent the modifications to the low-volume hospital payment policy
enacted by section 50204 of the Bipartisan Budget Act of 2018. Many
commenters urged CMS to collaborate with Congress to extend or make
permanent the modifications to the low-volume hospital payment policy.
Other commenters stated that it is not the intent of Congress for the
low-volume hospital payment policy to revert back to the historical
statutory requirements. Some of these commenters believe that CMS is
ignoring the congressional intent of this policy and denying a group of
IPPS providers low-volume hospital payments with the reversion to the
policy that was originally established for FY 2005. These commenters
requested expanding eligibility for the discharge criteria to match the
statutory requirement to include IPPS providers with 200-799
discharges. These commenters did not provide any data analysis in
support of their comments to expand the low-volume hospital adjustment
to qualifying hospitals that have more than 200 and less than 800 total
discharges. A commenter requested that CMS update its regression
analysis. The commenter stated that empirical justification used by CMS
to determine the discharge criteria of less than 200 discharges is
dated and that no rationale to support the ongoing validity of the
previous analysis was provided in the proposed rule. The commenter also
noted that even if the low-volume hospital discharge criteria were
expanded to less than 800 total discharges, there would still only be a
small number of hospitals to qualify for low-volume payment adjustment.
Response: We appreciate the commenters sharing their support for
legislative action. We disagree that is contrary to the congressional
intent for the low-volume hospital policy to revert back to the policy
established under the original historical statutory requirements. As
noted earlier in the preamble of this final rule and as discussed in
response to public comments in the FY 2013 IPPS/LTCH PPS final rule (77
FR 53408 through 53409), the FY 2014 IPPS/LTCH PPS final rule (78 50612
through 50613), and the FY 2018 IPPS/LTCH PPS final rule (82 FR 38184
through 38189) to implement the original low-volume hospital payment
adjustment provision, and as mandated by statute, we developed an
empirically justified adjustment based on the relationship between
costs and total discharges of hospitals with less than 800 total
(Medicare and non-Medicare) discharges. Specifically, we performed
several regression analyses to evaluate the relationship between
hospitals' costs per case and discharges, and found that an adjustment
for hospitals with less than 200 total discharges is most consistent
with the statutory requirement to provide for additional payments to
low-volume hospitals where there is empirical evidence that higher
incremental costs are associated with lower numbers of discharges (69
FR 49101 through 49102). Based on these analyses, we established a low-
volume hospital policy under which qualifying hospitals with less than
200 total discharges receive a payment adjustment of an additional 25
percent. (Section 1886(d)(12)(B)(iii) of the Act limits the applicable
percentage increase adjustment to no more than 25 percent.) In the
future, we may reevaluate the low-volume hospital adjustment policy;
that is, the definition of a low-volume hospital and the payment
adjustment. However, we are not aware of any analysis or empirical
evidence that would support expanding the originally established low-
volume hospital adjustment policy and we did not make any proposals
regarding the low-volume hospital payment adjustment for FY 2023. For
these reasons, we are not making any changes to the low-volume hospital
payment adjustment policy in this final rule.
Comment: Some commenters urged CMS to expedite any changes to the
definition of a low-volume hospital and the methodology for calculating
the payment adjustment for low-volume hospitals, should Congress extend
the current policy. They requested that low-volume hospital payments be
restored quickly so that impacted providers are able to continue to
provide quality care.
Response: We appreciate the commenters' request and, as in the
past, we will make every effort to implement any extension of the low-
volume payment policy as expeditiously as possible.
Comment: A commenter questioned how a hospital would qualify for
low-volume payments while also adhering to the inpatient hospitals
Conditions of Participation (CoP) since only hospitals with less than
200 total discharges would be eligible for the low-volume hospital
adjustment beginning in FY 2023. The commenter argues that IPPS
hospitals cannot adhere to the average daily census (ADC) and average
length of stay (ALOS) thresholds in the discussion of the factors for
state agencies to consider when certifying a facility as an inpatient
hospital in the State Operations Manual (SOM).\214\ Specifically, the
commenter cites ``the ALOS of two midnights'' benchmark and the
expectation ``to maintain an average daily census (ADC) of two
patients.''
---------------------------------------------------------------------------
\214\ https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-17-44-Revised-102717.pdf.
---------------------------------------------------------------------------
Response: While we appreciate the commenter's concern regarding
compliance with the COPs and hospitals' certification as an inpatient
hospital, it is not clear to us why a low-volume hospital payment
adjustment criterion of less than 200 discharges would prevent a
hospital from meeting ``the ADC and ALOS thresholds required for
maintaining its certification and status as an inpatient facility.''
The low-volume payment adjustment provides an additional payment to
hospitals that meet the low-volume hospital qualifying criteria and
does not directly impact a hospital's ADC or ALOS. We also note that
CMS considers multiple factors when determining certification for
inpatient hospitals. ADC and ALOS are factors in determining a
hospital's eligibility for specialized payment categories. Hospitals
are not required to have any specific number of inpatients for
certification. A hospital's ability to adhere to the inpatient hospital
CoPs is not relevant to the reversion to the low-volume hospital
payment requirements that were in effect prior to FY 2011.
After consideration of the public comments we received, we are
finalizing our proposals, without modification. Consistent with current
law, effective beginning FY 2023, the low-volume hospital definition
and payment adjustment methodology will revert back to the policy
established under statutory requirements that were in effect prior to
the amendments made by the Affordable Care Act and extended through
subsequent legislation (most recently the Bipartisan Budget Act of
2018).
4. Process for Requesting and Obtaining the Low-Volume Hospital Payment
Adjustment
In the FY 2011 IPPS/LTCH PPS final rule (75 FR 50238 through 50275
and 50414) and subsequent rulemaking, most recently in the FY 2022
IPPS/LTCH PPS final rule (86 FR 45219 through 45221), we discussed the
process for requesting and obtaining the low-volume hospital payment
adjustment.
Under this previously established process, a hospital makes a
written
[[Page 49063]]
request for the low-volume payment adjustment under Sec. 412.101 to
its MAC. This request must contain sufficient documentation to
establish that the hospital meets the applicable mileage and discharge
criteria. The MAC will determine if the hospital qualifies as a low-
volume hospital by reviewing the data the hospital submits with its
request for low-volume hospital status in addition to other available
data. Under this approach, a hospital will know in advance whether or
not it will receive a payment adjustment under the low-volume hospital
policy. The MAC and CMS may review available data such as the number of
discharges, in addition to the data the hospital submits with its
request for low-volume hospital status, to determine whether or not the
hospital meets the qualifying criteria. (For additional information on
our existing process for requesting the low-volume hospital payment
adjustment, we refer readers to the FY 2019 IPPS/LTCH PPS final rule
(83 FR 41399 through 41401).)
As explained earlier, for FY 2019 and subsequent fiscal years, the
discharge determination is made based on the hospital's number of total
discharges, that is, Medicare and non-Medicare discharges, as was the
case for FYs 2005 through 2010. Under Sec. 412.101(b)(2)(i) and (iii),
a hospital's most recently submitted cost report is used to determine
if the hospital meets the discharge criterion to receive the low-volume
payment adjustment in the current year. As discussed in the FY 2019
IPPS/LTCH PPS final rule (83 FR 41399 and 41400), we use cost report
data to determine if a hospital meets the discharge criterion because
this is the best available data source that includes information on
both Medicare and non-Medicare discharges. (For FYs 2011 through 2018,
the most recently available MedPAR data were used to determine the
hospital's Medicare discharges because non-Medicare discharges were not
used to determine if a hospital met the discharge criterion for those
years.) Therefore, a hospital must refer to its most recently submitted
cost report for total discharges (Medicare and non-Medicare) to decide
whether or not to apply for low-volume hospital status for a particular
fiscal year.
As also discussed in the FY 2019 IPPS/LTCH PPS final rule, in
addition to the discharge criterion, for FY 2019 and for subsequent
fiscal years, eligibility for the low-volume hospital payment
adjustment is also dependent upon the hospital meeting the applicable
mileage criterion specified in Sec. 412.101(b)(2)(i) or (iii) for the
fiscal year. Specifically, to meet the mileage criterion to qualify for
the low-volume hospital payment adjustment for FY 2023, a hospital must
be located more than 25 road miles from the nearest subsection (d)
hospital. (We define in Sec. 412.101(a) the term ``road miles'' to
mean ``miles'' as defined in Sec. 412.92(c)(1) (75 FR 50238 through
50275 and 50414).) For establishing that the hospital meets the mileage
criterion, the use of a web-based mapping tool as part of the
documentation is acceptable. The MAC will determine if the information
submitted by the hospital, such as the name and street address of the
nearest hospitals, location on a map, and distance from the hospital
requesting low-volume hospital status, is sufficient to document that
it meets the mileage criterion. If not, the MAC will follow up with the
hospital to obtain additional necessary information to determine
whether or not the hospital meets the applicable mileage criterion.
In accordance with our previously established process, a hospital
must make a written request for low-volume hospital status that is
received by its MAC by September 1 immediately preceding the start of
the Federal fiscal year for which the hospital is applying for low-
volume hospital status in order for the applicable low-volume hospital
payment adjustment to be applied to payments for its discharges for the
fiscal year beginning on or after October 1 immediately following the
request (that is, the start of the Federal fiscal year). For a hospital
whose request for low volume hospital status is received after
September 1, if the MAC determines the hospital meets the criteria to
qualify as a low-volume hospital, the MAC will apply the applicable
low-volume hospital payment adjustment to determine payment for the
hospital's discharges for the fiscal year, effective prospectively
within 30 days of the date of the MAC's low-volume status
determination.
Consistent with this previously established process, for FY 2023,
we proposed that a hospital must submit a written request for low-
volume hospital status to its MAC that includes sufficient
documentation to establish that the hospital meets the applicable
mileage and discharge criteria (as described earlier). Specifically,
for FY 2023, a hospital must make a written request for low-volume
hospital status that is received by its MAC no later than September 1,
2022, in order for the 25-percent, low-volume, add-on payment
adjustment to be applied to payments for its discharges beginning on or
after October 1, 2022. If a hospital's written request for low-volume
hospital status for FY 2023 is received after September 1, 2022, and if
the MAC determines the hospital meets the criteria to qualify as a low-
volume hospital, the MAC would apply the low-volume hospital payment
adjustment to determine the payment for the hospital's FY 2023
discharges, effective prospectively within 30 days of the date of the
MAC's low-volume hospital status determination.
Under this process, a hospital that qualified for the low-volume
hospital payment adjustment for FY 2022 may continue to receive a low-
volume hospital payment adjustment for FY 2023 without reapplying if it
meets both the discharge criterion and the mileage criterion applicable
for FY 2023. As discussed previously, for FY 2023 the discharge and the
mileage criteria are reverting to the statutory requirements that were
in effect prior to FY 2011, and to the preexisting low-volume hospital
qualifying criteria, as implemented in FY 2005 and specified in the
existing regulations at Sec. 412.101(b)(2)(i). As in previous years,
we proposed that such a hospital must send written verification that is
received by its MAC no later than September 1, 2022, stating that it
meets the mileage criterion applicable for FY 2023 (that is, is located
more than 25 road miles from the nearest ``subsection (d)'' hospital).
For FY 2023, we further proposed that this written verification must
also state, based upon the most recently submitted cost report, that
the hospital meets the discharge criterion applicable for FY 2023 (that
is, less than 200 discharges total, including both Medicare and non-
Medicare discharges). If a hospital's request for low-volume hospital
status for FY 2023 is received after September 1, 2022, and if the MAC
determines the hospital meets the criteria to qualify as a low-volume
hospital, the MAC will apply the 25-percent, low-volume, add-on payment
adjustment to determine the payment for the hospital's FY 2023
discharges, effective prospectively within 30 days of the date of the
MAC's low-volume hospital status determination.
We received no comments on our proposed process for requesting and
obtaining the low-volume hospital payment adjustment for FY 2023 and
therefore are finalizing this proposal without modification.
We note, in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41398
through 41401 and 41702), in accordance with the provisions of section
50204 of the Bipartisan Budget Act of 2018, for FY 2023 and subsequent
fiscal years, we made conforming changes to the regulations at 42 CFR
412.101 to reflect that the low-volume payment adjustment policy in
effect for these
[[Page 49064]]
years is the same low-volume hospital payment adjustment policy in
effect for FYs 2005 through 2010. Under these revisions, beginning with
FY 2023, consistent with current law, the low-volume hospital
qualifying criteria and payment adjustment methodology will return to
the criteria and methodology that were in effect prior to the
amendments made by the Affordable Care Act (that is, the low-volume
hospital payment policy in effect for FYs 2005 through 2010).
Therefore, no further revisions to the policy or to the regulations at
Sec. 412.101 are required to conform them to the statutory requirement
that the low-volume hospital policy in effect prior to the Affordable
Care Act will again be in effect for FY 2023 and subsequent years.
D. Changes in the Medicare-Dependent, Small Rural Hospital (MDH)
Program (Sec. 412.108)
1. Background for the MDH Program
Section 1886(d)(5)(G) of the Act provides special payment
protections, under the IPPS, to a Medicare-dependent, small rural
hospital (MDH). (For additional information on the MDH program and the
payment methodology, we refer readers to the FY 2012 IPPS/LTCH PPS
final rule (76 FR 51683 through 51684).) As discussed in section V.B.
of the preamble of this final rule, the MDH program provisions at
section 1886(d)(5)(G) of the Act will expire at the end of FY 2022.
Beginning with discharges occurring on or after October 1, 2022, all
hospitals that previously qualified for MDH status will be paid based
on the Federal rate.
Since the extension of the MDH program through FY 2012 provided by
section 3124 of the Affordable Care Act, the MDH program had been
extended by subsequent legislation as follows: section 606 of the ATRA
(Pub. L. 112- 240) extended the MDH program through FY 2013 (that is,
for discharges occurring before October 1, 2013). Section 1106 of the
Pathway for SGR Reform Act of 2013 (Pub. L. 113-67) extended the MDH
program through the first half of FY 2014 (that is, for discharges
occurring before April 1, 2014). Section 106 of the PAMA (Pub. L. 113-
93) extended the MDH program through the first half of FY 2015 (that
is, for discharges occurring before April 1, 2015). Section 205 of the
MACRA (Pub. L. 114-10) extended the MDH program through FY 2017 (that
is, for discharges occurring before October 1, 2017). Section 50205 of
the Bipartisan Budget Act (Pub. L. 115- 123) extended the MDH program
through FY 2022 (that is for discharges occurring before October 1,
2022). For additional information on the extensions of the MDH program
after FY 2012, we refer readers to the following Federal Register
documents:
The FY 2013 IPPS/LTCH PPS final rule (77 FR 53404 through
53405 and 53413 through 53414).
The FY 2013 IPPS notice (78 FR 14689).
The FY 2014 IPPS/LTCH PPS final rule (78 FR 50647 through
50649).
The FY 2014 interim final rule with comment period (79 FR
15025 through 15027).
The FY 2014 notice (79 FR 34446 through 34449).
The FY 2015 IPPS/LTCH PPS final rule (79 FR 50022 through
50024).
The August 2015 interim final rule with comment period (80
FR 49596).
The FY 2017 IPPS/LTCH PPS final rule (81 FR 57054 through
57057).
The FY 2018 notice (83 FR 18303 through 18305).
The FY 2019 IPPS/LTCH PPS final rule (83 FR 41429).
2. Expiration of the MDH Program
Because section 50205 of the Bipartisan Budget Act extended the MDH
program through FY 2022 only, beginning October 1, 2022, the MDH
program will no longer be in effect. Because the MDH program is not
authorized by statute beyond September 30, 2022, beginning October 1,
2022, all hospitals that previously qualified for MDH status under
section 1886(d)(5)(G) of the Act will no longer have MDH status and
will be paid based on the IPPS Federal rate.
When the MDH program was set to expire at the end of FY 2012, in
the FY 2013 IPPS/LTCH PPS final rule (77 FR 53404 through 53405), we
revised our sole community hospital (SCH) policies to allow MDHs to
apply for SCH status in advance of the expiration of the MDH program
and be paid as such under certain conditions. We codified these changes
in the regulations at Sec. 412.92(b)(2)(i) and (v). Specifically, the
existing regulations at Sec. 412.92(b)(2)(v) allow for an effective
date of an approval of SCH status that is the day following the
expiration date of the MDH program. We note that these same conditions
apply to MDHs that intend to apply for SCH status with the expiration
of the MDH program on September 30, 2022. Therefore, in order for an
MDH to receive SCH status effective October 1, 2022, the MDH must apply
for SCH status at least 30 days before the expiration of the MDH
program; that is, the MDH must apply for SCH status by September 1,
2022. The MDH also must request that, if approved as an SCH, the SCH
status be effective with the expiration of the MDH program; that is,
the MDH must request that the SCH status, if approved, be effective
October 1, 2022, immediately after its MDH status expires with the
expiration of the MDH program on September 30, 2022. We emphasize that
an MDH that applies for SCH status in anticipation of the expiration of
the MDH program would not qualify for the October 1, 2022, effective
date for SCH status if it does not apply by the September 1, 2022,
deadline. If the MDH does not apply by the September 1, 2022, deadline,
the hospital would instead be subject to the usual effective date for
SCH classification; that is, as of the date the MAC receives the
complete application as specified at Sec. 412.92(b)(2)(i).
We note that the regulations governing the MDH program are found at
Sec. 412.108 and the MDH program is also cited in the general payment
rules in the regulations at Sec. 412.90. As stated earlier, under
current law, the MDH program will expire at the end of FY 2022, which
is already reflected in Sec. Sec. 412.108 and 412.90(j). As such, we
did not propose specific amendments to the regulations at Sec. 412.108
or Sec. 412.90 to reflect the expiration of the MDH program. However,
we proposed that if the MDH program were to be extended by law, similar
to how it was extended through FY 2013, by the ATRA (Pub. L. 112-240);
through March 31, 2014, by the Pathway for SGR Reform Act of 2013 (Pub.
L. 113-167); through March 31, 2015, by the PAMA (Pub. L. 113-93);
through FY 2017, by the MACRA (Pub. L. 114-10); and most recently
through FY 2022, by the Bipartisan Budget Act of 2018 (Pub. L. 115-
123), we would make conforming changes to the regulations governing the
MDH program at Sec. 412.108(a)(1) and (c)(2)(iii) and the general
payment rules at Sec. 412.90(j) to reflect such an extension of the
MDH program. We stated that these conforming changes would only be made
if the MDH program were to be extended by statute beyond September 30,
2022. As of the time of the development of this final rule, there has
been no change in law to extend the MDH program beyond FY 2022.
Therefore, in this final rule, we are not making any additional changes
to the regulations governing the MDH program at Sec. 412.108 or the
general payment rules at Sec. 412.90.
Comment: Many commenters expressed support for extending the MDH
program or making the MDH program permanent and noted that they would
continue supporting congressional efforts to protect the MDH program.
Some commenters also
[[Page 49065]]
expressed support for an additional base year for calculating MDH
payments. A commenter urged CMS to remove the MDH program expiration
proposal from the final rule. Several state hospital associations
expressed their concern that hospitals in their states would experience
significant payment decreases as a result of the expiration of the MDH
program. A few commenters urged for action to be taken to ensure that
the MDH program is extended, while other commenters urged CMS to
explore alternatives and make immediate adjustments within its
authority to provide relief and mitigate negative impacts to rural
hospitals should Congress not act.
Response: While we appreciate the commenters' concerns about the
expiration of the MDH program and the financial impact to affected
providers if the MDH program is not extended beyond FY 2022, CMS does
not have the authority under current law to extend the MDH program
beyond the September 30, 2022 statutory expiration date. Similarly,
Section 1886(b)(3)(D) of the Act specifies the applicable base years or
``target amounts'' for hospitals classified as MDHs. These comments are
similar to comments we received previously, prior to the statutory
extension of the MDH program for FY 2018 through FY 2022 provided by
subsequent legislation, and discussed in the FY 2018 IPPS/LTCH PPS
final rule (82 FR 38220 through 38221). In response to the comment
urging CMS to explore other relief options should Congress not act, we
will consider this for future rulemaking and explore potential ways to
provide support to this subset of rural providers.
Comment: Several commenters expressed support for CMS' policy that
allows MDHs to apply for SCH status in advance of the expiration of the
MDH program and be paid as such under certain conditions. Some
commenters also requested that CMS also provide former MDHs with the
ability to rescind their newly acquired SCH status and reinstate their
MDH status in a seamless manner, if a retroactive extension to the MDH
program is made.
Response: We appreciate the commenters' support of our policy
allowing MDHs to apply for SCH status in advance of the expiration of
the MDH program and to be paid as such under certain conditions and
allow for a seamless transition from MDH classification to SCH
classification. In response to the suggestion that CMS provide former
MDHs with ability to rescind their newly acquired SCH status and
reinstate their MDH status in a seamless manner if a retroactive
extension to the MDH program is made, we understand the desire on the
part of hospitals for certainty in the face of MDH program expiration
and will consider for future rulemaking any potential mechanisms to
further streamline such transitions in connection with legislative
extensions of the MDH program. We note that under the current
regulations at Sec. 412.108(b)(4), the effective date for MDH
classification is as of the date the MAC receives the complete
application. A MDH that applied for and was classified as an SCH in
advance of the MDH expiration per the regulations at Sec.
412.92(b)(2)(v) could request a cancellation of its SCH status and
simultaneously re-apply for MDH status if the MDH program were to be
extended, and the MDH classification would be effective as of the date
that the MAC receives the complete application. This would allow a
former MDH to maintain special payment status as an SCH and then as an
MDH generally without interruption in the event the MDH program is
extended.
Comment: Commenters urged CMS to expedite restoration of MDH
status, should Congress act to extend these programs, stating that past
retroactive restorations have seen delays that caused significant cash
flow problems to affected hospitals. They requested that CMS move
expeditiously to restore payments so that these rural facilities are
able to continue to provide quality care to their communities and that
CMS clarify how it might handle program extensions, should Congress
enact legislation to extend them.
Response: We appreciate the commenters' sharing their concerns
relating to a retroactive restoration of the MDH program. As with past
extensions, CMS will evaluate enacted legislation to determine the most
appropriate approach to implement changes to the law, including
instructions to the MACs to reinstate MDH status to eligible hospitals.
As in the past, we will make every effort to implement any extension of
the MDH program as expeditiously as possible.
In summary, under current law, beginning October 1, 2022, all
hospitals that previously qualified for MDH status will no longer have
MDH status.
E. Indirect Medical Education (IME) Payment Adjustment Factor (Sec.
412.105)
Under the IPPS, an additional payment amount is made to hospitals
with residents in an approved graduate medical education (GME) program
in order to reflect the higher indirect patient care costs of teaching
hospitals relative to nonteaching hospitals. The payment amount is
determined by use of a statutorily specified adjustment factor. The
regulations regarding the calculation of this additional payment, known
as the IME adjustment, are located at Sec. 412.105. We refer readers
to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51680) for a full
discussion of the IME adjustment and IME adjustment factor. Section
1886(d)(5)(B)(ii)(XII) of the Act provides that, for discharges
occurring during FY 2008 and fiscal years thereafter, the IME formula
multiplier is 1.35.
Accordingly, for discharges occurring during FY 2023, the formula
multiplier is 1.35. We estimate that application of this formula
multiplier for the FY 2023 IME adjustment will result in an increase in
IPPS payment of 5.5 percent for every approximately 10 percent increase
in the hospital's resident-to-bed ratio.
We did not receive any comments regarding the IME adjustment
factor, which, as noted earlier, is statutorily required. Accordingly,
for discharges occurring during FY 2023, the IME formula multiplier is
1.35.
F. Payment for Indirect and Direct Graduate Medical Education Costs
(Sec. Sec. 412.105 and 413.75 Through 413.83)
1. Background
Section 1886(h) of the Act, as added by section 9202 of the
Consolidated Omnibus Budget Reconciliation Act (COBRA) of 1985 (Pub. L.
99-272) and as currently implemented in the regulations at 42 CFR
413.75 through 413.83, establishes a methodology for determining
payments to hospitals for the direct costs of approved graduate medical
education (GME) programs. Section 1886(h)(2) of the Act sets forth a
methodology for the determination of a hospital-specific base-period
per resident amount (PRA) that is calculated by dividing a hospital's
allowable direct costs of GME in a base period by its number of full-
time equivalent (FTE) residents in the base period. The base period is,
for most hospitals, the hospital's cost reporting period beginning in
FY 1984 (that is, October 1, 1983 through September 30, 1984). The base
year PRA is updated annually for inflation. In general, Medicare direct
GME payments are calculated by multiplying the hospital's updated PRA
by the weighted number of FTE residents working in all areas of the
hospital complex (and at nonprovider sites, when applicable), and the
hospital's Medicare share of total inpatient days.
Section 1886(d)(5)(B) of the Act provides for a payment adjustment
[[Page 49066]]
known as the indirect medical education (IME) adjustment under the IPPS
for hospitals that have residents in an approved GME program, in order
to account for the higher indirect patient care costs of teaching
hospitals relative to nonteaching hospitals. The regulations regarding
the calculation of this additional payment are located at 42 CFR
412.105. The hospital's IME adjustment applied to the DRG payments is
calculated based on the ratio of the hospital's number of FTE residents
training in either the inpatient or outpatient departments of the IPPS
hospital (and, for discharges occurring on or after October 1, 1997, at
non-provider sites, when applicable) to the number of inpatient
hospital beds.
The calculation of both direct GME payments and the IME payment
adjustment is affected by the number of FTE residents that a hospital
is allowed to count. Generally, the greater the number of FTE residents
a hospital counts, the greater the amount of Medicare direct GME and
IME payments the hospital will receive. In an attempt to end the
implicit incentive for hospitals to increase the number of FTE
residents, Congress, through the Balanced Budget Act of 1997 (Pub. L.
105-33), established a limit on the number of allopathic and
osteopathic residents that a hospital could include in its FTE resident
count for direct GME and IME payment purposes. Under section
1886(h)(4)(F) of the Act, for cost reporting periods beginning on or
after October 1, 1997, a hospital's unweighted FTE count of residents
for purposes of direct GME may not exceed the hospital's unweighted FTE
count for direct GME in its most recent cost reporting period ending on
or before December 31, 1996. Under section 1886(d)(5)(B)(v) of the Act,
a similar limit based on the FTE count for IME during that cost
reporting period is applied, effective for discharges occurring on or
after October 1, 1997. Dental and podiatric residents are not included
in this statutorily mandated cap.
As mentioned previously, Medicare direct GME payments are
calculated by multiplying the hospital's updated PRA by the weighted
number of FTE residents working in all areas of the hospital complex
(and at nonprovider sites, when applicable), and the hospital's
Medicare share of total inpatient days. Section 1886(h)(4) of the Act
specifies the methodology for determining the amount of FTE residents
to be included in a hospital's direct GME payment formula. That is, the
number of FTE residents training at a hospital (or in non-provider
sites as applicable) would not necessarily equal the sum of those FTE
residents used in the hospital's direct GME payment formula, since
certain rules and factors are applied to adjust the count of FTE
residents for direct GME payment purposes. First, section 1886(h)(4)(C)
of the Act requires that a ``weighting factor'' of either 1.0 or 0.5 be
applied to each FTE resident, as follows: In calculating the number of
FTE residents in an approved residency program on or after July 1,
1987, for a resident who is not in the resident's initial residency
period, the weighting factor is 0.50. Section 1886(h)(5)(F) of the Act
defines the term ``initial residency period'' as the ``period of board
eligibility,'' with certain exceptions. Finally, section 1886(h)(4)(G)
of the Act states that the term ``period of board eligibility'' means,
for a resident, the minimum number of years of formal training
necessary to satisfy the requirements for initial board eligibility in
the particular specialty for which the resident is training. The direct
GME calculation and our policy on applying the weighting factors to
each FTE resident based on the FTE resident's status within or beyond
the initial residency period (IRP) was established in the September 29,
1989, Federal Register (54 FR 40287, 40292, 40305 and 40306), and
implemented in the regulations at 42 CFR 413.86(f) (now 42 CFR
413.79(a) and (b)).
Thus, the FTE count used in the direct GME payment formula must be
a weighted FTE count when a hospital is training residents beyond their
IRPs. However, the direct GME FTE cap is an unweighted number. That is,
under section 1886(h)(4)(F) of the Act, for cost reporting periods
beginning on or after October 1, 1997, a hospital's unweighted FTE
count of residents for purposes of direct GME may not exceed the
hospital's unweighted FTE count for direct GME in its most recent cost
reporting period ending on or before December 31, 1996 (that is the
hospital's unweighted 1996 FTE cap or FTE cap). Regulations regarding
the FTE caps and unweighted FTE counts were first published in the
August 29, 1997, Federal Register (62 FR 45966). To address situations
where a hospital's weighted FTE count exceeds its unweighted 1996 FTE
cap, we established a policy effective for cost reporting periods
beginning on or after October 1, 1997, to bring the weighted FTE count
within the unweighted FTE cap using the following ratio on the Medicare
cost report: ((1996 unweighted FTE cap/current year unweighted FTE
count) x (current year total weighted FTE count)) (see 62 FR 46005 and
63 FR 26,330 (May 12, 1998)). In the August 1, 2001, Federal Register
(66 FR 39893 through 39896), we modified this ratio effective for cost
reporting periods beginning on or after October 1, 2001, to separately
account for a hospital's current year weighted primary care and
obstetrics/gynecology (OB/GYN) FTE count and primary care and OB/GYN
PRA, and current year weighted other FTE count and other PRA, as
follows: (FTE cap/unweighted total FTEs in the cost reporting period) x
(weighted primary care and OB/GYN FTEs in the cost reporting period)
plus (FTE cap/unweighted total FTEs in the cost reporting period) x
(weighted nonprimary care FTEs in the cost reporting period). The sum
of the products is the current year allowable weighted FTE count. In
addition, effective for cost reporting periods beginning on or after
October 1, 2001, the direct GME payment is calculated using two
separate rolling averages, one for primary care and OB/GYN FTE
residents, and one for nonprimary care FTE residents. These
calculations were implemented at 42 CFR 413.86(g)(4) and (5)
respectively, currently 42 CFR 413.79(c)(2)(iii) and (d)(3).
2. Milton S. Hershey Medical Center, et al. v. Becerra Litigation
On May 17, 2021, the U.S. District Court for the District of
Columbia ruled against CMS's method of calculating direct GME payments
to teaching hospitals when those hospitals' weighted FTE counts exceed
their direct GME FTE cap. In Milton S. Hershey Medical Center, et al.
v. Becerra (Slip. Op., 2021 WL 1966572, May 17, 2021), the court
ordered CMS to recalculate reimbursement owed, holding that CMS's
regulation impermissibly modified the statutory weighting factors
discussed previously. The plaintiffs in these consolidated cases
alleged that as far back as 2005, the proportional reduction that CMS
applied to the weighted FTE count when the weighted FTE count exceeded
the FTE cap conflicted with the Medicare statute, and it was an
arbitrary and capricious exercise of agency discretion under the
Administrative Procedure Act. The Court held that the proportional
reduction methodology improperly modified the weighting factors
statutorily assigned to residents and fellows. The court ordered CMS to
pay the plaintiffs according to a more favorable method.
For example, a hospital has a direct GME cap of 100, trains 90 FTE
residents weighted at 1.0 and 10 FTE fellows weighted at 0.5, for a
total unweighted
[[Page 49067]]
count of 100, and a total weighted FTE count of 95. Under current
methodology, the proportional reduction is: (100 cap/100 current year
unweighted count) x 95 (current year weighted count) = 95.
If that hospital adds 10 more fellows and exceeds the cap with an
unweighted total of 110 (90 residents and 20 fellows), its weighted FTE
count of 100 is reduced as follows: (100 cap/110 current year
unweighted count) x 100 (current year weighted count) = 90.91.
The plaintiffs stated that CMS's proportional reduction method
unlawfully reduced the weighting factor of 0.5 to an amount less than
that, thereby reducing the capped weighted FTE amount (100 reduced to
90.91 in the example) to which they were entitled for direct GME
payment purposes. The court granted the plaintiffs' motion for summary
judgment, denied defendant's, and remanded to the Agency so that it
could recalculate plaintiffs' reimbursement payments consistent with
the court's opinion. The court held that CMS's proportional reduction
methodology, enacted at 42 CFR 413.79(c)(2)(iii), was inconsistent with
the statutory weighting factors. In response to the court's decision,
in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28410 through 28412),
we proposed to implement a modified policy applicable to all teaching
hospitals, effective as of October 1, 2001, which would replace the
existing policy at 42 CFR 413.79(c)(2)(iii). While the proportional
reduction method struck down in Hershey was first effective for cost
reports beginning on or after October 1, 1997, we are unaware of any
open or reopenable NPRs for the 1997-2001 period where the proportional
reduction method caused a provider's payments to be lower than they
would be under our proposed new policy, but we welcomed comments
alerting us of such NPRs. The proportional reduction method was amended
to its present form effective for cost reporting periods beginning on
or after October 2001. (See current 42 CFR 413.79(c)(2)(ii) and (iii).)
Therefore, we proposed to modify the policy embodied in 42 CFR
413.79(c)(2)(iii), which the Court found in Hershey was inconsistent
with the statute.
The Court's decision in Hershey held that our prior rule governing
``computation of the approved number of full-time equivalent residents
in an approved medical residency training program'' (Sec. 1886(h)(4)
of the Act) was inconsistent with the statute. That statute further
requires us to ``establish rules consistent with this paragraph'' for
the computation of FTEs. Following our review of the district court's
reasoning in Hershey and the statute, we concluded that our existing
formula for computing the number of FTEs was inconsistent with the
statutory requirements. It is also our view that the combination of the
statutory requirement to ``establish rules'' and the Hershey court's
conclusion that our existing rules are inconsistent with statutory
requirements necessitates a new rulemaking. We further note that the
Hershey decision does not mandate an alternative payment method, and we
do not believe that the decision--or our independent conclusion that
the formula should be modified--forecloses alternatives to the
calculation method we finalize here. In the FY 2023 IPPS/LTCH PPS
proposed rule (87 FR 28411), we stated our belief that, in order to
comply with the statutory requirement to make rules governing the
computation of FTEs, it is necessary to engage in a retroactive
rulemaking to modify the statutorily-required rule effective for cost
reporting periods beginning on or after October 1, 2001. While Hershey
itself does not mandate this conclusion, we believe it would be
inconsistent with the statute to calculate past payments for open cost
reports based on a rule inconsistent with the law, particularly where a
court ordered us to recalculate payments to plaintiffs. Doing so via
notice-and-comment rulemaking is in the public interest because it will
permit interested stakeholders to comment on the proposed approach,
allow the agency to have the benefit of those comments in the
development of a final rule, and calculate payments for past open cost
years in a transparent, consistent, and efficient manner. This is
particularly true in this situation, where the existing policy was
promulgated via an interim final rule with comment period, and the
agency received no comments on the policy the court found unlawful.
In the proposed rule, we noted that because we proposed to
establish this policy retroactively, it would cover cost reporting
periods for which many NPRs have already been settled. Consistent with
Sec. 405.1885(c)(2), any final rule retroactively adopting the
proposed new policy would not be the basis for reopening final settled
NPRs.
After reviewing the statutory language regarding the direct GME FTE
cap and the court's reasoning, we decided to propose a modified policy
to be applied for cost reporting periods beginning on October 1, 2001,
as described previously. The proposed modified policy would address
situations for applying the FTE cap when a hospital's weighted FTE
count was greater than its FTE cap, but would not reduce the weighting
factor of residents that are beyond their IRP by an amount less than
0.5. Section 1886(h)(4)(F) of the Act states that for purposes of a
cost reporting period beginning on or after October 1, 1997, the total
number of FTE residents before application of weighting factors may not
exceed the number of such FTEs for the hospital's most recent cost
reporting period ending on or before December 31, 1996. Under current
policy, we interpreted this to mean that only a hospital's unweighted
(before application of weighting factors) allopathic and osteopathic
FTE count was compared to its FTE cap, and if the unweighted allopathic
and osteopathic FTE count exceeded the FTE cap, then the proportional
reduction is made to the weighted FTE counts. Under this modified
proposed policy, in the instance where a hospital's unweighted
allopathic and osteopathic FTE count exceeds its FTE cap, we proposed
to add a step to also compare the total weighted allopathic and
osteopathic FTE count to the FTE cap. If the total weighted allopathic
and osteopathic FTE count is equal to or less than the FTE cap, then no
adjustments would be made to the respective primary care & OB/GYN
weighted FTE counts or the other weighted FTE counts. If the total
weighted allopathic and osteopathic FTE count exceeds the FTE cap, then
we would adjust the respective primary care & OB/GYN weighted FTE
counts or the other weighted FTE counts to make the total weighted FTE
count equal the FTE cap, as follows:
((primary care & OB/GYN weighted FTEs/total weighted FTEs) x FTE cap))
+ ((other weighted FTEs/total weighted FTEs) x FTE cap)).
The sum would be the current year total allowable weighted FTE
count, which would be reported on Worksheet E-4, line 9, column 3.
More specific to the Medicare cost report, we proposed to revise
the instructions to Worksheet E-4, line 9 to state: If line 6 is less
than or equal to line 5, enter the amounts from line 8, columns 1 and
2, in columns 1 and 2, of this line. Otherwise, if the total weighted
FTE count from line 8, column 3 is greater than the amount on line 5,
then enter in column 1 the result of ((primary care & OBGYN weighted
FTEs/total weighted FTEs) x FTE cap)). Enter in column 2 the result of
((other weighted FTEs/total weighted FTEs) x FTE cap)). Enter in column
3 the sum of
((primary care & OBGYN weighted FTEs/total weighted FTEs) x FTE
[[Page 49068]]
cap)) + ((other weighted FTEs/total weighted FTEs) x FTE cap)).
Example : [Note--see the comments and responses later in this
section for a revised version of this Example 1] Hospital with an FTE
cap of 100 trains 120 FTEs with a weight of 1.0, and 105 FTEs with a
weight of 0.5, consisting of 70 weighted primary care & OBGYN FTEs and
35 weighted other FTEs. Since the total weighted count of 105
(Worksheet E-4, line 8, column 3) exceeds the FTE cap of 100 (Worksheet
E-4, line 5), the Hospital reports the following adjusted weighted FTE
counts on Worksheet E-4:
Line 9, column 1: ((70 weighted primary care & OBGYN FTEs/105 total
weighted FTEs) x 100 cap)) = 66.67.
Line 9, column 2: ((35 weighted other FTEs/105 total weighted FTEs)
x 100 cap)) = 33.33.
Line 9, column 3: 66.67 FTEs + 33.33 FTEs = 100.
Example 2: Hospital with an FTE cap of 100 trains 102 unweighted
FTEs, equating to 96 weighted FTEs. This 96-weighted count consists of
30 weighted primary care & OBGYN FTEs, and 66 weighted other FTEs.
Since the total weighted count of 96 (Worksheet E-4, line 8, column 3)
is less than the FTE cap of 100 (Worksheet E-4, line 5), then no
further adjustment is needed; enter the amounts from line 8, columns 1
and 2, in columns 1 and 2, of line 9.
Example 3: Hospital with a cap of 100 FTEs trains 90 FTEs with a
weight of 1.0, and 20 FTEs with a weight of 0.5. Since the total
weighted count is 100 (90 + (20 x 0.5)), then no further adjustment is
needed. Enter the amounts from line 8, columns 1 and 2, in columns 1
and 2 of line 9.
Comment: We received many comments supporting our proposed revision
to the weighted count methodology and to the Medicare cost reporting
instructions. Commenters urged CMS to finalize the proposed revision,
asserting it is required by the law and the court's order, and to
recalculate payments immediately, as over a year has passed since the
court order.
Response: We appreciate the commenters' support, and upon issuance
of this final rule, we will work with the MACs and other impacted
parties to recalculate and issue adjusted payments as soon as possible.
Comment: Many commenters urged CMS to abandon the proposal to use
retroactive rulemaking as the means of complying with the decision of
the Hershey court. These commenters stated that retroactive rulemaking
is strongly disfavored under the Medicare statute and permitted only
under limited circumstances as specified in section 1871(e)(1)(A) of
the Act, namely, when it is either necessary to comply with statutory
requirements (Sec. 1871(e)(1)(A)(i)) of the Act); or when failure to
apply the change retroactively would be contrary to the public interest
(Sec. 1871(e)(1)(A)(ii) of the Act). Commenters asserted that neither
of these exceptions applies in the present case.
With respect to the exception at section 1871(e)(1)(A)(i) of the
Act, commenters stated that retroactive rulemaking is not necessary for
CMS to comply with statutory requirements. Commenters said that the
Medicare statute is unambiguous with respect to the weighting of
residents and fellows, and that the proposed revision to the
methodology is the only way for CMS to comply with the statutory
directive and the Hershey decision, neither of which requires any
interpretation by the agency. Commenters also stated that the exception
at section 1871(e)(1)(A)(ii) does not apply, since it does not serve
the public interest for CMS to engage in retroactive rulemaking and to
entertain public comments on actions that the agency is required to
take under a legally binding court order. According to a commenter,
engaging in retroactive rulemaking in this instance implicitly
contradicts the court's decision, while others expressed concern that
it would create a precedent whereby CMS might invoke public interest in
receiving comments as a justification for virtually any retroactive
rule change. Commenters also stated that it is not necessary for CMS to
engage in retroactive rulemaking to benefit from public comments,
pointing out that in the past the agency has made retroactive policy
changes via program instruction and only submitted the policies to
public comment for purposes of prospective application.
Commenters also rejected the argument that retroactive rulemaking
in this instance is necessary to comply with the Supreme Court's ruling
in Azar v. Allina Health Services. Commenters observed that the Allina
ruling established the need for notice-and-comment rulemaking to change
a substantive legal standard governing payment where the agency engages
in ``gap-filling'' an ambiguous statute. However, as previously stated,
commenters believed that the statute is unambiguous with regard to the
weighting of residents and fellows, and that therefore there are no
gaps for the agency to fill. In other words, as stated by a commenter,
the proposed policy is already dictated by the statute as explained in
Hershey, and there is no room for CMS to substantively change the
policy enacted by Congress.
Furthermore, commenters disagreed with CMS's position, as
originally stated in the FY 2023 IPPS/LTCH proposed rule, that
retroactive rulemaking is necessary in the wake of the Hershey ruling
since the Secretary ``has no promulgated rule governing'' direct GME
payments to teaching hospitals over the cap for cost reporting periods
beginning on or after October 1, 2001 (87 FR 28411). A number of
commenters stated that the Hershey court did not leave CMS with a
regulatory void to fill, but merely ruled ``that the regulation is
unlawful as applied to the Plaintiffs''; even if the court had vacated
the existing regulation, these commenters asserted that notice-and-
comment rulemaking would not be required or appropriate to acquiesce to
the vacatur. By contrast, another commenter stated that the existing
regulation is a ``legal nullity'' in light of the Hershey decision, but
nevertheless stated that the statutory payment directive requires no
substantive change in policy and can be properly effectuated without
rulemaking.
Citing a number of examples, commenters observed that historically,
both before and after Allina, CMS has implemented policy changes to
resolve appeals or comply with court decisions without engaging in
retroactive rulemaking, and invoked its retroactive rulemaking
authority only under particular circumstances, such as in response to a
natural disaster or when a rule is published after a statute's
effective date. Only more recently, according to commenters, has CMS
inappropriately begun to engage in retroactive rulemaking in response
to litigation. Rather than engage in retroactive rulemaking to comply
with the Hershey decision, commenters urged CMS to make the change in
regulation prospectively and to employ other appropriate means, such as
program instruction to the MACs or settlement with hospitals, to
implement the proposed correction for past years.
While urging CMS to abandon retroactive rulemaking as the means of
complying with the Hershey decision, commenters stated that, if CMS
does engage in retroactive rulemaking, it should specify exactly which
hospitals and past cost reporting periods will be eligible for relief
under the revised policy. In particular, commenters pointed out that
CMS proposed that ``certain other providers'' will be eligible for
relief in addition to the plaintiffs in Hershey, but the preamble does
not make it clear who those
[[Page 49069]]
providers will be. These commenters stated that CMS should reopen all
cost reports within the three-year reopening period and recalculate
direct GME payments consistent with the statute. At a minimum, however,
the ``certain other providers'' should include any provider that, if
applicable, has an appeal pending with the Provider Reimbursement
Review Board or in federal court on the same issue as Hershey. In
addition, if CMS does not reopen all cost reports that are within the
three-year reopening period, it should nonetheless apply the
methodology any time a cost report is reopened and the direct GME
payment is altered. Other commenters likewise stated that hospitals
should be permitted to reopen their cost reports for the purpose of
recalculating their direct GME payments according to the revised
weighting methodology, and that CMS should not finalize any ongoing
cost report audits until the final rule has been issued.
Some commenters expressed concern that CMS's proposal to extend
relief to only certain providers is inconsistent with concept of
retroactive rulemaking. Another commenter objected to CMS's statement
that under 42 CFR 405.1885(c)(2), any final rule retroactively adopting
the proposed new policy would not be the basis for reopening final
settled NPRs (87 FR 28411). This commenter asserted that Sec.
405.1885(c)(2) does not apply to retroactive rulemaking, and that CMS's
proposal has ``no real retroactive effect'' if it does not serve as the
basis for reopening settled cost reports. Another commenter similarly
recommended that CMS make the new policy ``fully retroactive'' so that
even final settled NPRs subject to reopening may be reopened for the
purpose of applying the revised methodology. This commenter stated that
withholding relief from certain providers would be arbitrary and
capricious and result in CMS not fully complying with the statute.
Response: We appreciate the comments regarding our proposal to
implement the court's decision in Hershey retroactively, but for the
reasons that follow (as well as those stated in the proposed rule), we
are finalizing our policy as proposed, retroactive to 2001.
We agree with commenters who objected to our statement that there
is ``no promulgated rule governing'' direct GME payments to over-the-
cap hospitals. The Hershey court did not vacate the rule. We further
agree that the Hershey decision itself does not require us to engage in
retroactive rulemaking. However, the statute at issue states that
``[t]he Secretary shall establish rules consistent with this paragraph
for the computation of the number of full-time equivalent residents in
an approved medical residency training program.'' Section1886(h)(4)(A)
of the Act (emphasis added). And the Hershey court did say that the
rules at issue were not consistent with the statute. Following our
review of the Hershey court's reasoning and the statutory requirements,
we decided that our method for computing FTEs was not consistent with
statutory requirements. We therefore conclude that our existing rule,
which does not comply with the statute, should be modified
retroactively such that our FTE computation rules are consistent with
the statute and payments, including payments for open cost years in
past, are calculated pursuant to regulation.
Several commenters state that no rule is necessary because of an
express statutory mandate that fellows be counted as 0.5 FTE. We
disagree, for two reasons. First, there are two express statutory
mandates in the section cited by commenters: that the Secretary
promulgate rules, and that those rules weight fellows at 0.5 FTE (see
sections 1886(h)(4)(A) and 1886(h)(4)(C)(iv) of the Act). In other
words, the statutory language cited by commenters describes the content
of the rules the Secretary is required to promulgate, rather than
setting an independent statutory benchmark. Second, we disagree with
the commenters' position that the rule we proposed was the only
possible way to compute FTE counts in light of Hershey. Section
1886(h)(4)(C) is not the only relevant statutory provision governing
the content of the rule; section 1886(h)(4)(F)(i) of the Act requires
the rules to cap the number of unweighted residents based on a
hospital's FY 1996 FTE count. In Hershey itself, the court did not
mandate a particular method of calculation or require CMS to adopt the
plaintiffs' proposed calculation method. We believe that there is more
than one way to comply with the statutory requirements and the court's
order. Our decision in this rule does not mean that all other
alternatives were foreclosed by the Hershey decision. The Hershey court
decision held that the prior regulation governing FTE counting for
over-the-cap hospitals was unlawful. It did not mandate any particular
alternative approach. We further disagree with commenters to the extent
they suggest that we compute FTE counts without a rule in place for
doing so. As discussed elsewhere, the statute at issue requires the
Secretary to establish a rule.
Even if the Hershey decision did mandate a single method of
computing FTE counts, it was silent on how to incorporate that
computation into the three-year rolling average. Without a rule for
determining the inputs to the three-year-rolling average, which we
proposed and are now finalizing, it is impossible to calculate a given
provider's dollar reimbursement. Therefore, even if we agreed with
commenters that the Hershey decision provided sufficient guidance for
computing FTE counts and that no further rulemaking on that issue is
required, we would nonetheless consider it necessary to undergo
rulemaking to implement our response to the decision, that is, use its
requirements to develop a method for calculating reimbursement. For
these reasons, we disagree with commenters who believe that notice-and-
comment rulemaking is unnecessary to implement the Hershey decision,
including for past cost years.
We appreciate the comments about retroactive rulemaking here being
inconsistent with CMS's historical practice. Many of the examples
raised by commenters do not involve judicial decisions calling into
question agency rules, which is a key factor here, as we noted in the
proposed rule. The governing statute requires the Secretary to
promulgate rules governing reimbursement that are consistent with
statutory requirements, and the court's decision in Hershey concluded
that our existing rule was not consistent with those requirements. We
do not believe that using retroactive rulemaking in this instance is
inconsistent with our past practice.
We acknowledge that our statutory authority to engage in
retroactive rulemaking is limited by section 1871(e)(1)(A) of the Act.
As previously discussed, we believe that the explicit statutory
requirement that the Secretary promulgate a rule governing GME
reimbursement renders retroactive application here ``necessary to
comply with statutory requirements.'' 1871(e)(1)(A)(i). If we
promulgated this rule prospectively only, a necessary result would be
that some hospitals would receive GME reimbursement based on a
computation of FTE equivalents that was not established by rule. We
emphasize again that the rule at issue in Hershey and the rule we
promulgate here are not merely statutory gap-fillers. The statute
affirmatively requires us to promulgate a rule.
[[Page 49070]]
In the alternative, and even if it were permissible to compute the
number of FTEs without a rule governing the methodology for doing so,
we believe that retroactive rulemaking here is in the public interest
(section 1871(e)(1)(A)(ii) of the Act). In response to comments, we
want to make clear that we believe that public notice-and-comment will
benefit the rulemaking process generally. As we noted in the preamble,
there was limited public comment on the key provisions of the original
rulemaking that the Hershey court found inconsistent with statutory
requirements. And we acknowledge--and we do not believe that commenters
disagree--that it is necessary to recalculate past payments in light of
the Hershey decision. The public interest will be served by having past
payments calculated in the same way as future payments, and given our
view that it is necessary to engage in notice-and-comment rulemaking to
implement the Hershey decision, we believe it is sensible and efficient
to calculate past payments based on a formula promulgated with the
benefit of notice-and-comment rulemaking. We do not mean to imply that
the public interest requires consistency between past payments and
future payments in all conceivable situations. However, where--as
here-- payment was set by a regulation that a court held inconsistent
with substantive statutory requirements and the agency engages in new
notice-and-comment rulemaking to implement that judicial ruling, there
is a public benefit in having past payments calculated via the same
method as future payments. This is particularly true where the statute
at issue requires that payments be calculated pursuant to a rule. We
therefore believe that this is a case where the public interest in
having a rule applicable to all payments, both past and future,
justifies retroactive rulemaking. It would be contrary to the public
interest for plaintiffs in Hershey and other judicial challenges to
have their payments calculated by a different methodology (whether more
or less generous than the methodology established by regulation) than
other providers that are otherwise similarly situated. Retroactive
rulemaking in this situation, benefits the public interest by achieving
parity in payment among similarly situated hospitals.
We also believe that the public interest is served by having
payments for past open cost years calculated in a transparent,
efficient, and not administratively burdensome fashion, an interest
that is served by promulgating a rule (following notice-and-comment)
that applies to those cost years. This rule will allow us to calculate
payments to hospitals with open cost reports based on a universal and
transparent formula, and it will allow many hospitals (and MACs) to
avoid the administrative expense of calculating payments based on a
formula that the agency has concluded should not be applied. The public
interest is further served by reducing the need for hospitals to file
administrative appeals in order to obtain the benefit of the new
payment formula.
We appreciate comments regarding the applicability of 42 CFR
405.1885(c)(2) to this rule. We disagree that 405.1885(c)(2) does not
apply to retroactive rules. The text of the regulation does not support
that proposed carve-out. The rule we proposed--and finalize here--is a
``change of legal interpretation or policy by CMS in a regulation . . .
made in response to judicial precedent,'' and thus it is ``not a basis
for reopening a CMS or contractor determination.'' Some commenters
urged us to apply 42 CFR 405.1885(c)(1) to direct contractors to reopen
cost reports, but we note that paragraph (c)(1) allows CMS to do so
(``CMS may direct a contractor . . . to reopen and revise'') subject to
the prohibited reopening's in paragraph (c)(2). We disagree that this
rule will have no ``real retroactive effect,'' as a number of hospitals
will receive increased reimbursement for past cost reporting years.
We further disagree that it is arbitrary and capricious to apply
405.1885(c)(2) here. This is not the first time that we have made a
policy change that could potentially affect closed cost reports, and we
have previously declined to direct reopening of closed cost reports
consistent with the policy favoring finality embedded in
405.1885(c)(2). For example, we permitted qualifying hospitals to
request application of a policy change made in the FY 2020 IPPS rule to
FYs 2011 through 2017, ``subject to the reopening rules at 42 CFR
405.1885.'' (84 FR 42349) We believe that the policy we finalize here
is consistent with our past practice and our general approach toward
finality.
Comment: Many commenters appreciated that CMS proposed that ``If
the number of FTE residents weighted in accordance with paragraph (b)
of this section does not exceed [the FTE cap], then the allowable
weighted FTE count is the actual weighted FTE count.'' However, some
commenters pointed out that CMS's proposed change to the instructions
for line 9 of Worksheet E-4 does not contain language reflecting this
scenario and requested that CMS add a third sentence to the proposed
changes to the instructions for line 9. The sentence should state as
follows: ``If the total weighted FTE count from line 8, column 3 is
less than or equal to the amount on line 5, then enter the amounts from
line 8, columns 1 and 2, in columns 1 and 2 of this line.''
Response: We agree with the commenters' request and will revise the
proposed instructions to Worksheet E-4, line 9 to address the
commenters' request. However, since we are adding the sentence
requested by the commenters, then we are removing the following: ``If
line 6 is less than or equal to line 5, enter the amounts from line 8,
columns 1 and 2, in columns 1 and 2, of this line.'' This latter
sentence is not necessary, since if line 6 is less than or equal to
line 5, then by default line 8, column 3 will also be less than or
equal to line 5. We are revising the instructions to Worksheet E-4,
line 9 to state: If the total weighted FTE count from line 8, column 3
is less than or equal to the amount on line 5, then enter the amounts
from line 8, columns 1 and 2, in columns 1 and 2 of this line (emphasis
added). Otherwise, if the total weighted FTE count from line 8, column
3 is greater than the amount on line 5, then enter in column 1 the
result of ((primary care & OBGYN weighted FTEs/total weighted FTEs) x
FTE cap)). Enter in column 2 the result of ((other weighted FTEs/total
weighted FTEs) x FTE cap)). Enter in column 3 the sum of columns 1 and
2.
Under section 1886(h)(4)(G)(i) and 42 CFR 413.79(d)(3), a
hospital's weighted FTE count for payment purposes is the 3-year
average of its current year weighted FTEs, prior year weighted FTEs,
and penultimate year FTEs (for primary care & OBGYN FTEs and other FTEs
respectively). Effective for cost reporting periods beginning on or
after October 1, 2001, we proposed to implement this modified
methodology for the purpose of determining the prior year weighted FTE
count on line 12 of Worksheet E-4, and for the purpose of determining
the penultimate year's weighted FTE count on line 13 of Worksheet E-4,
even though the prior and penultimate years' FTE counts would be from
cost reporting periods prior to October 1, 2001. In this manner, the
modified methodology would be fully applied to determining the direct
GME payment for cost reporting periods beginning on or after October 1,
2001.
Therefore, we proposed to modify the cost report instructions on
Worksheet E-4, lines 12 and 13, respectively to state that effective
for cost reporting periods beginning on or after October 1, 2001, if
subject to the cap in the prior
[[Page 49071]]
year or penultimate year respectively, if the prior/penultimate year
total weighted FTE count from line 8, column 3 is greater than the
amount on line 5 from the prior/penultimate year, then enter in column
1 the result of ((primary care & OBGYN weighted FTEs/total weighted
FTEs) x FTE cap)). Enter in column 2 the result of ((other weighted
FTEs/total weighted FTEs) x FTE cap)) plus the amount on line 10,
column 2. These instructions do not in any way modify or reopen final-
settled prior and penultimate year NPRs.
Comment: Some commenters supported CMS's proposal to update the
cost report instructions for lines 12 and 13 of Worksheet E-4 to ensure
that the weighted resident FTE counts from the prior and penultimate
years will be updated to reflect the new direct GME payment formula.
However, the commenters pointed out that the proposed language for
lines 12 and 13 does not specify how to calculate the weighted FTE
count for the prior and/or penultimate years when the unweighted FTE
count from those years exceeds the FTE cap, but the weighted FTE count
from those years does not, and requested that CMS add a sentence to the
instructions for lines 12 and 13 stating: ``If the prior/penultimate
year total weighted FTE count from line 8, column 3 is less than or
equal to line 5 from the prior/penultimate year, then enter the amounts
from line 8, columns 1 and 2, in columns 1 and 2 of this line.''
Response: We agree with the commenters' request and are revising
the instructions on Worksheet E-4 lines 12 and 13 to state: Effective
for cost reporting periods beginning on or after October 1, 2001, if
the prior/penultimate year total weighted FTE count from line 8, column
3 is less than or equal to line 5 from the prior/penultimate year, then
enter the amounts from line 8, columns 1 and 2, in columns 1 and 2 of
this line (emphasis added). If subject to the cap in the prior year or
penultimate year respectively, if the prior/penultimate year total
weighted FTE count from line 8, column 3 is greater than the amount on
line 5 from the prior/penultimate year, then enter in column 1 the
result of ((primary care & OBGYN weighted FTEs/total weighted FTEs) x
FTE cap)). Enter in column 2 the result of ((other weighted FTEs/total
weighted FTEs) x FTE cap)) plus the amount on line 10, column 2.
Comment: Several commenters observed that CMS should have also
proposed to apply the revised direct GME weighting methodology to the
so-called ``section 422 MMA (Medicare Modernization Act) cap slots'' as
well. Specifically, many teaching hospitals received additional FTE
caps following a redistribution of unused FTE cap slots mandated by
section 422 of the MMA. Similar to the fellowship penalty, CMS applies
a proportional methodology when determining payment for section 422 cap
FTEs. The commenters suggested that CMS calculate the ``Section 422
Allowable Direct GME FTE Resident Count'' on Worksheet E-4, line 22 as
follows:
If the weighted FTEs on line 8 are less than or equal to
the adjusted FTE cap on line 5, the hospital would have entered the
weighted FTEs from line 8 on line 9. In this instance, the additional
section 422 cap slots are unnecessary, and the hospital would enter
zero on line 22.
If the weighted FTEs on line 8 are greater than the
adjusted FTE cap on line 5, the hospital would have entered the
adjusted FTE cap on line 9. In this instance, the hospital would
subtract line 9 from line 8 and proceed as follows:
[cir] If line 9 minus line 8 equals or exceeds the ``Section 422
Direct GME FTE Cap'' on line 20, then the hospital would enter the
amount from line 20 on line 22.
[cir] If line 9 minus line 8 is less than line 20, the hospital
would enter line 9 minus line 8 on line 20.
Response: We agree with the commenters' observation that the
revised methodology should apply to the MMA section 422 FTE cap, as the
mathematical cap concept is the same for the 422 FTE cap as it is for
the regular FTE cap. Accordingly, for portions of cost reporting
periods beginning on or after July 1, 2005, the effective date of
section 422 under 42 CFR 413.79(c)(4), we will revise Worksheet E-4,
line 22, as follows:
For portions of cost reporting periods beginning on or after July
1, 2005, if the weighted FTE count on line 8 is less than or equal to
the adjusted FTE cap on line 5, the hospital would have entered the
weighted FTEs from line 8 on line 9. In this instance, the additional
Sec. 422 cap slots are unnecessary; do not complete lines 22 through
24. If the weighted FTE count on line 8 is greater than the adjusted
FTE cap on line 5, the hospital would have entered the adjusted FTE cap
on line 9. In this instance, subtract line 9 from line 8. If line 9
minus line 8 equals or exceeds the ``Section 422 Direct GME FTE Cap''
on line 20, then enter the amount from line 20 on line 22. If line 9
minus line 8 is less than line 20, enter line 9 minus line 8 on line
22. (We note the commenters indicated ``enter line 9 minus line 8 on
line 20,'' but we believe they meant to say ``on line 22'').
We proposed to amend the regulations text at 42 CFR
413.79(c)(2)(iii) to state that, effective for cost reporting periods
beginning on or after October 1, 2001, if the hospital's unweighted
number of FTE residents exceeds the limit described in this section of
the final rule, and the number of weighted FTE residents in accordance
with Sec. 413.79(b) also exceeds that limit, the respective primary
care and obstetrics and gynecology weighted FTE counts and other
weighted FTE counts are adjusted to make the total weighted FTE count
equal the limit. If the number of FTE residents weighted in accordance
with Sec. 413.79(b) does not exceed that limit, then the allowable
weighted FTE count is the actual weighted FTE count.
Comment: A commenter requested that CMS make conforming changes to
the three-year rolling average regulation at. Sec. 413.79(d)(3) to
clarify that the weighted FTE counts for the ``preceding two cost
reporting periods'' must be calculated in accordance with the revised
payment formula at Sec. 413.79(c)(2)(iii).
Response: We agree to add a parenthetical to the regulations at
Sec. 413.79(d)(3) to state, ``For cost reporting periods beginning on
or after October 1, 2001, the hospital's weighted FTE counts for the
preceding two cost reporting periods are calculated in accordance with
the payment formula at 42 CFR 413.79(c)(2)(iii)).''
Comment: A commenter stated they would like to see the three-year
rolling average eliminated retroactive to October 1, 2001, as it would
delay implementation of CMS's proposed payment formula.
Response: Under section 1886(h)(4)(G)(i) and 42 CFR 413.79(d)(3), a
hospital's weighted FTE count for payment purposes is the 3-year
average of its current year weighted FTEs, prior year weighted FTEs,
and penultimate year weighted FTEs (for primary care & OBGYN FTEs and
other FTEs respectively). Our proposed interpretation of section
1886(h)(4)(F) of the Act regarding application of weighting factors
does not change this portion of the statute regarding application of
the 3-year rolling average. Therefore, we are not adopting the
commenter's request to eliminate application of the rolling average
under our proposed payment formula.
Comment: Some commenters requested that CMS correct or clarify
certain misstatements in the FY 2023 IPPS/LTCH PPS proposed rule
regarding the Hershey case. First, CMS should be clearer about the
position of the Hershey
[[Page 49072]]
plaintiffs. CMS described the position of the Hershey plaintiffs as
follows: ``The plaintiffs in these consolidated cases alleged that as
far back as 2005, the proportional reduction that CMS applied to the
weighted FTE count when the weighted FTE count exceeded the FTE cap
conflicted with the Medicare statute'' (87 FR 28410). According to the
commenters, this is an incomplete description of the plaintiffs'
position. The commenters stated that CMS's proportional reduction also
impermissibly reduces the weighted FTE count when the weighted FTE
count is less than unweighted FTE cap.
Second, the commenters believed that ``Example 1'' in the preamble
is misstated. In that example, a ``Hospital with an FTE cap of 100
trains 120 FTEs with a weight of 1.0 and 105 FTEs with a weight of 0.5,
consisting of 70 weighted primary care & OBGYN FTEs and 35 weighted
other FTEs'' (87 FR 28411). The ``total weighted count'' is ``105.''
The commenters noted that if the hospital trained 120 FTEs with a
weight of 1.0 and 105 FTEs with a weight of 0.5, its unweighted FTE
count would be 225 (120 + 105), and its weighted FTE count would be
172.5 ((120 x 1.0) + (105 x 0.5)), not 105. The commenters believed
that CMS intended this example to say that the hospital had an
unweighted FTE count of 120 and a weighted FTE count of 105. The 105
weighted FTEs would consist of 90 FTEs weighted at 1.0 and 30 FTEs
weighted at 0.5.
Response: Regarding the first point about not fully capturing
Plaintiffs' position, we acknowledge the commenters' assertion that the
plaintiffs in Hershey argued that CMS's proportional reduction
impermissibly reduced the weighted FTE count when the weighted FTE
count was less than unweighted FTE cap.
Regarding the second point that the commenters believe that Example
1 is misstated, we acknowledge the confusing wording, and we are
providing a corrected Example 1 as follows:
Example 1 Revised: Hospital with an FTE cap of 100 trains 120
unweighted FTEs, consisting of 105 weighted FTEs (90 FTEs weighted at
1.0 and 30 FTEs weighted at 0.5 = 105 weighted FTEs). The 105 weighted
FTEs further consists of 70 weighted primary care & OBGYN FTEs and 35
weighted other FTEs. Since the total weighted count of 105 (Worksheet
E-4, line 8, column 3) exceeds the FTE cap of 100 (Worksheet E-4, line
5), the Hospital reports the following adjusted weighted FTE counts on
Worksheet E-4:
Line 9, column 1: ((70 weighted primary care & OBGYN FTEs/105 total
weighted FTEs) x 100 cap)) = 66.67.
Line 9, column 2: ((35 weighted other FTEs/105 total weighted FTEs)
x 100 cap)) = 33.33.
Line 9, column 3: 66.67 FTEs + 33.33 FTEs = 100.
Comment: A commenter requested clarification on the implications of
the Medicare direct GME formula change for hospitals that participate
in the Children's Hospitals Graduate Medical Education (CHGME) program
administered by HRSA.
Response: Since the CHGME program is administered by HRSA and not
by CMS, we defer to HRSA to determine the implications of CMS's change
to the Medicare direct GME payment formula.
After consideration of comments received, we are finalizing our
proposed policy and regulations text at 42 CFR 413.79(c)(2)(iii) to
state that, effective for cost reporting periods beginning on or after
October 1, 2001, if the hospital's unweighted number of FTE residents
exceeds the limit described in this section of the final rule, and the
number of weighted FTE residents in accordance with Sec. 413.79(b)
also exceeds that limit, the respective primary care and obstetrics and
gynecology weighted FTE counts and other weighted FTE counts are
adjusted to make the total weighted FTE count equal the limit. If the
number of FTE residents weighted in accordance with Sec. 413.79(b)
does not exceed that limit, then the allowable weighted FTE count is
the actual weighted FTE count. In response to comments, we are also
making a conforming change to the regulations text at 42 CFR
413.79(d)(3) regarding application to the 3-year rolling average to
state that for cost reporting periods beginning on or after October 1,
2001, the hospital's weighted FTE counts for the preceding two cost
reporting periods are calculated in accordance with the payment formula
at Sec. 413.79(c)(2)(iii). In addition, in response to comments, we
are applying the new payment methodology to the MMA section 422 FTE
cap.
3. Reasonable Cost Payment for Nursing and Allied Health Education
Programs
a. General
Under section 1861(v) of the Act, Medicare has historically paid
providers for Medicare's share of the costs that providers incur in
connection with approved educational activities. Approved nursing and
allied health (NAH) education programs are those that are, in part,
operated by a provider, and meet State licensure requirements, or are
recognized by a national accrediting body. The costs of these programs
are excluded from the definition of inpatient hospital operating costs
and are not included in the calculation of payment rates for hospitals
or hospital units paid under the IPPS, IRF PPS, or IPF PPS, and are
excluded from the rate-of-increase ceiling for certain facilities not
paid on a PPS. These costs are separately identified and ``passed
through'' (that is, paid separately on a reasonable cost basis).
Existing regulations on NAH education program costs are located at
Sec. 413.85. The most recent rulemakings on these regulations were in
the January 12, 2001 final rule (66 FR 3358 through 3374), and in the
August 1, 2003, final rule (68 FR 45423 and 45434).
b. Medicare+Choice Nursing and Allied Health Education Payments
Section 541 of the Balanced Budget Refinement Act (BBRA) of 1999
provides for additional payments to hospitals for costs of nursing and
allied health education associated with services to Medicare+Choice
(now called Medicare Advantage (MA)) enrollees. Hospitals that operate
approved nursing or allied health education programs and receive
Medicare reasonable cost reimbursement for these programs would receive
additional payments from MA organizations. Section 541 of the BBRA
limits total spending under the provision to no more than $60 million
in any calendar year (CY). (In this document, we refer to the total
amount of $60 million or less as the payment ``pool''.) Section 541 of
the BBRA also provides that direct graduate medical education (GME)
payments for Medicare+Choice utilization are reduced to the extent that
these additional payments are made for nursing and allied health
education programs. This provision was effective for portions of cost
reporting periods occurring in a CY, on or after January 1, 2000.
Section 512 of the Benefits Improvement and Protection Act (BIPA)
of 2000 changed the formula for determining the additional amounts to
be paid to hospitals for MA nursing and allied health costs. Under
section 541 of the BBRA, the additional payment amount was determined
based on the proportion of each individual hospital's nursing and
allied health education payment to total nursing and allied health
education payments made to all hospitals. However, this formula did not
account for a hospital's specific MA utilization. Section 512 of the
BIPA revised this payment formula to specifically account for each
hospital's
[[Page 49073]]
MA utilization. This provision was effective for portions of cost
reporting periods occurring in a calendar year, beginning with CY 2001,
and was implemented in the August 1, 2001 IPPS final rule (66 FR 39909
and 39910).
The regulations at 42 CFR 413.87 codified both statutory
provisions. We first implemented the BBRA NAH MA provision in the
August 1, 2000 IPPS interim final rule with comment period (IFC) (65 FR
47036 through 47039). In that IFC, we outlined the qualifying
conditions for a hospital to receive the NAH MA payment, how we would
calculate the NAH MA payment pool, and how a qualifying hospital would
calculate its ``share'' of payment from that pool. Determining a
hospital's NAH MA payment essentially involves applying a ratio of the
hospital-specific NAH Part A payments, total inpatient days, and MA
inpatient days, to national totals of those same amounts, from cost
reporting periods ending in the fiscal year that is 2 years prior to
the current calendar year. The formula is as follows:
(((Hospital NAH pass-through payment/Hospital Part A Inpatient Days) *
Hospital MA Inpatient Days)/((National NAH pass-through payment/
National Part A Inpatient Days) * National MA Inpatient Days)) *
Current Year Payment Pool.
With regard to determining the total national amounts for NAH pass-
through payment, Part A inpatient days, and MA inpatient days, we note
that section 1886(l) of the Act, as added by section 541 of the BBRA,
gives the Secretary the discretion to ``estimate'' the national
components of the formula noted previously. For example, section
1886(l)(2)(A) of the Act states that the Secretary would estimate the
ratio of payments for all hospitals for portions of cost reporting
periods occurring in the year under subsection 1886(h)(3)(D) to total
direct GME payments estimated for the same portions of periods under
subsection 1886(h)(3) of the Act. Accordingly, we made the following
statements in the August 1, 2000 IFC:
Each year, we would determine and publish in a final rule
and a final rule the total amount of nursing and allied health
education payments made across all hospitals during the fiscal year
that is 2 years prior to the current calendar year (65 FR 47038). We
would use the best available cost reporting data for the applicable
hospitals from the Hospital Cost Report Information System (HCRIS) for
cost reporting periods in the fiscal year that is 2 years prior to the
current calendar year (65 FR 47038).
To calculate the pool, in accordance with section 1886(l)
of the Act, we would ``estimate'' a total amount for each calendar
year, not to exceed $60 million (65 FR 47038).
To calculate the proportional reduction to Medicare+Choice
(now MA) Direct GME payments, we stated that the percentage is
estimated by calculating the ratio of the Medicare+Choice nursing and
allied health payment ``pool'' for the current calendar year to the
projected total Medicare+Choice direct GME payments made across all
hospitals for the current calendar year. We stated that the projections
of Medicare+Choice direct GME and Part A direct GME are based on the
best available cost report data from the HCRIS (for example, for
calendar year 2000, the projections are based on the best available
cost report data from HCRIS 1998), and these payment amounts were
increased using the increases allowed by section 1886(h) of the Act for
these services (using the percentage applicable for the current
calendar year for Medicare+Choice direct GME and the Consumer Price
Index (CPI) increases for Part A direct GME). We also stated that we
would publish the applicable percentage reduction each year in the IPPS
proposed and final rules (65 FR 47038).
Thus, in the August 1, 2000, IFC, we described our policy regarding
the timing and source of the national data components for the NAH MA
add-on payment and the percent reduction to the direct GME MA payments,
and we stated that we would publish the rates for each calendar year in
the IPPS proposed and final rules. While the rates for CY 2000 were
published in the August 1, 2000, IFC (see 65 FR 47038 and 47039), the
rates for subsequent CYs were only issued through Change Requests (CRs)
(CR 2692, CR 11642, CR 12407). After recent issuance of the CY 2019
rates in CR 12407 on August 19, 2021, we reviewed our update
procedures, and were reminded that the August 1, 2000 IFC states that
we would publish the NAH MA rates and direct GME percent reduction
every year in the IPPS rules. Accordingly, for CY 2020 and forward, the
NAH MA add-on rates will be proposed and included in the IPPS proposed
and final rules, and we are also reiterating the data sources we would
use.
In the FY 2023 IPPS/LTCH PPS proposed rule, we proposed the NAH MA
add-on rates as well as the direct GME MA percent reductions for CYs
2020 and 2021. We proposed to issue the rates for CYs 2020 and 2021
because we believe we have sufficient HCRIS data to develop the rates
for these years, and these rate years are most needed to ensure
accurate and timely cost report settlements of cost reports with
portions overlapping with CYs 2020 and 2021. We expect to propose to
issue the rates for CY 2022 in the FY 2024 IPPS/LTCH PPS proposed rule,
and the rates for CY 2023 in the FY 2025 IPPS/LTCH PPS proposed rule,
and so forth.
Consistent with the use of HCRIS data for past calendar years, for
CY 2020, we proposed to use data from cost reports ending in FY 2018
HCRIS (the fiscal year that is 2 years prior to CY 2020) to compile
these national amounts: NAH pass-through payment, Part A Inpatient
Days, MA Inpatient Days. We proposed to use data from cost reports
ending in FY 2019 HCRIS (the fiscal year that is 2 years prior to CY
2021) to compile the same national amounts for CY 2021.
For the proposed rule, we accessed the HCRIS data from the fourth
quarterly HCRIS update of 2021. However, to calculate the ``pool'' and
the direct GME MA percent reduction, we ``project'' Part A direct GME
payments and MA direct GME payments for the current calendar years,
which in this final rule, are CYs 2020 and 2021, based on the ``best
available cost report data from the HCRIS'' (65 FR 47038). Next,
consistent with the method we described previously from the August 1,
2000 IFC, we increased these payment amounts from midpoint to midpoint
of the appropriate calendar year using the increases allowed by section
1886(h) of the Act for these services (using the percentage applicable
for the current calendar year for MA direct GME, and the Consumer Price
Index-Urban (CPI-U) increases for Part A direct GME. For CY 2020, the
direct GME projections are based on FY 2019 HCRIS. For CY 2021, the
direct GME projections are based on FY 2019 HCRIS. For CYs 2020 and
2021, the proposed national rates and percentages, and their data
sources are set forth in this table. We stated in the proposed rule
that we intend to update these numbers in the FY 2023 final rule based
on the latest available cost report data.
[[Page 49074]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.130
We did not propose any changes to the regulations text at 42 CFR
413.87, as our proposal to include the nursing and allied health MA
rates in the IPPS rulemaking was consistent with current regulations.
Comment: A commenter requested clarification on the calculation of
the direct GME MA percent reduction and questioned if it is separate
from the allocation of funds used for the NAH pass-through payment.
Response: We appreciate the commenter's request for clarification.
As explained previously in the background section, under sections 541
of the BBRA and 512 of BIPA, hospitals that operate approved nursing or
allied health education programs and receive Medicare reasonable cost
reimbursement for these programs would receive additional payments for
services associated with MA enrollees. Section 541 of the BBRA limits
total spending under the provision to no more than $60 million in any
calendar year (CY). Section 541 of the BBRA also provides for estimated
reductions in direct GME MA payments, which are to equal the estimated
total additional MA NAH payments. Thus, nationally, the estimated
reductions to direct GME MA payments would not be more than $60 million
in any CY. However, on a hospital-specific basis, the direct GME MA
percent reduction is not necessarily tied to receipt of the MA NAH add-
on payment. That is, hospitals that are both teaching hospitals
receiving direct GME payments and that operate approved NAH programs
may be affected by both aspects of these laws; such hospitals may
receive both a payment for MA NAH, while also receiving a reduced
direct GME MA payment. Hospitals that only operate NAH programs may
only receive the MA NAH payment; conversely, teaching hospitals with no
approved NAH programs would only receive the reduced direct GME MA
payment.
We received numerous comments regarding various aspects of the MA
NAH add-on and the direct GME MA percent reduction, expressing
opposition to reconciliation of overpayments, voicing concerns
regarding reimbursement that does not adequately reflect current costs
and nursing and healthcare workforce shortages, and opposing reductions
to direct GME payments to fund NAH programs. While concerns expressed
in these comments may be important, we did not specifically make
proposals related to those concerns. These comments are out of scope,
and therefore, we are not responding to them at this time.
For this final rule, consistent with the use of HCRIS data for past
calendar years, for CY 2020, we use data from cost reports ending in FY
2018 HCRIS (the fiscal year that is 2 years prior to CY 2020) to
compile these national amounts: NAH pass-through payment, Part A
Inpatient Days, MA Inpatient Days. We use data from cost reports ending
in FY 2019 HCRIS (the fiscal year that is 2 years prior to CY 2021) to
compile the same national amounts for CY 2021. For this final rule, we
accessed the HCRIS data from the first quarterly HCRIS update of 2022.
However, to calculate the ``pool'' and the direct GME MA percent
reduction, we ``project'' Part A direct GME payments and MA direct GME
payments for the current calendar years, which in this final rule, are
CYs 2020 and 2021 as the best available cost report data. Next,
consistent with the method we described previously from the August 1,
2000 IFC, we increased these payment amounts from midpoint to midpoint
of the appropriate calendar year using the increases allowed by section
1886(h) of the Act for these services (using the percentage applicable
for the current calendar year for MA direct GME, and the Consumer Price
Index-Urban (CPI-U) increases for Part A direct GME. For CY 2020, the
direct GME projections are based on FY 2019 HCRIS. For CY 2021, the
direct GME projections are based on FY 2019 HCRIS. For CYs 2020 and
2021, the final national rates and percentages, and their data sources
are set forth in this table.
[[Page 49075]]
[GRAPHIC] [TIFF OMITTED] TR10AU22.131
In summary, after consideration of the public comments received, we
are finalizing our proposal to use NAH MA add-on rates as well as the
direct GME MA percent reductions for CYs 2020 and 2021, based on
sufficient HCRIS data to develop the rates for these years. We expect
to propose to issue the rates for CY 2022 in the FY 2024 IPPS/LTCH PPS
proposed rule, and the rates for CY 2023 in the FY 2025 IPPS/LTCH PPS
proposed rule, and so forth.
4. Allowance of Medicare GME Affiliation Agreements Within Certain
Rural Track FTE Limitations
Sections 1886(h)(4)(F) and 1886(d)(5)(B)(v) of the Act established
limits on the number of allopathic and osteopathic residents that
hospitals may count for purposes of calculating direct GME payments and
the IME adjustment, respectively, thereby establishing hospital-
specific direct GME and IME full-time equivalent (FTE) resident caps.
However, under the authority granted by section 1886(h)(4)(H)(ii) of
the Act, the Secretary may issue rules to allow institutions that are
members of the same affiliated group to apply their direct GME and IME
FTE resident caps on an aggregate basis through a Medicare GME
affiliation agreement. The Secretary's regulations permit hospitals,
through a Medicare GME affiliation agreement, to increase or decrease
their IME and direct GME FTE resident caps to reflect the rotation of
residents among affiliated hospitals for agreed-upon academic years.
Consistent with the broad authority conferred by the statute, we
established criteria for defining an ``affiliated group'' and an
``affiliation agreement'' in both the August 29, 1997, final rule (62
FR 45966, 46006) and the May 12, 1998, final rule (63 FR 26318). In the
August 1, 2002, IPPS final rule (67 FR 50069), we amended our
regulations to require that each Medicare GME affiliation agreement
must have a shared rotational arrangement. The term ``Medicare GME
affiliation agreement'' is defined at 42 CFR 413.75(b) as a written,
signed, and dated agreement by responsible representatives of each
respective hospital in a Medicare GME affiliated group, as defined in
Sec. 413.75(b), that specifies--
The term of the Medicare GME affiliation agreement (which,
at a minimum is 1 year), beginning on July 1 of a year;
Each participating hospital's direct and indirect GME FTE
caps in effect prior to the Medicare GME affiliation;
The total adjustment to each hospital's FTE caps in each
year that the Medicare GME affiliation agreement is in effect, for both
direct GME and IME, that reflects a positive adjustment to one
hospital's direct and indirect FTE caps that is offset by a negative
adjustment to the other hospital's (or hospitals') direct and indirect
FTE caps of at least the same amount;
The adjustment to each participating hospital's FTE counts
resulting from the FTE resident's (or residents') participation in a
shared rotational arrangement at each hospital participating in the
Medicare GME affiliated group for each year the Medicare GME
affiliation agreement is in effect. This adjustment to each
participating hospital's FTE count is also reflected in the total
adjustment to each hospital's FTE caps (in accordance with in
accordance with paragraph (3) of this definition); and
The names of the participating hospitals and their
Medicare provider numbers.
We also define the term ``Shared Rotational Arrangement'' in that
section of our rules as a residency training program under which a
resident(s) participates in training at two or more hospitals in that
program.
To encourage the training of residents in rural areas, section
407(c) of the Medicare, Medicaid, and SCHIP Balanced Budget Refinement
Act of 1999 (Pub. L. 106-113) (BBRA) amended section 1886(h)(4)(H) of
the Act to add a provision (subsection (iv)) stating that, in the case
of a hospital that is not located in a rural area (an urban hospital)
that establishes separately accredited approved medical residency
training programs (or rural tracks) in a rural area, or has an
accredited training program with an integrated rural track, the
Secretary shall adjust the urban hospital's cap on the number of FTE
residents under section 1886(h)(4)(F) of the Act, in an appropriate
manner in order to encourage training of physicians in rural areas.
Historically, the Accreditation Council for Graduate Medical Education
(ACGME) has separately accredited family medicine programs in the ``1-2
format'' (meaning, residents in the 1-2 format receive their first year
experience at a core family medicine program, and their second and
third year experiences at another site, which may or may not be rural).
Section 407(c) of Public Law 106-113 was effective for direct GME
payments to hospitals for cost reporting periods beginning on or after
April 1, 2000, and for IME payments applicable to discharges occurring
on or after April 1, 2000. We refer readers to the August 1, 2000,
interim final rule with comment period (65 FR 47025, 47033 through
47037) and the FY 2002 IPPS final rule (66 FR 39828, 39902 through
39909) where we implemented section 407(c) of Public Law 106-113. The
regulations for establishing rural track FTE limitations are located at
42 CFR 413.79(k) for direct GME and at 42 CFR 412.105(f)(1)(x) for IME.
(We note that additional legislative and regulatory changes were made
to Rural Track Programs in the December 27, 2021 final rule, 86 FR
73445.)
When we first implemented the rural track regulations in the August
1, 2000 IFC, we specified that the caps associated with rural tracks
are separate and distinct from a hospital's general FTE caps.
Specifically, we defined Rural track FTE limitation at 42 CFR 413.75(b)
as the maximum number of residents training in a rural track residency
program that an urban hospital may include in its FTE count and that is
in
[[Page 49076]]
addition to the number of FTE residents already included in the
hospital's FTE cap (emphasis added). As a result, the rural track FTE
limitations are not part of the regular FTE caps that hospitals may
aggregate in Medicare GME affiliation agreements.
The rural track FTE limitations are calculated in the same manner
as the adjustments to any allowable new program, in accordance with 42
CFR 413.79(e)(1). That is, at the end of the 5-year cap building window
for the rural track program, the urban hospital's and rural hospital
respective IME and direct GME rural track FTE limitations are
calculated as the product of three factors (limited to the number of
accredited slots for each program):
The highest total number of FTE residents trained in any
program year during the fifth year of the first new program's existence
at all of the hospitals to which the residents in the program rotate.
The number of years in which residents are expected to
complete the program, based on the minimum accredited length for each
type of program.
The ratio of the number of FTE residents in the new
program that trained at the hospital over the entire 5-year period to
the total number of FTE residents that trained at all hospitals over
the entire 5-year period.
Thus, while the calculated rural track FTE limitations calculated
at the end of the 5-year window may reflect the division of the
rotations between the urban and rural hospitals over the 5 initial
years of the program, the future rotations amounts may change somewhat
(albeit adhering to greater than 50 percent of the duration of the
training occurring in the rural hospital/rural area). As rotations
shift to meet patient care needs, the respective rural track FTE
limitations may not quite match the amount of FTEs actually training in
the urban and rural hospitals. There has been request that the same
flexibility with cap sharing afforded to teaching hospitals to share
general FTE cap slots via Medicare GME affiliation agreements also be
afforded to urban and rural teaching hospitals that together train
residents in a rural track program. This flexibility would allow the
urban and rural hospitals to share their rural track FTE limitations in
a manner that best matches the rotations occurring in the urban and
rural hospitals. Stakeholders representing urban-rural training
partnerships specifically raised this request with regard to separately
accredited 1-2 family medicine programs that have existed for a number
of years, and either already have established their rural track FTE
limitations, or have just recently reached or will reach the end of
their 5-year cap building windows.
We have considered this request and agree it would be equitable to
allow an urban and rural hospital jointly training residents in a 1-2
separately accredited family medicine program to aggregate their
respective IME and direct GME rural track FTE limitations and enter
into a ``Rural Track Medicare GME Affiliation Agreement'' to share
those cap slots, and facilitate the cross-training of residents. We
proposed to allow urban and rural hospitals that participate in the
same separately accredited 1-2 family medicine rural track program and
have rural track FTE limitations to enter into ``Rural Track Medicare
GME Affiliation Agreements.'' We proposed that programs that are not
separately accredited in the 1-2 format and are not in family medicine
would not be permitted to enter into ``Rural Track Medicare GME
Affiliation Agreements'' under this proposal. These Rural Track
Medicare GME Affiliation Agreements, which we proposed to define in
this final rule, will be structured similarly to regular Medicare GME
affiliation agreements, but we proposed two distinct requirements.
First, in an effort to ensure that regular FTE caps and FTE
residents in non-rural track programs are not commingled with the rural
track FTE residents, and that rural track FTE limitations are not being
used to provide additional cap slots for non-rural track FTE residents,
we proposed that the responsible representatives of each urban and
rural hospital entering into the Rural Track Medicare GME Affiliation
Agreement must attest in that written agreement that each participating
hospital's FTE counts and rural track FTE limitations in the agreement
do not reflect FTE residents nor FTE caps associated with programs
other than the rural track program. We noted this attestation is
important for both the urban and rural hospital, as both urban and
rural hospitals may have regular FTE caps that could be part of regular
Medicare GME affiliation agreements (see 42 CFR 413.79(e)(1)(iv) and
(v) and 413.79(f)). Second, we proposed to only allow urban and rural
hospitals to participate in Rural Track Medicare GME Affiliated Groups
if they are separately accredited 1-2 family medicine programs that
have rural track FTE limitations in place prior to October 1, 2022. We
proposed to choose these criteria and this date of October 1, 2022, as
the date by which eligible hospitals must have rural track FTE
limitations in place because the effective date of section 127 of the
Consolidated Appropriations Act (CAA) is cost reporting periods
beginning on or after October 1, 2022, and we proposed to limit this
proposal to only rural track FTE limitations established under the BBRA
of 1999 that are unaffected by section 127 of the CAA. In this final
rule, we are distinguishing between rural track programs with rural
track FTE limitations associated with the BBRA of 1999 in effect prior
to October 1, 2022, and Rural Track Programs (RTPs, defined at 42 CFR
413.75(b)) started or expanded to new participating sites under the
authority of section 127 of the CAA. We explain this distinction later
in this section of the final rule.
First, we refer readers to the December 27, 2021, final rule (86 FR
73445) for details about section 127 of the CAA. Generally, that
provision removes the requirement that rural track programs be
separately accredited, places in statute (previously in regulation) the
requirement that rural track residents must spend greater than 50
percent of their training time in a rural area, and allows urban and
rural hospitals to receive adjustments to their rural track FTE
limitations for adding new rural training sites to an existing rural
track program. In that December 27, 2021, final rule, we addressed a
comment (86 FR 73456) that requested whether multiple rural hospital
training sites added under the new section 127 authority may share
their rural track FTE limitations via a Medicare GME affiliation
agreement. We responded that effective October 1, 2022, we are not
permitting the formation of Medicare GME affiliated groups for the
purpose of aggregating and cross-training RTP FTE limitations. First,
we explained that we believe Medicare GME affiliated groups for RTPs
would be premature, as only starting October 1, 2022, would hospitals
have the first opportunity to add additional participating sites.
Subsequently, there would be the 5-year cap building period in which
Medicare GME affiliations are not permitted, even under existing
Medicare GME affiliation agreement rules (42 CFR 413.79(f)). Second, we
stated that before we create Medicare GME affiliation agreements unique
to RTPs, we believe it would be best to first modify the Medicare cost
report form to add spaces for the hospitals to indicate the number of
any additional RTP FTEs, and the caps applicable to those FTEs. We also
stated that we wish to assess flexibility within a hospital's own total
RTP FTE limitation, before sharing those slots with other hospitals. We
would need to be vigilant to ensure
[[Page 49077]]
that the RTP FTE limitations are not comingled with regular FTE cap
adjustments currently used in Medicare GME affiliation agreements.
Therefore, we concluded with our belief that it is best to reassess
allowing Medicare GME affiliation agreements for RTP FTE limitations at
some point in the future. For these same reasons, at this time, we
believe it is appropriate to only propose to allow rural track Medicare
GME affiliation agreements with urban and rural hospitals that have a
rural track FTE limitation in place prior to October 1, 2022. We will
assess allowing these agreements with RTP FTE limitations established
after October 1, 2022, in the future.
We proposed the following new definitions and requirements at 42
CFR 413.75(b):
``Rural track Medicare GME affiliated group'' is an urban
hospital and a rural hospital that participates in a rural track
program defined in 42 CFR 413.75(b), and that have rural track FTE
limitations in effect prior to October 1, 2022, and that comply with 42
CFR 413.79(f)(1) through (6) for Medicare GME affiliated groups.
``Rural track Medicare GME affiliation agreement'' is a
written, signed, and dated agreement by responsible representatives of
each respective hospital in a rural track Medicare GME affiliated
group, as defined in 42 CFR 413.75(b), that specifies--
++ A statement attesting that each participating hospital's FTE
counts and rural track FTE limitations in the agreement do not reflect
FTE residents nor FTE caps associated with programs other than the
rural track program.
++ The term of the rural track Medicare GME affiliation agreement
(which, at a minimum is 1 year), beginning on July 1 of a year;
++ Each participating hospital's direct and indirect GME rural
track FTE limitations in effect prior to the rural track Medicare GME
affiliation;
++ The total adjustment to each hospital's rural track FTE
limitations in each year that the rural track Medicare GME affiliation
agreement is in effect, for both direct GME and IME, that reflects a
positive adjustment to one hospital's direct and indirect rural track
FTE limitations that is offset by a negative adjustment to the other
hospital's (or hospitals') direct and indirect rural track FTE
limitations of at least the same amount;
++ The adjustment to each participating hospital's FTE counts
resulting from the FTE resident's (or residents') participation in a
shared rotational arrangement at each hospital participating in the
rural track Medicare GME affiliated group for each year the Medicare
GME affiliation agreement is in effect. This adjustment to each
participating hospital's FTE count is also reflected in the total
adjustment to each hospital's rural track FTE limitations (in
accordance with paragraph (iii) of the definition (regarding the total
adjustment to each hospital's rural track FTE limitations previously
noted)); and
++ The names of the participating hospitals and their Medicare
provider numbers.
In addition, we proposed to require that no later than July 1 of
the residency year during which the rural track Medicare GME
affiliation agreement will be in effect, the urban and rural hospital
must submit the signed agreement to the CMS contractor or MAC servicing
the hospital and send a copy to the CMS Central Office. The hospitals
may submit amendments to the adjustments to their respective rural
track FTE limitations to the MAC with a copy to CMS by June 30 of the
residency year that the agreement is in effect. We proposed that
eligible urban and rural hospitals may enter into rural track Medicare
GME affiliation agreements effective with the July 1, 2023, academic
year.
With regard to how the rural track Medicare GME affiliation
adjustments would be reported on the Medicare cost report, first, for
background, we noted in the proposed rule that on the previous Medicare
cost report CMS-Form-2552-96, the rural track FTE limitation was
combined, together with the ``cap'' add-on for new (non-rural track)
programs on Worksheet E, Part A, line 3.05, and on Worksheet E-3, Part
IV, line 3.02. On the current cost report CMS-Form-2552-10, the rural
track FTE limitation is, likewise, combined together with the ``cap''
add-on for new (non-rural track) programs on Worksheet E, Part A, line
6, and on Worksheet E-4, line 2. We stated in the proposed rule that
going forward, we intend to add lines to the cost report to accommodate
separate reporting of urban or rural hospital rural track FTE
limitations, and the positive or negative adjustments made to the rural
track FTE limitations, including those applicable to the affiliated
agreements.
In summary, we proposed to allow urban and rural hospitals that
participate in the same separately accredited 1-2 family medicine rural
track program and have rural track FTE limitations to enter into
``Rural Track Medicare GME Affiliation Agreements''. We proposed that
programs that are not separately accredited in the 1-2 format and are
not in family medicine would not be permitted to enter into ``Rural
Track Medicare GME Affiliation Agreements'' under this proposal. We
proposed to add new definitions at 42 CFR 413.75(b) of rural track
Medicare GME affiliated group and rural track Medicare GME affiliation
agreement. We also proposed to require that the responsible
representatives of each urban and rural hospital entering into the
rural track Medicare GME affiliation agreement must attest in that
agreement that each participating hospital's FTE counts and rural track
FTE limitations in the agreement do not reflect FTE residents nor FTE
caps associated with programs other than the rural track program. In
addition, we proposed to only allow urban and rural hospitals to
participate in rural track Medicare GME affiliated groups if they have
rural track FTE limitations in place prior to October 1, 2022. We
proposed that eligible urban and rural hospitals may enter into rural
track Medicare GME affiliation agreements effective with the July 1,
2023, academic year.
Comment: The majority of commenters strongly supported CMS's
proposal to enable rural training flexibilities through Medicare GME
affiliation agreements between urban and rural hospitals that have
rural track programs. Some commenters ``applauded'' CMS for its
attention to rural GME training, and appreciated additional options for
cap flexibilities afforded to rural hospitals. A commenter stated that
the proposal will assist urban hospitals in providing flexibilities
needed to address disparities affected by geography and other social
determinants of care. Some commenters stated that the proposal will
help provide care to Medicare beneficiaries and may create interest for
future physicians to practice in rural settings. Many commenters who
supported the proposal also added that CMS should engage in future
rulemaking that will allow any RTP, not just those separately
accredited in family medicine that were established prior to October 1,
2022, to also engage in affiliation agreements following the conclusion
of the cap-building period.
Response: We thank the commenters for their feedback and support.
As we stated in the proposed rule, we proposed to only allow urban and
rural hospitals to participate in Rural Track Medicare GME Affiliated
Groups if they are separately accredited 1-2 family medicine programs
that have rural track FTE limitations in place prior to October 1,
2022. We stated that we are distinguishing between rural track programs
with rural track FTE
[[Page 49078]]
limitations associated with the BBRA of 1999 in effect prior to October
1, 2022, and Rural Track Programs (RTPs, defined at 42 CFR 413.75(b))
started or expanded to new participating sites under the authority of
section 127 of the CAA effective on or after October 1, 2022. We
explained that we are not permitting the formation of Medicare GME
affiliated groups for the purpose of aggregating and cross-training RTP
FTE limitations effective on or after October 1, 2022, because we
believe Medicare GME affiliated groups for RTPs would be premature, as
only starting October 1, 2022, would hospitals have the first
opportunity to add additional participating sites. Subsequently, there
would be the 5-year cap building period in which Medicare GME
affiliations would not be permitted, even under existing Medicare GME
affiliation agreement rules (42 CFR 413.79(f)). In addition, we stated
that before we created Medicare GME affiliation agreements unique to
RTPs, we believe it would be best to first modify the Medicare cost
report form to add spaces for the hospitals to indicate the number of
any additional RTP FTEs, and the caps applicable to those FTEs. We also
stated that we wished to assess flexibility within a hospital's own
total RTP FTE limitation, before sharing those slots with other
hospitals. We would need to be vigilant to ensure that the RTP FTE
limitations were not comingled with regular FTE cap adjustments
currently used in Medicare GME affiliation agreements. We concluded
with our belief that it would be best to reassess allowing Medicare GME
affiliation agreements for RTP FTE limitations at some point in the
future. For these same reasons, at this time, we believe it is
appropriate to only propose to allow rural track Medicare GME
affiliation agreements with urban and rural hospitals that have a
separately accredited rural track program and rural track FTE
limitation in place prior to October 1, 2022. We will assess allowing
these agreements with RTP FTE limitations established after October 1,
2022, in the future.
Comment: A commenter representing a group of organizations opposed
CMS's proposal to allow Medicare GME affiliation agreements for rural
track programs with FTE limitations prior to October 1, 2022, and did
not believe the use of affiliation agreements resolves concerns over
the inequity of the current method for determining a cap to be applied
to rural track programs. The commenter was concerned that the proposal
establishes additional barriers to many programs. The commenter
believed that the proposal is too narrow, limited only to family
medicine training, and only to separately accredited training tracks
established prior to the CAA 2021. Specifically, the commenter observed
that currently, CMS counts the time residents spend training at the
rural site, across five years, and the time spent in the urban setting,
and then counts the highest number (in any program year) during the
fifth year of the cap-setting window across all participating
hospitals. Because a rural track program typically has its residents
train in the urban hospital in year one, rather than in the rural
setting, the urban hospital gets more than its fair share of the cap,
and the rural site gets less than the actual number of FTEs training in
that site. When apportioned this way, rural sites are disadvantaged
compared to urban hospital sites. The commenter noted that a mechanism
already exists for Medicare affiliated groups to aggregate caps other
than ``rural FTE limitations,'' and stated that they ``are aware of
multiple occasions where such aggregation has occurred between urban
and rural hospitals, always to the disadvantage of the rural hospital
that has, for example, been acquired by the larger urban health system.
It seems unlikely that urban hospitals would give up ``rural FTE
limitation'' slots to benefit a participating rural hospital's cap . .
.'' The commenter stated that CMS has the authority to make changes to
the calculation of rural cap limitations as section 127 of the CAA
states that the Secretary shall ``adjust in an appropriate manner the
limitation under subparagraph (F) for such hospital and each such
hospital located in a rural area that participates in such a training''
(emphasis added). As such, beginning with cost reporting periods on or
after October 1, 2022, CMS is not restricted to only sharing positions
through an affiliation agreement but should set appropriate caps
associated with these training programs for the future, rather than
institute affiliation agreements. This commenter and another commenter
recommended that the solution is to count the highest year, rather than
using all five years when determining the ratio for cap apportionment.
Response: We appreciate the concerns raised by the commenter and
acknowledge the commenter's unique perspective on rural GME training.
We certainly want to initiate a payment mechanism that is inherently
equitable, and believe that a policy that we finalize should encourage,
rather than hinder, GME training in rural areas. However, we note that
the vast majority of commenters, including others with close ties to
rural GME training, have submitted comments in support of our proposal,
generally stating that this proposal will facilitate training in rural
settings.
With regard to the commenter's point that CMS's current methodology
of looking at all 5 years to apportion FTE caps disadvantages the rural
hospital in a RTP because the method gives more than the fair share of
FTE cap to the urban hospital, we acknowledge that there might be other
mathematical apportionment methods that, if tailor-made for RTPs, would
result in higher caps for the rural hospital. However, we note that
this current mathematical apportionment in the regulations at 42 CFR
413.79(e)(1) and (3) was first implemented for all hospitals in the
August 1, 2012 LTCH PPS/IPPS final rule (77 FR 53416 through 53424).
Then in the August 22, 2016 LTCH PPS/IPPS final rule, we adopted this
same cap apportionment methodology for rural track FTE limitations (81
FR 57026 through 57031), without any objection from commenters. Thus,
we have established a single, national policy for calculating FTE caps
for new programs and RTPs, and we have not proposed a change to this
national method in the proposed rule. While a ``one-size-fits-all''
method may not be optimal in all situations, we do not believe it is
advisable to alter the cap calculation for RTPs at this time. With the
advent of CAA section 127, and the expectation that RTPs will develop
not only in 3-year family medicine programs, but also in many other
specialties of differing lengths, it is not the right time to establish
an RTP cap calculation method, before we even understand what the RTP
landscape will be like over the next 5 or more years. At this point,
allowing Medicare GME affiliation agreements between the urban and
rural hospitals participating in the same RTP may be the better
solution, as it would allow the hospitals to customize their individual
caps, rather than CMS instituting yet another national cap calculation
methodology. Furthermore, because the majority of commenters supported
our proposal to allow Rural Track Medicare GME Affiliation Agreements,
we believe it is fair and appropriate to finalize our policy as
proposed. In the December 27, 2021 final rule (86 FR 73456), and as
reiterated in the proposed rule and in response to other comments in
this final rule, we already stated that we expect to reassess allowing
Medicare GME affiliation agreements for RTP FTE
[[Page 49079]]
limitations established after October 1, 2022 at some point in the
future. For these same reasons, and in conjunction with observing what
we hope will be robust growth and development of RTPs in many
specialties, not just family medicine, we are open to reassessing at
the appropriate time the viability of Rural Track Medicare GME
Affiliation Agreements for appropriate payment for urban and rural
hospitals participating in RTPs.
Comment: Another commenter who supported our proposal added that
they believe CMS's concerns about hospitals taking advantage of
affiliated agreements and comingled caps are misguided, and that
placing this limitation on affiliated agreements within RTPs is
inappropriate. The commenter asserted that urban and rural hospitals
participating in any RTP program for the benefit of rural communities
should be permitted this flexibility, as it would promote the adoption
of the model partnerships.
Response: As we stated in the proposed rule, when we first
implemented the rural track regulations in the August 1, 2000 IFC, we
specified that the caps associated with rural tracks are separate and
distinct from a hospital's general FTE caps. Specifically, we defined
the ``rural track FTE limitation'' at 42 CFR 413.75(b) as the maximum
number of residents training in a rural track residency program that an
urban hospital may include in its FTE count and that is in addition to
the number of FTE residents already included in the hospital's FTE cap
(emphasis added). As a result, the rural track FTE limitations are not
part of the regular FTE caps that hospitals may aggregate in Medicare
GME affiliation agreements. In the proposed rule, we proposed that the
responsible representatives of each urban and rural hospital entering
into the Rural Track Medicare GME Affiliation Agreement attest in that
written agreement that each participating hospital's FTE counts and
rural track FTE limitations in the agreement do not reflect FTE
residents nor FTE caps associated with programs other than the rural
track program. We noted this attestation is important for both the
urban and rural hospital, as both urban and rural hospitals may have
regular FTE caps that could be part of regular Medicare GME affiliation
agreements (see 42 CFR 413.79(e)(1)(iv) and (v) and 413.79(f)).
Accordingly, as long as it is possible for a hospital to have both
regular FTE caps and rural track FTE limitations, we believe it is
appropriate to have mechanisms in place to ensure those caps are not
inadvertently comingled. We do not believe these mechanisms limit the
flexibility of rural hospitals seeking to create model partnerships, as
the commenter asserts.
Comment: A commenter offered one minor suggestion on language used
to describe the programs encompassed in the proposal to allow Medicare
GME affiliation agreements within certain rural track FTE limitations.
The commenter offered these suggestions in the interest of accurate
references to ACGME terminology and processes. The commenter suggested
eliminating use of the outdated term ``1-2'' when referring to
separately accredited family medicine programs. CMS could instead
consider phrasing such as ``separately accredited family medicine
programs with caps in place as of October 1, 2022.''
Response: We appreciate the commenter's suggestion, and in this
final rule, we are finalizing our policy with respect to ``separately
accredited family medicine programs with rural track FTE limitations in
place as of October 1, 2022.''
After consideration of the public comments we received, we are
finalizing our proposal, without modification, to allow urban and rural
hospitals that participate in the same separately accredited family
medicine RTP and have rural track FTE limitations to enter into ``Rural
Track Medicare GME Affiliation Agreements''.
We are finalizing the following new definitions at 42 CFR 413.75(b)
and requirements:
Rural track Medicare GME affiliated group is an urban
hospital and a rural hospital that participates in a rural track
program defined in 42 CFR 413.75(b), and that have rural track FTE
limitations in effect prior to October 1, 2022, and that comply with 42
CFR 413.79(f)(1) through (6) for Medicare GME affiliated groups.
Rural track Medicare GME affiliation agreement is a
written, signed, and dated agreement by responsible representatives of
each respective hospital in a rural track Medicare GME affiliated
group, as defined in 42 CFR 413.75(b), that specifies--
++ A statement attesting that each participating hospital's FTE
counts and rural track FTE limitations in the agreement do not reflect
FTE residents nor FTE caps associated with programs other than the
rural track program.
++ The term of the rural track Medicare GME affiliation agreement
(which, at a minimum is 1 year), beginning on July 1 of a year;
++ Each participating hospital's direct and indirect GME rural
track FTE limitations in effect prior to the rural track Medicare GME
affiliation;
++ The total adjustment to each hospital's rural track FTE
limitations in each year that the rural track Medicare GME affiliation
agreement is in effect, for both direct GME and IME, that reflects a
positive adjustment to one hospital's direct and indirect rural track
FTE limitations that is offset by a negative adjustment to the other
hospital's (or hospitals') direct and indirect rural track FTE
limitations of at least the same amount;
++ The adjustment to each participating hospital's FTE counts
resulting from the FTE resident's (or residents') participation in a
shared rotational arrangement at each hospital participating in the
rural track Medicare GME affiliated group for each year the Medicare
GME affiliation agreement is in effect. This adjustment to each
participating hospital's FTE count is also reflected in the total
adjustment to each hospital's rural track FTE limitations (in
accordance with paragraph (iii)); and
++ The names of the participating hospitals and their Medicare
provider numbers.
In addition, we are requiring that no later than July 1 of the
residency year during which the rural track Medicare GME affiliation
agreement will be in effect, the urban and rural hospital must submit
the signed agreement to the CMS contractor or MAC servicing the
hospital and send a copy to the CMS Central Office. The hospitals may
submit amendments to the adjustments to their respective rural track
FTE limitations to the MAC with a copy to CMS by June 30 of the
residency year that the agreement is in effect. Eligible urban and
rural hospitals may enter into rural track Medicare GME affiliation
agreements effective with the July 1, 2023, academic year.
With regard to how the rural track Medicare GME affiliation
adjustments would be reported on the Medicare cost report, first, for
background, we note that on the previous Medicare cost report CMS-Form-
2552-96, the rural track FTE limitation was combined, together with the
``cap'' add-on for new (non-rural track) programs on Worksheet E, Part
A, line 3.05, and on Worksheet E-3, Part IV, line 3.02. On the current
cost report CMS-Form-2552-10, the rural track FTE limitation is,
likewise, combined together with the ``cap'' add-on for new (non-rural
track) programs on Worksheet E, Part A, line 6, and on Worksheet E-4,
line 2. Going forward, we intend to add lines to the cost report to
accommodate separate reporting of urban or rural hospital rural
[[Page 49080]]
track FTE limitations, and the positive or negative adjustments made to
the rural track FTE limitations, including those applicable to the
affiliated agreements.
G. Payment Adjustment for Certain Clinical Trial and Expanded Access
Use Immunotherapy Cases (Sec. Sec. 412.85 and 412.312)
Effective for FY 2021, we created MS-DRG 018 for cases that include
procedures describing CAR T-cell therapies, which were reported using
ICD-10-PCS procedure codes XW033C3 or XW043C3 (85 FR 58599 through
58600). Effective for FY 2022, we revised MS-DRG 018 to include cases
that report the procedure codes for CAR T-cell and non-CAR T-cell
therapies and other immunotherapies (86 FR 44798 through 448106). We
refer the reader to section II.D.17. of the preamble of this final rule
for discussion of the agenda items for the March 8-9, 2022 ICD-10
Coordination and Maintenance Committee meeting relating to new
procedure codes to describe the administration of a CAR T-cell or
another type of gene or cellular therapy product, as well as our
established process for determining the MS-DRG assignment for codes
approved at the March meeting.
Effective for FY 2021, we modified our relative weight methodology
for MS-DRG 018 in order to develop a relative weight that is reflective
of the typical costs of providing CAR T-cell therapies relative to
other IPPS services. Specifically, under our finalized policy we do not
include claims determined to be clinical trial claims that group to MS-
DRG 018 when calculating the average cost for MS-DRG 018 that is used
to calculate the relative weight for this MS-DRG, with the additional
refinements that: (a) when the CAR T-cell therapy product is purchased
in the usual manner, but the case involves a clinical trial of a
different product, the claim will be included when calculating the
average cost for MS DRG 018 to the extent such claims can be identified
in the historical data; and (b) when there is expanded access use of
immunotherapy, these cases will not be included when calculating the
average cost for MS-DRG 018 to the extent such claims can be identified
in the historical data (85 FR 58600). The term ``expanded access''
(sometimes called ``compassionate use'') is a potential pathway for a
patient with an immediately life-threatening condition or serious
disease or condition to gain access to an investigational medical
product (drug, biologic, or medical device) for treatment outside of
clinical trials when no comparable or satisfactory alternative therapy
options are available.\215\
---------------------------------------------------------------------------
\215\